﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Reynolds, R
   Hartnett, ME
   Atkinson, JP
   Giclas, PC
   Rosner, B
   Seddon, JM
AF Reynolds, Robyn
   Hartnett, M. Elizabeth
   Atkinson, John P.
   Giclas, Patricia C.
   Rosner, Bernard
   Seddon, Johanna M.
TI Plasma Complement Components and Activation Fragments: Associations with
   Age-Related Macular Degeneration Genotypes and Phenotypes
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ACYLATION-STIMULATING PROTEIN; C-REACTIVE PROTEIN; BODY-MASS INDEX;
   FACTOR-B; VARIANT; RISK; SUSCEPTIBILITY; MACULOPATHY; GENES; HTRA1
AB PURPOSE. Several genes encoding complement system components and fragments are associated with age-related macular degeneration (AMD). This study was conducted to determine whether alterations in circulating levels of these markers of complement activation and regulation are also independently associated with advanced AMD and whether they are related to AMD genotypes.
   METHODS. Plasma and DNA samples were selected from individuals in our AMD registry who had progressed to or developed the advanced stages of AMD, including 58 with geographic atrophy and 62 with neovascular disease. Subjects of similar age and sex, but without AMD, and who did not progress were included as controls (n = 60). Plasma complement components (C3, CFB, CFI, CFH, and factor D) and activation fragments (Bb, C3a, C5a, iC3b, and SC5b-9) were analyzed. DNA samples were genotyped for seven single-nucleotide polymorphisms in six genes previously shown to be associated with AMD: CFB, CFH, C2, C3, and CFI and the LOC387715/ARMS2 gene region. The association between AMD and each complement biomarker was assessed by using logistic regression, controlling for age, sex, and proinflammatory risk factors: smoking and body mass index (BMI). Functional genomic analyses were performed to assess the relationship between the complement markers and genotypes. Concordance, or C, statistics were calculated to assess the effect of complement components and activation fragments in an AMD gene-environment prediction model.
   RESULTS. The highest quartiles of Bb and C5a were significantly associated with advanced AMD, when compared with the lowest quartiles. In multivariate models without genetic variants, the odds ratio (OR) for Bb was 3.3 (95% confidence interval [CI] = 1.3-8.6), and the OR for C5a was 3.6 (95% CI = 1.2-10.3). With adjustment for genetic variants, these ORs were substantially higher. The alternative pathway regulator CFH was inversely associated with AMD in the model without genotypes (OR = 0.3; P = 0.01). Positive associations were found between BMI and plasma C3, CFB, CFH, iC3b, and C3a. There were also significant associations between C5a fragment and LOC387715/ARMS2 and C3 genotypes (P for trend = 0.02, 0.04), respectively. C statistics for models with behavioral and genetic factors increased to 0.94 +/- 0.20 with the addition of C3a, Bb, and C5a.
   CONCLUSIONS. Increased levels of activation fragments Bb and C5a are independently associated with AMD. Higher BMI is related to increased levels of complement components. C5a is associated with AMD genotypes. C statistics are stronger with the addition of C3a, Bb, and C5a in predictive models. Results implicate ongoing activation of the alternative complement pathway in AMD pathogenesis. (Invest Ophthalmol Vis Sci. 2009; 50: 5818-5827) DOI:10.1167/iovs.09-3928
C1 [Reynolds, Robyn; Seddon, Johanna M.] Tufts Univ, Sch Med, Tufts Med Ctr, Ophthalm Epidemiol & Genet Serv,Dept Ophthalmol, Boston, MA 02111 USA.
   [Hartnett, M. Elizabeth] Univ N Carolina, Sch Med, Dept Ophthalmol, Chapel Hill, NC USA.
   [Atkinson, John P.] Washington Univ, Dept Med, Div Rheumatol, St Louis, MO USA.
   [Giclas, Patricia C.] Natl Jewish Hlth, Allergy & Immunol Div, Dept Pediat, Denver, CO USA.
   [Rosner, Bernard] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Lab, Boston, MA 02115 USA.
C3 Tufts Medical Center; Tufts University; University of North Carolina;
   University of North Carolina Chapel Hill; University of North Carolina
   School of Medicine; Washington University (WUSTL); National Jewish
   Health; Harvard University; Brigham & Women's Hospital; Harvard Medical
   School
RP Seddon, JM (通讯作者)，Tufts Univ, Sch Med, Tufts Med Ctr, Ophthalm Epidemiol & Genet Serv,Dept Ophthalmol, 800 Washington St,Box 450, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
RI Mohammed, Imran/J-8271-2012
OI Mohammed, Imran/0000-0002-8412-0768
FU National Eye Institute [R01-EY11309]; Research to Prevent Blindness
   Inc., New York, NY; Massachusetts Lions Eye Research Fund Inc.,
   Northboro, MA; American Macular Degeneration Foundation, MA; Macular
   Degeneration Research Fund of the Ophthalmic Epidemiology and Genetics
   Service; New England Eye Center; Tufts Medical Center; Tufts University
   School of Medicine; NATIONAL EYE INSTITUTE [R01EY013982, R01EY011309]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASES [R01AI037618] Funding Source: NIH RePORTER
FX Supported in part by Grant R01-EY11309 from the National Eye Institute;
   unrestricted grants from Research to Prevent Blindness Inc., New York,
   NY; the Massachusetts Lions Eye Research Fund Inc., Northboro, MA; the
   American Macular Degeneration Foundation, MA; and the Macular
   Degeneration Research Fund of the Ophthalmic Epidemiology and Genetics
   Service, the New England Eye Center, Tufts Medical Center, Tufts
   University School of Medicine (JMS).
CR ATKINSON JP, 2009, KELLEYS TXB RHEUMATO, P323
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fang CJ, 2008, BRIT J HAEMATOL, V143, P336, DOI 10.1111/j.1365-2141.2008.07324.x
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Harbeck RJ, 1991, DIAGNOSTIC IMMUNOLOG
   Hernandez-Mijares A, 2007, INT J OBESITY, V31, P927, DOI 10.1038/sj.ijo.0803543
   Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lynch AM, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.07.044
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Paglialunga S, 2008, AM J PHYSIOL-ENDOC M, V294, pE521, DOI 10.1152/ajpendo.00590.2007
   Pattrick M, 2009, MOL IMMUNOL, V46, P755, DOI 10.1016/j.molimm.2008.09.013
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2006, NUTRITION, V22, P441, DOI 10.1016/j.nut.2005.12.004
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   Wamba PCF, 2008, EUR J ENDOCRINOL, V159, P781, DOI 10.1530/EJE-08-0467
   Warnberg J, 2006, AM J CLIN NUTR, V84, P505
   WHITE RT, 1992, J BIOL CHEM, V267, P9210
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 41
TC 230
Z9 253
U1 0
U2 16
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2009
VL 50
IS 12
BP 5818
EP 5827
DI 10.1167/iovs.09-3928
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 527GS
UT WOS:000272355900043
PM 19661236
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Tano, Y
   Bressler, NM
   Ishibashi, T
   Ohji, M
   Shiraga, F
   Takahashi, K
   Weisberger, A
   Yuzawa, M
AF Tano, Yasuo
   Bressler, Neil M.
   Ishibashi, Tatsuro
   Ohji, Masahito
   Shiraga, Fumio
   Takahashi, Kanji
   Weisberger, Annemarie
   Yuzawa, Mitsuko
CA Japanese Age Related Macular
TI Photodynamic therapy with verteporfin in Japanese patients with
   subfoveal choroidal neovascularization secondary to age-related macular
   degeneration (AMD): Results of the Japanese AMD Trial (JAT) extension
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; Japanese
   patients; Japanese AMD trial; verteporfin
ID RANDOMIZED CLINICAL-TRIALS; VISUAL IMPAIRMENT; TAP; EYE; PREVALENCE;
   ADULTS
AB Purpose: To evaluate the longer term safety of verteporfin therapy in Japanese patients with subfoveal classic choroidal neovascularization (CNV) due to age-related macular degeneration (AMD).
   Methods: Patients completing 12 months of the Japanese AMD Trial (JAT) were eligible to enter the extension phase if the investigator judged they would potentially benefit from further verteporfin therapy. Patients had follow-up visits every 3 months, receiving verteporfin therapy in the study eye if leakage from CNV was observed on fluorescein angiography. Mean change from baseline in best-corrected visual acuity was a safety variable in the extension.
   Results: Of the 51 patients entering the study extension, 46 (90%) completed 24 months. Adverse events were similar to those in the first 12 months of JAT; no cumulative toxic effect of verteporfin therapy was identified. Mean visual acuity letter score in the study eye increased from 50.8 (20/100(+1)) at baseline to 54.0 (20/80(-1)) at month 24. At month 24, six patients (13%) had lost 15 or more letters of visual acuity, of whom four (9%) had lost 30 or more letters.
   Conclusion: Verteporfin therapy was shown to be safe and effective through 24 months in Japanese patients with subfoveal CNV due to AMD, supporting its long-term use in these patients.
C1 [Ohji, Masahito] Shiga Univ Med Sci, Dept Ophthalmol, Otsu, Shiga 5202192, Japan.
C3 Shiga University of Medical Science
RP Ohji, M (通讯作者)，Shiga Univ Med Sci, Dept Ophthalmol, Seta Tsukinowa Cho, Otsu, Shiga 5202192, Japan.
EM ohji@belle.shiga-med.ac.jp
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Chan WM, 2006, JPN J OPHTHALMOL, V50, P161, DOI 10.1007/s10384-005-0259-z
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dimitrov PN, 2003, INVEST OPHTH VIS SCI, V44, P5075, DOI 10.1167/iovs.02-0457
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Lim JI, 1998, RETINA-J RET VIT DIS, V18, P435
   MATSUI M, 1989, Nippon Ganka Gakkai Zasshi, V93, P883
   PIERAMICI DJ, 1994, ARCH OPHTHALMOL-CHIC, V112, P1043, DOI 10.1001/archopht.1994.01090200049020
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   *TREATM AG REL MAC, 2005, ARCH OPHTHALMOL-CHIC, V123, P1283
   *TREATM AG REL MAC, 2006, GRAEFES ARCH CLIN EX, V244, P1132
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   2005, RETINA, V25, P119
NR 19
TC 8
Z9 8
U1 0
U2 0
PU SPRINGER TOKYO
PI TOKYO
PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD APR
PY 2008
VL 52
IS 2
BP 99
EP 107
DI 10.1007/s10384-008-0512-3
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 331AY
UT WOS:000257986300004
PM 18626732
DA 2022-11-30
ER

PT J
AU Nagineni, CN
   Kommineni, VK
   Ganjbaksh, N
   Nagineni, KK
   Hooks, JJ
   Detrick, B
AF Nagineni, Chandrasekharam N.
   Kommineni, Vijay K.
   Ganjbaksh, Nader
   Nagineni, Krishnasai K.
   Hooks, John J.
   Detrick, Barbara
TI Inflammatory Cytokines Induce Expression of Chemokines by Human Retinal
   Cells: Role in Chemokine Receptor Mediated Age-related Macular
   Degeneration
SO AGING AND DISEASE
LA English
DT Article
DE Age-related macular degeneration; Retinal pigment epithelium; Retina;
   Inflammation; Choroidal neovascularization; Chemokines; CCR3
ID PIGMENT EPITHELIAL-CELLS; INDUCED CHOROIDAL NEOVASCULARIZATION;
   INTERNATIONAL UNION; EOTAXIN RECEPTOR; CCR3; ANGIOGENESIS; EOSINOPHILS;
   MECHANISMS; INHIBITION; THERAPY
AB Chemokine reeptor-3 (CCR-3) was shown to be associated with choroidal neovascularization (CNV) in age-related macular degeneration (AMD). AMD is a vision threatening retinal disease that affects the aging population world-wide. Retinal pigment epithelium and choroid in the posterior part of the retina are the key tissues targeted in the pathogenesis of CNV in AMD. We used human retinal pigment epithelial (HRPE) and choroidal fibroblast (HCHF) cells, prepared from aged adult human donor eyes, to evaluate the expression of major CCR-3 ligands, CCL-5, CCL -7, CCL-11, CCL-24 and CCL-26. Microarray analysis of gene expression in HRPE cells treated with inflammatory cytokine mix (ICM= IFN-gamma+TNF-alpha+IL-1 beta) revealed 75 and 23-fold increase in CCL-5 and CCL-7 respectively, but not CCL-11, CCL-24 and CCL-26. Chemokine secretion studies of the production of CCL5 and CCL7 by HRPE corroborated with the gene expression analysis data. When the HRPE cells were treated with either individual cytokines or the ICM, both CCL-5 and CCL-7 were produced in a dose dependent manner. Similar to the gene expression data, the ICM did not enhance HRPE production of CCL-11, CCL-24 and CCL-26. CCL-11 and CCL-26 were increased with IL-4 treatment and this HRPE production was augmented in the presence of TNF-alpha and IL1 beta When HCHF cells were treated with either individual cytokines or the ICM, both CCL-5 and CCL-7 were produced in a dose dependent fashion. IL-4 induced low levels of CCL-11 and CCL-26 in HCHF and this production was significantly enhanced by TNF-alpha. Under these conditions, neither HRPE nor HCHF were demonstrated to produce CCL-24. These data demonstrate that chronic inflammation triggers CCL-5 and CCL-7 release by HRPE and HCHF and the subsequent interactions with CCR3 may participate in pathologic processes in AMD.
C1 [Nagineni, Chandrasekharam N.; Kommineni, Vijay K.; Ganjbaksh, Nader; Hooks, John J.] NEI, Lab Immunol, NIH, Bethesda, MD 20892 USA.
   [Nagineni, Krishnasai K.] Univ Maryland, Sch Publ Policy, College Pk, MD 20742 USA.
   [Detrick, Barbara] Johns Hopkins Univ, Dept Pathol, Sch Med, Baltimore, MD 21205 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University System of Maryland; University of Maryland College
   Park; Johns Hopkins University
RP Detrick, B (通讯作者)，Johns Hopkins Med Inst, Baltimore, MD USA.
EM naginenic@mail.nih.gov; bdetrick@jhmi.edu
FU intramural research program of the National Eye Institute, National
   Institutes of Health
FX This research was supported by intramural research program of the
   National Eye Institute, National Institutes of Health.
CR Ambati BK, 2003, INVEST OPHTH VIS SCI, V44, P590, DOI 10.1167/iovs.02-0685
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bachelerie F, 2014, PHARMACOL REV, V66, P1, DOI 10.1124/pr.113.007724
   Berger O, 1999, MOL MED, V5, P795, DOI 10.1007/BF03401992
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Bousquenaud M, 2012, CARDIOVASC RES, V94, P519, DOI 10.1093/cvr/cvs140
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491
   Crane IJ, 1998, CELL IMMUNOL, V98, ps230
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Eyman D, 2009, J CELL PHYSIOL, V220, P376, DOI 10.1002/jcp.21776
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145
   Hooks JJ, 2008, J IMMUNOL, V180, P3789, DOI 10.4049/jimmunol.180.6.3789
   Humbles AA, 2002, P NATL ACAD SCI USA, V99, P1479, DOI 10.1073/pnas.261462598
   Ishida Y, 2012, J CLIN INVEST, V122, P711, DOI 10.1172/JCI43027
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Li YW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017106
   Lilly CM, 2001, AM J RESP CELL MOL, V25, P673, DOI 10.1165/ajrcmb.25.6.f222
   Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706
   Marmor M. F., 1998, RETINAL PIGMENT EPIT, DOI [10.1098/rsif.2015.0563, DOI 10.1098/RSIF.2015.0563]
   Mason AB, 2009, J MOL CELL BIOL, V1, P17, DOI 10.1093/jmcb/mjp011
   Mizutani T, 2013, INVEST OPHTH VIS SCI, V54, P1564, DOI 10.1167/iovs.11-9095
   Momma Y, 2003, INVEST OPHTH VIS SCI, V44, P2026, DOI 10.1167/iovs.02-0980
   Murphy PM, 2000, PHARMACOL REV, V52, P145
   Nagineni CN, 2007, J CELL PHYSIOL, V210, P192, DOI 10.1002/jcp.20839
   Nagineni CN, 2014, AGING DIS, V5, P88, DOI 10.14366/AD.2014.050088
   Nagineni CN, 2012, J CELL PHYSIOL, V227, P116, DOI 10.1002/jcp.22708
   Nagineni CN, 2005, J CELL PHYSIOL, V203, P35, DOI 10.1002/jcp.20213
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   NAGINENI CN, 1994, CLIN DIAGN LAB IMMUN, V1, P569, DOI 10.1128/CDLI.1.5.569-577.1994
   Nakamura H, 2001, AM J PHYSIOL-LUNG C, V281, pL1288, DOI 10.1152/ajplung.2001.281.5.L1288
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Odaka M, 2007, INT ARCH ALLERGY IMM, V143, P84, DOI 10.1159/000101412
   Olson JL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1221, DOI 10.1001/archopht.125.9.1221
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437
   Salcedo R, 2001, J IMMUNOL, V166, P7571, DOI 10.4049/jimmunol.166.12.7571
   Shi G, 2008, INVEST OPHTH VIS SCI, V49, P4620, DOI 10.1167/iovs.08-1816
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   Speyer CL, 2011, J INVEST SURG, V24, P18, DOI 10.3109/08941939.2010.521232
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Suffee N, 2011, BIOCHEM SOC T, V39, P1649, DOI 10.1042/BST20110651
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Wang HB, 2011, INVEST OPHTH VIS SCI, V52, P8271, DOI 10.1167/iovs.11-8230
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Westerweel PE, 2008, THROMB HAEMOSTASIS, V99, P794, DOI 10.1160/TH07-10-0628
   Xie P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028933
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zlotnik A, 2012, IMMUNITY, V36, P705, DOI 10.1016/j.immuni.2012.05.008
NR 62
TC 20
Z9 22
U1 0
U2 1
PU INT SOC AGING & DISEASE
PI FORT WORTH
PA EDITORIAL OFF, 3400 CAMP BOWIE BLVD, FORT WORTH, TX 76106 USA
SN 2152-5250
J9 AGING DIS
JI Aging Dis.
PD DEC
PY 2015
VL 6
IS 6
BP 444
EP 455
PG 12
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA DE2DE
UT WOS:000370435900005
PM 26618046
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Stattin, M
   Forster, J
   Ahmed, D
   Haas, AM
   Graf, A
   Krepler, K
   Ansari-Shahrezaei, S
AF Stattin, Martin
   Forster, Julia
   Ahmed, Daniel
   Haas, Anna-Maria
   Graf, Alexandra
   Krepler, Katharina
   Ansari-Shahrezaei, Siamak
TI Seven-Year Visual and Anatomical Outcomes of Intravitreal Vascular
   Endothelial Growth Factor Inhibition for Neovascular Age-Related Macular
   Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB To evaluate 7-year visual and anatomical outcomes of intravitreal injections (IVI) with antivascular endothelial growth factor (anti-VEGF) for neovascular age-related macular degeneration (nAMD) based on a personalized pro re nata (PRN) regimen. Methods. Anonymized data of 124 consecutive eyes in 121 patients with treatment-naive nAMD were initially collected in 2010. Of those, 45 received anti-VEGF IVI at least every 6months until 2017 in one single center in Austria and hence were retrospectively analyzed. All eyes had been initiated on a loading dose of 3 monthly IVI with different anti-VEGF agents followed by a PRN regimen in the first year. At year 2, monitoring as well as therapeutic intervention could be prolonged every 2weeks up to intervals of 3months without capping treatment. Primary outcome measure was the change of visual acuity (VA) assessed by Early Treatment Diabetic Retinopathy Study charts at 4 meters (ETDRS) in letters-counting every correctly read letter-and converted to Snellen. Secondary outcome measures were number of injections and change of central retinal thickness (CMT) from baseline. Results. Mean baseline VA was 20/63 + 1 (0.63 +/- 0.26 ETDRS) and declined to 20/100 + 2 (0.45 +/- 0.33) with an overall loss of 9 letters ETDRS after 7years (p. 0.001). An average of 3.5 +/- 1.9 IVI was given per year and eye. Mean CMT at baseline was 322 +/- 95 mu m, decreased by 52 mu m to 270 +/- 70 mu m within the first year, and remained below baseline at year 7 (271 +/- 106 mu m; p < 0.001). Conclusions. Our data confirm an absolute vision loss in eyes compromised by nAMD after 7 years of continuous VEGF inhibition. -e visual decline was significantly related to baseline VA as well as the number of injections. We suggest following patients thoroughly independent of the initial VA and a greater incentive for the physician to treat.
C1 [Stattin, Martin; Forster, Julia; Ahmed, Daniel; Haas, Anna-Maria; Krepler, Katharina; Ansari-Shahrezaei, Siamak] Karl Landsteiner Inst Retinal Res & Imaging, Vienna, Austria.
   [Stattin, Martin; Ahmed, Daniel; Haas, Anna-Maria; Krepler, Katharina; Ansari-Shahrezaei, Siamak] Rudolf Fdn Hosp, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.
   [Graf, Alexandra] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Spitalgasse 23, A-1090 Vienna, Austria.
   [Ansari-Shahrezaei, Siamak] Med Univ Graz, Dept Ophthalmol, Auenbruggerpl 1, A-8036 Graz, Austria.
C3 Medical University of Vienna; Medical University of Graz
RP Ansari-Shahrezaei, S (通讯作者)，Karl Landsteiner Inst Retinal Res & Imaging, Vienna, Austria.; Ansari-Shahrezaei, S (通讯作者)，Rudolf Fdn Hosp, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.; Ansari-Shahrezaei, S (通讯作者)，Med Univ Graz, Dept Ophthalmol, Auenbruggerpl 1, A-8036 Graz, Austria.
EM siamak.ansari-shahrezaei@wienkav.at
OI Ansari Shahrezaei, Siamak/0000-0001-8032-4686; Graf,
   Alexandra/0000-0003-0035-2658
CR Berg K, 2017, ACTA OPHTHALMOL, V95, P796, DOI 10.1111/aos.13522
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Danyliv A, 2017, ADV THER, V34, P611, DOI 10.1007/s12325-017-0484-0
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Pedrosa AC, 2016, CLIN OPHTHALMOL, V10, P541, DOI 10.2147/OPTH.S90913
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Stattin M, 2019, ACTA OPHTHALMOL, V97, pE131, DOI 10.1111/aos.13840
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group, OPHTHALMOLOGY, V121, P1092
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Zhu MD, 2015, GRAEF ARCH CLIN EXP, V253, P1217, DOI 10.1007/s00417-014-2799-8
NR 28
TC 2
Z9 2
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD FEB 14
PY 2020
VL 2020
AR 8345850
DI 10.1155/2020/8345850
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QJ7IP
UT WOS:000619860300001
PM 32211201
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Tsai, DC
   Chen, SJ
   Huang, CC
   Yuan, MK
   Leu, HB
AF Tsai, Der-Chong
   Chen, Shih-Jen
   Huang, Chin-Chou
   Yuan, May-Kang
   Leu, Hsin-Bang
TI Age-Related Macular Degeneration and Risk of Degenerative Dementia among
   the Elderly in Taiwan A Population-Based Cohort Study
SO OPHTHALMOLOGY
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; CENTRAL SEROUS CHORIORETINOPATHY;
   ALZHEIMERS-DISEASE; COGNITIVE IMPAIRMENT; JAPANESE PATIENTS; EYE
   DISEASE; BETA; MACULOPATHY; ANGIOGENESIS; PREVALENCE
AB Purpose: To investigate the relationship between age-related macular degeneration (AMD) and future development of Alzheimer's disease (AD) or senile dementia.
   Design: A longitudinal case-control study using the Taiwan National Health Insurance Research Database.
   Participants: From 2001 to 2009, the newly diagnosed AMD cases aged >= 65 years in the database were recruited as the AMD cohort (n = 4993). Of those, there were 540 with and 4453 without exudative AMD diagnoses. Subjects without any AMD, matched for age, gender, and time of enrollment, were randomly sampled as the control cohort (n = 24 965) for comparison.
   Methods: Alzheimer's disease/senile dementia-free survival analysis was assessed using a Kaplane-Meier method. Cox proportional hazard regressions were performed to calculate the hazard ratios (HR) of AD or senile dementia for the 2 cohorts after adjusting for preexisting comorbidities and number of clinical visits.
   Main Outcome Measures: The first-ever diagnosis of AD or senile dementia during the observation period.
   Results: Of the 29 958 sampled subjects, 1589 (5.3%) were diagnosed with AD or senile dementia during a mean follow-up period of 4.4 years, including 294 (5.9%) from the AMD cohort and 1295 (5.2%) from the control cohort. The incidence of AD or senile dementia was higher in patients with AMD than in the controls (P = 0.044), with an HR of 1.44 (95% confidence interval [CI], 1.26-1.64) after adjusting for covariates. The stratified analysis showed that the adjusted HR for AD or senile dementia was 1.35 (95% CI, 0.89-2.06) for exudative AMD versus the controls and 1.44 (95% CI, 1.26-1.65) for nonexudative AMD versus the controls.
   Conclusions: This study provides large-scale, population-based evidence that AMD, especially nonexudative AMD, is independently associated with an increased risk of subsequent AD or senile dementia development. (C) 2015 by the American Academy of Ophthalmology.
C1 [Tsai, Der-Chong] Natl Yang Ming Univ Hosp, Dept Ophthalmol, Yilan, Taiwan.
   [Tsai, Der-Chong; Chen, Shih-Jen; Huang, Chin-Chou; Yuan, May-Kang; Leu, Hsin-Bang] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan.
   [Chen, Shih-Jen] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Huang, Chin-Chou] Natl Yang Ming Univ, Inst Pharmacol, Taipei 112, Taiwan.
   [Huang, Chin-Chou; Leu, Hsin-Bang] Natl Yang Ming Univ, Cardiovasc Res Ctr, Taipei 112, Taiwan.
   [Huang, Chin-Chou; Leu, Hsin-Bang] Taipei Vet Gen Hosp, Dept Med, Div Cardiol, Taipei, Taiwan.
   [Huang, Chin-Chou] Taipei Vet Gen Hosp, Dept Med Res & Educ, Taipei, Taiwan.
   [Yuan, May-Kang] Natl Yang Ming Univ Hosp, Dept Radiol, Yilan, Taiwan.
   [Leu, Hsin-Bang] Taipei Vet Gen Hosp, Healthcare & Management Ctr, Taipei 112, Taiwan.
C3 National Yang Ming Chiao Tung University; Taipei Veterans General
   Hospital; National Yang Ming Chiao Tung University; National Yang Ming
   Chiao Tung University; Taipei Veterans General Hospital; Taipei Veterans
   General Hospital; Taipei Veterans General Hospital
RP Leu, HB (通讯作者)，Taipei Vet Gen Hosp, Healthcare & Management Ctr, 201,Sec 2,Shih Pai Rd, Taipei 112, Taiwan.
EM hbleu@vghtpe.gov.tw
FU National Yang-Ming University Hospital, Yilan, Taiwan [RD 2014-024];
   Taipei Veterans General Hospital, Taipei, Taiwan [V99B1-011, V99C1-125,
   V100B-013]; Yen Tjing Ling Medical Foundation, Taipei, Taiwan [CI-97-13,
   CI-98-16]; MOST-Free Style Excellent Project (NCTU-NYMU-UCSD); National
   Science Council [NSC 100-2314-B-075-055]
FX Supported in part by research grants from RD 2014-024 from National
   Yang-Ming University Hospital, Yilan, Taiwan; V99B1-011, V99C1-125, and
   V100B-013 from Taipei Veterans General Hospital, Taipei, Taiwan;
   CI-97-13 and CI-98-16 from the Yen Tjing Ling Medical Foundation,
   Taipei, Taiwan; MOST-2015-Free Style Excellent Project (NCTU-NYMU-UCSD),
   and NSC 100-2314-B-075-055 from the National Science Council. The
   sponsor or funding organization had no role in the design or conduct of
   this research.
CR Al-Salem Khalil M, 2014, Retina, V34, P868, DOI 10.1097/IAE.0000000000000006
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   Biron KE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023789
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Chen SN, 2015, RETINA-J RET VIT DIS, V35, P231, DOI 10.1097/IAE.0000000000000278
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Chung SD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120003
   Chung SD, 2015, ACTA OPHTHALMOL, V93, pE176, DOI 10.1111/aos.12478
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Ikram MK, 2012, J NEUROL NEUROSUR PS, V83, P917, DOI 10.1136/jnnp-2011-301628
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jefferies WA, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt230
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Keenan TDL, 2014, JAMA OPHTHALMOL, V132, P63, DOI 10.1001/jamaophthalmol.2013.5696
   Keenan TDL, 2012, BRIT J OPHTHALMOL, V96, P413, DOI 10.1136/bjophthalmol-2011-300338
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Lindekleiv H, 2013, EYE, V27, P1281, DOI 10.1038/eye.2013.181
   Liu CK, 1996, J FORMOS MED ASSOC, V95, P762
   Liu CK, 1998, NEUROLOGY, V50, P1572, DOI 10.1212/WNL.50.6.1572
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Ong SY, 2012, ARCH OPHTHALMOL-CHIC, V130, P895, DOI 10.1001/archophthalmol.2012.152
   Pham TQ, 2006, GERONTOLOGY, V52, P353, DOI 10.1159/000094984
   Rozzini L, 2014, AM J ALZHEIMERS DIS, V29, P256, DOI 10.1177/1533317513517032
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Tarkowski E, 2002, NEUROBIOL AGING, V23, P237, DOI 10.1016/S0197-4580(01)00285-8
   Tsai DC, 2014, RETINA-J RET VIT DIS, V34, P1867, DOI 10.1097/IAE.0000000000000159
   Tsai DC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066858
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Vagnucci AH, 2003, LANCET, V361, P605, DOI 10.1016/S0140-6736(03)12521-4
   Wong TY, 2002, AM J OPHTHALMOL, V134, P828
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
   Yang SP, 2004, NEUROBIOL AGING, V25, P283, DOI 10.1016/S0197-4580(03)00111-8
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
NR 39
TC 40
Z9 40
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2015
VL 122
IS 11
BP 2327
EP +
DI 10.1016/j.ophtha.2015.07.033
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CU4IQ
UT WOS:000363491800036
PM 26337003
DA 2022-11-30
ER

PT J
AU Boltz, A
   Ruiss, M
   Jonas, JB
   Tao, Y
   Rensch, F
   Weger, M
   Garhofer, G
   Frantal, S
   El-Shabrawi, Y
   Schmetterer, L
AF Boltz, Agnes
   Ruiss, Manuel
   Jonas, Jost B.
   Tao, Yong
   Rensch, Florian
   Weger, Martin
   Garhoefer, Gerhard
   Frantal, Sophie
   El-Shabrawi, Yosuf
   Schmetterer, Leopold
TI Role of Vascular Endothelial Growth Factor Polymorphisms in the
   Treatment Success in Patients with Wet Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; FACTOR GENE POLYMORPHISMS; CHOROIDAL
   NEOVASCULARIZATION; VEGF POLYMORPHISMS; BREAST-CANCER; RANIBIZUMAB;
   RISK; ASSOCIATION; BEVACIZUMAB; ROTTERDAM
AB Purpose: Along with environmental risk factors such as smoking, hypertension, and atherosclerosis, genetic susceptibility is a primary contributor to the development and progression of exudative age-related macular degeneration (AMD). Vascular endothelial growth factor (VEGF) is a central angiogenic regulator and there has been general agreement now that it is an important trigger for the progression of exudative AMD. In the present study, we tested the hypothesis that VEGF gene polymorphisms play a role in the treatment success with VEGF inhibitors in patients with exudative AMD.
   Design: Prospective cohort study.
   Participants: We included 185 eyes of 141 patients with exudative AMD who were scheduled for their first treatment with intravitreally administered bevacizumab in this trial.
   Methods: All patients were aged >50 years and had angiographically verified exudative AMD. Blood from the finger pad was collected on blood cards for genotyping for the VEGF polymorphisms rs1413711, rs3025039, rs2010963, rs833061, rs699947, rs3024997, and rs1005230. At each follow-up visit, visual acuity was reassessed and an ophthalmic examination was carried out. Visual acuity outcome, number of retreatments, and overall time of treatment were analyzed in dependence of the VEGF polymorphisms.
   Main Outcome Measures: Mean change in visual acuity at the end of the treatment period.
   Results: The included patients were reinjected with bevacizumab 1 to 15 times, resulting in a total treatment period of 42 to 1182 days. In univariate analysis only the G/G genotypes of rs3024997 and rs2010963 compared with all other 5 single nucleotide polymorphisms (SNPs) showed a significantly lower visual acuity at the end of treatment. In multivariate analysis including parameters such as time, baseline visual acuity, and number of reinjections, none of the SNPs showed a significant correlation.
   Conclusions: The current study indicates that VEGF polymorphisms are not major predictors of anti-VEGF treatment success in patients with exudative AMD.
   Financial Disclosure(s): The authors have no proprietary or commercial interest in any of the materials discussed in this article. Ophthalmology 2012;119:1615-1620 (C) 2012 by the American Academy of Ophthalmology.
C1 [Boltz, Agnes; Ruiss, Manuel; Garhoefer, Gerhard; Schmetterer, Leopold] Med Univ Vienna, Dept Clin Pharmacol, A-1090 Vienna, Austria.
   [Boltz, Agnes; Schmetterer, Leopold] Med Univ Vienna, Ctr Med Phys & Biomed Engn, A-1090 Vienna, Austria.
   [Jonas, Jost B.; Tao, Yong; Rensch, Florian] Heidelberg Univ, Dept Ophthalmol, D-6800 Mannheim, Germany.
   [Weger, Martin; El-Shabrawi, Yosuf] Med Univ Graz, Dept Ophthalmol, Graz, Austria.
   [Frantal, Sophie] Med Univ Vienna, Ctr Med Stat Informat & Intelligence Syst, A-1090 Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna; Ruprecht
   Karls University Heidelberg; Medical University of Graz; Medical
   University of Vienna
RP Schmetterer, L (通讯作者)，Med Univ Vienna, Dept Clin Pharmacol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM leopold.schmetterer@meduniwien.ac.at
OI Schmetterer, Leopold/0000-0002-7189-1707
CR Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Appelmann I, 2010, RECENT RESULTS CANC, V180, P51, DOI 10.1007/978-3-540-78281-0_5
   Augustin Albert J, 2006, Expert Opin Emerg Drugs, V11, P725, DOI 10.1517/14728214.11.4.725
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Boltz A, 2010, SPEKTRUM AUGENHEILKD, V24, P296, DOI 10.1007/s00717-010-0445-3
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Churchill AJ, 2008, INVEST OPHTH VIS SCI, V49, P3611, DOI 10.1167/iovs.07-1383
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   DiLoreto DA, 2003, ARCH OPHTHALMOL-CHIC, V121, P1586, DOI 10.1001/archopht.121.11.1586
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fang AM, 2009, MOL VIS, V15, P2710
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hawkins BS, 2011, MOL VIS, V5, P26
   Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037
   Janik-Papis K, 2009, EXP MOL PATHOL, V87, P234, DOI 10.1016/j.yexmp.2009.09.005
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Krippl P, 2003, INT J CANCER, V106, P468, DOI 10.1002/ijc.11238
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Qu Y, 2011, OPHTHALMIC RES, V45, P142, DOI 10.1159/000319543
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Richardson AJ, 2007, MOL VIS, V13, P2148
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Schneider BP, 2008, J CLIN ONCOL, V26, P4672, DOI 10.1200/JCO.2008.16.1612
   Schultheis AM, 2008, CLIN CANCER RES, V14, P7554, DOI 10.1158/1078-0432.CCR-08-0351
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tang NP, 2009, ANN EPIDEMIOL, V19, P740, DOI 10.1016/j.annepidem.2009.03.002
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
NR 44
TC 26
Z9 31
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2012
VL 119
IS 8
BP 1615
EP 1620
DI 10.1016/j.ophtha.2012.02.001
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 982YA
UT WOS:000307080100019
PM 22521084
DA 2022-11-30
ER

PT J
AU Barak, A
   Hauser, D
   Yipp, P
   Morse, L
   Leigh, B
   Kubo, D
   Goldberg, Z
   Earle, J
   Handa, JT
AF Barak, A
   Hauser, D
   Yipp, P
   Morse, L
   Leigh, B
   Kubo, D
   Goldberg, Z
   Earle, J
   Handa, JT
TI A phase I trial of stereotactic external beam radiation for subfoveal
   choroidal neovascular membranes in age-related macular degeneration
SO BRITISH JOURNAL OF RADIOLOGY
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIAL; RADIOTHERAPY; THERAPY; TELETHERAPY
AB Effective treatment for neovascular age-related macular degeneration (AMD) is currently limited. Radiation therapy, a therapeutic approach with known antiangiogenic properties, has been investigated as a modality to prevent severe visual loss in AMD. Most of the studies using external beam radiation employed < 25 Gy to the whole eye, which is below the dose of radiation that is toxic to the retina and optic nerve (similar to 50 Gy and similar to 59 Gy, respectively). Stereotactic fractionated external beam radiation (St-EBR) is a method that allows radiation to be delivered to a small, defined area. We investigated the effects of St-EBR in incremental doses up to 40 Gy on neovascular AMD. Patients with clinical signs and fluorescein angiography demonstrating neovascular AMD, visual acuity (VA) better than 20/400 and ineligible for laser treatment (MPS criteria) or who refused to have laser photocoagulation were enrolled in the study. Each patient was treated with radiation at incremental dosages from 20 Gy to 40 Gy. After completion of the radiation course, all patients were followed-up at 3 and 7 weeks and 3, 6, and 12 months. Best-corrected VA (ETDRS), slit-lamp and fluorescein angiographic evaluations were performed at each visit. 94 eyes of 89 patients were treated from October 1997 to April 2000. The VA was 0.82 +/- 0.35 before treatment, 0.83 +/- 0.36 at 6 months, and 0.89 +/- 0.33 at 12 months. No patients suffered any significant acute side effects. No significant benefits in either VA or in membrane size were derived from increasing the doses of radiation. Our results are consistent with trends of a palliative benefit of radiotherapy in neovascular AMD and support further investigation of radiotherapy. Since there is no evidence that therapeutic effectiveness is dose dependent, our data provide no justification for potentially dangerous escalations in radiation dosage for treating neovascular AMD.
C1 Univ Calif Davis, Dept Ophthalmol, Sacramento, CA 95817 USA.
   Univ Calif Davis, Dept Radiat Oncol, Sacramento, CA 95817 USA.
C3 University of California System; University of California Davis;
   University of California System; University of California Davis
RP Barak, A (通讯作者)，Tel Aviv Sourasky Med Ctr, Dept Ophthalmol, 6 Weizmann St, IL-64239 Tel Aviv, Israel.
OI Morse, Lawrence/0000-0002-1758-2348
CR Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   Bhavsar A, 2004, RETINA-J RET VIT DIS, V24, P512
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   Char DH, 1999, AM J OPHTHALMOL, V127, P574, DOI 10.1016/S0002-9394(99)00038-0
   Ciulla TA, 2002, AM J OPHTHALMOL, V134, P905, DOI 10.1016/S0002-9394(02)01821-4
   Finger PT, 1996, OPHTHALMOLOGY, V103, P878, DOI 10.1016/S0161-6420(96)30592-7
   GORDON KB, 1995, INT J RADIAT ONCOL, V31, P1123, DOI 10.1016/0360-3016(95)00062-4
   GUYER DR, 1986, ARCH OPHTHALMOL-CHIC, V104, P702, DOI 10.1001/archopht.1986.01050170092029
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   Hart PM, 1997, FRONT RADIAT THER ON, V30, P229
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   Kobayashi H, 2000, AM J OPHTHALMOL, V130, P617, DOI 10.1016/S0002-9394(00)00534-1
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   Prettenhofer U, 2004, STRAHLENTHER ONKOL, V180, P91, DOI 10.1007/s00066-004-1177-6
   Sivagnanavel V, 2004, COCHRANE DB SYST REV, V4
   Spaide RF, 1998, OPHTHALMOLOGY, V105, P24, DOI 10.1016/S0161-6420(98)90980-0
   Spaide RF, 1999, OPHTHALMOLOGY, V106, P2254, DOI 10.1016/S0161-6420(99)90524-9
   Stalmans P, 1997, RETINA-J RET VIT DIS, V17, P481
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   Tholen AM, 2000, KLIN MONATSBL AUGENH, V216, P112, DOI 10.1055/s-2000-10528
   Tholen AM, 1998, OPHTHALMOLOGE, V95, P691, DOI 10.1007/s003470050337
   Valmaggia C, 2002, AM J OPHTHALMOL, V133, P521, DOI 10.1016/S0002-9394(02)01336-3
NR 24
TC 11
Z9 11
U1 0
U2 0
PU BRITISH INST RADIOLOGY
PI LONDON
PA 36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND
SN 0007-1285
EI 1748-880X
J9 BRIT J RADIOL
JI Br. J. Radiol.
PD SEP
PY 2005
VL 78
IS 933
BP 827
EP 831
DI 10.1259/bjr/17631422
PG 5
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA 961LP
UT WOS:000231664200010
PM 16110105
DA 2022-11-30
ER

PT J
AU Nahen, K
   Benyamini, G
   Loewenstein, A
AF Nahen, Kester
   Benyamini, Gideon
   Loewenstein, Anat
TI Evaluation of a Self-Imaging SD-OCT System for Remote Monitoring of
   Patients with Neovascular Age Related Macular Degeneration
SO KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
LA English
DT Article
DE remote patient monitoring; telemedicine; optical coherence tomography;
   age related macular degeneration; artificial intelligence
AB Background The treatment of patients with neovascular agerelated macular degeneration (nAMD) requires frequent office visits to identify fluid in the retina that requires treatment. Frequent office-based examinations using optical coherence tomography (OCT) are a burden on patients and their care givers. The development of OCT systems that can be self-operated by patients at home offers the potential for precise remote monitoring and improved individualized therapy.
   Patients/Material and Methods An investigational spectral domain OCT system (Notal Vision Home OCT, NVHO) for automatic patient-guided self-imaging intended for commercialization was evaluated in a total of 69 study participants with neovascular age-related macular degeneration with regard to image quality and usability. An artificial intelligencebased algorithm was used to identify, quantify and map intraand subretinal fluids.
   Results Successful imaging with the NHVO was performed in all patients and in 93% of the enrolled eyes. The positive percent agreement and negative percent agreement for detection of fluid, intraretinal fluid, and subretinal fluid in at least one of three consecutive NHVO images was 97/95%, 96/94% and 100/98%, respectively, when compared to commercial inoffice OCT systems. In 1.4% of the recorded eyes, fluid was only detected outside of the central 10 x 10 degrees field of view but seen on a commercial OCT system with a larger field of view. The device operation for scanning their own eyes without assistance was rated by 95% of patients as easy. The analysis and depiction of fluid distribution and volume in a longitudinal case study illustrated the acute nature and anti-VEGF therapy response of nAMD.
   Conclusion The evaluated OCT system for home use meets the requirements for self-controlled imaging by nAMD patients with regard to image quality, field of view and usability. Image analysis based on artificial intelligence can potentially support clinicians in the assessment and utilization of large amounts of data generated by daily home OCT imaging.
C1 [Nahen, Kester] Notal Vis Inc, Corp Leadership, Manassas, VA 20109 USA.
   [Benyamini, Gideon] Notal Vis Ltd, Corp Leadership, Tel Aviv, Israel.
   [Loewenstein, Anat] Tel Aviv Sourasky Med Ctr, Ophthalmol, Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky
   Medical Center
RP Nahen, K (通讯作者)，Notal Vis Inc, 7717 Coppermine Dr, Manassas, VA 20109 USA.
EM kester@nahen.net
CR [Anonymous], 2020, BEOVU FACHINFORMATIO
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Chakravarthy U, 2016, OPHTHALMOLOGY, V123, P1731, DOI 10.1016/j.ophtha.2016.04.005
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Essex RW, 2016, OPHTHALMOLOGY, V123, P2393, DOI 10.1016/j.ophtha.2016.07.012
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FU DJ, 2020, OPHTHALMOLOGY, DOI DOI 10.1016/J.OPHTHA.2020.06.038
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Maloca P, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.4.8
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mulligan K, 2020, JAMA OPHTHALMOL, V138, P40, DOI 10.1001/jamaophthalmol.2019.4557
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
NR 14
TC 10
Z9 10
U1 0
U2 0
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0023-2165
EI 1439-3999
J9 KLIN MONATSBL AUGENH
JI Klinische Monatsblat. Augenheilkunde
PD DEC
PY 2020
VL 237
IS 12
BP 1410
EP 1418
DI 10.1055/a-1271-6834
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PG3AO
UT WOS:000599611900007
PM 33285588
DA 2022-11-30
ER

PT J
AU Chandra, S
   Arpa, C
   Menon, D
   Khalid, H
   Hamilton, R
   Nicholson, L
   Pal, B
   Fasolo, S
   Hykin, P
   Keane, PA
   Sivaprasad, S
AF Chandra, Shruti
   Arpa, Cristina
   Menon, Deepthy
   Khalid, Hagar
   Hamilton, Robin
   Nicholson, Luke
   Pal, Bishwanath
   Fasolo, Sandro
   Hykin, Philip
   Keane, Pearse A.
   Sivaprasad, Sobha
TI Ten-year outcomes of antivascular endothelial growth factor therapy in
   neovascular age-related macular degeneration
SO EYE
LA English
DT Article
ID GEOGRAPHIC ATROPHY; VISUAL-ACUITY; RANIBIZUMAB; AFLIBERCEPT
AB Purpose Single center, noninterventional cohort study to assess 10-year visual and anatomical outcomes following initiation of treatment with antivascular endothelial growth factor (anti-VEGF) agents in neovascular age-related macular degeneration (AMD) patients. Neovascular AMD patients initiated on intravitreal anti-VEGF injections in 2008-2009 and continued to be followed up for at least 10 years were included in this study. Methods The Moorfields OpenEyes database was searched for all patients who were initiated on anti-VEGF therapy for neovascular AMD in 2008-2009 and the visual acuity (VA) in Early Diabetic Retinopathy Study (ETDRS) letters and injection records were analyzed for those who have had at least 10-year follow-up. The spectral-domain optical coherence tomography (SD-OCT) scans, color fundus photos, and fundus fluorescein angiography (FA) were graded by two retinal physicians. The outcomes were also compared between those with good and poor VA outcomes based on pre-defined criteria. The primary end point was change in VA at 10 years; secondary outcomes included percentage with VA of 20/40 or better, 20/70 or better, VA gains and losses, anatomic outcomes and number of injections. Results After a mean of 10.04 years after initiation of anti-VEGF therapy, the mean decline in VA from baseline was -2.1 ETDRS letters (SD 19.9, p = 0.65). One hundred eyes (67.1%) achieved a VA threshold of 20/70 or better, 33.5% achieved a VA of 20/40 or better, and 76.5% eyes maintained VA defined as a loss of less than 15 letters. Fourteen percent of study eyes had VA of 20/200 or worse and 23.5% declined by 15 letters or more. 87.5% of eyes were switched from ranibizumab to aflibercept during the course of 10 years and the eyes received a mean of 52.2 (SD 18.1) injections over 10 years. From this cohort, 87 (58.3%) eyes are having on-going treatment. On OCT, 34.9% had persistent fluid at the last visit, 6.7% patients showed new onset atrophy compared to baseline, and 43.7% had increased area of macular atrophy. The mean area of atrophy at the final visit was 4.15 mm(2). Comparison between the good and worse visual outcome groups showed lower baseline VA, fovea-involving atrophy and final area of atrophy had a statistically significant negative effect on the final visual outcome (p < 0.05). Conclusions Regular monitoring and anti-VEGF treatment over 10 years reduce the risk of visual loss of 15 letters or more in patients with neovascular AMD. The most common cause of substantial visual decline was macular atrophy.
C1 [Chandra, Shruti; Arpa, Cristina; Menon, Deepthy; Khalid, Hagar; Hamilton, Robin; Nicholson, Luke; Pal, Bishwanath; Fasolo, Sandro; Hykin, Philip; Keane, Pearse A.; Sivaprasad, Sobha] Moorfields Eye Hosp, Natl Inst Hlth Res, Moorfields Biomed Res Ctr, London, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP Chandra, S (通讯作者)，Moorfields Eye Hosp, Natl Inst Hlth Res, Moorfields Biomed Res Ctr, London, England.
EM Shruti.chandra@nhs.net
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659; Arpa, Cristina/0000-0001-9299-0061;
   Keane, Pearse/0000-0002-9239-745X; Chandra, Shruti/0000-0002-2634-9775
FU NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS
   Foundation Trust; UCL Institute of Ophthalmology
FX We would like to thank the Moorfields Medical Retina Group for their
   contribution and collation of patients. The research was supported by
   the NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS
   Foundation Trust and UCL Institute of Ophthalmology.
CR Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Fasler K, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-027441
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Kaiser PK, 2017, OPHTHALMOL RETINA, V1, P304, DOI 10.1016/j.oret.2017.01.004
   Kaynak S, 2018, TURK OFTALMOL DERG, V48, P81, DOI 10.4274/tjo.27448
   Keenan TD, 2019, OPHTHALMOL RETINA, V4, P3
   Lee AY, 2015, BRIT J OPHTHALMOL, V99, P1045, DOI 10.1136/bjophthalmol-2014-306229
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Qin VL, 2018, RETINA-J RET VIT DIS, V38, P1500, DOI 10.1097/IAE.0000000000001753
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarraf D, 2016, OPHTHALMOLOGY, V123, P2213, DOI 10.1016/j.ophtha.2016.07.007
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Wada I, 2019, GRAEF ARCH CLIN EXP, V257, P1411, DOI 10.1007/s00417-019-04361-8
NR 21
TC 35
Z9 35
U1 2
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD OCT
PY 2020
VL 34
IS 10
BP 1888
EP 1896
DI 10.1038/s41433-020-0764-9
EA JAN 2020
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NQ3AN
UT WOS:000509176300001
PM 31980748
OA Green Submitted, Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Christenbury, JG
   Phasukkijwatana, N
   Gilani, F
   Freund, KB
   Sadda, S
   Sarraf, D
AF Christenbury, Joseph G.
   Phasukkijwatana, Nopasak
   Gilani, Fatimah
   Freund, K. Bailey
   Sadda, Srinivas
   Sarraf, David
TI PROGRESSION OF MACULAR ATROPHY IN EYES WITH TYPE 1 NEOVASCULARIZATION
   AND AGE-RELATED MACULAR DEGENERATION RECEIVING LONG-TERM INTRAVITREAL
   ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY An Optical Coherence
   Tomographic Angiography Analysis
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE Type 1 neovascularization; OCT angiography; anti-VEGF therapy;
   geographic atrophy; age-related macular degeneration
ID RETINAL-PIGMENT EPITHELIUM; GOOD VISUAL-ACUITY; GEOGRAPHIC ATROPHY;
   CHOROIDAL THICKNESS; RANIBIZUMAB; ANCHOR
AB Purpose: To evaluate the size and location of macular atrophy in eyes with Type-1 neovascularization (NV) and age-related macular degeneration receiving chronic intravitreal anti-vascular endothelial growth factor therapy.
   Methods: A retrospective review of a case series of 27 eyes with Type-1 NV and retinal pigment epithelial detachment (PED) having a minimum of 12 months follow-up was performed. Demographic information and visual acuity at baseline and the final follow-up were collected. Spectral-domain optical coherence tomography (OCT) and near-infrared reflectance were analyzed at 6-month intervals to detect and measure macular atrophy. Location and area (in square millimeter) of macular atrophy were measured using Heidelberg software tools. Also, OCT angiography was used to colocalize the area of Type-1 NV flow versus the location of atrophy.
   Results: Twenty-seven eyes of 27 patients were included in this analysis. The median visual acuity was 20/50, mean age was 82.7 years, and mean number of injections was 29.5. A larger percentage of eyes (59.3%) developed atrophy predominantly eccentric to the PED versus predominantly overlying the PED (11.1%) when measured with spectral-domain OCT and near-infrared imaging. At the final follow-up, there was a larger area of atrophy surrounding the fibrovascular PED (mean, 3.326 mm(2)) than overlying it (mean, 0.542 mm(2)), and this was statistically significant (P = 0.0118). En-face OCT images were overlaid with OCT angiography in 11 eyes, and a predominantly eccentric pattern of atrophy was identified in 9 of 11 eyes. Using this method, the mean area of atrophy predominantly overlying the Type-1 NV was 1.652 mm(2) (range of 0-10.464 mm(2)), whereas the area of atrophy predominantly eccentric to the neovascular complex was 4.345 mm(2) (range of 0.705-13.758 mm(2)), and this was statistically significant (P = 0.0465). The average rate of atrophy progression was 1.04 mm(2)/year (SD 0.938).
   Conclusion: With long-term anti-vascular endothelial growth factor therapy for eyes with Type-1 NV secondary to age-related macular degeneration, macular atrophy tends to develop predominantly eccentric to the PED and the neovascular flow imaged on OCT angiography. With chronic vascular endothelial growth factor suppression, Type-1 NV may evolve into a multilayered PED that may confer a protective effect to the overlying retinal pigment epithelium and outer retina.
C1 [Christenbury, Joseph G.; Phasukkijwatana, Nopasak; Sarraf, David] Univ Calif Los Angeles, Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90095 USA.
   [Gilani, Fatimah; Freund, K. Bailey] Vitreous Macula Retina Consultants, New York, NY USA.
   [Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, 550 1St Ave, New York, NY 10016 USA.
   [Sadda, Srinivas] Univ Calif Los Angeles, Doheny Eye Inst, Retina & Macular Dis Div, Los Angeles, CA 90095 USA.
   [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
C3 University of California System; University of California Los Angeles;
   New York University; Doheny Eye Institute; University of California
   System; University of California Los Angeles; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles
   Healthcare System
RP Sarraf, D (通讯作者)，Univ Calif Los Angeles, Stein Eye Inst, 100 Stein Plaza, Los Angeles, CA 90095 USA.
EM dsarraf@ucla.edu
RI Phasukkijwatana, Nopasak/T-8630-2019; Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU Macula Foundation, Inc, New York, NY; Allergan; Heidelberg; Genentech;
   Optovue; Regeneron
FX Supported in part by The Macula Foundation, Inc, New York, NY.; K. B.
   Freund is a consultant to Genentech, Optos, Optovue, Heidelberg
   Engineering, and Bayer HealthCare. D. Sarraf is a consultant to Bayer,
   Genentech, Novartis, and Optovue and receives research grants from
   Allergan, Heidelberg, Genentech, Optovue and Regeneron. The remaining
   authors have no conflicting interests to disclose.
CR Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   Bhavsar KV, 2014, SAUDI J OPHTHALMOL, V28, P129, DOI 10.1016/j.sjopt.2014.03.001
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chen XJ, 2016, RETINA-J RET VIT DIS, V36, pS50, DOI 10.1097/IAE.0000000000001271
   Dansingani KK, 2015, OSLI RETINA, V46, P907, DOI 10.3928/23258160-20151008-02
   Dhrami-Gavazi E, 2015, INT J RETINA VITREOU, V1, P1
   Govetto A, 2017, BRIT J OPHTHALMOL, V101, P764, DOI 10.1136/bjophthalmol-2016-309281
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242
   KLEIN ML, 1989, OPHTHALMOLOGY, V96, P1416
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Kumar N, 2013, OPHTHALMOLOGY, V120, P334, DOI 10.1016/j.ophtha.2012.07.076
   Kuroda Y, 2016, AM J OPHTHALMOL, V161, P94, DOI 10.1016/j.ajo.2015.09.032
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Rahimy E, 2014, RETINA-J RET VIT DIS, V34, P1289, DOI 10.1097/IAE.0000000000000130
   Razavi S, 2015, AM J OPHTHALMOL, V160, P1006, DOI 10.1016/j.ajo.2015.08.009
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sarks J, 2006, BRIT J OPHTHALMOL, V90, P442, DOI 10.1136/bjo.2005.083022
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Vaclavik V, 2008, OPHTHALMOLOGY, V115, P342, DOI 10.1016/j.ophtha.2007.04.023
   VANDER JF, 1989, OPHTHALMOLOGY, V96, P1422
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 35
TC 30
Z9 30
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2018
VL 38
IS 7
BP 1276
EP 1288
DI 10.1097/IAE.0000000000001766
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP2CX
UT WOS:000440630000009
PM 28723848
DA 2022-11-30
ER

PT J
AU Hwang, JC
   Chan, JWK
   Chang, S
   Smith, RT
AF Hwang, John Chopin
   Chan, Jackie W. K.
   Chang, Stanley
   Smith, R. Theodore
TI Predictive value of fundus autofluorescence for development of
   geographic atrophy in age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; THRESHOLD SELECTION; GRADING SYSTEM;
   LIPOFUSCIN; MACULOPATHY; RPE; CLASSIFICATION; DYSTROPHY; DRUSEN; CELLS
AB PURPOSE. It has been suggested that lipofuscin accumulation, as measured by increased fundus autofluorescence (FAF), precedes progression or development of junctional zone geographic atrophy (GA) in age-related macular degeneration (AMD). The tools of biomedical image analysis were used to measure the probabilistic relationship of GA progression to increased FAF.
   METHODS. Serial AF images of eight eyes of six patients with AMD with GA were registered on computer. The images were leveled with a 12-zone quadratic polynomial mathematical model to minimize background variability. Semiautomated segmentation of GA was performed on the leveled images. Increased FAF was defined as a gray level greater than 2 standard deviations above the leveled image mean, identified on the initial image with automated segmentation, and measured as a fraction of the 250-mu m border zone surrounding the initial GA lesion. Areas of GA lesions were identified on the final image. The positive predictive value (PPV) of increased FAF was determined as the probability that any pixel with increased FAF in the initial image would become part of new GA in the final image. Relative PPV was determined relative to the total quantity of new GA. The NPV (NPV) of increased FAF was calculated as the probability that any pixels without increased FAF would not become atrophic. The relative NPV was determined similarly. A similar analysis was also conducted with a 500-mu m border zone to determine the predictive value of proximity to the original GA lesion ("proximity") for GA progression.
   RESULTS. As a fraction of the geographic atrophy border zone, the mean new GA was 0.44 +/- 0.20, and the mean increased FAF was 0.06 +/- 0.06. The mean PPV of increased FAF for new GA formation was 0.50 +/- 0.26. Compared with the relative PPV of chance of 1.0, the mean relative PPV of increased FAF was 1.15 +/- 0.28. The mean NPV of increased FAF was 0.57 +/- 0.20. The mean relative NPV of increased FAF was 1.00 +/- 0.02. In the 500-mu m border zone, the mean relative PPV of FAF and of proximity were essentially equal (1.56 +/- 0.70 and 1.52 +/- 0.26, respectively), whereas the mean relative NPV Of proximity was significantly greater than that of FAF (1.26 +/- 0.19 and 1.01 +/- 0.01, respectively, P = 0.02)
   CONCLUSIONS. The results of digital image analysis suggest that although increased FAF may have a modest PPV for new GA development, the relative PPV is generally no greater than chance. Similarly, the relative NPV demonstrates negligible difference from chance and is also lower than the relative NPV of proximity. This suggests that increased FAF, though a disease manifestation, is not a strong risk factor for development or extension of GA.
C1 Columbia Univ, Dept Ophthalmol, New York, NY 10032 USA.
C3 Columbia University
RP Smith, RT (通讯作者)，Columbia Univ, Dept Ophthalmol, 635 W 165 St,314, New York, NY 10032 USA.
EM rts1@columbia.edu
RI Chang, Stanley/AAL-2741-2021
OI HWANG, JOHN/0000-0001-7384-1968; smith, theodore/0000-0002-1693-943X
FU NEI NIH HHS [R01 EY015520-01A2, R01 EY015520-02, R01 EY015520] Funding
   Source: Medline; NATIONAL EYE INSTITUTE [R01EY015520] Funding Source:
   NIH RePORTER
CR Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   BOULTON M, 1989, INVEST OPHTH VIS SCI, V30, P82
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   FRANGIEH GT, 1982, ARCH OPHTHALMOL-CHIC, V100, P1115
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Katz ML, 1996, MECH AGEING DEV, V92, P159, DOI 10.1016/S0047-6374(96)01817-9
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   OGORMAN S, 1988, ARCH OPHTHALMOL-CHIC, V106, P1261
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   RUCKMANN A, 1997, INVEST OPHTH VIS SCI, V38, P478
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Smith RT, 2005, INVEST OPHTH VIS SCI, V46, P2940, DOI 10.1167/iovs.04-0778
   Smith RT, 2005, ARCH OPHTHALMOL-CHIC, V123, P200, DOI 10.1001/archopht.123.2.200
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sunness JS, 1999, MOL VIS, V5
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009
NR 30
TC 84
Z9 88
U1 0
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2006
VL 47
IS 6
BP 2655
EP 2661
DI 10.1167/iovs.05-1027
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 048LQ
UT WOS:000237949000053
PM 16723483
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Casalino, G
   Bandello, F
   Chakravarthy, U
AF Casalino, Giuseppe
   Bandello, Francesco
   Chakravarthy, Usha
TI Changes in Neovascular Lesion Hyperreflectivity After Anti-VEGF
   Treatment in Age-Related Macular Degeneration: An Integrated Multimodal
   Imaging Analysis
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE color fundus photography; hyperreflective material; multimodal imaging;
   neovascular age-related macular degeneration; retinal angiography;
   spectral-domain optical coherence tomography
ID OPTICAL COHERENCE TOMOGRAPHY; GROWTH-FACTOR THERAPY; CHOROIDAL
   NEOVASCULARIZATION; ANGIOGRAPHY
AB PURPOSE. To correlate presence of hyperreflective material (HRM) on spectral-domain optical coherence tomography (SD-OCT) with color fundus photography (CFP) in patients with different subtypes of neovascular age-related macular degeneration (n-AMD).
   METHODS. Retrospective assessments were made at baseline and months 1, 3, and 12 after initiation of treatment. At baseline, CFP images were graded for the presence of blood, fibrin and lipid exudates, and retinal angiograms for n-AMD subtype. At the four selected visits, SD-OCT scans were graded for HRM type (well-defined or undefined) and location (subretinal, intraretinal, and subretinal pigment epithelium [RPE]), integrity of RPE, ellipsoid zone, and external limiting membrane (ELM).
   RESULTS. A total of 121 eyes with active n-AMD from 117 patients were included. At baseline, undefined HRM was strongly associated with fibrin on CFP (chi(2) = 39.87; P < 0.001). The overall prevalence of HRM decreased from 85.9% at baseline to 52.9% by month 12. From baseline to month 12, undefined HRM decreased (53.7% vs. 7.4%, respectively) and well-defined HRM increased (32.2% vs. 45.5%, respectively). Sub-RPE HRM, which was infrequent at baseline, increased up to 30.6% by month 12. At month 12, eyes with no HRM had the best mean final best-corrected visual acuity (BCVA), and those with undefined HRM the worst. Multivariate regression analysis showed that ELM disruption at both baseline and month 12 was a negative predictive factor for final BCVA (P = 0.001 and P < 0.001, respectively), whereas presence of subretinal fluid at month 12 and number of treatments were positive predictors for final BCVA (P = 0.007 and P = 0.041, respectively), but the covariates describing HRM did not reach statistical significance in these models.
   CONCLUSIONS. In eyes with n-AMD, location and morphology of HRM changed after anti-VEGF treatment, and differences were observed in the various choroidal neovascularization (CNV) subtypes. After anti-VEGF treatment, it was well-defined HRM in the sub-RPE space that was observed mostly.
C1 [Casalino, Giuseppe; Chakravarthy, Usha] Queens Univ Belfast, Ophthalmol Macular Serv, Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland.
   [Casalino, Giuseppe; Chakravarthy, Usha] Queens Univ Belfast, Ctr Med Expt, Belfast, Antrim, North Ireland.
   [Casalino, Giuseppe; Bandello, Francesco] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Dept Ophthalmol, Milan, Italy.
C3 Queens University Belfast; Queens University Belfast; Vita-Salute San
   Raffaele University; IRCCS Ospedale San Raffaele
RP Chakravarthy, U (通讯作者)，Queens Univ Belfast, Ctr Med Expt, Sch Med Dent & Biomed Sci, Inst Clin Sci, Block A Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.
EM U.Chakravarthy@qub.ac.uk
RI Casalino, Giuseppe/I-1729-2019; bandello, francesco/AAH-2405-2019
OI Casalino, Giuseppe/0000-0002-0208-0740; bandello,
   francesco/0000-0003-3238-9682; Chakravarthy, Usha/0000-0002-2606-3734
CR Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
   Charafeddin W, 2015, OSLI RETINA, V46, P523, DOI 10.3928/23258160-20150521-03
   Coscas F, 2015, INVEST OPHTH VIS SCI, V56, P4129, DOI 10.1167/iovs.15-16735
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Giani A, 2011, RETINA-J RET VIT DIS, V31, P942, DOI 10.1097/IAE.0b013e31820a68cc
   Hogg R, 2003, BRIT J OPHTHALMOL, V87, P609, DOI 10.1136/bjo.87.5.609
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Introini U, 2012, EYE, V26, P976, DOI 10.1038/eye.2012.75
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Ores R, 2014, AM J OPHTHALMOL, V158, P354, DOI 10.1016/j.ajo.2014.04.025
   Sayanagi K, 2009, BRIT J OPHTHALMOL, V93, P622, DOI 10.1136/bjo.2008.151977
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Shah VP, 2014, RETINA-J RET VIT DIS, V34, P1281, DOI 10.1097/IAE.0000000000000166
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Witkin AJ, 2009, OPHTHALMOLOGY, V116, P956, DOI 10.1016/j.ophtha.2008.12.018
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 26
TC 29
Z9 29
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2016
VL 57
IS 9
BP OCT288
EP OCT298
DI 10.1167/iovs.15-18753
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DW9MY
UT WOS:000383985400027
PM 27409485
OA gold
DA 2022-11-30
ER

PT J
AU Leon, PE
   Saviano, S
   Zanei, A
   Pastore, MR
   Guaglione, E
   Mangogna, A
   Tognetto, D
AF Leon, Pia E.
   Saviano, Sandro
   Zanei, Andrea
   Pastore, Marco R.
   Guaglione, Elvira
   Mangogna, Alessandro
   Tognetto, Daniele
TI Spontaneous or secondary to intravitreal injections of anti-angiogenic
   agents retinal pigment epithelial tears in age-related macular
   degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE retinal pigment epithelial; age-related macular degeneration; tears;
   visual acuity; anti-vascular endothelial growth factor treatment
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION; BEVACIZUMAB
   AVASTIN; VEGF THERAPY; FOLLOW-UP; PATHOGENESIS; RANIBIZUMAB; DETACHMENT;
   EYES
AB AIM: To evaluate the visual function evolution of retinal pigment epithelial (RPE) tears in patients with age-related macular degeneration (AMD) according to type of occurrence [spontaneous or secondary to anti-vascular endothelial growth factor (anti-VEGF) injection] and the topographic location of the tear after a two-year follow-up period.
   METHODS: A total of 15 eyes of 14 patients with RPE tears in exudative AMD were analyzed retrospectively at the University Eye Clinic of Trieste. Inclusion criteria were: patient age of 50 or older with AMD and RPE tears both spontaneous occurring or post anti-VEGF treatment. Screening included: careful medical history, complete ophthalmological examination, fluorescein angiography (FA), indocyanine green angiography (ICG), autofluorescence and infrared imaging and optical coherence tomography (OCT). Patients were evaluated every month for visual acuity (VA), fundus examination and OCT. Other data reported were: presence of PED, number of injections before the tear, location of the lesion.
   RESULTS: Mean follow-up was 24wk (SD +/- 4wk). A total of 15 eyes were studied for RPE tear. In 6 cases (40%), the RPE tears occurred within two years of anti-VEGF injections the others occurred spontaneously. In 13 cases (86.6%), the RPE tear was associated with pigment epithelial detachment (PED). In 7 cases (46.6%), the RPE tear occurred in the central area of the retina and involved the fovea. Two lesions were found in the parafoveal region, six in the extra-macular area. In all cases visual acuity decreased at the end of the follow-up period (P<0.01) independently of the type or the topographical location of the lesion.
   CONCLUSION: RPE tear occurs in exudative AMD as a spontaneous complication or in relation to anti-VEGF injections. Visual acuity decreased significantly and gradually in the follow-up period in all cases. No correlation was found between visual loss and the type of onset or the topographic location of the tears.
C1 [Leon, Pia E.; Saviano, Sandro; Zanei, Andrea; Pastore, Marco R.; Guaglione, Elvira; Mangogna, Alessandro; Tognetto, Daniele] Univ Eye Clin Trieste, Osped Maggiore, I-34125 Trieste, Italy.
C3 University of Trieste
RP Leon, PE (通讯作者)，Univ Eye Clin Trieste, Osped Maggiore, Piazza Ospitale 1, I-34125 Trieste, Italy.
EM pialeon@libero.it
RI Mangogna, Alessandro/B-7278-2013; Pastore, Marco/AAH-7984-2020; Leon,
   Pia/ABD-9487-2020
OI Mangogna, Alessandro/0000-0001-7910-1274; Pastore,
   Marco/0000-0002-4725-1590; 
CR Chang LK, 2007, EUR J OPHTHALMOL, V17, P674
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P857, DOI 10.1097/IAE.0b013e3180342c42
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   CHUANG EL, 1988, AM J OPHTHALMOL, V105, P285, DOI 10.1016/0002-9394(88)90011-6
   Coco RM, 2012, OPHTHALMOLOGICA, V228, P78, DOI 10.1159/000338730
   COSCAS G, 1990, ARCH OPHTHALMOL-CHIC, V108, P1687, DOI 10.1001/archopht.1990.01070140041025
   Deker WL, 1983, OPHTHALMOLOGY, V90, P507
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Giovannini A, 2000, RETINA-J RET VIT DIS, V20, P37, DOI 10.1097/00006982-200001000-00007
   Gutfleisch M, 2011, EYE, V25, P1181, DOI 10.1038/eye.2011.146
   Introini U, 2012, GRAEF ARCH CLIN EXP, V250, P1283, DOI 10.1007/s00417-012-1955-2
   Lee GKY, 2007, GRAEF ARCH CLIN EXP, V245, P1225, DOI 10.1007/s00417-007-0536-2
   Lesniak SP, 2011, EUR J OPHTHALMOL, V21, P73, DOI 10.5301/EJO.2010.2285
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Moreira CA, 2013, RETINA-J RET VIT DIS, V33, P277, DOI 10.1097/IAE.0b013e318263d139
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Smth BT, 2009, RETINA, V29, P335
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
NR 23
TC 5
Z9 7
U1 0
U2 3
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD AUG 18
PY 2014
VL 7
IS 4
BP 681
EP 685
DI 10.3980/j.issn.2222-3959.2014.04.18
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN1NH
UT WOS:000340350100018
PM 25161943
DA 2022-11-30
ER

PT J
AU Junemann, AGM
   Stopa, P
   Michalke, B
   Chaudhri, A
   Reulbach, U
   Huchzermeyer, C
   Schlotzer-Schrehardt, U
   Kruse, FE
   Zrenner, E
   Rejdak, R
AF Juenemann, Anselm G. M.
   Stopa, Piotr
   Michalke, Bernhard
   Chaudhri, Anwar
   Reulbach, Udo
   Huchzermeyer, Cord
   Schloetzer-Schrehardt, Ursula
   Kruse, Friedrich E.
   Zrenner, Eberhart
   Rejdak, Robert
TI Levels of Aqueous Humor Trace Elements in Patients with Non-Exsudative
   Age-related Macular Degeneration: A Case-control Study
SO PLOS ONE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; CADMIUM ACCUMULATION; GENE-EXPRESSION; PC12
   CELLS; ZINC; COBALT; TOXICITY; HYPOXIA; PROTEIN; METALLOTHIONEIN
AB Trace elements might play a role in the complex multifactorial pathogenesis of age-related macular degeneration (AMD). The aim of this study was to measure alterations of trace elements levels in aqueous humor of patients with non-exsudative (dry) AMD. For this pilot study, aqueous humor samples were collected from patients undergoing cataract surgery. 12 patients with dry AMD (age 77.9 +/- 6.62, female 8, male 4) and 11 patients without AMD (age 66.6 +/- 16.7, female 7, male 4) were included. Aqueous levels of cadmium, cobalt, copper, iron, manganese, selenium, and zinc were measured by use of Flow-Injection-Inductively-Coupled-Plasma-Mass-Spectrometry (FI-ICP-MS), quality controlled with certified standards. Patients with AMD had significantly higher aqueous humor levels of cadmium (median: 0.70 mu mol/L, IQR: 0.40-0.84 vs. 0.06 mu mol/L; IQR: 0.01-.018; p = 0.002), cobalt (median: 3.1 mu mol/L, IQR: 2.62-3.15 vs. 1.17 mu mol/L; IQR: 0.95-1.27; p<0.001), iron (median: 311 mu mol/L, IQR: 289-329 vs. 129 mu mol/L; IQR: 111-145; p<0.001) and zinc (median: 23.1 mu mol/L, IQR: 12.9-32.6 vs. 5.1 mu mol/L; IQR: 4.4-9.4; p = 0.020) when compared with patients without AMD. Copper levels were significantly reduced in patients with AMD (median: 16.2 mu mol/L, IQR: 11.4-31.3 vs. 49.9 mu mol/L; IQR: 32.0-. 142.0; p = 0.022) when compared to those without. No significant differences were observed in aqueous humor levels of manganese and selenium between patients with and without AMD. After an adjustment for multiple testing, cadmium, cobalt, copper and iron remained a significant factor in GLM models (adjusted for age and gender of the patients) for AMD. Alterations of trace element levels support the hypothesis that cadmium, cobalt, iron, and copper are involved in the pathogenesis of AMD.
C1 [Juenemann, Anselm G. M.; Huchzermeyer, Cord; Schloetzer-Schrehardt, Ursula; Kruse, Friedrich E.] Univ Hosp Erlangen, Dept Ophthalmol, Erlangen, Germany.
   [Stopa, Piotr; Rejdak, Robert] Med Univ Lublin, Dept Gen Ophthalmol, Lublin, Poland.
   [Michalke, Bernhard] Helmholtz Zentrum Munchen, Inst Ecol Chem, Neuherberg, Germany.
   [Chaudhri, Anwar] Univ Erlangen Nurnberg, D-91054 Erlangen, Germany.
   [Reulbach, Udo] Trinity Coll Dublin, Dept Publ Hlth & Primary Care, Dublin, Ireland.
   [Zrenner, Eberhart] Ctr Ophthalmol, Tubingen, Germany.
   [Rejdak, Robert] Polish Acad Sci, Med Res Ctr, Dept Expt Pharmacol, Warsaw, Poland.
C3 University of Erlangen Nuremberg; Medical University of Lublin;
   Helmholtz Association; Helmholtz-Center Munich - German Research Center
   for Environmental Health; University of Erlangen Nuremberg; Trinity
   College Dublin; Eberhard Karls University of Tubingen; Eberhard Karls
   University Hospital; Polish Academy of Sciences
RP Junemann, AGM (通讯作者)，Univ Hosp Erlangen, Dept Ophthalmol, Erlangen, Germany.
EM anselm.juenemann@uk-erlangen.de
RI Reulbach, Udo/F-4239-2012; Jünemann, Anselm Gerhard Maria/GPK-8482-2022;
   Schmuki, Patrik/B-9720-2008
OI Reulbach, Udo/0000-0002-9527-157X; Rejdak, Robert/0000-0003-3321-2723
CR Erie JC, 2007, AM J OPHTHALMOL, V144, P414, DOI 10.1016/j.ajo.2007.05.020
   Erie JC, 2009, AM J OPHTHALMOL, V147, P276, DOI 10.1016/j.ajo.2008.08.014
   Erie JC, 2005, AM J OPHTHALMOL, V139, P888, DOI 10.1016/j.ajo.2004.12.007
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Karovic O, 2007, BIOCHEM PHARMACOL, V73, P694, DOI 10.1016/j.bcp.2006.11.008
   Klein R, 2008, OPHTHALMOLOGY, V115, P1460, DOI 10.1016/j.ophtha.2008.01.026
   Kowalski M, 2010, MED SCI MONITOR, V16, pCR190
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Moulis JM, 2010, BIOMETALS, V23, P877, DOI 10.1007/s10534-010-9336-y
   Nicolas MG, 1996, EXP EYE RES, V62, P399, DOI 10.1006/exer.1996.0045
   Olbryt M, 2006, GENE EXPRESSION, V13, P191, DOI 10.3727/000000006783991818
   Ortega R, 2009, TOXICOL LETT, V188, P26, DOI 10.1016/j.toxlet.2009.02.024
   Rousselet E, 2008, PROTEOMICS, V8, P2244, DOI 10.1002/pmic.200701067
   Sabolic I, 2010, BIOMETALS, V23, P897, DOI 10.1007/s10534-010-9351-z
   Terman A, 2006, CHEM-BIOL INTERACT, V163, P29, DOI 10.1016/j.cbi.2006.04.013
   Ugarte M, 2001, PROG NEUROBIOL, V64, P219, DOI 10.1016/S0301-0082(00)00057-5
   Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev
   Wills NK, 2008, EXP EYE RES, V87, P80, DOI 10.1016/j.exer.2008.04.013
   Wills NK, 2008, EXP EYE RES, V86, P41, DOI 10.1016/j.exer.2007.09.005
   Yuan Y, 2003, J BIOL CHEM, V278, P15911, DOI 10.1074/jbc.M300463200
   Zou WG, 2002, J NEUROSCI RES, V67, P837, DOI 10.1002/jnr.10168
   Zou WG, 2001, J NEUROSCI RES, V64, P646, DOI 10.1002/jnr.1118
   2001, ARCH OPHTHALMOL, V119, P1417
NR 24
TC 43
Z9 44
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 15
PY 2013
VL 8
IS 2
AR e56734
DI 10.1371/journal.pone.0056734
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 099EQ
UT WOS:000315603700075
PM 23457607
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Zhu, MD
   Wijeyakumar, W
   Syed, AR
   Joachim, N
   Hong, T
   Broadhead, GK
   Li, HT
   Luo, KH
   Chang, A
AF Zhu, Meidong
   Wijeyakumar, Wijeyanthy
   Syed, Adil R.
   Joachim, Nichole
   Hong, Thomas
   Broadhead, Geoffrey K.
   Li, Haitao
   Luo, Kehui
   Chang, Andrew
TI Vision-related quality of life: 12-month aflibercept treatment in
   patients with treatment-resistant neovascular age-related macular
   degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Vision-related quality of life (VR-QoL); Neovascular age-related macular
   degeneration (nAMD); Intravitreal aflibercept; Anti-vascular endothelial
   growth factor (anti-VEGF); Treatment resistant; Prospective clinical
   trial
ID RANDOMIZED CLINICAL-TRIAL; INTRAVITREAL AFLIBERCEPT; VISUAL-ACUITY;
   RANIBIZUMAB TREATMENT; EYE; DEPRESSION
AB To assess changes in vision-related quality of life (VR-QoL) among patients with treatment-resistant neovascular age-related macular degeneration (nAMD) following intravitreal aflibercept treatment over 48 weeks.
   We conducted a prospective study in which 49 patients with nAMD resistant to anti-vascular endothelial growth factor therapy were switched to intravitreal aflibercept. Patients were treated with three loading doses every 4 weeks followed by injections every 8 weeks, for a total of 48 weeks. Ophthalmic examinations performed at each visit included best-corrected visual acuity (BCVA) and central macular thickness (CMT) measurement. The National Eye Institute Visual Functioning Questionnaire 25 (NEI VFQ-25) was used to assess VR-QoL at baseline and weeks 24 and 48. Changes in NEI VFQ-25 composite and subscale scores were analyzed using paired t tests. The relationship between the change in VR-QoL and changes in BCVA and CMT, and the impact of the better-seeing eye (BSE, defined as the eye reading the greater number of letters at baseline) vs. the worse-seeing eye (WSE, the fellow eye to the BSE) were assessed.
   Mean NEI VFQ-25 composite scores improved significantly at weeks 24 and 48 compared to baseline (4.5 +/- 9.2 and 4.4 +/- 11.8, respectively, all p < 0.01). Among subscales, general vision and near and distance activities showed significant improvements at weeks 24 and 48 (all p < 0.05). Improvement in the NEI VFQ-25 composite score was significantly associated with increased BCVA at week 48 (beta coefficient = 0.43, p = 0.029), but not with change in CMT (beta coefficient = -0.007, p = 0.631). There was no association between VR-QoL changes and BSE or WSE.
   Despite previous anti-VEGF treatment in this cohort, overall VR-QoL improved following aflibercept therapy over 48 weeks. This improvement was related to improved vision in treatment eyes regardless of whether they were the BSE or WSE.
C1 [Zhu, Meidong; Wijeyakumar, Wijeyanthy; Syed, Adil R.; Joachim, Nichole; Hong, Thomas; Broadhead, Geoffrey K.; Li, Haitao; Chang, Andrew] Sydney Retina Clin & Day Surg, Level 13,Pk House,187 Macquarie St, Sydney, NSW 2000, Australia.
   [Zhu, Meidong; Wijeyakumar, Wijeyanthy; Syed, Adil R.; Joachim, Nichole; Hong, Thomas; Broadhead, Geoffrey K.; Li, Haitao; Chang, Andrew] Sydney Inst Vis Sci, Sydney, NSW, Australia.
   [Zhu, Meidong; Wijeyakumar, Wijeyanthy; Syed, Adil R.; Broadhead, Geoffrey K.; Chang, Andrew] Univ Sydney, Save Sight Inst, Sydney, NSW, Australia.
   [Luo, Kehui] Macquarie Univ, Dept Stat, Fac Sci & Engn, Sydney, NSW, Australia.
C3 University of Sydney; Macquarie University
RP Chang, A (通讯作者)，Sydney Retina Clin & Day Surg, Level 13,Pk House,187 Macquarie St, Sydney, NSW 2000, Australia.; Chang, A (通讯作者)，Sydney Inst Vis Sci, Sydney, NSW, Australia.; Chang, A (通讯作者)，Univ Sydney, Save Sight Inst, Sydney, NSW, Australia.
EM achang@sydneyretina.com.au
FU Bayer Corporation
FX Financial support was provided in part by Bayer Corporation. The sponsor
   had no role in the design or conduct of this research. The authors have
   full control of all primary data, and we agree to allow Graefe's Archive
   for Clinical and Experimental Ophthalmology to review our data upon
   request.
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Broadhead GK, 2015, RETINA-J RET VIT DIS, V35, P975, DOI 10.1097/IAE.0000000000000409
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown GC, 2007, OPHTHALMOLOGY, V114, P1170, DOI 10.1016/j.ophtha.2006.09.019
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown MM, 2001, OPHTHALMOLOGY, V108, P643, DOI 10.1016/S0161-6420(00)00635-7
   Chang AA, 2016, OPHTHALMIC RES, V55, P84, DOI 10.1159/000440886
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Copay AG, 2007, SPINE J, V7, P541, DOI 10.1016/j.spinee.2007.01.008
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1246, DOI 10.1016/j.ophtha.2013.12.032
   Finger RP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081042
   Gordois A, 2010, GLOBAL EC COST VISUA, P465
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hirneiss C, 2007, BRIT J OPHTHALMOL, V91, P481, DOI 10.1136/bjo.2006.102376
   Hirneiss C, 2014, CLIN OPHTHALMOL, V8, P1703, DOI 10.2147/OPTH.S64200
   Kane RL, 2006, AGE RELATED MACULAR, P364
   Leys A, 2008, EYE, V22, P792, DOI 10.1038/sj.eye.6702900
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mejico LJ, 2004, AM J OPHTHALMOL, V137, P908, DOI 10.1016/j.ajo.2003.12.038
   Miskala PH, 2007, OPHTHAL EPIDEMIOL, V14, P205, DOI 10.1080/09286580701502970
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   National Eye Institute, 2000, NAT EYE I 25 IT VIS
   Orr P, 2011, INVEST OPHTH VIS SCI, V52, P3354, DOI 10.1167/iovs.10-5645
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   SCOTT IU, 1994, ARCH OPHTHALMOL-CHIC, V112, P329, DOI 10.1001/archopht.1994.01090150059023
   Spilker B., 1990, QUALITY LIFE ASSESSM
   Suner IJ, 2009, INVEST OPHTH VIS SCI, V50, P3629, DOI 10.1167/iovs.08-3225
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   Yuzawa M, 2013, CLIN OPHTHALMOL, V7, P1325, DOI 10.2147/OPTH.S45248
NR 38
TC 7
Z9 7
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2017
VL 255
IS 3
BP 475
EP 484
DI 10.1007/s00417-016-3477-9
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EM0CO
UT WOS:000394986600005
PM 27572301
DA 2022-11-30
ER

PT J
AU Sakurada, Y
   Kubota, T
   Imasawa, M
   Tsumura, T
   Mabuchi, F
   Tanabe, N
   Iijima, H
AF Sakurada, Yoichi
   Kubota, Takeo
   Imasawa, Mitsuhiro
   Tsumura, Toyoaki
   Mabuchi, Fumihiko
   Tanabe, Naohiko
   Iijima, Hiroyuki
TI ANGIOGRAPHIC LESION SIZE ASSOCIATED WITH LOC387715 A69S GENOTYPE IN
   SUBFOVEAL POLYPOIDAL CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE LOC387715 A69S genotype; polypoidal choroidal vasculopathy; lesion size;
   lesion composition; fluorescein angiography; indocyanine green
   angiography
ID COMPLEMENT FACTOR-H; MACULAR DEGENERATION; PHOTODYNAMIC THERAPY;
   JAPANESE PATIENTS; INDOCYANINE GREEN; NEOVASCULARIZATION SECONDARY;
   CLINICAL CHARACTERISTICS; POLYMORPHISM; VERTEPORFIN; GENE
AB Purpose: To investigate whether the LOC387715/ARMS2 variants are associated with an angiographic phenotype, including lesion size and composition, in subfoveal polypoidal choroidal vasculopathy.
   Methods: Ninety-two subjects with symptomatic subfoveal polypoidal choroidal vasculopathy, whose visual acuity was from 0.1 to 0.5 on the Landolt chart, were genotyped for the LOC387715 polymorphism (rs10490924) using denaturing high-performance chromatography. The angiographic phenotype, including lesion composition and size, was evaluated by evaluators who were masked for the genotype. Lesion size was assessed by the greatest linear dimension based on fluorescein or indocyanine green angiography.
   Results: Although there was no statistically significant difference in lesion size on indocyanine green angiography (P = 0.36, Kruskal-Wallis test) and in lesion composition (P = 0.59, chi-square test) among the 3 genotypes, there was a statistically significant difference in lesion size on fluorescein angiography (P = 0.0022, Kruskal-Wallis test).
   Conclusion: The LOC387715 A69S genotype is not associated with lesion composition or size on indocyanine green angiography but with lesion size on fluorescein angiography in patients with subfoveal polypoidal choroidal vasculopathy. Because fluorescein angiography findings represent secondary exudative changes, including subretinal hemorrhages and retinal pigment epithelial detachment, the results in the present study likely indicate that the T allele at the LOC387715 gene is associated with the exudative activity of polypoidal lesions. RETINA 29:1522-1526, 2009
C1 [Sakurada, Yoichi; Imasawa, Mitsuhiro; Tsumura, Toyoaki; Mabuchi, Fumihiko; Tanabe, Naohiko; Iijima, Hiroyuki] Univ Yamanashi, Fac Med, Dept Ophthalmol, Chuo Ku, Yamanashi 4093898, Japan.
   [Sakurada, Yoichi; Kubota, Takeo] Univ Yamanashi, Fac Med, Dept Epigenet, Chuo Ku, Yamanashi 4093898, Japan.
C3 University of Yamanashi; University of Yamanashi
RP Iijima, H (通讯作者)，Univ Yamanashi, Fac Med, Dept Ophthalmol, Chuo Ku, Shimokato 1110, Yamanashi 4093898, Japan.
EM hiijimar@yamanashi.ac.jp
CR Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2007, GRAEF ARCH CLIN EXP, V245, P1421, DOI 10.1007/s00417-007-0564-y
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Iida Tomohiro, 2005, Nippon Ganka Gakkai Zasshi, V109, P383
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P309, DOI 10.1097/IAE.0b013e31814cef3a
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Ogino T, 2007, JPN J OPHTHALMOL, V51, P210, DOI 10.1007/s10384-007-0436-3
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Shuler RK, 2008, AM J OPHTHALMOL, V145, P303, DOI 10.1016/j.ajo.2007.09.027
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   2003, AM J OPHTHALMOL, V136, P1049
NR 31
TC 40
Z9 42
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV-DEC
PY 2009
VL 29
IS 10
BP 1522
EP 1526
DI 10.1097/IAE.0b013e3181af0d72
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 519SH
UT WOS:000271787600020
PM 19898184
DA 2022-11-30
ER

PT J
AU Shmueli, O
   Yehuda, R
   Szeskin, A
   Joskowicz, L
   Levy, J
AF Shmueli, Or
   Yehuda, Roei
   Szeskin, Adi
   Joskowicz, Leo
   Levy, Jaime
TI Progression of cRORA (Complete RPE and Outer Retinal Atrophy) in Dry
   Age-Related Macular Degeneration Measured Using SD-OCT
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; complete retinal pigment epithelium
   (RPE) and outer; retinal atrophy; OCT scan analysis; retinal atrophy
   progression
ID OPTICAL COHERENCE TOMOGRAPHY; GEOGRAPHIC ATROPHY; FUNDUS
   AUTOFLUORESCENCE; VISUAL-ACUITY; SECONDARY; GROWTH
AB Purpose: The purpose of this study was to evaluate the long-term rate of progression and baseline predictors of geographic atrophy (GA) using complete retinal pigment epithelium and outer retinal atrophy (cRORA) annotation criteria.
   Methods: This is a retrospective study. Columns of GA were manually annotated by two graders using a self-developed software on optical coherence tomography (OCT) B-scans and projected onto the infrared images. The primary outcomes were: (1) rate of area progression, (2) rate of square root area progression, and (3) rate of radial progression towards the fovea. The effects of 11 additional baseline predictors on the primary outcomes were analyzed: total area, focality (defined as the number of lesions whose area is >0.05 mm(2)), circularity, total lesion perimeter, minimum diameter, maximum diameter, minimum distance from the center, sex, age, presence/absence of hypertension, and lens status.
   Results: GA was annotated in 33 pairs of baseline and follow-up OCT scans from 33 eyes of 18 patients with dry age-related macular degeneration (AMD) followed for at least 6 months. The mean rate of area progression was 1.49 +/- 0.86 mm(2)/year (P < 0.0001 vs. baseline), and the mean rate of square root area progression was 0.33 +/- 0.15 mm/year (P < 0.0001 vs. baseline). The mean rate of radial progression toward the fovea was 0.07 +/- 0.11 mm/year. A multiple variable linear regression model (adjusted r(2) = 0.522) revealed that baseline focality and female sex were significantly correlated with the rate of GA area progression.
   Conclusions: GA area progression was quantified using OCT as an alternative to conventional measurements performed on fundus autofluorescence images. Baseline focality correlated with GA area progression rate and lesion's minimal distance from the center correlated with GA radial progression rate toward the center. These may be important markers for the assessment of GA activity.
   Translational Relevance: Advanced method linking specific retinal micro-anatomy to GA area progression analysis.
C1 [Shmueli, Or; Levy, Jaime] Hadassah Hebrew Univ Med Ctr, Dept Ophthalmol, Jerusalem, Israel.
   [Yehuda, Roei; Szeskin, Adi; Joskowicz, Leo] Hebrew Univ Jerusalem, Sch Comp Sci & Engn, Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hebrew University of Jerusalem
RP Levy, J (通讯作者)，Hebrew Univ Jerusalem, Dept Ophthalmol, Hadassah Med Ctr, IL-91120 Ein Kerem, Israel.
EM levjaime@gmail.com
RI Shmueli, Or/AHD-0983-2022
OI Shmueli, Or/0000-0003-3718-2664; Szeskin, Adi/0000-0002-3397-7964
CR Caire J, 2014, JAMA OPHTHALMOL, V132, P528, DOI 10.1001/jamaophthalmol.2013.8175
   Cleland SC, 2021, OPHTHALMOL RETINA, V5, P41, DOI 10.1016/j.oret.2020.07.006
   Domalpally A, 2013, OPHTHALMOLOGY, V120, P2666, DOI 10.1016/j.ophtha.2013.07.047
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Liefers B, 2020, OPHTHALMOLOGY, V127, P1086, DOI 10.1016/j.ophtha.2020.02.009
   Patnaik JL, 2020, OPHTHAL EPIDEMIOL, V27, P148, DOI 10.1080/09286586.2019.1701041
   Pfau M, 2019, RETINA-J RET VIT DIS, V39, P1527, DOI 10.1097/IAE.0000000000002206
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Sayegh RG, 2017, AM J OPHTHALMOL, V179, P118, DOI 10.1016/j.ajo.2017.03.031
   Schmitz-Valckenberg S, 2021, PROG RETIN EYE RES, V81, DOI 10.1016/j.preteyeres.2020.100893
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Shen LL, 2021, OPHTHALMOL RETINA, V5, P868, DOI 10.1016/j.oret.2020.12.002
   Shen LL, 2020, OPHTHALMOL RETINA, V4, P899, DOI 10.1016/j.oret.2020.03.020
   Shen LBL, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.1.2
   Simader C, 2014, AM J OPHTHALMOL, V158, P557, DOI 10.1016/j.ajo.2014.05.026
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Szeskin A, 2021, MED IMAGE ANAL, V72, DOI 10.1016/j.media.2021.102130
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS26, DOI 10.1097/IAE.0000000000001330
NR 21
TC 1
Z9 1
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JAN
PY 2022
VL 11
IS 1
AR 19
DI 10.1167/tvst.11.1.19
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1L9DR
UT WOS:000799581700018
PM 35029632
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Heussen, FM
   Ouyang, YL
   Sadda, SR
   Walsh, AC
AF Heussen, Florian M.
   Ouyang, Yanling
   Sadda, SriniVas R.
   Walsh, Alexander C.
TI Simple Estimation of Clinically Relevant Lesion Volumes Using Spectral
   Domain-Optical Coherence Tomography in Neovascular Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RANIBIZUMAB; SUBANALYSIS; STRATUS
AB PURPOSE. To evaluate simple methods of estimating the volume of clinically relevant features in neovascular age-related macular degeneration (NVAMD) using spectral domain-optical coherence tomography (SD-OCT).
   METHODS. Using a database of NVAMD cases imaged with macular cube (512 A-scans x 128 B-scans) SD-OCT scans, the authors retrospectively selected visits where cystoid macular edema (CME), subretinal fluid (SRF), or pigment epithelial detachments (PEDs) were evident. Patients with single visits were analyzed in the cross-sectional analysis (CSA) and those with a baseline visit and three or more follow-up visits in the longitudinal analysis (LA). The volume of each feature was measured by manual grading using validated grading software. Simplified measurements for each feature included: number of B-scans or A-scans involved and maximum height. Automated measurements of total macular volume and foveal central subfield were also collected from each machine. Correlations were performed between the volumes measured with 3D-OCTOR, automated measurements, and the simplified measures.
   RESULTS. Forty-five visits for 25 patients were included in this study: 26 cube scans from 26 eyes of 25 patients in the CSA and 24 scans from 5 eyes of 5 patients in the LA. The simplified measures that correlated best with manual grading in the CSA group were maximum lesion height for CME (r(2) value = 0.96) and B-scan count for SRF and PED volume (r(2) values of 0.88 and 0.70). In the LA group, intervisit differences were correlated. Change in B-scan count correlated well with change in SRF volume (r(2) = 0.97), whereas change in maximum height correlated with change in CME and PED volume (r(2) = 0.98 and 0.43, respectively).
   CONCLUSIONS. These data suggest that simplified estimators of some NVAMD lesion volumes exist and are accessible by clinicians without the need for specialized software or time-consuming manual segmentation. These simple approaches could enhance quantitative disease monitoring strategies in clinical trials and clinical practice. (Invest Ophthalmol Vis Sci. 2011;52:7792-7798) DOI:10.1167/iovs.11-8023
C1 [Walsh, Alexander C.] Univ So Calif, Keck Sch Med, Doheny Eye Inst, Los Angeles, CA 90033 USA.
   Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
C3 Doheny Eye Institute; University of Southern California; University of
   Southern California
RP Walsh, AC (通讯作者)，Univ So Calif, Keck Sch Med, Doheny Eye Inst, 1450 San Pablo St, Los Angeles, CA 90033 USA.
EM alexwalsh3@gmail.com
OI Heussen, Florian Moritz/0000-0003-0536-9870
FU National Eye Institute [EY03040, R01 EY014375]; Deutsche
   Forschungsgemeinschaft [He 6094/1-1]; NATIONAL EYE INSTITUTE
   [R01EY014375, P30EY003040] Funding Source: NIH RePORTER
FX Supported in part by National Eye Institute Grants EY03040 and R01
   EY014375, and Deutsche Forschungsgemeinschaft Grant He 6094/1-1.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Han IC, 2009, AM J OPHTHALMOL, V147, P847, DOI 10.1016/j.ajo.2008.11.019
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Keane PA, 2009, BRIT J OPHTHALMOL, V93, P1461, DOI 10.1136/bjo.2008.155846
   Krebs I, 2009, INVEST OPHTH VIS SCI, V50, P995, DOI 10.1167/iovs.08-2617
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Mylonas G, 2009, BRIT J OPHTHALMOL, V93, P1453, DOI 10.1136/bjo.2008.153643
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P1084, DOI 10.1167/iovs.07-1203
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   Sadda SR, 2010, RETINA-J RET VIT DIS, V30, P1390, DOI 10.1097/IAE.0b013e3181e44599
   Sadda SR, 2010, INVEST OPHTH VIS SCI, V51, P1071, DOI 10.1167/iovs.09-4325
NR 16
TC 8
Z9 8
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2011
VL 52
IS 10
BP 7792
EP 7798
DI 10.1167/iovs.11-8023
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 827YU
UT WOS:000295467200100
PM 21862646
OA Green Published
DA 2022-11-30
ER

PT J
AU Tuerksever, C
   Somfai, GM
   Oesch, S
   Machewitz, T
   Hasler, PW
   Zweifel, S
AF Tuerksever, Cengiz
   Somfai, Gabor Mark
   Oesch, Susanne
   Machewitz, Tobias
   Hasler, Pascal W.
   Zweifel, Sandrine
TI Hypothetical Switch of Anti-Vascular Endothelial Growth Factor in
   Neovascular Age-Related Macular Degeneration: An ARIES Post Hoc Analysis
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Article
DE Aflibercept; Age-related macular degeneration; Intravitreal injections;
   Optical coherence tomography; Treat-and-extend; Treatment outcome;
   Vascular endothelial growth factors
ID VISUAL-ACUITY; AFLIBERCEPT; PREVALENCE; MORPHOLOGY; IMPACT
AB Introduction: Switching to an alternative anti-vascular endothelial growth factor (anti-VEGF) agent has been suggested for patients with neovascular age-related macular degeneration (nAMD) who have a suboptimal response to initial therapy. However, post hoc analyses of some studies have shown that continuation of initial anti-VEGF therapy is, in many cases, associated with stable visual outcomes or gradual gains.
   Methods: This ARIES (ClinicalTrials.gov Identifier: NCT02581891) post hoc analysis describes outcomes in patients with treatment-naive nAMD receiving treat-and-extend intravitreal aflibercept (IVT-AFL) for 104 weeks, who were identified as meeting criteria for an early hypothetical switch. Patients were categorized retrospectively according to six criteria (presence of central intraretinal and/or subretinal fluid at week 8 or 24, with/without a next planned treatment interval <= 8 weeks, and with/without gains in best-corrected visual acuity [BCVA] <= 5 letters [with absolute BCVA < 70 letters]).
   Results: Hypothetical switch criteria were largely met due to the presence of central subretinal fluid rather than intraretinal fluid. Depending on the criterion, 8-46% of patients were considered to be hypothetical switchers. BCVA outcomes were not worse in the hypothetical switchers, irrespective of criteria. Using criteria of intraretinal/subretinal fluid at week 24 and a next planned treatment interval <= 8 weeks, mean changes in BCVA (letters) from baseline in hypothetical switchers and non-switchers were: + 6.1 (95% confidence interval [CI] 3.4, 8.8) and + 6.6 (95% CI 4.7, 8.6), respectively, at week 24; + 8.2 (95% CI 5.0, 11.3) and + 7.5 (95% CI 5.3, 9.7), respectively, at week 52; and + 5.7 (95% CI 1.3, 10.1) and + 3.4 (95% CI 0.1, 6.7), respectively, at week 104.
   Conclusions: In newly diagnosed nAMD, there appears little rationale for early switching from IVT-AFL since, with continuous proactive treatment, comparable visual gains can be achieved by patients meeting hypothetical switch criteria compared with those who initially respond well on a treat-and-extend regimen. However, further prospective studies are needed.
C1 [Tuerksever, Cengiz] VISTA Clin Binningen BL, CH-4201 Binningen, Switzerland.
   [Somfai, Gabor Mark] Werner H Spross Fdn Adv Res & Teaching Ophthalmol, Zurich, Switzerland.
   [Somfai, Gabor Mark] City Hosp Waid & Triemli, Dept Ophthalmol, Zurich, Switzerland.
   [Somfai, Gabor Mark] Semmelweis Univ, Dept Ophthalmol, Budapest, Hungary.
   [Oesch, Susanne] Bayer Schweiz AG, Med Dept, Zurich, Switzerland.
   [Machewitz, Tobias] Bayer AG, Med Affairs Stat, Berlin, Germany.
   [Hasler, Pascal W.] Univ Hosp Basel, Dept Ophthalmol, Basel, Switzerland.
   [Zweifel, Sandrine] Univ Hosp Zurich, Dept Ophthalmol, Zurich, Switzerland.
   [Zweifel, Sandrine] Univ Zurich, Zurich, Switzerland.
C3 Triemli Hospital; Semmelweis University; Bayer AG; Bayer AG; University
   of Basel; University of Zurich; University Zurich Hospital; University
   of Zurich
RP Tuerksever, C (通讯作者)，VISTA Clin Binningen BL, CH-4201 Binningen, Switzerland.
EM cengiz.tuerksever@vista.ch
FU Bayer AG, Germany; Bayer Consumer Care AG
FX The ARIES study was sponsored by Bayer AG, Germany. Bayer Consumer Care
   AG funded the post hoc analysis and is also responsible for funding the
   journal's Rapid Service and Open Access Fees.
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Arruabarrena C, 2021, J CLIN MED, V10, DOI 10.3390/jcm10153281
   Assi L, 2021, JAMA OPHTHALMOL, V139, P526, DOI 10.1001/jamaophthalmol.2021.0146
   Bajka A, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18115846
   Chaudhary V, 2022, RETINA-J RET VIT DIS, V42, P589, DOI 10.1097/IAE.0000000000003283
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Ferris FL, 2017, JAMA OPHTHALMOL, V135, P145, DOI 10.1001/jamaophthalmol.2016.4820
   Gale RP, 2019, EYE, V33, DOI 10.1038/s41433-018-0300-3
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Kodjikian L, 2021, EYE, V35, P2119, DOI 10.1038/s41433-021-01487-0
   Mitchell P, 2021, RETINA-J RET VIT DIS, V41, P1911, DOI 10.1097/IAE.0000000000003128
   Moshfeghi AA, 2020, OSLI RETINA, V51, pS6, DOI 10.3928/23258160-20200401-01
   Novartis, 2018, LUCENTIS RAN INJ INT
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Siedlecki J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64901-9
   Stattin M, 2021, OPHTHALMOL THER, V10, P935, DOI 10.1007/s40123-021-00381-y
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Wong DT, 2020, RETINA-J RET VIT DIS, V40, P1010, DOI 10.1097/IAE.0000000000002713
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zarbin M, 2019, OPHTHALMOLOGY, V126, P849, DOI 10.1016/j.ophtha.2019.01.003
   Zarbin MA, 2022, BRIT J OPHTHALMOL, V106, P1561, DOI 10.1136/bjophthalmol-2020-318688
NR 25
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD APR
PY 2022
VL 11
IS 2
BP 613
EP 627
DI 10.1007/s40123-021-00448-w
EA JAN 2022
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZU8LH
UT WOS:000745754700001
PM 35066801
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Taipale, C
   Lindholm, JM
   Kaarniranta, K
   Tuuminen, R
AF Taipale, Claudia
   Lindholm, Juha-Matti
   Kaarniranta, Kai
   Tuuminen, Raimo
TI Comparison of Two Different Treat-and-Extend Protocols with Aflibercept
   in Wet Age-Related Macular Degeneration: Two-Year Results
SO ADVANCES IN THERAPY
LA English
DT Article
DE Aflibercept; Anti-vascular endothelial growth factor; Treat-and-extend
   regimen; Wet age-related macular degeneration
ID RANIBIZUMAB; BLINDNESS; THERAPY; EYE
AB Introduction To optimize the aflibercept treat-and-extend protocol in wet age-related macular degeneration (wAMD) beyond the 1-year interim report. Methods This 2-year prospective randomized clinical trial included 52 eyes from 52 patients with treatment-naive wAMD. After the induction phase of three monthly aflibercept injections, patients were randomized 1:1 to two different treat-and-extend protocols. In the treat-and-extend protocol with moderate extensions (T&Em), the treatment interval was extended 1 week at a time up to 12 weeks, and then by 2 weeks up to 16 weeks. In the treat-and-extend protocol with rapid extensions (T&Er), the treatment interval was initially extended to 8 weeks, and then by 2 weeks up to 16 weeks. Main outcome measure was the number of given aflibercept injections. Results At the study end point at 2 years, the mean visual gain from the baseline was 7.9 +/- 14.5 letters in T&Em, compared to 10.8 +/- 16.5 letters in T&Er protocol (P = 0.726). The mean decrease in central subfield macular thickness was 203.0 +/- 167.4 mu m in T&Em and 192.3 +/- 160.2 mu m in T&Er protocol (P = 0.822). Treatment interval was 10.3 +/- 3.3 weeks in T&Em and 11.7 +/- 3.5 in T&Er protocol (P = 0.164) at the end of year 2. The total number of injections in 2 years was 14.1 +/- 3.1 in T&Em and 11.6 +/- 2.0 in T&Er (P = 0.002), and the number of injections during the second year was 5.4 +/- 1.8 and 4.4 +/- 1.4, respectively (P = 0.043). A total of 71% of the eyes in both treatment groups had a dry macula at the study end point. Conclusions At 2 years, the anatomical and functional responses between the two treatment groups were similar. However, the number of given aflibercept injections was smaller in the rapid extensions protocol.
C1 [Taipale, Claudia; Lindholm, Juha-Matti; Tuuminen, Raimo] Univ Helsinki, Helsinki Retina Res Grp, Helsinki, Finland.
   [Taipale, Claudia; Lindholm, Juha-Matti] Helsinki Univ Hosp, Dept Ophthalmol, Helsinki, Finland.
   [Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Kuopio, Finland.
   [Tuuminen, Raimo] Kymenlaakso Cent Hosp, Unit Ophthalmol, Kotka, Finland.
C3 University of Helsinki; University of Helsinki; Helsinki University
   Central Hospital; University of Eastern Finland; Kuopio University
   Hospital; University of Eastern Finland
RP Tuuminen, R (通讯作者)，Univ Helsinki, Helsinki Retina Res Grp, Helsinki, Finland.
EM raimo.tuuminen@helsinki.fi
FU Finnish Eye Foundation; Finnish Ophthalmological Society; Nissi
   Foundation; Orion Research Foundation; Paulo Foundation; Waldemar von
   Frenckell Foundation; Glaukooma tukisaatio LUX; HUS Specific Catchment
   Area (ERVA) Clinical Research Grant
FX The study was supported by grants from the Finnish Eye Foundation,
   Finnish Ophthalmological Society, the Nissi Foundation, Orion Research
   Foundation, the Paulo Foundation, the Waldemar von Frenckell Foundation,
   Glaukooma tukisaatio LUX, and the HUS Specific Catchment Area (ERVA)
   Clinical Research Grants. The Rapid Service Fees were covered by Bayer
   Pharma AG.
CR Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Decroos FC, 2017, AM J OPHTHALMOL, V180, P142, DOI 10.1016/j.ajo.2017.06.002
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Haga A, 2018, ACTA OPHTHALMOL, V96, pE393, DOI 10.1111/aos.13607
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Spaide RF, 2009, AM J OPHTHALMOL, V148, P1, DOI 10.1016/j.ajo.2009.04.010
   Taipale C, 2019, ACTA OPHTHALMOL, DOI [10.1111/aos.14231, DOI 10.1111/A0S.14231]
   Tuulonen A, 2016, ACTA OPHTHALMOL, V94, P730, DOI 10.1111/aos.13168
   Tuuminen R, 2017, ACTA OPHTHALMOL, V95, DOI 10.1111/aos.13501
   Nguyen V, 2019, OPHTHALMOLOGY, V126, P64, DOI 10.1016/j.ophtha.2018.08.023
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
NR 24
TC 4
Z9 4
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0741-238X
EI 1865-8652
J9 ADV THER
JI Adv. Ther.
PD MAY
PY 2020
VL 37
IS 5
BP 2256
EP 2266
DI 10.1007/s12325-020-01312-2
EA APR 2020
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA LK5DQ
UT WOS:000524964000002
PM 32277343
DA 2022-11-30
ER

PT J
AU Cennamo, G
   Montorio, D
   D'Alessandro, A
   Napolitano, P
   D'Andrea, L
   Tranfa, F
AF Cennamo, Gilda
   Montorio, Daniela
   D'Alessandro, Anna
   Napolitano, Pasquale
   D'Andrea, Luca
   Tranfa, Fausto
TI Prospective Study of Vessel Density by Optical Coherence Tomography
   Angiography After Intravitreal Bevacizumab in Exudative Age-Related
   Macular Degeneration
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Article
DE Age-related macular degeneration; Bevacizumab; Choroidal thickness;
   Macular thickness; Optical coherence tomography angiography; Spectral
   domain-optical coherence tomography; Vessel density
ID CHOROIDAL THICKNESS CHANGES; BLOOD-RETINAL BARRIER; RANIBIZUMAB;
   INJECTION; FLOW; AFLIBERCEPT; FEATURES; NEOVASCULARIZATION; AVASTIN;
   EYES
AB Introduction The aim of this study was to evaluate retinal and choriocapillaris (CC) vessel density, using optical coherence tomography angiography (OCTA), in the macular region at baseline and after three once-monthly intravitreal injections of bevacizumab (loading phase) in patients affected by exudative age-related macular degeneration (AMD). Methods A total 38 eyes of 38 patients with exudative AMD (16 women, 22 men; mean age 72.47 +/- 7.46 years) were included in this study. We evaluated vessel density in different macular areas (whole image, fovea and parafovea) of the superficial capillary plexus (SCP), deep capillary plexus (DCP) and CC. In addition, central macular thickness (CMT) and choroidal thickness in the foveal region and 500 mu m in the nasal and temporal directions were analyzed by enhanced depth image-OCT. Results There were no significant differences in vessel density in the SCP, DCP and CC after the loading phase compared to baseline (p > 0.05). In contrast, CMT (p = 0.039; 320.63 +/- 175.05 vs. 372.47 +/- 167.05 mu m) and subfoveal choroidal thickness (SFCT) (p < 0.001; 189.21 +/- 37.66 mu m vs 170.37 +/- 37.96 mu m) significantly decreased after the loading phase compared to baseline. No significant correlations were found between SFCT and CC vessel density in the fovea, and between CMT and SCP and DCP (p > 0.05) at baseline and after the loading phase. Also, best corrected visual acuity did not correlate with CMT, SCP and DCP at baseline and after treatment (p > 0.05). Conclusion Macular and choroidal thickness did not correlate with vessel density, but probably correlated to vascular exudation. The anti-VEGF treatment, acting on vascular hyperpermeability, determines the reduction of the retinal and choroidal exudation, resulting in a decrease of their thicknesses. Consequently, these parameters could reflect the effectiveness of the anti-VEGF injections for treating exudative AMD respect to OCTA parameters.
C1 [Cennamo, Gilda] Univ Naples Federico II, Eye Clin, Publ Hlth Dept, Naples, Italy.
   [Montorio, Daniela; D'Alessandro, Anna; Napolitano, Pasquale; D'Andrea, Luca; Tranfa, Fausto] Univ Naples Federico II, Dept Neurosci Reprod Sci & Dent, Naples, Italy.
C3 University of Naples Federico II; University of Naples Federico II
RP Cennamo, G (通讯作者)，Univ Naples Federico II, Eye Clin, Publ Hlth Dept, Naples, Italy.
EM xgilda@hotmail.com
RI Montorio, Daniela/AAJ-8687-2020
OI Napolitano, Pasquale/0000-0001-6044-7486; D'Andrea,
   Luca/0000-0002-1964-4899; Montorio, Daniela/0000-0003-1423-9621
CR Aghdam KA, 2016, LASER SURG MED, V48, P668, DOI 10.1002/lsm.22531
   Amarakoon S, 2019, ACTA OPHTHALMOL, V97, P107, DOI 10.1111/aos.13774
   Barak A, 2012, EUR J OPHTHALMOL, V22, P423, DOI 10.5301/ejo.5000074
   Branchini L, 2013, JAMA OPHTHALMOL, V131, P693, DOI 10.1001/jamaophthalmol.2013.692
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Coscas F, 2019, BRIT J OPHTHALMOL, V103, P1342, DOI 10.1136/bjophthalmol-2018-313065
   Coscas F, 2014, INVEST OPHTH VIS SCI, V55, P64, DOI 10.1167/iovs.13-12931
   Fang PP, 2019, RETINA-J RET VIT DIS, V39, P150, DOI 10.1097/IAE.0000000000001918
   Fontaine O, 2011, INVEST OPHTH VIS SCI, V52, P7400, DOI 10.1167/iovs.10-6646
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P1671, DOI 10.1167/iovs.09-4496
   Gamulescu MA, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/851648
   Ghassemifar R, 2006, CELL TISSUE RES, V323, P117, DOI 10.1007/s00441-005-0046-7
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Huang D, 2016, DEV OPHTHALMOL, V56, P6, DOI 10.1159/000442770
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kaur C, 2008, PROG RETIN EYE RES, V27, P622, DOI 10.1016/j.preteyeres.2008.09.003
   Klaassen I, 2013, PROG RETIN EYE RES, V34, P19, DOI 10.1016/j.preteyeres.2013.02.001
   Kniestedt Christoph, 2003, Ophthalmol Clin North Am, V16, P155, DOI 10.1016/S0896-1549(03)00013-0
   Landa G, 2009, OPHTHALMOLOGICA, V223, P370, DOI 10.1159/000227783
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mathew R, 2013, AM J OPHTHALMOL, V155, P720, DOI 10.1016/j.ajo.2012.11.003
   Mazaraki K, 2015, BRIT J OPHTHALMOL, V99, P1341, DOI 10.1136/bjophthalmol-2015-306636
   McDonnell EC, 2014, EUR J OPHTHALMOL, V24, P897, DOI 10.5301/ejo.5000509
   Micieli JA, 2012, ACTA OPHTHALMOL, V90, pE13, DOI 10.1111/j.1755-3768.2011.02209.x
   Mottet B, 2018, ACTA OPHTHALMOL, V96, pE783, DOI 10.1111/aos.13763
   Palkovits S, 2017, RETINA-J RET VIT DIS, V37, P2262, DOI 10.1097/IAE.0000000000001480
   Pilotto E, 2019, BRIT J OPHTHALMOL, V103, P67, DOI 10.1136/bjophthalmol-2017-311752
   Razavi S, 2015, AM J OPHTHALMOL, V160, P1006, DOI 10.1016/j.ajo.2015.08.009
   Regatieri Caio V, 2011, Ophthalmic Surg Lasers Imaging, V42 Suppl, pS56, DOI 10.3928/15428877-20110627-05
   Savastano MC, 2015, RETINA-J RET VIT DIS, V35, P2196, DOI 10.1097/IAE.0000000000000635
   Segal O, 2016, RETINA-J RET VIT DIS, V36, P259, DOI 10.1097/IAE.0000000000000690
   Sizmaz S, 2014, EUR J OPHTHALMOL, V24, P904, DOI 10.5301/ejo.5000478
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Spooner K, 2019, ACTA OPHTHALMOL, V97, pE706, DOI 10.1111/aos.14046
   Terasaki H, 2015, RETINA-J RET VIT DIS, V35, P1007, DOI 10.1097/IAE.0000000000000428
   Unlu C, 2017, INT OPHTHALMOL, V37, P147, DOI 10.1007/s10792-016-0242-3
NR 37
TC 8
Z9 8
U1 0
U2 1
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD MAR
PY 2020
VL 9
IS 1
BP 77
EP 85
DI 10.1007/s40123-019-00221-0
EA OCT 2019
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KT2AP
UT WOS:000493497400001
PM 31673999
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Banevicius, M
   Vilkeviciute, A
   Kriauciuniene, L
   Liutkeviciene, R
   Deltuva, VP
AF Banevicius, Mantas
   Vilkeviciute, Alvita
   Kriauciuniene, Loresa
   Liutkeviciene, Rasa
   Deltuva, Vytenis Pranas
TI The Association Between Variants of Receptor for Advanced Glycation End
   Products (RAGE) Gene Polymorphisms and Age-Related Macular Degeneration
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Glycosylation End Products, Advanced; Macular Degeneration;
   Polymorphism, Genetic
ID RETINAL-PIGMENT EPITHELIUM; ENDOPLASMIC-RETICULUM STRESS; BRUCHS
   MEMBRANE; INFLAMMATORY RESPONSES; UP-REGULATION; IN-VITRO; EXPRESSION;
   RISK; POPULATION; DISEASE
AB Background: Age-related macular degeneration (AMD) is the leading cause of blindness in people aged 65 years and older in developed countries. The pathogenesis of AMD has been linked to mechanisms involving inflammation, oxidative stress, and basal laminar deposit formation between retinal pigment epithelium (RPE) cells and the basal membrane, caused by advanced glycation end products (AGEs). AGEs are implicated in the pathogenesis of AMD through the AGE-and receptor for AGE (RAGE) interaction, which can be altered by polymorphisms of the RAGE gene. We examined RAGE rs1800624 and rs1800625 gene polymorphisms contributing to AMD development.
   Material/Methods: The study enrolled 300 patients with early AMD, 300 patients with exudative AMD, and 800 healthy controls. The genotyping was carried out using the RT-PCR method.
   Results: The analysis of two single nucleotide polymorphisms (SNPs) in the RAGE gene showed that rs1800624 was associated with a 1.6-fold decreased risk for exudative AMD under the dominant model after adjustment for age (OR=0.616; 95% CI: 0.394-0.963; p=0.034) and each copy of allele T at rs1800624 was associated with a 1.4-fold decreased risk for exudative AMD development under the additive model after adjustment for age (OR=0.701; 95% CI: 0.510-0.962; p=0.028). Analysis revealed that the rs1800625 allele G at rs1800625 was associated with a 1.5-fold increased risk for exudative AMD after adjustment for age (OR= 1.545; 95% CI: 1.003-2.379; p=0.048). These results suggested that the allele G at rs1800625 was a risk-allele for exudative AMD development. In haplotype analysis, A-G haplotype was significantly more frequently observed in exudative AMD patients compared to healthy controls (3.3% versus 1.4%, p=0.035).
   Conclusions: We revealed a significant association between RAGE gene rs1800624 and rs1800625 polymorphisms and AMD risk. We considered T allele at rs1800624 to be protective against AMD development, while allele G at rs1800625 was considered to be a marker of poor prognosis in AMD development.
C1 [Banevicius, Mantas; Kriauciuniene, Loresa; Liutkeviciene, Rasa] Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Kaunas, Lithuania.
   [Vilkeviciute, Alvita; Kriauciuniene, Loresa; Liutkeviciene, Rasa; Deltuva, Vytenis Pranas] Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences
RP Liutkeviciene, R (通讯作者)，Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Kaunas, Lithuania.; Liutkeviciene, R (通讯作者)，Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Kaunas, Lithuania.
EM rasa.liutkeviciene@kaunoklinikos.lt
CR Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   [Anonymous], 2011, AM J OPHTHALMOL, V132, P668
   Barile GR, 2005, INVEST OPHTH VIS SCI, V46, P2916, DOI 10.1167/iovs.04-1409
   Basta G, 2002, CIRCULATION, V105, P816, DOI 10.1161/hc0702.104183
   Belmokhtar K, 2016, ARTERIOSCL THROM VAS, V36, P800, DOI 10.1161/ATVBAHA.115.306349
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Bierhaus A, 2005, J MOL MED, V83, P876, DOI 10.1007/s00109-005-0688-7
   Botos I, 2011, STRUCTURE, V19, P447, DOI 10.1016/j.str.2011.02.004
   Cano M, 2011, AM J PATHOL, V179, P850, DOI 10.1016/j.ajpath.2011.04.010
   Chan CM, 2016, J CELL MOL MED, V20, P1749, DOI 10.1111/jcmm.12893
   Chen MQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109214
   Chen M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089548
   Cohen CR, 2012, GENE, V510, P7, DOI 10.1016/j.gene.2012.08.043
   Coughlan MT, 2009, J AM SOC NEPHROL, V20, P742, DOI 10.1681/ASN.2008050514
   Cunha C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027962
   de la Maza MP, 2009, REJUV RES, V11, P1041
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Villegas-Rodriguez ME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159175
   Farboud B, 1999, MOL VIS, V5, pU1
   Glenn JV, 2007, FASEB J, V21, P3542, DOI 10.1096/fj.06-7896com
   Glenn JV, 2009, BBA-GEN SUBJECTS, V1790, P1109, DOI 10.1016/j.bbagen.2009.04.016
   Glenn JV, 2009, INVEST OPHTH VIS SCI, V50, P441, DOI 10.1167/iovs.08-1724
   Goldin A, 2006, CIRCULATION, V114, P597, DOI 10.1161/CIRCULATIONAHA.106.621854
   Gomes LC, 2015, MOL CELL PROBE, V29, P503, DOI 10.1016/j.mcp.2015.10.001
   Gonzalez I, 2013, IMMUNOBIOLOGY, V218, P790, DOI 10.1016/j.imbio.2012.09.005
   Goulart AC, 2008, CLIN CHIM ACTA, V398, P95, DOI 10.1016/j.cca.2008.08.020
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hashim Z, 2011, AGE, V33, P377, DOI 10.1007/s11357-010-9177-1
   Hoffmann S, 2002, GRAEF ARCH CLIN EXP, V240, P996, DOI 10.1007/s00417-002-0568-6
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Inagi R, 2011, METHOD ENZYMOL, V491, P361, DOI 10.1016/B978-0-12-385928-0.00020-1
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kaji Y, 2007, INVEST OPHTH VIS SCI, V48, P858, DOI 10.1167/iovs.06-0495
   Kalea AZ, 2009, CLIN SCI, V116, P621, DOI 10.1042/CS20080494
   Kay P, 2014, INVEST OPHTH VIS SCI, V55, P926, DOI 10.1167/iovs.13-13239
   Kim J, 2016, MOL MED REP, V14, P3655, DOI 10.3892/mmr.2016.5702
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Lee J, 2013, EYE, V27, P266, DOI 10.1038/eye.2012.276
   Leu ST, 2002, EXP EYE RES, V74, P141, DOI 10.1006/exer.2001.1112
   Lin T, 2013, CYTOKINE, V62, P369, DOI 10.1016/j.cyto.2013.03.027
   Lindholm E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002546
   Lubitz I, 2016, AGING CELL, V15, P309, DOI 10.1111/acel.12436
   Ma WC, 2007, INVEST OPHTH VIS SCI, V48, P1355, DOI 10.1167/iovs.06-0738
   McFarlane S, 2005, BRIT J OPHTHALMOL, V89, P107, DOI 10.1136/bjo.2004.045914
   Ni JQ, 2009, MOL CELL PROTEOMICS, V8, P1921, DOI 10.1074/mcp.M900127-MCP200
   Ohgami N, 2001, J BIOL CHEM, V276, P3195, DOI 10.1074/jbc.M006545200
   PAN H, 2014, SCI REP UK, V4
   Park SW, 2015, ONCOTARGET, V6, P35263, DOI 10.18632/oncotarget.5894
   Pawlak AM, 2008, ANN NY ACAD SCI, V1126, P59, DOI 10.1196/annals.1433.066
   Prasad P, BMC MED GENET, V210, P52
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Ramasamy R, 2009, J LEUKOCYTE BIOL, V86, P505, DOI 10.1189/jlb.0409230
   Reitmeir P, 2017, AGE AGEING, V46, P481, DOI 10.1093/ageing/afw234
   Roehlecke C, 2016, GRAEF ARCH CLIN EXP, V254, P2361, DOI 10.1007/s00417-016-3463-2
   Sakiene R, 2016, ADV MED, V2016
   Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI14002
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Su S, 2015, J DENT RES, V94, P403, DOI 10.1177/0022034514566215
   Su SC, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001396
   Sun S, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0584-4
   Sun XH, 2016, MED SCI MONITOR, V22, P2105, DOI 10.12659/MSM.895689
   Tian J, 2005, P NATL ACAD SCI USA, V102, P11846, DOI 10.1073/pnas.0504759102
   Uchiki T, 2012, AGING CELL, V11, P1, DOI 10.1111/j.1474-9726.2011.00752.x
   Wang ZT, 2014, WORLD J GASTROENTERO, V20, P2397, DOI 10.3748/wjg.v20.i9.2397
   Willett TL, 2014, CURR OSTEOPOROS REP, V12, P329, DOI 10.1007/s11914-014-0214-3
   Wu MX, 2017, BRIT J OPHTHALMOL, V101, P976, DOI 10.1136/bjophthalmol-2016-309418
   Xie JL, 2013, CELL SIGNAL, V25, P2185, DOI 10.1016/j.cellsig.2013.06.013
   Xie JJ, 2008, J BIOL CHEM, V283, P27255, DOI 10.1074/jbc.M801622200
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Yoon KD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041309
   Yu XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076966
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Yue LL, 2016, J CELL MOL MED, V20, P1966, DOI 10.1111/jcmm.12888
   Zhang L, 2012, J BIOL CHEM, V287, P1520, DOI 10.1074/jbc.M111.275990
   Zong H, 2010, DIABETOLOGIA, V53, P2656, DOI 10.1007/s00125-010-1900-z
NR 78
TC 4
Z9 4
U1 0
U2 2
PU INT SCIENTIFIC LITERATURE, INC
PI SMITHTOWN
PA 361 FOREST LANE, SMITHTOWN, NY 11787 USA
SN 1643-3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD JAN 10
PY 2018
VL 24
BP 190
EP 199
DI 10.12659/MSM.905311
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FT4WB
UT WOS:000423154800001
PM 29317590
OA Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Liisborg, C
AF Liisborg, Charlotte
TI Age-related macular degeneration and myeloproliferative neoplasms-A
   common pathway
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
ID C-REACTIVE PROTEIN; NF-KAPPA-B; T-CELLS; POLYCYTHEMIA-VERA; ESSENTIAL
   THROMBOCYTHEMIA; CHRONIC INFLAMMATION; PLASMA-LEVELS; CANCER; RISK;
   DISEASE
AB Age-related macular degeneration (AMD) is the most common cause of irreversible vision loss and blindness in high-income countries. It is a progressive retinal disease leading to damage of the cells responsible for central vision. The early stages of the disease are often asymptomatic, while late-stage AMD, which is divided into two entities, neovascular AMD and geographic atrophy (GA), both show vision loss, though generally with different progression rates. Drusen and pigmentary abnormalities in the retina characterise early AMD, while nAMD and GA show angiogenesis in and atrophy of the retina, respectively. The aetiology is multifactorial and, in addition to ageing, which is the most significant risk factor for developing AMD, environmental-and genetic risk factors are implicated in the pathogenesis. Research has focused on local changes in the eye where inflammation has been found to play an essential role, but studies also point to systemic alterations and especially systemic inflammation to be involved in the pathogenesis.
   The Philadelphia-negative myeloproliferative neoplasms (MPN) are a group of haematological cancers with an acquired genetic defect of the pluripotent haematopoietic stem cell, characterised by excess haematopoiesis of the myeloid cell lineage. The diseases have been found to evolve in a biological continuum from early cancer state, essential thrombocythemia, over polycythaemia vera (PV), to the advanced myelofibrosis stage (PMF). The symptoms in these patients are often a result of the changes in the blood composition, hyperviscosity, microvascular disturbances, and reduced tissue perfusion. The major causes of morbidity and mortality are thromboembolic-and haemorrhagic events, and leukemic transformation. A group of mutations that drive the MPNs has been identified, e.g., the JAK2V617F mutation, which results in deregulation of the JAK/ STAT signal transduction pathway important, for instance, in cell differentiation and survival. A previous large register study has shown that patients with MPNs have an increased risk of neovascular AMD, and a pilot study has shown an increased prevalence of intermediate AMD. We wish to study this further in a larger scale study. Several studies have also shown that systemic inf lammation plays an essential role in both the initiation and progression of the malignant cell clone in MPNs. From this knowledge, a "Human inf lammation model" has been developed. Since then, the MPNs has been used as model diseases for a similar inf lammation model for the development of Alzheimer's disease. In this PhD project, we would like to investigate systemic inf lammation in relation to drusen presence. We will do this by comparing systemic immunological markers previously investigated in patients with AMD and compare with MPN. We are primarily interested in systemic immunological differences between patients with MPN and drusen ( MPNd) and MPN with normal retinas (MPNn).
   This thesis consists of two main studies. Study I investigated the prevalence of retinal changes associated with AMD and the prevalence of different AMD stages in 200 patients with MPN (paper I). Study II examined immunological similarities between AMD and MPNs. This study was divided into three substudies exploring systemic markers of inflammation, ageing and angiogenesis, respectively. This was done in four types of patients: nAMD, intermediate AMD (iAMD), MPNd and MPNn. Investigating, differences between MPNd and MPNn, will make it possible to identify changes in the immune system, relevant for AMD pathogenesis. Additionally, we will compare patients with MPNs with patients with iAMD and nAMD.
   In study I (Paper I), we found that patients with MPNs have a significantly higher prevalence of large drusen and consequently AMD from an earlier age compared to the estimates from three large population- -based studies. We also found that drusen prevalence was associated with a higher neutrophil-to-lymphocyte ratio indicating a higher level of chronic low-grade inflammation in patients with drusen compared to those without drusen.
   In study II (papers II, III and IV), we found immunological differences between patients with MPNd and MPNn. When we investigated markers of inflammation, we found a higher level of systemic inflammation in MPNd than MPNn. This was indicated by a higher inflammation score (based on levels of pro-inflammatory markers), a higher neutrophil-to-lymphocyte ratio, and indications of a deregulated complement system. When examining markers of ageing, we found signs of accelerated immune ageing in MPNd compared to MPNn, shown by more senescent effector memory T cells.
   Finally, when exploring a marker of angiogenesis, we found a lower CXCR3 expression on monocytes and T cells in nAMD compared to iAMD, MPNd and MPNn, in line with previous studies of nAMD compared to healthy controls. Further, we found decreasing CXCR3 expression over the MPN biological continuum. These studies indicate CXCR3 involvement in both nAMD and PMF, two disease stages characterised by angiogenesis and fibrosis.
   From the results of this PhD project, we can conclude that the prevalence of drusen and AMD is increased in patients with MPN compared to the general population. Further, our results show that systemic inflammation may play a far more essential role in AMD pathogenesis than previously anticipated. We, therefore, propose an AMD model (Figure 18) where inflammation can initiate and accelerate the normal age-dependent accumulation of debris in the retina, which later evolve into drusen, resulting in increased local inflammation, and over time early-and intermediate AMD. This results in the increased risk of developing the late debilitating stages of AMD.
C1 [Liisborg, Charlotte] Zealand Univ Hosp, Dept Ophthalmol, Roskilde, Denmark.
RP Liisborg, C (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Roskilde, Denmark.
EM liisborg@c.dk
OI Liisborg, Charlotte/0000-0002-6353-6027
CR Adams B, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00210
   Alonso-Fernandez P, 2008, J AM GERIATR SOC, V56, P2244, DOI 10.1111/j.1532-5415.2008.02018.x
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Andersen M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183620
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Moro-Garcia MA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00107
   Bak M, 2020, CANCERS, V12, DOI 10.3390/cancers12092700
   Bak M, 2017, JAMA OPHTHALMOL, V135, P835, DOI 10.1001/jamaophthalmol.2017.2011
   Balestrieri ML, 2008, CARDIOVASC RES, V78, P250, DOI 10.1093/cvr/cvn029
   Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0
   Barbui T, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0054-y
   Barcellini W, 2013, LEUKEMIA RES, V37, P1509, DOI 10.1016/j.leukres.2013.09.001
   Barosi G, 2014, CURR HEMATOL MALIG R, V9, P331, DOI 10.1007/s11899-014-0227-0
   Barosi G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035631
   Bektas A, 2017, J LEUKOCYTE BIOL, V102, P977, DOI 10.1189/jlb.3RI0716-335R
   Blann AD, 2000, BLOOD COAGUL FIBRIN, V11, P623, DOI 10.1097/00001721-200010000-00006
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Calle MC, 2012, DIABETES METAB, V38, P183, DOI 10.1016/j.diabet.2011.11.006
   Callender LA, 2018, AGING CELL, V17, DOI 10.1111/acel.12675
   Campos C, 2014, EXP GERONTOL, V54, P130, DOI 10.1016/j.exger.2014.01.008
   Cavalloni C, 2017, ONCOTARGET, V8, P33416, DOI 10.18632/oncotarget.16797
   Chakravarthy U, 2020, OPHTHALMOL RETINA, V4, P662, DOI 10.1016/j.oret.2020.01.012
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chan WK, 2013, J IMMUNOL, V191, P1625, DOI 10.4049/jimmunol.1300111
   Chapman NA, 2019, CLIN EXP OPHTHALMOL, V47, P106, DOI 10.1111/ceo.13343
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Chen M, 2016, CURR MOL MED, V16, P412, DOI 10.2174/1566524016666160324130031
   Chen M, 2019, PROG RETIN EYE RES, V69, P159, DOI 10.1016/j.preteyeres.2018.10.003
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Christensen AS, 2014, LEUKEMIA RES, V38, P490, DOI 10.1016/j.leukres.2014.01.014
   Christensen K, 2008, P NATL ACAD SCI USA, V105, P13274, DOI 10.1073/pnas.0804931105
   Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127
   Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144
   Cordua S, 2019, BLOOD, V134, P469, DOI 10.1182/blood.2019001113
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Cunningham C, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0117-2
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Danish National Chronic Myeloid Neoplasia Study Group, 2015, ANN CHRON MYEL NEOPL
   Dawson SR, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-78
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600-065X.2012.01099.x
   Dimberg A, 2010, CURR TOP MICROBIOL, V341, P59, DOI 10.1007/82_2010_21
   Drew W, 2018, EXP GERONTOL, V105, P70, DOI 10.1016/j.exger.2017.12.020
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Ehlers S, 2010, TRENDS IMMUNOL, V31, P184, DOI 10.1016/j.it.2010.02.003
   Ellulu MS, 2017, ARCH MED SCI, V13, P851, DOI 10.5114/aoms.2016.58928
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Ezzat MK, 2008, BRIT J OPHTHALMOL, V92, P976, DOI 10.1136/bjo.2007.129742
   Faber C, 2013, OPHTHALMOLOGY, V120, P2310, DOI 10.1016/j.ophtha.2013.04.014
   Falk MK, 2014, INVEST OPHTH VIS SCI, V55, P4050, DOI 10.1167/iovs.14-14107
   Fan YH, 2013, PROTEIN CELL, V4, P176, DOI 10.1007/s13238-013-2084-3
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fisher DAC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.683401
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27
   Franceschi C, 2000, ANN NY ACAD SCI, V908, P244
   Frederiksen H, 2011, BLOOD, V118, P6515, DOI 10.1182/blood-2011-04-348755
   Fritsch RD, 2005, J IMMUNOL, V175, P6489, DOI 10.4049/jimmunol.175.10.6489
   Fulop T, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01960
   Germolec DR, 2018, METHODS MOL BIOL, V1803, P57, DOI 10.1007/978-1-4939-8549-4_5
   Ghosh S., 2019, COMMUN BIOL, V21, P1
   Goronzy JJ, 2015, J IMMUNOL, V194, P4073, DOI 10.4049/jimmunol.1500046
   Groom JR, 2011, IMMUNOL CELL BIOL, V89, P207, DOI 10.1038/icb.2010.158
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hansson GK, 2009, J THROMB HAEMOST, V7, P328, DOI 10.1111/j.1538-7836.2009.03416.x
   Hansson GK, 2006, ANNU REV PATHOL-MECH, V1, P297, DOI 10.1146/annurev.pathol.1.110304.100100
   Hasselbalch HC, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01877-3
   Hasselbalch HC, 2019, SEMIN IMMUNOPATHOL, V41, P5, DOI 10.1007/s00281-018-0700-2
   Hasselbalch HC, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/102476
   Hasselbalch HC, 2015, EUR J HAEMATOL, V94, P96, DOI 10.1111/ejh.12437
   Hasselbalch HC, 2013, LEUKEMIA RES, V37, P214, DOI 10.1016/j.leukres.2012.10.020
   Hasselbalch HC, 2012, BLOOD, V119, P3219, DOI 10.1182/blood-2011-11-394775
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Hoermann G, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/869242
   Holmes C, 2013, NEUROPATH APPL NEURO, V39, P51, DOI 10.1111/j.1365-2990.2012.01307.x
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Hou YJ, 2019, NAT REV NEUROL, V15, P565, DOI 10.1038/s41582-019-0244-7
   Hughes CE, 2018, FEBS J, V285, P2944, DOI 10.1111/febs.14466
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kim SY, 2021, KOREAN J INTERN MED, V36, P45, DOI 10.3904/kjim.2020.319
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kolb H., 2007, WEBVISION ORG RETINA
   Kristinsson SY, 2010, HAEMATOL-HEMATOL J, V95, P1216, DOI 10.3324/haematol.2009.020412
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Larsen TS, 2007, EUR J HAEMATOL, V79, P508, DOI 10.1111/j.1600-0609.2007.00960.x
   Lathe R, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-36
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Lemster BH, 2008, J IMMUNOL, V180, P1979, DOI 10.4049/jimmunol.180.3.1979
   Lentsch AB, 2000, J PATHOL, V190, P343
   Liisborg C, 2020, CANCERS, V12, DOI 10.3390/cancers12030573
   Ling M, 2019, CLIN LAB MED, V39, P579, DOI 10.1016/j.cll.2019.07.006
   Liukkonen M, 2022, ACTA OPHTHALMOL, V100, DOI 10.1111/j.1755-3768.2022.001
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Luque LFM, 2019, CURR HEMATOL MALIG R, V14, P145, DOI 10.1007/s11899-019-00508-w
   Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706
   Lynch AM, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.10.12
   Lynch AM, 2020, BMJ OPEN OPHTHALMOL, V5, DOI 10.1136/bmjophth-2019-000361
   Lynch AM, 2020, EUR J OPHTHALMOL, V30, P1061, DOI 10.1177/1120672119857896
   Machalinska A, 2009, OPHTHALMIC RES, V42, P54, DOI 10.1159/000219686
   Martinez-Alberquilla I, 2022, AGEING RES REV, V74, DOI 10.1016/j.arr.2021.101553
   Mathieu P, 2010, CLIN PHARMACOL THER, V87, P407, DOI 10.1038/clpt.2009.311
   McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007
   McGuinness MB, 2018, JAMA OPHTHALMOL, V136, P139, DOI 10.1001/jamaophthalmol.2017.4782
   McMullin MF, 2020, CANCERS, V12, DOI 10.3390/cancers12071810
   Medinger M, 2014, MEMO-MAG EUR MED ONC, V7, P206, DOI 10.1007/s12254-014-0142-z
   Medinger M, 2009, BRIT J HAEMATOL, V146, P150, DOI 10.1111/j.1365-2141.2009.07726.x
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Mikkelsen SU, 2018, CANCER MED-US, V7, P3571, DOI 10.1002/cam4.1619
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Modjtahedi BS, 2018, AM J OPHTHALMOL, V188, P111, DOI 10.1016/j.ajo.2018.01.012
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Netea MG, 2017, NAT IMMUNOL, V18, P826, DOI 10.1038/ni.3790
   Niazi S, 2019, ACTA OPHTHALMOL, V97, P558, DOI 10.1111/aos.14072
   Niccoli T, 2012, CURR BIOL, V22, pR741, DOI 10.1016/j.cub.2012.07.024
   Nielsen MK, 2019, ACTA OPHTHALMOL, V97, P84, DOI 10.1111/aos.13894
   Nowak JZ, 2014, EXPERT OPIN DRUG SAF, V13, P687, DOI 10.1517/14740338.2014.915939
   Park DH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01007
   Pawelec G, 2018, EXP GERONTOL, V105, P4, DOI 10.1016/j.exger.2017.10.024
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   PENFOLD PL, 1986, INVEST OPHTH VIS SCI, V27, P364
   Peniket A.J., 2002, CPD B CELLULAR PATHO, V4, P35
   Pereira BI, 2020, NAT IMMUNOL, V21, P684, DOI 10.1038/s41590-020-0643-3
   Pittet MJ, 2000, J IMMUNOL, V164, P1148, DOI 10.4049/jimmunol.164.3.1148
   REISNER SA, 1992, AM J MED, V93, P498, DOI 10.1016/0002-9343(92)90576-W
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricci F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218242
   Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0
   Ristau T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093459
   Roizenblatt M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113688
   Romagnani P, 2004, TRENDS IMMUNOL, V25, P201, DOI 10.1016/j.it.2004.02.006
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Schnabolk G, 2019, ADV EXP MED BIOL, V1185, P27, DOI 10.1007/978-3-030-27378-1_5
   Schnabolk G, 2019, INVEST OPHTH VIS SCI, V60, P3520, DOI 10.1167/iovs.18-26444
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Sedeh FB, 2017, DAN MED J, V64
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Shallis RM, 2021, HEMATOL ONCOL CLIN N, V35, P177, DOI 10.1016/j.hoc.2020.11.005
   Shallis RM, 2020, BLOOD REV, V42, DOI 10.1016/j.blre.2020.100706
   Shen EM, 2017, SCI REP-UK, V7, P1, DOI 10.1038/srep43027
   Singh A, 2012, AM J OPHTHALMOL, V154, P193, DOI 10.1016/j.ajo.2012.01.036
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Soulas C, 2009, AM J PATHOL, V174, P1808, DOI 10.2353/ajpath.2009.081010
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spivak JL, 2017, NEW ENGL J MED, V376, P2168, DOI 10.1056/NEJMra1406186
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Stoll G, 2006, STROKE, V37, P1923, DOI 10.1161/01.STR.0000226901.34927.10
   Subhi Y, 2017, AGING-US, V9, P2436, DOI 10.18632/aging.101329
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Tefferi A, 2013, LEUKEMIA, V27, P1874, DOI 10.1038/leu.2013.163
   Tefferi A, 2015, JAMA ONCOL, V1, P97, DOI 10.1001/jamaoncol.2015.89
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Vallejo AN, 2011, AGEING RES REV, V10, P354, DOI 10.1016/j.arr.2010.09.006
   Van Acker HH, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00892
   van Beek JHGM, 2016, INTERFACE FOCUS, V6, DOI 10.1098/rsfs.2015.0079
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wagner BD, 2022, OPHTHAL EPIDEMIOL, V29, P139, DOI 10.1080/09286586.2021.1910314
   Walker KA, 2019, ACS CHEM NEUROSCI, V10, P3340, DOI 10.1021/acschemneuro.9b00333
   Weng NP, 2009, TRENDS IMMUNOL, V30, P306, DOI 10.1016/j.it.2009.03.013
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu XQ, 2021, DRUG AGING, V38, P817, DOI 10.1007/s40266-021-00885-z
   Zhang ZY, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2896036
NR 177
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD OCT
PY 2022
VL 100
SU 271
SI SI
BP 3
EP 35
DI 10.1111/aos.15247
PG 33
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 5C1VT
UT WOS:000864055400002
PM 36200281
DA 2022-11-30
ER

PT J
AU Bonyadi, MHJ
   Yaseri, M
   Bonyadi, M
   Soheilian, M
AF Bonyadi, Mohammad Hossein Jabbarpoor
   Yaseri, Mehdi
   Bonyadi, Mortaza
   Soheilian, Masoud
TI Association of ARMS2/LOC387715 A69S, CFH Y402H, and CFH I62V
   polymorphisms with retinal angiomatous proliferation compared with
   typical age-related macular degeneration: a meta-analysis
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Review
DE Meta-analysis; ARMS2/LOC387715 A69S; CFH Y402H; CFH I62V; Age-related
   macular degeneration (AMD); Retinal angiomatous proliferation (RAP);
   Mechanism of pathogenesis
ID COMPLEMENT FACTOR-H; POLYPOIDAL CHOROIDAL VASCULOPATHY; JAPANESE
   POPULATION; GENE POLYMORPHISMS; RISK ALLELES; ARMS2; SUSCEPTIBILITY;
   NEOVASCULARIZATION; MACULOPATHY; ANASTOMOSIS
AB To compare the published results of studies on the genotype association of ARMS2/LOC387715 A69S, CFH Y402H, and CFH I62V in cases diagnosed as retinal angiomatous proliferation (RAP) versus neovascular age-related macular degeneration (AMD) or healthy controls.
   Heterogeneity of studies was evaluated using Cochran's Q test and I-square index. To modify the heterogeneity in the variables, we used random effects model. Meta-analysis was performed using STATA.
   Four studies were included with 1076 neovascular AMD patients, 222 RAP cases, and 2276 control subjects. Pooled overall odds ratios for RAP/AMD were 1.15 (95% CI 0.60-2.18) for GT versus GG, 3.52 (95% CI 1.25-9.91) for TT versus GG ARMS2, 0.98 (95% CI 0.22-4.29) for GA versus AA, 1.00 (95% CI 0.25-4.02) for GG versus AA CFHI62V, 0.57 (95% CI 0.35-0.93) for CT versus TT CFH Y402H, and 0.40 (95% CI 0.22-0.74) for CC versus TT CFH Y402H. Regression analysis showed that ARMS2 TT genotype has a statistically significant effect on RAP versus AMD compared to CFH genotypes (P < 0.001).
   This meta-analysis disclosed a stronger effect of ARMS2 genotypes in RAP cases compared with CFH Y402H and I62V genotypes.
C1 [Bonyadi, Mohammad Hossein Jabbarpoor; Soheilian, Masoud] Shahid Beheshti Univ Med Sci, Ocular Tissue Engn Res Ctr, Ophthalm Res Ctr, Pasdaran Ave,Boustan 9th St, Tehran, Iran.
   [Yaseri, Mehdi] Univ Tehran Med Sci, Dept Biostat & Epidemiol, Tehran, Iran.
   [Bonyadi, Mortaza] Univ Tabriz, Ctr Excellence Biodivers, Fac Nat Sci, Tabriz, Iran.
C3 Shahid Beheshti University Medical Sciences; Tehran University of
   Medical Sciences; University of Tabriz
RP Bonyadi, MHJ (通讯作者)，Shahid Beheshti Univ Med Sci, Ocular Tissue Engn Res Ctr, Ophthalm Res Ctr, Pasdaran Ave,Boustan 9th St, Tehran, Iran.
EM mhbonyadi@yahoo.com
RI Soheilian, Masoud/AAW-4743-2020; Hossein, Jabbarpoor Bonyadi
   Mohammad/A-1886-2014; Yaseri, Mehdi/I-1645-2018
OI Yaseri, Mehdi/0000-0002-4066-873X; Soheilian, Masoud/0000-0001-7508-426X
FU Ophthalmic Research Center, Shahid Beheshti University of Medical
   Sciences, Tehran, Iran
FX The authors would like to acknowledge the support provided by Ophthalmic
   Research Center, Shahid Beheshti University of Medical Sciences, Tehran,
   Iran.
CR Bonyadi MHJ, 2016, CURR EYE RES, V41, P1519, DOI 10.3109/02713683.2016.1158274
   Bottoni F, 2005, ARCH OPHTHALMOL-CHIC, V123, P1644, DOI 10.1001/archopht.123.12.1644
   Caramoy A, 2014, ACTA OPHTHALMOL, V92, P745, DOI 10.1111/aos.12437
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maguire MG, 2016, JAMA OPHTHALMOL, V134, P674, DOI 10.1001/jamaophthalmol.2016.0669
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Ohkuma Y, 2014, CLIN OPHTHALMOL, V8, P143, DOI 10.2147/OPTH.S56483
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Scott AW, 2010, EYE, V24, P491, DOI 10.1038/eye.2009.311
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Tanaka K, 2011, MOL VIS, V17, P2751
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tong Y, 2010, MOL VIS, V16, P1958
   Viola F, 2009, RETINA-J RET VIT DIS, V29, P732, DOI 10.1097/IAE.0b013e3181a395cb
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Xu YT, 2012, INT J OPHTHALMOL-CHI, V5, P125, DOI 10.3980/j.issn.2222-3959.2012.02.02
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yoneyama S, 2014, OPHTHALMIC GENET, V35, P151, DOI 10.3109/13816810.2014.921313
NR 33
TC 3
Z9 3
U1 0
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD DEC
PY 2017
VL 37
IS 6
BP 1397
EP 1409
DI 10.1007/s10792-016-0413-2
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FL1PB
UT WOS:000413985800021
PM 28005184
DA 2022-11-30
ER

PT J
AU Subhi, Y
   Henningsen, GO
   Larsen, CT
   Sorensen, MS
   Sorensen, TL
AF Subhi, Yousif
   Henningsen, Gitte O.
   Larsen, Charlotte T.
   Sorensen, Mette S.
   Sorensen, Torben L.
TI Foveal Morphology Affects Self-Perceived Visual Function and Treatment
   Response in Neovascular Age-Related Macular Degeneration: A Cohort Study
SO PLOS ONE
LA English
DT Article
ID QUALITY-OF-LIFE; VISION-RELATED FUNCTION; QUESTIONNAIRE NEI-VFQ;
   RANIBIZUMAB TREATMENT; PHOTORECEPTOR INTEGRITY; SUBGROUP ANALYSIS;
   CLINICAL-TRIAL; ACUITY; PREDICTORS; EYES
AB Objectives: To investigate the relationship between foveal morphology and self-perceived visual function in patients with neovascular age-related macular degeneration (AMD) and whether foveal characteristics are associated with Ranibizumab treatment response on the self-perceived visual function.
   Methods: This prospective cohort study included patients with newly diagnosed neovascular AMD found eligible for treatment with Ranibizumab. Foveal morphology of both eyes was assessed using spectral-domain optical coherence tomography and all patients were interviewed using the 39-item National Eye Institute Visual Function Questionnaire (VFQ). Patients were re-interviewed 3 and 12 months after initiation of treatment with Ranibizumab. We evaluated foveal morphology at baseline in relation to VFQ scores at baseline and clinically meaningful changes in VFQ after 3 and 12 months.
   Results: VFQ scores correlated with central foveal thickness, central foveal thickness of neuroretina (CFN), foveal RPE elevation, foveal integrity of the photoreceptor inner segment/outer segment junction (IS/OS), and external limiting membrane. In a multiple linear regression model, only best-corrected visual acuity of the better eye (p<0.001) and the IS/OS status in the better eye (p = 0.012) remained significant (Adjusted R-2 = 0.418). Lower baseline VFQ and a baseline CFN within 170-270 mu m in the better eye were both associated with a clinically meaningful increase in the VFQ scores after 3 and 12 months. An absent foveal IS/OS band in the better eye was associated with a clinically meaningful decrease in the VFQ scores at 12 months.
   Conclusions: Foveal morphology in the better eye influences the self-perceived visual function in patients with neovascular AMD and possesses a predictive value for change in the self-perceived visual function at 3 and 12 months after initiation of treatment. These findings may help clinicians provide patients more individualized information of their disease and treatment prognosis from a patient-perceived point-of-view.
C1 [Subhi, Yousif; Henningsen, Gitte O.; Larsen, Charlotte T.; Sorensen, Mette S.; Sorensen, Torben L.] Copenhagen Univ Hosp Roskilde, Dept Ophthalmol, Clin Eye Res Unit, Roskilde, Denmark.
   [Subhi, Yousif; Sorensen, Torben L.] Univ Copenhagen, Copenhagen, Denmark.
C3 University of Copenhagen; University of Copenhagen
RP Sorensen, TL (通讯作者)，Copenhagen Univ Hosp Roskilde, Dept Ophthalmol, Clin Eye Res Unit, Roskilde, Denmark.
EM torbenls@dadlnet.dk
RI Subhi, Yousif/ABG-6330-2020; Sørensen, Torben Lykke L/N-1417-2014
OI Subhi, Yousif/0000-0001-6620-5365; Sørensen, Torben Lykke
   L/0000-0002-6790-0199
FU Region Zealand Research Foundation
FX This work is supported by the Region Zealand Research Foundation. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Akagi-Kurashige Y, 2012, GRAEF ARCH CLIN EXP, V250, P1129, DOI 10.1007/s00417-012-1928-5
   Bauer P, 2008, KLIN MONATSBL AUGENH, V225, P376, DOI 10.1055/s-2008-1027264
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Brundage M, 2011, QUAL LIFE RES, V20, P653, DOI 10.1007/s11136-010-9793-3
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Chhablani J, 2013, INT J OPHTHALMOL-CHI, V6, P62, DOI 10.3980/j.issn.2222-3959.2013.01.13
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kurashige Y, 2012, RETINA-J RET VIT DIS, V32, P792, DOI 10.1097/IAE.0b013e3182278b98
   Leys A, 2008, EYE, V22, P792, DOI 10.1038/sj.eye.6702900
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Marella M, 2010, INVEST OPHTH VIS SCI, V51, P2878, DOI 10.1167/iovs.09-4494
   Margolis MK, 2002, PHARMACOECONOMICS, V20, P791, DOI 10.2165/00019053-200220120-00001
   Marques IR, 2013, OPHTHALMOLOGICA, V229, P158, DOI 10.1159/000343709
   Miskala PH, 2007, OPHTHAL EPIDEMIOL, V14, P205, DOI 10.1080/09286580701502970
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Orr P, 2011, INVEST OPHTH VIS SCI, V52, P3354, DOI 10.1167/iovs.10-5645
   Pappuru RR, 2011, INVEST OPHTH VIS SCI, V52, P6743, DOI 10.1167/iovs.10-6723
   Pesudovs K, 2010, J CATARACT REFR SURG, V36, P718, DOI 10.1016/j.jcrs.2009.11.019
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Revicki DA, 2010, INVEST OPHTH VIS SCI, V51, P712, DOI 10.1167/iovs.09-3766
   Richter-Mueksch S, 2006, GRAEF ARCH CLIN EXP, V244, P154, DOI 10.1007/s00417-005-0063-y
   Rubin GS, 2000, INVEST OPHTH VIS SCI, V41, P3327
   Sabour-Pickett S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/268438
   Shin HJ, 2012, GRAEF ARCH CLIN EXP, V250, P61, DOI 10.1007/s00417-011-1774-x
   Shin HJ, 2011, RETINA-J RET VIT DIS, V31, P1627, DOI 10.1097/IAE.0b013e31820d3d01
   Sorensen MS, 2011, DAN MED BULL, V58
   Sorensen TL, 2011, ACTA OPHTHALMOL, V89, pE97, DOI 10.1111/j.1755-3768.2010.01899.x
   Suner IJ, 2009, INVEST OPHTH VIS SCI, V50, P3629, DOI 10.1167/iovs.08-3225
   Tuulonen A, 2009, ACTA OPHTHALMOL, V87, P820, DOI 10.1111/j.1755-3768.2009.01532.x
   Watanabe K, 2013, JAMA OPHTHALMOL, V131, P172, DOI 10.1001/jamaophthalmol.2013.686
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 39
TC 23
Z9 23
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 11
PY 2014
VL 9
IS 3
AR e91227
DI 10.1371/journal.pone.0091227
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AC9GM
UT WOS:000332842400059
PM 24618706
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Mai, E
   Chan, J
   Goon, L
   Ego, BK
   Bevers, J
   Wong, T
   Wong, M
   Corpuz, R
   Xi, HK
   Wu, J
   Schneider, K
   Seshasayee, D
   Grimbaldeston, M
   Nakamura, G
   Indjeian, VB
   Campagne, MV
   Loyet, KM
   Comps-Agrar, L
AF Mai, Elaine
   Chan, Joyce
   Goon, Levina
   Ego, Braeden K.
   Bevers, Jack
   Wong, Tiffany
   Wong, Manda
   Corpuz, Racquel
   Xi, Hongkang
   Wu, Jia
   Schneider, Kellen
   Seshasayee, Dhaya
   Grimbaldeston, Michele
   Nakamura, Gerald
   Indjeian, Vahan B.
   Campagne, Menno van Lookeren
   Loyet, Kelly M.
   Comps-Agrar, Laetitia
TI Development of an ultra-sensitive human IL-33 biomarker assay for
   age-related macular degeneration and asthma drug development
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE IL-33; ST2; iPCR; Biomarker; Age-related macular degeneration; Asthma
ID IMMUNE-RESPONSE; INTERLEUKIN-33; ST2; CYTOKINE; DISEASE; ANTIGENS;
   DOMAIN; PCR
AB Background: Over the past decade, human Interleukin 33 (hIL-33) has emerged as a key contributor to the pathogenesis of numerous inflammatory diseases. Despite the existence of several commercial hIL-33 assays spanning multiple platform technologies, their ability to provide accurate hIL-33 concentration measurements and to differentiate between active (reduced) and inactive (oxidized) hIL-33 in various matrices remains uncertain. This is especially true for lower sample volumes, matrices with low hIL-33 concentrations, and matrices with elevated levels of soluble Interleukin 1 Receptor-Like 1 (sST2), an inactive form of ST2 that competes with membrane bound ST2 for hIL-33 binding.
   Results: We tested the performance of several commercially available hIL-33 detection assays in various human matrices and found that most of these assays lacked the sensitivity to accurately detect reduced hIL-33 at biologically relevant levels (sub-to-low pg/mL), especially in the presence of human sST2 (hsST2), and/or lacked sufficient target specificity.To address this, we developed and validated a sensitive and specific enzyme-linked immunosorbent assay (ELISA) capable of detecting reduced and total hIL-33 levels even in the presence of high concentrations of sST2. By incorporating the immuno-polymerase chain reaction (iPCR) platform, we further increased the sensitivity of this assay for the reduced form of hIL-33 by similar to 52-fold. Using this hIL-33 iPCR assay, we detected hIL-33 in postmortem human vitreous humor (VH) samples from donors with age-related macular degeneration (AMD) and found significantly increased hIL-33 levels when compared to control individuals. No statistically significant difference was observed in aqueous humor (AH) from AMD donors nor in plasma and nasosorption fluid (NF) from asthma patients compared to control individuals.
   Conclusions: Unlike existing commercial hIL-33 assays, our hIL-33 bioassays are highly sensitive and specific and can accurately quantify hIL-33 in various human clinical matrices, including those with high levels of hsST2. Our results provide a proof of concept of the utility of these assays in clinical trials targeting the hIL-33/hST2 pathway.
C1 [Mai, Elaine; Chan, Joyce; Goon, Levina; Ego, Braeden K.; Loyet, Kelly M.; Comps-Agrar, Laetitia] Genentech Inc, Dept Biochem & Cellular Pharmacol, San Francisco, CA 94080 USA.
   [Bevers, Jack; Xi, Hongkang; Wu, Jia; Schneider, Kellen; Seshasayee, Dhaya; Nakamura, Gerald] Genentech Inc, Dept Antibody Engn, San Francisco, CA 94080 USA.
   [Wong, Tiffany; Wong, Manda; Corpuz, Racquel] Genentech Inc, Dept Struct Biol, San Francisco, CA 94080 USA.
   [Grimbaldeston, Michele; Indjeian, Vahan B.] Genentech Inc, Dept OMNI Biomarker Dev, San Francisco, CA 94080 USA.
   [Xi, Hongkang; Campagne, Menno van Lookeren] Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA.
   [Goon, Levina] Exelixis, Dept Biol & Compound Repository, Alameda, CA USA.
   [Ego, Braeden K.] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA.
   [Campagne, Menno van Lookeren] Amgen Inc, Amgen Res, Dept Inflammat & Oncol, San Francisco, CA USA.
C3 Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding;
   Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Exelixis,
   Inc.; Stanford University; Amgen
RP Comps-Agrar, L (通讯作者)，Genentech Inc, Dept Biochem & Cellular Pharmacol, San Francisco, CA 94080 USA.
EM compsagl@gene.com
OI Comps-Agrar, Laetitia/0000-0002-5260-6536; Wong,
   Manda/0000-0001-5830-1517
FU Genentech, Inc./Hoffmann La-Roche
FX This study was supported by Genentech, Inc./Hoffmann La-Roche.
CR Allakhverdi Z, 2007, J IMMUNOL, V179, P2051, DOI 10.4049/jimmunol.179.4.2051
   Augustine J, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1625-y
   Barbour M, 2014, EUR J IMMUNOL, V44, P3320, DOI 10.1002/eji.201444671
   Bessa J, 2014, J AUTOIMMUN, V55, P33, DOI 10.1016/j.jaut.2014.02.012
   Bhutto IA, 2016, BRIT J OPHTHALMOL, V100, P720, DOI 10.1136/bjophthalmol-2015-308290
   Cayrol C, 2018, IMMUNOL REV, V281, P154, DOI 10.1111/imr.12619
   Cayrol C, 2014, CURR OPIN IMMUNOL, V31, P31, DOI 10.1016/j.coi.2014.09.004
   Cohen ES, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9327
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Gadani SP, 2015, NEURON, V85, P703, DOI 10.1016/j.neuron.2015.01.013
   Goldstein LD, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0551-y
   Griesenauer B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00475
   Hayakawa H, 2007, J BIOL CHEM, V282, P26369, DOI 10.1074/jbc.M704916200
   Hu JY, 2020, MUCOSAL IMMUNOL, V13, P919, DOI 10.1038/s41385-020-0288-4
   Jahromi SR, 2014, J ASTHMA, V51, P1004, DOI 10.3109/02770903.2014.938353
   Kearley J, 2015, IMMUNITY, V42, P566, DOI 10.1016/j.immuni.2015.02.011
   Ketelaar ME, 2016, CLIN EXP ALLERGY, V46, P884, DOI 10.1111/cea.12718
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   Lefrancais E, 2014, P NATL ACAD SCI USA, V111, P15502, DOI 10.1073/pnas.1410700111
   Lefrancais E, 2012, P NATL ACAD SCI USA, V109, P1673, DOI 10.1073/pnas.1115884109
   Liew FY, 2016, NAT REV IMMUNOL, V16, P676, DOI 10.1038/nri.2016.95
   Lingel A, 2009, STRUCTURE, V17, P1398, DOI 10.1016/j.str.2009.08.009
   Liu X, 2013, P NATL ACAD SCI USA, V110, P14918, DOI 10.1073/pnas.1308651110
   Lu YM, 2016, BIOANALYSIS, V8, P1067, DOI 10.4155/bio-2016-0003
   Mahneh SB, 2015, INT ARCH ALLERGY IMM, V168, P193, DOI 10.1159/000442413
   Makrinioti H, 2014, LANCET RESP MED, V2, P226, DOI 10.1016/S2213-2600(13)70261-3
   Malou N, 2011, TRENDS MICROBIOL, V19, P295, DOI 10.1016/j.tim.2011.03.004
   Momen T, 2017, INT J PREVENTIVE MED, V8, DOI 10.4103/ijpvm.IJPVM_179_16
   Moussion C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003331
   Niemeyer CM, 2007, NAT PROTOC, V2, P1918, DOI 10.1038/nprot.2007.267
   Saluja R, 2015, CLIN TRANSL ALLERGY, V5, DOI 10.1186/s13601-015-0076-5
   SANO T, 1992, SCIENCE, V258, P120, DOI 10.1126/science.1439758
   Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015
   Takeuchi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137358
   Theodoropoulou S, 2017, J PATHOL, V241, P45, DOI 10.1002/path.4816
   Voloshyna I, 2015, CLIN EXP ALLERGY, V45, P1554, DOI 10.1111/cea.12516
   Xi HK, 2016, J EXP MED, V213, P189, DOI 10.1084/jem.20150894
   Zhang JH, 2014, ANAL BIOCHEM, V463, P61, DOI 10.1016/j.ab.2014.06.024
NR 38
TC 2
Z9 2
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD DEC 20
PY 2021
VL 19
IS 1
AR 517
DI 10.1186/s12967-021-03189-3
PG 15
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA XS5SN
UT WOS:000732968600008
PM 34930320
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Mariani, A
   Deli, A
   Ambresin, A
   Mantel, I
AF Mariani, Alessandro
   Deli, Angeliki
   Ambresin, Aude
   Mantel, Irmela
TI Characteristics of eyes with secondary loss of visual acuity receiving
   variable dosing ranibizumab for neovascular age-related macular
   degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Anti-VEGF; Ranibizumab; Visual acuity
   loss; Pigment epithelial detachment
ID PIGMENT EPITHELIAL TEARS; INTRAVITREAL BEVACIZUMAB INJECTION; SUBGROUP
   ANALYSIS; AMD; MEMBRANES; THERAPY; VERTEPORFIN; DETACHMENT; ANCHOR
AB The aim of this work is to investigate the characteristics of eyes failing to maintain visual acuity (VA) receiving variable dosing ranibizumab for neovascular age-related macular degeneration (nAMD) after three initial loading doses.
   A consecutive series of patients with nAMD, who, after three loading doses of intravitreal ranibizumab (0.5 mg each), were re-treated for fluid seen on optical coherence tomography. After exclusion of eyes with previous treatment, follow-up less than 12 months, or missed visits, 99 patients were included in the analysis. The influence of baseline characteristics, initial VA response, and central retinal thickness (CRT) fluctuations on the VA stability from month 3 to month 24 were analyzed using subgroups and multiple regression analyses.
   Mean follow-up duration was 21.3 months (range 12-40 months, 32 patients followed-up for a parts per thousand yen24 months). Secondary loss of VA (loss of five letters or more) after month 3 was seen in 30 patients (mean VA improvement from baseline +5.8 letters at month 3, mean loss from baseline -5.3 letters at month 12 and -9.7 at final visit up to month 24), while 69 patients maintained vision (mean gain +8.9 letters at month 3, +10.4 letters at month 12, and +12.8 letters at final visit up to month 24). Secondary loss of VA was associated with the presence of pigment epithelial detachment (PED) at baseline (p 0.01), but not with baseline fibrosis/atrophy/hemorrhage, CRT fluctuations, or initial VA response. Chart analysis revealed additional individual explanations for the secondary loss of VA, including retinal pigment epithelial tears, progressive fibrosis, and atrophy.
   Tissue damage due to degeneration of PED, retinal pigment epithelial tears, progressive fibrosis, progressive atrophy, or massive hemorrhage, appears to be relevant in causing secondary loss of VA despite vascular endothelial growth factor suppression. PED at baseline may represent a risk factor.
C1 [Mariani, Alessandro; Deli, Angeliki; Ambresin, Aude; Mantel, Irmela] Univ Lausanne, Jules Gonin Eye Hosp, Dept Ophthalmol, CH-1000 Lausanne 7, Switzerland.
C3 University of Lausanne
RP Mantel, I (通讯作者)，Univ Lausanne, Jules Gonin Eye Hosp, Dept Ophthalmol, 15 Av France,Case Postale 133, CH-1000 Lausanne 7, Switzerland.
EM i.mantel.widmer@gmx.ch
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Arias L, 2007, EUR J OPHTHALMOL, V17, P992, DOI 10.1177/112067210701700622
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gerding H, 2010, KLIN MONATSBL AUGENH, V227, P294, DOI 10.1055/s-0029-1245209
   Gerding H, 2011, GRAEF ARCH CLIN EXP, V249, P653, DOI 10.1007/s00417-011-1636-6
   Giani A, 2010, RETINA-J RET VIT DIS, V30, P607, DOI 10.1097/IAE.0b013e3181c2e09d
   Heimes B, 2011, GRAEF ARCH CLIN EXP, V249, P639, DOI 10.1007/s00417-010-1524-5
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Konstantinidis L, 2010, ACTA OPHTHALMOL, V88, P736, DOI 10.1111/j.1755-3768.2009.01547.x
   Kook D, 2008, OPHTHALMOLOGE, V105, P158, DOI 10.1007/s00347-007-1561-6
   Mantel I, 2008, OPHTHALMOLOGICA, V222, P321, DOI 10.1159/000144075
   Menghini M, 2010, KLIN MONATSBL AUGENH, V227, P244, DOI 10.1055/s-0029-1245203
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Tao Y, 2010, RETINA-J RET VIT DIS, V30, P1426, DOI 10.1097/IAE.0b013e3181d5e964
   Weinberger AWA, 2007, AM J OPHTHALMOL, V144, P294, DOI 10.1016/j.ajo.2007.03.024
NR 29
TC 31
Z9 33
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD NOV
PY 2011
VL 249
IS 11
BP 1635
EP 1642
DI 10.1007/s00417-011-1734-5
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 838NP
UT WOS:000296299600004
PM 21725716
OA Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Spaide, RF
   Yannuzzi, L
   Freund, KB
   Mullins, R
   Stone, E
AF Spaide, Richard F.
   Yannuzzi, Lawrence
   Freund, K. Bailey
   Mullins, Robert
   Stone, Edwin
TI EYES WITH SUBRETINAL DRUSENOID DEPOSITS AND NO DRUSEN Progression of
   Macular Findings
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE atrophy; age-related macular degeneration; drusen; macular
   neovascularization; optical coherence tomography; pseudodrusen;
   subretinal drusenoid deposits
ID AGE-RELATED MACULOPATHY; RETICULAR PSEUDODRUSEN; PATTERN DYSTROPHY;
   RISK-FACTORS; FUNDUS AUTOFLUORESCENCE; PHENOTYPIC VARIATION; GEOGRAPHIC
   ATROPHY; DEGENERATION; PREVALENCE; CHOLESTEROL
AB Purpose: To investigate the macular changes over time in eyes containing subretinal drusenoid deposits (also known as pseudodrusen) with no drusen >63 mu m.
   Methods: A consecutive series of patients were examined with color fundus photography, optical coherence tomography, and autofluorescence imaging with fluorescein angiography used as necessary. Exclusionary criteria included macular neovascularization, history of retinal surgery, pseudoxanthoma elasticum, and drusen >63 mu m.
   Results: There were 85 eyes of 54 patients. The mean age at baseline was 83.6 (+/- 7.8) years, and there were 17 men. The mean follow-up was 5.0 (+/- 2.9) years. At initial optical coherence tomography examination, 12 eyes had extrafoveal atrophy and 17 eyes had vitelliform deposits, which were yellowish white subretinal collections that showed intense hyperautofluorescence. During follow-up, 11 eyes lost vitelliform material. After the disappearance of small deposits, focal hyperpigmentation remained. Loss of larger deposits was associated with noteworthy sequela; six developed subfoveal atrophy and one macular neovascularization close to regressing vitelliform material. Subfoveal geographic atrophy developed in four other eyes without vitelliform material by extension from areas of extrafoveal atrophy. Macular neovascularization developed in seven eyes over follow-up. The CFH Y402H and ARMS2 A69S allele frequencies were 57% and 48.9%, respectively, which is similar to a group of age-related macular degeneration controls. One patient had a novel PRPH2 mutation, but did not have a vitelliform deposit; the remainder had a normal PRPH2 and BEST1 coding sequences.
   Conclusion: Eyes with subretinal drusenoid deposits and no drusen >63 mm have significant risk for the development of both neovascularization and geographic atrophy, the fundamental components of late age-related macular degeneration. An intermediate step in some eyes was the development of a vitelliform deposit, an entity not traditionally associated with age-related macular degeneration, but in these patients, the material seemed to be an important component of the disease pathophysiology. This vitelliform deposit was not associated with genetic markers for pattern dystrophy or Best disease.
C1 [Spaide, Richard F.; Yannuzzi, Lawrence; Freund, K. Bailey] Vitreous Retina & Macula Consultants New York, 460 Pk Ave, New York, NY 10022 USA.
   [Mullins, Robert; Stone, Edwin] Univ Iowa, Stephen A Wynn Inst Vis Res, Dept Ophthalmol & Visual Sci, Carver Coll Med, Iowa City, IA USA.
C3 Vitreous Retina Macula Consultants of New York; University of Iowa
RP Spaide, RF (通讯作者)，Vitreous Retina & Macula Consultants New York, 460 Pk Ave, New York, NY 10022 USA.
EM rickspaide@gmail.com
RI Mullins, Robert F/I-6717-2013; Spaide, Richard/ABD-7368-2020; Freund, K.
   Bailey/V-7488-2018
OI Stone, Edwin M./0000-0003-3343-4414; Freund, K.
   Bailey/0000-0002-7888-9773; Mullins, Robert/0000-0002-5006-0891
CR Agarwal A, 2005, ARCH OPHTHALMOL-CHIC, V123, P923, DOI 10.1001/archopht.123.7.923
   APFELSTEDTSYLLA E, 1995, BRIT J OPHTHALMOL, V79, P28, DOI 10.1136/bjo.79.1.28
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   BARONDES M, 1990, BRIT J OPHTHALMOL, V74, P180, DOI 10.1136/bjo.74.3.180
   Barteselli G, 2014, OPHTHALMOLOGY, V121, P709, DOI 10.1016/j.ophtha.2013.10.016
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLAIR CJ, 1975, ARCH OPHTHALMOL-CHIC, V93, P19, DOI 10.1001/archopht.1975.01010020023003
   Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   Chien JL, 2017, CURR OPIN OPHTHALMOL, V28, P228, DOI 10.1097/ICU.0000000000000361
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Connell PP, 2009, J OPHTHALMOL, V2009, DOI 10.1155/2009/360764
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Duncan KG, 2009, BRIT J OPHTHALMOL, V93, P1116, DOI 10.1136/bjo.2008.144006
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P297, DOI 10.1136/bjo.73.4.297
   Fliesler SJ, 2010, J LIPID RES, V51, P3399, DOI 10.1194/jlr.R010538
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2011, RETINA-J RET VIT DIS, V31, P13, DOI 10.1097/IAE.0b013e3181ea48ba
   Gass J D, 1972, Trans Am Ophthalmol Soc, V70, P409
   Gass J.D., 1967, AM J OPHTHALMOL, V63, P1
   Gass JD., 1997, STEREOSCOPIC ATLAS M, V1
   Gliem M, 2015, OPHTHALMOLOGY, V122, P1555, DOI 10.1016/j.ophtha.2015.04.035
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Huisingh C, 2016, INVEST OPHTH VIS SCI, V57, P739, DOI 10.1167/iovs.15-18316
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   Invernizzi A, 2017, AM J OPHTHALMOL, V175, P68, DOI 10.1016/j.ajo.2016.11.014
   Ishida BY, 2006, BRIT J OPHTHALMOL, V90, P616, DOI 10.1136/bjo.2005.085076
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   KIMIZUKA Y, 1993, RETINA-J RET VIT DIS, V13, P129, DOI 10.1097/00006982-199313020-00007
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lee MY, 2014, RETINA-J RET VIT DIS, V34, P69, DOI 10.1097/IAE.0b013e318295f701
   Lima LH, 2012, RETINA-J RET VIT DIS, V32, P647, DOI 10.1097/IAE.0b013e31823fb847
   Mann SS, 2011, GRAEF ARCH CLIN EXP, V249, P209, DOI 10.1007/s00417-010-1483-x
   MARMOR MF, 1977, AM J OPHTHALMOL, V84, P32, DOI 10.1016/0002-9394(77)90320-8
   Massin P, 1999, OPHTHALMOLOGY, V106, P1821, DOI 10.1016/S0161-6420(99)90356-1
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Pellegrini M, 2016, OPHTHALMOLOGY, V123, P1879, DOI 10.1016/j.ophtha.2016.05.041
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sawa M, 2006, OPHTHALMOLOGY, V113, P814, DOI 10.1016/j.ophtha.2006.01.037
   Schultz ZD, 2011, AUST J CHEM, V64, P611, DOI 10.1071/CH11019
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Small KW, 2016, OPHTHALMOLOGY, V123, P9, DOI 10.1016/j.ophtha.2015.10.006
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Spaide R, 2008, RETINA-J RET VIT DIS, V28, P5, DOI 10.1097/IAE.0b013e318158eca4
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Tomi A, 2014, J Med Life, V7 Spec No. 4, P4
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Viola F, 2014, RETINA-J RET VIT DIS, V34, P1428, DOI 10.1097/IAE.0000000000000073
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
   WELEBER RG, 1993, ARCH OPHTHALMOL-CHIC, V111, P1531, DOI 10.1001/archopht.1993.01090110097033
   Wilde C, 2016, EYE, V30, P817, DOI 10.1038/eye.2016.46
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Zarubina AV, 2016, OPHTHALMOLOGY, V123, P1090, DOI 10.1016/j.ophtha.2015.12.034
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   Zweifel SA, 2011, RETINA-J RET VIT DIS, V31, P229, DOI 10.1097/IAE.0b013e3181f049bd
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 71
TC 15
Z9 15
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2019
VL 39
IS 1
BP 12
EP 26
DI 10.1097/IAE.0000000000002362
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ4QS
UT WOS:000480736000012
PM 30312263
DA 2022-11-30
ER

PT J
AU Omori, T
   Oguchi, Y
   Machida, T
   Kato, Y
   Ishida, Y
   Ojima, A
   Itagaki, K
   Shintake, H
   Tomita, R
   Kasai, A
   Sugano, Y
   Ogasawara, M
   Sekine, H
   Sekiryu, T
AF Omori, Tomoko
   Oguchi, Yasuharu
   Machida, Takeshi
   Kato, Yutaka
   Ishida, Yumi
   Ojima, Akira
   Itagaki, Kanako
   Shintake, Hiroaki
   Tomita, Ryutaro
   Kasai, Akihito
   Sugano, Yukinori
   Ogasawara, Masashi
   Sekine, Hideharu
   Sekiryu, Tetsuju
TI Evidence for Activation of Lectin and Classical Pathway Complement
   Components in Aqueous Humor of Neovascular Age-Related Macular
   Degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Lectin pathway; Classical pathway; Age-related macular degeneration;
   Complement component C4; Aqueous humor
ID FACTOR-H POLYMORPHISM; SERINE PROTEASE-2; PREVALENCE; BINDING; INJURY;
   ADULTS; SYSTEM
AB Purpose: The complement system is activated via 3 different pathways; the lectin pathway (LP), classical pathway (CP), and alternative pathway. To investigate the possible roles for the LP or CP in the development of neovascular age-related macular degeneration (nAMD), we compared aqueous humor levels of complement proteins of the LP and CP between eyes with nAMD and those with cataract as controls. Methods: Seventeen eyes from 17 patients with treatment-naive nAMD and 9 eyes from 9 patients with cataract were studied. Aqueous humor samples were collected before intravitreal aflibercept or ranibizumab injection for the nAMD patients and before cataract surgery for the cataract patients. Aqueous humor levels of complement C4 of the LP and CP, complement C3 of all 3 complement pathways, and mannose-binding lectin-associated serine protease (MASP)-2 of the LP were measured by enzyme-linked immunosorbent assay. Aqueous humor levels of C4a and C3a, the activation products of C4 and C3, respectively, were measured by a bead-based immunoassay. The ratios of C4a to C4 and C3a to C3, representing the degree of C4 and C3 activation, respectively, were calculated in individual patients. Results: The aqueous humor levels of C4, C3, and MASP-2 were significantly lower in the nAMD eyes compared to the controls (p = 0.008, p = 0.011, and p = 0.018, respectively). In contrast, the aqueous humor levels of C4a and C3a, as well as the C4a/C4 and C3a/C3 ratios, were significantly higher in the nAMD eyes compared to the controls (p = 0.039, p = 0.003, p < 0.001, and p < 0.001, respectively). Conclusions: This study provides evidence for significant intraocular activation of either or both of the LP and CP in nAMD eyes that might be involved in the development of nAMD. The significantly lower levels of MASP-2 in the aqueous humor of the nAMD eyes were likely due to MASP-2 consumption by activation of the LP.
C1 [Omori, Tomoko; Machida, Takeshi; Ishida, Yumi; Sekine, Hideharu] Fukushima Med Univ, Dept Immunol, 1 Hikarigaoka, Fukushima 9601295, Japan.
   [Oguchi, Yasuharu; Kato, Yutaka; Ojima, Akira; Itagaki, Kanako; Shintake, Hiroaki; Tomita, Ryutaro; Kasai, Akihito; Sugano, Yukinori; Ogasawara, Masashi; Sekiryu, Tetsuju] Fukushima Med Univ, Dept Ophthalmol, Fukushima, Japan.
C3 Fukushima Medical University; Fukushima Medical University
RP Sekine, H (通讯作者)，Fukushima Med Univ, Dept Immunol, 1 Hikarigaoka, Fukushima 9601295, Japan.
EM sekine@fmu.ac.jp
FU Japan Society for the Promotion of Science [17K16975]; Japanese
   Association for Complement Research; Fukushima Medical University
FX We thank Dr. Tatsuya Okada, professor at the Department of Natural
   Sciences, Fukushima Medical University, for advices on statistics used
   in this study. This work was supported by a Grantin-Aid for Scientific
   Research (no. 17K16975) from the Japan Society for the Promotion of
   Science, a Grant for Strategic Research Promotion from Fukushima Medical
   University, and a Research Grant from the Japanese Association for
   Complement Research.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Joseph K, 2013, J BIOL CHEM, V288, P12753, DOI 10.1074/jbc.M112.421891
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Liszewski MK, 2017, ANNU REV PATHOL-MECH, V12, P25, DOI 10.1146/annurev-pathol-012615-044145
   MONDINO BJ, 1984, INVEST OPHTH VIS SCI, V25, P483
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Sallenbach S, 2011, PEDIAT ALLERG IMM-UK, V22, P424, DOI 10.1111/j.1399-3038.2010.01104.x
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   SCHUMAKER VN, 1976, BIOCHEMISTRY-US, V15, P5175, DOI 10.1021/bi00668a035
   Thiel S, 2007, GENES IMMUN, V8, P154, DOI 10.1038/sj.gene.6364373
   WILD G, 1990, CLIN EXP IMMUNOL, V80, P167
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang Y, 2003, J IMMUNOL, V171, P2734, DOI 10.4049/jimmunol.171.5.2734
   Yaseen S, 2017, FASEB J, V31, P2210, DOI 10.1096/fj.201601306R
   Zhang M, 2013, INT J CARDIOL, V166, P499, DOI 10.1016/j.ijcard.2011.11.032
NR 20
TC 5
Z9 5
U1 1
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PD MAY
PY 2020
VL 63
IS 3
BP 252
EP 258
DI 10.1159/000503258
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LO8JM
UT WOS:000533872000005
PM 31645047
DA 2022-11-30
ER

PT J
AU Terluk, MR
   Ebeling, MC
   Fisher, CR
   Kapphahn, RJ
   Yuan, C
   Kartha, RV
   Montezuma, SR
   Ferrington, DA
AF Terluk, Marcia R.
   Ebeling, Mara C.
   Fisher, Cody R.
   Kapphahn, Rebecca J.
   Yuan, Ching
   Kartha, Reena, V
   Montezuma, Sandra R.
   Ferrington, Deborah A.
TI N-Acetyl-L-cysteine Protects Human Retinal Pigment Epithelial Cells from
   Oxidative Damage: Implications for Age-Related Macular Degeneration
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID REDOX REGULATION; STRESS; RPE; ACETYLCYSTEINE; GLUTATHIONE;
   ANTIOXIDANTS; NEOVASCULARIZATION; PATHOGENESIS; DISEASE; TARGET
AB Age-related macular degeneration (AMD) involves the loss of retinal pigment epithelium (RPE) and photoreceptors and is one of the leading causes of blindness in the elderly. Oxidative damage to proteins, lipids, and DNA has been associated with RPE dysfunction and AMD. In this study, we evaluated oxidative stress in AMD and the efficacy of antioxidant, N-acetyl-L-cysteine (NAC), in protecting RPE from oxidative damage. To test this idea, primary cultures of RPE from human donors with AMD (n = 32) or without AMD (No AMD, n = 21) were examined for expression of NADPH oxidase (NOX) genes, a source of reactive oxygen species (ROS). Additionally, the cells were pretreated with NAC for 2 hours and then treated with either hydrogen peroxide (H2O2) or tert-butyl hydroperoxide (t-BHP) to induce cellular oxidation. Twenty-four hours after treatment, ROS production, cell survival, the content of glutathione (GSH) and adenosine triphosphate (ATP), and cellular bioenergetics were measured. We found increased expression of p22phox, a NOX regulator, in AMD cells compared to No AMD cells (p = 0.02). In both AMD and No AMD cells, NAC pretreatment reduced t-BHP-induced ROS production and protected from H2O2-induced cell death and ATP depletion. In the absence of oxidation, NAC treatment improved mitochondrial function in both groups (p < 0.01). Conversely, the protective response exhibited by NAC was disease-dependent for some parameters. In the absence of oxidation, NAC significantly reduced ROS production (p < 0.001) and increased GSH content (p = 0.02) only in RPE from AMD donors. Additionally, NAC-mediated protection from H2O2-induced GSH depletion (p = 0.04) and mitochondrial dysfunction (p < 0.05) was more pronounced in AMD cells compared with No AMD cells. These results demonstrate the therapeutic benefit of NAC by mitigating oxidative damage in RPE. Additionally, the favorable outcomes observed for AMD RPE support NAC's relevance and the potential therapeutic value in treating AMD.
C1 [Terluk, Marcia R.; Ebeling, Mara C.; Fisher, Cody R.; Kapphahn, Rebecca J.; Yuan, Ching; Montezuma, Sandra R.; Ferrington, Deborah A.] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55455 USA.
   [Terluk, Marcia R.; Kartha, Reena, V] Univ Minnesota, Dept Expt & Clin Pharmacol, Ctr Orphan Drug Res, Minneapolis, MN 55455 USA.
   [Fisher, Cody R.; Ferrington, Deborah A.] Univ Minnesota, Grad Program Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities
RP Ferrington, DA (通讯作者)，Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55455 USA.
EM ferri013@umn.edu
RI Kartha, Reena/AAG-3969-2021
OI Kartha, Reena/0000-0002-1692-1539; Ferrington,
   Deborah/0000-0003-2561-7464
FU Foundation Fighting Blindness [TA-NMT-0613-0620-UMN]; National
   Institutes of Health (NIH)/National Eye Institute [R01EY026012,
   R01EY028554]; NIH/National Institute on Aging [T32-AG029796]; Elaine and
   Robert Larson Endowed Vision Research Chair; Lindsay Family Foundation;
   Macular Degeneration Research; NATIONAL EYE INSTITUTE [R01EY028554]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG029796]
   Funding Source: NIH RePORTER
FX The authors wish to acknowledge the contribution of the Lions Gift of
   Sight (St. Paul, MN) personnel for their assistance in procuring the
   eyes and Kathy Goode and Sung Lee for photographing and processing eye
   tissue. The authors also thank the donors and their families for their
   essential contributions to the research. This work was supported in part
   by the Foundation Fighting Blindness (grant number
   TA-NMT-0613-0620-UMN), the National Institutes of Health (NIH)/National
   Eye Institute (grant numbers R01EY026012 and R01EY028554 (to DAF)), the
   NIH/National Institute on Aging (grant number T32-AG029796 (to MRT and
   CRF)), the Elaine and Robert Larson Endowed Vision Research Chair (to
   DAF), the Lindsay Family Foundation, and the Macular Degeneration
   Research (provided by an anonymous benefactor).
CR Akyol-Salman I, 2010, J OCUL PHARMACOL TH, V26, P329, DOI 10.1089/jop.2010.0001
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005
   Birben E, 2012, WORLD ALLERGY ORGAN, V5, P9, DOI 10.1097/WOX.0b013e3182439613
   Buschini E, 2015, CLIN OPHTHALMOL, V9, P563, DOI 10.2147/OPTH.S59724
   Chang CC, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9015765
   COHEN SM, 1994, BRIT J OPHTHALMOL, V78, P791, DOI 10.1136/bjo.78.10.791
   Cotgreave I A, 1997, Adv Pharmacol, V38, P205
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Dilger RN, 2007, J ANIM SCI, V85, P1712, DOI 10.2527/jas.2006-835
   Dosa E, 2017, FLUIDS BARRIERS CNS, V14, DOI 10.1186/s12987-017-0075-0
   Du L, 2017, BIOMED PHARMACOTHER, V85, P136, DOI 10.1016/j.biopha.2016.11.108
   Eichler W, 2008, EXP EYE RES, V87, P342, DOI 10.1016/j.exer.2008.06.017
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Foresti R, 2015, PHARMACOL RES, V99, P296, DOI 10.1016/j.phrs.2015.07.006
   Franco R, 2012, ANTIOXID REDOX SIGN, V17, P1694, DOI 10.1089/ars.2012.4553
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Gu JY, 2010, ADV EXP MED BIOL, V664, P411, DOI 10.1007/978-1-4419-1399-9_47
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Iacovelli J, 2016, INVEST OPHTH VIS SCI, V57, P1038, DOI 10.1167/iovs.15-17758
   Kagan DB, 2012, CLIN OPHTHALMOL, V6, P1471, DOI 10.2147/OPTH.S35139
   Kalinina EV, 2014, BIOCHEMISTRY-MOSCOW+, V79, P1562, DOI 10.1134/S0006297914130082
   Kanter MZ, 2006, AM J HEALTH-SYST PH, V63, P1821, DOI 10.2146/ajhp060050
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim Min-Ho, 2003, Korean J Ophthalmol, V17, P19
   Laragione T, 2003, P NATL ACAD SCI USA, V100, P14737, DOI 10.1073/pnas.2434516100
   Lee SY, 2011, J CELL PHYSIOL, V226, P1843, DOI 10.1002/jcp.22508
   Li KR, 2016, SCI REP-UK, V6, DOI 10.1038/srep25525
   Li QH, 2008, MOL THER, V16, P1688, DOI 10.1038/mt.2008.164
   Li XM, 2018, BIOCHEM BIOPH RES CO, V502, P166, DOI 10.1016/j.bbrc.2018.05.141
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Lu L, 2006, J CELL PHYSIOL, V206, P119, DOI 10.1002/jcp.20439
   Majid ASA, 2013, BIOL PHARM BULL, V36, P1095, DOI 10.1248/bpb.b13-00023
   de Toda IM, 2020, J GERONTOL A-BIOL, V75, P613, DOI 10.1093/gerona/glz033
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Mousavi M., 2013, J OPTOM, V6, P176, DOI [10.1016/j.optom.2013.07.002, DOI 10.1016/j.optom.2013.07.002]
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   O'Brien WJ, 2009, MOL VIS, V15, P2535
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Osada H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178627
   Qin L, 2014, GRAEF ARCH CLIN EXP, V252, P23, DOI 10.1007/s00417-013-2418-0
   Qiu FF, 2017, INVEST OPHTH VIS SCI, V58, P5065, DOI 10.1167/iovs.17-22091
   Qiu YG, 2015, SCI REP-UK, V5, DOI 10.1038/srep14362
   Ray PD, 2012, CELL SIGNAL, V24, P981, DOI 10.1016/j.cellsig.2012.01.008
   St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Tu G, 2016, MOL MED REP, V13, P2320, DOI 10.3892/mmr.2016.4797
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Wang KJ, 2015, BIOCHEM BIOPH RES CO, V468, P541, DOI 10.1016/j.bbrc.2015.10.117
   Whyte AJ, 2010, J EMERG MED, V39, P607, DOI 10.1016/j.jemermed.2008.05.007
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang J, 2018, INT J MOL MED, V42, P123, DOI 10.3892/ijmm.2018.3612
   Zafarullah M, 2003, CELL MOL LIFE SCI, V60, P6, DOI 10.1007/s000180300001
   Zheng QX, 2014, EXP EYE RES, V125, P1, DOI 10.1016/j.exer.2014.05.001
NR 57
TC 25
Z9 26
U1 1
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD AUG 14
PY 2019
VL 2019
AR 5174957
DI 10.1155/2019/5174957
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA IT6UD
UT WOS:000483009400001
PM 31485293
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Yehoshua, Z
   Rosenfeld, PJ
   Gregori, G
   Feuer, WJ
   Falcao, M
   Lujan, BJ
   Puliafito, C
AF Yehoshua, Zohar
   Rosenfeld, Philip J.
   Gregori, Giovanni
   Feuer, William J.
   Falcao, Manuel
   Lujan, Brandon J.
   Puliafito, Carmen
TI Progression of Geographic Atrophy in Age-Related Macular Degeneration
   Imaged with Spectral Domain Optical Coherence Tomography
SO OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; BEAVER DAM EYE; RISK-FACTORS;
   NATURAL-HISTORY; POOLED FINDINGS; 3 CONTINENTS; HIGH-SPEED; MACULOPATHY;
   DISEASE; AUTOFLUORESCENCE
AB Purpose: To determine the area and enlargement rate (ER) of geographic atrophy (GA) in patients with age-related macular degeneration (AMD) using the spectral domain optical coherence tomography (SD-OCT) fundus image.
   Design: Prospective, longitudinal, natural history study.
   Participants: Eighty-six eyes of 64 patients with >= 6 months of follow-up.
   Methods: Patients with GA secondary to AMD were enrolled in this study. Macular scans were performed using the Cirrus SD-OCT (Carl Zeiss Meditec, Dublin, CA). The areas of GA identified on the SD-OCT fundus images were quantified using a digitizing tablet. Reproducibility of these measurements was assessed and the ER of GA was calculated. The usefulness of performing square root transformations of the lesion area measurements was explored.
   Main Outcome Measures: Enlargement rate of GA.
   Results: At baseline, 27% of eyes had a single area of GA. The mean total area at baseline was 4.59 mm(2) (1.8 disc areas [DA]). The mean follow-up time was 1.24 years. Reproducibility, as assessed with the intraclass correlation coefficient (ICC), was excellent on both the original area scale (ICC = 0.995) and the square root scale (ICC = 0.996). Intergrader differences were not an important source of variability in lesion size measurement (ICC = 0.999, 0.997). On average, the ER of GA per year was 1.2 mm(2) (0.47 DA; range, 0.01-3.62 mm(2)/year). The ER correlated with the initial area of GA (r = 0.45; P < 0.001), but there were variable growth rates for any given baseline area. When the square root transformation of the lesion area measurements was used as a measure of lesion size, the ER (0.28 mm/yr) was not correlated with baseline size (r = -0.09; P = 0.40). In this cohort of lesions, no correlation was found between ER and length of follow-up. Square root transformation of the data helped to facilitate sample size estimates for controlled clinical trials involving GA.
   Conclusions: The SD-OCT fundus image can be used to visualize and quantify GA. Advantages of this approach include the convenience and assurance of using a single imaging technique that permits simultaneous visualization of GA along with the loss of photoreceptors and the retinal pigment epithelium that should correlate with the loss of visual function.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2011;118:679-686 (C) 2011 by the American Academy of Ophthalmology.
C1 [Yehoshua, Zohar; Rosenfeld, Philip J.; Gregori, Giovanni; Feuer, William J.; Falcao, Manuel; Lujan, Brandon J.; Puliafito, Carmen] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
C3 Bascom Palmer Eye Institute; University of Miami
RP Rosenfeld, PJ (通讯作者)，Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@med.miami.edu
RI Falcao/AAQ-8509-2020
OI Falcao/0000-0003-4718-0910
FU Carl Zeiss Meditec, Inc., Dublin, CA; Research to Prevent Blindness.
   Inc., NEI core center [P30 EY014801]; H.A. & Mary K. Chapman Charitable
   Trust; Florman Family Foundation, Inc.; Jerome A. Yavitz Charitable
   Foundation; Carl and Lily Pforzheimer Foundation, Inc.; Emma Clyde Hodge
   Memorial Foundation; Gemcon Family Foundation; American Physicians
   Fellowship for Medicine in Israel; Fulbright Scholarship; Portuguese
   Society of Ophthalmology Scholarship; NATIONAL EYE INSTITUTE
   [P30EY014801] Funding Source: NIH RePORTER
FX Research supported by a grant from Carl Zeiss Meditec, Inc., Dublin, CA,
   an unrestricted grant from Research to Prevent Blindness. Inc., NEI core
   center grant P30 EY014801 to the University of Miami, the H.A. & Mary K.
   Chapman Charitable Trust, Florman Family Foundation, Inc., Jerome A.
   Yavitz Charitable Foundation, Carl and Lily Pforzheimer Foundation,
   Inc., Emma Clyde Hodge Memorial Foundation and the Gemcon Family
   Foundation. Zohar Yehoshua is a Recipient of a Fellowship Grant from the
   American Physicians Fellowship for Medicine in Israel. Manuel Falcao
   received a Fulbright Scholarship and Portuguese Society of Ophthalmology
   Scholarship.
CR Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Budenz DL, 2008, OPHTHALMOLOGY, V115, P661, DOI 10.1016/j.ophtha.2007.05.035
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Dreyhaupt J, 2005, OPHTHAL EPIDEMIOL, V12, P353, DOI 10.1080/09286580591005723
   Fleiss J.L., 1986, DESIGN ANAL CLIN EXP
   Fleiss JL, 1981, STAT METHODS RATES P, P218
   HAMMER M, 1995, PHYS MED BIOL, V40, P963, DOI 10.1088/0031-9155/40/6/001
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jiao SL, 2005, OPT EXPRESS, V13, P444, DOI 10.1364/OPEX.13.000444
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lujan BJ, 2008, OPHTHAL SURG LAS IM, V39, pS8
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   POTTER JW, 1981, J AM OPTOM ASSOC, V52, P503
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitz-Valckenberg S, 2008, AM J OPHTHALMOL, V146, P183, DOI 10.1016/j.ajo.2008.04.006
   Scholl HPN, 2003, GRAEF ARCH CLIN EXP, V241, P39, DOI 10.1007/s00417-002-0602-8
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Srinivasan VJ, 2008, INVEST OPHTH VIS SCI, V49, P1571, DOI 10.1167/iovs.07-0838
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 2006, RETINA-J RET VIT DIS, V26, P666, DOI 10.1097/00006982-200607000-00013
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
   Yasuno Y, 2007, OPT EXPRESS, V15, P6121, DOI 10.1364/OE.15.006121
NR 36
TC 170
Z9 172
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2011
VL 118
IS 4
BP 679
EP 686
DI 10.1016/j.ophtha.2010.08.018
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 744DS
UT WOS:000289075200011
PM 21035861
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Snow, KK
   Cote, J
   Yang, WN
   Davis, NJ
   Seddon, JM
AF Snow, KK
   Cote, J
   Yang, WN
   Davis, NJ
   Seddon, JM
TI Association between reproductive and hormonal factors and age-related
   maculopathy in postmenopausal women
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER DAM EYE; MACULAR DEGENERATION; RISK-FACTORS;
   CARDIOVASCULAR-DISEASE; REPLACEMENT THERAPY; LENS OPACITIES; PREVALENCE;
   MORTALITY; ESTROGENS; CATARACTS
AB PURPOSE: The relationships between reproductive risk factors, including use of hormone replacement therapy and oral contraceptives and severity of age,related maculopathy (ARM) among postmenopausal women were evaluated. We hypothesized that exposure to endogenous or exogenous estrogens would be associated with a reduced risk of advanced ARM.
   DESIGN. Cross-sectional study.
   METHODS: The 394 subjects were postmenopausal women with ARM. Logistic regression analysis was used to compare the effects of several reproductive factors across two groups: 193 subjects with nonadvanced ARM and 201 subjects with advanced ARM.
   RESULTS: Women with ARM who had used postmenopausal estrogen therapy in the past had significantly lower odds of advanced ARM than nonusers, after controlling for other known and potential risk factors (odds ratio [OR] = 0.5, 95% confidence interval [Cl] = 0.30 to 0.98). Older age at menarche was associated with increased odds of advanced ARM (OR = 1.16, 95% CI 1.00 to 1.35).
   CONCLUSIONS: These findings suggest that exposure to exogenous estrogens may have a beneficial effect of reducing the risk of advanced types of ARM in postmenopausal women with ARM. Few therapeutic or preventive measures currently exist for ARM; therefore, these results deserve further evaluation.
C1 Massachusetts Eye & Ear Infirm, Epidemiol Unit, Boston, MA 02114 USA.
   Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
C3 Harvard University; Massachusetts Eye & Ear Infirmary; Harvard
   University; Harvard T.H. Chan School of Public Health; Harvard
   University; Harvard Medical School
RP Seddon, JM (通讯作者)，Massachusetts Eye & Ear Infirm, Epidemiol Unit, 243 Charles St, Boston, MA 02114 USA.
CR *AG REL EYE DIS ST, 1992, AG REL EYE DIS STUD
   BASS KM, 1993, ARCH INTERN MED, V153, P2209, DOI 10.1001/archinte.153.19.2209
   CALAF I, 1997, INT J FERTIL WOME S2, V42, P329
   COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256
   FOLSOM AR, 1995, AM J PUBLIC HEALTH, V85, P1128, DOI 10.2105/AJPH.85.8_Pt_1.1128
   GRAY RH, 1994, EYE, V8, P368, DOI 10.1038/eye.1994.83
   Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701
   Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501
   HIRVELA H, 1995, OPHTHALMOLOGY, V102, P108
   Klein B E, 1994, Trans Am Ophthalmol Soc, V92, P289
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   Klein BEK, 2000, AM J OPHTHALMOL, V130, P322, DOI 10.1016/S0002-9394(00)00474-8
   Klein BEK, 1998, ARCH OPHTHALMOL-CHIC, V116, P219, DOI 10.1001/archopht.116.2.219
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Leske MC, 1997, INT J EPIDEMIOL, V26, P1314, DOI 10.1093/ije/26.6.1314
   MALTZMAN BA, 1979, ANN OPHTHALMOL, V11, P1197
   MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028
   Mosca L, 1997, CIRCULATION, V96, P2468
   Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   SEGATO T, 1993, AGING-CLIN EXP RES, V5, P165, DOI 10.1007/BF03324151
   Smith M, 1997, INTERLEND DOC SUPPLY, V25, P3
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Snow KK, 2000, INT J FERTIL WOMEN M, V45, P301
   Subbiah MTR, 1998, P SOC EXP BIOL MED, V217, P23
   VARGA M, 1976, Annals of Ophthalmology, V8, P925
   Vessey MP, 1998, BRIT J OPHTHALMOL, V82, P538, DOI 10.1136/bjo.82.5.538
   VINGERLING JR, 1995, BRIT MED J, V310, P1570, DOI 10.1136/bmj.310.6994.1570
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yannuzzi LA, 1996, ARCH OPHTHALMOL-CHIC, V114, P545
NR 29
TC 53
Z9 58
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2002
VL 134
IS 6
BP 842
EP 848
AR PII S0002-9394(02)01755-5
DI 10.1016/S0002-9394(02)01755-5
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 624BA
UT WOS:000179738600007
PM 12470752
DA 2022-11-30
ER

PT J
AU Augustin, AJ
   Schmidt-Erfurth, U
AF Augustin, AJ
   Schmidt-Erfurth, U
TI Verteporfin therapy combined with intravitreal triamcinolone in all
   types of choroidal neovascularization due to age-related macular
   degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID PHOTODYNAMIC THERAPY; ACETONIDE; EXPRESSION; INJECTION; ENDOPHTHALMITIS
AB Objective: To evaluate the efficacy and safety of photodynamic therapy with verteporfin combined with intravitreal triamcinolone in choroidal neovascularization secondary to age-related macular degeneration (AMD).
   Design: Prospective, noncomparative, interventional case series. Participants: One hundred eighty-four patients undergoing treatment for neovascular AMD atone retinal referral center.
   Methods: One hundred eighty-four eyes of 184 consecutive patients (63.6% female, 36.4% male) with a mean age of 76.5 years and a follow-up of a median of 38.8 weeks (range, 12-103) were included in a case series. One hundred forty-eight (80.4%) patients had subfoveal choroidal neovascularization, 19 patients (10.3%) had juxtafoveal choroidal neovascularization, and 17 patients (9.2%) had extrafoveal choroidal neovascularization. Verteporfin photodynamic therapy was performed using the recommended standard procedure. A solution containing 25 mg of triamcinolone was injected intravitreally 16 hours after photodynamic therapy in 184 patients. The combined therapy procedure was repeated at the 3-month follow-up visits whenever persistent choroidal neovascularization leakage was documented angiographically.
   Main Outcome Measures: Mean change in best-refracted visual acuity (VA) between baseline and the last visit, and number of treatments necessary to achieve absence of leakage.
   Results: Visual acuity improved in the majority of patients (baseline VA, mean 20/125) by a mean increase of 1.22 Snellen lines and 1.43 lines using laser interferometry (P < 0.01). The mean number of required treatments was 1.21. Twenty-three eyes (12.5%) required 2 treatments, 6 eyes (3.26%) required 3 treatments, and 1 eye (0.5%) required 4 treatments. The combination treatment including laser and intravitreal steroid administration was well tolerated. Forty-six patients (25%) required glaucoma therapy due to a transient steroid-induced intraocular pressure (IOP) increase. Twelve patients (6.5%) were on topical medication for preexisting glaucoma. Two patients (1%) whose IOP increase could not be controlled with topical therapy required surgery.
   Conclusions: Verteporfin photodynamic therapy combined with intravitreal triamcinolone may improve the outcome of standard verteporfin photodynamic therapy in the treatment of choroidal neovascularization secondary to AMD. A significant improvement in VA was observed in a majority of treated patients and was maintained during the maximum follow-up. In addition, retreatment rates were lower than anticipated.
C1 Kliikum Karlsruhe, Dept Ophthalmol, D-76133 Karlsruhe, Germany.
   Med Univ Vienna, Dept Ophthalmol, Vienna, Austria.
C3 Medical University of Vienna
RP Augustin, AJ (通讯作者)，Kliikum Karlsruhe, Dept Ophthalmol, Moltkestr 90, D-76133 Karlsruhe, Germany.
EM 106020.560@compuserve.com
OI Augustin, Prof. Dr. Albert J./0000-0003-1591-0536
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Ceciliani F, 2002, PROTEIN PEPTIDE LETT, V9, P211, DOI 10.2174/0929866023408779
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   Gollnick SO, 2003, BRIT J CANCER, V88, P1772, DOI 10.1038/sj.bjc.6600864
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P24, DOI 10.1136/bjo.87.1.24
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Jonas JB, 2002, GRAEF ARCH CLIN EXP, V240, P872, DOI 10.1007/s00417-002-0547-y
   Kent D, 2003, MOL VIS, V9, P747
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V136, P791, DOI 10.1016/S0002-9394(03)00483-5
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penfold PL, 2000, CLIN EXP IMMUNOL, V121, P458, DOI 10.1046/j.1365-2249.2000.01316.x
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Peyman GA, 2004, RETINA-J RET VIT DIS, V24, P488, DOI 10.1097/00006982-200406000-00032
   Rankin James A, 2004, AACN Clin Issues, V15, P3, DOI 10.1097/00044067-200401000-00002
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Sutter FKP, 2003, BRIT J OPHTHALMOL, V87, P972, DOI 10.1136/bjo.87.8.972
   THARP A, 1994, OPHTHALMIC SURG LAS, V25, P576
   Wingate RJB, 1999, AUST NZ J OPHTHALMOL, V27, P431
   WORMALD R, 2003, COCHRANE DB SYST REV
NR 29
TC 132
Z9 148
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2006
VL 113
IS 1
BP 14
EP 22
DI 10.1016/j.ophtha.2005.09.002
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 998JJ
UT WOS:000234314400003
PM 16360209
DA 2022-11-30
ER

PT J
AU Chatziralli, I
   Stavrakas, P
   Theodossiadis, G
   Ananikas, K
   Dimitriou, E
   Theodossiadis, P
AF Chatziralli, Irini
   Stavrakas, Panagiotis
   Theodossiadis, George
   Ananikas, Konstantinos
   Dimitriou, Eleni
   Theodossiadis, Panagiotis
TI The Impact of Epiretinal Membrane in Neovascular Age-Related Macular
   Degeneration Treatment: A Spectral-Domain Optical Coherence Tomography
   Study
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE AMD; epiretinal membrane; ranibizumab; treatment
ID VITREOMACULAR TRACTION; PHOTORECEPTOR LAYER; PREVALENCE; RANIBIZUMAB;
   THERAPY; DISEASE; EYES
AB Purpose: The purpose of this prospective study was to evaluate the impact of epiretinal membrane (ERM) on anatomical and functional results in patients with wet age-related macular degeneration (AMD) treated with intravitreal anti-vascular endothelial growth (anti-VEGF) injections. Methods: Participants in the study were 48 patients with either wet AMD alone (AMD group, n = 27) or AMD and ERM (AMD/ERM group, n = 21). All patients received intravitreal anti-VEGF injections (three monthly injections and PRN thereafter) and were followed up for at least 12 months. All participants had best-corrected visual acuity (BCVA) measurement and spectral domain-optical coherence tomography (SD-OCT) at each visit, while fluorescein angiography was performed at baseline and then at the discretion of the physician. Results: There was a statistically significant improvement in BCVA at month 12 compared to baseline in each group (p < 0.001 for both groups), while the two groups did not differ significantly regarding BCVA at the end of the follow-up (p = 0.056). Additionally, there was a statistically significant reduction in CRT in both groups at month 12 (p < 0.001 for AMD group and p = 0.004 for AMD/ERM group) with no statistically significant difference between the groups (p = 0.183). Patients in the AMD group had a lower percentage of subretinal fluid (25.9%) than patients in the AMD/ERM group (52.4%) at the end of the follow-up, while ellipsoid zone disruption was found to be more profound in the AMD/ERM group (38.1%) than in the AMD group (18.5%). Patients in the AMD/ERM group needed more injections (7.1 +/- 2.0 injections) than patients in the AMD group (4.8 +/- 1.7 injections). Conclusions: Patients in the AMD/ERM group had a higher percentage of subretinal and intraretinal fluid and ellipsoid zone interruption during the follow-up period. Anti-VEGF treatment appeared to have a beneficial effect in both groups, although the AMD/ERM group needed more injections compared to the AMD group.
C1 [Chatziralli, Irini; Stavrakas, Panagiotis; Theodossiadis, George; Ananikas, Konstantinos; Dimitriou, Eleni; Theodossiadis, Panagiotis] Univ Athens, Attikon Hosp, Dept Ophthalmol 2, Athens, Greece.
C3 National & Kapodistrian University of Athens; University Hospital
   Attikon
RP Chatziralli, I (通讯作者)，28 Papanastasiou St, Athens 17342, Greece.
EM eirchat@yahoo.gr
RI Chatziralli, Irini/AAG-4779-2020
OI Chatziralli, Irini/0000-0001-8523-1024; Ananikas,
   Konstantinos/0000-0002-6057-3420; Stavrakas,
   Panagiotis/0000-0002-0570-6438
CR Alkin Z, 2013, SCI WORLD J, DOI 10.1155/2013/958724
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Bu SC, 2014, RETINA-J RET VIT DIS, V34, P2317, DOI 10.1097/IAE.0000000000000349
   Byon IS, 2015, OPHTHALMOLOGICA, V234, P91, DOI 10.1159/000437058
   Chatziralli I, 2017, EUR J OPHTHALMOL, V27, P86, DOI 10.5301/ejo.5000807
   Cho HJ, 2017, J OCUL PHARMACOL TH, V33, P452, DOI 10.1089/jop.2016.0178
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Karaca EE, 2015, RETINA-J RET VIT DIS, V35, P1540, DOI 10.1097/IAE.0000000000000531
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Lee SM, 2018, RETINA-J RET VIT DIS, V38, P541, DOI 10.1097/IAE.0000000000001559
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Pierro L, 2012, CLIN OPHTHALMOL, V6, P219, DOI 10.2147/OPTH.S27656
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Theodossiadis PG, 2014, EUR J OPHTHALMOL, V24, P582, DOI 10.5301/ejo.5000412
   Theodossiadis PG, 2011, AM J OPHTHALMOL, V151, P973, DOI 10.1016/j.ajo.2010.12.014
   Weber-Krause Brigitte, 1996, Ophthalmologe, V93, P660, DOI 10.1007/s003470050054
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yu J, 2014, MOL BIOSYST, V10, P2558, DOI 10.1039/c4mb00240g
NR 21
TC 3
Z9 3
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PY 2018
VL 33
IS 5
BP 651
EP 656
DI 10.1080/08820538.2017.1395892
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GM5CX
UT WOS:000438148800010
PM 29115893
DA 2022-11-30
ER

PT J
AU Hogg, RE
   Silva, R
   Staurenghi, G
   Murphy, G
   Santos, AR
   Rosina, C
   Chakravarthy, U
AF Hogg, Ruth E.
   Silva, Rufino
   Staurenghi, Giovanni
   Murphy, George
   Santos, Ana R.
   Rosina, Chiara
   Chakravarthy, Usha
TI Clinical Characteristics of Reticular Pseudodrusen in the Fellow Eye of
   Patients with Unilateral Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID MULTIFOCAL ELECTRORETINOGRAM; SEVERITY SCALE; GRADING SYSTEM;
   MACULOPATHY; DISEASE; DRUSEN; SENSITIVITY; PREVALENCE; RISK
AB Purpose: To describe associations between reticular pseudodrusen, individual characteristics, and retinal function.
   Design: Cohort study.
   Participants: We recruited 105 patients (age range, 52-93 years) who had advanced neovascular age-related macular degeneration (AMD) in only 1 eye from 3 clinical centers in Europe.
   Methods: Minimum follow-up was 12 months. The eye selected for study was the fellow eye without advanced disease. Clinical measures of vision were distance visual acuity, near visual acuity, and results of the Smith-Kettlewell low-luminance acuity test (SKILL). Fundus imaging included color photography, red-free imaging, blue autofluorescence imaging, fluorescein angiography, indocyanine green angiography, and optical coherence tomography using standardized protocols. These were used to detect progression to neovascular AMD in the study eye during follow-up. All imaging outputs were graded for the presence or absence of reticular pseudodrusen (RPD) using a multimodal approach. Choroidal thickness was measured at the foveal center and at 2 other equidistant locations from the fovea (1500 mu m) nasally and temporally. Metrics on retinal thickness and volume were obtained from the manufacturer-supplied automated segmentation readouts.
   Main Outcome Measures: Presence of RPD, distance visual acuity, near visual acuity, SKILL score, choroidal thickness, retinal thickness, and retinal volume.
   Results: Reticular pseudodrusen was found in 43 participants (41%) on 1 or more imaging method. The SKILL score was significantly worse in those with reticular drusen (mean score +/- standard deviation [SD, 38 +/- 12) versus those without (mean score +/- SD, 33 +/- 9) (P - 0.034). Parafoveal retinal thickness, parafoveal retinal volume, and all of the choroidal thickness parameters measured were significantly lower in those with reticular drusen than in those without. The presence of RPD was associated with development of neovascular AMD when corrected for age and sex (odds ratio, 5.5; 95% confidence interval, 1.1-28.8; P = 0.042). All participants in whom geographic atrophy developed during follow-up had visible RPD at baseline.
   Conclusions: Significant differences in retinal and choroidal anatomic features, visual function, and risk factor profile exist in unilateral neovascular AMD patients with RPD compared with those without; therefore, such patients should be monitored carefully because of the risk of developing bilateral disease. (C) 2014 by the American Academy of Ophthalmology.
C1 [Hogg, Ruth E.; Murphy, George; Chakravarthy, Usha] Queens Univ Belfast, Ctr Med Expt, Belfast, Antrim, North Ireland.
   [Silva, Rufino] Ctr Hos & Univ Coimbra, Ophthalmol Unit, Coimbra, Portugal.
   [Silva, Rufino] Univ Coimbra, Fac Med, Coimbra, Portugal.
   [Silva, Rufino; Santos, Ana R.] Assoc Innovat & Biomed Res Light & Image, Coimbra, Portugal.
   [Staurenghi, Giovanni; Rosina, Chiara] Univ Milan, Eye Clin, Dept Clin Sci Luigi Sacco, Sacco Hosp, Milan, Italy.
C3 Queens University Belfast; Universidade de Coimbra; Centro Hospitalar e
   Universitario de Coimbra (CHUC); Universidade de Coimbra; Universidade
   de Coimbra; University of Milan; Luigi Sacco Hospital
RP Chakravarthy, U (通讯作者)，Royal Victoria Hosp, Ctr Med Expt, Inst Clin Sci A, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.
EM u.chakravarthy@qub.ac.uk
RI Silva, Rufino M/J-2817-2012; Mitchell, Paul/P-1498-2014; Hogg, Ruth
   E./ABC-9602-2020; santos, ana/GWV-5678-2022; Staurenghi,
   Giovanni/K-4388-2017
OI Silva, Rufino M/0000-0001-8676-0833; Hogg, Ruth E./0000-0001-9413-2669;
   Chakravarthy, Usha/0000-0002-2606-3734; B M Santos, Ana
   Rita/0000-0003-3761-3292; Staurenghi, Giovanni/0000-0002-2299-5251
FU Pfizer, Inc; Novartis; Pfizer, Inc., New York, New York [A9011051];
   Pfizer; Bayer; Allergan; Alcon; THEA
FX The author(s) have made the following disclosure(s):; Usha Chakravarthy
   - Financial support - Pfizer, Inc.; G. Staurenghi: Consultant-Heidelberg
   Engineering, Zeiss Meditec; Lecturer-Novartis, Allergan, Zeiss, Alcon;
   Financial support-Novartis.; Supported by an educational grant from
   Pfizer, Inc., New York, New York (grant no.: A9011051 [U.C., R.S.,
   G.S.]).; R. Silva: Grant support-Pfizer (during the conduct of the
   study); Novartis, Bayer; Personal fees-Bayer, Allergan, Alcon, and THEA
   (outside the submitted work); Lecturer-Bayer; Member of Advisory Board:
   Novartis, Bayer, Allergan, Alcon, THEA.
CR Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   Alten F, 2012, INVEST OPHTH VIS SCI, V53, P6263, DOI 10.1167/iovs.12-10094
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Feigl B, 2004, CURR EYE RES, V29, P327, DOI 10.1080/02713680490516198
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Gin TJ, 2011, INVEST OPHTH VIS SCI, V52, P9267, DOI 10.1167/iovs.11-8517
   HaegerstromPortnoy G, 1997, INVEST OPHTH VIS SCI, V38, P207
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P1061, DOI 10.1001/archophthalmol.2011.212
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 26
TC 81
Z9 82
U1 0
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2014
VL 121
IS 9
BP 1748
EP 1755
DI 10.1016/j.ophtha.2014.03.015
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO2KY
UT WOS:000341151800025
PM 24856310
DA 2022-11-30
ER

PT J
AU Synowiec, E
   Blasiak, J
   Zaras, M
   Szaflik, J
   Szaflik, JP
AF Synowiec, Ewelina
   Blasiak, Janusz
   Zaras, Malgorzata
   Szaflik, Jerzy
   Szaflik, Jacek P.
TI Association between polymorphisms of the DNA base excision repair genes
   MUTYH and hOGG1 and age-related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE age-related macular degeneration; AMD; MUTYH; hOGG1; gene polymorphism;
   DNA glycosylases
ID COMPLEMENT FACTOR-H; OXIDATIVELY DAMAGED DNA; CANCER-RISK; JAPANESE
   POPULATION; COLORECTAL-CANCER; INTRACELLULAR-LOCALIZATION; SER(326)CYS
   POLYMORPHISM; FAMILY-HISTORY; DISEASE; OGG1
AB Age-Related Macular Degeneration (AMD) is an eye disease that results in progressive and irreversible loss of central vision and is considered as the primary cause of visual impairment, including blindness, in the elderly in industrialized countries. Oxidative stress has been implicated in the pathogenesis of AMD. The hOGG1 and the MUTYH genes play an important role in the repair of oxidatively damaged DNA in the base excision repair pathway. The DNA glycosylases encoded by the hOGG1 and MUTYH genes initiate this pathway by recognizing and removing 8-oxoguanine and adenine paired with 8-oxoguanine, respectively. Our study was designed to examine the association between the c.977C>G polymorphism (rs1052133) of the hOGG1 gene and the c.972G>C polymorphism (rs3219489) of the MUTYH gene and AMD as well as the modulation of this association by some clinical and lifestyle factors. Genotypes were determined in DNA from blood of 271 AMD patients, including 101 with wet and 170 with dry form of the disease and 105 sex- and age-matched individuals without AMD. We observed an association between AMD, dry and wet forms of AMD and the C/G genotype and the G allele of the c.977C>G-hOGG1 polymorphism (p 0.006; 0.009; 0.021 and 0.004; 0.005; 0.016 respectively). On the other hand, the QC genotype and the C allele reduced the risk of AMD as well as of its dry form or wet form (p 0.002; 0.003; 0.010 and 0.004; 0.005; 0.016, respectively). Therefore, the associations we detected were driven by the dry AMD. We observed some statistically significant association between the occurrence of AMD and its dry and wet forms and genotypes of the other polymorphism, the c.972G>C-MUTYH polymorphism, but due to borderline character of all this association we do not consider them as medically relevant. Our findings suggest that the c.977C>G-hOGG1 polymorphism may be associated with dry AMD. Further studies are needed to determine possible association between AMD and the c.972G>C-MUTYH polymorphism. (c) 2012 Elsevier Ltd. All rights reserved.
C1 [Zaras, Malgorzata; Szaflik, Jerzy; Szaflik, Jacek P.] Med Univ Warsaw, Dept Ophthalmol, PL-03710 Warsaw, Poland.
   [Zaras, Malgorzata; Szaflik, Jerzy; Szaflik, Jacek P.] Samodzielny Publi Klini Szpital Okulisty, PL-03710 Warsaw, Poland.
   [Synowiec, Ewelina; Blasiak, Janusz] Univ Lodz, Dept Mol Genet, PL-90236 Lodz, Poland.
C3 Medical University of Warsaw; University of Lodz
RP Szaflik, JP (通讯作者)，Med Univ Warsaw, Dept Ophthalmol, Ul Sierakowskiego 13, PL-03710 Warsaw, Poland.
EM szaflik@ophthalmology.pl
OI Szaflik, Jerzy/0000-0002-7601-1326; Synowiec,
   Ewelina/0000-0002-0730-4491; Blasiak, Janusz/0000-0001-9539-9584
FU Ministry of Science and Higher Education [N N402 248336]
FX This study was supported by the grant number N N402 248336 of Ministry
   of Science and Higher Education.
CR Ali M, 2008, GASTROENTEROLOGY, V135, P499, DOI 10.1053/j.gastro.2008.04.035
   Andreassen PR, 2006, CARCINOGENESIS, V27, P883, DOI 10.1093/carcin/bgi319
   Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016
   Baynes JW, 2002, ANN NY ACAD SCI, V959, P360, DOI 10.1111/j.1749-6632.2002.tb02107.x
   Bojanowski Christine M, 2005, Trans Am Ophthalmol Soc, V103, P37
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233
   Choi JY, 2003, BREAST CANCER RES TR, V79, P59, DOI 10.1023/A:1023305826726
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dherin C, 1999, NUCLEIC ACIDS RES, V27, P4001, DOI 10.1093/nar/27.20.4001
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Essers J, 2006, CURR OPIN CELL BIOL, V18, P240, DOI 10.1016/j.ceb.2006.03.004
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fuse N, 2011, AM J OPHTHALMOL, V151, P550, DOI 10.1016/j.ajo.2010.08.048
   Geirsdottir A, 2007, AM J OPHTHALMOL, V143, P889, DOI 10.1016/j.ajo.2006.11.057
   Goode EL, 2002, CANCER EPIDEM BIOMAR, V11, P1513
   Gorgun E, 2010, INVEST OPHTH VIS SCI, V51, P4732, DOI 10.1167/iovs.09-4842
   Guven M, 2007, MOL VIS, V13, P12
   Guven M, 2011, OPHTHALMIC RES, V46, P31, DOI 10.1159/000321940
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hahn P, 2006, NEUROREPORT, V17, P1803, DOI 10.1097/WNR.0b013e3280107776
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamajima N, 2002, J MOL DIAGN, V4, P103, DOI 10.1016/S1525-1578(10)60688-5
   Hashiguchi K, 2004, NUCLEIC ACIDS RES, V32, P5596, DOI 10.1093/nar/gkh863
   Hung RJ, 2005, AM J EPIDEMIOL, V162, P925, DOI 10.1093/aje/kwi318
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Janik-Papis K, 2009, EXP MOL PATHOL, V87, P234, DOI 10.1016/j.yexmp.2009.09.005
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Johnson AB, 2007, MUTAT RES-FUND MOL M, V618, P149, DOI 10.1016/j.mrfmmm.2006.10.007
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kasahara M, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-49
   Kasai H, 2002, FREE RADICAL BIO MED, V33, P450, DOI 10.1016/S0891-5849(02)00818-3
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kunkel T A, 1999, Trends Genet, V15, P93, DOI 10.1016/S0168-9525(98)01664-3
   Lee PH, 2008, NUCLEIC ACIDS RES, V36, pD820, DOI 10.1093/nar/gkm904
   MCCORD JM, 1985, NEW ENGL J MED, V312, P159
   MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitra S, 2001, ENVIRON MOL MUTAGEN, V38, P180, DOI 10.1002/em.1070
   Miyaishi A, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-10
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Nakabeppu Y, 2001, PROG NUCLEIC ACID RE, V68, P75
   National Eye Institute US National Institutes of health, 2010, FACTS AG REL MAC DEG
   Ng PC, 2006, ANNU REV GENOM HUM G, V7, P61, DOI 10.1146/annurev.genom.7.080505.115630
   Nishioka K, 1999, MOL BIOL CELL, V10, P1637, DOI 10.1091/mbc.10.5.1637
   Ohtsubo T, 2000, NUCLEIC ACIDS RES, V28, P1355, DOI 10.1093/nar/28.6.1355
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   Reddy MB, 2004, NUTR REV, V62, P120, DOI 10.1301/nr.2004.mar.120-124
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scholl HPN, 2007, MOL VIS, V13, P196
   Shinmura K, 2001, ANTIOXID REDOX SIGN, V3, P597, DOI 10.1089/15230860152542952
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Szaflik JP, 2009, MUTAT RES-FUND MOL M, V669, P169, DOI 10.1016/j.mrfmmm.2009.06.008
   Takezaki T, 2002, INT J CANCER, V99, P624, DOI 10.1002/ijc.10400
   Tao H, 2008, CANCER SCI, V99, P355, DOI 10.1111/j.1349-7006.2007.00694.x
   Ting AYC, 2009, CURR OPIN OPHTHALMOL, V20, P369, DOI 10.1097/ICU.0b013e32832f8016
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Unal M, 2007, EXP EYE RES, V85, P328, DOI 10.1016/j.exer.2007.06.003
   Wang AL, 2008, MOL VIS, V14, P644
   Weiss JM, 2005, MOL CARCINOGEN, V42, P127, DOI 10.1002/mc.20067
   Welch KD, 2002, FREE RADICAL BIO MED, V32, P577, DOI 10.1016/S0891-5849(02)00760-8
   Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290
   World Health Organization (WHO), 2009, PRIOR EYE DIS
NR 72
TC 18
Z9 18
U1 0
U2 6
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD MAY
PY 2012
VL 98
BP 58
EP 66
DI 10.1016/j.exer.2012.02.008
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 944DG
UT WOS:000304178000009
PM 22469746
DA 2022-11-30
ER

PT J
AU Barbosa, DTQ
   Mendes, TS
   Cintron-Colon, HR
   Wang, SY
   Bhisitkul, RB
   Singh, K
   Lin, SC
AF Barbosa, D. T. Q.
   Mendes, T. S.
   Cintron-Colon, H. R.
   Wang, S. Y.
   Bhisitkul, R. B.
   Singh, K.
   Lin, S. C.
TI Age-related macular degeneration and protective effect of HMG Co-A
   reductase inhibitors (statins): results from the National Health and
   Nutrition Examination Survey 2005-2008
SO EYE
LA English
DT Article
DE age-related macular degeneration; HMG Co-A reductase inhibitors;
   statins; NHANES
ID CHOLESTEROL-LOWERING MEDICATIONS; CHOROIDAL NEOVASCULARIZATION; 5-YEAR
   INCIDENCE; RISK; PROGRESSION; MACULOPATHY; ASSOCIATION; PREVENTION;
   PREVALENCE
AB Purpose To determine the association of hydroxymethylglutarylcoenzyme A (HMG Co-A) reductase inhibitor (statin) use with the prevalence of age-related macular degeneration (AMD).
   Methods This cross-sectional study included 5604 participants in the National Health and Nutrition Examination Survey (NHANES) from 2005 to 2008, >= 40 years of age, who were ascertained with regard to the diagnosis of AMD, the use of statins, and comorbidities and health-related behaviors such as smoking.
   Results The mean age of participants denying or confirming a history of AMD was 68 (SEM 0.90) and 55 (SEM 0.36) years, respectively. Individuals 68 years of age or older who were classified as long-term users of statins had statistically significant less self-reported AMD (odds ratio (OR) 0.64, 95% confidence interval (CI) 0.49-0.84; P - 0.002), after adjusting for potential confounding variables. No significant association was found between the prevalence of AMD and statin consumption among subjects between 40 and 67 years of age (OR 1.61, 95% CI 0.85-3.03; P = 0.137).
   Conclusions Our results suggest a possible beneficial effect of statin intake for the prevention of AMD in individuals 68 years of age or older.
   Eye (2014) 28, 472-480; doi: 10.1038/eye.2014.8; published online 7 February 2014
C1 [Barbosa, D. T. Q.; Mendes, T. S.; Cintron-Colon, H. R.; Wang, S. Y.; Bhisitkul, R. B.; Lin, S. C.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA.
   [Singh, K.] Stanford Univ, Dept Ophthalmol, Stanford, CA 94305 USA.
C3 University of California System; University of California San Francisco;
   Stanford University
RP Lin, SC (通讯作者)，Univ Calif San Francisco, Dept Ophthalmol, 10 Koret Way,Room K301, San Francisco, CA 94143 USA.
EM LinS@vision.ucsf.edu
RI Mendes, Thais Sousa/R-7735-2019
OI Mendes, Thais Sousa/0000-0001-5568-9958; Cintron-Colon,
   Hector/0000-0001-9233-2640; Wang, Sophia/0000-0003-0916-9403
FU NIH-NEI [EY002162]; NATIONAL EYE INSTITUTE [P30EY002162] Funding Source:
   NIH RePORTER
FX This study was supported by NIH-NEI EY002162-Core Grant for Vision
   Research, That Man May See, Inc., Research to Prevent Blindness.
CR Beri A, 2009, AM J CARDIOVASC DRUG, V9, P361, DOI 10.2165/11315710-000000000-00000
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   Chuo JY, 2007, OPHTHAL EPIDEMIOL, V14, P367, DOI 10.1080/09286580701421684
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Damico FM, 2012, ARQ BRAS OFTALMOL, V75, P71, DOI 10.1590/S0004-27492012000100016
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Drobek-Slowik Monika, 2008, Klin Oczna, V110, P50
   Fernandez AB, 2012, OPHTHALMOLOGY, V119, P765, DOI 10.1016/j.ophtha.2011.09.044
   Fong DS, 2010, AM J OPHTHALMOL, V149, P955, DOI 10.1016/j.ajo.2009.12.037
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Garcia Lozano Isabel, 2012, Rev Esp Geriatr Gerontol, V47, P214, DOI 10.1016/j.regg.2011.11.011
   Gehlbach P, 2012, COCHRANE DB SYST REV, V3
   Guymer RH, 2008, CLIN INTERV AGING, V3, P581
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Kaiserman N, 2009, CURR EYE RES, V34, P304, DOI 10.1080/02713680902741670
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 2007, AM J OPHTHALMOL, V144, P1, DOI 10.1016/j.ajo.2007.02.047
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Maguire MG, 2009, OPHTHALMOLOGY, V116, P2381, DOI 10.1016/j.ophtha.2009.06.055
   MARTINI E, 1991, Annali di Ottalmologia e Clinica Oculistica, V117, P1121
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McGwin G, 2006, ARCH OPHTHALMOL-CHIC, V124, P33, DOI 10.1001/archopht.124.1.33
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   National Center for Health Statistics, NAT HLTH NUTR EX SUR
   National Center for Health Statistics, 2007, NAT HLTH NUTR EX SUR
   Peponis V, 2010, CLIN OPHTHALMOL, V4, P865
   Sagara N, 2007, EXP EYE RES, V84, P1074, DOI 10.1016/j.exer.2007.02.005
   Shalev V, 2011, OPHTHAL EPIDEMIOL, V18, P83, DOI 10.3109/09286586.2011.560746
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   Tobert JA, 2003, NAT REV DRUG DISCOV, V2, P517, DOI 10.1038/nrd1112
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Wong Ian Yat Hin, 2011, International Ophthalmology, V31, P73, DOI 10.1007/s10792-010-9397-5
NR 40
TC 20
Z9 23
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD APR
PY 2014
VL 28
IS 4
BP 472
EP 480
DI 10.1038/eye.2014.8
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AE9VT
UT WOS:000334360000016
PM 24503725
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Arrigo, A
   Saladino, A
   Aragona, E
   Mercuri, S
   Introini, U
   Bandello, F
   Parodi, MB
AF Arrigo, Alessandro
   Saladino, Andrea
   Aragona, Emanuela
   Mercuri, Stefano
   Introini, Ugo
   Bandello, Francesco
   Parodi, Maurizio Battaglia
TI Different Outcomes of Anti-VEGF Treatment for Neovascular AMD according
   to Neovascular Sutypes and Baseline Features: 2-Year Real-Life Clinical
   Outcomes
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID MACULAR DEGENERATION; RANIBIZUMAB; AFLIBERCEPT; THERAPY
AB Purpose. To evaluate the effects of anti-VEGF treatment of neovascular age-related macular degeneration (nAMD) in a real-life clinical setting. Methods. Study design is a retrospective case series. Naive nAMD patients treated with intravitreal injection of aflibercept or ranibizumab were analyzed over a 24-month follow-up. Each patient received the loading dose, followed by a PRN regimen. Patients were further subdivided into subgroups according to macular neovascularization type, best corrected visual acuity (BCVA) at baseline (BCVA>0.3 LogMAR and BCVA <= 0.3 LogMAR), and different anti-VEGF drugs. Primary outcome was the changes in BCVA and central macular thickness (CMT) over 24 months. Secondary outcomes included the influence of the selected drug and of the baseline BCVA on the final outcomes. Results. 439 patients (224 males; 51%) with naive AMD-related macular neovascularization were included in the analyses. Mean age was 78 +/- 8 years old. Compared to baseline evaluations, not significant BCVA changes were found at 1-year and 2-year examinations. CMT was significantly reduced at both 1-year and 2-year follow-ups (p<0.01). Classic, polypoidal choroidal vasculopathy and mixed subtypes significantly correlated with worse visual outcome (p<0.01). Overall, baseline BCVA significantly correlated with both 1-year and 2-year follow-up changes (p<0.01). Moreover, BCVA at 1-year significantly correlated with BCVA changes at 2-year follow-up (p<0.01). Furthermore, CMT changes from baseline significantly correlated with both 1-year and 2-year follow-up measurements (p<0.01). Conclusion. Anti-VEGF approach is generally effective in stopping nAMD progression in our real-life analysis. No difference was found comparing patients treated with ranibizumab and aflibercept, nor in patients with drug switching.
C1 [Arrigo, Alessandro; Saladino, Andrea; Aragona, Emanuela; Mercuri, Stefano; Introini, Ugo; Bandello, Francesco; Parodi, Maurizio Battaglia] IRCCS San Raffaele Sci Inst, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Arrigo, A (通讯作者)，IRCCS San Raffaele Sci Inst, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
EM arrigo.alessandro@hsr.it; a.saladino@studenti.unisr.it;
   aragona.emanuela@hsr.it; mercuristef@gmail.com; introini.ugo@hsr.it;
   bandello.francesco@hsr.it; maubp@yahoo.it
OI Battaglia Parodi, Maurizio/0000-0002-0385-7961; Arrigo,
   Alessandro/0000-0003-4715-8414; bandello, francesco/0000-0003-3238-9682
CR Abugreen S, 2003, BRIT J OPHTHALMOL, V87, P307, DOI 10.1136/bjo.87.3.307
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Garweg JG, 2017, J OCUL PHARMACOL TH, V33, P567, DOI 10.1089/jop.2017.0031
   Guo MY, 2019, ACTA OPHTHALMOL, V97, pE1, DOI 10.1111/aos.13825
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Nixon DR, 2017, CLIN OPHTHALMOL, V11, P715, DOI 10.2147/OPTH.S131343
   Parodi MB, 2020, EUR J OPHTHALMOL, V30, P1461, DOI 10.1177/1120672119880386
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Schmid MK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135050
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Weber M, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2017-000109
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
NR 20
TC 4
Z9 4
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD MAY 25
PY 2021
VL 2021
AR 5516981
DI 10.1155/2021/5516981
PG 5
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA TC9VP
UT WOS:000668985800002
PM 34124243
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Xu, YL
   Guan, N
   Xu, J
   Yang, XF
   Ma, K
   Zhou, HY
   Zhang, F
   Snellingen, T
   Jiao, YQ
   Liu, XP
   Wang, NL
   Liu, NP
AF Xu, Yule
   Guan, Ning
   Xu, Jun
   Yang, Xiufen
   Ma, Kai
   Zhou, Haiying
   Zhang, Feng
   Snellingen, Torkel
   Jiao, Yiqun
   Liu, Xipu
   Wang, Ningli
   Liu, Ningpu
TI Association of CFH, LOC387715, and HTRA1 polymorphisms with exudative
   age-related macular degeneration in a northern Chinese population
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT-FACTOR-H; JAPANESE POPULATION; GENE POLYMORPHISM; BEIJING
   EYE; Y402H POLYMORPHISM; CIGARETTE-SMOKING; CHROMOSOME 10Q26;
   ADULT-POPULATION; POOLED FINDINGS; NO ASSOCIATION
AB Purpose: Variants in complement factor H (CFH), the hypothetical LOC387715, and the high-temperature requirement A-1 (HTRA1) genes have been reported to be associated with age-related macular degeneration (AMD). The purpose of this study was to investigate the association of reported common single-nucleotide polymorphisms ( SNPs) in CFH, LOC387715, and HTRA1 with exudative AMD in a northern Chinese population.
   Methods: A cohort of 121 unrelated patients with exudative AMD and 132 control subjects were enrolled in this study. Genomic DNA was extracted from blood leukocytes. Genotyping for SNPs rs1061170: T > C in CFH ( Y402H), rs10490924: G > T in LOC387715 (A69S), and rs11200638: G > A in the promoter of HTRA1 was performed using a polymerase chain reaction (PCR) method followed by allele-specific restriction enzyme digestion and direct sequencing.
   Results: The Y402H variant in CFH was not associated with exudative AMD in our study population. Frequencies of Y402H was 10.3% in AMD cases and 8.0% in controls (p = 0.353). Significant associations were detected for exudative AMD with SNPs rs10490924: G > T in LOC387715 ( A69S), and rs11200638: G > A in the promoter of HTRA1. The risk Tallele frequency of rs10490924 in LOC387715 was 64.9% in cases versus 43.2% in controls (p < 0.001). The odds ratio for risk of AMD was 1.56 (95% CI; 0.80-3.03) for the GT genotype and 5.45 ( 95% CI; 2.59-11.49) for the TT genotype. The A allele frequency of rs11200638 in the HTRA1 promoter was 67.8% in cases versus 42.4% in controls (p < 0.001). The odds ratio was 2.75 ( 95% CI; 1.34-5.64) for the GA genotype and 7.90 ( 95% CI; 3.61-17.26) for the AA genotype. An odds ratio of 7.94 ( 95% CI; 3.49-18.04) was obtained for carriers with both TT genotype in LOC387715 and AA genotype in the HTRA1 promoter.
   Conclusions: Our data suggest that the LOC387715 and HTRA1 polymorphisms are associated with a higher risk of exudative AMD in northern Chinese. We found no association of CFH Y402H with exudative AMD. The low frequency of CFH Y402H variant was further confirmed in this study population.
C1 [Xu, Yule; Guan, Ning; Xu, Jun; Yang, Xiufen; Ma, Kai; Zhou, Haiying; Zhang, Feng; Wang, Ningli; Liu, Ningpu] Capital Med Univ, Beijing Tongren Eye Ctr, Beijing 100730, Peoples R China.
   [Snellingen, Torkel; Jiao, Yiqun; Liu, Xipu] Beijing Sekwa Eye Hosp, Beijing, Peoples R China.
C3 Capital Medical University
RP Liu, NP (通讯作者)，Capital Med Univ, Beijing Tongren Eye Ctr, Beijing 100730, Peoples R China.
EM nliu001@gmail.com
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chen LJ, 2006, MOL VIS, V12, P1536
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Mori M, 2005, J HUM GENET, V50, P264, DOI 10.1007/s10038-005-0246-8
   Okamoto H, 2006, MOL VIS, V12, P156
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Souied EH, 2005, MOL VIS, V11, P1135
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tsai HJ, 2001, AM J HUM GENET, V69, P1236, DOI 10.1086/324646
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   WANG JJ, 2007, OPHTHALMOLOGY
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weger M, 2007, MOL VIS, V13, P1274
   WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YOSHIDA T, HTRA1 PROMOTER POLYM
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 53
TC 61
Z9 73
U1 0
U2 3
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JUL 28
PY 2008
VL 14
IS 165
BP 1373
EP 1381
PG 9
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 336DZ
UT WOS:000258345800001
PM 18682812
DA 2022-11-30
ER

PT J
AU Kabedi, NN
   Kayembe, DL
   Elongo, GM
   Mwanza, JC
AF Kabedi, Nelly N.
   Kayembe, David L.
   Elongo, Gloria M.
   Mwanza, Jean-Claude
TI Polypoidal Choroidal Vasculopathy in Congolese Patients
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; MACULAR DEGENERATION; RISK-FACTORS;
   CHINESE; HYPERTENSION; DIAGNOSIS; DISEASE; ANGIOGRAPHY; PREVALENCE;
   FEATURES
AB Purpose. Polypoidal choroidal vasculopathy (PCV) is a visually debilitating disease that mostly affects people of African and Asian heritage. Indocyanine green angiography (ICGA) is the recommended exploratory method for definitive diagnosis. The disease has been extensively described in Asians and Caucasians, but not in Africans. This study was conducted to document the clinical presentation and optical coherence tomography features of polypoidal choroidal vasculopathy (PCV) in Congolese patients. Methods. A prospective case series of patients with PCV was performed between January 2017 and June 2019. Routine ocular examination was performed including best corrected visual acuity measurement, slit-lamp examination, dilated direct fundoscopy, and spectral domain optical coherence tomography (OCT). The diagnosis was based on a combination of clinical and OCT signs. Results. Fourteen patients were diagnosed with PCV during this period. The average age was 64.7 +/- 6.9 years. There were 8 females. Ten (71.4%) patients had systemic hypertension. Most patients (n = 9, 64.3%) had bilateral involvement. Blurred vision was the most common complaint (71.4%). The main clinical presentation was subretinal exudates, seen in 19 (82.6%) eyes of 11 (78.6%) patients and subretinal hemorrhage in 10 (43.5%) eyes. Macular localization was found in 16 eyes (69.5%) of 12 (85.7%) patients. Drusen were observed in 35.7% of the patients. On OCT imaging, thumb-like pigment epithelial detachment and subretinal exudation were the most frequent features, observed in 92.9% and 71.4% of the patients, respectively. Conclusions. PCV in Congolese patients showed features that are more similar to those observed in Caucasians. In this setting where indocyanine green angiography is not available, OCT facilitates the diagnosis of PCV.
C1 [Kabedi, Nelly N.; Kayembe, David L.; Elongo, Gloria M.; Mwanza, Jean-Claude] Univ Kinshasa, Sch Med, Dept Ophthalmol, Kinshasa, DEM REP CONGO.
   [Mwanza, Jean-Claude] Univ N Carolina, Sch Med, Dept Ophthalmol, Chapel Hill, NC 27515 USA.
C3 Universite de Kinshasa; University of North Carolina; University of
   North Carolina Chapel Hill; University of North Carolina School of
   Medicine
RP Mwanza, JC (通讯作者)，Univ Kinshasa, Sch Med, Dept Ophthalmol, Kinshasa, DEM REP CONGO.; Mwanza, JC (通讯作者)，Univ N Carolina, Sch Med, Dept Ophthalmol, Chapel Hill, NC 27515 USA.
EM nelkabedi@gmail.com; pdavidkayembe@gmail.com; gloremelongo@gmail.com;
   jean-claude_mwanza@med.unc.edu
RI Mwanza, Jean-Claude/L-4235-2017; Mwanza, Jean-Claude/AAR-1519-2020
OI Mwanza, Jean-Claude/0000-0002-2346-5885; Kabedi,
   Nelly/0000-0001-5118-3861
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Alasil Tarek, 2017, Int J Retina Vitreous, V3, P9, DOI 10.1186/s40942-017-0060-4
   Alasil T, 2015, AM J OPHTHALMOL, V159, P634, DOI 10.1016/j.ajo.2014.12.012
   Baek J, 2019, INVEST OPHTH VIS SCI, V60, P590, DOI 10.1167/iovs.18-24244
   Bhoomibunchoo C, 2017, CLIN OPHTHALMOL, V11, P317, DOI 10.2147/OPTH.S126226
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Chaikitmongkol V, 2018, AM J OPHTHALMOL, V192, P77, DOI 10.1016/j.ajo.2018.05.005
   Chang Young Suk, 2016, Korean J Ophthalmol, V30, P198, DOI 10.3341/kjo.2016.30.3.198
   Cheng HC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110818
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2017, SCI REP-UK, V7, DOI 10.1038/srep41386
   Chung YR, 2016, CAN J OPHTHALMOL, V51, P348, DOI 10.1016/j.jcjo.2016.02.012
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   de Mello PC, 2007, EYE, V21, P1247, DOI 10.1038/sj.eye.6702929
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Fan Q, 2017, INT J EPIDEMIOL, V46, P1891, DOI 10.1093/ije/dyx189
   Fujiwara K, 2018, SEMIN OPHTHALMOL, V33, P813, DOI 10.1080/08820538.2018.1506483
   Guyomarch J, 2008, J FR OPHTALMOL, V31, P579, DOI 10.1016/S0181-5512(08)75458-5
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   He SK, 2013, MOL VIS, V19, P665
   Hertz RP, 2005, ARCH INTERN MED, V165, P2098, DOI 10.1001/archinte.165.18.2098
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Ho CPS, 2018, INDIAN J OPHTHALMOL, V66, P1727, DOI 10.4103/ijo.IJO_975_18
   Hou J, 2011, GRAEF ARCH CLIN EXP, V249, P975, DOI 10.1007/s00417-010-1575-7
   Huang CH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37384-y
   Ilginis T, 2012, ACTA OPHTHALMOL, V90, pe487, DOI 10.1111/j.1755-3768.2011.02329.x
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Iwama D, 2008, JPN J OPHTHALMOL, V52, P116, DOI 10.1007/s10384-007-0503-9
   Kameda T, 2007, CLIN EXP OPHTHALMOL, V35, P596, DOI 10.1111/j.1442-9071.2007.01554.x
   Kika TM, 2016, CARDIOVASC J AFR, V27, P361, DOI 10.5830/CVJA-2016-036
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kim Joon-Bom, 2017, Curr Ophthalmol Rep, V5, P176, DOI 10.1007/s40135-017-0137-0
   Kim JY, 2016, GRAEF ARCH CLIN EXP, V254, P1505, DOI 10.1007/s00417-015-3228-3
   Kokame GT, 2016, OSLI RETINA, V47, P737, DOI 10.3928/23258160-20160808-07
   Kumar A, 2019, THER ADV OPHTHALMOL, V11, DOI 10.1177/2515841419831152
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lee J, 2018, RETINA
   Li ML, 2016, SCI REP-UK, V6, DOI 10.1038/srep38342
   Li Y, 2014, OPHTHALMOLOGY, V121, P2290, DOI 10.1016/j.ophtha.2014.06.016
   Lip PL, 2000, EYE, V14, P695, DOI 10.1038/eye.2000.186
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Oluleye TS, 2013, CLIN OPHTHALMOL, V7, P1373, DOI 10.2147/OPTH.S47511
   Ratanasukon M, 2018, CLIN OPHTHALMOL, V12, P2177, DOI 10.2147/OPTH.S178228
   Sa Ho-Seok, 2005, Korean J Ophthalmol, V19, P275
   Sakurada Y, 2013, RETINA-J RET VIT DIS, V33, P841, DOI 10.1097/IAE.0b013e31826ffe9d
   Sayanagi K, 2015, BRIT J OPHTHALMOL, V99, P29, DOI 10.1136/bjophthalmol-2013-304658
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Seibel I, 2018, KLIN MONATSBL AUGENH, V235, P994, DOI 10.1055/a-0656-6867
   Semoun O, 2016, BRIT J OPHTHALMOL, V100, P1028, DOI 10.1136/bjophthalmol-2015-307494
   Shantha J. G., 2016, RETINA TODAY, V3, P64
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Singh SR, 2019, INDIAN J OPHTHALMOL, V67, P1121, DOI 10.4103/ijo.IJO_1757_18
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   Thomas SJ, 2018, J AM HEART ASSOC, V7, DOI [10.1161/jaha.117.007988, 10.1161/JAHA.117.007988]
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yeung Ling, 2004, Chang Gung Med J, V27, P366
   Yoon JS, 2007, YONSEI MED J, V48, P225, DOI 10.3349/ymj.2007.48.2.225
NR 66
TC 4
Z9 4
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD JAN 20
PY 2020
VL 2020
AR 4103871
DI 10.1155/2020/4103871
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KH8KP
UT WOS:000510899600001
PM 32051763
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Clark, ME
   McGwin, G
   Neely, D
   Feist, R
   Mason, JO
   Thomley, M
   White, MF
   Ozaydin, B
   Girkin, CA
   Owsley, C
AF Clark, Mark E.
   McGwin, Gerald, Jr.
   Neely, David
   Feist, Richard
   Mason, John O., III
   Thomley, Martin
   White, Milton F., Jr.
   Ozaydin, Bunyamin
   Girkin, Christopher A.
   Owsley, Cynthia
TI Association between retinal thickness measured by spectral-domain
   optical coherence tomography (OCT) and rod-mediated dark adaptation in
   non-exudative age-related maculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID DEGENERATION; IMPAIRMENT; LAYER
AB Aim To examine associations between retinal thickness and rod-mediated dark adaptation in older adults with non-exudative age-related maculopathy (ARM) or normal macular health.
   Methods A cross-sectional study was conducted with 74 adults >= 50 years old from the comprehensive ophthalmology and retina services of an academic eye centre. ARM presence and disease severity in the enrolment eye was defined by the masked grading of stereofundus photos using the Clinical Age-Related Maculopathy grading system. High-definition, spectral-domain optical coherence tomography was used to estimate retinal thickness in a grid of regions in the macula. Rod-mediated dark adaptation, recovery of light sensitivity after a photo-bleach, was measured over a 20-min period for a 500 nm target presented at 5 degrees on the inferior vertical meridian. Main outcomes of interest were retinal thickness in the macula (mu m) and parameters of rod-mediated dark adaptation (second slope, third slope, average sensitivity, final sensitivity).
   Results In non-exudative disease retinal thickness was decreased in greater disease severity; thinner retina was associated with reductions in average and final rod-mediated sensitivity even after adjustment for age and visual acuity.
   Conclusions Impairment in rod-mediated dark adaptation in non-exudative ARM is associated with macular thinning.
C1 [Clark, Mark E.; McGwin, Gerald, Jr.; Neely, David; Feist, Richard; Mason, John O., III; Thomley, Martin; White, Milton F., Jr.; Ozaydin, Bunyamin; Girkin, Christopher A.; Owsley, Cynthia] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA.
   [McGwin, Gerald, Jr.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35294 USA.
   [McGwin, Gerald, Jr.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA.
   [Ozaydin, Bunyamin] Univ Alabama Birmingham, Dept Elect & Comp Engn, Birmingham, AL 35294 USA.
   [Ozaydin, Bunyamin] Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Owsley, C (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol, 700 S 18th St,Suite 609, Birmingham, AL 35294 USA.
EM owsley@uab.edu
OI Girkin, Chris/0000-0002-9676-4499; Ozaydin,
   Bunyamin/0000-0002-6775-0450; Girkin, Christopher/0000-0002-5781-7682
FU National Institutes of Health [R01-AG04212, R21-EY14071]; EyeSight
   Foundation of Alabama; Research to Prevent Blindness; Alfreda J.
   Schueler Trust; Able Trust; NATIONAL EYE INSTITUTE [R21EY014071] Funding
   Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
   [T35HL007473] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING
   [R01AG004212] Funding Source: NIH RePORTER
FX This research was supported by National Institutes of Health grants
   R01-AG04212 and R21-EY14071, the EyeSight Foundation of Alabama,
   Research to Prevent Blindness, the Alfreda J. Schueler Trust, and the
   Able Trust.
CR Chan A, 2006, RETINA-J RET VIT DIS, V26, P655, DOI 10.1097/00006982-200607000-00011
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   DOWLING JE, 1960, NATURE, V188, P114, DOI 10.1038/188114a0
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   LAMB TD, 1980, NATURE, V287, P349, DOI 10.1038/287349a0
   Marmor M. F., 1998, RETINAL PIGMENT EPIT, DOI [10.1098/rsif.2015.0563, DOI 10.1098/RSIF.2015.0563]
   McGwin G, 1999, BEHAV RES METH INS C, V31, P712, DOI 10.3758/BF03200752
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   PUGH EN, 1975, J PHYSIOL-LONDON, V248, P393, DOI 10.1113/jphysiol.1975.sp010981
   Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557
   Rushton W.A.H., 1955, Optica Acta, V1, P183
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Sung KR, 2009, OPHTHALMOLOGY, V116, P1119, DOI 10.1016/j.ophtha.2009.01.004
   SUNNESS JS, 1989, OPHTHALMOLOGY, V96, P375, DOI 10.1016/S0161-6420(89)32883-1
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
NR 26
TC 20
Z9 20
U1 0
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2011
VL 95
IS 10
BP 1427
EP 1432
DI 10.1136/bjo.2010.190355
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 822VL
UT WOS:000295078000020
PM 21289019
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Nguyen, NX
   Weismann, M
   Trauzettel-Klosinski, S
AF Nguyen, Nhung Xuan
   Weismann, Malte
   Trauzettel-Klosinski, Susanne
TI Improvement of reading speed after providing of low vision aids in
   patients with age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; low vision aids; reading ability;
   reading speed
ID QUALITY-OF-LIFE; REHABILITATION; PSYCHOPHYSICS; PERFORMANCE; SCOTOMA;
   SPAN
AB Purpose:
   Age-related macular degeneration (AMD) is the most common cause of severe visual impairment, including loss of reading ability, among elderly persons in developed countries. The aim of the present study was to evaluate reading ability before and after providing of appropriate low vision aids.
   Methods:
   Five hundred and thirty patients with different stages of AMD (age 82 +/- 8 years) were included in this retrospective study. All patients underwent a standardized ophthalmological examination including evaluation of magnification requirement and careful providing of low vision aids. Before and after the provision of low vision aids, reading speed [words per minute (wpm)] was evaluated using standardized reading texts.
   Results:
   For the whole group, the average best-corrected distance visual acuity of the better eye was 0.18 +/- 0.15, with 69% of patients having visual acuity of 0.1 (20/200) or better. The mean magnification requirement was 7.4 +/- 6.3-fold (range 2-25). Visual rehabilitation was achieved with optical visual aids in 58% of patients, whereas 42% of patients needed electronically closed-circuit TV systems. Mean reading speed was 20 +/- 33 wpm before and increased significantly to 72 +/- 35 (p < 0.0001) after the provision of low vision aids for the whole group. Between patients with visual acuity < 0.1 and patients with visual acuity of 0.1 or better, there are highly significant differences in reading speed before (0.4 +/- 3.8 versus 20 +/- 28 wpm, p < 0.0001) and after providing of visual aids (40 +/- 13 versus 84 +/- 30 wpm, p < 0.0001). Patients with severe visual impairment (visual acuity < 0.1) showed significantly lower improvement of reading speed compared to patients with visual acuity of 0.1 or better following rehabilitation (p < 0.0001). Before providing of low vision aids, only 16% of patients were able to read; in contrast, reading ability was achieved in 94% of patients after the provision of low vision aids for the whole group.
   Conclusion:
   Our results indicate the great value of low vision rehabilitation through adequate providing of vision aids for the improvement of reading ability, with a highly significant increase of reading speed without training of eccentric viewing in patients with retained central fixation. The prompt implementation of low vision aids in patients with macular degeneration will help them to maintain and regain their reading ability, which can lead to an increase in independence, communication, mental agility and quality of life.
C1 [Nguyen, Nhung Xuan] Univ Tubingen, Ctr Ophthalmol, Low Vis Clin, D-72076 Tubingen, Germany.
   Univ Tubingen, Ctr Ophthalmol, Res Lab, D-72076 Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Eberhard Karls University of Tubingen; Eberhard Karls
   University Hospital
RP Nguyen, NX (通讯作者)，Univ Tubingen, Ctr Ophthalmol, Low Vis Clin, Schleichstr 12-16, D-72076 Tubingen, Germany.
EM nhung.nguyen@med.uni-tuebingen.de
FU Herbert-Funke Foundation; Hildebrandt Foundation
FX Part of this study was presented at ARVO 2007, May 6-10, 2007, Fort
   Lauderdale, FL, USA. This study was supported by the Herbert-Funke
   Foundation and the Hildebrandt Foundation. The authors thank C. Gehrlich
   and S. Mayer for the recruitment of patients and data collection.
CR Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Frohlich SJ, 2006, OPHTHALMOLOGE, V103, P1038, DOI 10.1007/s00347-006-1427-3
   Hahn GA, 2006, BRIT J OPHTHALMOL, V90, P480, DOI 10.1136/bjo.2005.087379
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Legge GE, 1997, VISION RES, V37, P1999, DOI 10.1016/S0042-6989(97)00017-5
   LEGGE GE, 1985, VISION RES, V25, P253, DOI 10.1016/0042-6989(85)90118-X
   LEGGE GE, 1992, INVEST OPHTH VIS SCI, V33, P677
   LEGGE GE, 1989, OPTOMETRY VISION SCI, V66, P843, DOI 10.1097/00006324-198912000-00008
   McCabe P, 2000, Ophthalmic Epidemiol, V7, P259, DOI 10.1076/opep.7.4.259.4173
   Nguyen NX, 2008, OPHTHALMOLOGE, V105, P563, DOI 10.1007/s00347-007-1651-5
   Nguyen NX, 2007, ACTA OPHTHALMOL SCAN, V85, P877, DOI 10.1111/j.1600-0420.2007.00963.x
   NILSSON UL, 1990, CLIN VISION SCI, V6, P3
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   Radner W, 2002, GRAEF ARCH CLIN EXP, V240, P461, DOI 10.1007/s00417-002-0443-5
   RAYNER K, 1975, COGNITIVE PSYCHOL, V7, P65, DOI 10.1016/0010-0285(75)90005-5
   Rubin GS, 2001, EYE, V15, P430, DOI 10.1038/eye.2001.148
   Trauzettel-Klosinski S., 2003, VIS IMPAIR RES, V5, P83, DOI [10.1076/vimr.5.2.83.26264, DOI 10.1076/VIMR.5.2.83.26264]
   TRAUZETTELKLOSINSKI S, 1994, NEURO-OPHTHALMOLOGY, V14, P15, DOI 10.3109/01658109409019482
   WHITTAKER SG, 1993, OPTOMETRY VISION SCI, V70, P54, DOI 10.1097/00006324-199301000-00010
NR 20
TC 60
Z9 61
U1 0
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2009
VL 87
IS 8
BP 849
EP 853
DI 10.1111/j.1755-3768.2008.01423.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 524RQ
UT WOS:000272161000007
PM 19141148
OA Bronze
DA 2022-11-30
ER

PT J
AU Schmidt-Erfurth, U
   Sacu, S
AF Schmidt-Erfurth, Ursula
   Sacu, Stefan
CA Early Retreatment Study Grp
TI Randomized multicenter trial of more intense and standard early
   verteporfin treatment of neovascular age-related macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC
   THERAPY; INTRAVITREAL TRIAMCINOLONE; CLINICAL-TRIALS; LESION SIZE; TAP
AB Purpose: To compare efficacy and safety of a more intense regimen versus a standard one for retreatment of neovascular age-related macular degeneration (AMD) during the early period of verteporfin therapy (VT).
   Design: Prospective, randomized, multicenter clinical trial.
   Participants: Two hundred three patients with predominantly classic choroidal neovascularization (CNV) secondary to AMD.
   Methods: During the first 6 months of VT, patients underwent retreatment every 2 (group A) or 3 (group B) months. After 6 months, both groups underwent retreatment every 3 months for as long as CNV activity was documented.
   Main Outcome Measures: Best-corrected visual acuity (BCVA) measured every 6 months, mean number of treatments per patient during 24 months' follow-up, proportions of patients in each group losing at least 3 lines of vision or gaining at least 1 line, greatest linear dimension (GLD) of the lesion as documented by fluorescein angiography every 6 months, and relationship between initial lesion size and BCVA.
   Results: At all follow-up times, mean BCVAs were similar for groups A and B. Mean numbers of photodynamic therapy treatments were similar for both groups (4.07 vs. 4.36; P = 0.451, paired t test). A lower proportion (51.9% vs. 56.7%) of patients in group A had lost at least 3 lines of vision at 24 months. Groups A and B had similar increases in mean lesion size from baseline to 24 months (2104-3056 mu m and 2179-3020 mu m). At 24 months, patients in group A with a baseline lesion GLD of :<= 2000 mu m had significantly less mean loss of vision than patients in group A with a GLD of >2000 mu m (P = 0.032); differences also were significant for group A with GLD of <= 2000 mu m versus group B with GLD of <= 2000 mu m (P = 0.041) or GLD of >2000 mu m (P = 0.045); and mean vision losses from baseline were 8, 17, 15, and 14 letters, respectively.
   Conclusions: Overall outcomes regarding visual benefit, lesion anatomic features, and number of retreatments after 6 months were similar for patients receiving more intense or standard early therapy. An unplanned retrospective analysis showed that there was significantly less vision loss when the more intense regimen was used to treat smaller lesions. Ophthalmology 2008;115:134-140 (c) 2008 by the American Academy of Ophthalmology,
C1 [Schmidt-Erfurth, Ursula; Sacu, Stefan] Med Univ Vienna, Dept Ophthalmol, A-1090 Vienna, Austria.
C3 Medical University of Vienna
RP Sacu, S (通讯作者)，Med Univ Vienna, Dept Ophthalmol, AKH 8I,Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM stefan.sacu@meduniwien.ac.at
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Arias L, 2005, BRIT J OPHTHALMOL, V89, P312, DOI 10.1136/bjo.2004.050997
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Eter N, 2006, BIODRUGS, V20, P167, DOI 10.2165/00063030-200620030-00004
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   HOLM S, 1979, SCAND J STAT, V6, P65
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Michels S, 2005, OPHTHALMOLOGY, V112, P2070, DOI 10.1016/j.ophtha.2005.06.034
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2006, ARCH OPHTHALMOL-CHIC, V124, P561, DOI 10.1001/archopht.124.4.561
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Zhang J, 1997, CONTROL CLIN TRIALS, V18, P204, DOI 10.1016/S0197-2456(96)00129-8
NR 18
TC 6
Z9 6
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2008
VL 115
IS 1
BP 134
EP 140
DI 10.1016/j.ophtha.2007.02.033
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 248FK
UT WOS:000252137300020
PM 18166408
DA 2022-11-30
ER

PT J
AU Wang, HY
   Barteselli, G
   Freeman, WR
   Lee, SN
   Chhablani, J
   El-Emam, S
   Cheng, LY
AF Wang, Haiyan
   Barteselli, Giulio
   Freeman, William R.
   Lee, Su Na
   Chhablani, Jay
   El-Emam, Sharif
   Cheng, Lingyun
TI Temporal pattern of resolution/recurrence of choroidal
   neovascularization during bevacizumab therapy for wet age-related
   macular degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE bevacizumab; age-related macular degeneration; recurrence; anti-vascular
   endothelial growth factor therapy
ID ANTI-VEGF THERAPY; COHERENCE TOMOGRAPHY; RANIBIZUMAB; TACHYPHYLAXIS; AMD
AB AIM: To characterize temporal pattern of resolution and recurrence of naive choroidal neovascularization (CNV) secondary to wet age -related macular degeneration (AMD) treated with intravitreal bevacizumab on as needed regimen, and to analyze baseline risk factors for CNV resolution or recurrence.
   METHODS: Ninety-one eyes of 80 patients with newly diagnosed wet AMD were retrospectively studied. All eyes were treated with a round of three monthly intravitreal bevacizumab injections, followed by one additional 'bonus' injection after resolution of CNV activity. During follow -up, eyes were monitored with fluorescein angiography, optical coherence tomography, and best -corrected visual acuity (BCVA). In case of recurrences of CNV activity, eyes were retreated with other rounds of bevacizumab injections following the same treatment protocol.
   RESULTS: Over a median follow -up of 532d, the median resolution time of CNV activity in the first, second, and third treatment round was 98d, 126d, and 111d, respectively. The median recurrence time for the three rounds was 154d, 126d, and 151d, respectively. No significant difference in resolution time (P=0.09) or in recurrence time (P=0.11) was detected among treatment rounds. Age (P=0.0082) and lens status (P=0.035) were found to be associated with CNV resolution; for every 1-year increase in age there was 4% greater chance of CNV resolution; Phakic eyes demonstrated a 33% better chance to experience CNV resolution than pseudophakic eyes. For CNV recurrence, lens status (P=0.0009) and gender (P=0.0446) were found to be predictive; pseudophakic eyes had a 3.69 -fold greater risk to experience recurrence of CNV activity compared to phakic eyes; males had a 2.19 -fold greater risk to experience recurrence of CNV activity than females. No significant BCVA changes among three treatment rounds were noted (P=0.56).
   CONCLUSION: Resolution time and recurrence time of CNV activity were not significantly different among treatment rounds, suggesting absence of tachyphylaxis to bevacizumab. A cautious decision should be made upon discontinuing treatment in wet AMD eyes of younger or pseudophakic patients, which showed slower response to bevacizumab. In addition, wet AMD eyes of male or pseudophakic patients should be evaluated more carefully after stopping the treatment, because they may have early reactivation of the CNV. BCVA was preserved by bevacizumab treatment despite multiple recurrences.
C1 [Wang, Haiyan; Barteselli, Giulio; Freeman, William R.; Lee, Su Na; Chhablani, Jay; El-Emam, Sharif; Cheng, Lingyun] Univ Calif San Diego, Dept Ophthalmol, Jacobs Retina Ctr, Shiley Eye Ctr, La Jolla, CA 92037 USA.
C3 University of California System; University of California San Diego
RP Cheng, LY (通讯作者)，Shiley Eye Ctr, Dept Ophthalmol, 0946 Joan & Irwin Jacobs Retina Ctr,9415 Campus P, La Jolla, CA 92037 USA.
EM cheng@eyecenter.ucsd.edu
RI Emam, Sharif El/AAA-6627-2020
OI Emam, Sharif El/0000-0001-6357-0471; Barteselli,
   Giulio/0000-0003-0533-1135; Chhablani, Jay/0000-0003-1772-3558
FU NIH [R01EY007366, R01EY018589, R01EY020617]; RPB incorporated and
   unrestricted funds from Jacobs Retina Center; NATIONAL EYE INSTITUTE
   [P30EY022589] Funding Source: NIH RePORTER
FX NIH grants R01EY007366 and R01EY018589 (WRF), R01EY020617 (LC), and "RPB
   incorporated and unrestricted funds from Jacobs Retina Center"
CR AGUILAR HE, 1995, RETINA-J RET VIT DIS, V15, P428
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heimes B, 2011, GRAEF ARCH CLIN EXP, V249, P639, DOI 10.1007/s00417-010-1524-5
   Hoerster R, 2011, BRIT J OPHTHALMOL, V95, P1424, DOI 10.1136/bjo.2010.201129
   Horster R, 2011, GRAEF ARCH CLIN EXP, V249, P645, DOI 10.1007/s00417-010-1588-2
   Khurana RN, 2010, OPHTHALMOLOGY, V117, P1376, DOI 10.1016/j.ophtha.2009.11.039
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Plafker SM, 2012, INT REV CEL MOL BIO, V298, P135, DOI 10.1016/B978-0-12-394309-5.00004-3
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
NR 19
TC 10
Z9 12
U1 1
U2 3
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD OCT 18
PY 2013
VL 6
IS 5
BP 600
EP 605
DI 10.3980/j.issn.2222-3959.2013.05.09
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 236GM
UT WOS:000325783500009
PM 24195033
DA 2022-11-30
ER

PT J
AU Mathis, T
   Dimassi, S
   Loria, O
   Sudhalkar, A
   Bilgic, A
   Denis, P
   Pradat, P
   Kodjikian, L
AF Mathis, Thibaud
   Dimassi, Sarra
   Loria, Olivier
   Sudhalkar, Aditya
   Bilgic, Alper
   Denis, Philippe
   Pradat, Pierre
   Kodjikian, Laurent
TI Retinal Vascularization Analysis on Optical Coherence Tomography
   Angiography before and after Intraretinal or Subretinal Fluid Resorption
   in Exudative Age-Related Macular Degeneration: A Pilot Study
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; exudation; optical coherence
   tomography angiography
AB The aim was to analyze the variations in macular vascularization on optical coherence tomography angiography (OCTA) according to the presence of intraretinal fluid (IRF) induced by exudative age-related macular degeneration (AMD). We included exudative AMD patients with IRF and/or subretinal fluid (SRF) and age-matched control eyes. All patients underwent a macular 6 x 6 mm swept-source OCTA. The mean perfusion density (MPD) and mean vascular density (MVD) were calculated in the superficial (SCP) and the deep (DCP) capillary plexus at two timepoints: during an episode of exudation (T0) and after its total resorption (T1). A total of 22 eyes in the IRF +/- SRF group, 11 eyes in the SRF group and 11 eyes in the healthy group were analyzed. At T0, the IRF +/- SRF group showed significantly lower MPD and MVD than healthy eyes in the SCP (p < 0.001) and DCP (p < 0.001). At T1, MPD and MVD significantly increased from T0 in the SCP (p = 0.027 and p = 0.0093) and DCP (p = 0.013 and p = 0.046) but remained statistically lower than in the healthy eyes. For the SRF group, only the DCP showed significantly lower MPD (p = 0.012) and MVD (p = 0.046) in comparison to the healthy eyes at T0. The present study shows that retinal vascular changes do occur in the case of exudative AMD.
C1 [Mathis, Thibaud; Dimassi, Sarra; Loria, Olivier; Denis, Philippe; Kodjikian, Laurent] Univ Claude Bernard Lyon 1, Ctr Hosp Univ Croix Rousse, Hosp Civils Lyon, Serv Ophtalmol, F-69004 Lyon, France.
   [Mathis, Thibaud; Loria, Olivier; Kodjikian, Laurent] Mateis, UMR CNRS 5510, F-69100 Lyon, France.
   [Sudhalkar, Aditya; Bilgic, Alper] Alphavis Augenzentrum, D-27568 Bremerhaven, Germany.
   [Sudhalkar, Aditya] MS Sudhalkar Med Res Fdn, Baroda 390001, Gujarat, India.
   [Pradat, Pierre] Univ Claude Bernard Lyon 1, Ctr Hosp Univ Croix Rousse, Hosp Civils Lyon, Ctr Rech Clin, F-69004 Lyon, France.
C3 CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard
   Lyon 1; Institut National des Sciences Appliquees de Lyon - INSA Lyon;
   CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard
   Lyon 1
RP Kodjikian, L (通讯作者)，Univ Claude Bernard Lyon 1, Ctr Hosp Univ Croix Rousse, Hosp Civils Lyon, Serv Ophtalmol, F-69004 Lyon, France.; Kodjikian, L (通讯作者)，Mateis, UMR CNRS 5510, F-69100 Lyon, France.
EM thibaud.mathis@chu-lyon.fr; dimassarra@hotmail.com;
   olivier.loria@chu-lyon.fr; adityasudhalkar@icloud.com;
   drbilgicalper@yahoo.com; philippe.denis@chu-lyon.fr;
   pierre.pradat@chu-lyon.fr; Laurent.kodjikian@chu-lyon.fr
RI Mathis, Thibaud/R-3696-2016; kodjikian, laurent/A-3025-2015
OI Mathis, Thibaud/0000-0002-1418-1872; Bilgic, Alper/0000-0001-8403-0853;
   kodjikian, laurent/0000-0002-3908-6716
CR Agarwal A, 2011, GASS ATLAS MACULAR D, P1357
   Ashraf M, 2018, ACTA OPHTHALMOL, V96, P120, DOI 10.1111/aos.13565
   Bagherinia H, 2017, INVEST OPHTH VIS SCI, V58
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chetrit M, 2018, RETINA-J RET VIT DIS, V38, P2073, DOI 10.1097/IAE.0000000000001829
   Cicinelli MV, 2018, BRIT J OPHTHALMOL, V102, P1192, DOI 10.1136/bjophthalmol-2017-311317
   Daruich A, 2018, PROG RETIN EYE RES, V63, P20, DOI 10.1016/j.preteyeres.2017.10.006
   Deng Y, 2019, OPHTHALMOLOGICA, V242, P69, DOI 10.1159/000499608
   Eastline M, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.3.6
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Kim JM, 2019, SEMIN OPHTHALMOL, V34, P168, DOI 10.1080/08820538.2019.1620791
   Kim KS, 2008, ACTA OPHTHALMOL, V86, DOI 10.1111/j.1755-3768.2008.01175.x
   Kim SW, 2019, CURR PHARM DESIGN, V25, P184, DOI 10.2174/1381612825666190319165824
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KORNZWEIG AL, 1966, ARCH OPHTHALMOL-CHIC, V75, P326
   Loria O, 2021, RETINA-J RET VIT DIS, V41, P1809, DOI 10.1097/IAE.0000000000003102
   Mane V, 2016, RETINA-J RET VIT DIS, V36, pS102, DOI 10.1097/IAE.0000000000001289
   Mastropasqua L, 2017, RETINA-J RET VIT DIS, V37, P247, DOI 10.1097/IAE.0000000000001145
   McClintic SM, 2018, OPHTHALMOL RETINA, V2, P931, DOI 10.1016/j.oret.2018.01.014
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Pilotto E, 2019, BRIT J OPHTHALMOL, V103, P67, DOI 10.1136/bjophthalmol-2017-311752
   Rochepeau C, 2018, AM J OPHTHALMOL, V194, P26, DOI 10.1016/j.ajo.2018.07.004
   Sampson DM, 2017, INVEST OPHTH VIS SCI, V58, P3065, DOI 10.1167/iovs.17-21551
   Scharf J, 2021, J CLIN MED, V10, DOI 10.3390/jcm10040751
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2016, RETINA-J RET VIT DIS, V36, P1823, DOI 10.1097/IAE.0000000000001158
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Toto L, 2017, BRIT J OPHTHALMOL, V101, P774, DOI 10.1136/bjophthalmol-2016-309160
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Wang JJ, 2004, BRIT J OPHTHALMOL, V88, P104, DOI 10.1136/bjo.88.1.104
   Wickremasinghe SS, 2016, RETINA-J RET VIT DIS, V36, P1331, DOI 10.1097/IAE.0000000000000902
   Xu XY, 2015, IEEE T MED IMAGING, V34, P1616, DOI 10.1109/TMI.2015.2408632
   You QS, 2020, AM J OPHTHALMOL, V209, P206, DOI 10.1016/j.ajo.2019.09.004
NR 40
TC 1
Z9 1
U1 1
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD APR
PY 2021
VL 10
IS 7
AR 1524
DI 10.3390/jcm10071524
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA RL0JR
UT WOS:000638671200001
PM 33917364
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Learoyd, AE
   Tufail, A
   Bunce, C
   Keane, PA
   Kernohan, A
   Robinson, E
   Jaber, A
   Sadiq, S
   Harper, R
   Lawrenson, J
   Vale, L
   Waterman, H
   Douiri, A
   Balaskas, K
AF Learoyd, Annastazia E.
   Tufail, Adnan
   Bunce, Catey
   Keane, Pearse A.
   Kernohan, Ashleigh
   Robinson, Emily
   Jaber, Alijazy
   Sadiq, Saqlain
   Harper, Robert
   Lawrenson, John
   Vale, Luke
   Waterman, Heather
   Douiri, Abdel
   Balaskas, Konstantinos
CA FENETRE Study Grp
TI FENETRE study: quality-assured follow-up of quiescent neovascular
   age-related macular degeneration by non-medical practitioners: study
   protocol and statistical analysis plan for a randomised controlled trial
SO BMJ OPEN
LA English
DT Article
DE ophthalmology; organisation of health services; protocols & guidelines
AB Objective Management of age-related macular degeneration (AMD) places a high demand on already constrained hospital-based eye services. This study aims to assess the safety and quality of follow-up within the community led by suitably trained non-medical practitioners for the management of quiescent neovascular AMD (QnAMD).
   Methods/design This is a prospective, multisite, randomised clinical trial. 742 participants with QnAMD will be recruited and randomised to either continue hospital-based secondary care or to receive follow-up within a community setting. Participants in both groups will be monitored for disease reactivation over the course of 12 months and referred for treatment as necessary. Outcomes measures will assess the non-inferiority of primary care follow-up accounting for accuracy of the identification of disease reactivation, patient loss to follow-up and accrued costs and the budget impact to the National Health Service.
   Ethics and dissemination Research ethics approval was obtained from the London Bloomsbury Ethics Committee. The results of this study will be disseminated through academic peer-reviewed publications, conferences and collaborations with eye charities to insure the findings reach the appropriate patient populations.
C1 [Learoyd, Annastazia E.; Robinson, Emily; Douiri, Abdel] Kings Coll London, Sch Populat Hlth & Environm Sci, London, England.
   [Tufail, Adnan; Keane, Pearse A.; Jaber, Alijazy; Sadiq, Saqlain; Balaskas, Konstantinos] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Reserch Ctr, London, England.
   [Tufail, Adnan; Keane, Pearse A.; Jaber, Alijazy; Sadiq, Saqlain; Balaskas, Konstantinos] UCL Inst Ophthalmol, London, England.
   [Bunce, Catey] Royal Marsden NHS Fdn Trust, Royal Marsden Clin Trials Unit, London, England.
   [Kernohan, Ashleigh; Vale, Luke] Newcastle Univ, Populat Hlth Sci Inst, Newcastle Upon Tyne, Tyne & Wear, England.
   [Harper, Robert] Univ Manchester, Fac Biol Med & Hlth, Div Pharm & Optometry, Manchester, Lancs, England.
   [Lawrenson, John] City Univ London, Div Optometry & Visual Sci, London, England.
   [Waterman, Heather] Cardiff Univ, Dept Healthcare Sci, Cardiff, Wales.
C3 University of London; King's College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; University College London; Royal Marsden NHS
   Foundation Trust; Newcastle University - UK; University of Manchester;
   City University London; Cardiff University
RP Balaskas, K (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Reserch Ctr, London, England.; Balaskas, K (通讯作者)，UCL Inst Ophthalmol, London, England.
EM konstantinos.balaskas@moorfields.nhs.uk
RI Balaskas, Konstantinos/ABD-5979-2020
OI Balaskas, Konstantinos/0000-0002-7690-6277; Harper,
   Robert/0000-0001-5437-2553; Douiri, Abdel/0000-0002-4354-4433; Kernohan,
   Ashleigh/0000-0002-5514-3186; Lawrenson, John/0000-0002-2031-6390;
   Learoyd, Annastazia/0000-0001-6964-9041; Robinson,
   Emily/0000-0002-6692-5415; Bunce, Catey/0000-0002-0935-3713; Vale,
   Luke/0000-0001-8574-8429; Keane, Pearse/0000-0002-9239-745X; SADIQ,
   SAQLAIN/0000-0001-7375-328X
FU Moorfields Eye Hospital National Health Service (NHS) Foundation Trust;
   National Institute for Health Research (NIHR) Health Technology
   Assessment grant; NIHR Applied Research Collaboration South London at
   King's College Hospital NHS Foundation Trust; Royal College of
   Physicians; NIHR Biomedical Research Centre based at Guy's and St
   Thomas' NHS Foundation Trust and King's College London
FX This study is sponsored by Moorfields Eye Hospital National Health
   Service (NHS) Foundation Trust and is funded by an National Institute
   for Health Research (NIHR) Health Technology Assessment grant. AEL and
   AD also acknowledge funding support from the NIHR Applied Research
   Collaboration South London at King's College Hospital NHS Foundation
   Trust and the Royal College of Physicians, as well as the support from
   the NIHR Biomedical Research Centre based at Guy's and St Thomas' NHS
   Foundation Trust and King's College London.
CR Amoaku W, 2012, EYE, V26, pS2, DOI 10.1038/eye.2011.343
   Burns A., 2019, UNIT COSTS HLTH SOCI
   Caro JJ, 2012, MED DECIS MAKING, V32, P667, DOI 10.1177/0272989X12454577
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Devlin NJ, 2018, HEALTH ECON, V27, P7, DOI 10.1002/hec.3564
   Ehlken C, 2020, GRAEF ARCH CLIN EXP, V258, P2077, DOI 10.1007/s00417-020-04798-2
   Gale RP, 2019, EYE, V33, DOI 10.1038/s41433-018-0300-3
   Hollingworth W, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-018289
   Madhusudhana KC, 2016, BRIT J OPHTHALMOL, V100, P1617, DOI 10.1136/bjophthalmol-2015-308077
   National Institute for Health and Care Excellence, 2013, GUID METH TECHN APPR
   National Institute of Clinical Excellence (NICE), 2018, GUID NG82 AG REL MAC
   NHS trust and NHS foundation trusts, 2018, REF COST COLL NAT SC
   Pocock SJ, 2015, J AM COLL CARDIOL, V66, P2886, DOI 10.1016/j.jacc.2015.10.051
   Quartilho A, 2016, EYE, V30, P602, DOI 10.1038/eye.2015.288
   Reeves BC, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010685
   Sullivan SD, 2014, VALUE HEALTH, V17, P5, DOI 10.1016/j.jval.2013.08.2291
   The Royal College of Ophthalmologists, 2015, WAY FORW AG REL MAC
   Townsend D, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007400
   Violato M, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011121
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 20
TC 1
Z9 1
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD MAY
PY 2021
VL 11
IS 5
AR e049411
DI 10.1136/bmjopen-2021-049411
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA ZL9IB
UT WOS:000763981800010
PM 33980536
OA gold, Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Johnston, SS
   Wilson, K
   Huang, A
   Smith, D
   Varker, H
   Turpcu, A
AF Johnston, Stephen S.
   Wilson, Kathleen
   Huang, Alice
   Smith, David
   Varker, Helen
   Turpcu, Adam
TI Retrospective Analysis of First-Line Anti-Vascular Endothelial Growth
   Factor Treatment Patterns in Wet Age-Related Macular Degeneration
SO ADVANCES IN THERAPY
LA English
DT Article
DE Anti-vascular endothelial growth factor; Healthcare expenditures;
   Healthcare utilization; Intravitreal; Ophthalmology; Retrospective wet
   age-related macular degeneration
ID MACULOPATHY; PREVALENCE
AB This study compared the number of, and expenditures on, first-line intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections between patients who were treated with aflibercept or ranibizumab for wet age-related macular degeneration (AMD).
   This was a retrospective cohort study based on U.S. administrative claims data. Selected patients had initiated first-line intravitreal anti-VEGF treatment with ranibizumab or aflibercept (index date) between November 18, 2011 and April 30, 2013, were aged a parts per thousand yen18 years on the index date, had 12 months of continuous insurance enrollment prior to the index date (baseline period), were diagnosed with wet AMD during the baseline period or on the index date, and had at least 6 or 12 months of follow-up enrollment after the index date without switching to a different anti-VEGF agent (follow-up periods). Outcomes measured within the 6 and 12 month follow-up periods included the number of, and healthcare expenditures on, intravitreal anti-VEGF injections. Multivariable regressions compared the outcomes between aflibercept and ranibizumab.
   The 6 months analyses included 319 aflibercept patients and 1,054 ranibizumab patients (12 month analyses: 57 and 374, respectively). Over the first 6 months after the index date, neither the number of injections (aflibercept mean = 3.8 +/- A 1.6; ranibizumab mean = 3.9 +/- A 1.9) nor the expenditures on injections (aflibercept mean = $7 468 +/- A $4 211; ranibizumab mean = $7 816 +/- A $4 834) differed significantly between aflibercept patients and ranibizumab patients (in multivariable regression treating ranibizumab as reference: incidence rate ratio = 0.97, 95% confidence interval [CI] 0.91-1.03, P = 0.277; cost ratio = 0.96, 95% CI 0.89-1.04, P = 0.338). Differences were also insignificant in the 12 month analyses. The overall mean days between injections differed by only 1.8 (95% CI 1.3-2.3) days between the aflibercept patients and ranibizumab patients (42.4 and 40.6, respectively).
   Aflibercept and ranibizumab were used at a similar frequency resulting in similar intravitreal anti-VEGF injection healthcare expenditures among wet AMD patients initiating first-line intravitreal anti-VEGF treatment.
C1 [Johnston, Stephen S.; Wilson, Kathleen; Huang, Alice; Smith, David; Varker, Helen] Truven Hlth Analyt, Bethesda, MD 20814 USA.
   [Turpcu, Adam] Genentech Inc, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech
RP Johnston, SS (通讯作者)，Truven Hlth Analyt, 7700 Old Georgetown Rd,Ste 650, Bethesda, MD 20814 USA.
EM stephen.johnston@truvenhealth.com
FU Genetech Inc.
FX Stephen Johnston, Kathleen Wilson, Alice Huang, David Smith, Helen
   Varker, and Adam Turpcu all made the following contributions: (1)
   substantial contributions to conception and design, acquisition of data,
   or analysis and interpretation of data; (2) drafting the article and
   revising it critically for important intellectual content; and (3) final
   approval of the version to be published. The authors wish to acknowledge
   Diana Stetsovsky for assistance with statistical programming.
   Sponsorship and article processing charges for this study was funded by
   Genetech Inc. Stephen S. Johnston is the guarantor for this article and
   takes full responsibility for the integrity of the work as a whole.
CR American Academy of Ophthalmology, 2011, AG REL MAC DEG PREF
   [Anonymous], 2013, EYL PACK INS, DOI Tarrytown, NY
   [Anonymous], 2013, LUC PACK INS
   [Anonymous], 2011, MAC PACK INS
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   LEIBOWITZ HM, 1980, SURV OPHTHALMOL S, V24, P428
   National Center for Health Statistics, INT CLASS DIS
NR 11
TC 29
Z9 30
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0741-238X
EI 1865-8652
J9 ADV THER
JI Adv. Ther.
PD DEC
PY 2013
VL 30
IS 12
BP 1111
EP 1127
DI 10.1007/s12325-013-0078-4
PG 17
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 277MA
UT WOS:000328822400008
PM 24310208
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Schmidt, JC
   Rodrigues, EB
   Meyer, CH
   Kroll, P
AF Schmidt, JC
   Rodrigues, EB
   Meyer, CH
   Kroll, P
TI Is membrane extraction in cases of exudative age-related macular
   degeneration still up-to-date? A 4-year resume
SO OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   subretinal surgery
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; LASER PHOTOCOAGULATION;
   PHOTODYNAMIC THERAPY; SURGICAL REMOVAL; SURGERY; TRANSLOCATION;
   SECONDARY; LESIONS
AB Background: Age-related macular degeneration (AMD) is a frequent cause of an irreversible loss of the ability to read. The non-exudative form of AMD has not been therapeutically approached in the past in contrast to the exudative form with choroidal neovascularizations (CNVs). Parafoveal laser coagulation can be applied, and in cases of subfoveal location a pars plana vitrectomy with subretinal resection of the CNV is possible. Material and Methods: Since 1995, we have operated 46 eyes of 45 patients with CNV developing from AMD. Patient ages ranged from 63 to 85 years (mean 71.8 years). Pre- and postoperatively we performed vision tests, fluorescence angiographies with sodium fluorescein and indocyanine green. Follow-up times ranged from 3 to 28 months (mean 12.3 months). Results: Pre- operative vision was 0.10 (range: hand movements to 0.4). Postoperative vision at the end of the follow-up period was 0.12 (range: hand movements to 0.4). Vision at the end of the follow-up was lower in 41%, unchanged in 20% and improved in 39%. In 43 eyes, a non-exudative form of AMD developed. Two eyes had a recurrent CNV, which was removed successfully with a second pars plana vitrectomy. Three patients developed a retinal detachment, which was successfully treated by pars plana vitrectomy, encircling buckle and gas tamponade. Conclusions: We still have to wait for the results of the photodynamic study trials and a randomized study of macular dislocation. Subretinal removal of the CNV by pars plana vitrectomy allows a stabilization of the visual function in most of our cases of AMD. This method inhibits the development of large pseudotumour-like scars. Postoperatively remaining pigment epithelial defects with choroidal atrophies however limit a visual rehabilitation so that reading vision can only be achieved in cases with good pre-operative vision. Longterm results of photodynamic therapy are still lacking and have to show its effectiveness over greater time spans. Copyright (C) 2003 S. Karger AG, Basel.
C1 Univ Marburg, Zentrum Augenheilkunde, DE-35033 Marburg, Germany.
C3 Philipps University Marburg
RP Rodrigues, EB (通讯作者)，Univ Marburg, Zentrum Augenheilkunde, Robert Koch Str 4, DE-35033 Marburg, Germany.
RI Meyer, Carsten/A-3981-2017
OI Meyer, Carsten/0000-0002-0530-5298
CR ADELBERG DA, 1995, RETINA-J RET VIT DIS, V15, P198, DOI 10.1097/00006982-199515030-00003
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   Arnold J, 1997, GRAEF ARCH CLIN EXP, V235, P208, DOI 10.1007/BF00941761
   Bressler NM, 2000, INVEST OPHTH VIS SCI, V41, P624
   CONNOR TB, 1994, RETINA-J RET VIT DIS, V14, P125, DOI 10.1097/00006982-199414020-00005
   COSCAS G, 1991, ARCH OPHTHALMOL-CHIC, V109, P1258, DOI 10.1001/archopht.1991.01080090082028
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Eter N, 1997, OPHTHALMOLOGE, V94, P826, DOI 10.1007/s003470050211
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   Gandorfer A, 1998, OPHTHALMOLOGE, V95, P408, DOI 10.1007/s003470050289
   Giovannini A, 1999, BRIT J OPHTHALMOL, V83, P438, DOI 10.1136/bjo.83.4.438
   Giovannini A, 1999, OPHTHALMOLOGICA, V213, P139, DOI 10.1159/000027408
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Holz FG, 1997, FRONT RADIAT THER ON, V30, P238
   Horle S, 2000, OPHTHALMOLOGICA, V214, P122, DOI 10.1159/000027480
   Koch FHJ, 1997, OPHTHALMOLOGICA, V211, P283
   Maas S, 1995, Eur J Ophthalmol, V5, P48
   Merrill PT, 1999, OPHTHALMOLOGY, V106, P782, DOI 10.1016/S0161-6420(99)90167-7
   Pauleikhoff D., 1992, Ophthalmologe, V89, P363
   Pauleikhoff D., 1994, Ophthalmologe, V91, P730
   Pieramici DJ, 2000, AM J OPHTHALMOL, V130, P419, DOI 10.1016/S0002-9394(00)00533-X
   Schmidt J, 1999, KLIN MONATSBL AUGENH, V215, P247, DOI 10.1055/s-2008-1034708
   SCHMIDT J, 1999, KLIN MONATSBL AUG S2, V215, P14
   Schmidt-Erfurth U, 1998, OPHTHALMOLOGE, V95, P725, DOI 10.1007/s003470050343
   Thoelen A, 1995, Ger J Ophthalmol, V4, P137
   Wolf S, 1999, GRAEF ARCH CLIN EXP, V237, P51, DOI 10.1007/s004170050194
NR 27
TC 3
Z9 4
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD NOV-DEC
PY 2003
VL 217
IS 6
BP 401
EP 407
DI 10.1159/000073069
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 741LN
UT WOS:000186459700004
PM 14573972
DA 2022-11-30
ER

PT J
AU Algvere, PV
   Steen, B
   Seregard, S
   Kvanta, A
AF Algvere, Peep V.
   Steen, Bjoern
   Seregard, Stefan
   Kvanta, Anders
TI A prospective study on intravitreal bevacizumab (Avastin (R)) for
   neovascular age-related macular degeneration of different durations
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; bevacizumab; choroidal
   neovascularization; ETDRS visual acuity; intravitreal injections;
   optical coherence tomography
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; INJECTION;
   MEMBRANES; RANIBIZUMAB; PENETRATION; SECONDARY; TOXICITY; RETINA; SAFETY
AB Purpose: Choroidal neovascularization (CNV) accounts for 85-90% of severe visual impairment in age-related macular degeneration (AMD). Vascular endothelial growth factor (VEGF) is a major factor mediating angiogenesis, and VEGF inhibitors have become a new treatment modality. In this prospective study, we used bevacizumab (Avastin (R)), a recombinant monoclonal antibody to VEGF, to treat neovascular AMD.
   Methods: The case material comprised 36 subjects (26 females, 10 males) aged 65-88 years with subfoveal neovascular AMD with all subtypes of CNV. There were two categories of patients: category I, long-standing CNV (12 months or more), preoperative visual acuity (VA) 0.16 (mean); category II, CNV (duration < 12 months), preoperative VA 0.25 (mean). Evaluation protocol included the Early Treatment Diabetic Retinopathy Study (ETDRS) VA, clinical ophthalmological examination, fluorescein angiography and optical coherence tomography (OCT). Intravitreal injections of bevacizumab (Avastin (R)) (IVB), 1.25 mg (0.05 ml), were given under an operating microscope and aseptic conditions in a theatre for surgery with intervals of 4 or 6 weeks during the first 3 months and subsequently according to clinical assessment. The follow-up was 6 months in all cases.
   Results: At 6 months, mean VA had improved by 4.6 ETDRS letters in the entire case material (P = 0.001), by 3.9 letters in category I (duration 12 months or more) and by 6.0 letters in category II (duration < 12 months). A total of 148 IVB (mean 4.1 injections/eye) were delivered during 6 months, the first 3 months comprising 3.1 IVB (mean) and the last 3 months 1.0 IVB (mean). No eyes suffered visual decline of 15 ETDRS letters. Fluorescein angiograms displayed stabilization or regression of CNV activity; OCT showed resorption of intraretinal oedema and subretinal fluid. No severe complications occurred but recurrence was common, and repeated IVBs were necessary in most cases during the 6-month period.
   Conclusion: When addressing the issue of frequency of IBV, we observed that 6-week intervals were sufficient because VA and CNV lesions generally stabilized at 4 weeks. The gain in VA was promising in eyes with < 12 months CNV duration. Even in eyes with a longer CNV duration, a slight visual improvement was observed when retinal oedema resorbed, although subretinal fibrosis and general cellular damage certainly limited recovery.
C1 [Algvere, Peep V.; Steen, Bjoern; Seregard, Stefan; Kvanta, Anders] St Eriks Eye Hosp, Karolinska Inst, SE-11282 Stockholm, Sweden.
C3 Karolinska Institutet
RP Algvere, PV (通讯作者)，St Eriks Eye Hosp, Karolinska Inst, Polhemsgatan 50, SE-11282 Stockholm, Sweden.
EM peep.algvere@sankterik.se
CR Aggio FB, 2007, GRAEF ARCH CLIN EXP, V245, P215, DOI 10.1007/s00417-006-0412-5
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2006, AM J OPHTHALMOL, V142, P162, DOI 10.1016/j.ajo.2006.03.058
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Luke M, 2006, BRIT J OPHTHALMOL, V90, P1178, DOI 10.1136/bjo.2006.094995
   Luthra S, 2006, RETINA-J RET VIT DIS, V26, P512, DOI 10.1097/01.iae.0000222547.35820.52
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
NR 27
TC 71
Z9 74
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2008
VL 86
IS 5
BP 482
EP 489
DI 10.1111/j.1600-0420.2007.01113.x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 329AP
UT WOS:000257839600003
PM 18162062
OA Bronze
DA 2022-11-30
ER

PT J
AU Inana, G
   Murat, C
   An, WJ
   Yao, X
   Harris, IR
   Cao, J
AF Inana, George
   Murat, Christopher
   An, Weijun
   Yao, Xiang
   Harris, Ian R.
   Cao, Jing
TI RPE phagocytic function declines in age-related macular degeneration and
   is rescued by human umbilical tissue derived cells
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Age-related macular degeneration; Cell therapy; Human umbilical tissue
   derived cells; Retinal pigment epithelium; Phagocytosis; Receptor
   tyrosine kinase; Bridge molecules
ID RETINAL-PIGMENT EPITHELIUM; MITOCHONDRIAL OXIDATIVE STRESS; FUNDUS
   AUTOFLUORESCENCE; LIPOFUSCIN ACCUMULATION; GEOGRAPHIC ATROPHY; IRON
   HOMEOSTASIS; RHO-GTPASES; MERTK GENE; PATHOGENESIS; MUTATIONS
AB Background: Age-related macular degeneration (AMD) is a leading cause of blindness among the elderly characterized by retinal pigment epithelium (RPE) degeneration with accumulation of abnormal intracellular deposits (lipofuscin) and photoreceptor death. RPE is vital for the retina and integrity of photoreceptors through its phagocytic function which is closely linked to formation of lipofuscin through daily phagocytosis of discarded photoreceptor outer segments (POS). Although phagocytosis has been implicated in AMD, it has not been directly shown to be altered in AMD. RPE phagocytic defect was previously shown to be rescued by subretinal injection of human umbilical tissue derived cells (hUTC) in a rodent model of retinal degeneration (RCS rat) through receptor tyrosine kinase (RTK) ligands and bridge molecules. Here, we examined RPE phagocytic function directly in the RPE from AMD patients and the ability and mechanisms of hUTC to affect phagocytosis in the human RPE.
   Methods: Human RPE was isolated from the post-mortem eyes of normal and AMD-affected subjects and cultured. RPE phagocytic function was measured in vitro using isolated POS. The effects of hUTC conditioned media, recombinant RTK ligands brain-derived neurotrophic factor (BDNF), hepatocyte growth factor (HGF), and glial cell-derived neurotrophic factor (GDNF), as well as bridge molecules milk-fat-globule-EGF-factor 8 (MFG-E8), thrombospondin (TSP)-1, and TSP-2 on phagocytosis were also examined in phagocytosis assays using isolated POS. RNA was isolated from normal and AMD RPE treated with hUTC conditioned media and subjected to transcriptome profiling by RNASeq and computational analyses.
   Results: RPE phagocytosis, while showing a moderate decline with age, was significantly reduced in AMD RPE, more than expected for age. hUTC conditioned media stimulated phagocytosis in the normal human RPE and significantly rescued the phagocytic dysfunction in the AMD RPE. RTK ligands and bridge molecules duplicated the rescue effect. Moreover, multiple molecular pathways involving phagocytosis, apoptosis, oxidative stress, inflammation, immune activation, and cholesterol transport were affected by hUTC in the RPE.
   Conclusions: We demonstrated for the first time RPE phagocytic dysfunction in AMD, highlighting its likely importance in AMD, and the ability of hUTC to correct this dysfunction, providing insights into the therapeutic potential of hUTC for AMD.
C1 [Inana, George; Murat, Christopher; An, Weijun] Univ Miami, Bascom Palmer Eye Inst, Dept Ophthalmol, Sch Med, 1638 NW 10th Ave, Miami, FL 33136 USA.
   [Yao, Xiang] Janssen Res & Dev LLC, San Diego, CA 92121 USA.
   [Harris, Ian R.; Cao, Jing] Janssen Res & Dev LLC, Spring House, PA 19477 USA.
C3 Bascom Palmer Eye Institute; University of Miami; Johnson & Johnson;
   Johnson & Johnson USA; Janssen Biotech Inc; Johnson & Johnson; Johnson &
   Johnson USA; Janssen Biotech Inc
RP Inana, G (通讯作者)，Univ Miami, Bascom Palmer Eye Inst, Dept Ophthalmol, Sch Med, 1638 NW 10th Ave, Miami, FL 33136 USA.; Cao, J (通讯作者)，Janssen Res & Dev LLC, Spring House, PA 19477 USA.
EM ginana@med.miami.edu; jcao5@its.jnj.com
FU University of Miami; Janssen RD
FX The work described was performed under a sponsored research agreement
   between University of Miami and Janssen R&D.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   [Anonymous], 2006, POL J ENV STUD
   Apte RS, PATENT INHIBITION CH
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Brea-Fernandez AJ, 2008, BRIT J OPHTHALMOL, V92, P1419, DOI 10.1136/bjo.2008.139204
   Bulloj A, 2013, EXP EYE RES, V113, P9, DOI 10.1016/j.exer.2013.05.002
   Cao J, 2016, STEM CELLS, V34, P367, DOI 10.1002/stem.2239
   Chen H, 2009, INVEST OPHTH VIS SCI, V50, P1895, DOI 10.1167/iovs.08-2850
   Chen L, 2016, MOL MED REP, V13, P3249, DOI 10.3892/mmr.2016.4890
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Crichton R., 2001, INORGANIC BIOCH IRON
   Crouch RK, 2015, PROG MOL BIOL TRANSL, V134, P449, DOI 10.1016/bs.pmbts.2015.06.005
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Ebermann I, 2007, HUM MUTAT, V28, P571, DOI 10.1002/humu.20478
   Emerson MV, 2007, BIODRUGS, V21, P245, DOI 10.2165/00063030-200721040-00005
   Ethen CM, 2007, INVEST OPHTH VIS SCI, V48, P3469, DOI 10.1167/iovs.06-1058
   Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   FEENEYBURNS L, 1983, T OPHTHAL SOC UK, V103, P416
   Fine SL, 2005, AM J OPHTHALMOL, V139, P405, DOI 10.1016/j.ajo.2004.11.050
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   FUCHS U, 1991, INVEST OPHTH VIS SCI, V32, P3178
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hall MO, 2003, ADV EXP MED BIOL, V533, P331
   Haralampus-Grynaviski NM, 2003, P NATL ACAD SCI USA, V100, P3179, DOI 10.1073/pnas.0630280100
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Katz ML, 2002, ARCH GERONTOL GERIAT, V34, P359, DOI 10.1016/S0167-4943(02)00012-2
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Kim S.-Y., 2015, MACROPHAGE, V2, pe698
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   KLEIN BEK, 1992, INVEST OPHTH VIS SCI, V33, P2224
   Koike M, 2003, MOL CELL NEUROSCI, V22, P146, DOI 10.1016/S1044-7431(03)00035-6
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Mackay DS, 2010, MOL VIS, V16, P369
   Malek G, 2014, CELL MOL LIFE SCI, V71, P4617, DOI 10.1007/s00018-014-1709-x
   Mao HY, 2014, INVEST OPHTH VIS SCI, V55, P4613, DOI 10.1167/iovs.14-14633
   Mao Yingyu, 2015, Small GTPases, V6, P89, DOI 10.4161/21541248.2014.989785
   McHenry CL, 2004, INVEST OPHTH VIS SCI, V45, P1456, DOI 10.1167/iovs.03-0909
   MCLAREN MJ, 1993, INVEST OPHTH VIS SCI, V34, P317
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1
   Nandrot EE, 2004, J EXP MED, V200, P1539, DOI 10.1084/jem.20041447
   Niedergang F, 2005, CURR TOP MICROBIOL, V291, P43
   Nowak J.Z., 2005, MAG OKUL, V2
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   NOWAK JZ, 2005, MAG OKUL, V2, P103
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Petrukhin K, 2007, EXPERT OPIN THER TAR, V11, P625, DOI 10.1517/14728222.11.5.625
   Qin SF, 2008, J BIOL CHEM, V283, P6744, DOI 10.1074/jbc.M708848200
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Rozanowska M, 2004, INVEST OPHTH VIS SCI, V45, P1052, DOI 10.1167/iovs.03-0277
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schiller MR, 2006, CELL SIGNAL, V18, P1834, DOI 10.1016/j.cellsig.2006.01.022
   Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302
   Schmitz G, 2001, CURR OPIN LIPIDOL, V12, P129, DOI 10.1097/00041433-200104000-00006
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Seo SJ, 2012, EXP EYE RES, V101, P60, DOI 10.1016/j.exer.2012.05.013
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strick DJ, 2010, EXP EYE RES, V91, P786, DOI 10.1016/j.exer.2010.05.006
   Strick DJ, 2009, INVEST OPHTH VIS SCI, V50, P2427, DOI 10.1167/iovs.08-3058
   Sundelin S, 1998, CURR EYE RES, V17, P851, DOI 10.1076/ceyr.17.8.851.5146
   Tada A, 2006, MOL VIS, V12, P441
   THOMAS MA, 1991, AM J OPHTHALMOL, V111, P1, DOI 10.1016/S0002-9394(14)76888-6
   Thompson DA, 2002, AM J HUM GENET, V70, P224, DOI 10.1086/338455
   Tschernutter M, 2006, BRIT J OPHTHALMOL, V90, P718, DOI 10.1136/bjo.2005.084897
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   vonRuckmann A, 1997, ARCH OPHTHALMOL-CHIC, V115, P609, DOI 10.1001/archopht.1997.01100150611006
   Wang GF, 2012, INT J OPHTHALMOL-CHI, V5, P609, DOI 10.3980/j.issn.2222-3959.2012.05.13
   Warburton S, 2005, MOL VIS, V11, P1122
   Wolf G, 2003, NUTR REV, V61, P342, DOI 10.1301/nr.2003.oct.342-346
   Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290
   Yang ZL, 2008, J CLIN INVEST, V118, P2908, DOI 10.1172/JCI35891
   Yefimova MG, 2002, INVEST OPHTH VIS SCI, V43, P537
   Zacchigna S, 2009, J NEUROSCI, V29, P2297, DOI 10.1523/JNEUROSCI.2034-08.2009
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhao L, 2007, MOL VIS, V13, P873
NR 101
TC 47
Z9 48
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD MAR 13
PY 2018
VL 16
AR 63
DI 10.1186/s12967-018-1434-6
PG 15
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FZ9UY
UT WOS:000427958400003
PM 29534722
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kim, IK
   Ji, F
   Morrison, MA
   Adams, S
   Zhang, Q
   Lane, AM
   Capone, A
   Dryja, TP
   Ott, J
   Miller, JW
   DeAngelis, MM
AF Kim, Ivana K.
   Ji, Fei
   Morrison, Margaux A.
   Adams, Scott
   Zhang, Qingrun
   Lane, Anne Marie
   Capone, Antonio
   Dryja, Thaddeus P.
   Ott, Jurg
   Miller, Joan W.
   DeAngelis, Margaret M.
TI Comprehensive analysis of CRP, CFH Y402H and environmental risk factors
   on risk of neovascular age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; DISCORDANT SIB PAIRS; Y402H
   VARIANT; POLYMORPHISM; GENE; ASSOCIATION; HAPLOTYPE; PROMOTER; ALLELES
AB Purpose: To examine if the gene encoding C-reactive protein (CRP), a biomarker of inflammation, confers risk for neovascular age-related macular degeneration (AMD) in the presence of other modifiers of inflammation, including body mass index (BMI), diabetes, smoking, and complement factor H (CFH) Y402 genotype. Additionally we examined the degree to which CRP common variation was in linkage disequilibrium (LD) within our cohort.
   Methods: We ascertained 244 individuals from 104 families where at least one member had neovascular AMD, and a sibling had normal maculae and was past the age of the index patient's diagnosis of neovascular AMD. We employed a direct sequencing approach to analyze the 5'-promoter region as well as the entire coding region and the 3'-untranslated region of the CRP gene. CFH Y402 genotype data was available for all participants. Lifestyle and medical factors were obtained via administration of a standardized questionnaire. The family-based association test, haplotype analysis, McNemar's test, and conditional logistic regression were used to determine significant associations and interactions. Haploview was used to calculate the degree of LD (r(2)) between all CRP variants identified.
   Results: Six single nucleotide polymorphisms (SNPs; rs3091244, rs1417938, rs1800947, rs1130864, rs1205, and rs3093068) comprised one haplotype block of which only rs1130864 and rs1417938 were in high LD (r(2)= 0.94). SNP rs3093068 was in LD but less so with rs3093059 (r(2)= 0.83), which is not part of the haplotype block. Six SNPs made up six different haplotypes with = 5% frequency, none of which were significantly associated with AMD risk. No statistically significant association was detected between any of the nine common variants in CRP and neovascular AMD when considering disease status alone or when controlling for smoking exposure, BMI, diabetes, or CFH genotype. Significant interactions were not found between CRP genotypes and any of the risk factors studied. No novel CRP variation was identified.
   Conclusions: We provide evidence that if elevated serum/plasma levels of CRP are associated with neovascular AMD, it is likely not due to genetic variation within CRP, but likely due to variations in some other genetic as well as epidemiological factors.
C1 [Kim, Ivana K.; Morrison, Margaux A.; Adams, Scott; Lane, Anne Marie; Dryja, Thaddeus P.; Miller, Joan W.; DeAngelis, Margaret M.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA.
   [Ji, Fei; Ott, Jurg] Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA.
   [Zhang, Qingrun; Ott, Jurg] Chinese Acad Sci, Beijing Inst Genom, Beijing, Peoples R China.
   [Capone, Antonio] William Beaumont Hosp, Royal Oak, MI 48072 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Rockefeller University; Chinese Academy of Sciences; Beijing
   Institute of Genomics, CAS; Beaumont Health
RP DeAngelis, MM (通讯作者)，Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
EM margaret_deangelis@hms.harvard.edu
OI Kim, Ivana/0000-0003-0310-6129
FU Ruth and Milton Steinbach Fund, New york, NY; Lincy Foundation, Beverly
   Hills; National Science Foundation of China, Beijing, China [30730057,
   30700442]; National Institutes of Health, Bethesda [EY014458, EY14104,
   MH44292]; NATIONAL EYE INSTITUTE [R01EY014458, P30EY014104] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH044292,
   R37MH044292] Funding Source: NIH RePORTER
FX This work was supported by grants from the Ruth and Milton Steinbach
   Fund, New York, NY; Lincy Foundation, Beverly Hills, CA; Massachusetts
   Lions, New Bedford, MA; Friends of the Massachusetts Eye and Ear
   Infirmary ( MEEI), Boston, MA; Genetics of Age- Related Macular
   Degeneration Fund, MEEI, Boston, MA; Research to Prevent Blindness, New
   York, NY; Marion W. and Edward F. Knight AMD Fund, Boston, MA; National
   Science Foundation of China, Beijing, China (30730057 and 30700442); and
   the National Institutes of Health, Bethesda, MD (EY014458, EY14104, and
   MH44292).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Boehnke M, 1998, AM J HUM GENET, V62, P950, DOI 10.1086/301787
   Brull DJ, 2003, ARTERIOSCL THROM VAS, V23, P2063, DOI 10.1161/01.ATV.0000084640.21712.9C
   Carlson CS, 2008, AM J HUM GENET, V82, P251, DOI 10.1016/j.ajhg.2007.12.007
   Danik JS, 2006, ANN HUM GENET, V70, P705, DOI 10.1111/j.1469-1809.2006.00272.x
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   DeAngelis MM, 2004, ARCH OPHTHALMOL-CHIC, V122, P575, DOI 10.1001/archopht.122.4.575
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hawkins MA, 2004, OBES RES, V12, p107S, DOI 10.1038/oby.2004.275
   Horvath S, 2004, GENET EPIDEMIOL, V26, P61, DOI 10.1002/gepi.10295
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kovacs A, 2005, ATHEROSCLEROSIS, V178, P193, DOI 10.1016/j.atherosclerosis.2004.08.018
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lowe GDO, 2005, J THROMB HAEMOST, V3, P1618, DOI 10.1111/j.1538-7836.2005.01416.x
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   Miller DT, 2005, ANN HUM GENET, V69, P623, DOI 10.1111/j.1529-8817.2005.00210.x
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   RISCH N, 1995, SCIENCE, V268, P1584, DOI 10.1126/science.7777857
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Suk HJ, 2005, ATHEROSCLEROSIS, V178, P139, DOI 10.1016/j.atherosclerosis.2004.07.033
   Szalai AJ, 2005, J MOL MED, V83, P440, DOI 10.1007/s00109-005-0658-0
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zee RYL, 2002, ATHEROSCLEROSIS, V162, P217, DOI 10.1016/S0021-9150(01)00703-1
NR 32
TC 36
Z9 36
U1 0
U2 3
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD AUG 11
PY 2008
VL 14
IS 177
BP 1487
EP 1495
PG 9
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 344JT
UT WOS:000258923600001
PM 18704199
DA 2022-11-30
ER

PT J
AU Schroeder, M
   Kjellstrom, U
   Lovestam-Adrian, M
AF Schroeder, Marion
   Kjellstrom, Ulrika
   Lovestam-Adrian, Monica
TI Electrophysiological evaluation and 18-month follow-up of two regimens
   with aflibercept for neovascular age-related macular degeneration
SO DOCUMENTA OPHTHALMOLOGICA
LA English
DT Article
DE Neovascular age-related macular degeneration; Full-field
   electroretinography; Multifocal electroretinography; Treat-and-extend;
   Aflibercept
ID TREAT-AND-EXTEND; OPTICAL COHERENCE TOMOGRAPHY; VEGF TRAP-EYE;
   MULTIFOCAL ELECTRORETINOGRAPHY; RETINAL FUNCTION; INTRAVITREAL
   INJECTION; ISCEV STANDARD; RANIBIZUMAB; OUTCOMES; THERAPY
AB Purpose To compare two aflibercept treatment regimens and the electrophysiological outcome concerning cone and rod function in age-related macular degeneration (nAMD) over 18 months. Methods 41 patients with treatment-naive nAMD were randomized 1:1 to either arm 1 or 2. Arm 1 received three consecutive monthly aflibercept injections, followed by bimonthly treatment until week 52. Thereafter, a treat-and-extend (TAE) regimen was applied. Arm 2 was treated according to a TAE protocol throughout the 18-month follow-up. We assessed visual acuity (VA), central retinal thickness (CRT), injection rate and interval, and evaluated cone and rod function with full-field and multifocal electroretinography (ffERG, mERG). Results There were no statistically significant differences in mean baseline VA, lesion type, age, gender, or symptom duration between the two arms. During the 18-month follow-up, mean VA improved in arm 1 (n = 19) from 63.5 +/- 10.5 to 69.1 +/- 9.2 letters; p = 0.098; and in arm 2 (n = 20) from 66.8 +/- 13.6 to 73.9 +/- 9.0 letters; p = .002. In both arms, mean CRT was significantly reduced; p < 0.000. At month 18, we found no significant difference in the number of injections or injection intervals between groups. Arm 1 had received 11.3 +/- 1.7 injections vs. 10.9 +/- 2.0 in arm 2. The mean injection interval was 9.2 +/- 3.4 weeks vs. 9.5 +/- 3.1, with 52% (n = 10) on the maximum 12-week interval in arm 1, and 50% (n = 10) in arm 2. The combined rod-cone a-wave amplitude significantly decreased over time; p = 0.043. The isolated rod b-wave amplitude showed a statistically significant decline; p = 0.026. The overall mERG amplitude and implicit time remained unchanged over time; p = 0.878 vs. p = 0.922. The central ring 1 mERG amplitude improved; p = 0.041, with an unaffected implicit time. Conclusions After 18 months, both treatments arms have received a similar number of injections at comparable intervals. Electrophysiological evaluation shows no signs of toxicity concerning cone function. But ffERGs for the combined and isolated rod response have declined, possibly reflecting either toxic effects of the drug to rods or the natural course of the disease itself.
C1 [Schroeder, Marion; Kjellstrom, Ulrika; Lovestam-Adrian, Monica] Lund Univ, Skane Univ Hosp, Dept Clin Sci Lund, Ophthalmol, Lund, Sweden.
   [Schroeder, Marion] Lund Univ, Dept Ophthalmol, S-22185 Lund, Sweden.
C3 Lund University; Skane University Hospital; Lund University
RP Schroeder, M (通讯作者)，Lund Univ, Skane Univ Hosp, Dept Clin Sci Lund, Ophthalmol, Lund, Sweden.; Schroeder, M (通讯作者)，Lund Univ, Dept Ophthalmol, S-22185 Lund, Sweden.
EM marion.schroeder@med.lu.se
FU Lund University; Bayer AB; Stiftelsen for synskadadeifd Malmohuslan
FX Open access funding provided by Lund University. This study was funded
   by grants from Bayer AB and Stiftelsen for synskadadeifd Malmohuslan.
   The authors have full control of all primary data and agree to allow the
   journal to review the data on request.
CR Adrian ML, 2019, ACTA OPHTHALMOL, V97, P91, DOI 10.1111/aos.13864
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   BIRCH DG, 1992, ARCH OPHTHALMOL-CHIC, V110, P1571, DOI 10.1001/archopht.1992.01080230071024
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   BROWN KT, 1962, NATURE, V193, P958, DOI 10.1038/193958a0
   Campa C, 2011, INVEST OPHTH VIS SCI, V52, P3446, DOI 10.1167/iovs.10-6588
   Dias JRD, 2019, RETINA-J RET VIT DIS, V39, P648, DOI 10.1097/IAE.0000000000002001
   Dias JRDO, 2017, RETINA-J RET VIT DIS, V37, P1499, DOI 10.1097/IAE.0000000000001385
   Dimopoulos IS, 2013, INVEST OPHTH VIS SCI, V54, P5186, DOI 10.1167/iovs.13-12194
   Feigl B, 2007, CLIN OPHTHALMOL, V1, P167
   De Almeida INF, 2015, ARQ BRAS OFTALMOL, V78, P105, DOI 10.5935/0004-2749.20150027
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Green DG, 1999, VISUAL NEUROSCI, V16, P727, DOI 10.1017/S0952523899164125
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holopigian K, 1997, OPTOMETRY VISION SCI, V74, P152, DOI 10.1097/00006324-199703000-00026
   Hood DC, 2012, DOC OPHTHALMOL, V124, P1, DOI 10.1007/s10633-011-9296-8
   Januschowski K, 2014, ACTA OPHTHALMOL, V92, pe305, DOI 10.1111/aos.12300
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Ju Rui-Hong, 2017, Nan Fang Yi Ke Da Xue Xue Bao, V37, P933
   Jurklies B, 2002, GRAEF ARCH CLIN EXP, V240, P244, DOI 10.1007/s00417-002-0439-1
   KARPE G., 1950, ACTA OPHTHALMOL, V28, P301
   Kertes PJ, 2020, JAMA OPHTHALMOL, V138, P244, DOI 10.1001/jamaophthalmol.2019.5540
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Lashay A, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/2602918
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   McCulloch DL, 2015, DOC OPHTHALMOL, V130, P1, DOI 10.1007/s10633-014-9473-7
   Moschos MM, 2011, CLIN EXP OPTOM, V94, P268, DOI 10.1111/j.1444-0938.2011.00589.x
   Myers AC, 2012, CURR EYE RES, V37, P399, DOI 10.3109/02713683.2011.611609
   Nishimura T, 2020, DOC OPHTHALMOL, V141, P137, DOI 10.1007/s10633-020-09758-z
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   Park Joo Youn, 2011, Korean J Ophthalmol, V25, P161, DOI 10.3341/kjo.2011.25.3.161
   Pedersen KB, 2016, GRAEF ARCH CLIN EXP, V254, P1897, DOI 10.1007/s00417-016-3323-0
   Pedersen KB, 2010, RETINA-J RET VIT DIS, V30, P1025, DOI 10.1097/IAE.0b013e3181cafc8f
   PENN RD, 1969, NATURE, V223, P201, DOI 10.1038/223201a0
   Ramon D, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.6.23
   Reinsberg M, 2017, CLIN OPHTHALMOL, V11, P621, DOI 10.2147/OPTH.S123513
   Robson JG, 1998, DOC OPHTHALMOL, V95, P187, DOI 10.1023/A:1001891904176
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Skaat A, 2011, ACTA OPHTHALMOL, V89, pe269, DOI 10.1111/j.1755-3768.2010.02005.x
   Tahir Humza J, 2018, Invest Ophthalmol Vis Sci, V59, pAMD202, DOI 10.1167/iovs.18-24227
   Takayama K, 2017, RETINA-J RET VIT DIS, V37, P553, DOI 10.1097/IAE.0000000000001225
   TIAN N, 1995, VISION RES, V35, P1359, DOI 10.1016/0042-6989(95)98715-L
   Torres-Soriano ME, 2012, RETINA-J RET VIT DIS, V32, P972, DOI 10.1097/IAE.0b013e318229b1de
   WELEBER RG, 1981, INVEST OPHTH VIS SCI, V20, P392
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   ZEIDLER I, 1959, Acta Ophthalmol (Copenh), V37, P294
NR 51
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0012-4486
EI 1573-2622
J9 DOC OPHTHALMOL
JI Doc. Ophthalmol.
PD APR
PY 2022
VL 144
IS 2
BP 99
EP 115
DI 10.1007/s10633-021-09863-7
EA FEB 2022
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0R7HW
UT WOS:000761308100001
PM 35218455
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Schauwvlieghe, AME
   Dijkman, G
   Hooymans, JM
   Verbraak, FD
   Hoyng, CB
   Dijkgraaf, MGW
   Peto, T
   Vingerling, JR
   Schlingemann, RO
AF Schauwvlieghe, A. M. E.
   Dijkman, G.
   Hooymans, J. M.
   Verbraak, F. D.
   Hoyng, C. B.
   Dijkgraaf, M. G. W.
   Peto, T.
   Vingerling, J. R.
   Schlingemann, R. O.
TI Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients
   with Exudative Age-Related Macular Degeneration. The BRAMD Study
SO PLOS ONE
LA English
DT Article
ID PHARMACOKINETICS; TRIAL
AB Purpose
   To compare the effectiveness of bevacizumab and ranibizumab in the treatment of exudative age-related macular degeneration (AMD).
   Design
   Multicentre, randomized, controlled, double-masked clinical trial in 327 patients. The noninferiority margin was 4 letters.
   Patients
   Patients >= 60 years of age with primary or recurrent sub-or juxtafoveal choroidal neovascularization (CNV) secondary to AMD with a total area of CNV < 12 disc areas and a best corrected visual acuity (BCVA) score between 20 and 78 letters on an EDTRS like chart in the study eye.
   Methods
   Monthly intravitreal injections with 1.25 mg bevacizumab or 0.5mg ranibizumab were given during one year. Intention to treat with last observation carried forward analysis was performed.
   Main Outcome Measures
   Primary outcome was the change in BCVA in the study eye from baseline to 12 months.
   Results
   The mean gain in BCVA was 5.1 (+/- 14.1) letters in the bevacizumab group (n = 161) and 6.4 (+/- 12.2) letters in the ranibizumab group (n = 166) (p = 0.37). The lower limit of the 95% confidence interval of the difference in BCVA gain was 3.72. The response to bevacizumab was more varied; 24% of patients showed a gain of >= 15 letters, 11% a loss of >= 15 letters and 65% a gain or loss < 15 letters compared to 19%, 5% and 76% respectively for ranibizumab (p = 0.038). No significant differences in absolute CRT and CRT change (p = 0.13) or in the presence of subretinal or intraretinal fluid (p = 0.14 and 0.10, respectively) were observed. However, the presence of any fluid on SD-OCT (subretinal and/or intraretinal) differed significantly (p = 0.020), with definite fluid on SD-OCT in 45% of the patients for bevacizumab versus 31% for ranibizumab. The occurrence of serious adverse events and adverse events was similar, with 34 SAEs and 256 AEs in the bevacizumab group and 37 SAEs and 299 AEs in the ranibizumab group (p = 0.87 and p = 0.48, respectively).
   Conclusions
   Bevacizumab was not inferior to ranibizumab. The response to bevacizumab was more varied with higher percentages of both gainers and losers and more frequently observed retinal fluid on SD-OCT at 12 months when compared to the ranibizumab group.
C1 [Schauwvlieghe, A. M. E.; Verbraak, F. D.; Schlingemann, R. O.] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
   [Verbraak, F. D.; Schlingemann, R. O.] Univ Amsterdam, Dept Ophthalmol, Ocular Angiogenesis Grp, Amsterdam, Netherlands.
   [Verbraak, F. D.; Schlingemann, R. O.] Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
   [Dijkman, G.] Leiden Univ, Med Ctr, Dept Ophthalmol, Leiden, Netherlands.
   [Hooymans, J. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Ophthalmol, NL-9713 AV Groningen, Netherlands.
   [Hoyng, C. B.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 ED Nijmegen, Netherlands.
   [Dijkgraaf, M. G. W.] Univ Amsterdam, Acad Med Ctr, Clin Res Unit, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
   [Peto, T.] Moorfields Eye Hosp, Natl Inst Hlth Res, Biomed Res Ctr, London, England.
   [Peto, T.] Moorfields Eye Hosp, Univ Coll London, Inst Ophthalmol, Reading Ctr, London, England.
   [Vingerling, J. R.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Vingerling, J. R.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Verbraak, F. D.] Univ Amsterdam, Acad Med Ctr, Dept Biomed Engn & Phys, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
   [Schlingemann, R. O.] Netherlands Inst Neurosci, Amsterdam, Netherlands.
C3 University of Amsterdam; Academic Medical Center Amsterdam; University
   of Amsterdam; University of Amsterdam; Leiden University; Leiden
   University Medical Center (LUMC); Leiden University - Excl LUMC;
   University of Groningen; Radboud University Nijmegen; University of
   Amsterdam; Academic Medical Center Amsterdam; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; Erasmus University Rotterdam; Erasmus MC; Erasmus
   University Rotterdam; Erasmus MC; University of Amsterdam; Royal
   Netherlands Academy of Arts & Sciences; Netherlands Institute for
   Neuroscience (NIN-KNAW)
RP Schlingemann, RO (通讯作者)，Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.; Schlingemann, RO (通讯作者)，Netherlands Inst Neurosci, Amsterdam, Netherlands.
EM r.schlingemann@amc.uva.nl
RI Peto, Tunde/G-8812-2018
OI Peto, Tunde/0000-0001-6265-0381; Verbraak, Frank D/0000-0001-7560-1423;
   Schauwvlieghe, Ann-Sofie/0000-0002-0020-4842
FU Netherlands Organisation for Health Research and Development; Dutch
   health insurance companies
FX This work was funded by The Netherlands Organisation for Health Research
   and Development (http://www.zonmw.nl/en/) (r.s). This study was
   supported by Dutch health insurance companies. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR [Anonymous], 2002, Drugs R D, V3, P28
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   de KR, 2013, J BIOPHOTONICS, V6, P314, DOI [10.1002/jbio.201200018, DOI 10.1002/JBIO.201200018]
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Sivaprasad S, 2013, BRIT MED BULL, V105, P201, DOI 10.1093/bmb/ldt004
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
NR 18
TC 44
Z9 46
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 20
PY 2016
VL 11
IS 5
AR e0153052
DI 10.1371/journal.pone.0153052
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DM4BV
UT WOS:000376291500003
PM 27203434
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Chang, W
   Garg, SJ
   Maturi, R
   Hsu, J
   Sivalingam, A
   Gupta, SA
   Regillo, CD
   Ho, AC
AF Chang, Woohyok
   Garg, Sunir J.
   Maturi, Raj
   Hsu, Jason
   Sivalingam, Arunan
   Gupta, Seema A.
   Regillo, Carl D.
   Ho, Allen C.
TI Management of Thick Submacular Hemorrhage With Subretinal Tissue
   Plasminogen Activator and Pneumatic Displacement for Age-Related Macular
   Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULAR LESIONS; PARS-PLANA VITRECTOMY; INJECTION; GAS;
   RANIBIZUMAB; SECONDARY; DRAINAGE; RABBITS
AB PURPOSE: To evaluate the outcome of pars plana vitrectomy, subretinal tissue plasminogen activator (t-PA) infusion and intraocular gas tamponade with and without postsurgical antivascular endothelial growth factor (VEGF) injection for thick submacular hemorrhage due to exudative age-related macular degeneration (AMD).
   DESIGN: Retrospective, comparative, interventional case series.
   METHODS: SETTING: 2 retina referral centers. The patient population included 101 eyes of 101 patients with neovascular AMD and thick submacular hemorrhage who underwent surgical displacement of the hemorrhage with or without postoperative anti-VEGF injections. Main outcome measures included degree of blood displacement, best and final postoperative visual acuity (VA), and adverse events. Snellen acuity was converted to logMAR for statistical analysis.
   RESULTS: All patients were followed for a minimum of 3 months. (mean, 15.3 months, range, 3-70 months). In 83 (82%) of 101 eyes, the procedure resulted in complete hemorrhage displacement from the fovea. Mean preoperative VA was 20/2255 (2.05 logMAR). The acuity significantly improved to 20/893 (1.65 logMAR) at month 1 (P < 0.001) at month 1; 20/678 (1.53 logMAR) at month 3 (P < 0.001), and 20/1150 (1.76 logMAR) at month 12 (P = 0.002). Best postoperative visual acuity improved by at least 1 line in 83 (82%) of 101 eyes, and 19.6% of eyes gained 3 lines or more at month 3. The visual acuity of the group of eyes that received postoperative anti-VEGF injection (n = 39) showed greater visual acuity improvement 6 months postoperatively compared to the group of eyes that did not receive postoperative anti-VEGF. Postoperative complications included vitreous hemorrhage in 2 eyes, rhegmatogenous retinal detachment in 4 eyes, and recurrent thick subretinal hemorrhage in 6 eyes.
   CONCLUSIONS: Vitrectomy with subretinal t-PA injection and gas tamponade was found to be relatively effective for displacement of thick submacular hemorrhage with a significant improvement in visual acuity. There is a loss of acuity over time; the addition of postoperative anti-VEGF therapy may help maintain the visual acuity gains. (C) 2014 by Elsevier Inc. All rights reserved.
C1 [Chang, Woohyok; Garg, Sunir J.; Hsu, Jason; Sivalingam, Arunan; Gupta, Seema A.; Regillo, Carl D.; Ho, Allen C.] Wills Eye Hosp & Res Inst, Mid Atlantic Retina, Retina Serv, Philadelphia, PA USA.
   [Maturi, Raj] Midwest Eye Inst, Indianapolis, IN USA.
C3 Jefferson University
RP Garg, SJ (通讯作者)，Thomas Jefferson Univ, Wills Eye Hosp, Mid Atlantic Retina, Retina Serv, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM sunirgarg@yahoo.com
OI Ho, Allen/0000-0003-3921-608X; Maturi, Raj/0000-0002-8894-1846
FU J. ARCH MCNAMARA RETINA RESEARCH FUND, PHILADELPHIA, PA
FX THE STUDY INCLUDED FUNDING FROM THE J. ARCH MCNAMARA RETINA RESEARCH
   FUND, PHILADELPHIA, PA. DESIGN AND. conduct of study (W.C., S.D., CR.);
   Collection, management, analysis, and interpretation of data (W.C.,
   S.G., R.M., J.H., A.S., S.A., C.R., A.H.); Preparation, review, or
   approval of manuscript (W.C., S.D., A.H., J.H., C.R.).
CR Arias L, 2010, CLIN OPHTHALMOL, V4, P67
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cakir M, 2010, EUR J OPHTHALMOL, V20, P565, DOI 10.1177/112067211002000305
   Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   Daneshvar H, 1999, CAN J OPHTHALMOL, V34, P385
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Gopalakrishan M, 2007, RETINA-J RET VIT DIS, V27, P329, DOI 10.1097/01.iae.0000231544.43093.40
   Guthoff R, 2011, RETINA-J RET VIT DIS, V31, P36, DOI 10.1097/IAE.0b013e3181e37884
   Handwerger BA, 2001, ARCH OPHTHALMOL-CHIC, V119, P28
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hesse L, 2000, RETINA-J RET VIT DIS, V20, P500, DOI 10.1097/00006982-200009000-00011
   Kamei M, 1999, AM J OPHTHALMOL, V128, P739, DOI 10.1016/S0002-9394(99)00239-1
   Kim JH, 2013, OPHTHALMOLOGY
   Lee SS, 2010, INVEST OPHTH VIS SCI, V51, P2135, DOI 10.1167/iovs.09-3582
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   LIM JI, 1995, OPHTHALMOLOGY, V102, P1393, DOI 10.1016/S0161-6420(95)30858-5
   Lincoff H, 2008, RETINA-J RET VIT DIS, V28, P56, DOI 10.1097/IAE.0b013e31806e60db
   Mizutani T, 2011, GRAEF ARCH CLIN EXP, V249, P1153, DOI 10.1007/s00417-011-1649-1
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sacu S, 2009, EYE, V23, P1404, DOI 10.1038/eye.2008.267
   Sandhu SS, 2010, CLIN OPHTHALMOL, V4, P637
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Shah SP, 2009, OPHTHAL SURG LAS IM, V40, P308, DOI 10.3928/15428877-20090430-16
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Stopa M, 2007, RETINA-J RET VIT DIS, V27, P370, DOI 10.1097/IAE.0b013e3180439bc9
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Vander JF, 1991, OPHTHALMOLOGY
   WADE EC, 1990, ARCH OPHTHALMOL-CHIC, V108, P973, DOI 10.1001/archopht.1990.01070090075043
   Yang Po-Min, 2005, Chang Gung Med J, V28, P852
NR 39
TC 65
Z9 65
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2014
VL 157
IS 6
BP 1250
EP 1257
DI 10.1016/j.ajo.2014.02.007
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AJ4KF
UT WOS:000337644400019
PM 24531021
DA 2022-11-30
ER

PT J
AU Guo, WM
   Wan, JL
   Zhang, F
   Liu, MQ
   Tan, MQ
   Bian, W
AF Guo, Wenmei
   Wan, Junli
   Zhang, Feng
   Liu, Mingqiong
   Tan, Mingqiong
   Bian, Wei
TI Development and Pilot-Testing of a Patient Decision-Making Aid for
   Nutrition in Age-Related Macular Degeneration
SO PATIENT PREFERENCE AND ADHERENCE
LA English
DT Article
DE age -related macular degeneration; nutrition; decision -making aid
ID EYE DISEASE; SUPPLEMENTATION; RANIBIZUMAB
AB Objective: We described the development and pilot-testing of an application based patient decision-making aid (PDA) for nutrition in age-related macular degeneration (AMD). Alpha-testing and beta-testing were performed to explore the PDA's usability, acceptability, and comprehensibility in the design stage and in "real-life" conditions. Methods: A nutrition PDA was developed in this study by a multidisciplinary steering committee that consisted of ophthalmologists, nurses, nutritionists, and methodologists using a systematic development process. The PDA was based on a smartphone native installation and a free-to-use app. First, based on information from literature reviews and focus group interviews for needs assessment, we developed a decision aid prototype. Second, we conducted the alpha testing to explore the acceptability, usability, and comprehen-sibility of the PDA prototype among 18 AMD patients. Third, a before/after study was conducted to assess changes in the attitudes, risk perceptions, intentions, knowledge, decisional conflicts, and decision self-efficacy of 33 AMD patients. Results: The alpha test proved that the nutrition PDA is acceptable and usable. In the beta test, after the AMD participants used the PDA, their scores for knowledge [mean = 13.3, standard deviation (SD) = 2.92], attitude (mean = 18.97, SD = 2.19), decision self -efficacy (mean = 23.94, SD = 6.04), and preparation significantly increased (mean = 26.30, SD = 4.90), and their score for decisional conflict significantly decreased (mean = 10.15, SD = 3.66). There was no significant difference in anxiety (mean = 2.64, SD = 1.08) before and after the use of the PDA. The mean score in the system usability scale was above 70 (mean = 72.61; SD = 5.38), which indicates the good usability of the PDA. With regard to the PDA acceptability, the scores for satisfaction with its comprehensibility, satisfaction with its attractiveness, and satisfaction with its emotional support were 5.49 (SD = 1.03), 5.30 (SD = 1.40), and 4.91(SD = 1.07), respectively, which show its adequate acceptability. Conclusion: Our study showed that the nutrition PDA was an acceptable and suitable instrument for AMD patients and fit the values of all its stakeholders. This study is an important step in supporting shared decision-making, which has the potential to provide a more patient-centered and value-based nutrition health system for individuals with different types of AMD.
C1 [Guo, Wenmei; Wan, Junli; Zhang, Feng; Liu, Mingqiong; Tan, Mingqiong; Bian, Wei] Third Mil Med Univ, Army Med Univ, Southwest Hosp, Southwest Eye Hosp, Chongqing, Peoples R China.
   [Guo, Wenmei; Wan, Junli; Zhang, Feng; Liu, Mingqiong; Tan, Mingqiong; Bian, Wei] Key Lab Visual Damage & Regenerat & Restorat Chong, Chongqing, Peoples R China.
   [Bian, Wei] Third Mil Med Univ, Army Med Univ, Southwest Hosp, Southwest Eye Hosp, Chongqing 400038, Peoples R China.
C3 Army Medical University; Army Medical University
RP Bian, W (通讯作者)，Third Mil Med Univ, Army Med Univ, Southwest Hosp, Southwest Eye Hosp, Chongqing 400038, Peoples R China.
EM bianwei@Tmmu.edu.cn
FU Chongqing Science and health joint medical research project
   [2020FYYX052]; Army Medical Uni-versity Excellent Youth Fund
   [XZ-2019-505-054]
FX Funding This study was funded by the Chongqing Science and health joint
   medical research project (2020FYYX052) and Army Medical Uni-versity
   Excellent Youth Fund (XZ-2019-505-054) .
CR Balaratnasingam C, 2015, CLIN OPHTHALMOL, V9, P2355, DOI 10.2147/OPTH.S80040
   Bian W, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-031020
   Bol N, 2014, HEALTH COMMUN, V29, P678, DOI 10.1080/10410236.2013.771560
   Broadhead GK, 2015, NUTR REV, V73, P448, DOI 10.1093/nutrit/nuv005
   Brooke J., 1996, USABILITY EVALUATION, P189, DOI DOI 10.1201/9781498710411-35
   Brouwers MC, 2010, PREV MED, V51, P421, DOI 10.1016/j.ypmed.2010.08.005
   Carneiro A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6469138
   Chapman NA, 2019, CLIN EXP OPHTHALMOL, V47, P106, DOI 10.1111/ceo.13343
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Coulter A, 2013, BMC MED INFORM DECIS, V13, DOI 10.1186/1472-6947-13-S2-S2
   Cox CE, 2019, ANN INTERN MED, V170, P285, DOI 10.7326/M18-2335
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Downie LE, 2014, OPTOMETRY VISION SCI, V91, P821, DOI 10.1097/OPX.0000000000000285
   Elwyn G, 2006, BMJ-BRIT MED J, V333, P417, DOI 10.1136/bmj.38926.629329.AE
   Elwyn G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004705
   Essink-Bot ML, 2016, GASTROENT RES PRACT, V2016, DOI 10.1155/2016/7292369
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub4
   Fung CH, 2021, J CLIN SLEEP MED, V17, P121, DOI 10.5664/jcsm.8798
   Graham I, 1995, USER MANUAL PREPARAT
   Howick J, 2016, OXFORD LEVELS EVIDEN
   Jaspers MWM, 2009, INT J MED INFORM, V78, P340, DOI 10.1016/j.ijmedinf.2008.10.002
   Jin GM, 2019, CLIN EXP OPHTHALMOL, V47, P1019, DOI 10.1111/ceo.13580
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kent C, 2007, REV OPHTHALMOL, V14, P31
   Kushniruk AW, 2004, J BIOMED INFORM, V37, P56, DOI 10.1016/j.jbi.2004.01.003
   Lancaster GA, 2004, J EVAL CLIN PRACT, V10, P307, DOI 10.1111/j..2002.384.doc.x
   Lee EO, 2013, NEW ENGL J MED, V368, P6, DOI 10.1056/NEJMp1209500
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nota I, 2017, BMC MED INFORM DECIS, V17, DOI 10.1186/s12911-017-0433-5
   O'Connor AM, 1995, USER MANUAL DECISION
   OConnor AM, 1993, USER MANUAL DECISION, P1
   OConnor AM, 2006, OTTAWA DECISION SUPP
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schonberg MA, 2014, JAMA INTERN MED, V174, P417, DOI 10.1001/jamainternmed.2013.13639
   Shah SU, 2013, CAN J OPHTHALMOL, V48, P204, DOI 10.1016/j.jcjo.2013.01.013
   Shum JWH, 2017, BMJ OPEN OPHTHALMOL, V2, DOI 10.1136/bmjophth-2017-000100
   Spatz ES, 2017, JAMA-J AM MED ASSOC, V317, P1309, DOI 10.1001/jama.2017.0616
   Stevens R, 2017, BRIT J VISUAL IMPA, V35, P185, DOI 10.1177/0264619616683989
   Stevens R, 2014, BRIT J VISUAL IMPA, V32, P77, DOI 10.1177/0264619613519341
   Stevens R, 2015, CLIN NUTR ESPEN, V10, pE112, DOI 10.1016/j.clnesp.2015.03.080
   Swanson MW, 2012, OPTOMETRY VISION SCI, V89, pE23, DOI 10.1097/OPX.0b013e31826a3d85
   The Joanna Briggs Institute (JBI), 2020, J BRIGGS I REV MAN 2
   The Joanna Briggs Institute Levels of Evidence and Grades of Recommendation Working Party, 2014, SUPPORTING DOCUMENT
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Turner S., 2002, Computers in Libraries, V22, P37
   US Department of Health and Human Services, 2006, ERS BAS WEB DES US
   van der Bij Akke K, 2003, Community Genet, V6, P84, DOI 10.1159/000073003
   Zdenkowski N, 2016, BREAST, V26, P31, DOI 10.1016/j.breast.2015.12.007
NR 49
TC 0
Z9 0
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-889X
J9 PATIENT PREFER ADHER
JI Patient Prefer. Adherence
PY 2022
VL 16
BP 2567
EP 2577
DI 10.2147/PPA.S377748
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 4U2BB
UT WOS:000858604700001
PM 36128576
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hayashi, Y
   Iwasaki, Y
   Waza, M
   Shibata, H
   Akagi, A
   Kimura, A
   Inuzuka, T
   Satoh, K
   Kitamoto, T
   Yoshida, M
   Shimohata, T
AF Hayashi, Yuichi
   Iwasaki, Yasushi
   Waza, Masahiro
   Shibata, Hideaki
   Akagi, Akio
   Kimura, Akio
   Inuzuka, Takashi
   Satoh, Katsuya
   Kitamoto, Tetsuyuki
   Yoshida, Mari
   Shimohata, Takayoshi
TI Clinicopathological findings of an MM2-cortical-type sporadic
   Creutzfeldt-Jakob disease patient with cortical blindness during a
   course of glaucoma and age-related macular degeneration
SO PRION
LA English
DT Article
DE Creutzfeldt-Jakob disease; MM2-cortical-type sporadic Creutzfeldt-Jakob
   disease; cortical blindness; diffusion-weighted MRI; elderly patient;
   ocular disease; dementia
ID CONSENSUS CLASSIFICATION; CEREBROSPINAL-FLUID; PRION DISEASE; SYSTEM
AB Here, we report an autopsy-verified patient with MM2-coritical-type sporadic Creutzfeldt-Jakob disease (MM2C-type sCJD) presenting cortical blindness during a course of glaucoma and age-related macular degeneration, and focus on the difficulties involved in early clinical diagnosis. An 83-year-old man was admitted to our hospital 15 months after the onset of cortical blindness, and 9 months after the onset of progressive dementia. Neurological examination revealed dementia, frontal signs, visual disturbance, dysphagia, myoclonus and exaggerated tendon reflexes in the four extremities. Diffusion-weighted MRI (DW-MRI) showed cortical hyperintensities predominantly in the bilateral occipital lobes. PRNP gene analysis showed no mutations with methionine homozygosity at codon 129. Cerebrospinal fluid (CSF) examination revealed elevation of 14-3-3 and total tau protein. The symptoms progressed gradually, and the patient died of aspiration pneumonia, 30 months after the onset. Neuropathological examination revealed extensive large confluent vacuole-type spongiform changes in the cerebral cortices. Prion protein (PrP) immunostaining showed perivascular and plaque-type PrP deposits. We diagnosed our patient as MM2C-type sCJD. There are two difficulties in the early clinical diagnosis of MM2C-type sCJD with ocular disease in the elderly; delayed utilization of DW-MRI, and accompaniment of ocular disease. For early diagnosis of MM2C-type sCJD, we conclude that clinician should perform DW-MRI for patients with isolated dementia or cortical visual disturbance.
C1 [Hayashi, Yuichi; Shibata, Hideaki; Kimura, Akio; Inuzuka, Takashi; Shimohata, Takayoshi] Gifu Univ, Dept Neurol, Grad Sch Med, 1-1 Yanagido, Gifu 5011194, Japan.
   [Iwasaki, Yasushi; Akagi, Akio; Yoshida, Mari] Aichi Med Univ, Autopsy Ctr Prion Dis, Inst Med Sci Aging, Nagakute, Aichi, Japan.
   [Waza, Masahiro] Kakamigahara Rehabil Hosp, Dept Neurol, Kakamigahara, Japan.
   [Inuzuka, Takashi] Gifu Municipal Hosp, Dept Neurol, Gifu, Japan.
   [Satoh, Katsuya] Nagasaki Univ, Grad Sch Med, Dept Locomot Rehabil Sci, Nagasaki, Japan.
   [Kitamoto, Tetsuyuki] Tohoku Univ, Sch Med, Div CJD Sci & Technol, Dept Prion Res,Ctr Translat & Adv Anim Res Human, Sendai, Miyagi, Japan.
C3 Gifu University; Aichi Medical University; Gifu Municipal Hospital;
   Nagasaki University; Tohoku University
RP Shimohata, T (通讯作者)，Gifu Univ, Dept Neurol, Grad Sch Med, 1-1 Yanagido, Gifu 5011194, Japan.
EM shimohata@gmail.com
RI Iwasaki, Yasushi/AAF-1253-2020
OI Waza, Masahiro/0000-0002-1582-4745; Hayashi, Yuichi/0000-0003-4048-3513;
   iwasaki, yasushi/0000-0002-0059-3104
FU Research Committee of Prion Disease and Slow Virus infection, the
   Ministry of Health, Labour and Welfare of Japan; Research Committee of
   Prion Disease Surveillance, the Ministry of Health, Labour and Welfare
   of Japan
FX This work was supported by grants-in-aid from the Research Committee of
   Prion Disease and Slow Virus infection (for TK, YI, and KS), and from
   the Research Committee of Prion Disease Surveillance (for TK, KS, and
   TI), the Ministry of Health, Labour and Welfare of Japan.
CR Akagi A, 2018, PRION, V12, P54, DOI 10.1080/19336896.2017.1414130
   Appleby BS, 2019, CURR OPIN PHARMACOL, V44, P15, DOI 10.1016/j.coph.2018.11.006
   Armstrong RA, 2006, CLIN EXP OPTOM, V89, P3, DOI 10.1111/j.1444-0938.2006.00001.x
   Atarashi R, 2011, NAT MED, V17, P175, DOI 10.1038/nm.2294
   Baiardi S, 2016, J ALZHEIMERS DIS, V50, P465, DOI 10.3233/JAD-150668
   Crutch SJ, 2017, ALZHEIMERS DEMENT, V13, P870, DOI 10.1016/j.jalz.2017.01.014
   Fernandez-Vega I, 2015, NEUROPATHOLOGY, V35, P56, DOI 10.1111/neup.12150
   Fujita K, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000649
   Hamaguchi T, 2005, NEUROLOGY, V64, P643, DOI 10.1212/01.WNL.0000151847.57956.FA
   Hayashi Y, 2017, PRION, V11, P454, DOI 10.1080/19336896.2017.1377876
   Hayashi Y, 2017, J NEUROL SCI, V377, P95, DOI 10.1016/j.jns.2017.04.004
   Isfahani SA, 2017, SAGE OPEN MED CASE R, V5, DOI 10.1177/2050313X17744482
   Ishizawa K, 2000, J NEUROPATH EXP NEUR, V59, P513, DOI 10.1093/jnen/59.6.513
   Iwasaki Y, 2006, ACTA NEUROPATHOL, V112, P561, DOI 10.1007/s00401-006-0111-7
   Iwasaki Y, 2017, NEUROPATHOLOGY, V37, P174, DOI 10.1111/neup.12355
   KITAMOTO T, 1992, AM J PATHOL, V140, P1285
   Kobayashi A, 2010, J VIROL, V84, P3230, DOI 10.1128/JVI.02387-09
   Krasnianski A, 2006, ARCH NEUROL-CHICAGO, V63, P876, DOI 10.1001/archneur.63.6.876
   Niimi Y, 2008, NEUROPATHOLOGY, V28, P645, DOI 10.1111/j.1440-1789.2008.00904.x
   Nozaki I, 2006, NEUROLOGY, V67, P531, DOI 10.1212/01.wnl.0000228224.35678.60
   Parchi P, 1999, ANN NEUROL, V46, P224, DOI 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W
   Parchi P, 2012, ACTA NEUROPATHOL, V124, P517, DOI 10.1007/s00401-012-1002-8
   Saito Y, 2011, NEUROPATHOLOGY, V31, P523, DOI 10.1111/j.1440-1789.2010.01181.x
   Satoh K, 2006, CELL MOL NEUROBIOL, V26, P45, DOI 10.1007/s10571-006-9370-z
   Shrestha R, 2016, NEUROCASE, V22, P243, DOI 10.1080/13554794.2015.1135963
   Takada LT, 2013, SEMIN NEUROL, V33, P348, DOI 10.1055/s-0033-1359314
NR 26
TC 5
Z9 5
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1933-6896
EI 1933-690X
J9 PRION
JI Prion
PD JAN 1
PY 2019
VL 13
IS 1
BP 124
EP 131
DI 10.1080/19336896.2019.1631680
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA IE1XQ
UT WOS:000472179500001
PM 31219399
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Gillies, MC
   Walton, RJ
   Arnold, JJ
   McAllister, IL
   Simpson, JM
   Hunyor, AP
   Guymer, R
   Essex, RW
   Morlet, N
   Barthelmes, D
AF Gillies, Mark C.
   Walton, Richard J.
   Arnold, Jennifer J.
   McAllister, Ian L.
   Simpson, Judy M.
   Hunyor, Alex P.
   Guymer, Robyn
   Essex, Rohan W.
   Morlet, Nigel
   Barthelmes, Daniel
TI Comparison of Outcomes from a Phase 3 Study of Age-Related Macular
   Degeneration with a Matched, Observational Cohort
SO OPHTHALMOLOGY
LA English
DT Article
ID SUBGROUP ANALYSIS; VISUAL OUTCOMES; RANIBIZUMAB; BEVACIZUMAB;
   PREDICTORS; EYES
AB Objective: To compare outcomes of intravitreal therapy from an observational study cohort with those of participants receiving treatment in the Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab (MARINA) for the treatment of neovascular age-related macular degeneration (wet AMD).
   Design: Database observational study. Participants in the observational cohort were chosen to match demographic features and entry criteria of the treatment group from MARINA. Outcomes over 12 months were compared.
   Participants: Eight hundred twenty-one anti-vascular endothelial growth factor (anti-VEGF)-naive eyes treated with ranibizumab with 12 months or more of follow-up were included in the total Fight Retinal Blindness! (FRB-All) cohort, whereas a subset of this cohort of 401 eyes who were matched to the MARINA treatment group were included as the FRB-MARINA cohort.
   Intervention: Intravitreal ranibizumab therapy of 0.5 mg for wet AMD.
   Methods: Visual acuity (VA) in logarithm of the minimum angle of resolution (logMAR) letters and treatments given were recorded continuously and anonymously in an electronic database for 12 months. Locally weighted scatterplot smoothing (LOESS) regression was used to plot change in visual acuity data over the course of 12 months for both the FRB-All cohort and the FRB-MARINA cohort, whereas results from the MARINA trial were taken from the published study report.
   Main Outcome Measures: Change in VA in logMAR letters over 12 months, treatment, and visit intensity.
   Results: Mean visual acuity improvement after 12 months in FRB-MARINA (+5.5 letters) was similar to that of the 0.5-mg group from MARINA (+7.2 letters). Improvement in FRB-ALL was slightly less (+4.9 letters). Mean treatment effect compared with the MARINA control group was similar for the MARINA treated group (+17.6 letters) and the FRB-MARINA cohort (+15.9 letters). A mean of 7.3 injections in 12 months was received by the observational cohorts.
   Conclusions: Similarity of mean VA improvement in the matched observational cohort with that of the phase 3 clinical trial suggests that these results can be achieved in real-world clinical practice with a modified treatment regimen. (C) 2014 by the American Academy of Ophthalmology.
C1 [Gillies, Mark C.; Walton, Richard J.; Barthelmes, Daniel] Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW 2006, Australia.
   [Arnold, Jennifer J.] Marsden Eye Specialists, Parramatta, Australia.
   [McAllister, Ian L.] Univ Western Australia, Lions Eye Inst, Ctr Ophthalmol & Vis Sci, Nedlands, WA 6009, Australia.
   [Simpson, Judy M.] Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia.
   [Hunyor, Alex P.] Retina Associates, Chatswood, NSW, Australia.
   [Guymer, Robyn] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Dept Ophthalmol, Melbourne, Vic, Australia.
   [Essex, Rohan W.] Australian Natl Univ, Acad Unit Ophthalmol, Canberra, ACT, Australia.
   [Morlet, Nigel] Univ Western Australia, Dept Populat Hlth, Perth, WA 6009, Australia.
   [Barthelmes, Daniel] Univ Zurich, Univ Zurich Hosp, Dept Ophthalmol, Zurich, Switzerland.
C3 University of Sydney; Lions Eye Institute; University of Western
   Australia; University of Sydney; Centre for Eye Research Australia;
   Royal Victorian Eye & Ear Hospital; University of Melbourne; Australian
   National University; University of Western Australia; University of
   Zurich; University Zurich Hospital
RP Gillies, MC (通讯作者)，Save Sight Inst, South Block,8 Macquarie St, Sydney, NSW 2000, Australia.
EM mark.gillies@sydney.edu.au
RI Hunyor, Alex/AAT-8205-2021
OI Hunyor, Alex/0000-0002-8182-6167; Simpson, Judy M/0000-0001-5172-3004;
   Guymer, Robyn/0000-0002-9441-4356; Essex, Rohan/0000-0001-5323-0334
FU Royal Australian and New Zealand College of Ophthalmologists Eye
   Foundation, Sydney; National Health and Medical Research Council,
   Canberra, Australia [2010-1012]; National Health and Medical Research
   Council; Walter and Gertrud Siegenthaler Foundation Zurich, Switzerland;
   Swiss National Foundation
FX Supported by a grant from the Royal Australian and New Zealand College
   of Ophthalmologists Eye Foundation, Sydney (2007-2009); and the National
   Health and Medical Research Council, Canberra, Australia (grant no.:
   2010-1012). Mark Gillies is a Sydney Medical Foundation Fellow and is
   supported by an National Health and Medical Research Council
   practitioner fellowship. Daniel Barthelmes was supported by the Walter
   and Gertrud Siegenthaler Foundation Zurich, Switzerland, and the Swiss
   National Foundation. Robyn Guymer is a National Health and Medical
   Research Council practitioner fellow.
CR Biarnes M, 2011, EUR J OPHTHALMOL, V21, P282, DOI 10.5301/EJO.2010.5766
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Gillies MC, 2013, INVEST OPHTH VIS SCI, V54, P5754, DOI 10.1167/iovs.13-11993
   Gillies MC, 2013, RETINA
   Heimes B, 2011, GRAEF ARCH CLIN EXP, V249, P639, DOI 10.1007/s00417-010-1524-5
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V286, P821, DOI 10.1001/jama.286.7.821
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kumar A, 2011, BRIT J OPHTHALMOL, V95, P530, DOI 10.1136/bjo.2009.171868
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Menghini M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042014
   NEWCOMBE RG, 1987, BRIT J OPHTHALMOL, V71, P645, DOI 10.1136/bjo.71.9.645
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Tao Y, 2010, J OCUL PHARMACOL TH, V26, P79, DOI 10.1089/jop.2009.0095
   Temple R, 2010, CLIN PHARMACOL THER, V88, P774, DOI 10.1038/clpt.2010.233
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 22
TC 38
Z9 38
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2014
VL 121
IS 3
BP 676
EP 681
DI 10.1016/j.ophtha.2013.09.050
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AC3FT
UT WOS:000332401800017
PM 24290801
DA 2022-11-30
ER

PT J
AU Touma-Falci, L
   Moreira-Neto, CA
   Taleb, AC
   Prieto, MB
   Packer, T
   Oliveira, JCB
   Birck, MG
   Julian, GS
   Forestiero, FJ
AF Touma-Falci, Liane
   Moreira-Neto, Carlos Augusto
   Taleb, Alexandre Chater
   Prieto, Marcela Bach
   Packer, Thais
   Oliveira, Julio Cesar Barbour
   Birck, Marina Gabriela
   Julian, Guilherme Silva
   Forestiero, Francisco Jose
TI Age-related macular degeneration and resource utilization in the
   Brazilian public healthcare system: a real-world retrospective study
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Real world data; Datasus;
   Antiangiogenic treatment; Public health system
ID VITRECTOMY; PREVALENCE
AB Background Age-related macular degeneration (AMD) is a disease that causes damage in the macular region of the retina, leading to irreversible blindness. This study aims to understand the profile and care of patients with AMD and its cost at the Brazilian public health system to identify AMD-care needs. Methods This is a retrospective observational study of AMD with real-world data from the Brazilian public healthcare system, using DATASUS claim databases. Patients with AMD were selected from 01/Jan/2014 to 31/Jan/2020; had at least one claim of ICD10 code H35.3 (Degeneration of macula and posterior pole), and were submitted to one of two procedures exclusively available for AMD patients - optical coherence tomography (OCT) and medical treatment of retinal disease (antiangiogenic); aged >= 18 years at first ICD10 claim, and presenting at least 1 year of follow-up in the database. We described patients' characteristics, healthcare resource utilization and cost, and the antiangiogenic intravitreal treatment received by AMD patients, including the number of doses and interval time between them. Results Patients searching for AMD treatment since 2014 were mostly females (59%), white (61%), and a mean age of 72 years. They were mainly located in the Southeast (87%), and few patients were found in the North (1%) and Central-West (1.5%) regions, probably reflecting where the Brazilian guideline to treat AMD (Protocolo Clinico e Diretrizes Terapeuticas - PCDT) was incorporated as routine care for AMD. The average antiangiogenic dose of 2.5 antiangiogenic therapies within a year was below the expected. Most injections had an interval time of 20 to 40 days between doses, although some patients were treated more than 100 days. Another setback is that patients traveled longer distances for OCT and antiangiogenic treatment than overall AMD-healthcare, between 10 and 100 km. Conclusions AMD patients seem to be undertreated, as they receive a mean of 2.5 doses of antiangiogenic treatment within a year. Inequalities among regions are evident, as the Southeast and South regions comprise almost all patients receiving the treatment from the public health system, probably reflecting the region with more access to AMD care according to PCDT recommendations.
C1 [Touma-Falci, Liane; Prieto, Marcela Bach; Packer, Thais; Forestiero, Francisco Jose] Novartis Biociencias SA, Vicente Rao Ave 90, BR-04636000 Sao Paulo, SP, Brazil.
   [Moreira-Neto, Carlos Augusto] Hosp Olhos Parana, Curitiba, PR, Brazil.
   [Taleb, Alexandre Chater] Univ Fed Goias, Reference Ctr Ophthalmol, Goiania, Go, Brazil.
   [Oliveira, Julio Cesar Barbour; Birck, Marina Gabriela; Julian, Guilherme Silva] IQVIA Brasil, Sao Paulo, SP, Brazil.
C3 Universidade Federal de Goias
RP Forestiero, FJ (通讯作者)，Novartis Biociencias SA, Vicente Rao Ave 90, BR-04636000 Sao Paulo, SP, Brazil.
EM francisco.forestiero@novartis.com
OI Chater Taleb, Alexandre/0000-0002-8732-7369; Barbour Oliveira, Julio
   Cesar/0000-0002-9990-9016; Julian, Guilherme/0000-0002-3487-2240
FU Novartis Brazil
FX This study was conducted by IQVIA Brazil and sponsored by Novartis
   Brazil.
CR Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Campos DF, 2017, VALUE HEALTH, V20, pA321
   Figueiredo FA., 2018, PROTOCOLO CLIN DIRET, P1
   Furtado JM, 2019, OPHTHAL EPIDEMIOL, V26, P345, DOI 10.1080/09286586.2019.1624783
   IBGE-Instituto Brasileiro de Geografia e Estatistica, 2021, REV BRASILEIRA BIOME, V37, P529
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Kimura S, 2016, GRAEF ARCH CLIN EXP, V254, P1731, DOI 10.1007/s00417-016-3314-1
   Lim LGR., 2008, GARNER KLINTWORTHS P, V3
   Liu L, 2011, INVEST OPHTH VIS SCI, V52, P1023, DOI 10.1167/iovs.10-6431
   Ministerio da Saude, DATASUS SIGTAP
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Oguido APMT, 2008, ARQ BRAS OFTALMOL, V71, P375, DOI 10.1590/S0004-27492008000300013
   Nunes BP., 2018, MULTIMORBIDITY BRAZI, P1
   Roller AB, 2010, OPHTHALMOLOGY, V117, P1381, DOI 10.1016/j.ophtha.2009.11.007
   Romani Flávio Antônio, 2005, Arq. Bras. Oftalmol., V68, P649, DOI 10.1590/S0004-27492005000500015
   Santos Laura Patrícia Ferreira, 2005, Arq. Bras. Oftalmol., V68, P229, DOI 10.1590/S0004-27492005000200014
   Schargus M, 2020, CLIN OPHTHALMOL, V14, P897, DOI 10.2147/OPTH.S207978
   Schellini SA, 2009, BMC OPHTHALMOL, V9, DOI 10.1186/1471-2415-9-8
   Schramm K, 2014, ACTA OPHTHALMOL, V92, P465, DOI 10.1111/aos.12326
   Sodre SL, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7562-y
   Sodre SL., 2019, CUSTOS BENEFICIOS CO
   Tavares F., 2015, TREATMENT OPTIONS AG, P1
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
NR 24
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD DEC 13
PY 2021
VL 21
IS 1
AR 430
DI 10.1186/s12886-021-02181-1
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XN8TQ
UT WOS:000729771800002
PM 34903203
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Okada, M
   Mitchell, P
   Finger, RP
   Eldem, B
   Talks, SJ
   Hirst, C
   Paladini, L
   Barratt, J
   Wong, TY
   Loewenstein, A
AF Okada, Mali
   Mitchell, Paul
   Finger, Robert P.
   Eldem, Bora
   Talks, S. James
   Hirst, Ceri
   Paladini, Luciano
   Barratt, Jane
   Wong, Tien Yin
   Loewenstein, Anat
TI Nonadherence or Nonpersistence to Intravitreal Injection Therapy for
   Neovascular Age-Related Macular Degeneration A Mixed-Methods Systematic
   Review
SO OPHTHALMOLOGY
LA English
DT Review
DE Adherence; persistence; nonadherence; nonpersistence; compliance;
   intravitreal; anti-VEGF; age-related macular degeneration.
ID ANTI-VEGF TREATMENT; GROWTH-FACTOR THERAPY; RANIBIZUMAB TREATMENT;
   TREATMENT PATTERNS; ADHERENCE; OUTCOMES; DISCONTINUATION; AFLIBERCEPT;
   PATIENT; EXPERIENCES
AB Topic: Systematic review of risk factors for nonadherence and nonpersistence to intravitreal antievascular endothelial growth factor (VEGF) injection therapy for neovascular age-related macular degeneration (nAMD).
   Clinical Relevance: Lack of adherence (nonadherence) or undertreatment (nonpersistence) with respect to evidence from clinical trials remains a significant barrier to optimizing real-world outcomes for patients with nAMD. Contributing factors and strategies to address this are poorly understood.
   Methods: Studies that reported factors for nonadherence and nonpersistence to anti-VEGF therapy as well as studies examining strategies to improve this were included. Trial eligibility and data extraction were conducted according to Cochrane review methods. Risk of bias was assessed using the Mixed Method Assessment Tool and certainty of evidence evaluated according to the GRADE Confidence in the Evidence from Reviews of Qualitative Research tool. Data were collated descriptively.
   Results: Of the 1284 abstract results screened, 124 articles were assessed in full and 37 studies met the inclusion criteria. Definitions of nonadherence and nonpersistence varied or were not reported. Nonpersistence occurred early, with up to 50% of patients stopping treatment by 24 months. High rates of nonadherence were similarly reported, occurring in 32% to 95% of patients. Certainty of this finding was downgraded to a moderate level because of the heterogeneity in definitions used across studies. Multiple factors determine nonadherence and nonpersistence, including at the condition, therapy, patient, social/economic, and health systems/healthcare team levels. Moderate quality evidence points to lower baseline vision and poorer response to treatment as condition-related variables. The effects of other factors were of lower certainty, predominantly due to small numbers and potential biases in retrospective assessment. Although many factors are not modifiable (e.g., patient comorbidity), other factors are potentially correctable (e.g., lack of transport or mismatched patient expectations). Evidence on strategies to improve adherence and persistence is limited, but where available, these have proven effective.
   Conclusions: Awareness of factors related to poor patient adherence and persistence in nAMD could help identify at-risk populations and improve real-world outcomes. Further work is required to develop uniform definitions and establish high-quality evidence on interventions that can be easily implemented. Ophthalmology 2021;128:234247 (C)2020 by the American Academy of Ophthalmology
C1 [Okada, Mali] Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia.
   [Mitchell, Paul] Univ Sydney, Dept Ophthalmol, Sydney, NSW, Australia.
   [Finger, Robert P.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Eldem, Bora] Hacettepe Univ, Dept Ophthalmol, Ankara, Turkey.
   [Talks, S. James] Newcastle Upon Tyne Hosp NHS Fdn, Newcastle Upon Tyne, Tyne & Wear, England.
   [Hirst, Ceri] Bayer Consumer Care, Basel, Switzerland.
   [Paladini, Luciano] Kantar Hlth Care, Sao Paulo, Brazil.
   [Barratt, Jane] Int Federat Ageing, Toronto, ON, Canada.
   [Wong, Tien Yin] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Wong, Tien Yin] Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program, Singapore, Singapore.
   [Loewenstein, Anat] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Div Ophthalmol, Tel Aviv, Israel.
C3 Royal Victorian Eye & Ear Hospital; University of Sydney; University of
   Bonn; Hacettepe University; Newcastle Upon Tyne Hospitals NHS Foundation
   Trust; National University of Singapore; Singapore National Eye Center;
   National University of Singapore; Tel Aviv University; Sackler Faculty
   of Medicine; Tel Aviv Sourasky Medical Center
RP Okada, M (通讯作者)，Royal Victorian Eye & Ear Hosp, 32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM Mali.Okada@eyeandear.org.au
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264
FU Kantar Health; Bayer Pharmaceuticals
FX Development of this manuscript for publication, specifically assistance
   with parts of the literature review, language translation, and initial
   data extraction support, was provided by Kantar Health, with the
   financial support of Bayer Pharmaceuticals. However, the study design,
   final data extraction, data analysis and manuscript writing were
   performed by the primary author (M.O.).
CR Angermann R, 2019, GRAEF ARCH CLIN EXP, V257, P2119, DOI 10.1007/s00417-019-04414-y
   [Anonymous], 2003, ADHERENCE LONG TERM
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Best AL, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/4610129
   Bobykin E V, 2014, Vestn Oftalmol, V130, P88
   Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Boyle J, 2018, PSYCHOL HEALTH MED, V23, P127, DOI 10.1080/13548506.2016.1274040
   Boyle J, 2015, PSYCHOL HEALTH MED, V20, P296, DOI 10.1080/13548506.2014.936886
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Budenz DL, 2009, OPHTHALMOLOGY, V116, pS43, DOI 10.1016/j.ophtha.2009.06.022
   Chang A, 2018, CLIN EXP OPHTHALMOL, V46, P92
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   Droege KM, 2014, GRAEF ARCH CLIN EXP, V252, P31, DOI 10.1007/s00417-013-2412-6
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Ehlken C, 2018, RETINA, V38
   Ehlken C, 2018, CLIN OPHTHALMOL, V12, P11, DOI 10.2147/OPTH.S151611
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Garcia-Perez LE, 2013, DIABETES THER, V4, P175, DOI 10.1007/s13300-013-0034-y
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Guerci B, 2019, DIABETES THER, V10, P437, DOI 10.1007/s13300-019-0590-x
   Hahn SR, 2009, OPHTHALMOLOGY, V116, pS37, DOI 10.1016/j.ophtha.2009.06.023
   Hanemoto T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189035
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heimes B, 2016, OPHTHALMOLOGE, V113, P925, DOI 10.1007/s00347-016-0275-z
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hong QN, 2018, EDUC INFORM, V34, P285, DOI 10.3233/EFI-180221
   Husler S, 2013, KLIN MONATSBL AUGENH, V230, P1251, DOI 10.1055/s-0033-1351029
   Iida T, 2016, CLIN OPHTHALMOL, V10, P2505, DOI 10.2147/OPTH.S120803
   Kim JH, 2017, RETINA-J RET VIT DIS, V37, P2254, DOI 10.1097/IAE.0000000000001494
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Krivosic V, 2017, J FR OPHTALMOL, V40, P642, DOI 10.1016/j.jfo.2017.03.005
   Lad EM, 2014, AM J OPHTHALMOL, V158, P537, DOI 10.1016/j.ajo.2014.05.014
   Liakopoulos S, 2020, BR J OPHTHALMOL
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3
   Massamba N, 2015, EYE, V29, P1453, DOI 10.1038/eye.2015.128
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nunes RP, 2010, ARQ BRAS OFTALMOL, V73, P146, DOI 10.1590/S0004-27492010000200009
   Obeid A, 2018, JAMA OPHTHALMOL, V136, P1251, DOI 10.1001/jamaophthalmol.2018.3578
   Oishi A, 2011, EUR J OPHTHALMOL, V21, P777, DOI 10.5301/EJO.2011.7430
   Ozturk M, 2018, CLIN EXP OPHTHALMOL, V46, P407, DOI 10.1111/ceo.13085
   Polar O, 2017, TURK OFTALMOL DERG, V47, P205, DOI 10.4274/tjo.28003
   Ramakrishnan MS, 2020, JAMA OPHTHALMOL, V138, P237, DOI 10.1001/jamaophthalmol.2019.4577
   Rasmussen A, 2017, ACTA OPHTHALMOL, V95, P128, DOI 10.1111/aos.13233
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Senra H, 2016, GRAEF ARCH CLIN EXP, V254, P1873, DOI 10.1007/s00417-016-3384-0
   Sii S, 2018, EYE, V32, P673, DOI 10.1038/eye.2017.271
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Spooner KL, 2018, CLIN OPHTHALMOL, V12, P2483, DOI 10.2147/OPTH.S185052
   Subhi Y, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/7194927
   Varano M, 2015, CLIN OPHTHALMOL, V9, P2243, DOI 10.2147/OPTH.S92548
   Vaze A, 2014, RETINA-J RET VIT DIS, V34, P1774, DOI 10.1097/IAE.0000000000000173
   Westborg I, 2018, OPHTHAL EPIDEMIOL, V25, P176, DOI 10.1080/09286586.2017.1397701
   Wintergerst MWM, 2018, OPHTHALMOLOGE, V115, P1035, DOI 10.1007/s00347-017-0610-z
NR 54
TC 38
Z9 39
U1 4
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2021
VL 128
IS 2
BP 234
EP 247
DI 10.1016/j.ophtha.2020.07.060
EA JAN 2021
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PV3GY
UT WOS:000609880500013
PM 32763265
OA Bronze, Green Published
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Sridhar, J
   Hsu, J
   Shahlaee, A
   Garg, SJ
   Spirn, MJ
   Fineman, MS
   Vander, J
AF Sridhar, Jayanth
   Hsu, Jason
   Shahlaee, Abtin
   Garg, Sunir J.
   Spirn, Marc J.
   Fineman, Mitchell S.
   Vander, James
TI Topical Dorzolamide-Timolol With Intravitreous Anti-Vascular Endothelial
   Growth Factor for Neovascular Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID SYSTEMIC BETA-BLOCKERS; CHOROIDAL NEOVASCULARIZATION; ADRENERGIC SYSTEM;
   MOUSE MODEL; THERAPY; RANIBIZUMAB; EFFICACY; PHARMACOKINETICS;
   BEVACIZUMAB; COMBINATION
AB IMPORTANCE There is a subset of eyes with neovascular age-related macular degeneration (AMD) that have persistent exudation despite fixed-interval intravitreous anti-vascular endothelial growth factor (VEGF) injections.
   OBJECTIVE To evaluate the effect of topical dorzolamide hydrochloride-timolol maleate on anatomic and functional outcomes in eyes with neovascular AMD and incomplete response to anti-VEGF therapy.
   DESIGN, SETTING, AND PARTICIPANTS An exploratory, prospective single-arm interventional study at a tertiary referral academic private practice. Patients with neovascular AMD and persistent macular edema despite fixed-interval intravitreous anti-VEGF therapy were enrolled. Baseline spectral-domain optical coherence tomography and clinical data, including visual acuity and intraocular pressure, were obtained at enrollment and from one visit before enrollment. The study was performed at the Retina Service of Wills Eye Hospital and the offices of Mid Atlantic Retina from February 1, 2015, through September 30, 2015. Patients were followed up for at least 2 visits after enrollment. Central subfield thickness, maximum subretinal fluid height, and maximum pigment epithelial detachment height from spectral-domain optical coherence tomography were recorded at each visit.
   INTERVENTIONS Enrolled eyes received a regimen of topical dorzolamide-timolol twice daily and continued to receive the same intravitreous anti-VEGF therapy at the same interval as received before enrollment for the duration of the study.
   MAIN OUTCOMES AND MEASURES Change in central subfield thickness was the primary outcome measure. Changes in maximum subretinal fluid height, maximum pigment epithelial detachment height, and visual acuity were the secondary outcome measures.
   RESULTS Ten patients (10 eyes) completed the study. The mean age of the patients was 78.2 years (age range, 65-91 years), and 6 were male. Eight eyes received intravitreous aflibercept, and 2 eyes received intravitreous ranibizumab. All study eyes had been receiving long-term anti-VEGF therapy with the same medication before study enrollment for a mean of 21.9 injections. The mean central subfield thickness decreased from 419.7 mu m at enrollment to 334.1 mu m at the final visit (P =.01). The mean maximum subretinal fluid height decreased from 126.6 mu m at enrollment to 49.5 mu m at the final visit (P =.02). The mean maximum pigment epithelial detachment height decreased from 277.4 mu m at enrollment to 239.9 mu m at the final visit (P =.12). The mean logMAR visual acuity were 0.54 at enrollment and 0.48 at the final visit (P =.60).
   CONCLUSIONS AND RELEVANCE These data suggest that topical dorzolamide-timolol may reduce central subfield thickness and subretinal fluid in eyes with persistent exudation despite consistent, fixed-interval intravitreous anti-VEGF treatment for neovascular AMD.
C1 [Sridhar, Jayanth; Hsu, Jason; Shahlaee, Abtin; Garg, Sunir J.; Spirn, Marc J.; Fineman, Mitchell S.; Vander, James] Thomas Jefferson Univ, Retina Serv, Wills Eye Hosp, Mid Atlantic Retina, 840 Walnut St,Ste 1020, Philadelphia, PA 19107 USA.
C3 Jefferson University
RP Hsu, J (通讯作者)，Thomas Jefferson Univ, Retina Serv, Wills Eye Hosp, Mid Atlantic Retina, 840 Walnut St,Ste 1020, Philadelphia, PA 19107 USA.
EM jhsu@midatlanticretina.com
FU J. Arch McNamara, MD, Fund for Retina Research and Education at Wills
   Eye Hospital
FX This study was funded in part by the J. Arch McNamara, MD, Fund for
   Retina Research and Education at Wills Eye Hospital.
CR Adijanto J, 2009, J GEN PHYSIOL, V133, P603, DOI 10.1085/jgp.200810169
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Barthelmes D, 2015, BRIT J OPHTHALMOL, V99, P359, DOI 10.1136/bjophthalmol-2014-305514
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brubaker RF, 2000, OPHTHALMOLOGY, V107, P283, DOI 10.1016/S0161-6420(99)00044-5
   Byeon SH, 2009, GRAEF ARCH CLIN EXP, V247, P35, DOI 10.1007/s00417-008-0917-1
   Casini G, 2014, PROG RETIN EYE RES, V42, P103, DOI 10.1016/j.preteyeres.2014.06.001
   Ersoy L, 2014, GRAEF ARCH CLIN EXP, V252, P889, DOI 10.1007/s00417-013-2519-9
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Genead MA, 2012, RETINA-J RET VIT DIS, V32, P826, DOI 10.1097/IAE.0b013e3182215ae9
   Genead MA, 2010, ARCH OPHTHALMOL-CHIC, V128, P1146, DOI 10.1001/archophthalmol.2010.172
   Genead MA, 2010, ARCH OPHTHALMOL-CHIC, V128, P190, DOI 10.1001/archophthalmol.2009.398
   General Assembly of the World Medical Association, 2014, J Am Coll Dent, V81, P14
   Gomi F, 2012, RETINA-J RET VIT DIS, V32, P1804, DOI 10.1097/IAE.0b013e31825be87f
   Grover S, 2006, AM J OPHTHALMOL, V141, P850, DOI 10.1016/j.ajo.2005.12.030
   Hanout M, 2015, CURR OPIN OPHTHALMOL, V26, P149, DOI 10.1097/ICU.0000000000000153
   Harris A, 2003, BRIT J OPHTHALMOL, V87, P753, DOI 10.1136/bjo.87.6.753
   Harris A, 2001, AM J OPHTHALMOL, V132, P490, DOI 10.1016/S0002-9394(01)01158-8
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Klein R, 2014, OPHTHALMOLOGY, V121, P1604, DOI 10.1016/j.ophtha.2014.03.005
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Lavine JA, 2013, JAMA OPHTHALMOL, V131, P376, DOI 10.1001/jamaophthalmol.2013.1476
   Martini D, 2011, J NEUROCHEM, V119, P1317, DOI 10.1111/j.1471-4159.2011.07530.x
   Montero JA, 2013, RETINA-J RET VIT DIS, V33, P508, DOI 10.1097/IAE.0b013e3182695ba0
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Noergaard MH, 2008, INVEST OPHTH VIS SCI, V49, P1136, DOI 10.1167/iovs.07-0508
   Remky A, 2005, ACTA OPHTHALMOL SCAN, V83, P154, DOI 10.1111/j.1600-0420.2005.00406.x
   Ristori C, 2011, INVEST OPHTH VIS SCI, V52, P155, DOI 10.1167/iovs.10-5536
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Stewart MW, 2007, RETINA-J RET VIT DIS, V27, P1196, DOI 10.1097/IAE.0b013e318158ea28
   Terashima H, 1996, JPN J OPHTHALMOL, V40, P142
   Thomas AS, 2015, RETINA-J RET VIT DIS, V35, P1964, DOI 10.1097/IAE.0000000000000603
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Veritti D, 2013, J OCUL PHARMACOL TH, V29, P437, DOI 10.1089/jop.2012.0173
   Witkin AJ, SEMIN OPHTHALMOL
   Zhu MD, 2015, GRAEF ARCH CLIN EXP, V253, P1217, DOI 10.1007/s00417-014-2799-8
NR 39
TC 16
Z9 16
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD APR
PY 2016
VL 134
IS 4
BP 437
EP 443
DI 10.1001/jamaophthalmol.2016.0045
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DJ1UA
UT WOS:000373988900021
PM 26914218
OA Bronze
DA 2022-11-30
ER

PT J
AU Patnaik, JL
   Lynch, AM
   Pecen, PE
   Jasso, M
   Hanson, K
   Mathias, MT
   Palestine, AG
   Mandava, N
AF Patnaik, Jennifer L.
   Lynch, Anne M.
   Pecen, Paula E.
   Jasso, Maria
   Hanson, Kara
   Mathias, Marc T.
   Palestine, Alan G.
   Mandava, Naresh
TI The impact of advanced age-related macular degeneration on the National
   Eye Institute's Visual Function Questionnaire-25
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age&#8208; related macular degeneration; choroidal neovascularization;
   geographic atrophy; visual function questionnaire
ID QUALITY-OF-LIFE; RESPONSIVENESS; RANIBIZUMAB; ACUITY
AB Purpose To assess visual function among patients diagnosed with age-related macular degeneration (AMD) by stage of disease and laterality.
   Methods This is a cross-sectional cohort study of 739 AMD patients and their responses to the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) at time of study enrolment. Patients with AMD were categorized into Early/Intermediate AMD and three groups of advanced AMD: (i) neovascular AMD (NV), (ii) geographic atrophy (GA) and (iii) Both Advanced forms. These three advanced stages were further stratified into unilateral or bilateral advanced disease. Mean composite scores and subscale scores for 12 different areas were based on a 100-point scale with the lowest and highest possible scores set at 0 and 100, respectively. Scores for the advanced AMD groups were compared with Early/Intermediate AMD using general linear modelling.
   Results A total of 739 AMD patients (294 Early/Intermediate, 115 GA, 168 NVAMD and 162 Both Advanced) were included in the analysis. Mean composite scores were highest among Early/Intermediate patients (89.9), followed by patients diagnosed with unilateral disease in the Both Advanced (88.0) and NV (86.1) groups. Mean composite scores were similar for bilateral NV (82.9) and unilateral GA (81.7), and mean scores were lowest for the bilateral GA (71.3) and bilateral Both Advanced (68.5) groups. In general, this pattern persisted across the twelve subscales as well. Subscale scores ranged from a low of 35.1 for driving among bilateral Both Advanced patients to a high of 99.2 for colour vision among patients with unilateral Both Advanced. Overall, patients with unilateral advanced disease consistently had higher mean scores than their bilateral counterparts. The largest difference was 19.5 composite score points between the unilateral and bilateral Both Advanced groups, there was a difference of 10.4 points between the GA groups, and a relatively small difference of 3.2 points between the NV groups.
   Conclusions We found large differences in visual function as reported from the VFQ-25 across the different types of advanced stage AMD groups and number of eyes affected with advanced AMD. These findings demonstrate the importance of accounting for the type and number of eyes affected by advanced stage AMD.
C1 [Patnaik, Jennifer L.; Lynch, Anne M.; Pecen, Paula E.; Jasso, Maria; Hanson, Kara; Mathias, Marc T.; Palestine, Alan G.; Mandava, Naresh] Univ Colorado, Dept Ophthalmol, Sch Med, Mail Stop F731,1675 Aurora Court, Aurora, CO 80045 USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus
RP Patnaik, JL (通讯作者)，Univ Colorado, Dept Ophthalmol, Sch Med, Mail Stop F731,1675 Aurora Court, Aurora, CO 80045 USA.
EM Jennifer.Patnaik@cuanschutz.edu
OI Patnaik, Jennifer/0000-0002-0375-0187
FU Research to Prevent Blindness, Inc., New York, NY; Frederic C. Hamilton
   Macular Degeneration Center; Colorado Clinical&Translational Sciences
   Institute (CCSTI); Development and Informatics Service Center (DISC)
   from NIH/NCRR
FX Support from a grant to the Department of Ophthalmology from Research to
   Prevent Blindness, Inc., New York, NY, and the Frederic C. Hamilton
   Macular Degeneration Center and the Colorado Clinical&Translational
   Sciences Institute (CCSTI) with the Development and Informatics Service
   Center (DISC) from NIH/NCRR.
CR Bressler NM, 2013, OPHTHALMOLOGY, V120, P160, DOI 10.1016/j.ophtha.2012.07.027
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Coleman AL, 2010, AM J OPHTHALMOL, V150, P683, DOI 10.1016/j.ajo.2010.05.030
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2008, QUAL LIFE RES, V17, P559, DOI 10.1007/s11136-008-9327-4
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Inan S, 2019, SAO PAULO MED J, V137, P25, DOI 10.1590/1516-3180.2018.0195071218
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Lynch AM, 2019, RETINA-J RET VIT DIS, V39, P656, DOI 10.1097/IAE.0000000000002023
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Orr P, 2011, INVEST OPHTH VIS SCI, V52, P3354, DOI 10.1167/iovs.10-5645
   Patnaik JL, 2020, OPHTHAL EPIDEMIOL, V27, P148, DOI 10.1080/09286586.2019.1701041
   Patnaik JL, 2019, OPHTHALMOL RETINA, V3, P336, DOI 10.1016/j.oret.2018.11.004
   Paulus YM, 2017, QUAL LIFE RES, V26, P2139, DOI 10.1007/s11136-017-1547-z
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Revicki DA, 2010, INVEST OPHTH VIS SCI, V51, P712, DOI 10.1167/iovs.09-3766
   Roh M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196481
   Suner IJ, 2009, INVEST OPHTH VIS SCI, V50, P3629, DOI 10.1167/iovs.08-3225
   Ugurlu SK, 2017, EYE, V31, P395, DOI 10.1038/eye.2016.219
   van Asten F, 2015, ACTA OPHTHALMOL, V93, P126, DOI 10.1111/aos.12610
   Zhou LX, 2016, CLIN INTERV AGING, V11, P215, DOI 10.2147/CIA.S102213
NR 23
TC 6
Z9 6
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2021
VL 99
IS 7
BP 750
EP 755
DI 10.1111/aos.14731
EA DEC 2020
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WD6YR
UT WOS:000603413800001
PM 33377625
DA 2022-11-30
ER

PT J
AU Chiu, CJ
   Conley, YP
   Gorin, MB
   Gensler, G
   Lai, CQ
   Shang, F
   Taylor, A
AF Chiu, Chung-Jung
   Conley, Yvette P.
   Gorin, Michael B.
   Gensler, Gary
   Lai, Chao-Qiang
   Shang, Fu
   Taylor, Allen
TI Associations between Genetic Polymorphisms of Insulin-like Growth Factor
   Axis Genes and Risk for Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID FACTOR-BINDING PROTEIN-1; DIETARY GLYCEMIC INDEX; BREAST-CANCER RISK; I
   IGF-I; CIRCULATING LEVELS; ENDOTHELIAL-CELLS; IGFBP-3 LEVELS; RECEPTOR;
   EXPRESSION; SERUM
AB PURPOSE. To investigate whether insulin-like growth factor (IGF) axis genes, together with a novel dietary risk factor, the dietary glycemic index (dGI), and body mass index (BMI) affect the risk for age-related macular degeneration (AMD).
   METHODS. This case-control study involved 962 subjects originally recruited through the Age-Related Eye Disease Study (AREDS) Genetic Repository. After those with missing covariates or invalid calorie intake (n = 23), diabetes (n = 59), and non-Caucasian race (n = 16) were excluded, 864 participants were used, including 209 AREDS category 1 participants (control group), 354 category 2 or 3 participants (drusen group), and 301 category 4 participants (advanced AMD group). A total of 25 single-nucleotide polymorphisms (SNPs) selected from IGF-1 (n = 9), IGF-2 (n = 1), IGF binding protein 1 (IGFBP1; n = 3), IGFBP3 (n = 3), acid-labile subunit of IGFBP (IGFALS; n = 2), IGF1 receptor (IGF1R; n = 4), and IGF2R (n = 3) were genotyped. SNP-AMD associations were measured with geno-type, allele chi(2) tests and Armitage's trend test. Odds ratios (OR), 95% confidence intervals (CIs), and SNP-exposure interactions were evaluated by multivariate logistic regression.
   RESULTS. One SNP (rs2872060) in IGF1R revealed a significant association with advanced AMD (P-allele = 0.0009, P-trend = 0.0008; the significance level was set at 0.05/25 = 0.002 for multiple comparisons). The risk allele (G) in the heterozygous and homozygous states (OR, 1.67 and 2.93; 95% CI, 1.03-2.71 and 1.60-5.36, respectively) suggests susceptibility and an additive effect on AMD risk. Further stratification analysis remained significant for both neovascularization (OR, 1.49 and 2.61; 95% CI, 0.90-2.48 and 1.39-4.90, respectively) and geographic atrophy (OR, 2.57 and 4.52; 95% CI, 0.99-6.71 and 1.49-13.74, respectively). The G allele interaction analysis with BMI was significant for neovascularization (P = 0.042) but not for geographic atrophy (P = 0.47). No significant interaction was found with dGI.
   CONCLUSIONS. These data suggest a role of IGF1R on the risk for advanced AMD in this group of subjects. (Invest Ophthalmol Vis Sci. 2011;52:9099-9107) DOI: 10.1167/iovs.11-7782
C1 [Chiu, Chung-Jung; Lai, Chao-Qiang; Shang, Fu; Taylor, Allen] Tufts Univ, USDA, Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
   [Conley, Yvette P.] Univ Pittsburgh, Sch Nursing, Dept Hlth Promot & Dev, Pittsburgh, PA 15261 USA.
   [Conley, Yvette P.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
   [Gorin, Michael B.] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Gensler, Gary] Emmes Corp, AREDS Coordinating Ctr, Rockville, MD USA.
C3 Tufts University; United States Department of Agriculture (USDA);
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; University of California System;
   University of California Los Angeles; University of California Los
   Angeles Medical Center; David Geffen School of Medicine at UCLA; Emmes
   Corporation
RP Chiu, CJ (通讯作者)，Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.
EM cj.chiu@tufts.edu; allen.taylor@tufts.edu
OI Lai, Chao-Qiang/0000-0003-1107-8375; Conley, Yvette/0000-0002-1784-6067
FU U.S. Department of Agriculture [1950-5100-060-01A]; National Institutes
   of Health (NIH) [R01-13250, R01 21212, R03-EY014183-01A2, R01
   EY021826-01]; Johnson and Johnson; American Health Assistance
   Foundation; Ross Aging Initiative; NATIONAL EYE INSTITUTE [R01EY013250,
   R01EY021212, R03EY014183, R01EY021826] Funding Source: NIH RePORTER
FX Supported by the U.S. Department of Agriculture under agreement,
   1950-5100-060-01A (C-JC, AT); Grants R01-13250, R01 21212, and
   R03-EY014183-01A2 from the National Institutes of Health (NIH) (AT);
   grants from the Johnson and Johnson Focused Giving Program and American
   Health Assistance Foundation (AT), and the Ross Aging Initiative and NIH
   Grant R01 EY021826-01 (C-JC). The funding sources had no role in the
   design and conduct of the study; the collection, analysis, and
   interpretation of the data; or the preparation, review, and approval of
   the manuscript. Any opinions, findings, conclusions, or recommendations
   expressed in this publication are those of the authors and do not
   necessarily reflect the views or policies of the U. S. Department of
   Agriculture, nor does mention of trade names, commercial products, or
   organizations imply endorsement by the U. S. Government.
CR Adewoye AH, 2006, CLIN INFECT DIS, V43, P593, DOI 10.1086/506356
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anderson CD, 2011, CIRC-CARDIOVASC GENE, V4, P188, DOI 10.1161/CIRCGENETICS.110.957928
   Aoi N, 2010, HEREDITAS, V147, P215, DOI 10.1111/j.1601-5223.2010.02174.x
   ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775
   Beppu Y, 2005, CANCER RES, V65, P4775, DOI 10.1158/0008-5472.CAN-04-3332
   Brand-Miller JC, 2005, AM J CLIN NUTR, V82, P350, DOI 10.1093/ajcn/82.2.350
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Canzian F, 2006, BRIT J CANCER, V94, P299, DOI 10.1038/sj.bjc.6602936
   Chen JW, 2005, J CLIN ENDOCR METAB, V90, P366, DOI 10.1210/jc.2004-0039
   Cheng I, 2006, JNCI-J NATL CANCER I, V98, P123, DOI 10.1093/jnci/djj013
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2007, EXP EYE RES, V84, P229, DOI 10.1016/j.exer.2006.05.015
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Chiu CJ, 2009, OPHTHALMOLOGY, V116, P939, DOI 10.1016/j.ophtha.2008.12.025
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P880, DOI 10.1093/ajcn/83.4.880
   Chiu CJ, 2002, CANCER EPIDEM BIOMAR, V11, P646
   Chiu CJ, 2001, J DENT RES, V80, P2055, DOI 10.1177/00220345010800120601
   Cooper GM, 2007, NAT GENET, V39, pS22, DOI 10.1038/ng2054
   de la Monte SM, 2005, J ALZHEIMERS DIS, V7, P45
   Diaz-Rodriguez E, 2005, FEBS LETT, V579, P4020, DOI 10.1016/j.febslet.2005.06.016
   Economou MA, 2008, INVEST OPHTH VIS SCI, V49, P2620, DOI 10.1167/iovs.07-0742
   Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033
   Foster-Powell K, 2002, AM J CLIN NUTR, V76, P5, DOI 10.1093/ajcn/76.1.5
   Frystyk J, 2004, GROWTH HORM IGF RES, V14, P337, DOI 10.1016/j.ghir.2004.06.001
   Furstenberger G, 2002, LANCET ONCOL, V3, P298, DOI 10.1016/S1470-2045(02)00731-3
   GoodmanGruen D, 1997, AM J EPIDEMIOL, V145, P970, DOI 10.1093/oxfordjournals.aje.a009065
   GRANT MB, 1993, REGUL PEPTIDES, V48, P267, DOI 10.1016/0167-0115(93)90356-D
   GULER HP, 1987, NEW ENGL J MED, V317, P137, DOI 10.1056/NEJM198707163170303
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hall K., 1999, Journal of Endocrinological Investigation, V22, P48
   Harrela M, 1996, J CLIN INVEST, V98, P2612, DOI 10.1172/JCI119081
   Haurigot V, 2009, J BIOL CHEM, V284, P22961, DOI 10.1074/jbc.M109.014787
   Holzenberger M, 2004, EXP GERONTOL, V39, P1761, DOI 10.1016/j.exger.2004.08.017
   Hong Soon-Sun, 2004, Cancer Res Treat, V36, P343, DOI 10.4143/crt.2004.36.6.343
   Hong Y, 1997, J ENDOCRINOL, V153, P251, DOI 10.1677/joe.0.1530251
   Hupfeld CJ, 2007, ANNU REV PHYSIOL, V69, P561, DOI 10.1146/annurev.physiol.69.022405.154626
   Janssen JAMJL, 1998, CLIN ENDOCRINOL, V48, P471
   JENKINS DJA, 1981, AM J CLIN NUTR, V34, P362, DOI 10.1093/ajcn/34.3.362
   Juul A, 2003, GROWTH HORM IGF RES, V13, P113, DOI 10.1016/S1096-6374(03)00038-8
   Kaaks R, 2001, P NUTR SOC, V60, P91, DOI 10.1079/PNS200070
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Katz LEL, 2002, J CLIN ENDOCR METAB, V87, P2978, DOI 10.1210/jc.87.6.2978
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Kim JJ, 2002, GROWTH HORM IGF RES, V12, P84, DOI 10.1054/ghir.2002.0265
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kurinij N, 1998, INT C DIET ASS MEAS
   Lambooij AC, 2003, INVEST OPHTH VIS SCI, V44, P2192, DOI 10.1167/iovs.02-0410
   Larsson O, 2005, BRIT J CANCER, V92, P2097, DOI 10.1038/sj.bjc.6602627
   Le Marchand L, 2005, CANCER EPIDEM BIOMAR, V14, P1319, DOI 10.1158/1055-9965.EPI-04-0847
   Lee KW, 2002, J ENDOCRINOL, V175, P33, DOI 10.1677/joe.0.1750033
   MA J, 2010, PLOS ONE, V5
   Macdonald K, 2009, CANCER EPIDEMIOL, V33, P37, DOI 10.1016/j.canep.2009.04.014
   McCarty CA, 1996, B WORLD HEALTH ORGAN, V74, P353
   Messier Claude, 2005, Neural Plasticity, V12, P311, DOI 10.1155/NP.2005.311
   Miller BS, 2005, CANCER RES, V65, P10123, DOI 10.1158/0008-5472.CAN-05-2752
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Nielsen DM, 1999, GENET RES, V74, P271, DOI 10.1017/S0016672399004231
   Nyomba BLG, 1997, J CLIN ENDOCR METAB, V82, P2177, DOI 10.1210/jc.82.7.2177
   Oufattole M, 2006, ENDOCRINOLOGY, V147, P2138, DOI 10.1210/en.2005-1269
   Patel AV, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002578
   Poulaki V, 2004, AM J PATHOL, V165, P457, DOI 10.1016/S0002-9440(10)63311-1
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Rajpathak SN, 2009, DIABETES-METAB RES, V25, P3, DOI 10.1002/dmrr.919
   Rezgui D, 2009, J MOL ENDOCRINOL, V42, P341, DOI 10.1677/JME-08-0154
   Rosendahl AH, 2011, BREAST CANCER RES TR, V127, P785, DOI 10.1007/s10549-010-1277-1
   Rosenthal R, 2004, BIOCHEM BIOPH RES CO, V323, P1203, DOI 10.1016/j.bbrc.2004.08.219
   Ruberte J, 2004, J CLIN INVEST, V113, P1149, DOI 10.1172/JCI200419478
   Ryu E, 2010, MOL VIS, V16, P2811
   Sall JW, 2004, EXP EYE RES, V79, P465, DOI 10.1016/j.exer.2004.06.007
   Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001
   Sasieni PD, 1997, BIOMETRICS, V53, P1253, DOI 10.2307/2533494
   Spraul CW, 2002, GRAEF ARCH CLIN EXP, V240, P227, DOI 10.1007/s00417-002-0441-7
   Suga K, 2001, JPN J CANCER RES, V92, P127, DOI 10.1111/j.1349-7006.2001.tb01074.x
   Taverne CW, 2010, BREAST CANCER RES TR, V123, P843, DOI 10.1007/s10549-010-0778-2
   THISSEN JP, 1994, ENDOCR REV, V15, P80, DOI 10.1210/er.15.1.80
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Treins C, 2006, BIOCHEM BIOPH RES CO, V342, P1197, DOI 10.1016/j.bbrc.2006.02.088
   Treins C, 2005, MOL ENDOCRINOL, V19, P1304, DOI 10.1210/me.2004-0239
   Tsai FJ, 2003, J CLIN LAB ANAL, V17, P259, DOI 10.1002/jcla.10106
   Ukkola O, 2001, DIABETOLOGIA, V44, P2231, DOI 10.1007/s001250100034
   Ulbig M W, 1995, Ger J Ophthalmol, V4, P264
   Vaessen N, 2001, DIABETES, V50, P637, DOI 10.2337/diabetes.50.3.637
   Verhaeghe J, 1996, AM J OBSTET GYNECOL, V175, P1180, DOI 10.1016/S0002-9378(96)70025-X
   Weng CY, 2009, CURR EYE RES, V34, P867, DOI 10.3109/02713680903177890
   WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366
   WOLEVER TMS, 1994, AM J CLIN NUTR, V59, P1265, DOI 10.1093/ajcn/59.6.1265
   Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472
   ZAPF J, 1984, CLIN ENDOCRINOL META, V13, P3, DOI 10.1016/S0300-595X(84)80006-7
   Zavras AI, 2003, CANCER RES, V63, P296
   Zhao RH, 2009, MOL CARCINOGEN, V48, P982, DOI 10.1002/mc.20562
NR 94
TC 17
Z9 21
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2011
VL 52
IS 12
BP 9099
EP 9107
DI 10.1167/iovs.11-7782
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 856IB
UT WOS:000297631400044
PM 22058336
OA Green Published
DA 2022-11-30
ER

PT J
AU Tricco, AC
   Thomas, SM
   Lillie, E
   Veroniki, AA
   Hamid, JS
   Pham, B
   Lee, TH
   Agarwal, A
   Sharpe, JP
   Scott, A
   Warren, R
   Brahmbhatt, R
   Macdonald, E
   Janoudi, G
   Muni, RH
   Francisconi, CLM
   Richter, T
   Straus, SE
AF Tricco, Andrea C.
   Thomas, Sonia M.
   Lillie, Erin
   Veroniki, Areti Angeliki
   Hamid, Jemila S.
   Pham, Ba'
   Lee, Taehoon
   Agarwal, Arnav
   Sharpe, Jane P.
   Scott, Alistair
   Warren, Rachel
   Brahmbhatt, Ronak
   Macdonald, Erin
   Janoudi, Ghayath
   Muni, Rajeev H.
   Francisconi, Carolina L. M.
   Richter, Trevor
   Straus, Sharon E.
TI Anti-vascular endothelial growth factor therapy for age-related macular
   degeneration: a systematic review and network meta-analysis
SO SYSTEMATIC REVIEWS
LA English
DT Review
DE Ranibizumab; Bevacizumab; Aflibercept; Conbercept; Brolucizumab;
   Anti-vascular endothelial growth factor; Age-related macular
   degeneration
AB Background: The comparative safety and efficacy between anti-vascular endothelial growth factor agents (anti-VEGFs) and between combined therapies for patients with neovascular age-related macular degeneration (nAMD) is unclear. We conducted a systematic review to examine the comparative safety and efficacy anti-VEGFs for adults with nAMD.
   Methods: Studies were identified through MEDLINE, EMBASE, and Cochrane CENTRAL (inception to June 3, 2019), grey literature, and scanning reference lists. Two reviewers independently screened citations and full-text articles to identify randomized controlled trials (RCTs), extracted data, and appraised risk of bias. Pairwise random-effects meta-analysis and Bayesian network meta-analysis (NMA) were conducted. The primary outcomes were the proportion of patients experiencing moderate vision gain (>= 15 letters on the Early Treatment Diabetic Retinopathy Study chart) and the proportion of patients experiencing moderate vision loss (<= 15 letters).
   Results: After screening 3647 citations and 485 potentially relevant full-text articles, 92 RCTs with 24,717 patients were included. NMA (34 RCTs, 8809 patients, 12 treatments) showed small differences among anti-VEGFs in improving the proportion of patients with moderate vision gain, with the largest for conbercept versus broluczumab (OR 0.15, 95% CrI: 0.05-0.56), conbercept versus ranibizumab (OR 0.17, 95% CrI: 0.05-0.59), conbercept versus aflibercept (OR 0.19, 95% CrI: 0.06-0.65), and conbercept versus bevacizumab (OR 0.2, 95% CrI: 0.06-0.69). In NMA (36 RCTs, 9081 patients, 13 treatments) for the proportion of patients with moderate vision loss, small differences were observed among anti-VEGFs, with the largest being for conbercept versus aflibercept (OR 0.24, 95% CrI: 0-4.29), conbercept versus brolucizumab (OR 0.24, 95% CrI: 0-4.71), conbercept versus bevacizumab (OR 0.26, 95% CrI: 0-4.65), and conbercept versus ranibizumab (OR 0.27, 95% CrI: 0-4.67).
   Conclusion: The only observed differences were that ranibizumab, bevacizumab, aflibercept, and brolucizumab were statistically superior to conbercept in terms of the proportion of patients with nAMD who experienced moderate vision gain. However, this finding is based on indirect evidence through one small trial comparing conbercept with placebo. This does not account for drug-specific differences when assessing anatomic and functional treatment efficacy in variable dosing regimens.
C1 [Tricco, Andrea C.; Thomas, Sonia M.; Lillie, Erin; Veroniki, Areti Angeliki; Pham, Ba'; Lee, Taehoon; Sharpe, Jane P.; Scott, Alistair; Warren, Rachel; Brahmbhatt, Ronak; Macdonald, Erin; Straus, Sharon E.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Knowledge Translat Program, Unity Hlth Toronto, 209 Victoria St,East Bldg, Toronto, ON M5B 1T8, Canada.
   [Tricco, Andrea C.] Univ Toronto, Dalla Lana Sch Publ Hlth, Div Epidemiol, 155 Coll St,Room 500, Toronto, ON M5T 3M7, Canada.
   [Tricco, Andrea C.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Dalla Lana Sch Publ Hlth, 155 Coll St,Room 500, Toronto, ON M5T 3M7, Canada.
   [Tricco, Andrea C.] Queens Univ, Queens Collaborat Hlth Care Qual Joanna Briggs In, Ctr Excellence, Sch Nursing, Kingston, ON K7L 3N6, Canada.
   [Veroniki, Areti Angeliki] Univ Ioannina, Sch Educ, Dept Primary Educ, Ioannina 45500, Mpizani, Greece.
   [Veroniki, Areti Angeliki] Imperial Coll, Dept Surg & Canc, Fac Med, Inst Reprod & Dev Biol, Exhibit Rd, London SW7 2BU, England.
   [Hamid, Jemila S.] Univ Ottawa, Dept Math & Stat, 150 Louis Pasteur Pvt, Ottawa, ON K1N 6N5, Canada.
   [Agarwal, Arnav] McMaster Univ, Dept Clin Epidemiol & Biostat, 1280 Main St West, Hamilton, ON L8S 4K1, Canada.
   [Agarwal, Arnav] Univ Toronto, Dept Med, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.
   [Macdonald, Erin] Univ Toronto, Inst Hlth Policy Management & Evaluat, 6th Floor,155 Coll St, Toronto, ON M5T 3M7, Canada.
   [Janoudi, Ghayath; Richter, Trevor] Canadian Agcy Drugs & Technol Hlth CADTH, 865 Carling Ave, Ottawa, ON K1S 5S8, Canada.
   [Muni, Rajeev H.; Francisconi, Carolina L. M.] Univ Toronto, Dept Ophthalmol & Vis Sci, St Michaels Hosp, Unity Hlth Toronto, Toronto, ON, Canada.
   [Straus, Sharon E.] Univ Toronto, Dept Geriatr Med, 27 Kings Coll Circle, Toronto, ON M5S 1A1, Canada.
C3 University of Toronto; Li Ka Shing Knowledge Institute; University
   Toronto Affiliates; Saint Michaels Hospital Toronto; University of
   Toronto; University of Toronto; Queens University - Canada; University
   of Ioannina; Imperial College London; University of Ottawa; McMaster
   University; University of Toronto; University of Toronto; University of
   Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto;
   University of Toronto
RP Tricco, AC (通讯作者)，Queens Univ, Queens Collaborat Hlth Care Qual Joanna Briggs In, Ctr Excellence, Sch Nursing, Kingston, ON K7L 3N6, Canada.
EM Andrea.Tricco@unityhealth.to
RI Agarwal, Arnav/J-1553-2014; Tricco, Andrea/B-9920-2011
OI Agarwal, Arnav/0000-0002-0931-7851; Tricco, Andrea/0000-0002-4114-8971
FU Canadian Institutes for Health Research/Drug Safety and Effectiveness
   Network (CIHR DSEN) MAGIC grant [DMC-166263]; Tier 1 Canada Research
   Chair in Knowledge Translation; Tier 2 Canada Research Chair in
   Knowledge Synthesis; European Union's Horizon 2020 [754936]
FX This work was supported by the Canadian Institutes for Health
   Research/Drug Safety and Effectiveness Network (CIHR DSEN) MAGIC grant
   (grant #DMC-166263). SES is funded by a Tier 1 Canada Research Chair in
   Knowledge Translation and ACT is funded by a Tier 2 Canada Research
   Chair in Knowledge Synthesis. AAV was funded from the European Union's
   Horizon 2020 [No. 754936].
CR AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   American Academy of Ophthalmology Retina/Vitreous Panel, 2015, PREF PRACT PATT GUID
   [Anonymous], 2021, LANCET GLOB HEALTH, V9, P160
   [Anonymous], 2018, AGE RELATED MACULAR
   [Anonymous], 2016, CADTH THERAPEUTIC RE, V3
   Bayer, 2015, VEGF TRAP EYE INVEST
   Chaimani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076654
   Chan AW, 2005, BMJ-BRIT MED J, V330, P753, DOI 10.1136/bmj.38356.424606.8F
   Del Giovane C, 2013, STAT MED, V32, P25, DOI 10.1002/sim.5512
   Evans JR, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001775.pub2
   Evans JR, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004004.pub3
   Fadda V, 2011, BRIT J OPHTHALMOL, V95, P1476, DOI 10.1136/bjophthalmol-2011-300316
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Furukawa TA, 2006, J CLIN EPIDEMIOL, V59, P7, DOI 10.1016/j.jclinepi.2005.06.006
   Geltzer A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005022.pub3
   Greene W.H., 2012, ECONOMETRIC ANAL, V7th
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Guyer DR, 1997, ARCH OPHTHALMOL-CHIC, V115, P865
   Haddaway NR, 2018, ENVIRON EVID, V7, DOI [10.1186/s13750-018-0140-4, 10.1186/s13750-018-0121-7]
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Knowledge Translation Program, 2014, SYNTHESISR
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Littell J.H., 2008, SYSTEMATIC REV METAA
   Lunn D, 2009, STAT MED, V28, P3049, DOI 10.1002/sim.3680
   Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3
   McGowan J, 2016, J CLIN EPIDEMIOL, V75, P40, DOI 10.1016/j.jclinepi.2016.01.021
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1186/2046-4053-4-1, 10.1136/bmj.b2535, 10.1136/bmj.i4086]
   National Institute for Health and Clinical Excellence (NICE), 2004, RAD AG REL MAC DEG I
   Nikolakopoulou A, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003082
   Oklahoma State University Center for Health Sciences, 2012, RED FLUEN PHOT THER
   Papakonstantinou T, 2020, CAMPBELL SYST REV, V16, DOI 10.1002/cl2.1080
   QLT Inc, 2011, REDUCED FLUENCE VISU
   Reddy U, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005138.pub2
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Riley RD, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d549
   Robson RC, 2019, J CLIN EPIDEMIOL, V106, P121, DOI 10.1016/j.jclinepi.2018.10.003
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Rouse B, 2017, INTERN EMERG MED, V12, P103, DOI 10.1007/s11739-016-1583-7
   Salanti G, 2011, J CLIN EPIDEMIOL, V64, P163, DOI 10.1016/j.jclinepi.2010.03.016
   Schmid-Kubista KE, 2011, CURR EYE RES, V36, P958, DOI 10.3109/02713683.2011.597536
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Sterne J., 2016, META ANAL STATA UPDA
   Trinquart L, 2016, ANN INTERN MED, V164, P666, DOI 10.7326/M15-2521
   Turner RM, 2012, INT J EPIDEMIOL, V41, P818, DOI 10.1093/ije/dys041
   Veroniki AA, 2018, J CLIN EPIDEMIOL, V100, P122, DOI 10.1016/j.jclinepi.2018.02.009
   Veroniki AA, 2016, J CLIN EPIDEMIOL, V76, P193, DOI 10.1016/j.jclinepi.2016.02.016
NR 47
TC 1
Z9 1
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2046-4053
J9 SYST REV-LONDON
JI Syst. Rev.
PD DEC 20
PY 2021
VL 10
IS 1
AR 315
DI 10.1186/s13643-021-01864-6
PG 15
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA XQ9NF
UT WOS:000731866800001
PM 34930439
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hariri, A
   Nittala, MG
   Sadda, SR
AF Hariri, Amirhossein
   Nittala, Muneeswar G.
   Sadda, SriniVas R.
TI Outer Retinal Tubulation as a Predictor of the Enlargement Amount of
   Geographic Atrophy in Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL-COHERENCE-TOMOGRAPHY; PROGRESSION; EPITHELIUM; EYES
AB Purpose: To determine the prognostic value of outer retinal tubulation (ORT) in the enlargement amount of geographic atrophy (GA) in eyes with age-related macular degeneration (AMD).
   Design: Cohort study.
   Participants: One hundred eight fellow untreated eyes of 143 patients with GA resulting from AMD enrolled in the MAHALO study (clinicaltrials. gov identifier, NCT01229215) who completely satisfied the study term and had gradable spectral-domain optical coherence tomography (OCT) images obtained at both baseline and month 18 visits.
   Methods: The MAHALO study enrolled 143 subjects into a phase 1b/2 multicenter, randomized, single-masked, sham-injection controlled clinical trial of the safety, tolerability, and evidence of activity of lampalizumab in patients with GA associated with AMD. Spectral-domain optical coherence tomography images were obtained at multiple time points in both eyes, although only the baseline and month 18 data of the fellow (nonstudy) eyes were considered in this exploratory analysis. The Cirrus HD-OCT review software was used for automatic segmentation and measurement of GA areas, with manual correction of segmentation errors by certified OCT graders. Baseline OCT images also were assessed for the presence of ORT. The enlargement amount of GA in eyes with ORT was compared with that of eyes without ORT.
   Main Outcome Measures: Comparison of the enlargement amount of GA in eyes with and without ORT.
   Results: Twenty-four of these 108 eyes demonstrated evidence of ORT. The amount of enlargement of GA in eyes with ORT was significantly slower than that of eyes without ORT (1.85 +/- 0.78 vs. 2.67 +/- 1.61; P = 0.001). This difference remained significant when considering subgroups with unifocal or multifocal GA lesions, because eyes with ORT in both subgroups had a slower enlargement amount of GA than eyes without ORT (2.91 +/- 1.70 vs. 2.08 +/- 0.88 [P = 0.01], in eyes with multifocal GA lesions; and 2.24 +/- 1.40 vs. 1.63 +/- 0.57 [P = 0.02], in eyes with unifocal GA lesions).
   Conclusions: In eyes with ORT, GA lesions seem to enlarge at a significantly slower rate than those of eyes without ORT. The presence of ORT may need to be accounted for in longitudinal studies of GA. (C) 2015 by the American Academy of Ophthalmology.
C1 [Hariri, Amirhossein; Nittala, Muneeswar G.; Sadda, SriniVas R.] Doheny Eye Inst, Doheny Image Reading Ctr, Los Angeles, CA 90033 USA.
   [Hariri, Amirhossein; Nittala, Muneeswar G.; Sadda, SriniVas R.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
C3 Doheny Eye Institute; University of Southern California
RP Sadda, SR (通讯作者)，Univ So Calif, Keck Sch Med, Dept Ophthalmol, 1450 San Pablo St,DEI 3623, Los Angeles, CA 90033 USA.
EM ssadda@doheny.org
RI Nittala, Muneeswar/AAT-7533-2020; Mitchell, Paul/P-1498-2014
FU Carl Zeiss Meditec, Inc., Dublin, CA; Optos Inc., Dunfermline, UK;
   Optovue, Inc., Fremont, CA; Genentech, Inc., South San Francisco,
   California
FX The author(s) have made the following disclosure(s): S.R.S.: Consultant
   - Genentech, Inc., South San Francisco, CA; Regeneron, Inc., Tarrytown,
   New York; and Allergan, Inc., Irvine, CA; Financial support - Carl Zeiss
   Meditec, Inc., Dublin, CA; Optos Inc., Dunfermline, UK; and Optovue,
   Inc., Fremont, CA; Scientific advisory board - Heidelberg Engineering,
   Heidelberg, Germany; Co-inventor of Doheny intellectual property related
   to optical coherence tomography - licensed by Topcon Medical Systems
   (Tokyo, Japan).; Genentech, Inc., South San Francisco, California, is
   the sponsor of the MAHALO study (clincialtrials.gov identifier,
   NCT01229215).
CR Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Gamulescu MA, 2010, J OCUL PHARMACOL TH, V26, P213, DOI 10.1089/jop.2009.0126
   Goldberg NR, 2013, RETINA-J RET VIT DIS, V33, P1871, DOI 10.1097/IAE.0b013e318296b12f
   Hanhart J, 2014, EYE, V28, P646, DOI 10.1038/eye.2014.94
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Iriyama Aya, 2013, Retina, V33, P1462, DOI 10.1097/IAE.0b013e31828221ae
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Wolff B, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/542417
   Wolff B, 2011, ACTA OPHTHALMOL, V89, pE496, DOI 10.1111/j.1755-3768.2011.02144.x
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 16
TC 42
Z9 46
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2015
VL 122
IS 2
BP 407
EP 413
DI 10.1016/j.ophtha.2014.08.035
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AZ5WT
UT WOS:000348290000034
PM 25315664
DA 2022-11-30
ER

PT J
AU Arnold, C
   Winter, L
   Frohlich, K
   Jentsch, S
   Dawczynski, J
   Jahreis, G
   Bohm, V
AF Arnold, Christin
   Winter, Lisa
   Froehlich, Kati
   Jentsch, Susanne
   Dawczynski, Jens
   Jahreis, Gerhard
   Boehm, Volker
TI Macular Xanthophylls and omega-3 Long-Chain Polyunsaturated Fatty Acids
   in Age-Related Macular Degeneration A Randomized Trial
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT OPTICAL-DENSITY; SERUM CONCENTRATIONS; ANTIOXIDANT CAPACITY;
   VITAMIN-E; LUTEIN; CAROTENOIDS; ZEAXANTHIN; PLASMA; RISK; TOCOPHEROLS
AB Importance: It has been shown that the functionality of the macula lutea depends on the nutritional uptake of lutein and zeaxanthin and that it is inversely associated with the risk of age-related macular degeneration (AMD). Additionally, omega-3 long-chain polyunsaturated fatty acids (LC-PUFAs) may also be protective.
   Objective: To investigate the effect of a 12-month intervention with macular xanthophylls and omega-3 LC-PUFAs on xanthophylls and fatty acids in plasma, antioxidant capacity, and optical density of the macular pigment of patients with nonexudative AMD.
   Design: The LUTEGA study was a randomized, double-blind, placebo-controlled, parallel clinical trial that was conducted for 12 months.
   Setting: University Eye Hospital and Institute of Nutrition, Friedrich Schiller University Jena, Germany.
   Participants: A total of 172 individuals with nonexudative AMD.
   Intervention: Individuals were enrolled and randomly divided as follows: placebo group, group 1 (a capsule containing 10 mg of lutein, 1 mg of zeaxanthin, 100 mg of docosahexaenoic acid, and 30 mg of eicosapentaenoic acid administered each day), and group 2 (same substances but twice the dose used in group 1). One hundred forty-five participants completed the study successfully.
   Main Outcome Measures: Plasma xanthophyll concentrations and fatty acid profiles, optical density of the macular pigment, and antioxidant capacity in plasma (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid [Trolox] equivalent antioxidant capacity and photochemiluminescence).
   Results: The concentrations of the administered carotenoids in plasma as well as the optical density of themacular pigment increased significantly in the groups randomized to receive supplementary macular xanthophylls and omega-3 LC-PUFAs after 1 month of intervention and remained at this level through the end of the study. Use of the double dose resulted in a beneficial alteration of the fatty acid profile in the plasma of patients with AMD in comparison with the dose in group 1. The lipophilic antioxidant capacity in plasma was significantly elevated with the intervention.
   Conclusions and Relevance: A supplement containing a fixed combination of lutein, zeaxanthin, and omega-3 LC-PUFAs during 12 months significantly improved plasma antioxidant capacity, circulating macular xanthophyll levels, and the optical density of the macular pigment.
   Trial Registration: clinicaltrials.gov Identifier: NCT00763659
C1 [Arnold, Christin; Winter, Lisa; Froehlich, Kati; Boehm, Volker] Univ Jena, Inst Nutr, Bioact Plant Prod Res Grp, D-07743 Jena, Germany.
   [Jahreis, Gerhard] Univ Jena, Inst Nutr, Dept Nutr Physiol, D-07743 Jena, Germany.
   [Jentsch, Susanne; Dawczynski, Jens] Univ Eye Hosp, Jena, Germany.
C3 Friedrich Schiller University of Jena; Friedrich Schiller University of
   Jena
RP Bohm, V (通讯作者)，Univ Jena, Inst Nutr, Dornburger Str 25-29, D-07743 Jena, Germany.
EM Volker.Boehm@uni-jena.de
FU Novartis GmbH, Germany; Carl Zeiss Meditec, Jena, Germany
FX The study was supported by Novartis GmbH, Germany, and Carl Zeiss
   Meditec, Jena, Germany.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Al-Delaimy WK, 2004, PUBLIC HEALTH NUTR, V7, P713, DOI 10.1079/PHN2004598
   Alves-Rodrigues A, 2004, TOXICOL LETT, V150, P57, DOI 10.1016/j.toxlet.2003.10.031
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   BOXENBAUM H, 1995, J CLIN PHARMACOL, V35, P763, DOI 10.1002/j.1552-4604.1995.tb04117.x
   BRITTON G, 2004, CAROTENOIDS HDB, V4, P61
   Broekmans WMR, 2002, AM J CLIN NUTR, V76, P595, DOI 10.1093/ajcn/76.3.595
   Calder PC, 2006, AM J CLIN NUTR, V83, p1505S, DOI 10.1093/ajcn/83.6.1505S
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Ciulla TA, 2001, OPHTHALMOLOGY, V108, P730, DOI 10.1016/S0161-6420(00)00655-2
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   Dawczynski J, 2011, KLIN MONATSBL AUGENH, V228, P57, DOI 10.1055/s-0029-1245353
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   Frohlich K, 2006, BRIT J NUTR, V95, P734, DOI 10.1079/BJN20051657
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Kuhnt K, 2011, EUR J LIPID SCI TECH, V113, P1281, DOI 10.1002/ejlt.201100037
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Lopez PM, 2003, EUR J CLIN NUTR, V57, pS22, DOI 10.1038/sj.ejcn.1601805
   MILLER NJ, 1993, CLIN SCI, V84, P407, DOI 10.1042/cs0840407
   Miller NJ, 1996, FEBS LETT, V384, P240, DOI 10.1016/0014-5793(96)00323-7
   Muller L, 2010, MOL NUTR FOOD RES, V54, P731, DOI 10.1002/mnfr.200900399
   Neuner B, 2009, ADDICT BEHAV, V34, P938, DOI 10.1016/j.addbeh.2009.05.015
   Olmedilla B, 1997, CANCER LETT, V114, P179, DOI 10.1016/S0304-3835(97)04656-9
   Parker RS, 1996, FASEB J, V10, P542, DOI 10.1096/fasebj.10.5.8621054
   Popov I, 1999, METHOD ENZYMOL, V300, P437
   Richer Stuart, 2007, Optometry, V78, P213, DOI 10.1016/j.optm.2006.10.019
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Schulze MB, 2001, ANN NUTR METAB, V45, P181, DOI 10.1159/000046727
   Schweitzer D, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3526358
   Scott KJ, 1996, BRIT J NUTR, V75, P409, DOI 10.1079/BJN19960143
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Shao A, 2006, REGUL TOXICOL PHARM, V45, P289, DOI 10.1016/j.yrtph.2006.05.007
   Simonelli F, 2002, CLIN CHIM ACTA, V320, P111, DOI 10.1016/S0009-8981(02)00056-6
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Thurmann PA, 2005, AM J CLIN NUTR, V82, P88
   Thurnham DI, 2007, NUTR RES REV, V20, P163, DOI 10.1017/S0954422407842235
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   Tunon J, 2009, SURV OPHTHALMOL, V54, P339, DOI 10.1016/j.survophthal.2009.02.003
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 43
TC 39
Z9 39
U1 0
U2 20
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAY
PY 2013
VL 131
IS 5
BP 564
EP 572
DI 10.1001/jamaophthalmol.2013.2851
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 163JY
UT WOS:000320333300001
PM 23519529
DA 2022-11-30
ER

PT J
AU Yin, XB
   He, T
   Yang, SS
   Cui, H
   Jiang, WL
AF Yin, Xiaobei
   He, Ting
   Yang, Shanshan
   Cui, Hui
   Jiang, Wenlan
TI Efficacy and Safety of Antivascular Endothelial Growth Factor
   (Anti-VEGF) in Treating Neovascular Age-Related Macular Degeneration
   (AMD): A Systematic Review and Meta-analysis
SO JOURNAL OF IMMUNOLOGY RESEARCH
LA English
DT Review
ID PHOTODYNAMIC THERAPY; DIABETIC-RETINOPATHY; RANIBIZUMAB; BEVACIZUMAB;
   TRIAL; INFLAMMATION; VERTEPORFIN; PREVALENCE; OUTCOMES
AB This study is aimed at assessing the efficacy and safety of antivascular endothelial growth factor (anti-VEGF) inhibitors in treating age-related macular degeneration (AMD). PubMed, Embase, and Cochrane library were searched. Weighted mean difference (WMD) and relative risk (RR) with 95% confidence interval (CI) were applied to assess outcomes. Eighteen randomized controlled trials involved 8,847 neovascular AMD patients were selected for the meta-analysis. Pegaptanib (WMD: 6.70; P < 0.001) and ranibizumab (WMD: 17.80; P < 0.001) were associated with greater BCVA changes than control after 1 year. Bevacizumab was linked with less changes in central macular thickness after 1 year compared to control (WMD: -38.50; P < 0.001), but more changes compared to ranibizumab (WMD: 10.69; P=0.024). The incidence of gain of 15 or more letter visual acuity after 1 year was increased when compared with bevacizumab versus control (RR: 7.80; P=0.001), pegaptanib versus control (RR: 2.83; P=0.015), and ranibizumab versus control (RR: 3.92; P=0.003). Moreover, ranibizumab was associated with more BCVA changes and an increased incidence of gain of 15 or more letter visual acuity after 2 years compared with control (RR: 5.77; P < 0.001). This study found that most anti-VEGF inhibitors provided better efficacy than non-anti-VEGF intervention, and the treatment effectiveness among various anti-VEGF agents was equally effective.
C1 [Yin, Xiaobei; Yang, Shanshan; Jiang, Wenlan] Affiliated Hosp Qingdao Univ, Dept Ophthalmol, Qingdao 266003, Shandong, Peoples R China.
   [He, Ting] Beijing Puren Hosp, Beijing 100010, Peoples R China.
   [Cui, Hui] Peoples Liberat Army Gen Hosp, Med Ctr 3, Sr Dept Ophthalmol, Beijing 100039, Peoples R China.
C3 Qingdao University; Chinese People's Liberation Army General Hospital
RP Yin, XB (通讯作者)，Affiliated Hosp Qingdao Univ, Dept Ophthalmol, Qingdao 266003, Shandong, Peoples R China.
EM yxb_0926@163.com; yingyuanting2021@163.com; sherry1216@163.com;
   961790407@qq.com; wenlan7@126.com
FU Natural Science Foundation of Shandong Province [ZR2018BH013]; China
   Postdoctoral Science Foundation [2017M612214]
FX AcknowledgmentsThis work was supported by the Natural Science Foundation
   of Shandong Province (grant number ZR2018BH013) and the China
   Postdoctoral Science Foundation (grant number 2017M612214).
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   Ades AE, 2005, MED DECIS MAKING, V25, P646, DOI 10.1177/0272989X05282643
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Amano S, 1998, INVEST OPHTH VIS SCI, V39, P18
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bianchi E, 2015, FOLIA MORPHOL, V74, P33, DOI 10.5603/FM.2015.0006
   Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chen GH, 2015, RETINA-J RET VIT DIS, V35, P187, DOI 10.1097/IAE.0000000000000301
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Deeks JJ., 2020, COCHRANE HDB SYSTEMA, V1
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Feher J, 2018, INT J IMMUNOPATH PH, V31, DOI 10.1177/0394632017748841
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   MALECAZE F, 1994, ARCH OPHTHALMOL-CHIC, V112, P1476, DOI 10.1001/archopht.1994.01090230090028
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Nguyen CL, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0785-3
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sacu S, 2009, EYE, V23, P2223, DOI 10.1038/eye.2008.423
   Schauwvlieghe AME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153052
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Scholler A, 2014, WIEN KLIN WOCHENSCHR, V126, P355, DOI 10.1007/s00508-014-0539-z
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Scott AW, 2013, CURR OPIN OPHTHALMOL, V24, P190, DOI 10.1097/ICU.0b013e32835fefee
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Taurone S, 2020, EUR REV MED PHARMACO, V24, P10319, DOI 10.26355/eurrev_202010_23379
   Taurone S, 2019, IMMUNOL RES, V67, P280, DOI 10.1007/s12026-019-09087-7
   Tobias A., 1999, STATA TECH B, V47, P15
   Tolentino MJ, 2002, AM J OPHTHALMOL, V133, P373, DOI 10.1016/S0002-9394(01)01381-2
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 54
TC 0
Z9 0
U1 1
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-8861
EI 2314-7156
J9 J IMMUNOL RES
JI J Immunol. Res.
PD APR 15
PY 2022
VL 2022
AR 6004047
DI 10.1155/2022/6004047
PG 11
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 1W4LP
UT WOS:000806746800001
PM 35465351
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Rodrigo, F
   Ruiz-Moreno, JM
   Garcia, JB
   Torregrosa, ME
   Segura, JV
   Pinero, DP
AF Rodrigo, Fermin
   Maria Ruiz-Moreno, Jose
   Bernabe Garcia, Juan
   Eugenia Torregrosa, Maria
   Vicente Segura, Jose
   Pinero, David P.
TI Color Doppler imaging of the retrobulbar circulation and plasmatic
   biomarkers of vascular risk in age-related macular degeneration: A pilot
   study
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; B12 vitamin; color Doppler imaging;
   exudative age-related macular degeneration; folic acid; homocysteine
ID C-REACTIVE PROTEIN; CHOROIDAL BLOOD-FLOW; PRESSURE
AB Purpose: To evaluate preliminarily and compare the level of plasmatic biomarkers of vascular risk in patients with and without exudative age-related macular degeneration (ARMD) and to relate it to vascular resistance alterations in the ophthalmic artery (OA), central retinal artery (CRA), posterior temporal ciliary artery (PTCA), and posterior nasal ciliary artery (PNCA). Methods: Color Doppler imaging of the OA, CRA, PTCA, and PNCA was performed in 30 eyes of 30 cataract patients (control group) as well as in 30 eyes of 30 patients with naive exudative ARMD (study group), measuring the peak systolic velocity, end-diastolic velocity (EDV), and Pourcelot resistive index (RI). Likewise, in both groups, a blood test was performed to determine the plasmatic levels of homocysteine, C-reactive protein (CRP), B12 vitamin, and folic acid. Results: A positive and significant correlation was found between the level of CRP and RI of the OA in the ARMD group (r = 0.498, P = 0.005), with an increased RI in all arteries compared to controls, although differences only reached statistical significance for the PTCA (P = 0.035). Likewise, a significantly lower EDV for the CRA was found in ARMD eyes compared to controls (P = 0.041). In the study group, significantly higher plasmatic levels of homocysteine (P = 0.042) and CRP (P = 0.046) were found. In contrast, no significant differences were found between groups in the levels of folic acid (P = 0.265) and B12 vitamin (P = 0.520). Conclusion: The decrease of the choroidal perfusion related to hyperhomocysteinemia, and increase in the CRP plasmatic levels may play an etiological role on the exudative ARMD. This should be investigated in future studies with larger samples of patients.
C1 [Rodrigo, Fermin; Bernabe Garcia, Juan; Eugenia Torregrosa, Maria] Marina Baixa Hosp, Dept Ophthalmol, Villajoyosa, Spain.
   [Maria Ruiz-Moreno, Jose] Univ Castilla La Mancha, Ciudad Real, Spain.
   [Vicente Segura, Jose] Miguel Hernandez Univ, Ctr Operat Res, Elche, Spain.
   [Pinero, David P.] Univ Alicante, Dept Opt Pharmacol & Anat, Crta San Vicente Del Raspeig S-N, Alicante 03016, Spain.
C3 Universidad de Castilla-La Mancha; Universidad Miguel Hernandez de
   Elche; Universitat d'Alacant
RP Pinero, DP (通讯作者)，Univ Alicante, Dept Opt Pharmacol & Anat, Crta San Vicente Del Raspeig S-N, Alicante 03016, Spain.
EM david.pinyero@ua.es
RI Segura-Heras, José Vicente/ABC-3363-2020
OI Segura-Heras, José Vicente/0000-0002-0884-0472; Ruiz-Moreno, Jose
   M/0000-0001-9636-0788; Torregrosa Quesada, Maria
   Eugenia/0000-0003-4732-7177; Torregrosa,
   Jose-Vicente/0000-0001-5160-3248
FU Ministry of Economy and Competitiveness of Spain [MTM2014-56233-P]
FX The author J.V. Segura has been partially supported by the Ministry of
   Economy and Competitiveness of Spain, MTM2014-56233-P.
CR Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Cabrera AP, 2016, INVEST OPHTH VIS SCI, V57, P5910, DOI 10.1167/iovs.16-19727
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Colak E, 2011, OPHTHALMIC RES, V46, P125, DOI 10.1159/000323815
   Fitzgerald MEC, 2005, EXP EYE RES, V81, P478, DOI 10.1016/j.exer.2005.03.008
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Joshi MS, 2012, CARDIOVASC PATHOL, V21, P428, DOI 10.1016/j.carpath.2011.12.003
   Keles S, 2014, CLIN OPHTHALMOL, V8, P1573, DOI 10.2147/OPTH.S66160
   Leung H, 2003, INVEST OPHTH VIS SCI, V44, P2900, DOI 10.1167/iovs.02-1114
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Pelikant-Malecka I, 2015, PHARMACOL REP, V67, P818, DOI 10.1016/j.pharep.2015.03.020
   Rohrschneider K, 2012, OPHTHALMOLOGE, V109, P369, DOI 10.1007/s00347-012-2525-z
   Sandhu R, 2007, EYE, V21, P506, DOI 10.1038/sj.eye.6702242
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Yun C, 2016, INVEST OPHTH VIS SCI, V57, P6604, DOI 10.1167/iovs.16-19989
NR 20
TC 4
Z9 4
U1 0
U2 2
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD JAN
PY 2018
VL 66
IS 1
BP 89
EP 93
DI 10.4103/ijo.IJO_488_17
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FX8JP
UT WOS:000426338600018
PM 29283130
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kaiser, PK
   Blodi, BA
   Shapiro, H
   Acharya, NR
AF Kaiser, Peter K.
   Blodi, Barbara A.
   Shapiro, Howard
   Acharya, Nisha R.
CA MARINA Study Grp
TI Angiographic and optical coherence tomographic results of the MARINA
   study of ranibizumab in neovascular age-related macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR
AB Objective: To assess pharmacodynamic responses to ranibizumab, an inhibitor of vascular endothelial growth factor A (VEGF-A), in a study of the treatment of minimally classic or occult with no classic choroidal neovascularization secondary to age-related macular degeneration (AMD) (designated MARINA [Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD]) and to compare these responses with those in a sham-injection control group.
   Design: Retrospective (prespecified and ad hoc) analyses of 24-month data.
   Participants: Seven hundred sixteen patients, randomized to 0.3-mg ranibizumab (n = 238), 0.5-mg ranibizumab (n = 240), or a sham injection (n = 238).
   Methods: Stereoscopic fundus photography and fluorescein angiography (FA) were done at baseline and months 3, 6, 12, and 24. Optical coherence tomography (OCT) was performed at a subset of investigative sites (46 patients) at baseline, day 7, and months 1 and 12.
   Main Outcome Measures: Prespecified secondary end points were mean change from baseline in total area of choroidal neovascularization and total area of leakage from choroidal neovascularization at months 12 and 24. Prespecified exploratory FA end points included mean change from baseline in the areas of the choroidal neovascularization lesion and serous sensory retinal detachment (SSRD) at months 12 and 24. Post hoc exploratory FA outcome measures included the proportion of patients with no leakage from choroidal neovascularization and mean change from baseline over time in the area of subretinal fibrous tissue/disciform scar. The prespecified exploratory end point for OCT was mean change from baseline over time in center point thickness.
   Results: At 12 and 24 months, statistically significant benefits of ranibizumab over sham treatment were observed for mean change from baseline in the areas of choroidal neovascularization lesion, total choroidal neovascularization, leakage from choroidal neovascularization, SSRD, and disciform scar/subretinal fibrosis. At 12 months (final OCT), the mean change in foveal center point thickness on OCT was a significant decrease in the ranibizumab group compared with the sham group.
   Conclusions: Patients with minimally classic or occult with no classic neovascular AMD treated with ranibizumab demonstrated improvement that was consistent for visual acuity, FA, and OCT outcomes and superior to that in sham-treated patients.
C1 Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
   Univ Wisconsin, Fundus Photog Reading Ctr, Madison, WI USA.
   Genentech Inc, San Francisco, CA 94080 USA.
   Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA.
C3 Cleveland Clinic Foundation; University of Wisconsin System; University
   of Wisconsin Madison; Roche Holding; Genentech; University of California
   System; University of California San Francisco
RP Kaiser, PK (通讯作者)，Cleveland Clin Fdn, Cole Eye Inst, 9500 Euclid Ave,Desk I3, Cleveland, OH 44195 USA.
EM pkkaiser@aol.com
OI Kaiser, Peter/0000-0001-5126-045X
CR ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 10
TC 166
Z9 176
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2007
VL 114
IS 10
BP 1868
EP 1875
DI 10.1016/j.ophtha.2007.04.030
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 214XU
UT WOS:000249772500011
PM 17628683
DA 2022-11-30
ER

PT J
AU Park, SJ
   Lee, JH
   Ahn, S
   Park, KH
AF Park, Sang Jun
   Lee, Ju Hyun
   Ahn, Soyeon
   Park, Kyu Hyung
TI Cataract Surgery and Age-Related Macular Degeneration in the 2008-2012
   Korea National Health and Nutrition Examination Survey
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID RISK-FACTORS; BEAVER DAM; VISUAL IMPAIRMENT; EYE DISEASE; MACULOPATHY;
   ASSOCIATION; PREVALENCE
AB IMPORTANCE In the past, concern has been raised that cataract surgery may be associated with the incidence or progression of age-related macular degeneration (AMD); inconsistent findings from previous studies have puzzled clinicians. In addition, data addressing this association in Asian populations and in the era of phacoemulsification are scarce.
   OBJECTIVE To determine the associations between cataract surgery and AMD in a representative Korean population.
   DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study used a multistage, probability-cluster survey sample to produce nationally representative estimates. Data were analyzed from the Korea National Health and Nutrition Examination Survey (KNHANES), which included results for cataract surgery status and AMD grading from 2008 to 2012. A total of 20 419 participants 40 years or older were included. Data were analyzed from February 5 to August 20, 2015.
   MAIN OUTCOMES AND MEASURES The association between cataract surgery and AMD was assessed in each right and left eye using logistic regression models and in both eyes using generalized estimating equation models. Sample weights were applied to adjust for survey design, nonresponse, and stratification to generate nationally representative population-based results.
   RESULTS From the 20 419 eligible individuals (11 642 women [51.9%] and 5777 men [48.1%]; mean [SE] age, 55.83 [0.14] years), 17 987 had information regarding cataract surgery status and gradable fundus photographs of at least 1 eye. A total of 34 863 eyes (17 616 right eyes and 17 247 left eyes) underwent analysis. Of these, 1264 right eyes (5.5%) and 1235 left eyes (5.4%) had cataract surgery. Of 1056 right eyes and 949 left eyes with any AMD (early or late), 167 right eyes (15.2%) and 147 left eyes (13.7%) had cataract surgery. The analyses did not show any association between cataract surgery and any form of AMD (early, late, and all) except in left eyes, where cataract surgery was associated with late AMD (odds ratio, 2.34; 95% CI, 1.13-4.85).
   CONCLUSIONS AND RELEVANCE The results suggest that the association between cataract surgery and AMD is uncertain in the current era of phacoemulsification. The association for left eyes might be a chance finding.
C1 [Park, Sang Jun; Park, Kyu Hyung] Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Ophthalmol, Songnam, South Korea.
   [Park, Sang Jun] Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul, South Korea.
   [Lee, Ju Hyun; Ahn, Soyeon] Seoul Natl Univ, Bundang Hosp, Med Res Collaborating Ctr, Div Stat, Songnam, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU)
RP Park, KH (通讯作者)，Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Ophthalmol, 82 Gumi Ro 173 Beon Gil, Songnam 463707, Gyeonggi Do, South Korea.
EM jiani4@snu.ac.kr
FU National Research Foundation of Korea - Ministry of Education, Science,
   and Technology [NRF-2015R1D1A1A02062194]
FX This study was supported by grant NRF-2015R1D1A1A02062194 from the
   National Research Foundation of Korea, awarded by the Ministry of
   Education, Science, and Technology.
CR Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Fraser-Bell S, 2010, AM J OPHTHALMOL, V149, P735, DOI 10.1016/j.ajo.2009.11.013
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   General Assembly of the World Medical Association, 2014, J Am Coll Dent, V81, P14
   Ho L, 2008, INVEST OPHTH VIS SCI, V49, P4795, DOI 10.1167/iovs.08-2066
   Hooper CY, 2009, CLIN EXP OPHTHALMOL, V37, P570, DOI 10.1111/j.1442-9071.2009.02095.x
   Kaiserman I, 2007, OPHTHALMOLOGY, V114, P278, DOI 10.1016/j.ophtha.2006.10.019
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kessel L, 2015, ACTA OPHTHALMOL, V93, P593, DOI 10.1111/aos.12665
   Klein BEK, 2012, OPHTHALMOLOGY, V119, P1628, DOI 10.1016/j.ophtha.2012.01.050
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Kweon S, 2014, INT J EPIDEMIOL, V43, P69, DOI 10.1093/ije/dyt228
   Lai E, 2014, CURR OPIN OPHTHALMOL, V25, P35, DOI 10.1097/ICU.0000000000000016
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee PP, 2003, ARCH OPHTHALMOL-CHIC, V121, P1303, DOI 10.1001/archopht.121.9.1303
   Park SJ, 2015, JAMA OPHTHALMOL, V133, P1267, DOI 10.1001/jamaophthalmol.2015.3055
   Park SJ, 2015, OPHTHALMOLOGY, V122, P129, DOI 10.1016/j.ophtha.2014.07.039
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pollack A, 1998, OPHTHALMIC SURG LAS, V29, P286
   SPERDUTO RD, 1981, ARCH OPHTHALMOL-CHIC, V99, P1004
   Wang J J, 1999, Ophthalmic Epidemiol, V6, P317, DOI 10.1076/opep.6.4.317.4182
   Wang JJ, 2012, OPHTHALMOLOGY, V119, P2298, DOI 10.1016/j.ophtha.2012.07.003
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Xu L, 2011, GRAEF ARCH CLIN EXP, V249, P981, DOI 10.1007/s00417-010-1571-y
   Yoon Kyung Chul, 2015, Korean J Ophthalmol, V29, P359, DOI 10.3341/kjo.2015.29.6.359
   Yoon Kyung-Chul, 2011, Korean J Ophthalmol, V25, P421, DOI 10.3341/kjo.2011.25.6.421
   Youssef PN, 2011, EYE, V25, P1, DOI 10.1038/eye.2010.149
NR 35
TC 14
Z9 14
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUN
PY 2016
VL 134
IS 6
BP 621
EP 626
DI 10.1001/jamaophthalmol.2016.0453
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DR0KL
UT WOS:000379596300002
PM 27031332
OA Bronze
DA 2022-11-30
ER

PT J
AU Schmid, MK
   Bachmann, LM
   Fas, L
   Kessels, AG
   Job, OM
   Thiel, MA
AF Schmid, Martin K.
   Bachmann, Lucas M.
   Faes, Livia
   Kessels, Alfons G.
   Job, Oliver M.
   Thiel, Michael A.
TI Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab
   in age-related macular degeneration: a trade-off analysis
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID VERTEPORFIN PLUS RANIBIZUMAB; ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL
   NEOVASCULARIZATION; LUCENTIS; AVASTIN; THERAPY
AB Topic To quantify the gain in visual acuity and serious side effects of ranibizumab, bevacizumab and aflibercept in age-related macular degeneration (AMD).
   Clinical relevance There is an ongoing debate about the optimal treatment of AMD with these three antivascular endothelial growth factor (anti-VEGF) treatments.
   Methods Network meta-analyses. (Pre)Medline, EMBASE, SCOPUS, Cochrane Library (until April 2013), Science Citation Index and reference lists were searched for placebo-controlled randomised trials or head-to-head comparisons. Outcomes were 1-year follow-up data of visual acuity (letters gained) and serious (vascular death, any death, stroke, myocardial infarction, transient ischaemic attack) and thrombotic events. Two investigators independently assessed eligibility and quality of included studies and extracted data.
   Results 11 trials (enrolling 8341 patients) assessing five active treatments were included. Compared with placebo, all anti-VEGF treatments had a significantly higher percentage of letters gained: ranibizumab 0.3 mg 2.39% (95% CI 1.59 to 3.19; p<0.001), ranibizumab 0.5 mg 3.56% (95% CI 2.58 to 4.13; p<0.001), bevacizumab 1.25 mg 2.14% (95% CI 0.47 to 3.82; p=0.012), aflibercept 0.5 mg 2.91% (95% CI 0.99 to 4.82; p=0.003) and aflibercept 2 mg 3.44% (95% CI 1.73 to 5.14; p<0.001). Compared with placebo, serious side effects were higher in all other treatments: ranibizumab 0.3 mg 4.41% (95% CI 3.42 to 5.40; p<0.001), ranibizumab 0.5 mg 5.33% (95% CI 4.37 to 6.30; p<0.001), bevacizumab 1.25 mg 5.58% (95% CI 3.567 to 7.60; p<0.001), aflibercept 0.5 mg 5.65% (95% CI (3.28 to 8.02; p<0.001) and aflibercept 2 mg 5.29% (95% CI 3.18 to 7.39; p<0.001). Compared with placebo, systemic thrombotic events also occurred more often in all other treatments.
   Conclusions The study revealed only a modest superiority of aflibercept 2 mg and ranibizumab 0.5 mg over other formulations and dosages.
C1 [Schmid, Martin K.; Job, Oliver M.; Thiel, Michael A.] Cantonal Hosp Lucerne, Eye Clin, CH-6000 Luzern 16, Switzerland.
   [Bachmann, Lucas M.; Faes, Livia] Medignition Inc, Res Consultants, Zug, Switzerland.
   [Kessels, Alfons G.] Maastricht Univ, Dept Clin Epidemiol & Med Technol Assessment, Med Ctr, Maastricht, Netherlands.
C3 Lucerne Cantonal Hospital; Maastricht University
RP Schmid, MK (通讯作者)，Cantonal Hosp Lucerne, Eye Clin, Spitalstr, CH-6000 Luzern 16, Switzerland.
EM martin.schmid@luks.ch
OI , Lucas/0000-0002-9868-154X
CR Abouammoh M, 2011, CURR OPIN OPHTHALMOL, V22, P152, DOI 10.1097/ICU.0b013e32834595d0
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buser N, 2012, EUR UROL, V62, P1040, DOI 10.1016/j.eururo.2012.08.060
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Fadda V, 2011, BRIT J OPHTHALMOL, V95, P1476, DOI 10.1136/bjophthalmol-2011-300316
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kessels AGH, 2013, OA EPIDEMIOL, V1, P1
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lu G, 2004, STAT MED, V23, P3105, DOI 10.1002/sim.1875
   Lumley T, 2002, STAT MED, V21, P2313, DOI 10.1002/sim.1201
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   National Institute for Health and Care Excellence (NICE), 2013, AFL SOL INJ TREAT WE
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Raftery JP, 2007, BRIT MED J, V334, P381, DOI 10.1136/bmj.39128.708565.3A
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574
   Schmucker C, 2010, CURR OPIN OPHTHALMOL, V21, P218, DOI 10.1097/ICU.0b013e3283386783
   Vedula SS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub2
NR 26
TC 64
Z9 67
U1 0
U2 27
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2015
VL 99
IS 2
BP 141
EP 146
DI 10.1136/bjophthalmol-2014-305149
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AZ5UG
UT WOS:000348285500001
PM 25271911
DA 2022-11-30
ER

PT J
AU Jaffe, GJ
   Eliott, D
   Wells, JA
   Prenner, JL
   Papp, A
   Patel, S
AF Jaffe, Glenn J.
   Eliott, Dean
   Wells, John A.
   Prenner, Jonathan L.
   Papp, Andras
   Patel, Samir
TI A Phase 1 Study of Intravitreous E10030 in Combination with Ranibizumab
   in Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID PDGF-B; CHOROIDAL THICKNESS; TUMOR VASCULATURE; PERICYTE; VEGF;
   INJECTION; THERAPY; CELLS; ANGIOGENESIS; VERTEPORFIN
AB Purpose: To assess the safety and tolerability of E10030 (Fovista; Ophthotech, New York, NY), a platelet-derived growth factor (PDGF) antagonist, when administered in combination with an anti-vascular endothelial growth factor (VEGF) agent, ranibizumab (Lucentis; Genentech, South San Francisco, CA) 0.5 mg, by intravitreal injection in participants with neovascular age-related macular degeneration (NVAMD).
   Design: Prospective phase 1 clinical trial.
   Participants: A total of 23 participants diagnosed with NVAMD and aged 50 years or older were enrolled.
   Methods: Part 1 included 15 participants. Three participants received a single intravitreal E10030 (0.03 mg) injection and were subsequently given intravitreal ranibizumab (0.5 mg) injections at weeks 2, 6, and 10. Twelve participants (3 per group) received E10030 (0.03, 0.3, 1.5, or 3.0 mg) in combination with ranibizumab (0.5 mg) at day 0, month 1, and month 2 in an ascending manner. In Part 2 (8 participants), E10030 (0.3, 1.5, or 3.0 mg) in combination with ranibizumab (0.5 mg) was injected at day 0, month 1, and month 2.
   Main Outcome Measures: Safety at week 12 was the primary outcome and included assessment of vital signs, laboratory tests, and serial eye examinations. Other safety metrics included assessment through week 24 of Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity (VA) and biomarker changes evaluated by optical coherence tomography (OCT) and fluorescein angiography (FA).
   Results: All doses of intravitreal E10030 administered in combination with ranibizumab were well tolerated. No dose-limiting toxicities or relevant safety events were noted at any dose level during the study. Investigators did not report adverse events related to E10030 or ranibizumab. Mean VA change was a gain of 14 letters, and 59% of participants gained >= 15 letters from baseline at week 12. On FA at week 12, there was an 85.5% mean reduction from baseline in choroidal neovascularization (CNV) size. On OCT at the week 12 visit, there was a mean decrease in center point thickness and central subfield thickness of 38.9% and 33.7%, respectively.
   Conclusions: Intravitreal E10030 administered at doses up to 3 mg in combination with ranibizumab was well tolerated without evidence of systemic or ocular toxicity in participants with NVAMD. The changes in both mean VA and imaging biomarkers suggest a favorable short-term safety profile for the combination therapy of E10030 and ranibizumab. (C) 2016 by the American Academy of Ophthalmology.
C1 [Jaffe, Glenn J.] Duke Univ, Dept Ophthalmol, Durham, NC 27710 USA.
   [Eliott, Dean] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA.
   [Wells, John A.] Palmetto Retina Ctr, Columbia, SC USA.
   [Prenner, Jonathan L.] Rutgers Med Sch, New Jersey Retina, Newark, NJ USA.
   [Papp, Andras] Semmelweis Univ, H-1085 Budapest, Hungary.
   [Patel, Samir] Ophthotech, New York, NY USA.
C3 Duke University; Harvard University; Harvard Medical School;
   Massachusetts Eye & Ear Infirmary; Rutgers State University New
   Brunswick; Rutgers State University Medical Center; Semmelweis
   University
RP Jaffe, GJ (通讯作者)，Duke Univ, Ctr Eye, Dept Ophthalmol, Box 3802, Durham, NC 27710 USA.
EM jaffe001@mc.duke.edu
FU Ocata; Neurotech; Juvenile Diabetes Research Foundation; Thrombogenics;
   Acucela Scientific Advisory Board; Ophthotech; Regeneron; Genentech;
   Iconic Pharmaceuticals; LPath; Allergan; Alcon; PanOptica
FX D.E.: Consultant - Alcon, Alimera, Allergan, Arctic, Bausch & Lomb,
   Biogen, Genentech, Ophthotech, Regeneron, Avalanche, Foundation Fighting
   Blindness; Research funds - Ocata, Neurotech, Juvenile Diabetes Research
   Foundation; Personal fees - Thrombogenics; Acucela Scientific Advisory
   Board.; J.A.W.: Grants - Ophthotech, Regeneron, Genentech, Iconic
   Pharmaceuticals, LPath, Allergan, Alcon, PanOptica; Consultant - Iconic
   Pharmaceuticals, PanOptica.
CR Akiyama H, 2006, J CELL PHYSIOL, V207, P407, DOI 10.1002/jcp.20583
   Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708
   Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7
   Balasubramanian SA, 2014, TRANSL RES, V164, P179, DOI 10.1016/j.trsl.2014.04.005
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Erber R, 2003, FASEB J, V17, P338, DOI 10.1096/fj.03-0271fje
   FOLKMAN J, 1992, J BIOL CHEM, V267, P10931
   Hall AP, 2006, TOXICOL PATHOL, V34, P763, DOI 10.1080/01926230600936290
   Hellstrom M, 1999, DEVELOPMENT, V126, P3047
   Holekamp NM, 2014, AM J OPHTHALMOL, V157, P825, DOI 10.1016/j.ajo.2013.12.018
   Humphreys BD, 2010, AM J PATHOL, V176, P85, DOI 10.2353/ajpath.2010.090517
   Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lin SL, 2008, AM J PATHOL, V173, P1617, DOI 10.2353/ajpath.2008.080433
   Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sizmaz S, 2014, EUR J OPHTHALMOL, V24, P904, DOI 10.5301/ejo.5000478
NR 25
TC 60
Z9 70
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2016
VL 123
IS 1
BP 78
EP 85
DI 10.1016/j.ophtha.2015.09.004
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CZ4GE
UT WOS:000367060700028
PM 26499921
OA Bronze
DA 2022-11-30
ER

PT J
AU Wu, ZC
   Luu, CD
   Ayton, LN
   Goh, JK
   Lucci, LM
   Hubbard, WC
   Hageman, JL
   Hageman, GS
   Guymer, RH
AF Wu, Zhichao
   Luu, Chi D.
   Ayton, Lauren N.
   Goh, Jonathan K.
   Lucci, Lucia M.
   Hubbard, William C.
   Hageman, Jill L.
   Hageman, Gregory S.
   Guymer, Robyn H.
TI Optical Coherence Tomography-Defined Changes Preceding the Development
   of Drusen-Associated Atrophy in Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID GEOGRAPHIC ATROPHY; NATURAL-HISTORY; PROGRESSION; SECONDARY;
   AUTOFLUORESCENCE; MACULOPATHY
AB Purpose: To characterize the pathological changes preceding the development of drusen-associated atrophy in eyes with age-related macular degeneration (AMD) using spectral-domain optical coherence tomography (SD-OCT).
   Design: Longitudinal and cross-sectional retrospective observational study.
   Participants: A total of 181 participants with intermediate AMD in at least 1 eye (141 unilateral, 40 bilateral) were assessed longitudinally. A total of 230 participants with bilateral intermediate AMD (40 longitudinal participants with an additional 190 participants) were analyzed cross-sectionally.
   Methods: Spectral-domain OCT, color fundus photography (CFP), near-infrared reflectance, and fundus autofluorescence imaging were performed in all participants at cross-section and every 3 months for up to 30 months in the longitudinal study. Spectral-domain OCT volume scans were examined for features that portend the development of drusen-associated atrophy, and the topography, prevalence, and risk factors of these features were determined through cross-sectional analysis.
   Main Outcome Measures: The pathological features on SD-OCT preceding the development of drusen-associated atrophy and the characteristics of these features.
   Results: Twenty areas from 16 eyes of 16 participants developed drusen-associated atrophy after an average of 20 months (range, 8-30 months). Spectral-domain OCT features unique in these areas included: subsidence of the outer plexiform layer (OPL) and inner nuclear layer (INL), and development of a hyporeflective wedge-shaped band within the limits of the OPL. These characteristics were termed "nascent geographic atrophy" (nGA), describing features that portend the development of drusen-associated atrophy. Cross-sectional examination of participants with bilateral intermediate AMD revealed that independent risk factors for the presence of nGA included the presence of pigmentary changes (odds ratio [OR], 16.84; 95% confidence interval [CI], 2.42-117.24) and nGA in the fellow eye (OR, 4.15; 95% CI, 1.12-15.34); nGA was present in 21.9% of participants with drusen > 125 mu m and pigmentary changes in both eyes.
   Conclusions: This study identified pathological changes occurring before the development of drusen-associated atrophy using SD-OCT, which we defined as nGA. Although nGA is undetectable on CFP, it is important for determining the risk of future vision loss in AMD and could be used as an earlier surrogate end point in interventional trials targeting the early stages of AMD. (C) 2014 by the American Academy of Ophthalmology.
C1 [Wu, Zhichao; Luu, Chi D.; Ayton, Lauren N.; Goh, Jonathan K.; Guymer, Robyn H.] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic 3010, Australia.
   [Lucci, Lucia M.; Hubbard, William C.; Hageman, Jill L.; Hageman, Gregory S.] Univ Utah, Dept Ophthalmol & Visual Sci, John A Moran Eye Ctr, Salt Lake City, UT USA.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Utah System of Higher Education; University of
   Utah
RP Guymer, RH (通讯作者)，Ctr Eye Res Australia, Macular Res Unit, Level 1,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM rh.guymer@unimelb.edu.au
RI Ayton, Lauren/AAV-2977-2021
OI Ayton, Lauren/0000-0001-9907-084X; Guymer, Robyn/0000-0002-9441-4356;
   Luu, Chi/0000-0002-7604-7097
FU National Health and Medical Research Council (NHMRC) Project [1027624];
   NHMRC practitioner fellowship [529905]; Macular Degeneration Foundation
   Research; National Institutes of Health [R24 EY017404]; NHMRC Centre for
   Clinical Research Excellence Award [529923]; Research to Prevent
   Blindness, Inc.; NATIONAL EYE INSTITUTE [R24EY017404] Funding Source:
   NIH RePORTER
FX Supported by the National Health and Medical Research Council (NHMRC)
   Project Grant (1027624), NHMRC practitioner fellowship (R. H. G.,
   #529905), a Macular Degeneration Foundation Research Grant (G. S. H. and
   R. H. G.), National Institutes of Health Grant R24 EY017404 (G. S. H.),
   and an unrestricted grant to the University of Utah John A. Moran Eye
   Center and Department of Ophthalmology and Visual Sciences from Research
   to Prevent Blindness, Inc. Centre for Eye Research Australia receives
   Operational Infrastructure Support from the Victorian Government and is
   supported by an NHMRC Centre for Clinical Research Excellence Award
   (#529923).
CR Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   Chen TC, 2005, ARCH OPHTHALMOL-CHIC, V123, P1715, DOI 10.1001/archopht.123.12.1715
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Mauschitz MM, 2012, INVEST OPHTH VIS SCI, V53, P4932, DOI 10.1167/iovs.12-9711
   Mones J, 2013, OPHTHALMOLOGY, V120, P829, DOI 10.1016/j.ophtha.2012.09.054
   Mones J, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.026
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wolf-Schnurrbusch UEK, 2008, INVEST OPHTH VIS SCI, V49, P3095, DOI 10.1167/iovs.07-1460
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 25
TC 156
Z9 158
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2014
VL 121
IS 12
BP 2415
EP 2422
DI 10.1016/j.ophtha.2014.06.034
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AU3JR
UT WOS:000345509500026
PM 25109931
DA 2022-11-30
ER

PT J
AU Hwang, N
   Kwon, MY
   Woo, JM
   Chung, SW
AF Hwang, Narae
   Kwon, Min-Young
   Woo, Je Moon
   Chung, Su Wol
TI Oxidative Stress-Induced Pentraxin 3 Expression Human Retinal Pigment
   Epithelial Cells Is Involved in the Pathogenesis of Age-Related Macular
   Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE pentraxin 3; human retinal pigment epithelial cells; age-related macular
   degeneration; oxidative stress; sodium iodate antioxidants
ID RPE; PATHWAY
AB (1) Background: Age-related macular degeneration (AMD) is closely related with retinal pigment epithelial (RPE) cell dysfunction. Although the exact pathogenesis of AMD remains largely unknown, oxidative stress-induced RPE damage is believed to be one of the primary causes. We investigated the molecular mechanisms of pentraxin 3 (PTX3) expression and its biological functions during oxidative injury. (2) Methods: Using enzyme-linked immunosorbent assays and real-time reverse transcription-polymerase chain reaction, we analyzed mRNA and protein levels of PTX3 in the presence or absence of oxidative stress inducer, sodium iodate (NaIO3), in primary human H-RPE and ARPE-19 cells. Furthermore, we assessed cell death, antioxidant enzyme expression, and AMD-associated gene expression to determine the biological functions of PTX3 under oxidative stress. (3) Results: NaIO3 increased PTX3 expression, in a dose- and time-dependent manner, in H-RPE and ARPE-19 cells. We found phosphorylated Akt, a downstream target of the PI3 kinase pathway, phosphor- mitogen-activated protein kinase kinase 1/2 (ERK), and intracellular reactive oxygen species (ROS) were predominantly induced by NaIO3. NaIO3-induced PTX3 expression was decreased in the presence of phosphoinositide 3 (PI3) kinase inhibitors, ERK inhibitors, and ROS scavengers. Furthermore, NaIO3 enhanced mRNA expression of antioxidant enzymes such as glucose-6-phosphate dehydrogenase (G6PDH), catalase (CAT), and glutathione S-reductase (GSR) in the control shRNA expressing RPE cells, but not in hPTX3 shRNA expressing RPE cells. Interestingly, NaIO3 did not induce mRNA expression of AMD marker genes, such as complement factor I (CFI), complement factor H (CFH), apolipoprotein E (APOE), and toll-like receptor 4 (TLR4) in hPTX3 shRNA expressing RPE cells. 4) Conclusions: These results suggest that PTX3 accelerates RPE cell death and might be involved in AMD development in the presence of oxidative stress.
C1 [Hwang, Narae; Kwon, Min-Young; Chung, Su Wol] Univ Ulsan, Coll Nat Sci, Sch Biol Sci, 93 Daehak Ro, Ulsan 44610, South Korea.
   [Kwon, Min-Young] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA.
   [Kwon, Min-Young] Harvard Med Sch, Boston, MA 02115 USA.
   [Woo, Je Moon] Univ Ulsan, Coll Med, Ulsan Univ Hosp, Dept Ophthalmol, Ulsan 44033, South Korea.
C3 University of Ulsan; Harvard University; Brigham & Women's Hospital;
   Harvard University; Harvard Medical School; University of Ulsan; Ulsan
   University Hospital
RP Chung, SW (通讯作者)，Univ Ulsan, Coll Nat Sci, Sch Biol Sci, 93 Daehak Ro, Ulsan 44610, South Korea.
EM skfo1319@naver.com; youngpower-v@hanmail.net; limbus68@naver.com;
   swchung@ulsan.ac.kr
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education [NRF-2014R1A6A1030318]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF), funded by the
   Ministry of Education (NRF-2014R1A6A1030318 to S.W.C.).
CR Bellezza I, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01280
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Cao GF, 2012, MOL MED REP, V5, P54, DOI 10.3892/mmr.2011.582
   Chan CM, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0531-z
   Cheng SC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20122957
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Girmens JF, 2012, INTRACTABLE RARE DIS, V1, P103, DOI 10.5582/irdr.2012.v1.3.103
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Hwang Narae, 2016, Korean J Ophthalmol, V30, P468
   Inana G, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1434-6
   Juel HB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132800
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Kunes P, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/920517
   Liu XB, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111835
   Min JK, 2015, OCUL IMMUNOL INFLAMM, V23, P205, DOI 10.3109/09273948.2014.891755
   Moalli F, 2011, J BIOMED BIOTECHNOL, P1, DOI 10.1155/2011/830421
   Nita Malgorzata, 2016, Oxid Med Cell Longev, V2016, P3164734, DOI 10.1155/2016/3164734
   Presta M, 2007, J CELL MOL MED, V11, P723, DOI 10.1111/j.1582-4934.2007.00061.x
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Samuel W, 2008, J NEUROCHEM, V106, P591, DOI 10.1111/j.1471-4159.2008.05409.x
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   Wang L, 2016, J PATHOL, V240, P495, DOI 10.1002/path.4811
   Woo JM, 2013, MOL VIS, V19, P303
   Yang IH, 2015, INVEST OPHTH VIS SCI, V56, P761, DOI 10.1167/iovs.14-15299
NR 26
TC 18
Z9 18
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC
PY 2019
VL 20
IS 23
AR 6028
DI 10.3390/ijms20236028
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA JY5AR
UT WOS:000504428300210
PM 31795454
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Pang, CE
   Freund, KB
AF Pang, Claudine E.
   Freund, K. Bailey
TI Intravitreal Polypoidal Choroidal Vasculopathy in Radiation Retinopathy
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
AB A 30-year-old woman diagnosed with choroidal melanoma and treated with plaque radiation and transpupillary thermotherapy 5 years earlier presented with recalcitrant proliferative radiation retinopathy despite multiple intravitreal anti-vascular endothelial growth factor injections. Swept-source and spectral-domain optical coherence tomography (OCT) demonstrated intravitreal polyps lying on the surface of atrophied chorioretinal tissue. Fluorescein angiography (FA) revealed leakage from these saccular choroidal neovasculopathic vessels adjacent to a large zone of poor choroidal perfusion. Intravitreal polypoidal choroidal vasculopathy may be associated with radiation retinopathy and is well-demonstrated with swept-source and spectral-domain OCT and FA.
C1 [Pang, Claudine E.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Pang, Claudine E.; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY USA.
   [Freund, K. Bailey] NYU, Sch Med, New York, NY USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; New York University
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,Fifth Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU LuEsther T. Mertz Retinal Research Center; Manhattan Eye, Ear and Throat
   Hospital; Macula Foundation
FX Supported by LuEsther T. Mertz Retinal Research Center; Manhattan Eye,
   Ear and Throat Hospital; and the Macula Foundation.
CR Bianciotto C, 2010, OPHTHALMOLOGY, V117, P1005, DOI 10.1016/j.ophtha.2009.10.015
   Gunduz K, 1999, ARCH OPHTHALMOL-CHIC, V117, P609
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Pitkanen L, 2014, ACTA OPHTHALMOL, V92, P101, DOI 10.1111/aos.12210
   Spaide RF, 1999, OPHTHALMOLOGY, V106, P2254, DOI 10.1016/S0161-6420(99)90524-9
   Spaide RF, 2002, AM J OPHTHALMOL, V133, P709, DOI 10.1016/S0002-9394(02)01331-4
   Takahashi K, 1998, AM J OPHTHALMOL, V125, P367, DOI 10.1016/S0002-9394(99)80148-2
NR 7
TC 4
Z9 5
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD NOV-DEC
PY 2014
VL 45
IS 6
BP 585
EP 588
DI 10.3928/23258160-20141008-04
PG 4
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA AY0PQ
UT WOS:000347299300016
PM 25347829
DA 2022-11-30
ER

PT J
AU Sengul, A
   Rasier, R
   Ciftci, C
   Artunay, O
   Kockar, A
   Bahcecioglu, H
   Yuzbasioglu, E
AF Sengul, A.
   Rasier, R.
   Ciftci, C.
   Artunay, O.
   Kockar, A.
   Bahcecioglu, H.
   Yuzbasioglu, E.
TI Short-term effects of intravitreal ranibizumab and bevacizumab
   administration on 24-h ambulatory blood pressure monitoring recordings
   in normotensive patients with age-related macular degeneration
SO EYE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; COHERENCE TOMOGRAPHY FINDINGS; HYPERTENSIVE
   PATIENTS; INJECTION; AVASTIN; ANGIOGENESIS; THERAPY; SAFETY; MANAGEMENT;
   DIPPERS
AB Purpose To evaluate effects of intravitreal ranibizumab and bevacizumab administration on ambulatory blood pressure monitoring (ABPM) recordings in normotensive patients with age-related macular degeneration (AMD).
   Patients and methods A total of 72 patients (mean age: 61.8(6.2) years, 52.8% were females) diagnosed with AMD were included in this study as divided into ranibizumab (n = 34) and bevacizumab (n = 38) treatment groups. Twenty-four hour, nighttime, and daytime ABMP values for systolic and diastolic BP were recorded in study groups before and after the third intravitreal injection of ranibizumab or bevacizumab.
   Results Ranibizumab injection had no impact on ABPM recordings and dipping status. In the bevacizumab group, increased daytime (129.0(6.6) vs 127.7(6.6) mm Hg, P = 0.002) and nighttime systolic (116.9(7.5) vs 112.6(7.1) mmHg, p<0.001) BP and decreased daytime diastolic (80.1(6.5) vs 82.4(6.1) mm Hg, P = 0.001) BP were noted in the post-injection period. Also, percentage of non-dippers was significantly increased from 5.3% at pre-injection to 28.9% (P = 0.004) at the post-injection period.
   Conclusion In conclusion, given that it has no significant impact on ABPM recordings and dipping status, in our study, intravitreal ranibizumab injection may be the better choice in the management of AMD.
C1 [Sengul, A.; Rasier, R.; Kockar, A.; Yuzbasioglu, E.] Istanbul Bilim Univ, Sch Med, Dept Ophtalmol, Istanbul, Turkey.
   [Ciftci, C.] Istanbul Bilim Univ, Sch Med, Dept Cardiol, Istanbul, Turkey.
   [Artunay, O.] Istanbul Med Hosp, Dept Ophtalmol, Istanbul, Turkey.
C3 Demiroglu Bilim University; Demiroglu Bilim University; Medipol Hospital
RP Sengul, A (通讯作者)，Sisli Florence Nightingale Hastanesi, Dept Ophtalmol, Abide I Hurriyet Caddesi 290, TR-36640 Istanbul, Turkey.
EM ealper_sengul@yahoo.com
RI Rasier, Rifat/AHB-8857-2022; Rasier, Rifat/AAK-4259-2021; Koçkar,
   Alev/GPX-8090-2022
OI Rasier, Rifat/0000-0003-0963-7991; Koçkar, Alev/0000-0002-1457-8511;
   sengul, elvan alper/0000-0003-1313-6970
CR Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Barron H., MEDWATCH GENENTECH I
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Dincer M, 2006, ANN PHARMACOTHER, V40, P2278, DOI 10.1345/aph.1H244
   Felmeden DC, 2003, AM J HYPERTENS, V16, P11, DOI 10.1016/S0895-7061(02)03149-7
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Grothey A, 2008, J CLIN ONCOL, V26, P5326, DOI 10.1200/JCO.2008.16.3212
   Kamba T, 2007, BRIT J CANCER, V96, P1788, DOI 10.1038/sj.bjc.6603813
   Kernt M, 2007, ACTA OPHTHALMOL SCAN, V85, P119, DOI 10.1111/j.1600-0420.2006.00819.x
   Kiss S, 2014, CLIN OPHTHALMOL, V8, P1611, DOI 10.2147/OPTH.S60893
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee K, 2009, RETINA-J RET VIT DIS, V29, P1409, DOI 10.1097/IAE.0b013e3181b21056
   Mancia G, 2014, BLOOD PRESSURE, V23, P3, DOI 10.3109/08037051.2014.868629
   Mansoor GA, 2002, J HUM HYPERTENS, V16, P237, DOI 10.1038/sj.jhh.1001383
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mourad JJ, 2008, ANN ONCOL, V19, P927, DOI 10.1093/annonc/mdm550
   OBRIEN E, 1988, LANCET, V2, P397
   Palatini P, 2004, BLOOD PRESS MONIT, V9, P297, DOI 10.1097/00126097-200412000-00005
   Pande A, 2007, ANTICANCER RES, V27, P3465
   PICKERING TG, 1991, CLIN CARDIOL, V14, P557
   PICKERING TG, 1990, CIRCULATION, V81, P700, DOI 10.1161/01.CIR.81.2.700
   Rasier R, 2009, EYE, V23, P1714, DOI 10.1038/eye.2008.360
   Reimann Manja, 2013, Exp Transl Stroke Med, V5, P7, DOI 10.1186/2040-7378-5-7
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Risimic D, 2013, HELL J CARDIOL, V54, P435
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sane David C., 2004, Angiogenesis, V7, P193, DOI 10.1007/s10456-004-2699-3
   SHIMADA K, 1992, J HYPERTENS, V10, P875
   Staessen JA, 1999, JAMA-J AM MED ASSOC, V282, P539, DOI 10.1001/jama.282.6.539
   Steeghs N, 2008, CLIN CANCER RES, V14, P3470, DOI 10.1158/1078-0432.CCR-07-5050
   U.S. Food and Drug Administration, OFF LAB INV US MARK
   Vaklavas C, 2010, ONCOLOGIST, V15, P130, DOI 10.1634/theoncologist.2009-0252
   Ventola C Lee, 2009, P T, V34, P428
   VERDECCHIA P, 1994, HYPERTENSION, V24, P793, DOI 10.1161/01.HYP.24.6.793
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491
   Yang RH, 1996, J CARDIOVASC PHARM, V27, P838, DOI 10.1097/00005344-199606000-00011
   Yang RH, 1998, J PHARMACOL EXP THER, V284, P103
   Zeb A, 2007, JCPSP-J COLL PHYSICI, V17, P448
   Ziemssen Focke, 2009, International Ophthalmology, V29, P213, DOI 10.1007/s10792-008-9221-7
NR 45
TC 7
Z9 7
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAY
PY 2017
VL 31
IS 5
BP 677
EP 683
DI 10.1038/eye.2016.305
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EU4YF
UT WOS:000401036900003
PM 28060360
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Andreoli, MT
   Morrison, MA
   Kim, BJ
   Chen, L
   Adams, SM
   Miller, JW
   Deangelis, MM
   Kim, IK
AF Andreoli, Michael T.
   Morrison, Margaux A.
   Kim, Ben J.
   Chen, Ling
   Adams, Scott M.
   Miller, Joan W.
   Deangelis, Margaret M.
   Kim, Ivana K.
TI Comprehensive Analysis of Complement Factor H and LOC387715/ARMS2/HTRA1
   Variants With Respect to Phenotype in Advanced Age-Related Macular
   Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID LOC387715 GENOTYPES; STRONG ASSOCIATION; Y402H VARIANT; RISK;
   POLYMORPHISM; HTRA1; CFH
AB PURPOSE: To examine the interaction of genotypic variation of 16 single-nucleotide polymorphisms (SNP) in the complement factor H (CFH) and LOC387715/ARMS2/HTRA1 loci with clinical characteristics of age-related macular degeneration (AMD).
   DESIGN: Retrospective cohort study.
   METHODS: Eighty,four patients with neovascular AMD were genotyped using direct sequencing or Sequenom iPLEX technology. The Fisher exact test, Cochran-Mantel-Haenszel statistics, and Mann-Whitney U test were used to assess the effect of each SNP with respect to the following phenotypic manifestations: age at diagnosis, gender, affected eye, study and fellow eye visual acuity at diagnosis and at last follow-up, study eye best acuity during follow-up, presence of large drusen and retinal pigment epithelium (RPE) hyperpigmentation in study and fellow eye, choroidal neovascularization (CNV) angiographic subtype (classic vs occult), CNV size, presence of wet AMD in fellow eye, presence of dry AMD in fellow eye, and smoking history.
   RESULTS: Only SNPs in the LOC387715/ARMS2/HTRA1 (10q26) region were associated with disease phenotypes. The polymorphisms rs10664316 and rs1049331 were associated with a decreased risk of poor visual acuity during follow-up and at diagnosis; rs2672598 and rs2293870 were associated with a decreased risk of RPE hyperpigmentation; rs10664316 was associated with a de, creased risk of RPE hyperpigmentation with large drusen in the study eye, but an increased risk of large drusen in the fellow eye; rs11200638 was associated with an increased risk of larger CNV; rs10490924 and rs11200638 were associated with younger age of diagnosis.
   CONCLUSIONS: Several polymorphisms examined in the LOC387715/ARMS2/HTRA1 locus, but none in the CFH region, correlated with specific phenotypic attributes of AMD. (Am J Ophthalmol 2009; 148: 869-874. (C) 2009 by Elsevier Inc. All rights reserved.)
C1 [Kim, Ben J.; Chen, Ling; Miller, Joan W.; Kim, Ivana K.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Retina Serv, Boston, MA 02114 USA.
   [Andreoli, Michael T.; Morrison, Margaux A.; Adams, Scott M.; Deangelis, Margaret M.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Ocular Mol Genet Inst, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Harvard University; Harvard Medical School; Massachusetts Eye
   & Ear Infirmary
RP Kim, IK (通讯作者)，Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Retina Serv, Boston, MA 02114 USA.
EM ivana_kim@meei.harvard.edu
RI Kim, Benjamin/AAG-3786-2019; Chen, Ling/AAM-1821-2021; DeAngelis,
   e/J-7863-2015
OI Kim, Benjamin/0000-0003-0230-3868; Kim, Ivana/0000-0003-0310-6129;
   Miller, Joan/0000-0003-2046-3996
FU LINCY FOUNDATION, BEVERLY HILLS, CALIFORNIA; MASSACHUSETTS LIONS, NEW
   BEDFORD, Massachusetts; Eannelli for Macular Degeneration Fund, MEEI,
   Boston, Massachusetts; Genetics of Age-Related Macular Degeneration
   Fund, MEEI, Boston, Massachusetts; Research to Prevent Blindness Inc,
   New York, New York; Marion W. and Edward F. Knight Age-Related Macular
   Degeneration Fund, Boston, Massachusetts; National Institutes of Health,
   Bethesda, Maryland [EY014458]; Fight For Sight, New York, New York;
   NATIONAL EYE INSTITUTE [P30EY014104, R01EY014458] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH044292, R37MH044292]
   Funding Source: NIH RePORTER
FX THIS STUDY WAS SUPPORTED BY THE LINCY FOUNDATION, BEVERLY HILLS,
   CALIFORNIA; MASSACHUSETTS LIONS, NEW BEDFORD, Massachusetts; Eannelli
   for Macular Degeneration Fund, MEEI, Boston, Massachusetts; Genetics of
   Age-Related Macular Degeneration Fund, MEEI, Boston, Massachusetts;
   Research to Prevent Blindness Inc, New York, New York; Marion W. and
   Edward F. Knight Age-Related Macular Degeneration Fund, Boston,
   Massachusetts; Grant No. EY014458 from the National Institutes of
   Health, Bethesda, Maryland; and Fight For Sight, New York, New York. Dr
   Ivana Kim is a consultant for Genentech Inc. Dr DeAngelis serves on the
   scientific advisory board for ArcticD.x and is a consultant for
   Observant LLC and Genentech Inc. Involved in design and conduct of study
   (BJ.K., M.M.D., I.K.K., J.W.M.); collection and management of data
   (B.J.K., SAM.A., M.M.D., I.K.K., J.W.M.); analysis and interpretation of
   data (M.T.A., M.A.M., L.C., B.J.K., M.M.D., I.K.K.);and preparation
   (M.T.A., M.A.M., L.C., M.M.D., I.K.K.) and review and approval of the
   manuscript (M.T.A., M.A.M., B.J.K., L.C., S.M.A., M.M.D., I.K.K.,
   J.W.M.). The study protocol was approved by the Massachusetts Eye and
   Ear Infirmary Institutional Review Board. The study is in accordance
   with Health Insurance Portability and Accountability Act regulations and
   conforms to the tenets of the Declaration of Helsinki.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   Chen HY, 2008, VISION RES, V48, P690, DOI 10.1016/j.visres.2007.10.014
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Droz I, 2008, BRIT J OPHTHALMOL, V92, P513, DOI 10.1136/bjo.2007.127811
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Gibbs D, 2008, VISION RES, V48, P685, DOI 10.1016/j.visres.2007.10.022
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Leveziel N, 2008, INVEST OPHTH VIS SCI, V49, P3090, DOI 10.1167/iovs.07-1540
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shuler RK, 2008, AM J OPHTHALMOL, V145, P303, DOI 10.1016/j.ajo.2007.09.027
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Souied EH, 2005, MOL VIS, V11, P1135
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zhang H, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-51
NR 26
TC 47
Z9 54
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2009
VL 148
IS 6
BP 869
EP 874
DI 10.1016/j.ajo.2009.07.002
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 530BP
UT WOS:000272564200010
PM 19796758
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Aykutlu, MS
   Guclu, H
   Doganlar, ZB
   Kurtdere, AK
   Doganlar, O
AF Aykutlu, Merve Sambel
   Guclu, Hande
   Doganlar, Zeynep Banu
   Kurtdere, Ayse Kardelen
   Doganlar, Oguzhan
TI MicroRNA-184 attenuates hypoxia and oxidative stress-related injury via
   suppressing apoptosis, DNA damage and angiogenesis in an in vitro
   age-related macular degeneration model
SO TOXICOLOGY IN VITRO
LA English
DT Article
DE Age related macular degeneration; ARPE 19; Bevacizumab; miR-155; miR-184
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; DOWN-REGULATION;
   RPE CELLS; EXPRESSION; BEVACIZUMAB; PROGRESSION; THERAPY; ATROPHY;
   CANCER
AB Age-related macular degeneration (AMD) is one of the leading causes of blindness worldwide, particularly in developed countries. Recently, microRNAs (miRs) have become popular research area to develop new treatment options of AMD. However, interaction between hsa-miR-184 and AMD remain largely unexplored. In this study, sub-lethal levels of Deforoxamine Mesylate salt (DFX) and H2O2 were applied to ARPE-19 cells to establish a severe in vitro AMD model, via durable hypoxia and oxidative stress. We found that up-regulation of miR-184 level in AMD can suppress hypoxia-related angiogenic signals through HIF-1 alpha/VEGF/MMPs axis. Also, miR-184 suppressed the hypoxia sensor miR-155 and genes in the EGFR/PI3K/AKT pathway, which is an alternative pathway in angiogenesis. To investigate the mechanism behind this protective effect, we evaluated the impact of miR-184 on retinal apoptosis in a model of AMD. miR-184 inhibited retinal apoptosis by upregulating BCL-2 and downregulating pro-apoptototic BAX, TRAIL, Caspase 3 and 8 signals as well as p53. Taken together, miR-184 attenuates retinal cell damage induced by severe AMD pathologies through suppressing hypoxia, angiogenesis and apoptosis. The safety profile of miR-184 was observed to be similar to Bevacizumab, which is in wide use clinically, but miR-184 was found to provide a more effective therapeutic potential by regulating simultaneously multiple pathologies.
C1 [Aykutlu, Merve Sambel; Guclu, Hande] Trakya Univ, Fac Med, Dept Ophthalmol, TR-22030 Edirne, Turkey.
   [Doganlar, Zeynep Banu; Kurtdere, Ayse Kardelen; Doganlar, Oguzhan] Trakya Univ, Fac Med, Dept Med Biol, TR-22030 Edirne, Turkey.
   [Aykutlu, Merve Sambel] Edirne Sultan 1st Murat State Hosp, Ophthalmol Dept, Edirne, Turkey.
C3 Trakya University; Trakya University; Edirne State Hospital
RP Aykutlu, MS (通讯作者)，Trakya Univ, Fac Med, Dept Ophthalmol, TR-22030 Edirne, Turkey.; Aykutlu, MS (通讯作者)，Edirne Sultan 1st Murat State Hosp, Ophthalmol Dept, Edirne, Turkey.
EM mervesambel@hotmail.com; zdoganlar@trakya.edu.tr; doganlar@trakya.edu.tr
FU Trakya University Scientific Research Fund [TUBAP 2019/181]
FX The Trakya University Scientific Research Fund provided support for this
   study (TUBAP 2019/181).
CR Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0
   Agarwal A, 2016, DEV OPHTHALMOL, V55, P276, DOI 10.1159/000438951
   Albayrak D, 2021, BIOCHEM GENET, V59, P159, DOI 10.1007/s10528-020-09996-5
   Alvarez Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007867
   Berber P, 2017, MOL DIAGN THER, V21, P31, DOI 10.1007/s40291-016-0234-z
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Brar VS, 2010, MOL VIS, V16, P1848
   Bruning U, 2011, MOL CELL BIOL, V31, P4087, DOI 10.1128/MCB.01276-10
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Choudhary S, 2005, TOXICOL APPL PHARM, V204, P122, DOI 10.1016/j.taap.2004.08.023
   Connor KM, 2009, NAT PROTOC, V4, P1565, DOI 10.1038/nprot.2009.187
   Dalal M, 2013, GRAEF ARCH CLIN EXP, V251, P2705, DOI 10.1007/s00417-013-2375-7
   De Cilla S, 2017, CELL PHYSIOL BIOCHEM, V42, P1725, DOI 10.1159/000479441
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Derrick T, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1367-8
   Dimmeler S, 2000, CIRC RES, V87, P434
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Guclu H, 2018, CUTAN OCUL TOXICOL, V37, P291, DOI 10.1080/15569527.2018.1456548
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Jiang C, 2016, ONCOTARGET, V7, P52340, DOI 10.18632/oncotarget.10566
   Karar J, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00051
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kerr DJ, 2004, NAT CLIN PRACT ONCOL, V1, P39, DOI 10.1038/ncponc0026
   Kim Sukjin, 2015, Korean J Ophthalmol, V29, P424, DOI 10.3341/kjo.2015.29.6.424
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kong W, 2014, ONCOGENE, V33, P679, DOI 10.1038/onc.2012.636
   Kuo CN, 2012, MOL MED REP, V6, P701, DOI 10.3892/mmr.2012.986
   Lanford RE, 2010, SCIENCE, V327, P198, DOI 10.1126/science.1178178
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Malik D, 2014, BRIT J OPHTHALMOL, V98, P11, DOI 10.1136/bjophthalmol-2014-305302
   McGarry T, 2018, FREE RADICAL BIO MED, V125, P15, DOI 10.1016/j.freeradbiomed.2018.03.042
   Murad N, 2014, FEBS J, V281, P5251, DOI 10.1111/febs.13066
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Park JK, 2017, FASEB J, V31, P257, DOI 10.1096/fj.201600746R
   Rabin DM, 2013, AGING-US, V5, P51
   Ranjbar M, 2016, CELL PHYSIOL BIOCHEM, V38, P737, DOI 10.1159/000443030
   Roper J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025132
   Sasore T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105280
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   Subrizi A, 2015, PHARM RES-DORDR, V32, P211, DOI 10.1007/s11095-014-1456-6
   Tisi A, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010064
   Wang DA, 2017, INT J CLIN EXP PATHO, V10, P2754
   Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang DG, 2016, SCI REP-UK, V6, DOI 10.1038/srep35316
   Yang HJ, 2019, EXP EYE RES, V188, DOI 10.1016/j.exer.2019.107792
   Zhuang Z, 2015, MOL VIS, V21, P1173
   Zieske JD, 2000, PROG RETIN EYE RES, V19, P257, DOI 10.1016/S1350-9462(99)00018-X
   Zong RR, 2016, INVEST OPHTH VIS SCI, V57, P1398, DOI 10.1167/iovs.15-17417
NR 51
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-2333
EI 1879-3177
J9 TOXICOL IN VITRO
JI Toxicol. Vitro
PD SEP
PY 2022
VL 83
AR 105413
DI 10.1016/j.tiv.2022.105413
PG 11
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA 3J4XS
UT WOS:000833399900001
PM 35690295
DA 2022-11-30
ER

PT J
AU Sobrin, L
   Ripke, S
   Yu, Y
   Fagerness, J
   Bhangale, TR
   Tan, PL
   Souied, EH
   Buitendijk, GHS
   Merriam, JE
   Richardson, AJ
   Raychaudhuri, S
   Reynolds, R
   Chin, KA
   Lee, AY
   Leveziel, N
   Zack, DJ
   Campochiaro, P
   Smith, RT
   Barile, GR
   Hogg, RE
   Chakravarthy, U
   Behrens, TW
   Uitterlinden, AG
   van Duijn, CM
   Vingerling, JR
   Brantley, MA
   Baird, PN
   Klaver, CCW
   Allikmets, R
   Katsanis, N
   Graham, RR
   Ioannidis, JPA
   Daly, MJ
   Seddon, JM
AF Sobrin, Lucia
   Ripke, Stephan
   Yu, Yi
   Fagerness, Jesen
   Bhangale, Tushar R.
   Tan, Perciliz L.
   Souied, Eric H.
   Buitendijk, Gabrielle H. S.
   Merriam, Joanna E.
   Richardson, Andrea J.
   Raychaudhuri, Soumya
   Reynolds, Robyn
   Chin, Kimberly A.
   Lee, Aaron Y.
   Leveziel, Nicolas
   Zack, Donald J.
   Campochiaro, Peter
   Smith, R. Theodore
   Barile, Gaetano R.
   Hogg, Ruth E.
   Chakravarthy, Usha
   Behrens, Timothy W.
   Uitterlinden, Andre G.
   van Duijn, Cornelia M.
   Vingerling, Johannes R.
   Brantley, Milam A., Jr.
   Baird, Paul N.
   Klaver, Caroline C. W.
   Allikmets, Rando
   Katsanis, Nicholas
   Graham, Robert R.
   Ioannidis, John P. A.
   Daly, Mark J.
   Seddon, Johanna M.
TI Heritability and Genome-Wide Association Study to Assess Genetic
   Differences between Advanced Age-related Macular Degeneration Subtypes
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; SERINE-PROTEASE; RISK; VARIANT; SUSCEPTIBILITY;
   HTRA1; POLYMORPHISM; MACULOPATHY; DISEASE; PROGRESSION
AB Purpose: To investigate whether the 2 subtypes of advanced age-related macular degeneration (AMD), choroidal neovascularization (CNV), and geographic atrophy (GA) segregate separately in families and to identify which genetic variants are associated with these 2 subtypes.
   Design: Sibling correlation study and genome-wide association study (GWAS).
   Participants: For the sibling correlation study, 209 sibling pairs with advanced AMD were included. For the GWAS, 2594 participants with advanced AMD subtypes and 4134 controls were included. Replication cohorts included 5383 advanced AMD participants and 15 240 controls.
   Methods: Participants had the AMD grade assigned based on fundus photography, examination, or both. To determine heritability of advanced AMD subtypes, a sibling correlation study was performed. For the GWAS, genome-wide genotyping was conducted and 6 036 699 single nucleotide polymorphisms (SNPs) were imputed. Then, the SNPs were analyzed with a generalized linear model controlling for genotyping platform and genetic ancestry. The most significant associations were evaluated in independent cohorts.
   Main Outcome Measures: Concordance of advanced AMD subtypes in sibling pairs and associations between SNPs with GA and CNV advanced AMD subtypes.
   Results: The difference between the observed and expected proportion of siblings concordant for the same subtype of advanced AMD was different to a statistically significant degree (P = 4.2 x 10(-5)), meaning that in siblings of probands with CNV or GA, the same advanced subtype is more likely to develop. In the analysis comparing participants with CNV to those with GA, a statistically significant association was observed at the ARMS2/HTRA1 locus (rs10490924; odds ratio [OR], 1.47; P = 4.3 x 10(-9)), which was confirmed in the replication samples (OR, 1.38; P = 7.4 x 10(-14) for combined discovery and replication analysis).
   Conclusions: Whether CNV versus GA develops in a patient with AMD is determined in part by genetic variation. In this large GWAS meta-analysis and replication analysis, the ARMS2/HTRA1 locus confers increased risk for both advanced AMD subtypes, but imparts greater risk for CNV than for GA. This locus explains a small proportion of the excess sibling correlation for advanced AMD subtype. Other loci were detected with suggestive associations that differ for advanced AMD subtypes and deserve follow-up in additional studies.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2012; 119: 1874-1885 (C) 2012 by the American Academy of Ophthalmology.
C1 [Seddon, Johanna M.] Tufts Univ, Ophthalm Epidemiol & Genet Serv, Dept Ophthalmol, New England Eye Ctr,Tufts Med Ctr,Sch Med, Boston, MA 02111 USA.
   [Sobrin, Lucia] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA.
   [Ripke, Stephan; Fagerness, Jesen; Daly, Mark J.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
   [Ripke, Stephan; Fagerness, Jesen; Daly, Mark J.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
   [Bhangale, Tushar R.] Genentech Inc, Dept Bioinformat & Computat Biol, San Francisco, CA 94080 USA.
   [Tan, Perciliz L.; Katsanis, Nicholas] Duke Univ, Ctr Human Dis Modeling, Durham, NC USA.
   [Tan, Perciliz L.; Katsanis, Nicholas] Duke Univ, Dept Cell Biol, Durham, NC USA.
   [Tan, Perciliz L.; Katsanis, Nicholas] Duke Univ, Dept Pediat, Durham, NC 27706 USA.
   [Souied, Eric H.; Leveziel, Nicolas] Univ Paris Est Creteil, Hop Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Souied, Eric H.; Leveziel, Nicolas] UPEC, Fac Med Henri Mondor, Dept Ophthalmol, Creteil, France.
   [Buitendijk, Gabrielle H. S.; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Dept Epidemiol, Rotterdam, Netherlands.
   [Merriam, Joanna E.; Smith, R. Theodore; Barile, Gaetano R.; Allikmets, Rando] Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
   [Richardson, Andrea J.; Baird, Paul N.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Raychaudhuri, Soumya] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA.
   [Raychaudhuri, Soumya] Brigham & Womens Hosp, Div Rheumatol, Boston, MA 02115 USA.
   [Lee, Aaron Y.] Washington Univ, Sch Med, St Louis, MO USA.
   [Lee, Aaron Y.] Barnes Retina Inst, St Louis, MO USA.
   [Zack, Donald J.; Campochiaro, Peter] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, McKusick Nathans Inst Genet Med,Dept Ophthalmol, Baltimore, MD 21205 USA.
   [Zack, Donald J.; Campochiaro, Peter] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.
   [Zack, Donald J.] UPMC, Dept Mol Biol & Genet, Paris, France.
   [Zack, Donald J.] UPMC, Inst Vis, Paris, France.
   [Hogg, Ruth E.; Chakravarthy, Usha] Queens Univ Belfast, Ctr Vis & Vasc Sci, Belfast, Antrim, North Ireland.
   [Behrens, Timothy W.; Graham, Robert R.] Genentech Inc, Immunol Tissue Growth & Repair ITGR Human Genet G, San Francisco, CA USA.
   [Uitterlinden, Andre G.] Erasmus MC, Dept Epidemiol, Dept Internal Med, Rotterdam, Netherlands.
   [Brantley, Milam A., Jr.] Vanderbilt Univ, Deparment Ophthalmol & Visual Sci, Nashville, TN USA.
   [Allikmets, Rando] Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA.
   [Ioannidis, John P. A.] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece.
   [Ioannidis, John P. A.] Stanford Univ, Dept Med, Sch Med, Stanford Prevent Res Ctr, Stanford, CA 94305 USA.
   [Ioannidis, John P. A.] Stanford Univ, Dept Hlth Res & Policy, Sch Med, Stanford, CA USA.
   [Ioannidis, John P. A.] Tufts Univ, Sch Med, Ctr Genet Epidemiol & Modeling, ICRHPS, Boston, MA 02111 USA.
   [Ioannidis, John P. A.] Tufts Univ, Sch Med, Tufts Clin & Translat Sci Inst, Tufts Med Ctr, Boston, MA 02111 USA.
C3 Tufts Medical Center; Tufts University; Harvard University; Harvard
   Medical School; Massachusetts Eye & Ear Infirmary; Harvard University;
   Massachusetts General Hospital; Harvard University; Massachusetts
   Institute of Technology (MIT); Broad Institute; Roche Holding;
   Genentech; Duke University; Duke University; Duke University; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Assistance Publique
   Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC);
   Hopital Universitaire Henri-Mondor - APHP; Erasmus University Rotterdam;
   Erasmus MC; Columbia University; Centre for Eye Research Australia;
   Royal Victorian Eye & Ear Hospital; University of Melbourne; Harvard
   University; Brigham & Women's Hospital; Harvard University; Brigham &
   Women's Hospital; Washington University (WUSTL); Washington University
   (WUSTL); Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; UDICE-French Research Universities; Sorbonne Universite;
   UDICE-French Research Universities; Sorbonne Universite; Queens
   University Belfast; Roche Holding; Genentech; Erasmus University
   Rotterdam; Erasmus MC; Vanderbilt University; Columbia University;
   University of Ioannina; Stanford University; Stanford University; Tufts
   University; Tufts Medical Center; Tufts University
RP Seddon, JM (通讯作者)，Tufts Univ, Ophthalm Epidemiol & Genet Serv, Dept Ophthalmol, New England Eye Ctr,Tufts Med Ctr,Sch Med, 800 Washington St,450, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
RI Ripke, Stephan/AAK-5486-2021; Hogg, Ruth E./ABC-9602-2020; Lee,
   Aaron/AAT-2839-2020; Klaver, Caroline C.W./A-2013-2016; Allikmets,
   Rando/ABD-4533-2021; Katsanis, Nicholas/E-1837-2012; Daly, Mark
   J/B-2453-2017; Ioannidis, John P. A./G-9836-2011
OI Hogg, Ruth E./0000-0001-9413-2669; Daly, Mark J/0000-0002-0949-8752;
   Baird, Paul/0000-0002-1305-3502; ripke, stephan/0000-0003-3622-835X;
   Raychaudhuri, Soumya/0000-0002-1901-8265; Chakravarthy,
   Usha/0000-0002-2606-3734; Van Duijn, Cornelia/0000-0002-2374-9204;
   Klaver, Caroline/0000-0002-2355-5258; Sobrin, Lucia/0000-0003-1575-0819;
   Nicolas, Leveziel/0000-0001-8533-9457; Lee, Aaron/0000-0002-7452-1648;
   Katsanis, Nicholas/0000-0002-2480-0171; smith,
   theodore/0000-0002-1693-943X; Zack, Don/0000-0002-7966-1973
FU National Institutes of Health, Bethesda, Maryland [R01-EY11309,
   R01-EY13435, R24-EY017404, K12-EY16335]; Massachusetts Lions Eye
   Research Fund, Inc., New Bedford, Massachusetts; Research to Prevent
   Blindness, Inc., New York, New York; Foundation Fighting Blindness,
   Owing Mills, Maryland; Macula Vision Research Foundation, West
   Conshohocken, Pennsylvania; Kaplen Foundation, Tenafly, New Jersey;
   Widgeon Point Charitable Foundation, Armonk, New York; Alcon Research
   Institute, Fort Worth, Texas; Fight for Sight Postdoctoral Award, New
   York, New York; National Health & Medical Research Council of Australia
   Centre for Clinical Research Excellence, Canberra, Australia [529923];
   American Macular Degeneration Foundation, Northampton, Massachusetts;
   Macular Degeneration Research Fund of the Ophthalmic Epidemiology and
   Genetics Service, New England Eye Center, Tufts Medical Center, Tufts
   University School of Medicine, Boston, Massachusetts; National Eye
   Institute, National Institutes of Health, Bethesda, Maryland [EY012211,
   EY012261, EY012279]; National Institute of Mental Health, Bethesda,
   Maryland [R01 MH67257, R01 MH59588, R01 MH59571, R01 MH59565, R01
   MH59587, R01 MH60870, R01 MH59566, R01 MH59586, R01 MH61675, R01
   MH60879, R01 MH81800, U01 MH46276, U01 MH46289 U01 MH46318, U01 MH79469,
   U01 MH79470]; NATIONAL EYE INSTITUTE [K12EY016335, R01EY011309,
   R01EY013435, R24EY017404, U10EY012279] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF MENTAL HEALTH [U01MH079470, R01MH059588,
   U01MH079469, R01MH061675, U01MH046289, R01MH059587, R01MH081800,
   R01MH059565, R01MH060879, R01MH059571, R01MH059566, R01MH060870,
   R01MH059586, R01MH067257] Funding Source: NIH RePORTER
FX Supported in part by an anonymous donor for the research of Johanna M.
   Seddon; the National Institutes of Health, Bethesda, Maryland (grant
   nos.: R01-EY11309, R01-EY13435, R24-EY017404, and K12-EY16335);
   Massachusetts Lions Eye Research Fund, Inc., New Bedford, Massachusetts;
   unrestricted grants and a Career Development Award from Research to
   Prevent Blindness, Inc., New York, New York; Foundation Fighting
   Blindness, Owing Mills, Maryland; The Macula Vision Research Foundation,
   West Conshohocken, Pennsylvania; Kaplen Foundation, Tenafly, New Jersey;
   Widgeon Point Charitable Foundation, Armonk, New York; Alcon Research
   Institute, Fort Worth, Texas; Fight for Sight Postdoctoral Award, New
   York, New York; National Health & Medical Research Council of Australia
   Centre for Clinical Research Excellence, Canberra, Australia (grant no.:
   529923, Translational Clinical Research in Major Eye Diseases); American
   Macular Degeneration Foundation, Northampton, Massachusetts; and the
   Macular Degeneration Research Fund of the Ophthalmic Epidemiology and
   Genetics Service, New England Eye Center, Tufts Medical Center, Tufts
   University School of Medicine, Boston, Massachusetts. Centre for Eye
   Research Australia receives Operational Infrastructure Support from the
   Victoria Government, Victoria, Australia. Funding support for the NEI
   Study of Age-Related Macular Degeneration (NEI-AMD) was provided by the
   National Eye Institute, National Institutes of Health, Bethesda,
   Maryland. Funding support for the Genome-Wide Association of
   Schizophrenia Study was provided by the National Institute of Mental
   Health, Bethesda, Maryland (grant nos.: R01 MH67257, R01 MH59588, R01
   MH59571, R01 MH59565, R01 MH59587, R01 MH60870, R01 MH59566, R01
   MH59586, R01 MH61675, R01 MH60879, R01 MH81800, U01 MH46276, U01 MH46289
   U01 MH46318, U01 MH79469, and U01 MH79470). The funding organizations
   had no role in the design or conduct of this research. Complications of
   Age-Related Macular Degeneration Prevention Trial supported by Grants
   EY012211, EY012261, and EY012279 from the National Eye Institute,
   National Institutes of Health, Bethesda, Maryland.
CR An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Complications Age-Related Macular, 2008, OPHTHALMOLOGY, V115, P1474, DOI 10.1016/j.ophtha.2008.03.008
   Complications of Age-Related Macular Degeneration Prevention Trial Study Group, 2004, Clin Trials, V1, P91
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DelaPaz MA, 1997, AM J OPHTHALMOL, V124, P331, DOI 10.1016/S0002-9394(14)70825-6
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kathiresan S, 2009, NAT GENET, V41, P334, DOI 10.1038/ng.327
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Korn JM, 2008, NAT GENET, V40, P1253, DOI 10.1038/ng.237
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Manolio TA, 2007, NAT GENET, V39, P1045, DOI 10.1038/ng2127
   Marth GT, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-9-r84
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2008, ALBERT JAKOBIECS PRI, V1, P413
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Shuler RK, 2008, AM J OPHTHALMOL, V145, P303, DOI 10.1016/j.ajo.2007.09.027
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Sobrin L, 2010, EUR J HUM GENET, V18, P496, DOI 10.1038/ejhg.2009.185
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 44
TC 61
Z9 62
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2012
VL 119
IS 9
BP 1874
EP 1885
DI 10.1016/j.ophtha.2012.03.014
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 030OY
UT WOS:000310581200023
PM 22705344
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Seddon, JM
   Reynolds, R
   Yu, Y
   Daly, MJ
   Rosner, B
AF Seddon, Johanna M.
   Reynolds, Robyn
   Yu, Yi
   Daly, Mark J.
   Rosner, Bernard
TI Risk Models for Progression to Advanced Age-Related Macular Degeneration
   Using Demographic, Environmental, Genetic, and Ocular Factors
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; BODY-MASS INDEX; DIETARY-FAT; VITAMIN-C; VARIANT;
   ASSOCIATION; SUSCEPTIBILITY; POLYMORPHISM; MACULOPATHY; HTRA1
AB Purpose: To expand our predictive models for progression to advanced stages of age-related macular degeneration (AMD) based on demographic, environmental, genetic, and ocular factors, using longer follow-up, time varying analyses, calculation of absolute risks, adjustment for competing risks, and detailed baseline AMD and drusen status.
   Design: Prospective, longitudinal study.
   Participants: We included 2937 individuals in the Age-Related Eye Disease Study, of which 819 subjects progressed to advanced AMD during 12 years of follow-up.
   Methods: Cox proportional hazards regression analyses were performed to calculate hazard ratios for progression. Covariates included demographic and environmental factors, 6 variants in 5 genes, baseline macular drusen size, and presence and type of advanced AMD in 1 eye at baseline. To assess the ability of risk scores based on all covariates to discriminate between progressors and nonprogressors, an algorithm was developed and the area under the receiver operating characteristic curve (AUC) was calculated. To validate the overall model, the total sample was randomly subdivided into derivation and test samples. Another model was built based on the derivation sample and assessed for calibration and discrimination in the test sample. Sample sizes needed for testing new treatments in clinical trials were estimated based on models with and without genetic variables.
   Main Outcome Measures: Progression to advanced AMD, including geographic atrophy and neovascular disease.
   Results: In multivariate models, age, smoking, body mass index, single nucleotide polymorphisms in the CFH, ARMS2/HTRA1, C3, C2, and CFB genes, as well as presence of advanced AMD in 1 eye and drusen size in both eyes were all independently associated with progression. The AUC for progression at 10 years in the model with genetic factors, drusen size, and environmental covariates was 0.915 in the total sample. In the test sample, based on a model estimated from the derivation sample, the AUC was 0.908. The sample sizes needed for clinical trials were estimated to be lower when genetic susceptibility was considered.
   Conclusions: Factors reflective of nature and nurture were incorporated into an expanded algorithm for risk prediction, which performed very well in both derivation and test samples. Risk scores and predicted progression rates will be useful for AMD surveillance and for designing clinical trials.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2011;118:2203-2211 (C) 2011 by the American Academy of Ophthalmology.
C1 [Seddon, Johanna M.] New England Eye Ctr, Tufts Med Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA 02111 USA.
   [Seddon, Johanna M.; Reynolds, Robyn; Yu, Yi] Tufts Univ, Sch Med, Ophthalm Epidemiol & Genet Serv, Boston, MA 02111 USA.
   [Daly, Mark J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
   [Rosner, Bernard] Harvard Univ, Sch Med, Channing Lab, Boston, MA 02115 USA.
C3 Tufts Medical Center; Tufts University; Harvard University;
   Massachusetts General Hospital; Harvard University; Harvard Medical
   School
RP Seddon, JM (通讯作者)，New England Eye Ctr, Tufts Med Ctr, Ophthalm Epidemiol & Genet Serv, 800 Washington St 450, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
RI Daly, Mark J/B-2453-2017; Mitchell, Paul/P-1498-2014
OI Daly, Mark J/0000-0002-0949-8752; 
FU National Institutes of Health [RO1-EY11309]; Massachusetts Lions Eye
   Research Fund Inc., New Bedford, MA; Research to Prevent Blindness Inc.,
   New York, NY; American Macular Degeneration Foundation, Northampton, MA;
   Tufts Medical Center; Ophthalmic Epidemiology and Genetics Service,
   Tufts Medical Center, Tufts University School of Medicine; NATIONAL EYE
   INSTITUTE [U10EY011309, R01EY011309] Funding Source: NIH RePORTER
FX Supported by grant RO1-EY11309 from the National Institutes of Health;
   the Massachusetts Lions Eye Research Fund Inc., New Bedford, MA;
   unrestricted grants from Research to Prevent Blindness Inc., New York,
   NY; the American Macular Degeneration Foundation, Northampton, MA;
   Virginia B Smith Fund, Tufts Medical Center; and the Age-Related Macular
   Degeneration Research Fund, Ophthalmic Epidemiology and Genetics
   Service, Tufts Medical Center, Tufts University School of Medicine.
CR de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Farwick A, 2009, EYE, V23, P2238, DOI 10.1038/eye.2008.426
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mckay GJ, 2010, MOL VIS, V16, P194
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosner B, 2009, BIOMETRICS, V65, P188, DOI 10.1111/j.1541-0420.2008.01062.x
   Rosner B., 2011, FUNDAMENTALS BIOSTAT, P774
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2008, ALBERT JAKOBIECS PRI, V1, P413
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Ying GS, 2011, OPHTHALMOLOGY, V118, P332, DOI 10.1016/j.ophtha.2010.06.030
NR 34
TC 131
Z9 138
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2011
VL 118
IS 11
BP 2203
EP 2211
DI 10.1016/j.ophtha.2011.04.029
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 842EG
UT WOS:000296573500016
PM 21959373
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Gupta, OP
   Shienbaum, G
   Patel, AH
   Fecarotta, C
   Kaiser, RS
   Regillo, CD
AF Gupta, Omesh P.
   Shienbaum, Gary
   Patel, Avni H.
   Fecarotta, Christopher
   Kaiser, Richard S.
   Regillo, Carl D.
TI A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related
   Macular Degeneration Clinical and Economic Impact
SO OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB AVASTIN; TRIAL
AB Purpose: To evaluate the visual outcome, number of injections, and direct medical cost of a "treat and extend" regimen (TER) in managing neovascular age-related macular degeneration (nAMD) with intravitreal ranibizumab.
   Design: Retrospective, interventional, consecutive case series.
   Participants: Ninety-two eyes of 92 patients met the entry criteria from May 2006 to May 2008.
   Methods: All patients with treatment-naive nAMD were treated monthly until no intraretinal or subretinal fluid was observed on optical coherence tomography (OCT). The treatment intervals were then sequentially lengthened by 2 weeks until signs of exudation recurred. The interval was individualized for each patient in an attempt to maintain an exudation-free macula.
   Main Outcome Measures: Change from baseline visual acuity, proportion of eyes losing <3 lines and gaining >= 3 lines at 1 year of follow-up, annual mean number of injections, change from baseline OCT central retinal thickness (CRT), maximum period of extension, and adverse ocular and systemic events.
   Results: The mean follow-up was 1.52 years. Mean Snellen visual acuity improved from 20/135 at baseline to 20/77 at 1 year follow-up (P < 0.001) and 20/83 at 2 years follow-up (P = 0.002). The proportion of eyes that lost < 3 Snellen visual acuity lines at final follow-up was 96% and the proportion that gained >= 3 Snellen visual acuity lines was 32%. The mean OCT CRT decreased from 303 mu m at baseline to 238 mu m at 1 year follow-up (P < 0.001). The mean number of injections over the first year and between years 1 and 2 was 8.36 and 7.45, respectively. The mean maximum period of extension was 79.9 days. No adverse ocular or systemic events were reported during the follow-up period. The direct annual medical cost per patient was $ 16 114.52 for the TER. The direct annual medical cost per patient ranged from $ 15 880.07 to $ 28 314.16 based on previous clinical trial protocols.
   Conclusions: Eyes with nAMD experienced significant visual improvement when managed with intravitreal ranibizumab using a TER. This treatment approach also was associated with significantly fewer patient visits, injections, and direct annual medical cost compared with monthly injections such as in the phase III clinical trials.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2010; 117: 2134-2140 (C) 2010 by the American Academy of Ophthalmology.
C1 [Gupta, Omesh P.; Shienbaum, Gary; Patel, Avni H.; Fecarotta, Christopher; Kaiser, Richard S.; Regillo, Carl D.] Thomas Jefferson Univ, Wills Eye Inst, Retina Serv, Philadelphia, PA 19107 USA.
C3 Jefferson University
RP Gupta, OP (通讯作者)，Temple Univ Hosp & Med Sch, 3401 N Broad St,Zone C Parkinson Pavil 6th Floor, Philadelphia, PA 19140 USA.
EM ogupta@hotmail.com
FU Heed Ophthalmic Foundation; Ronald G. Michels Fellowship Foundation
FX Supported by the Heed Ophthalmic Foundation (OPG) and the Ronald G.
   Michels Fellowship Foundation Award (OPG).
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Mantel I, 2008, OPHTHALMOLOGICA, V222, P321, DOI 10.1159/000144075
   *NAT ADV EY COUNC, 1998, VIS RES NAT PLAN 199, pR6
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
NR 16
TC 229
Z9 234
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2010
VL 117
IS 11
BP 2134
EP 2140
DI 10.1016/j.ophtha.2010.02.032
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 668JI
UT WOS:000283264200015
PM 20591490
DA 2022-11-30
ER

PT J
AU Baek, JH
   Lim, D
   Park, KH
   Chae, JB
   Jang, H
   Lee, J
   Chung, H
AF Baek, Je-Hyun
   Lim, Daehan
   Park, Kyu Hyung
   Chae, Jae-Byoung
   Jang, Hyoik
   Lee, Jonghyun
   Chung, Hyewon
TI Quantitative proteomic analysis of aqueous humor from patients with
   drusen and reticular pseudodrusen in age-related macular degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Complement; Drusen; Reticular
   pseudodrusen; SWATH-MS
ID COMPLEMENT FACTOR-H; CELLS-IMPLICATIONS; KERATAN SULFATE; PROTEIN;
   DEPOSITS; EYES; MALONDIALDEHYDE; MEMBRANE; PRODUCTS; CULTURE
AB BackgroundTo identify novel biomarkers related to the pathogenesis of dry age-related macular degeneration (AMD), we adopted a human retinal pigment epithelial (RPE) cell culture model that mimics some features of dry AMD including the accumulation of intra- and sub-RPE deposits. Then, we investigated the aqueous humor (AH) proteome using a data-independent acquisition method (sequential window acquisition of all theoretical fragment ion mass spectrometry) for dry AMD patients and controls.MethodsAfter uniformly pigmented polarized monolayers of human fetal primary RPE (hfRPE) cells were established, the cells were exposed to 4-hydroxy-2-nonenal (4-HNE), followed by Western blotting, immunofluorescence analysis and ELISA of cells or conditioned media for several proteins of interest. Data-dependent acquisition for identification of the AH proteome and SWATH-based mass spectrometry were performed for 11 dry AMD patients according to their phenotypes (including soft drusen and reticular pseudodrusen [RPD]) and 2 controls (3 groups).ResultsIncreased intra- and sub-RPE deposits were observed in 4-HNE-treated hfRPE cells compared with control cultures based on APOA1, cathepsin D, and clusterin immunoreactivity. Additionally, the differential abundance of proteins in apical and basal chambers with or without 4-HNE treatment confirmed the polarized secretion of proteins from hfRPE cells. A total of 119 proteins were quantified in dry AMD patients and controls by SWATH-MS. Sixty-five proteins exhibited significantly altered abundance among the three groups. A two-dimensional principal component analysis plot was generated to identify typical proteins related to the pathogenesis of dry AMD. Among the identified proteins, eight proteins, including APOA1, CFHR2, and CLUS, were previously considered major components or regulators of drusen. Three proteins (SERPINA4, LUM, and KERA proteins) have not been previously described as components of drusen or as being related to dry AMD. Interestingly, the LUM and KERA proteins, which are related to extracellular matrix organization, were upregulated in both RPD and soft drusen.ConclusionsDifferential protein expression in the AH between patients with drusen and RPD was quantified using SWATH-MS in the present study. Detailed proteomic analyses of dry AMD patients might provide insights into the in vivo biology of drusen and RPD.
C1 [Baek, Je-Hyun] Seegene Med Fdn, R&D Ctr Clin Mass Spectrometry, Seoul 04805, South Korea.
   [Lim, Daehan; Chae, Jae-Byoung; Jang, Hyoik; Chung, Hyewon] Konkuk Univ, Sch Med, Dept Ophthalmol, Med Ctr, 120-1 Neungdong Ro, Seoul, South Korea.
   [Park, Kyu Hyung] Seoul Natl Univ, Dept Ophthalmol, Coll Med, Bundang Hosp, Seongnam 13620, South Korea.
   [Lee, Jonghyun] Inje Univ, Coll Med, Ilsan Paik Hosp, Dept Ophthalmol, Goyang 10380, South Korea.
C3 Konkuk University; Konkuk University Medical Center; Seoul National
   University (SNU); Inje University
RP Chung, H (通讯作者)，Konkuk Univ, Sch Med, Dept Ophthalmol, Med Ctr, 120-1 Neungdong Ro, Seoul, South Korea.
EM hchung@kuh.ac.kr
OI Baek, Je-Hyun/0000-0003-4974-8397
FU National Research Foundation of Korea (NRF) - Ministry of Science and
   ICT [NRF-2017R1E1A1A01073964]
FX This research was supported by the National Research Foundation of Korea
   (NRF) funded by the Ministry of Science and ICT
   (NRF-2017R1E1A1A01073964).
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Al Gwairi O, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/2913612
   Ali SAM, 2011, J VET MED SCI, V73, P439, DOI 10.1292/jvms.10-0464
   Alten F, 2015, BR J OPHTHALMOL
   Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Baek JH, 2009, J PROTEOME RES, V8, P3625, DOI 10.1021/pr800853k
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Bloch SB, 2012, AM J OPHTHALMOL
   Bonilha VL, 2004, MOL CELL PROTEOMICS, V3, P1119, DOI 10.1074/mcp.M400106-MCP200
   Bressler NM, 2006, ARCH OPHTHALMOL
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Ethen CM, 2007, INVEST OPHTH VIS SCI, V48, P3469, DOI 10.1167/iovs.06-1058
   Funderburgh JL, 2000, GLYCOBIOLOGY, V10, P951, DOI 10.1093/glycob/10.10.951
   Gangalum RK, 2011, J BIOL CHEM, V286, P3261, DOI 10.1074/jbc.M110.160135
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Gliem M, 2015, OPHTHALMOLOGY, V122, P1555, DOI 10.1016/j.ophtha.2015.04.035
   Gliem M, 2015, JAMA OPHTHALMOL, V133, P581, DOI 10.1001/jamaophthalmol.2015.117
   Grassi G, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.249
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Hageman GS, 2001, PROG RETIN EYE RES
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Kang GY, 2014, J PROTEOME RES, V13, P581, DOI 10.1021/pr400751k
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kay P, 2013, J CELL MOL MED, V17, P833, DOI 10.1111/jcmm.12070
   Keenan TDL, 2014, INVEST OPHTH VIS SCI, V55, P5370, DOI 10.1167/iovs.14-14126
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Kovach JL, 2016, OPHTHALMOLOGY, V123, P921, DOI 10.1016/j.ophtha.2015.10.036
   KRUSIUS T, 1986, J BIOL CHEM, V261, P8237
   Kurien BT, 2008, AUTOIMMUN REV, V7, P567, DOI 10.1016/j.autrev.2008.04.019
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Lee H, 2014, BMB REP, V47, P292, DOI 10.5483/BMBRep.2014.47.5.193
   Lee WK, 2014, B KOREAN CHEM SOC, V35, P933, DOI 10.5012/bkcs.2014.35.3.933
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mitchell P, 2014, PLOS ONE
   Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261
   Nikitovic D, 2014, MATRIX BIOL, V35, P206, DOI 10.1016/j.matbio.2013.09.003
   Pavelic SK, 2015, BBA-MOL BASIS DIS, V1852, P1833, DOI 10.1016/j.bbadis.2015.06.006
   Rofagha S, 2013, OPHTHALMOLOGY
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Seong KM, 2007, FEBS LETT, V581, P2567, DOI 10.1016/j.febslet.2007.04.064
   Sivaprasad S, 2016, SURV OPHTHALMOL, V61, P521, DOI 10.1016/j.survophthal.2016.02.005
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P3859, DOI 10.1167/iovs.05-0672
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zhang Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129945
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
NR 54
TC 18
Z9 18
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD NOV 7
PY 2018
VL 18
AR 289
DI 10.1186/s12886-018-0941-9
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GZ8JO
UT WOS:000449736900001
PM 30404605
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Csaky, KG
   Dugel, PU
   Pierce, AJ
   Fries, MA
   Kelly, DS
   Danis, RP
   Wurzelmann, JI
   Xu, CF
   Hossain, M
   Trivedi, T
AF Csaky, Karl G.
   Dugel, Pravin U.
   Pierce, Amy J.
   Fries, Michael A.
   Kelly, Deborah S.
   Danis, Ronald P.
   Wurzelmann, John I.
   Xu, Chun-Fang
   Hossain, Mohammad
   Trivedi, Trupti
TI Clinical Evaluation of Pazopanib Eye Drops versus Ranibizumab
   Intravitreal Injections in Subjects with Neovascular Age-Related Macular
   Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; CHOROIDAL NEOVASCULARIZATION; KINASE INHIBITOR;
   DOSING REGIMEN; THERAPY; PHARMACOGENETICS; POLYMORPHISM; VERTEPORFIN
AB Purpose: To evaluate pazopanib eye drops in subjects with active subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
   Design: Multicountry, randomized, parallel-group, double-masked, active and placebo-controlled, dose-ranging study of eye drops.
   Participants: A total of 510 subjects (93% white; 58% female; mean age, 75.3 years) whose AMD was previously managed by anti-vascular endothelial growth factor intravitreal injections.
   Methods: Treatments administered for 52 weeks included placebo eye drops instilled 4 times daily (n = 73); pazopanib 5 mg/ml instilled 3 (n = 72) or 4 times daily (n = 74); pazopanib 10 mg/ml instilled 2 (n = 73), 3 (n = 73), or 4 times daily (n = 72); or ranibizumab injection administered once every 4 weeks (n = 73). In addition, for all eye drop treatment groups, open-label ranibizumab was administered as needed.
   Main Outcome Measures: The main outcome measures were best-corrected visual acuity (BCVA) and injection frequency assessed at week 52. Safety was assessed every 4 weeks and pazopanib plasma concentrations were determined at weeks 4 and 24.
   Results: At week 52, pazopanib, with allowance for as-needed ranibizumab injections, was noninferior to monthly ranibizumab as well as to as-needed ranibizumab administered with placebo eye drops in maintaining BCVA (estimated BCVA gains of 0.3-1.8 vs. 1.4 vs. 0.2 letters, respectively). Pazopanib treatment did not reduce as-needed ranibizumab injections by >= 50% (prespecified efficacy criterion). At week 52, there were no clinically meaningful changes from baseline in retinal thickness or morphology, CNV size, or lesion characteristics on optical coherence tomography or fluorescein angiography. Complement factor H genotype had no effect on the responses to pazopanib and/or ranibizumab (BCVA, injection rate, or optical coherence tomography/fluorescein angiography changes). Steady-state concentrations of pazopanib in plasma seemed to be reached by week 4. The most common ocular adverse events related to pazopanib and ranibizumab were application site pain (3%) and injection site hemorrhage (1%), respectively. No treatment-related serious adverse events were reported.
   Conclusions: Pazopanib was well tolerated. Daily pazopanib eye drops in neovascular AMD subjects did not result in therapeutic benefit beyond that obtained with ranibizumab alone. (C) 2015 by the American Academy of Ophthalmology.
C1 [Csaky, Karl G.] Retina Fdn Southwest, Dallas, TX USA.
   [Dugel, Pravin U.] Retinal Consultants Arizona, Phoenix, AZ USA.
   [Pierce, Amy J.; Fries, Michael A.; Kelly, Deborah S.; Wurzelmann, John I.; Xu, Chun-Fang; Hossain, Mohammad; Trivedi, Trupti] GlaxoSmithKline, King Of Prussia, PA USA.
   [Danis, Ronald P.] Univ Wisconsin, Madison, WI USA.
C3 Retina Foundation of the Southwest; GlaxoSmithKline; University of
   Wisconsin System; University of Wisconsin Madison
RP Wurzelmann, JI (通讯作者)，GlaxoSmithKline, ATTN 5-4617,POB 13398,5 Moore Dr, Res Triangle Pk, NC 27709 USA.
EM wurzelma@gmail.com
OI Xu, Chun-Fang/0000-0002-8747-0683
FU GlaxoSmithKline (GSK)
FX Sponsored by GlaxoSmithKline (GSK). Medical writing support was
   sponsored by GSK and was provided by Cullen T. Vogelson, PhD, and Usha
   Sivaprasad, PhD, of Illuminated Research, LLC (Fort Worth, TX).
CR Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042464
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Danis R, 2014, BRIT J OPHTHALMOL, V98, P172, DOI 10.1136/bjophthalmol-2013-303117
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Hanout M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/830837
   Ho AC, 2008, INVEST OPHTHALMOL VI, V49
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kumar R, 2007, MOL CANCER THER, V6, P2012, DOI 10.1158/1535-7163.MCT-07-0193
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Takahashi K, 2009, ARCH OPHTHALMOL-CHIC, V127, P494, DOI 10.1001/archophthalmol.2009.27
   Yafai Y, 2011, EUR J PHARMACOL, V666, P12, DOI 10.1016/j.ejphar.2011.05.016
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 28
TC 43
Z9 44
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2015
VL 122
IS 3
BP 579
EP 588
DI 10.1016/j.ophtha.2014.09.036
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CC2DF
UT WOS:000350154600028
PM 25432081
DA 2022-11-30
ER

PT J
AU Mathalone, N
   Arodi-Golan, A
   Sar, S
   Wolfson, Y
   Shalem, M
   Lavi, I
   Geyer, O
AF Mathalone, Nurit
   Arodi-Golan, Anat
   Sar, Shaul
   Wolfson, Yulia
   Shalem, Mordechai
   Lavi, Idit
   Geyer, Orna
TI Sustained elevation of intraocular pressure after intravitreal
   injections of bevacizumab in eyes with neovascular age-related macular
   degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Bevacizumab; Intraocular pressure (IOP); Age-related macular
   degeneration (AMD)
ID REPACKAGED BEVACIZUMAB; RANIBIZUMAB; GLAUCOMA
AB The use of intravitreal anti-VEGF agents in general, and of bevacizumab (Avastin) in particular, has become the common first-line treatment of neovascular age-related macular degeneration (AMD). Several reports addressed the possible elevation of intraocular pressure (IOP) following intravitreal injection of anti-VEGF. The aim of this study was to determine the prevalence of sustained IOP elevation following intravitreal bevacizumab injections for neovascular AMD and identify possible risk factors for the development of increased IOP.
   This retrospective cohort study included 174 consecutive patients (201 eyes) receiving intravitreal bevacizumab (1.25 mg/0.05 ml) as treatment for neovascular AMD. The records of the study patients were reviewed for age, gender, history of glaucoma, phakic status, IOP levels, length of follow-up, total number of injections, intervals between injections, and IOP management in eyes that exhibited IOP elevation. Sustained IOP elevation was defined as IOP a parts per thousand yen22 mmHg and a change from baseline of a parts per thousand yen6 mmHg recorded on at least two consecutive visits and lasting a parts per thousand yen30 days. Risk factors for an IOP increase were identified from the association between the studied variables and IOP elevations.
   Sustained IOP elevation was found in 22 of 201 eyes (11%). The increased IOP was controlled with topical medications in all eyes. Among the variables studied, only male gender [OR = 3.1, 95% CI (1.1, 8.5) p = 0.029] and length of interval between injections < 8 weeks [OR = 3.0, 95%CI (1.1, 7.9), p = 0.028] emerged as risk factors for IOP elevation in a multivariable model. The prevalence of IOP elevation was significantly higher when the interval between injections was < 8 weeks than a parts per thousand yen8 weeks (17.6 and 6%, respectively, p = 0.009). Pre-existing glaucoma was not associated with IOP elevation (p = 0.9).
   Sustained IOP elevations can occur in normotensive eyes undergoing intravitreal bevacizumab treatment for neovascular AMD. This phenomenon was related to shorter intervals between injections, with 8 weeks being taken as the cut-off point. AMD eyes that receive intravitreal bevacizumab injections need to be monitored for IOP changes, especially those in which the intervals between injections are < 8 weeks.
C1 [Mathalone, Nurit; Arodi-Golan, Anat; Sar, Shaul; Wolfson, Yulia; Shalem, Mordechai; Geyer, Orna] Carmel Hosp, Dept Ophthalmol, Haifa, Israel.
   [Mathalone, Nurit; Arodi-Golan, Anat; Sar, Shaul; Wolfson, Yulia; Shalem, Mordechai; Geyer, Orna] Technion Israel Inst Technol, Bruce Rappaport Med Sch, Haifa, Israel.
   [Lavi, Idit] Carmel Hosp, Dept Community Med & Epidemiol, Haifa, Israel.
C3 Clalit Health Services; Carmel Medical Center; Technion Israel Institute
   of Technology; Clalit Health Services; Carmel Medical Center
RP Mathalone, N (通讯作者)，Carmel Hosp, Dept Ophthalmol, 7 Michal St, Haifa, Israel.
EM matnurit@yahoo.com
OI Geyer, Orna/0000-0003-2253-9034
CR Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P779, DOI 10.1007/s00417-007-0754-7
   Blackwell B, 2002, AM J OPHTHALMOL, V134, P499
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Hohn F, 2010, GRAEF ARCH CLIN EXP, V248, P1371, DOI 10.1007/s00417-010-1382-1
   Kahook MY, 2010, RETINA-J RET VIT DIS, V30, P887, DOI 10.1097/IAE.0b013e3181d50cea
   Kahook MY, 2009, OPHTHAL SURG LAS IM, V40, P293, DOI 10.3928/15428877-20090430-12
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   LESKE MC, 1994, ARCH OPHTHALMOL-CHIC, V112, P821, DOI 10.1001/archopht.1994.01090180121046
   Liu L, 2011, INVEST OPHTH VIS SCI, V52, P1023, DOI 10.1167/iovs.10-6431
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Sniegowski M, 2010, OPEN OPHTHALMOL J, V4, P28, DOI 10.2174/1874364101004010028
   Tseng JJ, 2012, J GLAUCOMA, V21, P241, DOI 10.1097/IJG.0b013e31820d7d19
NR 14
TC 73
Z9 76
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2012
VL 250
IS 10
BP 1435
EP 1440
DI 10.1007/s00417-012-1981-0
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 013ZR
UT WOS:000309345300005
PM 22434210
DA 2022-11-30
ER

PT J
AU Pearce, E
   Sivaprasad, S
   Chong, NV
AF Pearce, E.
   Sivaprasad, S.
   Chong, N. V.
TI Comparing fixation location and stability in patients with neovascular
   age-related macular degeneration treated with or without Ranibizumab
SO EYE
LA English
DT Article
DE age-related macular degeneration; ranibizumab; fixation; eccentric;
   visual rehabilitation; low vision
ID SCANNING LASER OPHTHALMOSCOPE; OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL
   NEOVASCULARIZATION; RETINAL LOCUS; SCOTOMA
AB Purpose To compare fixation location and stability in patients with neovascular age-related macular degeneration (AMD) treated with or without ranibizumab.
   Methods Patients were recruited from the Macular Clinic of the King's College Hospital in London. Two groups of patients with neovascular AMD with at least 12 months of follow-up were included in the study. The treated group was treated with ranibizumab while the untreated group did not have any treatment. Best corrected visual acuity (BCVA) with modified ETDRS chart, fixation location and stability as measured with Nidek MP1, central retinal thickness as measured by Zeiss Cirrus SD-optical coherent tomography (OCT), and lesion size as measured by Topcon TRC-50IX camera were analysed and correlated.
   Results In total, 102 eyes were included in the study with 76 in the ranibizumab-treated group and 26 in the untreated group. There were no significantly demographic differences between the two groups. However, as expected, the treated group has significantly better vision (48.5 vs 15.5 letters, P < 0.0001) and smaller lesions (10.8 vs 18.3 mm(2), P = 0.004), the central macular thickness as measured by OCT also showed a trend of normalised macular thickness (252 vs 282 microns, P = 0.07). The location of fixation was significantly more central in the ranibizumab-treated group (chi(2) 17.9, P < 0.0001) with over 50% of eyes with predominantly central fixation. Majority (84.6%) of the patients in the untreated group had predominantly eccentric fixation. Fixation stability was significantly better in the ranibizumab-treated group as compared with the untreated group, using both the software provided by the MP1 machine (chi(2) 21.8, P < 0.0001) and the mean log bivariate contour ellipse area calculated from the raw data obtained from the machine (3.64 vs 4.39 in treated and untreated group respectively, P < 0.0001).
   Conclusion Low vision rehabilitation strategy for this group of patients in the ranibizumab era will be very different from those used in untreated patients with dense central scotoma. Further studies on the visual rehabilitation in the ranibizumab-treated patients should consider fixation characteristics of the patients. Eye (2011) 25, 149-153; doi: 10.1038/eye.2010.167; published online 19 November 2010
C1 [Chong, N. V.] Univ Oxford, Oxford Eye Hosp, Oxford OX3 9DU, England.
   [Chong, N. V.] Univ London, Kings Coll Hosp, Laser & Retinal Res Unit, London, England.
C3 University of Oxford; King's College Hospital NHS Foundation Trust;
   King's College Hospital; University of London
RP Chong, NV (通讯作者)，Univ Oxford, Oxford Eye Hosp, Headley Way, Oxford OX3 9DU, England.
EM victor@eretina.org
RI Sivaprasad, S./D-6876-2015; Chong, Victor/Q-6565-2018
OI Sivaprasad, S./0000-0001-8952-0659; Chong, Victor/0000-0002-7693-522X
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Crossland MD, 2009, RETINA-J RET VIT DIS, V29, P651, DOI 10.1097/IAE.0b013e318196bd65
   Fornos AP, 2006, INVEST OPHTH VIS SCI, V47, P1439, DOI 10.1167/iovs.05-0973
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P1671, DOI 10.1167/iovs.09-4496
   Fujii GY, 2003, AM J OPHTHALMOL, V136, P1067, DOI 10.1016/S0002-9394(03)00663-9
   GOODRICH GL, 1986, AM J OPTOM PHYS OPT, V63, P119
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   Palmer S, 2010, BRIT J OPHTHALMOL, V94, P494, DOI 10.1136/bjo.2008.152231
   Preacher K. J., 2001, CALCULATION CHI SQUA
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Stelmack JA, 2004, J REHABIL RES DEV, V41, P729, DOI 10.1682/JRRD.2003.08.0136
   TIMBERLAKE GT, 1987, INVEST OPHTH VIS SCI, V28, P1268
   Witkin AJ, 2009, OPHTHALMOLOGY, V116, P956, DOI 10.1016/j.ophtha.2008.12.018
NR 15
TC 11
Z9 13
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2011
VL 25
IS 2
BP 149
EP 153
DI 10.1038/eye.2010.167
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 719FR
UT WOS:000287187300003
PM 21102492
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Seddon, JM
   Cote, J
   Davis, N
   Rosner, B
AF Seddon, JM
   Cote, J
   Davis, N
   Rosner, B
TI Progression of age-related macular degeneration - Association with body
   mass index, waist circumference, and waist-hip ratio
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID CORONARY-HEART-DISEASE; DIETARY-FAT; RISK-FACTORS;
   CARDIOVASCULAR-DISEASE; HORMONE REPLACEMENT; CIGARETTE-SMOKING; 5-YEAR
   INCIDENCE; MACULOPATHY; EXERCISE; HEALTH
AB Background: Individuals with early or intermediate stages of age-related macular degeneration (AMD) make up a large and growing segment of our elderly population. To advise these high-risk patients regarding preventive measures, we evaluated anthropomorphic, behavioral, and medical factors associated with progression to the advanced stages of AMD associated with visual loss.
   Methods: The design was a prospective cohort study in a hospital-based retinal practice. The 261 participants were 60 years or older, with some sign of nonadvanced AMD and visual acuity of 20/200 or better in at least 1 eye. The average follow-up time was 4.6 years, and the total person-years of follow-up was 1198. Factors associated with rates of progression to advanced AMD were assessed by the Cox proportional hazards model.
   Outcome Measures: Progression to geographic atrophy and neovascular disease.
   Results: Higher body mass index (calculated as weight in kilograms divided by the square of height in meters) increased the risk for progression to the advanced forms of AMD. Relative risk (RR) was 2.35 (95% confidence interval [CI], 1.27-4.34) for a body mass index of at least 30, and 2.32 (95% CI, 1.32-4.07) for a body mass index of 25 to 29, relative to the lowest category, (<25) after controlling for other factors (P=.007 for trend). Higher waist circumference was associated with a 2-fold increased risk for progression (RR for the highest tertile compared with the lowest, 2.04; 95% CI, 1.12-3.72), with a significant trend for increasing risk with a greater waist circumference (P=.02). Higher waist-hip ratio also increased the risk for progression (RR, 1.84; 95% CI, 1.07-3.15) for the highest tertile compared with lowest (P=.02 for trend). More physical activity tended to be associated with a reduced rate of progression (25% reduction for 3 times per week vigorous activity vs none, P=.05 to P=.07). Relative risks for smoking ranged from 1.48 to 1.99, but were not statistically significant.
   Conclusions: Results provide new information regarding modifiable factors for individuals with the early or intermediate stages of this disease. Overall and abdominal obesity increased the risk for progression to advanced AMD, and more physical activity tended to decrease risk. These preventive measures deserve additional research and greater emphasis.
C1 Massachusetts Eye & Ear Infirm, Epidemiol Unit, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
   Harvard Univ, Sch Med, Dept Med Biostat, Boston, MA USA.
   Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
C3 Harvard University; Massachusetts Eye & Ear Infirmary; Harvard
   University; Harvard Medical School; Harvard University; Harvard Medical
   School; Harvard University; Harvard T.H. Chan School of Public Health;
   Harvard University; Harvard T.H. Chan School of Public Health
RP Seddon, JM (通讯作者)，Massachusetts Eye & Ear Infirm, Epidemiol Unit, 243 Charles St, Boston, MA 02114 USA.
EM johanna_seddon@meei.harvard.edu
FU NEI NIH HHS [EY 11309] Funding Source: Medline
CR *AG REL EYE DIS ST, 1992, AG REL EYE DIS STUD
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Baik I, 2000, AM J EPIDEMIOL, V152, P264, DOI 10.1093/aje/152.3.264
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   CHYLACK LT, 1989, ARCH OPHTHALMOL-CHIC, V107, P991, DOI 10.1001/archopht.1989.01070020053028
   Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
   COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256
   DelaPaz MA, 1997, AM J OPHTHALMOL, V124, P331, DOI 10.1016/S0002-9394(14)70825-6
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Friedrich MJ, 2002, JAMA-J AM MED ASSOC, V287, P1382, DOI 10.1001/jama.287.11.1382
   Hu FB, 2000, JAMA-J AM MED ASSOC, V283, P2961, DOI 10.1001/jama.283.22.2961
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Janssen I, 2002, ARCH INTERN MED, V162, P2074, DOI 10.1001/archinte.162.18.2074
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Kraus WE, 2002, NEW ENGL J MED, V347, P1483, DOI 10.1056/NEJMoa020194
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Manson JE, 2002, NEW ENGL J MED, V347, P716, DOI 10.1056/NEJMoa021067
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   *NAT ADV EYE COUNC, 1998, NIH PUBL
   *NAT HLTH CTR HLTH, 1997, MMWR-MORBID MORTAL W, V46, P198
   *NIH NAT EYE I PRE, 2002, VIS PROBL US PREV AD
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   SEDDON JM, 1990, INVEST OPHTH VIS SCI, V31, P1592
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   Snow KK, 2000, INT J FERTIL WOMEN M, V45, P301
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Stampfer MJ, 2000, NEW ENGL J MED, V343, P16, DOI 10.1056/NEJM200007063430103
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Tanasescu N, 2002, JAMA-J AM MED ASSOC, V288, P1994, DOI 10.1001/jama.288.16.1994
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Visser M, 1999, JAMA-J AM MED ASSOC, V282, P2131, DOI 10.1001/jama.282.22.2131
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zhu SK, 2002, AM J CLIN NUTR, V76, P743, DOI 10.1093/ajcn/76.4.743
NR 54
TC 271
Z9 282
U1 0
U2 18
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUN
PY 2003
VL 121
IS 6
BP 785
EP 792
DI 10.1001/archopht.121.6.785
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 687ZY
UT WOS:000183408600004
PM 12796248
OA Bronze
DA 2022-11-30
ER

PT J
AU Savastano, MC
   Minnella, AM
   Tamburrino, A
   Giovinco, G
   Ventre, S
   Falsini, B
AF Savastano, Maria Cristina
   Minnella, Angelo Maria
   Tamburrino, Antonello
   Giovinco, Gaspare
   Ventre, Salvatore
   Falsini, Benedetto
TI Differential Vulnerability of Retinal Layers to Early Age-Related
   Macular Degeneration: Evidence by SD-OCT Segmentation Analysis
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related maculopathy; automated segmentation analysis; ischemia;
   postreceptoral retina; spectral domain optical coherence tomography
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION; FUNDUS
   AUTOFLUORESCENCE; COMPLEX DIFFUSION; GROWTH-FACTOR; MACULOPATHY;
   POLYMORPHISM; DISEASE; IMAGES; RISK
AB PURPOSE. We evaluated layer-by-layer retinal thickness in spectral-domain optical coherence tomography (SD-OCT), determined by automated segmentation analysis (ASA) software in healthy and early age-related maculopathy (ARM) eyes.
   METHODS. There were 57 eyes (specifically, 19 healthy eyes under 60 years old, 19 healthy eyes over 60, and 19 ARM eyes) recruited into this cross-sectional study. The mean ages were 36.78 (SD, +/- 613.82), 69.89 (SD, +/- 66.14), and 66.10 (SD, +/- 68.67) years, respectively, in the three study groups. The SD-OCT scans were transferred into a dedicated software program that performed automated segmentation of different retinal layers.
   RESULTS. Automated layer segmentation showed clear boundaries between the following layers: retinal nerve fiber layer (RNFL), ganglion cell layer plus inner plexiform layer (GCL+IPL), inner nuclear layer plus outer plexiform layer (INL+OPL), outer nuclear layer (ONL), and RPE complex. The thickness of the RNFL, ONL, and RPE layers did not show a statistically significant change across the three groups by ANOVA (P = 0.10, P = 0.09, P = 0.15, respectively). The thickness of GCL vertical bar IPL and INL vertical bar OPL was significantly different across the groups (P < 0.01), being reduced in the ARM eyes compared to healthy eyes, under and over 60 years old.
   CONCLUSIONS. The early morphologic involvement of the GCL+IPL and INL+OPL layers in ARM eyes, as revealed by the ASA, could be related to early anatomic changes described in the inner retina of ARM eyes. This finding may represent a morphologic correlation to the deficits in postreceptoral retinal function in ARM eyes.
C1 [Savastano, Maria Cristina; Minnella, Angelo Maria; Falsini, Benedetto] Univ Cattolica Sacro Cuore, Inst Ophthalmol, I-00168 Rome, Italy.
   [Tamburrino, Antonello; Ventre, Salvatore] Univ Cassino, Dipartimento Automaz Elettromagnetismo Ingn Infor, I-03043 Cassino, FR, Italy.
   [Giovinco, Gaspare] Univ Cassino, DiMSAT, I-03043 Cassino, FR, Italy.
C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   University of Cassino; University of Cassino
RP Savastano, MC (通讯作者)，Univ Cattolica Sacro Cuore, Policlin A Gemelli, Largo A Gemelli 8, I-00168 Rome, Italy.
EM crisav8@virgilio.it
RI Savastano, Maria Cristina/I-5355-2015; Falsini, Benedetto/AAC-5907-2022;
   minnella, angelo maria/AAQ-6250-2020; Falsini, Benedetto/V-1070-2019
OI Savastano, Maria Cristina/0000-0003-1397-4333; minnella, angelo
   maria/0000-0001-5896-5313; Falsini, Benedetto/0000-0002-1694-1062;
   Giovinco, Gaspare/0000-0001-6779-5774; Falsini,
   Benedetto/0000-0002-3569-4968; TAMBURRINO, Antonello/0000-0003-2462-6350
CR Aguirre-Lamban J, 2011, INVEST OPHTH VIS SCI, V52, P6206, DOI 10.1167/iovs.10-5743
   Arden GB, 2005, BRIT J OPHTHALMOL, V89, P764, DOI 10.1136/bjo.2004.062547
   Bagci AM, 2008, AM J OPHTHALMOL, V146, P679, DOI 10.1016/j.ajo.2008.06.010
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chiu CJ, 2011, INVEST OPHTH VIS SCI, V52, P9099, DOI 10.1167/iovs.11-7782
   Clark ME, 2011, BRIT J OPHTHALMOL, V95, P1427, DOI 10.1136/bjo.2010.190355
   Cringle SJ, 2002, INVEST OPHTH VIS SCI, V43, P1922
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Feigl B, 2007, EYE, V21, P689, DOI 10.1038/sj.eye.6702389
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Fernandez DC, 2005, OPT EXPRESS, V13, P10200, DOI 10.1364/OPEX.13.010200
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Gilboa G, 2002, LECT NOTES COMPUT SC, V2350, P399
   Gilboa G, 2001, LECT NOTES COMPUT SC, V2106, P299
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Huang YJ, 1998, INVEST OPHTH VIS SCI, V39, P2405
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Issa PC, 2008, ARCH OPHTHALMOL-CHIC, V126, P1463, DOI 10.1001/archopht.126.10.1463
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kellner U, 2010, RETINA-J RET VIT DIS, V30, P6, DOI 10.1097/IAE.0b013e3181b8348b
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Le Tien V, 2008, AM J OPHTHALMOL, V146, P520, DOI 10.1016/j.ajo.2008.05.031
   Li YY, 1996, IEEE T IMAGE PROCESS, V5, P987, DOI 10.1109/83.503914
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Menke MN, 2005, OPHTHAL SURG LAS IM, V36, P310, DOI 10.3928/1542-8877-20050701-10
   Mishra A, 2009, OPT EXPRESS, V17, P23719, DOI 10.1364/OE.17.023719
   Nishiguchi KM, 2012, INVEST OPHTH VIS SCI, V53, P508, DOI 10.1167/iovs.11-8425
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Piccardi M, 2009, OPHTHALMIC RES, V41, P194, DOI 10.1159/000217723
   Pocrnich CE, 2012, GRAEF ARCH CLIN EXP, V250, P515, DOI 10.1007/s00417-011-1871-x
   Quellec G, 2010, IEEE T MED IMAGING, V29, P1321, DOI 10.1109/TMI.2010.2047023
   Vaclavik V, 2008, OPHTHALMOLOGY, V115, P342, DOI 10.1016/j.ophtha.2007.04.023
   Williams GA, 2004, OPHTHALMOLOGY, V111, P1055, DOI 10.1016/j.ophtha.2004.02.004
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yazdanpanah A, 2011, IEEE T MED IMAGING, V30, P484, DOI 10.1109/TMI.2010.2087390
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zerbib J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007341
NR 45
TC 44
Z9 45
U1 0
U2 8
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2014
VL 55
IS 1
BP 560
EP 566
DI 10.1167/iovs.13-12172
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AB6DG
UT WOS:000331877200066
PM 24408984
DA 2022-11-30
ER

PT J
AU Ladas, ID
   Kotsolis, AI
   Papakostas, TD
   Rouvas, AA
   Karagiannis, DA
   Vergados, I
AF Ladas, Ioannis D.
   Kotsolis, Athanasios I.
   Papakostas, Thanos D.
   Rouvas, Alexandros A.
   Karagiannis, Dimitrios A.
   Vergados, Ioannis
TI Intravitreal bevacizumab combined with photodynamic therapy for the
   treatment of occult choroidal neovascularization associated with serous
   pigment epithelium detachment in age-related macular degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; bevacizumab; occult choroidal
   neovascularization; photodynamic therapy; serous pigment epithelium
   detachment
ID GUIDED LASER PHOTOCOAGULATION; RANIBIZUMAB; INJECTION; AVASTIN
AB Purpose: To evaluate the efficacy of intravitreal injection of bevacizurnab combined with photodynamic therapy (PDT) for the treatment of occult choroidal neovascularization (CNV) associated with serous pigment epithelium detachment (s-PED) due to age-related macular degeneration (AMD).
   Methods: In this retrospective study, six patients (six eyes) with subfoveal occult CNV associated with s-PED due to AMD were treated with intravitreal bevacizurnab combined with PDT. All patients were treated at baseline with PDT followed by intravitreal bevacizumab 1.25 mg 1 hour later. Afterwards, according to the findings of optical coherence tomography and fluorescein angiography, repeat bevacizurnab injections were given, if necessary, monthly for three doses followed by further doses every 3 months. PDT was repeated every 3 months according to the same criteria. Follow-up time was 9 months.
   Results: All patients completed their treatment during the first 3 months from baseline. Best-corrected visual acuity (BCVA) improved or remained stable related to the baseline values in all patients at the end of the follow-up time. Mean BCVA improved from 20/67 to 20/42. S-PED and subretinal fluid decreased or disappeared. The mean central 1-mm retinal thickness was reduced from baseline value for the 9-month follow-up period by 128 mu m.
   Conclusion: Intravitreal bevacizumab combined with PDT seems to be a promising treatment with good functional and anatomical results for occult CNV associated with s-PED due to AMD.
C1 Univ Athens, Sch Med, Dept Ophthalmol 1, GR-11527 Athens, Greece.
   Univ Athens, Sch Med, Dept Ophthalmol 2, GR-11527 Athens, Greece.
   Ophthalmiatrio Athens, Dept B, Athens, Greece.
C3 Athens Medical School; National & Kapodistrian University of Athens;
   Athens Medical School; National & Kapodistrian University of Athens
RP Ladas, ID (通讯作者)，8 Meg Alexandrou Str,15236 P Penteli, Athens, Greece.
EM t_papakostas@yahoo.com
CR Aggio FB, 2006, ACTA OPHTHALMOL SCAN, V84, P831, DOI 10.1111/j.1600-0420.2006.00764.x
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Axer-Siegel R, 2004, ARCH OPHTHALMOL-CHIC, V122, P453, DOI 10.1001/archopht.122.4.453
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brancato R, 2000, RETINA-J RET VIT DIS, V20, P134, DOI 10.1097/00006982-200003000-00004
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Jonas JB, 2006, EUR J OPHTHALMOL, V16, P774, DOI 10.1177/112067210601600522
   LADAS ID, 2007, IN PRESS ARCH OPHTHA
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Lim JI, 1997, AM J OPHTHALMOL, V123, P524, DOI 10.1016/S0002-9394(14)70178-3
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, p[e1, 12]
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   SLAKTER JS, 1994, ARCH OPHTHALMOL-CHIC, V112, P465, DOI 10.1001/archopht.1994.01090160041020
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
NR 21
TC 28
Z9 29
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2007
VL 27
IS 7
BP 891
EP 896
DI 10.1097/IAE.0b013e3180ca9ad9
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 212QT
UT WOS:000249612600013
PM 17891013
DA 2022-11-30
ER

PT J
AU Urban, B
   Szwabowicz, M
   Bakunowicz-Lazarczyk, A
AF Urban, Beata
   Szwabowicz, Magdalena
   Bakunowicz-Lazarczyk, Alina
TI Effect of Repeated Intravitreal Ranibizumab and Aflibercept Injections
   on the Cornea in Patients with Age-Related Macular Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAOCULAR PHARMACOKINETICS; ENDOTHELIUM; COMPLICATIONS; BEVACIZUMAB;
   INHIBITORS; OUTCOMES; EYE
AB Purpose. To assess the effect of repeated intravitreal ranibizumab injections (RI) and aflibercept injections (AI) on the corneal endothelium and central corneal thickness (CCT) in patients with age-related macular degeneration (AMD).Materials and Methods. In the retrospective study, 110 eyes of 106 patients, aged 52 to 93 years, were analyzed. Fifty eyes were treated only with RI (I group), and 60 eyes were treated only with AI (II group). Every patient received one intravitreal injection of 0.5 mg of ranibizumab once a month or 2 mg of aflibercept for 3 subsequent months. Each patient received only 3 injections during the whole observation period. Corneal analysis was obtained with the specular microscope. Examinations were performed before initial treatment, after each injection, and 6 months after the first injection. Analysis included corneal endothelial cell density (ECD), hexagonal cell percentage (% Hex), coefficient of variation (CoV), and CCT.Results. There was a statistically significant ECD loss, regardless of the type of the anti-VEGF agent. The mean ECD value in the I group was 2397 +/- 459 cells/mm(2)before RI, 2389 +/- 459 cells/mm(2)after the first RI, 2386 +/- 467 cells/mm(2)after the second RI, 2378 +/- 475 cells/mm(2)after the third RI, and 2357 +/- 460 cells/mm(2)6 months after the first RI. The mean ECD value in the II group was 2448 +/- 493 cells/mm(2)before treatment, 2456 +/- 498 cells/mm(2)after the first AI, 2426 +/- 496 cells/mm(2)after the second AI, 2402 +/- 488 cells/mm(2)after the third AI, and 2348 +/- 473 cells/mm(2)6 months after the first AI. In comparison with the group treated with RI, the group treated with AI presented a greater ECD loss at each measuring point. The percentage of hexagonal cells was decreased in both groups. There was a slight increase in polymegathism in both treated groups. Ranibizumab proved to cause a small increase in CCT, while CCT remained unchanged in the aflibercept group.Conclusions. Repeated intravitreal injections of 0.5 mg of ranibizumab or 2 mg of aflibercept can influence the morphology of the corneal endothelium but not CCT.
C1 [Urban, Beata; Bakunowicz-Lazarczyk, Alina] Med Univ Bialystok, Dept Pediat Ophthalmol & Strabismus, Waszyngtona 17, PL-15274 Bialystok, Poland.
   [Szwabowicz, Magdalena] Municipal Hosp Olsztyn, Dept Ophthalmol, Niepodleglosci 44, PL-10045 Olsztyn, Poland.
C3 Medical University of Bialystok
RP Urban, B (通讯作者)，Med Univ Bialystok, Dept Pediat Ophthalmol & Strabismus, Waszyngtona 17, PL-15274 Bialystok, Poland.
EM urbanbea@umb.edu.pl; madzia.karwat@gmail.com; alina.lazarczyk@umb.edu.pl
CR Ari S, 2015, J OCUL PHARMACOL TH, V31, P100, DOI 10.1089/jop.2014.0005
   Arslan GD, 2019, CUTAN OCUL TOXICOL, V38, P344, DOI 10.1080/15569527.2019.1616749
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Benítez-Herreros J., 2010, Arch Soc Esp Oftalmol, V85, P329, DOI 10.1016/j.oftal.2010.09.011
   Day S, 2011, AM J OPHTHALMOL, V152, P266, DOI 10.1016/j.ajo.2011.01.053
   Do DV, 2020, RETINA-J RET VIT DIS, V40, P643, DOI 10.1097/IAE.0000000000002566
   Emerson MV, 2008, CLIN OPHTHALMOL, V2, P377
   Eng KT, 2006, CLIN INTERV AGING, V1, P451, DOI 10.2147/ciia.2006.1.4.451
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Gharbiya M, 2018, J CELL PHYSIOL, V233, P8874, DOI 10.1002/jcp.26806
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho Y.-J., 2014, TAIWAN J OPHTHALMOLO, V4, P120, DOI [10.1016/j.tjo.2014.04.004, DOI 10.1016/J.TJO.2014.04.004]
   Joshi M, 2019, J FAM MED PRIM CARE, V8, P2429, DOI 10.4103/jfmpc.jfmpc_314_19
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Lass JH, 2018, CORNEA, V37, P596, DOI 10.1097/ICO.0000000000001535
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Merz PR, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0978-9
   Muto T, 2019, CLIN OPHTHALMOL, V13, P373, DOI 10.2147/OPTH.S177506
   Ohr M, 2012, THER ADV CHRONIC DIS, V3, P153, DOI 10.1177/2040622312446007
   Park SJ, 2016, INVEST OPHTH VIS SCI, V57, P2612, DOI 10.1167/iovs.16-19204
   Perez-Rico C, 2010, CORNEA, V29, P849, DOI 10.1097/ICO.0b013e3181ca33d2
   Reich O, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0617-x
   Rimpela AK, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11010009
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   Wilhelm A, 2015, OPHTHALMOLOGE, V112, P346, DOI 10.1007/s00347-014-3116-y
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 29
TC 2
Z9 2
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD JUN 9
PY 2020
VL 2020
AR 4928905
DI 10.1155/2020/4928905
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MC7NV
UT WOS:000543469700001
PM 32587759
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kiernan, DF
   Hariprasad, SM
   Rusu, IM
   Mehta, SV
   Mieler, WF
   Jager, RD
AF Kiernan, Daniel F.
   Hariprasad, Seenu M.
   Rusu, Irene M.
   Mehta, Sahil V.
   Mieler, William F.
   Jager, Rama D.
TI EPIDEMIOLOGY OF THE ASSOCIATION BETWEEN ANTICOAGULANTS AND INTRAOCULAR
   HEMORRHAGE IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anticoagulant; antiplatelet; aspirin;
   clopidogrel; Coumadin; epidemiology; intraocular hemorrhage; subretinal
   hemorrhage; vitreous hemorrhage
ID ANTIPLATELET; ASPIRIN; THERAPY; COMPLICATIONS; PREVALENCE; CATARACT
AB Purpose: To determine the cumulative incidence and annual incidence of intraocular hemorrhage (subretinal hemorrhage or vitreous hemorrhage) in patients with neovascular age-related macular degeneration (AMD) and association with daily antiplatelet or anticoagulant (AP/AC) medication usage (aspirin, clopidogrel, and warfarin), age, gender, hypertension, diabetes mellitus, or bilateral neovascular AMD.
   Methods: Retrospective cross-sectional study in a tertiary university setting. Data on 195 eyes of 195 patients without previous intraocular hemorrhage examined over 73 months were reviewed.
   Results: Ninety-six of 195 patients (49.2%) were taking daily AP/ACs. Of patients taking daily AP/AC agents, 63.5% had hemorrhage compared with 29.2% of patients not taking (odds ratio = 4.21; 95% confidence interval = 1.42-8.46; P < 0.001). The overall annual incidence of intraocular hemorrhage was 0.14% per year. Among patients taking daily AP/AC, the cumulative incidence (61 of 96, 63.5%) and annual incidence (0.10%) of concurrent intraocular hemorrhage were significantly greater compared with patients not taking them (29 of 99, 29.2% and 0.04%, respectively; P < 0.0001). Fourteen of 18 patients (77%) taking more than 1 daily AP/AC had occurrence of intraocular hemorrhage. Antiplatelet or anticoagulant usage was an independent risk factor for the development of intraocular hemorrhage. The use of any agent resulted in a significantly increased risk of developing intraocular hemorrhage. Additionally, presence of bilateral neovascular AMD was a significant association in those taking daily AP/ACs, whereas age was a significant association in those not taking daily AP/AC agents.
   Conclusion: All three daily AP/AC types were significantly associated with an increased risk of the development intraocular hemorrhage in patients with neovascular AMD, whereas gender, hypertension, and diabetes were not. Age was not significantly associated with hemorrhage in patients taking daily AP/AC agents, whereas the presence of bilateral neovascular AMD was significantly associated with hemorrhage. These findings indicate that the AP/AC use may predispose patients with neovascular AMD to intraocular hemorrhage more so than age and duration of disease alone. While the risk that discontinuing these medicines would pose to the patients' health may be too great to justify, ensuring that an appropriate medication dosage is maintained should be a priority within this patient population. RETINA 30:1573-1578, 2010
C1 [Jager, Rama D.] Univ Retina & Macula Associates PC, Oak Forest, IL 60452 USA.
   [Kiernan, Daniel F.; Mieler, William F.] Univ Illinois, Dept Ophthalmol & Visual Sci, Illinois Eye & Ear Infirm, Chicago, IL USA.
   [Hariprasad, Seenu M.; Rusu, Irene M.; Mehta, Sahil V.; Jager, Rama D.] Univ Chicago Hosp, Dept Surg, Sect Ophthalmol, Chicago, IL 60637 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Chicago;
   University of Illinois System
RP Jager, RD (通讯作者)，Univ Retina & Macula Associates PC, 6320 W 159th St,Suite A, Oak Forest, IL 60452 USA.
EM rjager@uretina.com
FU Research to Prevent Blindness
FX Supported by Research to Prevent Blindness.
CR Angiolillo DJ, 2009, AM J CARDIOL, V103, p40A, DOI 10.1016/j.amjcard.2008.11.023
   Barequet IS, 2007, AM J OPHTHALMOL, V144, P719, DOI 10.1016/j.ajo.2007.07.029
   Benzimra JD, 2009, EYE, V23, P10, DOI 10.1038/sj.eye.6703069
   *CDC, 2005 US CTR DIS CONT
   *CENS, 2000 US CENS DAT
   *CENS, 2006 US CENS DAT
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Complications Age-Related Macular, 2008, OPHTHALMOLOGY, V115, P1474, DOI 10.1016/j.ophtha.2008.03.008
   Dayani PN, 2007, AM J OPHTHALMOL, V144, P451, DOI 10.1016/j.ajo.2007.05.006
   Dayani Pouya N, 2006, Trans Am Ophthalmol Soc, V104, P149
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Giansanti F, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006931.pub2
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Hegge Karly A, 2009, S D Med, V62, P15
   Hochman MA, 1997, SURV OPHTHALMOL, V42, P195, DOI 10.1016/S0039-6257(97)00089-1
   Jneid Hani, 2003, Expert Opin Emerg Drugs, V8, P349, DOI 10.1517/eoed.8.2.349.21131
   Law SK, 2008, AM J OPHTHALMOL, V145, P736, DOI 10.1016/j.ajo.2007.12.007
   Levine MN, 2001, CHEST, V119, p108S, DOI 10.1378/chest.119.1_suppl.108S
   LEWIS H, 1988, GRAEF ARCH CLIN EXP, V226, P59, DOI 10.1007/BF02172720
   Lutsep HL, 2009, AM J MED, V122, P21, DOI 10.1016/j.amjmed.2009.02.007
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   Meyer CH, 2008, AM J OPHTHALMOL, V145, P386, DOI 10.1016/j.ajo.2007.10.008
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Parkin B, 2000, BRIT J OPHTHALMOL, V84, P1426, DOI 10.1136/bjo.84.12.1426
   Schulman S, 2003, NEW ENGL J MED, V349, P675, DOI 10.1056/NEJMcp025373
   Superstein R, 2000, CAN J OPHTHALMOL, V35, P385, DOI 10.1016/S0008-4182(00)80126-X
   Tilanus MAD, 2000, GRAEF ARCH CLIN EXP, V238, P482, DOI 10.1007/PL00007887
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   WATZKE RC, 1988, CLIN OPHTHALMOLOGY, V3, P3
   Weir CR, 2000, ACTA OPHTHALMOL SCAN, V78, P492, DOI 10.1034/j.1600-0420.2000.078004492.x
   Wolff T, 2009, ANN INTERN MED, V150, P405, DOI 10.7326/0003-4819-150-6-200903170-00009
   WOLTER JR, 1965, AM J OPHTHALMOL, V59, P1044, DOI 10.1016/0002-9394(65)93421-5
NR 33
TC 55
Z9 56
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV-DEC
PY 2010
VL 30
IS 10
BP 1573
EP 1578
DI 10.1097/IAE.0b013e3181e2266d
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 678HL
UT WOS:000284064600003
PM 21060269
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Tan, JSL
   Wang, JJ
   Flood, V
   Rochtchina, E
   Smith, W
   Mitchell, P
AF Tan, Jennifer S. L.
   Wang, Jie Jin
   Flood, Victoria
   Rochtchina, Elena
   Smith, Wayne
   Mitchell, Paul
TI Dietary antioxidants and the long-term incidence of age-related macular
   degeneration - The Blue Mountains Eye Study
SO OPHTHALMOLOGY
LA English
DT Article
ID NUTRITION EXAMINATION SURVEY; RANDOMIZED CONTROLLED-TRIAL; VITAMIN-E
   SUPPLEMENTATION; BETA-CAROTENE; ALPHA-TOCOPHEROL; NATIONAL-HEALTH;
   GRADING SYSTEM; ZINC INTAKE; ORAL ZINC; MACULOPATHY
AB Purpose: To assess the relationship between baseline dietary and supplement intakes of antioxidants and the long-term risk of incident age-related macular degeneration (AMD).
   Design: Australian population-based cohort study.
   Participants: Of 3654 baseline (1992-1994) participants initially 49 years of older, 2454 were reexamined after 5 years, 10 years, or both.
   Methods: Stereoscopic retinal photographs were graded using the Wisconsin Grading System. Data on potential risk factors were collected. Energy-adjusted intakes of alpha-carotene; beta-carotene; beta-cryptoxanthin; lutein and zeaxanthin; lycopene; vitamins A, C, and E; and iron and zinc were the study factors. Discrete logistic models assessed AMD risk. Risk ratios (RRs) and 95% confidence intervals (CIs) were calculated after adjusting for age, gender, smoking, and other risk factors.
   Main Outcome Measures: Incident early, late, and any AMD.
   Results: For dietary lutein and zeaxanthin, participants in the top tertile of intake had a reduced risk of incident neovascular AMD (RR, 0.35; 95% CI, 0.13-0.92), and those with above median intakes had a reduced risk of indistinct soft or reticular drusen (RR, 0.66; 95% CI, 0.48-0.92). For total zinc intake the RR comparing the top decile intake with the remaining population was 0.56 (95% CI, 0.32-0.97) for any AMD and 0.54 (95% CI, 0.30-0.97) for early AMD. The highest compared with the lowest tertile of total P-carotene intake predicted incident neovascular AMD (RR, 2.68; 95% CI, 1.03-6.96; P = 0.029, for trend). Similarly, beta-carotene intake from diet alone predicted neovascular AMD (RR comparing tertile 3 with tertile 1, 2.40; 95% CI, 0.98-5.91; P = 0.027, for trend). This association was evident in both ever and never smokers. Higher intakes of total vitamin E predicted late AMD (RR compared with the lowest tertile, 2.83; 95% CI, 1.28-6.23; and RR, 2.55; 95% CI, 1.14-5.70 for the middle and highest tertiles, respectively; P = 0.22, for trend).
   Conclusions: In this population-based cohort study, higher dietary lutein and zeaxanthin intake reduced the risk of long-term incident AMD. This study confirmed the Age-Related Eye Disease Study finding of protective influences from zinc against AMD. Higher P-carotene intake was associated with an increased risk of AMD.
C1 [Tan, Jennifer S. L.; Wang, Jie Jin; Flood, Victoria; Rochtchina, Elena; Mitchell, Paul] Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Wang, Jie Jin] Univ Sydney, Dept Mol & Microbial Biosci, Human Nutr Unit, Sydney, NSW 2006, Australia.
   [Smith, Wayne] Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2308, Australia.
C3 University of Sydney; Westmead Institute for Medical Research;
   University of Sydney; University of Newcastle
RP Mitchell, P (通讯作者)，Westmead Hosp, Eye Clin, Hawkesbury Rd, Westmead, NSW 2145, Australia.
RI Mitchell, Paul/P-1498-2014; Flood, Victoria M/A-8732-2016; Wang, Jie
   Jin/P-1499-2014; Flood, Victoria/H-2279-2011; wang, jie/GRS-0942-2022
OI Flood, Victoria M/0000-0001-5310-7221; Wang, Jie
   Jin/0000-0001-9491-4898; 
CR *AG REL EY DIS STU, MAN PROC
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho EY, 2001, ANN EPIDEMIOL, V11, P328, DOI 10.1016/S1047-2797(01)00217-4
   Christen WG, 1999, AM J EPIDEMIOL, V149, P476, DOI 10.1093/oxfordjournals.aje.a009836
   CHUGAHUJA JK, 1993, J AM DIET ASSOC, V93, P318, DOI 10.1016/0002-8223(93)91559-9
   CONGALTON AA, 1969, STATUS PRESTIGE AUST, P48
   Dasch B, 2005, GRAEF ARCH CLIN EXP, V243, P1028, DOI 10.1007/s00417-005-1176-z
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   *DEP COMM SERV HLT, 1990, NUTTAB90 DEP COMM SE
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   Grahn BH, 2001, J AM COLL NUTR, V20, P106, DOI 10.1080/07315724.2001.10719022
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Koh HH, 2004, EXP EYE RES, V79, P21, DOI 10.1016/j.exer.2004.03.001
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Lonn E, 2005, JAMA-J AM MED ASSOC, V293, P1338, DOI 10.1001/jama.293.11.1338
   MALINOW MR, 1980, INVEST OPHTH VIS SCI, V19, P857
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   Smith W, 1998, AUST NZ J PUBL HEAL, V22, P456, DOI 10.1111/j.1467-842X.1998.tb01414.x
   Smith W, 1997, AM J OPHTHALMOL, V124, P838, DOI 10.1016/S0002-9394(14)71702-7
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   Stur M, 1996, INVEST OPHTH VIS SCI, V37, P1225
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P224, DOI 10.1034/j.1600-0420.1998.760220.x
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366
   WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780
NR 49
TC 277
Z9 288
U1 1
U2 55
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2008
VL 115
IS 2
BP 334
EP 341
DI 10.1016/j.ophtha.2007.03.083
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 258AJ
UT WOS:000252840500018
PM 17664009
DA 2022-11-30
ER

PT J
AU Toth, CA
   Decroos, FC
   Ying, GS
   Stinnett, SS
   Heydary, CS
   Burns, R
   Maguire, M
   Martin, D
   Jaffe, GJ
AF Toth, Cynthia A.
   Decroos, Francis Char
   Ying, Gui-Shuang
   Stinnett, Sandra S.
   Heydary, Cynthia S.
   Burns, Russell
   Maguire, Maureen
   Martin, Daniel
   Jaffe, Glenn J.
TI IDENTIFICATION OF FLUID ON OPTICAL COHERENCE TOMOGRAPHY BY TREATING
   OPHTHALMOLOGISTS VERSUS A READING CENTER IN THE COMPARISON OF
   AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE OCT; age-related macular degeneration; bevacizumab; ranibizumab; optical
   coherence tomography; subretinal fluid; intraretinal fluid; pigment
   epithelial detachment; CATT; choroidal neovascularization
ID DOSING REGIMEN; RANIBIZUMAB; BEVACIZUMAB; SAFETY
AB Purpose:To examine treatment decisions by ophthalmologists versus reading center fluid identification from optical coherence tomography in Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).Methods:Fluid in 6,210 optical coherence tomography scans (598 patients) in as needed treatment arm of CATT Year 1 was compared with ophthalmologist's treatment: positive fluid agreement (PFA, fluid+, treatment+) and positive fluid discrepancy (PFD, fluid+, treatment-), negative fluid agreement (fluid-, treatment-) and negative fluid discrepancy (fluid-, treatment+). For PFDs, fluid location and visual acuity were characterized.Results:Treatment and reading center fluid determination agreed in 72.1% (53.0% PFA, 19.1% negative fluid agreement) and disagreed in 27.9% (25.7% PFD, 2.2% negative fluid discrepancy) of visits, with no discrepancies for 20.9% of patients. Compared with PFA, PFD occurred more commonly with lower total foveal thickness (mean SD: 265 +/- 103 PFD, 366 +/- 151 m PFA), presence of intraretinal fluid only, smaller fluid areas (PFA areas greater than twice those of PFD, P < 0.001), and greater decrease in retinal and lesion thickness. Mean acuities before, at, and after PFD were 65.8, 66.9, and 66.3 letters.Conclusion:Treatment decisions by ophthalmologists matched reading center fluid determination in the majority of visits. More pronounced response to treatment and smaller foci of fluid likely contributed to PFD. Positive fluid discrepancy did not have substantial impact on subsequent visual acuity.
C1 [Toth, Cynthia A.; Decroos, Francis Char; Stinnett, Sandra S.; Heydary, Cynthia S.; Burns, Russell; Jaffe, Glenn J.] Duke Univ, Ctr Eye, Dept Ophthalmol, Durham, NC 27710 USA.
   [Ying, Gui-Shuang; Maguire, Maureen] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Martin, Daniel] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
C3 Duke University; University of Pennsylvania; Cleveland Clinic Foundation
RP Toth, CA (通讯作者)，Duke Reading Ctr, DUMC Box 3802, Durham, NC 27710 USA.
EM cynthia.toth@duke.edu
RI Toth, Cynthia/L-5534-2019
OI Toth, Cynthia/0000-0002-2324-0854; Stinnett, Sandra/0000-0001-7192-0195
FU NATIONAL EYE INSTITUTE [U10EY017825] Funding Source: NIH RePORTER; NEI
   NIH HHS [U10 EY017825] Funding Source: Medline
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CATT, COMP AG REL MAC DEG
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Folgar FA, 2014, OPHTHALMOLOGY, V121, P1956, DOI 10.1016/j.ophtha.2014.04.020
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rahman W, 2013, GRAEF ARCH CLIN EXP, V251, P1483, DOI 10.1007/s00417-012-2199-x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosner B, 2003, BIOMETRICS, V59, P1089, DOI 10.1111/j.0006-341X.2003.00125.x
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Wojtkowski M, 2004, AM J OPHTHALMOL, V138, P412, DOI 10.1016/j.ajo.2004.04.049
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 21
TC 35
Z9 35
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2015
VL 35
IS 7
BP 1303
EP 1314
DI 10.1097/IAE.0000000000000483
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CM2AA
UT WOS:000357480600003
PM 26102433
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Radeke, MJ
   Radeke, CM
   Shih, YH
   Hu, J
   Bok, D
   Johnson, LV
   Coffey, PJ
AF Radeke, Monte J.
   Radeke, Carolyn M.
   Shih, Ying-Hsuan
   Hu, Jane
   Bok, Dean
   Johnson, Lincoln V.
   Coffey, Pete J.
TI Restoration of mesenchymal retinal pigmented epithelial cells by TGF
   beta pathway inhibitors: implications for age-related macular
   degeneration
SO GENOME MEDICINE
LA English
DT Article
ID GROWTH-FACTOR-BETA; GENOME-WIDE ASSOCIATION; COMPLEMENT FACTOR-H;
   DIFFERENTIAL EXPRESSION ANALYSIS; ALTERED GENE-EXPRESSION; RHO-KINASE
   PATHWAY; S-TRANSFERASE M1; APOLIPOPROTEIN-E; WOUND REPAIR; RPE CELLS
AB Background: Age-related macular degeneration (AMD) is a leading cause of blindness. Most vision loss occurs following the transition from a disease of deposit formation and inflammation to a disease of neovascular fibrosis and/or cell death. Here, we investigate how repeated wound stimulus leads to seminal changes in gene expression and the onset of a perpetual state of stimulus-independent wound response in retinal pigmented epithelial (RPE) cells, a cell-type central to the etiology of AMD.
   Methods: Transcriptome wide expression profiles of human fetal RPE cell cultures as a function of passage and time post-plating were determined using Agilent 44 K whole genome microarrays and RNA-Seq. Using a systems level analysis, differentially expressed genes and pathways of interest were identified and their role in the establishment of a persistent mesenchymal state was assessed using pharmacological-based experiments.
   Results: Using a human fetal RPE cell culture model that considers monolayer disruption and subconfluent culture as a proxy for wound stimulus, we show that prolonged wound stimulus leads to terminal acquisition of a mesenchymal phenotype post-confluence and altered expression of more than 40 % of the transcriptome. In contrast, at subconfluence fewer than 5 % of expressed transcripts have two-fold or greater expression differences after repeated passage. Protein-protein and pathway interaction analysis of the genes with passage-dependent expression levels in subconfluent cultures reveals a 158-node interactome comprised of two interconnected modules with functions pertaining to wound response and cell division. Among the wound response genes are the TGF beta pathway activators: TGFB1, TGFB2, INHBA, INHBB, GDF6, CTGF, and THBS1. Significantly, inhibition of TGFBR1/ACVR1B mediated signaling using receptor kinase inhibitors both forestalls and largely reverses the passage-dependent loss of epithelial potential; thus extending the effective lifespan by at least four passages. Moreover, a disproportionate number of RPE wound response genes have altered expression in neovascular and geographic AMD, including key members of the TGF beta pathway.
   Conclusions: In RPE cells the switch to a persistent mesenchymal state following prolonged wound stimulus is driven by lasting activation of the TGF beta pathway. Targeted inhibition of TGF beta signaling may be an effective approach towards retarding AMD progression and producing RPE cells in quantity for research and cell-based therapies.
C1 [Radeke, Monte J.; Radeke, Carolyn M.; Shih, Ying-Hsuan; Johnson, Lincoln V.; Coffey, Pete J.] Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA.
   [Hu, Jane; Bok, Dean] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye & Brain Res Inst, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Hu, Jane; Bok, Dean] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye & Brain Res Inst, Dept Neurobiol, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Santa Barbara;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA
RP Radeke, MJ (通讯作者)，Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA.
EM monte.radeke@lifesci.ucsb.edu
OI Coffey, Peter/0000-0002-5427-2939
FU BrightFocus Foundation [M2011064]; California Institute for Regenerative
   Medicine [LA1-02086]; Beckmann Initiative for Macular Research
   [BIMR-1312]; National Institute of Health [EY R24-EY017404]; NATIONAL
   EYE INSTITUTE [P30EY000331] Funding Source: NIH RePORTER
FX The authors acknowledge the following funding: the BrightFocus
   Foundation (M2011064, MJR), California Institute for Regenerative
   Medicine (LA1-02086, PC), Beckmann Initiative for Macular Research
   (BIMR-1312, PC and MJR), and the National Institute of Health (EY
   R24-EY017404, LVJ and DB). The authors would also like to thank Lisa
   Conti for scientific insight and review of the manuscript.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Attisano L, 1996, MOL CELL BIOL, V16, P1066
   Baghy K, 2012, J HISTOCHEM CYTOCHEM, V60, P262, DOI 10.1369/0022155412438104
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282
   Berasi SP, 2011, GROWTH FACTORS, V29, P128, DOI 10.3109/08977194.2011.593178
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   Booij Judith C, 2010, PLoS One, V5, pe9341, DOI 10.1371/journal.pone.0009341
   Brion M, 2011, ACTA OPHTHALMOL, V89, pE12, DOI 10.1111/j.1755-3768.2010.02040.x
   Cabello-Verrugio C, 2007, J BIOL CHEM, V282, P18842, DOI 10.1074/jbc.M700243200
   Chen CC, 2009, INT J BIOCHEM CELL B, V41, P771, DOI 10.1016/j.biocel.2008.07.025
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Clarke LE, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4505
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Croze RH, 2014, STEM CELL TRANSL MED, V3, P1066, DOI 10.5966/sctm.2014-0079
   Cuny GD, 2008, BIOORG MED CHEM LETT, V18, P4388, DOI 10.1016/j.bmcl.2008.06.052
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eming SA, 2007, J INVEST DERMATOL, V127, P514, DOI 10.1038/sj.jid.5700701
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2012, INVEST OPHTH VIS SCI, V53, P2112, DOI 10.1167/iovs.11-8785
   Fritsche LG, 2009, HUM MUTAT, V30, P1048, DOI 10.1002/humu.20957
   Fuhrmann S, 2000, DEVELOPMENT, V127, P4599
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Gellibert FO, 2004, J MED CHEM, V47, P4494, DOI 10.1021/jm0400247
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Graham JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074094
   GRISANTI S, 1995, INVEST OPHTH VIS SCI, V36, P391
   Gu H, 2012, RETINA-J RET VIT DIS, V32, P1967, DOI 10.1097/IAE.0b013e31824dae04
   Guo CM, 2009, CURR EYE RES, V34, P852, DOI 10.3109/02713680903128935
   Guven M, 2011, OPHTHALMIC RES, V46, P31, DOI 10.1159/000321940
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0
   Hu J, 2001, MOL VIS, V7, P14
   Hu J, 2010, METHODS MOL BIOL, V652, P55, DOI 10.1007/978-1-60327-325-1_2
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Ichida JK, 2009, CELL STEM CELL, V5, P491, DOI 10.1016/j.stem.2009.09.012
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65
   Inumaru J, 2009, GENES CELLS, V14, P703, DOI 10.1111/j.1365-2443.2009.01303.x
   JAFFE GJ, 1994, INVEST OPHTH VIS SCI, V35, P2924
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Julian Linda, 2014, Small GTPases, V5, pe29846, DOI 10.4161/sgtp.29846
   KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q
   Khankan R, 2011, INVEST OPHTH VIS SCI, V52, P5068, DOI 10.1167/iovs.11-7191
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   KUBOTA T, 1989, BIOCHEM BIOPH RES CO, V162, P1453, DOI 10.1016/0006-291X(89)90837-1
   KVANTA A, 1994, OPHTHALMIC RES, V26, P361, DOI 10.1159/000267502
   Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58
   Launay S, 2008, CELL DEATH DIFFER, V15, P1408, DOI 10.1038/cdd.2008.82
   Lee S C, 1999, Korean J Ophthalmol, V13, P16
   Lee SC, 2001, OPHTHALMIC RES, V33, P80, DOI 10.1159/000055648
   Lee SC, 2001, YONSEI MED J, V42, P271, DOI 10.3349/ymj.2001.42.3.271
   Lenga Y, 2008, CIRC RES, V102, P319, DOI 10.1161/CIRCRESAHA.107.160408
   Leung T, 1996, MOL CELL BIOL, V16, P5313
   Lin TX, 2009, NAT METHODS, V6, P805, DOI [10.1038/NMETH.1393, 10.1038/nmeth.1393]
   Liu XP, 2013, NAT CELL BIOL, V15, P829, DOI 10.1038/ncb2765
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051
   MATSUMOTO M, 1994, INVEST OPHTH VIS SCI, V35, P4245
   Mazerbourg S, 2005, J BIOL CHEM, V280, P32122, DOI 10.1074/jbc.M504629200
   McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Merle BMJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079848
   Meyers KJ, 2014, INVEST OPHTH VIS SCI, V55, P587, DOI 10.1167/iovs.13-13216
   MOREN A, 1994, J BIOL CHEM, V269, P32469
   Mori T, 1999, J CELL PHYSIOL, V181, P153, DOI 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P6576, DOI 10.1167/iovs.12-10219
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Neill T, 2013, FEBS J, V280, P2353, DOI 10.1111/febs.12148
   Neill T, 2012, J BIOL CHEM, V287, P5492, DOI 10.1074/jbc.M111.283499
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Newman AM, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-117
   NODA M, 1988, J BIOL CHEM, V263, P13916
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Oz O, 2006, EUR J OPHTHALMOL, V16, P105
   Patel S, 2005, J AM SOC NEPHROL, V16, P1977, DOI 10.1681/ASN.2004110943
   Pillaire MJ, 1999, EXP EYE RES, V68, P193, DOI 10.1006/exer.1998.0583
   REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831
   Riquelme C, 2001, J BIOL CHEM, V276, P3589, DOI 10.1074/jbc.M004602200
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Schneider D, 2012, BIOCHEM BIOPH RES CO, V419, P221, DOI 10.1016/j.bbrc.2012.01.151
   Schofield AV, 2013, CRIT REV BIOCHEM MOL, V48, P301, DOI 10.3109/10409238.2013.786671
   SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26775
   SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923
   Schwegler J S, 1997, Mol Vis, V3, P10
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shiga A, 2011, HUM MOL GENET, V20, P1800, DOI 10.1093/hmg/ddr063
   Slavotinek AM, 2011, MOL GENET METAB, V104, P448, DOI 10.1016/j.ymgme.2011.09.029
   SONG MK, 1990, J CELL PHYSIOL, V143, P196, DOI 10.1002/jcp.1041430127
   Sonnemann KJ, 2011, ANNU REV CELL DEV BI, V27, P237, DOI 10.1146/annurev-cellbio-092910-154251
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Sulyok S, 2004, MOL CELL ENDOCRINOL, V225, P127, DOI 10.1016/j.mce.2004.07.011
   Sun YY, 2013, INVEST OPHTH VIS SCI, V54, P8199, DOI 10.1167/iovs.13-12867
   TAKEUCHI Y, 1994, J BIOL CHEM, V269, P32634
   TANIHARA H, 1993, INVEST OPHTH VIS SCI, V34, P413
   Thumkeo D, 2013, EUR J CELL BIOL, V92, P303, DOI 10.1016/j.ejcb.2013.09.002
   Tojo M, 2005, CANCER SCI, V96, P791, DOI 10.1111/j.1349-7006.2005.00103.x
   Uchida H, 2008, CURR EYE RES, V33, P199, DOI 10.1080/02713680701852090
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Vogt J, 2011, CELL SIGNAL, V23, P1831, DOI 10.1016/j.cellsig.2011.06.019
   Wang FE, 2010, FASEB J, V24, P1552, DOI 10.1096/fj.08-125856
   Wang SS, 2013, FEBS J, V280, P2644, DOI 10.1111/febs.12256
   Wei JL, 2013, CELL BIOL INT, V37, P725, DOI 10.1002/cbin.10082
   Whitmore SS, 2013, MOL VIS, V19, P2274
   Wynn TA, 2011, J EXP MED, V208, P1339, DOI 10.1084/jem.20110551
   YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Ruiz-Loredo AY, 2011, J CELL PHYSIOL, V226, P414, DOI 10.1002/jcp.22347
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   Zerbib J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007341
   Zhang K, 2013, INT J MOL MED, V32, P464, DOI 10.3892/ijmm.2013.1396
   Zhang L, 2012, J BIOL CHEM, V287, P1520, DOI 10.1074/jbc.M111.275990
   Zheng YP, 2004, INVEST OPHTH VIS SCI, V45, P668, DOI 10.1167/iovs.02-0808
NR 147
TC 66
Z9 66
U1 1
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1756-994X
J9 GENOME MED
JI Genome Med.
PD JUN 19
PY 2015
VL 7
AR 58
DI 10.1186/s13073-015-0183-x
PG 19
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA CM0OH
UT WOS:000357377300001
PM 26150894
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Simonelli, F
   Frisso, G
   Testa, F
   di Fiore, R
   Vitale, DF
   Manitto, MP
   Brancato, R
   Rinaldi, E
   Sacchetti, L
AF Simonelli, F.
   Frisso, G.
   Testa, F.
   di Fiore, R.
   Vitale, D. F.
   Manitto, M. P.
   Brancato, R.
   Rinaldi, E.
   Sacchetti, L.
TI Polymorphism p.402Y > H in the complement factor H protein is a risk
   factor for age related macular degeneration in an Italian population
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID APOLIPOPROTEIN-E; MACULOPATHY; GENE; ASSOCIATION; PREVALENCE;
   SUSCEPTIBILITY; SYSTEM
AB Aims: To evaluate the complement factor H (CFH) p. 402Y > H polymorphism as a risk factor in age related macular degeneration (AMD) in an Italian population.
   Methods: 104 unrelated Italian AMD patients and 131 unrelated controls were screened for the CFH polymorphism p. 402Y > H (c.1277 T > C), which has been associated with AMD. Retinography was obtained for patients and controls; the AMD diagnosis was confirmed by fluorescein angiograms. The c. 1277 T. C polymorphism was genotyped with the TaqMan real time polymerase chain reaction single nucleotide polymorphism assay.
   Results: The frequency of c.1277C allele was higher in AMD patients than in controls (57.2% v 39.3%; p < 0.001). The odds ratio (OR; logistic regression analysis) for AMD was 3.9 (95% confidence interval (CI): 1.9 to 8.2) for CC homozygotes. The CC genotype conferred a higher risk for sporadic (OR 4.6; CI: 2.0 to 10.5) than for familial AMD (OR 2.9; CI: 1.0 to 8.4). Genotypes were not related to either age at AMD diagnosis or to AMD phenotype. However, geographic atrophy and choroidal neovascularisation were more frequent in sporadic than in familial AMD (p=0.027). Overall, the percentage of population attributable risk for the CC genotype was 28% (95% CI: 18% to 33%).
   Conclusion: The association between the p. 402Y > H (c.1277T > C) polymorphism and AMD applies to the Italian population and the CC genotype is more frequent in sporadic than in familial AMD cases.
C1 Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy.
   Univ Naples 2, Dipartimento Oftalmol, Naples, Italy.
   CEINGE, Biotecnol Avanzate, Naples, Italy.
   Ist IRCCS, Fdn Salvatore Maugeri, Benevento, Italy.
   Univ Milan, Dipartimento Oftalmol HSR, Milan, Italy.
C3 University of Naples Federico II; Universita della Campania Vanvitelli;
   CEINGE Biotecnologie Avanzate; Istituti Clinici Scientifici Maugeri
   IRCCS; University of Milan
RP Sacchetti, L (通讯作者)，Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Via S Pansini 5, I-80131 Naples, Italy.
EM sacchetti@dbbm.unina.it
RI Simonelli, Francesca/AHE-7571-2022; Frisso, Giulia/A-5675-2014; Testa,
   Francesco/J-3185-2012
OI Simonelli, Francesca/0000-0001-8520-6769; FRISSO,
   Giulia/0000-0003-3487-7743; Testa, Francesco/0000-0002-1482-1577
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   EVERELDIOGLU C, 2003, DOC OPHTHALMOL, V132, P191
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Ott J, 2004, NEUROLOGY, V63, P955, DOI 10.1212/WNL.63.6.955
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Schultz Dennis W, 2005, Ophthalmic Genet, V26, P101, DOI 10.1080/13816810590968023
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Souied EH, 2005, MOL VIS, V11, P1135
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 28
TC 56
Z9 71
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2006
VL 90
IS 9
BP 1142
EP 1145
DI 10.1136/bjo.2006.096487
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 076ZP
UT WOS:000239997700023
PM 16774956
OA Green Published
DA 2022-11-30
ER

PT J
AU Cheung, CMG
   Li, X
   Cheng, CY
   Zheng, YF
   Mitchell, P
   Wang, JJ
   Wong, TY
AF Cheung, Chui Ming Gemmy
   Li, Xiang
   Cheng, Ching-Yu
   Zheng, Yingfeng
   Mitchell, Paul
   Wang, Jie Jin
   Wong, Tien Yin
TI Prevalence, Racial Variations, and Risk Factors of Age-Related Macular
   Degeneration in Singaporean Chinese, Indians, and Malays
SO OPHTHALMOLOGY
LA English
DT Article
ID CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR-DISEASE; EYE DISEASES;
   RURAL-POPULATION; POOLED FINDINGS; TERM INCIDENCE; MACULOPATHY; RATES;
   EPIDEMIOLOGY; METHODOLOGY
AB Objective: To describe the prevalence and risk factors for age-related macular degeneration (AMD) in a multiethnic Asian cohort of Chinese, Malay, and Indian persons.
   Design: Population-based cross-sectional study.
   Participants: A total of 10 033 persons (3280 Malay, 3400 Indian, and 3353 Chinese; response rate, 75%) 40 years of age or older residing in Singapore.
   Methods: We performed comprehensive systemic and ocular examinations, retinal photography, and laboratory investigations for all participants. We graded early and late AMD signs from retinal photographs using the modified Wisconsin AMD grading scale. We calculated the age-standardized prevalence of AMD using the 2010 Singapore adult population and analyzed risk factors for AMD using logistic regression models.
   Main Outcome Measures: Early and late AMD.
   Results: Of the 9799 participants with gradable photographs, 588 had early AMD and 60 had late AMD. The age-standardized prevalence was 5.1% (95% confidence interval [CI], 4.6-5.5) for early AMD and 0.5% (95% CI, 0.4-0.6) for late AMD. The prevalence of early AMD was similar between Chinese (5.7%) and Indian (4.5%; P = 0.27) persons and lower in Malays (3.5%; P = 0.002 compared with Chinese; P = 0.09 compared with Indians); in contrast, the prevalence for late AMD was similar across ethnic groups (Chinese, 0.6%; Indian, 0.3%; and Malay, 0.3%; P = 0.20). Risk factors for early AMD were older age (odds ratio [OR], 1.40 per 5-year increase in age; 95% CI, 1.33-1.47), male gender (OR, 1.81; 95% CI, 1.43-2.29), hypertension (OR, 1.28; 95% CI, 1.02-1.61), and hyperopic refraction (OR, 1.17 per 1-diopter increase in spherical equivalent; 95% CI, 1.11-1.24). Risk factors for late AMD include older age (OR, 1.87 per 5-year increase in age; 95% CI, 1.54-2.19), smoking more than 5 packs per week (OR, 3.63; 95% CI, 1.34-9.80), and presence of chronic kidney disease (OR, 2.17; 95% CI, 1.22-3.88).
   Conclusions: Early AMD is more common in Chinese and Indians than in Malays, but there were no racial variations in the prevalence of late AMD. (C) 2014 by the American Academy of Ophthalmology.
C1 [Cheung, Chui Ming Gemmy; Wong, Tien Yin] Singapore Natl Eye Ctr, Singapore 168751, Singapore.
   [Cheung, Chui Ming Gemmy; Li, Xiang; Cheng, Ching-Yu; Zheng, Yingfeng; Wong, Tien Yin] Singapore Eye Res Inst, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy; Cheng, Ching-Yu; Wong, Tien Yin] Natl Univ Singapore, Yong Loo Lin Sch Med, Saw Swee Hock Sch Publ Hlth, Singapore 117595, Singapore.
   [Cheung, Chui Ming Gemmy; Cheng, Ching-Yu; Wong, Tien Yin] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Li, Xiang] Natl Univ Singapore, Dept Stat & Appl Probabil, Singapore 117548, Singapore.
   [Mitchell, Paul; Wang, Jie Jin] Univ Sydney, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Wang, Jie Jin; Wong, Tien Yin] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center; National University of Singapore;
   National University of Singapore; National University of Singapore;
   University of Sydney; Centre for Eye Research Australia; Royal Victorian
   Eye & Ear Hospital; University of Melbourne
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Cheng, Ching-Yu/Y-2229-2019; Zheng, Yingfeng/CAE-9225-2022; wang,
   jie/GRS-0942-2022; Wong, Tien Yin/AAC-9724-2020; Zheng,
   Yingfeng/AAE-2983-2022; Wang, Jie Jin/P-1499-2014; Mitchell,
   Paul/P-1498-2014
OI Cheng, Ching-Yu/0000-0003-0655-885X; Zheng,
   Yingfeng/0000-0002-0914-7864; Wong, Tien Yin/0000-0002-8448-1264; Wang,
   Jie Jin/0000-0001-9491-4898; Cheung, Chui Ming Gemmy/0000-0003-3358-3516
FU Biomedical Research Council [08/1/35/19/550]; National Medical Research
   Council, Singapore, Republic of Singapore [STaR/0003/2008]
FX Supported by the Biomedical Research Council (grant no.: 08/1/35/19/550)
   and the National Medical Research Council (grant no.: STaR/0003/2008),
   Singapore, Republic of Singapore.
CR Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P764, DOI 10.1016/j.ajo.2012.10.013
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939
   Fay MP, 1997, STAT MED, V16, P791
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gan W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042010
   Gao BX, 2011, BMC NEPHROL, V12, DOI 10.1186/1471-2369-12-62
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   Lavanya R, 2009, OPHTHAL EPIDEMIOL, V16, P325, DOI 10.3109/09286580903144738
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Liew G, 2008, J AM SOC NEPHROL, V19, P806, DOI 10.1681/ASN.2007080844
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nangia V, 2011, RETINA-J RET VIT DIS, V31, P1179, DOI 10.1097/IAE.0b013e3181f57ff2
   Nations United, 2011, WORLD POP PROSP 2010, V1
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Nitsch D, 2009, OPHTHAL EPIDEMIOL, V16, P181, DOI 10.1080/09286580902863064
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pan CW, 2013, OPHTHALMOLOGY, V120, P2058, DOI 10.1016/j.ophtha.2013.03.028
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Singapore Department of Statistics, CENS POP 2010 ADV CE
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stein JD, 2011, INVEST OPHTH VIS SCI, V52, P6842, DOI 10.1167/iovs.11-7179
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tao Y, 2010, EYE, V24, P648, DOI 10.1038/eye.2009.160
   Thompson CL, 2007, HUM MOL GENET, V16, P2135, DOI 10.1093/hmg/ddm164
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   VanderBeek BL, 2011, AM J OPHTHALMOL, V152, P273, DOI 10.1016/j.ajo.2011.02.004
   Wang S, 2009, OPHTHALMOLOGY, V116, P2373, DOI 10.1016/j.ophtha.2009.05.041
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
   World Health Organization, GLOB DAT VIS IMP 201
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
NR 46
TC 69
Z9 72
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2014
VL 121
IS 8
BP 1598
EP 1603
DI 10.1016/j.ophtha.2014.02.004
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO2KR
UT WOS:000341151100024
PM 24661862
DA 2022-11-30
ER

PT J
AU Tsymanava, A
   Uhlig, CE
AF Tsymanava, Anna
   Uhlig, Constantin E.
TI Intravitreal recombinant tissue plasminogen activator without and with
   additional gas injection in patients with submacular haemorrhage
   associated with age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; pneumatic displacement; submacular
   haemorrhage; tissue plasminogen activator
ID CHOROIDAL NEOVASCULAR MEMBRANE; SUBRETINAL HEMORRHAGE; PNEUMATIC
   DISPLACEMENT; WARFARIN THERAPY; RETINAL TOXICITY; NATURAL-HISTORY;
   MANAGEMENT; BEVACIZUMAB; REMOVAL; MACULOPATHY
AB Purpose: To compare intravitreal recombinant tissue plasminogen activator (rt-PA) treatment with and without gas injection in patients with submacular haemorrhage associated with age-related macular degeneration.
   Methods: We conducted a retrospective, non-randomized comparative case study of 110 eyes from 76 women and 34 men (mean age 78.1 +/- 6.9 years). Evaluations of the data were performed for baseline visit (t1), and visits 13 weeks (t2), 3 months (t3) and 6 months after (t4). The patients were classified according to gas treatment into group A (without gas, n = 46) and group B (with gas, n = 64) and according to rt-PA-dosage into group A1 and B1 (50 mu g), group A2 and B2 (100 mu g), and group A3 and B3 (200 mu g).
   Results: At t4, the patients in group A had a median increase of 0.4 logMAR, and those in group B had a decrease of 0.1 logMAR (p = 0.183). The best corrected visual acuity (BCVA) remained stable or increased in 55% and 62% of patients in groups A and B, respectively (p = 0.151), in 50% and 68% of patients in groups A1 and B1, respectively (p = 0.620), in 40% and 100% of patients in groups A2 and B2, respectively (p = 0.250), and in 75% and 63% of patients in groups A3 and B3, respectively (p = 0.463). Complications were observed in 13.6% of patients.
   Conclusions: Best results were obtained in patients treated with 50 and 100 mu g of rt-PA and in those cases BCVA development was more beneficial if additional gas was injected.
C1 [Tsymanava, Anna; Uhlig, Constantin E.] Univ Clin Muenster, Univ Eye Hosp, D-48129 Munster, Germany.
C3 University of Munster
RP Uhlig, CE (通讯作者)，Univ Clin Muenster, Univ Eye Hosp, Domagstr 15, D-48129 Munster, Germany.
EM uhligc@uni-muenster.de
CR Agarwal M, 2010, INDIAN J OPHTHALMOL, V58, P170, DOI 10.4103/0301-4738.60078
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bohm MRR, 2007, KLIN MONATSBL AUGENH, V224, P129, DOI 10.1055/s-2007-962955
   Chaudhry NA, 1999, OPHTHALMIC SURG LAS, V30, P176
   Chawla S, 2009, INDIAN J OPHTHALMOL, V57, P155, DOI 10.4103/0301-4738.45511
   Chen W L, 1999, Zhonghua Yi Xue Za Zhi (Taipei), V62, P268
   Daneshvar H, 1999, CAN J OPHTHALMOL, V34, P385
   GAINEY SP, 1989, AM J OPHTHALMOL, V108, P142, DOI 10.1016/0002-9394(89)90008-1
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Heriot W, 1996, VAIL VITR M VAIL CO
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   Hochman MA, 1997, SURV OPHTHALMOL, V42, P195, DOI 10.1016/S0039-6257(97)00089-1
   Hohn F, 2010, OPHTHALMOLOGE, V107, P328, DOI 10.1007/s00347-009-2004-3
   Hrach CJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P659
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Kamei M, 1996, AM J OPHTHALMOL, V121, P267, DOI 10.1016/S0002-9394(14)70274-0
   LAATIKAINEN L, 1995, ACTA OPHTHALMOL SCAN, V73, P361
   McKibbin M, 2010, EYE, V24, P994, DOI 10.1038/eye.2009.271
   Meyer CH, 2008, AM J OPHTHALMOL, V145, P386, DOI 10.1016/j.ajo.2007.10.008
   MORIARTY AP, 1995, EYE, V9, P582, DOI 10.1038/eye.1995.144
   Narendran N, 2003, ACTA OPHTHALMOL SCAN, V81, P38, DOI 10.1034/j.1600-0420.2003.00020.x
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Rowley SA, 2004, BRIT J OPHTHALMOL, V88, P573, DOI 10.1136/bjo.2003.027466
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   Steller A, 2004, OPHTHALMOLOGE, V101, P500, DOI 10.1007/s00347-003-0924-x
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Tripathi RC, 2005, BRIT J OPHTHALMOL, V89, P1390, DOI 10.1136/bjo.2005.074401
   Tsai San-Chang, 2003, Kaohsiung Journal of Medical Sciences, V19, P608
NR 36
TC 11
Z9 11
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2012
VL 90
IS 7
BP 633
EP 638
DI 10.1111/j.1755-3768.2011.02115.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 030DG
UT WOS:000310548500019
PM 21332673
OA Bronze
DA 2022-11-30
ER

PT J
AU Wu, J
   Zhang, JF
AF Wu, Jing
   Zhang, Jingfa
TI Neovascular Remodeling and Subretinal Fibrosis as Biomarkers for
   Predicting Incomplete Response to Anti-VEGF Therapy in Neovascular
   Age-Related Macular Degeneration
SO FRONTIERS IN BIOSCIENCE-LANDMARK
LA English
DT Article
DE neovascular age-related macular degeneration; choroidal
   neovascularization; anti-VEGF; neovascular remodeling; subretinal
   fibrosis
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; ENDOTHELIAL GROWTH-FACTOR; BEVACIZUMAB
AB Purpose: To compare the progression of neovascular remodeling and subretinal fibrosis in neovascular age-related macular degeneration (NVAMD) after anti-vascular endothelial growth factor (VEGF) therapy. Methods: Twenty eyes from 20 patients with subretinal fibrosis complicating NVAMD were retrospectively reviewed. All patients complied with at least three consecutive monthly intravitreal treatments and final follow-up visit at 12 months after the initial anti-VEGF treatment of aflibercept or ranibizumab. Using optical coherence tomography angiography (OCTA), the central macular thickness (CMT), microvascular density in the superficial capillary plexus (SCP), deep capillary plexus (DCP), choroidal neovascularization (CNV) lesions, as well as subretinal fibrotic lesions were compared between baseline and final visit. Results: The mean number for anti-VEGF injections was 4.40 +/- 0.88 during the 12 months of follow-up. There was no significant difference in best-corrected visual acuity (BCVA) and vascular density in SCP and DCP (p > 0.05) between baseline and final follow-up. The CMT decreased from 434.95 +/- 87.62 mu m at baseline to 365.15 +/- 78.92 mu m at final visit (p = 0.02). Compared with the baseline, the fine vessels, such as capillary tufts, regressed and the relative density of CNV lesion decreased by 19.12% (p = 0.01), while the relative density of the subretinal fibrosis increased approximately 1.21-fold (p = 0.03) at the final follow-up. Conclusions: The progression of neovascular remodeling and subretinal fibrosis may serve as biomarkers to predict incomplete response to anti-VEGF therapy in patients with NVAMD. Subretinal fibrosis complicating NVAMD remains a major obstacle for the management of NVAMD, and anti-VEGF treatment is a potential therapeutic strategy to target neovascular remodeling and subretinal fibrosis as either an additive or alternative therapeutic approach for NVAMD.
C1 [Wu, Jing; Zhang, Jingfa] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Ophthalmol, Shanghai Peoples Hosp 1, Shanghai 200080, Peoples R China.
   [Wu, Jing; Zhang, Jingfa] Shanghai Engn Ctr Precise Diag & Treatment Eye Di, Shanghai Engn Ctr Visual Sci & Photomed, Shanghai Key Lab Ocular Fundus Dis, Natl Clin Res Ctr Eye Dis, Shanghai 200080, Peoples R China.
C3 Shanghai Jiao Tong University
RP Zhang, JF (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Ophthalmol, Shanghai Peoples Hosp 1, Shanghai 200080, Peoples R China.; Zhang, JF (通讯作者)，Shanghai Engn Ctr Precise Diag & Treatment Eye Di, Shanghai Engn Ctr Visual Sci & Photomed, Shanghai Key Lab Ocular Fundus Dis, Natl Clin Res Ctr Eye Dis, Shanghai 200080, Peoples R China.
EM 13917311571@139.com
FU National Nat-ural Science Foundation of China [82171062]
FX This work was supported by grants from National Nat-ural Science
   Foundation of China (82171062) .
CR Agron E, 2021, OPHTHALMOLOGY, V128, P425, DOI 10.1016/j.ophtha.2020.08.018
   Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   Bo QY, 2019, JAMA OPHTHALMOL, V137, P642, DOI 10.1001/jamaophthalmol.2019.0449
   Dansingani KK, 2016, AM J OPHTHALMOL, V169, P235, DOI 10.1016/j.ajo.2016.06.031
   Gao SS, 2016, OPT LETT, V41, P496, DOI 10.1364/OL.41.000496
   Hu TT, 2019, EXP EYE RES, V180, P43, DOI 10.1016/j.exer.2018.11.022
   Jiao CH, 2019, RETINA-J RET VIT DIS, V39, P265, DOI 10.1097/IAE.0000000000001952
   Kraus MF, 2014, BIOMED OPT EXPRESS, V5, P2591, DOI 10.1364/BOE.5.002591
   Little K, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-02033-7
   Little K, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.4.3
   Mantel I, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.594087
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuda Y, 2019, MOL THER-NUCL ACIDS, V17, P819, DOI 10.1016/j.omtn.2019.07.018
   McMenamin PG, 2019, PROG RETIN EYE RES, V70, P85, DOI 10.1016/j.preteyeres.2018.12.002
   Mettu PS, 2021, PROG RETIN EYE RES, V82, DOI 10.1016/j.preteyeres.2020.100906
   National Eye Institute, 2020, AGE RELATED MACULAR
   O'Koren EG, 2016, SCI REP-UK, V6, DOI 10.1038/srep20636
   Phasukkijwatana N, 2017, BRIT J OPHTHALMOL, V101, P597, DOI 10.1136/bjophthalmol-2016-308815
   Sohn EH, 2012, ARCH OPHTHALMOL-CHIC, V130, P1127, DOI 10.1001/archophthalmol.2012.1611
   Souied EH, 2016, DEV OPHTHALMOL, V56, P86, DOI 10.1159/000442783
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Strittmatter K, 2016, AM J PATHOL, V186, P1890, DOI 10.1016/j.ajpath.2016.02.018
   Van Geest RJ, 2012, BRIT J OPHTHALMOL, V96, P587, DOI 10.1136/bjophthalmol-2011-301005
   Xiao H, 2021, BRIT J OPHTHALMOL, V105, P103, DOI 10.1136/bjophthalmol-2019-315763
   Yu C, 2020, TRENDS NEUROSCI, V43, P433, DOI 10.1016/j.tins.2020.03.012
NR 26
TC 0
Z9 0
U1 3
U2 3
PU IMR PRESS
PI ROBINSON
PA 112 ROBINSON RD, ROBINSON, SINGAPORE
SN 2768-6701
EI 2768-6698
J9 FRONT BIOSCI-LANDMRK
JI Front. Biosci.
PD APR 20
PY 2022
VL 27
IS 4
AR 135
DI 10.31083/j.fbl2704135
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 1J2YJ
UT WOS:000797787000005
PM 35468694
OA gold
DA 2022-11-30
ER

PT J
AU Boulanger-Scemama, E
   Querques, G
   About, F
   Puche, N
   Srour, M
   Mane, V
   Massannba, N
   Canoui-Poitrine, F
   Souied, EH
AF Boulanger-Scemama, E.
   Querques, G.
   About, F.
   Puche, N.
   Srour, M.
   Mane, V.
   Massannba, N.
   Canoui-Poitrine, F.
   Souied, E. H.
TI Ranibizumab for exudative age-related macular degeneration: A five year
   study of adherence to follow-up in a real-life setting
SO JOURNAL FRANCAIS D OPHTALMOLOGIE
LA English
DT Article
DE Anti-vascular endothelial growth factor; Exudative age-related macular
   degeneration; Long-term follow-up; Ranibizumab
AB Purpose. - To analyze adherence to follow-up over 5 years in patients treated with intravitreal ranibizumab for exudative age-related macular degeneration (AMD) in a tertiary health care center. To investigate factors associated with failure to continue follow-up.
   Methods. - Retrospective chart review of all consecutive patients with exudative AMD, who received their first intravitreal ranibizumab injection at the Creteil Intercommunal University Hospital Eye Clinic between October 1, 2006 and March 31, 2007. Patient clinical characteristics at baseline and at the last follow-up visit were recorded. Distance from home to hospital was measured for each patient. A multiple-choice telephone survey was conducted for patients lost to follow-up to determine the main reasons for failure to continue follow-up.
   Results. - Two hundred and one patients were included. The rate of loss to follow-up over the 5-year period was 57% (115/201). Fifty-eight patients lost to follow-up completed the questionnaire. The main reasons reported by patients for follow-up discontinuation were long distance from home to hospital (51.7%, 30/58), subjective dissatisfaction with the benefits of intravitreal injections (34.5%, 20/58), and the excessive burden of periodic follow-up visits (24.1%, 14/58). Three factors were significantly associated with follow-up discontinuation: high age at baseline (82.2 vs. 76.5 years, P < 0.001), poor best-corrected visual acuity (BCVA) at baseline (42.5 vs. 51.0 letters, P=0.020), and long distance from home to hospital (132 vs. 17.1 km, P<0.001).
   Conclusion. - In this study, adherence to follow-up over 5 years was poor. Age and BCVA at baseline and distance from home to hospital were independently associated with long-term adherence. (C) 2015 Published by Elsevier Masson SAS.
C1 [Boulanger-Scemama, E.; Querques, G.; Puche, N.; Srour, M.; Mane, V.; Massannba, N.; Souied, E. H.] Paris Est Creteil Univ, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, F-94000 Creteil, France.
   [About, F.; Canoui-Poitrine, F.] Paris Est Creteil Univ, Henri Mondor Hosp, Dept Publ Hlth, F-94010 Creteil, France.
   [About, F.; Canoui-Poitrine, F.] Paris Est Creteil Univ, LIC, EA4393, F-94010 Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Assistance Publique Hopitaux Paris (APHP); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire
   Henri-Mondor - APHP; Universite Paris-Est-Creteil-Val-de-Marne (UPEC)
RP Souied, EH (通讯作者)，Paris Est Creteil Univ, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM eric.souied@chicreteil.fr
RI Canoui-Poitrine, Florence/R-4474-2018
OI Canoui-Poitrine, Florence/0000-0001-9970-6051; Querques,
   Giuseppe/0000-0002-3292-9581; About, Fredegonde/0000-0002-3561-8041
CR Abraham P, 2010, AM J OPHTHALMOL, V150, p315e1
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Droege KM, 2014, GRAEF ARCH CLIN EXP, V252, P31, DOI 10.1007/s00417-013-2412-6
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Oishi A, 2011, EUR J OPHTHALMOL, V21, P777, DOI 10.5301/EJO.2011.7430
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Pushpoth S, 2012, BRIT J OPHTHALMOL, V96, P1469, DOI 10.1136/bjophthalmol-2012-302167
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
NR 17
TC 75
Z9 77
U1 0
U2 4
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0181-5512
EI 1773-0597
J9 J FR OPHTALMOL
JI J. Fr. Ophthamol.
PD SEP
PY 2015
VL 38
IS 7
BP 620
EP 627
DI 10.1016/j.jfo.2014.11.015
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CR2TU
UT WOS:000361184300014
PM 25913443
DA 2022-11-30
ER

PT J
AU Brechner, RJ
   Rosenfeld, PJ
   Babish, JD
   Caplan, S
AF Brechner, Ross J.
   Rosenfeld, Philip J.
   Babish, J. Daniel
   Caplan, Stuart
TI Pharmacotherapy for Neovascular Age-Related Macular Degeneration: An
   Analysis of the 100% 2008 Medicare Fee-For-Service Part B Claims File
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB AVASTIN; OCCULT CHOROIDAL NEOVASCULARIZATION;
   PHOTODYNAMIC THERAPY; ELDERLY AMERICANS; UNITED-STATES; SHORT-TERM;
   RANIBIZUMAB; SECONDARY; VERTEPORFIN; 6-MONTH
AB PURPOSE: To describe the usage patterns of pharmacological treatments for neovascular age-related macular degeneration (AMD) in Medicare fee-for-service beneficiaries.
   DESIGN: Retrospective review of all Medicare fee-for-service Part B claims for neovascular AMD during 2008.
   METHODS: Medicare beneficiaries having undergone treatment were identified. The data collected for each visit for a given beneficiary included age, race, gender, Medicare region, state/zip code of residence, date of visit, whether or not the beneficiary had a treatment, the type and amount of drug, and dollars paid by Medicare. The main outcome measures were the number and rate of treatments, the types of drugs used for treatment, and the payments for these drugs.
   RESULTS: Of the 222 886 unique beneficiaries, 146 276 (64.4%) received bevacizumab and 80 929 (35.6%) received ranibizumab. A total of 824 525 injections were performed with 480 025 injections of bevacizumab (58%) and 336 898 injections of ranibizumab (41%). National rates of injections per 100 000 fee-for-service Part B Medicare beneficiaries for bevacizumab and ranibizumab were 1506 and 1057, respectively. Total payments by Medicare were $20 290 952 for bevacizumab and $536 642 693 for ranibizumab. In 39 out of 50 states, the rate of injection was higher for bevacizumab compared with ranibizumab.
   CONCLUSIONS: In 2008, bevacizumab was used at a higher rate than ranibizumab for the treatment of neovascular AMD. Even though bevacizumab accounted for 58% of all injections, Medicare paid $516 million more for ranibizumab than bevacizumab. These data suggest that despite its off-label designation, intravitreal bevacizumab is currently the standard-of-care treatment for neovascular AMD in the United States. (Am J Ophthalmol 2011;151:887-895. Published by Elsevier Inc.)
C1 [Brechner, Ross J.; Babish, J. Daniel; Caplan, Stuart] Ctr Medicare, Woodlawn, MD 21244 USA.
   [Brechner, Ross J.; Babish, J. Daniel; Caplan, Stuart] Ctr Medicaid Serv, Woodlawn, MD 21244 USA.
   [Rosenfeld, Philip J.] Univ Miami Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL USA.
C3 Centers for Medicare & Medicaid Services; Centers for Medicare &
   Medicaid Services; Bascom Palmer Eye Institute; University of Miami
RP Brechner, RJ (通讯作者)，Ctr Medicare, MS C-1-09,7500 Secur Blvd, Woodlawn, MD 21244 USA.
EM ross.brechner@cms.hhs.gov
FU Genentech
FX THE AUTHORS INDICATE NO FUNDING SUPPORT. PREVIOUSLY, PHILIP J. ROSENFELD
   HAS RECEIVED CLINICAL RESEARCH grants from Genentech and payments for
   participating in Genentech's Advisory Boards and speaker's bureau
   program, but no support or payments have been received in the past 2
   years. Involved in design and conduct of the study (R.J.B., P.J.R.,
   J.D.B., S.C.); collection (R.J.B.), management (R.J.B.), analysis
   (R.J.B., P.J.R., J.D.B.), and interpretation of the data (R.J.B.,
   P.J.R.); and preparation, review, or approval of the manuscript (R.J.B.,
   P.J.R., J.D.B., S.C.). IRB approval for this non-trial public
   de-identified data is not applicable. The study has been approved by
   ethics committee at Centers for Medicare and Medicaid Services, Wood
   lawn, Maryland.
CR Aggio FB, 2007, GRAEF ARCH CLIN EXP, V245, P215, DOI 10.1007/s00417-006-0412-5
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Anastasopoulos E, 2006, AM J OPHTHALMOL, V142, P1081, DOI 10.1016/j.ajo.2006.06.058
   [Anonymous], 1999, ARCH OPHTHALMOL, V117, P1329
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Azad RV, 2008, JPN J OPHTHALMOL, V52, P52, DOI 10.1007/s10384-007-0496-4
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Bhatnagar P, 2007, RETINA-J RET VIT DIS, V27, P846, DOI 10.1097/IAE.0b013e31813c68b7
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Coleman AL, 2008, OPHTHALMOLOGY, V115, P18, DOI 10.1016/j.ophtha.2007.04.016
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Furino C, 2009, ACTA OPHTHALMOL, V87, P404, DOI 10.1111/j.1755-3768.2008.01262.x
   Ghazi NG, 2008, RETINA-J RET VIT DIS, V28, P689, DOI 10.1097/IAE.0b013e318162d982
   Giansanti F, 2007, EUR J OPHTHALMOL, V17, P230, DOI 10.1177/112067210701700213
   Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097/IAE.0b013e318042b53f
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Jonas JB, 2007, ACTA OPHTHALMOL SCAN, V85, P563, DOI 10.1111/j.1600-0420.2007.00891.x
   Jyothi S, 2010, EYE, V24, P816, DOI 10.1038/eye.2009.219
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Levy Jaime, 2009, International Ophthalmology, V29, P349, DOI 10.1007/s10792-008-9243-1
   Liao DP, 2008, OPEN OPHTHALMOL J, V2, P37, DOI 10.2174/1874364100802010037
   Madhusudhana KC, 2007, BRIT J OPHTHALMOL, V91, P1716, DOI 10.1136/bjo.2006.108639
   MEKJAVIC PJ, 2009, ACTA OPHTHA IN PRESS
   Melamud A, 2008, AM J OPHTHALMOL, V146, P91, DOI 10.1016/j.ajo.2008.03.014
   Pedersen R, 2007, ACTA OPHTHALMOL SCAN, V85, P526, DOI 10.1111/j.1600-0420.2007.00895.x
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Stepien KE, 2009, RETINA-J RET VIT DIS, V29, P1067, DOI 10.1097/IAE.0b013e3181b1bb06
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Wysong A, 2009, ARCH OPHTHALMOL-CHIC, V127, P320, DOI 10.1001/archophthalmol.2008.613
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
   Ziemssen F, 2009, DRUG AGING, V26, P295, DOI 10.2165/00002512-200926040-00002
   Zlateva GP, 2007, RETINA-J RET VIT DIS, V27, P1292, DOI 10.1097/01.iae.0000300915.81866.b8
   2001, ARCH OPHTHALMOL, V119, P198
NR 54
TC 107
Z9 108
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2011
VL 151
IS 5
BP 887
EP 895
DI 10.1016/j.ajo.2010.11.017
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 760WB
UT WOS:000290353800021
PM 21310390
DA 2022-11-30
ER

PT J
AU Krebs, I
   Schmetterer, L
   Boltz, A
   Told, R
   Vecsei-Marlovits, V
   Egger, S
   Schonherr, U
   Haas, A
   Ansari-Shahrezaei, S
   Binder, S
AF Krebs, Ilse
   Schmetterer, Leopold
   Boltz, Agnes
   Told, Reinhard
   Vecsei-Marlovits, Veronika
   Egger, Stefan
   Schoenherr, Ulrich
   Haas, Anton
   Ansari-Shahrezaei, Siamak
   Binder, Susanne
CA MANTA Res Grp
TI A randomised double-masked trial comparing the visual outcome after
   treatment with ranibizumab or bevacizumab in patients with neovascular
   age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL BEVACIZUMAB;
   PHOTODYNAMIC THERAPY; VERTEPORFIN; LUCENTIS; SAFETY; INJECTIONS; AVASTIN
AB Aim The current accepted standard treatment for neovascular age-related macular degeneration (AMD) consists of antivascular endothelial growth factor agents including ranibizumab and bevacizumab. The aim of the study was to examine whether bevacizumab is inferior to ranibizumab with respect to maintaining/improving visual acuity.
   Methods In this prospective randomised parallel group multicentre trial patients aged more than 50 years with treatment naive nAMD were included at 10 Austrian centres. Patients were randomised to treatment either with 0.5 mg ranibizumab or 1.25 mg bevacizumab. Both groups received three initial monthly injections and thereafter monthly evaluation of visual acuity and the activity of the lesion. Re-treatment was scheduled as needed. Outcome measures were early treatment of diabetic retinopathy visual acuity, retinal thickness, lesion size and safety evaluation.
   Results A total of 321 patients were recruited of which four had to be excluded due to different reasons. Of the 317 remaining patients 154 were randomised into the bevacizumab group and 163 into the ranibizumab group. At month 12, there was a mean increase of early treatment of diabetic retinopathy visual acuity of 4.9 letters in the bevacizumab and 4.1 letters in the ranibizumab group (p=0.78). Furthermore, there were no significant differences in the decrease of retinal thickness, change of lesion size and number of adverse events between the groups.
   Conclusions Bevacizumab was equivalent to ranibizumab for visual acuity at all time points over 1 year. There was no significant difference of decrease of retinal thickness or number of adverse events.
C1 [Krebs, Ilse; Ansari-Shahrezaei, Siamak; Binder, Susanne] Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Vienna, Austria.
   [Krebs, Ilse; Ansari-Shahrezaei, Siamak; Binder, Susanne] Rudolph Fdn Clin, Dept Ophthalmol, Vienna, Austria.
   [Schmetterer, Leopold; Boltz, Agnes; Told, Reinhard] Med Univ Vienna, Dept Clin Pharmacol, A-1030 Vienna, Austria.
   [Schmetterer, Leopold; Boltz, Agnes; Told, Reinhard] Med Univ Vienna, Ctr Med Phys & Biomed Engn, A-1030 Vienna, Austria.
   [Vecsei-Marlovits, Veronika] Hosp Hietzing, Dept Ophthalmol, Vienna, Austria.
   [Egger, Stefan] Med Univ Salzburg, Dept Ophthalmol, Salzburg, Austria.
   [Schoenherr, Ulrich] Hosp Barmherzige Bruder Linz, Dept Ophthalmol, Linz, Austria.
   [Haas, Anton] Med Univ Graz, Dept Ophthalmol, Graz, Austria.
C3 Ludwig Boltzmann Institute; Medical University of Vienna; Medical
   University of Vienna; Hietzing Hospital; Konventhospital Der
   Barmherzigen Bruder; Medical University of Graz
RP Krebs, I (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Rudolf Fdn Clin, Teaching Hosp, Juchgasse 25, A-1030 Vienna, Austria.
EM Ilse.Krebs@wienkav.at
OI Schmetterer, Leopold/0000-0002-7189-1707; Told,
   Reinhard/0000-0003-2046-7081
FU Austrian ophthalmologic society; Ludwig Boltzmann Institute of
   Retinology and Biomicroscopic Lasersurgery
FX The study was supported by the Austrian ophthalmologic society, by the
   Ludwig Boltzmann Institute of Retinology and Biomicroscopic
   Lasersurgery, and by the participating study centres themselves.
CR Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, AM J OPHTHALMOL, V133, P168, DOI 10.1016/S0002-9394(01)01237-5
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Krebs I, 2011, INVEST OPHTH VIS SCI, V52, P6925, DOI 10.1167/iovs.10-6612
   Krebs I, 2011, BRIT J OPHTHALMOL, V95, P1552, DOI 10.1136/bjo.2010.194670
   Krebs I, 2009, ACTA OPHTHALMOL, V87, P611, DOI 10.1111/j.1755-3768.2008.01312.x
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Patel JJ, 2012, J EVAL CLIN PRACT, V18, P247, DOI 10.1111/j.1365-2753.2010.01546.x
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmucker C, 2010, CURR OPIN OPHTHALMOL, V21, P218, DOI 10.1097/ICU.0b013e3283386783
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Tufail A, 2010, BMJ-BRIT MED J, V340, P2459
   Van der Reis MI, 2011, RETINA-J RET VIT DIS, V31, P1449, DOI 10.1097/IAE.0b013e3182278ab4
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
NR 24
TC 147
Z9 151
U1 0
U2 21
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2013
VL 97
IS 3
BP 266
EP 271
DI 10.1136/bjophthalmol-2012-302391
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 092ZW
UT WOS:000315162500007
PM 23292928
DA 2022-11-30
ER

PT J
AU Lin, YH
   Peng, T
   Li, Y
   Liu, Y
AF Lin, Yanhui
   Peng, Ting
   Li, Ying
   Liu, Yu
TI The frequency of early age-related macular degeneration and its
   relationship with dietary pattern in Hunan, China: a cross-sectional
   study
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Dietary pattern; Frequency; Salt
   intake; Health examination
ID URINARY SODIUM; SALT INTAKE; CARDIOVASCULAR-DISEASE; KETONE-BODIES;
   PREVALENCE; MACULOPATHY; POPULATION; INDUCTION; MORTALITY; EXCRETION
AB Purpose To estimate the frequency of age-related macular degeneration (AMD) among people who underwent health examination in Hunan, China and to determine the relationship between dietary pattern and the risk of AMD. Methods The Questionnaire was used to collect dietary data from 56,775 study participants of >= 50 years old who underwent health examination at the Department of Health Management, the Third Xiangya Hospital of Central South University between January 2017 and December 2019. The diagnosis of AMD was based on the results of color fundus photography (CFP), spectral-domain optical coherence tomography (OCT) and multispectral imaging (MSI). After excluding participants with incomplete records or other ocular disease that may affect the results of fundus examination, a total of 43,672 study participants were included. The univariate and multivariate logistic regression analyses were used to determine the relationship between dietary pattern and the frequency of AMD. Results Among the 43,672 study participants, 1080 (2.5%) had early AMD: the frequencies were 2.6% (n = 674) in men and 2.3% (n = 406) in women; the frequencies were 1.0% (n = 289), 3.6% (n = 401), 9.1% (n = 390) in 50-59, 60-69, >= 70 years old, respectively. And the age-standard frequency was 6.6% over the 60 years old in Hunan China. The high-salt intake increased the risk of early AMD [odds ratio (OR) = 1.61, 95% confidence interval (CI) = 1.54-1.68], whereas the intake of meat decreased the risk (OR = 0.90, 95% CI = 0.81-0.99). Conclusion In Hunan China, there was a high frequency of early AMD detected through health examination over the 60 years old. And high-salt intake increases the risk of early AMD, whereas intake of meat decreases the risk. Modulating the dietary pattern and reducing the salt intake as an AMD prevention strategy warrant further study.
C1 [Lin, Yanhui; Peng, Ting; Li, Ying] Cent South Univ, Xiangya Hosp 3, Hlth Management Ctr, Changsha, Hunan, Peoples R China.
   [Liu, Yu] Cent South Univ, Xiangya Hosp 3, Dept Ophthalmol, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.
C3 Central South University; Central South University
RP Liu, Y (通讯作者)，Cent South Univ, Xiangya Hosp 3, Dept Ophthalmol, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.
EM 490259632@qq.com
CR [Anonymous], 1992, Arch Ophthalmol, V110, P1701
   [Anonymous], 2021, OFFICE LEADING GROUP
   Brownlow ML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075713
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   CIRILLO M, 1994, KIDNEY INT, V46, P1133, DOI 10.1038/ki.1994.376
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   GBD 2015 Risk Factors Collaborators, 2016, Lancet, V388, P1659, DOI 10.1016/S0140-6736(16)31679-8
   Han YM, 2018, MOL CELL, V71, P1064, DOI 10.1016/j.molcel.2018.07.036
   Hertz L, 2015, J NEUROCHEM, V134, P7, DOI 10.1111/jnc.13107
   Hollborn M, 2016, MOL BIOL REP, V43, P803, DOI 10.1007/s11033-016-4016-9
   Hollborn M, 2015, MOL VIS, V21, P360
   Jin GM, 2018, BRIT J OPHTHALMOL, V102, P625, DOI 10.1136/bjophthalmol-2017-310368
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mente A, 2018, LANCET, V392, P496, DOI [10.1016/S0140-6736(18)31376-X, 10.1016/s0140-6736(18)31376-x]
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Meshi A, 2019, RETINA-J RET VIT DIS, V39, P1333, DOI 10.1097/IAE.0000000000002156
   Motozawa N, 2019, OPHTHALMOL THER, V8, P527, DOI 10.1007/s40123-019-00207-y
   Mozaffarian D, 2014, NEW ENGL J MED, V371, P624, DOI 10.1056/NEJMoa1304127
   Newman JC, 2017, CELL METAB, V26, P547, DOI 10.1016/j.cmet.2017.08.004
   O'Donnell MJ, 2013, EUR HEART J, V34, P1034, DOI 10.1093/eurheartj/ehs409
   Raff U, 2012, ATHEROSCLEROSIS, V222, P235, DOI 10.1016/j.atherosclerosis.2012.02.006
   Roberts MN, 2017, CELL METAB, V26, P539, DOI 10.1016/j.cmet.2017.08.005
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Song PG, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.020703
   Stevenson W, 2016, CLIN OPHTHALMOL, V10, P527, DOI 10.2147/OPTH.S97722
   Tanaka T, 2002, J HUM HYPERTENS, V16, P97, DOI 10.1038/sj.jhh.1001307
   THIMM F, 1992, ADV EXP MED BIOL, V317, P793
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Veech RL, 2017, IUBMB LIFE, V69, P305, DOI 10.1002/iub.1627
   Veltmann M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147312
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   Yang PT, 2019, ASIA PAC J CLIN NUTR, V28, P845, DOI 10.6133/apjcn.201912_28(4).0022
   Ye HH, 2014, INVEST OPHTH VIS SCI, V55, P6374, DOI 10.1167/iovs.14-14899
   Yu Dongmei, 2016, Zhonghua Yu Fang Yi Xue Za Zhi, V50, P217, DOI 10.3760/cma.j.issn.0253-9624.2016.03.005
NR 38
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JUL 27
PY 2022
VL 22
IS 1
AR 324
DI 10.1186/s12886-022-02549-x
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3G2YU
UT WOS:000831222200002
PM 35896997
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Okada, M
   Kandasamy, R
   Chong, EW
   Mcguiness, M
   Guymer, RH
AF Okada, Mali
   Kandasamy, Rathika
   Chong, Elaine W.
   Mcguiness, Myra
   Guymer, Robyn H.
TI The Treat-and-Extend Injection Regimen Versus Alternate Dosing
   Strategies in Age-related Macular Degeneration: A Systematic Review and
   Meta-analysis
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID RANIBIZUMAB; OUTCOMES
AB PURPOSE: To assess outcomes of the treat-and-extend (T&E) injection regimen for neovascular age-related macular degeneration (AMD) as compared to either a monthly or a pro re nata (PRN) treatment strategy.
   DESIGN: Systematic review and meta-analysis.
   METHODS: Studies that compared the T&E regimen with either monthly or PRN dosing for treatment-naive AMD were included. Trial eligibility, data extraction, and risk of bias were assessed according to Cochrane review methods. Estimates were pooled using random effects meta-analysis.
   RESULTS: Four eligible studies were identified, all using ranibizumab (total N = 940 eyes), including 2 randomized controlled trials comparing T&E to monthly and 2 retrospective reviews comparing T&E to PRN. No studies evaluating aflibercept were identified. Improvements in vision and central retinal thickness were similar between T&E and monthly at 12 months, with a mean difference of -1.79 letters (95% confidence interval [CI]: 3.70, 0.13) and 3.76 mu m (95% CI:-13.78, 21.30) in favor of monthly injections. In contrast, visual gains were higher in the T&E compared to the PRN group (difference of +6.18 letters, 95% CI: 3.28, 9.08). Fewer injections were required using the T&E regimen when compared to monthly (mean of -1.6 and -6.9 injections at 12 and 24 months, respectively). A mean of 1.44 more injections was required for the T&E compared to PRN regimen at 12 months; however, this was achieved with fewer visits.
   CONCLUSION: Despite the growing preference for the T&E regimen, there is limited head-to-head evidence comparing dosing strategies. The evidence available, however, suggests that at 12 months, T&E is comparable to monthly and superior to PRN dosing for both efficacy and safety outcomes when using ranibizumab. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Okada, Mali; Kandasamy, Rathika; Chong, Elaine W.; Guymer, Robyn H.] Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia.
   [Kandasamy, Rathika; Chong, Elaine W.; Mcguiness, Myra; Guymer, Robyn H.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Kandasamy, Rathika; Chong, Elaine W.; Mcguiness, Myra; Guymer, Robyn H.] Univ Melbourne, Dept Surg Ophthalmol, Melbourne, Vic, Australia.
C3 Royal Victorian Eye & Ear Hospital; Centre for Eye Research Australia;
   Royal Victorian Eye & Ear Hospital; University of Melbourne
RP Chong, EW (通讯作者)，Royal Victorian Eye & Ear Hosp, 32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM Elaine.Chong@eyeandear.org.au
OI Guymer, Robyn/0000-0002-9441-4356; McGuinness, Myra/0000-0002-5422-040X
FU NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL OF AUSTRALIA FELLOWSHIP
   [GNT1103013]
FX SUPPORTED BY NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL OF AUSTRALIA
   FELLOWSHIP GNT1103013 (RGH). C.E.R.A. receives operational
   infrastructure support from the Victorian Government.
CR Abdelfattah NS, 2017, OPHTHALMOLOGY, V124, P215, DOI 10.1016/j.ophtha.2016.10.002
   American Society of Retina Specialists, 2014, ANN PREF TRENDS SURV
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gemenetzi M, 2017, OPHTHALMOL THER, V6, P79, DOI 10.1007/s40123-017-0087-5
   Ghosh W, 2016, ADV THER, V33, P1660, DOI 10.1007/s12325-016-0367-9
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Haga A, 2018, ACTA OPHTHALMOL, V96, pE393, DOI 10.1111/aos.13607
   Hanemoto T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189035
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Johnston RL, 2017, ADV THER, V34, P703, DOI 10.1007/s12325-017-0483-1
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rufai SR, 2017, EYE, V31, P1337, DOI 10.1038/eye.2017.67
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2018, BRIT J OPHTHALMOL, V102, P460, DOI 10.1136/bjophthalmol-2017-310822
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 27
TC 51
Z9 51
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2018
VL 192
BP 184
EP 197
DI 10.1016/j.ajo.2018.05.026
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP9HA
UT WOS:000441226900026
PM 29885297
DA 2022-11-30
ER

PT J
AU Huang, H
   Liu, Y
   Wang, L
   Li, W
AF Huang, Hu
   Liu, Ying
   Wang, Lei
   Li, Wen
TI Age-related macular degeneration phenotypes are associated with
   increased tumor necrosis-alpha and subretinal immune cells in aged Cxcr5
   knockout mice
SO PLOS ONE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; CHEMOKINE RECEPTOR; OXIDATIVE STRESS; DENDRITIC
   CELLS; ACCUMULATION; INFLAMMATION; RANIBIZUMAB; EXPRESSION; MICROGLIA;
   CXCL13
AB The role of chemokine receptor in age-related macular degeneration (AMD) remains elusive. The objective of this study is to investigate the role of chemokine receptor Cxcr5 in the pathogenesis of AMD. Cxcr5 gene expression levels (mRNA and protein) are higher in the retina and retinal pigment epithelium (RPE) of aged C57BL/6 wild type mice than younger ones. Vascular and glial cells express Cxcr5 and its ligand Cxcl13 in mouse retina. Aged Cxcr5 knockout ((-/-)) mice develop both early and late AMD-like pathological features. White and yellow spots, which look like drusen in humans, were identified with fundscopic examination. Drusen-like sub-RPE deposits with dome-shaped morphology were characterized on the sections. RPE vacuolization, swelling, and sub-RPE basal deposits were illustrated with light and transmission electron microscope (TEM). TEM further illustrated degenerated and disorganized RPE basal infoldings, phagosomes and melanosomes inside RPE, as well as abnormal photoreceptor outer segments. Lipofuscin granules and lipid droplets in the subretinal space, RPE, and choroid were revealed with fluorescence microscope and oil-red-O staining. Increased IgG in RPE/choroid were determined with Western blots (WB). WB and immunofluorescence staining determined RPE zona occuldens (ZO)-1 protein reduction and abnormal subcellular localization. TUNEL staining, outer nuclear layer (ONL) measurement and electroretinogram (ERG) recording indicated that photoreceptors underwent apoptosis, degeneration, and functional impairment. Additionally, spontaneous neovascularization (NV)-like lesions develop in the subretinal space of aged Cxcr5(-/-) mice. The underlying mechanisms are associated with increased subretinal F4/80(+) immune cells, some of which contain RPE marker RPE65, and up-regulation of the multifunctional cytokine tumor necrosis factor-alpha (TNF-alpha) in RPE/choroid and retina. These findings suggest that Cxcr5 itself may be involved in the protection of RPE and retinal cells during aging and its loss may lead to AMD-like pathological changes in aged mice.
C1 [Huang, Hu; Liu, Ying; Wang, Lei; Li, Wen] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21218 USA.
   [Liu, Ying] Aier Eye Hosp, Changsha, Hunan, Peoples R China.
   [Li, Wen] Cent South Univ, Sch Ophthalmol, Changsha, Hunan, Peoples R China.
C3 Johns Hopkins University; Johns Hopkins Medicine; Central South
   University
RP Huang, H (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21218 USA.
EM hhuang27@jhmi.edu
RI Wang, Lei/C-1902-2015
OI Wang, Lei/0000-0002-7957-1003
FU Brightfocus Foundation [118211]; Wilmer Pooled Professor Funds; NATIONAL
   EYE INSTITUTE [P30EY001765] Funding Source: NIH RePORTER
FX This work is supported by Brightfocus Foundation (118211; H.H.), Wilmer
   Pooled Professor Funds (H.H.), and an unrestricted gift from RBP
   (Wilmer). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.; We
   sincerely thank Dr. Rhonda Grebe for assistance with TEM, Dr. Sean
   Hackett for providing the genomic DNA for the controls of rd8 PCR
   genotyping, and Drs. Long Zhao, Junsong Gong, and Tomohiro Masuda for
   the help with ERG instrument. We also sincerely thank Drs. James Handa
   and Debashis Sinha for the critical discussions about the study and Dr.
   Gerard A. Lutty for reading and editing the manuscript. This work was
   supported by Brightfocus Foundation (H.H.), Wilmer Pooled Professor
   Funds (H.H.), and an unrestricted gift from RBP (Wilmer).
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anand A, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/365046
   Balkwill FR, 2012, J PATHOL, V226, P148, DOI 10.1002/path.3029
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan CC, 2003, OPHTHALMOLOGY, V110, P421, DOI 10.1016/S0161-6420(02)01737-2
   Chang B, 2013, INVEST OPHTH VIS SCI, V54, P4974, DOI 10.1167/iovs.13-12289
   Chinnery HR, 2012, NEUROBIOL AGING, V33, P1769, DOI 10.1016/j.neurobiolaging.2011.03.010
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Flynn G, 2003, J NEUROIMMUNOL, V136, P84, DOI 10.1016/S0165-5728(03)00009-2
   Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5
   Gass J D, 1972, Trans Am Ophthalmol Soc, V70, P409
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Howard OMZ, 2005, BLOOD, V105, P4207, DOI 10.1182/blood-2004-07-2697
   Huang H, 2012, INVEST OPHTHALMOL VI, V53
   Huang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071808
   Huang H, 2011, INVEST OPHTH VIS SCI, V52, P1336, DOI 10.1167/iovs.10-5768
   Kanda A, 2008, BRIT J OPHTHALMOL, V92, P448, DOI 10.1136/bjo.2007.131581
   Kanno M, 2007, NEUROIMMUNOLOGY RES, P193
   Kizil C, 2012, NEURAL DEV, V7, DOI 10.1186/1749-8104-7-27
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Krumbholz M, 2006, BRAIN, V129, P200, DOI 10.1093/brain/awh680
   Li YW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017106
   Luhmann UFO, 2013, EXP EYE RES, V107, P80, DOI 10.1016/j.exer.2012.11.015
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Ma W, 2014, INVEST OPHTHALMOL VI, V55
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Maugeri A, 2000, AM J HUM GENET, V67, P960, DOI 10.1086/303079
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Molenberghs G., 2000, LINEAR MIXED MODELS
   Murakami Y, 2014, CELL DEATH DIFFER, V21, P270, DOI 10.1038/cdd.2013.109
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Raoul W, 2008, OPHTHAL RES, V40, P115, DOI 10.1159/000119860
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saeki H, 2000, EUR J IMMUNOL, V30, P2808, DOI 10.1002/1521-4141(200010)30:10<2808::AID-IMMU2808>3.0.CO;2-K
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Vessey KA, 2012, INVEST OPHTH VIS SCI, V53, P7833, DOI 10.1167/iovs.12-10650
   Wang L, 2014, BBA-MOL CELL RES, V1843, P1248, DOI 10.1016/j.bbamcr.2014.03.016
   Weiss N, 2010, J NEUROIMMUNOL, V223, P131, DOI 10.1016/j.jneuroim.2010.03.009
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
NR 53
TC 23
Z9 23
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 10
PY 2017
VL 12
IS 3
AR e0173716
DI 10.1371/journal.pone.0173716
PG 23
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EN6CJ
UT WOS:000396091800072
PM 28282423
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Morales-Canton, V
   Quiroz-Mercado, H
   Velez-Montoya, R
   Zavala-Ayala, A
   Moshfeghi, AA
   Shusterman, EM
   Kaiser, PK
   Sanislo, SR
   Gertner, M
   Moshfeghi, DM
AF Morales-Canton, Virgilio
   Quiroz-Mercado, Hugo
   Velez-Montoya, Raul
   Zavala-Ayala, Alicia
   Moshfeghi, Andrew A.
   Shusterman, E. Mark
   Kaiser, Peter K.
   Sanislo, Steven R.
   Gertner, Michael
   Moshfeghi, Darius M.
TI 16 and 24 Gy Low-voltage X-ray Irradiation With Ranibizumab Therapy for
   Neovascular Age-Related Macular Degeneration: 12-Month Outcomes
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PROTON-BEAM IRRADIATION;
   RADIATION-THERAPY; STEREOTACTIC RADIOSURGERY; PLAQUE RADIOTHERAPY;
   SAFETY; BRACHYTHERAPY; MEMBRANES; SECONDARY; TRIAL
AB PURPOSE: To describe the 12-month safety and efficacy outcomes of 16 or 24 Gy radiation using low-voltage x-ray irradiation in conjunction with intravitreal ranibizumab for neovascular age-related macular degeneration (AMD).
   DESIGN: Prospective, phase I, open-label, nonrandomized uncontrolled safety study.
   METHODS: SETTING: Institutional. STUDY POPULATION: Neovascular AMD patients. INTERVENTION: One x-ray irradiation treatment at 16 or 24 Gy was administered externally through 3 locations in the inferior pars plana. After 2 initial monthly loading doses of ranibizumab, subsequent ranibizumab was administered according to predetermined criteria. MAIN OUTCOME MEASURES: Visual acuity, number of ianibizumab injections, safety and efficacy metrics at 12 months.
   RESULTS: Forty-seven eyes of 47 patients were enrolled and completed 12 months of follow-up: 16 Gy (n = 28) and 24 Gy (n = 19). There was no evidence of radiation retinopathy, optic neuropathy, or cataract. The mean visual acuity improved in both groups: +8.4 +/- 11.9 letters and +7.8 +/- 12 letters for 16 and 24 Gy, respectively. In both groups, 100% of subjects lost <15 letters, with 76% and 79% gaining >= 0 letters in the 16 Gy and 24 Gy groups, respectively. Patients received a mean of 1.0 additional injection over 12 months. The mean change in optical coherence tomography central subfield thickness from baseline to month 12 was -107 and -87 mu m for the 16 Gy and 24 Gy groups, respectively.
   CONCLUSION: One treatment of 16 or 24 Gy low-voltage x-ray therapy with as-needed ranibizumab appears safe in subjects with neovascular AMD at 12 months. An overall improvement in visual acuity was observed. No radiation-related adverse effects were reported. ((c) 2013 by Elsevier Inc. All rights reserved.)
C1 [Morales-Canton, Virgilio; Quiroz-Mercado, Hugo; Velez-Montoya, Raul; Zavala-Ayala, Alicia] IAP, Assoc Evitar Ceguera Mexico, Mexico City, DF, Mexico.
   [Quiroz-Mercado, Hugo; Velez-Montoya, Raul] Univ Colorado, Dept Ophthalmol, Denver, CO 80202 USA.
   [Moshfeghi, Andrew A.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Palm Beach Gardens, FL USA.
   [Shusterman, E. Mark; Gertner, Michael] Oraya Therapeut Inc, Newark, CA USA.
   [Kaiser, Peter K.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Sanislo, Steven R.; Moshfeghi, Darius M.] Stanford Univ, Sch Med, Byers Eye Inst, Horngren Family Vitreoretinal Ctr,Dept Ophthalmol, Palo Alto, CA 94303 USA.
C3 University of Colorado System; University of Colorado Denver; Bascom
   Palmer Eye Institute; Cleveland Clinic Foundation; Stanford University
RP Moshfeghi, DM (通讯作者)，Stanford Univ, Sch Med, Byers Eye Inst, Horngren Family Vitreoretinal Ctr,Dept Ophthalmol, 2452 Watson Ct, Palo Alto, CA 94303 USA.
EM dariusm@stanford.edu
RI Canton, Virgilio/AAF-7047-2021
OI Moshfeghi, Darius Mohammad/0000-0003-2254-292X; Kaiser,
   Peter/0000-0001-5126-045X
FU Thrombogenics, Inc
FX D.M.M.: Oraya, Inc, consultant, equity; Genentech, Thrombogenics,
   Synergetics, consultant; Convene, LLC, OcuBell, Inc, Versavision, LLC,
   In Situ Therapeutics, LLC, Realm Global LLC, equity; V.C.M., H.Q.M.,
   S.R.S.: Oraya, Inc, consultant; M.G.: Oraya, Inc, intellectual property,
   equity; P.K.K.: Research to Prevent Blindness, research; Bayer,
   Genentech, Regeneron, Kanghong, Novartis, consultant; Oraya, Inc,
   consultant, equity; A.A.M.: Genentech, Inc, Allergan, Inc, Bausch &
   Lomb, Inc, Alcon, Inc, Valeant, Inc, consultant/speaker; Eyetech, Inc,
   Alimera, Inc, consultant; Thrombogenics, Inc, research funding;
   Optistent, Inc, equity; E.M.S.: Oraya, Inc, employee, equity. The
   authors indicate no funding support. Contributions of authors: design
   and conduct H.Q.M., R.V.M., A.Z.A., A.A.M., E.M.S., P.K.K., S.R.S.,
   M.G., D.M.M.); collection (V.M.C., H.Q.M., R.V.M., A.Z.A., E.M.S.,
   S.R.S., M.G., D.M.M.); management (V.M.C., H.Q.M., R.V.M., E.M.S.,
   S.R.S., M.G., D.M.M.); analysis and interpretation (V.M.C., H.Q.M.,
   R.V.M., A.Z.A., A.A.M., E.M.S., P.K.K., S.R.S., M.G., D.M.M.);
   preparation (V.M.C., H.Q.M., R.V.M., A.Z.A., A.A.M., E.M.S., P.K.K.,
   S.R.S., M.G., D.M.M.); review/approval (V.M.C., H.Q.M., R.V.M., A.Z.A.,
   A.A.M., E.M.S., P.K.K., S.R.S., M.G., D.M.M.). This trial was registered
   at ClinicalTrials.gov (NCT01217762).
CR Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Avila MP, 2009, RETINA-J RET VIT DIS, V29, P157, DOI 10.1097/IAE.0b013e3181985915
   Barakat MR, 2011, ARCH OPHTHALMOL-CHIC, V129, P628, DOI 10.1001/archophthalmol.2011.99
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Canton VM, 2011, OPHTHAL SURG LAS IM, V42, P468, DOI 10.3928/15428877-20110804-01
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   Chakravarthy U, 2000, BRIT J RADIOL, V73, P305, DOI 10.1259/bjr.73.867.10817048
   Evans JR, 2010, COCHRANE DB SYST REV, V5
   Finger PT, 1996, OPHTHALMOLOGY, V103, P878, DOI 10.1016/S0161-6420(96)30592-7
   Finger PT, 2003, BRIT J OPHTHALMOL, V87, P1497, DOI 10.1136/bjo.87.12.1497
   Finger PT, 1999, AM J OPHTHALMOL, V127, P170, DOI 10.1016/S0002-9394(98)00389-4
   Flaxel CJ, 2000, EYE, V14, P155, DOI 10.1038/eye.2000.46
   Gertner M, 2010, MED PHYS, V37, P600, DOI 10.1118/1.3291648
   Hanlon J, 2011, INVEST OPHTH VIS SCI, V52, P2334, DOI 10.1167/iovs.10-6421
   Hanlon J, 2009, MED PHYS, V36, P3671, DOI 10.1118/1.3168554
   Jaakkola A, 2005, OPHTHALMOLOGY, V112, P567, DOI 10.1016/j.ophtha.2004.11.029
   Jaakkola A, 1999, ACTA OPHTHALMOL SCAN, V77, P57, DOI 10.1034/j.1600-0420.1999.770113.x
   Jaakkola A, 2001, EUR J OPHTHALMOL, V11, P269, DOI 10.1177/112067210101100310
   Jaakkola A, 1998, GRAEF ARCH CLIN EXP, V236, P24, DOI 10.1007/s004170050038
   Lee C, 2008, MED PHYS, V35, P5151, DOI 10.1118/1.2990780
   Moshfeghi AA, 2012, BRIT J OPHTHALMOL, V96, P1320, DOI 10.1136/bjophthalmol-2011-301222
   Moshfeghi AA, 2011, OPHTHAL SURG LAS IM, V42, P460, DOI 10.3928/15428877-20110804-03
   Moshfeghi DM, 2011, BRIT J OPHTHALMOL, V95, P185, DOI 10.1136/bjo.2009.163907
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Singh RP, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/615214
   Sivagnanavel V, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004004.PUB2
   Taddei PJ, 2010, PHYS MED BIOL, V55, P7037, DOI 10.1088/0031-9155/55/23/S06
   Zambarakji HJ, 2006, OPHTHALMOLOGY, V113, P2012, DOI 10.1016/j.ophtha.2006.05.036
NR 29
TC 6
Z9 6
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2013
VL 155
IS 6
BP 1000
EP 1008
DI 10.1016/j.ajo.2013.01.015
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 157JU
UT WOS:000319893200005
PM 23497847
DA 2022-11-30
ER

PT J
AU Piermarocchi, S
   Saviano, S
   Parisi, V
   Tedeschi, M
   Panozzo, G
   Scarpa, G
   Boschi, G
   Lo Giudice, G
AF Piermarocchi, Stefano
   Saviano, Sandro
   Parisi, Vincenzo
   Tedeschi, Massimiliano
   Panozzo, Giacomo
   Scarpa, Giuseppe
   Boschi, Giorgio
   Lo Giudice, Giuseppe
CA Carmis Study Grp
TI Carotenoids in Age-related Maculopathy Italian Study (CARMIS): two-year
   results of a randomized study
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Carotenoids; Lutein; Macular pigment;
   Zeaxanthin
ID MACULAR DEGENERATION; VITAMIN-C; OPTICAL-DENSITY; HUMAN RETINA;
   ZEAXANTHIN; PIGMENT; LUTEIN; PREVALENCE; EYE; IDENTIFICATION
AB PURPOSE. The high concentration of carotenoids in the macula, plus evidence linking oxidative stress to age-related macular degeneration (AMD) and carotenoids to antioxidation, generated the hypothesis that higher antioxidant intakes can prevent AMD. The aim of this study was to determine whether nutritional supplementation with a targeted nutritional supplement improves visual acuity and visual function in AMD.
   METHODS. In this multicenter, prospective open-label randomized study, 145 patients were randomly assigned to 2 different treatment groups. Interventions were lutein (10 mg), zeaxanthin (1 mg), astaxanthin (4 mg; AZYR SIFI, Catania, Italy), and antioxidants/vitamins supplementation formula or no dietary supplementation for 2 years. Primary outcome was mean changes in visual acuity (VA) at 12 and 24 months. Other measures included contrast sensitivity (CS) and National Eye Institute visual function questionnaire (NEI VFQ-25) scores at 12 and 24 months.
   RESULTS. Patients in the treated group showed stabilization of VA with significantly (p=0.003) better VA scores (81.4 +/- 7.2) compared to the nontreated group (76.8 +/- 8.9) at 24-month follow-up. An improvement in CS (p=0.001) and final mean NEI VFQ-25 composite scores at 12 and 24 months higher in treated group compared to nontreated group were also shown (p<0.001).
   CONCLUSIONS. Patients treated with lutein/zeaxanthin and astaxanthin together with other nutrients were more likely to report clinically meaningful stabilization/improvements in VA, CS, and visual function through 24 months compared with nontreated subjects. Further studies are needed with more patients and for longer periods of time.
C1 [Lo Giudice, Giuseppe] San Antonio Hosp, San Paolo Ophthalm Ctr, I-35100 Padua, Italy.
   [Piermarocchi, Stefano] Univ Padua, Dept Ophthalmol, Padua, Italy.
   [Saviano, Sandro] Univ Trieste, Dept Ophthalmol, Trieste, Italy.
   [Parisi, Vincenzo; Tedeschi, Massimiliano] Fdn GB Bietti Inst IRCCS, Rome, Italy.
   [Panozzo, Giacomo] Fdn Theia, Verona, Italy.
   [Scarpa, Giuseppe; Boschi, Giorgio] Ca Foncello Hosp, Dept Ophthalmol, Treviso, Italy.
C3 ULSS 6 Euganea; Ospedale Sant'antonio Padova; University of Padua;
   University of Trieste; IRCCS - Fondazione "G.B. Bietti" per lo Studio e
   la Ricerca in Oftalmologia; ULSS 2 Marca TV; Ospedale Ca' Foncello
   Treviso
RP Lo Giudice, G (通讯作者)，San Antonio Hosp, San Paolo Ophthalm Ctr, Via Facciolati 71, I-35100 Padua, Italy.
EM gvofta@libero.it
RI Parisi, Vincenzo/J-6137-2018; LO GIUDICE, GIUSEPPE/GQB-0418-2022
OI Battaglia Parodi, Maurizio/0000-0002-0385-7961
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   BONE RA, 1992, VISION RES, V32, P105, DOI 10.1016/0042-6989(92)90118-3
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Eter N, 2006, BIODRUGS, V20, P167, DOI 10.2165/00063030-200620030-00004
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   Higuera-Ciapara I, 2006, CRIT REV FOOD SCI, V46, P185, DOI 10.1080/10408690590957188
   Hussein G, 2006, J NAT PROD, V69, P443, DOI 10.1021/np050354+
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Landrum J T, 1997, Adv Pharmacol, V38, P537
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Sommerburg O, 1999, CURR EYE RES, V19, P491, DOI 10.1076/ceyr.19.6.491.5276
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
NR 24
TC 68
Z9 72
U1 2
U2 34
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAR-APR
PY 2012
VL 22
IS 2
BP 216
EP 225
DI 10.5301/ejo.5000069
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 952IW
UT WOS:000304787200013
PM 22009916
DA 2022-11-30
ER

PT J
AU Bressler, NM
   Bressler, SB
   Childs, AL
   Haller, JA
   Hawkins, BS
   Lewis, H
   MacCumber, MW
   Marsh, MJ
   Redford, M
   Sternberg, P
   Thomas, MA
   Williams, GA
AF Bressler, NM
   Bressler, SB
   Childs, AL
   Haller, JA
   Hawkins, BS
   Lewis, H
   MacCumber, MW
   Marsh, MJ
   Redford, M
   Sternberg, P
   Thomas, MA
   Williams, GA
CA Submacular Surg Trials SST Res Grp
TI Surgery for hemorrhagic choroidal neovascular lesions of age-related
   macular degeneration: Ophthalmic findings - SST report no. 13
SO OPHTHALMOLOGY
LA English
DT Article
ID TISSUE-PLASMINOGEN ACTIVATOR; SUBRETINAL HEMORRHAGE; SUBMACULAR
   HEMORRHAGE; PNEUMATIC DISPLACEMENT; SURGICAL REMOVAL; NATURAL-HISTORY;
   MANAGEMENT; INJECTION; VITRECTOMY
AB Purpose: To present best-corrected visual acuity (BCVA) findings and other clinical outcomes from eyes of patients enrolled in one of the Submacular Surgery Trials (SST) evaluating surgical removal versus observation of predominantly hemorrhagic subfoveal choroidal neovascularization (CNV) associated with age-related macular degeneration.
   Design: Randomized clinical trial (SST Group B Trial).
   Participants: Eligible patients had subfoveal choroidal neovascular lesions greater than 3.5 disk areas (8.9 mm(2)) composed of at least 50% blood (either blood or CNV underlying the center of the foveal avascular zone) and BCVA of 20/100 to light perception in the study eye.
   Intervention: Patients were assigned randomly at time of enrollment to observation or surgical removal of blood and any associated CNV.
   Main Outcome Measure: A successful outcome was defined a priori as either improvement in visual acuity (VA), no change in VA, or a decline in VA of no more than 1 line (7 letters) from baseline to the 24-month examination based on an intent-to-treat analysis.
   Results. Of 336 patients enrolled, 168 were assigned to each treatment arm; treatment arms were balanced by baseline characteristics. Of 1501 expected examinations 3 months through 36 months after baseline, 1370 (91%) were performed. Loss of greater than or equal to2 lines (greater than or equal to8 letters) of VA occurred in 56% of surgery eyes, versus 59% of observation eyes examined at 24 months. Although severe loss of VA was not the primary outcome of interest, surgery more often prevented such loss: 36% in the observation arm versus 21% in the surgery arm at the 24-month examination (x(2) p = 0.004). Of initially phakic eyes, the cumulative percentage that had undergone cataract surgery by 24 months was 44% in the surgery arm, compared with 6% in the observation arm. Twenty-seven eyes (16%) in the surgical arm, compared with 3 eyes (2%) in the observation arm, had a rhegmatogenous retinal detachment (RD).
   Conclusions: Submacular surgery as performed in the SST Group B Trial did not increase the chance of stable or improved VA (the primary outcome of interest) and was associated with a high risk of rhegmatogenous RD, but did reduce the risk of severe VA loss in comparison with observation. (C) 2004 by the American Academy of Ophthalmology.
C1 Wilmer Clin Trials & Biometry, SST Coordinating Ctr, Baltimore, MD 21205 USA.
RP Bressler, NM (通讯作者)，Wilmer Clin Trials & Biometry, SST Coordinating Ctr, 550 N Broadway,9th Floor, Baltimore, MD 21205 USA.
EM nmboffice@jhmi.edu
OI Mann, Ashley/0000-0003-3553-5470
FU NEI NIH HHS [U10 EY011558-07, U10 EY011557-08, U10 EY011557, U10
   EY11547, U10 EY011547, U10 EY011558, EY11558, U10 EY011547-07, EY11557]
   Funding Source: Medline; NATIONAL EYE INSTITUTE [U10EY011547,
   U10EY011557, U10EY011558] Funding Source: NIH RePORTER
CR *AM AC OPHTH RET P, PREF PRACT PATT AG R
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   ARMITAGE P, 1987, STATISTICAL METHODS, P372
   Arnold J, 2002, RETINA-J RET VIT DIS, V22, P6
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P1557, DOI 10.1001/archopht.1995.01100120087016
   Childs AL, 2004, OPHTHALMOLOGY, V111, P2007, DOI 10.1016/j.ophtha.2004.07.024
   COX DR, 1989, ANAL BINARY DATA, P66
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   HANSCOM TA, 1987, ARCH OPHTHALMOL-CHIC, V105, P1722
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   HILLIS A, 1986, J CHRON DIS, V39, P595, DOI 10.1016/0021-9681(86)90184-0
   IBANEZ HE, 1995, ARCH OPHTHALMOL-CHIC, V113, P62, DOI 10.1001/archopht.1995.01100010064022
   Kamei M, 1996, AM J OPHTHALMOL, V121, P267, DOI 10.1016/S0002-9394(14)70274-0
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   KIMURA AE, 1994, RETINA-J RET VIT DIS, V14, P83, DOI 10.1097/00006982-199401000-00018
   Krepler K, 2000, RETINA-J RET VIT DIS, V20, P251, DOI 10.1097/00006982-200003000-00005
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   Matsuo T, 2001, ACTA OPHTHALMOL SCAN, V79, P533, DOI 10.1034/j.1600-0420.2001.790522.x
   Miskala PH, 2004, OPHTHALMOLOGY, V111, P1981, DOI 10.1016/j.ophtha.2004.07.022
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   *SAS INC, 2001, SAS VERSION 8 2
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   SNEDECOR GW, 1980, STATISTICAL METHODS, P144
   *SST, NTIS PUBL
   *SST RES GROUP, IN PRESS RETINA
   *SST RES GROUP, 2004, ARCH OPHTHALMOL-CHIC, V122, P857
   *SST RES GROUP, IN PRESS ARCH OPHTHA
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   *SUBM SURG TRIALS, IN PRESS ARCH OPHTHA
   Talic I, 2022, LEARN INSTR, V81, DOI [10.1016/j.learninstruc.2022.101594, 10.1016/j.ajo.2004.02.011]
   VANDER JF, 1991, OPHTHALMOLOGY, V98, P23
   WADE EC, 1990, ARCH OPHTHALMOL-CHIC, V108, P973, DOI 10.1001/archopht.1990.01070090075043
   Zhang HP, 1996, STAT MED, V15, P37, DOI 10.1002/(SICI)1097-0258(19960115)15:1<37::AID-SIM144>3.0.CO;2-0
NR 46
TC 195
Z9 200
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2004
VL 111
IS 11
BP 1993
EP 2006
DI 10.1016/j.ophtha.2004.07.023
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 866JZ
UT WOS:000224771100004
PM 15522364
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Nagineni, CN
   Kommineni, VK
   William, A
   Detrick, B
   Hooks, JJ
AF Nagineni, Chandrasekharam N.
   Kommineni, Vijay K.
   William, Abitha
   Detrick, Barbara
   Hooks, John J.
TI Regulation of VEGF Expression in Human Retinal Cells by Cytokines:
   Implications for the Role of Inflammation in Age-Related Macular
   Degeneration
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL-CELLS; CHOROIDAL
   NEOVASCULAR MEMBRANES; C-REACTIVE PROTEIN; VISUAL FUNCTION; OCULAR
   NEOVASCULARIZATION; DIFFERENTIAL EXPRESSION; VASCULAR-PERMEABILITY;
   IMMUNE-RESPONSE; DRUSEN
AB Chronic inflammation is implicated in the pathogenesis of age-related macular degeneration (AMD). Choroidal neovascularization (CNV) observed in exudative form of AMD results in vision loss. Human retinal pigment epithelial cell (HRPE) layer and choroidal tissue are the primary pathological sites in AMD. Pathological and therapeutic evidences have strongly indicated the vascular endothelial growth factor (VEGF) molecules as critical components in CNV pathogenesis. In these studies, we used human primary HRPE and choroidal fibroblast cells (HCHF) prepared from adult donor eyes. The effects of inflammatory cytokine (IFN-gamma+TNF-alpha+IL-1 beta) mix (ICM) on global gene expression profiles in HRPE cells, revealed 10- and 9-fold increase in VEGF-A and VEGF-C expression, respectively. The microarray results were validated by quantitative RT-PCR and secretion of VEGFs proteins. IL-1 beta is the most potent in inducing VEGFs secretion followed by IFN-gamma and TNF-alpha, and the secretion was more effective in the presence of 2 and 3 cytokines. NF-kappa B and JAK-STAT pathway, but not HIF-1 alpha, Sp-1, Sp-3, and STAT-3, transcription factors were upregulated and translocated to nucleus by ICM treatment. The mRNA levels of VEGF-A and VEGF-C and secretion of these proteins were also significantly enhanced by ICM in HCHF cells. The secretion of other angiogenic molecules, PEDF, SDF-1 alpha, endostatin, and angiopoietins was not affected by ICM. Our results show that the inflammatory cytokines enhance secretion of VEGF-A and VEGF-C by HRPE and HCHF cells. These studies indicate that VEGFs secreted by these cells initiate and promote pathological choroidal and retinal noevascularization processes in AMD. J. Cell. Physiol. 227: 116-126, 2012. (C) 2011 Wiley Periodicals, Inc.
C1 [Nagineni, Chandrasekharam N.; Hooks, John J.] NEI, Immunol & Virol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Detrick, Barbara] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Johns Hopkins University
RP Nagineni, CN (通讯作者)，NEI, Immunol & Virol Sect, Immunol Lab, NIH, Bldg 10,Room 10B16, Bethesda, MD 20892 USA.
EM naginenic@nei.nih.gov; hooksj@nei.nih.gov
FU National Eye Institute, National Institutes of Health, Bethesda,
   Maryland, USA; NATIONAL EYE INSTITUTE [ZIAEY000277] Funding Source: NIH
   RePORTER
FX This research was supported by the Intramural Research Program of the
   National Eye Institute, National Institutes of Health, Bethesda,
   Maryland, USA.
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Campochiaro PA, 2004, EXPERT OPIN BIOL TH, V4, P1395, DOI 10.1517/14712598.4.9.1395
   Cao RH, 2004, CIRC RES, V94, P664, DOI 10.1161/01.RES.0000118600.91698.BB
   Chilov D, 1997, J BIOL CHEM, V272, P25176, DOI 10.1074/jbc.272.40.25176
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946
   Elner SG, 2006, EXP EYE RES, V83, P374, DOI 10.1016/j.exer.2006.01.013
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   FORRESTER JV, 1990, CURR EYE RES, V9, P183, DOI 10.3109/02713689008999440
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hooks JJ, 2008, J IMMUNOL, V180, P3789, DOI 10.4049/jimmunol.180.6.3789
   Joukov V, 1996, EMBO J, V15, P290
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kutty RK, 2010, BIOCHEM BIOPH RES CO, V402, P390, DOI 10.1016/j.bbrc.2010.10.042
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Marmor M. F., 1998, RETINAL PIGMENT EPIT, DOI [10.1098/rsif.2015.0563, DOI 10.1098/RSIF.2015.0563]
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Martin G, 2004, GRAEF ARCH CLIN EXP, V242, P321, DOI 10.1007/s00417-003-0838-y
   Nagineni CN, 2007, J CELL PHYSIOL, V210, P192, DOI 10.1002/jcp.20839
   Nagineni CN, 2005, J CELL PHYSIOL, V203, P35, DOI 10.1002/jcp.20213
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   NAGINENI CN, 1994, CLIN DIAGN LAB IMMUN, V1, P569, DOI 10.1128/CDLI.1.5.569-577.1994
   Nagineni CN, 1996, CYTOKINE, V8, P622, DOI 10.1006/cyto.1996.0083
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Noel A, 2007, TRENDS MOL MED, V13, P345, DOI 10.1016/j.molmed.2007.06.005
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987
   Yang D, 2007, EXP EYE RES, V85, P462, DOI 10.1016/j.exer.2007.06.013
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang SX, 2007, PROG RETIN EYE RES, V26, P1, DOI 10.1016/j.preteyeres.2006.09.002
NR 57
TC 95
Z9 98
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JAN
PY 2012
VL 227
IS 1
BP 116
EP 126
DI 10.1002/jcp.22708
PG 11
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA 860IR
UT WOS:000297942500014
PM 21374591
DA 2022-11-30
ER

PT J
AU Peddada, RR
AF Peddada, Ram R.
TI Bruch's membrane diffusivity for vascular endothelial growth factors may
   explain variable response to wet age-related macular degeneration
   treatment: Clinical implications
SO MEDICAL HYPOTHESES
LA English
DT Article
AB The hypothesis presented is that diffusivity of vascular endothelial growth factors (VEGF) across Bruch's membrane is an important parameter that distinguishes prompt and slow responders to anti-VEGF treatment in wet age-related macular degeneration (AMD). Accordingly, slow-responders have a high diffusivity and will attain peak VEGF levels on the choroidal side of Bruch's membrane rapidly, probably before or around the time of the next monthly anti-VEGF injection.
   If a fixed dose of anti-VEGF is used at each monthly treatment (as is the current practice), depending on the initial level of VEGF at that time of injection, VEGF with each treatment will vary. Therefore, diffusion will occur at a different concentration gradient in each treatment cycle subsequent to the injection. Hence, by Fick's Second Law of Diffusion, the slope of the concentration versus time curve for each treatment cycle will be different from the preceding cycle. This leads to a different peak concentration just prior to the next monthly injection.
   So, when a fixed dose of the anti-VEGF is used at each monthly treatment peak VEGF level fluctuates instead of going down continuously which prolongs the treatment. Thus, doses of anti-VEGF may have to be tapered to decrease the concentration gradient and to slow down the rate of diffusion of VEGF.
   Diffusivity of Bruch's membrane with regards to VEGF is a simple concept that can explain the variable response to anti-VEGF treatment in wet AMD. If validated through clinical trial the treatment protocol for wet AMD can be more precise and tailored to individual patients. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Peddada, Ram R.] Alabama Coll Osteopath Med, Dothan, AL 36303 USA.
RP Peddada, RR (通讯作者)，Alabama Coll Osteopath Med, Clin Fac, 445 Hlth Sci Blvd, Dothan, AL 36303 USA.
EM ram.r.peddada@gmail.com
CR Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Panton R.L., 1984, INCOMPRESSIBLE FLOW
NR 3
TC 1
Z9 1
U1 0
U2 3
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD DEC
PY 2014
VL 83
IS 6
BP 835
EP 837
DI 10.1016/j.mehy.2014.10.022
PG 3
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA AY5EJ
UT WOS:000347595600044
PM 25468789
DA 2022-11-30
ER

PT J
AU Habibi, I
   Kort, F
   Sfar, I
   Chebil, A
   Bouraoui, R
   Ben Abdallah, T
   Gorgi, Y
   El Matri, L
AF Habibi, I.
   Kort, F.
   Sfar, I.
   Chebil, A.
   Bouraoui, R.
   Ben Abdallah, T.
   Gorgi, Y.
   El Matri, L.
TI Effect of Risk Alleles in CFH, C3, and VEGFA on the Response to
   Intravitreal Bevacizumab in Tunisian Patients with Neovascular
   Age-related Macular Degeneration
SO KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
LA English
DT Review
DE AMD; factor H; VEGF; C3; anti-VEGF therapy
ID ENDOTHELIAL GROWTH-FACTOR; RANIBIZUMAB; POLYMORPHISMS; PHARMACOGENETICS
AB Purpose. The aim of this pharmacogenetic study was to evaluate the impact of high-risk alleles in factor H, factor C3 and vascular endothelial growth factor (VEGF) on the response to intravitreal bevacizumab in patients with neovascular age-related macular degeneration (AMD) in a Tunisian population.
   Methods. Ninety patients with active neovascular AMD treated with intravitreal bevacizumab injections were enrolled in the study. Treatment response was evaluated by comparing BCVA at baseline and at 12 months. Patients were classified into either "poor responders" (PR) or "good responders" (GR). Single nucleotide polymorphism (SNP) genotyping was performed for rs1061170 in FH, rs2230199 in C3 and rs699947, rs2010963 and rs3025039 in VEGF. The association between genotype and visual response at 12 months was assessed.
   Results. Seventy-seven participants were assigned to the GR group and 13 to the PR group. No correlation was found between FH, C3 and VEGF variant alleles and treatment response. However, haplotype analysis of rs699947 ((-2578) C/A), rs2010963 ((+405) C/G) and rs3025039 ((+936) C/T) SNPs revealed that the AGT haplotype was associated with a poor response at 12months (p = 0.048). No association was found between treatment response and the cumulative effect of all high-risk alleles of C3, FH and VEGF. All three types of CNV were found in both groups at a comparable frequency.
   Conclusions. The VEGF haplotype TGA could be used as a marker for poor visual prognosis in Tunisian patients with neovascular AMD treated with bevacizumab.
C1 [Habibi, I.; Sfar, I.; Ben Abdallah, T.; Gorgi, Y.] Univ Tunis El Manar, Charles Nicolle Hosp, Res Lab Renal Transplantat & Immunopathol LR03SP0, Tunis, Tunisia.
   [Habibi, I.; Kort, F.; Chebil, A.; Bouraoui, R.; El Matri, L.] Hedi Rais Inst Ophthalmol, Dept Ophthalmol B, Res Lab Oculogenet LR14SP01, Tunis, Tunisia.
C3 Universite de Tunis-El-Manar; Hopital Charles Nicolle; Universite de
   Tunis-El-Manar; Institut Hedi Raies d'ophtalmologie de Tunis
RP El Matri, L (通讯作者)，Hedi Rais Inst Ophthalmol, Dept Ophthalmol B, Blvd 9 Avril Bab Saadoun, Tunis 1006, Tunisia.
EM leilaelmatri@planet.tn
FU Tunisian Immunology Research Laboratory [LR03SP01]
FX This study was supported by a grant from the Tunisian Immunology
   Research Laboratory (LR03SP01) Fund.
CR Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Lambrechts D, 2003, NAT GENET, V34, P383, DOI 10.1038/ng1211
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Park UC, 2014, RETINA-J RET VIT DIS, V34, P288, DOI 10.1097/IAE.0b013e3182979e1e
   Schneider BP, 2008, J CLIN ONCOL, V26, P4672, DOI 10.1200/JCO.2008.16.1612
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Watson CJ, 2000, CYTOKINE, V12, P1232, DOI 10.1006/cyto.2000.0692
NR 10
TC 8
Z9 10
U1 0
U2 5
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0023-2165
EI 1439-3999
J9 KLIN MONATSBL AUGENH
JI Klinische Monatsblat. Augenheilkunde
PD APR
PY 2016
VL 233
IS 4
BP 465
EP 470
DI 10.1055/s-0041-111801
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DK6ON
UT WOS:000375043500039
PM 27116510
DA 2022-11-30
ER

PT J
AU Doguizi, S
   Ozdek, S
AF Doguizi, Sibel
   Ozdek, Sengul
TI PIGMENT EPITHELIAL TEARS ASSOCIATED WITH ANTI-VEGF THERAPY Incidence,
   Long-term Visual Outcome, and Relationship with Pigment Epithelial
   Detachment in Age-related Macular Degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE retinal pigment epithelium tears; vascular endothelial growth factor;
   ranibizumab; bevacizumab; retinal pigment epithelial detachment; macular
   degeneration
ID INTRAVITREAL BEVACIZUMAB INJECTION; OPTICAL COHERENCE TOMOGRAPHY; RPE
   TEARS; RANIBIZUMAB; SECONDARY; RISK
AB Purpose: To evaluate the prevalence of retinal pigment epithelium (RPE) tears associated with anti-VEGF therapy and its relation with retinal pigment epithelial detachment (PED).
   Methods: A total of 226 patients with exudative age-related macular degeneration treated with intravitreal anti-VEGF were included retrospectively in the study. The presence of RPE tears; the effect of the presence, height, and duration of PED on the rate of RPE tears; and change in visual acuity during follow-up were recorded.
   Results: Among 226 study patients, 28 (12.3%) had RPE tears. The RPE tear rate was significantly higher in patients with vascularized PED (vPED) than in those without PED (19.7% vs. 2.1%; P < 0.001). The change in visual acuity after the formation of RPE tear was not statistically significant (on logMAR scale: 0.92 +/- 0.49 initially, 0.89 +/- 0.41 after the RPE tear, 0.96 +/- 0.45 at the last follow-up; P = 0.613). Pigment epithelial detachment height >580 mu m (odds ratio = 69.4; 95% confidence interval = 16.7-288.1) and PED duration <= 4.5 months (odds ratio = 166.7; 95% confidence interval = 15.2-1000) were found to be significant risk factors for RPE tear formation.
   Conclusion: The RPE tears are not infrequent among eyes treated with intravitreal anti-VEGFs. The presence, increased height, and shorter duration of vPED are potential risk factors for RPE tears associated with anti-VEGF therapy.
C1 [Doguizi, Sibel; Ozdek, Sengul] Gazi Univ, Dept Ophthalmol, TR-6172 Ankara, Turkey.
C3 Gazi University
RP Doguizi, S (通讯作者)，Gazi Univ, Dept Ophthalmol, TR-6172 Ankara, Turkey.
EM eryigits@yahoo.com
RI Özdek, Şengül/CAF-5314-2022
OI Özdek, Şengül/0000-0002-7494-4106
CR Arias L, 2007, EUR J OPHTHALMOL, V17, P992, DOI 10.1177/112067210701700622
   Bakri SJ, 2007, AM J OPHTHALMOL, V143, P505, DOI 10.1016/j.ajo.2006.11.047
   Carvounis PE, 2007, AM J OPHTHALMOL, V143, P504, DOI 10.1016/j.ajo.2006.11.028
   Chan CK, 2007, EUR J OPHTHALMOL, V17, P674, DOI 10.1177/112067210701700432
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P857, DOI 10.1097/IAE.0b013e3180342c42
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   CHUANG EL, 1988, EYE, V2, P106, DOI 10.1038/eye.1988.22
   Coco RM, 2012, OPHTHALMOLOGICA, V228, P78, DOI 10.1159/000338730
   Garg S, 2008, CLIN EXP OPHTHALMOL, V36, P252, DOI 10.1111/j.1442-9071.2008.01710.x
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Gelisken F, 2009, EYE, V23, P694, DOI 10.1038/sj.eye.6703098
   Gelisken F, 2006, ACTA OPHTHALMOL SCAN, V84, P833, DOI 10.1111/j.1600-0420.2006.00765.x
   GOLDSTEIN BG, 1987, BRIT J OPHTHALMOL, V71, P676, DOI 10.1136/bjo.71.9.676
   GREEN SN, 1983, RETINA-J RET VIT DIS, V3, P16, DOI 10.1097/00006982-198300310-00004
   Gutfleisch M, 2011, EYE, V25, P1181, DOI 10.1038/eye.2011.146
   Hartnett ME, 2003, EXP EYE RES, V77, P593, DOI 10.1016/S0014-4835(03)00189-1
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Kiss C, 2007, ACTA OPHTHALMOL SCAN, V85, P902, DOI 10.1111/j.1600-0420.2007.00928.x
   Konstantinidis L, 2010, ACTA OPHTHALMOL, V88, P736, DOI 10.1111/j.1755-3768.2009.01547.x
   Kook D, 2008, OPHTHALMOLOGE, V105, P158, DOI 10.1007/s00347-007-1561-6
   Lee GKY, 2007, GRAEF ARCH CLIN EXP, V245, P1225, DOI 10.1007/s00417-007-0536-2
   Leitritz M, 2008, EYE, V22, P1504, DOI 10.1038/eye.2008.145
   Mathews JP, 2007, EYE, V21, P1004, DOI 10.1038/sj.eye.6702805
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Nicolo M, 2006, EUR J OPHTHALMOL, V16, P770, DOI 10.1177/112067210601600521
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Shah CP, 2006, AM J OPHTHALMOL, V142, P1070, DOI 10.1016/j.ajo.2006.07.037
   Singh RP, 2006, AM J OPHTHALMOL, V142, P160, DOI 10.1016/j.ajo.2006.03.051
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
   Wong LJ, 2008, RETINA-J RET VIT DIS, V28, P1151, DOI 10.1097/IAE.0b013e31817e100f
NR 37
TC 41
Z9 44
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2014
VL 34
IS 6
BP 1156
EP 1162
DI 10.1097/IAE.0000000000000056
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AI8GP
UT WOS:000337149000017
PM 24296398
DA 2022-11-30
ER

PT J
AU Zarbin, M
   Tsuboi, M
   Hill, LF
   Stoilov, I
AF Zarbin, Marco
   Tsuboi, Min
   Hill, Lauren F.
   Stoilov, Ivaylo
TI Simulating an Anti-Vascular Endothelial Growth Factor Switch in
   Neovascular Age-Related Macular Degeneration A HARBOR Subanalysis
SO OPHTHALMOLOGY
LA English
DT Article
ID 2.0 MG RANIBIZUMAB; AFLIBERCEPT; EFFICACY; SAFETY
AB Purpose: A simulated switching study assessed the effects of continuing the same anti-vascular endothelial growth factor (VEGF) treatment among patients who typically are considered for a therapy switch. Post hoc analysis of data from HARBOR was undertaken. Patients with neovascular age-related macular degeneration who demonstrated a suboptimal response after 3 or 6 months of ranibizumab treatment were identified as switching candidates. Rather than switching, however, patients continued on ranibizumab treatment, and visual and anatomic outcomes from the point of the hypothetical switch were examined.
   Design: Post hoc analysis of the phase 3 HARBOR clinical trial.
   Participants: Patients were included in 3- and 6-month switcher analyses if they received 3 of 3 initial monthly ranibizumab doses and 5 of 6 initial monthly ranibizumab doses, respectively, and met all the following: 5-letter or fewer gain from baseline, best-corrected visual acuity (BCVA) 20/40 or worse, and intraretinal or subretinal fluid with central foveal thickness (CFT) equal to or greater than central subfield thickness.
   Methods: Patient data were examined at months 3 and 6 to identify those who met predetermined switching criteria. Best-corrected visual acuity and CFT were examined from the point at which switching criteria were met through months 6, 12, 18, and 24 of HARBOR and compared with those who did not meet the criteria.
   Main Outcome Measures: Outcome measures included mean BCVA and CFT change over time from the point (month 3 or 6) at which switching criteria were met.
   Results: By months 3 and 6, only 44 of 1059 patients (4.2%) and 37 of 769 patients (4.8%), respectively, met the inclusion criteria for hypothetical switching. Patients who met switching criteria at month 3 gained, on average, 5.3 letters from months 3 to 12 and 2.7 letters from months 3 to 24. Month 6 switchers gained, on average, 1.6 letters from months 6 to 12 and 1.8 letters from months 6 to 24. Both groups experienced significant CFT reductions over 24 months.
   Conclusions: Month 3 hypothetical switchers achieved vision and anatomic improvement while continuing their original ranibizumab treatment. Month 6 switcher outcomes replicated those commonly reported in published anti-VEGF switching studies: stable vision or nominal improvements in vision with continued substantial anatomic improvement. (C) 2019 by the American Academy of Ophthalmology.
C1 [Zarbin, Marco] Rutgers State Univ, New Jersey Med Sch, Inst Ophthalmol & Visual Sci, Newark, NJ USA.
   [Tsuboi, Min; Hill, Lauren F.; Stoilov, Ivaylo] Genentech Inc, San Francisco, CA 94080 USA.
C3 Rutgers State University Newark; Rutgers State University New Brunswick;
   Rutgers State University Medical Center; Roche Holding; Genentech
RP Zarbin, M (通讯作者)，Rutgers State Univ, New Jersey Med Sch, Inst Ophthalmol & Visual Sci, Doctors Off Ctr, Room 6155,90 Bergen St, Newark, NJ 07103 USA.
EM zarbin@earthlink.net
OI Zarbin, Marco/0000-0002-7811-7132; Hill, Lauren/0000-0002-9443-2167;
   Tsuboi, Min/0000-0001-8518-2031
CR BTG International Inc, 2018, CROFAB PRESCR INF
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Ferris FL, 2017, JAMA OPHTHALMOL, V135, P145, DOI 10.1001/jamaophthalmol.2016.4820
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Genentech Inc., 2018, AV
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Kasap M, 2008, J THEOR BIOL, V253, P446, DOI 10.1016/j.jtbi.2008.03.018
   Kitchens JW, 2013, CLIN OPHTHALMOL, V7, P1987, DOI 10.2147/OPTH.S39635
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Morton V, 2003, BRIT MED J, V326, P1083, DOI 10.1136/bmj.326.7398.1083
   Regeneron Pharmaceuticals Inc., 2018, EYEL
   Seguin-Greenstein S, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4095852
   Singh RP, 2018, 2018 GLOBAL TRENDS R
   Spooner K, 2017, CLIN OPHTHALMOL, V11, P161, DOI 10.2147/OPTH.S125676
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 16
TC 6
Z9 6
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2019
VL 126
IS 6
BP 849
EP 855
DI 10.1016/j.ophtha.2019.01.003
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HY6YD
UT WOS:000468275600021
PM 30641096
OA hybrid
DA 2022-11-30
ER

PT J
AU Smailhodzic, D
   Klaver, CCW
   Klevering, BJ
   Boon, CJF
   Groenewoud, JMM
   Kirchhof, B
   Daha, MR
   den Hollander, AI
   Hoyng, CB
AF Smailhodzic, Dzenita
   Klaver, Caroline C. W.
   Klevering, B. Jeroen
   Boon, Camiel J. F.
   Groenewoud, Joannes M. M.
   Kirchhof, Bernd
   Daha, Mohamed R.
   den Hollander, Anneke I.
   Hoyng, Carel B.
TI Risk Alleles in CFH and ARMS2 Are Independently Associated with Systemic
   Complement Activation in Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID FACTOR-H POLYMORPHISM; GENOMEWIDE-SCAN; SERPING1 GENE; SUSCEPTIBILITY;
   VARIANT; MACULOPATHY; LOC387715; HTRA1; INDIVIDUALS; COMPONENTS
AB Purpose: Systemic complement activation is associated with age-related macular degeneration (AMD) and has mainly been attributed to a risk allele in the complement factor H (CFH) gene. Whether other important AMD genes also influence complement activation is unclear. In the present case-control study, complement activity and concentrations of complement components and their activation products are measured in AMD patients and in unaffected controls and correlated with genetic variants in the CFH, ARMS2, C3, CFI, and CFB genes.
   Design: Case-control study.
   Participants: A cohort of 197 confirmed AMD patients and 150 unaffected age-matched controls were recruited prospectively for the study.
   Methods: Hemolytic complement assays (AP50, CP50, and LP50), complement components (C3, CFB, CFI, and CFH), and the activation products (C3d, C5a, and SC5b-9) were analyzed in serum or plasma. The DNA samples were genotyped for 5 single nucleotide polymorphisms (SNPs) previously associated with AMD in the CFH, ARMS2, C3, CFB, and CFI genes.
   Main Outcome Measures: Complement concentrations and their associations with SNPs in the CFH, ARMS2, C3, CFB, and CFI genes.
   Results: The AMD patients had increased activation of the alternative complement pathway (P = 0.003) and elevated levels of complement activation components C3d (P < 0.0001) and C5a (P < 0.0001), CFB (P < 0.0001), and an increased C3d/C3 ratio (P < 0.0001) calculated as a measure of C3 activation. While the CFH risk genotype was significantly associated with the elevated C3d/C3 ratios obtained, in the absence of CFH risk alleles the ARMS2 risk genotype also showed significantly increased levels of complement activation (P = 0.013). Furthermore, the carriers of the CFB protective allele had lower CFB concentrations.
   Conclusions: The current study found evidence showing that in AMD risk alleles in CFH and ARMS2 are independently associated with complement activation. Especially the C3d/C3 ratio seems to be a strong marker for AMD. The findings suggest that CFH and ARMS2 share a common pathway in the pathogenesis of AMD.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2012; 119: 339-346 (C) 2012 by the American Academy of Ophthalmology.
C1 [Smailhodzic, Dzenita; Klevering, B. Jeroen; Boon, Camiel J. F.; den Hollander, Anneke I.; Hoyng, Carel B.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6526 EX Nijmegen, Netherlands.
   [Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Klaver, Caroline C. W.] Erasmus MC, Dept Biostat, Rotterdam, Netherlands.
   [Groenewoud, Joannes M. M.] Radboud Univ Nijmegen, Med Ctr, Dept Epidemiol Biostat & HTA, NL-6526 EX Nijmegen, Netherlands.
   [Kirchhof, Bernd] Univ Cologne, Dept Ophthalmol, D-50931 Cologne, Germany.
   [Daha, Mohamed R.] Leiden Univ, Med Ctr, Dept Nephrol, Leiden, Netherlands.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6526 EX Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Erasmus University Rotterdam; Erasmus MC;
   Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; Radboud University Nijmegen; University of Cologne; Leiden
   University; Leiden University Medical Center (LUMC); Leiden University -
   Excl LUMC; Radboud University Nijmegen
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Philips van Leydenlaan 15, NL-6526 EX Nijmegen, Netherlands.
EM A.denHollander@ohk.umcn.nl
RI Klevering, B.J./L-4434-2015; Klaver, Caroline C.W./A-2013-2016; Hoyng,
   C.B./H-8050-2014; Hollander, Anneke den/N-4911-2014; Groenewoud, Hans
   JMM/R-3588-2017; Boon, CJF/P-7534-2014
OI Groenewoud, Hans JMM/0000-0002-4974-150X; Klaver,
   Caroline/0000-0002-2355-5258; Boon, CJF/0000-0002-6737-7932
FU Netherlands Organisation for Scientific Research [016.096.309]; MD
   fonds; Oogfonds; Landelijke Stichting voor Blinden en Slechtzienden;
   Algemene Nederlandse Vereniging ter Voorkoming van Blindheid; Stichting
   Researchfonds Oogheelkunde; Stichting Nederlands Oogheelkundig
   Onderzoek; Stichting Blindenhulp; Blindenstichting
FX Supported by the Netherlands Organisation for Scientific Research (grant
   016.096.309), the MD fonds, Oogfonds, Landelijke Stichting voor Blinden
   en Slechtzienden, Algemene Nederlandse Vereniging ter Voorkoming van
   Blindheid, Stichting Researchfonds Oogheelkunde, Stichting Nederlands
   Oogheelkundig Onderzoek, Stichting Blindenhulp, and the Gelderse
   Blindenstichting.
CR Allikmets R, 2009, LANCET, V374, P875, DOI 10.1016/S0140-6736(09)61618-4
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Black S, 2004, J BIOL CHEM, V279, P48487, DOI 10.1074/jbc.R400025200
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   COULPIER M, 1995, CLIN EXP IMMUNOL, V101, P142
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gibbs D, 2008, VISION RES, V48, P685, DOI 10.1016/j.visres.2007.10.022
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grooteman M P, 1995, ASAIO J, V41, P215
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hart ML, 2004, MOL IMMUNOL, V41, P165, DOI 10.1016/j.molimm.2004.03.013
   Hawkins JR, 2002, HUM MUTAT, V19, P543, DOI 10.1002/humu.10060
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jarva H, 1999, J IMMUNOL, V163, P3957
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Park KH, 2009, MOL VIS, V15, P200
   REDDINGIUS RE, 1993, PERITON DIALYSIS INT, V13, P214
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   ROTHER E, 1993, CLIN RHEUMATOL, V12, P31, DOI 10.1007/BF02231555
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Scholl HP, 2008, PLOS ONE, V3, pe2593
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seelen MA, 2005, J IMMUNOL METHODS, V296, P187, DOI 10.1016/j.jim.2004.11.016
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Siezenga MA, 2009, CLIN EXP IMMUNOL, V157, P98, DOI 10.1111/j.1365-2249.2009.03959.x
   Tong Y, 2010, MOL VIS, V16, P1958
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 55
TC 111
Z9 115
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2012
VL 119
IS 2
BP 339
EP 346
DI 10.1016/j.ophtha.2011.07.056
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 887SO
UT WOS:000299950300023
PM 22133792
DA 2022-11-30
ER

PT J
AU Goldman, DR
   Freund, KB
   McCannel, CA
   Sarraf, D
AF Goldman, Darin R.
   Freund, K. Bailey
   McCannel, Colin A.
   Sarraf, David
TI PERIPHERAL POLYPOIDAL CHOROIDAL VASCULOPATHY AS A CAUSE OF PERIPHERAL
   EXUDATIVE HEMORRHAGIC CHORIORETINOPATHY A Report of 10 Eyes
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-vascular endothelial growth
   factor; choroidal neovascular membrane; fluorescein angiography;
   indocyanine green angiography; optical coherence tomography; peripheral
   exudative hemorrhagic chorioretinopathy; peripheral retina; polypoidal
   choroidal vasculopathy; type 1 neovascularization
AB Purpose: Polypoidal choroidal vasculopathy (PCV) is characterized by polyp-like subretinal pigment epithelium vascular abnormalities predominantly found in the macula and peripapillary region. Less commonly, PCV can be found peripherally and be a cause of peripheral exudative hemorrhagic chorioretinopathy (PEHCR). We sought to further describe the clinical spectrum of this ill-defined subgroup of PEHCR.
   Methods: A retrospective observational case series, of 10 eyes of 8 patients diagnosed with PEHCR caused by peripheral PCV, was conducted. In all cases, the presence of PCV was confirmed with indocyanine green angiography and/or fluorescein angiography and optical coherence tomography. The clinical presentation, natural history, and clinical outcomes with or without intervention were studied.
   Results: Patients with PEHCR caused by peripheral PCV were most commonly men, white, asymptomatic, and had a concomitant diagnosis of age-related macular degeneration. The mean age was 70 years (range, 59-82 years) with a mean follow-up of 32.5 months (range, 4-91 months). Four patients had unilateral involvement with minimal subretinal hemorrhage that resolved spontaneously, one patient had unilateral involvement outside the macula that responded to anti-vascular endothelial growth factor therapy, one patient had unilateral involvement with subretinal hemorrhage threatening the macula that responded to anti-vascular endothelial growth factor therapy, and two patients had extensive bilateral subretinal hemorrhage requiring surgical intervention. Both patients with multiple lesions in one eye had bilateral lesions (two of eight patients). Lesions were most commonly located in the temporal periphery (8 of 10 eyes).
   Conclusion: A new subclassification is proposed that includes both eyes with polyps and those without polyps within the spectrum of disease described previously as PEHCR. Within the spectrum of disease described previously as PEHCR exists a subgroup of lesions caused by peripheral PCV, which has not been well defined before this report. The largest case series to date of eyes with PEHCR due to peripheral PCV, a unique form of type 1 neovascularization, is further classified and described. These eyes have a spectrum of disease, including small, medium-sized, and large lesions. Although most eyes with PEHCR from peripheral PCV experience a benign course with spontaneous resolution, a subset of eyes may experience macula-threatening hemorrhage, requiring treatment with laser-based therapies, anti-vascular endothelial growth factor injections, or surgical intervention. RETINA 33:48-55, 2013
C1 [Sarraf, David] Univ Calif Los Angeles, Geffen Sch Med, Retinal Disorders & Ophthalm Genet Div, Dept Ophthalmol,Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
   [Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, New York, NY 10016 USA.
   [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Dept Ophthalmol, Los Angeles, CA USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; New York University; Vitreous Retina Macula
   Consultants of New York; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); VA Greater Los Angeles Healthcare System
RP Sarraf, D (通讯作者)，Univ Calif Los Angeles, Geffen Sch Med, Retinal Disorders & Ophthalm Genet Div, Dept Ophthalmol,Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
EM dsarraf@ucla.edu
RI ; Freund, K. Bailey/V-7488-2018
OI McCannel, Colin Archibald/0000-0003-0774-6414; Freund, K.
   Bailey/0000-0002-7888-9773
FU Macula Foundation, Inc., New York, New York; Karl Kirchgessner
   Foundation
FX This study was partly funded by a grant from the Macula Foundation,
   Inc., New York, New York, and partly funded by a grant from the Karl
   Kirchgessner Foundation.
CR Annesley W H Jr, 1980, Trans Am Ophthalmol Soc, V78, P321
   Bruee Claudia, 2009, Retin Cases Brief Rep, V3, P364, DOI 10.1097/01.ICB.0000361956.91203.e4
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Karagiannis DA, 2009, CLIN INTERV AGING, V4, P315
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Mantel I, 2009, AM J OPHTHALMOL, V148, P932, DOI 10.1016/j.ajo.2009.06.032
   Shields CL, 2009, OPHTHALMOLOGY, V116, P529, DOI 10.1016/j.ophtha.2008.10.015
   Yannuzzi LA, 1998, ARCH OPHTHALMOL-CHIC, V116, P382
NR 11
TC 33
Z9 33
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2013
VL 33
IS 1
BP 48
EP 55
DI 10.1097/IAE.0b013e31825df12a
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 069GE
UT WOS:000313422500006
PM 22836900
DA 2022-11-30
ER

PT J
AU Pameijer, EM
   Heus, P
   Damen, JAA
   Spijker, R
   Hooft, L
   Ringens, PJ
   Imhof, SM
   van Leeuwen, R
AF Pameijer, Els M.
   Heus, Pauline
   Damen, Johanna A. A.
   Spijker, Rene
   Hooft, Lotty
   Ringens, Peter J.
   Imhof, Saskia M.
   van Leeuwen, Redmer
TI What did we learn in 35 years of research on nutrition and supplements
   for age-related macular degeneration: a systematic review
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE age-related macular degeneration; AMD; Cochrane; nutrition; supplements;
   systematic review
ID ATHEROSCLEROSIS RISK; OXIDATIVE STRESS; EYE DISEASE; PROGRESSION;
   ZEAXANTHIN; ALCOHOL; BURDEN; LUTEIN
AB The aim of this paper is to summarize all available evidence from systematic reviews, randomized controlled trials (RCTs) and comparative nonrandomized studies (NRS) on the association between nutrition and antioxidant, vitamin, and mineral supplements and the development or progression of age-related macular degeneration (AMD). The Cochrane Database of Systematic Reviews, Cochrane register CENTRAL, MEDLINE and Embase were searched and studies published between January 2015 and May 2021 were included. The certainty of evidence was assessed according to the GRADE methodology. The main outcome measures were development of AMD, progression of AMD, and side effects. We included 7 systematic reviews, 7 RCTs, and 13 NRS. A high consumption of specific nutrients, i.e. beta-carotene, lutein and zeaxanthin, copper, folate, magnesium, vitamin A, niacin, vitamin B6, vitamin C, docosahexaenoic acid, and eicosapentaenoic acid, was associated with a lower risk of progression of early to late AMD (high certainty of evidence). Use of antioxidant supplements and adherence to a Mediterranean diet, characterized by a high consumption of vegetables, whole grains, and nuts and a low consumption of red meat, were associated with a decreased risk of progression of early to late AMD (moderate certainty of evidence). A high consumption of alcohol was associated with a higher risk of developing AMD (moderate certainty of evidence). Supplementary vitamin C, vitamin E, or beta-carotene were not associated with the development of AMD, and supplementary omega-3 fatty acids were not associated with progression to late AMD (high certainty of evidence). Research in the last 35 years included in our overview supports that a high intake of specific nutrients, the use of antioxidant supplements and adherence to a Mediterranean diet decrease the risk of progression of early to late AMD.
C1 [Pameijer, Els M.; Imhof, Saskia M.; van Leeuwen, Redmer] UMC Utrecht, Dept Ophthalmol, NL-3508 GA Utrecht, Netherlands.
   [Heus, Pauline; Damen, Johanna A. A.; Spijker, Rene; Hooft, Lotty] Univ Utrecht, Cochrane Netherlands, UMC Utrecht, Utrecht, Netherlands.
   [Heus, Pauline; Damen, Johanna A. A.; Spijker, Rene; Hooft, Lotty] Univ Utrecht, Julius Ctr Hlth Sci & Primary Care, UMC Utrecht, Utrecht, Netherlands.
   [Ringens, Peter J.] Maastricht Univ, Med Ctr, Dept Ophthalmol, Maastricht, Netherlands.
C3 Utrecht University; Utrecht University Medical Center; Utrecht
   University; Utrecht University; Maastricht University
RP van Leeuwen, R (通讯作者)，UMC Utrecht, Dept Ophthalmol, NL-3508 GA Utrecht, Netherlands.
EM r.vanleeuwen@umcutrecht.nl
OI Spijker, Rene/0000-0003-4445-1201; van Leeuwen,
   Redmer/0000-0002-9007-7276
FU ProjektDEAL
FX Open access funding enabled and organized by ProjektDEAL.
CR Agron E, 2021, OPHTHALMOLOGY, V128, P425, DOI 10.1016/j.ophtha.2020.08.018
   Akuffo KO, 2017, INVEST OPHTH VIS SCI, V58, P5347, DOI 10.1167/iovs.16-21192
   Broadhead GK, 2019, GRAEF ARCH CLIN EXP, V257, P31, DOI 10.1007/s00417-018-4163-x
   Chapman NA, 2019, CLIN EXP OPHTHALMOL, V47, P106, DOI 10.1111/ceo.13343
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Christen WG, 2020, JAMA OPHTHALMOL, V138, P1280, DOI 10.1001/jamaophthalmol.2020.4409
   Christen WG, 2021, ACTA OPHTHALMOL, V99, pE285, DOI 10.1111/aos.14538
   De Koning-Backus APM, 2019, AM J OPHTHALMOL, V198, P70, DOI 10.1016/j.ajo.2018.09.036
   Dighe S, 2020, BRIT J OPHTHALMOL, V104, P1070, DOI 10.1136/bjophthalmol-2019-314813
   Dinu M, 2019, EUR J NUTR, V58, P2123, DOI 10.1007/s00394-018-1771-5
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub4
   Garcia-Layana A, 2021, NUTRIENTS, V13, DOI 10.3390/nu13041253
   Gopinath B, 2020, CLIN NUTR, V39, P580, DOI 10.1016/j.clnu.2019.03.009
   Gopinath B, 2018, J ACAD NUTR DIET, V118, P2311, DOI 10.1016/j.jand.2018.07.012
   Gopinath B, 2018, AM J CLIN NUTR, V108, P381, DOI 10.1093/ajcn/nqy114
   Grant A, 2021, OPHTHAL EPIDEMIOL, V28, P86, DOI 10.1080/09286586.2020.1853179
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Joachim N, 2018, OPHTHALMOL RETINA, V2, P684, DOI 10.1016/j.oret.2017.10.019
   Jones M, 2020, OPHTHAL EPIDEMIOL, V27, P399, DOI 10.1080/09286586.2020.1762229
   Keenan TD, 2020, OPHTHALMOLOGY, V127, P1515, DOI 10.1016/j.ophtha.2020.04.030
   Lawrenson JG, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010015.pub3
   Lin H, 2017, OPHTHAL EPIDEMIOL, V24, P311, DOI 10.1080/09286586.2017.1290259
   Machida N., 2020, NUTRIENTS, V12, P1
   Maki KC, 2014, ADV NUTR, V5, P7, DOI 10.3945/an.113.004929
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Piatti A, 2020, EUR J OPHTHALMOL, V30, P376, DOI 10.1177/1120672119836007
   Rehm J, 2009, LANCET, V373, P2223, DOI 10.1016/S0140-6736(09)60746-7
   Shea BJ, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j4008
   Silver RE., 2017, INVEST OPHTH VIS SCI, V58, P4579
   Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919
   Tarsilla M., 2010, COCHRANE HDB SYSTEMA, V6, P142, DOI [DOI 10.1002/9781119536604, 10.1002/9781119536604.ch23]
   Tisdale AK, 2019, JAMA OPHTHALMOL, V137, P543, DOI 10.1001/jamaophthalmol.2019.0292
   Vittorio AF, 2020, RETINA-J RET VIT DIS, V40, P1696, DOI 10.1097/IAE.0000000000002679
   Waugh N, 2018, HEALTH TECHNOL ASSES, V22, P1, DOI 10.3310/hta22270
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu DF, 2003, ALCOHOL RES HEALTH, V27, P277
   Zhong YY, 2021, EUR J NUTR, V60, P3013, DOI 10.1007/s00394-020-02445-4
NR 40
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2022
VL 100
IS 8
BP E1541
EP E1552
DI 10.1111/aos.15191
EA JUN 2022
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 6D4SX
UT WOS:000809884400001
PM 35695158
DA 2022-11-30
ER

PT J
AU Toto, L
   Borrelli, E
   Mastropasqua, R
   Di Antonio, L
   Doronzo, E
   Carpineto, P
   Mastropasqua, L
AF Toto, Lisa
   Borrelli, Enrico
   Mastropasqua, Rodolfo
   Di Antonio, Luca
   Doronzo, Emanuele
   Carpineto, Paolo
   Mastropasqua, Leonardo
TI Association between outer retinal alterations and microvascular changes
   in intermediate stage age-related macular degeneration: an optical
   coherence tomography angiography study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SOURCE OCT ANGIOGRAPHY; CHOROIDAL BLOOD-FLOW; GEOGRAPHIC ATROPHY;
   MACULOPATHY; LAYER; DRUSEN; EYES; AMD
AB Aims To investigate associations between changes in retinal vessels and alterations detected by spectral domain optical coherence tomography (SD-OCT) scans in intermediate stage age-related macular degeneration (AMD).
   Methods Thirty eyes of 30 patients with intermediate dry AMD were enrolled in the study. Of the cohort study, 15 eyes (changes-AMD group) showed OCT changes preceding the development of drusen-associated atrophy. A control group of healthy subjects was selected for statistical comparisons. All patients underwent an ophthalmologic evaluation, including OCT angiography (OCTA) and SD-OCT scans. Main outcome measures were superficial vessel density, deep vessel density, macular thickness.
   Results Foveal macular thickness was 215.2 +/- 32.9 mu m in changes-AMD patients and was significantly thinner than no changes-AMD patients (248.3 +/- 23.3 mu m, p=0.002) and healthy subjects (268.1 +/- 19.2 mu m, p<0.0001). Furthermore, in the parafoveal area, the thicknesses of both the inner retina and the outer retina were reduced in the changes-AMD group, after comparison with the two other groups. Parafoveal superficial vascular plexus flow density was 43.3 +/- 2.7% in changes-AMD patients and was decreased compared with the no changes-AMD group (48.7 +/- 3.3%, p=0.003) and healthy controls (50.4 +/- 6.1%, p=0.001). A direct correlation of the superficial plexus flow density with the inner retina parafoveal macular thickness (R-2=0.761, p=0.028) was found.
   Conclusions We demonstrated an association between SD-OCT signs and retinal blood supply in patients with intermediate AMD and we showed that patients with signs predicting development of geographic atrophy have a reduced flow in superficial vascular plexus and damage of the inner and the outer retina.
C1 [Toto, Lisa; Borrelli, Enrico; Di Antonio, Luca; Doronzo, Emanuele; Carpineto, Paolo; Mastropasqua, Leonardo] Univ G dAnnunzio, Ophthalmol Clin, Dept Med & Sci Ageing, I-66100D Chieti, Italy.
   [Mastropasqua, Rodolfo] Univ Verona, Ophthalmol Unit, Dept Neurol Neuropsychol Morphol & Movement Sci, Verona, Italy.
C3 G d'Annunzio University of Chieti-Pescara; University of Verona
RP Borrelli, E (通讯作者)，Univ G DAnnunzio, Dept Ophthalmol, Via Vestini, I-66100 Chieti, Italy.
EM borrelli.enrico@yahoo.com
RI Borrelli, Enrico/AAR-3693-2020; Toto, Lisa/K-3473-2018; Carpineto,
   Paolo/AAN-9688-2020; Mastropasqua, Rodolfo/AAC-6453-2022
OI Borrelli, Enrico/0000-0003-2815-5031; Toto, Lisa/0000-0001-5311-5184; 
CR Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Feigl B, 2007, EYE, V21, P689, DOI 10.1038/sj.eye.6702389
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Huang YP, 2014, OSLI RETINA, V45, P382, DOI 10.3928/23258160-20140909-08
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jia YL, 2012, BIOMED OPT EXPRESS, V3, DOI 10.1364/BOE.3.003127
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Leveziel N, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000328981
   Lumbroso B, 2015, CLIN GUIDE ANGIO OCT
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Mones J, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.026
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Remsch H, 2000, GRAEF ARCH CLIN EXP, V238, P960, DOI 10.1007/s004170000202
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   Savastano MC, 2015, RETINA-J RET VIT DIS, V35, P2196, DOI 10.1097/IAE.0000000000000635
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wang JJ, 2004, BRIT J OPHTHALMOL, V88, P104, DOI 10.1136/bjo.88.1.104
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zerbib J, 2014, GRAEF ARCH CLIN EXP, V252, P899, DOI 10.1007/s00417-013-2537-7
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 34
TC 39
Z9 39
U1 0
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2017
VL 101
IS 6
BP 774
EP 779
DI 10.1136/bjophthalmol-2016-309160
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EW2ZG
UT WOS:000402363900017
PM 27625163
DA 2022-11-30
ER

PT J
AU Landa, G
   Rosen, RB
   Pilavas, J
   Garcia, PMT
AF Landa, Gennady
   Rosen, Richard B.
   Pilavas, John
   Garcia, Patricia M. T.
TI Drusen Characteristics Revealed by Spectral-Domain Optical Coherence
   Tomography and Their Corresponding Fundus Autofluorescence Appearance in
   Dry Age-Related Macular Degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Spectral-domain optical coherence tomography; Drusen; Autofluorescence
ID RETINAL-PIGMENT EPITHELIUM; GEOGRAPHIC ATROPHY; HIGH-RISK; LIPOFUSCIN;
   EYES; CLASSIFICATION; MACULOPATHY; MICROGLIA; PATTERNS; LESIONS
AB Purpose: To analyze the relationship between drusen morphology revealed by spectral-domain optical coherence tomography (SD-OCT) and corresponding fundus autofluorescence (FAF) features of the same drusen using the Heidelberg Retina Angiograph 2 (HRA2), in patients with dry age-related macular degeneration (AMD). Methods: Dry AMD patients were imaged with SD-OCT and HRA2 on the same day. SD-OCT B scans were then precisely overlaid onto the HRA2 images, and the SD-OCT morphological characteristics of the drusen were correlated with the corresponding FAF appearance. The analyzed morphological features of the drusen included: size, status of the inner segment/outer segment (IS-OS) junctional layer above the drusen, shape of the drusen, internal reflectivity, homogeneity and presence of overlaying hyperreflective foci. The FAF characteristics of each druse were rated as hyperautofluorescent, hypoautofluorescent or normally autofluorescent. Spearman's correlation coefficient was used to analyze the correlation between the 2 primary outcomes: SD-OCT morphology of the drusen and their autofluorescent appearance. Results: 431 drusen in 32 eyes of 16 dry AMD patients were evaluated. Of the 7 morphological characteristics assessed by SD-OCT, only drusen size and the status of the IS-OS layer above the drusen were strongly correlated with the autofluorescent appearance (r = 0.78, p < 0.001, and r = 0.58, p < 0.001, respectively). The strength of correlation with other features appeared less robust: homogeneity (r = 0.38; p = 0.001), shape (r = 0.29; p = 0.004), reflectivity (r = 0.28; p = 0.004) and presence of overlaying foci (r = 0.25; p = 0.12). Conclusions: Autofluorescent changes most strongly correlate with drusen size and disruption of the IS-OS layer and may be useful as an additional functional-morphological feature by which drusen and their impact upon overlying photoreceptors may be judged. Copyright (C) 2011 S. Karger AG, Basel
C1 [Landa, Gennady; Rosen, Richard B.; Garcia, Patricia M. T.] New York Eye & Ear Infirm, Dept Ophthalmol, Retina Ctr, New York, NY 10003 USA.
   [Landa, Gennady; Rosen, Richard B.; Garcia, Patricia M. T.] New York Med Coll, Dept Ophthalmol, Valhalla, NY 10595 USA.
   [Pilavas, John] Univ Louisville, Louisville, KY 40292 USA.
C3 New York Eye & Ear Infirmary of Mount Sinai; New York Medical College;
   University of Louisville
RP Rosen, RB (通讯作者)，New York Eye & Ear Infirm, Dept Ophthalmol, Retina Ctr, 310 E 14th St, New York, NY 10003 USA.
EM rrosen@nyee.edu
FU Bendheim-Lowenstein Retinal Fund; Gladys Brookes Foundation
FX Gennady Landa, none. Richard B. Rosen received support from the
   Bendheim-Lowenstein Retinal Fund and the Gladys Brookes Foundation, and
   is a member of the Scientific Advisory Board of OPKO/OTI (Miami, Fla.,
   USA). John Pilavas, none. Patricia M.T. Garcia is a consultant of
   OPKO/OTI (Miami, Fla., USA).
CR Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Einbock W, 2005, GRAEF ARCH CLIN EXP, V243, P300, DOI 10.1007/s00417-004-1027-3
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Hamada S, 2006, EYE, V20, P199, DOI 10.1038/sj.eye.6701852
   Hassenstein A, 2009, CLIN EXP OPHTHALMOL, V37, P130, DOI 10.1111/j.1442-9071.2009.02017.x
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Knudtson MD, 2004, INVEST OPHTH VIS SCI, V45, P2135, DOI 10.1167/iovs.03-1085
   KOHNO T, 1982, JPN J OPHTHALMOL, V26, P53
   Landa G, 2011, J OCUL PHARMACOL TH, V27, P77, DOI 10.1089/jop.2010.0109
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Marmorstein AD, 2002, INVEST OPHTH VIS SCI, V43, P2435
   Mennel S, 2005, OPHTHALMOLOGICA, V219, P350, DOI 10.1159/000088377
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P1101, DOI 10.1097/IAE.0b013e3181451617
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Schmitz-Valckenberg S, 2002, GRAEF ARCH CLIN EXP, V240, P73, DOI 10.1007/s00417-001-0413-3
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Spital G, 1998, KLIN MONATSBL AUGENH, V213, P23, DOI 10.1055/s-2008-1034939
   Stopa M, 2008, RETINA-J RET VIT DIS, V28, P298, DOI 10.1097/IAE.0b013e3181567798
   von Ruckmann A, 1998, KLIN MONATSBL AUGENH, V213, P32, DOI 10.1055/s-2008-1034940
   von Ruckmann A, 1998, KLIN MONATSBL AUGENH, V213, P81, DOI 10.1055/s-2008-1034951
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   Wolf-Schnurrbusch UEK, 2008, INVEST OPHTH VIS SCI, V49, P3095, DOI 10.1167/iovs.07-1460
   Wolf-Schnurrbusch UEK, 2009, INVEST OPHTH VIS SCI, V50, P3432, DOI 10.1167/iovs.08-2970
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
NR 35
TC 21
Z9 21
U1 0
U2 7
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2012
VL 47
IS 2
BP 81
EP 86
DI 10.1159/000324988
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 883WF
UT WOS:000299664900004
PM 21757965
DA 2022-11-30
ER

PT J
AU Ho, L
   van Leeuwen, R
   Witteman, JCM
   van Duijn, CM
   Uitterlinden, AG
   Hofman, A
   de Jong, PTVM
   Vingerling, JR
   Klaver, CCW
AF Ho, Lintje
   van Leeuwen, Redmer
   Witteman, Jacqueline C. M.
   van Duijn, Cornelia M.
   Uitterlinden, Andre G.
   Hofman, Albert
   de Jong, Paulus T. V. M.
   Vingerling, Johannes R.
   Klaver, Caroline C. W.
TI Reducing the Genetic Risk of Age-Related Macular Degeneration With
   Dietary Antioxidants, Zinc, and omega-3 Fatty Acids The Rotterdam Study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; MITOCHONDRIAL-DNA DAMAGE;
   RETINAL-PIGMENT EPITHELIUM; N-3 FATTY-ACIDS; OXIDATIVE STRESS; KAPPA-B;
   POLYMORPHISM; HTRA1; MACULOPATHY
AB Objective: To investigate whether dietary nutrients can reduce the genetic risk of early age-related macular degeneration (AMD) conferred by the genetic variants CFH Y402H and LOC387715 A69S in a nested case-control study.
   Methods: For 2167 individuals (>= 55 years) from the population-based Rotterdam Study at risk of AMD, dietary intake was assessed at baseline using a semiquantitative food frequency questionnaire and genetic variants were determined using TaqMan assay. Incident early AMD was determined on fundus photographs at 3 follow-up visits (median follow-up, 8.6 years). The synergy index was used to evaluate biological interaction between risk factors; hazard ratios were calculated to estimate risk of early AMD in strata of nutrient intake and genotypes.
   Results: Five hundred seventeen participants developed early AMD. Significant synergy indices supported the possibility of biological interaction between CFH Y402H and zinc, beta-carotene, lutein/zeaxanthin, and eicosapentaenoic/docosahexaenoic acid (EPA/DHA) and between LOC387715 A69S and zinc and EPA/DHA (all P < .05). Homozygotes of CFH Y402H with dietary intake of zinc in the highest tertile reduced their hazard ratio of early AMD from 2.25 to 1.27. For intakes of beta-carotene, lutein/zeaxanthin, and EPA/DHA, these risk reductions were from 2.54 to 1.47, 2.63 to 1.72, and 1.97 to 1.30, respectively. Carriers of LOC387715 A69S with the highest intake of zinc and EPA/DHA reduced their risk from 1.70 to 1.17 and 1.59 to 0.95, respectively (all P trends <.05).
   Conclusions: High dietary intake of nutrients with antioxidant properties reduces the risk of early AMD in those at high genetic risk. Therefore, clinicians should provide dietary advice to young susceptible individuals to postpone or prevent the vision-disabling consequences of AMD.
C1 [Ho, Lintje; van Leeuwen, Redmer; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, NL-3000 CA Rotterdam, Netherlands.
   [Ho, Lintje; Witteman, Jacqueline C. M.; van Duijn, Cornelia M.; Uitterlinden, Andre G.; Hofman, Albert; de Jong, Paulus T. V. M.; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, NL-3000 CA Rotterdam, Netherlands.
   [Uitterlinden, Andre G.] Erasmus MC, Genet Lab, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands.
   [de Jong, Paulus T. V. M.] Royal Netherlands Acad Arts & Sci, Netherlands Inst Neurosci, Amsterdam, Netherlands.
   [de Jong, Paulus T. V. M.] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Royal Netherlands
   Academy of Arts & Sciences; Netherlands Institute for Neuroscience
   (NIN-KNAW); University of Amsterdam; Academic Medical Center Amsterdam
RP Klaver, CCW (通讯作者)，Erasmus MC, Dept Ophthalmol, POB 2040, NL-3000 CA Rotterdam, Netherlands.
EM c.c.w.klaver@erasmusmc.nl
RI Klaver, Caroline C.W./A-2013-2016
OI Van Duijn, Cornelia/0000-0002-2374-9204; Klaver,
   Caroline/0000-0002-2355-5258
FU Netherlands Organization for Scientific Research, the Hague; Optimix,
   Amsterdam, the Netherlands; Neyenburgh, Bunnik, the Netherlands; Physico
   Therapeutic Institute, Rotterdam, the Netherlands; Swart van Essen,
   Rotterdam; Blindenpenning, Amsterdam; Sint Laurens Institute, Rotterdam;
   Bevordering van Volkskracht, Rotterdam; Blindenhulp, the Hague;
   Rotterdamse Blindenbelangen Association, Rotterdam; OOG, the Hague;
   kfHein, Utrecht, the Netherlands; Prins Bernhard Cultuurfonds,
   Amsterdam; Van Leeuwen Van Lignac, Rotterdam; Algemene Nederlandse
   Vereniging ter Voorkoming van Blind-heid, Doorn, the Netherlands;
   Oogfonds Nederland, Utrecht; MD Fonds, Utrecht; Lijf en Leven, Krimpen
   aan de Ijssel, the Netherlands; Topcon Europe BV, Capelle aan de Ijsse,
   the Netherlands
FX This study was supported by the Netherlands Organization for Scientific
   Research, the Hague; Optimix, Amsterdam, the Netherlands; Neyenburgh,
   Bunnik, the Netherlands; Physico Therapeutic Institute, Rotterdam, the
   Netherlands; Swart van Essen, Rotterdam; Blindenpenning, Amsterdam; Sint
   Laurens Institute, Rotterdam; Bevordering van Volkskracht, Rotterdam;
   Blindenhulp, the Hague; Rotterdamse Blindenbelangen Association,
   Rotterdam; OOG, the Hague; kfHein, Utrecht, the Netherlands; Prins
   Bernhard Cultuurfonds, Amsterdam; Van Leeuwen Van Lignac, Rotterdam;
   Algemene Nederlandse Vereniging ter Voorkoming van Blind-heid, Doorn,
   the Netherlands; Oogfonds Nederland, Utrecht; MD Fonds, Utrecht; and
   Lijf en Leven, Krimpen aan de Ijssel, the Netherlands. An unrestricted
   grant was obtained from Topcon Europe BV, Capelle aan de Ijsse, the
   Netherlands.
CR Agrawal A, 2003, IMMUNOLOGY, V108, P539, DOI 10.1046/j.1365-2567.2003.01608.x
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blom AM, 2003, ARCH BIOCHEM BIOPHYS, V418, P108, DOI 10.1016/j.abb.2003.08.018
   Botto LD, 2001, AM J EPIDEMIOL, V153, P1016, DOI 10.1093/aje/153.10.1016
   Brighenti F, 2005, BRIT J NUTR, V93, P619, DOI 10.1079/BJN20051400
   Chakraborti T, 2000, CELL SIGNAL, V12, P607, DOI 10.1016/S0898-6568(00)00111-X
   Chen WQ, 2005, INVEST OPHTH VIS SCI, V46, P4342, DOI 10.1167/iovs.05-0601
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Erlinger TP, 2001, ARCH INTERN MED, V161, P1903, DOI 10.1001/archinte.161.15.1903
   ERNST E, 1991, EUR J CLIN INVEST, V21, P77, DOI 10.1111/j.1365-2362.1991.tb01362.x
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Francis PJ, 2008, MOL VIS, V14, P1395
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   GOLDBOHM RA, 1994, EUR J CLIN NUTR, V48, P253
   Guan ZX, 2003, J INORG BIOCHEM, V97, P199, DOI 10.1016/S0162-0134(03)00291-5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hennig B, 1999, J AM COLL NUTR, V18, P152, DOI 10.1080/07315724.1999.10718843
   Hofman A, 2009, EUR J EPIDEMIOL, V24, P553, DOI 10.1007/s10654-009-9386-z
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klipstein-Grobusch K, 1998, EUR J CLIN NUTR, V52, P588, DOI 10.1038/sj.ejcn.1600611
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Malaiyandi LM, 2005, J NEUROCHEM, V93, P1242, DOI 10.1111/j.1471-4159.2005.03116.x
   Micallef MA, 2009, EUR J CLIN NUTR, V63, P1154, DOI 10.1038/ejcn.2009.20
   Powell SR, 2000, J NUTR, V130, p1447S, DOI 10.1093/jn/130.5.1447S
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rothman KJ., 2008, MODERN EPIDEMIOLOGY, V3
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Sheu SS, 2006, BBA-MOL BASIS DIS, V1762, P256, DOI 10.1016/j.bbadis.2005.10.007
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   van Poppel G., 1998, Journal of Food Composition and Analysis, V11, P112, DOI 10.1006/jfca.1998.0568
   van Poppel G, 1998, LANCET, V351, P1099, DOI 10.1016/S0140-6736(98)24015-3
   Voleti B, 2005, J IMMUNOL, V175, P3386, DOI 10.4049/jimmunol.175.5.3386
   Wang AL, 2008, MOL VIS, V14, P644
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Willett W., 2013, NUTR EPIDEMIOLOGY, V3rd
   Winkler BS, 1999, MOL VIS, V5
   World Health Organization, 2008, GLOB BURD DIS 2004 U, P28
   YAMAMOTO K, 1975, INT ARCH ALLER A IMM, V48, P653, DOI 10.1159/000231353
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zago MP, 2001, FREE RADICAL BIO MED, V31, P266, DOI 10.1016/S0891-5849(01)00583-4
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 70
TC 137
Z9 140
U1 2
U2 23
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUN
PY 2011
VL 129
IS 6
BP 758
EP 766
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 776UJ
UT WOS:000291563500011
PM 21670343
OA Bronze
DA 2022-11-30
ER

PT J
AU Roh, M
   Selivanova, A
   Shin, HJ
   Miller, JW
   Jackson, ML
AF Roh, Miin
   Selivanova, Alexandra
   Shin, Hyun Joon
   Miller, Joan W.
   Jackson, Mary Lou
TI Visual acuity and contrast sensitivity are two important factors
   affecting vision-related quality of life in advanced age-related macular
   degeneration
SO PLOS ONE
LA English
DT Article
ID FUNCTION QUESTIONNAIRE; ASSOCIATION; DISABILITY; VALIDITY; THERAPY
AB Purpose
   Vision loss from age-related macular degeneration (AMD) has a profound effect on vision-related quality of life (VRQoL). The pupose of this study is to identify clinical factors associated with VRQoL using the Rasch- calibrated NEI VFQ-25 scales in bilateral advanced AMD patients.
   Methods
   We retrospectively reviewed 47 patients (mean age 83.2 years) with bilateral advanced AMD. Clinical assessment included age, gender, type of AMD, high contrast visual acuity (VA), history of medical conditions, contrast sensitivity (CS), central visual field loss, report of Charles Bonnet Syndrome, current treatment for AMD and Rasch-calibrated NEI VFQ-25 visual function and socioemotional function scales. The NEI VFQ visual function scale includes items of general vision, peripheral vision, distance vision and near vision-related activity while the socioemotional function scale includes items of vision related-social functioning, role difficulties, dependency, and mental health. Multiple regression analysis (structural regression model) was performed using fixed item parameters obtained from the one-parameter item response theory model.
   Results
   Multivariate analysis showed that high contrast VA and CS were two factors influencing VRQoL visual function scale (beta = -0.25, 95% CI-0.37 to -0.12, p<0.001 and beta = 0.35, 95% CI 0.25 to 0.46, p<0.001) and socioemontional functioning scale (beta = -0.2, 95% CI -0.37 to -0.03, p = 0.023, and beta = 0.3, 95% CI 0.18 to 0.43, p = 0.001). Central visual field loss was not assoicated with either VRQoL visual or socioemontional functioning scale (beta = -0.08, 95% CI-0.28 to 0.12,p = 0.44 and beta = -0.09, 95% CI -0.03 to 0.16, p = 0.50, respectively).
   Conclusion
   In patients with vision impairment secondary to bilateral advanced AMD, high contrast VA and CS are two important factors affecting VRQoL.
C1 [Roh, Miin; Selivanova, Alexandra; Miller, Joan W.] Harvard Med Sch, Dept Ophthalmol, Massachusetts Eye & Ear, Boston, MA USA.
   [Shin, Hyun Joon] Harvard Med Sch, Dept Med, VA Boston Hlth Care syst, Div Aging,Brigham & Womens Hosp, Boston, MA USA.
   [Jackson, Mary Lou] VGH Univ British Coumbia, Eye Care Ctr, Vancouver, BC, Canada.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Harvard University; Brigham & Women's Hospital; Harvard
   Medical School; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); VA Boston Healthcare System; University of British
   Columbia
RP Jackson, ML (通讯作者)，VGH Univ British Coumbia, Eye Care Ctr, Vancouver, BC, Canada.
EM marylou.jackson@vch.ca
OI Shin, Hyun Joon/0000-0001-5781-0643; Roh, Miin/0000-0003-3346-754X
FU Eye Pharmaceutical; Ear/Valeant Pharmaceutical; ONL Therapeutics, LLC
FX MR, SA, HS and MJ have nothing to disclose. JWM reports personal fees
   from Amgen, Inc., personal fees from KalVista Pharmaceuticals, Ltd.,
   non-financial support from Maculogix, Inc., personal fees from Biogen
   Idec, Inc., personal fees from Alcon Research Council, grants from Lowy
   Medical Research Institute, Ltd., outside the submitted work; In
   addition, Dr. Miller has a patent Mass. Eye and Ear/Valeant
   Pharmaceuticals with royalties paid to Mass. Eye and Ear, and a patent
   ONL Therapeutics, LLC with royalties paid to ONL Therapeutics, LLC. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   Bellmann C, 2003, GRAEF ARCH CLIN EXP, V241, P968, DOI 10.1007/s00417-003-0689-6
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Bond T.G., 2015, APPLYING RASCH MODEL, V3rd ed., DOI DOI 10.4324/9781315814698
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1901
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   DeMars C., 2010, ITEM RESPONSE THEORY
   Fleckenstein M, 2017, OPHTHALMOLOGY
   Fletcher DC, 2006, OPTOMETRY VISION SCI, V83, P178, DOI 10.1097/01.opx.0000204510.08026.7f
   Fujii GY, 2003, AM J OPHTHALMOL, V136, P1067, DOI 10.1016/S0002-9394(03)00663-9
   Hochberg C, 2012, INVEST OPHTH VIS SCI, V53, P3201, DOI 10.1167/iovs.12-9469
   Linacre J.M, 2016, RASCH MODEL COMPUTER
   Lu IRR, 2005, STRUCT EQU MODELING, V12, P263, DOI 10.1207/s15328007sem1202_5
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mantyjarvi M, 2001, J CATARACT REFR SURG, V27, P261, DOI 10.1016/S0886-3350(00)00562-9
   Marella M, 2010, INVEST OPHTH VIS SCI, V51, P2878, DOI 10.1167/iovs.09-4494
   Maynard ML, 2016, ACTA OPHTHALMOL, DOI DOI 10.1111/AOS.12758
   Midena E, 2007, EUR J OPHTHALMOL, V17, P63, DOI 10.1177/112067210701700109
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Pelli DG, 2013, VISION RES, V90, P10, DOI 10.1016/j.visres.2013.04.015
   Pesudovs K, 2010, J CATARACT REFR SURG, V36, P718, DOI 10.1016/j.jcrs.2009.11.019
   Revicki DA, 2010, INVEST OPHTH VIS SCI, V51, P712, DOI 10.1167/iovs.09-3766
   Schmidt-Erfurth UM, 2004, OPHTHALMOLOGY, V111, P931, DOI 10.1016/j.ophtha.2003.12.025
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   World Health Organization, 2012, GLOB DAT VIS IMP 201
   World Health Organization, PREV BLINDN VIS IMP
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
NR 32
TC 32
Z9 33
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 10
PY 2018
VL 13
IS 5
AR e0196481
DI 10.1371/journal.pone.0196481
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GF3JM
UT WOS:000431851700020
PM 29746512
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Cantsilieris, S
   White, SJ
   Richardson, AJ
   Guymer, RH
   Baird, PN
AF Cantsilieris, Stuart
   White, Stefan J.
   Richardson, Andrea J.
   Guymer, Robyn H.
   Baird, Paul N.
TI Comprehensive Analysis of Copy Number Variation of Genes at Chromosome 1
   and 10 Loci Associated with Late Age Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID C-REACTIVE PROTEIN; FACTOR-H CFH; SEGMENTAL DUPLICATIONS; CFHR1-CFHR3
   DELETION; POLYMORPHISM; RISK; REARRANGEMENTS; SUSCEPTIBILITY;
   PREDISPOSES; HAPLOTYPE
AB Copy Number Variants (CNVs) are now recognized as playing a significant role in complex disease etiology. Age-related macular degeneration (AMD) is the most common cause of irreversible vision loss in the western world. While a number of genes and environmental factors have been associated with both risk and protection in AMD, the role of CNVs has remained largely unexplored. We analyzed the two major AMD risk-associated regions on chromosome 1q32 and 10q26 for CNVs using Multiplex Ligation-dependant Probe Amplification. The analysis targeted nine genes in these two key regions, including the Complement Factor H (CFH) gene, the 5 CFH-related (CFHR) genes representing a known copy number "hotspot", the F13B gene as well as the ARMS2 and HTRA1 genes in 387 cases of late AMD and 327 controls. No copy number variation was detected at the ARMS2 and HTRA1 genes in the chromosome 10 region, nor for the CFH and F13B genes at the chromosome 1 region. However, significant association was identified for the CFHR3-1 deletion in AMD cases (p = 2.38x10(-12)) OR = 0.31, CI-0.95 (0.23-0.44), for both neovascular disease (nAMD) (p = 8.3x10(-9)) OR = 0.36 CI-0.95 (0.25-0.52) and geographic atrophy (GA) (p = 1.5x10(-6)) OR = 0.36 CI-0.95 (0.25-0.52) compared to controls. In addition, a significant association with deletion of CFHR1-4 was identified only in patients who presented with bilateral GA (p = 0.02) (OR = 7.6 CI-0.95 1.38-41.8). This is the first report of a phenotype specific association of a CNV for a major subtype of AMD and potentially allows for pre-diagnostic identification of individuals most likely to proceed to this end stage of disease.
C1 [Cantsilieris, Stuart; Richardson, Andrea J.; Guymer, Robyn H.; Baird, Paul N.] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia.
   [Cantsilieris, Stuart; White, Stefan J.] Monash Inst Med Res, Ctr Reprod & Dev, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Monash University
RP Cantsilieris, S (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia.
EM pnb@unimelb.edu.au
OI Baird, Paul/0000-0002-1305-3502; Guymer, Robyn/0000-0002-9441-4356
FU National Health and Medical Research Council (NHMRC) Centre for Clinical
   Research Excellence [529923]; NHMRC [1008979]
FX This study was supported by the National Health and Medical Research
   Council (NHMRC) Centre for Clinical Research Excellence
   #529923-Translational Clinical Research in Major Eye Diseases and NHMRC
   Project Grant #1008979 and NHMRC practitioner fellowship (RHG). CERA and
   MIMR receives Operational Infrastructure Support from the Victorian
   Government. The information contained in this manuscript has not been
   published before. The authors have no financial interests or
   involvements with companies regarding this work. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   Alkan C, 2009, NAT GENET, V41, P1061, DOI 10.1038/ng.437
   Bhattacharya T, 2009, NAT MED, V15, P1112, DOI 10.1038/nm1009-1112
   Campbell CD, 2011, AM J HUM GENET, V88, P317, DOI 10.1016/j.ajhg.2011.02.004
   Casilli F, 2002, HUM MUTAT, V20, P218, DOI 10.1002/humu.10108
   Cooper GM, 2011, NAT GENET, V43, P838, DOI 10.1038/ng.909
   de Cid R, 2009, NAT GENET, V41, P211, DOI 10.1038/ng.313
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Fanciulli M, 2007, NAT GENET, V39, P721, DOI 10.1038/ng2046
   Fellermann K, 2006, AM J HUM GENET, V79, P439, DOI 10.1086/505915
   Field SF, 2009, NAT MED, V15, P1115, DOI 10.1038/nm1009-1115
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Gonzalez E, 2005, SCIENCE, V307, P1434, DOI 10.1126/science.1101160
   Guymer RH, 2006, MED J AUST, V184
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hebecker M, 2010, MOL IMMUNOL, V47, P1347, DOI 10.1016/j.molimm.2009.12.005
   Hollox EJ, 2008, NAT GENET, V40, P23, DOI 10.1038/ng.2007.48
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Hughes AE, 2010, NAT GENET, V42, P555, DOI 10.1038/ng0710-555
   Janssen B, 2005, NEUROGENETICS, V6, P29, DOI 10.1007/s10048-004-0204-1
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kubista KE, 2011, MOL VIS, V17, P2080
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Mamtani M, 2010, GENES IMMUN, V11, P155, DOI 10.1038/gene.2009.71
   Marques RB, 2010, PLOS ONE, V5
   McKinney C, 2010, ANN RHEUM DIS, V69, P1711, DOI 10.1136/ard.2009.123588
   Mihlan M, 2009, MOL IMMUNOL, V46, P335, DOI 10.1016/j.molimm.2008.10.029
   Moore I, 2010, BLOOD, V115, P379, DOI 10.1182/blood-2009-05-221549
   Nguyen DQ, 2006, PLOS GENET, V2, P198, DOI 10.1371/journal.pgen.0020020
   Notini AJ, 2008, CYTOGENET GENOME RES, V123, P270, DOI 10.1159/000184717
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Raychaudhuri S, 2010, NAT GENET, V42, P553, DOI 10.1038/ng0710-553
   Resnikoff S, 2008, B WORLD HEALTH ORGAN, V86, P63, DOI 10.2471/BLT.07.041210
   Richardson AJ, 2010, INVEST OPHTH VIS SCI, V51, P4932, DOI 10.1167/iovs.09-5114
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Saugier-Veber P, 2006, EUR J HUM GENET, V14, P1009, DOI 10.1038/sj.ejhg.5201661
   Sawitzke J, 2011, OPHTHALMOLO IN PRESS
   Schmid-Kubista KE, 2009, INVEST OPHTH VIS SCI, V50, P5070, DOI 10.1167/iovs.09-3975
   Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056
   Sharp AJ, 2005, AM J HUM GENET, V77, P78, DOI 10.1086/431652
   Sivakumaran TA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025598
   Sudmant PH, 2010, SCIENCE, V330, P641, DOI 10.1126/science.1197005
   White S, 2002, AM J HUM GENET, V71, P365, DOI 10.1086/341942
   White SJ, 2007, CYTOGENET GENOME RES, V118, P19, DOI 10.1159/000106437
   White SJ, 2004, METHOD CELL BIOL, V75, P751
   White SJ, 2004, HUM MUTAT, V24, P86, DOI 10.1002/humu.20054
   Zhao J, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002079
   Zipfel PF, 2007, PLOS GENET, V3, P387, DOI 10.1371/journal.pgen.0030041
NR 51
TC 16
Z9 16
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 25
PY 2012
VL 7
IS 4
AR e35255
DI 10.1371/journal.pone.0035255
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 959VP
UT WOS:000305345200031
PM 22558131
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Felszeghy, S
   Viiri, J
   Paterno, JJ
   Hyttinen, JMT
   Koskela, A
   Chen, M
   Leinonen, H
   Tanila, H
   Kivinen, N
   Koistinen, A
   Toropainen, E
   Amadio, M
   Smedowski, A
   Reinisalo, M
   Winiarczyk, M
   Mackiewicz, J
   Mutikainen, M
   Ruotsalainen, AK
   Kettunen, M
   Jokivarsi, K
   Sinha, D
   Kinnunen, K
   Petrovski, G
   Blasiak, J
   Bjorkoy, G
   Koskelainen, A
   Skottman, H
   Urtti, A
   Salminen, A
   Kannan, R
   Ferrington, DA
   Xu, HP
   Levonen, AL
   Tavi, P
   Kauppinen, A
   Kaarniranta, K
AF Felszeghy, Szabolcs
   Viiri, Johanna
   Paterno, Jussi J.
   Hyttinen, Juha M. T.
   Koskela, Ali
   Chen, Mei
   Leinonen, Henri
   Tanila, Heikki
   Kivinen, Niko
   Koistinen, Arto
   Toropainen, Elisa
   Amadio, Marialaura
   Smedowski, Adrian
   Reinisalo, Mika
   Winiarczyk, Mateusz
   Mackiewicz, Jerzy
   Mutikainen, Maija
   Ruotsalainen, Anna-Kaisa
   Kettunen, Mikko
   Jokivarsi, Kimmo
   Sinha, Debasish
   Kinnunen, Kati
   Petrovski, Goran
   Blasiak, Janusz
   Bjorkoy, Geir
   Koskelainen, Ari
   Skottman, Heli
   Urtti, Arto
   Salminen, Antero
   Kannan, Ram
   Ferrington, Deborah A.
   Xu, Heping
   Levonen, Anna-Liisa
   Tavi, Pasi
   Kauppinen, Anu
   Kaarniranta, Kai
TI Loss of NRF-2 and PGC-1 alpha genes leads to retinal pigment epithelium
   damage resembling dry age-related macular degeneration
SO REDOX BIOLOGY
LA English
DT Article
DE Aging; Autophagy; Degeneration; Oxidative stress; Protein aggregation;
   Proteasome
ID TRANSCRIPTION FACTOR NRF2; OXIDATIVE STRESS; ANTIOXIDANT RESPONSE;
   AUTOPHAGY; CELLS; MICE; RPE; DYSREGULATION; INFLAMMATION; DEGRADATION
AB Age-related macular degeneration (AMD) is a multi-factorial disease that is the leading cause of irreversible and severe vision loss in the developed countries. It has been suggested that the pathogenesis of dry AMD involves impaired protein degradation in retinal pigment epithelial cells (RPE). RPE cells are constantly exposed to oxidative stress that may lead to the accumulation of damaged cellular proteins, DNA and lipids and evoke tissue deterioration during the aging process. The ubiquitin-proteasome pathway and the lysosomal/autophagosomal pathway are the two major proteolytic systems in eukaryotic cells. NRF-2 (nuclear factor-erythroid 2-related factor-2) and PGC-1 alpha (peroxisome proliferator-activated receptor gamma coactivator-1 alpha) are master transcription factors in the regulation of cellular detoxification. We investigated the role of NRF-2 and PGC-1 alpha in the regulation of RPE cell structure and function by using global double knockout (dKO) mice. The NRF-2/PGC-1 alpha dKO mice exhibited significant age-dependent RPE degeneration, accumulation of the oxidative stress marker, 4-HNE (4-hydroxynonenal), the endoplasmic reticulum stress markers GRP78 (glucose-regulated protein 78) and ATF4 (activating transcription factor 4), and damaged mitochondria. Moreover, levels of protein ubiquitination and autophagy markers p62/SQSTM1 (sequestosome 1), Beclin-1 and LC3B (microtubule associated protein 1 light chain 3 beta) were significantly increased together with the Iba-1 (ionized calcium binding adaptor molecule 1) mononuclear phagocyte marker and an enlargement of RPE size. These histopathological changes of RPE were accompanied by photoreceptor dysmorphology and vision loss as revealed by electroretinography. Consequently, these novel findings suggest that the NRF-2/PGC-1 alpha dKO mouse is a valuable model for investigating the role of proteasomal and autophagy clearance in the RPE and in the development of dry AMD.
C1 [Felszeghy, Szabolcs] Univ Eastern Finland, Inst Dent, Kuopio, Finland.
   [Felszeghy, Szabolcs] Univ Eastern Finland, Inst Biomed, Kuopio, Finland.
   [Viiri, Johanna; Paterno, Jussi J.; Hyttinen, Juha M. T.; Koskela, Ali; Kivinen, Niko; Reinisalo, Mika; Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Kuopio, Finland.
   [Paterno, Jussi J.; Kivinen, Niko; Kinnunen, Kati; Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio, Finland.
   [Chen, Mei; Xu, Heping] Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, Belfast, Antrim, North Ireland.
   [Leinonen, Henri; Tanila, Heikki; Mutikainen, Maija; Ruotsalainen, Anna-Kaisa; Kettunen, Mikko; Jokivarsi, Kimmo; Levonen, Anna-Liisa; Tavi, Pasi] Univ Eastern Finland, AL Virtanen Inst Mol Sci, Kuopio, Finland.
   [Koistinen, Arto] Univ Eastern Finland, SIB Labs, Kuopio, Finland.
   [Toropainen, Elisa; Reinisalo, Mika; Urtti, Arto; Kauppinen, Anu] Univ Eastern Finland, Sch Pharm, Fac Hlth Sci, Kuopio, Finland.
   [Amadio, Marialaura] Univ Pavia, Sect Pharmacol, Dept Drug Sci, Pavia, Italy.
   [Smedowski, Adrian] Med Univ Silesia, Sch Med Katowice, Chair & Dept Physiol, Katowice, Poland.
   [Winiarczyk, Mateusz] Univ Life Sci Lublin, Dept Epizootiol, Lublin, Poland.
   [Winiarczyk, Mateusz; Mackiewicz, Jerzy] Med Univ Lublin, Dept Vitreoretinal Surg, Lublin, Poland.
   [Sinha, Debasish] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
   [Petrovski, Goran] Univ Oslo, Oslo Univ Hosp, Dept Ophthalmol, Ctr Eye Res, Oslo, Norway.
   [Blasiak, Janusz] Univ Lodz, Dept Mol Genet, Lodz, Poland.
   [Bjorkoy, Geir] Norwegian Univ Sci & Technol, Ctr Mol Inflammat Res, Trondheim, Norway.
   [Bjorkoy, Geir] Norwegian Univ Sci & Technol, Dept Canc Res & Mol Med, Trondheim, Norway.
   [Bjorkoy, Geir] Univ Coll Sor Trondelag, Dept Technol, Trondheim, Norway.
   [Koskelainen, Ari] Aalto Univ, Dept Neurosci & Biomed Engn, Sch Sci, Aalto, Finland.
   [Skottman, Heli] Univ Tampere, BioMediTech Inst, Fac Med & Life Sci, Tampere, Finland.
   [Urtti, Arto] Univ Helsinki, Div Pharmaceut Biosci, Ctr Drug Res, Helsinki, Finland.
   [Salminen, Antero] Univ Eastern Finland, Dept Neurol, Kuopio, Finland.
   [Kannan, Ram] Doheny Eye Inst, Arnold & Mabel Beckman Macular Res Ctr, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Ferrington, Deborah A.] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN USA.
C3 University of Eastern Finland; University of Eastern Finland; University
   of Eastern Finland; Kuopio University Hospital; University of Eastern
   Finland; Queens University Belfast; University of Eastern Finland;
   University of Eastern Finland; University of Eastern Finland; University
   of Pavia; Medical University Silesia; University of Life Sciences in
   Lublin; Medical University of Lublin; Johns Hopkins University; Johns
   Hopkins Medicine; University of Oslo; University of Lodz; Norwegian
   University of Science & Technology (NTNU); Norwegian University of
   Science & Technology (NTNU); Norwegian University of Science &
   Technology (NTNU); Aalto University; Tampere University; University of
   Helsinki; University of Eastern Finland; Doheny Eye Institute;
   University of Minnesota System; University of Minnesota Twin Cities
RP Kaarniranta, K (通讯作者)，Univ Eastern Finland, Dept Ophthalmol, Kuopio, Finland.; Kaarniranta, K (通讯作者)，Kuopio Univ Hosp, Kuopio, Finland.
EM kai.kaarniranta@uef.fi
RI Paterno, Jussi/AAY-5526-2020; Kettunen, Mikko I/K-2299-2012; Xu,
   Heping/A-4430-2008; Smedowski, Adrian/ABA-1031-2021; Koistinen,
   Arto/GLR-0659-2022; Leinonen, Henri/V-2684-2019; Winiarczyk,
   Mateusz/S-9712-2019; kannan, ram/ABB-7154-2020
OI Paterno, Jussi/0000-0002-5442-4314; Kettunen, Mikko
   I/0000-0002-2004-660X; Xu, Heping/0000-0003-4000-931X; Smedowski,
   Adrian/0000-0001-8528-955X; Leinonen, Henri/0000-0002-0388-832X; kannan,
   ram/0000-0002-1583-3414; Ferrington, Deborah/0000-0003-2561-7464;
   Mackiewicz, Jerzy/0000-0003-0984-8908; Skottman,
   Heli/0000-0002-4127-8792; Koistinen, Arto/0000-0001-7601-9806; Blasiak,
   Janusz/0000-0001-9539-9584; Ruotsalainen,
   Anna-Kaisa/0000-0002-8512-3768; Hyttinen, Juha/0000-0002-3414-4032;
   Petrovski, Goran/0000-0003-2905-9252; Winiarczyk,
   Mateusz/0000-0001-9704-3848; Levonen, Anna-Liisa/0000-0002-6575-2137
FU Kuopio University Hospital [5503743]; Finnish Eye Foundation; Finnish
   Funding Agency for Technology and Innovation; Health Research Council of
   the Academy of Finland [218050, 296840]; Paivikki and Sakari Sohlberg
   Foundation; Evald and Hilda Nissi Foundation; Finnish Cultural
   Foundation-North-Savo; Lindsay Family Foundation; National Science
   Centre, Poland [2017/27/B/NZ3/00872]
FX This work was supported by the Kuopio University Hospital (KK) (Grant
   Number 5503743), the Finnish Eye Foundation (JJP, KK), the Finnish
   Funding Agency for Technology and Innovation (AK, KK), the Health
   Research Council of the Academy of Finland (KK, HS) (Grant Numbers
   218050 and 296840), the Paivikki and Sakari Sohlberg Foundation (KK,
   HS), the Evald and Hilda Nissi Foundation and the Finnish Cultural
   Foundation-North-Savo (AKoi), the Lindsay Family Foundation and an
   anonymous donor for AMD research (DAF), National Science Centre, Poland
   (JB) (Grant number 2017/27/B/NZ3/00872). The researchers are very
   grateful to Mrs. Anne Seppanen, Mrs. Anne Karppinen, Mrs Virpi
   Miettinen, Mr. Anthony Rodriguez and Mr. Eric Barron for their skillful
   technical assistance.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Aquilano K, 2013, ANTIOXID REDOX SIGN, V18, P386, DOI 10.1089/ars.2012.4615
   Baldelli S, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.458
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Boya P, 2016, PROG RETIN EYE RES, V55, P206, DOI 10.1016/j.preteyeres.2016.08.001
   Chen M, 2016, AGING CELL, V15, P436, DOI 10.1111/acel.12447
   Chiba T., 1997, BIOCHEM BIOPH RES CO, V236, P313
   Cruz-Guilloty F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088201
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Demishtei A., 2017, AUTOPHAGY, V9, P1
   Dou G, 2012, OXID STRESS APPL BAS, P241, DOI 10.1007/978-1-61779-606-7_11
   Egger A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031272
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Ferrington DA, 2016, EXP EYE RES, V145, P269, DOI 10.1016/j.exer.2016.01.018
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   He SK, 2008, GRAEF ARCH CLIN EXP, V246, P677, DOI 10.1007/s00417-008-0770-2
   Hirotsu Y, 2012, NUCLEIC ACIDS RES, V40, P10228, DOI 10.1093/nar/gks827
   Hohn A, 2011, FREE RADICAL BIO MED, V50, P585, DOI 10.1016/j.freeradbiomed.2010.12.011
   Hyttinen JMT, 2017, AGEING RES REV, V36, P64, DOI 10.1016/j.arr.2017.03.006
   Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Jeong HS, 2013, MOL CELL BIOCHEM, V375, P81, DOI 10.1007/s11010-012-1530-5
   Jing GJ, 2012, EXP DIABETES RES, DOI 10.1155/2012/589589
   Johansson I, 2015, AUTOPHAGY, V11, P1636, DOI 10.1080/15548627.2015.1061170
   Juuti-Uusitalo K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051089
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kansanen E, 2013, REDOX BIOL, V1, P45, DOI 10.1016/j.redox.2012.10.001
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Khadka A., 2016, INVEST OPHTH VIS SCI, V57, P1038
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Koga H, 2011, AGEING RES REV, V10, P205, DOI 10.1016/j.arr.2010.02.001
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Korovila I, 2017, REDOX BIOL, V13, P550, DOI 10.1016/j.redox.2017.07.008
   Lau A, 2010, MOL CELL BIOL, V30, P3275, DOI 10.1128/MCB.00248-10
   Leinonen H, 2016, HUM MOL GENET, V25, P3810, DOI 10.1093/hmg/ddw228
   Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904
   Liu J, 2016, SCI REP-UK, V6, DOI 10.1038/srep20639
   Liu WJ, 2016, CELL MOL BIOL LETT, V21, DOI 10.1186/s11658-016-0031-z
   Luckoff A, 2017, NAT PROTOC, V12, P1136, DOI 10.1038/nprot.2017.032
   Marmolino D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010025
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Mehalow AK, 2003, HUM MOL GENET, V12, P2179, DOI 10.1093/hmg/ddg232
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Pajares M, 2016, AUTOPHAGY, V12, P1902, DOI 10.1080/15548627.2016.1208889
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Piippo N, 2014, BBA-MOL CELL RES, V1843, P3038, DOI 10.1016/j.bbamcr.2014.09.015
   Rodgers JT, 2007, P NATL ACAD SCI USA, V104, P12861, DOI 10.1073/pnas.0702509104
   Rodriguez-Muela N, 2013, AGING CELL, V12, P478, DOI 10.1111/acel.12072
   Roginska D, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5306790
   Salminen A, 2013, INT J MOL SCI, V14, P3834, DOI 10.3390/ijms14023834
   Schnell SA, 1999, J HISTOCHEM CYTOCHEM, V47, P719, DOI 10.1177/002215549904700601
   Sinha D, 2016, EXP EYE RES, V144, P46, DOI 10.1016/j.exer.2015.08.018
   Smith S. B., 2013, RETINA-J RET VIT DIS, V1, P529
   Sukseree S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161640
   Takayama K, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/8694641
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Valapala M, 2014, AUTOPHAGY, V10, P480, DOI 10.4161/auto.27292
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Wei YH, 2011, FREE RADICAL BIO MED, V51, P216, DOI 10.1016/j.freeradbiomed.2011.04.026
   Weymouth AE, 2008, PROG RETIN EYE RES, V27, P1, DOI 10.1016/j.preteyeres.2007.09.003
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Zhang Y, 2017, MOL VIS, V23, P228
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
NR 65
TC 78
Z9 78
U1 3
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-2317
J9 REDOX BIOL
JI Redox Biol.
PD JAN
PY 2019
VL 20
BP 1
EP 12
DI 10.1016/j.redox.2018.09.011
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA HM3GK
UT WOS:000459361500001
PM 30253279
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kuehlewein, L
   Dustin, L
   Sagong, M
   Hariri, A
   Mendes, TS
   Rofagha, S
   Bhisitkul, RB
   Sadda, SR
AF Kuehlewein, Laura
   Dustin, Laurie
   Sagong, Min
   Hariri, Amirhossein
   Mendes, Thais S.
   Rofagha, Soraya
   Bhisitkul, Robert B.
   Sadda, SriniVas R.
TI Predictors of Macular Atrophy Detected by Fundus Autofluorescence in
   Patients With Neovascular Age-Related Macular Degeneration After
   Long-Term Ranibizumab Treatment
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; GEOGRAPHIC ATROPHY; VERTEPORFIN;
   PROGRESSION; OUTCOMES; HORIZON; ANCHOR; MARINA; EYES
AB BACKGROUND AND OBJECTIVE: To study the relationship between baseline morphologic characteristics of the choroidal neovascular (CNV) lesion and long-term development of macular atrophy in eyes with neovascular age-related macular degeneration (AMD) treated with ranibizumab (Lucentis; Genentech, South San Francisco, CA).
   PATIENTS AND METHODS: Certified graders evaluated baseline and 7-year follow-up (SEVEN-UP study) images of 41 eyes from the MARINA/ANCHOR and HORIZON trials. Using GRADOR software and stepwise linear regression, graders correlated lesion characteristics on fluorescein angiography (FA) at both visits with areas of definite decreased autofluorescence (DDAF) on fundus autofluorescence (FAF) imaging at the SEVEN-UP visit.
   RESULTS: Three of 41 eyes (7.3%) had macular atrophy on FA at baseline (mean +/- standard deviation [SD] size: 0.29 mm(2) +/- 1.50 mm(2)), 29 (70.7%) at SEVEN-UP (mean +/- standard deviation [SD] area: 7.42 mm(2) +/- 7.97 mm(2)). On FAF imaging at the SEVEN-UP visit, all 41 eyes (100%) had DDAF (mean +/- SD size: 10.29 mm(2) +/- 8.07 mm(2)). Variables significantly associated with area of DDAF at the SEVEN-UP visit were the area of leaking CNV lesion components (coefficient: 0.953; P <.001), the area of other lesion components (coefficient: 1.094; P = .038), and the area of retinal pigment epithelial (RPE) atrophy (coefficient: 1.334; P = .040) on baseline FA imaging.
   CONCLUSION: The area of DDAF at more than 7 years after initiation of ranibizumab therapy was 35% larger than the original CNV lesion. The baseline area of leaking CNV and other components of the CNV lesion and the baseline area of RPE atrophy were important predictors of the area of definite decreased autofluorescence, presumably corresponding to areas of photoreceptor and RPE loss. The findings from this study may guide hypothesis generation for future AMD trials.
C1 [Kuehlewein, Laura; Sagong, Min; Hariri, Amirhossein; Sadda, SriniVas R.] Univ Calif Los Angeles, David Geffen Sch Med, Doheny Eye Inst, Los Angeles, CA 90095 USA.
   [Dustin, Laurie] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
   [Sagong, Min] Yeungnam Univ, Coll Med, Dept Ophthalmol, Daegu, South Korea.
   [Mendes, Thais S.; Rofagha, Soraya; Bhisitkul, Robert B.] UCSF Sch Med, Dept Ophthalmol, San Francisco, CA USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; University of Southern
   California; Yeungnam University; University of California System;
   University of California San Francisco
RP Sadda, SR (通讯作者)，Doheny Eye Inst, 1355 San Pablo St,DVRC 100, Los Angeles, CA 90033 USA.
EM SSadda@doheny.org
RI Mendes, Thais Sousa/R-7735-2019
OI Mendes, Thais Sousa/0000-0001-5568-9958
FU Genentech; GlaxoSmithKline; Santen; Regeneron; Carl Zeiss Meditec;
   Optos; Allergan
FX Dr. Bhisitkul received a research grant from Genentech and
   GlaxoSmithKline; received consulting fees/honoraria from Genentech and
   Santen; is on the advisory board for Allergan, Bausch + Lomb, Aerpio,
   Zoma, and Iconic; and has stock options with Zodera. Dr. Rofagha
   received a research grant from Regeneron. Dr. Sadda is a consultant for
   Carl Zeiss Meditec, Optos, Allergan, Genentech, Alcon, Novartis, and
   Iconic and received financial support from Carl Zeiss Meditec, Optos,
   Allergan, and Genentech. The remaining authors report no relevant
   financial disclosures.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2007, INVEST OPHTH VIS SCI, V48, P349, DOI 10.1167/iovs.06-0493
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Keane PA, 2009, INVEST OPHTH VIS SCI, V50, P3378, DOI 10.1167/iovs.08-2728
   Kniestedt Christoph, 2003, Ophthalmol Clin North Am, V16, P155, DOI 10.1016/S0896-1549(03)00013-0
   Marsiglia M, 2015, RETINA-J RET VIT DIS, V35, P966, DOI 10.1097/IAE.0000000000000460
   Mokwa NF, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/385915
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Steinberg JS, 2015, BRIT J OPHTHALMOL, V99, P1289, DOI 10.1136/bjophthalmol-2014-306535
NR 19
TC 13
Z9 13
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD MAR
PY 2016
VL 47
IS 3
BP 224
EP 231
DI 10.3928/23258160-20160229-04
PG 8
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA DP9VF
UT WOS:000378844900005
PM 26985795
DA 2022-11-30
ER

PT J
AU Tanaka, E
   Chaikitmongkol, V
   Bressler, SB
   Bressler, NM
AF Tanaka, Erika
   Chaikitmongkol, Voraporn
   Bressler, Susan B.
   Bressler, Neil M.
TI Vision-Threatening Lesions Developing with Longer-Term Follow-up after
   Treatment of Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; GROWTH-FACTOR THERAPY;
   PHOTODYNAMIC THERAPY; EYE DISEASE; RANIBIZUMAB; VERTEPORFIN;
   ASSOCIATION; HORIZON; ATROPHY; ANCHOR
AB Purpose: To assess the development of vision-threatening lesions at least 3.5 years after initiating antivascular endothelial growth factor (VEGF) for choroidal neovascularization (CNV) in eyes with age-related macular degeneration (AMD).
   Design: Retrospective cohort study.
   Participants: A total of 75 patients (81 eyes) with CNV secondary to AMD who received intravitreous anti-VEGF treatment and were followed for at least 3.5 years after initiating treatment.
   Methods: Retrospective record review of patients initiating anti-VEGF treatment between November 2005 and June 2008 at a university-based institution for whom at least 3.5 years of follow-up was available at the same institution. Main Outcome Measures: Predominantly hemorrhagic lesions or geographic atrophy (GA).
   Results: Among 75 patients (81 eyes; 59% were women; median age, 78 years), mean follow-up was 4.9 years and at least 6 years for 40%. Median visual acuity (VA) was 20/80 (interquartile range [IQR], 20/50-20/100) initially, 20/63 (IQR, 20/40-20/160) at 2 years, 20/80 (IQR, 20/40-20/200) at 3.5 years, and 20/63 (IQR 20/32-20/200) at 6 years. Six eyes (7%) had predominantly hemorrhagic lesions initially, whereas this developed in an additional 3 eyes (4%, 95% confidence interval [CI], 1% to 10%) in 3.5 years and in 1 additional eye (1%, 95% CI, 0.03% to 7%) at more than 3.5 years of follow-up. Initially, GA within or overlapping the boundary of the entire CNV was present in 4 eyes (5%) and outside this boundary in 8 eyes (10%). Geographic atrophy enlarged in each eye over time. The only eyes that developed GA outside the CNV boundary were those that had GA outside the lesion at baseline. Additional atrophy within the boundary of CNV defined at baseline, termed "atrophic disciform scars," developed in 5 eyes (6%), all within 4 years of treatment initiation.
   Conclusions: Longer-term follow-up of neovascular AMD managed with anti-VEGF therapy suggests that predominantly hemorrhagic lesions may develop within 3.5 years of initiating therapy and more than 3.5 years after initiating therapy. In contrast, new areas of GA beyond the boundaries of the CNV lesion as defined at initiation of anti- VEGF therapy seem unlikely to develop if there is no GA outside of the CNV lesion initially. (C) 2015 by the American Academy of Ophthalmology.
C1 [Tanaka, Erika] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   [Chaikitmongkol, Voraporn; Bressler, Susan B.; Bressler, Neil M.] Johns Hopkins Univ Hosp, Wilmer Eye Inst, Retina Div, Baltimore, MD 21287 USA.
   [Chaikitmongkol, Voraporn] Chiang Mai Univ, Fac Med, Dept Ophthalmol, Retina Div, Chiang Mai 50000, Thailand.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   Medicine; Chiang Mai University
RP Bressler, NM (通讯作者)，Johns Hopkins Univ Hosp, Maumenee 752,600 N Wolfe St, Baltimore, MD 21287 USA.
EM nmboffice@jhmi.edu
OI Chaikitmongkol, Voraporn/0000-0003-0426-7602
FU Staff Development Fund of Faculty of Medicine, Chiang Mai University;
   Julia G. Levy, PhD Professorship; Research to Prevent Blindness
   Clinician-Scientist Award; James P. Gills Professorship
FX Funded by the Staff Development Fund of Faculty of Medicine, Chiang Mai
   University (V.C.), the Julia G. Levy, PhD Professorship (S.B.B.),
   Research to Prevent Blindness Clinician-Scientist Award (S.B.B.), the
   James P. Gills Professorship (N.M.B.), and unrestricted contributions by
   donors to retina research of S.B.B. and N.M.B. to the Johns Hopkins
   University. The sponsor or funding organization had no role in the
   design or conduct of this research.
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler NM, 2012, RETINA-J RET VIT DIS, V32, P1821, DOI 10.1097/IAE.0b013e31825db6ba
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen CJ, 2013, OPHTHALMOLOGY AGEING, P107
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Gutfleisch M, 2011, EYE, V25, P1181, DOI 10.1038/eye.2011.146
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kaul S, 2013, JAMA INTERN MED, V173, P264, DOI 10.1001/jamainternmed.2013.2530
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McCannel CA, 2011, RETINA-J RET VIT DIS, V31, P654, DOI 10.1097/IAE.0b013e31820a67e4
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scott AW, 2013, CURR OPIN OPHTHALMOL, V24, P190, DOI 10.1097/ICU.0b013e32835fefee
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   *SUBM SURG TRIALS, 2005, RETINA, V25, P253
   Tseng JJ, 2012, J GLAUCOMA, V21, P241, DOI 10.1097/IJG.0b013e31820d7d19
NR 24
TC 22
Z9 23
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2015
VL 122
IS 1
BP 153
EP 161
DI 10.1016/j.ophtha.2014.07.046
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AX1XK
UT WOS:000346737000032
PM 25283060
DA 2022-11-30
ER

PT J
AU Rasmussen, A
   Bloch, SB
   Fuchs, J
   Hansen, LH
   Larsen, M
   LaCour, M
   Lund-Andersen, H
   Sander, B
AF Rasmussen, Annette
   Bloch, Sara B.
   Fuchs, Josefine
   Hansen, Louise H.
   Larsen, Michael
   LaCour, Morten
   Lund-Andersen, Henrik
   Sander, Birgit
TI A 4-Year Longitudinal Study of 555 Patients Treated with Ranibizumab for
   Neovascular Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID VISUAL OUTCOMES; PREDICTORS; BLINDNESS; REGIMEN
AB Objective: To investigate the visual outcome, pattern of discontinuation, ocular complications, and mortality of patients treated with a variable ranibizumab dosing regimen for neovascular age-related macular degeneration (AMD) for 4 years.
   Design: Retrospective chart review supplemented with clinical examination.
   Participants: Six hundred eyes of 555 patients initiated intravitreal treatment with vascular endothelial growth factor inhibition for neovascular AMD in 2007 in a community-based hospital.
   Methods: Patient data from a database were retrieved from 2007 through 2011. Descriptive evaluation of the main outcome measures was carried out for the cohort of patients. A group of patients who had been discontinued because of apparent disease inactivity was reexamined.
   Main Outcome Measures: Best-corrected visual acuity (BCVA; Snellen), number of intravitreal injections, causes of discontinuations, ocular complications, and standardized mortality rate.
   Results: One hundred ninety-two eyes (32%) were still receiving active treatment after 4 years. The mean BCVA in the 192 eyes was unchanged from the start (baseline, 0.30; 4-year follow-up, 0.32; P>0.3). Visual acuity after the third loading dose was associated significantly with the outcome (P<0.0001) and was a better predictor than baseline acuity. The mean number of injections was 5.5 per year. For 408 eyes (68%), discontinuation of treatment was motivated by the following 4 reasons: lack of apparent treatment response (28%), failure to appear at follow-up (11%), death (9%), and disease inactivity (20%, 120 eyes). Treatment was resumed later in 18% of patients discontinued because of inactivity. Sixty-seven eyes were reexamined in 2012 from the group of patients with disease inactivity. The final visual acuity by then had decreased significantly from the time of discontinuation, from 0.38 to 0.15 (P = 0.001). Endophthalmitis occurred in 2 eyes of 7584 injections. A total of 125 patients had died, corresponding to 75% of the mean mortality in the community.
   Conclusions: One third of the eyes were still receiving active treatment after 4 years and had stable visual acuity. One third of fellow eyes (eyes at risk) started treatment during the 4 years. One fifth of discontinued eyes resumed treatment, indicating that close follow-up should be maintained for patients discontinued because of disease inactivity. The ocular complication rate was 0.2%, and the mortality rate was below expected. (C) 2013 by the American Academy of Ophthalmology.
C1 [Rasmussen, Annette; Bloch, Sara B.; Fuchs, Josefine; Hansen, Louise H.; Larsen, Michael; LaCour, Morten; Lund-Andersen, Henrik; Sander, Birgit] Glostrup Cty Hosp, Dept Ophthalmol, Copenhagen, Denmark.
   [Rasmussen, Annette; Bloch, Sara B.; Fuchs, Josefine; Larsen, Michael; LaCour, Morten; Lund-Andersen, Henrik; Sander, Birgit] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
C3 University of Copenhagen; University of Copenhagen
RP Rasmussen, A (通讯作者)，Glostrup Cty Hosp, Dept Ophthalmol, Nordre Ringvej 57, DK-2600 Glostrup, Denmark.
EM annette.rasmussen@regionh.dk
RI Larsen, Michael/E-9620-2010; la Cour, Morten/L-1600-2013
OI Larsen, Michael/0000-0002-5172-5891; Dornonville de la Cour,
   Morten/0000-0002-7712-9772
FU Novartis; Pfizer; Alcon; GlaxoSmithKline; Bayer; Allergan; Eli Lilly;
   GSK; Vaern om Synet; Danish Agency for Science, Technology and
   Innovation; Oejenfonden; VELUX Foundation, Denmark; Lundbeck Foundation,
   Denmark; Glostrup Hospital, Copenhagen, Denmark
FX Annette Rasmussen - Financial support - Novartis; Michael Larsen -
   Advisory board - Novartis, Pfizer, Thrombogenics; Financial support -
   Novartis, Pfizer, Alcon, GlaxoSmithKline, Bayer, Allergan; Lecturer -
   Novartis, Pfizer, Novo Nordisk, GlaxoSmithKline; Henrik Lund-Andersen -
   Financial support - Novartis, Pfizer, Alcon, GlaxoSmithKline, Bayer,
   Allergan, Eli Lilly; Birgit Sander - Financial support - Novartis,
   Pfizer, Alcon, GSK, Bayer, Allergan, Eli Lilly, Vaern om Synet, The
   Danish Agency for Science, Technology and Innovation, and Oejenfonden;
   Supported by The VELUX Foundation, Denmark; The Lundbeck Foundation,
   Denmark; and Glostrup Hospital, Copenhagen, Denmark. The funding
   organizations had no role in the design or conduct of this research.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Arias L, 2011, RETINA-J RET VIT DIS, V31, P1261, DOI 10.1097/IAE.0b013e318207d152
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Pushpoth S, 2012, BRIT J OPHTHALMOL, V96, P1469, DOI 10.1136/bjophthalmol-2012-302167
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   Solomon SD, 2009, RETINA-J RET VIT DIS, V29, P1080, DOI 10.1097/IAE.0b013e3181b1baeb
   Wolf S, 2011, BRIT J OPHTHALMOL, V95, P1713, DOI 10.1136/bjophthalmol-2011-300471
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 23
TC 77
Z9 80
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2013
VL 120
IS 12
BP 2630
EP 2636
DI 10.1016/j.ophtha.2013.05.018
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 255OL
UT WOS:000327249600049
PM 23830760
DA 2022-11-30
ER

PT J
AU Grunwald, JE
   Daniel, E
   Ying, GS
   Pistilli, M
   Maguire, MG
   Alexander, J
   Whittock-Martin, R
   Parker, CR
   Sepielli, K
   Blodi, BA
   Martin, DF
AF Grunwald, Juan E.
   Daniel, Ebenezer
   Ying, Gui-shuang
   Pistilli, Maxwell
   Maguire, Maureen G.
   Alexander, Judith
   Whittock-Martin, Revell
   Parker, Candace R.
   Sepielli, Krista
   Blodi, Barbara A.
   Martin, Daniel F.
CA CATT Res Grp
TI Photographic Assessment of Baseline Fundus Morphologic Features in the
   Comparison of Age-related Macular Degeneration Treatments Trials
SO OPHTHALMOLOGY
LA English
DT Article
ID OCCULT CHOROIDAL NEOVASCULARIZATION; VISUAL-ACUITY; RANIBIZUMAB;
   VERTEPORFIN
AB Objective: To describe the methods used for assessment of baseline fundus characteristics from color photography and fluorescein angiography (FA) in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) and to describe the relationship between these characteristics and visual acuity.
   Design: Randomized, masked, multicenter trial.
   Participants: This investigation included 1185 participants of the CATT study.
   Methods: Baseline stereoscopic color fundus photographs and FAs of participants in the CATT study were assessed at a central fundus photograph reading center by masked readers. Replicate assessments of random samples of photographs were performed to assess intragrader and intergrader agreements. The association of the lesion characteristics with baseline visual acuity was assessed using analyses of variance and correlation coefficients.
   Main Outcome Measures: Intragrader and intergrader reproducibility, visual acuity, and lesion characteristics.
   Results: Intragrader and intergrader reproducibility showed agreements ranging from 75% to 100% and weighted kappa values ranging from 0.48 to 1.0 for qualitative determinations. The intraclass correlation coefficients were 0.96 to 0.97 for quantitative measurements of choroidal neovascularization (CNV) area and total area of CNV lesion. The mean visual acuity varied by the type of pathologic features in the foveal center: 64.5 letters (standard error, 0.7 letters) for fluid only, 59.0 letters (standard error, 0.5 letters) for CNV, and 58.7 letters (standard error, 1.3 letters) for hemorrhage (P<0.001). Fibrotic or atrophic scar present in the lesion, but not under the center of the fovea, also was associated with a markedly reduced visual acuity of 48.4 letters (standard error, 2.2 letters; P<0.0001). Although total area of CNV lesion was correlated weakly with visual acuity when all participants were assessed (Spearman correlation coefficient, rho = -0.16; P<0.001), the correlation was stronger within patients with predominantly classic lesions (rho = -0.42; P<0.001).
   Conclusions: These results show that the methodology used for grading CATT fundus images has good reproducibility. As expected, larger total CNV lesion area and pathologic findings such as hemorrhage, fibrosis, and atrophy at baseline are associated with decreased visual acuity.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2012;119:1634-1641 (C) 2012 by the American Academy of Ophthalmology.
C1 [Grunwald, Juan E.] Univ Penn, Dept Ophthalmol, Fundus Photog Reading Ctr, Scheie Eye Inst,Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Grunwald, Juan E.; Daniel, Ebenezer; Ying, Gui-shuang; Pistilli, Maxwell; Maguire, Maureen G.; Alexander, Judith; Whittock-Martin, Revell; Parker, Candace R.; Sepielli, Krista] Univ Penn, Dept Ophthalmol, Ctr Prevent Ophthalmol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Ying, Gui-shuang; Maguire, Maureen G.] Univ Penn, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Alexander, Judith] Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Blodi, Barbara A.] Univ Wisconsin, Dept Ophthalmol, Madison, WI USA.
   [Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; University of
   Pennsylvania; Pennsylvania Medicine; University of Pennsylvania;
   Pennsylvania Medicine; Johns Hopkins University; Johns Hopkins Bloomberg
   School of Public Health; University of Wisconsin System; University of
   Wisconsin Madison; Cleveland Clinic Foundation
RP Grunwald, JE (通讯作者)，Univ Penn, Dept Ophthalmol, Fundus Photog Reading Ctr, Scheie Eye Inst,Perelman Sch Med, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA.
EM Juan.Grunwald@uphs.upenn.edu
OI Daniel, Ebenezer/0000-0002-2027-2316; Pistilli,
   Maxwell/0000-0002-4266-4150
FU National Eye Institute, National Institutes of Health, Bethesda,
   Maryland [U10 EY017823, U10 EY017825, U10 EY017826, U10 EY017828];
   NATIONAL EYE INSTITUTE [U10EY017826, U10EY017825, U10EY017828,
   U10EY017823] Funding Source: NIH RePORTER
FX Supported by the National Eye Institute, National Institutes of Health,
   Bethesda, Maryland (grant nos.: U10 EY017823, U10 EY017825, U10
   EY017826, and U10 EY017828).
CR Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Diabetic Retinopathy Clinical Research Network (DRCRnet), 2005, VIS ACT REFR TEST MA
   Fernandes LHS, 2002, RETINA-J RET VIT DIS, V22, P557, DOI 10.1097/00006982-200210000-00005
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Hogg R, 2003, BRIT J OPHTHALMOL, V87, P609, DOI 10.1136/bjo.87.5.609
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Klein ML, 2011, AM J OPHTHALMOL, V151, P161, DOI 10.1016/j.ajo.2010.07.020
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Maguire MG, 1999, AGE RELATED MACULAR, P17
   Marmor MF, 1996, AM J OPHTHALMOL, V122, P382, DOI 10.1016/S0002-9394(14)72065-3
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2010, RETINA-J RET VIT DIS, V30, P1390, DOI 10.1097/IAE.0b013e3181e44599
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 20
TC 50
Z9 50
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2012
VL 119
IS 8
BP 1634
EP 1641
DI 10.1016/j.ophtha.2012.02.013
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 982YA
UT WOS:000307080100022
PM 22512984
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Cai, H
   Gong, J
   Noggle, S
   Paull, D
   Rizzolo, LJ
   Del Priore, LV
   Fields, MA
AF Cai, Hui
   Gong, Jie
   Noggle, Scott
   Paull, Daniel
   Rizzolo, Lawrence J.
   Del Priore, Lucian, V
   Fields, Mark A.
CA NYSCF Global Stem Cell Array Tea
TI Altered transcriptome and disease-related phenotype emerge only after
   fibroblasts harvested from patients with age-related macular
   degeneration are differentiated into retinal pigment epithelium
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Fibroblast; Human induced pluripotent
   stem cells; Retinal pigment epithelium; Transcriptome; Gene expression;
   Mitochondria; Differentiation
ID COMPLEX I; FAMILY; RPE; CELLS; MODEL
AB We have reported previously that retinal pigment epithelium (RPE) differentiated from induced pluripotent stem cells (iPSC) generated from fibroblasts of patients with age-related macular degeneration (AMD) exhibit a retinal degenerative disease phenotype and a distinct transcriptome compared to age-matched controls. Since the genetic composition of the iPSC and RPE are inherited from fibroblasts, we investigated whether differential behavior was present in the parental fibroblasts and iPSC prior to differentiation of the cell lines into RPE. Principal component analyses revealed significant overlap (essentially no differences) in the transcriptome of fibroblasts between AMD and controls. After reprogramming, there was no significant difference in the transcriptome of iPSC generated from AMD versus normal donors. In contrast, the transcriptome of RPE derived from iPSC segregated into two distinct clusters of AMD-derived cells versus controls. Interestingly, mitochondrial dysfunction in AMD-derived RPE was evident after approximately two months in culture. Moreover, these differences in mitochondrial dysfunction were not evident in the parental fibroblasts and iPSC. This study demonstrates an altered transcriptome and impaired mitochondrial function in RPE derived from AMD patients versus controls, and demonstrates these differences are not present in the original fibroblasts or iPSC. These results suggest that pathology in AMD is triggered upon differentiation of parent cells into RPE. More study of this phenomenon could advance the current understandings of the etiology of AMD and the development of novel therapeutic targets.
C1 [Cai, Hui; Gong, Jie; Rizzolo, Lawrence J.; Del Priore, Lucian, V; Fields, Mark A.] Yale Univ, Dept Ophthalmol & Visual Sci, Sch Med, 300 George St,Suite 8100, New Haven, CT 06510 USA.
   [Rizzolo, Lawrence J.] Yale Univ, Dept Surg, Sch Med, POB 208062, New Haven, CT 06520 USA.
   [Noggle, Scott; Paull, Daniel; NYSCF Global Stem Cell Array Tea] NYSCF, Res Inst, 619 West 54th St, New York, NY 10019 USA.
C3 Yale University; Yale University; The New York Stem Cell Foundation
RP Fields, MA (通讯作者)，Yale Univ, Dept Ophthalmol & Visual Sci, Sch Med, 300 George St,Suite 8100, New Haven, CT 06510 USA.
EM mark.fields@yale.edu
OI Rizzolo, Lawrence/0000-0002-2393-8419
FU Research to Prevent Blindness (RPB) , Inc., New York, NY; Alonzo Family
   Fund; Leir Family Fund
FX This work was supported in part by an unrestricted/challenge award to
   Yale Eye Center from the Research to Prevent Blindness (RPB) , Inc., New
   York, NY, the Alonzo Family Fund, and the Leir Family Fund.
CR Alves CJ, 2015, FRONT CELL NEUROSCI, V9, DOI [10.3389/fncel.2015.00332, 10.3389/fncel.2015.00289]
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Berardo A, 2020, J NEUROL, V267, P823, DOI 10.1007/s00415-019-09619-z
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Carroll J.D., 2001, INT ENCY SOCIAL BEHA, P10189
   EISEN A, 1995, MUSCLE NERVE, V18, P741, DOI 10.1002/mus.880180711
   Ferraiuolo L, 2011, NAT REV NEUROL, V7, P616, DOI 10.1038/nrneurol.2011.152
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Fields MA, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100803
   Fields MA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177763
   Fischmeister R, 2005, J PHYSIOL-LONDON, V562, P477, DOI 10.1113/jphysiol.2004.075622
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Galloway CA, 2017, P NATL ACAD SCI USA, V114, pE8214, DOI 10.1073/pnas.1710430114
   Gaudet P, 2017, METHODS MOL BIOL, V1446, P25, DOI 10.1007/978-1-4939-3743-1_3
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Gong J, 2020, STEM CELL TRANSL MED, V9, P364, DOI 10.1002/sctm.19-0321
   Gong J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143272
   Gouras P, 2016, GRAEF ARCH CLIN EXP, V254, P1221, DOI 10.1007/s00417-016-3342-x
   Grassmann F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0418-0
   Guo J, 2018, CURR EYE RES, V43, P647, DOI 10.1080/02713683.2018.1431285
   Hsu CC, 2018, STEM CELL RES, V29, P134, DOI 10.1016/j.scr.2018.03.019
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kaya IE, 2017, COMPUT METH PROG BIO, V140, P19, DOI 10.1016/j.cmpb.2016.11.011
   Landgrebe J, 2002, GENOME BIOL, V3
   Mimaki M, 2012, BBA-BIOENERGETICS, V1817, P851, DOI 10.1016/j.bbabio.2011.08.010
   Nashine S, 2019, EXP EYE RES, V189, DOI 10.1016/j.exer.2019.107701
   Nikolaienko RM, 2016, J BIOL CHEM, V291, P21335, DOI 10.1074/jbc.M116.742163
   Paull D, 2015, NAT METHODS, V12, P885, DOI [10.1038/NMETH.3507, 10.1038/nmeth.3507]
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Poulter N, 1999, AM J HYPERTENS, V12, p92S
   Rizzolo LJ, 2007, MOL VIS, V13, P1259
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   Sheikh Saba, 2013, J Neurodegener Dis, V2013, P563481, DOI 10.1155/2013/563481
   Singh R, 2015, MOL THER, V23, P1700, DOI 10.1038/mt.2015.141
   Singh R, 2013, HUM MOL GENET, V22, P593, DOI 10.1093/hmg/dds469
   Sun H, 2002, P NATL ACAD SCI USA, V99, P4008, DOI 10.1073/pnas.052692999
   Sun Y, 2015, P NATL ACAD SCI USA, V112, P10401, DOI 10.1073/pnas.1504387112
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Tosi GM, 2017, INVEST OPHTH VIS SCI, V58, P162, DOI 10.1167/iovs.16-20922
   Tucker B, 2008, INVEST OPHTH VIS SCI, V49, P1686, DOI 10.1167/iovs.07-1058
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
NR 43
TC 2
Z9 2
U1 0
U2 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUN
PY 2021
VL 207
AR 108576
DI 10.1016/j.exer.2021.108576
EA APR 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SQ8CT
UT WOS:000660578500001
PM 33895162
OA hybrid
DA 2022-11-30
ER

PT J
AU Samkoe, KS
   Clancy, AA
   Karotki, A
   Wilson, BC
   Cramb, DT
AF Samkoe, Kimberley S.
   Clancy, Aisling A.
   Karotki, Aliaksandr
   Wilson, Brian C.
   Cramb, David T.
TI Complete blood vessel occlusion in the chick chorioallantoic membrane
   using two-photon excitation photodynamic therapy: implications for
   treatment of wet age-related macular degeneration
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE age-related macular degeneration; two-photon excitation; photodynamic
   therapy; chorioallantoic membrane
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; IN-VIVO MODEL; TRANSPORT
   FUNCTIONS; VERTEPORFIN; GROWTH; ANGIOGENESIS; CAM; PHOTOSENSITIZERS;
   VESICLES; KINETICS
AB Complete blood vessel occlusion is required for the treatment of age-related macular degeneration (AMD). AMD is the leading cause of blindness in developed countries and current treatment regimes have potential to cause collateral damage, or do not remove pre-existing unwanted vasculature. It has been proposed that two-photon excitation (TPE) photodynamic therapy (PDT) can be applied to cause local blood vessel occlusion without damaging surrounding retinal tissues. The in ovo chicken chorioallantoic membrane (CAM) is used as the model for vascularization in the wet form of AMD; novel techniques for the utilization of the CAM are reported Com. plete occlusion of CAM vessels similar to 15 mu m in diameter is achieved using the clinically approved photosensitizer Verteporfin (Visudyne (R), QLT, Incorporated, Vancouver, British Columbia, Canada) and TPE activation. The average and peak irradiances used for treatment are 3.3 x 10(6) W/cm(2) and 3.7 x 10(11) W/cm(2), respectively. A total fluence of 1.1 x 106 W/cm(2) is the dosage required for successful occlusion, and it is expected that for optimal conditions it will be much less. These results are the first proof-of-principle evidence in the literature that indicate TPE-PDT can be used to occlude small blood vessels. Further investigation will help determine the utility of TPE-PDT for treating wet AMD, perhaps through targeting feeder vessels. (C) 2007 Society of Photo-Optical Instrumentation Engineers.
C1 Univ Calgary, Dept Chem, Calgary, AB T2N 1N4, Canada.
   Univ Toronto, Ontario Canc Inst, Div Biophys & Bioimaging, Toronto, ON, Canada.
C3 University of Calgary; University of Toronto; University Toronto
   Affiliates; University Health Network Toronto
RP Cramb, DT (通讯作者)，Univ Calgary, Dept Chem, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.
EM dcramb@ucalgary.ca
RI Clancy, Aisling A/A-2152-2013
OI Clancy, Aisling/0000-0003-0892-004X; Wilson, Brian
   C./0000-0001-5543-666X
CR Bhawalkar J D, 1997, J Clin Laser Med Surg, V15, P201
   Cramb DT, 2001, PROC SPIE, V4262, P41, DOI 10.1117/12.424585
   DeFouw LM, 2000, MICROVASC RES, V60, P212, DOI 10.1006/mvre.2000.2276
   Fisher WG, 1997, PHOTOCHEM PHOTOBIOL, V66, P141, DOI 10.1111/j.1751-1097.1997.tb08636.x
   Frederiksen PK, 2001, J AM CHEM SOC, V123, P1215, DOI 10.1021/ja003468a
   Ghazi NG, 2001, RETINA-J RET VIT DIS, V21, P478, DOI 10.1097/00006982-200110000-00010
   GOTTFRIED V, 1995, J PHOTOCH PHOTOBIO B, V30, P115, DOI 10.1016/1011-1344(95)07180-A
   Goyan R, 2001, J PHYS CHEM B, V105, P2322, DOI 10.1021/jp0026235
   Goyan RL, 2000, PHOTOCHEM PHOTOBIOL, V72, P821, DOI 10.1562/0031-8655(2000)072<0821:NITPEO>2.0.CO;2
   Gratton E, 2005, BIOPHOTONICS: OPTICAL SCIENCE AND ENGINEERING FOR THE 21ST CENTURY, P1, DOI 10.1007/0-387-24996-6_1
   Gryziewicz L, 2005, ADV DRUG DELIVER REV, V57, P2092, DOI 10.1016/j.addr.2005.09.009
   Hammer-Wilson MJ, 1999, J PHOTOCH PHOTOBIO B, V53, P44, DOI 10.1016/S1011-1344(99)00124-4
   Harding S, 2001, EYE, V15, P407, DOI 10.1038/eye.2001.145
   Hornung R, 1999, J PHOTOCH PHOTOBIO B, V49, P41, DOI 10.1016/S1011-1344(99)00014-7
   Karotki A, 2006, PHOTOCHEM PHOTOBIOL, V82, P443, DOI 10.1562/2005-08-24-RA-657
   Kelly KM, 2004, LASER SURG MED, V34, P407, DOI 10.1002/lsm.20041
   Khurana M, 2006, PROC SPIE, V6343, DOI 10.1117/12.706554
   King BA, 2004, PHOTOCHEM PHOTOBIOL, V80, P1, DOI 10.1562/2004-03-01-RA-093.1
   Klueh U, 2003, J BIOMED MATER RES A, V67A, P838, DOI 10.1002/jbm.a.10059
   Konig K, 1999, P SOC PHOTO-OPT INS, V3592, P43, DOI 10.1117/12.351512
   Kourlas H, 2006, CLIN THER, V28, P36, DOI 10.1016/j.clinthera.2006.01.009
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   Kruk M, 2003, J LUMIN, V105, P45, DOI 10.1016/S0022-2313(03)00096-6
   Lange N, 2001, INVEST OPHTH VIS SCI, V42, P38
   Leonenko ZV, 2000, BBA-BIOMEMBRANES, V1509, P131, DOI 10.1016/S0005-2736(00)00288-1
   Li H, 2006, LASER SURG MED, V38, P754, DOI 10.1002/lsm.20387
   Lim DS, 2006, PHOTOCHEM PHOTOBIOL, V82, P600, DOI 10.1562/2005-09-13-RA-683
   Liu J, 2002, J PHOTOCH PHOTOBIO B, V68, P156, DOI 10.1016/S1011-1344(02)00379-2
   Madsen SJ, 2000, PHOTOCHEM PHOTOBIOL, V72, P128, DOI 10.1562/0031-8655(2000)072<0128:PTOHGS>2.0.CO;2
   Melkonian G, 2000, TOXICOL APPL PHARM, V163, P26, DOI 10.1006/taap.1999.8789
   Patterson GH, 2000, BIOPHYS J, V78, P2159, DOI 10.1016/S0006-3495(00)76762-2
   Pegaz B, 2006, EUR J PHARM SCI, V28, P134, DOI 10.1016/j.ejps.2006.01.008
   Pegaz B, 2005, PHOTOCHEM PHOTOBIOL, V81, P1505, DOI 10.1562/2005-02-23-RA-448
   Reinke MH, 1999, OPHTHALMOLOGY, V106, P1915, DOI 10.1016/S0161-6420(99)90401-3
   Ribatti D, 2001, ANAT RECORD, V264, P317, DOI 10.1002/ar.10021
   Ribatti D, 1999, J CELL SCI, V112, P4213
   Richardson Mary, 2003, Current Drug Targets - Cardiovascular & Haematological Disorders, V3, P155, DOI 10.2174/1568006033481492
   Samkoe KS, 2006, PHOTOCHEM PHOTOBIOL, V82, P152, DOI 10.1562/2005-05-28-RA-549
   Samkoe KS, 2003, J BIOMED OPT, V8, P410, DOI 10.1117/1.1577117
   SANDAU K, 1994, J MICROSC-OXFORD, V175, P205, DOI 10.1111/j.1365-2818.1994.tb03486.x
   Schlatter P, 1997, MICROVASC RES, V54, P65, DOI 10.1006/mvre.1997.2022
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2005, OPHTHALMOLOGY, V112, P2061, DOI 10.1016/j.ophtha.2005.09.007
   Schmidt-Erfurth U, 1998, GRAEF ARCH CLIN EXP, V236, P365, DOI 10.1007/s004170050092
   Schmidt-Erfurth UM, 2002, OPHTHALMOLOGY, V109, P1256, DOI 10.1016/S0161-6420(02)01059-X
   Schneider M, 2000, PROG BIOM O, V1, P60, DOI 10.1117/12.379882
   Schnurrbusch UEK, 2001, BRIT J OPHTHALMOL, V85, P1086, DOI 10.1136/bjo.85.9.1086
   Schwille P, 2001, CELL BIOCHEM BIOPHYS, V34, P383, DOI 10.1385/CBB:34:3:383
   So PTC, 2000, ANNU REV BIOMED ENG, V2, P399, DOI 10.1146/annurev.bioeng.2.1.399
   Soubrane G, 2001, BRIT J OPHTHALMOL, V85, P483, DOI 10.1136/bjo.85.4.483
   Staurenghi G, 1998, OPHTHALMOLOGY, V105, P2297, DOI 10.1016/S0161-6420(98)91232-5
   STEWART ME, 1969, EXP CELL RES, V58, P93, DOI 10.1016/0014-4827(69)90119-0
   Strauss WSL, 1997, J PHOTOCH PHOTOBIO B, V39, P176, DOI 10.1016/S1011-1344(97)00002-X
   Swift JL, 2006, BIOPHYS J, V90, P1396, DOI 10.1529/biophysj.105.069526
   TEREPKA AR, 1969, EXP CELL RES, V58, P107, DOI 10.1016/0014-4827(69)90120-7
   TOBITA S, 1986, ACS SYM SER, P219
   Valdes TI, 2003, J BIOMED MATER RES A, V67A, P215, DOI 10.1002/jbm.a.10055
   Valdes TI, 2002, J BIOMED MATER RES, V62, P273, DOI 10.1002/jbm.10152
   Vargas A, 2004, INT J PHARMACEUT, V286, P131, DOI 10.1016/j.ijpharm.2004.07.029
NR 60
TC 63
Z9 65
U1 0
U2 30
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083-3668
EI 1560-2281
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD MAY-JUN
PY 2007
VL 12
IS 3
AR 034025
DI 10.1117/1.2750663
PG 14
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA 196TG
UT WOS:000248504500029
PM 17614733
OA Bronze
DA 2022-11-30
ER

PT J
AU Bastawrous, A
   Mathenge, W
   Peto, T
   Shah, N
   Wing, K
   Rono, H
   Weiss, HA
   Macleod, D
   Foster, A
   Burton, M
   Kuper, H
AF Bastawrous, Andrew
   Mathenge, Wanjiku
   Peto, Tunde
   Shah, Nisha
   Wing, Kevin
   Rono, Hillary
   Weiss, Helen A.
   Macleod, David
   Foster, Allen
   Burton, Matthew
   Kuper, Hannah
TI Six-Year Incidence and Progression of Age-Related Macular Degeneration
   in Kenya Nakuru Eye Disease Cohort Study
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID 5-YEAR INCIDENCE; RISK-FACTORS; MACULOPATHY
AB IMPORTANCE The incidence of age-related macular degeneration (AMD) is unknown in Africa.
   OBJECTIVE To estimate the 6-year cumulative incidence and progression of AMD in older adults (>= 50 years old) in Nakuru, Kenya.
   DESIGN, SETTING, AND PARTICIPANTS This study assessed a population-based cohort with 6-year follow-up of 4414 participants who had a complete assessment. Random cluster sampling with probability proportionate to size procedures was used to select a representative, cross-sectional sample of adults 50 years and older from January 26, 2007, through November 11, 2008. A 6-year follow-up was undertaken from January 7, 2013, through March 12, 2014. On both occasions, a comprehensive ophthalmic examination was performed that included logMAR visual acuity, digital retinal photography, and grading of images at Moorfields Eye Hospital Reading Centre. Data were collected on general health and risk factors.
   MAIN OUTCOMES AND MEASURES Incident AMD in participants with no AMD at baseline and progression from early to late AMD.
   RESULTS A total of 1453 of the 2900 individuals (50.1%) at risk for AMD were followed up after 6 years (mean [SD] age, 60.7 [8.2] years; 635 female [49.5%]; 799 Kikuyu [62.3%], 324 Kalenjin [25.3%], and 159 other [12.4%]); 1282 had data on AMD status at follow-up. Of these, 202 developed early AMD, and no participants developed late AMD. The 6-year weighted (for loss to follow-up) cumulative incidence of early AMD was 164.2 per 1000 persons (95% CI, 136.7-195.9 per 1000 persons). Two individuals with baseline early AMD from the 142 at risk had developed late AMD at follow-up, with a 6-year cumulative incidence of progression from early to late AMD of 24.5 per 1000 persons (95% CI, 5.0-111.7 per 1000 persons). Cumulative incidence of AMD increased with age (>= 80 years old vs 50-59 years old: 1.8; 95% CI, 0.9-3.5) and was higher in women (female vs male: 1.6; 95% CI, 1.2-2.1) and persons with diabetes (diabetes vs no diabetes: 1.7; 95% CI, 1.0-2.8).
   CONCLUSIONS AND RELEVANCE In Kenya, more than 100 000 estimated new cases of AMD, mainly early AMD, will develop every year in individuals 50 years or older, although a 50% loss to follow-up and wide CIs for progression to late AMD limit definitive conclusions from these findings.
C1 [Bastawrous, Andrew; Rono, Hillary; Foster, Allen; Burton, Matthew; Kuper, Hannah] London Sch Hyg & Trop Med, Int Ctr Eye Hlth, Clin Res Dept, Keppel St, London WC1E 7HT, England.
   [Mathenge, Wanjiku] Rwanda Int Inst Ophthalmol, Kigali, Rwanda.
   [Mathenge, Wanjiku] Dr Agarwals Eye Hosp, Kigali, Rwanda.
   [Peto, Tunde; Wing, Kevin] London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London, England.
   [Peto, Tunde] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Shah, Nisha] Natl Hlth Serv Fdn Trust, Moorfields Eye Hosp, Natl Inst Hlth Res, Biomed Res Ctr, London, England.
   [Shah, Nisha] UCL, Inst Ophthalmol, London, England.
   [Rono, Hillary] Kitale Eye Unit, Kitale, Kenya.
   [Weiss, Helen A.; Macleod, David] London Sch Hyg & Trop Med, Med Res Council Trop Epidemiol Grp, Dept Infect Dis Epidemiol, London, England.
   [Burton, Matthew] Natl Hlth Serv Fdn Trust, Moorfields Eye Hosp, London, England.
C3 University of London; London School of Hygiene & Tropical Medicine;
   University of London; London School of Hygiene & Tropical Medicine;
   Queens University Belfast; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust; University of
   London; University College London; University of London; London School
   of Hygiene & Tropical Medicine; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust
RP Bastawrous, A (通讯作者)，London Sch Hyg & Trop Med, Int Ctr Eye Hlth, Clin Res Dept, Keppel St, London WC1E 7HT, England.
EM andrew.bastawrous@lshtm.ac.uk
RI weiss, helen/ABC-7823-2021; Peto, Tunde/G-8812-2018; MATHENGE,
   WANJIKU/W-3993-2019; Wing, Kevin/I-7807-2015
OI weiss, helen/0000-0003-3547-7936; Peto, Tunde/0000-0001-6265-0381;
   Foster, Allen/0000-0003-2368-4436; Wing, Kevin/0000-0003-2335-9641;
   Macleod, David/0000-0002-2371-5709; Burton, Matthew/0000-0003-1872-9169
FU Medical Research Council [G1001934, G0700837]; Fight for Sight [1310];
   British Council for the Prevention of Blindness; International Glaucoma
   Association; Wellcome Trust [098481/Z/12/Z]; Department for
   International Development; National Institute for Health Research
   Biomedical Research Centre at Moorfields Eye Hospital; University
   College London Institute of Ophthalmology; MRC [G0700837, G1001934]
   Funding Source: UKRI
FX This study was supported by grant G1001934 from the Medical Research
   Council, grant 1310 from Fight for Sight, the British Council for the
   Prevention of Blindness, and the International Glaucoma Association (Dr
   Bastawrous). Dr Burton is supported by grant 098481/Z/12/Z from the
   Wellcome Trust. Dr Weiss is supported by grant G0700837 from the Medical
   Research Council and Department for International Development. Dr Peto
   is supported by National Institute for Health Research Biomedical
   Research Centre at Moorfields Eye Hospital and University College London
   Institute of Ophthalmology.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Bastawrous A, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-60
   Bastawrous A, 2014, TROP MED INT HEALTH, V19, P600, DOI 10.1111/tmi.12276
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Chang MA, 2008, INVEST OPHTH VIS SCI, V49, P2395, DOI 10.1167/iovs.07-1584
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Delcourt C, 2005, AM J OPHTHALMOL, V140, P924, DOI 10.1016/j.ajo.2005.05.002
   Jonasson F, 2005, OPHTHALMOLOGY, V112, P132, DOI 10.1016/j.ophtha.2004.07.020
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mathenge W, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001393
   Pascolini D, 2010, BR J OPHTHALMOL, V96, P614, DOI DOI 10.1136/BJ0PHTHALM0L-2011-300539
   Woo JH, 2009, ACTA OPHTHALMOL, V87, P262, DOI 10.1111/j.1755-3768.2008.01376.x
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
NR 19
TC 10
Z9 10
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUN
PY 2017
VL 135
IS 6
BP 631
EP 638
DI 10.1001/jamaophthalmol.2017.1109
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EX8AT
UT WOS:000403471700026
PM 28494075
OA Green Accepted, hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Silva, R
   Axer-Siegel, R
   Eldem, B
   Guymer, R
   Kirchhof, B
   Papp, A
   Seres, A
   Gekkieva, M
   Nieweg, A
   Pilz, S
AF Silva, Rufino
   Axer-Siegel, Ruth
   Eldem, Bora
   Guymer, Robyn
   Kirchhof, Bernd
   Papp, Andras
   Seres, Andras
   Gekkieva, Margarita
   Nieweg, Annette
   Pilz, Stefan
CA SECURE Study Grp
TI The SECURE Study Long-Term Safety of Ranibizumab 0.5 mg in Neovascular
   Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID VERTEPORFIN PHOTODYNAMIC THERAPY; RANIBIZUMAB; TRIAL
AB Objective: To evaluate long-term safety of intravitreal ranibizumab 0.5-mg injections in neovascular age-related macular degeneration (nAMD).
   Design: Twenty-four-month, open-label, multicenter, phase IV extension study.
   Participants: Two hundred thirty-four patients previously treated with ranibizumab for 12 months in the EXCITE/SUSTAIN study.
   Methods: Ranibizumab 0.5 mg administered at the investigator's discretion as per the European summary of product characteristics 2007 (SmPC, i.e., ranibizumab was administered if a patient experienced a best-corrected visual acuity [BCVA] loss of >5 Early Treatment Diabetic Retinopathy Study letters measured against the highest visual acuity [VA] value obtained in SECURE or previous studies [EXCITE and SUSTAIN], attributable to the presence or progression of active nAMD in the investigator's opinion).
   Main Outcome Measures: Incidence of ocular or nonocular adverse events (AEs) and serious AEs, mean change in BCVA from baseline over time, and the number of injections.
   Results: Of 234 enrolled patients, 210 (89.7%) completed the study. Patients received 6.1 (mean) ranibizumab injections over 24 months. Approximately 42% of patients had 7 or more visits at which ranibizumab was not administered, although they had experienced a VA loss of more than 5 letters, indicating either an undertreatment or that factors other than VA loss were considered for retreatment decision by the investigator. The most frequent ocular AEs (study eye) were retinal hemorrhage (12.8%; 1 event related to study drug), cataract (11.5%; 1 event related to treatment procedure), and increased intraocular pressure (6.4%; 1 event related to study drug). Cataract reported as serious due to hospitalization for cataract surgery occurred in 2.6% of patients; none was suspected to be related to study drug or procedure. Main nonocular AEs were hypertension and nasopharyngitis (9.0% each). Arterial thromboembolic events were reported in 5.6% of the patients. Five (2.1%) deaths occurred during the study, none related to the study drug or procedure. At month 24, mean BCVA declined by 4.3 letters from the SECURE baseline.
   Conclusions: The SECURE study showed that ranibizumab administered as per a VA-guided flexible dosing regimen recommended in the European ranibizumab SmPC at the investigator's discretion was well tolerated over 2 years. No new safety signals were identified in patients who received ranibizumab for a total of 3 years. On average, patients lost BCVA from the SECURE study baseline, which may be the result of disease progression or possible undertreatment.
C1 [Silva, Rufino] Univ Coimbra, Coimbra Univ Hosp, Dept Ophthalmol, Fac Med, P-3000075 Coimbra, Portugal.
   [Silva, Rufino] Assoc Innovat & Biomed Res Light & Image AIBILI, Coimbra, Portugal.
   [Axer-Siegel, Ruth] Rabin Med Ctr, Dept Ophthalmol, Petah Tiqwa, Israel.
   [Axer-Siegel, Ruth] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
   [Eldem, Bora] Hacettepe Univ, Fac Med, Dept Ophthalmol, TR-06100 Ankara, Turkey.
   [Guymer, Robyn] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Kirchhof, Bernd] Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, D-50931 Cologne, Germany.
   [Papp, Andras] Semmelweis Univ Budapest, Dept Ophthalmol, Budapest, Hungary.
   [Seres, Andras] Budapest Retina Associates Kft, Budapest, Hungary.
   [Gekkieva, Margarita; Nieweg, Annette; Pilz, Stefan] Novartis Pharma AG, Basel, Switzerland.
C3 Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra
   (CHUC); Universidade de Coimbra; Rabin Medical Center; Tel Aviv
   University; Sackler Faculty of Medicine; Hacettepe University; Centre
   for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Cologne; Semmelweis University;
   Novartis
RP Silva, R (通讯作者)，Univ Coimbra, Coimbra Univ Hosp, Dept Ophthalmol, Fac Med, Av Bissaya Barreto, P-3000075 Coimbra, Portugal.
EM rufino.silva@oftalmologia.co.pt
RI Hoyng, C.B./H-8050-2014; Silva, Rufino M/J-2817-2012; Casaroli-Marano,
   Ricardo Pedro/D-4535-2014
OI Silva, Rufino M/0000-0001-8676-0833; Casaroli-Marano, Ricardo
   Pedro/0000-0003-1812-9323; Gibson, Jonathan M/0000-0002-9281-5244;
   Guymer, Robyn/0000-0002-9441-4356
FU Allergan; Pfizer; Novartis; THEA; Bayer; Bausch Lomb; Novartis Pharma AG
   Switzerland; Novartis Pharma AG, Basel, Switzerland
FX Rufino Silva: Financial Support - International Advisory Board Member,
   Allergan, Pfizer, Novartis; THEA, Bayer.; Bora Eldem: Financial support,
   advisory board - Novartis, Pfizer, Allergan, Bayer, and Bausch & Lomb.;
   Robyn Guymer: Australian Advisory board - Novartis and Bayer.; Margarita
   Gekkieva: Employee - Novartis Pharma AG Switzerland.; Annette Nieweg:
   Employee - Novartis Pharma AG Switzerland.; Stefan Pilz: Employee -
   Novartis Pharma AG Switzerland.; Sponsored by Novartis Pharma AG, Basel,
   Switzerland, which participated in the design of the study; conducting
   the study; data collection; management, analysis, and interpretation of
   the data; and preparation, review, or approval of the manuscript. The
   study is registered with www.clinicaltrial.gov under number NCT00504959.
   Proprietary or commercial disclosure may be found after the references.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   European Medicines Agency, LUC SUMM PROD CHAR
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schmidt-Erfurth U, 2010, EXPERT OPIN DRUG SAF, V9, P149, DOI 10.1517/14740330903418422
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 22
TC 65
Z9 68
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2013
VL 120
IS 1
BP 130
EP 139
DI 10.1016/j.ophtha.2012.07.026
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 063PI
UT WOS:000313011700020
PM 23021093
DA 2022-11-30
ER

PT J
AU Butler, JM
   Sharif, U
   Ali, M
   McKibbin, M
   Thompson, JP
   Gale, R
   Yang, YC
   Inglehearn, C
   Paraoan, L
AF Butler, Joe M.
   Sharif, Umar
   Ali, Manir
   McKibbin, Martin
   Thompson, Joseph P.
   Gale, Richard
   Yang, Yit C.
   Inglehearn, Chris
   Paraoan, Luminita
TI A missense variant in CST3 exerts a recessive effect on susceptibility
   to age-related macular degeneration resembling its association with
   Alzheimer's disease
SO HUMAN GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; CYSTATIN-C; COMMON VARIANTS; IDENTIFIES
   VARIANTS; LOCI; METAANALYSIS; GENE; POLYMORPHISM; GENOTYPE; REGION
AB Age-related macular degeneration (AMD) and Alzheimer's disease (AD) are degenerative, multifactorial diseases involving age-related accumulation of extracellular deposits linked to dysregulation of protein homeostasis. Here, we strengthen the evidence that an nsSNP (p.Ala25Thr) in the cysteine proteinase inhibitor cystatin C gene CST3, previously confirmed by meta-analysis to be associated with AD, is associated with exudative AMD. To our knowledge, this is the first report highlighting a genetic variant that increases the risk of developing both AD and AMD. Furthermore, we demonstrate that the risk associated with the mutant allele follows a recessive model for both diseases. We perform an AMD-CST3 case-control study genotyping 350 exudative AMD Caucasian individuals. Bringing together our data with the previously reported AMD-CST3 association study, the evidence of a recessive effect on AMD risk is strengthened (OR = 1.89, P = 0.005). This effect closely resembles the AD-CST3 recessive effect (OR = 1.73, P = 0.005) previously established by meta-analysis. This resemblance is substantiated by the high correlation between CST3 genotype and effect size across the two diseases (R (2) = 0.978). A recessive effect is in line with the known function of cystatin C, a potent enzyme inhibitor. Its potency means that, in heterozygous individuals, a single functional allele is sufficient to maintain its inhibitory function; only homozygous individuals will lack this form of proteolytic regulation. Our findings support the hypothesis that recessively acting variants account for some of the missing heritability of multifactorial diseases. Replacement therapy represents a translational opportunity for individuals homozygous for the mutant allele.
C1 [Butler, Joe M.; Sharif, Umar; Paraoan, Luminita] Univ Liverpool, Inst Ageing & Chron Dis, Dept Eye & Vis Sci, Liverpool L69 3GA, Merseyside, England.
   [Ali, Manir; Thompson, Joseph P.; Inglehearn, Chris] Univ Leeds, Ophthalmol & Neurosci, Leeds LS9 7TF, W Yorkshire, England.
   [McKibbin, Martin] St James Univ Hosp, Dept Ophthalmol, Leeds LS9 7TF, W Yorkshire, England.
   [Gale, Richard] York Hosp, Dept Ophthalmol, York YO31 8HE, N Yorkshire, England.
   [Yang, Yit C.] Royal Wolverhampton NHS Trust, Ophthalmol, Wolverhampton WV10 0QP, W Midlands, England.
C3 University of Liverpool; University of Leeds; Saint James's University
   Hospital
RP Paraoan, L (通讯作者)，Univ Liverpool, Inst Ageing & Chron Dis, Dept Eye & Vis Sci, Liverpool L69 3GA, Merseyside, England.
EM lparaoan@liv.ac.uk
RI Ali, Manir/ABE-5251-2020; Paraoan, Luminita/K-1066-2016; Inglehearn,
   Chris/GYD-9783-2022
OI Ali, Manir/0000-0003-3204-3788; Paraoan, Luminita/0000-0001-7568-7116;
   Thompson, Joseph/0000-0002-0254-1295
FU Royal Wolverhamptom Hospitals NHS Trust; AgeUK; Wellcome Trust
   Biomedical Vacation Scholarship
FX The authors acknowledge The Royal Wolverhamptom Hospitals NHS Trust for
   supporting this research. Research in Paraoan laboratory is supported by
   AgeUK. JT was supported by a Wellcome Trust Biomedical Vacation
   Scholarship. Thanks to Dr. Jose Luis Ivorra (Ophthalmology and
   Neuroscience, University of Leeds, UK) for assistance with accessing the
   data from the Exome Variant Server. JB wishes to express gratitude for
   the guidance and inspiration of Prof. Jenny Barrett and Prof. Tim Bishop
   (University of Leeds, UK) within the field of statistics and genetic
   epidemiology.
CR Akerblom A, 2014, AM HEART J, V168, P96, DOI 10.1016/j.ahj.2014.03.010
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Ardeljan D, 2013, EUR J HUM GENET, V21, P1152, DOI 10.1038/ejhg.2013.14
   Bagos PG, 2008, STAT APPL GENET MOL, V7, DOI 10.2202/1544-6115.1408
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   BARRETT AJ, 1984, BIOCHEM BIOPH RES CO, V120, P631, DOI 10.1016/0006-291X(84)91302-0
   Benussi L, 2003, NEUROBIOL DIS, V13, P15, DOI 10.1016/S0969-9961(03)00012-3
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Curtis David, 2013, Adv Appl Bioinform Chem, V6, P29, DOI 10.2147/AABC.S44332
   Escobar MA, 2013, HAEMOPHILIA, V19, P648, DOI 10.1111/hae.12137
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gaudet D, 2013, GENE THER, V20, P361, DOI 10.1038/gt.2012.43
   Gibson G, 2012, NAT REV GENET, V13, P135, DOI 10.1038/nrg3118
   Hageman GS, 2012, AGE RELATED MACULAR
   Harold D, 2009, NAT GENET, V41, P1088, DOI 10.1038/ng.440
   Hollingworth P, 2011, NAT GENET, V43, P429, DOI 10.1038/ng.803
   Hook VYH, 2008, J BIOL CHEM, V283, P7745, DOI 10.1074/jbc.M708362200
   Hua Y, 2012, INT J NEUROSCI, V122, P431, DOI 10.3109/00207454.2012.672502
   Hunt KA, 2013, NATURE, V498, P232, DOI 10.1038/nature12170
   Jun GG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025775
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kaeser SA, 2007, NAT GENET, V39, P1437, DOI 10.1038/ng.2007.23
   Keenan TDL, 2014, JAMA OPHTHALMOL, V132, P63, DOI 10.1001/jamaophthalmol.2013.5696
   Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802
   Lambert JC, 2009, NAT GENET, V41, P1094, DOI 10.1038/ng.439
   Lettre G, 2007, GENET EPIDEMIOL, V31, P358, DOI 10.1002/gepi.20217
   Logue MW, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.12.007
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Mi W, 2007, NAT GENET, V39, P1440, DOI 10.1038/ng.2007.29
   Naj AC, 2011, NAT GENET, V43, P436, DOI 10.1038/ng.801
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   R Core Team, 2014, R LANG ENV STAT COMP
   Ratnayaka A, 2007, EXP EYE RES, V84, P1135, DOI 10.1016/j.exer.2006.01.030
   Seshadri S, 2010, JAMA-J AM MED ASSOC, V303, P1832, DOI 10.1001/jama.2010.574
   The Cochrane Collaboration, 2012, REV MAN REVMAN VERS
   Turner RM, 2000, STAT MED, V19, P3417, DOI 10.1002/1097-0258(20001230)19:24<3417::AID-SIM614>3.3.CO;2-C
   Yang HC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034840
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhao YH, 2015, MOL NEUROBIOL, V52, P533, DOI 10.1007/s12035-014-8886-3
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
NR 42
TC 21
Z9 22
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-6717
EI 1432-1203
J9 HUM GENET
JI Hum. Genet.
PD JUL
PY 2015
VL 134
IS 7
BP 705
EP 715
DI 10.1007/s00439-015-1552-7
PG 11
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA CK0YD
UT WOS:000355930700003
PM 25893795
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Garweg, JG
   Gerhardt, C
   Kodjikian, L
   Pfister, IB
AF Garweg, Justus G.
   Gerhardt, Christin
   Kodjikian, Laurent
   Pfister, Isabel B.
TI Real-Life Experience with Aflibercept and Ranibizumab in the Treatment
   of Newly Diagnosed Neovascular Age-Related Macular Degeneration over 24
   Months
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
DE neovascular age-related macular degeneration; anti-VEGF drugs;
   intravitreal injections; Ranibizumab; Aflibercept; treat-and-extend
   protocol
ID INTRAVITREAL RANIBIZUMAB; SUBGROUP ANALYSIS; OUTCOMES; AMD; BEVACIZUMAB;
   DETACHMENT; RETREATMENT; RESPONDERS; CONVERSION; INJECTION
AB Purpose: Comparative data appertaining to the long-term effects of Aflibercept or Ranibizumab in newly diagnosed cases of neovascular age-related macular degeneration (nAMD) over follow-up periods exceeding 12 months in clinical routine are scarce.
   Methods: In this retrospective comparative analysis, a case series of patients with treatment-naive nAMD and requiring anti-vascular endothelial growth factor (VEGF) therapy in a routine clinical setting were treated with either Aflibercept [Afl (n = 106)] or Ranibizumab [Ran (n = 47)]. During the drug-loading phase, 3 monthly injections were administered. Thereafter, a treat-and-extend protocol was pursued for a maximum of 24 months. Ran was administered predominantly in eyes with classical lesions; Afl was administered in all others. The primary outcome parameters included anatomical and functional stability after 24 months.
   Results: Patients were comparable regarding age, gender distribution, and lens status. Fewer patients presented with intraretinal fluid in the Afl- than in the Ran group at diagnosis (46.2% vs. 67.4%; P = 0.02), but not after the drug-loading phase. After the drug-loading phase, visual acuity [-4.2 letters (Afl) vs. -4.5 letters (Ran); P = 0.78] and the central foveal thickness remained stable. Linked to the lesion type, the number of scheduled clinical visits during the course of 24 months was higher for the Ran-than for the Afl group [11.9 +/- 4.7 visits (Ran) vs. 8.4 +/- 3.1 visits (Afl); P = 0.0005]. However, the total number of injections was similar [10.5 +/- 2.8 (Ran) vs. 11.7 +/- 3.6 (Afl); P = 0.06].
   Conclusions: Based on tailoring according to the lesion type in cases of nAMD, the anatomical and the functional outcomes of treatment with either Afl or Ran were comparable for a maximum of 2 years.
C1 [Garweg, Justus G.; Gerhardt, Christin; Pfister, Isabel B.] Rotkreuz & Berner Augenklin Lindenhofspital, Swiss Eye Inst, Bern, Switzerland.
   [Garweg, Justus G.; Gerhardt, Christin; Pfister, Isabel B.] Univ Bern, Bern, Switzerland.
   [Kodjikian, Laurent] Univ Claude Bernard Lyon 1, Croix Rousse Univ Hosp, Dept Ophthalmol, Lyon, France.
C3 University of Bern; CHU Lyon; UDICE-French Research Universities;
   Universite Claude Bernard Lyon 1
RP Garweg, JG (通讯作者)，Berner Augenklin Lindenhofspital, Swiss Eye Inst, Bremgartenstr 119, CH-3012 Bern, Switzerland.
EM justus.garweg@swiss-eye-institute.com
FU Novartis; Bayer
FX J.G.G. advises several pharmaceutical companies (Alcon, Allergan, Bayer,
   Novartis) and participates in a number of industry-sponsored (Novartis,
   Bayer) and independent international multicenter clinical studies in the
   fields of AMD and diabetic retinopathy. These activities had no bearing
   on the study that gave rise to the submitted article, for which J.G.G.
   received neither direct nor indirect financial support. None of the
   authors have conflicts of interest with any of the presented data.
CR Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Chatziralli I, 2016, OPHTHALMOLOGY, V123, P1762, DOI 10.1016/j.ophtha.2016.05.002
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Fassnacht-Riederle H, 2014, GRAEF ARCH CLIN EXP, V252, P1705, DOI 10.1007/s00417-014-2589-3
   Garweg JG, 2017, OPHTHALMOL RETINA, V1, P210, DOI 10.1016/j.oret.2016.10.017
   Heussen FM, 2014, GRAEF ARCH CLIN EXP, V252, P909, DOI 10.1007/s00417-013-2553-7
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Hoffmann AE, 2016, KLIN MONATSBL AUGENH, V233, P1260, DOI 10.1055/s-0042-101551
   Inoue M, 2016, AM J OPHTHALMOL, V169, P95, DOI 10.1016/j.ajo.2016.06.021
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kim JH, 2016, GRAEF ARCH CLIN EXP, V254, P2101, DOI 10.1007/s00417-016-3353-7
   Messenger WB, 2014, BRIT J OPHTHALMOL, V98, P1205, DOI 10.1136/bjophthalmol-2013-304829
   Parodi MB, 2013, AM J OPHTHALMOL, V155, P103, DOI 10.1016/j.ajo.2012.07.001
   Pinheiro-Costa J, 2015, OPHTHALMOLOGICA, V233, P155, DOI 10.1159/000381221
   Sadda SR, 2010, RETINA-J RET VIT DIS, V30, P1390, DOI 10.1097/IAE.0b013e3181e44599
   Sarraf D, 2016, OPHTHALMOLOGY, V123, P2213, DOI 10.1016/j.ophtha.2016.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Thorell MR, 2014, OSLI RETINA, V45, P526, DOI 10.3928/23258160-20141118-07
   Verner-Cole EA, 2012, DRUG TODAY, V48, P317, DOI 10.1358/dot.2012.48.5.1805931
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   Yazdi MH, 2015, EXPERT OPIN BIOL TH, V16, P1
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 29
TC 10
Z9 10
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD SEP
PY 2017
VL 33
IS 7
BP 567
EP 572
DI 10.1089/jop.2017.0031
PG 6
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA FF8XA
UT WOS:000409299900010
PM 28557667
DA 2022-11-30
ER

PT J
AU Okamoto, T
   Shinoda, H
   Kurihara, T
   Nagai, N
   Tsubota, K
   Ozawa, Y
AF Okamoto, Tomohiro
   Shinoda, Hajime
   Kurihara, Toshihide
   Nagai, Norihiro
   Tsubota, Kazuo
   Ozawa, Yoko
TI Intraoperative and fluorescein angiographic findings of a secondary
   macular hole associated with age-related macular degeneration treated by
   pars plana vitrectomy
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Vitreo-retinal interface; Macular hole
ID INTERNAL-LIMITING MEMBRANE; RANIBIZUMAB; SURGERY
AB Background: Macular hole results from a tractional force at the vitreo-retinal interface which is developed by modification and subsequent degeneration of the posterior precortical vitreous and the internal limiting membrane (ILM). Meanwhile, the wet type of age-related macular degeneration (AMD) is caused by the submacular formation of choroidal neovascularization (CNV). Although exudative changes derived from CNV may cause epiretinal membrane (ERM) formation, which can also cause tractional force at the vitreo-retinal interface, there have been few reports of AMD-associated macular hole development in which the full thickness of the retinal tissue is completely torn by the tractional force. Moreover, intraoperative finding of macular hole associated with AMD with a possible involvement of subretinal lesion has not been described.
   Case presentation: A 78-year-old man diagnosed with wet AMD with subretinal fluid and mild cataract received 8 treatments with intravitreal pegaptanib. After AMD remission, he developed a secondary macular hole in the same eye. He underwent a pars plana vitrectomy that successfully closed the macular hole. Intraoperatively, it was found that the patient's vitreous was formed and that the ERM and ILM were adherent, suggesting the involvement of a tractional force at the vitreo-retinal interface due to an inflammatory reaction related to AMD and/or intravitreally injected chemical compounds, resulting in macular hole development. Changes in the condition of his AMD and the RPE were observed on a fluorescein angiogram (FA) and an indocyanine green angiogram (IA) that preceded macular hole development, suggesting that subretinal changes may also have been involved in the pathogenesis.
   Conclusion: These clinical data, including the intraoperative findings and the temporal changes in the angiograms, suggest that an inflammatory reaction at the vitreo-retinal interface and subretinal lesion related to AMD contribute to the macular hole development in AMD patients treated with intravitreal injection.
C1 [Okamoto, Tomohiro; Shinoda, Hajime; Kurihara, Toshihide; Nagai, Norihiro; Ozawa, Yoko] Keio Univ, Sch Med, Lab Retinal Cell Biol, Shinjuku Ku, Tokyo 1608582, Japan.
   [Okamoto, Tomohiro; Shinoda, Hajime; Kurihara, Toshihide; Nagai, Norihiro; Tsubota, Kazuo; Ozawa, Yoko] Keio Univ, Sch Med, Dept Ophthalmol, Shinjuku Ku, Tokyo 1608582, Japan.
C3 Keio University; Keio University
RP Ozawa, Y (通讯作者)，Keio Univ, Sch Med, Lab Retinal Cell Biol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM ozawa@a5.keio.jp
RI Kurihara, Toshihide/ABA-7058-2020; Ozawa, Yoko/AAH-9888-2020
OI Kurihara, Toshihide/0000-0002-5457-2720; 
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Cornish KS, 2014, OPHTHALMOLOGY, V121, P649, DOI 10.1016/j.ophtha.2013.10.020
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jackson TL, 2013, RETINA-J RET VIT DIS, V33, P1503, DOI 10.1097/IAE.0b013e31829232fd
   Kadonosono K, 2000, ARCH OPHTHALMOL-CHIC, V118, P1116, DOI 10.1001/archopht.118.8.1116
   KISHI S, 1990, ARCH OPHTHALMOL-CHIC, V108, P979, DOI 10.1001/archopht.1990.01070090081044
   Park DW, 1999, OPHTHALMOLOGY, V106, P1392, DOI 10.1016/S0161-6420(99)00730-7
   Querques G, 2009, ACTA OPHTHALMOL, V87, P235, DOI 10.1111/j.1755-3768.2008.01226.x
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Sakamoto T, 2009, GRAEF ARCH CLIN EXP, V247, P1153, DOI 10.1007/s00417-009-1118-2
   Steel DH, 2013, EYE, V27, P212
NR 16
TC 6
Z9 6
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD SEP 30
PY 2014
VL 14
AR 114
DI 10.1186/1471-2415-14-114
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AW5LA
UT WOS:000346315500001
PM 25270019
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU An, E
   Lu, XN
   Flippin, J
   Devaney, JM
   Halligan, B
   Hoffman, E
   Csaky, K
   Hathout, Y
AF An, Eunkyung
   Lu, Xiaoning
   Flippin, Jessica
   Devaney, Joseph M.
   Halligan, Brian
   Hoffman, Eric
   Csaky, Karl
   Hathout, Yetrib
TI Secreted proteome profiling in human RPE cell cultures derived from
   donors with age related macular degeneration and age matched healthy
   donors
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE AMD; retinal pigment epithelial cells; drusen; SILAC; secreted proteins;
   clusterin; complement factor H; SPARC
ID ENDOTHELIAL GROWTH-FACTOR; FACTOR-H POLYMORPHISM; AMINO-ACIDS; MATRIX
   METALLOPROTEINASES; EXTRACELLULAR-MATRIX; BINDING-PROTEIN; BRUCHS
   MEMBRANE; DRUSEN; EXPRESSION; CLUSTERIN
AB Age-related macular degeneration (AMD) is characterized by progressive loss of central vision, which is attributed to abnormal accumulation of macular deposits called "drusen" at the interface between the basal surface of the retinal pigment epithelium (RPE) and Bruch's membrane. In the most severe cases, drusen deposits are accompanied by the growth of new blood vessels that breach the RPE layer and invade photoreceptors. In this study, we hypothesized that RPE secreted proteins are responsible for drusen formation and choroidal neovascularization. We used stable isotope labeling by amino acids in cell culture (SILAC) in combination with LC-MS/MS analysis and ZoomQuant quantification to assess differential protein secretion by RPE cell cultures prepared from human autopsy eyes of AMD donors (diagnosed by histological examinations of the macula and genotyped for the Y402H-complement factor H variant) and age-matched healthy control donors. In general, RPE cells were found to secrete a variety of extracellular matrix proteins, complement factors, and protease inhibitors that have been reported to be major constituents of drusen (hallmark deposits in AMD). Interestingly, RPE cells from AMD donors secreted 2 to 3-fold more galectin 3 binding protein, fibronectin, clusterin, matrix metalloproteinase-2 and pigment epithelium derived factor than RPE cells from age-matched healthy donors. Conversely, secreted protein acidic and rich in cysteine (SPARC) was found to be down regulated by 2-fold in AMD RPE cells versus healthy RPE cells. Ingenuity pathway analysis grouped these differentially secreted proteins into two groups; those involved in tissue development and angiogenesis and those involved in complement regulation and protein aggregation such as clusterin. Overall, these data strongly suggest that RPE cells are involved in the biogenesis of drusen and the pathology of AMD.
C1 Childrens Natl Med Ctr, Ctr Genet Med, Washington, DC 20010 USA.
   George Washington Univ, Inst Biomed Sci, Program Biochem & Mol Genet, Washington, DC 20052 USA.
   Med Coll Wisconsin, Bioinformat Human & Mol Genet Ctr, Milwaukee, WI 53226 USA.
   NIH, NEI, Bethesda, MD 20892 USA.
C3 Children's National Health System; George Washington University; Medical
   College of Wisconsin; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI)
RP Hathout, Y (通讯作者)，Childrens Natl Med Ctr, Ctr Genet Med, Washington, DC 20010 USA.
EM yhathout@cnmcresearch.org
RI Halligan, Brian/N-5166-2015
OI Halligan, Brian/0000-0002-9553-4253; Hoffman, Eric/0000-0001-6470-5139
FU Intramural NIH HHS Funding Source: Medline
CR ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   Alexander JJ, 2005, J AM SOC NEPHROL, V16, P52, DOI 10.1681/ASN.2004090778
   Alge CS, 2003, INVEST OPHTH VIS SCI, V44, P3629, DOI 10.1167/iovs.02-1225
   Algvere PV, 2003, ACTA OPHTHALMOL SCAN, V81, P427, DOI 10.1034/j.1600-0420.2003.00157.x
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bailey RW, 2001, BIOCHEMISTRY-US, V40, P11828, DOI 10.1021/bi010135x
   Blagoev B, 2003, NAT BIOTECHNOL, V21, P315, DOI 10.1038/nbt790
   Bok D, 2002, P NATL ACAD SCI USA, V99, P14619, DOI 10.1073/pnas.242607899
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Chlenski A, 2002, CANCER RES, V62, P7357
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   DeMattos RB, 2002, P NATL ACAD SCI USA, V99, P10843, DOI 10.1073/pnas.162228299
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eichler W, 2002, INVEST OPHTH VIS SCI, V43, P2767
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Everley PA, 2004, MOL CELL PROTEOMICS, V3, P729, DOI 10.1074/mcp.M400021-MCP200
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1206, DOI 10.1016/0002-9394(71)90964-0
   Foster LJ, 2006, J PROTEOME RES, V5, P64, DOI 10.1021/pr0502626
   Gao GQ, 2002, J BIOL CHEM, V277, P9492, DOI 10.1074/jbc.M108004200
   Gehrmann ML, 2004, J PROTEOME RES, V3, P1063, DOI 10.1021/pr049906k
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gronborg M, 2006, MOL CELL PROTEOMICS, V5, P157, DOI 10.1074/mcp.M500178-MCP200
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   Gruhler A, 2005, MOL CELL PROTEOMICS, V4, P1697, DOI 10.1074/mcp.M500190-MCP200
   Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720
   Hageman G.S., 1999, MOL VIS, V3, P25
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Halligan BD, 2005, J AM SOC MASS SPECTR, V16, P302, DOI 10.1016/j.jasms.2004.11.014
   Hathout Y, 2005, J PROTEOME RES, V4, P620, DOI 10.1021/pr049749p
   Hiscott P, 2002, EYE, V16, P393, DOI 10.1038/sj.eye.6700196
   Hittel DS, 2003, J PHYSIOL-LONDON, V548, P401, DOI 10.1113/jphysiol.2002.036616
   Hoffman EP, 2004, NAT REV GENET, V5, P229, DOI 10.1038/nrg1297
   Ibarrola N, 2003, ANAL CHEM, V75, P6043, DOI 10.1021/ac034931f
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   LESCHEY KH, 1990, INVEST OPHTH VIS SCI, V31, P839
   Leu ST, 2002, EXP EYE RES, V74, P141, DOI 10.1006/exer.2001.1112
   Livak KJ, 1999, GENET ANAL-BIOMOL E, V14, P143, DOI 10.1016/S1050-3862(98)00019-9
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Martin G, 2004, GRAEF ARCH CLIN EXP, V242, P321, DOI 10.1007/s00417-003-0838-y
   Murata T, 1996, LAB INVEST, V74, P819
   NEWSOME DA, 1987, AM J OPHTHALMOL, V104, P373, DOI 10.1016/0002-9394(87)90227-3
   Nozaki M, 2006, J CLIN INVEST, V116, P422, DOI 10.1172/JCI26316
   Ong SE, 2003, METHODS, V29, P124, DOI 10.1016/S1046-2023(02)00303-1
   Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200
   Pauleikhoff D, 1990, Fortschr Ophthalmol, V87, P429
   Plantner JJ, 1998, EXP EYE RES, V67, P637, DOI 10.1006/exer.1998.0552
   ROSENBERG ME, 1995, INT J BIOCHEM CELL B, V27, P633, DOI 10.1016/1357-2725(95)00027-M
   Sage EH, 2003, J BIOL CHEM, V278, P37849, DOI 10.1074/jbc.M302946200
   Sakaguchi H, 2002, EXP EYE RES, V74, P547, DOI 10.1006/exer.2002.1186
   Sasaki T, 1998, EMBO J, V17, P1606, DOI 10.1093/emboj/17.6.1606
   Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463
   TANIHARA H, 1993, INVEST OPHTH VIS SCI, V34, P413
   Tian Q, 2004, MOL CELL PROTEOMICS, V3, P960, DOI 10.1074/mcp.M400055-MCP200
   VANDERSCHAFT TL, 1993, GRAEF ARCH CLIN EXP, V231, P470, DOI 10.1007/BF02044234
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zhang GA, 2006, J PROTEOME RES, V5, P581, DOI 10.1021/pr050362b
NR 64
TC 105
Z9 110
U1 0
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD OCT 6
PY 2006
VL 5
IS 10
BP 2599
EP 2610
DI 10.1021/pr060121j
PG 12
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 091UF
UT WOS:000241053100012
PM 17022631
DA 2022-11-30
ER

PT J
AU Marazita, MC
   Duguor, A
   Marquioni-Ramella, MD
   Figueroa, JM
   Suburo, AM
AF Marazita, Mariela C.
   Duguor, Andrea
   Marquioni-Ramella, Melisa D.
   Figueroa, Juan M.
   Suburo, Angela M.
TI Oxidative stress-induced premature senescence dysregulates VEGF and CFH
   expression in retinal pigment epithelial cells: Implications for
   Age-related Macular Degeneration
SO REDOX BIOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; ENDOTHELIAL GROWTH-FACTOR; C-REACTIVE PROTEIN;
   CELLULAR SENESCENCE; DNA-DAMAGE; SECRETORY PHENOTYPE; AQUEOUS-HUMOR;
   CIGARETTE-SMOKING; RISK; EYES
AB Oxidative stress has a critical role in the pathogenesis of Age-related Macular Degeneration (AMD), a multifactorial disease that includes age, gene variants of complement regulatory proteins and smoking as the main risk factors. Stress-induced premature cellular senescence (SIPS) is postulated to contribute to this condition. In this study, we hypothesized that oxidative damage, promoted by endogenous or exogenous sources, could elicit a senescence response in RPE cells, which would in turn dysregulate the expression of major players in AMD pathogenic mechanisms. We showed that exposure of a human RPE cell line (ARPE-19) to a cigarette smoke concentrate (CSC), not only enhanced Reactive Oxygen Species (ROS) levels, but also induced 8-Hydroxydeoxyguanosine-immunoreactive (8-OHdG) DNA lesions and phosphorylated-Histone 2AX-immunoreactive (p-H2AX) nuclear foci. CSC-nuclear damage was followed by premature senescence as shown by positive senescence associated-beta-galactosidase (SA-beta-Gal) staining, and p16(INK4a) and p21(Waf-Cip1) protein upregulation. N-acetylcysteine (NAC) treatment, a ROS scavenger, decreased senescence markers, thus supporting the role of oxidative damage in CSC-induced senescence activation. ARPE-19 senescent cultures were also established by exposure to hydrogen peroxide (H2O2), which is an endogenous stress source produced in the retina under photo-oxidation conditions. Senescent cells upregulated the proinflammatory cytokines IL-6 and IL-8, the main markers of the senescence-associated secretory phenotype (SASP). Most important, we show for the first time that senescent ARPE-19 cells upregulated vascular endothelial growth factor (VEGF) and simultaneously downregulated complement factor H (CFH) expression. Since both phenomena are involved in AMD pathogenesis, our results support the hypothesis that SIPS could be a principal player in the induction and progression of AMD. Moreover, they would also explain the striking association of this disease with cigarette smoking. (C) 2015 The Authors. Published by Elsevier B.V.
C1 [Marazita, Mariela C.; Marquioni-Ramella, Melisa D.; Suburo, Angela M.] Univ Austral, Fac Ciencias Biomed, Cell & Mol Med, Pilar, Argentina.
   [Duguor, Andrea; Figueroa, Juan M.] Fdn Pablo Cassara, Buenos Aires, DF, Argentina.
C3 Austral University
RP Suburo, AM (通讯作者)，Univ Austral, Fac Ciencias Biomed, Cell & Mol Med, B1629AHJ, Pilar, Argentina.
EM amsuburo@austral.edu.ar
OI Marquioni Ramella, Melisa Daniela/0000-0003-3377-9789
FU Universidad Austral; CONICET; Ministerio de Ciencia, Tecnologia e
   Innovacion Productiva, Argentina [PICT 2010-2632, PICT 2013-3200];
   Fundacion Pablo Cassara
FX MCM and AMS are members of the Research Career, Consejo Nacional de
   Investigaciones Cientificas y Tecnologicas (CONICET) Argentina. MDMR is
   a Research Fellow supported by Universidad Austral and CONICET. Funding
   for this research was provided by the Ministerio de Ciencia, Tecnologia
   e Innovacion Productiva, Argentina (PICT 2010-2632 and PICT 2013-3200),
   Universidad Austral and Fundacion Pablo Cassara.
CR Abdelmohsen K, 2015, WIRES RNA, V6, P615, DOI 10.1002/wrna.1297
   Ablonczy Z, 2014, FASEB J, V28, P2369, DOI 10.1096/fj.13-248021
   Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Aoshiba K, 2012, EUR RESPIR J, V39, P1368, DOI 10.1183/09031936.00050211
   Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhayadia R, 2015, J Gerontol Series A Biol Sci, V71, P1
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Bischof O, 2015, IUBMB LIFE, V67, P255, DOI 10.1002/iub.1373
   Bora NS, 2015, MOL IMMUNOL, V63, P176, DOI 10.1016/j.molimm.2014.07.012
   Cadet J, 2010, FREE RADICAL BIO MED, V49, P9, DOI 10.1016/j.freeradbiomed.2010.03.025
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233
   Campisi J, 2014, INTERD T GERONT GERI, V39, P45, DOI 10.1159/000358899
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Cao LN, 2013, INVEST OPHTH VIS SCI, V54, P3738, DOI 10.1167/iovs.13-11612
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chinta SJ, 2015, EXP GERONTOL, V68, P3, DOI 10.1016/j.exger.2014.09.018
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   Coppe JP, 2006, J BIOL CHEM, V281, P29568, DOI 10.1074/jbc.M603307200
   Coppe JP, 2011, J BIOL CHEM, V286, P36396, DOI 10.1074/jbc.M111.257071
   Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fossel M, 2002, ANN NY ACAD SCI, V959, P14, DOI 10.1111/j.1749-6632.2002.tb02078.x
   Glotin AL, 2008, FREE RADICAL BIO MED, V44, P1348, DOI 10.1016/j.freeradbiomed.2007.12.023
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P537, DOI 10.1136/bjo.2007.123190
   Honda S, 2002, BRIT J OPHTHALMOL, V86, P159, DOI 10.1136/bjo.86.2.159
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Jones DP, 2015, REDOX BIOL, V5, P71, DOI 10.1016/j.redox.2015.03.004
   Jubri Z, 2013, NUTR J, V12, DOI 10.1186/1475-2891-12-2
   Kabasawa S, 2011, OPHTHALMOLOGY, V118, P1082, DOI 10.1016/j.ophtha.2010.10.012
   Kasibhatla S., 2006, ACRIDINE ORANGE ETHI
   Kent DL, 2014, MOL VIS, V20, P46
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610
   Lamb TD, 2006, INVEST OPHTH VIS SCI, V47, P5138, DOI 10.1167/iovs.06-0849
   Lechanteur YTE, 2015, JAMA OPHTHALMOL, V133, P533, DOI 10.1001/jamaophthalmol.2015.18
   Lee SF, 2011, METHOD CELL BIOL, V103, P99, DOI 10.1016/B978-0-12-385493-3.00005-X
   Leung KW, 2009, MOL IMMUNOL, V46, P1374, DOI 10.1016/j.molimm.2008.12.001
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu CQ, 2015, INT J MOL MED, V35, P169, DOI 10.3892/ijmm.2014.1993
   Liu J, 2015, AM J PHYSIOL-CELL PH, V308, pC621, DOI 10.1152/ajpcell.00096.2014
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Lykkesfeldt J, 2000, AM J CLIN NUTR, V71, P530
   Lyzogubov VV, 2010, AM J PATHOL, V177, P1870, DOI 10.2353/ajpath.2010.091168
   Marin-Castano ME, 2006, INVEST OPHTH VIS SCI, V47, P4098, DOI 10.1167/iovs.05-1230
   Marquioni-Ramella MD, 2015, PHOTOCH PHOTOBIO SCI, V14, P1560, DOI 10.1039/c5pp00188a
   Matsunaga H, 1999, INVEST OPHTH VIS SCI, V40, P197
   Miao H, 2012, MOL VIS, V18, P574
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Mishima K, 1999, INVEST OPHTH VIS SCI, V40, P1590
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Nakamura AJ, 2008, EPIGENET CHROMATIN, V1, DOI 10.1186/1756-8935-1-6
   Naylor RM, 2013, CLIN PHARMACOL THER, V93, P105, DOI 10.1038/clpt.2012.193
   Neuner B, 2009, ADDICT BEHAV, V34, P938, DOI 10.1016/j.addbeh.2009.05.015
   O'Loghlen A, 2015, AGING CELL, V14, P1113, DOI 10.1111/acel.12404
   Olivieri F, 2015, ONCOTARGET, V6, P35509, DOI 10.18632/oncotarget.5899
   Ovadya Y, 2014, BIOGERONTOLOGY, V15, P627, DOI 10.1007/s10522-014-9529-9
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Patil CK, 2005, MECH AGEING DEV, V126, P1040, DOI 10.1016/j.mad.2005.08.001
   PRYOR WA, 1990, FREE RADICAL BIO MED, V8, P275, DOI 10.1016/0891-5849(90)90075-T
   Rippe C, 2012, EXP GERONTOL, V47, P45, DOI 10.1016/j.exger.2011.10.004
   Rippo MR, 2014, EXP GERONTOL, V56, P154, DOI 10.1016/j.exger.2014.03.002
   Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Sene A, 2015, TRENDS MOL MED, V21, P43, DOI 10.1016/j.molmed.2014.10.005
   Serrano M, 2015, TRENDS CELL BIOL, V25, P634, DOI 10.1016/j.tcb.2015.09.011
   Siemerink MJ, 2010, DEV OPHTHALMOL, V46, P4, DOI 10.1159/000320006
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Succoio M, 2015, J PROTEOMICS, V128, P18, DOI 10.1016/j.jprot.2015.07.010
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Tchkonia T, 2013, J CLIN INVEST, V123, P966, DOI 10.1172/JCI64098
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tsai YY, 2008, INVEST OPHTH VIS SCI, V49, P693, DOI 10.1167/iovs.07-0125
   Velarde MC, 2013, INTERD TOP GERONTOL, V38, P17, DOI 10.1159/000343572
   Wang Z, 2013, METHODS MOL BIOL, V1048, P135, DOI 10.1007/978-1-62703-556-9_11
   Winkler B S, 1999, Mol Vis, V5, P32
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodell A, 2014, ADV EXP MED BIOL, V801, P301, DOI 10.1007/978-1-4614-3209-8_38
   YAMASHITA H, 1992, RETINA-J RET VIT DIS, V12, P59, DOI 10.1097/00006982-199212010-00012
   Yu AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048501
   Yu AL, 2009, INVEST OPHTH VIS SCI, V50, P926, DOI 10.1167/iovs.07-1003
   Zhou HW, 2004, RHEUMATOLOGY, V43, P555, DOI 10.1093/rheumatology/keh127
   Zhu DH, 2009, J BIOL CHEM, V284, P9529, DOI 10.1074/jbc.M809393200
NR 93
TC 122
Z9 125
U1 1
U2 89
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-2317
J9 REDOX BIOL
JI Redox Biol.
PD APR
PY 2016
VL 7
BP 78
EP 87
DI 10.1016/j.redox.2015.11.011
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DA0JB
UT WOS:000367482300010
PM 26654980
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Coleman, AL
   Seitzman, RL
   Cummings, SR
   Yu, F
   Cauley, JA
   Ensrud, KE
   Stone, KL
   Hochberg, MC
   Pedula, KL
   Thomas, EL
   Mangione, CM
AF Coleman, Anne L.
   Seitzman, Robin L.
   Cummings, Steven R.
   Yu, Fei
   Cauley, Jane A.
   Ensrud, Kristine E.
   Stone, Katie L.
   Hochberg, Marc C.
   Pedula, Kathryn L.
   Thomas, Edgar L.
   Mangione, Carol M.
CA Study Osteoporotic Fractures Res G
TI The Association of Smoking and Alcohol Use With Age-related Macular
   Degeneration in the Oldest Old: The Study of Osteoporotic Fractures
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER DAM EYE; BLUE MOUNTAINS EYE; RISK-FACTORS; CIGARETTE-SMOKING;
   5-YEAR INCIDENCE; WHITE WOMEN; MACULOPATHY; PREVALENCE; CONSUMPTION;
   METAANALYSIS
AB PURPOSE: To estimate the incidence of age-related macular degeneration (AMD) and the association of smoking and alcohol in a population of older women.
   DESIGN: Prospective cohort study.
   METHODS: Subjects were women who attended the Study of Osteoporotic Fractures year-10 and year-15 follow,up clinic visits and had fundus photographs taken at both visits (n = 1958; 245 Black and 1713 White subjects; mean age at year 10 visit, 78.2 years). Forty, five degree stereoscopic fundus photographs were graded for AMD. Logistic regression was used to test whether risk factors were associated with incident AMD.
   RESULTS: The overall 5-year AMD incidence was 24.1% (95% confidence interval [CI], 21.7 to 26.6) for early and 5.7% (95% Cl, 4.6 to 6.8) for late. Early AMD incidence in White subjects ranged from 21.9% in those aged 74 to 79 years to 33.2% in those 80 to 84 years, but was observed at the slightly lower rate of 29.0% in subjects >= 85 years (trend P < .0001). After confounder adjustment, alcohol consumption was significantly associated with an elevated risk of incident early AMD (odds ratio [OR], 1.57; 95% CI, 1.18 to 2.11). There was an increased risk of early AMD among subjects aged 80 years or older who were smoking compared to those younger than 80 years who were not smoking (OR, 5.49; 95% CI, 1.57 to 19.20; P for interaction = .026).
   CONCLUSIONS: The magnitude of the greater-than additive effect of smoking on the age-adjusted risk of AMD reinforces recommendations to quit smoking even for older individuals. (Am J Ophthalmol 2010;149: 160-169. (c) 2010 by Elsevier Inc. All rights reserved.)
C1 [Coleman, Anne L.; Seitzman, Robin L.; Yu, Fei] Univ Calif Los Angeles, Dept Ophthalmol, Jules Stein Eye Inst, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   [Coleman, Anne L.] Univ Calif Los Angeles, Dept Epidemiol, Sch Publ Hlth, Los Angeles, CA 90095 USA.
   [Yu, Fei] Univ Calif Los Angeles, Dept Biostat, Sch Publ Hlth, Los Angeles, CA 90095 USA.
   [Cummings, Steven R.; Stone, Katie L.] Calif Pacific Med Ctr Res Inst, San Francisco Coordinating Ctr, San Francisco, CA USA.
   [Cauley, Jane A.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
   [Ensrud, Kristine E.] Univ Minnesota, Vet Affairs Med Ctr, Minneapolis, MN USA.
   [Ensrud, Kristine E.] Univ Minnesota, Dept Med, Minneapolis, MN USA.
   [Ensrud, Kristine E.] Univ Minnesota, Dept Epidemiol, Minneapolis, MN USA.
   [Hochberg, Marc C.] Univ Maryland, Div Rheumatol, Baltimore, MD 21201 USA.
   [Pedula, Kathryn L.] Kaiser Permanente Ctr Hlth Res, Portland, OR USA.
   [Thomas, Edgar L.] RetinaVitreous Associates Med Grp, Beverly Hills, CA USA.
   [Mangione, Carol M.] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; University of California System; University of
   California Los Angeles; California Pacific Medical Center; California
   Pacific Medical Center Research Institute; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); University of Pittsburgh; University
   of Minnesota System; University of Minnesota Twin Cities; US Department
   of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis
   VA Health Care System; University of Minnesota System; University of
   Minnesota Twin Cities; University of Minnesota System; University of
   Minnesota Twin Cities; University System of Maryland; University of
   Maryland Baltimore; Kaiser Permanente; University of California System;
   University of California Los Angeles; University of California Los
   Angeles Medical Center; David Geffen School of Medicine at UCLA
RP Coleman, AL (通讯作者)，Univ Calif Los Angeles, Dept Ophthalmol, Jules Stein Eye Inst, David Geffen Sch Med, 100 Stein Plaza, Los Angeles, CA 90095 USA.
EM colemana@ucla.edu
OI Cauley, Jane A/0000-0003-0752-4408; Ensrud, Kristine/0000-0002-9069-3036
FU NATIONAL INSTITUTES OF HEALTH, BETHESDA, MARYLAND [EY013626-03, AG05407,
   AR35582, AGO5394, AR35584, AR35583, R01 AG005407, R01 AG027576-22, 2 R01
   AG005394-22A1, 2 R01 A0027574-22A1]; Research to Prevent Blindness, New
   York, New York; UCLA Center for Health Improvement in Minority Elders
   (CHIME)/Resource Centers for Minority Aging Research (RCMAR), Los
   Angeles, California, National Institutes of Health, National Institute
   of Aging, Bethesda, Maryland [AG-02-004]; NATIONAL EYE INSTITUTE
   [U10EY013626] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582,
   R01AR035584, R01AR035583] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE ON AGING [R01AG005407, R01AG027576, R01AG005394, R01AG027574]
   Funding Source: NIH RePORTER
FX THIS STUDY WAS SUPPORTED BY THE NATIONAL INSTITUTES OF HEALTH, BETHESDA,
   MARYLAND (GRANT NO. EY013626-03), and Research to Prevent Blindness, New
   York, New York. The Study of Osteoporotic Fractures (SOF) is Supported
   by Public Health Service research grants from the National Institutes of
   Health, Bethesda, Maryland (AG05407, AR35582, AGO5394, AR35584, AR35583,
   R01 AG005407, R01 AG027576-22, 2 R01 AG005394-22A1, and 2 R01
   A0027574-22A1). Dr Mangione was Supported by the UCLA Center for Health
   Improvement in Minority Elders (CHIME)/Resource Centers for Minority
   Aging Research (RCMAR), Los Angeles, California, National Institutes of
   Health, National Institute of Aging, Bethesda, Maryland (AG-02-004). The
   authors indicate no financial conflict of interest. Involved in design
   and conduct of study (A.L.C., S.R.C., J.A.C., K.E.E., K.L.S., M.C.H.,
   C.M.M.); collection and management of data (A.L.C., S.R.C., J.A.C.,
   K.E.E., K.L.S., M.C.H., C.M.M.); analysis and interpretation of data
   (A.L.C., R.L.S., S.R.C., F.Y., J.A.C., K.E.E., K.L.S., M.C.H., K.L.P.,
   E.L.T., C.M.M.); and preparation (A.L.C., R.L.S., F.Y.) and review and
   approval of the manuscript (A.L.C., R.L.S., S.R.C., F.Y., J.A.C.,
   K.E.E., K.L.S., M.C.H., K.L.P., E.L.T., C.M.M.). Institutional Review
   Board approvals were obtained from UCLA; UCSF; the University of
   Maryland; the University of Minnesota; Kaiser Permamente Center for
   Health Research Northwest; and the University of Pittsburgh prior to the
   Study. The study complied with the tenets of the Declaration of Helsinki
   related to the treatment of human subjects.
CR Afifi AA, 2007, ANNU REV PUBL HEALTH, V28, P95, DOI 10.1146/annurev.publhealth.28.082206.094100
   Alberg AJ, 2002, TOXICOLOGY, V180, P121, DOI 10.1016/S0300-483X(02)00386-4
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   BETTMAN JW, 1958, ARCH OPHTHALMOL-CHIC, V59, P481
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Cauley JA, 2005, JAMA-J AM MED ASSOC, V293, P2102, DOI 10.1001/jama.293.17.2102
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Lautenschlager NT, 1996, NEUROLOGY, V46, P641, DOI 10.1212/WNL.46.3.641
   Leske MC, 2004, OPHTHALMOLOGY, V111, P706, DOI 10.1016/j.ophtha.2003.07.003
   LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Moss SE, 1998, OPHTHALMOLOGY, V105, P789, DOI 10.1016/S0161-6420(98)95016-3
   Obisesan TO, 1998, J AM GERIATR SOC, V46, P1
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   RITTER LL, 1995, AM J OPHTHALMOL, V120, P190, DOI 10.1016/S0002-9394(14)72607-8
   Rudnicka AR, 2006, INVEST OPHTH VIS SCI, V47, P4254, DOI 10.1167/iovs.06-0299
   Schmidt S, 2005, MOL VIS, V11, P941
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   vanLeeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P955
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
NR 34
TC 31
Z9 33
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2010
VL 149
IS 1
BP 160
EP 169
DI 10.1016/j.ajo.2009.07.025
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 539PY
UT WOS:000273270300024
PM 19796757
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Larsen, M
   Schmidt-Erfurth, U
   Lanzetta, P
   Wolf, S
   Simader, C
   Tokaji, E
   Pilz, S
   Weisberger, A
AF Larsen, Michael
   Schmidt-Erfurth, Ursula
   Lanzetta, Paolo
   Wolf, Sebastian
   Simader, Christian
   Tokaji, Erika
   Pilz, Stefan
   Weisberger, Annemarie
CA MONT BLANC Study Grp
TI Verteporfin plus Ranibizumab for Choroidal Neovascularization in
   Age-related Macular Degeneration Twelve-month MONT BLANC Study Results
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; RANDOMIZED CLINICAL-TRIALS; PHOTODYNAMIC
   THERAPY; DOSING REGIMEN; FACTOR VEGF; EFFICACY; OCCULT
AB Purpose: To compare the efficacy and safety of same-day verteporfin photodynamic therapy (PDT) and intravitreal ranibizumab combination treatment versus ranibizumab monotherapy in neovascular age-related macular degeneration.
   Design: Prospective, multicenter, double-masked, randomized, active-controlled trial.
   Participants: We included 255 patients with all types of active subfoveal choroidal neovascularization.
   Methods: Patients were randomized 1: 1 to as-needed (pro re nata; PRN) combination (standard-fluence verteporfin 6 mg/m(2) PDT and ranibizumab 0.5 mg) or PRN ranibizumab monotherapy (sham infusion [5% dextrose] PDT and ranibizumab 0.5 mg). Patients received 3 consecutive monthly injections followed by PRN retreatments based on protocol-specific retreatment criteria.
   Main Outcome Measures: Mean change in best-corrected visual acuity (BCVA) from baseline to month 12, and the proportion of patients with treatment-free interval >= 3 months at any timepoint after month 2.
   Results: The mean change in BCVA at month 12 was +2.5 and +4.4 letters in the combination and monotherapy groups, respectively (P = 0.0048; difference: - 1.9 letters [95% confidence interval, -5.76 to 1.86], for having achieved noninferiority with a margin of 7 letters). The proportion of patients with a treatment-free interval of >= 3 months at any timepoint after month 2 was high, but did not show a clinically relevant difference between the treatment groups. Secondary efficacy endpoints included the mean number of ranibizumab retreatments after month 2 (1.9 and 2.2 with combination and monotherapy, respectively [P = 0.1373]). The time to first ranibizumab retreatment after month 2 was delayed by 34 days (about 1 monthly visit) with combination (month 6) versus monotherapy (month 5). At month 12, mean +/- standard error central retinal thickness decreased by 115.3 +/- 9.04 mu m in the combination group and 107.7 +/- 11.02 mu m in the monotherapy group. The mean number of verteporfin/sham PDT treatments was comparable in the 2 groups (combination, 1.7; monotherapy, 1.9). The safety profiles of the 2 groups were comparable, with a low incidence of ocular serious adverse events.
   Conclusions: The combination PRN treatment regimen with verteporfin PDT and ranibizumab was effective in achieving BCVA gain comparable with ranibizumab monotherapy; however, the study did not show benefits with respect to reducing the number of ranibizumab retreatment over 12 months. The combination therapy was well tolerated.
C1 [Larsen, Michael] Univ Copenhagen, Glostrup Hosp, Dept Ophthalmol, Glostrup, Denmark.
   [Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, Vienna, Austria.
   [Lanzetta, Paolo] Univ Udine, Dept Ophthalmol, I-33100 Udine, Italy.
   [Wolf, Sebastian] Univ Bern, Inselspital, Dept Ophthalmol, CH-3010 Bern, Switzerland.
   [Simader, Christian] Med Univ Vienna, Vienna Reading Ctr, Vienna, Austria.
   [Tokaji, Erika; Pilz, Stefan] Novartis Pharma AG, Basel, Switzerland.
   [Weisberger, Annemarie] Novartis Pharmaceut, E Hanover, NJ USA.
C3 University of Copenhagen; Medical University of Vienna; University of
   Udine; University of Bern; University Hospital of Bern; Medical
   University of Vienna; Novartis; Novartis
RP Larsen, M (通讯作者)，Univ Copenhagen, Glostrup Hosp, Dept Ophthalmol, Glostrup, Denmark.
EM miclar01@glo.regionh.dk
RI Wolf, Sebastian/B-8782-2008; Larsen, Michael/E-9620-2010
OI Wolf, Sebastian/0000-0002-7467-7028; Larsen,
   Michael/0000-0002-5172-5891; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311; Simader, Christian/0000-0002-1784-2883
FU Alcon; Bayer; Novartis; Novartis Pharma AG, Basel, Switzerland;
   Molecular Partners
FX Ursula Schmidt-Erfurth - Consultant - Alcon, Bayer, Novartis; Lecture
   fees - Alcon, Bayer, Novartis.; Funded by Novartis Pharma AG, Basel,
   Switzerland, and is registered with Clinicaltrials.gov (NCT00433017).;
   Sebastian Wolf - Consultant - Novartis, Molecular Partners, Allergan,
   Bayer; Lecture fees - Novartis and Molecular Partners.
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gollnick SO, 2003, BRIT J CANCER, V88, P1772, DOI 10.1038/sj.bjc.6600864
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kaiser PK, 2007, CURR MED RES OPIN, V23, P477, DOI 10.1185/030079907X167624
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Parmeggiani F, 2008, INVEST OPHTH VIS SCI, V49, P3100, DOI 10.1167/iovs.07-1654
   Parmeggiani F, 2007, PHARMACOGENET GENOM, V17, P1039, DOI 10.1097/FPC.0b013e3282f12a4e
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2005, OPHTHALMOLOGY, V112, P2061, DOI 10.1016/j.ophtha.2005.09.007
   Schmidt-Erfurth U, 2008, BRIT J OPHTHALMOL, V92, P1628, DOI 10.1136/bjo.2007.135277
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Shams Naveed, 2006, Ophthalmol Clin North Am, V19, P335
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Wolf-Schnurrbusch UEK, 2011, ACTA OPHTHALMOL, V89, P585, DOI 10.1111/j.1755-3768.2009.01747.x
NR 25
TC 96
Z9 100
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2012
VL 119
IS 5
BP 992
EP 1000
DI 10.1016/j.ophtha.2012.02.002
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 933XM
UT WOS:000303399800016
PM 22424834
DA 2022-11-30
ER

PT J
AU Pilotto, E
   Vujosevic, S
   Melis, R
   Convento, E
   Sportiello, P
   Alemany-Rubio, E
   Segalina, S
AF Pilotto, Elisabetta
   Vujosevic, Stela
   Melis, Riccardo
   Convento, Enrica
   Sportiello, Patrik
   Alemany-Rubio, Ernesto
   Segalina, Sara
TI Short wavelength fundus autofluorescence versus near-infrared fundus
   autofluorescence, with microperimetric correspondence, in patients with
   geographic atrophy due to age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PROGRESSION; RPE
AB Aim To compare standard short-wavelength fundus autofluorescence (SW-FAF) and near infrared-wavelength fundus autofluorescence (NIR-FAF) in detecting geographic atrophy (GA) secondary to age-related macular degeneration, and its retinal sensitivity impairment.
   Methods Twenty-five consecutive patients (36 eyes) affected by GA were studied by means of fundus autofluorescence imaging, using both SW-FAF (excitation: 488 nm, emission >500 nm) and NIR-FAF (excitation: 787 nm, emission >800 nm). All patients underwent microperimetry to assess fixation characteristics and retinal sensitivity.
   Results In the extrafoveal region, the total hypoautofluorescent (hypo-FAF) area was significantly wider with NIR-FAF than with SW-FAF (8.03 +/- 6.68 mm(2) vs 7.37 +/- 6.34 mm(2) respectively; p=0.005). In the foveal area, the total hypo-FAF area was smaller with NIR-FAF than with SW-FAF (0.19 +/- 0.03 mm(2) versus 0.42 +/- 0.12 mm(2) respectively; p-0.008). Foveal sparing was larger at NIR-FAF compared with SW-FAF (p=0.021). In nine cases (25%) the site of fixation was hypoautofluorescent on SW-FAF, but normal on NIR-FAF with preserved retinal sensitivity.
   Conclusions Standard SW-FAF may overestimate GA in the foveal area, correctly detected by NIR-FAF. In the extrafoveal area, SW-FAF may underestimate GA. Standard SW-FAF should be integrated with NIR FAF when detecting and following GA to avoid inconsistent results and misinterpretation, from both a morphological and functional perspective. Microperimetry helps to quantify retinal sensitivity in GA.
C1 [Pilotto, Elisabetta; Melis, Riccardo; Convento, Enrica; Sportiello, Patrik; Alemany-Rubio, Ernesto; Segalina, Sara] Univ Padua, Dept Ophthalmol, I-35128 Padua, Italy.
   [Vujosevic, Stela; Segalina, Sara] Fdn GB Bietti Oftalmol, IRCCS, Rome, Italy.
   [Alemany-Rubio, Ernesto] Cuban Eye Inst Ramon Pando Ferrer, Havana, Cuba.
C3 University of Padua; IRCCS - Fondazione "G.B. Bietti" per lo Studio e la
   Ricerca in Oftalmologia
RP Pilotto, E (通讯作者)，Univ Padua, Dept Ophthalmol, Via Giustiniani 2, I-35128 Padua, Italy.
EM elisabetta.pilotto@unipd.it
RI Vujosevic, Stela/AAI-4874-2020
OI Vujosevic, Stela/0000-0001-6773-9967
CR Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Gibbs D, 2009, INVEST OPHTH VIS SCI, V50, P4386, DOI 10.1167/iovs.09-3471
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Kayatz P, 2001, INVEST OPHTH VIS SCI, V42, P241
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Kellner S, 2009, AM J OPHTHALMOL, V147, P895, DOI 10.1016/j.ajo.2008.12.023
   Kellner U, 2010, RETINA-J RET VIT DIS, V30, P6, DOI 10.1097/IAE.0b013e3181b8348b
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Leonard DS, 1997, INVEST OPHTH VIS SCI, V38, P1094
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Peters S, 2000, OPHTHALMIC RES, V32, P52, DOI 10.1159/000055589
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 2006, RETINA-J RET VIT DIS, V26, P666, DOI 10.1097/00006982-200607000-00013
   SUNNESS JS, 1995, AM J OPHTHALMOL, V119, P143, DOI 10.1016/S0002-9394(14)73866-8
   Vujosevic S, 2006, INVEST OPHTH VIS SCI, V47, P3044, DOI 10.1167/iovs.05-1141
NR 24
TC 35
Z9 35
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2011
VL 95
IS 8
BP 1140
EP 1144
DI 10.1136/bjo.2010.187344
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 793ST
UT WOS:000292844100021
PM 20974627
DA 2022-11-30
ER

PT J
AU Jain, S
   Kishore, K
   Sharma, YR
AF Jain, Sachin
   Kishore, Kamal
   Sharma, Yog Raj
TI Intravitreal anti-VEGF monotherapy for thick submacular hemorrhage of
   less than 1 week duration secondary to neovascular age-related macular
   degeneration
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Anti-VEGF injections; bevacizumab; neovascular age-related macular
   degeneration; ranibizumab; submacular hemorrhage
ID TISSUE-PLASMINOGEN ACTIVATOR; PARS-PLANA VITRECTOMY; PNEUMATIC
   DISPLACEMENT; SUBRETINAL HEMORRHAGE; MANAGEMENT; RANIBIZUMAB;
   BEVACIZUMAB; MEMBRANE; INJECTION; THERAPY
AB Aim: To investigate the role of anti-VEGF monotherapy in patients with thick submacular hemorrhage (SMH) of <= 1 week duration secondary to neovascular age-related macular degeneration (N-AMD). Materials and Methods: A retrospective chart review of 14 eyes of 14 patients presenting with acute decrease in central vision of <= 1 week duration secondary to a thick SMH measuring >= 2 MPS disk areas from N-AMD was performed. Intravitreal injections of bevacizumab 1.25 mg (13 eyes) or ranibizumab 0.5 mg (1 eye) were given monthly until resolution of SMH and less frequently thereafter, based on treat-and-extend approach utilizing spectral domain optical coherence tomography (SDOCT). Patients with follow-up of >= 6 months were included. Results: Patients presented after a median of 4 (range 1-7) days from the onset of SMH. Mean lesion size was 27.9 mm(2) (range 5.47-100, median 15), with blood comprising 77-98% of the lesion. Presenting visual acuity (VA) ranged from 20/60 to hand motions (median 20/200). Patients received a mean of 11.4 (range 5-20) injections over 18.4 (range 7-50) months. SMH resolved in all eyes in a mean of 4.8 (range 2-8) months. At 6 months follow-up, mean VA gain was -0.54 logMAR (range: -1.5 to +1, Snellen range 20/25-20/400, median 20/100, P = 0.0037), with 11 gaining >= 0.2 logMAR. Mean change in VA from baseline at final follow-up was -0.58 logMAR (range -1.6 to +1, Snellen range 20/30-20/400, median 20/60; P = 0.0022). Conclusion: A good anatomical and visual outcome can be accomplished in patients with thick SMH secondary to N-AMD treated with anti-VEGF monotherapy within 1 week.
C1 [Jain, Sachin; Kishore, Kamal] Univ Illinois, Coll Med, Dept Surg, Chicago, IL 60680 USA.
   [Jain, Sachin; Kishore, Kamal] Illinois Retina Inst, Peoria, IL USA.
   [Sharma, Yog Raj] All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Dept Vitreoretinal Surg, New Delhi 110029, India.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; All India Institute of Medical
   Sciences (AIIMS) New Delhi; Dr. Rajendra Prasad Centre for Ophthalmic
   Sciences
RP Kishore, K (通讯作者)，5016 N Univ St,Suite 106, Peoria, IL 61614 USA.
EM kishorekvn@comcast.net
CR Agarwal M, 2010, INDIAN J OPHTHALMOL, V58, P170, DOI 10.4103/0301-4738.60078
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   Charles S, 2007, VITREOUS MICROSURGER, P168
   Chawla S, 2009, INDIAN J OPHTHALMOL, V57, P155, DOI 10.4103/0301-4738.45511
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   GEHRS KM, 1992, ARCH OPHTHALMOL-CHIC, V110, P833, DOI 10.1001/archopht.1992.01080180105036
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Guthoff R, 2011, RETINA-J RET VIT DIS, V31, P36, DOI 10.1097/IAE.0b013e3181e37884
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hesgaard HB, 2012, ACTA OPHTHALMOL, V90, pe498, DOI 10.1111/j.1755-3768.2011.02352.x
   Levine JP, 2009, RETINA-J RET VIT DIS, V29, P1074, DOI 10.1097/IAE.0b013e3181b09443
   Mahesh Gopalakrishnan, 2003, Indian Journal of Ophthalmology, V51, P349
   Martin DF, 2012, OPHTHALMOLOGY, V119, P1388
   McKibbin M, 2010, EYE, V24, P994, DOI 10.1038/eye.2009.271
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sacu S, 2009, EYE, V23, P1404, DOI 10.1038/eye.2008.267
   Schulze-Bonsel K, 2006, INVEST OPHTH VIS SCI, V47, P1236, DOI 10.1167/iovs.05-0981
   Shah SP, 2009, OPHTHAL SURG LAS IM, V40, P308, DOI 10.3928/15428877-20090430-16
   Singh Preetam, 1999, Indian Journal of Ophthalmology, V47, P254
   Steel DHW, 2011, BRIT J OPHTHALMOL, V95, P1051, DOI 10.1136/bjo.2010.182253
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Thompson John T, 2005, Trans Am Ophthalmol Soc, V103, P98
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Treumer F, 2012, BRIT J OPHTHALMOL, V96, P708, DOI 10.1136/bjophthalmol-2011-300655
   WADE EC, 1990, ARCH OPHTHALMOL-CHIC, V108, P973, DOI 10.1001/archopht.1990.01070090075043
NR 34
TC 5
Z9 5
U1 0
U2 1
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD SEP
PY 2013
VL 61
IS 9
BP 490
EP 496
DI 10.4103/0301-4738.119432
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 239PR
UT WOS:000326038400004
PM 24104707
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Vottonen, P
   Kankaanpaa, E
AF Vottonen, Pasi
   Kankaanpaa, Eila
TI Cost-effectiveness of treating wet age-related macular degeneration at
   the Kuopio University Hospital in Finland based on a two-eye Markov
   transition model
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE aflibercept; bevacizumab; cost-effectiveness; exudative age-related
   macular degeneration; ranibizumab
AB PurposeWet age-related macular degeneration (AMD) is the leading cause of blindness worldwide, which can be treated with regular intraocular anti-vascular endothelial growth factor (VEGF) injections. In this study, we wanted to evaluate whether less frequent injections of aflibercept would make it more cost-effective when compared with ranibizumab and low priced bevacizumab.
   MethodsWe used a two-eye model to simulate the progression and the treatment of the disease. We selected an 8-year period, 3-month cycles and five health states based on the visual acuity of the better-seeing eye. The transition probabilities and utilities attached to the health states were gathered from previous studies. We conducted the analysis from the hospital perspective and we used the health care costs obtained from Kuopio University Hospital. The costs of intraocular adverse events were taken into account.
   ResultsThe incremental cost-effectiveness ratio (ICER) with 3% discount rate (Euro/QALY) for aflibercept compared with monthly bevacizumab was 1801228 and when compared with ranibizumab given as needed, the ICER was minus 3716943. The sensitivity analysis showed that a change of 20% of the estimated model parameters or a longer follow-up period did not influence these conclusions.
   ConclusionA two-eye Markov transition model was developed to analyse the cost-effectiveness of wet AMD treatment, as quality of life years (QALYs) are largely based on thevisual acuity of the better-seeing eye. Monthly injected bevacizumab was the most cost-effective treatment and monthly ranibizumab the least effective.
C1 [Vottonen, Pasi] Kuopio Univ Hosp, Dept Ophthalmol, POB 1777, Kuopio 70211, Finland.
   [Kankaanpaa, Eila] Univ Eastern Finland, Fac Social Sci & Business Studies, Dept Hlth & Social Management, Kuopio, Finland.
C3 Kuopio University Hospital; University of Eastern Finland; University of
   Eastern Finland
RP Vottonen, P (通讯作者)，Kuopio Univ Hosp, Dept Ophthalmol, POB 1777, Kuopio 70211, Finland.
EM pasi.vottonen@kuh.fi
RI Kankaanpää, Eila/AAY-7015-2021
OI Kankaanpää, Eila/0000-0001-5719-5783
NR 0
TC 12
Z9 17
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2016
VL 94
IS 7
BP 652
EP 656
DI 10.1111/aos.13185
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EA5BI
UT WOS:000386631400022
PM 27481048
DA 2022-11-30
ER

PT J
AU Menon, G
   Chandran, M
   Sivaprasad, S
   Chavan, R
   Narendran, N
   Yang, Y
AF Menon, G.
   Chandran, M.
   Sivaprasad, S.
   Chavan, R.
   Narendran, N.
   Yang, Y.
TI Is it necessary to use three mandatory loading doses when commencing
   therapy for neovascular age-related macular degeneration using
   bevacizumab? (BeMOc Trial)
SO EYE
LA English
DT Article
DE bevacizumab; loading dose; age-related macular degeneration; choroidal
   neovascularisation
ID INTRAVITREAL BEVACIZUMAB; RANIBIZUMAB TREATMENT; VISUAL-ACUITY
AB Purpose To determine whether a Pro Re Nata (PRN) regimen with three initial mandatory loading doses results in better functional and anatomical outcome compared with a PRN regimen without initial loading when using intravitreal bevacizumab in patients with minimal classic or occult choroidal neovascularisation secondary to age-related macular degeneration.
   Methods Patients were randomised (1 : 1) to Loading (LD group) or No Loading (NLD group) and treated with open label intravitreal bevacizumab. In the LD group, patients received two mandatory doses after the baseline dose before entering the PRN phase and in the NLD group, patients did not receive mandatory doses after the baseline dose. Six-weekly evaluations were performed up to week 54 and retreatment was done based on OCT criteria. Visual stability and reduction in central retinal thickness were compared between groups.
   Results 49 patients were in the NLD group and 50 patients were in the LD group. At the 12-month end point, 84% of the patients in the LD group achieved visual stability (<15 letter loss) compared with 67% of the patients in the NLD group (P<0.05). The mean reduction in central macular thickness was 105.35 mu m in the LD group and 81.45 mu m in the NLD group (P>0.05). There was no significant difference in scores of VFQ-25 questionnaire testing between the two groups and no serious ocular or systemic side effects were observed.
   Conclusion The results supported our hypothesis that a loading dose leads to slightly better visual stability in terms of proportions of patients experiencing moderate visual loss, but did not support the hypothesised difference in anatomical outcome.
C1 [Menon, G.; Chandran, M.] Frimley Pk NHS Fdn Trust, Frimley GU16 7UJ, Surrey, England.
   [Sivaprasad, S.] Kings Coll Hosp NHS Fdn Trust, London, England.
   [Chavan, R.; Narendran, N.; Yang, Y.] Royal Wolverhampton Hosp NHS Trust, Wolverhampton, W Midlands, England.
C3 King's College Hospital NHS Foundation Trust
RP Menon, G (通讯作者)，Frimley Pk NHS Fdn Trust, Portsmouth Rd, Frimley GU16 7UJ, Surrey, England.
EM geeta.menon@fph-tr.nhs.uk
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659
CR Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   El-Mollayess GM, 2012, AM J OPHTHALMOL, V153, P481, DOI 10.1016/j.ajo.2011.08.018
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Olajumoke S, 2011, CLIN EXP OPHTHALMOL, V39, P3
   Rathore D, 2012, BRIT J VISUAL IMPA, V30, P160, DOI 10.1177/0264619612457926
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Suner IJ, 2011, ASS RES VIS OPHTH AN
   Tufail A, 2010, BMJ-BRIT MED J, V340, pc2459
   Williams TA, 2011, EYE, V25, P1617, DOI 10.1038/eye.2011.224
NR 16
TC 21
Z9 21
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD AUG
PY 2013
VL 27
IS 8
BP 959
EP 963
DI 10.1038/eye.2013.93
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 198AC
UT WOS:000322893000009
PM 23743535
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Korobelnik, JF
   Moore, N
   Blin, P
   Dharmani, C
   Berdeaux, G
AF Korobelnik, Jean-Francois
   Moore, Nicholas
   Blin, Patrick
   Dharmani, Chandrabhan
   Berdeaux, Gilles
TI Estimating the yearly number of eyes with treatable neovascular
   age-related macular degeneration using a direct standardization method
   and a Markov model
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; VERTEPORFIN THERAPY;
   PHOTODYNAMIC THERAPY; NATURAL COURSE; LOW-VISION; BLINDNESS; TAP;
   MACULOPATHY; IMPACT; RISK
AB PURPOSE. To estimate the number of treatable eyes with neovascular subfoveal age-related macular degeneration (ARMD) in France.
   METHODS. A literature search for studies documenting neovascular ARMD incidence rates and direct standardization according to age and gender were performed. Projection to the year 2025 was based on OECD ( Organization for Economic and Co-operation Development) data. A cohort of patients aged 75 years was simulated by a seven-state Markov model. The mean treatment duration was fixed arbitrarily at 2 years. The probability of ARMD in the second eye was fixed at 30% at 5 years. Monthly mortality incidence was modeled from INSEE (Institut National de la Statistique et des Etudes Economiques) mortality tables. The time horizon of the model was 25 years. Sensitivity analyses were performed.
   RESULTS. Based on the Rotterdam Study, 30,192 citizens per year will develop ARMD in one eye. Among them, 17,585 will be neovascular and 13,805 neovascular subfoveal ARMD. Taking into account the second eye, mortality, and a 2-year treatment duration, the number of neovascular subfoveal treatable eyes yearly would be 37,019 by 2025. Treatment duration was the most sensitive parameter. The number of eyes would be 18,899, 53,204, 67,535, and 80,162, for treatment lasting 1, 3, 4, and 5 years, respectively. A 2% yearly increase is expected up to 2025, due to population aging and the 1950s baby boom.
   CONCLUSIONS. According to the study model, the yearly number of subfoveal neovascular ARMD treatable eyes in France will be 37,019 by 2025. Average treatment duration was the most sensitive parameter.
C1 Alcon France, F-92563 Rueil Malmaison, France.
   Conservatoire Natl Arts & Metiers, Paris, France.
   Mattson Jack Grp, St Louis, MO USA.
   INSERM, Unite 657, Bordeaux, France.
   Univ Victor Segalen, Dept Pharmacol, Bordeaux, France.
   Hop Pellegrin, CHU Bordeaux, Dept Ophthalmol, F-33076 Bordeaux, France.
C3 Novartis; Alcon; heSam Universite; Conservatoire National Arts & Metiers
   (CNAM); Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Universite de Bordeaux;
   CHU Bordeaux
RP Berdeaux, G (通讯作者)，Alcon France, 4 Rue Henri St Claire Deville, F-92563 Rueil Malmaison, France.
EM gillesberdeaux@alconlabs.com
RI KOROBELNIK, Jean-Francois/A-5448-2016
OI Blin, Patrick/0000-0003-4005-7928
CR [Anonymous], J OFFICIEL REPUBLIQU
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold JJ, 2000, BRIT MED J, V321, P741, DOI 10.1136/bmj.321.7263.741
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Billotte C, 2004, J CATARACT REFR SURG, V30, P2064, DOI 10.1016/j.jcrs.2004.05.003
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   Brezin Antoine Pierre, 2005, Health Qual Life Outcomes, V3, P27, DOI 10.1186/1477-7525-3-27
   Brezin AP, 2005, ARCH OPHTHALMOL-CHIC, V123, P1117, DOI 10.1001/archopht.123.8.1117
   Brezin AP, 2004, BRIT J OPHTHALMOL, V88, P1330, DOI 10.1136/bjo.2003.039180
   CHANDRA SR, 1974, AM J OPHTHALMOL, V78, P579, DOI 10.1016/S0002-9394(14)76293-2
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   *GESCH ARB, 2001, PHOT THER VERT ALT M
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   HEIER JS, 2006, OPHTHALMOLOGY, V113, P642
   Hjelmgren J, 2001, Value Health, V4, P225, DOI 10.1046/j.1524-4733.2001.43040.x
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MARGHERIO RR, 2000, RETINA, P20325
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   MERGIER J, 1998, B ARIBA, V2, P2
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MOISSEIEV J, 1995, ARCH OPHTHALMOL-CHIC, V113, P185, DOI 10.1001/archopht.1995.01100020069031
   *OECD HLTH DAT, 2005, STAT IND 30 COUNTR
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   ROBINSON R, 1994, BRIT J OPHTHALMOL, V78, P736, DOI 10.1136/bjo.78.10.736
   Rosenberg T, 1996, ACTA OPHTHALMOL SCAN, V74, P399
   *ROYAL NAT I BLIND, 1996, OFF NAT STAT MID 199
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   *SBU, 2001, PHOT TREATM MAC DEG
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Sternberg P, 2003, OPHTHALMOLOGY, V110, P971, DOI 10.1016/S0161-6420(03)00098-8
   STRAHLMAN ER, 1983, ARCH OPHTHALMOL-CHIC, V101, P1191
   TEETERS VW, 1973, AM J OPHTHALMOL, V76, P1
   *UN, 1999, WORLD POP PROSP 1998
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   WORMALD R, 1994, BRIT J OPHTHALMOL, V78, P733, DOI 10.1136/bjo.78.10.733
NR 47
TC 10
Z9 11
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2006
VL 47
IS 10
BP 4270
EP 4276
DI 10.1167/iovs.05-1467
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 088AU
UT WOS:000240784700013
PM 17003415
DA 2022-11-30
ER

PT J
AU Bergmann, M
   Schutt, F
   Holz, FG
   Kopitz, J
AF Bergmann, M
   Schutt, F
   Holz, FG
   Kopitz, J
TI Inhibition of the ATP-driven proton pump in RPE lysosomes by the major
   lipofuscin fluorophore A2-E may contribute to the pathogenesis of
   age-related macular degeneration
SO FASEB JOURNAL
LA English
DT Article
DE retinal disease; ATPase; proton transport; phagocytosis; autophagy
ID RETINAL-PIGMENT EPITHELIUM; DEGRADATIVE FUNCTIONS; MODEL MEMBRANES;
   OUTER SEGMENTS; CELL-SURFACE; A2E; COMPONENT; AUTOPHAGY; ACCUMULATION;
   APOPTOSIS
AB Lipofuscin accumulation in the retinal pigment epithelium (RPE) is associated with various blinding retinal diseases, including age-related macular degeneration (AMD). The major lipofuscin fluorophor A2-E is thought to play an important pathogenetic role. In previous studies A2-E was shown to severely impair lysosomal function of RPE cells. However, the underlying molecular mechanism remained obscure. Using purified lysosomes from RPE cells we now demonstrate that A2-E is a potent inhibitor of the ATP-driven proton pump located in the lysosomal membrane. Such inhibition of proton transport to the lysosomal lumen results in an increase of the lysosomal pH with subsequent inhibition of lysosomal hydrolases. An essential task of the lysosomal apparatus of postmitotic RPE for normal photoreceptor function is phagocytosis and degradation of membranous discs shed from photoreceptor outer segments (POS) and of biomolecules from autophagy. When the lysosomes of cultured RPE cells were experimentally loaded with A2-E, we observed intracellular accumulation of exogenously added POS with subsequent congestion of the phagocytic process. Moreover, the autophagic sequestration of cytoplasmic material was also markedly reduced after A2-E loading. These data support the hypothesis that A2-E-induced lysosomal dysfunction contributes to the pathogenesis of AMD and other retinal diseases associated with excessive lipofuscin accumulation.
C1 Heidelberg Univ, Dept Mol Pathol, D-69120 Heidelberg, Germany.
   Heidelberg Univ, Dept Ophthalmol, D-69120 Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg; Ruprecht Karls University
   Heidelberg
RP Kopitz, J (通讯作者)，Heidelberg Univ, Dept Mol Pathol, Neuenheimer Feld 220, D-69120 Heidelberg, Germany.
EM juergen-kopitz@med.uni-heidelberg.de
CR Bahr BA, 2002, J NEUROCHEM, V83, P481, DOI 10.1046/j.1471-4159.2002.01192.x
   Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200
   Bermann M, 2001, EXP EYE RES, V72, P191
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Brown D, 2002, INT J MED MICROBIOL, V291, P433
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Burke JM, 1998, INVEST OPHTH VIS SCI, V39, P1478
   CARO LHP, 1988, EUR J BIOCHEM, V175, P325, DOI 10.1111/j.1432-1033.1988.tb14200.x
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   DAVIS AA, 1995, INVEST OPHTH VIS SCI, V36, P955
   De S, 2002, J GEN PHYSIOL, V120, P147, DOI 10.1085/jgp.20028566
   DEGUCHI J, 1994, INVEST OPHTH VIS SCI, V35, P568
   Dermine JF, 2001, J BIOL CHEM, V276, P18507, DOI 10.1074/jbc.M101113200
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   Finbow ME, 1997, BIOCHEM J, V324, P697, DOI 10.1042/bj3240697
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   Glazer LC, 2002, OPHTHALMOL CLIN N AM, V15, pviii
   Glazer Liane Clamen, 2002, Ophthalmol Clin North Am, V15, P93, DOI 10.1016/S0896-1549(01)00011-6
   Gong XH, 2001, P NATL ACAD SCI USA, V98, P9104, DOI 10.1073/pnas.161282998
   GORDON AH, 1980, NATURE, V286, P79, DOI 10.1038/286079a0
   GORDON PB, 1986, BIOMED BIOCHIM ACTA, V45, P1635
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   IVY GO, 1984, SCIENCE, V226, P985, DOI 10.1126/science.6505679
   JONAS AJ, 1989, BIOCHIM BIOPHYS ACTA, V984, P257, DOI 10.1016/0005-2736(89)90290-3
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303
   Kopitz J, 1998, J BIOL CHEM, V273, P11205, DOI 10.1074/jbc.273.18.11205
   KOPITZ J, 1994, CLIN CHIM ACTA, V227, P121, DOI 10.1016/0009-8981(94)90141-4
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Lamb LE, 2001, ARCH BIOCHEM BIOPHYS, V393, P316, DOI 10.1006/abbi.2001.2492
   Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   London E, 2002, CURR OPIN STRUC BIOL, V12, P480, DOI 10.1016/S0959-440X(02)00351-2
   LULLMANNRAUCH R, 1981, A GRAEF ARCH KLIN EX, V215, P297, DOI 10.1007/BF00407668
   MACKENZIE AH, 1983, AM J MED, V75, P5, DOI 10.1016/0002-9343(83)91264-0
   Martens JR, 2001, J BIOL CHEM, V276, P8409, DOI 10.1074/jbc.M009948200
   MARTINEZ CM, 1990, CELL BIOL INT REP, V14, P255, DOI 10.1016/S0309-1651(05)80008-6
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Mousavi SA, 2001, BBA-BIOMEMBRANES, V1510, P243, DOI 10.1016/S0005-2736(00)00354-0
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   O'Neill C, 2001, DRUG AGING, V18, P233, DOI 10.2165/00002512-200118040-00001
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Roberts JE, 2002, PHOTOCHEM PHOTOBIOL, V75, P184, DOI 10.1562/0031-8655(2002)075<0184:TROAIP>2.0.CO;2
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SCHNEIDER DL, 2003, METHOD ENZYMOL, V157, P591
   Schneider P, 1997, MICROSC RES TECHNIQ, V36, P253
   Schraermeyer U, 1997, EXP EYE RES, V65, P277, DOI 10.1006/exer.1997.0339
   Schraermeyer U, 1999, PIGM CELL RES, V12, P219, DOI 10.1111/j.1600-0749.1999.tb00755.x
   Schutt F, 2002, GRAEF ARCH CLIN EXP, V240, P983, DOI 10.1007/s00417-002-0558-8
   Schutt F, 2002, FEBS LETT, V528, P217, DOI 10.1016/S0014-5793(02)03312-4
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   SCHUTT F, 2003, IN PRESS INVEST OPHT
   SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200
   Sundelin S, 1998, CURR EYE RES, V17, P851, DOI 10.1076/ceyr.17.8.851.5146
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Taute A, 2002, BIOCHEM BIOPH RES CO, V298, P5, DOI 10.1016/S0006-291X(02)02387-2
   Uhlen P, 2003, ANN NY ACAD SCI, V986, P514, DOI 10.1111/j.1749-6632.2003.tb07237.x
   Wan FY, 2002, ARCH BIOCHEM BIOPHYS, V404, P285, DOI 10.1016/S0003-9861(02)00280-1
   Wassell J, 1999, J BIOL CHEM, V274, P23828, DOI 10.1074/jbc.274.34.23828
   Winchester B G, 2001, Eur J Paediatr Neurol, V5 Suppl A, P11, DOI 10.1053/ejpn.2000.0428
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zang Y, 2001, CELL DEATH DIFFER, V8, P477, DOI 10.1038/sj.cdd.4400843
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
NR 74
TC 166
Z9 180
U1 1
U2 5
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD JAN
PY 2004
VL 18
IS 1
BP 562
EP +
DI 10.1096/fj.03-0289fje
PG 20
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 772EX
UT WOS:000188829300024
PM 14715704
DA 2022-11-30
ER

PT J
AU Neuner, B
   Wellmann, J
   Dasch, B
   Dietzel, M
   Farwick, A
   Stoll, M
   Pauleikhoff, D
   Hense, HW
AF Neuner, Bruno
   Wellmann, Juergen
   Dasch, Burkhard
   Dietzel, Martha
   Farwick, Astrid
   Stoll, Monika
   Pauleikhoff, Daniel
   Hense, Hans-Werner
TI LOC387715, smoking and their prognostic impact on visual functional
   status in age-related macular degeneration - The Muenster Aging and
   Retina Study (MARS) cohort
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE age-related maculopathy; smoking; genes; prognosis; visual functional
   status
ID COMPLEMENT FACTOR-H; QUALITY-OF-LIFE; RISK-FACTORS; MACULOPATHY;
   ASSOCIATION; POLYMORPHISM; PROGRESSION; GENETICS; HISTORY; EYE
AB Purpose: To prospectively evaluate the impact of homozygosity in the A69S-SNP of the LOC387715-gene, smoking history, and their interaction on visual functional status (v-FS) in age-related macular degeneration (AMD). Methods: The Muenster Aging and Retina Study (MARS) cohort (n = 656; 58.8% women, mean age 70.2 years) was followed over a mean of 2.5 years. AMD-status, genotype and smoking history were assessed at baseline. V-FS [from 0 (low) to 100 (unimpaired) points in general-, near- and far-vision], were AMD-status assessed at baseline and at follow-up. Linear models with stepwise adjustments for covariates were used to analyze decline of v-FS over time. Results: In initial models, homozygosity for the A69S-variant was negatively associated with all three dimensions of the v-FS. After including smoking history, ever smoking was negatively associated with declines in near and far vision (-4.82 and -5.12 points, respectively; each p 0.05). In smokers homozygous for the A69S-variant the number of cigarettes smoked per day (smoking intensity) was negatively associated with all three dimensions of the v-FS (interaction term each p 0.05). Time since smoking cessation in former smokers protected against declines in near and far vision. These effects were independent of the AMD-status at baseline. Conclusions: The interaction of homozygosity for the A69S-variant and smoking intensity had a negative impact on general-, near-, and far visual functional status independent of AMD-status. Quitting smoking seemed to have a time-dependent protective effect on near and far vision.
C1 [Neuner, Bruno; Wellmann, Juergen; Dasch, Burkhard; Dietzel, Martha; Farwick, Astrid; Hense, Hans-Werner] Univ Munster, Clin Epidemiol Sect, Inst Epidemiol Social Med, D-48149 Munster, Germany.
   [Dietzel, Martha; Pauleikhoff, Daniel] St Franziskus Hosp, Dept Ophthalmol, Munster, Germany.
   [Stoll, Monika] Univ Munster, Genet Epidemiol Sect, Leibniz Inst Arteriosclerosis Res, Munster, Germany.
C3 University of Munster; St. Franziskus-Hospital; University of Munster
RP Neuner, B (通讯作者)，Univ Munster, Clin Epidemiol Sect, Inst Epidemiol Social Med, D-48149 Munster, Germany.
EM neuner@uni-muenster.de
CR Chakravarthy Usha, 2005, Curr Opin Ophthalmol, V16, P179, DOI 10.1097/01.icu.0000163035.37957.c2
   Dasch B, 2005, OPHTHALMOLOGE, V102, P1057, DOI 10.1007/s00347-005-1225-3
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   FRISON L, 1992, STAT MED, V11, P1685, DOI 10.1002/sim.4780111304
   Fuhs A, 2005, KLIN MONATSBL AUGENH, V222, P649, DOI 10.1055/s-2005-858367
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Goetz SM, 2000, SOZ PRAVENTIV MED, V45, P134, DOI 10.1007/BF01299284
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Harrington J, 2004, PATIENT EDUC COUNS, V52, P7, DOI 10.1016/S0738-3991(03)00017-X
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Leffondre K, 2002, AM J EPIDEMIOL, V156, P813, DOI 10.1093/aje/kwf122
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Neuner B, 2007, ANN EPIDEMIOL, V17, P615, DOI 10.1016/j.annepidem.2007.03.005
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   *SAS, 2000, VERS 9 1
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Weale R, 2006, LANCET, V368, P1235, DOI 10.1016/S0140-6736(06)69512-3
NR 26
TC 13
Z9 13
U1 0
U2 1
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0928-6586
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PY 2008
VL 15
IS 3
BP 148
EP 154
DI 10.1080/09286580802105830
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 318CN
UT WOS:000257069300003
PM 18569809
DA 2022-11-30
ER

PT J
AU Cho, JH
   Park, YJ
   Cho, SC
   Ryoo, NK
   Cho, KH
   Park, SJ
   Park, KH
   Woo, SJ
AF Cho, Joon Hee
   Park, Young Joo
   Cho, Soo Chang
   Ryoo, Na-Kyung
   Cho, Kwan Hyuk
   Park, Sang Jun
   Park, Kyu Hyung
   Woo, Se Joon
TI POSTTREATMENT POLYP REGRESSION AND RISK OF MASSIVE SUBMACULAR HEMORRHAGE
   IN EYES WITH POLYPOIDAL CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; polypoidal choroidal vasculopathy;
   polyp regression; indocyanine green angiography; optical coherence
   tomography; submacular hemorrhage; subretinal hemorrhage; survival
   analysis
ID VERTEPORFIN PHOTODYNAMIC THERAPY; RANIBIZUMAB; MONOTHERAPY; COMBINATION;
   FEATURES; EFFICACY; EVEREST; SAFETY
AB Purpose: To study the association between the risk of massive submacular hemorrhage (SMH) and polyp regression after initial treatment of polypoidal choroidal vasculopathy using long-term follow-up data. Methods: Retrospective study of 223 patients who were diagnosed with polypoidal choroidal vasculopathy and were followed up for up to 11 years. Subjects were categorized into "regression" and "no regression" groups, according to their polyp status after the initial treatment. Kaplan-Meier survival analyses were performed on development of massive SMH. The association between treatment methods and the occurrence of massive SMH was also analyzed. Results: The incidence rates of massive SMH at 3, 6, and 9 years in the "no regression" group were 6.50, 22.59, and 38.03%, respectively, and in the "regression" group were 1.14, 6.47, and 10.92%, respectively (P = 0.005, log-rank test). The hazard ratio of massive SMH was 3.677 for cluster-type polyps and 0.271 for polyp regression after initial treatment. A higher rate of polyp regression was associated with photodynamic therapy (PDT) than anti-VEGF monotherapy (64.4 vs. 33.3%, P < 0.001). Additional anti-VEGF treatments after initial PDT showed lower risk of massive SMH than PDT only. (9.5 vs 38.5%, P = 0.005). Conclusion: The long-term risk of massive SMH after initial treatment on polypoidal choroidal vasculopathy is significantly higher in eyes with persistent polyps than those with regressed polyps. Ophthalmologists should pay attention to the risk of massive SMH and the polyp status when treating polypoidal choroidal vasculopathy.
C1 [Cho, Joon Hee; Park, Young Joo; Cho, Soo Chang; Ryoo, Na-Kyung; Cho, Kwan Hyuk; Park, Sang Jun; Park, Kyu Hyung; Woo, Se Joon] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Bundang Hosp, Seongnam, South Korea.
   [Cho, Joon Hee] Hyemin Eye Hosp, Seoul, South Korea.
   [Cho, Soo Chang] Kyungpook Natl Univ Hosp, Dept Ophthalmol, Daegu, South Korea.
   [Ryoo, Na-Kyung] Vet Hlth Serv Med Ctr, Dept Ophthalmol, Seoul, South Korea.
   [Cho, Kwan Hyuk] Moons Eye Clin, Suwon, South Korea.
C3 Seoul National University (SNU); Kyungpook National University;
   Kyungpook National University Hospital; Veterans Health Service Medical
   Center
RP Woo, SJ (通讯作者)，Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, 82,Gumi Ro 173 Beon Gil, Seongnam Si 13620, Gyeonggi Do, South Korea.
EM sejoon1@snu.ac.kr
FU National Research Foundation of Korea (NRF) - Korean government (MSIP)
   [2016R1D1A1B03934724]
FX Supported by the National Research Foundation of Korea (NRF) grant
   (2016R1D1A1B03934724) funded by the Korean government (MSIP).
CR Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Cho JH, 2016, AM J OPHTHALMOL, V169, P79, DOI 10.1016/j.ajo.2016.06.014
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Kang HM, 2013, AM J OPHTHALMOL, V155, P438, DOI 10.1016/j.ajo.2012.09.020
   Kikushima W, 2017, GRAEF ARCH CLIN EXP, V255, P311, DOI 10.1007/s00417-016-3467-y
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0305-2
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Tang K, 2015, INT J OPHTHALMOL-CHI, V8, P1056, DOI 10.3980/j.issn.2222-3959.2015.05.36
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
NR 16
TC 17
Z9 17
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2020
VL 40
IS 3
BP 468
EP 476
DI 10.1097/IAE.0000000000002384
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LA1RI
UT WOS:000523731700010
PM 30422938
DA 2022-11-30
ER

PT J
AU Tulka, S
   Geis, B
   Baulig, C
   Knippschild, S
   Krummenauer, F
AF Tulka, Sabrina
   Geis, Berit
   Baulig, Christine
   Knippschild, Stephanie
   Krummenauer, Frank
TI Validity of sample sizes in publications of randomised controlled trials
   on the treatment of age-related macular degeneration: cross-sectional
   evaluation
SO BMJ OPEN
LA English
DT Article
ID CLINICAL-TRIALS; JOURNALS; QUALITY
AB Objective The aim of this cross-sectional study was to examine the completeness and accuracy of the reporting of sample size calculations in randomised controlled trial (RCT) publications on the treatment of age-related macular degeneration (AMD).
   Methods A sample of 97 RCTs published between 2004 and 2014 was reviewed for the calculation of their sample size. It was examined whether a (complete) description of the sample size calculation was presented. Furthermore, the sample size was recalculated, whenever possible based on the published details, in order to verify the reported number of patients.
   Primary outcome measure The primary endpoint of this cross-sectional investigation was a described sample size calculation that was reproducible, complete and correct (maximum tolerated deviation between reported and replicated sample size +/- 2 participants per trial arm).
   Results A total of 50 publications (52%) did not provide any information on the justification of the number of patients included. Only 17 publications (18%) provided all the necessary parameters for recalculation; 8 of 97 (8%, 95%-CI: 4% to 16%) publications achieved the primary endpoint. The median relative deviation between reported and recalculated sample sizes was 1%, with a range from -43% to +66%.
   Conclusion Although a transparent sample size legitimation is a crucial determinant of an RCT's methodological validity, more than half of the RCT publications considered failed to report them. Furthermore, reported sample size legitimations were often incomplete or incorrect. In summary, clinical authors should pay more attention to the transparent reporting of sample size calculation, and clinical journal reviewers may opt to reproduce reported sample size calculations.
   Synopsis More than half of the analysed RCT publications on the treatment of AMD did not report a transparent sample size calculation. Only 8% reported a complete and correct sample size calculation.
C1 [Tulka, Sabrina; Geis, Berit; Baulig, Christine; Knippschild, Stephanie; Krummenauer, Frank] Univ Witten Herdecke, Inst Med Biometry & Epidemiol, Fac Hlth, Witten, Germany.
C3 Witten Herdecke University
RP Tulka, S (通讯作者)，Univ Witten Herdecke, Inst Med Biometry & Epidemiol, Fac Hlth, Witten, Germany.
EM sabrina.tulka@uni-wh.de
RI Prof. Dr. Baulig, Christine/HDN-2311-2022; Baulig, Christine/L-3550-2019
FU Leonard Stinnes Foundation [KS 11535]
FX This work was supported by Leonard Stinnes Foundation grant number,
   internal reference, KS 11535.
CR Abdulatif M, 2015, BRIT J ANAESTH, V115, P699, DOI 10.1093/bja/aev166
   Baulig C, 2019, COMP REV SEARCH STRA
   Baulig C, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-021912
   Castellini G, 2016, ARCH PHYS MED REHAB, V97, P1195, DOI 10.1016/j.apmr.2016.02.013
   Chan AW, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2299
   Charles P, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1732
   Chow JTY, 2018, CAN J ANESTH, V65, P611, DOI 10.1007/s12630-018-1109-z
   Clark T, 2013, BMJ, V346
   ICH, 1998, UK INT C HARM
   Koletsi D, 2014, EUR J ORTHODONT, V36, P67, DOI 10.1093/ejo/cjt005
   Koletsi D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085949
   Krummenauer F, 2002, BRIT J OPHTHALMOL, V86, P946, DOI 10.1136/bjo.86.9.946
   Lee PH, 2017, EUR J INTERN MED, V40, P16, DOI 10.1016/j.ejim.2016.10.008
   Martin J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010166
   Moher David, 2012, Int J Surg, V10, P28, DOI 10.1016/j.ijsu.2011.10.001
   Olberg B, 2017, INT J TECHNOL ASSESS, V33, P103, DOI 10.1017/S0266462317000265
NR 16
TC 2
Z9 2
U1 2
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD OCT
PY 2019
VL 9
IS 10
AR e030312
DI 10.1136/bmjopen-2019-030312
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA KK6XG
UT WOS:000512882200134
PM 31601589
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Landa, G
   Su, E
   Garcia, PMT
   Seiple, WH
   Rosen, RB
AF Landa, Gennady
   Su, Emily
   Garcia, Patricia M. T.
   Seiple, William H.
   Rosen, Richard B.
TI INNER SEGMENT-OUTER SEGMENT JUNCTIONAL LAYER INTEGRITY AND CORRESPONDING
   RETINAL SENSITIVITY IN DRY AND WET FORMS OF AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE spectral-domain OCT; inner segment-outer segment junctional layer;
   photoreceptors; microperimetry
ID OPTICAL COHERENCE TOMOGRAPHY; FOVEAL PHOTORECEPTOR LAYER; VISUAL-ACUITY;
   EDEMA; MICROPERIMETRY; RESOLUTION; EYES; FEATURES; ASSOCIATION
AB Purpose: To investigate a relationship between the inner segment-outer segment (IS-OS) junctional layer integrity and the overlying retinal sensitivity assessed by Spectral OCT/SLO (spectral-domain optical coherence tomography) and microperimetry testing in patients with dry and wet forms of age-related macular degeneration (AMD).
   Methods: Spectral-domain optical coherence tomography examination and microperimetry testing were performed in 55 eyes of 43 consecutive patients with AMD. Microperimetry maps were registered onto three-dimensional retinal topography maps, and point-to-point analysis of correlation between microperimetric retinal sensitivities and corresponding status of the underlying IS-OS junctional layer was performed. In addition, the analysis of correlation between the best-corrected visual acuity and the integrity of IS-OS layer in the center of the fovea also was performed.
   Results: Retinal sensitivity was inversely and strongly correlated with the integrity of IS-OS layer in both dry and wet forms of AMD (correlation coefficient [r] = -0.75 [95% confidence interval, 0.49-0.88], P < 0.001, and -0.79 [95% confidence interval, 0.61-0.89], P < 0.001, respectively). The correlation between the best-corrected visual acuity and the integrity of IS-OS layer in the center of fovea was less significant (r = 20.58 [95% confidence interval, 0.19-0.79], P = 0.02, for dry AMD, and r = -0.6 [95% confidence interval, 0.32-0.78], P = 0.015, for wet AMD).
   Conclusion: Retinal sensitivity consistently correlated with the status of underlying IS-OS junctional layer in both dry and wet forms of AMD. Loss of IS-OS layer is significantly associated with poor retinal sensitivity, assessed by microperimetry. Compared with visual acuity, functional testing with microperimetry appears to more consistently correlate with changes in the outer retina, such as IS-OS junctional integrity, especially, in patients with wet AMD.
   RETINA 31: 364-370, 2011
C1 [Landa, Gennady; Garcia, Patricia M. T.; Seiple, William H.; Rosen, Richard B.] New York Eye & Ear Infirm, Retina Ctr, Dept Ophthalmol, New York, NY 10003 USA.
   [Landa, Gennady; Su, Emily; Garcia, Patricia M. T.; Rosen, Richard B.] New York Med Coll, Dept Ophthalmol, Valhalla, NY 10595 USA.
   [Seiple, William H.] Lighthouse Int, New York, NY USA.
C3 New York Eye & Ear Infirmary of Mount Sinai; New York Medical College
RP Rosen, RB (通讯作者)，New York Eye & Ear Infirm, Retina Ctr, Dept Ophthalmol, 310 E 14th St, New York, NY 10003 USA.
EM rrosen@nyee.edu
OI Seiple, William/0000-0002-5750-650X
FU Department of Veterans Affairs, Rehabilitation Research and Development
   Service; Foundation Fighting Blindness; Hope for Vision;
   Bendheim-Lowenstein Retinal Fund; Gladys Brooks Foundation; Wise Family
   Foundation
FX W. H. Seiple received support from the Department of Veterans Affairs,
   Rehabilitation Research and Development Service; the Foundation Fighting
   Blindness; and the Hope for Vision. R. B. Rosen received support from
   the Bendheim-Lowenstein Retinal Fund, the Gladys Brooks Foundation, and
   the Wise Family Foundation and is a member of the Scientific Advisory
   Board of OPKO/OTI (Miami, FL).
CR Chang LK, 2008, RETINA-J RET VIT DIS, V28, P969, DOI 10.1097/IAE.0b013e3181744165
   Dinc UA, 2008, EUR J OPHTHALMOL, V18, P595, DOI 10.1177/112067210801800416
   Eandi CM, 2005, RETINA-J RET VIT DIS, V25, P417, DOI 10.1097/00006982-200506000-00004
   Hangai M, 2009, ARCH OPHTHALMOL-CHIC, V127, P1307, DOI 10.1001/archophthalmol.2009.250
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Kumar A, 2007, GRAEF ARCH CLIN EXP, V245, P360, DOI 10.1007/s00417-006-0456-6
   Landa G, 2010, OPHTHALMIC RES, V43, P92, DOI 10.1159/000247593
   Larsson J, 2005, AM J OPHTHALMOL, V139, P802, DOI 10.1016/j.ajo.2004.12.054
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Murakami T, 2007, AM J OPHTHALMOL, V143, P171, DOI 10.1016/j.ajo.2006.08.030
   Ojima Y, 2008, AM J OPHTHALMOL, V146, P77, DOI 10.1016/j.ajo.2008.02.016
   Ota M, 2008, RETINA-J RET VIT DIS, V28, P1502, DOI 10.1097/IAE.0b013e3181840b3c
   Ota M, 2008, AM J OPHTHALMOL, V145, P273, DOI 10.1016/j.ajo.2007.09.019
   Ota M, 2007, BRIT J OPHTHALMOL, V91, P1644, DOI 10.1136/bjo.2007.118497
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Parravano M, 2009, RETINA-J RET VIT DIS, V29, P329, DOI 10.1097/IAE.0b013e31819093e6
   Piccolino FC, 2005, AM J OPHTHALMOL, V139, P87, DOI 10.1016/j.ajo.2004.08.037
   Rohrschneider K, 2008, PROG RETIN EYE RES, V27, P536, DOI 10.1016/j.preteyeres.2008.07.003
   Sakamoto A, 2009, GRAEF ARCH CLIN EXP, V247, P1325, DOI 10.1007/s00417-009-1107-5
   Sano M, 2009, AM J OPHTHALMOL, V147, P313, DOI 10.1016/j.ajo.2008.08.002
   Sayanagi K, 2009, BRIT J OPHTHALMOL, V93, P622, DOI 10.1136/bjo.2008.151977
   Smith AJ, 2008, OPHTHALMOLOGY, V115, P1923, DOI 10.1016/j.ophtha.2008.05.025
   Villate N, 2005, AM J OPHTHALMOL, V139, P280, DOI 10.1016/j.ajo.2004.09.029
   Witkin AJ, 2006, AM J OPHTHALMOL, V142, P945, DOI 10.1016/j.ajo.2006.07.024
   Yamaike N, 2009, RETINA-J RET VIT DIS, V29, P757, DOI 10.1097/IAE.0b013e31819d4fbf
NR 26
TC 90
Z9 93
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2011
VL 31
IS 2
BP 364
EP 370
DI 10.1097/IAE.0b013e3181e91132
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 711JG
UT WOS:000286586500022
PM 21221051
DA 2022-11-30
ER

PT J
AU Ono, A
   Shiragami, C
   Manabe, S
   Takasago, Y
   Osaka, R
   Kobayashi, M
   Yamashita, A
   Tsujikawa, A
   Hirooka, K
AF Ono, Aoi
   Shiragami, Chieko
   Manabe, Saki
   Takasago, Yukari
   Osaka, Rie
   Kobayashi, Mamoru
   Yamashita, Ayana
   Tsujikawa, Akitaka
   Hirooka, Kazuyuki
TI One-year outcomes of fixed treatment of intravitreal aflibercept for
   exudative age-related macular degeneration and the factor of visual
   prognosis
SO MEDICINE
LA English
DT Article
DE aflibercept; central retinal thickness; exudative age-related macular
   degeneration; macular atrophy; microperimetry; retinal sensitivity;
   subfoveal choroidal thickness
ID PIGMENT EPITHELIAL ATROPHY; SUBFOVEAL CHOROIDAL THICKNESS; GROWTH-FACTOR
   TREATMENT; TREATMENTS TRIALS; GEOGRAPHIC ATROPHY; FACTOR THERAPY;
   RANIBIZUMAB; VEGF; CHORIOCAPILLARIS; PROGRESSION
AB The aim of this study was to investigate the efficacy of periodic intravitreal aflibercept (IVA) in exudative age-related macular degeneration, and to explore the predictive factors for visual outcome.
   This is a prospective interventional case series.
   Fifty-two eyes of 52 treatment-naive age-related-macula-degeneration patients were enrolled. All participants received IVA bimonthly following 3 monthly loading dose. The primary endpoint was change in best corrected visual acuity (BCVA) and central retinal thickness (CRT), and the secondary outcomes included changes in subfoveal choroidal thickness (SCT), macular atrophy (MA), and retinal average sensitivity (AS) determined by microperimetry at 12 months compared with baseline. The predictive factors for the change of BCVA were examined.
   Of 52 enrolled patients, 4 patients were drop out. Remaining 48 patients were examined. Mean logMAR BCVA significantly improved from 0.42 +/- 0.37 at baseline to 0.29 +/- 0.34 at 12 months (P=.008). Mean CRT and SCT significant reduced from 285.6 +/- 135.2 mu m, 247.9 +/- 96.7 mu m at baseline to 233.4 +/- 98.0 mu m, 208.1 +/- 94.6 mu m at 12 months, respectively (P<.001). At 12 months, 35 eyes of 48 eyes (72.3%) were archived dry macula. MA occurred in 7 eyes of 35 eyes with dry macula at 12 months (20.0%). AS was significant improved (P=.027) between baseline (median: 15.7dB) and 12 months (median: 19.5dB). The BCVA of the cases with MA involved fovea was significant worse. Age was significantly predicted for the BCVA at 12 months.
   IVA administered over 1 year improved BCVA, AS, and morphological findings, and the predictive factors for BCVA were age and MA-involved fovea.
C1 [Ono, Aoi; Shiragami, Chieko; Manabe, Saki; Takasago, Yukari; Osaka, Rie; Kobayashi, Mamoru; Yamashita, Ayana; Hirooka, Kazuyuki] Kagawa Univ, Fac Med, Dept Ophthalmol, 1750-1 Ikenobe Miki Cho, Takamatsu, Kagawa 7610793, Japan.
   [Tsujikawa, Akitaka] Kyoto Univ, Fac Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
C3 Kagawa University; Kyoto University
RP Shiragami, C (通讯作者)，Kagawa Univ, Fac Med, Dept Ophthalmol, 1750-1 Ikenobe Miki Cho, Takamatsu, Kagawa 7610793, Japan.
EM chappi@med.kagawa-u.ac.jp
OI Tsujikawa, Akitaka/0000-0003-0779-7799
FU Bayer (Osaka, Japan); Novartis (Tokyo, Japan); Alcon (Tokyo, Japan);
   Ministry of Education, Culture, Sports, Science, and Technology of Japan
   [26462689]; Pfizer (Tokyo, Japan); Bayer (Whippany, NJ); Santen (Osaka,
   Japan); Senju (Osaka, Japan); AMO Japan (Tokyo, Japan); Hoya (Tokyo,
   Japan); Kowa (Nagoya, Japan); Ministry of Health, Labour and Welfare of
   Japan; Japan Society for the Promotion of Science (Tokyo, Japan); Bayer
   Yakuhin, Osaka, Japan
FX S.C. received funding from Bayer (Osaka, Japan). H.K. received a funding
   from Novartis (Tokyo, Japan), Alcon (Tokyo, Japan), and Grant-in-Aid for
   Scientific Research from the Ministry of Education, Culture, Sports,
   Science, and Technology of Japan (26462689). T.A. received funding from
   Pfizer (Tokyo, Japan), Bayer (Whippany, NJ), Novartis (Tokyo, Japan),
   Santen (Osaka, Japan), Senju (Osaka, Japan), Alcon (Tokyo, Japan), AMO
   Japan (Tokyo, Japan), Hoya (Tokyo, Japan), Kowa (Nagoya, Japan), the
   Ministry of Health, Labour and Welfare of Japan, and the Japan Society
   for the Promotion of Science (Tokyo, Japan).; This study was supported
   by funding from Bayer Yakuhin, Osaka, Japan. The funding organization
   had no role in the design; in the collection, analyais, or
   interpretation of data; in the writing of the report; or in the decision
   to submit the article for publication.
CR Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   Alexander P, 2012, EYE, V26, P678, DOI 10.1038/eye.2012.7
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Bolz M, 2010, BRIT J OPHTHALMOL, V94, P185, DOI 10.1136/bjo.2008.143974
   Coleman DJ, 2013, BRIT J OPHTHALMOL, V97, P1020, DOI 10.1136/bjophthalmol-2013-303143
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kim M, 2016, INDIAN J OPHTHALMOL, V64, P427, DOI 10.4103/0301-4738.187659
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Okada K, 2009, CLIN OPHTHALMOL, V3, P483
   Querques G, 2012, BRIT J OPHTHALMOL, V96, P1479, DOI 10.1136/bjophthalmol-2012-302191
   Richard G, 2015, OPHTHALMOLOGY, V122, P2497, DOI 10.1016/j.ophtha.2015.08.014
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shiragami C, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006422
   Sikorav A, 2016, BR J OPHTHALMOL
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
NR 28
TC 3
Z9 3
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD AUG
PY 2018
VL 97
IS 31
AR e11737
DI 10.1097/MD.0000000000011737
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GR1AS
UT WOS:000442259200095
PM 30075585
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Weber, M
   Dominguez, M
   Coscas, F
   Faure, C
   Baillif, S
   Kodjikian, L
   Cohen, SY
AF Weber, Michel
   Dominguez, Marcel
   Coscas, Florence
   Faure, Celine
   Baillif, Stephanie
   Kodjikian, Laurent
   Cohen, Salomon-Yves
TI Impact of intravitreal aflibercept dosing regimens in treatment-naive
   patients with neovascular age-related macular degeneration: 2-year
   results of RAINBOW
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Intravitreal aflibercept; Neovascular age-related macular degeneration;
   France; Real-world; Observational
ID THERAPY
AB BackgroundTo review treatment outcomes from real-world data of patients with neovascular age-related macular degeneration (nAMD) treated with intravitreal aflibercept (IVT-AFL) injection.MethodsRAINBOW (ClinicalTrials.gov, NCT02279537) is an ongoing, observational, 4-year study to monitor the effectiveness and safety of IVT-AFL in patients with nAMD in clinical practice in France. Treatment-naive patients diagnosed with nAMD who had been prescribed IVT-AFL by their treating physician were eligible. The regimens of interest were regular treatment interval cohort (patients who received three initial monthly IVT-AFL injections followed by regular injections every 2months) and two irregular treatment interval cohorts (with and without three initial monthly injections). Here we describe results at 24months in patients according to IVT-AFL treatment regimen.ResultsThe mean change in best-corrected visual acuity (BCVA) with IVT-AFL from baseline to 24months was +3.0 letters in the overall population (P<0.05 vs baseline). The mean change was positive for the regular and irregular treatment interval cohorts with initial doses (+4.9 and+4.0 letters, respectively; P<0.05 vs baseline) and negative for the irregular treatment interval cohort without initial doses (-2.5 letters; P=0.365 vs baseline) at 24months. The mean overall number of IVT-AFL injections over 12 and 24months was 6.0 and 8.8, respectively. The most common ocular adverse events were lack of efficacy (6.3%), vitreous floaters (2.7%), and increased lacrimation (1.7%).ConclusionsIn the real-world RAINBOW study, visual outcomes observed at 24months were consistent with results from the primary endpoint at 12months. In this study, treatment-naive patients who received three initial IVT-AFL doses and regular IVT-AFL treatment over the first 24months experienced better visual outcomes than patients who received no initial doses and an irregular treatment regimen.Trial registrationwww.ClinicalTrials.gov (NCT02279537). Registered 29 October 2014.
C1 [Weber, Michel] CHU Hotel Dieu, F-44000 Nantes, France.
   [Dominguez, Marcel] Ctr Retine Galien, Bordeaux, France.
   [Coscas, Florence] Ctr Odeon, Paris, France.
   [Faure, Celine] Ramsay Gen Sante, Clin St Martin, Caen, France.
   [Baillif, Stephanie] CHU Nice, Hop Pasteur 2, Nice, France.
   [Kodjikian, Laurent] Univ Lyon 1, Croix Rousse Univ Hosp, Hosp Civils Lyon, Lyon, France.
   [Kodjikian, Laurent] CNRS UMR Mateis, Villeurbanne, France.
   [Cohen, Salomon-Yves] Ctr Imagerie & Laser, Paris, France.
C3 Nantes Universite; CHU de Nantes; CHU Nice; CHU Lyon; UDICE-French
   Research Universities; Universite Claude Bernard Lyon 1; Institut
   National des Sciences Appliquees de Lyon - INSA Lyon
RP Weber, M (通讯作者)，CHU Hotel Dieu, F-44000 Nantes, France.
EM weber.michel@bbox.fr
RI baillif, stephanie/AAX-9883-2020
OI baillif, stephanie/0000-0003-1700-8570; Faure,
   Celine/0000-0002-7435-7518
FU Bayer HealthCare SAS, France
FX The RAINBOW study was funded by Bayer HealthCare SAS, France. Bayer
   participated in the design of the study; analysis and interpretation of
   the data; and development of the manuscript. Bayer was responsible for
   the conduct of the study and oversight of the collection and management
   of data.
CR Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Berger M, 2017, WHITE PAPER FRAMEWOR
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Framme C, 2018, OPHTHALMOL RETINA, V2, P539, DOI 10.1016/j.oret.2017.09.017
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   Patel PJ, 2017, CLIN OPHTHALMOL, V11, P1957, DOI 10.2147/OPTH.S145732
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Weber M, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2017-000109
   Wierzbicka N., 2015, JHPOR, V1, P15, DOI DOI 10.7365/JHPOR.2015.1.3
NR 10
TC 8
Z9 8
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD MAY 25
PY 2020
VL 20
IS 1
DI 10.1186/s12886-020-01468-z
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LU4GA
UT WOS:000537714300004
PM 32450838
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Schmitz-Valckenberg, S
   Steinberg, JS
   Fleckenstein, M
   Visvalingam, S
   Brinkmann, CK
   Holz, FG
AF Schmitz-Valckenberg, Steffen
   Steinberg, Julia S.
   Fleckenstein, Monika
   Visvalingam, Sivatharisini
   Brinkmann, Christian K.
   Holz, Frank G.
TI Combined Confocal Scanning Laser Ophthalmoscopy and Spectral-Domain
   Optical Coherence Tomography Imaging of Reticular Drusen Associated with
   Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; FUNDUS AUTOFLUORESCENCE; HIGH-RISK; MACULOPATHY;
   POLYMORPHISM; EYE; EPIDEMIOLOGY; PSEUDODRUSEN; PREVALENCE; DISEASE
AB Purpose: To determine microstructural retinal alterations associated with reticular drusen in patients with age-related macular degeneration (AMD) using high-resolution in vivo imaging techniques.
   Design: Retrospective case series.
   Participants: A total of 116 eyes of 78 AMD patients with reticular drusen were examined.
   Methods: Simultaneous spectral-domain optical coherence tomography (SD OCT; 870 nm, 40 000 A-scans/sec) and near-infrared confocal scanning laser ophthalmoscopy (cSLO; 830 nm) were performed using a combined imaging instrument (Spectralis HRA + OCT, Heidelberg Engineering, Heidelberg, Germany). Individual anatomic layers in SD OCT were evaluated and correlated to en face cSLO fundus imaging.
   Main Outcome Measures: Description of corresponding structural changes in areas of reticular drusen.
   Results: Reticular drusen appeared as an interlacing network of round or oval irregularities by near-infrared cSLO reflectance imaging. On SD OCT, reticular drusen corresponded to marked changes at a level anterior to the retinal pigment epithelium (RPE) and Bruch's membrane complex to the interface of inner and outer photoreceptor segment layer (IPRL). Individual reticular drusen correlated to focal elevations of the IPRL, accumulation of highly reflective material below the IPRL, and an increased distance between the IPRL and RPE.
   Conclusions: The findings indicate that the morphologic substrate of reticular drusen is the accumulation of highly reflective material within outer retinal layers anterior to the RPE. This is in contrast to previous assumptions pointing toward a localization of abnormal material at the level of the inner choroid. Although the origin of the material is unknown, the results may indicate a role for primary abnormalities in the neurosensory retina. Because reticular drusen represent high-risk markers for the progression of AMD, their ready identification is relevant both for natural history studies as well as for interventional trials.
C1 [Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   Univ Bonn, GRADE Reading Ctr, D-53127 Bonn, Germany.
C3 University of Bonn; University of Bonn
RP Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM steffen.schmitz-valckenberg@ukb.uni-bonn.de
OI Fleckenstein, Monika/0000-0001-8321-8037
FU German Research Council (DFG), Bonn, Germany [Ho 1926/1-3]; German
   Society of Ophthalmology (DOG), Munich, Germany
FX Supported by the German Research Council (DFG; grant no.: Ho 1926/1-3),
   Bonn, Germany; and a German Society of Ophthalmology (DOG) Research
   Grant, Munich, Germany.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Farwick A, 2009, EYE, V23, P2238, DOI 10.1038/eye.2008.426
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HELB HM, ACTA OPHTHA IN PRESS
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Knudtson MD, 2004, INVEST OPHTH VIS SCI, V45, P2135, DOI 10.1167/iovs.03-1085
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Pircher M, 2006, INVEST OPHTH VIS SCI, V47, P5487, DOI 10.1167/iovs.05-1589
   Scholl HPN, 2007, MOL VIS, V13, P196
   Scholl HPN, 2005, OPHTHALMOLOGE, V102, P1029, DOI 10.1007/s00347-005-1270-y
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wojtkowski M, 2004, AM J OPHTHALMOL, V138, P412, DOI 10.1016/j.ajo.2004.04.049
NR 33
TC 126
Z9 132
U1 0
U2 23
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2010
VL 117
IS 6
BP 1169
EP 1176
DI 10.1016/j.ophtha.2009.10.044
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 603QZ
UT WOS:000278224400012
PM 20163861
DA 2022-11-30
ER

PT J
AU Bakri, SJ
   Thorne, JE
   Ho, AC
   Ehlers, JP
   Schoenberger, SD
   Yeh, S
   Kim, SJ
AF Bakri, Sophie J.
   Thorne, Jennifer E.
   Ho, Allen C.
   Ehlers, Justis P.
   Schoenberger, Scott D.
   Yeh, Steven
   Kim, Stephen J.
TI Safety and Efficacy of Anti-Vascular Endothelial Growth Factor Therapies
   for Neovascular Age-Related Macular Degeneration A Report by the
   American Academy of Ophthalmology
SO OPHTHALMOLOGY
LA English
DT Article
ID VERTEPORFIN PHOTODYNAMIC THERAPY; INTRAOCULAR-PRESSURE;
   COST-EFFECTIVENESS; CHOROIDAL NEOVASCULARIZATION; VEGF-TRAP;
   RANIBIZUMAB; BEVACIZUMAB; PEGAPTANIB; WET; TRIALS
AB Purpose: To review the evidence on the safety and efficacy of anti-vascular endothelial growth factor (VEGF) therapies for the treatment of neovascular age-related macular degeneration (AMD).
   Methods: A literature search of the PubMed and Cochrane Library databases was last conducted in February 2017; there were no date restrictions, and the search was limited to studies published in English. The combined searches yielded 191 citations, 28 of which were selected because they were clinical trials and were deemed clinically relevant for the Ophthalmic Technology Assessment Committee Retina/Vitreous Panel to review in full. The panel methodologist then assigned a level of evidence rating to each study.
   Results: Sixteen of the 28 citations provided level I evidence supporting the use of anti-VEGF agents for neovascular AMD, including intravitreal ranibizumab, aflibercept, and bevacizumab. Eight studies reviewed provided level II evidence, and 4 studies provided level III evidence, but only the level I studies are included in this assessment. There are long-term follow-up data on the efficacy of ranibizumab and bevacizumab (>= 5 years), but these data are subject to the bias of incomplete follow-up.
   Conclusions: Review of the literature indicates that intravitreal injection of anti-VEGF therapy is safe and effective for neovascular AMD over 2 years, the period for which data are available. Further research is needed to evaluate the long-term safety and comparative efficacy of these agents. (C) 2018 by the American Academy of Ophthalmology
C1 [Bakri, Sophie J.] Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA.
   [Thorne, Jennifer E.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Div Ocular Immunol,Dept Ophthalmol, Baltimore, MD 21205 USA.
   [Ho, Allen C.] Wills Eye Hosp & Res Inst, Philadelphia, PA USA.
   [Ehlers, Justis P.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Schoenberger, Scott D.] Retina Phys & Surg Inc, Dayton, OH USA.
   [Yeh, Steven] Emory Univ, Sch Med, Dept Ophthalmol, Atlanta, GA 30322 USA.
   [Kim, Stephen J.] Vanderbilt Univ, Sch Med, Dept Ophthalmol, Nashville, TN 37212 USA.
C3 Mayo Clinic; Johns Hopkins University; Johns Hopkins Medicine; Jefferson
   University; Cleveland Clinic Foundation; Retina Associates of Cleveland,
   Inc.; Emory University; Vanderbilt University
RP Bakri, SJ (通讯作者)，Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA.
OI Ho, Allen/0000-0003-3921-608X
FU American Academy of Ophthalmology
FX Funded without commercial support by the American Academy of
   Ophthalmology.
CR American Academy of Ophthalmology Retina/Vitreous Panel, 2015, PREF PRACT PATT GUID
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bakri SJ, 2009, EYE, V23, P181, DOI 10.1038/sj.eye.6702938
   Bakri SJ, 2014, OPHTHALMOLOGY, V121, P1102, DOI 10.1016/j.ophtha.2013.11.029
   Bressler NM, 2012, RETINA-J RET VIT DIS, V32, P1821, DOI 10.1097/IAE.0b013e31825db6ba
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Dedania VS, 2015, RETINA-J RET VIT DIS, V35, P841, DOI 10.1097/IAE.0000000000000520
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1246, DOI 10.1016/j.ophtha.2013.12.032
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kodjikian L, 2014, GRAEF ARCH CLIN EXP, V252, P1529, DOI 10.1007/s00417-014-2764-6
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lee JH, 2005, P NATL ACAD SCI USA, V102, P18902, DOI 10.1073/pnas.0509069102
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Meredith TA, 2015, OPHTHALMOLOGY, V122, P817, DOI 10.1016/j.ophtha.2014.10.027
   Mitchell P, 2011, PHARMACOECONOMICS, V29, P107, DOI 10.2165/11585520-000000000-00000
   Nwanze CC, 2012, CLIN MED INSIGHTS-TH, V4, P29, DOI 10.4137/CMT.S7439
   Oxford Centre for Evidence-based Medicine, 2009, LEVELS EVIDENCE
   Patel JJ, 2012, J EVAL CLIN PRACT, V18, P247, DOI 10.1111/j.1365-2753.2010.01546.x
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   U.S. Food and Drug Administration Center for Drug Evaluation and Research, 12538743 BLA US FOOD
   U.S. Food and Drug Administration Center for Drug Evaluation and Research, 21756S018 NDA US FOO
   U.S. Food and Drug Administration Center for Drug Evaluation and Research, 125156 BLA US FOOD D
NR 48
TC 81
Z9 85
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2019
VL 126
IS 1
BP 55
EP 63
DI 10.1016/j.ophtha.2018.07.028
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HE6PG
UT WOS:000453531300020
PM 30077616
OA Bronze
DA 2022-11-30
ER

PT J
AU Chae, B
   Jung, JJ
   Mrejen, S
   Gallego-Pinazo, R
   Yannuzzi, NA
   Patel, SN
   Chen, CY
   Marsiglia, M
   Boddu, S
   Freund, KB
AF Chae, Bora
   Jung, Jesse J.
   Mrejen, Sarah
   Gallego-Pinazo, Roberto
   Yannuzzi, Nicolas A.
   Patel, Samir N.
   Chen, Christine Y.
   Marsiglia, Marcela
   Boddu, Sucharita
   Freund, K. Bailey
TI Baseline Predictors for Good Versus Poor Visual Outcomes in the
   Treatment of Neovascular Age-Related Macular Degeneration With
   Intravitreal Anti-VEGF Therapy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; treat-and-extend regimen; anatomical
   classification system; anti-VEGF; choroidal neovascularization
ID ENDOTHELIAL GROWTH-FACTOR; C-REACTIVE PROTEIN; ST-SEGMENT ELEVATION;
   CHOROIDAL NEOVASCULARIZATION; GEOGRAPHIC ATROPHY; SUBGROUP ANALYSIS;
   TREATMENTS TRIALS; EXTEND PROTOCOL; RANIBIZUMAB; BEVACIZUMAB
AB PURPOSE. To examine the baseline factors associated with good (20/60 or better) versus poor (20/200 or worse) visual outcomes in eyes with treatment-naive neovascular age-related macular degeneration (AMD) receiving intravitreal antivascular endothelial growth factor (VEGF) on a treat-and-extend regimen (TER).
   METHODS. An observational, retrospective series of patients managed with a TER, identified as having either good or poor visual outcomes, was examined. A multivariate regression analysis of baseline characteristics identified factors associated with good and poor vision at 2, 3, and 4 years. Neovascular subtypes were identified using fluorescein angiography (FA) alone and the anatomic classification system with FA and optical coherence tomography (OCT).
   RESULTS. One hundred thirty-eight patients (154 eyes) fit the inclusion criteria at 2 years, 106 patients (113 eyes) at 3 years, and 72 patients (74 eyes) at 4 years. In the multivariate analysis, type 1 lesions, according to anatomic classification, had better vision at 24 months (95% CI: [3.1, 82.7], P = 0.01), 36 months (95% CI: [1.97, 24.17], P = 0.003), and 48 months (95% CI: [2.01, 65.47], P = 0.006). Clopidogrel use was associated with poor vision at 24 months (95% CI: [0.03, 0.68], P = 0.013). Vision at 3 months was the best predictor of vision at year 4 (beta = -4.277, P = 0.002).
   CONCLUSIONS. Eyes with neovascular AMD managed with a TER of anti-VEGF therapy having type 1 neovascularization at baseline were more likely to maintain good vision over 4 years, whereas clopidogrel use predicted poor vision at 2 years. Vision at 3 months was the best predictor for favorable long-term vision.
C1 [Chae, Bora; Jung, Jesse J.; Boddu, Sucharita; Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, New York, NY 10016 USA.
   [Chae, Bora; Jung, Jesse J.; Mrejen, Sarah; Gallego-Pinazo, Roberto; Chen, Christine Y.; Marsiglia, Marcela; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Jung, Jesse J.; Mrejen, Sarah; Gallego-Pinazo, Roberto; Chen, Christine Y.; Marsiglia, Marcela; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Jung, Jesse J.; Marsiglia, Marcela; Freund, K. Bailey] Columbia Univ Coll Phys & Surg, Edward S Harkness Eye Inst, New York, NY 10032 USA.
   [Gallego-Pinazo, Roberto] Univ & Polytech Hosp La Fe, Dept Ophthalmol, Valencia, Spain.
   [Yannuzzi, Nicolas A.; Patel, Samir N.] Weill Cornell Med Coll, New York, NY USA.
   [Chen, Christine Y.] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia.
   [Chen, Christine Y.] Univ Melbourne, Ctr Eye Res Australia, East Melbourne, Australia.
C3 New York University; Vitreous Retina Macula Consultants of New York;
   Manhattan Eye Ear & Throat Hospital; Columbia University; Cornell
   University; Monash University; Centre for Eye Research Australia;
   University of Melbourne
RP Freund, KB (通讯作者)，Macula Consultants New York, Retina, Vitreous, 460 Pk Ave,Fifth Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Mrejen, Sarah/G-2089-2016; Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cao JJ, 2007, CIRCULATION, V116, P32, DOI 10.1161/CIRCULATIONAHA.106.645606
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Freund KB, RETINA IN PRESS
   Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Keilhauer CN, 2013, EUR J MED GENET, V56, P72, DOI 10.1016/j.ejmg.2012.10.005
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sabatine MS, 2005, NEW ENGL J MED, V352, P1179, DOI 10.1056/NEJMoa050522
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Steinhubl SR, 2002, JAMA-J AM MED ASSOC, V288, P2411, DOI 10.1001/jama.288.19.2411
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Stone TW, 2014, ASRS 2014 PREFERENCE
   Vassilev ZP, 2015, INVEST OPHTH VIS SCI, V56, P1585, DOI 10.1167/iovs.14-16271
   Wang SB, 2015, BRIT J OPHTHALMOL, V99, P365, DOI 10.1136/bjophthalmol-2014-305793
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Yasuma TR, 2010, MOL VIS, V16, P2923
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Yusuf S, 2001, NEW ENGL J MED, V345, P494
NR 41
TC 34
Z9 35
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2015
VL 56
IS 9
BP 5040
EP 5047
DI 10.1167/iovs.15-16494
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CT5WW
UT WOS:000362882800001
PM 26237196
OA Green Published
DA 2022-11-30
ER

PT J
AU Velissari, A
   Skalidakis, I
   Oliveira, SC
   Koutsandrea, C
   Kitsos, G
   Petersen, MB
   Kroupis, C
AF Velissari, Aliki
   Skalidakis, Iosif
   Oliveira, Samantha C.
   Koutsandrea, Chryssanthi
   Kitsos, George
   Petersen, Michael B.
   Kroupis, Christos
TI Novel association of FCGR2A polymorphism with age-related macular
   degeneration (AMD) and development of a novel CFH real-time genotyping
   method
SO CLINICAL CHEMISTRY AND LABORATORY MEDICINE
LA English
DT Article
DE age-related macular degeneration (AMD); CFH; C-reactive protein (CRP);
   FCGR2A; real-time PCR melting curve analysis; single nucleotide
   polymorphisms (SNPs)
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; GENOME-WIDE ASSOCIATION;
   FC-GAMMA RECEPTORS; PCR DETECTION; RISK-FACTORS; VARIANT; GENETICS;
   INDIVIDUALS; GENES
AB Background: Age-related macular degeneration (AMD) is a degenerative ocular disease, which may lead to loss of central vision. In Caucasian populations, a strong correlation has been established with polymorphism Y402H (rs1061170) in the complement factor H gene (CFH). The H131R polymorphism (rs1801274) in the FCGR2A gene has been associated with many inflammatory diseases, but has not been investigated in relation to AMD. The goal of our study was the development of a novel method for Y402H (g.43097C>T) genotyping, the confirmation of its association with AMD in the Greek population and the investigation of the H131R polymorphism in AMD.
   Methods: DNAs were extracted from blood samples of 120 patients with the severe wet form of AMD and 103 age-and sex-matched controls, all of whom were clinically evaluated. A real-time PCR and melting curve analysis method for Y402H genotyping was developed in the LightCycler platform, after in silico design of appropriate primers and probes. Genotyping for H131R was performed using a realtime PCR method previously described by our group.
   Results: The novel genotyping method for Y402H in the CFH gene is fast, reproducible (Efficiency = 1.79, reproducibility CVCq = 3.33%, Tm C allele 53.36 degrees C and T allele 61.91 degrees C,Delta Tm = 8.55) and accurate as results were confirmed with the gold standard DNA Sequencing method.
   Conclusions: The present study confirmed the association between CFH Y402H SNP and wet AMD in the Greek population (OR = 1.77, p = 0.002). FCGR2A H131R polymorphism was investigated for the first time in this present study for possible correlation with wet AMD and a statistically significant association was detected (OR = 1.74, p = 0.006), that awaits further confirmation in a larger set of samples.
C1 [Kroupis, Christos] Univ Athens, Sch Med, Attikon Univ Gen Hosp, Dept Clin Biochem & Mol Diagnost, Athens 12461, Greece.
   [Velissari, Aliki; Oliveira, Samantha C.] Univ Athens, Sch Med, Attikon Univ Gen Hosp, Dept Clin Biochem, Athens 12461, Greece.
   [Skalidakis, Iosif; Koutsandrea, Chryssanthi] Univ Athens, Sch Med, G Gennimatas Gen Hosp, Dept Ophthalmol 1, Athens 12461, Greece.
   [Kitsos, George] Univ Ioannina, Univ Gen Hosp Ioannina, Dept Ophthalmol, GR-45110 Ioannina, Greece.
   [Petersen, Michael B.] Aalborg Univ Hosp, Dept Clin Genet, Aalborg, Denmark.
   [Petersen, Michael B.] Aalborg Univ Hosp, Dept Clin Med, Aalborg, Denmark.
C3 Athens Medical School; National & Kapodistrian University of Athens;
   University Hospital Attikon; Athens Medical School; National &
   Kapodistrian University of Athens; University Hospital Attikon; Athens
   Medical School; National & Kapodistrian University of Athens; University
   Hospital Ioannina; University of Ioannina; Aalborg University; Aalborg
   University Hospital; Aalborg University; Aalborg University Hospital
RP Kroupis, C (通讯作者)，Univ Athens, Sch Med, Attikon Univ Gen Hosp, Dept Clin Biochem & Mol Diagnost, 1 Rimini St, Athens 12461, Greece.
EM ckroupis@med.uoa.gr
RI Petersen, Michael Bjørn B/D-1483-2017; Kroupis, Christos/K-2725-2013
OI Petersen, Michael Bjørn B/0000-0003-0316-8207; Kroupis,
   Christos/0000-0002-5876-2599
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Barbosa DTQ, 2014, EYE, V28, P472, DOI 10.1038/eye.2014.8
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chiras D, 2015, CRIT REV CL LAB SCI, V52, P12, DOI 10.3109/10408363.2014.968703
   Dinu V, 2007, GENET EPIDEMIOL, V31, P224, DOI 10.1002/gepi.20204
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Khor CC, 2011, NAT GENET, V43, P1241, DOI 10.1038/ng.981
   Kim IK, 2008, MOL VIS, V14, P1487
   Kokotas H, 2011, CLIN CHEM LAB MED, V49, P601, DOI 10.1515/CCLM.2011.091
   Kroupis C, 2008, CLIN CHIM ACTA, V390, P141, DOI 10.1016/j.cca.2007.12.024
   Kroupis C, 2010, GENET TEST MOL BIOMA, V14, P839, DOI 10.1089/gtmb.2010.0108
   Kroupis C, 2009, CLIN BIOCHEM, V42, P1685, DOI 10.1016/j.clinbiochem.2009.07.026
   Lehrnbecher T, 1999, BLOOD, V94, P4220, DOI 10.1182/blood.V94.12.4220.424k08_4220_4232
   Lu JH, 2008, NATURE, V456, P989, DOI 10.1038/nature07468
   Marioli DI, 2009, GRAEF ARCH CLIN EXP, V247, P1547, DOI 10.1007/s00417-009-1129-z
   Mello E, 2012, CLIN CHEM LAB MED, V50, P1031, DOI 10.1515/cclm-2011-0859
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Perlee LT, 2013, OPHTHALMOLOGY, V120, P1880, DOI 10.1016/j.ophtha.2013.02.007
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Sole X, 2006, BIOINFORMATICS, V22, P1928, DOI 10.1093/bioinformatics/btl268
   Ting AYC, 2009, CURR OPIN OPHTHALMOL, V20, P369, DOI 10.1097/ICU.0b013e32832f8016
   Wang Y, 2010, EXP EYE RES, V91, P135, DOI 10.1016/j.exer.2010.02.008
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Willcocks LC, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001161
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 46
TC 5
Z9 5
U1 0
U2 2
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 1434-6621
EI 1437-4331
J9 CLIN CHEM LAB MED
JI Clin. Chem. Lab. Med.
PD SEP
PY 2015
VL 53
IS 10
BP 1521
EP 1529
DI 10.1515/cclm-2014-0920
PG 9
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA CQ8IT
UT WOS:000360851500017
PM 25811666
DA 2022-11-30
ER

PT J
AU Abbas, RO
   Azzazy, HME
AF Abbas, Radwa O.
   Azzazy, Hassan M. E.
TI Association of Single Nucleotide Polymorphisms in CFH, ARMS2 and HTRA1
   Genes with Risk of Age-related Macular Degeneration in Egyptian Patients
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Age-related macular degeneration; ARMS2; CFH; Egypt; HTRA1
ID COMPLEMENT-FACTOR-H; SUSCEPTIBILITY LOCI; Y402H POLYMORPHISM; GENOME
   SCAN; LOC387715 GENOTYPES; JAPANESE POPULATION; HEMICENTIN-1 GENES;
   CHINESE POPULATION; CHROMOSOME 10Q26; VARIANT
AB Background: Age-related macular degeneration (AMD) is one of the leading causes of blindness in the elderly worldwide. Several single nucleotide polymorphisms (SNPs) have been linked to the risk of developing AMD. We aimed to examine the association between AMD and SNPs on CFH, ARMS2 and HTRA1 in Egyptians, a previously unstudied population.
   Materials and methods: Genomic DNA was extracted from 26 AMD patients and 20 controls. Genotyping was performed using PCR followed by allele-specific restriction digestion and direct sequencing.
   Results: CFH rs1061170 was significantly associated with AMD with the frequency of the risk C allele being 0.53 in patients and 0.17 in controls (p<0.017). The odds ratio (OR) for the TC genotype was 5.5 (95% CI: 1.1-26.4) and for combined TC+CC genotypes was 8 (95% CI: 1.7-37.1). ARMS2 rs10490924 was also significantly associated with the risk allele T found at a frequency of 0.5 in AMD and 0.15 in controls (p<0.017, chi(2) test). The OR for the TG genotype was 4.667 (95% CI: 1.2-18.4) and for combined TG+TT genotypes was 7 (95% CI: 1.8-26.5). HTRA1 rs11200638 also was significantly associated, with the risk allele A found at a frequency of 0.44 in patients and 0.17 in controls (p<0.017, chi(2) test). OR for GA genotype was 5 (95% CI: 1.2-20.9) and for the combined GA+AA genotypes was 6 (95% CI: 1.4-24.7).
   Conclusions: Our data demonstrates significant association between AMD and rs1061170 on CFH, rs10490924 on ARMS2 and rs11200638 on HTRA1 in Egyptian patients. These findings are in agreement with previous findings in Caucasians.
C1 [Abbas, Radwa O.; Azzazy, Hassan M. E.] Amer Univ Cairo, Dept Chem, New Cairo, Egypt.
   [Azzazy, Hassan M. E.] Amer Univ Cairo, Yousef Jameel Sci & Technol Res Ctr, New Cairo, Egypt.
C3 Egyptian Knowledge Bank (EKB); American University Cairo; Egyptian
   Knowledge Bank (EKB); American University Cairo
RP Azzazy, HME (通讯作者)，Amer Univ Cairo, AUC Ave,SSE 1184,POB 74, New Cairo, Egypt.
EM hazzazy@aucegypt.edu
RI Azzazy, Hassan M. E./G-6831-2013
OI Azzazy, Hassan/0000-0003-2047-4222
FU Youssef Jameel (YJ-STRC, AUC)
FX This work has been funded by a grant from Mr Youssef Jameel (YJ-STRC,
   AUC) to Dr H. Azzazy.
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Baird PN, 2009, CLIN EXP OPHTHALMOL, V37, P814, DOI 10.1111/j.1442-9071.2009.02136.x
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Chamberlain M, 2006, SURV OPHTHALMOL, V51, P576, DOI 10.1016/j.survophthal.2006.08.003
   Chen LJ, 2006, MOL VIS, V12, P1536
   Chowers I, 2008, MOL VIS, V14, P1829
   Chu J, 2008, CHINESE MED J-PEKING, V121, P2525, DOI 10.1097/00029330-200812020-00011
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Cousins SW, 2005, MACULAR DEGENERATION, P167, DOI 10.1007/3-540-26977-0_10
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2007, CURR OPIN GENET DEV, V17, P228, DOI 10.1016/j.gde.2007.04.004
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2007, BRIT J OPHTHALMOL, V91, P576, DOI 10.1136/bjo.2006.105577
   Francis PJ, 2008, MOL VIS, V14, P1395
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Hageman Gregory S., 2011, Human Genomics, V5, P420
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kaufman SR, 2009, GERIATRICS, V64, P16
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Okamoto H, 2006, MOL VIS, V12, P156
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   Pulido JS, 2007, OPHTHALMIC GENET, V28, P203, DOI 10.1080/13816810701649617
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seitsonen S, 2006, MOL VIS, V12, P796
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Souied EH, 2005, MOL VIS, V11, P1135
   Soysal Y, 2012, DNA CELL BIOL, V31, P322, DOI 10.1089/dna.2011.1214
   Spaide RF, 2005, ESSENT OPHTHALMOL, P95
   Teixeira AG, 2010, ACTA OPHTHALMOL, V88, pE165, DOI 10.1111/j.1755-3768.2010.01932.x
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Xu YL, 2008, MOL VIS, V14, P1373
   Yang X, 2010, BRIT J OPHTHALMOL, V94, P1211, DOI 10.1136/bjo.2009.165811
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zanke B, 2010, CAN J OPHTHALMOL, V45, P22, DOI 10.3129/i09-209
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Ziskind A, 2008, OPHTHALMIC GENET, V29, P117, DOI 10.1080/13816810802216472
NR 59
TC 11
Z9 11
U1 0
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD DEC
PY 2013
VL 34
IS 4
BP 209
EP 216
DI 10.3109/13816810.2012.762934
PG 8
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA 251YB
UT WOS:000326969200004
PM 23362846
DA 2022-11-30
ER

PT J
AU Camacho, N
   Barteselli, G
   Nezgoda, JT
   El-Emam, S
   Cheng, LY
   Bartsch, DU
   Freeman, WR
AF Camacho, Natalia
   Barteselli, Giulio
   Nezgoda, Joseph T.
   El-Emam, Sharif
   Cheng, Lingyun
   Bartsch, Dirk-Uwe
   Freeman, William R.
TI Significance of the hyperautofluorescent ring associated with choroidal
   neovascularisation in eyes undergoing anti-VEGF therapy for wet
   age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Imaging; Macula
ID FUNDUS AUTOFLUORESCENCE PATTERNS; CENTRAL SEROUS CHORIORETINOPATHY;
   SCANNING LASER OPHTHALMOSCOPE; GEOGRAPHIC ATROPHY; JUNCTIONAL ZONE;
   DISEASE; CLASSIFICATION; PROGRESSION; LIPOFUSCIN
AB Aim To characterise the presence of a hyperautofluorescent (HAF) ring associated with choroidal neovascularisation (CNV) complex in patients with wet age-related macular degeneration (AMD).
   Methods Fundus autofluorescence images and spectral-domain optical coherence tomography (OCT) scans from 362 eyes with wet AMD were reviewed. The presence and size of an HAF ring associated with the CNV complex was evaluated. A subgroup of 64 treatment-naive eyes with new-onset CNV was studied to analyse the relationship between pretreatment OCT characteristics and the presence of the HAF ring.
   Results An HAF ring was present in 38% of the entire cohort of eyes and in 39% of treatment-naive eyes. The presence of the HAF ring was significantly correlated with the extent of baseline subretinal fluid (SRF) on OCT (p=0.0113), the number of antivascular endothelial growth factor (VEGF) injections (p=0.0439) and the number of treatment cycles (p=0.0154). Eyes with an HAF ring were more likely to have disruption of the ellipsoid zone line once the SRF was resolved compared with eyes without an HAF ring (p=0.0002). In multivariate analysis, the best predictors for HAF ring were the baseline area of SRF (p=0.0449) and the number of anti-VEGF treatments received (p=0.0568).
   Conclusions Nearly 40% of wet AMD eyes had an HAF ring. In treatment-naive eyes, the HAF ring had a significant association with SRF and was found as early as the baseline measurement and as long as 18months after beginning treatment, persisting for up to 6years after the initial diagnosis. Its association with baseline SRF and disruption of the ellipsoid zone line of the photoreceptors on OCT could indicate continuous stress on the outer retinal structures after exposure to prolonged SRF and/or transmitted autofluorescence from loss of the photoreceptors overlying the retinal pigment epithelium.
C1 [Camacho, Natalia; Barteselli, Giulio; Nezgoda, Joseph T.; El-Emam, Sharif; Cheng, Lingyun; Bartsch, Dirk-Uwe; Freeman, William R.] Univ Calif San Diego, Dept Ophthalmol, Shiley Eye Inst, Jacobs Retina Ctr, La Jolla, CA 92037 USA.
   [Barteselli, Giulio] Genentech Inc, San Francisco, CA 94080 USA.
   [El-Emam, Sharif] Tanta Univ, Dept Ophthalmol, Tanta, Egypt.
C3 University of California System; University of California San Diego;
   Roche Holding; Genentech; Egyptian Knowledge Bank (EKB); Tanta
   University
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Dept Ophthalmol, Shiley Eye Ctr, Jacobs Retina Ctr,Shiley Eye Inst, 0946,9415 Campus Point Dr, La Jolla, CA 92037 USA.
EM freeman@eyecenter.ucsd.edu
RI Emam, Sharif El/AAA-6627-2020
OI Emam, Sharif El/0000-0001-6357-0471; Barteselli,
   Giulio/0000-0003-0533-1135
FU NIH [R01EY007366, R01EY020617]; Research to Prevent Blindness;
   Pan-American Ophthalmological Foundation (PAOF); Retina Research
   Foundation; NATIONAL EYE INSTITUTE [R01EY020617, R01EY007366] Funding
   Source: NIH RePORTER
FX This study was supported by NIH grants R01EY007366 (WRF) and R01EY020617
   (LC), and in part by an unrestricted fund from Research to Prevent
   Blindness to the Department of Ophthalmology, University of California
   San Diego. NC has funding by the Pan-American Ophthalmological
   Foundation (PAOF) and Retina Research Foundation.
CR Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   Chen FK, 2010, INVEST OPHTH VIS SCI, V51, P4207, DOI 10.1167/iovs.09-4728
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dandekar SS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1507, DOI 10.1001/archopht.123.11.1507
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Dolar-Szczasny Joanna, 2011, Klin Oczna, V113, P326
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Greenberg JP, 2014, JAMA OPHTHALMOL, V132, P437, DOI 10.1001/jamaophthalmol.2013.7987
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kim SK, 2013, AM J OPHTHALMOL, V156, P157, DOI 10.1016/j.ajo.2013.02.016
   Lima LH, 2012, RETINA-J RET VIT DIS, V32, P1385, DOI 10.1097/IAE.0b013e3182398107
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P825, DOI 10.1016/j.ophtha.2005.01.003
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Tan CS, 2013, OPHTHALMOLOGY, V120, P1271, DOI 10.1016/j.ophtha.2012.12.002
   Teke MY, 2014, INT J OPHTHALMOL-CHI, V7, P350, DOI 10.3980/j.issn.2222-3959.2014.02.29
   Vaclavik V, 2008, OPHTHALMOLOGY, V115, P342, DOI 10.1016/j.ophtha.2007.04.023
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
NR 27
TC 7
Z9 7
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2015
VL 99
IS 9
BP 1277
EP 1283
DI 10.1136/bjophthalmol-2014-306226
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CQ2VL
UT WOS:000360460000026
PM 25777818
OA Bronze
DA 2022-11-30
ER

PT J
AU Tan, ACS
   Jordan-Yu, JM
   Vyas, CH
   Gan, ATL
   Teo, KYC
   Chan, CM
   Mathur, R
   Wong, TY
   Chakravarthy, U
   Ming, GC
AF Tan, Anna C. S.
   Jordan-Yu, Janice Marie
   Vyas, Chinmayi Himanshuroy
   Gan, Alfred Tau Liang
   Teo, Kelvin Yi Chong
   Chan, Choi Mun
   Mathur, Ranjana
   Wong, Tien Yin
   Chakravarthy, Usha
   Ming, Gemmy Chui
TI OPTICAL COHERENCE TOMOGRAPHY FEATURES OF POLYPOIDAL LESION CLOSURE IN
   POLYPOIDAL CHOROIDAL VASCULOPATHY TREATED WITH AFLIBERCEPT
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; optical coherence tomography; ocular
   imaging; polypoidal lesion closure
ID MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; RANIBIZUMAB; BEVACIZUMAB
AB Purpose: To evaluate whether optical coherence tomography (OCT) can determine polypoidal lesion (PL) perfusion in polypoidal choroidal vasculopathy eyes after 12 months of aflibercept monotherapy. Polypoidal lesion perfusion status, assessed by indocyanine green angiography, is an important anatomical outcome in polypoidal choroidal vasculopathy management.
   Methods: Post hoc data from a prospective randomized, open-label, study in eyes with polypoidal choroidal vasculopathy undergoing monotherapy with aflibercept evaluated PL perfusion status based on indocyanine green angiography (gold standard) and OCT features from baseline to 12 months.
   Results: Individual PLs (110 in total) from 48 eyes (48 patients) showed at 12 months; 57/110 PLs (51.8%) were closed on indocyanine green angiography. At 12 months, eyes with closed PLs were more likely to have the following OCT features: 1) no subretinal fluid (67.1% vs. 32.9%), 2) smaller pigment epithelial detachment height (67.2 [+/- 43.8] vs. 189.2 [+/- 104.9] mm), 3) densely hyperreflective pigment epithelial detachment contents (84.0% vs. 16.0%), 4) an absence of a hyperreflective ring(64.0% vs. 36.0%), and a 5) indistinct overlying retinal pigment epithelial (71.4% vs. 28.6%) (all P < 0.05). The three highest performing OCT features that differentiated perfused from closed PLs were (1), (3), and (4) (area under the receiver operating characteristic curve 0.85, 0.73, and 0.70, respectively). A combination of these three features achieved an area under the receiver operating characteristic curve of 0.90.
   Conclusion: Polypoidal lesion closure, an important anatomical treatment outcome in polypoidal choroidal vasculopathy typically defined by indocyanine green angiography, can be accurately detected by specific OCT features.
C1 [Tan, Anna C. S.; Jordan-Yu, Janice Marie; Vyas, Chinmayi Himanshuroy; Gan, Alfred Tau Liang; Teo, Kelvin Yi Chong; Chan, Choi Mun; Mathur, Ranjana; Wong, Tien Yin; Ming, Gemmy Chui] Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Avenue, Singapore, Singapore.
   [Tan, Anna C. S.; Teo, Kelvin Yi Chong; Chan, Choi Mun; Mathur, Ranjana; Wong, Tien Yin; Ming, Gemmy Chui] Duke NUS Med Sch, Singapore, Singapore.
   [Tan, Anna C. S.; Teo, Kelvin Yi Chong; Chan, Choi Mun; Mathur, Ranjana; Wong, Tien Yin; Ming, Gemmy Chui] Natl Univ Singapore, Singapore, Singapore.
   [Chakravarthy, Usha] Queens Univ Belfast, Ophthalmol & Vis Sci, Belfast, Antrim, North Ireland.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; National University of Singapore;
   Queens University Belfast
RP Ming, GC (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Avenue, Singapore, Singapore.
EM gemmy.cheung.c.m@singhealth.com.sg
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264
FU National Medical Research Council of Singapore [NMRC/OFLCG/004a/2018]
FX This study was funded by the National Medical Research Council of
   Singapore (NMRC/OFLCG/004a/2018). The funding sources had no role in the
   design or conduct of the study; collection, management, analysis, and
   interpretation of the data; preparation, review, or approval of the
   manuscript; or the decision to submit the manuscript for publication.
CR Chaikitmongkol V, 2019, JAMA OPHTHALMOL, V137, P661, DOI 10.1001/jamaophthalmol.2019.0565
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chang CJ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241230
   Chen YFN, 2017, CAN J OPHTHALMOL, V52, P475, DOI 10.1016/j.jcjo.2017.02.014
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2017, RETINA-J RET VIT DIS, V37, P1464, DOI 10.1097/IAE.0000000000001391
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Cho JH, 2020, RETINA-J RET VIT DIS, V40, P468, DOI 10.1097/IAE.0000000000002384
   Cho JH, 2016, AM J OPHTHALMOL, V169, P79, DOI 10.1016/j.ajo.2016.06.014
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Lam WC, 2020, CAN J OPHTHALMOL, V55, P199, DOI 10.1016/j.jcjo.2019.10.011
   Li ML, 2019, OPHTHALMOL RETINA, V3, P99, DOI 10.1016/j.oret.2018.08.008
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Ozkaya A, 2013, MIDDLE EAST AFR J OP, V20, P360, DOI 10.4103/0974-9233.120005
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Teo KYC, 2022, BRIT J OPHTHALMOL, V106, P987, DOI 10.1136/bjophthalmol-2020-318354
   Tsujikawa A, 2007, RETINA-J RET VIT DIS, V27, P832, DOI 10.1097/IAE.0b013e318150d864
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   Yang Z, 2010, BIOMETRICAL J, V52, P638, DOI 10.1002/bimj.201000035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Zhao XY, 2021, RETINA-J RET VIT DIS, V41, P1675, DOI 10.1097/IAE.0000000000003098
NR 30
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2022
VL 42
IS 1
BP 114
EP 122
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XS3RA
UT WOS:000732829100024
PM 34412103
DA 2022-11-30
ER

PT J
AU Wu, WC
   Chen, JT
   Tsai, CY
   Wu, CL
   Cheng, CK
   Shen, YD
   Tsai, A
   Wu, PC
AF Wu, Wen-Chuan
   Chen, Jiann-Torng
   Tsai, Ching-Yao
   Wu, Chien-Liang
   Cheng, Cheng-Kuo
   Shen, Yun-Dun
   Tsai, Arslan
   Wu, Pei-Chang
TI A 12-month, prospective, observational study of ranibizumab in
   treatment-naive Taiwanese patients with neovascular age-related macular
   degeneration: the RACER study
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE nAMD; Observational; Ranibizumab; Real-world; Taiwan; Treatment-na&#239;
   ve
ID VISUAL-ACUITY; CLINICAL-PRACTICE; OUTCOMES; AMD; THERAPY
AB Background The current National Health Insurance scheme in Taiwan reimburses 3 initial plus 4 additional injections of ranibizumab 0.5 mg for eligible patients with neovascular age-related macular degeneration (nAMD). The Ranibizumab AMD Clinical Efficacy in Real-world practice (RACER) study aimed to observe the effectiveness of ranibizumab injections under this reimbursement system. Methods RACER was a 12-month, prospective, observational study conducted in treatment-naive, adult Taiwanese patients with nAMD. Patients received intravitreal ranibizumab 0.5 mg injections in adherence with local prescribing information. Results Of 161 patients enrolled, 114 (70.8%) completed the 12-month study. Overall, patients received a mean (standard deviation [SD]) of 4.3 (1.7) ranibizumab injections. The mean (SD, [95% confidence interval], P value) gain in best-corrected visual acuity (BCVA) from baseline at Month 3 was 5.2 (12.2, [3.1, 7.3] letters, P < 0.0001) and at Month 12 was 3.4 (15.4, [0.2-6.6] letters, P = 0.0352). Mean central retinal thickness also decreased from baseline at Months 3 and 12 (both P < 0.001). In subgroup analyses, better treatment outcomes at Months 3 and 12 were observed among patients who received a loading dose and those who had a shorter duration of nAMD at baseline. Adverse events were reported in 58.4% of patients; most (94.4%) were mild-to-moderate in severity and 98.8% were deemed unrelated to study treatment. Conclusions Treatment with ranibizumab 0.5 mg resulted in significant improvements in visual outcomes among treatment-naive Taiwanese patients with nAMD. Early treatment and frequent dosing in the real-world setting may be the key to achieving better outcomes.
C1 [Wu, Wen-Chuan] Kaohsiung Med Univ, Chung Ho Mem Hosp, Kaohsiung, Taiwan.
   [Chen, Jiann-Torng] Triserv Gen Hosp, Natl Def Med Ctr, Chenggong Rd, Taipei, Taiwan.
   [Tsai, Ching-Yao] Taipei City Hosp, Zhengzhou Rd, Taipei, Taiwan.
   [Wu, Chien-Liang] Municipal Wan Fang Hosp, Xinglong Rd, Taipei, Taiwan.
   [Cheng, Cheng-Kuo] Shin Kong Wu Ho Su Mem Hosp, Taipei, Taiwan.
   [Shen, Yun-Dun] Taipei Med Univ, Shung Ho Hosp, New Taipei, Taiwan.
   [Tsai, Arslan] Novartis Taiwan, Clin Dev & Med Affairs, Taipei, Taiwan.
   [Wu, Pei-Chang] Kaohsiung Chang Gung Mem Hosp, Dept Ophthalmol, Dapi Rd, Kaohsiung, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Medical University Hospital;
   National Defense Medical Center; Tri-Service General Hospital; Taipei
   City Hospital; Taipei Municipal WanFang Hospital; Shin Kong Wu Ho Su
   Memorial Hospital; Chang Gung Memorial Hospital
RP Wu, PC (通讯作者)，Kaohsiung Chang Gung Mem Hosp, Dept Ophthalmol, Dapi Rd, Kaohsiung, Taiwan.
EM wpc@adm.cgmh.org.tw
FU Novartis (Taiwan) Co. Ltd., Taipei, Taiwan
FX The study was funded and sponsored by Novartis (Taiwan) Co. Ltd.,
   Taipei, Taiwan. The sponsor had a role in the study design, study
   conduct, data collection, data analysis, data interpretation, and
   manuscript preparation.
CR Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang YS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25864-0
   Chen S, 2017, EURETINA 2017 FREE P
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Genentech Inc, 2014, LUC PRESCR INF
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Heimes B, 2011, GRAEF ARCH CLIN EXP, V249, P639, DOI 10.1007/s00417-010-1524-5
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Huang EJC, 2014, EYE, V28, P705, DOI 10.1038/eye.2014.55
   Massamba N, 2015, EYE, V29, P1453, DOI 10.1038/eye.2015.128
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
NR 16
TC 2
Z9 2
U1 1
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD DEC 25
PY 2020
VL 20
IS 1
AR 462
DI 10.1186/s12886-020-01715-3
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PA6UA
UT WOS:000595766800001
PM 33238968
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Finger, RP
   Wiedemann, P
   Blumhagen, F
   Pohl, K
   Holz, FG
AF Finger, Robert P.
   Wiedemann, Peter
   Blumhagen, Francisca
   Pohl, Karin
   Holz, Frank G.
TI Treatment patterns, visual acuity and quality-of-life outcomes of the
   WAVE study - A noninterventional study of ranibizumab treatment for
   neovascular age-related macular degeneration in Germany
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; clinical trial; neovascularization;
   treatment medical
AB Purpose: To evaluate effectiveness, tolerability and safety of repeated intravitreal injections of 0.5mg ranibizumab for the treatment of neovascular age-related macular degeneration in routine medical practice in Germany. Methods: A noninterventional study with 3470 patients treated in 274 medical centres according to German guidelines, with monthly intravitreal injections of 0.5mg ranibizumab during upload (3months) followed by a maintenance phase (9months) with reinjections if medically indicated. Results: Mean injection rate was 4.34 (SE=0.05; median=3.0). Best-corrected visual acuity (BCVA) remained stable (mean change 0.02 LogMAR, SE=0.01, p=0.0169) and central retinal thickness (CRT) decreased (by -78.9m, SE=2.95m, p<0.0001). The NEI-VFQ 25 summary score showed a positive stabilization with a mean change of 0.73 (SE=0.37, p=0.0501) compared with baseline. Adverse events were documented for 6.5% of the patients with 3.9% of these events being classified as serious. Conclusions: The number of administered intravitreal injections of ranibizumab over the first year of treatment was very low but still achieved a stabilization of BCVA, a reduction in CRT and maintained vision-related quality of life. The management of patients with neovascular AMD in Germany needs to be improved to achieve better treatment results.
C1 [Finger, Robert P.; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   [Wiedemann, Peter] Univ Leipzig, Dept Ophthalmol, D-04109 Leipzig, Germany.
   [Blumhagen, Francisca; Pohl, Karin] Novartis Pharma GmbH, Novartis Ophthalm, Nurnberg, Germany.
C3 University of Bonn; Leipzig University; Novartis
RP Holz, FG (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM frank.holz@ukb.uni-bonn.de
OI Finger, Robert P/0000-0003-4253-7597
FU Novartis Pharma Germany
FX The WAVE study was funded by Novartis Pharma Germany.
CR Bandukwala T, 2010, CAN J OPHTHALMOL, V45, P590, DOI 10.3129/i10-082
   Bloch SB, 2011, ACTA OPHTHALMOL
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Framme C, 2012, ACTA OPHTHALMOL, V90, P49, DOI 10.1111/j.1755-3768.2010.01940.x
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kumar A, 2011, BRIT J OPHTHALMOL, V95, P530, DOI 10.1136/bjo.2009.171868
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Marella M, 2010, INVEST OPHTH VIS SCI, V51, P2878, DOI 10.1167/iovs.09-4494
   Mariani A, 2011, GRAEF ARCH CLIN EXP, V249, P1635, DOI 10.1007/s00417-011-1734-5
   Meyer CH, 2008, OPHTHALMOLOGE, V105, P125, DOI 10.1007/s00347-008-1702-6
   Meyer CH, 2011, ACTA OPHTHALMOL, V89, P70, DOI 10.1111/j.1755-3768.2010.02064.x
   Pauleikhoff D, 2011, Ophthalmologe, V108, P85, DOI 10.1007/s00347-010-2326-1
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Revicki DA, 2010, INVEST OPHTH VIS SCI, V51, P712, DOI 10.1167/iovs.09-3766
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schalnus R, 2010, OPHTHALMOLOGICA, V224, P176, DOI 10.1159/000239236
   Shona O, 2011, CLIN EXP OPHTHALMOL, V39, P5, DOI 10.1111/j.1442-9071.2010.02424.x
   Spaide RF, 2009, AM J OPHTHALMOL, V148, P1, DOI 10.1016/j.ajo.2009.04.010
NR 22
TC 123
Z9 129
U1 0
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2013
VL 91
IS 6
BP 540
EP 546
DI 10.1111/j.1755-3768.2012.02493.x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 202GG
UT WOS:000323201500027
PM 23171290
DA 2022-11-30
ER

PT J
AU Yu, WH
   Dong, SQ
   Zhao, CT
   Wang, HN
   Dai, F
   Yang, JY
AF Yu, Weihong
   Dong, Shuqian
   Zhao, Chuntao
   Wang, Haina
   Dai, Fei
   Yang, Jingyun
TI Cumulative association between age-related macular degeneration and less
   studied genetic variants in PLEKHA1/ARMS2/HTRA1: a meta and gene-cluster
   analysis
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Macular degeneration; Polymorphism; Meta-analysis; Gene-cluster analysis
ID COMPLEMENT FACTOR-H; VISUAL IMPAIRMENT; CHROMOSOME 10Q26; RISK-FACTORS;
   HTRA1; SUSCEPTIBILITY; PREVALENCE; ARMS2; POLYMORPHISMS; CFH
AB The objective of this study is to examine the cumulative effect of the less studied genetic variants in PLEKHA1/ARMS2/HTRA1 on age-related macular degeneration (AMD). We performed an extensive literature search for studies on the association between AMD and the less studied genetic variants in PLEKHA1/ARMS2/HTRA1. Multiple meta-analyses were performed to evaluate the association between individual genetic variants and AMD. A gene-cluster analysis was used to investigate the cumulative effect of these less studied genetic variants on AMD. A total of 23 studies from 20 published papers met the eligibility criteria and were included in our analyses. Several genetic variants in the gene cluster are significantly associated with AMD in our meta-analyses or in individual studies. Gene-cluster analysis reveals a strong cumulative association between these genetic variants in this gene cluster and AMD (p < 10(-5)). However, two previously suspected SNPs in ARMS2, including rs2736911, the SNP having the largest number of studies in our meta-analyses; and rs3793917, the SNP with the largest sample size, were not significantly associated with AMD (both p's > 0.12). Sensitivity analyses reveal significant association of AMD with rs2736911 in Chinese but not in Caucasian, with c.372_815del443ins54 in Caucasian but not in Chinese, and with rs1049331 in both ethnic groups. These less studied genetic variants have a significant cumulative effect on wet AMD. Our study provides evidence of the joint contribution of genetic variants in PLEKHA1/ARMS2/HTRA1 to AMD risk, in addition to the two widely studied genetic variants whose association with AMD was well established.
C1 [Yu, Weihong] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
   [Dong, Shuqian] Zhengzhou Univ, Dept Ophthalmol, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China.
   [Zhao, Chuntao] Univ Texas SW Med Ctr Dallas, Dept Dev Biol, Dallas, TX 75390 USA.
   [Wang, Haina] Shandong Univ, Coll Pharmaceut Sci, Jinan, Shandong, Peoples R China.
   [Dai, Fei] Xi An Jiao Tong Univ, Div Gastroenterol, Coll Med, Affiliated Hosp 2, Xian 710049, Peoples R China.
   [Yang, Jingyun] Penn State Univ, Methodol Ctr, University Pk, PA 16801 USA.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College Hospital; Zhengzhou University; University
   of Texas System; University of Texas Southwestern Medical Center Dallas;
   Shandong University; Xi'an Jiaotong University; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); Pennsylvania State
   University; Pennsylvania State University - University Park
RP Yu, WH (通讯作者)，Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
EM yuweihong.pumch@gmail.com; jingyuny@gmail.com
RI Yang, Jingyun/D-5361-2009
OI Yang, Jingyun/0000-0002-3495-3710
FU National Institute on Drug Abuse (NIDA) [P50DA010075-16]; NIH/NCI [R01
   CA168676]; NATIONAL CANCER INSTITUTE [R01CA168676] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA010075] Funding Source:
   NIH RePORTER
FX This research was supported by Award Number P50DA010075-16 from the
   National Institute on Drug Abuse (NIDA) and NIH/NCI R01 CA168676. The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of NIDA or the National
   Institutes of Health. The sponsor or funding organization had no role in
   the design or conduct of this research.
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Borenstein M., 2011, INTRO INFORM PROCESS, DOI DOI 10.1016/B978-0-12-209005-9.50005-9
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheng Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053665
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher R, 1932, BIOL MONOGRAPHS MANU
   Fisher SA, 2007, BRIT J OPHTHALMOL, V91, P576, DOI 10.1136/bjo.2006.105577
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Gotoh N, 2010, JPN J OPHTHALMOL, V54, P609, DOI 10.1007/s10384-010-0865-2
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kanda A, 2010, MOL VIS, V16, P1317
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Leveziel N, 2007, MOL VIS, V13, P2153
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Liu MM, 2011, INVEST OPHTH VIS SCI, V52, P3129, DOI 10.1167/iovs.10-6735
   Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5
   Park JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031243
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Ricci F, 2009, ARCH OPHTHALMOL-CHIC, V127, P1368, DOI 10.1001/archophthalmol.2009.237
   Richardson AJ, 2010, INVEST OPHTH VIS SCI, V51, P4932, DOI 10.1167/iovs.09-5114
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Sheng XG, 2013, OXFORD B ECON STAT, V75, P624, DOI 10.1111/j.1468-0084.2012.00705.x
   SIMES RJ, 1986, BIOMETRIKA, V73, P751, DOI 10.2307/2336545
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Teper SJ, 2012, MED SCI MONITOR, V18, pPR1, DOI 10.12659/MSM.882447
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tong Y, 2010, MOL VIS, V16, P1958
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Zaykin DV, 2002, GENET EPIDEMIOL, V22, P170, DOI 10.1002/gepi.0042
   Zhang H, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-51
NR 51
TC 9
Z9 9
U1 0
U2 17
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD OCT
PY 2013
VL 40
IS 10
BP 5551
EP 5561
DI 10.1007/s11033-013-2656-6
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 238LQ
UT WOS:000325948400004
PM 24013816
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Mazzoli, LS
   Urata, CN
   Kasahara, N
AF Mazzoli, Livia S.
   Urata, Carla N.
   Kasahara, Niro
TI Face memory deficits in subjects with eye diseases: a comparative
   analysis between glaucoma and age-related macular degeneration patients
   from a developing country
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Glaucoma; Age-related macular degeneration; Face perception
ID RECOGNITION; PERFORMANCE; DISABILITY
AB Purpose Older people present significant declines in face recognition with age. Spatial vision (high-contrast acuity) and age are the best predictors of face recognition. Visual disabilities are more common in the older population due to aging eye diseases. The purpose of the study was to compare the face recognition memory deficit between primary open angle glaucoma (POAG) and age-related macular degeneration (ARMD) patients living in a developing country. Methods This was a cross-sectional, observational study. The sample comprised 64 patients with POAG, 48 with ARMD, and 52 controls. All groups were matched for age, gender, comorbidity, and ethnic distribution. Evidence of cognitive impairment was ruled out and subjects with even mild cognitive impairment were not included in the study. After a complete eye examination including measurement of the best-corrected visual acuity, fundus evaluation, and automated visual field, all subjects underwent the Cambridge face memory test (CFMT). CFMT score in percentage (%) was the main outcome measure and data were compared with ANOVA. Results The mean age was 66.6 +/- 9.2, 69.8 +/- 9.3, and 63.4 +/- 7.3 years, for POAG, ARMD, and controls, respectively (P = 0.152). Gender, ethnicity, and comorbidity were evenly distributed among the groups. The CFMT score was 53.3 +/- 15.2%, 49.8 +/- 14.2%, and 62.1 +/- 15.9% for POAG, ARMD, and controls, respectively (P < 0.001). Conclusion ARMD and POAG patients have higher face recognition memory deficit as compared to normal controls. This might be due to a visual disability.
C1 [Mazzoli, Livia S.; Urata, Carla N.; Kasahara, Niro] Irmandade Santa Casa Misericordia Sao Paulo, Rua Sao Mauro,292, BR-02526050 Sao Paulo, SP, Brazil.
   [Kasahara, Niro] Santa Casa Sao Paulo Sch Med Sci, Sao Paulo, Brazil.
RP Kasahara, N (通讯作者)，Irmandade Santa Casa Misericordia Sao Paulo, Rua Sao Mauro,292, BR-02526050 Sao Paulo, SP, Brazil.; Kasahara, N (通讯作者)，Santa Casa Sao Paulo Sch Med Sci, Sao Paulo, Brazil.
EM niro.kasahara@fcmsantacasasp.edu.br
RI Kasahara, Niro/P-4631-2019
OI Kasahara, Niro/0000-0003-4101-0304
CR Barnes CS, 2011, OPTOMETRY VISION SCI, V88, P188, DOI 10.1097/OPX.0b013e318205a17c
   Bate S, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00491
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRUCE V, 1986, BRIT J PSYCHOL, V77, P305, DOI 10.1111/j.2044-8295.1986.tb02199.x
   BULLIMORE MA, 1991, INVEST OPHTH VIS SCI, V32, P2020
   Cypel Marcela C., 2004, International Ophthalmology, V25, P267, DOI 10.1007/s10792-005-0077-9
   Duchaine B, 2006, NEUROPSYCHOLOGIA, V44, P576, DOI 10.1016/j.neuropsychologia.2005.07.001
   FERRIS SH, 1980, J GERONTOL, V35, P707, DOI 10.1093/geronj/35.5.707
   Glen FC, 2013, VISION RES, V82, P42, DOI 10.1016/j.visres.2013.02.010
   Glen FC, 2012, INVEST OPHTH VIS SCI, V53, P5451, DOI 10.1167/iovs.11-8538a
   Heering A, 2014, DEV PSYCHOBIOL, V56, P96, DOI [10.1002/dev.21094, DOI 10.1002/DEV.21094]
   Hodapp E, 1993, CLIN DECISIONS GLAUC
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Lamont AC, 2005, MEM COGNITION, V33, P1017, DOI 10.3758/BF03193209
   Ng KYY, 2007, ASIAN J GERONTOLOGY, V2, P93
   O'Donnell O, 2007, CAD SAUDE PUBLICA, V23, P2820, DOI 10.1590/S0102-311X2007001200003
   OWSLEY C, 1987, BRIT J OPHTHALMOL, V71, P791, DOI 10.1136/bjo.71.10.791
   OWSLEY C, 1981, INVEST OPHTH VIS SCI, V21, P362
   Ramulu P, 2009, CURR OPIN OPHTHALMOL, V20, P92, DOI 10.1097/ICU.0b013e32832401a9
   Roux-Sibilon A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193465
   Rubin GS, 1989, DOES CONTRAST SENSIT, P130
   Schafer A, 2018, INVEST OPHTH VIS SCI, V59, P4921, DOI 10.1167/iovs.18-24875
   Taylor DJ, 2018, GRAEF ARCH CLIN EXP, V256, P815, DOI 10.1007/s00417-017-3879-3
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
NR 24
TC 5
Z9 6
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2019
VL 257
IS 9
BP 1941
EP 1946
DI 10.1007/s00417-019-04380-5
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IR9NP
UT WOS:000481772100015
PM 31154471
DA 2022-11-30
ER

PT J
AU Weingessel, B
   Mihaltz, K
   Vecsei-Marlovits, PV
AF Weingessel, Birgit
   Mihaltz, Kata
   Vecsei-Marlovits, Pia Veronika
TI Predictors of 1-year visual outcome in OCT analysis comparing
   ranibizumab monotherapy versus combination therapy with PDT in
   exsudative age-related macular degeneration
SO WIENER KLINISCHE WOCHENSCHRIFT
LA English
DT Article
DE Ranibizumab; OCT; PDT; Visual outcome; Combination therapy; Age-related
   macular degeneration
ID OPTICAL COHERENCE TOMOGRAPHY; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   VERTEPORFIN PHOTODYNAMIC THERAPY; RANDOMIZED CLINICAL-TRIALS;
   INTRAVITREAL BEVACIZUMAB; SUBGROUP ANALYSIS; PLUS RANIBIZUMAB; DOSING
   REGIMEN; FOLLOW-UP; TRIAMCINOLONE
AB The aim of this study was to find predictive factors of 1-year visual outcome, analyzing novel optical coherence tomography (OCT) biomarkers in exsudative age-related macular degeneration (choroidal neovascularization (CNV)) in two groups of different treatment modalities.
   In all, 34 consecutive patients with new-onset CNV were randomized 1:1 to receive either ranibizumab monotherapy or ranibizumab combined with photodynamic therapy (PDT) with verteporfin. After three initial injections with ranibizumab, re-treatment was performed according to an as-needed scheme; PDT was performed once at baseline. Best-corrected visual acuity (BCVA) and OCT parameters like central macular volume (CMV), central macular thickness (or central retinal thickness (CRT)), subretinal and intraretinal fluid, fibrovascular lesion thickness, or inner segment/outer segment (IS/OS) junction were analyzed.
   After 12 months, a visual gain of 6.1 letters was found in the monotherapy group, whereas patients in the combination therapy group lost -aEuroe4.8 letters from baseline to the 12-month visit. CMV and CRT decreased considerably between baseline and month 2-3 in both groups, with a following slight increase until month 12. Additional application of PDT had negative effect to 12-month BCVA, whereas higher baseline BCVA and integrity of the IS/OS junction at month 12 had positive effect to 12-month BCVA.
   Better baseline BCVA and the integrity of IS/OS junction at 12-month visit were the most important predictive factors for final BCVA. Combination therapy caused worse final BCVA and a higher degree of IS/OS disruption.
C1 [Weingessel, Birgit; Mihaltz, Kata; Vecsei-Marlovits, Pia Veronika] Hietzing Hosp, Dept Ophthalmol, Wolkersbergenstr 1, A-1130 Vienna, Austria.
   [Weingessel, Birgit; Vecsei-Marlovits, Pia Veronika] Karl Landsteiner Inst Proc Optimizat & QM Catarac, Wolkersbergenstr 1, A-1130 Vienna, Austria.
C3 Hietzing Hospital
RP Mihaltz, K (通讯作者)，Hietzing Hosp, Dept Ophthalmol, Wolkersbergenstr 1, A-1130 Vienna, Austria.
EM kata.mihaltz@wienkav.at
RI Weingessel, Birgit/AAM-6617-2021; Weingessel, Birgit/ABD-5201-2021
OI Weingessel, Birgit/0000-0002-1110-0432
CR Barouch Fina C., 2004, International Ophthalmology Clinics, V44, P23, DOI 10.1097/00004397-200404430-00005
   Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   BRESSLER NM, 1988, RETINA-J RET VIT DIS, V8, P109, DOI 10.1097/00006982-198808020-00005
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Carneiro AM, 2010, RETINA-J RET VIT DIS, V30, P85, DOI 10.1097/IAE.0b013e3181c700a9
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gamulescu MA, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/851648
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Keane PA, 2012, INVEST OPHTH VIS SCI, V53, P1152, DOI 10.1167/iovs.11-8130
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krebs I, 2013, ACTA OPHTHALMOL, V91, pE178, DOI 10.1111/aos.12018
   Ladewig MS, 2008, GRAEF ARCH CLIN EXP, V246, P17, DOI 10.1007/s00417-007-0654-x
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lie S, 2010, ACTA OPHTHALMOL, V88, P212, DOI 10.1111/j.1755-3768.2008.01405.x
   Lim JY, 2012, ACTA OPHTHALMOL, V90, P61, DOI 10.1111/j.1755-3768.2009.01841.x
   Mataix J, 2010, RETINA-J RET VIT DIS, V30, P1190, DOI 10.1097/IAE.0b013e3181d2f172
   Okada K, 2009, CLIN OPHTHALMOL, V3, P483
   Ozturk T, 2012, INT J OPHTHALMOL-CHI, V5, P377, DOI 10.3980/j.issn.2222-3959.2012.03.25
   Potter MJ, 2010, BRIT J OPHTHALMOL, V94, P174, DOI 10.1136/bjo.2008.155531
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rudnisky CJ, 2010, RETINA-J RET VIT DIS, V30, P548, DOI 10.1097/IAE.0b013e3181bcf1b8
   Sayed KM, 2011, GRAEF ARCH CLIN EXP, V249, P1449, DOI 10.1007/s00417-011-1672-2
   Schadlu R, 2007, GRAEF ARCH CLIN EXP, V245, P1667, DOI 10.1007/s00417-007-0619-0
   Spielberg L, 2010, GRAEF ARCH CLIN EXP, V248, P943, DOI 10.1007/s00417-009-1256-6
   Vallance JH, 2010, EYE, V24, P1561, DOI 10.1038/eye.2010.84
   Wolf-Schnurrbusch UEK, 2011, ACTA OPHTHALMOL, V89, P585, DOI 10.1111/j.1755-3768.2009.01747.x
NR 37
TC 5
Z9 5
U1 0
U2 5
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0043-5325
EI 1613-7671
J9 WIEN KLIN WOCHENSCHR
JI Wien. Klin. Wochen.
PD AUG
PY 2016
VL 128
IS 15-16
BP 560
EP 565
DI 10.1007/s00508-015-0772-0
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA DV1JD
UT WOS:000382676200003
PM 25787216
DA 2022-11-30
ER

PT J
AU Loeven, MA
   van Gemst, JJ
   Schophuizen, CMS
   Tilakaratna, V
   van den Heuvel, LP
   Day, AJ
   Klevering, BJ
   van der Vlag, J
AF Loeven, Markus A.
   van Gemst, Jasper J.
   Schophuizen, Carolien M. S.
   Tilakaratna, Viranga
   van den Heuvel, Lambert P.
   Day, Anthony J.
   Klevering, B. Jeroen
   van der Vlag, Johan
TI A Novel Choroidal Endothelial Cell Line Has a Decreased Affinity for the
   Age-Related Macular Degeneration-Associated Complement Factor H Variant
   402H
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; choriocapillaris; cell line;
   glycocalyx; complement system
ID RAT CHORIOCAPILLARIS; GENETIC-VARIANTS; BRUCHS MEMBRANE; PERMEABILITY;
   BINDING; SYSTEM; COMMON; RARE; FENESTRATIONS; HEMEPROTEINS
AB PURPOSE. Choroidal endothelial cells play a central role in the pathogenesis of age-related macular degeneration (AMD). Protocols for isolating primary choroidal endothelial cells have been described but require access to human donor eyes, which is a limiting factor. Therefore, a conditionally immortalized choroidal endothelial cell (ciChEnC) line has been established.
   METHODS. Choroidal endothelial cells were selected by magnetic-activated cell sorting and conditionally immortalized using temperature-sensitive simian virus 40 large T antigen and human telomerase. The cell line obtained was characterized based on expression of endothelial marker proteins and endothelial cell-specific responses to various stimuli. Binding of AMD-associated and non-AMD variants of complement factor H in the context of a recombinant CCP6-8 (complement control protein domains 6-8) construct was determined using ELISA.
   RESULTS. ciChEnCs maintained morphology and von Willebrand factor and vascular endothelial cadherin expression for up to 27 passages. The cells internalized acetylated low-density lipoprotein, formed tubes on Matrigel, and increased intercellular adhesion molecule-1 expression in response to tumor necrosis factor-a. Cells grew into dense monolayers with barrier function and showed characteristics of choriocapillary cells, such as expression of plasmalemma vesicle-associated protein, human leukocyte antigen ABC, carbonic anhydrase IV, and membrane indentations reflecting fenestrations. ciChEnCs synthesized glycosaminoglycans chondroitin sulfate and the complement factor H ligand heparan sulfate. Interestingly, binding of the AMD-associated 402H variant of factor H to ciChEnC was significantly decreased compared to the 402Y variant.
   CONCLUSIONS. A novel ciChEnC cell line with choriocapillary characteristics has been established and should greatly facilitate investigation of the pathogenesis of AMD in the context of the choriocapillary microenvironment.
C1 [Loeven, Markus A.; van Gemst, Jasper J.; van der Vlag, Johan] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Mol Life Sci, Dept Nephrol, Nijmegen, Netherlands.
   [Schophuizen, Carolien M. S.; van den Heuvel, Lambert P.] Radboud Univ Nijmegen, Med Ctr, Dept Pediat Pediat Nephrol, Nijmegen, Netherlands.
   [Tilakaratna, Viranga; Day, Anthony J.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Sch Biol Sci,Div Cell Matrix Biol & Regenerat Med, Wellcome Trust Ctr Cell Matrix Res,Fac Biol Med &, Manchester, Lancs, England.
   [van den Heuvel, Lambert P.] Katholieke Univ Leuven, Dept Pediat Nephrol, Dept Growth & Regenerat, Leuven, Belgium.
   [Klevering, B. Jeroen] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen; University of
   Manchester; KU Leuven; Radboud University Nijmegen
RP van der Vlag, J (通讯作者)，Radbound Univ, Med Ctr, Dept Nephrol 480, Geert Grootepl 10, NL-6525 GA Nijmegen, Netherlands.
EM Johan.vanderVlag@radboudumc.nl
RI Van der Vlag, Johan/E-4636-2010; van den Heuvel, L.P.W.J./H-8044-2014;
   van den Heuvel, Lambertus/AAM-1772-2021
OI Van der Vlag, Johan/0000-0001-7843-5918; van den Heuvel,
   L.P.W.J./0000-0003-3917-6727; van den Heuvel,
   Lambertus/0000-0003-3917-6727
FU Radboud University Medical Center PhD fellow program; Medical Research
   Council UK [K00441]; MRC [MR/K004441/1] Funding Source: UKRI; Medical
   Research Council [MR/K004441/1] Funding Source: researchfish
FX Supported by the Radboud University Medical Center PhD fellow program
   and the Medical Research Council UK (Grant K00441).
CR ADAMS DH, 1994, LANCET, V343, P831, DOI 10.1016/S0140-6736(94)92029-X
   Ahmado A, 2011, INVEST OPHTH VIS SCI, V52, P7148, DOI 10.1167/iovs.10-6374
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Arnaoutova I, 2009, ANGIOGENESIS, V12, P267, DOI 10.1007/s10456-009-9146-4
   Baba T, 2009, INVEST OPHTH VIS SCI, V50, P3503, DOI 10.1167/iovs.08-2614
   BERNSTEIN M. H., 1965, INVEST OPHTHAL MOL, V4, P1016
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Browning AC, 2005, BRIT J OPHTHALMOL, V89, P1343, DOI 10.1136/bjo.2004.063602
   BURNS MS, 1992, CURR EYE RES, V11, P863, DOI 10.3109/02713689209033484
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Clark SJ, 2011, INVEST OPHTH VIS SCI, V52, P6511, DOI 10.1167/iovs.11-7909
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Garsen M, 2016, J AM SOC NEPHROL, V27, P3545, DOI 10.1681/ASN.2015091070
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   HAGEMAN GS, 1991, P NATL ACAD SCI USA, V88, P2716, DOI 10.1073/pnas.88.7.2716
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Langford-Smith A, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00025
   Langford-Smith A, 2014, J INNATE IMMUN, V6, P407, DOI 10.1159/000356513
   Loeven MA, 2015, MOL IMMUNOL, V63, P203, DOI 10.1016/j.molimm.2014.08.005
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nakanishi M, 2016, INVEST OPHTH VIS SCI, V57, P2213, DOI 10.1167/iovs.15-17934
   Parente R, 2017, CELL MOL LIFE SCI, V74, P1605, DOI 10.1007/s00018-016-2418-4
   PINO RM, 1986, AM J ANAT, V177, P63, DOI 10.1002/aja.1001770108
   PINO RM, 1981, J HISTOCHEM CYTOCHEM, V29, P281, DOI 10.1177/29.2.7252121
   PINO RM, 1982, AM J ANAT, V164, P333, DOI 10.1002/aja.1001640404
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Reitsma S, 2007, PFLUG ARCH EUR J PHY, V454, P345, DOI 10.1007/s00424-007-0212-8
   Rops AL, 2004, KIDNEY INT, V66, P2193, DOI 10.1111/j.1523-1755.2004.66009.x
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sano Y, 2010, J CELL PHYSIOL, V225, P519, DOI 10.1002/jcp.22232
   Satchell SC, 2006, KIDNEY INT, V69, P1633, DOI 10.1038/sj.ki.5000277
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Sedgwick JB, 2002, J ALLERGY CLIN IMMUN, V110, P752, DOI 10.1067/mai.2002.128581
   Singh A, 2007, J AM SOC NEPHROL, V18, P2885, DOI 10.1681/ASN.2007010119
   Skeie JM, 2008, INVEST OPHTH VIS SCI, V49, P5574, DOI 10.1167/iovs.08-1984
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   SPITZNAS M, 1975, INVEST OPHTH VISUAL, V14, P98
   Stan RV, 1999, P NATL ACAD SCI USA, V96, P13203, DOI 10.1073/pnas.96.23.13203
   Triebwasser MP, 2015, INVEST OPHTH VIS SCI, V56, P6873, DOI 10.1167/iovs.15-17432
   van Gemst JJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167336
   VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034
   Wang HB, 2016, MOL VIS, V22, P189
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Whitmore SS, 2013, MOL VIS, V19, P2274
   Wilmer MJ, 2010, CELL TISSUE RES, V339, P449, DOI 10.1007/s00441-009-0882-y
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 52
TC 8
Z9 8
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2018
VL 59
IS 2
BP 722
EP 730
DI 10.1167/iovs.IOVS-17-22893
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FX8LO
UT WOS:000426346300014
PM 29392318
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Courtenay, MD
   Cade, WH
   Schwartz, SG
   Kovach, JL
   Agarwal, A
   Wang, GF
   Haines, JL
   Pericak-Vance, MA
   Scott, WK
AF Courtenay, Monique D.
   Cade, William H.
   Schwartz, Stephen G.
   Kovach, Jaclyn L.
   Agarwal, Anita
   Wang, Gaofeng
   Haines, Jonathan L.
   Pericak-Vance, Margaret A.
   Scott, William K.
TI Set-Based Joint Test of Interaction Between SNPs in the VEGF Pathway and
   Exogenous Estrogen Finds Association With Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; case-control study; epidemiology;
   statistics; candidate genes
ID COMPLEMENT FACTOR-H; GENE-ENVIRONMENT INTERACTION; FACTOR EXPRESSION;
   MACULOPATHY; VARIANT; SUSCEPTIBILITY; INCREASES; RESPONSES; SMOKING;
   GROWTH
AB PURPOSE. Age-related macular degeneration (AMD) is the leading cause of irreversible visual loss in developed countries. Its etiology includes genetic and environmental factors. Although VEGFA variants are associated with AMD, the joint action of variants within the VEGF pathway and their interaction with nongenetic factors have not been investigated.
   METHODS. Affymetrix 6.0 chipsets were used to genotype 668,238 single nucleotide polymorphisms (SNPs) in 1207 AMD cases and 686 controls. Environmental exposures were collected by questionnaire. A set-based test was conducted using the chi(2) statistic at each SNP derived from Kraft's two degree of freedom (2df) joint test. Pathway- and gene-based test statistics were calculated as the mean of all independent SNP statistics. Phenotype labels were permuted 10,000 times to generate an empirical P value.
   RESULTS. While a main effect of the VEGF pathway was not identified, the pathway was associated with neovascular AMD in women when accounting for birth control pill (BCP) use (P = 0.017). Analysis of VEGF's subpathways showed that SNPs in the proliferation subpathway were associated with neovascular AMD (P = 0.029) when accounting for BCP use. Nominally significant genes within this subpathway were also observed. Stratification by BCP use revealed novel significant genetic effects in women who had taken BCPs.
   CONCLUSIONS. These results illustrate that some AMD genetic risk factors may be revealed only when complex relationships among risk factors are considered. This shows the utility of exploring pathways of previously associated genes to find novel effects. It also demonstrates the importance of incorporating environmental exposures in tests of genetic association at the SNP, gene, or pathway level.
C1 [Courtenay, Monique D.; Pericak-Vance, Margaret A.; Scott, William K.] Univ Miami, Dr John T Macdonald Fdn, Miller Sch Med, Dept Human Genet, Miami, FL 33136 USA.
   [Cade, William H.; Wang, Gaofeng; Pericak-Vance, Margaret A.; Scott, William K.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
   [Schwartz, Stephen G.; Kovach, Jaclyn L.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Agarwal, Anita] Vanderbilt Univ, Dept Ophthalmol, Nashville, TN 37235 USA.
   [Haines, Jonathan L.] Vanderbilt Univ, Ctr Human Genet Res, Nashville, TN 37235 USA.
C3 University of Miami; University of Miami; Bascom Palmer Eye Institute;
   University of Miami; Vanderbilt University; Vanderbilt University
RP Scott, WK (通讯作者)，Univ Miami, Hussman Inst Human Genom, 1501 NW 10th Ave,BRB 414, Miami, FL 33136 USA.
EM bscott@med.miami.edu
RI Haines, Jonathan/C-3374-2012
OI Haines, Jonathan/0000-0002-4351-4728; Scott, William/0000-0001-9336-6404
FU National Institutes of Health Grant [R01-EY012118]; National Institutes
   of Health Center Grant [P30-EY014801]; Research to Prevent Blindness,
   New York, New York; NATIONAL EYE INSTITUTE [R01EY012118] Funding Source:
   NIH RePORTER
FX Supported by National Institutes of Health Grant R01-EY012118 and
   partially supported by resources from National Institutes of Health
   Center Grant P30-EY014801 and an unrestricted grant to the University of
   Miami from Research to Prevent Blindness, New York, New York.
CR Abecasis GR, 2001, BIOINFORMATICS, V17, P742, DOI 10.1093/bioinformatics/17.8.742
   Ayala-Haedo JA, 2010, ANN HUM GENET, V74, P195, DOI 10.1111/j.1469-1809.2010.00570.x
   Ball LJ, 2009, MOL CELL ENDOCRINOL, V299, P204, DOI 10.1016/j.mce.2008.10.050
   Bebo BF, 2009, GLIA, V57, P777, DOI 10.1002/glia.20805
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boverhof DR, 2008, MOL PHARMACOL, V73, P82, DOI 10.1124/mol.107.040451
   Conklin BS, 2002, AM J PATHOL, V160, P413, DOI 10.1016/S0002-9440(10)64859-6
   CULLINANBOVE K, 1993, ENDOCRINOLOGY, V133, P829, DOI 10.1210/en.133.2.829
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Edwards DRV, 2010, INVEST OPHTH VIS SCI, V51, P1873, DOI 10.1167/iovs.09-4000
   Edwards TL, 2008, LECT NOTES COMPUT SC, V4973, P24, DOI 10.1007/978-3-540-78757-0_3
   Fong CJ, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-151
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   GAUDERMAN WJ, 2006, QUANTO 1 1 COMPUTER
   Gui Hongsheng, 2011, BMC Res Notes, V4, P386, DOI 10.1186/1756-0500-4-386
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holmans P, 2010, ADV GENET, V72, P141, DOI [10.1016/B978-0-12-380862-2.00007-2, 10.1016/S0065-2660(10)72007-1]
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kashiwagi T, 2000, ACTA NEUROBIOL EXP, V60, P9
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kinnamon DD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030238
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Korn JM, 2008, NAT GENET, V40, P1253, DOI 10.1038/ng.237
   Kraft P, 2007, HUM HERED, V63, P111, DOI 10.1159/000099183
   Kwekel JC, 2005, PHYSIOL GENOMICS, V23, P327, DOI 10.1152/physiolgenomics.00175.2005
   Liu JZ, 2010, AM J HUM GENET, V87, P139, DOI 10.1016/j.ajhg.2010.06.009
   Madsen BE, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000384
   Meyer RD, 2011, ONCOGENE, V30, P2198, DOI 10.1038/onc.2010.597
   Miki Y, 2007, BONE, V40, P876, DOI 10.1016/j.bone.2006.11.029
   Naj AC, 2013, ANN HUM GENET, V77, P215, DOI 10.1111/ahg.12011
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wang K, 2010, NAT REV GENET, V11, P843, DOI 10.1038/nrg2884
   Wei Y, 2012, INVEST OPHTH VIS SCI, V53, P2845, DOI 10.1167/iovs.11-8684
   Wei Y, 2011, INVEST OPHTH VIS SCI, V52, P4780, DOI 10.1167/iovs.10-6350
   Werle-Schneider G, 2006, INT J TOXICOL, V25, P379, DOI 10.1080/10915810600846963
   Wu MC, 2011, AM J HUM GENET, V89, P82, DOI 10.1016/j.ajhg.2011.05.029
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zong Y, 2012, CURR MED CHEM, V19, P770, DOI 10.2174/092986712798992066
NR 52
TC 4
Z9 4
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2014
VL 55
IS 8
BP 4873
EP 4879
DI 10.1167/iovs.14-14494
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ9DV
UT WOS:000343145500023
PM 25015356
OA Green Published
DA 2022-11-30
ER

PT J
AU Chiu, CJ
   Klein, R
   Milton, RC
   Gensler, G
   Taylor, A
AF Chiu, C-J
   Klein, R.
   Milton, R. C.
   Gensler, G.
   Taylor, A.
TI Does eating particular diets alter the risk of age-related macular
   degeneration in users of the Age-Related Eye Disease Study supplements?
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID GLYCEMIC INDEX; ANTIOXIDANTS; CARBOHYDRATE; PROGRESSION; ZINC
AB Background: Recent information suggests that the Age-Related Eye Disease Study (AREDS) supplement, enhanced intake of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), and reducing dietary glycaemic index (dGI) are protective against advanced age-related macular degeneration (AMD).
   Methods: Dietary information was collected at baseline, and fundus photograph grades were obtained during the 8-year trial period from 2924 eligible AREDS AMD trial participants. Using the eye as the unit of analysis and multifailure Cox proportional-hazards regression, the risk of AMD progression was related to dietary intake in the four arms of the trial.
   Results: Independent of AREDS supplementation, higher intakes of DHA (>= 64.0 vs < 26.0 mg/day) (hazard ratio (HR) = 0.73, 95% confidence interval (CI), 0.57 to 0.94), EPA (>= 42.3 vs < 12.7 mg/day) (HR = 0.74, 95% CI 0.59 to 0.94), and lower dGI (dGI, < 75.2 vs >= 81.5) (HR = 0.76, 95% CI 0.60 to 0.96) were associated with a lower risk for progression to advanced AMD. Participants consuming a lower dGI and higher DHA or EPA had the lowest risk (p value for synergistic interaction < 0.001). Only participants in the "placebo'' (p value for antagonistic interaction = 0.006) benefited from a higher DHA intake against early AMD progression (HR = 0.58, 95% CI 0.37 to 0.92; P-trend = 0.01).
   Conclusions: The findings show an association of consuming a diet rich in DHA with a lower progression of early AMD. In addition to the AREDS supplement, a lower dGI with higher intakes of DHA and EPA was associated with a reduced progression to advanced AMD.
C1 [Chiu, C-J] Tufts Univ, Lab Nutr & Vis Res, Jean Mayer USDA, Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
   [Chiu, C-J; Taylor, A.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Klein, R.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Milton, R. C.; Gensler, G.] EMMES Corp, AREDS Coordinating Ctr, Rockville, MD USA.
C3 Tufts University; United States Department of Agriculture (USDA); Tufts
   University; University of Wisconsin System; University of Wisconsin
   Madison; Emmes Corporation
RP Chiu, CJ (通讯作者)，Tufts Univ, Lab Nutr & Vis Res, Jean Mayer USDA, Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.
EM cj.chiu@tufts.edu
FU National Institutes of Health [1950-5100-060-01A, R01-13250,
   R03-EY014183-01A2]; Johnson & Johnson Focused Giving Program; American
   Health Assistance Foundation; NATIONAL EYE INSTITUTE [R01EY013250,
   R03EY014183] Funding Source: NIH RePORTER
FX Financial support for this project has been provided by the US
   Department of Agriculture under agreements, 1950-5100-060-01A (C-JC, AT)
   and R01-13250 and R03-EY014183-01A2 from the National Institutes of
   Health (AT); grants (AT) from the Johnson & Johnson Focused Giving
   Program and American Health Assistance Foundation, and to C-JC from the
   Ross Aging Initiative.
CR Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976
   Anil E, 2007, P NUTR SOC, V66, P60, DOI 10.1017/S0029665107005307
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2007, EXP EYE RES, V84, P229, DOI 10.1016/j.exer.2006.05.015
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P880, DOI 10.1093/ajcn/83.4.880
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Foster-Powell K, 2002, AM J CLIN NUTR, V76, P5, DOI 10.1093/ajcn/76.1.5
   Gebauer SK, 2006, AM J CLIN NUTR, V83, p1526S, DOI 10.1093/ajcn/83.6.1526S
   Jampol LM, 2001, JAMA-J AM MED ASSOC, V286, P2466
   JENKINS DJA, 1981, AM J CLIN NUTR, V34, P362, DOI 10.1093/ajcn/34.3.362
   Jenkins DJA, 2002, AM J CLIN NUTR, V76, p266S, DOI 10.1093/ajcn/76.1.266S
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Kurinij N, 1998, INT C DIET ASS MEAS
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   Stitt AW, 2005, ANN NY ACAD SCI, V1043, P582, DOI 10.1196/annals.1338.066
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Willett W., 2013, NUTR EPIDEMIOLOGY, V3rd
   WOLEVER TMS, 1994, AM J CLIN NUTR, V59, P1265, DOI 10.1093/ajcn/59.6.1265
NR 24
TC 53
Z9 53
U1 0
U2 14
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2009
VL 93
IS 9
BP 1241
EP 1246
DI 10.1136/bjo.2008.143412
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 498JL
UT WOS:000270135500027
PM 19508997
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Lazic, R
   Gabric, N
AF Lazic, Ratimir
   Gabric, Nikica
TI Verteporfin therapy and intravitreal bevacizumab combined and alone in
   choroidal neovascularization due to age-related macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; NATURAL-HISTORY; AVASTIN; TRIAMCINOLONE;
   RANIBIZUMAB
AB Objective: To evaluate the efficacy and safety of photodynamic therapy (PDT) with verteporfin combined with intravitreal bevacizumab in choroidal neovascularization (CNV) owing to age-related macular degeneration (AMD) in comparison with individual monotherapies used as controls.
   Design: Randomized controlled pilot clinical trial.
   Participants: Males or females, aged >= 50 years, with minimally classic or occult CNV owing to AMD in at least 1 eye that had never been treated previously.
   Methods: One hundred sixty-five eyes in 165 subjects (53 males, 112 females) aged between 60 and 87 years (mean [standard deviation]: 75.7 [6.0] years) were randomly assigned to receive either a single PDT session with verteporfin (PDT group; n = 55), or a single administration of intravitreal bevacizumab (1.25 mg; BEV group; n = 55), or their combination (COMB group; n = 55). In the COMB group, bevacizumab was administered within 1 hour of PDT. Subjects were followed up at 1 and 3 months after treatment. Ophthalmic evaluations including optical coherence tomography, fluorescein angiography, and visual acuity (VA) and central foveal thickness (CFT) measurements were performed at each visit.
   Main Outcome Measures: Changes from baseline in best-corrected VA and CFT measured at 1- and 3-month follow-up visits.
   Results: One hundred fifty-six subjects (54 BEV, 50 PDT, and 52 COMB) completed the study. At the 3-month follow-up, significant improvements in best-corrected VA were observed in the BEV and COMB groups (0.079 and 0.223 logarithm of the minimum angle of resolution [IogMAR], respectively; P<0.0001 for both). In the PDT group, a slight worsening was noted. Significant reductions of CFT were observed in the 3 groups (-34.0 mu m [BEV], -59.6 mu m [COMB], and -50.5 mu m [PDT]; P<0.0001 for all). At the 1-month follow-up, 46 subjects (16 BEV, 29 COMB, and 1 PDT) had an improvement >0.2 IogMAR in best-corrected VA; at 3-month follow-up, this improvement persisted in 23 subjects (1 BEV, 22 COMB, and 0 PDT).
   Conclusions: Significant improvements in best-corrected VA after 1 month and their maintenance over a 3-month period were observed after verteporfin PDT combined with intravitreal bevacizumab. These results should be confirmed in larger and long-term prospective randomized trials.
C1 Eye Clin Svjetlost, Zagreb 10000, Croatia.
RP Lazic, R (通讯作者)，Eye Clin Svjetlost, Bukovacka 27, Zagreb 10000, Croatia.
EM ratimir.lazic@svjetlost.hr
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Ali F, 2004, ARCH OPHTHALMOL-CHIC, V122, P710, DOI 10.1001/archopht.122.5.710
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Polito A, 2006, ANN ACAD MED SINGAP, V35, P145
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
NR 20
TC 115
Z9 123
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2007
VL 114
IS 6
BP 1179
EP 1185
DI 10.1016/j.ophtha.2007.03.006
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 174AC
UT WOS:000246912600023
PM 17544776
DA 2022-11-30
ER

PT J
AU Muether, PS
   Hermann, MM
   Koch, K
   Fauser, S
AF Muether, Philipp Sebastian
   Hermann, Manuel M.
   Koch, Konrad
   Fauser, Sascha
TI Delay between medical indication to anti-VEGF treatment in age-related
   macular degeneration can result in a loss of visual acuity
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Ranibizumab treatment; Health insurance; Treatment delay; Exsudative
   AMD; Visual acuity; OCT; Choroidal neovascularization
ID RANIBIZUMAB
AB Background Complicated approval procedures and limited short-term surgical capacities can result in time delays between the definition of a medical indication for ranibizumab treatment in active neovascular age-related macular degeneration (AMD) and the starting of treatment. This study aimed to evaluate changes in visual acuity and central retinal thickness over time, and their consequences for the patients concerned.
   Methods Sixty-nine patients indicated for first-time ranibizumab treatment and 21 patients with necessary re-treatment were included in the study. Visual acuity and spectral domain optical coherence tomography (SD-OCT) central retinal thickness at the time of the indication examination were compared to values at the first-time treatment and during recurrent ranibizumab treatment.
   Results For first-time treatment, the delay between indication and treatment was significantly higher for patients with vision loss compared to those without vision loss (31.6 +/- A 20.5 vs. 24.0 +/- A 8.3 days, p = 0.012). The increase in OCT central retinal thickness was 50.4 +/- A 92.8 mu m for patients with vision loss compared to 5.1 +/- A 63.4 mu m for those without vision loss, p = 0.029. A 1.1 logMAR line difference in vision loss was significant at p = 0.01 for patients with a delay in treatment of less than or equal to 28 days (48/69 patients, 69.7%) compared to those with a delay of more than 28 days (21/69 patients, 30.3%).
   Conclusions Even though average visual decay was slow at about one logMAR line over 110 days, individual patients (8.7%) experienced rapid loss of one or more lines within 21 days. Administrative procedures should therefore be expedited so that delays do not exceed 2 weeks for the sake of vision preservation in individual patients.
C1 [Muether, Philipp Sebastian] Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, D-50924 Cologne, Germany.
   [Muether, Philipp Sebastian; Hermann, Manuel M.; Koch, Konrad; Fauser, Sascha] Univ Cologne, Ctr Ophthalmol, D-50924 Cologne, Germany.
C3 University of Cologne; University of Cologne
RP Muether, PS (通讯作者)，Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, Kerpener Str 62, D-50924 Cologne, Germany.
EM philmuether@mac.com
FU Koeln Fortune Program/Faculty of Medicine, University of Cologne
FX Supported by the Koeln Fortune Program/Faculty of Medicine, University
   of Cologne
CR Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   *EMEA, 2007, EMEA SCI DISC LUCENT, P54
   *EMEA, 2007, LUC COMB PROD INF
   *EMEA, 2008, EMEAHC715, P54
   Oliver-Fernandez M, 2005, CAN J OPHTHALMOL, V40, P313, DOI 10.1016/S0008-4182(05)80074-2
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 10
TC 56
Z9 57
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2011
VL 249
IS 5
BP 633
EP 637
DI 10.1007/s00417-010-1520-9
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 756SN
UT WOS:000290035100002
PM 20865421
DA 2022-11-30
ER

PT J
AU Hussain, AA
   Lee, Y
   Marshall, J
AF Hussain, Ali A.
   Lee, Yunhee
   Marshall, John
TI Understanding the complexity of the matrix metalloproteinase system and
   its relevance to age-related diseases: Age-related macular degeneration
   and Alzheimer's disease
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Extracellular matrix; Metalloproteinases; Protein aggregation; Macular
   degeneration; Alzheimer's disease
ID HUMAN BRUCHS MEMBRANE; AMYLOID PRECURSOR PROTEIN;
   SORSBYS-FUNDUS-DYSTROPHY; RETINA TREATMENT SRT; A-BETA-PEPTIDE; TISSUE
   INHIBITOR; MATRIX-METALLOPROTEINASE-9 DIMERS; HYDRAULIC CONDUCTIVITY;
   STRUCTURAL-CHANGES; GENE-EXPRESSION
AB Extracellular matrices (ECMs) are maintained by tightly coupled processes of continuous synthesis and degradation. The degradative arm is mediated by a family of proteolytic enzymes called the matrix metalloproteinases (MMPs). These enzymes are released as latent proteins (pro-MMPs) and on activation are capable of degrading most components of an ECM. Activity of these enzymes is checked by the presence of tissue inhibitors of MMPs (TIMPs) and current opinion holds that the ratio of TIMPs/MMPs determines the relative rate of degradation. Thus, elevated ratios are thought to compromise degradation leading to the accumulation of abnormal ECM material, whilst diminished ratios are thought to lead to excessive ECM degradation (facilitating angiogenesis and the spread of cancer cells).
   Our recent work has shown this system to be far more complex. MMP species tend to undergo covalent modification leading to homo- and hetero-dimerization and aggregation resulting in the formation of very large macromolecular weight MMP complexes (LMMCs). In addition, the various MMP species also show a bound-free compartmentalisation. The net result of these changes is to reduce the availability of the latent forms of MMPs for the activation process. An assessment of the degradation potential of the MMP system in any tissue must therefore take into account the degree of sequestration of the latent MMP species, a protocol that has not previously been addressed. Taking into consideration the complexities already described, we will present an analysis of the MMP system in two common neurodegenerative disorders, namely age-related macular degeneration (AMD) and Alzheimer's disease (AD).
C1 [Hussain, Ali A.; Marshall, John] UCL Inst Ophthalmol, Dept Genet, 11-43 Bath St, London EC1V 9EL, England.
   [Lee, Yunhee] Alt Regen Co Ltd, Yongin, South Korea.
C3 University of London; University College London
RP Hussain, AA (通讯作者)，UCL Inst Ophthalmol, Dept Genet, 11-43 Bath St, London EC1V 9EL, England.
EM alyhussain@aol.com; bestuni@gmail.com; Eye.marshall@googlemail.com
FU Department of Health through National Institute for Health Research;
   BRACE (Bristol Research into Alzheimer's and Care of the Elderly);
   Brains for Dementia Research; Medical Research Council
FX The authors acknowledge financial support from the Department of Health
   through the award made by the National Institute for Health Research to
   Moorfields Eye Hospital NHS Foundation Trust and University College
   London Institute of Ophthalmology for a Biomedical Research Centre for
   Ophthalmology. The views expressed in this publication are those of the
   authors and not necessarily those of the Department of Health.; We would
   also like to thank the Bristol Eye Bank UK for donor human eyes and the
   South West Dementia Brain Bank (SWDBB), UK., for providing brain tissue
   for this study. The SWDBB is supported by BRACE (Bristol Research into
   Alzheimer's and Care of the Elderly), Brains for Dementia Research and
   the Medical Research Council.
CR Ahir A, 2002, INVEST OPHTH VIS SCI, V43, P458
   Ahmad M, 2006, J BIOCHEM, V139, P517, DOI 10.1093/jb/mvj054
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Andrew RJ, 2016, J BIOL CHEM, V291, P19235, DOI 10.1074/jbc.R116.746032
   BACKSTROM JR, 1992, J NEUROCHEM, V58, P983, DOI 10.1111/j.1471-4159.1992.tb09352.x
   Backstrom JR, 1996, J NEUROSCI, V16, P7910
   Baranger K, 2017, FRONT MOL NEUROSCI, V9, DOI 10.3389/fnmol.2016.00163
   Baranger K, 2016, CELL MOL LIFE SCI, V73, P217, DOI 10.1007/s00018-015-1992-1
   Baranger K, 2014, PROG BRAIN RES, V214, P313, DOI 10.1016/B978-0-444-63486-3.00014-1
   Barbolina MV, 2008, SEMIN CELL DEV BIOL, V19, P24, DOI 10.1016/j.semcdb.2007.06.008
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401
   Brinkmann R, 2000, LASER SURG MED, V27, P451, DOI 10.1002/1096-9101(2000)27:5<451::AID-LSM1006>3.0.CO;2-1
   Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   CAPON MRC, 1989, OPHTHALMOLOGY, V96, P1769
   Chami L, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-52
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chin JR, 1997, DEVELOPMENT, V124, P1519
   Christensen LP, 2009, ADV FOOD NUTR RES, V55, P1, DOI 10.1016/S1043-4526(08)00401-4
   Colige A, 1997, P NATL ACAD SCI USA, V94, P2374, DOI 10.1073/pnas.94.6.2374
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio C.A., 2013, RETINA-J RET VIT DIS, VVolume 1, P465
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   De Strooper B, 2010, PHYSIOL REV, V90, P465, DOI 10.1152/physrev.00023.2009
   Dentchev T, 2003, MOL VIS, V9, P184
   Dufour A, 2010, J BIOL CHEM, V285, P35944, DOI 10.1074/jbc.M109.091769
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329
   Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200
   FIOTTI N, 2007, GENET MED, V4, P272
   Flower DR, 1996, BIOCHEM J, V318, P1
   Fornoni A, 2002, J AM SOC NEPHROL, V13, P2068, DOI 10.1097/01.ASN.0000022421.86757.8D
   Framme C, 2008, LASER SURG MED, V40, P616, DOI 10.1002/lsm.20685
   Framme C, 2009, CURR EYE RES, V34, P568, DOI 10.1080/02713680902964892
   GRINDLE CFJ, 1978, T OPHTHAL SOC UK, V98, P172
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Guan KP, 2003, UROLOGY, V61, P719, DOI 10.1016/S0090-4295(02)02429-9
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Guymer R.H., 2018, OPHTHALMOLOGY, P1
   HAMLIN CR, 1971, BIOCHIM BIOPHYS ACTA, V236, P458, DOI 10.1016/0005-2795(71)90226-1
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Hemandez-Guillamon M., 2015, J BIOL CHEM, V290, P15078
   Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7
   Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Hsu TI, 2015, ONCOGENE, V34, P826, DOI 10.1038/onc.2014.22
   Hussain AA, 2010, EXP EYE RES, V90, P703, DOI 10.1016/j.exer.2010.02.013
   Hussain AA, 2002, J OPT SOC AM A, V19, P166, DOI 10.1364/JOSAA.19.000166
   Hussain AA, 2004, FOCUS ON MACULAR DEGENERATION RESEARCH, P59
   Hussain AA, 2014, INVEST OPHTH VIS SCI, V55, P2358, DOI 10.1167/iovs.13-12503
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   Hussain AA, 2010, INVEST OPHTH VIS SCI, V51, P2363, DOI 10.1167/iovs.09-4259
   Hussain Ali Aijaz, 2017, J Neurodegener Dis, V2017, P4810232, DOI 10.1155/2017/4810232
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   JACOBSON SG, 1995, NAT GENET, V11, P27, DOI 10.1038/ng0995-27
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jorissen E, 2010, J NEUROSCI, V30, P4833, DOI 10.1523/JNEUROSCI.5221-09.2010
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kang KS, 2007, BIOL PHARM BULL, V30, P917, DOI 10.1248/bpb.30.917
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kitts DD, 2000, MOL CELL BIOCHEM, V203, P1, DOI 10.1023/A:1007078414639
   KJELDSEN L, 1993, J BIOL CHEM, V268, P10425
   KLEINER DE, 1993, BIOCHEMISTRY-US, V32, P1583, DOI 10.1021/bi00057a024
   Klenotic PA, 2004, J BIOL CHEM, V279, P30469, DOI 10.1074/jbc.M403026200
   Kuhn PH, 2010, EMBO J, V29, P3020, DOI 10.1038/emboj.2010.167
   Kumar A, 2010, INVEST OPHTH VIS SCI, V51, P2664, DOI 10.1167/iovs.09-4195
   Lee S.J., 1981, KOREAN BIOCH J, V14, P1
   Lee Y, 2015, INVEST OPHTH VIS SCI, V56, P8403, DOI 10.1167/iovs.15-16936
   Lim GP, 1997, J NEUROCHEM, V68, P1606
   Lim JM, 2002, J CATARACT REFR SURG, V28, P697, DOI 10.1016/S0886-3350(01)01236-6
   Liu Q, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-17
   Lu L, 2009, BIOORGAN MED CHEM, V17, P7548, DOI 10.1016/j.bmc.2009.09.009
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Mang J.J., 2012, INVEST OPHTH VIS SCI, V53, P2928
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Marshall J., 1998, RETINAL PIGMENT EPIT, P669
   MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705
   Metz VV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041823
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Mott JD, 1997, KIDNEY INT, V52, P1302, DOI 10.1038/ki.1997.455
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nagai N, 2009, INVEST OPHTH VIS SCI, V50, P1903, DOI 10.1167/iovs.08-2383
   Nagase H, 2003, BIOCHEM SOC SYMP, V70, P201, DOI 10.1042/bss0700201
   Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491
   NAKAJIMA M, 1993, CANCER RES, V53, P5802
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nowak JZ, 2011, MIL PHARM MED, V1, P20
   Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446
   Overall CM, 2004, BIOL CHEM, V385, P493, DOI 10.1515/BC.2004.058
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   PARK AJ, 1991, J BIOL CHEM, V266, P1584
   Patryas L, 2013, GRAEF ARCH CLIN EXP, V251, P1821, DOI 10.1007/s00417-013-2324-5
   Pelosini L, 2013, RETINA-J RET VIT DIS, V33, P548, DOI 10.1097/IAE.0b013e3182670fea
   Pilcher BK, 1999, ANN NY ACAD SCI, V878, P12, DOI 10.1111/j.1749-6632.1999.tb07671.x
   Py NA, 2014, FRONT AGING NEUROSCI, V6, DOI [10.3389/tnagi.2014.00247, 10.3389/fnagi.2014.00247]
   Qiu J, 2014, GENET MOL RES, V13, P3586, DOI 10.4238/2014.May.9.2
   Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rivera S, 2019, CELL MOL LIFE SCI, V76, P3167, DOI 10.1007/s00018-019-03178-2
   Rivera S, 2010, J NEUROSCI, V30, P15337, DOI 10.1523/JNEUROSCI.3467-10.2010
   ROHER AE, 1994, BIOCHEM BIOPH RES CO, V205, P1755, DOI 10.1006/bbrc.1994.2872
   ROIDER J, 1993, P NATL ACAD SCI USA, V90, P8643, DOI 10.1073/pnas.90.18.8643
   Roomi MW, 2014, INT J ONCOL, V44, P986, DOI 10.3892/ijo.2013.2235
   Roomi MW, 2015, ONCOL LETT, V9, P2871, DOI 10.3892/ol.2015.3132
   Rossello A, 2016, CURR DRUG TARGETS, V17, P1908, DOI 10.2174/1389450117666160727143618
   Sagare A, 2007, NAT MED, V13, P1029, DOI 10.1038/nm1635
   Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Selkoe DJ, 2016, EMBO MOL MED, V8, P595, DOI 10.15252/emmm.201606210
   Selvais C, 2011, FASEB J, V25, P2770, DOI 10.1096/fj.10-169508
   Shimajiri S, 1999, FEBS LETT, V455, P70, DOI 10.1016/S0014-5793(99)00863-7
   Smine A, 1997, CURR EYE RES, V16, P925, DOI 10.1076/ceyr.16.9.925.5044
   SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   Starr AE, 2012, J BIOL CHEM, V287, P5848, DOI 10.1074/jbc.M111.314609
   STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   Treumer F, 2012, EXP EYE RES, V97, P63, DOI 10.1016/j.exer.2012.02.011
   TRIEBEL S, 1992, FEBS LETT, V314, P386, DOI 10.1016/0014-5793(92)81511-J
   Upadhya AG, 1997, HEPATOLOGY, V26, P922, DOI 10.1002/hep.510260418
   VATER CA, 1979, BIOCHEM J, V181, P639, DOI 10.1042/bj1810639
   Walker DG, 2006, J LEUKOCYTE BIOL, V79, P596, DOI 10.1189/jlb.0705377
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023
   WOESSNER JF, 1995, METHOD ENZYMOL, V248, P510
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yan L, 2001, J BIOL CHEM, V276, P37258, DOI 10.1074/jbc.M106089200
   Yan P, 2006, J BIOL CHEM, V281, P24566, DOI 10.1074/jbc.M602440200
   Ye S, 2000, MATRIX BIOL, V19, P623, DOI 10.1016/S0945-053X(00)00102-5
   Yin KJ, 2006, J NEUROSCI, V26, P10939, DOI 10.1523/JNEUROSCI.2085-06.2006
   YU BS, 1985, CHEM-BIOL INTERACT, V56, P303, DOI 10.1016/0009-2797(85)90013-4
   Yun UJ, 2013, BIOCHEM PHARMACOL, V85, P1441, DOI 10.1016/j.bcp.2013.02.025
   Zhang L, 2008, J BIOL CHEM, V283, P35507, DOI 10.1074/jbc.M806948200
NR 143
TC 8
Z9 11
U1 1
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JAN
PY 2020
VL 74
AR 100775
DI 10.1016/j.preteyeres.2019.100775
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KK1AP
UT WOS:000512482800005
PM 31473329
DA 2022-11-30
ER

PT J
AU van Asten, F
   Evers-Birkenkamp, KU
   van Lith-Verhoeven, JJC
   de Jong-Hesse, Y
   Hoppenreijs, VPT
   Hommersom, RF
   Scholten, AM
   Hoyng, CB
   Klaver, JHJ
AF van Asten, Freekje
   Evers-Birkenkamp, Kim U.
   van Lith-Verhoeven, Janneke J. C.
   de Jong-Hesse, Yvonne
   Hoppenreijs, Vincent P. T.
   Hommersom, Richard F.
   Scholten, Agnes M.
   Hoyng, Carel B.
   Klaver, Johannes H. J.
CA HELIOS Study Grp
TI A prospective, observational, open-label, multicentre study to
   investigate the daily treatment practice of ranibizumab in patients with
   neovascular age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE daily practice; neovascular AMD; observational; quality of life;
   ranibizumab; visual acuity
ID QUALITY-OF-LIFE; VISUAL-ACUITY; INTRAVITREAL RANIBIZUMAB;
   CLINICAL-PRACTICE; OUTCOMES; SAFETY; IMPAIRMENT; PREVALENCE; THERAPY
AB PurposeThe HELIOS (Health Economics with Lucentis in Observational Settings) study was designed on request of the Dutch Health Authority for an observational study to assess the effectiveness and safety of ranibizumab for neovascular age-related macular degeneration (wet AMD) in daily practice.
   MethodsThe HELIOS study was a 2-year prospective, observational, open-label, multicentre study involving 14 sites. Patients with wet AMD were enrolled and observed for a period of 24months. The data were collected at baseline and at the visits closest around the time-points 3, 6, 12, 18 and 24months after inclusion.
   ResultsTreatment with ranibizumab resulted in prevention of vision loss. The mean ETDRS score increased from 45.1 letters at baseline to 48.5 letters at 24months. This was achieved with a mean of 7.8 injections over 24months. Stabilization of visual acuity was also reflected by the scores on the quality of life EQ-5D questionnaire, which did not significantly change over the study period. The more subjective EQ-VAS questionnaire showed an overall improvement. The VFQ-25 questionnaire was also mostly stable over time. After 24months, 32.2% of the patients gained 1 letter and 17.1% gained >15 letters. Patients completing the loading phase were better responders, as demonstrated by increased long-term visual acuity. In addition, ranibizumab was well tolerated and had a safety profile commonly seen in routine clinical practice.
   ConclusionThis study demonstrates that also in daily practice ranibizumab was effective in preventing vision loss over a period of 24months. No new safety findings were identified.
C1 [van Asten, Freekje; Hoyng, Carel B.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 ED Nijmegen, Netherlands.
   [Evers-Birkenkamp, Kim U.] Novartis Pharma BV, Arnhem, Netherlands.
   [van Lith-Verhoeven, Janneke J. C.] St Elizabeth Hosp, Dept Ophthalmol, Tilburg, Netherlands.
   [de Jong-Hesse, Yvonne] Vrije Univ Amsterdam Med Ctr, Dept Ophthalmol, Amsterdam, Netherlands.
   [Hoppenreijs, Vincent P. T.] Deventer Hosp, Dept Ophthalmol, Deventer, Netherlands.
   [Hommersom, Richard F.] Maxima Med Ctr, Dept Ophthalmol, Veldhoven, Netherlands.
   [Scholten, Agnes M.; Klaver, Johannes H. J.] OMC Haarlem, Haarlem, Netherlands.
C3 Radboud University Nijmegen; Novartis; Elisabeth-TweeSteden Ziekenhuis
   (ETZ); Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER;
   Deventer Hospital; Maxima Medical Center
RP van Asten, F (通讯作者)，Philips van Leydenlaan 15, NL-6525 EX Nijmegen, Netherlands.
EM Freekje.vanAsten@radboudumc.nl
RI Hoyng, C.B./H-8050-2014; Klaver, Caroline C.W./A-2013-2016; van Asten,
   Freekje/P-6028-2015
OI van Asten, Freekje/0000-0002-8141-4234
FU Novartis Pharma B.V.
FX This study was sponsored by Novartis Pharma B.V. The authors would like
   to thank M. Geel from QPS Netherlands B.V. for support in writing the
   manuscript and J. van Es from QPS Netherlands B.V. for statistical
   analysis. The following principal investigators were members of the
   HELIOS study group: J.H.J. Klaver, OMC Haarlem, Haarlem; C.B. Hoyng,
   Radboud university medical center, Nijmegen; A. J. Raijmakers, Rijnland
   Ziekenhuis, Leiderdorp; J. J. C. van Lith-Verhoeven, Sint Elisabeth
   Ziekenhuis, Tilburg; A.H.F. Rulo, F.D. Verbraak and R.O. Schlingemann,
   Oogziekenhuis Zonnestraal, Hilversum; C.F. Hommersom, Maxima Medisch
   Centrum, Veldhoven; Y. de Jong-Hesse, VU Medical Center Amsterdam; E.H.
   Bosch-Driessen, Flevoziekenhuis, Almere; M.H. Smeets, Jeroen Bosch
   Ziekenhuis, s'-Hertogenbosch; A. Goncalves, St. Jans Gasthuis, Weert; H.
   J. Klomp, Ziekenuis Nij Smellinghe, Drachten; V.P.T. Hoppenreijs,
   Deventer Ziekenhuis, Deventer; J. J. Dito; OPSIS Oogartsenpraktijk,
   Amstelveen. The Netherlands.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gerding H, 2011, GRAEF ARCH CLIN EXP, V249, P653, DOI 10.1007/s00417-011-1636-6
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Lala C, 2013, ACTA OPHTHALMOL, V91, P526, DOI 10.1111/j.1755-3768.2012.02457.x
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Rotsos T, 2010, CLIN OPHTHALMOL, V4, P1271, DOI 10.2147/OPTH.S14684
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
NR 28
TC 25
Z9 25
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2015
VL 93
IS 2
BP 126
EP 133
DI 10.1111/aos.12610
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CB8SC
UT WOS:000349900200029
PM 25488348
OA Bronze
DA 2022-11-30
ER

PT J
AU Caire, J
   Recalde, S
   Velazquez-Villoria, A
   Garcia-Garcia, L
   Reiter, N
   Anter, J
   Fernandez-Robredo, P
   Garcia-Layana, A
AF Caire, Josemaria
   Recalde, Sergio
   Velazquez-Villoria, Alvaro
   Garcia-Garcia, Laura
   Reiter, Nicholas
   Anter, Jaouad
   Fernandez-Robredo, Patricia
   Garcia-Layana, Alfredo
CA Spanish Multictr Grp AMD
TI Growth of Geographic Atrophy on Fundus Autofluorescence and
   Polymorphisms of CFH, CFB, C3, FHR1-3, and ARMS2 in Age-Related Macular
   Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; PROGRESSION; ASSOCIATION; DISEASE; DRUSEN; RISK;
   SUSCEPTIBILITY; LOC387715; GENES; EYE
AB IMPORTANCE Identification of the genetic risk factors that contribute to geographic atrophy (GA) could lead to advancements in interventional trials and/or therapeutic approaches for combating vision loss.
   OBJECTIVE To investigate whether single-nucleotide polymorphisms (SNPs) are associated with the presence and progression of established GA in age-related macular degeneration (AMD).
   DESIGN, SETTING, AND PARTICIPANTS Prospective, controlled, multicenter study of 154 patients with GA/AMD and 141 age-matched control participants at 8 Spanish hospitals.
   MAIN OUTCOMES AND MEASURES Samples of DNA were collected to analyze SNPs within AMD-related genes (CFH, CFB, C3, FHR1-3, and ARMS2). Fundus autofluorescence imaging was used to evaluate GA progression during a 2-year period in 73 patients with GA/AMD. Finally, logistic regression was used to analyze the associations of SNPs, age, body mass index, and cigarette smoking with the rate of progression and relative growth of GA.
   RESULTS This case-control analysis revealed a significant (P <.05) association between the presence of GA and SNPs within CFH, ARMS2, and FHR1-3. Moreover, logistic regression analysis identified significant associations of the rate of progression with genetic polymorphisms (CFH-402His [P =.04] and CFH-6211e [P =.04]) and demographic factors (sex [P =.02] and age [P =.02]), whereas relative growth was associated with 1 polymorphism (CFB-32Gln [P =.04]).
   CONCLUSIONS AND RELEVANCE Taken together, our findings confirm that genetic risk factors related to the presence of GA are not identical to those associated with GA progression. In fact, we demonstrate that gene variants of CFH and CFB, as well as demographic risk factors, confer significant risk for GA progression ( both rate of progression and relative growth) within a Spanish population.
C1 [Caire, Josemaria; Recalde, Sergio; Velazquez-Villoria, Alvaro; Garcia-Garcia, Laura; Reiter, Nicholas; Fernandez-Robredo, Patricia] Univ Navarra, Ophthalmol Expt Lab, E-31080 Pamplona, Spain.
   [Caire, Josemaria; Velazquez-Villoria, Alvaro; Garcia-Layana, Alfredo] Univ Navarra Clin, Dept Ophthalmol, Pamplona 31008, Navarra, Spain.
   [Anter, Jaouad] Ctr Invest Biol & Ciber Enfermedades Raras, Dept Cellular & Mol Med, Madrid, Spain.
C3 University of Navarra; University of Navarra; CIBER - Centro de
   Investigacion Biomedica en Red; CIBERER; Consejo Superior de
   Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones
   Biologicas (CIB)
RP Garcia-Layana, A (通讯作者)，Univ Navarra Clin, Dept Ophthalmol, Irunlarrea S-N, Pamplona 31008, Navarra, Spain.
EM aglayana@unav.es
RI Gomez-Ramirez, Ana María/AAB-4677-2019; Martin, Rosa Maria
   Coco/H-4511-2015; Recalde, Sergio/D-1815-2017
OI Gomez-Ramirez, Ana María/0000-0001-7953-7289; Martin, Rosa Maria
   Coco/0000-0002-1811-1417; Recalde, Sergio/0000-0002-9328-9725; Zapata,
   Miguel Angel/0000-0002-0096-4569; Ruiz-Moreno, Jose
   M/0000-0001-9636-0788
FU Ministerio de Ciencia e Innovacion [RDO7/0062]; Ministerio de Economia y
   Competitividad [Plll/00898, RETICS RD12/0034];  [P108/1705]
FX This study was supported in part by grants P108/1705 and Red Tematica de
   Investigacion Cooperativa en Salud (RETICS) RDO7/0062 from the
   Ministerio de Ciencia e Innovacion and grants Plll/00898 and RETICS
   RD12/0034 from the Ministerio de Economia y Competitividad. Drs Recalde,
   Fernandez-Robredo, and Garcia-Layana and Ms Garcia-Garcia are members of
   RETICS RDO7/0062 and RD12/0034.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bearelly S, 2010, ADV EXP MED BIOL, V664, P395, DOI 10.1007/978-1-4419-1399-9_45
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P6552, DOI 10.1167/iovs.11-7298
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   García Layana Alfredo, 2011, Arch Soc Esp Oftalmol, V86, P101, DOI 10.1016/j.oftal.2011.03.005
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 2008, AM J OPHTHALMOL, V146, P692
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Luo L, 2008, VISION RES, V48, P494, DOI 10.1016/j.visres.2007.11.013
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Martinez-Barricarte R, 2012, INVEST OPHTH VIS SCI, V53, P1087, DOI 10.1167/iovs.11-8709
   Recalde S, 2008, OPHTHALMOLOGY, V115, P916, DOI 10.1016/j.ophtha.2007.12.012
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
NR 30
TC 24
Z9 24
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAY
PY 2014
VL 132
IS 5
BP 528
EP 534
DI 10.1001/jamaophthalmol.2013.8175
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AJ7QW
UT WOS:000337892500003
PM 24557084
OA Bronze
DA 2022-11-30
ER

PT J
AU Schultz, DW
   Klein, ML
   Humpert, AJ
   Luzier, CW
   Persun, V
   Schain, M
   Mahan, A
   Runckel, C
   Cassera, M
   Vittal, V
   Doyle, TM
   Martin, TM
   Weleber, RG
   Francis, PJ
   Acott, TS
AF Schultz, DW
   Klein, ML
   Humpert, AJ
   Luzier, CW
   Persun, V
   Schain, M
   Mahan, A
   Runckel, C
   Cassera, M
   Vittal, V
   Doyle, TM
   Martin, TM
   Weleber, RG
   Francis, PJ
   Acott, TS
TI Analysis of the ARMD1 locus: evidence that a mutation in HEMICENTIN-1 is
   associated with age-related macular degeneration in a large family
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID MATRIX METALLOPROTEINASES; MACULOPATHY; EXPRESSION; PREVALENCE;
   INHIBITOR; SCAN; GENE; PAIR
AB Age-related macular degeneration (AMD) is a common cause of severe vision loss. Identification of the genes involved in AMD will lead to a better understanding of this disease at the molecular level, which will eventually lead to early detection, prevention and treatment. Previously, we mapped the ARMD1 gene to 1q25-31 in a large family with AMD. Here, we narrow the ARMD1 locus to 14.9 Mb between LAMB2 and D1S3469, a region containing 50 known genes. Twenty candidate genes within this region were screened for mutations. Only one DNA variation, an A16,263G transition in exon 104 of HEMICENTIN-1, was found to segregate exclusively with the disease haplotype in members of this large family with AMD. This variation produces a non-conservative substitution of arginine for glutamine at amino acid position 5345 (Gln5345Arg). It was also identified in 11 other individuals, all of whom share a haplotype, which envelops HEMICENTIN-1, with the large AMD family. The affected status of all but one of those individuals conforms to the age-dependent penetrance observed in AMD. The amino acid at position 5345 of HEMICENTIN-1 was conserved as glutamine in eight species analyzed. RT-PCR analysis demonstrated that exon 104 of HEMICENTIN-1 is alternatively spliced in various cell types. Exclusive segregation of Gln5345Arg with the disease haplotype in this large family, amino acid conservation of glutamine at this position among mammals, the non-conservative nature of the substitution and similarities to EFEMP1 support the conclusion that HEMICENTIN-1 is the ARMD1 gene.
C1 Oregon Hlth & Sci Univ, CERES, Casey Eye Inst, Macular Degenerat Ctr, Portland, OR 97239 USA.
   Oregon Hlth & Sci Univ, Casey Eye Inst, Dept Ophthalmol, Portland, OR 97239 USA.
   Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA.
   Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA.
   Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA.
C3 Oregon Health & Science University; Oregon Health & Science University;
   Oregon Health & Science University; Oregon Health & Science University;
   Oregon Health & Science University
RP Schultz, DW (通讯作者)，Oregon Hlth & Sci Univ, CERES, Casey Eye Inst, Macular Degenerat Ctr, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM schultzd@ohsu.edu
OI Cassera, Maria/0000-0002-5118-8352; Mahan, Alison/0000-0003-4284-8467
FU NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000334] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R01EY012203, R01EY013139, R01EY008247,
   R01EY003279] Funding Source: NIH RePORTER; NCRR NIH HHS [5 M01 RR000334]
   Funding Source: Medline; NEI NIH HHS [EY 10527, EY 03279, EY 13139, EY
   12203, EY 08247] Funding Source: Medline
CR ALEXANDER JP, 1990, INVEST OPHTH VIS SCI, V31, P2520
   ALEXANDER JP, 1991, INVEST OPHTH VIS SCI, V32, P172
   Carpten JD, 2000, GENOMICS, V64, P1, DOI 10.1006/geno.1999.6051
   Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Gorin MB, 1999, MOL VIS, V5, pU31
   Hageman GS, 1999, MOL VIS, V5
   Handford PA, 2000, BBA-MOL CELL RES, V1498, P84, DOI 10.1016/S0167-4889(00)00085-9
   Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Oefner P. J., 1995, American Journal of Human Genetics, V57, pA266
   Ott J., 1991, ANAL HUMAN GENETIC L
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Silverman MD, 2001, INVEST OPHTH VIS SCI, V42, P2861
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Underhill PA, 1997, GENOME RES, V7, P996, DOI 10.1101/gr.7.10.996
   Valdar WSJ, 2002, PROTEINS, V48, P227, DOI 10.1002/prot.10146
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vogel BE, 2001, DEVELOPMENT, V128, P883
   Vranka JA, 1997, CURR EYE RES, V16, P102, DOI 10.1076/ceyr.16.2.102.5086
   WALLACE RB, 1979, NUCLEIC ACIDS RES, V6, P3543, DOI 10.1093/nar/6.11.3543
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Wirtz MK, 1997, AM J HUM GENET, V60, P296
   Yan H, 2000, NATURE, V403, P723, DOI 10.1038/35001659
NR 29
TC 138
Z9 154
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD DEC 15
PY 2003
VL 12
IS 24
BP 3315
EP 3323
DI 10.1093/hmg/ddg348
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 753GT
UT WOS:000187224200012
PM 14570714
OA Bronze
DA 2022-11-30
ER

PT J
AU Alaimo, A
   Di Santo, MC
   Rubio, APD
   Chaufan, G
   Linares, GG
   Perez, OE
AF Alaimo, Agustina
   Carolina Di Santo, Mariana
   Dominguez Rubio, Ana Paula
   Chaufan, Gabriela
   Garcia Linares, Guadalupe
   Edgardo Perez, Oscar
TI Toxic effects of A2E in human ARPE-19 cells were prevented by
   resveratrol: a potential nutritional bioactive for age-related macular
   degeneration treatment
SO ARCHIVES OF TOXICOLOGY
LA English
DT Article
DE Resveratrol; N-retinylidene-N-retinylethanolamine (A2E); Age-related
   macular degeneration; Retinal pigment epithelial cells; Oxidative
   stress; Transepithelial electrical resistance (TEER)
ID RETINAL-PIGMENT EPITHELIUM; LIPOFUSCIN FLUOROPHORE; TRANS-RESVERATROL;
   PROLIFERATION; DYSFUNCTION; EXPRESSION; APOPTOSIS; STRESS; GROWTH; RPE
AB Age-related macular degeneration (AMD) is a late-onset retinal disease and the leading cause of central vision loss in the elderly. Degeneration of retinal pigment epithelial cells (RPE) is a crucial contributing factor responsible for the onset and progression of AMD. The toxic fluorophore N-retinyl-N-retinylidene ethanolamine (A2E), a major lipofuscin component, accumulates in RPE cells with age. Phytochemicals with antioxidant properties may have a potential role in both the prevention and treatment of this age-related ocular disease. Particularly, there is an increased interest in the therapeutic effects of resveratrol (RSV), a naturally occurring polyphenol (3,4 ',5-trihydroxystilbene). However, the underlying mechanism of the RSV antioxidative effect in ocular diseases has not been well explored. We hypothesized that this bioactive compound may have beneficial effects for AMD. To this end, to investigate the potential profits of RSV against A2E-provoked oxidative damage, we used human RPE cell line (ARPE-19). RSV (25 mu M) attenuates the cytotoxicity and the typical morphological characteristics of apoptosis observed in 25 mu M A2E-laden cells. RSV pretreatment strengthened cell monolayer integrity through the preservation of the transepithelial electrical resistance and reduced the fluorescein isothiocyanate (FITC)-dextran diffusion rate as well as cytoskeleton architecture. In addition, RSV exhorts protective effects against A2E-induced modifications in the intracellular redox balance. Finally, RSV also prevented A2E-induced mitochondrial network fragmentation. These findings reinforce the idea that RSV represents an attractive bioactive for therapeutic intervention against ocular diseases associated with oxidative stress such as AMD.
C1 [Alaimo, Agustina; Carolina Di Santo, Mariana; Dominguez Rubio, Ana Paula; Edgardo Perez, Oscar] Univ Buenos Aires, Fac Ciencias Exactas & Nat, Inst Quim Biol Ciencias Exactas & Nat IQUIBICEN, CONICET,Dept Quim Biol,Lab Interdisciplinario Din, Pabellon 2,Ciudad Univ, RA-1428 Buenos Aires, DF, Argentina.
   [Chaufan, Gabriela] Univ Buenos Aires, Fac Ciencias Exactas & Nat, Inst Quim Biol Ciencias Exactas & Nat IQUIBICEN, CONICET,Dept Quim Biol,Lab Enzimol Estres Oxidat, Pabellon 2,Ciudad Univ, RA-1428 Buenos Aires, DF, Argentina.
   [Garcia Linares, Guadalupe] Univ Buenos Aires, Fac Ciencias Exactas & Nat, Unidad Microanal & Metodos Fis Quim Organ UMYMFOR, Dept Quim Organ,Lab Biocatalisis,CONICET, Pabellon 2,Ciudad Univ, RA-1428 Buenos Aires, DF, Argentina.
C3 Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET);
   University of Buenos Aires; Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET); University of Buenos Aires; Consejo
   Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University
   of Buenos Aires
RP Alaimo, A; Perez, OE (通讯作者)，Univ Buenos Aires, Fac Ciencias Exactas & Nat, Inst Quim Biol Ciencias Exactas & Nat IQUIBICEN, CONICET,Dept Quim Biol,Lab Interdisciplinario Din, Pabellon 2,Ciudad Univ, RA-1428 Buenos Aires, DF, Argentina.
EM aalaimo@qb.fcen.uba.ar; cdisanto@qb.fcen.uba.ar; apaudr@qb.fcen.uba.ar;
   gchaufan@qb.fcen.uba.ar; linares@qo.fcen.uba.ar;
   oscarperez@qb.fcen.uba.ar
RI Rubio, Ana Paula Domínguez/AAF-8201-2021
OI Rubio, Ana Paula Domínguez/0000-0003-4499-8397; Perez, Oscar
   E/0000-0002-8223-1077; Chaufan, Gabriela/0000-0002-4727-2084
FU ANPCyT PICT Joven [2016-1151]; PICT [2015-3866, 2017-1683]; UBACyT
   [20020150100079BA]; PIP 2017 [11220170100420CO]; Consejo Nacional de
   Investigaciones Cientificas y Tecnicas (CONICET)
FX The present report was supported by grants from the ANPCyT PICT Joven
   2016-1151, PICT (Start Up 2015-3866 and 2017-1683), UBACyT
   20020150100079BA, PIP 2017 11220170100420CO and Consejo Nacional de
   Investigaciones Cientificas y Tecnicas (CONICET). Authors thank Dr.
   Damian Dorfman and BSc. Hernan Dieguez (CEFYBO-CONICET, Argentina) for
   their support in the experimental ophthalmic field. We also appreciated
   the advice of Prof. Dr. Valeria Levi and BSc. Mariano Smoler
   (IQUIBI-CEN-CONICET, Argentina) who shared with us their knowledge about
   cytoskeleton analysis techniques with us.
CR Abba Y, 2015, ADV VIROL, V2015, DOI 10.1155/2015/184241
   Abdelgawad IY, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030627
   Abe T, 2003, INVEST OPHTH VIS SCI, V44, P4097, DOI 10.1167/iovs.02-0867
   Abu-Amero KK, 2016, NUTRIENTS, V8, DOI 10.3390/nu8040200
   Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Alaimo A, 2019, ARCH TOXICOL, V93, P1401, DOI 10.1007/s00204-019-02409-6
   Alaimo A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091848
   Alaimo A, 2011, NEUROCHEM INT, V59, P297, DOI 10.1016/j.neuint.2011.06.001
   Albuquerque RV, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134768
   Ao J, 2018, CLIN EXP OPHTHALMOL, V46, P670, DOI 10.1111/ceo.13121
   Bai L, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-77
   Barar Jaleh, 2009, J Ophthalmic Vis Res, V4, P238
   Bartolak-Suki E, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081812
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Berman K, 2006, INT PSYCHOGERIATR, V18, P415, DOI 10.1017/S1041610205002905
   Bianchi E, 2013, INT J MOL MED, V31, P232, DOI 10.3892/ijmm.2012.1164
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Bola C, 2014, GRAEF ARCH CLIN EXP, V252, P699, DOI 10.1007/s00417-014-2604-8
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Bungau S, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9783429
   Chan CM, 2015, INT J MOL SCI, V16, P5789, DOI 10.3390/ijms16035789
   Chaufan G, 2014, INT J TOXICOL, V33, P29, DOI 10.1177/1091581813517906
   Chen C, 2017, MOL MED REP, V15, P2289, DOI 10.3892/mmr.2017.6252
   Chen Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018139
   Deak M, 2003, MONATSH CHEM, V134, P883, DOI 10.1007/s00706-002-0554-z
   Del Bo' C, 2019, NUTRIENTS, V11, DOI 10.3390/nu11061355
   Dieguez HH, 2019, FREE RADICAL BIO MED, V131, P72, DOI 10.1016/j.freeradbiomed.2018.11.035
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Feoktistova Maria, 2016, Cold Spring Harb Protoc, V2016, DOI 10.1101/pdb.prot087379
   Fernandez-Robredo P, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/510285
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Franklin-Tong VE, 2008, BIOCHEM J, V413, P389, DOI 10.1042/BJ20080320
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gagliardi PA, 2019, CELL MOL LIFE SCI, V76, P3571, DOI 10.1007/s00018-019-03153-x
   Gambini J, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/837042
   Ha JH, 2014, J NUTR, V144, P799, DOI 10.3945/jn.113.186957
   Hao XN, 2016, INT J OPHTHALMOL-CHI, V9, P1725, DOI 10.18240/ijo.2016.12.04
   He Y, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14696
   Huang CX, 2015, INVEST OPHTH VIS SCI, V56, P6196, DOI 10.1167/iovs.15-16795
   Iuga C, 2012, J ORG CHEM, V77, P3868, DOI 10.1021/jo3002134
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kang JH, 2016, ARCH PHARM RES, V39, P1703, DOI 10.1007/s12272-016-0839-0
   Kim SR, 2008, EXP EYE RES, V86, P975, DOI 10.1016/j.exer.2008.03.016
   King RE, 2005, CHEM-BIOL INTERACT, V151, P143, DOI 10.1016/j.cbi.2004.11.003
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Kotchabhakdi KKJSYKKWN, 2006, ARVO ANN M, V47, P2077
   Koushki M, 2018, FOOD SCI NUTR, V6, P2473, DOI 10.1002/fsn3.855
   Kozlowski MR, 2015, J OCUL PHARMACOL TH, V31, P87, DOI 10.1089/jop.2014.0071
   Kurgvietiene L, 2016, MEDICINA-LITHUANIA, V52, P148, DOI 10.1016/j.medici.2016.03.003
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lee BL, 2016, NUTR RES, V36, P1402, DOI 10.1016/j.nutres.2016.11.008
   Lee CS, 2015, YONSEI MED J, V56, P1678, DOI 10.3349/ymj.2015.56.6.1678
   Legros F, 2002, MOL BIOL CELL, V13, P4343, DOI 10.1091/mbc.E02-06-0330
   Li WN, 2016, INT J FOOD SCI NUTR, V67, P650, DOI 10.1080/09637486.2016.1189886
   Li ZR, 2013, MOL VIS, V19, P1656
   Lin CH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071799
   Madreiter-Sokolowski CT, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101117
   Maugeri G, 2017, J CELL BIOCHEM, V118, P2371, DOI 10.1002/jcb.25899
   McBride H, 2013, BBA-MOL CELL RES, V1833, P148, DOI 10.1016/j.bbamcr.2012.11.001
   McCarthy C, 2016, SCI REP-UK, V6, DOI 10.1038/srep32683
   Mehta J, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7100147
   Mennel S, 2006, KLIN MONATSBL AUGENH, V223, P568, DOI 10.1055/s-2006-926479
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moine E, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7120197
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Mukherjee S, 2010, DOSE-RESPONSE, V8, P478, DOI 10.2203/dose-response.09-015.Mukherjee
   NABI IR, 1993, J CELL SCI, V104, P37
   Orgovan G, 2017, J PHARMACEUT BIOMED, V138, P322, DOI 10.1016/j.jpba.2016.09.019
   Pannu N, 2019, BIOMED PHARMACOTHER, V109, P2237, DOI 10.1016/j.biopha.2018.11.075
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Park SI, 2017, J PHARM PHARMACOL, V69, P334, DOI 10.1111/jphp.12691
   Parmar VM, 2018, STEM CELL RES, V27, P95, DOI 10.1016/j.scr.2018.01.014
   Pavan B, 2018, DRUG DISCOV TODAY, V23, P1672, DOI 10.1016/j.drudis.2018.06.009
   Perez-Torres I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102098
   Pintea A, 2011, J OCUL PHARMACOL TH, V27, P315, DOI 10.1089/jop.2010.0144
   Prokhorova EA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30652-x
   Quintana-Cabrera R, 2018, BIOCHEM BIOPH RES CO, V500, P94, DOI 10.1016/j.bbrc.2017.04.088
   Ramirez-Garza SL, 2018, NUTRIENTS, V10, DOI 10.3390/nu10121892
   Rashid A, 2016, ADV EXP MED BIOL, V854, P757, DOI 10.1007/978-3-319-17121-0_101
   Rashtbari S, 2017, ADV PHARM BULL, V7, P349, DOI 10.15171/apb.2017.042
   Ruweler M, 2009, CHEM-BIOL INTERACT, V182, P128, DOI 10.1016/j.cbi.2009.09.003
   Salehi B, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6030091
   Sarubbo F, 2017, CURR MED CHEM, V24, P4245, DOI 10.2174/0929867324666170724102743
   Sheu SJ, 2013, INVEST OPHTH VIS SCI, V54, P6426, DOI 10.1167/iovs.13-12024
   Shlisky J, 2017, ADV NUTR, V8, P17, DOI 10.3945/an.116.013474
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sripathi SR, 2016, PROTEIN J, V35, P179, DOI 10.1007/s10930-016-9659-9
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Tang DL, 2019, CELL RES, V29, P347, DOI 10.1038/s41422-019-0164-5
   Tarau IS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143578
   Tufarelli V, 2017, CURR DRUG METAB, V18, P905, DOI 10.2174/1389200218666170925124004
   Ungvari Z, 2011, EXERC SPORT SCI REV, V39, P128, DOI 10.1097/JES.0b013e3182141f80
   Wang L, 2018, INT J MOL MED, V41, P2764, DOI 10.3892/ijmm.2018.3467
   Wang Y, 2017, EXP EYE RES, V160, P45, DOI 10.1016/j.exer.2017.04.010
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yuan HD, 2016, MOLECULES, V21, DOI 10.3390/molecules21050559
   Zhang B, 2013, CANCER RES, V73, P6700, DOI 10.1158/0008-5472.CAN-13-1411
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
   Zhang X, 2018, LIFE SCI, V207, P234, DOI 10.1016/j.lfs.2018.06.010
   Zhao DY, 2020, CRIT REV FOOD SCI, V60, P597, DOI 10.1080/10408398.2018.1546668
   Ziegler CC, 2004, J NUTR, V134, P5, DOI 10.1093/jn/134.1.5
   Zou X, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.190
   Zou XL, 2018, INT J OPHTHALMOL-CHI, V11, P1594, DOI 10.18240/ijo.2018.10.04
NR 106
TC 15
Z9 15
U1 0
U2 14
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5761
EI 1432-0738
J9 ARCH TOXICOL
JI Arch. Toxicol.
PD FEB
PY 2020
VL 94
IS 2
BP 553
EP 572
DI 10.1007/s00204-019-02637-w
EA DEC 2019
PG 20
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA KQ0AZ
UT WOS:000501374200001
PM 31792590
DA 2022-11-30
ER

PT J
AU Colak, E
   Ignjatovic, S
   Radosavljevic, A
   Zoric, L
AF Colak, Emina
   Ignjatovic, Svetlana
   Radosavljevic, Aleksandra
   Zoric, Lepsa
TI The association of enzymatic and non-enzymatic antioxidant defense
   parameters with inflammatory markers in patients with exudative form of
   age-related macular degeneration
SO JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION
LA English
DT Article
DE age-related macular degeneration; oxidative stress; antioxidants;
   inflammation
ID C-REACTIVE PROTEIN; OXIDATIVE STRESS; AMD; INTERLEUKIN-6; PATHOGENESIS;
   MACULOPATHY; DYSFUNCTION; PROGRESSION; RISK
AB There are evidence that oxidative stress and inflammation are involved in the pathogenesis of the age-related macular degeneration (AMD). The aim of this study was to analyze the antioxidant defense parameters and inflammatory markers in patients with exudative form of AMD (eAMD), their mutual correlations and association with the specific forms of AMD. The cross-sectional study, included 75 patients with the eAMD, 31 patients with the early form, and 87 aged-matched control subjects. Significantly lower SOD, TAS and albumin values and higher GR, CRP and IL-6 were found in the eAMD compared to the early form (p<0.05). Significant negative correlations were found between GPx and fibrinogen (r = -0.254), TAS and IL-6 (r = -0.999) and positive correlations between uric acid and CRP (r = 0.292), IL-6 and uric acid (r = 0.398) in the eAMD. A significant association of CRP (OR: 1.16, 95% CI: 1.03-1.32, p = 0.018), fibrinogen (OR: 2.21, 95% CI: 1.14-4.85, p = 0.021), TAS (OR: 7.45, 95% CI: 3.97-14.35, p = 0.0001), albumin (OR: 1.25, 95% CI: 1.11-1.41, p = 0.0001) and uric acid (OR: 1.006, 95% CI: 1.00-1.02, p = 0.003) was found with the eAMD. In conclusion it may be suggested, there is a significant impairment of antioxidant and inflammatory parameter levels in eAMD patients. In addition, significant association exists between the tested inflammatory markers and antioxidant parameters with late-eAMD.
C1 [Colak, Emina; Ignjatovic, Svetlana] Univ Belgrade, Sch Pharm, Clin Ctr Serbia, Inst Med Biochem, Belgrade 11000, Serbia.
   [Radosavljevic, Aleksandra] Univ Belgrade, Sch Med, Clin Ctr Serbia, Inst Ophthalmol,Med Retina Dept, Belgrade 11000, Serbia.
   [Zoric, Lepsa] Fac Med, Clin Ctr, Clin Eye Dis, Kosovska Mitrovica 38200, Serbia.
C3 Clinical Centre of Serbia; University of Belgrade; Clinical Centre of
   Serbia; University of Belgrade
RP Colak, E (通讯作者)，Univ Belgrade, Sch Pharm, Clin Ctr Serbia, Inst Med Biochem, Belgrade 11000, Serbia.
EM eminacolak@sbb.rs
RI Radosavljevic, Aleksandra/K-3730-2014; Čolak, Emina/AAQ-1969-2021;
   Radosavljevic, Aleksandra/AAK-2407-2020
OI Radosavljevic, Aleksandra/0000-0002-8859-5103; Čolak,
   Emina/0000-0003-1901-3146; Radosavljevic, Aleksandra/0000-0002-8859-5103
FU Ministry of Science, Technology and Development of the Republic of
   Serbia [175036]
FX This study was conducted as a part of the projects No. 175036
   financially supported by the Ministry of Science, Technology and
   Development of the Republic of Serbia.
CR AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   Behndig A, 1998, INVEST OPHTH VIS SCI, V39, P471
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   BURSTEIN SA, 1994, STEM CELLS, V12, P386, DOI 10.1002/stem.5530120405
   COHEN SM, 1994, BRIT J OPHTHALMOL, V78, P791, DOI 10.1136/bjo.78.10.791
   Colak E, 2005, ANN MED, V37, P613, DOI 10.1080/07853890500330193
   Colak E., 2008, J MED BIOCHEM, V27, P1, DOI DOI 10.2478/V10011-007-0049-X
   Colak E, 2012, AGING CLIN EXP RES, V24, P588, DOI 10.3275/8593
   Colak E, 2012, BIOCHEM MEDICA, V22, P39
   Colak E, 2011, OPHTHALMIC RES, V46, P125, DOI 10.1159/000323815
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   de Jong PT, 2005, INVEST OPHTHALMOL VI, V46
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   Goldberg D.M., 1974, METHODS ENZYMATIC AN, V3rd, P258
   GOLDSTEIN S, 1988, FREE RADICAL BIO MED, V4, P295, DOI 10.1016/0891-5849(88)90050-0
   Horwath-Winter J, 2009, ACTA OPHTHALMOL, V87, P188, DOI 10.1111/j.1755-3768.2008.01215.x
   Hubner-Wozniak E, 2011, J MED BIOCHEM, V30, P103, DOI 10.2478/v10011-011-0008-4
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Indo HP, 2015, J CLIN BIOCHEM NUTR, V56, P1, DOI 10.3164/jcbn.14-42
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klouche M, 2000, CIRCULATION, V101, P1799, DOI 10.1161/01.CIR.101.15.1799
   Krohne TU, 2010, INVEST OPHTH VIS SCI, V51, P553, DOI 10.1167/iovs.09-3755
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   MILLER NJ, 1993, CLIN SCI, V84, P407, DOI 10.1042/cs0840407
   Nagaoka T, 2008, INVEST OPHTH VIS SCI, V49, P2053, DOI 10.1167/iovs.07-1387
   Nikoli-Kokic A, 2010, J MED BIOCHEM, V29, P189, DOI 10.2478/v10011-010-0018-7
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   PAGLIA DE, 1967, J LAB CLIN MED, V70, P158
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Subramani S, 2010, Med J Malaysia, V65, P36
   Suzuki M, 2007, MOL VIS, V13, P772
   Venza I, 2012, AGING CLIN EXP RES, V24, P21, DOI 10.3275/7659
   Verma S, 2003, AM J PHYSIOL-REG I, V285, pR1253, DOI 10.1152/ajpregu.00170.2003
   Virgolici Bogdana, 2007, Rom J Intern Med, V45, P59
   Wakamatsu TH, 2008, ARQ BRAS OFTALMOL, V71, P72, DOI 10.1590/S0004-27492008000700015
   Winkler BS, 1999, MOL VIS, V5
   Yamato M, 2014, J CLIN BIOCHEM NUTR, V55, P11, DOI 10.3164/jcbn.14-4
NR 42
TC 15
Z9 15
U1 0
U2 3
PU JOURNAL CLINICAL BIOCHEMISTRY & NUTRITION
PI KYOTO
PA KYOTO PREFECTURAL UNIV MED, GRAD SCH MEDICAL SCIENCE, DEPT MOLECULAR
   GASTROENTEROLOGY & HEPATOLOGY, KYOTO, 602-8566, JAPAN
SN 0912-0009
EI 1880-5086
J9 J CLIN BIOCHEM NUTR
JI J. Clin. Biochem. Nutr.
PD MAR 1
PY 2017
VL 60
IS 2
BP 100
EP 107
DI 10.3164/jcbn.16-30
PG 8
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA ET1PB
UT WOS:000400040200004
PM 28366988
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Sardell, RJ
   Persad, PJ
   Pan, SS
   Whitehead, P
   Adams, LD
   Laux, RA
   Fortun, JA
   Brantley, MA
   Kovach, JL
   Schwartz, SG
   Agarwal, A
   Haines, JL
   Scott, WK
   Pericak-Vance, MA
AF Sardell, Rebecca J.
   Persad, Patrice J.
   Pan, Samuel S.
   Whitehead, Patrice
   Adams, Larry D.
   Laux, Renee A.
   Fortun, Jorge A.
   Brantley, Milam A., Jr.
   Kovach, Jaclyn L.
   Schwartz, Stephen G.
   Agarwal, Anita
   Haines, Jonathan L.
   Scott, William K.
   Pericak-Vance, Margaret A.
TI Progression Rate From Intermediate to Advanced Age-Related Macular
   Degeneration Is Correlated With the Number of Risk Alleles at the CFH
   Locus
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration (AMD); genetics; progression
ID COMPLEMENT FACTOR-H; SUSCEPTIBILITY GENES; DISEASE PROGRESSION;
   GEOGRAPHIC ATROPHY; ASSOCIATION; VARIANT; C3; MACULOPATHY; EYE;
   POLYMORPHISMS
AB PURPOSE. Progression rate of age-related macular degeneration (AMD) varies substantially, yet its association with genetic variation has not been widely examined.
   METHODS. We tested whether progression rate from intermediate AMD to geographic atrophy (GA) or choroidal neovascularization (CNV) was correlated with genotype at seven single nucleotide polymorphisms (SNPs) in the four genes most strongly associated with risk of advanced AMD. Cox proportional hazards survival models examined the association between progression time and SNP genotype while adjusting for age and sex and accounting for variable follow-up time, right censored data, and repeated measures (left and right eyes).
   RESULTS. Progression rate varied with the number of risk alleles at the CFH: rs10737680 but not the CFH: rs1061170 (Y402H) SNP; individuals with two risk alleles progressed faster than those with one allele (hazard ratio [HR] = 1.61, 95% confidence interval [CI] = 1.08-2.40, P < 0.02, n = 547 eyes), although this was not significant after Bonferroni correction. This signal was likely driven by an association at the correlated protective variant, CFH: rs6677604, which tags the CFHR1-3 deletion; individuals with at least one protective allele progressed more slowly. Considering GA and CNV separately showed that the effect of CFH: rs10737680 was stronger for progression to CNV.
   CONCLUSIONS. Results support previous findings that AMD progression rate is influenced by CFH, and suggest that variants within CFH may have different effects on risk versus progression. However, since CFH: rs10737680 was not significant after Bonferroni correction and explained only a relatively small portion of variation in progression rate beyond that explained by age, we suggest that additional factors contribute to progression.
C1 [Sardell, Rebecca J.; Persad, Patrice J.; Pan, Samuel S.; Whitehead, Patrice; Adams, Larry D.; Scott, William K.; Pericak-Vance, Margaret A.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, 1501 NW 10th Ave,BRB 319, Miami, FL 33136 USA.
   [Laux, Renee A.; Haines, Jonathan L.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Fortun, Jorge A.; Kovach, Jaclyn L.; Schwartz, Stephen G.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Brantley, Milam A., Jr.; Agarwal, Anita] Vanderbilt Univ, Med Ctr, Ophthalmol & Visual Sci, Nashville, TN USA.
C3 University of Miami; Case Western Reserve University; Bascom Palmer Eye
   Institute; University of Miami; Vanderbilt University
RP Pericak-Vance, MA (通讯作者)，Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, 1501 NW 10th Ave,BRB 319, Miami, FL 33136 USA.
EM mpericak@med.miami.edu
RI Haines, Jonathan/C-3374-2012
OI Haines, Jonathan/0000-0002-4351-4728; Scott, William/0000-0001-9336-6404
FU National Eye Institute (NEI) [EY012118]; National Institutes of Health
   (NIH) Center Core Grant [P30EY014801]; Research to Prevent Blindness,
   New York; CIDR contract [HHSN268201200008I]; NEI T32 training grant
   [5T32EY023194-02];  [EY022310];  [1X01HG006934-01]; NATIONAL EYE
   INSTITUTE [R01EY022310, T32EY023194, U10EY012118, P30EY014801,
   R01EY012118] Funding Source: NIH RePORTER
FX Supported by National Eye Institute (NEI) Grant EY012118 (MAP-V, WKS,
   JLH, and AA), National Institutes of Health (NIH) Center Core Grant
   P30EY014801 (University of Miami), and an unrestricted grant from
   Research to Prevent Blindness, New York (University of Miami).
   Genotyping conducted as part of the International AMD Gene Consortium
   exome-chip project was supported by CIDR contract number
   HHSN268201200008I and funded by EY022310 (JLH) and 1X01HG006934-01 (to
   Goncalo R. Abecasis). RJS and PJP were supported by a NEI T32 training
   grant (5T32EY023194-02).
CR Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   Auguie B., 2017, GRIDEXTRA MISCELLANE
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Caire J, 2014, JAMA OPHTHALMOL, V132, P528, DOI 10.1001/jamaophthalmol.2013.8175
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chew EY, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12914
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Farwick A, 2010, INVEST OPHTH VIS SCI, V51, P731, DOI 10.1167/iovs.09-3953
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Gangnon RE, 2015, JAMA OPHTHALMOL, V133, P125, DOI 10.1001/jamaophthalmol.2014.4252
   Gangnon RE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1169, DOI 10.1001/archophthalmol.2012.693
   Glynn RJ, 2000, AM J EPIDEMIOL, V151, P965, DOI 10.1093/oxfordjournals.aje.a010140
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heagerty PJ, 2000, BIOMETRICS, V56, P337, DOI 10.1111/j.0006-341X.2000.00337.x
   Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Klein BEK, 2007, AM J OPHTHALMOL, V144, P961, DOI 10.1016/j.ajo.2007.08.016
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   O'Connell J, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004234
   Owzar K, 2012, GENET EPIDEMIOL, V36, P538, DOI 10.1002/gepi.21645
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P539, DOI 10.1007/s00417-002-0507-6
   Perlee LT, 2013, OPHTHALMOLOGY, V120, P1880, DOI 10.1016/j.ophtha.2013.02.007
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Raychaudhuri S, 2010, NAT GENET, V42, P553, DOI 10.1038/ng0710-553
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2000, MOL VIS, V6, P287
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087047
   Seddon JM, 2013, JAMA OPHTHALMOL, V131, P448, DOI 10.1001/jamaophthalmol.2013.2578
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Therneau MT, 2015, R TOP DOC
   Tikellis G, 2007, EYE, V21, P169, DOI 10.1038/sj.eye.6702151
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
NR 58
TC 14
Z9 14
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2016
VL 57
IS 14
BP 6107
EP 6115
DI 10.1167/iovs.16-19519
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EI3HG
UT WOS:000392380000032
PM 27832277
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Chen, CY
   Melo, E
   Jakob, P
   Friedlein, A
   Elsasser, B
   Goettig, P
   Kueppers, V
   Delobel, F
   Stucki, C
   Dunkley, T
   Fauser, S
   Schilling, O
   Iacone, R
AF Chen, Chia-yi
   Melo, Esther
   Jakob, Peter
   Friedlein, Arno
   Elsaesser, Brigitta
   Goettig, Peter
   Kueppers, Verena
   Delobel, Frederic
   Stucki, Corinne
   Dunkley, Tom
   Fauser, Sascha
   Schilling, Oliver
   Iacone, Roberto
TI N-Terminomics identifies HtrA1 cleavage of thrombospondin-1 with
   generation of a proangiogenic fragment in the polarized retinal pigment
   epithelial cell model of age-related macular degeneration
SO MATRIX BIOLOGY
LA English
DT Article
DE Age-related degeneration; Serine protease HtrA1; Polarized secretome
   analysis; Angiogenesis
ID SERINE-PROTEASE HTRA1; POLYPOIDAL CHOROIDAL VASCULOPATHY; BINDING
   COMPETITIVE INHIBITOR; PEPTIDE LIBRARIES; PROTEOMIC IDENTIFICATION;
   INCREASED EXPRESSION; CHROMOSOME 10Q26; CATHEPSIN-B; IN-VITRO;
   SPECIFICITY
AB Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the elderly population. Variants in the HTRA1-ARMS2 locus have been linked to increased AMD risk. In the present study we investigated the impact of elevated HtrA1 levels on the retina pigment epithelial (RPE) secretome using a polarized culture system. Upregulation of HtrA1 alters the abundance of key proteins involved in angiogenesis and extracellular matrix remodeling. Thrombospondin-1, an angiogenesis modulator, was identified as a substrate for HtrA1 using terminal amine isotope labeling of substrates in conjunction with HtrA1 specificity profiling. HtrA1 cleavage of thrombospondin-1 was further corroborated by in vitro cleavage assays and targeted proteomics together with small molecule inhibition of HtrA1. While thrombospondin-1 is anti-angiogenic, the proteolytically released N-terminal fragment promotes the formation of tube-like structure by endothelial cells. Taken together, our findings suggest a mechanism by which increased levels of HtrA1 may contribute to AMD pathogenesis.
   The proteomic data has been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the data set identifier. For quantitative secretome analysis, project accession: PXD007691, username: reviewer45093@ebi.ac.uk , password: 1FUpS6Yq. For TAILS analysis, project accession: PXD007139, username: reviewer76731@ebi.ac.uk , password: sNbMp7xK. (C) 2018 The Authors. Published by Elsevier B.V.
C1 [Chen, Chia-yi; Schilling, Oliver] Univ Freiburg, Fac Med, Inst Mol Med & Cell Res, Freiburg, Germany.
   [Melo, Esther; Kueppers, Verena; Delobel, Frederic; Stucki, Corinne; Fauser, Sascha; Iacone, Roberto] F Hoffmann La Roche Ltd, Roche Pharma Res & Early Dev, Neurosci Ophthalmol & Rare Dis Discovery & Transl, Roche Innovat Ctr Basel, Grenzacherstr 124, CH-4070 Basel, Switzerland.
   [Jakob, Peter; Friedlein, Arno; Dunkley, Tom] F Hoffmann La Roche Ltd, Roche Pharma Res & Early Dev, Pharmaceut Sci, Roche Innovat Ctr Basel, Grenzacherstr 124, CH-4070 Basel, Switzerland.
   [Elsaesser, Brigitta; Goettig, Peter] Univ Salzburg, Div Struct Biol, Dept Biosci, Billrothstr 11, A-5020 Salzburg, Austria.
   [Schilling, Oliver] Univ Freiburg, MOSS Ctr Biol Signaling Studies, D-79104 Freiburg, Germany.
   [Schilling, Oliver] German Canc Consortium DKTK, D-69120 Heidelberg, Germany.
   [Schilling, Oliver] German Canc Res Ctr, D-69120 Heidelberg, Germany.
C3 University of Freiburg; Roche Holding; Roche Holding; Salzburg
   University; University of Freiburg; Helmholtz Association; German Cancer
   Research Center (DKFZ); Helmholtz Association; German Cancer Research
   Center (DKFZ)
RP Schilling, O (通讯作者)，Stefan Meier Str 17, D-79104 Freiburg, Germany.
EM oliver.schilling@mol-med.uni-freiburg.de
RI Schilling, O/AAC-8302-2019; Goettig, Peter/K-4508-2019
OI Goettig, Peter/0000-0002-2430-1970; Elsaesser,
   Brigitta/0000-0002-9087-243X; Schilling, Oliver/0000-0001-7678-7653
FU Deutsche Forschungsgemeinschaft [SCHI 871/5, SCHI 871/8, SCHI 871/9,
   SCHI 871/11, INST 39/900-1, SFB850]; Excellence Initiative of the German
   Federal and State Governments [EXC 294]; Austrian Science Fund (FWF)
   [M1901]
FX OS acknowledges support by Deutsche Forschungsgemeinschaft (SCHI 871/5,
   SCHI 871/8, SCHI 871/9, SCHI 871/11, INST 39/900-1, and SFB850-Project
   Z1), and the Excellence Initiative of the German Federal and State
   Governments (EXC 294, BIOSS). BE thanks the Austrian Science Fund (FWF)
   for the Lise-Meitner Grant (no. M1901). We thank Alejandro Gomez-Auli
   for providing the LIMMA script for statistical analysis.
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Baldi A, 2002, ONCOGENE, V21, P6684, DOI 10.1038/sj.onc.1205911
   Bein K, 2000, J BIOL CHEM, V275, P32167, DOI 10.1074/jbc.M003834200
   Bhutto IA, 2008, ARCH OPHTHALMOL-CHIC, V126, P670, DOI 10.1001/archopht.126.5.670
   Biniossek ML, 2016, MOL CELL PROTEOMICS, V15, P2515, DOI 10.1074/mcp.O115.056671
   Campioni M, 2010, MOL CANCER RES, V8, P1248, DOI 10.1158/1541-7786.MCR-09-0473
   Chen CY, 2017, METHODS MOL BIOL, V1574, P197, DOI 10.1007/978-1-4939-6850-3_14
   Cheng Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053665
   Chu Q, 2016, J AM CHEM SOC, V138, P9473, DOI 10.1021/jacs.6b03463
   Clausen T, 2011, NAT REV MOL CELL BIO, V12, P152, DOI 10.1038/nrm3065
   Craig R, 2004, BIOINFORMATICS, V20, P1466, DOI 10.1093/bioinformatics/bth092
   Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004
   Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707
   Day A.J., 2018, MATRIX BIOL
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   do Outeiro-Bernstein MAF, 2002, MATRIX BIOL, V21, P311, DOI 10.1016/S0945-053X(02)00010-0
   Eckhard U, 2016, MATRIX BIOL, V49, P37, DOI 10.1016/j.matbio.2015.09.003
   Eigenbrot C, 2012, STRUCTURE, V20, P1040, DOI 10.1016/j.str.2012.03.021
   Escher C, 2012, PROTEOMICS, V12, P1111, DOI 10.1002/pmic.201100463
   Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094
   Friedrich U, 2015, HUM MOL GENET, V24, P6361, DOI 10.1093/hmg/ddv346
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gomez-Auli A, 2016, BIOCHIMIE, V122, P88, DOI 10.1016/j.biochi.2015.10.009
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   Grau S, 2005, P NATL ACAD SCI USA, V102, P6021, DOI 10.1073/pnas.0501823102
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   HOGG PJ, 1993, J BIOL CHEM, V268, P7139
   HOGG PJ, 1992, BIOCHEMISTRY-US, V31, P265, DOI 10.1021/bi00116a036
   HOGG PJ, 1993, J BIOL CHEM, V268, P21811
   Hou J, 2005, J CELL BIOCHEM, V94, P470, DOI 10.1002/jcb.20328
   Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406
   Iejima Daisuke, 2015, J Stem Cells, V10, P193
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kanda A, 2010, MOL VIS, V16, P1317
   Kay P, 2013, J CELL MOL MED, V17, P833, DOI 10.1111/jcmm.12070
   Kim SJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep11872
   Kleifeld O, 2010, NAT BIOTECHNOL, V28, P281, DOI 10.1038/nbt.1611
   Koczorowska MM, 2016, MOL ONCOL, V10, P40, DOI 10.1016/j.molonc.2015.08.001
   Kumar S, 2014, INVEST OPHTH VIS SCI, V55, P3842, DOI 10.1167/iovs.13-13111
   Lange PF, 2011, NAT METHODS, V8, P703, DOI 10.1038/nmeth.1669
   Launay S, 2008, CELL DEATH DIFFER, V15, P1408, DOI 10.1038/cdd.2008.82
   LAWLER J, 1986, ANN NY ACAD SCI, V485, P273, DOI 10.1111/j.1749-6632.1986.tb34589.x
   Lee NV, 2006, EMBO J, V25, P5270, DOI 10.1038/sj.emboj.7601400
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   MacLean B, 2010, BIOINFORMATICS, V26, P966, DOI 10.1093/bioinformatics/btq054
   Makawita S, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.008599
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Martins LM, 2003, J BIOL CHEM, V278, P49417, DOI 10.1074/jbc.M308659200
   Melo E, 2018, EBIOMEDICINE, V27, P258, DOI 10.1016/j.ebiom.2017.12.011
   Miyajima-Uchida H, 2000, INVEST OPHTH VIS SCI, V41, P561
   Murphy-Ullrich JE, 2017, MATRIX BIOL
   Nakayama M, 2014, INVEST OPHTH VIS SCI, V55, P6514, DOI 10.1167/iovs.14-14453
   Ng TK, 2016, SCI REP-UK, V6, DOI 10.1038/srep28639
   RabhiSabile S, 1996, FEBS LETT, V386, P82, DOI 10.1016/0014-5793(96)00408-5
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Ricard-Blum S., 2017, MATRIX BIOL
   Risor MW, 2014, BIOCHEMISTRY-US, V53, P3851, DOI 10.1021/bi401633w
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Rusnati M, 2010, PHARMACEUTICALS-BASE, V3, P1241, DOI 10.3390/ph3041241
   Schilling O, 2008, NAT BIOTECHNOL, V26, P685, DOI 10.1038/nbt1408
   Schilling O, 2011, METHODS MOL BIOL, V753, P257, DOI 10.1007/978-1-61779-148-2_17
   Shahinian H, 2013, EXPERT REV PROTEOMIC, V10, P421, DOI 10.1586/14789450.2013.841547
   Shridhar V, 2002, CANCER RES, V62, P262
   Sigloch FC, 2016, BBA-MOL CELL RES, V1863, P2700, DOI 10.1016/j.bbamcr.2016.08.005
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Staniszewska I, 2007, CIRC RES, V100, P1308, DOI 10.1161/01.RES.0000266662.98355.66
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Taraboletti G, 2000, FASEB J, V14, P1674
   Tholen S, 2014, CELL MOL LIFE SCI, V71, P899, DOI 10.1007/s00018-013-1406-1
   TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497
   Truebestein L, 2011, NAT STRUCT MOL BIOL, V18, P386, DOI 10.1038/nsmb.2013
   Uno K, 2006, BRIT J OPHTHALMOL, V90, P48, DOI 10.1136/bjo.2005.074005
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Wang GF, 2013, EXP EYE RES, V112, P102, DOI 10.1016/j.exer.2013.04.019
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Zhao ZG, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0524-z
NR 80
TC 17
Z9 19
U1 0
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0945-053X
EI 1569-1802
J9 MATRIX BIOL
JI Matrix Biol.
PD SEP
PY 2018
VL 70
BP 84
EP 101
DI 10.1016/j.matbio.2018.03.013
PG 18
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA GU3IE
UT WOS:000445169000009
PM 29572155
OA hybrid
DA 2022-11-30
ER

PT J
AU Saxena, N
   George, PP
   Heng, BH
   Lim, TH
   Yong, SO
AF Saxena, Nakul
   George, Pradeep Paul
   Heng, Bee Hoon
   Lim, Tock Han
   Yong, Shao Onn
TI Cost-effectiveness of anti-oxidant vitamins plus zinc treatment to
   prevent the progression of intermediate age-related macular
   degeneration. A Singapore perspective
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; anti-oxidant vitamins;
   cost-effectiveness analysis; Singapore
ID BETA-CAROTENE; EYE; PREVALENCE; RANIBIZUMAB; UTILITY; BURDEN; TRIAL
AB Purpose: To determine if providing high dose anti-oxidant vitamins and zinc treatment age-related eye disease study (AREDS formulation) to patients with intermediate age-related macular degeneration (AMD) aged 40-79 years from Singapore is cost-effective in preventing progression to wet AMD. Methods: A hypothetical cohort of category 3 and 4 AMD patients from Singapore was followed for 5 calendar years to determine the number of patients who would progress to wet AMD given the following treatment scenarios: (a) AREDS formulation or placebo followed by ranibizumab (as needed) for wet AMD. (b) AREDS formulation or placebo followed by bevacizumab (monthly) for wet AMD. (c) AREDS formulation or placebo followed by aflibercept (VIEW I and II trial treatment regimen) Costs were estimated for the above scenarios from the providers' perspective, and cost-effectiveness was measured by cost per disability-adjusted life year (DALY) averted with a disability weight of 0.22 for wet AMD. The costs were discounted at an annual rate of 3%. Results: Over 5400 patients could be prevented from progressing to wet AMD cumulatively if AREDS formulation were prescribed. AREDS formulation followed by ranibizumab was cost-effective compared to placebo-ranibizumab or placebo-aflibercept combinations (cost per DALY averted: SGD$23,662.3 and SGD$21,138.8, respectively). However, bevacizumab (monthly injections) alone was more cost-effective compared to AREDS formulation followed by bevacizumab. Conclusion: Prophylactic treatment with AREDS formulation for intermediate AMD patients followed by ranibizumab or for patients who progressed to wet AMD was found to be cost-effective. These findings have implications for intermediate AMD screening, treatment and healthcare planning in Singapore.
C1 [Saxena, Nakul; George, Pradeep Paul; Heng, Bee Hoon] Natl Healthcare Grp, Dept Hlth Serv & Outcomes Res, Singapore 138543, Singapore.
   [Lim, Tock Han; Yong, Shao Onn] Tan Tock Seng Hosp, Dept Ophthalmol, Singapore, Singapore.
C3 Tan Tock Seng Hospital
RP Saxena, N (通讯作者)，Natl Healthcare Grp, Dept Hlth Serv & Outcomes Res, 3 Fusionopolis Link,403-08 Nexus One North, Singapore 138543, Singapore.
EM nakul_saxena@nhg.com.sg
RI George, Pradeep Paul/ABE-9925-2020
OI George, Pradeep Paul/0000-0003-4743-1425
CR Bandello F, 2007, INVEST OPHTH VIS SCI, V48, P96, DOI 10.1167/iovs.06-0283
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Eong KGA, 2012, EYE, V26, P379, DOI 10.1038/eye.2011.218
   Garattini Livio, 2004, Eur J Health Econ, V5, P22
   Hay J W, 1998, Value Health, V1, P187, DOI 10.1046/j.1524-4733.1998.130187.x
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P450, DOI 10.1136/bjo.2003.035279
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell J, 2007, ARCH OPHTHALMOL-CHIC, V125, P1266, DOI 10.1001/archopht.125.9.1266
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Patel JJ, 2012, J EVAL CLIN PRACT, V18, P247, DOI 10.1111/j.1365-2753.2010.01546.x
   Rein DB, 2007, OPHTHALMOLOGY, V114, P1319, DOI 10.1016/j.ophtha.2006.10.041
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   SNODDERLY DM, 1995, AM J CLIN NUTR S, V62, P14485
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
NR 27
TC 4
Z9 5
U1 0
U2 6
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD JUN
PY 2015
VL 63
IS 6
BP 516
EP 523
DI 10.4103/0301-4738.158533
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CP8JG
UT WOS:000360139200011
PM 26265643
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wang, XY
   Sawada, T
   Sawada, O
   Saishin, Y
   Liu, P
   Ohji, M
AF Wang, Xiying
   Sawada, Tomoko
   Sawada, Osamu
   Saishin, Yoshitsugu
   Liu, Ping
   Ohji, Masahito
TI Serum and Plasma Vascular Endothelial Growth Factor Concentrations
   Before and After Intravitreal Injection of Aflibercept or Ranibizumab
   for Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CANCER-PATIENTS; VEGF-TRAP; PHARMACOKINETICS; BEVACIZUMAB; VERTEPORFIN;
   INHIBITION; PEGAPTANIB; SAFETY; MODEL
AB PURPOSE: To evaluate serum and plasma vascular endothelial growth factor (VEGF) concentrations in neovascular age-related macular degeneration patients treated bimonthly with an intravitreal injection of aflibercept or ranibizumab.
   DESIGN: Prospective, interventional case series.
   METHODS: This study includes 17 eyes of 17 patients treated with 2 mg aflibercept (the aflibercept group), 15 eyes of 15 patients treated with 0.5 mg ranibizumab (the ranibizumab group), and 12 patients with cataract (the control group). Serum and plasma VEGF concentrations were quantified using the enzyme-linked immunosorbent assay.
   RESULTS: At baseline, mean serum VEGF concentration (in picograms per milliliter) did not differ significantly among the 3 groups (P = .99). In the aflibercept group, it was 28.3 pg/mL at baseline, decreased to below the detectable limit at 1 week (P < .0001), increased to 11.7 pg/mL at 1 month, which was still significantly less than the baseline level (P < .001), and returned to 23.9 pg/mL (P = .35) at 2 months. In the ranibizumab group, there were no significant differences. At baseline, mean plasma VEGF concentration did not differ significantly among the 3 groups (P = .64). In the aflibercept group, it was 16.2 at baseline, decreased to less than the detectable limit at 1 week (P < .01) and at 1 month (P < .05), and returned to 13.6 pg/mL at 2 months (P = .73). In the ranibizumab group, there were no significant differences.
   CONCLUSIONS: Aflibercept significantly decreased serum and plasma VEGF concentrations 1 month after injection; however, ranibizumab had no significant effect on either serum or plasma VEGF level. (C) 2014 by Elsevier Inc. All rights reserved.
C1 [Wang, Xiying; Sawada, Tomoko; Saishin, Yoshitsugu; Ohji, Masahito] Shiga Univ Med Sci, Dept Ophthalmol, Otsu, Shiga 5202192, Japan.
   [Wang, Xiying; Liu, Ping] Harbin Med Univ, Affiliated Hosp 1, Hosp Eye, Ctr Eye,Key Lab Harbin Med Univ, Harbin, Peoples R China.
C3 Shiga University of Medical Science; Harbin Medical University
RP Sawada, T (通讯作者)，Shiga Univ Med Sci, Dept Ophthalmol, Otsu, Shiga 5202192, Japan.
EM tsawada@belle.shiga-med.ac.jp
FU Bayer; Santen; Novartis; Alcon; Pfizer; Shionogi; Sanwa Kagaku; Senju;
   Otsuka; Kowa; Ministry of Education, Culture, Sports, Science and
   Technology, Japan [24592668]; Ministry of Health, Labour and Welfare,
   Japan
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST and the following were reported. Dr
   Ohji received consulting fees from Bayer, Santen, and Novartis; lecture
   fees from Alcon, Novartis, Bayer, Santen, Pfizer, Shionogi, Sanwa
   Kagaku, Senju, Otsuka, and Kowa; grant support from the Ministry of
   Education, Culture, Sports, Science and Technology, Japan (Grant number
   24592668) and the Ministry of Health, Labour and Welfare, Japan; and is
   a consultant to Alcon, Novartis, Bayer, Santen, Pfizer, Shionogi, and
   Sanwa Kagaku. Supported in part by Grant 24592668 from the Ministry of
   Education, Culture, Sports, Science, and Technology, Japan and a Grant
   from the Ministry of Health, Labour and Welfare, Japan. The funding
   organizations had no role in the design or conduct of this study.
   Involved in Design and conduct of study (M.O.); Data collection (X.W.,
   T.S.); Analysis and interpretation of data (X.W., T.S.); Provision of
   materials, patients, or resources (T.S., OS., Y.S., M.O.); Statistical
   expertise (X.W., T.S.); Obtaining funding (M.O.); Literature search
   (X.W.); Administrative, technical, or logistic support (X.W., T.S.,
   P.L., M.O.); Writing article (X.W.); and Review and approval of article
   (X.W., T.S., M.O.).
CR Ahn JK, 2009, AM J OPHTHALMOL, V148, P718, DOI 10.1016/j.ajo.2009.06.012
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Baffert F, 2006, AM J PHYSIOL-HEART C, V290, pH547, DOI 10.1152/ajpheart.00616.2005
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   BRAMBELL FW, 1964, NATURE, V203, P1352, DOI 10.1038/2031352a0
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Christoforidis JB, 2012, CURR EYE RES, V37, P1171, DOI 10.3109/02713683.2012.727521
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Ghetie V, 2002, IMMUNOL RES, V25, P97, DOI 10.1385/IR:25:2:097
   Gu XY, 2014, CURR EYE RES, V39, P518, DOI 10.3109/02713683.2013.848899
   Haas P, 2011, CURR EYE RES, V36, P143, DOI 10.3109/02713683.2010.533808
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Jonas JB, 2007, OPHTHAL RES, V39, P139, DOI 10.1159/000102935
   Kakinoki M, 2012, INVEST OPHTH VIS SCI, V53, P5877, DOI 10.1167/iovs.12-10164
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Liu MH, 2002, ANN THORAC SURG, V73, P819, DOI 10.1016/S0003-4975(01)03404-X
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Machalinska A, 2011, J OCUL PHARMACOL TH, V27, P471, DOI 10.1089/jop.2011.0091
   Miyake T, 2010, INVEST OPHTH VIS SCI, V51, P1606, DOI 10.1167/iovs.09-4140
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Nalluri SR, 2008, JAMA-J AM MED ASSOC, V300, P2277, DOI 10.1001/jama.2008.656
   Resnikoff S, 2002, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sawada O, 2010, RETINA-J RET VIT DIS, V30, P1034, DOI 10.1097/IAE.0b013e3181ce74c8
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   Stewart MA, 2011, ADV GLOB CHANGE RES, V45, P1, DOI [10.1007/978-94-007-0934-8_1, 10.4081/eye.2011.e5]
   US Food and Drug Administration, FDA LAB INF
   Wang XY, 2014, GRAEF ARCH CLIN EXP, V252, P1033, DOI 10.1007/s00417-013-2505-2
   Wynendaele W, 1999, ANN ONCOL, V10, P965, DOI 10.1023/A:1008377921886
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
NR 39
TC 67
Z9 69
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2014
VL 158
IS 4
BP 738
EP 744
DI 10.1016/j.ajo.2014.06.009
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ1PI
UT WOS:000342552900012
PM 24973606
DA 2022-11-30
ER

PT J
AU Jeon, S
   Lee, WK
   Kim, KS
AF Jeon, Sohee
   Lee, Won Ki
   Kim, Kyu Seop
TI ADJUSTED RETREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY AFTER
   COMBINATION THERAPY Results at 3 Years
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE adjusted retreatment; combination therapy; intravitreal bevacizumab;
   photodynamic therapy; polypoidal choroidal vasculopathy
ID VERTEPORFIN PHOTODYNAMIC THERAPY; INDOCYANINE GREEN ANGIOGRAPHY;
   BRANCHING VASCULAR NETWORK; INTRAVITREAL BEVACIZUMAB; MACULAR
   DEGENERATION; FOLLOW-UP; NEOVASCULAR MEMBRANES; RANIBIZUMAB; EFFICACY;
   SAFETY
AB Purpose: The purpose of this study was to evaluate the 3-year outcome of adjusted retreatment with photodynamic therapy (PDT), thermal laser, and intravitreal bevacizumab (IVB) after their initial PDT/IVB combination therapy for polypoidal choroidal vasculopathy.
   Methods: Data on 40 treatment-naive eyes of 38 patients with polypoidal choroidal vasculopathy were reviewed, all initially subjected to whole-lesion PDT/IVB. When retreating persistent or recurrent exudation, the aim was to reduce PDT frequency and spot size, avoiding whole-lesion PDT when feasible. Distinct polyps were thus selectively targeted using PDT and/or laser, routinely combined with IVB. If polyps were absent or questionable, IVB monotherapy was given.
   Results: At Year 3, the mean logarithm of minimal angle of resolution best-corrected visual acuity improved from 0.67 (Snellen equivalent of 20/93) to 0.55 (Snellen equivalent of 20/70), but the improvement was not statistically significant (P = 0.076). Best-corrected visual acuity remained stable or improved in 33 eyes (82.5%). The mean number of combination treatments and total IVB courses were 1.66 (range, 1-4) and 5.92 (range, 1-18), respectively. Five eyes (12.5%) required focal laser treatment for extrafoveal polypoidal lesions during follow-up.
   Conclusion: Compared with reported 3-year outcomes of PDT as monotherapy for polypoidal choroidal vasculopathy, this approach proved favorable in improving or stabilizing visual acuity and reducing cumulative PDT exposure.
C1 [Jeon, Sohee; Lee, Won Ki; Kim, Kyu Seop] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Ophthalmol, Seoul 137701, South Korea.
C3 Catholic University of Korea; Seoul St. Mary's Hospital
RP Lee, WK (通讯作者)，Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Ophthalmol, 505 Banpo Dong, Seoul 137701, South Korea.
EM wklee@catholic.ac.kr
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Freund KB, 2006, ARCH OPHTHALMOL-CHIC, V124, P487, DOI 10.1001/archopht.124.4.487
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Kim KS, 2011, JPN J OPHTHALMOL, V55, P370, DOI 10.1007/s10384-011-0045-z
   Kim M, 2011, OPHTHALMOLOGICA, V226, P205, DOI 10.1159/000330793
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   Lee YH, 2011, RETINA-J RET VIT DIS, V31, P1287, DOI 10.1097/IAE.0b013e3182003ccd
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Sayanagi K, 2007, GRAEF ARCH CLIN EXP, V245, P1569, DOI 10.1007/s00417-007-0582-9
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schnurrbusch UEK, 2001, BRIT J OPHTHALMOL, V85, P1086, DOI 10.1136/bjo.85.9.1086
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Wakabayashi T, 2012, BRIT J OPHTHALMOL, V96, P394, DOI 10.1136/bjo.2011.204123
   Yamashita A, 2010, AM J OPHTHALMOL, V149, P465, DOI 10.1016/j.ajo.2009.09.020
NR 35
TC 14
Z9 16
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2013
VL 33
IS 6
BP 1193
EP 1200
DI 10.1097/IAE.0b013e318276e096
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 151IU
UT WOS:000319454700016
PM 23508074
DA 2022-11-30
ER

PT J
AU Muqit, MMK
   Le Mer, Y
   Holz, FG
   Sahel, JA
AF Muqit, Mahiul M. K.
   Le Mer, Yannick
   Holz, Frank G.
   Sahel, Jose A.
TI Long-term observations of macular thickness after subretinal
   implantation of a photovoltaic prosthesis in patients with atrophic
   age-related macular degeneration
SO JOURNAL OF NEURAL ENGINEERING
LA English
DT Article
DE subretinal; prosthesis; age-related macular degeneration; optical
   coherence tomography; retinal thickness
ID PREVALENCE
AB Objective. Subretinal prostheses electrically stimulate the residual inner retinal neurons to partially restore vision. We investigated the changes in neurosensory macular structures and it is thickness associated with subretinal implantation in geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Approach. Using optical coherence tomography, changes in distance between electrodes and retinal inner nuclear layer (INL) as well as alterations in thickness of retinal layers were measured over time above and near the subretinal chip implanted within the atrophic area. Retinal thickness (RT) was quantified across the implant surface and edges as well as outside the implant zone to compare with the natural macular changes following subretinal surgery, and the natural course of dry AMD. Main results. GA was defined based on complete retinal pigment epithelium and outer retinal atrophy (cRORA). Based on the analysis of three patients with subretinal implantation, we found that the distance between the implant and the target cells was stable over the long-term follow-up. Total RT above the implant decreased on average, by 39 +/- 12 mu m during 3 months post-implantation, but no significant changes were observed after that, up to 36 months of the follow-up. RT also changed near the temporal entry point areas outside the implantation zone following the surgical trauma of retinal detachment. There was no change in the macula cRORA nasal to the implanted zone, where there was no surgical trauma or manipulation. Significance. The surgical delivery of the photovoltaic subretinal implant causes minor RT changes that settle after 3 months, and then remain stable over long-term with no adverse structural or functional effects. Distance between the implant and the INL remains stable up to 36 months of the follow-up.
C1 [Muqit, Mahiul M. K.] Moorfields Eye Hosp, Vitreoretinal Serv, London, England.
   [Muqit, Mahiul M. K.] UCL, Inst Ophthalmol, London, England.
   [Le Mer, Yannick; Sahel, Jose A.] Fdn Ophtalmol A de Rothschild, Dept Ophthalmol, Paris, France.
   [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Sahel, Jose A.] Quinze Vingts Natl Eye Hosp, Clin Invest Ctr INSERM DGOS 1423, Paris, France.
   [Sahel, Jose A.] Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15261 USA.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   University of Bonn; CHNO des Quinze-Vingts; UDICE-French Research
   Universities; Sorbonne Universite; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh
RP Muqit, MMK (通讯作者)，Moorfields Eye Hosp, Vitreoretinal Serv, London, England.; Muqit, MMK (通讯作者)，UCL, Inst Ophthalmol, London, England.
EM Mahi.Muqit1@nhs.net
OI Muqit, Mahiul/0000-0003-1161-3956
FU Pixium Vision SA; Sight Again project (via Structural R&D Projects for
   Competitiveness and Investment for the Future funding managed by
   BpiFrance); Clinical Investigation Center at the Quinze-Vingts National
   Hospital; Inserm-DGOS, France; LabEx LIFESENSES [ANR-10-LABX-65]; IHU
   FOReSIGHT [ANR-18-IAHU-01]; NIH [P30 EY08098]; Research to Prevent
   Blindness, New York; National Institute for Health and Care Research, UK
FX We thank the participating patients; the Pixium Vision team who
   designed, fabricated, and tested the PRIMA system; the Scientific and
   Medical Advisory Board of Pixium Vision for its guidance on the clinical
   trial design; and all the scientific, research and development, medical,
   and clinical research staff who continue the patient care,
   rehabilitation, and evaluation. Studies were supported by: Pixium Vision
   SA; the Sight Again project (via Structural R&D Projects for
   Competitiveness and Investment for the Future funding managed by
   BpiFrance) and the Clinical Investigation Center at the Quinze-Vingts
   National Hospital, which is supported in part by the Inserm-DGOS, France
   and by LabEx LIFESENSES (ANR-10-LABX-65) and IHU FOReSIGHT
   (ANR-18-IAHU-01) Grants. J A S is supported in part by the NIH CORE
   Grant P30 EY08098, and by unrestricted Grant from Research to Prevent
   Blindness, New York. Biomedical Research Centre at Moorfields Eye
   Hospital is acknowledged and supported in part by the National Institute
   for Health and Care Research, UK
CR Ebneter A, 2016, INVEST OPHTH VIS SCI, V57, pOCT299, DOI 10.1167/iovs.15-18865
   Faude F, 2001, J NEUROCYTOL, V30, P379
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Goetz GA, 2013, J NEURAL ENG, V10, DOI 10.1088/1741-2560/10/5/056021
   Gregori NZ, 2018, AM J OPHTHALMOL, V193, P87, DOI 10.1016/j.ajo.2018.06.012
   Ho E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21447-1
   Ho E, 2018, J NEUROPHYSIOL, V119, P389, DOI 10.1152/jn.00872.2016
   Humayun MS, 2009, IEEE ENG MED BIO, P4566, DOI 10.1109/IEMBS.2009.5332695
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P471, DOI 10.1097/00006982-200208000-00012
   Lorach H, 2015, NAT MED, V21, P476, DOI 10.1038/nm.3851
   Mathieson K, 2012, NAT PHOTONICS, V6, P391, DOI [10.1038/nphoton.2012.104, 10.1038/NPHOTON.2012.104]
   Mazzoni F, 2008, J NEUROSCI, V28, P14282, DOI 10.1523/JNEUROSCI.4968-08.2008
   Menke MN, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14412
   Muqit MMK, 2019, OPHTHALMOLOGY, V126, P637, DOI 10.1016/j.ophtha.2018.11.010
   Palanker D, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28125-x
   Palanker D, 2020, OPHTHALMOLOGY, V127, P1097, DOI 10.1016/j.ophtha.2020.02.024
   Pfau M, 2020, JAMA OPHTHALMOL, V138, P1026, DOI 10.1001/jamaophthalmol.2020.2914
   Pinheiro J., 2006, MIXED EFFECTS MODELS
   Rizzo S, 2019, JAMA OPHTHALMOL, V137, P272, DOI 10.1001/jamaophthalmol.2018.6375
   Russell VL., 2022, EMMEANS ESTIMATED MA
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Santos A, 1997, ARCH OPHTHALMOL-CHIC, V115, P511, DOI 10.1001/archopht.1997.01100150513011
   Stingl K, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00445
   Stingl K, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.0077
   Team RC, 2013, R LANG ENV STAT COMP
   Titchener SA, 2022, TRANSL VIS SCI TECHN, V11, DOI 10.1167/tvst.11.6.12
   Wang DL, 2019, OPHTHALMOL RETINA, V3, P1035, DOI 10.1016/j.oret.2019.07.016
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang QQ, 2022, AM J OPHTHALMOL, V244, P79, DOI 10.1016/j.ajo.2022.08.012
NR 29
TC 0
Z9 0
U1 2
U2 2
PU IOP Publishing Ltd
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 1741-2560
EI 1741-2552
J9 J NEURAL ENG
JI J. Neural Eng.
PD OCT 1
PY 2022
VL 19
IS 5
AR 055011
DI 10.1088/1741-2552/ac9645
PG 12
WC Engineering, Biomedical; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Neurosciences & Neurology
GA 5U1RE
UT WOS:000876329700001
PM 36174540
DA 2022-11-30
ER

PT J
AU Park, KH
   Choi, AJ
   Yoon, J
   Lim, D
   Woo, SJ
   Park, SJ
   Kim, HC
   Chung, H
AF Park, Kyu Hyung
   Choi, Ae Jin
   Yoon, Jeehyun
   Lim, Daehan
   Woo, Se Joon
   Park, Sang Jun
   Kim, Hyung Chan
   Chung, Hyewon
TI Wnt Modulators in the Aqueous Humor Are Associated With Outer Retinal
   Damage Severity in Patients With Neovascular Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; Wnt; aqueous humor; optical coherence
   tomography; CNV
ID ENDOTHELIAL GROWTH-FACTOR; INHIBITORY FACTOR-I; ANGIOMATOUS
   PROLIFERATION; TYPE-3; EXPRESSION; PROTEINS; POLYMORPHISMS; PROGRESSION;
   ACTIVATION; PATHWAY
AB PURPOSE. To investigate the associations of the Wnt modulators Wnt inhibitory factor 1 (WIF-1) and Dickkopf 3 (DKK-3) in the aqueous humor with neovascular age-related macular degeneration (nAMD) and to determine their clinical implications.
   METHODS. Seventy-four nAMD patients initially treated with an intravitreal injection of ranibizumab (IVR) and 74 age- and sex- matched controls were studied. Aqueous humor WIF-1 and DKK- 3 levels were measured by Western blotting and an ELISA before and 1 month after two consecutive IVRs (pre- and post-IVR). Visual acuity assessments and spectral domain optical coherence tomography were performed pre- and post-IVR.
   RESULTS. Western blotting showed increased WIF-1 and DKK-3 in 12 nAMD patients compared with 12 controls. The ELISA analysis demonstrated elevated WIF-1 (pre) and DKK-3 (pre) in 62 patients compared with 62 controls (54.7 vs. 23.0 and 114.3 vs. 93.0 ng/mL, respectively). In multivariate analyses, high WIF-1 (pre) levels were associated with increased disruption in the photoreceptor junction's inner and outer segments (IS/OS) (pre and post) and high WIF-1 (post) levels. Interestingly, WIF-1 (pre) levels were significantly higher in type 3 neovascularization (NV) patients than in type 1 or 2 NV (90.5 +/- 36.7 vs. 48.3 +/- 22.5 and 41.3 +/- 28.8 ng/mL, respectively). However, choroidal thickness was not correlated with WIF-1 levels.
   CONCLUSIONS. We report, for the first time, the possibility of phenotypic, anatomic, and ocular proteomic correlations, demonstrating correlated WIF-1 and DKK-3 upregulation in nAMD patients' aqueous humor. Secreted WIF-1, reflecting the degree of retinal structure damage, may be a new biomarker for the retina's healthy and disease states.
C1 [Park, Kyu Hyung; Woo, Se Joon; Park, Sang Jun] Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Ophthalmol, Songnam, South Korea.
   [Choi, Ae Jin; Yoon, Jeehyun; Lim, Daehan; Kim, Hyung Chan; Chung, Hyewon] Konkuk Univ, Sch Med, Dept Ophthalmol, Seoul 143729, South Korea.
   [Kim, Hyung Chan; Chung, Hyewon] Konkuk Univ, Med Ctr, Dept Ophthalmol, Seoul 143729, South Korea.
C3 Seoul National University (SNU); Konkuk University; Konkuk University
   Medical Center; Konkuk University; Konkuk University Medical Center
RP Chung, H (通讯作者)，Konkuk Univ, Med Ctr, Sch Med, Dept Ophthalmol, 120-1 Neungdong Ro, Seoul 143729, South Korea.
EM hchung@kuh.ac.kr
RI Park, Sang Jun/C-3234-2015
OI Park, Sang Jun/0000-0003-0542-2758
FU National Research Foundation of Korea - Ministry of Science, ICT, and
   Future Planning [NRF-2012M3A9B2028333, NRF-2012R1A1A11012171]
FX Supported by the National Research Foundation of Korea funded by the
   Ministry of Science, ICT, and Future Planning (NRF-2012M3A9B2028333 and
   NRF-2012R1A1A11012171). The authors alone are responsible for the
   content and writing of the paper.
CR Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379
   Chen Y, 2009, MICROVASC RES, V78, P119, DOI 10.1016/j.mvr.2009.02.005
   Chung H, 2012, OPHTHALMOLOGY, V119, P1056, DOI 10.1016/j.ophtha.2011.11.018
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Dell'Omo R, 2012, AM J OPHTHALMOL, V153, P155, DOI 10.1016/j.ajo.2011.06.001
   Easwaran V, 2003, CANCER RES, V63, P3145
   El Nakamura R, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-52
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hackam AS, 2004, INVEST OPHTH VIS SCI, V45, P2929, DOI 10.1167/iovs.03-1184
   Hou HA, 2011, BRIT J CANCER, V105, P1927, DOI 10.1038/bjc.2011.471
   Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899
   Hu Y, 2013, INVEST OPHTH VIS SCI, V54, P141, DOI 10.1167/iovs.12-10281
   Hunter DD, 2004, MOL CELL NEUROSCI, V27, P477, DOI 10.1016/j.mcn.2004.08.003
   Kang GY, 2014, J PROTEOME RES, V13, P581, DOI 10.1021/pr400751k
   Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175
   Kawakami K, 2009, CANCER RES, V69, P8603, DOI 10.1158/0008-5472.CAN-09-2534
   Lee H, 2014, BMB REP, V47, P292, DOI 10.5483/BMBRep.2014.47.5.193
   Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2
   Liu H, 2003, DEV DYNAM, V227, P323, DOI 10.1002/dvdy.10315
   Liu H, 2006, INVEST OPHTH VIS SCI, V47, P5088, DOI 10.1167/iovs.06-0403
   Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389
   McBain VA, 2011, RETINA-J RET VIT DIS, V31, P1043, DOI 10.1097/IAE.0b013e3181fe54c7
   Osakada F, 2007, J NEUROSCI, V27, P4210, DOI 10.1523/JNEUROSCI.4193-06.2007
   Scott AW, 2010, EYE, V24, P491, DOI 10.1038/eye.2009.311
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Xu Y, 2013, J MOL NEUROSCI, V49, P250, DOI 10.1007/s12031-012-9917-z
   Yamazaki T, 2014, RETINA-J RET VIT DIS, V34, P1316, DOI 10.1097/IAE.0000000000000086
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
   Yi H, 2007, INVEST OPHTH VIS SCI, V48, P5733, DOI 10.1167/iovs.07-0097
NR 36
TC 10
Z9 11
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2014
VL 55
IS 9
BP 5522
EP 5530
DI 10.1167/iovs.14-14566
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ9DX
UT WOS:000343146900006
PM 25034605
DA 2022-11-30
ER

PT J
AU French, DD
   Margo, CE
AF French, Dustin D.
   Margo, Curtis E.
TI AGE-RELATED MACULAR DEGENERATION, ANTI-VASCULAR ENDOTHELIAL GROWTH
   FACTOR AGENTS, AND SHORT-TERM MORTALITY A Postmarketing Medication
   Safety and Surveillance Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE bevacizumab; exudative age-related macular degeneration; ranibizumab;
   pharmacoepidemiology; drug safety; anti-VEGF
ID MYOCARDIAL-INFARCTION; RANIBIZUMAB; RISK; VERTEPORFIN; INDICATOR;
   THERAPIES; VETERANS
AB Purpose: To compare short-term (1 year) survival of subjects treated for exudative age-related macular degeneration (AMD) with those with AMD who received no treatment.
   Methods: This was a case-control study. Beneficiaries of the Veterans Health Administration aged >= 55 years with a diagnosis of AMD in fiscal years 2007-2009 were included in this study. Veterans Health Administration clinical and pharmacy data sets were linked with a national Veterans Health Administration mortality registry. Anti-vascular endothelial growth factor exposure was identified through pharmacy records, coupled to procedure code for intravitreous injection and diagnosis code of exudative AMD. Control group consisted of patients with coded diagnosis of dry AMD and no pharmacy claims for case-defining medications. Cox proportional hazard model was adjusted for age, gender, number of injections, and ocular and medical comorbidities. The main outcome measure was hazard of death according to medication exposure.
   Results: A total of 3,210 patients received intravitreous injections for exudative AMD. There were 117,364 nonexposed patients with dry AMD. Twelve-month all-cause mortality in the exposed and control groups were 3.9% and 4.5%, respectively. When adjusted for age, gender, and ocular and medical comorbidities, the death hazard was 0.89 (95% confidence interval, 0.74-1.06). The risk of all-cause mortality was similar for patients receiving bevacizumab and ranibizumab.
   Conclusion: Twelve-month all-cause mortality in a population of predominately men with exudative AMD and a high prevalence of medical comorbidities was unaffected by exposure to therapeutic levels of vitreous bevacizumab and ranibizumab. Commonly used anti-vascular endothelial growth factor agents for exudative AMD do not adversely impact short-term survival in men. RETINA 31: 1036-1042, 2011
C1 [French, Dustin D.] Indiana Univ Sch Med, Dept Gen Internal Med & Geriatr, VA Ctr Excellence Implementing Evidence Based Pra, Regenstrief Inst Inc, Indianapolis, IN 46202 USA.
   [Margo, Curtis E.] Univ S Florida, Coll Med, Dept Ophthalmol, Tampa, FL USA.
   [Margo, Curtis E.] Univ S Florida, Coll Med, Dept Pathol, Tampa, FL USA.
   [Margo, Curtis E.] James A Haley Vet Hosp, Tampa, FL 33612 USA.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University-Purdue University Indianapolis; Regenstrief Institute Inc;
   State University System of Florida; University of South Florida; State
   University System of Florida; University of South Florida; US Department
   of Veterans Affairs; Veterans Health Administration (VHA); James A.
   Haley Veterans Hospital
RP French, DD (通讯作者)，Indiana Univ Sch Med, Dept Gen Internal Med & Geriatr, VA Ctr Excellence Implementing Evidence Based Pra, Regenstrief Inst Inc, HSR&D 11H,1481 W 10th St, Indianapolis, IN 46202 USA.
EM dustin.french2@va.gov
OI French, Dustin/0000-0003-4064-3206
FU Department of Veterans Affairs [HFP 04-148]
FX Supported by the Department of Veterans Affairs Health Services Research
   and Development Grant, HFP 04-148.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Buch H, 2005, OPHTHALMOLOGY, V112, P305, DOI 10.1016/j.ophtha.2004.08.025
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Cowper DC, 2002, ANN EPIDEMIOL, V12, P462, DOI 10.1016/S1047-2797(01)00285-X
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Enseleit F, 2010, CURR HYPERTENS REP, V12, P33, DOI 10.1007/s11906-009-0082-x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gottlieb SS, 1997, LANCET, V349, P662, DOI 10.1016/S0140-6736(97)22010-6
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Lauer MS, 1999, J AM COLL CARDIOL, V34, P618, DOI 10.1016/S0735-1097(99)00250-8
   LAUER MS, 2003, JAMA-J AM MED ASSOC, V289, P275
   Liao DP, 2008, OPEN OPHTHALMOL J, V2, P37, DOI 10.2174/1874364100802010037
   Nelson KM, 2007, PUBLIC HEALTH REP, V122, P93, DOI 10.1177/003335490712200113
   Pope GC, 2000, DIAGNOSTIC COST GROU
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmucker C, 2010, CURR OPIN OPHTHALMOL, V21, P218, DOI 10.1097/ICU.0b013e3283386783
   Selim AJ, 2006, MED CARE, V44, P359, DOI 10.1097/01.mlr.0000204119.27597.f1
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
NR 22
TC 14
Z9 17
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2011
VL 31
IS 6
BP 1036
EP 1042
DI 10.1097/IAE.0b013e31821dc66f
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 769JT
UT WOS:000291009400004
PM 21836410
DA 2022-11-30
ER

PT J
AU Cho, BJ
   Heo, JW
   Shin, JP
   Ahn, J
   Kim, TW
   Chung, H
AF Cho, Bum-Joo
   Heo, Jang Won
   Shin, Jae Pil
   Ahn, Jeeyun
   Kim, Tae Wan
   Chung, Hum
TI Association between Reproductive Factors and Age-Related Macular
   Degeneration in Postmenopausal Women: The Korea National Health and
   Nutrition Examination Survey 2010-2012
SO PLOS ONE
LA English
DT Article
ID RISK-FACTORS; HORMONE REPLACEMENT; VISUAL IMPAIRMENT; MACULOPATHY;
   LACTATION; PREVALENCE; ESTROGEN; THERAPY; EYE; POPULATION
AB Purpose: To examine the association between female reproductive factors and age-related macular degeneration (AMD) in postmenopausal women.
   Design: Nationwide population-based cross-sectional study.
   Methods: A nationally representative dataset acquired from the 2010-2012 Korea National Health and Nutrition Examination Survey was analyzed. The dataset involved information for 4,377 postmenopausal women aged >= 50 years with a fundus photograph evaluable for AMD in either eye. All participants were interviewed using standardized questionnaires to determine reproductive factors including menstruation, pregnancy, parity, lactation, and hormonal use. The association between reproductive factors and each type of AMD was investigated.
   Results: The mean age of the study participants was 63.1 +/- 0.2 years. Mean ages at menarche and menopause were 16.1 +/- 0.0 and 49.2 +/- 0.1 years, respectively. The overall prevalence rates of early and late AMD were 11.2% (95% confidence interval [CI], 10.1-12.5) and 0.8% (95% CI, 0.5-1.2), respectively. When adjusted for age, neither smoking nor alcohol use was associated with the presence of any AMD or late AMD. Multivariate logistic regression analysis revealed age (OR, 1.12 per 1 year), duration of lactation (OR, 0.91 per 6 months), and duration of use of oral contraceptive pills (OCP) (OR, 1.10 per 6 months) as associated factors for late AMD. The other variables did not yield a significant correlation with the risk of any AMD or late AMD.
   Conclusion: After controlling for confounders, a longer duration of lactation appeared to protect against the development of late AMD. A longer duration of OCP use was associated with a higher risk of late AMD.
C1 [Cho, Bum-Joo; Heo, Jang Won; Ahn, Jeeyun; Kim, Tae Wan; Chung, Hum] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul, South Korea.
   [Cho, Bum-Joo; Heo, Jang Won; Chung, Hum] Seoul Natl Univ Hosp, Dept Ophthalmol, Seoul 110744, South Korea.
   [Shin, Jae Pil] Kyungpook Natl Univ, Sch Med, Dept Ophthalmol, Taegu, South Korea.
   [Ahn, Jeeyun; Kim, Tae Wan] Seoul Natl Univ, Boramae Med Ctr, Seoul Metropolitan Govt, Dept Ophthalmol, Seoul, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University Hospital; Kyungpook National University; Seoul
   National University (SNU); Seoul National University Hospital
RP Heo, JW (通讯作者)，Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul, South Korea.
EM jangwonheo@gmail.com
OI Ahn, Jeeyun/0000-0001-9017-1652; Cho, Bum-Joo/0000-0002-0244-388X
CR Abramov Y, 2004, MENOPAUSE, V11, P62, DOI 10.1097/01.GME.0000074701.19603.11
   [Anonymous], 2013, AM J OPHTHALMOL
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P764, DOI 10.1016/j.ajo.2012.10.013
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Christin-Maitre S, 2013, BEST PRACT RES CL EN, V27, P3, DOI 10.1016/j.beem.2012.11.004
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Connell PP, 2009, J OPHTHALMOL, V2009, DOI 10.1155/2009/360764
   Edwards DRV, 2010, INVEST OPHTH VIS SCI, V51, P1873, DOI 10.1167/iovs.09-4000
   Erke MG, 2013, BRIT J OPHTHALMOL, V97, P1036, DOI 10.1136/bjophthalmol-2012-302461
   Fagerhaug TN, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1070
   Feskanich D, 2008, ARCH OPHTHALMOL-CHIC, V126, P519, DOI 10.1001/archopht.126.4.519
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Gemmy Cheung CM, 2013, AM J OPHTHALMOL, V155, pe761
   Haan MN, 2006, ARCH OPHTHALMOL-CHIC, V124, P988, DOI 10.1001/archopht.124.7.988
   KJOS SL, 1993, OBSTET GYNECOL, V82, P451
   Klein BEK, 2000, AM J OPHTHALMOL, V130, P322, DOI 10.1016/S0002-9394(00)00474-8
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   La Corte AIC, 2008, J RENIN-ANGIO-ALDO S, V9, P221, DOI 10.1177/1470320308096405
   McClure CK, 2012, AM J OBSTET GYNECOL, V207, DOI 10.1016/j.ajog.2012.04.030
   Nirmalan PK, 2004, INVEST OPHTH VIS SCI, V45, P4273, DOI 10.1167/iovs.04-0285
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P1740, DOI 10.1167/iovs.02-0775
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Schwarz EB, 2009, OBSTET GYNECOL, V113, P974, DOI 10.1097/01.AOG.0000346884.67796.ca
   Sitruk-Ware R, 2013, BEST PRACT RES CL EN, V27, P13, DOI 10.1016/j.beem.2012.09.004
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   Stuebe AM, 2005, JAMA-J AM MED ASSOC, V294, P2601, DOI 10.1001/jama.294.20.2601
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Urrutia RP, 2013, OBSTET GYNECOL, V122, P380, DOI 10.1097/AOG.0b013e3182994c43
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Wiegratz I, 2004, CONTRACEPTION, V70, P97, DOI 10.1016/j.contraception.2004.03.004
   Williams MJA, 2006, J EPIDEMIOL COMMUN H, V60, P146, DOI 10.1136/jech.2005.039222
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yoon Kyung-Chul, 2011, Korean J Ophthalmol, V25, P421, DOI 10.3341/kjo.2011.25.6.421
NR 36
TC 10
Z9 10
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 15
PY 2014
VL 9
IS 7
AR e102816
DI 10.1371/journal.pone.0102816
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AM6RN
UT WOS:000339992400105
PM 25025761
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Dasch, B
   Fuhs, A
   Schmidt, J
   Behrens, T
   Meister, A
   Wellmann, J
   Fobker, M
   Pauleikhoff, D
   Hense, HW
AF Dasch, B
   Fuhs, A
   Schmidt, J
   Behrens, T
   Meister, A
   Wellmann, J
   Fobker, M
   Pauleikhoff, D
   Hense, HW
TI Serum levels of macular carotenoids in relation to age-related
   maculopathy - The Muenster Aging and Retina Study (MARS)
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related maculopathy; age-related macular degeneration; macular
   carotenoids; lutein; zeaxanthin
ID PIGMENT OPTICAL-DENSITY; 3RD NATIONAL-HEALTH; 5-YEAR INCIDENCE;
   RISK-FACTORS; LUTEIN; ZEAXANTHIN; ANTIOXIDANT; DEGENERATION; NUTRIENTS;
   ZINC
AB Backgorund: It has been hypothesized that the macular carotenoids, lutein and zeaxanthin, may protect against age-related maculopathy. We evaluated the association between blood concentrations of lutein (L) and zeaxanthin (Z) and age-related maculopathy (ARM) in a case-control analysis of the baseline examination of the Muenster Ageing and Retina Study (MARS). Methods: Of the 1060 participants aged 59-82 years at baseline, 910 (85.9%) with bilateral gradable fundus photographs and complete data for the carotenoids and potential confounders were included. The Rotterdam classification system was used for definition of ARM stages. Multivariate linear regression methods were applied to model the relationship between macular carotenoids and the presence of ARM. Results: The participants' mean age was 70.9+5.5 years, 59.9% were female, 20.8% had a normal bilateral fundus, and 48.5% showed signs of early ARM (uni- or bilateral) and 30.7% of late ARM (in at least one eye). In study participants with L and/or Z supplementation (15.6%), the median serum levels for L (Z) were approximately 2 times (1.5 times) higher than in subjects with no supplementation. After exclusion of subjects with L and/or Z supplementation, no statistically significant bivariate relationship was observed between the serum levels of L or Z and the presence of ARM. Multivariate regression models, adjusting for age, gender, smoking, body-mass index, and HDL-cholesterol blood levels, produced adjusted mean serum levels of 0.124, 0.112, and 0.131 mu g/ml for L and 0.019, 0.020, and 0.022 mu g/ml for Z in subjects with normal fundus, early ARM, and late ARM, respectively. Conclusion: In this large study, the serum concentrations of L and Z were not related to the prevalence of ARM. However, the large proportion of study participants taking L and/or Z supplementation may have affected these results.
C1 Univ Munster, Inst Epidemiol & Social Med, D-48149 Munster, Germany.
   St Franziskus Hosp Muenster, Dept Ophthalmol, Munster, Germany.
   Univ Munster, Inst Clin Chem & Lab Med, D-48149 Munster, Germany.
C3 University of Munster; St. Franziskus-Hospital; University of Munster
RP Hense, HW (通讯作者)，Univ Munster, Inst Epidemiol & Social Med, Domagkstr 3, D-48149 Munster, Germany.
EM hense@uni-muenster.de
CR [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2004, ARCH BIOCHEM BIOPHYS, V430, P70, DOI 10.1016/j.abb.2004.03.015
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   Broekmans WMR, 2002, AM J CLIN NUTR, V76, P595, DOI 10.1093/ajcn/76.3.595
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   CLEVIDENCE BA, 1993, METHOD ENZYMOL, V214, P33
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Dachtler M, 2001, ANAL CHEM, V73, P667, DOI 10.1021/ac000635g
   Davies NP, 2004, PROG RETIN EYE RES, V23, P533, DOI 10.1016/j.preteyeres.2004.05.004
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Gruber M, 2004, J NUTR, V134, P2387, DOI 10.1093/jn/134.9.2387
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hammond BR, 2002, INVEST OPHTH VIS SCI, V43, P47
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Semba RD, 2003, MED HYPOTHESES, V61, P465, DOI 10.1016/S0306-9877(03)00198-1
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Trieschmann M, 2003, GRAEF ARCH CLIN EXP, V241, P1006, DOI 10.1007/s00417-003-0796-4
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Winkler BS, 1999, MOL VIS, V5
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Young AJ, 2001, ARCH BIOCHEM BIOPHYS, V385, P20, DOI 10.1006/abbi.2000.2149
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
NR 47
TC 30
Z9 31
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2005
VL 243
IS 10
BP 1028
EP 1035
DI 10.1007/s00417-005-1176-z
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 976GR
UT WOS:000232721500011
PM 15909159
DA 2022-11-30
ER

PT J
AU Mauget-Faysse, M
   Cornut, PL
   El-Maftouhi, MQ
   Leys, A
AF Mauget-Faysse, Martine
   Cornut, Pierre-Loic
   El-Maftouhi, Maddalena Quaranta
   Leys, Anita
TI Polypoidal choroidal vasculopathy in tilted disk syndrome and high
   myopia with staphyloma
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CENTRAL SEROUS CHORIORETINOPATHY; VORTEX VEIN OCCLUSION;
   RETINAL-DETACHMENT; SUBRETINAL LEAKAGE; OPTIC DISK
AB center dot PURPOSE: To describe polypoidal choroidal vasculopathy as a complication of tilted disk syndrome and high myopia with staphyloma.
   center dot DESIGN: Retrospective interventional case series.
   center dot METHODS: This report was a multicenter evaluation of six patients (eight eyes) with tilted disk syndrome or high myopia that was complicated by posterior staphyloma. Complete ophthalmic examination that included fluores, cein angiography, optical coherence tomography (OCT), and indocyanine green angiography (ICG-A) was performed in all patients.
   center dot RESULTS: All patients had macular abnormalities and visual loss. Fundus examination and fluorescein angiography showed typical features of tilted disk syndrome (five patients; six eyes) or high myopia (one patient; two eyes) with staphyloma that was associated with polypot, dal choroidal vasculopathy. OCT and ICG,A confirmed the presence of polypoidal dilations in the choroid. Seven eyes were treated with laser photocoagulation or verteporfin,photodynamic therapy (V-PDT), although one eye did not require treatment. Visual acuity at the final visit had improved in three eyes, deteriorated in three eyes, and remained unchanged in two eyes.
   center dot CONCLUSION: Polypoidal choroidal vasculopathy is a potential cause of visual loss in tilted disk syndrome and high myopia. We postulate that choroidal abnormalities at the border of staphylomas induce blood-flow disturbances that are similar to those disturbances that are observed in chronic central serous chorioretinopathy, which is another condition that occasionally is associated with polypoidal choroidal vasculopathy. The pathogenesis remains unclear, and further study is required to better understand the formation of choroidal polypoidal dilations in these conditions.
C1 Rabelais Ophthalmol Ctr, F-69003 Lyon, France.
   Lyon E Herriot Univ Hosp, Dept Ophthalmol, Lyon, France.
   Univ Hosp Leuven, Dept Ophthalmol, Louvain, Belgium.
C3 CHU Lyon; KU Leuven; University Hospital Leuven
RP Mauget-Faysse, M (通讯作者)，Rabelais Ophthalmol Ctr, 12-14 Rue Rabelais, F-69003 Lyon, France.
EM centrerabelais@wanadoo.fr
CR APPLE DJ, 1982, SURV OPHTHALMOL, V27, P3, DOI 10.1016/0039-6257(82)90111-4
   Chan WM, 2003, BRIT J OPHTHALMOL, V87, P1453, DOI 10.1136/bjo.87.12.1453
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Cohen SY, 1998, OPHTHALMOLOGY, V105, P1831, DOI 10.1016/S0161-6420(98)91024-7
   GIUFFRE G, 1991, INT OPHTHALMOL, V15, P1, DOI 10.1007/BF00150971
   HAYREH SS, 1973, BRIT J OPHTHALMOL, V57, P217, DOI 10.1136/bjo.57.4.217
   HAYREH SS, 1982, ARCH OPHTHALMOL-CHIC, V100, P1481, DOI 10.1001/archopht.1982.01030040459019
   Leys AM, 2002, RETINA-J RET VIT DIS, V22, P659, DOI 10.1097/00006982-200210000-00025
   Quaranta M, 2000, GRAEF ARCH CLIN EXP, V238, P101
   STUR M, 1988, AM J OPHTHALMOL, V105, P98, DOI 10.1016/0002-9394(88)90135-3
   Takahashi K, 2000, AM J OPHTHALMOL, V129, P191, DOI 10.1016/S0002-9394(99)00425-0
   Tatlipinar S, 2005, NEURO-OPHTHALMOLOGY, V29, P49, DOI 10.1080/01658100590933370
   Theodossiadis PG, 2006, GRAEF ARCH CLIN EXP, V244, P122, DOI 10.1007/s00417-005-0018-3
   Vongphanit J, 2002, AM J OPHTHALMOL, V133, P679, DOI 10.1016/S0002-9394(02)01339-9
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
NR 15
TC 43
Z9 47
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2006
VL 142
IS 6
BP 970
EP 975
DI 10.1016/j.ajo.2006.06.063
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 114MU
UT WOS:000242671100010
PM 17046703
DA 2022-11-30
ER

PT J
AU Oluleye, TS
   Babalola, YO
   Majekodunmi, OI
   Ijaduola, MA
AF Oluleye, T. S.
   Babalola, Y. O.
   Majekodunmi, O., I
   Ijaduola, M. A.
TI Macular diseases in Ibadan, Nigeria
SO NIGERIAN JOURNAL OF CLINICAL PRACTICE
LA English
DT Article
DE Age-related macular degeneration; atrophic maculopathy; choroidal
   neovascular membrane; Nigerians
AB Background: Retina diseases including the diseases of the macular are underreported in developing countries of sub-Sahara Africa including Nigeria. Method: A retrospective review of retinal register of cases presenting to the retinal clinic of the University College Hospital, Ibadan within 4 years (December 2015, to November 2019). Demographics and clinical data of all patients with macula diseases were retrieved. Data were analysed using the Statistical Package for Social Sciences IBM (SPSS-IBM), version 22 (SPSS Inc., Chicago, Illinois, USA), and reported as frequency distributions and percentages. Results: A total of 1291 retinal cases were seen during the period under review, out of which 322 cases were diseases of the macula, representing 24.9% of retinal cases seen. The top 3 common causes of macular disease found in the study were dry Age-related Macular Degeneration (AMD) 63 (19.6%); Macula oedema 53 (16.5%) and Non-AMD atrophic maculopathy (from Retinitis Pigmentosa, chloroquine maculopathy and hereditary causes) 51 (15.9%) representing more than 50% of cases. Macular holes 48 (14.9%); Non-AMD macular scar (Toxoplasmosis, Trauma) 37 (11.5%) and choroidal neovascular membrane (CNVM) 26 (8.1%) are other important causes. Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) 17 (5.3%) is an emerging cause of macular disease in the retina unit of the University College Hospital Ibadan. Conclusion: Age-related macular degeneration (AMD), Macular oedema and Non-AMD atrophic maculopathy are major causes of macular disease presentation in the retinal clinic of the University College Hospital Ibadan, Nigeria. CNVM and IPCV are emerging causes.
C1 [Oluleye, T. S.; Babalola, Y. O.; Majekodunmi, O., I; Ijaduola, M. A.] Univ Coll Hosp, Dept Ophthalmol, Retina & Vitreous Unit, Ibadan, Oyo State, Nigeria.
C3 University of Ibadan; University College Hospital, Ibadan
RP Oluleye, TS (通讯作者)，Univ Coll Hosp, Dept Ophthalmol, Ibadan, Oyo State, Nigeria.
EM jeff1oluleye@gmail.com
CR Akinkugbe OO, 1997, NONCOMMUNICABLE DIS, P1
   AMONI SS, 1983, ANN OPHTHALMOL, V15, P384
   Campochiaro PA, 2011, OPHTHALMOLOGY, V118, P2041, DOI 10.1016/j.ophtha.2011.02.038
   Frank R N, 2000, Trans Am Ophthalmol Soc, V98, P109
   Gohdes Dorothy M, 2005, Prev Chronic Dis, V2, pA17
   GREGOR Z, 1978, BRIT J OPHTHALMOL, V62, P547, DOI 10.1136/bjo.62.8.547
   Leske MC, 2004, OPHTHALMOLOGY, V111, P706, DOI 10.1016/j.ophtha.2003.07.003
   Li JQ., 2017, RETINAL DIS EUROPE
   Makwanga EKJ, 2006, 104 DOG ANN M
   Nwosu S N, 2000, Ophthalmic Epidemiol, V7, P41, DOI 10.1076/0928-6586(200003)7:1;1-2;FT041
   Oluleye TS, 2016, EYE, V30, P64, DOI 10.1038/eye.2015.185
   Oluleye TS, 2013, CLIN OPHTHALMOL, V7, P1373, DOI 10.2147/OPTH.S47511
   Oluleye TS, 2006, EYE, V20, P1461, DOI 10.1038/sj.eye.6702343
   Onakpoya OH, 2008, J NATL MED ASSOC, V100, P1286, DOI 10.1016/S0027-9684(15)31506-6
   Sobngwi E, 2001, DIABETES METAB, V27, P628
   Uhumwangho O M, 2015, J West Afr Coll Surg, V5, P1
   Uhumwangho OM, 2015, ANN AFR MED, V14, P163, DOI 10.4103/1596-3519.158522
   World Health Organization, INCR LIF EXP NIG HIG
   Yorston D, 2002, EYE, V16, P353, DOI 10.1038/sj.eye.6700188
NR 19
TC 0
Z9 0
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 1119-3077
J9 NIGER J CLIN PRACT
JI Niger. J. Clin. Pract.
PD MAR
PY 2021
VL 24
IS 3
BP 341
EP 344
DI 10.4103/njcp.njcp_408_20
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA RB1UN
UT WOS:000631901500007
PM 33723107
DA 2022-11-30
ER

PT J
AU Baek, J
   Lee, JH
   Lee, WK
AF Baek, Jiwon
   Lee, Jae Hyung
   Lee, Won Ki
TI CLINICAL RELEVANCE OF AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR LEVELS
   IN POLYPOIDAL CHOROIDAL VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy (PCV); vascular endothelial growth
   factor (VEGF); aqueous humor; choroidal thickness; anti-VEGF treatment
ID OPTICAL COHERENCE TOMOGRAPHY; VERTEPORFIN PHOTODYNAMIC THERAPY; MACULAR
   DEGENERATION; HUMOR LEVELS; RANIBIZUMAB; THICKNESS; NEOVASCULARIZATION;
   HYPERPERMEABILITY; COMPLEMENT; DISEASE
AB Purpose: To investigate vascular endothelial growth factor ( VEGF) level according to the clinical and imaging features, and to explore its relationship with the responsiveness to anti-VEGF treatment in eyes with polypoidal choroidal vasculopathy.
   Methods: Aqueous samples were collected from 62 eyes of 62 patients with treatment naive polypoidal choroidal vasculopathy. Vascular endothelial growth factor levels were measured using enzyme-linked immunosorbent assay. Baseline best-corrected visual acuity, central macular thickness, subfoveal choroidal thickness, greatest linear dimension of the lesion, and the presence of hemorrhage were included in the analysis. The effects of 3 monthly intravitreal ranibizumab injections on best-corrected visual acuity and central macular thickness were assessed.
   Results: Baseline VEGF level was negatively correlated with subfoveal choroidal thickness ( r = -0.33, P = 0.01). Other variables had no correlation with VEGF level. The mean change in central macular thickness after anti-VEGF treatment was -51 +/- 64 mm, which is positively correlated with VEGF concentration ( r = 0.30, P = 0.04) and negatively correlated with subfoveal choroidal thickness ( r = -0.35, P = 0.02).
   Conclusion: Vascular endothelial growth factor level demonstrated a negative correlation with baseline subfoveal choroidal thickness and was associated with response to anti VEGF treatment. These findings suggest that VEGF has a variable contribution to the pathogenesis of polypoidal choroidal vasculopathy depending on choroid thickness.
C1 [Baek, Jiwon; Lee, Jae Hyung; Lee, Won Ki] Catholic Univ Korea, Dept Ophthalmol & Visual Sci, Seoul St Marys Hosp, Coll Med, Seoul, South Korea.
C3 Catholic University of Korea; Seoul St. Mary's Hospital
RP Lee, WK (通讯作者)，Catholic Univ Korea, Dept Ophthalmol, Seoul St Marys Hosp, Coll Med, 222 Banpo Daero, Seoul 06591, South Korea.
EM wklee@catholic.ac.kr
OI Baek, Jiwon/0000-0001-6736-5379
FU Novartis; Bayer; Allergan; Alcon; Santen
FX W. K. Lee has served on advisory boards for Novartis, Bayer, Allergan,
   Alcon, and Santen and has received consultancy fees from these
   companies. He has received payments for lectures from Novartis, Bayer,
   Allergan, and Alcon. The other authors have no financial/conflicting
   interests to disclose.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cha DM, 2013, INVEST OPHTH VIS SCI, V54, P7038, DOI 10.1167/iovs.13-12730
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kim H, 2016, GRAEF ARCH CLIN EXP, V254, P1497, DOI 10.1007/s00417-015-3221-x
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lee MY, 2013, AM J OPHTHALMOL, V156, P343, DOI 10.1016/j.ajo.2013.04.001
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Muether PS, 2013, RETINA-J RET VIT DIS, V33, P1809, DOI 10.1097/IAE.0b013e318285cd9e
   Noma H, 2008, EYE, V22, P42, DOI 10.1038/sj.eye.6702498
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Rishi P, 2013, EYE, V27, P1038, DOI 10.1038/eye.2013.106
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sonoda S, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-43
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 40
TC 13
Z9 13
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2017
VL 37
IS 5
BP 943
EP 950
DI 10.1097/IAE.0000000000001284
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EW0IO
UT WOS:000402173400036
PM 27617539
DA 2022-11-30
ER

PT J
AU Johnston, RL
   Carius, HJ
   Skelly, A
   Ferreira, A
   Milnes, F
   Mitchell, P
AF Johnston, Robert L.
   Carius, Hans-Joachim
   Skelly, Adrian
   Ferreira, Alberto
   Milnes, Fran
   Mitchell, Paul
TI A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular
   Age-Related Macular Degeneration (nAMD) in Australia and the United
   Kingdom
SO ADVANCES IN THERAPY
LA English
DT Article
DE Anti-vascular endothelial growth factor; Neovascular age-related macular
   degeneration; Pro re nata regimen Ranibizumab; Real-world data;
   Treat-and-extend regimen; Visual acuity
ID EXTEND; OUTCOMES
AB Introduction: Neovascular age-related macular degeneration (nAMD) is the leading cause of vision loss among persons aged 65 years and older. Anti-vascular endothelial growth factor (anti-VEGF) treatment is the recommended standard of care. The current study compares the effectiveness of ranibizumab in routine clinical practice in two countries that generally apply two different treatment regimens, treat-and-extend (T& E) in Australia or pro re nata (PRN) in the UK.
   Methods: This retrospective, comparative, non-randomised cohort study is based on patients' data from electronic medical record (EMR) databases in Australia and the UK. Treatment regimens were defined based on location, with Australia as a proxy for analysing T& E and UK as a proxy for analysing PRN. The study included patients with a diagnosis of nAMD who started treatment with ranibizumab between January 2009 and July 2014. A total of 647 eyes of 570 patients in Australia and 3187 eyes of 2755 patients in the UK with complete 12-months follow-up were analysed.
   Results: Baseline patient characteristics were comparable between the two cohorts. After 1 year of treatment, T& E-treated eyes achieved higher mean (+/- SE) visual acuity (VA) gains (5.00 +/- 0.54 letters [ 95% confidence interval (CI) 3.93-6.06]) than PRN-treated eyes [ 3.04 +/- 0.24 letters (95% CI 2.57-3.51); difference in means 2.07 +/- 0.69 (95% CI 0.73-3.41), p<0.001]. Non-inferiority of T& E compared to PRN was concluded based on the change in mean visual acuity gains at 12 months. Over the 12-month follow-up, T& E-treated eyes received a higher mean [+/- standard deviation (SD)] number of injections (9.29 +/- 2.43) than PRN-treated eyes (6.04 +/- 2.19) (p<0.0001).Australian patients had a lower mean (+/- SD) number of total clinic visits ( 10.29 +/- 2.90) than UK patients ( 11.47 +/- 2.93) ( p<0.0001).
   Conclusion: The higher injection frequency in the T& E cohort may account for the trend toward improved vision.
C1 [Johnston, Robert L.] Royal Coll Ophthalmologists Natl Ophthalmol, London, England.
   [Johnston, Robert L.] Gloucestershire Hosp NHS Fdn Trust, Cheltenham, Glos, England.
   [Carius, Hans-Joachim] QuintilesIMS, Frankfurt, Germany.
   [Skelly, Adrian; Ferreira, Alberto; Milnes, Fran] Novartis Pharma AG, Basel, Switzerland.
   [Mitchell, Paul] Univ Sydney, Westmead Millennium Inst, Dept Ophthalmol, Westmead, NSW, Australia.
C3 Gloucestershire Hospitals NHS Foundation Trust; IQVIA; Novartis;
   University of Sydney; Westmead Institute for Medical Research
RP Ferreira, A (通讯作者)，Novartis Pharma AG, Basel, Switzerland.
EM alberto.ferreira@novartis.com
RI Mitchell, Paul/P-1498-2014
FU Novartis PharmaAG, Basel, Switzerland
FX Novartis PharmaAG, Basel, Switzerland
CR Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Epstein M, 2008, PHARMACOEPIDEM DR S, V17, P200, DOI 10.1002/pds.1471
   European Medicines Agency, LUC EPAR PROD INF AN
   European Medicines Agency, LUC RAN EPAR SUMM PU
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Hatz K, 2016, BRIT J OPHTHALMOL, V100, P1341, DOI 10.1136/bjophthalmol-2015-307299
   Johnston RL, 2016, OPHTHALMOLOGY, V123, P2386, DOI 10.1016/j.ophtha.2016.07.037
   Liew G, 2016, EYE, V30, P1462, DOI 10.1038/eye.2016.149
   Mario SP, GLOBAL DATA VISUAL I
   Mitchell P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101072
   NICE technology appraisal guidance [TA155], RAN PEG TREATM AG RE
   Novartis, NOV ANN LIC CHANG LE
   Novartis Pharmaceuticals Australia Pty Limited, LUCENTIS RAN RBE PRO
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Therapeutic Goods Administration, AUSTR PUBL ASS REP R
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Vandenbroucke JP, 2014, INT J SURG, V12, P1500, DOI 10.1016/j.ijsu.2014.07.014
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 22
TC 38
Z9 39
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0741-238X
EI 1865-8652
J9 ADV THER
JI Adv. Ther.
PD MAR
PY 2017
VL 34
IS 3
BP 703
EP 712
DI 10.1007/s12325-017-0483-1
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA EQ3NB
UT WOS:000397978600009
PM 28144918
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Demirel, S
   Batioglu, F
   Ozmert, E
   Erenler, F
AF Demirel, Sibel
   Batioglu, Figen
   Ozmert, Emin
   Erenler, Feyza
TI The Effect of Multiple Injections of Ranibizumab on Retinal Nerve Fiber
   Layer Thickness in Patients with Age-Related Macular Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Intraocular pressure; optic coherence tomography; optic nerve head;
   ranibizumab; retinal nerve fiber
ID ENDOTHELIAL GROWTH-FACTOR; INTRAOCULAR-PRESSURE; INTRAVITREAL
   RANIBIZUMAB; FACTOR THERAPY; FACTOR-A; SURVIVAL; CELLS; VEGF;
   PHOTORECEPTORS; VERTEPORFIN
AB Purpose: To evaluate the effects of multiple intravitreal injections of ranibizumab on retinal nerve fiber layer (RNFL) thickness in patients with wet age-related macular degeneration (AMD).
   Methods: This observational, comparative study included patients with 10 or more total ranibizumab injections and involved the measurement of RNFL thickness at baseline. Twenty-nine eyes of 29 consecutive patients were evaluated via intraocular pressure (IOP) and measurements of the total and nasal RNFL thicknesses at the initial and final follow-up by using optical coherence tomography. The RNFL thickness values of the fellow eyes and 27 healthy eyes were used as the control group. The mean total and nasal RNFL thicknesses of the injection group were compared with those of the other two groups. At each visit, at every three injections, the IOP values of the study group were recorded and compared. The relationship between the number of injections and the mean RNFL thickness was assessed.
   Results: The mean number of injections was 13.88 +/- 3.81 (10-24). The mean RNFL thickness of the injection group was 92.3 +/- 7.7 mu m at baseline and 92.46 +/- 8.1 mu m at the last follow-up (p = 0.7). There were no statistically significant differences between the mean total and nasal RNFL thicknesses of the eyes with injections and the fellow eyes with no injections (p = 0.379, p = 0.897, respectively) or between those with injections and the healthy control group (p = 0.159, p = 0.273, respectively). There were no correlations between the number of injections and the mean total and nasal RNFL thicknesses (p = 0.854, p = 0.25, respectively). There was no statistical difference between the initial and final IOPs (p = 0.760).
   Conclusion: Long-term treatment with anti-vascular endothelial growth factor (VEGF) agents did not lead to significant changes in RNFL thickness in a patient population with wet AMD. Chronic therapy with intravitreal anti-VEGF agents does not appear to adversely affect RNFL thickness.
C1 [Demirel, Sibel; Batioglu, Figen; Ozmert, Emin; Erenler, Feyza] Ankara Univ, Fac Med, Dept Ophthalmol, TR-06100 Ankara, Turkey.
C3 Ankara University
RP Demirel, S (通讯作者)，Ankara Univ, Fac Med, Dept Ophthalmol, GOP, Koza Sokak,Mesa Ikizler Sitesi 70-40, Cankaya, Turkey.
EM drsibeldemireltr@yahoo.com.tr
RI Demirel, Sibel/AAQ-4282-2020; Batıoğlu, Figen/AAQ-3727-2020; Erenler,
   Feyza/ABB-7806-2021; DEMIREL, SIBEL/GQH-3232-2022
OI Demirel, Sibel/0000-0002-6430-6565; Batıoğlu, Figen/0000-0002-5834-7512;
   Erenler, Feyza/0000-0002-7677-6556; DEMIREL, SIBEL/0000-0002-2477-9974
CR Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Bakri SJ, 2009, EYE, V23, P181, DOI 10.1038/sj.eye.6702938
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   D'Amore PA, 2007, AM J PATHOL, V171, P14, DOI 10.2353/ajpath.2007.070385
   Fong AHC, 2013, CLIN INTERV AGING, V8, P467, DOI 10.2147/CIA.S36811
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Hoang QV, 2012, OPHTHALMOLOGY, V119, P321, DOI 10.1016/j.ophtha.2011.08.011
   Horsley MB, 2010, AM J OPHTHALMOL, V150, P558, DOI 10.1016/j.ajo.2010.04.029
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martinez-de-la-Casa JM, 2012, INVEST OPHTH VIS SCI, V53, P6214, DOI 10.1167/iovs.12-9875
   Miki A, 2010, J CELL PHYSIOL, V224, P262, DOI 10.1002/jcp.22129
   Miyamoto K, 2000, AM J PATHOL, V156, P1733, DOI 10.1016/S0002-9440(10)65044-4
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Nishimura T, 2012, CLIN OPHTHALMOL, V6, P1073, DOI 10.2147/OPTH.S31674
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999
   Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092
   Tseng JJ, 2012, J GLAUCOMA, V21, P241, DOI 10.1097/IJG.0b013e31820d7d19
NR 29
TC 29
Z9 30
U1 0
U2 16
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD JAN
PY 2015
VL 40
IS 1
BP 87
EP 92
DI 10.3109/02713683.2014.917190
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AW0IA
UT WOS:000345973700010
PM 24871814
DA 2022-11-30
ER

PT J
AU Cebeci, Z
   Bayraktar, S
   Oray, M
   Kir, N
AF Cebeci, Zafer
   Bayraktar, Serife
   Oray, Merih
   Kir, Nur
TI Silent polypoidal choroidal vasculopathy in a patient with angioid
   streaks
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Polyps; Choroid; Choroidal neovascularization; Fluorescein angiography;
   Indocyanine green; Retinal pigment epithelium; Tomography, optical
   coherence; Vascular endothelial growth factor A; Angioid streaks
ID PSEUDOXANTHOMA ELASTICUM; NEOVASCULARIZATION
AB We present a case of silent polypoidal choroidal vasculopathy (PCV) in a patient with angioid streaks. PCV was detected during a routine ophthalmic examination and confirmed by fluorescein angiography, indocyanine green angiography, and optical coherence tomography. After 2 years of follow-up, the PCV remained silent without any complications. We report this rare coexistence and review literature on this topic.
C1 [Cebeci, Zafer; Bayraktar, Serife; Oray, Merih; Kir, Nur] Istanbul Univ, Istanbul Fac Med, Dept Ophthalmol, Istanbul, Turkey.
C3 Istanbul University
RP Cebeci, Z (通讯作者)，Goz Hastaliklari AD Capa, Istanbul Tip Fak, TR-34390 Istanbul, Turkey.
EM zafceb@gmail.com
RI Kir, Nur/AAT-9664-2020; Oray, Merih/AAD-6003-2020; cebeci,
   zafer/AAD-5110-2020; bayraktar, serife/AAD-2618-2020
CR Baillif-Gostoli S, 2010, GRAEF ARCH CLIN EXP, V248, P1845, DOI 10.1007/s00417-010-1328-7
   Gheduzzi D, 2003, ULTRASTRUCT PATHOL, V27, P375, DOI 10.1080/01913120390248584
   Gliem M, 2013, RETINA-J RET VIT DIS, V33, P1300, DOI 10.1097/IAE.0b013e3182914d2b
   Ishida T, 2013, INT OPHTHALMOL, V33, P305, DOI 10.1007/s10792-012-9657-7
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Nakagawa S, 2013, RETINA-J RET VIT DIS, V33, P825, DOI 10.1097/IAE.0b013e31826b0bbe
   Nakanishi H, 2008, RETINA-J RET VIT DIS, V28, P1493, DOI 10.1097/IAE.0b013e318183589c
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Toyama T, 2014, EYE, V28, P992, DOI 10.1038/eye.2014.132
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 10
TC 2
Z9 2
U1 0
U2 0
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD MAY-JUN
PY 2016
VL 79
IS 3
BP 200
EP 201
DI 10.5935/0004-2749.20160058
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DS5EV
UT WOS:000380804900017
PM 27463636
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Guymer, RH
   Baird, PN
   Varsamidis, M
   Busija, L
   Dimitrov, PN
   Aung, KZ
   Makeyeva, GA
   Richardson, AJ
   Lim, L
   Robman, LD
AF Guymer, Robyn H.
   Baird, Paul N.
   Varsamidis, Mary
   Busija, Lucy
   Dimitrov, Peter N.
   Aung, Khin Zaw
   Makeyeva, Galina A.
   Richardson, Andrea J.
   Lim, Lyndell
   Robman, Liubov D.
TI Proof of Concept, Randomized, Placebo-Controlled Study of the Effect of
   Simvastatin on the Course of Age-Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID REDUCTASE INHIBITORS STATINS; SEVERITY SCALE; A REDUCTASE; MACULOPATHY;
   PROGRESSION; GENE; RISK; CLASSIFICATION; PREVENTION
AB Background: HMG Co-A reductase inhibitors are ubiquitous in our community yet their potential role in age-related macular degeneration (AMD) remains to be determined.
   Methodology/Principal Findings: Objectives: To evaluate the effect of simvastatin on AMD progression and the effect modification by polymorphism in apolipoprotein E (ApoE) and complement factor H (CFH) genes. Design: A proof of concept double-masked randomized controlled study. Participants: 114 participants aged 53 to 91 years, with either bilateral intermediate AMD or unilateral non-advanced AMD (with advanced AMD in fellow eye), BCVA >= 20/60 in at least one eye, and a normal lipid profile. Intervention: Simvastatin 40 mg/day or placebo, allocated 1:1. Main outcome measures: Progression of AMD either to advanced AMD or in severity of non-advanced AMD. Results. The cumulative AMD progression rates were 70% in the placebo and 54% in the simvastatin group. Intent to treat multivariable logistic regression analysis, adjusted for age, sex, smoking and baseline AMD severity, showed a significant 2-fold decrease in the risk of progression in the simvastatin group: OR 0.43 (0.18-0.99), p = 0.047. Post-hoc analysis stratified by baseline AMD severity showed no benefit from treatment in those who had advanced AMD in the fellow eye before enrolment: OR 0.97 (0.27-3.52), p = 0.96, after adjusting for age, sex and smoking. However, there was a significant reduction in the risk of progression in the bilateral intermediate AMD group compared to placebo [adjusted OR 0.23 (0.07-0.75), p = 0.015]. The most prominent effect was observed amongst those who had the CC (Y402H) at risk genotype of the CFH gene [OR 0.08 (0.02-0.45), p = 0.004]. No evidence of harm from simvastatin intervention was detected.
   Conclusion/Significance: Simvastatin may slow progression of non-advanced AMD, especially for those with the at risk CFH genotype CC (Y402H). Further exploration of the potential use of statins for AMD, with emphasis on genetic subgroups, is warranted.
C1 [Guymer, Robyn H.; Baird, Paul N.; Varsamidis, Mary; Busija, Lucy; Dimitrov, Peter N.; Aung, Khin Zaw; Makeyeva, Galina A.; Richardson, Andrea J.; Lim, Lyndell; Robman, Liubov D.] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, East Melbourne, Vic, Australia.
   [Busija, Lucy] Deakin Univ, Biostat Unit, Fac Hlth, Burwood, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Deakin University
RP Robman, LD (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, East Melbourne, Vic, Australia.
EM liubov@unimelb.edu.au
RI Busija, Lucy/Y-6064-2019
OI Busija, Lucy/0000-0001-7464-9089; Lim, Lyndell/0000-0003-2491-685X;
   Baird, Paul/0000-0002-1305-3502; Guymer, Robyn/0000-0002-9441-4356
FU Ian Potter Foundation; John Reid Charitable Trust; Royal Victorian Eye
   and Ear Hospital; National Health and Medical Research Council (NHMRC)
   through a Centre for Clinical Research Excellence award [529923, 529905,
   1028444]; Wagstaff Fellowship; NHMRC award "Centre for Clinical Research
   Excellence" [529923]
FX This work was supported by grants from the Ian Potter Foundation, John
   Reid Charitable Trust and Royal Victorian Eye and Ear Hospital. Merck
   Sharp and Dohme supplied the active simvastatin and placebo medication.
   The National Health and Medical Research Council (NHMRC) supported the
   study through a Centre for Clinical Research Excellence award to
   CERA(#529923), a Practitioner Fellowship (#529905) to RHG and a Senior
   Research Fellowship (#1028444) to PNB. LDR was supported by the Wagstaff
   Fellowship. CERA receives operational infrastructure from the Victorian
   Government. CERA is a recepient of the NHMRC award "Centre for Clinical
   Research Excellence" #529923. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Adams MKM, 2012, AM J EPIDEMIOL, V175, P511, DOI 10.1093/aje/kwr329
   ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957
   ALBERTS AW, 1988, AM J CARDIOL, V62, pJ10, DOI 10.1016/0002-9149(88)90002-1
   Aung KZ, 2009, OPHTHAL EPIDEMIOL, V16, P254, DOI [10.3109/09286580902864419, 10.1080/09286580902864419]
   *AUSTR GOV, 2008, MOST COMM US DRUGS A
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chuo JY, 2007, OPHTHAL EPIDEMIOL, V14, P367, DOI 10.1080/09286580701421684
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Dupont W. D., 2009, PS POWER SAMPLE SIZE
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fong DS, 2010, AM J OPHTHALMOL, V149, P955, DOI 10.1016/j.ajo.2009.12.037
   Gehlbach P, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub2
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Guymer RH, 2008, CLIN INTERV AGING, V3, P581
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Jones P, 1998, AM J CARDIOL, V81, P582, DOI 10.1016/S0002-9149(97)00965-X
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2008, OPHTHALMOLOGY, V115, P1460, DOI 10.1016/j.ophtha.2008.01.026
   Klein R, 2007, AM J OPHTHALMOL, V144, P1, DOI 10.1016/j.ajo.2007.02.047
   Maguire MG, 2009, OPHTHALMOLOGY, V116, P2381, DOI 10.1016/j.ophtha.2009.06.055
   Mant A, 2007, BRIT J CLIN PHARMACO, V63, P125, DOI 10.1111/j.1365-2125.2006.02735.x
   MARTINI E, 1991, Annali di Ottalmologia e Clinica Oculistica, V117, P1121
   McCarty CA, 2001, MJA, V175, P17
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   National Heart Foundation of Australia, 2001, MED J AUST S, V175, pS57
   Ridker PM, 2008, NEW ENGL J MED, V359, P2195, DOI 10.1056/NEJMoa0807646
   Ridker PM, 2009, LANCET, V373, P1175, DOI 10.1016/S0140-6736(09)60447-5
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Seipp Michael T, 2009, J Biomol Tech, V20, P160
   Shalev V, 2011, OPHTHAL EPIDEMIOL, V18, P83, DOI 10.3109/09286586.2011.560746
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Tsao SW, 2013, DRUG AGING, V30, P205, DOI 10.1007/s40266-013-0061-4
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   VanderBeek BL, 2013, RETINA-J RET VIT DIS, V33, P414, DOI 10.1097/IAE.0b013e318276e0cf
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Zhou Q, 2010, CIRC J, V74, P818, DOI 10.1253/circj.CJ-10-0110
NR 45
TC 49
Z9 50
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 31
PY 2013
VL 8
IS 12
AR e83759
DI 10.1371/journal.pone.0083759
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 284NF
UT WOS:000329325200120
PM 24391822
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Szabo, SM
   Hedegaard, M
   Chan, K
   Thorlund, K
   Christensen, R
   Vorum, H
   Jansen, JP
AF Szabo, Shelagh M.
   Hedegaard, Morten
   Chan, Keith
   Thorlund, Kristian
   Christensen, Robin
   Vorum, Henrik
   Jansen, Jeroen P.
TI Ranibizumab vs. aflibercept for wet age-related macular degeneration:
   network meta-analysis to understand the value of reduced frequency
   dosing
SO CURRENT MEDICAL RESEARCH AND OPINION
LA English
DT Article
DE Age-related macular degeneration; Network meta-analysis; Systematic
   review; Vascular endothelial growth factor inhibitors
ID ENDOTHELIAL GROWTH-FACTOR; FACTOR TRAP-EYE
AB Objective:
   Although a reduced aflibercept (2.0mg) injection frequency relative to the approved dosing posology is included in national treatment guidelines for wet age-related macular degeneration (AMD), there is limited evidence of its comparative efficacy. The objective was to compare the efficacy and safety of reduced frequency dosing for aflibercept, relative to other approved and marketed vascular endothelial growth factor inhibitors for wet AMD, over 12 months.
   Research design and methods:
   Based on a systematic literature review performed according to a pre-specified protocol, a Bayesian network meta-analysis (NMA) was conducted to indirectly compare posologies of aflibercept and ranibizumab (0.5mg). The efficacy outcome, mean change from baseline in best-corrected visual acuity (BCVA) on the ETDRS chart, was evaluated at 3 and 12 months; and safety data at 12 months. Standard NMA models were used to analyze change at 3 months, and fractional polynomial regression over 12 months. Safety data were analyzed using binomial models with a logistic link function.
   Results:
   Five trials formed a complete evidence network. At 3 months, all posologies of aflibercept and ranibizumab resulted in similar changes in BCVA. Over 12 months, approved posologies of aflibercept and ranibizumab resulted in similar changes from baseline, between 6.7 (95% credible interval [CrI], 5.5, 7.8) and 9.1 (8.1, 10.1) ETDRS letters; however, reduced frequency aflibercept was associated with a smaller change (1.8 letters, [-25.9, 29.2]). There was a trend towards a greater change in BCVA, with increasing frequency of dosing. All posologies performed similarly with respect to safety, and CrIs were wide.
   Conclusions:
   Approved posologies of ranibizumab and aflibercept are similarly effective treatments for wet AMD. Reduced frequency aflibercept was associated with the poorest visual outcomes, and sample sizes were small. Findings from these analyses provide novel evidence of the comparative efficacy and safety of aflibercept and ranibizumab for wet AMD.
C1 [Szabo, Shelagh M.; Chan, Keith; Thorlund, Kristian] Redwood Outcomes, Vancouver, BC, Canada.
   [Hedegaard, Morten] Novartis Healthcare, Copenhagen, Denmark.
   [Christensen, Robin] Copenhagen Univ Hosp, Parker Inst, Dept Rheumatol, Copenhagen, Denmark.
   [Vorum, Henrik] Aalborg Univ Hosp, Dept Ophthalmol, Aalborg, Denmark.
   [Jansen, Jeroen P.] Redwood Outcomes, San Francisco, CA 94133 USA.
C3 University of Copenhagen; Aalborg University; Aalborg University
   Hospital
RP Jansen, JP (通讯作者)，Redwood Outcomes, 1714 Stockton St,3rd floor, San Francisco, CA 94133 USA.
EM jjansen@redwoodoutcomes.com
OI Jansen, Jeroen Paul/0000-0003-2686-9217; Christensen,
   Robin/0000-0002-6600-0631
FU Novartis
FX This study was funded by Novartis.
CR Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Brooks SP, 1998, J COMPUT GRAPH STAT, V7, P434, DOI 10.2307/1390675
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Caldwell DM, 2005, BMJ-BRIT MED J, V331, P897, DOI 10.1136/bmj.331.7521.897
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Dias S., 2011, NICE DSU TECHNICAL S
   Dias S, 2013, MED DECIS MAKING, V33, P607, DOI 10.1177/0272989X12458724
   EMA, EYL INN AFL SUMM PRO
   EMA, LUC INN RAN SUMM PRO
   Fadda V, 2011, BRIT J OPHTHALMOL, V95, P1476, DOI 10.1136/bjophthalmol-2011-300316
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Genentech, 2015, LUC RAN INJ FULL PRE
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Hodgson RBT, 2014, INDIRECT TREATMENT C
   Jansen JP, 2015, STAT MED, V34, P2294, DOI 10.1002/sim.6492
   Jansen JP, 2011, VALUE HEALTH, V14, P417, DOI 10.1016/j.jval.2011.04.002
   Kiss S, 2015, ASS RES VIS OPHTH DE
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lu G, 2004, STAT MED, V23, P3105, DOI 10.1002/sim.1875
   Malcolm WAHR, 2015, ISPOR 20 ANN INT M P
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Reich O, 2015, RISK MANAG HEALTHC P, V8, P55, DOI 10.2147/RMHP.S80536
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Spiegelhalter D., 2003, WINBUGS USER MANUAL
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Treatment Age Related Macular Dege, 2005, ARCH OPHTHALMOL-CHIC, V123, P1283
   Virgili G, 2011, CURR DRUG TARGETS, V12, P212, DOI 10.2174/138945011794182665
NR 35
TC 16
Z9 16
U1 0
U2 10
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0300-7995
EI 1473-4877
J9 CURR MED RES OPIN
JI Curr. Med. Res. Opin.
PD NOV 2
PY 2015
VL 31
IS 11
BP 2031
EP 2042
DI 10.1185/03007995.2015.1084909
PG 12
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA CV7SR
UT WOS:000364475600001
PM 26296050
DA 2022-11-30
ER

PT J
AU Figurska, M
AF Figurska, Malgorzata
TI Retinal pigment epithelial tears following ranibizumab therapy for
   fibrovascular retinal pigment epithelial detachment due to occult
   age-related macular degeneration
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE retinal pigment epithelial tears; ranibizumab; occult exudative AMD
ID INTRAVITREAL BEVACIZUMAB INJECTION; SECONDARY
AB Background: The aim of this paper is to report the incidence of retinal pigment epithelial (RPE) tears in patients treated with ranibizumab for subfoveal fibrovascular retinal pigment epithelial detachment (FVPED) due to occult age-related macular degeneration (AMD).
   Material/Methods: Thirty patients were treated according to the following schedule: saturation phase, further treatment was based on activity of the degeneration process. Visual acuity (VA), optical coherence tomography (OCT) and fluorescein angiography (FA) parameters were evaluated and compared.
   Results: Patients had a mean improvement of +4.7+/-8.1 letters at month 12. The mean number of needed injections was 6.8+/-1.8 (range, 3 to 9). RPE tears in fovea occurred in 8 cases (27% of all patients). Analysis of variance revealed significant upper mean values of ETDRS letters for the subgroup without RPE tears. Mean values of PED height were significant upper for RPE tears without baseline. Statistical analysis revealed that in the subgroup without RPE tears mean values of VA significantly differed in succeeding periods compare to baseline (P<0.001). Visual improvement or stabilization was observed in 90.9% of patients without RPE tears (significant improvement of 15 or more letters in 22.7%-5/22) and in 87.5% of patients with RPE tears (significant improvement was not observed). Baseline leakage parameters, lesion and leakage parameters at month 12 were significantly higher in patients with RPE tears. The chi-square test revealed statistically significant associations between RPE tears and subretinal fluid in OCT (P<0.05) at month 12.
   Conclusions: In eyes with FVPED and RPE tears treated with ranibizumab, stabilization of visual acuity without significant improvement is predictable. One of the risk factors common to RPE tears may be baseline leakage parameters and pretreatment distorted RPE contour in OCT. During ranibizumab therapy in eyes with RPE tears, upper parameters of FVPED height may occur without significant differences in fovea and macula volume compare to eyes without RPE tears.
C1 Mil Inst Med, Dept Ophthalmol, PL-04141 Warsaw, Poland.
C3 Military Institute of Aviation Medicine
RP Figurska, M (通讯作者)，Mil Inst Med, Dept Ophthalmol, Szaserow 128 St, PL-04141 Warsaw, Poland.
EM malgorzata-figurska@wp.pl
CR Arias L, 2007, EUR J OPHTHALMOL, V17, P992, DOI 10.1177/112067210701700622
   Bakri SJ, 2007, AM J OPHTHALMOL, V143, P505, DOI 10.1016/j.ajo.2006.11.047
   Carvounis PE, 2007, AM J OPHTHALMOL, V143, P504, DOI 10.1016/j.ajo.2006.11.028
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Czarkowska-Paczek B, 2010, MED SCI MONITOR, V16, pBR147
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   Gelisken F, 2009, EYE, V23, P694, DOI 10.1038/sj.eye.6703098
   Gelisken F, 2006, ACTA OPHTHALMOL SCAN, V84, P833, DOI 10.1111/j.1600-0420.2006.00765.x
   Goldstein M, 2005, EYE, V19, P1315, DOI 10.1038/sj.eye.6701765
   Kiss C, 2007, ACTA OPHTHALMOL SCAN, V85, P902, DOI 10.1111/j.1600-0420.2007.00928.x
   Konstantinidis L, 2010, ACTA OPHTHALMOL, V88, P736, DOI 10.1111/j.1755-3768.2009.01547.x
   Krejca M, 2010, MED SCI MONITOR, V16, pBR89
   KRISHAN NR, 1985, AM J OPHTHALMOL, V100, P698, DOI 10.1016/0002-9394(85)90626-9
   Lee GKY, 2007, GRAEF ARCH CLIN EXP, V245, P1225, DOI 10.1007/s00417-007-0536-2
   Leitritz M, 2008, EYE, V22, P1504, DOI 10.1038/eye.2008.145
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   Moroz I, 2009, OPHTHAL SURG LAS IM, V40, P570, DOI 10.3928/15428877-20091030-06
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Shah CP, 2006, AM J OPHTHALMOL, V142, P1070, DOI 10.1016/j.ajo.2006.07.037
   Shiraki K, 2001, GRAEF ARCH CLIN EXP, V239, P430, DOI 10.1007/s004170100304
   Smith BT, 2009, RETINA-J RET VIT DIS, V29, P335, DOI 10.1097/IAE.0b013e318195cad5
   Torrón-Fernández-Blanco C., 2007, Arch Soc Esp Oftalmol, V82, P245
   Tsujikawa A, 2007, RETINA-J RET VIT DIS, V27, P832, DOI 10.1097/IAE.0b013e318150d864
NR 26
TC 4
Z9 4
U1 0
U2 4
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
SN 1643-3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD JAN
PY 2012
VL 18
IS 1
BP CR32
EP CR38
DI 10.12659/MSM.882198
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 883VT
UT WOS:000299663700016
PM 22207117
OA Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Lim, FPM
   Loh, BK
   Cheung, CMG
   Lim, LS
   Chan, CM
   Wong, DWK
AF Lim, F. P. M.
   Loh, B. K.
   Cheung, C. M. G.
   Lim, L. S.
   Chan, C. M.
   Wong, D. W. K.
TI Evaluation of focal choroidal excavation in the macula using
   swept-source optical coherence tomography
SO EYE
LA English
DT Article
ID EYES
AB Purpose To evaluate imaging findings of patients with focal choroidal excavation (FCE) in the macula using swept-source optical coherence tomography (SS-OCT) and correlate it clinically.
   Methods Prospective observational case series. Eleven consecutive patients (12 eyes) with FCE were described. Data on demographics and clinical presentation were collected and imaging findings (including color photography, fundus autofluorescence imaging, fluorescein angiography, indocyanine green angiography, spectral-domain optical coherence tomography, and SS-OCT) were analyzed.
   Results The primary diagnosis was epiretinal membrane (two eyes), choroidal neovascularization (one eye), polypoidal choroidal vasculopathy (three eyes), central serous chorioretinopathy (one eye), and dry age-related macular degeneration (two eyes). Eleven out of 12 of the lesions were conforming. One presented with a nonconforming lesion that progressed to a conforming lesion. One eye had multiFCE and two had two overlapping choroidal excavations. Using the SS-OCT, we found the choroid to be thinned out at the area of FCE but sclera remained normal. The choroidal tissue beneath the FCE was abnormal, with high internal reflectivity and poor visualization of choroidal vessels. There was loss of contour of the outer choroidal boundary that appeared to be pulled inward by this abnormal choroidal tissue. A suprachoroidal space was noted beneath this choroidal tissue and the choroidal-scleral interface was smooth. Repeat SS-OCT 6 months after presentation showed the area of excavation to be stable in size.
   Conclusion FCE can be associated with epiretinal membrane, central serous chorioretinopathy, and age-related macular degeneration. The choroid was thinned out in the area of FCE.
C1 [Lim, F. P. M.; Loh, B. K.; Cheung, C. M. G.; Lim, L. S.; Chan, C. M.; Wong, D. W. K.] Singapore Natl Eye Ctr, Dept Ophthalmol, Singapore 168751, Singapore.
   [Loh, B. K.; Cheung, C. M. G.; Lim, L. S.; Chan, C. M.; Wong, D. W. K.] Singapore Eye Res Inst, Singapore, Singapore.
   [Loh, B. K.; Cheung, C. M. G.; Lim, L. S.; Chan, C. M.; Wong, D. W. K.] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117548, Singapore.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center; National University of Singapore
RP Loh, BK (通讯作者)，Singapore Natl Eye Ctr, Dept Ophthalmol, Vitreoretinal Serv, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM loh.boon.kwang@snec.com.sg
OI Cheung, Chui Ming Gemmy/0000-0003-3358-3516; Wong,
   Damon/0000-0003-4601-9121
FU Singapore National Eye Centre
FX We would like to thank all the staff and allied health in the Singapore
   National Eye Centre for their support in this case series. This research
   received no specific grant from any funding agency in the public,
   commercial, or not-for-profit sectors.
CR Abe Sachi, 2010, Retin Cases Brief Rep, V4, P373, DOI 10.1097/ICB.0b013e3181babe7e
   Ellabban AA, 2013, AM J OPHTHALMOL, V155, P320, DOI 10.1016/j.ajo.2012.08.007
   GILBERT C, 1988, EYE, V2, pS140, DOI 10.1038/eye.1988.140
   Jampol LM, 2006, RETINA-J RET VIT DIS, V26, P1072, DOI 10.1097/01.iae.0000248819.86737.a5
   Katome T, 2012, CASE REP OPHTHALM, V3, P96, DOI 10.1159/000337880
   Kobayashi W, 2012, CLIN OPHTHALMOL, V6, P1373, DOI 10.2147/OPTH.S33879
   Margolis R, 2011, ARCH OPHTHALMOL-CHIC, V129, P1320, DOI 10.1001/archophthalmol.2011.148
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Obata R, 2013, RETINA-J RET VIT DIS, V33, P1201, DOI 10.1097/IAE.0b013e31827b6452
   Ohno-Matsui K, 2012, AM J OPHTHALMOL, V154, P382, DOI 10.1016/j.ajo.2012.02.010
   Wakabayashi Y, 2010, ACTA OPHTHALMOL, V88, pe87, DOI 10.1111/j.1755-3768.2010.01895.x
NR 11
TC 19
Z9 20
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD SEP
PY 2014
VL 28
IS 9
BP 1088
EP 1094
DI 10.1038/eye.2014.78
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AP4QX
UT WOS:000342064400006
PM 24946847
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Sagkriotis, A
   Chakravarthy, U
   Griner, R
   Doyle, O
   Wintermantel, T
   Clemens, A
AF Sagkriotis, Alexandros
   Chakravarthy, Usha
   Griner, Ray
   Doyle, Orla
   Wintermantel, Tim
   Clemens, Andreas
TI Application of machine learning methods to bridge the gap between
   non-interventional studies and randomized controlled trials in
   ophthalmic patients with neovascular age-related macular degeneration
SO CONTEMPORARY CLINICAL TRIALS
LA English
DT Article
DE Decision model; Machine learning; Neovascular age-related macular
   degeneration; Non-interventional study; Predictive analytics; Real world
   evidence
ID 2.0 MG RANIBIZUMAB; CHOROIDAL NEOVASCULARIZATION; BEVACIZUMAB; OUTCOMES;
   EFFICACY; SAFETY; VEGF; AFLIBERCEPT; REGIMENS; COHORT
AB Purpose: The effectiveness of intravitreal anti-vascular endothelial growth factor agents is usually lower in real world settings compared with randomized clinical trials (RCTs), often limiting the use of real-world evidence (RWE) in regulatory and healthcare decisions. The current analysis aimed to develop and validate an algorithm to explain the difference in outcomes between RWE studies and RCTs in patients with neovascular age-related macular degeneration.
   Methods: The algorithm was developed using ranibizumab real world data (RWD) from the US and validated on Australian and UK RWD. A decision model was developed using machine learning principles, in which the model learns how to partition the most influential factors (out of 59 variables) so that they maximally relate to the change in visual acuity (VA) over 12 months.
   Results: The algorithm identified baseline VA <73 Early Treatment Diabetic Retinopathy Study letters, presence of baseline subretinal fluid, and administration of three loading doses by Day 90 from drug initiation as the characteristics with the greatest impact on VA at month 12. When applying the different criteria, RWE outcomes became similar to those obtained in known RCTs.
   Conclusion: Machine learning techniques can be used to classify real world cohorts and identify subsets of patients who benefit to the same extent as that reported in RCTs. This methodology may support the translation of clinical trial findings to treatment performance in the clinical practice setting.
C1 [Sagkriotis, Alexandros; Clemens, Andreas] Novartis Pharma AG, Basel, Switzerland.
   [Chakravarthy, Usha] Queens Univ Belfast, Dept Ophthalmol, Belfast, Antrim, North Ireland.
   [Griner, Ray] IQVIA Real World Insights, Danbury, CT USA.
   [Clemens, Andreas] Univ Freiburg, Heart Ctr Freiburg Univ, Fac Med, Dept Cardiol & Angiol 1, Freiburg, Germany.
   [Doyle, Orla] IQVIA Real World Insight, London, England.
   [Wintermantel, Tim] IQVIA Real World Insights, Saint Prex, Switzerland.
C3 Novartis; Queens University Belfast; Universitats Herzzentrum Freiburg;
   University of Freiburg
RP Sagkriotis, A (通讯作者)，Novartis Pharma AG, Basel, Switzerland.
EM alexandros.sagkriotis@novartis.com
FU Novartis Pharma AG, Basel, Switzerland; IQVIA
FX The study was co-funded by Novartis Pharma AG, Basel, Switzerland and
   IQVIA. Medical writing support was provided by Carol Crawford at
   Novartis Ireland Ltd. and funded by Novartis Pharma AG, Basel
   Switzerland.
CR Ackland P, 2012, INDIAN J OPHTHALMOL, V60, P380, DOI 10.4103/0301-4738.100531
   Anderson M, 2019, J CLIN EPIDEMIOL, V105, P50, DOI 10.1016/j.jclinepi.2018.09.003
   Ashraf M, 2018, ACTA OPHTHALMOL, V96, P120, DOI 10.1111/aos.13565
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Crowther M, 2013, HEMATOL-AM SOC HEMAT, P15, DOI 10.1182/asheducation-2013.1.15
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Eldem BM, 2015, ACTA OPHTHALMOL, V93, pE458, DOI 10.1111/aos.12540
   Evans RN, 2020, OPHTHALMOLOGY, V127, P1191, DOI 10.1016/j.ophtha.2020.03.020
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Galloway N.R., 2006, AGING EYECOMMON EYE, P201
   Garrison LP, 2007, VALUE HEALTH, V10, P326, DOI 10.1111/j.1524-4733.2007.00186.x
   Gill J., 2017, 2 RWE LOND SCH EC
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Hykin P, 2016, CLIN OPHTHALMOL, V10, P87, DOI 10.2147/OPTH.S92627
   Johnston RL, 2017, ADV THER, V34, P703, DOI 10.1007/s12325-017-0483-1
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Leung King Fai Calvin, 2018, Vision (Basel), V2, DOI 10.3390/vision2010005
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuki K, 2016, SCI STUD READ, V20, P20, DOI 10.1080/10888438.2015.1107073
   Menghini M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042014
   Milnes F, 2016, VALUE HEALTH, V19, pA561, DOI 10.1016/j.jval.2016.09.1245
   Nallamothu BK, 2008, CIRCULATION, V118, P1294, DOI 10.1161/CIRCULATIONAHA.107.703579
   NICE, 2019, NAT I HLTH CAR EXC E
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Ziemssen F, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0401-y
NR 39
TC 5
Z9 5
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1551-7144
EI 1559-2030
J9 CONTEMP CLIN TRIALS
JI Contemp. Clin. Trials
PD MAY
PY 2021
VL 104
AR 106364
DI 10.1016/j.cct.2021.106364
EA MAR 2021
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA UP3HB
UT WOS:000695272900024
PM 33746023
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Abbou, EJ
   Connor, GB
   Artes, PH
   Abadi, RV
AF Abbou, Emily J.
   Connor, Gillian B.
   Artes, Paul H.
   Abadi, Richard V.
TI Visual loss and visual hallucinations in patients with age-related
   macular degeneration (Charles Bonnet Syndrome)
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID MINI-MENTAL-STATE; BONNET,CHARLES SYNDROME; VISION; PREVALENCE; PEOPLE;
   PERCEPTION; DISORDERS; ATTENTION; ANATOMY; CORTEX
AB PURPOSE. The condition in which visual hallucinations (VHs) are solely associated with a visual impairment is termed Charles Bonnet Syndrome (CBS). The study was undertaken to investigate whether the extent of visual acuity (VA) loss and central visual field loss predisposes a patient with age-related macular degeneration (AMD) to develop a CBS VH and, in addition, whether the progression in loss is mirrored in the complexity of the VHs reported. VH phenomenology and CBS prevalence were also examined.
   METHODS. Sixty-six patients (age range, 63-96 years, mean +/- SD 81.2 +/- 7.1 years) with bilateral AMD were questioned as to whether they had experienced any hallucinatory episodes exclusive to vision. The four-point primary inclusion criterion ensured that all patients had bilateral AMD, a bilateral central scotoma, best monocular VA poorer than or equal to 0.6 logMAR (logarithm of the minimum angle of resolution) and intact cognition (using the Mini Mental State Examination for the Blind and the Telephone Interview for Cognitive Status). The patients who did not report VH were classified into the non-VH group, with the remainder in the VH group. An extended Institute of Psychiatry Structural Interview characterized the phenomenology of the VH. A secondary inclusion criterion subdivided the VH group into the apparent CBS group, in which personal medical history may have contributed to VH generation, and the manifest CBS group, where VHs were solely as a result of the visual loss.
   RESULTS. Fifty-three patients met the primary inclusion criterion: 32 were classified into the non-VH group and 21 into the VH group. The VH group were slightly younger (median difference, 4 years, P = 0.03) and appeared to have a lower VA (median difference, 0.20 logMAR, P = 0.08) and a more extensive visual field loss (P = 0.06) than did the non-VH group. However, when these variables were evaluated simultaneously by logistic regression, only age emerged as a statistically significant predictor of VH (odds ratio 0.88, 95% confidence interval [CI] 0.8 - 0.99, P = 0.03). The prevalence of apparent CBS and manifest CBS in the AMD population was found to be 25% and 15%, respectively. With no clinical and phenomenological differences between the two CBS groups, the secondary inclusion criterion was withdrawn, the VH group was renamed the CBS group, and a prevalence of 40% was recalculated. Of the 82 visual phenomena experienced by the CBS group, 21 were classified as simple VHs and 39 as complex VHS, with the remainder classified as either entopic phenomena or visual inference. Patients who experienced both simple and complex VHs appeared to have a greater visual field loss (P = 0.06) compared with those patients who reported either solely simple or solely complex VHs.
   CONCLUSIONS. The extent of visual loss did not appear to be a predictor for the likelihood of a patient with AMD experiencing a CBS VH, nor was the progression of loss reflected in the complexity of the VHs reported.
C1 Univ Manchester, Fac Life Sci, Manchester M60 1QD, Lancs, England.
C3 University of Manchester
RP Abadi, RV (通讯作者)，Univ Manchester, Fac Life Sci, Moffat Bldg,Sackville St, Manchester M60 1QD, Lancs, England.
EM r.abadi@manchester.ac.uk
RI Artes, Paul/A-2603-2008
OI Artes, Paul/0000-0003-3574-8396
CR Abraham HD, 1996, NEUROPSYCHOPHARMACOL, V14, P285, DOI 10.1016/0893-133X(95)00136-2
   APA, 1994, DIAGN STAT MAN MENT
   BENTALL RP, 1990, PSYCHOL BULL, V107, P82, DOI 10.1037/0033-2909.107.1.82
   Brandt J., 1988, NEUROPSY NEUROPSY BE, V1, P111
   Bressloff PC, 2002, NEURAL COMPUT, V14, P473, DOI 10.1162/089976602317250861
   Bressloff PC, 2001, PHILOS T R SOC B, V356, P299, DOI 10.1098/rstb.2000.0769
   BROWN GC, 1992, ARCH OPHTHALMOL-CHIC, V110, P1251, DOI 10.1001/archopht.1992.01080210069027
   Burke W, 2002, J NEUROL NEUROSUR PS, V73, P535, DOI 10.1136/jnnp.73.5.535
   COGAN DG, 1973, A GRAEF ARCH KLIN EX, V188, P139, DOI 10.1007/BF00407835
   Cohen SY, 2000, AM J OPHTHALMOL, V129, P815, DOI 10.1016/S0002-9394(00)00374-3
   Collerton D, 2005, BEHAV BRAIN SCI, V28, P737
   COPELAND JRM, 1976, PSYCHOL MED, V6, P439, DOI 10.1017/S0033291700015889
   CRANE WG, 1994, OPHTHALMOL CLIN N AM, V7, P143
   DEMORSIER G, 1936, SCHWEIZ MED WOCHENSC, V66, P700
   Ermentrout B, 1998, REP PROG PHYS, V61, P353, DOI 10.1088/0034-4885/61/4/002
   ERMENTROUT GB, 1979, BIOL CYBERN, V34, P137, DOI 10.1007/BF00336965
   Feldman R., 1997, TRENDS NEUROSCI, V20, P544, DOI [10.1016/s0166-2236(97)85575-0, DOI 10.1016/S0166-2236(97)85575-0]
   Fernandez A, 1997, J NERV MENT DIS, V185, P195, DOI 10.1097/00005053-199703000-00009
   Ffytche DH, 1998, NAT NEUROSCI, V1, P738, DOI 10.1038/3738
   ffytche DH, 1999, BRAIN, V122, P1247, DOI 10.1093/brain/122.7.1247
   FITZGERALD RG, 1971, AM J PSYCHIAT, V127, P1533, DOI 10.1176/ajp.127.11.1533
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Girkin CA, 2001, SURV OPHTHALMOL, V45, P379, DOI 10.1016/S0039-6257(00)00208-3
   GOLD K, 1989, COMPR PSYCHIAT, V30, P90, DOI 10.1016/0010-440X(89)90122-3
   GROSSBERG S, 2006, J INT NEUROPSYCH SOC, V6, P583
   HOLROYD S, 1992, AM J PSYCHIAT, V149, P1701
   Holroyd S, 1996, J GERIATR PSYCH NEUR, V9, P171, DOI 10.1177/089198879600900403
   KOMEL HW, 1985, J NEUROL NEUROSUR PS, V48, P29
   LANCE JW, 1976, BRAIN, V99, P719, DOI 10.1093/brain/99.4.719
   Madill SA, 2005, BRIT J OPHTHALMOL, V89, P785, DOI 10.1136/bjo.2005.066027
   Manford M, 1998, BRAIN, V121, P1819, DOI 10.1093/brain/121.10.1819
   Mattis S., 1988, DEMENTIA RATING SCAL
   Menon GJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P349, DOI 10.1001/archopht.123.3.349
   Menon GJ, 2003, SURV OPHTHALMOL, V48, P58, DOI 10.1016/S0039-6257(02)00414-9
   Mewasingh LD, 2002, PEDIATR NEUROL, V26, P143, DOI 10.1016/S0887-8994(01)00358-7
   Nadarajah J, 1998, AUST NZ J OPHTHALMOL, V26, P63, DOI 10.1111/j.1442-9071.1998.tb01444.x
   Nesher R, 2001, J GLAUCOMA, V10, P396, DOI 10.1097/00061198-200110000-00006
   Nixon PA, 2006, AM J MED, V119, DOI 10.1016/j.amjmed.2005.12.022
   NORTONWILLSON L, 1987, FAM PRACT, V4, P27, DOI 10.1093/fampra/4.1.27
   Ohayon MM, 2000, PSYCHIAT RES, V97, P153, DOI 10.1016/S0165-1781(00)00227-4
   Pessoa L, 1998, BEHAV BRAIN SCI, V21, P723
   Reischies FM, 1997, BRIT J PSYCHIAT, V171, P449, DOI 10.1192/bjp.171.5.449
   ROSENBAUM F, 1987, J AM GERIATR SOC, V35, P66, DOI 10.1111/j.1532-5415.1987.tb01321.x
   Safran A B, 1996, Curr Opin Ophthalmol, V7, P53, DOI 10.1097/00055735-199612000-00009
   Santhouse AM, 2000, BRAIN, V123, P2055, DOI 10.1093/brain/123.10.2055
   SCHULTZ G, 1993, J NERV MENT DIS, V181, P639, DOI 10.1097/00005053-199310000-00011
   Schultz G, 1996, PERCEPTION, V25, P715, DOI 10.1068/p250715
   SCHULTZ G, 1991, PERCEPTION, V20, P809, DOI 10.1068/p200809
   Scott IU, 2001, AM J OPHTHALMOL, V131, P590, DOI 10.1016/S0002-9394(01)00833-9
   Shiraishi Y, 2004, J PSYCHIATR RES, V38, P207, DOI 10.1016/S0022-3956(03)00090-6
   Sweetman S.C, 2004, MARTINDALE COMPLETE
   Tan CSH, 2004, BRIT J OPHTHALMOL, V88, P1325, DOI 10.1136/bjo.2004.041947
   TEUNISSE RJ, 1995, BRIT J PSYCHIAT, V166, P254, DOI 10.1192/bjp.166.2.254
   Teunisse RJ, 1996, LANCET, V347, P794, DOI 10.1016/S0140-6736(96)90869-7
   TEUNISSE RJ, 1994, COMPR PSYCHIAT, V35, P70, DOI 10.1016/0010-440X(94)90172-4
   TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x
NR 56
TC 57
Z9 57
U1 0
U2 27
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2007
VL 48
IS 3
BP 1416
EP 1423
DI 10.1167/iovs.06-0942
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 142YF
UT WOS:000244686500061
PM 17325191
DA 2022-11-30
ER

PT J
AU Feng, L
   Chen, S
   Dai, HT
   Dorajoo, R
   Liu, JJ
   Kong, JF
   Yin, XY
   Ren, YQ
AF Feng, Lei
   Chen, Si
   Dai, Huatuo
   Dorajoo, Rajkumar
   Liu, Jianjun
   Kong, Jinfeng
   Yin, Xianyong
   Ren, Yunqing
TI Discovery of Novel Genetic Risk Loci for Acute Central Serous
   Chorioretinopathy and Genetic Pleiotropic Effect With Age-Related
   Macular Degeneration
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE central serous chorioretinopathy; gene; association; pleiotropic effect;
   risk loci; age-related macular degeneration
ID GENOME-WIDE ASSOCIATION; COMPLEMENT FACTOR-H; COMMON VARIANTS;
   SUSCEPTIBILITY
AB Background Central serous chorioretinopathy (CSC) is a severe and heterogeneous chorioretinal disorder. Shared clinical manifestations between CSC and age-related macular degeneration (AMD) and the confirmation of CFH as genetic risk locus for both CSC and AMD suggest possible common pathophysiologic mechanisms between two diseases. Methods To advance the understanding of genetic susceptibility of CSC and further investigate genetic pleiotropy between CSC and AMD, we performed genetic association analysis of 38 AMD-associated single nucleotide polymorphisms (SNPs) in a Chinese CSC cohort, consisting of 464 patients and 548 matched healthy controls. Results Twelve SNPs were found to be associated with CSC at nominal significance (p < 0.05), and four SNPs on chromosomes 1, 4, and 15 showed strong associations whose evidences surpassed Bonferroni (BF)-corrected significance [rs1410996, odds ratios (OR) = 1.47, p = 2.37 x 10(-5); rs1329428, OR = 1.40, p = 3.32 x 10(-4); rs4698775, OR = 1.45, p = 2.20 x 10(-4); and rs2043085, OR = 1.44, p = 1.91 x 10(-4)]. While the genetic risk effects of rs1410996 and rs1329428 (within the well-established locus CFH) are correlated (due to high LD), rs4698775 on chromosome 4 and rs2043085 on chromosome 15 are novel risk loci for CSC. Polygenetic risk score (PRS) constructed by using three independent SNPs (rs1410996, rs4698775, and rs2043085) showed highly significant association with CSC (p = 2.10 x 10(-7)), with the top 10% of subjects with high PRS showing 6.39 times higher risk than the bottom 10% of subjects with lowest PRS. Three SNPs were also found to be associated with clinic manifestations of CSC patients. In addition, by comparing the genetic effects (ORs) of these 38 SNPs between CSC and AMD, our study revealed significant, but complex genetic pleiotropic effect between the two diseases. Conclusion By discovering two novel genetic risk loci and revealing significant genetic pleiotropic effect between CSC and AMD, the current study has provided novel insights into the role of genetic composition in the pathogenesis of CSC.
C1 [Feng, Lei; Chen, Si; Kong, Jinfeng] Zhejiang Univ, Affiliated Hosp 2, Eye Ctr, Sch Med, Hangzhou, Peoples R China.
   [Chen, Si] Shanghai Sixth Peoples Hosp, Dept Ophthalmol, Jinshan Branch, Shanghai, Peoples R China.
   [Dai, Huatuo; Ren, Yunqing] Zhejiang Univ, Childrens Hosp, Natl Clin Res Ctr Child Hlth, Dept Dermatol,Sch Med, Hangzhou, Peoples R China.
   [Dai, Huatuo; Ren, Yunqing] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Dermatol, Hangzhou, Peoples R China.
   [Dorajoo, Rajkumar; Liu, Jianjun] Agcy Sci Technol & Res, Genome Inst Singapore, Singapore, Singapore.
   [Liu, Jianjun] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore.
   [Yin, Xianyong] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA.
   [Yin, Xianyong] Univ Michigan, Sch Publ Hlth, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
C3 Zhejiang University; Shanghai Jiao Tong University; Zhejiang University;
   Zhejiang University; Agency for Science Technology & Research (A*STAR);
   A*STAR - Genome Institute of Singapore (GIS); National University of
   Singapore; University of Michigan System; University of Michigan;
   University of Michigan System; University of Michigan
RP Ren, YQ (通讯作者)，Zhejiang Univ, Childrens Hosp, Natl Clin Res Ctr Child Hlth, Dept Dermatol,Sch Med, Hangzhou, Peoples R China.; Ren, YQ (通讯作者)，Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Dermatol, Hangzhou, Peoples R China.; Yin, XY (通讯作者)，Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA.; Yin, XY (通讯作者)，Univ Michigan, Sch Publ Hlth, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
EM xianyongyin@gmail.com; yqren@zju.edu.cn
OI Dorajoo, Rajkumar/0000-0001-6608-2051
FU National Nature Science Foundation of China [81870648, 82070949,
   81872520]
FX The work was supported by grants from the National Nature Science
   Foundation of China (81870648, 82070949, and 81872520).
CR Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Balaratnasingam C, 2016, OPHTHALMOLOGY, V123, P1541, DOI 10.1016/j.ophtha.2016.03.017
   Breukink MB, 2015, INVEST OPHTH VIS SCI, V56, P5608, DOI 10.1167/iovs.15-17343
   Chang CC, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742-015-0047-8
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Daruich A, 2017, RETINA-J RET VIT DIS, V37, P1905, DOI 10.1097/IAE.0000000000001443
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   de Jong EK, 2015, OPHTHALMOLOGY, V122, P562, DOI 10.1016/j.ophtha.2014.09.026
   Desai UR, 2003, J NATL MED ASSOC, V95, P553
   Dorner GT, 2003, INVEST OPHTH VIS SCI, V44, P3947, DOI 10.1167/iovs.02-0855
   Ersoz MG, 2019, BRIT J OPHTHALMOL, V103, P725, DOI 10.1136/bjophthalmol-2018-312431
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gamazon ER, 2018, NAT GENET, V50, P956, DOI 10.1038/s41588-018-0154-4
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Hosoda Y, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0712-z
   Hosoda Y, 2018, P NATL ACAD SCI USA, V115, P6261, DOI 10.1073/pnas.1802212115
   How ACSW, 2006, ANN ACAD MED SINGAP, V35, P77
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Karkhaneh R, 2022, EYE, V36, P1061, DOI 10.1038/s41433-021-01579-x
   Karska-Basta I, 2020, J PHYSIOL PHARMACOL, V71, P235, DOI 10.26402/jpp.2020.2.07
   Karska-Basta I, 2021, J CLIN MED, V10, DOI 10.3390/jcm10051087
   Karska-Basta I, 2021, ACTA OPHTHALMOL, V99, pE222, DOI 10.1111/aos.14547
   Kitzmann AS, 2008, OPHTHALMOLOGY, V115, P169, DOI [10.1016/j.ophtha.2007.02.032, 10.1016/j.ophtha.2008.01.009]
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Liew G, 2013, CLIN EXP OPHTHALMOL, V41, P201, DOI 10.1111/j.1442-9071.2012.02848.x
   Miki A, 2018, INVEST OPHTH VIS SCI, V59, P5542, DOI 10.1167/iovs.18-25497
   Miki A, 2014, OPHTHALMOLOGY, V121, P1067, DOI 10.1016/j.ophtha.2013.11.020
   Mohabati D, 2019, RETINA-J RET VIT DIS, V39, P2303, DOI 10.1097/IAE.0000000000002333
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Oosterhuis JA, 1996, GRAEF ARCH CLIN EXP, V234, P337, DOI 10.1007/BF00220710
   Schellevis RL, 2018, JAMA OPHTHALMOL, V136, P1128, DOI 10.1001/jamaophthalmol.2018.3190
   Schubert C, 2014, HUM MUTAT, V35, P859, DOI 10.1002/humu.22551
   Tsai DC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066858
   van Dijk EHC, 2017, JAMA OPHTHALMOL, V135, P446, DOI 10.1001/jamaophthalmol.2017.0245
   Wang M, 2008, ACTA OPHTHALMOL, V86, P126, DOI 10.1111/j.1600-0420.2007.00889.x
   Watanabe K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01261-5
   Weenink AC, 2001, OPHTHALMOLOGICA, V215, P183, DOI 10.1159/000050855
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 40
TC 1
Z9 1
U1 2
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD AUG 20
PY 2021
VL 9
DI 10.3389/fcell.2021.696885
PG 10
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA UQ4LC
UT WOS:000696035800001
PM 34490249
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Thomas, M
   Wolfson, Y
   Zayit-Soudry, S
   Bressler, SB
   Bressler, NM
AF Thomas, Merina
   Wolfson, Yulia
   Zayit-Soudry, Shiri
   Bressler, Susan B.
   Bressler, Neil M.
TI Qualifying to Use a Home Monitoring Device for Detection of Neovascular
   Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID SEVERITY SCALE; EYE DISEASE; RANIBIZUMAB; TRIAL
AB IMPORTANCE Patients with intermediate age-related macular degeneration (AMD) using a home monitoring device have less loss of visual acuity, on average, at detection of choroidal neovascularization than do individuals using standard care monitoring techniques. Understanding the frequency with which patients are likely to initiate using a home monitoring device successfully is important in planning implementation of the device into practice.
   OBJECTIVES To determine the frequency with which patients with intermediate AMD qualify to use a home monitoring device and to establish a reliable baseline reference value with the device to monitor their AMD for progression to choroidal neovascularization.
   DESIGN, SETTING, AND PARTICIPANTS Between October 8, 2010, and May 20, 2011, a total of 131 eligible participants within a university-based retina practice with intermediate AMD in the study eye and visual acuity of 20/63 or better completed an in-clinic qualification test for the home device. Intermediate AMD was defined as multiple intermediate-sized drusen or at least 1 large druse. If both eyes were eligible, the eye with better visual acuity was selected as the study eye. If both eyes had the same visual acuity, the patient used the eye with subjectively better vision. Analysis was performed between August 1, 2011, and January 11, 2014.
   MAIN OUTCOMES AND MEASURES The proportion of patients with reliable qualification test results and a test score predictive of successful home use of a monitoring device for detecting neovascular AMD, and the proportion who established a baseline reference value at home.
   RESULTS A total of 129 participants (98.5%; 95% CI, 96.4%-99.9%) had reliable qualification test results; 91 participants (69.5%; 95% CI, 61.6%-77.4%) who completed this test attained a score that suggested they would be able to successfully use the home device. Among the 91 participants who could initiate home testing, 83 did so, including 80 participants (87.9%; 95% CI, 81.2%-94.6%) who established a baseline value that could be used as a reference for future monitoring. Younger participants were more likely to qualify for home testing (mean [SD] age, 73.1 [8.4] vs 81.1 [7.1] years; P < .001). Visual acuity at study enrollment did not appear to be associated with successful qualification (mean visual acuity for those who did and did not qualify was 20/28 and 20/31, respectively; P = .10).
   CONCLUSIONS AND RELEVANCE These data suggest that the in-office qualification test is a useful screening tool to identify patients who may benefit from the home device. In any given retina practice, our data suggest an estimated 61.6% to 77.4% of patients with intermediate AMD should be able to produce reliable initial test results in the office test using the home monitoring device and pass a qualification test to initiate home monitoring. Subsequently, 81.2% to 94.6% of patients should be able to establish a home baseline reference value for future monitoring.
C1 [Thomas, Merina; Wolfson, Yulia; Zayit-Soudry, Shiri; Bressler, Susan B.; Bressler, Neil M.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Baltimore, MD 21205 USA.
   [Thomas, Merina] Univ Illinois, Eye & Ear Infirm, Univ Illinois Hosp & Hlth Syst, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA.
   [Zayit-Soudry, Shiri] Rambam Hlth Care Campus, Dept Ophthalmol, Haifa, Israel.
C3 Johns Hopkins University; Johns Hopkins Medicine; University of Illinois
   System; University of Illinois Chicago; University of Illinois Chicago
   Hospital; Rambam Health Care Campus
RP Bressler, NM (通讯作者)，Johns Hopkins Univ Hosp, 600 N Wolfe St,Maumenee Bldg,Off 752, Baltimore, MD 21287 USA.
EM nmboffice@jhmi.edu
OI Zayit Soudry, Shiri/0000-0002-8736-1823
FU Notal Vision; Research to Prevent Blindness; National Institutes of
   Health through the Vanderbilt School of Medicine Medical Scholars
   Program [5TL1RR024978-04]; NATIONAL CENTER FOR RESEARCH RESOURCES
   [TL1RR024978] Funding Source: NIH RePORTER
FX Notal Vision, Inc, provided the home monitoring devices used by study
   participants. Notal Vision provides research support to the Johns
   Hopkins University School of Medicine managed and negotiated by the
   school's Office of Research Administration for research, for which Drs
   N. M. Bressler and S. B. Bressler are principal investigators. Dr S. B.
   Bressler reported receiving support through a Clinician-Scientist Award
   from Research to Prevent Blindness. This study was supported by National
   Institutes of Health grant 5TL1RR024978-04 through the Vanderbilt School
   of Medicine Medical Scholars Program, unrestricted donations for
   research to the Johns Hopkins University School of Medicine, Research to
   Prevent Blindness (Drs S. B. Bressler and N. M. Bressler), the Julia G
   Levy, PhD, Professor of Ophthalmology (Dr S. B. Bressler), and the James
   P. Gills Professor of Ophthalmology (Dr N. M. Bressler).
CR ACHARD OA, 1995, AM J OPHTHALMOL, V120, P322, DOI 10.1016/S0002-9394(14)72162-2
   AMSLER M, 1947, OPHTHALMOLOGICA, V114, P248, DOI 10.1159/000300476
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   LAKSHMINARAYANAN V, 1995, INT OPHTHALMOL, V19, P109, DOI 10.1007/BF00133181
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SCHUCHARD RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P776, DOI 10.1001/archopht.1993.01090060064024
   WARABI T, 1986, EXP NEUROL, V92, P686, DOI 10.1016/0014-4886(86)90309-2
   Zaidi FH, 2004, EYE, V18, P503, DOI 10.1038/sj.eye.6700708
NR 18
TC 5
Z9 6
U1 0
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD DEC
PY 2015
VL 133
IS 12
BP 1425
EP 1430
DI 10.1001/jamaophthalmol.2015.3684
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CZ4RV
UT WOS:000367091300011
PM 26468999
OA Bronze
DA 2022-11-30
ER

PT J
AU Zhang, J
   Bai, Y
   Huang, L
   Qi, Y
   Zhang, Q
   Li, S
   Wu, Y
   Li, X
AF Zhang, J.
   Bai, Y.
   Huang, L.
   Qi, Y.
   Zhang, Q.
   Li, S.
   Wu, Y.
   Li, X.
TI Protective effect of autophagy on human retinal pigment epithelial cells
   against lipofuscin fluorophore A2E: implications for age-related macular
   degeneration
SO CELL DEATH & DISEASE
LA English
DT Article
ID RPE LIPOFUSCIN; BISRETINOIDS; PATHOGENESIS; INHIBITION; ACTIVATION;
   MECHANISMS; PRODUCTS; DISEASE; HEALTH; DAMAGE
AB Age-related macular degeneration (AMD) is the leading cause of central vision loss in the elderly. Degeneration of retinal pigment epithelial (RPE) cells is a crucial causative factor responsible for the onset and progression of AMD. A2E, a major component of toxic lipofuscin implicated in AMD, is deposited in RPE cells with age. However, the mechanism whereby A2E may contribute to the pathogenesis of AMD remains unclear. We demonstrated that A2E was a danger signal of RPE cells, which induced autophagy and decreased cell viability in a concentration-and time-dependent manner. Within 15 min after the treatment of RPE with 25 mu M A2E, the induction of autophagosome was detected by transmission electron microscopy. After continuous incubating RPE cells with A2E, intense punctate staining of LC3 and increased expression of LC3-II and Beclin-1 were identified. Meanwhile, the levels of intercellular adhesion molecule (ICAM), interleukin (IL) 1 beta, IL2, IL-6, IL-8, IL-17A, IL-22, macrophage cationic peptide (MCP)-1, stromal cell-derived factor (SDF)-1, and vascular endothelial growth factor A (VEGFA) were elevated. The autophagic inhibitor 3-methyladenine (3-MA) and activator rapamycin were also used to verify the effect of autophagy on RPE cells against A2E. Our results revealed that 3-MA decreased the autophagosomes and LC3 puncta induced by A2E, increased inflammation-associated protein expression including ICAM, IL1 beta, IL2, IL-6, IL-8, IL-17A, IL-22, and SDF-1, and upregulated VEGFA expression. Whereas rapamycin augmented the A2E-mediated autophagy, attenuated protein expression of inflammation-associated and angiogenic factors, and blocked the Akt/mTOR pathway. Taken together, A2E induces autophagy in RPE cells at the early stage of incubation, and this autophagic response can be inhibited by 3-MA or augmented by rapamycin via the mTOR pathway. The enhancement of autophagy has a protective role in RPE cells against the adverse effects of A2E by reducing the secretion of inflammatory cytokines and VEGFA.
C1 [Zhang, J.; Bai, Y.; Huang, L.; Qi, Y.; Zhang, Q.; Li, S.; Li, X.] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100044, Peoples R China.
   [Zhang, J.; Bai, Y.; Huang, L.; Qi, Y.; Zhang, Q.; Li, S.; Li, X.] Minist Educ, Key Lab Vis Loss & Restorat, Beijing 100044, Peoples R China.
   [Zhang, J.; Bai, Y.; Huang, L.; Qi, Y.; Zhang, Q.; Li, S.; Li, X.] Beijing Key Lab Diag & Treatment Retinal & Choroi, Beijing 100044, Peoples R China.
   [Wu, Y.] Xiamen Univ, Eye Inst, Fujian Prov Key Lab Ophthalmol & Visual Sci, Xiamen 361102, Fujian Provine, Peoples R China.
C3 Peking University; Xiamen University
RP Li, X (通讯作者)，Peking Univ, Peoples Hosp, Dept Ophthalmol, Xizhimen South St 11, Beijing 100044, Peoples R China.
EM yalinw@xmu.edu.cn; drlixiaoxin@163.com
OI Huang, Lan/0000-0001-9594-4722
FU Beijing Nova Program [Z131102000413004]; China Postdoctoral Science
   Foundation [2015M570901]; National Basic Research Program of China (973
   Program) [2011CB510200]; National Natural Science Foundation of China
   [81470649, 81271018]
FX This work was supported by the Beijing Nova Program (Z131102000413004),
   the China Postdoctoral Science Foundation (2015M570901), the National
   Basic Research Program of China (973 Program, 2011CB510200), the
   National Natural Science Foundation of China Grant (81470649) and the
   National Natural Science Foundation of China Grant (81271018). Funding
   institutions had no role in the study design, data collection and
   analysis, the decision to publish, or preparation of the manuscript.
   Thanks to Professor Martin J Jager as she provided us valuable
   suggestions for English editing during the process of revising the
   manuscript. Thanks to Bin Wang for his help with the immunostaining
   analysis.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Choi AMK, 2013, NEW ENGL J MED, V368, P1845, DOI 10.1056/NEJMc1303158
   Cuervo AM, 2005, AUTOPHAGY, V1, P131, DOI 10.4161/auto.1.3.2017
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   ELDRED GE, 1993, NATURE, V364, P396
   Ferrington D., 2015, PROG RETIN EYE RES
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gordois A, 2012, GLOB PUBLIC HEALTH, V7, P465, DOI 10.1080/17441692.2011.634815
   Herm RJ, 2008, NEW ENGL J MED, V359, P1735
   Herrmann P, 2013, OPHTHALMOLOGE, V110, P377, DOI 10.1007/s00347-012-2779-5
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta K, 2012, FUTURE MED CHEM, V4, P2153, DOI [10.4155/FMC.12.169, 10.4155/fmc.12.169]
   Kaarniranta K, 2010, ACTA OPHTHALMOL, V88, P387, DOI 10.1111/j.1755-3768.2009.01840.x
   KATZ ML, 1986, MECH AGEING DEV, V35, P291, DOI 10.1016/0047-6374(86)90131-4
   Kim SH, 2008, J NEUROSCI RES, V86, P2943, DOI 10.1002/jnr.21738
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Liu EY, 2012, J CELL SCI, V125, P2349, DOI 10.1242/jcs.093708
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Nair S, 2012, CELL CYCLE, V11, P2092, DOI 10.4161/cc.20317
   Nociari MM, 2014, P NATL ACAD SCI USA, V111, pE1402, DOI 10.1073/pnas.1400530111
   Paglin S, 2005, CANCER RES, V65, P11061, DOI 10.1158/0008-5472.CAN-05-1083
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Razani B, 2012, CELL METAB, V15, P534, DOI 10.1016/j.cmet.2012.02.011
   Roberts JE, 2002, PHOTOCHEM PHOTOBIOL, V75, P184, DOI 10.1562/0031-8655(2002)075<0184:TROAIP>2.0.CO;2
   Saadat KASM, 2014, FEBS OPEN BIO, V4, P1007, DOI 10.1016/j.fob.2014.11.003
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Shrivastava S, 2012, J VIROL, V86, P8705, DOI 10.1128/JVI.00616-12
   Sin HPY, 2013, ACTA OPHTHALMOL, V91, P6, DOI 10.1111/j.1755-3768.2011.02357.x
   Sparrow JR, 2014, J CLIN MED, V3, P1302, DOI 10.3390/jcm3041302
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Stahl A, 2008, FEBS LETT, V582, P3097, DOI 10.1016/j.febslet.2008.08.005
   Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Wielgus AR, 2012, PHOTOCHEM PHOTOBIOL, V88, P1320, DOI 10.1111/j.1751-1097.2012.01174.x
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 51
TC 67
Z9 67
U1 1
U2 22
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD NOV
PY 2015
VL 6
AR e1972
DI 10.1038/cddis.2015.330
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CZ5PU
UT WOS:000367155300011
PM 26561782
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Klein, R
   Deng, YZ
   Klein, BEK
   Hyman, L
   Seddon, J
   Frank, RN
   Wallace, RB
   Hendrix, SL
   Kuppermann, BD
   Langer, RD
   Kuller, L
   Brunner, R
   Johnson, KC
   Thomas, AM
   Haan, M
AF Klein, Ronald
   Deng, Yingzi
   Klein, Barbara E. K.
   Hyman, Leslie
   Seddon, Johanna
   Frank, Robert N.
   Wallace, Robert B.
   Hendrix, Susan L.
   Kuppermann, Baruch D.
   Langer, Robert D.
   Kuller, Lewis
   Brunner, Robert
   Johnson, Karen C.
   Thomas, Asha M.
   Haan, Mary
TI Cardiovascular disease, its risk factors and treatment, and age-related
   macular degeneration: Women's health initiative sight exam ancillary
   study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER-DAM EYE; POOLED FINDINGS; 3 CONTINENTS; STATIN USE; CHOROIDAL
   NEOVASCULARIZATION; 5-YEAR INCIDENCE; MEDICATION USE; MACULOPATHY;
   ASSOCIATION; PREVALENCE
AB center dot PURPOSE: To examine the association of cardiovascular disease (CVD), CVD risk factors, and CVD treatment with age related macular degeneration (AMD).
   center dot DESIGN: Observational analysis of a randomized clinical trial.
   center dot METHODS: SETTINGS: The Women's Health Initiative Sight Examination (WHISE), an ancillary study to the Women's Health Initiative's clinical trial of hormone replacement therapy. STUDY POPULATION: A total of 4,288 women age 63 years and older. OBSERVATION PROCEDURES: Information on CVD and its risk factors were obtained from a standardized questionnaire and examination. MAIN OUTCOME MEASURE: AMD as deter, mined by standardized grading of fundus photographs.
   center dot RESULTS: Prevalence of any AMD was 21.4% (n = 919). Of those with AMD, 5.8% (n = 53) had signs of exudative AMD (n = 39) or pure geographic atrophy (n = 14), limiting the power to examine associations. Significant associations between late AMD and CVD risk factors were (odds ratio [OR], 95% confidence interval [CI]) older age (1.19, 1.13 to 1.27, P < .0001), more pack years smoked (1.02 per pack,year smoked, 1.003 to 1.03, P = .01), systolic blood pressure (0.84 per 10 mm Hg, 0.71 to 0.995, P = .04), report of taking calcium channel blockers (2.49, 1.21 to 5.12, P = .04), self-reported history of diabetes (2.00, 1.01 to 3.96, P = .05), and greater body mass index (1.05 per 1 kg/m(2), 1.001 to 1.10, P = .05). History of myocardial infarction, stroke, use of statins, or white blood cell count was not associated with AMD.
   center dot CONCLUSIONS: Results suggest that smoking, use of calcium channel blockers, diabetes, and obesity are risk factors for late AMD in women. However, the association of late AMD with systolic blood pressure and the effects of other CVD risk factors on early AMD need to be further explored.
C1 Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA.
   SUNY Stony Brook, Div Epidemiol, Dept Prevent Med, Stony Brook, NY 11794 USA.
   Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA.
   Wayne State Univ, Kresge Eye Inst, Detroit, MI USA.
   Univ Iowa, Dept Epidemiol, Iowa City, IA USA.
   Wayne State Univ, Sch Med, Dept Obstet & Gynecol, Hutzel Hosp, Detroit, MI 48201 USA.
   Univ Calif Irvine, Dept Ophthalmol, Irvine, CA USA.
   Geisinger Hlth Syst, Outcomes Res Inst, Ctr Hlth Res, Danville, PA USA.
   Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
   Univ Nevada, Sch Med, Reno, NV 89557 USA.
   Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA.
   MedStar Res Inst, Washington, DC USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Michigan System; University of Michigan; State University
   of New York (SUNY) System; SUNY Community College; State University of
   New York (SUNY) Stony Brook; Harvard University; Harvard Medical School;
   Massachusetts Eye & Ear Infirmary; Wayne State University; University of
   Iowa; Wayne State University; University of California System;
   University of California Irvine; Geisinger Health System; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Nevada System of Higher Education (NSHE); University of
   Nevada Reno; University of Tennessee System; University of Tennessee
   Health Science Center
RP Klein, R (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, 610 N Walnut St,4th Floor WARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
RI Haan, Mary N/Y-9354-2018
OI Haan, Mary N/0000-0001-9312-4501
FU WOMEN&apos;S HEALTH INITIATIVE - OFFICE OF THE DIRECTOR NIH
   [N01WH032113, N01WH022110] Funding Source: NIH RePORTER; NEI NIH HHS
   [R01 EY011309] Funding Source: Medline; WHI NIH HHS [N01 WH022110-024]
   Funding Source: Medline
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61
   BISCHOFF PM, 1983, AM J OPHTHALMOL, V96, P398, DOI 10.1016/S0002-9394(14)77839-0
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   FRYCZKOWSKI AW, 1988, ANN OPHTHALMOL, V20, P299
   Haan MN, 2006, ARCH OPHTHALMOL-CHIC, V124, P988, DOI 10.1001/archopht.124.7.988
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   HIDAYAT AA, 1985, OPHTHALMOLOGY, V92, P512
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   Klein R, 2004, AM J OPHTHALMOL, V137, P747, DOI 10.1016/j.ajo.2004.01.037
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   KORNZWEIG AL, 1977, ANN OPHTHALMOL, V9, P753
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   National Heart Lung and Blood Institute, 1998, NIH PUBL
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2006, RETINA, P1017
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Stefanick ML, 2003, ANN EPIDEMIOL, V13, pS78, DOI 10.1016/S1047-2797(03)00045-0
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   van Leeuwen R, 2001, BRIT MED J, V323, P1308, DOI 10.1136/bmj.323.7324.1308a
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 50
TC 94
Z9 99
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2007
VL 143
IS 3
BP 473
EP 483
DI 10.1016/j.ajo.2006.11.058
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 141CZ
UT WOS:000244555700013
PM 17317391
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Tepelus, TC
   Hariri, AH
   Balasubramanian, S
   Sadda, SR
AF Tepelus, Tudor C.
   Hariri, Amir H.
   Balasubramanian, Siva
   Sadda, SriniVas R.
TI Reproducibility of Macular Thickness Measurements in Eyes Affected by
   Dry Age-Related Macular Degeneration From Two Different SD-OCT
   Instruments
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; TIME-DOMAIN; RESOLUTION; DISEASES; EDEMA
AB BACKGROUND AND OBJECTIVE: To compare macular thickness measurement algorithms of two different spectral-domain optical coherence tomography (SD-OCT) devices in eyes affected by dry age-related macular degeneration (AMD).
   PATIENTS AND METHODS: Patients with dry AMD and healthy volunteers from the retina clinic of the Doheny Eye Center - UCLA were imaged using two different SDOCT devices: the RS-3000 Advance (Nidek, Padova, Italy) and the Cirrus HD-OCT (Carl Zeiss Meditec, Dublin, CA). All patients had been previously diagnosed with drusen or geographic atrophy due to AMD. The commercial instrument software was used to generate the macular retinal thickness measurements, and measurements were compared between devices.
   RESULTS: Eighty-five diseased eyes from 49 patients and 16 healthy control eyes from eight normal volunteers were included in this study. The macular thickness measurements generated by the two instruments in eyes with AMD differed significantly in mean retinal thickness in the foveal center subfield (257.34 mu m +/- 51.72 mu m using the Nidek OCT vs. 238.20 mu m +/- 51.89 mu m using the Cirrus OCT; P < .001). The mean difference in macular thickness between the two devices was 19.14 mu m +/- 5.84 mu m for diseased eyes and 17.06 mu m +/- 5.28 mu m in normal control eyes, and this was not statistically different between the two groups (P > .05). The macular thickness measurements in diseased eyes, as evaluated by the two different instruments, however, showed excellent correlation (r = 0.99; P < .001), with an intraclass correlation coefficient of 0.99 (95% confidence interval, 0.98-0.99). Post hoc evaluation of cases with larger differences also showed differences in foveal center selection and variabilities in boundary selection with specific pathology.
   CONCLUSION: Macular thickness measurements provided by the Nidek and Cirrus OCT instruments in eyes with dry AMD are highly correlated but show a consistent difference, which may allow the use of a standard correction factor to be applied to better interrelate measurements between the devices.
C1 [Tepelus, Tudor C.; Hariri, Amir H.; Balasubramanian, Siva; Sadda, SriniVas R.] Doheny Eye Inst, Doheny Image Reading Ctr, Los Angeles, CA 90033 USA.
   [Tepelus, Tudor C.; Hariri, Amir H.; Balasubramanian, Siva; Sadda, SriniVas R.] UCLA, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA
RP Sadda, SR (通讯作者)，Doheny Eye Inst, 1355 San Pablo St,DVRC 211, Los Angeles, CA 90033 USA.
EM SSadda@doheny.org
FU Optos; Carl Zeiss Meditec
FX Dr. Sadda is a consultant for and receives research support from Optos
   and Carl Zeiss Meditec; serves as a consultant for Centervue; and has
   access to research instruments provided by Heidelberg Engineering,
   Topcon Medical Systems, Optos, Carl Zeiss Meditec, Nidek, and Centervue.
   The remaining authors report no relevant financial disclosures.
CR Alam S, 2006, OPHTHALMOLOGY, V113, P1425, DOI 10.1016/j.ophtha.2006.03.020
   Alkuraya Hisham, 2005, International Ophthalmology, V26, P93, DOI 10.1007/s10792-006-9007-8
   Chen TC, 2005, ARCH OPHTHALMOL-CHIC, V123, P1715, DOI 10.1001/archopht.123.12.1715
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Forte R, 2009, EYE, V23, P2071, DOI 10.1038/eye.2008.363
   Fujimoto H, 2008, OPHTHALMOLOGY, V115, P1494, DOI 10.1016/j.ophtha.2008.01.021
   Giammaria D, 2011, RETINA-J RET VIT DIS, V31, P707, DOI 10.1097/IAE.0b013e3181eef401
   Giani A, 2010, AM J OPHTHALMOL, V150, P815, DOI 10.1016/j.ajo.2010.06.025
   Ho J, 2009, OPHTHALMOLOGY, V116, P1960, DOI 10.1016/j.ophtha.2009.03.034
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Huang JJ, 2009, RETINA-J RET VIT DIS, V29, P980, DOI 10.1097/IAE.0b013e3181a2c1a7
   Ibrahim MA, 2012, EYE, V26, P454, DOI 10.1038/eye.2011.293
   Karam EZ, 2007, BRIT J OPHTHALMOL, V91, P1139, DOI 10.1136/bjo.2007.114074
   Ko TH, 2004, OPHTHALMOLOGY, V111, P2033, DOI 10.1016/j.ophtha.2004.05.021
   Leung CKS, 2008, INVEST OPHTH VIS SCI, V49, P4893, DOI 10.1167/iovs.07-1326
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Massin P, 2001, ARCH OPHTHALMOL-CHIC, V119, P1135, DOI 10.1001/archopht.119.8.1135
   Muscat S, 2002, INVEST OPHTH VIS SCI, V43, P490
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Sull AC, 2010, RETINA-J RET VIT DIS, V30, P235, DOI 10.1097/IAE.0b013e3181bd2c3b
   Wilkins JR, 1996, OPHTHALMOLOGY, V103, P2142, DOI 10.1016/S0161-6420(96)30377-1
   Wolf-Schnurrbusch UEK, 2009, INVEST OPHTH VIS SCI, V50, P3432, DOI 10.1167/iovs.08-2970
NR 22
TC 2
Z9 2
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD JUN
PY 2018
VL 49
IS 6
BP 410
EP 415
DI 10.3928/23258160-20180601-05
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA GK4EJ
UT WOS:000436108300005
PM 29927468
DA 2022-11-30
ER

PT J
AU Diez, GR
   Campos, SS
   Giusto, NM
   Salvador, GA
AF Rodriguez Diez, G.
   Sanchez Campos, S.
   Giusto, N. M.
   Salvador, G. A.
TI Specific roles for Group V secretory PLA(2) in retinal iron-induced
   oxidative stress. Implications for age-related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE retina; iron; PLA(2); oxidative stress; AMD; acyltransferases
ID NF-KAPPA-B; PHOSPHOLIPASE A(2) ISOFORMS; ALZHEIMERS-DISEASE; SIGNALING
   PATHWAYS; SYNAPTIC ENDINGS; KNOCKOUT MICE; HOMEOSTASIS; CELLS;
   CYCLOOXYGENASE-2; IDENTIFICATION
AB Iron accumulation and oxidative stress are hallmarks of retinas from patients with age-related macular degeneration (AMD). We have previously demonstrated that iron-overloaded retinas are a good in vitro model for the study of retinal degeneration during iron-induced oxidative stress. In this model we have previously characterized the role of cytosolic phospholipase A(2) (cPLA(2)) and calcium-independent isoform (iPLA(2)). The aim of the present study was to analyze the implications of Group V secretory PLA(2) (sPLA(2)), another member of PLA(2) family, in cyclooxygenase (COX)-2 and nuclear factor kappa B (NF-kappa B) regulation. We found that sPLA(2) is localized in cytosolic fraction in an iron concentration-dependent manner. By immunoprecipitation (IP) assays we also demonstrated an increased association between Group V sPLA(2) and COX-2 in retinas exposed to iron overload. However, COX-2 activity in IP assays was observed to decrease in spite of the increased protein levels observed. p65 (RelA) NF-kappa B levels were increased in nuclear fractions from retinas exposed to iron. In the presence of ATK (cPLA(2) inhibitor) and YM 26734 (sPLA(2) inhibitor), the nuclear localization of both p65 and p50 NF-kappa B subunits was restored to control levels in retinas exposed to iron-induced oxidative stress. Membrane repair mechanisms were also analyzed by studying the participation of acyltransferases in phospholipid remodeling during retinal oxidation stress. Acidic phospholipids, such as phosphatidylinositol (PI) and phosphatidylserine (PS), were observed to show an inhibited acylation profile in retinas exposed to iron while phosphatidylethanolamine (PE) showed the opposite. The use of PLA(2) inhibitors demonstrated that PS is actively deacylated during iron-induced oxidative stress. Results from the present study suggest that Group V sPLA(2) has multiple intracellular targets during iron-induced retinal degeneration and that the specific role of sPLA(2) could be related to inflammatory responses by its participation in NF-kappa B and COX-2 regulation. (C) 2013 Elsevier Ltd. All rights reserved.
C1 Univ Nacl Sur, Inst Invest Bioquim Bahia Blanca, RA-8000 Bahia Blanca, Buenos Aires, Argentina.
   Consejo Nacl Invest Cient & Tecn, RA-8000 Bahia Blanca, Buenos Aires, Argentina.
C3 National University of the South; Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET)
RP Salvador, GA (通讯作者)，Ctr Cient & Tecnol CONICET Bahia Blanca, Inst Invest Bioquim Bahia Blanca, Edificio E1,Camino Carrindanga Km 7, RA-8000 Bahia Blanca, Buenos Aires, Argentina.
EM salvador@criba.edu.ar
RI Salvador, Gabriela/GOJ-7718-2022
FU Universidad Nacional del Sur (UNS); Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET) [PIP 11220090100687]; Fundacion
   Florencio Fiorini; Agencia Nacional de Promocion Cientifica y
   Tecnologica (ANPCYT) [PICT-2010-0936]
FX This work was supported by grants from the Universidad Nacional del Sur
   (UNS), the Consejo Nacional de Investigaciones Cientificas y Tecnicas
   (CONICET) [grant number PIP 11220090100687], the Fundacion Florencio
   Fiorini and the Agencia Nacional de Promocion Cientifica y Tecnologica
   (ANPCYT) [grant number PICT-2010-0936].
CR Balboa MA, 2003, J BIOL CHEM, V278, P48059, DOI 10.1074/jbc.M305904200
   Bazan NG, 2002, PROSTAG OTH LIPID M, V68-9, P197, DOI 10.1016/S0090-6980(02)00031-X
   Blasiak J, 2011, FRONT BIOSCI-LANDMRK, V16, P1551, DOI 10.2741/3804
   Blasiak Janusz, 2009, Klin Oczna, V111, P174
   Boilard E, 2010, EMBO MOL MED, V2, P172, DOI 10.1002/emmm.201000072
   Boyanovsky BB, 2010, CYTOKINE, V50, P50, DOI 10.1016/j.cyto.2009.12.009
   Castagnet PI, 1997, ARCH BIOCHEM BIOPHYS, V340, P124, DOI 10.1006/abbi.1996.9876
   Chakraborti S, 2003, CELL SIGNAL, V15, P637, DOI 10.1016/S0898-6568(02)00144-4
   Cindrova-Davies T, 2007, AM J PATHOL, V170, P1511, DOI 10.2353/ajpath.2007.061035
   Curfs DMJ, 2008, J BIOL CHEM, V283, P21640, DOI 10.1074/jbc.M710584200
   Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Franchi A, 2000, MEDICINA-BUENOS AIRE, V60, P580
   Hadziahmetovic M, 2008, INVEST OPHTH VIS SCI, V49, P2728, DOI 10.1167/iovs.07-1472
   Hadziahmetovic M, 2011, AM J PATHOL, V179, P335, DOI 10.1016/j.ajpath.2011.03.033
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P109, DOI 10.1167/iovs.10-6113
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   Kell DB, 2010, ARCH TOXICOL, V84, P825, DOI 10.1007/s00204-010-0577-x
   Kolko M, 2003, NEUROSCI LETT, V338, P164, DOI 10.1016/S0304-3940(02)01385-X
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Loh A, 2009, BBA-GEN SUBJECTS, V1790, P637, DOI 10.1016/j.bbagen.2008.11.001
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Lukinova N, 2009, INVEST OPHTH VIS SCI, V50, P1440, DOI 10.1167/iovs.08-2545
   Mackenzie GG, 2007, J CELL PHYSIOL, V210, P246, DOI 10.1002/jcp.20861
   Mateos MV, 2010, BBA-BIOMEMBRANES, V1798, P624, DOI 10.1016/j.bbamem.2009.12.008
   Moses GSD, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-28
   Murakami M, 2004, BIOL PHARM BULL, V27, P1158, DOI 10.1248/bpb.27.1158
   Murakami M, 2011, J BIOCHEM, V150, P233, DOI 10.1093/jb/mvr088
   Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065
   Osborn MT, 1999, BIOTECHNIQUES, V27, P887, DOI 10.2144/99275bm02
   Perez-Chacon G, 2009, BBA-MOL CELL BIOL L, V1791, P1103, DOI 10.1016/j.bbalip.2009.08.007
   Richardson DR, 2004, ANN NY ACAD SCI, V1012, P326, DOI 10.1196/annals.1306.026
   Diez GR, 2012, NEUROCHEM INT, V61, P749, DOI 10.1016/j.neuint.2012.06.012
   ROTSTEIN NP, 1987, LIPIDS, V22, P253, DOI 10.1007/BF02533988
   Ruiperez V, 2007, J IMMUNOL, V179, P631, DOI 10.4049/jimmunol.179.1.631
   Ruland J, 2011, NAT IMMUNOL, V12, P709, DOI 10.1038/ni.2055
   Saegusa J, 2008, J BIOL CHEM, V283, P26107, DOI 10.1074/jbc.M804835200
   Salvador GA, 2011, NEUROTOXICOLOGY, V32, P75, DOI 10.1016/j.neuro.2010.11.006
   SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335
   Sen R, 2011, NAT IMMUNOL, V12, P686, DOI 10.1038/ni.2071
   Smale ST, 2011, NAT IMMUNOL, V12, P689, DOI 10.1038/ni.2070
   Uranga RM, 2007, J NEUROSCI RES, V85, P2924, DOI 10.1002/jnr.21406
   Whitnall M, 2012, P NATL ACAD SCI USA, V109, P20590, DOI 10.1073/pnas.1215349109
   Youdim MBH, 2005, MECH AGEING DEV, V126, P317, DOI 10.1016/j.mad.2004.08.023
NR 46
TC 13
Z9 13
U1 0
U2 11
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
J9 EXP EYE RES
JI Exp. Eye Res.
PD AUG
PY 2013
VL 113
BP 172
EP 181
DI 10.1016/j.exer.2013.05.019
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 198OH
UT WOS:000322931700023
DA 2022-11-30
ER

PT J
AU Dentchev, T
   Milam, AH
   Lee, VMY
   Trojanowski, JQ
   Dunaief, JL
AF Dentchev, T
   Milam, AH
   Lee, VMY
   Trojanowski, JQ
   Dunaief, JL
TI Amyloid-beta is found in drusen from some age-related macular
   degeneration retinas, but not in drusen from normal retinas
SO MOLECULAR VISION
LA English
DT Article
ID GEOGRAPHIC ATROPHY
AB Purpose: Age-related macular degeneration (AMD) is the most common cause of irreversible vision loss in the elderly. Increased understanding of the pathogenesis is necessary. Amyloid-beta (Abeta), a major extracellular deposit in Alzheimer's disease plaques, has recently been found in drusen, the hallmark extracellular deposit in AMD. The goal of this study was to characterize the distribution and frequency of Abeta deposits in drusen from AMD and normal post mortem human retinas to gain additional insight about the potential role of Abeta in AMD patho genesis.
   Methods: Immunocytochemistry was performed with three Abeta antibodies on sections from 9 normal and 9 AMD (3 early, 3 geographic atrophy, 3 exudative AMD) retinas. Five sections from each eye were evaluated. Abeta positive deposits in drusen were identified using epifluorescence and confocal microscopy. Antibodies were pre-adsorbed with Abeta peptide to verify specificity. Some sections were stained with PAS-hematoxylin to aid in evaluation of morphology.
   Results: To test and optimize immunocytochemistry, Abeta was detected in amyloid plaques from Alzheimer's brains. Abeta label was blocked by pre-adsorption of antibody with Abeta peptide, verifying specificity. Four of the 9 AMD retinas and none of the 9 normal retinas had Abeta positive drusen. Two of the early AMD eyes had a few Abeta positive drusen, each with a few Abeta-containing vesicles, and 2 of the geographic atrophy (GA) eyes had many Abeta positive drusen with many Abeta containing vesicles.
   Conclusions: Abeta was present in 4 of 9 AMD eyes. Within these eyes, Abeta localized to a subset of drusen. None of the 9 normal eyes surveyed, some of which had small drusen, were A beta positive. Abetapositive vesicles were most numerous in GA eyes at the edges of atrophy, the region at risk for further degeneration. These results suggest that Abeta in drusen correlates with the location of degenerating photoreceptors and retinal pigment epithelium (RPE) cells. Further work will be necessary to determine whether Abeta deposition in drusen may contribute to or result from retinal degeneration.
C1 Univ Penn, FM Kirby Ctr Mol Ophthalmol, Scheie Eye Inst, Philadelphia, PA 19104 USA.
   Univ Penn, Dept Pathol & Lab Med, Inst Aging, Alzheimers Dis Ctr,Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; University of
   Pennsylvania; Pennsylvania Medicine
RP Dunaief, JL (通讯作者)，305 Stellar Chance Labs,422 Curie Blvd, Philadelphia, PA 19104 USA.
EM jdunaief@mail.med.upenn.edu
FU NEI NIH HHS [EY00417] Funding Source: Medline; NIA NIH HHS [AG-10124,
   AG-11542] Funding Source: Medline; NATIONAL INSTITUTE ON AGING
   [P30AG010124, P01AG011542] Funding Source: NIH RePORTER
CR Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Giasson BI, 2002, FREE RADICAL BIO MED, V32, P1264, DOI 10.1016/S0891-5849(02)00804-3
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Milam AH, 2001, METH MOLEC MED, V47, P71, DOI 10.1385/1-59259-085-3:71
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Selkoe DJ, 2002, J CLIN INVEST, V110, P1375, DOI 10.1172/JCI200216783
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002
   Westlind-Danielsson A, 2001, BIOCHEMISTRY-US, V40, P14736, DOI 10.1021/bi010375c
NR 10
TC 196
Z9 224
U1 0
U2 10
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD MAY 14
PY 2003
VL 9
IS 27
BP 184
EP 190
PG 7
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 685AC
UT WOS:000183237800001
PM 12764254
DA 2022-11-30
ER

PT J
AU Ho, M
   Woo, DCF
   Chan, VCK
   Young, AL
   Brelen, ME
AF Ho, Mary
   Woo, Donald C. F.
   Chan, Vesta C. K.
   Young, Alvin L.
   Brelen, Marten E.
TI Treatment of polypoidal choroidal vasculopathy by photodynamic therapy,
   aflibercept and dexamethasone triple therapy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; DIABETIC MACULAR EDEMA; INTRAVITREAL
   AFLIBERCEPT; VEGF-TRAP; TRIAMCINOLONE ACETONIDE; RANIBIZUMAB;
   BEVACIZUMAB; DEGENERATION; INJECTION; NEOVASCULARIZATION
AB Polypoidal choroidal vasculopathy is a relatively common type of degenerative macular disease among the Chinese population. This study aims to describe the therapeutic responses to combination therapy with photodynamic therapy, intravitreal aflibercept and intravitreal dexamethasone in patients with polypoidal choroidal vasculopathy. A prospective series of 17 eyes of 13 patients suffering from treatment-naive polypoidal choroidal vasculoapathy were recruited. All cases received triple therapy with photodynamic therapy, intravitreal aflibercept and intravitreal dexamethasone and one year outcomes were reported. The baseline visual acuity was 0.65logMAR +/- 0.38 ( Snellen 20/80 to 20/100). The visual acuity at 1 week, 3 months, 6 months and one year after treatment were significantly improved to 0.522logMAR +/- 0.365 (P < 0.04) (Snellen 20/70), 0.363logMAR +/- 0.382 (Snellen 20/50; P < 0.001), 0.377logMAR +/- 0.440 (Snellen 20/50; p = 0.005), and 0.35logMAR +/- 0.407 (Snellen 20/40; P < 0.001), respectively. The baseline central foveal thickness (CFT) on optical coherence tomography (OCT) was 394.7 +/- 70.6 mu m. CFT at 6 months and 1 year after treatment were significantly reduced to 259 +/- 54 mu m (p = 0.004) and 271 +/- 49.7 mu m(p = 0.016), respectively. Triple therapy with photodynamic therapy, intravitreal aflibercept and intravitreal dexamethasone is an effective treatment for polypoidal choroidal vasculopathy. The majority of cases responded well with significant responses observed as early as 1 week after initiation of therapy.
C1 [Ho, Mary; Chan, Vesta C. K.; Young, Alvin L.; Brelen, Marten E.] Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Woo, Donald C. F.] Hong Kong Ophthalm Associates, Kowloon, Hong Kong, Peoples R China.
   [Young, Alvin L.; Brelen, Marten E.] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Prince of Wales Hospital; Chinese
   University of Hong Kong
RP Brelen, ME (通讯作者)，Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.; Brelen, ME (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
EM marten.brelen@cuhk.edu.hk
RI Brelen, Marten E./D-1133-2016
CR Antonetti DA, 2002, J NEUROCHEM, V80, P667, DOI 10.1046/j.0022-3042.2001.00740.x
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Bandello F, 2010, OPHTHALMOLOGICA, V224, P41, DOI 10.1159/000315161
   Boyer DS, 2014, OPHTHALMOLOGY, V121, P1904, DOI 10.1016/j.ophtha.2014.04.024
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Gillies MC, 2006, OPHTHALMOLOGY, V113, P1533, DOI 10.1016/j.ophtha.2006.02.065
   GOMI F, 2008, THE BRITISH JOURNAL, V92, P70, DOI DOI 10.1136/BJ0.2007.122283
   Haller JA, 2010, OPHTHALMOLOGY, V117, P1134, DOI 10.1016/j.ophtha.2010.03.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Ho M, 2014, EYE, V28, P1469, DOI 10.1038/eye.2014.222
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Hosokawa M, 2015, BRIT J OPHTHALMOL, V99, P1087, DOI 10.1136/bjophthalmol-2014-305275
   Ikuno Y, 2015, OPHTHALMOLOGY, V122, P1220, DOI 10.1016/j.ophtha.2015.01.025
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Khurana RN, 2015, RETINA-J RET VIT DIS, V35, P1640, DOI 10.1097/IAE.0000000000000515
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Koizumi H, 2015, BRIT J OPHTHALMOL, V99, P1284, DOI 10.1136/bjophthalmol-2014-306432
   Kokame Gregg T, 2014, Trans Am Ophthalmol Soc, V112, P74
   KOKAME GT, 2010, THE BRITISH JOURNAL, V94, P297, DOI DOI 10.1136/BJ0.2008.150029
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2004, AM J OPHTHALMOL, V137, P826, DOI 10.1016/j.ajo.2003.11.079
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Nakata I, 2013, GRAEF ARCH CLIN EXP, V251, P1073, DOI 10.1007/s00417-012-2137-y
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Postelmans L, 2004, AM J OPHTHALMOL, V138, P803, DOI 10.1016/j.ajo.2004.06.033
   Saito M, 2014, RETINA-J RET VIT DIS, V34, P2192, DOI 10.1097/IAE.0000000000000236
   Sakai T, 2014, BRIT J OPHTHALMOL, V98, P1642, DOI 10.1136/bjophthalmol-2014-305189
   Schachat AP, 2013, AM J OPHTHALMOL, V156, P1, DOI 10.1016/j.ajo.2013.04.009
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   STEWART MW, 2008, THE BRITISH JOURNAL, V92, P667, DOI DOI 10.1136/BJ0.2007.134874
   Tamura H, 2005, INVEST OPHTH VIS SCI, V46, P1440, DOI 10.1167/iovs.04-0905
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wang K, 2008, BIOL PHARM BULL, V31, P1541, DOI 10.1248/bpb.31.1541
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yamashita M, 2014, CLIN OPHTHALMOL, V8, P343, DOI 10.2147/OPTH.S56539
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 45
TC 5
Z9 6
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 16
PY 2016
VL 6
AR 36870
DI 10.1038/srep36870
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EC5LO
UT WOS:000388177000001
PM 27848983
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Roshanipour, N
   Shahriyari, E
   Laleh, MG
   Vahedi, L
   Gerami, SM
   Khamaneh, A
AF Roshanipour, Nasrin
   Shahriyari, Elham
   Ghaffari Laleh, Maryam
   Vahedi, Leila
   Mirjand Gerami, Sousan
   Khamaneh, Amin
TI Associations of TLR4 and IL-8 genes polymorphisms with age-related
   macular degeneration (AMD): a systematic review and meta-analysis
SO OPHTHALMIC GENETICS
LA English
DT Review
DE Age-related macular degeneration (AMD); TLR4; IL-8; CXCL8; meta-analysis
ID INTERLEUKIN-8 GENE; CANCER-RISK; RECEPTOR 4; CROHNS-DISEASE;
   SUSCEPTIBILITY; EXPRESSION; REGION; ROLES; CELLS; D299G
AB Background The results of different studies have indicated the possible associations of TLR4 and IL-8 genes polymorphisms with Age-related Macular Degeneration (AMD). A meta-analysis study was designed to evaluate the possible associations of TLR4 (rs4986790/c.896A>G and rs4986791/ c.1196 C > T) and IL-8 (rs4073/c.251A>T and rs2227306/c.781 C > T) genes polymorphisms with AMD. Method A systematic literature search was carried out in PubMed, Embase, Web of Science, and Scopus databases to identify relevant publications. Pooled Odds Ratio (OR) with 95% Confidence Interval (CI) was used to evaluate the power of association. Results A total of 12 case-control studies with 4804 AMD patients and 4422 healthy controls were included in this meta-analysis. The analysis of genotypic and allelic models demonstrated significant associations between IL-8 c.781 C > T (CC vs. TT+TC: OR = 0.62 [0.48-0.81], P < .01; CC vs. TC: OR = 0.65 [0.48-0.89], P < .01; TT vs. CC: OR = 1.64 [1.04-2.57], P = .03; and C vs. T: OR = 0.71 [0.65-0.79], P < .01) and risk of AMD, which all of them passed Bonferroni correction for multiple testing (P-value <= 0.01), except for TT vs. CC model. In addition, we found associations under the genotypic model of TLR4 c.896A>G (AA vs. AG+GG: OR = 0.73 [0.55-0.97], P = .03; and AA vs. AG: OR = 0.71 [0.53-0.95], P = .02) although after Bonferroni correction (P '-value<0.02) none of these associations remained significant. However, the data from this meta-analysis declined the associations of TLR4 c.1196 C > T and IL-8 c.251A>T polymorphisms with AMD. Conclusion The current meta-analysis study suggested that IL-8 c.781 C > T polymorphism is associated with susceptibility to AMD.
C1 [Roshanipour, Nasrin] Islamic Azad Univ, Sch Genet, Dept Biol, Tabriz Branch, Tabriz, Iran.
   [Roshanipour, Nasrin; Shahriyari, Elham; Ghaffari Laleh, Maryam; Vahedi, Leila; Mirjand Gerami, Sousan] Tabriz Univ Med Sci, Imam Reza Hosp, Liver & Gastrointestinal Dis Res Ctr, Tabriz, Iran.
   [Shahriyari, Elham; Ghaffari Laleh, Maryam] Univ Tabriz, Fac Nat Sci, Ctr Excellence Biodivers, Tabriz, Iran.
   [Ghaffari Laleh, Maryam; Khamaneh, Amin] Tabriz Univ Med Sci, Fac Med, Res Ctr Evidence Based Med, Tabriz, Iran.
C3 Islamic Azad University; Tabriz University of Medical Science;
   University of Tabriz; Tabriz University of Medical Science
RP Laleh, MG (通讯作者)，Univ Tabriz, Fac Nat Sci, Ctr Excellence Biodivers, Tabriz, Iran.
EM maryam.ghaffari69@gmail.com
OI Shahriyari, Elham/0000-0002-7861-6767; Ghaffari Laleh,
   Maryam/0000-0002-5321-0824
FU Research Center for Evidence-Based Medicine, Tabriz University of
   Medical Sciences, Tabriz, Iran [65193]
FX This study was funded by the Research Center for Evidence-Based
   Medicine, Tabriz University of Medical Sciences, Tabriz, Iran [grant
   number 65193].
CR Ambreen F, 2015, MOL VIS, V21, P985
   Ao R, 2015, GASTROENT RES PRACT, V2015, DOI 10.1155/2015/141070
   Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048
   Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1
   Benakanakere MR, 2016, SCI REP-UK, V6, DOI 10.1038/srep31180
   Cai XJ, 2015, MED SCI MONITOR, V21, P625, DOI 10.12659/MSM.892557
   Cascella Raffaella, 2018, Oncotarget, V9, P7812, DOI 10.18632/oncotarget.23241
   Chen C, 2017, MOL MED REP, V15, P2289, DOI 10.3892/mmr.2017.6252
   Chen CH, 2020, J FORMOS MED ASSOC, V119, P1201, DOI 10.1016/j.jfma.2019.10.016
   Chen L, 2016, MOL MED REP, V13, P3249, DOI 10.3892/mmr.2016.4890
   Chen M, 2019, INVEST OPHTH VIS SCI, V60, P1105, DOI 10.1167/iovs.18-25922
   Cho YE, 2009, INVEST OPHTH VIS SCI, V50, P5614, DOI 10.1167/iovs.09-3688
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   de Oliveira JG, 2015, TUMOR BIOL, V36, P9159, DOI 10.1007/s13277-015-3593-x
   Despriet DDG, 2008, INVEST OPHTH VIS SCI, V49, P364, DOI 10.1167/iovs.07-0656
   Ding L, 2017, ONCOTARGET, V8, P100593, DOI 10.18632/oncotarget.21543
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fu ZQ, 2018, DIGESTION, V97, P250, DOI 10.1159/000485027
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P537, DOI 10.1136/bjo.2007.123190
   Guven M, 2016, CURR EYE RES, V41, P856, DOI 10.3109/02713683.2015.1067326
   Hacking D, 2004, GENES IMMUN, V5, P274, DOI 10.1038/sj.gene.6364067
   Hautamaki A, 2015, ACTA OPHTHALMOL, V93, P726, DOI 10.1111/aos.12799
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701
   Huang Q, 2011, J CANCER RES CLIN, V137, P1147, DOI 10.1007/s00432-011-0981-5
   Hull J, 2000, THORAX, V55, P1023, DOI 10.1136/thorax.55.12.1023
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Kohno H, 2013, J BIOL CHEM, V288, P15326, DOI 10.1074/jbc.M112.448712
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Lechner J, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0820-y
   Luo C, 2010, INVEST OPHTH VIS SCI, V51, P5697, DOI 10.1167/iovs.10-5407
   Ozato K, 2002, BIOTECHNIQUES, P66
   Ricci F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066978
   Robinson E, 2015, J APPL PHYSIOL, V119, P508, DOI 10.1152/japplphysiol.00334.2015
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Sarli A, 2017, CLIN OPHTHALMOL, V11, P1347, DOI 10.2147/OPTH.S134538
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Shahriyari E, 2019, J INFLAMM-LOND, V16, DOI 10.1186/s12950-019-0230-2
   Shen XY, 2010, DIGESTION, V81, P69, DOI 10.1159/000260417
   Tsai YY, 2008, INVEST OPHTH VIS SCI, V49, P693, DOI 10.1167/iovs.07-0125
   Wang XB, 2015, J CELL MOL MED, V19, P1218, DOI 10.1111/jcmm.12466
   Wang XM, 2018, CYTOKINE, V111, P230, DOI 10.1016/j.cyto.2018.08.024
   Wang Z, 2018, CANCER MANAG RES, V10, P2589, DOI 10.2147/CMAR.S165631
   Wang ZM, 2013, GENE, V522, P168, DOI 10.1016/j.gene.2013.03.066
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zhang K, 2013, EUR J CANCER, V49, P946, DOI 10.1016/j.ejca.2012.09.022
   Zhang Y, 2019, IMMUNOL INVEST, V48, P169, DOI 10.1080/08820139.2018.1508228
   Zhao JL, 2017, MEDICINE, V96, DOI [10.1097/MD.0000000000007909, 10.1097/md.0000000000007909]
   Zhu DH, 2009, AGING-US, V1, P740, DOI 10.18632/aging.100078
NR 50
TC 1
Z9 1
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD NOV 2
PY 2021
VL 42
IS 6
BP 641
EP 649
DI 10.1080/13816810.2021.1955274
EA JUL 2021
PG 9
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA XC4ZZ
UT WOS:000675364700001
PM 34287094
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Elias, FTS
   da Silva, EN
   Belfort, R
   Silva, MT
   Atallah, AN
AF Silva Elias, Flavia Tavares
   da Silva, Everton Nunes
   Belfort, Rubens, Jr.
   Silva, Marcus Tolentino
   Atallah, Alvaro Nagib
TI Treatment Options for Age-Related Macular Degeneration: A Budget Impact
   Analysis from the Perspective of the Brazilian Public Health System
SO PLOS ONE
LA English
DT Article
ID BEVACIZUMAB; RANIBIZUMAB; DISEASES; AVASTIN; PEOPLE; RISK; EYE
AB Background
   Age-related macular degeneration (AMD) is a disease that causes reduced visual acuity and blindness. The new treatment options for AMD are not provided by the Brazilian public health system.
   Objective
   To conduct a budget impact analysis of three scenarios for the introduction of AMD treatments: all the medications (verteporfin, ranibizumab, and bevacizumab-the reference scenario), ranibizumab alone, and bevacizumab alone.
   Methods
   The basic assumption was that the Brazilian public health system would treat the entire target population with AMD aged >70 years between 2008 and 2011. The size of the population of interest was estimated from official population projections and the prevalence of the disease was obtained from a systematic review. Medication prices were estimated by weighting their market values with correction factors to take account of the public procurement policy. The possibility of aliquoting bevacizumab was also considered. A panel of experts was consulted to estimate the market share of the different medications for the reference scenario. The incremental costs of the ranibizumab-alone and bevacizumab-alone scenarios compared to the reference scenario were calculated. Univariate sensitivity analyses were run to check the robustness of the model.
   Results
   In four years, the Brazilian public health system would have treated 1,136,349 individuals with AMD. The annual costs of treating one patient would have been US$476.65 for bevacizumab, US$11,469.39 for ranibizumab, and US$4,376.28 for verteporfin. The incremental cost of the ranibizumab-alone scenario would have been US$1,878,318,056.00 in four years, while the incremental cost for the bevacizumab-alone scenario would have been a reduction of US$4,978,326,359.00 (i.e., a cost saving) in the same period. The bevacizumab-alone option was found to represent a cost saving across sensitivity analyses.
   Conclusion
   The introduction of bevacizumab for the treatment of AMD is recommended for the Brazilian Public Health System.
C1 [Silva Elias, Flavia Tavares] Fundacao Oswaldo Cruz, Brasilia, DF, Brazil.
   [da Silva, Everton Nunes] Univ Brasilia, Brasilia, DF, Brazil.
   [Belfort, Rubens, Jr.; Atallah, Alvaro Nagib] Univ Fed Sao Paulo, Sao Paulo, SP, Brazil.
   [Silva, Marcus Tolentino] Univ Fed Amazonas, Manaus, Amazonas, Brazil.
C3 Fundacao Oswaldo Cruz; Universidade de Brasilia; Universidade Federal de
   Sao Paulo (UNIFESP); Universidade Federal de Amazonas
RP Elias, FTS (通讯作者)，Fundacao Oswaldo Cruz, Brasilia, DF, Brazil.
EM flavia.tselias@gmail.com
RI Atallah, Álvaro N/K-7182-2013; Silva, Marcus Tolentino/J-1791-2014
OI Silva, Marcus Tolentino/0000-0002-7186-9075; Silva,
   Everton/0000-0001-8747-4185
CR American Academy of Ophthalmology, 2008, PREF PRACT PATT AG R
   Andriolo RB, 2009, SAO PAULO MED J, V127, P84, DOI 10.1590/S1516-31802009000200006
   Antoniak Katarzyna, 2008, Klin Oczna, V110, P211
   Bakri SJ, 2006, RETINA-J RET VIT DIS, V26, P519, DOI 10.1097/01.iae.0000225354.92444.7a
   BRAZIL, 2012, BANC PREC SAUD BPS N, V2009, P2010
   BRAZIL, 2008, BRATS B BRAS AV TECN, V6
   BRAZIL. Ministerio da Saude. Secretaria de Atencao a Saude, 2012, MIN SAUD SECR AT SAU
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Ferreira-Da-Silva AL, 2012, CAD SAUDE PUBLICA, V28, P1223, DOI 10.1590/S0102-311X2012000700002
   Fraser-Bell S, 2005, AM J OPHTHALMOL, V139, P30, DOI 10.1016/j.ajo.2004.08.029
   Gonzalez S, 2012, AM J OPHTHALMOL, V153, P196, DOI 10.1016/j.ajo.2011.11.023
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hutton D, 2014, HEALTH AFFAIR, V33, P931, DOI 10.1377/hlthaff.2013.0832
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   Malta DC, 2011, EPIDEMIOL SERV SAUDE, V20, P425, DOI 10.5123/S1679-49742011000400002
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mauskopf JA, 2007, VALUE HEALTH, V10, P336, DOI 10.1111/j.1524-4733.2007.00187.x
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   National Institute of Health and Care Excellence, 2008, TECHN APPR GUID
   Paim J, 2011, LANCET, V377, P1778, DOI 10.1016/S0140-6736(11)60054-8
   World Health Organization, 2003, PRIOR EYE DIS
   WORMALD R, 2003, COCHRANE DB SYST REV
   Zimmermann I, 2012, VALUE HEALTH, V15, pA569, DOI 10.1016/j.jval.2012.08.2052
NR 30
TC 5
Z9 6
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 12
PY 2015
VL 10
IS 10
AR e0139556
DI 10.1371/journal.pone.0139556
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CT6YZ
UT WOS:000362961100011
PM 26457416
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Weger, M
   Renner, W
   Steinbrugger, I
   Kofer, K
   Wedrich, A
   Groselj-Strele, A
   El-Shabrawi, Y
   Schmut, O
   Haas, A
AF Weger, Martin
   Renner, Wilfried
   Steinbrugger, Iris
   Koefer, Katharina
   Wedrich, Andreas
   Groselj-Strele, Andrea
   El-Shabrawi, Yosuf
   Schmut, Otto
   Haas, Anton
TI Association of the HTRA1 -625G > A promoter gene polymorphism with
   exudative age-related macular degeneration in a Central European
   population
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT-FACTOR-H; Y402H VARIANT; JAPANESE POPULATION; HEMICENTIN-1
   GENES; EXTENDED FAMILIES; GENOMEWIDE-SCAN; NO ASSOCIATION; RISK;
   SUSCEPTIBILITY; CFH
AB PURPOSE: Exudative age-related macular degeneration (AMD) is one of the most common causes of severe visual loss. Both environmental and genetic factors, such as the complement factor H (CFH) 402H allele, have been associated with AMD. Recently, the HTRA1 -625A allele was identified as a novel risk marker in both a North American and a Chinese population. The present study was performed to evaluate the association of the HTRA1 -625A allele with exudative AMD in a Central European population.
   METHODS: The present case-control study included 242 patients with exudative AMD and 157 control subjects. Genotypes of the HTRA1 -625G>A polymorphism were determined by a 5'-exonuclease assay (TaqMan). Determination of CFH Y402H genotypes was done by allele specific digestion of polymerase chain products.
   RESULTS: Carriers of the HTRA1 -625AA genotype were found significantly more often in AMD patients than among control subjects (27.7% versus 5.1%; p < 0.001). Binary logistic regression analysis binary logistic regression analysis revealed an odds ratio (OR) of 2.7 (95% confidence interval (CI): 1.1-6.8) for AMD among subjects heterozygous for the HTRA1 -625A allele compared to those with the wildtype genotype, when adjusted for CFH Y402H genotypes (p=0.034). The OR increased to 10.2 (95% CI: 3.0-34.5) among subjects homozygous for the HTRA1 -625A allele (p < 0.001). The OR for AMD among heterozygous carriers of the CFH 402H variant was 3.6 (95% CI: 1.6-7.8) compared to those with the wildtype genotype, when adjusted for HTRA1 -625G>A genotypes (p=0.001). The OR increased to 9.8 (95% CI: 3.7-25.9) among subjects homozygous for the CFH 402HH genotype (p < 0.001). Interaction terms between CFH and HTRA1 genotypes were not significantly associated with AMD.
   CONCLUSIONS: Our data suggest that both the HTRA1 -625A allele and the CFH 402H allele are independently associated with exudative AMD in a Central European population.
C1 Med Univ Graz, Dept Ophthalmol, A-8036 Graz, Austria.
   Med Univ Graz, Med & Chem Lab Diagnost, Inst Clin, Graz, Austria.
   Med Univ Graz, Ctr Med Res, Graz, Austria.
C3 Medical University of Graz; Medical University of Graz; Medical
   University of Graz
RP Haas, A (通讯作者)，Med Univ Graz, Dept Ophthalmol, Auenbruggerpl 4, A-8036 Graz, Austria.
EM anton.haas@meduni-graz.at
RI Wedrich, Andreas/AAE-9171-2020
OI Groselj-Strele, Andrea/0000-0002-0709-5458
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Barral S, 2006, INVEST OPHTH VIS SCI, V47, P5453, DOI 10.1167/iovs.06-0655
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   DESAN A, 2006, SCIENCE, V314, P989
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Grassi MA, 2007, ARCH OPHTHALMOL-CHIC, V125, P93, DOI 10.1001/archopht.125.1.93
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2007, NAT GENET, V39, P567, DOI 10.1038/ng0407-567c
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Kim IY, 2005, J BIOCHEM MOL BIOL, V38, P1
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mathura JR, 2000, INVEST OPHTH VIS SCI, V41, P592
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Okamoto H, 2006, MOL VIS, V12, P156
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schuster N, 2002, CELL TISSUE RES, V307, P1, DOI 10.1007/s00441-001-0479-6
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seitsonen S, 2006, MOL VIS, V12, P796
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Souied EH, 2005, MOL VIS, V11, P1135
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 63
TC 46
Z9 47
U1 0
U2 0
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JUL 24
PY 2007
VL 13
IS 138-42
BP 1274
EP 1279
PG 6
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 198SC
UT WOS:000248646800001
PM 17679948
DA 2022-11-30
ER

PT J
AU Siqueira, RC
   Belissimo, LM
   Pinho, TS
   Dourado, LFN
   Alves, AP
   de Paiva, MRB
   Ajero, U
   Cunha, AD
AF Siqueira, Rubens Camargo
   Belissimo, Laura Madureira
   Pinho, Tainara Souza
   Nunes Dourado, Lays Fernanda
   Alves, Ana Paula
   Brandao de Paiva, Mayara Rodrigues
   Ajero, Ubirajara
   Cunha Junior, Armando da Silva
TI Short-Term Results of Photobiomodulation Using Light-Emitting Diode
   Light of 670 nm in Eyes with Age-Related Macular Degeneration
SO PHOTOBIOMODULATION PHOTOMEDICINE AND LASER SURGERY
LA English
DT Article
DE photobiomodulation; age-related macular degeneration; LED; Warp 10
ID IMPROVES VISUAL-ACUITY; LASER THERAPY; OXIDASE; PHOTORECEPTOR;
   PREVALENCE; DISEASE
AB Objective: To evaluate the short-term result of retinal functional behavior in patients with dry age-related macular degeneration (AMD) corrected by photobiomodulation (PBM) with 670 nm light-emitting diode (LED) light. Materials and methods: Ten patients with dry AMD underwent a treatment consisting of nine PBM sessions with LED light of 670 nm with two cycles of 50 mW/cm(2), producing 4 J/cm(2) per dose in 88 sec. The studied eye was compared with the baseline (before therapy), and after nine PBM sessions, the following aspects were evaluated: best-corrected visual acuity (VA), retinal sensitivity, and characteristics of the correction area by the fundus automated perimetry using the Compass system. A functional and structural assessment of the retina was also performed using the multifocal electroretinography (ERG), optical coherence tomography (OCT), fluorescence retinography (FR), and autofluorescence (AF). All examinations were performed 1, 4, and 16 weeks after the therapy. The Chi-square and Student's t-tests were used for comparisons. The analyses followed the 95% confidence level (p-value <= 0.05). Results: The BCVA significantly improved, from an average of 1.1 to 0.98 LogMAR (p = 0.01). The visual field examination, according to the parameters of mean deviation, standard deviation, and index of deviation of background perimeter, showed a significant improvement of -12.6% to -10.6%, 10.54% to 9.89%, and 56% to 60%, respectively (p = 0.02, 0.03, and 0.02, respectively). No participant had an adverse effect during the follow-up period; neither did any participant experience abnormalities in OCT, ERG, FR, and AF findings. Conclusions: In this short-term study, the PBM technique in patients with dry AMD showed the potential to improve VA and macular perimetry without causing significant adverse events. A larger number of patients and a longer follow-up will be necessary to further assess the success of this technique in these patients.
C1 [Siqueira, Rubens Camargo; Pinho, Tainara Souza] Rubens Siqueira Res Ctr, Saldanha Marinho 2815 Conj 42, BR-15010100 Sao Jose Do Rio Preto, SP, Brazil.
   [Siqueira, Rubens Camargo; Belissimo, Laura Madureira] Fac Med Sao Jose do Rio Preto FAMERP, Sao Jose Do Rio Preto, Brazil.
   [Nunes Dourado, Lays Fernanda; Brandao de Paiva, Mayara Rodrigues; Cunha Junior, Armando da Silva] Univ Fed Minas Gerais, Fac Pharm, Belo Horizonte, MG, Brazil.
   [Alves, Ana Paula; Ajero, Ubirajara] Univ Fed Minas Gerais, Inst Exact Sci, Phys Dept, Belo Horizonte, MG, Brazil.
C3 Universidade de Sao Paulo; Faculdade de Medicina de Sao Jose do Rio
   Preto (FAMERP); Universidade Federal de Minas Gerais; Universidade
   Federal de Minas Gerais
RP Siqueira, RC (通讯作者)，Rubens Siqueira Res Ctr, Saldanha Marinho 2815 Conj 42, BR-15010100 Sao Jose Do Rio Preto, SP, Brazil.
EM siqueiraretina@gmail.com
RI Cunha, Armando/G-1157-2012
OI Cunha, Armando/0000-0002-1161-8936; Paiva, Mayara Rodrigues Brandao
   de/0000-0002-6449-7904; Alves, Ana Paula/0000-0003-0594-8215
CR Akuffo KO, 2015, BRIT J OPHTHALMOL, V99, P1037, DOI 10.1136/bjophthalmol-2014-305768
   Albarracin R, 2011, INVEST OPHTH VIS SCI, V52, P3582, DOI 10.1167/iovs.10-6664
   Begum R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057828
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   DAUBEN WG, 1982, P NATL ACAD SCI USA, V79, P5115, DOI 10.1073/pnas.79.16.5115
   de Freitas LF, 2016, IEEE J SEL TOP QUANT, V22, DOI 10.1109/JSTQE.2016.2561201
   Dompe C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061724
   Eells JT, 2004, MITOCHONDRION, V4, P559, DOI 10.1016/j.mito.2004.07.033
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Grewal MK, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041001
   Hamblin MR, 2018, PHOTOCHEM PHOTOBIOL, V94, P199, DOI 10.1111/php.12864
   Hashmi JT, 2010, LASER SURG MED, V42, P450, DOI 10.1002/lsm.20950
   Ivandic BT, 2008, PHOTOMED LASER SURG, V26, P241, DOI 10.1089/pho.2007.2132
   Ivandic BT, 2012, PHOTOMED LASER SURG, V30, P167, DOI 10.1089/pho.2011.3089
   Karu TI, 2010, IUBMB LIFE, V62, P607, DOI 10.1002/iub.359
   KATO M, 1981, PHOTOBIOCH PHOTOBIOP, V2, P263
   Kokkinopoulos I, 2013, NEUROBIOL AGING, V34, P602, DOI 10.1016/j.neurobiolaging.2012.04.014
   Markowitz SN, 2020, RETINA-J RET VIT DIS, V40, P1471, DOI 10.1097/IAE.0000000000002632
   Merry G., 2012, INVESTIG OPHTHALMOL, V53, P2049
   Merry GF, 2017, ACTA OPHTHALMOL, V95, pE270, DOI 10.1111/aos.13354
   Mure LS, 2019, SCIENCE, V366, P1251, DOI 10.1126/science.aaz0898
   Rojas JC, 2011, EYE BRAIN, V3, P49, DOI 10.2147/EB.S21391
   Sand A, 2012, PROG RETIN EYE RES, V31, P287, DOI 10.1016/j.preteyeres.2012.03.003
   Tang J, 2014, BRIT J OPHTHALMOL, V98, P1013, DOI 10.1136/bjophthalmol-2013-304477
   Tata DB, 2011, LASER PHOTONICS REV, V5, P1, DOI 10.1002/lpor.200900032
   Wang JS, 2011, PROG RETIN EYE RES, V30, P115, DOI 10.1016/j.preteyeres.2010.11.001
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200
   Wu SA, 2014, ANTIOXID REDOX SIGN, V20, P733, DOI 10.1089/ars.2013.5229
NR 29
TC 0
Z9 0
U1 0
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
EI 2578-5478
J9 PHOTOBIOMOD PHOTOMED
JI Photobiomodulation Photomed. Laser Surg.
PD SEP 1
PY 2021
VL 39
IS 9
BP 581
EP 586
DI 10.1089/photob.2021.0005
PG 6
WC Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Surgery
GA US6EK
UT WOS:000697519900002
PM 34546108
DA 2022-11-30
ER

PT J
AU VanderBeek, BL
   Zacks, DN
   Talwar, N
   Nan, B
   Musch, DC
   Stein, JD
AF VanderBeek, Brian L.
   Zacks, David N.
   Talwar, Nidhi
   Nan, Bin
   Musch, David C.
   Stein, Joshua D.
TI Racial Differences in Age-Related Macular Degeneration Rates in the
   United States: A Longitudinal Analysis of a Managed Care Network
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RISK-FACTORS; PREVALENCE; EYE; MACULOPATHY; POPULATION; ATHEROSCLEROSIS
AB PURPOSE: To compare the incidence, prevalence, and hazard of nonexudative and exudative age-related macular degeneration (AMD) among different races throughout the United States.
   DESIGN: Retrospective longitudinal cohort study.
   METHODS: Billing records of all encounters for 2 259 061 beneficiaries aged >= 40 enrolled in a large, national US managed care network from 2001 through 2007 were reviewed and the incidence and prevalence of nonexudative and exudative AMD were determined and stratified by race. Cox regression analyses determined the hazard of nonexudative and exudative AMD for each race, with adjustment for confounders.
   RESULTS: During the study, 113 234 individuals (5.0%) were diagnosed with nonexudative and 17 181 (0.76%) with exudative AMD. After adjustment for confounders, blacks had a significantly reduced hazard of nonexudative (hazard ratio [HR] = 0.75, 95% confidence interval [CI]: 0.71-0.79) and exudative AMD (HR = 0.70, 95% CI: 0.59-0.83) at age 60 and a reduced hazard of nonexudative (HR = 0.56, 95% CI: 0.52-0.60) and exudative AMD (HR = 0.45, 95% CI: 0.37-0.54) at age 80 relative to whites. Similar comparisons for Latinos demonstrated an 18% reduced hazard for nonexudative AMD at age 80 (HR = 0.82, 95% CI: 0.76-0.88) relative to whites. Asian Americans showed a 28% increased hazard for nonexudative AMD at age 60 (HR = 1.28, 95% CI: 1.20-1.36) but a 46% decreased hazard for exudative AM!) at age 80 (HR = 0.54, 95% CI: 0.40-0.73).
   CONCLUSIONS: Racial minorities, including Latinos and Asian Americans, do not appear to have similar risks of developing nonexudative and exudative AMD as whites. Additional studies using other sources should be conducted to determine the generalizability of this study's findings to other groups. (Am J Ophthalmol 2011;152:273-282. (C) 2011 by Elsevier Inc. All rights reserved.)
C1 [Stein, Joshua D.] Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA.
   [Nan, Bin] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48105 USA.
   [Musch, David C.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48105 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan
RP Stein, JD (通讯作者)，Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, 1000 Wall St, Ann Arbor, MI 48105 USA.
EM jdstein@med.umich.edu
RI Zacks, David/I-4394-2013
OI VanderBeek, Brian L./0000-0003-4953-118X; Zacks,
   David/0000-0001-8592-5165; Stein, Joshua/0000-0003-2937-6987; Musch,
   David/0000-0002-4164-3841
FU NATIONAL EYE INSTITUTE (BETHESDA, Maryland) [EY019511]; Blue Cross Blue
   Shield of Michigan Foundation, Detroit, Michigan; Research to Prevent
   Blindness (New York, New York); Pfizer, Inc.; NATIONAL EYE INSTITUTE
   [K23EY019511] Funding Source: NIH RePORTER
FX PUBLICATION OF THIS ARTICLE WAS SUPPORTED BY GRANT EY019511 FROM THE
   NATIONAL EYE INSTITUTE (BETHESDA, Maryland) K23 Mentored Clinician
   Scientist Award (J.D.S.); Blue Cross Blue Shield of Michigan Foundation,
   Detroit, Michigan (J.D.S.); an unrestricted grant from Research to
   Prevent Blindness (New York, New York), Research to Prevent Blindness
   Lew R. Wasserman Merit Award (D.C.M.), and Research to Prevent Blindness
   Sybil B. Harrington Special Scholar Award for Macular Degeneration
   (D.N.Z.). The authors have no proprietary interest in any material
   discussed in this manuscript. Drs Musch and Stein receive research
   support from Pfizer, Inc. Dr. Musch is on the advisory board, and is a
   consultant for Glaukos Corp. Involved in preparation of manuscript
   (B.V.B., D.C.M., D.N.Z., J.D.S.), design and conduct of study (B.N.,
   B.V.B., D.C.M., D.N.Z., J.D.S., N.T.), collection and management of
   study data (J.D.S., N.T.), and analysis of data (B.N., B.V.B., D.C.M.,
   D.N.Z., J.D.S., N.T.). The University of Michigan Institutional Review
   Board determined this study was exempt from requiring IRB approval since
   the data are completely de-identified.
CR [Anonymous], 2006, CURRENT PROCEDURAL T
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   CNAAN A, 1989, STAT MED, V8, P1255, DOI 10.1002/sim.4780081009
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   DeFrank Jessica T, 2007, Prev Chronic Dis, V4, pA60
   Emanuelli Andres, 2005, P R Health Sci J, V24, P287
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   Sloan FA, 2003, ARCH OPHTHALMOL-CHIC, V121, P1462, DOI 10.1001/archopht.121.10.1462
   U. S. Census Bureau, US QUICK FACTS US CE
   U.S. Census Bureau, 2009, FACTS FEAT HISP HER
   *US CENS BUR, 2009, POP PROJ
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   2010, US PERCENT ADULTS WH
   2006, CLIN MODIFICATION, V1
   2006, CLIN MODIFICATION, V2
NR 28
TC 45
Z9 47
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2011
VL 152
IS 2
BP 273
EP 282
DI 10.1016/j.ajo.2011.02.004
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 799WW
UT WOS:000293317900019
PM 21696700
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kondo, N
   Bessho, H
   Honda, S
   Negi, A
AF Kondo, Naoshi
   Bessho, Hiroaki
   Honda, Shigeru
   Negi, Akira
TI Complement Factor H Y402H Variant and Risk of Age-Related Macular
   Degeneration in Asians: A Systematic Review and Meta-Analysis
SO OPHTHALMOLOGY
LA English
DT Review
ID JAPANESE POPULATION; GENE POLYMORPHISMS; CHINESE POPULATION; CFH GENE;
   FACTOR-B; FACTOR-I; ASSOCIATION; SUSCEPTIBILITY; INCREASES; DISEASE
AB Purpose: To investigate whether the Y402H variant in the complement factor H gene is associated with age-related macular degeneration (AMD) in Asian populations.
   Design: Meta-analysis of previous publications.
   Participants: Case-control groups of subjects with AMD and controls from 13 association studies.
   Methods: We performed a meta-analysis of the association between Y402H and AMD in Asian populations using data available from 13 case-control studies involving 3973 subjects. Summary odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using fixed-and random-effects models. The Q-statistic test was used to assess heterogeneity, and Egger's test was used to evaluate publication bias. Sensitivity analysis, cumulative meta-analysis, and meta-regression analysis were also performed.
   Main Outcome Measures: Allele and genotype frequencies of the Y402H variant.
   Results: The Y402H variant showed a significant summary OR of 1.97 (95% CI, 1.54-2.52; P < 0.001; allelic contrast model) per allele. Possession of at least 1 copy of the C allele increased the disease risk by 1.97-fold (95% CI, 1.63-2.39; P < 0.001; dominant model) and accounted for 8.8% of the attributable risk of AMD in Asian populations. Sensitivity analysis indicated the robustness of our findings, and evidence of publication bias was not observed in our meta-analysis. Meta-regression analysis indicated no significant effect of baseline study characteristics on the summary effect size. Cumulative meta-analysis revealed that the summary ORs were stable and the 95% CIs narrowed with the accumulation of data over time.
   Conclusions: Our analysis provides substantial evidence that the Y402H variant is significantly associated with AMD in Asian populations. Our results expand the number of confirmed AMD susceptibility loci for Asians populations, which provide a better understanding of the genetic architecture underlying disease susceptibility and may advance the potential for preclinical prediction in future genetic tests by a combined evaluation of inherited susceptibility with previously established loci.
C1 [Kondo, Naoshi; Bessho, Hiroaki; Honda, Shigeru; Negi, Akira] Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol,Chuo Ku, Kobe, Hyogo 6500017, Japan.
   [Kondo, Naoshi] Johns Hopkins Univ, Wilmer Eye Inst, Johns Hopkins Sch Med, Baltimore, MD 21218 USA.
C3 Kobe University; Johns Hopkins University; Johns Hopkins Medicine
RP Kondo, N (通讯作者)，Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM nskondo@gmail.com
RI Honda, Shigeru/W-4761-2019
OI Kondo, Naoshi/0000-0001-6025-3876
CR Boon CJF, 2009, MOL IMMUNOL, V46, P1573, DOI 10.1016/j.molimm.2009.02.013
   Chu J, 2008, CHINESE MED J-PEKING, V121, P2525, DOI 10.1097/00029330-200812020-00011
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gao Y, 2010, RETINA-J RET VIT DIS, V30, P443, DOI 10.1097/IAE.0b013e3181c2e086
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Ioannidis JPA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000841
   Ioannidis JPA, 2004, NAT GENET, V36, P1312, DOI 10.1038/ng1474
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2010, EUR J HUM GENET, V18, P634, DOI 10.1038/ejhg.2009.243
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P1416, DOI 10.1097/IAE.0b013e318184661d
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   MOLD C, 1984, J IMMUNOL, V133, P882
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Okamoto H, 2006, MOL VIS, V12, P156
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   Schmidt CQ, 2008, CLIN EXP IMMUNOL, V151, P14, DOI 10.1111/j.1365-2249.2007.03553.x
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V
   WHITTEMORE AS, 1983, AM J EPIDEMIOL, V117, P76, DOI 10.1093/oxfordjournals.aje.a113518
   Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864
   XU Y, 2010, MOL VIS, V14, P1373
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 39
TC 45
Z9 49
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2011
VL 118
IS 2
BP 339
EP 344
DI 10.1016/j.ophtha.2010.06.040
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 715IJ
UT WOS:000286876500018
PM 20869121
DA 2022-11-30
ER

PT J
AU Adams, CM
   Anderson, K
   Artman, G
   Bizec, JC
   Cepeda, R
   Elliott, J
   Fassbender, E
   Ghosh, M
   Hanks, S
   Hardegger, LA
   Hosagrahara, VP
   Jaffee, B
   Jendza, K
   Ji, N
   Johnson, L
   Lee, W
   Liu, DL
   Liu, F
   Long, D
   Ma, FP
   Mainolfi, N
   Meredith, EL
   Miranda, K
   Peng, Y
   Poor, S
   Powers, J
   Qu, YB
   Rao, C
   Shen, SY
   Sivak, JM
   Solovay, C
   Tarsa, P
   Woolfenden, A
   Zhang, C
   Zhang, YQ
AF Adams, Christopher M.
   Anderson, Karen
   Artman, Gerald, III
   Bizec, Jean-Claude
   Cepeda, Rosemarie
   Elliott, Jason
   Fassbender, Elizabeth
   Ghosh, Malay
   Hanks, Shawn
   Hardegger, Leo A.
   Hosagrahara, Vinayak P.
   Jaffee, Bruce
   Jendza, Keith
   Ji, Nan
   Johnson, Leland
   Lee, Wendy
   Liu, Donglei
   Liu, Fang
   Long, Debby
   Ma, Fupeng
   Mainolfi, Nello
   Meredith, Erik L.
   Miranda, Karl
   Peng, Yao
   Poor, Stephen
   Powers, James
   Qu, Yubin
   Rao, Chang
   Shen, Siyuan
   Sivak, Jeremy M.
   Solovay, Catherine
   Tarsa, Peter
   Woolfenden, Amber
   Zhang, Chun
   Zhang, Yiqin
TI The Discovery of
   N-(1-Methy1-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6-((methylamino)met
   hyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2
   Inhibitor Specifically Designed for Topical Ocular Delivery, as a
   Therapy for Neovascular Age-Related Macular Degeneration
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; DRUG-DELIVERY; CHOROIDAL NEOVASCULARIZATION;
   RANIBIZUMAB; MODEL; ANGIOGENESIS; AFLIBERCEPT; EYE
AB A noninvasive topical ocular therapy for the treatment of neovascular or "wet" age-related macular degeneration would provide a patient administered alternative to the current standard of care, which requires physician administered intravitreal injections. This manuscript describes a novel strategy for the use of in vivo models of choroidal neovascularization (CNV) as the primary means of developing SAP. related to efficacy from topical administration. Ultimately, this effort led to the discovery of acrizanib (LHA510), a small molecule VEGFR-2 inhibitor with potency and efficacy in rodent CNV models, limited systemic exposure after topical ocular administration, multiple formulation options, and an acceptable rabbit ocular PK profile.
C1 [Adams, Christopher M.; Artman, Gerald, III; Elliott, Jason; Hardegger, Leo A.; Jendza, Keith; Ji, Nan; Johnson, Leland; Liu, Donglei; Ma, Fupeng; Mainolfi, Nello; Meredith, Erik L.; Miranda, Karl; Powers, James; Rao, Chang; Solovay, Catherine; Zhang, Chun] Novartis Inst BioMed Res, Global Discovery Chem, 250 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Anderson, Karen; Cepeda, Rosemarie; Fassbender, Elizabeth; Hanks, Shawn; Jaffee, Bruce; Long, Debby; Poor, Stephen; Qu, Yubin; Shen, Siyuan; Sivak, Jeremy M.; Woolfenden, Amber; Zhang, Yiqin] Novartis Inst BioMed Res, Ophthalmol, 250 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Peng, Yao] Alcon Novartis Co, Ocular Pharmacokinet & Disposit, 201 South Freeway, Ft Worth, TX 76134 USA.
   [Bizec, Jean-Claude; Hosagrahara, Vinayak P.; Lee, Wendy] Novartis Inst BioMed Res, Pharmacokinet Sci, 250 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Tarsa, Peter] Novartis Inst BioMed Res, Chem & Pharmaceut Profiling, 250 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Ghosh, Malay] Novartis Pharmaceut, Global Drug Dev Tech Res & Dev, 6201 South Freeway, Ft Worth, TX 76134 USA.
   [Ji, Nan; Mainolfi, Nello] Kymera Therapeut LLC, 400 Technol Sq, Cambridge, MA 02139 USA.
   [Sivak, Jeremy M.] Univ Toronto, Sch Med, Dept Ophthalmol & Vis Sci, 60 Leonard Ave, Toronto, ON M5T 2S8, Canada.
   [Sivak, Jeremy M.] Krembil Res Inst, Div Vis Sci, 60 Leonard Ave, Toronto, ON M5T 2S8, Canada.
   [Miranda, Karl] MyHth Ctr, 45 Sheppard Ave East,Suite 301, Toronto, ON M2N 5W9, Canada.
   [Johnson, Leland] WuXi AppTec55 Cambridge Pkwy, Cambridge, MA 02142 USA.
   [Artman, Gerald, III] Celgene Corp, 86 Morris Ave, Summit, NJ 07901 USA.
   [Hardegger, Leo A.] Novartis Pharmaceut Chem & Analyt Dev, CH-4002 Basel, Switzerland.
   [Hosagrahara, Vinayak P.] EMD Serono Res & Dev Inst Inc, 45A Middlesex Turnpike, Billerica, MA 01821 USA.
   [Rao, Chang] Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.
   [Fassbender, Elizabeth] Vertex Pharmaceut, 50 Northern Ave, Boston, MA 02210 USA.
   [Bizec, Jean-Claude] 12 Rue Petit Landau, F-68440 Habsheim, France.
   [Peng, Yao] Covance Labs Inc, 3402 Kinsman Blvd, Madison, WI 53704 USA.
C3 Novartis; Novartis; Novartis; Novartis; Novartis; University of Toronto;
   Krembil Research Institute; Bristol-Myers Squibb; Celgene Corporation;
   Merck KGaA; EMD Serono Inc.; Nanyang Technological University & National
   Institute of Education (NIE) Singapore; Nanyang Technological
   University; Vertex Pharmaceuticals; Covance
RP Adams, CM (通讯作者)，Novartis Inst BioMed Res, Global Discovery Chem, 250 Massachusetts Ave, Cambridge, MA 02139 USA.
EM ChristopherM.Adams@novartis.com
RI Sivak, Jeremy/AAA-3467-2022
OI Sivak, Jeremy/0000-0002-8776-223X; Adams,
   Christopher/0000-0002-5246-884X
FU Novartis Institute for Biomedical Research Pharmacokinetic Sciences
   group; Novartis Institute for Biomedical Research Analytical Sciences
   group; OPKD group of Alcon, a Novartis Company
FX We acknowledge the contribution of the Novartis Institute for Biomedical
   Research Analytical Sciences group for aiding in compound
   characterization. We also thank the Novartis Institute for Biomedical
   Research Pharmacokinetic Sciences group, the Novartis Institute for
   Biomedical Research Analytical Sciences group, and the OPKD group of
   Alcon, a Novartis Company, for support in conducting pharmacokinetic
   studies, bioanalytics, and in vitro ADME assessments. We also recognize
   Aaron Huang and Matthias Eberstadt for project management support and
   Ronald Newton for helpful discussions related to toxicological
   profiling.
CR Barar J, 2008, EXPERT OPIN DRUG DEL, V5, P567, DOI [10.1517/17425247.5.5.567, 10.1517/17425247.5.5.567 ]
   Bold G, 2016, J MED CHEM, V59, P132, DOI 10.1021/acs.jmedchem.5b01582
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Csaky KG, 2015, OPHTHALMOLOGY, V122, P579, DOI 10.1016/j.ophtha.2014.09.036
   Davies NM, 2000, CLIN EXP PHARMACOL P, V27, P558, DOI 10.1046/j.1440-1681.2000.03288.x
   del Amo EM, 2017, PROG RETIN EYE RES, V57, P134, DOI 10.1016/j.preteyeres.2016.12.001
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   *EUR MED AG, 2016, NEV
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Gadek T, 2011, AAPS ADV PHARM SCI, V2, P111, DOI 10.1007/978-1-4419-9920-7_5
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Geroski DH, 2001, ADV DRUG DELIVER REV, V52, P37, DOI 10.1016/S0169-409X(01)00193-4
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grisanti S, 2015, RETINA-J RET VIT DIS, V35, P764, DOI 10.1097/IAE.0000000000000385
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holmes K, 2007, CELL SIGNAL, V19, P2003, DOI 10.1016/j.cellsig.2007.05.013
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hubschman JP, 2009, CLIN OPHTHALMOL, V3, P155
   Ji N, 2010, TETRAHEDRON LETT, V51, P6799, DOI 10.1016/j.tetlet.2010.10.073
   Johnson L, 2013, SYNTHESIS-STUTTGART, V45, P171, DOI 10.1055/s-0032-1317935
   JOUSSEN AM, 2016, ARVO 2016 ANN M 427
   Keefe D, 2011, ONCOLOGIST, V16, P432, DOI 10.1634/theoncologist.2010-0271
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lad EM, 2014, AM J OPHTHALMOL, V158, P537, DOI 10.1016/j.ajo.2014.05.014
   Meredith EL, 2015, J MED CHEM, V58, P9273, DOI 10.1021/acs.jmedchem.5b01227
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Mogi M, 2013, ANNU REP MED CHEM, V48, P353, DOI 10.1016/B978-0-12-417150-3.00022-3
   Musumeci F, 2012, J MED CHEM, V55, P10797, DOI 10.1021/jm301085w
   Palanki MSS, 2008, J MED CHEM, V51, P1546, DOI 10.1021/jm7011276
   Poor SH, 2014, INVEST OPHTH VIS SCI, V55, P6525, DOI 10.1167/iovs.14-15067
   Robbie SJ, 2013, INVEST OPHTH VIS SCI, V54, P1490, DOI 10.1167/iovs.12-10169
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Runkle EA, 2011, METHODS MOL BIOL, V686, P133, DOI 10.1007/978-1-60761-938-3_5
   Varano M, 2015, CLIN OPHTHALMOL, V9, P2243, DOI 10.2147/OPTH.S92548
   Zhu YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094743
NR 36
TC 15
Z9 15
U1 0
U2 15
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD FEB 22
PY 2018
VL 61
IS 4
BP 1622
EP 1635
DI 10.1021/acs.jmedchem.7b01731
PG 14
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA FX6TT
UT WOS:000426220900016
PM 29400470
DA 2022-11-30
ER

PT J
AU Branisteanu, DC
   Branisteanu, DE
   Feraru, CI
   Branisteanu, CI
   Moraru, A
   Zemba, M
   Balta, F
AF Branisteanu, Daniel Constantin
   Branisteanu, Daciana Elena
   Feraru, Crenguta Ioana
   Branisteanu, Catalina Ioana
   Moraru, Andreea
   Zemba, Mihail
   Balta, Florian
TI Influence of unilateral intravitreal bevacizumab injection on the
   incidence of symptomatic choroidal neovascularization in the fellow eye
   in patients with neovascular age-related macular degeneration (Review)
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Review
DE symptomatic choroidal neovascularization; fellow-eye; bevacizumab;
   neovascular age-related macular degeneration; systemic exposure
ID RANIBIZUMAB
AB Neovascular age-related macular degeneration (neovascular ARMD) represents only 10% of ARMD cases but is responsible, if untreated, for quick and severe central vision loss due to major macular changes. The presence of choroidal neovascularization (CNV) in one eye is associated with an approximately 10% risk of CNV development in the fellow eye each year. Intravitreal anti-VEGF therapy has quickly evolved as the standard treatment in neovascular ARMD in the last decade due to significant anatomical and functional improvements, especially in the early stages. In many reports an improvement in the untreated fellow eye was mentioned and systemic exposure was soon confirmed for all anti-VEGF agents after unilateral intravitreal injection. In particular, bevacizumab intravitreal injection is followed by a consistent reduction of serum VEGF levels and the drug was shown to have the longest serum half-life raising important debates about its safety. Once bevacizumab was detected in the fellow eye of an animal model after unilateral injection, the possible influence on fellow eye conversion rate into neovascular ARMD was questioned. Although comparative studies have not found statistically significant differences between drugs regarding the incidence of symptomatic CNV in the fellow eye during treatment, we observed, on a retrospective 36-month evaluation, a reduced incidence of symptomatic CNV in the fellow eye that might be explained by the consistent systemic exposure of bevacizumab.
C1 [Branisteanu, Daniel Constantin; Feraru, Crenguta Ioana; Moraru, Andreea] Grigore T Popa Univ Med & Pharm, Dept Ophthalmol, Iasi 700115, Romania.
   [Branisteanu, Daniel Constantin] Retina Ctr, Eye Clin, Iasi 700126, Romania.
   [Branisteanu, Daciana Elena] Grigore T Popa Univ Med & Pharm, Dept Dermatol, 16 Univ St, Iasi 700115, Romania.
   [Branisteanu, Catalina Ioana] Grigore T Popa Univ Med & Pharm, Iasi 700115, Romania.
   [Zemba, Mihail; Balta, Florian] Carol Davila Univ Med & Pharm, Dept Ophthalmol, Bucharest 020021, Romania.
C3 Grigore T Popa University of Medicine & Pharmacy; Grigore T Popa
   University of Medicine & Pharmacy; Grigore T Popa University of Medicine
   & Pharmacy; Carol Davila University of Medicine & Pharmacy
RP Branisteanu, DE (通讯作者)，Grigore T Popa Univ Med & Pharm, Dept Dermatol, 16 Univ St, Iasi 700115, Romania.
EM debranisteanu@yahoo.com; mhlzmb@yahoo.com
RI Branisteanu, Daniel Constantin/AGZ-3495-2022
CR American Society of Retina Specialists, 2018, PREF TRENDS SURV 201
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Bakbak B, 2013, J OCUL PHARMACOL TH, V29, P728, DOI 10.1089/jop.2013.0049
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brnisteanu DC, 2015, REV ROM BIOET, V13
   Bro T, 2020, GRAEF ARCH CLIN EXP, V258, P503, DOI 10.1007/s00417-019-04569-8
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Elshout M, 2018, ACTA OPHTHALMOL, V96, P770, DOI 10.1111/aos.13824
   Fasler K, 2020, BRIT J OPHTHALMOL, V104, P684, DOI 10.1136/bjophthalmol-2019-314446
   Filip-Ciubotaru F, 2016, MED-SURG J, V120, P29
   Garcia-Quintanilla L, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11080365
   Isildak H, 2018, CASE REP OPHTHALMOL, V2018, DOI 10.1155/2018/8561895
   Karaca C, 2013, JAMA OPHTHALMOL, V131, P1099, DOI 10.1001/jamaophthalmol.2013.400
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Low A, 2019, BRIT J OPHTHALMOL, V103, P442, DOI 10.1136/bjophthalmol-2018-312691
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Malbin B., 2019, JVRD, V3, P86
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Parikh R, 2019, JAMA OPHTHALMOL, V137, P914, DOI 10.1001/jamaophthalmol.2019.1947
   Peyman M, 2019, J CURR OPHTHALMOL, V31, P55, DOI 10.1016/j.joco.2018.09.007
   Rasmussen A, 2017, EYE, V31, P978, DOI 10.1038/eye.2016.324
   Rosenfield A, 2009, MATERNAL AND CHILD HEALTH: GLOBAL CHALLENGES, PROGRAMS AND POLICIES, P3, DOI 10.1007/b106524_1
   Schauwvlieghe AME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153052
   Solomon SD, 2007, ARCH OPHTHALMOL-CHIC, V125, P1323
   Stanca HT, 2019, EXP THER MED, V18, P4993, DOI 10.3892/etm.2019.7858
   Villegas VM, 2017, EXPERT OPIN DRUG DEL, V14, P273, DOI 10.1080/17425247.2016.1213240
   Wu ZQ, 2008, ANN ACAD MED SINGAP, V37, P591
   Yanagi Y, 2018, JAMA OPHTHALMOL, V136, P905, DOI 10.1001/jamaophthalmol.2018.2154
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
NR 35
TC 4
Z9 4
U1 2
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
EI 1792-1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD DEC
PY 2020
VL 20
IS 6
AR 182
DI 10.3892/etm.2020.9312
PG 4
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA OZ9VS
UT WOS:000595267100059
PM 33101472
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Querques, G
   Querques, L
   Rafaeli, O
   Canoui-Poitrine, F
   Bandello, F
   Souied, EH
AF Querques, Giuseppe
   Querques, Lea
   Rafaeli, Omer
   Canoui-Poitrine, Florence
   Bandello, Francesco
   Souied, Eric H.
TI Preferential Hyperacuity Perimeter as a Functional Tool for Monitoring
   Exudative Age-Related Macular Degeneration in Patients Treated by
   Intravitreal Ranibizumab
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; VISUAL FUNCTION; DISCRIMINATION; LUCENTIS;
   PHP
AB PURPOSE. To analyze the response to anti vascular endothelial growth factor (VEGF) treatment for exudative age-related macular degeneration (AMD), with respect to changes in the Preferential Hyperacuity Perimeter (PHP), best-corrected visual acuity (BCVA), and spectral-domain optical coherence tomography (SD-OCT), and to investigate whether the PHP score predicts the need for reinjection.
   METHODS. Consecutive patients with newly diagnosed exudative AMD underwent the PHP metamorphopsia test, BCVA, and SD-OCT at five time points after initiation of ranibizumab therapy (0.05 mL/0.5 mg). At the third and sixth months, reevaluation for additional injections was done. The relationships between PHP, BCVA, and SD-OCT parameters over time as well as their ability to predict the need for reinjection were examined.
   RESULTS. Analysis included 17 eyes (17 patients, 70% females; mean age, 83.2 years). The mean PHP metamorphopsia test score improved from 25.6 +/- 41 (baseline) to 10.7 +/- 20.1 (P < 0.05) over 6 months, after a mean of 4.2 (+/- 1.0) injections. Mean reduction in SD-OCT parameters well reflected the functional improvements as evaluated by PHP (Spearman correlation = 0.9, P < 0.05). Mean BCVA did not improve over 6 months (0.6 vs. 0.58 logMAR), and neither correlated with SD-OCT morphologic changes (Spearman correlation = 0.1, P > 0.05) nor with PHP functional changes (Spearman correlation = 0.1, P > 0.05). The PHP predicted the need for reinjection with an accuracy of 75% (sensitivity, 83 +/- 12%; specificity, 67 +/- 15%), whereas a combination of all the measurements (PHP, BCVA, and SD-OCT) yielded an accuracy of 87% (sensitivity, 83 +/- 12%; specificity, 90 +/- 10%).
   CONCLUSIONS. Improvement in the metamorphopsia test score after intravitreal injections of ranibizumab, as well as its ability to predict the need for retreatment, suggest that PHP may be used to monitor response to anti-VEGF therapy in patients with exudative AMD. (Invest Ophthalmol Vis Sci. 2011;52:7012-7018) DOI:10.1167/iovs.11-7517
C1 [Querques, Giuseppe; Querques, Lea; Souied, Eric H.] Univ Paris 12, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, F-94000 Creteil, France.
   [Querques, Lea; Bandello, Francesco] Univ Vita Salute San Raffaele, Dept Ophthalmol, Milan, Italy.
   [Rafaeli, Omer] Notal Vis Ltd, Tel Aviv, Israel.
   [Canoui-Poitrine, Florence] Hop Henri Mondor, AP HP, Serv Sante Publ, F-94010 Creteil, France.
   [Canoui-Poitrine, Florence] Univ Paris Est, Clin Invest Lab, Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Vita-Salute San Raffaele University; Assistance Publique Hopitaux Paris
   (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital
   Universitaire Henri-Mondor - APHP; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC)
RP Querques, G (通讯作者)，Univ Paris 12, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
RI bandello, francesco/AAH-2405-2019; Canoui-Poitrine, Florence/R-4474-2018
OI bandello, francesco/0000-0003-3238-9682; Canoui-Poitrine,
   Florence/0000-0001-9970-6051; Querques, Giuseppe/0000-0002-3292-9581
CR Alster Y, 2005, OPHTHALMOLOGY, V112, P1758, DOI 10.1016/j.ophtha.2005.06.008
   Arimura E, 2011, INVEST OPHTH VIS SCI, V52, P128, DOI 10.1167/iovs.09-3535
   Bedell HE, 2009, OPTOMETRY VISION SCI, V86, P485, DOI 10.1097/OPX.0b013e31819fa6e2
   BLAND JM, 1995, BRIT MED J, V310, P446, DOI 10.1136/bmj.310.6977.446
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   *CPAT RES GROUP, 2008, OPHTHALMOLOGY, V115, P1474
   Das R, 2009, RETINA-J RET VIT DIS, V29, P1013, DOI 10.1097/IAE.0b013e3181a91dbf
   Doris N, 2001, BRIT J OPHTHALMOL, V85, P184, DOI 10.1136/bjo.85.2.184
   Fletcher DC, 2006, OPTOMETRY VISION SCI, V83, P178, DOI 10.1097/01.opx.0000204510.08026.7f
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Goldstein M, 2005, RETINA-J RET VIT DIS, V25, P296
   Hogg R, 2003, BRIT J OPHTHALMOL, V87, P609, DOI 10.1136/bjo.87.5.609
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Liu L, 2010, OPTOMETRY VISION SCI, V87, P532, DOI 10.1097/OPX.0b013e3181e3dc10
   Loewenstein A, 2003, OPHTHALMOLOGY, V110, P966, DOI 10.1016/S0161-6420(03)00074-5
   Loewenstein A, 2007, RETINA-J RET VIT DIS, V27, P873, DOI 10.1097/IAE.0b013e318050d2ec
   Loewenstein A, 2010, RETINA-J RET VIT DIS, V30, P1058, DOI 10.1097/IAE.0b013e3181d1a75e
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Querques G, 2008, AM J OPHTHALMOL, V146, P135, DOI 10.1016/j.ajo.2008.02.017
   Querques G, 2011, BRIT J OPHTHALMOL, V95, P986, DOI 10.1136/bjo.2010.190942
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Trevino R, 2008, OPHTHAL PHYSL OPT, V28, P183, DOI 10.1111/j.1475-1313.2008.00561.x
   Wang YZ, 2002, INVEST OPHTH VIS SCI, V43, P2055
NR 29
TC 16
Z9 16
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2011
VL 52
IS 9
BP 7012
EP 7018
DI 10.1167/iovs.11-7517
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 815SI
UT WOS:000294548300084
PM 21885622
DA 2022-11-30
ER

PT J
AU Matonti, F
   Korobelnik, JF
   Dot, C
   Gualino, V
   Soler, V
   Mrejen, S
   Delyfer, MN
   Baillif, S
   Streho, M
   Gascon, P
   Creuzot-Garcher, C
   Kodjikian, L
AF Matonti, Frederic
   Korobelnik, Jean-Francois
   Dot, Corinne
   Gualino, Vincent
   Soler, Vincent
   Mrejen, Sarah
   Delyfer, Marie-Noelle
   Baillif, Stephanie
   Streho, Mate
   Gascon, Pierre
   Creuzot-Garcher, Catherine
   Kodjikian, Laurent
TI Comparative Effectiveness of Intravitreal Anti-Vascular Endothelial
   Growth Factor Therapies for Managing Neovascular Age-Related Macular
   Degeneration: A Meta-Analysis
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE age-related macular degeneration (AMD); aflibercept; comparative
   therapies; effectiveness; intravitreal anti-vascular endothelial growth
   factor; meta-analysis; ranibizumab; treat-and-extend; pro re nata
   regimen
ID TREAT-AND-EXTEND; VERTEPORFIN PLUS RANIBIZUMAB; PHOTODYNAMIC THERAPY;
   CHOROIDAL NEOVASCULARIZATION; COMBINATION THERAPY; RISK-FACTORS; EYE
   DISEASE; TRAP-EYE; 0.5 MG; AFLIBERCEPT
AB Intravitreal injections (IVI) of anti-vascular endothelial growth factor (anti-VEGF) have become the standard of care for age-related macular degeneration (AMD). Although most pivotal trials have used monthly injections, alternative strategies that enable the injections to be administered on a more flexible schedule, including pro re nata (PRN) and treat-and-extend (T&E) regimens, are being applied more frequently. This review sought to provide further scientific evidence about the visual outcomes and treatment burden among the currently available anti-VEGF agents and regimens, including aflibercept, ranibizumab, abicipar and brolucizumab. To this end, a systematic review of published randomized studies was conducted from the MEDLINE and EMBASE databases and the Cochrane library, and a meta-analysis was applied to the obtained data using single-means modeling to compare the efficacy and maintenance among the different available treatments and regimens at Years 1 and 2. Quality analysis identified the best-informed data for modeling purposes. Overall, 47 relevant publications were retrieved for the analysis. Superior efficacy, meaning that there were observed improvements in visual acuity (VA) and central retinal thickness (CRT), occurred with monthly versus PRN regimens, yet a higher IVI number was also observed. Conversely, the T&E regimens displayed similar efficacy to the monthly regimens, but with a reduced IVI number. Aflibercept T&E exhibited similar efficacy to ranibizumab T&E, but with significantly lower IVI numbers at both Year 1 (p < 0.0001) and Year 2 (p = 0.0011). Though all of the regimens resulted in maintained efficacy between Years 1 and 2, the required IVI number varied. The retrieved data did not enable other regimens or newer anti-VEGF agents such as brolucizumab to be compared. In conclusion, the T&E regimens were shown to be the most efficient, optimizing durable effectiveness whilst minimizing the IVI number in newly diagnosed exudative AMD, with aflibercept requiring the lowest IVI number.
C1 [Matonti, Frederic; Gascon, Pierre] Ctr Monticelli Paradis, 433 Bis Rue Paradis, F-13008 Marseille, France.
   [Matonti, Frederic] Aix Marseille Univ, Natl Ctr Sci Res CNRS, Timone Neurosci Institue INT, F-13008 Marseille, France.
   [Matonti, Frederic] Clin Juge, Grp Almav Sante, F-13008 Marseille, France.
   [Korobelnik, Jean-Francois; Delyfer, Marie-Noelle] Bordeaux Univ Hosp, Dept Ophthalmol, F-33000 Bordeaux, France.
   [Korobelnik, Jean-Francois; Delyfer, Marie-Noelle] Bordeaux Univ, UMR1219, BPH, INSERM, F-33000 Bordeaux, France.
   [Dot, Corinne] Desgenettes Mil Hosp, Dept Ophthalmol, F-69003 Lyon, France.
   [Gualino, Vincent] Clin Honore Cave, Dept Ophthalmol, F-82000 Montauban, Tarn & Garonne, France.
   [Gualino, Vincent; Soler, Vincent] Toulouse Univ Hosp, Ophthalmol Dept, Unite Retine, Hop Pierre Paul Riquet, F-31300 Toulouse, France.
   [Gualino, Vincent] Pl Baylac,TSA 40031, F-9 Toulouse, France.
   [Gualino, Vincent] Univ Paris, Ophthalmol Dept, Hop Lariboisiere, AP HP, F-75014 Paris, France.
   [Soler, Vincent] Univ Toulouse III, F-31000 Toulouse, France.
   [Soler, Vincent] Ctr Natl Rech Sci, CERCO UMR 5549, F-31000 Toulouse, France.
   [Mrejen, Sarah] Ctr Imagerie & Laser, F-75015 Paris, France.
   [Mrejen, Sarah] Ctr Hosp Natl Ophtalmol 1520, F-75012 Paris, France.
   [Baillif, Stephanie] Cote dAzur Univ, Dept Ophthalmol, Pasteur 2 Univ Hosp, F-06108 Nice, France.
   [Streho, Mate] Explore Vis Ctr, F-75001 Paris, France.
   [Streho, Mate] Lariboisiere Hosp, Dept Ophthalmol, F-75010 Paris, France.
   [Gascon, Pierre] Aix Marseille Univ, Dept Ophthalmol, Hop Nord, Chemin Bourrely, F-13008 Marseille, France.
   [Creuzot-Garcher, Catherine] Univ Hosp, Dept Ophthalmol, CHU Dijon, F-21000 Dijon, France.
   [Kodjikian, Laurent] Croix Rousse Univ Hosp, Hosp Civils Lyon, Dept Ophthalmol, F-69002 Lyon, France.
   [Kodjikian, Laurent] Univ Lyon, UMR CNRS 5510 Mateis, F-69622 Villeurbanne, France.
C3 Centre National de la Recherche Scientifique (CNRS); UDICE-French
   Research Universities; Aix-Marseille Universite; CHU Bordeaux; Institut
   National de la Sante et de la Recherche Medicale (Inserm); CHU de
   Toulouse; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research
   Universities; Universite Paris Cite; Universite de Toulouse; Universite
   Toulouse III - Paul Sabatier; Centre National de la Recherche
   Scientifique (CNRS); CNRS - National Institute for Biology (INSB);
   Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU
   Nice; UDICE-French Research Universities; Universite Cote d'Azur;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities;
   Universite Paris Cite; UDICE-French Research Universities; Aix-Marseille
   Universite; Assistance Publique-Hopitaux de Marseille; CHU Dijon
   Bourgogne; CHU Lyon; Centre National de la Recherche Scientifique
   (CNRS); Institut National des Sciences Appliquees de Lyon - INSA Lyon
RP Matonti, F (通讯作者)，Ctr Monticelli Paradis, 433 Bis Rue Paradis, F-13008 Marseille, France.; Matonti, F (通讯作者)，Clin Juge, Grp Almav Sante, F-13008 Marseille, France.
EM frederic.matonti@free.fr; jean-francois.korobelnik@chu-bordeaux.fr;
   corinnedot.pro@hotmail.fr; vincent.gualino@gmail.com;
   vincesoler@yahoo.fr; sarahmrejen.uretsky@gmail.com;
   marie-noelle.delyfer@chu-bordeaux.fr; baillif.s@chu-nice.fr;
   mstreho@yahoo.fr; pierre.gascon3@gmail.com;
   catherine.creuzot-garcher@chu-dijon.fr; laurent.kodjikian@chu-lyon.fr
RI ; kodjikian, laurent/A-3025-2015
OI baillif, stephanie/0000-0003-1700-8570; Korobelnik,
   Jean-Francois/0000-0002-4438-9535; kodjikian,
   laurent/0000-0002-3908-6716; SOLER, Vincent/0000-0002-3837-0619;
   Matonti, Frederic/0000-0002-6180-3937; Gascon,
   Pierre/0000-0002-2012-8808
FU BAYER France - BAYER France
FX This research was funded by BAYER France and The APC was funded by BAYER
   France.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bro T, 2020, GRAEF ARCH CLIN EXP, V258, P503, DOI 10.1007/s00417-019-04569-8
   Broadhead GK, 2014, ACTA OPHTHALMOL, V92, P713, DOI 10.1111/aos.12463
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2013, EYE, V27, P1429, DOI 10.1038/eye.2013.233
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Daien V, 2021, BRIT J OPHTHALMOL, V105, P1475, DOI 10.1136/bjophthalmol-2020-317434
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   Eldem BM, 2015, ACTA OPHTHALMOL, V93, pE458, DOI 10.1111/aos.12540
   Feltgen N, 2017, GRAEF ARCH CLIN EXP, V255, P923, DOI 10.1007/s00417-017-3589-x
   Gallemore RP, 2017, CLIN OPHTHALMOL, V11, P223, DOI 10.2147/OPTH.S119510
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Haidich AB, 2010, HIPPOKRATIA, V14, P29
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kertes PJ, 2020, JAMA OPHTHALMOL, V138, P244, DOI 10.1001/jamaophthalmol.2019.5540
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Khurana RN, 2021, OPHTHALMOLOGY, V128, P1027, DOI 10.1016/j.ophtha.2020.11.017
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, ACTA OPHTHALMOL, V91, pE178, DOI 10.1111/aos.12018
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Kunimoto D, 2020, OPHTHALMOLOGY, V127, P1331, DOI 10.1016/j.ophtha.2020.03.035
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Li E, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012208.pub2
   Li XX, 2017, J OCUL PHARMACOL TH, V33, P435, DOI 10.1089/jop.2016.0071
   Li XX, 2016, OPHTHALMOLOGICA, V236, P20
   Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 2019, INVEST OPHTH VIS SCI, V60
   Moher D, 2015, SYST REV-LONDON, V4, DOI [10.1186/2046-4053-4-1, 10.1186/s13643-015-0087-2]
   Mori R, 2017, OPHTHALMOLOGICA, V238, P17, DOI 10.1159/000468950
   Mozetic V, 2019, SAO PAULO MED J, V137, P530, DOI 10.1590/1516-3180.2019.010317092019
   Nunes RP, 2019, ARQ BRAS OFTALMOL, V82, P225, DOI 10.5935/0004-2749.20190043
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Ranchod TM, 2013, RETINA-J RET VIT DIS, V33, P1600, DOI 10.1097/IAE.0b013e318285cb71
   Ricci F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218242
   Russo A, 2018, CLIN OPHTHALMOL, V12, P587, DOI 10.2147/OPTH.S159672
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Semeraro F, 2019, BRIT J CLIN PHARMACO, V85, P908, DOI 10.1111/bcp.13871
   Semeraro F, 2015, RETINA-J RET VIT DIS, V35, P1547, DOI 10.1097/IAE.0000000000000525
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Soderberg AC, 2012, BRIT J OPHTHALMOL, V96, P714, DOI 10.1136/bjophthalmol-2011-300721
   Solomon SD, 2019, OPHTHALMIC RES, V62, P190, DOI 10.1159/000501372
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Staurenghi G, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-019-1251-6
   Taipale C, 2020, ACTA OPHTHALMOL, V98, P267, DOI 10.1111/aos.14231
   Vallance JH, 2010, EYE, V24, P1561, DOI 10.1038/eye.2010.84
   Weingessel B, 2016, WIEN KLIN WOCHENSCHR, V128, P560, DOI 10.1007/s00508-015-0772-0
   Williams PD, 2012, CLIN OPHTHALMOL, V6, P1519, DOI 10.2147/OPTH.S31010
   Wykoff CC, 2018, BRIT J OPHTHALMOL, V102, P460, DOI 10.1136/bjophthalmol-2017-310822
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
NR 66
TC 1
Z9 1
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD APR
PY 2022
VL 11
IS 7
AR 1834
DI 10.3390/jcm11071834
PG 19
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 0K6HO
UT WOS:000780890100001
PM 35407439
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Gabrielle, PH
   Nguyen, V
   Arnold, JJ
   Bhandari, S
   Viola, F
   Tigchelaar-Besling, OAM
   Garay-Aramburu, G
   O'Toole, L
   Cheung, CMG
   Barthelmes, D
   Creuzot-Garcher, C
   Gillies, M
AF Gabrielle, Pierre-Henry
   Vuong Nguyen
   Arnold, Jennifer J.
   Bhandari, Sanjeeb
   Viola, Francesco
   Tigchelaar-Besling, Odette A. M.
   Garay-Aramburu, Gonzaga
   O'Toole, Louise
   Cheung, Chui Ming Gemmy
   Barthelmes, Daniel
   Creuzot-Garcher, Catherine
   Gillies, Mark
TI Three-Year Outcomes of Neovascular Age-Related Macular Degeneration in
   Eyes That Do Not Develop Macular Atrophy or Subretinal Fibrosis
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE macular atrophy; subretinal fibrosis; age-related macular degeneration;
   VEGF inhibitors
ID VISUAL-ACUITY; RANIBIZUMAB; PREVALENCE; MORPHOLOGY; EXTEND; TREAT; RISK
AB Purpose: To report the 36-month treatment outcomes of eyes with neovascular age-related macular degeneration (nAMD) receiving vascular endothelial growth factor (VEGF) inhibitors in daily practice who did not develop either subretinal fibrosis (SRFi) or macular atrophy (MA).
   Methods: This is a retrospective analysis of data from the Fight Retinal Blindness registry. Treatment-naive eyes starting intravitreal injection of VEGF inhibitors for nAMD from January 1, 2010, to September 1, 2017, and did not have SRFI and MA at baseline were tracked.
   Results: We identified 2478 eligible eyes, of which 1712 eyes did not develop SRFi or MA, 291 developed extrafoveal SRFI or MA, and 475 developed subfoveal SRFi or MA over 36 months. The estimated visual acuity stabilized from 6 months to 36 months in eyes that did not develop SRFI or MA with a mean (95% confidence interval [CI]) change in VA of -1 (-2, 0) letters, whereas eyes that developed extrafoveal (-3 [-5, -2] letters) or subfoveal (-10 [-11, -8] letters) SRFi or MA declined in vision in the same period. Eyes with no or extrafoveal SRFi or MA over 36 months were more likely to maintain their visual improvement from six months to 36 months (odds ratio [OR; 95% CI] = 2.3 [1.5, 3.3] for absence vs. subfoveal SRFi or MA, P <= 0.01 and OR = 2.0 [1.2, 3.4] for extrafoveal vs. subfoveal MA or SRFi, P = 0.01).
   Conclusions: Treatment-naive nAMD eyes receiving VEGF inhibitors maintain their initial six-month visual improvement over three years if they do not develop SRFI or MA. Translational Relevance: The nAMD is still a major cause of blindness despite antian-giogenic treatments. We found that eyes that did not develop subretinal fibrosis or macular atrophy maintained their initial vision improvement for at least three years, suggesting that identifying treatments for these complications is the final barrier to achieving excellent outcomes in nAMD.
C1 [Gabrielle, Pierre-Henry; Vuong Nguyen; Bhandari, Sanjeeb; Barthelmes, Daniel; Gillies, Mark] Univ Sydney, Sydney Med Sch, Save Sight Inst, Discipline Ophthalmol, Sydney, NSW, Australia.
   [Gabrielle, Pierre-Henry; Creuzot-Garcher, Catherine] Dijon Univ Hosp, Dept Ophthalmol, Dijon, France.
   [Arnold, Jennifer J.] Marsden Eye Specialists, Sydney, NSW, Australia.
   [Viola, Francesco] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy.
   [Tigchelaar-Besling, Odette A. M.] Amphia Hosp, Dept Ophthalmol, Breda, Netherlands.
   [Garay-Aramburu, Gonzaga] Araba Univ Hosp, Unidad Gest Clin Oftalmol, Araba, Spain.
   [O'Toole, Louise] Mater Private Hosp, Dept Ophthalmol, Dublin, Ireland.
   [Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Barthelmes, Daniel] Univ Zurich, Univ Hosp Zurich, Dept Ophthalmol, Zurich, Switzerland.
C3 University of Sydney; CHU Dijon Bourgogne; IRCCS Ca Granda Ospedale
   Maggiore Policlinico; University of Milan; Amphia Hospital; University
   Hospital of Araba; Mater Private Hospital; Singapore National Eye
   Center; University of Zurich; University Zurich Hospital
RP Gabrielle, PH (通讯作者)，Sydney Eye Hosp, Save Sight Inst, 8 Macquarie St, Sydney, NSW 2000, Australia.
EM phgabrielle@gmail.com
RI GABRIELLE, Pierre-Henry/Y-4971-2018
OI GABRIELLE, Pierre-Henry/0000-0002-9688-4845
FU "La Fondation de France" research fellowship program; Macular Disease
   Foundation Australia; Bayer; Novartis
FX Supported by an educational grant from "La Fondation de France" research
   fellowship program, a grant from the Macular Disease Foundation
   Australia, and unrestricted educational grants from Bayer and Novartis.
CR Arevalo JF, 2016, RETINA-J RET VIT DIS, V36, P859, DOI 10.1097/IAE.0000000000000827
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Cho HJ, 2021, ACTA OPHTHALMOL, V99, pE540, DOI 10.1111/aos.14631
   Nguyen CL, 2019, OPHTHALMOLOGY, V126, P735, DOI 10.1016/j.ophtha.2018.11.036
   Daien V, 2020, BRIT J OPHTHALMOL, V104, P1064, DOI 10.1136/bjophthalmol-2019-315055
   Daniel E, 2018, OPHTHALMOLOGY, V125, P1037, DOI 10.1016/j.ophtha.2018.01.004
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Dong LM, 2003, OPHTHAL EPIDEMIOL, V10, P149, DOI 10.1076/opep.10.3.149.15080
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Mones J, 2020, OPHTHALMOLOGICA, V243, P1, DOI 10.1159/000502747
   Okeagu CU, OPHTHALMOL RETINA, V2021, P23
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Spooner KL, 2020, OPHTHALMOLOGY, V127, P1663, DOI 10.1016/j.ophtha.2020.06.019
   Teo KYC, 2020, RETINA-J RET VIT DIS, V40, P2285, DOI 10.1097/IAE.0000000000002779
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI 10.1016/j.jclinepi.2007.11.008
   Zhu MD, 2015, GRAEF ARCH CLIN EXP, V253, P1217, DOI 10.1007/s00417-014-2799-8
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD NOV
PY 2021
VL 10
IS 13
AR 5
DI 10.1167/tvst.10.13.5
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XU4XV
UT WOS:000734270600003
PM 34730771
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wang, Q
   Zhao, HS
   Li, L
AF Wang, Qin
   Zhao, Hai-Sheng
   Li, Li
TI Association between complement factor I gene polymorphisms and the risk
   of age-related macular degeneration: a Meta-analysis of literature
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE complement factors I; age-related macular degeneration; age-related
   maculopathy; single-nucleotide polymorphisms; Meta-analysis
ID CHINESE POPULATION; COMMON VARIANT; SUSCEPTIBILITY; PREVALENCE;
   ACTIVATION; LIPC
AB AIM: To systematically review the association between complement factors I (CFI) polymorphisms and age related macular degeneration (AMD) and to explore whether CFI polymorphisms are associated with AMD.
   METHODS: Meta-analysis of articles published from 1995 to January 2015 of articles involved with AMD and polymorphisms of the CFI gene. Eligible data were pooled in a Meta-analysis, analyzing using STATA software (version 12.0), Review Manager (version 5.2) and different models based on the heterogeneity of effect sizes. Egger's test, Begg's rank correlation methods were used to evaluate for publication bias.
   RESULTS: Thirteen articles were eligible, describing two loci polymorphisms of the CFI gene (of which 12 articles focus on rs10033900T>C and 3 articles focus on rs2285714C>T). For rs10033900T>C, the results of our study revealed that having a mutant allele C, TC, CC and TC+CC was associated with a decreased risk of AMD in all population groups studied (C versus T models, OR=0.84, 95% CI: 0.72-0.99, P=0.04; TC versus TT models OR= 0.89, 95% CI: 0.88-0.99, P=0.04; CC versus TT models, OR=0.76, 95% CI: 0.60-0.98, 60.03; TC+CC versus TT models, OR=0.81, 95% CI:0.65-0.99, P=0.04). We found that C allele were related to lower AMD risk in the Caucasian population by subgroup analysis, but there was no association with AMD under the allele and genotypes comparison in Asian studies. For rs2285714 C>T, the TC, TT genotypes contributed to a higher risk of AMD, compared with the CC carriers and CT+CC (OR=1.34, 95%CI: 1.09-1.63, P=0.004; OR=1.50, 95%CI: 1.25-1.80, P<0.0001).
   CONCLUSION: This Meta-analysis suggests that CFI rs10033900T>C and rs2285714C>T polymorphisms may contribute to AMD.
C1 [Wang, Qin; Zhao, Hai-Sheng] Chongqing Med Univ, Affiliated Hosp 2, Dept Ophthalmol, 76 Linjiang Rd, Chongqing 400010, Peoples R China.
   [Wang, Qin; Li, Li] Chongqing Med Univ, Affiliated Hosp 2, Ctr Ophthalmol, 76 Linjiang Rd, Chongqing 400010, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University
RP Zhao, HS (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Ophthalmol, 76 Linjiang Rd, Chongqing 400010, Peoples R China.; Li, L (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Ctr Ophthalmol, 76 Linjiang Rd, Chongqing 400010, Peoples R China.
EM doctorzhaohaisheng@aliyun.com; shp9820@163.com
FU Scientific Research Project of Traditional Chinese Medicine of Health
   and Family Planning Commission of Chongqing [ZY20150243]
FX Supported by the Scientific Research Project of Traditional Chinese
   Medicine of Health and Family Planning Commission of Chongqing
   (ZY20150243).
CR Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Cipriani V, 2012, EUR J HUM GENET, V20, P1, DOI 10.1038/ejhg.2011.118
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fraczek LA, 2010, MOL IMMUNOL, V48, P9, DOI 10.1016/j.molimm.2010.08.016
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kondo N, 2010, EUR J HUM GENET, V18, P634, DOI 10.1038/ejhg.2009.243
   Losonczy G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050181
   Peter I, 2011, AM J OPHTHALMOL, V152, P1005, DOI 10.1016/j.ajo.2011.05.016
   Qian DG, 2014, EUR J HUM GENET, V22, P1417, DOI 10.1038/ejhg.2014.37
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seddon JM, 2010, MOL VIS, V16, P2412
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Wu Pei-bei, 2013, Zhonghua Yan Ke Za Zhi, V49, P350
   Yang F, 2014, OPHTHALMOLOGICA, V232, P37, DOI 10.1159/000358241
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
NR 23
TC 7
Z9 7
U1 0
U2 14
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD FEB 18
PY 2016
VL 9
IS 2
BP 298
EP 305
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DC9OU
UT WOS:000369551700023
PM 26949655
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Peiretti, E
   Iovino, C
   Sacconi, R
   Caminiti, G
   Querques, G
AF Peiretti, Enrico
   Iovino, Claudio
   Sacconi, Riccardo
   Caminiti, Giulia
   Querques, Giuseppe
TI OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY CHARACTERISTICS OF POLYPOIDAL
   CHOROIDAL VASCULOPATHY SECONDARY TO CHRONIC CENTRAL SEROUS
   CHORIORETINOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE central serous chorioretinopathy; optical coherence tomography;
   angiography; polypoidal choroidal vasculopathy
ID IMAGE ARTIFACTS; NEOVASCULARIZATION; UPDATE; AGE
AB Purpose: To report diagnostic capability of optical coherence tomography angiography (OCTA) in detecting polypoidal choroidal vasculopathy and its morphologic characteristics in white patients with chronic central serous chorioretinopathy.
   Methods: Retrospective consecutive series of 20 eyes (17 consecutive patients) with a diagnosis of polypoidal choroidal vasculopathy secondary to chronic central serous chorioretinopathy based on clinical and multimodal imaging were included. All patients underwent a complete ophthalmologic examination, including best-correct visual acuity, fundus autofluorescence, fluorescein and indocyanine green angiography, spectral-domain optical coherence tomography, and OCTA.
   Results: In all eyes (100%), OCTA revealed the branching vascular network as a hyperflow lesion in both choriocapillaris and outer retina layers. Segmentation of the choriocapillaris in OCTA, in correspondence of the polypoidal dilation detected at indocyanine green angiography, showed a hyperflow round structure in 75% of cases and hypoflow round structure in 15%. Two of 20 eyes (10%) had no detectable polyps on OCTA.
   Conclusion: Optical coherence tomography angiography is a noninvasive imaging modality allowing a good visualization of both branching vascular network and polyp dilations. Our findings suggest that OCTA is a useful tool in the investigation of chronic central serous chorioretinopathy complicated by polypoidal choroidal vasculopathy.
C1 [Peiretti, Enrico; Iovino, Claudio; Caminiti, Giulia] Univ Cagliari, Eye Clin, Dept Surg Sci, Cagliari, Italy.
   [Sacconi, Riccardo; Querques, Giuseppe] Univ Vita Salute San Raffaele, IRCCS Osped San Raffaele, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
C3 University of Cagliari; Vita-Salute San Raffaele University; IRCCS
   Ospedale San Raffaele
RP Querques, G (通讯作者)，Univ Vita Salute San Raffaele, IRCCS Osped San Raffaele, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
EM giuseppe.querques@hotmail.it
RI Iovino, Claudio/O-7680-2019
OI Iovino, Claudio/0000-0003-1984-0555; Querques,
   Giuseppe/0000-0002-3292-9581; Sacconi, Riccardo/0000-0003-2891-2012
CR Carvalho-Recchia CA, 2002, OPHTHALMOLOGY, V109, P1834, DOI 10.1016/S0161-6420(02)01117-X
   CASTROCORREIA J, 1992, DOC OPHTHALMOL, V81, P379
   Chen FK, 2016, CLIN EXP OPHTHALMOL, V44, P388, DOI 10.1111/ceo.12683
   Cheung CMG, 2017, RETINA-J RET VIT DIS, V37, P1464, DOI 10.1097/IAE.0000000000001391
   Costanzo E, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/134783
   Ferrara D, 2016, PROG RETIN EYE RES, V52, P130, DOI 10.1016/j.preteyeres.2015.10.002
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Gemenetzi M, 2010, EYE, V24, P1743, DOI 10.1038/eye.2010.130
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kim JY, 2016, GRAEF ARCH CLIN EXP, V254, P1505, DOI 10.1007/s00417-015-3228-3
   Koh A.H.C., 1999, INVESTIG OPHTHALMOL, V40, P5958
   Liew G, 2013, CLIN EXP OPHTHALMOL, V41, P201, DOI 10.1111/j.1442-9071.2012.02848.x
   Manayath GJ, 2018, RETINA-J RET VIT DIS, V38, P1195, DOI 10.1097/IAE.0000000000001665
   Maruko I, 2017, RETIN CASES BRIEF RE
   Miura M, 2015, INVEST OPHTH VIS SCI, V56, P3179, DOI 10.1167/iovs.14-16252
   Nicholson B, 2013, SURV OPHTHALMOL, V58, P103, DOI 10.1016/j.survophthal.2012.07.004
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Park Han Sang, 2012, Korean J Ophthalmol, V26, P15, DOI 10.3341/kjo.2012.26.1.15
   Peiretti E, 2015, RETINA-J RET VIT DIS, V35, P1360, DOI 10.1097/IAE.0000000000000529
   SCHATZ H, 1992, OPHTHALMOLOGY, V99, P63
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   Tanaka K, 2017, BRIT J OPHTHALMOL, V101, P51, DOI 10.1136/bjophthalmol-2016-309264
   Toyama T, 2014, EYE, V28, P992, DOI 10.1038/eye.2014.132
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   YANNUZZI LA, 1987, RETINA-J RET VIT DIS, V7, P111, DOI 10.1097/00006982-198700720-00009
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
NR 30
TC 15
Z9 16
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2019
VL 39
IS 9
BP 1693
EP 1700
DI 10.1097/IAE.0000000000002234
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KC9EB
UT WOS:000507473000009
PM 29965937
DA 2022-11-30
ER

PT J
AU Popp, NA
   Yu, DK
   Green, B
   Chew, EY
   Ning, BT
   Chan, CC
   Tuo, JS
AF Popp, Nicholas A.
   Yu, Dianke
   Green, Bridgett
   Chew, Emily Y.
   Ning, Baitang
   Chan, Chi-Chao
   Tuo, Jingsheng
TI Functional single nucleotide polymorphism in IL-17A 3 untranslated
   region is targeted by miR-4480 in vitro and may be associated with
   age-related macular degeneration
SO ENVIRONMENTAL AND MOLECULAR MUTAGENESIS
LA English
DT Article
DE microRNA; age-related macular degeneration; inflammation; IL-17A; SNPs;
   epigenetics; genetics
ID NLRP3 INFLAMMASOME; MICRORNAS; DISEASE; CELLS; INDUCTION
AB Age-related macular degeneration (AMD) is a leading cause of irreversible central vision loss in the elderly. Genetic factors contributing to AMD include single nucleotide polymorphisms (SNPs) in immune-related genes including CFH, C2, CFI, C9, and C3, thus implicating these pathways in AMD pathogenesis. MicroRNAs (miRNAs) are powerful regulators of gene expression and execute this function by binding to the 3 untranslated region (3UTR) of target mRNAs, leading to mRNA degradation. In this study, we searched for the possible association of SNPs in the 3UTR region of IL-17A, a gene implicated in AMD pathogenesis without any previous SNP association with AMD. Using two independent sample cohorts of Caucasian subjects, six SNPs in the IL-17A 3-UTR were selected for genotyping based on bioinformatic predictions of the SNP effect on microRNA binding. The SNP rs7747909 was found to be associated with AMD (P<0.05) in the NEI cohort, using a dominant model logistic regression. Luciferase reporter gene assays and RNA electrophoretic mobility shift assays were performed using ARPE-19 cells to confirm the preferential binding of microRNAs to the major allele of the SNP. Our findings support the hypothesis that microRNA-mediated gene dysregulation may play a role in the pathogenesis of AMD. Environ. Mol. Mutagen. 57:58-64, 2016. (c) 2015 Wiley Periodicals, Inc.
C1 [Popp, Nicholas A.; Chan, Chi-Chao; Tuo, Jingsheng] NEI, Immunol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.
   [Yu, Dianke; Green, Bridgett; Ning, Baitang] US FDA, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA.
   [Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); US Food & Drug Administration (FDA); National Institutes of
   Health (NIH) - USA; NIH National Eye Institute (NEI)
RP Tuo, JS (通讯作者)，NEI, Immunopathol Sect, Immunol Lab, 10 Ctr Dr,Bldg 10,Room 10N103, Bethesda, MD 20892 USA.
EM jingsheng.tuo@nih.gov
OI Ning, Baitang/0000-0003-0798-0331; Popp, Nicholas/0000-0001-9374-3070
FU NEI Intramural Research Program
FX Grant sponsor: NEI Intramural Research Program.
CR Abelson JF, 2005, SCIENCE, V310, P317, DOI 10.1126/science.1116502
   Amadi-Obi A, 2007, NAT MED, V13, P711, DOI 10.1038/nm1585
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Ardeljan D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095900
   Ardeljan D, 2013, EUR J HUM GENET, V21, P1152, DOI 10.1038/ejhg.2013.14
   Bazzoni F, 2009, P NATL ACAD SCI USA, V106, P5282, DOI 10.1073/pnas.0810909106
   Chang TC, 2007, ANNU REV GENOM HUM G, V8, P215, DOI 10.1146/annurev.genom.8.080706.092351
   Chu XK, 2014, AGE, V36, P1453, DOI 10.1007/s11357-014-9627-2
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ender C, 2010, J CELL SCI, V123, P1819, DOI 10.1242/jcs.055210
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gong J, 2012, HUM MUTAT, V33, P254, DOI 10.1002/humu.21641
   Gorroochurn P, 2007, GENET MED, V9, P325, DOI 10.1097/GIM.0b013e3180676d79
   Greene CS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005639
   Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002
   Hu ZH, 2011, COMP FUNCT GENOM, DOI 10.1155/2011/910769
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lalor SJ, 2011, J IMMUNOL, V186, P5738, DOI 10.4049/jimmunol.1003597
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Luger D, 2008, J EXP MED, V205, P799, DOI 10.1084/jem.20071258
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604
   Sabatel C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016979
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   Sonkoly E, 2008, SEMIN CANCER BIOL, V18, P131, DOI 10.1016/j.semcancer.2008.01.005
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Tuo JS, 2014, AM J OPHTHALMOL, V157, P728, DOI 10.1016/j.ajo.2013.12.014
   Turchinovich A, 2012, RNA BIOL, V9, P1066, DOI 10.4161/rna.21083
   Wang SS, 2012, FUTURE MED CHEM, V4, P277, DOI 10.4155/fmc.11.176
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yu DK, 2015, SCI REP-UK, V5, DOI 10.1038/srep08534
   Zhang SR, 2015, INFLAMMATION, V38, P658, DOI 10.1007/s10753-014-9973-3
NR 38
TC 13
Z9 14
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0893-6692
EI 1098-2280
J9 ENVIRON MOL MUTAGEN
JI Environ. Mol. Mutagen.
PD JAN
PY 2016
VL 57
IS 1
BP 58
EP 64
DI 10.1002/em.21982
PG 7
WC Environmental Sciences; Genetics & Heredity; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Genetics & Heredity; Toxicology
GA DB7MT
UT WOS:000368700300007
PM 26765636
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Miyazaki, M
   Nakamura, H
   Kubo, M
   Kiyohara, Y
   Oshima, Y
   Ishibashi, T
   Nose, Y
AF Miyazaki, M
   Nakamura, H
   Kubo, M
   Kiyohara, Y
   Oshima, Y
   Ishibashi, T
   Nose, Y
TI Risk factors for age related maculopathy in a Japanese population: the
   Hisayama study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER DAM EYE; BLUE-MOUNTAINS EYE; MACULAR DEGENERATION;
   GENERAL-POPULATION; GRADING SYSTEM; PREVALENCE; NEOVASCULARIZATION;
   CATARACTS
AB Aims: To examine the risk factors for age related maculopathy (ARM) in a sample Japanese population.
   Methods: In 1998, a cross sectional community survey was conducted among residents of Hisayama. A total of 596 men and 886 women living in Hisayama, Japan, aged 50 years or older consented to participate in the study. Each participant underwent a comprehensive examination that included an ophthalmic examination. The presence of ARM was determined by grading from fundus examination by indirect ophthalmoscopy, slit lamp examination, and colour fundus photographs. Using these cross sectional data, logistic regression analyses were performed to determine the risk factors for ARM. The following 10 possible risk factors were used: age, cataract, hypertension (history), hypertension (history or examination), diabetes, hyperlipidaemia, current smoker, alcohol intake, BMI, and WBC.
   Results: ARM was detected in 19.5% of men and 14.9% of women. Men were found to have a significantly higher prevalence of ARM than women. Multiple logistic regression analysis showed that age and hypertension (history or examination) were significantly associated with ARM in men, whereas only age was a significant risk factor for ARM in women.
   Conclusions: This study suggests that higher age and male sex are relevant risk factors for ARM in Japan. In addition, hypertension is a relevant risk factor in men.
C1 Kyushu Univ, Dept Med Informat Sci, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan.
   Kyushu Univ, Dept Med & Clin Sci, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan.
   Kyushu Univ, Dept Ophthalmol, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan.
C3 Kyushu University; Kyushu University; Kyushu University
RP Miyazaki, M (通讯作者)，Kyushu Univ, Dept Med Informat Sci, Grad Sch Med Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
RI Kubo, Michiaki/N-7947-2015
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1686
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P191, DOI 10.1001/archopht.1994.01090140067025
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   OHMORI S, 1994, J HYPERTENS, V12, P1191
   OHMURA T, 1993, DIABETOLOGIA, V36, P1198, DOI 10.1007/BF00401066
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   RITTER LL, 1995, AM J OPHTHALMOL, V120, P190, DOI 10.1016/S0002-9394(14)72607-8
   SANDBERG MA, 1993, OPHTHALMOLOGY, V100, P1009
   *SAS I INC, 1989, SAS STAT US GUID VER, V2, P1071
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   SPERDUTO RD, 1981, ARCH OPHTHALMOL-CHIC, V99, P1004
   Tanizaki Y, 2000, STROKE, V31, P2616, DOI 10.1161/01.STR.31.11.2616
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yuzawa M, 1997, INT OPHTHALMOL, V21, P1, DOI 10.1023/A:1005845521424
NR 31
TC 66
Z9 73
U1 0
U2 1
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2003
VL 87
IS 4
BP 469
EP 472
DI 10.1136/bjo.87.4.469
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 660XM
UT WOS:000181860300023
PM 12642312
OA Green Submitted, Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Kato, A
   Yasukawa, T
   Sugita, I
   Yoshida, M
   Nozaki, M
   Hirano, Y
   Kondo, J
   Abe, T
   Sugita, K
   Okita, T
   Morita, H
   Takase, N
   Ogura, Y
AF Kato, Aki
   Yasukawa, Tsutomu
   Sugita, Iichiro
   Yoshida, Munenori
   Nozaki, Miho
   Hirano, Yoshio
   Kondo, Junko
   Abe, Tomohiro
   Sugita, Kimiko
   Okita, Takahide
   Morita, Hiroshi
   Takase, Noriaki
   Ogura, Yuichiro
TI Mental Status and Feasibility of an Intravitreal Ranibizumab
   Treat-and-Extend Regimen in Patients with Neovascular Age-Related
   Macular Degeneration
SO ADVANCES IN THERAPY
LA English
DT Article
DE Anti-vascular endothelial growth factor therapy; Hospital Anxiety and
   Depression Scale; Neovascular age-related macular degeneration;
   Treat-and-extend regimen
ID QUALITY-OF-LIFE; HEALTH RESOURCE UTILIZATION; BURDEN; PREVALENCE;
   ILLNESS; ANXIETY
AB Introduction Anti-vascular endothelial growth factor (VEGF) therapy is the first-choice treatment for neovascular age-related macular degeneration (nvAMD); however, patients often are burdened physically, financially, and mentally. We investigated the relationship between mental status and feasibility of an intravitreal ranibizumab treat-and-extend (TAE) regimen for nvAMD. Methods In this prospective, multicenter study, 75 patients with nvAMD received ranibizumab intravitreally in a TAE regimen. After two monthly injections, the injection intervals were extended step-by-step to 6, 8, 12, and 16 weeks in eyes with dry maculas on optical coherence tomography (OCT) and, if exudation persisted or relapsed, shortened by one step. The best corrected visual acuity (BCVA) measurement and OCT were performed at baseline and on the same days of the scheduled injections. At baseline, all patients completed a survey, the Hospital Anxiety and Depression Scale (HADS), regarding mental burden. At week 52, patients on the TAE regimen for 1 year completed the HADS and a questionnaire designated to assess treatment-associated mental status. Results Fifty-one patients (68%) completed the 1-year TAE regimen; 24 eyes (32%) discontinued the TAE regimen because of the rescue treatment, difficulty in completing clinical visits, or financial burden. In 51 eyes on the TAE regimen for 1 year, the mean BCVAs improved from 64.3 letters at baseline to 71.6 letters at week 52. The mean anxiety and depression scores on HADS decreased significantly (p < 0.01) after the 1-year treatment. Women tended to have higher anxiety scores, possibly associated with fear of injection and recurrence, while some men had higher depression scores potentially associated with financial burden, difficulty in completing clinical visits, and subsequent interruption of the TAE regimen especially in eyes with low treatment efficacy. Conclusions A TAE regimen of intravitreal ranibizumab injections preserves vision in eyes with nvAMD and reduces mental burden associated with disease relapse.
C1 [Kato, Aki; Yasukawa, Tsutomu; Yoshida, Munenori; Nozaki, Miho; Hirano, Yoshio; Morita, Hiroshi; Takase, Noriaki; Ogura, Yuichiro] Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi, Japan.
   [Sugita, Iichiro; Kondo, Junko; Abe, Tomohiro; Sugita, Kimiko; Okita, Takahide] Sugita Eye Hosp, Nagoya, Aichi, Japan.
   [Kato, Aki] Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.
C3 Nagoya City University; Nagoya City University
RP Kato, A (通讯作者)，Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi, Japan.; Kato, A (通讯作者)，Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.
EM akikato@med.nagoya-cu.ac.jp
FU Novartis Pharma K. K. (Tokyo, Japan)
FX This study, including the journal's Rapid Service Fee, was supported by
   Novartis Pharma K. K. (Tokyo, Japan).
CR Augustin A, 2007, INVEST OPHTH VIS SCI, V48, P1498, DOI 10.1167/iovs.06-0761
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Pauleikhoff D, 2009, OPHTHALMOLOGE, V106, P242, DOI 10.1007/s00347-008-1797-9
   Paulus YM, 2017, QUAL LIFE RES, V26, P2139, DOI 10.1007/s11136-017-1547-z
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruiz-Moreno JM, 2008, CURR MED RES OPIN, V24, P2103, DOI [10.1185/03007990802214300 , 10.1185/03007990802214300]
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Soubrane G, 2008, J FR OPHTALMOL, V31, P138, DOI 10.1016/S0181-5512(08)70346-2
   Talic I, 2022, LEARN INSTR, V81, DOI [10.1016/j.learninstruc.2022.101594, 10.1016/j.ajo.2004.02.011]
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2018, BRIT J OPHTHALMOL, V102, P460, DOI 10.1136/bjophthalmol-2017-310822
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 23
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0741-238X
EI 1865-8652
J9 ADV THER
JI Adv. Ther.
PD MAR
PY 2022
VL 39
IS 3
BP 1403
EP 1416
DI 10.1007/s12325-022-02052-1
EA FEB 2022
PG 14
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 0D1TB
UT WOS:000749980900001
PM 35112307
DA 2022-11-30
ER

PT J
AU Moshfeghi, AA
   Morales-Canton, V
   Quiroz-Mercado, H
   Velez-Montoya, R
   Zavala-Ayala, A
   Shusterman, EM
   Kaiser, PK
   Sanislo, SR
   Gertner, M
   Moshfeghi, DM
AF Moshfeghi, Andrew A.
   Morales-Canton, Virgilio
   Quiroz-Mercado, Hugo
   Velez-Montoya, Raul
   Zavala-Ayala, Alicia
   Shusterman, Eugene Mark
   Kaiser, Peter K.
   Sanislo, Steven R.
   Gertner, Michael
   Moshfeghi, Darius M.
TI 16 Gy low-voltage x-ray irradiation followed by as needed ranibizumab
   therapy for age-related macular degeneration: 12 month outcomes of a
   'radiation-first' strategy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; EXTERNAL-BEAM RADIOTHERAPY;
   PLAQUE RADIOTHERAPY; TRIAL; SECONDARY; SAFETY
AB Background and objective To describe 'radiation-first' combination treatment with a non-invasive, low-voltage x-ray irradiation system followed by as needed ranibizumab for neovascular age-related macular degeneration (AMD).
   Study design and methods Phase I study of non-invasive, low-voltage 16 Gy x-ray irradiation delivered in three beams via the inferior pars plana in patients with active neovascular AMD. Ranibizumab was administered as needed per protocol. Patients were followed monthly for safety and efficacy over 12 months.
   Results 13 patients were enrolled and completed 12 months follow-up. Safety was good with no serious ocular/non-ocular adverse events or radiation-related ocular complications. 11 patients lost <15 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters, seven gained >= 0 ETDRS letters and 0 gained >= 15 ETDRS letters. Patients received a total of 31 subsequent ranibizumab injections (of possible 156) over the 12 months following x-ray irradiation. Mean time to first injection was 3.9 months. One patient received no ranibizumab injections, three patients received one injection, four patients received two injections, and five patients received three or more injections.
   Conclusions After 12 months, non-invasive, low-voltage x-ray irradiation with as needed ranibizumab rescue therapy demonstrated good safety with a visual acuity stabilising effect and reduction in retinal thickness in patients with neovascular AMD.
C1 [Sanislo, Steven R.; Moshfeghi, Darius M.] Stanford Univ, Sch Med, Dept Ophthalmol, Horngren Family Vitreoretinal Ctr,Byers Eye Inst, Palo Alto, CA 94303 USA.
   [Moshfeghi, Andrew A.] Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, Palm Beach Gardens, FL USA.
   [Morales-Canton, Virgilio; Quiroz-Mercado, Hugo; Velez-Montoya, Raul; Zavala-Ayala, Alicia] Assoc Evitar Ceguera Mexico IAP, Dept Retina, Mexico City, DF, Mexico.
   [Quiroz-Mercado, Hugo; Velez-Montoya, Raul] Univ Colorado, Denver Hlth Med Ctr, Dept Ophthalmol, Denver, CO USA.
   [Shusterman, Eugene Mark; Gertner, Michael] Oraya Therapeut Inc, Newark, CA USA.
   [Kaiser, Peter K.] Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
C3 Stanford University; Bascom Palmer Eye Institute; Denver Health Medical
   Center; University of Colorado System; University of Colorado Denver;
   Cleveland Clinic Foundation
RP Moshfeghi, DM (通讯作者)，Stanford Univ, Sch Med, Dept Ophthalmol, Horngren Family Vitreoretinal Ctr,Byers Eye Inst, 2452 Watson Court, Palo Alto, CA 94303 USA.
EM dariusm@stanford.edu
RI Canton, Virgilio/AAF-7047-2021
OI Kaiser, Peter/0000-0001-5126-045X; Moshfeghi, Darius
   Mohammad/0000-0003-2254-292X
FU Thrombogenics, Inc.; Palm Beach Community Trust Fund; Oraya
   Therapeutics; Neovista; Novartis
FX DMM (Oraya, Inc., consultant, equity); VMC, RVM, HQM, SRS (Oraya, Inc.,
   consultant), MG (Oraya, Inc., intellectual property, equity); PKK
   (Research to Prevent Blindness, research; Bayer, Genentech, Regeneron,
   Kanghong, Novartis, consultant; Oraya, Inc., consultant, equity); AAM
   (Genentech, Inc., Allergan, Inc., Bausch & Lomb, Inc,,
   consultant/speaker; Eyetech, Inc., Alimera, Inc., consultant;
   Thrombogenics, Inc., research funding; Palm Beach Community Trust Fund;
   funding); EMS (Oraya, Inc employee, equity).; This work was funded by
   Oraya Therapeutics, Neovista, Novartis.
CR Aisenbrey S, 2003, GRAEF ARCH CLIN EXP, V241, P269, DOI 10.1007/s00417-003-0634-8
   Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Avila MP, 2009, RETINA-J RET VIT DIS, V29, P157, DOI 10.1097/IAE.0b013e3181985915
   Chakravarthy U, 2000, BRIT J RADIOL, V73, P305, DOI 10.1259/bjr.73.867.10817048
   Char DH, 1999, AM J OPHTHALMOL, V127, P574, DOI 10.1016/S0002-9394(99)00038-0
   Churei Hisahiko, 2004, Radiat Med, V22, P398
   Emery RS, 1998, MED PHYS, V25, P1491, DOI 10.1118/1.598324
   Finger PT, 2003, BRIT J OPHTHALMOL, V87, P1497, DOI 10.1136/bjo.87.12.1497
   Finger PT, 1999, AM J OPHTHALMOL, V127, P170, DOI 10.1016/S0002-9394(98)00389-4
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   Jaakkola A, 1999, ACTA OPHTHALMOL SCAN, V77, P57, DOI 10.1034/j.1600-0420.1999.770113.x
   Jaakkola A, 2001, EUR J OPHTHALMOL, V11, P269, DOI 10.1177/112067210101100310
   Jaakkola A, 1998, GRAEF ARCH CLIN EXP, V236, P24, DOI 10.1007/s004170050038
   Marcus D, 2004, AM J OPHTHALMOL, V138, P818, DOI 10.1016/j.ajo.2004.06.081
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Canton VM, 2012, OPHTHAL SURG LAS IM, V43, P20, DOI 10.3928/15428877-20111129-01
   Morales-Canton V, 2011, OPHTHAL SURG LAS IM, V42, P1
   Moshfeghi AA, 2011, OPHTHAL SURG LAS IM, V42, P1
   Moshfeghi DM, 2011, BRIT J OPHTHALMOL, V95, P185, DOI 10.1136/bjo.2009.163907
   Prettenhofer U, 2004, STRAHLENTHER ONKOL, V180, P91, DOI 10.1007/s00066-004-1177-6
   Sivagnanavel V, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004004.PUB2
   Stevenson MR, 2005, BRIT J OPHTHALMOL, V89, P1045, DOI 10.1136/bjo.2003.030445
   Valmaggia C, 2002, AM J OPHTHALMOL, V133, P521, DOI 10.1016/S0002-9394(02)01336-3
NR 25
TC 10
Z9 10
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2012
VL 96
IS 10
BP 1320
EP 1324
DI 10.1136/bjophthalmol-2011-301222
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 012DK
UT WOS:000309215500010
PM 22895887
DA 2022-11-30
ER

PT J
AU Ladas, ID
   Chatziralli, IP
   Kotsolis, AI
   Douvali, M
   Georgalas, I
   Theodossiadis, PG
   Rouvas, AA
AF Ladas, Ioannis D.
   Chatziralli, Irini P.
   Kotsolis, Athanasios I.
   Douvali, Maria
   Georgalas, Ilias
   Theodossiadis, Panagiotis G.
   Rouvas, Alexandros A.
TI Intravitreal Ranibizumab versus Thermal Laser Photocoagulation in the
   Treatment of Extrafoveal Classic Choroidal Neovascularization Secondary
   to Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Extrafoveal choroidal
   neovascularization; Ranibizumab; Thermal laser
ID VERTEPORFIN PHOTODYNAMIC THERAPY; SUBGROUP ANALYSIS; JUXTAFOVEAL; MARINA
AB Background: To compare the efficacy of thermal laser photocoagulation versus intravitreal ranibizumab for the treatment of extrafoveal classic choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Methods: We conducted a retrospective study on 24 eyes with extrafoveal classic CNV secondary to AMD, treated either with thermal laser photocoagulation (group 1) or with intravitreal ranibizumab (group 2). Visual acuity, number of injections/sessions and recurrence rate were assessed. Results: The mean follow-up time was 23.6 +/- 2.26 and 19.1 +/- 9.74 months for group 1 and 2, respectively. Mean best corrected visual acuity (BCVA) of groups 1 and 2 was 0.59 +/- 0.32 and 0.46 +/- 0.30 logMAR, respectively (p = 0.343). At the end of the follow-up, mean BCVA of group 1 was 0.92 +/- 0.35 and of group 20.16 +/- 0.12 logMAR and differed statistically compared to baseline (p = 0.02 and p = 0.006, respectively). There was a statistically significant difference between the two groups as far as BCVA at the end of the follow-up was concerned (p < 0.0001). The patients in group 1 received on average 1.38 sessions of thermal laser photocoagulation, while patients in group 2 received on average 4 injections of ranibizumab. The recurrence rate in the laser group was 84.6%, while in the ranibizumab group it was 18.2% (p < 0.001). Specifically, the mean time of recurrence in the laser group was 11.5 months, whereas in the ranibizumab group it was 18 months (p = 0.048). Conclusion: Intravitreal ranibizumab showed promising results in BCVA improvement and decrease in macular thickness in patients with extrafoveal classic CNV due to AMD, with a small number of injections. Laser photocoagulation treatment presented worsening in BCVA and high recurrence rate in our study with long-term follow-up. Copyright (C) 2012 S. Karger AG, Basel
C1 [Ladas, Ioannis D.; Chatziralli, Irini P.; Kotsolis, Athanasios I.; Georgalas, Ilias] Univ Athens, Med Sch Athens, Dept Ophthalmol 1, Athens, Greece.
   [Douvali, Maria; Theodossiadis, Panagiotis G.; Rouvas, Alexandros A.] Univ Athens, Med Sch Athens, Dept Ophthalmol 2, Athens, Greece.
C3 National & Kapodistrian University of Athens; National & Kapodistrian
   University of Athens
RP Rouvas, AA (通讯作者)，Attikon Univ Hosp, Dept Ophthalmol 2, 1 Rimini St, GR-12462 Athens, Greece.
EM alexander.rouvas@gmail.com
RI Chatziralli, Irini/AAG-4779-2020; Georgalas, Ilias/AAD-5946-2019
OI Chatziralli, Irini/0000-0001-8523-1024; Georgalas,
   Ilias/0000-0002-6171-5865
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Arevalo JF, 2008, RETINA-J RET VIT DIS, V28, P1387, DOI 10.1097/IAE.0b013e3181884ff4
   Arias L, 2009, RETINA-J RET VIT DIS, V29, P1444, DOI 10.1097/IAE.0b013e3181ae712d
   Beaumont PE, 2006, ARCH OPHTHALMOL-CHIC, V124, P807, DOI 10.1001/archopht.124.6.807
   Bhatnagar P, 2007, RETINA-J RET VIT DIS, V27, P846, DOI 10.1097/IAE.0b013e31813c68b7
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Coscas G, 1982, Bull Mem Soc Fr Ophtalmol, V94, P149
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Han DP, 2010, EYE, V24, P713, DOI 10.1038/eye.2009.122
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Ladas DD, 2003, OPHTHALMOLOGICA, V217, P194, DOI 10.1159/000068973
   Ladas ID, 2004, EUR J OPHTHALMOL, V14, P315, DOI 10.1177/112067210401400406
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Mikuni Eri, 2003, Nippon Ganka Gakkai Zasshi, V107, P695
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spitzer MS, 2008, CLIN OPHTHALMOL, V2, P1
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Voelker M, 2005, GRAEF ARCH CLIN EXP, V243, P1241, DOI 10.1007/s00417-005-0021-8
   Wachtlin J, 2005, GRAEF ARCH CLIN EXP, V243, P438, DOI 10.1007/s00417-004-1071-z
   Zarbin M, 2007, OPTOMETRY VISION SCI, V84, pE559, DOI 10.1097/OPX.0b013e3180de4dd7
NR 33
TC 6
Z9 6
U1 0
U2 9
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2012
VL 228
IS 2
BP 93
EP 101
DI 10.1159/000337347
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 981EP
UT WOS:000306950000004
PM 22571933
DA 2022-11-30
ER

PT J
AU Williams, PT
AF Williams, Paul T.
TI Prospective Study of Incident Age-Related Macular Degeneration in
   Relation to Vigorous Physical Activity during a 7-Year Follow-up
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID BODY-MASS INDEX; CARDIOVASCULAR RISK-FACTORS; C-REACTIVE PROTEIN;
   CORONARY-HEART-DISEASE; BLUE-MOUNTAINS-EYE; BEAVER DAM EYE; DIETARY-FAT;
   MALE RUNNERS; WEIGHT-LOSS; MEN
AB PURPOSE. To test whether the risk of age-related macular degeneration (AMD) decreases with vigorous physical activity.
   METHODS. This was a prospective study of self-reported clinically diagnosed macular degeneration in male (n = 29,532) and female (n = 12,176) runners followed prospectively for 7.7 years. Survival analyses of incident AMD versus average running distance (kilometers per day), cardiorespiratory fitness (10-km footrace performance), body mass index (BMI), cigarette use, and diet at baseline.
   RESULTS. The 110 men and 42 women reporting incident AMD were older than those unaffected (mean +/- SE: 54.81 +/- 0.97 vs. 44.86 +/- 0.06 years), and the men were significantly more likely to have once smoked cigarettes (50.6 vs. 41.2%, P = 0.04 when adjusted for age). Age- and sex-adjusted AMD risk was greater in the men and women who consumed more meat (3.17 +/- 0.20 vs. 2.55 +/- 0.02 servings/wk) and less fruit (9.41 +/- 0.70 vs. 10.92 +/- 0.05 pieces/wk). The men and women reporting incident AMD ran for exercise significantly less than those who remained unaffected, when adjustment was made for age and sex (4.57 +/- 0.30 vs. 5.34 +/- 0.02 km/d, P <= 0.01). When adjusted for age, sex, diet, and smoking history, the relative risk for AMD decreased 10% per km/d increment in running distance. Moreover, compared with the men and women who averaged less than 2 km/d, those averaging 2 to 4 km/d had 19% lower adjusted risk, and those averaging >= 4 km/d had 42% to 54% lower adjusted AMD risk.
   CONCLUSIONS. Higher doses of vigorous exercise (running) are associated with lower incident AMD risk independent of weight, cardiorespiratory fitness, and cigarette use. Limitations of the analyses include the select nature of the sample and reliance on self-report of both running history and clinically diagnosed AMD. (Invest Ophthalmol Vis Sci. 2009; 50: 101-106) DOI: 10.1167/iovs.08-2165
C1 Ernest Orlando Lawrence Berkeley Natl Lab, Div Life Sci, Donner Lab, Berkeley, CA 94720 USA.
C3 United States Department of Energy (DOE); Lawrence Berkeley National
   Laboratory
RP Williams, PT (通讯作者)，Ernest Orlando Lawrence Berkeley Natl Lab, Div Life Sci, Donner Lab, Berkeley, CA 94720 USA.
EM ptwilliams@lbl.gov
FU National Heart Lung and Blood Institute [HL-45652, HL-072110]; National
   Institute of Diabetes and Digestive and Kidney Diseases [DK-066738];
   Department of Energy [DE-AC03-76SF00098]; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTE [R55HL045652, R01HL072110, R01HL045652] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASES [R01DK066738] Funding Source: NIH RePORTER
FX Supported in part by Grants HL-45652 and HL-072110 from the National
   Heart Lung and Blood Institute and by Grant DK-066738 from the National
   Institute of Diabetes and Digestive and Kidney Diseases. The study was
   conducted at the Ernest Orlando Lawrence Berkeley Laboratory supported
   by Department of Energy DE-AC03-76SF00098 to the University of
   California.
CR Abalain JH, 2002, CLIN CHIM ACTA, V326, P97, DOI 10.1016/S0009-8981(02)00288-7
   BALKE B, 1959, US ARM FORCES MED J, V10, P875
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Chuo JY, 2007, OPHTHAL EPIDEMIOL, V14, P367, DOI 10.1080/09286580701421684
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   COOPER KH, 1968, J AMER MED ASSOC, V203, P201, DOI 10.1001/jama.203.3.201
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Guymer RH, 2006, MED J AUSTRALIA, V184, P455, DOI 10.5694/j.1326-5377.2006.tb00318.x
   Haskell WL, 2007, MED SCI SPORT EXER, V39, P1423, DOI 10.1161/CIRCULATIONAHA.107.185649
   Hellerstein H K, 1977, Ann N Y Acad Sci, V301, P484, DOI 10.1111/j.1749-6632.1977.tb38224.x
   Hu FB, 1999, AM J CLIN NUTR, V69, P243
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Kullo IJ, 2007, J APPL PHYSIOL, V102, P1374, DOI 10.1152/japplphysiol.01028.2006
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Leitzmann MF, 1998, ANN INTERN MED, V128, P417, DOI 10.7326/0003-4819-128-6-199803150-00001
   Leitzmann MF, 1999, NEW ENGL J MED, V341, P777, DOI 10.1056/NEJM199909093411101
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   Moeini HA, 2005, BRIT J OPHTHALMOL, V89, P964, DOI 10.1136/bjo.2005.066241
   Mozaffarieh M, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-20
   Schaumberg DA, 2000, AM J CLIN NUTR, V72, P1495
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tomaszewski M, 2003, ARTERIOSCL THROM VAS, V23, P1640, DOI 10.1161/01.ATV.0000087036.75849.0B
   US Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Verdaet D, 2004, ATHEROSCLEROSIS, V176, P303, DOI 10.1016/j.atherosclerosis.2004.05.007
   VIDAURRI JS, 1984, OPHTHALMOLOGICA, V188, P243, DOI 10.1159/000309370
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Williams PT, 2008, AM J GASTROENTEROL, V103, P2239, DOI 10.1111/j.1572-0241.2008.01944.x
   Williams PT, 2008, MED SCI SPORT EXER, V40, P998, DOI 10.1249/MSS.0b013e31816722a9
   Williams PT, 2008, AM J CLIN NUTR, V87, P1480, DOI 10.1093/ajcn/87.5.1480
   Williams PT, 2007, ARTERIOSCL THROM VAS, V27, P1811, DOI 10.1161/ATVBAHA.107.141853
   Williams PT, 2008, MED SCI SPORT EXER, V40, P1733, DOI 10.1249/MSS.0b013e31817b8eba
   Williams PT, 2005, MED SCI SPORT EXER, V37, P1329, DOI 10.1249/01.mss.0000174894.05236.45
   Williams PT, 1997, ARCH INTERN MED, V157, P191, DOI 10.1001/archinte.157.2.191
   Williams PT, 2004, INT J OBESITY, V28, P120, DOI 10.1038/sj.ijo.0802480
   WILLIAMS PT, 1990, METABOLISM, V39, P460, DOI 10.1016/0026-0495(90)90003-U
   WILLIAMS PT, 1994, METABOLISM, V43, P917, DOI 10.1016/0026-0495(94)90277-1
   Williams PT, 2001, MED SCI SPORT EXER, V33, P754, DOI 10.1097/00005768-200105000-00012
   WILLIAMS PT, 2008, INVEST OPHTH VIS SCI, V49, P95
   WILLIAMS PT, STROKE IN PRESS
   WOOD PD, 1988, NEW ENGL J MED, V319, P1173, DOI 10.1056/NEJM198811033191801
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 64
TC 42
Z9 42
U1 0
U2 10
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2009
VL 50
IS 1
BP 101
EP 106
DI 10.1167/iovs.08-2165
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 390YP
UT WOS:000262199900014
PM 18566466
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Liukkonen, MPK
   Paterno, JJ
   Kivinen, N
   Siintamo, L
   Koskela, AKJ
   Kaarniranta, K
AF Liukkonen, Mikko P. K.
   Paterno, Jussi J.
   Kivinen, Niko
   Siintamo, Leea
   Koskela, Ali K. J.
   Kaarniranta, Kai
TI Epithelial-mesenchymal transition-related serum markers ET-1, IL-8 and
   TGF-beta 2 are elevated in a Finnish wet age-related macular
   degeneration cohort
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; biomarker; cardiovascular disease;
   endothelin 1; epithelial-mesenchymal transition; interleukin 8; serum;
   transforming growth factor-beta 2
ID ENDOTHELIAL GROWTH-FACTOR; BLOOD-COAGULATION; CYTOKINE LEVELS;
   MECHANISMS; CELLS; VEGF; INTERLEUKIN-8; BEVACIZUMAB; PROTEIN;
   POLYMORPHISMS
AB Purpose It has been hypothesized that epithelial-mesenchymal transition (EMT) may occur in the retinal pigment epithelium of advanced stage age-related macular degeneration (AMD). Various serum and plasma growth factors and inflammatory mediators have been linked to AMD. We were interested in finding out whether systemic levels of EMT-associated markers were altered in the serum of wet AMD patients. Serum biomarkers associated with the various pathological processes of AMD may present an avenue towards identifying and characterizing the birth mechanisms of wet AMD, its progression and severity, paving the way towards the application of precision medicine. Methods We chose to measure the serum levels of known biomarkers of EMT - EGF (epidermal growth factor), ET-1 (endothelin 1), IL-8 (interleukin 8), TGF-beta 1 and TGF-beta 2 (transforming growth factor-beta 1 and 2) and VEGF-A (vascular endothelial growth factor A) - using enzyme-linked immunosorbent assays. We measured them from 71 Finnish wet AMD patients who were receiving intravitreal anti-VEGF-A injection treatments, as well as 64 age-adjusted controls. Results We found significantly elevated levels of ET-1, IL-8 and TGF-beta 2 in the serums of wet AMD patients. Conclusions ET-1, IL-8 and TGF-beta 2 appear to be useful serum biomarkers in understanding active wet AMD. However, we cannot conclude that local retinal EMT-processes could be observed from the corresponding systemic serum biomarkers in patients undergoing anti-VEGF-A treatments.
C1 [Liukkonen, Mikko P. K.; Paterno, Jussi J.; Koskela, Ali K. J.; Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio, Finland.
   [Paterno, Jussi J.; Kivinen, Niko; Siintamo, Leea; Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio, Finland.
C3 University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland
RP Liukkonen, MPK (通讯作者)，Univ Eastern Finland, Yliopistonranta 1, Kuopio 70210, Finland.
EM mikko.liukkonen@uef.fi
OI Liukkonen, Mikko/0000-0002-4259-4041
FU Academy of Finland [296840, 333302]; Kuopio University Hospital VTR
   grant [5503743]; Sigrid Juselius Foundation; Paivikki and Sakari
   Sohlberg Foundation; Finnish Cultural Foundation [65191877]; Finnish Eye
   Foundation; University of Eastern Finland
FX Thanks to Anne Seppanen for technical guidance, Kati Monttinen for
   sample and patient data collection and curation, Tuomas Selander for
   power calculations, and Kuopio University Hospital ophthalmology
   department staff for AMD patient care. This work received funding from
   the Academy of Finland (296840, 333302), the Kuopio University Hospital
   VTR grant (5503743), the Sigrid Juselius Foundation, the Paivikki and
   Sakari Sohlberg Foundation, the University of Eastern Finland
   strategical support, the Finnish Cultural Foundation (65191877) and the
   Finnish Eye Foundation.
CR Abu El-Asrar AM, 2015, EXP EYE RES, V132, P179, DOI 10.1016/j.exer.2015.01.023
   Agrawal R, 2019, INVEST OPHTH VIS SCI, V60, P376, DOI 10.1167/iovs.18-24387
   Ambreen F, 2015, MOL VIS, V21, P985
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Ang MJ, 2021, CLIN EXP OPHTHALMOL, V49, P118, DOI 10.1111/ceo.13892
   Apostolakis S, 2009, CARDIOVASC RES, V84, P353, DOI 10.1093/cvr/cvp241
   Ashraf M, 2017, EYE, V31, P1523, DOI 10.1038/eye.2017.81
   Barton M, 2014, LIFE SCI, V118, P97, DOI 10.1016/j.lfs.2014.09.009
   Bester J, 2016, SCI REP-UK, V6, DOI 10.1038/srep32188
   Blasiak J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041684
   Bonfiglio V, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249558
   Branchford BR, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00142
   Brat DJ, 2005, NEURO-ONCOLOGY, V7, P122, DOI 10.1215/S1152851704001061
   Cabral T, 2018, OPHTHALMOL RETINA, V2, P31, DOI 10.1016/j.oret.2017.04.004
   Chen XY, 2020, MOL VIS, V26, P517
   Clozel M, 2005, ANN MED, V37, P2, DOI 10.1080/07853890410018925
   Cohen SY, 2012, RETINA-J RET VIT DIS, V32, P1480, DOI 10.1097/IAE.0b013e318240a516
   Courau T, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85974
   Davenport AP, 2016, PHARMACOL REV, V68, P357, DOI 10.1124/pr.115.011833
   Dechkhajorn W, 2020, SCIENTIFICA, V2020, DOI 10.1155/2020/5843958
   Derhaschnig U, 2002, AM J HYPERTENS, V15, P207, DOI 10.1016/S0895-7061(01)02327-5
   Dhaun N, 2012, BRIT J PHARMACOL, V167, P720, DOI 10.1111/j.1476-5381.2012.02070.x
   Di Salvatore M, 2017, ONCOTARGET, V8, P16887, DOI 10.18632/oncotarget.14810
   Dirican A, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0905-8
   Dropmann A, 2016, ONCOTARGET, V7, P19499, DOI 10.18632/oncotarget.6967
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   FERRI C, 1995, DIABETES, V44, P431, DOI 10.2337/diabetes.44.4.431
   Garcia-Quintanilla L, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11080365
   Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189
   Grant K, 2003, BRIT J CANCER, V88, P163, DOI 10.1038/sj.bjc.6700750
   Hanna A, 2019, FRONT CARDIOVASC MED, V6, DOI 10.3389/fcvm.2019.00140
   Hautamaki A, 2014, OPHTHALMOLOGY, V121, P973, DOI 10.1016/j.ophtha.2013.11.035
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Jain R, 2007, AM J RESP CELL MOL, V37, P38, DOI 10.1165/rcmb.2006-0353OC
   Jeon S, 2012, OCUL IMMUNOL INFLAMM, V20, P360, DOI 10.3109/09273948.2012.709576
   Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530
   Kapiotis S, 1997, ARTERIOSCL THROM VAS, V17, P2861, DOI 10.1161/01.ATV.17.11.2861
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Kevane B, 2018, J THROMB HAEMOST, V16, P1572, DOI 10.1111/jth.14159
   Kida T, 2016, EPMA J, V7, DOI 10.1186/s13167-016-0066-2
   Kim CS, 2006, INT J OBESITY, V30, P1347, DOI 10.1038/sj.ijo.0803259
   Kim J, 2016, ONCOTARGET, V7, P85021, DOI 10.18632/oncotarget.13116
   Kimawaha P, 2020, J GASTROINTEST ONCOL, V11, P304, DOI 10.21037/jgo.2019.01.03
   Kovacic JC, 2019, J AM COLL CARDIOL, V73, P190, DOI 10.1016/j.jacc.2018.09.089
   Kowalczyk A, 2015, ARCH IMMUNOL THER EX, V63, P41, DOI 10.1007/s00005-014-0310-1
   Lankhorst S, 2016, AM J PHYSIOL-REG I, V310, pR230, DOI 10.1152/ajpregu.00373.2015
   Lechner J, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0820-y
   Leung KW, 2009, MOL IMMUNOL, V46, P1374, DOI 10.1016/j.molimm.2008.12.001
   Li BG, 1999, HYPERTENSION, V33, P271, DOI 10.1161/01.HYP.33.1.271
   Li SJ, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/2678017
   Little K, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-02033-7
   Long XX, 2016, INT J ONCOL, V48, P5, DOI 10.3892/ijo.2015.3234
   Lynch AM, 2020, EUR J OPHTHALMOL, V30, P1061, DOI 10.1177/1120672119857896
   Machalinska A., 2021, KLIN OCZ ACTA OPHTHA, V116, P16
   Medici D, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/6962801
   Montes-Worboys A, 2010, EUR RESPIR J, V35, P160, DOI 10.1183/09031936.00146808
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Nath M, 2017, INDIAN J OPHTHALMOL, V65, P191, DOI 10.4103/ijo.IJO_866_16
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Pache Mona, 2002, Med Sci Monit, V8, pCR616
   Pandey AK, 2018, HYPERTENSION, V71, pE1, DOI 10.1161/HYPERTENSIONAHA.117.10271
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Principe DR, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt369
   Rodriguez-Pascual F, 2014, LIFE SCI, V118, P156, DOI 10.1016/j.lfs.2013.12.024
   Ross B, 2010, AM J RESP CELL MOL, V42, P16, DOI 10.1165/rcmb.2009-0175TR
   Rubens C, 2001, CHEST, V120, P1562, DOI 10.1378/chest.120.5.1562
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Salani D, 2000, AM J PATHOL, V157, P1537, DOI 10.1016/S0002-9440(10)64791-8
   Schaumberg DA, 1999, ANN EPIDEMIOL, V9, P166, DOI 10.1016/S1047-2797(98)00049-0
   SCHULZ E, 1995, KIDNEY INT, V47, P795, DOI 10.1038/ki.1995.121
   Seccia TM, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003888
   Shi ML, 2011, NATURE, V474, P343, DOI 10.1038/nature10152
   Shu DY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124271
   Singh M, 2018, PHARMACOL THERAPEUT, V182, P80, DOI 10.1016/j.pharmthera.2017.08.009
   Sorensen JO, 2020, ACTA OPHTHALMOL, V98, P384, DOI 10.1111/aos.14295
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Subhi Y, 2019, ACTA OPHTHALMOL, V97, P99, DOI 10.1111/aos.13886
   Tanase DM, 2019, INT J HYPERTENS, V2019, DOI 10.1155/2019/3159283
   Tas F, 2014, TUMOR BIOL, V35, P7233, DOI 10.1007/s13277-014-1984-z
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Tiainen L, 2019, CLIN BREAST CANCER, V19, pE522, DOI 10.1016/j.clbc.2019.03.006
   Tosi GM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113363
   Tosi GM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26442-0
   Trivedi RH, 2011, J OCUL PHARMACOL TH, V27, P477, DOI 10.1089/jop.2010.0100
   Tuuminen R, 2017, ACTA OPHTHALMOL, V95, DOI 10.1111/aos.13501
   Velez-Montoya R, 2013, RETINA-J RET VIT DIS, V33, P1487, DOI 10.1097/IAE.0b013e318271f265
   Walshe TE, 2009, ARTERIOSCL THROM VAS, V29, P1185, DOI 10.1161/ATVBAHA.109.186742
   Wang YF, 2021, MOL MED REP, V23, DOI 10.3892/mmr.2021.12028
   Willis BC, 2007, AM J PHYSIOL-LUNG C, V293, pL525, DOI 10.1152/ajplung.00163.2007
   Wu MH, 2014, ONCOGENE, V33, P1725, DOI 10.1038/onc.2013.109
   Wu XY, 2010, CLIN CHIM ACTA, V411, P1296, DOI 10.1016/j.cca.2010.05.006
   Wu Z., 2021, OPHTHALMOL RETINA
   Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277
   Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5
   Yadav H, 2011, CELL METAB, V14, P67, DOI 10.1016/j.cmet.2011.04.013
   Yamamoto N, 2005, OPHTHALMIC RES, V37, P29, DOI 10.1159/000083019
   Yang BW, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106532
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Zeng F, 2014, SEMIN CELL DEV BIOL, V28, P2, DOI 10.1016/j.semcdb.2014.01.011
   Zhang F, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0835-z
   Zhang Y, 2018, MOL VIS, V24, P340
   Zhao ZW, 2017, ONCOL LETT, V13, P4577, DOI 10.3892/ol.2017.6034
   Zhou M, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00501
NR 104
TC 4
Z9 4
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2022
VL 100
IS 5
BP E1153
EP E1162
DI 10.1111/aos.15051
EA OCT 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2R9UK
UT WOS:000711092600001
PM 34699684
DA 2022-11-30
ER

PT J
AU Van Hove, I
   Van Bergen, T
   Etienne, I
   Holgado, A
   Afonina, IS
   Beyaert, R
   Feyen, JH
   Hu, TT
AF Van Hove, Inge
   Van Bergen, Tine
   Etienne, Isabelle
   Holgado, Aurora
   Afonina, Inna S.
   Beyaert, Rudi
   Feyen, Jean Hm
   Hu, Tjing-Tjing
TI IL-33trap-mediated IL-33 neutralization does not exacerbate choroidal
   neovascularization, but fails to protect against retinal degeneration in
   a dry age-related macular degeneration model
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE IL-33; IL-33trap; Age-related macular degeneration; Choroidal
   neovascularization; Sodium iodate
ID SODIUM IODATE; PIGMENT EPITHELIUM; GROWTH-FACTOR; EXPRESSION; CELLS;
   INTERLEUKIN-33; PHOTORECEPTOR; ACTIVATION; INFLAMMASOME; MACROPHAGES
AB The progressive and sight-threatening disease, age-related macular degeneration (AMD), is a growing public health concern due to ageing demographics, with the highest unmet medical need for the advanced stage of dry AMD, geographic atrophy. The pathogenesis underlying AMD is driven by a complex interplay of genetic and environmental factors. There is ample evidence that inflammation is strongly involved in AMD development. Interleukin-33 (IL-33) has been proposed to be critically involved in retinal degeneration, but a protective role in eye pathophysiology was also demonstrated. The current study investigated the therapeutic potential of IL33trap, a novel IL-33-neutralizing biologic, in dry AMD/geographic atrophy and, based on controversial data regarding the protective versus detrimental functions of IL-33 in neovascularization, evaluated the risk of progression to wet AMD by IL-33 neutralization. Repeated intravitreal (IVT) injections of IL-33trap in the mouse laser-induced choroidal neovascularization model did not exacerbate neovascularization or leakage, while it significantly inhibited inflammatory cell infiltration in the retinal pigment epithelium and choroid. On the contrary, IVT treatment with IL-33trap significantly induced retinal inflammation and could not prevent retinopathy induction in the mouse sodium iodate (NaIO3) model. Overall, these data suggest a complex and dichotomous role of IL-33 in eye pathology and indicate that IL-33 neutralization is not able to prevent onset and progression of dry AMD pathogenesis.
C1 [Van Hove, Inge; Van Bergen, Tine; Etienne, Isabelle; Feyen, Jean Hm; Hu, Tjing-Tjing] Oxurion NV, Gaston Geenslaan 1, B-3001 Heverlee, Belgium.
   [Holgado, Aurora; Afonina, Inna S.; Beyaert, Rudi] Univ Gent VIB, Unit Mol Signal Transduct Inflammat, Ctr Inflammat Res, Ghent, Belgium.
   [Holgado, Aurora; Afonina, Inna S.; Beyaert, Rudi] Univ Ghent, Dept Biomed Mol Biol, Ghent, Belgium.
C3 Flanders Institute for Biotechnology (VIB); Ghent University; Ghent
   University
RP Van Hove, I (通讯作者)，Oxurion NV, Gaston Geenslaan 1, B-3001 Heverlee, Belgium.
EM inge.vanhove@oxurion.com
OI Van Bergen, Tine/0000-0002-8761-9214; Holgado,
   Aurora/0000-0001-6724-2758; Van Hove, Inge/0000-0002-3125-0438; Afonina,
   Inna/0000-0001-8894-5305; Beyaert, Rudi/0000-0002-5704-582X
FU  [F2016/IOFAdvanced/307]
FX Work in the Beyaert lab was funded by a grant (F2016/IOFAdvanced/307)
   from the 'Industrial Research FundGhent University'.
CR Altara R, 2018, CARDIOVASC RES, V114, P1578, DOI 10.1093/cvr/cvy166
   Augustine J, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1625-y
   Balaratnasingam C, 2015, CLIN OPHTHALMOL, V9, P2355, DOI 10.2147/OPTH.S80040
   Balser C, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1419-2
   Barbour M, 2014, EUR J IMMUNOL, V44, P3320, DOI 10.1002/eji.201444671
   Behnke V, 2020, CELL MOL LIFE SCI, V77, P781, DOI 10.1007/s00018-019-03419-4
   Berkowitz BA, 2017, INVEST OPHTH VIS SCI, V58, P3286, DOI 10.1167/iovs.17-21850
   Bhutto Imran A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD143, DOI 10.1167/iovs.18-24245
   Bosco A, 2011, J COMP NEUROL, V519, P599, DOI 10.1002/cne.22516
   Braun H, 2018, BIOCHEM PHARMACOL, V148, P238, DOI 10.1016/j.bcp.2018.01.010
   Burton MJ, 2021, LANCET GLOB HEALTH, V9, pE489, DOI 10.1016/S2214-109X(20)30488-5
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Chen L, 2016, MOL MED REP, V13, P3249, DOI 10.3892/mmr.2016.4890
   Choi YS, 2009, BLOOD, V114, P3117, DOI 10.1182/blood-2009-02-203372
   Copland DA, 2018, INVEST OPHTH VIS SCI, V59, pAMD83, DOI 10.1167/iovs.18-23893
   Demyanets S, 2013, J MOL CELL CARDIOL, V60, P16, DOI 10.1016/j.yjmcc.2013.03.020
   Demyanets S, 2011, ARTERIOSCL THROM VAS, V31, P2080, DOI 10.1161/ATVBAHA.111.231431
   Dridi S, 2012, P NATL ACAD SCI USA, V109, P13781, DOI 10.1073/pnas.1206494109
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Fairlie-Clarke K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02596
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fletcher EL, 2020, OPHTHAL PHYSL OPT, V40, P128, DOI 10.1111/opo.12671
   Fu AKY, 2016, P NATL ACAD SCI USA, V113, pE2705, DOI 10.1073/pnas.1604032113
   Gao Y, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00095
   Georgiadis A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015730
   Ghosh S, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0588-y
   Griesenauer B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00475
   Hagbi-Levi S, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/8535273
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hanus J, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.54
   He HJ, 2019, J CELL MOL MED, V23, P3495, DOI 10.1111/jcmm.14246
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Holgado A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01422
   Holgado A, 2019, J ALLERGY CLIN IMMUN, V144, P204, DOI 10.1016/j.jaci.2019.02.028
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Isnadi MFA, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/5346413
   Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0
   Jaffe G.J., 2020, OPHTHALMOLOG
   Jang KH, 2019, EXP EYE RES, V180, P8, DOI 10.1016/j.exer.2018.11.026
   Kannan R, 2014, NEURAL REGEN RES, V9, P2044, DOI 10.4103/1673-5374.147927
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kim HL, 2018, NEUROCHEM RES, V43, P1010, DOI 10.1007/s11064-018-2508-9
   Kiuchi K, 2002, CURR EYE RES, V25, P373, DOI 10.1076/ceyr.25.6.373.14227
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Korhonen P, 2015, BRAIN BEHAV IMMUN, V49, P322, DOI 10.1016/j.bbi.2015.06.013
   Kyosseva SV, 2016, OPHTHALMOL EYE DIS, V8, P23, DOI 10.4137/OED.S32200
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Liu J, 2018, EBIOMEDICINE, V33, P196, DOI 10.1016/j.ebiom.2018.06.003
   Liu XC, 2012, INFLAMMATION, V35, P776, DOI 10.1007/s10753-011-9379-4
   Makarev E, 2014, AGING-US, V6, P1064, DOI 10.18632/aging.100711
   Moriguchi M, 2018, INVEST OPHTH VIS SCI, V59, P3476, DOI 10.1167/iovs.17-23532
   Nork TM, 2011, ARCH OPHTHALMOL-CHIC, V129, P1042, DOI 10.1001/archophthalmol.2011.210
   Ohtaka K, 2006, CURR EYE RES, V31, P347, DOI 10.1080/02713680600629797
   Park DH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01007
   Pinto SM, 2018, J CELL COMMUN SIGNAL, V12, P615, DOI 10.1007/s12079-018-0464-4
   Pomeshchik Y, 2015, BRAIN BEHAV IMMUN, V44, P68, DOI 10.1016/j.bbi.2014.08.002
   Rastoin O, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134627
   Reyns G.E., 2016, J MOL GENET MED, V10, P202, DOI [10.4172/1747- 0862.1000202, DOI 10.4172/1747-0862.1000202]
   Rinninella E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111677
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sepah YJ, 2014, SAUDI J OPHTHALMOL, V28, P111, DOI 10.1016/j.sjopt.2014.03.008
   Shah RS, 2015, JOVE-J VIS EXP, DOI 10.3791/53502
   Singalavanija A, 2000, RETINA-J RET VIT DIS, V20, P378, DOI 10.1097/00006982-200007000-00010
   Stahl A, 2020, DTSCH ARZTEBL INT, V117, P513, DOI 10.3238/arztebl.2020.0513
   Taniguchi K, 2013, J INVEST ALLERG CLIN, V23, P428
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Theodoropoulou S, 2017, J PATHOL, V241, P45, DOI 10.1002/path.4816
   Theodoropoulou Sofia, 2015, Lancet, V385 Suppl 1, pS97, DOI 10.1016/S0140-6736(15)60412-3
   Tohari AM, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8090341
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Van der Jeught K., 2020, JCI INSIGHT, V5, DOI [10.1172/jci.insight.136073, DOI 10.1172/JCI.INSIGHT.136073]
   Venu Gopal Reddy Y C, 2018, Int J Retina Vitreous, V4, P27, DOI 10.1186/s40942-018-0130-2
   Villegas VM, 2017, EXPERT OPIN DRUG DEL, V14, P273, DOI 10.1080/17425247.2016.1213240
   Volland S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125631
   Wagenfeld L, 2007, NEW ENGL J MED, V357, P1264, DOI 10.1056/NEJMc070128
   Will-Orrego A, 2018, J OCUL PHARMACOL TH, V34, P489, DOI 10.1089/jop.2017.0131
   Xi HK, 2016, J EXP MED, V213, P189, DOI 10.1084/jem.20150894
   Xiao JH, 2017, INVEST OPHTH VIS SCI, V58, P1801, DOI 10.1167/iovs.16-21392
   Xiao YF, 2018, MOL IMMUNOL, V101, P550, DOI 10.1016/j.molimm.2018.08.026
   Xu L, 2018, P NATL ACAD SCI USA, V115, P10475, DOI 10.1073/pnas.1802724115
   Yerramothu P, 2018, EYE, V32, P491, DOI 10.1038/eye.2017.241
   Young BM, 2019, MOL THER-METH CLIN D, V14, P113, DOI 10.1016/j.omtm.2019.06.001
   Zeiss CJ, 2010, VET PATHOL, V47, P396, DOI 10.1177/0300985809359598
   Zhou P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098275
   Zieger M, 2016, ONCOTARGET, V7, P9620, DOI 10.18632/oncotarget.7330
NR 87
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUN
PY 2021
VL 207
AR 108608
DI 10.1016/j.exer.2021.108608
EA MAY 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SQ8BB
UT WOS:000660573800006
PM 33930400
DA 2022-11-30
ER

PT J
AU Cabral, D
   Coscas, F
   Pereira, T
   Laiginhas, R
   Rodrigues, C
   Francais, C
   Nogueira, V
   Falcao, M
   Miere, A
   Lupidi, M
   Coscas, G
   Souied, E
AF Cabral, Diogo
   Coscas, Florence
   Pereira, Telmo
   Laiginhas, Rita
   Rodrigues, Catarina
   Francais, Catherine
   Nogueira, Vanda
   Falcao, Manuel
   Miere, Alexandra
   Lupidi, Marco
   Coscas, Gabriel
   Souied, Eric
TI IMPLICATIONS OF THE MORPHOLOGIC PATTERNS OF TYPE 1 MACULAR
   NEOVASCULARIZATION ON MACULAR ATROPHY GROWTH ON PATIENTS UNDER
   ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; macular atrophy; macular
   neovascularization; anti-vascular endothelial growth factor; multimodal
   imaging; optical coherence tomography angiography
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; GEOGRAPHIC ATROPHY; CHOROIDAL
   NEOVASCULARIZATION; DEGENERATION; PROGRESSION
AB Purpose: To evaluate the correspondence between macular atrophy (MA) progression and Type 1 macular neovascularization morphology during long-term anti-vascular endothelial growth factor treatment for exudative neovascular age-related macular degeneration.
   Methods: Retrospective review of consecutive patients with complete retinal pigment epithelium and outer retina atrophy overlying or in the proximity of macular neovascularization. The assessment of MA was based on spectral domain optical coherence tomography, en-face near infra-red imaging and fundus autofluorescence. Macular neovascularization blood flow morphology was evaluated by swept-source optical coherence tomography-angiography. Qualitative features were categorized per ETDRS sector as: immature, mature; and hypermature pattern. An automatic analysis was designed in MATLAB coding language to compute MA per ETDRS. Measurements were compared between the baseline and the last follow-up visit.
   Results: Twenty eyes from 20 patients were included; the mean age was 85.4 (8.3) years. The median follow-up was 1.85 (1.0-2.4) years and the median anti-vascular endothelial growth factor injection rate during follow-up was 4.0 (2.0-5.0) injections/year. During follow-up, sectors with persistence of an immature blood flow pattern had a lower MA growth rate than sectors with mature macular neovascularization flow patterns (P = 0.001).
   Conclusion: The presence of an immature blood flow pattern on optical coherence tomography-angiography is associated with a lower progression rate of MA.
C1 [Cabral, Diogo; Rodrigues, Catarina; Nogueira, Vanda] Inst Oftalmol Dr Gama Pinto, Lisbon, Portugal.
   [Cabral, Diogo; Pereira, Telmo] Univ Nova Lisboa, NOVA Med Sch 1, CEDOC, Lisbon, Portugal.
   [Cabral, Diogo; Pereira, Telmo] Univ Nova Lisboa, Fac Ciencias Med, Lisbon, Portugal.
   [Cabral, Diogo; Coscas, Florence; Francais, Catherine; Coscas, Gabriel] Ctr Ophtalmol Odeon, 113 Bd St Germain, Paris, France.
   [Coscas, Florence; Miere, Alexandra; Coscas, Gabriel; Souied, Eric] Univ Paris Est Creteil XII, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Laiginhas, Rita; Falcao, Manuel] Univ Porto, Ctr Hosp Entre Douro & Vouga, PDICSS, Fac Med, Porto, Portugal.
   [Lupidi, Marco] Univ Perugia, S Maria Misericordia Hosp, Dept Surg & Biomed Sci, Sect Ophthalmol, Perugia, Italy.
C3 Universidade Nova de Lisboa; Universidade Nova de Lisboa; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Universidade do
   Porto; University of Perugia
RP Coscas, F (通讯作者)，Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM coscas.f@gmail.com
RI Miere, Alexandra/AIC-4074-2022
OI Miere, Alexandra/0000-0003-4123-8210; Laiginhas,
   Rita/0000-0001-7275-6470; Pereira, Telmo/0000-0002-6903-9187; Rodrigues,
   Catarina/0000-0002-6097-2114
CR Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Capuano V, 2017, AM J OPHTHALMOL, V182, P45, DOI 10.1016/j.ajo.2017.07.009
   Christenbury JG, 2018, RETINA-J RET VIT DIS, V38, P1276, DOI 10.1097/IAE.0000000000001766
   Coscas F, 2019, BRIT J OPHTHALMOL, V103, P1342, DOI 10.1136/bjophthalmol-2018-313065
   Coscas F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205513
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Dansingani KK, 2015, OSLI RETINA, V46, P907, DOI 10.3928/23258160-20151008-02
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Miere A, 2019, RETINA-J RET VIT DIS, V39, P548, DOI 10.1097/IAE.0000000000001964
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Querques G, 2012, BRIT J OPHTHALMOL, V96, P1479, DOI 10.1136/bjophthalmol-2012-302191
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sandberg R, 2008, SCIENCE, V320, P1643, DOI 10.1126/science.1155390
   Spaide RF., 2019, OPHTHALMOLOGY
   Spaide RF, 2017, RETINA-J RET VIT DIS, V37, P609, DOI 10.1097/IAE.0000000000001575
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
NR 27
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2021
VL 41
IS 2
BP 287
EP 295
DI 10.1097/IAE.0000000000002842
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SL0VU
UT WOS:000656635200020
PM 32355125
DA 2022-11-30
ER

PT J
AU Song, X
   Xu, Q
   Li, HM
   Fan, Q
   Zheng, YF
   Zhang, Q
   Chu, CY
   Zhang, ZC
   Yuan, CL
   Ning, MA
   Bian, C
   Ma, K
   Qu, Y
AF Song, Xian
   Xu, Qian
   Li, Haiming
   Fan, Qian
   Zheng, Yefeng
   Zhang, Qiang
   Chu, Chunyan
   Zhang, Zhicheng
   Yuan, Chenglang
   Ning, Munan
   Bian, Cheng
   Ma, Kai
   Qu, Yi
TI Automatic quantification of retinal photoreceptor integrity to predict
   persistent disease activity in neovascular age-related macular
   degeneration using deep learning
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Article
DE neovascular age-related macular degeneration; image analysis; deep
   learning; optical coherence tomography; anti-VEGF therapy; retinal
   photoreceptor
ID EXTERNAL LIMITING MEMBRANE; OPTICAL COHERENCE TOMOGRAPHY; DISRUPTION;
   VEGF
AB PurposeUsing deep learning (DL)-based technique, we identify risk factors and create a prediction model for refractory neovascular age-related macular degeneration (nAMD) characterized by persistent disease activity (PDA) in spectral domain optical coherence tomography (SD-OCT) images. Materials and methodsA total of 671 typical B-scans were collected from 186 eyes of 186 patients with nAMD. Spectral domain optical coherence tomography images were analyzed using a classification convolutional neural network (CNN) and a fully convolutional network (FCN) algorithm to extract six features involved in nAMD, including ellipsoid zone (EZ), external limiting membrane (ELM), intraretinal fluid (IRF), subretinal fluid (SRF), pigment epithelium detachment (PED), and subretinal hyperreflective material (SHRM). Random forest models were probed to predict 1-year disease activity (stable, PDA, and cured) based on the quantitative features computed from automated segmentation and evaluated with cross-validation. ResultsThe algorithm to segment six SD-OCT features achieved the mean accuracy of 0.930 (95% CI: 0.916-0.943), dice coefficients of 0.873 (95% CI: 0.847-0.899), a sensitivity of 0.873 (95% CI: 0.844-0.910), and a specificity of 0.922 (95% CI: 0.905-0.940). The six-metric model including EZ and ELM achieved the optimal performance to predict 1-year disease activity, with an area under the receiver operating characteristic (ROC) curve (AUC) of 0.980, the accuracy of 0.930, the sensitivity of 0.920, and the specificity of 0.962. The integrity of EZ and ELM significantly improved the performance of the six-metric model than that of the four-metric model. ConclusionThe prediction model reveals the potential to predict PDA in nAMD eyes. The integrity of EZ and ELM constituted the strongest predictive factor for PDA in nAMD eyes in real-world clinical practice. The results of this study are a significant step toward image-guided prediction of long-term disease activity in the management of nAMD and highlight the importance of the automatic identification of photoreceptor layers.
C1 [Song, Xian; Xu, Qian; Li, Haiming; Fan, Qian; Qu, Yi] Shandong Univ, Qilu Hosp, Dept Geriatr, Jinan, Peoples R China.
   [Zheng, Yefeng; Zhang, Qiang; Chu, Chunyan; Yuan, Chenglang; Ning, Munan; Ma, Kai] Tencent Healthcare, Shenzhen, Peoples R China.
   [Zhang, Zhicheng; Bian, Cheng] ByteDance, Xiaohe Healthcare, Guangzhou, Peoples R China.
C3 Shandong University
RP Qu, Y (通讯作者)，Shandong Univ, Qilu Hosp, Dept Geriatr, Jinan, Peoples R China.
EM yiqucn@sdu.edu.cn
FU Qilu Hospital of Shandong University; Key Area Research and Development
   Program of Guangdong Province, China [2018B010111001]; Technique
   Innovation 2030 - "New Generation Artificial Intelligence" Project
   [2019AAA0104100]
FX This study was partly supported by the New Technology Funding of Qilu
   Hospital of Shandong University. YZ, QZ, KM, CC, CY, and MN received
   financial support from the Key Area Research and Development Program of
   Guangdong Province, China (Grant No. 2018B010111001), and the Technique
   Innovation 2030- "New Generation Artificial Intelligence" Project (Grant
   No. 2019AAA0104100).
CR Araujo RS, 2018, BIOCHIMIE, V155, P104, DOI 10.1016/j.biochi.2018.06.019
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, P3240, DOI 10.1167/iovs.16-21053
   Chen XJ, 2012, INVEST OPHTH VIS SCI, V53, P8042, DOI 10.1167/iovs.12-10083
   Cheng SY, 2020, P NATL ACAD SCI USA, V117, P13094, DOI 10.1073/pnas.2000339117
   Coscas F, 2015, INVEST OPHTH VIS SCI, V56, P4129, DOI 10.1167/iovs.15-16735
   Cuenca N, 2020, PROG RETIN EYE RES, V77, DOI 10.1016/j.preteyeres.2019.100828
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   Derouiche A, 2012, NEUROCHEM RES, V37, P2513, DOI 10.1007/s11064-012-0824-z
   Ding XY, 2018, GRAEF ARCH CLIN EXP, V256, P1831, DOI 10.1007/s00417-018-4060-3
   Dolz-Marco R, 2017, OPHTHALMOLOGY, V124, P1353, DOI 10.1016/j.ophtha.2017.03.043
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Hilely A, 2021, BRIT J OPHTHALMOL, V105, P1415, DOI 10.1136/bjophthalmol-2020-317326
   Holz FG, 2021, BRIT J OPHTHALMOL, DOI 10.1136/bjophthalmol-2021-319211
   Jaffe GJ, 2021, OPHTHALMOL RETINA, V5, P855, DOI 10.1016/j.oret.2020.12.009
   Jain A, 2013, MOL VIS, V19, P1760
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Loo J, 2020, OPHTHALMOLOGY, V127, P793, DOI 10.1016/j.ophtha.2019.12.015
   Martin DF, 2020, OPHTHALMOLOGY, V127, pS135, DOI 10.1016/j.ophtha.2020.01.029
   Mettu PS, 2021, PROG RETIN EYE RES, V82, DOI 10.1016/j.preteyeres.2020.100906
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Saxena S, 2017, RETINA-J RET VIT DIS, V37, P344, DOI 10.1097/IAE.0000000000001163
   Stoller GL, 2016, JAMA OPHTHALMOL, V134, P545, DOI 10.1001/jamaophthalmol.2016.0379
   Tan CS, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01582-y
   Toth CA, 2015, RETINA-J RET VIT DIS, V35, P1303, DOI 10.1097/IAE.0000000000000483
   Wolf-Schnurrbusch UEK, 2011, INVEST OPHTH VIS SCI, V52, P3334, DOI 10.1167/iovs.10-6097
   Woronkowicz M, 2020, GRAEF ARCH CLIN EXP, V258, P2373, DOI 10.1007/s00417-020-04869-4
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Xu YP, 2017, BIOMED OPT EXPRESS, V8, P4061, DOI 10.1364/BOE.8.004061
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
   Zekavat SM, 2022, OPHTHALMOLOGY, V129, P694, DOI 10.1016/j.ophtha.2022.02.001
NR 30
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD AUG 18
PY 2022
VL 16
AR 952735
DI 10.3389/fnins.2022.952735
PG 11
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 4G5CP
UT WOS:000849214700001
PM 36061600
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Shin, YI
   Kim, JM
   Lee, MW
   Jo, YJ
   Kim, JY
AF Shin, Yong-Il
   Kim, Ju Mi
   Lee, Min-Woo
   Jo, Young-Joon
   Kim, Jung-Yeul
TI Characteristics of the Foveal Microvasculature in Asian Patients with
   Dry Age-Related Macular Degeneration: An Optical Coherence Tomography
   Angiography Study
SO OPHTHALMOLOGICA
LA English
DT Article
DE Dry age-related macular degeneration; Optical coherence tomography
   angiography; Ganglion cell-inner plexiform layer; Vessel density;
   Perfusion density
ID NERVE-FIBER LAYER; GANGLION-CELL COMPLEX; INNER PLEXIFORM LAYER;
   CHOROIDAL THICKNESS; PREVALENCE; MACULOPATHY; CHORIOCAPILLARIS; ATROPHY;
   QUANTIFICATION; DRUSEN
AB Purpose: To evaluate changes in the foveal microvasculature in patients with dry age-related macular degeneration (dry AMD) using optical coherence tomography angiography (OCTA). Methods: Eighty-three eyes with dry AMD and 83 age- and sex-matched normal eyes were enrolled. A 3 x 3 mm(2) OCTA (Zeiss HD-OCT 5000 with AngioPlex; Carl Zeiss Meditec, Dublin, CA, USA) scan was used to acquire images. Vessel density (VD), perfusion density (PD), and the foveal avascular zone (FAZ) of the superficial capillary plexus were analyzed. Results: The VD of the full area, central area, and inner ring of the dry AMD patients (18.61, 8.41, and 20.45, respectively) were significantly lower than those of the controls (20.06, 11.09, and 22.51, respectively). The PD of the full area, central area, and inner ring of the dry AMD patients (0.34, 0.15, and 0.37, respectively) were also significantly lower than those of the controls (0.36, 0.19, and 0.40, respectively). The FAZ area and perimeter in the dry AMD patients (0.29 mm(2) and 2.47 mm, respectively) were larger than those in the controls (0.23 mm(2) and 2.09 mm, respectively). The FAZ circularity index in the dry AMD patients was smaller than that in the controls (0.61 vs. 0.66). Using univariate linear regression, age, best-corrected visual acuity (BCVA), central macular thickness (CMT), and ganglion cell-inner plexiform layer (GC-IPL) thickness were associated with both VD and PD of the full area. Using multivariate analysis, only GC-IPL thickness was significantly associated with the VD and PD of the full area (p = 0.001 and p = 0.004, respectively). Conclusions: OCTA revealed changes in the foveal microcirculation of patients with dry AMD. Age, BCVA, CMT, and GC-IPL thickness should be considered when analyzing the OCTA data of patients with dry AMD. GC-IPL thickness is particularly important during clinical evaluation of VD and PD in patients with dry AMD.
C1 [Shin, Yong-Il; Kim, Ju Mi; Lee, Min-Woo; Jo, Young-Joon; Kim, Jung-Yeul] Chungnam Natl Univ, Dept Ophthalmol, Coll Med, Daejeon, South Korea.
C3 Chungnam National University
EM kimjy@cnu.ac.kr
OI Kim, Jung yeul/0000-0003-3679-1310
CR [Anonymous], 1999, CONTROL CLIN TRIALS, DOI 10.1016/S0197-2456(99)00031-8
   Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   Borrelli E, 2017, AM J OPHTHALMOL, V181, P1, DOI 10.1016/j.ajo.2017.06.005
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Cicinelli MV, 2018, BRIT J OPHTHALMOL, V102, P1192, DOI 10.1136/bjophthalmol-2017-311317
   De Vitis LA, 2016, OPHTHALMIC RES, V56, P155, DOI 10.1159/000447094
   Durbin MK, 2017, JAMA OPHTHALMOL, V135, P370, DOI 10.1001/jamaophthalmol.2017.0080
   Francis PJ, 2003, BRIT J OPHTHALMOL, V87, P512, DOI 10.1136/bjo.87.4.512-a
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Kim K, 2018, BRIT J OPHTHALMOL, V102, P1226, DOI 10.1136/bjophthalmol-2017-311149
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kojima M, 2004, RETINA-J RET VIT DIS, V24, P297, DOI 10.1097/00006982-200404000-00017
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Meenken C, 1998, ANN NEUROL, V43, P534, DOI 10.1002/ana.410430420
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Munk MR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177059
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Remsch H, 2000, GRAEF ARCH CLIN EXP, V238, P960, DOI 10.1007/s004170000202
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Rogala J, 2015, INVEST OPHTH VIS SCI, V56, P1689, DOI 10.1167/iovs.14-16221
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Savastano MC, 2015, RETINA-J RET VIT DIS, V35, P2196, DOI 10.1097/IAE.0000000000000635
   Shin IH, 2018, RETINA-J RET VIT DIS, V38, P253, DOI 10.1097/IAE.0000000000001535
   Sigler EJ, 2013, INVEST OPHTH VIS SCI, V54, P6307, DOI 10.1167/iovs.13-12653
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Tornerup NR, 2000, OPHTHALMOLOGY, V107, P397, DOI 10.1016/S0161-6420(99)00053-6
   Toto L, 2017, BRIT J OPHTHALMOL, V101, P774, DOI 10.1136/bjophthalmol-2016-309160
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2004, BRIT J OPHTHALMOL, V88, P104, DOI 10.1136/bjo.88.1.104
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Yenice E, 2015, EYE, V29, P1076, DOI 10.1038/eye.2015.86
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 41
TC 5
Z9 5
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD MAR
PY 2020
VL 243
IS 2
BP 145
EP 153
DI 10.1159/000503295
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LE6EW
UT WOS:000526817700009
PM 31645037
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Wei, WB
   Xu, L
   Wang, YX
AF Jonas, Jost B.
   Wei, Wen Bin
   Xu, Liang
   Wang, Ya Xing
TI Systemic inflammation and eye diseases. The Beijing Eye Study
SO PLOS ONE
LA English
DT Article
ID C-REACTIVE PROTEIN; COMPLEMENT FACTOR-H; POLYPOIDAL CHOROIDAL
   VASCULOPATHY; TYPE-2 DIABETES-MELLITUS; MACULAR DEGENERATION; COGNITIVE
   IMPAIRMENT; RISK-FACTORS; RETINOPATHY; ASSOCIATION; PREVALENCE
AB Purpose
   Systemic inflammation is potentially associated with ocular diseases such as late age-related macular degeneration (AMD). Using the serum concentration of high-sensitive C-reactive protein (hs-CRP) as surrogate of systemic inflammation, we examined potential associations between the serum hs-CRP concentration and the presence and degree of eye diseases.
   Methods
   The population-based Beijing Eye Study included 3468 Chinese individuals. The study participants underwent a standardized interview and a detailed ophthalmic examination. The serum concentration of hs-CRP was determined.
   Results
   Out of 3468 participants, 2452 (70.7%) individuals (mean age:63.4 +/- 9.4 year; range:50-91 years) had hs-CRP measurements (mean:1.96 +/- 4.07mg/L). In multivariate analysis, higher serum concentration of hs-CRP was significantly (regression coefficient r: 0.21) associated with a higher level of diabetic retinopathy (P= 0.007; standardized regression coefficient beta:0.06; non-standardized regression coefficient B:1.35; 95% confidence interval (CI):0.37,2.22) and polypoidal choroidal vasculopathy (P= 0.002;beta:0.06;B:6.22;95% CI:2.24,10.2) after adjusting for higher serum concentration of high-density lipoproteins (P<0.001;beta:-0.12;B:-1.31;95%CI:-1.77,-0.85), higher body mass index (P= 0.01; beta:0.06;B:0.06;95%CI:0.01, 0.11), lower level of education (P = 0.04;beta:-0.06;B:0.22;95%CI:-0.42,-0.02), lower cognitive function score (P= 0.01;beta:-0.07;B:-0.08;95% CI:-0.13,-0.02). If the presences of other ocular diseases were added to the model, the presence of glaucoma (P = 0.99), open-angle glaucoma (P = 0.80), angle-closure glaucoma (P= 0.67), pseudoexfoliation (P = 0.18), nuclear cataract (P = 0.30), cortical cataract (P = 0.15), subcapsular cataract (P= 0.59), retinal vein occlusions (P= 0.33), central serous choroidopathy (P = 0.44), early stage of age-related macular degeneration (AMD) (P = 0.46), intermediate stage of AMD (P= 0.20) and late stage of AMD (P= 0.91) including geographic atrophy (P= 0.60) or neovascular AMD (P= 0.68) were not significantly associated with the serum concentration of hs-CRP.
   Conclusions
   In Chinese aged 50+ years, higher serum concentration of hs-CRP was significantly associated with a higher level of diabetic retinopathy and higher frequency of polypoidal choroidal vasculopathy. Other major ocular disorders, namely glaucoma including open-angle glaucoma and angle-closure glaucoma, pseudoexfoliation, nuclear, cortical or subcapsular cataract, retinal vein occlusions, central serous choroidopathy, early, intermediate or late stage of AMD including geographic atrophy, were not significantly associated with hs-CRP serum concentrations. It suggests that these diseases, in contrast to diabetic retinopathy and polypoidal choroidal vasculopathy, were not associated with a major systemic inflammatory component.
C1 [Jonas, Jost B.; Xu, Liang; Wang, Ya Xing] Capital Med Univ, Beijing Tongren Hosp, Beijing Key Lab Ophthalmol & Visual Sci, Beijing Tongren Eye Ctr,Beijing Inst Ophthalmol, Beijing, Peoples R China.
   [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Mannheim, Germany.
   [Wei, Wen Bin] Capital Med Univ, Beijing Tongren Hosp, Beijing Key Lab Intraocular Tumor Diag & Treatmen, Beijing Tongren Eye Ctr, Beijing, Peoples R China.
C3 Capital Medical University; Ruprecht Karls University Heidelberg;
   Capital Medical University
RP Wang, YX (通讯作者)，Capital Med Univ, Beijing Tongren Hosp, Beijing Key Lab Ophthalmol & Visual Sci, Beijing Tongren Eye Ctr,Beijing Inst Ophthalmol, Beijing, Peoples R China.; Wei, WB (通讯作者)，Capital Med Univ, Beijing Tongren Hosp, Beijing Key Lab Intraocular Tumor Diag & Treatmen, Beijing Tongren Eye Ctr, Beijing, Peoples R China.
EM weiwenbintr@163.com; yaxingw@gmail.com
RI wang, YA XING/K-9671-2016
OI wang, YA XING/0000-0003-2749-7793; Jonas, Jost/0000-0003-2972-5227
FU National Natural Science Foundation of China [81570835]
FX Supported by National Natural Science Foundation of China (grant #
   81570835). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Aryan Z, 2018, ANN NUTR METAB, V72, P287, DOI 10.1159/000488537
   Cheng HC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110818
   Chirco KR, 2016, J PATHOL, V240, P173, DOI 10.1002/path.4766
   Chuengsamarn S, 2017, DIABETES METAB SYND, V11, P103, DOI 10.1016/j.dsx.2016.08.012
   Cipriani V, 2017, JAMA OPHTHALMOL, V135, P909, DOI 10.1001/jamaophthalmol.2017.2191
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dong N, 2015, INVEST OPHTH VIS SCI, V56, P4177, DOI 10.1167/iovs.15-16470
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Jonas JB, 2009, ACTA OPHTHALMOL, V87, P247, DOI 10.1111/j.1755-3768.2008.01385.x
   Joussen AM, 2004, FASEB J, V18, P1450, DOI 10.1096/fj.03-1476fje
   Kaptoge S, 2012, NEW ENGL J MED, V367, P1310, DOI 10.1056/NEJMoa1107477
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Laursen JVN, 2013, CURR EYE RES, V38, P174, DOI 10.3109/02713683.2012.713153
   Lim LS, 2010, INVEST OPHTH VIS SCI, V51, P4458, DOI 10.1167/iovs.09-4939
   Noble JM, 2010, ARCH NEUROL-CHICAGO, V67, P87, DOI 10.1001/archneurol.2009.308
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Peng DF, 2015, BMC ENDOCR DISORD, V15, DOI 10.1186/s12902-015-0006-5
   Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921
   Roberts RO, 2009, ALZHEIMERS DEMENT, V5, P398, DOI 10.1016/j.jalz.2009.01.025
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Sabatine MS, 2007, CIRCULATION, V115, P1528, DOI 10.1161/CIRCULATIONAHA.106.649939
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Sasongko MB, 2015, DIABETIC MED, V32, P686, DOI 10.1111/dme.12640
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Song J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144406
   Tang J, 2011, PROG RETIN EYE RES, V30, P343, DOI 10.1016/j.preteyeres.2011.05.002
   Wang YX, 2010, AM J OPHTHALMOL, V150, P917, DOI 10.1016/j.ajo.2010.06.037
   Xu J, 2013, OPHTHALMOLOGY, V120, P2023, DOI 10.1016/j.ophtha.2013.03.009
   Yan YN, 2015, OPHTHALMOLOGY, V122, P1873, DOI 10.1016/j.ophtha.2015.05.031
   Yang HS, 2014, INVEST OPHTH VIS SCI, V55, P5989, DOI 10.1167/iovs.14-14864
   Yang XF, 2016, INT J OPHTHALMOL-CHI, V9, P111, DOI 10.18240/ijo.2016.01.19
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhou JQ, 2013, OPHTHALMOLOGY, V120, P803, DOI 10.1016/j.ophtha.2012.09.033
   ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008
NR 39
TC 8
Z9 9
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 3
PY 2018
VL 13
IS 10
AR e0204263
DI 10.1371/journal.pone.0204263
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GV7VQ
UT WOS:000446342400046
PM 30281641
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Solomon, SD
   Lindsley, K
   Vedula, SS
   Krzystolik, MG
   Hawkins, BS
AF Solomon, Sharon D.
   Lindsley, Kristina
   Vedula, Satyanarayana S.
   Krzystolik, Magdalena G.
   Hawkins, Barbara S.
TI Anti-vascular endothelial growth factor for neovascular age-related
   macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE Angiogenesis Inhibitors [therapeutic use]; Antibodies, Monoclonal
   [therapeutic use]; Antibodies, Monoclonal, Humanized [therapeutic use];
   Aptamers, Nucleotide [therapeutic use]; Choroidal Neovascularization;
   Intravitreal Injections; Macular Degeneration [drug therapy]; Porphyrins
   [therapeutic use]; Randomized Controlled Trials as Topic; Ranibizumab;
   Vascular Endothelial Growth Factor A [antagonists & inhibitors]; Visual
   Acuity [drug effects]; Aged; Humans; Middle Aged
ID VERTEPORFIN PHOTODYNAMIC THERAPY; BEVACIZUMAB AVASTIN THERAPY;
   VISION-RELATED FUNCTION; COST-UTILITY ANALYSIS; INTRAVITREAL
   BEVACIZUMAB; CHOROIDAL NEOVASCULARIZATION; VISUAL-ACUITY; RANIBIZUMAB
   TREATMENT; PEGAPTANIB SODIUM; CLINICAL-TRIAL
AB Background
   Age-related macular degeneration (AMD) is the most common cause of uncorrectable severe vision loss in people aged 55 years and older in the developed world. Choroidal neovascularization (CNV) secondary to neovascular AMD accounts for most AMD-related severe vision loss. Anti-vascular endothelial growth factor (anti-VEGF) agents, injected intravitreally, aim to block the growth of abnormal blood vessels in the eye to prevent vision loss and, in some instances, improve vision.
   Objectives
   To investigate: (1) the ocular and systemic effects of, and quality of life associated with, intravitreally injected anti-VEGF agents (pegaptanib, ranibizumab, and bevacizumab) for the treatment of neovascular AMD compared with no anti-VEGF treatment; and (2) the relative effects of one anti-VEGF agent compared with another when administered in comparable dosages and regimens.
   Search methods
   We searched Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group Trials Register) (2014, Issue 3), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLD MEDLINE (January 1946 to March 2014), EMBASE (January 1980 to March 2014), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 toMarch 2014), the meta Register of Controlled Trials (mRCT) (www.controlledtrials.com), Clinical Trials.gov (www.clinicaltrials.gov) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We used no date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 27 March 2014.
   Selection criteria
   We included randomized controlled trials (RCTs) that evaluated pegaptanib, ranibizumab, or bevacizumab versus each other or a control treatment (e.g., sham treatment or photodynamic therapy). All trials followed participants for at least one year.
   Data collection and analysis
   Two review authors independently screened records, extracted data, and assessed risks of bias. We contacted trial authors for additional data. We analyzed outcomes as risk ratios (RRs) or mean differences (MDs). We used the standard methodological procedures expected by The Cochrane Collaboration.
   Main results
   We included 12 RCTs including a total of 5496 participants with neovascular AMD (the number of participants per trial ranged from 28 to 1208). One trial compared pegaptanib, three trials ranibizumab, and two trials bevacizumab versus controls; six trials compared bevacizumab with ranibizumab. Four trials were conducted by pharmaceutical companies; none of the eight studies which evaluated bevacizumab were funded by pharmaceutical companies. The trials were conducted at various centers across five continents (North and South America, Europe, Asia and Australia). The overall quality of the evidence was very good, with most trials having an overall low risk of bias.
   When compared with control treatments, participants who received any of the three anti-VEGF agents were more likely to have gained 15 letters or more of visual acuity, lost fewer than 15 letters of visual acuity, and had vision 20/200 or better after one year of follow up. Visual acuity outcomes after bevacizumab and ranibizumab were similar when the same regimens were compared in the same RCTs, despite the substantially lower cost for bevacizumab compared with ranibizumab. No trial directly compared pegaptanib with other anti-VEGF agents; however, when compared with controls, ranibizumab or bevacizumab yielded larger improvements in visual acuity outcomes than pegaptanib.
   Participants treated with anti-VEGFs showed improvements in morphologic outcomes (e.g., size of CNV or central retinal thickness) compared with participants not treated with anti-VEGF agents. There was less reduction in central retinal thickness among bevacizumab-treated participants than among ranibizumab-treated participants after one year (MD -13.97 mu m; 95% confidence interval (CI) -26.52 to -1.41); however, this difference is within the range of measurement error and we did not interpret it as being clinically meaningful.
   Ocular inflammation and increased intraocular pressure after intravitreal injection were the most frequently reported serious ocular adverse events. Endophthalmitis was reported in fewer than 1% of anti-VEGF treated participants; no cases were reported in control groups. The occurrence of serious systemic adverse events was comparable across anti-VEGF-treated groups and control groups; however, the numbers of events and trial participants may have been insufficient to detect a meaningful difference between groups. Data for visual function, quality of life, and economic outcomes were sparsely measured and reported.
   Authors' conclusions
   The results of this review indicate the effectiveness of anti-VEGF agents (pegaptanib, ranibizumab, and bevacizumab) in terms of maintaining visual acuity; ranibizumab and bevacizumab were also shown to improve visual acuity. The information available on the adverse effects of each medication do not suggest a higher incidence of potentially vision-threatening complications with intravitreal injection compared with control interventions; however, clinical trial sample sizes may not have been sufficient to detect rare safety outcomes. Research evaluating variable dosing regimens with anti-VEGF agents, effects of long-term use, combination therapies (e.g., anti-VEGF treatment plus photodynamic therapy), and other methods of delivering the agents should be incorporated into future Cochrane reviews.
C1 [Solomon, Sharon D.; Hawkins, Barbara S.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
   [Lindsley, Kristina] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 North Wolfe St,Mail Room E6132, Baltimore, MD 21205 USA.
   [Vedula, Satyanarayana S.] Johns Hopkins Univ, Baltimore, MD USA.
   [Krzystolik, Magdalena G.] Southern New England Retina Associates, Providence, RI USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Bloomberg School of Public Health; Johns
   Hopkins University
RP Lindsley, K (通讯作者)，Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 North Wolfe St,Mail Room E6132, Baltimore, MD 21205 USA.
EM klindsley@jhu.edu
FU Southern New England Retina Associates, Providence RI, USA; Brown
   University, USA; Johns Hopkins Medical Institutions, Johns Hopkins
   University, USA; National Eye Institute, National Institutes of Health,
   USA [1 U01 EY020522]; Wilmer Eye Institute from Research to Prevent
   Blindness, New York, New York, USA; National Institute for Health
   Research (NIHR), UK; Department of Health; NIHR; NATIONAL EYE INSTITUTE
   [U01EY020522] Funding Source: NIH RePORTER
FX Internal sources; Southern New England Retina Associates, Providence RI,
   USA.; Brown University, USA.; Johns Hopkins Medical Institutions, Johns
   Hopkins University, USA.; External sources; Cochrane Eyes and Vision
   Group US Project supported by Grant 1 U01 EY020522, National Eye
   Institute, National Institutes of Health, USA.; SDS and BSH received
   support during the preparation of this review from an unrestricted grant
   to the Wilmer Eye Institute from Research to Prevent Blindness, New
   York, New York, USA.; National Institute for Health Research (NIHR),
   UK.; Richard Wormald, Co-ordinating Editor for the Cochrane Eyes and
   Vision Group (CEVG) acknowledges financial support for his CEVG research
   sessions from the Department of Health through the award made by the
   National Institute for Health Research to Moorfields Eye Hospital NHS
   Foundation Trust and UCL Institute of Ophthalmology for a Specialist
   Biomedical Research Centre for Ophthalmology.; The NIHR also funds the
   CEVG Editorial Base in London.; The views expressed in this publication
   are those of the authors and not necessarily those of the NIHR, NHS, or
   the Department of Health.
CR Abba K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008122.pub2
   Abraham P, EUR VITREORETINAL 1
   Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Age-Related Eye Disease Study Research Group, 2001, ARCH OPHTHALMOL-CHIC, V119, P1414
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Alexander SG, 2006, INVESTIGATIVE OPHTHA, V47
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 2012, REV MAN REVMAN COMP
   [Anonymous], 2012, OPHTHALMOLOGY, V119, P1508
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Apte RS, 2007, OPHTHALMOLOGY, V114, P1702, DOI 10.1016/j.ophtha.2007.02.021
   Barbazetto I, 2010, RETINA-J RET VIT DIS, V30, P1376, DOI 10.1097/IAE.0b013e3181dcfb0b
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Benz MS, 2008, INVESTIGATIVE OPHTHA, V49
   Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Bolz M, 2008, INVESTIGATIVE OPHTHA, V49
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler NM, 2013, OPHTHALMOLOGY, V120, P160, DOI 10.1016/j.ophtha.2012.07.027
   Bressler NM, 2012, RETINA-J RET VIT DIS, V32, P1821, DOI 10.1097/IAE.0b013e31825db6ba
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Bressler NM, 2006, EUR VITREORETINAL 2
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown DM, 2006, INVESTIGATIVE OPHTHA, V47
   Brown DM, 2008, RANIBIZUMAB LUCENTIS, P78
   Brown DM, 2007, INVESTIGATIVE OPHTHA, V48
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Bunce C, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-58
   Carneiro AM, 2012, CLIN OPHTHALMOL, V6, P1149, DOI 10.2147/OPTH.S33017
   Centers for Medicare and Medicaid Services, A49034 CTR MED MED S
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chakravarthy U., 2006, EFFICACY SAFETY PEGA, P116
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, BRIT J OPHTHALMOL, V96, P1351, DOI 10.1136/bjophthalmol-2011-301444
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Chang TS, 2006, INVESTIGATIVE OPHTHA, V47
   Chang TS, 2006, EUR VITREORETINAL 2
   Chang TS, 2006, RANIBIZUMAB LUCENTIS, P106
   Chang TS, 2007, INVESTIGATIVE OPHTHA, V48
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Christoforidis JB, 2005, INVEST OPHTH VIS SCI, V46
   Ciulla TA, 2007, INVESTIGATIVE OPHTHA, V48
   Cohen D, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2006
   Cohen SY, 2008, GRAEF ARCH CLIN EXP, V246, P1527, DOI 10.1007/s00417-008-0890-8
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Costagliola C, 2010, BRIT J OPHTHALMOL, V94, P180, DOI 10.1136/bjo.2009.159343
   Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   D'Amico DF, 2005, MACUGEN NEOVASCULAR, P261
   D'Amico DJ, 2004, INVESTIGATIVE OPHTHA, V45
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Donahue SP, 2010, AM J OPHTHALMOL, V150, P287, DOI 10.1016/j.ajo.2010.04.006
   Earnshaw SR, 2007, CLIN THER, V29, P2096, DOI 10.1016/j.clinthera.2007.09.001
   Erdokur O, 2009, RETINA VITREUS, V17, P245
   Eyetech Pharmaceuticals Inc Pfizer. Inc., PEG SOD INJ TREATM N
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P701, DOI 10.1097/IAE.0b013e3180654240
   Fang K, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/676049
   FDA, MAC PEG SOD INJ TREA
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Fletcher EC, 2008, OPHTHALMOLOGY, V115, P2192, DOI 10.1016/j.ophtha.2008.07.018
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GHAFOUR IM, 1983, BRIT J OPHTHALMOL, V67, P209, DOI 10.1136/bjo.67.4.209
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gragoudas ES, 2004, INVESTIGATIVE OPHTHA, V45
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Hahn R, 2007, OPHTHALMOLOGE, V104, P588, DOI 10.1007/s00347-007-1547-4
   Hatta Y, 2010, RETINA-J RET VIT DIS, V30, P495, DOI 10.1097/IAE.0b013e3181bcedbe
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2005, AM SOC RET SPEC 23 A
   Heier JS, 2007, INVESTIGATIVE OPHTHA, V48
   Heier JS, 2006, INVESTIGATIVE OPHTHA, V47
   Heier JS, 2006, OPHTHALMOLOGY, V113, pe1, DOI DOI 10.1016/J.0PHTHA.2005.10.052)
   HERNANDEZPASTOR LJ, 2010, INVEST OPHTHALMOL, V248, P467, DOI DOI 10.1007/S00417-009-1156-9
   HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001
   Ho A, 2006, RANIBIZUMAB NEOVASCU, P108
   Ho AC, 2008, RANIBIZUMAB LUCENTIS, P164
   Ho AC, 2008, INVESTIGATIVE OPHTHA, V49
   Holekamp NM, 2006, 2 YEAR FA OCT RESULT, P194
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Hurley Susan F, 2008, Cost Eff Resour Alloc, V6, P12, DOI 10.1186/1478-7547-6-12
   HYMAN L, 1987, EYE, V1, P330, DOI 10.1038/eye.1987.53
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Jackson TL, 2014, RETINA-J RET VIT DIS, V34, P568, DOI 10.1097/IAE.0b013e3182a487be
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Hernandez-Pastor LJ, 2008, CLIN THER, V30, P2436, DOI 10.1016/j.clinthera.2008.12.025
   Javitt JC, 2008, VALUE HEALTH, V11, P563, DOI 10.1111/j.1524-4733.2007.00283.x
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kaiser PK, 2006, SUBGROUPS ANAL ONE Y, P195
   Keane PA, 2012, INVEST OPHTH VIS SCI, V53, P1152, DOI 10.1167/iovs.11-8130
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Kokame GT., 2006, ANATOMIC OUTCOMES MA, P110
   Korobelnik JF., EUR VITREORETINAL 1
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Krzystolik MG, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139
   Kuppermann BD, 2005, V I S I O N STUDY RE, P178
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Laganovska G, 2013, 1 IN HUMAN RESULTS R, P136
   Lai TYY, 2009, RETINA-J RET VIT DIS, V29, P1218, DOI 10.1097/IAE.0b013e3181b32c45
   Lanzetta P., 2008, INVESTIGATIVE OPHTHA, V49
   Lanzetta P, EUR VITREORETINAL 1
   Larsen Michael, 2005, Ugeskr Laeger, V167, P3301
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Leys A, 2008, EYE, V22, P792, DOI 10.1038/sj.eye.6702900
   Li J, 2013, INT J OPHTHALMOL-CHI, V6, P169, DOI 10.3980/j.issn.2222-3959.2013.02.12
   Li XX, 2012, OPHTHALMOLOGY, V119, P2087, DOI 10.1016/j.ophtha.2012.05.016
   Loewenstein A, EUR VITREORETINAL 1
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Maguire Maureen G, 2012, LDI Issue Brief, V17, P1
   Marcus DM, 2008, INVESTIGATIVE OPHTHA, V49
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martin DF, COMP AG REL MAC DEG
   Matthe E, 2011, OPHTHALMOLOGE, V108, P337, DOI 10.1007/s00347-010-2300-y
   McDonald HR, 2006, ONE YEAR RESULTS ANC, P114
   Messori A, 2010, AM J OPHTHALMOL, V149, P867, DOI 10.1016/j.ajo.2009.12.039
   Michels M, 2008, INVESTIGATIVE OPHTHA, V49
   Michels SM, 2007, INVESTIGATIVE OPHTHA, V48
   Mieler W., 2005, INVESTIGATIVE OPHTHA, V46
   Mieler WF, EUR VITREORETINAL 1
   Mieler WF, 2006, INVESTIGATIVE OPHTHA, V47
   Miller JW, 2006, INVESTIGATIVE OPHTHA, V47
   Mills E, 2007, J CLIN EPIDEMIOL, V60, P456, DOI 10.1016/j.jclinepi.2006.09.001
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Modarres M, 2009, RETINA-J RET VIT DIS, V29, P319, DOI 10.1097/IAE.0b013e318198148e
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Neubauer AS, 2007, KLIN MONATSBL AUGENH, V224, P727, DOI 10.1055/s-2007-963470
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Nowak MS, 2012, MED SCI MONITOR, V18, pCR374, DOI 10.12659/MSM.882907
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Parodi MB, 2012, ARCH OPHTHALMOL-CHIC, V130, P934, DOI 10.1001/archophthalmol.2011.2617
   Patel M, 2006, EUR VITREORETINAL SO
   Patel PJ, 2007, INVESTIGATIVE OPHTHA, V48
   Patel PJ, 2011, INVEST OPHTH VIS SCI, V52, P3089, DOI 10.1167/iovs.10-6208
   Patel PJ, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-56
   Prager F, 2008, INVESTIGATIVE OPHTHA, V49
   Pulido Jose S, 2002, Trans Am Ophthalmol Soc, V100, P85
   Pulido JS, 2005, CAN J OPHTHALMOL, V40, P332, DOI 10.1016/S0008-4182(05)80076-6
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rakic JM, 2005, NEW ENGL J MED, V352, P1720
   Rasmussen A, 2014, CURR OPIN OPHTHALMOL, V25, P158, DOI 10.1097/ICU.0000000000000050
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Regillo CD, VISION SPECIFIC QUAL
   Regillo CD, 2008, PIER STUDY GROUP RAN, P166
   Reichel E, 2008, RANIBIZUMAB LUCENTIS, P168
   Reichel E, 2006, SUBGROUP ANAL 2 YEAR, P194
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rosenfeld PJ, 2007, INVESTIGATIVE OPHTHA, V48
   Rosenfeld PJ, 2008, INVESTIGATIVE OPHTHA, V49
   Sacu S, 2009, EYE, V23, P2223, DOI 10.1038/eye.2008.423
   Sadda SR, 2007, INVESTIGATIVE OPHTHA, V48
   Sadda SR, 2010, RETINA-J RET VIT DIS, V30, P1390, DOI 10.1097/IAE.0b013e3181e44599
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmid-Kubista KE, 2009, BRIT J OPHTHALMOL, V93, P914, DOI 10.1136/bjo.2008.144410
   Schmid-Kubista KE, 2011, CURR EYE RES, V36, P958, DOI 10.3109/02713683.2011.597536
   Schmid-Kubista KE, 2008, INVESTIGATIVE OPHTHA, V49
   Schmidt-Erfurth U, EUR VITREORETINAL 1
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Schmucker C, 2010, CURR OPIN OPHTHALMOL, V21, P218, DOI 10.1097/ICU.0b013e3283386783
   Schwartz SG, 2007, INVESTIGATIVE OPHTHA, V48
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Singerman LI, 2006, 2 YEAR SYSTEMIC SAFE, P120
   Sjolie Anne Katrin, 2005, Ugeskr Laeger, V167, P3267
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Slakter JS, 2007, INVESTIGATIVE OPHTHA, V48
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Solomon SD, 2007, ARCH OPHTHALMOL-CHIC, V125, P1323
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Subramanian ML, 2010, AM J OPHTHALMOL, V149, P867, DOI 10.1016/j.ajo.2009.12.040
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
   Suner IJ, 2007, INVESTIGATIVE OPHTHA, V48
   Suner IJ, 2009, INVEST OPHTH VIS SCI, V50, P3629, DOI 10.1167/iovs.08-3225
   Sutter FK, 2008, INVESTIGATIVE OPHTHA, V49
   Tano Y., 2008, INVESTIGATIVE OPHTHA, V49
   Tano Y, 2010, ACTA OPHTHALMOL, V88, P309, DOI 10.1111/j.1755-3768.2009.01843.x
   Tano Yasuo, 2008, Nippon Ganka Gakkai Zasshi, V112, P590
   Tielsch JA, 1994, VISION PROBLEMS US R
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Vallance JH, 2010, EYE, V24, P1561, DOI 10.1038/eye.2010.84
   Van Kerckhoven W, 2001, Bull Soc Belge Ophtalmol, P75
   Vedula SS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub2
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
   Webster MK, 2007, INVESTIGATIVE OPHTHA, V48
   Webster MK, 2006, INVESTIGATIVE OPHTHA, V47
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Weinberg DV, 2013, OPHTHALMOLOGY, V120, P1278, DOI 10.1016/j.ophtha.2012.11.042
   Win PH, 2008, INVESTIGATIVE OPHTHA, V49
   Wolf S, 2008, INVESTIGATIVE OPHTHA, V49
   Wolf S, 2011, BRIT J OPHTHALMOL, V95, P1713, DOI 10.1136/bjophthalmol-2011-300471
   Wolowacz SE, 2007, PHARMACOECONOMICS, V25, P863, DOI 10.2165/00019053-200725100-00005
   Wormald R, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub2
   Yang YC, 2007, INVESTIGATIVE OPHTHA, V48
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Yu EB, 2007, INVESTIGATIVE OPHTHA, V48
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
   Zlateva G, 2006, INVESTIGATIVE OPHTHA, V47
NR 219
TC 236
Z9 241
U1 4
U2 46
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2014
IS 8
AR CD005139
DI 10.1002/14651858.CD005139.pub3
PG 158
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA V43TJ
UT WOS:000209703400002
PM 25170575
OA Green Accepted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Seddon, JM
   Cote, J
   Rosner, B
AF Seddon, JM
   Cote, J
   Rosner, B
TI Progression of age-related macular degeneration - Association with
   dietary fat, transunsaturated fat, nuts, and fish intake
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID CORONARY-HEART-DISEASE; FOOD FREQUENCY QUESTIONNAIRE; SUDDEN CARDIAC
   DEATH; CLASSIFICATION-SYSTEM; VITAMIN-C; RISK; MACULOPATHY; CONSUMPTION;
   WOMEN; SMOKING
AB Background: Individuals with early or intermediate stages of age-related macular degeneration (AMD) make up a large, growing segment of the elderly population. Evidence is sparse regarding modifiable factors that may decrease the risk of progression to the advanced forms of AMD.
   Objective: To advise patients with a high risk for advanced forms of AMD about preventive measures through our evaluation of the relationship between dietary fat intake and the progression of early or intermediate AMD to the advanced stages of the disease associated with visual loss.
   Design: A prospective cohort study with an average follow-up time of 4.6 years.
   Setting: A hospital-based clinical retinal practice specializing in macular degeneration.
   Patients: The 261 participants were aged 60 years and older and had some sign of nonexudative AMD and visual acuity of 20/200 or better in at least 1 eye.
   Main Outcome Measure: Progression to advanced AMD, which was defined as having geographic atrophy or neovascular disease.
   Results: Higher total fat intake increased the risk of progression to the advanced forms of AMD, with a relative risk (RR) of 2.90 (95% confidence interval, 1.15-7.32) for the highest fat-intake quartile relative to the lowest fat-intake quartile, after controlling for other factors (P trend=.01). Animal fat intake was associated with a 2-fold increased risk of progression (RR, 2.29 for the highest quartile compared with the lowest quartile; 95% confidence interval, 0.91-5.72), although the trend for increasing risk with higher animal fat intake was not significant (P=.09). Higher vegetable fat intake had a stronger relationship with increased risk of AMD progression with an RR of 3.82 (95% confidence interval, 1.58-9.28) for the highest quartile compared with the lowest quartile (P trend=.003). Saturated, monounsaturated, polyunsaturated, and transunsaturated fats increased the likelihood of progression (RR, 2.09 and P trend=.08; RR, 2.21 and P trend=.04; RR, 2.28 and P trend=.04; RR, 2.39 and P trend=.008, respectively). Higher fish intake was associated with a lower risk of AMD progression among subjects with lower linoleic acid intake. Processed baked goods, which are higher in some of these fats, increased the rate of AMD progression approximately 2-fold, and huts were protective.
   Conclusions: Among individuals with the early or intermediate stages of AMD, total and specific types of fat intake, as well as some fat-containing food groups, modified the risk of progression to advanced AMD. Fish intake and nuts reduced risk. Since advanced AMD is associated with visual loss and reduced quality of life, these preventive measures deserve additional research and greater emphasis.
C1 Massachusetts Eye & Ear Infirm, Epidemiol Unit, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02138 USA.
   Harvard Univ, Sch Med, Dept Med, Boston, MA 02138 USA.
   Harvard Univ, Sch Med, Dept Biostat, Boston, MA 02138 USA.
   Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
C3 Harvard University; Massachusetts Eye & Ear Infirmary; Harvard
   University; Harvard Medical School; Harvard University; Harvard Medical
   School; Harvard University; Harvard Medical School; Harvard University;
   Harvard T.H. Chan School of Public Health; Harvard University; Harvard
   T.H. Chan School of Public Health
RP Seddon, JM (通讯作者)，Massachusetts Eye & Ear Infirm, Epidemiol Unit, 243 Charles St, Boston, MA 02114 USA.
OI Ho, Allen/0000-0003-3921-608X
FU NEI NIH HHS [R01 EY011309] Funding Source: Medline
CR *AG REL EYE DIS ST, 1992, AG REL EYE DIS STUD
   AJANI UA, 1994, INVEST OPHTH VIS SCI, V35, P2725
   Albert CM, 1998, JAMA-J AM MED ASSOC, V279, P23, DOI 10.1001/jama.279.1.23
   Albert CM, 2002, ARCH INTERN MED, V162, P1382, DOI 10.1001/archinte.162.12.1382
   Ascherio A, 1996, BMJ-BRIT MED J, V313, P84, DOI 10.1136/bmj.313.7049.84
   Baik I, 2000, AM J EPIDEMIOL, V152, P264, DOI 10.1093/aje/152.3.264
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   CHYLACK LT, 1989, ARCH OPHTHALMOL-CHIC, V107, P991, DOI 10.1001/archopht.1989.01070020053028
   COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Dreher ML, 1996, NUTR REV, V54, P241, DOI 10.1111/j.1753-4887.1996.tb03941.x
   Feldman EB, 2002, J NUTR, V132, p1062S, DOI 10.1093/jn/132.5.1062S
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102
   Hu FB, 1998, BMJ-BRIT MED J, V317, P1341, DOI 10.1136/bmj.317.7169.1341
   Jiang R, 2002, JAMA-J AM MED ASSOC, V288, P2554, DOI 10.1001/jama.288.20.2554
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kris-Etherton Penny M., 2002, American Journal of Medicine, V113, p71S
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   MENSINK RP, 1990, NEW ENGL J MED, V323, P439, DOI 10.1056/NEJM199008163230703
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   *NAT ADV EYE COUNC, 1999, NIH PUBL
   *NAT I HLTH NAT EY, 2002, VIS PROBL US PREV AD, V3
   SEDDON JM, 1990, INVEST OPHTH VIS SCI, V31, P1592
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Thylefors B, 1998, AM J OPHTHALMOL, V125, P90, DOI 10.1016/S0002-9394(99)80239-6
   Willett W., 1990, NUTR EPIDEMIOLOGY
   WILLETT WC, 1994, AM J PUBLIC HEALTH, V84, P722, DOI 10.2105/AJPH.84.5.722
   WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086
NR 37
TC 279
Z9 297
U1 0
U2 15
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD DEC
PY 2003
VL 121
IS 12
BP 1728
EP 1737
DI 10.1001/archopht.121.12.1728
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 751XK
UT WOS:000187115200008
PM 14662593
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Saito, M
   Kano, M
   Itagaki, K
   Oguchi, Y
   Sekiryu, T
AF Saito, Masaaki
   Kano, Mariko
   Itagaki, Kanako
   Oguchi, Yasuharu
   Sekiryu, Tetsuju
TI SWITCHING TO INTRAVITREAL AFLIBERCEPT INJECTION FOR POLYPOIDAL CHOROIDAL
   VASCULOPATHY REFRACTORY TO RANIBIZUMAB
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; MACULAR
   DEGENERATION; PHOTODYNAMIC THERAPY; VEGF TRAP; NEOVASCULAR MEMBRANES;
   VERTEPORFIN; BEVACIZUMAB; TACHYPHYLAXIS; EXPRESSION
AB Purpose: To clarify the efficacy of switching to intravitreal aflibercept injection to treat polypoidal choroidal vasculopathy refractory to ranibizumab.
   Methods: In this retrospective study, 43 eyes of 42 patients (mean age, 76.5 years) with polypoidal choroidal vasculopathy treated with aflibercept (2 mg/0.05 mL) were reviewed. A treatment history of 3 consecutive monthly intravitreal injections of ranibizumab as an induction phase followed by a pro re nata maintenance phase over 12 months was seen for all patients. All patients who were refractory to ranibizumab (defined as having persist subretinal or intraretinal fluid by optical coherence tomography and unchanged or decreased visual acuity compared with the time of the first ranibizumab injection, despite receiving the last 3 consecutive monthly intravitreal ranibizumab injections after 12 months).
   Results: The mean logarithm of the minimum angle of resolution best-corrected visual acuity levels (Snellen equivalent) improved significantly (P = 0.0074) from 0.38 (20/48) at baseline to 0.34 (20/43) 3 months after switching to aflibercept (Month 3) (mean best-corrected visual acuity improvement, 0.47 line). The central retinal thickness decreased significantly (P < 0.0001) from 245 mu m at baseline to 131 mu m at Month 3. Of 30 eyes with polypoidal lesions at baseline, the polypoidal lesions regressed completely in 15 eyes (50%) at Month 3.
   Conclusion: Administering intravitreal aflibercept injection for patients with polypoidal choroidal vasculopathy refractory to ranibizumab maintained or improved visual acuity and reduced or eliminated exudative lesions and occluding polypoidal lesions without adverse events with short-term follow-up.
C1 [Saito, Masaaki; Kano, Mariko; Itagaki, Kanako; Oguchi, Yasuharu; Sekiryu, Tetsuju] Fukushima Med Univ, Sch Med, Dept Ophthalmol, Fukushima 9601295, Japan.
C3 Fukushima Medical University
RP Saito, M (通讯作者)，Fukushima Med Univ, Sch Med, Dept Ophthalmol, 1 Hikariga Oka, Fukushima 9601295, Japan.
EM smasaaki@fmu.ac.jp
RI Saito, Masaaki/ABI-2783-2020
OI Saito, Masaaki/0000-0003-1494-6350; Sekiryu, Tetsuju/0000-0001-8042-2729
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Otsuji T, 2013, CLIN OPHTHALMOL, V7, P1487, DOI 10.2147/OPTH.S46317
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Saito M, 2013, GRAEFES ARCH CLIN EX
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1250, DOI 10.1097/IAE.0b013e318236e503
   Saito M, 2011, RETINA-J RET VIT DIS, V31, P1589, DOI 10.1097/IAE.0b013e31820f4b21
   Saito Masaaki, 2009, Nippon Ganka Gakkai Zasshi, V113, P792
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018
   Tano Yasuo, 2009, Nippon Ganka Gakkai Zasshi, V113, P1098
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Zachary I, 2006, CIRCULATION, V114, P173
NR 43
TC 41
Z9 43
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2014
VL 34
IS 11
BP 2192
EP 2201
DI 10.1097/IAE.0000000000000236
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AT0DK
UT WOS:000344607100012
PM 25077530
DA 2022-11-30
ER

PT J
AU Zuber-Laskawiec, K
   Kubicka-Trzaska, A
   Karska-Basta, I
   Pociej-Marciak, W
   Romanowska-Dixon, B
AF Zuber-Laskawiec, K.
   Kubicka-Trzaska, A.
   Karska-Basta, I
   Pociej-Marciak, W.
   Romanowska-Dixon, B.
TI NON-RESPONSIVENESS AND TACHYPHYLAXIS TO ANTI-VASCULAR ENDOTHELIAL GROWTH
   FACTOR TREATMENT IN NAIVE PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR
   DEGENERATION
SO JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
LA English
DT Article
DE age-related macular degeneration; central retinal thickness; best
   corrected visual acuity; anti-vascular endothelial growth factor
   therapy; tachyphylaxis; non-responsiveness
ID PIGMENT EPITHELIAL DETACHMENT; RANIBIZUMAB TREATMENT; VEGF; AFLIBERCEPT;
   MANAGEMENT; INHIBITORS; THERAPIES; AMD
AB Age-related macular degeneration (AMD) is a leading cause of central visual loss in people aged over 50 years in well developed countries. Although the anti-vascular endothelial growth factor (VEGF) therapy has become a standard treatment for exudative AMD, its effectiveness may be limited in some cases. We aimed to assess the prevalence of non-responsiveness and tachyphylaxis to anti-VEGF drugs in patients with exudative AMD. The study included 63 initially treatment-naive AMD patients who were analyzed for non-responsiveness and tachyphylaxis to intravitreal injections (NI) of ranibizumab and aflibercept. The participants were enrolled in a National Healthcare Fund (NHF) Therapeutic Program for the Treatment of Exudative AMD. Best-corrected visual acuity (BCVA) and morphological features of a disease activity assessed in optical coherence tomography (OCT) were evaluated during a 12-month follow-up. The percentage of non-responders achieved 22.2% (14 eyes). No significant correlation was found between the type of VEGF inhibitor and a negative response to therapy. Eight patients (12.7%) developed early tachyphylaxis, which was more common in eyes treated with aflibercept (P = 0.04). The presence of serous pigment epithelium detachment (sPED) at baseline was associated with non-responsiveness as determined by both BCVA (OR 18.2, 95% CI 2.86 - 248; P = 0.021) and OCT features (OR 23.0, 95% CI 1.80 - 321; P = 0.030). Eyes treated with aflibercept showed statistically significant greater BCVA improvement (P = 0.0034) and central retinal thickness (CRT) reduction (P = 0.0129) as compared to ranibizumab group during a loading phase of therapy. In a maintain phase of treatment the differences in BCVA and CRT between these two groups were not statistically significant, however eyes treated with aflibercept still showed better functional and anatomical results. Anti-VEGF therapy is an effective method of treatment for exudative AMD, however some patients may show week or no positive reaction or may develop tachyphylaxis. Awareness of these possible negative effects is an important clinical problem in the long-term management of AMD patients with VEGF inhibitors.
C1 [Zuber-Laskawiec, K.; Kubicka-Trzaska, A.; Karska-Basta, I; Pociej-Marciak, W.; Romanowska-Dixon, B.] Jagiellonian Univ, Fac Med, Dept Opthalmol, Med Coll, 38 Kopernika St, PL-31501 Krakow, Poland.
   [Zuber-Laskawiec, K.; Kubicka-Trzaska, A.; Karska-Basta, I; Pociej-Marciak, W.; Romanowska-Dixon, B.] Univ Hosp, Clin Opthalmol & Ocular Oncol, Krakow, Poland.
C3 Jagiellonian University; Collegium Medicum Jagiellonian University
RP Zuber-Laskawiec, K (通讯作者)，Jagiellonian Univ, Fac Med, Dept Opthalmol, Med Coll, 38 Kopernika St, PL-31501 Krakow, Poland.
EM katarzyna.zuber-laskawiec@uj.edu.pl
RI Karska-Basta, Izabella/AAT-4361-2021
CR Amadio M, 2016, PHARMACOL RES, V103, P253, DOI 10.1016/j.phrs.2015.11.027
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Augsburger M, 2019, GRAEF ARCH CLIN EXP, V257, P1889, DOI 10.1007/s00417-019-04404-0
   Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Bellezza I, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01280
   Bluestone JA, 2011, IMMUNOL REV, V241, P5, DOI 10.1111/j.1600-065X.2011.01019.x
   Broadhead GK, 2015, RETINA-J RET VIT DIS, V35, P975, DOI 10.1097/IAE.0000000000000409
   Broadhead GK, 2014, ACTA OPHTHALMOL, V92, P713, DOI 10.1111/aos.12463
   Copland DA, 2018, INVEST OPHTH VIS SCI, V59, pAMD83, DOI 10.1167/iovs.18-23893
   Dirani A, 2015, AM J OPHTHALMOL, V160, P732, DOI 10.1016/j.ajo.2015.06.025
   Enseleit F, 2017, OPHTHALMOLOGICA, V238, P205, DOI 10.1159/000478665
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gharbiya M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273754
   Hara C, 2019, GRAEF ARCH CLIN EXP, V257, P2559, DOI 10.1007/s00417-019-04456-2
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hu ZZ, 2015, BRIT J OPHTHALMOL, V99, P593, DOI 10.1136/bjophthalmol-2014-305488
   Koike N, 2019, CLIN OPHTHALMOL, V13, P1247, DOI 10.2147/OPTH.S206910
   Korybalska K, 2017, J PHYSIOL PHARMACOL, V68, P397
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Kubicka-Trzaska A, 2019, KLIN OCZNA, V121, P34
   Kubicka-Trzaska Agnieszka, 2016, Klin Oczna, V118, P114
   Lanzetta P, 2013, BRIT J OPHTHALMOL, V97, P1497, DOI 10.1136/bjophthalmol-2013-303394
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Papadopoulos Z, 2019, EUR J OPHTHALMOL, V29, P368, DOI 10.1177/1120672119832432
   Parmeggiani F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/435607
   Pikkel J, 2018, INT OPHTHALMOL, V38, P2031, DOI 10.1007/s10792-017-0695-z
   Santarelli M, 2015, EXPERT OPIN PHARMACO, V16, P1769, DOI 10.1517/14656566.2015.1067679
   Sarraf D, 2016, OPHTHALMOLOGY, V123, P2213, DOI 10.1016/j.ophtha.2016.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu MX, 2017, BRIT J OPHTHALMOL, V101, P976, DOI 10.1136/bjophthalmol-2016-309418
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Zinkernagel MS, 2016, OPHTHALMOLOGICA, V235, P42, DOI 10.1159/000441428
NR 36
TC 15
Z9 16
U1 0
U2 3
PU POLISH PHYSIOLOGICAL SOC
PI GRZEGORZECKA
PA JAGIELLONIAN UNIV SCHOOL MED, INST PHYSIOLOGY, 31-531 KRAKOW, 16
   GRZEGORZECKA, POLAND
SN 0867-5910
J9 J PHYSIOL PHARMACOL
JI J. Physiol. Pharmacol.
PD OCT
PY 2019
VL 70
IS 5
BP 779
EP 785
DI 10.26402/jpp.2019.5.13
PG 7
WC Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology
GA KU6TE
UT WOS:000519846400005
PM 32009630
DA 2022-11-30
ER

PT J
AU Sulzbacher, F
   Kiss, C
   Kaider, A
   Roberts, P
   Munk, M
   Kroh, ME
   Sayegh, R
   Schmidt-Erfurth, U
AF Sulzbacher, Florian
   Kiss, Christopher
   Kaider, Alexandra
   Roberts, Philipp
   Munk, Marion
   Kroh, Maria Elisabeth
   Sayegh, Ramzi
   Schmidt-Erfurth, Ursula
TI Correlation of OCT Characteristics and Retinal Sensitivity in
   Neovascular Age-Related Macular Degeneration in the Course of Monthly
   Ranibizumab Treatment
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID PIGMENT EPITHELIAL DETACHMENT; VISUAL-ACUITY; BEVACIZUMAB; SECONDARY;
   THERAPY; EYES
AB PURPOSE. To evaluate the functional treatment response 3 months and 12 months after monthly ranibizumab in neovascular age-related macular degeneration (NAMD).
   METHODS. Twenty-six eyes showing treatment-naive NAMD were examined with the Heidelberg Spectralis OCT (SD-OCT) and the Nidek MP-1 microperimeter (MP) at baseline, after 3 months, and after 12 months of monthly ranibizumab therapy. Each test point of light sensitivity was transferred to the corresponding location on SD-OCT, and subsequently the microperimetric results were evaluated with respect to the following OCT findings: neovascular complex (NVC), subretinal fluid (SRF), intraretinal fluid (IRF), intraretinal cystoid space (IRCS), serous pigment epithelium detachment (SPED), and fibrovascular pigment epithelium detachment (FPED).
   RESULTS. Loci of an initial NVC improved significantly from a mean retinal sensitivity value of 2.6 dB +/- 0.8 dB at baseline to 7.4 dB +/- 0.9 dB (P < 0.0001) at month 12. Initial SRF, IRF, and IRCS improved significantly from a mean value of 5.1 dB +/- 0.9 dB to 12.4 dB +/- 0.9 dB (P < 0.0001), 4.0 dB +/- 1.0 dB to 9.3 dB +/- 0.9 dB (P < 0.0001), and 3.4 dB +/- 0.9 dB to 8.2 dB +/- 0.9 dB (P < 0.0001), respectively. An initial SPED improved significantly from a mean retinal sensitivity value of 1.9 dB +/- 1.1 dB at baseline to 9.4 dB +/- 1.1 dB (P < 0.0001) at month 12; a FPED improved significantly from 5.2 dB +/- 0.9 dB at baseline to 7.6 dB +/- 0.9 dB (P < 0.0001) at month 12.
   CONCLUSIONS. Functional benefit could be detected at all locations of macular pathology, with a lower benefit in the case of FPED and in the case of additional IRCS, and a marked benefit for all types of macular edema. (https://eudract.ema.europa.eu/, number 2006-005684-26.) (Invest Ophthalmol Vis Sci. 2013;54:1310-1315) DOI:10.1167/iovs.12-11046
C1 [Sulzbacher, Florian; Kiss, Christopher; Roberts, Philipp; Munk, Marion; Kroh, Maria Elisabeth; Sayegh, Ramzi; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, A-1090 Vienna, Austria.
   [Kaider, Alexandra] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Sect Clin Biometr, A-1090 Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Kiss, C (通讯作者)，Med Univ Vienna, Dept Ophthalmol & Optometry, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM christopher.kiss@meduniwien.ac.at
OI Schmidt-Erfurth, Ursula/0000-0002-7788-7311
CR [Anonymous], 1986, Arch Ophthalmol, V104, P694
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Freeman WR, 2011, RETINA-J RET VIT DIS, V31, P1812, DOI 10.1097/IAE.0b013e31821987a4
   Gamulescu MA, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/851648
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Issa PC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012864
   Kim YM, 2012, AM J OPHTHALMOL, V154, P164, DOI 10.1016/j.ajo.2012.01.030
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Mariani A, 2011, GRAEF ARCH CLIN EXP, V249, P1635, DOI 10.1007/s00417-011-1734-5
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Sulzbacher F, 2012, INVEST OPHTH VIS SCI, V53, P6448, DOI 10.1167/iovs.11-9162
NR 21
TC 15
Z9 15
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2013
VL 54
IS 2
BP 1310
EP 1315
DI 10.1167/iovs.12-11046
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 100BS
UT WOS:000315670300051
PM 23349430
DA 2022-11-30
ER

PT J
AU Evans, RN
   Reeves, BC
   Maguire, MG
   Martin, DF
   Muldrew, A
   Peto, T
   Rogers, C
   Chakravarthy, U
AF Evans, Rebecca N.
   Reeves, Barnaby C.
   Maguire, Maureen G.
   Martin, Daniel F.
   Muldrew, Alyson
   Peto, Tunde
   Rogers, Chris
   Chakravarthy, Usha
TI Associations of Variation in Retinal Thickness With Visual Acuity and
   Anatomic Outcomes in Eyes With Neovascular Age-Related Macular
   Degeneration Lesions Treated With Anti-Vascular Endothelial Growth
   Factor Agents
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; ANGIOFIBROTIC SWITCH; EXTEND; VEGF;
   RANIBIZUMAB; REGIMEN; BEVACIZUMAB; MORPHOLOGY
AB IMPORTANCE When initiating anti-vascular endothelial growth factor (VEGF) treatment for patients with neovascular age-related macular degeneration (nAMD), knowledge of prognostic factors is important for advising patients and guiding treatment. We hypothesized that eyes with greater fluctuation in retinal thickness over time have worse outcomes than eyes with less variation.
   OBJECTIVE To investigate whether visual and anatomic outcomes in eyes with nAMD initiating anti-VEGF treatment are associated with fluctuations in retinal thickness.
   DESIGN, SETTING, AND PARTICIPANTS In this study using data from the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) and the Inhibition of VEGF in Age-Related Choroidal Neovascularization (IVAN) randomized clinical trial, people with previously untreated nAMD were included. Data were collected from February 2008 to November 2012, and data were analyzed from April 2017 to April 2020.
   MAIN OUTCOMES AND MEASURES Foveal center point thicknesses (FCPTs) were extracted from 1165 study eyes from CATT and 566 study eyes from the IVAN trial, excluding those with 3 measurements or less. For each eye, the SD of FCPT was calculated. Eyes were grouped by FCPT SD quartile. Associations of FCPT SD quartile with outcomes were quantified at month 24 or the last available visit by linear or logistic regression, adjusting for baseline best-corrected visual acuity (BCVA) and randomized allocations to drug and treatment regimen, for BCVA, development of fibrosis, and development of macular atrophy.
   RESULTS Of the 1731 included patients, 1058 (61.1%) were female, and the mean (SD) age was 78.6 (7.4) years. The median (interquartile range) FCPT SD was 40.2 (27.1-61.2) in the IVAN cohort and 59.0 (38.3-89.4) in the CATT cohort. After adjustment for baseline BCVA and trial allocations, BCVA worsened significantly across the quartiles of FCPT SD; the difference between the first and fourth quartiles was -6.27 Early Treatment Diabetic Retinopathy Study letters (95% CI, -8.45 to -4.09). The risk of developing fibrosis and macular atrophy also increased across FCPT SD quartiles. Odds ratios ranged from 1.40 (95% CI, 1.03 to 1.91) for quartile 2 to 1.95 (95% CI, 1.42 to 2.68) for quartile 4 for fibrosis and from 1.32 (95% CI, 0.90 to 1.92) for quartile 2 to 2.10 (95% CI, 1.45 to 3.05) for quartile 4 for macular atrophy.
   CONCLUSIONS AND RELEVANCE Greater variation in retinal thickness in eyes with nAMD during treatment with anti-VEGF was associated with worse BCVA and development of fibrosis and macular atrophy in these post hoc analyses, despite protocol-directed treatment frequency. Practitioners may want to consider variation in retinal thickness when advising patients about their prognosis.
C1 [Evans, Rebecca N.; Reeves, Barnaby C.; Rogers, Chris] Univ Bristol, Bristol Med Sch, Bristol Trials Ctr, Clin Trials & Evaluat Unit, Bristol, Avon, England.
   [Maguire, Maureen G.] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Muldrew, Alyson; Peto, Tunde; Chakravarthy, Usha] Queens Univ Belfast, Royal Victoria Hosp, Belfast, Antrim, North Ireland.
C3 University of Bristol; University of Pennsylvania; Cleveland Clinic
   Foundation; Queens University Belfast
RP Reeves, BC (通讯作者)，Univ Bristol, Bristol Med Sch, Bristol Trials Ctr, Clin Trials & Evaluat,Bristol Royal Infirm, Level 7,Queens Bldg, Bristol BS2 8HW, Avon, England.
EM barney.reeves@bristol.ac.uk
OI Evans, Rebecca/0000-0002-7119-8187; Reeves, Barnaby/0000-0002-5101-9487
FU National Institute for Health Research UK Health Technology Assessment
   (HTA) Programme [07/36/01]
FX The National Institute for Health Research UK Health Technology
   Assessment (HTA) Programme funded the IVAN trial (reference No.
   07/36/01).
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Bailey C, 2019, OPHTHALMOLOGY, V126, P75, DOI 10.1016/j.ophtha.2018.07.013
   Casalino G, 2018, OPHTHALMOL RETINA, V2, P451, DOI 10.1016/j.oret.2017.08.019
   Casalino G, 2016, INVEST OPHTH VIS SCI, V57, pOCT288, DOI 10.1167/iovs.15-18753
   Chakravarthy U, 2019, OPHTHALMOL RETINA, V3, P8, DOI 10.1016/j.oret.2018.09.001
   Chakravarthy U, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19780
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Doris N, 2001, BRIT J OPHTHALMOL, V85, P184, DOI 10.1136/bjo.85.2.184
   Ghanta S, 2015, AM J PHYSIOL-HEART C, V308, pH1065, DOI 10.1152/ajpheart.00598.2014
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Hatz K, 2016, BRIT J OPHTHALMOL, V100, P1341, DOI 10.1136/bjophthalmol-2015-307299
   Holekamp NM, 2014, AM J OPHTHALMOL, V157, P825, DOI 10.1016/j.ajo.2013.12.018
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kvannli L, 2017, ACTA OPHTHALMOL, V95, P678, DOI 10.1111/aos.13356
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Muether PS, 2012, OPHTHALMOLOGY, V119, P2082, DOI 10.1016/j.ophtha.2012.07.041
   Pron G, 2014, Ont Health Technol Assess Ser, V14, P1
   Roberts PK, 2019, INVEST OPHTH VIS SCI, V60, P304, DOI 10.1167/iovs.18-25189
   Rufai SR, 2017, EYE, V31, P1337, DOI 10.1038/eye.2017.67
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   van Asten F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197670
   Van Geest RJ, 2012, BRIT J OPHTHALMOL, V96, P587, DOI 10.1136/bjophthalmol-2011-301005
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
NR 30
TC 39
Z9 40
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD OCT
PY 2020
VL 138
IS 10
BP 1043
EP 1051
DI 10.1001/jamaophthalmol.2020.3001
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PO1YX
UT WOS:000604967700010
PM 32816002
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Neudorfer, M
   Fuhrer, AE
   Zur, D
   Barak, A
AF Neudorfer, Meira
   Fuhrer, Audelia Eshel
   Zur, Dinah
   Barak, Adiel
TI The role of posterior vitreous detachment on the efficacy of
   anti-vascular endothelial growth factor intravitreal injection for
   treatment of neovascular age-related macular degeneration
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; bevacizumab; intravitreal injections;
   optical coherence tomography; posterior vitreous detachment; ultrasound
ID VITREOMACULAR ADHESION; TREATMENT OUTCOMES; FACTOR THERAPY; RANIBIZUMAB;
   RISK; BEVACIZUMAB; INTERFACE; ULTRASONOGRAPHY; PREVALENCE; CLEARANCE
AB Purpose: A prospective cohort study investigating the effect of posterior vitreous detachment (PVD) on the efficacy of intravitreal bevacizumab for exudative age-related macular degeneration (AMD), in view of evidence that the vitreoretinal interface impacts the severity of the disease. Methods: Treatment-naive AMD eyes with (+) complete PVD and without (-) PVD on ultrasonography received three monthly and then pro re nata bevacizumab injections. Best-corrected visual acuity (BCVA) on Snellen charts and optical coherence tomography (OCT) findings were recorded for 12 months. Secondary analysis included PVD definition and group allocation according to OCT baseline scan. Results: Forty-one eyes of 34 patients met the inclusion criteria. At 12 months, median BCVA improved by 0.12 logMAR in the PVD+ group [interquartile range (IQR)-0.52, 0.03, P = 0.140] and remained the same in the PVD-group (IQR-0.12, 0.15, P = 0.643). Median central retinal thickness improved by 43.5 mu m and 43 mu m in the PVD+ (IQR-143, 3, P = 0.016) and PVD-group (IQR-90,-14, P = 0.008), respectively. All parameters were similar in the two groups at final follow up (P > 0.05). The secondary analysis included 32 eyes of 26 patients and showed no significant differences between the groups at the 12 months endpoint (P > 0.05). Conclusion: Our findings show no significant impact of PVD as assessed by ultrasound or by OCT on visual and anatomical outcomes in exudative AMD treated with bevacizumab.
C1 [Neudorfer, Meira; Fuhrer, Audelia Eshel; Zur, Dinah; Barak, Adiel] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Sackler Fac Med, Div Ophthalmol, Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky
   Medical Center
RP Neudorfer, M (通讯作者)，Tel Aviv Sourasky Med Ctr, 6 Weizman St, IL-6423906 Tel Aviv, Israel.
EM meiraneu@netvision.net.il
RI Zur, Dinah/AAX-7620-2020
CR Ahn SJ, 2014, INVEST OPHTH VIS SCI, V55, P567, DOI 10.1167/iovs.13-13054
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Ashraf M, 2018, ACTA OPHTHALMOL, V96, P120, DOI 10.1111/aos.13565
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chin HS, 2005, RETINA-J RET VIT DIS, V25, P556, DOI 10.1097/00006982-200507000-00002
   Cuilla TA, 2015, OPHTHALMOLOGY, V122, P1203, DOI 10.1016/j.ophtha.2015.02.031
   DOFT BH, 1985, OPHTHALMOLOGY, V92, P1601, DOI 10.1016/S0161-6420(85)33838-1
   Duker JS, 2013, OPHTHALMOLOGY, V120, P2611, DOI 10.1016/j.ophtha.2013.07.042
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Geck U, 2013, GRAEF ARCH CLIN EXP, V251, P1691, DOI 10.1007/s00417-013-2266-y
   Goldenberg DT, 2011, RETINA-J RET VIT DIS, V31, P393, DOI 10.1097/IAE.0b013e3181e586b2
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Houston SK, 2015, RETINA-J RET VIT DIS, V35, P1757, DOI 10.1097/IAE.0000000000000663
   Kicova N, 2012, ACTA OPHTHALMOL, V90, pE264, DOI 10.1111/j.1755-3768.2011.02330.x
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mayr-Sponer U, 2013, OPHTHALMOLOGY, V120, P2620, DOI 10.1016/j.ophtha.2013.05.032
   McKibbin MA, 2015, RETINA-J RET VIT DIS, V35, P1951, DOI 10.1097/IAE.0000000000000587
   Menghini M, 2010, KLIN MONATSBL AUGENH, V227, P227
   Moisseiev E, 2015, RETINA-J RET VIT DIS, V35, P1323, DOI 10.1097/IAE.0000000000000500
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Novack RL, 2015, OPHTHALMOLOGY, V122, P796, DOI 10.1016/j.ophtha.2014.10.006
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Parchand S, 2014, SEMIN OPHTHALMOL, V29, P236, DOI 10.3109/08820538.2013.821506
   Piermarocchi S, 2015, ACTA OPHTHALMOL, V93, pE451, DOI 10.1111/aos.12587
   Quiram PA, 2007, RETINA-J RET VIT DIS, V27, P1090, DOI 10.1097/IAE.0b013e3180654229
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Sadiq MA, 2016, OPHTHALMOLOGY, V123, P324, DOI 10.1016/j.ophtha.2015.09.032
   Schulze-Bonsel K, 2006, INVEST OPHTH VIS SCI, V47, P1236, DOI 10.1167/iovs.05-0981
   Sebag J, 2005, Trans Am Ophthalmol Soc, V103, P473
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Terao R, 2014, JPN J OPHTHALMOL, V58, P139, DOI 10.1007/s10384-013-0302-4
   Uney GO, 2014, RETINA-J RET VIT DIS, V34, P32, DOI 10.1097/IAE.0b013e318295f72e
   Weber-Krause Brigitte, 1996, Ophthalmologe, V93, P660, DOI 10.1007/s003470050054
   Xie P, 2017, BRIT J OPHTHALMOL, V101, P1003, DOI 10.1136/bjophthalmol-2017-310155
NR 39
TC 5
Z9 5
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD DEC
PY 2018
VL 66
IS 12
BP 1802
EP 1807
DI 10.4103/ijo.IJO_373_18
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HB0BS
UT WOS:000450676000023
PM 30451182
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Feng, L
   Hu, JH
   Chen, J
   Xie, X
AF Feng, Lei
   Hu, Jiang-hua
   Chen, Jie
   Xie, Xin
TI An efficacy analysis of anti-vascular endothelial growth factor therapy
   for choroidal neovascularization secondary to multifocal choroiditis and
   comparison with wet age-related macular degeneration
SO JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B
LA English
DT Article
DE Wet age-related macular degeneration (AMD); Multifocal choroiditis
   (MFC); Juxtafoveal choroidal neovascularization (CNV); Anti-vascular
   endothelial growth factor (VEGF) therapy
ID PHOTODYNAMIC THERAPY; PANUVEITIS; BEVACIZUMAB; MEMBRANES; UVEITIS;
   RANIBIZUMAB; VEGF
AB To evaluate the effect of anti-vascular endothelial growth factor (VEGF) on juxtafoveal choroidal neovascularization (CNV) secondary to multifocal choroiditis (MFC) and wet age-related macular degeneration (AMD). Methods: In this retrospective, comparative study, 20 unique eyes with CNV were divided into two groups: 10 patients affected by MFC and 10 patients diagnosed with wet AMD. They all received local intravitreal (IVT) injections of ranibizumab, with 6 months of follow-up. Retreatment injections were performed based on findings suggestive of active neovascularization.
   Significant improvements were observed in the juxtafoveal CNV lesions, and average central macular thickness decreased in both groups following the anti-VEGF therapy (P < 0.05). The average number of injections used in MFC patients was 1.6, while three injections on average were used in wet AMD patients (Z=-2.844, P=0.009). Best-corrected visual acuity was significantly improved in MFC patients after anti-VEGF therapy (P < 0.05), and there was no significant difference in wet AMD patients between before anti-VEGF therapy and 6 months later (P > 0.05).
   IVT ranibizumab resulted in good clinical outcomes for juxtafoveal CNV secondary to MFC and wet AMD, but the average number of injections used in MFC was fewer than that used in wet AMD over a 6-month observation period. Compared with the wet AMD group, visual acuity was obviously improved in the MFC group at 6 months.
C1 [Feng, Lei; Hu, Jiang-hua; Xie, Xin] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Ctr Eye, Hangzhou 310009, Zhejiang, Peoples R China.
   [Chen, Jie] First Hosp Jiaxing, Dept Ophthalmol, Jiaxing 314000, Peoples R China.
C3 Zhejiang University
RP Xie, X (通讯作者)，Zhejiang Univ, Sch Med, Affiliated Hosp 2, Ctr Eye, Hangzhou 310009, Zhejiang, Peoples R China.
EM xiexin163@163.com
FU National Natural Science Foundation of China [81500760]
FX Project supported by the National Natural Science Foundation of China
   (No. 81500760)
CR Alexandru Malciolu Radu, 2016, Rom J Ophthalmol, V60, P9
   Cheung CMG, 2011, NEW ENGL J MED, V365, P2237, DOI 10.1056/NEJMc1107895
   D'Ambrosio E, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/450428
   Dardabounis D, 2013, BMJ CASE REP, V2013
   Dunlop AAS, 1998, ARCH OPHTHALMOL-CHIC, V116, P801, DOI 10.1001/archopht.116.6.801
   Fine HF, 2009, RETINA-J RET VIT DIS, V29, P8, DOI 10.1097/IAE.0b013e318187aff9
   Flaxel CJ, 1998, EYE, V12, P266, DOI 10.1038/eye.1998.62
   Gerth C, 2006, EUR J OPHTHALMOL, V16, P111, DOI 10.1177/112067210601600118
   Gulati N, 2011, BRIT J OPHTHALMOL, V95, P162, DOI 10.1136/bjo.2009.177279
   Haen SP, 2008, AM J OPHTHALMOL, V145, P847, DOI 10.1016/j.ajo.2008.01.008
   Hochman MA, 1999, INT OPHTHALMOL CLIN, V39, P303, DOI 10.1097/00004397-199903910-00026
   Iannetti L, 2013, EUR J OPHTHALMOL, V23, P114, DOI 10.5301/ejo.5000192
   Julian K, 2011, ACTA OPHTHALMOL, V89, P179, DOI 10.1111/j.1755-3768.2010.02046.x
   Jutley G, 2011, EYE, V25, P675, DOI 10.1038/eye.2011.24
   Kuo IC, 2000, INT OPHTHALMOL CLIN, V40, P111, DOI 10.1097/00004397-200004000-00009
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Miller DG, 2006, OPTOMETRY VISION SCI, V83, P316, DOI 10.1097/01.opx.0000216019.88256.eb
   Perentes Y, 2002, KLIN MONATSBL AUGENH, V219, P311, DOI 10.1055/s-2002-30662
   Rouvas A, 2011, RETINA-J RET VIT DIS, V31, P871, DOI 10.1097/IAE.0b013e3182003ca8
   Shimada H, 2008, JPN J OPHTHALMOL, V52, P282, DOI 10.1007/s10384-008-0566-2
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P545, DOI 10.1097/00006982-200210000-00003
   Starita Carla, 2007, Dev Ophthalmol, V39, P122, DOI 10.1159/000098504
   THOMAS MA, 1994, OPHTHALMOLOGY, V101, P1384
   Thurau S, 2010, OPHTHALMOLOGE, V107, P79, DOI 10.1007/s00347-009-2116-9
   Tsutsumi-Miyahara C, 2004, BRIT J OPHTHALMOL, V88, P1217, DOI 10.1136/bjo.2003.036392
NR 26
TC 3
Z9 4
U1 0
U2 11
PU ZHEJIANG UNIV
PI HANGZHOU
PA EDITORIAL BOARD, 20 YUGU RD, HANGZHOU, 310027, PEOPLES R CHINA
SN 1673-1581
EI 1862-1783
J9 J ZHEJIANG UNIV-SC B
JI J. Zhejiang Univ.-SCI. B
PD APR
PY 2018
VL 19
IS 4
BP 327
EP 332
DI 10.1631/jzus.B1700535
PG 6
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Research & Experimental Medicine
GA GD5FV
UT WOS:000430532500008
PM 29616508
OA Green Published
DA 2022-11-30
ER

PT J
AU Chua, B
   Flood, V
   Rochtchina, E
   Wang, JJ
   Smith, W
   Mitchell, P
AF Chua, Brian
   Flood, Victoria
   Rochtchina, Elena
   Wang, Jie Jin
   Smith, Wayne
   Mitchell, Paul
TI Dietary fatty acids and the 5-year incidence of age-related maculopathy
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID FOOD-FREQUENCY QUESTIONNAIRE; MACULAR DEGENERATION; DOCOSAHEXAENOIC
   ACID; FISH INTAKE; RISK; PROGRESSION; RETINA; PATHOGENESIS; VALIDITY;
   DISEASE
AB Objective: To assess longitudinal associations between dietary fat and incident age-related maculopathy (ARM) in an older, population-based, historical cohort.
   Methods: A total of 3654 persons, 49 years or older, participated in the Blue Mountains Eye Study (1992-1994); 2335 (75.1% of survivors) were reexamined after 5 years (1997-1999). Dietary data were collected from 2895 people (79%) at baseline by means of a semiquantitative food frequency questionnaire to calculate dietary fat intakes. Presence of ARM was graded from retinal photographs (Wisconsin ARM Grading System). Logistic regression adjusted for age, sex, vitamin C intake, and smoking.
   Results: Participants with the highest vs lowest quintiles of n-3 polyunsaturated fat intake had lower risk of incident early ARM (odds ratio [95% confidence interval], 0.41 [0.22-0.75). A 40% reduction of incident early ARM was associated with fish consumption at least once a week (odds ratio [95% confidence interval], 0.58 [0.370.90]), whereas fish consumption at least 3 times per week could reduce the incidence of late ARM (odds ratio [95% confidence interval], 0.25 [0.06-1.00]). We found no association between incident ARM and butter, margarine, or nut consumption.
   Conclusions: A regular diet high in n-3 polyunsaturated fat, especially from fish, suggests protection against early and late ARM in this older Australian cohort. Our study could not confirm deleterious effects of higher polyunsaturated fat intakes reported by other clinic-based studies.
C1 Univ Sydney, Westmead Millennium Inst, Eye Clin, Dept Ophthalmol,Ctr Vis Res, Westmead, NSW 2145, Australia.
   Vis Cooperat Res Ctr, Sydney, NSW, Australia.
   Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2308, Australia.
   Univ Sydney, Dept Mol & Microbial Biosci, Sydney, NSW 2006, Australia.
   Univ Sydney, Dept Publ Hlth, Sydney, NSW 2006, Australia.
C3 University of Sydney; Westmead Institute for Medical Research; Visa Inc;
   University of Newcastle; University of Sydney; University of Sydney
RP Mitchell, P (通讯作者)，Univ Sydney, Westmead Hosp, Eye Clin, Dept Ophthalmol,Ctr Vis Res, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM paul_mitchell@wmi.usyd.edu.au
RI Flood, Victoria/H-2279-2011; wang, jie/GRS-0942-2022; Mitchell,
   Paul/P-1498-2014; Flood, Victoria M/A-8732-2016; Wang, Jie
   Jin/P-1499-2014
OI Flood, Victoria M/0000-0001-5310-7221; Wang, Jie Jin/0000-0001-9491-4898
CR Ascherio A, 1996, BMJ-BRIT MED J, V313, P84, DOI 10.1136/bmj.313.7049.84
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Clifton PM, 2004, J NUTR, V134, P874, DOI 10.1093/jn/134.4.874
   Department of Community Services and Health, 1995, NUTTAB95 NUTR DAT TA
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Flood VM, 2004, PUBLIC HEALTH NUTR, V7, P751, DOI 10.1079/PHN2004604
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   HOOPER L, 2001, COCHRANE DB SYST REV, V3
   JONES GP, 1997, FOOD NUTR AUSTR ASIA, P205
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   MANN NJ, 2003, NUTR DIETA, V600, P42
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Moriguchi K, 2003, EXP EYE RES, V77, P167, DOI 10.1016/S0014-4835(03)00114-3
   Murayama K, 2002, EXP EYE RES, V74, P671, DOI 10.1006/exer.2002.1151
   Rotstein NP, 2003, INVEST OPHTH VIS SCI, V44, P2252, DOI 10.1167/iovs.02-0901
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Smith W, 1998, AUST NZ J PUBL HEAL, V22, P456, DOI 10.1111/j.1467-842X.1998.tb01414.x
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   U.S. Department of Health and Human Services and U.S. Department of Agriculture, 2005, DIET GUID AM 2005
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 27
TC 112
Z9 117
U1 0
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUL
PY 2006
VL 124
IS 7
BP 981
EP 986
DI 10.1001/archopht.124.7.981
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 064XE
UT WOS:000239123200006
PM 16832021
OA Bronze
DA 2022-11-30
ER

PT J
AU Kondo, N
   Honda, S
   Kuno, SI
   Negi, A
AF Kondo, Naoshi
   Honda, Shigeru
   Kuno, Shin-ichi
   Negi, Akira
TI Role of RDBP and SKIV2L Variants in the Major Histocompatibility Complex
   Class III Region in Polypoidal Choroidal Vasculopathy Etiology
SO OPHTHALMOLOGY
LA English
DT Article
ID FACTOR-H POLYMORPHISM; COMPONENT 2 C2; FACTOR-B BF; MACULAR
   DEGENERATION; ASSOCIATION ANALYSIS; GEOGRAPHIC ATROPHY; GENE
   POLYMORPHISMS; RISK; CFH; SUSCEPTIBILITY
AB Purpose: To investigate whether polymorphisms in 4 tightly linked genes of the major histocompatibility complex class III-complement component 2 (C2), complement factor B (CFB), RD RNA-binding protein (RDBP), and superkiller viralicidic activity 2-like (SKIV2L)-are associated with polypoidal choroidal vasculopathy (PCV).
   Design: Cross-sectional study.
   Participants: A case-control group of 136 PCV subjects and 183 unrelated controls.
   Methods: We performed an association analysis between PCV and polymorphisms across the C2-CFB-RDBP-SKIV2L region in a Japanese population, genotyping 13 single nucleoticle polymorphisms (SNPs) spanning this region, including rs9332739 (E318D), rs547154, rs4151667 (L9H), and rs641153 (R32Q) that are known to be associated with age-related macular degeneration (AMD). Genotyping was conducted using TaqMan technology (Applied Biosystems, Foster City, CA). We also examined population stratification in our study cohort.
   Main Outcome Measures: Allele and haplotype frequencies of the variants across the C2-CFB-RDBP-SKIV2L region.
   Results: We initially scanned the C2-CFB locus using 11 SNPs that capture the majority of common variations in this locus. We found a significant omnibus haplotype association and a single disease-protective haplotype, but individually, none of the 11 SNPs were associated with PCV. Further studies led to the identification of 2 untested allelic variants in RDBP (rs3880457) and SKIV2L (rs2075702) that were located on the protective haplotype. We also analyzed these 2 SNPs, detecting a significant association with a decreased risk of developing PCV (for both SNPs, allelic P = 0.0038 and per allele odds ratio = 0.31 [95% confidence interval, 0.13-0.71]). The 2 SNPs were correlated (r(2) = 1) in our dataset. Haplotype analysis and conditional testing demonstrated that either rs3880457 or rs2075702 could fully account for the omnibus haplotype association detected across the C2-CFB-RDBP-SKIV2L region. Population stratification analyses excluded stratification artifacts in our study cohort.
   Conclusions: Our results do not support any major role of the 4 AMD-associated variants in the risk of developing PCV, but favor a predominant association with the RDBP-SKIV2L variants, which has some potential implications for pathobiological differences between PCV and neovascular AMD. Further genetic characterization of this locus will provide additional insights into the genetic basis of PCV susceptibility.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2009;116:1502-1509 (C) 2009 by the American Academy of Ophthalmology.
C1 [Honda, Shigeru] Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol,Chuo Ku, Kobe, Hyogo 6500017, Japan.
   [Kuno, Shin-ichi] Fdn Biomed Res & Innovat, Translat Res Informat Ctr, Kobe, Hyogo, Japan.
   [Kuno, Shin-ichi] Kobe Univ, Grad Sch Med, Clin Genome Informat Ctr, Kobe, Hyogo 6500017, Japan.
C3 Kobe University; Institute for Biomedical Research & Innovation (IBRI);
   Kobe University
RP Honda, S (通讯作者)，Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM sighonda@med.kobe-u.ac.jp
RI Honda, Shigeru/W-4761-2019
OI Kondo, Naoshi/0000-0001-6025-3876
FU Ministry of Education Science. Mid culture. Tokyo, Japan [20592042]
FX Supported by a Grant-in Aid (C) 20592042 from the Ministry of Education
   Science. Mid culture. Tokyo, Japan. The funding organization had no role
   in the design or conduct of this research.
CR Balding DJ, 2006, NAT REV GENET, V7, P781, DOI 10.1038/nrg1916
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Falush D, 2003, GENETICS, V164, P1567
   Fernando MMA, 2007, PLOS GENET, V3, P2109, DOI 10.1371/journal.pgen.0030192
   Fernando MMA, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000024
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Horton R, 2004, NAT REV GENET, V5, P889, DOI 10.1038/nrg1489
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Kubo M, 2007, NAT GENET, V39, P212, DOI 10.1038/ng1945
   Kwan T, 2008, NAT GENET, V40, P225, DOI 10.1038/ng.2007.57
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   LEE SG, 1995, GENOMICS, V25, P660, DOI 10.1016/0888-7543(95)80008-A
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   Muallem H, 2007, HUM GENET, V121, P421, DOI 10.1007/s00439-007-0327-1
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nyholt DR, 2004, AM J HUM GENET, V74, P765, DOI 10.1086/383251
   Pritchard JK, 2000, GENETICS, V155, P945
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Purcell S, 2007, BIOINFORMATICS, V23, P255, DOI 10.1093/bioinformatics/btl580
   Qu XD, 1998, NUCLEIC ACIDS RES, V26, P4068, DOI 10.1093/nar/26.17.4068
   Richardson AJ, 2009, INVEST OPHTH VIS SCI, V50, P540, DOI 10.1167/iovs.08-2423
   Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Wang N, 2002, AM J HUM GENET, V71, P1227, DOI 10.1086/344398
   Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864
   Yamada K, 2004, BIOL PSYCHIAT, V56, P683, DOI 10.1016/j.biopsych.2004.08.015
   Yamada K, 2007, P NATL ACAD SCI USA, V104, P2815, DOI 10.1073/pnas.0610765104
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZY, 1998, GENOMICS, V53, P338, DOI 10.1006/geno.1998.5499
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 56
TC 23
Z9 26
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2009
VL 116
IS 8
BP 1502
EP 1509
DI 10.1016/j.ophtha.2009.03.004
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 480CT
UT WOS:000268710200014
PM 19556007
DA 2022-11-30
ER

PT J
AU Cashman, SM
   Gracias, J
   Adhi, M
   Kumar-Singh, R
AF Cashman, Siobhan M.
   Gracias, Jessica
   Adhi, Mehreen
   Kumar-Singh, Rajendra
TI Adenovirus-mediated delivery of Factor H attenuates complement C-3
   induced pathology in the murine retina: a potential gene therapy for
   age-related macular degeneration
SO JOURNAL OF GENE MEDICINE
LA English
DT Article
DE AMD; complement; Factor H; gene therapy; mouse model; retina
ID MEMBRANE ATTACK COMPLEX; PIGMENT EPITHELIUM; IN-VIVO; CELLS; EXPRESSION;
   AMD; PHOTORECEPTORS; VECTORS; DISEASE; SYSTEM
AB Background Age-related macular degeneration (AMD) is the most common cause of blindness in the elderly, with no therapy available for 90% of patients. Recent genetic evidence implicates activation of complement in the pathogenesis of AMD. We have recently discovered that adenovirus (Ad)-mediated expression of complement component C3 (AdCMVC3) in the murine retina recapitulates many of the pathological features found in human AMD. In the present study, utilizing a gene therapy approach, we examine whether Ad-mediated expression of complement Factor H (AdCAGfH) attenuates AdCMVC3-mediated retinal pathology.
   Methods AdCMVC3 was co-injected with either AdCAGfH or a negative control virus expressing green fluorescent protein (AdCMVGFP) into the subretinal space of adult mice. The resulting retinal pathology was analyzed by histology and immunocytochemistry and retinal function was quantified by electroretinography.
   Results Morphological and functional analyses indicated that AdCMVC3-mediated retinal pathology could be attenuated by AdCAGfH. Specifically, endothelial cell proliferation was reduced by 91% and atrophy of retinal pigment epithelium (RPE) could be attenuated by 69%. AdCAGfH injected eyes exhibited 90-150% greater A-wave and 120-180% greater B-wave amplitudes relative to control eyes. Immunocytochemical analysis of rhodopsin and RPE65 was consistent with the rescue of photoreceptors and RPE in AdCAGfH injected eyes.
   Conclusions C3-induced pathology in murine retina can be attenuated by Ad-mediated expression of Factor H. Expression of Factor H is worthy of further study as a potential gene therapy for AMD. Copyright (C) 2015 John Wiley & Sons, Ltd.
C1 [Kumar-Singh, Rajendra] Tufts Univ, Sch Med, Dept Dev Mol & Chem Biol, Boston, MA 02111 USA.
   Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
C3 Tufts University; Tufts University
RP Kumar-Singh, R (通讯作者)，Tufts Univ, Sch Med, Dept Dev Mol & Chem Biol, 136 Harrison Ave, Boston, MA 02111 USA.
EM rajendra.kumar-singh@tufts.edu
RI Adhi, Mehreen/AAS-9733-2021
OI Kumar-Singh, Rajendra/0000-0002-7754-0713; Gracias,
   Jessica/0000-0002-1730-7821
FU Ellison Foundation; Virginia B Smith Trust; National Institute of
   Health/NEI [EY021805, EY013837]; Department of Defense/TATRC; Paul and
   Phyllis Fireman Foundation; NATIONAL EYE INSTITUTE [R01EY013837,
   R01EY021805] Funding Source: NIH RePORTER
FX We wish to thank Kerstin Birke for provding technical assistance. The
   present study was supported by grants to RKS from The Ellison
   Foundation, The Virginia B Smith Trust, The National Institute of
   Health/NEI (EY021805 and EY013837), The Department of Defense/TATRC and
   The Paul and Phyllis Fireman Foundation. SMC, JG and MA performed the
   research. SMC and RK contributed to study design, data analysis and
   writing of the paper. All authors declare that they have no conflicts of
   interest.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   BENZAQUEN LR, 1994, J EXP MED, V179, P985, DOI 10.1084/jem.179.3.985
   Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003
   Casaroli-Marano RP, 1999, INVEST OPHTH VIS SCI, V40, P2062
   Cashman SM, 2007, MOL THER, V15, P1640, DOI 10.1038/sj.mt.6300203
   Cashman SM, 2011, INVEST OPHTH VIS SCI, V52, P3436, DOI 10.1167/iovs.10-6002
   Cashman SM, 2002, MOL THER, V6, P813, DOI 10.1006/mthe.2002.0806
   Chuang JZ, 2010, MOL BIOL CELL, V21, P3017, DOI 10.1091/mbc.E09-10-0907
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gerth C, 2009, DOC OPHTHALMOL, V118, P63, DOI 10.1007/s10633-008-9133-x
   Green W R, 1999, Mol Vis, V5, P27
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   HALPERIN JA, 1993, J CLIN INVEST, V91, P1974, DOI 10.1172/JCI116418
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P58, DOI 10.1016/S0161-6420(96)30731-8
   Hiscott P, 2002, EYE, V16, P393, DOI 10.1038/sj.eye.6700196
   Holers VM, 2014, ANNU REV IMMUNOL, V32, P433, DOI 10.1146/annurev-immunol-032713-120154
   Kam JH, 2013, AM J PATHOL, V183, P480, DOI 10.1016/j.ajpath.2013.04.008
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   KRISTENSEN T, 1986, P NATL ACAD SCI USA, V83, P3963, DOI 10.1073/pnas.83.11.3963
   Lyzogubov VV, 2010, AM J PATHOL, V177, P1870, DOI 10.2353/ajpath.2010.091168
   Mandal NA, 2006, INVEST OPHTH VIS SCI, V47, P4091, DOI 10.1167/iovs.05-1655
   Markiewski MM, 2007, AM J PATHOL, V171, P715, DOI 10.2353/ajpath.2007.070166
   Marmorstein AD, 2001, TRAFFIC, V2, P867, DOI 10.1034/j.1600-0854.2001.21202.x
   MARSHALL J, 1979, BRIT J OPHTHALMOL, V63, P181, DOI 10.1136/bjo.63.3.181
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Niculescu F, 1997, J IMMUNOL, V158, P4405
   Nishiguchi KM, 2012, INVEST OPHTH VIS SCI, V53, P508, DOI 10.1167/iovs.11-8425
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Ramirez JM, 2001, EXP EYE RES, V73, P601, DOI 10.1006/exer.2001.1061
   Ramo K, 2008, INVEST OPHTH VIS SCI, V49, P4126, DOI 10.1167/iovs.08-2025
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   Shelley EJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P483, DOI 10.1001/archophthalmol.2008.622
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   von Leithner PL, 2009, AM J PATHOL, V175, P412, DOI 10.2353/ajpath.2009.080927
   Williams JAE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068616
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 45
TC 15
Z9 18
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1099-498X
EI 1521-2254
J9 J GENE MED
JI J. Gene. Med.
PD DEC
PY 2015
VL 17
IS 10-12
BP 229
EP 243
DI 10.1002/jgm.2865
PG 15
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA DA3DN
UT WOS:000367676800002
PM 26369397
DA 2022-11-30
ER

PT J
AU Wood, JM
   Lacherez, PF
   Black, AA
   Cole, MH
   Boon, MY
   Kerr, GK
AF Wood, Joanne M.
   Lacherez, Philippe F.
   Black, Alex A.
   Cole, Michael H.
   Boon, Mei Ying
   Kerr, Graham K.
TI Postural Stability and Gait among Older Adults with Age-Related
   Maculopathy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID VISUAL STABILIZATION; WATERLOO VISION; MOBILITY; FALLS; RISK;
   POPULATION; VALIDITY
AB PURPOSE. To assess the postural stability and gait characteristics of adults with age-related maculopathy (ARM) and to identify the visual factors associated with postural stability and gait in this clinical population.
   METHODS. Participants included 80 individuals with a range of severity of ARM (mean age, 77.2 years). Binocular visual function measures included visual acuity, contrast sensitivity, and merged binocular visual fields. Postural stability was assessed on both a firm and a foam surface using center-of-pressure measures derived from a force platform. Forty three of the participants underwent a three-dimensional motion analysis to quantify gait characteristics, including walking velocity, proportion of time spent with both feet in contact with the ground (double-support time), stride length, and step width.
   RESULTS. After adjustment for age, sex, self-reported physical function, and cataract severity, all the vision measures were significantly associated with postural stability on the foam surface, with contrast sensitivity being the strongest correlate. In the analysis of the gait measures, only contrast sensitivity was significantly associated with walking velocity, step width, or stride length, whereas contrast sensitivity and visual field loss were both significantly associated with double-support time.
   CONCLUSIONS. Impaired contrast sensitivity was associated with postural instability, slower walking velocity, increased step width, and reduced stride length. Impairments in either contrast sensitivity or visual fields were associated with increased double-support time. This result suggests that loss of contrast sensitivity and visual fields in patients with ARM can lead to balance and mobility problems. (Invest Ophthalmol Vis Sci. 2009; 50: 482-487) DOI:10.1167/iovs.08-1942
C1 [Wood, Joanne M.; Lacherez, Philippe F.; Black, Alex A.; Boon, Mei Ying] Queensland Univ Technol, Sch Optometry, Brisbane, Qld 4059, Australia.
   [Wood, Joanne M.; Lacherez, Philippe F.; Black, Alex A.; Cole, Michael H.; Boon, Mei Ying; Kerr, Graham K.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4059, Australia.
   [Cole, Michael H.; Kerr, Graham K.] Queensland Univ Technol, Sch Human Movement Studies, Brisbane, Qld 4059, Australia.
C3 Queensland University of Technology (QUT); Queensland University of
   Technology (QUT); Queensland University of Technology (QUT); University
   of Queensland
RP Wood, JM (通讯作者)，Queensland Univ Technol, Sch Optometry, Brisbane, Qld 4059, Australia.
EM j.wood@qut.edu.au
RI Cole, Michael H/O-6816-2018; Boon, Mei Ying/F-2194-2016; Black,
   Alex/I-9727-2012; Kerr, Graham/I-9705-2012
OI Boon, Mei Ying/0000-0002-9759-8402; Black, Alex/0000-0002-8671-5167;
   Kerr, Graham/0000-0002-1008-256X; Cole, Michael/0000-0003-1817-7528;
   Lacherez, Philippe/0000-0001-5717-4966; , Joanne/0000-0002-0776-7736
FU NHMRC (National Health and Medical Research Council)
FX Supported by the NHMRC (National Health and Medical Research Council)
   Prevention of Injuries in Older People Partnership in Injury grant.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   BROWN B, 1986, AM J OPTOM PHYS OPT, V63, P733
   Chan GNY, 2005, CLIN BIOMECH, V20, P396, DOI 10.1016/j.clinbiomech.2004.12.005
   Chia EM, 2006, ANN ACAD MED SINGAP, V35, P461
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Coleman AL, 2007, J AM GERIATR SOC, V55, P357, DOI 10.1111/j.1532-5415.2007.01094.x
   ELLIOTT DB, 1995, OPHTHAL PHYSL OPT, V15, P553, DOI 10.1016/0275-5408(95)00025-9
   Hassan SE, 2002, OPTOMETRY VISION SCI, V79, P697, DOI 10.1097/00006324-200211000-00007
   Heun R, 1998, INT J GERIATR PSYCH, V13, P368, DOI 10.1002/(SICI)1099-1166(199806)13:6<368::AID-GPS775>3.3.CO;2-0
   KADABA MP, 1990, J ORTHOP RES, V8, P383, DOI 10.1002/jor.1100080310
   Klein R, 2005, AM J OPHTHALMOL, V140, P129, DOI 10.1016/j.ajo.2004.12.049
   Kuyk T, 1999, J REHABIL RES DEV, V36, P303
   Lord SR, 2000, GERONTOLOGY, V46, P306, DOI 10.1159/000022182
   Lord SR, 2003, PHYS THER, V83, P237, DOI 10.1093/ptj/83.3.237
   Lord SR, 1996, AGE AGEING, V25, P292, DOI 10.1093/ageing/25.4.292
   LORD SR, 1991, J GERONTOL, V46, pM69, DOI 10.1093/geronj/46.3.M69
   Maki BE, 1997, J AM GERIATR SOC, V45, P313, DOI 10.1111/j.1532-5415.1997.tb00946.x
   McLean SG, 2005, BRIT J SPORT MED, V39, P355, DOI 10.1136/bjsm.2005.018598
   Nelson-Quigg JM, 2000, INVEST OPHTH VIS SCI, V41, P2212
   Perry J., 1992, GAIT ANAL NORMAL PAT
   SPAULDING SJ, 1994, OPTOMETRY VISION SCI, V71, P770, DOI 10.1097/00006324-199412000-00007
   SPAULDING SJ, 1995, GAIT POSTURE, V3, P227
   SUDARSKY L, 1990, NEW ENGL J MED, V322, P1441
   Tabachnick B.G., 2007, USING MULTIVARIATE S, V5
   TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604
   TURANO K, 1994, OPTOMETRY VISION SCI, V71, P761, DOI 10.1097/00006324-199412000-00006
   Turano KA, 1996, INVEST OPHTH VIS SCI, V37, P1483
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VERBAKEN JH, 1986, AM J OPTOM PHYS OPT, V63, P724
   Vuillerme N, 2007, NEUROSCI LETT, V421, P173, DOI 10.1016/j.neulet.2007.03.076
   Wilcox D T, 1989, J Am Optom Assoc, V60, P504
   Woollacott MH, 1997, PHYS THER, V77, P646, DOI 10.1093/ptj/77.6.646
NR 32
TC 67
Z9 68
U1 0
U2 15
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2009
VL 50
IS 1
BP 482
EP 487
DI 10.1167/iovs.08-1942
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 390YP
UT WOS:000262199900062
PM 18791170
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Guymer, RH
   Rosenfeld, PJ
   Curcio, CA
   Holz, FG
   Staurenghi, G
   Freund, KB
   Schmitz-Valckenberg, S
   Sparrow, J
   Spaide, RF
   Tufail, A
   Chakravarthy, U
   Jaffe, GJ
   Csaky, K
   Sarraf, D
   Mones, JM
   Tadayoni, R
   Grunwald, J
   Bottoni, F
   Liakopoulos, S
   Pauleikhoff, D
   Pagliarini, S
   Chew, EY
   Viola, F
   Fleckenstein, M
   Blodi, BA
   Lim, TH
   Chong, V
   Lutty, J
   Bird, AC
   Sadda, SR
AF Guymer, Robyn H.
   Rosenfeld, Philip J.
   Curcio, Christine A.
   Holz, Frank G.
   Staurenghi, Giovanni
   Freund, K. Bailey
   Schmitz-Valckenberg, Steffen
   Sparrow, Janet
   Spaide, Richard F.
   Tufail, Adnan
   Chakravarthy, Usha
   Jaffe, Glenn J.
   Csaky, Karl
   Sarraf, David
   Mones, Jordi M.
   Tadayoni, Ramin
   Grunwald, Juan
   Bottoni, Ferdinando
   Liakopoulos, Sandra
   Pauleikhoff, Daniel
   Pagliarini, Sergio
   Chew, Emily Y.
   Viola, Francesco
   Fleckenstein, Monika
   Blodi, Barbara A.
   Lim, Tock Han
   Chong, Victor
   Lutty, Jerry
   Bird, Alan C.
   Sadda, Srinivas R.
TI Incomplete Retinal Pigment Epithelial and Outer Retinal Atrophy in
   Age-Related Macular Degeneration Classification of Atrophy Meeting
   Report 4
SO OPHTHALMOLOGY
LA English
DT Article
ID SUBRETINAL DRUSENOID DEPOSITS; GEOGRAPHIC-ATROPHY; RETICULAR
   PSEUDODRUSEN; PROGRESSION; EYES; CLASSIFICATION; PREDICTOR; FEATURES
AB Purpose: To describe the defining features of incomplete retinal pigment epithelium (RPE) and outer retinal atrophy (iRORA), a consensus term referring to the OCT-based anatomic changes often identified before the development of complete RPE and outer retinal atrophy (cRORA) in age-related macular degeneration (AMD). We provide descriptive OCT and histologic examples of disease progression.
   Design: Consensus meeting.
   Participants: Panel of retina specialists, including retinal imaging experts, reading center leaders, and retinal histologists.
   Methods: As part of the Classification of Atrophy Meeting (CAM) program, an international group of experts analyzed and discussed longitudinal multimodal imaging of eyes with AMD. Consensus was reached on a classification system for OCT-based structural alterations that occurred before the development of atrophy secondary to AMD. New terms of iRORA and cRORA were defined. This report describes in detail the CAM consensus on iRORA.
   Main Outcome Measures: Defining the term iRORA through OCT imaging and longitudinal cases showing progression of atrophy, with histologic correlates.
   Results: OCT was used in cases of early and intermediate AMD as the base imaging method to identify cases of iRORA. In the context of drusen, iRORA is defined on OCT as (1) a region of signal hypertransmission into the choroid, (2) a corresponding zone of attenuation or disruption of the RPE, and (3) evidence of overlying photoreceptor degeneration. The term iRORA should not be used when there is an RPE tear. Longitudinal studies confirmed the concept of progression from iRORA to cRORA.
   Conclusions: An international consensus classification for OCT-defined anatomic features of iRORA are described and examples of longitudinal progression to cRORA are provided. The ability to identify these OCT changes reproducibly is essential to understand better the natural history of the disease, to identify high-risk signs of progression, and to study early interventions. Longitudinal data are required to quantify the implied risk of vision loss associated with these terms. The CAM classification provides initial definitions to enable these future endeavors, acknowledging that the classification will be refined as new data are generated. (C) 2019 by the American Academy of Ophthalmology
C1 [Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res, Dept Surg Ophthalmol, Melbourne, Vic, Australia.
   [Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, Birmingham, AL USA.
   [Holz, Frank G.; Schmitz-Valckenberg, Steffen; Fleckenstein, Monika] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Staurenghi, Giovanni; Bottoni, Ferdinando] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Eye Clin, Milan, Italy.
   [Freund, K. Bailey; Spaide, Richard F.] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Sparrow, Janet] Columbia Univ, Dept Ophthalmol, Med Ctr, New York, NY 10027 USA.
   [Sparrow, Janet] Columbia Univ, Dept Pathol & Cell Biol, Med Ctr, New York, NY USA.
   [Tufail, Adnan; Bird, Alan C.] UCL, Inst Ophthalmol, London, England.
   [Chakravarthy, Usha] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Jaffe, Glenn J.] Duke Univ, Dept Ophthalmol, Durham, NC USA.
   [Csaky, Karl] Retina Fdn Southwest, Dallas, TX USA.
   [Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Los Angeles, CA 90095 USA.
   [Mones, Jordi M.] Macula Fdn, Inst Macula & Barcelona, Barcelona, Spain.
   [Tadayoni, Ramin] Univ Paris 7 Sorbonne, Hop Lariboisiere, AP HP, Dept Ophthalmol, Paris, France.
   [Grunwald, Juan] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Liakopoulos, Sandra] Univ Cologne, Dept Ophthalmol, Cologne, Germany.
   [Pauleikhoff, Daniel] St Franziskus Hosp, Dept Ophthalmol, Munster, Germany.
   [Pagliarini, Sergio] Univ Hosp Coventry & Warwickshire, Dept Ophthalmol, Coventry, W Midlands, England.
   [Chew, Emily Y.] NEI, NIH, Bethesda, MD 20892 USA.
   [Viola, Francesco] Univ Milan, Osped Maggiore Policlin, Ca Granda Fdn, Milan, Italy.
   [Blodi, Barbara A.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Fundus Photograph Reading Ctr, Sch Med & Publ Hlth, Madison, WI USA.
   [Lim, Tock Han] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, Singapore, Singapore.
   [Chong, Victor] Univ Oxford, Oxford, England.
   [Lutty, Jerry] Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, Baltimore, MD 21287 USA.
   [Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Doheny Eye Inst, Los Angeles, CA 90095 USA.
C3 Royal Victorian Eye & Ear Hospital; University of Melbourne; Bascom
   Palmer Eye Institute; University of Miami; University of Alabama System;
   University of Alabama Birmingham; University of Bonn; University of
   Milan; Luigi Sacco Hospital; Vitreous Retina Macula Consultants of New
   York; Columbia University; Columbia University; University of London;
   University College London; Queens University Belfast; Duke University;
   Retina Foundation of the Southwest; University of California System;
   University of California Los Angeles; University of California Los
   Angeles Medical Center; David Geffen School of Medicine at UCLA;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities;
   Universite Paris Cite; University of Pennsylvania; University of
   Cologne; St. Franziskus-Hospital; University of Warwick; National
   Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI);
   IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan;
   University of Wisconsin System; University of Wisconsin Madison; Tan
   Tock Seng Hospital; University of Oxford; Johns Hopkins University;
   Johns Hopkins Medicine; Doheny Eye Institute; University of California
   System; University of California Los Angeles; University of California
   Los Angeles Medical Center; David Geffen School of Medicine at UCLA
RP Guymer, RH (通讯作者)，Ctr Eye Res Australia, Level 7,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM rhg@unimelb.edu.au
RI Spaide, Richard/ABD-7368-2020; mones, jordi/CAJ-2963-2022; viola,
   francesco/AAK-5583-2020; Chong, Victor/Q-6565-2018; Freund, K.
   Bailey/V-7488-2018
OI mones, jordi/0000-0003-3685-2160; viola, francesco/0000-0003-1208-913X;
   Curcio, Christine/0000-0001-9769-1538; Chong,
   Victor/0000-0002-7693-522X; Tufail, Adnan/0000-0001-6131-7640; Freund,
   K. Bailey/0000-0002-7888-9773
FU National Institutes of Health, Bethesda, Maryland [R01EY06019, P30
   EY003039]; National Institutes of Health [R01EY024091, R01EY12951, R24
   EY027285, P30EY019007]; EyeSight Foundation of Alabama; International
   Retinal Research Foundation; Edward N. and Della L. Thome Foundation;
   Arnold and Mabel Beckman Initiative for Macular Research; Research to
   Prevent Blindness, Inc, New York, New York; Lowy Research Medical
   Institute; National Health & Medical Research Council of Australia
   [GNT1103013]; Foundation Fighting Blindness; National Institute for
   Health Research Biomedical Research Centre Moorfields Eye Hospital,
   London, United Kingdom; Macula Foundation, New York
FX Acquisition of human donor eyes and the Project MACULA website were
   supported by the National Institutes of Health, Bethesda, Maryland
   (grant nos.: R01EY06019 [C.A.C.] and P30 EY003039 [C.A.C.]), the
   National Institutes of Health (grant nos.: R01EY024091 [J.S.],
   R01EY12951 [J.S.], R24 EY027285 [J.S.], and P30EY019007 [J.S.]);
   EyeSight Foundation of Alabama (C.A.C.); International Retinal Research
   Foundation (C.A.C.); the Edward N. and Della L. Thome Foundation
   (C.A.C.; J.S.); the Arnold and Mabel Beckman Initiative for Macular
   Research (C.A.C.; J.S.); Research to Prevent Blindness, Inc, New York,
   New York (C.A.C., J.S.); the Lowy Research Medical Institute (A.C.B.);
   the National Health & Medical Research Council of Australia (fellowship
   no.: GNT1103013 [R.H.G.]); Foundation Fighting Blindness (J.S.); and the
   National Institute for Health Research Biomedical Research Centre
   Moorfields Eye Hospital, London, United Kingdom (A.T.).
   Clinicopathologic correlation supported by the Macula Foundation, New
   York (C.A.C.).
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bottoni F, 2011, INVEST OPHTH VIS SCI, V52, P4439, DOI 10.1167/iovs.10-6732
   Cheng QE, 2018, OPHTHALMOL RETINA, V2, P518, DOI 10.1016/j.oret.2017.08.018
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Csaky K, 2017, INVEST OPHTH VIS SCI, V58, P3456, DOI 10.1167/iovs.17-22339
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Dolz-Marco R, 2018, AM J OPHTHALMOL, V193, P166, DOI 10.1016/j.ajo.2018.06.020
   Dolz-Marco R, 2017, OPHTHALMOLOGY, V124, P1353, DOI 10.1016/j.ophtha.2017.03.043
   Edwards MM, 2017, INVEST OPHTH VIS SCI, V58, P1352, DOI 10.1167/iovs.16-21229
   Ferrara D, 2017, INVEST OPHTH VIS SCI, V58, P3519, DOI 10.1167/iovs.17-21696
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2019, OPHTHALMOLOGICA, V241, P61, DOI 10.1159/000491402
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Guo JL, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0737-y
   Guymer RH, 2018, OPHTHALMOL RETINA, V2, P515, DOI 10.1016/j.oret.2018.03.004
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Landa G, 2012, EYE, V26, P61, DOI 10.1038/eye.2011.237
   Li ML, 2019, RETINA-J RET VIT DIS, V39, P802, DOI 10.1097/IAE.0000000000002461
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   Mones J, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.026
   Nassisi M, 2019, BRIT J OPHTHALMOL, V103, P911, DOI 10.1136/bjophthalmol-2018-312643
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schaal KB, 2017, AM J OPHTHALMOL, V174, P145, DOI 10.1016/j.ajo.2016.11.002
   Schmitz-Valckenberg S, 2017, OPHTHALMOLOGICA, V237, P11, DOI 10.1159/000455074
   Schmitz-Valckenberg S, 2016, RETINA-J RET VIT DIS, V36, P2250, DOI 10.1097/IAE.0000000000001258
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Stetson PF, 2014, INVEST OPHTH VIS SCI, V55, P792, DOI 10.1167/iovs.13-13199
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Veerappan M, 2016, OPHTHALMOLOGY, V123, P2554, DOI 10.1016/j.ophtha.2016.08.047
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P1546, DOI 10.1167/iovs.14-16211
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 44
TC 75
Z9 76
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2020
VL 127
IS 3
BP 394
EP 409
DI 10.1016/j.ophtha.2019.09.035
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KN4ST
UT WOS:000514829200017
PM 31708275
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Cheng, Q
   Saaddine, JB
   Klein, R
   Rothenberg, R
   Chou, CF
   Il'yasova, D
AF Cheng, Qi
   Saaddine, Jinan B.
   Klein, Ronald
   Rothenberg, Richard
   Chou, Chiu-Fang
   Il'yasova, Dora
TI Early Age-related Macular Degeneration with Cardiovascular and Renal
   Comorbidities: An Analysis of the National Health and Nutrition
   Examination Survey, 2005-2008
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Early AMD; Cardiovascular and renal conditions; Comorbidity; NHANES
ID CHRONIC KIDNEY-DISEASE; RISK-FACTORS; MYOCARDIAL-INFARCTION; CUMULATIVE
   INCIDENCE; OXIDATIVE STRESS; NATURAL-HISTORY; PREVALENCE; MACULOPATHY;
   ATHEROSCLEROSIS; ASSOCIATION
AB Purpose: A cross sectional study was designed to examine the relationship of early age-related macular degeneration (AMD) with comorbidities of cardiovascular and renal conditions in the representative population using National Health and Nutrition Examination Survey (NHANES), 2005-2008.
   Methods: Participants (>= 40 years) who underwent retinal photography were included. Early AMD was defined by the retinal digital images. The comorbidities were self-reported stroke and heart disease (HD), including angina pectoris (AP), coronary heart disease (CHD), congestive heart failure (CHF), and myocardial infarction (MI). Chronic kidney disease (CKD) was determined based on self-report, estimation of glomerular filtration rate (GFR), or the level of urine albumin.
   Results: The age-adjusted odds ratio (OR) and 95% CI for having early AMD for persons with the selected conditions were: 2.6 (1.9, 3.6) for any type of HD. When the conditions were considered separately, ORs (95% CIs) were: 2.0 (1.2, 3.4) for AP; 2.5 (1.6, 3.8) for CHD; 2.4 (1.6, 3.6) for MI; 2.3 (1.3, 3.9) for CHF; 3.3 (2.2, 5.0) for stroke; and 2.4 (1.8, 3.2) for CKD. Covariable-adjusted ORs (AOR) were attenuated for all examined conditions, but remained statistically significant. Having any single condition (AOR [95%CI]: 2.7 [1.5, 4.8]) was significantly associated with early AMD, as was having >= 2 conditions (AOR [95%CI]: 5.2 [3.0, 9.0]). The strongest association was between early AMD and the combination of HD and stroke (AOR [95% CI]: 6.3 [2.9, 13.8]).
   Conclusion: Cardiovascular and renal comorbidities are associated with early AMD in a representative sample of the US general population.
C1 [Cheng, Qi; Rothenberg, Richard; Il'yasova, Dora] Georgia State Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Urban Life Bldg,Suite 878,140 Decatur St, Atlanta, GA 30303 USA.
   [Saaddine, Jinan B.; Chou, Chiu-Fang] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA.
   [Klein, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA.
C3 University System of Georgia; Georgia State University; Centers for
   Disease Control & Prevention - USA; University of Wisconsin System;
   University of Wisconsin Madison
RP Il'yasova, D (通讯作者)，Georgia State Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Urban Life Bldg,Suite 878,140 Decatur St, Atlanta, GA 30303 USA.
EM dilyasova@gsu.edu
CR Akpek EK, 2013, AM J MANAG CARE, V19, pS67
   Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Cardarelli WJ, 2013, AM J MANAG CARE, V19, pS85
   Centers for Disease Control and Prevention (CDC) National Center for Health Statistics, 2017, NATL HLTH NUTR EXAMI
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Choi J, 2011, OPHTHAL EPIDEMIOL, V18, P259, DOI 10.3109/09286586.2011.602509
   Chong EW, 2014, OPTOMETRY VISION SCI, V91, P860, DOI 10.1097/OPX.0000000000000288
   Chowdhury R, 2014, ANN INTERN MED, V160, P398, DOI 10.7326/M13-1788
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dasch B, 2005, OPHTHALMOLOGE, V102, P1057, DOI 10.1007/s00347-005-1225-3
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939
   Fernandez AB, 2012, OPHTHALMOLOGY, V119, P765, DOI 10.1016/j.ophtha.2011.09.044
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Golan S, 2011, GRAEF ARCH CLIN EXP, V249, P179, DOI 10.1007/s00417-010-1489-4
   Horton M, 2010, NEUROEPIDEMIOLOGY, V35, P83, DOI 10.1159/000311013
   Howard KP, 2014, INVEST OPHTH VIS SCI, V55, P2592, DOI 10.1167/iovs.13-13763
   Ikram MK, 2012, STROKE, V43, P1681, DOI 10.1161/STROKEAHA.112.654632
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Klein R, 2013, OPHTHALMOLOGY, V120, P1012, DOI 10.1016/j.ophtha.2012.11.003
   Klein R, 2013, JAMA OPHTHALMOL, V131, P383, DOI 10.1001/jamaophthalmol.2013.713
   Klein R, 2009, ARCH OPHTHALMOL-CHIC, V127, P193, DOI 10.1001/archophthalmol.2008.551
   Liao DP, 2008, OPEN OPHTHALMOL J, V2, P37, DOI 10.2174/1874364100802010037
   Liew G, 2008, J AM SOC NEPHROL, V19, P806, DOI 10.1681/ASN.2007080844
   Liutkeviciene R, 2012, CURR EYE RES, V37, P94, DOI 10.3109/02713683.2011.629069
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Popolo A, 2013, FREE RADICAL RES, V47, P346, DOI 10.3109/10715762.2013.779373
   Rein DB, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12818
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tonelli M, 2014, NEPHRON CLIN PRACT, V128, P319, DOI 10.1159/000362458
   Wieberdink RG, 2011, STROKE, V42, P2138, DOI 10.1161/STROKEAHA.111.616359
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089600
   Yoon JL, 2015, J KOREAN MED SCI, V30, P162, DOI 10.3346/jkms.2015.30.2.162
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 45
TC 7
Z9 7
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PY 2017
VL 24
IS 6
BP 413
EP 419
DI 10.1080/09286586.2017.1337911
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FN4AG
UT WOS:000415944200009
PM 28891729
DA 2022-11-30
ER

PT J
AU Avila, MP
   Farah, ME
   Santos, A
   Carla, L
   Fuji, G
   Rossi, J
   Nau, J
AF Avila, Marcos P.
   Farah, Michael E.
   Santos, Arturo
   Carla, Livia
   Fuji, Gildo
   Rossi, Juliana
   Nau, Jeffrey
TI THREE-YEAR SAFETY AND VISUAL ACUITY RESULTS OF EPIMACULAR
   (90)STRONTIUM/(90)YTTRIUM BRACHYTHERAPY WITH BEVACIZUMAB FOR THE
   TREATMENT OF SUBFOVEAL CHOROIDAL NEOVASCULARIZATION SECONDARY TO
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; subfoveal choroidal
   neovascularization; epiretinal brachytherapy; bevacizumab; radiation;
   anti-VEGF therapy; combination therapy
ID RADIATION-THERAPY; SUBRETINAL NEOVASCULARIZATION; PLAQUE RADIOTHERAPY;
   RANIBIZUMAB; IRRADIATION; UVEITIS
AB Purpose: To evaluate the long-term safety and visual acuity outcomes associated with epimacular strontium 90 brachytherapy combined with intravitreal bevacizumab for the treatment of subfoveal choroidal neovascularization because of age-related macular degeneration.
   Methods: Thirty-four treatment-naive patients with predominantly classic, minimally classic, and occult subfoveal choroidal neovascularization lesions participated in this prospective, 2-year, nonrandomized multicenter study. Subjects from 1 center (n = 19) were reconsented and followed-up for 3 years. Each subject received a single 24-Gy beta irradiation treatment via an intraocular delivery device and 2 planned injections of bevacizumab at treatment and 1 month later. Additional bevacizumab therapy was permitted based on prespecified retreatment criteria. Adverse events were observed, and best-corrected visual acuity was measured using Early Treatment Diabetic Retinopathy Study vision charts. Subjects were evaluated every 3 months during the first year of follow-up and every 6 months during Years 2 and 3 of follow-up.
   Results: All 34 subjects were followed-up for 24 months and 19 were followed-up through 36 months. With up to 24 months of follow-up, 12 of 24 phakic patients (50%) exhibited >= 2 grades of progression in Lens Opacification Classification System (LOCS) II lens classification; 5 eyes underwent cataract extraction before the Month 36 visit. There was 1 case of nonproliferative retinopathy identified at 36 months of follow-up that did not have an adverse effect on visual acuity, was stable at 43 months of follow-up, and was isolated to the parafoveal region. Mean best-corrected visual acuity demonstrated an average gain of +15.0 and -4.9 letters at 12 months and 24 months, respectively; the drop in mean gain at Month 24 was largely attributable to cataract formation. At 36 months (n = 19), the mean best-corrected visual acuity was +3.9, 90% (17 of 19) of eyes had lost <15 letters from baseline, 53% (10 of 19) had gained >= 1 letter, and 21% (4 of 19) had gained >= 15 letters. Through 36 months, 11 eyes required additional bevacizumab retreatment therapy and received a mean of 3.0 injections (range, 2-7 injections).
   Conclusion: Epimacular brachytherapy shows promise as a therapeutic option for subfoveal neovascular age-related macular degeneration. The procedure was safe and well tolerated, with a reasonable risk-benefit profile that warrants further study in larger subject populations. The most common adverse event was cataract progression/formation. Surgical complications are similar to those expected from standard vitrectomy trials. This novel device is currently being evaluated in two prospective, randomized, controlled trials in treatment-naive subjects (CABERNET) and in subjects already treated with anti-vascular endothelial growth factor therapy (MERLOT). RETINA 32:10-18, 2012
C1 [Avila, Marcos P.; Carla, Livia] Fed Univ Goiana, CBCO, Goiania, Brazil.
   [Farah, Michael E.; Fuji, Gildo; Rossi, Juliana] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Santos, Arturo] Med Ctr Puerta de Hierro, Ctr Med & Surg Retina, Guadalajara, Jalisco, Mexico.
   [Nau, Jeffrey] NeoVista Inc, Newark, CA USA.
C3 Universidade Federal de Sao Paulo (UNIFESP)
RP Avila, MP (通讯作者)，Univ Fed Goias, Ctr Referencia Oftalmol, BR-74210010 Goiania, Go, Brazil.
EM marcosavila@cbco.com.br
RI Santos, Arturo/GQQ-1431-2022; Farah, Michel Eid E/F-3285-2012; Santos,
   Arturo/O-3420-2019
OI Farah, Michel Eid E/0000-0001-5951-0193; 
CR Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Avila MP, 2009, RETINA-J RET VIT DIS, V29, P157, DOI 10.1097/IAE.0b013e3181985915
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   BROWN G, 2009, EVIDENCE BASED OPHTH, V10, P107
   Callanan DG, 2008, ARCH OPHTHALMOL-CHIC, V126, P1191, DOI 10.1001/archopht.126.9.1191
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   Chieh JJ, 2008, AM J OPHTHALMOL, V146, P589, DOI 10.1016/j.ajo.2008.05.035
   DEGOWIN RL, 1974, J LAB CLIN MED, V84, P42
   Finger PT, 1996, OPHTHALMOLOGY, V103, P878, DOI 10.1016/S0161-6420(96)30592-7
   Finger PT, 2003, BRIT J OPHTHALMOL, V87, P1497, DOI 10.1136/bjo.87.12.1497
   Finger PT, 1999, AM J OPHTHALMOL, V127, P170, DOI 10.1016/S0002-9394(98)00389-4
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Genentech, 2010, LUC PRESCR INF
   Gunduz K, 1999, ARCH OPHTHALMOL-CHIC, V117, P609
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Jaakkola A, 2005, OPHTHALMOLOGY, V112, P567, DOI 10.1016/j.ophtha.2004.11.029
   Jaakkola A, 1999, ACTA OPHTHALMOL SCAN, V77, P57, DOI 10.1034/j.1600-0420.1999.770113.x
   Kirwan JF, 2003, EYE, V17, P207, DOI 10.1038/sj.eye.6700306
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
NR 22
TC 18
Z9 18
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2012
VL 32
IS 1
BP 10
EP 18
DI 10.1097/IAE.0b013e31822528fc
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 870IE
UT WOS:000298661800003
PM 21817963
DA 2022-11-30
ER

PT J
AU Capoluongo, E
   Concolino, P
   Piccardi, M
   Marangoni, D
   Mello, E
   Minnella, AM
   Savastano, C
   Fadda, A
   Zuppi, C
   Bisti, S
   Falsini, B
AF Capoluongo, Ettore
   Concolino, Paola
   Piccardi, Marco
   Marangoni, Dario
   Mello, Enrica
   Minnella, Angelo Maria
   Savastano, Cristina
   Fadda, Antonello
   Zuppi, Cecilia
   Bisti, Silvia
   Falsini, Benedetto
TI Retinal function and CFH-ARMS2 polymorphisms analysis: a pilot study in
   Italian AMD patients
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Age-related macular degeneration; Complement factor H; Early diagnosis;
   Electroretinography; Flicker sensitivity; Gene polymorphisms
ID COMPLEMENT FACTOR-H; AGE-RELATED MACULOPATHY; MACULAR DEGENERATION;
   FLICKER SENSITIVITY; OUTER-RETINA; HTRA1; GENE; SUPPLEMENTATION;
   ADAPTATION; MODULATION
AB Two major susceptibility genes, complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2), have been implicated in age-related macular degeneration (AMD) pathogenesis. We analyzed the association between CFH rs1061170 and/or ARMS2 rs10490924 polymorphisms with central retinal function properties, as evaluated by focal electroretinogram (fERG). Forty early AMD patients, with preserved visual acuity and typical macular lesions, underwent fERG recording (in response to 41 Hz flicker stimuli presented to the central 18 degrees) and CFH/ARMS2 genotyping. Mean fERG amplitude and sensitivity decreased in patients carrying CFH rs1061170 polymorphism (p < 0.01), compared with wild type ones, although visual acuity and funduscopic features were similar across the 2 groups. No significant fERG phase changes were observed. No association was detected between ARMS2 (rs10490924) polymorphism and fERG parameters. Our findings indicate that CFH (rs1061170) polymorphism impacts significantly on retinal function in early AMD patients, and support the hypothesis that dysfunctional CFH might result in early retinal function loss due to a reduction in the immune antioxidant defense mechanism. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Capoluongo, Ettore; Concolino, Paola; Mello, Enrica; Zuppi, Cecilia] Univ Cattolica Sacro Cuore, Ist Biochim Clin, Rome, Italy.
   [Piccardi, Marco; Marangoni, Dario; Minnella, Angelo Maria; Savastano, Cristina; Falsini, Benedetto] Univ Cattolica Sacro Cuore, Ist Oftalmol, Rome, Italy.
   [Fadda, Antonello] Ist Super Sanita, Lab Ingn Biomed, I-00161 Rome, Italy.
   [Bisti, Silvia] Univ Aquila, Dipartimento Tecnol Biomed, I-67100 Laquila, Italy.
C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Istituto Superiore di Sanita (ISS); University of L'Aquila
RP Concolino, P (通讯作者)，Catholic Univ, Largo A Gemelli 8, I-00168 Rome, Italy.
EM paolaconcolino78@libero.it
RI Savastano, Maria Cristina/I-5355-2015; Falsini, Benedetto/AAC-5907-2022;
   minnella, angelo maria/AAQ-6250-2020; concolino, paola/AAB-7427-2022;
   Piccardi, Marco/AAA-7849-2019; Falsini, Benedetto/V-1070-2019; Fadda,
   Antonello/J-1560-2012
OI Savastano, Maria Cristina/0000-0003-1397-4333; minnella, angelo
   maria/0000-0001-5896-5313; Falsini, Benedetto/0000-0002-1694-1062;
   Fadda, Antonello/0000-0001-7004-5245; Falsini,
   Benedetto/0000-0002-3569-4968; PICCARDI, Marco/0000-0002-9836-7534;
   Concolino, Paola/0000-0002-3472-8898; CAPOLUONGO, Ettore
   Domenico/0000-0003-4402-8403
CR Allikmets R, 2008, NAT GENET, V40, P820, DOI 10.1038/ng0708-820
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bush RA, 1996, J OPT SOC AM A, V13, P557, DOI 10.1364/JOSAA.13.000557
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995
   Feigl B, 2011, INVEST OPHTH VIS SCI, V52, P1145, DOI 10.1167/iovs.10-5967
   FIORENTINI A, 1981, INVEST OPHTH VIS SCI, V21, P490
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Haines JL, 2007, P NATL ACAD SCI USA, V104, P16725, DOI 10.1073/pnas.0708151104
   Jackson GR, 1998, VISION RES, V38, P3655, DOI 10.1016/S0042-6989(98)00044-3
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kanda A, 2010, MOL VIS, V16, P1317
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Mello E, 2012, CLIN CHEM LAB MED, V50, P1031, DOI 10.1515/cclm-2011-0859
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   NELSON JI, 1984, J CLIN NEUROPHYSIOL, V1, P409
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   Piccardi M, 2009, OPHTHALMIC RES, V41, P194, DOI 10.1159/000217723
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schatz H., 1989, RETINA, P3
   Scholl HPN, 2007, MOL VIS, V13, P196
   SEIPLE W, 1992, VISION RES, V32, P2043, DOI 10.1016/0042-6989(92)90065-Q
   Seiple W, 1996, J OPT SOC AM A, V13, P658, DOI 10.1364/JOSAA.13.000658
   SEIPLE WH, 1986, INVEST OPHTH VIS SCI, V27, P1123
   SEIPLE WH, 1993, INVEST OPHTH VIS SCI, V34, P2638
   SEIPLE WH, 1986, AM J OPTOM PHYS OPT, V63, P1
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   WU S, 1995, VISION RES, V35, P2943, DOI 10.1016/0042-6989(95)00087-G
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
NR 40
TC 5
Z9 5
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0197-4580
EI 1558-1497
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD AUG
PY 2012
VL 33
IS 8
AR 1852.e5
DI 10.1016/j.neurobiolaging.2012.03.008
PG 8
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 969QN
UT WOS:000306070800062
PM 22552255
DA 2022-11-30
ER

PT J
AU Cabrera, AP
   Stoddard, J
   Tierno, IS
   Matisioudis, N
   Agarwal, M
   Renner, L
   Palegar, N
   Neuringer, M
   McGill, T
   Ghosh, K
AF Cabrera, Andrea P.
   Stoddard, Jonathan
   Santiago Tierno, Irene
   Matisioudis, Nikolaos
   Agarwal, Mahesh
   Renner, Lauren
   Palegar, Neha
   Neuringer, Martha
   McGill, Trevor
   Ghosh, Kaustabh
TI Increased cell stiffness contributes to complement-mediated injury of
   choroidal endothelial cells in a monkey model of early age-related
   macular degeneration
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE choroid; endothelial cells; complement activation; stiffness;
   mechanotransduction; Rho; Rac; actin; age-related macular degeneration
ID CONTRACTILITY; ARTERIES; CULTURE
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the aging population. Yet no therapies exist for similar to 85% of all AMD patients who have the dry form that is marked by degeneration of the retinal pigmented epithelium (RPE) and underlying choroidal vasculature. As the choroidal vessels are crucial for RPE development and maintenance, understanding how they degenerate may lead to effective therapies for dry AMD. One likely causative factor for choroidal vascular loss is the cytolytic membrane attack complex (MAC) of the complement pathway that is abundant on choroidal vessels of humans with early dry AMD. To examine this possibility, we studied the effect of complement activation on choroidal endothelial cells (ECs) isolated from a rhesus monkey model of early AMD that, we report, exhibits MAC deposition and choriocapillaris endothelial loss similar to that seen in human early AMD. Treatment of choroidal ECs from AMD eyes with complement-competent normal human serum caused extensive actin cytoskeletal injury that was significantly less pronounced in choroidal ECs from young normal monkey eyes. We further show that ECs from AMD eyes are significantly stiffer than their younger counterparts and exhibit peripheral actin organization that is distinct from the longitudinal stress fibers in young ECs. Finally, these differences in complement susceptibility and mechanostructural properties were found to be regulated by the differential activity of the small GTPases Rac and Rho, because Rac inhibition in AMD cells led to simultaneous reduction in stiffness and complement susceptibility, while Rho inhibition in young cells exacerbated complement injury. Thus, by identifying cell stiffness and cytoskeletal regulators Rac and Rho as important determinants of complement susceptibility, the current findings offer a new mechanistic insight into choroidal vascular loss in early AMD that warrants further investigation for assessment of translational potential. (C) 2022 The Pathological Society of Great Britain and Ireland.
C1 [Cabrera, Andrea P.; Palegar, Neha; Ghosh, Kaustabh] Univ Calif Riverside, Dept Bioengn, Riverside, CA 92521 USA.
   [Stoddard, Jonathan; Renner, Lauren; Neuringer, Martha; McGill, Trevor] Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Div Neurosci, Beaverton, OR USA.
   [Santiago Tierno, Irene; Agarwal, Mahesh; Ghosh, Kaustabh] Univ Calif Los Angeles, Dept Ophthalmol, Los Angeles, CA USA.
   [Santiago Tierno, Irene; Ghosh, Kaustabh] Univ Calif Los Angeles, Mol Cellular & Integrated Physiol Interdept PhD P, Los Angeles, CA USA.
   [Santiago Tierno, Irene; Matisioudis, Nikolaos; Agarwal, Mahesh; Ghosh, Kaustabh] Doheny Eye Inst, Pasadena, CA USA.
   [Neuringer, Martha; McGill, Trevor] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA.
   [Cabrera, Andrea P.] Univ New Mexico, Dept Ophthalmol & Visual Sci, Albuquerque, NM 87131 USA.
   [Matisioudis, Nikolaos] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA.
C3 University of California System; University of California Riverside;
   Oregon Health & Science University; Oregon National Primate Research
   Center; University of California System; University of California Los
   Angeles; University of California System; University of California Los
   Angeles; Doheny Eye Institute; Oregon Health & Science University;
   University of New Mexico; University of Pennsylvania
RP Ghosh, K (通讯作者)，Univ Calif Los Angeles, Dept Ophthalmol, Doheny Eye Inst, 150 N Orange Grove Blvd, Pasadena, CA 91103 USA.
EM ghoshk@ucla.edu
RI Agarwal, Mahesh/GQG-8702-2022
OI Agarwal, Mahesh/0000-0002-0529-0196; GHOSH, KAUSTABH/0000-0001-8185-9180
FU BrightFocus Foundation [M2016161]; BCOE at UC Riverside; Doheny Eye
   Institut; W.M. Keck Foundation; Research to Prevent Blindness, Inc.; NIH
   [51OD011092, S10RR024585, P30EY010572]
FX Acknowledgement is made to the donors of Macular Degeneration Research,
   a program of the BrightFocus Foundation, for support of this research
   (Grant M2016161 to KG). This work was also supported by the Initial
   Complement Funds provided by the BCOE at UC Riverside (to KG), Start-up
   Funds provided by the Doheny Eye Institute (to KG), The Stephen Ryan
   Initiative for Macular Research (RIMR) Special Grant from W.M. Keck
   Foundation (to Doheny Eye Institute), an Unrestricted Grant from
   Research to Prevent Blindness, Inc. (to KG and UCLA Ophthalmology), and
   NIH grants 51OD011092 and S10RR024585 (to ONPRC), and P30EY010572 (to
   the Casey Eye Institute).
CR Benedicto I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15374
   Birukova AA, 2007, AM J PHYSIOL-LUNG C, V293, pL199, DOI 10.1152/ajplung.00020.2007
   Boucher E, 2019, CURR TOP MEMBR, V84, P17, DOI 10.1016/bs.ctm.2019.07.004
   Browning AC, 2005, BRIT J OPHTHALMOL, V89, P1343, DOI 10.1136/bjo.2004.063602
   Cabrera AP, 2016, INVEST OPHTH VIS SCI, V57, P5910, DOI 10.1167/iovs.16-19727
   Chirco KR, 2016, EXP EYE RES, V146, P393, DOI 10.1016/j.exer.2015.09.003
   Donato AJ, 2018, CIRC RES, V123, P825, DOI 10.1161/CIRCRESAHA.118.312563
   Eitzen G, 2003, BBA-MOL CELL RES, V1641, P175, DOI 10.1016/S0167-4889(03)00087-9
   Ghosh K, 2008, P NATL ACAD SCI USA, V105, P11305, DOI 10.1073/pnas.0800835105
   Ghosh K, 2007, ADV DRUG DELIVER REV, V59, P1306, DOI 10.1016/j.addr.2007.08.014
   Ghosh K, 2007, BIOMATERIALS, V28, P671, DOI 10.1016/j.biomaterials.2006.09.038
   Gorgoulis V, 2019, CELL, V179, P813, DOI 10.1016/j.cell.2019.10.005
   Gutierrez LM, 2012, INT REV CEL MOL BIO, V295, P109, DOI 10.1016/B978-0-12-394306-4.00009-5
   Hadziahmetovic M, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.612812
   Huveneers S, 2015, CIRC RES, V116, P895, DOI 10.1161/CIRCRESAHA.116.305720
   Huynh J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002761
   Janmey PA, 2020, PHYSIOL REV, V100, P695, DOI 10.1152/physrev.00013.2019
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kothapalli D, 2012, CELL REP, V2, P1259, DOI 10.1016/j.celrep.2012.09.018
   Kotliar KE, 2011, BRIT J OPHTHALMOL, V95, P675, DOI 10.1136/bjo.2010.181263
   Kunschmann T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43975-0
   Lampi MC, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao0475
   Lehmann GL, 2020, J EXP MED, V217, DOI 10.1084/jem.20190730
   Lutty GA, 2020, EXP EYE RES, V192, DOI 10.1016/j.exer.2020.107939
   Mammoto A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2774
   Marnmoto A, 2008, CURR OPIN HEMATOL, V15, P228, DOI 10.1097/MOH.0b013e3282fa7445
   Mohan RR, 2016, MOL VIS, V22, P1280
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Mullins RF, 2014, ADV EXP MED BIOL, V801, P283, DOI 10.1007/978-1-4614-3209-8_36
   NRC, 2011, GUIDE CARE USE LAB A, V8th, DOI [10.17226/12910, DOI 10.17226/12910]
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Sahu A, 2003, MOL IMMUNOL, V39, P557, DOI 10.1016/S0161-5890(02)00212-2
   Schaefer A, 2015, J CELL SCI, V128, P2221, DOI 10.1242/jcs.163055
   Scott HA, 2016, INTEGR BIOL-UK, V8, P869, DOI 10.1039/c6ib00084c
   Topham PS, 1999, KIDNEY INT, V55, P1763, DOI 10.1046/j.1523-1755.1999.00407.x
   Voigt AP, 2020, MICROVASC RES, V131, DOI 10.1016/j.mvr.2020.104031
   Wang MY, 2014, GERONTOLOGY, V60, P519, DOI 10.1159/000362548
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Yang X, 2016, FASEB J, V30, P601, DOI 10.1096/fj.15-277962
   Yeung T, 2005, CELL MOTIL CYTOSKEL, V60, P24, DOI 10.1002/cm.20041
   Zeng SM, 2016, J PATHOL, V238, P446, DOI 10.1002/path.4669
NR 44
TC 0
Z9 0
U1 3
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
EI 1096-9896
J9 J PATHOL
JI J. Pathol.
PD JUL
PY 2022
VL 257
IS 3
BP 314
EP 326
DI 10.1002/path.5892
EA APR 2022
PG 13
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA 1T6IZ
UT WOS:000779273400001
PM 35239183
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Nowak, JZ
AF Nowak, Jerzy Z.
TI Oxidative stress, polyunsaturated fatty acids-derived oxidation products
   and bisretinoids as potential inducers of CNS diseases: focus on
   age-related macular degeneration
SO PHARMACOLOGICAL REPORTS
LA English
DT Review
DE oxidative stress; polyunsaturated fatty acids peroxidation;
   docosahexaenoic acid; carboxyalkylpyrroles; bisretinoids; retina;
   age-related macular degeneration
ID RETINAL-PIGMENT EPITHELIUM; DOCOSAHEXAENOIC ACID; PHOTOOXIDATION
   PRODUCTS; DOCOSAPENTAENOIC ACID; COMPLEMENT ACTIVATION; RPE LIPOFUSCIN;
   FREE-RADICALS; DAMAGE; PATHOGENESIS; INFLAMMATION
AB Many pathologies of the central nervous system (CNS) originate from excess of reactive free radicals, notably reactive oxygen species (ROS), and oxidative stress. A phenomenon which usually runs in parallel with oxidative stress is unsaturated lipid peroxidation, which, via a chain reaction, contributes to the progression of disbalanced redox homeostasis. Among long-chain (LC) polyunsaturated fatty acids (PUFAs) abundantly occurring in the CNS, docosahexaenoic acid (DHA), a member of omega-3 LC-PUFAs, deserves special attention, as it is avidly retained and uniquely concentrated in the nervous system, particularly in retinal photoreceptors and synaptic membranes; owing to the presence of the six double bonds between carbon atoms in its polyene chain (C=C), DHA is exquisitely sensitive to oxidative damage. In addition to oxidative stress and LC-PUFAs peroxidation, other stress-related mechanisms may also contribute to the development of various CNS malfunctions, and a good example of such mechanisms is the process of lipofuscin formation occurring particularly in the retina, an integral part of the CNS. The retinal lipofuscin is formed and accumulated by the retinal pigment epithelial (RPE) cells as a consequence of both visual process taking place in photoreceptor-RPE functional complex and metabolic insufficiency of RPE lysosomal compaitment. Among various retinal lipofuscin constituents, bisretinoids, originating from all-trans retinal substrate-a photometabolite of visual pigment cofactor 11-cis-retinal (responsible for photon capturing), are endowed with cytotoxic and complement-activating potential which increases upon illumination and oxidation. This survey deals with oxidative stress, PUFAs (especially DHA) peroxidation products of carboxyalkylpyrrole type and bisretinoids as potential inducers of the CNS pathology. A focus is put on vision-threatening disease, i.e., age-related macular degeneration (AMD), as an example of the CNS disorder whose pathogenesis has strong background in both oxidative stress and lipid peroxidation products.
C1 Polish Acad Sci, Inst Pharmacol, Sci Board, PL-31343 Krakow, Poland.
C3 Polish Academy of Sciences
RP Nowak, JZ (通讯作者)，Polish Acad Sci, Inst Pharmacol, Sci Board, Smetna 12, PL-31343 Krakow, Poland.
EM jznowak07@gmail.com
CR Agostoni C, 2012, EFSA J, V10, DOI 10.2903/j.efsa.2012.2815
   Alfadda AA, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/936486
   Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   ALVAREZ RA, 1994, INVEST OPHTH VIS SCI, V35, P402
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   [Anonymous], 2006, POL J ENV STUD
   Bazan NG, 2006, TRENDS NEUROSCI, V29, P263, DOI 10.1016/j.tins.2006.03.005
   Bazan NG, 2011, ANNU REV NUTR, V31, P321, DOI 10.1146/annurev.nutr.012809.104635
   Bazan NG, 2009, J LIPID RES, V50, pS400, DOI 10.1194/jlr.R800068-JLR200
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhandary B, 2013, INT J MOL SCI, V14, P434, DOI 10.3390/ijms14010434
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cai X, 2012, FRONT BIOSCI-LANDMRK, V17, P1976, DOI 10.2741/4033
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   del Rio LA, 2011, ARCH BIOCHEM BIOPHYS, V506, P1, DOI 10.1016/j.abb.2010.10.022
   Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Evans T. A., 2008, AM J BIOCH BIOTECHNO, V4, P61, DOI DOI 10.3844/AJBBSP.2008.61.72
   Fossel M, 2004, CELLS AGING HUMAN DI, P504
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gu XR, 2003, J ORG CHEM, V68, P3749, DOI 10.1021/jo026721t
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Hollyfield JG, 2003, ADV EXP MED BIOL, V533, P83
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Jang YP, 2005, J BIOL CHEM, V280, P39732, DOI 10.1074/jbc.M504933200
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kaur K, 1997, CHEM RES TOXICOL, V10, P1387, DOI 10.1021/tx970112c
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kherjee PKM, 2007, PROSTAG LEUKOTR ESS, V77, P233, DOI 10.1016/j.plefa.2007.10.022
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Kim SR, 2007, P NATL ACAD SCI USA, V104, P19273, DOI 10.1073/pnas.0708714104
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klettner Alexa, 2012, Front Biosci (Schol Ed), V4, P392
   Krohne TU, 2010, EXP EYE RES, V90, P261, DOI 10.1016/j.exer.2009.10.014
   Lin PY, 2010, BIOL PSYCHIAT, V68, P140, DOI 10.1016/j.biopsych.2010.03.018
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   Lu L, 2009, BIOORGAN MED CHEM, V17, P7548, DOI 10.1016/j.bmc.2009.09.009
   Lukiw Walter J., 2009, V99, P55, DOI 10.1159/000192996
   Malhotra JD, 2007, ANTIOXID REDOX SIGN, V9, P2277, DOI 10.1089/ars.2007.1782
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101
   Murdaugh LS, 2011, J MASS SPECTROM, V46, P90, DOI 10.1002/jms.1865
   Novo E, 2008, FIBROGENESIS TISSUE, V1, DOI 10.1186/1755-1536-1-5
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   NOWAK JZ, 1988, TRENDS PHARMACOL SCI, V9, P80, DOI 10.1016/0165-6147(88)90167-8
   Nowak JZ, 2011, MIL PHARM MED, V1, P20
   Nowak JZ, 2012, MIL PHARM MED, V4, P1
   Nowak JZ, 2011, MIL PHARM MED, V3, P30
   Ozawa Y, 2012, CURR PHARM DESIGN, V18, P51, DOI 10.2174/138161212798919101
   Peet M, 2008, ISR J PSYCHIATR REL, V45, P19
   Plafker SM, 2012, INT REV CEL MOL BIO, V298, P135, DOI 10.1016/B978-0-12-394309-5.00004-3
   Querques G, 2011, J NUTR METAB, V2011, DOI 10.1155/2011/748361
   Roberts JE, 2001, J PHOTOCH PHOTOBIO B, V64, P136, DOI 10.1016/S1011-1344(01)00196-8
   Ross BM, 2009, PROSTAG LEUKOTR ESS, V81, P309, DOI 10.1016/j.plefa.2009.10.004
   Rozanowska M, 2004, INVEST OPHTH VIS SCI, V45, P1052, DOI 10.1167/iovs.03-0277
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Salomon RG, 2011, CHEM RES TOXICOL, V24, P1803, DOI 10.1021/tx200206v
   Sayre LM, 1996, CHEM RES TOXICOL, V9, P1194, DOI 10.1021/tx960094j
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Schutt F, 2007, GRAEF ARCH CLIN EXP, V245, P391, DOI 10.1007/s00417-006-0376-5
   Serhan CN, 2011, CHEM REV, V111, P5922, DOI 10.1021/cr100396c
   Shinohara M, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00081
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sparrow JR, 2010, ADV EXP MED BIOL, V703, P63, DOI 10.1007/978-1-4419-5635-4_5
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Tanito M, 2009, J LIPID RES, V50, P807, DOI 10.1194/jlr.M800170-JLR200
   Terman Alexei, 2006, Molecular Aspects of Medicine, V27, P471, DOI 10.1016/j.mam.2006.08.006
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Trouw LA, 2011, IMMUNOL LETT, V138, P35, DOI 10.1016/j.imlet.2011.02.014
   Uchiki T, 2012, AGING CELL, V11, P1, DOI 10.1111/j.1474-9726.2011.00752.x
   Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001
   Wallace Douglas C., 1998, Biofactors, V7, P187
   WANG N, 1992, CURR EYE RES, V11, P783, DOI 10.3109/02713689209000751
   West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421
   Wu YL, 2010, P NATL ACAD SCI USA, V107, P7275, DOI 10.1073/pnas.0913112107
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yu DY, 2005, EXP EYE RES, V80, P745, DOI 10.1016/j.exer.2005.01.018
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 85
TC 108
Z9 111
U1 1
U2 38
PU POLISH ACAD SCIENCES INST PHARMACOLOGY
PI KRAKOW
PA SMETNA 12, 31-343 KRAKOW, POLAND
SN 1734-1140
J9 PHARMACOL REP
JI Pharmacol. Rep.
PD MAR-APR
PY 2013
VL 65
IS 2
BP 288
EP 304
DI 10.1016/S1734-1140(13)71005-3
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 297QP
UT WOS:000330270300004
PM 23744414
DA 2022-11-30
ER

PT J
AU Shin, YU
   Lim, HW
   Hong, EH
   Kang, MH
   Seong, M
   Nam, E
   Cho, H
AF Shin, Yong Un
   Lim, Han Woong
   Hong, Eun Hee
   Kang, Min Ho
   Seong, Mincheol
   Nam, Eunwoo
   Cho, Heeyoon
TI The association between periodontal disease and age-related macular
   degeneration in the Korea National health and nutrition examination
   survey A cross-sectional observational study
SO MEDICINE
LA English
DT Article
DE age-related macular degeneration; epidemiology; inflammation; Korean;
   periodontal disease
ID HORMONE REPLACEMENT THERAPY; LONG-TERM INCIDENCE; C-REACTIVE PROTEIN;
   RISK-FACTORS; INTRAOCULAR-PRESSURE; PREVALENCE; METAANALYSIS;
   MACULOPATHY; ADULTS; TEAR
AB Periodontal disease (PD) is associated with various systemic diseases. We investigated the association between PD and age-related macular degeneration (AMD).
   For this population-based, cross-sectional study, we enrolled 13,072 adults at least 40 years of age with gradable retinal fundus photographs and community periodontal index (CPI) data from the Korean National Health and Nutrition Examination Survey (KNHANES) (2008-2010 and 2012). Participants were divided into a middle age group (age <= 62 years) and old age group (age >62 years). PD was divided into 2 categories of mild and severe. Logistic regression analysis was used to evaluate the association between PD and AMD (early and late).
   The prevalence of PD and AMD in the study population was 37.4%+/- 0.8% and 5.6%+/- 0.2%, respectively. Overall, there was no significant difference in the proportion of participants with PD between those with and without AMD. Only participants with AMD in the middle age group had more any PD than those without AMD (P=0.031). Multivariate logistic regression model after adjusting for all confounding factors showed that PD was not significantly associated with AMD (odds ratio [OR] 1.03, 95% confidence interval [CI] 0.86-1.22). However, according to degree of PD, participants with severe PD in the middle age group were 1.61 times more likely to have AMD (OR 1.61, 95% CI 1.02-2.54).
   Our data, collected from an Asian population, showed that only severe PD is independently associated with AMD in individuals aged 62 years or younger.
C1 [Shin, Yong Un; Lim, Han Woong; Hong, Eun Hee; Kang, Min Ho; Seong, Mincheol; Cho, Heeyoon] Hanyang Univ, Dept Ophthalmol, Coll Med, 222 Wangimni Ro, Seoul 04763, South Korea.
   [Nam, Eunwoo] Hanyang Univ, Biostat Consulting & Res Lab, Seoul, South Korea.
C3 Hanyang University; Hanyang University
RP Cho, H (通讯作者)，Hanyang Univ, Dept Ophthalmol, Coll Med, 222 Wangimni Ro, Seoul 04763, South Korea.
EM hycho@hanyang.ac.kr
RI SHIN, Yong-Un/AAI-9824-2020; SHIN, Yong Un/V-7668-2017; Lim,
   HW/GRY-3517-2022
OI SHIN, Yong Un/0000-0003-1251-8985; 
FU Hanyang University [201400000003108]
FX This work was supported by the research fund of Hanyang University
   (201400000003108).
CR Altinas O, 2004, OPHTHALMOLOGICA, V218, P120, DOI 10.1159/000076148
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Borgnakke WS, 2013, J CLIN PERIODONTOL, V40, pS135, DOI [10.1111/jcpe.12080, 10.1902/jop.2013.1340013]
   Boutin A, 2013, AM J PERINAT, V30, P537, DOI 10.1055/s-0032-1329687
   Brzozowska Aleksandra, 2012, Klin Oczna, V114, P29
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Chung JH, 2016, J PERIODONTOL, P1
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0
   Han K, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001839
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Karesvuo P, 2013, J PERIODONTOL, V84, P58, DOI 10.1902/jop.2012.110643
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kingman A, 2002, PERIODONTOL 2000, V29, P11, DOI 10.1034/j.1600-0757.2002.290102.x
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   Kweon S, 2014, INT J EPIDEMIOL, V43, P69, DOI 10.1093/ije/dyt228
   Kwon YE, 2011, J CLIN PERIODONTOL, V38, P781, DOI 10.1111/j.1600-051X.2011.01756.x
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lockhart PB, 2012, CIRCULATION, V125, P2520, DOI 10.1161/CIR.0b013e31825719f3
   Marques CPC, 2016, CLIN EXP IMMUNOL, V183, P187, DOI 10.1111/cei.12708
   Mawardi HH, 2015, SAUDI MED J, V36, P150, DOI 10.15537/smj.2015.2.9424
   Nguyen C M, 2015, J Oral Biol Craniofac Res, V5, P203, DOI 10.1016/j.jobcr.2015.06.008
   Oh IH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153624
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140-6736(05)67728-8
   Roh MI, 2008, YONSEI MED J, V49, P931, DOI 10.3349/ymj.2008.49.6.931
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Sharma P, 2016, J CLIN PERIODONTOL, V43, P104, DOI 10.1111/jcpe.12502
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Uncu G, 2006, GYNECOL ENDOCRINOL, V22, P501, DOI 10.1080/09513590600917919
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Wagley S, 2015, RETINA-J RET VIT DIS, V35, P982, DOI 10.1097/IAE.0000000000000427
   World Health Organization, 2013, ORAL HLTH SURVEYS BA, V5th edn, p., P19
NR 40
TC 12
Z9 13
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD APR
PY 2017
VL 96
IS 14
AR e6418
DI 10.1097/MD.0000000000006418
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA ER2YL
UT WOS:000398660600015
PM 28383406
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Liu, RT
   Gao, JY
   Cao, SJ
   Sandhu, N
   Cui, JZ
   Chou, CL
   Fang, E
   Matsubara, JA
AF Liu, Ruozhou Tom
   Gao, Jiangyuan
   Cao, Sijia
   Sandhu, Navroop
   Cui, Jing Z.
   Chou, Chai Lin
   Fang, Edward
   Matsubara, Joanne A.
TI Inflammatory Mediators Induced by Amyloid-Beta in the Retina and RPE In
   Vivo: Implications for Inflammasome Activation in Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ISCHEMIA-REPERFUSION INJURY; ENDOTHELIAL GROWTH-FACTOR; PIGMENT
   EPITHELIAL-CELLS; GENE-EXPRESSION; TNF-ALPHA; COMPLEMENT ACTIVATION;
   ANIMAL-MODEL; CYTOKINE; DRUSEN; INTERLEUKIN-6
AB PURPOSE. Drusen are hallmarks of age-related macular degeneration (AMD). Amyloid-beta 1-40 (A beta 1-40), a constituent of drusen, is known to stimulate inflammatory pathways in RPE; however, its effect in vivo is not known. The purpose of this study was to examine the effect of A beta 1-40 on cytokine expression and inflammasome activation relevant to AMD in an animal model.
   METHODS. Wild-type rats received intravitreal injections of A beta 1-40, and eyes were taken at days 1, 4, 14, and 49 postinjection. The RPE, neuroretina, and vitreous were analyzed for cytokine expression, inflammasome activation, and microglial response via RT-PCR, immunohistochemistry, and suspension array assay. Retinal cell loss was assessed via apoptotic markers and retinal thickness.
   RESULTS. A beta 1-40 stimulated upregulation of IL-6, TNF-alpha, IL-1 beta, IL-18, caspase-1, NLRP3, and XAF1 genes in the RPE/choroid and the neuroretina. Increased IL-1 beta and IL-6 immunoreactivity was found in retinal sections, and elevated levels of IL-1 beta and IL-18 were found in the vitreous of A beta-injected eyes. A beta 1-40 induced a moderate increase in CD11b/c-reactive cells on day 1 postinjection only. No evidence of the proapoptotic XAF1 protein, p53, TUNEL immunoreactivity, or retinal thinning was observed.
   CONCLUSIONS. These results confirm earlier in vitro work and support the proinflammatory role of drusen component A beta 1-40 in the RPE and retina. Inflammasome activation may be responsible for this effect in vivo. This model is useful for understanding cellular triggers of inflammasome activation and proposed early inflammatory events in the outer retina associated with the etiology of AMD. (Invest Ophthalmol Vis Sci. 2013;54:2225-2237) DOI: 10.1167/iovs.12-10849
C1 [Liu, Ruozhou Tom; Gao, Jiangyuan; Cao, Sijia; Cui, Jing Z.; Chou, Chai Lin; Fang, Edward; Matsubara, Joanne A.] Univ British Columbia, Dept Ophthalmol & Visual Sci, Fac Med, Vancouver, BC V5Z 3N9, Canada.
   [Sandhu, Navroop] Queens Univ, Fac Hlth Sci, Sch Med, Kingston, ON, Canada.
C3 University of British Columbia; Queens University - Canada
RP Matsubara, JA (通讯作者)，Univ British Columbia, Dept Ophthalmol & Visual Sci, 2550 Willow St, Vancouver, BC V5Z 3N9, Canada.
EM jms@mail.ubc.ca
RI Chou, Chai Lin/C-2331-2008
OI Chou, Chai Lin/0000-0003-4754-0488
FU Canadian Institute of Health Research (CIHR) [MOP 97806]
FX Supported by Canadian Institute of Health Research (CIHR) Grant MOP
   97806 (JAM).
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson PJB, 2008, CLIN OPHTHALMOL, V2, P801
   Bian ZM, 2001, EXP EYE RES, V73, P111, DOI 10.1006/exer.2001.1019
   Bian ZM, 2011, INVEST OPHTH VIS SCI, V52, P8646, DOI 10.1167/iovs.11-7570
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Chen Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018139
   Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200
   Davis D, 2012, TECH NOTE 2861 PRINC
   Dentchev T, 2003, MOL VIS, V9, P184
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   ELNER SG, 1995, CURR EYE RES, V14, P1045, DOI 10.3109/02713689508998529
   ELNER VM, 1992, EXP EYE RES, V54, P361, DOI 10.1016/0014-4835(92)90048-W
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Guo L, 2010, INVEST OPHTH VIS SCI, V51, P6504, DOI 10.1167/iovs.10-5551
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636
   Hangai M, 1996, OPHTHALMIC RES, V28, P248, DOI 10.1159/000267910
   Hogg RE, 2007, OPHTHALMOLOGY, V114, P1027
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Howlett DR, 2011, EXP BRAIN RES, V214, P185, DOI 10.1007/s00221-011-2819-4
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   JAFFE GJ, 1992, EXP EYE RES, V55, P325, DOI 10.1016/0014-4835(92)90197-Z
   Jiang K, 2012, J CLIN EXP OPHTHALMO, V3, P1
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469
   Keller M, 2008, CELL, V132, P818, DOI 10.1016/j.cell.2007.12.040
   Kempkensteffen C, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-276
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Landa G, 2008, CURR EYE RES, V33, P1011, DOI 10.1080/02713680802484637
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
   Medhurst AD, 2000, J NEUROSCI METH, V98, P9, DOI 10.1016/S0165-0270(00)00178-3
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Mor F, 2004, J IMMUNOL, V172, P4618, DOI 10.4049/jimmunol.172.7.4618
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nakazawa T, 2006, MOL VIS, V12, P867
   Nakazawa T, 2011, INVEST OPHTH VIS SCI, V52, P1384, DOI 10.1167/iovs.10-6509
   Ning A, 2008, INVEST OPHTH VIS SCI, V49, P5136, DOI 10.1167/iovs.08-1849
   Noma H, 2009, OPHTHALMOLOGY, V116, P87, DOI 10.1016/j.ophtha.2008.09.034
   Peinnequin Andre, 2004, BMC Immunology, V5, P1, DOI 10.1186/1471-2172-5-3
   Pfizer, 2012, EFF SAF TOL STUD RN6
   PLANCK SR, 1993, CURR EYE RES, V12, P205, DOI 10.3109/02713689308999465
   Prakasam A, 2010, J ALZHEIMERS DIS, V20, P1243, DOI 10.3233/JAD-2010-100210
   Rosenbaum DM, 2010, J NEUROSCI RES, V88, P1569, DOI 10.1002/jnr.22314
   Sanchez RN, 2003, INVEST OPHTH VIS SCI, V44, P4006, DOI 10.1167/iovs.03-0040
   Schutyser E, 2003, CYTOKINE GROWTH F R, V14, P409, DOI 10.1016/S1359-6101(03)00049-2
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Walsh DT, 2005, NEUROPATH APPL NEURO, V31, P491, DOI 10.1111/j.1365-2990.2005.00666.x
   Walsh DT, 2002, NEUROBIOL DIS, V10, P20, DOI 10.1006/nbdi.2002.0485
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Xia Y, 2006, MOL CELL BIOCHEM, V286, P67, DOI 10.1007/s11010-005-9094-2
   Yang P, 2004, INVEST OPHTH VIS SCI, V45, P2438, DOI 10.1167/iovs.03-0805
   Yang P, 2007, INVEST OPHTH VIS SCI, V48, P3341, DOI 10.1167/iovs.06-1340
   Yehoshua Z, 2011, SEMIN OPHTHALMOL, V26, P167, DOI 10.3109/08820538.2011.577132
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
NR 67
TC 104
Z9 111
U1 1
U2 16
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2013
VL 54
IS 3
BP 2225
EP 2237
DI 10.1167/iovs.12-10849
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 117GV
UT WOS:000316942400085
PM 23462752
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Curcio, CA
   McGwin, G
   Sadda, SR
   Hui, Z
   Clark, ME
   Sloan, KR
   Swain, T
   Crosson, JN
   Owsley, C
AF Curcio, Christine A.
   McGwin, Gerald, Jr.
   Sadda, Srinivas R.
   Hui, Zhihong
   Clark, Mark E.
   Sloan, Kenneth R.
   Swain, Thomas
   Crosson, Jason N.
   Owsley, Cynthia
TI Functionally validated imaging endpoints in the Alabama study on early
   age-related macular degeneration 2 (ALSTAR2): design and methods
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Aging; Retina; Macula; Dark
   adaptation; Light sensitivity; Rods; Cones; Spectral domain optical
   coherence tomography; Quantitative autofluorescence
ID MEDIATED DARK-ADAPTATION; C-REACTIVE PROTEIN; SUBRETINAL DRUSENOID
   DEPOSITS; COMPLEMENT FACTOR-H; CONTRAST SENSITIVITY; BRUCHS MEMBRANE;
   VISUAL-ACUITY; FUNDUS AUTOFLUORESCENCE; GEOGRAPHIC ATROPHY; LAYER
   THICKNESS
AB Background Age-related macular degeneration (AMD), a leading cause of irreversible vision impairment in the United States and globally, is a disease of the photoreceptor support system involving the retinal pigment epithelium (RPE), Bruch's membrane, and the choriocapillaris in the setting of characteristic extracellular deposits between outer retinal cells and their blood supply. Research has clearly documented the selective vulnerability of rod photoreceptors and rod-mediated (scotopic) vision in early AMD, including delayed rod-mediated dark adaptation (RMDA) and impaired rod-mediated light and pattern sensitivity. The unifying hypothesis of the Alabama Study on Early Macular Degeneration (ALSTAR2) is that early AMD is a disease of micronutrient deficiency and vascular insufficiency, due to detectable structural changes in the retinoid re-supply route from the choriocapillaris to the photoreceptors. Functionally this is manifest as delayed rod-mediated dark adaptation and eventually as rod-mediated visual dysfunction in general. Methods A cohort of 480 older adults either in normal macular health or with early AMD will be enrolled and followed for 3 years to examine cross-sectional and longitudinal associations between structural and functional characteristics of AMD. Using spectral domain optical coherence tomography, the association between (1) subretinal drusenoid deposits and drusen, (2) RPE cell bodies, and (3) the choriocapillaris' vascular density and rod- and cone-mediated vision will be examined. An accurate map and timeline of structure-function relationships in aging and early AMD gained from ALSTAR2, especially the critical transition from aging to disease, will identify major characteristics relevant to future treatments and preventative measures. Discussion A major barrier to developing treatments and prevention strategies for early AMD is a limited understanding of the temporal interrelationships among structural and functional characteristics while transitioning from aging to early AMD. ALSTAR2 will enable the development of functionally valid, structural biomarkers for early AMD, suitable for use in forthcoming clinical trials as endpoint/outcome measures. The comprehensive dataset will also allow hypothesis-testing for mechanisms that underlie the transition from aging to AMD, one of which is a newly developed Center-Surround model of cone resilience and rod vulnerability.
C1 [Curcio, Christine A.; McGwin, Gerald, Jr.; Clark, Mark E.; Sloan, Kenneth R.; Swain, Thomas; Crosson, Jason N.; Owsley, Cynthia] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, 1720 Univ Blvd,Suite 609, Birmingham, AL 35294 USA.
   [McGwin, Gerald, Jr.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
   [Sadda, Srinivas R.; Hui, Zhihong] Doheny Eye Inst, POB 86228, Los Angeles, CA 90033 USA.
   [Sloan, Kenneth R.] Univ Alabama Birmingham, Coll Arts & Sci, Dept Comp Sci, Birmingham, AL 35294 USA.
   [Crosson, Jason N.] Retina Consultants Alabama, Birmingham, AL 35233 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham; Doheny
   Eye Institute; University of Alabama System; University of Alabama
   Birmingham
RP Owsley, C (通讯作者)，Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, 1720 Univ Blvd,Suite 609, Birmingham, AL 35294 USA.
EM owsley@uab.edu
OI Owsley, Cynthia/0000-0003-3424-011X
FU National Institutes of Health [R01EY029595, P30EY03039]; EyeSight
   Foundation of Alabama; Research to Prevent Blindness; Dorsett Davis
   Discovery Fund; Alfreda J. Schueler Trust; Carl G. and Pauline Buck
   Trust
FX This research is funded by the National Institutes of Health
   (R01EY029595, P30EY03039), EyeSight Foundation of Alabama, Research to
   Prevent Blindness, Dorsett Davis Discovery Fund, Alfreda J. Schueler
   Trust, and the Carl G. and Pauline Buck Trust. The funding bodies had no
   role in the design of the study, collection, analysis, and
   interpretation of data, and writing the manuscript.
CR Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   Ahmad KM, 2003, VISUAL NEUROSCI, V20, P189, DOI 10.1017/S0952523803202091
   Arden GB., 1991, PRINCIPLES PRACTICE, P475
   Arditi A, 2005, INVEST OPHTH VIS SCI, V46, P2225, DOI 10.1167/iovs.04-1198
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Balaratnasingam C, 2015, INVEST OPHTH VIS SCI, V56, P7859, DOI 10.1167/iovs.15-17532
   BAYLOR DA, 1980, J PHYSIOL-LONDON, V309, P591, DOI 10.1113/jphysiol.1980.sp013529
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Chen KG, 2019, OPHTHALMOLOGY, V126, P856, DOI 10.1016/j.ophtha.2018.09.039
   Chen W, 2012, EUR J OPHTHALMOL, V22, P590, DOI 10.5301/ejo.5000092
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chirco KR, 2016, J PATHOL, V103, P17456
   Cimarolli VR, 2016, CLIN OPHTHALMOL, V10, P55, DOI 10.2147/OPTH.S80489
   Clark ME, 2011, BRIT J OPHTHALMOL, V95, P1427, DOI 10.1136/bjo.2010.190355
   Copland DA, 2018, INVEST OPHTH VIS SCI, V59, pAMD83, DOI 10.1167/iovs.18-23893
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Csaky K, 2017, INVEST OPHTH VIS SCI, V58, P3456, DOI 10.1167/iovs.17-22339
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Curcio CA, 2019, OPHTHALMOLOGY, V126, P866, DOI 10.1016/j.ophtha.2018.12.024
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dougherty BE, 2005, OPTOMETRY VISION SCI, V82, P970, DOI 10.1097/01.opx.0000187844.27025.ea
   DOWLING JE, 1960, NATURE, V188, P114, DOI 10.1038/188114a0
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Ficher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41
   Finger RP, 2019, OPHTHALMOLOGICA, V241, P61, DOI 10.1159/000491402
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Flynn OJ, 2018, INVEST OPHTH VIS SCI, V59, P2411, DOI 10.1167/iovs.17-22874
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Garlipp MA, 2013, EXP EYE RES, V113, P192, DOI 10.1016/j.exer.2013.02.003
   Gillies M, 2020, AM J OPHTHALMOL, V210, P116, DOI 10.1016/j.ajo.2019.10.007
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Greenberg JP, 2013, INVEST OPHTH VIS SCI, V54, P5684, DOI 10.1167/iovs.13-12445
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4
   Helb HM, 2008, RETINA-J RET VIT DIS, V28, P808, DOI 10.1097/IAE.0b013e31816d81aa
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Hu ZH, 2017, NEUROPHOTONICS, V4, DOI 10.1117/1.NPh.4.1.011012
   Jackson GR, 2005, MACULAR DEGENERATION, P45, DOI 10.1007/3-540-26977-0_3
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jackson GR, 2000, VISION RES, V40, P2467, DOI 10.1016/S0042-6989(00)00108-5
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jones BW, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00103
   Jones BW, 2003, J COMP NEUROL, V464, P1, DOI 10.1002/cne.10703
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   LAMB TD, 1981, VISION RES, V21, P1773, DOI 10.1016/0042-6989(81)90211-X
   LAMB TD, 1980, NATURE, V287, P349, DOI 10.1038/287349a0
   LAMB TD, 1998, J PHYSIOL LONDON P, V506, pP8
   Lamb TD, 2006, INVEST OPHTH VIS SCI, V47, P5138, DOI 10.1167/iovs.06-0849
   Lauer N, 2011, J IMMUNOL, V187, P4374, DOI 10.4049/jimmunol.1002488
   Leibrock CS, 1998, EYE, V12, P511, DOI 10.1038/eye.1998.139
   Li BX, 2011, BIOCHEMISTRY-US, V50, P2541, DOI 10.1021/bi101906y
   Lin YH, 2012, FASEB J, V26, P81, DOI 10.1096/fj.11-192914
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Markowitz M, 2018, CAN J OPHTHALMOL, V53, P3, DOI 10.1016/j.jcjo.2017.10.042
   Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1
   Maynard ML, 2016, ACTA OPHTHALMOL, V94, pE772, DOI 10.1111/aos.13112
   McGuigan DB, 2016, INVEST OPHTH VIS SCI, V57, P3118, DOI 10.1167/iovs.16-19302
   McGuinness MB, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.5.3
   Mullins RF, 2019, OPHTHALMOLOGY, V126, P591, DOI 10.1016/j.ophtha.2018.10.037
   Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x
   Newman EA, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0195
   Nolan JM, 2016, INVEST OPHTH VIS SCI, V57, P3429, DOI 10.1167/iovs.16-19520
   Obana A, 2017, INVEST OPHTH VIS SCI, V58, P5157, DOI 10.1167/iovs.17-22347
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2008, J VISUAL IMPAIR BLIN, V102, P621, DOI 10.1177/0145482X0810201007
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.15
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   Pang CE, 2016, RETINA-J RET VIT DIS, V36, P1408, DOI 10.1097/IAE.0000000000001069
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   POKORNY J, 1987, APPL OPTICS, V26, P1437, DOI 10.1364/AO.26.001437
   Polyak SL, 1957, VERTEBREATE VISUAL S
   Powner MB, 2013, OPHTHALMOLOGY, V120, P2344, DOI 10.1016/j.ophtha.2013.04.013
   Powner MB, 2010, OPHTHALMOLOGY, V117, P2407, DOI 10.1016/j.ophtha.2010.04.001
   Puell MC, 2012, INVEST OPHTH VIS SCI, V53, P7310, DOI 10.1167/iovs.11-8649
   PUGH EN, 1975, J PHYSIOL-LONDON, V248, P413, DOI 10.1113/jphysiol.1975.sp010982
   Quinn N, 2019, PROG RETIN EYE RES, V68, P83, DOI 10.1016/j.preteyeres.2018.10.001
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rosenfeld PJ, 2019, AM J OPHTHALMOL, V204, P26, DOI 10.1016/j.ajo.2019.02.036
   Rushton W.A.H., 1955, Optica Acta, V1, P183
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Santos NA, 2006, BRAZ J MED BIOL RES, V39, P791, DOI 10.1590/S0100-879X2006000600012
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Schultz R, 2018, INVEST OPHTH VIS SCI, V59
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Sevilla MB, 2016, AM J OPHTHALMOL, V165, P65, DOI 10.1016/j.ajo.2016.02.021
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Spaide RF, 2018, RETINA, V39, P12
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Steinberg JS, 2015, OPHTHALMOLOGICA, V233, P35, DOI 10.1159/000368168
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Syrbe S, 2018, EXP EYE RES, V167, P110, DOI 10.1016/j.exer.2017.12.004
   Thomas SE, 2016, J LIPID RES, V57, P1865, DOI 10.1194/jlr.M070193
   Trieschmann M, 2003, GRAEF ARCH CLIN EXP, V241, P1006, DOI 10.1007/s00417-003-0796-4
   Uji A, 2017, JAMA OPHTHALMOL, V135, P1197, DOI 10.1001/jamaophthalmol.2017.3904
   Vachali PP, 2013, ARCH BIOCHEM BIOPHYS, V539, P181, DOI 10.1016/j.abb.2013.07.008
   Vinberg F, 2014, VISION RES, V101, P108, DOI 10.1016/j.visres.2014.06.003
   Vitale S, 2016, JAMA OPHTHALMOL, V134, P1041, DOI 10.1001/jamaophthalmol.2016.2383
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang Q, 1996, INVEST OPHTH VIS SCI, V37, P2234
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P3714, DOI 10.1167/iovs.15-18294
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Zarubina AV, 2016, OPHTHALMOLOGY, V123, P1090, DOI 10.1016/j.ophtha.2015.12.034
   Zhang TJ, 2015, AM J OPHTHALMOL, V160, P290, DOI 10.1016/j.ajo.2015.04.034
   Zhang YH, 2020, OPHTHALMOL RETINA, V4, P274, DOI 10.1016/j.oret.2019.10.012
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
NR 130
TC 14
Z9 14
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD MAY 19
PY 2020
VL 20
IS 1
AR 196
DI 10.1186/s12886-020-01467-0
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LS9BL
UT WOS:000536673900001
PM 32429847
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kavanagh, D
   Yu, Y
   Schramm, EC
   Triebwasser, M
   Wagner, EK
   Raychaudhuri, S
   Daly, MJ
   Atkinson, JP
   Seddon, JM
AF Kavanagh, David
   Yu, Yi
   Schramm, Elizabeth C.
   Triebwasser, Michael
   Wagner, Erin K.
   Raychaudhuri, Soumya
   Daly, Mark J.
   Atkinson, John P.
   Seddon, Johanna M.
TI Rare genetic variants in the CFI gene are associated with advanced
   age-related macular degeneration and commonly result in reduced serum
   factor I levels
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID HEMOLYTIC-UREMIC SYNDROME; COMPLEMENT FACTOR-I; FACTOR-H; HIGH-RISK;
   MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; CLINICAL PHENOTYPE; SYNDROME
   AHUS; MUTATIONS; ACTIVATION; CELLS
AB To assess a potential diagnostic and therapeutic biomarker for age-related macular degeneration (AMD), we sequenced the complement factor I gene (CFI) in 2266 individuals with AMD and 1400 without, identifying 231 individuals with rare genetic variants. We evaluated the functional impact by measuring circulating serum factor I (FI) protein levels in individuals with and without rare CFI variants. The burden of very rare (frequency < 1/1000) variants in CFI was strongly associated with disease (P = 1.1 x 10(-8)). In addition, we examined eight coding variants with counts a parts per thousand yen5 and saw evidence for association with AMD in three variants. Individuals with advanced AMD carrying a rare CFI variant had lower mean FI compared with non-AMD subjects carrying a variant (P < 0.001). Further new evidence that FI levels drive AMD risk comes from analyses showing individuals with a CFI rare variant and low FI were more likely to have advanced AMD (P = 5.6 x 10(-5)). Controlling for covariates, low FI increased the risk of advanced AMD among those with a variant compared with individuals without advanced AMD with a rare CFI variant (OR 13.6, P = 1.6 x 10(-4)), and also compared with control individuals without a rare CFI variant (OR 19.0, P = 1.1 x 10(-5)). Thus, low FI levels are strongly associated with rare CFI variants and AMD. Enhancing FI activity may be therapeutic and measuring FI provides a screening tool for identifying patients who are most likely to benefit from complement inhibitory therapy.
C1 [Kavanagh, David] Newcastle Univ, Int Ctr Life, Inst Med Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   [Yu, Yi; Wagner, Erin K.; Seddon, Johanna M.] Tufts Med Ctr, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA USA.
   [Schramm, Elizabeth C.; Triebwasser, Michael; Atkinson, John P.] Washington Univ, Sch Med, Dept Med, Div Rheumatol, St Louis, MO 63110 USA.
   [Raychaudhuri, Soumya; Daly, Mark J.] Partners HealthCare Ctr Personalized Genet Med, Boston, MA USA.
   [Raychaudhuri, Soumya; Daly, Mark J.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
   [Raychaudhuri, Soumya] Brigham & Womens Hosp, Div Genet Rheumatol Immunol & Allergy, Boston, MA 02115 USA.
   [Raychaudhuri, Soumya] Univ Manchester, Fac Med & Human Sci, Manchester, Lancs, England.
   [Daly, Mark J.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Seddon, Johanna M.] Tufts Univ, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA.
C3 Newcastle University - UK; Tufts Medical Center; Washington University
   (WUSTL); Partners Healthcare System; Harvard University; Massachusetts
   Institute of Technology (MIT); Broad Institute; Harvard University;
   Brigham & Women's Hospital; University of Manchester; Harvard
   University; Massachusetts General Hospital; Tufts University; Tufts
   University
RP Kavanagh, D (通讯作者)，Tufts Med Ctr, 800 Washington St 450, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
RI Kavanagh, David/E-8498-2011; Daly, Mark J/B-2453-2017
OI Kavanagh, David/0000-0003-4718-0072; Daly, Mark J/0000-0002-0949-8752;
   Raychaudhuri, Soumya/0000-0002-1901-8265
FU National Institute of Health [R01-EY11309, K08AR055688, U01HG0070033,
   F30HL103072, R01-AI041592, U54 HL112303]; Edward N. & Della L. Thome
   Memorial Foundation; Doris Duke Clinical Scientist Development Award;
   Protein Core Facility of the Rheumatic Diseases Core by National
   Institute of Arthritis and Musculoskeletal and Skin Diseases part of the
   National Institutes of Health [P30 AR48335]; Massachusetts Lions Eye
   Research Fund, Inc.; Foundation Fighting Blindness; Research to Prevent
   Blindness; American Macular Degeneration Foundation; Macular
   Degeneration Research Fund of the Ophthalmic Epidemiology and Genetics
   Service, New England Eye Center, Tufts Medical Center, Tufts University
   School of Medicine; Fight for Sight; Wellcome Trust; NATIONAL EYE
   INSTITUTE [R01EY011309] Funding Source: NIH RePORTER; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTE [F30HL103072, U54HL112303] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
   [R01AI041592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR048335,
   K08AR055688] Funding Source: NIH RePORTER
FX This work was supported in part by National Institute of Health grants
   R01-EY11309 (J.M.S.), K08AR055688 (S.R.), U01HG0070033 (S.R.),
   F30HL103072 (M.T.), R01-AI041592 (J.P.A.), U54 HL112303 (J.P.A.); Edward
   N. & Della L. Thome Memorial Foundation (J.P.A.); the Doris Duke
   Clinical Scientist Development Award; the Protein Core Facility of the
   Rheumatic Diseases Core supported by National Institute of Arthritis and
   Musculoskeletal and Skin Diseases, part of the National Institutes of
   Health, under award number P30 AR48335 (J.P.A.), Massachusetts Lions Eye
   Research Fund, Inc. (J.M.S.); the Foundation Fighting Blindness
   (J.M.S.); Research to Prevent Blindness Challenge grant to the New
   England Eye Center, Department of Ophthalmology, Tufts University School
   of Medicine; American Macular Degeneration Foundation (J.M.S.); and the
   Macular Degeneration Research Fund of the Ophthalmic Epidemiology and
   Genetics Service, New England Eye Center, Tufts Medical Center, Tufts
   University School of Medicine. D.K. is a Wellcome Trust Intermediate
   Clinical Fellow and is funded by Fight for Sight. The content is solely
   the responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health. Funding to pay the
   Open Access publication charges for this article was provided by the
   Wellcome Trust.
CR Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
   Alexander P, 2014, MOL VIS, V20, P1253
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Bienaime F, 2010, KIDNEY INT, V77, P339, DOI 10.1038/ki.2009.472
   Bresin E, 2013, J AM SOC NEPHROL, V24, P475, DOI 10.1681/ASN.2012090884
   Caprioli J, 2006, BLOOD, V108, P1267, DOI 10.1182/blood-2005-10-007252
   Cayci FS, 2012, PEDIATR NEPHROL, V27, P2327, DOI 10.1007/s00467-012-2283-9
   de Paula PF, 2003, SCAND J IMMUNOL, V58, P572, DOI 10.1046/j.1365-3083.2003.01326.x
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Ferreira VP, 2009, J IMMUNOL, V182, P7009, DOI 10.4049/jimmunol.0804031
   Fremeaux-Bacchi V, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.019083
   Fremeaux-Bacchi V, 2013, CLIN J AM SOC NEPHRO, V8, P554, DOI 10.2215/CJN.04760512
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Harbeck RJ, 1991, DIAGNOSTIC IMMUNOLOG
   Harris CL, 2012, TRENDS IMMUNOL, V33, P513, DOI 10.1016/j.it.2012.06.001
   JULEN N, 1992, EUR J IMMUNOL, V22, P213, DOI 10.1002/eji.1830220131
   Kavanagh D, 2008, MOL IMMUNOL, V45, P95, DOI 10.1016/j.molimm.2007.05.004
   Kavanagh D, 2013, SEMIN NEPHROL, V33, P508, DOI 10.1016/j.semnephrol.2013.08.003
   Lachmann PJ, 2009, ADV IMMUNOL, V104, P115, DOI 10.1016/S0065-2776(08)04004-2
   LACHMANN PJ, 1975, CLIN EXP IMMUNOL, V21, P109
   Lay E, 2015, CLIN EXP IMMUNOL, V181, P314, DOI 10.1111/cei.12437
   Le Quintrec M, 2008, AM J TRANSPLANT, V8, P1694, DOI 10.1111/j.1600-6143.2008.02297.x
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maga TK, 2010, HUM MUTAT, V31, pE1445, DOI 10.1002/humu.21256
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Minta JO, 1998, BBA-GENE STRUCT EXPR, V1442, P286, DOI 10.1016/S0167-4781(98)00189-4
   Nilsson SC, 2007, MOL IMMUNOL, V44, P1835, DOI 10.1016/j.molimm.2006.10.005
   Nilsson SC, 2011, MOL IMMUNOL, V48, P1611, DOI 10.1016/j.molimm.2011.04.004
   Nilsson SC, 2010, EUR J IMMUNOL, V40, P172, DOI 10.1002/eji.200939280
   Noris M, 2010, CLIN J AM SOC NEPHRO, V5, P1844, DOI 10.2215/CJN.02210310
   Pickering MC, 2007, J EXP MED, V204, P1249, DOI 10.1084/jem.20070301
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Regillo C. D., 2013, 117 ANN AAO M NEW OR
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rose KL, 2008, J CLIN INVEST, V118, P608, DOI 10.1172/JCI32525
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sullivan M, 2010, ANN HUM GENET, V74, P17, DOI 10.1111/j.1469-1809.2009.00554.x
   Timar KK, 2007, MOL IMMUNOL, V44, P2943, DOI 10.1016/j.molimm.2007.01.007
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Westra D, 2010, NEPHROL DIAL TRANSPL, V25, P2195, DOI 10.1093/ndt/gfq010
   Wong EKS, 2013, MOL IMMUNOL, V56, P199, DOI 10.1016/j.molimm.2013.05.224
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
NR 54
TC 85
Z9 87
U1 0
U2 18
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JUL 1
PY 2015
VL 24
IS 13
BP 3861
EP 3870
DI 10.1093/hmg/ddv091
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA CM2PO
UT WOS:000357523900021
PM 25788521
OA Green Published, Green Submitted, hybrid
DA 2022-11-30
ER

PT J
AU Francis, PJ
   Hamon, SC
   Ott, J
   Weleber, RG
   Klein, ML
AF Francis, P. J.
   Hamon, S. C.
   Ott, J.
   Weleber, R. G.
   Klein, M. L.
TI Polymorphisms in C2, CFB and C3 are associated with progression to
   advanced age related macular degeneration associated with visual loss
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID COMPLEMENT FACTOR-H; BODY-MASS INDEX; ENVIRONMENTAL ASSOCIATIONS; GENE
   POLYMORPHISMS; VARIANT; SUSCEPTIBILITY; AREDS; RISK; MACULOPATHY;
   ALLELES
AB Background: Age related macular degeneration (AMD) is a leading cause of blindness. AMD is a complex disorder caused by genetic and environmental factors in which single nucleotide polymorphisms (SNPs) in the genes CFH and LOC387715/HTRA1/ARMS2 have prognostic importance for progression to advanced AMD (with visual loss). CFH may also have a pharmacogenetic role by affecting treatment response to widely used nutritional supplements. This paper examines other AMD susceptibility genes to determine if these genotypes influenced disease progression and treatment response.
   Methods: Three cohorts, totalling 3137 individuals, were genotyped for SNPs in 13 genes previously published to be associated with advanced AMD (other than CFH and LOC387715/ARMS2/HTRA1). Those genes found associated were then evaluated for their involvement in disease progression. Interactions between the genes and with AREDS (Age-Related Eye Disease Study) nutritional supplements were investigated.
   Results: Positive independent associations were noted in SNPs in the genes C2 (p=0.0001, odds ratio (OR) 0.35, 95% confidence interval (CI) 0.2 to 0.6), CFB (p=0.0001, OR 0.35, 95% CI 0.2 to 0.6), C3 (p=0.0001, OR 3.91, 95% CI 1.94 to 7.88), APOE (epsilon 4, p=0.01, OR 0.50, 95% CI 0.29 to 0.86) and VEGFA (p=0.01, OR 2.23, 95% CI 1.06 to 4.68). C2/CFB and C3 were independently related to progression from early/intermediate to advanced AMD with OR 0.32 (95% CI 0.14 to 0.73) and 3.32 (95% CI 1.46 to 7.59), respectively. Gene-gene and pharmacogenetic interactions were not observed. No preferential associations were observed with geographic atrophy or choroidal neovascularisation.
   Conclusion: This study provides insights into the genetic pathogenesis of AMD. Five genes have now been shown to be independently involved in progression from intermediate disease (before vision loss has occurred) to advanced disease in which blindness is frequent.
C1 [Francis, P. J.; Weleber, R. G.; Klein, M. L.] Oregon Hlth & Sci Univ, Casey Eye Inst, Macular Degenerat Ctr, Portland, OR 97239 USA.
   [Hamon, S. C.] Rockefeller Univ, New York, NY 10021 USA.
   [Ott, J.] Chinese Acad Sci, Beijing Inst Genom, Beijing, Peoples R China.
C3 Oregon Health & Science University; Rockefeller University; Chinese
   Academy of Sciences; Beijing Institute of Genomics, CAS
RP Francis, PJ (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Inst, Macular Degenerat Ctr, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM francisp@ohsu.edu
FU National Institutes of Health (NIH) National Eye Institute
   [R01-EY12203]; Foundation Fighting Blindness; Owing Mills; Macular
   Degeneration Center Research Fund; Casey Eye Institute; Oregon Health &
   Science University, Portland; Research to Prevent Blindness, New York,
   NY; China NSF [30730057]; NATIONAL EYE INSTITUTE [R01EY012203] Funding
   Source: NIH RePORTER
FX This work is supported by grants from the National Institutes of Health
   (NIH) National Eye Institute R01-EY12203 (MLK); the Foundation Fighting
   Blindness, Owing Mills, MD (PJF, RGW); the Macular Degeneration Center
   Research Fund, Casey Eye Institute, Oregon Health & Science University,
   Portland (MLK, PJF), and Research to Prevent Blindness, New York, NY
   (unrestricted grant to Casey Eye Institute, Career Development Award to
   PJF) and China NSF grant no. 30730057 (JO).
CR Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Baird PN, 2004, AM J OPHTHALMOL, V138, P665, DOI 10.1016/j.ajo.2004.04.053
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
NR 30
TC 97
Z9 108
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD MAY
PY 2009
VL 46
IS 5
BP 300
EP 307
DI 10.1136/jmg.2008.062737
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 439YY
UT WOS:000265665200002
PM 19015224
DA 2022-11-30
ER

PT J
AU Rahman, W
   Chen, FK
   Yeoh, J
   da Cruz, L
AF Rahman, Waheeda
   Chen, Fred Kuanfu
   Yeoh, Jonathan
   da Cruz, Lyndon
TI Enhanced depth imaging of the choroid in patients with neovascular
   age-related macular degeneration treated with anti-VEGF therapy versus
   untreated patients
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Macular degeneration; Enhanced depth imaging; Optical coherence
   tomography; Ranibizumab; Bevacizumab; Vascular endothelial growth
   factor; Anti-VEGF
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; INTRAVITREAL
   INJECTION; MORPHOMETRIC-ANALYSIS; BRUCHS MEMBRANE; PRIMATE EYE;
   BEVACIZUMAB; THICKNESS; RANIBIZUMAB; CHORIOCAPILLARIS
AB To compare the subfoveal choroidal thickness (SFCT) between patients with neovascular age-related macular degeneration (nAMD) who had multiple intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents and those with treatment-na < ve nAMD.
   This retrospective case-control study included 15 patients in group 1 (nAMD in one eye which had received at least three anti-VEGF injections and early AMD in the fellow eye) and 15 patients in group 2 (newly diagnosed nAMD in one eye which had not received any treatment and early AMD in the fellow eye). They underwent enhanced depth imaging optical coherence tomography (OCT), and two OCT readers manually measured the SFCT. Inter-ocular difference in SFCT (nAMD eye minus fellow eye) was calculated for each patient.
   The nAMD eyes in group 1 had received a median (range) of four (3-8) intravitreal injections of anti-VEGF agents, and the OCT scans were performed at a median (range) of 9 (4-17) months after the first injection. The median inter-ocular difference in SFCT in groups 1 and 2 were not significantly different (13.5 and 3.0 mu m in groups 1 and 2 respectively, p = 0.60). There was also no statistically significant difference in SFCT between nAMD and fellow eyes (p = 0.16), although there was a trend for greater median SFCT in the nAMD eyes.
   The data from this small cohort suggests that no gross reduction in SFCT appears in nAMD patients after a time interval of at least 4 months between initiating repeated treatment with anti-VEGF therapy and OCT imaging. However, a study with a much larger sample size or longitudinal design is required to detect possible small fluctuations in SFCT in nAMD eyes receiving anti-VEGF therapy.
C1 [Rahman, Waheeda] Moorfields Eye Hosp, Med Retina Serv, London, England.
   [Chen, Fred Kuanfu; Yeoh, Jonathan; da Cruz, Lyndon] Moorfields Eye Hosp, London, England.
   [Chen, Fred Kuanfu; da Cruz, Lyndon] Moorfields Eye Hosp, NIHR BMRC, London, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust
RP Rahman, W (通讯作者)，Moorfields Eye Hosp, Med Retina Serv, London, England.
EM waheedarahman2002@yahoo.co.uk
RI , Fred/B-8158-2013
OI , Fred/0000-0003-2809-9930
CR BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakraborty R, 2011, INVEST OPHTH VIS SCI, V52, P5121, DOI 10.1167/iovs.11-7364
   Chen FK, 2012, INVEST OPHTH VIS SCI, V53, P975, DOI 10.1167/iovs.11-8771
   Esmaeelpour M, 2010, INVEST OPHTH VIS SCI, V51, P5260, DOI 10.1167/iovs.10-5196
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Ikuno Y, 2009, INVEST OPHTH VIS SCI, V50, P3876, DOI 10.1167/iovs.08-3325
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   McBain VA, 2011, RETINA-J RET VIT DIS, V31, P1043, DOI 10.1097/IAE.0b013e3181fe54c7
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Rahman W, 2011, INVEST OPHTH VIS SCI, V52, P2267, DOI 10.1167/iovs.10-6024
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Sakurai K, 2009, INVEST OPHTH VIS SCI, V50, P4905, DOI 10.1167/iovs.07-1542
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schraermeyer U, 2009, OPHTHALMOLOGE, V106, P619, DOI 10.1007/s00347-008-1835-7
   Schraermeyer U, 2012, GRAEF ARCH CLIN EXP, V250, P1303, DOI 10.1007/s00417-012-2055-z
   Shimomura Y, 2009, GRAEF ARCH CLIN EXP, V247, P1089, DOI 10.1007/s00417-009-1054-1
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
NR 25
TC 19
Z9 19
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUN
PY 2013
VL 251
IS 6
BP 1483
EP 1488
DI 10.1007/s00417-012-2199-x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 150VP
UT WOS:000319419800005
PM 23160538
DA 2022-11-30
ER

PT J
AU Liu, X
   Zhang, LW
   Wang, JH
   Zeng, HL
   Zou, JL
   Tan, W
   Zhao, H
   He, Y
   Shi, JM
   Yoshida, S
   Li, YP
   Zhou, YD
AF Liu, Xiao
   Zhang, Liwei
   Wang, Jiang-Hui
   Zeng, Huilan
   Zou, Jingling
   Tan, Wei
   Zhao, Han
   He, Yan
   Shi, Jingming
   Yoshida, Shigeo
   Li, Yunping
   Zhou, Yedi
TI Investigation of circRNA Expression Profiles and Analysis of
   circRNA-miRNA-mRNA Networks in an Animal (Mouse) Model of Age-Related
   Macular Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Circular RNA; competing endogenous RNA network; microarray; choroidal
   neovascularization; age-related macular degeneration
ID INDUCED CHOROIDAL NEOVASCULARIZATION; CIRCULAR RNAS; IDENTIFICATION;
   INHIBITION; BIOMARKERS
AB Purposes: To (i) identify dysregulated circular RNAs (circRNAs) and (ii) elucidate their potential functions in an animal (mouse) model of choroidal neovascularization (CNV), a prominent feature of neovascular age-related macular degeneration (AMD). Methods: Expression profiles for circRNA were identified by microarray analysis. Selected circRNAs were confirmed by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). Bioinformatic analyses of identified circRNAs were performed to predict (i) circRNA/microRNA interactions and (ii) occurrence of competing endogenous RNA (ceRNA) networks. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were applied to predict both the biological functions and potential pathways of the altered parental genes involved in CNV. Results: Microarray analysis indicated that 100 circRNAs in RPE-choroid-sclera complexes from CNV mice were significantly altered compared with those from control mice (fold change >= 1.5, p < .05). Of these, six were validated by qRT-PCR, and included up-regulated mmu_circRNA_20332 and mmu_circRNA_19388, and down-regulated mmu_circRNA_36481, mmu_circRNA_006555, mmu_circRNA_012588, and mmu_circRNA_005578. GO analysis revealed that the altered parental genes involved in ceRNA networks were mostly enriched in immune system processes and portions of neurons. KEGG analysis revealed that these altered parental genes were also amplified in extracellular matrix (ECM)-receptor interactions, chemokine signaling pathways, and advanced glycation end-product (AGE)-receptors for advanced glycation end-product (RAGE) signaling pathways in diabetic complications. Conclusion: The study identified statistically significant differences between CNV-mouse circRNAs and control mouse circRNAs, suggesting that circRNAs play vital roles in the pathogenesis of CNV. It is, therefore, reasonable to consider circRNAs as potential therapeutic targets for regulating CNV in AMD patients.
C1 [Liu, Xiao; Zhang, Liwei; Zeng, Huilan; Zou, Jingling; Tan, Wei; Zhao, Han; He, Yan; Shi, Jingming; Li, Yunping; Zhou, Yedi] Cent South Univ, Xiangya Hosp 2, Dept Ophthalmol, Changsha 410011, Hunan, Peoples R China.
   [Liu, Xiao; Zhang, Liwei; Zeng, Huilan; Zou, Jingling; Tan, Wei; Zhao, Han; He, Yan; Shi, Jingming; Li, Yunping; Zhou, Yedi] Hunan Clin Res Ctr Ophthalm Dis, Changsha, Peoples R China.
   [Wang, Jiang-Hui] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Australia.
   [Wang, Jiang-Hui] Univ Melbourne, Dept Surg, Ophthalmol, East Melbourne, Australia.
   [Yoshida, Shigeo] Kurume Univ, Dept Ophthalmol, Sch Med, Kurume, Fukuoka, Japan.
C3 Central South University; Centre for Eye Research Australia; Royal
   Victorian Eye & Ear Hospital; University of Melbourne; Kurume University
RP Zhou, YD (通讯作者)，Cent South Univ, Xiangya Hosp 2, Dept Ophthalmol, Changsha 410011, Hunan, Peoples R China.
EM zhouyedi@csu.edu.cn
RI He, Yan/AAF-4204-2021; 刘, 骁/GSJ-2956-2022; Wang, Jiang-Hui/AAW-4653-2020
OI He, Yan/0000-0003-4357-4082; Wang, Jiang-Hui/0000-0002-1551-9660; Zhou,
   Yedi/0000-0002-8948-1108
FU National Natural Science Foundation of China [81800855, 81600714,
   81500746]; Natural Science Foundation of Hunan Province [2018JJ3765,
   2017JJ2364]; Changsha Science and Technology Project [kq1907075];
   Department of Science and Technology, Hunan [2015TP2007]
FX This work was supported by National Natural Science Foundation of China
   [No. 81800855, 81600714 and 81500746]; Natural Science Foundation of
   Hunan Province [No. 2018JJ3765 and 2017JJ2364]; Changsha Science and
   Technology Project [kq1907075]; and Department of Science and
   Technology, Hunan [No.2015TP2007].
CR Askou AL, 2018, ACTA OPHTHALMOL, V96, P9, DOI 10.1111/aos.13407
   Boeckel JN, 2015, CIRC RES, V117, P884, DOI 10.1161/CIRCRESAHA.115.306319
   Bolha L, 2017, INT J GENOMICS, V2017, DOI 10.1155/2017/6218353
   Campa C, 2008, INVEST OPHTH VIS SCI, V49, P1178, DOI 10.1167/iovs.07-1194
   Cao MJ, 2019, INT J MED SCI, V16, P1356, DOI 10.7150/ijms.35149
   Coughlin B, 2016, SCI REP-UK, V6, DOI 10.1038/srep23794
   Dang RY, 2017, BIOCHEM BIOPH RES CO, V490, P104, DOI 10.1016/j.bbrc.2017.05.164
   Fauser S, 2015, SURV OPHTHALMOL, V60, P138, DOI 10.1016/j.survophthal.2014.11.002
   Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
   Gu YH, 2017, OPHTHALMIC RES, V58, P176, DOI 10.1159/000479156
   Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993
   Kobayashi Y, 2016, LAB INVEST, V96, P1178, DOI 10.1038/labinvest.2016.99
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   LeBlanc ME, 2019, EXP EYE RES, V181, P120, DOI 10.1016/j.exer.2019.01.009
   Lechner J, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0820-y
   Li CY, 2017, BIOMED PHARMACOTHER, V95, P1514, DOI 10.1016/j.biopha.2017.09.064
   Liu J, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0630-y
   Liu X, 2018, BIOCHEM BIOPH RES CO, V503, P2277, DOI 10.1016/j.bbrc.2018.06.149
   Lyu J, 2019, EXP EYE RES, V184, P278, DOI 10.1016/j.exer.2019.03.017
   Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nakama T, 2015, GENE THER, V22, P127, DOI 10.1038/gt.2014.112
   Parsons N, 2019, MOL IMMUNOL, V108, P8, DOI 10.1016/j.molimm.2019.02.001
   Shang QF, 2019, EPIGENOMICS-UK, V11, P787, DOI 10.2217/epi-2019-0029
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Wang GQ, 2019, BIOL OPEN, V8, DOI 10.1242/bio.042838
   Wawrzyniak O, 2018, ACTA BIOCHIM POL, V65, P497, DOI 10.18388/abp.2018_2639
   Zhang LW, 2020, INT J MED SCI, V17, P292, DOI 10.7150/ijms.37804
   Zhang LW, 2019, CURR EYE RES, V44, P1226, DOI 10.1080/02713683.2019.1625407
   Zhang SJ, 2017, INVEST OPHTH VIS SCI, V58, P6500, DOI 10.1167/iovs.17-22698
   Zhong ZY, 2017, CANCER LETT, V403, P305, DOI 10.1016/j.canlet.2017.06.027
   Zhu W, 2017, INT J NANOMED, V12, P7589, DOI 10.2147/IJN.S140275
NR 33
TC 6
Z9 8
U1 1
U2 12
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD SEP 1
PY 2020
VL 45
IS 9
BP 1173
EP 1180
DI 10.1080/02713683.2020.1722179
EA FEB 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NG7TH
UT WOS:000513083300001
PM 31979995
DA 2022-11-30
ER

PT J
AU Rasmussen, A
   Sander, B
   Larsen, M
   Brandi, S
   Fuchs, J
   Hansen, LH
   Lund-Andersen, H
AF Rasmussen, Annette
   Sander, Birgit
   Larsen, Michael
   Brandi, Sara
   Fuchs, Josefine
   Hansen, Louise H.
   Lund-Andersen, Henrik
TI Neovascular age-related macular degeneration treated with ranibizumab or
   aflibercept in the same large clinical setting: visual outcome and
   number of injections
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE aflibercept; clinical practice; neovascular age-related macular
   degeneration; ranibizumab; visual acuity
ID VEGF TRAP
AB Purpose: To study visual outcome and number of annual injections in treatment-naive patients with neovascular age-related macular degeneration (nAMD) before and after a change in first-line therapy from ranibizumab to aflibercept in a high-volume clinical practice.
   Methods: This was a retrospective chart review of routine clinical practice. The study included 1027 treatment-naive patients, 559 of whom started intravitreal ranibizumab therapy in 2011-2012 and 468 of whom started intravitreal aflibercept therapy in 2013-2014, a fixed loading dose of three injections followed by a pro re nata treatment regimen used in both periods.
   Results: Snellen best-corrected visual acuity (BCVA) at baseline and after one year was 0.23 and 0.31 (p < 0.0001), respectively, for patients treated with ranibizumab and 0.25 and 0.33 (p < 0.0001) for patients treated with aflibercept, last observation carried forward. The share of patients (73%) still in treatment with ranibizumab at year 1 had a baseline BCVA of 0.26 but 0.40 at year 1 (p < 0.0001), and the patients (75%) still in treatment with aflibercept at year 1 had a baseline BCVA of 0.28 but 0.42 at year 1 (p < 0.0001). Proportional visual gains for both cohorts were comparable for one year (p = 0.14). The number of injections given within year 1 including first injection was 6.9 for ranibizumab and 5.9 for aflibercept (p < 0.0001). In patients continuing treatment through year 1, the number of injections was 8.0 for ranibizumab and 6.6 for aflibercept (p < 0.0001). The two cohorts had similar cause-of-discontinuation profiles.
   Conclusion: Treatment of nAMD at a single centre in two sequential cohorts yielded comparable BCVA outcomes with 15% fewer injections of aflibercept compared to ranibizumab.
C1 [Rasmussen, Annette; Sander, Birgit; Larsen, Michael; Brandi, Sara; Fuchs, Josefine; Hansen, Louise H.; Lund-Andersen, Henrik] Rigshosp Glostrup, Dept Ophthalmol, Nordre Ringvej 57, DK-2600 Glostrup, Denmark.
   [Rasmussen, Annette; Sander, Birgit; Larsen, Michael; Fuchs, Josefine; Hansen, Louise H.; Lund-Andersen, Henrik] Univ Copenhagen, Copenhagen, Denmark.
C3 University of Copenhagen
RP Rasmussen, A (通讯作者)，Rigshosp Glostrup, Dept Ophthalmol, Nordre Ringvej 57, DK-2600 Glostrup, Denmark.
EM annette.rasmussen@regionh.dk
RI Larsen, Michael/E-9620-2010
OI Larsen, Michael/0000-0002-5172-5891
FU Lundbeck Foundation; Glostrup Hospital; Novartis; Pfizer; Novo Nordisk;
   GlaxoSmithKline
FX The Lundbeck Foundation and Glostrup Hospital provided financial support
   and the Department of Ophthalmology, Rigshospitalet-Glostrup, received
   an unrestricted grant from Novartis used in part to support the
   electronic medical record system. These funding organizations did not
   play any role in the design or conduct of this research.; The authors
   have made the following disclosure(s): A. R. received travel support
   from Novartis. S.B.B. received travel support and lecture fees from
   Novartis. J.F received travel support from Novartis. L.H.H. is an
   advisory board member for Bayer and received travel support and lecture
   fees from Novartis. M.L. is an advisory board member for Novartis,
   Pfizer and ThromboGenics and received lecture fees from Novartis,
   Pfizer, Novo Nordisk and GlaxoSmithKline. H.L-A. has no financial
   disclosures. B.S. has no financial disclosures.
CR Bohni SC, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0101-4
   Dirani A, 2015, AM J OPHTHALMOL, V160, P732, DOI 10.1016/j.ajo.2015.06.025
   Ferreira A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133968
   Frennesson CI, 2014, ACTA OPHTHALMOL, V92, P216, DOI 10.1111/aos.12091
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Schmid MK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135050
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Szabo SM, 2015, CURR MED RES OPIN, V31, P2031, DOI 10.1185/03007995.2015.1084909
NR 12
TC 14
Z9 15
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2017
VL 95
IS 2
BP 128
EP 132
DI 10.1111/aos.13233
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EP3QO
UT WOS:000397297000023
PM 27535819
DA 2022-11-30
ER

PT J
AU Ahlers, C
   Michels, S
   Beckendorf, A
   Birngruber, R
   Schmidt-Erfurth, U
AF Ahlers, Christian
   Michels, Stephan
   Beckendorf, Arne
   Birngruber, Reginald
   Schmidt-Erfurth, Ursula
TI Three-dimensional imaging of pigment epithelial detachment in
   age-related macular degeneration using optical coherence tomography,
   retinal thickness analysis and topographic angiography
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE choroidal neovascularization; pigment epithelial detachment (PED);
   topographic angiography; retinal thickness analyzer; age-related macular
   degeneration (AMD); optical coherence tomography; imaging
ID CHOROIDAL NEOVASCULARIZATION; VERTEPORFIN THERAPY; REPEATABILITY; EYES;
   TAP
AB Introduction: New diagnostic tools such as the retinal thickness analyzer (RTA), optical coherence tomography (OCT), and topographic angiography (TAG) were introduced into clinical ophthalmology during the last years giving the examiner new insights into anatomical and functional aspects of macular disease. In this study, advantages and disadvantages of the new imaging methods have been evaluated in patients with serous (sPED) and fibrovascular pigment epithelial detachments (fPED) secondary to age-related macular degeneration (AMD). Methods: TAG, using fluorescein angiography (FA), provides a three-dimensional profile of the fluorescein pattern based on the analysis of a set of 32 confocal images over a depth of 4 mm. RTA and OCT provide cross-sectional images of the neurosensory retina and the retinal pigment epithelium-choriocapillary complex as well as retinal thickness data encoded in a false color map. We compared and evaluated these modalities in 15 patients with fPED and 15 patients with sPED secondary to AMD. Results: In patients with classic fPED, TAG detected neovascular structures and delineated their configuration. In sPEDs, pooling of extravascular fluid was detected in a dome-shaped configuration. OCT provided detailed information on the neurosensory retina's structures but failed to detect the neovascular membrane in fPED. Mapping the retinal thickness, RTA and OCT both failed to detect the PED and showed typical algorithm error-based patterns. Conclusions: TAG OCT and RTA are useful imaging modalities in the evaluation of AMD cases. TAG visualizes the vascular configuration, dynamic perfusion, and leakage changes. OCT and RTA are able to complementarily document intra-, subretinal, and sub-RPE fluid accumulation secondary to CNV. However, OCT seems to be more efficient in imaging AMD-related pathologies than RTA, as this modality is often compromised by intra- or subretinal structural abnormalities. Nevertheless, all modalities may provide further valuable insight into AMD pathogenesis, enhance diagnostic quality, and improve the assessment of therapeutic effects.
C1 Med Univ Vienna, A-1090 Vienna, Austria.
   Univ Schleswig Holstein, Eye Clin, Med Laser Ctr, Kiel, Germany.
C3 Medical University of Vienna; University of Kiel; Schleswig Holstein
   University Hospital
RP Ahlers, C (通讯作者)，Med Univ Vienna, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM christian.ahlers@meduniwien.ac.at
RI Birngruber, Reginald/Q-2342-2016
CR Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   DECASTRO E, 1987, IEEE T MED IMAGING, V6, P74, DOI 10.1109/TMI.1987.4307800
   Fukuchi T, 2001, GRAEF ARCH CLIN EXP, V239, P424, DOI 10.1007/s004170100296
   Koozekanani D, 2000, INVEST OPHTH VIS SCI, V41, P1486
   Muscat S, 2002, INVEST OPHTH VIS SCI, V43, P490
   Pires I, 2002, ARCH OPHTHALMOL-CHIC, V120, P1301, DOI 10.1001/archopht.120.10.1301
   Polito A, 2002, AM J OPHTHALMOL, V134, P240, DOI 10.1016/S0002-9394(02)01528-3
   Schaudig U, 2001, OPHTHALMOLOGE, V98, P26, DOI 10.1007/s003470170196
   Schmidt-Erfurth U, 1999, OPHTHALMOLOGE, V96, P797, DOI 10.1007/s003470050499
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2001, INVEST OPHTH VIS SCI, V42, P2386
   Seddon J, 2001, RETINA-J RET VIT DIS, P1039
   Sickenberg M, 2001, OPHTHALMOLOGICA, V215, P247, DOI 10.1159/000050869
   *TAL TECHN LTD, US MAN
   Teschner S, 2003, OPHTHALMOLOGY, V110, P687, DOI 10.1016/S0161-6420(02)01972-3
   WORMALD R, 2003, COCHRANE DB SYST REV
   Zeimer R, 1998, OPHTHALMOLOGY, V105, P224, DOI 10.1016/S0161-6420(98)92743-9
   *ZEISS HUMPHR SYST, 2001, ARB OCT 2 US MAN OCT
NR 19
TC 20
Z9 20
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2006
VL 244
IS 10
BP 1233
EP 1239
DI 10.1007/s00417-006-0418-z
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 087FX
UT WOS:000240729400003
PM 16977431
DA 2022-11-30
ER

PT J
AU Dieguez, HH
   Calanni, JS
   Romeo, HE
   Alaimo, A
   Fleitas, MFG
   Iaquinandi, A
   Chianelli, MS
   Sarmiento, MIK
   Sande, PH
   Rosenstein, RE
   Dorfman, D
AF Dieguez, Hernan H.
   Calanni, Juan S.
   Romeo, Horacio E.
   Alaimo, Agustina
   Gonzalez Fleitas, Maria F.
   Iaquinandi, Agustina
   Chianelli, Monica S.
   Keller Sarmiento, Maria, I
   Sande, Pablo H.
   Rosenstein, Ruth E.
   Dorfman, Damian
TI Enriched environment and visual stimuli protect the retinal pigment
   epithelium and photoreceptors in a mouse model of non-exudative
   age-related macular degeneration
SO CELL DEATH & DISEASE
LA English
DT Article
ID NEUROTROPHIC FACTOR; OXIDATIVE STRESS; TRANSCRIPTION FACTOR; MOTOR
   FUNCTION; MULLER CELLS; DNA DAMAGE; MITOCHONDRIAL; RAT; EXPRESSION;
   GROWTH
AB Non-exudative age-related macular degeneration (NE-AMD), the main cause of blindness in people above 50 years old, lacks effective treatments at the moment. We have developed a new NE-AMD model through unilateral superior cervical ganglionectomy (SCGx), which elicits the disease main features in C57Bl/6J mice. The involvement of oxidative stress in the damage induced by NE-AMD to the retinal pigment epithelium (RPE) and outer retina has been strongly supported by evidence. We analysed the effect of enriched environment (EE) and visual stimulation (VS) in the RPE/outer retina damage within experimental NE-AMD. Exposure to EE starting 48 h post-SCGx, which had no effect on the choriocapillaris ubiquitous thickness increase, protected visual functions, prevented the thickness increase of the Bruch's membrane, and the loss of the melanin of the RPE, number of melanosomes, and retinoid isomerohydrolase (RPE65) immunoreactivity, as well as the ultrastructural damage of the RPE and photoreceptors, exclusively circumscribed to the central temporal (but not nasal) region, induced by experimental NE-AMD. EE also prevented the increase in outer retina/RPE oxidative stress markers and decrease in mitochondrial mass at 6 weeks post-SCGx. Moreover, EE increased RPE and retinal brain-derived neurotrophic factor (BDNF) levels, particularly in Muller cells. When EE exposure was delayed (dEE), starting at 4 weeks post-SCGx, it restored visual functions, reversed the RPE melanin content and RPE65-immunoreactivity decrease. Exposing animals to VS protected visual functions and prevented the decrease in RPE melanin content and RPE65 immunoreactivity. These findings suggest that EE housing and VS could become an NE-AMD promising therapeutic strategy.
C1 [Dieguez, Hernan H.; Calanni, Juan S.; Gonzalez Fleitas, Maria F.; Iaquinandi, Agustina; Chianelli, Monica S.; Keller Sarmiento, Maria, I; Sande, Pablo H.; Rosenstein, Ruth E.; Dorfman, Damian] Univ Buenos Aires, Sch Med, Dept Human Biochem,CEFyBO, Lab Retinal Neurochem & Expt Ophthalmol,CONICET, Buenos Aires, DF, Argentina.
   [Romeo, Horacio E.] Pontifical Catholic Univ Argentina, Sch Engn & Agr Sci, BIOMED UCA CONICET, Buenos Aires, DF, Argentina.
   [Alaimo, Agustina] Univ Buenos Aires, Sch Exact & Nat Sci, Dept Biol Chem,CONICET,IQUIBICEN, Interdisciplinary Lab Cellular Dynam & Nanotools, Buenos Aires, DF, Argentina.
C3 Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET);
   University of Buenos Aires; Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET); University of Buenos Aires
RP Dorfman, D (通讯作者)，Univ Buenos Aires, Sch Med, Dept Human Biochem,CEFyBO, Lab Retinal Neurochem & Expt Ophthalmol,CONICET, Buenos Aires, DF, Argentina.
EM ddorfman@fmed.uba.ar
OI alaimo, agustina/0000-0002-8070-9620
FU Agencia Nacional de Promocion Cientifica y Tecnologica [PICT 1563, PICT
   2731]; Universidad de Buenos Aires [20020100100678]; Consejo Nacional de
   Investigaciones Cientificas y Tecnicas [PIP 0707]
FX The following funding fonts were used in this work: Agencia Nacional de
   Promocion Cientifica y Tecnologica [PICT 1563, PICT 2731]; Universidad
   de Buenos Aires [20020100100678]; Consejo Nacional de Investigaciones
   Cientificas y Tecnicas [PIP 0707], Argentina.
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Barone I, 2014, MOL VIS, V20, P1545
   Barone I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050726
   Belayev A, 2003, BRAIN RES, V964, P121, DOI 10.1016/S0006-8993(02)04089-1
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biernaskie J, 2001, J NEUROSCI, V21, P5272, DOI 10.1523/JNEUROSCI.21-14-05272.2001
   Blasiak J, 2013, INT J MOL SCI, V14, P2996, DOI 10.3390/ijms14022996
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Brigadski T, 2020, CELL TISSUE RES, V382, P15, DOI 10.1007/s00441-020-03253-2
   Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003
   Briones T L, 2000, Biol Res Nurs, V1, P299, DOI 10.1177/109980040000100406
   Buschini E, 2015, CLIN OPHTHALMOL, V9, P563, DOI 10.2147/OPTH.S59724
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Chen XP, 2017, CELL PHYSIOL BIOCHEM, V41, P1445, DOI 10.1159/000468368
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Dayhaw-Barker P, 2002, INT J TOXICOL, V21, P451, DOI 10.1080/10915810290169873
   Dieguez HH, 2020, J PINEAL RES, V68, DOI 10.1111/jpi.12643
   Dieguez HH, 2019, FREE RADICAL BIO MED, V131, P72, DOI 10.1016/j.freeradbiomed.2018.11.035
   Dieguez HH, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.031641
   Dorfman D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101829
   Dorfman D, 2013, EXP NEUROL, V240, P146, DOI 10.1016/j.expneurol.2012.11.017
   Faherty CJ, 2003, DEV BRAIN RES, V141, P55, DOI 10.1016/S0165-3806(02)00642-9
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Fleitas MFG, 2020, MOL NEUROBIOL, V57, P435, DOI 10.1007/s12035-019-01715-5
   FOX MW, 1965, ANIM BEHAV, V13, P232, DOI 10.1016/0003-3472(65)90040-0
   Franklin TB, 2006, BRAIN RES, V1095, P1, DOI 10.1016/j.brainres.2006.04.025
   Fleitas MFG, 2020, J NEUROCHEM, V152, P103, DOI 10.1111/jnc.14885
   Fleitas MFG, 2019, EXP EYE RES, V178, P198, DOI 10.1016/j.exer.2018.10.007
   Gu L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200417
   Hackett SF, 1998, BRAIN RES, V789, P201, DOI 10.1016/S0006-8993(97)01440-6
   Hackett SF, 1997, EXP EYE RES, V64, P865, DOI 10.1006/exer.1996.0256
   Ishida K, 1997, CURR EYE RES, V16, P96, DOI 10.1076/ceyr.16.2.96.5093
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kaarniranta K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102374
   Karampelas M, 2013, BRIT J OPHTHALMOL, V97, P1256, DOI 10.1136/bjophthalmol-2013-303219
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Lambros ML, 2016, ADV EXP MED BIOL, V854, P67, DOI 10.1007/978-3-319-17121-0_10
   Landi S, 2007, FASEB J, V21, P130, DOI 10.1096/fj.06-6083com
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   Liu ZZ, 1997, J NEUROSCI, V17, P8749
   Ma HW, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-019-2216-7
   Machalinska A, 2013, EXP EYE RES, V112, P68, DOI 10.1016/j.exer.2013.04.004
   Mao HY, 2014, INVEST OPHTH VIS SCI, V55, P4613, DOI 10.1167/iovs.14-14633
   Ming M, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-53
   Mukherjee PK, 2007, P NATL ACAD SCI USA, V104, P13152, DOI 10.1073/pnas.0705949104
   Nebbioso M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071693
   Nithianantharajah J, 2006, NAT REV NEUROSCI, V7, P697, DOI 10.1038/nrn1970
   Nygren J, 2005, J CEREBR BLOOD F MET, V25, P1625, DOI 10.1038/sj.jcbfm.9600157
   OHLSSON AL, 1995, STROKE, V26, P644, DOI 10.1161/01.STR.26.4.644
   Okoye G, 2003, J NEUROSCI, V23, P4164
   Ortin-Martinez A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113798
   Portela-Camino JA, 2018, OPTOMETRY VISION SCI, V95, P523, DOI 10.1097/OPX.0000000000001222
   Prusky GT, 2000, BEHAV BRAIN RES, V114, P11, DOI 10.1016/S0166-4328(00)00186-8
   Seki M, 2005, NEUROCHEM RES, V30, P1163, DOI 10.1007/s11064-005-7936-7
   Seki M, 2003, INVEST OPHTH VIS SCI, V44, P3211, DOI 10.1167/iovs.02-1089
   Sozda CN, 2010, J NEUROTRAUM, V27, P1047, DOI 10.1089/neu.2010.1313
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Steinle JJ, 2002, EXP EYE RES, V74, P761, DOI 10.1006/exer.2002.1182
   Sun HM, 2010, CURR NEUROVASC RES, V7, P268, DOI 10.2174/156720210793180819
   Szabadfi K, 2009, BRAIN RES, V1259, P107, DOI 10.1016/j.brainres.2009.01.004
   Tekin MI, 2018, INVEST OPHTH VIS SCI, V59, P2833, DOI 10.1167/iovs.18-24030
   Veritti D, 2020, EXPERT OPIN PHARMACO, V21, P773, DOI 10.1080/14656566.2020.1736557
   Volland S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125631
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wright CB, 2015, PROG MOL BIOL TRANSL, V134, P433, DOI 10.1016/bs.pmbts.2015.06.009
   Yilmaz M, 2013, CURR BIOL, V23, P2011, DOI 10.1016/j.cub.2013.08.015
   Yu KW, 2020, J MOL NEUROSCI, V70, P413, DOI 10.1007/s12031-019-01428-3
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang M, 2009, CURR EYE RES, V34, P791, DOI 10.1080/02713680903086018
   Zhang XF, 2020, ICCAD-IEEE ACM INT, DOI 10.1145/3400302.3415609
NR 70
TC 1
Z9 1
U1 0
U2 3
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD DEC 4
PY 2021
VL 12
IS 12
AR 1128
DI 10.1038/s41419-021-04412-1
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA XI7UO
UT WOS:000726311700002
PM 34864827
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Elshout, M
   Webers, CA
   van der Reis, MI
   de Jong-Hesse, Y
   Schouten, JS
AF Elshout, Mari
   Webers, Carroll A.
   van der Reis, Margriet I.
   de Jong-Hesse, Yvonne
   Schouten, Jan S.
TI Tracing the natural course of visual acuity and quality of life in
   neovascular age-related macular degeneration: a systematic review and
   quality of life study
SO BMC OPHTHALMOLOGY
LA English
DT Review
DE Age-related macular degeneration; Natural progression; Visual acuity;
   Quality of life; Prognosis; Cost-effectiveness
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; TRANSPUPILLARY THERMOTHERAPY;
   COST-EFFECTIVENESS; OCCULT CNV; RADIOTHERAPY; RANIBIZUMAB; AFLIBERCEPT;
   ANGIOGRAPHY; PROGNOSIS; GLAUCOMA
AB Background: Describing the natural course of neovascular age-related macular degeneration (nAMD) is essential in discussing prognosis and treatment options with patients and to support cost-effectiveness studies.
   Methods: First, we performed a literature search in PubMed, Embase, and Cochrane. We included randomized clinical trials and prospective observational studies reporting visual acuity (VA) in non-treated patients, 24 studies in total. We integrated VA data using best fit on Lineweaver-Burke plots and modelled with non-linear regression using reciprocal terms. Second, we performed a quality-of-life (QoL) study in nAMD patients. We measured VA with Radner reading charts and QoL with the Health Utilities Index issue 3 (HUI-3) questionnaire in 184 participants. We studied the relation VA-QoL with linear regression. Third, with Monte Carlo simulation, we integrated the VA model from the literature review and the relation VA-QoL from the QoL study.
   Results: Visual acuity was 0.4 and 0.07 after 5 years in the better-seeing, and worse-seeing eye, respectively. After 4.3 years, VA was < 0.5 in the better-seeing eye; < 0.3 after 7 years; 0.05 after 17 years. QoL score decreased from 0. 6 to 0.45 after 10 years.
   Conclusions: The natural course of nAMD in both eyes needs to be considered when informing patients. Visual acuity in the best eye decreases to below 0.5 in 4.3 years. This affects QoL significantly.
C1 [Elshout, Mari; Webers, Carroll A.; van der Reis, Margriet I.; Schouten, Jan S.] Maastricht Univ, Med Ctr, Univ Eye Clin Maastricht, POB 5800, NL-6202 AZ Maastricht, Netherlands.
   [de Jong-Hesse, Yvonne] Vrije Univ Amsterdam, Med Ctr, Dept Ophthalmol, Amsterdam, Netherlands.
C3 Maastricht University; Maastricht University Medical Centre (MUMC);
   Vrije Universiteit Amsterdam
RP Elshout, M (通讯作者)，Maastricht Univ, Med Ctr, Univ Eye Clin Maastricht, POB 5800, NL-6202 AZ Maastricht, Netherlands.
EM m.elshout@st-anna.nl
RI Webers, Carroll A.B./D-1130-2010
FU Dutch organization for health research and development; ZonMw, The
   Hague, The Netherlands [152001002]
FX This study was supported by the Dutch organization for health research
   and development.; ZonMw, The Hague, The Netherlands, grant number
   152001002. The funding organization had no role in the design or conduct
   of this research.
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1232
   [Anonymous], 1996, Arch Ophthalmol, V114, P400
   Behrendt CE, 2004, OPHTHAL EPIDEMIOL, V11, P359, DOI 10.1080/09286580490515125
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bowker SL, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-17
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   CARDILLOPICCOLINO F, 1989, J FR OPHTALMOL, V12, P869
   DAMICO DJ, 2003, OPHTHALMOLOGY, V110, P2384
   Elshout M, 2016, OPHTHALMOLOGY, V123, P2408, DOI 10.1016/j.ophtha.2016.07.015
   Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   Eter Nicole, 2001, International Ophthalmology, V24, P13, DOI 10.1023/A:1014445524293
   Feeny D, 2002, MED CARE, V40, P113, DOI 10.1097/00005650-200202000-00006
   Ghosh W, 2016, ADV THER, V33, P1660, DOI 10.1007/s12325-016-0367-9
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Gustavsson C, 2005, ACTA OPHTHALMOL SCAN, V83, P148, DOI 10.1111/j.1600-0420.2005.00427.x
   Jaakkola A, 2005, OPHTHALMOLOGY, V112, P567, DOI 10.1016/j.ophtha.2004.11.029
   Jones CA, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-1
   Kaiser PK, 2009, CURR MED RES OPIN, V25, P1853, DOI 10.1185/03007990903038616
   Kobayashi H, 2000, AM J OPHTHALMOL, V130, P617, DOI 10.1016/S0002-9394(00)00534-1
   Krebs I, 2007, GRAEF ARCH CLIN EXP, V245, P376, DOI 10.1007/s00417-006-0424-1
   Mandai M, 2000, JPN J OPHTHALMOL, V44, P530, DOI 10.1016/S0021-5155(00)00217-3
   Medeiros FA, 2015, OPHTHALMOLOGY, V122, P293, DOI 10.1016/j.ophtha.2014.08.014
   Myint K, 2006, ACTA OPHTHALMOL SCAN, V84, P328, DOI 10.1111/j.1600-0420.2005.00623.x
   Pece A, 2000, ARCH OPHTHALMOL-CHIC, V118, P630
   Radner T, 1998, KLIN MONATSBL AUGENH, V213, P174, DOI 10.1055/s-2008-1034969
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Russell SR, 2007, SURV OPHTHALMOL, V52, pS79, DOI 10.1016/j.survophthal.2006.11.005
   Schmier JK, 2016, PHARMACOECONOMICS, V34, P259, DOI 10.1007/s40273-015-0347-y
   Schneider U, 2005, ACTA OPHTHALMOL SCAN, V83, P141, DOI 10.1111/j.1600-0420.2005.00443.x
   Shah AR, 2007, AM J OPHTHALMOL, V143, P83, DOI 10.1016/j.ajo.2006.09.043
   Shah AR, 2009, OPHTHALMOLOGY, V116, P1901, DOI 10.1016/j.ophtha.2009.03.055
   SOUBRANE G, 1990, OPHTHALMOLOGY, V97, P649
   Tholen AM, 2000, KLIN MONATSBL AUGENH, V216, P112, DOI 10.1055/s-2000-10528
   Valmaggia C, 2002, AM J OPHTHALMOL, V133, P521, DOI 10.1016/S0002-9394(02)01336-3
   van Gestel A, 2010, VALUE HEALTH, V13, P358, DOI 10.1111/j.1524-4733.2009.00678.x
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 40
TC 14
Z9 14
U1 1
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JUL 11
PY 2017
VL 17
AR 120
DI 10.1186/s12886-017-0514-3
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FB0TB
UT WOS:000405856400002
PM 28693519
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Becerra, EM
   Morescalchi, F
   Gandolfo, F
   Danzi, P
   Nascimbeni, G
   Arcidiacono, B
   Semeraro, F
AF Becerra, E. M.
   Morescalchi, F.
   Gandolfo, F.
   Danzi, P.
   Nascimbeni, G.
   Arcidiacono, B.
   Semeraro, F.
TI Clinical Evidence of Intravitreal Triamcinolone Acetonide in the
   Management of Age-Related Macular Degeneration
SO CURRENT DRUG TARGETS
LA English
DT Review
DE Intravitreal triamcinolone acetonide; age related macular degeneration;
   choroidal neovascularization; intraocular steroids; photodynamic therapy
ID RETINAL ANGIOMATOUS PROLIFERATION; SUBFOVEAL CHOROIDAL
   NEOVASCULARIZATION; ENDOTHELIAL GROWTH-FACTOR; COMBINED PHOTODYNAMIC
   THERAPY; INTERCELLULAR-ADHESION MOLECULE-1; POSTERIOR SUBTENON
   INJECTION; INTRAOCULAR-PRESSURE; COMBINATION THERAPY; NONINFECTIOUS
   ENDOPHTHALMITIS; TRABECULAR MESHWORK
AB Triamcinolone acetonide (TA) is one of the first pharmacologic compounds evaluated for the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). The most important effects of TA consist in the stabilisation of the blood-retinal barrier and the down-regulation of inflammation. TA also has antiangiogenic and anti-fibrotic properties. The peculiar characteristic of being well tolerated by ocular tissues and the capability to remain active for many months after a single intravitreal injection, make this drug a safe and effective alternative. In the past decade, intravitreal injection of TA (IVTA) has emerged as a useful treatment of several ocular diseases such as uveitis, macular edema secondary to retinal vasculature disease, neovascularisation and vitreoretinopathy.
   In this paper, we review all the available evidence of its use in AMD as mono-therapy or in combination with other treatments, and we discuss which role TA will play in the treatment of AMD in the future.
   The first experiences with IVTA as monotherapy for the treatment of exudative AMD reported a positive outcome in transiently reducing the leakage from CNV. However, in the long-term follow-up, IVTA as monotherapy had no effect on the risk of severe visual acuity loss, despite a significant anti-angiogenic effect found 3 months after the treatment. Consequently, studies using the combination of IVTA and photodynamic therapy (PDT), which acts synergistically, were performed. They reported to improve vision and to reduce the number of re-treatments with PDT.
   A large number of publications confirmed the positive synergic role of combining TA and PDT (therapies) for the treatment of all types of CNV: classic or predominantly classic, occult or minimally classic and RAP (Retinal Angiomatous Proliferation) lesions. The advantages registered with the use of IVTA plus PDT compared to PDT alone were partially limited by the side effects, such as the rapid evolution of cataract. Nevertheless, cataract surgery may stimulate the development of CNV (result in stimulating CNV). However, in large, randomized, clinical trials on combination therapy of TA and PDT, visual acuity failed to show an improvement, even though the lesion size and subretinal fluid had decreased, compared to controls treated with PDT alone. Some authors reported an increased risk of developing macular atrophy after the combination therapy with IVTA and PDT. Reduction of the PDT fluence rate in association with the use of steroids resulted in reducing the risk of macular atrophy and in a better visual acuity outcome.
   The introduction of anti-VEGF-based drugs has revolutionized the treatment of AMD and has replaced all the previous therapies used for CNV. Visual improvement becomes an expectation in a higher proportion of patients, previously limited to minimizing vision loss. Anti-VEGF therapy also resulted in superior visual improvement compared to all types of combination therapy with IVT and PDT. Nevertheless, anti-VEGF monotherapy also has many limitations due to the need of repetitive treatments, increased costs and tachyphylaxis. Treatment regimens involving TA in combination therapy with anti-VEGF and PDT may preserve benefits for substantially longer periods. A question remains open on whether a combination treatment with anti-VEGF, triamcinolone and/or PDT may be a treatment option in patients with exudative AMD, by offering, with one cycle of therapy, functional VA benefits comparable to those observed with continued monthly anti-VEGF therapy. Further trials, of higher scientific significance, are needed to study the potential of these treatment options.
C1 [Becerra, E. M.] Univ Nacl Cordoba, Dept Ophthalmol, RA-5000 Cordoba, Argentina.
   [Morescalchi, F.; Gandolfo, F.; Danzi, P.; Nascimbeni, G.; Arcidiacono, B.; Semeraro, F.] Univ Brescia, Clin Oculist, Brescia, Italy.
C3 National University of Cordoba; University of Brescia
RP Becerra, EM (通讯作者)，Univ Nacl Cordoba, Dept Ophthalmol, CC 495, RA-5000 Cordoba, Argentina.
EM emilianophth@yahoo.com.ar
RI Semeraro, Francesco fs/K-8667-2016
OI Semeraro, Francesco fs/0000-0002-2275-4917
CR Agurto-Rivera Ricardo, 2005, BMC Ophthalmol, V5, P27
   Ahmadieh Hamid, 2007, BMC Ophthalmol, V7, P10, DOI 10.1186/1471-2415-7-10
   Arevalo JF, 2005, GRAEF ARCH CLIN EXP, V243, P1180, DOI 10.1007/s00417-005-1177-y
   Arias L, 2008, GRAEF ARCH CLIN EXP, V246, P245, DOI 10.1007/s00417-007-0642-1
   Arias L, 2006, OPHTHALMOLOGY, V113, P2243, DOI 10.1016/j.ophtha.2006.04.039
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Axer-Siegel R, 2002, OPHTHALMOLOGY, V109, P1726, DOI 10.1016/S0161-6420(02)01149-1
   Axer-Siegel R, 2006, OPHTHAL SURG LAS IM, V37, P455, DOI 10.3928/15428877-20061101-02
   Baath J, 2007, J OCUL PHARMACOL TH, V23, P304, DOI 10.1089/jop.2006.125
   Bakri SJ, 2008, RETINA-J RET VIT DIS, V28, P996, DOI 10.1097/IAE.0b013e31816c6868
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Beer PM, 2003, OPHTHALMOLOGY, V110, P681, DOI 10.1016/S0161-6420(02)01969-3
   Bergh FT, 1999, J NEUROL, V246, P292, DOI 10.1007/s004150050349
   Blaha GR, 2008, OPHTHAL SURG LAS IM, V39, P6, DOI 10.3928/15428877-20080101-02
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Borrillo JL, 2003, ARCH OPHTHALMOL-CHIC, V121, P558, DOI 10.1001/archopht.121.4.558
   Boscia F, 2005, EUR J OPHTHALMOL, V15, P513, DOI 10.1177/112067210501500418
   Boscia F, 2006, GRAEF ARCH CLIN EXP, V244, P1224, DOI 10.1007/s00417-005-0205-2
   Bottoni F, 2005, ARCH OPHTHALMOL-CHIC, V123, P1644, DOI 10.1001/archopht.123.12.1644
   Bottoni F, 2006, GRAEF ARCH CLIN EXP, V244, P1528, DOI 10.1007/s00417-006-0311-9
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Brooks HL, 2004, ARCH OPHTHALMOL-CHIC, V122, P1801, DOI 10.1001/archopht.122.12.1801
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Cekic O, 2005, AM J OPHTHALMOL, V139, P993, DOI 10.1016/j.ajo.2005.01.022
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Chan WM, 2006, BRIT J OPHTHALMOL, V90, P337, DOI 10.1136/bjo.2005.081299
   Chaudhary V, 2007, OPHTHALMOLOGY, V114, P2183, DOI 10.1016/j.ophtha.2007.02.013
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chen SDM, 2004, BRIT J OPHTHALMOL, V88, P843, DOI 10.1136/bjo.2003.033589
   Ciulla TA, 2003, BRIT J OPHTHALMOL, V87, P1032, DOI 10.1136/bjo.87.8.1032
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Colucciello M, 2008, J OCUL PHARMACOL TH, V24, P15, DOI 10.1089/jop.2007.0080
   COSTA RA, 2000, RETINA, V23, P159
   Costagliola C, 2007, AM J OPHTHALMOL, V144, P449, DOI 10.1016/j.ajo.2007.05.025
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Du Lei, 2006, Yan Ke Xue Bao, V22, P156
   Edelman JL, 2005, EXP EYE RES, V80, P249, DOI 10.1016/j.exer.2004.09.013
   Ergun E, 2006, AM J OPHTHALMOL, V142, P10, DOI 10.1016/j.ajo.2006.02.048
   Ferrario A, 2000, CANCER RES, V60, P4066
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Folkman J, 1992, Semin Cancer Biol, V3, P89
   Freund KB, 2006, ARCH OPHTHALMOL-CHIC, V124, P487, DOI 10.1001/archopht.124.4.487
   Frimpong-Boateng A, 2009, ACTA OPHTHALMOL, V87, P183, DOI 10.1111/j.1755-3768.2008.01213.x
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gamulescu MA, 2009, KLIN MONATSBL AUGENH, V226, P60, DOI 10.1055/s-2008-1027729
   Garcia-Arumi J, 2005, BRIT J OPHTHALMOL, V89, P1112, DOI 10.1136/bjo.2005.067744
   Gillies MC, 2007, AM J OPHTHALMOL, V144, P134, DOI 10.1016/j.ajo.2007.03.019
   Gillies MC, 2006, OPHTHALMOLOGY, V113, P1533, DOI 10.1016/j.ophtha.2006.02.065
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gillies MC, 2005, OPHTHALMOLOGY, V112, P139, DOI 10.1016/j.ophtha.2004.07.017
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   Gilson MM, 2007, OPHTHALMOLOGY, V114, P1713, DOI 10.1016/j.ophtha.2007.03.071
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hahn R, 2007, OPHTHALMOLOGE, V104, P588, DOI 10.1007/s00347-007-1547-4
   HAN D, 1994, NEUROCHEM INT, V24, P339, DOI 10.1016/0197-0186(94)90112-0
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   HELM CJ, 1995, AM J OPHTHALMOL, V120, P55, DOI 10.1016/S0002-9394(14)73759-6
   HIDA T, 1986, AM J OPHTHALMOL, V101, P190, DOI 10.1016/0002-9394(86)90593-3
   Hollborn M, 2007, INVEST OPHTH VIS SCI, V48, P4360, DOI 10.1167/iovs.06-1234
   Inoue M, 2004, AM J OPHTHALMOL, V138, P1046, DOI 10.1016/j.ajo.2004.05.028
   IP MS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1412
   Iriyama A, 2008, GRAEF ARCH CLIN EXP, V246, P339, DOI 10.1007/s00417-007-0667-5
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   Ishikawa K, 2009, RETINA-J RET VIT DIS, V29, P803, DOI 10.1097/IAE.0b013e31819c631a
   Islam MS, 2007, EYE, V21, P321, DOI 10.1038/sj.eye.6702304
   Itaya H, 2001, THROMB HAEMOSTASIS, V85, P171, DOI 10.1055/s-0037-1612921
   Iwama D, 2008, BRIT J OPHTHALMOL, V92, P1352, DOI 10.1136/bjo.2008.141754
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Johnson D, 1997, ARCH OPHTHALMOL-CHIC, V115, P375, DOI 10.1001/archopht.1997.01100150377011
   Jonas JB, 2008, EYE, V22, P869, DOI 10.1038/sj.eye.6702734
   Jonas JB, 2006, AM J OPHTHALMOL, V141, P579, DOI 10.1016/j.ajo.2005.10.007
   Jonas JB, 2005, AM J OPHTHALMOL, V139, P1073, DOI 10.1016/j.ajo.2005.01.032
   Jonas JB, 2005, EUR J OPHTHALMOL, V15, P462, DOI 10.1177/112067210501500407
   Jonas JB, 2005, EYE, V19, P163, DOI 10.1038/sj.eye.6701438
   Jonas JB, 2004, BRIT J OPHTHALMOL, V88, P1557, DOI 10.1136/bjo.2003.039552
   Jonas JB, 2004, AM J OPHTHALMOL, V138, P158, DOI 10.1016/j.ajo.2004.02.025
   Jonas JB, 2004, ARCH OPHTHALMOL-CHIC, V122, P218, DOI 10.1001/archopht.122.2.218
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Jonas JB, 2002, BRIT J OPHTHALMOL, V86, P1066, DOI 10.1136/bjo.86.9.1066
   Jonas JB, 2002, BRIT J OPHTHALMOL, V86, P1450, DOI 10.1136/bjo.86.12.1450-a
   Jonas JB, 2005, OPHTHALMOLOGY, V112, P593, DOI 10.1016/j.ophtha.2004.10.042
   JONAS JB, 2009, ACTA OPHTHALMOL 0427
   Jonas JB, 2009, OPHTHALMIC RES, V41, P21, DOI 10.1159/000162113
   Jones R, 2006, CURR OPIN OPHTHALMOL, V17, P163
   Kato A, 2005, RETINA-J RET VIT DIS, V25, P503, DOI 10.1097/00006982-200506000-00017
   Krebs I, 2008, GRAEF ARCH CLIN EXP, V246, P237, DOI 10.1007/s00417-007-0651-0
   Krebs I, 2007, GRAEF ARCH CLIN EXP, V245, P376, DOI 10.1007/s00417-006-0424-1
   Krieglstein TR, 2006, BRIT J OPHTHALMOL, V90, P1357, DOI 10.1136/bjo.2006.092536
   Kubota T, 2006, J GLAUCOMA, V15, P117, DOI 10.1097/00061198-200604000-00007
   Larsson J, 2005, CLIN EXP OPHTHALMOL, V33, P544, DOI 10.1111/j.1442-9071.2005.01082.x
   Lassota N, 2008, ACTA OPHTHALMOL, V86, P495, DOI [10.1111/j.1600-0420.2007.01127.x, 10.1111/j.1755-3768.2008.01412.x]
   Lee J, 2007, RETINA-J RET VIT DIS, V27, P1205, DOI 10.1097/IAE.0b013e31815ec367
   Lee YA, 2009, EYE, V23, P645, DOI 10.1038/eye.2008.17
   Li YH, 2002, BIOL NEONATE, V82, P22, DOI 10.1159/000064148
   Liggett PE, 2006, AM J OPHTHALMOL, V142, P1072, DOI 10.1016/j.ajo.2006.07.029
   Lo Giudice G, 2008, EUR J OPHTHALMOL, V18, P652, DOI 10.1177/112067210801800429
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   Carrero JL, 2008, ARCH OPHTHALMOL-CHIC, V126, P142, DOI 10.1001/archophthalmol.2007.20
   Luttrull JK, 2007, RETINA-J RET VIT DIS, V27, P688, DOI 10.1097/IAE.0b013e318030e999
   Mansoor S, 2009, PHARM RES-DORDR, V26, P770, DOI 10.1007/s11095-008-9812-z
   Mantel I, 2006, EUR J OPHTHALMOL, V16, P705, DOI 10.1177/112067210601600507
   Margherio RR, 2000, RETINA-J RET VIT DIS, V20, P325, DOI 10.1097/00006982-200007000-00001
   Matsuda S, 2005, INVEST OPHTH VIS SCI, V46, P1062, DOI 10.1167/iovs.04-0761
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Miller DW, 2003, OPHTHALMOLOGE, V100, P92, DOI 10.1007/s00347-002-0760-4
   Montero JA, 2009, BRIT J OPHTHALMOL, V93, P166, DOI 10.1136/bjo.2008.141903
   Moshfeghi AA, 2004, AM J OPHTHALMOL, V138, P489, DOI 10.1016/j.ajo.2004.03.025
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V136, P791, DOI 10.1016/S0002-9394(03)00483-5
   Mueller AJ, 1998, AM J OPHTHALMOL, V125, P158, DOI 10.1016/S0002-9394(99)80085-3
   MUELLER AJ, 2009, J OCUL PHARMACOL TH, V25, P159
   Nauck M, 1998, EUR J PHARMACOL, V341, P309, DOI 10.1016/S0014-2999(97)01464-7
   Nelson ML, 2003, RETINA-J RET VIT DIS, V23, P686, DOI 10.1097/00006982-200310000-00014
   Nicolo M, 2006, RETINA-J RET VIT DIS, V26, P58, DOI 10.1097/00006982-200601000-00010
   Nussenblatt RB, 2009, CURR OPIN INVEST DR, V10, P434
   Ober MD, 2006, AM J OPHTHALMOL, V142, P597, DOI 10.1016/j.ajo.2006.05.041
   Patel S, 2009, RETINA-J RET VIT DIS, V29, pS45, DOI 10.1097/IAE.0b013e3181ad22d5
   Pece A, 2001, RETINA-J RET VIT DIS, V21, P661, DOI 10.1097/00006982-200112000-00017
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penfold PL, 2000, CLIN EXP IMMUNOL, V121, P458, DOI 10.1046/j.1365-2249.2000.01316.x
   Penfold PL, 2002, INVEST OPHTH VIS SCI, V43, P3125
   Piermarocchi S, 2008, ARCH OPHTHALMOL-CHIC, V126, P1367, DOI 10.1001/archopht.126.10.1367
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Reche-Frutos J, 2007, EUR J OPHTHALMOL, V17, P979, DOI 10.1177/112067210701700619
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rhee DJ, 2006, BRIT J OPHTHALMOL, V90, P999, DOI 10.1136/bjo.2006.090340
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Richards A, 2007, ADV IMMUNOL, V96, P141, DOI 10.1016/S0065-2776(07)96004-6
   Rodriguez-Coleman H, 2004, ARCH OPHTHALMOL-CHIC, V122, P1085, DOI 10.1001/archopht.122.7.1085
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roth DB, 2008, OPHTHAL SURG LAS IM, V39, P12, DOI 10.3928/15428877-20080101-11
   Roth DB, 2007, RETINA-J RET VIT DIS, V27, P1201, DOI 10.1097/IAE.0b013e3180ed45a6
   Roth DB, 2003, ARCH OPHTHALMOL-CHIC, V121, P1279, DOI 10.1001/archopht.121.9.1279
   Rouvas AA, 2009, RETINA-J RET VIT DIS, V29, P536, DOI 10.1097/IAE.0b013e318196b1de
   Ruiz-Moreno JM, 2006, EUR J OPHTHALMOL, V16, P426, DOI 10.1177/112067210601600311
   Ruiz-Moreno JM, 2007, RETINA-J RET VIT DIS, V27, P458, DOI 10.1097/IAE.0b013e318030c77c
   Ruiz-Moreno JM, 2009, J GLAUCOMA, V18, P69, DOI 10.1097/IJG.0b013e31816b3037
   Sacu S, 2008, BRIT J OPHTHALMOL, V92, P1347, DOI 10.1136/bjo.2008.137885
   Sacu S, 2009, EYE, V23, P2223, DOI 10.1038/eye.2008.423
   Sakimoto S, 2005, AM J OPHTHALMOL, V139, P917, DOI 10.1016/j.ajo.2004.10.046
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schmidt-Erfurth UM, 2003, INVEST OPHTH VIS SCI, V44, pU297
   Schnurrbusch UEK, 2005, ARCH OPHTHALMOL-CHIC, V123, P1347, DOI 10.1001/archopht.123.10.1347
   Scott IU, 2009, ARCH OPHTHALMOL-CHIC, V127, P1115, DOI 10.1001/archophthalmol.2009.233
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Singh CN, 2008, RETINA-J RET VIT DIS, V28, P789, DOI 10.1097/IAE.0b013e31817082d7
   Smiddy WE, 2009, OPHTHALMOLOGY, V116, P481, DOI 10.1016/j.ophtha.2008.10.029
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spandau UHM, 2005, BRIT J OPHTHALMOL, V89, P745, DOI 10.1136/bjo.2004.052563
   Sutter FK, 2007, KLIN MONATSBL AUGENH, V224, P297, DOI 10.1055/s-2007-962949
   Sutter FK, 2006, KLIN MONATSBL AUGENH, V223, P376, DOI 10.1055/s-2006-926564
   Tammewar AM, 2008, BRIT J OPHTHALMOL, V92, P810, DOI 10.1136/bjo.2007.126227
   TANO Y, 1980, AM J OPHTHALMOL, V89, P131, DOI 10.1016/0002-9394(80)90239-1
   TANO Y, 1980, AM J OPHTHALMOL, V90, P810, DOI 10.1016/S0002-9394(14)75196-7
   Tatar O, 2009, ARCH OPHTHALMOL-CHIC, V127, P275, DOI 10.1001/archophthalmol.2008.602
   Tektas OY, 2009, EXP EYE RES, V88, P769, DOI 10.1016/j.exer.2008.11.025
   Thompson JT, 2006, AM J OPHTHALMOL, V141, P629, DOI 10.1016/j.ajo.2005.11.050
   Van de Moere A, 2005, OPHTHALMOLOGY, V112, P1897, DOI 10.1016/j.ophtha.2005.06.018
   van de Moere A, 2007, AM J OPHTHALMOL, V143, P701, DOI 10.1016/j.ajo.2006.10.045
   Vasconcelos-Santos DV, 2008, RETINA-J RET VIT DIS, V28, P573, DOI 10.1097/IAE.0b013e31816079e8
   Wang YS, 2002, GRAEF ARCH CLIN EXP, V240, P42, DOI 10.1007/s00417-001-0398-y
   Weber U, 2005, OPHTHALMOLOGE, V102, P355, DOI 10.1007/s00347-004-1117-y
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Yang P, 2009, INVEST OPHTH VIS SCI, V50, P3473, DOI 10.1167/iovs.08-3202
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yeung CK, 2003, INVEST OPHTH VIS SCI, V44, P5293, DOI 10.1167/iovs.03-0490
   Yilmaz T, 2009, OPHTHALMOLOGY, V116, P902, DOI 10.1016/j.ophtha.2009.02.002
   Yip PP, 2009, BRIT J OPHTHALMOL, V93, P754, DOI 10.1136/bjo.2008.150987
   Zhang XY, 2007, OPHTHAL RES, V39, P241, DOI 10.1159/000104833
NR 178
TC 44
Z9 47
U1 0
U2 3
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-4501
EI 1873-5592
J9 CURR DRUG TARGETS
JI Curr. Drug Targets
PD FEB
PY 2011
VL 12
IS 2
BP 149
EP 172
PG 24
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 720RX
UT WOS:000287299000003
PM 20887246
DA 2022-11-30
ER

PT J
AU Bhandari, S
   Nguyen, V
   Arnold, J
   Young, S
   Banerjee, G
   Gillies, M
   Barthelmes, D
AF Bhandari, Sanjeeb
   Nguyen, Vuong
   Arnold, Jennifer
   Young, Stephanie
   Banerjee, Gayatri
   Gillies, Mark
   Barthelmes, Daniel
TI Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular
   Age-Related Macular Degeneration Data from the Fight Retinal Blindness!
   Registry
SO OPHTHALMOLOGY
LA English
DT Article
ID EXTEND INTRAVITREAL THERAPY; 2-YEAR OUTCOMES; VISUAL-ACUITY; BEVACIZUMAB
AB Purpose: Ranibizumab and aflibercept are both approved for the treatment of neovascular age-related macular degeneration (nAMD). Herein, we compare the 3-year treatment outcomes of the 2 in routine clinical practice.
   Design: Retrospective analysis of data from a prospectively designed observational outcomes registry, the Fight Retinal Blindness! project.
   Participants: Treatment-naiive eyes starting nAMD treatment from December 1, 2013 through December 31, 2015, with either ranibizumab or aflibercept that were tracked in the registry.
   Methods: Visual acuity (VA) was analyzed annually in completers (those who completed 3 years of treatment) and in all eyes (completers, noncompleters, and those who switched treatment ).
   Main Outcome Measures: The primary outcome was mean change in VA (number of letters read on a logarithm of the minimum angle of resolution chart).
   Results: A total of 965 eyes of 897 patients (ranibizumab, 499 eyes [469 patients]; aflibercept, 466 eyes [432 patients) were identified. The mean VA and the type of the choroidal neovascularization (CNV) at the start of treatment were similar between the 2 groups. The group receiving ranibizumab was older. The crude mean VA change of +1.5 letters (95% confidence interval [CI], 0-3.1 letters) in the ranibizumab group and of +1.6 letters (95% CI, -0.2 to 3.3 letters; P = 0.97) in the aflibercept group at 3 years in all eyes was similar, as was the adjusted mean VA change, +0.3 letters (95% CI, -1.5 to 2.0 letters) versus +1.0 letters (95% CI, -0.7 to 2.8 letters; P = 0.66). Both treatment groups received a median of 18 injections from a median of 21 clinical visits. The adjusted proportion of clinical visits when the CNV was graded active over 3 years was similar between ranibizumab (43%) and aflibercept (51%; P = 0.9). More switches from ranibizumab to aflibercept (P < 0.001) took place than vice versa. The proportion of eyes that did not complete 3 years of treatment in each of the group was similar (P = 0.21).
   Conclusions: Neither ranibizumab nor aflibercept was superior to the other in terms of VA outcomes and treatment frequency at 3 years for nAMD. (C) 2019 by the American Academy of Ophthalmology
C1 [Bhandari, Sanjeeb; Nguyen, Vuong; Gillies, Mark; Barthelmes, Daniel] Univ Sydney, Sydney Med Sch, Discipline Ophthalmol & Eye Hlth, Save Sight Inst, Level 1,South Block,8 Macquarie St, Sydney, NSW 2000, Australia.
   [Arnold, Jennifer] Marsden Eye Specialists, Parramatta, Australia.
   [Young, Stephanie] Gladesville Eye Specialists, Gladesville, Australia.
   [Banerjee, Gayatri] Nepean Valley Eye Surg, Nepean, Australia.
   [Barthelmes, Daniel] Univ Zurich, Univ Hosp Zurich, Dept Ophthalmol, Zurich, Switzerland.
C3 University of Sydney; University of Zurich; University Zurich Hospital
RP Bhandari, S (通讯作者)，Univ Sydney, Sydney Med Sch, Discipline Ophthalmol & Eye Hlth, Save Sight Inst, Level 1,South Block,8 Macquarie St, Sydney, NSW 2000, Australia.
EM sbha5189@uni.sydney.edu.au
OI BHANDARI, SANJEEB/0000-0002-4110-4274
FU Macular Disease Foundation Australia; Bayer; Novartis
FX The Fight Retinal Blindness! project is supported by a grant from the
   Macular Disease Foundation Australia and unrestricted educational grants
   from Bayer and Novartis.
CR [Anonymous], ESTIMATED MARGINAL M
   [Anonymous], PREF PRACT PATT GUID
   [Anonymous], 2018, MIXED EFFECTS COX MO
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Barthelmes D, 2018, GRAEF ARCH CLIN EXP, V256, P1839, DOI 10.1007/s00417-018-4061-2
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Barthelmes D, 2016, BRIT J OPHTHALMOL, V100, P1640, DOI 10.1136/bjophthalmol-2015-308090
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Beaumont PE, 2014, OPHTHALMOLOGY, V121, pE4, DOI 10.1016/j.ophtha.2013.09.020
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cepeda MS, 2003, AM J EPIDEMIOL, V158, P280, DOI 10.1093/aje/kwg115
   Chakravarthy U, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2018-000226
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Therneau T.M., 2018, PACKAGE SURVIVAL ANA
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wood SN, 2011, J R STAT SOC B, V73, P3, DOI 10.1111/j.1467-9868.2010.00749.x
NR 28
TC 14
Z9 14
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2020
VL 127
IS 3
BP 369
EP 376
DI 10.1016/j.ophtha.2019.10.006
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KN4ST
UT WOS:000514829200015
PM 31757494
DA 2022-11-30
ER

PT J
AU Pinelli, R
   Bertelli, M
   Scaffidi, E
   Fulceri, F
   Busceti, CL
   Biagioni, F
   Fornai, F
AF Pinelli, Roberto
   Bertelli, Miorica
   Scaffidi, Elena
   Fulceri, Federica
   Busceti, Carla L.
   Biagioni, Francesca
   Fornai, Francesco
TI Measurement of drusen and their correlation with visual symptoms in
   patients affected by age-related macular degeneration
SO ARCHIVES ITALIENNES DE BIOLOGIE
LA English
DT Article
DE Age-related macular degeneration; Neurodegeneration; Autophagy; Drusen;
   Metamorphopsia; Retinal anatomy; Pigment epithelium
ID RETINAL-PIGMENT; SNELLEN CHART; MECHANISMS; EYE; RESVERATROL;
   INCLUSIONS; DEPOSITS; DISEASE; LUTEIN
AB Age-related macular degeneration (AMD) is a common retinal disorder, which became more and more prevalent in the last decades. AMD is now the most prevalent cause of blindness in the western world. The disorder is classified into two phenotypes named dry and wet AMD. This is based on the recruitment of novel blood vessels and inflammatory exudates in wet AMD. In both phenotypes, the pathological hallmark is the presence of proteinaceous aggregates called drusen, which mostly accumulate between the choroid and the retinal pigment. Drusen in dry AMD represent the evident pathological finding although they are present, though less defined, in wet AMD. In AMD drusen are supposed to be a pathogenic trigger of the disorder. In fact, drusen may mechanically alter retinal function. A novel hypothesis exists, suggesting that a metabolic defect (systemic or focal within the retinal pigment epithelium) may be the real determinant of visual impairment, while causing the concomitant accumulation of proteinaceous debris and lipids forming the drusen. Here we face such an issue by analyzing the retinal anatomy to correlate visual impairment with the occurrence of drusen number, size and the extent of a drusenoid area in the foveal region. A comparison is made with wet AMD where new vessels and retinal exudates prevail. The study is carried out in 120 patients affected by dry or wet AMD and 21 patients where paradoxical findings are described. The main question consists in inferring whether the occurrence of visual impairment is due, in fact, to a drusen-dependent mechanical damage or drusen just occurs as an independent consequence of an upstream metabolic alteration, which concomitantly impairs the visual process. The present data indicate that, despite a significant difference in visual function between mild and severe AMD patients in the amount of drusen exists, a strong correlation between drusen and visual impairment does not occur. This suggests that drusen and visual deterioration develop as a consequence of similar upstream biochemical alterations but it is likely that drusen do not produce visual deterioration. This is strengthened here by extreme clinical conditions, where visual impairment is severe with a slight alteration in the planar pattern of the retina or, vice versa an extended drusenoid area occurs concomitantly with fair visual acuity, contrast sensitivity and lack of metamorphopsia. A biochemical analysis of key areas in the function of specific domains in the pigment epithelium as described in the accompanying manuscript should help to better disclose the real morpho-functional deficit, which takes place in AMD.
C1 [Pinelli, Roberto; Bertelli, Miorica; Scaffidi, Elena] Switzerland Eye Res Inst, SERI, Lugano, Switzerland.
   [Fulceri, Federica] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy.
   [Busceti, Carla L.; Biagioni, Francesca; Fornai, Francesco] IRCCS Neuromed, Pozzilli, IS, Italy.
   [Fornai, Francesco] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Via Roma 55, I-56126 Pisa, Italy.
C3 University of Pisa; IRCCS Neuromed; University of Pisa
RP Fornai, F (通讯作者)，Univ Pisa, Dept Translat Res & New Technol Med & Surg, Via Roma 55, I-56126 Pisa, Italy.
EM francesco.fornai@unipi.it
CR Algvere PV, 2016, ACTA OPHTHALMOL, V94, P427, DOI 10.1111/aos.13011
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Bergen AA, 2019, PROG RETIN EYE RES, V70, P55, DOI 10.1016/j.preteyeres.2018.12.003
   Bola C, 2014, GRAEF ARCH CLIN EXP, V252, P699, DOI 10.1007/s00417-014-2604-8
   Bungau S, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9783429
   Buscemi S, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091321
   Chen FK, 2014, ASIA-PAC J OPHTHALMO, V3, P277, DOI 10.1097/APO.0000000000000007
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Fornai F, 2003, CNS NEUROL DISORD-DR, V2, P149, DOI 10.2174/1568007033482904
   Fornai F, 2005, BRAIN RES BULL, V65, P275, DOI 10.1016/j.brainresbull.2004.12.009
   Fornai F, 2003, J NEUROSCI, V23, P8955
   Fornai F, 2002, ANN NY ACAD SCI, V965, P381
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Girmens JF, 2012, INTRACTABLE RARE DIS, V1, P103, DOI 10.5582/irdr.2012.v1.3.103
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson AT, 1998, COMPUT METH PROG BIO, V57, P161, DOI 10.1016/S0169-2607(98)00036-4
   Jones BW, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00103
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Losa GA, 1996, MODERN PATHOL, V9, P174
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Mandelbrot BB, 1998, SCIENCE, V279, P783
   Mares J, 2016, ANNU REV NUTR, V36, P571, DOI 10.1146/annurev-nutr-071715-051110
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Munia I, 2020, NUTRIENTS, V12, DOI 10.3390/nu12030879
   Neal SE, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.4.32
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Pfeiffer RL, 2020, PROG RETIN EYE RES, V74, DOI 10.1016/j.preteyeres.2019.07.004
   Pinelli R, 2020, ARCH ITAL BIOL, V158, P24, DOI 10.12871/00039829202013
   Pinelli R, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155563
   Pollreisz A, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.2.26
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Rohrer B, 2018, ADV EXP MED BIOL, V1074, P45, DOI 10.1007/978-3-319-75402-4_6
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Schink A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203907
   Seddon J, 2001, RETINA-J RET VIT DIS, P1039
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Su D, 2016, OPHTHALMOLOGY, V123, P737, DOI 10.1016/j.ophtha.2015.12.003
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   TOLENTINO MJ, 1994, VISION RES, V34, P409, DOI 10.1016/0042-6989(94)90099-X
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang Y, 2015, MOLECULES, V20, P22395, DOI 10.3390/molecules201219785
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu KY, 2018, CAN J OPHTHALMOL, V53, P168, DOI 10.1016/j.jcjo.2017.08.006
   Zarbin M, 2019, STEM CELL TRANSL MED, V8, P466, DOI 10.1002/sctm.18-0282
   Zarbin MA, 2014, DEV OPHTHALMOL, V53, P1, DOI 10.1159/000358536
NR 55
TC 3
Z9 3
U1 0
U2 1
PU PISA UNIV PRESS
PI PISA
PA LUNGARNO A PACINOTTI 43, 56100 PISA, ITALY
SN 0003-9829
J9 ARCH ITAL BIOL
JI Arch. Ital. Biol.
PD DEC
PY 2020
VL 158
IS 3-4
BP 82
EP 104
DI 10.12871/000398292020343
PG 23
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA RH2IY
UT WOS:000636050200003
PM 33821470
DA 2022-11-30
ER

PT J
AU Wysokinski, D
   Szaflik, J
   Sklodowska, A
   Kolodziejska, U
   Dorecka, M
   Romaniuk, D
   Wozniak, K
   Blasiak, J
   Szaflik, JP
AF Wysokinski, Daniel
   Szaflik, Jerzy
   Sklodowska, Anna
   Kolodziejska, Urszula
   Dorecka, Mariola
   Romaniuk, Dorota
   Wozniak, Katarzyna
   Blasiak, Janusz
   Szaflik, Jacek Pawel
TI The A Allele of the-576G > A Polymorphism of the Transferrin Gene Is
   Associated with the Increased Risk of Age-Related Macular Degeneration
   in Smokers
SO TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; iron metabolism; transferrin gene;
   transferrin receptor; genetic polymorphism
ID CIGARETTE-SMOKING; OXIDATIVE DAMAGE; IRON; DISEASE; REGION; SNPS;
   PATHOGENESIS; INFLAMMATION; MACULOPATHY; PATTERN
AB Age-related macular degeneration (AMD) is the leading cause of blindness among the elderly in developed countries, and its pathogenesis is underlined by genetic and environmental factors. Oxidative stress is a major environmental risk factor of AMD; namely, AMD is associated with the increased level of reactive oxygen species, which may be produced in reactions catalyzed by iron present in the retina. Therefore, variability of the genes of iron metabolism may be important in the AMD risk. In the present study, we analyzed the association between AMD and the -576G > A polymorphism of the transferrin gene or the 1892C > T polymorphism of the transferrin receptor 2 (TFR2) gene in 278 patients with AMD and 105 controls. The former polymorphism is located in the promoter region of the transferrin gene and may affect the level of its transcription, while the latter is a synonymous mutation in the exon 16, which may affect the efficiency of translation of TFR2 mRNA. Transferrin and TFR2 are important in iron homeostasis. The A allele of the -576A > G polymorphism was significantly associated with the increased risk of AMD in tobacco smokers, whereas the 1892C > T polymorphism did not influence the risk of AMD related to smoking. Moreover, each polymorphism does not influence the risk of AMD associated with age, sex or the family history of the disease. In conclusion, the A allele of the -576A > G polymorphism of the transferrin gene may increase the risk of AMD in smokers.
C1 [Szaflik, Jerzy; Sklodowska, Anna; Kolodziejska, Urszula; Szaflik, Jacek Pawel] Med Univ Warsaw, Dept Ophthalmol, PL-03710 Warsaw, Poland.
   [Szaflik, Jerzy; Sklodowska, Anna; Kolodziejska, Urszula; Szaflik, Jacek Pawel] Samodzielny Publiczny Szpital Okulistyczny, PL-03710 Warsaw, Poland.
   [Wysokinski, Daniel; Wozniak, Katarzyna; Blasiak, Janusz] Univ Lodz, Dept Mol Genet, PL-90131 Lodz, Poland.
   [Dorecka, Mariola; Romaniuk, Dorota] Med Univ Silesia, Dept Ophthalmol, Katowice, Poland.
C3 Medical University of Warsaw; University of Lodz; Medical University
   Silesia
RP Szaflik, JP (通讯作者)，Med Univ Warsaw, Dept Ophthalmol, Sierakowskiego 13, PL-03710 Warsaw, Poland.
EM szaflik@ophthalmology.pl
RI Wozniak, Katarzyna/R-9226-2018
OI Wozniak, Katarzyna/0000-0001-6666-7973; Blasiak,
   Janusz/0000-0001-9539-9584; Szaflik, Jerzy/0000-0002-7601-1326; Dorecka,
   Mariola/0000-0003-1768-9628
FU Polish Ministry of Science and Higher Education [N N402 248 336];
   European Union
FX This work was supported by grant N N402 248 336 from Polish Ministry of
   Science and Higher Education. Daniel Wysokinski is a recipient of D-RIM
   2<SUP>nd</SUP> edition fellowship co-funded by the European Union under
   the European Social Fund: "HUMAN - BEST INVESTMENT".
CR ADRIAN GS, 1986, GENE, V49, P167, DOI 10.1016/0378-1119(86)90277-5
   Ayala-Haedo JA, 2010, ANN HUM GENET, V74, P195, DOI 10.1111/j.1469-1809.2010.00570.x
   Ayonrinde OT, 2008, CRIT REV CL LAB SCI, V45, P451, DOI 10.1080/10408360802335716 
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Biasiotto G, 2008, HAEMATOLOGICA, V93, P309, DOI 10.3324/haematol.11942
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Buckland PR, 2004, BBA-MOL BASIS DIS, V1690, P238, DOI 10.1016/j.bbadis.2004.06.023
   Chen JX, 2009, CANCER BIOL THER, V8, P1699, DOI 10.4161/cbt.8.18.9146
   Chowers I, 2006, INVEST OPHTH VIS SCI, V47, P2135, DOI 10.1167/iovs.05-1135
   Chu J, 2008, CHINESE MED J-PEKING, V121, P2525, DOI 10.1097/00029330-200812020-00011
   Chua ACG, 2007, CRIT REV CL LAB SCI, V44, P413, DOI 10.1080/10408360701428257
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Dhubhghaill SSN, 2010, ADV EXP MED BIOL, V664, P437, DOI 10.1007/978-1-4419-1399-9_50
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   Fairweather-Tait SJ, 2007, GENES NUTR, V2, P15, DOI 10.1007/s12263-007-0007-8
   Frank R N, 2000, Trans Am Ophthalmol Soc, V98, P109
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Graham RM, 2008, J HEPATOL, V48, P327, DOI 10.1016/j.jhep.2007.10.009
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Huang X, 2008, LANCET ONCOL, V9, P803, DOI 10.1016/S1470-2045(08)70200-6
   Hunt R, 2009, METHODS MOL BIOL, V578, P23, DOI 10.1007/978-1-60327-411-1_2
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   KUILILEA DW, 2004, ANN NY ACAD SCI, V1019, P365
   Lee PL, 2001, BLOOD CELL MOL DIS, V27, P539, DOI 10.1006/bcmd.2001.0418
   Lee SJ, 2010, CLIN EXP OPHTHALMOL, V38, P698, DOI 10.1111/j.1442-9071.2010.02316.x
   Lukinova N, 2009, INVEST OPHTH VIS SCI, V50, P1440, DOI 10.1167/iovs.08-2545
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Pietrangelo A, 2005, SEMIN LIVER DIS, V25, P450, DOI 10.1055/s-2005-923316
   Pokharel S, 2009, J NEPAL MED ASSOC, V48, P217
   Qin S, 2007, DRUG DEVELOP RES, V68, P213, DOI 10.1002/ddr.20185
   Qu M, 2008, J PSYCHIATR RES, V42, P877, DOI 10.1016/j.jpsychires.2007.10.005
   Sanfilippo PG, 2010, SURV OPHTHALMOL, V55, P561, DOI 10.1016/j.survophthal.2010.07.003
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Shastry BS, 2009, METHODS MOL BIOL, V578, P3, DOI 10.1007/978-1-60327-411-1_1
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Wood RJ, 2004, AGEING RES REV, V3, P355, DOI 10.1016/j.arr.2004.04.002
   Zecca L, 2004, NAT REV NEUROSCI, V5, P863, DOI 10.1038/nrn1537
NR 48
TC 10
Z9 10
U1 0
U2 4
PU TOHOKU UNIV MEDICAL PRESS
PI SENDAI
PA 2-1, SEIRYO-MACHI, AOBA-KU, SENDAI, MIYAGI 980-8575, JAPAN
SN 0040-8727
EI 1349-3329
J9 TOHOKU J EXP MED
JI Tohoku J. Exp. Med.
PD APR
PY 2011
VL 223
IS 4
BP 253
EP 261
DI 10.1620/tjem.223.253
PG 9
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA 757ZV
UT WOS:000290129500003
PM 21422745
OA Bronze
DA 2022-11-30
ER

PT J
AU Grierson, R
   Meyer-Rusenberg, B
   Kunst, F
   Berna, MJ
   Richard, G
   Thill, M
AF Grierson, Rebecca
   Meyer-Ruesenberg, Birthe
   Kunst, Frank
   Berna, Marc J.
   Richard, Gisbert
   Thill, Michelle
TI Endothelial Progenitor Cells and Plasma Vascular Endothelial Growth
   Factor and Stromal Cell-Derived Factor-1 During Ranibizumab Treatment
   for Neovascular Age-Related Macular Degeneration
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID RETINAL VEIN OCCLUSION; CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL
   BEVACIZUMAB; HEMATOPOIETIC STEM; VEGF; PHARMACOKINETICS; MOBILIZATION;
   CYTOKINES; RECRUITMENT; RETINOPATHY
AB Purpose: To evaluate endothelial progenitor cell [late outgrowth endothelial progenitor cells (OECs)], vascular endothelial growth factor (VEGF), and stromal cell-derived factor 1 alpha (SDF-1 alpha) plasma levels as potential biomarkers before and during ranibizumab (Lucentis (R)) treatment for neovascular age-related macular degeneration (nvAMD). Methods: Thirty-one patients with untreated nvAMD presenting for 3 consecutive intravitreal ranibizumab injections and a follow-up visit at 4 weeks intervals were enrolled. Peripheral blood was collected before each injection and at the follow-up visit and OEC clusters were cultured and evaluated according to previously published protocols. VEGF and SDF-1 alpha plasma levels were measured by enzyme-linked immunosorbent assay and compared to values from healthy young and old control. Results: Patients with a high OEC count before treatment presented significantly more often with a short symptom duration and a smaller choroidal neovascularization size. VEGF plasma levels were significantly higher in nvAMD (282.4 +/- 195.2 pg/mL) compared to young (45.5 +/- 6.8 pg/mL) and old control (46.1 +/- 8.5 pg/mL). OEC levels decreased nonsignificantly during ranibizumab treatment, returning to baseline levels after the third injection. VEGF and SDF-1 alpha plasma levels decreased significantly during treatment toward control values. Patients needing retreatment after 3 ranibizumab injections had significantly higher VEGF plasma levels at pretreatment compared to patients not needing further treatment. Conclusions: The results presented here suggest that VEGF plasma levels may warrant further evaluation regarding biological, therapeutical, and predictive implications in nvAMD.
C1 [Grierson, Rebecca; Meyer-Ruesenberg, Birthe; Kunst, Frank; Richard, Gisbert; Thill, Michelle] Univ Med Ctr Hamburg Eppendorf, Dept Ophthalmol, D-20246 Hamburg, Germany.
   [Berna, Marc J.] Univ Med Ctr Hamburg Eppendorf, Dept Internal Med, D-20246 Hamburg, Germany.
C3 University of Hamburg; University Medical Center Hamburg-Eppendorf;
   University of Hamburg; University Medical Center Hamburg-Eppendorf
RP Thill, M (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Dept Ophthalmol, Martinistr 52, D-20246 Hamburg, Germany.
EM michelle.berna@pt.lu
FU Faculty of Medicine of the University Hamburg (Forschungsforderungsfonds
   Medizin, Nachwuchsforderung)
FX This work was supported by a research grant from the Faculty of Medicine
   of the University Hamburg (Forschungsforderungsfonds Medizin,
   Nachwuchsforderung).
CR ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   Ahn JK, 2009, AM J OPHTHALMOL, V148, P718, DOI 10.1016/j.ajo.2009.06.012
   AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Arimura N, 2009, OPHTHALMOLOGY, V116, P921, DOI 10.1016/j.ophtha.2008.12.024
   Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2009, OPHTHALMOLOGY, V116, P2158, DOI 10.1016/j.ophtha.2009.04.038
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Chan WM, 2008, RETINA-J RET VIT DIS, V28, P1308, DOI 10.1097/IAE.0b013e31818358b2
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   De Falco E, 2004, BLOOD, V104, P3472, DOI 10.1182/blood-2003-12-4423
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P369, DOI 10.1016/j.exer.2004.10.005
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371
   Fischer C, 2007, CELL, V131, P463, DOI 10.1016/j.cell.2007.08.038
   Funatsu H, 2002, AM J OPHTHALMOL, V133, P537, DOI 10.1016/S0002-9394(02)01323-5
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Funk M, 2009, INVEST OPHTH VIS SCI, V50, P1025, DOI 10.1167/iovs.08-2510
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Gehling UM, 2000, BLOOD, V95, P3106
   Guerin E, 2008, MICROVASC RES, V75, P302, DOI 10.1016/j.mvr.2007.12.001
   Hattori K, 2001, BLOOD, V97, P3354, DOI 10.1182/blood.V97.11.3354
   Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005
   Hou HY, 2006, CURR EYE RES, V31, P1051, DOI 10.1080/02713680601100459
   Jain RK, 2009, NAT REV CLIN ONCOL, V6, P327, DOI 10.1038/nrclinonc.2009.63
   Lai TYY, 2009, RETINA-J RET VIT DIS, V29, P1218, DOI 10.1097/IAE.0b013e3181b32c45
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Li Y, 2006, INVEST OPHTH VIS SCI, V47, P1646, DOI 10.1167/iovs.05-1092
   Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071
   Lip PL, 2000, INVEST OPHTH VIS SCI, V41, P2115
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Machalinska A, 2011, J OCUL PHARMACOL TH, V27, P471, DOI 10.1089/jop.2011.0091
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Moore MAS, 2001, ANN NY ACAD SCI, V938, P36
   Murayama T, 2002, EXP HEMATOL, V30, P967, DOI 10.1016/S0301-472X(02)00867-6
   Murukesh N, 2010, BRIT J CANCER, V102, P8, DOI 10.1038/sj.bjc.6605483
   Noma H, 2005, AM J OPHTHALMOL, V140, P256, DOI 10.1016/j.ajo.2005.03.003
   Petit I, 2007, TRENDS IMMUNOL, V28, P299, DOI 10.1016/j.it.2007.05.007
   Roh MI, 2010, GRAEF ARCH CLIN EXP, V248, P635, DOI 10.1007/s00417-009-1254-8
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Roodhart JM, 2008, CURR CLIN PHARMACOL, V3, P132, DOI 10.2174/157488408784293705
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2010, EXPERT OPIN DRUG SAF, V9, P149, DOI 10.1517/14740330903418422
   Sengupta N, 2003, INVEST OPHTH VIS SCI, V44, P4908, DOI 10.1167/iovs.03-0342
   Siegel AB, 2008, J CLIN ONCOL, V26, P2992, DOI 10.1200/JCO.2007.15.9947
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Thill M, 2008, INVEST OPHTH VIS SCI, V49, P2696, DOI 10.1167/iovs.07-0955
   Tomita M, 2004, STEM CELLS, V22, P21, DOI 10.1634/stemcells.22-1-21
   Tsai DC, 2006, OPHTHALMOLOGICA, V220, P246, DOI 10.1159/000093079
   Yoder MC, 2009, BBA-REV CANCER, V1796, P50, DOI 10.1016/j.bbcan.2009.04.002
   Yodoi Y, 2007, INVEST OPHTH VIS SCI, V48, P5464, DOI 10.1167/iovs.07-0093
   Zagzag D, 2008, AM J PATHOL, V173, P545, DOI 10.2353/ajpath.2008.071197
NR 54
TC 8
Z9 11
U1 0
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD JUL-AUG
PY 2013
VL 29
IS 6
BP 530
EP 538
DI 10.1089/jop.2012.0013
PG 9
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 180SJ
UT WOS:000321616400005
PM 23573802
DA 2022-11-30
ER

PT J
AU Hatz, K
   Prunte, C
AF Hatz, Katja
   Pruente, Christian
TI Changing from a pro re nata treatment regimen to a treat and extend
   regimen with ranibizumab in neovascular age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Macula; Degeneration
ID GROWTH-FACTOR THERAPY; 2.0 MG RANIBIZUMAB; RETINA SPECIALISTS; DOSING
   REGIMEN; EFFICACY; SAFETY; PROTOCOL
AB Background Treat and extend (TE) treatment regimens have the potential to reduce the treatment burden placed upon patients receiving ranibizumab for neovascular age-related macular degeneration (nAMD). This study aimed to analyse changes in best corrected visual acuity (BCVA) and anatomical parameters in patients switching from a pro re nata (PRN) to a TE regimen during routine clinical practice.
   Methods Retrospective, consecutive, comparative case series of treatment-naive patients who were initially treated with 0.5mg ranibizumab according to a PRN schedule, and subsequently switched to a TE schedule (12-month follow-up).
   Results 146 eyes from 134 consecutive treatment-naive patients were included. Mean BCVA (decimalSD) increased from 0.39 +/- 0.23 to 0.55 +/- 0.22 (p<0.001) during the PRN loading regimen, declining to 0.49 +/- 0.22 (p<0.001) during the PRN maintenance phase (mean duration 17months; range 3-55). Following the switch to TE, BCVA improved to 0.55 +/- 0.23 and 0.56 +/- 0.24 by 6 and 12months, respectively (p<0.001). Mean intraindividual variance in BCVA was higher during the PRN phase than at 12months for TE (0.30 +/- 0.18 vs 0.09 +/- 0.08, respectively; p<0.001). After switching to TE, mean central retinal thickness decreased from 355 +/- 112 mu m to 330 +/- 105 and 320 +/- 103 mu m at 6 and 12months, respectively (p<0.001). Mean number of visits per month was higher during PRN than TE periods (1.05 +/- 0.13 vs 0.73 +/- 0.18; respectively; p<0.001).
   Conclusions A TE regimen can improve and stabilise patient outcomes in nAMD compared with PRN, with the potential to reduce the healthcare resource burden incurred from fixed monitoring requirements.
C1 [Hatz, Katja; Pruente, Christian] Vista Klin, Hauptstasse 55, CH-4102 Binningen, Switzerland.
   [Hatz, Katja; Pruente, Christian] Kantonsspital Liestal, Dept Ophthalmol, Liestal, Switzerland.
   [Hatz, Katja; Pruente, Christian] Univ Basel, Basel, Switzerland.
C3 Kantonsspital Baselland; University of Basel
RP Prunte, C (通讯作者)，Vista Klin, Hauptstasse 55, CH-4102 Binningen, Switzerland.
EM christian@pruente.ch
FU Novartis Pharma AG, Basel, Switzerland
FX Editorial assistance in the development of this manuscript was provided
   by Fishawack Communications Ltd, Knutsford, UK; this service was funded
   by Novartis Pharma AG, Basel, Switzerland.
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   [Anonymous], 2014, LUC SUMM PROD CHAR
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Jeng KW, 2014, RETINA-J RET VIT DIS, V34, P1796, DOI 10.1097/IAE.0000000000000182
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Rayess N, 2015, AM J OPHTHALMOL, V159, P85, DOI 10.1016/j.ajo.2014.09.033
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Xing L, 2014, CAN J OPHTHALMOL, V49, P261, DOI 10.1016/j.jcjo.2014.03.009
NR 25
TC 35
Z9 37
U1 1
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2016
VL 100
IS 10
BP 1341
EP 1345
DI 10.1136/bjophthalmol-2015-307299
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DX8YW
UT WOS:000384679400007
PM 26755642
DA 2022-11-30
ER

PT J
AU De Almeida, INF
   De Almeida, LNF
   Sobrinho, EFD
   Gomes, BD
   Souza, GD
   Rosa, AAM
   Silveira, LCL
AF Frota De Almeida, Izabela Negrao
   Frota De Almeida, Luciana Negrao
   De Almeida Sobrinho, Edmundo Frota
   Gomes, Bruno Duarte
   Souza, Givago Da Silva
   Marques Rosa, Alexandre Antonio
   Silveira, Luiz Carlos L.
TI Optical coherence tomography and multifocal electroretinography of
   patients with advanced neovascular age-related macular degeneration
   before, during, and after treatment with ranibizumab
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Macular degeneration/drug therapy; Antibodies; monoclonal,
   humanized/therapeutic use; Tomography; optical coherence;
   Electroretinography; Intravitreal injections
ID RETINAL FUNCTION; INTRAVITREAL BEVACIZUMAB; QUANTITATIVE SUBANALYSIS;
   VEGF; DRUSEN
AB Purpose: To evaluate retinal morphology and function of patients with advanced neovascular age-related macular degeneration (AMD) before, during, and after treatment with ranibizumab.
   Methods: Twenty-one eyes diagnosed with advanced AMD were studied with optical coherence tomography (OCT) and multifocal electroretinography (mfERG). Three intravitreal injections of ranibizumab were administered at 1-month intervals. Evaluations were performed before the first injection (D0) and at 30 (D30), 60 (D60), and 90 days (D90) after the first injection and compared to an age-matched control group (n=21 eyes).
   Results: The thickness of macular retinal layers increased before treatment due to the presence of intraretinal fluid. A thick retinal pigment epithelium-choriocapillaris complex (RPE-CC) suggested the presence of choroidal neovascular membrane. Intraretinal edema decreased after treatment (P<0.01), but persisting RPE-CC thickness resulted in a subretinal scar. Three different annular retinal areas were studied with mfERG (from center to periphery: rings R1, R2, and R3). The amplitude of the first negative component (N1) decreased in R1, R2, and R3 at D30, D60, and D90 when compared with that in controls (P<0.05); the N1 implicit time was delayed in R3 at D30 (P<0.05). The amplitude of the first positive component (P1) was reduced in R1 and R2 at D30, D60, and D90 when compared with that in controls (P<0.01); the P1 implicit time was delayed in R1 at D0 and D60 (P<0.05), in R2 at D0, D30, and D90 (P<0.01), and in R3 at D30 and D60 (P<0.05).
   Conclusion: Ranibizumab reduces intraretinal edema, even in advanced cases. Central macular activity appeared to increase after the initiation of treatment, improving over time.
C1 [Frota De Almeida, Izabela Negrao] Complexo Hosp Padre Bento Guarulhos, Sao Paulo, SP, Brazil.
   [Frota De Almeida, Luciana Negrao; Gomes, Bruno Duarte; Souza, Givago Da Silva; Silveira, Luiz Carlos L.] Fed Univ Para, Inst Ciencias Biol, BR-66059 Belem, PA, Brazil.
   [De Almeida Sobrinho, Edmundo Frota; Marques Rosa, Alexandre Antonio] Fed Univ Para, Inst Ciencias Saude, BR-66059 Belem, PA, Brazil.
   [De Almeida Sobrinho, Edmundo Frota; Marques Rosa, Alexandre Antonio] Fed Univ Para, Hosp Univ Bettina Ferro Souza, BR-66059 Belem, Para, Brazil.
   [Souza, Givago Da Silva; Silveira, Luiz Carlos L.] Fed Univ Para, Nucleo Med Trop, BR-66059 Belem, Para, Brazil.
   [Silveira, Luiz Carlos L.] Ceuma Univ, Sao Luis, MA, Brazil.
C3 Universidade Federal do Para; Universidade Federal do Para; Universidade
   Federal do Para; Universidade Federal do Para; Universidade Ceuma
RP De Almeida, INF (通讯作者)，Rua Dr Sergio Meira 230,94-2, BR-01153010 Sao Paulo, SP, Brazil.
EM almeidaizabela@gmail.com
RI Souza, Givago/W-6393-2019
OI Souza, Givago/0000-0002-4525-3971; Almeida, Izabela/0000-0001-7968-2427
FU FINEP IBN Net; CNPq-PRONEX/FAPESPA [2268, 316799/2009]; CNPq
   [620037/2008-3, 476744/2009-1, 475860/2010-1]; CAPES-PROCAD [182/2007]
FX This study was supported by FINEP IBN Net; CNPq-PRONEX/FAPESPA #2268 and
   #316799/2009; CNPq #620037/2008-3, #476744/2009-1, and #475860/2010-1;
   and CAPES-PROCAD #182/2007.
CR Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen CZ, 2004, DOC OPHTHALMOL, V109, P1
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Feigl B, 2007, CLIN OPHTHALMOL, V1, P167
   Fortune B, 2002, J OPT SOC AM A, V19, P173, DOI 10.1364/JOSAA.19.000173
   Frota de Almeida IN, 2011, INV OPHTHALMOL VIS S, V52
   Fujimoto JG., 2004, OPTICAL COHERENCE TO, V2nd
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Gerth C, 2009, DOC OPHTHALMOL, V118, P63, DOI 10.1007/s10633-008-9133-x
   Greenstein VC, 2000, INVEST OPHTH VIS SCI, V41, P3655
   Hood DC, 2012, DOC OPHTHALMOL, V124, P1, DOI 10.1007/s10633-011-9296-8
   Jurklies B, 2002, GRAEF ARCH CLIN EXP, V240, P244, DOI 10.1007/s00417-002-0439-1
   Karagiannis DA, 2009, CLIN INTERV AGING, V4, P457
   Kashani AH, 2009, INVEST OPHTH VIS SCI, V50, P3366, DOI 10.1167/iovs.08-2691
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Miguel NCO, 2012, INVEST OPHTH VIS SCI, V53, P7904, DOI 10.1167/iovs.12-10283
   Oguido APMT, 2008, ARQ BRAS OFTALMOL, V71, P375, DOI 10.1590/S0004-27492008000300013
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Myers AC, 2012, CURR EYE RES, V37, P399, DOI 10.3109/02713683.2011.611609
   Neveu MM, 2006, DOC OPHTHALMOL, V113, P71, DOI 10.1007/s10633-006-9016-y
   Robinson GS, 2001, FASEB J, V15, P1215, DOI 10.1096/fj.00-0598fje
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
NR 30
TC 1
Z9 2
U1 0
U2 4
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD MAR-APR
PY 2015
VL 78
IS 2
BP 105
EP 109
DI 10.5935/0004-2749.20150027
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CH5CB
UT WOS:000354050800010
PM 25945532
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU You, JY
   Chung, H
   Kim, HC
AF You, Ja Young
   Chung, Hyewon
   Kim, Hyung Chan
TI Evaluation of Changes in Choroidal Neovascularization Secondary to
   Age-related Macular Degeneration after Anti-VEGF Therapy Using Spectral
   Domain Optical Coherence Tomography
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Bevacizumab; Choroidal
   neovascularization; Ranibizumab; Spectral domain optical coherence
   tomography
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL BEVACIZUMAB; RANIBIZUMAB;
   MEMBRANES; VERTEPORFIN; PREVALENCE; EFFICACY; EYE; OCT
AB Purpose: To evaluate the changes in choroidal neovascularization (CNV) after anti-VEGF therapy for treatment of age-related macular degeneration (AMD) using spectral domain optical coherence tomography (SD OCT).
   Materials and Methods: This retrospective study included 65 eyes of 65 patients with CNV secondary to AMD. All patients underwent SD OCT before and 4 weeks after three intravitreal injections of bevacizumab (bevacizumab group) or ranibizumab (ranibizumab group). The diameter and thickness of CNV were measured from SD OCT images.
   Results: Retinal edema was completely resolved in 57%, partially resolved in 28% and unchanged in 15% of all post-injection SD OCTs. The resolution rate of retinal edema was not significantly different between the bevacizumab and ranibizumab group (p = 0.960). In all CNV types, the diameter of CNV did not show significant change after treatment; the average diameter changed from 2923 to 2888 mu m in classic CNV and from 2378 to 2338 mu m in occult CNV in bevacizumab group; from 2691 to 2580 mu m in classic CNV and from 2731 to 2337 mu m in occult CNV in ranibizumab group. However, the thickness of CNV showed a significant reduction in classic CNV of both the bevacizumab group (from 301 to 233 mu m, p = 0.012, reduction rate 22%) and the ranibizumab group (from 258 to 213 mu m, p = 0.025, reduction rate 17%). In occult CNV, the thickness of CNV showed a significant reduction only in the ranibizumab group (from 163 to 146 mu m, p = 0.033, reduction rate 10%).
   Conclusions: Anti-VEGF therapy for the treatment of AMD may reduce the thickness of CNV and thus result in morphologic stability of CNV. Although morphologic regression of CNV is not achieved, further CNV growth could be arrested with anti-VEGF therapy.
C1 [You, Ja Young; Chung, Hyewon; Kim, Hyung Chan] Konkuk Univ, Sch Med, Dept Ophthalmol, Med Ctr, Seoul 143729, South Korea.
C3 Konkuk University; Konkuk University Medical Center
RP Kim, HC (通讯作者)，Konkuk Univ, Sch Med, Dept Ophthalmol, Med Ctr, 4-12 Hwayang Dong, Seoul 143729, South Korea.
EM eyekim@kuh.ac.kr
FU Konkuk University Medical Center
FX This work was supported by the Konkuk University Medical Center Research
   Grant 2011.
CR Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bolz M, 2008, OPHTHALMOLOGE, V105, P650, DOI 10.1007/s00347-007-1639-1
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P1671, DOI 10.1167/iovs.09-4496
   Framme C, 2009, CURR EYE RES, V34, P568, DOI 10.1080/02713680902964892
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Golbaz I, 2009, OPHTHALMOLOGE, V106, P1103, DOI 10.1007/s00347-008-1880-2
   Jackson TL, 2003, INVEST OPHTH VIS SCI, V44, P2141, DOI 10.1167/iovs.02-1027
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Keane PA, 2009, AM J OPHTHALMOL, V148, P242, DOI 10.1016/j.ajo.2009.03.004
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Ueno Chikako, 2010, Nippon Ganka Gakkai Zasshi, V114, P983
   Wachtlin J, 2005, GRAEF ARCH CLIN EXP, V243, P438, DOI 10.1007/s00417-004-1071-z
NR 25
TC 17
Z9 17
U1 0
U2 1
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0271-3683
J9 CURR EYE RES
JI Curr. Eye Res.
PD MAY
PY 2012
VL 37
IS 5
BP 438
EP 445
DI 10.3109/02713683.2011.647227
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 927NP
UT WOS:000302914900013
PM 22510011
DA 2022-11-30
ER

PT J
AU Rim, TH
   Lee, AY
   Ting, DS
   Teo, K
   Betzler, BK
   Teo, ZL
   Yoo, TK
   Lee, G
   Kim, Y
   Lin, AC
   Kim, SE
   Tham, YC
   Kim, SS
   Cheng, CY
   Wong, TY
   Cheung, CMG
AF Rim, Tyler Hyungtaek
   Lee, Aaron Y.
   Ting, Daniel S.
   Teo, Kelvin
   Betzler, Bjorn Kaijun
   Teo, Zhen Ling
   Yoo, Tea Keun
   Lee, Geunyoung
   Kim, Youngnam
   Lin, Andrew C.
   Kim, Seong Eun
   Tham, Yih Chung
   Kim, Sung Soo
   Cheng, Ching-Yu
   Wong, Tien Yin
   Cheung, Chui Ming Gemmy
TI Detection of features associated with neovascular age-related macular
   degeneration in ethnically distinct data sets by an optical coherence
   tomography: trained deep learning algorithm
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Degeneration; Epidemiology; Neovascularisation; Retina
ID AUTOMATED DETECTION
AB Background The ability of deep learning (DL) algorithms to identify eyes with neovascular age-related macular degeneration (nAMD) from optical coherence tomography (OCT) scans has been previously established. We herewith evaluate the ability of a DL model, showing excellent performance on a Korean data set, to generalse onto an American data set despite ethnic differences. In addition, expert graders were surveyed to verify if the DL model was appropriately identifying lesions indicative of nAMD on the OCT scans. Methods Model development data set-12 247 OCT scans from South Korea; external validation data set-91 509 OCT scans from Washington, USA. In both data sets, normal eyes or eyes with nAMD were included. After internal testing, the algorithm was sent to the University of Washington, USA, for external validation. Area under the receiver operating characteristic curve (AUC) and precision-recall curve (AUPRC) were calculated. For model explanation, saliency maps were generated using Guided GradCAM. Results On external validation, AUC and AUPRC remained high at 0.952 (95% CI 0.942 to 0.962) and 0.891 (95% CI 0.875 to 0.908) at the individual level. Saliency maps showed that in normal OCT scans, the fovea was the main area of interest; in nAMD OCT scans, the appropriate pathological features were areas of model interest. Survey of 10 retina specialists confirmed this. Conclusion Our DL algorithm exhibited high performance for nAMD identification in a Korean population, and generalised well to an ethnically distinct, American population. The model correctly focused on the differences within the macular area to extract features associated with nAMD.
C1 [Rim, Tyler Hyungtaek; Ting, Daniel S.; Teo, Kelvin; Teo, Zhen Ling; Tham, Yih Chung; Cheng, Ching-Yu; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore 168751, Singapore.
   [Rim, Tyler Hyungtaek; Ting, Daniel S.; Teo, Kelvin; Tham, Yih Chung; Cheng, Ching-Yu; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program Eye ACP, Singapore, Singapore.
   [Lee, Aaron Y.] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA.
   [Betzler, Bjorn Kaijun] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore.
   [Yoo, Tea Keun] Aerosp Med Ctr, Dept Ophthalmol, Republ Korea Air Force, Cheongju, South Korea.
   [Lee, Geunyoung; Kim, Youngnam] Medi Whale Inc, Seoul, South Korea.
   [Lin, Andrew C.] NYU, Dept Ophthalmol, NYU Langone Hlth, Sch Med, 550 1St Ave, New York, NY 10016 USA.
   [Kim, Seong Eun] CHA Univ, Dept Opthalmol, CHA Bundang Med Ctr, Seongnam, South Korea.
   [Kim, Sung Soo] Yonsei Univ, Severance Hosp, Inst Vis Res, Dept Opthalmol,Coll Med, Seoul, South Korea.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; University of Washington; University
   of Washington Seattle; National University of Singapore; New York
   University; NYU Langone Medical Center; Pochon Cha University; Yonsei
   University; Yonsei University Health System
RP Kim, SS (通讯作者)，Yonsei Univ, Dept Ophthalmol, Coll Med, Severance Hosp, Seoul 169856, South Korea.; Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore 168751, Singapore.
EM semekim@yuhs.ac; cheung.c.m@snec.com.sg
RI Cheng, Ching-Yu/Y-2229-2019; Yoo, Tae Keun/Q-3620-2019; Chung,
   Yih/AIF-2414-2022; Wong, Tien Yin/AAC-9724-2020
OI Cheng, Ching-Yu/0000-0003-0655-885X; Yoo, Tae Keun/0000-0003-0890-8614;
   Chung, Yih/0000-0002-6752-797X; Wong, Tien Yin/0000-0002-8448-1264; Kim,
   Sung Soo/0000-0002-0574-7993; Ting, Daniel Shu Wei/0000-0003-2264-7174;
   Betzler, Bjorn/0000-0002-4843-7514; Lee, Aaron/0000-0002-7452-1648; Rim,
   Tyler Hyungtaek/0000-0001-6465-2620; Teo, Kelvin/0000-0002-7458-7081;
   Bidwai, Pooja Vishal/0000-0002-3077-4395
FU Agency for Science, Technology and Research of Singapore [A19D1b0095];
   National Medical Research Council of Singapore [NMRC/OFLCG/004a/2018,
   NMRC/CIRG/1488/2018]; National Institutes of Health Grants NIH/NEI
   [K23EY029246]; Research to Prevent Blindness
FX This work was supported by the Agency for Science, Technology and
   Research of Singapore (A19D1b0095), the National Medical Research
   Council of Singapore (NMRC/OFLCG/004a/2018; NMRC/CIRG/1488/2018), the
   National Institutes of Health Grants NIH/NEI K23EY029246, and by an
   unrestricted grant from Research to Prevent Blindness. The sponsors or
   funding organisations had no role in the design or conduct of this
   research.
CR Bhatia KK, 2020, RETINA-J RET VIT DIS, V40, P1549, DOI 10.1097/IAE.0000000000002640
   Brown JM, 2018, JAMA OPHTHALMOL, V136, P803, DOI 10.1001/jamaophthalmol.2018.1934
   Burlina PM, 2018, JAMA OPHTHALMOL, V136, P1359, DOI 10.1001/jamaophthalmol.2018.4118
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Chang BC, 2010, HEALTHC INFORM RES, V16, P60, DOI 10.4258/hir.2010.16.1.60
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Hood DC, 2018, OPHTHALMOLOGY, V125, P1207, DOI 10.1016/j.ophtha.2018.04.020
   Kashani AH, 2010, AM J OPHTHALMOL, V149, P496, DOI 10.1016/j.ajo.2009.09.025
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Klikauer T, 2016, TRIPLEC-COMMUN CAPIT, V14, P260
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Poplin R, 2018, NAT BIOMED ENG, V2, P158, DOI 10.1038/s41551-018-0195-0
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Selvaraju RR, 2020, INT J COMPUT VISION, V128, P336, DOI 10.1007/s11263-019-01228-7
   Simonyan K., 2015, ARXIV
   Ting DSW, 2019, PROG RETIN EYE RES, V72, DOI 10.1016/j.preteyeres.2019.04.003
   Ting DSW, 2019, BRIT J OPHTHALMOL, V103, P577, DOI 10.1136/bjophthalmol-2018-313290
   Ting DSW, 2019, BRIT J OPHTHALMOL, V103, P167, DOI 10.1136/bjophthalmol-2018-313173
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Xu K, 2015, PR MACH LEARN RES, V37, P2048
   Yoo TK, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0135-8
   Zhou B, 2016, PROC CVPR IEEE, P2921, DOI 10.1109/CVPR.2016.319
NR 27
TC 10
Z9 10
U1 1
U2 8
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2021
VL 105
IS 8
BP 1133
EP 1139
DI 10.1136/bjophthalmol-2020-316984
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TQ6SQ
UT WOS:000678409900018
PM 32907811
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Mantel, I
   Zola, M
   De Massougnes, S
   Dirani, A
   Bergin, C
AF Mantel, Irmela
   Zola, Marta
   De Massougnes, Sophie
   Dirani, Ali
   Bergin, Ciara
TI Factors influencing macular atrophy growth rates in neovascular
   age-related macular degeneration treated with ranibizumab or aflibercept
   according to an observe-and-plan regimen
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE macula; degeneration; neovascularisation; imaging; retina
ID PIGMENT EPITHELIAL ATROPHY; GEOGRAPHIC ATROPHY; PROGRESSION; OUTCOMES;
   RISK
AB Background/aims To investigate the factors associated with macular atrophy (MA) growth rates in neovascular age-related macular degeneration treated with either ranibizumab or aflibercept. Methods We obtained data from two identical prospective studies using ranibizumab or aflibercept under observe-and-plan variable dosing regimens. We analysed eyes that presented MA within 2 years. After applying square root transformations to MA sizes, we calculated MA growth rate from baseline to the year 2 endpoint and used univariate and multivariate analyses to detect ocular and treatment factors associated with the MA growth rate. Results Included were 109 eyes from 101 patients (mean age 80.6 years). The mean square-root-transformed MA growth rate was 0.54 +/- 0.34 mm/year. The univariate analyses revealed that MA growth rates were significantly associated with lower baseline visual acuities (p=0.001) and thicker subretinal tissue complexes (p=0.006) and near-significantly associated with the presence of pigment epithelium detachment (p=0.057) and choroidal neovascularisation subtypes (p=0.069). Our multivariate analysis confirmed the significance of lower baseline visual acuities (p=0.008) and pigment epithelium detachments higher than 200 mu m (p=0.035). Furthermore, MA growth rates in neovascular eyes significantly correlated with MA growth rates in non-neovascular fellow eyes (n=61; p=0.003). Conclusion MA growth rates were associated with ocular factors in the study eyes and the fellow eyes but not with the drug or the number of injections within this variable dosing regimen.
C1 [Mantel, Irmela; Zola, Marta; De Massougnes, Sophie; Dirani, Ali; Bergin, Ciara] Univ Lausanne, Jules Gonin Eye Hosp, Fdn Asile Aveugles, Dept Ophthalmol, Lausanne, Switzerland.
C3 University of Lausanne
RP Mantel, I (通讯作者)，Jules Gonin Eye Hosp, CH-1004 Lausanne, Switzerland.
EM irmela.mantel@fa2.ch
CR Abdelfattah NS, 2017, OPHTHALMOLOGY, V124, P215, DOI 10.1016/j.ophtha.2016.10.002
   Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Caire J, 2014, JAMA OPHTHALMOL, V132, P528, DOI 10.1001/jamaophthalmol.2013.8175
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Gianniou C, 2015, EYE, V29, P450, DOI 10.1038/eye.2014.321
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Parvin P, 2017, GRAEF ARCH CLIN EXP, V255, P2127, DOI 10.1007/s00417-017-3762-2
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
NR 24
TC 8
Z9 8
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2019
VL 103
IS 7
BP 900
EP 905
DI 10.1136/bjophthalmol-2018-312430
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IF4HJ
UT WOS:000473042100006
PM 30166328
DA 2022-11-30
ER

PT J
AU Maggio, E
   Deiro, AP
   Mete, M
   Sartore, M
   Polito, A
   Prigione, G
   Guerriero, M
   Pertile, G
AF Maggio, Emilia
   Peroglio Deiro, Antonio
   Mete, Maurizio
   Sartore, Mauro
   Polito, Antonio
   Prigione, Guido
   Guerriero, Massimo
   Pertile, Grazia
TI Intravitreal Recombinant Tissue Plasminogen Activator and Sulphur
   Hexafluoride Gas for Submacular Haemorrhage Displacement in Age-Related
   Macular Degeneration: Looking behind the Blood
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Gas displacement; Recombinant tissue
   plasminogen activator; Submacular haemorrhage; Sulphur hexafluoride
ID CHOROIDAL NEOVASCULAR LESIONS; ENDOTHELIAL GROWTH-FACTOR; PNEUMATIC
   DISPLACEMENT; SUBRETINAL HEMORRHAGE; MANAGEMENT; INJECTION; RANIBIZUMAB;
   TRANSLOCATION; BEVACIZUMAB; SAFETY
AB Purpose: To evaluate the effectiveness of recombinant tissue plasminogen activator (rtPA) and sulphur hexafluoride gas (SF6) intravitreal injection for the displacement of large submacular haemorrhages (SMH) secondary to neovascular age-related macular degeneration and for guiding the selection of additional treatments or observations for choroidal neovascularization (CNV). Methods: The medical records of consecutive patients with recent-onset, large SMH, treated at Sacro Cuore Hospital from January 2004 to May 2016, were retrospectively analysed. All eyes underwent a 0.05-mL intravitreal injection of 50 mu g rtPA, 0.3 mL of 100% SF6, and then face-down positioning. Afterwards, the eyes received additional treatments for CNV or observation, based on the severity and extent of the underlying pathology. The multimodal imaging features revealed after blood displacement were analysed and then correlated to the treatment selected as a second therapeutic option. Results: A total of 96 eyes met the inclusion criteria and was evaluated in this study. SMH was displaced from the fovea in the majority of the eyes (76%), allowing several diagnostic tools to evaluate the underlying macular features. In 19 cases (19.8%) exhibiting severe macular damage, no additional treatment was applied. In the remaining eyes, subsequent treatments included anti-vascular endothelial growth factor injections (44.8%), photodynamic therapy (n = 2), and submacular surgery (35.4%). Statistically significant correlations were found between the macular findings revealed after blood displacement and the additional treatments or observations selected for the underlying disease. The mean follow-up was 35 months. Improvements in visual acuity were statistically significant up to 3 years. Conclusion: Intravitreal rtPA and gas injection was found to be effective for the displacement of large SMH, allowing postoperative diagnostic testing, and thus guiding the opportunity to apply further treatments. The addition of subsequent individualized treatments may allow long-term visual gain in selected cases.
C1 [Maggio, Emilia; Peroglio Deiro, Antonio; Mete, Maurizio; Sartore, Mauro; Polito, Antonio; Prigione, Guido; Pertile, Grazia] IRCCS Sacro Cuore Don Calabria Hosp, Dept Ophthalmol, Negrar, Italy.
   [Guerriero, Massimo] Univ Verona, Dept Comp Sci, Verona, Italy.
C3 IRCCS Sacro Cuore Don Calabria; University of Verona
RP Maggio, E (通讯作者)，IRCCS Sacro Cuore Don Calabria Hosp, Dept Ophthalmol, Via Don Sempreboni 5, IT-37024 Verona, Italy.
EM emi_maggio@yahoo.it
RI Mete, Maurizio/C-2149-2018; Pertile, Grazia/AAC-4956-2022
OI Maggio, Emilia/0000-0001-5656-820X
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNER JD, 1994, OPHTHALMOLOGY, V101, P672
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cakir M, 2010, EUR J OPHTHALMOL, V20, P565, DOI 10.1177/112067211002000305
   Cereda MG, 2010, GRAEF ARCH CLIN EXP, V248, P37, DOI 10.1007/s00417-009-1201-8
   Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   Chang W, 2014, AM J OPHTHALMOL, V157, P1250, DOI 10.1016/j.ajo.2014.02.007
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Daruich A, 2016, MOL VIS, V22, P1332
   Fujikawa M, 2013, RETINA-J RET VIT DIS, V33, P1908, DOI 10.1097/IAE.0b013e318287d99d
   GILLIES A, 1983, ANN OPHTHALMOL, V15, P1068
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Gopalakrishan M, 2007, RETINA-J RET VIT DIS, V27, P329, DOI 10.1097/01.iae.0000231544.43093.40
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   JOHNSON MW, 1990, ARCH OPHTHALMOL-CHIC, V108, P259, DOI 10.1001/archopht.1990.01070040111042
   Kamei M, 1999, AM J OPHTHALMOL, V128, P739, DOI 10.1016/S0002-9394(99)00239-1
   Kamei M, 2000, Semin Ophthalmol, V15, P44
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Luke M, 2007, BRIT J OPHTHALMOL, V91, P1077, DOI 10.1136/bjo.2006.111260
   Mizutani T, 2011, GRAEF ARCH CLIN EXP, V249, P1153, DOI 10.1007/s00417-011-1649-1
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Polito A, 2011, BRIT J OPHTHALMOL, V95, P74, DOI 10.1136/bjo.2009.170381
   Ron Y, 2007, OPHTHALMOLOGICA, V221, P57, DOI 10.1159/000096524
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Skaf AR, 2011, SEMIN OPHTHALMOL, V26, P181, DOI 10.3109/08820538.2011.577133
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Tal K, 2018, OPHTHALMIC RES, V59, P235, DOI 10.1159/000477621
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Tsymanava A, 2012, ACTA OPHTHALMOL, V90, P633, DOI 10.1111/j.1755-3768.2011.02115.x
   van Romunde SHM, 2015, OPHTHALMOLOGY, V122, P1366, DOI 10.1016/j.ophtha.2015.03.012
   van Romunde SH, 2017, RETINA, P0275
   van Zeeburg EJT, 2013, OPHTHALMOLOGICA, V229, P1, DOI 10.1159/000343066
   van Zeeburg EJT, 2012, AM J OPHTHALMOL, V153, P120, DOI 10.1016/j.ajo.2011.06.007
NR 39
TC 5
Z9 5
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD MAY
PY 2020
VL 243
IS 3
BP 224
EP 235
DI 10.1159/000505752
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LO2CU
UT WOS:000533434600008
PM 31905361
DA 2022-11-30
ER

PT J
AU Ashok, A
   Chaudhary, S
   Wise, AS
   Rana, NA
   McDonald, D
   Kritikos, AE
   Lindner, E
   Singh, N
AF Ashok, Ajay
   Chaudhary, Suman
   Wise, Aaron S.
   Rana, Neil A.
   McDonald, Dallas
   Kritikos, Alexander E.
   Lindner, Ewald
   Singh, Neena
TI Release of Iron-Loaded Ferritin in Sodium Iodate-Induced Model of Age
   Related Macular Degeneration: An In-Vitro and In-Vivo Study
SO ANTIOXIDANTS
LA English
DT Article
DE ferritin; exosomes; age-related macular degeneration; lysosomes; sodium
   iodate
ID RETINAL-PIGMENT EPITHELIUM; CATHEPSIN-D; MICE; ACCUMULATION;
   PHAGOCYTOSIS; DEGRADATION; FEATURES; PATHWAY; DAMAGE; CELLS
AB To evaluate the role of iron in sodium iodate (NaIO3)-induced model of age-related macular degeneration (AMD) in ARPE-19 cells in-vitro and in mouse models in-vivo. ARPE-19 cells, a human retinal pigment epithelial cell line, was exposed to 10 mM NaIO3 for 24 h, and the expression and localization of major iron modulating proteins was evaluated by Western blotting (WB) and immunostaining. Synthesis and maturation of cathepsin-D (cat-D), a lysosomal enzyme, was evaluated by quantitative reverse-transcriptase polymerase chain reaction (RT-qPCR) and WB, respectively. For in-vivo studies, C57BL/6 mice were injected with 40 mg/kg mouse body weight of NaIO3 intraperitoneally, and their retina was evaluated after 3 weeks as above. NaIO3 induced a 10-fold increase in ferritin in ARPE-19 cells, which co-localized with LC3II, an autophagosomal marker, and LAMP-1, a lysosomal marker. A similar increase in ferritin was noted in retinal lysates and retinal sections of NaIO3-injected mice by WB and immunostaining. Impaired synthesis and maturation of cat-D was also noted. Accumulated ferritin was loaded with iron, and released from retinal pigmented epithelial (RPE) cells in Perls' and LAMP-1 positive vesicles. NaIO3 impairs lysosomal degradation of ferritin by decreasing the transcription and maturation of cat-D in RPE cells. Iron-loaded ferritin accumulates in lysosomes and is released in lysosomal membrane-enclosed vesicles to the extracellular milieu. Accumulation of ferritin in RPE cells and fusion of ferritin-containing vesicles with adjacent photoreceptor cells is likely to create an iron overload, compromising their viability. Moreover, reduced activity of cat-D is likely to promote accumulation of other cellular debris in lysosomal vesicles, contributing to AMD-like pathology.
C1 [Ashok, Ajay; Chaudhary, Suman; Wise, Aaron S.; Rana, Neil A.; McDonald, Dallas; Kritikos, Alexander E.; Singh, Neena] Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44106 USA.
   [Lindner, Ewald] Med Univ Graz, Dept Ophthalmol, Auenbruggerpl 4, A-8036 Graz, Austria.
C3 Case Western Reserve University; Medical University of Graz
RP Singh, N (通讯作者)，Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44106 USA.
EM axa864@case.edu; sxc1351@case.edu; asw80@case.edu; nar66@case.edu;
   djm259@case.edu; aek103@case.edu; ewald.lindner@medunigraz.at;
   neena.singh@case.edu
RI Lindner, Ewald/AEM-1071-2022; Lindner, Ewald/CAG-1831-2022; ashok,
   ajay/AAN-3367-2020
OI Lindner, Ewald/0000-0001-9651-8573; ashok, ajay/0000-0003-4354-1467;
   Wise, Aaron/0000-0002-4035-2241; Singh, Neena/0000-0001-8369-7517;
   Chaudhary, Suman/0000-0003-2260-6444; Kritikos,
   Alex/0000-0002-5814-4141; Rana, Neil/0000-0003-0688-2932
FU National Institutes of Health [NS092145]; National Institutes of Health
   from NINDS [NS092145]
FX The authors would like to thank Ramkumar Srinivasagan, Tanu Parmar, and
   Vipul M. Parmar for their input and Sachin Pillai for assisting with
   experiments. The authors thank the Visual Sciences Research Center Core
   Facilities at CWRU (supported by the National Institutes of Health grant
   P30 EY11373). This work was supported by the National Institutes of
   Health grant number NS092145 from NINDS.
CR Ashok A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197290
   Ashok A, 2020, EXP EYE RES, V190, DOI 10.1016/j.exer.2019.107890
   Ashok A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49482-6
   Ashok A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24786-1
   Asthana A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08821-1
   Atienzar-Aroca S, 2018, J CELL MOL MED, V22, P5244, DOI 10.1111/jcmm.13730
   Baksi S., 2017, SCI REP-UK, V7, P1
   Balmer J, 2015, INT J MOL SCI, V16, P15086, DOI 10.3390/ijms160715086
   Bassal M, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10030696
   Bellelli R, 2016, CELL REP, V14, P411, DOI 10.1016/j.celrep.2015.12.065
   Biesemeier A, 2015, EXP EYE RES, V137, P39, DOI 10.1016/j.exer.2015.05.019
   Bird A, 2021, BRIT J OPHTHALMOL, V105, P1469, DOI 10.1136/bjophthalmol-2020-317447
   Chen H, 2009, INVEST OPHTH VIS SCI, V50, P1895, DOI 10.1167/iovs.08-2850
   Chiou B, 2018, PHARMACEUTICALS-BASE, V11, DOI 10.3390/ph11040124
   Chowers G, 2017, INVEST OPHTH VIS SCI, V58, P2239, DOI 10.1167/iovs.16-21255
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Fujimaki M, 2019, MOL CELL BIOL, V39, DOI 10.1128/MCB.00010-19
   Ganz T, 2013, PHYSIOL REV, V93, P1721, DOI 10.1152/physrev.00008.2013
   Gnana-Prakasam JP, 2008, BIOCHEM J, V411, P79, DOI 10.1042/BJ20071377
   Gnana-Prakasam JP, 2012, BIOCHEM J, V441, P599, DOI 10.1042/BJ20111148
   Hadziahmetovic M, 2008, INVEST OPHTH VIS SCI, V49, P2728, DOI 10.1167/iovs.07-1472
   Hadziahmetovic M, 2012, TRANSL VIS SCI TECHN, V1, DOI 10.1167/tvst.1.3.2
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2006, NEUROREPORT, V17, P1803, DOI 10.1097/WNR.0b013e3280107776
   Hanus J, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.54
   Hou XW, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.14.13
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Klingeborn M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05102-9
   Kwon W, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.604205
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin YC, 2018, J OCUL PHARMACOL TH, V34, P500, DOI 10.1089/jop.2017.0073
   Masaldan S, 2018, REDOX BIOL, V14, P100, DOI 10.1016/j.redox.2017.08.015
   Mendes-Jorge L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106974
   Moriguchi M, 2018, INVEST OPHTH VIS SCI, V59, P3476, DOI 10.1167/iovs.17-23532
   Nai A, 2021, HAEMATOLOGICA, V106, P795, DOI 10.3324/haematol.2019.241232
   REGAN CM, 1980, EXP EYE RES, V30, P183, DOI 10.1016/0014-4835(80)90112-8
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Runwal G, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46657-z
   Song DL, 2016, EXP EYE RES, V151, P122, DOI 10.1016/j.exer.2016.08.008
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tripathi AK, 2017, J ALZHEIMERS DIS, V58, P1109, DOI 10.3233/JAD-170097
   Truman-Rosentsvit M, 2018, BLOOD, V131, P342, DOI 10.1182/blood-2017-02-768580
   Wang JM, 2014, INVEST OPHTH VIS SCI, V55, P1941, DOI 10.1167/iovs.13-13075
   Yadati T, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071679
   Zaidi N, 2008, BIOCHEM BIOPH RES CO, V376, P5, DOI 10.1016/j.bbrc.2008.08.099
   Zhang XY, 2016, SCI REP-UK, V6, DOI 10.1038/srep37279
   Zhang YH, 2010, ANTIOXID REDOX SIGN, V13, P999, DOI 10.1089/ars.2010.3129
   Zhao J, 2017, INVEST OPHTH VIS SCI, V58, P2152, DOI 10.1167/iovs.17-21557
NR 49
TC 0
Z9 0
U1 5
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD AUG
PY 2021
VL 10
IS 8
AR 1253
DI 10.3390/antiox10081253
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA UF6HB
UT WOS:000688671700001
PM 34439501
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ying, GS
   Maguire, MG
AF Ying, Gui-shuang
   Maguire, Maureen G.
CA Complications Age-Related Macular
TI Development of a Risk Score for Geographic Atrophy in Complications of
   the Age-related Macular Degeneration Prevention Trial
SO OPHTHALMOLOGY
LA English
DT Article
ID OPERATING CHARACTERISTIC CURVE; LONG-TERM INCIDENCE; POOLED FINDINGS;
   PROGRESSION; SMOKING; MODEL; RANIBIZUMAB; ASSOCIATION; VALIDATION;
   DISEASE
AB Objective: To develop a risk score for developing geographic atrophy (GA) involving easily obtainable information among patients with bilateral large drusen.
   Design: Cohort study within a multicenter randomized clinical trial.
   Participants: We included 1052 participants with >= 10 large (>= 125 mu m) drusen and visual acuity >= 20/40 in each eye.
   Methods: In the Complications of Age-related Macular Degeneration (AMD) Prevention Trial (CAPT), 1 eye of each participant was randomly assigned to laser treatment and the contralateral eye was assigned to observation to evaluate whether laser treatment of drusen could prevent vision loss. Gradings by a reading center were used to identify: CAPT end point GA (total area of GA [>250 mu m] >1 disc area), GA (>175 mu m) involving the foveal center (CGA), and GA of any size and location (any GA). Established risk factors (age, smoking status, hypertension, Age-related Eye Disease Study simple severity scale score), both with and without a novel risk factor (night vision score), were used in assigning risk points. The risk scores were evaluated for the ability to discriminate and calibrate GA risk.
   Main Outcome Measures: Development of end point GA, CGA, and any GA.
   Results: Among 942 CAPT participants who completed 5 years of follow-up and did not have any GA at baseline, 6.8% participants developed CAPT end point GA, 9.6% developed CGA, and 34.4% developed any GA. The 5-year incidence of end point GA in 1 or both eyes of a participant increased with the 15-point GA risk score, from 0.6% for <7 points to 15% for >= 12 points. The 5-factor risk score predicted development of GA moderately well with the area under the receiver operating characteristic curve (AUC) 0.76 (95% confidence interval [CI], 0.71-0.81) for end point GA; 0.76 (95% CI, 0.71-0.80) for CGA, and 0.68 (95% CI, 0.65-0.72) for any GA. Prediction from the risk score without the night vision score had lower AUCs (range, 0.67-0.72).
   Conclusions: If validated in other patients, the GA risk score will be useful for identifying high-risk patients for clinical trials of prevention of GA and for clinical assessment of GA risk in early AMD patients.
C1 [Ying, Gui-shuang] Univ Penn, CAPT Coordinating Ctr, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania
RP Ying, GS (通讯作者)，Univ Penn, CAPT Coordinating Ctr, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA.
EM gsying@mail.med.upenn.edu
FU National Eye Institute, National Institutes of Health, Department of
   Health and Human Services [EY012211, EY012261, EY012279]; NATIONAL EYE
   INSTITUTE [U10EY012279] Funding Source: NIH RePORTER
FX Supported by grants EY012211, EY012261, and EY012279, from the National
   Eye Institute, National Institutes of Health, Department of Health and
   Human Services.
CR Altman DG, 2000, STAT MED, V19, P453, DOI 10.1002/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.3.CO;2-X
   [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   Brier G.W., 1950, MONTHLY WEATHER REVI, V78, P1, DOI DOI 10.1175/1520-0493(1950)078<0001:VOFEIT>2.0.CO;2
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Choi BCK, 1998, AM J EPIDEMIOL, V148, P1127
   Complications Age-Related Macular, 2008, OPHTHALMOLOGY, V115, P1474, DOI 10.1016/j.ophtha.2008.03.008
   Complications of Age-Related Macular Degeneration Prevention Trial Study Group, 2004, Clin Trials, V1, P91
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   D'Agostino RB, 2001, JAMA-J AM MED ASSOC, V286, P180, DOI 10.1001/jama.286.2.180
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   EFRON B, 1993, MONOGRAPHS STAT APPL, V57, P168
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gordon MO, 2007, OPHTHALMOLOGY, V114, P10, DOI 10.1016/j.ophtha.2006.08.031
   Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Margolis DJ, 2002, J CLIN EPIDEMIOL, V55, P518, DOI 10.1016/S0895-4356(01)00512-1
   Medeiros FA, 2005, ARCH OPHTHALMOL-CHIC, V123, P1351, DOI 10.1001/archopht.123.10.1351
   Medeiros FA, 2008, PROG BRAIN RES, V173, P15, DOI 10.1016/S0079-6123(08)01102-3
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sullivan LM, 2004, STAT MED, V23, P1631, DOI 10.1002/sim.1742
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Ying GS, 2008, OPHTHALMOLOGY, V115, P1876, DOI 10.1016/j.ophtha.2008.05.023
   Ying GS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1147, DOI 10.1001/archophthalmol.2009.189
NR 34
TC 23
Z9 23
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2011
VL 118
IS 2
BP 332
EP 338
DI 10.1016/j.ophtha.2010.06.030
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 715IJ
UT WOS:000286876500017
PM 20801521
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ferrante, N
   Ritrovato, D
   Bitonti, R
   Furneri, G
AF Ferrante, Nicola
   Ritrovato, Daniela
   Bitonti, Rossella
   Furneri, Gianluca
TI Cost-effectiveness analysis of brolucizumab versus aflibercept for the
   treatment of neovascular age-related macular degeneration (nAMD) in
   Italy
SO BMC HEALTH SERVICES RESEARCH
LA English
DT Article
DE Brolucizumab; Neovascular age-related macular degeneration; nAMD;
   Cost-effectiveness
AB Background Age-related macular degeneration (AMD) is a common and chronic eye condition characterized by the presence of progressive degenerative abnormalities in the central retina (macula). Notably, neovascular, or wet, AMD (nAMD) occurs when new, abnormal blood vessels grow under the macula causing scarring of the macula itself and resulting in a loss of central vision, visual distortion, and an impaired capacity of perceiving colour contrast and intensity. Brolucizumab, a new generation anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody, was approved by the European Medicines Agency for the treatment of nAMD. The aim of this analysis is to evaluate the cost-effectiveness profile of brolucizumab, compared to the main therapeutic alternative available (aflibercept), for the treatment of nAMD. Methods The simulation of costs and outcomes was carried out using a Markov model over a time horizon of 15 years. In base-case, treatment effectiveness inputs for brolucizumab and aflibercept were extracted from the HAWK and HARRIER studies and from a network meta-analysis. The Italian National Healthcare Service (NHS) perspective was considered, therefore only healthcare direct costs (treatment acquisition, administration, adverse events, disease monitoring) were analysed. In the alternative scenarios, the societal perspective and a prolonged time horizon were considered. Model robustness was tested through sensitivity analyses. Results In the base-case analysis, brolucizumab was dominant over aflibercept (+ 0.11 years QALY gained and -euro15,679 costs). Both one-way deterministic and probabilistic sensitivity analyses confirmed the robustness and reliability of base-case results. The results of the probabilistic sensitivity analysis showed that when the willingness to pay is equal to euro50,000 per QALY gained, brolucizumab would be dominant in 84% of simulations and in the remaining simulations brolucizumab would be cost-effective compared to aflibercept. Results of the alternative scenarios and sensitivity analyses confirmed the results of base-case. Conclusion The cost-utility analysis shows that brolucizumab is dominant over aflibercept. Treatment with brolucizumab reduces the economic impact of nAMD and determined a slight increase of quality-adjusted survival. This analysis gives a high level of confidence that the treatment with brolucizumab would reduce the burden of intravitreal injections, compared to aflibercept, a relevant therapeutic alternative in Italy.
C1 [Ferrante, Nicola; Ritrovato, Daniela] Novartis Farma SpA, Milan, Italy.
   [Bitonti, Rossella; Furneri, Gianluca] EBMA Consulting, Melegnano, MI, Italy.
C3 Novartis
RP Furneri, G (通讯作者)，EBMA Consulting, Melegnano, MI, Italy.
EM gianluca.furneri@ebmaconsulting.com
FU Novartis Farma S.p.A.
FX Novartis Farma S.p.A. provided funding for pharmacoeconomic support on
   the development of the analysis.
CR Agenzia Italiana del Farmaco (AIFA), GU SER GEN 235 07 10
   Agenzia Italiana del Farmaco (AIFA), RICL MED US UM BEOV
   American Academy of Ophtalmology, WHAT IS MAC DEG
   Brown GC, 2007, OPHTHALMOLOGY, V114, P1170, DOI 10.1016/j.ophtha.2006.09.019
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Christ SL, 2008, INVEST OPHTH VIS SCI, V49, P3318, DOI 10.1167/iovs.08-1676
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   European Network for Health Technology Assessment (EUnetHTA), 2020, BROL TREATM AD NEOV
   Hodgson R, 2017, ADV THER, V34, P2360, DOI 10.1007/s12325-017-0620-x
   Istituto nazionale di statistica (ISTAT), 2019, TAV MORT POP RES
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Ministero della salute, 2013, TAR PREST AMB GU 23
   Mitchell P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101072
   Muscio A, 2011, CLIN TER, V162, pE187
   National Institute for Health and Care Excellence, 2010, TA229 DEX INTR IMPL
   National Institute for Health and Care Excellence, 2013, TA409 SINGL TECHN AP
   National Institute for Health and Care Excellence (NICE), 2018, NICE GUID NG 82 AG R
   National Observatory on the Use of Medicines (OsMed), US MED IT
   Novartis, 2019, GEST PREST REL SOMM
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
NR 24
TC 1
Z9 1
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1472-6963
J9 BMC HEALTH SERV RES
JI BMC Health Serv. Res.
PD APR 29
PY 2022
VL 22
IS 1
AR 573
DI 10.1186/s12913-022-07972-w
PG 11
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services
GA 0V8OI
UT WOS:000788599100002
PM 35484540
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Muangnoi, C
   Sharif, U
   Bhuket, PRN
   Rojsitthisak, P
   Paraoan, L
AF Muangnoi, Chawanphat
   Sharif, Umar
   Bhuket, Pahweenvaj Ratnatilaka Na
   Rojsitthisak, Pornchai
   Paraoan, Luminita
TI Protective Effects of Curcumin Ester Prodrug, Curcumin Diethyl
   Disuccinate against H2O2-Induced Oxidative Stress in Human Retinal
   Pigment Epithelial Cells: Potential Therapeutic Avenues for Age-Related
   Macular Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE age related macular degeneration; retinal pigment epithelium; oxidative
   stress; curcumin; curcumin diethyl disuccinate
ID RADICAL SCAVENGING PROPERTIES; REACTIVE OXYGEN; INDUCED APOPTOSIS;
   INCLUSION-BODIES; ERK ACTIVATION; UP-REGULATION; CANCER CELLS; HUMAN
   RPE; ANTIOXIDANT; EXPRESSION
AB Oxidative stress-induced damage to the retinal pigmented epithelium (RPE), a specialised post-mitotic monolayer that maintains retinal homeostasis, contributes to the development of age-related macular degeneration (AMD). Curcumin (Cur), a naturally occurring antioxidant, was previously shown to have the ability to protect RPE cells from oxidative stress. However, poor solubility and bioavailability makes Cur a poor therapeutic agent. As prodrug approaches can mitigate these limitations, we compared the protective properties of the Cur prodrug curcumin diethyl disuccinate (CurDD) against Cur in relation to oxidative stress induced in human ARPE-19 cells. Both CurDD and Cur significantly decreased H2O2-induced reactive oxygen species (ROS) production and protected RPE cells from oxidative stress-induced death. Both drugs exerted their protective effects through the modulation of p44/42 (ERK) and the involvement of downstream molecules Bax and Bcl-2. Additionally, the expression of antioxidant enzymes HO-1 and NQO1 was also enhanced in cells treated with CurDD and Cur. In all cases, CurDD was more effective than its parent drug against oxidative stress-induced damage to ARPE-19 cells. These findings highlight CurDD as a more potent drug compared to Cur against oxidative stress and indicate that its protective effects are exerted through modulation of key apoptotic and antioxidant molecular pathways.
C1 [Muangnoi, Chawanphat] Chulalongkorn Univ, Fac Pharmaceut Sci, Pharmaceut Chem & Nat Prod Program, Bangkok 10330, Thailand.
   [Muangnoi, Chawanphat; Bhuket, Pahweenvaj Ratnatilaka Na; Rojsitthisak, Pornchai] Chulalongkorn Univ, Nat Prod Ageing & Chron Dis Res Unit, Bangkok 10330, Thailand.
   [Sharif, Umar; Paraoan, Luminita] Univ Liverpool, Inst Ageing & Chron Dis, Dept Eye & Vis Sci, Liverpool L7 8TX, Merseyside, England.
   [Rojsitthisak, Pornchai] Chulalongkorn Univ, Fac Pharmaceut Sci, Dept Food & Pharmaceut Chem, Bangkok 10330, Thailand.
C3 Chulalongkorn University; Chulalongkorn University; University of
   Liverpool; Chulalongkorn University
RP Rojsitthisak, P (通讯作者)，Chulalongkorn Univ, Nat Prod Ageing & Chron Dis Res Unit, Bangkok 10330, Thailand.; Paraoan, L (通讯作者)，Univ Liverpool, Inst Ageing & Chron Dis, Dept Eye & Vis Sci, Liverpool L7 8TX, Merseyside, England.; Rojsitthisak, P (通讯作者)，Chulalongkorn Univ, Fac Pharmaceut Sci, Dept Food & Pharmaceut Chem, Bangkok 10330, Thailand.
EM pornchai.r@chula.ac.th; lparaoan@liverpool.ac.uk
RI Paraoan, Luminita/K-1066-2016; Bhuket, Pahweenvaj Ratnatilaka
   Na/S-5228-2019
OI Paraoan, Luminita/0000-0001-7568-7116; Bhuket, Pahweenvaj Ratnatilaka
   Na/0000-0001-9506-4477
FU 90th Anniversary Chulalongkorn University Fund under
   Ratchadaphiseksomphot Endowment Fund from Graduate School, Chulalongkorn
   University [GCUGR1125602002D]; Graduate School, Chulalongkorn
   University; Faculty of Pharmaceutical Sciences, Chulalongkorn University
FX This study was supported by the 90th Anniversary Chulalongkorn
   University Fund under Ratchadaphiseksomphot Endowment Fund from Graduate
   School, Chulalongkorn University (Grant No. GCUGR1125602002D). Mr.
   Chawanphat Muangnoi received the Overseas Research Experience
   Scholarship from the Graduate School and the Faculty of Pharmaceutical
   Sciences, Chulalongkorn University for conducting cell experiments at
   Institute of Ageing and Chronic Disease, University of Liverpool,
   Liverpool, UK.
CR Abet V, 2017, EUR J MED CHEM, V127, P810, DOI 10.1016/j.ejmech.2016.10.061
   Ahmado A, 2011, INVEST OPHTH VIS SCI, V52, P7148, DOI 10.1167/iovs.10-6374
   Ak T, 2008, CHEM-BIOL INTERACT, V174, P27, DOI 10.1016/j.cbi.2008.05.003
   Ambegaokar SS, 2003, NEUROENDOCRINOL LETT, V24, P469
   Arumugam B, 2019, MOL VIS, V25, P47
   Atienzar-Aroca S, 2016, J CELL MOL MED, V20, P1457, DOI 10.1111/jcmm.12834
   Barot M, 2012, MED CHEM, V8, P753, DOI 10.2174/157340612801216283
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhujade A, 2013, FOOD FUNCT, V4, P338, DOI 10.1039/c2fo30167a
   Bhuket PRN, 2019, RSC ADV, V9, P4626, DOI 10.1039/c8ra08594c
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Chen M, 2018, NEURAL REGEN RES, V13, P742, DOI 10.4103/1673-5374.230303
   Costa Vitor, 2001, Molecular Aspects of Medicine, V22, P217, DOI 10.1016/S0098-2997(01)00012-7
   Cui Hang, 2012, J Signal Transduct, V2012, P646354, DOI 10.1155/2012/646354
   Cui QL, 2016, MOL MED REP, V13, P1381, DOI 10.3892/mmr.2015.4657
   Dai PP, 2017, CELL PHYSIOL BIOCHEM, V41, P661, DOI 10.1159/000457945
   Dai W, 2018, BRAIN RES BULL, V140, P65, DOI 10.1016/j.brainresbull.2018.03.020
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Garg Tarun K, 2003, BMC Ophthalmol, V3, P5, DOI 10.1186/1471-2415-3-5
   Giansanti V, 2013, J CELL MOL MED, V17, P103, DOI 10.1111/j.1582-4934.2012.01652.x
   Grune T, 2004, INT J BIOCHEM CELL B, V36, P2519, DOI 10.1016/j.biocel.2004.04.020
   Hecquet C, 2002, INVEST OPHTH VIS SCI, V43, P3091
   Hollborn M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059603
   Ishii T, 2002, METHOD ENZYMOL, V348, P182, DOI 10.1016/S0076-6879(02)48637-5
   Jian Z, 2011, J INVEST DERMATOL, V131, P1420, DOI 10.1038/jid.2011.56
   Jitoe-Masuda A, 2013, CURR PHARM DESIGN, V19, P2084
   Kalt W, 2010, J AGR FOOD CHEM, V58, P4001, DOI 10.1021/jf903038r
   Kang ES, 2007, FREE RADICAL BIO MED, V43, P535, DOI 10.1016/j.freeradbiomed.2007.05.006
   Kay P, 2013, J CELL MOL MED, V17, P833, DOI 10.1111/jcmm.12070
   Kim YK, 2005, J APPL TOXICOL, V25, P374, DOI 10.1002/jat.1081
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3
   Lee JC, 2010, RADIAT RES, V173, P590, DOI 10.1667/RR1522.1
   Lee WJ, 2015, ARCH TOXICOL, V89, P1103, DOI 10.1007/s00204-014-1300-0
   Li XD, 2017, NUTRIENTS, V9, DOI 10.3390/nu9040414
   LILES MR, 1991, ARCH OPHTHALMOL-CHIC, V109, P1285, DOI 10.1001/archopht.1991.01080090111033
   Lin K, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.25
   Liu WD, 2016, J DRUG TARGET, V24, P694, DOI 10.3109/1061186X.2016.1157883
   Liu XZ, 2015, IEEE T SERV COMPUT, V8, P2, DOI 10.1109/TSC.2014.2304729
   Mandal MNA, 2009, FREE RADICAL BIO MED, V46, P672, DOI 10.1016/j.freeradbiomed.2008.12.006
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Mitra A., 2014, ADV OPHTHALMOL VIS S, V1, P19
   Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386
   Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200
   Paraoan L, 2004, TRAFFIC, V5, P884, DOI 10.1111/j.1600-0854.2004.00230.x
   Park JS, 2011, J NEUROCHEM, V119, P909, DOI 10.1111/j.1471-4159.2011.07395.x
   Patel A., 2018, DRUG DELIVERY RETINA, P327, DOI [10.1007/978-3-319-95807-1_19, DOI 10.1007/978-3-319-95807-1_19]
   Premanand C, 2006, INVEST OPHTH VIS SCI, V47, P2179, DOI 10.1167/iovs.05-0580
   Rautio J, 2008, NAT REV DRUG DISCOV, V7, P255, DOI 10.1038/nrd2468
   RICHTER C, 1992, MUTAT RES, V275, P249, DOI 10.1016/0921-8734(92)90029-O
   Rozanowska M, 1999, FREE RADICAL BIO MED, V26, P518, DOI 10.1016/S0891-5849(98)00234-2
   Samuel W, 2017, MOL VIS, V23, P60
   Sarna T, 2003, EXP EYE RES, V76, P89, DOI 10.1016/S0014-4835(02)00247-6
   Sreejayan, 1997, J PHARM PHARMACOL, V49, P105, DOI 10.1111/j.2042-7158.1997.tb06761.x
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tong WG, 2005, BIOCHEM BIOPH RES CO, V335, P949, DOI 10.1016/j.bbrc.2005.07.166
   Voisin A, 2018, EXP EYE RES, V177, P76, DOI 10.1016/j.exer.2018.07.017
   Wang XJ, 2018, MOL CELL BIOCHEM, V443, P37, DOI 10.1007/s11010-017-3208-5
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Wichitnithad W, 2011, MOLECULES, V16, P1888, DOI 10.3390/molecules16021888
   Winkler BS, 1999, MOL VIS, V5
   Woo JM, 2012, MOL VIS, V18, P901
   Yang CH, 2009, BRAIN RES, V1282, P133, DOI 10.1016/j.brainres.2009.05.009
   Yu CC, 2012, FREE RADICAL BIO MED, V52, P660, DOI 10.1016/j.freeradbiomed.2011.11.021
   Zhang H, 2014, FREE RADICAL BIO MED, V69, P219, DOI 10.1016/j.freeradbiomed.2014.01.025
   Zhao HL, 2019, INT J MOL MED, V43, P936, DOI 10.3892/ijmm.2018.4027
   Zhao LL, 2017, THER CLIN RISK MANAG, V13, DOI 10.2147/TCRM.S141738
   Zhu C, 2017, BIOMED PHARMACOTHER, V88, P124, DOI 10.1016/j.biopha.2016.11.089
   Zhu W, 2015, DRUG DES DEV THER, V9, P5337, DOI 10.2147/DDDT.S84979
   Zhuang SG, 2007, AM J PHYSIOL-RENAL, V292, pF440, DOI 10.1152/ajprenal.00170.2006
   Zorov DB, 2014, PHYSIOL REV, V94, P909, DOI 10.1152/physrev.00026.2013
NR 76
TC 26
Z9 26
U1 2
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL 1
PY 2019
VL 20
IS 13
AR 3367
DI 10.3390/ijms20133367
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA IL1EG
UT WOS:000477041100251
PM 31323999
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Ferreira, A
   Sagkriotis, A
   Olson, M
   Lu, JS
   Makin, C
   Milnes, F
AF Ferreira, Alberto
   Sagkriotis, Alexandros
   Olson, Melvin
   Lu, Jingsong
   Makin, Charles
   Milnes, Fran
TI Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept
   for Neovascular Age-Related Macular Degeneration in Routine Clinical
   Practice in the USA
SO PLOS ONE
LA English
DT Article
ID VISUAL-ACUITY; DISEASE; EYE; VERTEPORFIN; PREVALENCE; MECHANISMS; SAFETY
AB Purpose
   To compare treatment patterns of intravitreal ranibizumab and aflibercept for the management of neovascular age-related macular degeneration (nAMD) in a real-world setting over the first 12 months of treatment.
   Methods
   A proprietary clinical database was used to identify treatment-naive patients with nAMD in the USA with claims for ranibizumab or aflibercept between November 1, 2011 and November 30, 2013 and with follow-up of at least 12 months. Patients were considered treatment-naive if they had no anti-VEGF treatment code for 6 months before the index date. Mean numbers of injections and of non-injection visits to a treating physician were compared between the two treatment cohorts (ranibizumab or aflibercept). In addition, the mean interval between doses was also investigated.
   Results
   Patient characteristics were similar for those receiving either ranibizumab (n = 5421) or aflibercept (n = 3506) at the index date. The mean (+/- standard deviation) numbers of injections received by patients treated with ranibizumab (4.9 +/- 3.3) or aflibercept (5.2 +/- 2.9) were not clinically different. The mean number of non-injection visits was 2.8 +/- 2.8 and 2.1 +/- 2.5 for ranibizumab and aflibercept, respectively. Mean dosing interval was 51.0 days (+/- 41.8 days) in patients receiving ranibizumab and 54.1 days (+/- 36.0 days) in those receiving aflibercept. Results were robust to sensitivity analyses for definition of treatment-naive, length of follow-up and treatment in the index eye only.
   Conclusions
   Limited data exist regarding real-world treatment patterns of aflibercept for the management of nAMD. Our results suggest that, in routine clinical practice, patients receive a comparable number of injections in the first year of treatment with ranibizumab or aflibercept.
C1 [Ferreira, Alberto; Sagkriotis, Alexandros; Olson, Melvin; Milnes, Fran] Novartis Pharma AG, Basel, Switzerland.
   [Lu, Jingsong; Makin, Charles] IMS Hlth, Plymouth Meeting, PA USA.
C3 Novartis
RP Ferreira, A (通讯作者)，Novartis Pharma AG, Basel, Switzerland.
EM alberto.ferreira@novartis.com
FU Novartis Pharma AG, Basel, Switzerland
FX Novartis Pharma AG, Basel, Switzerland funded this study. AF, AS, MO and
   FM are employees of Novartis Pharma AG. JL and CM are employees of IMS
   Health, USA, which received funding from Novartis Pharma AG, Basel,
   Switzerland.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   American Society of Retina Specialists, 2013, PREF TRENDS PAT SURV
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bandello F, 2008, DRUG AGING, V25, P255, DOI 10.2165/00002512-200825030-00007
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   EMA, 2012, EYL SUMM PROD CHAR
   EMA, 2013, LUC SUMM PROD CHAR
   FDA, 2013, LUC PRESCR INF
   FDA, 2013, EYL PRESCR INF
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2012, INTRAVITREAL AFLIBER
   Holekamp NM, 2014, AM J OPHTHALMOL, V157, P825, DOI 10.1016/j.ajo.2013.12.018
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Hyman L, 1992, EPIDEMIOLOGY OF AMD
   Johnston SS, 2013, ADV THER, V30, P1111, DOI 10.1007/s12325-013-0078-4
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross AH, 2013, EYE, V27, P56, DOI 10.1038/eye.2012.225
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Stewart MW, 2012, CLIN OPHTHALMOL, V6, P1175, DOI 10.2147/OPTH.S33372
   Sunness J S, 1998, Geriatrics, V53, P70
   Sunness JS., 1998, GERIATRICS, V53, P77
NR 28
TC 42
Z9 42
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 24
PY 2015
VL 10
IS 7
AR e0133968
DI 10.1371/journal.pone.0133968
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CN7NT
UT WOS:000358622000183
PM 26208030
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Unver, YB
   Yavuz, GA
   Bekiroglu, N
   Presti, P
   Li, W
   Sinclair, SH
AF Uenver, Y. B.
   Yavuz, G. A.
   Bekiroglu, N.
   Presti, P.
   Li, W.
   Sinclair, S. H.
TI Relationships between clinical measures of visual function and anatomic
   changes associated with bevacizumab treatment for choroidal
   neovascularization in age-related macular degeneration
SO EYE
LA English
DT Article
DE age-related macular degeneration; anatomic outcome; bevacizumab; avastin
   treatment; vision outcome; central field acuity testing
ID OPTICAL COHERENCE TOMOGRAPHY; INTRAVITREAL BEVACIZUMAB; PHOTODYNAMIC
   THERAPY; FIXATION PATTERNS; CENTRAL SCOTOMAS; AVASTIN; ACUITY;
   SECONDARY; EYES
AB Purpose This pilot study was undertaken to examine the relationships between clinical measures of visual function and anatomic changes occurring in the eyes treated with bevacizumab for choroidal neovascularization (CNV) due to age-related macular degeneration (AMD).
   Methods A retrospective review was conducted for 50 eyes that had been treated with at least three injections of bevicizumab for CNV due to AMD, and followed for at least 6 months. Vision outcomes included best-corrected ETDRS chart acuity, scored by best-line read (ETDRS line) and by total letters read (ETDRS letter), and two measures obtained from central acuity perimetry with 98% Michelson contrast targets, the best acuity within 6 degrees of fixation (BA6 degrees), and global macular acuity (GMA), representing a weighted average of the acuities thresholded at all intercepts within a 10 degrees radius of fixation. Assessment of anatomic outcomes included fibrosis, atrophy, and subretinal hemorrhage grading on fundus photography, CNV size, pigment epithelial detachment (PED) size and grading of CNV leakage on fluorescein angiography, and central retinal PED, and subretinal fluid (SRF) thickness on optical coherence tomography.
   Results Logistic regression analysis showed an association between the vision outcomes of EDTRS letter and BA6 degrees with the change in SRF thickness (R-2: 0.47 and 0.35, respectively). The outcome of the vision measurement of GMA was associated with the change in SRF thickness, in CNV thickness, and in CNV fibrosis grade (R-2: 0.34). No association was noted between the outcomes of ETDRS line with the change in any anatomic outcomes.
   Conclusion Acuity perimetry outcomes in this study seemed to offer improved understanding of the relationship between the vision outcomes and the measured anatomic changes. It seemed that neither ocular coherence tomography nor fluorescein angiography alone offered sufficient morphologic markers for prediction of functional outcomes.
C1 [Uenver, Y. B.] Beyoglu Eye Training & Res Hosp, TR-19035 Istanbul, Turkey.
   [Yavuz, G. A.] Duzce Univ, Sch Med, Dept Ophthalmol, Duzce, Turkey.
   [Bekiroglu, N.] Marmara Univ, Sch Med, Dept Biostat, Istanbul, Turkey.
   [Presti, P.] Georgia Inst Technol, Interact Multimedia Technol Ctr, Atlanta, GA 30332 USA.
   [Li, W.; Sinclair, S. H.] Drexel Univ, Sch Med, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Sinclair, S. H.] Vimetrics LLC, Media, PA USA.
C3 Istanbul Prof Dr N Resat Belger Beyoglu Eye Training & Research
   Hospital; Duzce University; Marmara University; University System of
   Georgia; Georgia Institute of Technology; Drexel University
RP Unver, YB (通讯作者)，Beyoglu Eye Training & Res Hosp, 311 E Baltimore Ave 1st Floor,Suite 100, TR-19035 Istanbul, Turkey.
EM yaprakbanu@gmail.com
FU TUBITAK
FX This study was supported by TUBITAK.
CR Abraham-Marin ML, 2007, GRAEF ARCH CLIN EXP, V245, P651, DOI 10.1007/s00417-006-0411-6
   Aggio FB, 2007, GRAEF ARCH CLIN EXP, V245, P215, DOI 10.1007/s00417-006-0412-5
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Gonzalez EG, 2007, INVEST OPHTH VIS SCI, V48, P4838, DOI 10.1167/iovs.06-1240
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   HOFFMAN JE, 1995, PERCEPT PSYCHOPHYS, V57, P787, DOI 10.3758/BF03206794
   Jonas JB, 2007, ACTA OPHTHALMOL SCAN, V85, P563, DOI 10.1111/j.1600-0420.2007.00891.x
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.0.CO;2-N
   Krebs I, 2005, BRIT J OPHTHALMOL, V89, P1184, DOI 10.1136/bjo.2005.067389
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   LEVY J, 2008, INT OPHTHALMOL
   Moore T, 1999, SCIENCE, V285, P1914, DOI 10.1126/science.285.5435.1914
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Pedersen R, 2007, ACTA OPHTHALMOL SCAN, V85, P526, DOI 10.1111/j.1600-0420.2007.00895.x
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Sahni J, 2005, BRIT J OPHTHALMOL, V89, P316, DOI 10.1136/bjo.2004.043364
   Salinas-Alaman A, 2005, AM J OPHTHALMOL, V140, P23, DOI 10.1016/j.ajo.2005.01.044
   Sinclair S H, 1999, Semin Ophthalmol, V14, P214, DOI 10.3109/08820539909069540
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Sunness JS, 2005, AM J OPHTHALMOL, V140, P1085, DOI 10.1016/j.ajo.2005.07.040
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   VOGEL GL, 1995, J BEHAV OPTOM, V6, P3
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 34
TC 14
Z9 15
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2009
VL 23
IS 2
BP 453
EP 460
DI 10.1038/eye.2008.349
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 406US
UT WOS:000263321000035
PM 19039333
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Silva, R
   Berta, A
   Larsen, M
   Macfadden, W
   Feller, C
   Mones, J
AF Silva, Rufino
   Berta, Andras
   Larsen, Michael
   Macfadden, Wayne
   Feller, Chrystel
   Mones, Jordi
CA TREND Study Grp
TI Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related
   Macular Degeneration Results with Ranibizumab from the TREND Study
SO OPHTHALMOLOGY
LA English
DT Article
ID VISUAL IMPAIRMENT; PROSPECTIVE TRIAL; PREVALENCE; EFFICACY; OUTCOMES;
   BEVACIZUMAB; MACULOPATHY; THERAPY; SAFETY; MG
AB Purpose: To evaluate the efficacy and safety of ranibizumab 0.5 mg treat-and-extend (T& E) versus monthly regimens in patients with neovascular age-related macular degeneration (nAMD) from the TReat and extEND (TREND) study.
   Design: A 12-month phase 3b visual acuity (VA) assessor-masked, multicenter, randomized, interventional study.
   Participants: Six hundred fifty patients.
   Methods: Treatment-naive nAMD patients (age, >= 50 years) were randomized 1: 1 to receive either a ranibizumab 0.5 mg T& E (n = 323) or monthly (n = 327) regimen.
   Main Outcomes Measures: The primary objective was to show noninferiority of ranibizumab 0.5 mg T& E versus monthly regimen, as assessed by the change in best-corrected VA (BCVA) from baseline to the end of the study. Secondary objectives included change in retinal central subfield thickness (CSFT) from baseline to the end of study, treatment exposure, and safety.
   Results: Overall, 89.8% (T& E) and 90.2% (monthly) of patients completed the study. Patient demographic and baseline characteristics were well balanced between the 2 treatment groups. The T& E regimen was noninferior (P < 0.001) to the monthly regimen, with a least squares mean BCVA change from baseline of 6.2 versus 8.1 letters to the end of study, respectively. In both treatment groups, most BCVA improvements occurred during the first 6 months and were maintained until the end of the study. The mean change in CSFT from baseline to the end of study was 169.2 mm and 173.3 mm in the T& E and monthly groups, respectively. Fewer injections were required in patients receiving the T& E (8.7) versus monthly (11.1) regimen, with mean number of postbaseline visits of 8.9 and 11.2, respectively. Types and rates of adverse events were comparable between the treatment groups.
   Conclusions: Ranibizumab 0.5 mg administered according to a T& E regimen was statistically noninferior and clinically comparable with a monthly regimen in improving VA from baseline to the end of study. No new safety signals for ranibizumab were identified. (C) 2017 American Academy of Ophthalmology. Published by Elsevier Inc.
C1 [Silva, Rufino] CHUC, Dept Ophthalmol, Praceta Prof Mota Pinto, P-3000075 Coimbra, Portugal.
   [Silva, Rufino] Univ Coimbra, Fac Med, Inst Biomed Imaging & Life Sci, Coimbra, Portugal.
   [Silva, Rufino] Assoc Innovat & Biomed Res Light & Image AIBILI, Coimbra, Portugal.
   [Berta, Andras] Univ Debrecen, Dept Ophthalmol, Fac Med, Med & Hlth Sci Ctr, Debrecen, Hungary.
   [Larsen, Michael] Univ Copenhagen, Rigshosp, Dept Ophthalmol, Copenhagen, Denmark.
   [Larsen, Michael] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
   [Macfadden, Wayne; Feller, Chrystel] Novartis Pharma AG, Basel, Switzerland.
   [Mones, Jordi] Inst Macula, Barcelona, Spain.
   [Mones, Jordi] Barcelona Macula Fdn, Barcelona, Spain.
C3 Universidade de Coimbra; Universidade de Coimbra; Universidade de
   Coimbra; University of Debrecen; Rigshospitalet; University of
   Copenhagen; University of Copenhagen; Novartis
RP Silva, R (通讯作者)，CHUC, Dept Ophthalmol, Praceta Prof Mota Pinto, P-3000075 Coimbra, Portugal.
EM rufino.silva@oftalmologia.co.pt
RI Silva, Rufino M/J-2817-2012; mones, jordi/CAJ-2963-2022; Larsen,
   Michael/E-9620-2010
OI Silva, Rufino M/0000-0001-8676-0833; mones, jordi/0000-0003-3685-2160;
   Larsen, Michael/0000-0002-5172-5891
FU Bayer; Alimera; Angelini; THEA; Allergan; Novartis; Alcon; Roche;
   Ophthotech; Novartis Pharma AG, Basel, Switzerland
FX The author(s) have made the following disclosure(s): R.S.: Consultant -
   Allergan, Alimera, Alcon, Bayer, Novartis, THEA; Financial support -
   Bayer, Alimera, Angelini, THEA, Allergan, Novartis; M.L.: Consultant,
   Lecturer, Financial support (to institution) - Novartis, Allergan,
   Alcon, Roche; J.M.: Consultant - Novartis, Allergan, Bayer, Alcon,
   Ophthotech, Notal Vision, Alimera, Genentech; Financial support -
   Novartis, Bayer, Alcon, Ophthotech, Roche; Lecturer - Novartis,
   Allergan, Ophthotech; This study was funded and managed by Novartis
   Pharma AG, Basel, Switzerland.
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cachulo MD, 2016, ACTA OPHTHALMOL, V94, pE442, DOI 10.1111/aos.12950
   Chen YFN, 2016, RETINA-J RET VIT DIS, V36, P272, DOI 10.1097/IAE.0000000000000691
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Ferreras, 2014, J CLIN EXP OPHTHALMO, V5, P1
   Gianniou C, 2015, EYE, V29, P450, DOI 10.1038/eye.2014.321
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Solomon SD, 2014, COCHRANE DB SYST REV, V8, P1
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Stewart MW, 2015, J CLIN MED, V4, P1079, DOI 10.3390/jcm4051079
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 34
TC 156
Z9 158
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2018
VL 125
IS 1
BP 57
EP 65
DI 10.1016/j.ophtha.2017.07.014
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FT0CC
UT WOS:000422787000027
PM 28893454
OA Green Published, hybrid
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Rush, RB
   Rush, SW
   Aragon, AV
   Ysasaga, JE
AF Rush, Ryan B.
   Rush, Sloan W.
   Aragon, Antonio V., II
   Ysasaga, J. Edward
TI Evaluation of Choroidal Neovascularization With Indocyanine Green
   Angiography in Neovascular Age-Related Macular Degeneration Subjects
   Undergoing Intravitreal Bevacizumab Therapy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID FLUORESCEIN ANGIOGRAPHY; RANIBIZUMAB; VIDEOANGIOGRAPHY; FEATURES; TREAT;
   OUTCOMES
AB PURPOSE: To report the clinical implications of interval changes in choroidal neovascularization (CNV) size measured by indocyanine green (ICG) angiography in neovascular age-related macular degeneration (AMD) patients undergoing intravitreal bevacizumab therapy.
   DESIGN: Retrospective, consecutive chart review.
   METHODS: The charts of neovascular AMD patients who underwent intravitreal bevacizumab therapy using a treat-and-extend dosing schedule were reviewed. ICG angiographic CNV surface areas were measured at baseline, 2 months, 6 months, and 12 months in each subject. The primary outcome was change in CNV size. Secondary outcomes included the correlation of change in CNV surface area with change in best-corrected visual acuity (BCVA), change in central macular thickness on optical coherence tomography (OCT), and the number of injections delivered over the 12-month study interval.
   RESULTS: A total of 123 subjects were included in the analysis. The baseline CNV size was 1.9 mm(2) +/- 2.5 mm(2). CNV size was 1.66 mm(2) +/- 2.11 mm(2) at 2 months, 1.60 mm(2) +/- 2.23 mm(2) at 6 months, and 1.50 mm(2) +/- 2.12 mm(2) at 12 months. The change in CNV size from baseline was not statistically significant at any of the follow-up intervals. A decrease in CNV size of 33% or more at 2 months was associated with a significant decrease in CNV size at 12 months (P = .0096), complete resolution of CNV at 12 months (P = .0013), and a decrease in the number of injections delivered over the study interval (P = .0165). Complete resolution of CNV at 12 months occurred in 7.3% of subjects. Subjects that had complete resolution of CNV at 12 months were significantly more likely to gain 3 more lines of BCVA at the end of the study interval (P = .0131). No significant correlation was found between CNV size and change in central macular thickness on OCT.
   CONCLUSIONS: Our study suggests that change in CNV size on ICG angiography may help the clinician predict the clinical course of neovascular AMD subjects undergoing intravitreal bevacizumab therapy using a treat-and-extend dosing schedule. ((C) 2014 by Elsevier Inc. All rights reserved.)
C1 [Rush, Ryan B.; Aragon, Antonio V., II; Ysasaga, J. Edward] Southwest Retina Specialists, Amarillo, TX 79106 USA.
   [Rush, Ryan B.; Rush, Sloan W.; Aragon, Antonio V., II; Ysasaga, J. Edward] Panhandle Eye Grp, Amarillo, TX USA.
   [Rush, Ryan B.; Rush, Sloan W.; Aragon, Antonio V., II; Ysasaga, J. Edward] Texas Tech Univ, Hlth Sci Ctr, Amarillo, TX USA.
C3 Texas Tech University System; Texas Tech University; Texas Tech
   University Health Science Center; Texas Tech University Health Sciences
   Center Amarillo
RP Rush, RB (通讯作者)，Southwest Retina Specialists, 7411 Wallace Blvd, Amarillo, TX 79106 USA.
EM Ryanbradfordrush21@hotmail.com
OI Rush, Ryan/0000-0003-2790-6155
CR AVVAD FK, 1995, OPHTHALMOLOGY, V102, P401
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CHANG TS, 1994, RETINA-J RET VIT DIS, V14, P114, DOI 10.1097/00006982-199414020-00004
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Guyer DR, 1996, OPHTHALMOLOGY, V103, P2054, DOI 10.1016/S0161-6420(96)30388-6
   Jumper JM, 2012, PREFERENCES TRENDS S
   Lee BL, 1996, RETINA-J RET VIT DIS, V16, P64, DOI 10.1097/00006982-199616010-00011
   Nakajima Masami, 1997, Nippon Ganka Gakkai Zasshi, V101, P584
   Nishiguchi K, 2000, JPN J OPHTHALMOL, V44, P668
   Obana A, 1999, BRIT J OPHTHALMOL, V83, P429, DOI 10.1136/bjo.83.4.429
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rush RB, 2014, RETINA-J RET VIT DIS, V34, P846, DOI 10.1097/IAE.0000000000000033
   Schneider U, 1996, GER J OPHTHALMOL, V5, P6
   Semoun O, 2009, BRIT J OPHTHALMOL, V93, P182, DOI 10.1136/bjo.2008.145235
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Trabucchi G, 1996, GRAEF ARCH CLIN EXP, V234, P294, DOI 10.1007/BF00220703
   Watzke RC, 2000, OPHTHALMOLOGY, V107, P1601, DOI 10.1016/S0161-6420(00)00218-9
   Wolf S, 1996, GER J OPHTHALMOL, V5, P251
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   Yannuzzi LA, 2011, AM J OPHTHALMOL, V151, P745, DOI 10.1016/j.ajo.2011.01.043
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 24
TC 15
Z9 15
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2014
VL 158
IS 2
BP 337
EP 344
DI 10.1016/j.ajo.2014.05.007
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN6EB
UT WOS:000340686600018
PM 24844972
DA 2022-11-30
ER

PT J
AU Amarakoon, S
   Martinez-Ciriano, JP
   van den Born, LI
   Baarsma, S
   Missotten, T
AF Amarakoon, Sankha
   Martinez-Ciriano, Jose P.
   van den Born, L. Ingeborgh
   Baarsma, Seerp
   Missotten, Tom
TI Bevacizumab in age-related macular degeneration: a randomized controlled
   trial on the effect of on-demand therapy every 4 or 8 weeks
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; bevacizumab; treatment; anti-VEGF
ID SINGLE INTRAVITREAL INJECTION; INTRAOCULAR PHARMACOKINETICS;
   RANIBIZUMAB; VERTEPORFIN; OUTCOMES; AVASTIN
AB Purpose Intravitreal anti-vascular endothelial growth factor (VEGF) injections are an effective treatment for neovascular age-related macular degeneration (nARMD). Bevacizumab appears to be a cost-effective off-label anti-VEGF alternative to ranibizumab, but an optimal injection schedule has not yet been determined. In this study, we investigate whether on-demand bevacizumab treatment every 8 weeks is non-inferior to on-demand bevacizumab every 4 weeks in treating nARMD. Methods A total of 120 nARMD patients were randomly assigned to an on-demand regimen of intravitreal bevacizumab (IVB) every 4 (n = 60) or 8 weeks (n = 60). The primary outcome was visual acuity (VA) change after 1 year of treatment. Results Visual acuity (VA) improved between baseline and 1 year in both treatment groups. The mean change in the VA score at 1 year was not significantly different between bevacizumab administration on-demand every 4 weeks [5.6 +/- 10.2 Early Treatment Diabetic Retinopathy Study (ETDRS) letter] or 8 weeks (4.6 +/- 12.0 ETDRS letters). A reduction in the central retinal thickness was observed in both groups. At 1 year, the mean decrease in central foveal thickness ranged from 61 +/- 90 mu m in the 4-week group to 91 +/- 83 mu m in the 8-week group (p = 0.07). The mean number of IVB treatments during the study period was 8.7 +/- 2.3 in the 4-week group and 5.9 +/- 1.0 in the 8-week group. Conclusion At 1 year, bevacizumab administration on-demand every 8 weeks was non-inferior to administration every 4 weeks. The results strongly suggest that bevacizumab acts longer than 4 weeks in ARMD, reducing the burden of injections for patients.
C1 [Amarakoon, Sankha; Martinez-Ciriano, Jose P.; van den Born, L. Ingeborgh; Baarsma, Seerp; Missotten, Tom] Rotterdam Eye Hosp, Schiedamsevest 180, NL-3011 BH Rotterdam, Netherlands.
   [Amarakoon, Sankha] Rotterdam Ophthalm Inst, Rotterdam, Netherlands.
C3 Rotterdam Eye Hospital
RP Missotten, T (通讯作者)，Rotterdam Eye Hosp, Schiedamsevest 180, NL-3011 BH Rotterdam, Netherlands.
EM t.missotten@oogziekenhuis.nl
FU Stichting voor Ooglijders Funding Source: Medline; SWOO-Flieringa
   Funding Source: Medline
CR Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown GC, 2007, OPHTHALMOLOGY, V114, P1170, DOI 10.1016/j.ophtha.2006.09.019
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Frennesson Christina, 2007, Lakartidningen, V104, P486
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Jorstad OK, 2017, ACTA OPHTHALMOL, V95, P460, DOI 10.1111/aos.13480
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Kvannli L, 2017, ACTA OPHTHALMOL, V95, P678, DOI 10.1111/aos.13356
   Lushchyk T, 2013, ACTA OPHTHALMOL, V91, pe456, DOI 10.1111/aos.12119
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Real JP, 2016, ACTA OPHTHALMOL, V94, pE803, DOI 10.1111/aos.13153
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Solomon SD, 2016, OPHTHALMOLOGY, V123, P70, DOI 10.1016/j.ophtha.2015.09.002
   Sonmez K, 2011, RETINA-J RET VIT DIS, V31, P645, DOI 10.1097/IAE.0b013e3182012d18
   Vottonen P, 2016, ACTA OPHTHALMOL, V94, P652, DOI 10.1111/aos.13185
NR 28
TC 11
Z9 12
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2019
VL 97
IS 1
BP 107
EP 112
DI 10.1111/aos.13774
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HJ0SF
UT WOS:000456872000029
PM 30369062
OA Bronze
DA 2022-11-30
ER

PT J
AU Schmucker, CM
   Rucker, G
   Sommer, H
   Virgili, G
   Loke, YK
   Oeller, P
   Agostini, H
   Ehlken, C
AF Schmucker, Christine M.
   Ruecker, Gerta
   Sommer, Harriet
   Virgili, Gianni
   Loke, Yoon K.
   Oeller, Patrick
   Agostini, Hansjuergen
   Ehlken, Christoph
TI Treatment as Required versus Regular Monthly Treatment in the Management
   of Neovascular Age-Related Macular Degeneration: A Systematic Review and
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID 2.0 MG RANIBIZUMAB; ANTI-VEGF; EFFICACY; SAFETY; VERTEPORFIN
AB Background
   To investigate whether treatment as required 'pro re nata' (PRN) versus regular monthly treatment regimens lead to differences in outcomes in neovascular age-related macular degeneration (nAMD). Regular monthly administration of vascular endothelial growth factor (VEGF) inhibitors is an established gold standard treatment, but this approach is costly. Replacement of monthly by PRN treatment can only be justified if there is no difference in patient relevant outcomes.
   Methods Systematic review and meta-analysis. The intervention was PRN treatment and the comparator was monthly treatment with VEGF-inhibitors. Four bibliographic databases were searched for randomised controlled trials comparing both treatment regimens directly (head-to-head studies). The last literature search was conducted in December 2014. Risk of bias assessment was performed after the Cochrane Handbook for Systematic Reviews of Interventions.
   Findings
   We included 3 head-to-head studies (6 reports) involving more than 2000 patients. After 2 years, the weighted mean difference in best corrected visual acuity (BCVA) was 1.9 (95% CI 0.5 to 3.3) ETDRS letters in favour of monthly treatment. Systemic adverse events were higher in PRN treated patients, but these differences were not statistically significant. After 2 years, the total number of intravitreal injections required by the patients in the PRN arms were 8.4 (95% CI 7.9 to 8.9) fewer than those having monthly treatment. The studies were considered to have a moderate risk of bias.
   Conclusions
   PRN treatment resulted in minor but statistically significant decrease in mean BCVA which may not be clinically meaningful. There is a small increase in risk of systemic adverse events for PRN treated patients. Overall, the results indicate that an individualized treatment approach with anti-VEGF using visual acuity and OCT-guided re-treatment criteria may be appropriate for most patients with nAMD.
C1 [Schmucker, Christine M.; Oeller, Patrick] Univ Freiburg, Med Ctr, Cochrane Germany, D-79110 Freiburg, Germany.
   [Ruecker, Gerta; Sommer, Harriet] Univ Freiburg, Med Ctr, Inst Med Biometry & Stat, D-79104 Freiburg, Germany.
   [Virgili, Gianni] Univ Florence, Dept Translat Surg & Med, Florence, Italy.
   [Loke, Yoon K.] Univ E Anglia, Norwich Med Sch, Norwich NR4 7TJ, Norfolk, England.
   [Agostini, Hansjuergen; Ehlken, Christoph] Univ Eye Ctr Freiburg, D-79106 Freiburg, Germany.
C3 University of Freiburg; University of Freiburg; University of Florence;
   University of East Anglia
RP Schmucker, CM (通讯作者)，Univ Freiburg, Med Ctr, Cochrane Germany, Berliner Allee 29, D-79110 Freiburg, Germany.
EM schmucker@cochrane.de
RI Rücker, Gerta/B-2965-2009; Virgili, Gianni/P-6607-2014
OI Rücker, Gerta/0000-0002-2192-2560; Schmucker,
   Christine/0000-0002-1188-3158; Virgili, Gianni/0000-0002-9960-2989
FU German National Association of Statutory Health Insurance Funds; German
   Health Technology Assessment
FX This systematic review is based on a broader research project funded by
   the German National Association of Statutory Health Insurance Funds
   http://www.gkvspitzenverband.de/english/about_us/about_us.jsp). The
   research project in full is published in a German Health Technology
   Assessment
   (https://www.g-ba.de/downloads/40-2683191/2015-04-16_135-SN_Einleitung-B
   eratungsverfahren_OCT_Antrag-Anlage.pdf.). The views and opinions
   expressed in the present systematic review are those of the authors and
   do not necessarily reflect those of the funding organization. The
   funding organization had no role in the design or conduct of the present
   systematic review.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Berkman ND, 2014, AHRQ METHODS EFFECTI
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Jiang S, 2014, J CLIN PHARM THER, V39, P234, DOI 10.1111/jcpt.12146
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Sigford DK, 2015, CLIN OPHTHALMOL, V9, P773, DOI 10.2147/OPTH.S77067
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Thulliez M, 2014, JAMA OPHTHALMOL, V132, P1317, DOI 10.1001/jamaophthalmol.2014.2333
NR 22
TC 14
Z9 14
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 14
PY 2015
VL 10
IS 9
AR e0137866
DI 10.1371/journal.pone.0137866
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CR8KS
UT WOS:000361601100159
PM 26368921
OA Green Published, Green Accepted, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Winkler, TW
   Grassmann, F
   Brandl, C
   Kiel, C
   Gunther, F
   Strunz, T
   Weidner, L
   Zimmermann, ME
   Korb, CA
   Poplawski, A
   Schuster, AK
   Muller-Nurasyid, M
   Peters, A
   Rauscher, FG
   Elze, T
   Horn, K
   Scholz, M
   Canadas-Garre, M
   McKnight, AJ
   Quinn, N
   Hogg, RE
   Kuchenhoff, H
   Heid, IM
   Stark, KJ
   Weber, BHF
AF Winkler, Thomas W.
   Grassmann, Felix
   Brandl, Caroline
   Kiel, Christina
   Guenther, Felix
   Strunz, Tobias
   Weidner, Lorraine
   Zimmermann, Martina E.
   Korb, Christina A.
   Poplawski, Alicia
   Schuster, Alexander K.
   Mueller-Nurasyid, Martina
   Peters, Annette
   Rauscher, Franziska G.
   Elze, Tobias
   Horn, Katrin
   Scholz, Markus
   Canadas-Garre, Marisa
   McKnight, Amy Jayne
   Quinn, Nicola
   Hogg, Ruth E.
   Kuechenhoff, Helmut
   Heid, Iris M.
   Stark, Klaus J.
   Weber, Bernhard H. F.
TI Genome-wide association meta-analysis for early age-related macular
   degeneration highlights novel loci and insights for advanced disease
SO BMC MEDICAL GENOMICS
LA English
DT Article
DE Genome-wide association study (GWAS); Meta-analysis; Age-related macular
   degeneration (AMD); Early AMD; CD46; TYR; International AMD genomics
   consortium (IAMDGC); UK biobank (UKBB); Machine-learning; Automated
   phenotyping
ID MEMBRANE COFACTOR PROTEIN; RISK-FACTORS; GWAS; CD46; VARIANTS; RARE;
   CLASSIFICATION; EXPRESSION; EFFICIENT; RESOURCE
AB Background Advanced age-related macular degeneration (AMD) is a leading cause of blindness. While around half of the genetic contribution to advanced AMD has been uncovered, little is known about the genetic architecture of early AMD. Methods To identify genetic factors for early AMD, we conducted a genome-wide association study (GWAS) meta-analysis (14,034 cases, 91,214 controls, 11 sources of data including the International AMD Genomics Consortium, IAMDGC, and UK Biobank, UKBB). We ascertained early AMD via color fundus photographs by manual grading for 10 sources and via an automated machine learning approach for > 170,000 photographs from UKBB. We searched for early AMD loci via GWAS and via a candidate approach based on 14 previously suggested early AMD variants. Results Altogether, we identified 10 independent loci with statistical significance for early AMD: (i) 8 from our GWAS with genome-wide significance (P < 5 x 10(- 8)), (ii) one previously suggested locus with experiment-wise significance (P < 0.05/14) in our non-overlapping data and with genome-wide significance when combining the reported and our non-overlapping data (together 17,539 cases, 105,395 controls), and (iii) one further previously suggested locus with experiment-wise significance in our non-overlapping data. Of these 10 identified loci, 8 were novel and 2 known for early AMD. Most of the 10 loci overlapped with known advanced AMD loci (nearARMS2/HTRA1, CFH,C2,C3,CETP,TNFRSF10A,VEGFA, APOE), except two that have not yet been identified with statistical significance for any AMD. Among the 17 genes within these two loci, in-silico functional annotation suggestedCD46andTYRas the most likely responsible genes. Presence or absence of an early AMD effect distinguished the known pathways of advanced AMD genetics (complement/lipid pathways versus extracellular matrix metabolism). Conclusions Our GWAS on early AMD identified novel loci, highlighted shared and distinct genetics between early and advanced AMD and provides insights into AMD etiology. Our data provide a resource comparable in size to the existing IAMDGC data on advanced AMD genetics enabling a joint view. The biological relevance of this joint view is underscored by the ability of early AMD effects to differentiate the major pathways for advanced AMD.
C1 [Winkler, Thomas W.; Brandl, Caroline; Guenther, Felix; Weidner, Lorraine; Zimmermann, Martina E.; Heid, Iris M.; Stark, Klaus J.] Univ Regensburg, Dept Genet Epidemiol, Regensburg, Germany.
   [Grassmann, Felix; Brandl, Caroline; Kiel, Christina; Strunz, Tobias; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Regensburg, Germany.
   [Grassmann, Felix] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
   [Grassmann, Felix] Univ Aberdeen, Inst Med Sci, Aberdeen, Scotland.
   [Brandl, Caroline] Univ Hosp Regensburg, Dept Ophthalmol, Regensburg, Germany.
   [Guenther, Felix; Kuechenhoff, Helmut] Ludwig Maximilians Univ Munchen, Dept Stat, Stat Consulting Unit StaBLab, Munich, Germany.
   [Korb, Christina A.; Schuster, Alexander K.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Ophthalmol, Mainz, Germany.
   [Poplawski, Alicia; Mueller-Nurasyid, Martina] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Med Biostat Epidemiol & Informat, Mainz, Germany.
   [Mueller-Nurasyid, Martina] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Genet Epidemiol, Neuherberg, Germany.
   [Mueller-Nurasyid, Martina] Hosp Ludwig Maximilians Univ LMU Munich, Dept Internal Med Cardiol 1, Munich, Germany.
   [Mueller-Nurasyid, Martina] Ludwig Maximilians Univ Munchen, Fac Med, IBE, Genet Epidemiol, Munich, Germany.
   [Peters, Annette] German Ctr Diabet Res DZD, Neuherberg, Germany.
   [Peters, Annette] Helmholtz Zentrum Munchen, Res Ctr Environm Hlth, Inst Epidemiol, Neuherberg, Germany.
   [Rauscher, Franziska G.; Elze, Tobias; Horn, Katrin; Scholz, Markus] Univ Leipzig, Leipzig Res Ctr Civilizat Dis LIFE, Leipzig, Germany.
   [Rauscher, Franziska G.; Horn, Katrin; Scholz, Markus] Univ Leipzig, Inst Med Informat Stat & Epidemiol IMISE, Leipzig, Germany.
   [Elze, Tobias] Harvard Med Sch, Schepens Eye Res Inst, Boston, MA 02115 USA.
   [Canadas-Garre, Marisa; McKnight, Amy Jayne; Quinn, Nicola; Hogg, Ruth E.] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Weber, Bernhard H. F.] Univ Hosp Regensburg, Inst Clin Human Genet, Regensburg, Germany.
C3 University of Regensburg; University of Regensburg; Karolinska
   Institutet; University of Aberdeen; University of Regensburg; University
   of Munich; Johannes Gutenberg University of Mainz; Johannes Gutenberg
   University of Mainz; Helmholtz Association; Helmholtz-Center Munich -
   German Research Center for Environmental Health; University of Munich;
   University of Munich; Helmholtz Association; Helmholtz-Center Munich -
   German Research Center for Environmental Health; Leipzig University;
   Leipzig University; Harvard University; Harvard Medical School; Schepens
   Eye Research Institute; Queens University Belfast; University of
   Regensburg
RP Winkler, TW (通讯作者)，Univ Regensburg, Dept Genet Epidemiol, Regensburg, Germany.
EM thomas.winkler@klinik.uni-regensburg.de
RI Hogg, Ruth E./ABC-9602-2020; Peters, Annette/A-6117-2011; Rauscher,
   Franziska/AAV-8222-2021; Strunz, Tobias/ABB-6300-2020; Strunz,
   Tobias/ABD-9798-2021; Müller-Nurasyid, Martina/I-8735-2018
OI Hogg, Ruth E./0000-0001-9413-2669; Peters, Annette/0000-0001-6645-0985;
   Rauscher, Franziska/0000-0003-0183-0340; Strunz,
   Tobias/0000-0002-3744-9595; Müller-Nurasyid,
   Martina/0000-0003-3793-5910; Schulze, Alicia/0000-0003-2527-0763;
   Winkler, Thomas/0000-0003-0292-5421; Kiel,
   Christina/0000-0003-3154-4847; Grassmann, Felix/0000-0003-1390-7528
FU German Federal Ministry of Education and Research (BMBF) [01ER1206,
   01ER1507]; University of Regensburg; government of Rhineland-Palatinate
   [AZ 961-386261/733]; Johannes Gutenberg-University of Mainz; Boehringer
   Ingelheim; PHILIPS Medical Systems; Deutsche Ophthalmologische
   Gesellschaft; Berufsverband der Augenarzte Deutschland e.V.; NIH [R01
   EY022310]; DFG [HE 3690/5-1]; Helmholtz Zentrum Munchen - German
   Research Center for Environmental Health; German Federal Ministry of
   Education and Research (BMBF); State of Bavaria; Munich Center of Health
   Sciences (MC-Health); LudwigMaximilians-Universitat; Leipzig Research
   Centre for Civilization Diseases (LIFE); European Union; European
   Regional Development Fund (ERDF); Free State of Saxony within the
   framework of the excellence initiative [713-241202, 14505/2470,
   14575/2470]; German Federal Ministry of Education and Research: i:DSem -
   Integrative data semantics in systems medicine [031 L0026]; Lions
   Foundation; GrimshawGudewicz Foundation; Research to Prevent Blindness;
   BrightFocus Foundation; Alice Adler Fellowship; NEI [R21EY030142,
   R21EY030631, R01EY030575, P30EYE003790]; Atlantic Philanthropies;
   Economic and Social Research Council; UKCRC Centre of Excellence for
   Public Health Northern Ireland; Centre for Ageing Research and
   Development in Ireland; Office of the First Minister and Deputy First
   Minister; Health and Social Care Research and Development Division of
   the Public Health Agency; Wellcome Trust/Wolfson Foundation; Queen's
   University Belfast; Science Foundation Ireland; Department for the
   Economy, Northern Ireland US [15/IA/3152]; Economic and Social Research
   Council [ES/L008459/1]; German Research Foundation (DFG) [HE-3690/5-1];
   National Institutes of Health (NIH) [R01 EY RES 511967]; Academy of
   Sciences Leopoldina [LPDS 2018-06]; Helmut-Ecker-Foundation [05/17];
   German Research Foundation [GR 5065/1-1]; Projekt DEAL; 
   [HHSN268201200008I]; ESRC [ES/L008459/1] Funding Source: UKRI
FX The AugUR study was supported by grants from the German Federal Ministry
   of Education and Research (BMBF 01ER1206, BMBF 01ER1507 to I.M.H.) and
   the University of Regensburg. The Gutenberg Health Study is funded
   through the government of Rhineland-Palatinate (,Stiftung
   Rheinland-Pfalz fur Innovation", contract AZ 961-386261/733), the
   research programs "Wissenschafft Zukunft" and "Center for Translational
   Vascular Biology (CTVB)" of the Johannes Gutenberg-University of Mainz,
   and its contract with Boehringer Ingelheim and PHILIPS Medical Systems,
   including an unrestricted grant for the Gutenberg Health Study.
   Alexander K Schuster (A.K.S.) holds the professorship for ophthalmic
   healthcare research endowed by,Stiftung Auge "and financed by,Deutsche
   Ophthalmologische Gesellschaft "and,Berufsverband der Augenarzte
   Deutschland e.V.". The International AMD Genomics Consortium (IAMDGC) is
   supported by a grant from NIH (R01 EY022310). Genotyping was supported
   by a contract (HHSN268201200008I) to the Center for Inherited Disease
   Research (http://amdgenetics.org/).In-depth analyses to estimate genetic
   effects in the IAMDGC data was supported by DFG HE 3690/5-1 to Iris M
   Heid (I.M.H.). The KORA study was initiated and financed by the
   Helmholtz Zentrum Munchen - German Research Center for Environmental
   Health, which is funded by the German Federal Ministry of Education and
   Research (BMBF) and by the State of Bavaria. Furthermore, KORA research
   was supported within the Munich Center of Health Sciences (MC-Health),
   LudwigMaximilians-Universitat, as part of LMUinnovativ. This publication
   is supported by the Leipzig Research Centre for Civilization Diseases
   (LIFE), an organizational unit affiliated to the Medical Faculty of
   Leipzig University. LIFE is funded by means of the European Union, by
   the European Regional Development Fund (ERDF) and by funds of the Free
   State of Saxony within the framework of the excellence initiative
   (project numbers: 713-241202, 14505/2470, 14575/2470). Franziska G.
   Rauscher (F.G.R.) is supported by a grant from the German Federal
   Ministry of Education and Research: i:DSem - Integrative data semantics
   in systems medicine (031 L0026). Tobias Elze (T.E.) is funded by the
   Lions Foundation, GrimshawGudewicz Foundation, Research to Prevent
   Blindness, BrightFocus Foundation, Alice Adler Fellowship, NEI
   R21EY030142,NEI R21EY030631, NEI R01EY030575, and NEI Core Grant
   P30EYE003790. The Atlantic Philanthropies, the Economic and Social
   Research Council, the UKCRC Centre of Excellence for Public Health
   Northern Ireland, the Centre for Ageing Research and Development in
   Ireland, the Office of the First Minister and Deputy First Minister, the
   Health and Social Care Research and Development Division of the Public
   Health Agency, the Wellcome Trust/Wolfson Foundation and Queen's
   University Belfast provide core financial support for NICOLA. Marisa
   Canadas-Garre (M.C.G.) is supported by Science Foundation Ireland and
   the Department for the Economy, Northern Ireland US partnership award
   (15/IA/3152). The molecular data employed for the NICOLAcohort were
   funded by Economic and Social Research Council (ES/L008459/1). The
   analyses were supported by German Research Foundation (DFG HE-3690/5-1
   to I.M.H.) and by the National Institutes of Health (NIH R01 EY RES
   511967 to I.M.H.). Felix Grassmann (F.G.) was a Leopoldina Postdoctoral
   Fellow (Grant No. LPDS 2018-06) funded by the Academy of Sciences
   Leopoldina. The position of Tobias Strunz (T.S.) is financed by the
   Helmut-Ecker-Foundation (#05/17 to B.H.F.W.) and of Christina Kiel
   (C.K.; ) by a grant from the German Research Foundation to F.G. and
   B.H.F.W. (GR 5065/1-1). The funding bodies played no role in the design
   of the study and collection, analysis, and interpretation of data and in
   writing the manuscript. Open access funding provided by Projekt DEAL.
CR Aguet F, 2017, NATURE, V550, P204, DOI 10.1038/nature24277
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Auton A., 2015, NATURE, V7571, P68, DOI 10.1038/nature15393
   Beck T, 2014, EUR J HUM GENET, V22, P949, DOI 10.1038/ejhg.2013.274
   Brandl C, 2018, SCI REP, V8, P1
   Brandl C, 2019, INVEST OPHTH VIS SCI, V60, P1581, DOI 10.1167/iovs.18-25332
   Brandl C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167181
   Bryan JM, 2018, HUM MOL GENET, V27, P3325, DOI 10.1093/hmg/ddy239
   Bulik-Sullivan BK, 2015, NAT GENET, V47, P291, DOI 10.1038/ng.3211
   Bult CJ, 2019, NUCLEIC ACIDS RES, V47, pD801, DOI 10.1093/nar/gky1056
   Bycroft C, 2018, NATURE, V562, P203, DOI 10.1038/s41586-018-0579-z
   Canela-Xandri O, 2018, NAT GENET, V50, P1593, DOI 10.1038/s41588-018-0248-z
   Cardone J, 2011, CLIN EXP IMMUNOL, V164, P301, DOI 10.1111/j.1365-2249.2011.04400.x
   Cattaneo R, 2004, J VIROL, V78, P4385, DOI 10.1128/JVI.78.9.4385-4388.2004
   De Raadt A, 2019, ED PSYCHOL MEAS
   Devlin A. B., 2013, BIOMETRICS, V55, P997
   Fabregat A, 2018, NUCLEIC ACIDS RES, V46, pD649, DOI [10.1093/nar/gkx1132, 10.1093/nar/gkz1031]
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Forte R, 2012, ACTA OPHTHALMOL, V90, pE281, DOI 10.1111/j.1755-3768.2011.02331.x
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Galvan-Femenia I, 2018, J MED GENET, V55, P765, DOI 10.1136/jmedgenet-2018-105437
   Gao X, 2008, GENET EPIDEMIOL
   Gao XR, 2019, HUM MOL GENET, V28, P1162, DOI 10.1093/hmg/ddy422
   Garrity ST, 2018, INVEST OPHTH VIS SCI, V59, pAMD48, DOI 10.1167/iovs.18-24158
   Gorski M, 2019, GENET EPIDEMIOL, V43, P559, DOI 10.1002/gepi.22204
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Grassmann F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0418-0
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Guenther F, 2020, GENET EPIDEMIOL, V44, P759, DOI 10.1002/gepi.22336
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Han X, 2020, J HUM GENET, V10, P1
   Haralambieva IH, 2017, HUM GENET, V136, P421, DOI 10.1007/s00439-017-1768-9
   Harrer M., 2019, DOING METAANALYSIS R
   Higgins JPT., 2022, COCHRANE HDB SYSTEMA
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Hormozdiari F, 2016, AM J HUM GENET, V99, P1245, DOI 10.1016/j.ajhg.2016.10.003
   Huedo-Medina TB, 2006, PSYCHOL METHODS, V11, P193, DOI 10.1037/1082-989X.11.2.193
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kichaev G, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004722
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Korb CA, 2014, GRAEF ARCH CLIN EXP, V252, P1403, DOI 10.1007/s00417-014-2591-9
   Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377
   Lewis RA., 1993, GENEREVIEWS
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   MacArthur J, 2017, NUCLEIC ACIDS RES, V45, pD896, DOI 10.1093/nar/gkw1133
   McCarthy S, 2016, NAT GENET, V48, P1279, DOI 10.1038/ng.3643
   McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4
   oav B, 1995, J ROYAL STAT SOC B
   Ratnapriya R, 2019, NAT GENET, V51, P606, DOI 10.1038/s41588-019-0351-9
   SEYA T, 1989, BIOCHEM J, V264, P581, DOI 10.1042/bj2640581
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stokowski RP, 2007, AM J HUM GENET, V81, P1119, DOI 10.1086/522235
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Walter K, 2015, NATURE, V526, P82, DOI 10.1038/nature14962
   Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340
   Winkel T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207519
   Winkler TW, 2014, NAT PROTOC, V9, P1192, DOI 10.1038/nprot.2014.071
   Winkler TW, 2018, JOINT VIEW GENETIC V, P9
   Yang J, 2012, NAT GENET, V44, P369, DOI 10.1038/ng.2213
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Zhan XW, 2016, BIOINFORMATICS, V32, P1423, DOI 10.1093/bioinformatics/btw079
NR 61
TC 16
Z9 16
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1755-8794
J9 BMC MED GENOMICS
JI BMC Med. Genomics
PD AUG 26
PY 2020
VL 13
IS 1
AR 120
DI 10.1186/s12920-020-00760-7
PG 18
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA NJ7YC
UT WOS:000566257800001
PM 32843070
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Waldstein, SM
   Simader, C
   Staurenghi, G
   Chong, NV
   Mitchell, P
   Jaffe, GJ
   Lu, CX
   Katz, TA
   Schmidt-Erfurth, U
AF Waldstein, Sebastian M.
   Simader, Christian
   Staurenghi, Giovanni
   Chong, N. Victor
   Mitchell, Paul
   Jaffe, Glenn J.
   Lu, Chengxing
   Katz, Todd A.
   Schmidt-Erfurth, Ursula
TI Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for
   Neovascular Age-Related Macular Degeneration in the VIEW Trials
SO OPHTHALMOLOGY
LA English
DT Article
AB Purpose: To compare the efficacy of intravitreal aflibercept and ranibizumab on the exudative activity of neovascular age-related macular degeneration (nAMD) using optical coherence tomography (OCT) and to correlate morphologic findings with visual acuity (VA) outcomes.
   Design: Post hoc analysis of the prospective VIEW trials.
   Participants: Data of 1815 patients randomized to 0.5 mg ranibizumab every 4 weeks (Q4wks), 2 mg aflibercept Q4wks, or 2 mg aflibercept every 8 weeks (Q8wks).
   Methods: Standardized OCT evaluation was performed by masked reading centers for the presence of intraretinal cystoid fluid (IRC), subretinal fluid (SRF), and pigment epithelial detachment (PED). Rates of feature resolution were compared between drugs and regimen. Associations between morphologic features and VA were analyzed using multivariate modeling.
   Main Outcome Measures: Resolution rates of IRC, SRF, and PED, and associations between morphology and VA.
   Results: At baseline, the proportions of eyes with IRC, SRF, and PED were balanced between the aflibercept and ranibizumab groups. At week 12, IRC resolved in 50% of eyes with both agents. Subretinal fluid resolved in 70% of pooled aflibercept-treated eyes and in 59% of ranibizumab-treated eyes, and PED resolved in 29% and 24% of pooled aflibercept-treated eyes and ranibizumab-treated eyes, respectively. At week 52, IRC resolved in 57% (aflibercept Q4wks), 50% (aflibercept Q8wks), and 52% (ranibizumab) of patients; SRF resolved in 75% (both aflibercept Q4wks/Q8wks) and 66% (ranibizumab) of patients; and PED resolved in 40% (aflibercept Q4wks), 34% (aflibercept Q8wks), and 28% (ranibizumab) of patients. During fixed dosing (weeks 12-52) all exudative features showed synchronized fluctuations after treatment-free visits in the Q8wks aflibercept regimen. During pro re nata dosing (weeks 52-96), greater proportions of patients showed recurrent fluid in all treatment arms. Presence of IRC was generally associated with lower VA at baseline, which translated into poorer final VA outcomes.
   Conclusions: Fluid resolution in all compartments was consistently greater for aflibercept Q4wks than for aflibercept Q8wks and ranibizumab. At week 52, Q8wks aflibercept-treated eyes were, on average, as dry as or drier than with ranibizumab despite the extended treatment interval. Independent of agent or regimen, preexisting morphologic features of the retina at baseline markedly influenced VA outcomes. (C) 2016 by the American Academy of Ophthalmology.
C1 [Waldstein, Sebastian M.; Simader, Christian; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, Vienna Reading Ctr, Christian Doppler Lab Ophthalm Image Anal, Vienna, Austria.
   [Staurenghi, Giovanni] Univ Milan, Sch Ophthalmol 2, Sacco Hosp, Eye Clin,Dept Clin Sci Luigi Sacco, Milan, Italy.
   [Chong, N. Victor] Univ Oxford, Oxford Eye Hosp, Oxford, England.
   [Mitchell, Paul] Univ Sydney, Dept Ophthalmol, Sydney, NSW 2006, Australia.
   [Mitchell, Paul] Westmead Inst Med Res, Sydney, NSW, Australia.
   [Jaffe, Glenn J.] Duke Univ, Duke Reading Ctr, Durham, NC USA.
   [Lu, Chengxing; Katz, Todd A.] Bayer HealthCare, Whippany, NJ USA.
C3 Medical University of Vienna; University of Milan; Luigi Sacco Hospital;
   University of Oxford; University of Sydney; University of Sydney;
   Westmead Institute for Medical Research; Duke University; Bayer AG;
   Bayer Healthcare Pharmaceuticals
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Spitalgasse 23, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
RI Mitchell, Paul/P-1498-2014; Staurenghi, Giovanni/K-4388-2017; Chong,
   Victor/Q-6565-2018
OI Schmidt-Erfurth, Ursula/0000-0002-7788-7311; Staurenghi,
   Giovanni/0000-0002-2299-5251; Waldstein, Sebastian/0000-0003-2899-6279;
   Chong, Victor/0000-0002-7693-522X
FU Regeneron Pharmaceuticals, Inc. (Tarrytown, NY); Bayer HealthCare, Inc.
   (Whippany, NY)
FX Financial support was received from Regeneron Pharmaceuticals, Inc.
   (Tarrytown, NY) and Bayer HealthCare, Inc. (Whippany, NY), which
   conducted the VIEW trials and participated in data collection, data
   analysis, and review and approval of the manuscript.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Penha FM, 2013, RETINA-J RET VIT DIS, V33, P459, DOI 10.1097/IAE.0b013e31827d2657
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Ritter M, 2011, BRIT J OPHTHALMOL, V95, P381, DOI 10.1136/bjo.2009.175976
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schlegl Thomas, 2015, Inf Process Med Imaging, V24, P437, DOI 10.1007/978-3-319-19992-4_34
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Vogl Wolf-Dieter, 2015, Inf Process Med Imaging, V24, P152, DOI 10.1007/978-3-319-19992-4_12
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
NR 15
TC 90
Z9 94
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2016
VL 123
IS 7
BP 1521
EP 1529
DI 10.1016/j.ophtha.2016.03.037
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DP3KC
UT WOS:000378391100024
PM 27157149
DA 2022-11-30
ER

PT J
AU Riaz, M
   Lores-Motta, L
   Richardson, AJ
   Lu, Y
   Montgomery, G
   Omar, A
   Koenekoop, RK
   Chen, J
   Muether, P
   Altay, L
   Schick, T
   Fauser, S
   Smailhodzic, D
   van Asten, F
   de Jong, EK
   Hoyng, CB
   Burdon, KP
   MacGregor, S
   Guymer, RH
   den Hollander, AI
   Baird, PN
AF Riaz, Moeen
   Lores-Motta, Laura
   Richardson, Andrea J.
   Lu, Yi
   Montgomery, Grant
   Omar, Amer
   Koenekoop, Robert K.
   Chen, John
   Muether, Philipp
   Altay, Lebriz
   Schick, Tina
   Fauser, Sascha
   Smailhodzic, Dzenita
   van Asten, Freekje
   de Jong, Eiko K.
   Hoyng, Carel B.
   Burdon, Kathryn P.
   MacGregor, Stuart
   Guymer, Robyn H.
   den Hollander, Anneke I.
   Baird, Paul N.
TI GWAS study using DNA pooling strategy identifies association of variant
   rs4910623 in OR52B4 gene with anti-VEGF treatment response in
   age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; ENDOTHELIAL GROWTH-FACTOR; RANIBIZUMAB;
   SUSCEPTIBILITY; EXPRESSION
AB Pooled DNA based GWAS to determine genetic association of SNPs with visual acuity (VA) outcome in anti-vascular endothelial growth factor (anti-VEGF) treated neovascular age-related macular degeneration (nAMD) patients. We performed pooled DNA based GWAS on 285 anti-VEGF treated nAMD patients using high density Illumina 4.3 M array. Primary outcome was change in VA in Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 6 months of anti-VEGF treatment (patients who lost >= 5 ETDRS letters classified as non-responders and all remaining classified as responders). GWAS analysis identified 44 SNPs of interest: 37 with strong evidence of association (p < 9 x 10(-8)), 2 in drug resistance genes (p < 5 x 10(-6)) and 5 nonsynonymous changes (p < 1 x 10(-4)). In the validation phase, individual genotyping of 44 variants showed three SNPs (rs4910623 p = 5.6 x 10(-5), rs323085 p = 6.5 x 10(-4) and rs10198937 p = 1.30 x 10(-3)) remained associated with VA response at 6 months. SNP rs4910623 also associated with treatment response at 3 months (p = 1.5 x 10(-3)). Replication of these three SNPs in 376 patients revealed association of rs4910623 with poor VA response after 3 and 6 months of treatment (p = 2.4 x 10(-3) and p = 3.5 x 10(-2), respectively). Meta-analysis of both cohorts (673 samples) confirmed association of rs4910623 with poor VA response after 3 months (p = 1.2 x 10(-5)) and 6 months (p = 9.3 x 10(-6)) of treatment in nAMD patients.
C1 [Riaz, Moeen; Richardson, Andrea J.; Guymer, Robyn H.; Baird, Paul N.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Riaz, Moeen; Richardson, Andrea J.; Guymer, Robyn H.; Baird, Paul N.] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic 3010, Australia.
   [Lores-Motta, Laura; Smailhodzic, Dzenita; van Asten, Freekje; de Jong, Eiko K.; Hoyng, Carel B.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Donders Inst Brain Cognit & Behaviour, Nijmegen, Netherlands.
   [Lu, Yi; MacGregor, Stuart] QIMR Berghofer Med Res Inst, Stat Genet Lab, Brisbane, Qld, Australia.
   [Montgomery, Grant] QIMR Berghofer Med Res Inst, Mol Epidemiol, Brisbane, Qld, Australia.
   [Omar, Amer] Montreal Retina Inst, Westmount, PQ, Canada.
   [Koenekoop, Robert K.] McGill Univ, Ctr Hlth, Paediat Surg Human Genet & Ophthalmol, Montreal, PQ, Canada.
   [Chen, John] McGill Univ, Ctr Hlth, Dept Ophthalmol, Montreal, PQ, Canada.
   [Muether, Philipp; Altay, Lebriz; Schick, Tina; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
   [Burdon, Kathryn P.] Univ Tasmania, Menzies Inst Med Res, Hobart, Tas, Australia.
   [Burdon, Kathryn P.] Flinders Univ S Australia, Dept Ophthalmol, Adelaide, SA, Australia.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, Nijmegen, Netherlands.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Radboud University Nijmegen; QIMR Berghofer
   Medical Research Institute; QIMR Berghofer Medical Research Institute;
   McGill University; McGill University; University of Cologne; University
   of Tasmania; Menzies Institute for Medical Research; Flinders University
   South Australia; Radboud University Nijmegen
RP Baird, PN (通讯作者)，Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.; Baird, PN (通讯作者)，Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic 3010, Australia.
EM pnb@unimelb.edu.au
RI Koenekoop, Robert/AAT-6676-2021; Macgregor, Stuart/C-6442-2009; Omar,
   Amer/M-5342-2019; Burdon, Kathryn/AAD-2334-2022; Hollander, Anneke
   den/N-4911-2014; Burdon, Kathryn/A-5026-2009; van Asten,
   Freekje/P-6028-2015; Lu, Yi/G-9292-2018; de Jong, Eiko/P-3407-2015;
   Montgomery, Grant W/B-7148-2008
OI Macgregor, Stuart/0000-0001-6731-8142; Omar, Amer/0000-0003-1520-392X;
   Burdon, Kathryn/0000-0001-8217-1249; Burdon,
   Kathryn/0000-0001-8217-1249; van Asten, Freekje/0000-0002-8141-4234; Lu,
   Yi/0000-0001-9933-3654; de Jong, Eiko/0000-0001-6520-0407; Montgomery,
   Grant W/0000-0002-4140-8139; Baird, Paul/0000-0002-1305-3502;
   Lores-Motta, Laura/0000-0002-2423-9126; Guymer,
   Robyn/0000-0002-9441-4356
FU National Health and Medical Research Council of Australia (NHMRC)
   [1008979, 1028444]; University of Melbourne Australia; European Union's
   Seventh Framework Programme for research, technological development and
   demonstration [317472]; Foundation Fighting Blindness Canada; Canadian
   Institutes for Health Research
FX We thank all the clinicians, nurses and research staff who participated
   in patient recruitment. We acknowledge funding from the National Health
   and Medical Research Council of Australia (NHMRC) project grant 1008979
   and Senior Research Fellowship 1028444 (PNB). Melbourne International
   research Scholarship and Melbourne International fee remission
   scholarship from the University of Melbourne Australia (MR). The Centre
   for Eye Research Australia (CERA) receives Operational Infrastructure
   Support from the Victorian Government. This project has received funding
   from the European Union's Seventh Framework Programme for research,
   technological development and demonstration under grant agreement no.
   317472 (EyeTN). R.K. Koenekoop is supported by the Foundation Fighting
   Blindness Canada and the Canadian Institutes for Health Research.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Baylor DA, 1998, EYE, V12, P521, DOI 10.1038/eye.1998.140
   Earp MA, 2014, HUM GENET, V133, P481, DOI 10.1007/s00439-013-1383-3
   Fauser S, 2015, SURV OPHTHALMOL, V60, P138, DOI 10.1016/j.survophthal.2014.11.002
   Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Flower DR, 1999, BBA-REV BIOMEMBRANES, V1422, P207, DOI 10.1016/S0304-4157(99)00006-4
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Hagstrom SA, 2015, OPHTHALMOLOGY, V122, P1563, DOI 10.1016/j.ophtha.2015.04.024
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kim SH, 2015, BIOCHEM BIOPH RES CO, V460, P404, DOI 10.1016/j.bbrc.2015.03.046
   Leveziel N, 2010, INVEST OPHTH VIS SCI, V51, P2620, DOI 10.1167/iovs.09-4423
   Lores-Motta L, 2016, PHARMACOGENET GENOM, V26, P20, DOI 10.1097/FPC.0000000000000180
   Lu Y, 2012, TWIN RES HUM GENET, V15, P615, DOI 10.1017/thg.2012.38
   Macgregor S, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl136
   Macgregor S, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkm1060
   Macgregor S, 2007, EUR J HUM GENET, V15, P501, DOI 10.1038/sj.ejhg.5201768
   Marchler-Bauer A, 2015, NUCLEIC ACIDS RES, V43, pD222, DOI 10.1093/nar/gku1221
   Pearson JV, 2007, AM J HUM GENET, V80, P126, DOI 10.1086/510686
   Pluznick JL, 2013, P NATL ACAD SCI USA, V110, P4410, DOI 10.1073/pnas.1215927110
   Pronin A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096435
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schrauwen I, 2009, AM J HUM GENET, V84, P328, DOI 10.1016/j.ajhg.2009.01.023
   Sherva R, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-51
   Skibola CF, 2009, NAT GENET, V41, P873, DOI 10.1038/ng.419
   Solovieff N, 2010, BLOOD, V115, P1815, DOI 10.1182/blood-2009-08-239517
   Tsilimbaris MK, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4367631
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wagner AH, 2013, EXP EYE RES, V111, P105, DOI 10.1016/j.exer.2013.03.004
   Ward LD, 2012, NUCLEIC ACIDS RES, V40, pD930, DOI 10.1093/nar/gkr917
   Wei P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046887
   Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340
NR 40
TC 16
Z9 16
U1 1
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 28
PY 2016
VL 6
AR 37924
DI 10.1038/srep37924
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ED0XR
UT WOS:000388567700001
PM 27892514
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Berg, K
   Pedersen, TR
   Sandvik, L
   Bragadottir, R
AF Berg, Karina
   Pedersen, Terje R.
   Sandvik, Leiv
   Bragadottir, Ragnheidur
TI Comparison of Ranibizumab and Bevacizumab for Neovascular Age-Related
   Macular Degeneration According to LUCAS Treat-and-Extend Protocol
SO OPHTHALMOLOGY
LA English
DT Article
ID TRIAL
AB Purpose: To compare the efficacy and safety of bevacizumab versus ranibizumab when administered according to a treat-and-extend protocol for the treatment of neovascular age-related macular degeneration (AMD).
   Design: Multicenter, randomized, noninferiority trial with a noninferiority limit of 5 letters.
   Participants: Patients aged >= 50 years with previously untreated neovascular AMD in 1 eye and best-corrected visual acuity (BCVA) between 20/25 and 20/320.
   Methods: Patients were randomly assigned to receive ranibizumab 0.5 mg or bevacizumab 1.25 mg intra-vitreal injections. Monthly injections were given until inactive disease was achieved. The patients were then followed with a gradual extension of treatment interval by 2 weeks at a time up to a maximum of 12 weeks. If signs of recurrent disease appeared, the treatment interval was shortened by 2 weeks at a time.
   Main Outcome Measures: Change in visual acuity at 1 year.
   Results: Between March 2009 and July 2012, 441 patients were randomized at 10 ophthalmological centers in Norway. The 1-year visit was completed by 371 patients. In the per protocol analysis at 1 year, bevacizumab was equivalent to ranibizumab, with 7.9 and 8.2 mean letters gained, respectively (95% confidence interval [CI] of mean difference, -2.4 to 2.9; P = 0.845). The intention-to-treat analysis was concordant. There was no significant difference in measured central retinal thickness (CRT), with a mean decrease of -112 mu m for bevacizumab and -120 mu m for ranibizumab (95% CI of mean difference, -13 to 28; P = 0.460). There was a statistically significant difference (P = 0.001) between the drugs regarding the number of treatments: 8.9 for bevacizumab and 8.0 for ranibizumab. There were fewer arteriothrombotic events in the bevacizumab group (1.4%) than in the ranibizumab group (4.5%) (P = 0.050) and significantly more cardiac events in the ranibizumab group (P = 0.036). However, patients treated with ranibizumab more often had a history of myocardial infarction (P = 0.021).
   Conclusions: Bevacizumab and ranibizumab had equivalent effects on visual acuity at 1 year when administered according to a treat-and-extend protocol. The visual acuity results at 1 year were comparable to those of other clinical trials with monthly treatment. The numbers of serious adverse events were small. (C) 2015 by the American Academy of Ophthalmology.
C1 [Berg, Karina; Bragadottir, Ragnheidur] Oslo Univ Hosp, Dept Ophthalmol, Oslo, Norway.
   [Berg, Karina; Pedersen, Terje R.; Bragadottir, Ragnheidur] Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway.
   [Pedersen, Terje R.] Oslo Univ Hosp, Dept Endocrinol Morbid Obes & Prevent Med, Oslo, Norway.
   [Sandvik, Leiv] Oslo Univ Hosp, Dept Stat Epidemiol & Hlth Econ, Oslo, Norway.
C3 University of Oslo; University of Oslo; University of Oslo; University
   of Oslo
RP Bragadottir, R (通讯作者)，Oslo Univ Hosp, Dept Ophthalmol, Oslo, Norway.
EM ragnheib@medisin.uio.no
FU Oslo University Hospital, Oslo, Norway
FX Funded by the Oslo University Hospital, Oslo, Norway. The funding
   organization had no role in the design of the study but aided in the
   conduct of the study and data management.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Spaide RF, 2009, AM J OPHTHALMOL, V148, P1, DOI 10.1016/j.ajo.2009.04.010
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
NR 13
TC 259
Z9 269
U1 0
U2 22
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2015
VL 122
IS 1
BP 146
EP 152
DI 10.1016/j.ophtha.2014.07.041
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AX1XK
UT WOS:000346737000031
PM 25227499
OA Bronze
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Abedi, F
   Wickremasinghe, S
   Richardson, AJ
   Islam, AFM
   Guymer, RH
   Baird, PN
AF Abedi, Farshad
   Wickremasinghe, Sanjeewa
   Richardson, Andrea J.
   Islam, Amirul F. M.
   Guymer, Robyn H.
   Baird, Paul N.
TI Genetic Influences on the Outcome of Anti-Vascular Endothelial Growth
   Factor Treatment in Neovascular Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; HTRA1 GENE; INTRAVITREAL RANIBIZUMAB; PHOTODYNAMIC
   THERAPY; STRONG ASSOCIATION; VARIANT; RISK; SUSCEPTIBILITY;
   POLYMORPHISMS; LOC387715
AB Purpose: To determine the association of genetic variants in known age-related macular degeneration (AMD) risk-associated genes with outcome of anti-vascular endothelial growth factor (VEGF) treatment in neovascular AMD.
   Design: Prospective cohort study.
   Participants: We enrolled 224 consecutive patients with neovascular AMD at the Royal Victorian Eye and Ear Hospital, Australia.
   Methods: Patients were treated with 3 initial monthly ranibizumab or bevacizumab injections followed by 9 months of "as required" injections based on clinician's decision at each follow-up visit according to retreatment criteria. Seventeen single nucleotide polymorphisms (SNPs) in known AMD risk-associated genes including CFH (rs800292, rs3766404, rs1061170, rs2274700 and rs393955), HTRA1 (rs11200638), CFHR1-5 (rs10922153, rs16840639, rs6667243, and rs1853883), LOC387715/ARMS2 (rs3793917 and rs10490924), C3 (rs2230199 and rs1047286), C2 (rs547154), CFB (rs641153) and F13B (rs6003) were examined. Multivariate analysis was used to determine the role of each SNP in treatment outcome.
   Main Outcome Measures: The influence of selected SNPs on mean change in visual acuity (VA) at 12 months.
   Results: Mean baseline VA was 51 +/- 16.8 Early Treatment Diabetic Retinopathy Study letters. Overall, the mean change in VA from baseline was +3.2 +/- 14.9 letters at 12 months. The AA (homozygote risk) genotype at rs11200638 - HTRA1 promoter SNP (P = 0.001) and GG (homozygote risk) genotype at rs10490924 (A69S) in LOC387715/ARMS2 (P = 0.002) were each significantly associated with poorer VA outcome at 12 months after multiple correction. Mean +/- standard deviation change in VA from baseline in patients with AA genotype at rs11200638 was -2.9 +/- 15.2 letters after 12 months compared with +5.1 +/- 14.1 letters in patients with AG or GG genotypes at this SNP. Patients with either of these genotypes were also significantly more likely to lose > 15 letters after 12 months. SNPs rs11200638 and rs10490924 were in high linkage disequilibrium (r(2) = 0.92). None of the other examined SNPs was associated with outcome.
   Conclusions: The HTRA1 promoter SNP (rs11200638) and A69S at LOC387715/ARMS2 were associated with a poorer visual outcome for ranibizumab or bevacizumab treatment in neovascular AMD, suggesting strong pharmacogenetic associations with anti-VEGF treatment. This finding could aid in applying more individualized treatment regimens based on patients' genotype to achieve optimal treatment response in AMD. (C) 2013 by the American Academy of Ophthalmology.
C1 [Abedi, Farshad; Wickremasinghe, Sanjeewa; Richardson, Andrea J.; Islam, Amirul F. M.; Guymer, Robyn H.; Baird, Paul N.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 3010, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Abedi, F (通讯作者)，Ctr Eye Res Australia, 32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM abedifarshad@yahoo.com
RI Islam, Fakir M Amirul/P-6665-2015
OI Islam, Fakir M Amirul/0000-0003-3897-3302; Baird,
   Paul/0000-0002-1305-3502; Guymer, Robyn/0000-0002-9441-4356
FU National Health and Medical Research Council (NHMRC) [590205, 1008979,
   529923, 529905, 1028444]; Macular Vision Loss Support Society of
   Australia
FX Funded by the National Health and Medical Research Council (NHMRC)
   project grants 590205 and 1008979, an NHMRC- Clinical Research
   Excellence grant 529923 - Translational Clinical Research in Major Eye
   Diseases, NHMRC practitioner fellowship 529905 (R.H.G.), NHMRC Senior
   Research Fellowship 1028444 (P.N.B.), and the Macular Vision Loss
   Support Society of Australia. The Centre for Eye Research Australia
   (CERA) receives Operational Infrastructure Support from the Victorian
   Government. The sponsor or funding organizations had no role in the
   design or conduct of this research.
CR Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fuse N, 2011, AM J OPHTHALMOL, V151, P550, DOI 10.1016/j.ajo.2010.08.048
   Gibbs D, 2008, VISION RES, V48, P685, DOI 10.1016/j.visres.2007.10.022
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jiang H, 2009, RETINA-J RET VIT DIS, V29, P974, DOI 10.1097/IAE.0b013e3181a3b90e
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Lepre T, 2011, AM J OPHTHALMOL, V152, P325, DOI 10.1016/j.ajo.2011.04.021
   Leveziel N, 2010, M S-MED SCI, V26, P509
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Richardson AJ, 2010, INVEST OPHTH VIS SCI, V51, P4932, DOI 10.1167/iovs.09-5114
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Shuler RK, 2008, AM J OPHTHALMOL, V145, P303, DOI 10.1016/j.ajo.2007.09.027
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Soysal Y, 2012, DNA CELL BIOL, V31, P322, DOI 10.1089/dna.2011.1214
   Tang NP, 2009, ANN EPIDEMIOL, V19, P740, DOI 10.1016/j.annepidem.2009.03.002
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tocharus J, 2004, DEV GROWTH DIFFER, V46, P257
   Tong Y, 2010, MOL VIS, V16, P1958
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zhang L, 2012, J BIOL CHEM, V287, P1520, DOI 10.1074/jbc.M111.275990
NR 38
TC 56
Z9 59
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2013
VL 120
IS 8
BP 1641
EP 1648
DI 10.1016/j.ophtha.2013.01.014
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 196LW
UT WOS:000322778000026
PM 23582991
DA 2022-11-30
ER

PT J
AU McKeague, C
   Margrain, TH
   Bailey, C
   Binns, AM
AF McKeague, Claire
   Margrain, Tom H.
   Bailey, Clare
   Binns, Alison M.
TI Low-level night-time light therapy for age-related macular degeneration
   (ALight): study protocol for a randomized controlled trial
SO TRIALS
LA English
DT Article
DE Age-related macular degeneration; Biomarker; Hypoxia; Light mask;
   Randomized controlled trial
ID DARK-ADAPTATION; CHROMATIC SENSITIVITY; NEURORETINAL FUNCTION; VISUAL
   IMPAIRMENT; NATURAL-HISTORY; PERFUSION; HYPOXIA; TRANSMISSION;
   MACULOPATHY; PREVENTION
AB Background: Age-related macular degeneration (AMD) is the leading cause of blindness among older adults in the developed world. The only treatments currently available, such as ranibizumab injections, are for neovascular AMD, which accounts for only 10 to 15% of people with the condition. Hypoxia has been implicated as one of the primary causes of AMD, and is most acute at night when the retina is most metabolically active. By increasing light levels at night, the metabolic requirements of the retina and hence the hypoxia will be considerably reduced. This trial seeks to determine whether wearing a light mask that emits a dim, green light during the night can prevent the progression of early AMD.
   Methods/design: ALight is a Phase I/IIa, multicentre, randomized controlled trial. Sixty participants (55 to 88 years old) with early AMD in one eye and neovascular AMD (nAMD) in the fellow eye will be recruited from nAMD clinics. They will be randomized (in the ratio 1:1), either to receive the intervention or to be in the untreated control group, stratified according to risk of disease progression. An additional 40 participants with healthy retinal appearance, or early AMD only, will be recruited for a baseline cross-sectional analysis. The intervention is an eye mask that emits a dim green light to illuminate the retina through closed eyelids at night. This is designed to reduce the metabolic activity of the retina, thereby reducing the potential risk of hypoxia. Participants will wear the mask every night for 12 months. Ophthalmologists carrying out monthly assessments will be masked to the treatment group, but participants will be aware of their treatment group. The primary outcome measure is the proportion of people who show disease progression during the trial period in the eye with early AMD. A co-primary outcome measure is the rate of retinal adaptation. As this is a trial of a CE-marked device for an off-label indication, a further main aim of this trial is to assess safety of the mask in the cohort of participants with AMD.
C1 [McKeague, Claire; Margrain, Tom H.; Binns, Alison M.] Cardiff Univ, Sch Optometry & Vis Sci, Cardiff CF24 4LU, S Glam, Wales.
   [Bailey, Clare] Bristol Eye Hosp, Bristol BS1 2LX, Avon, England.
   [Binns, Alison M.] City Univ London, Sch Hlth Sci, Div Optometry & Visual Sci, London EC1V 0HB, England.
C3 Cardiff University; Bristol Eye Hospital; City University London
RP Binns, AM (通讯作者)，Cardiff Univ, Sch Optometry & Vis Sci, Cardiff CF24 4LU, S Glam, Wales.
EM alison.binns.1@city.ac.uk
OI Margrain, Tom/0000-0003-1280-0809; Binns, Alison/0000-0001-8621-498X
FU College of Optometrists, UK
FX This trial is funded by a research grant from the College of
   Optometrists, UK. The device manufacturer, Polyphotonix Medical Ltd, is
   providing the light masks and technical support for the trial free of
   charge. Both the College of Optometrists and Polyphotonix have the right
   to review manuscripts bearing their name before publication, but the
   chief investigator has ultimate authority over the protocol, trial
   conduct and content of any publications.
CR AHMED J, 1993, INVEST OPHTH VIS SCI, V34, P516
   Ando K, 1996, BIOL PSYCHIAT, V39, P22, DOI 10.1016/0006-3223(95)00109-3
   [Anonymous], 1500422007 BS EN ISO
   Arden GB, 2011, EYE, V25, P1546, DOI 10.1038/eye.2011.264
   Arden GB, 2010, EYE, V24, P1149, DOI 10.1038/eye.2009.328
   Arden GB, 2001, BRIT J OPHTHALMOL, V85, P366, DOI 10.1136/bjo.85.3.366
   Bjelakovic G, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD007176.pub2, 10.1590/1516-3180.20151332T1]
   BRINCHMANNHANSEN O, 1989, AVIAT SPACE ENVIR MD, V60, P1183
   Bunce C, 2010, EYE LOND, V24, P1692, DOI DOI 10.1038/EYE.2010.122
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   Ciulla TA, 2001, ACTA OPHTHALMOL SCAN, V79, P108, DOI 10.1034/j.1600-0420.2001.079002108.x
   Connolly DM, 2008, INVEST OPHTH VIS SCI, V49, P820, DOI 10.1167/iovs.07-1004
   Connolly DM, 2006, VISION RES, V46, P1784, DOI 10.1016/j.visres.2005.10.027
   Connolly DM, 2009, OPTOMETRY VISION SCI, V86, P1368, DOI 10.1097/OPX.0b013e3181be9d89
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   DargentMolina P, 1996, LANCET, V348, P145, DOI 10.1016/S0140-6736(96)01440-7
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Economics A, 2009, EC A FUT SIGHT LOSS
   Feigl B, 2008, INVEST OPHTH VIS SCI, V49, P807, DOI 10.1167/iovs.07-0994
   Feigl B, 2007, CLIN EXP OPTOM, V90, P263, DOI 10.1111/j.1444-0938.2007.00152.x
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Gaffney AJ, 2011, OPTOMETRY VISION SCI, V88, P1080, DOI 10.1097/OPX.0b013e3182223697
   HAGINS WA, 1989, P NATL ACAD SCI USA, V86, P1224, DOI 10.1073/pnas.86.4.1224
   Karakucuk S, 2004, AVIAT SPACE ENVIR MD, V75, P364
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Margrain TH, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-57
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   MOSELEY MJ, 1988, OPHTHAL PHYSL OPT, V8, P229, DOI 10.1111/j.1475-1313.1988.tb01043.x
   Neelam K, 2008, OPHTHAL EPIDEMIOL, V15, P389, DOI 10.1080/09286580802154275
   O'Neill-Biba M, 2010, OPHTHAL PHYSL OPT, V30, P705, DOI 10.1111/j.1475-1313.2010.00775.x
   Pavlidis M, 2005, OPHTHALMOLOGICA, V219, P404, DOI 10.1159/000088387
   REMULLA JFC, 1995, BRIT J OPHTHALMOL, V79, P558, DOI 10.1136/bjo.79.6.558
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   ROBINSON J, 1991, VISION RES, V31, P1837, DOI 10.1016/0042-6989(91)90031-Y
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Stelmack JA, 2004, INVEST OPHTH VIS SCI, V45, P3919, DOI 10.1167/iovs.04-0208
   Tinjust D, 2002, AVIAT SPACE ENVIR MD, V73, P1189
   VINGRYS AJ, 1987, DOC OPHTHALMOL, V66, P171, DOI 10.1007/BF00140454
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   WINN B, 1994, INVEST OPHTH VIS SCI, V35, P1132
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wyszechki G, 1982, COLOUR SCI CONCEPTS
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
NR 52
TC 11
Z9 15
U1 1
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1745-6215
J9 TRIALS
JI Trials
PD JUN 24
PY 2014
VL 15
AR 246
DI 10.1186/1745-6215-15-246
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA AL4BQ
UT WOS:000339078200001
PM 24965385
OA Green Published, Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Scorolli, L
   Corazza, D
   Morara, M
   Vismara, S
   Lugaresi, ML
   Meduri, RA
AF Scorolli, L
   Corazza, D
   Morara, M
   Vismara, S
   Lugaresi, ML
   Meduri, RA
TI Argon laser vs. subthreshold infrared (810-nm) diode laser macular grid
   photocoagulation in nonexudative age-related macular degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
DE argon laser photocoagulation; infrared (810-nm) diode laser
   photocoagulation; drusen; age-related macular degeneration
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RISK-FACTORS; DRUSEN;
   MACULOPATHY; PROGNOSIS
AB Background: A diode laser can be used to create a subthreshold (invisible end point) lesion in patients with age-related macular degeneration (AMD). This has the potential benefit of localizing the treatment effect to the retinal pigment epithelium and sparing more of the overlying sensory retina. We performed a study to compare the safety and efficacy of argon laser and subthreshold infrared (810-nm) diode laser macular grid photocoagulation in reducing the number of drusen in patients with AMD.
   Methods: We reviewed the charts of 144 patients with bilateral early-stage nonexudative AMD, characterized by soft drusen. One eye of each patient was treated, and the other eye served as a control. Seventy-eight eyes of 78 patients with a mean age of 67.5 (standard deviation [SD] 8.3) years underwent argon laser macular grid photocoagulation at a university-affiliated hospital in Bologna, Italy, and 66 eyes of 66 patients with a mean age of 66.4 (SD 6.3) years underwent subthreshold infrared (810-nm) diode laser macular grid photocoagulation at a private clinic in Bologna. Each group was classified into three subgroups based on the number of drusen (more than 20, 10 to 20, or less than 10). The patients underwent fluorescein angiography, fundus examination, measurement of far (Snellen chart) and near (Jaeger chart) best corrected visual acuity, and visual field and contrast sensitivity testing. The mean length of follow-up was 18 (SD 0.5) months.
   Results: At 18 months, far and near best corrected visual acuity were statistically significantly improved in the treatment groups compared with the untreated group (p < 0.001, Mann-Whitney U test). There was no significant difference in visual acuity between the treatment groups. Compared with baseline, the number of drusen was significantly reduced in both treatment groups (p < 0.001). Evolution of the disease was observed in the untreated group. The visual field was slightly but significantly reduced after argon laser treatment (p < 0.001) but not, diode laser treatment; the difference in visual field between the two groups was not significant. There was a slight reduction in contrast sensitivity, particularly with night vision, after argon laser treatment but not diode laser treatment. The difference between the two treatment groups was significant (p < 0.01).
   Interpretation: Subthreshold infrared diode macular grid photocoagulation may be a safe and viable method for preventing progression of nonexudative AMD.
C1 Univ Bologna, St Orsola Malpighi Hosp, Dept Pathophysiol Opt, Bologna, Italy.
   Univ Bologna, St Orsola Malpighi Hosp, Dept Surg Intens Care & Organ Transplantat, Bologna, Italy.
C3 IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of
   Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University
   of Bologna
RP Scorolli, L (通讯作者)，Via Zuccardi Merli 1, I-40141 Bologna, Italy.
RI Lugaresi, Marialuisa/ABC-7320-2021
OI Lugaresi, Marialuisa/0000-0002-0965-9595
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   BRESSLER SB, 1999, RETINAVITREOUS MACUL, P75
   Cleasby G W, 1979, Mod Probl Ophthalmol, V20, P141
   COSCAS G, 2001, TERAPIA MACULOPATIE, P11
   DORIN G, 2001, TERAPIA MACULOPATIE, P81
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   FRENNESSON IC, 1995, BRIT J OPHTHALMOL, V79, P905, DOI 10.1136/bjo.79.10.905
   Gass J D, 1971, Trans Am Acad Ophthalmol Otolaryngol, V75, P580
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   ORZALESI N, 1991, DEGENERAZIONE MACULA, P113
   RICCI R, 1998, ANN OTTAMOL CLIN OCU, V124, P293
   Rodanant N, 2002, AM J OPHTHALMOL, V134, P577, DOI 10.1016/S0002-9394(02)01691-4
NR 17
TC 13
Z9 19
U1 0
U2 0
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD OCT
PY 2003
VL 38
IS 6
BP 489
EP 495
DI 10.1016/S0008-4182(03)80028-5
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 733LL
UT WOS:000186001700007
PM 14620037
DA 2022-11-30
ER

PT J
AU Altunel, O
   Ozsaygili, C
AF Altunel, Orhan
   Ozsaygili, Cemal
TI Assessment of choriocapillaris/Sattler and Haller layer changes after
   intravitreal injection in eyes with neovascular age-related macular
   degeneration: aflibercept vs ranibizumab
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; Choriocapillaris; Sattler layer; Haller layer; Neovascular
   age-related macular degeneration; Ranibizumab
ID ENDOTHELIAL GROWTH-FACTOR; SUBFOVEAL CHOROIDAL THICKNESS; THERAPY; VEGF
AB Purpose To evaluate the changes in choriocapillaris (CC)/Sattler and Haller layer thicknesses in eyes with neovascular age-related macular degeneration (nAMD) after aflibercept or ranibizumab injections. Study design Retrospective. Methods A total of 70 eyes of 70 patients with treatment-naive exudative nAMD were treated with 3 consecutive injections of aflibercept (IVA) or ranibizumab (IVR). CC/Sattler and Haller layer thicknesses were measured at the nasal and temporal regions 1000 mu m from the center of the fovea by enhanced-depth imaging optical coherence tomography at baseline and after the 3 monthly intravitreal injections. In addition, the hyperfluorescence region (HF) was measured as the largest horizontal diameter of the hyperfluorescence area on the early-middle phase fluorescein angiographic images at baseline and after the 3 loading doses. Results After the 3 consecutive injections, the mean reductions in the nasal/temporal CC/Sattler layer thicknesses in the IVR and IVA groups were - 10.1 +/- 2.3/ - 8.5 +/- 1.8 and - 25.2 +/- 15.2/ - 19.4 +/- 12.8 mu m, respectively. Also, the mean reductions in the nasal/temporal Haller layer thicknesses in the IVR and IVA groups were - 6.5 +/- 3.6/ - 7.2 +/- 7.9 and - 9.5 +/- 8.0/ - 7.0 +/- 6.2 mu m, respectively. The changes in the CC/Sattler layer thicknesses of the IVA group were greater than those of the IVR group (P < .001); however, the changes in the Haller layer thickness were similar between the groups (P > .05). The mean decrease in the HF size of the IVA group was greater than that of the IVR group (P < .001). Conclusions Aflibercept treatment has a more pronounced effect on the CC/Sattler layer. Such results may indicate that aflibercept treatment influences choroidal neovascularization, possibly by reducing the capillary permeability associated with active neovascularization in the CC layer.
C1 [Altunel, Orhan] Kutahya Hlth Sci Univ, Sch Med, Dept Ophthalmol, Kutahya, Turkey.
   [Ozsaygili, Cemal] Kayseri City Educ & Res Hosp, Dept Ophthalmol, Kayseri, Turkey.
C3 Kutahya Health Sciences University
RP Altunel, O (通讯作者)，Kutahya Hlth Sci Univ, Sch Med, Dept Ophthalmol, Kutahya, Turkey.
EM orhanaltunel@hotmail.com
RI OZSAYGILI, CEMAL/AAH-3081-2019
OI OZSAYGILI, CEMAL/0000-0002-8236-1728
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Branchini L, 2013, JAMA OPHTHALMOL, V131, P693, DOI 10.1001/jamaophthalmol.2013.692
   Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Dell'Omo R, 2012, AM J OPHTHALMOL, V153, P155, DOI 10.1016/j.ajo.2011.06.001
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gharbiya M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273754
   Hata M, 2014, INVEST OPHTH VIS SCI, V55, P7874, DOI 10.1167/iovs.14-14610
   Inan S, 2019, CURR EYE RES, V44, P908, DOI 10.1080/02713683.2019.1600195
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kaya F, 2017, J FR OPHTALMOL, V40, P832, DOI 10.1016/j.jfo.2017.04.014
   Kim JH, 2015, INVEST OPHTH VIS SCI, V56, P1909, DOI 10.1167/iovs.14-16000
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Korb CA, 2014, GRAEF ARCH CLIN EXP, V252, P1403, DOI 10.1007/s00417-014-2591-9
   Lee H, 2020, RETINA-J RET VIT DIS, V40, P1704, DOI 10.1097/IAE.0000000000002678
   Lipecz A, 2019, GEROSCIENCE, V41, P813, DOI 10.1007/s11357-019-00138-3
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Razavi S, 2015, AM J OPHTHALMOL, V160, P1006, DOI 10.1016/j.ajo.2015.08.009
   Sacu S, 2011, INVEST OPHTH VIS SCI, V52, P3046, DOI 10.1167/iovs.10-5842
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P1693, DOI 10.1007/s00417-015-3260-3
NR 31
TC 0
Z9 0
U1 0
U2 11
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAR
PY 2022
VL 66
IS 2
BP 159
EP 166
DI 10.1007/s10384-021-00894-w
EA JAN 2022
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZI3VQ
UT WOS:000738421700001
PM 34982296
DA 2022-11-30
ER

PT J
AU Faatz, H
   Rothaus, K
   Ziegler, M
   Book, M
   Spital, G
   Heimes-Bussmann, B
   Pauleikhoff, D
   Lommatzsch, A
AF Faatz, Henrik
   Rothaus, Kai
   Ziegler, Martin
   Book, Marius
   Spital, Georg
   Heimes-Bussmann, Britta
   Pauleikhoff, Daniel
   Lommatzsch, Albrecht
TI Correlation of retinal alterations with vascular structure of macular
   neovascularisation in swept-source optical coherence tomography
   angiography in age-related macular degeneration
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE MNV-morphology; Imaging; Age-related macular degeneration;
   OCT-angiography; Choroidal neovascularization
ID CHOROIDAL NEOVASCULARIZATION; SUBRETINAL HEMORRHAGE; IDENTIFICATION;
   OUTCOMES
AB Purpose The aim of this study was to find out whether the vascular architecture of untreated macular neovascularisations (MNV) in neovascular age-related macular degeneration (nAMD) as visualised with optic coherence tomography angiography (OCTA) is associated with functional and known morphological alterations of the retina in optic coherence tomography (SD-OCT). Methods The study design was retrospective with consecutive patient inclusion. In 107 patients with newly diagnosed nAMD, MNV were detected by means of OCTA and automated quantitative vascular analysis was performed. The MNV characteristics measured were area, flow density, total vascular length (sumL), density of vascular nodes (numN), fractal dimension (FD) and average vascular width (avgW). These parameters were assessed for associations with vision (BCVA), central retinal thickness (CRT), fluid distribution, the elevation of any pigment epithelial detachment (PED), the occurrence of subretinal haemorrhage and atrophy. Results BCVA was significantly worse with greater MNV area and sumL. Fluid distribution differed significantly in relation to area (p < 0.005), sumL (p < 0.005) and FD (p = 0.001). Greater PED height was significantly associated with higher numN (p < 0.05) and lower avgW (p < 0.05). Atrophy was present significantly more often in MNV with larger area (p < 0.05), higher sumL (p < 0.05) and higher flow density (p = 0.002). None of the MNV parameters had a significant association with CRT or the occurrence of haemorrhage. Conclusion OCTA is not restricted to evaluation of secondary changes but offers the opportunity to analyse the vascular structure of MNV in detail. Differences in vascular morphology are associated with certain secondary changes in retinal morphology. There are thus grounds for optimism that further research may identify and classify OCTA-based markers to permit more individualised treatment of nAMD.
C1 [Faatz, Henrik; Rothaus, Kai; Ziegler, Martin; Book, Marius; Spital, Georg; Heimes-Bussmann, Britta; Pauleikhoff, Daniel; Lommatzsch, Albrecht] St Franziskus Hosp, Dept Ophthalmol, Munster, Germany.
   [Faatz, Henrik; Pauleikhoff, Daniel; Lommatzsch, Albrecht] Univ Hosp Duisburg Essen, Achim Wessing Inst Imaging Ophthalmol, Essen, Germany.
   [Pauleikhoff, Daniel; Lommatzsch, Albrecht] Univ Duisburg Essen, Dept Ophthalmol, Essen, Germany.
C3 St. Franziskus-Hospital; University of Duisburg Essen; University of
   Duisburg Essen
RP Faatz, H (通讯作者)，St Franziskus Hosp, Dept Ophthalmol, Munster, Germany.
EM henrik.faatz@augen-franziskus.de
OI Faatz, Henrik/0000-0002-5363-0052; Heimes-Bussmann,
   Britta/0000-0003-3898-1679
FU Dr. Werner Jackstadt-Foundation
FX We would like to gratefully acknowledge the support of the Dr. Werner
   Jackstadt-Foundation for our research project.
CR ALSHEIKH M, 2017, RETINA PHILADELPHIA
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, P3240, DOI 10.1167/iovs.16-21053
   Brucher VC, 2020, GRAEF ARCH CLIN EXP, V258, P701, DOI 10.1007/s00417-019-04553-2
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   COLIJN J, 2017, OPHTHALMOLOGY
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Faatz H, 2021, OPHTHALMOLOGE, V118, P154, DOI 10.1007/s00347-020-01136-z
   Faatz H, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000369
   Faatz H, 2019, EYE, V33, P1466, DOI 10.1038/s41433-019-0429-8
   Grechenig C, 2021, RETINA-J RET VIT DIS, V41, P2221, DOI 10.1097/IAE.0000000000003180
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Karampelas M, 2020, OPHTHALMOL THER, V9, P739, DOI 10.1007/s40123-020-00291-5
   KODJIKIAN L, 2021, OPHTHALMOL RETINA, P135
   Nakano Y, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216304
   NOVOTNY HR, 1961, CIRCULATION, V24, P82, DOI 10.1161/01.CIR.24.1.82
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Steinle NC, 2021, OPHTHALMOL RETINA, V5, P141, DOI 10.1016/j.oret.2020.07.003
   Sulzbacher F, 2017, ACTA OPHTHALMOL, V95, P414, DOI 10.1111/aos.13364
   Team RC, 2013, R LANG ENV STAT COMP
   Told R, 2021, CURR EYE RES, V46, P1002, DOI 10.1080/02713683.2020.1849734
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Wang R, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1163-5
   Ying GS, 2016, OPHTHALMOLOGY, V123, P352, DOI 10.1016/j.ophtha.2015.09.046
   Zhang QQ, 2017, OPHTHALMOL RETINA, V1, P124, DOI 10.1016/j.oret.2016.08.005
NR 30
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD MAY
PY 2022
VL 42
IS 5
BP 1553
EP 1562
DI 10.1007/s10792-021-02149-6
EA JAN 2022
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1J8UR
UT WOS:000742263100001
PM 35028773
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Chen, H
   Mo, M
   Liu, GY
   Gong, YM
   Yu, KD
   Xu, GZ
AF Chen, Han
   Mo, Miao
   Liu, Guang-Yu
   Gong, Yang-Ming
   Yu, Ke-Da
   Xu, Ge-Zhi
TI Interaction of two functional genetic variants LOXL1 rs1048661 and VEGFA
   rs3025039 on the risk of age-related macular degeneration in Chinese
   women
SO ANNALS OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Single-nucleotide polymorphism (SNP); gene-gene interaction; LOXL1;
   VEGFA; age-related macular degeneration
ID POLYMORPHISMS
AB Background: Cumulative evidence indicates that LOXL1 and VEGF-a play important roles in extracellular matrix formation and angiogenesis, respectively. The disorder of extracellular matrix and angiogenesis are the key factors of pathogenesis of age-related macular degeneration (AMD). We hypothesized that rs1048661 (T>G) in the LOXL1 gene and rs3025039 (C>T) in the VEGFA gene might be associated with risk of AMD.
   Methods: A total of 533 unrelated Chinese subjects, 286 cases (247 with early AMD and 39 with late neovascular AMD) and 247 controls, were included in the study. The gene sequences of LOXL1 rs1048661 and VEGFA rs3025039 were amplified by polymerase chain reaction and genotyped. Interaction between rs1048661 and rs3025039 on AMD risk was also assessed.
   Results: LOXL1 rs1048661 but not VEGFA rs3025039 was associated with a significantly increased risk of AMD. The adjusted odds ratio was 1.6 (95% CI, 1.1-2.5) for rs1048661 TT + GT genotype compared with GG homozygotes in the dominant model analysis. Moreover, there was a significant gene-gene interaction between these two polymorphic loci. In VEGFA rs3025039 CC + CT genotype which indicated sufficient expression of VEGF-a, LOXL1 rs1048661 had odds ratios of 1.7 (95% CI, 1.1-2.7) for early AMD and 3.6 (95% CI, 1.1-12.3) for late neovascular AMD in the dominant model analysis. However, LOXL1 rs1048661 did not confer the risk of AMD in subjects harboring VEGFA rs3025039 TT genotype which indicated decreased expression of VEGF-a.
   Conclusions: Our findings suggest that LOXL1 rs1048661 (T>G) may be involved in the risk of AMD. In addition, LOXL1 rs1048661 and VEGFA rs3025039 interacted to confer the development of AMD, especially for late-stage neovascular AMD. Our data need to be further validated.
C1 [Chen, Han; Xu, Ge-Zhi] Fudan Univ, Eye Ear Nose & Throat Hosp, Dept Ophthalmol, 83 Fenyang Rd, Shanghai 200031, Peoples R China.
   [Mo, Miao] Fudan Univ, Shanghai Canc Ctr, Dept Canc Prevent, Shanghai, Peoples R China.
   [Mo, Miao] Fudan Univ, Shanghai Canc Ctr, Clin Stat Ctr, Shanghai, Peoples R China.
   [Liu, Guang-Yu; Yu, Ke-Da] Fudan Univ, Dept Breast Surg, Shanghai Canc Ctr, Shanghai, Peoples R China.
   [Gong, Yang-Ming] Shanghai Municipal Ctr Dis Prevent & Control, Dept Canc Control & Prevent, Shanghai, Peoples R China.
C3 Fudan University; Fudan University; Fudan University; Fudan University;
   Shanghai Center for Disease Control & Prevention
RP Xu, GZ (通讯作者)，Fudan Univ, Eye Ear Nose & Throat Hosp, Dept Ophthalmol, 83 Fenyang Rd, Shanghai 200031, Peoples R China.; Yu, KD (通讯作者)，Fudan Univ, Fudan Univ Shanghai Canc Ctr, Dept Breast Surg, Shanghai Med Coll, 270 Dong An Rd, Shanghai 200032, Peoples R China.
EM yukeda@163.com; xugezhi@gmail.com
FU National Natural Science Foundation of China [81672600, 81722032]; 2018
   Shanghai Youth Excellent Academic Leader, Fudan Zhuoshi Project, Study
   on comprehensive prevention and control of common eye diseases in Xuhui
   District [XHLHGG201807]; Shanghai Key Laboratory of Visual Impairment
   and Restoration
FX Supported by grants from the National Natural Science Foundation of
   China (81672600, and 81722032), 2018 Shanghai Youth Excellent Academic
   Leader, Fudan Zhuoshi Project, Study on comprehensive prevention and
   control of common eye diseases in Xuhui District (XHLHGG201807), and
   Shanghai Key Laboratory of Visual Impairment and Restoration.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Barker HE, 2012, NAT REV CANCER, V12, P540, DOI 10.1038/nrc3319
   Founti P, 2015, ANN HUM GENET, V79, P431, DOI 10.1111/ahg.12128
   Fuse N, 2011, AM J OPHTHALMOL, V151, P550, DOI 10.1016/j.ajo.2010.08.048
   Iturbide A, 2015, FEBS J, V282, P1768, DOI 10.1111/febs.12961
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Liu SC, 2019, BMC MED GENET, V20, DOI 10.1186/s12881-019-0756-4
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mo M, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-276
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Thorleifsson G, 2007, SCIENCE, V317, P1397, DOI 10.1126/science.1146554
   Waugh N, 2018, HEALTH TECHNOL ASSES, V22, P1, DOI 10.3310/hta22270
   Yadav BK, 2017, ANN CLIN LAB SCI, V47, P144
   Yildiz BK, 2016, OPHTHALMIC RES, V56, P132, DOI 10.1159/000446186
   Yu KD, 2009, FASEB J, V23, P2274, DOI 10.1096/fj.08-124073
   Zhao J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172709
NR 16
TC 1
Z9 1
U1 0
U2 0
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2305-5839
EI 2305-5847
J9 ANN TRANSL MED
JI ANN. TRANSL. MED.
PD JUL
PY 2020
VL 8
IS 13
AR 818
DI 10.21037/atm-20-2447
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA MM3DZ
UT WOS:000550036800011
PM 32793663
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Jonasson, F
   Arnarsson, A
   Sasaki, H
   Peto, T
   Sasaki, K
   Bird, AC
AF Jonasson, F
   Arnarsson, A
   Sasaki, H
   Peto, T
   Sasaki, K
   Bird, AC
TI The prevalence of age-related maculopathy in Iceland - Reykjavik eye
   study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; LENS OPACIFICATION; GEOGRAPHIC ATROPHY; GRADING
   SYSTEM
AB Objective: To examine the age- and sex-specific prevalence of age-related maculopathy (ARM) and agerelated macular degeneration (AMD) in citizens of Reykjavik, Iceland,who were 50 years and older.
   Design: Random sample, cross sectional.
   Materials and Methods: Response rate was 75.8%. The presence and severity of various characteristics of drusen and pigmentary changes that are typical of ARM and AMD were determined by grading stereoscopic color fundus photographs, using the international classification and grading system for ARM and AMD.
   Results: We were able to evaluate 1021 right-eye and 1020 left-eye macular photographs. There was no statistically significant difference between right and left eyes. In people aged 50 to 59 years, 4.8% of participants (95% confidence interval [CI], 2.6-7.0) were found to have intermediate soft drusen measuring 63 to 125 pm in either eye; 1.2% (95% Cl, 0.0-2.3) had large soft distinct drusen larger than 125 pm; and 0.6% (95% Cl, 0.0-1.4) had large soft, crystalline, or semisolid drusen. The same figures for those 80 years and older were 18.2% (95% Cl, 9.8-26.6),10.9% (95% Cl, 4.0-17.8), and 25.5% (95% Cl, 18.4-32.6), respectively. Geographic atrophy was found in either eye in 9.2% of those participants 70 years and older (95% Cl, 5.6-12.7), and exudative macular degeneration was found in 2.3% of participants 70 years and older (95% Cl, 0.5-4.1).
   Conclusion: Geographic atrophy was found to be more common in our study than in other population-based studies.
C1 Univ Iceland, Eye Dept, Dept Ophthalmol, IS-101 Reykjavik, Iceland.
   Kanazawa Med Univ, Eye Dept, Uchinada, Ishikawa 92002, Japan.
   Moorfields Eye Hosp, London, England.
   Inst Ophthalmol, London, England.
C3 University of Iceland; Kanazawa Medical University; University of
   London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust; University of London; University College London
RP Jonasson, F (通讯作者)，Univ Iceland, Eye Dept, Dept Ophthalmol, Landspitalinn, IS-101 Reykjavik, Iceland.
RI Jonasson, Fridbert/ABA-9889-2021; Peto, Tunde/M-2081-2013
OI Peto, Tunde/0000-0001-6265-0381
CR AMARSSON A, 2000, PROGR LENS CATARACT, V35, P12
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   *FAO UN, 1988, FAO FISH STAT 1986 C
   GHAFOUR IM, 1983, BRIT J OPHTHALMOL, V67, P209, DOI 10.1136/bjo.67.4.209
   Gottfredsdottir MS, 1999, ACTA OPHTHALMOL SCAN, V77, P422, DOI 10.1034/j.1600-0420.1999.770413.x
   Gudmundsson H, 2000, EUR J HUM GENET, V8, P743, DOI 10.1038/sj.ejhg.5200527
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HYMAN L, 1992, AGE RELATED MACULAR, P9
   Jonasson F, 1987, Acta Ophthalmol Suppl, V182, P40
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katoh N, 2001, ACTA OPHTHALMOL SCAN, V79, P154, DOI 10.1034/j.1600-0420.2001.079002154.x
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   LAATIKAINEN L, 1995, ACTA OPHTHALMOL SCAN, V73, P105
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Pauleikhoff D, 1992, Ger J Ophthalmol, V1, P12
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sasaki H, 2000, OPHTHALMOLOGICA, V214, P412, DOI 10.1159/000027535
   Sigurdsson G, 2000, OSTEOPOROSIS INT, V11, P1031, DOI 10.1007/s001980070024
   *STAT CORP, 2001, STAT STAT SOFTW REL
   Steingrimsdottir L., 1993, Scandinavian Journal of Nutrition/Naringsforskning, V37, P10
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P410
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
NR 28
TC 88
Z9 90
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAR
PY 2003
VL 121
IS 3
BP 379
EP 385
DI 10.1001/archopht.121.3.379
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 653YP
UT WOS:000181464900011
PM 12617709
OA Bronze
DA 2022-11-30
ER

PT J
AU Bohni, SC
   Howell, JP
   Bittner, M
   Faes, L
   Bachmann, LM
   Thiel, MA
   Schmid, MK
AF Boehni, S. C.
   Howell, J. P.
   Bittner, M.
   Faes, L.
   Bachmann, L. M.
   Thiel, M. A.
   Schmid, M. K.
TI Blood flow velocity measured using the Retinal Function Imager predicts
   successful ranibizumab treatment in neovascular age-related macular
   degeneration: early prospective cohort study
SO EYE
LA English
DT Article
ID INTRAVITREAL INJECTION; BEVACIZUMAB; METAANALYSIS
AB Purpose Anti-VEGF treatment has a potent vasoconstrictive effect. Early changes of retinal blood flow velocity (RBFV) measured using the Retinal Function Imager (RFI) combined with indicators of vascular status may help in predicting the visual outcome 1 month post injection in patients with neovascular age-related macular degeneration (nvAMD) under ranibizumab treatment. To develop a simple prediction model based on the change in RBFV 3 days post injection and indicators of a patient's vascular status to assess the probability of a successful visual outcome 1 month post injection.
   Methods RBFV measured using RFI were prospectively collected pre-injection and 3 days post injection in 18 eyes of 15 patients. Indicators of vascular status (history of hypertension, diabetes mellitus without retinal affection, and smoking) were assessed by medical history. By univariate analyses, parameters associated with visual outcome were weighted (-1 to 6 points). A multivariate logistic regression model with the categorized visual outcome parameter (>= 0 letters gained after 1 month) as the dependent variate and the sum score as the independent variate (continuous scale) was used to estimate the score value-specific probabilities of letters gained >= 0 1 month post injection.
   Results The indicators of vascular status negatively influenced the likelihood of a letter gain >= 0 whereas an increase in the arterial RBFV strongly increased it. The area under the receiver operating characteristics curve for these parameters investigated was 0.71 (95% CI: 0.43-1.00).
   Conclusion Changes in the arterial RBFV following 3 days after ranibizumab injection combined with three indicators of the vascular status identified nvAMD patients with favorable visual outcome accurately.
C1 [Boehni, S. C.; Howell, J. P.; Bittner, M.; Faes, L.; Thiel, M. A.; Schmid, M. K.] Cantonal Hosp Lucerne, Eye Clin, Luzern, Switzerland.
   [Bachmann, L. M.] Medignit Inc, Res Consultants, Zurich, Switzerland.
C3 Lucerne Cantonal Hospital
RP Bohni, SC (通讯作者)，Augenklin Luzerner Kantonsspital, Spitalstr, CH-6000 Luzern, Switzerland.
EM sophie.boehni@luks.ch
OI , Lucas/0000-0002-9868-154X
FU Novartis AG, Switzerland
FX Dr Bohni's and Dr Bittner's work was funded via an unrestricted
   educational grant from Novartis AG, Switzerland.
CR Barak A, 2012, EUR J OPHTHALMOL, V22, P423, DOI 10.5301/ejo.5000074
   Beutelspacher SC, 2011, GRAEF ARCH CLIN EXP, V249, P1855, DOI 10.1007/s00417-011-1757-y
   Birger Y, 2011, GRAEF ARCH CLIN EXP, V249, P1587, DOI 10.1007/s00417-011-1716-7
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Burgansky-Eliash Z, 2014, CURR EYE RES, V39, P304, DOI 10.3109/02713683.2013.840384
   Burgansky-Eliash Z, 2012, RETINA-J RET VIT DIS, V32, P112, DOI 10.1097/IAE.0b013e31821ba2c4
   Burgansky-Eliash Z, 2010, RETINA-J RET VIT DIS, V30, P765, DOI 10.1097/IAE.0b013e3181c596c6
   Chen YM, 2006, AM J PHYSIOL-LUNG C, V291, pL378, DOI 10.1152/ajplung.00424.2005
   Faes L, 2014, EYE, V28, P788, DOI 10.1038/eye.2014.104
   Feng X, 2013, CHINESE MED J-PEKING, V126, P1944, DOI 10.3760/cma.j.issn.0366-6999.20130282
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Fontaine O, 2011, INVEST OPHTH VIS SCI, V52, P7400, DOI 10.1167/iovs.10-6646
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gutfreund S, 2013, GRAEF ARCH CLIN EXP, V251, P1507, DOI 10.1007/s00417-013-2325-4
   Izhaky D, 2009, JPN J OPHTHALMOL, V53, P345, DOI 10.1007/s10384-009-0689-0
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Landa Gennady, 2012, International Ophthalmology, V32, P211, DOI 10.1007/s10792-012-9547-z
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P304, DOI 10.1097/IAE.0b013e3181e91108
   Micieli JA, 2012, ACTA OPHTHALMOL, V90, pE13, DOI 10.1111/j.1755-3768.2011.02209.x
   Nelson DA, 2011, CLIN OPHTHALMOL, V5, P1095, DOI 10.2147/OPTH.S20103
   Otsuji T, 2013, CLIN OPHTHALMOL, V7, P1487, DOI 10.2147/OPTH.S46317
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Toklu Y, 2011, ACTA OPHTHALMOL, V89, pE41, DOI 10.1111/j.1755-3768.2010.02075.x
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 27
TC 3
Z9 4
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAY
PY 2015
VL 29
IS 5
BP 630
EP 636
DI 10.1038/eye.2015.10
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CH5JC
UT WOS:000354070900006
PM 25721520
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Dakin, HA
   Wordsworth, S
   Rogers, CA
   Abangma, G
   Raftery, J
   Harding, SP
   Lotery, AJ
   Downes, SM
   Chakravarthy, U
   Reeves, BC
AF Dakin, Helen A.
   Wordsworth, Sarah
   Rogers, Chris A.
   Abangma, Giselle
   Raftery, James
   Harding, Simon P.
   Lotery, Andrew J.
   Downes, Susan M.
   Chakravarthy, Usha
   Reeves, Barnaby C.
CA IVAN Study Investigators
TI Cost-effectiveness of ranibizumab and bevacizumab for age-related
   macular degeneration: 2-year findings from the IVAN randomised trial
SO BMJ OPEN
LA English
DT Article
ID ECONOMIC-EVALUATION; MODEL
AB Objective: To assess the incremental cost and cost-effectiveness of continuous and discontinuous regimens of bevacizumab (Avastin) and ranibizumab (Lucentis) for neovascular age-related macular degeneration (nAMD) from a UK National Health Service (NHS) perspective.
   Design: A within-trial cost-utility analysis with a 2-year time horizon, based on a multicentre factorial, non-inferiority randomised controlled trial.
   Setting: 23 hospital ophthalmology clinics.
   Participants: 610 patients aged >= 50 years with untreated nAMD in the study eye.
   Interventions: 0.5 mg ranibizumab or 1.25 mg bevacizumab given continuously (monthly) or discontinuously (as-needed) for 2 years.
   Main outcome measures: Quality-adjusted life-years (QALYs).
   Results: Total 2-year costs ranged from 3002 pound/patient ($4700; 95% CI 2601 pound to 3403) pound for discontinuous bevacizumab to 18 pound 590/patient ($29 106; 95% CI 18 pound 258 to 18 pound 922) for continuous ranibizumab. Ranibizumab was significantly more costly than bevacizumab for both continuous (+14 pound 989/patient ($23 468); 95% CI 14 pound 522 to 15 pound 456; p<0.001) and discontinuous treatment (+8498 pound ($13 305); 95% CI 7700 pound to 9295; pound p<0.001), with negligible difference in QALYs. Continuous ranibizumab would only be cost-effective compared with continuous bevacizumab if the NHS were willing to pay 3.5 million ($5.5 million) per additional QALY gained. Patients receiving continuous bevacizumab accrued higher total costs (+599 pound ($938); 95% CI 91 pound to 1107; pound p=0.021) than those receiving discontinuous bevacizumab, but also accrued non-significantly more QALYs (+0.020; 95% CI -0.032 to 0.071; p=0.452). Continuous bevacizumab therefore cost 30 pound 220 ($47 316) per QALY gained versus discontinuous bevacizumab. However, bootstrapping demonstrated that if the NHS is willing to pay 20 pound 000/QALY gained, there is a 37% chance that continuous bevacizumab is cost-effective versus discontinuous bevacizumab.
   Conclusions: Ranibizumab is not cost-effective compared with bevacizumab, being substantially more costly and producing little or no QALY gain. Discontinuous bevacizumab is likely to be the most cost-effective of the four treatment strategies evaluated in this UK trial, although there is a 37% chance that continuous bevacizumab is cost-effective.
C1 [Dakin, Helen A.; Wordsworth, Sarah] Univ Oxford, Hlth Econ Res Ctr, Nuffield Dept Populat Hlth, Oxford, England.
   [Rogers, Chris A.; Reeves, Barnaby C.] Univ Bristol, Sch Clin Sci, Clin Trials & Evaluat Unit, Bristol, Avon, England.
   [Abangma, Giselle] Swiss Re Serv Ltd, Res & Dev, London, England.
   [Raftery, James] Univ Southampton, Southampton, Hants, England.
   [Harding, Simon P.] Univ Liverpool, Inst Ageing & Chron Dis, Dept Eye & Vis Sci, Liverpool L69 3BX, Merseyside, England.
   [Lotery, Andrew J.] Univ Southampton, Fac Med, Acad Unit Clin & Expt Sci, Southampton SO9 5NH, Hants, England.
   [Downes, Susan M.] Oxford Univ Hosp NHS Trust, Oxford Eye Hosp, Oxford, England.
   [Chakravarthy, Usha] Queens Univ Belfast, Ctr Med Expt, Belfast, Antrim, North Ireland.
C3 University of Oxford; University of Bristol; University of Southampton;
   University of Liverpool; University of Southampton; Oxford University
   Hospitals NHS Foundation Trust; Queens University Belfast
RP Dakin, HA (通讯作者)，Univ Oxford, Hlth Econ Res Ctr, Nuffield Dept Populat Hlth, Oxford, England.
EM helen.dakin@dph.ox.ac.uk
OI Lotery, Andrew/0000-0001-5541-4305; Harding, Simon/0000-0003-4676-1158;
   Chakravarthy, Usha/0000-0002-2606-3734; Dakin,
   Helen/0000-0003-3255-748X; Reeves, Barnaby/0000-0002-5101-9487;
   Wordsworth, Sarah/0000-0002-2361-3040
FU National Institute for Health Research (NIHR) Health Technology
   Assessment (HTA) programme [07/36/01]; MRC [MR/K025643/1] Funding
   Source: UKRI; Medical Research Council [MR/K025643/1] Funding Source:
   researchfish; National Institute for Health Research [07/36/01] Funding
   Source: researchfish
FX The IVAN trial is funded by the National Institute for Health Research
   (NIHR) Health Technology Assessment (HTA) programme (project number
   07/36/01) and a full report will be published in Health Technology
   Assessment.
CR Bayer Plc, 2013, SUMMARY PRODUCT CHAR
   Briggs AH, 2001, HEALTH ECON, V10, P179, DOI 10.1002/hec.584
   British Medical Association, 2011, BRIT NATL FORMULARY, V62
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Curtis L., 2011, UNIT COSTS HLTH SOCI, P91
   Curtis L., 2011, UNIT COSTS HLTH SOCI, P177
   Curtis L, 2011, UNIT COSTS HLTH SOCI, P129
   Curtis L., 2011, SECONDARY UNIT COSTS, P129
   Curtis L., 2011, SECONDARY UNIT COSTS, P177
   Curtis L., 2011, SECONDARY UNIT COSTS, P91
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Dakin H, 2013, HEALTH ECON, V22, P22, DOI 10.1002/hec.1812
   Department of Health, 2011, PBR OP GUID TAR 2011
   Department of Health and Social Care, 2011, NAT SCHED REF COSTS
   Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002
   Drummond MF, 2005, METHODS EC EVALUATIO
   Fletcher EC, 2008, OPHTHALMOLOGY, V115, P2192, DOI 10.1016/j.ophtha.2008.07.018
   General Medical Council, 2021, ETH GUID DOCT
   Gower EW, 2010, RETINA-J RET VIT DIS, V30, P212, DOI 10.1097/IAE.0b013e3181babd8e
   Gray A., 2011, APPL METHODS COST EF
   Hallstrom AP, 1998, MED CARE, V36, P433, DOI 10.1097/00005650-199803000-00019
   Hernandez-Pastor LJ, 2010, GRAEF ARCH CLIN EXP, V248, P467, DOI 10.1007/s00417-009-1156-9
   Jonsson B, 1997, INT J TECHNOL ASSESS, V13, P49, DOI 10.1017/S0266462300010229
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Mitchell P, 2011, PHARMACOECONOMICS, V29, P107, DOI 10.2165/11585520-000000000-00000
   National Institute for Health and Clinical Excellence, 2008, SOC VAL JUDG PRINC D, V2nd
   National Institute for Health and Clinical Excellence, 2008, RAN PEG TREATM AG RE
   National Institute of health and Care Excellence, 2013, GUID METH TECHN APPR
   Neubauer AS, 2010, CLIN THER, V32, P1343, DOI 10.1016/j.clinthera.2010.07.010
   Patel JJ, 2012, J EVAL CLIN PRACT, V18, P247, DOI 10.1111/j.1365-2753.2010.01546.x
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Royston P, 2007, STATA J, V7, P445, DOI 10.1177/1536867X0700700401
   Smiddy WE, 2009, OPHTHALMOLOGY, V116, P481, DOI 10.1016/j.ophtha.2008.10.029
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067
   Yanagi Yasuo, 2011, Nippon Ganka Gakkai Zasshi, V115, P825
NR 41
TC 50
Z9 52
U1 0
U2 21
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2014
VL 4
IS 7
AR e005094
DI 10.1136/bmjopen-2014-005094
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA AM2ZS
UT WOS:000339720900055
PM 25079928
OA Green Published, gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Catanzaro, M
   Lanni, C
   Basagni, F
   Rosini, M
   Govoni, S
   Amadio, M
AF Catanzaro, Michele
   Lanni, Cristina
   Basagni, Filippo
   Rosini, Michela
   Govoni, Stefano
   Amadio, Marialaura
TI Eye-Light on Age-Related Macular Degeneration: Targeting Nrf2-Pathway as
   a Novel Therapeutic Strategy for Retinal Pigment Epithelium
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE Nrf2; age-related macular degeneration (AMD); retinal pigment epithelium
   (RPE); oxidative stress; pharmacological modulation; cytoprotection;
   HO1; p62
ID OXIDATIVE STRESS-RESPONSE; TRANSCRIPTION FACTOR NRF2;
   MOLECULAR-MECHANISMS; PATHWAY; AUTOPHAGY; CELLS; RPE; DEGRADATION;
   REGULATOR; DISEASE
AB Age-related macular degeneration (AMD) is a common disease with a multifactorial aetiology, still lacking effective and curative therapies. Among the early events triggering AMD is the deterioration of the retinal pigment epithelium (RPE), whose fundamental functions assure good health of the retina. RPE is physiologically exposed to high levels of oxidative stress during its lifespan; thus, the integrity and well-functioning of its antioxidant systems are crucial to maintain RPE homeostasis. Among these defensive systems, the Nrf2-pathway plays a primary role. Literature evidence suggests that, in aged and especially in AMD RPE, there is an imbalance between the increased pro-oxidant stress, and the impaired endogenous detoxifying systems, finally reverberating on RPE functions and survival. In thisin vitrostudy on wild type (WT) and Nrf2-silenced (siNrf2) ARPE-19 cells exposed to various AMD-relatednoxae(H2O2, 4-HNE, MG132 + Bafilomycin), we show that the Nrf2-pathway activation is a physiological protective stress response, leading downstream to an up-regulation of the Nrf2-targets HO1 and p62, and that a Nrf2 impairment predisposes the cells to a higher vulnerability to stress. In search of new pharmacologically active compounds potentially useful for AMD, four nature-inspired hybrids (NIH) were individually characterized as Nrf2 activators, and their pharmacological activity was investigated in ARPE-19 cells. The Nrf2 activator dimethyl-fumarate (DMF; 10 mu M) was used as a positive control. Three out of the four tested NIH (5 mu M) display both direct and indirect antioxidant properties, in addition to cytoprotective effects in ARPE-19 cells under pro-oxidant stimuli. The observed pro-survival effects require the presence of Nrf2, with the exception of the lead compound NIH1, able to exert a still significant, albeit lower, protection even in siNrf2 cells, supporting the concept of the existence of both Nrf2-dependent and independent pathways mediating pro-survival effects. In conclusion, by using some pharmacological tools as well as a reference compound, we dissected the role of the Nrf2-pathway in ARPE-19 stress response, suggesting that the Nrf2 induction represents an efficient defensive strategy to prevent the stress-induced damage.
C1 [Catanzaro, Michele; Lanni, Cristina; Govoni, Stefano; Amadio, Marialaura] Univ Pavia, Dept Drug Sci, Sect Pharmacol, Pavia, Italy.
   [Basagni, Filippo; Rosini, Michela] Univ Bologna, Dept Pharm & Biotechnol, Bologna, Italy.
C3 University of Pavia; University of Bologna
RP Amadio, M (通讯作者)，Univ Pavia, Dept Drug Sci, Sect Pharmacol, Pavia, Italy.
EM marialaura.amadio@unipv.it
RI Basagni, Filippo/GXG-7199-2022
OI LANNI, CRISTINA/0000-0002-3061-4738; Basagni,
   Filippo/0000-0003-0710-4251
FU University of Pavia [BSR1744747]; Italian Ministry of University and
   Research; RFO
FX This work was supported by the University of Pavia [to MA, grant number
   BSR1744747; 2017] and the Italian Ministry of University and Research
   [to MA, FFABR2017]. The University of Bologna is acknowledged by MR
   [Grants from RFO].
CR Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   Amadio M, 2008, CURR PHARM DESIGN, V14, P2651, DOI 10.2174/138161208786264052
   Amadio M, 2016, PHARMACOL RES, V103, P253, DOI 10.1016/j.phrs.2015.11.027
   Amadio Marialaura, 2014, Front Cell Neurosci, V8, P459, DOI 10.3389/fncel.2014.00459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Basagni F, 2019, FUTURE MED CHEM, V11, P707, DOI 10.4155/fmc-2018-0423
   Batliwala S, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1703810
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Chen JB, 2009, INVEST OPHTH VIS SCI, V50, P936, DOI 10.1167/iovs.08-2439
   Cui RZ, 2020, OPHTHALMIC RES, V63, P404, DOI 10.1159/000504891
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Diaz GM, 2018, AUTOIMMUN REV, V17, P1240, DOI 10.1016/j.autrev.2018.07.001
   Ethen CM, 2007, INVEST OPHTH VIS SCI, V48, P3469, DOI 10.1167/iovs.06-1058
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Foresti R, 2015, PHARMACOL RES, V99, P296, DOI 10.1016/j.phrs.2015.07.006
   Fresta CG, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030776
   Giudice A, 2010, METHODS MOL BIOL, V647, P37, DOI 10.1007/978-1-60761-738-9_3
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Hu X, 2019, J CELL BIOCHEM, V120, P4514, DOI 10.1002/jcb.27739
   Hyttinen JMT, 2014, AGEING RES REV, V18, P16, DOI 10.1016/j.arr.2014.07.002
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Jiang T, 2015, FREE RADICAL BIO MED, V88, P199, DOI 10.1016/j.freeradbiomed.2015.06.014
   Kaarniranta K, 2005, NEUROSCI LETT, V382, P185, DOI 10.1016/j.neulet.2005.03.009
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Lambros ML, 2016, ADV EXP MED BIOL, V854, P67, DOI 10.1007/978-3-319-17121-0_10
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin PH, 2008, BBA-MOL CELL RES, V1783, P1826, DOI 10.1016/j.bbamcr.2008.05.008
   Loboda A, 2016, CELL MOL LIFE SCI, V73, P3221, DOI 10.1007/s00018-016-2223-0
   Lu MC, 2016, MED RES REV, V36, P924, DOI 10.1002/med.21396
   Marchesi N, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4956080
   McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200
   Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003
   Pajares M, 2016, AUTOPHAGY, V12, P1902, DOI 10.1080/15548627.2016.1208889
   Pietrucha-Dutczak M, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00834
   Robledinos-Anton N, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9372182
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Serafini MM, 2020, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01597
   Shao Y, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/1479571
   Simoni E, 2017, ACS CHEM NEUROSCI, V8, P1618, DOI 10.1021/acschemneuro.7b00100
   Simoni E, 2016, CHEMMEDCHEM, V11, P1309, DOI 10.1002/cmdc.201500422
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tang ZH, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1701-3
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Viiri J, 2010, MOL VIS, V16, P1399
   Wang L, 2016, ADV EXP MED BIOL, V854, P17, DOI 10.1007/978-3-319-17121-0_3
   Zhang HQ, 2015, FREE RADICAL BIO MED, V88, P314, DOI 10.1016/j.freeradbiomed.2015.05.036
   Zhao HL, 2019, INT J MOL MED, V43, P936, DOI 10.3892/ijmm.2018.4027
   Zhao J, 2012, CURR EYE RES, V37, P955, DOI 10.3109/02713683.2012.700753
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zhou YQ, 2019, CURR MOL MED, V19, P172, DOI 10.2174/1566524019666190424131704
   Zhu C, 2017, BIOMED PHARMACOTHER, V88, P124, DOI 10.1016/j.biopha.2016.11.089
NR 54
TC 11
Z9 12
U1 3
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUN 5
PY 2020
VL 11
AR 844
DI 10.3389/fphar.2020.00844
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA MC1ZL
UT WOS:000543093900001
PM 32581803
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Christen, WG
   Manson, JE
   Glynn, RJ
   Gaziano, JM
   Chew, EY
   Buring, JE
   Hennekens, CH
AF Christen, William G.
   Manson, JoAnn E.
   Glynn, Robert J.
   Gaziano, J. Michael
   Chew, Emily Y.
   Buring, Julie E.
   Hennekens, Charles H.
TI Beta carotene supplementation and age-related maculopathy in a
   randomized trial of US physicians
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION;
   CARDIOVASCULAR-DISEASE; CLINICAL-TRIALS; VITAMIN-E; LASER
   PHOTOCOAGULATION; PHOTODYNAMIC THERAPY; ALPHA-TOCOPHEROL; WOMENS HEALTH;
   FOLLOW-UP
AB Objective: To test whether beta carotene supplementation affects the incidence of age-related maculopathy ( ARM) in a large-scale randomized trial. D
   esign: Randomized, double-masked, placebo-controlled trial among 22 071 apparently healthy US male physicians aged 40 to 84 years. Participants were randomly assigned to receive beta carotene (50 mg every other day) or placebo.
   Main Outcome Measure: Incident ARM responsible for a reduction in best-corrected visual acuity to 20/30 or worse.
   Results: After 12 years of treatment and follow-up, there were 162 cases of ARM in the beta carotene group vs 170 cases in the placebo group ( relative risk [RR], 0.96; 95% confidence interval [CI], 0.78-1.20). The results were similar for the secondary end points of ARM with or without vision loss ( 275 vs 274 cases; RR, 1.01; 95% CI, 0.86-1.20) and advanced ARM ( 63 vs 66 cases; RR, 0.97; 95% CI, 0.69-1.37).
   Conclusions: These randomized data relative to 12 years of treatment among a large population of apparently healthy men indicate that beta carotene supplementation has no beneficial or harmful effect on the incidence of ARM. Long-term supplemental use of beta carotene neither decreases nor increases the risk of ARM.
C1 Brigham & Womens Hosp, Div Prevent Med, Dept Med, Boston, MA 02215 USA.
   Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA.
   Massachusetts Vet Epidemiol Res & Informat Ctr, Dept Vet Affairs Boston Healthcare Syst, Boston, MA USA.
   NEI, Bethesda, MD 20892 USA.
   Univ Miami, Sch Med, Dept Med, Miami, FL USA.
   Univ Miami, Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL USA.
   Florida Atlantic Univ, Dept Biomed Sci, Ctr Excellence Biomed & Marine Biotechnol, Boca Raton, FL 33431 USA.
C3 Harvard University; Brigham & Women's Hospital; Harvard University;
   Harvard T.H. Chan School of Public Health; Harvard University; Harvard
   T.H. Chan School of Public Health; Harvard University; Harvard Medical
   School; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Harvard University; VA Boston Healthcare System;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University of Miami; University of Miami; State University System
   of Florida; Florida Atlantic University
RP Christen, WG (通讯作者)，Brigham & Womens Hosp, Div Prevent Med, Dept Med, 900 Commonwealth Ave E, Boston, MA 02215 USA.
EM wchristen@rics.bwh.harvard.edu
FU NATIONAL CANCER INSTITUTE [R01CA040360, R01CA097193] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R01EY006633] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND
   DIGESTIVE AND KIDNEY DISEASES [P30DK040561] Funding Source: NIH
   RePORTER; Intramural NIH HHS [Z99 EY999999] Funding Source: Medline; NCI
   NIH HHS [R01 CA097193, R01 CA040360, CA 34944, CA 40360, R01 CA034944]
   Funding Source: Medline; NEI NIH HHS [EY 06633] Funding Source: Medline;
   NHLBI NIH HHS [HL 34595, R01 HL026490, R01 HL034595, HL 26490] Funding
   Source: Medline; NIDDK NIH HHS [P30 DK040561-11, P30 DK040561] Funding
   Source: Medline
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bohm F, 1998, FEBS LETT, V436, P387, DOI 10.1016/S0014-5793(98)01173-9
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   Christen WG, 2000, ANN EPIDEMIOL, V10, P125, DOI 10.1016/S1047-2797(99)00042-3
   Fekrat S, 1996, Curr Opin Ophthalmol, V7, P65, DOI 10.1097/00055735-199606000-00011
   Fotouhi N, 1996, AM J CLIN NUTR, V63, P553, DOI 10.1093/ajcn/63.4.553
   Goodman GE, 2004, J NATL CANCER I, V96, P1743, DOI 10.1093/jnci/djh320
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greenberg ER, 1996, JAMA-J AM MED ASSOC, V275, P699, DOI 10.1001/jama.275.9.699
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801
   HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301
   Hogg R, 2004, CURR EYE RES, V29, P387, DOI 10.1080/02713680490517890
   Jampol LM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1634, DOI 10.1001/archopht.121.11.1634
   Jampol LM, 2001, JAMA-J AM MED ASSOC, V286, P2466
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Lee IM, 1999, J NATL CANCER I, V91, P2102, DOI 10.1093/jnci/91.24.2102
   Lee IM, 2005, JAMA-J AM MED ASSOC, V294, P56, DOI 10.1001/jama.294.1.56
   Lippman SM, 2005, JNCI-J NATL CANCER I, V97, P94, DOI 10.1093/jnci/dji009
   Manson Joann E., 1995, Annals of Epidemiology, V5, P261, DOI 10.1016/1047-2797(94)00091-7
   Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Moeller SM, 2000, J AM COLL NUTR, V19, p522S, DOI 10.1080/07315724.2000.10718975
   *NAT ADV EYE COUNC, 2004, NIH PUBL
   NIKI E, 1995, AM J CLIN NUTR, V62, P1322, DOI 10.1093/ajcn/62.6.1322S
   SATTERFIELD S, 1990, AM J PREV MED, V6, P290, DOI 10.1016/S0749-3797(18)30997-8
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P224, DOI 10.1034/j.1600-0420.1998.760220.x
   Virtamo J, 2003, JAMA-J AM MED ASSOC, V290, P476, DOI 10.1001/jama.290.4.476
   Young AJ, 2001, ARCH BIOCHEM BIOPHYS, V385, P20, DOI 10.1006/abbi.2000.2149
NR 35
TC 22
Z9 22
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAR
PY 2007
VL 125
IS 3
BP 333
EP 339
DI 10.1001/archopht.125.3.333
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 145DR
UT WOS:000244846000005
PM 17353403
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Gaffney, AJ
   Binns, AM
   Margrain, TH
AF Gaffney, Allannah J.
   Binns, Alison M.
   Margrain, Tom H.
TI Topography of Cone Dark Adaptation Deficits in Age-Related Maculopathy
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE age-related maculopathy; dark adaptation; retinal eccentricity;
   diagnostic potential; psychophysics
ID VISUAL-PIGMENT REGENERATION; FOVEAL FLICKER SENSITIVITY; MACULAR
   DEGENERATION; PHOTODYNAMIC THERAPY; ROD; IMPAIRMENT; EYES; SEVERITY;
   RECOVERY; DISEASE
AB Purpose. Despite widespread agreement that dark adaptation is abnormal in age-related maculopathy (ARM), the optimal retinal location for detection of this deficit is unclear. We quantified the diagnostic potential of cone dark adaptation as a function of retinal eccentricity and compared this with the diagnostic potential of the time to the rod-cone-break (RCB).
   Methods. Cone dark adaptation was monitored after an 80% cone photopigment bleach in 10 subjects with ARM and 10 age-matched controls, using four achromatic annuli (0.5, 2, 7, and 12 degrees radius) centered on the fovea. Threshold recovery data were modeled and the time constant of cone recovery (tau), final cone threshold, and time to RCB were determined. Diagnostic potential was evaluated by constructing receiver operating characteristic curves for these parameters.
   Results. Cone tau was significantly longer for the ARM group at 2, 7, and 12 degrees. The greatest difference between groups was observed at 12 from fixation. At this location, the mean tau was 3.49 (+/- 2.02) min and 0.64 (+/- 0.38) min for ARM and control subjects, respectively (p = 0.002), and time to RCB was 17.68 (+/- 5.37) min and 9.05 (+/- 2.11) min for ARM and control subjects, respectively (p = 0.001). Correspondingly, receiver operating characteristic curves showed that the diagnostic potential of dark adaptometry is greatest for stimuli presented 12 degrees from fixation; for cone tau, the area under the curve = 0.99 +/- 0.02 and for time to RCB, area under the curve = 0.96 +/- 0.04.
   Conclusions. This study has shown cone-mediated dark adaptation to be significantly impaired in ARM. Our results provide compelling evidence in support of the diagnostic potential of cone dark adaptation and the use of annular stimuli at 12 degrees. The observation that cone tau is highly diagnostic at this eccentricity is significant clinically because this parameter may be quantified within a few minutes. (Optom Vis Sci 2011; 88: 1080-1087)
C1 [Gaffney, Allannah J.; Binns, Alison M.; Margrain, Tom H.] Cardiff Univ, Sch Optometry & Vis Sci, Cardiff CF24 4LU, S Glam, Wales.
C3 Cardiff University
RP Margrain, TH (通讯作者)，Cardiff Univ, Sch Optometry & Vis Sci, Maindy Rd, Cardiff CF24 4LU, S Glam, Wales.
EM margrainth@cf.ac.uk
OI Binns, Alison/0000-0001-8621-498X; Margrain, Tom/0000-0003-1280-0809
FU College of Optometrists, UK
FX This study was funded by a research grant from the College of
   Optometrists, UK.
CR Binns AM, 2007, INVEST OPHTH VIS SCI, V48, P2806, DOI 10.1167/iovs.06-0392
   Brainard DH, 2001, ENCY IMAGING SCI TEC, V18, P172
   Bressler NM, 2000, INVEST OPHTH VIS SCI, V41, P624
   BROWN B, 1986, OPHTHAL PHYSL OPT, V6, P81, DOI 10.1111/j.1475-1313.1986.tb00704.x
   BROWN B, 1986, AM J OPTOM PHYS OPT, V63, P450
   BROWN B, 1983, AM J OPTOM PHYS OPT, V60, P645
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   COLLINS M, 1989, CLIN VISION SCI, V4, P145
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   HOLLINS M, 1973, J GEN PHYSIOL, V62, P430, DOI 10.1085/jgp.62.4.430
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3150
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3136
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3143
   McGwin G, 1999, BEHAV RES METH INS C, V31, P712, DOI 10.3758/BF03200752
   METHA AB, 1993, BEHAV RES METH INSTR, V25, P371, DOI 10.3758/BF03204528
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Pianta MJ, 2000, J PHYSIOL-LONDON, V528, P591, DOI 10.1111/j.1469-7793.2000.00591.x
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   SANDBERG MA, 1995, RETINA-J RET VIT DIS, V15, P407, DOI 10.1097/00006982-199515050-00006
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Wang JS, 2011, PROG RETIN EYE RES, V30, P115, DOI 10.1016/j.preteyeres.2010.11.001
   Wang JS, 2009, CURR BIOL, V19, P1665, DOI 10.1016/j.cub.2009.07.054
   Zele AJ, 2008, OPTOMETRY VISION SCI, V85, P309, DOI 10.1097/OPX.0b013e31816be9e3
NR 39
TC 18
Z9 18
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-5488
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD SEP
PY 2011
VL 88
IS 9
BP 1080
EP 1087
DI 10.1097/OPX.0b013e3182223697
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 812HJ
UT WOS:000294281600008
PM 21705940
DA 2022-11-30
ER

PT J
AU Loewenstein, A
   Ferencz, JR
   Lang, YR
   Yeshurun, I
   Pollack, A
   Siegal, R
   Lifshitz, T
   Karp, J
   Roth, D
   Bronner, G
   Brown, J
   Mansour, S
   Friedman, S
   Michels, M
   Johnston, R
   Rapp, M
   Havilio, M
   Rafaeli, O
   Manor, Y
AF Loewenstein, Anat
   Ferencz, Joseph R.
   Lang, Yaron
   Yeshurun, Itamar
   Pollack, Ayala
   Siegal, Ruth
   Lifshitz, Tova
   Karp, Joseph
   Roth, Daniel
   Bronner, Guri
   Brown, Justin
   Mansour, Sam
   Friedman, Scott
   Michels, Mark
   Johnston, Richards
   Rapp, Moshe
   Havilio, Moshe
   Rafaeli, Omer
   Manor, Yair
TI TOWARD EARLIER DETECTION OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO
   AGE-RELATED MACULAR DEGENERATION Multicenter Evaluation of a
   Preferential Hyperacuity Perimeter Designed as a Home Device
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; cho-roidal neovascularization; early
   detection; home device monitoring; preferential hyperacuity perimetry
ID SUBGROUP ANALYSIS; RANIBIZUMAB; VERTEPORFIN; MEMBRANES; THERAPY; PHP
AB Purpose: The primary purpose of this study was to evaluate the ability of a home device preferential hyperacuity perimeter to discriminate between patients with choroidal neovascularization (CNV) and intermediate age-related macular degeneration (AMD), and the secondary purpose was to investigate the dependence of sensitivity on lesion characteristics.
   Methods: All participants were tested with the home device in an unsupervised mode. The first part of this work was retrospective using tests performed by patients with intermediate AMD and newly diagnosed CNV. In the second part, the classifier was prospectively challenged with tests performed by patients with intermediate AMD and newly diagnosed CNV. The dependence of sensitivity on lesion characteristics was estimated with tests performed by patients with CNV of both parts.
   Results: In 66 eyes with CNV and 65 eyes with intermediate AMD, both sensitivity and specificity were 0.85. In the retrospective part (34 CNV and 43 intermediate AMD), sensitivity and specificity were 0.85 +/- 0.12 (95% confidence interval) and 0.84 +/- 0.11 (95% confidence interval), respectively. In the prospective part (32 CNV and 22 intermediate AMD), sensitivity and specificity were 0.84 +/- 0.13 (95% confidence interval) and 0.86 +/- 0.14 (95% confidence interval), respectively. Chi-square analysis showed no dependence of sensitivity on type (P = 0.44), location (P = 0.243), or size (P = 0.73) of the CNV lesions.
   Conclusion: A home device preferential hyperacuity perimeter has good sensitivity and specificity in discriminating between patients with newly diagnosed CNV and intermediate AMD. Sensitivity is not dependent on lesion characteristics. RETINA 30:1058-1064, 2010
C1 [Ferencz, Joseph R.] Meir Med Ctr, Kefar Sava, Israel.
   [Lang, Yaron] HaEmek Med Ctr, Afula, Israel.
   [Yeshurun, Itamar] Wolfson Med Ctr, Holon, Israel.
   [Pollack, Ayala] Kaplan Med Ctr, Rehovot, Israel.
   [Siegal, Ruth] Rabin Med Ctr, Petah Tiqwa, Israel.
   [Lifshitz, Tova] Soroka Med Ctr, Beer Sheva, Israel.
   [Karp, Joseph] Machon Mor, Ramat Gan, Israel.
   [Roth, Daniel] Retina Vitreous Ctr, Toms River, NJ USA.
   [Bronner, Guri] Retinal & Ophthalm Consultants, Foxman Foxman & Margolis, Northfield, NJ USA.
   [Brown, Justin] Charlotte Eye Ear Nose & Throat Associates, Charlotte, NC USA.
   [Mansour, Sam] Virginia Retina Ctr, Leesburg, VA USA.
   [Friedman, Scott] Cent Florida Retina Inst, Lakeland, FL USA.
   [Michels, Mark] Retina Care Specialists, Palm Beach Gardens, FL USA.
   [Johnston, Richards] Edina Retina Consultants, Edina, MN USA.
   [Rapp, Moshe; Havilio, Moshe; Rafaeli, Omer; Manor, Yair] Notal Vis Ltd, Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Emek Medical Center;
   Hebrew University of Jerusalem; Kaplan Medical Center; Rabin Medical
   Center; Ben Gurion University; Soroka Medical Center
RP Loewenstein, A (通讯作者)，Tel Aviv Med Ctr & Sch Med, Dept Ophthalmol, 6 Weitzmann St, IL-64239 Tel Aviv, Israel.
EM anatlow@tasmc.health.gov.il
RI Mansour, Sam Edward/AAV-9655-2020
OI Mansour, Sam Edward/0000-0002-0345-0467
CR ACHARD OA, 1995, AM J OPHTHALMOL, V120, P322, DOI 10.1016/S0002-9394(14)72162-2
   Alster Y, 2005, OPHTHALMOLOGY, V112, P1758, DOI 10.1016/j.ophtha.2005.06.008
   Bedell HE, 2009, OPTOMETRY VISION SCI, V86, P485, DOI 10.1097/OPX.0b013e31819fa6e2
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   Bressler SB, 2005, RETINA-J RET VIT DIS, V25, P253
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Complications Age-Related Macular, 2008, OPHTHALMOLOGY, V115, P1474, DOI 10.1016/j.ophtha.2008.03.008
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Goldstein M, 2005, RETINA-J RET VIT DIS, V25, P296
   Isaac David Leonardo Cruvinel, 2007, Arq. Bras. Oftalmol., V70, P771, DOI 10.1590/S0004-27492007000500009
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kampmeier J, 2006, KLIN MONATSBL AUGENH, V223, P752, DOI 10.1055/s-2006-926880
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klatt C, 2006, OPHTHALMOLOGE, V103, P945, DOI 10.1007/s00347-006-1381-0
   Loewenstein A, 2003, OPHTHALMOLOGY, V110, P966, DOI 10.1016/S0161-6420(03)00074-5
   Loewenstein A, 2007, RETINA-J RET VIT DIS, V27, P873, DOI 10.1097/IAE.0b013e318050d2ec
   *MPS GROUP, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   VANDER JF, 1989, OPHTHALMOLOGY, V96, P1422
   Zaidi FH, 2004, EYE, V18, P503, DOI 10.1038/sj.eye.6700708
NR 26
TC 26
Z9 26
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL-AUG
PY 2010
VL 30
IS 7
BP 1058
EP 1064
DI 10.1097/IAE.0b013e3181d1a75e
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 622CE
UT WOS:000279635600010
PM 20234332
DA 2022-11-30
ER

PT J
AU Hautamaki, A
   Seitsonen, S
   Holopainen, JM
   Moilanen, JA
   Kivioja, J
   Onkamo, P
   Jarvela, I
   Immonen, I
AF Hautamaki, Asta
   Seitsonen, Sanna
   Holopainen, Juha M.
   Moilanen, Jukka A.
   Kivioja, Jarno
   Onkamo, Paivi
   Jarvela, Irma
   Immonen, Ilkka
TI The genetic variant rs4073 A -> T of the Interleukin-8 promoter region
   is associated with the earlier onset of exudative age-related macular
   degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE exudative age-related macular degeneration; genetic associations;
   interleukin-8; single nucleotide polymorphism
ID COMPLEMENT-FACTOR-H; C-REACTIVE PROTEIN; AQUEOUS-HUMOR;
   ENDOTHELIAL-CELLS; CIGARETTE-SMOKING; LOC387715 A69S; RISK;
   POLYMORPHISM; EXPRESSION; SUSCEPTIBILITY
AB Purpose: To study the association of the single nucleotide polymorphism (SNP) rs4073 in the interleukin-8 (IL-8) promoter region with the diagnosis and age of onset of exudative age-related macular degeneration (AMD) in association with the known genetic risk factors for AMD and tobacco smoking.
   Methods: Medical records, smoking history and angiograms or fundus photographs of 301 patients with exudative AMD, 72 patients with dry AMD and 119 control subjects were analysed retrospectively. The associations of IL-8 rs4073 A -> T, CFH rs1061170 T -> C, ARMS2 rs10490924 G -> T and C3 rs2230199 C -> G SNPs with the presence of AMD and with the age of onset of exudative AMD were analysed.
   Results: Younger age of exudative AMD onset was associated with the homozygous AA genotype of IL-8 rs4073 (p = 0.009, Mann-Whitney U-test), CC genotype of CFH rs1061170 (p = 0.016), TT genotype of ARMS2 rs10490924 (p = 0.001) and with current smoking (p = 0.002). The risk alleles C in CFH rs1061170 (p < 0.0001, Pearson chi-square) and T in ARMS2 rs10490924 (p < 0.0001), as well as smoking (p < 0.0001), were more prevalent in AMD patients compared with controls. No association was found between the IL-8 rs4073 genotype and the presence of AMD.
   Conclusion: Out of the factors associated with the earlier onset of exudative AMD, only the genotype of IL-8 rs4073 did not appear as a risk factor for AMD in general. IL-8 may have a role in accelerating the development of the choroidal neovascularization in exudative AMD.
C1 [Hautamaki, Asta; Seitsonen, Sanna; Holopainen, Juha M.; Moilanen, Jukka A.; Immonen, Ilkka] Univ Helsinki, Dept Ophthalmol, Helsinki, Finland.
   [Hautamaki, Asta; Seitsonen, Sanna; Holopainen, Juha M.; Moilanen, Jukka A.; Immonen, Ilkka] Helsinki Univ Hosp, Helsinki, Finland.
   [Kivioja, Jarno; Jarvela, Irma] Univ Helsinki, Dept Med Genet, Helsinki, Finland.
   [Onkamo, Paivi] Univ Helsinki, Dept Biol & Environm Sci, Helsinki, Finland.
C3 University of Helsinki; University of Helsinki; Helsinki University
   Central Hospital; University of Helsinki; University of Helsinki
RP Hautamaki, A (通讯作者)，Univ Helsinki, Cent Hosp, Dept Ophthalmol, POB 220, Helsinki 00029, Finland.
EM asta.hautamaki@hus.fi
RI Jarvela, Irma/L-5836-2013; Hautamaki, Asta/G-3098-2014
OI Jarvela, Irma/0000-0002-1770-6187; Hautamaki, Asta/0000-0002-9454-8434;
   Kivioja, Jarno/0000-0002-4046-0963
FU Eye Foundation, Helsinki, Finland; Evald and Hilda Nissi Foundation,
   Helsinki, Finland; Eye and Tissue Bank Foundation, Helsinki, Finland;
   Mary and Georg C. Ehrnrooth Foundation, Helsinki, Finland
FX This work was supported by grants from The Eye Foundation, Helsinki,
   Finland; The Evald and Hilda Nissi Foundation, Helsinki, Finland; The
   Eye and Tissue Bank Foundation, Helsinki, Finland, and Mary and Georg C.
   Ehrnrooth Foundation, Helsinki, Finland.
CR Abdel-Malak NA, 2008, BLOOD, V111, P4145, DOI 10.1182/blood-2007-08-110338
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   DEFORGE LE, 1993, J BIOL CHEM, V268, P25568
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P537, DOI 10.1136/bjo.2007.123190
   Hacking D, 2004, GENES IMMUN, V5, P274, DOI 10.1038/sj.gene.6364067
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hautamaki A, 2014, OPHTHALMOLOGY, V121, P973, DOI 10.1016/j.ophtha.2013.11.035
   Hautamaki A, 2013, RETINA-J RET VIT DIS, V33, P1815, DOI 10.1097/IAE.0b013e318285cf92
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Hildebrand F, 2007, CYTOKINE, V37, P192, DOI 10.1016/j.cyto.2007.03.008
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Hull J, 2000, THORAX, V55, P1023, DOI 10.1136/thorax.55.12.1023
   Hull J, 2001, AM J HUM GENET, V69, P413, DOI 10.1086/321291
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Keilhauer CN, 2013, EUR J MED GENET, V56, P72, DOI 10.1016/j.ejmg.2012.10.005
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Lechanteur YTE, 2015, JAMA OPHTHALMOL, V133, P533, DOI 10.1001/jamaophthalmol.2015.18
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Martin D, 2009, J BIOL CHEM, V284, P6038, DOI 10.1074/jbc.C800207200
   Miao H, 2012, MOL VIS, V18, P574
   Mizukami Y, 2005, NAT MED, V11, P992, DOI 10.1038/nm1294
   Ohyauchi M, 2005, GUT, V54, P330, DOI 10.1136/gut.2003.033050
   Petreaca ML, 2007, MOL BIOL CELL, V18, P5014, DOI 10.1091/mbc.E07-01-0004
   Ricci F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066978
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seitsonen S, 2006, MOL VIS, V12, P796
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Shuler RK, 2008, AM J OPHTHALMOL, V145, P303, DOI 10.1016/j.ajo.2007.09.027
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Stentz FB, 2006, BIOCHEM BIOPH RES CO, V346, P721, DOI 10.1016/j.bbrc.2006.05.159
   Strandberg A, 2004, J CLIN EPIDEMIOL, V57, P415, DOI 10.1016/j.jclinepi.2003.09.013
   Taguchi A, 2005, CANCER EPIDEM BIOMAR, V14, P2487, DOI 10.1158/1055-9965.EPI-05-0326
   Tsai YY, 2008, INVEST OPHTH VIS SCI, V49, P693, DOI 10.1167/iovs.07-0125
   van der Net JB, 2008, EUR J HUM GENET, V16, P1111, DOI 10.1038/ejhg.2008.59
   Wang Y, 2010, EXP EYE RES, V91, P135, DOI 10.1016/j.exer.2010.02.008
   Yang IH, 2015, INVEST OPHTH VIS SCI, V56, P761, DOI 10.1167/iovs.14-15299
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhu DH, 2009, AGING-US, V1, P740, DOI 10.18632/aging.100078
NR 51
TC 17
Z9 18
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2015
VL 93
IS 8
BP 726
EP 733
DI 10.1111/aos.12799
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DA2VI
UT WOS:000367654500027
PM 26154559
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Townsend, D
   Reeves, BC
   Taylor, J
   Chakravarthy, U
   O'Reilly, D
   Hogg, RE
   Mills, N
AF Townsend, D.
   Reeves, B. C.
   Taylor, J.
   Chakravarthy, U.
   O'Reilly, D.
   Hogg, R. E.
   Mills, N.
TI Health professionals' and service users' perspectives of shared care for
   monitoring wet age-related macular degeneration: a qualitative study
   alongside the ECHoES trial
SO BMJ OPEN
LA English
DT Article
ID FOLLOW-UP; GLAUCOMA; OPTOMETRISTS
AB Objectives: To explore the views of eye health professionals and service users on shared community and hospital care for wet or neovascular age-related macular degeneration (nAMD).
   Method: Using maximum variation sampling, 5 focus groups and 10 interviews were conducted with 23 service users and 24 eye health professionals from across the UK (consisting of 8 optometrists, 6 ophthalmologists, 6 commissioners, 2 public health representatives and 2 clinical eye care advisors to local Clinical Commissioning Groups). Data were transcribed verbatim and analysed thematically using constant comparative techniques derived from grounded theory methodology.
   Results: The needs and preferences of those with nAMD appear to be at odds with the current service being provided. There was enthusiasm among health professionals and service users about the possibility of shared care for nAMD as it was felt to have the potential to relieve hospital eye service burden and represent a more patient-centred option, but there were a number of perceived barriers to implementation. Some service users and ophthalmologists voiced concerns about optometrist competency and the potential for delays with referrals to secondary care if stable nAMD became active again. The health professionals were divided as to whether shared care was financially more efficient than the current model of care. Specialist training for optometrists, under the supervision of ophthalmologists, was deemed to be the most effective method of training and was perceived to have the potential to improve the communication and trust that shared care would require.
   Conclusions: While shared care is perceived to represent a promising model of nAMD care, voiced concerns suggest that there would need to be greater collaboration between ophthalmology and optometry, in terms of interprofessional trust and communication.
C1 [Townsend, D.; Mills, N.] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England.
   [Reeves, B. C.; Taylor, J.] Univ Bristol, Bristol Royal Infirm, Sch Clin Sci, Bristol, Avon, England.
   [Chakravarthy, U.; Hogg, R. E.] Queens Univ Belfast, Inst Clin Sci, Ctr Med Expt, Belfast, Antrim, North Ireland.
   [O'Reilly, D.] Queens Univ Belfast, Inst Clin Sci, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
C3 University of Bristol; Bristol Royal Infirmary; University of Bristol;
   Queens University Belfast; Queens University Belfast
RP Townsend, D (通讯作者)，Univ Bristol, Sch Social & Community Med, Bristol, Avon, England.
EM daisy.townsend@bristol.ac.uk
RI Hogg, Ruth E./ABC-9602-2020
OI Hogg, Ruth E./0000-0001-9413-2669; Reeves, Barnaby/0000-0002-5101-9487;
   Elliott, Daisy/0000-0001-8143-9549; Chakravarthy,
   Usha/0000-0002-2606-3734; Mills, Nicola/0000-0002-2960-2940
FU National Institute for Health Technology Assessment (NIHR HTA) programme
   [11/129/195]; MRC ConDuCT-II Hub (Collaboration and Innovation for
   Difficult or Complex Randomised Controlled Trials in Invasive
   procedures) [MR/K025643/1]; Economic and Social Research Council
   [ES/L007509/1] Funding Source: researchfish; Medical Research Council
   [MC_CF023241, MR/K025643/1] Funding Source: researchfish; National
   Institute for Health Research [11/129/195, NF-SI-0514-10114] Funding
   Source: researchfish; Public Health Agency [STL/4918/13] Funding Source:
   researchfish; ESRC [ES/L007509/1] Funding Source: UKRI; MRC
   [MR/K025643/1] Funding Source: UKRI
FX This research was funded by the National Institute for Health Technology
   Assessment (NIHR HTA) programme (project number: 11/129/195), with
   support from the MRC ConDuCT-II Hub (Collaboration and Innovation for
   Difficult or Complex Randomised Controlled Trials in Invasive
   procedures-MR/K025643/1), of which NM is a member and DT an affiliated
   member.
CR Amoaku W, 2012, EYE, V26, pS2, DOI 10.1038/eye.2011.343
   [Anonymous], 2008, RAN PEG TREATM AG RE
   Bennion AE, 2012, SOC SCI MED, V75, P976, DOI 10.1016/j.socscimed.2012.04.023
   Bhargava JS, 2008, BRIT J OPHTHALMOL, V92, P1601, DOI 10.1136/bjo.2008.140483
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   Burton AE, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003306
   Collett JL, 2011, SOC SCI RES, V40, P513, DOI 10.1016/j.ssresearch.2010.08.008
   Gray SF, 1997, J PUBLIC HEALTH MED, V19, P431, DOI 10.1093/oxfordjournals.pubmed.a024673
   Gray SF, 2000, BRIT J OPHTHALMOL, V84, P456, DOI 10.1136/bjo.84.5.456
   Holtzer-Goor KM, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-14
   Konstantakopoulou E, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004781
   Minassian DC, 2011, BRIT J OPHTHALMOL, V95, P1433, DOI 10.1136/bjo.2010.195370
   Mitchell J, 2002, BRIT J OPHTHALMOL, V86, P777, DOI 10.1136/bjo.86.7.777
   Myint J, 2010, OPHTHAL PHYSL OPT, V30, P847, DOI 10.1111/j.1475-1313.2010.00792.x
   O'Connor PM, 2012, MED J AUSTRALIA, V196, P646, DOI 10.5694/mja11.10856
   Rapport F, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-54
   RNIB, 2013, FUT SIGHT LOSS UK 1
   Strauss A., 1998, BASICS QUALITATIVE R, P57
NR 18
TC 14
Z9 14
U1 2
U2 17
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2015
VL 5
IS 4
AR e007400
DI 10.1136/bmjopen-2014-007400
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC General & Internal Medicine
GA CI4GB
UT WOS:000354705000093
PM 25900465
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Gopinath, B
   Liew, G
   Russell, J
   Cosatto, V
   Burlutsky, G
   Mitchell, P
AF Gopinath, Bamini
   Liew, Gerald
   Russell, Joanna
   Cosatto, Victoria
   Burlutsky, George
   Mitchell, Paul
TI Intake of key micronutrients and food groups in patients with late-stage
   age-related macular degeneration compared with age-sex-matched controls
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID DIETARY ANTIOXIDANTS; 10-YEAR INCIDENCE; GENETIC RISK; ZINC;
   MACULOPATHY; PROGRESSION; PREVALENCE; QUESTIONNAIRE; AUSTRALIA; PATTERNS
AB Background Knowledge of the risk factor profile of patients presenting with late-stage age-related macular degeneration (AMD) could help identify the most frequent modifiable AMD precursors among people who are referred for treatment. We aimed to assess dietary behaviours by comparing adjusted mean intakes of micronutrients and major food groups (fruits, vegetables, fish) among patients with AMD and a sample of age-sex-matched controls.
   Methods Cross-sectional analysis of 480 late AMD cases and 518 population-based age-sex-matched controls with no AMD signs. AMD cases (aged 60+ years) were those presenting for treatment to a hospital eye clinic in Sydney, Australia, during 2012-2015. The comparator group were obtained from a cohort study (Blue Mountains Eye Study; Sydney, Australia) during 2002-2009. Dietary intake was assessed using a semiquantitative food-frequency questionnaire. AMD lesions were assessed from retinal photographs.
   Results After multivariable adjustment, patients with late-stage AMD compared with controls had significantly lower intakes of vitamin E (7.4 vs 9.8 mg/day; p<0.0001), beta-carotene (6232 vs 7738 mu g/day; p<0.0001), vitamin C (161 vs 184 mg/day; p=0.0002) and folate (498.3 vs 602 mu g/day; p<0.0001); but had higher intakes of zinc (13.0 vs 11.9 mg/day; p<0.0001). A significantly lower proportion of patients with late AMD met the recommended intake of vegetables than controls: 52.9% versus 64.5%; p=0.0002.
   Conclusions This study showed significant differences in intakes of vitamins C and E, beta-carotene, folate and vegetables between patients with late-stage AMD and healthy controls, and thus has provided a better understanding of the nutritional intake of patients presenting with advanced AMD.
C1 [Gopinath, Bamini; Liew, Gerald; Cosatto, Victoria; Burlutsky, George; Mitchell, Paul] Univ Sydney, Ctr Vis Res, Westmead Inst Med Res, Sydney, NSW, Australia.
   [Russell, Joanna] Univ Wollongong, Sch Hlth & Soc, Fac Social Sci, Sydney, NSW, Australia.
C3 University of Sydney; Westmead Institute for Medical Research;
   University of Wollongong
RP Gopinath, B (通讯作者)，Univ Sydney, Westmead Hosp, Ctr Vis Res, Westmead Inst Med Res, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM bamini.gopinath@sydney.edu.au
RI Gopinath, Bamini/K-4286-2019; Liew, Gerald/AAB-6870-2022; Russell,
   Joanna/U-6078-2019; Mitchell, Paul/P-1498-2014
OI Gopinath, Bamini/0000-0003-3573-359X; Russell,
   Joanna/0000-0002-0223-9256
FU Macular Disease Foundation Australia; Australian National Health and
   Medical Research Council [974159, 991407, 211069, 262120]; Blackmores
   and Macular Disease Foundation Australia Dr Paul Beaumont Fellowship
FX This study is funded by the Macular Disease Foundation Australia. The
   Blue Mountains Eye and Hearing Studies were supported by the Australian
   National Health and Medical Research Council (Grant Nos 974159, 991407,
   211069, 262120). BG is supported by a Blackmores and Macular Disease
   Foundation Australia Dr Paul Beaumont Fellowship.
CR Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Department of Community Services and Health, 1995, NUTTAB95 NUTR DAT TA
   Department of Community Services and Health, 1990, NUTTAB90 NUTR DAT TA
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   Gopinath B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122548
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   KLEIN BEK, 1989, INVEST OPHTH VIS SCI, V30, P304
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Merle BMJ, 2016, AM J CLIN NUTR, V103, P1135, DOI 10.3945/ajcn.115.117606
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   National Health & Medical Research Council, 2003, DIET GUID AUSTR AD
   Ng WT, 2006, CLIN EXP OPHTHALMOL, V34, P9, DOI 10.1111/j.1442-9071.2006.01141.x
   Rangan AM, 2012, NUTRIENTS, V4, P611, DOI 10.3390/nu4070611
   Shah SU, 2013, CAN J OPHTHALMOL, V48, P204, DOI 10.1016/j.jcjo.2013.01.013
   Smith W, 1998, AUST NZ J PUBL HEAL, V22, P456, DOI 10.1111/j.1467-842X.1998.tb01414.x
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366
   WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780
NR 33
TC 12
Z9 12
U1 0
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2017
VL 101
IS 8
BP 1027
EP 1031
DI 10.1136/bjophthalmol-2016-309490
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FA8BV
UT WOS:000405672100006
PM 27899367
DA 2022-11-30
ER

PT J
AU SanGiovanni, JP
   Rosen, R
   Kaushal, S
AF SanGiovanni, J. P.
   Rosen, R.
   Kaushal, S.
TI Application and Interpretation of Genome-Wide Association (GWA) Studies
   for Informing Pharmacogenomic Research - Examples from the Field of
   Age-Related Macular Degeneration
SO CURRENT MOLECULAR MEDICINE
LA English
DT Article
DE Age-related macular degeneration; genome wide association; ligand;
   pharmacogenetic; pharmacogenomic; system; target
ID ACTIVATED PROTEIN-KINASES; ENDOTHELIAL GROWTH-FACTOR; DOPAMINE D-3
   RECEPTOR; CHOROIDAL NEOVASCULARIZATION; HISTONE DEACETYLASE; INDUCED
   RETINOPATHY; COMPLEX TRAITS; VALPROIC ACID; FATTY-ACIDS; RISK
AB Genome-wide association (GWA) studies apply broad DNA scans on hundreds-of-thousands of common sequence variants in thousands of people for the purpose of mapping trait- or disease-related loci. We provide examples of ligand- and target-based studies from the field of age-related macular degeneration (AMD) to demonstrate the value of the GWA approach in confirmatory and exploratory pharmacogenomics research. Complementing this genomic analysis, we used a simple biochemical retinal pigment epithelium (RPE) oxidative, apoptotic high throughput screening (HTS) assay to identify compounds. This ligand-to-target-to DNA sequence variant-to disease approach provided guidance on rational design of preclinical studies and identified associations between: 1) valproic acid and advanced AMD-associated genes with the capacity to alter GABA-succinate signaling (ALDH5A1, CACNA1C, SUCLA2, and GABBR2) and chromatin remodeling (HDAC9); and 2) Ropinirole and a geographic atrophy-associated gene (DRD3) with the capacity to alter systems involved in cAMP-PKA signaling. In both applications of our method, the breadth of GWA findings allowed efficient expansion of results to identify enriched pathways and additional ligands capable of targeting pathway constituents. A disease associated SNP-to gene-to target-to ligand approach provided guidance to inform preventive and therapeutic preclinical studies investigating roles of targets in: 1) PPAR-RXR transcription complex constituents for neovascular AMD; and 2) the stress activated MAPK signaling cascade constituents for advanced AMD. Our conclusion is that publically available data from GWA studies can be used successfully with open-access genomics, proteomics, structural chemistry, and pharmacogenomics databases in an efficient, rational approach to streamline the processes of planning and implementation for confirmatory and exploratory pre-clinical studies of preventive or therapeutic pharmacologic treatments for complex diseases.
C1 [SanGiovanni, J. P.] NEI, Bethesda, MD 20892 USA.
   [Rosen, R.] New York Eye & Ear Infirm, New York, NY 10009 USA.
   [Kaushal, S.] Retina Specialty Inst, Gainesville, FL 32605 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); New York Eye & Ear Infirmary of Mount Sinai
RP SanGiovanni, JP (通讯作者)，NEI, Bethesda, MD 20892 USA.
EM jpsangio@post.harvard.edu
RI SanGiovanni, John Paul/AAU-3895-2020
FU NEI Intramural Research Program
FX The data used for the original genetic analyses were obtained from the
   NEI Study of Age-Related Macular Degeneration (NEI-AMD) Database found
   at
   http://www.ncbi.nlm.nih.gov/projects/gap/cgibin/study.cgi?study_id=phs00
   0182.v2.p1. We thank NEI-AMD participants and the NEI-AMD Research
   Groups for their valuable contributions to this research. Extant GWA
   study findings were published by Fritsche et al. [23] JPSG was supported
   by the NEI Intramural Research Program.
CR Almeida LN, 2012, GRAEF ARCH CLIN EXP, V250, P185, DOI 10.1007/s00417-011-1807-5
   Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   Altshuler D, 2008, SCIENCE, V322, P881, DOI 10.1126/science.1156409
   Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Barrett JC, 2006, NAT GENET, V38, P659, DOI 10.1038/ng1801
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874
   Bogatcheva NV, 2003, J INVEST MED, V51, P341, DOI 10.1136/jim-51-06-30
   Bradbury C, 2005, LEUKEMIA, V19, P1751, DOI 10.1038/sj.leu.2403910
   Bromberg-White JL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006956
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Cano MD, 2008, PPAR RES, V2008, DOI 10.1155/2008/821592
   Cao GF, 2012, MOL MED REP, V5, P54, DOI 10.3892/mmr.2011.582
   Chen GK, 2007, AM J HUM GENET, V81, P397, DOI 10.1086/519794
   Chiu CJ, 2011, INVEST OPHTH VIS SCI, V52, P9099, DOI 10.1167/iovs.11-7782
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Cichon S, 2009, AM J PSYCHIAT, V166, P540, DOI 10.1176/appi.ajp.2008.08091354
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Craddock N, 2010, NATURE, V464, P713, DOI 10.1038/nature08979
   de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669
   Du HJ, 2013, P NATL ACAD SCI USA, V110, P2377, DOI 10.1073/pnas.1221729110
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Eberle MA, 2007, PLOS GENET, V3, P1827, DOI 10.1371/journal.pgen.0030170
   Favret S, 2013, AGING-US, V5, P427, DOI 10.18632/aging.100563
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Ghodke-Puranik Y, 2013, PHARMACOGENET GENOM, V23, P236, DOI 10.1097/FPC.0b013e32835ea0b2
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Guma M, 2009, P NATL ACAD SCI USA, V106, P8760, DOI 10.1073/pnas.0902659106
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman G.S., 1995, ORIANIZATION RETINA
   Hattori M, 2010, NUCLEIC ACIDS RES, V38, pW652, DOI 10.1093/nar/gkq367
   He YJ, 2011, TRENDS MOL MED, V17, P244, DOI 10.1016/j.molmed.2011.01.007
   Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106
   Hoggart CJ, 2008, GENET EPIDEMIOL, V32, P179, DOI 10.1002/gepi.20292
   Hornan DM, 2007, INVEST OPHTH VIS SCI, V48, P5388, DOI 10.1167/iovs.07-0355
   Huang L, 2009, AM J HUM GENET, V84, P235, DOI 10.1016/j.ajhg.2009.01.013
   Jakobsdottir J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000337
   Jeanneteau F, 2006, P NATL ACAD SCI USA, V103, P10753, DOI 10.1073/pnas.0508189103
   Johannessen CU, 2003, CNS DRUG REV, V9, P199
   Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682
   Joyal JS, 2012, ACTA PAEDIATR, V101, P819, DOI 10.1111/j.1651-2227.2012.02692.x
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Keech AC, 2007, LANCET, V370, P1687, DOI 10.1016/S0140-6736(07)61607-9
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koto T, 2007, INVEST OPHTH VIS SCI, V48, P4328, DOI 10.1167/iovs.06-1148
   Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177
   Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Lee PH, 2012, BIOINFORMATICS, V28, P1797, DOI 10.1093/bioinformatics/bts191
   Lundstrom K, 1996, BIOCHEM BIOPH RES CO, V225, P1068, DOI 10.1006/bbrc.1996.1296
   Manolio TA, 2008, J CLIN INVEST, V118, P1590, DOI 10.1172/JCI34772
   Manolio TA, 2013, NAT REV GENET, V14, P549, DOI 10.1038/nrg3523
   Manolio TA, 2013, GENET MED, V15, P258, DOI 10.1038/gim.2012.157
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   Manolio TA, 2009, ANNU REV MED, V60, P443, DOI 10.1146/annurev.med.60.061907.093117
   Marchini J, 2007, NAT GENET, V39, P906, DOI 10.1038/ng2088
   McCarroll SA, 2010, NAT GENET, V42, P365, DOI 10.1038/ng0510-365
   McCarthy MI, 2008, NAT REV GENET, V9, P356, DOI 10.1038/nrg2344
   McCarthy MI, 2008, HUM MOL GENET, V17, pR156, DOI 10.1093/hmg/ddn289
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Murata T, 2000, INVEST OPHTH VIS SCI, V41, P2309
   Pages G, 2000, J BIOL CHEM, V275, P26484, DOI 10.1074/jbc.M002104200
   Pe'er I, 2008, GENET EPIDEMIOL, V32, P381, DOI 10.1002/gepi.20303
   Pe'er I, 2006, NAT GENET, V38, P663, DOI 10.1038/ng1816
   Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200
   Pons M, 2011, AM J PATHOL, V178, P2665, DOI 10.1016/j.ajpath.2011.02.006
   Purcell SM, 2009, NATURE, V460, P748, DOI 10.1038/nature08185
   Sabatti C, 2003, GENETICS, V164, P829
   Sabatti Chiara, 2007, Methods Mol Biol, V376, P195
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071239
   SanGiovanni JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053155
   SanGiovanni JP, 2009, ARCH OPHTHALMOL-CHIC, V127, P110, DOI 10.1001/archophthalmol.2008.518
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   SanGiovanni JP, 2009, INVEST OPHTH VIS SCI, V50, P3096
   Sapieha P, 2008, NAT MED, V14, P1067, DOI 10.1038/nm.1873
   Sapieha P, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001571
   Schuetz A, 2008, J BIOL CHEM, V283, P11355, DOI 10.1074/jbc.M707362200
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Sheets KG, 2010, MOL VIS, V16, P320
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Smoller JW, 2013, LANCET, V381, P1371, DOI 10.1016/S0140-6736(12)62129-1
   Stahl A, 2010, CIRC RES, V107, P495, DOI 10.1161/CIRCRESAHA.110.221317
   Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568
   Su LD, 2012, INT IMMUNOPHARMACOL, V14, P606, DOI 10.1016/j.intimp.2012.09.010
   Taylor A, 2012, AUTOPHAGY, V8, P1404, DOI 10.4161/auto.21150
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P18, DOI 10.1111/j.1442-9071.2011.02581.x
   VANDENBERG RJ, 1993, EXP BRAIN RES, V93, P279, DOI 10.1007/BF00228395
   Wakefield J, 2009, GENET EPIDEMIOL, V33, P79, DOI 10.1002/gepi.20359
   Ward LD, 2012, NAT BIOTECHNOL, V30, P1095, DOI 10.1038/nbt.2422
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   Weng CY, 2009, CURR EYE RES, V34, P867, DOI 10.3109/02713680903177890
   Xu J, 2011, FASEB J, V25, P2221, DOI 10.1096/fj.10-178350
   Yang JA, 2010, NAT GENET, V42, P565, DOI 10.1038/ng.608
   Zheng XFS, 2012, AGING-US, V4, P375, DOI 10.18632/aging.100469
NR 107
TC 2
Z9 2
U1 0
U2 3
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566-5240
EI 1875-5666
J9 CURR MOL MED
JI Curr. Mol. Med.
PY 2014
VL 14
IS 7
BP 814
EP 832
DI 10.2174/1566524014666140811113606
PG 19
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA AO0QN
UT WOS:000341016100003
PM 25109799
DA 2022-11-30
ER

PT J
AU SanGiovanni, JP
   Arking, DE
   Iyengar, SK
   Elashoff, M
   Clemons, TE
   Reed, GF
   Henning, AK
   Sivakumaran, TA
   Xu, XM
   Dewan, A
   Agron, E
   Rochtchina, E
   Sue, CM
   Wang, JJ
   Mitchell, P
   Hoh, J
   Francis, PJ
   Klein, ML
   Chew, EY
   Chakravarti, A
AF SanGiovanni, John Paul
   Arking, Dan E.
   Iyengar, Sudha K.
   Elashoff, Michael
   Clemons, Traci E.
   Reed, George F.
   Henning, Alice K.
   Sivakumaran, Theru A.
   Xu, Xuming
   DeWan, Andrew
   Agron, Elvira
   Rochtchina, Elena
   Sue, Carolyn M.
   Wang, Jie Jin
   Mitchell, Paul
   Hoh, Josephine
   Francis, Peter J.
   Klein, Michael L.
   Chew, Emily Y.
   Chakravarti, Aravinda
TI Mitochondrial DNA Variants of Respiratory Complex I that Uniquely
   Characterize Haplogroup T2 Are Associated with Increased Risk of
   Age-Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
AB Background: Age-related macular degeneration (AMD), a chronic neurodegenerative and neovascular retinal disease, is the leading cause of blindness in elderly people of western European origin. While structural and functional alterations in mitochondria (mt) and their metabolites have been implicated in the pathogenesis of chronic neurodegenerative and vascular diseases, the relationship of inherited variants in the mitochondrial genome and mt haplogroup subtypes with advanced AMD has not been reported in large prospective cohorts.
   Methodology/Prinicipal Findings: We examined the relationship of inherited mtDNA variants with advanced AMD in 1168 people using a three-stage design on samples from 12-year and 10-year prospective studies on the natural history of age-related eye disease. In Stage I we resequenced the entire genome in 99 elderly AMD-free controls and 215 people with advanced AMD from the 12-year study. A consistent association with AMD in 14 of 17 SNPs characterizing the mtDNA T haplogroup emerged. Further analysis revealed these associations were driven entirely by the T2 haplogroup, and characterized by two variants in Complex I genes (A11812G of MT-ND4 and A14233G of MT-ND6). We genotyped T haplogroups in an independent sample of 490 cases and 61 controls from the same study (Stage II) and in 56 cases and 246 controls from the 10-year study (Stage III). People in the T2 haplogroup were approximately 2.5 times more likely to have advanced AMD than their peers (odds ratio [OR] = 2.54, 95%CI 1.36-4.80, P <= 0.004) after considering the totality of evidence. Findings persisted after considering the impact of AMD-associated variants A69S and Y402H (OR = 5.19, 95%CI 1.19-22.69, P <= 0.029).
   Conclusion: Loci defining the mtDNA T2 haplogroup and Complex I are reasonable targets for novel functional analyses and therapeutic research in AMD.
RP SanGiovanni, JP (通讯作者)，NEI, NIH, Bethesda, MD 20892 USA.
EM jpsangio@post.harvard.edu
RI SanGiovanni, John Paul/AAU-3895-2020; /S-1190-2019; wang,
   jie/GRS-0942-2022; Mitchell, Paul/P-1498-2014; Wang, Jie Jin/P-1499-2014
OI /0000-0001-7488-250X; Wang, Jie Jin/0000-0001-9491-4898; DeWan,
   Andrew/0000-0002-7679-8704
FU Intramural NIH HHS [ZIA EY000489-01, Z99 EY999999] Funding Source:
   Medline; NEI NIH HHS [R01 EY012203, R01 EY015771, R01EY015771, EY015810,
   R01-EY12203, 01-EY-0-2127, R01 EY015810] Funding Source: Medline;
   NATIONAL EYE INSTITUTE [ZIAEY000489, ZIEEY000487, R01EY012203,
   N01EY002127, R01EY015810] Funding Source: NIH RePORTER
CR *AREDS RES GROUP, 2008, DEF FIN AG REL MAC D
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Chomyn A, 2001, J BIOENERG BIOMEMBR, V33, P251, DOI 10.1023/A:1010791204961
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cutler DJ, 2001, GENOME RES, V11, P1913, DOI 10.1101/gr.197201
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   La Morgia C, 2008, NEUROLOGY, V70, P762, DOI 10.1212/01.wnl.0000295505.74234.d0
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Maitra A, 2004, GENOME RES, V14, P812, DOI 10.1101/gr.2228504
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Novembre J, 2008, NATURE, V456, P98, DOI 10.1038/nature07331
   Reme CE, 1998, PROG RETIN EYE RES, V17, P443, DOI 10.1016/S1350-9462(98)00009-3
   Samuels DC, 2006, AM J HUM GENET, V78, P713, DOI 10.1086/502682
   Saxena R, 2006, AM J HUM GENET, V79, P54, DOI 10.1086/504926
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102
   Vogel RO, 2007, J BIOL CHEM, V282, P7582, DOI 10.1074/jbc.M609410200
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wright AF, 2004, NAT GENET, V36, P1153, DOI 10.1038/ng1448
NR 30
TC 71
Z9 76
U1 1
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 12
PY 2009
VL 4
IS 5
AR e5508
DI 10.1371/journal.pone.0005508
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 444VZ
UT WOS:000266009800006
PM 19434233
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Bian, W
   Wan, JL
   Tan, MQ
   Su, J
   Yuan, Y
   Wang, ZH
   Li, SY
AF Bian, Wei
   Wan, Junli
   Tan, Mingqiong
   Su, Jun
   Yuan, Yi
   Wang, Zonghua
   Li, Shiying
TI Predictors of health-related quality of life in Chinese patients
   receiving treatment for neovascular age-related macular degeneration: a
   prospective longitudinal study
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Health-related quality of life;
   Predictor; Longitudinal study
ID VISION-RELATED FUNCTION; RANIBIZUMAB TREATMENT; IMPACT; DEPRESSION; EYE;
   MANAGEMENT; THERAPY; ANXIETY; TRIAL
AB Background Age-related macular degeneration (AMD) is currently the leading cause of irreversible visual impairment in developed countries and seriously affects the health-related quality of life (HRQoL) of patients. However, the majority of the research in this area employs cross-sectional design; longitudinal research investigating changes in HRQoL and influencing factors is limited. The aim of this study was to use a longitudinal study design to investigate descriptive trends in HRQoL and their predictive factors in Chinese AMD patients receiving treatment with vascular endothelial growth factor inhibitors (anti-VEGF) at baseline and follow-ups. Methods In a sample of 142 AMD patients from the outpatient clinic of the Southwest Eye Hospital, a tertiary major hospital in the southwest of China, each patient completed a self-administered questionnaire assessing demographics, clinical features, HRQoL, depression, anxiety, coping style, social support, and self-efficacy at baseline and at 1-, 3-, 6-, and 12-month follow-up appointments. Results The total score of HRQoL fluctuated, with the highest score at the 6-month follow-up and the lowest score at baseline. Multivariable linear regression showed the predictors of HRQoL are best-corrected visual acuity (BCVA), income level, depression, and visual acuity (VA) of the treated eye at baseline; BCVA, income, and depression at the 1-month follow-up; duration, area of residence, gender, VA of the treated eye, BCVA, income, anxiety, social support, self-efficacy, and depression at the 3-month follow-up; gender, BCVA, income, anxiety, social support, self-efficacy, depression, negative coping, and positive coping at the 6-month follow-up; and BCVA, social support, self-efficacy, and depression at the 12-month follow-up. Conclusions The HRQoL and its predictive factors in Chinese AMD patients receiving anti-VEGF treatment fluctuated over time. It is suggested that medical staff should get more information when planning precise care for improving patients' HRQoL.
C1 [Bian, Wei; Wan, Junli; Tan, Mingqiong; Su, Jun; Li, Shiying] Amy Med Univ, Southwest Hosp, Mil Med Univ 3, Southwest Eye Hosp, Chongqing 400038, Peoples R China.
   [Bian, Wei; Wan, Junli; Tan, Mingqiong; Su, Jun; Li, Shiying] Key Lab Visual Damage & Regenerat & Restorat Chon, GaotanyanSt 29, Chongqing 400038, Peoples R China.
   [Yuan, Yi] Army Med Univ, Sch Basic Med, Mil Med Univ 3, Chongqing 400038, Peoples R China.
   [Wang, Zonghua] Army Med Univ, Sch Nursing, Mil Med Univ 3, Gaotanyan St 29, Chongqing 400038, Peoples R China.
C3 Army Medical University; Army Medical University; Army Medical
   University
RP Li, SY (通讯作者)，Amy Med Univ, Southwest Hosp, Mil Med Univ 3, Southwest Eye Hosp, Chongqing 400038, Peoples R China.; Li, SY (通讯作者)，Key Lab Visual Damage & Regenerat & Restorat Chon, GaotanyanSt 29, Chongqing 400038, Peoples R China.; Wang, ZH (通讯作者)，Army Med Univ, Sch Nursing, Mil Med Univ 3, Gaotanyan St 29, Chongqing 400038, Peoples R China.
EM zonghua910@tmmu.edu.cn; shiying_li@126.com
RI Li, Shiying/AAL-4898-2021
OI Li, Shiying/0000-0001-9783-9520
FU Army Medical University Excellent Youth Fund [XZ-2019-505-054];
   Chongqing Social Science Planning Youth Project [2018QNSH42]; National
   Nature Science Foundation of China [81974138]
FX This study was funded by the Army Medical University Excellent Youth
   Fund (XZ-2019-505-054), Chongqing Social Science Planning Youth Project
   (2018QNSH42), National Nature Science Foundation of China (81974138).
   The funding bodies had no role in the design of the study and
   collection, analysis, and interpretation of data and in the writing of
   the manuscript.
CR Augustin A, 2007, INVEST OPHTH VIS SCI, V48, P1498, DOI 10.1167/iovs.06-0761
   Bian W, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-018756
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Casten RJ, 2002, J VISUAL IMPAIR BLIN, V96, P399, DOI 10.1177/0145482X0209600603
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Chatziralli I, 2017, SEMIN OPHTHALMOL, V32, P772, DOI 10.1080/08820538.2016.1181192
   Coleman AL, 2010, AM J OPHTHALMOL, V150, P683, DOI 10.1016/j.ajo.2010.05.030
   Dawson SR, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-78
   Fenwick EK, 2018, BRIT J OPHTHALMOL, V102, P377, DOI 10.1136/bjophthalmol-2017-310532
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1246, DOI 10.1016/j.ophtha.2013.12.032
   Han Mei, 2011, Journal of Shandong University (Health Sciences), V49, P160
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Herndon JE, 2008, J CLIN ONCOL, V26, P4116, DOI 10.1200/JCO.2008.16.7460
   Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4
   Inoue M, 2014, CLIN OPHTHALMOL, V8, P1711, DOI 10.2147/OPTH.S68293
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Karampelas M, 2015, OPHTHALMOL THER, V4, P43, DOI 10.1007/s40123-015-0031-5
   Khadka J, 2016, OPTOMETRY VISION SCI, V93, P1485, DOI 10.1097/OPX.0000000000000992
   Kim J, 2010, JPN J OPHTHALMOL, V54, P325, DOI 10.1007/s10384-010-0825-x
   Kong F, 2013, SOC INDIC RES, V110, P271, DOI 10.1007/s11205-011-9930-6
   Leys A, 2008, EYE, V22, P792, DOI 10.1038/sj.eye.6702900
   Matamoros E, 2015, OPHTHALMOLOGICA, V234, P151, DOI 10.1159/000433448
   Mathew RS, 2011, OPHTHAL PHYSL OPT, V31, P375, DOI 10.1111/j.1475-1313.2011.00848.x
   McCloud C, 2014, OPTOMETRY VISION SCI, V91, P966, DOI 10.1097/OPX.0000000000000320
   Mudrak J, 2016, EUR J AGEING, V13, P5, DOI 10.1007/s10433-015-0352-1
   Orr P, 2011, INVEST OPHTH VIS SCI, V52, P3354, DOI 10.1167/iovs.10-5645
   Pirschel Chris, 2016, ONS Connect, V31, P12
   Radloff L, 1977, APPL PSYCH MEAS, V1, P385, DOI DOI 10.1177/014662167700100306
   Radvay X, 2007, J VESTIBUL RES-EQUIL, V17, P183
   Rees G, 2010, DISABIL REHABIL, V32, P808, DOI 10.3109/09638280903304193
   Rovner BW, 2014, OPHTHALMOLOGY, V121, P2204, DOI 10.1016/j.ophtha.2014.05.002
   Ryan B, 2014, CLIN EXP OPTOM, V97, P209, DOI 10.1111/cxo.12157
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   Schwarzer R., 1995, JERUSALEM
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   Sturrock BA, 2015, INVEST OPHTH VIS SCI, V56, P2416, DOI 10.1167/iovs.14-16223
   Tanja B, 2004, GERONTOLOGIST, V6, P6
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Vukicevic M, 2016, EYE, V30, P413, DOI 10.1038/eye.2015.235
   Wang CW, 2008, OPTOMETRY VISION SCI, V85, P1091, DOI 10.1097/OPX.0b013e31818b9f23
   Wang LL, 2015, CHINESE MED J-PEKING, V128, P1154, DOI 10.4103/0366-6999.156083
   WILCOX BL, 1981, AM J COMMUN PSYCHOL, V9, P371, DOI 10.1007/BF00918169
   Yamamoto KN, 2017, CANCER RES, V77, P3325, DOI 10.1158/0008-5472.CAN-16-1208
   Yuan CR, 2015, CANCER NURS, V38, P333, DOI 10.1097/NCC.0000000000000290
   Yuzawa M, 2013, CLIN OPHTHALMOL, V7, P1325, DOI 10.2147/OPTH.S45248
   Zhu Wanlu, 2014, Zhonghua Yan Ke Za Zhi, V50, P189
NR 46
TC 3
Z9 3
U1 1
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JUL 16
PY 2020
VL 20
IS 1
AR 291
DI 10.1186/s12886-020-01561-3
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA MP7HT
UT WOS:000552373200002
PM 32677913
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Owsley, C
   Huisingh, C
   Clark, ME
   Jackson, GR
   McGwin, G
AF Owsley, Cynthia
   Huisingh, Carrie
   Clark, Mark E.
   Jackson, Gregory R.
   McGwin, Gerald, Jr.
TI Comparison of Visual Function in Older Eyes in the Earliest Stages of
   Age-related Macular Degeneration to Those in Normal Macular Health
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; aging; dark adaptation; functional
   endpoints; visual function
ID MEDIATED DARK-ADAPTATION; VITAMIN-A; MULTIFOCAL ELECTRORETINOGRAM;
   FUNDUS AUTOFLUORESCENCE; RHODOPSIN LEVELS; RETINAL FUNCTION; FELLOW EYE;
   ROD; SENSITIVITY; ACUITY
AB Purpose: To compare the ability of several visual functional tests in terms of the strength of their associations with the earliest phases of age-related macular degeneration (AMD), which bears on their potential to serve as functional endpoints in evaluating treatments for early AMD and prevention strategies.
   Materials and methods: Eyes from adults >= 60 years old were identified as being in normal macular health or in the earliest stages of AMD (steps 2, 3 or 4) through grading of color stereo-fundus photos by an experienced grader masked to all other study variables who used the 9-step Age-Related Eye Disease Study (AREDS) classification system for AMD severity. Visual function was assessed using the following tests: best-corrected visual acuity, low luminance visual acuity, spatial contrast sensitivity, macular cone-mediated light sensitivity and rod-mediated dark adaptation.
   Results: A total of 1260 eyes were tested from 640 participants; 1007 eyes were in normal macular health (defined as step 1 in AREDS system) and 253 eyes had early AMD (defined as steps 2, 3 or 4). Adjusting for age and gender, early AMD eyes had two times the odds of having delayed rod-mediated dark adaptation than eyes in normal macular health (p = 0.0019). Visual acuity, low luminance acuity, spatial contrast sensitivity and macular light sensitivity did not differ between normal eyes and early AMD eyes.
   Conclusions: Eyes in the earliest phases of AMD were two times more likely to have delayed rod-mediated dark adaptation, as assessed by the rod-intercept, as compared to older eyes in normal macular health, whereas there was no difference in early AMD versus normal eyes in tests of visual acuity, low luminance acuity, macular light sensitivity and spatial contrast sensitivity.
C1 [Owsley, Cynthia; Huisingh, Carrie; Clark, Mark E.; McGwin, Gerald, Jr.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, 700 S 18th St,Suite 609, Birmingham, AL 35294 USA.
   [Jackson, Gregory R.] MacuLogix Inc, Hummelstown, PA USA.
   [McGwin, Gerald, Jr.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Owsley, C (通讯作者)，Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, 700 S 18th St,Suite 609, Birmingham, AL 35294 USA.
EM owsley@uab.edu
OI Huisingh, Carrie/0000-0002-7010-2024
FU National Institute on Aging of the National Institutes of Health,
   Research to Prevent Blindness [R01AG04212]; EyeSight Foundation of
   Alabama; Alfreda J. Schueler Trust; NATIONAL INSTITUTE ON AGING
   [R01AG004212] Funding Source: NIH RePORTER
FX This research was supported by the National Institute on Aging of the
   National Institutes of Health (R01AG04212), Research to Prevent
   Blindness, the EyeSight Foundation of Alabama, and the Alfreda J.
   Schueler Trust.
CR Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   BRENTON RS, 1986, OPHTHALMOLOGICA, V193, P56, DOI 10.1159/000309679
   Cankova Z, 2011, EXP EYE RES, V93, P947, DOI 10.1016/j.exer.2011.10.016
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dimitrov PN, 2012, INVEST OPHTH VIS SCI, V53, P5213, DOI 10.1167/iovs.11-8958
   DOWLING JE, 1958, P NATL ACAD SCI USA, V44, P648, DOI 10.1073/pnas.44.7.648
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   ELLIOTT DB, 1991, CLIN VISION SCI, V6, P471
   Elsner AE, 2002, J OPT SOC AM A, V19, P215, DOI 10.1364/JOSAA.19.000215
   Feigl B, 2004, CURR EYE RES, V29, P327, DOI 10.1080/02713680490516198
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Garlipp MA, 2013, EXP EYE RES, V113, P192, DOI 10.1016/j.exer.2013.02.003
   Haymes SA, 2006, INVEST OPHTH VIS SCI, V47, P2739, DOI 10.1167/iovs.05-1419
   Jackson GR, 2005, MACULAR DEGENERATION, P45, DOI 10.1007/3-540-26977-0_3
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jackson GR, 2014, OPTOMETRY VISION SCI, V91, P925, DOI 10.1097/OPX.0000000000000247
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KATZ ML, 1993, EXP EYE RES, V56, P671, DOI 10.1006/exer.1993.1084
   KEMP CM, 1988, EXP EYE RES, V46, P185, DOI 10.1016/S0014-4835(88)80076-9
   KEMP CM, 1989, EXP EYE RES, V49, P49
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Lovie-Kitchin Jan, 2005, Clin Exp Optom, V88, P292
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   Patel PJ, 2009, INVEST OPHTH VIS SCI, V50, P2621, DOI 10.1167/iovs.08-2407
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Vujosevic S, 2011, OPHTHALMOLOGICA, V225, P155, DOI 10.1159/000320340
NR 48
TC 48
Z9 48
U1 0
U2 14
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PY 2016
VL 41
IS 2
BP 266
EP 272
DI 10.3109/02713683.2015.1011282
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL1NF
UT WOS:000375398200016
PM 25802989
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ulanczyk, Z
   Grabowicz, A
   Mozolewska-Piotrowska, K
   Safranow, K
   Kawa, MP
   Palucha, A
   Krawczyk, M
   Sikora, P
   Matczynska, E
   Machalinski, B
   Machalinska, A
AF Ulanczyk, Zofia
   Grabowicz, Aleksandra
   Mozolewska-Piotrowska, Katarzyna
   Safranow, Krzysztof
   Kawa, Milosz Piotr
   Palucha, Andrzej
   Krawczyk, Mariusz
   Sikora, Piotr
   Matczynska, Ewa
   Machalinski, Boguslaw
   Machalinska, Anna
TI Genetic factors associated with age-related macular degeneration:
   identification of a novel PRPH2 single nucleotide polymorphism
   associated with increased risk of the disease
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age&#8208; related macular degeneration; ARMS; CFH; PRPH2; sequencing;
   SNP; SNV
ID COMPLEMENT FACTOR-H; ENDOTHELIAL DYSFUNCTION; VARIANT; SUSCEPTIBILITY;
   PERIPHERIN/RDS; ANGIOGENESIS; INFLAMMATION; Y402H; AMD; PROGRESSION
AB Purpose Age-related macular degeneration (AMD) is associated with multiple environmental and genetic risk factors. Two main risk factors for AMD are variants in the CFH and ARMS2/HTRA1 genes. We investigated over 2000 variants in AMD patients and controls using high-throughput sequencing methods to search for variants associated with AMD.
   Methods A total of 296 AMD patients and 100 controls were enrolled in this study. Genetic analysis was performed with the Illumina NextSeq 500 system.
   Results Multivariate analysis of patients and controls, adjusted for age, sex and smoking status (pack-years), revealed that three SNPs were strong risk factors independently associated with AMD: CFH Y402H, ARMS A69S and PRPH2 c.582-67T>A (rs3818086). The TC genotype in CFH Y402H was associated with 1.90-fold higher odds, and the CC genotype was associated with 5.66-fold higher odds of AMD compared with the TT genotype. The GT genotype in ARMS A69S was associated with 2.40-fold higher odds, and the TT genotype was associated with 6.75-fold higher odds of disease compared with the GG genotype. In the case of rs3818086, the A allele could be considered a 'risk' allele, since AA + TA genotypes were associated with 2.33-fold higher odds of AMD compared with the TT genotype.
   Conclusions Although PRPH2 mutations have been previously implicated in various forms of retinal degeneration, to the best of our knowledge, this study is the first to show that the rs3818086 variant increases the risk for AMD more than two times. Further studies on larger cohorts are required to elucidate how this variant affects protein structure.
C1 [Ulanczyk, Zofia; Kawa, Milosz Piotr; Machalinski, Boguslaw] Pomeranian Med Univ, Dept Gen Pathol, Szczecin, Poland.
   [Grabowicz, Aleksandra; Mozolewska-Piotrowska, Katarzyna; Machalinska, Anna] Pomeranian Med Univ, Dept Ophthalmol 1, Al Powstancow Wlkp 72, PL-70111 Szczecin, Poland.
   [Safranow, Krzysztof] Pomeranian Med Univ, Dept Biochem & Med Chem, Szczecin, Poland.
   [Palucha, Andrzej; Krawczyk, Mariusz; Sikora, Piotr; Matczynska, Ewa] Genomed SA, Warsaw, Poland.
C3 Pomeranian Medical University; Pomeranian Medical University; Pomeranian
   Medical University
RP Machalinska, A (通讯作者)，Pomeranian Med Univ, Dept Ophthalmol 1, Al Powstancow Wlkp 72, PL-70111 Szczecin, Poland.
EM annam@pum.edu.pl
RI Safranow, Krzysztof/B-5127-2015
OI Safranow, Krzysztof/0000-0001-9415-2758
FU Polish National Centre for Research and Development
   [STRATEGMED1/234261/2NCBR/2014]
FX This work was supported by Polish National Centre for Research and
   Development (grant number: STRATEGMED1/234261/2NCBR/2014).
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Armstrong Richard A, 2015, J Stem Cells, V10, P171
   Ayoub T, 2009, J ROY SOC MED, V102, P56, DOI 10.1258/jrsm.2009.080298
   Baird PN, 2007, CLIN EXP OPHTHALMOL, V35, P194, DOI 10.1111/j.1442-9071.2007.01477.x
   BASCOM RA, 1992, NEURON, V8, P1171, DOI 10.1016/0896-6273(92)90137-3
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Bonyadi MHJ, 2016, CURR EYE RES, V41, P1519, DOI 10.3109/02713683.2016.1158274
   Boon CJF, 2008, PROG RETIN EYE RES, V27, P213, DOI 10.1016/j.preteyeres.2008.01.002
   Boyle EA, 2014, BIOINFORMATICS, V30, P2670, DOI 10.1093/bioinformatics/btu353
   Cascella R, 2018, PROG RETIN EYE RES, V63, P132, DOI 10.1016/j.preteyeres.2017.11.004
   Chakraborty D, 2016, HUM MOL GENET, V25, P3500, DOI 10.1093/hmg/ddw193
   Chakravarthy U, 2013, OPHTHALMOLOGY, V120, P342, DOI 10.1016/j.ophtha.2012.08.004
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Conley SM, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017376
   Cooper David N, 2010, Hum Genomics, V4, P284
   Farnoodian M, 2017, CLIN SCI, V131, P1763, DOI 10.1042/CS20170066
   Farwick A, 2009, EYE, V23, P2238, DOI 10.1038/eye.2008.426
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gangnon RE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1169, DOI 10.1001/archophthalmol.2012.693
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Horie-Inoue K, 2014, BIOCHEM BIOPH RES CO, V452, P263, DOI 10.1016/j.bbrc.2014.08.013
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Lee J, 2012, J DENT RES, V91, P142, DOI 10.1177/0022034511421200
   Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp324, 10.1093/bioinformatics/btp100]
   Litwinska Z, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00286
   Loewen CJR, 2001, J BIOL CHEM, V276, P22388, DOI 10.1074/jbc.M011710200
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Mandal NA, 2006, INVEST OPHTH VIS SCI, V47, P4091, DOI 10.1167/iovs.05-1655
   Martin M., 2011, EMBNET J, V17, P10, DOI [DOI 10.14806/EJ.17.1.200, 10.14806/ej.17.1.200]
   McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Restrepo NA, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14246
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Saunier V, 2018, JAMA OPHTHALMOL, V136, P473, DOI 10.1001/jamaophthalmol.2018.0504
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shastry BS, 1999, OPHTHALMOLOGICA, V213, P165, DOI 10.1159/000027413
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2012, ARCH OPHTHALMOL-CHIC, V130, P116, DOI 10.1001/archopthalmol.2011.1370
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   Van der Auwera Geraldine A, 2013, Curr Protoc Bioinformatics, V43, DOI [10.1002/0471250953.bi1201s43, 10.1002/0471250953.bi1110s43]
   Stuck MW, 2016, PROG RETIN EYE RES, V52, P47, DOI 10.1016/j.preteyeres.2015.12.002
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Ulanczyk Z, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225750
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Wang L, 2016, J PHYSIOL BIOCHEM, V72, P583, DOI 10.1007/s13105-016-0496-2
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
NR 63
TC 1
Z9 1
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2021
VL 99
IS 7
BP 739
EP 749
DI 10.1111/aos.14721
EA DEC 2020
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WD6YR
UT WOS:000601091800001
PM 33354892
DA 2022-11-30
ER

PT J
AU Dev, MK
   Wood, JM
   Black, AA
AF Dev, Mahesh K.
   Wood, Joanne M.
   Black, Alex A.
TI The effect of low light levels on postural stability in older adults
   with age-related macular degeneration
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Article
DE age-related macular degeneration; low light levels; mesopic; older
   adults; postural stability; sway; visual impairment
ID MEDIATED DARK-ADAPTATION; ROBSON CONTRAST SENSITIVITY; LOW-LUMINANCE;
   VISUAL-ACUITY; SPATIAL ORIENTATION; DUAL TASKING; RISK-FACTORS; VISION;
   FALLS; BALANCE
AB Purpose To investigate the effect of low light levels on postural stability in older adults with and without age-related macular degeneration (AMD).
   Methods Participants included 28 older adults [14 with AMD (mean age +/- S.D., 83.4 +/- 6.7 years) and 14 controls with normal vision (74.6 +/- 3.3 years)]. Postural stability was assessed with eyes open on both a firm and foam surface under four lighting conditions in a randomised order: photopic (similar to 436 lux, vertically at the eye), sudden reduction to mesopic (similar to 436 to similar to 1 lux), adapted mesopic (similar to 1 lux) and adapted mesopic with a light emitting diode (LED) door frame lighting system (similar to 1.3 lux), using the root mean square (RMS) of the centre of pressure measures derived from an electronic force plate in the anterior-posterior (AP) and medio-lateral (ML) directions. Visual function was assessed binocularly (visual acuity, contrast sensitivity and visual fields), physical function was assessed using standardised measures (sit-to-stand, grip strength and the timed walk test) and self-reported difficulties under low light levels were recorded using the Low Luminance Questionnaire. Data were analysed using linear mixed models.
   Results For all participants, low light levels significantly increased postural sway on the foam surface in the AP (p = 0.01) but not ML (p = 0.80) direction, but had no effect on postural stability on the firm surface. On the foam surface, while AP-RMS sway was significantly greater in the sudden (p < 0.001) and adapted (p = 0.02) mesopic compared to the photopic condition, sway for the adapted mesopic with the LED lighting system was not significantly different to the photopic condition (p = 0.20). On the foam surface, AP-RMS (p = 0.02) and ML-RMS (p < 0.001) sway were significantly greater in the AMD compared to the control group. None of the measures of visual function was significantly associated with AP- or ML-RMS sway.
   Conclusions On the foam surface, low light levels significantly reduced postural stability in older adults with and without AMD, and postural stability was significantly reduced for the AMD group compared to controls, regardless of light level. Importantly, the LED lighting system reduced sway under mesopic conditions, which was not significantly greater than that measured under photopic conditions in either group. These findings have important implications for enhancing the visual environment for older adults with and without AMD to improve postural stability and reduce the risk of falls in low lighting environments.
C1 [Dev, Mahesh K.; Wood, Joanne M.; Black, Alex A.] Queensland Univ Technol, Sch Optometry & Vis Sci, Ctr Vis & Eye Res, Brisbane, Qld, Australia.
   [Dev, Mahesh K.; Wood, Joanne M.; Black, Alex A.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia.
C3 Queensland University of Technology (QUT); Queensland University of
   Technology (QUT)
RP Dev, MK (通讯作者)，Queensland Univ Technol, Sch Optometry & Vis Sci, Ctr Vis & Eye Res, Brisbane, Qld, Australia.
EM maheshkumar.dev@hdr.qut.edu.au
RI Black, Alex/I-9727-2012; Dev, Mahesh Kumar/T-9113-2019
OI Black, Alex/0000-0002-8671-5167; Dev, Mahesh Kumar/0000-0003-1339-8727;
   , Joanne/0000-0002-0776-7736
FU School of Optometry and Vision Science, Queensland University of
   Technology
FX We would like to express our gratitude to the School of Optometry and
   Vision Science, Queensland University of Technology for providing
   funding support for this study. We would also like to thank all research
   participants for their generosity of time and helping with this study.
   We would also like to thank Ursula White for help with recruiting
   participants.
CR Acton JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039944
   Agostini V, 2016, GAIT POSTURE, V43, P233, DOI 10.1016/j.gaitpost.2015.10.003
   Anand V, 2003, INVEST OPHTH VIS SCI, V44, P4670, DOI 10.1167/iovs.03-0455
   Anand V, 2003, INVEST OPHTH VIS SCI, V44, P2885, DOI 10.1167/iovs.02-1031
   Anand V, 2002, OPHTHAL PHYSL OPT, V22, P528, DOI 10.1046/j.1475-1313.2002.00067.x
   Bailey IL, 2013, VISION RES, V90, P2, DOI 10.1016/j.visres.2013.05.004
   Birt CM, 1997, OPHTHALMOLOGY, V104, P1126, DOI 10.1016/S0161-6420(97)30173-0
   Bohannon RW, 2010, ISOKINET EXERC SCI, V18, P235, DOI 10.3233/IES-2010-0389
   Brooke-Wavell K, 2002, GERONTOLOGY, V48, P293, DOI 10.1159/000065252
   CAMPBELL AJ, 1989, J GERONTOL, V44, pM112, DOI 10.1093/geronj/44.4.m112
   Chari Satyan R, 2016, Pilot Feasibility Stud, V2, P1
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Curb JD, 2006, J AM GERIATR SOC, V54, P737, DOI 10.1111/j.1532-5415.2006.00700.x
   ELLIOTT DB, 1990, OPHTHAL PHYSL OPT, V10, P21, DOI 10.1111/j.1475-1313.1990.tb01100.x
   ELLIOTT DB, 1995, OPHTHAL PHYSL OPT, V15, P553, DOI 10.1016/0275-5408(95)00025-9
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Figueiro MG, 2008, LIGHTING RES TECHNOL, V40, P111, DOI 10.1177/1477153507084198
   Figueiro MG, 2012, AGE AGEING, V41, P392, DOI 10.1093/ageing/afr166
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   HORAK FB, 1989, NEUROBIOL AGING, V10, P727, DOI 10.1016/0197-4580(89)90010-9
   Horiuchi K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184552
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Keel S, 2017, JAMA OPHTHALMOL, V135, P1242, DOI 10.1001/jamaophthalmol.2017.4182
   Kinsella-Shaw JM, 2006, J MOTOR BEHAV, V38, P251, DOI 10.3200/JMBR.38.4.251-264
   Kotecha A, 2013, INVEST OPHTH VIS SCI, V54, P5408, DOI 10.1167/iovs.12-12026
   Kubicki A, 2014, NEUROSCI LETT, V577, P89, DOI 10.1016/j.neulet.2014.06.014
   Lamb SE, 2005, J AM GERIATR SOC, V53, P1618, DOI 10.1111/j.1532-5415.2005.53455.x
   Lord SR, 2000, GERONTOLOGY, V46, P306, DOI 10.1159/000022182
   Lord SR, 2001, J AM GERIATR SOC, V49, P508, DOI 10.1046/j.1532-5415.2001.49107.x
   MANCHESTER D, 1989, J GERONTOL, V44, pM118
   Mantyjarvi M, 2001, J CATARACT REFR SURG, V27, P261, DOI 10.1016/S0886-3350(00)00562-9
   Maynard ML, 2016, ACTA OPHTHALMOL, V94, pE772, DOI 10.1111/aos.13112
   McIlroy WE, 1997, CLIN BIOMECH, V12, P66, DOI 10.1016/S0268-0033(96)00040-X
   MCMURDO MET, 1991, GERONTOLOGY, V37, P221
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.15
   Owsley C, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0274-5
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   PAULUS WM, 1984, BRAIN, V107, P1143, DOI 10.1093/brain/107.4.1143
   Peracha M, 2013, INVEST OPHTH VIS SCI, V54
   Puell MC, 2012, INVEST OPHTH VIS SCI, V53, P7310, DOI 10.1167/iovs.11-8649
   Rogers ME, 2003, PREV MED, V36, P255, DOI 10.1016/S0091-7435(02)00028-2
   Rugelj D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103903
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   SIMONEAU GG, 1992, J GERONTOL, V47, pM151, DOI 10.1093/geronj/47.5.M151
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Szabo SM, 2008, J AM GERIATR SOC, V56, P800, DOI 10.1111/j.1532-5415.2008.01666.x
   Tabrett DR, 2012, OPHTHAL PHYSL OPT, V32, P156, DOI 10.1111/j.1475-1313.2012.00892.x
   Thayaparan K, 2007, BRIT J OPHTHALMOL, V91, P749, DOI 10.1136/bjo.2006.109280
   Thompson AC, 2018, INVEST OPHTH VIS SCI, V59, P289, DOI 10.1167/iovs.17-22528
   TURANO K, 1994, OPTOMETRY VISION SCI, V71, P761, DOI 10.1097/00006324-199412000-00006
   Turano KA, 1996, INVEST OPHTH VIS SCI, V37, P1483
   WADE MG, 1995, J GERONTOL B-PSYCHOL, V50, pP51, DOI 10.1093/geronb/50B.1.P51
   Wade MG, 1997, PHYS THER, V77, P619, DOI 10.1093/ptj/77.6.619
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wood JM, 2009, INVEST OPHTH VIS SCI, V50, P482, DOI 10.1167/iovs.08-1942
   Wu ZC, 2016, BRIT J OPHTHALMOL, V100, P395, DOI 10.1136/bjophthalmol-2015-306621
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Ying GS, 2008, OPHTHALMOLOGY, V115, P1876, DOI 10.1016/j.ophtha.2008.05.023
NR 63
TC 0
Z9 0
U1 1
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
EI 1475-1313
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD JUL
PY 2021
VL 41
IS 4
BP 853
EP 863
DI 10.1111/opo.12827
EA APR 2021
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA SS9CB
UT WOS:000641463000001
PM 33878195
DA 2022-11-30
ER

PT J
AU Hallam, TM
   Marchbank, KJ
   Harris, CL
   Osmond, C
   Shuttleworth, VG
   Griffiths, H
   Cree, AJ
   Kavanagh, D
   Lotery, AJ
AF Hallam, Thomas M.
   Marchbank, Kevin J.
   Harris, Claire L.
   Osmond, Clive
   Shuttleworth, Victoria G.
   Griffiths, Helen
   Cree, Angela J.
   Kavanagh, David
   Lotery, Andrew J.
TI Rare Genetic Variants in Complement Factor I Lead to Low FI Plasma
   Levels Resulting in Increased Risk of Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; complement factor I; aqueous humor;
   complement system; rare genetic variants
ID HEMOLYTIC-UREMIC SYNDROME; THROMBOTIC MICROANGIOPATHY; C3B INACTIVATOR;
   3RD COMPONENT; CFI GENE; PROTEIN; MUTATIONS; ASSOCIATION; REQUIREMENT;
   ACTIVATION
AB PURPOSE. Rare genetic variants in complement factor I (CFI) that cause low systemic levels of the protein (FI) have been reported as a strong risk factor for advanced age-related macular degeneration (AMD). This study set out to replicate these findings.
   METHODS. FI levels were measured by sandwich ELISA in an independent cohort of 276 patients with AMD and 205 elderly controls. Single-nucleotide polymorphism genotyping and Sanger sequencing were used to assess genetic variability.
   RESULTS. The median FI level was significantly lower in those individuals with AMD and a rare CFI variant (28.3 mu g/mL) compared to those with AMD without a rare CFI variant (38.8 mu g/mL, P = 0.004) or the control population with (41.7 mu g/mL, P = 0.0085) or without (41.5 mu g/mL, P < 0.0001) a rare CFI variant. Thirty-six percent of patients with AMD with a rare CFI variant had levels below the fifth percentile, compared to 6% in controls with CFI variants. Multiple regression analyses revealed a decreased FI level associated with a rare CFI variant was a risk factor for AMD (early or late AMD: odds ratio [OR] 12.05, P = 0.03; early AMD: OR 30.3, P = 0.02; late AMD: OR 10.64, P < 0.01). Additionally, measurement of FI in aqueous humor revealed a large FI concentration gradient between systemic circulation and the eye (similar to 286-fold).
   CONCLUSIONS. Rare genetic variants in CFI causing low systemic FI levels are strongly associated with AMD. The impermeability of the Bruch's membrane to FI will have implications for therapeutic replacement of FI in individuals with CFI variants and low FI levels at risk of AMD.
C1 [Hallam, Thomas M.; Marchbank, Kevin J.; Harris, Claire L.; Shuttleworth, Victoria G.; Kavanagh, David] Newcastle Univ, Translat & Clin Res Inst, Complement Therapeut Res Grp, Newcastle Upon Tyne, Tyne & Wear, England.
   [Hallam, Thomas M.; Marchbank, Kevin J.; Harris, Claire L.; Shuttleworth, Victoria G.; Cree, Angela J.] Royal Victoria Infirm, Natl Renal Complement Therapeut Ctr, Newcastle Upon Tyne, Tyne & Wear, England.
   [Hallam, Thomas M.; Griffiths, Helen; Cree, Angela J.; Lotery, Andrew J.] Univ Southampton, Clin & Expt Sci, Fac Med, Southampton, Hants, England.
   [Osmond, Clive] Univ Southampton, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England.
C3 Newcastle University - UK; Newcastle University - UK; University of
   Southampton; University of Southampton
RP Lotery, AJ (通讯作者)，Univ Southampton, Fac Med, Univ Hosp Southampton, Clin & Expt Sci, South Lab & Path Block,Mailpoint 806,Level D, Southampton SO16 6YD, Hants, England.; Kavanagh, D (通讯作者)，Royal Victoria Infirm, Natl Renal Complement Therapeut Ctr, aHUS Serv, Bldg 26,Queen Victoria Rd, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
EM david.kavanagh@ncl.ac.uk; a.j.lotery@soton.ac.uk
RI ; Kavanagh, David/E-8498-2011
OI marchbank, kevin james/0000-0003-1312-5411; Kavanagh,
   David/0000-0003-4718-0072; Lotery, Andrew/0000-0001-5541-4305; Osmond,
   Clive/0000-0002-9054-4655; Hallam, Thomas/0000-0002-4632-9640; Cree,
   Angela/0000-0002-1987-8900
FU National Institute for Health Research (NIHR) Newcastle Biomedical
   Research Centre at Newcastle upon Tyne Hospitals NHS Foundation Trust;
   NIHR Southampton Clinical Research Facility at University Hospital
   Southampton NHS Foundation Trust; Alexion Pharmaceuticals via Complement
   UK; Fight for Sight; Wellcome Trust; Medical Research Council; Kidney
   Research UK; Complement UK; NIHR Senior Investigator award; Gift of
   Sight appeal
FX Supported and funded by National Institute for Health Research (NIHR)
   Newcastle Biomedical Research Centre at Newcastle upon Tyne Hospitals
   NHS Foundation Trust and the NIHR Southampton Clinical Research Facility
   at University Hospital Southampton NHS Foundation Trust; Alexion
   Pharmaceuticals via Complement UK (TMH); Fight for Sight, the Wellcome
   Trust, the Medical Research Council and Kidney Research UK, and
   Complement UK (DK); NIHR Senior Investigator award, the Gift of Sight
   appeal, and Complement UK (AJL).Y
CR Alexander P, 2014, MOL VIS, V20, P1253
   ALPER CA, 1972, P NATL ACAD SCI USA, V69, P2910, DOI 10.1073/pnas.69.10.2910
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bienaime F, 2010, KIDNEY INT, V77, P339, DOI 10.1038/ki.2009.472
   Blereau E, 2017, GEOSCI FRONT, V8, P1, DOI 10.1016/j.gsf.2016.07.003
   Brocklebank V, 2018, CLIN J AM SOC NEPHRO, V13, P300, DOI 10.2215/CJN.00620117
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fakhouri F, 2010, J AM SOC NEPHROL, V21, P859, DOI 10.1681/ASN.2009070706
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   GITLIN JD, 1975, J EXP MED, V141, P1221, DOI 10.1084/jem.141.5.1221
   Gleeson PJ, 2016, IMMUNOBIOLOGY, V221, P1124, DOI 10.1016/j.imbio.2016.05.002
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Kavanagh D, 2005, J AM SOC NEPHROL, V16, P2150, DOI 10.1681/ASN.2005010103
   Kavanagh D, 2008, MOL IMMUNOL, V45, P95, DOI 10.1016/j.molimm.2007.05.004
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Khandhadia S, 2013, OPHTHALMOLOGY, V120, P1612, DOI 10.1016/j.ophtha.2013.01.004
   Lachmann PJ, 2019, IMMUNOBIOLOGY, V224, P511, DOI 10.1016/j.imbio.2019.05.003
   Lashkari K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195751
   Le Quintrec M, 2008, AM J TRANSPLANT, V8, P1694, DOI 10.1111/j.1600-6143.2008.02297.x
   Li MY, 2014, HUM MOL GENET, V23, P4001, DOI 10.1093/hmg/ddu114
   LISZEWSKI MK, 1991, ANNU REV IMMUNOL, V9, P431, DOI 10.1146/annurev.iy.09.040191.002243
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   MEDOF ME, 1982, J EXP MED, V156, P1739, DOI 10.1084/jem.156.6.1739
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   NAGASAWA S, 1977, IMMUNOCHEMISTRY, V14, P749, DOI 10.1016/0019-2791(77)90345-7
   Osborne AJ, 2018, J IMMUNOL, V200, P2464, DOI 10.4049/jimmunol.1701695
   PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257
   Pras E, 2015, J MED GENET, V52, P484, DOI 10.1136/jmedgenet-2015-103130
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Scholl HP, 2008, PLOS ONE, V3, P1
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   SHIRAISHI S, 1975, IMMUNOCHEMISTRY, V12, P935, DOI 10.1016/0019-2791(75)90256-6
   Tseng Min-Hua, 2018, Oncotarget, V9, P8502, DOI 10.18632/oncotarget.23907
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   WHALEY K, 1976, SCIENCE, V193, P1011, DOI 10.1126/science.948757
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 43
TC 18
Z9 18
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2020
VL 61
IS 6
AR 18
DI 10.1167/iovs.61.6.18
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MD7MJ
UT WOS:000544154500019
PM 32516404
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Boyer, DS
   Heier, JS
   Brown, DM
   Francom, SF
   Ianchulev, T
   Rubio, RG
AF Boyer, David S.
   Heier, Jeffrey S.
   Brown, David M.
   Francom, Steven F.
   Ianchulev, Tsontcho
   Rubio, Roman G.
TI A Phase IIIb Study to Evaluate the Safety of Ranibizumab in Subjects
   with Neovascular Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID VERTEPORFIN
AB Objective: To evaluate the safety and efficacy of intravitreal ranibizumab in a large population of subjects with neovascular age-related macular degeneration (AMD).
   Design: Twelve-month randomized (cohort 1) or open-label (cohort 2) multicenter clinical trial.
   Participants: A total of 4300 subjects with angiographically determined subfoveal choroidal neovascularization (CNV) secondary to AMD.
   Methods: Cohort 1 subjects were randomized 1:1 to receive 0.3 mg (n = 1169) or 0.5 mg (n = 1209) intravitreal ranibizumab for 3 monthly loading doses. Dose groups were stratified by AMD treatment history (treatment-naive vs. previously treated). Cohort 1 subjects were retreated on the basis of optical coherence tomography (OCT) or visual acuity (VA) criteria. Cohort 2 subjects (n = 1922) received an initial intravitreal dose of 0.5 mg ranibizumab and were retreated at physician discretion. Safety was evaluated at all visits.
   Main Outcome Measures: Safety outcomes included the incidence of ocular and nonocular adverse events (AEs) and serious adverse events (SAEs). Efficacy outcomes included changes in best-corrected VA over time.
   Results: Some 81.7% of cohort 1 subjects and 49.9% of cohort 2 subjects completed the 12-month study. The average total number of ranibizumab injections was 4.9 for cohort 1 and 3.6 for cohort 2. The incidence of vascular and nonvascular deaths during the 12-month study was 0.9% and 0.7% in the cohort 1 0.3 mg group, 0.8% and 1.5% in the cohort 1 0.5 mg group, and 0.7% and 0.9% in cohort 2, respectively. The incidence of death due to unknown cause was 0.1% in both cohort 1 dose groups and cohort 2. The number of vascular deaths and deaths due to unknown cause did not differ across cohorts or dose groups. Stroke rates were 0.7%, 1.2%, and 0.6% in the 0.3 mg and 0.5 mg groups and cohort 2, respectively. At month 12, cohort 1 treatment -naive subjects had gained an average of 0.5 (0.3 mg) and 2.3 (0.5 mg) VA letters and previously treated subjects had gained 1.7 (0.3 mg) and 2.3 (0.5 mg) VA letters.
   Conclusions: Intravitreal ranibizumab was safe and well tolerated in a large population of subjects with neovascular AMD. Ranibizumab had a beneficial effect on VA. Future investigations will seek to establish optimal dosing regimens for persons with neovascular AMD.
C1 [Boyer, David S.] Retina Vitreous Associates Med Grp, Los Angeles, CA USA.
   [Heier, Jeffrey S.] Ophthalm Consultants Boston, Boston, MA USA.
   [Brown, David M.] Vitreoretinal Consultants, Houston, TX USA.
   [Francom, Steven F.; Ianchulev, Tsontcho; Rubio, Roman G.] Genentech Inc, San Francisco, CA 94080 USA.
C3 Retina Vitreous Associates Medical Group; Ophthalmic Consultants of
   Boston; Roche Holding; Genentech
RP Boyer, DS (通讯作者)，1127 Wilshire Blvd,Suite 1620, Los Angeles, CA 90017 USA.
EM vitdoc@aol.com
CR Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 7
TC 260
Z9 281
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2009
VL 116
IS 9
BP 1731
EP 1739
DI 10.1016/j.ophtha.2009.05.024
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 489PG
UT WOS:000269432100021
PM 19643495
DA 2022-11-30
ER

PT J
AU Wei, YL
   Liao, HX
   Ye, J
AF Wei, Yanli
   Liao, Hongxia
   Ye, Jian
TI Therapeutic effects of various therapeutic strategies on non-exudative
   age-related macular degeneration: A PRISMA-compliant network
   meta-analysis of randomized controlled trials
SO MEDICINE
LA English
DT Review
DE age-related macular degeneration; best-corrected visual acuity;
   geographic atrophy; meta-analysis
ID GEOGRAPHIC ATROPHY SECONDARY; QUALITY-OF-LIFE; CLINICAL-TRIAL;
   PROGRESSION; DRUSEN
AB Purpose:Age-related macular degeneration (AMD) is a chronic progressive central retinal disease. Geographic atrophy (GA) is a late stage of dry AMD (DAMD) and is a slowly but inexorably progressive disease that causes irreversible blindness over time. We aimed to assess various therapeutic strategies for DAMD and GA treatment by network meta-analysis.Methods:We searched PubMed, Embase, and the Cochrane Library to identify randomized controlled trials (RCTs) of atrophic AMD treatments published prior to December 16, 2017. Best-corrected visual acuity (BCVA) and change in GA area were evaluated to reflect therapeutic effects. A random-effects network meta-analysis, with a frequentist framework, was used to assess the effectiveness of therapeutic strategies for DAMD treatment.Results:We included 22 articles that assessed 16 types of regimens and 2482 patients in our meta-analysis. The network meta-analysis results showed that zinc-monocysteine (98.1%) was the most likely to improve BCVA (logMAR), followed by alprostadil (84.0%), eculizumab (70.5%), and rheohemapheresis (67.3%). In BCVA (letters) outcomes, rheohemapheresis (99.6%), lampalizumab (69.5%), and the antioxidant complex (67.9%) showed marked benefits in visual function recovery. Regarding the outcome of GA area change, isopropyl unoprostone (IU) (88.6%) might have the best GA area reduction; however, there was no significant difference between IU and the blank control.Conclusions:Zinc-monocysteine and rheohemapheresis showed significantly better effects on BCVA (logMAR) improvement, and compared with the blank control, rheohemapheresis and the antioxidant complex showed better effects on BCVA (letters) improvement. Other treatments have potential effects on DAMD, including alprostadil, eculizumab, and lampalizumab. However, there is no effective treatment for GA area reduction.
C1 [Wei, Yanli; Liao, Hongxia; Ye, Jian] Army Mil Med Univ, Dept Ophthalmol, Res Inst Field Surg, Daping Hosp, 10 Changjiangzhilu, Chongqing, Peoples R China.
C3 Army Medical University
RP Ye, J (通讯作者)，Army Mil Med Univ, Dept Ophthalmol, Res Inst Field Surg, Daping Hosp, 10 Changjiangzhilu, Chongqing, Peoples R China.
EM swordyeplus@sina.com
CR Ades AE, 2005, MED DECIS MAKING, V25, P646, DOI 10.1177/0272989X05282643
   Augustin AJ, 2013, EXPERT OPIN INV DRUG, V22, P803, DOI 10.1517/13543784.2013.794782
   Blaha M, 2013, ATHEROSCLEROSIS SUPP, V14, P179, DOI 10.1016/j.atherosclerosissup.2012.10.023
   Borrelli E, 2012, INT J OPHTHALMOL-CHI, V5, P708, DOI 10.3980/j.issn.2222-3959.2012.06.11
   Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Dawczynski J, 2013, GRAEF ARCH CLIN EXP, V251, P2711, DOI 10.1007/s00417-013-2376-6
   Dugel PU, 2015, RETINA-J RET VIT DIS, V35, P1173, DOI 10.1097/IAE.0000000000000606
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385
   Jaffe GJ, 2015, AM J OPHTHALMOL, V160, P1226, DOI 10.1016/j.ajo.2015.08.024
   Koss MJ, 2009, GRAEF ARCH CLIN EXP, V247, P1297, DOI 10.1007/s00417-009-1113-7
   Li DD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145066
   Li HL, 2017, EXPERT OPIN INV DRUG, V26, P1103, DOI 10.1080/13543784.2017.1369042
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Newsome DA, 2008, CURR EYE RES, V33, P591, DOI 10.1080/02713680802178437
   Petrou PA, 2015, INVEST OPHTH VIS SCI, V56, P330, DOI 10.1167/iovs.14-15877
   Pierson RF, 2016, VALUE HEALTH, V19, pA127, DOI 10.1016/j.jval.2016.03.1861
   Pulido Jose S, 2006, Trans Am Ophthalmol Soc, V104, P221
   Rencova E, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/359747
   Rencova E, 2011, ACTA OPHTHALMOL, V89, P463, DOI 10.1111/j.1755-3768.2009.01710.x
   Richer S, 1996, J Am Optom Assoc, V67, P30
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Rodanant N, 2002, AM J OPHTHALMOL, V134, P577, DOI 10.1016/S0002-9394(02)01691-4
   Sacconi R, 2017, OPHTHALMOL THER, V6, P69, DOI 10.1007/s40123-017-0086-6
   Sadda SR, 2016, RETINA-J RET VIT DIS, V36, P1806, DOI 10.1097/IAE.0000000000001283
   Shiragami C, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006422
   Tao Y, 2016, TOHOKU J EXP MED, V240, P209, DOI 10.1620/tjem.240.209
   Trinquart L, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-150
   Wong WT, 2013, INVEST OPHTH VIS SCI, V54, P2941, DOI 10.1167/iovs.13-11650
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
NR 37
TC 4
Z9 4
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD MAY
PY 2018
VL 97
IS 21
AR e10422
DI 10.1097/MD.0000000000010422
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GI3YL
UT WOS:000434307900003
PM 29794727
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Miura, M
   Makita, S
   Iwasaki, T
   Yasuno, Y
AF Miura, Masahiro
   Makita, Shuichi
   Iwasaki, Takuya
   Yasuno, Yoshiaki
TI Three-Dimensional Visualization of Ocular Vascular Pathology by Optical
   Coherence Angiography In Vivo
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; RETINAL-BLOOD-FLOW;
   ULTRAHIGH-RESOLUTION; HIGH-SPEED; TOMOGRAPHIC FEATURES; PENETRATION;
   VELOCITY
AB PURPOSE. To demonstrate the clinical application of a noninvasive, three-dimensional, vascular imaging technique called Doppler optical coherence angiography (OCA). To evaluate the vascular architecture of polypoidal choroidal vasculopathy (PCV) using Doppler OCA.
   METHODS. The authors prospectively examined the eyes of four healthy subjects and 15 PCV patients. Three-dimensional vascular flow imaging was performed using high-speed, high-resolution, and high-penetration spectral-domain Doppler optical coherence tomography. Two-dimensional images of the retina, choroid, and vascular lesions were obtained simultaneously.
   RESULTS. Distribution of blood flow detected by Doppler OCA imaging corresponded well with that by indocyanine angiographic imaging. PCV lesions were localized in the space between the retinal pigment epithelium and the Bruch's membrane.
   CONCLUSIONS. The authors found using Doppler OCA that PCV lesions are similar in architecture to choroidal neovascularization in age-related macular degeneration. Doppler OCA facilitates rapid and noninvasive examination of exudative macular diseases. (Invest Ophthalmol Vis Sci. 2011;52:2689-2695) DOI:10.1167/iovs.10-6282
C1 [Miura, Masahiro; Iwasaki, Takuya] Tokyo Med Univ, Ibaraki Med Ctr, Dept Ophthalmol, Inashiki, Ibaraki 3000395, Japan.
   [Miura, Masahiro; Makita, Shuichi; Iwasaki, Takuya; Yasuno, Yoshiaki] Univ Tsukuba, Computat Opt & Ophthalmol Grp, Ibaraki, Japan.
   [Makita, Shuichi; Yasuno, Yoshiaki] Univ Tsukuba, Computat Opt Grp, Ibaraki, Japan.
C3 Tokyo Medical University; University of Tsukuba; University of Tsukuba
RP Miura, M (通讯作者)，Tokyo Med Univ, Ibaraki Med Ctr, Dept Ophthalmol, 3-20-1 Chuo, Inashiki, Ibaraki 3000395, Japan.
EM m-miura@tokyo-med.ac.jp
RI Yasuno, Yoshiaki/F-2586-2011; Makita, Shuichi/G-3806-2011
OI Yasuno, Yoshiaki/0000-0003-1645-7948; Makita,
   Shuichi/0000-0002-6614-3640
FU Japan Science and Technology Agency
FX Supported in part by the Japan Science and Technology Agency through a
   program of the Development of Systems and Technology for Advanced
   Measurement and Analysis.
CR Abe S, 2010, OPHTHAL SURG LAS IM, V41, pe1
   An L, 2008, OPT EXPRESS, V16, P11438, DOI 10.1364/OE.16.011438
   Bachmann AH, 2007, OPT EXPRESS, V15, P408, DOI 10.1364/OE.15.000408
   BARTSCH DU, 1994, EXP EYE RES, V58, P161, DOI 10.1006/exer.1994.1004
   BRIERS JD, 1982, INVEST OPHTH VIS SCI, V22, P255
   Cense B, 2004, OPT EXPRESS, V12, P2435, DOI 10.1364/OPEX.12.002435
   Chen ZP, 1997, OPT LETT, V22, P64, DOI 10.1364/OL.22.000064
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Izatt JA, 1997, OPT LETT, V22, P1439, DOI 10.1364/OL.22.001439
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee ECW, 2006, OPT EXPRESS, V14, P4403, DOI 10.1364/OE.14.004403
   Leitgeb RA, 2003, OPT EXPRESS, V11, P3116, DOI 10.1364/OE.11.003116
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Makita S, 2010, SPIE P, V7550
   Makita S, 2008, OPT LETT, V33, P836, DOI 10.1364/OL.33.000836
   Makita S, 2006, OPT EXPRESS, V14, P7821, DOI 10.1364/OE.14.007821
   Michelson G, 1996, J GLAUCOMA, V5, P99
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Povazay B, 2003, OPT EXPRESS, V11, P1980, DOI 10.1364/OE.11.001980
   Saito M, 2008, RETINA-J RET VIT DIS, V28, P459, DOI 10.1097/IAE.0b013e318156db60
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Szkulmowska A, 2009, OPT EXPRESS, V17, P10584, DOI 10.1364/OE.17.010584
   TAMAKI Y, 1994, INVEST OPHTH VIS SCI, V35, P3825
   Tateiwa H, 2002, GRAEF ARCH CLIN EXP, V240, P354, DOI 10.1007/s00417-002-0459-x
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Unterhuber A, 2005, OPT EXPRESS, V13, P3252, DOI 10.1364/OPEX.13.003252
   Vakoc BJ, 2009, IEEE T MED IMAGING, V28, P814, DOI 10.1109/TMI.2009.2012891
   Wang YM, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2772871
   White BR, 2003, OPT EXPRESS, V11, P3490, DOI 10.1364/OE.11.003490
   Wojtkowski M, 2004, OPT EXPRESS, V12, P2404, DOI 10.1364/OPEX.12.002404
   YANNUZZI LA, 1986, OPHTHALMOLOGY, V93, P611
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yasuno Y, 2009, INVEST OPHTH VIS SCI, V50, P405, DOI 10.1167/iovs.08-2272
   Yasuno Y, 2007, OPT EXPRESS, V15, P6121, DOI 10.1364/OE.15.006121
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 45
TC 46
Z9 47
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2011
VL 52
IS 5
BP 2689
EP 2695
DI 10.1167/iovs.10-6282
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 757TQ
UT WOS:000290111000024
PM 21273541
DA 2022-11-30
ER

PT J
AU Hamade, N
   Hodge, WG
   Rakibuz-Zaman, M
   Malvankar-Mehta, MS
AF Hamade, Noura
   Hodge, William G.
   Rakibuz-Zaman, Muhammad
   Malvankar-Mehta, Monali S.
TI The Effects of Low-Vision Rehabilitation on Reading Speed and Depression
   in Age Related Macular Degeneration: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID OLDER-ADULTS; SELF-MANAGEMENT; BURDEN; AMD
AB Importance
   Age related macular degeneration (AMD) is a progressive eye disease that, as of 2015, has affected 11 million people in the U.S. and 1.5 million in Canada causing central vision blindness. By 2050, this number is expected to double to 22 million. Eccentric vision is the target of low-vision rehabilitation aids and programs for patients with AMD, which are thought to improve functional performance by improving reading speed and depression.
   Objective
   This study evaluates the effect of various low-vision rehabilitation strategies on reading speed and depression in patients 55 and older with AMD.
   Data Sources
   Computer databases including MEDLINE (OVID), EMBASE (OVID), BIOSIS Previews (Thomson-Reuters), CINAHL (EBSCO), Health Economic Evaluations Database (HEED), ISI Web of Science (Thomson-Reuters) and the Cochrane Library (Wiley) were searched from the year 2000 to January 2015.
   Study Selection
   Included papers were research studies with a sample size of 20 eyes or greater focused on AMD in adults aged 55 or older with low vision (20/60 or lower).
   Data Extraction and Synthesis
   Two independent reviewers screened and extracted relevant data from the included articles. Standardized mean difference (SMD) was chosen as an effect size to perform meta-analysis using STATA. Fixed-and random-effect models were developed based on heterogeneity.
   Main Outcomes
   Reading Speed and Depression Scores.
   Results
   A total of 9 studies (885 subjects) were included. Overall, a significant improvement in reading speed was found with a SMD of 1.01 [95% CI: 0.05 to 1.97]. Low-vision rehabilitation strategies including micro-perimetric biofeedback, microscopes teaching program significantly improved reading speed. Eccentric viewing training showed the maximum improvement in reading speed. In addition, a non-significant improvement in depression scores was found with a SMD of -0.44 [95% CI: -0.96 to 0.09].
   Conclusion
   A considerable amount of research is required in the area of low-vision rehabilitation strategies for patients with AMD. Based on current research, low-vision rehabilitation aids improve reading speed. However, they do not have a significant effect on depression scores in those 55 and older with AMD.
C1 [Hamade, Noura; Hodge, William G.; Rakibuz-Zaman, Muhammad; Malvankar-Mehta, Monali S.] Univ Western Ontario, Schulich Sch Med & Dent, Dept Epidemiol & Biostat, London, ON, Canada.
   [Hodge, William G.; Malvankar-Mehta, Monali S.] Univ Western Ontario, Schulich Sch Med & Dent, Dept Ophthalmol, London, ON, Canada.
   [Malvankar-Mehta, Monali S.] St Josephs Hosp, Ivey Eye Inst, Dept Ophthalmol, 268 Grosvenor St, London, ON N6A 4V2, Canada.
C3 Western University (University of Western Ontario); Western University
   (University of Western Ontario); McGill University; Western University
   (University of Western Ontario)
RP Malvankar-Mehta, MS (通讯作者)，Univ Western Ontario, Schulich Sch Med & Dent, Dept Epidemiol & Biostat, London, ON, Canada.; Malvankar-Mehta, MS (通讯作者)，Univ Western Ontario, Schulich Sch Med & Dent, Dept Ophthalmol, London, ON, Canada.; Malvankar-Mehta, MS (通讯作者)，St Josephs Hosp, Ivey Eye Inst, Dept Ophthalmol, 268 Grosvenor St, London, ON N6A 4V2, Canada.
EM Monali.Malvankar@schulich.uwo.ca
FU Canadian National Institute for the Blind (CNIB) Barbara Tuck MacPhee
   Award [M - R - 14 - 351]
FX This research has been funded by Canadian National Institute for the
   Blind (CNIB) Barbara Tuck MacPhee Award, grant number: M - R - 14 - 351.
   Received by MSMM and WBH. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.; The author would like to thank Alex Mao as well as John
   Castello for help with finalizing search strategies for the review. In
   addition to the Ivey Eye Institute and the University of Western
   Ontario. This research has been funded by, Canadian National Institute
   for the Blind (CNIB) Barbara Tuck MacPhee Award. Dr. Monali
   Malvankar-Mehta is the corresponding author. She works independently of
   CNIB and she takes the responsibility for the integrity of the data and
   accuracy of the data analysis.
CR Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bright Focus Foundation, 2015, MAC DEG FACTS STAT
   Brody BL, 2006, J AM GERIATR SOC, V54, P1557, DOI 10.1111/j.1532-5415.2006.00881.x
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Canadian National Institute for the Blind (CNIB), FAST FACTS VIS LOSS
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Cheong AMY, 2009, OPTOMETRY VISION SCI, V86, P1078, DOI 10.1097/OPX.0b013e3181b4c4d9
   Cimarolli VR, 2012, CLIN REHABIL, V26, P748, DOI 10.1177/0269215511429162
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   Eaton A., 2013, PHARMACOTHERAPY J HU
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Elliott D, 1991, IMPROVING RELIABILIT
   Girdler SJ, 2010, BRIT J OPHTHALMOL, V94, P223, DOI 10.1136/bjo.2008.147538
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928
   Horowitz A, 2006, J GERONTOL B-PSYCHOL, V61, pS274, DOI 10.1093/geronb/61.5.S274
   Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   Scanlan JM, 2004, J VISUAL IMPAIR BLIN, V98, P601, DOI 10.1177/0145482X0409801005
   Seiple W, 2011, INVEST OPHTH VIS SCI, V52, P2938, DOI 10.1167/iovs.10-6137
   Smith HJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P1042, DOI 10.1001/archopht.123.8.1042
   Vingolo EM, 2007, APPL PSYCHOPHYS BIOF, V32, P185, DOI [10.1007/s10484-007-9038-6, 10.1007/sl0484-007-9038-6]
NR 24
TC 13
Z9 13
U1 0
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 14
PY 2016
VL 11
IS 7
AR e0159254
DI 10.1371/journal.pone.0159254
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Science & Technology - Other Topics
GA DR0DZ
UT WOS:000379579500111
PM 27414030
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Fung, AE
   Palanki, R
   Bakri, SJ
   Depperschmidt, E
   Gibson, A
AF Fung, Anne E.
   Palanki, Ram
   Bakri, Sophie J.
   Depperschmidt, Eric
   Gibson, Andrea
TI Applying the CONSORT and STROBE Statements to Evaluate the Reporting
   Quality of Neovascular Age-related Macular Degeneration Studies
SO OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB AVASTIN; OCCULT CHOROIDAL NEOVASCULARIZATION;
   VERTEPORFIN PHOTODYNAMIC THERAPY; VISUAL-ACUITY; CLINICAL-TRIALS;
   SECONDARY; RANIBIZUMAB; DETACHMENT; PEGAPTANIB
AB Purpose: To evaluate the quality of reporting in the neovascular age-related macular degeneration (nvAMD) literature by applying the Consolidated Standards for Reporting Trials (CONSORT) and Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement writing standards.
   Design: CONSORT and STROBE impact analysis; literature review.
   Participants: Phase III randomized controlled trials (RCTs) of verteporfin photodynamic therapy, pegaptanib, and ranibizumab, and interventional case studies of bevacizumab for nvAMD.
   Methods: A literature search identified eligible articles published before October 31, 2007. We assessed the report quality of Phase III RCTs using the CONSORT statement and case series publications using the STROBE statement, both with indicators relevant to nvAMD.
   Main Outcome Measures: Presence or absence of CONSORT or STROBE statement indicators.
   Results: Seven publications of Phase III RCTs and 29 publications on bevacizumab interventional case studies for nvAMD met our inclusion criteria. Of 37 possible CONSORT writing guideline items, the mean report quality for RCTs was 30.6 (83%), with a range from 23 to 35 (65%-95%). Of 35 possible STROBE writing guideline items, the mean report quality grade for intravitreal bevacizumab case series was 23 (70%), with a range from 16 to 31 (46%-94%). Among the bevacizumab studies, more than 90% reported scientific background, drug dose and administration, baseline characteristics, unadjusted results, and adverse events. Fewer than 20% reported study size calculations, handling of missing data, or a discussion of bias.
   Conclusions: Since the adoption of the CONSORT standards by Ophthalmology and other journals in 1996, the reporting quality for RCTs has further improved among this cohort of nvAMD articles. On the other hand, no reporting standards for case series have existed until the recent publication of the STROBE statement. In this first application of the STROBE standards to ophthalmology, we found that the small interventional studies in our series had an average reporting score lower than the RCTs, but also that some individual scores were higher than the RCTs. This outcome demonstrates that good, useful articles can be written about small studies. Although not a direct measure of the quality of a study, good reporting allows a reader to assess the validity and applicability of the study's findings.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2009;116:286-296 (C) 2009 by the American Academy of Ophthalmology.
C1 [Fung, Anne E.] Calif Pacific Med Ctr, San Francisco, CA 94115 USA.
   [Palanki, Ram; Depperschmidt, Eric; Gibson, Andrea] Genentech Inc, San Francisco, CA 94080 USA.
   [Bakri, Sophie J.] Mayo Clin, Dept Ophthalmol, Rochester, MI USA.
C3 California Pacific Medical Center; Roche Holding; Genentech; Mayo Clinic
RP Fung, AE (通讯作者)，Calif Pacific Med Ctr, 2100,Webster St 214, San Francisco, CA 94115 USA.
EM annefungmd@yahoo.com
FU Genentech and Santen
FX The author(s) have made the following disclosure(s): AF did not receive
   any funding support for the conduct or authorship of this study but is a
   consultant to Genentech and Santen. RP, AG, and ED are employed by
   Genentech. SB did not receive any funding support for the conduct or
   authorship of this study but has served on advisory boards for Genentech
   and Novartis.
CR Abraham-Marin ML, 2007, GRAEF ARCH CLIN EXP, V245, P651, DOI 10.1007/s00417-006-0411-6
   Aggio FB, 2007, GRAEF ARCH CLIN EXP, V245, P215, DOI 10.1007/s00417-006-0412-5
   Ahmad K, 2007, LANCET INFECT DIS, V7, P10, DOI 10.1016/S1473-3099(06)70670-3
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Beck RW, 2007, OPHTHALMOLOGY, V114, P1804, DOI 10.1016/j.ophtha.2007.06.047
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bossuyt PM, 2003, CLIN CHEM, V49, P1, DOI 10.1373/49.1.1
   Bossuyt PM, 2003, ANN INTERN MED, V138, P40, DOI 10.7326/0003-4819-138-1-200301070-00010
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Coleman AL, 2002, AM J OPHTHALMOL, V134, P599, DOI 10.1016/S0002-9394(02)01652-5
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Costagliola C, 2007, AM J OPHTHALMOL, V144, P449, DOI 10.1016/j.ajo.2007.05.025
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   DiLoreto DA, 2003, ARCH OPHTHALMOL-CHIC, V121, P1586, DOI 10.1001/archopht.121.11.1586
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P701, DOI 10.1097/IAE.0b013e3180654240
   GAUDERMAN WJ, 1992, ARCH OPHTHALMOL-CHIC, V110, P690, DOI 10.1001/archopht.1992.01080170112036
   Giansanti F, 2007, EUR J OPHTHALMOL, V17, P230, DOI 10.1177/112067210701700213
   Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097/IAE.0b013e318042b53f
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Jabs DA, 2005, AM J OPHTHALMOL, V139, P900, DOI 10.1016/j.ajo.2004.12.009
   Joeres S, 2008, OPHTHALMOLOGY, V115, P347, DOI 10.1016/j.ophtha.2007.03.082
   Jonas JB, 2007, ACTA OPHTHALMOL SCAN, V85, P563, DOI 10.1111/j.1600-0420.2007.00891.x
   Ladas ID, 2007, RETINA-J RET VIT DIS, V27, P891, DOI 10.1097/IAE.0b013e3180ca9ad9
   Ladewig MS, 2008, GRAEF ARCH CLIN EXP, V246, P17, DOI 10.1007/s00417-007-0654-x
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P451, DOI 10.1097/IAE.0b013e318030ea80
   Minckler D, 1999, OPHTHALMOLOGY, V106, P11, DOI 10.1016/S0161-6420(99)90569-9
   Moher D, 2001, BMC Med Res Methodol, V1, P2, DOI 10.1186/1471-2288-1-2
   Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5
   Pedersen R, 2007, ACTA OPHTHALMOL SCAN, V85, P526, DOI 10.1111/j.1600-0420.2007.00895.x
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sanchez-Thorin JC, 2001, OPHTHALMOLOGY, V108, P410, DOI 10.1016/S0161-6420(00)00500-5
   Scherer RW, 1998, JAMA-J AM MED ASSOC, V280, P269, DOI 10.1001/jama.280.3.269
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   *STROBE STAT, 2007, STROBE CHECKL VERS 4
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Vandenbroucke JP, 2007, EPIDEMIOLOGY, V18, P805, DOI 10.1097/EDE.0b013e3181577511
   von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 53
TC 58
Z9 61
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2009
VL 116
IS 2
BP 286
EP 296
DI 10.1016/j.ophtha.2008.09.014
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 403QW
UT WOS:000263098100019
PM 19091408
DA 2022-11-30
ER

PT J
AU Bohni, SC
   Bittner, M
   Howell, JP
   Bachmann, LM
   Faes, L
   Schmid, MK
AF Boehni, Sophie C.
   Bittner, Mario
   Howell, Jeremy P.
   Bachmann, Lucas M.
   Faes, Livia
   Schmid, Martin K.
TI Comparison of Eylea (R) with Lucentis (R) as first-line therapy in
   patients with treatment-naive neovascular age-related macular
   degeneration in real-life clinical practice: retrospective case-series
   analysis
SO BMC OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL AFLIBERCEPT; VEGF TRAP;
   ANATOMICAL OUTCOMES; RANIBIZUMAB; BEVACIZUMAB; TACHYPHYLAXIS; EYES;
   CONVERSION; RESISTANT
AB Background: To identify differences between Ranibizumab and Aflibercept in treatment-naive patients with neovascular age-related macular degeneration (nvAMD) in a real-life clinical setting.
   Methods: We compared two groups of patients with a fairly similar prognosis either receiving Aflibercept or Ranibizumab within a pro re nata regimen for 1 year. Changes in visual acuity (letters) and central foveal thickness (CFT) and frequency of injections after completing the loading phase were evaluated using two separate multivariate mixed linear models.
   Results: When correcting for baseline differences between the Aflibercept (11 eyes) and Ranibizumab (16 eyes) group, there was neither divergence in visual acuity (-0.97 letters (95 % CI. -6.06-4.12); p = 0.709), nor a significant difference in the reduction of CFT (-25.16 mu m, 95 % CI; (-78.01-27.68); p = 0.351) between the two groups 1 year after treatment initiation. Also, the number of injection did not differ (0.04 (95 % CI; -0.16-0.09); p = 0.565).
   Conclusion: In contrast to health claims, treatment-naive nvAMD, Ranibizumab and Aflibercept were equivalent in terms of functional and morphologic outcomes and number of injections when studied in real-life clinical practice.
C1 [Boehni, Sophie C.; Bittner, Mario; Howell, Jeremy P.; Schmid, Martin K.] Cantonal Hosp Lucerne, Eye Clin, CH-6000 Luzern 16, Switzerland.
   [Bachmann, Lucas M.; Faes, Livia] Medignit Inc Res Consultants, Zurich, Switzerland.
C3 Lucerne Cantonal Hospital
RP Bohni, SC (通讯作者)，Cantonal Hosp Lucerne, Eye Clin, Spitalstr, CH-6000 Luzern 16, Switzerland.
EM sophie.boehni@luks.ch
OI , Lucas/0000-0002-9868-154X
FU Novartis AG, Switzerland
FX Dr. Bohni's work was funded via an unrestricted educational grant from
   Novartis AG, Switzerland. All authors have no proprietary interest.
CR Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Fassnacht-Riederle H, 2014, GRAEF ARCH CLIN EXP, V252, P1705, DOI 10.1007/s00417-014-2589-3
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heussen FM, 2014, GRAEF ARCH CLIN EXP, V252, P909, DOI 10.1007/s00417-013-2553-7
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Johnston SS, 2013, ADV THER, V30, P1111, DOI 10.1007/s12325-013-0078-4
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Messenger WB, 2014, BRIT J OPHTHALMOL, V98, P1205, DOI 10.1136/bjophthalmol-2013-304829
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Patel KH, 2013, EYE, V27, P668
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P1732, DOI 10.1167/iovs.02-0809
   Reich O, 2015, RISK MANAG HEALTHC P, V8, P55, DOI 10.2147/RMHP.S80536
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schmidt-Erfurth U, 2013, OPHTHALMOLOGY
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Yamashita M, 2014, CLIN OPHTHALMOL, V8, P343, DOI 10.2147/OPTH.S56539
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 27
TC 14
Z9 14
U1 1
U2 11
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD AUG 20
PY 2015
VL 15
AR 109
DI 10.1186/s12886-015-0101-4
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CP4CV
UT WOS:000359830500001
PM 26289356
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Gomi, F
   Migita, H
   Sakaguchi, T
   Okada, H
   Sugawara, T
   Hikichi, Y
   Hanemoto, T
   Nishijima, K
   Matsubara, H
   Wakiyama, H
   Kawashima, S
   Sato, H
   Tagawa, S
   Yoshizawa, T
   Kurakazu, T
   Inoue, K
   Miyake, T
   Ota, K
   Shiraki, K
   Nakai, Y
   Kurimoto, Y
   Kusaka, S
   Hoshiai, S
   Ohira, A
   Morimoto, M
   Tabuchi, H
   Sato, K
   Inoue, Y
   Sato, S
   Katai, N
   Obana, A
   Kabayama, J
   Yamaji, H
   Ozaki, S
   Sueda, J
   Hanasaki, H
   Nishide, T
   Yonezawa, H
   Kawamoto, K
   Kamimoto, H
   Hayashi, A
   Honda, M
   Miura, M
   Obata, R
   Saito, I
   Oh, H
   Maeno, T
   Ishibashi, K
   Fukushima, Y
   Sakamoto, T
   Kawahara, A
   Ogino, T
   Arai, J
   Sato, H
   Ida, Y
   Nakamura, S
   Yokouchi, H
   Suzuki, M
   Hara, K
   Hino, Y
   Watanabe, R
   Mitarai, K
   Miyamoto, K
   Akimoto, M
   Ishii, K
   Takagi, H
   Kanda, N
   Fukuchi, T
   Kaneda, M
   Tsujinaka, H
   Suzuki, H
   Tanifuji, Y
   Uemura, A
   Ikeda, T
   Imaizumi, H
   Yoshida, K
   Ishida, S
   Sakuraba, T
   Horie, Y
AF Gomi, Fumi
   Migita, Hideyuki
   Sakaguchi, Toshiaki
   Okada, Hiromi
   Sugawara, Tamotsu
   Hikichi, Yusuke
   Hanemoto, Tsukasa
   Nishijima, Kazuaki
   Matsubara, Hisashi
   Wakiyama, Harumi
   Kawashima, Sachio
   Sato, Hiroaki
   Tagawa, Shigeki
   Yoshizawa, Toyohisa
   Kurakazu, Toshiaki
   Inoue, Kenji
   Miyake, Takatomo
   Ota, Koichi
   Shiraki, Kunihiko
   Nakai, Yoshihide
   Kurimoto, Yasuo
   Kusaka, Shunji
   Hoshiai, Shigeru
   Ohira, Akihiko
   Morimoto, Masahiro
   Tabuchi, Hitoshi
   Sato, Kaori
   Inoue, Yasushi
   Sato, Sakura
   Katai, Naomichi
   Obana, Akira
   Kabayama, Junkichi
   Yamaji, Hidetaka
   Ozaki, Shiro
   Sueda, Jun
   Hanasaki, Hidetoshi
   Nishide, Tadayuki
   Yonezawa, Hirofumi
   Kawamoto, Koji
   Kamimoto, Hidenori
   Hayashi, Atsushi
   Honda, Miki
   Miura, Masahiro
   Obata, Ryo
   Saito, Isao
   Oh, Hideyasu
   Maeno, Takatoshi
   Ishibashi, Kazuki
   Fukushima, Yoko
   Sakamoto, Taiji
   Kawahara, Akiteru
   Ogino, Tetsuo
   Arai, Jun
   Sato, Hiroyuki
   Ida, Yosuke
   Nakamura, Satoshi
   Yokouchi, Hirotaka
   Suzuki, Misa
   Hara, Kazuyuki
   Hino, Yasukazu
   Watanabe, Ryo
   Mitarai, Keiichi
   Miyamoto, Kazuhisa
   Akimoto, Masayuki
   Ishii, Kiyoshi
   Takagi, Hitoshi
   Kanda, Naotaka
   Fukuchi, Takeo
   Kaneda, Masahiro
   Tsujinaka, Hiroki
   Suzuki, Hisaharu
   Tanifuji, Yasuhiro
   Uemura, Akinori
   Ikeda, Tsunehiko
   Imaizumi, Hiroko
   Yoshida, Kenji
   Ishida, Susumu
   Sakuraba, Tomoki
   Horie, Yukihiro
CA Participating Investigators
TI Vision-related quality of life in Japanese patients with wet age-related
   macular degeneration treated with intravitreal aflibercept in a
   real-world setting
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Intravitreal aflibercept; NEI-VFQ-25; Wet age-related macular
   degeneration; J-PMS
ID RANIBIZUMAB TREATMENT; VISUAL IMPAIRMENT; PREVALENCE; INJECTION;
   OUTCOMES; SAFETY; ACUITY; EYE
AB Purpose To evaluate vision-related quality of life (QoL) in wet age-related macular degeneration (wAMD) patients receiving intravitreal aflibercept (IVT-AFL). Study design Prospective, observational Japanese postmarketing surveillance study. Methods All decisions were made by the treating physician. QoL was assessed using the 25-item National Eye Institute-Visual Functioning Questionnaire (NEI-VFQ-25) composite score administered at baseline, 6 months, and 12 months (primary assessment). Secondary assessments included NEI-VFQ-25 subscale scores, resource use, and best-corrected visual acuity (BCVA; logarithm of the minimum angle of resolution [logMAR]). Results In total, 576 patients (baseline), 555 patients (6 months), and 446 patients (12 months) were included. The mean (SD) number of IVT-AFL injections was 3.5 (1.2) at 6 months and 4.6 (2.2) at 12 months. The mean (SD) improvement from baseline in the NEI-VFQ-25 composite score was 3.1 (11.1) at 6 months and 2.7 (12.3) at 12 months (P < .0001). For the NEI-VFQ-25 subscale scores, the mean change was >= 4 (minimally important difference) for general vision, near vision, and mental health at 6 months, and for general vision and mental health at 12 months (all P < .0001). A significant improvement from baseline was found in mean BCVA (logMAR) at 6 months (-0.1) and 12 months (-0.1) (P < .0001). The mean change from baseline in the NEI-VFQ-25 scores was greatest in patients with improved BCVA (gain of <= -0.3 logMAR units or >= 15 letters) after treatment. Conclusion IVT-AFL was associated with significant improvements in QoL and visual acuity in Japanese patients with wAMD in a real-world setting.
C1 [Gomi, Fumi] Hyogo Coll Med Hosp, Nishinomiya, Hyogo, Japan.
   [Migita, Hideyuki; Sakaguchi, Toshiaki; Hikichi, Yusuke] Bayer Yakuhin, Osaka, Japan.
   [Okada, Hiromi; Sugawara, Tamotsu] CMIC Co Ltd, Tokyo, Japan.
C3 Hyogo College of Medicine; Bayer AG; CMIC Holdings Co Ltd
RP Hikichi, Y (通讯作者)，Bayer Yakuhin, Osaka, Japan.
EM yusuke.hikichi@bayer.com
RI Kaneda, Masahiro/E-3117-2010
OI Kaneda, Masahiro/0000-0003-0660-7156; Gomi, Fumi/0000-0003-0807-8817;
   Hanemoto, Tsukasa/0000-0002-2444-4234; Hikichi,
   Yusuke/0000-0002-1699-6821
FU Bayer Yakuhin
FX The statistical analyses were performed by CMIC and were funded by Bayer
   Yakuhin. Medical writing assistance was provided by PAREXEL and funded
   by Bayer Yakuhin. Study group investigators: The Participating
   Investigators were Tsukasa Hanemoto, Kazuaki Nishijima, Hisashi
   Matsubara, Harumi Wakiyama, Sachio Kawashima, Hiroaki Sato, Shigeki
   Tagawa, Toyohisa Yoshizawa, Toshiaki Kurakazu, Kenji Inoue, Takatomo
   Miyake, Koichi Ota, Kunihiko Shiraki, Yoshihide Nakai, Yasuo Kurimoto,
   Shunji Kusaka, Shigeru Hoshiai, Akihiko Ohira, Masahiro Morimoto,
   Hitoshi Tabuchi, Kaori Sato, Yasushi Inoue, Sakura Sato, Naomichi Katai,
   Akira Obana, Junkichi Kabayama, Hidetaka Yamaji, Shiro Ozaki, Jun Sueda,
   Hidetoshi Hanasaki, Tadayuki Nishide, Hirofumi Yonezawa, Koji Kawamoto,
   Hidenori Kamimoto, Atsushi Hayashi, Miki Honda, Masahiro Miura, Ryo
   Obata, Isao Saito, Hideyasu Oh, Takatoshi Maeno, Kazuki Ishibashi, Yoko
   Fukushima, Taiji Sakamoto, Akiteru Kawahara, Tetsuo Ogino, Jun Arai,
   Hiroyuki Sato, Yosuke Ida, Satoshi Nakamura, Hirotaka Yokouchi, Misa
   Suzuki, Kazuyuki Hara, Yasukazu Hino, Ryo Watanabe, Keiichi Mitarai,
   Kazuhisa Miyamoto, Masayuki Akimoto, Kiyoshi Ishii, Hitoshi Takagi,
   Naotaka Kanda, Takeo Fukuchi, Masahiro Kaneda, Hiroki Tsujinaka,
   Hisaharu Suzuki, Yasuhiro Tanifuji, Akinori Uemura, Tsunehiko Ikeda,
   Hiroko Imaizumi, Kenji Yoshida, Susumu Ishida, Tomoki Sakuraba, and
   Yukihiro Horie. All Participating Investigators provided and cared for
   the study patients and collected data.
CR [Anonymous], 2016, EYL
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jin J, 2013, MOL CELL BIOCHEM, V381, P267, DOI 10.1007/s11010-013-1710-y
   Nakae K MK, 2006, GERIATR MED, V44, P1221
   Ogura Y, 2015, BRIT J OPHTHALMOL, V99, P92, DOI 10.1136/bjophthalmol-2014-305076
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Roberts CB, 2010, ARCH OPHTHALMOL-CHIC, V128, P766, DOI 10.1001/archophthalmol.2010.86
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Suner IJ, 2009, INVEST OPHTH VIS SCI, V50, P3629, DOI 10.1167/iovs.08-3225
   Suzukamo Yoshimi, 2005, Health Qual Life Outcomes, V3, P65, DOI 10.1186/1477-7525-3-65
   Takahashi Kanji, 2012, Nippon Ganka Gakkai Zasshi, V116, P1150
   Tamura H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133628
   Wako Rina, 2014, Nippon Ganka Gakkai Zasshi, V118, P495
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Yuzawa M, 2015, OPHTHALMOLOGY, V122, P571, DOI 10.1016/j.ophtha.2014.09.024
   Yuzawa M, 2013, CLIN OPHTHALMOL, V7, P1325, DOI 10.2147/OPTH.S45248
NR 21
TC 6
Z9 6
U1 0
U2 6
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD NOV
PY 2019
VL 63
IS 6
BP 437
EP 447
DI 10.1007/s10384-019-00687-2
EA OCT 2019
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JL0ST
UT WOS:000493485000001
PM 31673841
DA 2022-11-30
ER

PT J
AU Mori, K
   Gehlbach, PL
   Kabasawa, S
   Kawasaki, I
   Oosaki, M
   Iizuka, H
   Katayama, S
   Awata, T
   Yoneya, S
AF Mori, Keisuke
   Gehlbach, Peter L.
   Kabasawa, Sho
   Kawasaki, Izumi
   Oosaki, Masataka
   Iizuka, Hiroyuki
   Katayama, Shigehiro
   Awata, Takuya
   Yoneya, Shin
TI Coding and noncoding variants in the CFH gene and cigarette smoking
   influence the risk of age-related macular degeneration in a Japanese
   population
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT-FACTOR-H; POLYPOIDAL CHOROIDAL VASCULOPATHY; HEMICENTIN-1
   GENES; STRONG ASSOCIATION; NO ASSOCIATION; POLYMORPHISM; SUSCEPTIBILITY;
   Y402H; MACULOPATHY; LOC387715
AB PURPOSE. Ethnic variation has been reported in age- related macular degeneration ( AMD) - associated Y402H polymorphism in complement factor H ( CFH). This variation is evident in the Japanese population. Recently a strong association between a novel single- nucleotide polymorphism ( SNP; rs1410996) in the CFH gene and AMD has been identified in Caucasian patients. The present study was undertaken to investigate whether four coding and noncoding variants of the CFH gene, including rs1410996, are associated with AMD in native, unrelated Japanese patients.
   METHODS. A total of 188 patients with AMD and 139 control subjects without AMD were recruited for the study. Four SNPs ( rs800292, rs1061170, rs1410996, and rs2274700) in the CFH gene were assessed by genotyping assay. The information regarding systemic conditions and lifestyle including smoking were documented in each subject by standardized questionnaire.
   RESULTS. The intronic SNP ( rs1410996) and the synonymous SNP ( rs2274700) were associated with a significant risk of AMD ( P = 2.37 X 10(-5) and 3.52 X 10(-5), respectively). A significant association was also noted between a coding variant ( rs800292, I62V) and AMD ( P = 8.63 X 10(-6)). In contrast, the Y402H variant showed no significant association with AMD ( P = 0.101). Two common haplotypes also demonstrated significant association with AMD ( P = 1.08 X 10(-3) and 2.00 X 10(-5)). Among the environmental factors, smoking alone had a significant association with AMD ( P = 1.17 X 10(-4)).
   CONCLUSIONS. Although the Y402H variant was not significantly associated with AMD, other coding and noncoding variants in the CFH gene including rs1410996 and smoking moderately influenced the risk of AMD in a Japanese population.
C1 Saitama Med Univ, Dept Ophthalmol, Saitama, Japan.
   Saitama Med Univ, Div Endocrinol & Diabet, Dept Med, Saitama, Japan.
   Saitama Med Univ, Ctr Biomed Res, Div Radio Isotope Lab, Saitama, Japan.
   Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA.
C3 Saitama Medical University; Saitama Medical University; Saitama Medical
   University; Johns Hopkins University
RP Mori, K (通讯作者)，Saitama Med Sch, Dept Ophthalmol, 38 Morohongo, Saitama 3500495, Japan.
EM keisuke@saitama-med.ac.jp
OI Awata, Takuya/0000-0003-2622-8129
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   Chang TS, 1999, CAN J OPHTHALMOL, V34, P266
   Chen LJ, 2006, MOL VIS, V12, P1536
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   CONSORTIUM TIH, 2003, NATURE, V426, P789
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2007, BRIT J OPHTHALMOL, V91, P966, DOI 10.1136/bjo.2007.114090
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gordon D, 2002, HUM HERED, V54, P22, DOI 10.1159/000066696
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Okamoto H, 2006, MOL VIS, V12, P156
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seitsonen S, 2006, MOL VIS, V12, P796
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Souied EH, 2005, MOL VIS, V11, P1135
   The Age-Related Eye Disease Study Research Group, 2005, AM J OPHTHALMOL, V112, P533
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 42
TC 58
Z9 62
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2007
VL 48
IS 11
BP 5315
EP 5319
DI 10.1167/iovs.07-0426
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 228MU
UT WOS:000250734800059
PM 17962488
DA 2022-11-30
ER

PT J
AU Johnson, PT
   Betts, KE
   Radeke, MJ
   Hageman, GS
   Anderson, DH
   Johnson, LV
AF Johnson, P. T.
   Betts, K. E.
   Radeke, M. J.
   Hageman, G. S.
   Anderson, D. H.
   Johnson, L. V.
TI Individuals homozygous for the age-related macular degeneration
   risk-conferring variant of complement factor H have elevated levels of
   CRP in the choroid
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE eye; retinal pigmented epithelium (RPE); alternative pathwa
ID C-REACTIVE PROTEIN; APOPTOTIC CELLS; CARDIOVASCULAR-DISEASE; DRUSEN;
   INFLAMMATION; BINDING; COMMON; GENE; POLYMORPHISM; ASSOCIATION
AB Polymorphisms in the complement factor H gene (CFH) are associated with a significantly increased risk for, or protection against, the development of age-related macular degeneration (AMD). The most documented risk-conferring single-nucleoticle polymorphism results in a tyrosine-to-histidine substitution at position 402 (Y402H) of the CFH protein. In this work, we examined the ocular distributions and relative abundance of CFH, several CFH-binding proteins, and abundant serum proteins in the retinal pigmented epithelium (RPE), Bruch's membrane, and choroid (RPE-choroid) in CFH homozygotes possessing either the "at-risk" 402HH or "normal" 402YY variants. Although CFH immunoreactivity is high in the choroid and in drusen, no differences in CFH-labeling patterns between genotypes are apparent. In contrast, at-risk individuals have significantly higher levels of the CFH-binding protein, C-reactive protein (CRP), in the choroidal stroma. Immunoblots confirm that at-risk individuals have approximate to 2.5-fold higher levels of CRP in the RPE-choroid; no significant differences in the levels of CFH or other serum proteins are detected. Similarly, we find no differences in CFH transcription levels in the RPE-choroid nor evidence for local ocular CRP transcription. Increased levels of CRP in the choroid may reflect a state of chronic inflammation that is a by-product of attenuated CFH complement-inhibitory activity in those who possess the CFH at-risk allele. Because the CRP-binding site in CFH lies within the domain containing the Y402H polymorphism, it is also possible that the AMD risk-conferring allele alters the binding properties of CFH, thereby leading to choroidal CRP deposition, contributing to AMD pathogenesis.
C1 Univ Calif Santa Barbara, Neurosci Res Inst, Ctr Study Macular Degenerat, Santa Barbara, CA 93106 USA.
   Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
C3 University of California System; University of California Santa Barbara;
   University of Iowa
RP Johnson, PT (通讯作者)，Univ Calif Santa Barbara, Neurosci Res Inst, Ctr Study Macular Degenerat, Santa Barbara, CA 93106 USA.
EM p_johnso@lifesci.ucsb.edu
FU NATIONAL EYE INSTITUTE [R24EY014799, R24EY017404, R01EY011527] Funding
   Source: NIH RePORTER; NEI NIH HHS [R01 EY011527, EY14799, EY11527,
   EY017404, R24 EY014799, R24 EY017404] Funding Source: Medline
CR Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Bharadwaj D, 1999, J EXP MED, V190, P585, DOI 10.1084/jem.190.4.585
   Black S, 2004, J BIOL CHEM, V279, P48487, DOI 10.1074/jbc.R400025200
   Bodman-Smith KB, 2002, IMMUNOLOGY, V107, P252, DOI 10.1046/j.1365-2567.2002.01481.x
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CROWELL RE, 1991, J IMMUNOL, V147, P3445
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Doronzo G, 2005, J LAB CLIN MED, V146, P287, DOI 10.1016/j.lab.2005.07.010
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353
   Giannakis E, 2001, INT IMMUNOPHARMACOL, V1, P433, DOI 10.1016/S1567-5769(00)00040-0
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359
   IWAMOTO N, 1994, NEUROSCI LETT, V177, P23, DOI 10.1016/0304-3940(94)90035-3
   Jarva H, 1999, J IMMUNOL, V163, P3957
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   Miller DT, 2005, ANN HUM GENET, V69, P623, DOI 10.1111/j.1529-8817.2005.00210.x
   Mold C, 2002, J AUTOIMMUN, V19, P147, DOI 10.1006/jaut.2002.0615
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Pasceri V, 2000, CIRCULATION, V102, P2165
   Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45
   REYNOLDS GD, 1987, ARCH PATHOL LAB MED, V111, P265
   ROBEY FA, 1984, J BIOL CHEM, V259, P7311
   Saunders RE, 2006, HUM MUTAT, V27, P21, DOI 10.1002/humu.20268
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Seddon JM, 2006, NUTRITION, V22, P441, DOI 10.1016/j.nut.2005.12.004
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   VOLANAKI.JE, 1971, P SOC EXP BIOL MED, V136, P612
   VOLANAKIS JE, 1974, J IMMUNOL, V113, P9
   Williams TN, 2004, ARTERIOSCL THROM VAS, V24, P61, DOI 10.1161/01.ATV.0000104014.24367.16
   Zipfel PF, 2002, BIOCHEM SOC T, V30, P971, DOI 10.1042/bst0300971
NR 51
TC 176
Z9 183
U1 0
U2 6
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 14
PY 2006
VL 103
IS 46
BP 17456
EP 17461
DI 10.1073/pnas.0606234103
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 108OP
UT WOS:000242249400070
PM 17079491
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Liang, GH
   Ma, WH
   Luo, YN
   Yin, JY
   Hao, LL
   Zhong, JX
AF Liang, Gaohua
   Ma, Wenhao
   Luo, Yanni
   Yin, Jiayang
   Hao, Lili
   Zhong, Jingxiang
TI Identification of differentially expressed and methylated genes and
   construction of a co-expression network in age-related macular
   degeneration
SO ANNALS OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Age-related macular degeneration (AMD); methylation; weighted gene
   co-expression network analysis (WGCNA); pathway; co-expression module
AB Background: Age-related macular degeneration (AMD) is the leading cause of blindness for people over 50 years old worldwide. The purpose of this study was to identify differentially expressed and methylated genes (DEMGs) and construct a co-expression network for AMD. Methods: Microarray expression (GSE29801 dataset) and DNA methylation (GSE102952 dataset) profiles were retrieved from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) and differentially methylated genes (DMGs) were analyzed between AMD retina tissues and normal retina tissues. A protein-protein interaction (PPI) network was constructed and hub genes were screened, followed by functional enrichment analysis. Then, weighted gene co-expression network analysis (WGCNA) was conducted. The ARPE-19 cells were maintained in a hypoxic state to construct an AMD cellular model. Enzyme-linked immunosorbent assay (ELISA) and the real-time qPCR (RT-qPCR) were performed for validation. Results: After overlapping, 16 hypermethylated and down-regulated genes and 15 hypomethylated and up regulated genes were identified for extramacular AMD. A total of 4 hub genes (LMNB2, EMD, HLA-A, and HLA-B) were screened for AMD in the extramacular retina. Furthermore, 13 hypermethylated and down regulated genes and 31 hypomethylated and up-regulated genes were identified for macular AMD. Among them, 11 hub genes (HLA-A, HLA-B, HLA-DRB1, IFITM3, SAT1, MAOB, CHRDL1, FSTL1, HSPA1A, AR, and YAP1) were considered hub genes. The DEMGs were distinctly related with immune-related biological processes and pathways. A total of 16 co-expression modules were constructed, of which 2 significantly correlated with AMD. The genes in the 2 modules were involved in various crucial signaling pathways. The HIF1 alpha and VEGF levels were significantly up-regulated in cell supernatant of hypoxia-induced ARPE-19 cells, indicating that the AMD cellular model was successfully established. Hub genes including CHRDL, FSTL1, and IFITM3 displayed significantly higher expression in hypoxia-induced ARPE-19 cells compared to normal cells. Greater up-regulation of CHRDL, FSTL1, and IFITM3 expression was found in hypoxiainduced ARPE-19 cells than in normal cells. Conclusions: These findings offered several key DEMGs and pathways for AMD and constructed AMDrelated co-expression modules, deepening understanding of the pathogenesis of AMD.
C1 [Liang, Gaohua; Yin, Jiayang; Hao, Lili; Zhong, Jingxiang] Jinan Univ, Affiliated Hosp 1, Dept Ophthalmol, 613 West Huangpu Ave, Guangzhou 510632, Peoples R China.
   [Liang, Gaohua; Ma, Wenhao; Luo, Yanni] Youjiang Med Univ Nationalities, Affiliated Hosp, Dept Ophthalmol, Baise, Peoples R China.
   [Zhong, Jingxiang] Jinan Univ, Ophthalmol Inst, 601 West Huangpu Ave, Guangzhou 510630, Peoples R China.
C3 Jinan University; Youjiang Medical University for Nationalities; Jinan
   University
RP Zhong, JX (通讯作者)，Jinan Univ, Affiliated Hosp 1, Dept Ophthalmol, 613 West Huangpu Ave, Guangzhou 510632, Peoples R China.; Zhong, JX (通讯作者)，Jinan Univ, Ophthalmol Inst, 601 West Huangpu Ave, Guangzhou 510630, Peoples R China.
EM zjx85221206@126.com
FU Natural Science Foundation of Guangxi [2020GXNSFAA259054]; First Batch
   of High-Level Talent Scientific Research Projects of the Affiliated
   Hospital of Youjiang Medical University for Nationalities [R20196340,
   Y20196304]; Fund of Baise Scientific Research and Technology Development
   Plan [Baise 20184708]
FX This work was funded by Natural Science Foundation of Guangxi
   (2020GXNSFAA259054) ; The First Batch of High-Level Talent Scientific
   Research Projects of the Affiliated Hospital of Youjiang Medical
   University for Nationalities in 2019 (R20196340, Y20196304) ; and The
   Fund of Baise Scientific Research and Technology Development Plan (Baise
   20184708) .
CR Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Caputo V, 2021, EUR J OPHTHALMOL, V31, P2856, DOI 10.1177/11206721211028054
   Cosker KE, 2016, NAT NEUROSCI, V19, P690, DOI 10.1038/nn.4280
   De Andrade WP, 2020, ONCOL LETT, V19, P359, DOI 10.3892/ol.2019.11095
   Dedeurwaerder S, 2011, EPIGENOMICS-UK, V3, P771, DOI [10.2217/EPI.11.105, 10.2217/epi.11.105]
   Ersoy L, 2016, BRIT J OPHTHALMOL, V100, P1047, DOI 10.1136/bjophthalmol-2015-306806
   Farkas MH, 2021, ADV EXP MED BIOL, V1256, P221, DOI 10.1007/978-3-030-66014-7_9
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   Gemenetzi M, 2020, CELL MOL LIFE SCI, V77, P807, DOI 10.1007/s00018-019-03421-w
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559
   Li Y, 2020, MOL MED REP, V21, P575, DOI 10.3892/mmr.2019.10850
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu X, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1750-7
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nashine S, 2019, EXP EYE RES, V189, DOI 10.1016/j.exer.2019.107701
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nie E, 2019, ONCOGENE, V38, P2706, DOI 10.1038/s41388-018-0596-2
   Oliver VF, 2015, EPIGENETICS-US, V10, P698, DOI 10.1080/15592294.2015.1060388
   Park JH, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav0316
   Pidsley R, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-293
   Porter LF, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0608-2
   Regueiro C, 2019, ARTHRITIS RHEUMATOL, V71, P331, DOI 10.1002/art.40738
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   SanGiovanni JP, 2017, CLIN CHEM LAB MED, V55, P763, DOI 10.1515/cclm-2016-0898
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shen YC, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01392-2
   Sun YY, 2019, AM J TRANSL RES, V11, P5514
   Takagi S, 2018, JPN J OPHTHALMOL, V62, P568, DOI 10.1007/s10384-018-0611-8
   von Mering C, 2003, NUCLEIC ACIDS RES, V31, P258, DOI 10.1093/nar/gkg034
   Xiao H, 2019, J CANCER, V10, P6779, DOI 10.7150/jca.35223
   Xu YZ, 2019, MOD RHEUMATOL, V29, P984, DOI 10.1080/14397595.2018.1519148
   Xu ZX, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015083
   Yang Q, 2019, GENE, V716, DOI 10.1016/j.gene.2019.144010
   Yip AM, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-22
   Zeng D, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00703
NR 38
TC 2
Z9 2
U1 3
U2 3
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2305-5839
EI 2305-5847
J9 ANN TRANSL MED
JI ANN. TRANSL. MED.
PD FEB
PY 2022
VL 10
IS 4
AR 223
DI 10.21037/atm-21-7043
PG 19
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA ZQ0KV
UT WOS:000766803800005
PM 35280389
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chan, WM
   Lai, TYY
   Wong, AL
   Tong, JP
   Liu, DTL
   Lam, DSC
AF Chan, WM
   Lai, TYY
   Wong, AL
   Tong, JP
   Liu, DTL
   Lam, DSC
TI Combined photodynamic therapy and intravitreal triamcinolone injection
   for the treatment of subfoveal choroidal neovascularisation in age
   related macular degeneration: a comparative study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIAL; TREATED RAT MODEL; ENDOTHELIAL-CELLS;
   ACETONIDE; VERTEPORFIN; EXPRESSION; LESIONS
AB Aim: To evaluate the outcomes of combined intravitreal triamcinolone (IVTA) and photodynamic therapy (PDT) with verteporfin in the treatment of subfoveal choroidal neovascularisation (CNV) caused by age related macular degeneration (AMD).
   Methods: 48 eyes from 48 patients with subfoveal CNV caused by AMD were prospective recruited, with 24 eyes treated with combined PDT with IVTA and compared with a control group of 24 eyes which received PDT monotherapy. In the combined treatment group, IVTA was performed immediately after PDT as an outpatient procedure. The mean number of treatments, mean logMAR best corrected visual acuity (BCVA), mean line of visual acuity changes, and proportion of patients without moderate visual loss at 1 year were compared between the combined and monotherapy groups.
   Results: At 1 year the logMAR BCVA for the PDT with IVTA group changed from 0.88 to 0.95 (p = 0.32 compared with baseline), whereas the logMAR BCVA for the monotherapy group reduced from 0.74 to 1.09 (p < 0.001 compared with baseline). A significantly higher proportion of patients who had PDT with IVTA did not develop moderate visual loss at 1 year compared with the monotherapy group (70.8% and 33.3% respectively, p = 0.009). Eyes which had combined treatment had significantly fewer lines lost compared with monotherapy alone (0.7 and 3.5 lines respectively, p = 0.015). Subgroup analysis showed that PDT with IVTA is effective in preventing visual loss in both predominately classic and occult CNV groups. The mean number of treatments for the combined and monotherapy groups was 1.5 and 1.96 respectively (p = 0.076).
   Conclusions: Combined PDT with IVTA appeared more effective statistically at 12 months for stabilisation of vision (< 3 logMAR lines change) compared with PDT monotherapy. Further randomised control trials might be justified to conclude the efficacy of PDT with IVTA.
C1 Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
   Univ Hong Kong, Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
   Zhejiang Univ, Affiliated Hosp 1, Coll Med, Zheyi Eye Ctr, Hangzhou, Zhejiang, Peoples R China.
C3 University of Hong Kong; Chinese University of Hong Kong; Prince of
   Wales Hospital; University of Hong Kong; Zhejiang University
RP Chan, WM (通讯作者)，Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, 147K Argyle St, Hong Kong, Peoples R China.
EM cwm6373@netvigator.com
RI Lam, Dennis/AAL-1211-2020; Lai, Timothy Y Y/AAC-2120-2020
OI Lai, Timothy Y Y/0000-0002-7832-6428
CR ANTOSZYK AN, 1993, GRAEF ARCH CLIN EXP, V231, P34, DOI 10.1007/BF01681698
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Ciulla TA, 2003, BRIT J OPHTHALMOL, V87, P1032, DOI 10.1136/bjo.87.8.1032
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Flower RW, 2001, AM J OPHTHALMOL, V132, P85, DOI 10.1016/S0002-9394(01)00872-8
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   Lai TYY, 2004, AM J OPHTHALMOL, V137, P826, DOI 10.1016/j.ajo.2003.11.079
   Matsuda S, 2005, INVEST OPHTH VIS SCI, V46, P1062, DOI 10.1167/iovs.04-0761
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V135, P343, DOI 10.1016/S0002-9394(02)01936-0
   Penfold PL, 2002, INVEST OPHTH VIS SCI, V43, P3125
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Wachtlin J, 2003, GRAEF ARCH CLIN EXP, V241, P518, DOI 10.1007/s00417-003-0650-8
   Wang YS, 2002, GRAEF ARCH CLIN EXP, V240, P42, DOI 10.1007/s00417-001-0398-y
NR 23
TC 57
Z9 64
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2006
VL 90
IS 3
BP 337
EP 341
DI 10.1136/bjo.2005.081299
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 013QS
UT WOS:000235424800026
PM 16488958
OA Green Published
DA 2022-11-30
ER

PT J
AU Joachim, N
   Mitchell, P
   Rochtchina, E
   Tan, AG
   Wang, JJ
AF Joachim, Nichole
   Mitchell, Paul
   Rochtchina, Elena
   Tan, Ava Grace
   Wang, Jie Jin
TI Incidence and Progression of Reticular Drusen in Age-related Macular
   Degeneration Findings from an Older Australian Cohort
SO OPHTHALMOLOGY
LA English
DT Article
ID BLUE-MOUNTAINS EYE; LONG-TERM INCIDENCE; BLOOD-CELL COUNT; INFLAMMATORY
   MARKERS; GEOGRAPHIC ATROPHY; 10-YEAR INCIDENCE; 5-YEAR INCIDENCE;
   GRADING SYSTEM; RISK-FACTORS; MACULOPATHY
AB Purpose: To assess the 15-year incidence and progression of reticular drusen and associations of this lesion with age-related macular degeneration (AMD) risk factors.
   Design: Population-based cohort.
   Participants: Blue Mountains Eye Study participants (n = 3654) 49 years of age and older attended baseline examinations; of these, 75.8%, 76.7%, and 56.1% of survivors attended 5-year, 10-year, and 15-year follow-up examinations, respectively.
   Methods: Color retinal photographs were obtained and comprehensive questionnaires were administered at each visit, and DNA samples were genotyped. Fundus autofluorescence images were not available. Reticular drusen identified from photographs were confirmed with side-by-side grading using the Wisconsin AMD grading protocol. Incidence was assessed using Kaplan-Meier product limit survival methods, controlling for competing risk of death. Associations between smoking, fish consumption, serum lipids, systemic and dietary factors, the CFH single nucleotide polymorphism (SNP) rs1061170 and ARMS2 SNP rs10490924, and the 15-year incidence of reticular drusen were analyzed in discrete logistic regression models. Generalized estimating equation models were used to analyze eye-specific relationships between these risk factors and 5-year progression from reticular drusen to late AMD.
   Main Outcome Measures: Incidence and progression of reticular drusen.
   Results: The 15-year cumulative incidence of reticular drusen was 4.0% (n = 95). Increasing age (per decade increase; odds ratio [OR], 3.4; 95% confidence interval [CI], 2.6-4.4), female sex (OR, 2.0; 95% CI, 1.3-3.2), and presence of risk alleles of CFH-rs1061170 (OR, 1.8; 95% CI, 1.3-2.4) or ARMS2-rs10490924 (OR, 3.0; 95% CI, 2.1-4.4) were associated with higher reticular drusen incidence. Current smoking at baseline predicted higher reticular drusen incidence (OR 2.1, 95% CI 1.0-4.5) after adjusting for age, sex, CFH-rs1061170 and ARMS2-rs10490924 polymorphisms. Of 118 eyes with reticular drusen, 40 (33.9%) developed late AMD over 5 years. A higher proportion of eyes with reticular drusen located outside versus within the macular area progressed to late AMD (50.0% vs. 37.8%). Dietary luteinezeaxanthin intake was associated with decreased likelihood of progression from reticular drusen to late AMD (adjusted OR, 0.5; 95% CI, 0.3-1.0).
   Conclusions: Known AMD risk factors were associated with greater long-term risk of reticular drusen. Neither total area nor central location of reticular drusen predicted 5-year progression to late AMD. Increased consumption of luteinezeaxanthin predicted a lower risk of progression. Ophthalmology 2014;121: 917925 (C) 2014 by the American Academy of Ophthalmology.
C1 [Joachim, Nichole; Mitchell, Paul; Rochtchina, Elena; Tan, Ava Grace; Wang, Jie Jin] Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Sydney, NSW 2006, Australia.
   [Joachim, Nichole; Mitchell, Paul; Rochtchina, Elena; Tan, Ava Grace; Wang, Jie Jin] Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
   [Wang, Jie Jin] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; Centre for Eye Research Australia; University of
   Melbourne
RP Wang, JJ (通讯作者)，Univ Sydney, Westmead Hosp, Ctr Vis Res, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM jiejin.wang@sydney.edu.au
RI Wang, Jie Jin/P-1499-2014; Mitchell, Paul/P-1498-2014; wang,
   jie/GRS-0942-2022
OI Wang, Jie Jin/0000-0001-9491-4898; Tan, Ava Grace/0000-0003-3344-0339
CR [Anonymous], 2004, SAS STAT 9 1 US GUID, P1609
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   CHUGAHUJA JK, 1993, J AM DIET ASSOC, V93, P318, DOI 10.1016/0002-8223(93)91559-9
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Food Standards Australia New Zealand, NUTTAB 2010
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Lee MY, 2012, BRIT J OPHTHALMOL, V96, P1222, DOI 10.1136/bjophthalmol-2011-301207
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   Lewis J, 1990, NUTTAB 90 NUTR DATA
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   National Health and Medical Research Council, 2009, AUSTR GUID RED HLTH, P31
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Shankar A, 2007, ATHEROSCLEROSIS, V192, P177, DOI 10.1016/j.atherosclerosis.2006.04.029
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P1061, DOI 10.1001/archophthalmol.2011.212
   Steinberg JS, 2013, INVEST OPHTH VIS SCI, V54, P4054, DOI 10.1167/iovs.12-11538
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Wang JJ, 2004, BRIT J OPHTHALMOL, V88, P104, DOI 10.1136/bjo.88.1.104
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 38
TC 78
Z9 79
U1 0
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2014
VL 121
IS 4
BP 917
EP 925
DI 10.1016/j.ophtha.2013.10.043
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AE2MV
UT WOS:000333808100024
PM 24332537
DA 2022-11-30
ER

PT J
AU Brandl, C
   Breinlich, V
   Stark, KJ
   Enzinger, S
   Assenmacher, M
   Olden, M
   Grassmann, F
   Graw, J
   Heier, M
   Peters, A
   Helbig, H
   Kuchenhoff, H
   Weber, BHF
   Heid, IM
AF Brandl, Caroline
   Breinlich, Valentin
   Stark, Klaus J.
   Enzinger, Sabrina
   Assenmacher, Matthias
   Olden, Matthias
   Grassmann, Felix
   Graw, Jochen
   Heier, Margit
   Peters, Annette
   Helbig, Horst
   Kuechenhoff, Helmut
   Weber, Bernhard H. F.
   Heid, Iris M.
TI Features of Age-Related Macular Degeneration in the General Adults and
   Their Dependency on Age, Sex, and Smoking: Results from the German KORA
   Study
SO PLOS ONE
LA English
DT Article
ID CARDIOVASCULAR RISK-FACTORS; LONG-TERM INCIDENCE; SEVERITY SCALE; EYE
   DISEASE; 10-YEAR INCIDENCE; CATARACT-SURGERY; POOLED FINDINGS;
   PREVALENCE; MACULOPATHY; CLASSIFICATION
AB Age-related macular degeneration (AMD) is a vision impairing disease of the central retina characterized by early and late forms in individuals older than 50 years of age. However, there is little knowledge to what extent also younger adults are affected. We have thus set out to estimate the prevalence of early AMD features and late AMD in a general adult population by acquiring color fundus images in 2,840 individuals aged 25 to 74 years of the Cooperative Health Research in the Region of Augsburg project (KORA) in South Germany. Among the 2,546 participants with gradable images for each eye, 10.9% (n = 277) had early AMD features (applying the 9-step Age-Related Eye Disease Study Severity Scale), 0.2% (n = 6) had late AMD. Prevalence increased with age, reaching 26.3% for early AMD features and 1.9% for late AMD at the age 70+. However, signs of early AMD were found in subjects as young as 25 years, with the risk for early AMD features increasing linearly by years of age in men, and, less consistent with a linear increase, in women. Risk for early AMD features increased linearly by pack years of smoking in men, not in women, nor was there any association with other lifestyle or metabolic factors. By providing much sought-after prevalence estimates for AMD from Central Europe, our data underscores a substantial proportion of the adult population with signs of early AMD, including individuals younger than 50 years. This supports the notion that early AMD features in the young might be under-acknowledged.
C1 [Brandl, Caroline; Stark, Klaus J.; Olden, Matthias; Heid, Iris M.] Univ Regensburg, Dept Genet Epidemiol, Regensburg, Germany.
   [Brandl, Caroline; Helbig, Horst] Univ Hosp Regensburg, Dept Ophthalmol, Regensburg, Germany.
   [Brandl, Caroline; Breinlich, Valentin; Grassmann, Felix; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Regensburg, Germany.
   [Enzinger, Sabrina; Assenmacher, Matthias; Kuechenhoff, Helmut] Ludwig Maximilians Univ Munchen, Stat Consulting Unit, StaBLab, Dept Stat, Munich, Germany.
   [Graw, Jochen] Helmholtz Zentrum Munchen, Inst Dev Genet, Neuherberg, Germany.
   [Heier, Margit; Peters, Annette] Helmholtz Zentrum Munchen, Inst Epidemiol 2, Neuherberg, Germany.
   [Heid, Iris M.] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Genet Epidemiol, Neuherberg, Germany.
C3 University of Regensburg; University of Regensburg; University of
   Regensburg; University of Munich; Helmholtz Association;
   Helmholtz-Center Munich - German Research Center for Environmental
   Health; Helmholtz Association; Helmholtz-Center Munich - German Research
   Center for Environmental Health; Helmholtz Association; Helmholtz-Center
   Munich - German Research Center for Environmental Health
RP Heid, IM (通讯作者)，Univ Regensburg, Dept Genet Epidemiol, Regensburg, Germany.; Heid, IM (通讯作者)，Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Genet Epidemiol, Neuherberg, Germany.
EM iris.heid@klinik.uni-regensburg.de
RI Peters, Annette/A-6117-2011; Stark, Klaus/L-7367-2013; Heier,
   Margit/AAT-5280-2020
OI Peters, Annette/0000-0001-6645-0985; Stark, Klaus/0000-0002-7832-1942;
   Assenmacher, Matthias/0000-0003-2154-5774; Grassmann,
   Felix/0000-0003-1390-7528; Brandl, Caroline/0000-0001-8223-6137; Graw,
   Jochen/0000-0003-0298-9660; Weber, Bernhard H.F./0000-0002-8808-7723;
   Kuchenhoff, Helmut/0000-0002-6372-2487
FU German Federal Ministry of Education and Research (BMBF) [01ER1206,
   01ER1507]; Helmholtz Zentrum Munchen German Research Center for
   Environmental Health; State of Bavaria; Munich Center of Health Sciences
   (MC-Health), Ludwig-Maximilians-Universitat, as part of LMUinnovativ
FX The analytical work in this study is supported in part by grants from
   the German Federal Ministry of Education and Research (BMBF 01ER1206 and
   01ER1507) to I.M.H. The KORA study was initiated and financed by the
   Helmholtz Zentrum Munchen German Research Center for Environmental
   Health, which is funded by the German Federal Ministry of Education and
   Research (BMBF) and by the State of Bavaria. Furthermore, KORA research
   was supported within the Munich Center of Health Sciences (MC-Health),
   Ludwig-Maximilians-Universitat, as part of LMUinnovativ. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Akuffo KO, 2015, BRIT J OPHTHALMOL, V99, P1037, DOI 10.1136/bjophthalmol-2014-305768
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bitsios P, 1996, AGE AGEING, V25, P432, DOI 10.1093/ageing/25.6.432
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   BUTLER JS, 1987, REV ECON STAT, V69, P644, DOI 10.2307/1935959
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Erke MG, 2014, ACTA OPHTHALMOL, V92, P662, DOI 10.1111/aos.12346
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Holle R, 2005, GESUNDHEITSWESEN, V67, pS19, DOI 10.1055/s-2005-858235
   Holzapfel C, 2010, INT J OBESITY, V34, P1538, DOI 10.1038/ijo.2010.79
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Kaarniranta K, 2015, CURR EYE RES, V40, P226, DOI 10.3109/02713683.2014.925933
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim YJ, 2004, J R STAT SOC B, V66, P337, DOI 10.1046/j.1369-7412.2003.05316.x
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Korb CA, 2014, GRAEF ARCH CLIN EXP, V252, P1403, DOI 10.1007/s00417-014-2591-9
   La TY, 2014, CURR EYE RES, V39, P1232, DOI 10.3109/02713683.2014.907431
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Meisinger C, 2005, DIABETOLOGIA, V48, P27, DOI 10.1007/s00125-004-1604-3
   Neuner B, 2009, ADDICT BEHAV, V34, P938, DOI 10.1016/j.addbeh.2009.05.015
   Risk factors associated with age-related macular degeneration, 2000, OPHTHALMOLOGY, P107
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, NEW ENGL J MED, V364, P1966, DOI 10.1056/NEJMe1103334
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stratmann B, 2014, CARDIOVASC DIABETOL, V13, DOI 10.1186/1475-2840-13-90
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Vitale S, 2016, JAMA OPHTHALMOL, V134, P1041, DOI 10.1001/jamaophthalmol.2016.2383
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2012, OPHTHALMOLOGY, V119, P2298, DOI 10.1016/j.ophtha.2012.07.003
   Wichmann HE, 2005, GESUNDHEITSWESEN, V67, pS26, DOI 10.1055/s-2005-858226
   Winkler G, 1998, Z ERNAHRUNGSWISS, V37, P234, DOI 10.1007/s003940050022
   WINN B, 1994, INVEST OPHTH VIS SCI, V35, P1132
   Wolfram C, 2012, WEISSBUCH SITUATION
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wood S.N., 2017, GEN ADDITIVE MODELS, V2, DOI DOI 10.1201/9781315370279
   Wood SN, 2006, AUST NZ J STAT, V48, P445, DOI 10.1111/j.1467-842X.2006.00450.x
   Wood SN, 2003, J ROY STAT SOC B, V65, P95, DOI 10.1111/1467-9868.00374
   Ying GS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1147, DOI 10.1001/archophthalmol.2009.189
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 61
TC 21
Z9 22
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 28
PY 2016
VL 11
IS 11
AR e0167181
DI 10.1371/journal.pone.0167181
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EE3FE
UT WOS:000389472400096
PM 27893849
OA Green Published, Green Submitted, gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Wang, K
   Hsieh, MJ
   Chien, HW
   Lee, CY
   Yeh, CB
   Huang, JY
   Yang, SF
AF Wang, Kai
   Hsieh, Ming-Ju
   Chien, Hsiang-Wen
   Lee, Chia-Yi
   Yeh, Chao-Bin
   Huang, Jing-Yang
   Yang, Shun-Fa
TI Medical Compliance of Fibrate and the Decreased Risk of Age-Related
   Macular Degeneration in Dyslipidemia-Related Diseases: A
   Population-Based Cohort Study
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE age-related macular degeneration; epidemiology; fibrate; dyslipidemia;
   compliance
ID RECEPTOR BLOCKERS; EYE DISEASE; PREVALENCE; ASSOCIATION; INHIBITORS;
   STATINS
AB The purpose of the current study is to evaluate the incidence of age-related macular degeneration (AMD) in dyslipidemia-related diseases with or without the use of fibrate. Patients were defined as dyslipidemia-related diseases according to the diagnostic code and lab exam arrangement, then the population was divided into those with fibrate application and those without via 1:2 ratios of propensity-score matching. The primary outcome is the development of AMD after dyslipidemia-related diseases by the Cox proportional hazard regression. Besides, the relationship between the medical compliance of fibrate, presented as medical possession ratio (MPR), and the AMD development was also analyzed. A total of 22,917 patients and 45,834 individuals were enrolled in the study and control groups. There were 572 and 1181 events of any AMD development in the study and control groups which showed identical risk of AMD (aHR: 0.94, 95% CI: 0.85-1.04). However, a reduced risk of any AMD was found in those patients reached a baseline MPR more than 20% (aHR: 0.729, 95% CI: 0.599-0.887, p = 0.0016) and overall MPR more than 5% three years after the diagnosis of dyslipidemia-related diseases (aHR: 0.712, 95% CI: 0.557-0.909, p = 0.0065). Besides, a lower risk of dry-AMD was also found in those patients with the above conditions (aHR: 0.736, 95% CI: 0.599-0.906, p = 0.0038 and aHR: 0.721, 95% CI: 0.557-0.934, p = 0.0133, respectively). In conclusion, the use of fibrate with fair initial medical compliance will decrease the incidence of AMD in patients with dyslipidemia-related diseases, especially for the development of dry-AMD.
C1 [Wang, Kai; Chien, Hsiang-Wen] Cathay Gen Hosp, Dept Ophthalmol, Taipei 106, Taiwan.
   [Wang, Kai; Chien, Hsiang-Wen] Sijhih Cathay Gen Hosp, Dept Ophthalmol, New Taipei 211, Taiwan.
   [Wang, Kai] Fu Jen Catholic Univ, Sch Med, Coll Med, New Taipei 242, Taiwan.
   [Hsieh, Ming-Ju; Huang, Jing-Yang; Yang, Shun-Fa] Chung Shan Med Univ, Inst Med, Taichung 402, Taiwan.
   [Hsieh, Ming-Ju] Changhua Christian Hosp, Oral Canc Res Ctr, Changhua 500, Taiwan.
   [Hsieh, Ming-Ju] China Med Univ, Grad Inst Biomed Sci, Taichung 404, Taiwan.
   [Lee, Chia-Yi] Show Chwan Mem Hosp, Dept Ophthalmol, Changhua 500, Taiwan.
   [Yeh, Chao-Bin] Chung Shan Med Univ, Sch Med, Dept Emergency Med, Taichung 402, Taiwan.
   [Yeh, Chao-Bin] Chung Shan Med Univ Hosp, Dept Emergency Med, Taichung 402, Taiwan.
   [Huang, Jing-Yang; Yang, Shun-Fa] Chung Shan Med Univ Hosp, Dept Med Res, Taichung 402, Taiwan.
C3 Cathay General Hospital; Cathay General Hospital; Fu Jen Catholic
   University; Chung Shan Medical University; Changhua Christian Hospital;
   China Medical University Taiwan; Show Chwan Memorial Hospital; Chung
   Shan Medical University; Chung Shan Medical University; Chung Shan
   Medical University Hospital; Chung Shan Medical University; Chung Shan
   Medical University Hospital
RP Yang, SF (通讯作者)，Chung Shan Med Univ, Inst Med, Taichung 402, Taiwan.; Yang, SF (通讯作者)，Chung Shan Med Univ Hosp, Dept Med Res, Taichung 402, Taiwan.
EM cgh04979@cgh.org.tw; 170780@cch.org.tw; bmw35chien1@gmail.com;
   ao6u.3msn@hotmail.com; sky5ff@gmail.com; wchinyang@gmail.com;
   ysf@csmu.edu.tw
RI Yang, Shun-Fa/AAN-1519-2020; Hsieh, Ming-Ju/GQB-3025-2022
OI Yang, Shun-Fa/0000-0002-0365-7927; Huang, Jing-Yang/0000-0002-0794-9388;
   Yeh, Chao-Bin/0000-0002-3978-5576; Lee, Chia-Yi/0000-0002-5719-0488;
   Hsieh, Ming-Ju/0000-0001-9726-3234
CR Bag-Ozbek A, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-014-0497-6
   Bergen AA, 2019, PROG RETIN EYE RES, V70, P55, DOI 10.1016/j.preteyeres.2018.12.003
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen YY, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/1649156
   Clifford S, 2014, CURR MED RES OPIN, V30, P1071, DOI 10.1185/03007995.2014.884491
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Durrington P, 2003, LANCET, V362, P717, DOI 10.1016/S0140-6736(03)14234-1
   Fraser-Bell S, 2017, CLIN EXP OPHTHALMOL, V45, P45, DOI 10.1111/ceo.12905
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Frolkis JP, 2002, AM J MED, V113, P625, DOI 10.1016/S0002-9343(02)01303-7
   Fu ZJ, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910473
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gonzalez L, 2016, VASC ENDOVASC SURG, V50, P119, DOI 10.1177/1538574416628655
   Ikeda N, 2021, J HEALTH SERV RES PO, V26, P106, DOI 10.1177/1355819620949574
   Jung UJ, 2014, INT J MOL SCI, V15, P6184, DOI 10.3390/ijms15046184
   Kijlstra A, 2015, OPHTHALMIC RES, V54, P64, DOI 10.1159/000432401
   Kopin L, 2017, ANN INTERN MED, V167, pITC81, DOI 10.7326/AITC201712050
   Lazreg S, 2016, OPHTHALMIC RES, V56, P145, DOI 10.1159/000446844
   Lee H, 2019, YONSEI MED J, V60, P679, DOI 10.3349/ymj.2019.60.7.679
   Lee JS, 2017, DIABETES CARE, V40, P529, DOI 10.2337/dc16-1958
   Levin LA, 2018, ASIA-PAC J OPHTHALMO, V7, P246, DOI 10.22608/APO.2018299
   Luo RJ, 2010, CHINESE MED J-PEKING, V123, P2662, DOI 10.3760/cma.j.issn.0366-6999.2010.19.008
   Ma L, 2015, SCI REP-UK, V5, DOI 10.1038/srep18280
   Maralani HG, 2015, RETINA-J RET VIT DIS, V35, P459, DOI 10.1097/IAE.0000000000000338
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Pan L, 2016, ATHEROSCLEROSIS, V248, P2, DOI 10.1016/j.atherosclerosis.2016.02.006
   Rathnakumar Krishnamoorthy, 2018, Journal of Basic and Clinical Physiology and Pharmacology, V29, P195, DOI 10.1515/jbcpp-2017-0001
   Roizenblatt M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113688
   Saklayen MG, 2018, CURR HYPERTENS REP, V20, DOI 10.1007/s11906-018-0812-z
   Shalev V, 2011, OPHTHAL EPIDEMIOL, V18, P83, DOI 10.3109/09286586.2011.560746
   Shen JH, 2016, DISCOV MED, V22, P129
   Sherling DH, 2017, J CARDIOVASC PHARM T, V22, P365, DOI 10.1177/1074248416686187
   Supuran CT, 2019, EXPERT OPIN THER PAT, V29, P761, DOI 10.1080/13543776.2019.1671353
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Thomas AS, 2015, RETINA-J RET VIT DIS, V35, P1964, DOI 10.1097/IAE.0000000000000603
   Valdez Connie A, 2005, J Manag Care Pharm, V11, P499
   Vassilev ZP, 2015, INVEST OPHTH VIS SCI, V56, P1585, DOI 10.1167/iovs.14-16271
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yau JWY, 2008, INTERN MED J, V38, P904, DOI 10.1111/j.1445-5994.2008.01720.x
NR 41
TC 1
Z9 1
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD JAN
PY 2021
VL 18
IS 1
AR 301
DI 10.3390/ijerph18010301
PG 13
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA PP9UE
UT WOS:000606197700001
PM 33401577
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Shinojima, A
   Sawa, M
   Mori, R
   Sekiryu, T
   Oshima, Y
   Kato, A
   Hara, C
   Saito, M
   Sugano, Y
   Ashikari, M
   Hirano, Y
   Asato, H
   Nakamure, M
   Matsune, K
   Kuno, N
   Kimure, E
   Nishiyama, T
   Yuzawa, M
   Ishibashi, T
   Ogura, Y
   Lida, T
   Gomi, F
   Yasukawa, T
AF Shinojima, Ari
   Sawa, Miki
   Mori, Ryusaburo
   Sekiryu, Tetsuju
   Oshima, Yuji
   Kato, Aki
   Hara, Chikako
   Saito, Masaaki
   Sugano, Yukinori
   Ashikari, Masayuki
   Hirano, Yoshio
   Asato, Hitomi
   Nakamure, Mayumi
   Matsune, Kiyoshi
   Kuno, Noriyuki
   Kimure, Erika
   Nishiyama, Takeshi
   Yuzawa, Mitsuko
   Ishibashi, Tatsuro
   Ogura, Yuichiro
   Lida, Tomohiro
   Gomi, Fumi
   Yasukawa, Tsutomu
TI Five-year follow-up of fundus autofluorescence and retinal sensitivity
   in the fellow eye in exudative age-related macular degeneration in Japan
SO PLOS ONE
LA English
DT Article
ID VISUAL FUNCTION; 2ND EYE; MICROPERIMETRY; RISK
AB Purpose
   To assess the 5-year change in abnormal fundus autofluorescence (FAF) patterns and retinal sensitivity in the fellow eye of Japanese patients with unilateral exudative age-related macular degeneration (AMD).
   Methods
   Patients with unilateral exudative AMD who developed abnormal FAF in the fellow eyes were enrolled. FAF imaging and microperimetry were performed at baseline and follow-ups. FAF findings were classified into 8 patterns based on the International Fundus Autofluorescence Classification Group to assess retinal sensitivity. Forty-five points covering the central 12 degrees on microperimetry were superimposed onto the FAF images. Each point was classified depending on the distance from the abnormal FAF. "Close" was defined as the portion within 1 degree from the border of any abnormal FAF, and "Distant" was defined as the portion over 1 degree from the border of abnormal FAF. To investigate the association between the retinal sensitivity and distance from the abnormal FAF, hierarchical linear mixed-effect models were used with the distance, time and time squared from baseline months), and angle (degrees) as fixed effects. Differences among patients, eyes, and test point locations were considered successively nested random effects.
   Results
   We studied 66 fellow eyes with abnormal FAF. Twenty-seven eyes were followed-up during the 5 years. In the 13 of 27 eyes (48%), the abnormal FAF patterns had changed during the 5 years. We found retinal sensitivity was associated significantly with the distance from the abnormal FAF ("Distant": p< 0.001, time2 from baseline: p< 0.001, angle: p< 0.001). The mean retinal sensitivity of the "Close" tended to deteriorate after the third year and eventually showed the similar sensitivity as the portion within the abnormal FAF.
   Conclusion
   FAF patterns can change about half during the 5 years and the retinal sensitivity near abnormal FAF tends to deteriorate after the third year.
C1 [Shinojima, Ari; Mori, Ryusaburo; Yuzawa, Mitsuko] Nihon Univ, Dept Visual Sci, Div Ophthalmol, Sch Med, Tokyo, Japan.
   [Shinojima, Ari] Keio Univ, Dept Ophthalmol, Sch Med, Tokyo, Japan.
   [Sawa, Miki; Hara, Chikako; Gomi, Fumi] Osaka Univ, Dept Ophthalmol, Grad Sch Med, Suita, Osaka, Japan.
   [Sekiryu, Tetsuju; Saito, Masaaki; Sugano, Yukinori; Lida, Tomohiro] Fukushima Med Univ, Dept Ophthalmol, Sch Med, Fukushima, Japan.
   [Oshima, Yuji; Asato, Hitomi; Ishibashi, Tatsuro] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Fukuoka, Japan.
   [Kato, Aki; Ashikari, Masayuki; Hirano, Yoshio; Ogura, Yuichiro; Yasukawa, Tsutomu] Nagoya City Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med Sci, Nagoya, Aichi, Japan.
   [Saito, Masaaki] Akita Univ, Grad Sch Med, Dept Ophthalmol, Akita, Japan.
   [Saito, Masaaki] Akita Univ, Fac Med, Akita, Japan.
   [Nakamure, Mayumi; Matsune, Kiyoshi; Kuno, Noriyuki; Kimure, Erika] Santen Pharmaceut Co Ltd, Ikoma, Japan.
   [Kuno, Noriyuki] Japan Innovat Therapeut Inc, Nagoya, Aichi, Japan.
   [Nishiyama, Takeshi] Aichi Med Univ, Dept Publ Hlth, Sch Med, Nagakute, Aichi, Japan.
   [Lida, Tomohiro] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo, Japan.
   [Gomi, Fumi] Hyogo Coll Med, Dept Ophthalmol, Nishinomiya, Hyogo, Japan.
C3 Nihon University; Keio University; Osaka University; Fukushima Medical
   University; Kyushu University; Nagoya City University; Akita University;
   Akita University; Santen Pharmaceutical Co Ltd; Aichi Medical
   University; Tokyo Women's Medical University; Hyogo College of Medicine
RP Yasukawa, T (通讯作者)，Nagoya City Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med Sci, Nagoya, Aichi, Japan.
EM yasukawa@med.nagoya-cu.ac.jp
RI Shinojima, Ari/AAR-4442-2021; Saito, Masaaki/ABI-2783-2020
OI Shinojima, Ari/0000-0003-2322-0332; Saito, Masaaki/0000-0003-1494-6350;
   Gomi, Fumi/0000-0003-0807-8817; Hirano, Yoshio/0000-0002-9173-0839
FU Santen Pharmaceutical Co., Ltd.; JSPS KAKENHI [JP19K18893]
FX Santen Pharmaceutical Co., Ltd. provided support in the form of
   honoraria for speaking and/or organizing at meetings (AS, MS, RM, TS,
   Yuji Oshima, TI, Yuichiro Ogura, FG, TY), but did not have any
   additional role in the study design, data analysis, decision to publish,
   or preparation of the manuscript. Santen Pharmaceutical Co., Ltd.
   provided support in the form of salaries for authors [MN, KM, NK, and
   EK], but did not have any additional role in the study design, data
   analysis, decision to publish, or preparation of the manuscript. The
   specific roles of these authors are articulated in the `author
   contributions' section. This work was also supported by JSPS KAKENHI
   Grant Number JP19K18893.
CR American Academy of Ophthalmology, 2015, AG REL MAC DEG PPP U
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Birtel J, 2019, AM J OPHTHALMOL, V199, P19, DOI 10.1016/j.ajo.2018.10.021
   Brandl C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167181
   Cassels NK, 2018, SURV OPHTHALMOL, V63, P40, DOI 10.1016/j.survophthal.2017.05.007
   Einbock W, 2005, GRAEF ARCH CLIN EXP, V243, P300, DOI 10.1007/s00417-004-1027-3
   Hariri AH, 2016, AM J OPHTHALMOL, V168, P122, DOI 10.1016/j.ajo.2016.05.007
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kiziltunc PB, 2018, TURK OFTALMOL DERG, V48, P304, DOI 10.4274/tjo.69260
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Midena E, 2010, OPHTHALMOLOGY, V117, P1571, DOI 10.1016/j.ophtha.2009.12.044
   Nomura Y, 2019, GRAEF ARCH CLIN EXP, V257, P1591, DOI 10.1007/s00417-019-04332-z
   Ozdemir H, 2008, EYE, V22, P204, DOI 10.1038/sj.eye.6702563
   Ozdemir H, 2008, EUR J OPHTHALMOL, V18, P799, DOI 10.1177/112067210801800522
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Rim TH, 2017, BRIT J OPHTHALMOL, V101, P1367, DOI 10.1136/bjophthalmol-2016-309952
   Rohrschneider K, 2005, AM J OPHTHALMOL, V139, P125, DOI 10.1016/j.ajo.2004.08.060
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Shinojima A, 2016, OPHTHALMOLOGICA, V235, P208, DOI 10.1159/000444885
   Springer C, 2005, OPHTHALMOLOGY, V112, P848, DOI 10.1016/j.ophtha.2004.11.051
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   The Royal College of Ophthalmologists, AG REL MAC DEG GUID
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   Vingolo EM, 2017, EUR J OPHTHALMOL, V27, P352, DOI 10.5301/ejo.5000904
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Yasukawa T, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213161
   2001, AM J OPHTHALMOL, V132, P668, DOI DOI 10.1016/S0002-9394(01)01218-1
NR 29
TC 1
Z9 2
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 6
PY 2020
VL 15
IS 3
AR e0229694
DI 10.1371/journal.pone.0229694
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA LQ8TR
UT WOS:000535271600016
PM 32142523
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ma, L
   Dou, HL
   Huang, YM
   Lu, XR
   Xu, XR
   Qian, F
   Zou, ZY
   Pang, HL
   Dong, PC
   Xiao, X
   Wang, X
   Sun, TT
   Lin, XM
AF Ma, Le
   Dou, Hong-Liang
   Huang, Yang-Mu
   Lu, Xin-Rong
   Xu, Xian-Rong
   Qian, Fang
   Zou, Zhi-Yong
   Pang, Hong-Lei
   Dong, Peng-Cheng
   Xiao, Xin
   Wang, Xun
   Sun, Ting-Ting
   Lin, Xiao-Ming
TI Improvement of Retinal Function in Early Age-Related Macular
   Degeneration After Lutein and Zeaxanthin Supplementation: A Randomized,
   Double-Masked, Placebo-Controlled Trial
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT OPTICAL-DENSITY; MULTIFOCAL ELECTRORETINOGRAM; DIETARY
   SUPPLEMENTATION; VISUAL-ACUITY; EYE DISEASE; CAROTENOIDS; MACULOPATHY;
   ANTIOXIDANT; RISK; GUIDELINES
AB PURPOSE: To examine the effects of lutein and zeaxanthin supplementation on retinal function using multi-focal electroretinograms (mfERG) in patients with early age-related macular degeneration (AMD).
   DESIGN: Randomized, double-masked, placebo-controlled trial.
   METHODS: One hundred eight subjects with early AMD were randomly assigned to receive 10 mg/d lutein (n = 27), 20 mg/d lutein (n = 27), 10 mg/d lutein plus 10 mg/d zeaxanthin (n = 27), or placebo (n = 27) for 48 weeks. Thirty-six age-matched controls without AMD were also enrolled to compare baseline data with early AMD patients. MfERG responses and macular pigment optical densities (MPODs) were recorded and analyzed at baseline and at 24 and 48 weeks.
   RESULTS: There were significant reductions in N1P1 response densities in ring 1 to ring 3 in early AMD patients compared with the controls (P < .05), whereas neither N1P1 response densities in ring 4 to ring 6 nor P1 peak latencies significantly changed. After 48-week supplementation, the N1P1 response densities showed significant increases in ring 1 for the 20 mg lutein group and for the lutein and zeaxanthin group, and in ring 2 for the 20 mg lutein group. The increases in MPOD related positively to the increases in N1P1 response density in ring 1 and ring 2 for nearly all active treatment groups. N1P1 response densities in ring 3 to ring 6 or P1 peak latencies in all rings did not change significantly in any group.
   CONCLUSION: Early functional abnormalities of the central retina in the early AMD patients could be improved by lutein and zeaxanthin supplementation. These improvements may be potentially attributed to the elevations in MPOD. (Am J Ophthalmol 2012;154: 625-634. (C) 2012 by Elsevier Inc. All rights reserved.)
C1 [Ma, Le; Huang, Yang-Mu; Xu, Xian-Rong; Zou, Zhi-Yong; Dong, Peng-Cheng; Xiao, Xin; Wang, Xun; Sun, Ting-Ting; Lin, Xiao-Ming] Peking Univ, Sch Publ Hlth, Dept Nutr & Food Hyg, Beijing 100871, Peoples R China.
   [Dou, Hong-Liang; Lu, Xin-Rong; Qian, Fang; Pang, Hong-Lei] Peking Univ, Hosp 3, Ctr Eye, Beijing 100871, Peoples R China.
C3 Peking University; Peking University
RP Lin, XM (通讯作者)，38 Xueyuan Rd, Beijing 100191, Peoples R China.
EM linbjmu@bjmu.edu.cn
RI Zou, Zhiyong/P-8066-2019
OI Zou, Zhiyong/0000-0001-5049-5425; Huang, Yangmu/0000-0002-3660-1276; ma,
   le/0000-0001-7592-9779
FU National Natural Science Foundation of China, Beijing, People's Republic
   of China [NSFC-30872113]
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF Interest and none were reported. Publication
   of this article was supported by the National Natural Science Foundation
   of China (NSFC-30872113), Beijing, People's Republic of China. The
   funding organizations had no role in the design or conduct of this
   study. Involved in design and conduct of the study (L.M., H.-L.D.,
   X.-M.L.); collection of the data (L.M., H.-L.D., Y.-M.H., X.-R.L.,
   X.-R.X., F.Q., Z.-Y.Z., H.-L.P., P.-C.D., X.X., X.W., T.-T.S., X.-M.L.);
   management, analysis, and interpretation of the data (L.M., H.-L.D.,
   X.-M.L.); preparation (L.M.), critical revision (L.M., H.-L.D.,
   X.-M.L.), and final approval of the manuscript (all authors); provision
   of materials, patients, or resources (H.-L.D.,X.-R.L., F.Q., H.-L.P.);
   statistical expertise (L.M., H.-L.D., X.-M.L.); obtaining funding
   (X.-M.L.); literature search (L.M., X.-M.L.); and administrative,
   technical, and logistical support (L.M., H.-L.D., X.-M.L.). The
   Institutional Review Board (IR13) of Peking University approved this
   study prospectively. Informed consent for the research was obtained from
   all patients, and the study followed the tenets of the Declaration of
   Helsinki. This clinical trial has been registered at
   http://www.clinicaltrials.gov (NCT01528605).
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Albert GI, 2008, COMP BIOCHEM PHYS B, V151, P70, DOI 10.1016/j.cbpb.2008.05.014
   Barker FM, 2011, INVEST OPHTH VIS SCI, V52, P3934, DOI 10.1167/iovs.10-5898
   Bearse MA, 2006, PROG RETIN EYE RES, V25, P425, DOI 10.1016/j.preteyeres.2006.07.001
   Bhosale P, 2007, INVEST OPHTH VIS SCI, V48, P543, DOI 10.1167/iovs.06-0558
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Cangemi Francis E, 2007, BMC Ophthalmol, V7, P3, DOI 10.1186/1471-2415-7-3
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Chucair AJ, 2007, INVEST OPHTH VIS SCI, V48, P5168, DOI 10.1167/iovs.07-0037
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Connolly EE, 2011, INVEST OPHTH VIS SCI, V52, P9207, DOI 10.1167/iovs.11-8025
   Davies NP, 2004, PROG RETIN EYE RES, V23, P533, DOI 10.1016/j.preteyeres.2004.05.004
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Delori FC, 2004, ARCH BIOCHEM BIOPHYS, V430, P156, DOI 10.1016/j.abb.2004.05.016
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   Feigl B, 2007, CLIN OPHTHALMOL, V1, P167
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gin TJ, 2011, INVEST OPHTH VIS SCI, V52, P9267, DOI 10.1167/iovs.11-8517
   Hood DC, 2008, DOC OPHTHALMOL, V116, P1, DOI 10.1007/s10633-007-9089-2
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Joseph JA, 1999, J NEUROSCI, V19, P8114
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Leung Ivan Y-F, 2008, Optometry, V79, P266, DOI 10.1016/j.optm.2007.03.017
   Leung IYF, 2004, INVEST OPHTH VIS SCI, V45, P3244, DOI 10.1167/iovs.02-1233
   Li BX, 2010, ARCH BIOCHEM BIOPHYS, V504, P56, DOI 10.1016/j.abb.2010.07.024
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Mackay AM, 2007, DOC OPHTHALMOL, V115, P69, DOI 10.1007/s10633-007-9056-y
   Marmor MF, 2003, DOC OPHTHALMOL, V106, P105, DOI 10.1023/A:1022591317907
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Minassian DC, 2011, BRIT J OPHTHALMOL, V95, P1433, DOI 10.1136/bjo.2010.195370
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Mullins RF, 2011, INVEST OPHTH VIS SCI, V52, P1606
   Murdaugh LS, 2010, EXP EYE RES, V90, P564, DOI 10.1016/j.exer.2010.01.014
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Sasaki M, 2009, INVEST OPHTH VIS SCI, V50, P1433, DOI 10.1167/iovs.08-2493
   Stahl W, 2001, BIOFACTORS, V15, P95, DOI 10.1002/biof.5520150209
   Subczynski WK, 2010, ARCH BIOCHEM BIOPHYS, V504, P61, DOI 10.1016/j.abb.2010.05.015
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Thomson LR, 2002, EXP EYE RES, V75, P529, DOI 10.1006/exer.2002.2050
   Trieschmann M, 2006, GRAEF ARCH CLIN EXP, V244, P1565, DOI 10.1007/s00417-006-0289-3
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Wasmuth S, 2009, INVEST OPHTH VIS SCI, V50, P5304, DOI 10.1167/iovs.08-3326
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Whitehead AJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1038, DOI 10.1001/archopht.124.7.1038
   Zeimer MB, 2010, RETINA-J RET VIT DIS, V30, P1282, DOI 10.1097/IAE.0b013e3181e096dd
NR 50
TC 56
Z9 59
U1 0
U2 35
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2012
VL 154
IS 4
BP 625
EP 634
DI 10.1016/j.ajo.2012.04.014
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 018UK
UT WOS:000309691800003
PM 22835510
DA 2022-11-30
ER

PT J
AU Bonyadi, MHJ
   Yaseri, M
   Bonyadi, M
   Soheilian, M
   Nikkhah, H
AF Bonyadi, Mohammad Hossein Jabbarpoor
   Yaseri, Mehdi
   Bonyadi, Mortaza
   Soheilian, Masoud
   Nikkhah, Homayoun
TI Association of combined cigarette smoking and ARMS2/LOC387715 A69S
   polymorphisms with age-related macular degeneration: A meta-analysis
SO OPHTHALMIC GENETICS
LA English
DT Review
DE Age-related macular degeneration (AMD); ARA452/LOC387715 A695; cigarette
   smoking; mechanism of pathogenesis; meta-analysis; rs10490924;
   synergistic effect
ID C-REACTIVE PROTEIN; COMPLEMENT FACTOR-H; IN-VITRO; SUSCEPTIBILITY;
   MACULOPATHY; LOC387715; ARMS2; RISK; PREVALENCE; GENE
AB Purpose: The age-related maculopathy susceptibility2 (ARM52)/LOC387715 A695 (rs10490924) polymorphism and cigarette smoking have been shown to have significant association with AMD: In this meta-analysis we used the results of available association studies of combined ARM52/LOC387715 genotypes and cigarette smoking with AMD to estimate the possible synergistic or multiplicative effects.
   Methods: Heterogeneity of studies was evaluated using the Cochran Q-test and the I-square index. To compensate for the heterogeneity of the variables in the study we used a random effects model. Meta analysis was performed using STATA. To estimate the additive or supra-additive effects, we calculated relative excess risk due to interaction (RERI), attributable proportion due to interaction (AP), synergy index (S); and multiplicative index (V).
   Results: We could include four studies with 1982 AMD patients and 1797 control subjects. Considering the GG-no smoking as a reference line the meta-analysis result of AMD odds ratios for stratified combined factors was 3.05 (95% CI 2.32-4.02) for nonGG-no smoking, 2.24 (95% CI 1.39-3.63) for GG-smoking and 4.59 (95% CI 3.51-6.01) for nonGG-smoking. The meta-analysis of synergy analysis revealed RERI = 2.01 (95% CI 1.01-3.25), AP = 0.40 (95% CI 0.22-0.54), 5 = 2.02 (95% CI 1.35-3.01), and V = 1.31 (95% CI 094-1.83).
   Conclusion: This analysis revealed the synergistic effect of these two factors indicating that there is a common pathway of ARMS2/LOC387715 and smoking in AMD pathogenesis which maybe the complement system pathway.
C1 [Bonyadi, Mohammad Hossein Jabbarpoor; Soheilian, Masoud; Nikkhah, Homayoun] Shahid Beheshti Univ Med Sci, Ophthalm Res Ctr, Ocular Tissue Engn Res Ctr, Tehran, Iran.
   [Yaseri, Mehdi] Univ Tehran Med Sci, Dept Biostat & Epidemiol, Tehran, Iran.
   [Bonyadi, Mortaza] Univ Tabriz, Ctr Excellence Biodivers, Fac Nat Sci, Tabriz, Iran.
C3 Shahid Beheshti University Medical Sciences; Tehran University of
   Medical Sciences; University of Tabriz
RP Bonyadi, MHJ (通讯作者)，Ophthalm Res Ctr, Pasdaran Ave,Boustan 9th St, Tehran 16666, Iran.
EM mhbonyadi@yahoo.com
RI Nikkhah, Homayoun/AAW-4663-2020; Hossein, Jabbarpoor Bonyadi
   Mohammad/A-1886-2014; Soheilian, Masoud/AAW-4743-2020; Yaseri,
   Mehdi/I-1645-2018
OI Nikkhah, Homayoun/0000-0002-2414-4661; Yaseri,
   Mehdi/0000-0002-4066-873X; Soheilian, Masoud/0000-0001-7508-426X
CR Andersson T, 2005, EUR J EPIDEMIOL, V20, P575, DOI 10.1007/s10654-005-7835-x
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   Black S, 2004, J BIOL CHEM, V279, P48487, DOI 10.1074/jbc.R400025200
   Bonyadi MR, 2016, STUD COMPUT INTELL, V605, P1, DOI 10.1007/978-3-319-18781-5_1
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dietrich T, 2007, EUR J CARDIOV PREV R, V14, P694, DOI 10.1097/HJR.0b013e328270b913
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   GICLAS PC, 1979, J IMMUNOL, V122, P146
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Kaliappan S, 2008, FEBS LETT, V582, P3451, DOI 10.1016/j.febslet.2008.09.009
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Keilhauer CN, 2013, EUR J MED GENET, V56, P72, DOI 10.1016/j.ejmg.2012.10.005
   KEW RR, 1985, J CLIN INVEST, V75, P1000, DOI 10.1172/JCI111760
   Khand F, 2015, J PAK MED ASSOC, V65, P59
   Khoo CM, 2011, NUTR DIABETES, V1, DOI 10.1038/nutd.2011.4
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Lechanteur YTE, 2015, JAMA OPHTHALMOL, V133, P533, DOI 10.1001/jamaophthalmol.2015.18
   Lee SJ, 2010, CLIN EXP OPHTHALMOL, V38, P698, DOI 10.1111/j.1442-9071.2010.02316.x
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mullins Robert F., 2007, International Ophthalmology Clinics, V47, P1, DOI 10.1097/IIO.0b013e31802bd3e6
   Pons M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016722
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Tong Y, 2010, MOL VIS, V16, P1958
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Wang XF, 2010, HUM HERED, V70, P269, DOI 10.1159/000321967
   Wannamethee SG, 2005, EUR HEART J, V26, P1765, DOI 10.1093/eurheartj/ehi183
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Xu YT, 2012, INT J OPHTHALMOL-CHI, V5, P125, DOI 10.3980/j.issn.2222-3959.2012.02.02
   Yasuma TR, 2010, MOL VIS, V16, P2923
   Zou GY, 2008, AM J EPIDEMIOL, V168, P212, DOI 10.1093/aje/kwn104
NR 38
TC 6
Z9 6
U1 0
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD AUG
PY 2017
VL 38
IS 4
BP 308
EP 313
DI 10.1080/13816810.2016.1237664
PG 6
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA FE1OM
UT WOS:000407987500002
PM 28095100
DA 2022-11-30
ER

PT J
AU Zarranz-Ventura, J
   Liew, G
   Johnston, RL
   Xing, W
   Akerele, T
   McKibbin, M
   Downey, L
   Natha, S
   Chakravarthy, U
   Bailey, C
   Khan, R
   Antcliff, R
   Armstrong, S
   Varma, A
   Kumar, V
   Tsaloumas, M
   Mandal, K
   Bunce, C
   Tufail, A
AF Zarranz-Ventura, Javier
   Liew, Gerald
   Johnston, Robert L.
   Xing, Wen
   Akerele, Toks
   McKibbin, Martin
   Downey, Louise
   Natha, Salim
   Chakravarthy, Usha
   Bailey, Clare
   Khan, Rehna
   Antcliff, Richard
   Armstrong, Stewart
   Varma, Atul
   Kumar, Vineeth
   Tsaloumas, Marie
   Mandal, Kaveri
   Bunce, Catey
   Tufail, Adnan
CA United Kingdom Age-Related Macular
TI The Neovascular Age-Related Macular Degeneration Database Report 2:
   Incidence, Management, and Visual Outcomes of Second Treated Eyes
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; VISUAL-ACUITY; INTRAVITREAL RANIBIZUMAB;
   PHARMACOKINETICS; ASSOCIATION; EYE; CERTIFICATIONS; PROGRESSION;
   CONVERSION; THERAPY
AB Purpose: To study the characteristics of second treated eyes in patients with neovascular age-related macular degeneration (nAMD) treated with ranibizumab in the United Kingdom National Health Service.
   Design: Multicenter national nAMD database study. Participants: Twelve thousand nine hundred fifty-one treatment-naive eyes of 11 135 patients receiving 92 976 ranibizumab injections.
   Methods: Up to 5 years of routinely collected, anonymized data within electronic medical record systems were extracted remotely from 14 centers. Participating centers exclusively used ranibizumab to treat nAMD (loading phase of 3 monthly injections followed by monthly visits and pro re nata re-treatment). The minimum data set included: age, logarithm of the minimum angle of resolution (logMAR) visual acuity (VA) at baseline and at all subsequent visits, and injection episodes.
   Main Outcome Measures: Baseline, change and actual VA over 3 years, and number of treatments and clinic visits.
   Results: During the study, 1816 (16.3%) of the 11 135 patients received treatment to the fellow eye. Mean baseline and final VA were 0.66 (standard deviation, 0.32) and 0.65 (0.40) for first treated eyes and 0.41 (0.34) and 0.56 (0.40) for second treated eyes. The rate of VA loss after the loading phase was similar in first and second treated eyes (0.03 and 0.05 logMAR units/year). When fellow eyes with baseline VA worse than 20/200 were excluded to restrict analyses to eyes at risk of nAMD, the rate of second-eye involvement was 14.0% per year (42%/3 years). Mean number of injections/visits in years 1, 2, and 3 were similar for first and second treated eyes (5.6/8.2, 3.9/8.0, 3.8/8.2 and 5.5/8.7, 3.6/9.4, and 3.8/9.1, respectively).
   Conclusions: Second treated eyes with nAMD commence treatment with better baseline VA, do not show significant vision gain but maintain better VA than first treated eyes at all time points for at least 3 years, making them the more important eye functionally. These data highlight the high burden of second eye involvement, with almost half of all eyes at risk requiring bilateral treatment by 3 years, and the need for regular monitoring of fellow eyes for best visual outcomes which theoretically may reduce the benefits of extended monitoring regimens. (C) 2014 by the American Academy of Ophthalmology.
C1 [Zarranz-Ventura, Javier; Liew, Gerald; Johnston, Robert L.; Xing, Wen; Akerele, Toks; McKibbin, Martin; Downey, Louise; Natha, Salim; Chakravarthy, Usha; Bailey, Clare; Khan, Rehna; Antcliff, Richard; Armstrong, Stewart; Varma, Atul; Kumar, Vineeth; Tsaloumas, Marie; Mandal, Kaveri; Bunce, Catey; Tufail, Adnan] Moorfields Eye Hosp NHS Trust, London EC1V 2PD, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP Tufail, A (通讯作者)，Moorfields Eye Hosp NHS Trust, 162 City Rd, London EC1V 2PD, England.
EM Adnan.Tufail@moorfields.nhs.uk
RI Zarranz-Ventura, Javier/AAB-5390-2021; Liew, Gerald/AAB-6870-2022
OI Zarranz-Ventura, Javier/0000-0003-2338-8143; Chakravarthy,
   Usha/0000-0002-2606-3734; Tufail, Adnan/0000-0001-6131-7640; Bunce,
   Catey/0000-0002-0935-3713
FU RANZCO Eye Foundation/Novartis; Department of Health's National
   Institute for Health Research Biomedical Research Centre for
   Ophthalmology at Moorfields Eye Hospital; University College London
   Institute of Ophthalmology, London, United Kingdom; Novartis
   Pharmaceuticals; Spanish Retina y Vitreous Society (Sociedad Espanola de
   Retina y Vitreo)
FX The author(s) have made the following disclosure(s): Robert L. Johnston:
   Employee-Medisoft Limited (the electronic medical record software
   provider from which data were extracted), Leeds, United Kingdom. Gerald
   Liew: Financial support - RANZCO Eye Foundation/Novartis. Supported in
   part by the Department of Health's National Institute for Health
   Research Biomedical Research Centre for Ophthalmology at Moorfields Eye
   Hospital and the University College London Institute of Ophthalmology,
   London, United Kingdom. The views expressed in the publication are those
   of the authors and not necessarily those of the Department of Health.
   Supported in part by an unrestricted research award from Novartis
   Pharmaceuticals. No member or affiliate of Novartis had any input into
   data analysis, interpretation of the data or writing the manuscript.
   Javier Zarranz-Ventura is a grant recipient of the Spanish Retina y
   Vitreous Society (Sociedad Espanola de Retina y Vitreo).
CR Arias L, 2011, RETINA-J RET VIT DIS, V31, P1261, DOI 10.1097/IAE.0b013e318207d152
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bandukwala T, 2010, CAN J OPHTHALMOL, V45, P590, DOI 10.3129/i10-082
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bunce C, 2008, EYE, V22, P905, DOI 10.1038/sj.eye.6702767
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Friberg TR, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.02.048
   Friberg TR, 2012, INVEST OPHTH VIS SCI, V53, P1742, DOI 10.1167/iovs.11-9338
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim IK, 2008, MOL VIS, V14, P1487
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Lange C, 2009, GRAEF ARCH CLIN EXP, V247, P137, DOI 10.1007/s00417-008-0926-0
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Minassian DC, 2011, BRIT J OPHTHALMOL, V95, P1433, DOI 10.1136/bjo.2010.195370
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Pai ASI, 2009, ARCH OPHTHALMOL-CHIC, V127, P1339, DOI 10.1001/archophthalmol.2009.239
   Pieramici D J, 1998, Curr Opin Ophthalmol, V9, P38, DOI 10.1097/00055735-199806000-00007
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross AH, 2013, EYE, V27, P56, DOI 10.1038/eye.2012.225
   Rotsos T, 2010, CLIN OPHTHALMOL, V4, P1271, DOI 10.2147/OPTH.S14684
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Sinapis CI, 2011, CLIN OPHTHALMOL, V5, P697, DOI 10.2147/OPTH.S19555
   Submacular Surgery Trials Research Group, 2007, Arch Ophthalmol, V125, P1323
   The National Institute for Health and Care Excellence, RAN PEG TREATM AG RE
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Williams TA, 2011, EYE, V25, P1617, DOI 10.1038/eye.2011.224
NR 41
TC 67
Z9 69
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2014
VL 121
IS 10
BP 1966
EP 1975
DI 10.1016/j.ophtha.2014.04.026
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ3ME
UT WOS:000342697300026
PM 24953791
DA 2022-11-30
ER

PT J
AU Abedi, F
   Wickremasinghe, S
   Richardson, AJ
   Makalic, E
   Schmidt, DF
   Sandhu, SS
   Baird, PN
   Guymer, RH
AF Abedi, Farshad
   Wickremasinghe, Sanjeewa
   Richardson, Andrea J.
   Makalic, Enes
   Schmidt, Daniel F.
   Sandhu, Sukhpal S.
   Baird, Paul N.
   Guymer, Robyn H.
TI Variants in the VEGFA Gene and Treatment Outcome after Anti-VEGF
   Treatment for Neovascular Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; ACUTE MOUNTAIN-SICKNESS; INTRAVITREAL
   RANIBIZUMAB; SUBGROUP ANALYSIS; BEVACIZUMAB; EFFICACY; THERAPY; REGIMEN;
   ANCHOR; AMD
AB Purpose: To determine the association of genetic variants of the VEGFA gene with outcome of anti-vascular endothelial growth factor (VEGF) treatment in neovascular age-related macular degeneration (AMD).
   Design: A prospective cohort study.
   Participants: We included 201 consecutive patients receiving anti-VEGF injections for neovascular AMD.
   Methods: Patients were followed over 12 months. They were treated with 3 initial monthly ranibizumab or bevacizumab injections. Thereafter, the decision to retreat was made by clinicians at each follow-up visit on the basis of retreatment criteria. Seven tagged single nucleotide polymorphisms (tSNPs) in the VEGFA gene were selected and examined. Multivariate data analysis was used to determine the role of each tSNP in treatment outcome.
   Main Outcome Measures: The influence of selected VEGFA tSNPs on visual acuity (VA) outcome at 6 months.
   Results: Mean baseline VA was 51 +/- 17 Early Treatment Diabetic Retinopathy Study (ETDRS) letter scores. Overall, the mean change in VA from baseline was +6.5 +/- 12, +4.4 +/- 13.4, and +2.3 +/- 14.6 letters at 3, 6, and 12 months, respectively. The tSNP rs3025000 was the only SNP significantly associated (P<1 x 10(-4)) with visual outcome at 6 months with multiple correction. The presence of the T allele (TC or TT genotypes) at this tSNP predicted a better outcome of +7 letters at 6 months compared with the CC genotype. In a subgroup analysis, presence of the T allele predicted a significantly higher chance of the patients belonging to the responder group (gain of >= 5 letters from baseline) after 3, 6, and 12 months treatment (odds ratio, 2.7, 3.5, and 2.4; 95% confidence interval, 1.46-5.07, 1.82-6.71, and 1.27-4.57, respectively) than any other outcome group.
   Conclusions: Pharmacogenetic association with anti-VEGF treatments may influence the visual outcomes in neovascular AMD. In patients with the T allele in tSNP rs3025000, there was a significantly better visual outcome at 6 months and a greater chance of the patients belonging to the responder group with anti-VEGF treatment at 3, 6, and 12 months. The VA outcomes of patients harboring the T allele at SNP rs3025000 were comparable with those of the pivotal clinical trials but with fewer injections, making the treatment perhaps more cost effective in certain subgroups of patients.
C1 [Abedi, Farshad; Wickremasinghe, Sanjeewa; Richardson, Andrea J.; Sandhu, Sukhpal S.; Baird, Paul N.; Guymer, Robyn H.] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic 3002, Australia.
   [Makalic, Enes; Schmidt, Daniel F.] Univ Melbourne, Ctr MEGA Epidemiol, Melbourne, Vic 3002, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Melbourne
RP Abedi, F (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM abedifarshad@yahoo.com
OI Guymer, Robyn/0000-0002-9441-4356; Baird, Paul/0000-0002-1305-3502;
   Makalic, Enes/0000-0003-3017-0871
FU National Health and Medical Research Council (NHMRC) [590205, 1008979];
   NHMRC-Clinical Research Excellence grant [529923]; NHMRC practitioner
   fellowship; NHMRC Research Fellowship; Macular Vision Loss Support
   Society of Australia
FX This project was partly funded by the National Health and Medical
   Research Council (NHMRC) project grants 590205 and 1008979, an
   NHMRC-Clinical Research Excellence grant 529923, NHMRC practitioner
   fellowship (R. H. G.), NHMRC Research Fellowship (P.N.B.), and the
   Macular Vision Loss Support Society of Australia. The Centre for Eye
   Research Australia (CERA) receives Operational Infrastructure Support
   from the Victorian Government. The sponsor or funding organizations had
   no role in the design or conduct of this research.
CR Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Ding H, 2011, RESPIRATION, V81, P236, DOI 10.1159/000322850
   Dumont L, 2000, BRIT MED J, V321, P267, DOI 10.1136/bmj.321.7256.267
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Gerding H, 2011, GRAEF ARCH CLIN EXP, V249, P653, DOI 10.1007/s00417-011-1636-6
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Lantry LE, 2007, CURR OPIN MOL THER, V9, P592
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Nagineni CN, 2012, J CELL PHYSIOL, V227, P116, DOI 10.1002/jcp.22708
   Nakata I, 2011, JPN J OPHTHALMOL, V55, P435, DOI 10.1007/s10384-011-0061-z
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Teper SJ, 2010, MOL VIS, V16, P2598
   van Patot MCT, 2005, J APPL PHYSIOL, V98, P1626, DOI 10.1152/japplphysiol.00589.2004
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
NR 22
TC 61
Z9 63
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2013
VL 120
IS 1
BP 115
EP 121
DI 10.1016/j.ophtha.2012.10.006
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 063PI
UT WOS:000313011700018
PM 23149126
DA 2022-11-30
ER

PT J
AU Friberg, TR
   Bilonick, RA
   Brennen, PM
AF Friberg, Thomas R.
   Bilonick, Richard A.
   Brennen, Peter M.
TI Risk Factors for Conversion to Neovascular Age-related Macular
   Degeneration Based on Longitudinal Morphologic and Visual Acuity Data
SO OPHTHALMOLOGY
LA English
DT Article
ID DRUSEN; LASER; PHOTOCOAGULATION
AB Purpose: To use longitudinal quantitative morphologic and visual acuity (VA) data to investigate the risk of choroidal neovascularization (CNV) event occurrence in eyes with dry age-related macular degeneration (AMD).
   Design: Prospective observational study.
   Participants: A total of 513 participants (844 eyes) followed longitudinally in one center enrolled in the Age-Related Eye Disease Study (AREDS) or the Prophylactic Treatment of AMD Study (PTAMD).
   Methods: We assessed images of previously obtained fundus photographs for the presence of macular pigmentation, drusen area, and drusen distribution (number and size), and fellow eye CNV status at baseline. Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) at each visit and the age of each subject were obtained. We used a longitudinal logistic mixed-effects model with random intercepts fitted to event occurrences to assess risk on a per eye basis.
   Main Outcome Measures: Odds ratios for CNV event.
   Results: Thirty-one subjects (6.0%) had events. Only VA changes over time and follow-up interval showed statistically significant effects. Several statistical models that included VA at the previous visit were used. In 2 models, 3 categories of VA were used: <= 75 letters, >75 and <= 85 letters, and >85 letters. Two categories were used for follow-up: <= 3 years versus >3 years or <= 1 year versus >1 year. In the first model with categorization at 3 years, a decrease in acuity from the >85 letter category to <= 75 letters increased the odds of CNV by 16.9 times (P = 0.022). In the model with categorization at 1 year, a decrease in acuity from the >85-letter category to <= 75 letters increased the odds of CNV by 21.4 times (P = 0.0175). Differences between the follow-up intervals were significant (P = 0.043) and indicated a more than 7-fold increase in the odds. Changes in morphologic features of the macula did not show significant effects.
   Conclusions: A decrease in VA to <= 75 ETDRS letters in an eye with an initial ETDRS baseline acuity of >85 letters increases the likelihood of CNV by approximately 20-fold. This likelihood also increases with aging.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2012;xx:xxx (c) 2012 by the American Academy of Ophthalmology.
C1 [Friberg, Thomas R.; Bilonick, Richard A.; Brennen, Peter M.] Univ Pittsburgh, UPMC Eye Ctr, Pittsburgh, PA 15213 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Friberg, TR (通讯作者)，Univ Pittsburgh, UPMC Eye Ctr, 203 Lothrop St,Suite 824, Pittsburgh, PA 15213 USA.
EM friberg@pitt.edu
FU Eye and Ear Foundation of Pittsburgh, Pennsylvania
FX Supported by the Eye and Ear Foundation of Pittsburgh, Pennsylvania, and
   an unrestricted grant from William J. Mcvay, MD, Pittsburgh,
   Pennsylvania.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Complications Age-Related Macular, 2008, OPHTHALMOLOGY, V115, P1474, DOI 10.1016/j.ophtha.2008.03.008
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Friberg TR, 2007, OPHTHAL SURG LAS IM, V38, P126, DOI 10.3928/15428877-20070301-07
   Friberg TR, 2006, OPHTHALMOLOGY, V113, P612, DOI 10.1016/j.ophtha.2005.10.066
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   Rodanant N, 2002, AM J OPHTHALMOL, V134, P577, DOI 10.1016/S0002-9394(02)01691-4
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shah AR, 2009, CURR OPIN OPHTHALMOL, V20, P182, DOI 10.1097/ICU.0b013e328329b669
   Solomon SD, 2009, RETINA-J RET VIT DIS, V29, P1080, DOI 10.1097/IAE.0b013e3181b1baeb
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
NR 15
TC 12
Z9 12
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2012
VL 119
IS 7
DI 10.1016/j.ophtha.2012.02.048
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 968UQ
UT WOS:000306011000026
PM 22551740
DA 2022-11-30
ER

PT J
AU Sugino, IK
   Sun, Q
   Springer, C
   Cheewatrakoolpong, N
   Liu, T
   Li, H
   Zarbin, MA
AF Sugino, Ilene K.
   Sun, Qian
   Springer, Carola
   Cheewatrakoolpong, Noounanong
   Liu, Tong
   Li, Hong
   Zarbin, Marco A.
TI Two Bioactive Molecular Weight Fractions of a Conditioned Medium Enhance
   RPE Cell Survival on Age-Related Macular Degeneration and Aged Bruch's
   Membrane
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; retinal pigment epithelium; cell
   transplantation; Bruch's membrane; cell survival
ID PIGMENT EPITHELIAL-CELLS; OUTER SEGMENT PHAGOCYTOSIS; LEUCINE-RICH
   PROTEOGLYCANS; KINASE PATHWAY SUPPRESSES; TISSUE GROWTH-FACTOR;
   TGF-BETA; PROTEIN-S; EXPRESSION; PROLIFERATION; TGF-BETA-2
AB Purpose: To characterize molecular weight fractions of bovine corneal endothelial cell conditioned medium (CM) supporting retinal pigment epithelium (RPE) cell survival on aged and age-related macular degeneration (AMD) Bruch's membrane.
   Methods: CM was subject to size separation using centrifugal filters. Retentate and filtrate fractions were tested for bioactivity by analyzing RPE survival on submacular Bruch's membrane of aged and AMD donor eyes and behavior on collagen I-coated tissue culture wells. Protein and peptide composition of active fractions was determined by mass spectrometry.
   Results: Two bioactive fractions, 3-kDa filtrate and a 10-50-kDa fraction, were necessary for RPE survival on aged and AMD Bruch's membrane. The 3-kDa filtrate, but not the 10-50-kDa fraction, supported RPE growth on collagen 1-coated tissue culture plates. Mass spectrometry of the 10-50-kDa fraction identified 175 extracellular proteins, including growth factors and extracellular matrix molecules. Transforming growth factor (TGF) b-2 was identified as unique to active CM. Peptides representing 29 unique proteins were identified in the 3-KDa filtrate.
   Conclusions: These results indicate there is a minimum of two bioactive molecules in CM, one found in the 3-kDa filtrate and one in the 10-50-kDa fraction, and that bioactive molecules in both fractions must be present to ensure RPE survival on Bruch's membrane. Mass spectrometry analysis suggested proteins to test in future studies to identify proteins that may contribute to CM bioactivity.
   Translational Relevance: Results of this study are the first steps in development of an adjunct to cell-based therapy to ensure cell transplant survival and functionality in AMD patients.
C1 [Sugino, Ilene K.; Sun, Qian; Springer, Carola; Cheewatrakoolpong, Noounanong; Zarbin, Marco A.] Rutgers New Jersey Med Sch, Inst Ophthalmol & Visual Sci, Newark, NJ USA.
   [Liu, Tong; Li, Hong] Rutgers New Jersey Med Sch, Neuroprote Core Facil, Ctr Adv Prote Res, Dept Biochem & Mol Biol, Newark, NJ USA.
C3 Rutgers State University New Brunswick; Rutgers State University Medical
   Center; Rutgers State University New Brunswick; Rutgers State University
   Medical Center
RP Zarbin, MA (通讯作者)，Inst Ophthalmol & Visual Sci, 90 Bergen St, Newark, NJ 07101 USA.
EM zarbin@earthlink.net
OI Li, Hong/0000-0001-5731-5335; Zarbin, Marco/0000-0002-7811-7132
FU Foundation Fighting Blindness; Lincy Foundation; Research to Prevent
   Blindness; Eye Institute of New Jersey; Janice Mitchell Vassar and Ashby
   John Mitchell Fellowship; Joseph J. and Marguerite DiSepio Retina
   Research Fund; Eng Family Fund for Excellence in Ophthalmology; New
   Jersey Healthcare Foundation; William L. Seery Endowment Fund; Alfonse
   A. Cinotti, M.D./Lions Eye Research Chair; New Jersey Lions Eye Research
   Foundation; National Institutes of Health [NS046593]; NATIONAL INSTITUTE
   OF NEUROLOGICAL DISORDERS AND STROKE [P30NS046593] Funding Source: NIH
   RePORTER
FX Supported by grants from the Foundation Fighting Blindness, the Lincy
   Foundation, an unrestricted grant from Research to Prevent Blindness,
   the Eye Institute of New Jersey, the Janice Mitchell Vassar and Ashby
   John Mitchell Fellowship, the Joseph J. and Marguerite DiSepio Retina
   Research Fund, the Eng Family Fund for Excellence in Ophthalmology, the
   New Jersey Healthcare Foundation, the William L. Seery Endowment Fund,
   the Alfonse A. Cinotti, M.D./Lions Eye Research Chair, and the New
   Jersey Lions Eye Research Foundation. The mass spectrometry study was
   funded in part by National Institutes of Health Grant NS046593 to the
   Neuroproteomics Core Facility (HL).
CR Ablonczy Z, 2007, EXP EYE RES, V85, P762, DOI 10.1016/j.exer.2007.08.010
   Bharti K, 2014, INVEST OPHTH VIS SCI, V55, P1191, DOI 10.1167/iovs.13-13481
   Byeon SH, 2010, INVEST OPHTH VIS SCI, V51, P1190, DOI 10.1167/iovs.09-4144
   Chen SJ, 2013, FEBS J, V280, P2120, DOI 10.1111/febs.12136
   Chu YK, 2013, INVEST OPHTH VIS SCI, V54, P7329, DOI 10.1167/iovs.13-12149
   DAS A, 1990, ARCH OPHTHALMOL-CHIC, V108, P421, DOI 10.1001/archopht.1990.01070050119045
   De Winter P, 2008, GROWTH FACTORS, V26, P80, DOI 10.1080/08977190802025602
   Farach-Carson MC, 2008, MATRIX BIOL, V27, P150, DOI 10.1016/j.matbio.2007.09.007
   Gamulescu MA, 2006, EXP EYE RES, V83, P212, DOI 10.1016/j.exer.2005.12.007
   GRANT MB, 1990, CURR EYE RES, V9, P323, DOI 10.3109/02713689008999620
   Gullapalli Vamsi K, 2004, Trans Am Ophthalmol Soc, V102, P123
   Gullapalli VG, 2005, THESIS
   Hafizi S, 2006, FEBS J, V273, P5231, DOI 10.1111/j.1742-4658.2006.05529.x
   Hafizi S, 2006, CYTOKINE GROWTH F R, V17, P295, DOI 10.1016/j.cytogfr.2006.04.004
   Hall MO, 2005, EXP EYE RES, V81, P581, DOI 10.1016/j.exer.2005.03.017
   Hall MO, 2001, EXP EYE RES, V73, P509, DOI 10.1006/exer.2001.1062
   Hartnett ME, 2003, EXP EYE RES, V77, P593, DOI 10.1016/S0014-4835(03)00189-1
   Hauck SM, 2008, MOL CELL PROTEOMICS, V7, P1349, DOI 10.1074/mcp.M700456-MCP200
   He SK, 2008, INVEST OPHTH VIS SCI, V49, P4078, DOI 10.1167/iovs.07-1302
   Iozzo RV, 2010, FEBS J, V277, P3864, DOI 10.1111/j.1742-4658.2010.07797.x
   Itoh Y, 2007, EXP EYE RES, V84, P464, DOI 10.1016/j.exer.2006.10.017
   Ivanova V P, 2012, Tsitologiia, V54, P823
   Jeong EY, 2013, NEUROSCI LETT, V548, P249, DOI 10.1016/j.neulet.2013.05.038
   Julien S, 2008, MOL VIS, V14, P1358
   Jung S., 2012, STEM CELLS INT, V2012, DOI [DOI 10.1155/2012/123030, 10.1155/2012/123030]
   Kaven C, 2000, CURR EYE RES, V20, P480, DOI 10.1076/0271-3683(200006)20:6;1-Y;FT480
   Khankan R, 2011, INVEST OPHTH VIS SCI, V52, P5068, DOI 10.1167/iovs.11-7191
   Lee B, 2011, J CLIN INVEST, V121, P3005, DOI 10.1172/JCI46358
   LESCHEY KH, 1990, INVEST OPHTH VIS SCI, V31, P839
   Li R, 2007, INVEST OPHTH VIS SCI, V48, P5722, DOI 10.1167/iovs.07-0327
   Lim UM, 2013, J PROTEOME RES, V12, P3496, DOI 10.1021/pr400352n
   Lipson KE, 2012, FIBROGENESIS TISSUE, V5, DOI 10.1186/1755-1536-5-S1-S24
   MARSHALL GE, 1994, GRAEF ARCH CLIN EXP, V232, P133, DOI 10.1007/BF00176781
   Nagai N, 2009, INVEST OPHTH VIS SCI, V50, P1903, DOI 10.1167/iovs.08-2383
   Nagineni CN, 2005, J CELL PHYSIOL, V203, P35, DOI 10.1002/jcp.20213
   Ong CHP, 2003, HISTOL HISTOPATHOL, V18, P1275, DOI 10.14670/HH-18.1275
   Ortega N, 2002, J CELL SCI, V115, P4201, DOI 10.1242/jcs.00106
   Ramasamy S, 2013, ARCH BIOCHEM BIOPHYS, V534, P71, DOI 10.1016/j.abb.2013.02.004
   Saika S, 2005, LAB INVEST, V85, P838, DOI 10.1038/labinvest.3700294
   Sarrazin S, 2006, BBA-REV CANCER, V1765, P25, DOI 10.1016/j.bbcan.2005.08.004
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Sipes JM, 1999, J BIOL CHEM, V274, P22755, DOI 10.1074/jbc.274.32.22755
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Soulez M, 2010, STEM CELLS, V28, P810, DOI 10.1002/stem.403
   Spraul CW, 2000, OPHTHALMIC RES, V32, P244, DOI 10.1159/000055621
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P9598, DOI 10.1167/iovs.11-8400
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P4979, DOI 10.1167/iovs.10-5386
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P1345, DOI 10.1167/iovs.10-6112
   Sugioka K, 2013, EXP EYE RES, V115, P13, DOI 10.1016/j.exer.2013.06.020
   van der Valk J, 2010, TOXICOL IN VITRO, V24, P1053, DOI 10.1016/j.tiv.2010.03.016
   Vater C, 2011, ACTA BIOMATER, V7, P463, DOI 10.1016/j.actbio.2010.07.037
   Weng CY, 2009, CURR EYE RES, V34, P867, DOI 10.3109/02713680903177890
   Yokoyama K, 2012, GRAEF ARCH CLIN EXP, V250, P15, DOI 10.1007/s00417-011-1766-x
   Zarbin Marco A, 2003, Trans Am Ophthalmol Soc, V101, P499
   Zhao B, 2006, BRIT J OPHTHALMOL, V90, P1052, DOI 10.1136/bjo.2006.091215
   Zhu J, 2013, INT J OPHTHALMOL-CHI, V6, P8, DOI 10.3980/j.issn.2222-3959.2013.01.02
NR 56
TC 9
Z9 9
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JAN
PY 2016
VL 5
IS 1
AR 8
DI 10.1167/tvst.5.1.8
PG 22
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ED2IZ
UT WOS:000388668800008
PM 26933521
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Shin, HJ
   Kim, SN
   Chung, H
   Kim, TE
   Kim, HC
AF Shin, Hyun Jin
   Kim, Soo-Nyung
   Chung, Hyewon
   Kim, Tae-Eun
   Kim, Hyung Chan
TI Intravitreal Anti-Vascular Endothelial Growth Factor Therapy and Retinal
   Nerve Fiber Layer Loss in Eyes With Age-Related Macular Degeneration: A
   Meta-Analysis
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; anti-vascular endothelial growth
   factor; retinal nerve fiber layer
ID OPTICAL COHERENCE TOMOGRAPHY; INTRAOCULAR-PRESSURE; RANIBIZUMAB;
   THICKNESS; BEVACIZUMAB; INJECTIONS; SURVIVAL; OUTCOMES
AB PURPOSE. Clinical study findings regarding the association between repeated injections of intravitreal anti-vascular endothelial growth factor (VEGF) and the risk of retinal nerve fiber layer (RNFL) thinning in patients with age-related macular degeneration (AMD) have been inconsistent. We investigated this association by using a meta-analysis.
   METHODS. In August 2015, we systematically reviewed PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. Two independent evaluators identified eligible articles by using predetermined selection criteria. Average RNFL thickness before and after intravitreal anti-VEGF injections was examined by using data obtained at baseline and at the last follow-up visit.
   RESULTS. Six studies on 288 eyes were ultimately included. The meta-analysis revealed that average RNFL thickness following repeated anti-VEGF injections was not significantly different from baseline (mean difference [MD] = -0.171, 95% confidence interval [CI]: -0.371 to 0.029, P = 0.093) or control group measurements (MD = -0.091, 95% CI: -0.517 to 0.335, P = 0.674). However, subgroup analyses by the methodologic quality of study revealed a significant RNFL thickness loss in two low-biased, controlled experimental studies (MD = -0.534, 95% CI: -0.783 to -0.286, P = 0.001), but not in four observational studies (MD = - 0.038, 95% CI: -0.171 to 0.095, P = 0.576).
   CONCLUSIONS. There was no association between anti-VEGF injections and RNFL thickness changes when all studies were examined together. However, when two low-biased, controlled clinical trials were separately examined, repeated anti-VEGF injection was associated with RNFL loss. Large-scale, prospective studies are needed to determine long-term effects of anti-VEGF treatments on the RNFL in AMD patients.
C1 [Shin, Hyun Jin; Chung, Hyewon; Kim, Hyung Chan] Konkuk Univ, Med Ctr, Sch Med, Dept Ophthalmol, 120-1 Neundong Ro, Seoul 143729, South Korea.
   [Kim, Soo-Nyung] Konkuk Univ, Med Ctr, Sch Med, Dept Obstet & Gynecol, Seoul, South Korea.
   [Kim, Tae-Eun] Konkuk Univ, Med Ctr, Sch Med, Dept Clin Pharmacol, Seoul, South Korea.
C3 Konkuk University; Konkuk University Medical Center; Konkuk University;
   Konkuk University Medical Center; Konkuk University; Konkuk University
   Medical Center
RP Kim, HC (通讯作者)，Konkuk Univ, Med Ctr, Sch Med, Dept Ophthalmol, 120-1 Neundong Ro, Seoul 143729, South Korea.
EM eyekim@kuh.ac.kr
RI Shin, Hyunjin/ABF-6057-2021
CR Aziz O, 2006, ANN SURG ONCOL, V13, P413, DOI 10.1245/ASO.2006.05.045
   Bakri SJ, 2009, EYE, V23, P181, DOI 10.1038/sj.eye.6702938
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bendschneider D, 2010, J GLAUCOMA, V19, P475, DOI 10.1097/IJG.0b013e3181c4b0c7
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Demirel S, 2015, CURR EYE RES, V40, P87, DOI 10.3109/02713683.2014.917190
   El-Ashry MF, 2015, CLIN OPHTHALMOL, V9, P1269, DOI 10.2147/OPTH.S80704
   Entezari Morteza, 2014, J Ophthalmic Vis Res, V9, P449, DOI 10.4103/2008-322X.150815
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P1044, DOI 10.1097/IAE.0b013e3180592ba6
   Foxton RH, 2013, AM J PATHOL, V182, P1379, DOI 10.1016/j.ajpath.2012.12.032
   Garcia-Martin E, 2011, MULT SCLER J, V17, P830, DOI 10.1177/1352458510397414
   Garcia-Martin E, 2012, OPHTHALMOLOGY, V119, P1705, DOI 10.1016/j.ophtha.2012.01.046
   Girkin CA, 2011, OPHTHALMOLOGY, V118, P2403, DOI 10.1016/j.ophtha.2011.06.013
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Horsley MB, 2010, AM J OPHTHALMOL, V150, P558, DOI 10.1016/j.ajo.2010.04.029
   Kahook MY, 2009, OPHTHAL SURG LAS IM, V40, P293, DOI 10.3928/15428877-20090430-12
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martinez-de-la-Casa JM, 2012, INVEST OPHTH VIS SCI, V53, P6214, DOI 10.1167/iovs.12-9875
   Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b4037, 10.1371/journal.pmed.1000097]
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Park CH, 2014, J KOREAN OPHTHALMOL, V55, P693
   Parlak M, 2015, INT OPHTHALMOL, V35, P473, DOI 10.1007/s10792-014-9972-2
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas A, 2009, OPHTHALMOLOGICA, V223, P383, DOI 10.1159/000228590
   Shin HJ, 2014, INVEST OPHTH VIS SCI, V55, P2403, DOI 10.1167/iovs.13-13769
   Sobaci G, 2013, INT J OPHTHALMOL-CHI, V6, P211, DOI 10.3980/j.issn.2222-3959.2013.02.20
   Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999
   Sterne JAC, 2001, BMJ-BRIT MED J, V323, P101, DOI 10.1136/bmj.323.7304.101
   Sterne JAC, 2001, J CLIN EPIDEMIOL, V54, P1046, DOI 10.1016/S0895-4356(01)00377-8
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Sung KR, 2009, OPHTHALMOLOGY, V116, P1119, DOI 10.1016/j.ophtha.2009.01.004
   Wells GSB., 2013, NEWCASTLE OTTAWA SCA
   Yancopoulos GD, 2010, CELL, V143, P13, DOI 10.1016/j.cell.2010.09.028
   Zachary I, 2005, NEUROSIGNALS, V14, P207, DOI 10.1159/000088637
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 42
TC 33
Z9 35
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2016
VL 57
IS 4
BP 1798
EP 1806
DI 10.1167/iovs.15-18404
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL8XY
UT WOS:000375926700038
PM 27077733
OA gold
DA 2022-11-30
ER

PT J
AU Ibrahim, MA
   Do, DV
   Sepah, YJ
   Shah, SM
   Van Anden, E
   Hafiz, G
   Donahue, JK
   Rivers, R
   Balkissoon, J
   Handa, JT
   Campochiaro, PA
   Nguyen, QD
AF Ibrahim, Mohamed A.
   Do, Diana V.
   Sepah, Yasir J.
   Shah, Syed M.
   Van Anden, Elizabeth
   Hafiz, Gulnar
   Donahue, J. Kevin
   Rivers, Richard
   Balkissoon, Jai
   Handa, James T.
   Campochiaro, Peter A.
   Nguyen, Quan Dong
TI Vascular disrupting agent for neovascular age related macular
   degeneration: a pilot study of the safety and efficacy of intravenous
   combretastatin a-4 phosphate
SO BMC PHARMACOLOGY & TOXICOLOGY
LA English
DT Article
DE Angiogenesis; Neovascularization; Ocular pharmacology; Retinal
   degeneration; Combretastatin A-4 Phosphate; CA4P; Vascular disrupting
   agents; VDA
ID BEVACIZUMAB AVASTIN THERAPY; PHASE-I; SYSTEMIC BEVACIZUMAB; A4
   PHOSPHATE; RETINOPATHY; SCHEDULE; TOXICITY; TRIAL
AB Background: This study was designed to assess the safety, tolerability, and efficacy of intravenous infusion of CA4P in patients with neovascular age-related macular degeneration (AMD).
   Methods: Prospective, interventional, dose-escalation clinical trial. Eight patients with neovascular AMD refractory to at least 2 sessions of photodynamic therapy received CA4P at a dose of 27 or 36 mg/m(2) as weekly intravenous infusion for 4 consecutive weeks. Safety was monitored by vital signs, ocular and physical examinations, electrocardiogram, routine laboratory tests, and collection of adverse events. Efficacy was assessed using retinal fluorescein angiography, optical coherence tomography, and best corrected visual acuity (BCVA).
   Results: The most common adverse events were elevated blood pressure (46.7%), QTc prolongation (23.3%), elevated temperature (13.3%), and headache (10%), followed by nausea and eye injection (6.7%). There were no adverse events that were considered severe in intensity and none resulted in discontinuation of treatment. There was reduction of the excess foveal thickness by 24.15% at end of treatment period and by 43.75% at end of the two-month follow-up (p = 0.674 and 0.161, respectively). BCVA remained stable throughout the treatment and follow-up periods.
   Conclusions: The safety profile of intravenous CA4P was consistent with that reported in oncology trials of CA4P and with the class effects of vascular disruptive agents; however, the frequency of adverse events was different. There are evidences to suggest potential efficacy of CA4P in neovascular AMD. However, the level of systemic safety and efficacy indicates that systemic CA4P may not be suitable as an alternative monotherapy to current standard-of-care therapy.
C1 [Ibrahim, Mohamed A.; Do, Diana V.; Sepah, Yasir J.; Shah, Syed M.; Van Anden, Elizabeth; Hafiz, Gulnar; Handa, James T.; Campochiaro, Peter A.; Nguyen, Quan Dong] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21287 USA.
   [Donahue, J. Kevin] Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21287 USA.
   [Donahue, J. Kevin] Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA.
   [Rivers, Richard] Johns Hopkins Univ, Sch Med, Dept Anesthesia, Baltimore, MD 21287 USA.
   [Balkissoon, Jai] OxiGene Inc, San Francisco, CA USA.
   [Do, Diana V.; Nguyen, Quan Dong] Univ Nebraska, Med Ctr, Stanley M Truhlsen Eye Inst, Omaha, NE USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Case Western Reserve University; Johns Hopkins University;
   University of Nebraska System; University of Nebraska Medical Center
RP Nguyen, QD (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 600 North Wolfe St,Maumenee 745, Baltimore, MD 21287 USA.
EM qnguyen4@jhmi.edu
CR Cooney MM, 2006, J CLIN ONCOL, V24, p300S
   Cooney MM, 2004, CLIN CANCER RES, V10, P96, DOI 10.1158/1078-0432.CCR-0364-3
   Dowlati A, 2002, CANCER RES, V62, P3408
   Duncan DD, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3494565
   Geitzenauer W, 2008, RETINA-J RET VIT DIS, V28, P1375, DOI 10.1097/IAE.0b013e3181863f96
   Griggs J, 2002, AM J PATHOL, V160, P1097, DOI 10.1016/S0002-9440(10)64930-9
   Griggs J, 2001, LANCET ONCOL, V2, P82, DOI 10.1016/S1470-2045(00)00224-2
   HU E, 1990, CANCER CHEMOTH PHARM, V26, P359, DOI 10.1007/BF02897294
   Koh DM, 2009, EUR RADIOL, V19, P2728, DOI 10.1007/s00330-009-1469-4
   Martel CL, 2005, J CLIN ONCOL, V23, p744S
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Nambu H, 2003, INVEST OPHTH VIS SCI, V44, P3650, DOI 10.1167/iovs.02-0985
   Patterson DM, 2007, DRUG FUTURE, V32, P1025, DOI 10.1358/dof.2007.032.12.1158960
   Rustin GJS, 2003, J CLIN ONCOL, V21, P2815, DOI 10.1200/JCO.2003.05.185
   Schmid-Kubista KE, 2009, BRIT J OPHTHALMOL, V93, P914, DOI 10.1136/bjo.2008.144410
   Siemann DW, 2009, EXPERT OPIN INV DRUG, V18, P189, DOI [10.1517/13543780802691068, 10.1517/13543780802691068 ]
   Siemann DW, 2005, CLIN CANCER RES, V11, P416
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P111, DOI 10.1016/j.ajo.2008.02.027
   Stevenson JP, 2003, J CLIN ONCOL, V21, P4428, DOI 10.1200/JCO.2003.12.986
NR 19
TC 26
Z9 27
U1 0
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2050-6511
J9 BMC PHARMACOL TOXICO
JI BMC Pharmacol. Toxicol.
PD JAN 14
PY 2013
VL 14
AR 7
DI 10.1186/2050-6511-14-7
PG 10
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 154SB
UT WOS:000319695100001
PM 23316779
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Gillies, MC
   Nguyen, V
   Daien, V
   Arnold, JJ
   Morlet, N
   Barthelmes, D
AF Gillies, Mark C.
   Vuong Nguyen
   Daien, Vincent
   Arnold, Jennifer J.
   Morlet, Nigel
   Barthelmes, Daniel
TI Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular
   Age-Related Macular Degeneration: Data from an Observational Study
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; DAILY CLINICAL-PRACTICE; INTRAVITREAL
   AFLIBERCEPT; VISUAL-ACUITY; VEGF-TRAP; TERM OUTCOMES; EXUDATIVE AMD;
   INHIBITORS; EFFICACY; SAFETY
AB Purpose: To directly compare visual acuity (VA) outcomes with ranibizumab vs. aflibercept for eyes with neovascular age-related macular degeneration (nAMD) treated in routine clinical practice.
   Design: Database observational study.
   Participants: Treatment-naive eyes with nAMD tracked by the Fight Retinal Blindness outcome registry that commenced antievascular endothelial growth factor therapy with ranibizumab or aflibercept between December 1, 2013, and January 31, 2015. Eyes were matched at baseline for VA, age, and choroidal neovascular membrane (CNV) size.
   Methods: Locally weighted scatterplot smoothing curves were used to display VA results. Eyes that switched or discontinued treatment were included with their last observation carried forward.
   Main Outcome Measures: Change in mean VA (number of letters read on a logarithm of the minimum angle of resolution chart); number of injections and visits; proportion of eyes with inactive CNV over 12 months.
   Results: We identified 394 eyes (197 treated with ranibizumab and 197 with aflibercept) from 372 patients who received treatment from 34 practitioners. Baseline parameters were well matched. The mean (standard deviation [SD]) VA of ranibizumab-treated eyes increased from 58.6 (20.3) letters at baseline to 62.3 (23.9) (+3.7 [95% confidence interval {CI} 1.4-6.1]) letters (P = 0.001), compared with 58.9 (19.2) letters at baseline to 63.1 (21.5) (+4.26 [95% CI 2.0-6.5]) letters (P < 0.001) for eyes receiving aflibercept. The difference in change in crude VA of 0.6 letters between the 2 groups was not statistically significant (P = 0.76), nor was the difference in adjusted mean VA of the 2 groups (P = 0.26). In completers, the mean (SD) numbers of injections (8.1 [2.1] vs. 8.0 [2.3]; P = 0.27) and visits (9.6 [3.0] vs. 9.5 [3.1]; P = 0.15) did not differ between the 2 groups. The adjusted proportion of eyes in which the CNV lesion was graded as inactive during the study was similar between the eyes receiving ranibizumab and aflibercept (74% vs. 77%, respectively; P = 0.63).
   Conclusions: Visual acuity outcomes at 12 months did not differ between ranibizumab and aflibercept used for nAMD in this large observational study, nor was a difference in treatment frequency found. (C) 2016 by the American Academy of Ophthalmology.
C1 [Gillies, Mark C.; Vuong Nguyen; Daien, Vincent; Barthelmes, Daniel] Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW 2050, Australia.
   [Daien, Vincent] Gui De Chauliac Hosp, Dept Ophthalmol, Montpellier, France.
   [Daien, Vincent] Inserm, U1061, Montpellier, France.
   [Arnold, Jennifer J.] Marsden Eye Specialists, Parramatta, Australia.
   [Morlet, Nigel] Univ Western Australia, Dept Populat Hlth, Perth, WA, Australia.
   [Barthelmes, Daniel] Univ Zurich, Univ Zurich Hosp, Dept Ophthalmol, Zurich, Switzerland.
C3 University of Sydney; Universite de Montpellier; CHU de Montpellier;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Montpellier; University of Western Australia; University
   of Zurich; University Zurich Hospital
RP Daien, V (通讯作者)，Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW 2050, Australia.
EM vincent.daien@sydney.edu.au
RI DAIEN, Vincent/Z-5516-2019
OI DAIEN, Vincent/0000-0001-5675-0861; Nguyen, Vuong/0000-0001-9070-9803
FU Sydney Medical Foundation; NHMRC; RANZCO Eye Foundation; Novartis;
   Bayer; Walter and Gertud Siegenthaler Foundation Zurich, Switzerland;
   Swiss National Foundation
FX M.C.G.: Supported as a Sydney Medical Foundation Fellow; supported by an
   NHMRC practitioner fellowship; Grants - NHMRC, RANZCO Eye Foundation;
   Grants and other - Novartis, and Bayer, during the conduct of the study;
   and is included as an inventor of the software used to track real-world
   outcomes in our study.; D.B.: Supported by the Walter and Gertud
   Siegenthaler Foundation Zurich, Switzerland, and the Swiss National
   Foundation.
CR American Academy of Ophthalmology Retina/Vitreous Panel, 2015, PREF PRACT PATT GUID
   Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Barthelmes D, 2016, BR J OPHTHALMOL
   Barthelmes D, 2015, BRIT J OPHTHALMOL, V99, P359, DOI 10.1136/bjophthalmol-2014-305514
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chang AA, 2016, OPHTHALMIC RES, V55, P84, DOI 10.1159/000440886
   Chavan R, 2014, CLIN OPHTHALMOL, V8, P717, DOI 10.2147/OPTH.S60763
   Chin-Yee D, 2015, BR J OPHTHALMOL
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Frennesson CI, 2014, ACTA OPHTHALMOL, V92, P216, DOI 10.1111/aos.12091
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P589, DOI 10.1016/j.ophtha.2014.10.001
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Gillies MC, 2013, INVEST OPHTH VIS SCI, V54, P5754, DOI 10.1167/iovs.13-11993
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heimes B, 2011, GRAEF ARCH CLIN EXP, V249, P639, DOI 10.1007/s00417-010-1524-5
   Heussen FM, 2014, GRAEF ARCH CLIN EXP, V252, P909, DOI 10.1007/s00417-013-2553-7
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Menghini M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042014
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   R Core Team. R: A, 2018, LANGUAGE ENV STAT CO
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarwar S, 2016, COCHRANE DB SYST REV, V2
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Singh RP, 2015, CLIN OPHTHALMOL, V9, P1759, DOI 10.2147/OPTH.S87043
   Souied EH, 2015, RETINA-J RET VIT DIS, V35, P1743, DOI 10.1097/IAE.0000000000000548
   Stuart EA, 2010, STAT SCI, V25, P1, DOI 10.1214/09-STS313
   Unnebrink K, 2001, STAT MED, V20, P3931, DOI 10.1002/sim.1149
   Walters SJ, 2009, PHARM STAT, V8, P163, DOI 10.1002/pst.334
   Yang JH, 2014, MOL PHARMACEUT, V11, P3421, DOI 10.1021/mp500160v
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Yu LL, 2011, BIOCHEM BIOPH RES CO, V408, P276, DOI 10.1016/j.bbrc.2011.04.014
NR 41
TC 49
Z9 49
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2016
VL 123
IS 12
BP 2545
EP 2553
DI 10.1016/j.ophtha.2016.08.016
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EE3YZ
UT WOS:000389539900022
PM 27707549
OA Bronze
DA 2022-11-30
ER

PT J
AU Bressler, NM
   Arnold, J
   Benchaboune, M
   Blumenkranz, MS
   Fish, GE
   Gragoudas, ES
   Lewis, H
   Schmidt-Erfurth, U
   Slakter, JS
   Bressler, SB
   Manos, K
   Hao, Y
   Haynes, L
   Koester, J
   Reaves, A
   Strong, HA
AF Bressler, NM
   Arnold, J
   Benchaboune, M
   Blumenkranz, MS
   Fish, GE
   Gragoudas, ES
   Lewis, H
   Schmidt-Erfurth, U
   Slakter, JS
   Bressler, SB
   Manos, K
   Hao, Y
   Haynes, L
   Koester, J
   Reaves, A
   Strong, HA
CA TAP Study Grp
TI Verteporfin therapy of subfoveal choroidal neovascularization in
   patients with age-related macular degeneration - Additional information
   regarding baseline lesion composition's impact on vision outcomes - TAP
   report No. 3
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
AB Objective: To explore how baseline lesion composition influenced vision outcomes in patients with age-related macular degeneration (AMD) undergoing photodynamic therapy with verteporfin (Visudyne) for subfoveal choroidal neovascularization (CNV) in the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy Investigation.
   Methods: Patients with subfoveal lesions secondary to AMD with evidence of classic CNV were categorized into 2 subgroups based on baseline color photographs and fluorescein angiograms assessed by graders at the Wilmer Photograph Reading Center (The Johns Hopkins University School of Medicine) before any outcome analyses as follows: (1) predominantly classic CNV (area of classic CNV greater than or equal to50% of the area of the entire lesion) or (2) minimally classic CNV (area of classic CNV <50% but >0% of the area of the entire lesion). Additional exploratory analyses were performed in the predominantly classic subgroup to investigate the effects of visual acuity, lesion size, prior laser photocoagulation, phakic status, micronutrient use, and presence of occult CNV on vision outcomes.
   Main Outcome Measures: Subgroup analyses of vision and fluorescein angiographic outcomes at 1 and 2 years after study enrollment were examined in an intent-to-treat analysis from 2 multicenter, double-masked, placebo-controlled, randomized clinical trials.
   Results: Compared with patients who had minimally classic CNV, patients with predominantly classic CNV had a worse initial mean visual acuity and smaller lesions and were more likely to have lesions that included blood or blocked fluorescence. When evaluated by treatment assignment and lesion composition, 84% to 88% completed the month 24 examination. In the subgroup with predominantly classic lesions, visual acuity outcomes were consistently better in verteporfin-treated patients. Outcomes for patients with predominantly classic lesions without occult CNV tended to be better than outcomes for patients with predominantly classic lesions with occult CNV, although the former tended to have smaller lesions and lower levels of visual acuity at baseline. Contrast sensitivity and fluorescein angiographic outcomes (total lesion size, progression of classic CNV, and absence of classic CNV) were better in verteporfin-treated patients than in placebo-treated patients in the predominantly classic and the minimally classic CNV subgroups. In patients with predominantly classic CNV, no interaction of the treatment benefit by phakic status, micronutrient use, or prior laser photocoagulation therapy was noted.
   Conclusions: Verteporfin therapy can safely reduce the risk of moderate and severe vision loss in patients with subfoveal lesions that are predominantly classic CNV secondary to AMD. While this benefit seemed to be even greater in the absence of occult CNV, the effect maybe related to the smaller lesions and worse visual acuity associated with predominantly classic lesions without occult CNV and not solely to the lesion composition itself. These analyses support initial reports that verteporfin therapy should be used to treat patients with AMD who have predominantly classic CNV, with or without occult CNV, but suggest that further investigations should be performed to determine if lesions with a minimally classic composition might benefit when they are smaller and have lower levels of visual acuity.
C1 Johns Hopkins Univ, Sch Med, Wilmer Photog Reading Ctr, Baltimore, MD 21205 USA.
C3 Johns Hopkins University
RP Bressler, NM (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Photog Reading Ctr, 550 N Broadway,Suite 115, Baltimore, MD 21205 USA.
EM nmboffice@jhmi.edu
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Rosenfeld PJ, 2001, INVEST OPHTH VIS SCI, V42, pS512
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
NR 6
TC 153
Z9 167
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD NOV
PY 2002
VL 120
IS 11
BP 1443
EP 1454
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 614RE
UT WOS:000179203400002
PM 12427056
DA 2022-11-30
ER

PT J
AU Folgar, FA
   Yuan, EL
   Sevilla, MB
   Chiu, SJ
   Farsiu, S
   Chew, EY
   Toth, CA
AF Folgar, Francisco A.
   Yuan, Eric L.
   Sevilla, Monica B.
   Chiu, Stephanie J.
   Farsiu, Sina
   Chew, Emily Y.
   Toth, Cynthia A.
CA Age Related Eye Disease Stu
TI Drusen Volume and Retinal Pigment Epithelium Abnormal Thinning Volume
   Predict 2-Year Progression of Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; SD-OCT; GEOGRAPHIC ATROPHY; AUTOMATIC
   SEGMENTATION; EYE DISEASE; REPRODUCIBILITY; QUANTIFICATION;
   CLASSIFICATION; MACULOPATHY; MORPHOLOGY
AB Purpose: To analyze the value of novel measures of retinal pigment epithelium-drusen complex (RPEDC) volume to predict 2-year disease progression of intermediate age-related macular degeneration (AMD).
   Design: Prospective, observational study.
   Participants: Three hundred forty-five AMD and 122 non-AMD participants enrolled in the Age Related Eye Disease Study 2 Ancillary Spectral-Domain (SD) Optical Coherence Tomography (OCT) study.
   Methods: High-density SD OCT macular volumes were obtained at yearly study visits. The RPEDC abnormal thickening (henceforth, OCT drusen) and RPEDC abnormal thinning (RAT) volumes were generated by semi-automated segmentation of total RPEDC within a 5-mm-diameter macular field.
   Main Outcome Measures: Volume change and odds ratio (OR) with 95% confidence intervals (CI) for progression to advanced AMD with choroidal neovascularization (CNV) or central geographic atrophy (GA).
   Results: Complete volumes were obtained in 265 and 266 AMD eyes and in 115 and 97 control eyes at baseline and at year 2, respectively. In AMD eyes, mean (standard deviation) OCT drusen volume increased from 0.08 mm(3) (0.16 mm(3)) to 0.10 mm(3) (0.23 mm(3); P < 0.001), and RAT volume increased from 8.3 x 10(-4) mm(3) (20.8 x 10(-4) mm(3)) to 18.4 x 10(-4) mm(3) (46.6 x 10(-4) mm(3); P < 0.001). Greater baseline OCT drusen volume was associated with 2-year progression to CNV (P = 0.002). Odds of developing CNV increased by 31% for every 0.1-mm(3) increase in baseline OCT drusen volume (OR, 1.31; 95% CI, 1.06-1.63; P = 0.013). Greater baseline RAT volume was associated with significant 2-year increase in RAT volume (P < 0.001), noncentral GA (P < 0.001), and progression to central GA (P < 0.001). Odds of developing central GA increased by 32% for every 0.001-mm(3) increase in baseline RAT volume (OR, 1.32; 95% CI, 1.14-1.53; P < 0.001). In non-AMD eyes, all volumes were significantly lower than AMD eyes and showed no significant 2-year change.
   Conclusions: Macular OCT drusen and RAT volumes increased significantly in AMD eyes over 2 years. These quantitative SD OCT biomarkers predict 2-year AMD progression and may serve as useful biomarkers for future clinical trials. (C) 2016 by the American Academy of Ophthalmology.
C1 [Folgar, Francisco A.; Yuan, Eric L.; Sevilla, Monica B.; Chiu, Stephanie J.; Farsiu, Sina; Toth, Cynthia A.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Chiu, Stephanie J.; Farsiu, Sina; Toth, Cynthia A.] Duke Univ, Dept Biomed Engn, Durham, NC 27710 USA.
   [Chew, Emily Y.] NEI, NIH, Bethesda, MD 20892 USA.
C3 Duke University; Duke University; National Institutes of Health (NIH) -
   USA; NIH National Eye Institute (NEI)
RP Toth, CA (通讯作者)，Duke Univ, Med Ctr 3802, Duke Eye Ctr, Durham, NC 27710 USA.
EM cynthia.toth@dm.duke.edu
RI Toth, Cynthia/L-5534-2019
OI Toth, Cynthia/0000-0002-2324-0854; Farsiu, Sina/0000-0003-4872-2902
FU Alcon (Fort Worth, TX); Genentech (South San Francisco, CA); NATIONAL
   EYE INSTITUTE [ZIAEY000489] Funding Source: NIH RePORTER
FX C.A.T.: Financial support - Alcon (Fort Worth, TX); Genentech (South San
   Francisco, CA); Royalties - Alcon (Fort Worth, TX); Patents - image
   processing; S.F. and C.A.T. have disclosed separate funding by the
   National Institutes of Health, but these grants did not fund this study.
   Supported by an unrestricted grant from Genentech (South San Francisco,
   CA), which had no role in the design or conduct of this research.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Chen Q, 2013, BIOMED OPT EXPRESS, V4, P2729, DOI 10.1364/BOE.4.002729
   Chen Q, 2013, MED IMAGE ANAL, V17, P1058, DOI 10.1016/j.media.2013.06.003
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Diniz B, 2015, EYE, V29, P272, DOI 10.1038/eye.2014.260
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Folgar FA, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.1.016014
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7595, DOI 10.1167/iovs.13-11762
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Schutze C, 2011, ACTA OPHTHALMOL, V89, P235, DOI 10.1111/j.1755-3768.2010.01955.x
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Stopa M, 2008, RETINA-J RET VIT DIS, V28, P298, DOI 10.1097/IAE.0b013e3181567798
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Yi K, 2009, BRIT J OPHTHALMOL, V93, P176, DOI 10.1136/bjo.2008.137356
   Ying GS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1147, DOI 10.1001/archophthalmol.2009.189
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 36
TC 61
Z9 63
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2016
VL 123
IS 1
BP 39
EP +
DI 10.1016/j.ophtha.2015.09.016
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CZ4GE
UT WOS:000367060700023
PM 26578448
DA 2022-11-30
ER

PT J
AU Chew, EY
   Clemons, TE
   SanGiovanni, JP
   Danis, RP
   Ferris, FL
   Elman, MJ
   Antoszyk, AN
   Ruby, AJ
   Orth, D
   Bressler, SB
   Fish, GE
   Hubbard, GB
   Klein, ML
   Chandra, SR
   Blodi, BA
   Domalpally, A
   Friberg, T
   Wong, WT
   Rosenfeld, PJ
   Agron, E
   Toth, CA
   Bernstein, PS
   Sperduto, RD
AF Chew, Emily Y.
   Clemons, Traci E.
   SanGiovanni, John Paul
   Danis, Ronald P.
   Ferris, Frederick L.
   Elman, Michael J.
   Antoszyk, Andrew N.
   Ruby, Alan J.
   Orth, David
   Bressler, Susan B.
   Fish, Gary E.
   Hubbard, George Baker
   Klein, Michael L.
   Chandra, Suresh R.
   Blodi, Barbara A.
   Domalpally, Amitha
   Friberg, Thomas
   Wong, Wai T.
   Rosenfeld, Philip J.
   Agron, Elvira
   Toth, Cynthia A.
   Bernstein, Paul S.
   Sperduto, Robert D.
CA AREDS2 Res Grp Authors Writing Tea
TI Secondary Analyses of the Effects of Lutein/Zeaxanthin on Age-Related
   Macular Degeneration Progression AREDS2 Report No. 3
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID LONG-TERM INCIDENCE; FATTY-ACID INTAKE; EYE DISEASE; CIGARETTE-SMOKING;
   FISH CONSUMPTION; BETA-CAROTENE; RISK-FACTORS; DIETARY-FAT; VITAMIN-A;
   ASSOCIATIONS
AB IMPORTANCE The Age-Related Eye Disease Study (AREDS) formulation for the treatment of age-related macular degeneration (AMD) contains vitamin C, vitamin E, beta carotene, and zinc with copper. The Age-Related Eye Disease Study 2 (AREDS2) assessed the value of substituting lutein/zeaxanthin in the AREDS formulation because of the demonstrated risk for lung cancer from beta carotene in smokers and former smokers and because lutein and zeaxanthin are important components in the retina.
   OBJECTIVE To further examine the effect of lutein/zeaxanthin supplementation on progression to late AMD.
   DESIGN, SETTING, PARTICIPANTS The Age-Related Eye Disease Study 2 is a multicenter, double-masked randomized trial of 4203 participants, aged 50 to 85 years, at risk for developing late AMD; 66% of patients had bilateral large drusen and 34% had large drusen and late AMD in 1 eye.
   INTERVENTIONS In addition to taking the original or a variation of the AREDS supplement, participants were randomly assigned in a factorial design to 1 of the following 4 groups: placebo; lutein/zeaxanthin, 10 mg/2 mg; omega-3 long-chain polyunsaturated fatty 3 acids, 1.0 g; or the combination.
   MAIN OUTCOMES AND MEASURES Documented development of late AMD by central, masked grading of annual retinal photographs or by treatment history.
   RESULTS In exploratory analysis of lutein/zeaxanthin vs no lutein/zeaxanthin, the hazard ratio of the development of late AMD was 0.90 (95% CI, 0.82-0.99; P = .04). Exploratory analyses of direct comparison of lutein/zeaxanthin vs beta carotene showed hazard ratios of 0.82 (95% CI, 0.69-0.96; P = .02) for development of late AMD, 0.78 (95% CI, 0.64-0.94; P = .01) for development of neovascular AMD, and 0.94 (95% CI, 0.70-1.26; P = .67) for development of central geographic atrophy. In analyses restricted to eyes with bilateral large drusen at baseline, the direct comparison of lutein/zeaxanthin vs beta carotene showed hazard ratios of 0.76 (95% CI, 0.61-0.96; P = .02) for progression to late AMD, 0.65 (95% CI, 0.49-0.85; P = .002) for neovascular AMD, and 0.98 (95% CI, 0.69-1.39; P = .91) for central geographic atrophy.
   CONCLUSION AND RELEVANCE The totality of evidence on beneficial and adverse effects from AREDS2 and other studies suggests that lutein/zeaxanthin could be more appropriate than beta carotene in the AREDS-type supplements.
C1 [Chew, Emily Y.] NIH, Div Epidemiol & Clin Res, Bethesda, MD 20892 USA.
   [Clemons, Traci E.; SanGiovanni, John Paul] EMMES Corp, Rockville, MD USA.
   [SanGiovanni, John Paul] NEI, Clin Trials Branch, Bethesda, MD 20892 USA.
   [Danis, Ronald P.] Univ Wisconsin Madison, Dept Ophthalmol, Bethesda, MD USA.
   [Ferris, Frederick L.; Agron, Elvira] NEI, Bethesda, MD 20892 USA.
   [Elman, Michael J.] Elman Retina Grp, Baltimore, MD USA.
   [Antoszyk, Andrew N.] Charlotte Eye Ear Nose & Throat, Charlotte, NC USA.
   [Ruby, Alan J.] William Beaumont Hosp, Associated Retinal Consultants, Royal Oak, MI 48072 USA.
   [Orth, David] Ingalls Mem Hosp, Harvey, IL USA.
   [Bressler, Susan B.] Johns Hopkins Univ Hosp, Wilmer Eye Inst, Dept Ophthalmol, Baltimore, MD 21287 USA.
   [Fish, Gary E.] Texas Retina Associates, Dallas, TX USA.
   [Hubbard, George Baker] Emory Univ, Atlanta, GA 30322 USA.
   [Klein, Michael L.] Oregon Hlth & Sci Univ, Casey Eye Inst, Dept Ophthalmol, Portland, OR USA.
   [Chandra, Suresh R.; Blodi, Barbara A.; Domalpally, Amitha] Univ Wisconsin Madison, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, Madison, WI USA.
   [Blodi, Barbara A.] Univ Wisconsin Madison, Fundus Photograph Reading Ctr, Madison, WI USA.
   [Friberg, Thomas] Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15261 USA.
   [Wong, Wai T.] NEI, Unit Neuron Glia Interact Retinal Dis, NIH, Bethesda, MD 20892 USA.
   [Rosenfeld, Philip J.] Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
   [Toth, Cynthia A.] Duke Univ, Med Ctr, Durham, NC USA.
   [Bernstein, Paul S.] Univ Utah, Hlth Sci Ctr, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT USA.
C3 National Institutes of Health (NIH) - USA; Emmes Corporation; National
   Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI);
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Beaumont Health; Johns Hopkins University; Johns Hopkins
   Medicine; Emory University; Oregon Health & Science University;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI); Bascom Palmer Eye Institute; Duke University; Utah
   System of Higher Education; University of Utah
RP Chew, EY (通讯作者)，NIH, Div Epidemiol & Clin Res, 10 Ctr Dr,MSC1204,Bldg 10-CRC,Room 3-2531, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
RI Toth, Cynthia/L-5534-2019; SanGiovanni, John Paul/AAU-3895-2020;
   Domalpally, Amitha/B-2367-2015; Wong, Wai/B-6118-2017
OI Toth, Cynthia/0000-0002-2324-0854; Wong, Wai/0000-0003-0681-4016; Elman,
   Michael/0000-0001-7726-9508; Domalpally, Amitha/0000-0002-8145-9619;
   Ferris, Frederick/0000-0002-4933-0639
FU National Eye Institute/National Institutes of Health (NEI/NIH),
   Department of Health and Human Services, Bethesda, Maryland
   [HHS-N-260-2005-00007-C, N01-EY-5-0007]; NIH institute Office of Dietary
   Supplements; NIH institute National Center for Complementary and
   Alternative Medicine; NIH institute National Institute on Aging; NIH
   institute National Heart, Lung and Blood Institute; NIH institute
   National Institute of Neurological Disorders and Stroke; NATIONAL EYE
   INSTITUTE [R01EY021532, ZIAEY000485, ZIAEY000463] Funding Source: NIH
   RePORTER
FX This study was supported by the intramural program funds and contracts
   from the National Eye Institute/National Institutes of Health (NEI/NIH),
   Department of Health and Human Services, Bethesda, Maryland (contract
   No. HHS-N-260-2005-00007-C and ADB contract No. N01-EY-5-0007). Funds
   were contributed to these contracts by the following NIH institutes:
   Office of Dietary Supplements, National Center for Complementary and
   Alternative Medicine, National Institute on Aging, National Heart, Lung
   and Blood Institute, and National Institute of Neurological Disorders
   and Stroke. The study medications and raw materials were provided by
   Alcon, Bausch and Lomb, DSM, and Pfizer.
CR ALBANES D, 1995, AM J CLIN NUTR, V62, P1427, DOI 10.1093/ajcn/62.6.1427S
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chew EY, JAMA OPHTHA IN PRESS
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Garrett Bridgette E., 2011, Morbidity and Mortality Weekly Report, V60, P109
   Hambidge M, 2003, J NUTR, V133, p1438S, DOI 10.1093/jn/133.5.1438S
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katz MH, 2006, MULTIVARIABLE ANAL P, P203
   Krinsky Norman I., 2005, Molecular Aspects of Medicine, V26, P459
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Omenn GS, 1996, J NATL CANCER I, V88, P1550, DOI 10.1093/jnci/88.21.1550
   Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2009, ARCH OPHTHALMOL-CHIC, V127, P110, DOI 10.1001/archophthalmol.2008.518
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   Swenor BK, 2010, OPHTHALMOLOGY, V117, P2395, DOI 10.1016/j.ophtha.2010.03.058
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tseng TS, 2010, J CANCER SURVIV, V4, P313, DOI 10.1007/s11764-010-0127-9
   WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084
NR 36
TC 253
Z9 260
U1 2
U2 62
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD FEB
PY 2014
VL 132
IS 2
BP 142
EP 149
DI 10.1001/jamaophthalmol.2013.7376
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AA8TJ
UT WOS:000331367600003
PM 24310343
OA Green Accepted, Bronze
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Heier, JS
   Brown, D
   Ciulla, T
   Abraham, P
   Bankert, JM
   Chong, S
   Daniel, PE
   Kim, IK
AF Heier, Jeffrey S.
   Brown, David
   Ciulla, Thomas
   Abraham, Prema
   Bankert, Joy M.
   Chong, Sandy
   Daniel, Paul E., Jr.
   Kim, Ivana K.
TI Ranibizumab for Choroidal Neovascularization Secondary to Causes Other
   Than Age-Related Macular Degeneration: A Phase I Clinical Trial
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL RANIBIZUMAB; PATHOLOGICAL
   MYOPIA; BEVACIZUMAB; EXPRESSION; THERAPY
AB Purpose: To investigate the safety and efficacy of ranibizumab for the treatment of choroidal neovascularization (CNV) secondary to causes other than age-related macular degeneration (AMD).
   Design: Multicenter, randomized, 12-month clinical trial.
   Participants: Thirty patients with CNV due to causes other than AMD, including pathologic myopia, ocular histoplasmosis, and angioid streaks.
   Methods: Participants were randomly assigned 1: 1 to monthly intravitreal injections of 0.5 mg ranibizumab or 3 monthly injections followed by dosing as needed (pro re nata [PRN]) at monthly follow-up visits.
   Main Outcome Measures: Outcome measures included the incidence of ocular and nonocular adverse events, the percentage of patients gaining >= 15 letters of visual acuity (VA) at 6 and 12 months from baseline, the percentage of patients losing >= 15 letters of VA at 6 and 12 months from baseline, and mean change in VA and central retinal thickness (CRT) at 6 and 12 months from baseline.
   Results: No serious ocular or systemic adverse events related to ranibizumab or the injection procedure were reported. Among patients who received monthly ranibizumab injections, 8 of 12 (66.7%) gained >= 15 letters of VA at both 6 and 12 months, and among patients who received PRN injections, 9 of 14 (64.3%) and 8 of 14 (57.1%) gained >= 15 letters of VA at 6 and 12 months, respectively. No patient in the study lost >= 15 letters of VA. Mean VA improved significantly from baseline by 23.9 +/- 5.4 (P = 0.001) and 21.1 +/- 4.3 letters (P = 0.0003) at 6 months and by 26.9 +/- 5.3 (P = 0.0003) and 19.2 +/- 3.8 letters (P = 0.0002) at 12 months in the monthly and PRN treatment arms, respectively. Mean CRT decreased significantly from baseline by 103.4 +/- 18.9 (P = 0.0005) and 161.1 +/- 43.7 mu m (P = 0.0034) at 6 months and by 109.3 +/- 19.5 (P = 0.0004) and 166.6 +/- 38.4 mu m (P = 0.001) at 12 months in the monthly and PRN treatment groups, respectively. No statistically significant difference was found between treatment groups in change in VA or CRT at any time point.
   Conclusions: Intravitreal ranibizumab, given as monthly injections or as 3 monthly injections followed by PRN dosing, showed a promising efficacy and safety profile in the treatment of CNV due to causes other than AMD.
C1 [Heier, Jeffrey S.; Bankert, Joy M.; Chong, Sandy; Daniel, Paul E., Jr.] Ophthalm Consultants Boston, Boston, MA 02114 USA.
   [Brown, David] Vitreoretinal Consultants, Houston, TX USA.
   [Ciulla, Thomas] Midwest Eye Inst, Indianapolis, IN USA.
   [Abraham, Prema] Black Hills Reg Eye Inst, Rapid City, SD USA.
   [Kim, Ivana K.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
C3 Ophthalmic Consultants of Boston; Harvard University; Massachusetts Eye
   & Ear Infirmary
RP Heier, JS (通讯作者)，Ophthalm Consultants Boston, 50 Staniford St,Suite 600, Boston, MA 02114 USA.
EM jsheier@eyeboston.com
RI Ciulla, Thomas/AAA-1299-2020
OI Ciulla, Thomas/0000-0001-5557-6777; Kim, Ivana/0000-0003-0310-6129
FU Genentech, Inc.; Alcon Laboratories; Allergan; Bausch Lomb; CoMentis;
   Eyemaginations; Fovea; Genentech; Genzyme; Heidelberg Engineering;
   iScience; Ista Pharmaceuticals; Jerini Ophthalmics; LPath; NeoVista;
   Neurotech; Notal Vision; Novartis Pharmaceuticals; Optherion;
   Optimedica; Oraya Therapeutics; Oxigene; Paloma; Pfizer Ophthalmics;
   Regeneron; Resolvyx Pharmaceuticals; Schering Plough Research Institute;
   Scyfix; Steba; VisionCare Ophthalmic Technologies; Alimera; Carl Zeiss
   Meditec; Othera; Pfizer; Glaxo-Smith-Kline; Optko; National Eye
   Institute/National Institutes of Health; Abraham: Genentech; Alcon;
   Novartis; Opko Health; Jerini Ophthalmic; Eli Lilly; VRT; Schering
   Plough
FX Financial Disclosure(s): The author(s) have made the following
   disclosure(s): J. S. Heier: Acucela (C), Alcon Laboratories (C, S),
   Allergan (C, S), Bausch & Lomb (C), CoMentis (S), Eyemaginations (C),
   Fovea (C), Genentech (C, S, L), Genzyme (C), Heidelberg Engineering (C,
   L), iScience (C, S), Ista Pharmaceuticals (C, S), Jerini Ophthalmics (C,
   S, L), LPath (C), NeoVista (C, S, L), Neurotech (S), Notal Vision (C),
   Novartis Pharmaceuticals (C, S), Optherion (C), Optimedica (R), Oraya
   Therapeutics (C), Oxigene (S), Paloma (C, S), Pfizer Ophthalmics (C, S),
   Regeneron (C, S, L), Resolvyx Pharmaceuticals (C), Schering Plough
   Research Institute (C), Scyfix (C), Steba (C), VisionCare Ophthalmic
   Technologies (C, S) D. Brown: Alcon Laboratories (C, S), Alimera (S),
   Allergan (C, S), Carl Zeiss Meditec (C), CoMentis (S), Eyemaginations
   (C), Genentech (C, S, L), Heidelberg Engineering (C, L), Jerini
   Ophthalmics (C, S, L), NeoVista (C, S, L), Neurotech (S), Novartis
   Pharmaceuticals (C, S), Oraya Therapeutics (C), Othera (S), Oxigene (S),
   Pfizer Ophthalmics (C, S), Regeneron (C, S, L), Steba (C) T. Ciulla:
   Neovista (C), Regeneron (C), Pfizer (C), Genentech (S), Regeneron (S),
   Allergan (S), Alimera (S), Othera (S), Glaxo-Smith-Kline (S), Optko (S),
   National Eye Institute/National Institutes of Health (S) P. Abraham:
   Genentech (C, S), Alcon (C, S), Novartis (C, S), Regeneron (S), Allergan
   (S), Opko Health (S), Jerini Ophthalmic (S), Pfizer (S), Eli Lilly (S),
   Alimera (S), VRT (S), Schering Plough (S) J. M. Bankert: none This study
   was funded by Genentech, Inc. The sponsor or funding organization had no
   role in the design or conduct of this research. Third-party medical
   writing logistical assistance, but not content sufficient to meet
   International Committee of Medical Journal Editors' criteria, was
   provided by Robert Romanelli, PhD, of ApotheCom Associates and was
   supported by Genentech, Inc.
CR Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Cui JZ, 2000, GRAEF ARCH CLIN EXP, V238, P326, DOI 10.1007/s004170050360
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Hubbard GB, 2004, ARCH OPHTHALMOL-CHIC, V122, P1597, DOI 10.1001/archopht.122.11.1597
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Konstantinidis L, 2009, GRAEF ARCH CLIN EXP, V247, P311, DOI 10.1007/s00417-008-0995-0
   Lai TYY, 2009, RETINA-J RET VIT DIS, V29, P750, DOI 10.1097/IAE.0b013e31819ed6bd
   Martin G, 2004, GRAEF ARCH CLIN EXP, V242, P321, DOI 10.1007/s00417-003-0838-y
   Mones JM, 2009, EYE, V23, P1276, DOI 10.1038/eye.2009.88
   Nguyen QD, 2008, AM J OPHTHALMOL, V145, P257, DOI 10.1016/j.ajo.2007.09.025
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruiz-Moreno JM, 2009, BRIT J OPHTHALMOL, V93, P448, DOI 10.1136/bjo.2008.145391
   Wiegand TW, 2009, BRIT J OPHTHALMOL, V93, P47, DOI 10.1136/bjo.2008.143461
NR 19
TC 38
Z9 38
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2011
VL 118
IS 1
BP 111
EP 118
DI 10.1016/j.ophtha.2010.04.016
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 701PF
UT WOS:000285832500018
PM 20678799
DA 2022-11-30
ER

PT J
AU Nakata, I
   Yamashiro, K
   Akagi-Kurashige, Y
   Miyake, M
   Kumagai, K
   Tsujikawa, A
   Liu, K
   Chen, LJ
   Liu, DTL
   Lai, TYY
   Sakurada, Y
   Yoneyama, S
   Cheng, CY
   Cackett, P
   Yeo, IY
   Tay, WT
   Cornes, BK
   Vithana, EN
   Aung, T
   Matsuo, K
   Matsuda, F
   Wong, TY
   Iijima, H
   Pang, CP
   Yoshimura, N
AF Nakata, Isao
   Yamashiro, Kenji
   Akagi-Kurashige, Yumiko
   Miyake, Masahiro
   Kumagai, Kyoko
   Tsujikawa, Akitaka
   Liu, Ke
   Chen, Li Jia
   Liu, David T. L.
   Lai, Timothy Y. Y.
   Sakurada, Yoichi
   Yoneyama, Seigo
   Cheng, Ching-Yu
   Cackett, Peter
   Yeo, Ian Y.
   Tay, Wan Ting
   Cornes, Belinda K.
   Vithana, Eranga N.
   Aung, Tin
   Matsuo, Keitaro
   Matsuda, Fumihiko
   Wong, Tien-Yin
   Iijima, Hiroyuki
   Pang, Chi Pui
   Yoshimura, Nagahisa
TI Association of Genetic Variants on 8p21 and 4q12 with Age-Related
   Macular Degeneration in Asian Populations
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT-FACTOR-H; POLYPOIDAL CHOROIDAL VASCULOPATHY; JAPANESE
   POPULATION; MACULOPATHY; CFH; POLYMORPHISM; PROGRESSION; LOC387715;
   PATHWAY; DISEASE
AB PURPOSE. To evaluate the association of genetic variants at chromosomes 8p21 and 4q12 with the risk of developing AMD and its two main subtypes, choroidal neovascular membrane (CNV) and polypoidal choroidal vasculopathy (PCV), in Asian populations.
   METHODS. The study population comprised 2360 patients with neovascular AMD (1013 typical AMD-CNV and 1282 PCV), and 3598 controls from four independent cohorts, two of Japanese xn = 4859) and two of Chinese (n = 1099) ethnicity. We performed a meta-analysis in case-control studies of two reported single nucleotide polymorphisms (SNPs) (rs13278062 at TNFRSF10A-LOC389641 on 8p21 and rs1713985 at REST-C4orf14-POLR2B-IGFBP7 on 4q12) by using logistic regression analysis adjusted for age and sex. Subgroup analysis by CNV and PCV subtypes were performed to evaluate the significance of these two variants.
   RESULTS. The reported association between rs13278062 at 8p21 and neovascular AMD was replicated in this population (P = 1.12 x 10(-4), odds ratio [OR] = 0.79, 95% confidence interval [CI] = 0.70-0.89). However, there was no association of rs1713985 at 4q12 with neovascular AMD, or its two subtypes, typical AMD-CNV and PCV (all P > 0.05). The study sample size had a statistical power of greater than 99% to detect an association of a risk allele with AMD with an OR of 1.30, as reported in the original study of rs1713985 and AMD.
   CONCLUSIONS. The present results did not replicate the reported association between rs1713985 at 4q12 and neovascular AMD. However, we confirmed the association between rs13278062 at 8p21 and neovascular AMD in Asian populations. (Invest Ophthalmol Vis Sci. 2012;53:6576-6581) DOI: 10.1167/iovs.12-10219
C1 [Liu, Ke; Chen, Li Jia; Liu, David T. L.; Lai, Timothy Y. Y.; Pang, Chi Pui] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Sakurada, Yoichi; Yoneyama, Seigo; Iijima, Hiroyuki] Univ Yamanashi, Fac Med, Dept Ophthalmol, Yamanashi, Japan.
   [Cheng, Ching-Yu; Cackett, Peter; Yeo, Ian Y.; Tay, Wan Ting; Cornes, Belinda K.; Vithana, Eranga N.; Aung, Tin; Wong, Tien-Yin] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Cheng, Ching-Yu; Cackett, Peter; Yeo, Ian Y.; Tay, Wan Ting; Cornes, Belinda K.; Vithana, Eranga N.; Aung, Tin; Wong, Tien-Yin] Singapore Eye Res Inst, Singapore, Singapore.
   [Nakata, Isao; Yamashiro, Kenji; Akagi-Kurashige, Yumiko; Miyake, Masahiro; Kumagai, Kyoko; Tsujikawa, Akitaka; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol, Kyoto 6068507, Japan.
   [Nakata, Isao; Akagi-Kurashige, Yumiko; Miyake, Masahiro; Matsuda, Fumihiko] Kyoto Univ, Grad Sch Med, Ctr Genom Med, Inserm U 852, Kyoto 6068507, Japan.
   [Cheng, Ching-Yu; Vithana, Eranga N.; Aung, Tin; Wong, Tien-Yin] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Cheng, Ching-Yu] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore.
   [Cheng, Ching-Yu] Duke NUS Grad Med Sch, Off Clin Sci, Ctr Quantitat Med, Singapore, Singapore.
   [Matsuo, Keitaro] Aichi Canc Ctr, Res Inst, Div Epidemiol & Prevent, Nagoya, Aichi 464, Japan.
   [Wong, Tien-Yin] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3010, Australia.
C3 Chinese University of Hong Kong; University of Yamanashi; Singapore
   National Eye Center; National University of Singapore; Singapore
   National Eye Center; Kyoto University; Kyoto University; National
   University of Singapore; National University of Singapore; National
   University of Singapore; Aichi Cancer Center; Centre for Eye Research
   Australia; University of Melbourne
RP Yamashiro, K (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara, Kyoto 6068507, Japan.
EM yamashro@kuhp.kyoto-u.ac.jp
RI Cheng, Ching-Yu/K-7017-2013; Matsuo, Keitaro/H-6758-2019; Lai, Timothy Y
   Y/AAC-2120-2020; Pang, Chi P/I-5388-2014; Miyake, Masahiro/V-1261-2019;
   Wong, Tien Yin/AAC-9724-2020; Cheng, Ching-Yu/Y-2229-2019; Chen, Li
   Jia/I-5078-2014
OI Cheng, Ching-Yu/0000-0003-0655-885X; Matsuo,
   Keitaro/0000-0003-1761-6314; Lai, Timothy Y Y/0000-0002-7832-6428;
   Miyake, Masahiro/0000-0001-7410-3764; Wong, Tien
   Yin/0000-0002-8448-1264; Cheng, Ching-Yu/0000-0003-0655-885X; Chen, Li
   Jia/0000-0003-3500-5840; Tsujikawa, Akitaka/0000-0003-0779-7799;
   Yamashiro, Kenji/0000-0001-9354-8558
FU Japan Society for the Promotion of Science, Tokyo, Japan [19390442,
   22791706, 23791972, 22791653]; Japanese National Society for the
   Prevention of Blindness; American Health Assistance Foundation
   [M2011068]; Endowment Fund for Lim Por-Yen Eye Genetics Research Centre;
   General Research Fund from the Research Grants Council, Hong Kong
   [473410]; SingHealth, Singapore [SHF/FG381P/2007]; National Medical
   Research Council, Singapore [STaR/0003/2008]; Biomedical Research
   Council, Singapore [BMRC 09/1/35/19/616, 08/1/35/19/550]
FX Supported by grants in part by grants-in-aid for scientific research
   (19390442, 22791706, 23791972, and 22791653) from the Japan Society for
   the Promotion of Science, Tokyo, Japan; by the Japanese National Society
   for the Prevention of Blindness; by funding from the American Health
   Assistance Foundation (M2011068); by a Endowment Fund for Lim Por-Yen
   Eye Genetics Research Centre and the General Research Fund from the
   Research Grants Council (473410), Hong Kong; and by grants from the
   SingHealth, Singapore (SHF/FG381P/2007), the National Medical Research
   Council, Singapore (STaR/0003/2008), and the Biomedical Research
   Council, Singapore (BMRC 09/1/35/19/616 and 08/1/35/19/550).
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Cheung CY, 2011, INVEST OPHTH VIS SCI, V52, P9629, DOI 10.1167/iovs.11-7481
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gauderman WJ, 2002, STAT MED, V21, P35, DOI 10.1002/sim.973
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamajima Nobuyuki, 2001, Asian Pac J Cancer Prev, V2, P99
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Hirakawa M, 2002, NUCLEIC ACIDS RES, V30, P158, DOI 10.1093/nar/30.1.158
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465
   Kawasaki A, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2516
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lavanya R, 2009, OPHTHAL EPIDEMIOL, V16, P325, DOI 10.3109/09286580903144738
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Miyagishima T, 2001, XENOBIOTIC METABOLIS, V16, P340
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Parihar A, 2008, LIFE SCI, V82, P1077, DOI 10.1016/j.lfs.2008.03.019
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340
NR 40
TC 18
Z9 21
U1 0
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2012
VL 53
IS 10
BP 6576
EP 6581
DI 10.1167/iovs.12-10219
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 016NQ
UT WOS:000309526200075
PM 22930721
DA 2022-11-30
ER

PT J
AU Grunwald, JE
   Pistilli, M
   Daniel, E
   Ying, GS
   Pan, W
   Jaffe, GJ
   Toth, CA
   Hagstrom, SA
   Maguire, MG
   Martin, DF
AF Grunwald, Juan E.
   Pistilli, Maxwell
   Daniel, Ebenezer
   Ying, Gui-Shuang
   Pan, Wei
   Jaffe, Glenn J.
   Toth, Cynthia A.
   Hagstrom, Stephanie A.
   Maguire, Maureen G.
   Martin, Daniel F.
CA Comparison Age-Related Macular Deg
TI Incidence and Growth of Geographic Atrophy during 5 Years of Comparison
   of Age-Related Macular Degeneration Treatments Trials
SO OPHTHALMOLOGY
LA English
DT Article
ID NATURAL-HISTORY; PROGRESSION; RISK; SUSCEPTIBILITY; AMD; RANIBIZUMAB;
   DISEASE; ARMS2; CFH; EYE
AB Purpose: To estimate the incidence, size, and growth rate of geographic atrophy (GA) during 5 years of follow-up among participants in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
   Design: Cohort within a clinical trial.
   Participants: Participants included in CATT.
   Methods: A total of 1185 CATT participants were randomly assigned to ranibizumab or bevacizumab treatment and to 3 treatment regimens. Participants were released from protocol treatment at 2 years and examined at approximately 5 years (N = 647). Two masked graders assessed the presence and size of GA in digital color photographs (CPs) and fluorescein angiograms (FAs) taken at baseline and years 1, 2, and 5. Cox proportional hazard models were used to identify risk factors for incidence of GA. Annual change in the square root of the total area of GA was the measure of growth. Multivariate linear mixed models including baseline demographic, treatment, and ocular characteristics on CP/FA and optical coherence tomography (OCT) as candidate risk factors were used to estimate adjusted growth rates, standard errors (SEs), and 95% confidence intervals (CIs).
   Main Outcome Measures: Geographic atrophy incidence and growth rate.
   Results: Among the 1011 participants who did not have GA at baseline and had follow-up images gradable for GA, the cumulative incidence was 12% at 1 year, 17% at 2 years, and 38% at 5 years. At baseline, older age, hypercholesterolemia, worse visual acuity, larger choroidal neovascularization (CNV) area, retinal angiomatous proliferation (RAP) lesion, GA in the fellow eye, and intraretinal fluid were associated with a higher risk of incident GA. Thicker subretinal tissue complex and presence of subretinal fluid were associated with less GA development. The overall GA growth rate was 0.33 mm/year (SE, 0.02 mm/year). Eyes treated with ranibizumab in the first 2 years of the clinical trial had a higher growth rate than eyes treated with bevacizumab (adjusted growth rate, 0.38 vs. 0.28 mm/year; P = 0.009). Geographic atrophy in the fellow eye, hemorrhage, and absence of sub-retinal pigment epithelium fluid at baseline were associated with a higher growth rate.
   Conclusions: Development of GA is common 5 years after initiating therapy. Several risk factors identified at 2 years of follow-up persist at 5 years of follow-up. (C) 2016 by the American Academy of Ophthalmology
C1 [Grunwald, Juan E.; Pistilli, Maxwell; Daniel, Ebenezer; Ying, Gui-Shuang; Pan, Wei; Maguire, Maureen G.] Univ Penn, Perelman Sch Med, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Jaffe, Glenn J.; Toth, Cynthia A.] Duke Univ, Dept Ophthalmol, Durham, NC USA.
   [Hagstrom, Stephanie A.; Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Duke University;
   Cleveland Clinic Foundation
RP Grunwald, JE (通讯作者)，Univ Penn, Dept Ophthalmol, 51 North 39th St, Philadelphia, PA 19104 USA.
EM juangrun@mail.med.upenn.edu
RI Toth, Cynthia/L-5534-2019; Mitchell, Paul/P-1498-2014
OI Toth, Cynthia/0000-0002-2324-0854; Pistilli, Maxwell/0000-0002-4266-4150
FU Genentech; NATIONAL EYE INSTITUTE [U10EY017825, U10EY017823,
   U10EY023530, U10EY017828, R21EY023689, U10EY017826] Funding Source: NIH
   RePORTER
FX C.A.T.: Research support - Genentech; Royalties - Alcon/Novartis.
CR BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Caire J, 2014, JAMA OPHTHALMOL, V132, P528, DOI 10.1001/jamaophthalmol.2013.8175
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   Domalpally A, 2013, OPHTHALMOLOGY, V120, P2666, DOI 10.1016/j.ophtha.2013.07.047
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Holz FG, 2015, INVEST OPHTH VIS SCI, V56
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mauschitz MM, 2012, INVEST OPHTH VIS SCI, V53, P4932, DOI 10.1167/iovs.12-9711
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Rasband WS., IMAGEJ
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
NR 30
TC 122
Z9 125
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2017
VL 124
IS 1
BP 97
EP 104
DI 10.1016/j.ophtha.2016.09.012
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EK4KZ
UT WOS:000393896900028
PM 28079023
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Fontaine, V
   Monteiro, E
   Fournie, M
   Brazhnikova, E
   Boumedine, T
   Vidal, C
   Balducci, C
   Guibout, L
   Latil, M
   Dilda, PJ
   Veillet, S
   Sahel, JA
   Lafont, R
   Camelo, S
AF Fontaine, Valerie
   Monteiro, Elodie
   Fournie, Mylene
   Brazhnikova, Elena
   Boumedine, Thinhinane
   Vidal, Cecile
   Balducci, Christine
   Guibout, Louis
   latil, MathilDe
   Dilda, Pierre J.
   Veillet, Stanislas
   Sahel, Jose-Alain
   Lafont, Rene
   Camelo, Serge
TI Systemic administration of the di-apocarotenoid norbixin (BIO201) is
   neuroprotective, preserves photoreceptor function and innibits A2E and
   lipofuscin accumulation in animal models of age-related macular
   degeneration and Stargardt disease
SO AGING-US
LA English
DT Article
DE norbixin; retinal function; A2E; AMD; Stargardt disease
ID PIGMENT EPITHELIAL-CELLS; RETINAL DEGENERATION; MOLECULAR-MECHANISMS;
   OXIDATIVE DAMAGE; MOUSE MODEL; MICE; ACTIVATION; COMPONENT; STRESS; RPE
AB Atrophic age-related macular degeneration (AMD) and Stargardt disease (STGD) are major blinding diseases affecting millions of patients worldwide, but no treatment is available. In dry AMD and STGD oxidative stress and subretinal accumulation of N-retinylidene-N-retinylethanolamine (A2E), a toxic by-product of the visual cycle, causes retinal pigment epithelium (RPE) and photoreceptor degeneration leading to visual impairment. Acute and chronic retinal degeneration following blue light damage (BLD) in BALB/c mice and aging of Abca4(-/-) Rdh8(-/-) mice, respectively, reproduce features of AMD and STGD. Efficacy of systemic administrations of 9'-cis-norbixin (norbixin), a natural di-apocarotenoid, prepared from Bixa orellana seeds with anti-oxidative properties, was evaluated during BLD in BALB/c mice, and in Abca4(-/-) Rdh8(-/-) mice of different ages, following three experimental designs: "preventive", "early curative" and "late curative" supplementations. Norbixin injected intraperitoneally in BALB/c mice, maintained scotopic and photopic electroretinogram amplitude and was neuroprotective. Norbixin chronic oral administration for 6 months in Abca4(-/-) Rdh8(-/-) mice following the "early curative" supplementation showed optimal neuroprotection and maintenance of photoreceptor function and reduced ocular A2E accumulation. Thus, norbixin appears promising as a systemic drug candidate for both AMD and STGD treatment.
C1 [Fontaine, Valerie; Monteiro, Elodie; Fournie, Mylene; Brazhnikova, Elena; Boumedine, Thinhinane; Vidal, Cecile; Sahel, Jose-Alain] Sorbonne Univ, CNRS, INSERM, Inst Vis, F-75012 Paris, France.
   [Balducci, Christine; Guibout, Louis; latil, MathilDe; Dilda, Pierre J.; Veillet, Stanislas; Lafont, Rene; Camelo, Serge] Sorbonne Univ, Biophytis, Campus Pierre & Marie Curie, F-75005 Paris, France.
C3 Centre National de la Recherche Scientifique (CNRS); Institut National
   de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French
   Research Universities; Sorbonne Universite
RP Camelo, S (通讯作者)，Sorbonne Univ, Biophytis, Campus Pierre & Marie Curie, F-75005 Paris, France.
EM serge.camelo@biophytis.com
RI LAFONT, Rene/GYA-4891-2022; Latil, Mathilde/E-2011-2017
OI Camelo, Serge/0000-0001-8733-8503
FU Biophytis; Programme Investissements d'Avenir IHU FOReSIGHT
   [ANR-18-IAHU-01]
FX This work was supported by Biophytis. The contribution of Dr L.N. Dinan
   for critical reading of the manuscript and language improvement is
   acknowledged. This work was completed with the support of the Programme
   Investissements d'Avenir IHU FOReSIGHT (ANR-18-IAHU-01). We are grateful
   to Michael Trichet from the IBPS EM platform for his help in analysing
   RPE cytoplasm lipofuscin.
CR Alaimo A, 2019, ARCH TOXICOL, V93, P1401, DOI 10.1007/s00204-019-02409-6
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Arnault E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071398
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   Brandstetter C, 2015, J MOL MED, V93, P905, DOI 10.1007/s00109-015-1275-1
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Chen Y, 2012, NRF2 AGE DEPENDENT R, DOI [10.5772/28167, DOI 10.5772/28167]
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Feng JY, 2014, OPHTHALMIC RES, V52, P224, DOI 10.1159/000363387
   Fernandes ACS, 2002, J NUTR BIOCHEM, V13, P411, DOI 10.1016/S0955-2863(02)00177-8
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Flynn E, 2014, INVEST OPHTH VIS SCI, V55, P5643, DOI 10.1167/iovs.14-14136
   Fontaine V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167793
   Gao Z, 2018, J BIOL CHEM, V293, P14507, DOI 10.1074/jbc.RA118.002447
   Getter T, 2019, J BIOL CHEM, V294, P9461, DOI 10.1074/jbc.RA119.008697
   Guha S, 2014, EXP EYE RES, V126, P68, DOI 10.1016/j.exer.2014.05.013
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Iriyama A, 2008, J BIOL CHEM, V283, P11947, DOI 10.1074/jbc.M708989200
   Iriyama A, 2009, J CELL PHYSIOL, V220, P469, DOI 10.1002/jcp.21792
   Issa PC, 2015, P NATL ACAD SCI USA, V112, P8415, DOI 10.1073/pnas.1506960112
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jiang D, 2019, INVEST OPHTH VIS SCI, V60, P1275, DOI 10.1167/iovs.18-24398
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klevering BJ, 2002, INVEST OPHTH VIS SCI, V43, P1980
   Lenis TL, 2018, P NATL ACAD SCI USA, V115, pE11120, DOI 10.1073/pnas.1802519115
   Lois N, 2001, ARCH OPHTHALMOL-CHIC, V119, P359, DOI 10.1001/archopht.119.3.359
   Luhmann UFO, 2015, HUM MOL GENET, V24, P128, DOI 10.1093/hmg/ddu424
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda A, 2006, INVEST OPHTH VIS SCI, V47, P4540, DOI 10.1167/iovs.06-0215
   Maeda A, 2012, NAT CHEM BIOL, V8, P170, DOI 10.1038/nchembio.759
   Maeda T, 2009, INVEST OPHTH VIS SCI, V50, P322, DOI 10.1167/iovs.08-2301
   Maeda T, 2012, PHOTOCHEM PHOTOBIOL, V88, P1309, DOI 10.1111/j.1751-1097.2012.01143.x
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Moon J, 2017, INTEGR BIOL-UK, V9, P436, DOI 10.1039/c7ib00032d
   Neuner B, 2009, ADDICT BEHAV, V34, P938, DOI 10.1016/j.addbeh.2009.05.015
   Parmar T, 2016, INVEST OPHTH VIS SCI, V57, P3257, DOI 10.1167/iovs.15-18993
   Poliakov E, 2014, MOL VIS, V20, P285
   Prokopiou E, 2018, INVEST OPHTH VIS SCI, V59, P2757, DOI 10.1167/iovs.17-23523
   Puntel A, 2015, BIOMATERIALS, V44, P103, DOI 10.1016/j.biomaterials.2014.12.019
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Roehlecke C, 2009, MOL VIS, V15, P1929
   Roehrs M, 2017, FOOD RES INT, V100, P771, DOI 10.1016/j.foodres.2017.08.005
   Rohini A, 2018, LIFE SCI, V209, P69, DOI 10.1016/j.lfs.2018.08.001
   Rotenstreich Y, 2003, OPHTHALMOLOGY, V110, P1151, DOI 10.1016/S0161-6420(03)00333-6
   Sacconi R, 2017, OPHTHALMOL THER, V6, P69, DOI 10.1007/s40123-017-0086-6
   Santos AAA, 2002, FOOD CHEM, V77, P393, DOI 10.1016/S0308-8146(01)00363-6
   Satyanarayana A, 2003, J FOOD SCI TECH MYS, V40, P131
   Schur RM, 2015, INVEST OPHTH VIS SCI, V56, P4936, DOI 10.1167/iovs.15-16522
   Sears AE, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.5.6
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Taubit T, 2018, PEERJ, V6, DOI 10.7717/peerj.5215
   Ueda K, 2016, P NATL ACAD SCI USA, V113, P6904, DOI 10.1073/pnas.1524774113
   Veerappan M, 2016, OPHTHALMOLOGY, V123, P2554, DOI 10.1016/j.ophtha.2016.08.047
   Wang J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0200-7
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Wu YL, 2010, P NATL ACAD SCI USA, V107, P7275, DOI 10.1073/pnas.0913112107
   Wu Y, 2015, INT J CLIN EXP PATHO, V8, P7403
   Zhang JY, 2015, J CLIN INVEST, V125, P2781, DOI 10.1172/JCI80950
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 65
TC 6
Z9 6
U1 1
U2 7
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD APR 15
PY 2020
VL 12
IS 7
BP 6151
EP 6171
DI 10.18632/aging.103014
PG 21
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA LE7WC
UT WOS:000526933400035
PM 32255762
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Singer, MA
   Awh, CC
   Sadda, S
   Freeman, WR
   Antoszyk, AN
   Wong, P
   Tuomi, L
AF Singer, Michael A.
   Awh, Carl C.
   Sadda, SriniVas
   Freeman, William R.
   Antoszyk, Andrew N.
   Wong, Pamela
   Tuomi, Lisa
TI HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal
   Neovascularization Secondary to Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID VERTEPORFIN PHOTODYNAMIC THERAPY
AB Objective: To evaluate the long-term safety and efficacy of multiple intravitreal ranibizumab injections (Lucentis, Genentech, Inc., South San Francisco, CA) administered at the investigator's discretion in patients with choroidal neovascularization secondary to age-related macular degeneration.
   Design: An open-label, multicenter, extension study.
   Participants: Patients who completed the controlled treatment phase of 1 of 3 prospective, randomized, 2-year clinical trials of ranibizumab were eligible for enrollment. Analyses were performed for 3 groups: (1) patients treated with ranibizumab in the initial study (ranibizumab treated-initial; n = 600); (2) patients randomized to control who crossed over to receive ranibizumab (ranibizumab treated-XO; n = 190); and (3) ranibizumab-naive patients (ranibizumab untreated; n = 63).
   Methods: Ranibizumab 0.5 mg was administered at the investigator's discretion. Adverse events (AEs) and Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) assessments were conducted at study visits every 3 to 6 months.
   Main Outcome Measures: Incidence and severity of AEs.
   Results: There was 1 occurrence of mild endophthalmitis per 3552 HORIZON injections in the ranibizumab treated-initial/ranibizumab treated-XO groups. There were no serious AE reports of lens damage, retinal tears, or rhegmatogenous retinal detachments in the study eyes. The proportion of patients with any single postdose intraocular pressure >= 30 mmHg was 9.2%, 6.6%, and 0%, and the proportion of patients with glaucoma was 3.2%, 4.2%, and 3.2% in the ranibizumab treated-initial, ranibizumab treated-XO, and ranibizumab untreated groups, respectively. Cataract AEs were less frequent in the ranibizumab untreated group: 6.3% versus 12.5% and 12.1% in the ranibizumab treated-initial and ranibizumab treated-XO groups, respectively. The proportion of patients with arterial thromboembolic events as defined by the Antiplatelet Trialists' Collaboration was 5.3% in the ranibizumab treated-initial and ranibizumab treated-XO groups, and 3.2% in the ranibizumab untreated group. At month 48 (2 years of HORIZON), the mean change in BCVA (ETDRS letters) relative to the initial study baseline was 2.0 in the ranibizumab treated-initial group versus -11.8 in the pooled ranibizumab treated-XO and ranibizumab untreated groups.
   Conclusions: Multiple ranibizumab injections were well tolerated for >= 4 years. With less frequent follow-up leading to less treatment, there was an incremental decline of the visual acuity (VA) gains achieved with monthly treatment.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2012;119:1175-1183 (C) 2012 by the American Academy of Ophthalmology.
C1 [Singer, Michael A.] Med Ctr Ophthalmol Associates, San Antonio, TX 78240 USA.
   [Awh, Carl C.] Tennessee Retina, Nashville, TN USA.
   [Sadda, SriniVas] Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Freeman, William R.] Univ Calif San Diego, Jacobs Retina Ctr, La Jolla, CA 92093 USA.
   [Antoszyk, Andrew N.] Charlotte Eye Ear Nose & Throat Associates, Charlotte, NC USA.
   [Wong, Pamela; Tuomi, Lisa] Genentech Inc, San Francisco, CA 94080 USA.
C3 Doheny Eye Institute; University of California System; University of
   California San Diego; Roche Holding; Genentech
RP Singer, MA (通讯作者)，Med Ctr Ophthalmol Associates, 9157 Huebner Rd, San Antonio, TX 78240 USA.
EM msinger@mcoaeyecare.com
FU Genentech, Inc, South San Francisco, California; Genentech, Inc
FX This study was funded by Genentech, Inc, South San Francisco,
   California.; The author(s) have made the following disclosure(s): The
   sponsor participated in the design and performance of the study; data
   collection, management, analysis, and interpretation; and preparation,
   review, and approval of the manuscript. Support for third-party writing
   and formatting assistance for this manuscript, provided by Ivo Stoilov,
   was provided by Genentech, Inc., Michael A. Singer: consultancy
   (Genentech, Inc, Allergan), speakers bureau (Genentech, Inc, Allergan);
   Carl C. Awh: speakers bureau (Genentech, Inc); research support
   (Genentech, Inc); SriniVas Sadda: reading center contract (Doheny Eye
   Institute); William R. Freeman: no conflicts; Andrew N. Antoszyk:
   consulting fee or honorarium (Genentech, Inc), consultancy (Alcon,
   Alimera), speakers bureau (Genentech, Inc); Pamela Wong and Lisa Tuomi:
   employees of Genentech Inc; Lisa Tuomi: equity or options in Roche.
CR ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown EG, 1999, DRUG SAFETY, V20, P109, DOI 10.2165/00002018-199920020-00002
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 11
TC 267
Z9 284
U1 0
U2 26
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2012
VL 119
IS 6
BP 1175
EP 1183
DI 10.1016/j.ophtha.2011.12.016
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 951JP
UT WOS:000304717100013
PM 22306121
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Hahn, GA
   Messias, A
   MacKeben, M
   Dietz, K
   Horwath, K
   Hyvarinen, L
   Leinonen, M
   Trauzettel-Klosinski, S
AF Hahn, Gesa Astrid
   Messias, Andre
   MacKeben, Manfred
   Dietz, Klaus
   Horwath, Karin
   Hyvarinen, Lea
   Leinonen, Markku
   Trauzettel-Klosinski, Susanne
TI Parafoveal letter recognition at reduced contrast in normal aging and in
   patients with risk factors for AMD
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Aging; Age-related maculopathy; Age-related macular degeneration;
   Retina; Macular function; Parafoveal function; Contrast sensitivity;
   Letter recognition
ID AGE-RELATED MACULOPATHY; MEDIATED DARK-ADAPTATION; BRUCHS MEMBRANE
   CHANGE; MACULAR DEGENERATION; VISUAL-ACUITY; PERIPHERAL-VISION; 2ND
   EYES; SENSITIVITY; ROTTERDAM; FIELD
AB Background Patients with early age-related maculopathy ( ARM) do not necessarily show obvious morphological signs or functional impairment. Many have good visual acuity, yet complain of decreased visual performance. The aim of this study was to investigate the aging effects on performance of parafoveal letter recognition at reduced contrast, and defects caused by early ARM and normal fellow eyes of patients with unilateral age-related macular degeneration (nfAMD).
   Methods Testing of the central visual field (8 radius) was performed by the Macular Mapping Test (MMT) using recognition of letters in 40 parafoveal target locations at four contrast levels (5, 10, 25 and 100%). Effects of aging were investigated in 64 healthy subjects aged 23 to 76 years (CTRL). In addition, 39 eyes (minimum visual acuity of 0.63; 20/30) from 39 patients with either no visible signs of ARM, while the fellow eye had advanced age-related macular degeneration (nfAMD; n=12), or early signs of ARM (eARM; n=27) were examined. Performance was expressed summarily as a "field score" (FS).
   Results Performance in the MMT begins to decline linearly with age in normal subjects from the age of 50 and 54 years on, at 5% and 10% contrast respectively. The differentiation between patients and CTRLs was enhanced if FS at 5% was analyzed along with FS at 10% contrast. In 8/12 patients from group nfAMD and in 18/27 from group eARM, the FS was statistically significantly lower than in the CTRL group in at least one of the lower contrast levels.
   Conclusion Using parafoveal test locations, a recognition task and diminished contrast increases the chance of early detection of functional defects due to eARM or nfAMD and can differentiate them from those due to aging alone.
C1 [Hahn, Gesa Astrid; Messias, Andre; Horwath, Karin; Trauzettel-Klosinski, Susanne] Univ Tubingen, Ctr Ophthalmol, D-72076 Tubingen, Germany.
   [Messias, Andre] Univ Sao Paulo, Dept Ophthalmol Otorhinolaringol & Head & Neck Su, BR-14049 Ribeirao Preto, Brazil.
   [MacKeben, Manfred] Smith Kettlewell Eye Res Inst, San Francisco, CA 94115 USA.
   [Dietz, Klaus] Univ Tubingen, Dept Med Biometry, D-72076 Tubingen, Germany.
   [Hyvarinen, Lea] Univ Helsinki, Fac Behav Sci, Helsinki, Finland.
   [Leinonen, Markku] Turku Univ Hosp, Dept Ophthalmol, FIN-20520 Turku, Finland.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Universidade de Sao Paulo; The Smith-Kettlewell Eye Research
   Institute; Eberhard Karls University of Tubingen; Eberhard Karls
   University Hospital; University of Helsinki; University of Turku
RP Trauzettel-Klosinski, S (通讯作者)，Univ Tubingen, Ctr Ophthalmol, Schleichstr 12-16, D-72076 Tubingen, Germany.
EM susanne.trauzettel-klosinski@med.uni-tuebingen.de
RI Messias, Andre/H-5801-2012; Messias, Andre MV/C-1560-2012; Dietz,
   Klaus/R-9268-2016
OI Messias, Andre/0000-0002-5328-9608; Messias, Andre
   MV/0000-0002-5328-9608; Dietz, Klaus/0000-0001-8503-9737
FU European Commission [QLK-CT-2002-00214]
FX This study was supported by the European Commission (QLK-CT-2002-00214,
   AMD-Read). The authors would like to thank Werner Inhoffen MD, PhD, and
   Malte Weismann, MD, from the University of Tubingen for their help with
   recruiting patients, and Claudia Gehrlich for support with patient
   examinations.
CR Anderson RS, 1996, J OPT SOC AM A, V13, P697, DOI 10.1364/JOSAA.13.000697
   Bellmann C, 2003, GRAEF ARCH CLIN EXP, V241, P968, DOI 10.1007/s00417-003-0689-6
   BIRD AC, 1992, BRIT J OPHTHALMOL, V76, P166, DOI 10.1136/bjo.76.3.166
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   CHANG B, 1995, OPHTHALMOLOGY, V102, P1380, DOI 10.1016/S0161-6420(95)30860-3
   CHENG AS, 1993, OPTOMETRY VISION SCI, V70, P89, DOI 10.1097/00006324-199302000-00001
   Chung STL, 2002, VISION RES, V42, P2137, DOI 10.1016/S0042-6989(02)00092-5
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Eisenbarth W, 2008, GRAEF ARCH CLIN EXP, V246, P27, DOI 10.1007/s00417-007-0641-2
   Fleiss J, 1973, STAT METHODS RATES P
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   FOLEY JM, 1981, VISION RES, V21, P1041, DOI 10.1016/0042-6989(81)90009-2
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Hyvarinen L, 1982, Fortschr Ophthalmol, V79, P166
   Johnson M, 2007, CURR EYE RES, V32, P791, DOI 10.1080/02713680701550660
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Lovie-Kitchin Jan, 2005, Clin Exp Optom, V88, P292
   Mackeben M., 2000, VISION REHABILITATIO, P158
   Mackeben M., 1999, PERIMETRY UPDATE 199, P307
   Messias A, 2007, INVEST OPHTH VIS SCI, V48, P5815, DOI 10.1167/iovs.06-0367
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   OWSLEY C, 1983, VISION RES, V23, P689, DOI 10.1016/0042-6989(83)90210-9
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P539, DOI 10.1007/s00417-002-0507-6
   RANDALL HG, 1966, ARCH OPHTHALMOL-CHIC, V75, P500
   ROY M, 1990, Eye (London), V4, P813
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Schneck ME, 2004, VISION RES, V44, P2317, DOI 10.1016/j.visres.2004.04.018
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   SJOSTRAND J, 1979, ACTA OPHTHALMOL, V57, P832
   Soubrane G, 2002, PRESSE MED, V31, P1282
   STANGOS N, 1995, OPHTHALMOLOGICA, V209, P194, DOI 10.1159/000310612
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Strasburger H, 1996, EUR J NEUROSCI, V8, P1787, DOI 10.1111/j.1460-9568.1996.tb01322.x
   STRASBURGER H, 1991, PERCEPT PSYCHOPHYS, V49, P495, DOI 10.3758/BF03212183
   SUNNESS JS, 1989, OPHTHALMOLOGY, V96, P375, DOI 10.1016/S0161-6420(89)32883-1
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   SWANN PG, 1990, OPHTHAL PHYSL OPT, V10, P149, DOI 10.1111/j.1475-1313.1990.tb00969.x
   TOLENTINO MJ, 1994, VISION RES, V34, P409, DOI 10.1016/0042-6989(94)90099-X
   Trauzettel-Klosinski S, 2003, GRAEF ARCH CLIN EXP, V241, P988, DOI 10.1007/s00417-003-0757-y
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
NR 51
TC 14
Z9 14
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2009
VL 247
IS 1
BP 43
EP 51
DI 10.1007/s00417-008-0919-z
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 384ND
UT WOS:000261750600006
PM 18751995
DA 2022-11-30
ER

PT J
AU Miskala, PH
   Bass, EB
   Bressler, NM
   Childs, AL
   Hawkins, BS
   Mangione, CM
   Marsh, MJ
AF Miskala, PH
   Bass, EB
   Bressler, NM
   Childs, AL
   Hawkins, BS
   Mangione, CM
   Marsh, MJ
CA Submacular Surg Trials SST Res Grp
TI Surgery for subfoveal choroidal neovascularization in age-related
   macular degeneration: Quality-of-Life findings - SST report no. 12
SO OPHTHALMOLOGY
LA English
DT Article
ID VISUAL FUNCTION QUESTIONNAIRE; GENERAL HEALTH; SCORES; ACUITY
AB Purpose: To describe health-related quality of life (HRQOL), overall and in patients with unilateral or bilateral choroidal neovascularization (CNV), in a clinical trial (Group N Trial) comparing observation and surgical removal of subfoveal CNV secondary to age-related macular degeneration (AMD).
   Design: Randomized clinical trial.
   Participants: Eligible patients had untreated subfoveal CNV and AMD, best-corrected visual acuity (VA) of 20/100 to 20/800, classic CNV on fluorescein angiography, and a total subfoveal lesion size of less than or equal to9.0 disc areas in the study eye.
   Methods: Health-related quality of life data (the National Eye Institute Visual Function Questionnaire [NEI-VFQ], 36-item Short Form Health Survey [SF-36], and Hospital Anxiety and Depression Scale [HADS]) and clinical data were collected at baseline and at 6, 12, 24, 36, and 48 months. Patients were divided into unilateral and bilateral CNV subgroups based on fluorescein angiographic and clinical evidence.
   Main Outcome Measure: Two-year change in the NEI-VFQ.
   Results. Of 454 patients enrolled, 228 were assigned to observation and 226 to surgery. At baseline, median overall NEI-VFQ scores were 67 in the observation group and 69 in the surgery group; by 2 years, the observation group had lost a median of 3 points (95% confidence interval [CI]: -6 to -2), and the surgery group gained a median of 1 point (CI: -1 to 3). The largest difference was observed for the mental health subscale, where the observation group lost a median of 5 points (CI: -5 to 0), and the surgery group gained a median of 5 points (CI: 0-10) by 2 years. Treatment differences in median 2-year changes in NEI-VFQ scores favored surgery by up to 10 points for unilateral cases and up to 8 points for bilateral cases. No treatment difference in 2-year change was observed for the SF-36 physical component summary; 2-year change in the mental component summary favored surgery by 2 points. Few patients (2%-4%) had HADS definite anxiety or depression at baseline or at 24 months.
   Conclusions: Although HRQOL outcomes were better in the submacular surgery arm than in the observation arm, surgery (per protocol) is not recommended because VA outcomes (reported elsewhere) were similar in the treatment arms. (C) 2004 by the American Academy of Ophthalmology.
C1 SST Coordinating Ctr, Baltimore, MD 21205 USA.
RP Miskala, PH (通讯作者)，SST Coordinating Ctr, 550 N Broadway,9th Floor, Baltimore, MD 21205 USA.
OI Mann, Ashley/0000-0003-3553-5470
FU NEI NIH HHS [U10 EY11547, EY11557, U10 EY011558-07, U10 EY011558,
   EY11558, U10 EY011547, U10 EY011557, U10 EY011547-07, U10 EY011557-08]
   Funding Source: Medline; NATIONAL EYE INSTITUTE [U10EY011558,
   U10EY011547, U10EY011557] Funding Source: NIH RePORTER
CR Childs AL, 2004, OPHTHALMOLOGY, V111, P2007, DOI 10.1016/j.ophtha.2004.07.024
   Childs AL, 2004, AM J OPHTHALMOL, V137, P373, DOI 10.1016/S0002-9394(03)00911-5
   Diggle PJ, 1994, ANAL LONGITUDINAL DA, P131
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   HILLIS A, 1986, J CHRON DIS, V39, P595, DOI 10.1016/0021-9681(86)90184-0
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Miskala PH, 2004, ARCH OPHTHALMOL-CHIC, V122, P758, DOI 10.1001/archopht.122.5.758
   Miskala PH, 2004, AM J OPHTHALMOL, V137, P961, DOI 10.1016/j.ajo.2003.11.018
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   *SAS INC, 2001, SAS VERS 8 2 CAR
   *SST RES GROUP, IN PRESS ARCH OPHTHA
   *SUBM SURG TRIALS, 2003, ARCH OPHTHALMOL-CHIC, V121, P1513
   *SUBM SURG TRIALS, IN PRESS ARCH OPHTHA
   *SUBM SURG TRIALS, 1998, NTIS PUBL
   Talic I, 2022, LEARN INSTR, V81, DOI [10.1016/j.learninstruc.2022.101594, 10.1016/j.ajo.2004.02.011]
   Ware JE, 1994, SF 36 PHYS MENTAL HL
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
   2000, SAS STAT US GUID VER, V2, P2085
   2000, SAS PROC GUID VERS 8, V2, P1404
   [No title captured]
NR 23
TC 57
Z9 59
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2004
VL 111
IS 11
BP 1981
EP 1992
DI 10.1016/j.ophtha.2004.07.022
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 866JZ
UT WOS:000224771100003
PM 15522363
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Wolowacz, SE
   Roskell, N
   Kelly, S
   Maciver, FM
   Brand, CS
AF Wolowacz, Sorrel E.
   Roskell, Neil
   Kelly, Steven
   Maciver, Fiona M.
   Brand, Chris S.
TI Cost effectiveness of pegaptanib for the treatment of age-related
   macular degeneration in the UK
SO PHARMACOECONOMICS
LA English
DT Article
ID CONTROLLED CLINICAL-TRIALS; DEPRESSION; VERTEPORFIN; MACULOPATHY;
   BLINDNESS; THERAPY; DISEASE; SODIUM; ADULTS
AB Background: Age-related macular degeneration (AMD) is the primary cause of vision loss in the elderly and results in significant economic and humanistic burden. The selective vascular endothelial growth factor inhibitor, pegaptanib (Macugen((R))) is indicated for patients with neovascular AMD. Guidance is needed regarding the cost effectiveness of treatment, any variation between sub-populations of differing clinical characteristics and the optimum duration of treatment.
   Objective: To estimate the cost effectiveness of pegaptanib versus best supportive care (BSC) for AMD from the perspective of the UK government, and to evaluate the impact of patient characteristics and differing treatment discontinuation scenarios.
   Methods: A cohort of 1000 patients aged >45 years with a best-corrected visual acuity (VA) in their better-seeing eye of <= 6/12 was modelled. Patients were either treated with pegaptanib (0.3mg every 6 weeks for a maximum of 2 years in their better-seeing eye only) or received BSC (no active treatment). Supportive services were provided for patients with a VA <= 6/60.
   A 10-year Markov model composed of 12 VA states (defined by individual Snellen lines) and a dead state was constructed.(1) Time-dependent transition probabilities for the loss and gain of Snellen lines were derived from parametric survival curves fitted to patient-level data from the VISION trials. Survival curves were fitted with treatment and baseline Snellen scores as covariates; additional curves were fitted with the addition of age, gender, lesion type or lesion size as covariates. Mortality rates were adjusted for the age, gender and VA of the population. Cost effectiveness was expressed as the incremental cost (IC) per vision-year saved and IC/QALY. Uncertainty was explored by probabilistic and univariate sensitivity analysis. Costs (year 2005 values) and outcomes were discounted at 3.5% per anum.
   Results: In the base-case analysis, treatment was targeted to patients with a VA of 6/12 to 6/95 and discontinued after 2 years, or earlier if VA fell below 6/95 or by >= 6 lines. The IC/QALY was estimated as 8023 pound (upper 95% CI 20 pound 641). Cost effectiveness varied by age (age <75 years = 2033 pound/QALY; age >= 75 years = 11 pound 657/QALY) and by pre-treatment VA (6/12-6/95 = 8023 pound/QALY; 6/12-6/60 = 6664 pound/QALY; 6/12-6/24 = 1920 pound/QALY). Gender and lesion type or size had little effect. Cost effectiveness was not sensitive to precise rules for treatment discontinuation, but was maximised if treatment was discontinued in patients no longer likely to benefit.
   Conclusions: The results suggest that pegaptanib treatment is likely to be cost effective across all groups studied, and marginally more cost effective in younger patients and those with better pre-treatment VA. Cost effectiveness appears to be optimised if treatment is discontinued after I year if individual patients' VA has dropped by >= 6 lines from pre-treatment levels, or at any time if it drops below 6/95. However, strict application of discontinuation rules does not appear to be necessary for pegaptanib to be cost effective. Clinical judgement and patient preference should be an important determinant in decisions about stopping treatment.
C1 Univ Manchester Sci Pk, RTI Hlth Solut, Manchester M15 6SE, Lancs, England.
   Pfizer Ltd, Surrey, England.
   Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England.
C3 Research Triangle Institute; University of Manchester; Pfizer;
   University of Sheffield
RP Wolowacz, SE (通讯作者)，Univ Manchester Sci Pk, RTI Hlth Solut, Lloyd St N, Manchester M15 6SE, Lancs, England.
EM swolowacz@rti.org
OI Wolowacz, Sorrel/0000-0001-5497-612X
CR Berman K, 2006, INT PSYCHOGERIATR, V18, P415, DOI 10.1017/S1041610205002905
   Brennan J, 2003, OSTEOPOROSIS INT, V14, P515, DOI 10.1007/s00198-003-1404-5
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   *BRIT MED ASS ROY, 2005, 50 BMA RPS
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   *CENTR OFF INF, DIR
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   CURITS L, 2005, UNIT COSTS HLTH SOCI
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   *DEP HLTH, 2004, NHS REF COSTS
   *DEP WORK PENS, 2003, HOUS BEN COUNC TAX B
   Dutton GN, 2000, BRIT J OPHTHALMOL, V84, P945, DOI 10.1136/bjo.84.9.945
   EVANS RL, 1983, PSYCHOL REP, V52, P603, DOI 10.2466/pr0.1983.52.2.603
   FITZGERALD RG, 1970, ARCH GEN PSYCHIAT, V22, P370
   Galaria II, 2000, INT PSYCHOGERIATR, V12, P435, DOI 10.1017/S1041610200006554
   *GOVT ACT DEP, 2003, POP PROJ 2003
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Javitt JC, 2007, OPHTHALMOLOGY, V114, P238, DOI 10.1016/j.ophtha.2006.07.054
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   Mills E, 2007, J CLIN EPIDEMIOL, V60, P456, DOI 10.1016/j.jclinepi.2006.09.001
   *NAT I CLIN EXC, 2003, GUID US PHOT THER AG
   National Institute for Health and Clinical Excellence, 2004, GUID METH TECHN APPR
   O'Neill C, 2001, DRUG AGING, V18, P233, DOI 10.2165/00002512-200118040-00001
   *OFF NAT STAT, 1994, KEY HLTH STAT GEN PR
   *OFF NAT STAT, 2001, MORT STAT GEN MORT R
   *PFIZ LTD, 2006, PEG SUMM PROD CHAR
   *PFIZ LTD, 2006, VISION TRIALS PAT LE
   *ROY COMM LONG TER, 1999, RESP AG LONG TERM CA
   *SCOTT EX HLTH DEP, 2005, PCSDD20055
   Scott IU, 2001, AM J OPHTHALMOL, V131, P584, DOI 10.1016/S0002-9394(01)00832-7
   *SCOTT MED CONS, 29006 SCOTT MED CONS
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   Thomas CM, 2003, BRIT J PSYCHIAT, V183, P514, DOI 10.1192/bjp.183.6.514
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
NR 36
TC 16
Z9 16
U1 0
U2 8
PU ADIS INT LTD
PI AUCKLAND
PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW
   ZEALAND
SN 1170-7690
J9 PHARMACOECONOMICS
JI Pharmacoeconomics
PY 2007
VL 25
IS 10
BP 863
EP 879
DI 10.2165/00019053-200725100-00005
PG 17
WC Economics; Health Care Sciences & Services; Health Policy & Services;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Business & Economics; Health Care Sciences & Services; Pharmacology &
   Pharmacy
GA 222UV
UT WOS:000250323800005
PM 17887807
DA 2022-11-30
ER

PT J
AU Rossant, F
   Paques, M
AF Rossant, Florence
   Paques, Michel
TI Normalization of series of fundus images to monitor the geographic
   atrophy growth in dry age-related macular degeneration
SO COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
LA English
DT Article
DE eye fundus images; normalization of series of images; geographic atrophy
   (GA); GA progression detection; GA progression representation;
   dry-age-related macular degeneration (ARMD)
ID SEGMENTATION
AB Background and Objective: Age-related macular degeneration (ARMD) is a degenerative disease that affects the retina, and the leading cause of visual loss. In its dry form, the pathology is characterized by the progressive, centrifugal expansion of retinal lesions, called geographic atrophy (GA). In infrared eye fundus images, the GA appears as localized bright areas and its growth can be observed in series of images acquired at regular time intervals. However, illumination distortions between the images make impossible the direct comparison of intensities in order to study the GA progress. Here, we propose a new method to compensate for illumination distortion between images. Methods: We process all images of the series so that any two images have comparable gray levels. Our approach relies on an illumination/reflectance model. We first estimate the pixel-wise illumination ratio between any two images of the series, in a recursive way; then we correct each image against all the others, based on those estimates. The algorithm is applied on a sliding temporal window to cope with large changes in reflectance. We also propose morphological processing to suppress illumination artefacts. Results: The corrected illumination function is homogeneous in the series, enabling the direct comparison of grey-levels intensities in each pixel, and so the detection of the GA growth between any two images. To demonstrate that, we present numerous experiments performed on a dataset of 18 series (328 images), manually segmented by an ophthalmologist. First, we show that the normalization preprocessing dramatically increases the contrast of the GA growth areas. Secondly, we apply segmentation algorithms derived from Otsu's thresholding to detect automatically the GA total growth and the GA progress between consecutive images. We demonstrate qualitatively and quantitatively that these algorithms, although fully automatic, unsupervised and basic, already lead to interesting segmentation results when applied to the normalized images. Colored maps representing the GA evolution can be derived from the segmentations. Conclusion: To our knowledge, the proposed method is the first one which corrects automatically and jointly the illumination inhomogeneity in a series of fundus images, regardless of the number of images, the size, shape and progression of lesion areas. This algorithm greatly facilitates the visual interpretation by the medical expert. It opens up the possibility of treating automatically each series as a whole (not just in pairs of images) to model the GA growth. (c) 2021 Elsevier B.V. All rights reserved.
C1 [Rossant, Florence] ISEP, 10 Rue Vanves, F-92130 Issy Les Moulineaux, France.
   [Paques, Michel] Quinze Vingts Hosp, Clin Invest Ctr 1423, 28 Rue Charenton, F-75012 Paris, France.
C3 CHNO des Quinze-Vingts; UDICE-French Research Universities; Sorbonne
   Universite
RP Rossant, F (通讯作者)，ISEP, 10 Rue Vanves, F-92130 Issy Les Moulineaux, France.
EM florence.rossant@isep.fr
OI Rossant, Florence/0000-0003-2517-5213
CR Deckert A, 2005, BMC Ophthalmol, V5, P8, DOI 10.1186/1471-2415-5-8
   Dupont G, 2020, J IMAGING, V6, DOI 10.3390/jimaging6070057
   Feeny AK, 2015, COMPUT BIOL MED, V65, P124, DOI 10.1016/j.compbiomed.2015.06.018
   Hu ZH, 2015, J MED IMAGING, V2, DOI 10.1117/1.JMI.2.1.014501
   Hu ZH, 2013, INVEST OPHTH VIS SCI, V54, P8375, DOI 10.1167/iovs.13-12552
   Kose C, 2008, COMPUT BIOL MED, V38, P611, DOI 10.1016/j.compbiomed.2008.02.008
   Kose C, 2010, J MED SYST, V34, P1, DOI 10.1007/s10916-008-9210-4
   Lee N, 2007, P ANN INT IEEE EMBS, P4965, DOI 10.1109/IEMBS.2007.4353455
   Lee N, 2008, CONF REC ASILOMAR C, P655, DOI 10.1109/ACSSC.2008.5074488
   Marrugo AG, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3652709
   Priya R., 2011, 2011 3rd International Conference on Electronics Computer Technology (ICECT 2011), P227, DOI 10.1109/ICECTECH.2011.5941690
   Ramsey DJ, 2014, RETINA-J RET VIT DIS, V34, P1296, DOI 10.1097/IAE.0000000000000069
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Troglio G, 2010, LECT NOTES COMPUT SC, V5997, P94, DOI 10.1007/978-3-642-12127-2_10
NR 14
TC 1
Z9 1
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0169-2607
EI 1872-7565
J9 COMPUT METH PROG BIO
JI Comput. Meth. Programs Biomed.
PD SEP
PY 2021
VL 208
AR 106234
DI 10.1016/j.cmpb.2021.106234
EA JUL 2021
PG 11
WC Computer Science, Interdisciplinary Applications; Computer Science,
   Theory & Methods; Engineering, Biomedical; Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Medical Informatics
GA UA9WS
UT WOS:000685505000010
PM 34229997
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Holmes, SM
   Micka, JA
   DeWerd, LA
AF Holmes, Shannon M.
   Micka, John A.
   DeWerd, Larry A.
TI Investigation of a Sr-90/Y-90 source for intra-ocular treatment of wet
   age-related macular degeneration
SO MEDICAL PHYSICS
LA English
DT Article
DE AMD; choroidal neovascularization; CNV; Sr-90/Y-90; brachytherapy;
   calibration
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY;
   RADIATION-THERAPY; RADIOTHERAPY; SECONDARY; PHOTOCOAGULATION
AB Purpose: The purpose of this study is to perform an extensive investigation of an approximately 2.5 mm long Sr-90/Y-90 source designed for treating wet age-related macular degeneration.
   Methods: As part of this investigation, a NIST-traceable absorbed dose to water calibration technique was established, and a source deployment verification test was developed. The influence of treatment cannula construction tolerance on the measurements as well as the dose delivered to the patient was investigated using the Monte Carlo code MCNP5. Variation between production cannulae was quantified experimentally using a well-type ionization chamber, and additional measurements along with Monte Carlo calculations of the collimating insert used for source deployment verification were performed to validate the model.
   Results: Maximum variation in the integrated target dose was seen when the source was shifted laterally within the treatment cannula. For the well chamber measurements, the observed standard deviation in ionization current for a single source placed in different reference cannulae was +/- 0.3%, with a maximum observed range of less than +/- 0.5%. Clinical cannulae in the collimating insert showed an average of 17.8% +/- 0.4% of the reference signal when sources were fully deployed compared to 18.5% predicted by Monte Carlo calculations. This discrepancy has been attributed primarily to construction of the collimator since the collimation gap was observed to be approximately 0.025-0.075 mm smaller than specified. Construction tolerance of the well chamber insert as well as position tolerance of the cannula tip were both investigated, and their influence on the predicted signal was quantified. Additional measurements along with Monte Carlo based calculations of the collimating insert with polyethylene spacers added to the setup were performed to validate the Monte Carlo model. The shimmed Monte Carlo and measured data agree to within 1%, which is a magnitude difference of approximately 0.1% of the reference signal.
   Conclusions: This investigation confirms that the signal for an acceptably deployed source in the collimating insert is between 17.5% and 21.5% of the reference signal, as calculated using Monte Carlo models. Clinical cannulae for which the source deployment verification measurement falls outside the acceptable range should not be used to treat patients. (C) 2009 American Association of Physicists in Medicine. [DOI: 10.1118/1.3213515]
C1 [Holmes, Shannon M.; Micka, John A.; DeWerd, Larry A.] Univ Wisconsin, Med Radiat Res Ctr, Madison, WI 53705 USA.
C3 University of Wisconsin System; University of Wisconsin Madison
RP Holmes, SM (通讯作者)，Univ Wisconsin, Med Radiat Res Ctr, Madison, WI 53705 USA.
EM shannon.m.holmes@gmail.com
FU NeoVista, Inc.
FX The authors would like to thank NeoVista, Inc., for partially funding
   this investigation. They also thank Chris Bonde and others at Standard
   Imaging, Inc., for their much appreciated assistance and input,
   especially with regard to the position check insert and the well chamber
   geometry. Thanks are also due to UWRCL and UWADCL customers, whose
   calibrations help support ongoing research at the UW-MRRC.
CR Avila MP, 2009, RETINA-J RET VIT DIS, V29, P157, DOI 10.1097/IAE.0b013e3181985915
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Chan WM, 2006, BRIT J OPHTHALMOL, V90, P337, DOI 10.1136/bjo.2005.081299
   DEWERD LA, 1995, MED PHYS, V22, P435, DOI 10.1118/1.597469
   Finger PT, 1999, AM J OPHTHALMOL, V127, P170, DOI 10.1016/S0002-9394(98)00389-4
   International Commission on Radiation Units and Measurements, 1997, 56 ICRU
   Jaakkola A, 2005, OPHTHALMOLOGY, V112, P567, DOI 10.1016/j.ophtha.2004.11.029
   Lee C, 2008, MED PHYS, V35, P5151, DOI 10.1118/1.2990780
   Marcus DM, 2004, BRIT J OPHTHALMOL, V88, P114, DOI 10.1136/bjo.88.1.114
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   Shiraga F, 1998, OPHTHALMOLOGY, V105, P662, DOI 10.1016/S0161-6420(98)94021-0
   Sivagnanavel V, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004004.PUB2
   Spaide RF, 1998, OPHTHALMOLOGY, V105, P24, DOI 10.1016/S0161-6420(98)90980-0
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   White M.C, 2003, LAUR031019 LOS AL NA
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 18
TC 7
Z9 7
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0094-2405
EI 2473-4209
J9 MED PHYS
JI Med. Phys.
PD OCT
PY 2009
VL 36
IS 10
BP 4370
EP 4378
DI 10.1118/1.3213515
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA 499SO
UT WOS:000270246000006
PM 19928067
DA 2022-11-30
ER

PT J
AU Seddon, JM
   George, S
   Rosner, B
   Rifai, N
AF Seddon, JM
   George, S
   Rosner, B
   Rifai, N
TI Progression of age-related macular degeneration - Prospective assessment
   of c-reactive protein, interleukin 6, and other cardiovascular
   biomarkers
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID CORONARY-HEART-DISEASE; NECROSIS-FACTOR-ALPHA; RISK-FACTORS;
   DIETARY-FAT; ADHESION MOLECULES; ALZHEIMERS-DISEASE; DRUSEN;
   ATHEROSCLEROSIS; ASSOCIATION; LIPOPROTEIN
AB Background: Age-related macular degeneration (AMD) and cardiovascular disease share common risk factors. Inflammatory biomarkers, including C-reactive protein (CRP), interleukin 6 (IL-6), soluble tumor necrosis factor alpha receptor 2, soluble intercellular and vascular adhesion molecules (intercellular adhesion molecule 1 and vascular cell adhesion molecule 1), and lipid biomarkers, including lipoprotein (a) and apolipoprotein B, have all been associated with cardiovascular disease. We previously found an association between AMD and CRP in a cross-sectional analysis, but the prospective relationships between AMD, CRP, and the other cardiovascular disease markers are unknown.
   Objective: To test the hypothesis that baseline cardiovascular disease biomarkers are associated with subsequent increased risk for progression of AMD.
   Design, Setting, and Participants: This prospective cohort study involved 251 participants aged 60 years and older who had some sign of nonexudative AMD and visual acuity of 20/200 or better in at least one eye at baseline. The AMD status was assessed by standardized grading of fundus photographs, and stored fasting blood specimens obtained at baseline were analyzed for levels of the various biomarkers. The average follow-up time was 4.6 years.
   Main Outcome Measures: Relationship between biomarkers and incidence rates of progression of AMD.
   Results: Comparing the highest quartile with the lowest quartile, CRP was associated with progression of AMD, with a multivariate adjusted relative risk (RR) of 2.10 (95% confidence interval [CI], 1.06-4.18; P for trend, .046) controlling for body mass index, smoking, and other cardiovascular variables and a multivariate adjusted RR of 2.02 (95% CI, 1.00-4.04; P for trend, .06) controlling additionally for antioxidant nutrients. Interleukin 6 was also related to progression of AMD, with a multivariate adjusted RR of 1.81 (95% CI, 0.97-3.36; P for trend, .03). Comparing the highest quartile with the lowest quartile, the effect estimates for vascular cell adhesion molecule 1 (multivariate adjusted RR, 1.94) and apolipoprotein B (adjusted RR, 1.39) were in the positive direction but were not statistically significant (P for trend, .08 and .24, respectively). The CRP and IL-6 levels were both significantly related to higher body mass index and current smoking.
   Conclusions: Higher levels of the systemic inflammatory markers CRP and IL-6 are independently associated with progression of AMD.
C1 Massachusetts Eye & Ear Infirm, Epidemiol Unit, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Childrens Hosp, Dept Ophthalmol, Cambridge, MA USA.
   Harvard Univ, Sch Med, Childrens Hosp, Dept Med, Cambridge, MA USA.
   Harvard Univ, Sch Med, Childrens Hosp, Dept Lab Med, Cambridge, MA USA.
   Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
C3 Harvard University; Massachusetts Eye & Ear Infirmary; Harvard
   University; Harvard University; Harvard University; Harvard University;
   Harvard T.H. Chan School of Public Health; Harvard University; Harvard
   T.H. Chan School of Public Health
RP Seddon, JM (通讯作者)，Massachusetts Eye & Ear Infirm, Epidemiol Unit, 243 Charles St, Boston, MA 02114 USA.
EM Johanna_Seddon@meei.harvard.edu
FU NATIONAL EYE INSTITUTE [R01EY013834, R01EY013982] Funding Source: NIH
   RePORTER; NEI NIH HHS [EY013982, EY013834] Funding Source: Medline
CR ADELMAN R, 2000, ANN M AM AC OPHTH OC
   AISEN PS, 1994, AM J PSYCHIAT, V151, P1105
   AJANI UA, 1994, INVEST OPHTH VIS SCI, V35, P2725
   Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Blankenberg S, 2001, CIRCULATION, V104, P1336, DOI 10.1161/hc3701.095949
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Carmena R, 2004, CIRCULATION, V109, P2, DOI 10.1161/01.CIR.0000131511.50734.44
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   De Simone M, 2003, J ENDOCRINOL INVEST, V26, P414, DOI 10.1007/BF03345196
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hall Nigel F, 2002, Expert Opin Pharmacother, V3, P803
   Hwang SJ, 1997, CIRCULATION, V96, P4219
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2004, AM J OPHTHALMOL, V137, P747, DOI 10.1016/j.ajo.2004.01.037
   Kuller LH, 1996, AM J EPIDEMIOL, V144, P537, DOI 10.1093/oxfordjournals.aje.a008963
   Lindsberg PJ, 2003, STROKE, V34, P2518, DOI 10.1161/01.STR.0000089015.51603.CC
   Marcovina SM, 2000, CLIN CHEM, V46, P1956
   McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425
   Morrow DA, 1998, J AM COLL CARDIOL, V31, P1460, DOI 10.1016/S0735-1097(98)00136-3
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nakashima Y, 1998, ARTERIOSCL THROM VAS, V18, P842, DOI 10.1161/01.ATV.18.5.842
   *NAT ADV EYE COUNC, 1999, NIH PUBL, V1
   Pavan PR, 1996, OPHTHALMOLOGY, V103, P586, DOI 10.1016/S0161-6420(96)30649-0
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Porsch-Oezcueruemez M, 1999, J AM COLL CARDIOL, V34, P1995, DOI 10.1016/S0735-1097(99)00473-8
   Pradhan AD, 2002, CIRCULATION, V106, P820, DOI 10.1161/01.CIR.0000025636.03561.EE
   Ridker PM, 2000, CIRCULATION, V101, P2149, DOI 10.1161/01.CIR.101.18.2149
   Ridker PM, 2000, CIRCULATION, V101, P1767, DOI 10.1161/01.CIR.101.15.1767
   Rifai N, 1999, CLIN CHEM, V45, P1967
   Seddon J. M., 1997, Investigative Ophthalmology and Visual Science, V38, pS676
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   TorreAmione G, 1996, CIRCULATION, V93, P704, DOI 10.1161/01.CIR.93.4.704
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Williams K, 2003, CIRCULATION, V108, P2312, DOI 10.1161/01.CIR.0000097113.11419.9E
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 51
TC 264
Z9 283
U1 0
U2 12
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUN
PY 2005
VL 123
IS 6
BP 774
EP 782
DI 10.1001/archopht.123.6.774
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 933LH
UT WOS:000229629400005
PM 15955978
OA Bronze
DA 2022-11-30
ER

PT J
AU Kimura, S
   Morizane, Y
   Toshima, S
   Hosogi, M
   Kumase, F
   Hosokawa, M
   Shiode, Y
   Fujiwara, A
   Shiraga, F
AF Kimura, Shuhei
   Morizane, Yuki
   Toshima, Shinji
   Hosogi, Mika
   Kumase, Fumiaki
   Hosokawa, Mio
   Shiode, Yusuke
   Fujiwara, Atsushi
   Shiraga, Fumio
TI Efficacy of vitrectomy and inner limiting membrane peeling in
   age-related macular degeneration resistant to anti-vascular endothelial
   growth factor therapy, with vitreomacular traction or epiretinal
   membrane
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Anti-vascular endothelial growth
   factor; Epiretinal membrane; Vitreomacular traction
ID RANIBIZUMAB; ADHESION; EDEMA
AB We assessed the efficacy of vitrectomy and inner limiting membrane (ILM) peeling, followed by anti-vascular endothelial growth factor (VEGF) therapy, anti-VEGF-resistant age-related macular degeneration (AMD) due to vitreomacular traction (VMT) or epiretinal membrane (ERM).
   We identified six patients with anti-VEGF-resistant AMD due to VMT or ERM amongst a total of 588 patients with AMD (821 eyes) referred to Okayama University Hospital between February 2012 and May 2014. These patients underwent vitrectomy to release the VMT (4 cases) or remove the ERM (2 cases), along with ILM peeling. The regimen used for intravitreal injections of anti-VEGF reagents after surgery was based on the severity of exudative changes in each patient. Preoperative and postoperative best-corrected visual acuity (BCVA) and central retinal thickness (CRT) measurements were compared.
   After vitrectomy and ILM peeling, all six patients responded to anti-VEGF therapy, which was then able to maintain dry retinas. Mean BCVA did not improve significantly (0.49 +/- 0.28 before vs. 0.43 +/- 0.38 after surgery, P = 0.538). However, mean CR was significantly decreased after surgery, from 423 +/- 83.5 mu m to 257 +/- 75.8 mu m (P = 0.0078).
   Vitrectomy and ILM peeling followed by anti-VEGF therapy may be a useful therapeutic option for anti-VEGF-resistant AMD with VMT or ERM.
C1 [Kimura, Shuhei; Morizane, Yuki; Toshima, Shinji; Hosogi, Mika; Kumase, Fumiaki; Hosokawa, Mio; Shiode, Yusuke; Fujiwara, Atsushi; Shiraga, Fumio] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Ophthalmol, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008558, Japan.
C3 Okayama University
RP Morizane, Y (通讯作者)，Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Ophthalmol, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008558, Japan.
EM moriza-y@okayama-u.ac.jp
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Baba T, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/372589
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Gandorfer A, 1999, RETINA, V20, P126
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Navarrete-Sanchis J, 2015, GRAEF ARCH CLIN EXP, V253, P713, DOI 10.1007/s00417-014-2745-9
   NEGI A, 1987, INVEST OPHTH VIS SCI, V28, P2099
   Park DW, 2003, OPHTHALMOLOGY, V110, P62, DOI 10.1016/S0161-6420(02)01440-9
   Roller AB, 2010, OPHTHALMOLOGY, V117, P1381, DOI 10.1016/j.ophtha.2009.11.007
   Sakamoto T, 2010, RETINA-J RET VIT DIS, V30, P856, DOI 10.1097/IAE.0b013e3181c969cb
   Schulze S, 2008, ACTA OPHTHALMOL, V86, P470, DOI 10.1111/j.1755-3768.2008.01210.x
   Stefansson E, 2009, GRAEF ARCH CLIN EXP, V247, P147, DOI 10.1007/s00417-008-0980-7
   Tachi N, 1996, AM J OPHTHALMOL, V122, P258, DOI 10.1016/S0002-9394(14)72018-5
   Tadayoni R, 2012, BRIT J OPHTHALMOL, V96, P1513, DOI 10.1136/bjophthalmol-2012-302035
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 20
TC 9
Z9 9
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2016
VL 254
IS 9
BP 1731
EP 1736
DI 10.1007/s00417-016-3314-1
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DU2HQ
UT WOS:000382032300008
PM 26951250
DA 2022-11-30
ER

PT J
AU Hageman, GS
   Hancox, LS
   Taiber, AJ
   Gehrs, KM
   Anderson, DH
   Johnson, LV
   Radeke, MJ
   Kavanagh, D
   Richards, A
   Atkinson, J
   Meri, S
   Bergeron, J
   Zernant, J
   Merriam, J
   Gold, B
   Allikmets, R
   Dean, M
AF Hageman, Gregory S.
   Hancox, Lisa S.
   Taiber, Andrew J.
   Gehrs, Karen M.
   Anderson, Don H.
   Johnson, Lincoln V.
   Radeke, Monte J.
   Kavanagh, David
   Richards, Anna
   Atkinson, John
   Meri, Seppo
   Bergeron, Julie
   Zernant, Jana
   Merriam, Joanna
   Gold, Bert
   Allikmets, Rando
   Dean, Michael
CA AMD Clinical Study Grp
TI Extended haplotypes in the complement factor H (CFH) and CFH-related
   (CFHR) family of genes protect against age-related macular degeneration:
   Characterization, ethnic distribution and evolutionary implications
SO ANNALS OF MEDICINE
LA English
DT Article
DE age-related macular degeneration; alternative pathway; complement;
   deletion; evolution; factor H; factor H-related; haplotype; vision
ID STRONG ASSOCIATION; Y402H VARIANT; POLYMORPHISM; RISK; MUTATIONS;
   MACULOPATHY; DELETION; DISEASE; DRUSEN; FHL-1/RECONECTIN
AB Background. Variants in the complement factor H gene (CFH) are associated with age-related macular degeneration (AMD). CFH and five CFH-related genes (CFHR1-5) lie within the regulators of complement activation (RCA) locus on chromosome 1q32.
   Aims and Methods. In this study, the structural and evolutionary relationships between these genes and AMD was refined using a combined genetic, molecular and immunohistochemical approach.
   Results. We identify and characterize a large, common deletion that encompasses both the CFHR1 and CFHR3 genes. CFHR1, an abundant serum protein, is absent in subjects homozygous for the deletion. Genotyping analyses of AMD cases and controls from two cohorts demonstrates that deletion homozygotes comprise 1.1% of cases and 5.7% of the controls (chi-square = 32.8; P = 1.6 E-09). CFHR1 and CFHR3 transcripts are abundant in liver, but undetectable in the ocular retinal pigmented epithelium/choroid complex. AMD-associated CFH/CFHR1/CFHR3 haplotypes are widespread in human populations.
   Conclusion. The absence of CFHR1 and/or CFHR3 may account for the protective effects conferred by some CFH haplotypes. Moreover, the high frequencies of the 402H allele and the delCFHR1/CFHR3 alleles in African populations suggest an ancient origin for these alleles. The considerable diversity accumulated at this locus may be due to selection, which is consistent with an important role for the CFHR genes in innate immunity.
C1 Univ Iowa, Dept Ophthalmol & Visual Sci, Cell Biol & Funct Genom Lab, Iowa City, IA 52240 USA.
   NCI, Lab Genom Divers, Frederick, MD 21701 USA.
   NCI, SAIC Frederick, Frederick, MD 21701 USA.
   Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA.
   Washington Univ, Sch Med, Dept Med, Div Rheumatol, St Louis, MO 63130 USA.
   Univ Helsinki, Haartman Inst, Dept Bacteriol & Immunol, FIN-00014 Helsinki, Finland.
   Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
   Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10027 USA.
C3 University of Iowa; National Institutes of Health (NIH) - USA; NIH
   National Cancer Institute (NCI); National Institutes of Health (NIH) -
   USA; NIH National Cancer Institute (NCI); Science Applications
   International Corporation (SAIC); SAIC-Frederick; University of
   California System; University of California Santa Barbara; Washington
   University (WUSTL); University of Helsinki; Columbia University;
   Columbia University
RP Hageman, GS (通讯作者)，Univ Iowa, Dept Ophthalmol & Visual Sci, Cell Biol & Funct Genom Lab, 11190E PFP,200 Hawkins Dr, Iowa City, IA 52240 USA.
EM dean@ncifcrf.gov
RI Dean, Michael C/G-8172-2012; Allikmets, Rando/ABD-4533-2021; Kavanagh,
   David/E-8498-2011; Mohammed, Imran/J-8271-2012; Richards,
   Anna/E-8337-2013; Dean, Michael/R-7501-2019
OI Dean, Michael C/0000-0003-2234-0631; Kavanagh,
   David/0000-0003-4718-0072; Mohammed, Imran/0000-0002-8412-0768; Meri,
   Seppo/0000-0001-9142-501X; Hancox, Lisa/0000-0003-1940-2619; Gehrs,
   Karen/0000-0003-4510-9678
FU Intramural NIH HHS [Z01 BC005652-15] Funding Source: Medline; NCI NIH
   HHS [N01-CO-12400, N01CO12400] Funding Source: Medline; NEI NIH HHS [R01
   EY011515-07S2, R01 EY011527, R01 EY11521, R01 EY011521, R01 EY013435-05,
   R24 EY017404, R01 EY011515, R01 EY11515, R01 EY013435, R01 EY011527-07]
   Funding Source: Medline
CR Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078
   BANDELT HJ, 1995, GENETICS, V141, P743
   Bandelt HJ, 1999, MOL BIOL EVOL, V16, P37, DOI 10.1093/oxfordjournals.molbev.a026036
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blackmore TK, 1998, INFECT IMMUN, V66, P1427, DOI 10.1128/IAI.66.4.1427-1431.1998
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Cann HM, 2002, SCIENCE, V296, P261
   Conrad DF, 2006, NAT GENET, V38, P75, DOI 10.1038/ng1697
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FEIFEL E, 1992, IMMUNOGENETICS, V36, P104, DOI 10.1007/BF00215286
   Forster P, 2001, MOL BIOL EVOL, V18, P1864, DOI 10.1093/oxfordjournals.molbev.a003728
   Friese MA, 1999, MOL IMMUNOL, V36, P809, DOI 10.1016/S0161-5890(99)00101-7
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heinen Stefan, 2006, Hum Mutat, V27, P292, DOI 10.1002/humu.9408
   Hellwage J, 1999, FEBS LETT, V462, P345, DOI 10.1016/S0014-5793(99)01554-9
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jokiranta TS, 2006, EMBO J, V25, P1784, DOI 10.1038/sj.emboj.7601052
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   McCarroll SA, 2006, NAT GENET, V38, P86, DOI 10.1038/ng1696
   Okamoto H, 2006, MOL VIS, V12, P156
   Oppermann M, 2006, CLIN EXP IMMUNOL, V144, P342, DOI 10.1111/j.1365-2249.2006.03071.x
   Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   Richards A, 2001, AM J HUM GENET, V68, P485, DOI 10.1086/318203
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Saunders RE, 2006, HUM MUTAT, V27, P21, DOI 10.1002/humu.20268
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seitsonen S, 2006, MOL VIS, V12, P796
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Sivaprasad S, 2006, EYE, V20, P867, DOI 10.1038/sj.eye.6702176
   Souied EH, 2005, MOL VIS, V11, P1135
   Stephens M, 2005, AM J HUM GENET, V76, P449, DOI 10.1086/428594
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Wiggs JL, 2006, ARCH OPHTHALMOL-CHIC, V124, P577, DOI 10.1001/archopht.124.4.577
   Woo THS, 1999, J MICROBIOL METH, V35, P23, DOI 10.1016/S0167-7012(98)00095-5
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zipfel PF, 2002, BIOCHEM SOC T, V30, P971, DOI 10.1042/bst0300971
   Zipfel PF, 1999, IMMUNOL TODAY, V20, P135, DOI 10.1016/S0167-5699(98)01432-7
NR 60
TC 198
Z9 206
U1 0
U2 16
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0785-3890
EI 1365-2060
J9 ANN MED
JI Ann. Med.
PY 2006
VL 38
IS 8
BP 592
EP 604
DI 10.1080/07853890601097030
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 125GY
UT WOS:000243431600006
PM 17438673
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Nguyen, V
   Daien, V
   Guymer, R
   Young, S
   Hunyor, A
   Fraser-Bell, S
   Hunt, A
   Gillies, MC
   Barthelmes, D
AF Vuong Nguyen
   Daien, Vincent
   Guymer, Robyn
   Young, Stephanie
   Hunyor, Alex
   Fraser-Bell, Samantha
   Hunt, Adrian
   Gillies, Mark C.
   Barthelmes, Daniel
CA Fight Retinal Blindness Study Grp
TI Projection of Long-Term Visual Acuity Outcomes Based on Initial
   Treatment Response in Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID SUBGROUP ANALYSIS; RANIBIZUMAB; THERAPY; REGIMENS; ANCHOR; MARINA
AB Purpose: To explore various methods for assessing the early response to vascular endothelial growth factor (VEGF) inhibitors for neovascular age-related macular degeneration and investigate their association with 3-year visual acuity (VA) outcomes.
   Design: Database study, prospectively designed.
   Participants: Treatment-naive eyes in the Fight Retinal Blindness! registry that commenced anti-VEGF therapy between January 1, 2007, and March 1, 2014, that received 3 anti-VEGF injections within the first 3 months.
   Methods: The early response was defined as occurring up until the fourth injection. Various early response metrics were explored: (1) achieving good VA (>= 70 letters; Snellen equivalent, 20/ 40), (2) absolute change in VA from baseline, (3) time to first grading of the choroidal neovascular lesion as inactive, and (4) maximum rate of VA change between successive injections.
   Main Outcome Measures: Proportion of eyes achieving >= 70 letters 3 years.
   Results: This study included 2051 treatment-naive eyes from 1828 patients. Achieving good vision at 3 years was associated significantly with (1) having good vision by the fourth injection (VA >= 70 vs. VA <70 letters: odds ratio [OR], 9.8; 95% confidence interval [CI], 6.5e14.7), (2) small (1-5 letters) or large (> 5 letters) early VA gains (vs. early VA loss: OR, 1.8; 95% CI, 1.2-2.6; P = 0.002; and OR, 1.8; 95% CI, 1.3-2.5; P < 0.001), (3) fewer injections until first grading of lesion inactivity (<= 3 vs. > 3 injections: OR, 1.6; 95% CI, 1.2-2.1; P < 0.001), (4) gradual change (between -4 and 4 letters) or rapid gains (>= 5 letters) between successive injections (vs. rapid loss: OR, 1.7; 95% CI, 1.1-2.6; P = 0.015; and OR, 1.6; 95% CI, 1.1-2.3; P = 0.018). Eyes that achieved small or large early gains had similar vision at 3 years (65.0 and 64.7 letters, respectively) and had better vision than eyes with early VA loss (57.2 letters).
   Conclusions: Attainment of good vision by the fourth injection was associated strongly with 3-year visual outcomes, whereas other early response parameters showed a moderate association. The early response during the initial 3 monthly injections can be a useful guide for subsequent treatment decisions. (C) 2018 by the American Academy of Ophthalmology
C1 [Vuong Nguyen; Daien, Vincent; Hunyor, Alex; Fraser-Bell, Samantha; Gillies, Mark C.; Barthelmes, Daniel] Univ Sydney, Save Sight Inst, Sydney Med Sch, 8 Macquarie St, Sydney, NSW 2000, Australia.
   [Daien, Vincent] Gui De Chauliac Hosp, Dept Ophthalmol, Montpellier, France.
   [Daien, Vincent] INSERM, U1061, Montpellier, France.
   [Guymer, Robyn] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia.
   [Young, Stephanie] Gladesville Retina, Gladesville, Australia.
   [Hunyor, Alex; Fraser-Bell, Samantha] Retina Associates, Chatswood, NSW, Australia.
   [Hunyor, Alex; Fraser-Bell, Samantha; Gillies, Mark C.] Sydney Eye Hosp, Sydney, NSW, Australia.
   [Hunt, Adrian] Westmead Hosp, Dept Ophthalmol, Westmead, NSW, Australia.
   [Barthelmes, Daniel] Univ Zurich, Univ Zurich Hosp, Dept Ophthalmol, Zurich, Switzerland.
C3 University of Sydney; Universite de Montpellier; CHU de Montpellier;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Montpellier; Centre for Eye Research Australia; Royal
   Victorian Eye & Ear Hospital; University of Melbourne; University of
   Sydney; University of Zurich; University Zurich Hospital
RP Nguyen, V (通讯作者)，Univ Sydney, Save Sight Inst, Sydney Med Sch, 8 Macquarie St, Sydney, NSW 2000, Australia.
EM phuc.nguyen@sydney.edu.au
RI Hunyor, Alex/AAT-8205-2021; Fraser-Bell, Samantha/ABE-8574-2020; DAIEN,
   Vincent/Z-5516-2019
OI Hunyor, Alex/0000-0002-8182-6167; Fraser-Bell,
   Samantha/0000-0001-5646-9359; DAIEN, Vincent/0000-0001-5675-0861;
   Nguyen, Vuong/0000-0001-9070-9803; Gillies, mark/0000-0001-8580-0274;
   Hunt, Adrian/0000-0002-6261-4679
FU Royal Australian New Zealand College of Ophthalmologists Eye Foundation;
   National Health and Medical Research Council (NHMRC), Australia; Macular
   Disease Foundation, Australia; Sydney Medical Foundation; Walter and
   Gertrud Siegenthaler Foundation, Zurich, Switzerland; Swiss National
   Foundation; French Society of Ophthalmology
FX Supported by the Royal Australian New Zealand College of
   Ophthalmologists Eye Foundation (2007e2009); the National Health and
   Medical Research Council (NHMRC), Australia (2010e2012; M.C.G., R.G.);
   the Macular Disease Foundation, Australia (M.C.G.); the Sydney Medical
   Foundation; the Walter and Gertrud Siegenthaler Foundation, Zurich,
   Switzerland (D.B.); the Swiss National Foundation (D.B.); and the French
   Society of Ophthalmology (V.D.). These supporting organizations had no
   role in the design or conduct of the research.
CR [Anonymous], 2016, R LANGUAGE ENV STAT
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Barthelmes D, 2016, BRIT J OPHTHALMOL, V100, P1640, DOI 10.1136/bjophthalmol-2015-308090
   Barthelmes D, 2015, BRIT J OPHTHALMOL, V99, P359, DOI 10.1136/bjophthalmol-2014-305514
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Essex RW, 2016, OPHTHALMOLOGY, V123, P2393, DOI 10.1016/j.ophtha.2016.07.012
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Gillies MC, 2017, OPHTHALMOLOGY, V124, pE31, DOI 10.1016/j.ophtha.2016.05.054
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Hagstrom SA, 2014, JAMA OPHTHALMOL, V132, P521, DOI 10.1001/jamaophthalmol.2014.109
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Hastie T., 1986, STAT SCI, V1, P297, DOI DOI 10.1214/SS/1177013604
   Hastie T. J., 2017, STAT MODELS S, P249
   Johnston RL, 2017, ADV THER, V34, P703, DOI 10.1007/s12325-017-0483-1
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mehta H, 2018, BRIT J OPHTHALMOL, V102, P479, DOI 10.1136/bjophthalmol-2017-310737
   Nakagawa S, 2013, METHODS ECOL EVOL, V4, P133, DOI 10.1111/j.2041-210x.2012.00261.x
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2018, OPHTHALMOL RETINA, V2, P24, DOI 10.1016/j.oret.2017.03.015
   von Elm E, 2007, PREV MED, V45, P247, DOI 10.1016/j.ypmed.2007.08.012
   Ying GS, 2015, OPHTHALMOLOGY, V122, P2523, DOI 10.1016/j.ophtha.2015.08.015
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 32
TC 17
Z9 18
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2019
VL 126
IS 1
BP 64
EP 74
DI 10.1016/j.ophtha.2018.08.023
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HE6PG
UT WOS:000453531300021
PM 30149035
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Garweg, JG
   Traine, PG
   Garweg, RA
   Wons, J
   Gerhardt, C
   Pfister, IB
AF Garweg, Justus G.
   Traine, Peter G.
   Garweg, Richard A.
   Wons, Juliana
   Gerhardt, Christin
   Pfister, Isabel B.
TI Continued anti-VEGF treatment does not prevent recurrences in eyes with
   stable neovascular age-related macular degeneration using a
   treat-and-extend regimen: a retrospective case series
SO EYE
LA English
DT Article
ID INTRAVITREAL AFLIBERCEPT; SPECTRAL-DOMAIN; VISUAL-ACUITY; RANIBIZUMAB;
   OUTCOMES; THERAPY; SAFETY
AB Background The continuation of anti-vascular endothelial growth factor (anti-VEGF) treatment after achieving stability in patients with neovascular age-related macular degeneration has generally been advocated. In our own patients, we thought to assess whether continued anti-VEGF treatment is capable of preventing recurrences. Methods In this retrospective observational case series, patients with stable disease either opted to continue treatment every 12-14 weeks (Group 1) or stopped treatment with subsequent follow-up visits every 8-12 weeks (Group 2). Results Of the 103 eyes of 103 patients achieving stability, 49 eyes continued treatment (Group 1), whereas treatment was stopped in 54 eyes undergoing regular follow-up (Group 2). Recurrent disease was observed in 21 (42.9%) and 33 (61.1%) cases in Group 1 and Group 2, respectively (p = 0.08). Time between achieving stable disease and recurrence was comparable between Group 1 and Group 2 (11.1 +/- 8.2 months vs. 9.2 +/- 6.7 months; p = 0.43). The number of visits between achieving stability and disease recurrence was similar, but not the number of injections (3.5 +/- 2.0 vs. 0.2 +/- 0.4; p < 0.001). Conclusions Continuing anti-VEGF therapy after achieving functional and morphological stability every 12-14 weeks does not prevent recurrences. Patients deserve to be informed of a potential lifetime risk of recurrences, even under continued therapy.
C1 [Garweg, Justus G.; Traine, Peter G.; Wons, Juliana; Gerhardt, Christin; Pfister, Isabel B.] Swiss Eye Inst, Rotkreuz, Switzerland.
   [Garweg, Justus G.; Traine, Peter G.; Wons, Juliana; Gerhardt, Christin; Pfister, Isabel B.] Berner Augenklin Lindenhofspital, Bern, Switzerland.
   [Garweg, Justus G.] Univ Bern, Bern Univ Hosp, Inselspital, Dept Ophthalmol, Bern, Switzerland.
   [Garweg, Justus G.; Garweg, Richard A.; Gerhardt, Christin] Univ Bern, Bern, Switzerland.
C3 University of Bern; University Hospital of Bern; University of Bern
RP Garweg, JG (通讯作者)，Swiss Eye Inst, Rotkreuz, Switzerland.; Garweg, JG (通讯作者)，Berner Augenklin Lindenhofspital, Bern, Switzerland.; Garweg, JG (通讯作者)，Univ Bern, Bern Univ Hosp, Inselspital, Dept Ophthalmol, Bern, Switzerland.; Garweg, JG (通讯作者)，Univ Bern, Bern, Switzerland.
EM Justus.garweg@swiss-eye-institute.com
FU Universitat Bern
FX Open Access funding provided by Universitat Bern.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Arendt P, 2019, RETINA-J RET VIT DIS, V39, P27, DOI 10.1097/IAE.0000000000001923
   Ashraf M, 2018, ACTA OPHTHALMOL, V96, P120, DOI 10.1111/aos.13565
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Charan Jaykaran, 2013, Indian J Psychol Med, V35, P121, DOI 10.4103/0253-7176.116232
   Nguyen CL, 2019, OPHTHALMOLOGY, V126, P735, DOI 10.1016/j.ophtha.2018.11.036
   Essex RW, 2016, OPHTHALMOLOGY, V123, P2393, DOI 10.1016/j.ophtha.2016.07.012
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Gutierrez MA, 2016, SCI REP-UK, V6, DOI 10.1038/srep29025
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Jones MK, 2017, PROG RETIN EYE RES, V58, P1, DOI 10.1016/j.preteyeres.2017.01.004
   Kaiser PK, 2017, OPHTHALMOL RETINA, V1, P304, DOI 10.1016/j.oret.2017.01.004
   Khurana RN, 2019, OPHTHALMOL RETINA, V3, P621, DOI 10.1016/j.oret.2019.04.013
   Kroeger H, 2019, FEBS J, V286, P399, DOI 10.1111/febs.14522
   Lowry EA, 2018, OPHTHALMOL RETINA, V2, P531, DOI 10.1016/j.oret.2017.10.002
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Nguyen V, 2019, OPHTHALMOL RETINA, V3, P623, DOI 10.1016/j.oret.2019.05.013
   Richard G, 2015, OPHTHALMOLOGY, V122, P2497, DOI 10.1016/j.ophtha.2015.08.014
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Nguyen V, 2019, OPHTHALMOLOGY, V126, P64, DOI 10.1016/j.ophtha.2018.08.023
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Yang J, 2019, AM J OPHTHALMOL, V208, P1, DOI 10.1016/j.ajo.2019.06.017
   Zhang QQ, 2017, INVEST OPHTH VIS SCI, V58, P1506, DOI 10.1167/iovs.16-20977
NR 30
TC 1
Z9 1
U1 0
U2 1
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD APR
PY 2022
VL 36
IS 4
BP 862
EP 868
DI 10.1038/s41433-021-01562-6
EA MAY 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZZ4YG
UT WOS:000646545100002
PM 33941877
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Wang, JJ
   Jakobsen, KB
   Smith, W
   Mitchell, P
AF Wang, JJ
   Jakobsen, KB
   Smith, W
   Mitchell, P
TI Refractive status and the 5-year incidence of age-related maculopathy:
   the Blue Mountains Eye Study
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related maculopathy; Blue Mountains Eye Study; incidence;
   population-based cohort; refractive error
ID MACULAR DEGENERATION; RISK-FACTORS; GRADING SYSTEM; PROGRESSION;
   AUSTRALIA
AB This study aimed to assess the longitudinal association between refraction and 5-year incident age-related maculopathy (ARM) in the Blue Mountains Eye Study population. The dataset included 3654 participants aged 49+ (82.4% of eligible) examined at baseline (1992-1994), and 2335 (75.1% of survivors) examined after 5 years. Retinal photograph grading followed the International ARM Classification. Incident ARM was assessed using a side-by-side comparison. Refraction was performed using autorefraction with subjective refinement. Spherical equivalent was calculated from spherical plus half the cylindrical power. After adjusting for age, sex and smoking, no association was found between baseline spherical equivalent and 5-year incident late or early ARM. Hyperopic right eyes had slightly higher incident rates for late (0.8%) and early (6.3%) ARM, compared with myopic (0.4% and 4.1%, respectively) or emmetropic (0.5% and 5.0%, respectively) right eyes. After multivariable adjustment, this study found no significant association between hyperopia and the 5-year incidence of late or early ARM. Left eyes or the combined data from both eyes had similar findings.
C1 Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Westmead Millennium Inst,Westmead Hosp, Sydney, NSW 2000, Australia.
   Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NSW, Australia.
C3 University of Sydney; Westmead Institute for Medical Research;
   University of Newcastle
RP Wang, JJ (通讯作者)，Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Westmead Millennium Inst,Westmead Hosp, C24, Sydney, NSW 2000, Australia.
EM jiejin_wang@wmi.usyd.edu.au
RI Mitchell, Paul/P-1498-2014; Wang, Jie Jin/P-1499-2014; Jakobsen,
   Kirsten/E-5645-2012; wang, jie/GRS-0942-2022
OI Wang, Jie Jin/0000-0001-9491-4898; 
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   HEIJL A, 1981, ARCH OPHTHALMOL-CHIC, V99, P832
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   KATZ J, 1994, INVEST OPHTH VIS SCI, V35, P2461
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   MITCHELL P, 2002, OPHTHALMOLOGY, V109, P1588
   SANDBERG MA, 1993, OPHTHALMOLOGY, V100, P1009
   Wang JJ, 1998, INVEST OPHTH VIS SCI, V39, P2167
   Wong TY, 2002, INVEST OPHTH VIS SCI, V43, P2869
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   ZEGER SL, 1989, BIOMETRICS, V45, P347
NR 20
TC 16
Z9 17
U1 0
U2 2
PU BLACKWELL PUBLISHING ASIA
PI CARLTON
PA 54 UNIVERSITY ST, P O BOX 378, CARLTON, VICTORIA 3053, AUSTRALIA
SN 1442-6404
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JUN
PY 2004
VL 32
IS 3
BP 255
EP 258
DI 10.1111/j.1442-9071.2004.00813.x
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 825GG
UT WOS:000221743400006
PM 15180836
DA 2022-11-30
ER

PT J
AU Adrian, ML
   Schroeder, M
   Westborg, I
AF Adrian, Monica Lovestam
   Schroeder, Marion
   Westborg, Inger
TI What about the fellow eye in treatment of neovascular age-related
   macular degeneration? Analysis of data from the Swedish macula register
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE anti-VEGF; fellow eye; neovascular macular degeneration; Swedish Macula
   Register
ID VISUAL OUTCOMES; RANIBIZUMAB; EXTEND; AMD
AB Purpose To analyse the development of neovascular age-related macular degeneration (nAMD) in the fellow eye in patients initially presenting with unilateral nAMD, using data from the Swedish Macula Register. Methods This observational study included data on treatment-naive patients who initially underwent unilateral treatment for nAMD, and then required bilateral treatment, between 2010 and 2018, according to the Swedish Macula Register (SMR). The data were also stratified according into three time periods (2010-2013; 2014-2016; 2017-2018). Treatment duration, best-corrected visual acuity (BCVA) in the first and second eye, number of injections in the first eye before falling ill in the second, and the time between the last injection in the first eye and the start of treatment of the fellow eye were analysed. Results 5216 out of 28 670 (18%) patients treated for nAMD subsequently required bilateral treatment. The mean age was 77.7 +/- 7.3 years, and 69% were female. The mean duration of treatment of the first eye before nAMD was diagnosed in the fellow eye was 1.58 years, and the mean number of injections in the first eye was 8.9 +/- 8.6. Best-corrected visual acuity, according to the ETDRS chart, was higher in the second eye at the time when treatment started in that eye compared to treatment start in the first eye: 62.8 (14.7) versus 57.6 (15.5); p < 0.001, and was higher in the 66% whose first eye was still undergoing treatment: 63.6 +/- 14.5 versus 61.0 +/- 14.8; p = 0.001. Conclusions The mean duration of treatment of the first eye before treatment started in the fellow eye was 19 months, and treatment of the second eye had started within 2 years in 61% of the patients. Best-corrected visual acuity was higher in the second eye than in the first eye at the start of treatment of that eye and was higher in the second eye at the start of treatment of that eye when the first eye was still being treated.
C1 [Adrian, Monica Lovestam; Schroeder, Marion] Lund Univ, Skane Univ Hosp, Dept Clin Sci Lund, Dept Ophthalmol, Lund, Sweden.
   [Westborg, Inger] Uppsala Univ, Dept Neurosci, Ophthalmol, Uppsala, Sweden.
C3 Lund University; Skane University Hospital; Uppsala University
RP Adrian, ML (通讯作者)，Lund Univ, Dept Ophthalmol, SE-22185 Lund, Sweden.
EM monica.lovestam_adrian@med.lu.se
FU Skane University Hospital (SUS) Research Grants; Foundation for the
   Visually Impaired in the County of Malmohus
FX This study was supported by Sk~ane University Hospital (SUS) Research
   Grants and the Foundation for the Visually Impaired in the County of
   Malm_ohus. We would also like to thank all the ophthalmology clinics in
   Sweden that register data in the Swedish Macula Register enabling
   studies such as this.
CR Adrian ML, 2019, ACTA OPHTHALMOL, V97, P91, DOI 10.1111/aos.13864
   Augsburger M, 2019, GRAEF ARCH CLIN EXP, V257, P1889, DOI 10.1007/s00417-019-04404-0
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Bek T, 2018, GRAEF ARCH CLIN EXP, V256, P2061, DOI 10.1007/s00417-018-4100-z
   Chew JK, 2017, OPHTHALMOLOGICA, V238, P23, DOI 10.1159/000469652
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Fasler K, 2020, BRIT J OPHTHALMOL, V104, P684, DOI 10.1136/bjophthalmol-2019-314446
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Hatz K, 2016, BRIT J OPHTHALMOL, V100, P1341, DOI 10.1136/bjophthalmol-2015-307299
   Joachim N, 2017, BRIT J OPHTHALMOL, V101, P1185, DOI 10.1136/bjophthalmol-2016-309729
   Kvannli L, 2017, ACTA OPHTHALMOL, V95, P678, DOI 10.1111/aos.13356
   Lee AY, 2015, BRIT J OPHTHALMOL, V99, P1045, DOI 10.1136/bjophthalmol-2014-306229
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Qin VL, 2018, RETINA-J RET VIT DIS, V38, P1500, DOI 10.1097/IAE.0000000000001753
   Rasmussen A, 2015, ACTA OPHTHALMOL, V93, P616, DOI 10.1111/aos.12781
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Svenska Makula Registret, 2019, ARSR 2019
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Volkmann I, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01397-x
   Westborg I, 2017, ACTA OPHTHALMOL, V95, P787, DOI 10.1111/aos.13539
   Wolf S, 2016, OPHTHALMOLOGICA, V236, P95, DOI 10.1159/000447725
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong TY, 2020, RETINA-J RET VIT DIS, V40, P599, DOI 10.1097/IAE.0000000000002768
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
NR 27
TC 0
Z9 0
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2022
VL 100
IS 7
BP 769
EP 774
DI 10.1111/aos.15094
EA JAN 2022
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 5E2FF
UT WOS:000745487700001
PM 35064747
DA 2022-11-30
ER

PT J
AU Plyukhova, AA
   Budzinskaya, MV
   Starostin, KM
   Rejdak, R
   Bucolo, C
   Reibaldi, M
   Toro, MD
AF Plyukhova, Anna A.
   Budzinskaya, Maria V.
   Starostin, Kirill M.
   Rejdak, Robert
   Bucolo, Claudio
   Reibaldi, Michele
   Toro, Mario D.
TI Comparative Safety of Bevacizumab, Ranibizumab, and Aflibercept for
   Treatment of Neovascular Age-Related Macular Degeneration (AMD): A
   Systematic Review and Network Meta-Analysis of Direct Comparative
   Studies
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE ranibizumab; bevacizumab; aflibercept; anti-vascular endothelial growth
   factor; neovascular age-related macular degeneration; meta-analysis;
   randomized controlled trials
ID INTRAVITREAL INJECTION; EVENTS
AB Background: Since the efficacy of ranibizumab (RBZ), bevacizumab (BVZ) and aflibercept (AFB) is comparable in neovascular age-related macular degeneration (AMD), we conducted a systematic review and meta-analysis to evaluate the long-term safety profiles of these agents, including ocular safety. Methods: Systematic review identifying randomized controlled trials (RCTs) comparing RBZ, BVZ and AFB directly published before March 2019. Serious ocular adverse events (SOAE) of special interest were endophthalmitis, pseudo-endophthalmitis, retinal pigment epithelium tear and newly identified macular atrophy. Results: Thirteen RCTs selected for meta-analysis (4952 patients, 8723 people-years follow-up): 10 compared RBZ vs. BVZ and three RBZ vs. AFB. There were no significant differences in almost all adverse events (systemic and ocular) between BVZ, RBZ and AFB in up to two years' follow-up. Macular atrophy was reported heterogeneously and not reported as SOAE in most trials. Conclusions: Direct comparison of RBZ, BVZ and AFB safety profiles in the RCT network meta-analytical setting have not revealed a consistent benefit of these three commonly used anti-vascular endothelial growth factor (anti-VEGF) agents in AMD. Network model ranking highlighted potential benefits of RBZ in terms of a systemic safety profile; however, this appears a hypothesis rather than a conclusion. Newly identified macular atrophy is underestimated in RCTs-future real-world data should be focused on SOAE.
C1 [Plyukhova, Anna A.; Budzinskaya, Maria V.] Sci Res Inst Eye Dis, Fed State Budget Sci Res Inst, Moscow 119021, Russia.
   [Starostin, Kirill M.] Sanofi Aventis SA, Med Affairs, Moscow 125009, Russia.
   [Rejdak, Robert; Toro, Mario D.] Med Univ Lublin, Dept Gen Ophthalmol Pediat Serv, PL-20079 Lublin, Poland.
   [Bucolo, Claudio] Univ Catania, Sch Med, Dept Biomed & Biotechnol Sci, I-95123 Catania, Italy.
   [Reibaldi, Michele] Univ Turin, Dept Ophthalmol, I-10126 Turin, Italy.
   [Toro, Mario D.] Wyszynski Univ, Fac Med, Coll Medicum Cardinal Stefan, PL-01815 Warsaw, Poland.
C3 Helmholtz National Medical Research Center of Eye Diseases; Russian
   Academy of Medical Sciences; Research Institute of Eye Diseases; Medical
   University of Lublin; University of Catania; University of Turin
RP Plyukhova, AA (通讯作者)，Sci Res Inst Eye Dis, Fed State Budget Sci Res Inst, Moscow 119021, Russia.; Reibaldi, M (通讯作者)，Univ Turin, Dept Ophthalmol, I-10126 Turin, Italy.
EM anna.plyukhova@gmail.com; m_budzinskaya@mail.ru; kirill_ms@yahoo.com;
   robertrejdak@yahoo.com; bucocla@unict.it; mreibaldi@libero.it;
   toro.mario@email.it
RI Reibaldi, Michele/AAL-1113-2021; Toro, Mario D/N-8051-2018; Toro,
   Mario/AAA-1371-2021; Starostin, Kirill/AAS-3439-2020
OI Bucolo, Claudio/0000-0002-4879-4140; Rejdak, Robert/0000-0003-3321-2723;
   Plyukhova, Anna/0000-0002-7390-759X; Reibaldi,
   Michele/0000-0003-1368-6729; Starostin, Kirill/0000-0001-6488-7980
FU "Foundation to support the development of Ophthalmology", Lublin, Poland
FX The study has been supported by the "Foundation to support the
   development of Ophthalmology", Lublin, Poland. The funders had no role
   in the design of the study; in the collection, analyses, or
   interpretation of data; in the writing of the manuscript, or in the
   decision to publish the results.
CR Andres-Guerrero V, 2017, ADV THER, V34, P378, DOI 10.1007/s12325-016-0461-z
   Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Baudin F, 2018, JAMA OPHTHALMOL, V136, P1352, DOI 10.1001/jamaophthalmol.2018.3939
   Chappelow A.V., 2010, RETINAL PHARMACOTHER, P128
   Christoforidis JB, 2017, INVEST OPHTH VIS SCI, V58, P5636, DOI 10.1167/iovs.17-22431
   Doshi RR, 2012, RETINA-J RET VIT DIS, V32, P473, DOI 10.1097/IAE.0B013E31822C2958
   Enslow R, 2016, OPHTHALMOL EYE DIS, V8, P31, DOI 10.4137/OED.S38863
   Ersoz MG, 2017, SURV OPHTHALMOL, V62, P493, DOI 10.1016/j.survophthal.2017.03.004
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Forooghian F, 2017, CAN J OPHTHALMOL, V52, P616, DOI 10.1016/j.jcjo.2017.04.016
   Friedrich JO, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-5
   Gemenetzi M, 2016, EYE, V31, P1
   Gupta A., 2017, DELHI J OPHTHALMOL, V27, P243, DOI DOI 10.7869/DJ0.258
   Marticorena J, 2012, MEDIAT INFLAMM, V2012, P1
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Platania CBM, 2015, FRONT PHARMACOL, V6, DOI [10.3389/fphar.2015.00248, 10.3389/tphar.7015.00248]
   Providencia J, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9276580
   Rucker G, 2015, BMC MED RES METHODOL, V15, DOI 10.1186/s12874-015-0060-8
   Sarraf David, 2014, Trans Am Ophthalmol Soc, V112, P142
   SCOTT L, 2014, INVEST OPHTH VIS SCI, V55
   Solomon SG, 2014, FRONT NEURAL CIRCUIT, V8, DOI 10.3389/fncir.2014.00096
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Thulliez M, 2014, JAMA OPHTHALMOL, V132, P1317, DOI 10.1001/jamaophthalmol.2014.2333
   van Asten F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197670
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Veroniki AA, 2018, J CLIN EPIDEMIOL, V100, P122, DOI 10.1016/j.jclinepi.2018.02.009
   Virgili G., 2017, COCHRANE DB SYST REV, V22
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang XY, 2014, INT J OPHTHALMOL-CHI, V7, P355, DOI 10.3980/j.issn.2222-3959.2014.02.30
NR 30
TC 35
Z9 36
U1 1
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAY
PY 2020
VL 9
IS 5
AR 1522
DI 10.3390/jcm9051522
PG 14
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA LY0OO
UT WOS:000540223800279
PM 32443612
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Massamba, N
   Dirani, A
   Butel, N
   Fardeau, C
   Bodaghi, B
   Ingram, A
   Lehoang, P
AF Massamba, Nathalie
   Dirani, Ali
   Butel, Nathalie
   Fardeau, Christine
   Bodaghi, Bahram
   Ingram, April
   Lehoang, Phuc
TI Evaluation of outer retinal tubulations in eyes switched from
   intravitreal ranibizumab to aflibercept for treatment of exudative
   age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; Outer retinal tubulations; Anti-VEGF; Exudative AMD;
   SD-OCT; Ranibizumab
ID ENDOTHELIAL GROWTH-FACTOR; PHOTORECEPTOR ROSETTES; THERAPY; PREVALENCE
AB To evaluate the changes of outer retinal tubulations (ORTs) as seen on spectral-domain optical coherence tomography (SD OCT) in eyes with neovascular age-related macular degeneration (AMD) where treatment was switched from intravitreal ranibizumab to intravitreal aflibercept.
   This was a prospective study of eyes diagnosed with neovascular AMD and previously treated with > 6 intravitreal ranibizumab injections and switched to aflibercept, conducted at a single centre (Department of Ophthalmology at Piti, Salpetriere Hospital, Paris VI University) from January to July 2015. Before and after treatment was switched from ranibizumab to aflibercept, SD-OCT was used to evaluate the presence of ORTs. Additional assessments in this patient group included best-corrected visual acuity (BCVA), fluorescein angiography (FA), indocyanine green angiography (ICGA). Changes in pigment epithelium detachments (PED), presence of intraretinal cysts, and presence of subretinal fluid (SRF) were also noted.
   Twenty-four eyes of 24 consecutive patients (15 female/nine male, mean age 70 years) diagnosed with neovascular AMD and previously treated with > 6 intravitreal ranibizumab injections and switched to aflibercept were included in the analysis. After receiving aflibercept, patients were followed for a mean of 6.1 months. Prior to treatment switch, 97 % of eyes showed ORTs, while after treatment switch to aflibercept, at the end of the study period, 75 % had ORTs (p = 0.219). Changes in BCVA (LogMAR) were not statistically significant (1.16 +/- 0.44 to 1.18 +/- 1.06, p = 0.12), however, a significant reduction in central macular thickness (CMT) (from 406 mu m +/- 112 to 263 mu m +/- 68, p = 0.001), PED (from 70.8 % to 41.7 % , p = 0.016), presence of intraretinal cysts (from 83.3 % to 33.3 %, p = 0.002) and SRF (from 91.7 % to 25 %, p = 0.001 ) were noted.
   After switching from ranibizumab treatment to aflibercept, ORTs remained present in 75 % of eyes, and significant reductions in CMT, PED, and SRF, and presence of intraretinal cysts were observed.
C1 [Massamba, Nathalie; Butel, Nathalie; Fardeau, Christine; Bodaghi, Bahram; Ingram, April; Lehoang, Phuc] UPMC, Pitie Salpetriere Hosp, Dept Ophthalmol, Paris, France.
   [Dirani, Ali] Univ Lausanne, Dept Ophthalmol, Lausanne, Switzerland.
   [Dirani, Ali] Jules Gonin Eye Hosp, Fdn Asylum Blind, Lausanne, Switzerland.
   [Ingram, April] Univ Paris VI, GH Pitie Salpetriere, Dept Ophthalmol, 47-83 Blvd Hop, F-75013 Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne
   Universite; University of Lausanne; Assistance Publique Hopitaux Paris
   (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French
   Research Universities; Sorbonne Universite
RP Ingram, A (通讯作者)，UPMC, Pitie Salpetriere Hosp, Dept Ophthalmol, Paris, France.; Ingram, A (通讯作者)，Univ Paris VI, GH Pitie Salpetriere, Dept Ophthalmol, 47-83 Blvd Hop, F-75013 Paris, France.
EM aprilingram@outlook.com
RI Bodaghi, Bahram/AAS-1160-2021
OI Bodaghi, Bahram/0000-0002-0962-5301; Fardeau,
   Christine/0000-0003-1935-2711; LeHoang, Phuc/0000-0003-4722-1831
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Coscas F, 2015, INVEST OPHTH VIS SCI, V56, P4129, DOI 10.1167/iovs.15-16735
   Dirani A, 2015, RETINA-J RET VIT DIS, V35, P1166, DOI 10.1097/IAE.0000000000000439
   Dirani A, 2015, AM J OPHTHALMOL, V160, P732, DOI 10.1016/j.ajo.2015.06.025
   Espina M, 2016, BRIT J OPHTHALMOL, V100, P819, DOI 10.1136/bjophthalmol-2015-307141
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gildener-Leapman JR, 2015, OSLI RETINA, V46, P345, DOI 10.3928/23258160-20150323-08
   Goldberg NR, 2013, RETINA-J RET VIT DIS, V33, P1871, DOI 10.1097/IAE.0b013e318296b12f
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jumper JM, 2011, AM SOC RETINAL SPECI
   Jung JJ, 2012, ARCH OPHTHALMOL-CHIC, V130, P1618, DOI 10.1001/archophthalmol.2012.1902
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee JY, 2014, OPHTHALMOLOGY, V121, P2423, DOI 10.1016/j.ophtha.2014.06.013
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   MILAM AH, 1990, OPHTHALMOLOGY, V97, P1620
   Moon Da Ru Chi, 2015, Korean J Ophthalmol, V29, P226, DOI 10.3341/kjo.2015.29.4.226
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Tulvatana W, 1999, ARCH OPHTHALMOL-CHIC, V117, P399, DOI 10.1001/archopht.117.3.399
   Wolff B, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/542417
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 25
TC 4
Z9 4
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2017
VL 255
IS 1
BP 61
EP 67
DI 10.1007/s00417-016-3423-x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EG9HS
UT WOS:000391370100009
PM 27397583
DA 2022-11-30
ER

PT J
AU Beirne, RO
   Hogg, RE
   Stevenson, MR
   Zlatkova, MB
   Chakravarthy, U
   Anderson, RS
AF Beirne, Raymond O.
   Hogg, Ruth E.
   Stevenson, Michael R.
   Zlatkova, Margarita B.
   Chakravarthy, Usha
   Anderson, Roger S.
TI Severity staging by early features of age-related maculopathy exhibits
   weak relationships with functional deficits on SWS grating acuity
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID SHORT-WAVELENGTH ACUITY; BLUE-ON-YELLOW; MACULAR DEGENERATION; CONTRAST
   SENSITIVITY; VISUAL-ACUITY; RETINITIS-PIGMENTOSA; SINUSOIDAL GRATINGS;
   AUTOMATED PERIMETRY; PERIPHERAL-VISION; FELLOW EYE
AB PURPOSE. To examine the relationship between short-wave-length-sensitive (SWS) resolution acuity and epidemiologically defined stages of early age-related maculopathy (ARM).
   METHODS. Subjects consisted of 88 adults aged 51 to 87 years. Psychophysical testing was undertaken in only one eye of each subject (the study eye). All study eyes had a LogMAR acuity of 0.30 (20/40 Snellen) or better. SWS and achromatic grating resolution acuity were measured at 6 eccentricity from the fovea. Stereoscopic color fundus photographs centered on the macula were taken on both eyes of each subject and were graded using the Wisconsin Age-Related Maculopathy Grading System (WARMGS). After grading, features of ARM were combined to assign a severity stage from 0 to 5 using the methods described by the Rotterdam Eye Study. Relationships between visual function, study eye ARM stage, and fellow eye status were examined with the use of standard statistical analysis.
   RESULTS. Although SWS resolution acuity was significantly reduced in eyes classified as having any ARM compared with eyes classified as having no ARM (P = 0.002), there was no relationship between the severity of functional deficits and the morphologic severity from stage 1 to stage 4. On reassigning subject eyes to a revised severity staging (stage 0, stages 1 to 4 combined, and stage 5), SWS acuity was significantly different among these three groups (P < 0.001). No significant relationship was found between achromatic resolution acuity and ARM staging. The status of the fellow eye (advanced macular degeneration present or absent) was not significantly related to visual function in the study eye.
   CONCLUSIONS. Significant functional deficits in SWS resolution acuity were found in eyes with ARM features, but the severity of functional loss did not correlate well with the currently accepted method of assigning a morphologic severity stage. Longitudinal studies may reveal further information on the relationships between functional deficits, ARM status, disease progression, and outcome.
C1 Univ Ulster, Sch Biomed Sci, Vis Sci Res Grp, Coleraine BT52 1SA, Londonderry, North Ireland.
   Queens Univ Belfast, Royal Grp Hosp Trust, Inst Clin Sci, Ctr Ophthalmol & Vis Sci, Belfast BT7 1NN, Antrim, North Ireland.
   Royal Grp Hosp Trust, Clin Res Support Ctr, Belfast, Antrim, North Ireland.
C3 Ulster University; Queens University Belfast
RP Beirne, RO (通讯作者)，Univ Ulster, Sch Biomed Sci, Vis Sci Res Grp, Coleraine BT52 1SA, Londonderry, North Ireland.
EM r.beirne@ulster.ac.uk
RI Hogg, Ruth E./ABC-9602-2020
OI Hogg, Ruth E./0000-0001-9413-2669; Chakravarthy,
   Usha/0000-0002-2606-3734; Beirne, Raymond/0000-0002-4831-2113
CR ALVAREZ SL, 1983, BRIT J OPHTHALMOL, V67, P508, DOI 10.1136/bjo.67.8.508
   Anderson RS, 2003, VISION RES, V43, P101, DOI 10.1016/S0042-6989(02)00410-8
   Anderson RS, 2002, VISION RES, V42, P981, DOI 10.1016/S0042-6989(02)00013-5
   APPLEGATE RA, 1987, APPL OPTICS, V26, P1458, DOI 10.1364/AO.26.001458
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Beirne RO, 2005, VISUAL NEUROSCI, V22, P79, DOI 10.1017/S0952523805221119
   Beirne RO, 2003, INVEST OPHTH VIS SCI, V44, P4780, DOI 10.1167/iovs.02-1072
   BOWMAN KJ, 1980, ACTA OPHTHALMOL, V58, P337
   CHENG AS, 1993, OPTOMETRY VISION SCI, V70, P89, DOI 10.1097/00006324-199302000-00001
   EISNER A, 1993, DOC OPHTH P, V56, P175
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   Ennis FA, 2000, CURR EYE RES, V20, P413
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   FRENNESSON C, 1995, DOC OPHTHALMOL, V90, P377, DOI 10.1007/BF01268123
   GREENSTEIN VC, 1989, INVEST OPHTH VIS SCI, V30, P1732
   HAEGERSTROMPORTNOY G, 1989, CLIN VISION SCI, V4, P165
   Holz F G, 1995, Ger J Ophthalmol, V4, P336
   JOHNSON CA, 1993, ARCH OPHTHALMOL-CHIC, V111, P651, DOI 10.1001/archopht.1993.01090050085035
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P205
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P539, DOI 10.1007/s00417-002-0507-6
   Remky A, 2005, BRIT J OPHTHALMOL, V89, P464, DOI 10.1136/bjo.2004.050260
   Remky A, 2001, BRIT J OPHTHALMOL, V85, P1432, DOI 10.1136/bjo.85.12.1432
   ROY M, 1990, Eye (London), V4, P813
   STANGOS N, 1995, OPHTHALMOLOGICA, V209, P194, DOI 10.1159/000310612
   SUNNESS JS, 1989, APPL OPTICS, V28, P1158, DOI 10.1364/AO.28.001158
   SWANSON WH, 1993, INVEST OPHTH VIS SCI, V34, P3045
   SWANSON WH, 1989, APPL OPTICS, V28, P1151, DOI 10.1364/AO.28.001151
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VINGERLING JR, 1995, OPHTHALMOLOGY, V39, P367
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Zlatkova MB, 2003, VISION RES, V43, P109, DOI 10.1016/S0042-6989(02)00411-X
NR 41
TC 7
Z9 9
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2006
VL 47
IS 10
BP 4624
EP 4631
DI 10.1167/iovs.05-1227
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 088AU
UT WOS:000240784700057
PM 17003460
DA 2022-11-30
ER

PT J
AU Owsley, C
   McGwin, G
   Jackson, GR
   Kallies, K
   Clark, M
AF Owsley, Cynthia
   McGwin, Gerald
   Jackson, Gregory R.
   Kallies, Katherine
   Clark, Mark
TI Cone- and rod-mediated dark adaptation impairment in age-related
   maculopathy
SO OPHTHALMOLOGY
LA English
DT Article
ID FACTOR-H POLYMORPHISM; VITAMIN-A; MACULAR DEGENERATION; RHODOPSIN
   LEVELS; VISUAL FUNCTION; EPIDEMIOLOGY; PROGRESSION; RECOVERY; THERAPY;
   EYE
AB Objective: To examine impairment in cone- versus rod-mediated dark adaptation in the parafovea of persons with age-related maculopathy (ARM).
   Design: Cross-sectional.
   Participants: Older adults with ARM at various severity levels from early to advanced (n = 83) and in good retinal health (n = 43), as determined by stereo fundus photographs evaluated with the Age-Related Eye Disease Study severity scale.
   Methods: Dark adaptation, both cone- and rod-mediated components, was measured with a modified Humphrey Field Analyzer using a target located 120 in the inferior visual field on the vertical meridian, after exposure to a 98% bleach. Information was collected on self-reported problems for activities at night or under dim illumination (Low Luminance Questionnaire [LLQ]) and for activities during daytime conditions (modified National Eye Institute Visual Function Questionnaire [NEI VFQ].
   Main Outcome Measures: Cone- and rod-mediated parameters of dark adaptation.
   Results: Compared with older adults in normal retinal health, ARM patients had significant impairments in rod-mediated parameters of dark adaptation (rod-cone break, rod slope, rod sensitivity) (P < 0.0001), which were increasingly abnormal as disease severity increased. Cone-mediated parameters (cone time constant and cone sensitivity) were not impaired. Low Luminance Questionnaire scores and NEI VFQ scores decreased with increased ARM severity (P = 0.0004 and P = 0.0005, respectively); the percent decrease in LLQ scores as a function of disease severity was larger in magnitude than the percent decrease in NEI VFQ scores.
   Conclusions: Disturbances in rod-mediated but not cone-mediated dark adaptation in the parafovea at 12 degrees in the inferior field on the vertical meridian are characteristic of ARM even in its early phases. Ophthalmology 2007,114:1728-1735 (c) 2007 by the American Academy of Ophthalmology.
C1 Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol & Int Hlth, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Sch Publ Hlth, Dept Surg, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Owsley, C (通讯作者)，Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, 700 S 18th St,Suite 609, Birmingham, AL 35294 USA.
EM owsley@uab.edu
FU NATIONAL EYE INSTITUTE [R21EY014071] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON AGING [R01AG004212] Funding Source: NIH RePORTER;
   NEI NIH HHS [R21-EY14071] Funding Source: Medline; NIA NIH HHS
   [R01-AG04212] Funding Source: Medline
CR [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   Bressler NM, 2000, INVEST OPHTH VIS SCI, V41, P624
   BROWN B, 1986, AM J OPTOM PHYS OPT, V63, P450
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   DOWLING JE, 1958, P NATL ACAD SCI USA, V44, P648, DOI 10.1073/pnas.44.7.648
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   Eter N, 2006, BIODRUGS, V20, P167, DOI 10.2165/00063030-200620030-00004
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Haimovici R, 2002, GRAEF ARCH CLIN EXP, V240, P90, DOI 10.1007/s00417-001-0417-z
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jackson GR, 2005, MACULAR DEGENERATION, P45, DOI 10.1007/3-540-26977-0_3
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 1998, VISION RES, V38, P3655, DOI 10.1016/S0042-6989(98)00044-3
   JACOBSON SG, 1986, OPHTHALMOLOGY, V93, P1604
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KATZ ML, 1993, EXP EYE RES, V56, P671, DOI 10.1006/exer.1993.1084
   KEMP CM, 1988, EXP EYE RES, V46, P185, DOI 10.1016/S0014-4835(88)80076-9
   KEMP CM, 1989, EXP EYE RES, V49, P49
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   LAMB TD, 1981, VISION RES, V21, P1773, DOI 10.1016/0042-6989(81)90211-X
   LAVAIL MM, 1981, INVEST OPHTH VIS SCI, V21, P638
   Leibrock CS, 1998, EYE, V12, P511, DOI 10.1038/eye.1998.139
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1
   McGwin G, 1999, BEHAV RES METH INS C, V31, P712, DOI 10.3758/BF03200752
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   PUGH EN, 1975, J PHYSIOL-LONDON, V248, P393, DOI 10.1113/jphysiol.1975.sp010981
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
NR 49
TC 116
Z9 118
U1 2
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2007
VL 114
IS 9
BP 1728
EP 1735
DI 10.1016/j.ophtha.2006.12.023
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 206LA
UT WOS:000249183700020
PM 17822978
DA 2022-11-30
ER

PT J
AU Zhu, ZT
   Wang, W
   Liao, H
   Keel, S
   Zhang, J
   He, MG
AF Zhu, Zhuoting
   Wang, Wei
   Liao, Huan
   Keel, Stuart
   Zhang, Jian
   He, Mingguang
TI Cross-sectional study of the association between cataract surgery and
   age-related macular degeneration in the era of phacoemulsification in
   the national health and nutrition examination survey 2005-2008
SO BMJ OPEN
LA English
DT Article
DE cataract and refractive surgery; epidemiology; ophthalmology
ID RISK-FACTORS; BEAVER DAM; VISUAL IMPAIRMENT; EYE DISEASE; MACULOPATHY;
   LIGHT; RANIBIZUMAB; PREVALENCE; EXTRACTION; OUTCOMES
AB Objective To determine the association between cataract surgery and age-related macular degeneration (AMD) in a representative US sample. Design Population-based, cross-sectional study. Setting The US National Health and Nutrition Examination Survey 2005-2008. Participants A total of 5401 participants aged >= 40 years had information in cataract surgery status and gradable retinal photographs for right eyes. Methods Cataract surgery status was obtained from questionnaire. Non-mydriatic fundus photographs were collected and AMD status was assessed. The associations between AMD and cataract surgery were evaluated in right eyes using logistic regression models. Results Of 338 right eyes with any AMD, 107 right eyes (28.9%) had cataract surgery. After adjusting for multiple variables, there were significant associations between cataract surgery and any AMD (OR 1.36; 95% CI 1.03 to 1.81) or late AMD (OR 2.48; 95% CI 1.01 to 6.09). No significant association was found between cataract surgery and early AMD after adjusting for multiple covariates (OR 1.20; 95% CI 0.91 to 1.59). Conclusion Our results suggest that cataract surgery is associated with the presence of AMD, particularly for late AMD. Longitudinal studies investigating the risk and progression of AMD after cataract surgery are needed in the era of phacoemulsification.
C1 [Zhu, Zhuoting; He, Mingguang] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Ophthalmol, Guangdong Eye Inst, Guangzhou, Peoples R China.
   [Zhu, Zhuoting; Wang, Wei; Zhang, Jian; He, Mingguang] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Peoples R China.
   [Liao, Huan] Univ Bonn, Inst Reconstruct Neurobiol, Neural Regenerat Grp, Bonn, Germany.
   [Keel, Stuart; He, Mingguang] Univ Melbourne, Ctr Eye Res, East Melbourne, Vic, Australia.
C3 Guangdong Academy of Medical Sciences & Guangdong General Hospital; Sun
   Yat Sen University; University of Bonn; Centre for Eye Research
   Australia; University of Melbourne
RP He, MG (通讯作者)，Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Ophthalmol, Guangdong Eye Inst, Guangzhou, Peoples R China.; He, MG (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Peoples R China.
EM mingguanghe@gmail.com
RI Wang, Wei/J-4000-2016
OI Wang, Wei/0000-0002-5273-3332; He, Mingguang/0000-0002-6912-2810
FU Fundamental Research Funds of the State Key Laboratory in Ophthalmology;
   University of Melbourne at Research Accelerator Program; CERA Foundation
FX Funding present work was supported by Fundamental Research Funds of the
   State Key Laboratory in Ophthalmology. Professor Mingguang He receives
   support from the University of Melbourne at Research Accelerator Program
   and the CERA Foundation. The Centre for Eye Research Australia receives
   Operational Infrastructure Support from the Victorian State Government.
   The sponsor or funding organization had no role in the design or conduct
   of this research.
CR Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Baatz H, 2008, INVEST OPHTH VIS SCI, V49, P1079, DOI 10.1167/iovs.07-0557
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Casparis H, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006757.pub3
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Dillon J, 2004, EXP EYE RES, V79, P753, DOI 10.1016/j.exer.2004.06.025
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Downie LE, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011977.pub2
   Forooghian F, 2009, OPHTHALMOLOGY, V116, P2093, DOI 10.1016/j.ophtha.2009.04.033
   Fraser-Bell S, 2010, AM J OPHTHALMOL, V149, P735, DOI 10.1016/j.ajo.2009.11.013
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Ho JD, 2018, ACTA OPHTHALMOL, V96, pe213, DOI 10.1111/aos.13511
   Ho L, 2008, INVEST OPHTH VIS SCI, V49, P4795, DOI 10.1167/iovs.08-2066
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Hu CC, 2017, ACTA OPHTHALMOL, V95, pE587, DOI 10.1111/aos.13204
   Kaiserman I, 2007, OPHTHALMOLOGY, V114, P278, DOI 10.1016/j.ophtha.2006.10.019
   Klein BEK, 2012, OPHTHALMOLOGY, V119, P1628, DOI 10.1016/j.ophtha.2012.01.050
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Kobelt G, 2002, J CATARACT REFR SURG, V28, P1742, DOI 10.1016/S0886-3350(02)01220-8
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Libre PE, 2003, AM J OPHTHALMOL, V136, P961, DOI 10.1016/S0002-9394(03)00906-1
   LIU IY, 1989, AM J PUBLIC HEALTH, V79, P765, DOI 10.2105/AJPH.79.6.765
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Park SJ, 2016, JAMA OPHTHALMOL, V134, P621, DOI 10.1001/jamaophthalmol.2016.0453
   Qian CX, 2014, SEMIN OPHTHALMOL, V29, P301, DOI 10.3109/08820538.2014.962166
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saraf SS, 2015, AM J OPHTHALMOL, V160, P487, DOI 10.1016/j.ajo.2015.06.006
   Schein OD, 2012, OPHTHAL EPIDEMIOL, V19, P257, DOI 10.3109/09286586.2012.698692
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Tabandeh H, 2012, J CATARACT REFR SURG, V38, P677, DOI 10.1016/j.jcrs.2011.10.036
   VANDERSCHAFT TL, 1994, BRIT J OPHTHALMOL, V78, P441, DOI 10.1136/bjo.78.6.441
   Wang JJ, 2016, OPHTHALMOLOGY, V123, P1829, DOI 10.1016/j.ophtha.2016.02.003
   Wang JJ, 2012, OPHTHALMOLOGY, V119, P2298, DOI 10.1016/j.ophtha.2012.07.003
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   WHO, 2011, USE GLYCATED HAEMOGL
   Xu L, 2011, GRAEF ARCH CLIN EXP, V249, P981, DOI 10.1007/s00417-010-1571-y
NR 39
TC 0
Z9 0
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PY 2020
VL 10
IS 9
AR e032745
DI 10.1136/bmjopen-2019-032745
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA NS5FN
UT WOS:000572287100012
PM 32895258
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Qiang, W
   Wei, R
   Chen, YJ
   Chen, DN
AF Qiang, Wei
   Wei, Ran
   Chen, Yongjiang
   Chen, Danian
TI Clinical Pathological Features and Current Animal Models of Type 3
   Macular Neovascularization
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Review
DE age-related macular degeneration (AMD); animal model; Type 3 macular
   neovascularization; retinal angiomatous proliferation (RAP); multimodal
   imaging; von Hippel; Lindau; hypoxia inducible factor (HIF);
   retinoblastoma gene (Rb1)
ID RETINAL ANGIOMATOUS PROLIFERATION; OPTICAL COHERENCE TOMOGRAPHY;
   ENDOTHELIAL GROWTH-FACTOR; DENSITY LIPOPROTEIN RECEPTOR; SERUM RESPONSE
   FACTOR; SUBFOVEAL CHOROIDAL THICKNESS; HIPPEL-LINDAU PROTEIN;
   CLINICOPATHOLOGICAL CORRELATION; PHOTODYNAMIC THERAPY; MOUSE MODEL
AB Type 3 macular neovascularization (MNV3), or retinal angiomatous proliferation (RAP), is a distinct type of neovascular age-related macular degeneration (AMD), which is a leading cause of vision loss in older persons. During the past decade, systematic investigation into the clinical, multimodal imaging, and histopathological features and therapeutic outcomes has provided important new insight into this disease. These studies favor the retinal origin of MNV3 and suggest the involvement of retinal hypoxia, inflammation, von Hippel-Lindau (VHL)-hypoxia-inducible factor (HIF)-vascular endothelial growth factor (VEGF) pathway, and multiple cell types in the development and progression of MNV3. Several mouse models, including the recently built Rb/p107/Vhl triple knockout mouse model by our group, have induced many of the histological features of MNV3 and provided much insight into the underlying pathological mechanisms. These models have revealed the roles of retinal hypoxia, inflammation, lipid metabolism, VHL/HIF pathway, and retinoblastoma tumor suppressor (Rb)-E2F cell cycle pathway in the development of MNV3. This article will summarize the clinical, multimodal imaging, and pathological features of MNV3 and the diversity of animal models that exist for MNV3, as well as their strengths and limitations.
C1 [Qiang, Wei; Wei, Ran; Chen, Danian] Sichuan Univ, West China Hosp, Res Lab Ophthalmol & Vis Sci, State Key Lab Biotherapy, Chengdu, Peoples R China.
   [Qiang, Wei; Wei, Ran; Chen, Danian] Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu, Peoples R China.
   [Chen, Yongjiang] Univ Waterloo, Sch Optometry & Vis Sci, Waterloo, ON, Canada.
C3 Sichuan University; Sichuan University; University of Waterloo
RP Chen, DN (通讯作者)，Sichuan Univ, West China Hosp, Res Lab Ophthalmol & Vis Sci, State Key Lab Biotherapy, Chengdu, Peoples R China.; Chen, DN (通讯作者)，Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu, Peoples R China.
EM danianchen2006@qq.com
RI Chen, Danian/GXV-7996-2022
OI Chen, Danian/0000-0002-6916-2978
FU National Natural Science Foundation of China [81870665]
FX Funding. This study was supported by a grant to DC from the National
   Natural Science Foundation of China (81870665).
CR Al-Salam S, 2013, INT J CLIN EXP PATHO, V6, P853
   Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249
   [Anonymous], 1997, DIAGNOSIS TREATMENT
   Arreola A, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.92193
   Baek J, 2016, INVEST OPHTH VIS SCI, V57, P1500, DOI 10.1167/iovs.15-18837
   Barben M, 2018, CELL DEATH DIFFER, V25, P2071, DOI 10.1038/s41418-018-0094-7
   Barben M, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0243-y
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Bjorkhem I, 2010, BIOCHEM BIOPH RES CO, V396, P46, DOI 10.1016/j.bbrc.2010.02.140
   Borrelli E, 2021, OPHTHALMOLOGICA, V244, P193, DOI 10.1159/000513051
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Bottoni F, 2005, ARCH OPHTHALMOL-CHIC, V123, P1644, DOI 10.1001/archopht.123.12.1644
   Boucher JM, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15699
   Brancato R, 2002, EUR J OPHTHALMOL, V12, P467, DOI 10.5301/EJO.2008.2283
   BURNS MS, 1992, CURR EYE RES, V11, P863, DOI 10.3109/02713689209033484
   Chai JY, 2004, FASEB J, V18, P1264, DOI 10.1096/fj.03-1232fje
   Chang B, 2018, INVEST OPHTH VIS SCI, V59, P5127, DOI 10.1167/iovs.18-25046
   Chang YS, 2016, ACTA OPHTHALMOL, V94, pE49, DOI 10.1111/aos.12748
   Chen D, 2004, CANCER CELL, V5, P539, DOI 10.1016/j.ccr.2004.05.025
   Chen Q, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.580884
   Chen Y, 2007, J BIOL CHEM, V282, P34420, DOI 10.1074/jbc.M611289200
   Chen Y, 2009, MICROVASC RES, V78, P119, DOI 10.1016/j.mvr.2009.02.005
   CRUYSBERG JRM, 1995, AM J OPHTHALMOL, V120, P597, DOI 10.1016/S0002-9394(14)72206-8
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Dasgupta P, 2006, J CLIN INVEST, V116, P2208, DOI 10.1172/JCI28164
   Davies Elizabeth Michele, 2019, Advances in Biological Regulation, V71, P69, DOI 10.1016/j.jbior.2018.11.008
   Domigan CK, 2014, CELL, V159, P473, DOI 10.1016/j.cell.2014.10.008
   Donati MC, 2006, OPHTHALMOLOGICA, V220, P31, DOI 10.1159/000089272
   Dorrell MI, 2009, J CLIN INVEST, V119, P611, DOI 10.1172/JCI35977
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fingler J, 2008, INVEST OPHTH VIS SCI, V49, P5055, DOI 10.1167/iovs.07-1627
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Foxton RH, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201810204
   Franco CA, 2013, DEVELOPMENT, V140, P2321, DOI 10.1242/dev.091074
   Franco CA, 2008, DEV CELL, V15, P448, DOI 10.1016/j.devcel.2008.07.019
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2006, ARCH OPHTHALMOL-CHIC, V124, P487, DOI 10.1001/archopht.124.4.487
   FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   Gau D, 2018, J CELL SCI, V131, DOI 10.1242/jcs.218222
   Gau D, 2017, ANGIOGENESIS, V20, P663, DOI 10.1007/s10456-017-9560-y
   Gharbiya M, 2014, RETINA-J RET VIT DIS, V34, P298, DOI 10.1097/IAE.0b013e3182979e62
   Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064
   Gong CJ, 2020, EXP EYE RES, V200, DOI 10.1016/j.exer.2020.108219
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   Gupta B, 2010, BRIT J OPHTHALMOL, V94, P672, DOI 10.1136/bjo.2009.166975
   Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Han JW, 2020, RETINA-J RET VIT DIS, V40, P1245, DOI 10.1097/IAE.0000000000002562
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Hasegawa E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106507
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   Hinkel R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4970
   Honda A, 2001, J LIPID RES, V42, P291
   Hu WZ, 2008, INVEST OPHTH VIS SCI, V49, P407, DOI 10.1167/iovs.07-0870
   Johnson V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132013
   Joussen AM, 2021, EYE, V35, P1305, DOI 10.1038/s41433-020-01377-x
   Joyal JS, 2016, NAT MED, V22, P439, DOI 10.1038/nm.4059
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   Kim JH, 2015, RETINA-J RET VIT DIS, V35, P2604, DOI 10.1097/IAE.0000000000000633
   Kim JH, 2014, BRIT J OPHTHALMOL, V98, P1066, DOI 10.1136/bjophthalmol-2013-304405
   Kim YK, 2016, RETINA-J RET VIT DIS, V36, P1516, DOI 10.1097/IAE.0000000000000952
   Klein ML, 2011, AM J OPHTHALMOL, V151, P161, DOI 10.1016/j.ajo.2010.07.020
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Kurihara T, 2010, DEVELOPMENT, V137, P1563, DOI 10.1242/dev.049015
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   Lane-Donovan C, 2017, J LIPID RES, V58, P1036, DOI 10.1194/jlr.R075507
   Lange C, 2011, INVEST OPHTH VIS SCI, V52, P5872, DOI 10.1167/iovs.11-7204
   Lange C, 2011, NEUROBIOL DIS, V41, P119, DOI 10.1016/j.nbd.2010.08.028
   Lange CAK, 2012, DEVELOPMENT, V139, P2340, DOI 10.1242/dev.070813
   Lee JH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186272
   Li C, 2007, ARCH OPHTHALMOL-CHIC, V125, P795, DOI 10.1001/archopht.125.6.795
   Li ML, 2018, OPHTHALMOLOGY, V125, P276, DOI 10.1016/j.ophtha.2017.08.019
   Li S, 2005, GENESIS, V41, P73, DOI 10.1002/gene.20097
   Liu CH, 2017, FASEB J, V31, P4665, DOI 10.1096/fj.201700336R
   Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4
   Low BE, 2014, INVEST OPHTH VIS SCI, V55, P387, DOI 10.1167/iovs.13-13278
   Luo L, 2013, ELIFE, V2, DOI 10.7554/eLife.00324
   Malamos P, 2018, OPHTHALMOLOGICA, V240, P213, DOI 10.1159/000487610
   Marquardt T, 2001, CELL, V105, P43, DOI 10.1016/S0092-8674(01)00295-1
   Marques JP, 2015, RETINA-J RET VIT DIS, V35, P1985, DOI 10.1097/IAE.0000000000000619
   Marticorena J, 2011, CURR DRUG TARGETS, V12, P199, DOI 10.2174/138945011794182683
   Martins A, 2018, OPHTHALMIC RES, V59, P88, DOI 10.1159/000481262
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mast N, 2011, INVEST OPHTH VIS SCI, V52, P594, DOI 10.1167/iovs.10-6021
   Matsumoto H, 2010, RETINA-J RET VIT DIS, V30, P425, DOI 10.1097/IAE.0b013e3181bd2d95
   Mehalow AK, 2003, HUM MOL GENET, V12, P2179, DOI 10.1093/hmg/ddg232
   Miere A, 2017, RETINA-J RET VIT DIS, V37, P1873, DOI 10.1097/IAE.0000000000001447
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2236, DOI 10.1097/IAE.0000000000000834
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Monson DM, 2008, ARCH OPHTHALMOL-CHIC, V126, P1664, DOI 10.1001/archopht.126.12.1664
   Montero JA, 2009, BRIT J OPHTHALMOL, V93, P166, DOI 10.1136/bjo.2008.141903
   Nagai N, 2015, AM J PATHOL, V185, P2534, DOI 10.1016/j.ajpath.2015.04.029
   Nagai N, 2014, INVEST OPHTH VIS SCI, V55, P3709, DOI 10.1167/iovs.14-13989
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2
   Okabe K, 2014, CELL, V159, P584, DOI 10.1016/j.cell.2014.09.025
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Olson EN, 2010, NAT REV MOL CELL BIO, V11, P353, DOI 10.1038/nrm2890
   Omarova S, 2012, J CLIN INVEST, V122, P3012, DOI 10.1172/JCI63816
   Park S, 2012, HISTOL HISTOPATHOL, V27, P975, DOI 10.14670/HH-27.975
   Perrott-Reynolds R, 2019, EYE, V33, P274, DOI 10.1038/s41433-018-0229-6
   Pikuleva IA, 2006, PHARMACOL THERAPEUT, V112, P761, DOI 10.1016/j.pharmthera.2006.05.014
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Polito A, 2006, ANN ACAD MED SINGAP, V35, P420
   Posern G, 2006, TRENDS CELL BIOL, V16, P588, DOI 10.1016/j.tcb.2006.09.008
   Querques G, 2015, RETINA-J RET VIT DIS, V35, P603, DOI 10.1097/IAE.0000000000000487
   Querques G, 2013, RETINA-J RET VIT DIS, V33, P1881, DOI 10.1097/IAE.0b013e3182923448
   Ravera V, 2016, RETINA-J RET VIT DIS, V36, P2274, DOI 10.1097/IAE.0000000000001152
   Rouvas AA, 2012, RETINA-J RET VIT DIS, V32, P1181, DOI 10.1097/IAE.0b013e318235d8ce
   Sacconi R, 2021, BRIT J OPHTHALMOL, V105, P222, DOI 10.1136/bjophthalmol-2020-316054
   Sacconi R, 2018, OPHTHALMOL RETINA, V2, P1097, DOI 10.1016/j.oret.2018.04.016
   Sawa M, 2014, RETINA-J RET VIT DIS, V34, P761, DOI 10.1097/01.iae.0000434566.57189.37
   Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366
   Scott AW, 2010, EYE, V24, P491, DOI 10.1038/eye.2009.311
   Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004
   Shimada H, 2007, GRAEF ARCH CLIN EXP, V245, P295, DOI 10.1007/s00417-006-0367-6
   Simons M, 2016, NAT REV MOL CELL BIO, V17, P611, DOI 10.1038/nrm.2016.87
   Skalet AH, 2017, RETINA-J RET VIT DIS, V37, P1620, DOI 10.1097/IAE.0000000000001672
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2019, RETINA-J RET VIT DIS, V39, P1451, DOI 10.1097/IAE.0000000000002412
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   Sun Y, 2017, J EXP MED, V214, P1753, DOI 10.1084/jem.20161645
   Sun Y, 2015, P NATL ACAD SCI USA, V112, P10401, DOI 10.1073/pnas.1504387112
   Tan ACS, 2017, RETINA-J RET VIT DIS, V37, P234, DOI 10.1097/IAE.0000000000001343
   THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794
   Tiebel O, 1999, ATHEROSCLEROSIS, V145, P239, DOI 10.1016/S0021-9150(99)00068-4
   Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Tsai ASH, 2017, SURV OPHTHALMOL, V62, P462, DOI 10.1016/j.survophthal.2017.01.008
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Usui V, 2015, J CLIN INVEST, V125, P2335, DOI 10.1172/JCI80297
   Usui-Ouchi A, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.137317
   Wang TX, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00234
   Wang YS, 2012, CELL, V151, P1332, DOI 10.1016/j.cell.2012.10.042
   Wei R, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.127889
   Weinl C, 2013, J CLIN INVEST, V123, P2193, DOI 10.1172/JCI64201
   Wert KJ, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2016.5
   Won JY, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/391384
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wright CB, 2020, P NATL ACAD SCI USA, V117, P2579, DOI 10.1073/pnas.1909761117
   Yamazaki T, 2014, RETINA-J RET VIT DIS, V34, P1316, DOI 10.1097/IAE.0000000000000086
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
   Zhang LJ, 2019, HUM MOL GENET, V28, P3475, DOI 10.1093/hmg/ddz159
   Zhang ZY, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2896036
NR 156
TC 3
Z9 3
U1 2
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD AUG 26
PY 2021
VL 15
AR 734860
DI 10.3389/fnins.2021.734860
PG 15
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA XM4UC
UT WOS:000728823200001
PM 34512255
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Joko, T
   Nagai, Y
   Mori, R
   Tanaka, K
   Oshima, Y
   Hikichi, Y
   Komori, T
   Carrasco, J
   Maculaitis, MC
   Will, O
   Beusterien, K
   Takahashi, K
AF Joko, Takeshi
   Nagai, Yoshimi
   Mori, Ryusaburo
   Tanaka, Koji
   Oshima, Yuji
   Hikichi, Yusuke
   Komori, Tetsushi
   Carrasco, Joao
   Maculaitis, Martine C.
   Will, Oliver
   Beusterien, Kathleen
   Takahashi, Kanji
TI Patient Preferences for Anti-Vascular Endothelial Growth Factor
   Treatment for Wet Age-Related Macular Degeneration in Japan: A Discrete
   Choice Experiment
SO PATIENT PREFERENCE AND ADHERENCE
LA English
DT Article
DE wet age-related macular degeneration; patient preference; anti-vascular
   endothelial growth factor treatment; dosing regimen; treat-and-extend
ID ANTI-VEGF TREATMENT; SHARED DECISION-MAKING; 2.0 MG RANIBIZUMAB;
   INTRAVITREAL AFLIBERCEPT; EXTEND; OUTCOMES; THERAPY; REGIMEN; EFFICACY;
   VERTEPORFIN
AB Background: In Japan, intravitreal anti-vascular endothelial growth factor (anti-VEGF) dosing regimens for wet age-related macular degeneration (wAMD) include pro re nata, every 2 months, and treat-and-extend, resulting in different outcomes and patient burden. Although reflecting patient preferences in treatment decision-making is desirable, few studies have examined this in Japan. This study assessed the patients willingness to trade-off between different dosing regimens.
   Patients and Methods: Patients with wAMD were recruited from four Japanese university hospitals to complete a face-to-face cross-sectional survey. In a discrete choice experiment, patients were asked to choose their preferred option from two anti-VEGF treatment profiles shown side-by-side across a series of choice tasks. The profiles varied on four attributes: number of injections in 12 months, number of physician consultations in 12 months, chance of 1-year visual acuity (VA) improvement, and chance of 2-year VA maintenance. Preference weights were estimated using hierarchical Bayes' models.
   Results: Overall, 120 patients (30 treatment naive and 90 anti-VEGF experienced) completed the survey. Patients were willing to accept an increase from three to approximately eight injections in 12 months to increase the chance of 1-year VA improvement from 25% to 40%. They would be willing to accept 11 injections in 12 months if the chance of 2-year VA maintenance increased from 80% to 96%. The most valued attributes were increasing the chance of 2-year VA maintenance and reducing the number of injections in 12 months, which were each about twice as important as decreasing physician consultations in 12 months and increasing the chance of 1-year VA improvement (p<0.001). Among the dosing regimens, patients most preferred treat-and-extend because of its higher chance of 2-year VA maintenance.
   Conclusion: Informing patients with wAMD about the likelihood of long-term VA maintenance when selecting treatment may increase the acceptance of an optimal treatment regimen and number of injections.
C1 [Joko, Takeshi] Matsuyama Red Cross Hosp, Dept Ophthalmol, 1 Bunkyocho, Matsuyama, Ehime 7908524, Japan.
   [Nagai, Yoshimi; Takahashi, Kanji] Kansai Med Univ, Dept Ophthalmol, Hirakata, Osaka, Japan.
   [Mori, Ryusaburo; Tanaka, Koji] Nihon Univ, Dept Visual Sci, Div Ophthalmol, Sch Med,Chiyoda Ku, Tokyo, Japan.
   [Oshima, Yuji] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Fukuoka, Japan.
   [Hikichi, Yusuke] Bayer Yakuhin Ltd, Dept Market Access, Chiyoda Ku, Tokyo, Japan.
   [Komori, Tetsushi] Bayer Yakuhin Ltd, Dept Res & Prod Dev, Kita Ku, Osaka, Japan.
   [Carrasco, Joao] Bayer Consumer Care AG, Dept Market Access, Basel, Canton Of Basel, Switzerland.
   [Maculaitis, Martine C.; Will, Oliver; Beusterien, Kathleen] Kantar, Hlth Div, New York, NY USA.
C3 Matsuyama Red Cross Hospital; Kansai Medical University; Nihon
   University; Kyushu University; Bayer AG; Bayer AG; Bayer AG
RP Joko, T (通讯作者)，Matsuyama Red Cross Hosp, Dept Ophthalmol, 1 Bunkyocho, Matsuyama, Ehime 7908524, Japan.
EM takeshijoko@matsuyama.jrc.or.jp
OI Komori, Tetsushi/0000-0001-7349-2438; Carrasco, Joao/0000-0001-7084-2674
FU Bayer Yakuhin, Ltd.
FX This study was funded by Bayer Yakuhin, Ltd. The funder was involved in
   the study design, data collection, data analysis, decision to publish,
   and preparation of the manuscript. Kantar, LLC. was contracted by Bayer
   Yakuhin, Ltd, and was involved in data collection, data analysis and
   medical writing.
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Baxter JM, 2016, EYE, V30, P698, DOI 10.1038/eye.2016.18
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bridges JFP, 2011, VALUE HEALTH, V14, P403, DOI 10.1016/j.jval.2010.11.013
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Clinic Mayo, WET MAC DEG
   Decroos FC, 2017, AM J OPHTHALMOL, V180, P142, DOI 10.1016/j.ajo.2017.06.002
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Ferreira A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133968
   Hack TF, 2006, PSYCHO-ONCOL, V15, P9, DOI 10.1002/pon.907
   Haga A, 2018, ACTA OPHTHALMOL, V96, pE393, DOI 10.1111/aos.13607
   Hauber AB, 2016, VALUE HEALTH, V19, P300, DOI 10.1016/j.jval.2016.04.004
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Hughes TM, 2018, AM J SURG, V216, P7, DOI 10.1016/j.amjsurg.2018.01.011
   Iida T, 2014, JHEOR, V2, P41, DOI DOI 10.36469/9887
   Iida T, 2016, CLIN OPHTHALMOL, V10, P2505, DOI 10.2147/OPTH.S120803
   Koh A, 2017, ASIA-PAC J OPHTHALMO, V6, P296, DOI 10.22608/APO.2016125
   Kuhfeld WF, 2010, SAS
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   Lindhiem O, 2014, CLIN PSYCHOL REV, V34, P506, DOI 10.1016/j.cpr.2014.06.002
   Mangham LJ, 2009, HEALTH POLICY PLANN, V24, P151, DOI 10.1093/heapol/czn047
   Mantel I, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.6
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Ministry of Education Culture Sports Science and Technology Minis-try of Health Labour and Welfare, ETH GUID MED HLTH RE
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mueller S, 2016, OPHTHALMOLOGY, V123, P876, DOI 10.1016/j.ophtha.2015.12.001
   Ohji M, 2017, 17 EURETINA C SEPT 7
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Quan HD, 2011, AM J EPIDEMIOL, V173, P676, DOI 10.1093/aje/kwq433
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rufai SR, 2017, EYE, V31, P1337, DOI 10.1038/eye.2017.67
   Schoenthaler A, 2018, J AM BOARD FAM MED, V31, P752, DOI 10.3122/jabfm.2018.05.180009
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Singh RP, 2018, AM J OPHTHAL CLIN TR, V1, DOI 10.25259/AJOCT-2-2018
   Stuart A, 2015, EYENET MAGAZINE, P27, DOI [10.3389/fped.2015.00027, DOI 10.3389/FPED.2015.00027]
   Takahashi Kanji, 2012, Nippon Ganka Gakkai Zasshi, V116, P1150
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Terano Y, 2018, 18 EURETINA C SEPT 2
   Uemura H, 2016, BMC UROL, V16, DOI 10.1186/s12894-016-0182-2
   van Asten F, 2015, ACTA OPHTHALMOL, V93, P126, DOI 10.1111/aos.12610
   Vennedey V, 2016, PATIENT PREFER ADHER, V10, P993, DOI 10.2147/PPA.S101584
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 57
TC 10
Z9 11
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-889X
J9 PATIENT PREFER ADHER
JI Patient Prefer. Adherence
PY 2020
VL 14
BP 553
EP 567
DI 10.2147/PPA.S228890
PG 15
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA KV4JR
UT WOS:000520449000001
PM 32214802
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Inan, S
   Baysal, Z
   Inan, UU
AF Inan, Sibel
   Baysal, Zeki
   Inan, Umit Ubeyt
TI Long-Term Changes in Submacular Choroidal Thickness after Intravitreal
   Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration:
   14-Mo Follow-Up
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Neovascular Age Related Macular Degeneration; Choroidal Thickness;
   Anti-VEGF
ID ENDOTHELIAL GROWTH-FACTOR; ANTI-VEGF THERAPY; SUBFOVEAL; EYES;
   AFLIBERCEPT; INJECTIONS
AB Purpose: To study (i) the long-term effects of intravitreal ranibizumab treatment on changes in submacular choroidal thickness and (ii) the relationship between any resulting changes in choroidal thickness and visual outcomes following such treatment in patients with neovascular age-related macular degeneration (n-AMD). Methods: Reviewed were medical records of 30 consecutive, treatment-naive, patients with unilateral n-AMD (n = 30 eyes) and unaffected fellow eyes (n = 26 eyes) (controls). Monthly injections of 0.5 mg ranibizumab were administered until stabilization of n-AMD, with additional injections as needed over the following 14-mo. Choroidal thickness was determined using enhanced-depth imaging-optical coherence tomography (EDI-OCT) before and after initiation of ranibizumab therapy. Choroidal thickness measurements were generated via manual segmentation. Results: The mean age of patients was 71.9 +/- 7.4 (56-83) years; the mean best-corrected visual acuity (BCVA) of affected eyes improved from 51.1 to 59.4 letters (p < 0.001); and the mean number of injections was 9.16 +/- 1.75. Subfoveal choroidal thickness decreased from 208.3 +/- 73.7 mu m at baseline to 185.3 +/- 70.1 mu m at mo-14 (p < 0.001), with significant (p < 0.001) decreases at all measured time points. Choroidal thickness also tended to decline in fellow eyes but was only statistically significant nasally 1,000 mu m (p =0.04). Mean changes in choroidal thickness did not correlate with BCVA at mo-14 (p = 0.76). Disciform scars and geographic atrophy (p = 0.017), and BCVA (p < 001) at baseline were predictive of visual outcome. Age (p = 0.001), reticular drusen (p = 0.004), and size of choroidal neovascularized area (p = 0.042) were predictive of decreases in choroidal thickness. Conclusions: Submacular choroidal thickness appeared to decrease significantly in eyes with n-AMD over a 14-mo period of ranibizumab treatment. No corresponding decrease in choroidal thickness occurred in fellow eyes.
C1 [Inan, Sibel] Hlth Sci Univ, Sch Med, Dept Ophthalmol, Afyon, Turkey.
   [Baysal, Zeki] Batman State Hosp, Dept Ophthalmol, Batman, Turkey.
   [Inan, Umit Ubeyt] Parkhayat Hosp, Dept Ophthalmol, Afyon, Turkey.
C3 Batman Regional State Hospital
RP Inan, S (通讯作者)，Hlth Sci Univ, Fac Med, Dept Ophthalmol, TR-03200 Afyon, Turkey.
EM drinan33@gmail.com
RI Inan, sibel/AAB-7691-2021
CR Abdolrahimzadeh S, 2016, RETINA-J RET VIT DIS, V36, P2329, DOI 10.1097/IAE.0000000000001097
   Azar G, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7438083
   Branchini L, 2013, JAMA OPHTHALMOL, V131, P693, DOI 10.1001/jamaophthalmol.2013.692
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ellabban AA, 2012, CLIN OPHTHALMOL, V6, P837, DOI 10.2147/OPTH.S30907
   Fan WY, 2018, GRAEF ARCH CLIN EXP, V256, P511, DOI 10.1007/s00417-017-3888-2
   Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
   Forte R, 2012, J OCUL PHARMACOL TH, V28, P69, DOI 10.1089/jop.2010.0181
   Gharbiya M, 2018, CURR EYE RES, V43, P391, DOI 10.1080/02713683.2017.1405045
   Gharbiya M, 2015, J OCUL PHARMACOL TH, V31, P357, DOI 10.1089/jop.2014.0160
   Hernandez-Martinez P, 2017, EUR J OPHTHALMOL, V27, P196, DOI 10.5301/ejo.5000860
   Iacono P, 2017, OPHTHALMIC RES, V57, P42, DOI 10.1159/000448955
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kim JH, 2016, BRIT J OPHTHALMOL, V100, P1634, DOI 10.1136/bjophthalmol-2015-308074
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Kumar JB, 2019, BRIT J OPHTHALMOL, V103, P918, DOI 10.1136/bjophthalmol-2018-312625
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Lu LN, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002967
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Mazaraki K, 2015, BRIT J OPHTHALMOL, V99, P1341, DOI 10.1136/bjophthalmol-2015-306636
   McDonnell EC, 2014, EUR J OPHTHALMOL, V24, P897, DOI 10.5301/ejo.5000509
   Minnella AM, 2016, BIODRUGS, V30, P353, DOI 10.1007/s40259-016-0179-0
   Kanadani TCM, 2018, OPHTHALMOLOGICA, V240, P200, DOI 10.1159/000488254
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Padron-Perez N, 2018, INVEST OPHTH VIS SCI, V59, P1119, DOI 10.1167/iovs.17-22144
   Rahman W, 2013, GRAEF ARCH CLIN EXP, V251, P1483, DOI 10.1007/s00417-012-2199-x
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Shao L, 2014, AM J OPHTHALMOL, V158, P702, DOI 10.1016/j.ajo.2014.05.023
   Sigler EJ, 2013, INVEST OPHTH VIS SCI, V54, P6307, DOI 10.1167/iovs.13-12653
   Sivaprasad S, 2016, SURV OPHTHALMOL, V61, P521, DOI 10.1016/j.survophthal.2016.02.005
   Sizmaz S, 2014, EUR J OPHTHALMOL, V24, P904, DOI 10.5301/ejo.5000478
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yun C, 2016, INVEST OPHTH VIS SCI, V57, P6604, DOI 10.1167/iovs.16-19989
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P1693, DOI 10.1007/s00417-015-3260-3
   Yun C, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0203-7
NR 40
TC 8
Z9 8
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD AUG 3
PY 2019
VL 44
IS 8
BP 908
EP 915
DI 10.1080/02713683.2019.1600195
EA APR 2019
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IS7QM
UT WOS:000466082800001
PM 30909756
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Chandra, S
   Rasheed, R
   Menon, D
   Patrao, N
   Lamin, A
   Gurudas, S
   Balaskas, K
   Pater, PJ
   Ali, N
   Sivaprasad, S
AF Chandra, Shruti
   Rasheed, Rajna
   Menon, Deepthy
   Patrao, Namritha
   Lamin, Ali
   Gurudas, Sarega
   Balaskas, Konstantinos
   Pater, Praveen J.
   Ali, Naser
   Sivaprasad, Sobha
TI Impact of injection frequency on 5-year real-world visual acuity
   outcomes of aflibercept therapy for neovascular age-related macular
   degeneration
SO EYE
LA English
DT Article
ID RANIBIZUMAB
AB Background To evaluate the impact of injection frequency on yearly visual outcomes of patients treated with intravitreal aflibercept for neovascular age-related macular degeneration (nAMD) over a period of 5 years in a tertiary ophthalmic centre. Design Single centre, retrospective cohort study. Participants Consecutive treatment-naive nAMD patients initiated on aflibercept injections 5 years ago. Methods The Moorfields OpenEyes database was searched for consecutive patients who were initiated on intravitreal aflibercept for nAMD in 2013-14 and the visual acuity (VA) in Early Diabetic Retinopathy Study (ETDRS) letters and injection records per year were recorded for a period of 5 years. Analyses of the whole cohort and a sub-sample of 5-year completers were done. The cohort was further grouped into Group A (on continuous treatment), Group B (early cessation of treatment) and Group C (interrupted treatment) to evaluate the relation between treatment frequency and visual outcomes. Main outcome measures The primary end point was change in VA at 5 years; secondary outcomes included proportion of eyes that gained or maintained VA, number of injections received and the effect of treatment frequency. Results Data were collected on 468 patients (512 eyes). Sixty-six percent of the patients completed 5-year follow-up. The mean age of the whole cohort was 79.5 +/- 8.5 years and the mean baseline VA was 58.3 +/- 15.4 letters. Amongst the completers, final VA change was -2.9 (SD 23.4) ETDRS letters and the cumulative number of injections over 5 years was 24.2 (10.6). Group A had three letter gain and received significantly higher cumulative number of injections over 5 years than Group B and C (31.8, 14.6 and 18.4 respectively, p = 0.001). After adjusting for age and baseline VA, on average, final VA was +8.0 letters higher in the >= 20 injections group than the <20 group (p = 0.001). Conclusions Aflibercept therapy results in sustained good visual outcome over 5 years in neovascular AMD eyes when early and persistent treatment is given.
C1 [Chandra, Shruti; Rasheed, Rajna; Menon, Deepthy; Patrao, Namritha; Lamin, Ali; Gurudas, Sarega; Balaskas, Konstantinos; Pater, Praveen J.; Ali, Naser; Sivaprasad, Sobha] Moorfields Eye Hosp NHS Fdn Trust, Natl Inst Hlth Res, Moorfields Biomed Res Ctr, London, England.
   [Chandra, Shruti; Rasheed, Rajna; Menon, Deepthy; Patrao, Namritha; Lamin, Ali; Gurudas, Sarega; Balaskas, Konstantinos; Pater, Praveen J.; Ali, Naser; Sivaprasad, Sobha] UCL Inst Ophthalmol, London, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London
RP Chandra, S (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, Natl Inst Hlth Res, Moorfields Biomed Res Ctr, London, England.; Chandra, S (通讯作者)，UCL Inst Ophthalmol, London, England.
EM shruti.chandra@nhs.net
RI Sivaprasad, S./D-6876-2015; Balaskas, Konstantinos/ABD-5979-2020
OI Sivaprasad, S./0000-0001-8952-0659; Balaskas,
   Konstantinos/0000-0002-7690-6277; Chandra, Shruti/0000-0002-2634-9775
FU NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS
   Foundation Trust and UCL Institute of Ophthalmology
FX I would like to thank the Moorfields Medical Retina Group for their
   contribution and collation of patients. The research was supported by
   the NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS
   Foundation Trust and UCL Institute of Ophthalmology.
CR Almuhtaseb H, 2017, EYE, V31, P1582, DOI 10.1038/eye.2017.108
   Budzinskaya M V, 2019, Vestn Oftalmol, V135, P107, DOI 10.17116/oftalma2019135051107
   Chevillard Gregory, 2011, CELL MOL LIFE SCI, V68, P3337, DOI [10.1007/s00018-011-0747-x, DOI 10.1007/S00018-011-0747-X, DOI 10.1038/S41433-019-0747-X]
   Decroos FC, 2017, AM J OPHTHALMOL, V180, P142, DOI 10.1016/j.ajo.2017.06.002
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Eleftheriadou M, 2018, OPHTHALMOL THER, V7, P361, DOI 10.1007/s40123-018-0139-5
   Eleftheriadou M, 2017, AM J OPHTHALMOL, V174, P160, DOI 10.1016/j.ajo.2016.09.038
   Framme C, 2018, OPHTHALMOL RETINA, V2, P539, DOI 10.1016/j.oret.2017.09.017
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kaiser PK, 2017, OPHTHALMOL RETINA, V1, P304, DOI 10.1016/j.oret.2017.01.004
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   Lee AY, 2017, BRIT J OPHTHALMOL, V101, P1683, DOI 10.1136/bjophthalmol-2016-309818
   Nishikawa K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39995-5
   Ohji M, 2017, 17 EUR SOC RET SPEC
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Rosenfeld PJ, 2011, NEW ENGL J MED, V364, P1966, DOI 10.1056/NEJMe1103334
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Weber M, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2017-000109
NR 21
TC 9
Z9 10
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2021
VL 35
IS 2
BP 409
EP 417
DI 10.1038/s41433-020-0851-y
EA APR 2020
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PX7VQ
UT WOS:000523951400001
PM 32265509
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Staurenghi, G
   Flower, RW
AF Staurenghi, G
   Flower, RW
TI Clinical observations supporting a theoretical model of choriocapillaris
   blood flow in treatment of choroidal neovascularization associated with
   age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID FEEDER VESSELS; PHOTOCOAGULATION
AB PURPOSE: To report clinical observations consistent with conclusions from a previous theoretical investigation indicating that photocoagulation of choroidal neovascularization (CNV) efferent vessels can be, in some instances, an effective treatment.
   DESIGN: Interventional case series.
   METHODS: In five eyes with age-related macular degeneration (five patients with mean age +/- SD of 65 +/- 11 years, range 55-79 years) requiring treatment of CNV. In each case, the appropriate treatment,vas location and photocoagulation of the CNV efferent vessels, since the afferent vessels were not identifiable or were located beneath the fovea. Targeted vessels were determined to be draining vessels by analysis of pretreatment high-speed indocyanine green (ICG) angiograms, and successful vessel closure by photocoagulation was demonstrated by posttreatment ICG angiograms. The eyes subsequently were followed from 2 to 12 months.
   RESULTS: After photocoagulation of efferent vessels, CNV-related retinal edema was significantly reduced or resolved within 1 to 4 days. Visual acuity became stabilized in three eyes and improved in two eyes. In a few days, metamorphopsia disappeared in four of the eyes and was stable for a period longer than the duration of the associated efferent vessel closure. Initial efferent vessel closure by photocoagulation persisted on average for 7 to 15 days, after which additional treatment was required. It is significant that in no case did hemorrhage result from the photocoagulation treatment.
   CONCLUSIONS: These observations are consistent with the earlier theoretical study prediction that photocoagulation of efferent CNV vessels can be effective in reducing CNV-associated edema. That no hemorrhage was induced by photocoagulation is consistent with the theoretical concept that there appears to be no direct hydrostatic connection between the CNV and its afferent vessels. Rather, that connection appears to be a functional one made through the choriocapillaris, which may dissipate excess CNV hydrostatic pressure produced by occlusion of a draining vessel. However, this finding is not intended to be a recommendation to attempt CNV efferent vessel photocoagulation. (C) 2002 by Elsevier Science Inc. All rights reserved.
C1 Univ Brescia, Dept Ophthalmol, Brescia, Italy.
   Univ Maryland, Dept Ophthalmol, Baltimore, MD 21201 USA.
   LuEsther T Mertz Retinal Res Lab, New York, NY USA.
   Manhattan Eye Ear & Throat Hosp, Macula Fdn, New York, NY 10021 USA.
C3 University of Brescia; University System of Maryland; University of
   Maryland Baltimore; Manhattan Eye Ear & Throat Hospital
RP Flower, RW (通讯作者)，11 Dellwood Court, Hunt Valley, MD 21030 USA.
RI Staurenghi, Giovanni/K-4388-2017
OI Staurenghi, Giovanni/0000-0002-2299-5251
CR Flower RW, 2001, AM J OPHTHALMOL, V132, P85, DOI 10.1016/S0002-9394(01)00872-8
   Flower RW, 2000, AM J OPHTHALMOL, V129, P501, DOI 10.1016/S0002-9394(99)00411-0
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Shiraga F, 1998, OPHTHALMOLOGY, V105, P662, DOI 10.1016/S0161-6420(98)94021-0
   Staurenghi G, 1998, OPHTHALMOLOGY, V105, P2297, DOI 10.1016/S0161-6420(98)91232-5
   YANNUZZI LA, 1982, OPHTHALMOLOGY, V89, P157
NR 6
TC 10
Z9 10
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2002
VL 133
IS 6
BP 801
EP 808
AR PII S0002-9394(02)01436-8
DI 10.1016/S0002-9394(02)01436-8
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 557RP
UT WOS:000175922200011
PM 12036672
DA 2022-11-30
ER

PT J
AU Oncel, D
   Manafi, N
   Nittala, MG
   Velaga, SB
   Stambolian, D
   Pericak-Vance, MA
   Haines, JL
   Sadda, SR
AF Oncel, Deniz
   Manafi, Navid
   Nittala, Muneeswar Gupta
   Velaga, Swetha Bindu
   Stambolian, Dwight
   Pericak-Vance, Margaret A.
   Haines, Jonathan L.
   Sadda, Srinivas R.
TI Effect of OCT B-Scan Density on Sensitivity for Detection of
   Intraretinal Hyperreflective Foci in Eyes with Age-Related Macular
   Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Intraretinal hyperreflective foci; IHRF; SD-OCT; age-related macular
   degeneration; AMD; OCT; retinal diseases
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL THICKNESS; SEVERITY SCALE;
   PROGRESSION; IMPACT; DISEASE; DRUSEN
AB Purpose To evaluate the impact of reducing the density of B-scans in an optical coherence tomography (OCT) volume on the sensitivity for detecting intraretinal hyperreflective foci (IHRF) in eyes with intermediate age-related macular degeneration (AMD) Methods A total of 165 eyes with intermediate AMD and IHRF were evaluated in this retrospective analysis. For each case, Cirrus HD-OCT volumes were imported into the reading center 3 D-OCTOR software. The number of IHRF cases was assessed based on all 128 B-scans (spaced 47 mu m apart), using a categorical scale (graded as 1-4, 5-9, 10-14, 15-19, and >20). Additionally, the B-scan densities in the volume were lowered to 64 B-scans (spaced 94 mu m apart), 43 B-scans (spaced 140 mu m apart), and 32 B-scans (spaced 188 mu m apart). The number of eyes with any IHRF and the numerical category of IHRF in the eye were used to compare the sensitivity at each reduced B-scan density against the reference 128 B-scan volume. Results In the primary analysis for the qualitative presence or absence of any IHRF, the sensitivity decreased to 98.2% (p = .32) with 64 B-scans, 92.7% (p = .001) with 43 B-scans, and 75.2% (p = .001) with 32 B-scans, compared with the 128 B-scan reference. With regard to the number of IHRF per eye, there was a significant difference (with a lower level chosen on the scale) when the B-scan density was reduced to 43 or 32 B-scans (p = .002 and p < .001, respectively). Conclusion Increasing the inter-B-scan spacing from 47 to 188 microns significantly reduced the ability to accurately determine whether IHRF were present in an eye. An increase in inter-B-scan spacing to 140 microns was associated with a significant misclassification of the IHRF quantity. These findings may be relevant in the design of OCT scanning protocols for studies utilizing these biomarkers for AMD progression.
C1 [Oncel, Deniz; Manafi, Navid; Nittala, Muneeswar Gupta; Velaga, Swetha Bindu; Sadda, Srinivas R.] Doheny Eye Inst, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   [Oncel, Deniz; Manafi, Navid; Nittala, Muneeswar Gupta; Velaga, Swetha Bindu; Sadda, Srinivas R.] Univ Calif Los Angeles, Dept Ophthalmol, David Geffen Sch Med, Los Angeles, CA USA.
   [Stambolian, Dwight] Univ Penn, Ophthalmol & Genet, Philadelphia, PA USA.
   [Pericak-Vance, Margaret A.] Univ Miami, Hussman Inst Human Genom, Miami, FL USA.
   [Haines, Jonathan L.] Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, Cleveland, OH USA.
   [Haines, Jonathan L.] Case Western Reserve Univ, Cleveland Inst Computat Biol, Cleveland, OH USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; University of
   Pennsylvania; University of Miami; Case Western Reserve University; Case
   Western Reserve University
RP Sadda, SR (通讯作者)，Doheny Image Reading Ctr, Doheny Eye Inst, 1355 San Pablo St,Suite 211, Los Angeles, CA 90033 USA.
EM ssadda@doheny.org
RI Manafi, Navid/AAM-7393-2020
OI Manafi, Navid/0000-0002-4610-402X
FU National Eye Institute of the National Institutes of Health
   [RO1EY023164, R01EY030614]
FX Research reported in this publication was supported by the National Eye
   Institute of the National Institutes of Health under Award Number
   RO1EY023164 and R01EY030614. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   National Institutes of Health.
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Baranano AE, 2012, ACTA OPHTHALMOL, V90, pE274, DOI 10.1111/j.1755-3768.2012.02398.x
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Corradetti G, 2021, CAN J OPHTHALMOL, V56, P325, DOI 10.1016/j.jcjo.2021.01.005
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Klein R, 2015, J CLIN MED, V4, P425, DOI 10.3390/jcm4030425
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   Lim MCC, 2005, INVEST OPHTH VIS SCI, V46, P974, DOI 10.1167/iovs.04-0828
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Nassisi M, 2018, INVEST OPHTH VIS SCI, V59, P3431, DOI 10.1167/iovs.18-24143
   Nittala MG, 2019, RETINA-J RET VIT DIS, V39, P1540, DOI 10.1097/IAE.0000000000002210
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   Sadda SR, 2010, INVEST OPHTH VIS SCI, V51, P1071, DOI 10.1167/iovs.09-4325
   Velaga SB, 2017, EYE, V31, P53, DOI 10.1038/eye.2016.260
   Waldstein SM, 2020, JAMA OPHTHALMOL, V138, P740, DOI 10.1001/jamaophthalmol.2020.1376
NR 24
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD SEP 2
PY 2022
VL 47
IS 9
BP 1294
EP 1299
DI 10.1080/02713683.2022.2081981
EA JUL 2022
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4A3GR
UT WOS:000823857800001
PM 35603911
DA 2022-11-30
ER

PT J
AU Augsburger, M
   Sarra, GM
   Imesch, P
AF Augsburger, Michele
   Sarra, Gian-Marco
   Imesch, Pascal
TI Treat and extend versus pro re nata regimens of ranibizumab and
   aflibercept in neovascular age-related macular degeneration: a
   comparative study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration (AMD); Pro re nata (PRN); Treat and
   extend (T&E); Anti-VEGF treatment; Aflibercept; Ranibizumab
ID BEVACIZUMAB; EFFICACY
AB Purpose To compare treatment efficacy of anti-VEGF medications following pro re nata (PRN, "as needed", monthly injections only in case of active disease) or treat and extend (T&E, progressive extension of treatment intervals up to 12 weeks depending on the clinical findings) treatment protocols in real-world conditions. Methods Retrospective, observational study. Patients diagnosed with age-related macular degeneration and without pre-treatment undergoing routine anti-VEGF treatment in one eye clinic in Switzerland were included. Treatment was performed according to local practices, using ranibizumab or aflibercept, and following T&E or PRN regimens. Changes in logMAR and injection intervals (time between two injections) for specific treatment periods were evaluated descriptively and using mixed models. Results In total, 1071 patients with 1332 treated eyes (ranibizumab/PRN 722, ranibizumab/T&E 191, aflibercept/T&E 419) were included in the analyses. At baseline, logMAR (mean +/- SD) was similar in both ranibizumab treatment groups (PRN 0.63 +/- 0.43, T&E 0.57 +/- 0.42). In the ranibizumab/PRN group, logMAR was about 0.1 lower for all time intervals in the initial and maintenance phases in comparison with baseline, indicating an improvement in VA. By comparison, logMAR improved more strongly in the ranibizumab/T&E group (16 to < 22 months, - 0.19 [- 0.23-0.15]) in comparison with baseline. Comparing ranibizumab/T&E vs. aflibercept/T&E groups, improvements in logMAR were similar over time. In the maintenance phase, the rate of patients with a clinically relevant improvement in visual acuity (> 0.2 logMAR) was higher in both T&E groups compared with the ranibizumab/PRN group. Injection intervals in the maintenance phase in ranibizumab/T&E group gradually expanded over time; whereas in the aflibercept/T&E group, injection intervals remained relatively stable. Conclusions Ranibizumab used according to T&E protocol yielded a stronger improvement in logMAR, compared with PRN protocol with longer injection intervals than aflibercept/T&E. This large real-world data assessment supports previous data on the superiority of T&E treatment.
C1 [Augsburger, Michele; Imesch, Pascal] EYEPARC Eye Clin, Spitalgasse 26, CH-3011 Bern, Switzerland.
   [Sarra, Gian-Marco] Augenpraxis Emme, Burgdorf, Switzerland.
RP Imesch, P (通讯作者)，EYEPARC Eye Clin, Spitalgasse 26, CH-3011 Bern, Switzerland.
EM pascal@imesch.com
RI Imesch, Pascal/AAP-3218-2021
OI Imesch, Pascal/0000-0001-9131-5873
FU GKM Gesellschaft fur Therapieforschung mbH
FX GKM Gesellschaft fur Therapieforschung mbH provided support in
   completion of this manuscript.
CR AAO Retina/Vitreous PPP Panel Hoskins Center for Quality Eye Care, 2015, AG REL MAC DEG PPP U
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Pilu S, 2008, AM J OPHTHALMOL, V145, P879, DOI 10.1016/j.ajo.2007.12.036
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
NR 17
TC 49
Z9 50
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2019
VL 257
IS 9
BP 1889
EP 1895
DI 10.1007/s00417-019-04404-0
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IR9NP
UT WOS:000481772100010
PM 31256237
OA hybrid
DA 2022-11-30
ER

PT J
AU Granstam, E
   Westborg, I
   Barkander, A
   Borjesson, M
   Lindahl, S
   Meszaros, E
   Wojciechowska-Zajac, A
   Wagner, P
   Albrecht, S
   Karlsson, N
   Bjarnhall, G
   Lovestam-Adrian, M
AF Granstam, Elisabet
   Westborg, Inger
   Barkander, Anna
   Borjesson, Malin
   Lindahl, Sara
   Meszaros, Eva
   Wojciechowska-Zajac, Anna
   Wagner, Philippe
   Albrecht, Susanne
   Karlsson, Niklas
   Bjarnhall, Gunilla
   Lovestam-Adrian, Monica
TI Reduced occurrence of severe visual impairment after introduction of
   anti-Vascular Endothelial Growth Factor in wet age-related macular
   degeneration - a population- and register-based study from northern
   Sweden
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE anti-vascular endothelial growth factor; low vision clinics; Swedish
   Macula Register; wet AMD
AB PurposeTo study the occurrence of severe visual impairment (SVI) and treatment outcome at 12months in patients treated for wet age-related macular degeneration (AMD) by use of data from the Swedish Macula Register (SMR) and referrals to the regional low vision clinics in five northern counties.
   MethodsReferrals to low vision clinics during 2005, 2009 and 2013 and treatment outcome at 12months from the SMR database from 2008 until 2013 in patients >65years of age in five northern counties were included in the survey.
   ResultsThe rate of referral due to AMD was significantly reduced during the time period (-48%; p<0.001). At 12months, a significant slight mean improvement in logMAR visual acuity (VA) was observed (-0.01, SD 0.37; p<0.001) after a mean of 5.02.3 anti-vascular endothelial growth factor (VEGF)-injections were administered. Age and low baseline VA was associated with less favourable visual outcome (p<0.001).
   ConclusionReferral rate to low vision clinic is a valuable tool for estimating occurrence of SVI and fell between the years 2005 until 2013. Data from the SMR showed improvement in visual acuity on the whole, but also identified patients at high risk for developing SVI during anti-VEGF-treatment.
C1 [Granstam, Elisabet; Wagner, Philippe] Uppsala Univ, Clin Res Ctr, Cty Council Vastmanland, Vasteras, Sweden.
   [Westborg, Inger] Umea Univ, Dept Clin Sci Ophthalmol, Umea, Sweden.
   [Barkander, Anna] Ostersund Cty Hosp, Dept Ophthalmol, Ostersund, Sweden.
   [Borjesson, Malin] Skelleftea Cty Hosp, Dept Ophthalmol, Skelleftea, Sweden.
   [Lindahl, Sara] Umea Univ Hosp, Dept Ophthalmol, Umea, Sweden.
   [Meszaros, Eva] Gavleborg Cty Hosp Gavle, Dept Ophthalmol, Gavle, Sweden.
   [Wojciechowska-Zajac, Anna] Sunderby Cty Hosp, Dept Ophthalmol, Sunderbyn, Sweden.
   [Albrecht, Susanne; Karlsson, Niklas; Bjarnhall, Gunilla] RC Syd, Swedish Macula Register, Karlskrona, Sweden.
   [Lovestam-Adrian, Monica] Lund Univ, IKVL Inst Clin Sci, Ophthalmol, Lund, Sweden.
C3 Uppsala University; Umea University; Umea University; Lund University
RP Granstam, E (通讯作者)，Vastmanland Cty Hosp, Swedish Ophthalmol Soc, Dept Ophthalmol, SE-72189 Vasteras, Sweden.
EM elisabet.granstam@ltv.se
RI Westborg, Inger/AAD-7108-2021
FU Swedish Macular Register, RC Syd, Karlskrona, Sweden
FX Funding was obtained from the Swedish Macular Register, RC Syd,
   Karlskrona, Sweden.
NR 0
TC 6
Z9 6
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2016
VL 94
IS 7
BP 646
EP 651
DI 10.1111/aos.13187
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EA5BI
UT WOS:000386631400021
PM 27545047
OA Bronze
DA 2022-11-30
ER

PT J
AU Tan, ACS
   Yanagi, Y
   Cheung, GCM
AF Tan, Anna C. S.
   Yanagi, Yasuo
   Cheung, Gemmy Chui Ming
TI COMPARISON OF MULTICOLOR IMAGING AND COLOR FUNDUS PHOTOGRAPHY IN THE
   DETECTION OF PATHOLOGICAL FINDINGS IN EYES WITH POLYPOIDAL CHOROIDAL
   VASCULOPATHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; multicolor; color fundus photography;
   ocular imaging
ID MACULAR DEGENERATION
AB Purpose: To compare the appearance and frequency of detection of common features in eyes with polypoidal choroidal vasculopathy using multicolor imaging (MC) or color fundus photography (CFP). Methods: Thirty-eight eyes with indocyanine green angiography-proven polypoidal choroidal vasculopathy, imaged with both MC and CFP, were graded by three independent retinal specialists. The presence of five prespecified pathological features (blood, exudation, polypoidal lesions, pigment epithelial detachments, and atrophy) was graded on each modality independently. Multimodal imaging including optical coherence tomography, fluorescein, and indocyanine green angiography was used as the gold standard. Results: Overall, there was no statistically significant difference in the ability of MC imaging compared with CFP in detecting the pathological features. Polypoidal lesions appear as small, dark green, round lesions which have higher contrast on MC compared with a nodular orange appearance seen on CFP. Polypoidal lesions can be identified noninvasively using both MC and CFP in about half of the cases. Conclusion: There are differences in the appearance of polypoidal choroidal vasculopathy-associated features on MC compared with CFP. Both modalities are comparable for the detection of pathological features in eyes with polypoidal choroidal vasculopathy. MC imaging may be considered as an alternative to CFP.
C1 [Tan, Anna C. S.; Yanagi, Yasuo; Cheung, Gemmy Chui Ming] Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore, Singapore.
   [Tan, Anna C. S.; Yanagi, Yasuo; Cheung, Gemmy Chui Ming] Singapore Eye Res Inst, Singapore, Singapore.
   [Tan, Anna C. S.; Cheung, Gemmy Chui Ming] Duke NUS Med Sch, Singapore, Singapore.
   [Yanagi, Yasuo] Asahikawa Med Univ, Dept Ophthalmol, Asahikawa, Hokkaido, Japan.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center; National University of Singapore;
   Asahikawa Medical College
RP Cheung, GCM (通讯作者)，Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore, Singapore.
EM gemmy.cheung.c.m@singhealth.com.sg
RI Yanagi, Yasuo/AAA-5441-2022
CR Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Cheung CMG, 2018, RETINA
   Feng HL, 2019, RETINA-J RET VIT DIS, V39, P972, DOI 10.1097/IAE.0000000000002111
   Graham KW, 2018, RETINA-J RET VIT DIS, V38, P1751, DOI 10.1097/IAE.0000000000001777
   Keane PA, 2014, OPHTHALMOLOGY, V121, P2489, DOI 10.1016/j.ophtha.2014.07.054
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Leisenring W, 2000, BIOMETRICS, V56, P345, DOI 10.1111/j.0006-341X.2000.00345.x
   McNemar Q, 1947, PSYCHOMETRIKA, V12, P153, DOI 10.1007/BF02295996
   Pang CE, 2014, AM J OPHTHALMOL, V158, P171, DOI 10.1016/j.ajo.2014.03.003
   Tan ACS, 2016, OPHTHALMOLOGICA, V236, P8, DOI 10.1159/000446857
   Tan CS, 2019, CLIN EXP OPHTHALMOL, V47, P621, DOI 10.1111/ceo.13462
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 18
TC 2
Z9 2
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2020
VL 40
IS 8
BP 1512
EP 1519
DI 10.1097/IAE.0000000000002638
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NA3ZC
UT WOS:000559752400019
PM 31464882
DA 2022-11-30
ER

PT J
AU Chen, SN
   Lai, CC
   Wang, JK
   Choi, HY
   Kuo, CN
   Tsai, CY
   Wang, HI
   Yang, CM
AF Chen, San-Ni
   Lai, Chi-Chun
   Wang, Jia-Kang
   Choi, Hin-Yeung
   Kuo, Chien-Neng
   Tsai, Ching-Yao
   Wang, Hsing-, I
   Yang, Chung-May
TI Ranibizumab reimbursement and treatment patterns for neovascular
   age-related macular degeneration in Taiwan- Results from the 12-month,
   observational RENOWNED study
SO JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
LA English
DT Article
DE Macular degeneration; Ranibizumab; Reimbursement; Taiwan; Visual acuity
ID QUALITY-OF-LIFE; JAPANESE PATIENTS; VISUAL-ACUITY; RISK-FACTORS; SAFETY;
   EFFICACY; SECONDARY; MULTICENTER; OUTCOMES; THERAPY
AB Background: The RENOWNED study investigated the treatment patterns, real-world effective-ness and safety of ranibizumab in Taiwanese patients with neovascular age-related macular degeneration (nAMD) treated with ranibizumab 0.5 mg in accordance with the first reimburse-ment scheme effective from 2012 to 2014.Methods: This study was a Phase IV, 12-month, open-label, prospective, observational study conducted in Taiwan. Patients with visual impairment due to nAMD initiating treatment with ranibizumab 0.5 mg were included. The primary endpoint was mean change in best -corrected visual acuity (BCVA) from Baseline at Month 3.Results: Overall, 202 patients with nAMD were included. Mean (standard deviation [SD]) BCVA Early Treatment Diabetic Retinopathy Study letters improved from Baseline (49.6 [21.5] let-ters) at Month 3 (+4.9 [11.8], P < 0.0001), and at Month 12 (+3.5 [14.1], P = 0.0043). The proportion of patients with nAMD who lost >5 letters at Months 3 and 12 was 13.6% (n = 27) and 26.6% (n = 37), respectively. Mean (SD) central retinal thickness decreased from Baseline (320.1 [127.2] mm) with a mean reduction of 49.1 (107.3) mm at Month 3 (P < 0.0001), but was not significant at Month 12 with a mean reduction of 11.6 (115.6) mm (P = 0.2861). Mean (SD) number of ranibizumab injections over 12 months was 3.1 (1.0). A mean treatment interval of 109.5 days was observed between the third and fourth injections. After limited reimbursed ranibizumab injections, 43.8% patients received other treatments. The safety find-ings are consistent with previous studies.Conclusion: Ranibizumab 0.5 mg treatment for 12 months under real-world settings improved visual outcomes in Taiwanese patients with nAMD.Copyright 2022, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Chen, San-Ni] Changhua Christian Hosp, Changhua, Taiwan.
   [Lai, Chi-Chun] Chang Gung Mem Hosp, Linkou, Taiwan.
   [Lai, Chi-Chun] Chang Gung Mem Hosp, Keelung, Taiwan.
   [Wang, Jia-Kang] Yuan Ze Univ, Far Eastern Mem Hosp, Dept Elect Engn, Taoyuan, Taiwan.
   [Choi, Hin-Yeung] Vet Gen Hosp, Taichung, Taiwan.
   [Choi, Hin-Yeung] Taichung Tzu Chi Gen Hosp, Taichung, Taiwan.
   [Kuo, Chien-Neng] Chang Gung Mem Hosp, Chiayi, Taiwan.
   [Tsai, Ching-Yao] Taipei City Hosp, Taipei, Taiwan.
   [Wang, Hsing-, I] Mackay Mem Hosp, Taipei, Taiwan.
   [Yang, Chung-May] Natl Taiwan Univ Hosp, Taipei, Taiwan.
   [Chen, San-Ni] China Med Univ Hosp, Taichung, Taiwan.
   [Yang, Chung-May] Sch Med, Dept Ophthalmol, 7 Zhongshan South Rd, Taipei 100, Taiwan.
C3 Changhua Christian Hospital; Chang Gung Memorial Hospital; Chang Gung
   Memorial Hospital; Far Eastern Memorial Hospital; Yuan Ze University;
   Buddhist Tzu Chi General Hospital; Chang Gung Memorial Hospital; Taipei
   City Hospital; Mackay Memorial Hospital; National Taiwan University;
   National Taiwan University Hospital; China Medical University Taiwan;
   China Medical University Hospital - Taiwan
RP Yang, CM (通讯作者)，Sch Med, Dept Ophthalmol, 7 Zhongshan South Rd, Taipei 100, Taiwan.
EM chungmay@ntu.edu.tw
OI YANG, CHUNG-MAY/0000-0003-4082-420X; Lai, Chi-Chun/0000-0001-9547-7212
CR Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chang YS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25864-0
   Chen SN, 2018, INT J OPHTHALMOL-CHI, V11, P1802, DOI 10.18240/ijo.2018.11.11
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Huang EJC, 2014, EYE, V28, P705, DOI 10.1038/eye.2014.55
   Joussen AM, 2009, DTSCH ARZTEBL INT, V106, P312, DOI 10.3238/arztebl.2009.0312
   Kwon OW, 2012, GRAEF ARCH CLIN EXP, V250, P1467, DOI 10.1007/s00417-012-1970-3
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Tano Y, 2011, ACTA OPHTHALMOL, V89, P208, DOI 10.1111/j.1755-3768.2010.02065.x
   Tano Y, 2010, ACTA OPHTHALMOL, V88, P309, DOI 10.1111/j.1755-3768.2009.01843.x
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Zhao JL, 2014, BIODRUGS, V28, P527, DOI 10.1007/s40259-014-0106-1
NR 17
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER TAIWAN
PI TAIPEI
PA RM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2,
   TAIPEI, 10449, TAIWAN
SN 0929-6646
EI 1876-0821
J9 J FORMOS MED ASSOC
JI J. Formos. Med. Assoc.
PD OCT
PY 2022
VL 121
IS 10
BP 2020
EP 2027
DI 10.1016/j.jfma.2022.02.005
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 4X0QR
UT WOS:000860557400017
PM 35279311
OA gold
DA 2022-11-30
ER

PT J
AU Ricci, F
   Zampatti, S
   D'Abbruzzi, F
   Missiroli, F
   Martone, C
   Lepre, T
   Pietrangeli, I
   Sinibaldi, C
   Peconi, C
   Novelli, G
   Giardina, E
AF Ricci, Federico
   Zampatti, Stefania
   D'Abbruzzi, Francesca
   Missiroli, Filippo
   Martone, Claudia
   Lepre, Tiziana
   Pietrangeli, Ilenia
   Sinibaldi, Cecilia
   Peconi, Cristina
   Novelli, Giuseppe
   Giardina, Emiliano
TI Typing of ARMS2 and CFH in Age-Related Macular Degeneration Case-Control
   Study and Assessment of Frequency in the Italian Population
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; CARDIOVASCULAR-DISEASE; CIGARETTE-SMOKING; RISK;
   SUSCEPTIBILITY; POLYMORPHISM; MACULOPATHY; STROKE; ASSOCIATION;
   LOC387715
AB Objectives: To determine the effects of the polymorphisms CFH Tyr402His and ARMS2 del443ins54 on susceptibility to age-related macular degeneration (AMD) and to find the frequencies of these single-nucleotide polymorphisms in an Italian population that was not examined clinically.
   Methods: A total of 286 control subjects (126 men and 160 women) and 159 white patients (73 men and 86 women) harboring exudative AMD in 1 eye were recruited. A third group of 182 DNA samples from blood donors of the same geographical areas were also typed to assess the frequency of CFH Tyr402His and ARMS2 del443ins54 polymorphisms in the general population. The data were analyzed statistically by a standard 2 X 2 table, Fisher exact tests, and odds ratios.
   Results: The deletion-insertion at chromosome 10q26 (del443ins54) showed the strongest association with AMD in terms of both P value and odds ratio (P=2.7 x 10(-15); odds ratio=3.25), and a highly significant association was also confirmed for Tyr402His at the CFH locus (P=9.9 x 10(-13); odds ratio=2.86). We found no differences in allele and genotype association between classic and occult choroidal neovascularization. We also observed that 39% of the samples in the general Italian population were at least 5.4 times more likely than control subjects to develop AMD.
   Conclusions: To our knowledge, this is the first confirmation of the association of del443ins54 in Italian patients with AMD, and we also confirmed the association of Tyr402His with CFH. Genetic analysis of the general population suggested that analysis of the ARMS2 and CFH risk alleles alone may be helpful in differentiating high-risk individuals (odds ratio > 5.00) from low-risk individuals (odds ratio < 0.45).
   Clinical Relevance: Individuals at high risk for developing AMD could be identified and selected for specific prevention programs. In this context, the development of prevention programs based on dietary antioxidants or on close monitoring of at-risk individuals should be considered or suggested.
C1 [Zampatti, Stefania; Martone, Claudia; Lepre, Tiziana; Pietrangeli, Ilenia; Sinibaldi, Cecilia; Peconi, Cristina; Novelli, Giuseppe; Giardina, Emiliano] Univ Roma Tor Vergata, Dept Biopathol, Ctr Excellence Genom Risk Assessment Multifactori, Sch Med, I-00133 Rome, Italy.
   [Zampatti, Stefania; Martone, Claudia; Lepre, Tiziana; Pietrangeli, Ilenia; Sinibaldi, Cecilia; Peconi, Cristina; Novelli, Giuseppe; Giardina, Emiliano] Fdn PTV Policlin Tor Vergata, Rome, Italy.
   [Ricci, Federico; D'Abbruzzi, Francesca; Missiroli, Filippo] Retina Fdn PTV Policlin Tor Vergata, Unita Operat Semplici, Dipartimentali Patol, Rome, Italy.
C3 University of Rome Tor Vergata
RP Giardina, E (通讯作者)，Univ Roma Tor Vergata, Dept Biopathol, Ctr Excellence Genom Risk Assessment Multifactori, Sch Med, Via Montpellier 1, I-00133 Rome, Italy.
EM emiliano.giardina@uniroma2.it
RI Novelli, Giuseppe/A-5195-2013; ricci, federico/AAC-3836-2020; Peconi,
   Cristina/AAC-4448-2019; Novelli, Giuseppe/T-8822-2019; Giardina,
   Emiliano/J-1965-2012; Zampatti, Stefania/AAC-4589-2022; Novelli,
   Giuseppe/GQB-3329-2022
OI Novelli, Giuseppe/0000-0002-7781-602X; ricci,
   federico/0000-0002-4224-9280; Zampatti, Stefania/0000-0003-2502-7157;
   Novelli, Giuseppe/0000-0002-7781-602X; Peconi,
   Cristina/0000-0002-6032-6497
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cackett P, 2008, BRIT J OPHTHALMOL, V92, P1564, DOI 10.1136/bjo.2008.143875
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Voko Z, 2003, NEUROLOGY, V61, P1273, DOI 10.1212/01.WNL.0000090458.67821.A3
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zhang H, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-51
NR 30
TC 30
Z9 30
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD OCT
PY 2009
VL 127
IS 10
BP 1368
EP 1372
DI 10.1001/archophthalmol.2009.237
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 505GK
UT WOS:000270679900018
PM 19822855
DA 2022-11-30
ER

PT J
AU Constable, IJ
   Pierce, CM
   Lai, CM
   Magno, AL
   Degli-Esposti, MA
   French, MA
   McAllister, IL
   Butler, S
   Barone, SB
   Schwartz, SD
   Blumenkranz, MS
   Rakoczy, EP
AF Constable, Ian J.
   Pierce, Cora M.
   Lai, Chooi-May
   Magno, Aaron L.
   Degli-Esposti, Mariapia A.
   French, Martyn A.
   McAllister, Ian L.
   Butler, Steve
   Barone, Samuel B.
   Schwartz, Steven D.
   Blumenkranz, Mark S.
   Rakoczy, Elizabeth P.
TI Phase 2a Randomized Clinical Trial: Safety and Post Hoc Analysis of
   Subretinal rAAV.sFLT-1 for Wet Age-related Macular Degeneration
SO EBIOMEDICINE
LA English
DT Article
DE Wet age related macular degeneration; AAV.sFLT-1; Gene therapy; Clinical
   trial
ID GENE-THERAPY; OCULAR NEOVASCULARIZATION; ADENOASSOCIATED VIRUS;
   CONGENITAL AMAUROSIS; IMMUNE-RESPONSE; VEGF-TRAP; INHIBITION;
   ANGIOGENESIS; RANIBIZUMAB; EXPRESSION
AB Background: We present the results of a Phase 2a randomized controlled trial investigating the safety, and secondary endpoints of subretinal rAAV.sFLT-1 gene therapy in patientswith active wet age-related macular degeneration (wAMD).
   Methods: All patients (n = 32), (ClinicalTrials.gov;NCT01494805), received ranibizumab injections at baseline and week 4, and thereafter according to prespecified criteria. Patients in the gene therapy group (n = 21) received rAAV.sFLT-1 (1 x 10(11) vg). All patients were assessed every 4 weeks to the week 52 primary endpoint.
   Findings: Ocular adverse events (AEs) in the rAAV.sFLT-1 group were mainly procedure related and self-resolved. All 11 phakic patients in the rAAV. sFLT-1 group showed progression of cataract following vitrectomy. No systemic safety signals were observed and none of the serious AEs were associated with rAAV. sFLT-1. AAV2 capsid was not detected and rAAV.sFLT-1 DNA was detected transiently in the tears of 13 patients. ELISPOT analysis did not identify any notable changes in T-cell response. In the rAAV.sFLT-1 group 12 patients had neutralizing antibodies (nAb) to AAV2. There was no change in sFLT-1 levels in bodily fluids. In the rAAV.sFLT-1 group, Best Corrected Visual Acuity (BCVA) improved by a median of 1.0 (IQR: -3.0 to 9.0) Early Treatment Diabetic Retinopathy Study (ETDRS) letters from baseline compared to a median of -5.0 (IQR: -17.5 to 1.0) ETDRS letters change in the control group. Twelve (57%) patients in the rAAV.sFLT-1 group maintained or improved vision compared to 4 (36%) in the control group. The median number of ranibizumab retreatments was 2.0 (IQR: 1.0 to 6.0) for the gene therapy group compared to 4.0 (IQR: 3.5 to 4.0) for the control group.
   Interpretation rAAV.sFLT-1 combined with the option for co-treatment appears to be a safe and promising approach to the treatment of wAMD. (C) 2016 The Authors. Published by Elsevier B.V.
C1 [Constable, Ian J.; Pierce, Cora M.; Lai, Chooi-May; Magno, Aaron L.; Degli-Esposti, Mariapia A.; McAllister, Ian L.; Rakoczy, Elizabeth P.] Lions Eye Inst, Nedlands, WA, Australia.
   [Constable, Ian J.; McAllister, Ian L.] Sir Charles Gairdner Hosp, Nedlands, WA, Australia.
   [Constable, Ian J.; Lai, Chooi-May; Degli-Esposti, Mariapia A.; McAllister, Ian L.; Rakoczy, Elizabeth P.] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Crawley, WA, Australia.
   [French, Martyn A.] Univ Western Australia, Sch Pathol & Lab Med, Crawley, WA, Australia.
   [French, Martyn A.] Univ Western Australia, Dept Clin Immunol, Crawley, WA, Australia.
   [Butler, Steve; Barone, Samuel B.] Avalanche Biotechnol Inc, Menlo Pk, CA USA.
   [Schwartz, Steven D.] Univ Calif Los Angeles, Los Angeles, CA 90024 USA.
   [Blumenkranz, Mark S.] Stanford Dept Ophthalmol, Byers Eye Inst, Palo Alto, CA USA.
C3 Lions Eye Institute; University of Western Australia; University of
   Western Australia; University of Western Australia; University of
   Western Australia; University of Western Australia; University of
   California System; University of California Los Angeles
RP Rakoczy, EP (通讯作者)，Univ Western Australia, Ctr Ophthalmol & Visual Sci, Crawley, WA, Australia.
EM Elizabeth.rakoczy@uwa.edu.au
RI Lai, Chooi-May/H-5224-2014
OI French, Martyn/0000-0002-4644-1982; constable, ian/0000-0002-2140-6478;
   Magno, Aaron/0000-0001-6099-819X; Degli-Esposti,
   Mariapia/0000-0002-7808-5935
FU National Health and Medical Research Council of Australia [AP1010405];
   Lions Eye Institute, Perth Australia; Avalanche Biotechnologies, Menlo
   Pk, CA, USA
FX National Health and Medical Research Council of Australia (AP1010405),
   Lions Eye Institute, Perth Australia, Avalanche Biotechnologies, Menlo
   Pk, CA, USA. Avalanche Biotechnologies had no role in the design but
   participated in the data management and data analysis of the manuscript.
   The other two funding agencies contribution was only financial.
CR Bennett J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002865
   BLANKENSHIP GW, 1985, OPHTHALMOLOGY, V92, P503
   Bouck N, 2002, TRENDS MOL MED, V8, P330, DOI 10.1016/S1471-4914(02)02362-6
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Lai CM, 2012, GENE THER, V19, P999, DOI 10.1038/gt.2011.169
   Lai CM, 2009, INVEST OPHTH VIS SCI, V50, P4279, DOI 10.1167/iovs.08-3253
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Lai CM, 2001, HUM GENE THER, V12, P1299, DOI 10.1089/104303401750270959
   Lai YKY, 2003, ADV EXP MED BIOL, V533, P447
   Lai YKY, 2002, GENE THER, V9, P804, DOI 10.1038/sj.gt.3301695
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Li QH, 2008, MOL VIS, V14, P1760
   Luo L, 2013, ELIFE, V2, DOI 10.7554/eLife.00324
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Naldini L, 2015, NATURE, V526, P351, DOI 10.1038/nature15818
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Pierce E. A., 2015, PERSPECT MED, V5
   Rakoczy E. P., 2015, LANCET
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Simonelli F, 2010, MOL THER, V18, P643, DOI 10.1038/mt.2009.277
   Testa F, 2013, OPHTHALMOLOGY, V120, P1283, DOI 10.1016/j.ophtha.2012.11.048
   Uehara H, 2015, AM J OPHTHALMOL, V159, P92, DOI 10.1016/j.ajo.2014.09.036
   Vasireddy V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061396
NR 31
TC 88
Z9 94
U1 0
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352-3964
J9 EBIOMEDICINE
JI EBioMedicine
PD DEC
PY 2016
VL 14
BP 168
EP 175
DI 10.1016/j.ebiom.2016.11.016
PG 8
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA EM4AP
UT WOS:000395256000023
PM 27865764
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Scott, IU
   Jacko, JA
   Sainfort, F
   Leonard, VK
   Kongnakorn, T
   Moloney, KP
AF Scott, Ingrid U.
   Jacko, Julie A.
   Sainfort, Francois
   Leonard, V. Kathlene
   Kongnakorn, Thitima
   Moloney, Kevin P.
TI The impact of auditory and haptic feedback on computer task performance
   in patients with age-related macular degeneration and control subjects
   with no known ocular disease
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; human-computer interaction; universal
   access; auditory feedback; haptic feedback
ID MULTIMODAL FEEDBACK; ACCURACY; COHORT
AB Purpose: To determine the impact of auditory and haptic (tactile) feedback on computer task performance of patients with age-related macular degeneration (AMD) compared to controls.
   Methods: Thirty patients with AMD and 29 similarly aged controls with no known ocular disease completed timed computer icon "drag and drop" tasks under all four possible conditions of presence or absence of auditory and haptic feedback in a two-factor repeated measures design. Patient recruitment was stratified by best eye acuity: 20/20-20/50; 20/6020/100; <20/100. Controls had best eye acuity !20/30. Task completion time was quantified using final target highlight time (FFHT) and total trial time, measured in milliseconds.
   Results: Mean - standard deviation (SD) FTHT with neither feedback type in the three patient and control groups was, respectively: 1,110 +/- 356, 1,682 +/- 1,069, 1,763 +/- 831, 924 +/- 533. Auditory feedback improved performance [%FTHT decrease, p-value] in all groups, respectively: 18%, P = 0.018; 38%, P = 0.054; 57%, P = 0.001; 19%, P = 0.001. Haptic feedback improved performance in the worst acuity AMD group and controls: 46%, P = 0.009; 17%, P = 0.038. In the worst acuity AMD group, auditory and/or haptic feedback was associated with a 4-6 second mean (for each task) reduction in total trial time.
   Conclusion: Auditory and haptic feedback can substantially increase performance speed of computer "drag and drop" tasks for patients with AMD, particularly in those patients with the most compromised vision.
C1 Penn State Coll Med, Dept Ophthalmol, Hershey, PA 17033 USA.
   Georgia Inst Technol, Dept Ind & Syst Engn, Atlanta, GA 30332 USA.
   Emory Univ, Sch Med, Wallace H Coulter Dept Biomed Engn, Atlanta, GA USA.
   Caro Res, Concord, MA USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health; University System of
   Georgia; Georgia Institute of Technology; Emory University
RP Scott, IU (通讯作者)，Penn State Coll Med, Dept Ophthalmol, 500 Univ Dr,HU19, Hershey, PA 17033 USA.
EM iscott@psu.edu
OI Scott, Ingrid/0000-0002-3908-7153
CR Birch J., 1979, CONGENITAL ACQUIRED, P83
   Brewster S., 1998, P INT C AUD DISPL IC, P1
   *EARL TREATM DIAB, 1980, MAN OP, P1
   Farnsworth D., 1947, FARNSWORTH DICHOTOMO, P1
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Jacko J., 2003, P SIGCHI C HUM FACT, P33, DOI DOI 10.1145/642611.642619
   Jacko J. A., 2004, CHI LETT, V6, P311
   Jacko JA, 2005, INT J HUM-COMPUT INT, V18, P183, DOI 10.1207/s15327590ijhc1802_4
   Jacko JA, 2003, LECT NOTES COMPUT SC, V2615, P3
   Jacko JA, 2000, INT J HUM-COMPUT INT, V12, P135, DOI 10.1207/S15327590IJHC1201_6
   Jacko JA, 2000, INT J HUM-COMPUT INT, V12, P151, DOI 10.1207/S15327590IJHC1201_7
   JACKO JA, 1999, P 9 ANN INT C HUM CO, P975
   Pappas C.J, 1999, P ASS COMP MACH C HU, P330
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Scott IU, 2002, AM J OPHTHALMOL, V134, P857, DOI 10.1016/S0002-9394(02)01795-6
   Scott IU, 2002, AM J OPHTHALMOL, V133, P350, DOI 10.1016/S0002-9394(01)01406-4
   Vitense H. S., 2002, Universal Access in the Information Society, V2, P76, DOI 10.1007/s10209-002-0038-2
NR 17
TC 2
Z9 2
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2006
VL 26
IS 7
BP 803
EP 810
DI 10.1097/01.iae.0000244269.29137.2f
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 180TQ
UT WOS:000247389300015
PM 16963855
DA 2022-11-30
ER

PT J
AU Nita, M
   Grzybowski, A
AF Nita, Malgorzata
   Grzybowski, Andrzej
TI Smoking and Eye Pathologies. A Systemic Review. Part II. Retina
   Diseases, Uveitis, Optic Neuropathies, Thyroid-Associated Orbitopathy
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE Tobacco smoking; retinopathy; ocular inflammation; optic neuropathy;
   orbitopathy; adults; children
ID COMPLEMENT FACTOR-H; AGE-RELATED MACULOPATHY; TOBACCO-ALCOHOL AMBLYOPIA;
   ENDOTHELIAL GROWTH-FACTOR; CYSTOID MACULAR EDEMA; I DIABETES-MELLITUS;
   BODY-MASS INDEX; CIGARETTE-SMOKING; RISK-FACTORS; MATRIX
   METALLOPROTEINASES
AB Background: Tobacco smoking has detrimental influence on human health.
   Aim: The analysis of influence of tobacco smoking on retina diseases, uveitis, optic neuropathies, and thyroid-associated orbitopathy in adults and children.
   Methods: A comprehensive review of the literature performed through MEDLINE and PubMed searches, covering the years 2000-2016.
   Results: In adults, tobacco smoking is a strong risk factor for age-related macular degeneration, polypoidal choroidal vasculopathy, uveitis and inflamed cystoid macular edema as well as Grave`s ophthalmopathy. Tobacco smoking reduces thickness of the retina and choroid, plays a role in episcleritis, sclerits, tobacco optic neuropathy, and Leber's hereditary optic neuropathy. In children, maternal smoking is a significant risk factor for stages 3 and 4 retinopathy of prematurity, optic nerve hypoplasia among babies with a birth weight over 2500 g and thinner retinal nerve fiber layer.
   Conclusion: Tobacco smoking plays an important role in the pathogenesis of many posterior eye segment diseases leading to blindness in adults and children.
C1 [Nita, Malgorzata] Domest & Specialized Med Ctr Dilmed, Katowice, Poland.
   [Grzybowski, Andrzej] Poznan City Hosp, Dept Ophthalmol, Poznan, Poland.
   [Grzybowski, Andrzej] Univ Warmia & Mazury, Fac Med, Chair Ophthalmol, Olsztyn, Poland.
C3 University of Warmia & Mazury
RP Grzybowski, A (通讯作者)，Jozef Strus Poznan City Hosp, Dept Ophthalmol, 3 Szwajcarska St, PL-361285 Poznan, Poland.
EM ae.grzybowski@gmail.com
RI Grzybowski, A/E-4486-2010
OI Grzybowski, A/0000-0002-3724-2391
CR Ambrose JA, 2004, J AM COLL CARDIOL, V43, P1731, DOI 10.1016/j.jacc.2003.12.047
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Ayala-Haedo JA, 2010, ANN HUM GENET, V74, P195, DOI 10.1111/j.1469-1809.2010.00570.x
   Bartalena L, 2000, ENDOCR REV, V21, P168, DOI 10.1210/er.21.2.168
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Behbehani R, 2005, BRIT J OPHTHALMOL, V89, P1543, DOI 10.1136/bjo.2005.079137
   Behbehani R, 2007, CLIN OPHTHALMOL, V1, P233
   Beranek M, 2008, MOL VIS, V14, P1114
   Beratis NG, 2000, J PEDIATR-US, V136, P760, DOI 10.1016/S0022-3476(00)42314-0
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bloomgarden ZT, 2007, AM J HEALTH-SYST PH, V64, pS8, DOI 10.2146/ajhp070331
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Boonman ZFHM, 2005, EYE, V19, P949, DOI 10.1038/sj.eye.6701731
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Carelli V, 2002, NEUROCHEM INT, V40, P573, DOI 10.1016/S0197-0186(01)00129-2
   Cawood TJ, 2007, J CLIN ENDOCR METAB, V92, P59, DOI 10.1210/jc.2006-1824
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   CHATURVEDI N, 1995, DIABETES CARE, V18, P785, DOI 10.2337/diacare.18.6.785
   Chaturvedi N, 2001, DIABETES CARE, V24, P284, DOI 10.2337/diacare.24.2.284
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Chheda LV, 2012, OPHTHALMOLOGY, V119, P333, DOI 10.1016/j.ophtha.2011.08.003
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Chua ACG, 2007, CRIT REV CL LAB SCI, V44, P413, DOI 10.1080/10408360701428257
   Ciancio G, 2010, RHEUMATOLOGY, V49, P501, DOI 10.1093/rheumatology/kep401
   Coleman AL, 2010, AM J OPHTHALMOL, V149, P160, DOI 10.1016/j.ajo.2009.07.025
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Conklin BS, 2002, AM J PATHOL, V160, P413, DOI 10.1016/S0002-9440(10)64859-6
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   CULLOM ME, 1993, ARCH OPHTHALMOL-CHIC, V111, P1482, DOI 10.1001/archopht.1993.01090110048021
   Cunningham ET, 2010, BRIT J OPHTHALMOL, V94, P813, DOI 10.1136/bjo.2009.178780
   CURCIO CA, 1990, J COMP NEUROL, V300, P5, DOI 10.1002/cne.903000103
   Czarnywojtek Agata, 2012, Przegl Lek, V69, P1140
   Danesh-Meyer H, 2000, SURV OPHTHALMOL, V44, P329, DOI 10.1016/S0039-6257(99)00117-4
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Delcourt C, 2011, INVEST OPHTH VIS SCI, V52, P5955, DOI 10.1167/iovs.10-6235
   Dervisogullari MS, 2014, CUTAN OCUL TOXICOL
   Dhubhghaill SSN, 2010, ADV EXP MED BIOL, V664, P437, DOI 10.1007/978-1-4419-1399-9_50
   Dom AM, 2011, INVEST OPHTH VIS SCI, V52, P4428, DOI 10.1167/iovs.10-5461
   Donaldson MJ, 2007, AM J OPHTHALMOL, V144, P812, DOI 10.1016/j.ajo.2007.08.023
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Eckstein A, 2003, BRIT J OPHTHALMOL, V87, P773, DOI 10.1136/bjo.87.6.773
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Egleton RD, 2009, PHARMACOL THERAPEUT, V121, P205, DOI 10.1016/j.pharmthera.2008.10.007
   Eliasson B, 2003, PROG CARDIOVASC DIS, V45, P405, DOI 10.1053/pcad.2003.00103
   Evereklioglu C, 2003, OPHTHAL PHYSL OPT, V23, P527, DOI 10.1046/j.1475-1313.2003.00148.x
   Fairweather-Tait SJ, 2007, GENES NUTR, V2, P15, DOI 10.1007/s12263-007-0007-8
   Fayol L, 2005, BIOL NEONATE, V87, P121, DOI 10.1159/000082128
   Fisher SA, 2007, HUM MUTAT, V28, P406, DOI 10.1002/humu.20464
   FOULDS WS, 1974, BRIT J OPHTHALMOL, V58, P386, DOI 10.1136/bjo.58.4.386
   Francis PJ, 2008, MOL VIS, V14, P1395
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   FREEMAN AG, 1988, J ROY SOC MED, V81, P103, DOI 10.1177/014107688808100219
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Galor A, 2010, BRIT J OPHTHALMOL, V94, P848, DOI 10.1136/bjo.2009.174466
   Giebel SJ, 2005, LAB INVEST, V85, P597, DOI 10.1038/labinvest.3700251
   Gilicze A, 2007, MOL IMMUNOL, V44, P2961, DOI 10.1016/j.molimm.2007.01.004
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grzybowski A, 2013, J NEUROL SCI, V332, P156, DOI 10.1016/j.jns.2013.06.006
   Grzybowski A, 2011, ACTA OPHTHALMOL, V89, P495, DOI 10.1111/j.1755-3768.2009.01853.x
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamilton MS, 2006, BRIT MED J, V333, P654, DOI 10.1136/bmj.333.7569.654-c
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   HARRINGTON DO, 1962, AM J OPHTHALMOL, V53, P967, DOI 10.1016/0002-9394(62)93018-0
   Hayreh SS, 2007, OPHTHALMOLOGY, V114, P804, DOI 10.1016/j.ophtha.2006.07.062
   HEATON JM, 1958, LANCET, V2, P286
   Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961
   Hegedus L, 2004, J ENDOCRINOL INVEST, V27, P265, DOI 10.1007/BF03345276
   HELM CJ, 1995, AM J OPHTHALMOL, V120, P55, DOI 10.1016/S0002-9394(14)73759-6
   Hirabayashi H, 2010, EYE, V24, P1024, DOI 10.1038/eye.2009.263
   Hirai FE, 2007, DIABETES CARE, V30, P1437, DOI 10.2337/dc06-2264
   Hoffmann D, 2001, CHEM RES TOXICOL, V14, P767, DOI 10.1021/tx000260u
   Hood DC, 2013, PROG RETIN EYE RES, V32, P1, DOI 10.1016/j.preteyeres.2012.08.003
   Houston TK, 2006, BMJ-BRIT MED J, V332, P1064, DOI 10.1136/bmj.38779.584028.55
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   JESTICO JV, 1984, J NEUROL NEUROSUR PS, V47, P573, DOI 10.1136/jnnp.47.6.573
   Jin M, 2001, RETINA-J RET VIT DIS, V21, P28, DOI 10.1097/00006982-200102000-00005
   Kaklamani VG, 2002, CLIN RHEUMATOL, V21, P341, DOI 10.1007/s100670200090
   Karamanos B, 2000, DIABETOLOGIA, V43, P348, DOI 10.1007/s001250050053
   KELLY SP, 2004, BRIT MED J, V328, P357
   Kennedy RD, 2011, OPTOMETRY, V82, P310, DOI 10.1016/j.optm.2010.10.014
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kiechl-Kohlendorfer U, 2010, ACTA PAEDIATR, V99, P1016, DOI 10.1111/j.1651-2227.2010.01749.x
   Kirby ML, 2010, INVEST OPHTH VIS SCI, V51, P6722, DOI 10.1167/iovs.10-5344
   Kirkman MA, 2009, BRAIN, V132, P2317, DOI 10.1093/brain/awp158
   Kiuchi K, 2008, INVEST OPHTH VIS SCI, V49, P1705, DOI 10.1167/iovs.07-0089
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1859, DOI 10.1016/j.ophtha.2008.08.023
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Klein R, 2010, OPHTHALMOLOGY, V117, P63, DOI 10.1016/j.ophtha.2009.06.051
   Klein R, 2009, OPHTHALMOLOGY, V116, P497, DOI 10.1016/j.ophtha.2008.10.016
   Knox DL, 2008, AM J OPHTHALMOL, V146, P479, DOI 10.1016/j.ajo.2008.05.019
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Kowluru RA, 2010, INVEST OPHTH VIS SCI, V51, P4320, DOI 10.1167/iovs.09-4851
   Kroon LA, 2007, AM J HEALTH-SYST PH, V64, P1917, DOI 10.2146/ajhp060414
   KRUMSIEK J, 1985, ACTA NEUROL SCAND, V72, P180
   Kuntzer T, 2002, REV NEUROL-FRANCE, V158, P1236
   La Torre G, 2013, EUR J EPIDEMIOL, V28, P445, DOI 10.1007/s10654-013-9798-7
   Langhans M, 1997, BRIT J OPHTHALMOL, V81, P365, DOI 10.1136/bjo.81.5.365
   Larsson LI, 1999, ACTA OPHTHALMOL SCAN, V77, P430, DOI 10.1034/j.1600-0420.1999.770415.x
   Lee Ji Hwan, 2010, Korean J Ophthalmol, V24, P267, DOI 10.3341/kjo.2010.24.5.267
   Lee S, 2013, J KOREAN MED SCI, V28, P769, DOI 10.3346/jkms.2013.28.5.769
   Lee SJ, 2010, CLIN EXP OPHTHALMOL, V38, P698, DOI 10.1111/j.1442-9071.2010.02316.x
   Leonard S, 2001, Nicotine Tob Res, V3, P203
   Lessell S, 1998, J NEURO-OPHTHALMOL, V18, P106
   Lim SL, 2008, THYROID, V18, P1297, DOI 10.1089/thy.2008.0044
   Lin P, 2010, OPHTHALMOLOGY, V117, P585, DOI 10.1016/j.ophtha.2009.08.011
   Liu K, 2013, OPHTHALMOLOGY, V120, P837, DOI 10.1016/j.ophtha.2012.10.003
   Loane E, 2008, BRIT J OPHTHALMOL, V92, P1163, DOI 10.1136/bjo.2007.135566
   Lois N, 2008, BRIT J OPHTHALMOL, V92, P1304, DOI 10.1136/bjo.2008.141168
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   McGinnity F G, 1993, Paediatr Perinat Epidemiol, V7, P417, DOI 10.1111/j.1365-3016.1993.tb00423.x
   Mercado C, 2007, CURR HYPERTENS REP, V9, P66, DOI 10.1007/s11906-007-0012-8
   Mohamed Q, 2007, JAMA-J AM MED ASSOC, V298, P902, DOI 10.1001/jama.298.8.902
   Moschos Marilita M, 2016, Oxid Med Cell Longev, V2016, P2905789, DOI 10.1155/2016/2905789
   Moss SE, 1996, OPHTHALMOLOGY, V103, P1438, DOI 10.1016/S0161-6420(96)30486-7
   Moura FC, 2010, INDIAN J OPHTHALMOL, V58, P143, DOI 10.4103/0301-4738.60087
   MUHLHAUSER I, 1986, DIABETOLOGIA, V29, P500, DOI 10.1007/BF00453501
   Mwanza JC, 2011, INVEST OPHTH VIS SCI, V52, P8323, DOI 10.1167/iovs.11-7962
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Naj AC, 2013, ANN HUM GENET, V77, P215, DOI 10.1111/ahg.12011
   Nakanishi H, 2010, INVEST OPHTH VIS SCI, V51, P6183, DOI 10.1167/iovs.09-4948
   Neuner B, 2009, ADDICT BEHAV, V34, P938, DOI 10.1016/j.addbeh.2009.05.015
   Nilsson PM, 2004, DIABETES METAB, V30, P261, DOI 10.1016/S1262-3636(07)70117-9
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Nussenblatt RB, 2010, UVEITIS FUNDAMENTALS, P210
   Orosz Z, 2007, AM J PHYSIOL-HEART C, V292, pH130, DOI 10.1152/ajpheart.00599.2006
   Pfeilschifter J, 1996, CLIN ENDOCRINOL, V45, P477, DOI 10.1046/j.1365-2265.1996.8220832.x
   Pons M, 2011, INVEST OPHTH VIS SCI, V52, P3842, DOI 10.1167/iovs.10-6254
   PRUMMEL MF, 1993, JAMA-J AM MED ASSOC, V269, P479, DOI 10.1001/jama.269.4.479
   Pueyo V, 2011, EARLY HUM DEV, V87, P331, DOI 10.1016/j.earlhumdev.2011.01.042
   Qin S, 2007, DRUG DEVELOP RES, V68, P213, DOI 10.1002/ddr.20185
   Raffetto JD, 2008, BIOCHEM PHARMACOL, V75, P346, DOI 10.1016/j.bcp.2007.07.004
   Ram FSF, 2011, EYE, V25, P123, DOI 10.1038/eye.2010.171
   Rizvi SW, 2001, CLIN EXP RHEUMATOL, V19, pS77
   Roesel M, 2011, GRAEF ARCH CLIN EXP, V249, P903, DOI 10.1007/s00417-010-1597-1
   Roesel M, 2011, EUR J OPHTHALMOL, V21, P625, DOI 10.5301/EJO.2011.6297
   Romero P, 2007, J DIABETES COMPLICAT, V21, P172, DOI 10.1016/j.jdiacomp.2006.07.008
   Rucker CW, 1946, AM ACAD OPHTHALMOL, P24
   Sadun A, 1998, Trans Am Ophthalmol Soc, V96, P881
   Sadun AA, 2011, CURR TREAT OPTION NE, V13, P109, DOI 10.1007/s11940-010-0100-y
   Santiesteban-Freixas R, 2010, SEMIN OPHTHALMOL, V25, P112, DOI 10.3109/08820538.2010.500267
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schaumberg DA, 2010, ARCH OPHTHALMOL-CHIC, V128, P1462, DOI 10.1001/archophthalmol.2010.261
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2005, MOL VIS, V11, P941
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Seddon JM, 2010, MOL VIS, V16, P2412
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Shea AK, 2008, NICOTINE TOB RES, V10, P267, DOI 10.1080/14622200701825908
   Shiau MY, 2006, MT SINAI J MED, V73, P1024
   Sidle EH, 2007, AM J PHYSIOL-REG I, V293, pR754, DOI 10.1152/ajpregu.00505.2006
   SILVETTE H, 1960, AM J OPHTHALMOL, V50, P71, DOI 10.1016/0002-9394(60)90842-4
   Sinclair SH, 2005, CLEV CLIN J MED, V72, P447, DOI 10.3949/ccjm.72.5.447
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   Sonmez K, 2008, OPHTHALMOLOGY, V115, P1065, DOI 10.1016/j.ophtha.2007.08.050
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Stratton IM, 2001, DIABETOLOGIA, V44, P156, DOI 10.1007/s001250051594
   STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804
   SUBAR AF, 1990, AM J PUBLIC HEALTH, V80, P1323, DOI 10.2105/AJPH.80.11.1323
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Tamakoshi A, 1997, BRIT J OPHTHALMOL, V81, P901, DOI 10.1136/bjo.81.10.901
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tao Y, 2010, EYE, V24, P648, DOI 10.1038/eye.2009.160
   Targher G, 1997, J CLIN ENDOCR METAB, V82, P3619, DOI 10.1210/jc.82.11.3619
   Thorlund MG, 2013, OPHTHALMOLOGICA, V230, P50, DOI 10.1159/000350813
   Thorne JE, 2008, AM J OPHTHALMOL, V145, P841, DOI 10.1016/j.ajo.2007.12.032
   Thornton J, 2007, EYE, V21, P1135, DOI 10.1038/sj.eye.6702603
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Thrailkill KM, 2007, DIABETES CARE, V30, P2321, DOI 10.2337/dc07-0162
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tornqvist K, 2002, ACTA OPHTHALMOL SCAN, V80, P300, DOI 10.1034/j.1600-0420.2002.800313.x
   Tsai CC, 2009, EYE, V23, P1725, DOI 10.1038/eye.2008.310
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   US Department of Health and Human Services, 2004, HLTH CONS SMOK REP S
   van Kooij B, 2008, EYE, V22, P256, DOI 10.1038/sj.eye.6702595
   Venza I, 2012, AGING CLIN EXP RES, V24, P530, DOI 10.3275/8477
   Vestergaard P, 2002, EUR J ENDOCRINOL, V146, P153, DOI 10.1530/eje.0.1460153
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   VOCTOR M, 1965, ARCH OPHTHALMOL-CHIC, V74, P649, DOI 10.1001/archopht.1965.00970040651011
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Wang JL, 2009, CURR VASC PHARMACOL, V7, P209, DOI 10.2174/157016109787455581
   Wang YX, 2011, ACTA OPHTHALMOL, V89, pE210, DOI 10.1111/j.1755-3768.2009.01787.x
   Wiersinga WM, 2013, CLIN ENDOCRINOL, V79, P145, DOI 10.1111/cen.12222
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wysokinski D, 2011, TOHOKU J EXP MED, V223, P253, DOI 10.1620/tjem.223.253
   Xu L, 2010, GRAEF ARCH CLIN EXP, V248, P1045, DOI 10.1007/s00417-009-1245-9
   Xu YL, 2008, MOL VIS, V14, P1373
   Yang R, 2007, ANN NY ACAD SCI, V1103, P196, DOI 10.1196/annals.1394.000
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Younge BR, 1996, OPTIC NERVE DISORDER, P163
   Zeidler R, 2007, APOPTOSIS, V12, P1927, DOI 10.1007/s10495-007-0102-8
   Zhang XZ, 2011, PREV CHRONIC DIS, V8
NR 210
TC 26
Z9 26
U1 0
U2 12
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2017
VL 23
IS 4
BP 639
EP 654
DI 10.2174/1381612823666170111095723
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA EN0FI
UT WOS:000395685300014
PM 28078992
DA 2022-11-30
ER

PT J
AU Loyet, KM
   Good, J
   Davancaze, T
   Sturgeon, L
   Wang, XD
   Yang, JH
   Le, KN
   Wong, M
   Hass, PE
   Campagne, MV
   Haughney, PC
   Morimoto, A
   Damico-Beyer, LA
   DeForge, LE
AF Loyet, Kelly M.
   Good, Jeremy
   Davancaze, Teresa
   Sturgeon, Lizette
   Wang, Xiangdan
   Yang, Jihong
   Le, Kha N.
   Wong, Maureen
   Hass, Philip E.
   Campagne, Menno van Lookeren
   Haughney, Peter C.
   Morimoto, Alyssa
   Damico-Beyer, Lisa A.
   DeForge, Laura E.
TI Complement Inhibition in Cynomolgus Monkeys by Anti-Factor D
   Antigen-Binding Fragment for the Treatment of an Advanced Form of Dry
   Age-Related Macular Degeneration
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID D MONOCLONAL-ANTIBODY; ALTERNATIVE PATHWAY; ACTIVATION; DRUSEN; MODEL;
   PROGRESSION; HYPOTHESIS; SYSTEM; SERUM; C3
AB Anti-factor D (AFD; FCFD4514S, lampalizumab) is a humanized IgG Fab fragment directed against factor D (fD), a rate-limiting serine protease in the alternative complement pathway (AP). Evaluation of AFD as a potential intravitreal (IVT) therapeutic for dry age-related macular degeneration patients with geographic atrophy (GA) is ongoing. However, it is unclear whether IVT administration of AFD can affect systemic AP activation and potentially compromise host-immune responses. We characterized the pharmacologic properties of AFD and assessed the effects of AFD administered IVT (2 or 20 mg) or intravenous (0.2, 2, or 20 mg) on systemic complement activity in cynomolgus monkeys. For the IVT groups, serum AP activity was reduced for the 20 mg dose group between 2 and 6 hours postinjection. For the intravenous groups, AFD inhibited systemic AP activity for periods of time ranging from 5 minutes (0.2 mg group) to 3 hours (20 mg group). Interestingly, the concentrations of total serum fD increased up to 10-fold relative to predose levels following administration of AFD. Furthermore, AFD was found to inhibit systemic AP activity only when the molar concentration of AFD exceeded that of fD. This occurred in cynomolgus monkeys at serum AFD levels >= 2 mu g/ml, a concentration 8-fold greater than the maximum serum concentration observed following a single 10 mg IVT dose in a clinical investigation in patients with GA. Based on these findings, the low levels of serum AFD resulting from IVT administration of a clinically relevant dose are not expected to appreciably affect systemic AP activity.
C1 [Loyet, Kelly M.; Sturgeon, Lizette; DeForge, Laura E.] Genentech Inc, Dept Biochem & Cellular Pharmacol, San Francisco, CA 94080 USA.
   [Good, Jeremy; Davancaze, Teresa; Wong, Maureen; Morimoto, Alyssa] Genentech Inc, Dept Assay Dev & Technol, San Francisco, CA 94080 USA.
   [Wang, Xiangdan; Yang, Jihong] Genentech Inc, Dept BioAnalyt Sci, San Francisco, CA 94080 USA.
   [Le, Kha N.; Haughney, Peter C.; Damico-Beyer, Lisa A.] Genentech Inc, Dept Pharmacokinet & Pharmacodynam, San Francisco, CA 94080 USA.
   [Hass, Philip E.] Genentech Inc, Dept Prot Chem, San Francisco, CA 94080 USA.
   [Campagne, Menno van Lookeren] Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding;
   Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche
   Holding; Genentech
RP Loyet, KM (通讯作者)，Genentech Inc, 1 DNA Way,MS 98, San Francisco, CA 94080 USA.
EM loyet.kelly@gene.com
RI Loyet, Kelly/AAD-7544-2021
OI Le, Kha/0000-0002-5446-819X
FU Genentech
FX This work was supported by Genentech. Support for third-party writing
   assistance by AnshinBioSolutions Services was provided by Genentech.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   BARNUM SR, 1984, J IMMUNOL METHODS, V67, P303, DOI 10.1016/0022-1759(84)90470-8
   Biesma DH, 2001, J CLIN INVEST, V108, P233, DOI 10.1172/JCI200112023
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   BOKISCH VA, 1970, J CLIN INVEST, V49, P2427, DOI 10.1172/JCI106462
   Carroll MV, 2011, ADV DRUG DELIVER REV, V63, P965, DOI 10.1016/j.addr.2011.06.005
   COOK KS, 1985, P NATL ACAD SCI USA, V82, P6480, DOI 10.1073/pnas.82.19.6480
   Davda JP, 2010, MABS-AUSTIN, V2, P576, DOI 10.4161/mabs.2.5.12833
   Do DV, 2014, RETINA-J RET VIT DIS, V34, P313, DOI 10.1097/IAE.0b013e3182979ddd
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fung M, 2001, J THORAC CARDIOV SUR, V122, P113, DOI 10.1067/mtc.2001.114777
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hayashi N, 2007, BRIT J CLIN PHARMACO, V63, P548, DOI 10.1111/j.1365-2125.2006.02803.x
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Katschke KJ, 2012, J BIOL CHEM, V287, P12886, DOI 10.1074/jbc.M112.345082
   Katschke KJ, 2009, J BIOL CHEM, V284, P10473, DOI 10.1074/jbc.M809106200
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Loyet KM, 2012, INVEST OPHTH VIS SCI, V53, P6628, DOI 10.1167/iovs.12-9587
   Makrides SC, 1998, PHARMACOL REV, V50, P59
   MAY JE, 1973, J IMMUNOL, V111, P1661
   Mayer M.M., 1961, EXPT IMMUNOCHEMISTRY, P133
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Onell A, 2005, J MOL RECOGNIT, V18, P307, DOI 10.1002/jmr.745
   PANGBURN MK, 1988, METHOD ENZYMOL, V162, P639
   PASCUAL M, 1988, KIDNEY INT, V34, P529, DOI 10.1038/ki.1988.214
   Prasad PS, 2010, MATURITAS, V66, P46, DOI 10.1016/j.maturitas.2010.02.006
   Ricklin D, 2007, NAT BIOTECHNOL, V25, P1265, DOI 10.1038/nbt1342
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Rohrer B, 2007, INVEST OPHTH VIS SCI, V48, P5282, DOI 10.1167/iovs.07-0282
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarma JV, 2011, CELL TISSUE RES, V343, P227, DOI 10.1007/s00441-010-1034-0
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Tanhehco EJ, 1999, TRANSPLANT P, V31, P2168, DOI 10.1016/S0041-1345(99)00297-3
   Undar A, 2002, ANN THORAC SURG, V74, P355, DOI 10.1016/S0003-4975(02)03656-1
   VOLANAKIS JE, 1985, NEW ENGL J MED, V312, P395, DOI 10.1056/NEJM198502143120702
   Wiesmann C, 2006, NATURE, V444, P217, DOI 10.1038/nature05263
   Yaspan B, 2014, INVEST OPHTH VIS SCI, V55
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 44
TC 35
Z9 42
U1 0
U2 2
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
EI 1521-0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD DEC
PY 2014
VL 351
IS 3
BP 527
EP 537
DI 10.1124/jpet.114.215921
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AT9AK
UT WOS:000345219800006
PM 25232192
DA 2022-11-30
ER

PT J
AU Mekjavic, PJ
   Gregorcic, B
   Oberc, C
   Podgorsek, S
AF Mekjavic, Polona Jaki
   Gregorcic, Bogdan
   Oberc, Cvetka
   Podgorsek, Slava
TI Treat-and-extend therapy using intravitreal aflibercept for neovascular
   age-related macular degeneration: 2-year real-world practice data from
   Slovenia
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; Anti-VEGF; Neovascular age-related macular degeneration;
   Real-world data; Treat and extend; Visual acuity
ID LONG-TERM OUTCOMES; RANIBIZUMAB; REGIMENS
AB BackgroundTo assess visual outcomes over 24months in patients with neovascular age-related macular degeneration (nAMD) who initiated intravitreal aflibercept therapy under a treat-and-extend (TE) regimen in real-world settings.MethodsIn this retrospective, observational, multicentre study in Slovenia, medical records of all treatment-naive patients with nAMD who started intravitreal aflibercept therapy between October 2013 and April 2015 were reviewed. The primary outcome measure was change in mean visual acuity (VA) from baseline to 24months in patients who received the TE regimen for 2years, assessed by standardised Early Treatment Diabetic Retinopathy Study charts and calculated as least-squares means. Other outcome measures included the numbers of injections and visits at 12months and 24months.ResultsThe primary analysis included 115 eyes of 105 patients who received TE treatment for 2years (Group A). The mean VA improved from 57.914.9 letters at baseline to 64.6 +/- 15.8 letters (+6.5 letters, p<0.0001) at 12months and 64.8 +/- 15.6 letters (+7.0 letters, p<0.0001) at 24months. The mean number of injections per eye was 8.4 +/- 1.9 and the mean number of visits was 8.8 +/- 1.7 at 12months; these numbers decreased to 6.1 +/- 2.0 and 6.4 +/- 1.9, respectively, at 24months. The additional analysis included 33 eyes of 33 patients who received TE treatment in Year 1, followed by pro re nata treatment in Year 2 (Group B). Compared with Group A whose vision improvement was maintained at 24months, the VA gain in Group B eyes seen at 12months (change in mean VA vs baseline: +6.9 letters, p=0.0008) was no longer present at 24months (change in mean VA vs baseline: +1.2 letters, p=0.5733).Conclusions Using the TE regimen in clinical practice, intravitreal aflibercept significantly improved visual outcomes in treatment-naive patients with nAMD, which were maintained over time. TE therapy with intravitreal aflibercept is a rational long-term strategy that can produce favourable outcomes in clinical practice.
C1 [Mekjavic, Polona Jaki] Univ Med Ctr Ljubljana, Eye Hosp, Grabloviceva 46, SI-1000 Ljubljana, Slovenia.
   [Mekjavic, Polona Jaki] Univ Ljubljana, Fac Med, Ljubljana, Slovenia.
   [Gregorcic, Bogdan] Gen Hosp Dr Franca Derganca, Eye Dept, Nova Gorica, Slovenia.
   [Oberc, Cvetka] Gen Hosp, Eye Dept, Novo Mesto, Slovenia.
   [Podgorsek, Slava] Gen Hosp, Eye Dept, Celje, Slovenia.
C3 University Medical Centre Ljubljana; University of Ljubljana
RP Mekjavic, PJ (通讯作者)，Univ Med Ctr Ljubljana, Eye Hosp, Grabloviceva 46, SI-1000 Ljubljana, Slovenia.; Mekjavic, PJ (通讯作者)，Univ Ljubljana, Fac Med, Ljubljana, Slovenia.
EM polona.jaki@guest.arnes.si
OI Jaki Mekjavic, Polona/0000-0003-1949-4525
FU Bayer Consumer Care AG, Basel, Switzerland
FX Bayer Consumer Care AG, Basel, Switzerland, provided funding for
   editorial support and additional statistical support. Bayer had no input
   into collecting and interpreting the data, or in writing the manuscript.
CR [Anonymous], CAUS BLIND VIS IMP
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Decroos FC, 2017, AM J OPHTHALMOL, V180, P142, DOI 10.1016/j.ajo.2017.06.002
   Eleftheriadou M, 2017, AM J OPHTHALMOL, V174, P160, DOI 10.1016/j.ajo.2016.09.038
   European Medicines Agency, 2011, LUC SUMM PROD CHAR
   European Medicines Agency, 2017, EYL SUMM PROD CHAR
   Gemenetzi M, 2017, OPHTHALMOL THER, V6, P79, DOI 10.1007/s40123-017-0087-5
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Johnston RL, 2017, ADV THER, V34, P703, DOI 10.1007/s12325-017-0483-1
   Ohr M, 2012, THER ADV CHRONIC DIS, V3, P153, DOI 10.1177/2040622312446007
   Rezaei KA, 2014 GLOBAL TRENDS R
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schlottmann PG, 2017, ASIA-PAC J OPHTHALMO, V6, P514, DOI 10.22608/APO.2017258
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Vardarinos A, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0451-1
   Warwick AN, 2016, INT J OPHTHALMOL-CHI, V9, P1156, DOI 10.18240/ijo.2016.08.12
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wykoff CC, 2018, BRIT J OPHTHALMOL, V102, P631, DOI 10.1136/bjophthalmol-2017-310941
   Zhang Y, 2017, INVEST OPHTH VIS SCI, V58, P5616, DOI 10.1167/iovs.17-22471
NR 25
TC 10
Z9 10
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD DEC 20
PY 2018
VL 18
AR 333
DI 10.1186/s12886-018-1005-x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HF2XQ
UT WOS:000454100400002
PM 30572850
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ristic, D
   Vukosavljevic, M
   Kontic, M
   Ristic, P
   Bokonjic, D
   Janicijevic-Petrovic, M
   Zecevic, AA
   Janicijevic, K
AF Ristic, Dragana
   Vukosavljevic, Miroslav
   Kontic, Marko
   Ristic, Petar
   Bokonjic, Dubravko
   Janicijevic-Petrovic, Mirjana
   Zecevic, Antoaneta Adzic
   Janicijevic, Katarina
TI Correlation between visual acuity, external limiting membrane and
   photoreceptor status in patients with neovascular age-related macular
   degeneration treated with bevacizumab
SO VOJNOSANITETSKI PREGLED
LA English
DT Article
DE retina; macular degeneration; neovascularization, pathologic;
   bevacizumab; tomography, optical coherence; fluorescein angiography
ID OPTICAL COHERENCE TOMOGRAPHY; SEGMENT/OUTER SEGMENT JUNCTION; CHOROIDAL
   NEOVASCULARIZATION; INTRAVITREAL BEVACIZUMAB; RANIBIZUMAB; MANAGEMENT;
   THERAPY; EYES
AB Background/Aim. The integrity of outer retinal structures, primarily the photoreceptor layer, is important because of its direct correlation with visual acuity. The aim of this study was to investigate the correlation between best-corrected visual acuity (BCVA), the foveal photoreceptor-inner segment/outer segment (IS/OS) junction and external limiting membrane (ELM) in patients with neovascular age-related macular degeneration (NVAMD) after the treatment with bevacizumab, as well as the correlation between the above-mentioned parameters and different types of neovascular membrane, classified by fluorescein angiography (FA). Methods. The study included 82 patients with NVAMD, treated with intravitreal bevacizumab. All patients underwent a basic ophthalmological examination, FA and optical coherence tomography (OCT). Based on the results of FA, all the patients were divided into two main groups - type I (the occult and minimally classic) and type II (classic and predominantly classic) of the choroidal neovascular membrane (CNV). The OCT images revealed either the presence or the absence of IS/OS and ELM. Results. After the treatment, the mean best corrected visual acuity improved significantly in both groups (p < 0.01). Preserved IS/OS and ELM were registered in a smaller number of patients as compared to the condition before the treatment (p < 0.01). After the treatment, the mean BCVA was significantly better in patients with preserved IS/OS and ELM (p < 0.01). In addition, we registered a higher number of patients with preserved ELM in the first group than in the second group (p < 0.01), whereas there was no significant difference in the integrity of IS/OS between the groups (p > 0.05). Conclusion. The patients with preserved IS/OS and ELM achieved better final visual acuity as compared to the patients without preserved IS/OS and ELM. In our patients, the absence of IS/OS and ELM were more frequent in type II (classic and predominantly classic) CNV than in type I (the occult and minimally classic) CNV.
C1 [Ristic, Dragana; Vukosavljevic, Miroslav; Kontic, Marko; Ristic, Petar; Bokonjic, Dubravko] Univ Def, Mil Med Acad, Fac Med, Belgrade, Serbia.
   [Ristic, Dragana; Vukosavljevic, Miroslav; Kontic, Marko] Mil Med Acad, Clin Ophthalmol, Crnotravska 17, Belgrade 11000, Serbia.
   [Ristic, Petar] Mil Med Acad, Endocrinol Clin, Belgrade, Serbia.
   [Bokonjic, Dubravko] Mil Med Acad, Natl Poison Control Ctr, Belgrade, Serbia.
   [Janicijevic-Petrovic, Mirjana; Janicijevic, Katarina] Clin Ctr Kragujevac, Clin Ophthalmol, Kragujevac, Serbia.
   [Janicijevic-Petrovic, Mirjana; Janicijevic, Katarina] Univ Kragujevac, Fac Med Sci, Kragujevac, Serbia.
   [Zecevic, Antoaneta Adzic] Clin Ctr Montenegro, Clin Ophthalmol, Podgorica, Montenegro.
   [Zecevic, Antoaneta Adzic] Univ Montenegro, Fac Med, Podgorica, Montenegro.
C3 University of Belgrade; University of Kragujevac; University of
   Montenegro
RP Ristic, D (通讯作者)，Mil Med Acad, Clin Ophthalmol, Crnotravska 17, Belgrade 11000, Serbia.
EM dadana25@yahoo.com
CR Agarwal A, 2015, CLIN OPHTHALMOL, V9, P1001, DOI [10.2147/OPTH.S59725, 10.2147/OPTH.S74959]
   American Academy of Ophthalmology, 2014, AG REL MAC DEG PREFF
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Hagan MJ, 1971, HISTOLOGY HUMAN EYE, P393
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kashani AH, 2009, INVEST OPHTH VIS SCI, V50, P3366, DOI 10.1167/iovs.08-2691
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Kwon Yoon Hyung, 2014, Korean J Ophthalmol, V28, P386, DOI 10.3341/kjo.2014.28.5.386
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mathew R, 2013, AM J OPHTHALMOL, V155, P720, DOI 10.1016/j.ajo.2012.11.003
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sayanagi K, 2009, BRIT J OPHTHALMOL, V93, P622, DOI 10.1136/bjo.2008.151977
   Shin HJ, 2011, RETINA-J RET VIT DIS, V31, P1627, DOI 10.1097/IAE.0b013e31820d3d01
   Tortorella P, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/853728
   Wong IY, 2012, CURR OPIN OPHTHALMOL, V23, P210, DOI 10.1097/ICU.0b013e3283524162
NR 21
TC 0
Z9 0
U1 0
U2 1
PU MILITARY MEDICAL ACAD-INI
PI BELGRADE
PA CRNOTRAVSKA 17, PO BOX 33-35, BELGRADE, 11040, SERBIA
SN 0042-8450
EI 2406-0720
J9 VOJNOSANIT PREGL
JI Vojnosanit. Pregl.
PY 2017
VL 74
IS 9
BP 849
EP 853
DI 10.2298/VSP150709149R
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FO2IJ
UT WOS:000416599300006
OA gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Jiang, JJ
   Chen, Y
   Zhang, HS
   Yuan, W
   Zhao, T
   Wang, N
   Fan, GH
   Zheng, DX
   Wang, ZJ
AF Jiang, Jingjing
   Chen, Yi
   Zhang, Hongsong
   Yuan, Wei
   Zhao, Tong
   Wang, Na
   Fan, Guohui
   Zheng, Dongxing
   Wang, Zhijun
TI Association between metformin use and the risk of age-related macular
   degeneration in patients with type 2 diabetes: a retrospective study
SO BMJ OPEN
LA English
DT Article
DE ophthalmology; geriatric medicine; diabetes & endocrinology; medical
   retina
ID VISUAL IMPAIRMENT; ANGIOTENSIN-II; MACULOPATHY; POPULATION;
   ATHEROSCLEROSIS; PREVALENCE; SMOKING; GLUCOSE; CANCER; COMMON
AB Objectives To investigate the effect of metformin on the decreased risk of developing age-related macular degeneration (AMD) in patients with type 2 diabetes mellitus (T2DM) for >= 10 years. Design A retrospective study. Participants Patients aged >= 50 with a diagnosis of T2DM no less than 10 years were included. Methods Variables predisposing to AMD were reviewed; the potential confounders related to T2DM or AMD were selected from literature records; AMD and diabetic retinopathy (DR) were diagnosed by funduscopy, optical coherence tomography and/or fluorescein angiography. The subgroup analysis was performed in early and late AMD. The protective effect of metformin was evaluated in duration-response and dose-response patterns. Results A total of 324 patients (115 metformin non-users and 209 users) were included in the final analysis. AMD was observed in 15.8% of metformin users and 45.2% of metformin non-users (p<0.0001). The ORs for any AMD, early AMD and late AMD present in patients with DR were 0.06 (0.02-0.20), 0.03 (0.00-0.20) and 0.17 (0.04-0.75). The serum high-density lipoprotein level was positively associated with the late AMD risk (p=0.0054). When analysed by the tertiles of cumulative duration, a similarly reduced risk was observed for the second (5-9 years) (OR: 0.24, 95% CI: 0.08 to 0.75) and third tertiles (>= 10 years) (OR: 0.22, 95% CI: 0.09 to 0.52) compared with the first tertile (<= 4 years). Conclusion Among patients with T2DM for >= 10 years, metformin users were less likely to develop any AMD and early AMD than non-users; however, the late AMD was not significantly associated with the use of metformin. Also, AMD was less prevalent in patients with DR. The prolonged metformin treatment with a high cumulative dose enhanced the protective effect against AMD. Metformin significantly reduces the AMD risk when the cumulative duration is >5 years.
C1 [Jiang, Jingjing; Chen, Yi; Zhang, Hongsong; Yuan, Wei; Zhao, Tong; Zheng, Dongxing; Wang, Zhijun] China Japan Friendship Hosp, Ophthalmol, Beijing, Peoples R China.
   [Wang, Na] China Japan Friendship Hosp, Endocrinol, Beijing, Peoples R China.
   [Fan, Guohui] China Japan Friendship Hosp, Inst Clin Med Sci, Beijing, Peoples R China.
C3 China-Japan Friendship Hospital; China-Japan Friendship Hospital;
   China-Japan Friendship Hospital
RP Wang, ZJ (通讯作者)，China Japan Friendship Hosp, Ophthalmol, Beijing, Peoples R China.
EM wangzj301@sina.com
OI Jiang, Jingjing/0000-0002-5077-1204
FU Hospital Youth Research Fund of China-Japan Friendship Hospital
   [2015-2-QN-31]; Beijing University of Chemical Technology - China-Japan
   Friendship Hospital Biomedical Translational Engineering Research Center
   Joint Fund [PYBZ1837]
FX The study was funded by Hospital Youth Research Fund of China-Japan
   Friendship Hospital (2015-2-QN-31) and Beijing University of Chemical
   Technology - China-Japan Friendship Hospital Biomedical Translational
   Engineering Research Center Joint Fund (PYBZ1837).
CR ALGVERE P, 1985, BRIT J OPHTHALMOL, V69, P416, DOI 10.1136/bjo.69.6.416
   Anisimov VN, 2015, ONCOTARGET, V6, P39398, DOI 10.18632/oncotarget.6347
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P823
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blitzer AL, 2021, JAMA OPHTHALMOL, V139, P302, DOI 10.1001/jamaophthalmol.2020.6331
   Borrone R, 2008, EUR J OPHTHALMOL, V18, P949, DOI 10.1177/112067210801800615
   Brown EE, 2019, ADV EXP MED BIOL, V1185, P477, DOI 10.1007/978-3-030-27378-1_78
   Brown EE, 2019, INVEST OPHTH VIS SCI, V60, P1470, DOI 10.1167/iovs.18-26422
   Brown EE, 2018, ADV EXP MED BIOL, V1074, P11, DOI 10.1007/978-3-319-75402-4_2
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Chae YK, 2016, ONCOTARGET, V7, P40767, DOI 10.18632/oncotarget.8194
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Chen YY, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/1649156
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P4430, DOI 10.1167/iovs.14-14379
   Choi JK, 2011, ARCH OPHTHALMOL-CHIC, V129, P196, DOI 10.1001/archophthalmol.2010.355
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Cummings M, 2008, CLIN OPHTHALMOL, V2, P369
   Fan SX, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.3.30
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539
   Frank RN, 2013, RETINA-J RET VIT DIS, V33, P899, DOI 10.1097/IAE.0b013e318287d882
   Han J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193031
   Hattori Y, 2006, HYPERTENSION, V47, P1183, DOI 10.1161/01.HYP.0000221429.94591.72
   He MS, 2018, DIABETES CARE, V41, P2202, DOI 10.2337/dc18-0707
   Hou XG, 2010, BIOCHEM BIOPH RES CO, V396, P199, DOI 10.1016/j.bbrc.2010.04.017
   Joe SG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119708
   Kanow MA, 2017, ELIFE, V6, DOI 10.7554/eLife.28899
   Khotcharrat Rossukon, 2015, Journal of the Medical Association of Thailand, V98, P790
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Lee H, 2019, YONSEI MED J, V60, P679, DOI 10.3349/ymj.2019.60.7.679
   Lee JH, 2013, AM J PHYSIOL-RENAL, V304, pF686, DOI 10.1152/ajprenal.00148.2012
   Masuda T, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9208489
   Moiseeva O, 2013, AGING CELL, V12, P489, DOI 10.1111/acel.12075
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Qin SF, 2008, INVEST OPHTH VIS SCI, V49, P1274, DOI 10.1167/iovs.07-1109
   Raman R, 2016, EYE, V30, P688, DOI 10.1038/eye.2016.14
   Raman R, 2010, ACTA DIABETOL, V47, P209, DOI 10.1007/s00592-009-0113-8
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Smith BT, 2007, CURR OPIN OPHTHALMOL, V18, P240, DOI 10.1097/ICU.0b013e32810c8e05
   Srinivasan S, 2017, EYE, V31, P1176, DOI 10.1038/eye.2017.47
   Tseng CH, 2017, ONCOTARGET, V8, P18802, DOI 10.18632/oncotarget.13390
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Vassilev ZP, 2015, INVEST OPHTH VIS SCI, V56, P1585, DOI 10.1167/iovs.14-16271
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Xu L, 2018, P NATL ACAD SCI USA, V115, P10475, DOI 10.1073/pnas.1802724115
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
   Zhao X, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2524174
   Zhu MM, 2016, ONCOTARGET, V7, P84190, DOI 10.18632/oncotarget.12391
NR 53
TC 0
Z9 0
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD APR
PY 2022
VL 12
IS 4
AR e054420
DI 10.1136/bmjopen-2021-054420
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 0V2XY
UT WOS:000788209000004
PM 35473747
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Aslam, TM
   Zaki, HR
   Mahmood, S
   Ali, ZC
   Ahmad, NA
   Thorell, MR
   Balaskas, K
AF Aslam, Tariq M.
   Zaki, Haider R.
   Mahmood, Sajjad
   Ali, Zaria C.
   Ahmad, Nur A.
   Thorell, Mariana R.
   Balaskas, Konstantinos
TI Use of a Neural Net to Model the Impact of Optical Coherence Tomography
   Abnormalities on Vision in Age-related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VISUAL-ACUITY; CHOROIDAL NEOVASCULARIZATION; REPEATABILITY; RANIBIZUMAB;
   MORPHOLOGY; FIBROSIS; FLUID; EYES
AB PURPOSE: To develop a neural network for the estimation of visual acuity from optical coherence tomography (OCT) images of patients with neovascular age-related macular degeneration (AMD) and to demonstrate its use to model the impact of specific controlled OCT changes on vision.
   DESIGN: Artificial intelligence (neural network) study.
   METHODS: We assessed 1400 OCT scans of patients with neovascular AMD. Fifteen physical features for each eligible OCT, as well as patient age, were used as input data and corresponding recorded visual acuity as the target data to train, validate, and test a supervised neural network. We then applied this network to model the impact on acuity of defined OCT changes in subretinal fluid, subretinal hyperreflective material, and loss of external limiting membrane (ELM) integrity.
   RESULTS: A total of 1210 eligible OCT scans were analyzed, resulting in 1210 data points, which were each 16-dimensional. A 10-layer feed-forward neural network with 1 hidden layer of 10 neurons was trained to predict acuity and demonstrated a root mean square error of 8.2 letters for predicted compared to actual visual acuity and a mean regression coefficient of 0.85. A virtual model using this network demonstrated the relationship of visual acuity to specific, programmed changes in OCT characteristics. When ELM is intact, there is a shallow decline in acuity with increasing subretinal fluid but a much steeper decline with equivalent increasing subretinal hyperreflective material. When ELM is not intact, all visual acuities are reduced. Increasing subretinal hyperreflective material or subretinal fluid in this circumstance reduces vision further still, but with a smaller gradient than when ELM is intact.
   CONCLUSIONS: The supervised machine learning neural network developed is able to generate an estimated visual acuity value from OCT images in a population of patients with AMD. These findings should be of clinical and research interest in macular degeneration, for example in estimating visual prognosis or highlighting the importance of developing treatments targeting more visually destructive pathologies. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Aslam, Tariq M.; Zaki, Haider R.; Balaskas, Konstantinos] Univ Manchester, Fac Biol Med & Hlth, Sch Pharm & Optometry, Manchester, Lancs, England.
   [Aslam, Tariq M.; Mahmood, Sajjad; Ali, Zaria C.; Thorell, Mariana R.; Balaskas, Konstantinos] NHS Cent Manchester Univ Hosp, Manchester Royal Eye Hosp, Manchester, Lancs, England.
   [Ahmad, Nur A.] Univ Teknol Mara Puncak Alam, Fac Hlth Sci, Dept Optometry, Selangor, Malaysia.
   [Thorell, Mariana R.] Hosp Banco Olhos Porto Alegre, Dept Ophthalmol, Porto Alegre, RS, Brazil.
C3 University of Manchester; Manchester Royal Eye Hospital; Universiti
   Teknologi MARA
RP Aslam, TM (通讯作者)，Manchester Royal Eye Hosp, Oxford Rd, Manchester, Lancs, England.
EM Tariq.aslam@cmft.nhs.uk
RI Balaskas, Konstantinos/ABD-5979-2020; Mahmood, Sajjad/AAK-7645-2021;
   Thorell, Mariana/AAA-9246-2021; najmee, aresya/ABD-7459-2020
OI Balaskas, Konstantinos/0000-0002-7690-6277; Ali,
   Zaria/0000-0002-8382-1415
FU Bayer; Novartis; Laboratoires Thea; Oraya; Bausch and Lomb
FX TARIQ M. ASLAM HAS RECEIVED FUNDING and educational grants from Bayer,
   Novartis, Laboratoires Thea, Oraya, and Bausch and Lomb. he following
   authors have no financial disclosures: Haider R. Zaki, Sajjad Mahmood,
   Zaria C. Ali, Nur A. Ahmad, Mariana R. Thorell, and Konstantinos
   Balaskas. All authors attest that they meet the current ICMJE criteria
   for authorship.
CR Agharezaei Laleh, 2016, Acta Inform Med, V24, P354, DOI 10.5455/aim.2016.24.354.359
   Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Aslam T, 2014, GRAEF ARCH CLIN EXP, V252, P201, DOI 10.1007/s00417-013-2421-5
   Baboo S.S., 2010, INT J ENV SCI, V1, P321, DOI DOI 10.7763/IJESD.2010.V1.63
   Balaskas K, 2016, RETINA, V37, P1297
   Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   Caballero S, 2009, EXP EYE RES, V88, P367, DOI 10.1016/j.exer.2008.07.012
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Keane PA, 2010, INVEST OPHTH VIS SCI, V51, P5431, DOI 10.1167/iovs.09-4846
   Kuhn M., 2005, MANUAL IMPLEMENTATIO, P2
   Marvin L., 2016, NEURAL NETWORKS MATL, P1
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P4347, DOI 10.1167/iovs.08-1935
   Peduzzi P, 1995, J CLIN EPIDEMIOL, V48, P1503, DOI 10.1016/0895-4356(95)00048-8
   Radhika Y., 2009, INT J COMPUT THEORY, V1, P55, DOI [10.7763/IJCTE.2009.V1.9, DOI 10.7763/IJCTE.2009.V1.9]
   Razmara J, 2016, HLTH INFORM J
   Ryu CL, 2016, RETINA-J RET VIT DIS, V36, P1324, DOI 10.1097/IAE.0000000000000877
   Schmidt-Erfurth U, 2017, OPHTHALMOL RETINA
   Wickremasinghe SS, 2016, RETINA-J RET VIT DIS, V36, P1331, DOI 10.1097/IAE.0000000000000902
   Zhang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068173
NR 21
TC 23
Z9 28
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2018
VL 185
BP 94
EP 100
DI 10.1016/j.ajo.2017.10.015
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FQ8TL
UT WOS:000418636000015
PM 29101008
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Azar, G
   Maftouhi, MQE
   Masella, JJ
   Mauget-Faysse, M
AF Azar, G.
   Maftouhi, M. Quaranta-El
   Masella, J-J.
   Mauget-Faysse, M.
TI Macular pigment density variation after supplementation of lutein and
   zeaxanthin using the Visucam((R)) 200 pigment module: Impact of
   age-related macular degeneration and lens status
SO JOURNAL FRANCAIS D OPHTALMOLOGIE
LA English
DT Article
DE Age-related macular degeneration; Macular pigment optical density;
   Lutein and zeaxanthin supplementation; Visucam((R)) 200
ID OPTICAL-DENSITY; IN-VIVO; AUTOFLUORESCENCE; CAROTENOIDS; RISK
AB Purpose. - To assess the evolution of macular pigment optical density (MPOD) following supplementation with various macular formulations obtained with the Visucam((R)) 200, and to study the factors affecting MPOD measurements.
   Materials and methods. - In this prospective, randomized, double-masked multicenter study, patients were divided into 2 groups: group A (patients without retinal pathology who underwent cataract surgery 1 month previously) and group B (patients with neovascular age-related macular degeneration [AMD] in one eye). In each group, half of the patients were randomly assigned to receive a food supplementation either with or without carotenoids (5 mg of Lutein and 1 mg of Zeaxanthin). Outcome measures included MPOD responses obtained with the Visucam((R)) 200 for one year.
   Results. - In total, 126 subjects ( 52 men, 74 women) with a mean age of 75.3 +/- 7.61 years were enrolled. Mean MPOD values at the time of inclusion were statistically lower in group A (0.088 density unit [DU]) compared to group B (0.163 DU, P < 0.05). No statistically significant increase in MPOD was noted in either group, even after discontinuation of the supplementation. By multiple regression analysis, age, female gender, lens status and the presence of AMD seemed to significantly affect MPOD measurements.
   Conclusion. - No significant improvement in MPOD seems to be detected with the Visucam((R)) 200 after carotenoid supplementation. The MPOD measurement seems to be highly affected by cataract extraction and the presence of AMD. (C) 2017 Elsevier Masson SAS. All rights reserved.
C1 [Azar, G.] Univ St Joseph, Univ St Esprit Kaslik, Fac Med, Eye & Ear Univ Hosp, Beirut, Lebanon.
   [Maftouhi, M. Quaranta-El] Rabelais Eye Clin Ctr, 16 Rue Rabelais, F-69003 Lyon, France.
   [Masella, J-J.] Ophthalmol Ctr Dauphine, 6 Blvd Agutte Sembat, F-38000 Grenoble, France.
   [Mauget-Faysse, M.] Rothschild Fdn, 25 Rue Manin, F-75019 Paris, France.
C3 Saint Joseph University Beirut
RP Azar, G (通讯作者)，Eye & Ear Hosp, POB 70-933, Naccache, Lebanon.
EM georgesazar@hotmail.com
FU Thea Laboratories
FX Funding was received from Thea Laboratories in support of this study as
   the form of supplementations provision.
CR Arnold C, 2013, JAMA OPHTHALMOL, V131, P564, DOI 10.1001/jamaophthalmol.2013.2851
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2004, ARCH BIOCHEM BIOPHYS, V430, P149, DOI 10.1016/j.abb.2004.04.029
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Ciulla TA, 2004, AM J OPHTHALMOL, V138, P582, DOI 10.1016/j.ajo.2004.05.057
   Creuzot-Garcher C, 2014, INVEST OPHTH VIS SCI, V55, P2941, DOI 10.1167/iovs.13-13568
   Dawczynski J, 2013, GRAEF ARCH CLIN EXP, V251, P2711, DOI 10.1007/s00417-013-2376-6
   Dennison JL, 2013, EXP EYE RES, V116, P190, DOI 10.1016/j.exer.2013.08.014
   Dietzel M, 2011, INVEST OPHTH VIS SCI, V52, P3452, DOI 10.1167/iovs.10-6713
   Hammond BR, 2005, OPTOMETRY VISION SCI, V82, P387, DOI 10.1097/01.OPX.0000162652.85875.D2
   Hammond BR, 1998, INVEST OPHTH VIS SCI, V39, P397
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   Howells O, 2011, GRAEF ARCH CLIN EXP, V249, P315, DOI 10.1007/s00417-010-1577-5
   Iannaccone A, 2007, INVEST OPHTH VIS SCI, V48, P1458, DOI 10.1167/iovs.06-0438
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jahn C, 2005, GRAEF ARCH CLIN EXP, V243, P222, DOI 10.1007/s00417-004-0995-7
   Johnson EJ, 2008, AM J CLIN NUTR, V87, P1521, DOI 10.1093/ajcn/87.5.1521
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krinsky NI, ANNU REV
   Leung Ivan Y-F, 2008, Optometry, V79, P266, DOI 10.1016/j.optm.2007.03.017
   Mackey DA, 2011, CLIN EXP OPHTHALMOL, V39, P462, DOI 10.1111/j.1442-9071.2010.02487.x
   Nolan JM, 2009, INVEST OPHTH VIS SCI, V50, P4777, DOI 10.1167/iovs.08-3277
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Schalch W, 1992, EXS, V62, P280
   Schweitzer D, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3526358
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Sommerburg O, 1999, CURR EYE RES, V19, P491, DOI 10.1076/ceyr.19.6.491.5276
   Tanito M, 2012, JPN J OPHTHALMOL, V56, P488, DOI 10.1007/s10384-012-0157-0
   Trieschmann M, 2003, GRAEF ARCH CLIN EXP, V241, P1006, DOI 10.1007/s00417-003-0796-4
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
NR 35
TC 12
Z9 12
U1 1
U2 8
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0181-5512
EI 1773-0597
J9 J FR OPHTALMOL
JI J. Fr. Ophthamol.
PD APR
PY 2017
VL 40
IS 4
BP 303
EP 313
DI 10.1016/j.jfo.2016.11.009
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EW0GX
UT WOS:000402168300016
PM 28336284
DA 2022-11-30
ER

PT J
AU van der Reis, MI
   Elshout, M
   Berendschot, TTJM
   de Jong-Hesse, Y
   Webers, CAB
   Schouten, JSAG
AF van der Reis, Margriet I.
   Elshout, M.
   Berendschot, Tos T. J. M.
   de Jong-Hesse, Yvonne
   Webers, Carroll A. B.
   Schouten, Jan S. A. G.
TI A systematic approach to evaluate practice-based process- and outcome
   data applied to the treatment of neovascular age-related macular
   degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; outcome study; visual acuity;
   Anti-VEGF; Ranibizumab; Bevacizumab; Photodynamic therapy
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL BEVACIZUMAB
   AVASTIN; PHOTODYNAMIC THERAPY; RANIBIZUMAB TREATMENT; VERTEPORFIN
   THERAPY; DOSING REGIMEN; VISUAL-ACUITY; FOLLOW-UP; SECONDARY; DELAY
AB Background Following the principles of value-based health care, outcomes and processes of daily-practice eye care need to be systematically evaluated. We illustrate an approach that can be used to support data-driven quality improvements. We used patient data regarding the treatment of neovascular age-related macular degeneration (nAMD). Methods In a cohort study, we reviewed medical records of patients with nAMD confirmed on fluorescein angiography (FA). Patients were treated with intravitreal injections with bevacizumab; ranibizumab; or photodynamic therapy (PDT). Visual acuity (VA), ophthalmic exam results and treatments were recorded. VA was compared between treatments by linear mixed model. Diagnosis was re-evaluated on the original FAs. Outcome analysis was performed by 1) selecting VA as the relevant outcome parameter; 2) Preventing selection by comparing treatments with historical untreated cohort and cohorts from the literature, 3) correcting for confounding due to lesion type, and 4) identifying relevant process variables that affect the outcome. These were severity of disease at presentation, and doctor- and patient dependent process variables. Results In total, 473 eyes were included. At 12 months, change in VA was 0.54, 0.48, 0.09, and 0.07 LogMAR in the no-treatment, photodynamic therapy (PDT), bevacizumab, and ranibizumab groups, respectively. Lesion type on FA differed between groups. Diagnosis of nAMD could not be confirmed in 104 patients. Patient delay, inaccurate diagnosis and treatment intervals may have impacted outcomes. Conclusions The effect of PDT was small to absent. Anti-VEGFs were effective and appeared as effective as in RCTs. Correct selection of a comparator cohort and addressing confounding, including confounding by indication and effect modification, are needed to achieve valid results and interpretation. Patient delay, diagnosis accuracy, indication for and application of treatment can potentially be improved to improve treatment outcomes. In a value-based care perspective, systematic evaluation of diagnostic accuracy, treatment indication, protocols, and outcomes of new interventions is needed at an early stage to improve outcomes.
C1 [van der Reis, Margriet I.; Elshout, M.; Berendschot, Tos T. J. M.; Webers, Carroll A. B.; Schouten, Jan S. A. G.] Maastricht Univ, Med Ctr, Univ Eye Clin Maastricht, POB 5800, NL-6202 AZ Maastricht, Netherlands.
   [de Jong-Hesse, Yvonne] Vrije Univ Amsterdam Med Ctr, Dept Ophthalmol, Amsterdam, Netherlands.
   [Schouten, Jan S. A. G.] Canisius Wilhelmina Ziekenhuis, Dept Ophthalmol, Nijmegen, Netherlands.
C3 Maastricht University; Maastricht University Medical Centre (MUMC);
   Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER;
   Canisius-Wilhelmina Hospital
RP Elshout, M (通讯作者)，Maastricht Univ, Med Ctr, Univ Eye Clin Maastricht, POB 5800, NL-6202 AZ Maastricht, Netherlands.
EM mari_elshout@hotmail.com
RI Berendschot, Tos TJM/M-8509-2016
OI Berendschot, Tos TJM/0000-0002-8101-939X
FU Dutch organization for health research and development ZonMw, The Hague,
   The Netherlands [152001002]
FX This study was supported by the Dutch organization for health research
   and development ZonMw, The Hague, The Netherlands, grant number
   152001002. The funding organization had no role in the design or conduct
   of this research.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bellerive C, 2012, CAN J OPHTHALMOL, V47, P165, DOI 10.1016/j.jcjo.2012.01.011
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Cosgrove T, 2013, HARV BUS REV
   Costagliola C, 2009, RETINA-J RET VIT DIS, V29, P1227, DOI 10.1097/IAE.0b013e3181b773e1
   Elshout M, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0514-3
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Ernst Benjamin J., 2010, International Ophthalmology, V30, P267, DOI 10.1007/s10792-009-9324-9
   Falkenstein IA, 2008, OPHTHALMOLOGY, V115, P319, DOI 10.1016/j.ophtha.2007.05.028
   Arevalo JF, 2010, OPHTHALMOLOGY, V117, P1974, DOI 10.1016/j.ophtha.2010.01.056
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gamulescu Maria-Andreea, 2010, International Ophthalmology, V30, P261, DOI 10.1007/s10792-009-9318-7
   Graber ML, 2012, JAMA-J AM MED ASSOC, V308, P1211, DOI 10.1001/2012.jama.11913
   Haddad WM, 2002, GRAEF ARCH CLIN EXP, V240, P31, DOI 10.1007/s00417-001-0404-4
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   Kaiser PK, 2009, CURR MED RES OPIN, V25, P1853, DOI 10.1185/03007990903038616
   Katz G, 2012, RETINA-J RET VIT DIS, V32, P293, DOI 10.1097/IAE.0b013e31821e20b0
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Luu ST, 2010, CLIN EXP OPHTHALMOL, V38, P659, DOI 10.1111/j.1442-9071.2010.02309.x
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mekjavic PJ, 2011, ACTA OPHTHALMOL, V89, P647, DOI 10.1111/j.1755-3768.2009.01740.x
   Michalova K, 2009, EYE, V23, P1633, DOI 10.1038/eye.2009.175
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Muni RH, 2008, RETINA-J RET VIT DIS, V28, P1421, DOI 10.1097/IAE.0b013e3181814470
   Porter ME, 2010, NEW ENGL J MED, V363, P2477, DOI 10.1056/NEJMp1011024
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Real JP, 2015, GRAEF ARCH CLIN EXP, V253, P1859, DOI 10.1007/s00417-014-2885-y
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Simader C, 2009, RANIBIZUMAB VISUAL A
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Takahashi H, 2015, RETINA-J RET VIT DIS, V35, P1331, DOI 10.1097/IAE.0000000000000513
   Tao Y, 2010, J OCUL PHARMACOL TH, V26, P79, DOI 10.1089/jop.2009.0095
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
NR 53
TC 0
Z9 0
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JAN 9
PY 2020
VL 20
IS 1
AR 21
DI 10.1186/s12886-020-1303-y
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KL8ED
UT WOS:000513649400004
PM 31918701
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Forooghian, F
   Agron, E
   Clemons, TE
   Ferris, FL
   Chew, EY
AF Forooghian, Farzin
   Agron, Elvira
   Clemons, Traci E.
   Ferris, Frederick L., III
   Chew, Emily Y.
CA AREDS Res Grp
TI Visual Acuity Outcomes after Cataract Surgery in Patients with
   Age-Related Macular Degeneration: Age-Related Eye Disease Study Report
   No. 27
SO OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; BEAVER DAM; MACULOPATHY; PREVALENCE; ASSOCIATION;
   PREDICTORS; EXTRACTION; 2ND
AB Objective: To evaluate visual acuity outcomes after cataract surgery in patients with varying degrees of age-related macular degeneration (AMD).
   Design: Cohort study.
   Participants: A total of 4757 participants enrolled in the Age-Related Eye Disease Study (AREDS), a prospective, multicenter, epidemiological study of the clinical course of cataract and AMD and a randomized controlled trial of antioxidants and minerals.
   Methods: Standardized lens and fundus photographs, performed at baseline and annual visits, were graded by a centralized reading center using standardized protocols for severity of AMD and lens opacities. History of cataract surgery was obtained every 6 months. Analyses were conducted using multivariate logistic regression.
   Main Outcome Measure: The change in best-corrected visual acuity (BCVA) after cataract surgery compared with preoperative BCVA.
   Results: Visual acuity results were analyzed for 1939 eyes that had cataract surgery during AREDS. The mean time from cataract surgery to measurement of postoperative BCVA was 6.9 months. After adjustment for age at surgery, gender, type, and severity of cataract, the mean change in visual acuity at the next study visit after the cataract surgery was as follows: Eyes without AMD gained 8.4 letters of acuity (P<0.0001), eyes with mild AMD gained 6.1 letters of visual acuity (P<0.0001), eyes with moderate AMD gained 3.9 letters (P<0.0001), and eyes with advanced AMD gained 1.9 letters (P = 0.04). The statistically significant gain in visual acuity after cataract surgery was maintained an average of 1.4 years after cataract surgery.
   Conclusions: On average, participants with varying severity of AMD benefited from cataract surgery with an increase in visual acuity postoperatively. This average gain in visual acuity persisted for at least 18 months.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2009; 116:2093-2100 (C) 2009 by the American Academy of Ophthalmology.
C1 [Forooghian, Farzin; Agron, Elvira; Ferris, Frederick L., III; Chew, Emily Y.] NEI, Clin Trials Branch, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Clemons, Traci E.] EMMES Corp, Rockville, MD USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Emmes Corporation
RP Chew, EY (通讯作者)，NEI, Clin Trials Branch, Div Epidemiol & Clin Applicat, NIH, Bldg 10,CRC Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
RI SanGiovanni, John Paul/AAU-3895-2020
OI Ferris, Frederick/0000-0002-4933-0639
FU National Eye Institute/National Institutes of Health, Department of
   Health and Human Services, Bethesda, Maryland; NATIONAL EYE INSTITUTE
   [ZIAEY000489, ZIEEY000487] Funding Source: NIH RePORTER
FX Supported by the intramural program funds and contracts from the
   National Eye Institute/National Institutes of Health, Department of
   Health and Human Services, Bethesda, Maryland.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Baratz KH, 1997, ARCH OPHTHALMOL-CHIC, V115, P1441, DOI 10.1001/archopht.1997.01100160611015
   Busbee BG, 2003, OPHTHALMOLOGY, V110, P2310, DOI 10.1016/S0161-6420(03)00796-6
   Busbee BG, 2002, OPHTHALMOLOGY, V109, P606, DOI 10.1016/S0161-6420(01)00971-X
   Chandrasekaran S, 2008, EYE, V22, P479, DOI 10.1038/sj.eye.6702854
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   de Jong PTVM, 2004, GRAEF ARCH CLIN EXP, V242, P103, DOI 10.1007/s00417-003-0833-3
   El Mallah MK, 2001, OPTOMETRY VISION SCI, V78, P683, DOI 10.1097/00006324-200109000-00014
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   JAVITT JC, 1993, ARCH OPHTHALMOL-CHIC, V111, P686, DOI 10.1001/archopht.1993.01090050120041
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein BEK, 2002, OPHTHALMOLOGY, V109, P2052, DOI 10.1016/S0161-6420(02)01249-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lamoureux EL, 2007, OPTOMETRY VISION SCI, V84, P683, DOI 10.1097/OPX.0b013e31812f755f
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   LIU IY, 1989, AM J PUBLIC HEALTH, V79, P765, DOI 10.2105/AJPH.79.6.765
   Lundqvist B, 2006, J CATARACT REFR SURG, V32, P1944, DOI 10.1016/j.jcrs.2006.06.023
   Lundstrom M, 2002, BRIT J OPHTHALMOL, V86, P1330, DOI 10.1136/bjo.86.12.1330
   Lundstrom M, 1999, BRIT J OPHTHALMOL, V83, P1272, DOI 10.1136/bjo.83.11.1272
   Pham TQ, 2007, EYE, V21, P324, DOI 10.1038/sj.eye.6702171
   Rutkow IM, 1997, ARCH SURG-CHICAGO, V132, P983
   SCHEIN OD, 1994, OPHTHALMOLOGY, V101, P1142
   SCHEIN OD, 1995, OPHTHALMOLOGY, V102, P817, DOI 10.1016/S0161-6420(95)30952-9
   Shuttleworth GN, 1998, BRIT J OPHTHALMOL, V82, P611, DOI 10.1136/bjo.82.6.611
   Sperduto RD, 2001, OPHTHALMOLOGY, V108, P1400
   STEINBERG EP, 1994, OPHTHALMOLOGY, V101, P1131
   Tan AG, 2004, CLIN EXP OPHTHALMOL, V32, P284, DOI 10.1111/j.1442-9071.2004.00817.x
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
NR 35
TC 43
Z9 43
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2009
VL 116
IS 11
BP 2093
EP 2100
DI 10.1016/j.ophtha.2009.04.033
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 512ZQ
UT WOS:000271291600009
PM 19700198
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Javitt, JC
   Zlateva, GP
   Earnshaw, SR
   Pleil, AM
   Graham, CN
   Brogan, AJ
   Shah, SN
   Adamis, AR
AF Javitt, Jonathan C.
   Zlateva, Gergana P.
   Earnshaw, Stephanie R.
   Pleil, Andreas M.
   Graham, Christopher N.
   Brogan, Anita J.
   Shah, Sonali N.
   Adamis, Anthony R.
TI Cost-effectiveness model for neovascular age-related macular
   degeneration: Comparing early and late treatment with pegaptanib sodium
   based on visual acuity
SO VALUE IN HEALTH
LA English
DT Article
DE age-related macular degeneration; cost-effectiveness; Markov model;
   pegaptanib
ID BLUE-MOUNTAINS-EYE; QUALITY-OF-LIFE; CONTROLLED CLINICAL-TRIALS;
   PHOTODYNAMIC THERAPY; RISK-FACTORS; MACULOPATHY; PROGRESSION;
   IMPAIRMENT; PREVALENCE; DISABILITY
AB Objective: To compare the cost-effectiveness of pegaptanib and usual care within three distinct cohorts of subfoveal neovascular age-related macular degeneration (NV-AMD) patients, that is, those with early, moderate, and late disease, using a comprehensive economic model.
   Methods: A Markov framework was used to model lifetime movement of a subfoveal NV-AMD cohort through health states based on visual acuity. The model takes a US payer perspective of patients over the age of 65 years. Clinical efficacy was based on published results for the 0.3 mg pegaptanib and usual care groups. Expert interviews were conducted to determine adverse event treatment patterns and vision rehabilitation resource use. Incidence and costs of comorbidities such as depression and fractures associated with the effects of declining visual acuity were based on our previously published analysis of Medicare data. Transition probabilities were derived from published clinical trial data for each 3-month cycle. Utilities were derived from published sources. Three runs of the model were conducted with cohorts of newly diagnosed patients. Patients were classified as having early, moderate, or late NV-AMD defined as visual acuity in the better-seeing eye of 20/40 to more than 20/80, 20/80 to more than 20/200, and 20/200 to more than 20/400, respectively. Costs and outcomes were discounted 3.0% per annum.
   Results: Incremental costs per vision-year gained and per quality-adjusted life-year (QALY) gained for early NV-AMD patients were approximately one-third those of patients with late disease ($15,279 vs. $57,230 and $36,282 vs. $132,381, respectively). On average, patients treated early with either pegaptanib or usual care incurred lower lifetime total direct costs than those treated later. Sensitivity analysis showed that base-case incremental costs per QALY gained for pegaptanib versus usual care were relatively robust.
   Conclusions: For patients with subfoveal NVAMD, treatment with pegaptanib should be started as early as possible to maximize the clinical and economic benefits.
C1 [Javitt, Jonathan C.] Potomac Inst Policy Studies, Arlington, VA USA.
   [Javitt, Jonathan C.] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
   [Zlateva, Gergana P.; Pleil, Andreas M.; Shah, Sonali N.] Pfizer Ophthalm, New York, NY USA.
   [Zlateva, Gergana P.; Pleil, Andreas M.; Shah, Sonali N.] Pfizer Ophthalm, La Jolla, CA USA.
   [Earnshaw, Stephanie R.; Graham, Christopher N.; Brogan, Anita J.] RTI Hlth Solut, Res Triangle Pk, NC USA.
   [Adamis, Anthony R.] OSI Eyetech Inc, New York, NY USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Pfizer; Pfizer;
   Research Triangle Institute
RP Javitt, JC (通讯作者)，1700 Penn Ave,Suite 400, Washington, DC 20006 USA.
EM jjavitt@pitac.us
RI Javitt, Jonathan/AAJ-5574-2021
OI Javitt, Jonathan/0000-0003-2371-1609; Brogan, Anita/0000-0002-9003-994X;
   Graham, Christopher/0000-0001-8165-7095; Earnshaw,
   Stephanie/0000-0003-2975-6509
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   Bandello F, 2007, INVEST OPHTH VIS SCI, V48, P96, DOI 10.1167/iovs.06-0283
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown GC, 2005, AM J OPHTHALMOL, V140, P679, DOI 10.1016/j.ajo.2005.04.061
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chia EM, 2004, INVEST OPHTH VIS SCI, V45, P71, DOI 10.1167/iovs.03-0661
   Coleman AL, 2004, OPHTHALMOLOGY, V111, P857, DOI 10.1016/j.ophtha.2003.09.033
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Deramo VA, 2003, ARCH OPHTHALMOL-CHIC, V121, P1297, DOI 10.1001/archopht.121.9.1297
   Earnshaw SR, 2005, VALUE HEALTH, V8, pA176, DOI 10.1016/S1098-3015(10)67688-7
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007
   HOYERT D, 2006, DEATHS FINAL DATA 20
   *ING INC, 2005, ESS RBRVS COMPR LIST
   Ivers RQ, 2003, J AM GERIATR SOC, V51, P356, DOI 10.1046/j.1532-5415.2003.51109.x
   JAVITT JC, 1989, OPHTHALMOLOGY, V96, P255
   JAVITT JC, 2006, INVEST OPHTHALMOL VI, V47
   Javitt JC, 2007, OPHTHALMOLOGY, V114, P238, DOI 10.1016/j.ophtha.2006.07.054
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Legood R, 2002, INJ PREV, V8, P155, DOI 10.1136/ip.8.2.155
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Meads C, 2004, BRIT J OPHTHALMOL, V88, P212, DOI 10.1136/bjo.2003.019471
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   *METLIFE MAT MARK, 2004, METLIFE MARK SURV NU
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Sharma S, 2005, CAN J OPHTHALMOL, V40, P369, DOI 10.1016/S0008-4182(05)80079-1
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   *US CENS BUR PUBL, 2005, US CENS 2000 SUMM FI
   *US DEP LAB, 2006, CURR SER US DEP LAB
   Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P3, DOI 10.1076/opep.10.1.3.13773
   Weinstein MC, 2003, VALUE HEALTH, V6, P9, DOI 10.1046/j.1524-4733.2003.00234.x
   ZHOU S, 2006, INVEST OPHTHALMOL VI, V47
NR 42
TC 20
Z9 20
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
EI 1524-4733
J9 VALUE HEALTH
JI Value Health
PD JUL-AUG
PY 2008
VL 11
IS 4
BP 563
EP 574
DI 10.1111/j.1524-4733.2007.00283.x
PG 12
WC Economics; Health Care Sciences & Services; Health Policy & Services
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Business & Economics; Health Care Sciences & Services
GA 333HZ
UT WOS:000258144900005
PM 18179676
OA Bronze
DA 2022-11-30
ER

PT J
AU Jia, HX
   Lu, B
   Zhao, Z
   Yu, Y
   Wang, FH
   Zhou, MW
   Sun, XD
AF Jia, Huixun
   Lu, Bing
   Zhao, Zhi
   Yu, Yang
   Wang, Fenghua
   Zhou, Minwen
   Sun, Xiaodong
TI Prediction of the short-term efficacy of anti-VEGF therapy for
   neovascular age-related macular degeneration using optical coherence
   tomography angiography
SO EYE AND VISION
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization; Optical
   coherence tomography angiography; Anti-VEGF
ID GROWTH-FACTOR THERAPY; CHOROIDAL NEOVASCULARIZATION; TYPE-1
   NEOVASCULARIZATION; VISUAL OUTCOMES; ASSOCIATION; PROGRESSION;
   RECURRENCE; PROJECTION; RISK
AB Background To evaluate whether the specific choroidal neovascularization (CNV) characteristics measured using optical coherence tomography angiography (OCTA) can predict the 6-month prognosis of neovascular age-related macular degeneration (nAMD) after anti-vascular endothelial growth factor (anti-VEGF) therapy. Methods Patients with type 1, type 2, or mixed-type neovascularization (NV) were prospectively included. Participants underwent an initial loading phase of three consecutive monthly intravitreal injections of Conbercept (0.5 mg) and were switched to a pro re nata (PRN) treatment strategy. OCTA images were evaluated for eyes that underwent follow-up assessments for more than 6 months. CNV lesions were manually segmented, and the CNV area, vessel area, greatest vascular caliber (GVC), and greatest linear dimension (GLD) were compared between responders and non-responders. Two masked graders independently measured the above-mentioned parameters using OCTA, and consistency was assessed using the intraclass correlation coefficient (ICC) values. Multiple logistic regression analysis was performed to evaluate the effect of a 3-month change in the CNV area, GLD, and GVC on the 6-month response to anti-VEGF agents. Results Among the 60 eyes of 60 patients with nAMD, 39 were responders and 21 were non-responders. The proportion of CNV types was significantly different between responders and non-responders (P = 0.009). Patients with type 2 or mixed NV seemed more likely to respond to the treatment (28.2% vs. 0.0%, and 30.8% vs. 23.8%, respectively). The change in GVC showed a significant difference between responders (- 4.98 +/- 17.17 mu m) and non-responders (11.01 +/- 14.10 mu m) after three monthly intravitreal anti-VEGF injections. Multiple logistic regression analysis showed that only the change in GVC remained significant after controlling for baseline GVC, injection number, and CNV type (adjusted OR = 1.083; P = 0.008). Conclusions Type 2 and mixed-type NV were significantly associated with a better response to anti-VEGF therapy. Changes in GVC after 3 months of treatment were significantly associated with a response to anti-VEGF therapy at 6 months.
C1 [Jia, Huixun; Lu, Bing; Zhao, Zhi; Yu, Yang; Wang, Fenghua; Zhou, Minwen; Sun, Xiaodong] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1, Shanghai Gen Hosp,Dept Ophthalmol, 100 Hai Ning Rd, Shanghai 200080, Peoples R China.
   [Lu, Bing; Wang, Fenghua; Zhou, Minwen; Sun, Xiaodong] Shanghai Key Lab Ocular Fundus Dis, Shanghai, Peoples R China.
   [Lu, Bing; Wang, Fenghua; Zhou, Minwen; Sun, Xiaodong] Natl Clin Res Ctr Eye Dis, Shanghai, Peoples R China.
   [Wang, Fenghua; Sun, Xiaodong] Shanghai Engn Ctr Visual Sci & Photomed, Shanghai, Peoples R China.
   [Wang, Fenghua; Zhou, Minwen; Sun, Xiaodong] Shanghai Engn Ctr Precise Diag & Treatment Eye Di, Shanghai, Peoples R China.
   [Sun, Xiaodong] Shanghai Jiao Tong Univ, Sch Med, Clin Res Inst, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Zhou, MW; Sun, XD (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1, Shanghai Gen Hosp,Dept Ophthalmol, 100 Hai Ning Rd, Shanghai 200080, Peoples R China.
EM zmw8008@163.com; xdsun@sjtu.edu.cn
FU Frontier Project of Hospital Development Center [SHDC12016105]; Clinical
   Research Innovation Team Project of Shanghai General Hospital
   [CTCCR-2016A02]; Scientific Project of Shanghai Municipal Health
   Commission [201940151]; Shanghai Collaborative Innovation Center for
   Translational Medicine [TM201917]; Shanghai Hospital Development Center
   [SHDC2020CR2040B, SHDC2020CR5014]
FX This work was supported by Frontier Project of Hospital Development
   Center (SHDC12016105), Clinical Research Innovation Team Project of
   Shanghai General Hospital (CTCCR-2016A02), Scientific Project of
   Shanghai Municipal Health Commission (201940151), Shanghai Collaborative
   Innovation Center for Translational Medicine (TM201917), and Shanghai
   Hospital Development Center (SHDC2020CR2040B and SHDC2020CR5014).
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Asai T, 2014, INVEST OPHTH VIS SCI, V55, P226, DOI 10.1167/iovs.13-12658
   Ashraf M, 2018, ACTA OPHTHALMOL, V96, P120, DOI 10.1111/aos.13565
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Bellou S, 2013, CANCER LETT, V338, P219, DOI 10.1016/j.canlet.2013.05.015
   Budzinskaya M V, 2017, Vestn Oftalmol, V133, P103, DOI 10.17116/oftalma20171334103-108
   Chae B, 2015, INVEST OPHTH VIS SCI, V56, P5040, DOI 10.1167/iovs.15-16494
   Coscas F, 2019, BRIT J OPHTHALMOL, V103, P1342, DOI 10.1136/bjophthalmol-2018-313065
   Coscas F, 2015, INVEST OPHTH VIS SCI, V56, P4129, DOI 10.1167/iovs.15-16735
   Costanzo E, 2016, INVEST OPHTH VIS SCI, V57, pOCT307, DOI 10.1167/iovs.15-18830
   Daniel E, 2018, OPHTHALMOLOGY, V125, P1037, DOI 10.1016/j.ophtha.2018.01.004
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   Giorno P, 2020, OPHTHALMOLOGICA, V243, P263, DOI 10.1159/000504755
   Keiner CM, 2019, CLIN OPHTHALMOL, V13, P1613, DOI 10.2147/OPTH.S204344
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Kwon Yoon Hyung, 2014, Korean J Ophthalmol, V28, P386, DOI 10.3341/kjo.2014.28.5.386
   Lee H, 2020, RETINA-J RET VIT DIS, V40, P1704, DOI 10.1097/IAE.0000000000002678
   Liu RY, 2019, INVEST OPHTH VIS SCI, V60, P4328, DOI 10.1167/iovs.18-24921
   Maruyama-Inoue M, 2018, GRAEF ARCH CLIN EXP, V256, P2089, DOI 10.1007/s00417-018-4121-7
   Mastropasqua L, 2017, RETINA-J RET VIT DIS, V37, P247, DOI 10.1097/IAE.0000000000001145
   Mettu PS, 2021, PROG RETIN EYE RES, V82, DOI 10.1016/j.preteyeres.2020.100906
   Miere A, 2019, RETINA-J RET VIT DIS, V39, P548, DOI 10.1097/IAE.0000000000001964
   Moons KGM, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001744
   Muakkassa NW, 2015, RETINA-J RET VIT DIS, V35, P2252, DOI 10.1097/IAE.0000000000000836
   Pavlou M, 2016, STAT MED, V35, P1159, DOI 10.1002/sim.6782
   Perrott-Reynolds R, 2019, EYE, V33, P274, DOI 10.1038/s41433-018-0229-6
   Roberts PK, 2019, INVEST OPHTH VIS SCI, V60, P304, DOI 10.1167/iovs.18-25189
   Roberts PK, 2017, RETINA-J RET VIT DIS, V37, P1492, DOI 10.1097/IAE.0000000000001400
   Roberts PK, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.14.1
   Shin HJ, 2011, RETINA-J RET VIT DIS, V31, P1627, DOI 10.1097/IAE.0b013e31820d3d01
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Subhi Y, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/7194927
   Suh MH, 2009, AM J OPHTHALMOL, V147, P473, DOI 10.1016/j.ajo.2008.09.020
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woronkowicz M, 2020, GRAEF ARCH CLIN EXP, V258, P2373, DOI 10.1007/s00417-020-04869-4
   Wu QR, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01390-4
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Ying GS, 2015, OPHTHALMOLOGY, V122, P2523, DOI 10.1016/j.ophtha.2015.08.015
   Zhang QQ, 2017, OPHTHALMOL RETINA, V1, P124, DOI 10.1016/j.oret.2016.08.005
NR 43
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2326-0254
J9 EYE VISION
JI Eye Vis.
PD MAY 1
PY 2022
VL 9
IS 1
AR 16
DI 10.1186/s40662-022-00287-1
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0Y1UB
UT WOS:000790179700001
PM 35505390
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Bakri, SJ
   Moshfeghi, DM
   Francom, S
   Rundle, AC
   Reshef, DS
   Lee, PP
   Schaeffer, C
   Rubio, RG
   Lai, P
AF Bakri, Sophie J.
   Moshfeghi, Darius M.
   Francom, Steve
   Rundle, Amy Chen
   Reshef, Daniel S.
   Lee, Paul P.
   Schaeffer, Carol
   Rubio, Roman G.
   Lai, Phillip
TI Intraocular Pressure in Eyes Receiving Monthly Ranibizumab in 2 Pivotal
   Age-Related Macular Degeneration Clinical Trials
SO OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-VEIN-OCCLUSION; GROWTH-FACTOR AGENTS; INTRAVITREAL INJECTIONS;
   OCULAR HYPERTENSION; STANDARD-CARE; BEVACIZUMAB; THERAPY; TRIAMCINOLONE;
   VERTEPORFIN; ELEVATION
AB Purpose: To characterize preinjection intraocular pressure (IOP) in eyes receiving monthly ranibizumab versus sham or verteporfin photodynamic therapy (PDT) for age-related macular degeneration (AMD).
   Design: Post hoc analysis of IOP data from 2 phase 3 clinical trials, the Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD (MARINA) and the Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD (ANCHOR) trial.
   Participants: All safety-evaluable patients who received 1 or more injections of sham or PDT or of ranibizumab and had 1 or more postbaseline IOP measurements recorded for the study eye.
   Methods: Preinjection IOP measurements for study eyes (n = 1125) and fellow eyes in MARINA and ANCHOR at baseline and at each monthly visit through month 24 were analyzed.
   Main Outcome Measures: End points evaluated were maximum preinjection IOP during the 24-month treatment period; any occurrence of absolute preinjection IOP of 21 mmHg or more, 25 mmHg or more, or 30 mmHg or more; any occurrence of IOP increase of 6 mmHg or more, 8 mmHg or more, or 10 mmHg or more from baseline; any combination of IOP increase of 6 mmHg or more or 8 mmHg or more from baseline with concurrent absolute preinjection IOP of 21 mmHg or more or 25 mmHg or more; glaucoma-related adverse events; new glaucoma medications used for 45 days or more; and glaucoma filtration or laser surgeries.
   Results: Across treatment groups, 60.1% to 70.9% of study eyes had a maximum preinjection IOP of less than 21 mmHg. Comparing ranibizumab 0.5 mg versus sham or PTD treatment, respectively: 39.9% versus 29.1% and 10.9% versus 5.1% had maximum preinjection IOPs of 21 mmHg or more or 25 mmHg or more, respectively; 44.1% versus 29.9% and 24.2% versus 13.6% had IOP increases from baseline of 6 mmHg or more or 8 mmHg or more, respectively; 26.1% versus 13.6% and 16.8% versus 9.0% had 1 or more IOP increase from baseline of 6 mmHg or more or 8 mmHg or more, respectively, with a concurrent IOP of 21 mmHg or more; 9.6% versus 3.7% and 7.5% versus 2.4% had 1 or more IOP increase from baseline of 6 mmHg or more or 8 mmHg or more, respectively, with a concurrent IOP of 25 mmHg or more. No differences were observed in fellow eyes.
   Conclusions: Most ranibizumab-treated eyes did not experience sustained preinjection IOP of 21 mmHg or more (> 2 consecutive visits) over 24 months. When evaluating the combined IOP end point, more ranibizumabtreated eyes had 1 or more IOP increase from baseline of 6 mmHg or more or 8 mmHg or more, with concurrent highest IOPs of 21 mmHg or more and 25 mmHg or more versus sham or PDT. Intraocular pressure should be monitored in eyes receiving ranibizumab. Ophthalmology 2014; 121: 1102-1108 (C) 2014 by the American Academy of Ophthalmology.
C1 [Bakri, Sophie J.] Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA.
   [Moshfeghi, Darius M.] Stanford Univ, Sch Med, Dept Ophthalmol, Horngren Family Vitreoretinal Ctr,Byers Eye Inst, Palo Alto, CA 94304 USA.
   [Francom, Steve; Rundle, Amy Chen; Reshef, Daniel S.; Schaeffer, Carol; Rubio, Roman G.; Lai, Phillip] Genentech Inc, San Francisco, CA 94080 USA.
   [Lee, Paul P.] Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA.
C3 Mayo Clinic; Stanford University; Roche Holding; Genentech; University
   of Michigan System; University of Michigan
RP Bakri, SJ (通讯作者)，Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA.
EM bakri.sophie@mayo.edu
OI Moshfeghi, Darius Mohammad/0000-0003-2254-292X
FU Genentech, Inc., South San Francisco, California; Research to Prevent
   Blindness, Inc., New York, New York
FX The author( s) have made the following disclosure( s): Paul P. Lee:
   Consultant-Genentech, Inc., Quorum Pharmaceuticals, Inc., and Pfizer,
   Inc.; Financial support-Genentech, Inc., Alcon Research Institute. Steve
   Francom: Employee-Genentech, Inc.; Equity ownere-F. Hoffman- La Roche
   Ltd. Amy Chen Rundle: Employee-Genentech, Inc.; Equity owner-F.
   Hoffman-La Roche Ltd. Daniel S. Reshef: Employee-Genentech, Inc.; Equity
   owner- F. Hoffman- La Roche Ltd. Carol Schaeffer: Employee-Genentech,
   Inc.; Equity owner-F. Hoffman- La Roche Ltd. Roman G. Rubio: Employee-
   Genentech, Inc.; Equity owner-F. Hoffman- La Roche Ltd. Phillip Lai:
   Employee-Genentech, Inc.; Equity ownereF. Hoffman- La Roche Ltd.
   Supported by Genentech, Inc., South San Francisco, California. The
   funding organization participated, in part, in the design and conduct of
   the study as well as the collection, management, analysis, and
   interpretation of the data. Dr. Bakri, Dr. Moshfeghi, and Dr. Lee have
   received no financial support for the development of this manuscript.
   Dr. Bakri was responsible for the inception of the study and supervised
   all aspects of the study. Dr. Bakri was supported in part by an
   unrestricted grant to the Mayo Clinic Department of Ophthalmology from
   Research to Prevent Blindness, Inc., New York, New York.
CR Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Bakri SJ, 2009, EYE, V23, P181, DOI 10.1038/sj.eye.6702938
   Bakri SJ, 2008, RETINA-J RET VIT DIS, V28, P996, DOI 10.1097/IAE.0b013e31816c6868
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Ip MS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1101, DOI 10.1001/archophthalmol.2009.234
   Kahook MY, 2009, OPHTHAL SURG LAS IM, V40, P293, DOI 10.3928/15428877-20090430-12
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Kotliar K, 2007, ACTA OPHTHALMOL SCAN, V85, P777, DOI 10.1111/j.1600-0420.2007.00939.x
   Liu L, 2011, INVEST OPHTH VIS SCI, V52, P1023, DOI 10.1167/iovs.10-6431
   Pershing S, 2013, OPHTHAL SURG LAS IM, V44, P460, DOI 10.3928/23258160-20130909-07
   Quigley HA, 2009, AM J OPHTHALMOL, V148, P657, DOI 10.1016/j.ajo.2009.08.009
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scott IU, 2012, ARCH OPHTHALMOL-CHIC, V130, P1517, DOI 10.1001/archophthalmol.2012.2728
   Sniegowski M, 2010, OPEN OPHTHALMOL J, V4, P28, DOI 10.2174/1874364101004010028
   Tseng JJ, 2012, J GLAUCOMA, V21, P241, DOI 10.1097/IJG.0b013e31820d7d19
   Wehrli SJ, 2012, RETINA-J RET VIT DIS, V32, P1295, DOI 10.1097/IAE.0b013e31823f0c95
NR 20
TC 70
Z9 71
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2014
VL 121
IS 5
BP 1102
EP 1108
DI 10.1016/j.ophtha.2013.11.029
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AG6BT
UT WOS:000335504200024
PM 24393349
DA 2022-11-30
ER

PT J
AU Jiang, S
   Park, C
   Barner, JC
AF Jiang, S.
   Park, C.
   Barner, J. C.
TI Ranibizumab for age-related macular degeneration: a meta-analysis of
   dose effects and comparison with no anti-VEGF treatment and bevacizumab
SO JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
LA English
DT Review
DE anti-VEGF; monthly; clinical trials; bevacizumab; as-needed
ID VERTEPORFIN PHOTODYNAMIC THERAPY; PREVALENCE
AB What is known and objectives
   Ranibizumab is used monthly or as-needed (PRN) for the treatment of age-related macular degeneration. However, which treatment regimen is more effective remains unknown. The objectives of this study are to: (i) compare the efficacy of monthly versus as-needed quarterly treatment; and (ii) compare the efficacy of ranibizumab 0 center dot 5mg treatment with: (a) no anti-vascular endothelial growth factor (VEGF); (b) ranibizumab 0 center dot 3mg; and (c) bevacizumab.
   Method
   This is a systematic meta-analytic review of randomized-controlled clinical trials of ranibizumab in neovascular AMD. Weighted multiple regression analyses were used to compare the monthly vs. PRN/quarterly treatment.
   Results
   Eight randomized controlled trials met our inclusion criteria. Patients on the monthly ranibizumab treatment had higher visual acuity letter gains (beta=0 center dot 441, P<0 center dot 05) compared with patients on as-needed/quarterly treatment. More patients on the monthly treatment gained >= 15 letters than as-needed/quarterly treatment (beta=0 center dot 582, P<0 center dot 05). Ranibizumab produced significantly higher improvement in visual acuity (d=1 center dot 20, z=7 center dot 14, P<0 center dot 05) and led to a higher proportion of patients gaining >= 15 letters (OR: 6 center dot 67; 95% CI 3 center dot 16-14 center dot 06; P<0 center dot 05) when compared with non-anti-VEGF. Ranibizumab did not show any advantage in visual acuity compared with bevacizumab. No significant differences were found between ranibizumab 0 center dot 3mg and 0 center dot 5mg.
   What is new and conclusion
   This is the first meta-analysis to systematically evaluate the efficacy of different treatment regimens for anti-VEGF therapy. Ranibizumab 0 center dot 3 or 0 center dot 5mg monthly treatment was more effective for neovascular AMD than non-anti-VEGF treatments but is no better than bevacizumab.
C1 [Jiang, S.; Park, C.; Barner, J. C.] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA.
C3 University of Texas System; University of Texas Austin
RP Barner, JC (通讯作者)，Univ Texas Austin, Coll Pharm Hlth Outcomes & Pharm Practice, 2409 Univ Ave STOP A1930, Austin, TX 78712 USA.
EM jbarner@austin.utexas.edu
CR AAO, 2008, PREF PRACT PATT AG R
   Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Genetech, 2013, DME CLIN TRIALS 2012
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   NHS, 2008, RAN PEGAPT TREATM RE
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
NR 28
TC 12
Z9 12
U1 0
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-4727
EI 1365-2710
J9 J CLIN PHARM THER
JI J. Clin. Pharm. Ther.
PD JUN
PY 2014
VL 39
IS 3
BP 234
EP 239
DI 10.1111/jcpt.12146
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AF4KB
UT WOS:000334679600003
PM 24635444
DA 2022-11-30
ER

PT J
AU Hogg, RE
   Chakravarthy, U
AF Hogg, R. E.
   Chakravarthy, U.
TI Visual function and dysfunction in early and late age-related
   maculopathy
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
ID SENILE MACULAR DEGENERATION; SCANNING LASER OPHTHALMOSCOPE;
   QUALITY-OF-LIFE; PREFERRED RETINAL LOCI; CHOROIDAL NEOVASCULARIZATION
   SECONDARY; CONE PATHWAY VULNERABILITY; FOVEAL FLICKER SENSITIVITY;
   CONTRAST SENSITIVITY; DARK-ADAPTATION; CENTRAL SCOTOMA
AB Late age-related maculopathy (ARM) is responsible for the majority of blind registrations in the Western world among persons over 50 years of age. It has devastating effects on quality of life and independence and is becoming a major public health concern. Current treatment options are limited and most aim to slow progression rather than restore vision; therefore, early detection to identify those patients most suitable for these interventions is essential.
   In this work, we review the literature encompassing the investigation of visual function in ARM in order to highlight those visual function parameters which are affected very early in the disease process. We pay particular attention to measures of acuity, contrast sensitivity (CS), cone function, electrophysiology, visual adaptation, central visual field sensitivity and metamorphopsia. We also consider the impact of bilateral late ARM on visual function as well as the relationship between measures of vision function and self-reported visual functioning.
   Much interest has centred on the identification of functional changes which may predict progression to neovascular disease; therefore, we outline the longitudinal studies, which to date have reported dark-adaptation time, short-wavelength cone sensitivity, colour-match area effect, dark-adapted foveal sensitivity, foveal flicker sensitivity, slow recovery from glare and slower foveal electroretinogram implicit time as functional risk factors for the development of neovascular disease.
   Despite progress in this area, we emphasise the need for longitudinal studies designed in light of developments in disease classification and retinal imaging, which would ensure the correct classification of cases and controls, and provide increased understanding of the natural course and progression of the disease and further elucidate the structure-function relationships in this devastating disorder. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Queens Univ Belfast, Belfast BT12 6BA, Antrim, North Ireland.
   Royal Victoria Hosp, Belfast BT12 6BA, Antrim, North Ireland.
C3 Queens University Belfast
RP Chakravarthy, U (通讯作者)，Queens Univ Belfast, Belfast BT12 6BA, Antrim, North Ireland.
EM u.chakravarthy@qub.ac.uk
RI Hogg, Ruth E./ABC-9602-2020
OI Hogg, Ruth E./0000-0001-9413-2669; Chakravarthy,
   Usha/0000-0002-2606-3734
CR Aaronson N K, 1988, Oncology (Williston Park), V2, P69
   Abadi RV, 1996, OPHTHAL PHYSL OPT, V16, P455, DOI 10.1046/j.1475-1313.1996.96000129.x
   ALEXANDER MF, 1988, ARCH OPHTHALMOL-CHIC, V106, P1543, DOI 10.1001/archopht.1988.01060140711040
   Altpeter E, 2000, VISION RES, V40, P1539, DOI 10.1016/S0042-6989(00)00059-6
   Anderson AJ, 2001, VISION RES, V41, P2449, DOI 10.1016/S0042-6989(01)00139-0
   Anderson AJ, 2000, VISION RES, V40, P2579, DOI 10.1016/S0042-6989(00)00121-8
   APPLEGATE RA, 1987, APPL OPTICS, V26, P1458, DOI 10.1364/AO.26.001458
   Arden GB, 2004, BRIT J OPHTHALMOL, V88, P1180, DOI 10.1136/bjo.2003.033480
   ARDEN GB, 1984, BRIT J OPHTHALMOL, V68, P878, DOI 10.1136/bjo.68.12.878
   ARDITI A, 1993, INVEST OPHTH VIS SCI, V34, P120
   *ARENDS, 2001, AM J OPHTHALMOL, V132, P668
   ATCHISON DA, 1990, OPTOMETRY VISION SCI, V67, P179, DOI 10.1097/00006324-199003000-00006
   Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   BAILEY IL, 1980, AM J OPTOM PHYS OPT, V57, P378
   BALDASARE J, 1986, J VISUAL IMPAIR BLIN, V80, P785
   Barca L, 1978, Mod Probl Ophthalmol, V19, P301
   Bartlett H, 2004, OPHTHAL PHYSL OPT, V24, P594, DOI 10.1111/j.1475-1313.2004.00245.x
   BARTLETT H, 2004, OPTOM PRACTISE, V5, P15
   Bellmann C, 2003, GRAEF ARCH CLIN EXP, V241, P968, DOI 10.1007/s00417-003-0689-6
   Bernardes R, 2002, SURV OPHTHALMOL, V47, P580, DOI 10.1016/S0039-6257(02)00355-7
   BIRD AC, 1974, BRIT J OPHTHALMOL, V58, P367, DOI 10.1136/bjo.58.4.367
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bowers Alex R, 2001, Clin Exp Optom, V84, P139
   Bowman K J, 1978, Mod Probl Ophthalmol, V19, P71
   BOWMAN KJ, 1980, AM J OPTOM PHYS OPT, V57, P145
   BOWMAN KJ, 1980, ACTA OPHTHALMOL, V58, P337
   BOWMAN KJ, 1984, DOCUMENTA OPHTHAL P, V39, P363
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   BROWN B, 1989, OPTOMETRY VISION SCI, V66, P426, DOI 10.1097/00006324-198907000-00003
   BROWN B, 1983, AM J OPTOM PHYS OPT, V60, P788
   BROWN B, 1986, AM J OPTOM PHYS OPT, V63, P450
   BROWN B, 1984, AM J OPTOM PHYS OPT, V61, P265
   BROWN B, 1983, AM J OPTOM PHYS OPT, V60, P645
   Brown B, 1987, CLIN EXP OPTOM, V70, P145
   Brown B, 1987, CLIN EXP OPTOM, V70, P112
   BULLIMORE MA, 1995, OPTOMETRY VISION SCI, V72, P125, DOI 10.1097/00006324-199502000-00011
   Burns SA, 2003, INVEST OPHTH VIS SCI, V44, P4061, DOI 10.1167/iovs.03-0124
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Calkins DJ, 2001, PROG RETIN EYE RES, V20, P255, DOI 10.1016/S1350-9462(00)00026-4
   Calkins DJ, 1998, J NEUROSCI, V18, P3373
   Campbell C J, 1972, Mod Probl Ophthalmol, V11, P98
   CAMPBELL FW, 1965, NATURE, V208, P191, DOI 10.1038/208191a0
   Carta A, 1998, CURR EYE RES, V17, P506, DOI 10.1076/ceyr.17.5.506.5191
   CELESIA GG, 1985, INVEST OPHTH VIS SCI, V26, P726
   CHENG AS, 1993, OPTOMETRY VISION SCI, V70, P89, DOI 10.1097/00006324-199302000-00001
   Cohen SY, 2003, GRAEF ARCH CLIN EXP, V241, P785, DOI 10.1007/s00417-003-0744-3
   COLLINS M, 1989, CLIN VISION SCI, V4, P145
   COLLINS M, 1989, CLIN VISION SCI, V4, P155
   Collins MJ, 1986, CLIN EXP OPTOM, V69, P223, DOI DOI 10.1111/J.1444-0938.1986.TB04596.X
   Comer GM, 2004, DRUG AGING, V21, P967, DOI 10.2165/00002512-200421150-00002
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   CUMMINGS RW, 1985, AM J OPTOM PHYS OPT, V62, P833
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   DACEY DM, 1993, VISUAL NEUROSCI, V10, P1081, DOI 10.1017/S0952523800010191
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   de Boer MR, 2004, OPHTHAL PHYSL OPT, V24, P257, DOI 10.1111/j.1475-1313.2004.00187.x
   DEMONASTERIO FM, 1981, SCIENCE, V213, P1278, DOI 10.1126/science.7268439
   Deruaz A, 2002, VISION RES, V42, P2947, DOI 10.1016/S0042-6989(02)00354-1
   Doris N, 2001, BRIT J OPHTHALMOL, V85, P184, DOI 10.1136/bjo.85.2.184
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   DUKEELDER WS, 1940, TXB OPHTHALMOLOGY, P2116
   Duret F, 1999, VISION RES, V39, P873, DOI 10.1016/S0042-6989(98)00179-5
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   El Mallah MK, 2000, BRIT J OPHTHALMOL, V84, P952, DOI 10.1136/bjo.84.9.952
   ELDRED KB, 1992, OPTOMETRY VISION SCI, V69, P46, DOI 10.1097/00006324-199201000-00007
   Elliott DB, 2001, INVEST OPHTH VIS SCI, V42, P1945
   Elsner AE, 2002, J OPT SOC AM A, V19, P215, DOI 10.1364/JOSAA.19.000215
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   ERIKSEN CW, 1977, B PSYCHONOMIC SOC, V9, P81, DOI 10.3758/BF03336936
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Evans JR, 2004, BRIT J OPHTHALMOL, V88, P365, DOI 10.1136/bjo.2003.019927
   Falsini B, 1999, GRAEF ARCH CLIN EXP, V237, P193, DOI 10.1007/s004170050218
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   Faubert J, 2000, J AM GERIATR SOC, V48, P375, DOI 10.1111/j.1532-5415.2000.tb04693.x
   FEIGL B, 2004, EYE, V30
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Fine EM, 1999, OPTOMETRY VISION SCI, V76, P764, DOI 10.1097/00006324-199911000-00025
   Fink W, 2004, J BIOMED OPT, V9, P149, DOI 10.1117/1.1625952
   FISH GE, 1989, OPHTHALMOLOGY, V96, P109
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   FRANCOIS J, 1961, VISION RES, V1, P201, DOI 10.1016/0042-6989(61)90001-3
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Fujii GY, 2003, AM J OPHTHALMOL, V136, P1067, DOI 10.1016/S0002-9394(03)00663-9
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   GLASER JS, 1977, AM J OPHTHALMOL, V83, P255, DOI 10.1016/0002-9394(77)90624-9
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREENSTEIN VC, 1989, INVEST OPHTH VIS SCI, V30, P1732
   GREENSTEIN VC, 1992, INVEST OPHTH VIS SCI, V33, P2781
   GUEZ JE, 1993, VISION RES, V33, P1271, DOI 10.1016/0042-6989(93)90213-G
   HAEGERSTROMPORTNOY G, 1989, CLIN VISION SCI, V4, P165
   Haimovici R, 2002, GRAEF ARCH CLIN EXP, V240, P90, DOI 10.1007/s00417-001-0417-z
   HART WM, 1983, OPHTHALMOLOGY, V90, P1028
   HART WM, 1987, SURV OPHTHALMOL, V32, P10, DOI 10.1016/0039-6257(87)90070-1
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   HEINEN SJ, 1992, VISION RES, V32, P365, DOI 10.1016/0042-6989(92)90145-9
   HENKES HE, 1954, AMA ARCH OPHTHALMOL, V51, P54, DOI 10.1001/archopht.1954.00920040056007
   Holopigian K, 1997, OPTOMETRY VISION SCI, V74, P152, DOI 10.1097/00006324-199703000-00026
   Holz F G, 1995, Ger J Ophthalmol, V4, P336
   HOME R, 1978, VISION RES, V18, P579, DOI 10.1016/0042-6989(78)90206-7
   HOOD DC, 1988, APPL OPTICS, V27, P1025, DOI 10.1364/AO.27.001025
   HYVARINEN L, 1983, ACTA OPHTHALMOL, V61, P161
   Jackson GR, 2004, INVEST OPHTH VIS SCI, V45, P3271, DOI 10.1167/iovs.04-0019
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 2000, VISION RES, V40, P2467, DOI 10.1016/S0042-6989(00)00108-5
   JUNGHARDT A, 1995, DOC OPHTHALMOL, V90, P229, DOI 10.1007/BF01203859
   Jurklies B, 2002, GRAEF ARCH CLIN EXP, V240, P244, DOI 10.1007/s00417-002-0439-1
   KIRYU J, 1995, INVEST OPHTH VIS SCI, V36, P1240
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   LAKSHMINARAYANAN V, 1995, INT OPHTHALMOL, V19, P109, DOI 10.1007/BF00133181
   LEFTON LA, 1974, J EXP PSYCHOL, V102, P975, DOI 10.1037/h0036542
   LEGGE GE, 1984, VISION RES, V24, P373, DOI 10.1016/0042-6989(84)90063-4
   LEGGE GE, 1985, VISION RES, V25, P253, DOI 10.1016/0042-6989(85)90118-X
   LEGGE GE, 1992, INVEST OPHTH VIS SCI, V33, P677
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   Leibrock CS, 1998, EYE, V12, P511, DOI 10.1038/eye.1998.139
   LENNERSTRAND G, 1982, ACTA OPHTHALMOL, V60, P497
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Linder M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1611
   Loewenstein A, 2003, OPHTHALMOLOGY, V110, P966, DOI 10.1016/S0161-6420(03)00074-5
   LOSHIN DS, 1984, ARCH OPHTHALMOL-CHIC, V102, P1303, DOI 10.1001/archopht.1984.01040031053022
   LOTT LA, 2002, INVEST OPHTHALMOL VI, V43
   Lovie-Kitchin JE, 2000, OPTOMETRY VISION SCI, V77, P412, DOI 10.1097/00006324-200008000-00008
   LOVIEKITCHIN JE, 1988, OPHTHAL PHYSL OPT, V8, P363, DOI 10.1111/j.1475-1313.1988.tb01170.x
   LOVIEKITCHIN JE, 1985, SENILE MACULAR DEGEN, P63
   Mackeben M, 1999, SPATIAL VISION, V12, P51, DOI 10.1163/156856899X00030
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   MARC RE, 1977, SCIENCE, V196, P454, DOI 10.1126/science.403607
   MARCUS M, 1983, ANN OPHTHALMOL, V15, P235
   Margolis MK, 2002, PHARMACOECONOMICS, V20, P791, DOI 10.2165/00019053-200220120-00001
   Marmor MF, 2000, SURV OPHTHALMOL, V44, P343, DOI 10.1016/S0039-6257(99)00113-7
   Marmor MF, 2003, DOC OPHTHALMOL, V106, P105, DOI 10.1023/A:1022591317907
   MARRON JA, 1982, AM J OPTOM PHYS OPT, V59, P413
   Massof RW, 2001, SURV OPHTHALMOL, V45, P531, DOI 10.1016/S0039-6257(01)00194-1
   MAYER MJ, 1995, VISION RES, V35, P1575, DOI 10.1016/0042-6989(94)00252-H
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3150
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3136
   MAYER MJ, 1994, INVEST OPHTH VIS SCI, V35, P1138
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3143
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   MCMAHON TT, 1991, INVEST OPHTH VIS SCI, V32, P567
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   MIDENA E, 1994, DOC OPHTHALMOL, V88, P179, DOI 10.1007/BF01204616
   MULDREW KA, 2003, INVEST OPHTHALMOL VI, V44
   Negishi C, 2001, ACTA OPHTHALMOL SCAN, V79, P271, DOI 10.1034/j.1600-0420.2001.790312.x
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   OWSLEY C, 1981, INVEST OPHTH VIS SCI, V21, P362
   Owsley Cynthia, 2003, Ophthalmol Clin North Am, V16, P171, DOI 10.1016/S0896-1549(03)00003-8
   Palmowski AM, 1999, OPHTHALMOLOGE, V96, P166, DOI 10.1007/s003470050389
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Pianta MJ, 2000, J PHYSIOL-LONDON, V528, P591, DOI 10.1111/j.1469-7793.2000.00591.x
   RAYNER K, 1978, PSYCHOL BULL, V85, P618, DOI 10.1037/0033-2909.85.3.618
   RAYNER K, 1979, SCIENCE, V206, P468, DOI 10.1126/science.504987
   Remky A, 2001, BRIT J OPHTHALMOL, V85, P1432, DOI 10.1136/bjo.85.12.1432
   REMULLA JFC, 1995, BRIT J OPHTHALMOL, V79, P558, DOI 10.1136/bjo.79.6.558
   Rosser DA, 2003, INVEST OPHTH VIS SCI, V44, P3278, DOI 10.1167/iovs.02-1100
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   Rubin GS, 2000, INVEST OPHTH VIS SCI, V41, P3327
   RUBINSTEIN MP, 1985, BR ORTHOPT J, V42, P45
   RYAN SJ, 1980, A GRAEF ARCH KLIN EX, V215, P1, DOI 10.1007/BF00413392
   Safran AB, 1999, BRIT J OPHTHALMOL, V83, P1341, DOI 10.1136/bjo.83.12.1341
   Sandberg MA, 1998, OPHTHALMOLOGY, V105, P441, DOI 10.1016/S0161-6420(98)93025-1
   SANDBERG MA, 1993, INVEST OPHTH VIS SCI, V34, P3477
   SANDBERG MA, 1995, RETINA-J RET VIT DIS, V15, P407, DOI 10.1097/00006982-199515050-00006
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schmidt-Erfurth UM, 2004, OPHTHALMOLOGY, V111, P931, DOI 10.1016/j.ophtha.2003.12.025
   Schmitt NJ, 2003, AM J OPHTHALMOL, V136, P314, DOI 10.1016/S0002-9394(03)00208-3
   Schneider U, 1996, GRAEF ARCH CLIN EXP, V234, P612, DOI 10.1007/BF00185293
   SCHUCHARD RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P776, DOI 10.1001/archopht.1993.01090060064024
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   SEIPLE WH, 1986, INVEST OPHTH VIS SCI, V27, P1123
   Shirao Y, 1997, JPN J OPHTHALMOL, V41, P174, DOI 10.1016/S0021-5155(97)00026-9
   SJOSTRAND J, 1977, ACTA OPHTHALMOL, V55, P507
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   SMITH VC, 1988, J OPT SOC AM A, V5, P2113, DOI 10.1364/JOSAA.5.002113
   SOKOL S, 1972, ARCH OPHTHALMOL-CHIC, V88, P619, DOI 10.1001/archopht.1972.01000030621010
   SPERLING HG, 1980, VISION RES, V20, P1117, DOI 10.1016/0042-6989(80)90049-8
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   STANGOS N, 1995, OPHTHALMOLOGICA, V209, P194, DOI 10.1159/000310612
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Sturr JF, 1997, VISION RES, V37, P475, DOI 10.1016/S0042-6989(96)00196-4
   Sunness JS, 1999, INT OPHTHALMOL CLIN, V39, P19, DOI 10.1097/00004397-199903940-00004
   SUNNESS JS, 1986, AM J OPTOM PHYS OPT, V63, P7
   SUNNESS JS, 1985, ARCH OPHTHALMOL-CHIC, V103, P811
   SUNNESS JS, 1995, INVEST OPHTH VIS SCI, V36, P1863
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Sunness JS, 2000, RETINA-J RET VIT DIS, V20, P162, DOI 10.1097/00006982-200002000-00009
   SUNNESS JS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1081, DOI 10.1001/archopht.1988.01060140237032
   SUNNESS JS, 1989, OPHTHALMOLOGY, V96, P375, DOI 10.1016/S0161-6420(89)32883-1
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   SWANN PG, 1991, OPHTHAL PHYSL OPT, V11, P59, DOI 10.1016/0275-5408(91)90012-8
   Takamine Y, 1998, GRAEF ARCH CLIN EXP, V236, P285, DOI 10.1007/s004170050079
   Tezel TH, 1996, OPHTHALMOLOGY, V103, P1829, DOI 10.1016/S0161-6420(96)30419-3
   TIMBERLAKE GT, 1987, INVEST OPHTH VIS SCI, V28, P1268
   TIMBERLAKE GT, 1986, INVEST OPHTH VIS SCI, V27, P1137
   Toi VV, 1994, J APPL PHYSL 1985, V482, P189
   TOLENTINO MJ, 1994, VISION RES, V34, P409, DOI 10.1016/0042-6989(94)90099-X
   TRUSIEWICZ D, 1984, COLOUR VISION DEFICI, V7, P371
   Valberg A, 2002, J OPT SOC AM A, V19, P223, DOI 10.1364/JOSAA.19.000223
   WALL M, 1987, OPHTHALMOLOGY, V94, P1126
   Walter P, 1999, GRAEF ARCH CLIN EXP, V237, P962, DOI 10.1007/s004170050331
   Wang JJ, 2000, INVEST OPHTH VIS SCI, V41, P49
   Wang YZ, 2002, INVEST OPHTH VIS SCI, V43, P2055
   WEITER JJ, 1984, ANN OPHTHALMOL, V16, P174
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
   WHITTAKER SG, 1993, OPTOMETRY VISION SCI, V70, P54, DOI 10.1097/00006324-199301000-00010
   WHITTAKER SG, 1988, INVEST OPHTH VIS SCI, V29, P268
   WOLKSTEIN M, 1980, OPHTHALMOLOGY, V87, P1140
   Zaidi FH, 2004, EYE, V18, P503, DOI 10.1038/sj.eye.6700708
   Zlatkova MB, 2001, VISION RES, V41, P3093, DOI 10.1016/S0042-6989(01)00191-2
   [No title captured]
NR 232
TC 128
Z9 131
U1 0
U2 28
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD MAY
PY 2006
VL 25
IS 3
BP 249
EP 276
DI 10.1016/j.preteyeres.2005.11.002
PG 28
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 058WD
UT WOS:000238694400001
PM 16580242
DA 2022-11-30
ER

PT J
AU Yang, K
   Liang, YB
   Gao, LQ
   Peng, Y
   Shen, R
   Duan, XR
   Friedman, DS
   Sun, LP
   Mitchell, P
   Wang, NL
   Wong, TY
   Wang, JJ
AF Yang, Ke
   Liang, Yuan Bo
   Gao, Li Qin
   Peng, Yi
   Shen, Ran
   Duan, Xin Rong
   Friedman, David S.
   Sun, Lan Ping
   Mitchell, Paul
   Wang, Ning Li
   Wong, Tien Yin
   Wang, Jie Jin
TI Prevalence of Age-Related Macular Degeneration in a Rural Chinese
   Population: The Handan Eye Study
SO OPHTHALMOLOGY
LA English
DT Article
ID RISK-FACTORS; JAPANESE POPULATION; ADULT-POPULATION; LOW-VISION;
   MACULOPATHY; BLINDNESS; CATARACT; IMPAIRMENT; AUSTRALIA
AB Purpose: To describe the prevalence of age-related degeneration (AMD) in a rural Chinese population and to assess its associations with age, gender, and smoking.
   Design: Population-based cross-sectional.
   Participants: Persons aged 30+ years, recruited between October 2006 and October 2007, from Yongnian County, Handan, Hebei Province, China.
   Methods: All participants underwent a standardized interview and comprehensive eye examinations, including digital retinal photography of both eyes. Trained graders assessed the presence and severity of AMD lesions following the modified Wisconsin Age-related Maculopathy Grading System (WARMGS) used in the Blue Mountains Eye Study (BMES). Direct age standardization to the world population (year 2000) was performed to compare the prevalence across different populations.
   Main Outcome Measures: AMD and WARMGS.
   Results: Of 6830 participates, fundus photographs were gradable for 6581 persons (96.4%), including 4049 aged 50+ years. Early and late AMD prevalence rates were 3.0% and 0.1%, respectively, among participants. The age-standardized prevalence rates among participants aged 50+ years were 4.7% and 0.2%, respectively. After controlling for age, men had a higher prevalence of early (3.9% vs. 2.3%, odds ratio [OR] 1.7; 95% confidence interval [CI], 1.3-2.2) and late AMD (0.1% vs. 0.03%; OR 3.5; CI, 0.4-33.4) compared with women. Older age (sex-adjusted OR 1.7; CI, 1.3-2.2 per decade of age) and current smoking (age-sex-adjusted OR 1.4; CI, 1.0-2.1) were significantly associated with early AMD prevalence. The proportion of current smokers was substantially higher in men (58.7%) than in women (0.3%). The attributable risk of early AMD from smoking among Chinese men was 24.2%. After controlling for current smoking, the excess prevalence of early AMD in men compared with women reduced by 50% (OR 1.4; 95% CI, 0.9-2.0).
   Conclusions: The prevalence of early AMD in this rural Chinese sample was similar to white persons in the BMES and Asian Malays in the Singapore Malay Eye Study. Late AMD prevalence, however, was lower. Higher prevalence rates for early and late AMD in men compared with women were largely attributed to substantially higher proportions of smokers in rural Chinese men than in women.
C1 [Yang, Ke; Liang, Yuan Bo; Gao, Li Qin; Peng, Yi; Duan, Xin Rong; Wang, Ning Li] Capital Med Univ, Beijing Tongren Eye Ctr, Beijing Tongren Hosp, Beijing Ophthalmol & Visual Sci Key Lab, Beijing 100730, Peoples R China.
   [Friedman, David S.] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
   [Friedman, David S.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA.
   [Mitchell, Paul; Wang, Jie Jin] Univ Sydney, Ctr Vision Res, Dept Ophthalmol, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
   [Wong, Tien Yin; Wang, Jie Jin] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia.
   [Wong, Tien Yin] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore Eye Res Inst, Singapore 117595, Singapore.
C3 Capital Medical University; Johns Hopkins University; Johns Hopkins
   Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of
   Public Health; University of Sydney; Westmead Institute for Medical
   Research; Centre for Eye Research Australia; Royal Victorian Eye & Ear
   Hospital; University of Melbourne; National University of Singapore;
   Singapore National Eye Center
RP Wang, NL (通讯作者)，Capital Med Univ, Beijing Tongren Eye Ctr, 1 Dongjiao Min Xiang, Beijing 100730, Peoples R China.
EM wningli@vip.163.com
RI Wang, Jie Jin/P-1499-2014; wang, jie/GRS-0942-2022; Wong, Tien
   Yin/AAC-9724-2020; Mitchell, Paul/P-1498-2014
OI Wang, Jie Jin/0000-0001-9491-4898; Wong, Tien Yin/0000-0002-8448-1264;
   Friedman, David/0000-0002-2055-5797; liang, Yuanbo/0000-0001-9685-7356
FU Ministry of Science and Technology, P.R. China [2007CB512201]; Program
   of Health Policy for Blindness Prevention, P.R. China; Bureau of Science
   and Technology of Handan City, P.R. China [2006-10903]; Beijing Tongren
   Hospital; Bureau of Health, Handan City, P.R. China
FX Supported by the National Basic Research Program of China (973 Program)
   (No. 2007CB512201) from the Ministry of Science and Technology, P.R.
   China, and the Program of Health Policy for Blindness Prevention, P.R.
   China. Partially funded by the Key Technologies R&D Program (No.
   2006-10903) from the Bureau of Science and Technology of Handan City,
   P.R. China. With additional support from Beijing Tongren Hospital and
   the key discipline fund of the Bureau of Health, Handan City, P.R.
   China.
CR [Anonymous], 1991, Ophthalmology, V98, P786
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chang TS, 1999, CAN J OPHTHALMOL, V34, P266
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Dandona L, 2001, INVEST OPHTH VIS SCI, V42, P908
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Liang YB, 2008, OPHTHALMOLOGY, V115, P1965, DOI 10.1016/j.ophtha.2008.05.030
   Liang YB, 2009, OPHTHAL EPIDEMIOL, V16, P115, DOI 10.1080/09286580902738159
   Michon JJ, 2002, BRIT J OPHTHALMOL, V86, P133, DOI 10.1136/bjo.86.2.133
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Murthy GVS, 2001, OPHTHALMOLOGY, V108, P679, DOI 10.1016/S0161-6420(00)00579-0
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Saw SM, 2004, OPHTHALMOLOGY, V111, P1161, DOI 10.1016/j.ophtha.2003.09.040
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Tsai CY, 2005, JPN J OPHTHALMOL, V49, P166, DOI 10.1007/s10384-004-0164-x
   VINDING T, 1989, ACTA OPHTHALMOL, V67, P609
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
NR 31
TC 61
Z9 67
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2011
VL 118
IS 7
BP 1395
EP 1401
DI 10.1016/j.ophtha.2010.12.030
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 786JL
UT WOS:000292303000024
PM 21444116
DA 2022-11-30
ER

PT J
AU Kanemura, H
   Go, MJ
   Shikamura, M
   Nishishita, N
   Sakai, N
   Kamao, H
   Mandai, M
   Morinaga, C
   Takahashi, M
   Kawamata, S
AF Kanemura, Hoshimi
   Go, Masahiro J.
   Shikamura, Masayuki
   Nishishita, Naoki
   Sakai, Noriko
   Kamao, Hiroyuki
   Mandai, Michiko
   Morinaga, Chikako
   Takahashi, Masayo
   Kawamata, Shin
TI Tumorigenicity Studies of Induced Pluripotent Stem Cell (iPSC)-Derived
   Retinal Pigment Epithelium (RPE) for the Treatment of Age-Related
   Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID SUBRETINAL IMPLANTATION; GENERATION
AB Basic studies of human pluripotential stem cells have advanced rapidly and stem cell products are now seeing therapeutic applications. However, questions remain regarding the tumorigenic potential of such cells. Here, we report the tumorigenic potential of induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium (RPE) for the treatment of wet-type, age-related macular degeneration (AMD). First, immunodeficient mouse strains (nude, SCID, NOD-SCID and NOG) were tested for HeLa cells' tumor-forming capacity by transplanting various cell doses subcutaneously with or without Matrigel. The 50% Tumor Producing Dose (TPD50 value) is the minimal dose of transplanted cells that generated tumors in 50% of animals. For HeLa cells, the TPD50 was the lowest when cells were embedded in Matrigel and transplanted into NOG mice (TPD50= 10(1.1), n = 75). The TPD50 for undifferentiated iPSCs transplanted subcutaneously to NOG mice in Matrigel was 10(2.12); (n = 30). Based on these experiments, 1610 6 iPSC-derived RPE were transplanted subcutaneously with Matrigel, and no tumor was found during 15 months of monitoring (n = 65). Next, to model clinical application, we assessed the tumor-forming potential of HeLa cells and iPSC 201B7 cells following subretinal transplantation of nude rats. The TPD50 for iPSCs was 10(4.73) (n = 20) and for HeLa cells 10(1.32) (n = 37) respectively. Next, the tumorigenicity of iPSC-derived RPE was tested in the subretinal space of nude rats by transplanting 0.8-1.5x10(4) iPSC-derived RPE in a collagen-lined (1 mmx1 mm) sheet. No tumor was found with iPSC-derived RPE sheets during 6-12 months of monitoring (n = 26). Considering the number of rodents used, the monitoring period, the sensitivity of detecting tumors via subcutaneous and subretinal administration routes and the incidence of tumor formation from the iPSC-derived RPE, we conclude that the tumorigenic potential of the iPSC-derived RPE was negligible.
C1 [Kanemura, Hoshimi; Go, Masahiro J.; Shikamura, Masayuki; Nishishita, Naoki; Kawamata, Shin] Fdn Biomed Res & Innovat, Div Cell Therapy, Kobe, Hyogo, Japan.
   [Kanemura, Hoshimi; Sakai, Noriko; Kamao, Hiroyuki; Mandai, Michiko; Morinaga, Chikako; Takahashi, Masayo; Kawamata, Shin] RIKEN Ctr Dev Biol, Lab Retinal Regenerat, Kobe, Hyogo, Japan.
   [Kamao, Hiroyuki] Kawasaki Med Sch, Dept Ophthalmol, Kurashiki, Okayama, Japan.
C3 Institute for Biomedical Research & Innovation (IBRI); RIKEN; Kawasaki
   Medical School
RP Kawamata, S (通讯作者)，Fdn Biomed Res & Innovat, Div Cell Therapy, Kobe, Hyogo, Japan.
EM kawamata@fbri.org
OI Kamao, Hiroyuki/0000-0002-2194-7063; kawamata, shin/0000-0001-5148-1949
FU JST Japan
FX This study was supported by funding from JST research grant "Safety
   Tests for Pluripotent Stem Cell (2010-2014)'' Japan. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Bailey AM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003685
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Hentze H, 2009, STEM CELL RES, V2, P198, DOI 10.1016/j.scr.2009.02.002
   Hu YT, 2012, OPHTHALMIC RES, V48, P186, DOI 10.1159/000338749
   Ishikawa F, 2005, BLOOD, V106, P1565, DOI 10.1182/blood-2005-02-0516
   Kanemura H, 2013, SCI REP-UK, V3, DOI 10.1038/srep02334
   Kuroda T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037342
   Lewis AM, 2005, REG IMPL NEOPL CELL
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Machida K, 2009, J TOXICOL SCI, V34, P123, DOI 10.2131/jts.34.123
   Maekawa M, 2011, NATURE, V474, P225, DOI 10.1038/nature10106
   Muller FJ, 2010, CELL STEM CELL, V6, P412, DOI 10.1016/j.stem.2010.04.009
   Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374
   Okano Hideyuki, 2009, Genome Inform, V23, P217
   Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Prockop DJ, 2010, MOL THER, V18, P1249, DOI 10.1038/mt.2010.99
   Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   WHO, 2010, REC EV AN CELL CULT
   World Health Organization, 2008, WHO TECHN REP SER, V878
NR 21
TC 119
Z9 125
U1 2
U2 25
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 14
PY 2014
VL 9
IS 1
AR e85336
DI 10.1371/journal.pone.0085336
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 292TQ
UT WOS:000329925800038
PM 24454843
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Lanzl, IM
   Seidova, SF
   Maier, M
   Lohmann, C
   Schmidt-Trucksass, A
   Halle, M
   Kotliar, KE
AF Lanzl, Ines M.
   Seidova, Seid-Fatima
   Maier, Mathias
   Lohmann, Chris
   Schmidt-Trucksaess, Arno
   Halle, Martin
   Kotliar, Konstantin E.
TI Dynamic retinal vessel response to flicker in age-related macular
   degeneration patients before and after vascular endothelial growth
   factor inhibitor injection
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; flicker stimulation; retinal vessels;
   vascular endothelial growth factor inhibitor
ID BLOOD-FLOW; VISUAL-ACUITY; STIMULATION; PRESSURE; DIAMETER; DISEASE;
   ARTERY
AB Purpose: Retinal vessel responses to flickering light are different in various systemic and ocular diseases and can be improved after successful therapy. We investigated retinal vessel response to flickering light in age-related macular degeneration (AMD) patients before and after treatment with a single intravitreal bevacizumab (Avastin (R)) injection.
   Methods: In 10 patients with exudative AMD [age: median (1.quartile; 3.quartile) 76.0 (73.5; 80.0) years], retinal vessel reactions were examined by Dynamic Vessel Analyser (DVA) before and 3 months after a single intravitreal application of bevacizumab (1.25 mg). A baseline measurement was followed by three consecutive monochromatic flicker stimulations (530-600 nm, 12.5 Hz, 20 seconds). Temporal retinal vessel reaction was analysed and compared with the reaction in healthy controls.
   Results: Mean arterial dilation at the end of flicker was not different in all groups. For veins this parameter amounted to: pre-treatment, 2.6 (1.7; 3.9)%; post-treatment, 2.9 (2.4; 4.0)%; control, 4.3 (3.2; 5.7)%; significant: pre-treatment-control (Dunnett's procedure, p < 0.05). Maximal dilation occurred in arteries at: pre-treatment, 17.5 (14.8; 32.5) seconds; post-treatment, 18.0 (16.6; 30.6) seconds; control, 14.5 (10.8; 17.3) seconds. Both AMD groups were slower (p < 0.05): in veins at 17.0 (14.5; 20.0) seconds, 12.8 (8.6; 14.8) seconds and 18.5 (17.1; 19.9) seconds, respectively; significant post-treatment-control (p < 0.05). In the post-treatment AMD group arterial constriction after stimulation occurred more slowly compared with the control group (p < 0.05).
   Conclusion: Dynamic retinal arterial and venous reactions to flickering light are altered in AMD compared with controls. Three months after a single injection of a vascular endothelial growth factor inhibitor, the investigated retinal dynamic vascular parameters were not altered in our study.
C1 [Lanzl, Ines M.; Seidova, Seid-Fatima; Maier, Mathias; Lohmann, Chris; Kotliar, Konstantin E.] Tech Univ Munich, Dept Ophthalmol, Munich, Germany.
   [Schmidt-Trucksaess, Arno; Halle, Martin] Tech Univ Munich, Dept Prevent & Sports Med, Munich, Germany.
C3 Technical University of Munich; Technical University of Munich
RP Kotliar, KE (通讯作者)，Tech Univ Munich, Augenklin Rechts Isar, Dept Ophthalmol, Ismaninger Str 22, D-81675 Munich, Germany.
EM kotliar@lrz.tum.de
RI Schmidt-Trucksäss, Arno/I-7673-2015
OI Schmidt-Trucksäss, Arno/0000-0002-4662-3911; Kotliar,
   Konstantin/0000-0003-2087-957X
FU Clinical Research Foundation KKF, Klinikum rechts der Isar Munchen
FX This work was supported by a grant from Clinical Research Foundation
   KKF, Klinikum rechts der Isar Munchen.
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Brandes RP, 2005, CARDIOVASC RES, V66, P286, DOI 10.1016/j.cardiores.2004.12.027
   Cioffi GA., 2003, ADLERS PHYSL EYE, V10th ed., P747
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dorner GT, 2003, AM J PHYSIOL-HEART C, V285, pH631, DOI 10.1152/ajpheart.00111.2003
   ELMAN M, 1994, RETINA, P68
   FALSINI B, 2002, OPHTHALMIC RES S1, V32, P133
   Forte P, 1997, LANCET, V349, P837, DOI 10.1016/S0140-6736(96)07631-3
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Garhofer G, 2004, J GLAUCOMA, V13, P340, DOI 10.1097/00061198-200408000-00013
   Garhofer G, 2010, ACTA OPHTHALMOL, V88, P717, DOI 10.1111/j.1755-3768.2009.01587.x
   GHAFOUR IM, 1983, BRIT J OPHTHALMOL, V67, P209, DOI 10.1136/bjo.67.4.209
   Glantz S., 1999, PRIMER BIOSTATISTICS
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Gugleta K, 2006, INVEST OPHTH VIS SCI, V47, P4034, DOI 10.1167/iovs.06-0351
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Kotliar KE, 2004, GRAEF ARCH CLIN EXP, V242, P377, DOI 10.1007/s00417-003-0847-x
   KU DD, 1982, SCIENCE, V218, P576, DOI 10.1126/science.7123259
   LANG GE, 1994, OPHTHALMOLOGY S, V101, P141
   Lanzl IM, 2006, DTSCH MED WOCHENS S6, V131, P180
   LATIES AM, 1967, ARCH OPHTHALMOL-CHIC, V77, P405, DOI 10.1001/archopht.1967.00980020407021
   LESNEFSKY EJ, 1987, AM HEART J, V114, P896, DOI 10.1016/0002-8703(87)90802-7
   LUSCHER TF, 1990, HYPERTENSION, V15, P482, DOI 10.1161/01.HYP.15.5.482
   LUSCHER TF, 1987, MAYO CLIN PROC, V62, P601
   MANDECKA A, 2008, DIABETES CARE, V31, pE52
   Matz RL, 2003, DRUG AGING, V20, P527, DOI 10.2165/00002512-200320070-00005
   Nagel E, 2004, INVEST OPHTH VIS SCI, V45, P1486, DOI 10.1167/iovs.03-0667
   Nagel E, 2004, GRAEF ARCH CLIN EXP, V242, P13, DOI 10.1007/s00417-003-0663-3
   Polak K, 2002, INVEST OPHTH VIS SCI, V43, P2721
   Riva CE, 2005, PROG RETIN EYE RES, V24, P183, DOI 10.1016/j.preteyeres.2004.07.002
   SARKS S, 1994, RETINA, P67
   Sato E, 2006, EYE, V20, P697, DOI 10.1038/sj.eye.6701951
   Seifertl B U, 2002, Biomed Tech (Berl), V47 Suppl 1 Pt 2, P678, DOI 10.1515/bmte.2002.47.s1b.678
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   Soliman W, 2008, ACTA OPHTHALMOL, V86, P365, DOI 10.1111/j.1600-0420.2007.01057.x
   TESFAMARIAM B, 1989, AM J PHYSIOL, V257, pH1327, DOI 10.1152/ajpheart.1989.257.5.H1327
   VONHANNO T, 2009, ACTA OPHTHALMOL
   Yildiz G, 2007, ANN NY ACAD SCI, V1100, P353, DOI 10.1196/annals.1395.038
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 45
TC 17
Z9 18
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2011
VL 89
IS 5
BP 472
EP 479
DI 10.1111/j.1755-3768.2009.01718.x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 792KH
UT WOS:000292742800034
PM 20102347
DA 2022-11-30
ER

PT J
AU Strunnikova, N
   Hilmer, S
   Flippin, J
   Robinson, M
   Hoffman, E
   Csaky, KG
AF Strunnikova, N
   Hilmer, S
   Flippin, J
   Robinson, M
   Hoffman, E
   Csaky, KG
TI Differences in gene expression profiles in dermal fibroblasts from
   control and patients with, age-related macular degeneration elicited by
   oxidative injury
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE dermal fibroblast; microarray; EASE; oxidative injury; age-related
   macular degeneration
ID APOLIPOPROTEIN-E; GROWTH-FACTORS; CELL-LINE; DRUSEN; STRESS; MODEL;
   PATHOGENESIS; EPITHELIUM; ANGIOGENESIS; DISEASE
AB The pathogenesis of age-related macular degeneration (AMD) is still unknown but there is growing evidence that a combination of both oxidative injury and genetic factors may play a role. One particle hypothesis proposes that dysregulation of multiple genes in response to an oxidative injury could contribute to the development of AMD. While direct examination of ocular cells from AMD patients is difficult, AMD also appears to have a systemic component. Therefore, as is the case with other central nervous diseases, peripheral sites may also manifest any underlying genetic abnormalities. For the present study, biopsy-derived fibroblasts from 4 patients with the early form and 4 patients with the late form of AMD and 3 age-matched control patients were grown in culture and treated with a nonlethal dose of the oxidative stimulus menadione. Gene expression patterns were quantitatively and qualitatively examined using Human Genome U95A GeneChips (Affymetrix) and verified by real-time PCR analysis. In response to the oxidative injury 755 genes were found to be upregutated at least twofold in one of the patients groups. Cluster analysis of expression profiles detected six patterns of dysregulation initiated by oxidative injury specific for the disease groups (98 genes total). Clusters of genes dysregulated by the sublethal oxidative injury in either early and/or late AMD groups were further categorized by over-representation of GO "biological process" categories using Expression Analysis Systematic Explorer (EASE) software. This approach demonstrated that four major functional gene groups including inflammatory/innate immune response, transcriptional regulation, cell cycle, and proliferation were significantly overrepresented (Fisher test ranging from 0.0393 to 0.00018) in both AMD patients groups in response to the oxidative injury. Despite the small number of patients in the study, specific biological and statistical differences in gene expression profiles between control and AMD patients were identified but only in the presence of an environmental stimulus. (c) 2005 Elsevier Inc. All rights reserved.
C1 NEI, NIH, Bethesda, MD 20892 USA.
   Childrens Natl Med Ctr, Washington, DC 20010 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Children's National Health System
RP Csaky, KG (通讯作者)，NEI, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM kcsaky@helix.nih.gov
FU NATIONAL EYE INSTITUTE [Z01EY000369] Funding Source: NIH RePORTER
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Alizadeh M, 2001, INVEST OPHTH VIS SCI, V42, P2706
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Benezra R, 2002, COLD SPRING HARB SYM, V67, P249, DOI 10.1101/sqb.2002.67.249
   Blalock EM, 2004, P NATL ACAD SCI USA, V101, P2173, DOI 10.1073/pnas.0308512100
   Blass J P, 1997, Aging (Milano), V9, P55
   Briggs CE, 2001, INVEST OPHTH VIS SCI, V42, P2229
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Campochiaro PA, 2003, ONCOGENE, V22, P6537, DOI 10.1038/sj.onc.1206773
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cui XQ, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-210
   Dasu MRK, 2004, J PATHOL, V202, P476, DOI 10.1002/path.1539
   Dunn KC, 1998, INVEST OPHTH VIS SCI, V39, P2744
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Frank R N, 1998, Trans Am Ophthalmol Soc, V96, P635
   Gibson GE, 1999, ANN NY ACAD SCI, V893, P79, DOI 10.1111/j.1749-6632.1999.tb07819.x
   Gibson GE, 2000, BBA-MOL BASIS DIS, V1502, P319, DOI 10.1016/S0925-4439(00)00057-0
   Gorin MB, 1999, MOL VIS, V5, pU31
   Green MJ, 2003, RHEUMATOLOGY, V42, P83, DOI 10.1093/rheumatology/keg037
   Guymer Robyn, 2001, Clin Exp Optom, V84, P182
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haghnegahdar H, 2000, J LEUKOCYTE BIOL, V67, P53, DOI 10.1002/jlb.67.1.53
   Hamdi HK, 2003, FRONT BIOSCI-LANDMRK, V8, pE305, DOI 10.2741/1019
   Hawkins BS, 1999, MOL VIS, V5
   Heneka MT, 2002, J NEUROSCI, V22, P2434, DOI 10.1523/JNEUROSCI.22-07-02434.2002
   Herzel H, 2001, CHAOS, V11, P98, DOI 10.1063/1.1336843
   Honda S, 2001, MOL VIS, V7, P63
   Husain Deeba, 2002, Ophthalmol Clin North Am, V15, P87, DOI 10.1016/S0896-1549(01)00009-8
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kao YR, 2003, CLIN CANCER RES, V9, P2807
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Kobor MS, 2002, BBA-GENE STRUCT EXPR, V1577, P261, DOI 10.1016/S0167-4781(02)00457-8
   Li LM, 2003, MOL CELL BIOL, V23, P2883, DOI 10.1128/MCB.23.8.2883-2892.2003
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lin ZS, 2003, LAB INVEST, V83, P765, DOI 10.1097/01.LAB.0000073130.58435.E5
   Liu HF, 2003, J BIOL CHEM, V278, P2541, DOI 10.1074/jbc.M210391200
   Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675
   Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Pritchard CC, 2001, P NATL ACAD SCI USA, V98, P13266, DOI 10.1073/pnas.221465998
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Ruzinova MB, 2003, CANCER CELL, V4, P277, DOI 10.1016/S1535-6108(03)00240-X
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schmidt S, 2000, MOL VIS, V6, P287
   Schuchhardt J, 2000, Nucleic Acids Res, V28, pE47, DOI 10.1093/nar/28.10.e47
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Takahashi T, 2000, AM J OPHTHALMOL, V130, P774, DOI 10.1016/S0002-9394(00)00772-8
   Tchetverikov I, 2004, ANN RHEUM DIS, V63, P881, DOI 10.1136/ard.2003.013243
   Tian J, 2004, PHYSIOL GENOMICS, V17, P170, DOI 10.1152/physiolgenomics.00179.2003
   Turini ME, 2002, ANNU REV MED, V53, P35, DOI 10.1146/annurev.med.53.082901.103952
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Vawter MP, 2001, BRAIN RES BULL, V55, P641, DOI 10.1016/S0361-9230(01)00522-6
   Watanabe Noboru, 2004, Curr Atheroscler Rep, V6, P112, DOI 10.1007/s11883-004-0099-1
   Wierzbicki AS, 2002, J NEUROCHEM, V80, P727, DOI 10.1046/j.0022-3042.2002.00766.x
   Winkler BS, 1999, MOL VIS, V5
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   WORDSWORTH P, 1995, BRIT MED BULL, V51, P249, DOI 10.1093/oxfordjournals.bmb.a072959
   Wright GW, 2003, BIOINFORMATICS, V19, P2448, DOI 10.1093/bioinformatics/btg345
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang CX, 2003, J CELL SCI, V116, P1915, DOI 10.1242/jcs.00390
NR 81
TC 9
Z9 9
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD SEP 15
PY 2005
VL 39
IS 6
BP 781
EP 796
DI 10.1016/j.freeradbiomed.2005.04.029
PG 16
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 960IJ
UT WOS:000231583500009
PM 16109308
DA 2022-11-30
ER

PT J
AU Christen, WG
   Glynn, RJ
   Chew, EY
   Albert, CM
   Manson, JE
AF Christen, William G.
   Glynn, Robert J.
   Chew, Emily Y.
   Albert, Christine M.
   Manson, Joann E.
TI Folic Acid, Pyridoxine, and Cyanocobalamin Combination Treatment and
   Age-Related Macular Degeneration in Women The Women's Antioxidant and
   Folic Acid Cardiovascular Study
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Article
ID ENDOTHELIAL FUNCTION; PLASMA HOMOCYSTEINE; MYOCARDIAL-INFARCTION;
   SECONDARY PREVENTION; CIGARETTE-SMOKING; NITRIC-OXIDE; B-VITAMINS; RISK;
   DISEASE; EVENTS
AB Background: Observational epidemiologic studies indicate a direct association between homocysteine concentration in the blood and the risk of age-related macular degeneration (AMD), but randomized trial data to examine the effect of therapy to lower homocysteine levels in AMD are lacking. Our objective was to examine the incidence of AMD in a trial of combined folic acid, pyridoxine hydrochloride (vitamin B-6), and cyanocobalamin (vitamin B-12) therapy.
   Methods: We conducted a randomized, double-blind, placebo-controlled trial including 5442 female health care professionals 40 years or older with preexisting cardiovascular disease or 3 or more cardiovascular disease risk factors. A total of 5205 of these women did not have a diagnosis of AMD at baseline and were included in this analysis. Participants were randomly assigned to receive a combination of folic acid (2.5 mg/d), pyridoxine hydrochloride (50 mg/d), and cyanocobalamin (1 mg/d) or placebo. Our main outcome measures included total AMD, defined as a self-report documented by medical record evidence of an initial diagnosis after randomization, and visually significant AMD, defined as confirmed incident AMD with visual acuity of 20/30 or worse attributable to this condition.
   Results: After an average of 7.3 years of treatment and follow-up, there were 55 cases of AMD in the combination treatment group and 82 in the placebo group (relative risk, 0.66; 95% confidence interval, 0.47-0.93 [P=.02]). For visually significant AMD, there were 26 cases in the combination treatment group and 44 in the placebo group (relative risk, 0.59; 95% confidence interval, 0.36-0.95 [P=.03]).
   Conclusions: These randomized trial data from a large cohort of women at high risk of cardiovascular disease indicate that daily supplementation with folic acid, pyridoxine, and cyanocobalamin may reduce the risk of AMD.
   Trial Registration: clinical trials. gov Identifier NCT00000161
C1 [Christen, William G.; Glynn, Robert J.; Albert, Christine M.; Manson, Joann E.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Prevent Med,Dept Med, Boston, MA 02215 USA.
   [Albert, Christine M.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Cardiovasc Med, Boston, MA 02215 USA.
   [Glynn, Robert J.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
   [Manson, Joann E.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   [Chew, Emily Y.] NEI, Bethesda, MD 20892 USA.
C3 Harvard University; Brigham & Women's Hospital; Harvard Medical School;
   Harvard University; Brigham & Women's Hospital; Harvard Medical School;
   Harvard University; Harvard T.H. Chan School of Public Health; Harvard
   University; Harvard T.H. Chan School of Public Health; National
   Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)
RP Christen, WG (通讯作者)，Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Prevent Med,Dept Med, 900 Commonwealth Ave E, Boston, MA 02215 USA.
EM wchristen@rics.bwh.harvard.edu
OI Albert, Christine/0000-0002-2081-1121
FU Intramural NIH HHS [Z99 EY999999] Funding Source: Medline; NEI NIH HHS
   [R01 EY006633-12, R01 EY006633-11, R01 EY006633-14, R01 EY006633-13, EY
   06633] Funding Source: Medline; NHLBI NIH HHS [R01 HL046959-10, HL
   46959, R01 HL046959-11, R01 HL046959-09, R01 HL046959-13, R01
   HL046959-07, R01 HL046959-12, R01 HL046959-08, R01 HL046959] Funding
   Source: Medline; NIDDK NIH HHS [P30 DK040561-13, P30 DK040561] Funding
   Source: Medline; NATIONAL EYE INSTITUTE [R01EY006633] Funding Source:
   NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046959]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND
   DIGESTIVE AND KIDNEY DISEASES [P30DK040561] Funding Source: NIH RePORTER
CR Albert CM, 2008, JAMA-J AM MED ASSOC, V299, P2027, DOI 10.1001/jama.299.17.2027
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P84, DOI 10.1016/S0002-9394(03)00864-X
   Bassuk SS, 2004, J WOMENS HEALTH, V13, P99, DOI 10.1089/154099904322836519
   Bazzano LA, 2006, JAMA-J AM MED ASSOC, V296, P2720, DOI 10.1001/jama.296.22.2720
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bonaa KH, 2006, NEW ENGL J MED, V354, P1578, DOI 10.1056/NEJMoa055227
   Chambers JC, 1999, ARTERIOSCL THROM VAS, V19, P2922, DOI 10.1161/01.ATV.19.12.2922
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   Clarke R, 2005, AM J CLIN NUTR, V82, P806, DOI 10.1093/ajcn/82.4.806
   Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015
   Cook NR, 2007, ARCH INTERN MED, V167, P1610, DOI 10.1001/archinte.167.15.1610
   Coral K, 2006, EYE, V20, P203, DOI 10.1038/sj.eye.6701853
   COX DR, 1972, J R STAT SOC B, V34, P187
   Domagala T B, 1998, J Cardiovasc Risk, V5, P239, DOI 10.1097/00043798-199808000-00006
   Doshi SN, 2002, CIRCULATION, V105, P22, DOI 10.1161/hc0102.101388
   Dudman NPB, 1999, CIRC RES, V84, P409, DOI 10.1161/01.RES.84.4.409
   EDERER F, 1973, ARCH OPHTHALMOL-CHIC, V89, P1
   Evers S, 1997, ARCH NEUROL-CHICAGO, V54, P1276, DOI 10.1001/archneur.1997.00550220074017
   Fassbender K, 1999, LANCET, V353, P1586
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   GLYNN RJ, 1992, ARCH OPHTHALMOL-CHIC, V110, P381, DOI 10.1001/archopht.1992.01080150079033
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Hassan A, 2004, BRAIN, V127, P212, DOI 10.1093/brain/awh023
   Hayden MR, 2004, NUTR J, V3, DOI 10.1186/1475-2891-3-4
   Heuberger RA, 2002, AM J CLIN NUTR, V76, P897, DOI 10.1093/ajcn/76.4.897
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Lange H, 2004, NEW ENGL J MED, V350, P2673, DOI 10.1056/NEJMoa032845
   Liem A, 2005, HEART, V91, P1213, DOI 10.1136/hrt.2004.035030
   Liem AH, 2004, INT J CARDIOL, V93, P175, DOI 10.1016/j.ijcard.2003.02.001
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Lonn E, 2006, NEW ENGL J MED, V354, P1567, DOI 10.1056/NEJMoa060900
   McDowell IFW, 2000, J NUTR, V130, p369S, DOI 10.1093/jn/130.2.369S
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Moat SJ, 2004, J NUTR BIOCHEM, V15, P64, DOI 10.1016/j.jnutbio.2003.08.010
   Nappo F, 1999, JAMA-J AM MED ASSOC, V281, P2113, DOI 10.1001/jama.281.22.2113
   *NAT EY I, 2004, NAT PLAN EY VIS RES
   Nowak M, 2005, EUR J OPHTHALMOL, V15, P764, DOI 10.1177/112067210501500617
   Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31
   Righetti M, 2003, MED SCI MONITOR, V9, pPI19
   Righetti M, 2006, BLOOD PURIFICAT, V24, P379, DOI 10.1159/000093680
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schnyder G, 2002, JAMA-J AM MED ASSOC, V288, P973, DOI 10.1001/jama.288.8.973
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Silverman MD, 2002, ARTERIOSCL THROM VAS, V22, P587, DOI 10.1161/01.ATV.0000014221.30108.08
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Stuhlinger MC, 2001, CIRCULATION, V104, P2569, DOI 10.1161/hc4601.098514
   Toole JF, 2004, JAMA-J AM MED ASSOC, V291, P565, DOI 10.1001/jama.291.5.565
   TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369
   UELAND PM, 1993, CLIN CHEM, V39, P1764
   Upchurch GR, 1997, J BIOL CHEM, V272, P17012, DOI 10.1074/jbc.272.27.17012
   Verhaar MC, 1998, CIRCULATION, V97, P237, DOI 10.1161/01.CIR.97.3.237
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wald DS, 2002, BMJ-BRIT MED J, V325, P1202, DOI 10.1136/bmj.325.7374.1202
   Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507
   Woo KS, 1999, J AM COLL CARDIOL, V34, P2002, DOI 10.1016/S0735-1097(99)00469-6
   Wrone EM, 2004, J AM SOC NEPHROL, V15, P420, DOI 10.1097/01.ASN.0000110181.64655.6C
   Zoungas S, 2006, J AM COLL CARDIOL, V47, P1108, DOI 10.1016/j.jacc.2005.10.064
NR 70
TC 100
Z9 105
U1 0
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9926
EI 1538-3679
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD FEB 23
PY 2009
VL 169
IS 4
BP 335
EP 341
DI 10.1001/archinternmed.2008.574
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 410SW
UT WOS:000263599600002
PM 19237716
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Berg, K
   Roald, AB
   Navaratnam, J
   Bragadottir, R
AF Berg, Karina
   Roald, Anca B.
   Navaratnam, Jesintha
   Bragadottir, Ragnheidur
TI An 8-year follow-up of anti-vascular endothelial growth factor treatment
   with a treat-and-extend modality for neovascular age-related macular
   degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE aflibercept; AMD; bevacizumab; ranibizumab; treat-and-extend
AB PurposeTo investigate long-term visual results of treatment with anti-vascular endothelial growth factor (VEGF) agents for neovascular age-related macular degeneration (nAMD) following a treat-and-extend regimen.
   MethodsRetrospective review of 155 patients who initiated treatment with bevacizumab for nAMD in one eye. At the final 8-year visit, 40 patients (26%) remained for follow-up. Mean change in best-corrected visual acuity (BCVA) was calculated compared to baseline values.
   ResultsMean BCVA improved significantly from baseline during the first year of treatment, with -0.11 logMAR units equivalent to 6.1 approximate Early Treatment Diabetic Retinopathy Study (approxETDRS) letters (p=<0.001). Mean BCVA was still significantly improved after 4years of treatment for the entire group of patients and after 6years of treatment for the subgroup of 40 patients who remained at the final 8-year visit. Thereafter, BCVA gradually declined and at 8years, there was a mean change of 0.05 logMAR units equivalent to 2.1 approxETDRS letters below baseline (p=0.530). Mean number of injections during the first year was 6.12.8 and during year 8 was 5.4 +/- 3.5. At 5years, fundus autofluorescence showed some degree of macular atrophy in all eyes. At the final 8-year visit, 87.5% of the eyes had stable neovascular lesions with no fluid on optical coherence tomography (OCT).
   ConclusionIn an everyday clinical setting, treatment of nAMD patients with a treat-and-extend modality provided improvement and stability of vision for several years. After 8years of follow-up, there was a decline in visual acuity (VA) that could be explained by macular atrophic development.
C1 [Berg, Karina; Roald, Anca B.; Navaratnam, Jesintha; Bragadottir, Ragnheidur] Oslo Univ Hosp, Dept Ophthalmol, Postboks 4956 Nydalen, N-0424 Oslo, Norway.
C3 University of Oslo
RP Berg, K (通讯作者)，Oslo Univ Hosp, Dept Ophthalmol, Postboks 4956 Nydalen, N-0424 Oslo, Norway.
EM karinabb@medisin.uio.no
NR 0
TC 45
Z9 45
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2017
VL 95
IS 8
BP 796
EP 802
DI 10.1111/aos.13522
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FP5FR
UT WOS:000417645900028
PM 28926190
OA Bronze
DA 2022-11-30
ER

PT J
AU Pemp, B
   Garhofer, G
   Lasta, M
   Schmidl, D
   Wolzt, M
   Schmetterer, L
AF Pemp, Berthold
   Garhofer, Gerhard
   Lasta, Michael
   Schmidl, Doreen
   Wolzt, Michael
   Schmetterer, Leopold
TI The effects of moxaverine on ocular blood flow in patients with
   age-related macular degeneration or primary open angle glaucoma and in
   healthy control subjects
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; blood flow; moxaverine; open angle
   glaucoma
ID RETINAL VESSEL ANALYZER; VISUAL-FIELD; OPTIC-NERVE; PHOSPHODIESTERASE;
   SILDENAFIL; CIRCULATION; EYE; REPRODUCIBILITY; PAPAVERINE; PARAMETERS
AB Purpose: The phosphodiesterase inhibitor moxaverine has been shown to increase choroidal blood flow (BF) in young healthy subjects. The present study was performed to investigate the effect of intravenously administered moxaverine on ocular BF in patients with age-related macular degeneration (AMD), primary open angle glaucoma (POAG) and in age-matched control subjects.
   Methods: Twenty patients with AMD, 20 patients with POAG and 20 control subjects were included. Moxaverine 150 mg was applied intravenously over 30 min. BF was measured in the choroid and in the optic nerve head (ONH) using laser-Doppler flowmetry and in retinal vessels combining laser-Doppler velocimetry with retinal vessel analysis before and 30, 60 and 90 min after start of drug administration. BF velocities in the retrobulbar vessels were measured using colour Doppler imaging.
   Results: Moxaverine increased choroidal BF by 9 +/- 22% (p = 0.012), ONH BF by 13 +/- 33% (p = 0.021), mean flow velocity in the ophthalmic artery by 23 +/- 34% (p < 0.001) and in the posterior ciliary arteries by 25 +/- 35% (p < 0.001). Moxaverine had no significant effect on retinal vessel diameters and retinal BF. There were no significant differences in any of the measured parameters between the three groups.
   Conclusion: The present study indicates that systemic administration of moxaverine increases choroidal and ONH BF in elderly patients with eye diseases associated with hypoperfusion and in age-matched controls. Further studies in patients are needed to investigate whether long-term treatment with moxaverine is clinically beneficial for patients with ocular diseases.
C1 [Pemp, Berthold; Garhofer, Gerhard; Lasta, Michael; Schmidl, Doreen; Wolzt, Michael; Schmetterer, Leopold] Med Univ Vienna, Dept Clin Pharmacol, A-1090 Vienna, Austria.
   [Schmetterer, Leopold] Med Univ Vienna, Ctr Biomed Engn & Phys, A-1090 Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Schmetterer, L (通讯作者)，Med Univ Vienna, Dept Clin Pharmacol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM leopold.schmetterer@meduniwien.ac.at
OI Schmidl, Doreen/0000-0001-5664-7768; Schmetterer,
   Leopold/0000-0002-7189-1707; Wolzt, Michael/0000-0001-6049-1890; Pemp,
   Berthold/0000-0002-0569-0229
FU Ursapharm Arzneimittel GmbH & Co. KG, Saarbruecken, Germany
FX Aspects of this study were presented on the EVER 2009 congress. This
   study was supported by a nonrestricted grant from Ursapharm Arzneimittel
   GmbH & Co. KG, Saarbruecken, Germany.
CR BERG G, 1987, ARCH INT PHARMACOD T, V290, P288
   BERNDT SF, 1976, N-S ARCH PHARMACOL, V294, P271, DOI 10.1007/BF00508395
   BONNER RF, 1990, DEV CARDIOVASC MED, V107, P17
   Chung HS, 1999, J OCUL PHARMACOL TH, V15, P233, DOI 10.1089/jop.1999.15.233
   Ciulla TA, 2002, ACTA OPHTHALMOL SCAN, V80, P468, DOI 10.1034/j.1600-0420.2002.800503.x
   Ciulla TA, 2001, ACTA OPHTHALMOL SCAN, V79, P108, DOI 10.1034/j.1600-0420.2001.079002108.x
   Feine-Haake G, 1975, MMW Munch Med Wochenschr, V117, P1131
   Flammer J, 2001, PROG RETIN EYE RES, V20, P319, DOI 10.1016/S1350-9462(00)00028-8
   Flammer J, 2002, PROG RETIN EYE RES, V21, P359, DOI 10.1016/S1350-9462(02)00008-3
   Garhofer G, 2010, ACTA OPHTHALMOL, V88, P717, DOI 10.1111/j.1755-3768.2009.01587.x
   GASPAR AZ, 1995, OPHTHALMOLOGICA, V209, P11, DOI 10.1159/000310566
   Grunwald JE, 2001, AM J OPHTHALMOL, V131, P751, DOI 10.1016/S0002-9394(00)00944-2
   Harris A, 2008, BRIT J OPHTHALMOL, V92, P469, DOI 10.1136/bjo.2007.131789
   Harris A, 2001, ACTA OPHTHALMOL SCAN, V79, P336, DOI 10.1034/j.1600-0420.2001.079004336.x
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kerr NM, 2009, CLIN EXP OPHTHALMOL, V37, P514, DOI 10.1111/j.1442-9071.2009.02070.x
   Koksal M, 2005, ACTA OPHTHALMOL SCAN, V83, P355, DOI 10.1111/j.1600-0420.2005.00422.x
   Konno T, 2007, LIFE SCI, V80, P1115, DOI 10.1016/j.lfs.2006.11.053
   Koseki N, 2008, OPHTHALMOLOGY, V115, P2049, DOI 10.1016/j.ophtha.2008.05.015
   LEE KC, 1993, METHOD FIND EXP CLIN, V15, P527
   Lesk MR, 2008, CAN J OPHTHALMOL, V43, P351, DOI 10.3129/i08-057
   LIEB WE, 1991, ARCH OPHTHALMOL-CHIC, V109, P527, DOI 10.1001/archopht.1991.01080040095036
   LINDEMAN HO, 1972, KLIN MONATSBL AUGENH, V161, P100
   Luksch A, 2005, BRIT J OPHTHALMOL, V89, P21, DOI 10.1136/bjo.2003.037671
   Luksch A, 2009, ACTA OPHTHALMOL, V87, P875, DOI 10.1111/j.1755-3768.2008.01388.x
   MANNHOLD R, 1988, ARZNEIMITTEL-FORSCH, V38-2, P1806
   Metelitsina TI, 2005, EXP EYE RES, V81, P159, DOI 10.1016/j.exer.2005.01.017
   Miwa T, 2009, EUR J PHARMACOL, V602, P112, DOI 10.1016/j.ejphar.2008.10.060
   Nordeck H, 1971, Munch Med Wochenschr, V113, P1006
   Paris Gianmarco, 2001, International Ophthalmology, V23, P355, DOI 10.1023/A:1014410932321
   Pemp B, 2008, CAN J OPHTHALMOL, V43, P295, DOI 10.3129/i08-049
   Polak K, 2000, BRIT J OPHTHALMOL, V84, P1285, DOI 10.1136/bjo.84.11.1285
   Polak K, 2003, INVEST OPHTH VIS SCI, V44, P4872, DOI 10.1167/iovs.03-0177
   Polska E, 2004, BRIT J OPHTHALMOL, V88, P533, DOI 10.1136/bjo.2003.028480
   Pournaras CJ, 2008, PROG RETIN EYE RES, V27, P284, DOI 10.1016/j.preteyeres.2008.02.002
   Resch H, 2009, INVEST OPHTH VIS SCI, V50, P358, DOI 10.1167/iovs.08-2460
   Resch H, 2009, ACTA OPHTHALMOL, V87, P731, DOI 10.1111/j.1755-3768.2008.01338.x
   RIVA CE, 1981, APPL OPTICS, V20, P117, DOI 10.1364/AO.20.000117
   RIVA CE, 1985, INVEST OPHTH VIS SCI, V26, P1124
   RIVA CE, 1992, EXP EYE RES, V55, P499, DOI 10.1016/0014-4835(92)90123-A
   RIVA CE, 1994, INVEST OPHTH VIS SCI, V35, P4273
   Riva CE, 2009, ACTA OPHTHALMOL
   SCHMIDSCHONBEIN H, 1988, ARZNEIMITTEL-FORSCH, V38-1, P710
   Siesky B, 2009, SURV OPHTHALMOL, V54, P33, DOI 10.1016/j.survophthal.2008.06.002
   TUKEY JW, 1985, BIOMETRICS, V41, P295, DOI 10.2307/2530666
   Uchida Hideya, 2002, Nippon Ganka Gakkai Zasshi, V106, P615
NR 46
TC 16
Z9 18
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2012
VL 90
IS 2
BP 139
EP 145
DI 10.1111/j.1755-3768.2010.01878.x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 899RW
UT WOS:000300834800017
PM 20456253
OA Bronze
DA 2022-11-30
ER

PT J
AU Silva, AS
   Teixeira, AG
   Bavia, L
   Lin, F
   Velletri, R
   Belfort, R
   Isaac, L
AF Silva, Aldacilene Souza
   Teixeira, Anderson Gustavo
   Bavia, Lorena
   Lin, Fabio
   Velletri, Roberta
   Belfort, Rubens, Jr.
   Isaac, Lourdes
TI Plasma levels of complement proteins from the alternative pathway in
   patients with age-related macular degeneration are independent of
   Complement Factor H Tyr(402)His polymorphism
SO MOLECULAR VISION
LA English
DT Article
ID C-REACTIVE PROTEIN; CHLAMYDIA-PNEUMONIAE INFECTION; Y402H POLYMORPHISM;
   FACTOR-B; FACTOR-I; ADVANCED AMD; RISK-FACTOR; ACTIVATION; DISEASE;
   ASSOCIATION
AB Purpose: To investigate the influence of the Factor H (CFH) Tyr(402)His polymorphism on the plasma levels of the alternative pathway proteins CFH, C3, Factor B (FB), Factor D (FD), and Factor I (FI) and the inflammatory marker C-reactive protein (CRP) in 119 patients with age-related macular degeneration (AMD) and 152 unrelated control individuals.
   Methods: Patients with AMD and the control group were separated according to CFH polymorphism, age, and gender. Plasma complement proteins and CRP concentrations were determined with enzyme-linked immunosorbent assay, immunodiffusion, or nephelometry.
   Results: Significant differences in the concentrations of FD and FI were observed between the patients with AMD and the control individuals. We observed significantly reduced FD plasma levels in patients with AMD. We also identified a significant decrease in CFH plasma levels in female patients with AMD in relation to female controls. Plasma FI levels were significantly increased in patients with AMD compared to the control group. Regarding gender, a significant increase in FI plasma levels was observed in male patients. Finally, we found no significant correlation between the CFH Tyr(402)His polymorphism and the CFH, C3, FB, FD, FI, and CRP plasma levels.
   Conclusions: Patients with AMD present altered levels of FD and FI in a manner independent of this CFH polymorphism, and gender apparently contributes to the plasma levels of these two proteins in patients with AMD and control individuals.
C1 [Silva, Aldacilene Souza; Bavia, Lorena; Lin, Fabio; Isaac, Lourdes] Univ Sao Paulo, Dept Imunol, Inst Ciencias Biomed, BR-05508900 Sao Paulo, Brazil.
   [Teixeira, Anderson Gustavo; Velletri, Roberta; Belfort, Rubens, Jr.] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
C3 Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP)
RP Isaac, L (通讯作者)，Univ Sao Paulo, Dept Imunol, Inst Ciencias Biomed, Av Prof Lineu Prestes 1730,Cidade Univ, BR-05508900 Sao Paulo, Brazil.
EM louisaac@icb.usp.br
RI Teixeira, Anderson/K-2320-2013; Bavia, Lorena/H-3750-2014; Belfort,
   Rubens/E-2252-2012; Isaac, Lourdes/I-7186-2012
OI Belfort, Rubens/0000-0002-8422-3898; Isaac, Lourdes/0000-0002-7746-8942;
   Teixeira, Anderson/0000-0001-7585-712X; Bavia,
   Lorena/0000-0003-1702-2284
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); FAPESP
FX This work was supported by the Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) and Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq). A.S. Silva and L. Bavia were recipients
   of graduate fellowships from FAPESP.
CR Agrawal A, 2005, MOL IMMUNOL, V42, P927, DOI 10.1016/j.molimm.2004.09.028
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6
   Biesma DH, 2001, J CLIN INVEST, V108, P233, DOI 10.1172/JCI200112023
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Bruck W, 2003, NEUROL SCI, V24, pS265, DOI 10.1007/s10072-003-0170-7
   Chen M, 2008, EXP EYE RES, V87, P543, DOI 10.1016/j.exer.2008.09.005
   Chowers I, 2008, MOL VIS, V14, P1829
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cummings M, 2008, CLIN OPHTHALMOL, V2, P369
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Greenfield JR, 2004, EUR J CLIN INVEST, V34, P590, DOI 10.1111/j.1365-2362.2004.01389.x
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430
   Hawkins MA, 2004, OBES RES, V12, p107S, DOI 10.1038/oby.2004.275
   HIEMSTRA PS, 1989, J CLIN INVEST, V84, P1957, DOI 10.1172/JCI114384
   Ishida O, 2003, BRIT J OPHTHALMOL, V87, P523, DOI 10.1136/bjo.87.5.523
   Jarvis JN, 1999, CLIN IMMUNOL, V93, P274, DOI 10.1006/clim.1999.4792
   Ji SR, 2006, ARTERIOSCL THROM VAS, V26, P935, DOI 10.1161/01.ATV.0000206211.21895.73
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jozsi M, 2008, TRENDS IMMUNOL, V29, P380, DOI 10.1016/j.it.2008.04.008
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klein R, 2004, AM J OPHTHALMOL, V137, P435, DOI 10.1016/j.ajo.2003.10.020
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KLUINNELEMANS HC, 1984, CLIN EXP IMMUNOL, V58, P724
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lowe GDO, 2005, J THROMB HAEMOST, V3, P1618, DOI 10.1111/j.1538-7836.2005.01416.x
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2
   Mandal NA, 2006, INVEST OPHTH VIS SCI, V47, P4091, DOI 10.1167/iovs.05-1655
   McGeer PL, 2004, PARKINSONISM RELAT D, V10, pS3, DOI 10.1016/j.parkreldis.2004.01.005
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   Miller YI, 2011, CIRC RES, V108, P235, DOI 10.1161/CIRCRESAHA.110.223875
   Mold C, 1999, IMMUNOPHARMACOLOGY, V42, P23, DOI 10.1016/S0162-3109(99)00007-7
   Niederkorn Jerry Y, 2005, Arch Soc Esp Oftalmol, V80, P437
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricklin D, 2007, NAT BIOTECHNOL, V25, P1265, DOI 10.1038/nbt1342
   Robman L, 2007, INVEST OPHTH VIS SCI, V48, P4007, DOI 10.1167/iovs.06-1434
   Rohrer B, 2007, INVEST OPHTH VIS SCI, V48, P5282, DOI 10.1167/iovs.07-0282
   Schlaf G, 2001, MOL IMMUNOL, V38, P231, DOI 10.1016/S0161-5890(01)00045-1
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Scholl HPN, 2005, OPHTHALMOLOGE, V102, P1029, DOI 10.1007/s00347-005-1270-y
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996
   Shen D, 2009, BRIT J OPHTHALMOL, V93, P405, DOI 10.1136/bjo.2008.145383
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Sivakumaran TA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025598
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Sjowall C, 2007, BIOCHEM BIOPH RES CO, V352, P251, DOI 10.1016/j.bbrc.2006.11.013
   Skerka C, 2007, MOL IMMUNOL, V44, P241, DOI 10.1016/j.molimm.2006.07.223
   Souied EH, 2005, MOL VIS, V11, P1135
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Suzuki M, 2007, MOL VIS, V13, P772
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tedeschi-Blok N, 2007, OPHTHALMOLOGY, V114, P99, DOI 10.1016/j.ophtha.2006.07.043
   Teixeira AG, 2010, ACTA OPHTHALMOL, V88, pE165, DOI 10.1111/j.1755-3768.2010.01932.x
   Vaith P, 1996, INT ARCH ALLERGY IMM, V111, P107, DOI 10.1159/000237354
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wener MH, 2000, J RHEUMATOL, V27, P2351
   WILLIAMS LW, 1988, ANN ALLERGY, V60, P293
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zeng JX, 2010, MOL VIS, V16, P2273
NR 85
TC 42
Z9 43
U1 0
U2 4
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD AUG 30
PY 2012
VL 18
IS 243
BP 2288
EP 2299
PG 12
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 001KP
UT WOS:000308459800001
PM 22969267
DA 2022-11-30
ER

PT J
AU Morizane, Y
   Shiraga, F
   Takasu, I
   Yumiyama, S
   Okanouchi, T
   Ohtsuki, H
AF Morizane, Y
   Shiraga, F
   Takasu, I
   Yumiyama, S
   Okanouchi, T
   Ohtsuki, H
TI Selection for inferior limited macular translocation on the basis of
   distance from the fovea to the inferior edge of the subfoveal choroidal
   neovascularization
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID DEGENERATION; MANAGEMENT
AB PURPOSE: To assess the visual outcome of inferior limited macular translocation in eyes selected based on the distance from the fovea to the inferior edge of the subfoveal choroidal neovascularization.
   DESIGN: Interventional case series.
   METHODS: We performed inferior limited macular translocation in 12 consecutive eyes (12 patients) with age-related macular degeneration or polypoidal choroidal vasculopathy, in which the choroidal neovascularization did not extend for more than half of one disk diameter inferior to the fovea.
   RESULTS: In all eyes, the choroidal neovascularization was moved to an extrafoveal location. In seven of the 12 eyes, postoperative vision was 20/40 or better. The Visual acuity improved by 2 or more lines in 11 eyes.
   CONCLUSION: Selection for inferior limited macular translocation on the basis of distance from the fovea to the inferior edge of the choroidal neovascularization may be associated with a greater likelihood of visual acuity improvement. (C) 2002 by Elsevier Science Inc. All rights reserved.
C1 Okayama Univ, Sch Med, Dept Ophthalmol, Okayama 7008558, Japan.
   Hiroshima City Hosp, Dept Ophthalmol, Hiroshima, Japan.
C3 Okayama University; Hiroshima City Hospital
RP Shiraga, F (通讯作者)，Okayama Univ, Sch Med, Dept Ophthalmol, 2-5-1 Shikata Cho, Okayama 7008558, Japan.
RI OHTSUKI, Hiroshi/B-1637-2011
CR de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   Fujii GY, 2001, INVEST OPHTH VIS SCI, V42, pS729
   Glacet-Bernard A, 2001, AM J OPHTHALMOL, V131, P78, DOI 10.1016/S0002-9394(00)00733-9
   Lewis H, 1999, AM J OPHTHALMOL, V128, P135, DOI 10.1016/S0002-9394(99)00207-X
   Pieramici DJ, 2000, AM J OPHTHALMOL, V130, P419, DOI 10.1016/S0002-9394(00)00533-X
NR 5
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2002
VL 133
IS 6
BP 848
EP 850
DI 10.1016/S0002-9394(02)01413-7
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 557RP
UT WOS:000175922200029
PM 12036690
DA 2022-11-30
ER

PT J
AU Wang, JY
   Ohno-Matsui, K
   Morita, I
AF Wang, Jiying
   Ohno-Matsui, Kyoko
   Morita, Ikuo
TI Elevated amyloid beta production in senescent retinal pigment
   epithelium, a possible mechanism of subretinal deposition of amyloid
   beta in age-related macular degeneration
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Amyloid beta; Retinal pigment epithelium; Age-related macular
   degeneration; Amyloid precursor protein; Neprilysin; beta-Secretase
ID A-BETA; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; SECRETASE ACTIVITY;
   DEGRADING ENZYMES; CLEAVING ENZYME; BRAIN; NEPRILYSIN; EXPRESSION; BACE2
AB Age-related macular degeneration (AMD) is the most common cause of legal blindness in the elderly individuals in developed countries. Subretinally-deposited amyloid beta (A beta) is a main contributor of developing AMD. However, the mechanism causing A beta deposition in AMD eyes is unknown. Aging is the most significant risk of AMD, thus, we examined the effect of aging on subretinal A beta deposition. mRNAs and cell lysates were isolated from retinal pigment epithelial (RPE) cells derived from 24-month-old (24M RPE) and 2-month-old (2M RPE) C57BL/6 mice. A beta concentration in culture supernatants was measured by ELISA. Activity and expression of proteins that regulate A beta level were examined by activity assay and real time PCR. Effect of beta-secretase (BACE) on A beta production was examined by siRNA silencing. A beta amounts in supernatants of 24M RPE were significantly higher than 2M RPE. Activity and mRNA levels of neprilysin, an A beta degrading enzyme, were significantly decreased in 24M RPE compared to 2M RPE. PCR analysis found that BACE2 was significantly more abundantly expressed than BACE1 in RPE cells, however, inactivation of BACE2 gene did not affect A beta production. BACE1 protein amounts did not differ between 24M and 2M RPE, however, BACE1 activity was significantly higher in 24M RPE compared to 2M RPE. There were no significant changes in the activities of alpha- or gamma-secretase between 2M and 24M RPE. In conclusion, RPE cells produce more amounts of A beta when they are senescent, and this is probably caused by a decrease in A beta degradation due to a reduction in the expression and activity of neprilysin and an increase in A beta synthesis due to increased activity of BACE1. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Wang, Jiying; Ohno-Matsui, Kyoko] Tokyo Med & Dent Univ, Dept Ophthalmol & Visual Sci, Bunkyo Ku, Tokyo 1138519, Japan.
   [Morita, Ikuo] Tokyo Med & Dent Univ, Sect Cellular Physiol Chem, Bunkyo Ku, Tokyo 1138519, Japan.
C3 Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental
   University (TMDU)
RP Ohno-Matsui, K (通讯作者)，Tokyo Med & Dent Univ, Dept Ophthalmol & Visual Sci, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.
EM k.ohno.oph@tmd.ac.jp
FU Japanese Society of Promotion of Science [23659808, 22390322]
FX The authors thank Prof. Duco Hamasaki for his critical discussion and
   final manuscript revision. Contact Grant sponsor: 23659808 and 22390322
   from Japanese Society of Promotion of Science.
CR Bennett BD, 2000, J BIOL CHEM, V275, P20647, DOI 10.1074/jbc.M002688200
   Bettegazzi B, 2011, EUR J NEUROSCI, V33, P236, DOI 10.1111/j.1460-9568.2010.07482.x
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boulton ME, 2008, ADV EXP MED BIOL, V613, P313, DOI 10.1007/978-0-387-74904-4_36
   Caccamo A, 2005, NEUROBIOL AGING, V26, P645, DOI 10.1016/j.neurobiolaging.2004.06.013
   Chow VW, 2010, NEUROMOL MED, V12, P1, DOI 10.1007/s12017-009-8104-z
   Dentchev T, 2003, MOL VIS, V9, P184
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Fahnoe DC, 2000, J CARDIOVASC PHARM, V36, pS22, DOI 10.1097/00005344-200036001-00009
   Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697
   Ferreira ST, 2007, IUBMB LIFE, V59, P332, DOI 10.1080/15216540701283882
   Fukumoto H, 2004, AM J PATHOL, V164, P719, DOI 10.1016/S0002-9440(10)63159-8
   Gelman BB, 2004, J NEUROVIROL, V10, P98, DOI 10.1080/13550280490279816
   Hartlage-Rubsamen M, 2003, GLIA, V41, P169, DOI 10.1002/glia.10178
   Hellstrom-Lindahl E, 2008, NEUROBIOL AGING, V29, P210, DOI 10.1016/j.neurobiolaging.2006.10.010
   Huse JT, 2003, J BIOL CHEM, V278, P17141, DOI 10.1074/jbc.M213303200
   Hussain I, 2000, MOL CELL NEUROSCI, V16, P609, DOI 10.1006/mcne.2000.0884
   Iwata N, 2002, J NEUROSCI RES, V70, P493, DOI 10.1002/jnr.10390
   Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Kametaka S, 2003, J BIOL CHEM, V278, P15239, DOI 10.1074/jbc.M208611200
   Kanemaru K, 1996, NEUROSCI LETT, V214, P196, DOI 10.1016/0304-3940(96)12893-7
   Koyama Y, 2008, INVEST OPHTH VIS SCI, V49, P2376, DOI 10.1167/iovs.07-1067
   KUROCHKIN IV, 1994, FEBS LETT, V345, P33, DOI 10.1016/0014-5793(94)00387-4
   Marmor M. F., 1998, RETINAL PIGMENT EPIT, DOI [10.1098/rsif.2015.0563, DOI 10.1098/RSIF.2015.0563]
   Miners JS, 2010, BRAIN PATHOL, V20, P794, DOI 10.1111/j.1750-3639.2010.00375.x
   Miners JS, 2008, BRAIN PATHOL, V18, P240, DOI 10.1111/j.1750-3639.2008.00132.x
   Miners JS, 2006, J NEUROPATH EXP NEUR, V65, P1012, DOI 10.1097/01.jnen.0000240463.87886.9a
   Mueller-Steiner S, 2006, NEURON, V51, P703, DOI 10.1016/j.neuron.2006.07.027
   Nistor A, 2007, NEUROBIOL AGING, V28, P1493, DOI 10.1016/j.neurobiolaging.2006.06.023
   Pardossi-Piquard R, 2006, J NEUROCHEM, V97, P1052, DOI 10.1111/j.1471-4159.2006.03822.x
   Placanica L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005088
   Saido TC, 1998, NEUROBIOL AGING, V19, pS69, DOI 10.1016/S0197-4580(98)00033-5
   Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741
   Silverberg GD, 2010, J NEUROPATH EXP NEUR, V69, P98, DOI 10.1097/NEN.0b013e3181c8ad2f
   Sun XL, 2006, FASEB J, V20, P1369, DOI 10.1096/FJ.05-5632COM
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tamagno E, 2002, NEUROBIOL DIS, V10, P279, DOI 10.1006/nbdi.2002.0515
   Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735
   Wang DS, 2005, J NEUROPATH EXP NEUR, V64, P378, DOI 10.1093/jnen/64.5.378
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zinn KM, 1979, RETINAL PIGMENT EPIT
NR 43
TC 36
Z9 38
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUN 22
PY 2012
VL 423
IS 1
BP 73
EP 78
DI 10.1016/j.bbrc.2012.05.085
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 983AE
UT WOS:000307087700013
PM 22634014
DA 2022-11-30
ER

PT J
AU Regillo, CD
   D'Amico, DJ
   Mieler, WF
   Schneebaum, C
   Beasley, CH
   Sullins, GT
AF Regillo, Carl D.
   D'Amico, Donald J.
   Mieler, William F.
   Schneebaum, Cary
   Beasley, Cliff H.
   Sullins, Gregory T.
TI Clinical safety profile of posterior juxtascleral depot administration
   of anecortave acetate 15 mg suspension as primary therapy or adjunctive
   therapy with photodynamic therapy for treatment of wet age-related
   macular degeneration
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE AMD; anecortave acetate; posterior juxtascleral depot administration;
   safety
ID ANGIOSTATIC ACTIVITY; STEROIDS; CAM
AB Objectives: Safety data for anecortave acetate 15 mg suspension (Retaane 15 mg, Alcon Research, Ltd., Ft. Worth, TX 76134) as primary or adjunctive therapy with photodynamic therapy are available for 358 patients with age-related macular degeneration who received this novel cortisene during clinical trials in which the drug was administered Via posterior juxtascleral depot every 6 months for 2 years.
   Methods: Detailed ophthalmic examinations, physical examinations, and adverse event reporting were used to characterize the clinical safety of anecortave acetate 15 mg and were monitored by an Independent Safety Committee.
   Results: Anecortave acetate 15 mg was safe and well tolerated in the overall patient population. No serious, treatment-related deaths were reported. Ocular adverse events assessed as related to anecortave acetate 15 mg were non-serious with one exception (retinal detachment), mild to moderate in intensity with one exception, generally resolved with or without treatment, and did not interrupt patient participation in the studies with two exceptions.
   Conclusions: Anecortave acetate 15 mg is safe and well-tolerated when administered as a posterior juxtascleral depot at 6-month intervals for use as primary therapy or as adjunctive therapy with PDT.
C1 Wills Eye Hosp & Res Inst, Retina Serv, Philadelphia, PA 19107 USA.
   Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Retina Serv, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA.
   Univ Chicago, Dept Ophthalmol & Visual Sci, Chicago, IL 60637 USA.
   Alcon Res Ltd, Med Monitor, Ft Worth, TX USA.
   Alcon Res Ltd, Invest Prod Safety, Ft Worth, TX USA.
C3 Jefferson University; Harvard University; Harvard Medical School;
   Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical
   School; University of Chicago; Novartis; Alcon; Novartis; Alcon
RP Regillo, CD (通讯作者)，Wills Eye Hosp & Res Inst, Retina Serv, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
CR BenEzra D, 1997, INVEST OPHTH VIS SCI, V38, P1954
   Clark A F, 1997, Expert Opin Investig Drugs, V6, P1867, DOI 10.1517/13543784.6.12.1867
   Clark AF, 2007, SURV OPHTHALMOL, V52, pS26, DOI 10.1016/j.survophthal.2006.11.003
   Clark AF, 1999, INVEST OPHTH VIS SCI, V40, P2158
   DAMICO DJ, 2003, OPHTHALMOLOGY, V110, P2384
   Kaiser PK, 2007, SURV OPHTHALMOL, V52, pS62, DOI 10.1016/j.survophthal.2006.10.015
   McNatt LG, 1999, J OCUL PHARMACOL TH, V15, P413, DOI 10.1089/jop.1999.15.413
   MCNATT LG, 1992, J STEROID BIOCHEM, V42, P687, DOI 10.1016/0960-0760(92)90109-V
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   Russell SR, 2007, SURV OPHTHALMOL, V52, pS79, DOI 10.1016/j.survophthal.2006.11.005
NR 10
TC 9
Z9 9
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD JAN
PY 2007
VL 52
SU 1
BP S70
EP S78
DI 10.1016/j.survophthal.2006.11.001
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 135KZ
UT WOS:000244153800009
PM 17240259
DA 2022-11-30
ER

PT J
AU Bonyadi, MHJ
   Yaseri, M
   Nikkhah, H
   Bonyadi, M
   Soheilian, M
AF Bonyadi, Mohammad Hossein Jabbarpoor
   Yaseri, Mehdi
   Nikkhah, Homayoun
   Bonyadi, Mortaza
   Soheilian, Masoud
TI Association of risk genotypes of ARMS2/LOC387715 A69S and CFH Y402H with
   age-related macular degeneration with and without reticular
   pseudodrusen: a meta-analysis
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE age-related macular degeneration; ARMS2; LOC387715 A69S; CFH I62V; CFH
   Y402H; meta-analysis; reticular pseudodrusen
ID SUBRETINAL DRUSENOID DEPOSITS; COMPLEMENT FACTOR-H; GEOGRAPHIC ATROPHY;
   DISEASE; SUSCEPTIBILITY; POLYMORPHISMS; PREVALENCE; MACULOPATHY; GENE
AB To pool the results of published data regarding association of ARMS2/LOC387715 A69S, CFH Y402H and CFH I62V genotypes with age-related macular degeneration (AMD) with and without reticular pseudodrusen (RPD). The results of this pooled data used to estimate the contribution of each of these genes in the pathogenesis of RPD. Heterogeneity of studies was evaluated using Cochran Q-test and I-2 index. To modify the heterogeneity in the variables, we used the random effects model. Meta-analysis was performed using STATA. Odds ratio (OR) of genotypes in each study was calculated. Six studies of AMD with RPD and AMD without RPD cases included in this analysis. Analysis of pooled data showed that risk genotypes frequency of ARMS2 A69S was significantly different between AMD with RPD and AMD without RPD [OR=1.82, 95% confidence interval (CI): 1.26-2.63 for GT versus GG ARMS2 A69S; OR=2.40, 95% CI: 1.50-3.84 for TT versus GG ARMS2 A69S]. Further analysis also showed that the risk genotype frequency of CFH Y402H was not significantly different between these two groups (OR=1.02, 95% CI: 0.69-1.50 for CT versus TT CFH Y402H; OR=1.09, 95% CI: 0.74-1.60 for CC versus TT CFH Y402H). Comparison of above-mentioned ORs revealed statistically higher values for GT and TT genotypes of ARMS2 A69S compared with CFH Y402H genotypes (p=0.011, p=0.014, respectively).Our analysis showed stronger contribution of ARMS2 in AMD with RPD group versus AMD without RPD group, in comparison with CFH genotypes.
C1 [Bonyadi, Mohammad Hossein Jabbarpoor; Nikkhah, Homayoun; Soheilian, Masoud] Shahid Beheshti Univ Med Sci, Ocular Tissue Engn Res Ctr, Ophthalm Res Ctr, Tehran, Iran.
   [Yaseri, Mehdi] Univ Tehran Med Sci, Dept Biostat & Epidemiol, Tehran, Iran.
   [Bonyadi, Mortaza] Univ Tabriz, Ctr Excellence Biodivers, Fac Nat Sci, Tabriz, Iran.
C3 Shahid Beheshti University Medical Sciences; Tehran University of
   Medical Sciences; University of Tabriz
RP Bonyadi, MHJ (通讯作者)，Ophthalm Res Ctr, Pasdaran Ave,Boustan 9th St, Tehran, Iran.
EM mhbonyadi@yahoo.com
RI Soheilian, Masoud/AAW-4743-2020; Hossein, Jabbarpoor Bonyadi
   Mohammad/A-1886-2014; Yaseri, Mehdi/I-1645-2018; Nikkhah,
   Homayoun/AAW-4663-2020
OI Yaseri, Mehdi/0000-0002-4066-873X; Nikkhah,
   Homayoun/0000-0002-2414-4661; Soheilian, Masoud/0000-0001-7508-426X
CR ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   Bonyadi M, 2016, ACTA OPHTHALMOL, V94, pE779, DOI 10.1111/aos.13143
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Puche N, 2013, RETINA-J RET VIT DIS, V33, P998, DOI 10.1097/IAE.0b013e31827b6483
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P1061, DOI 10.1001/archophthalmol.2011.212
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tong Y, 2010, MOL VIS, V16, P1958
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Yoneyama S, 2014, GRAEF ARCH CLIN EXP, V252, P1435, DOI 10.1007/s00417-014-2601-y
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 22
TC 15
Z9 15
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2018
VL 96
IS 2
BP e105
EP e110
DI 10.1111/aos.13494
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FW5PL
UT WOS:000425369200001
PM 28593728
OA Bronze
DA 2022-11-30
ER

PT J
AU Higgins, BE
   Taylor, DJ
   Binns, AM
   Crabb, DP
AF Higgins, Bethany E.
   Taylor, Deanna J.
   Binns, Alison M.
   Crabb, David P.
TI Are Current Methods of Measuring Dark Adaptation Effective in Detecting
   the Onset and Progression of Age-Related Macular Degeneration? A
   Systematic Literature Review
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Review
DE AdaptDx; Age-related macular degeneration; AMD; Dark adaptation; Dark
   adaptometer; Rod-intercept time; Systematic literature review
AB Introduction Dark adaptation (DA) has been proposed as a possible functional biomarker for age-related macular degeneration (AMD). In this systematic review we aim to evaluate current methodology used to assess DA in people with AMD, the evidence of precision in detecting the onset and progression of AMD, and the relationship between DA and other functional and structural measures. Methods MEDLINE, EMBASE, CINAHL, AMED, PsycINFO, PsycARTICLES were searched for studies published between January 2006 and January 2020 that assessed DA in people with AMD. Details of eligible studies including study design, characteristics of study population and outcomes were recorded. All included studies underwent quality appraisal using approved critical appraisal tools. This systematic review follows PRISMA guidelines (PROSPERO registration number: CRD42019129486). Results Forty-eight studies were eligible for inclusion, reporting a variety of instruments and protocols to assess different DA parameters. Twenty of these studies used the AdaptDx (MacuLogix, Hummelstown, PA, USA) instrument and assessed rod-intercept time (RIT). Most of these reported that RIT was delayed in people with AMD and this delay worsened with AMD severity. Four studies, involving 533 participants, reported estimates of diagnostic performance of AdaptDx to separate people with AMD from visually healthy controls. DA has been compared to other measures of visual function, patient-reported outcome measures (PROMs) and structural measures. Ten studies specifically considered evidence that the presence of certain structural abnormalities was associated with impaired DA in AMD. Conclusions This systematic review indicates overwhelming evidence of reasonable quality for an association between impaired DA and AMD. Data on the repeatability and reproducibility of DA measurement are sparse. There is evidence that structural abnormalities such as reticular drusen are associated with prolongation of DA time. Fewer studies have explored an association between DA and other measures of visual function or PROMs. We found no studies that had compared DA with performance-based measures.
C1 [Higgins, Bethany E.; Taylor, Deanna J.; Binns, Alison M.; Crabb, David P.] City Univ London, Sch Hlth Sci, Optometry & Visual Sci, London, England.
C3 City University London
RP Crabb, DP (通讯作者)，City Univ London, Sch Hlth Sci, Optometry & Visual Sci, London, England.
EM david.crabb.1@city.ac.uk
OI Crabb, David/0000-0001-8754-3902; Higgins, Bethany/0000-0002-4530-6156
CR Akuffo KO, 2017, INVEST OPHTH VIS SCI, V58, P5347, DOI 10.1167/iovs.16-21192
   Akuffo KO, 2017, BRIT J OPHTHALMOL, V101, P190, DOI 10.1136/bjophthalmol-2016-308418
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Aubert H., 1865, PHYSIOLOGIE NETZHAUT
   Beirne RO, 2019, CLIN EXP OPTOM, V102, P611, DOI 10.1111/cxo.12882
   Binns AM, 2018, INVEST OPHTH VIS SCI, V59, pAMD114, DOI 10.1167/iovs.18-24211
   Bossuyt PM, 2003, CLIN CHEM, V49, P1, DOI 10.1373/49.1.1
   BROWN B, 1983, AM J OPTOM PHYS OPT, V60, P645
   CASP, 2013, CASP CHECKLISTS CRIT
   Chen KG, 2019, OPHTHALMOLOGY, V126, P856, DOI 10.1016/j.ophtha.2018.09.039
   Clark ME, 2011, BRIT J OPHTHALMOL, V95, P1427, DOI 10.1136/bjo.2010.190355
   Cocce KJ, 2018, AM J OPHTHALMOL, V189, P127, DOI 10.1016/j.ajo.2018.02.012
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Dhalla MS, 2007, AM J OPHTHALMOL, V143, P596, DOI 10.1016/j.ajo.2006.12.033
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dimitrov PN, 2012, INVEST OPHTH VIS SCI, V53, P5213, DOI 10.1167/iovs.11-8958
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   Feigl B, 2011, INVEST OPHTH VIS SCI, V52, P1145, DOI 10.1167/iovs.10-5967
   Fidalgo BMR, 2015, OPHTHAL PHYSL OPT, V35, P315, DOI 10.1111/opo.12208
   Finger RP, 2019, OPHTHALMOLOGICA, V241, P61, DOI 10.1159/000491402
   Finger RP, 2011, INVEST OPHTH VIS SCI, V52, P8241, DOI 10.1167/iovs.11-7858
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Flynn OJ, 2018, INVEST OPHTH VIS SCI, V59, P2411, DOI 10.1167/iovs.17-22874
   Fraser RG, 2016, INVEST OPHTH VIS SCI, V57, P5436, DOI 10.1167/iovs.16-19295
   Gaffney AJ, 2013, DOC OPHTHALMOL, V127, P191, DOI 10.1007/s10633-013-9400-3
   Gaffney AJ, 2011, OPTOMETRY VISION SCI, V88, P1080, DOI 10.1097/OPX.0b013e3182223697
   Hecht S, 1937, J GEN PHYSIOL, V20, P831, DOI 10.1085/jgp.20.6.831
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Hosoda Y, 2018, P NATL ACAD SCI USA, V115, P6261, DOI 10.1073/pnas.1802212115
   Jackson GR, 2006, OPHTHAL PHYSL OPT, V26, P431, DOI 10.1111/j.1475-1313.2006.00390.x
   Jackson GR, 2014, OPTOMETRY VISION SCI, V91, P925, DOI 10.1097/OPX.0000000000000247
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   JBI, 2017, CRITICAL APPRAISAL T
   Lains I, 2018, RETINA-J RET VIT DIS, V38, P1145, DOI 10.1097/IAE.0000000000001659
   Lains I, 2018, AM J OPHTHALMOL, V190, P113, DOI 10.1016/j.ajo.2018.03.035
   Lains I, 2017, OPHTHALMOLOGY, V124, P1340, DOI 10.1016/j.ophtha.2017.03.061
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Luu CD, 2018, OPHTHALMOL RETINA, V2, P1206, DOI 10.1016/j.oret.2018.06.016
   McKeague C, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-246
   Mullins RF, 2019, OPHTHALMOLOGY, V126, P591, DOI 10.1016/j.ophtha.2018.10.037
   Neely D, 2017, RETINA-J RET VIT DIS, V37, P1329, DOI 10.1097/IAE.0000000000001454
   Newsome DA, 2009, CURR EYE RES, V34, P162, DOI 10.1080/02713680802647654
   Nguyen CT, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.17-23084
   Nice.org.uk, 2020, APPENDIX H APPRAISAL
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.15
   Owsley C, 2016, INVEST OPHTH VIS SCI, V57, P1782, DOI 10.1167/iovs.15-18962
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   Quartilho A, 2016, EYE, V30, P602, DOI 10.1038/eye.2015.288
   Richer S, 2014, NUTRIENTS, V6, P4404, DOI 10.3390/nu6104404
   Richer S, 2013, NUTRIENTS, V5, P1989, DOI 10.3390/nu5061989
   Richer SP, 2011, OPTOMETRY, V82, P667, DOI 10.1016/j.optm.2011.08.008
   Robinson DG, 2019, INVEST OPHTH VIS SCI, V60, P580, DOI 10.1167/iovs.18-25092
   Robinson DG, 2018, INVEST OPHTH VIS SCI, V59, P4531, DOI 10.1167/iovs.18-24284
   Rodrigo-Diaz E, 2019, INVEST OPHTH VIS SCI, V60, P5070, DOI 10.1167/iovs.19-27971
   Rodriguez JD, 2018, CLIN OPHTHALMOL, V12, P1325, DOI 10.2147/OPTH.S165658
   Sevilla MB, 2016, AM J OPHTHALMOL, V165, P65, DOI 10.1016/j.ajo.2016.02.021
   Tahir Humza J, 2018, Invest Ophthalmol Vis Sci, V59, pAMD202, DOI 10.1167/iovs.18-24227
   Tan RS, 2019, INVEST OPHTH VIS SCI, V60, P1511, DOI 10.1167/iovs.18-26385
   Taylor DJ, 2020, BRIT J OPHTHALMOL, V104, P529, DOI 10.1136/bjophthalmol-2019-313864
   Taylor DJ, 2018, GRAEF ARCH CLIN EXP, V256, P815, DOI 10.1007/s00417-017-3879-3
   Taylor DJ, 2017, INVEST OPHTH VIS SCI, V58, P1887, DOI 10.1167/iovs.16-21122
   Thompson AC, 2018, INVEST OPHTH VIS SCI, V59, P289, DOI 10.1167/iovs.17-22528
   VanderBeek BL, 2014, INVEST OPHTH VIS SCI, V55, P3148, DOI 10.1167/iovs.14-14317
   Veritas Health Innovation, 2019, COVIDENCE SYSTEMATIC
   Wolffsohn JS, 2006, BRIT J OPHTHALMOL, V90, P432, DOI 10.1136/bjo.2005.085787
   Yamashiro K, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072034
   Yazdanie M, 2017, OPHTHALMOLOGY, V124, P1332, DOI 10.1016/j.ophtha.2017.05.005
NR 77
TC 4
Z9 4
U1 1
U2 8
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD MAR
PY 2021
VL 10
IS 1
BP 21
EP 38
DI 10.1007/s40123-020-00323-0
EA FEB 2021
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QI3UY
UT WOS:000616427000001
PM 33565038
OA gold, Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Payakachat, N
   Summers, KH
   Pleil, AM
   Murawski, MM
   Thomas, J
   Jennings, K
   Anderson, JG
AF Payakachat, Nalin
   Summers, Kent H.
   Pleil, Andreas M.
   Murawski, Matthew M.
   Thomas, Joseph, III
   Jennings, Kristofer
   Anderson, James G.
TI Predicting EQ-5D utility scores from the 25-item National Eye Institute
   Vision Function Questionnaire (NEI-VFQ 25) in patients with age-related
   macular degeneration
SO QUALITY OF LIFE RESEARCH
LA English
DT Article
DE Mapping; NEI-VFQ 25; EQ-5D; Low vision; Age-related macular degeneration
   (AMD); Quality of life
ID QUALITY-OF-LIFE; VISUAL IMPAIRMENT; TOBIT-MODEL; HEALTH; INDEX; SF-12
AB In this study, we explored different statistical approaches to identify the best algorithm to predict EQ-5D utility scores from the NEI-VFQ 25 in patients with age-related macular degeneration (AMD).
   Ordinary least squares (OLS), Tobit, and censored least absolute deviation (CLAD) approaches were compared using cross-sectional data (primary dataset, n = 151) at screening from a phase I/II clinical trial in patients with AMD. Three models were specified in this study: full (includes all 12 dimensions of the NEI-VFQ 25), short (includes only the general health dimension and the composite score), and reduced model (using stepwise regression). To evaluate the predictive accuracy of the models, the mean absolute prediction error (MAPE), mean error, and root means squared error were calculated using in-sample cross-validation (within the primary dataset) and out-of-sample validation using an independent dataset (n = 393). The model that provided the lowest prediction errors was chosen as the best model.
   In-sample cross-validation and out-of-sample validation consistently demonstrated that, compared to other approaches, heteroscedasticity-adjusted OLS produced the lowest MAPE (mean values were 0.1400, 0.1593, respectively) for the full model, while CLAD performed best for the short and reduced models (mean values were 0.1299, 0.1483, respectively). The normality and homoscedasticity assumptions of both OLS and Tobit were rejected. CLAD, however, can accommodate these particular violations.
   The CLAD-short model is recommended for producing the EQ-5D utility scores when only the NEI-VFQ 25 data are available.
C1 [Payakachat, Nalin] Univ Arkansas Med Sci, Coll Pharm, Dept Pharm Practice, Div Pharmaceut Evaluat & Policy, Little Rock, AR 72205 USA.
   [Summers, Kent H.] Endo Pharmaceut Inc, Hlth Outcomes & PharmacoEcon HOPE, Chadds Ford, PA 19317 USA.
   [Pleil, Andreas M.] Pfizer Inc, Pfizer Global Pharmaceut, Worldwide Med & Outcomes Res, San Diego, CA 92121 USA.
   [Murawski, Matthew M.; Thomas, Joseph, III] Purdue Univ, Sch Pharm, Dept Pharm Practice, W Lafayette, IN 47907 USA.
   [Jennings, Kristofer] Purdue Univ, Dept Stat, W Lafayette, IN 47907 USA.
   [Anderson, James G.] Purdue Univ, Dept Sociol & Anthropol, W Lafayette, IN 47907 USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences;
   Endo Pharmaceuticals Inc.; Pfizer; Purdue University System; Purdue
   University; Purdue University West Lafayette Campus; Purdue University
   System; Purdue University; Purdue University West Lafayette Campus;
   Purdue University System; Purdue University; Purdue University West
   Lafayette Campus
RP Payakachat, N (通讯作者)，Univ Arkansas Med Sci, Coll Pharm, Dept Pharm Practice, Div Pharmaceut Evaluat & Policy, EDIII Slot 522-4,4301 W Markham St, Little Rock, AR 72205 USA.
EM npayakachat@uams.edu
RI Payakachat, Nalin/H-4666-2019
OI Payakachat, Nalin/0000-0002-9526-5356; Jennings,
   Kristofer/0000-0002-5442-9326; Murawski, Matthew/0000-0002-8612-0307
CR Austin PC, 2002, VALUE HEALTH, V5, P329, DOI 10.1046/j.1524-4733.2002.54128.x
   Austin PC, 2002, MED DECIS MAKING, V22, P152, DOI 10.1177/02729890222063035
   Austin PC, 2000, QUAL LIFE RES, V9, P901, DOI 10.1023/A:1008938326604
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brazier J, 2002, J HEALTH ECON, V21, P271, DOI 10.1016/S0167-6296(01)00130-8
   BRAZIER JE, 2008, REV STUDIES MAPPING
   Brazier J, 2005, APPL HEALTH ECON HEA, V4, P201, DOI 10.2165/00148365-200504040-00002
   Briggs AH, 2000, PHARMACOECONOMICS, V17, P479, DOI 10.2165/00019053-200017050-00006
   Buxton MJ, 2007, VALUE HEALTH, V10, P214, DOI 10.1111/j.1524-4733.2007.00171.x
   Chia EM, 2006, OPHTHAL EPIDEMIOL, V13, P371, DOI 10.1080/09286580600864794
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dobrez D, 2007, VALUE HEALTH, V10, P266, DOI 10.1111/j.1524-4733.2007.00181.x
   Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002
   Drummond MF., 2015, METHODS EC EVALUATIO, V4
   Finger RP, 2008, QUAL LIFE RES, V17, P559, DOI 10.1007/s11136-008-9327-4
   Forster MR, 2002, PHILOS SCI, V69, pS124, DOI 10.1086/341840
   Franks P, 2004, MED DECIS MAKING, V24, P247, DOI 10.1177/0272989X04265477
   Franks P, 2003, MED CARE, V41, P1277, DOI 10.1097/01.MLR.0000093480.58308.D8
   Fryback DG, 2003, QUAL LIFE RES, V12, P609
   Fryback DG, 1997, MED DECIS MAKING, V17, P1, DOI 10.1177/0272989X9701700101
   Gold M.R., 1996, COST EFFECTIVENESS H, P82
   Gold MR, 1998, MED CARE, V36, P778, DOI 10.1097/00005650-199806000-00002
   Gray AM, 2006, MED DECIS MAKING, V26, P18, DOI 10.1177/0272989X05284108
   Greene W. H., 2003, ECONOMETRIC ANAL
   Howell D.G., 2008, HDB SOCIAL SCI METHO
   Huang IC, 2008, HEALTH SERV RES, V43, P327, DOI 10.1111/j.1475-6773.2007.00745.x
   Hudson HL, 2006, OPHTHALMOLOGY, V113, P1987, DOI 10.1016/j.ophtha.2006.07.010
   KENNEDY P, 2003, GUIDE ECONOMETRIC, P281
   Koltowska-Haggstrom M, 2007, VALUE HEALTH, V10, P73, DOI 10.1111/j.1524-4733.2006.00146.x
   LEIBOWITZ H, 1973, SURV OPHTHALMOL, V24, P335
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Luo N, 2003, J RHEUMATOL, V30, P2268
   MacKinnon JG, 2002, CAN J ECON, V35, P615, DOI 10.1111/0008-4085.00147
   Macran S, 2003, MED CARE, V41, P218
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   MCINTOSH L, 2008, EYES INN ARVO 2008 A
   Mooney C.Z., 1995, BOOTSTRAPPING NONPAR
   *NAT I CLIN EXC, 2007, GUID METH T IN PRESS
   Nichol MB, 2001, MED DECIS MAKING, V21, P105, DOI 10.1177/02729890122062352
   Owen Christopher G, 2006, BMC Ophthalmol, V6, P24, DOI 10.1186/1471-2415-6-24
   POWELL JL, 1984, J ECONOMETRICS, V25, P303, DOI 10.1016/0304-4076(84)90004-6
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Ringsdorf L, 2006, J GLAUCOMA, V15, P414, DOI 10.1097/01.ijg.0000212252.72207.c2
   SAS Institute Inc, 2008, CRAY USERS GUIDE VER
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   *STAT, 2001, STAT TECHN B
   Sullivan PW, 2006, MED DECIS MAKING, V26, P401, DOI 10.1177/0272989X06290496
   Sullivan PW, 2005, MED CARE, V43, P736, DOI 10.1097/01.mlr.0000172050.67085.4f
   Ubel PA, 2003, QUAL LIFE RES, V12, P599, DOI 10.1023/A:1025119931010
   Varma R, 2006, OPHTHALMOLOGY, V113, P1846, DOI 10.1016/j.ophtha.2006.04.028
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WHO, 2004, MAGN CAUS VIS IMP
   WILLIAMS A, 1990, HEALTH POLICY, V16, P199
   Wu EQ, 2007, VALUE HEALTH, V10, P408, DOI 10.1111/j.1524-4733.2007.00195.x
NR 55
TC 37
Z9 37
U1 0
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0962-9343
EI 1573-2649
J9 QUAL LIFE RES
JI Qual. Life Res.
PD SEP
PY 2009
VL 18
IS 7
BP 801
EP 813
DI 10.1007/s11136-009-9499-6
PG 13
WC Health Care Sciences & Services; Health Policy & Services; Public,
   Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA 482JC
UT WOS:000268881000002
PM 19543808
DA 2022-11-30
ER

PT J
AU Kovacs, A
   Kiss, T
   Rarosi, F
   Somfai, GM
   Facsko, A
   Degi, R
AF Kovacs, Attila
   Kiss, Timea
   Rarosi, Ferenc
   Somfai, Gabor M.
   Facsko, Andrea
   Degi, Rozsa
TI The effect of ranibizumab and aflibercept treatment on the prevalence of
   outer retinal tubulation and its influence on retreatment in neovascular
   age-related macular degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Outer retinal tubulation; Prevalence; Anti-VEGF; Aflibercept;
   Retreatment; Subretinal hyperreflective material
ID OPTICAL-COHERENCE-TOMOGRAPHY
AB BackgroundWe aimed to analyze the differences in the prevalence of outer retinal tubulation (ORT) in neovascular age-related macular degeneration (AMD) treated with anti-vascular endothelial growth factor (anti-VEGF) agents, either aflibercept or ranibizumab. Our further aim was to examine the changes in the frequency of injections of ranibizumab before and after ORT appearance.MethodsTwo hundred thirty six eyes of 230 patients were included in the study (184 eyes treated with ranibizumab by pro re nata regimen (PRN), 52 eyes with aflibercept bimonthly) and followed for 6-24months. Using optical coherence tomography (OCT), the first appearance of ORT was documented, and fixed time point evaluations were also made every six months to determine the existence of ORT. The number of injections, the presence or absence of subretinal hyperreflective material (SHRM) at treatment initiation and visual acuity were also noted.ResultsThe survival analysis with Cox proportional hazard model showed no significant difference between the ranibizumab and aflibercept groups in relation to the development of ORT (p=0.79, hazard ratio 0.92). In the PRN treated ranibizumab group the number of injections showed significant decrease after ORT development (p=0.004). When SHRM was present at treatment initiation the chance of developing ORT was 2.75 and 11.14 times higher in the ranibizumab and aflibercept groups, respectively.ConclusionsThe prevalence of ORT increased over time independently from the chosen anti-VEGF drug. Our results suggest that upon the appearance of ORT a decrease in retreatments can be expected.
C1 [Kovacs, Attila; Kiss, Timea; Facsko, Andrea; Degi, Rozsa] Univ Szeged, Fac Med, Dept Ophthalmol, 10-11 Koranyi Fasor, H-6720 Szeged, Hungary.
   [Rarosi, Ferenc] Univ Szeged, Fac Med, Dept Med Phys & Informat, Szeged, Hungary.
   [Somfai, Gabor M.] Augenzentrum Pallas Kliniken, Olten, Switzerland.
   [Somfai, Gabor M.] Semmelweis Univ, Fac Med, Dept Ophthalmol, Budapest, Hungary.
C3 Szeged University; Szeged University; Semmelweis University
RP Degi, R (通讯作者)，Univ Szeged, Fac Med, Dept Ophthalmol, 10-11 Koranyi Fasor, H-6720 Szeged, Hungary.
EM degirozsa57@gmail.com
OI Somfai, Gabor Mark/0000-0001-6329-442X; Rarosi,
   Ferenc/0000-0002-1014-9242
CR Agresti A., 2012, CATEGORICAL DATA ANA
   Dirani A, 2015, RETINA-J RET VIT DIS, V35, P1166, DOI 10.1097/IAE.0000000000000439
   Dolz-Marco R, 2017, OPHTHALMOLOGY, V124, P1353, DOI 10.1016/j.ophtha.2017.03.043
   Faria-Correia F, 2013, OPHTHALMOLOGICA, V229, P147, DOI 10.1159/000346854
   Giachetti Filho Richard Geraldo, 2016, Int J Retina Vitreous, V2, P6, DOI 10.1186/s40942-016-0029-8
   Goldberg NR, 2013, RETINA-J RET VIT DIS, V33, P1871, DOI 10.1097/IAE.0b013e318296b12f
   Hariri A, 2015, OPHTHALMOLOGY, V122, P407, DOI 10.1016/j.ophtha.2014.08.035
   Hua R, 2015, SCI REP-UK, V5, DOI 10.1038/srep07661
   Iriyama Aya, 2013, Retina, V33, P1462, DOI 10.1097/IAE.0b013e31828221ae
   Jung JJ, 2012, ARCH OPHTHALMOL-CHIC, V130, P1618, DOI 10.1001/archophthalmol.2012.1902
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Lee JY, 2014, OPHTHALMOLOGY, V121, P2423, DOI 10.1016/j.ophtha.2014.06.013
   Litts KM, 2017, RETINA-J RET VIT DIS, V37, P978, DOI 10.1097/IAE.0000000000001265
   Litts KM, 2015, INVEST OPHTH VIS SCI, V56, P2243, DOI 10.1167/iovs.14-15838
   Litts KM, 2015, JAMA OPHTHALMOL, V133, P609, DOI 10.1001/jamaophthalmol.2015.126
   Massamba N, 2017, GRAEF ARCH CLIN EXP, V255, P61, DOI 10.1007/s00417-016-3423-x
   Preti RC, 2018, RETINA-J RET VIT DIS, V38, P1518, DOI 10.1097/IAE.0000000000001810
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Shah VP, 2014, RETINA-J RET VIT DIS, V34, P1281, DOI 10.1097/IAE.0000000000000166
   Wolff B, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/542417
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 22
TC 2
Z9 2
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD NOV 14
PY 2018
VL 18
AR 298
DI 10.1186/s12886-018-0960-6
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HA7RD
UT WOS:000450479800001
PM 30428856
OA Green Published, Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Bhattacharjee, S
   Zhao, YH
   Dua, P
   Rogaev, EI
   Lukiw, WJ
AF Bhattacharjee, Surjyadipta
   Zhao, Yuhai
   Dua, Prerna
   Rogaev, Evgeny I.
   Lukiw, Walter J.
TI microRNA-34a-Mediated Down-Regulation of the Microglial-Enriched
   Triggering Receptor and Phagocytosis-Sensor TREM2 in Age-Related Macular
   Degeneration
SO PLOS ONE
LA English
DT Article
ID NF-KAPPA-B; ALZHEIMERS-DISEASE AD; MYELOID CELLS-2; AMYLOID-BETA;
   EXPRESSION; ABUNDANCE; INSIGHTS; GENES; NEUROINFLAMMATION; TRANSCRIPTION
AB The aggregation of A beta 42-peptides and the formation of drusen in age-related macular degeneration (AMD) are due in part to the inability of homeostatic phagocytic mechanisms to clear self-aggregating A beta 42-peptides from the extracellular space. The triggering receptor expressed in myeloid/microglial cells-2 (TREM2), a trans-membrane-spanning, sensor-receptor of the immune-globulin/lectin-like gene superfamily is a critical component of A beta 42-peptide clearance. Here we report a significant deficit in TREM2 in AMD retina and in cytokine-or oxidatively-stressed microglial (MG) cells. RT-PCR, miRNA-array, LED-Northern and Western blot studies indicated up-regulation of a microglial-enriched NF-kappa B-sensitive miRNA-34a coupled to a down-regulation of TREM2 in the same samples. Bioinformatics/transfection-luciferase reporter assays indicated that miRNA-34a targets the 299 nucleotide TREM2-mRNA-3'UTR, resulting in TREM2 down-regulation. C8B4-microglial cells challenged with A beta 42 were able to phagocytose these peptides, while miRNA-34a down-regulated both TREM2 and the ability of microglial-cells to phagocytose. Treatment of TNF alpha-stressed MG cells with phenyl-butyl nitrone (PBN), caffeic-acid phenethyl ester (CAPE), the NF-B-inhibitor/resveratrol analog CAY10512 or curcumin abrogated these responses. Incubation of anti-miRNA-34a (AM-34a) normalized miRNA-34a abundance and restored TREM2 back to homeostatic levels. These data support five novel observations: (i) that a ROS-and NF-B-sensitive, miRNA-34a-mediated modulation of TREM2 may in part regulate the phagocytic response; (ii) that gene products encoded on two different chromosomes (miRNA-34a at chr1q36.22 and TREM2 at chr6p21.1) orchestrate a phagocytic-A beta 42-peptide clearance-system; (iii) that this NF-kB-mediated-miRNA-34a-TREM2 mechanism is inducible from outside of the cell; (iv) that when operating normally, this pathway can clear A beta 42 peptide monomers from the extracellular medium; and (v) that anti-NF-kB and/or anti-miRNA (AM)-based therapeutic strategies may be useful against deficits in TREM-2 receptor-based-sensing and -phagocytic signaling that promote pathogenic amyloidogenesis.
C1 [Bhattacharjee, Surjyadipta; Zhao, Yuhai; Lukiw, Walter J.] Louisiana State Univ, Hlth Sci Ctr, LSU Neurosci Ctr, New Orleans, LA 70112 USA.
   [Zhao, Yuhai] Louisiana State Univ, Hlth Sci Ctr, Dept Anat & Cell Biol, New Orleans, LA 70112 USA.
   [Dua, Prerna] Louisiana State Tech Univ, Ruston, LA 71270 USA.
   [Rogaev, Evgeny I.] Univ Massachusetts, Sch Med, Dept Psychiat, Brudnick Neuropsychiat Res Inst, Worcester, MA 01604 USA.
   [Rogaev, Evgeny I.; Lukiw, Walter J.] Russian Acad Sci, Dept Genom & Human Genet, Lab Evolutionary Genom, Vavilov Inst Gen Genet, Moscow 119991, Russia.
   [Rogaev, Evgeny I.] Moscow MV Lomonosov State Univ, Fac Bioengn & Bioinformat, Moscow 119234, Russia.
   [Lukiw, Walter J.] Louisiana State Univ, Hlth Sci Ctr, Dept Ophthalmol, New Orleans, LA 70112 USA.
   [Lukiw, Walter J.] Louisiana State Univ, Hlth Sci Ctr, Dept Neurol, New Orleans, LA 70112 USA.
C3 Louisiana State University System; Louisiana State University Health
   Sciences Center New Orleans; Louisiana State University System;
   Louisiana State University Health Sciences Center New Orleans;
   University of Massachusetts System; University of Massachusetts
   Worcester; Russian Academy of Sciences; Vavilov Institute of General
   Genetics; Lomonosov Moscow State University; Louisiana State University
   System; Louisiana State University Health Sciences Center New Orleans;
   Louisiana State University System; Louisiana State University Health
   Sciences Center New Orleans
RP Lukiw, WJ (通讯作者)，Louisiana State Univ, Hlth Sci Ctr, LSU Neurosci Ctr, New Orleans, LA 70112 USA.; Lukiw, WJ (通讯作者)，Russian Acad Sci, Dept Genom & Human Genet, Lab Evolutionary Genom, Vavilov Inst Gen Genet, Moscow 119991, Russia.; Lukiw, WJ (通讯作者)，Louisiana State Univ, Hlth Sci Ctr, Dept Ophthalmol, New Orleans, LA 70112 USA.; Lukiw, WJ (通讯作者)，Louisiana State Univ, Hlth Sci Ctr, Dept Neurol, New Orleans, LA 70112 USA.
EM wlukiw@lsuhsc.edu
RI Rogaev, Evgeny/AAN-7662-2020; Bhattacharjee, Surjyadipta/I-5354-2016;
   Bhattacharjee, Surjyadipta/AAD-7586-2021
OI Bhattacharjee, Surjyadipta/0000-0003-0185-553X; Bhattacharjee,
   Surjyadipta/0000-0003-0185-553X
FU COBRE III Pilot Project NIH/NIGMS Grant [P30-GM103340]; Research to
   Prevent Blindness (RPB); Louisiana Biotechnology Research Network
   (LBRN); NIH [NEI EY006311, NIA AG18031, NIA AG038834]; Russian Science
   Foundation [14-44-00077, 14-15-01121, 14-50-00029]; NIH NIA [AG029360];
   NATIONAL EYE INSTITUTE [R01EY006311] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM103340] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG038834,
   R01AG018031] Funding Source: NIH RePORTER
FX Research on miRNA in the Lukiw laboratory involving the innate-immune
   response in AD, AMD and in retinal disease, amyloidogenesis and
   neuroinflammation was supported through a COBRE III Pilot Project
   NIH/NIGMS Grant P30-GM103340, an unrestricted grant to the LSU Eye
   Center from Research to Prevent Blindness (RPB); the Louisiana
   Biotechnology Research Network (LBRN) and NIH grants NEI EY006311, NIA
   AG18031 and NIA AG038834.; This work was presented in part at the
   Association for Research in Vision and Ophthalmology (ARVO) Annual
   meeting 3-7 May 2015 in Denver CO, USA and at the Society for
   Neuroscience (SFN) Annual Conference 17-21 October 2015 in Chicago IL,
   USA. Sincere thanks are extended to Drs. L. Carver, H. LeBlanc, F.
   Culicchia, C. Eicken and C. Hebel for short post-mortem interval (PMI)
   human brain tissues or extracts, miRNA array work and initial data
   interpretation, and to D Guillot and AI Pogue for expert technical
   assistance. Thanks are also extended to the many neuropathologists,
   ophthalmologists, physicians and researchers of Canada, Russia and the
   US who have provided high quality, short post-mortem interval (PMI)
   human CNS and retinal tissues or total brain and retinal RNA for
   scientific study. Research on miRNA in the WJ Lukiw laboratory involving
   the innate-immune response in AD, AMD and retinal disease,
   amyloidogenesis and neuroinflammation was supported through a COBRE III
   Pilot Project NIH/NIGMS Grant P30-GM103340, an unrestricted grant to the
   LSU Eye Center from Research to Prevent Blindness (RPB); the Louisiana
   Biotechnology Research Network (LBRN) and NIH grants NEI EY006311, NIA
   AG18031 and NIA AG038834; research on aging and AD, miRNA, gene
   expression and bioinformatics in the EIR laboratory was supported, in
   part, by Russian Science Foundation grant No 14-44-00077 (miRNA and
   targets in the brain), grant No 14-15-01121 (AD-neurodegeneration
   related gene network analysis), No 14-50-00029 (computational
   bioinformatics). EIR is supported, in part, by NIH NIA AG029360.
CR Agostini M, 2014, ONCOTARGET
   Agostini M, 2011, P NATL ACAD SCI USA, V108, P21099, DOI 10.1073/pnas.1112063108
   Alexandrov PN, 2013, J INORG BIOCHEM, V128, P267, DOI 10.1016/j.jinorgbio.2013.05.010
   Alexandrov PN, 2011, NEUROREPORT, V22, P623, DOI 10.1097/WNR.0b013e3283497334
   Benitez BA, 2013, NEW ENGL J MED, V369, P1567, DOI 10.1056/NEJMc1306509
   Bhatnagar S, 2014, FRONT MOL NEUROSCI, V7, DOI 10.3389/fnmol.2014.00002
   Bhattacharjee S, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00062
   Boon RA, 2013, NATURE, V495, P107, DOI 10.1038/nature11919
   Boshette NB, 2014, REV NEUROL-FRANCE, V170, P151, DOI 10.1016/j.neurol.2013.11.002
   Boutajangout Allal, 2013, Int J Cell Biol, V2013, P576383, DOI 10.1155/2013/576383
   Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599
   Cady J, 2014, JAMA NEUROL, V71, P449, DOI 10.1001/jamaneurol.2013.6237
   Cardoso AL, 2016, CURR OPIN PHARMACOL, V26, P1, DOI 10.1016/j.coph.2015.09.001
   Colangelo V, 2002, J NEUROSCI RES, V70, P462, DOI 10.1002/jnr.10351
   Correale C, 2013, GASTROENTEROLOGY, V144, P346, DOI [10.1053/j.gastro.2012.10.040, 10.1053/j.gastro.2012.12.016]
   Cui JG, 2010, J BIOL CHEM, V285, P38951, DOI 10.1074/jbc.M110.178848
   Dorey E, 2014, NEUROSCI BULL, V30, P317, DOI 10.1007/s12264-013-1422-z
   Exley C, 2005, SUB CELL BIOCHEM, V38, P225
   Forabosco P, 2013, NEUROBIOL AGING, V34, P2699, DOI 10.1016/j.neurobiolaging.2013.05.001
   Ford JW, 2009, CURR OPIN IMMUNOL, V21, P38, DOI 10.1016/j.coi.2009.01.009
   Gao HF, 2013, J NEURO-ONCOL, V113, P221, DOI 10.1007/s11060-013-1119-1
   Griciuc A, 2013, NEURON, V78, P631, DOI 10.1016/j.neuron.2013.04.014
   Guerreiro R, 2013, NEW ENGL J MED, V369, P1569, DOI 10.1056/NEJMc1306509
   Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851
   Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267
   Henshall DC, 2014, CURR OPIN NEUROL, V27, P199, DOI 10.1097/WCO.0000000000000079
   Hickman SE, 2014, BIOCHEM PHARMACOL, V88, P495, DOI 10.1016/j.bcp.2013.11.021
   Hill JM, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00347
   Hill JM, 2015, NEUROCHEM RES
   Hu N, 2014, NEUROSCI LETT, V563, P51, DOI 10.1016/j.neulet.2014.01.004
   Jay TR, 2015, J EXP MED, V212, P287, DOI 10.1084/jem.20142322
   Jiang T, 2015, NEUROBIOL AGING, V36, P3176, DOI 10.1016/j.neurobiolaging.2015.08.019
   Jiang T, 2014, NEUROBIOL AGING, V35, P1243, DOI 10.1016/j.neurobiolaging.2013.11.026
   Jin SC, 2014, HUM MOL GENET
   Jones BM, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00094
   Jonsson T, 2013, NEW ENGL J MED, V368, P107, DOI 10.1056/NEJMoa1211103
   Junker A, 2009, BRAIN, V132, P3342, DOI 10.1093/brain/awp300
   Kleinberger G, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009093
   Kofman AV, 2013, CELL CYCLE, V12, P3500, DOI 10.4161/cc.26459
   Li J, 2012, BMC MOL BIOL, V13, DOI 10.1186/1471-2199-13-4
   Li XL, 2011, AGING-US, V3, P985, DOI 10.18632/aging.100371
   Li YY, 2011, NEUROSCI LETT, V499, P109, DOI 10.1016/j.neulet.2011.05.044
   Lukiw WJ, 2008, J BIOL CHEM, V283, P31315, DOI 10.1074/jbc.M805371200
   Lukiw WJ, 2007, NEUROREPORT, V18, P297, DOI 10.1097/WNR.0b013e3280148e8b
   Lukiw WJ, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00133
   Lukiw WJ, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00024
   Lukiw WJ, 2012, EXP NEUROL, V235, P484, DOI 10.1016/j.expneurol.2011.11.022
   Maciotta S, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00265
   Mager PP, 1998, MED RES REV, V18, P403, DOI 10.1002/(SICI)1098-1128(199811)18:6<403::AID-MED4>3.0.CO;2-C
   Mehler MF, 2007, PHYSIOL REV, V87, P799, DOI 10.1152/physrev.00036.2006
   Miyashita A, 2014, J ALZHEIMERS DIS, V41, P1031, DOI 10.3233/JAD-140225
   Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090
   Neumann H, 2013, NEW ENGL J MED, V368, P182, DOI 10.1056/NEJMe1213157
   Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647
   Olson MV, 2012, ANNU REV GENOM HUM G, V13, P1, DOI 10.1146/annurev-genom-090711-163825
   Paradowska-Gorycka A, 2013, HUM IMMUNOL, V74, P730, DOI 10.1016/j.humimm.2013.02.003
   Piccio L, 2007, EUR J IMMUNOL, V37, P1290, DOI 10.1002/eji.200636837
   Pogue AI, 2014, BRAIN RES, V1584, P73, DOI 10.1016/j.brainres.2014.03.042
   Pogue AL, 2014, FRONT NEUROL, V5, DOI [10.3389/fneur.2014.00262, 10.3389/fneur.2014.00043]
   Reitz C, 2014, BIOCHEM PHARMACOL, V88, P640, DOI 10.1016/j.bcp.2013.12.024
   Rivest S, 2015, CELL RES, V25, P535, DOI 10.1038/cr.2015.37
   Satoh J, 2012, CELL MOL NEUROBIOL, V32, P337, DOI 10.1007/s10571-011-9769-z
   Schmid CD, 2002, J NEUROCHEM, V83, P1309, DOI 10.1046/j.1471-4159.2002.01243.x
   Sethi P, 2009, NEUROSCI LETT, V459, P100, DOI 10.1016/j.neulet.2009.04.052
   Sharif O, 2008, IMMUNOBIOLOGY, V213, P701, DOI 10.1016/j.imbio.2008.07.008
   Sharova LV, 2009, DNA RES, V16, P45, DOI 10.1093/dnares/dsn030
   Shewmaker F, 2011, J BIOL CHEM, V286, P16533, DOI 10.1074/jbc.R111.227108
   Shinohara M, 2014, BRAIN
   Sieber MW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052982
   Srinivasan M, 2015, EXPERT OPIN THER TAR, V19, P471, DOI 10.1517/14728222.2014.989834
   Sundermeier TR, 2015, FASEB J
   Veleri S, 2015, DIS MODEL MECH, V8, P109, DOI 10.1242/dmm.017913
   Villegas-Llerena C, 2016, CURR OPIN NEUROBIOL, V36, P74, DOI 10.1016/j.conb.2015.10.004
   Vossel KA, 2013, JAMA NEUROL, V70, P1158, DOI 10.1001/jamaneurol.2013.136
   Wan YQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121975
   Wang XY, 2009, BRAIN RES BULL, V80, P268, DOI 10.1016/j.brainresbull.2009.08.006
   Wang YM, 2015, CELL, V160, P1061, DOI 10.1016/j.cell.2015.01.049
   Watson D, 2005, NEUROL RES, V27, P869, DOI 10.1179/016164105X49436
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang XG, 2014, MOL NEUROBIOL, V50, P119, DOI 10.1007/s12035-014-8652-6
   Zhao YH, 2014, MOL NEUROBIOL, V50, P97, DOI 10.1007/s12035-013-8595-3
   Zhao YH, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00131
   Zhao YH, 2013, NEUROREPORT, V24, P318, DOI 10.1097/WNR.0b013e32835fb6b0
   Zhao YH, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0015816, 10.1371/journal.pone.0016470]
NR 84
TC 90
Z9 93
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 7
PY 2016
VL 11
IS 3
AR e0150211
DI 10.1371/journal.pone.0150211
PG 21
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DG3SL
UT WOS:000371990100024
PM 26949937
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Schmidt-Erfurth, U
   Waldstein, SM
   Deak, GG
   Kundi, M
   Simader, C
AF Schmidt-Erfurth, Ursula
   Waldstein, Sebastian M.
   Deak, Gabor-Gyoergy
   Kundi, Michael
   Simader, Christian
TI Pigment Epithelial Detachment Followed by Retinal Cystoid Degeneration
   Leads to Vision Loss in Treatment of Neovascular Age-Related Macular
   Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL
   RANIBIZUMAB; DOSING REGIMEN; VISUAL-ACUITY; DISEASES; VEGF; THERAPY;
   IMPACT
AB Purpose: Intravitreal antiangiogenic therapy is the major therapeutic breakthrough in neovascular age-related macular degeneration (AMD). Optical coherence tomography (OCT) is the leading diagnostic tool, but solid criteria for optimal therapeutic outcomes are lacking. A comprehensive analysis of structure/function correlations using Food and Drug Administration-and European Medicines Agency-approved substances and fixed and flexible regimens was performed.
   Design: Post hoc analysis of a prospective, randomized multicenter clinical trial including 189 study sites.
   Participants: A total of 1240 patients with active neovascular AMD.
   Methods: Participants received intravitreal ranibizumab or aflibercept. A fixed regimen was used for 48 weeks followed by a flexible regimen until week 96. At monthly intervals, best-corrected visual acuity (BCVA) was measured and retinal morphology was assessed by standardized OCT, including intraretinal cysts (IRCs), subretinal fluid (SRF), and pigment epithelial detachment (PED), presenting with a width >= 400 mm or a height of >= 200 mu m. Results were correlated for each regimen, feature, and time.
   Main Outcome Measures: The BCVA outcomes in relation to retinal pathomorphology based on non-inferiority for all treatment arms.
   Results: In neovascular AMD, only IRC at baseline and persistent through week 12 had a negative impact on BCVA. With therapeutic intervention, exudative features such as IRC and SRF resolved rapidly in 74% of eyes, whereas PED responded only slowly with 38%. Independent of the type of regimen, fixed or flexible, retinal morphology correlated tightly with visual function. Intraretinal cysts consistently showed the lowest BCVA gains with either regimen or substance. With the switch from a fixed to a flexible pro re nata (PRN) regimen, progressive visual loss occurred exclusively in the group with primary PED presenting as the hallmark of neovascular activity and was induced by secondary formation of IRC in the neurosensory retina.
   Conclusions: The efficacy of antiangiogenic therapy in neovascular AMD is strongly determined by morphologic features. The subretinal pigment epithelium lesion underlying PED appears to be the primary indicator for progressive disease activity, whereas secondary cystoid degeneration is the most relevant imaging marker for visual function. Clinically, PED emerged as trigger for consecutive vision loss in PRN treatment. (C) 2015 by the American Academy of Ophthalmology.
C1 [Schmidt-Erfurth, Ursula; Waldstein, Sebastian M.; Deak, Gabor-Gyoergy; Simader, Christian] Med Univ Vienna, Dept Ophthalmol, AT-1090 Vienna, Austria.
   [Schmidt-Erfurth, Ursula; Waldstein, Sebastian M.; Deak, Gabor-Gyoergy; Simader, Christian] Med Univ Vienna, Vienna Reading Ctr, Christian Doppler Lab Ophthalm Image Anal, Vienna, Austria.
   [Kundi, Michael] Med Univ Vienna, Inst Environm Hlth, Dept Publ Hlth, Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna; Medical
   University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Spitalgasse 23, AT-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
OI Schmidt-Erfurth, Ursula/0000-0002-7788-7311; Waldstein,
   Sebastian/0000-0003-2899-6279
FU Austrian Federal Ministry of Economy, Family and Youth, National
   Foundation for Research, Technology and Development
FX Funded by the Austrian Federal Ministry of Economy, Family and Youth,
   National Foundation for Research, Technology and Development. The
   funding organization had no role in the design or conduct of this
   research.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Geitzenauer W, 2011, BRIT J OPHTHALMOL, V95, P171, DOI 10.1136/bjo.2010.182170
   Hawkes N., 2012, BMJ-BRIT MED J, V344, P3275
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Hong YJ, 2014, INVEST OPHTH VIS SCI, V55, P5016, DOI 10.1167/iovs.14-14005
   Iida T, 2003, RETINA-J RET VIT DIS, V23, P1, DOI 10.1097/00006982-200302000-00001
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Miskala PH, 2004, OPHTHALMOLOGY, V111, P1981, DOI 10.1016/j.ophtha.2004.07.022
   Querques G, 2012, GRAEF ARCH CLIN EXP, V250, P479, DOI 10.1007/s00417-011-1831-5
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Ritter M, 2011, BRIT J OPHTHALMOL, V95, P381, DOI 10.1136/bjo.2009.175976
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Scott AW, 2010, EYE, V24, P491, DOI 10.1038/eye.2009.311
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Sulzbacher F, 2012, INVEST OPHTH VIS SCI, V53, P6448, DOI 10.1167/iovs.11-9162
   Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2
NR 41
TC 134
Z9 139
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2015
VL 122
IS 4
BP 822
EP 832
DI 10.1016/j.ophtha.2014.11.017
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE3EX
UT WOS:000351710100031
PM 25578255
DA 2022-11-30
ER

PT J
AU Holz, FG
   Korobelnik, JF
   Lanzetta, P
   Mitchell, P
   Schmidt-Erfurth, U
   Wolf, S
   Markabi, S
   Schmidli, H
   Weichselberger, A
AF Holz, Frank G.
   Korobelnik, Jean-Francois
   Lanzetta, Paolo
   Mitchell, Paul
   Schmidt-Erfurth, Ursula
   Wolf, Sebastian
   Markabi, Sabri
   Schmidli, Heinz
   Weichselberger, Andreas
TI The Effects of a Flexible Visual Acuity-Driven Ranibizumab Treatment
   Regimen in Age-Related Macular Degeneration: Outcomes of a Drug and
   Disease Model
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID CLINICAL-TRIAL SIMULATION; ENDOTHELIAL GROWTH-FACTOR; EYE DISEASE;
   PARKINSONS-DISEASE; FISH INTAKE; PROGRESSION; ASSOCIATION; RISK;
   PHARMACOGENETICS; LEVODOPA
AB PURPOSE. Differences in treatment responses to ranibizumab injections observed within trials involving monthly (MARINA and ANCHOR studies) and quarterly (PIER study) treatment suggest that an individualized treatment regimen may be effective in neovascular age-related macular degeneration. In the present study, a drug and disease model was used to evaluate the impact of an individualized, flexible treatment regimen on disease progression.
   METHODS. For visual acuity (VA), a model was developed on the 12-month data from ANCHOR, MARINA, and PIER. Data from untreated patients were used to model patient-specific disease progression in terms of VA loss. Data from treated patients from the period after the three initial injections were used to model the effect of predicted ranibizumab vitreous concentration on VA loss. The model was checked by comparing simulations of VA outcomes after monthly and quarterly injections during this period with trial data. A flexible VA-guided regimen (after the three initial injections) in which treatment is initiated by loss of >5 letters from best previously observed VA scores was simulated.
   RESULTS. Simulated monthly and quarterly VA-guided regimens showed good agreement with trial data. Simulation of VA-driven individualized treatment suggests that this regimen, on average, sustains the initial gains in VA seen in clinical trials at month 3. The model predicted that, on average, to maintain initial VA gains, an estimated 5.1 ranibizumab injections are needed during the 9 months after the three initial monthly injections, which amounts to a total of 8.1 injections during the first year.
   CONCLUSIONS. A flexible, individualized VA-guided regimen after the three initial injections may sustain vision improvement with ranibizumab and could improve cost-effectiveness and convenience and reduce drug administration-associated risks. (Invest Ophthalmol Vis Sci. 2010; 51: 405-412) DOI:10.1167/iovs.09-3813
C1 [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, D-53227 Bonn, Germany.
   [Korobelnik, Jean-Francois] Univ Bordeaux, CHU Bordeaux, Dept Ophthalmol, Bordeaux, France.
   [Lanzetta, Paolo] Univ Udine, Dept Ophthalmol, I-33100 Udine, Italy.
   [Mitchell, Paul] Univ Sydney, Dept Ophthalmol, Sydney, NSW 2006, Australia.
   [Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol & Optometry, Vienna, Austria.
   [Wolf, Sebastian] Univ Bern, Dept Ophthalmol, Inselspital, Bern, Switzerland.
   [Markabi, Sabri; Schmidli, Heinz; Weichselberger, Andreas] Novartis Pharma AG, Basel, Switzerland.
C3 University of Bonn; CHU Bordeaux; UDICE-French Research Universities;
   Universite de Bordeaux; University of Udine; University of Sydney;
   Medical University of Vienna; University of Bern; Novartis
RP Holz, FG (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53227 Bonn, Germany.
EM frank.holz@ukb.uni-bonn.de
RI Mitchell, Paul/P-1498-2014; Wolf, Sebastian/B-8782-2008; KOROBELNIK,
   Jean-Francois/A-5448-2016
OI Wolf, Sebastian/0000-0002-7467-7028; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311
FU Novartis Pharma AG, Basel, Switzerland
FX Supported by Novartis Pharma AG, Basel, Switzerland, which
   unconditionally funded the editorial assistance provided by Sarah Feaver
   of Complete Medical Communications under the direction of the authors.
   The views and opinions expressed are those of the authors.
CR Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Barrett JS, 2007, EXPERT OPIN DRUG DIS, V2, P185, DOI 10.1517/17460441.2.2.185
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chan PLS, 2007, PHARM RES-DORDR, V24, P791, DOI 10.1007/s11095-006-9202-3
   Chan PLS, 2004, J PHARMACOKINET PHAR, V31, P243, DOI 10.1023/B:JOPA.0000039566.75368.59
   Chang MA, 2008, INVEST OPHTH VIS SCI, V49, P2395, DOI 10.1167/iovs.07-1584
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   CHONG V, 2007, 7 EURETINA C MONT CA
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   De Ridder F, 2005, BASIC CLIN PHARMACOL, V96, P235, DOI 10.1111/j.1742-7843.2005.pto960314.x
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   Gabrielsson J., 2007, PHARMACOKINETIC PHAR, V4th
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Jonas JB, 2007, OPHTHAL RES, V39, P139, DOI 10.1159/000102935
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Lockwood P, 2006, PHARM RES-DORDR, V23, P2050, DOI 10.1007/s11095-006-9048-8
   McLaren NC, 2003, PHARMACOGENOMICS J, V3, P197, DOI 10.1038/sj.tpj.6500181
   Nicolas CM, 2003, CLIN EXP OPHTHALMOL, V31, P465, DOI 10.1046/j.1442-9071.2003.00711.x
   *NOV PHARM AG, 2007, SUMM PROD CHAR LUC
   Parker C, 2006, BRIT J CANCER, V94, P1361, DOI 10.1038/sj.bjc.6603105
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Post TM, 2005, PHARM RES-DORDR, V22, P1038, DOI 10.1007/s11095-005-5641-5
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Reitman ML, 2007, J CLIN INVEST, V117, P1226, DOI 10.1172/JCI32133
   Robman L, 2007, CAN J OPHTHALMOL, V42, P720, DOI 10.3129/i07-116
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sanga S, 2006, EXPERT REV ANTICANC, V6, P1361, DOI 10.1586/14737140.6.10.1361
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Wakusawa R, 2008, AM J OPHTHALMOL, V146, P235, DOI 10.1016/j.ajo.2008.03.019
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wu SY, 1998, DIABETES CARE, V21, P725, DOI 10.2337/diacare.21.5.725
   XU L, 2006, AAPS M SAN ANT TX OC
   NCT00061594 STUDY CO
   NCT00056836 STUDY EV
   NCT00090623 STUDY RH
   NCT00331864 SUSTAIN
NR 43
TC 61
Z9 62
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2010
VL 51
IS 1
BP 405
EP 412
DI 10.1167/iovs.09-3813
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 539OI
UT WOS:000273264200055
PM 19661237
DA 2022-11-30
ER

PT J
AU Gonzalez-Lopez, JJ
   McGowan, G
   Chapman, E
   Yorston, D
AF Gonzalez-Lopez, J. J.
   McGowan, G.
   Chapman, E.
   Yorston, D.
TI Vitrectomy with subretinal tissue plasminogen activator and ranibizumab
   for submacular haemorrhages secondary to age-related macular
   degeneration: retrospective case series of 45 consecutive cases
SO EYE
LA English
DT Article
ID NATURAL-HISTORY; BEVACIZUMAB; DISPLACEMENT; INJECTION; LESIONS; RTPA;
   GAS
AB Purpose To assess the efficacy of small-gauge vitrectomy with subretinal recombinant tissue plasminogen activator (rtPA) and ranibizumab for submacular haemorrhages secondary to neovascular age-related macular degeneration (nAMD), and to identify the factors associated with visual outcome.
   Methods A retrospective case series was performed, including all patients who had small-gauge vitrectomy with subretinal rtPA and ranibizumab for submacular haemorrhages secondary to nAMD. All patients received three consecutive monthly injections of ranibizumab after the surgery, and were reviewed monthly and treated on a pro re nata regime.
   Results A total of 45 eyes of 45 patients were included in the study. Mean age was 77.07 +/- 9.67 years, and 32 of 45 patients (71.1%) were women. Surgery was performed on average 6.98 +/- 5.70 days after the onset of symptoms, and patients were observed for a follow-up period of 12.9 +/- 10.8 months. On average, visual acuity improved -0.59 +/- 0.61 LogMAR between presentation and last follow-up. Visual acuity improved in 33 patients (73.3%), remained unchanged in 10 patients (22.2%), and worsened in 2 patients (4.4%). Multiple linear regression showed that patients with smaller haemorrhages (P = 0.012) and prompt surgery (P = 0.008) had better final visual acuities. A haemorrhage area of <= 30 mm(2) had 91.3% sensitivity and 73.3% specificity for predicting a final visual acuity >= 6/60.
   Conclusion Small-gauge vitrectomy with subretinal rtPA and ranibizumab is effective for improving visual acuity in patients with submacular haemorrhages secondary to nAMD. Small haemorrhage area and prompt surgery are associated with better final visual acuity.
C1 [Gonzalez-Lopez, J. J.; McGowan, G.; Chapman, E.; Yorston, D.] NHS Greater Glasgow & Clyde, Tennent Inst Ophthalmol, Glasgow, Lanark, Scotland.
RP Gonzalez-Lopez, JJ (通讯作者)，Gartnavel Royal Hosp, Tennent Inst Ophthalmol, 1053 Great Western Rd, Glasgow G12 0YN, Lanark, Scotland.
EM juliojose.gonzalez@live.com
RI González-López, Julio J/A-3268-2009
OI González-López, Julio J/0000-0001-7210-7809
FU Alcon; Allergan; MSD; Novartis; Santen; Thea
FX JJG-L has received study grants from Alcon, Allergan, MSD, Novartis,
   Santen, and Thea, and is a consultant for Bayer. The other authors
   declare no conflict of interest.
CR Altaweel MM, 2015, OPHTHALMOLOGY, V122, P391, DOI 10.1016/j.ophtha.2014.08.020
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   Jain S, 2013, J HIGH ENERGY PHYS, DOI 10.1007/JHEP11(2013)037
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Klettner A, 2015, BRIT J OPHTHALMOL, V99, P864, DOI 10.1136/bjophthalmol-2014-306454
   Lange C, 2009, GRAEF ARCH CLIN EXP, V247, P137, DOI 10.1007/s00417-008-0926-0
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mayer WJ, 2013, ACTA OPHTHALMOL, V91, P274, DOI 10.1111/j.1755-3768.2011.02264.x
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Sacu S, 2009, EYE, V23, P1404, DOI 10.1038/eye.2008.267
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Treumer F, 2010, BRIT J OPHTHALMOL, V94, P48, DOI 10.1136/bjo.2009.164707
   Treumer F, 2012, BRIT J OPHTHALMOL, V96, P708, DOI 10.1136/bjophthalmol-2011-300655
   van Zeeburg EJT, 2013, OPHTHALMOLOGICA, V229, P1, DOI 10.1159/000343066
NR 23
TC 19
Z9 19
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUL
PY 2016
VL 30
IS 7
BP 929
EP 935
DI 10.1038/eye.2016.65
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DR0GS
UT WOS:000379586600004
PM 27055681
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Daien, V
   Nguyen, V
   Morlet, N
   Arnold, JJ
   Essex, RW
   Young, S
   Hunyor, A
   Gillies, MC
   Barthelmes, D
AF Daien, Vincent
   Vuong Nguyen
   Morlet, Nigel
   Arnold, Jennifer J.
   Essex, Rohan W.
   Young, Stephanie
   Hunyor, Alex
   Gillies, Mark C.
   Barthelmes, Daniel
CA Fight Retinal Blindness Study Grp
TI Outcomes and Predictive Factors After Cataract Surgery in Patients With
   Neovascular Age-related Macular Degeneration. The Fight Retinal
   Blindness! Project
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; POSTERIOR VITREOUS DETACHMENT; INTRAVITREAL
   BEVACIZUMAB; EYES; RISK
AB PURPOSE: To evaluate outcomes and predictive factors of visual acuity (VA) change after cataract surgery in patients being treated for neovascular age-related macular degeneration (nAMD).
   DESIGN: Retrospective, matched case-control study.
   METHODS: We studied eyes undergoing cataract surgery that had been tracked since they first started treatment for nAMD. These eyes were compared with a cohort of unoperated phakic eyes being treated for nAMD (3 per case) matched for treatment duration before cataract surgery, baseline VA, age, and length of follow-up.
   RESULTS: We included 124 patients that had cataract surgery and 372 matched controls. The mean (95% confidence interval) VA gained was 10.6 letters (7.8, 13.2; P < .001) 12 months after surgery; 26.0% had gained " lines and 1.6% had lost >= 3 lines of VA. Visual acuity (mean [standard deviation]) 12 months after surgery was higher in eyes that had cataract extraction compared with controls (65.8 [17.1] vs 61.3 [20.8] letters, respectively, P =.018). The proportion of visits where the choroidal neovascular (CNV) lesion was graded active and the mean number of injections were similar before and after surgery (P =.506 and P =.316, respectively), whereas both decreased in the control group, suggesting that surgery modestly increased the level of activity of the CNV lesion. Mean [SD] VA prior to surgery was lower in eyes that gained >= 15 letters-compared with eyes that gained 0.14 letters (40.2 [21.4] vs 62.1 [15.1], P < .001). Patients undergoing cataract surgery within the first 6 months of anti-VEGF therapy were more likely to lose rather than gain vision (20.8% lost vision vs 12.8% and 4.4% gaining >= 15 or 0-14 letters respectively, P =.023). Age, receiving an injection at least 2 weeks before surgery, and the CNV lesion type had no discernible association with VA outcomes.
   CONCLUSIONS: We found evidence of a modest effect of cataract surgery on CNV lesion activity in eyes being treated for nAMD. Despite this, visual outcomes were reassuringly good. Cataract surgery within 6 months of starting treatment for nAMD should be avoided if possible. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Daien, Vincent; Vuong Nguyen; Hunyor, Alex; Gillies, Mark C.; Barthelmes, Daniel] Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW, Australia.
   [Morlet, Nigel] Univ Western Australia, Dept Populat Hlth, Perth, WA, Australia.
   [Arnold, Jennifer J.] Marsden Eye Specialists, Parramatta, Australia.
   [Essex, Rohan W.] Australian Natl Univ, Acad Unit Ophthalmol, Acton, Australia.
   [Young, Stephanie] Gladesville Retina, Gladesville, Australia.
   [Daien, Vincent] Univ Hosp Montpellier, Montpellier, France.
   [Barthelmes, Daniel] Zurich Univ Hosp, Zurich, Switzerland.
C3 University of Sydney; University of Western Australia; Australian
   National University; Universite de Montpellier; CHU de Montpellier;
   University of Zurich; University Zurich Hospital
RP Daien, V (通讯作者)，Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW, Australia.
EM Vincent.daien@gmail.com
RI Hunyor, Alex/AAT-8205-2021; DAIEN, Vincent/Z-5516-2019
OI Hunyor, Alex/0000-0002-8182-6167; DAIEN, Vincent/0000-0001-5675-0861;
   Essex, Rohan/0000-0001-5323-0334; Nguyen, Vuong/0000-0001-9070-9803;
   Fraser-Bell, Samantha/0000-0001-5646-9359; Guymer,
   Robyn/0000-0002-9441-4356; lake, stewart/0000-0003-0078-3319
FU ROYAL AUSTRALIAN NZ College of Ophthalmologists Eye Foundation; National
   Health and Medical Research Council, Australia [NHMRC 20102012]; Macula
   Disease Foundation, Australia; NHMRC practitioner fellowship; Walter and
   Gertud Siegenthaler Foundation, Zurich, Switzerland; Swiss National
   Foundation; French Society of Ophthalmology; Servier; Novartis; Bayer
FX THE FIGHT RETINAL BLINDNESS PROJECT WAS SUPPORTED BY A GRANT FROM THE
   ROYAL AUSTRALIAN NZ College of Ophthalmologists Eye Foundation
   (2007-2009); a grant from the National Health and Medical Research
   Council, Australia (NHMRC 20102012); and a grant from the Macula Disease
   Foundation, Australia. Mark Gillies is a Sydney Medical Foundation
   Fellow and is supported by an NHMRC practitioner fellowship. Daniel
   Barthelmes was supported by the Walter and Gertud Siegenthaler
   Foundation, Zurich, Switzerland, and the Swiss National Foundation.
   Vincent Daien was supported by the research grant of the French Society
   of Ophthalmology and by Servier. Funding was also provided by Novartis
   and Bayer.
CR Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Baek JS, 2013, RETINA-J RET VIT DIS, V33, P467, DOI 10.1097/IAE.0b013e3182753b2a
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Casparis H, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006757.pub4
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Daien V, 2016, OPHTHALMOLOGY, V123, P663, DOI 10.1016/j.ophtha.2015.10.009
   Forooghian F, 2009, OPHTHALMOLOGY, V116, P2093, DOI 10.1016/j.ophtha.2009.04.033
   Furino C, 2009, J CATARACT REFR SURG, V35, P1518, DOI 10.1016/j.jcrs.2009.04.032
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Grixti A, 2014, ISRN OPHTHALMOL, V2014, DOI DOI 10.1155/2014/417603.
   Hahn P, 2016, OPHTHALMOLOGY, V123, P309, DOI 10.1016/j.ophtha.2015.06.040
   Hilford D, 2009, EYE, V23, P1388, DOI 10.1038/eye.2008.273
   Ho DE, 2011, J STAT SOFTW, V42
   Jonas JB, 2007, J OCUL PHARMACOL TH, V23, P599, DOI 10.1089/jop.2007.0050
   Kessel L, 2016, ACTA OPHTHALMOL, V94, P755, DOI 10.1111/aos.13120
   Lee TG, 2014, GRAEF ARCH CLIN EXP, V252, P1573, DOI 10.1007/s00417-014-2624-4
   Ozkaya Abdullah, 2014, Retina, V34, P853, DOI 10.1097/IAE.0000000000000024
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Rosenfeld PJ, 2011, AM J OPHTHALMOL, V152, P793, DOI 10.1016/j.ajo.2011.04.025
   Shalchi Z, 2017, AM J OPHTHALMOL, V177, P77, DOI 10.1016/j.ajo.2017.02.006
   Tabandeh H, 2012, J CATARACT REFR SURG, V38, P677, DOI 10.1016/j.jcrs.2011.10.036
   Team RC, 2013, R LANG ENV STAT COMP
   Uney GO, 2014, RETINA-J RET VIT DIS, V34, P32, DOI 10.1097/IAE.0b013e318295f72e
   US National Eye Institute, 2010, US AG SPEC PREV RAT
   von Elm E, 2007, ANN INTERN MED, V147, P573, DOI 10.7326/0003-4819-147-8-200710160-00010
   Weinberg DV, 2013, OPHTHALMOLOGY, V120, P1278, DOI 10.1016/j.ophtha.2012.11.042
NR 26
TC 12
Z9 12
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2018
VL 190
BP 50
EP 57
DI 10.1016/j.ajo.2018.03.012
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GI1AY
UT WOS:000434102800010
PM 29550186
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kuppermann, BD
   Patel, SS
   Boyer, DS
   Augustin, AJ
   Freeman, WR
   Kerr, KJ
   Guo, Q
   Schneider, S
   Lopez, FJ
AF Kuppermann, Baruch D.
   Patel, Sunil S.
   Boyer, David S.
   Augustin, Albert J.
   Freeman, William R.
   Kerr, Kevin J.
   Guo, Qiang
   Schneider, Susan
   Lopez, Francisco J.
CA Brimo DDS Gen I Study Grp
TI PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF BRIMONIDINE DRUG DELIVERY
   SYSTEM (BRIMO DDS) GENERATION 1 IN PATIENTS WITH GEOGRAPHIC ATROPHY
   SECONDARY TO AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; brimonidine; cyto; neuroprotection;
   cytoprotection; drug delivery; dry age-related macular degeneration;
   geographic atrophy; implant; nonexudative; sustained drug delivery
AB Purpose: To evaluate the safety and efficacy of Brimonidine Drug Delivery System (Brimo DDS), a biodegradable intravitreal implant, in the treatment of geographic atrophy (GA) secondary to age-related macular degeneration. Methods: Phase 2, randomized, multicenter, double-masked, 24-month study. Study eyes were treated (Day 1; Month 6 retreatment) with Brimo DDS 132 mu g (n = 49), Brimo DDS 264 mu g (n = 41), or sham procedure (n = 23). The primary timepoint for efficacy analysis was Month 12. Results: Mean GA area growth at Month 12 was 1.78 mm(2), 1.59 mm(2), and 2.19 mm(2) in the Brimo DDS 132 mu g, 264 mu g, and sham groups, respectively. Geographic atrophy area growth was consistently smaller with Brimo DDS 132 and 264 mu g than sham; between-group differences were significant (P <= 0.032) at Month 3. In patients with baseline lesion area >= 6 mm(2) (two-thirds of patients), GA lesion area and effective radius growth was reduced with Brimo DDS 132 and 264 mu g at Month 12 (P <= 0.050 vs. sham). Treatment-related adverse events were usually injection procedure-related. Conclusion: Brimo DDS demonstrated a favorable safety profile and reduced GA lesion area growth at Month 3. Lesion growth at Month 12 was reduced in patients with baseline GA lesion area >= 6 mm(2). The results support Phase 3 development.
C1 [Kuppermann, Baruch D.] Univ Calif Irvine, Gavin Herbert Eye Inst, Irvine, CA 92697 USA.
   [Patel, Sunil S.] West Texas Retina, Abilene, TX USA.
   [Boyer, David S.] Retina Vitreous Associates Med Grp, Los Angeles, CA USA.
   [Augustin, Albert J.] Staedt Klinikum Karlsruhe, Dept Ophthalmol, Karlsruhe, Germany.
   [Freeman, William R.] Univ Calif San Diego, Jacobs Retina Ctr, San Diego, CA 92103 USA.
   [Kerr, Kevin J.; Guo, Qiang; Schneider, Susan; Lopez, Francisco J.] Allergan Plc, Irvine, CA USA.
C3 University of California System; University of California Irvine; Retina
   Vitreous Associates Medical Group; Municipal Hospital Karlsruhe;
   University of California System; University of California San Diego;
   AbbVie; Allergan
RP Kuppermann, BD (通讯作者)，Univ Calif Irvine, Gavin Herbert Eye Inst, Irvine, CA 92697 USA.; Kuppermann, BD (通讯作者)，Univ Calif Irvine, Gavin Herbert Eye Inst, Dept Ophthalmol, 118 Med Surge 1,850 Hlth Sci Rd, Irvine, CA 92697 USA.
EM bdkupper@uci.edu
CR Biarnes M, 2015, AM J OPHTHALMOL, V160, P345, DOI 10.1016/j.ajo.2015.05.009
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Csaky K, 2017, INVEST OPHTH VIS SCI, V58, P3456, DOI 10.1167/iovs.17-22339
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Fisher DE, 2016, OPHTHALMOLOGY, V123, P1297, DOI 10.1016/j.ophtha.2015.12.026
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Kassa E, 2019, EXPERT OPIN BIOL TH, V19, P335, DOI 10.1080/14712598.2019.1575358
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Krupin T, 2011, AM J OPHTHALMOL, V151, P671, DOI 10.1016/j.ajo.2010.09.026
   Lenier S., 2018, MODERN RETINA
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Ortin-Martinez A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113798
   Ramirez C, 2016, J OCUL PHARMACOL TH, V32, P102, DOI 10.1089/jop.2015.0083
   Rosenfeld PJ, 2018, OPHTHALMOL RETINA, V2, P1028, DOI 10.1016/j.oret.2018.03.001
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Saylor M, 2009, ARCH OPHTHALMOL-CHIC, V127, P402, DOI 10.1001/archophthalmol.2009.9
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
NR 27
TC 21
Z9 21
U1 2
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2021
VL 41
IS 1
BP 144
EP 155
DI 10.1097/IAE.0000000000002789
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PR6YJ
UT WOS:000607379100020
PM 32134802
OA hybrid
DA 2022-11-30
ER

PT J
AU Cohen, MN
   O'Shaughnessy, D
   Fisher, K
   Cerami, J
   Awh, CC
   Salazar, DE
   Rosenfeld, P
   Heier, JS
AF Cohen, Michael N.
   O'Shaughnessy, Denis
   Fisher, Kate
   Cerami, Jennifer
   Awh, Carl C.
   Salazar, Daniel E.
   Rosenfeld, Philip
   Heier, Jeffrey S.
TI APEX: a phase II randomised clinical trial evaluating the safety and
   preliminary efficacy of oral X-82 to treat exudative age-related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Vitreous; Retina; Macula; Angiogenesis; Choroid; randomized controlled
   trial; Macular Degeneration; oral; exudative macular degeneration
ID CHOROIDAL NEOVASCULARIZATION; KINASE INHIBITOR; PDGF-B; CELLS
AB Purpose The safety and efficacy of X-82, an orally administered inhibitor of vascular endothelial growth factor (VEGF) and platelet-derived growth factor, was investigated for treatment of wet age-related macular degeneration (AMD) in a phase II clinical trial. Methods This phase II, randomised, double-masked, placebo-controlled trial enrolled subjects with a prior diagnosis of exudative AMD having received at least two intravitreal injections of anti-VEGF therapy. Subjects were randomised equally into four groups that received either daily 50mg, 100mg or 200mg dosages of X-82 or a placebo tablet. At each 4-week interval visit for 52 weeks, subjects were to be assessed to determine if rescue treatment was needed with anti-VEGF therapy. Results 157 patients were enrolled. Due to gastrointestinal and hepatobiliary adverse events and the fulfilment of the primary endpoint, the trial was stopped prematurely after a second interim analysis. The primary endpoint of non-inferiority of visual acuity compared with placebo was demonstrated in all groups receiving X-82 (p<0.001). There was a dose-dependent trend in the number of injections over a 52-week period, with the 50 mg (n=40), 100 mg (n=39), 200 mg (n=39) and placebo (n=39) group requiring 6.7, 6.0, 4.7 and 8.1 injections, respectively. Conclusions X-82 oral therapy in combination with pro re nata anti-VEGF injections showed non-inferiority in visual acuity outcomes while achieving a dose-dependent decrease in the number of anti-VEGF injections compared with placebo. Given the limited tolerability and safety issues observed, X-82 does not have a sufficient benefit to risk profile in treatment of patients with AMD.
C1 [Cohen, Michael N.; Heier, Jeffrey S.] Ophthalm Consultants Boston, Retina Serv, Boston, MA 02114 USA.
   [Cohen, Michael N.] Tufts Univ, Sch Med, New England Eye Ctr, Boston, MA 02111 USA.
   [O'Shaughnessy, Denis; Cerami, Jennifer; Salazar, Daniel E.] Tyrogenex Inc, Rockville, MD USA.
   [Fisher, Kate] IDDI Inc, Raleigh, NC USA.
   [Awh, Carl C.] Tennessee Retina, Nashville, TN USA.
   [Rosenfeld, Philip] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
C3 Ophthalmic Consultants of Boston; Tufts University; International Drug
   Development Institute; Bascom Palmer Eye Institute; University of Miami
RP Cohen, MN (通讯作者)，Ophthalm Consultants Boston, 50 Staniford St,Suite 600, Boston, MA 02114 USA.
EM mcohen@midatlanticretina.com
OI Cohen, Michael/0000-0002-9125-0499
FU Apellis Pharma; Genentech; GlaxoSmithKline; Hoffman-LaRoche; Merck
   Pharma; Ophthotec; PanOptica; Regeneron; Boehringer-Ingelheim; Carl
   Zeiss Meditec; Stealth Biotherapeutics; Tyrogenex Inc.; Aerie; Aerpio;
   Apellis; Clearside; Daiichi Sankyo; Genentech/Roche; Graybug; Gyroscope;
   Hemera; Janssen RD; KalVista; Novartis; Ophthotech; Optos; Optovue;
   Regenxbio; Thrombogenics
FX MNC-Allergan: Consultant/Advisory Board. DO-Tyrogenex Inc.: Employee.
   KF-None. JC -Tyrogenex Inc.: Consultant. CCA-Allergan: Advisory Board,
   Honoraium; Apellis Pharma: Investigator, Research Grant; ArcticDX:
   Consultant, Stockholder; Bausch +Lomb: Consultant, Honoraium; Genentech:
   Consultant, Investigator, Research Grant, Honoraium; GlaxoSmithKline:
   Investigator, Research Grant; Hoffman-LaRoche: Investigator, Research
   Grant; Katalyst Surgical: Consultant, Stockholder, Royalties; Merck
   Pharma: Investigator, Research Grant; Ophthotec: Investigator, Research
   Grant; PanOptica: Investigator, Research Grant; Regeneron: Investigator,
   Research Grant; Volk: Consultant, Honoraria. DES-Tyrogenex Inc:
   Consultant; Brace Pharma Capital (investor in Tyrogenex Inc.):
   Consultant PJR-Apellis: Consultant/Advisor, Equity Owner;
   Boehringer-Ingelheim: Grant Support, Consultant/Advisor; Carl Zeiss
   Meditec: Grant Support, Consultant/Advisor; Chengdu Kanghong Biotech:
   Consultant/Advisor; Healios K. K.: Consultant/Advisor; Hemera
   Biosciences: Consultant/Advisor; Isarna Pharmaceuticals:
   Consultant/Advisor; Lin Bioscience: Consultant/Advisor; MacRegen:
   Consultant/Advisor; Ocudyne: Consultant/Advisor, Equity Owner; Ocunexus:
   Consultant/Advisor; Stealth Biotherapeutics: Grant Support; Tyrogenex
   Inc.: Grant Support, Consultant/Advisor; Unity Biotechnology:
   Consultant/Advisor; Verana Health: Equity Owner. JSH-4D Molecular
   Technologies: Consultant/Advisor; Adverum: Consultant/Advisor, Equity
   Owner; Aerie: Consultant/Advisor, Grant Support; Aerpio:
   Consultant/Advisor, Grant Support; Aldeyra: Consultant/Advisor, Equity
   Owner; Alkahest: Consultant/Advisor; Allegro: Consultant/Advisor, Equity
   Owner; Allergan: Consultant/Advisor; Annexon: Consultant/Advisor;
   Apellis: Consultant/Advisor, Grant Support; Array: Consultant/Advisor;
   Asclepix: Consultant/Advisor; Clearside: Grant Support; Daiichi Sankyo:
   Grant Support; Eloxx: Consultant/Advisor; Galimedix: Consultant/Advisor;
   Genentech/Roche: Consultant/Advisor, Grant Support; Generation Bio:
   Consultant/Advisor; Graybug: Grant Support; Gyroscope: Grant Support;
   Interface: Consultant/Advisor; iRenix: Consultant/Advisor; Hemera: Grant
   Support; Janssen R&D: Consultant/Advisor, Grant Support; jCyte:
   Consultant/Advisor, Equity Owner; Kala: Consultant/Advisor; KalVista:
   Grant Support; Kanghong: Consultant/Advisor; Kodiak: Consultant/Advisor;
   NGM Biopharmaceuticals: Consultant/Advisor; Notal Vision:
   Consultant/Advisor; Novartis: Consultant/Advisor, Grant Support;
   Ocugenix: Consultant/Advisor; Ocular Therapeutix: Consultant/Advisor,
   Equity Owner; Boar meicos: Consultant/Advisor; Ophthotech: Grant
   Support; Optos: Grant Support; Optovue: Grant Support; Orbit/Gyroscope:
   Consultant/Advisor; Regeneron: Consultant/Advisor, Grant Support;
   Regenxbio: Consultant/Advisor, Grant Support; Retrotope:
   Consultant/Advisor; Santen: Consultant/Advisor; Scifluor:
   Consultant/Advisor; Shire: Consultant/Advisor; Stealth Biotherapeutics:
   Consultant/Advisor, Grant Support; Takeda: Consultant/Advisor;
   Thrombogenics: Grant Support; Tyrogenex Inc.: Grant Support; Voyant:
   Consultant/Advisor.
CR Bendell JC, 2019, ONCOLOGIST, V24, P455, DOI 10.1634/theoncologist.2018-0740
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Chung EJ, 2009, BRIT J OPHTHALMOL, V93, P958, DOI 10.1136/bjo.2008.149187
   Diago T, 2008, MAYO CLIN PROC, V83, P231
   Huang D., 2009, INVEST OPHTHALMOL VI, V50, P2966
   Jackson TL, 2017, JAMA OPHTHALMOL, V135, P761, DOI 10.1001/jamaophthalmol.2017.1571
   Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242
   Ophthotech Corp. InvestorsOphthotech Corp, INVESTORSPHTHOTECH A
   Paech F, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00367
   Reinmuth N, 2001, FASEB J, V15, P1239, DOI 10.1096/fj.00-0693fje
   Takahashi K, 2009, ARCH OPHTHALMOL-CHIC, V127, P494, DOI 10.1001/archophthalmol.2009.27
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 13
TC 5
Z9 5
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2021
VL 105
IS 5
BP 716
EP 722
DI 10.1136/bjophthalmol-2020-316511
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RQ5IG
UT WOS:000642451300020
PM 32586932
DA 2022-11-30
ER

PT J
AU Hodgson, R
   Reason, T
   Trueman, D
   Wickstead, R
   Kusel, J
   Jasilek, A
   Claxton, L
   Taylor, M
   Pulikottil-Jacob, R
AF Hodgson, Robert
   Reason, Timothy
   Trueman, David
   Wickstead, Rose
   Kusel, Jeanette
   Jasilek, Adam
   Claxton, Lindsay
   Taylor, Matthew
   Pulikottil-Jacob, Ruth
TI Challenges Associated with Estimating Utility in Wet Age-Related Macular
   Degeneration: A Novel Regression Analysis to Capture the Bilateral
   Nature of the Disease
SO ADVANCES IN THERAPY
LA English
DT Article
DE Age-related macular degeneration; Economic evaluation; Health technology
   assessment; Ophthalmology; Utilities; Utility values
ID RANDOMIZED CLINICAL-TRIAL; VISION-RELATED FUNCTION; HEALTH STATE
   UTILITY; QUALITY-OF-LIFE; RANIBIZUMAB; VALUES
AB The estimation of utility values for the economic evaluation of therapies for wet age-related macular degeneration (AMD) is a particular challenge. Previous economic models in wet AMD have been criticized for failing to capture the bilateral nature of wet AMD by modelling visual acuity (VA) and utility values associated with the better-seeing eye only.
   Here we present a de novo regression analysis using generalized estimating equations (GEE) applied to a previous dataset of time trade-off (TTO)-derived utility values from a sample of the UK population that wore contact lenses to simulate visual deterioration in wet AMD. This analysis allows utility values to be estimated as a function of VA in both the better-seeing eye (BSE) and worse-seeing eye (WSE).
   VAs in both the BSE and WSE were found to be statistically significant (p < 0.05) when regressed separately. When included without an interaction term, only the coefficient for VA in the BSE was significant (p = 0.04), but when an interaction term between VA in the BSE and WSE was included, only the constant term (mean TTO utility value) was significant, potentially a result of the collinearity between the VA of the two eyes. The lack of both formal model fit statistics from the GEE approach and theoretical knowledge to support the superiority of one model over another make it difficult to select the best model.
   Limitations of this analysis arise from the potential influence of collinearity between the VA of both eyes, and the use of contact lenses to reflect VA states to obtain the original dataset. Whilst further research is required to elicit more accurate utility values for wet AMD, this novel regression analysis provides a possible source of utility values to allow future economic models to capture the quality of life impact of changes in VA in both eyes.
C1 [Hodgson, Robert; Claxton, Lindsay; Taylor, Matthew] Univ York, York Hlth Econ Consortium, York, N Yorkshire, England.
   [Reason, Timothy; Trueman, David] Abacus Int, Bicester, Oxon, England.
   [Wickstead, Rose; Kusel, Jeanette; Jasilek, Adam] Costello Med Consulting Ltd, Cambridge, England.
   [Pulikottil-Jacob, Ruth] Novartis Pharmaceut UK Ltd, Surrey, England.
C3 University of York - UK; Costello Medical Consulting; Novartis
RP Wickstead, R (通讯作者)，Costello Med Consulting Ltd, Cambridge, England.
EM rose.wickstead@costellomedical.com
OI Hodgson, Robert/0000-0001-6962-2893; Trueman, David/0000-0002-7886-6467;
   Pulikottil-Jacob, Ruth/0000-0003-0630-960X
FU Novartis Pharmaceuticals UK Limited
FX Novartis Pharmaceuticals UK Limited.
CR Albrecht GL, 1999, SOC SCI MED, V48, P977, DOI 10.1016/S0277-9536(98)00411-0
   Aspinall A, 2007, BRIT J OPHTHALMOL, V91, P766, DOI 10.1136/bjo.2006.104679
   Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   Brazier J., 2016, MEASURING VALUING HL, V2, DOI 10.1093/med/9780198725923.001.0001
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Brown M M, 1999, Curr Opin Ophthalmol, V10, P221, DOI 10.1097/00055735-199906000-00012
   Butt T, 2017, APPL HEALTH ECON HEA, V15, P23, DOI 10.1007/s40258-016-0275-9
   Butt T, 2015, BRIT J OPHTHALMOL, V99, P540, DOI 10.1136/bjophthalmol-2014-305802
   Butt T, 2013, OPTOMETRY VISION SCI, V90, P855, DOI 10.1097/OPX.0b013e3182962318
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Claxton L, 2017, PHARMACOECONOMICS, V35, P237, DOI 10.1007/s40273-016-0459-z
   Czoski-Murray C, 2009, VALUE HEALTH, V12, P793, DOI 10.1111/j.1524-4733.2009.00527.x
   Dolan P, 1996, J HEALTH ECON, V15, P209, DOI 10.1016/0167-6296(95)00038-0
   Espallargues M, 2005, INVEST OPHTH VIS SCI, V46, P4016, DOI 10.1167/iovs.05-0072
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   National Institute for Health and Care Excellence (NICE), 2013, GUID METH TECHN APPR
   National Institute for Health and Care Excellence (NICE), 2008, RAN PEG TREATM AG RE
   National Institute for Health and Care Excellence (NICE), 2013, AFL SOL INJ TREAT WE
   Visser MS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169816
NR 20
TC 5
Z9 5
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0741-238X
EI 1865-8652
J9 ADV THER
JI Adv. Ther.
PD OCT
PY 2017
VL 34
IS 10
BP 2360
EP 2370
DI 10.1007/s12325-017-0620-x
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA FK9TK
UT WOS:000413853500011
PM 29019023
OA hybrid, Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Angermann, R
   Rauchegger, T
   Nowosielski, Y
   Casazza, M
   Bilgeri, A
   Ulmer, H
   Zehetner, C
AF Angermann, Reinhard
   Rauchegger, Teresa
   Nowosielski, Yvonne
   Casazza, Marina
   Bilgeri, Angelika
   Ulmer, Hanno
   Zehetner, Claus
TI Treatment compliance and adherence among patients with diabetic
   retinopathy and age-related macular degeneration treated by
   anti-vascular endothelial growth factor under universal health coverage
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Loss to follow-up; Compliance; Risk factors; Diabetic retinopathy;
   Age-related macular degeneration; Anti-vascular endothelial growth
   factor; Universal health coverage
ID PANRETINAL PHOTOCOAGULATION; VISUAL-ACUITY; FOLLOW-UP; RANIBIZUMAB;
   CARE; INSURANCE
AB Purpose To analyze and compare loss to follow-up (LTFU) rates between patients with diabetic retinopathy (DR) and those with neovascular age-related macular degeneration (nAMD) in patients, receiving treatment with anti-vascular endothelial growth factor (VEGF), under universal health coverage. Methods We retrospectively analyzed the relevant data of 1264 patients receiving anti-VEGF therapy, in this cohort study. The observation period ranged from September 01, 2015 to December 31, 2018. Intervals between each procedure and the subsequent follow-up examination were measured. Demographic data, visual acuity (VA), the type of transport for treatment access, and distance between the residence and clinic were evaluated as risk factors for LTFU. Results We collected data for 841 patients with nAMD (age, 81.0 (+/- 8.1 years)) and 423 patients with DR (age, 67.7 (+/- 12.1 years)). The rate of LTFU, for at least 6 months, was 28.8% and 2.9% for patients with DR and nAMD, respectively (p < 0.001). In the DR group, 18.9% patients were lost to follow-up exceeding > 12 months. Multivariate regression analysis showed that advanced age, lack of mobility, and need for assisted transport, poor final VA despite treatment, and decrease in vision during the observational period were independent risk factors for LTFU exceeding 12 months (p < 0.05). Conclusions We found a high long-term LTFU rate for patients with DR, despite treatment under universal health coverage. Considering the risk of disease progression, particularly in patients with chronic DR, strategies for better compliance and adherence to therapy should be considered for optimized patient care.
C1 [Angermann, Reinhard; Rauchegger, Teresa; Nowosielski, Yvonne; Casazza, Marina; Bilgeri, Angelika; Zehetner, Claus] Med Univ Innsbruck, Dept Ophthalmol, Anichstr 35, A-6020 Innsbruck, Austria.
   [Angermann, Reinhard] Paracelsus Med Univ Salzburg, Dept Ophthalmol, Salzburg, Austria.
   [Ulmer, Hanno] Med Univ Innsbruck, Dept Med Stat Informat & Hlth Econ, Innsbruck, Austria.
C3 Medical University of Innsbruck; Paracelsus Private Medical University;
   Medical University of Innsbruck
RP Zehetner, C (通讯作者)，Med Univ Innsbruck, Dept Ophthalmol, Anichstr 35, A-6020 Innsbruck, Austria.
EM claus.zehetner@i-med.ac.at
RI Rauchegger, Teresa/ABD-3420-2020; Angermann, Reinhard/ABG-1712-2021;
   Ulmer, Hanno/S-6615-2019
OI Rauchegger, Teresa/0000-0003-3439-6333; Angermann,
   Reinhard/0000-0002-1610-4619; Ulmer, Hanno/0000-0001-5911-1002;
   Zehetner, Claus/0000-0003-1405-7457
FU University of Innsbruck; Medical University of Innsbruck
FX Open access funding provided by University of Innsbruck and Medical
   University of Innsbruck.
CR Antonetti DA, 2012, NEW ENGL J MED, V366, P1227, DOI 10.1056/NEJMra1005073
   Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Cramer JA, 2008, INT J CLIN PRACT, V62, P76, DOI 10.1111/j.1742-1241.2007.01630.x
   Dervan E, 2008, IRISH J MED SCI, V177, P303, DOI 10.1007/s11845-008-0192-5
   Deshpande AD, 2008, PHYS THER, V88, P1254, DOI 10.2522/ptj.20080020
   Downer SR, 2005, MED J AUSTRALIA, V183, P366, DOI 10.5694/j.1326-5377.2005.tb07085.x
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Egan C, 2017, BRIT J OPHTHALMOL, V101, P75, DOI 10.1136/bjophthalmol-2016-309313
   Elam AR, 2013, SURV OPHTHALMOL, V58, P348, DOI 10.1016/j.survophthal.2012.07.005
   Gonzalez P, 2015, INVEST OPHTH VIS SCI, V56
   Gross JG, 2015, JAMA-J AM MED ASSOC, V314, P2137, DOI 10.1001/jama.2015.15217
   Li YJ, 2013, JAMA OPHTHALMOL, V131, P499, DOI 10.1001/jamaophthalmol.2013.1165
   Lian JX, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019989
   Nelson KM, 2005, HEALTH SERV RES, V40, P361, DOI 10.1111/j.1475-6773.2005.0d362.x
   Nwanyanwu KH, 2013, DIABETES CARE, V36, P1562, DOI 10.2337/dc12-0790
   Obeid A, 2018, JAMA OPHTHALMOL, V136, P1251, DOI 10.1001/jamaophthalmol.2018.3578
   Obeid A, 2019, OPHTHALMOLOGY, V126, P407, DOI 10.1016/j.ophtha.2018.07.027
   Obeid A, 2018, OPHTHALMOLOGY, V125, P1386, DOI 10.1016/j.ophtha.2018.02.034
   Paksin-Hall A, 2013, OPHTHAL EPIDEMIOL, V20, P281, DOI 10.3109/09286586.2013.789531
   Piccirillo JF, 2008, CRIT REV ONCOL HEMAT, V67, P124, DOI 10.1016/j.critrevonc.2008.01.013
   Saadine JB, 2008, RETINA-J RET VIT DIS, V28, P195, DOI 10.1097/IAE.0b013e318115169a
   Sivaprasad S, 2017, LANCET, V389, P2193, DOI 10.1016/S0140-6736(17)31193-5
   Trento M, 2002, DIABETIC MED, V19, P810, DOI 10.1046/j.1464-5491.2002.00784.x
   Vermeire E, 2001, J CLIN PHARM THER, V26, P331, DOI 10.1046/j.1365-2710.2001.00363.x
   Wang XX, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0635-7
   Weiss M, 2018, RETINA-J RET VIT DIS, V38, P2293, DOI 10.1097/IAE.0000000000001892
   Oladele CRW, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-259
   Wong TY, 2009, DIABETES CARE, V32, P2307, DOI 10.2337/dc09-0615
   World Health Organization, 2016, INT STAT CLASS DIS R
NR 29
TC 24
Z9 24
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2019
VL 257
IS 10
BP 2119
EP 2125
DI 10.1007/s00417-019-04414-y
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JN2DL
UT WOS:000496711200007
PM 31286206
OA hybrid
DA 2022-11-30
ER

PT J
AU Liu, YJ
   Ni, MM
   Wu, R
   Yang, ZR
   Zhu, XJ
   Chen, JY
AF Liu, Yunjie
   Ni, Mengmei
   Wu, Rui
   Yang, Zhirui
   Zhu, Xuejiao
   Chen, Jinyao
TI The level and efficacy of lutein in patients with age-related macular
   degeneration: a comprehensive systematic review and meta-analysis
SO ANNALS OF TRANSLATIONAL MEDICINE
LA English
DT Review
DE Lutein supplements; macular pigment optical density (MPOD); age-related
   macular degeneration (AMD)
ID PIGMENT OPTICAL-DENSITY; RISK-FACTORS; VISUAL IMPAIRMENT; VEGF
   EXPRESSION; FATTY-ACIDS; ZEAXANTHIN; SUPPLEMENTATION; MACULOPATHY;
   CAROTENOIDS; ANTIOXIDANT
AB Background: Lutein has been linked with various visual performance disorders, including age-related macular degeneration (AMD). However, previous studies evaluating the association between serum lutein and the risk of AMD showed results, and the efficacy of lutein intake in AMD patients remains unclear. Methods: To comprehensively estimate the relationship between lutein and AMD, a systematic review and meta-analysis was conducted by searching eligible randomized clinical trials (RCT) and case-control studies to study the association between lutein and AMD on the Cochrane Library, MEDLINE, Elsevier, PubMed, Web of Knowledge, Chinese National Knowledge Infrastructure (CNKI), and Chinese Biomedical Database (CBM) databases until April 2020. The weighted mean difference (WMD) with 95% confidence interval (95% CI) was adopted as the primary effect estimate. Meta-analysis was conducted using STATA 12.0. Results: Nine studies with 855 participants were included in this meta-analysis. The NOS scoring of five case-control studies ranged 5-9. For RCTs, two studies were rated with a low risk of bias, one study with a moderate risk of bias and one with a high risk of bias. The results increased significantly in macular pigment optical density (MPOD) (WMD =0.069; 95% CI: 0.040-0.098, P=0.000) among AMD patients taking lutein supplementation, while there was no difference in circulating lutein levels between AMD patients and controls (WMD =0.00; 95% CI: -0.01 to 0.00, P=0.310). Subgroup analysis suggested that the dose and duration of supplementation could significantly influence the MPOD level in AMD patients. In particular, we observed a larger increase in MPOD of AMD patients using a higher dose (20 mg/d) and longer treatment (>6 months). Conclusions: Although current evidence does not support circulating lutein as a biomarker for early screening of the high-risk AMD population, this study is the first meta-analysis to explore the relationship between lutein in blood and AMD patients. Given that lutein has a high safety profile as indicated by many studies, it is reasonable to give the current analysis result that high dose (20 mg/d) and long duration (>6 months) of lutein intake could be beneficial to AMD patients.
C1 [Liu, Yunjie; Ni, Mengmei; Yang, Zhirui; Chen, Jinyao] Sichuan Univ, West China Hosp 4, West China Sch Publ Hlth, Chengdu, Peoples R China.
   [Wu, Rui] Chongqing Ctr Dis Control & Prevent, Chongqing, Peoples R China.
   [Zhu, Xuejiao] Sichuan Univ, West China Sch Basic Med Sci & Forens Med, 16,Sect 3,Renmin South Rd, Chengdu 610041, Peoples R China.
C3 Sichuan University; Sichuan University
RP Zhu, XJ (通讯作者)，Sichuan Univ, West China Sch Basic Med Sci & Forens Med, 16,Sect 3,Renmin South Rd, Chengdu 610041, Peoples R China.; Chen, JY (通讯作者)，Sichuan Univ, West China Sch Publ Hlth, 16,Sect 3,Renmin South Rd, Chengdu 610041, Peoples R China.
EM zhuxuejiaozxj@163.com; umbrellayy@163.com
FU West China School of Public Health, Sichuan University
FX The authors are thankful for the guidance and support of the West China
   School of Public Health, Sichuan University.
CR [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Cardinault N, 2005, CLIN CHIM ACTA, V357, P34, DOI 10.1016/j.cccn.2005.01.030
   Chae SY, 2018, MOL MED REP, V18, P5182, DOI 10.3892/mmr.2018.9538
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Chung RWS, 2019, FOOD CHEM, V277, P573, DOI 10.1016/j.foodchem.2018.11.023
   Dagnelie G, 2000, Optometry, V71, P147
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Dong Yuan, 2012, Chinese Preventive Medicine, V13, P492
   Feng LW, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0227048
   Fernandez-Robredo P, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/213505
   Fernandez-Robredo P, 2009, CURR EYE RES, V34, P543, DOI 10.1080/02713680902963142
   Gao RY, 2018, J BINZHOU MED U, V41, P185
   Hammond BR, 2002, INVEST OPHTH VIS SCI, V43, P47
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Huang YM, 2015, BRIT J OPHTHALMOL, V99, P371, DOI 10.1136/bjophthalmol-2014-305503
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson EJ, 2014, NUTR REV, V72, P605, DOI 10.1111/nure.12133
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Koh HH, 2004, EXP EYE RES, V79, P21, DOI 10.1016/j.exer.2004.03.001
   Krinsky Norman I., 2005, Molecular Aspects of Medicine, V26, P459
   Lem DW, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10081255
   Li BX, 2010, ARCH BIOCHEM BIOPHYS, V504, P56, DOI 10.1016/j.abb.2010.07.024
   Li LH, 2020, NUTRIENTS, V12, DOI 10.3390/nu12061721
   Liew SHM, 2005, INVEST OPHTH VIS SCI, V46, P4430, DOI 10.1167/iovs.05-0519
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Madhavan J, 2018, PHARMACOGN MAG, V14, P268, DOI 10.4103/pm.pm_340_17
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Meagher KA, 2013, BRIT J NUTR, V110, P289, DOI 10.1017/S0007114512004837
   Muni RH, 2008, RETINA-J RET VIT DIS, V28, P1421, DOI 10.1097/IAE.0b013e3181814470
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Nian S, 2019, NEUROPROTECTION
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Ramkumar HL, 2013, J NUTR, V143, P1129, DOI 10.3945/jn.112.169649
   Ranard KM, 2017, EUR J NUTR, V56, P537, DOI 10.1007/s00394-017-1580-2
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer Stuart, 2007, Optometry, V78, P213, DOI 10.1016/j.optm.2006.10.019
   Rosenthal JM, 2006, INVEST OPHTH VIS SCI, V47, P5227, DOI 10.1167/iovs.05-1513
   SANDERS TAB, 1993, AM J CLIN NUTR, V57, P428, DOI 10.1093/ajcn/57.3.428
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Shao A, 2006, REGUL TOXICOL PHARM, V45, P289, DOI 10.1016/j.yrtph.2006.05.007
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Wang X, 2014, OPHTHALMIC RES, V52, P198, DOI 10.1159/000363327
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Wenzel AJ, 2007, OPHTHAL PHYSL OPT, V27, P329, DOI 10.1111/j.1475-1313.2007.00495.x
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Wolf-Schnurrbusch UEK, 2007, INVEST OPHTH VIS SCI, V48, P3783, DOI 10.1167/iovs.06-1218
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 58
TC 0
Z9 0
U1 6
U2 6
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2305-5839
EI 2305-5847
J9 ANN TRANSL MED
JI ANN. TRANSL. MED.
PD MAR
PY 2022
VL 10
IS 6
DI 10.21037/atm-22-173
EA MAR 2022
PG 13
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA 0R8BY
UT WOS:000770888200001
PM 35433928
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ruys, J
   Mangelschots, E
   Jacob, J
   Mergaerts, F
   Kozyreff, A
   Dirven, W
AF Ruys, Joke
   Mangelschots, Els
   Jacob, Julie
   Mergaerts, Filip
   Kozyreff, Alexandra
   Dirven, Werner
TI Intravitreal Aflibercept Treatment Strategies in Routine Clinical
   Practice of Neovascular Age-Related Macular Degeneration in Belgium: A
   Retrospective Observational Study
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Article
DE Aflibercept; Age-related macular degeneration; Intravitreal injections;
   Retina; Retina-Medical therapies
ID OUTCOMES; EFFICACY; SAFETY
AB Introduction STELLAR was a Belgian, multicentre, retrospective, observational chart review that described the utilization (number of injections and treatment regimen) and effectiveness of intravitreal aflibercept (IVT-AFL) in patients with anti-vascular endothelial growth factor (VEGF) treatment-naive neovascular age-related macular degeneration (nAMD) during the first 12 months of IVT-AFL treatment. Methods Patients initiating IVT-AFL between July 2013 and July 2017 were included in STELLAR. Primary endpoints were number of visits and IVT-AFL injections, and number of patients who received >= 7 versus < 7 IVT-AFL injections during the first 12 months of treatment. Results A total of 337 patients completed >= 12 months of IVT-AFL treatment. The mean number of visits and mean number of injections during the first 12 months was 9.8 and 7.1 injections, respectively (64% received >= 7 injections). Overall, 96% of patients received >= 3 initial monthly injections. Of the 337 patients, 180 received VT-AFL as needed (pro re nata), 141 received it as treat-and-extend dosing and 16 received it as fixed dosing. The proportion of patients who received treat-and-extend dosing increased year-on-year. Mean best-corrected visual acuity (BCVA) (+/- standard deviation) was 61.6 (+/- 14.9) Early Treatment Diabetic Retinopathy Study (ETDRS) letters at baseline and improved by + 3.9 and + 5.7 ETDRS letters at 3 and 12 months, respectively. Mean BCVA improvement was numerically greater in patients who received >= 7 versus < 7 injections during the first 12 months 7 (+ 6.5 vs. + 4.4 ETDRS letters) and in patients who received >= 3 versus < 3 initial monthly injections (+ 5.2 vs. - 0.25 ETDRS letters [3 at months]; + 5.9 vs + 1.2 ETDRS letters [at 12 months]). No specific adverse events were reported. Conclusion Most patients in this Belgian study received >= 7 IVT-AFL injections during a mean of 9.8 visits over the 12 months assessed. IVT-AFL was an effective treatment for nAMD in clinical practice, with numerically higher BCVA gains in patients receiving >= 7 versus < 7 injections over the first 12 months and >= 3 versus < 3 injections in the first 3 months.
C1 [Ruys, Joke] ZNA Middelheim, Dept Ophthalmol, Antwerp, Belgium.
   [Mangelschots, Els] Oogartsenpraktijk Alken, Alken, Belgium.
   [Jacob, Julie] UZ Leuven, Dept Ophthalmol, Leuven, Belgium.
   [Mergaerts, Filip] Oogartsenpraktijk Scherpenheuvel, Aarschot, Belgium.
   [Kozyreff, Alexandra] Clin Univ St Luc, Dept Ophthalmol, Brussels, Belgium.
   [Dirven, Werner] AZ Turnhout, Dept Ophthalmol, Turnhout, Belgium.
C3 ZNA Middelheim Hospital; KU Leuven; University Hospital Leuven;
   Universite Catholique Louvain; Cliniques Universitaires Saint-Luc
RP Ruys, J (通讯作者)，ZNA Middelheim, Dept Ophthalmol, Antwerp, Belgium.
EM joke.ruys@zna.be
FU Bayer SA/NV
FX This study was sponsored by Bayer SA/NV. Bayer SA/NV also funded the
   journal's Rapid Service Fees.
CR Almuhtaseb H, 2017, EYE, V31, P1582, DOI 10.1038/eye.2017.108
   Almuhtaseb H, 2017, EYE, V31, P878, DOI 10.1038/eye.2017.6
   American Academy of Ophthalmology, 2015, PREF PRACT PATT GUID
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Bayer Pharma AG, 2020, EYL AFL SOL INJ SUMM
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   CA McCannel, 2019, 2019 2020 BASIC CLIN
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Chevillard Gregory, 2011, CELL MOL LIFE SCI, V68, P3337, DOI [10.1007/s00018-011-0747-x, DOI 10.1007/S00018-011-0747-X, DOI 10.1038/S41433-019-0747-X]
   European-Medicines-Agency, 2017, GUID GOOD PHARM PRAC
   Framme C, 2018, OPHTHALMOL RETINA, V2, P539, DOI 10.1016/j.oret.2017.09.017
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2018, OPHTHALMOL RETINA, V2, P676, DOI 10.1016/j.oret.2017.10.017
   Lanzetta P, 2018, ACTA OPHTHALMOL, V96, pE911, DOI 10.1111/aos.13751
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Ozturk M, 2018, CLIN EXP OPHTHALMOL, V46, P407, DOI 10.1111/ceo.13085
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Traine PG, 2019, OPHTHALMOL RETINA, V3, P393, DOI 10.1016/j.oret.2019.01.018
   Weber M, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2017-000109
NR 21
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD DEC
PY 2020
VL 9
IS 4
BP 993
EP 1002
DI 10.1007/s40123-020-00300-7
EA SEP 2020
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PA9GG
UT WOS:000571665400001
PM 32946007
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Catchpole, T
   Daniels, T
   Perkins, J
   Csaky, KG
AF Catchpole, Timothy
   Daniels, Tad
   Perkins, Jill
   Csaky, Karl G.
TI Method development to quantify Bv8 expression in circulating CD11b+cells
   in patients with neovascular age-related macular degeneration (nvAMD)
   exhibiting Anti-VEGF refractoriness
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Neovascular age-related macular degeneration; Prokineticin-2 (Bv8);
   Anti-VEGF refractoriness; Gene expression
ID ENDOTHELIAL GROWTH-FACTOR; RANIBIZUMAB; CELLS; RESISTANCE; BIOMARKERS;
   THERAPY
AB A subset of neovascular age-related macular degeneration (nvAMD) subjects appears to be refractory to the effects of anti-VEGF treatment and require frequent intravitreal injections. Prokineticin-2 (Bv8) expression in CD11b+ cells has been linked to anti-VEGF response. We have developed a reproducible method to quantify gene expression in circulating CD11b + cells. Utilizing this method we tested the hypothesis that high Bv8 expression in circulating CD11b(+) cells is associated with anti-VEGF refractoriness in nvAMD patients. Two groups of nvAMD subjects undergoing treatment with anti-VEGF agents were recruited and classified as refractory or non-refractory to anti-VEGF treatment (n = 33 for each group). Two blood draws were obtained from each subject 1-9 months apart. Peripheral blood mononuclear cells (PBMCs) were isolated and CD11b(+) cells were purified via magnetic bead separation. RNA was purified, and relative expression of Bv8 among the subjects was compared via quantitative PCR analysis. Utilizing this approach no significant difference was detected in the mean LogRQ values between the first and second blood draws (t-test, p = 0.826) indicating low intra-patient variability and demonstrating good reproducibility of the assay. There was no significant difference in Bv8 expression between nvAMD subjects classified as refractory versus non-refractory. We were unable to find a correlation between Bv8 expression in CD11b + cells and anti-VEGF refractoriness in human nvAMD subjects. Relatively high expression in Bv8 in these subjects did not correlate with clinical treatment history, as measured by the frequency of injections. Utilizing this well characterized technique, studies are underway to examine alternative gene expression profiles in various circulating cell populations that may contribute to anti-VEGF refractoriness. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Catchpole, Timothy; Daniels, Tad; Perkins, Jill; Csaky, Karl G.] Retina Fdn Southwest, 9600 N Cent Expressway,Suite 200, Dallas, TX 75231 USA.
   [Csaky, Karl G.] Univ Texas Southwestern Med Ctr, Dept Ophthalmol, Dallas, TX USA.
   [Csaky, Karl G.] Texas Retina Associates, Dallas, TX USA.
C3 Retina Foundation of the Southwest; University of Texas System;
   University of Texas Southwestern Medical Center Dallas
RP Catchpole, T (通讯作者)，Retina Fdn Southwest, 9600 N Cent Expressway,Suite 200, Dallas, TX 75231 USA.
EM tcatch@retinafoundation.org
FU IST from Genentech, Inc [ML28043]
FX Financial support was provided in part by an IST from Genentech, Inc
   (ML28043).
CR Azam F, 2010, EUR J CANCER, V46, P1323, DOI 10.1016/j.ejca.2010.02.020
   Balasubramanian R, 2014, J CLIN ENDOCR METAB, V99, pE561, DOI 10.1210/jc.2013-2096
   Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Csaky KG, 2004, EXP EYE RES, V78, P1107, DOI 10.1016/j.exer.2004.01.010
   Eady JJ, 2005, PHYSIOL GENOMICS, V22, P402, DOI 10.1152/physiolgenomics.00080.2005
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P369, DOI 10.1016/j.exer.2004.10.005
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371
   Fauser S, 2015, SURV OPHTHALMOL, V60, P138, DOI 10.1016/j.survophthal.2014.11.002
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hagstrom SA, 2014, JAMA OPHTHALMOL, V132, P521, DOI 10.1001/jamaophthalmol.2014.109
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Helfrich I, 2010, J EXP MED, V207, P491, DOI 10.1084/jem.20091846
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shojaei F, 2007, NATURE, V450, P825, DOI 10.1038/nature06348
   Shojaei F, 2007, NAT BIOTECHNOL, V25, P911, DOI 10.1038/nbt1323
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Zhou JH, 2005, MOL VIS, V11, P414
NR 31
TC 4
Z9 5
U1 0
U2 0
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUL
PY 2016
VL 148
BP 45
EP 51
DI 10.1016/j.exer.2016.05.025
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DQ7GM
UT WOS:000379374900006
PM 27256991
DA 2022-11-30
ER

PT J
AU Richardson, AJ
   Islam, FMA
   Guymer, RH
   Baird, PN
AF Richardson, Andrea J.
   Islam, F. M. Amirul
   Guymer, Robyn H.
   Baird, Paul N.
TI Analysis of Rare Variants in the Complement Component 2 (C2) and Factor
   B (BF) Genes Refine Association for Age-Related Macular Degeneration
   (AMD)
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; RISK
AB PURPOSE. Several single-nucleotide polymorphisms (SNPs) in the C2 and BF genes have been associated with age-related macular degeneration (AMD) in Caucasian populations from the United States. The study was conducted to evaluate whether these SNPs are also associated with AMD in persons of Anglo-Celtic ethnicity in an Australian population.
   METHODS. Included in the study were 565 persons with AMD and 204 ethnically matched control subjects. All participants completed a standard health questionnaire, were given a fundus examination, and provided a blood sample for DNA extraction. Alleles were determined by a matrix-assisted desorption ionization-time of flight (MALDI-TOF)-based approach followed by statistical analysis.
   RESULTS. The C2 and BF genes indicated significant association with AMD of only two SNPs; rs547154 (IVS10) in the C2 gene (P = 9.1 x 10(-5)) and rs641153 (R32Q) in the BF gene (P = 7.0 x 10(-5)). No association with AMD was found for SNP rs9332739 (E318D) in the C2 gene or for rs4151667 (L9H), rs1048709 (R150R), rs4151659 (K565E), or rs2072633 (IVS17) in the BF gene. A protective haplotype of variants IVS10 and R32Q was associated with AMD (OR 0.29, 95% CI 0.20-0.42).
   CONCLUSIONS. In this study, the association of the IVS10 and R32Q variants in the C2 and BF genes in AMD was replicated. Haplotype analysis indicated association of these variants with AMD in an Australian population. Both IVS10 and R32Q variants were in strong linkage disequilibrium with each other (r(2) = 0.96). Although the E318D and L9H variants have shown association with AMD in previous studies, the findings were not in agreement. This demonstrates a refined pattern of association of these rare variants with AMD. (Invest Ophthalmol Vis Sci. 2009; 50: 540-543) DOI:10.1167/iovs.08-2423
C1 [Richardson, Andrea J.; Islam, F. M. Amirul; Guymer, Robyn H.; Baird, Paul N.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   [Guymer, Robyn H.] Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; University of Melbourne; Royal
   Victorian Eye & Ear Hospital
RP Richardson, AJ (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM andreajr@unimelb.edu.au
RI Islam, Fakir M Amirul/P-6665-2015
OI Islam, Fakir M Amirul/0000-0003-3897-3302; Baird,
   Paul/0000-0002-1305-3502; Guymer, Robyn/0000-0002-9441-4356
FU National Health and Medical Research Council of Australia; J. A. COM
   Foundation; Ophthalmic Research Institute of Australia
FX Supported by the National Health and Medical Research Council of
   Australia through a Clinical Fellowship (RHG), the J. A. COM Foundation,
   and the Ophthalmic Research Institute of Australia.
CR Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   CARTER KW, 2004, JLIN JAVA BASED LINK
   Cotton RGH, 2007, NAT GENET, V39, P433, DOI 10.1038/ng2024
   Dudbridge F, 2003, GENET EPIDEMIOL, V25, P115, DOI 10.1002/gepi.10252
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kruglyak L, 2008, NAT REV GENET, V9, P314, DOI 10.1038/nrg2316
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Taylor HR, 2005, MED J AUSTRALIA, V182, P565, DOI 10.5694/j.1326-5377.2005.tb06815.x
   YATES JRW, 2007, NEW ENGL J MED, V357, P19
NR 14
TC 35
Z9 39
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2009
VL 50
IS 2
BP 540
EP 543
DI 10.1167/iovs.08-2423
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 397MD
UT WOS:000262665900007
PM 18806293
DA 2022-11-30
ER

PT J
AU Bessho, H
   Honda, S
   Imai, H
   Negi, A
AF Bessho, Hiroaki
   Honda, Shigeru
   Imai, Hisanori
   Negi, Akira
TI NATURAL COURSE AND FUNDUSCOPIC FINDINGS OF POLYPOIDAL CHOROIDAL
   VASCULOPATHY IN A JAPANESE POPULATION OVER 1 YEAR OF FOLLOW-UP
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; natural course; clustered polypoidal
   lesion; statistical analysis; Japanese
ID MACULAR DEGENERATION; INTRAVITREAL BEVACIZUMAB; PHOTODYNAMIC THERAPY;
   NEOVASCULARIZATION; MULTICENTER; EFFICACY; HYOGO
AB Purpose: To evaluate the natural course and possible funduscopic risk factors for polypoidal choroidal vasculopathy in a Japanese population.
   Methods: The records of 42 eyes from 41 patients (27 men and 14 women) diagnosed as having polypoidal choroidal vasculopathy located in the macula between November 1999 and October 2005 were retrospectively reviewed. The funduscopic findings at the first visit were evaluated. The changes in the best-corrected visual acuity (BCVA) from the baseline to 12 months were analyzed. The lesion types (clustered vs. nonclustered) found on indocyanine green angiography were compared for changes in the BCVA from the initial visit to 12 months.
   Results: The mean age of the subjects was 73.8 +/- 8.0 years. The mean logarithm of the minimum angle of resolution (LogMAR) BCVA was 0.48 +/- 4.0 at baseline and deteriorated to 0.75 +/- 5.7 after 12 months, which was statistically significant (P = 0.00075). The mean LogMAR BCVA in the patients showing "nonclustered" polypoidal choroidal lesions on indocyanine green angiography was maintained for 12 months, while that of the "clustered" group decreased significantly during the same period (P = 0.0014).
   Conclusion: Polypoidal choroidal vasculopathy did not show a favorable outcome in terms of the mean BCVA 12 months after the initial visit. The clustered polypoidal choroidal lesions on indocyanine green angiography may be related to poor prognosis of polypoidal choroidal vasculopathy over the natural course. RETINA 31:1598-1602, 2011
C1 [Honda, Shigeru] Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol,Chuo Ku, Kobe, Hyogo 6500017, Japan.
C3 Kobe University
RP Honda, S (通讯作者)，Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM sighonda@med.kobe-u.ac.jp
RI Honda, Shigeru/W-4761-2019
OI Imai, Hisanori/0000-0001-8879-3604
CR Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Honda S, 2009, JPN J OPHTHALMOL, V53, P593, DOI 10.1007/s10384-009-0741-0
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Otsuji Tsuyoshi, 2006, Nippon Ganka Gakkai Zasshi, V110, P454
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Serhan CN, 2008, J PERIODONTOL, V79, P1520, DOI 10.1902/jop.2008.080231
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1572, DOI 10.1136/bjo.2006.112318corr1
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 28
TC 36
Z9 41
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2011
VL 31
IS 8
BP 1598
EP 1602
DI 10.1097/IAE.0b013e31820d3f28
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 814LS
UT WOS:000294456100019
PM 21478804
DA 2022-11-30
ER

PT J
AU Lashkari, K
   Teague, G
   Chen, H
   Lin, YQ
   Kumar, S
   McLaughlin, MM
   Lopez, FJ
AF Lashkari, Kameran
   Teague, Gianna
   Chen, Hong
   Lin, Yong-Qing
   Kumar, Sanjay
   McLaughlin, Megan M.
   LoPez, Francisco J.
TI A monoclonal antibody targeting amyloid beta (A beta) restores
   complement factor I bioactivity: Potential implications in age-related
   macular degeneration and Alzheimer's disease
SO PLOS ONE
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; HIGH-RISK; ACTIVATION; DRUSEN; DEPOSITS;
   PATHOGENESIS; RETINA; MODEL; VEGF; CFI
AB Activation of the alternative complement cascade has been implicated in the pathogenesis of age related macular degeneration (AMD) and Alzheimer's disease (AD). Amyloid beta (A beta), a component of drusen, may promote complement activation by inhibiting CFI bioactivity. We determined whether A beta reduced CFI bioactivity and whether antibodies against A beta including a monoclonal antibody, GSK933776 could restore CFI bioactivity. We also measured CFI bioactivity in plasma of subjects with AMD and AD. In support of the GSK933776 development program in AMD (geographic atrophy), we developed a quantitative assay to measure CFI bioactivity based on its ability to cleave C3b to iC3b, and repeated it in presence or absence of A beta and anti-A beta antibodies. Using this assay, we measured CFI bioactivity in plasma of 194 subjects with AMD, and in samples from subjects with AD that had been treated with GSK933776 as part of the GSK933776 development program in AD. A beta reduced the CFI bioactivity by 5-fold and pre-incubation with GSK933776 restored CFI bioactivity. In subjects with AMD, plasma CFI levels and bioactivity were not significantly different from non-AMD controls. However, we detected a positive linear trend, suggesting increasing activity with disease severity. In subjects with AD, we observed a 10% and 27% increase in overall CFI bioactivity after treatment with GSK933776 during the second and third dose. Our studies indicate that CFI enzymatic activity can be inhibited by A beta and be altered in proinflammatory diseases such as AMD and AD, in which deposition of A beta and activation of the alternative complement cascade are believed to play a key role in the disease process.
C1 [Lashkari, Kameran; Teague, Gianna] Harvard Med Sch, Mass Eye & Ear, Schepens Eye Res Inst, Boston, MA USA.
   [Chen, Hong; Lin, Yong-Qing] Alliance Pharma, Malvern, PA USA.
   [Kumar, Sanjay; McLaughlin, Megan M.; LoPez, Francisco J.] GlaxoSmithKline, Alternat Discovery & Dev, King Of Prussia, PA USA.
C3 Harvard University; Harvard Medical School; Schepens Eye Research
   Institute; Alliance Pharma Inc; GlaxoSmithKline
RP Lashkari, K (通讯作者)，Harvard Med Sch, Mass Eye & Ear, Schepens Eye Res Inst, Boston, MA USA.
EM kameran_lashkari@meei.harvard.edu
OI Lashkari, Kameran/0000-0003-3855-0246
FU GlaxoSmithKline, King of Prussia [4100111]
FX This work was supported by Grant #4100111, GlaxoSmithKline, King of
   Prussia, PA. https://us.gsk.com. The funder provided study materials and
   consulted on design of some of the experiments. The funder provided
   support in the form of salaries for authors [HC, YL, SK, MMMcL, FJL],
   but did not have any additional role in the study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. The specific roles of the authors are articulated in the
   author contribution section.
CR Alexander P, 2014, MOL VIS, V20, P1253
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Andreasen N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0098153
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x
   BOX GEP, 1974, TECHNOMETRICS, V16, P385, DOI 10.2307/1267668
   Catchpole I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065518
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Delrieu J, 2012, J NEUROCHEM, V120, P186, DOI 10.1111/j.1471-4159.2011.07458.x
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Ghosh K, 1998, J Biopharm Stat, V8, P645, DOI 10.1080/10543409808835266
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Koronyo-Hamaoui M, 2011, NEUROIMAGE, V54, pS204, DOI 10.1016/j.neuroimage.2010.06.020
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lashkari K, 2016, INVEST OPHTH VIS SCI, V57, P57
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Tan PL, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0079-x
   Team RC, 2013, R LANG ENV STAT COMP
   Tsiftsoglou SA, 2004, J IMMUNOL, V173, P367, DOI 10.4049/jimmunol.173.1.367
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zhao YH, 2015, MOL NEUROBIOL, V52, P533, DOI 10.1007/s12035-014-8886-3
NR 37
TC 18
Z9 19
U1 2
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 21
PY 2018
VL 13
IS 5
AR e0195751
DI 10.1371/journal.pone.0195751
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GG2QJ
UT WOS:000432537100002
PM 29782502
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Gelinas, N
   Lynch, AM
   Mathias, MT
   Palestine, AG
   Mandava, N
   Christopher, KL
   Patnaik, JL
AF Gelinas, Nathaniel
   Lynch, Anne M.
   Mathias, Marc T.
   Palestine, Alan G.
   Mandava, Naresh
   Christopher, Karen L.
   Patnaik, Jennifer L.
CA Univ Colorado Retina Res Grp
TI Gender as an effect modifier in the relationship between hypertension
   and reticular pseudodrusen in patients with early or intermediate
   age-related macular degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE reticular pseudodrusen; hypertension; gender; intermediate age-related
   macular degeneration
ID DISEASE
AB AIM: To determine whether the prevalence of treated hypertension is higher among males or females with early/ intermediate (e/i) age-related macular degeneration (AMD) with and without bilateral reticular pseudodrusen (RPD).
   METHODS: Retrospective review of the records of patients with e/iAMD who were recruited into the University of Colorado AMD registry between July 2014 and November 2019. Images were classified using the Beckman Initiative criteria and presence/absence of RPD. Patients were categorized into three groups: 1) e/iAMD with RPD; 2) e/iAMD without RPD; 3) control patients who did not have AMD. Multinomial logistic regression analysis was used for adjusted analysis with odds ratios (OR) and confidence intervals (CI).
   RESULTS: There were 260 patients with e/iAMD of which 101 had bilateral RPD and 159 had no RPD, and 221 controls. Overall, 62% of patients were female and the three groups did not differ by gender. When stratified by gender, the female e/iAMD/RPD group had a higher prevalence of hypertension, 64.1% vs 45.2% for controls, OR=2.2 (95%CI: 1.2-4.0). The frequency of hypertension in the e/iAMD/ no RPD group was 54.1% and did not significantly differ from the control group. Among males, prevalence rates of treated hypertension did not differ. There is a significant interaction of hypertension and gender for the e/iAMD/RPD group such that women with e/iAMD who had RPD were significantly more likely to have hypertension (P=0.042). This relationship was not significant in the e/iAMD/no RPD group (P=0.269).
   CONCLUSION: Among females treated hypertension is significantly higher among e/iAMD/RPD patients, whereas for males there is no significant association.
C1 [Gelinas, Nathaniel; Lynch, Anne M.; Mathias, Marc T.; Palestine, Alan G.; Mandava, Naresh; Christopher, Karen L.; Patnaik, Jennifer L.; Univ Colorado Retina Res Grp] Univ Colorado, Dept Ophthalmol, Sch Med, 1675 Aurora Court, Aurora, CO 80045 USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus
RP Patnaik, JL (通讯作者)，Univ Colorado, Dept Ophthalmol, Sch Med, 1675 Aurora Court, Aurora, CO 80045 USA.
EM Jennifer.Patnaik@cuanschutz.edu
FU National Eye Institute of the National Institutes of Health
   [R01EY032456]; Research to Prevent Blindness; NIH/NCATS Colorado CTSA
   [UL1 TR002535]
FX Supported by the National Eye Institute of the National Institutes of
   Health [No.R01EY032456 (AML)], Research to Prevent Blindness grant to
   the Department of Ophthalmology, University of Colorado, the Frederic C.
   Hamilton Macular Degeneration Center, the Sue AnschutzRogers Eye Center
   Research Fund and by NIH/NCATS Colorado CTSA (No.UL1 TR002535).
CR Abramson B, 2018, WOMEN HYPERTENSION 2
   Ahmad A, 2017, HYPERTENSION, V70, P19, DOI 10.1161/HYPERTENSIONAHA.117.08317
   Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   Domalpally A, 2019, OPHTHALMOLOGY, V126, P1659, DOI 10.1016/j.ophtha.2019.07.022
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Haas P, 2014, INVEST OPHTH VIS SCI, V55, P2674, DOI 10.1167/iovs.13-13338
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Lynch AM, 2020, BMJ OPEN OPHTHALMOL, V5, DOI 10.1136/bmjophth-2019-000361
   Lynch AM, 2020, EUR J OPHTHALMOL, V30, P1061, DOI 10.1177/1120672119857896
   McCarter RV, 2018, BRIT J OPHTHALMOL, V102, P483, DOI 10.1136/bjophthalmol-2017-310526
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Rabiolo A, 2017, CLIN OPHTHALMOL, V11, P1707, DOI 10.2147/OPTH.S130165
   Regitz-Zagrosek V, 2016, EUR HEART J, V37, P24, DOI 10.1093/eurheartj/ehv598
   Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046
   Rosa R, 2021, EUR J OPHTHALMOL, V31, P505, DOI 10.1177/1120672120914530
   SAITO Y, 1990, BRIT J OPHTHALMOL, V74, P702, DOI 10.1136/bjo.74.11.702
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089600
NR 19
TC 0
Z9 0
U1 0
U2 0
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD MAR 18
PY 2022
VL 15
IS 3
BP 461
EP 465
DI 10.18240/ijo.2022.03.14
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZS3HR
UT WOS:000768359800014
PM 35310058
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ng, WY
   Tan, GSW
   Ong, PG
   Cheng, CY
   Cheung, CYL
   Wong, DWK
   Mathur, R
   Chow, KY
   Wong, TY
   Cheung, GCM
AF Ng, Wei Yan
   Tan, Gavin Siew Wei
   Ong, Peng-Guan
   Cheng, Ching-Yu
   Cheung, Carol Yim-Lui
   Wong, Doric Wen Kuan
   Mathur, Ranjana
   Chow, Khuan Yew
   Wong, Tien Yin
   Cheung, Gummy Chui Ming
TI Incidence of Myocardial Infarction, Stroke, and Death in Patients With
   Age-Related Macular Degeneration Treated With Intravitreal Anti-Vascular
   Endothelial Growth Factor Therapy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ANTI-VEGF AGENTS; FACTOR INHIBITORS; ADVERSE EVENTS; CEREBROVASCULAR
   ACCIDENTS; RANIBIZUMAB; SAFETY; MANAGEMENT; INJECTION; MORTALITY;
   DISEASES
AB PURPOSE: To describe the rates of myocardial infarction (MI), stroke, and mortality in patients who have treatment with intravitreal anti vascular endothelial growth factor (anti-VEGF) injections for age-related macular degeneration (AMD).
   DESIGN: A retrospective population linkage study.
   METHOD: We identified patients aged 40 years and above who received treatment with intravitreal anti-VEGF injections for AMD from January 1, 2008 to December 31, 2011 at the Singapore National Eye Centre. We used a national record linkage database to identify patients who developed MI, stroke, and all-cause mortality after the first injection, excluding those with previous MI or stroke at baseline from the respective analysis. We compared rates of MI, stroke, and mortality to that of the total Singapore population.
   RESULTS: A total of 1182 individuals had an intravitreal anti-VEGF injection included in this analysis, with the majority receiving bevacizumab (n = 1011). Overall, 19 patients developed MI, 16 developed stroke, and there were 43 mortalities, giving an age-adjusted incidence rate of 350.2 per 100 000 person-years for MI, 299.3 per 100 000 person-years for stroke, and 778.9 per 100 000 person-years for mortality. This is comparable to the weighted incidence rates of the Singapore population (427.1 per 100 000 person-years for MI, 340.4 per 100 000 person-years for stroke, and 921.3 per 100 000 person-years for mortality).
   CONCLUSION: The incidence rate of MI, stroke, and death in this cohort of AMD patients treated with anti-VEGF was low, and was not significantly higher than the age-adjusted incidence rate of these events in the Singapore population. (C) 2015 by Elsevier Inc. All rights reserved.
C1 [Ng, Wei Yan; Tan, Gavin Siew Wei; Wong, Doric Wen Kuan; Mathur, Ranjana; Wong, Tien Yin; Cheung, Gummy Chui Ming] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore Natl Eye Ctr, Singapore 117548, Singapore.
   [Tan, Gavin Siew Wei; Ong, Peng-Guan; Cheng, Ching-Yu; Cheung, Carol Yim-Lui; Wong, Tien Yin; Cheung, Gummy Chui Ming] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore Eye Res Inst, Singapore 117548, Singapore.
   [Tan, Gavin Siew Wei; Cheng, Ching-Yu; Cheung, Carol Yim-Lui; Wong, Doric Wen Kuan; Mathur, Ranjana; Wong, Tien Yin; Cheung, Gummy Chui Ming] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117548, Singapore.
   [Tan, Gavin Siew Wei; Cheng, Ching-Yu; Cheung, Carol Yim-Lui; Wong, Doric Wen Kuan; Mathur, Ranjana; Wong, Tien Yin; Cheung, Gummy Chui Ming] Duke Natl Univ Singapore, Grad Sch Med, Ophthalmol Acad Clin Program, Singapore, Singapore.
   [Chow, Khuan Yew] Natl Registry Dis Off, Singapore, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; Singapore National Eye Center;
   National University of Singapore; National University of Singapore
RP Cheung, GCM (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM gemmy.cheung.c.m@snec.com.sg
RI Cheung, Carol Y./G-7895-2016; Cheung, Carol/AAF-1101-2020; Cheng,
   Ching-Yu/Y-2229-2019; Wong, Tien Yin/AAC-9724-2020
OI Cheung, Carol/0000-0002-9672-1819; Cheng, Ching-Yu/0000-0003-0655-885X;
   Wong, Tien Yin/0000-0002-8448-1264; Cheung, Carol/0000-0003-0869-859X;
   Cheung, Chui Ming Gemmy/0000-0003-3358-3516; Wong,
   Damon/0000-0003-4601-9121
FU Bayer; Novartis; GlaxoSmithKline; Roche
FX Board membership (D.W.: Alcon, Bayer, Novartis; G.C.: Bayer, Norvarts;
   W.T.Y.: Abbott, Novartis, Pfizer, Allergan, Bayer); Consultancy (G.C.:
   Bayer, Novartis; W.T.Y.: Abbott, Novartis, Pfizer, Allergan, Bayer);
   Grants (G.C.: Bayer, Novartis, GlaxoSmithKline, Roche); Lectures (G.C.:
   Bayer, Novartis); Manuscript (G.C.: Bayer, Novartis);
   Travel/accommodation.(G.C.: Allergan). The authors indicate no funding
   support.
CR American Society of Retina Specialists, 2011, PREF TRENDS PAT SURV
   [Anonymous], PREF TRENDS PAT SURV
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P7, DOI 10.1136/bjophthalmol-2013-303844
   Brand CS, 2012, EYE, V26, pS1, DOI 10.1038/eye.2012.32
   Bressler NM, 2012, RETINA-J RET VIT DIS, V32, P1821, DOI 10.1097/IAE.0b013e31825db6ba
   Campbell RJ, 2012, PREF TRENDS PAT SURV, V345, pe4203
   Campbell RJ, 2012, OPHTHALMOLOGY, V119, P1604, DOI 10.1016/j.ophtha.2012.05.028
   Campbell RJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4203
   Carneiro AM, 2011, OPHTHALMOLOGICA, V225, P211, DOI 10.1159/000323943
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cheung CYL, 2013, STROKE, V44, P2402, DOI 10.1161/STROKEAHA.113.001738
   Cheung CMG, 2013, LANCET, V382, P1230, DOI 10.1016/S0140-6736(13)61580-9
   Csaky K, 2009, AM J OPHTHALMOL, V148, P647, DOI 10.1016/j.ajo.2009.06.014
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Dafer Rima M, 2007, Semin Ophthalmol, V22, P201, DOI 10.1080/08820530701543024
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Kemp A, 2013, RETINA-J RET VIT DIS, V33, P920, DOI 10.1097/IAE.0b013e318276e07b
   Lim C. C., 2014, EUR J PREV CARDIOL
   Lim CC, 2014, 1 SING MYOC INF REG
   Lim LS, 2011, AM J OPHTHALMOL, V152, P329, DOI 10.1016/j.ajo.2011.05.040
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Ng WY, 2014, OPTOMETRY VISION SCI, V91, P872, DOI 10.1097/OPX.0000000000000283
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2010, EXPERT OPIN DRUG SAF, V9, P149, DOI 10.1517/14740330903418422
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574
   Singapore Department of Statistics, POP TRENDS 2013
   Singapore Stroke Registry National Registry of Diseases Office Ministry of Health Singapore., 2 SING STROK REG NAT
   Singapore Stroke Registry National Registry of Diseases Office Ministry of Health Singapore, SING STROK REG INT A
   Singapore Stroke Registry National Registry of Diseases Office Ministry of Health Singapore, 2005, 3 SING STROK REG NAT
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P1, DOI 10.1136/bjophthalmol-2014-305502
   SLEE VN, 1978, ANN INTERN MED, V88, P424, DOI 10.7326/0003-4819-88-3-424
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   Van der Reis MI, 2011, RETINA-J RET VIT DIS, V31, P1449, DOI 10.1097/IAE.0b013e3182278ab4
   Wong D, 2011, GRAEF ARCH CLIN EXP, V249, P161, DOI 10.1007/s00417-010-1574-8
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
NR 44
TC 22
Z9 23
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2015
VL 159
IS 3
BP 557
EP 564
DI 10.1016/j.ajo.2014.12.005
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CC1BV
UT WOS:000350077100019
PM 25497143
DA 2022-11-30
ER

PT J
AU Nicholson, BP
   Nigam, D
   Toy, B
   Stetson, PF
   Agron, E
   Jacobs-El, N
   Cunningham, D
   Cukras, C
   Wong, W
   Wiley, H
   Chew, E
   Ferris, F
   Meyerle, CB
AF Nicholson, Benjamin P.
   Nigam, Divya
   Toy, Brian
   Stetson, Paul F.
   Agron, Elvira
   Jacobs-El, Naima
   Cunningham, Denise
   Cukras, Catherine
   Wong, Wai
   Wiley, Henry
   Chew, Emily
   Ferris, Frederick
   Meyerle, Catherine B.
TI EFFECT OF RANIBIZUMAB ON HIGH-SPEED INDOCYANINE GREEN ANGIOGRAPHY AND
   MINIMUM INTENSITY PROJECTION OPTICAL COHERENCE TOMOGRAPHY FINDINGS IN
   NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   fluorescein angiography; indocyanine green angiography; macula; optical
   coherence tomography; ranibizumab; retina
ID OCCULT CHOROIDAL NEOVASCULARIZATION; VIDEOANGIOGRAPHY; AGREEMENT;
   THERAPY
AB Purpose: The purpose of this 1-year prospective study was to investigate how induction/pro re nata ranibizumab intravitreal treatment of eyes with neovascular age-related macular degeneration affects the anatomy of choroidal neovascularization (CNV) and the overlying outer retinal tissue.
   Methods: High-speed indocyanine green (HS-ICG) angiography measurements provided quantification of the CNV size in 60 patients followed for 1 year. Minimum intensity projection optical coherence tomography (MinIP OCT), a novel algorithm assessing minimum optical intensity between the internal limiting membrane and retinal pigment epithelium, measured the area of outer retinal disruption overlying the CNV. Fluorescein angiography was also assessed to evaluate late retinal leakage.
   Results: After 1 year, the mean area of CNV measured with indocyanine green angiography decreased by 5.8%. The mean area of MinIP OCT of outer retinal disruption overlying the CNV decreased by 4.2%. Mean area of fluorescein angiography leakage decreased by 6.3%. Both the area of outer retinal disruption measured with MinIP OCT and the area of leakage on fluorescein angiography typically exceeded the area of CNV on indocyanine green angiography at baseline and 1 year.
   Conclusion: Choroidal neovascularization treated with induction/pro re nata intravitreal ranibizumab for 1 year essentially remained static. Minimum intensity projection optical coherence tomography suggests that the area of outer retinal disruption overlying the CNV may be greater than the CNV itself and often correlates with the leakage area on fluorescein angiography. Additionally, there was minimal change in the area of outer retinal disruption on MinIP OCT even when fluid resolved. Measurements of the extent of CNV lesions based on indocyanine green angiography and MinIP OCT may provide useful outcome variables to help assess the CNV complex longitudinally and warrant further validation.
C1 [Nicholson, Benjamin P.; Nigam, Divya; Toy, Brian; Agron, Elvira; Jacobs-El, Naima; Cunningham, Denise; Cukras, Catherine; Wong, Wai; Wiley, Henry; Chew, Emily; Ferris, Frederick] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Stetson, Paul F.] Carl Zeiss Meditec, Adv Dev, Dublin, CA USA.
   [Meyerle, Catherine B.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21224 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Carl Zeiss AG; Johns Hopkins University; Johns Hopkins Medicine
RP Meyerle, CB (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 600 N Wolfe St, Baltimore, MD 21224 USA.
EM cmeyerl1@jhmi.edu
RI ; Wong, Wai/B-6118-2017
OI Ferris, Frederick/0000-0002-4933-0639; Toy, Brian/0000-0002-9612-5697;
   Wong, Wai/0000-0003-0681-4016
FU Intramural NIH HHS [ZIA EY000527-02] Funding Source: Medline; NATIONAL
   EYE INSTITUTE [ZIAEY000527, ZIEEY000487, ZIAEY000485] Funding Source:
   NIH RePORTER
CR Bland JM, 2007, J BIOPHARM STAT, V17, P571, DOI 10.1080/10543400701329422
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   DESTRO M, 1989, OPHTHALMOLOGY, V96, P846
   Dupas B, 2010, INVEST OPHTHALMOL VI, V51
   GUYER DR, 1992, OPHTHALMOLOGY, V99, P287
   Guyer DR, 2001, RETINA, P943
   HAYASHI K, 1985, OPHTHALMOLOGICA, V190, P30, DOI 10.1159/000309489
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Ni Z, 2009, OPHTHALMOLOGICA, V223, P401, DOI 10.1159/000228926
   Querques G, 2012, GRAEF ARCH CLIN EXP, V250, P479, DOI 10.1007/s00417-011-1831-5
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SORENSON JA, 1994, ARCH OPHTHALMOL-CHIC, V112, P473, DOI 10.1001/archopht.1994.01090160049021
   Srivastava SK, 2003, RETINA-J RET VIT DIS, V23, P712, DOI 10.1097/00006982-200310000-00019
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   Zayit-Soudry S, 2011, INVEST OPHTHALMOL VI, V52
   Zayit-Soudry S, 2010, INVEST OPHTHALMOL VI, V51
NR 19
TC 1
Z9 1
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2015
VL 35
IS 1
BP 58
EP 68
DI 10.1097/IAE.0000000000000260
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AX6WX
UT WOS:000347060000017
PM 25077529
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Rohrer, B
   Frazer-Abel, A
   Leonard, A
   Ratnapriya, R
   Ward, T
   Pietraszkiewicz, A
   O'Quinn, E
   Adams, K
   Swaroop, A
   Wolf, BJ
AF Rohrer, Baerbel
   Frazer-Abel, Ashley
   Leonard, Anthony
   Ratnapriya, Rinki
   Ward, Tyson
   Pietraszkiewicz, Alexandra
   O'Quinn, Elizabeth
   Adams, Katherine
   Swaroop, Anand
   Wolf, Bethany Jacobs
TI Association of age-related macular degeneration with complement
   activation products, smoking, and single nucleotide polymorphisms in
   South Carolinians of European and African descent
SO MOLECULAR VISION
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; FACTOR-H; ALTERNATIVE PATHWAY;
   CIGARETTE-SMOKING; OXIDATIVE STRESS; GENETIC-VARIANTS; PLASMA-LEVELS;
   FACTOR-I; RISK; RARE
AB Purpose: Smoking and the incidence of age-related macular degeneration (AMD) have been linked to an overactive complement system. Here, we examined in a retrospective cohort study whether AMD-associated single nucleotide polymorphisms (SNPs), smoking, ethnicity, and disease status are correlated with blood complement levels.
   Methods: Population: The study involved 91 AMD patients and 133 controls, which included 73% Americans of European descent (EUR) and 27% Americans of African descent (AFR) in South Carolina. Readouts: Participants were genotyped for 10 SNPs and systemic levels of complement factor H (CFH) activity, and the complement activation products C3a, C5a, and Bb were assessed. Main Outcome Measures: Univariate and multivariable logistic regression models were used to examine associations between AMD status and distinct readouts.
   Results: AMD affects EUR individuals more than AFRs. EUR but not AFR AMD subjects revealed higher levels of Factors C3a and Bb. In all subjects, a 10-unit increase in C3a levels was associated with an approximately 10% increase in the odds of being AMD-positive, and C3a and Bb were associated with smoking. While CFH activity levels were not correlated with AMD, a significant interaction was evident between patient age and CFH activity. Finally, EURs had lower odds of AMD with enhanced copies of rs1536304 (VEGFA) and higher odds with more copy numbers of rs3766404 (CFH).
   Conclusions: Our results support previous studies of systemic complement components being potential biomarkers for AMD, but they suggest that smoking and disease do not synergistically affect complement levels. We also suggest a novel susceptibility and protective haplotypes in the South Carolinian AMD population. Our studies indicate that augmented complement activation associated with advanced AMD could be attributed to a decrease in CFH activity in younger patients.
C1 [Rohrer, Baerbel; Leonard, Anthony; Ward, Tyson; O'Quinn, Elizabeth; Adams, Katherine] Med Univ South Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA.
   [Rohrer, Baerbel] Med Univ South Carolina, Dept Neurosci, Charleston, SC 29425 USA.
   [Rohrer, Baerbel] Ralph H Johnson VA Med Ctr, Div Res, Charleston, SC USA.
   [Frazer-Abel, Ashley] Univ Colorado, Sch Med, Exsera BioLabs, Denver, CO USA.
   [Ratnapriya, Rinki; Pietraszkiewicz, Alexandra; Swaroop, Anand] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD USA.
   [Wolf, Bethany Jacobs] Med Univ South Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA.
C3 Medical University of South Carolina; Medical University of South
   Carolina; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Ralph H Johnson VA Medical Center; University of
   Colorado System; University of Colorado Anschutz Medical Campus;
   University of Colorado Denver; National Institutes of Health (NIH) -
   USA; NIH National Eye Institute (NEI); Medical University of South
   Carolina
RP Rohrer, B (通讯作者)，Med Univ South Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA.
EM rohrer@musc.edu
OI Ratnapriya, Rinki/0000-0002-0469-4631; Leonard,
   Anthony/0000-0001-5904-4874; Wolf, Bethany/0000-0002-7124-5158
FU Department of Veterans Affairs merit award [RX000444, BX003050];
   National Institutes of Health [R01EY019320]; Smart State Endowment of
   the State of South Carolina; Intramural Research Program of the National
   Eye Institute [ZIAEY000546]; South Carolina Clinical & Translational
   Research Institute, Medical University of South Carolina's CTSA,
   NIH/NCRR [UL1RR029882]; Veterans Affairs [I01BX003050, I01RX000444]
   Funding Source: NIH RePORTER
FX The authors thank Drs. E Bowie, J Gross, N Patel and C Grice and the
   student volunteers, J Pire, G Beinbrink and L Crawford for help with
   identifying and recruiting patients and the patients who participated in
   this research making it possible. This work was sponsored in part by a
   Department of Veterans Affairs merit award RX000444 and BX003050 (B.R.),
   a National Institutes of Health grant R01EY019320 (B.R.), the Smart
   State Endowment of the State of South Carolina, the Intramural Research
   Program of the National Eye Institute (ZIAEY000546; A.S.), and the South
   Carolina Clinical & Translational Research Institute, Medical University
   of South Carolina's CTSA, NIH/NCRR Grant Number UL1RR029882.
CR Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fearon DT, 1998, SEMIN IMMUNOL, V10, P355, DOI 10.1006/smim.1998.0137
   Ferreira VP, 2006, J IMMUNOL, V177, P6308, DOI 10.4049/jimmunol.177.9.6308
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gorin MB, 2014, J CLIN MED, V3, P1335, DOI 10.3390/jcm3041335
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hecker LA, 2010, ADV EXP MED BIOL, V703, P49, DOI 10.1007/978-1-4419-5635-4_4
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Holers VM, 2003, CLIN IMMUNOL, V107, P140, DOI 10.1016/S1521-6616(03)00034-2
   Holers VM, 2000, IMMUNOPHARMACOLOGY, V49, P125, DOI 10.1016/S0162-3109(00)80298-2
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Joseph K, 2013, J BIOL CHEM, V288, P12753, DOI 10.1074/jbc.M112.421891
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   KEW RR, 1985, J CLIN INVEST, V75, P1000, DOI 10.1172/JCI111760
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Krilis M, 2017, ONCOTARGET, V8, P49016, DOI 10.18632/oncotarget.14940
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Lois N, 2008, BRIT J OPHTHALMOL, V92, P1304, DOI 10.1136/bjo.2008.141168
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Magen E, 2010, AM J MED SCI, V339, P415, DOI 10.1097/MAJ.0b013e3181d7d496
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Mohamed R, 2018, OPHTHALMOLOGICA, V240, P157, DOI 10.1159/000486403
   MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.bi.57.070188.001541
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Nakanishi H, 2010, INVEST OPHTH VIS SCI, V51, P6183, DOI 10.1167/iovs.09-4948
   Pavlov IY, 2011, CLIN LAB, V57, P225
   Pietraszkiewicz A, 2018, OPHTHALMOLOGY, V125, P398, DOI 10.1016/j.ophtha.2017.10.027
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Saksens NTM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0144367
   Sanchez-Corral P, 2004, MOL IMMUNOL, V41, P81, DOI 10.1016/j.molimm.2004.01.003
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Sharma NK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070193
   Silva AS, 2012, MOL VIS, V18, P2288
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Tan PL, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0079-x
   Told R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060424
   van Asten F, 2018, OPHTHALMOLOGY, V125, P559, DOI 10.1016/j.ophtha.2017.09.023
   VanderBeek BL, 2011, AM J OPHTHALMOL, V152, P273, DOI 10.1016/j.ajo.2011.02.004
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Volokhina EB, 2015, BLOOD, V126, P278, DOI 10.1182/blood-2015-03-637645
   Wehling C, 2017, CLIN EXP IMMUNOL, V187, P304, DOI 10.1111/cei.12890
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Woodell A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067894
   WYATT RJ, 1981, J CLIN LAB IMMUNOL, V6, P131
   Xu XY, 2017, AM J OPHTHALMOL, V175, P87, DOI 10.1016/j.ajo.2016.11.021
   Xu YL, 2008, MOL VIS, V14, P1373
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
NR 61
TC 14
Z9 14
U1 0
U2 3
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD FEB 8
PY 2019
VL 25
BP 79
EP 92
PG 14
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA HL8AN
UT WOS:000458963300001
PM 30820144
DA 2022-11-30
ER

PT J
AU Taylor, DJ
   Jones, L
   Binns, AM
   Crabb, DP
AF Taylor, Deanna J.
   Jones, Lee
   Binns, Alison M.
   Crabb, David P.
TI 'You've got dry macular degeneration, end of story': a qualitative study
   into the experience of living with non-neovascular age-related macular
   degeneration
SO EYE
LA English
DT Article
ID OLDER-ADULTS; VISUAL IMPAIRMENT; LIVED EXPERIENCE; HEALTH-CARE; VISION
   LOSS; CLASSIFICATION; ADJUSTMENT; PATIENT; PEOPLE; IMPACT
AB Background/objectives To investigate the impact of non-neovascular (dry) age-related macular degeneration (AMD) on the person with respect to diagnosis, vision loss and coping strategies. Subjects/methods Volunteers with dry AMD with a range of disease severity were given an eye examination and asked to describe aspects of their experience with dry AMD in a semi-structured interview. Interviews were audio-recorded, transcribed, and subjected to Framework analysis. Overarching themes were pre-defined, whilst subthemes were derived from the data. Results Twenty-seven participants (81% female), with early (n = 3), intermediate (n = 16) and advanced dry AMD (GA; n = 8) were interviewed. Median (interquartile range) age (years), logMAR binocular visual acuity and Pelli-Robson contrast sensitivity were 76 (71, 80), 0.2 (0.18, 0.40) and 1.65 (1.35, 1.93), respectively. Overarching themes (and subthemes) were: diagnosis (relationship with healthcare professional, psychological impact of diagnosis, and knowledge of AMD, both pre- and post-diagnosis), impact of visual loss (functional and psychological) and coping strategies (help from others and personal strategies). Many participants reported feelings of distress at the time of diagnosis and, particularly noteworthy, several reported a constant fear of their condition worsening. Conclusions Dry AMD, for which there is currently no treatment, can have a significant impact on individuals, even in its early stages, before significant functional vision loss is manifest, as well as in its intermediate and advanced stages. Results from this study offer important insight into the experience of living with dry AMD not previously explored. Moreover, the results have the potential to serve as an educational resource for eyecare professionals.
C1 [Taylor, Deanna J.; Jones, Lee; Binns, Alison M.; Crabb, David P.] Univ London, Sch Hlth Sci, Div Optometry & Visual Sci, Northampton Sq, London EC1V 0HB, England.
C3 University of London
RP Crabb, DP (通讯作者)，Univ London, Sch Hlth Sci, Div Optometry & Visual Sci, Northampton Sq, London EC1V 0HB, England.
EM David.Crabb.1@city.ac.uk
OI Crabb, David/0000-0001-8754-3902
FU Roche Products Ltd.
FX This study was funded as part of an unrestricted investigator-initiated
   research grant from Roche Products Ltd. UK. The sponsor or funding
   organisation had no role in the design of the study, collection and
   analysis of data and decision to publish.
CR Boxell EM, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-012790
   Boyle J, 2015, PSYCHOL HEALTH MED, V20, P296, DOI 10.1080/13548506.2014.936886
   Brown Melissa M., 2001, International Ophthalmology, V24, P123, DOI 10.1023/A:1021171000838
   Burton AE, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003306
   Burton AE, 2015, J HEALTH PSYCHOL, V20, P1285, DOI 10.1177/1359105313511134
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Cimarolli VR, 2012, CLIN REHABIL, V26, P748, DOI 10.1177/0269215511429162
   Cross V, 2009, CLIN OPHTHALMOL, V3, P1
   Dean S, 2017, BRIT J OPHTHALMOL, V101, P700, DOI 10.1136/bjophthalmol-2016-309955
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Gillespie-Gallery H, 2012, EYE, V26, P1302, DOI 10.1038/eye.2012.141
   Glen FC, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0119-7
   Glen FC, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-003996
   Hirneiss C, 2014, CLIN OPHTHALMOL, V8, P1703, DOI 10.2147/OPTH.S64200
   Hodge S, 2015, BRIT J VISUAL IMPA, V33, P200, DOI 10.1177/0264619615596198
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Jampel HD, 2007, AM J OPHTHALMOL, V144, P238, DOI 10.1016/j.ajo.2007.04.048
   Janz NK, 2001, OPHTHALMOLOGY, V108, P887, DOI 10.1016/S0161-6420(00)00624-2
   Jones RK, 2017, EYE, V31, P1117, DOI 10.1038/eye.2017.49
   Kleinschmidt JJ, 1999, J VISUAL IMPAIR BLIN, V93, P69, DOI 10.1177/0145482X9909300202
   Kotecha A, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009463
   Lacey J, 2009, EYE, V23, P924, DOI 10.1038/eye.2008.103
   Margrain TH, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-57
   Martin EB, 2015, PATIENT EDUC COUNS, V98, P1248, DOI 10.1016/j.pec.2015.07.031
   McCloud C, 2015, EYE, V29, P1561, DOI 10.1038/eye.2015.167
   McCloud C, 2014, OPTOMETRY VISION SCI, V91, P966, DOI 10.1097/OPX.0000000000000320
   McKeague C, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-246
   Mishra A, 2018, J SURG EDUC, V75, P417, DOI 10.1016/j.jsurg.2017.08.011
   Moore LW, 2000, WESTERN J NURS RES, V22, P571, DOI 10.1177/01939450022044601
   Moore LW, 2005, APPL NURS RES, V18, P110, DOI 10.1016/j.apnr.2004.06.014
   Moore LW, 2003, J ADV NURS, V43, P10
   Norwell C, 2005, INT C SER, V1282, P226
   Owsley C, 2006, REHABIL PSYCHOL, V51, P23, DOI 10.1037/0090-5550.51.1.23
   Pope C, 2000, BMJ-BRIT MED J, V320, P114, DOI 10.1136/bmj.320.7227.114
   Rubin GS, 2000, INVEST OPHTH VIS SCI, V41, P3327
   Smith TM, 2008, J VISUAL IMPAIR BLIN, V102, P725
   Stanford P, 2009, BRIT J VISUAL IMPA, V27, P129, DOI 10.1177/0264619609102216
   Subramanian A, 2012, INVEST OPHTHALMOL, V53, P4407
   Taylor DJ, 2018, OPHTHAL PHYSL OPT, V38, P98, DOI 10.1111/opo.12419
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042
   Varano M, 2016, CLIN OPHTHALMOL, V10, P257, DOI 10.2147/OPTH.S92616
   Wong EYH, 2004, J VISUAL IMPAIR BLIN, V98, P629, DOI 10.1177/0145482X0409801007
NR 44
TC 20
Z9 20
U1 1
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAR
PY 2020
VL 34
IS 3
BP 461
EP 473
DI 10.1038/s41433-019-0445-8
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA KO6UU
UT WOS:000515686100009
PM 31118490
OA Green Published, Green Accepted, hybrid
DA 2022-11-30
ER

PT J
AU Tomany, SC
   Cruickshanks, KJ
   Klein, R
   Klein, BEK
   Knudtson, MD
AF Tomany, SC
   Cruickshanks, KJ
   Klein, R
   Klein, BEK
   Knudtson, MD
TI Sunlight and the 10-year incidence of age-related maculopathy - The
   Beaver Dam eye study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; 5-YEAR INCIDENCE; VISUAL-ACUITY; PREVALENCE;
   EXPOSURE; RISK; PROGRESSION; POPULATION; LIGHT
AB Objective: To examine the association of sunlight exposure and indicators of sun sensitivity with the 10-year incidence of age-related maculopathy (ARM).
   Design: Population-based cohort study.
   Participants: We included persons aged 43 to 86 years at the baseline examination from 1988 to 1990, living in Beaver Dam, Wis, of whom 3684 persons underwent 5-year follow-up and 2764 underwent 10-year follow-up.
   Methods: Data on sun exposure and indicators of sun sensitivity were obtained from a standardized questionnaire administered at baseline and/or follow-up. We determined ARM status by grading stereoscopic color fundus photographs using the Wisconsin Age-Related Maculopathy Grading System.
   Main Outcome Measures: Incidence and progression of ARM.
   Results: While controlling for age and sex, we found that participants exposed to the summer sun for more than 5 hours a day during their teens, in their 30s, and at the baseline examination were at a higher risk of developing increased retinal pigment (risk ratio [RR], 3.17; 95% confidence interval [CI], 1.24-8.11; P=.01) and early ARM (RR, 2.14; 95% CI, 0.99-4.61; P=.05) by 10 years than those exposed less than 2 hours per day during the same periods. In participants reporting the highest summer sun exposure levels in their teens and 30s, the use of hats and sunglasses at least half the time during the same periods was associated with a decreased risk of developing soft indistinct drusen (RR, 0.55; 95% CI, 0.33-0.90; P=.02) and retinal pigment epithelial depigmentation (RR, 0.51; 95% CI, 0.29-0.91; P=.02). Participants who experienced more than 10 severe sunburns during their youth were more likely than those who experienced 1 or no burn to develop drusen with a 250-mum diameter or larger (RR, 2.52; 95% CI, 1.29-1.71; P=.01) by the 10-year examination. No relationships were found between UV-B exposure, winter leisure time spent outdoors, skin sun sensitivity, or number of bad sunburns experienced by the time of the baseline examination and the 10-year incidence and progression of ARM or its associated lesions.
   Conclusions: Few significant relationships between environmental exposure to light and the 10-year incidence and progression of ARM were found in the Beaver Dam Eye Study. Consistent with results from the baseline and 5-year follow-up examinations, significant associations were found between extended exposure to the summer sun and the 10-year incidence of early ARM and increased retinal pigment. A protective effect of hat and sunglasses use by participants while in their teens and 30s against the 10-year incidence of soft indistinct drusen and retinal pigment epithelial depigmentation was also found, but only in those who reported the highest amount of sun exposure during the same periods.
C1 Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   Univ Wisconsin, Sch Med, Dept Populat Hlth Sci, Madison, WI 53726 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison
RP Klein, R (通讯作者)，Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, 610 N Walnut St,450 WARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
OI Ferris, Frederick/0000-0002-4933-0639
FU NEI NIH HHS [EY 06594] Funding Source: Medline
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Augustin AJ, 2002, KLIN MONATSBL AUGENH, V219, P631, DOI 10.1055/s-2002-35164
   BORGES J, 1990, ARCH OPHTHALMOL-CHIC, V108, P727, DOI 10.1001/archopht.1990.01070070113047
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   HAM WT, 1982, AM J OPHTHALMOL, V93, P299, DOI 10.1016/0002-9394(82)90529-3
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   HOSMER DW, 1989, APPL LOGISTIC REGRES, P90
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1991, 91149823AS NTIS PB
   KLEIN R, 1995, 95273827 NTIS PB
   KLEIN R, 1991, 91184267AS NTIS PB
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   MYERS SM, 1994, T AM OPHTHAL SOC, V92, P775
   Roberts JE, 2001, J PHOTOCH PHOTOBIO B, V64, P136, DOI 10.1016/S1011-1344(01)00196-8
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Tielsch JA, 1995, VISION PROBLEMS US R, P1
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Winkler BS, 1999, MOL VIS, V5
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
NR 40
TC 195
Z9 224
U1 1
U2 22
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAY
PY 2004
VL 122
IS 5
BP 750
EP 757
DI 10.1001/archopht.122.5.750
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 819TU
UT WOS:000221339400010
PM 15136324
OA Bronze
DA 2022-11-30
ER

PT J
AU Sii, S
   Aspinall, P
   Borooah, S
   Dhillon, B
AF Sii, S.
   Aspinall, P.
   Borooah, S.
   Dhillon, B.
TI Exploring factors predicting changes in patients' expectations and
   psychosocial issues during the course of treatment with intravitreal
   injections for wet age-related macular degeneration
SO EYE
LA English
DT Article
ID RANIBIZUMAB; OUTCOMES; POPULATION; MODELS; CARE; EYE; UK
AB Purpose Patients with wet age-related macular degeneration (AMD) often require long courses of treatment. We investigate the psychosocial issues that could hinder compliance, including patient expectations of treatment. The aims of this study were to explore the factors related to changes in patient expectations, pain, and anxiety during treatment.
   Patients and methods A structured interview was carried out among 50 patients selected from the list attending the AMD unit at the Princess Alexandra Eye Pavilion (PAEP). The interview was based on a questionnaire. Additionally, a visual analogue scale was created as a tool for measuring patient expectations, pain, and anxiety. Data were analysed using multinomial regression analysis.
   Results There were significantly more patients who had a fall in expectations (P<0.05) during the course of treatment. A fall in expectations was found to be predicted by higher starting expectations (P=0.00001), greater decline in visual acuity (P= 0.008), and perceived deterioration of vision after starting treatment (P=0.013). Of the patients, 32% planned to stop attending for further injections. Planning to stop attending was correlated with worse final visual acuity (P=0.026, 95% CI). Pain and anxiety with intravitreal therapy (IVT) was significantly reduced when patients were accompanied to the clinic by a friend or relative (P<0.01) using Pearson's correlation (r= 0.597).
   Conclusion Patients require appropriate counselling at the start of a course of treatment to align expectations with perceived treatment outcomes in order to improve adherence. Additionally, a large minority of patients would consider stopping treatment. Patients' expectations should be assessed at relevant time points along a course of treatment.
C1 [Sii, S.] Royal Victoria Hosp, Dept Ophthalmol, 274 Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.
   [Aspinall, P.] Univ Edinburgh, Edinburgh, Midlothian, Scotland.
   [Aspinall, P.] Heriot Watt Univ, Royal Acad Engn Ctr Excellence Sustainable Bldg D, Sch Energy Geosci Infrastruct & Soc, Edinburgh, Midlothian, Scotland.
   [Borooah, S.] Shiley Eye Inst, La Jolla, CA USA.
   [Borooah, S.; Dhillon, B.] Univ Edinburgh, Sch Clin Sci, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland.
   [Dhillon, B.] Ophthalmol, Princess Alexandra Eye Pavil, Edinburgh, Midlothian, Scotland.
C3 University of Edinburgh; Heriot Watt University; University of Edinburgh
RP Sii, S (通讯作者)，Royal Victoria Hosp, Dept Ophthalmol, 274 Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.
EM samanthasii@doctors.org.uk
RI Borooah, Shyamanga/AAM-6581-2021
CR Basheer K, 2015, CLIN OPHTHALMOL, V9, P959, DOI 10.2147/OPTH.S76754
   Boyle J, 2015, PSYCHOL HEALTH MED, V20, P296, DOI 10.1080/13548506.2014.936886
   Chen XJ, 2012, J OCUL PHARMACOL TH, V28, P414, DOI 10.1089/jop.2011.0257
   Chua PYS, 2009, ARCH OPHTHALMOL-CHIC, V127, P939, DOI 10.1001/archophthalmol.2009.139
   Colenbrander A., 2002, P INT COUNC OPHTH 29
   Crossland M., 2007, VISUAL IMPAIRMENT RE, V9, P59, DOI DOI 10.1080/13882350701643582
   Jacob J, 2017, INT J OPHTHALMOL-CHI, V10, P81, DOI 10.18240/ijo.2017.01.14
   Joussen AM, 2007, SURV OPHTHALMOL, V52, P266, DOI 10.1016/j.survophthal.2007.02.010
   Keenan TDL, 2012, BRIT J OPHTHALMOL, V96, P413, DOI 10.1136/bjophthalmol-2011-300338
   Lange C, 2009, GRAEF ARCH CLIN EXP, V247, P137, DOI 10.1007/s00417-008-0926-0
   Magidson J, 2001, SOCIOL METHODOL, V31, P223, DOI 10.1111/0081-1750.00096
   Malik ANJ, 2013, BRIT J OPHTHALMOL, V97, P553, DOI 10.1136/bjophthalmol-2012-302067
   McCloud C, 2015, EYE, V29, P1561, DOI 10.1038/eye.2015.167
   Minassian DC, 2011, BRIT J OPHTHALMOL, V95, P1433, DOI 10.1136/bjo.2010.195370
   Mitchell J, 2002, BRIT J OPHTHALMOL, V86, P777, DOI 10.1136/bjo.86.7.777
   Mitchell J, 2007, QUAL LIFE RES, pA120
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Schmier JK, 2016, PHARMACOECONOMICS, V34, P259, DOI 10.1007/s40273-015-0347-y
   Segal O, 2016, ACTA OPHTHALMOL, V94, P203, DOI 10.1111/aos.12802
   Shalaby AK, 2016, EYE, V30, P1404, DOI 10.1038/eye.2016.154
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Zhu MD, 2015, GRAEF ARCH CLIN EXP, V253, P1217, DOI 10.1007/s00417-014-2799-8
NR 24
TC 14
Z9 14
U1 1
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD APR
PY 2018
VL 32
IS 4
BP 673
EP 678
DI 10.1038/eye.2017.271
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GD0XL
UT WOS:000430224300002
PM 29219960
OA Bronze, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Cheung, CMG
   Yanagi, Y
   Akiba, M
   Tan, A
   Mathur, R
   Chan, CM
   Yeo, I
   Wong, TY
AF Cheung, Chui Ming Gemmy
   Yanagi, Yasuo
   Akiba, Masahiro
   Tan, Anna
   Mathur, Ranjana
   Chan, Choi Mun
   Yeo, Ian
   Wong, Tien Y.
TI IMPROVED DETECTION AND DIAGNOSIS OF POLYPOIDAL CHOROIDAL VASCULOPATHY
   USING A COMBINATION OF OPTICAL COHERENCE TOMOGRAPHY AND OPTICAL
   COHERENCE TOMOGRAPHY ANGIOGRAPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; polypoidal choroidal vasculopathy; en
   face optical coherence tomography angiography (OCTA); cross-sectional
   OCTA
ID INDOCYANINE GREEN ANGIOGRAPHY; MACULAR DEGENERATION; FLUORESCEIN
   ANGIOGRAPHY; NEOVASCULARIZATION; RANIBIZUMAB; SPECIFICITY; THERAPY;
   EVEREST
AB Purpose: To assess the ability of optical coherence tomography (OCT) alone and in combination with OCT angiography (OCTA) to differentiate polypoidal choroidal vasculopathy (PCV) from neovascular age-related macular degeneration, as compared to fluorescein angiography and indocyanine green angiography.
   Methods: This is a cross-sectional study. All participants had a standardized history, clinical examination including measurement of best-corrected visual acuity, slit-lamp biomicroscopy, and indirect fundus examination, and underwent standardized imaging (color photography, fluorescein and indocyanine green angiography, OCT, and OCTA) after predefined protocols. We used a 2-step approach (Step 1: spectral domain OCT; Step 2: addition of OCTA) combining structural OCT and OCTA to differentiate 50 treatment-naive eyes with PCV, choroidal neovascularization, and retinal angiomatous proliferation and compared with the diagnosis based on fluorescein angiography and indocyanine green angiography. Spectral domain OCT signs used to diagnose PCV included presence of two out of three of any retinal pigment epithelium detachment (pigment epithelial detachment/double-layer sign), notched or narrow-peaked pigment epithelial detachment, or round subretinal pigment epithelium structure. Optical coherence tomography angiography signs used to diagnose PCV included presence of a localized subretinal pigment epithelium hyperflow signal in the cross-sectional OCTA and/or presence of a focal hyperflow sign in en face OCTA based on outer retina slab.
   Results: Based on fluorescein angiography and indocyanine green angiography, the diagnosis was choroidal neovascularization in 24 eyes, PCV in 23 eyes, and retinal angiomatous proliferation in 3 eyes. Based on spectral domain OCT signs, PCV was diagnosed in 19/23 (82.6%) eyes; however, specificity of OCT was only 51.9%. Cross-sectional OCTA showed a diffuse hyperflow signal in all 24 (100.0%) eyes with choroidal neovascularization, whereas a localized subretinal pigment epithelium hyperflow signal was detected in 19/23 (82.6%) eyes with PCV. En face OCTA only detected a nodular hyperflow signal in 10/23 eyes (43.5%) with PCV. Combination of OCT and OCTA achieved 82.6% sensitivity and 100.0% specificity for differentiating PCV from choroidal neovascularization/retinal angiomatous proliferation.
   Conclusion: Cross-sectional OCTA is more sensitive than en face OCTA in detecting flow signal in polyps. Combination of structural OCT and OCTA can be used to screen for PCV with a high level of sensitivity and specificity.
C1 [Cheung, Chui Ming Gemmy; Yanagi, Yasuo; Tan, Anna; Mathur, Ranjana; Chan, Choi Mun; Yeo, Ian; Wong, Tien Y.] Singapore Natl Eye Ctr, Med Retina Serv, Singapore, Singapore.
   [Akiba, Masahiro] Topcon Corp, Tokyo, Japan.
C3 Singapore National Eye Center; Topcon Corporation
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 438795, Singapore.
EM gemmy.cheung.c.m@singhealth.com.sg
RI Wong, Tien Yin/AAC-9724-2020; Yanagi, Yasuo/AAA-5441-2022; Yanagi,
   Yasuo/AAF-2670-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Yanagi, Yasuo/0000-0002-0362-7285;
   Cheung, Chui Ming Gemmy/0000-0003-3358-3516
CR Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Cheung CMG, 2017, RETINA-J RET VIT DIS, V37, P1464, DOI 10.1097/IAE.0000000000001391
   Cheung CMG, 2015, RETINA-J RET VIT DIS, V35, P1375, DOI 10.1097/IAE.0000000000000482
   Cheung CMG, 2014, RETINA-J RET VIT DIS, V34, P2397, DOI 10.1097/IAE.0000000000000255
   Chi YT, 2017, JAMA OPHTHALMOL, V135, P1310, DOI 10.1001/jamaophthalmol.2017.4360
   Coscas F, 2016, AM J OPHTHALMOL, V161, P160, DOI 10.1016/j.ajo.2015.10.008
   Coscas F, 2012, RETINA-J RET VIT DIS, V32, P1069, DOI 10.1097/IAE.0b013e318240a529
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Iacono P, 2014, OPHTHALMIC RES, V52, P25, DOI 10.1159/000358331
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Rebhun CB, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.6.4
   Saito M, 2008, RETINA-J RET VIT DIS, V28, P459, DOI 10.1097/IAE.0b013e318156db60
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Takayama K, 2017, EYE, V31, P45, DOI 10.1038/eye.2016.232
   Tan ACS, 2018, EYE, V32, P262, DOI 10.1038/eye.2017.181
   Tanaka K, 2017, BRIT J OPHTHALMOL, V101, P51, DOI 10.1136/bjophthalmol-2016-309264
   Teo KYC, 2017, RETINA
   Ting DSW, 2017, JAMA OPHTHALMOL, V135, P306, DOI 10.1001/jamaophthalmol.2016.5877
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   Tsai ASH, 2017, SURV OPHTHALMOL, V62, P462, DOI 10.1016/j.survophthal.2017.01.008
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 33
TC 26
Z9 29
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2019
VL 39
IS 9
BP 1655
EP 1663
DI 10.1097/IAE.0000000000002228
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KC9EB
UT WOS:000507473000005
PM 29927796
DA 2022-11-30
ER

PT J
AU Lamoureux, EL
   Pallant, JF
   Pesudovs, K
   Tennant, A
   Rees, G
   O'Connor, PM
   Keeffe, JE
AF Lamoureux, Ecosse L.
   Pallant, Julie F.
   Pesudovs, Konrad
   Tennant, Alan
   Rees, Gwyn
   O'Connor, Patricia M.
   Keeffe, Jill E.
TI Assessing participation in daily living and the effectiveness of
   rehabiliation in age related macular degeneration patients using the
   impact of vision impairment scale
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE AMD; participation in daily living; quality of life; Rasch analysis
ID QUALITY-OF-LIFE; CATARACT-SURGERY; VISUAL FUNCTION; RASCH;
   QUESTIONNAIRE; DEPRESSION; OUTCOMES; LIKERT; INDEX
AB Purpose: To assess if the Impact of Vision Impairment (IVI) is a valid instrument to measure participation in daily activities and rehabilitation in patients with age-related macular degeneration (AMD) and varying levels of visual impairment. Methods: Participants, recruited from a public eye hospital and low vision centers, completed the IVI questionnaire. The IVI and its three subscales were assessed for fit to the Rasch model. Unidimensionality, item fit, response category performance, and targeting of items to patients were assessed. Confirmatory factor analysis (CFA) was used to assess the three-factor model of the IVI in this sample of AMD patients. Results: 219 patients (mean SD age = 83.5 7.4 yr) were recruited. Of these, 22%, 55% and 23% had mild ( 6/12-6/18), moderate ( 6/18-6/60) and severe ( 6/60) vision loss, respectively. The IVI total and three subscales displayed discrete thresholds indicating that the respondents understood the response categories. The IVI items fitted the scale and unidimensionality was established. Person separation reliability for the IVI score was substantial (0.94) indicating that the scale can discriminate between several groups of AMD patients. The IVI items were significantly targeted to the AMD patients with the means of the two distributions shown to be very close (0.0 and 0.1, respectively). Substantial targeting was also evident for the subscales. Poorer visual acuity was significantly associated (ANOVA; F (2, 216) = 23.4; p 0.001) with greater restriction of participation suggesting that the IVI has substantial construct validity. CFA supported the IVI three-factor model which includes items from the "emotional well-being, "reading and accessing information" and "mobility and independence" subscales. Conclusions: Clinicians and researchers can reliably use the IVI to assess the impact on daily life and the effectiveness of clinical trials and rehabilitation interventions in patients with AMD across a range of vision loss.
C1 [Lamoureux, Ecosse L.; Rees, Gwyn; O'Connor, Patricia M.; Keeffe, Jill E.] Univ Melbourne, Ctr Eye Res Australia, Dept Ophthalmol, Melbourne, Vic 3002, Australia.
   [Lamoureux, Ecosse L.; O'Connor, Patricia M.; Keeffe, Jill E.] Vis CRC Sydney, Sydney, NSW, Australia.
   [Pallant, Julie F.; O'Connor, Patricia M.; Keeffe, Jill E.] Univ Melbourne, Sch Rural Hlth, Parkville, Vic 3052, Australia.
   [Pesudovs, Konrad] Flinders Med Ctr, Adelaide, SA, Australia.
   [Pesudovs, Konrad] Flinders Univ S Australia, NH&MRC Ctr Clin Eye Res, Adelaide, SA 5001, Australia.
   [Tennant, Alan] Univ Leeds, Fac Med & Hlth, Dept Rehabil Med, Leeds LS2 9JT, W Yorkshire, England.
C3 Centre for Eye Research Australia; University of Melbourne; University
   of Melbourne; Flinders Medical Centre; Flinders University South
   Australia; University of Leeds
RP Lamoureux, EL (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, Dept Ophthalmol, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM ecosse@unimelb.edu.au
RI Lamoureux, Ecosse/Z-5482-2019; Pesudovs, Konrad/T-9403-2019
OI Pesudovs, Konrad/0000-0002-6322-9369
CR Andrich D, 2003, RUMM 2020
   BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.88.3.588
   Byrne B. M., 2001, MULTIVARIATE APPL BO
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Frost N A, 1998, Ophthalmic Epidemiol, V5, P185, DOI 10.1076/opep.5.4.185.4191
   Garamendi E, 2006, VISION RES, V46, P1375, DOI 10.1016/j.visres.2005.07.007
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hair J. F., 2005, MULTIVARIATE DATA AN, V6th
   Hart PM, 1999, BRIT J OPHTHALMOL, V83, P1115, DOI 10.1136/bjo.83.10.1115
   Hassan SE, 2002, OPTOMETRY VISION SCI, V79, P697, DOI 10.1097/00006324-200211000-00007
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Heier JS, 2006, OPHTHALMOLOGY, V113, pe1, DOI DOI 10.1016/J.0PHTHA.2005.10.052)
   HEIER JS, 2006, OPHTHALMOLOGY, V113, P642
   Klein BEK, 2003, OPHTHALMOLOGY, V110, P644, DOI 10.1016/S0161-6420(02)01935-8
   Kline R. B., 1998, METHODOLOGY SOCIAL S, DOI DOI 10.1016/j.ecolecon.2004.11.002
   Lamoureux EL, 2007, OPTOMETRY VISION SCI, V84, P683, DOI 10.1097/OPX.0b013e31812f755f
   Lamoureux EL, 2007, OPTOMETRY VISION SCI, V84, P789, DOI 10.1097/OPX.0b013e3181334b83
   Lamoureux EL, 2007, INVEST OPHTH VIS SCI, V48, P1476, DOI 10.1167/iovs.06-0610
   Lamoureux EL, 2007, INVEST OPHTH VIS SCI, V48, P1001, DOI 10.1167/iovs.06-0361
   Lamoureux EL, 2006, INVEST OPHTH VIS SCI, V47, P4732, DOI 10.1167/iovs.06-0220
   Linacre J., 2002, USERS GUIDE WINSTEPS
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   MASTERS GN, 1982, PSYCHOMETRIKA, V47, P149, DOI 10.1007/BF02296272
   McGwin G, 2000, ACCIDENT ANAL PREV, V32, P735, DOI 10.1016/S0001-4575(99)00123-2
   Mitchell J, 2002, BRIT J OPHTHALMOL, V86, P777, DOI 10.1136/bjo.86.7.777
   Mitchell Jan, 2005, Health Qual Life Outcomes, V3, P25, DOI 10.1186/1477-7525-3-25
   Norquist JM, 2004, MED CARE, V42, P25, DOI 10.1097/01.mlr.0000103530.13056.88
   OShea JG, 1996, MED J AUSTRALIA, V165, P561, DOI 10.5694/j.1326-5377.1996.tb138643.x
   Pesudovs K, 2004, OPTOMETRY VISION SCI, V81, P769, DOI 10.1097/00006324-200410000-00009
   Pesudovs K, 2003, INVEST OPHTH VIS SCI, V44, P2892, DOI 10.1167/iovs.02-1075
   Pesudovs Konrad, 2006, BMC Ophthalmol, V6, P25, DOI 10.1186/1471-2415-6-25
   Rasch G., 1993, PROBABILISTIC MODELS
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Rovner BW, 2001, J AM GERIATR SOC, V49, P1097, DOI 10.1046/j.1532-5415.2001.49215.x
   Smith Everett V Jr, 2002, J Appl Meas, V3, P205
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   Tennant A, 2004, VALUE HEALTH, V7, pS22, DOI 10.1111/j.1524-4733.2004.7s106.x
   TENNANT A, 2006, RASCH MEASUREMENT T, V20, P1
   VANALPHEN A, 1994, J ADV NURS, V20, P196
   Weih LM, 2002, INVEST OPHTH VIS SCI, V43, P927
NR 43
TC 40
Z9 40
U1 1
U2 13
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD MAR-APR
PY 2008
VL 15
IS 2
BP 105
EP 113
DI 10.1080/09286580701840354
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 292NU
UT WOS:000255274200006
PM 18432494
DA 2022-11-30
ER

PT J
AU Hernandez-Moreno, L
   Senra, H
   Moreno, N
   Macedo, AF
AF Hernandez-Moreno, Laura
   Senra, Hugo
   Moreno, Natacha
   Macedo, Antonio Filipe
TI Is perceived social support more important than visual acuity for
   clinical depression and anxiety in patients with age-related macular
   degeneration and diabetic retinopathy?
SO CLINICAL REHABILITATION
LA English
DT Article
DE Depression; anxiety; social support; age-related eye disease
AB Objective:
   To investigate whether visual acuity has the same importance as a factor of depression and anxiety comparing with other psychological variables, particularly perceived social support, in patients diagnosed with age-related eye diseases, with and without low vision.
   Design:
   Observational cross-sectional study.
   Setting:
   Patients attending outpatient appointments at the department of ophthalmology of a general hospital in Portugal.
   Subjects:
   Patients with age-related macular degeneration and patients with diabetic retinopathy attending routine hospital appointments were recruited for this study.
   Measures:
   Anxiety and depression were measured using the hospital anxiety and depression scale and perceived social support using the multidimensional scale of perceived social support. Visual acuity was measured with ETDRS charts.
   Results:
   Of the 71 patients, 53 (75%) were diagnosed with diabetic retinopathy, 37 (52%) were female and age (mean +/- SD) was 69 +/- 12 years. Acuity in the better seeing eye was 0.41 +/- 0.33 logMAR. The mean anxiety score was 4.38 +/- 3.82 and depression 4.41 +/- 3.39. Clinically significant levels of anxiety were found in 21% (n = 15) of the participants and depression in 18%(n = 13). The total social support score was 5.29 +/- 0.61. Significant multivariate regression models were found for anxiety (R-2 = 0.21, P = 0.016) and for depression (R-2 = 0.32, P < 0.0001). Social support was independently associated with levels of anxiety and with levels of depression. Gender was independently associated with levels of anxiety.
   Conclusion:
   This study suggests that patients' perceived social support might be more important than visual acuity as a factor of clinical depression and anxiety in a sample of age-related eye disease patients.
C1 [Hernandez-Moreno, Laura; Macedo, Antonio Filipe] Univ Minho, Low Vis & Visual Rehabil Lab, Dept & Ctr Phys Optometry & Vis Sci, Braga, Portugal.
   [Senra, Hugo] Univ Coimbra, Ctr Res Neuropsychol & Cognit & Behav Intervent C, P-3000115 Coimbra, Portugal.
   [Senra, Hugo] Univ Essex, Sch Hlth & Social Care, Wivenhoe Pk, Colchester CO4 3SQ, Essex, England.
   [Moreno, Natacha] Hosp Santa Maria Maior EPE, Braga, Portugal.
   [Macedo, Antonio Filipe] Linnaeus Univ, Dept Med & Optometry, Norra Kajplan 6, S-39182 Kalmar, Sweden.
C3 Universidade do Minho; Universidade de Coimbra; University of Essex;
   Linnaeus University
RP Senra, H (通讯作者)，Univ Coimbra, Ctr Res Neuropsychol & Cognit & Behav Intervent C, P-3000115 Coimbra, Portugal.; Senra, H (通讯作者)，Univ Essex, Sch Hlth & Social Care, Wivenhoe Pk, Colchester CO4 3SQ, Essex, England.; Macedo, AF (通讯作者)，Linnaeus Univ, Dept Med & Optometry, Norra Kajplan 6, S-39182 Kalmar, Sweden.
EM antonio.macedo@lnu.se
RI Macedo, Antonio/I-8108-2013
OI Macedo, Antonio/0000-0003-3436-2010; Senra, Hugo/0000-0001-8054-6473
FU FCT [UID/FIS/04650/2013]; Essilor Portugal Lda
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This work
   was partially supported by Essilor Portugal Lda and FCT Strategic
   Funding UID/FIS/04650/2013.
CR Chang YC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128356
   Chou KL, 2007, J AFFECT DISORDERS, V102, P115, DOI 10.1016/j.jad.2006.12.013
   Coffey L, 2009, DIABETIC MED, V26, P1063, DOI 10.1111/j.1464-5491.2009.02802.x
   Cosh S, 2018, INT J GERIATR PSYCH, V33, P598, DOI 10.1002/gps.4827
   Dawson SR, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-78
   Fenwick E, 2012, CLIN EXP OPHTHALMOL, V40, P27, DOI 10.1111/j.1442-9071.2011.02599.x
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Frank CR, 2019, JAMA OPHTHALMOL, V137, P793, DOI 10.1001/jamaophthalmol.2019.1085
   Golden SH, 2008, JAMA-J AM MED ASSOC, V299, P2751, DOI 10.1001/jama.299.23.2751
   Hackett ML, 2014, INT J STROKE, V9, P1017, DOI 10.1111/ijs.12357
   Hernandez-Moreno L, 2020, OPHTHAL PHYSL OPT, V40, P350, DOI 10.1111/opo.12665
   Kan C, 2013, DIABETES CARE, V36, P480, DOI 10.2337/dc12-1442
   Macedo AF, 2017, ACTA OPHTHALMOL, V95, pe783, DOI 10.1111/aos.13430
   Noh JW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166238
   Ozbay Fatih, 2007, Psychiatry (Edgmont), V4, P35
   Pais-Ribeiro J, 2007, Psychol Health Med, V12, P225, DOI 10.1080/13548500500524088
   Papadopoulos K, 2014, RES DEV DISABIL, V35, P1734, DOI 10.1016/j.ridd.2014.02.019
   Pereira J.M., 2011, PSYCHOLOGICA-COIMBRA, V54, P331, DOI [DOI 10.14195/1647-8606_54_13, 10.14195/1647-8606_54_13]
   Schoevers RA, 2005, AM J GERIAT PSYCHIAT, V13, P31, DOI 10.1176/appi.ajgp.13.1.31
   Senra H, 2017, AM J OPHTHALMOL, V177, P213, DOI 10.1016/j.ajo.2017.03.005
   Senra H, 2016, GRAEF ARCH CLIN EXP, V254, P1873, DOI 10.1007/s00417-016-3384-0
   Senra H, 2015, OPHTHALMOLOGY, V122, P851, DOI 10.1016/j.ophtha.2014.10.022
   Shi Y, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00218
   Simning A, 2020, INT J GERIATR PSYCH, V35, P80, DOI 10.1002/gps.5221
   Singh R, 2009, CLIN REHABIL, V23, P281, DOI 10.1177/0269215508094710
   Sturrock BA, 2016, INVEST OPHTH VIS SCI, V57, P3032, DOI 10.1167/iovs.16-19110
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Vink D, 2008, J AFFECT DISORDERS, V106, P29, DOI 10.1016/j.jad.2007.06.005
   Wang YW, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00022
   Wang Z, 2019, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00761
   Williams R, 2004, DISABIL REHABIL, V26, P862, DOI 10.1080/09638280410001708878
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zheng YJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep46453
   Zurcher C, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0206069
NR 34
TC 8
Z9 8
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0269-2155
EI 1477-0873
J9 CLIN REHABIL
JI Clin. Rehabil.
PD SEP
PY 2021
VL 35
IS 9
BP 1341
EP 1347
AR 0269215521997991
DI 10.1177/0269215521997991
EA MAR 2021
PG 7
WC Rehabilitation
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Rehabilitation
GA TZ1WI
UT WOS:000631214100001
PM 33657906
OA Green Published, hybrid, Green Accepted
DA 2022-11-30
ER

PT J
AU Bonyadi, M
   Bonyadi, MHJ
   Yaseri, M
   Mohammadian, T
   Fotouhi, N
   Javadzadeh, A
   Soheilian, M
AF Bonyadi, Mortaza
   Bonyadi, Mohammad Hossein Jabbarpoor
   Yaseri, Mehdi
   Mohammadian, Tahereh
   Fotouhi, Nikou
   Javadzadeh, Alireza
   Soheilian, Masoud
TI Joint association of complement component 3 and CC-cytokine Iigand2
   (CCL2) or complement component 3 and CFH polymorphisms in age-related
   macular degeneration
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Age-related macular degeneration (AMD); C3 rs2230199 (R102G); CCL2-2518
   (rs1024611); CFH Y402H rs1061170; genetic polymorphism; synergistic
   association
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; R102G POLYMORPHISM; GENE; RISK;
   POPULATION; EXPRESSION; VARIANT; MCP-1
AB Background: To determine the joint effect of complement component 3(C3 R102G) with CC-cytokine Iigand2 (CCL2-2518) or complement factor H (CFH) Y402H polymorphisms on advanced age-related macular degeneration (AMD).
   Methods: In this case-control study, 233 patients with advanced AMD and 159 unrelated healthy controls enrolled for evaluation. Selected polymorphisms were determined by polymerase chain reaction and restriction fragment length polymorphism.
   Results: A combination of AA CCL2 (rs1024611) and GG C3 (R102G) genotypes resulted in a super-additivity of the risks: OR = 10.13, 95% CI 1.04-98.49, p = 0.04, adjusted OR = 7.74, 95% CI 0.71-84.75, p < 0.1, adjusted synergy indices: relative excess risk due to interaction (RERI) = 1.38, the attributable proportion due to interaction (AP) = 24.7% and the synergy index (S) = 1.43. Combination of at-risk genotypes of CFH Y402H and C3 R102G resulted in a strong super-additive risk: adjusted OR = 22.65, 95% CI 2.32-220.91, p = 0.007, adjusted AP = 90.4% and the S = 12.86. Attributable proportion of risk owing to C3-CCL2 and C3-CFH interaction calculated at 25% and 90% for advanced AMD.
   Conclusion: We have previously shown a strong association of C3 (R102G) and CFH Y402H with AMD whereas no association was found for CCL2-2518. This study enclosed strong synergistic association of risk genotypes of C3 and CFH Y402H with AMD. We also revealed synergistic influence of CC12-2518 and the at-risk genotype of the C3 in AMD with an estimated AP = 50.9% (adjusted AP = 24.7%). Present findings show that CCL2-2518 polymorphism is not an innocent bystander in AMD susceptibility when combined with the at-risk genotype of C3 (R102G).
C1 [Bonyadi, Mortaza; Mohammadian, Tahereh; Fotouhi, Nikou] Univ Tabriz, Fac Nat Sci, Ctr Excellence Biodivers, Tabriz, Iran.
   [Bonyadi, Mortaza] Tabriz Univ Med Sci, Liver & Gastrointestinal Dis Res Ctr, Tabriz, Iran.
   [Bonyadi, Mohammad Hossein Jabbarpoor; Soheilian, Masoud] Shahid Beheshti Univ Med Sci, Ocular Tissue Engn Res Ctr, Ophthalm Res Ctr, Boostan 9, Tehran, Iran.
   [Yaseri, Mehdi] Univ Tehran Med Sci, Dept Biostat & Epidemiol, Tehran, Iran.
   [Javadzadeh, Alireza] Tabriz Univ Med Sci, Dept Ophthalmol, Tabriz, Iran.
C3 University of Tabriz; Tabriz University of Medical Science; Shahid
   Beheshti University Medical Sciences; Tehran University of Medical
   Sciences; Tabriz University of Medical Science
RP Bonyadi, MHJ (通讯作者)，Shahid Beheshti Univ Med Sci, Ocular Tissue Engn Res Ctr, Ophthalm Res Ctr, Boostan 9, Tehran, Iran.
EM mhbonyadi@yahoo.com
RI Yaseri, Mehdi/I-1645-2018; Hossein, Jabbarpoor Bonyadi
   Mohammad/A-1886-2014; Soheilian, Masoud/AAW-4743-2020; Javadzadeh,
   Alireza/L-6424-2017
OI Yaseri, Mehdi/0000-0002-4066-873X; Javadzadeh,
   Alireza/0000-0002-5151-6125; Soheilian, Masoud/0000-0001-7508-426X
FU Centre of Excellence for Biodiversity, Faculty of Natural Sciences,
   University of Tabriz
FX This work was funded by the Centre of Excellence for Biodiversity,
   Faculty of Natural Sciences, University of Tabriz.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anand A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049905
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bonyadi M, 2016, OPHTHALMIC GENET, V30, P1
   Bonyadi M, 2016, ACTA OPHTHALMOL, V94, pE779, DOI 10.1111/aos.13143
   Bonyadi M, 2015, INT J DERMATOL, V54, P1269, DOI 10.1111/ijd.12940
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Cui L, 2010, INVEST OPHTH VIS SCI, V51, P1116, DOI 10.1167/iovs.09-4265
   Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027
   Despriet DDG, 2008, INVEST OPHTH VIS SCI, V49, P364, DOI 10.1167/iovs.07-0656
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Fenoglio C, 2004, NEUROBIOL AGING, V25, P1169, DOI 10.1016/j.neurobiolaging.2003.11.008
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Janssen BJC, 2006, NATURE, V444, P213, DOI 10.1038/nature05172
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Markiewski MM, 2007, AM J PATHOL, V171, P715, DOI 10.2353/ajpath.2007.070166
   R Core Team, 2014, R FDN STAT COMP
   Rovin BH, 1999, BIOCHEM BIOPH RES CO, V259, P344, DOI 10.1006/bbrc.1999.0796
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Thakkinstian A, 2011, AM J EPIDEMIOL, V173, P1365, DOI 10.1093/aje/kwr025
   Wang XF, 2010, HUM HERED, V70, P269, DOI 10.1159/000321967
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zerbib J, 2010, MOL VIS, V16, P1324
   Zou GY, 2008, AM J EPIDEMIOL, V168, P212, DOI 10.1093/aje/kwn104
NR 29
TC 4
Z9 4
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD AUG
PY 2017
VL 38
IS 4
BP 365
EP 370
DI 10.1080/13816810.2016.1242019
PG 6
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA FE1OM
UT WOS:000407987500012
PM 28095095
DA 2022-11-30
ER

PT J
AU Danner, M
   Vennedey, V
   Hiligsmann, M
   Fauser, S
   Gross, C
   Stock, S
AF Danner, Marion
   Vennedey, Vera
   Hiligsmann, Mickael
   Fauser, Sascha
   Gross, Christian
   Stock, Stephanie
TI How Well Can Analytic Hierarchy Process be Used to Elicit Individual
   Preferences? Insights from a Survey in Patients Suffering from
   Age-Related Macular Degeneration
SO PATIENT-PATIENT CENTERED OUTCOMES RESEARCH
LA English
DT Article
ID MULTICRITERIA DECISION-ANALYSIS; HEALTH TECHNOLOGY-ASSESSMENT;
   OF-THE-LITERATURE; CONJOINT-ANALYSIS; AHP; SCALE; PRIORITIES;
   RANIBIZUMAB; MANAGEMENT; TUTORIAL
AB Background In this study, we tested the feasibility of an interviewer-assisted analytic hierarchy process (AHP) in a special patient population with age-related macular degeneration (AMD).
   Objectives One aim was to generate preference weights regarding AMD treatment characteristics. A secondary aim was to explore the consistency of preference judgments and reasons for inconsistency.
   Methods We generated quantitative importance weights for decision criteria using the matrix multiplication method. A qualitative study component in the form of asking patients to think aloud throughout their judgments was implemented to facilitate understanding of quantitative findings. Consistency ratios were calculated as a measure of logical judgment performance within AHP. If consistency ratios exceeded 0.2, we explored reasons for inconsistency.
   Results We interviewed 86 patients and generated preference weights for criteria. Patients rated the injection's effect on visual function the highest (0.44), followed by the frequency of monitoring visits (0.18), approval status (0.13), injection frequency (0.13), and side effects (0.12). Inconsistency in judgments was prevalent at the subcriteria level. Whereas much of the observed inconsistency was due to an excessive use of high/extreme value judgments, these judgments seemed to result from patients reasonably trying to highlight their strong preferences.
   Conclusion Our study combines quantitative with qualitative data to explore patients' preference weights and decision processes using the AHP. It suggests that the type of inconsistency observed in judgments of AMD patients mostly results from rational decision making, not from error or lack of understanding. Further research should address which type and extent of inconsistency might be acceptable in different AHP settings.
C1 [Danner, Marion; Vennedey, Vera; Gross, Christian; Stock, Stephanie] Cologne Univ Hosp, Inst Hlth Econ & Clin Epidemiol, Gleueler Str 176-178, D-50935 Cologne, Germany.
   [Hiligsmann, Mickael] Maastricht Univ, CAPHRI Sch Primary Care & Publ Hlth, Dept Hlth Serv Res, Maastricht, Netherlands.
   [Fauser, Sascha] Cologne Univ Hosp, Ctr Ophthalmol, Cologne, Germany.
C3 University of Cologne; Maastricht University; University of Cologne
RP Danner, M (通讯作者)，Cologne Univ Hosp, Inst Hlth Econ & Clin Epidemiol, Gleueler Str 176-178, D-50935 Cologne, Germany.
EM marion.danner@uk-koeln.de; vera.vennedey@uk-koeln.de;
   m.hiligsmann@maastrichtuniversity.nl; sascha.fauser@uk-koeln.de;
   gross.chg@googlemail.com; stephanie.stock@uk-koeln.de
FU Bayer Vital GmbH, Germany
FX Financial support for this investigator-initiated study was provided by
   Bayer Vital GmbH, Germany (who markets the product aflibercept). The
   funding agreement ensured the author's independence in designing the
   study; collecting, analyzing, and interpreting the data; and writing and
   publishing the report. The authors Stephanie Stock, Christian Gross,
   Sascha Fauser, Mickael Hiligsmann, Vera Vennedey, and Marion Danner
   report no additional conflicts of interest.
CR Angelis A, 2016, PHARMACOECONOMICS, V34, P435, DOI 10.1007/s40273-015-0370-z
   Baxter JM, 2016, EYE, V30, P698, DOI 10.1038/eye.2016.18
   Benaim C, 2010, REV EPIDEMIOL SANTE, V58, P59, DOI 10.1016/j.respe.2009.09.004
   Bridges JFP, 2011, VALUE HEALTH, V14, P403, DOI 10.1016/j.jval.2010.11.013
   Clark MD, 2014, PHARMACOECONOMICS, V32, P883, DOI 10.1007/s40273-014-0170-x
   Danner M, 2016, PATIENT, V9, P47, DOI 10.1007/s40271-015-0122-3
   Danner M, 2011, INT J TECHNOL ASSESS, V27, P369, DOI 10.1017/S0266462311000523
   de Bekker-Grob EW, 2012, HEALTH ECON, V21, P145, DOI 10.1002/hec.1697
   Dolan JG, 2014, MED DECIS MAKING, V34, P746, DOI 10.1177/0272989X13513338
   Dolan JG, 2013, MED DECIS MAKING, V33, P59, DOI 10.1177/0272989X12453502
   DOLAN JG, 1989, MED DECIS MAKING, V9, P40, DOI 10.1177/0272989X8900900108
   Dong YC, 2008, EUR J OPER RES, V186, P229, DOI 10.1016/j.ejor.2007.01.044
   Droege KM, 2014, GRAEF ARCH CLIN EXP, V252, P31, DOI 10.1007/s00417-013-2412-6
   Finan JS, 1999, EUR J OPER RES, V112, P367, DOI 10.1016/S0377-2217(97)00411-6
   Forman E, 1998, EUR J OPER RES, V108, P165, DOI 10.1016/S0377-2217(97)00244-0
   Forman E, 2015, EXPERT CHOICE COMP H
   Forman E.H., 2001, NEW YORK WORLD SCI, DOI 10.1142/4281
   FORMAN EH, 1990, EUR J OPER RES, V48, P153, DOI 10.1016/0377-2217(90)90072-J
   HARKER PT, 1987, MANAGE SCI, V33, P1383, DOI 10.1287/mnsc.33.11.1383
   Helm R, 2004, JENA SCHR WIRTSCH, DOI [10.1504/IJMDM.2008.017408, DOI 10.1504/IJMDM.2008.017408]
   Ho MP, 2015, SURG ENDOSC, V29, P2984, DOI 10.1007/s00464-014-4044-2
   HOLDER RD, 1990, J OPER RES SOC, V41, P1073, DOI 10.1038/sj/jors/0411110
   Hummel JM, 2014, PATIENT, V7, P129, DOI 10.1007/s40271-014-0050-7
   Hummel JM, 2013, APPL HEALTH ECON HEA, V11, P499, DOI 10.1007/s40258-013-0051-z
   Hummel JMM, 2005, J REHABIL RES DEV, V42, P635, DOI 10.1682/JRRD.2004.07.0088
   Hummel MJM, 2012, PATIENT, V5, P225, DOI 10.2165/11635240-000000000-00000
   IJzerman MJ, 2012, PATIENT, V5, P45, DOI 10.2165/11587140-000000000-00000
   IJzerman MJ, 2008, PATIENT, V1, P265, DOI [10.2165/01312067-200801040-00008, 10.2165/1312067-200801040-00008]
   Ishizaka A, 2011, J OPER RES SOC, V62, P700, DOI 10.1057/jors.2010.23
   Ji P, 2003, J OPER RES SOC, V54, P896, DOI 10.1057/palgrave.jors.2601557
   Johnson FR, 2013, VALUE HEALTH, V16, P3, DOI 10.1016/j.jval.2012.08.2223
   Kinoshita E., 2005, WHY WE NEED AHP ANP
   Kuruoglu E, 2015, BMC MED INFORM DECIS, V15, DOI 10.1186/s12911-015-0183-1
   Liberatore MJ, 2008, EUR J OPER RES, V189, P194, DOI 10.1016/j.ejor.2007.05.001
   LOOTSMA FA, 1989, EUR J OPER RES, V40, P109, DOI 10.1016/0377-2217(89)90278-6
   Marsh K, 2014, PHARMACOECONOMICS, V32, P345, DOI 10.1007/s40273-014-0135-0
   Maruthur NM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126625
   Maruthur Nisa M, 2013, F1000Res, V2, P160, DOI 10.12688/f1000research.2-160.v1
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Mueller S, 2016, OPHTHALMOLOGY, V123, P876, DOI 10.1016/j.ophtha.2015.12.001
   Muhlbacher AC, 2016, GESUNDHEITSWESEN, V78, P326, DOI 10.1055/s-0034-1390474
   Orme BK, 2014, GETTING STARTED CONJ, V3rd
   Reddy BP, 2014, PUBLIC HEALTH, V128, P896, DOI 10.1016/j.puhe.2014.07.003
   SAATY TL, 1977, J MATH PSYCHOL, V15, P234, DOI 10.1016/0022-2496(77)90033-5
   SAATY TL, 1994, EUR J OPER RES, V74, P426, DOI 10.1016/0377-2217(94)90222-4
   Saaty TL, 2011, ANAL HIERARCHY PROCE, V6
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   van Til JA, 2008, ARCH PHYS MED REHAB, V89, P457, DOI 10.1016/j.apmr.2007.09.030
NR 49
TC 15
Z9 15
U1 0
U2 3
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1178-1653
EI 1178-1661
J9 PATIENT
JI Patient
PD OCT
PY 2016
VL 9
IS 5
BP 481
EP 492
DI 10.1007/s40271-016-0179-7
PG 12
WC Health Care Sciences & Services; Health Policy & Services
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services
GA DW3BW
UT WOS:000383518100011
PM 27255773
DA 2022-11-30
ER

PT J
AU Liu, BY
   Wei, L
   Meyerle, C
   Tuo, JS
   Sen, HN
   Li, ZY
   Chakrabarty, S
   Agron, E
   Chan, CC
   Klein, ML
   Chew, E
   Ferris, F
   Nussenblatt, RB
AF Liu, Baoying
   Wei, Lai
   Meyerle, Catherine
   Tuo, Jingsheng
   Sen, H. Nida
   Li, Zhiyu
   Chakrabarty, Sagarika
   Agron, Elvira
   Chan, Chi-Chao
   Klein, Michael L.
   Chew, Emily
   Ferris, Frederick
   Nussenblatt, Robert B.
TI Complement component C5a Promotes Expression of IL-22 and IL-17 from
   Human T cells and its Implication in Age-related Macular Degeneration
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
ID GROWTH-FACTOR-BETA; FACTOR-H POLYMORPHISM; CHOROIDAL NEOVASCULARIZATION;
   FACTOR-B; DIFFERENTIATION; ACTIVATION; GAMMA; RISK; INTERLEUKIN-6;
   INFLAMMATION
AB Background: Age related macular degeneration (AMD) is the leading cause of irreversible blindness in elderly populations worldwide. Inflammation, among many factors, has been suggested to play an important role in AMD pathogenesis. Recent studies have demonstrated a strong genetic association between AMD and complement factor H (CFH), the down-regulatory factor of complement activation. Elevated levels of complement activating molecules including complement component 5a (C5a) have been found in the serum of AMD patients. Our aim is to study whether C5a can impact human T cells and its implication in AMD.
   Methods: Human peripheral blood mononuclear cells (PBMCs) were isolated from the blood of exudative form of AMD patients using a Ficoll gradient centrifugation protocol. Intracellular staining and enzyme-linked immunosorbent assays were used to measure protein expression. Apoptotic cells were detected by staining of cells with the annexin-V and TUNEL technology and analyzed by a FACS Caliber flow cytometer. SNP genotyping was analyzed by TaqMan genotyping assay using the Real-time PCR system 7500.
   Results: We show that C5a promotes interleukin (IL)-22 and IL-17 expression by human CD4(+) T cells. This effect is dependent on B7, IL-1 beta and IL-6 expression from monocytes. We have also found that C5a could protect human CD4(+) cells from undergoing apoptosis. Importantly, consistent with a role of C5a in promoting IL-22 and IL-17 expression, significant elevation in IL-22 and IL-17 levels was found in AMD patients as compared to non-AMD controls.
   Conclusions: Our results support the notion that C5a may be one of the factors contributing to the elevated serum IL-22 and IL-17 levels in AMD patients. The possible involvement of IL-22 and IL-17 in the inflammation that contributes to AMD may herald a new approach to treat AMD.
C1 [Liu, Baoying; Wei, Lai; Tuo, Jingsheng; Sen, H. Nida; Li, Zhiyu; Chakrabarty, Sagarika; Chan, Chi-Chao; Nussenblatt, Robert B.] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Meyerle, Catherine; Agron, Elvira; Chew, Emily; Ferris, Frederick] NEI, Div Epidemiol & Clin Res, NIH, Bethesda, MD 20892 USA.
   [Klein, Michael L.] Oregon Hlth & Sci Univ, Macular Degenerat Ctr, Casey Eye Inst, Portland, OR 97239 USA.
   [Klein, Michael L.] Oregon Hlth & Sci Univ, Leonard Christensen Eye Pathol Lab, Casey Eye Inst, Portland, OR 97239 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); Oregon Health & Science University; Oregon Health &
   Science University
RP Nussenblatt, RB (通讯作者)，NEI, Immunol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.
EM drbob@nei.nih.gov
RI Wei, Lai/D-1088-2014
OI Tuo, Jingsheng/0000-0002-1372-7810; Ferris,
   Frederick/0000-0002-4933-0639
FU NIH, National Eye Institute; NATIONAL EYE INSTITUTE [ZIAEY000526,
   ZIAEY000222, ZICEY000457, ZIAEY000524, ZIAEY000527, ZIAEY000418,
   ZIEEY000482, ZIAEY000485, ZIAEY000497, ZIAEY000489, ZIAEY000464,
   ZIAEY000523] Funding Source: NIH RePORTER
FX We thank Dr. Anthony Adamis for kindly providing the C5aR antagonist;
   Rafael Villasmil for assistance with flow cytometric cell sorting; This
   research was supported by the Intramural Research Program of NIH,
   National Eye Institute.
CR Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   [Anonymous], 2011, N ENGL J MED
   Bradshaw EM, 2009, J IMMUNOL, V183, P4432, DOI 10.4049/jimmunol.0900576
   Caspi R, 2008, IMMUNOL RES, V42, P41, DOI 10.1007/s12026-008-8031-3
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fang CY, 2009, BLOOD, V114, P1005, DOI 10.1182/blood-2009-01-198283
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hubschman JP, 2009, CLIN OPHTHALMOL, V3, P155
   Hueber AJ, 2010, J IMMUNOL, V184, P3336, DOI 10.4049/jimmunol.0903566
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kiernan DF, 2009, EXPERT OPIN PHARMACO, V10, P2511, DOI 10.1517/14656560903160671
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lalli PN, 2008, BLOOD, V112, P1759, DOI 10.1182/blood-2008-04-151068
   Li ZQ, 2008, J IMMUNOL, V181, P5147, DOI 10.4049/jimmunol.181.7.5147
   Liu JB, 2008, J IMMUNOL, V180, P5882, DOI 10.4049/jimmunol.180.9.5882
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Manel N, 2008, NAT IMMUNOL, V9, P641, DOI 10.1038/ni.1610
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Nussenblatt RB, 2009, CURR OPIN INVEST DR, V10, P434
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Strainic MG, 2008, IMMUNITY, V28, P425, DOI 10.1016/j.immuni.2008.02.001
   Volpe E, 2008, NAT IMMUNOL, V9, P650, DOI 10.1038/ni.1613
   Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557
   Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497
   Wong Ian Yat Hin, 2011, International Ophthalmology, V31, P73, DOI 10.1007/s10792-010-9397-5
   Woodruff T.M., 2011, MOL IMMUNOL
   Xu RN, 2010, EUR J IMMUNOL, V40, P1079, DOI 10.1002/eji.200940015
   Yanamadala V, 2010, TRENDS MOL MED, V16, P69, DOI 10.1016/j.molmed.2009.12.001
   Yang L, 2008, NATURE, V454, P350, DOI 10.1038/nature07021
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505
NR 44
TC 115
Z9 122
U1 0
U2 14
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD JUL 15
PY 2011
VL 9
AR 111
DI 10.1186/1479-5876-9-111
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 807RP
UT WOS:000293917700001
PM 21762495
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Bhutto, IA
   McLeod, DS
   Merges, C
   Hasegawa, T
   Lutty, GA
AF Bhutto, I. A.
   McLeod, D. S.
   Merges, C.
   Hasegawa, T.
   Lutty, G. A.
TI Localisation of SDF-1 and its receptor CXCR4 in retina and choroid of
   aged human eyes and in eyes with age related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL-CELLS; HEMATOPOIETIC
   STEM-CELLS; IN-VITRO; EXPRESSION; ANGIOGENESIS; MIGRATION;
   NEOVASCULARIZATION; MACROPHAGE; CHEMOKINES
AB Aim: To examine the immunolocalisation of stromal cell derived factor 1 (SDF-1) and its receptor CXCR4 in aged control human donor eyes and eyes with age related macular degeneration (AMD).
   Methods: Postmortem eyes from eight aged control donors (mean age 79.8 years) and from 12 donors with AMD (mean age 83.9 years) were cryopreserved and sectioned through the macular region. SDF-1 and CXCR4 were localised using streptavidin alkaline phosphatase immunohistochemistry and then sections were bleached. Three independent masked observers scored the immunohistochemical reaction product.
   Results: In aged control retinas, SDF-1 immunoreactivity was most intense in inner photoreceptor matrix (IPM). CXCR4 showed a similar pattern of immunostaining, but was more prominent in inner segments of photoreceptors. In aged control and AMD choroid, SDF-1 and CXCR4 localisations were most prominent in retinal pigment epithelial (RPE) cells and choroidal stroma. However, the intensity for SDF-1 was significantly reduced in RPE (p < 0.0001) and choroidal stroma (p < 0.05) in late AMD eyes. SDF-1 and CXCR4 immunoreactivities were weak or nearly absent in disciform scars with choroidal neovascularisation (CNV). Circulating cells, presumably leucocytes, were most intensely positive for CXCR4.
   Conclusions: These results show that changes in distribution and relative levels of SDF-1/CXCR4 were not evident in early AMD. This suggests that SDF-1/CXCR4 may not contribute to the formation of CNV in AMD, in that CXCR4+ cells were not incorporated into neovascularisation. However, the examples of CNV studied were within disciform scars, so the authors cannot comment on the role of SDF-1/CXCR4 in the early stages of CNV formation.
C1 Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Lutty, GA (通讯作者)，Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, 170 Woods Res Bldg,600 N Wolfe St, Baltimore, MD 21287 USA.
EM galutty@jhmi.edu
FU NATIONAL EYE INSTITUTE [P30EY001765, R01EY016151] Funding Source: NIH
   RePORTER; NEI NIH HHS [R01 EY016151, EY-01765] Funding Source: Medline
CR Arenberg DA, 1997, METHOD ENZYMOL, V288, P190
   Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221
   Bailey AS, 2004, BLOOD, V103, P13, DOI 10.1182/blood-2003-05-1684
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bhutto IA, 2004, INVEST OPHTH VIS SCI, V45, P1544, DOI 10.1167/iovs.03-0862
   Butler JM, 2005, J CLIN INVEST, V115, P86, DOI 10.1172/JCI200522869
   Chalasani SH, 2003, J NEUROSCI, V23, P4601
   Cousins SW, 2002, AGE-RELATED MACULAR DEGENERATION, P27
   Crane IJ, 2000, J IMMUNOL, V165, P4372, DOI 10.4049/jimmunol.165.8.4372
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371
   Feil C, 1998, BIOCHEM BIOPH RES CO, V247, P38, DOI 10.1006/bbrc.1998.8499
   Forster R, 1998, J IMMUNOL, V160, P1522
   Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607
   Grant MB, 2003, ADV EXP MED BIOL, V522, P37
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1986, OPHTHALMOLOGY, V93, P1169
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Gupta SK, 1998, J BIOL CHEM, V273, P4282, DOI 10.1074/jbc.273.7.4282
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Link DC, 2005, IMMUNOL RES, V32, P169, DOI 10.1385/IR:32:1-3:169
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   LUTTY GA, 1993, INVEST OPHTH VIS SCI, V34, P477
   Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448
   MCLEOD DS, 1995, AM J PATHOL, V147, P642
   Mirshahi F, 2000, THROMB RES, V99, P587, DOI 10.1016/S0049-3848(00)00292-9
   Mohle R, 1998, BLOOD, V91, P4523, DOI 10.1182/blood.V91.12.4523.412k04_4523_4530
   Nagase H, 2002, J LEUKOCYTE BIOL, V71, P711
   Peled A, 1999, J CLIN INVEST, V104, P1199, DOI 10.1172/JCI7615
   Rempel SA, 2000, CLIN CANCER RES, V6, P102
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Salcedo R, 1999, AM J PATHOL, V154, P1125, DOI 10.1016/S0002-9440(10)65365-5
   Salcedo R, 2003, MICROCIRCULATION, V10, P359, DOI 10.1038/sj.mn.7800200
   SARKS SH, 2001, RETINA, P1064
   Sengupta N, 2003, INVEST OPHTH VIS SCI, V44, P4908, DOI 10.1167/iovs.03-0342
   Sengupta N, 2005, INVEST OPHTH VIS SCI, V46, P343, DOI 10.1167/iovs.04-0153
   SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180
   Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261
   Volin MV, 1998, BIOCHEM BIOPH RES CO, V242, P46, DOI 10.1006/bbrc.1997.7890
   Yu MJT, 2000, GROWTH FACTORS, V17, P301, DOI 10.3109/08977190009028973
   Zhang YF, 1997, INVEST OPHTH VIS SCI, V38, P1653
   Zhou JH, 2005, MOL VIS, V11, P414
NR 41
TC 28
Z9 32
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2006
VL 90
IS 7
BP 906
EP 910
DI 10.1136/bjo.2006.090357
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 053QR
UT WOS:000238320500027
PM 16597663
OA Green Published
DA 2022-11-30
ER

PT J
AU Kaur, I
   Katta, S
   Hussain, A
   Hussain, N
   Mathai, A
   Narayanan, R
   Hussain, A
   Reddy, RK
   Majji, AB
   Das, T
   Chakrabarti, S
AF Kaur, Inderjeet
   Katta, Saritha
   Hussain, Avid
   Hussain, Nazimul
   Mathai, Annie
   Narayanan, Raja
   Hussain, Anjli
   Reddy, Rajeev K.
   Majji, Ajit B.
   Das, Taraprasad
   Chakrabarti, Subhabrata
TI Variants in the 10q26 gene cluster (LOC387715 and HTRA1) exhibit
   enhanced risk of age-related macular degeneration along with CFH in
   Indian patients
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT-FACTOR-H; PROMOTER POLYMORPHISM; JAPANESE POPULATION; NO
   ASSOCIATION; SUSCEPTIBILITY; DISEASE; MACULOPATHY; INCREASES
AB PURPOSE. Single nucleotide polymorphisms (SNPs) in the LOC387715 (rs10490924), HTRA1 (rs11200638), and CFH (rs1061170) genes have been implicated in age-related macular degeneration (AMD). The present study was undertaken to determine the involvement of the LOC387715 and HTRA1 in an AMD cohort from India.
   METHODS. The coding region of LOC387715 (exon 1) and the promoter of HTRA1 were screened by resequencing in AMD cases and normal controls. Odds ratios were calculated to assess the risk of individual genotypes. Linkage disequilibrium (LD) and haplotype frequencies were estimated with Haplo-view software. Population attributable risk (PAR %) for the associated SNPs and their combined effects were calculated.
   RESULTS. Resequencing revealed seven different SNPs in these genes, of which significant associations were noted with the risk alleles of rs10490924 (T allele; P = 5.34 x 10(-12)) in LOC387715, and rs11200638 (A allele; P = 4.32 x 10(-12)) and rs2672598 (C allele; P = 3.39 x 10(-11)) in HTRA1 among the cases. Correspondingly, the homozygous risk genotypes TT, AA, and CC in these SNPs exhibited higher disease odds and PAR %. rs10490924 and rs11200638 were in tight LD (D', 0.90; 95% CI, 0.84-0.93). G-C-T-A-C was the risk haplotype (P = 8.04 x 10(-15)), whereas the G-C-G-G-T haplotype was protective (P = 2.01 x 10(-4)). The combined effect of the CFH (CC) and LOC387715 (TT) risk genotypes exhibited a PAR of 93.7% (OR, 73.89; 95% CI, 8.69-628.13).
   CONCLUSIONS. The present data provided an independent validation of the association of LOC387715 and HTRA1 SNPs, along with their risk estimates among Indian patients with AMD. These associations underscore their significant involvement in AMD susceptibility, which may be useful for predictive testing.
C1 [Kaur, Inderjeet; Katta, Saritha; Hussain, Avid; Chakrabarti, Subhabrata] LV Prasad Eye Inst, Kallam Anji Reddy Mol Genet Lab, Hyderabad, Andhra Pradesh, India.
   [Hussain, Nazimul; Mathai, Annie; Narayanan, Raja; Hussain, Anjli; Reddy, Rajeev K.; Majji, Ajit B.; Das, Taraprasad] LV Prasad Eye Inst, Kannuri Santhamma Retina Vitreous Serv, Hyderabad, Andhra Pradesh, India.
C3 L. V. Prasad Eye Institute; L. V. Prasad Eye Institute
RP Chakrabarti, S (通讯作者)，LV Prasad Eye Inst, Brien Holden Eye Res Ctr, Rd 2 Banjara Hills, Hyderabad 500034, Andhra Pradesh, India.
EM subho@lvpei.org
RI Chakrabarti, Subhabrata/F-2468-2015; Narayanan, Raja/AAT-3098-2021;
   Hussain, Nazimul/Q-7563-2019; Kaur, Inderjeet/ABD-1833-2021
OI Chakrabarti, Subhabrata/0000-0003-3717-4963; Narayanan,
   Raja/0000-0001-9688-5859; Hussain, Nazimul/0000-0001-6920-5168; 
CR Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Chen DQ, 2007, PROTEIN EXPRES PURIF, V54, P275, DOI 10.1016/j.pep.2007.03.017
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2007, BRIT J OPHTHALMOL, V91, P576, DOI 10.1136/bjo.2006.105577
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hintze J, 2007, NCSS PASS GESS
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   MOSFEGHI DM, 2007, RETINA, V27, P269
   Okamoto H, 2006, MOL VIS, V12, P156
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Sambrook J., 1989, MOL CLONING LAB MANU, P17
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   WANG JJ, 2007, OPHTHALMOLOGY   0731
   Weger M, 2007, MOL VIS, V13, P1274
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yoshida T, 2007, MOL VIS, V13, P545
NR 39
TC 53
Z9 55
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2008
VL 49
IS 5
BP 1771
EP 1776
DI 10.1167/iovs.07-0560
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 292UH
UT WOS:000255291100006
PM 18436811
DA 2022-11-30
ER

PT J
AU Chew, EY
   Clemons, TE
   Agron, E
   Sperduto, RD
   SanGiovanni, JP
   Davis, MD
   Ferris, FL
AF Chew, Emily Y.
   Clemons, Traci E.
   Agron, Elvira
   Sperduto, Robert D.
   SanGiovanni, John Paul
   Davis, Matthew D.
   Ferris, Frederick L., III
CA Age-Related Eye Dis Study Res Grp
TI Ten-Year Follow-up of Age-Related Macular Degeneration in the
   Age-Related Eye Disease Study AREDS Report No. 36
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID BETA-CAROTENE; ZINC
AB IMPORTANCE Providing long-term follow-up of the natural history of age-related macular degeneration (AMD) and associated risk factors will facilitate future epidemiologic studies and clinical trials.
   OBJECTIVE To describe 10-year progression rates to intermediate or advanced AMD.
   DESIGN, SETTING, AND PARTICIPANTS We observed the Age-Related Eye Disease Study (AREDS) participants for an additional 5 years after a randomized clinical trial of antioxidant vitamins and minerals was completed. Observation occurred at 11 clinical sites of medical retinal practices from academic institutions and community medical centers. Participants aged 55 to 80 years with no AMD or AMD of varying severity (n = 4757) were followed up in the AREDS trial for a median duration of 6.5 years. When the trial ended, 3549 of the 4203 surviving participants were followed for 5 additional years.
   EXPOSURE Treatment with antioxidant vitamins and minerals.
   MAIN OUTCOMES AND MEASURES Development of varying stages of AMD and changes in visual acuity. The rates of progression to large drusen and advanced AMD (neovascular AMD or central geographic atrophy) were evaluated using annual fundus photographs assessed centrally. Best-corrected visual acuity was measured at annual study visits.
   RESULTS The risk of progression to advanced AMD increased with increasing age (P = .01) and severity of drusen. Women (P =.005) and current smokers (P < .001) were at increased risk of neovascular AMD. In the oldest participants with the most severe AMD status at baseline, the risks of developing neovascular AMD and central geographic atrophy by 10 years were 48.1% and 26.0%, respectively. Similarly, rates of progression to large drusen increased with increasing severity of drusen at baseline, with 70.9% of participants with bilateral medium drusen progressing to large drusen and 13.8% to advanced AMD in 10 years. Median visual acuity at 10 years in eyes that had large drusen at baseline but never developed advanced AMD was 20/25; eyes that developed advanced AMD had a median visual acuity of 20/200.
   CONCLUSIONS AND RELEVANCE The natural history of AMD demonstrates relentless loss of vision in persons who developed advanced AMD. These progression data and the risk factor analyses may be helpful to investigators conducting research in clinic populations.
C1 [Chew, Emily Y.; Agron, Elvira; SanGiovanni, John Paul; Ferris, Frederick L., III] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Clemons, Traci E.; Sperduto, Robert D.] EMMES Corp, Rockville, MD USA.
   [Davis, Matthew D.] Univ Wisconsin, Dept Ophthalmol, Madison, WI 53706 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Emmes Corporation; University of Wisconsin System; University of
   Wisconsin Madison
RP Chew, EY (通讯作者)，NEI, Div Epidemiol & Clin Applicat, NIH, 10 Ctr Dr,MSC 1204,Bldg 10,CRC Room 3-2531, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
RI SanGiovanni, John Paul/AAU-3895-2020
OI Ferris, Frederick/0000-0002-4933-0639
FU National Eye Institute, National Institutes of Health, Department of
   Health and Human Services [N0I-EY-0-2127]; NATIONAL EYE INSTITUTE
   [N01EY002127, ZIAEY000485] Funding Source: NIH RePORTER
FX This study is supported by the intramural program funds and contract
   N0I-EY-0-2127 from the National Eye Institute, National Institutes of
   Health, Department of Health and Human Services.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   [Anonymous], 1999, CONTROL CLIN TRIALS, V20, P573
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   2001, ARCH OPHTHALMOL, V119, P1417
NR 9
TC 137
Z9 137
U1 0
U2 19
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAR
PY 2014
VL 132
IS 3
BP 272
EP 277
DI 10.1001/jamaophthalmol.2013.6636
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AC8HL
UT WOS:000332774000006
PM 24385141
OA Bronze
DA 2022-11-30
ER

PT J
AU Ambreen, F
   Ismail, M
   Qureshi, IZ
AF Ambreen, Fareeha
   Ismail, Muhammad
   Qureshi, Irfan Zia
TI Association of gene polymorphism with serum levels of inflammatory and
   angiogenic factors in Pakistani patients with age-related macular
   degeneration
SO MOLECULAR VISION
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; C-REACTIVE PROTEIN; PROMOTER POLYMORPHISM;
   FACTOR VEGF; INTERLEUKIN-6; MARKERS; RISK; CRP; SUSCEPTIBILITY;
   TRANSCRIPTION
AB Purpose: To study the association of serum levels of inflammatory mediators and angiogenic factors with genetic polymorphism in Pakistani age-related macular degeneration (AMD) patients.
   Methods: This was a cross-sectional and case-control study that included 90 AMD patients diagnosed through slit-lamp examination, fundoscopy, and ocular coherence tomography. For reference and comparison purposes, 100 healthy age-matched subjects (controls) were also recruited. IL-6, IL-8, VEGF, and CRP levels were estimated in the serum samples of patients and control subjects. Using restriction fragment length polymorphism, single nucleotide polymorphisms were studied in IL-6 (rs1800795, rs1800796, rs1800797), IL-8 (rs4073, rs2227306, rs2227543), VEGF (rs3025039, rs699947), and CRP genes (rs1205, rs1130864). Since the data were obtained from a sample population, the Box-Cox transformation algorithm was applied to reduce heterogeneity of error. Multivariate analyses of variance (M-ANOVA) were applied on the transformed data to investigate the association of serum levels of IL-6, IL-8, VEGF, and CRP with AMD. Genotype and allele frequencies were compared through chi(2) tests applying Hardy-Weinberg equilibrium. The serum concentrations of IL-6 and IL-8, VEGF, and CRP between homozygotes and heterozygotes were compared through one-way ANOVA. Significance level was p<0.05.
   Results: Compared to control subjects, serum IL-6 (p<0.0001), IL-8 (p<0.0001), VEGF (p<0.0001), and CRP (p<0.0001) levels were significantly elevated in the AMD patients. For rs1800795, patients with the GG genotype showed significantly raised levels of IL-6 compared to those with GC and CC genotypes (p<0.0001). Serum IL-8 levels were significantly higher in patients with the GG genotype compared to the GC and CC genotypes for the single nucleotide polymorphism (SNP) rs2227543 (p<0.002). Similarly, significantly higher VEGF levels were detected for genotype TT for rs3025039 SNP (p<0.038). However, no significant alteration in serum CRP levels was detected in hetero- or homozygotes for rs1205 and rs1130864 SNPs.
   Conclusions: Serum IL-6, IL-8, and VEGF levels are substantially increased in AMD, and the levels coincide with polymorphism in the respective gene. No such relationship appears to exist with regard to SNPs of CRP.
C1 [Ambreen, Fareeha; Qureshi, Irfan Zia] Quaid I Azam Univ, Lab Anim & Human Physiol, Islamabad, Pakistan.
   [Ismail, Muhammad] Inst Biomed & Genet Engn, Islamabad, Pakistan.
C3 Quaid I Azam University
RP Qureshi, IZ (通讯作者)，Quaid I Azam Univ, Dept Anim Sci, POB 45320, Islamabad, Pakistan.
EM irfanzia@qau.edu.pk
RI Yaylim, Ilhan/AAB-1154-2020
FU Higher Education Commission (HEC), Islamabad, Pakistan under the program
   "access to scientific instrumentation"; HEC [1061414Bm044]
FX The authors thank all the participants of the study, the patients and
   the control subjects. The research was supported by the funds provided
   by Higher Education Commission (HEC), Islamabad, Pakistan under the
   program "access to scientific instrumentation" and a graduate student
   scholarship grant (PIN No. 1061414Bm044) by the HEC to the principal
   author. Authors declare that they have no conflict of interest. We are
   grateful to Prof. Dr. Wajid Ali Khan, Chief Consultant and Prof. Dr.
   Nadeem Qureshi, Head Vitreo-retina Department and all the residents and
   staff of Al-Shifa Trust Eye hospital for their cooperation during the
   screening of the patients, to the Director NORI and Mrs. Shahnaz
   Murtaza, Head Diagnostics, NORI, Islamabad, for extending laboratory
   facilities to carry out ELISA. We are thankful to Dr. Kiran Afshan,
   Assistant Professor, Department of Animal Sciences, Quaid-i-Azam
   University, Islamabad, Pakistan for her advice on statistical analyses.
CR AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   Banks RE, 1998, BRIT J CANCER, V77, P956, DOI 10.1038/bjc.1998.158
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x
   Carlson CS, 2005, AM J HUM GENET, V77, P64, DOI 10.1086/431366
   Colak E, 2011, OPHTHALMIC RES, V46, P125, DOI 10.1159/000323815
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Du Clos TW, 2000, ANN MED, V32, P274, DOI 10.3109/07853890009011772
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fishman D, 1998, J CLIN INVEST, V102, P1369, DOI 10.1172/JCI2629
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Habibi I, 2014, BIOMARK RES, V2, DOI 10.1186/2050-7771-2-15
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Heinzmann A, 2004, J ALLERGY CLIN IMMUN, V114, P671, DOI 10.1016/j.jaci.2004.06.038
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Huang C, 2013, MOL VIS, V19, P1211
   Jain L, 2009, MOL CANCER THER, V8, P2496, DOI 10.1158/1535-7163.MCT-09-0302
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   KAUFFMANN DJH, 1994, INVEST OPHTH VIS SCI, V35, P900
   Kersey PJ, 2014, NUCLEIC ACIDS RES, V42
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kim IK, 2008, MOL VIS, V14, P1487
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Pankow JS, 2001, ATHEROSCLEROSIS, V154, P681, DOI 10.1016/S0021-9150(00)00586-4
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   Rennie D, 1997, JAMA-J AM MED ASSOC, V277, P922, DOI 10.1001/jama.277.11.922
   Robinson GS, 1996, P NATL ACAD SCI USA, V93, P4851, DOI 10.1073/pnas.93.10.4851
   Russell DW., 2001, MOL CLONING LAB MANU, V1, P112
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Simundic AM, 2011, BIOCHEM MEDICA, V21, P243
   Szalai AJ, 2005, J MOL MED, V83, P440, DOI 10.1007/s00109-005-0658-0
   Szmitko PE, 2003, CIRCULATION, V108, P1917, DOI 10.1161/01.CIR.0000089190.95415.9F
   Thiruvagounder M, 2010, BIOCHEM MEDICA, V20, P249
   Tong Y, 2010, MOL VIS, V16, P1958
   Tsai YY, 2008, INVEST OPHTH VIS SCI, V49, P693, DOI 10.1167/iovs.07-0125
   Turner DM, 1997, EUR J IMMUNOGENET, V24, P1, DOI 10.1111/j.1365-2370.1997.tb00001.x
   Vickers MA, 2002, CARDIOVASC RES, V53, P1029, DOI 10.1016/S0008-6363(01)00534-X
   Wang XY, 2014, AM J OPHTHALMOL, V158, P738, DOI 10.1016/j.ajo.2014.06.009
   Zhou JH, 2005, MOL VIS, V11, P414
NR 44
TC 27
Z9 28
U1 0
U2 3
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD AUG 29
PY 2015
VL 21
BP 985
EP 999
PG 15
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA CQ1HY
UT WOS:000360349100001
PM 26330749
DA 2022-11-30
ER

PT J
AU Lengyel, I
   Csutak, A
   Florea, D
   Leung, I
   Bird, AC
   Jonasson, F
   Peto, T
AF Lengyel, Imre
   Csutak, Adrienne
   Florea, Daniela
   Leung, Irene
   Bird, Alan C.
   Jonasson, Fridbert
   Peto, Tunde
TI A Population-Based Ultra-Widefield Digital Image Grading Study for
   Age-Related Macular Degeneration-Like Lesions at the Peripheral Retina
SO OPHTHALMOLOGY
LA English
DT Article
ID ASSOCIATION; LIMITATIONS; MACULOPATHY; AGREEMENT; CATARACT; DRUSEN
AB Purpose: Our understanding of the relevance of peripheral retinal abnormalities to disease in general and in age-related macular degeneration (AMD) in particular is limited by the lack of detailed peripheral imaging studies. The purpose of this study was to develop image grading protocols suited to ultra-widefield imaging (UWFI) in an aged population.
   Design: A cross-sectional study of a random population sample in which UWFI was introduced at the 12-year review of the Reykjavik Eye Study in Iceland.
   Participants: Five hundred seventy-six subjects 62 years of age or older.
   Methods: Ultra-widefield (up to 200 degrees) color and autofluorescence images were obtained using the Optos P200CAF laser scanning ophthalmoscope (Optos plc, Dunfermline, Scotland). The images were graded at Moorfields Eye Hospital Reading Centre primarily based on the International Classification for AMD. Macular and peripheral changes were graded using a standardized grid developed for this imaging method.
   Main Outcome Measures: Presence or absence of hard, crystalline, and soft drusen; retinal pigment epithelial changes; choroidal neovascularization (CNV); atrophy; and hypoautofluorescence and hyperautofluorescence were graded in the peripheral retina.
   Results: Of the eyes examined, 81.1% had AMD-like changes in the macula alone (13.6%), periphery alone (10.1%), and both periphery and macula (57.4%). There was no AMD-like CNV or pigment epithelial detachment in the periphery except in those cases in which these clearly originated from the macula. Seven patients had AMD-like atrophy in the periphery without end-stage disease in the macula. One patient with end-stage disease in the macula had normal periphery results on the color images. While analyzing the eyes, we detected pathologic appearances that were very reliably identified by graders.
   Conclusions: Phenotyping the retinal periphery using the categories defined by the International Classification confirmed the presence of wide-ranging AMD-like pathologic changes even in those without central sight-threatening macular disease. Based on our observations, we propose here new, reliably identifiable grading categories that may be more suited for population-based UWFI. (C) 2015 Published by Elsevier Inc. on behalf of American Academy of Ophthalmology.
C1 [Lengyel, Imre; Florea, Daniela; Bird, Alan C.] UCL, UCL Inst Ophthalmol, London, England.
   [Csutak, Adrienne; Florea, Daniela; Leung, Irene; Peto, Tunde] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London EC1V 2PD, England.
   [Csutak, Adrienne; Florea, Daniela; Leung, Irene; Peto, Tunde] UCL, Inst Ophthalmol, London, England.
   [Csutak, Adrienne] Univ Debrecen, Fac Med, Dept Ophthalmol, Debrecen, Hungary.
   [Jonasson, Fridbert] Univ Iceland, Fac Med, Reykjavik, Iceland.
C3 University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; University College London; University of Debrecen;
   University of Iceland
RP Peto, T (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, Dept Res & Dev, Reading Ctr, 162 City Rd, London EC1V 2PD, England.
EM Tunde.Peto@moorfields.nhs.uk
RI Lengyel, Imre/B-5217-2009; Jonasson, Fridbert/ABA-9889-2021; Peto,
   Tunde/G-8812-2018; Florea, Daniela I/J-9171-2016
OI Lengyel, Imre/0000-0001-7467-2174; Peto, Tunde/0000-0001-6265-0381;
   Florea, Daniela/0000-0003-1006-0560
FU Optos Plc; Bill Brown Charitable Trust, (London, England); Moorfields
   Eye Hospital Special Trustees, (London, England); UCL Graduate School
   Research Projects Fund, (London, England); Mercer Fund from Fight for
   Sight, (London, England); NIHR Biomedical Research Centre at Moorfields
   Eye Hospital NHS Foundation Trust; UCL Institute of Ophthalmology,
   (London, England)
FX Supported by the Bill Brown Charitable Trust, (London, England);
   Moorfields Eye Hospital Special Trustees, (London, England); UCL
   Graduate School Research Projects Fund, (London, England); and Mercer
   Fund from Fight for Sight, (London, England) and the NIHR Biomedical
   Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL
   Institute of Ophthalmology, (London, England). The study was funded in
   part by an unrestricted grant from Optos Plc. Optos Plc participated in
   data collection by providing an imaging team. The authors alone are
   responsible for the content and writing of the paper.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   BELL FC, 1983, ATLAS PERIPHERAL RET
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chou B, 2003, OPTOMETRY VISION SCI, V80, P671, DOI 10.1097/00006324-200310000-00007
   Chow SP, 2006, OPHTHALMOLOGY, V113, P833, DOI 10.1016/j.ophtha.2005.12.025
   Csutak A, 2010, EYE, V24, P1568, DOI 10.1038/eye.2010.85
   Flinn JM, 2014, METALLOMICS, V6, P1223, DOI 10.1039/c4mt00058g
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Jones WL, 2004, OPTOMETRY VISION SCI, V81, P165, DOI 10.1097/00006324-200403000-00007
   Kiel, 2012, OCULAR BLOOD FLOW, P16
   KIRKPATRICK JNP, 1995, BRIT J OPHTHALMOL, V79, P892, DOI 10.1136/bjo.79.10.892
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Neubauer AS, 2008, GRAEF ARCH CLIN EXP, V246, P229, DOI 10.1007/s00417-007-0631-4
   Neubauer AS, 2005, ACTA OPHTHALMOL SCAN, V83, P759, DOI 10.1111/j.1600-0420.2005.00532.x
   Ritchie CW, 2011, INVEST OPHTH VIS SCI, V52, P2
   Sasaki H, 2003, INVEST OPHTH VIS SCI, V44, P4210, DOI 10.1167/iovs.01-1221
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Witmer MT, 2013, CLIN OPHTHALMOL, V7, P389, DOI 10.2147/OPTH.S41731
   WYBAR KC, 1954, BRIT J OPHTHALMOL, V38, P513, DOI 10.1136/bjo.38.9.513
NR 20
TC 39
Z9 41
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2015
VL 122
IS 7
BP 1340
EP 1347
DI 10.1016/j.ophtha.2015.03.005
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CL0HI
UT WOS:000356621700016
PM 25870081
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Zhang, H
   Morrison, MA
   DeWan, A
   Adams, S
   Andreoli, M
   Huynh, N
   Regan, M
   Brown, A
   Miller, JW
   Kim, IK
   Hoh, J
   DeAngelis, MM
AF Zhang, Hong
   Morrison, Margaux A.
   DeWan, Andy
   Adams, Scott
   Andreoli, Michael
   Huynh, Nancy
   Regan, Maureen
   Brown, Alison
   Miller, Joan W.
   Kim, Ivana K.
   Hoh, Josephine
   DeAngelis, Margaret M.
TI The NEI/NCBI dbGAP database: Genotypes and haplotypes that may
   specifically predispose to risk of neovascular age-related macular
   degeneration
SO BMC MEDICAL GENETICS
LA English
DT Article
ID COMPLEMENT FACTOR-H; DISCORDANT SIB PAIRS; QUANTITATIVE TRAIT LOCI;
   FACTOR-XIII; B-SUBUNIT; POLYMORPHISM; PREVALENCE; GENE; MACULOPATHY;
   VARIANT
AB Background: To examine if the significantly associated SNPs derived from the genome wide allelic association study on the AREDS cohort at the NEI (dbGAP) specifically confer risk for neovascular age-related macular degeneration (AMD). We ascertained 134 unrelated patients with AMD who had one sibling with an AREDS classification 1 or less and was past the age at which the affected sibling was diagnosed (268 subjects). Genotyping was performed by both direct sequencing and Sequenom iPLEX system technology. Single SNP analyses were conducted with McNemar's Test (both 2 x 2 and 3 x 3 tests) and likelihood ratio tests (LRT). Conditional logistic regression was used to determine significant gene-gene interactions. LRT was used to determine the best fit for each genotypic model tested (additive, dominant or recessive).
   Results: Before release of individual data, p-value information was obtained directly from the AREDS dbGAP website. Of the 35 variants with P < 10(-6) examined, 23 significantly modified risk of neovascular AMD. Many variants located in tandem on 1q32q22 including those in CFH, CFHR4, CFHR2, CFHR5, F13B, ASPM and ZBTB were significantly associated with AMD risk. Of these variants, single SNP analysis revealed that CFH rs572515 was the most significantly associated with AMD risk (P < 10(-6)). Haplotype analysis supported our findings of single SNP association, demonstrating that the most significant haplotype, GATAGTTCTC, spanning CFH, CFHR4, and CFHR2 was associated with the greatest risk of developing neovascular AMD ( P < 10(-6)). Other than variants on 1q32-q22, only two SNPs, rs9288410 ( MAP2)on 2q34-q35 and rs2014307 (PLEKHA1/HTRA1) on 10q26 were significantly associated with AMD status (P =.03 and P < 10(-6) respectively). After controlling for smoking history, gender and age, the most significant gene-gene interaction appears to be between rs10801575 (CFH) and rs2014307 (PLEKHA1/HTRA1) (P < 10(-11)). The best genotypic fit for rs10801575 and rs2014307 was an additive model based on LRT. After applying a Bonferonni correction, no other significant interactions were identified between any other SNPs.
   Conclusion: This is the first replication study on the NEI dbGAP SNPs, demonstrating that alleles on 1q, 2q and 10q may predispose an individual to AMD.
C1 [Zhang, Hong; DeWan, Andy; Hoh, Josephine] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA.
   [Morrison, Margaux A.; Adams, Scott; Andreoli, Michael; Huynh, Nancy; Miller, Joan W.; Kim, Ivana K.; DeAngelis, Margaret M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Ophthalmol, Boston, MA USA.
   [Regan, Maureen; Brown, Alison] Harvard Univ, Sch Med, Partners Healthcare Ctr Genet & Genom, Cambridge, MA 02138 USA.
C3 Yale University; Harvard University; Harvard Medical School;
   Massachusetts General Hospital; Harvard University; Partners Healthcare
   System
RP Hoh, J (通讯作者)，Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA.
EM hong.zhang@yale.edu; margaux_morrison@meei.harvard.edu;
   andrew.dewan@yale.edu; scott_adams@meei.harvard.edu;
   michael_andreoli@meei.harvard.edu; nancy_huynh@meei.harvard.edu;
   MEREGAN@PARTNERS.ORG; ABROWN13@PARTNERS.ORG;
   joan_miller@meei.harvard.edu; ivana_kim@meei.harvard.edu;
   josephine.hoh@yale.edu
RI DeAngelis, e/J-7863-2015
OI Miller, Joan/0000-0003-2046-3996; Kim, Ivana/0000-0003-0310-6129; DeWan,
   Andrew/0000-0002-7679-8704
FU NATIONAL EYE INSTITUTE [P30EY014104, R01EY014458] Funding Source: NIH
   RePORTER; NEI NIH HHS [EY014458, EY14104, R01 EY014458, P30 EY014104]
   Funding Source: Medline
CR Bilic I, 2007, IMMUNOL LETT, V108, P1, DOI 10.1016/j.imlet.2006.09.007
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boehnke M, 1998, AM J HUM GENET, V62, P950, DOI 10.1086/301787
   Bond J, 2002, NAT GENET, V32, P316, DOI 10.1038/ng995
   CACERES A, 1992, NEURON, V9, P607, DOI 10.1016/0896-6273(92)90025-9
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   DeAngelis MM, 2004, ARCH OPHTHALMOL-CHIC, V122, P575, DOI 10.1001/archopht.122.4.575
   DEANGELIS MM, 2007, OPHTHALMOLOGY
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gul A, 2007, J NEUROGENET, V21, P153, DOI 10.1080/01677060701508594
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Horvath S, 2006, P NATL ACAD SCI USA, V103, P17402, DOI 10.1073/pnas.0608396103
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   JOHNSON GVW, 1992, J NEUROSCI RES, V33, P505, DOI 10.1002/jnr.490330402
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Komanasin N, 2005, J THROMB HAEMOST, V3, P2487, DOI 10.1111/j.1538-7836.2005.01624.x
   Kumar A, 2004, CLIN GENET, V66, P341, DOI 10.1111/j.1399-0004.2004.00304.x
   Mailman MD, 2007, NAT GENET, V39, P1181, DOI 10.1038/ng1007-1181
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mukai M, 2007, MECH DEVELOP, V124, P570, DOI 10.1016/j.mod.2007.05.001
   NONAKA M, 1993, GENOMICS, V15, P535, DOI 10.1006/geno.1993.1106
   REYCAMPOS J, 1988, J EXP MED, V167, P664, DOI 10.1084/jem.167.2.664
   RISCH N, 1995, SCIENCE, V268, P1584, DOI 10.1126/science.7777857
   Risch NJ, 1996, AM J HUM GENET, V58, P836
   RODRIGUEZ D, 1988, IMMUNOGENETICS, V28, P452
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Tissing WJE, 2007, BLOOD, V109, P3929, DOI 10.1182/blood-2006-11-056366
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 36
TC 55
Z9 64
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2350
J9 BMC MED GENET
JI BMC Med. Genet.
PD JUN 9
PY 2008
VL 9
AR 51
DI 10.1186/1471-2350-9-51
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 322ZR
UT WOS:000257414300001
PM 18541031
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Maugeri, A
   Barchitta, M
   Agodi, A
AF Maugeri, Andrea
   Barchitta, Martina
   Agodi, Antonella
TI The association between complement factor H rs1061170 polymorphism and
   age-related macular degeneration: a comprehensive meta-analysis
   stratified by stage of disease and ethnicity
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE ageing; complement factor H; disease subtype; race; retinal
   degeneration; single nucleotide polymorphisms
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; GENE POLYMORPHISMS; Y402H
   POLYMORPHISM; NO ASSOCIATION; CFH GENE; HTRA1 POLYMORPHISMS;
   CIGARETTE-SMOKING; VARIANT INCREASES; RISK; SUSCEPTIBILITY
AB Purpose The strength of association between complement factor H (CFH) rs1061170 polymorphism and age-related macular degeneration (AMD) differs between AMD subtypes and ethnicities. The main aim was to provide a systematic review and an updated meta-analysis stratified by stage of disease and ethnicity. Methods A literature search in the PubMed-Medline, EMBASE and Web of Science databases was conducted to identify epidemiological studies, published before September 2017, that included at least twp comparison groups (a control group with no signs of AMD and a case group of AMD patients). Genotype distribution, phenotype of the cases, ethnicity, mean age and gender ratio were collected. Odds ratios (ORs) and 95%CIs were estimated under the allelic, homozygous and heterozygous models. Sensitivity and subgroup analyses, by AMD subtype and ethnicity, were performed. Results The meta-analysis included data of 27 418 AMD patients and 32 843 controls from 76 studies. In Caucasians, the rs1061170 showed a significant association with early AMD (OR: 1.44; 95%CI 1.27-1.63), dry AMD (OR: 2.90; 95%CI 1.89-4.47) and wet AMD (OR: 2.46; 95%CI 2.15-2.83), under an allelic model. In Asians, the rs1061170 showed a significant association with advanced AMD (OR: 2.09; 95%CI 1.67-2.60), especially wet AMD (OR: 2.24; 95%CI 1.81-2.77). Conclusion Our work provides a more comprehensive meta-analysis of studies investigating the effect of the CFH rs1061170 polymorphism on AMD risk. These findings not only improve the assessment of disease risk associated with the polymorphism, but also constitute a scientific background to be translated into clinical practice for AMD prevention.
C1 [Maugeri, Andrea; Barchitta, Martina; Agodi, Antonella] Univ Catania, Dept Med Surg Sci & Adv Technol GF Ingrassia, Via S Sofia 87, I-95123 Catania, Italy.
C3 University of Catania
RP Agodi, A (通讯作者)，Univ Catania, Dept Med Surg Sci & Adv Technol GF Ingrassia, Via S Sofia 87, I-95123 Catania, Italy.
EM agodia@unict.it
RI Barchitta, Martina/AFV-8723-2022; Agodi, Antonella/B-3501-2011;
   Barchitta, Martina/A-1362-2015; Maugeri, Andrea/K-1018-2017; Agodi,
   Antonella/AIF-3938-2022
OI Agodi, Antonella/0000-0002-4405-8162; Barchitta,
   Martina/0000-0002-0905-5003; Maugeri, Andrea/0000-0003-2655-8574; Agodi,
   Antonella/0000-0002-4405-8162
CR Abbas RO, 2013, OPHTHALMIC GENET, V34, P209, DOI 10.3109/13816810.2012.762934
   Agbeko RS, 2010, PEDIATR CRIT CARE ME, V11, P561, DOI 10.1097/PCC.0b013e3181d900ba
   Almeida LN, 2013, OPHTHALMIC RES, V50, P117, DOI 10.1159/000350549
   Askou AL, 2018, ACTA OPHTHALMOL, V96, P9, DOI 10.1111/aos.13407
   Babanejad M, 2016, OPHTHALMIC GENET, V37, P144, DOI 10.3109/13816810.2014.955585
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Barchitta M, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/8486406
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bonyadi M, 2016, ACTA OPHTHALMOL, V94, pE779, DOI 10.1111/aos.13143
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   Buentello-Volante B, 2012, MOL VIS, V18, P2518
   Chakravarthy U, 2013, OPHTHALMOLOGY, V120, P342, DOI 10.1016/j.ophtha.2012.08.004
   Chen JH, 2013, MOL VIS, V19, P944
   Chen LJ, 2006, MOL VIS, V12, P1536
   Chowers I, 2008, MOL VIS, V14, P1829
   Chu J, 2008, CHINESE MED J-PEKING, V121, P2525, DOI 10.1097/00029330-200812020-00011
   Cobos E, 2018, ACTA OPHTHALMOL, V96, pe201, DOI 10.1111/aos.13519
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Delcourt C, 2011, INVEST OPHTH VIS SCI, V52, P5955, DOI 10.1167/iovs.10-6235
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dong L, 2011, NEUROSCI LETT, V488, P283, DOI 10.1016/j.neulet.2010.11.048
   Droz I, 2008, BRIT J OPHTHALMOL, V92, P513, DOI 10.1136/bjo.2007.127811
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fisher SA, 2007, BRIT J OPHTHALMOL, V91, P576, DOI 10.1136/bjo.2006.105577
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gangnon RE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1169, DOI 10.1001/archophthalmol.2012.693
   Garcia M, 2015, ACTA OPHTHALMOL, V93, pE658, DOI 10.1111/aos.12790
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Haapasalo K, 2008, MOL MICROBIOL, V70, P583, DOI 10.1111/j.1365-2958.2008.06347.x
   Haas P, 2009, EYE, V23, P2228, DOI 10.1038/eye.2008.422
   Habibi I, 2013, OPHTHALMIC RES, V49, P177, DOI 10.1159/000345068
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hao XF, 2015, INT J CLIN EXP PATHO, V8, P3186
   Hautamaki A, 2015, ACTA OPHTHALMOL, V93, P726, DOI 10.1111/aos.12799
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Higgins JPT, 2008, COCHRANE HDB SYSTEMA
   Huang LZ, 2014, INVEST OPHTH VIS SCI, V55, P2534, DOI 10.1167/iovs.13-13437
   Ioannidis JPA, 2004, NAT GENET, V36, P1312, DOI 10.1038/ng1474
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kalf RRJ, 2014, GENET MED, V16, P85, DOI 10.1038/gim.2013.80
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Kim YH, 2013, OPHTHALMIC GENET, V34, P151, DOI 10.3109/13816810.2012.749287
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P1416, DOI 10.1097/IAE.0b013e318184661d
   Losonczy G, 2011, ACTA OPHTHALMOL, V89, P255, DOI 10.1111/j.1755-3768.2009.01687.x
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Marioli DI, 2009, GRAEF ARCH CLIN EXP, V247, P1547, DOI 10.1007/s00417-009-1129-z
   Moher D, 2015, SYST REV-LONDON, V4, DOI [10.1186/2046-4053-4-1, 10.1186/s13643-015-0087-2]
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Narayanan R, 2007, OPHTHALMOLOGY, V114, P1327, DOI 10.1016/j.ophtha.2006.10.035
   Nazari Khanamiri Hossein, 2014, J Ophthalmic Vis Res, V9, P181
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Okur V, 2015, CLIN EXP OPHTHALMOL, V43, P47, DOI 10.1111/ceo.12376
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   Pulido JS, 2007, OPHTHALMIC GENET, V28, P203, DOI 10.1080/13816810701649617
   Quan YL, 2012, INT J OPHTHALMOL-CHI, V5, P242, DOI 10.3980/j.issn.2222-3959.2012.02.25
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricci F, 2009, ARCH OPHTHALMOL-CHIC, V127, P1368, DOI 10.1001/archophthalmol.2009.237
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Sharma NK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070193
   Simone B, 2013, HEALTH POLICY, V110, P214, DOI 10.1016/j.healthpol.2013.01.015
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Soheilian R, 2017, INT OPHTHALMOL, V37, P1161, DOI 10.1007/s10792-016-0373-6
   Souied EH, 2005, MOL VIS, V11, P1135
   Soysal Y, 2012, DNA CELL BIOL, V31, P322, DOI 10.1089/dna.2011.1214
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Sundaresan P, 2012, INVEST OPHTH VIS SCI, V53, P7492, DOI 10.1167/iovs.12-10073
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Tedeschi-Blok N, 2007, OPHTHALMOLOGY, V114, P99, DOI 10.1016/j.ophtha.2006.07.043
   Teixeira AG, 2010, ACTA OPHTHALMOL, V88, pE165, DOI 10.1111/j.1755-3768.2010.01932.x
   Teper SJ, 2012, MED SCI MONITOR, V18, pPR1, DOI 10.12659/MSM.882447
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   Velissari A, 2015, CLIN CHEM LAB MED, V53, P1521, DOI 10.1515/cclm-2014-0920
   Wang D, 2015, OPHTHALMIC GENET, V36, P303, DOI 10.3109/13816810.2014.881506
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Wu MX, 2016, OPHTHALMIC RES, V55, P135, DOI 10.1159/000442257
   Xu YL, 2008, MOL VIS, V14, P1373
   Yang X, 2010, BRIT J OPHTHALMOL, V94, P1211, DOI 10.1136/bjo.2009.165811
   Yucel D, 2012, OPHTHALMIC GENET, V33, P144, DOI 10.3109/13816810.2012.660225
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zerbib J, 2011, EXP EYE RES, V93, P382, DOI 10.1016/j.exer.2011.05.005
   Ziskind A, 2008, OPHTHALMIC GENET, V29, P117, DOI 10.1080/13816810802216472
NR 109
TC 15
Z9 16
U1 1
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2019
VL 97
IS 1
BP E8
EP E21
DI 10.1111/aos.13849
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HJ0SF
UT WOS:000456872000003
PM 30280493
OA Bronze
DA 2022-11-30
ER

PT J
AU Merle, BMJ
   Buaud, B
   Korobelnik, JF
   Bron, A
   Delyfer, MN
   Rougier, MB
   Savel, H
   Vaysse, C
   Creuzot-Garcher, C
   Delcourt, C
AF Merle, Benedicte M. J.
   Buaud, Benjamin
   Korobelnik, Jean-Francois
   Bron, Alain
   Delyfer, Marie-Noelle
   Rougier, Marie-Benedicte
   Savel, Helene
   Vaysse, Carole
   Creuzot-Garcher, Catherine
   Delcourt, Cecile
TI Plasma long-chain omega-3 polyunsaturated fatty acids and macular
   pigment in subjects with family history of age-related macular
   degeneration: the Limpia Study
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; macular pigment; nutrition;
   epidemiology; plasma omega-3 fatty acids
ID OPTICAL-DENSITY; DIETARY OMEGA-3-FATTY-ACIDS; SERUM CONCENTRATIONS;
   SUPPLEMENTAL LUTEIN; RISK-FACTORS; EYE DISEASE; ZEAXANTHIN; CAROTENOIDS;
   MACULOPATHY; PROGRESSION
AB PurposeIn numerous epidemiological studies, omega-3 polyunsaturated fatty acids (PUFAs) have been associated with a decreased risk of age-related macular degeneration (AMD). Beyond their structural, functional and neuroprotective roles, omega-3 PUFAs may favour the retinal accumulation of lutein and zeaxanthin and thus increase macular pigment optical density (MPOD). We examined the associations of MPOD with plasma omega-3 PUFAs in subjects with family history of AMD.
   MethodsThe Limpia study is a double-blind, placebo-controlled, prospective randomized clinical trial performed in 120 subjects. Subjects with at least one parent treated for neovascular AMD, aged 40-70, with a best corrected visual acuity (BCVA) >20/25, free of late AMD and other major eye conditions and with no use of supplement containing lutein or zeaxanthin the preceding year were recruited in Bordeaux and Dijon, France. At baseline, MPOD within 1 degrees of eccentricity was measured by modified Heidelberg retinal analyser (Heidelberg, Germany) and plasma omega-3 PUFAs by gas chromatography. Medical history and lifestyle data were collected from a standardized questionnaire. Associations of MPOD with plasma omega-3 PUFAs were assessed at the baseline examination, using mixed linear models adjusted for age, gender, centre, body mass index, smoking, plasma high-density lipoprotein (HDL) cholesterol and lutein+zeaxanthin.
   ResultsAfter multivariate adjustment, high MPOD was significantly associated with higher level of plasma docosapentaenoic acid (DPA) (=0.029, 95% CI: 0.003, 0.055; p=0.03). Plasma alpha linolenic, eicosapentaenoic and docosahexaenoic acids were not significantly associated with MPOD.
   ConclusionIn the Limpia study, high MPOD within 1 degrees was significantly associated with higher plasma levels of omega-3 DPA.
C1 [Merle, Benedicte M. J.; Korobelnik, Jean-Francois; Delyfer, Marie-Noelle; Delcourt, Cecile] Univ Bordeaux, UMR 1219, Team LEHA, Inserm,Bordeaux Populat Hlth Res Ctr, Bordeaux, France.
   [Buaud, Benjamin; Vaysse, Carole] ITERG Equipe Nutr Metab & Sante, Bordeaux, France.
   [Korobelnik, Jean-Francois; Delyfer, Marie-Noelle; Rougier, Marie-Benedicte] CHU Bordeaux, Dept Ophthalmol, Bordeaux, France.
   [Bron, Alain; Creuzot-Garcher, Catherine] CHU Dijon, Dept Ophthalmol, Dijon, France.
   [Savel, Helene] CHU Bordeaux, Pole Sante Publ USMR, Bordeaux, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite de Bordeaux; CHU
   Bordeaux; CHU Dijon Bourgogne; CHU Bordeaux
RP Merle, BMJ (通讯作者)，Univ Bordeaux, ISPED, INSERM, U1219, 146 Rue Leo Saignat,CS61292, F-33076 Bordeaux, France.
EM Benedicte.merle@isped.fr
RI Merle, Benedicte MJ/AAQ-5021-2021; Delcourt, Cecile/I-2627-2013;
   Delyfer, Marie-Noelle/T-3304-2019; KOROBELNIK,
   Jean-Francois/A-5448-2016; Merle, Benedicte MJ/F-1247-2015; Bron,
   Alain/AAP-8010-2020
OI Merle, Benedicte MJ/0000-0003-1332-0954; Delcourt,
   Cecile/0000-0002-2099-0481; Merle, Benedicte MJ/0000-0003-1332-0954;
   Bron, Alain/0000-0002-7265-931X; BUAUD, Benjamin/0000-0002-1076-0842;
   Vaysse, Carole/0000-0003-1769-2106
CR Alassane S, 2016, INVEST OPHTH VIS SCI, V57, P1160, DOI 10.1167/iovs.15-18007
   Arnold C, 2013, JAMA OPHTHALMOL, V131, P564, DOI 10.1001/jamaophthalmol.2013.2851
   Bazan NG, 2009, J LIPID RES, V50, pS400, DOI 10.1194/jlr.R800068-JLR200
   Berendschot TT, 2005, EXP EYE RES, V81, P602, DOI 10.1016/j.exer.2005.03.019
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   Bernstein PS, 2001, INVEST OPHTH VIS SCI, V42, P3331
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Borel P, 2011, ANN MED, V43, P47, DOI 10.3109/07853890.2010.531757
   Broekmans WMR, 2002, AM J CLIN NUTR, V76, P595, DOI 10.1093/ajcn/76.3.595
   Calvo MM, 2005, CRIT REV FOOD SCI, V45, P671, DOI 10.1080/10408690590957034
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   CLEVIDENCE BA, 1993, METHOD ENZYMOL, V214, P33
   Connolly EE, 2010, CURR EYE RES, V35, P335, DOI 10.3109/02713680903521951
   Creuzot-Garcher C, 2014, INVEST OPHTH VIS SCI, V55, P2941, DOI 10.1167/iovs.13-13568
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Delyfer MN, 2012, INVEST OPHTH VIS SCI, V53, P1204, DOI 10.1167/iovs.11-8721
   Dennison JL, 2013, EXP EYE RES, V116, P190, DOI 10.1016/j.exer.2013.08.014
   Dietzel M, 2011, INVEST OPHTH VIS SCI, V52, P3452, DOI 10.1167/iovs.10-6713
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Gorusupudi A, 2016, J LIPID RES, V57, P499, DOI 10.1194/jlr.P065540
   Hammond BR, 2002, INVEST OPHTH VIS SCI, V43, P47
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   Howells O, 2011, GRAEF ARCH CLIN EXP, V249, P315, DOI 10.1007/s00417-010-1577-5
   Johnson EJ, 2008, AM J CLIN NUTR, V87, P1521, DOI 10.1093/ajcn/87.5.1521
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Li BX, 2010, PHOTOCH PHOTOBIO SCI, V9, P1418, DOI 10.1039/c0pp00126k
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   McMahon A, 2010, BRIT J OPHTHALMOL, V94, P1127, DOI 10.1136/bjo.2008.149286
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Merle BMJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079848
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   Meyers KJ, 2014, INVEST OPHTH VIS SCI, V55, P587, DOI 10.1167/iovs.13-13216
   Meyers KJ, 2013, INVEST OPHTH VIS SCI, V54, P2333, DOI [10.1167/iovs.12-10867, 10.1167/iovs.13-13216]
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   OLSON JA, 1984, J NATL CANCER I, V73, P1439
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Richer Stuart, 2007, Optometry, V78, P213, DOI 10.1016/j.optm.2006.10.019
   Roberts RL, 2009, CLIN DERMATOL, V27, P195, DOI 10.1016/j.clindermatol.2008.01.011
   SanGiovanni JP, 2009, ARCH OPHTHALMOL-CHIC, V127, P110, DOI 10.1001/archophthalmol.2008.518
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2010, MOL VIS, V16, P2412
   Thomas TR, 2004, METABOLISM, V53, P749, DOI 10.1016/j.metabol.2003.12.019
   Thurnham DI, 2007, NUTR RES REV, V20, P163, DOI 10.1017/S0954422407842235
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   Tyssandier V, 2002, INT J VITAM NUTR RES, V72, P300, DOI 10.1024/0300-9831.72.5.300
   Yoshizako H, 2016, ACTA OPHTHALMOL, V94, pE411, DOI 10.1111/aos.13106
   Yu J, 2012, INVEST OPHTH VIS SCI, V53, P2106, DOI 10.1167/iovs.11-8518
   Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817
NR 63
TC 12
Z9 12
U1 2
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2017
VL 95
IS 8
BP e763
EP e769
DI 10.1111/aos.13408
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FP5FR
UT WOS:000417645900016
PM 28271618
OA Bronze
DA 2022-11-30
ER

PT J
AU Chowers, I
   Meir, T
   Lederman, M
   Goldenberg-Cohen, N
   Cohen, Y
   Banin, E
   Averbukh, E
   Hemo, I
   Pollack, A
   Axer-Siegel, R
   Weinstein, O
   Hoh, J
   Zack, DJ
   Galbinur, T
AF Chowers, Itay
   Meir, Tal
   Lederman, Michal
   Goldenberg-Cohen, Nitza
   Cohen, Yoram
   Banin, Eyal
   Averbukh, Edward
   Hemo, Itzhak
   Pollack, Ayala
   Axer-Siegel, Ruth
   Weinstein, Orly
   Hoh, Josephine
   Zack, Donald J.
   Galbinur, Tural
TI Sequence variants in HTRA1 and LOC387715/ARMS2 and phenotype and
   response to photodynamic therapy in neovascular age-related macular
   degeneration in populations from Israel
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT FACTOR-H; FACTOR HY402H POLYMORPHISM; PROMOTER POLYMORPHISM;
   JAPANESE POPULATION; GENE POLYMORPHISM; ASSOCIATION; RISK; CFH;
   SUSCEPTIBILITY; GENOTYPES
AB Purpose: Single nucleotide polymorphisms (SNPs) in the tightly linked LOC387715/ARMS2 and HTRA1 genes have been associated with age-related macular degeneration (AMD). We tested whether these SNPs are associated with AMD in Israeli populations, if they underlie variable phenotype and response to therapy in neovascular AMD (NVAMD), and if HTRA1 expression in vivo is associated with its promoter variant.
   Methods: Genotyping for the rs10490924 SNP in LOC387715/ARMS2 and the rs11200638 SNP in HTRA1 was performed on 255 NVAMD patients and 119 unaffected controls from Ashkenazi and Sephardic Jewish, and from Arab origins which are the main ethnic groups composing the Israeli population. Genotyping was correlated with phenotype and response to therapy among 143 patients who underwent photodynamic therapy (PDT). HTRA1 mRNA levels in white blood cells (WBCs), measured by quantitative PCR, were correlated with genotype in 27 participants.
   Results: Both SNPs were in almost complete linkage disequilibrium (D'=0.96- 1). Homozygotes for the T allele of rs10490924 had an odds ratio (OR) of 8.6, with a 95% confidence interval (CI) of 3.5-20.8, and homozygotes for the A allele of rs11200638 had an OR of 10.7, with a 95% CI of 3.2-35.7, for having AMD (p < 0.00001). There was no association among these SNPs and phenotype or response to PDT. HTRA1 mRNA levels in WBCs were not associated with rs11200638 genotypes.
   Conclusions: The rs10490924 SNP in LOC387715/ARMS2 and the rs11200638 SNP in HTRA1 are strongly associated with NVAMD in this Israeli population. These variants do not have a major contribution to the variable phenotype and response to PDT which characterize NVAMD.
C1 [Chowers, Itay; Meir, Tal; Lederman, Michal; Banin, Eyal; Averbukh, Edward; Hemo, Itzhak; Galbinur, Tural] Hadassah Hebrew Univ, Med Ctr, Dept Ophthalmol, IL-91120 Jerusalem, Israel.
   [Goldenberg-Cohen, Nitza; Axer-Siegel, Ruth] Rabin Med Ctr, Dept Ophthalmol, Petah Tiqwa, Israel.
   [Cohen, Yoram] Tel Aviv Univ, Chaim Sheba Med Ctr, Canc Res Ctr, IL-69978 Tel Aviv, Israel.
   [Pollack, Ayala] Kaplan Med Ctr, Dept Ophthalmol, Rehovot, Israel.
   [Weinstein, Orly] Soroka Univ, Dept Ophthalmol, Med Ctr, Beer Sheva, Israel.
   [Hoh, Josephine] Yale Univ, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA.
   [Zack, Donald J.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
C3 Hebrew University of Jerusalem; Hadassah University Medical Center;
   Rabin Medical Center; Chaim Sheba Medical Center; Tel Aviv University;
   Hebrew University of Jerusalem; Kaplan Medical Center; Ben Gurion
   University; Soroka Medical Center; Yale University; Johns Hopkins
   University; Johns Hopkins Medicine
RP Chowers, I (通讯作者)，Hadassah Hebrew Univ, Med Ctr, Dept Ophthalmol, POB 12000, IL-91120 Jerusalem, Israel.
EM chowers@hadassah.org.il
RI Goldenberg-Cohen, Nitza/O-1638-2019; Goldenberg-Cohen, Nitza/F-2936-2018
OI Goldenberg-Cohen, Nitza/0000-0002-5648-1873; Goldenberg-Cohen,
   Nitza/0000-0002-5648-1873; Zack, Don/0000-0002-7966-1973
FU Israel Science Fund [624/05]
FX We thank the individuals who provided blood samples for the purpose of
   the study. This study was supported in part by a grant from the Israel
   Science Fund (624/05).
CR Abu Asleh S, 2007, ISRAEL MED ASSOC J, V9, P656
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRANTLEY MA, 2008, EYE
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Canfield AE, 2007, BIOCHEM SOC T, V35, P669, DOI 10.1042/BST0350669
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Chen HY, 2008, VISION RES, V48, P690, DOI 10.1016/j.visres.2007.10.014
   Chowers I, 2008, MOL VIS, V14, P1829
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gibbs D, 2008, VISION RES, V48, P685, DOI 10.1016/j.visres.2007.10.022
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Leveziel N, 2008, INVEST OPHTH VIS SCI, V49, P3090, DOI 10.1167/iovs.07-1540
   Leveziel N, 2007, MOL VIS, V13, P2153
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P309, DOI 10.1097/IAE.0b013e31814cef3a
   Lu F, 2007, VISION RES, V47, P3120, DOI 10.1016/j.visres.2007.08.010
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Nebel A, 2001, AM J HUM GENET, V69, P1095, DOI 10.1086/324070
   Pulido JS, 2007, OPHTHALMIC GENET, V28, P203, DOI 10.1080/13816810701649617
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Seitsonen S, 2008, ACTA OPHTHALMOL, V86, P390, DOI 10.1111/j.1600-0420.2007.01050.x
   Shuler RK, 2008, AM J OPHTHALMOL, V145, P303, DOI 10.1016/j.ajo.2007.09.027
   SUBFOVEAL N, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Weger M, 2007, MOL VIS, V13, P1274
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yoshida T, 2007, MOL VIS, V13, P545
NR 40
TC 50
Z9 50
U1 1
U2 1
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD DEC 8
PY 2008
VL 14
IS 260-62
BP 2263
EP 2271
PG 9
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 413VV
UT WOS:000263821500003
PM 19065273
DA 2022-11-30
ER

PT J
AU Faatz, H
   Rothaus, K
   Ziegler, M
   Book, M
   Heimes-Bussmann, B
   Pauleikhoff, D
   Lommatzsch, A
AF Faatz, Henrik
   Rothaus, Kai
   Ziegler, Martin
   Book, Marius
   Heimes-Bussmann, Britta
   Pauleikhoff, Daniel
   Lommatzsch, Albrecht
TI Vascular Analysis of Type 1, 2, and 3 Macular Neovascularization in
   Age-Related Macular Degeneration Using Swept-Source Optical Coherence
   Tomography Angiography Shows New Insights into Differences of Pathologic
   Vasculature and May Lead to a More Personalized Understanding
SO BIOMEDICINES
LA English
DT Article
DE MNV morphology; imaging; age-related macular degeneration; OCT
   angiography; choroidal neovascularization
ID CHOROIDAL NEOVASCULARIZATION; QUANTITATIVE-ANALYSIS; OCT ANGIOGRAPHY;
   FEATURES; GROWTH
AB Background: The clinical appearance of macular neovascularization (MNV) in age-related macular degeneration (nAMD) varies widely, but so far, this has had no relevance in terms of therapeutic approaches or prognosis. Therefore, our purpose was to investigate if and which differences exist in the vascular architecture of MNV and to quantify them. Methods: In 90 patients with newly diagnosed nAMD, MNV was identified by means of optical coherence tomography angiography (OCTA), and automated quantitative vascular analysis was carried out. The analyzed vascular parameters were area, flow, fractal dimension (FD), total vascular length (sumL), number of vascular nodes (numN), flow, and average vessel caliber (avgW). The current classification of MNVs divides them according to their localization into type 1 (grown from the choroid below the RPE), type 2 (grown from the choroid through RPE), and type 3 (grown from the retina toward the RPE). We compared the analyzed vascular parameters of each of the three MNV types. Kruskal-Wallis test was applied, Dunn test was performed for post hoc analysis, and for pairwise comparison, p-values were adjusted using Bonferroni comparison. Results: Regarding the MNV area, there was no significant difference between types 1 and 2, but type 3 was significantly smaller than types 1 and 2 (p < 0.00001). For FD, types 1 and 2 did not differ significantly, but again, type 3 was lower than type 1 and 2 (p < 0.00001). The numN were significantly higher in types 1 and 3 than in 2 (p < 0.005), but not between types 1 and 3. No significant differences were found between MNV types for flow. As for sumL, types 1 and 2 did not differ significantly, but type 3 was significantly lower than types 1 and 2 (p < 0.00001). For avgW, there was no significant difference between types 1 and 2 or between types 2 and 3, but type 3 was significantly larger than type 1 (p < 0.05). Conclusions OCTA yields detailed information on the vascular morphology of MNV in patients with nAMD and is able to show differences among types 1, 2, and 3. Especially comparing types 1 and 2 with type 3 reveals significant differences in area, FD, sumL, and numN. One explanation could be the similar pathogenesis of types 1 and 2 with their origin in the choroid and their growth towards the retinal pigment epithelium (RPE), whereas type 3 originates in the deep capillary plexus. Between types 1 and 2, however, only the numN differ significantly, which could be due to the fact that type 1 spreads horizontally below the RPE and, thus, display more vascular branching, while type 2 grows more vertically through the RPE and under the neurosensory retina. Detailed information about the pathologic vasculature is important for proper monitoring of the disease and to assess the efficacy of medication, especially with regard to new substances. This should be taken into consideration in future studies.
C1 [Faatz, Henrik; Rothaus, Kai; Ziegler, Martin; Book, Marius; Heimes-Bussmann, Britta; Pauleikhoff, Daniel; Lommatzsch, Albrecht] St Franziskus Hosp, Dept Ophthalmol, D-48145 Munster, Germany.
   [Faatz, Henrik; Pauleikhoff, Daniel; Lommatzsch, Albrecht] Univ Essen Duisburg, Achim Wessing Inst Imaging Ophthalmol, D-45147 Essen, Germany.
   [Pauleikhoff, Daniel; Lommatzsch, Albrecht] Univ Essen Duisburg, Dept Ophthalmol, D-45147 Essen, Germany.
C3 St. Franziskus-Hospital; University of Duisburg Essen; University of
   Duisburg Essen
RP Faatz, H (通讯作者)，St Franziskus Hosp, Dept Ophthalmol, D-48145 Munster, Germany.; Faatz, H (通讯作者)，Univ Essen Duisburg, Achim Wessing Inst Imaging Ophthalmol, D-45147 Essen, Germany.
EM henrik.faatz@augen-franziskus.de; kai.rothaus@augen-franziskus.de;
   martin.ziegler@augen-franziskus.de; marius.book@augen-franziskus.de;
   britta.heimes@augen-franziskus.de; dapauleikhoff@muenster.de;
   albrecht.lommatzsch@augen-franziskus.de
OI Ziegler, Martin/0000-0001-8495-2276; Faatz, Henrik/0000-0002-5363-0052
FU Werner Jackstadt-Foundation
FX We would like to gratefully acknowledge the support of the Werner
   Jackstadt-Foundation for our research project.
CR Ahmed M, 2021, ANN MED SURG, V70, DOI 10.1016/j.amsu.2021.102826
   Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Al-Sheikh M, 2017, OSLI RETINA, V48, P385, DOI 10.3928/23258160-20170428-04
   Ammar MJ, 2020, CURR OPIN OPHTHALMOL, V31, P215, DOI 10.1097/ICU.0000000000000657
   Arrigo A, 2020, RETINA-J RET VIT DIS, V40, P2263, DOI 10.1097/IAE.0000000000002775
   Cabral D, 2021, RETINA-J RET VIT DIS, V41, P287, DOI 10.1097/IAE.0000000000002842
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Donato L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073484
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   Faatz H, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237785
   Faatz H, 2021, OPHTHALMOLOGE, V118, P154, DOI 10.1007/s00347-020-01136-z
   Faatz H, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000369
   Faatz H, 2019, EYE, V33, P1466, DOI 10.1038/s41433-019-0429-8
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Jin K, 2022, ACTA OPHTHALMOL, V100, pE512, DOI 10.1111/aos.14928
   Kim K, 2021, GRAEF ARCH CLIN EXP, V259, P2103, DOI 10.1007/s00417-021-05099-y
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lommatzsch C, 2019, CLIN OPHTHALMOL, V13, P2527, DOI 10.2147/OPTH.S230192
   Luo L, 2013, ELIFE, V2, DOI 10.7554/eLife.00324
   Nakano Y, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216304
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pauleikhoff D, 2019, GRAEF ARCH CLIN EXP, V257, P1381, DOI 10.1007/s00417-019-04323-0
   Phasukkijwatana N, 2017, BRIT J OPHTHALMOL, V101, P597, DOI 10.1136/bjophthalmol-2016-308815
   Querques G, 2016, DEV OPHTHALMOL, V56, P57, DOI 10.1159/000442779
   Rinaldi C, 2021, LIFE-BASEL, V11, DOI 10.3390/life11080767
   Rothaus K, 2005, LECT NOTES COMPUT SC, V3687, P502
   Ryu G, 2021, AM J OPHTHALMOL, V225, P57, DOI 10.1016/j.ajo.2020.12.026
   Scimone C, 2021, EXP EYE RES, V209, DOI 10.1016/j.exer.2021.108641
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Sulzbacher F, 2017, ACTA OPHTHALMOL, V95, P414, DOI 10.1111/aos.13364
   Xu JJ, 2021, OPHTHALMIC GENET, V42, P768, DOI 10.1080/13816810.2021.1952617
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Zhang QQ, 2017, OPHTHALMOL RETINA, V1, P124, DOI 10.1016/j.oret.2016.08.005
NR 36
TC 2
Z9 2
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2227-9059
J9 BIOMEDICINES
JI Biomedicines
PD MAR
PY 2022
VL 10
IS 3
AR 694
DI 10.3390/biomedicines10030694
PG 14
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA 0D1WQ
UT WOS:000775793500001
PM 35327496
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Holz, FG
   Minnella, AM
   Tuli, R
   Yoganathan, P
   Parikh, S
   Hamilton, R
AF Holz, Frank G.
   Minnella, Angelo M.
   Tuli, Raman
   Yoganathan, Pradeepa
   Parikh, Soumil
   Hamilton, Robin
CA LUMINOUS Study Grp
TI Ranibizumab treatment patterns in prior ranibizumab-treated neovascular
   age-related macular degeneration patients: Real-world outcomes from the
   LUMINOUS study
SO PLOS ONE
LA English
DT Article
ID VISUAL IMPAIRMENT; LEGAL BLINDNESS; POOLED ANALYSIS; AMD; PREVALENCE;
   SAFETY
AB Purpose
   To evaluate the effectiveness, safety, and treatment patterns of ranibizumab 0.5 mg in prior ranibizumab-treated patients with neovascular age-related macular degeneration (nAMD) enrolled in the LUMINOUS (TM) study.
   Patients and methods
   LUMINOUS, a 5-year, prospective, multicenter, observational study, recruited 30,138 adult patients (treatment-naive or prior ranibizumab-treated or other ocular treatments) across all approved indications for ranibizumab. Patients were treated as per local ranibizumab label of participating countries. Here we report the mean change in visual acuity (VA) at Year 1, treatment exposure, overall incidence of ocular, non-ocular adverse events (AEs) and serious AEs (SAEs) in prior ranibizumab-treated nAMD patients (n = 16,167).
   Results
   At baseline, the mean (standard deviation [SD]) age of patients was 78.4 (9.0) years, 59.0% were female, and 80.0% were Caucasian. At Year 1 (n = 10,168), the mean (SD) VA change was -1.6 (12.6) letters (baseline VA: 58.3 [19.0] letters) with a mean (SD) of 4.7 (3.1) ranibizumab injections. Stratified by duration of prior ranibizumab treatment of <1 (n = 4,112), 1 to <2 (n = 2,095), 2 to <3 (n = 1,506), 3 to <4 (n = 1,123), 4 to <5 (n = 689), and >= 5 (n = 256) years, the mean (SD) VA change at Year 1 were -1.2 (13.5), -2.0 (12.3), -2.0 (11.3), -1.9 (11.8), -2.5 (10.9), and 0.0 (11.2) letters, respectively. Mean (SD) VA change in patients who received <= 6 and >6 injections over 1 year was -1.8 (13.8) and +0.5 (12.5) letters, respectively. The rate of ocular/non-ocular AEs and SAEs across all prior ranibizumab-treated patients over 5 years were 13.29%/23.02% and 0.84%/13.66%, respectively.
   Conclusions
   Overall, regardless of the prior ranibizumab-treatment duration, VA was maintained in these patients at Year 1, and those receiving >= 6 injections showed a trend towards gaining letters. There were no new safety signals. These results may help inform routine clinical practice to appropriately treat nAMD patients with ranibizumab to achieve optimal visual outcomes.
C1 [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Minnella, Angelo M.] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli IRCCS, Dept Ophthalmol, Rome, Italy.
   [Tuli, Raman] Retina Ctr Ottawa, Ottawa, ON, Canada.
   [Tuli, Raman] Univ Ottawa, Dept Ophthalmol, Ottawa, ON, Canada.
   [Yoganathan, Pradeepa] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
   [Yoganathan, Pradeepa] Windsor Eye Associates, Windsor, ON, Canada.
   [Yoganathan, Pradeepa] Wayne State Univ, Kresge Eye Inst, Detroit, MI USA.
   [Parikh, Soumil] Novartis Pharma AG, Basel, Switzerland.
   [Hamilton, Robin] Moorfields Eye Hosp, Moorfields Eye Hosp NHS Fdn Trust, Dept Med Retina, London, England.
   [Hamilton, Robin] Moorfields Eye Hosp, Biomed Res Ctr BRC, Natl Inst Hlth Res NIHR, London, England.
C3 University of Bonn; Catholic University of the Sacred Heart; IRCCS
   Policlinico Gemelli; University of Ottawa; University of Toronto; Wayne
   State University; Novartis; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust; University of
   London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust
RP Hamilton, R (通讯作者)，Moorfields Eye Hosp, Moorfields Eye Hosp NHS Fdn Trust, Dept Med Retina, London, England.; Hamilton, R (通讯作者)，Moorfields Eye Hosp, Biomed Res Ctr BRC, Natl Inst Hlth Res NIHR, London, England.
EM Robin.Hamilton@moorfields.nhs.uk
OI Hamilton, Robin/0000-0003-2861-8761
FU Bayer; Centervue; Genentech/Roche; Heidelberg Engineering; Novartis;
   Zeiss; Allergan; Bayer Healthcare; Novartis Pharmaceutical; Thea
   Laboratoire; Roche; Apelis; Novartis Pharmaceuticals; Novartis Pharma
   AG, Basel, Switzerland
FX FGH receives grants from Bayer, Centervue, Genentech/Roche, Heidelberg
   Engineering, Novartis, and Zeiss, and is a consultant for Acucela,
   Alcon, Bayer, BoehringerIngelheim, Galimedix, Genentech, Heidelberg
   Engineering, Lin-Bioscience, Khanghong, Oxurion, Novartis, Roche, and
   Zeiss. AMM is a consultant for Thea Laboratoire and receives travel and
   meeting grant from Allergan, Bayer Healthcare, Novartis Pharmaceutical,
   Thea Laboratoire. RT receives grants from Novartis, Roche and Apelis and
   is a member of Advisory boards in Novartis, Bayer. PY receives honoraria
   and non-financial support from Bayer and Novartis, honoraria from Alcon,
   Alimera Sciences, Allergan, Bausch and Lomb, Genentech, and Knight
   Therapeutics. SP is an employee of Novartis Pharma AG, Basel,
   Switzerland. RH Consultant for Allergan, Bayer Healthcare, Novartis
   Pharmaceuticals, and Roche; receives grants from Bayer Healthcare,
   Novartis Pharmaceuticals and Roche; receives lecture fees from Allergan,
   Roche, Bayer Healthcare, and Novartis Pharmaceuticals. Funding was
   provided by Novartis Pharma AG, Basel, Switzerland for the overall study
   design and medical writing and editorial assistance for this article. In
   conjunction with the LUMINOUS study group, Novartis Pharma AG, Basel,
   Switzerland, participated in the design of the study; analysis and
   interpretation of the data; preparation, review, and approval of the
   manuscript; and decision to submit the manuscript for publication.
   Additionally, Novartis Pharma AG was responsible for the conduct of the
   study and oversight of the collection and management of data. The study
   is registered with www.clinicaltrials.gov (NCT01318941).
CR Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Borooah S, 2015, EYE, V29, P1156, DOI 10.1038/eye.2015.83
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   DSUR, 2018, NOV DAT FIL
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Holz FG, 2019, RETINA
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Johnston RL, 2017, ADV THER, V34, P703, DOI 10.1007/s12325-017-0483-1
   Johnston RL, 2016, OPHTHALMOLOGY, V123, P2386, DOI 10.1016/j.ophtha.2016.07.037
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Kim HS, 2018, J KOREAN MED SCI, V33, DOI 10.3346/jkms.2018.33.e213
   Lee AY, 2015, BRIT J OPHTHALMOL, V99, P1045, DOI 10.1136/bjophthalmol-2014-306229
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mitchell P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101072
   Pagliarini S, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/857148
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rousseau C, 2015, VALUE HLTH, V18, P2670
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zarbin MA, 2017, JAMA OPHTHALMOL, V135, P424, DOI 10.1001/jamaophthalmol.2017.0455
NR 26
TC 1
Z9 1
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 30
PY 2020
VL 15
IS 12
AR e0244183
DI 10.1371/journal.pone.0244183
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA PP1TQ
UT WOS:000605651300070
PM 33378369
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kume, A
   Ohshiro, T
   Sakurada, Y
   Kikushima, W
   Yoneyama, S
   Kashiwagi, K
AF Kume, Atsuki
   Ohshiro, Tomohiro
   Sakurada, Yoichi
   Kikushima, Wataru
   Yoneyama, Seigo
   Kashiwagi, Kenji
TI Treatment Patterns and Health Care Costs for Age-Related Macular
   Degeneration in Japan An Analysis of National Insurance Claims Data
SO OPHTHALMOLOGY
LA English
DT Article
ID RANIBIZUMAB; PREVALENCE; IMPROVEMENT; POPULATION; PEGAPTANIB; EFFICACY
AB Purpose: To investigate changes in the proportion of patients with age-related macular degeneration (AMD) visiting hospitals and to investigate factors associated with AMD, treatments, and medical expenses, as well as the outlook for AMD in Japan using a large health insurance database.
   Design: Analysis of national insurance claims data.
   Participants: People 40 years of age or older who were registered in the Japan Medical Data Center database.
   Methods: Patients with AMD were identified from 2005 through 2013 based on International Classification of Diseases, 10th revision, diagnosis codes. Changes in patient proportions, treatment procedures, and medical expenses were investigated during the study period. The data for each year were compared after adjustment based on the 2010 Japanese population annual census. The outlook for patients with AMD was predicted based on the combination of data in 2013 and an official future population prediction report.
   Main Outcome Measures: Changes in treatment patterns and health care costs in Japan.
   Results: A total of 3 401 299 participants were included in the analysis, and 3058 AMD patients were identified over the 9-year period. The proportion of patients with AMD increased significantly from 0.084% (95% confidence interval, 0.050%-0.119%) in 2005 to 0.26% (95% confidence interval, 0.24%-0.29%) in 2013 (P = 0.0001, Pearson correlation coefficient test). There were significantly more men than women (odds ratio, 1.25; 95% confidence interval, 1.14-1.37), and the proportion of patients with AMD increased rapidly with age. Photodynamic therapy was replaced by antievascular endothelial growth factor (VEGF) therapy as the predominant therapy from 2009 onward. Medical expenses per 10 000 persons increased from $1530 to $137 000 over the 9-year period. The proportion of AMD patients is predicted to increase in the future and will reach a maximum of 223 000 in 2035.
   Conclusions: The proportion of AMD patients visiting hospitals, medical expenses, and the frequency of anti-VEGF therapy increased significantly over the 9-year period. These increasing trends are predicted to continue in Japan. (C) 2016 by the American Academy of Ophthalmology.
C1 [Kume, Atsuki; Ohshiro, Tomohiro; Sakurada, Yoichi; Kikushima, Wataru; Yoneyama, Seigo; Kashiwagi, Kenji] Yamanashi Univ, Dept Ophthalmol, Chuo Yamanashi, Japan.
C3 University of Yamanashi
RP Kashiwagi, K (通讯作者)，Univ Yamanashi, Dept Ophthalmol, 1110 Shimo Kato, Chuo Yamanashi, Japan.
EM kenjik@yamanashi.ac.jp
OI Kashiwagi, Kenji/0000-0001-8506-8503
CR Adhi M, 2013, CURR OPIN OPHTHALMOL, V24, P213, DOI 10.1097/ICU.0b013e32835f8bf8
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Kashiwagi K, 2014, JPN J OPHTHALMOL, V58, P68, DOI 10.1007/s10384-013-0284-2
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, p[1376, e1]
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kimura S, 2010, J EPIDEMIOL, V20, P413, DOI 10.2188/jea.JE20090066
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Qualls LG, 2013, RETINA-J RET VIT DIS, V33, P854, DOI 10.1097/IAE.0b013e31826f065e
   Regatieri CV, 2012, RETINA-J RET VIT DIS, V32, P865, DOI 10.1097/IAE.0b013e318251a3a8
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Takahashi Kanji, 2012, Nippon Ganka Gakkai Zasshi, V116, P1150
   Takahashi Kanji, 2008, Nippon Ganka Gakkai Zasshi, V112, P1076
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Tano Y, 2010, ACTA OPHTHALMOL, V88, P309, DOI 10.1111/j.1755-3768.2009.01843.x
   Yasuda M, 2009, J EYE, V26, P25
   Yuzawa M, 2015, OPHTHALMOLOGY, V122, P571, DOI 10.1016/j.ophtha.2014.09.024
NR 32
TC 18
Z9 19
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2016
VL 123
IS 6
BP 1263
EP 1268
DI 10.1016/j.ophtha.2016.01.042
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DM7BD
UT WOS:000376506400022
PM 26927204
DA 2022-11-30
ER

PT J
AU Wilde, C
   Patel, M
   Lakshmanan, A
   Amankwah, R
   Dhar-Munshi, S
   Amoaku, W
AF Wilde, C.
   Patel, M.
   Lakshmanan, A.
   Amankwah, R.
   Dhar-Munshi, S.
   Amoaku, W.
TI Continuing Medical Education: The diagnostic accuracy of spectral-domain
   optical coherence tomography for neovascular age-related macular
   degeneration: a comparison with fundus fluorescein angiography
SO EYE
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; VISUAL IMPAIRMENT;
   PHOTOCOAGULATION; RANIBIZUMAB; GUIDELINES; LESIONS
AB Purpose To evaluate the diagnostic accuracy of spectral-domain optical coherence tomography (SD-OCT) for neovascular age-related macular degeneration (nAMD): a comparison against fundus fluorescein angiography (FFA).
   Methods A retrospective review of SD-OCT, colour fundus photographs (FP), and FFA of 411 consecutive patients referred to a rapid access Macular Clinic over a 4-year period was performed. FFA images were reviewed nonstereoscopically. SD-OCT images were acquired using the Topcon 3D OCT-1000 instrument. All FFA and OCT images were graded by at least two ophthalmologists independently. Side-by-side grading took place with immediate open discussion and adjudication. If there was disagreement between the two grading ophthalmologists or they were not 90% confident of their assigned grade, then adjudication by a third ophthalmologist was performed.
   Results A total of 278 eyes were graded as having choroidal neovascularisation (CNV) with SD-OCT and 231 diagnosed with FFA. The main diagnostic CNV classifications on FFA were: classic no occult in 27 eyes, predominantly classic in 16, minimally classic in 50, occult in 129, and 9 peripapillary membranes. There were a total of 47 false positives with SD-OCT: a rate of 16.9%. The sensitivity and specificity of SD-OCT alone for detecting CNV was 100 and 80.8%, respectively.
   Conclusion Our study confirms SD-OCT in comparison to the reference standard of nonstereoscopic FFA is highly sensitive at detecting newly presenting nAMD in the setting of a specialist AMD clinic where the investigations are interpreted by trained specialists. However, it does not seem accurate enough to replace FFA in the diagnosis on nAMD in current practice.
C1 [Wilde, C.; Amoaku, W.] Univ Nottingham, Queens Med Ctr, EENT Ctr, Ophthalmol & Vis Sci,Div Clin Neurosci, Nottingham NG7 2UH, England.
   [Patel, M.] Derby Hosp NHS Fdn Trust, Ophthalmol, Derby, England.
   [Lakshmanan, A.; Amankwah, R.; Dhar-Munshi, S.] Sherwood Forest Hosp NHS Fdn Trust, Eye Clin, Sutton In Ashfield, Notts, England.
C3 University of Nottingham
RP Amoaku, W (通讯作者)，Univ Nottingham, Queens Med Ctr, EENT Ctr, Ophthalmol & Vis Sci,Div Clin Neurosci, B Floor,Derby Rd, Nottingham NG7 2UH, England.
EM winfried.amoaku@nottingham.ac.uk
OI Amoaku, Winfried/0000-0001-5028-7984
FU Macular Society UK
FX This work was part funded by a research grant from the Macular Society
   UK. The views expressed are those of the authors.
CR Amissah-Arthur KN, 2012, EYE, V26, P394, DOI 10.1038/eye.2011.335
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Castillo MM, 2014, EYE, V28, P1399, DOI 10.1038/eye.2014.214
   Chakravarthy U, 2013, AGE RELATED MACULAR
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   Eter N, 2005, RETINA-J RET VIT DIS, V25, P691, DOI 10.1097/00006982-200509000-00002
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Keane PA, 2009, AM J OPHTHALMOL, V148, P242, DOI 10.1016/j.ajo.2009.03.004
   Khurana RN, 2010, OPHTHALMOLOGY, V117, P1376, DOI 10.1016/j.ophtha.2009.11.039
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kwan ASL, 2006, CLIN EXP OPHTHALMOL, V34, P33, DOI 10.1111/j.1442-9071.2006.01136.x
   Mokwa NF, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/385915
   Padnick-Silver L, 2012, RETINA-J RET VIT DIS, V32, P1045, DOI 10.1097/IAE.0b03e31823fb82b
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Sandhu SS, 2005, BRIT J OPHTHALMOL, V89, P967, DOI 10.1136/bjo.2004.060863
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sulzbacher F, 2011, AM J OPHTHALMOL, V152, P799, DOI 10.1016/j.ajo.2011.04.011
   Talks J, 2007, BRIT J OPHTHALMOL, V91, P600, DOI 10.1136/bjo.2006.108043
   YANNUZZI LA, 1986, OPHTHALMOLOGY, V93, P611
NR 24
TC 44
Z9 47
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAY
PY 2015
VL 29
IS 5
BP 602
EP 610
DI 10.1038/eye.2015.44
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CH5JC
UT WOS:000354070900002
PM 25907206
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Golestaneh, N
   Chu, Y
   Cheng, SK
   Cao, H
   Poliakov, E
   Berinstein, DM
AF Golestaneh, Nady
   Chu, Yi
   Cheng, Shuk Kei
   Cao, Hong
   Poliakov, Eugenia
   Berinstein, Daniel M.
TI Repressed SIRT1/PGC-1 alpha pathway and mitochondrial disintegration in
   iPSC-derived RPE disease model of age-related macular degeneration
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE AMD; RPE; Oxidative stress; Mitochondria; Cell viability; ROS; PGC-1
   alpha; SIRT1
ID PLURIPOTENT STEM-CELLS; RETINAL-PIGMENT EPITHELIUM; OXIDATIVE STRESS;
   ENERGY-EXPENDITURE; DIRECT PHOSPHORYLATION; EPIGENETIC MEMORY;
   SKELETAL-MUSCLE; ARPE-19 CELLS; PGC-1-ALPHA; AMPK
AB Background: Study of age related macular degeneration (AMD) has been hampered by lack of human models that represent the complexity of the disease. Here we have developed a human in vitro disease model of AMD to investigate the underlying AMD disease mechanisms.
   Methods: Generation of iPSCs from retinal pigment epithelium (RPE) of AMD donors, age-matched normal donors, skin fibroblasts of a dry AMD patient, and differentiation of iPSCs into RPE (AMD RPE-iPSC-RPE, normal RPE-iPSC-RPE and AMD Skin-iPSC-RPE, respectively). Immunostaining, cell viability assay and reactive oxygen species (ROS) production under oxidative stress conditions, electron microscopy (EM) imaging, ATP production and glycogen concentration assays, quantitative real time PCR, western blot, karyotyping.
   Results: The AMD RPE-iPSC-RPE and AMD Skin-iPSC-RPE present functional impairment and exhibit distinct disease phenotypes compared to RPE-iPSC-RPE generated from normal donors (Normal RPE-iPSC-RPE). The AMD RPE-iPSC-RPE and AMD Skin-iPSC-RPE show increased susceptibility to oxidative stress and produced higher levels of reactive oxygen species (ROS) under stress in accordance with recent reports. The susceptibility to oxidative stress-induced cell death in AMD RPE-iPSC-RPE and Skin-iPSC-RPE was consistent with inability of the AMD RPE-iPSC-RPE and Skin-iPSC-RPE to increase SOD2 expression under oxidative stress. Phenotypic analysis revealed disintegrated mitochondria, accumulation of autophagosomes and lipid droplets in AMD RPE-iPSC-RPE and AMD Skin-iPSC-RPE. Mitochondrial activity was significantly lower in AMD RPE-iPSC-RPE and AMD Skin-iPSC-RPE compared to normal cells and glycogen concentration was significantly increased in the diseased cells. Furthermore, Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 alpha), a regulator of mitochondrial biogenesis and function was repressed, and lower expression levels of NAD-dependent deacetylase sirtuin1 (SIRT1) were found in AMD RPE-iPSC-RPE and AMD Skin-iPSC-RPE as compared to normal RPE-iPSC-RPE.
   Conclusions: Our studies suggest SIRT1/PGC-1 alpha as underlying pathways contributing to AMD pathophysiology, and open new avenues for development of targeted drugs for treatment of this devastating neurodegenerative disease of the visual system.
C1 [Golestaneh, Nady; Chu, Yi; Cheng, Shuk Kei; Cao, Hong] Georgetown Univ, Med Ctr, Dept Ophthalmol, 3900 Reservoir Rd NW,Med Dent Bldg,Room NE203, Washington, DC 20057 USA.
   [Golestaneh, Nady] Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20007 USA.
   [Golestaneh, Nady] Georgetown Univ, Med Ctr, Dept Biochem & Mol & Cellular Biol, Washington, DC 20007 USA.
   [Poliakov, Eugenia] NEI, Retinal Cell & Mol Biol LRCMB, NIH, Bethesda, MD 20892 USA.
   [Berinstein, Daniel M.] Retina Grp Washington, Chevy Chase, MD 20815 USA.
C3 Georgetown University; Georgetown University; Georgetown University;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Golestaneh, N (通讯作者)，Georgetown Univ, Med Ctr, Dept Ophthalmol, 3900 Reservoir Rd NW,Med Dent Bldg,Room NE203, Washington, DC 20057 USA.; Golestaneh, N (通讯作者)，Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20007 USA.; Golestaneh, N (通讯作者)，Georgetown Univ, Med Ctr, Dept Biochem & Mol & Cellular Biol, Washington, DC 20007 USA.
EM ncg8@georgetown.edu
OI Golestaneh, Nady/0000-0001-7573-0962
FU Macular Degeneration Research, a program of BrightFocus Foundation
   [M2014039]; Prevention of Blindness Society of Metropolitan Washington
   (POB)
FX This work was funded in part by the Macular Degeneration Research
   (M2014039), a program of BrightFocus Foundation, and the Prevention of
   Blindness Society of Metropolitan Washington (POB).
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Bai P, 2011, CELL METAB, V13, P450, DOI 10.1016/j.cmet.2011.03.013
   Bar-Nur O, 2011, CELL STEM CELL, V9, P17, DOI 10.1016/j.stem.2011.06.007
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BOK D, 1993, J CELL SCI, P189
   Boren J, 2012, CELL DEATH DIFFER, V19, P1561, DOI 10.1038/cdd.2012.34
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813
   Canto C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Chang YC, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00191
   Cherry ABC, 2012, CELL, V148, P1110, DOI 10.1016/j.cell.2012.02.031
   Crunkhorn S, 2007, J BIOL CHEM, V282, P15439, DOI 10.1074/jbc.M611214200
   Egger A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031272
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Field MG, 2012, OPHTHAL SURG LAS IM, V43, P358, DOI 10.3928/15428877-20120712-02
   Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   Hu QR, 2010, STEM CELLS, V28, P1981, DOI 10.1002/stem.531
   Iacovelli J, 2016, INVEST OPHTH VIS SCI, V57, P1038, DOI 10.1167/iovs.15-17758
   Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104
   Jarrett Stuart G, 2013, Methods Mol Biol, V935, P227, DOI 10.1007/978-1-62703-080-9_16
   Jeninga EH, 2010, ONCOGENE, V29, P4617, DOI 10.1038/onc.2010.206
   Jones AWE, 2012, MITOCHONDRION, V12, P86, DOI 10.1016/j.mito.2011.09.009
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim K, 2010, NATURE, V467, P285, DOI 10.1038/nature09342
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Lee SJ, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/327167
   Lelliott CJ, 2006, PLOS BIOL, V4, P2042, DOI 10.1371/journal.pbio.0040369
   Liang HY, 2006, ADV PHYSIOL EDUC, V30, P145, DOI 10.1152/advan.00052.2006
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   McCord JM, 2005, BIOMED PHARMACOTHER, V59, P139, DOI 10.1016/j.biopha.2005.03.005
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Murphy MP, 2013, CELL METAB, V18, P145, DOI 10.1016/j.cmet.2013.07.006
   Na J, 2014, PROTEIN CELL, V5, P569, DOI 10.1007/s13238-014-0073-9
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Onder TT, 2012, CURR OPIN GENET DEV, V22, P500, DOI 10.1016/j.gde.2012.05.005
   Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889
   Piippo N, 2014, BBA-MOL CELL RES, V1843, P3038, DOI 10.1016/j.bbamcr.2014.09.015
   Poliakov E, 2014, MOL VIS, V20, P285
   Polo JM, 2010, NAT BIOTECHNOL, V28, P848, DOI 10.1038/nbt.1667
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Rose S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085436
   Saint-Geniez M, 2013, AM J PATHOL, V182, P255, DOI 10.1016/j.ajpath.2012.09.003
   SanGiovanni JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053155
   Schreck RR, 2001, CURR PROTOC HUM GENE, DOI [10.1002/0471142905.hga04as18, DOI 10.1002/0471142905.HGA04AS18(APPENDIX4:APPENDIX4A)]
   Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025
   Seo YH, 2008, AGING CELL, V7, P894, DOI 10.1111/j.1474-9726.2008.00436.x
   SHORE D, 1984, EMBO J, V3, P2817, DOI 10.1002/j.1460-2075.1984.tb02214.x
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   St-Pierre J, 2003, J BIOL CHEM, V278, P26597, DOI 10.1074/jbc.M301850200
   St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024
   STONE JF, 1995, MUTAT RES-DNAGING G, V338, P107, DOI 10.1016/0921-8734(95)00016-Y
   Sullivan GJ, 2010, MOL HUM REPROD, V16, P880, DOI 10.1093/molehr/gaq091
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Vainshtein A, 2015, AM J PHYSIOL-CELL PH, V308, pC710, DOI 10.1152/ajpcell.00380.2014
   Vainshtein A, 2015, SKELET MUSCLE, V5, DOI 10.1186/s13395-015-0033-y
   Valle I, 2005, CARDIOVASC RES, V66, P562, DOI 10.1016/j.cardiores.2005.01.026
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Villegas Jacob, 2005, Curr Protoc Mol Biol, VChapter 28, DOI 10.1002/0471142727.mb2803s71
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
NR 69
TC 68
Z9 69
U1 3
U2 18
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD DEC 20
PY 2016
VL 14
AR 344
DI 10.1186/s12967-016-1101-8
PG 17
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA EG5EQ
UT WOS:000391066700005
PM 27998274
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Woo, HJ
   Yu, CG
   Kumar, K
   Gold, B
   Reifman, J
AF Woo, Hyung Jun
   Yu, Chenggang
   Kumar, Kamal
   Gold, Bert
   Reifman, Jaques
TI Genotype distribution-based inference of collective effects in
   genome-wide association studies: insights to age-related macular
   degeneration disease mechanism
SO BMC GENOMICS
LA English
DT Article
DE Genome-wide association; Machine learning; Epistasis; Single-nucleotide
   polymorphism; Age-related macular degeneration
ID LOGISTIC-REGRESSION; VARIABLE SELECTION; GENE-GENE; SUSCEPTIBILITY;
   EPISTASIS; APOPTOSIS; PATHOLOGY; RISK
AB Background: Genome-wide association studies provide important insights to the genetic component of disease risks. However, an existing challenge is how to incorporate collective effects of interactions beyond the level of independent single nucleotide polymorphism (SNP) tests. While methods considering each SNP pair separately have provided insights, a large portion of expected heritability may reside in higher-order interaction effects.
   Results: We describe an inference approach (discrete discriminant analysis; DDA) designed to probe collective interactions while treating both genotypes and phenotypes as random variables. The genotype distributions in case and control groups are modeled separately based on empirical allele frequency and covariance data, whose differences yield disease risk parameters. We compared pairwise tests and collective inference methods, the latter based both on DDA and logistic regression. Analyses using simulated data demonstrated that significantly higher sensitivity and specificity can be achieved with collective inference in comparison to pairwise tests, and with DDA in comparison to logistic regression. Using age-related macular degeneration (AMD) data, we demonstrated two possible applications of DDA. In the first application, a genome-wide SNP set is reduced into a small number (similar to 100) of variants via filtering and SNP pairs with significant interactions are identified. We found that interactions between SNPs with highest AMD association were epigenetically active in the liver, adipocytes, and mesenchymal stem cells. In the other application, multiple groups of SNPs were formed from the genome-wide data and their relative strengths of association were compared using cross-validation. This analysis allowed us to discover novel collections of loci for which interactions between SNPs play significant roles in their disease association. In particular, we considered pathway-based groups of SNPs containing up to similar to 10,000 variants in each group. In addition to pathways related to complement activation, our collective inference pointed to pathway groups involved in phospholipid synthesis, oxidative stress, and apoptosis, consistent with the AMD pathogenesis mechanism where the dysfunction of retinal pigment epithelium cells plays central roles.
   Conclusions: The simultaneous inference of collective interaction effects within a set of SNPs has the potential to reveal novel aspects of disease association.
C1 [Woo, Hyung Jun; Yu, Chenggang; Kumar, Kamal; Reifman, Jaques] US Army Med Res & Mat Command, Biotechnol High Performance Comp Software Applica, Telemed & Adv Technol Res Ctr, Ft Detrick, MD 21702 USA.
   [Gold, Bert] NCI, Lab Genom Div, Frederick, MD 21701 USA.
C3 United States Department of Defense; United States Army; National
   Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
RP Reifman, J (通讯作者)，US Army Med Res & Mat Command, Biotechnol High Performance Comp Software Applica, Telemed & Adv Technol Res Ctr, Ft Detrick, MD 21702 USA.
EM jaques.reifman.civ@mail.mil
OI Kumar, Kamal/0000-0002-9470-6682; Woo, Jun/0000-0003-3220-2064
FU U.S. Army Medical Research and Materiel Command (Ft. Detrick, Maryland)
FX This work was supported by the U.S. Army Medical Research and Materiel
   Command (Ft. Detrick, Maryland). The opinions and assertions contained
   herein are the private views of the authors and are not to be construed
   as official or as reflecting the views of the U.S. Army or of the U.S.
   Department of Defense. This paper has been approved for public release
   with unlimited distribution.
CR Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Aurell E, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.090201
   Ayers KL, 2010, GENET EPIDEMIOL, V34, P879, DOI 10.1002/gepi.20543
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   BESAG J, 1975, J ROY STAT SOC D-STA, V24, P179, DOI 10.2307/2987782
   Bhattacharya S, 2012, INVEST OPHTH VIS SCI, V53, P8350, DOI 10.1167/iovs.12-10495
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Cai M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062495
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Clarke GM, 2011, NAT PROTOC, V6, P121, DOI 10.1038/nprot.2010.182
   Cordell HJ, 2009, NAT REV GENET, V10, P392, DOI 10.1038/nrg2579
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   EFRON B, 1975, J AM STAT ASSOC, V70, P892, DOI 10.2307/2285453
   Fabregat A, 2016, NUCLEIC ACIDS RES, V44, pD481, DOI 10.1093/nar/gkv1351
   Fan JQ, 2010, STAT SINICA, V20, P101
   Fan R, 2011, GENET EPIDEMIOL, V35, P706, DOI 10.1002/gepi.20621
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Flannagan RS, 2012, ANNU REV PATHOL-MECH, V7, P61, DOI 10.1146/annurev-pathol-011811-132445
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gao QS, 2011, BMC GENET, V12, DOI 10.1186/1471-2156-12-75
   Gauderman WJ, 2007, GENET EPIDEMIOL, V31, P383, DOI 10.1002/gepi.20219
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gold B, 2008, P NATL ACAD SCI USA, V105, P4340, DOI 10.1073/pnas.0800441105
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hastie TJ, 2011, ELEMENTS STAT LEARNI
   He QC, 2011, BIOINFORMATICS, V27, P1, DOI 10.1093/bioinformatics/btq600
   Hemani G, 2014, NATURE, V508, P249, DOI 10.1038/nature13005
   Herold C, 2009, BIOINFORMATICS, V25, P3275, DOI 10.1093/bioinformatics/btp596
   Jombart T, 2010, BMC GENET, V11, P94, DOI [10.1186/1471-2156-11-94, DOI 10.1186/1471-2156-11-94]
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kim YA, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1001095
   Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248
   Leroux MR, 2000, CURR BIOL, V10, pR260, DOI 10.1016/S0960-9822(00)00432-2
   Locke AE, 2015, NATURE, V518, P197, DOI 10.1038/nature14177
   Manolio TA, 2013, NAT REV GENET, V14, P549, DOI 10.1038/nrg3523
   Moore JH, 2006, J THEOR BIOL, V241, P252, DOI 10.1016/j.jtbi.2005.11.036
   Morcos F, 2011, P NATL ACAD SCI USA, V108, pE1293, DOI 10.1073/pnas.1111471108
   Morris AP, 2010, GENET EPIDEMIOL, V34, P188, DOI 10.1002/gepi.20450
   Munoz-Espin D, 2014, NAT REV MOL CELL BIO, V15, P482, DOI 10.1038/nrm3823
   Neale BM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001322
   Pan Qinxin, 2013, Methods Mol Biol, V1019, P465, DOI 10.1007/978-1-62703-447-0_22
   Park MY, 2008, BIOSTATISTICS, V9, P30, DOI 10.1093/biostatistics/kxm010
   Postic C, 2007, ANNU REV NUTR, V27, P179, DOI 10.1146/annurev.nutr.27.061406.093618
   PRESS SJ, 1978, J AM STAT ASSOC, V73, P699, DOI 10.2307/2286261
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Ripke S, 2014, NATURE, V511, P421, DOI 10.1038/nature13595
   Ritchie MD, 2001, AM J HUM GENET, V69, P138, DOI 10.1086/321276
   Roshan U, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr064
   Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830
   Sun MJ, 2006, J BIOL CHEM, V281, P4222, DOI 10.1074/jbc.M509769200
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Ueki M, 2012, PLOS GENET, V8, P141, DOI 10.1371/journal.pgen.1002625
   Wang K, 2010, NAT REV GENET, V11, P843, DOI 10.1038/nrg2884
   Wang WYS, 2005, NAT REV GENET, V6, P109, DOI 10.1038/nrg1522
   Wang YH, 2015, NAT REV MOL CELL BIO, V16, P678, DOI 10.1038/nrm4074
   Ward LD, 2012, NAT BIOTECHNOL, V30, P1095, DOI 10.1038/nbt.2422
   Wei WH, 2014, NAT REV GENET, V15, P722, DOI 10.1038/nrg3747
   Weismann D, 2012, BIOCHIM BIOPHYS ACTA, V1818, P65
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Welter D, 2014, NUCLEIC ACIDS RES, V42, pD1001, DOI 10.1093/nar/gkt1229
   Wilks SS, 1938, ANN MATH STAT, V9, P60, DOI 10.1214/aoms/1177732360
   Wood AR, 2014, NATURE, V514, pE3, DOI 10.1038/nature13691
   Wu MC, 2011, AM J HUM GENET, V89, P82, DOI 10.1016/j.ajhg.2011.05.029
   Wu TT, 2009, BIOINFORMATICS, V25, P714, DOI 10.1093/bioinformatics/btp041
   Wu XS, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001131
   Yu K, 2005, ANN HUM GENET, V69, P577, DOI 10.1111/j.1529-8817.2005.00193.x
   Zhang QR, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003627
NR 71
TC 11
Z9 11
U1 0
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD AUG 30
PY 2016
VL 17
AR 695
DI 10.1186/s12864-016-2871-3
PG 20
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA DY3HG
UT WOS:000384980800009
PM 27576376
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Korobelnik, JF
   Delcourt, C
   Creuzot-Garcher, C
   Melaine, A
   Chassetuillier, J
   Lejeune, A
   Benard, S
   Dupont-Benjamin, L
AF Korobelnik, Jean-Francois
   Delcourt, Cecile
   Creuzot-Garcher, Catherine
   Melaine, Asma
   Chassetuillier, Jules
   Lejeune, Anne
   Benard, Steve
   Dupont-Benjamin, Laure
TI Real-life management of neovascular age-related macular degeneration
   (nAMD) in France: a nationwide observational study using retrospective
   claims data
SO JOURNAL OF MEDICAL ECONOMICS
LA English
DT Article
DE Ophthalmology; neovascular age-related macular degeneration;
   intravitreal; anti-VEGF; retrospective; observational study; healthcare
   utilization; cost; France
ID TREAT-AND-EXTEND; DAILY CLINICAL-PRACTICE; GROWTH-FACTOR THERAPY;
   INTRAVITREAL RANIBIZUMAB; VISUAL OUTCOMES; CARE; BURDEN; SAFETY;
   MACULOPATHY; PREVALENCE
AB Aims Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is standard care for neovascular age-related macular degeneration (nAMD), but the recommended monthly injection regimen is burdensome. Evidence suggests low injection/monitoring frequencies in clinical practice and suboptimal vision outcomes. This observational cohort study uses administrative claims data from the French national healthcare system to assess anti-VEGF treatment patterns and nAMD-specific healthcare resource demands and costs. Patients and methods nAMD patients >= 50 years initiating intravitreal ranibizumab, aflibercept or bevacizumab treatment (2014-2015), and propensity score-matched non-nAMD patients (controls), were identified from the Echantillon Generaliste de Beneficiaires database. Outcomes of interest included anti-VEGF treatment patterns, and healthcare resource utilization and associated costs of patients vis-a-vis controls over 24 months. Results Study patients (n = 355) received (mean) 5.2 and 2.4 anti-VEGF injections over 0-12 and 12-24 months, respectively. Most patients (79.0%) remained on their initial anti-VEGF agent; among treatment switchers, the most common transition was from ranibizumab to aflibercept. During follow-up, nAMD patients were more likely than controls to require ophthalmology visits (99.7% vs. 44.8%), ocular procedures (optical coherence tomography/angiography/fundoscopy) (96.9% vs. 27.2%), cataract surgery (13.0% vs. 6.7%), and medical transports (38.0% vs. 31.9%). Mean numbers of ophthalmology visits (25.1 vs. 1.2) and medical transports (6.0 vs. 3.5) were higher (p<.01) among nAMD patients. Total reimbursed costs were two-fold higher for nAMD patients than controls (mean euro16,799 vs. euro8,255) due to higher treatment costs (euro6,847 vs. euro1,156), medical fees (euro1,858 vs. euro295), hospital fees (euro6,396 vs. euro5,235), and transport costs (euro358 vs. euro259). Excess total healthcare cost was (mean) euro5,279 and euro7,918 over the first 12 and 24 months of treatment, respectively. Conclusions Current intravitreal anti-VEGF treatment and monitoring requirements place a considerable economic burden on the French healthcare system. New intravitreal therapies with extended dosing intervals and predictable efficacy might reduce demand for ophthalmology services.
C1 [Korobelnik, Jean-Francois] Univ Hosp Ctr Bordeaux, Dept Ophthalmol, Bordeaux, France.
   [Korobelnik, Jean-Francois; Delcourt, Cecile] Univ Bordeaux, Bordeaux Populat Hlth Res Ctr BPH, INSERM, UMR1219, Bordeaux, France.
   [Creuzot-Garcher, Catherine; Dupont-Benjamin, Laure] Univ Hosp Ctr Dijon, Dept Ophthalmol, Dijon, France.
   [Melaine, Asma; Chassetuillier, Jules; Benard, Steve] Steve Consultants, Oullins, France.
   [Lejeune, Anne] AbbVie Co, Allergan, Courbevoie, France.
C3 CHU Bordeaux; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Universite de Bordeaux;
   CHU Dijon Bourgogne; AbbVie; Allergan
RP Dupont-Benjamin, L (通讯作者)，Allergan France SAS Tour CBX, 1 Passerelle Reflets, F-92400 Courbevoie, France.
EM laure.dupontbenjamin@abbvie.com
RI Delcourt, Cecile/I-2627-2013
OI Delcourt, Cecile/0000-0002-2099-0481; DUPONT-BENJAMIN,
   Laure/0000-0001-7748-0768; Korobelnik, Jean-Francois/0000-0002-4438-9535
FU Allergan, an AbbVie company, Irvine, CA, USA
FX This study was supported by a grant from Allergan, an AbbVie company,
   Irvine, CA, USA. Data collection and analysis were conducted by st~eve
   consultants, Oullins, France, and funded by Allergan, an AbbVie company,
   Irvine, CA, USA.
CR Agarwal A, 2015, CLIN OPHTHALMOL, V9, P1001, DOI [10.2147/OPTH.S59725, 10.2147/OPTH.S74959]
   Al-Khersan H, 2019, EXPERT OPIN PHARMACO, V20, P1879, DOI 10.1080/14656566.2019.1636031
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Bannay A, 2016, MED CARE, V54, P188, DOI 10.1097/MLR.0000000000000471
   Bezin J, 2017, PHARMACOEPIDEM DR S, V26, P954, DOI 10.1002/pds.4233
   Bonastre J, 2003, PHARMACOECONOMICS, V21, P181, DOI 10.2165/00019053-200321030-00003
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Cohen SY, 2011, GRAEF ARCH CLIN EXP, V249, P521, DOI 10.1007/s00417-010-1553-0
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Delcourt C, 2005, AM J OPHTHALMOL, V140, P924, DOI 10.1016/j.ajo.2005.05.002
   Eldem B, 2018, GRAEF ARCH CLIN EXP, V256, P963, DOI 10.1007/s00417-017-3890-8
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Gabai A, 2014, EUR J OPHTHALMOL, V24, P396, DOI 10.5301/ejo.5000385
   Haute Autorite de Sante (HAS) - Service evaluation economique et sante publique, 2011, SERV EV EC SANT PUBL
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   INSEE, CONS PRIC IND
   Institut national de la statistique et des etudes economiques, 2019, POP SEX AG 1 JAN 202
   Kataja M, 2018, BRIT J OPHTHALMOL, V102, P959, DOI 10.1136/bjophthalmol-2017-311055
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Korobelnik JF, 2006, INVEST OPHTH VIS SCI, V47, P4270, DOI 10.1167/iovs.05-1467
   Lally DR, 2012, CURR OPIN OPHTHALMOL, V23, P182, DOI 10.1097/ICU.0b013e328352411c
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matamoros E, 2015, OPHTHALMOLOGICA, V234, P151, DOI 10.1159/000433448
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moulis G, 2015, REV MED INTERNE, V36, P411, DOI 10.1016/j.revmed.2014.11.009
   Pikkel J, 2018, INT OPHTHALMOL, V38, P2031, DOI 10.1007/s10792-017-0695-z
   Plyukhova AA, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051522
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Santarelli M, 2015, EXPERT OPIN PHARMACO, V16, P1769, DOI 10.1517/14656566.2015.1067679
   Saunier V, 2018, JAMA OPHTHALMOL, V136, P473, DOI 10.1001/jamaophthalmol.2018.0504
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Souied EH, 2015, RETINA-J RET VIT DIS, V35, P1743, DOI 10.1097/IAE.0000000000000548
   Stewart MW, 2015, J CLIN MED, V4, P1079, DOI 10.3390/jcm4051079
   Storey PP, 2019, OPHTHALMOLOGY, V126, P1424, DOI 10.1016/j.ophtha.2019.04.037
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Zerbib J, 2017, J FR OPHTALMOL, V40, P723, DOI 10.1016/j.jfo.2017.05.009
   Zhao XY, 2021, ACTA OPHTHALMOL, V99, pE1041, DOI 10.1111/aos.14756
NR 51
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1369-6998
EI 1941-837X
J9 J MED ECON
JI J. Med. Econ.
PD JAN 1
PY 2021
VL 24
IS 1
BP 1087
EP 1097
DI 10.1080/13696998.2021.1971416
PG 11
WC Health Care Sciences & Services; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; General & Internal Medicine
GA UP3WE
UT WOS:000695312900001
PM 34420480
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Fernandez-Robredo, P
   Recalde, S
   Hernandez, M
   Zarranz-Ventura, J
   Molins, B
   Casaroli-Marano, RP
   Adan, A
   Saenz-de-Viteri, M
   Garcia-Layana, A
AF Fernandez-Robredo, Patricia
   Recalde, Sergio
   Hernandez, Maria
   Zarranz-Ventura, Javier
   Molins, Blanca
   Casaroli-Marano, Ricardo P.
   Adan, Alfredo
   Saenz-de-Viteri, Manuel
   Garcia-Layana, Alfredo
TI Novel Association of High c-Reactive Protein Levels and A69S at Risk
   Alleles in Wet Age-Related Macular Degeneration Women
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE C-reactive protein; wet macular degeneration; polymorphism; single
   nucleotide; gender differences; case-control studies
ID COMPLEMENT FACTOR-H; CARDIOVASCULAR-DISEASE; INFLAMMATORY MARKERS;
   POSTMENOPAUSAL WOMEN; ESTROGEN-RECEPTOR; POLYMORPHISM; GENDER; EYE;
   RETINA; SUSCEPTIBILITY
AB Purpose: To explore the relationship between plasma C-reactive protein (CRP) levels, the main ARMS2 gene single nucleotide polymorphism (SNP), and gender in patients with neovascular age-related macular degeneration (wet AMD).
   Methods: Our study included 131 patients with wetAMD [age-related eye disease study (AREDS) category 4] and 153 control participants (AREDS category 1) from two Spanish retinal units. CRP levels were determined on blood samples by high-sensitivity ELISA assay. According to their CRP level, subjects were categorized into three well-established CRP categories: low (< 1.00 mg/L, L-CRP), moderate (1-2.99 mg/L, M-CRP), and high (> 3.00 mg/L, H-CRP). Genomic DNA was extracted from oral swabs using QIAcube (Qiagen, Hilden, Germany) and the A69S; rs10490924 of ARMS2 gene was genotyped by allelic discrimination with validated TaqMan assays (Applied Biosystems, Foster City, CA, USA). Univariate and multivariate logistic regression adjusted for age was used to analyze the genomic frequencies and to calculate odds ratio (OR) using SNPStats software.
   Results: Considering CRP risk categories, H-CRP group showed a significant [OR 4.0 (1.9-8.3)] association with wetAMD compared to L-CRP group. The risk genotypes of A69S (TT) SNPs showed an association with wetAMD risk [OR 14.0 (4.8-40.8)]. Interestingly, the gender stratification of the CRP categories showed a significant increase in CRP levels in wetAMD women compared with control women [OR 6.9 (2.2-22.3)] and with wetAMD men [OR 4.6 (1.3-16.9)]. In addition, the subgroup analysis of CRP within A69S genotype and gender showed a link in women between the A69S and CRP levels in the AMD group compared to controls [OR 4.2 (1.4-12.6)].
   Conclusion: Our study shows, for the first time, that a different genetic association related with gender could contribute to AMD risk. As a consequence, the risk of female gender in the different CRP levels and A69S SNP frequencies could be taken into consideration to the established risk relationship of high levels of CRP and its association with risk A69S genotype.
C1 [Fernandez-Robredo, Patricia; Recalde, Sergio; Hernandez, Maria; Garcia-Layana, Alfredo] Clin Univ Navarra, Ophthalmol, Expt Ophthalmol Lab, Pamplona, Spain.
   [Fernandez-Robredo, Patricia; Recalde, Sergio; Hernandez, Maria; Garcia-Layana, Alfredo] Inst Invest Sanitaria Navarra IdiSNA, Pamplona, Spain.
   [Zarranz-Ventura, Javier; Molins, Blanca; Casaroli-Marano, Ricardo P.; Adan, Alfredo] Hosp Clin Barcelona, Inst Clin Oftalmol ICOF, Barcelona, Spain.
   [Zarranz-Ventura, Javier; Adan, Alfredo] Inst Invest Biomed August Pi i Sunyer IDIBAP, Fundacio Clin Recerca Biomed, Barcelona, Spain.
   [Saenz-de-Viteri, Manuel; Garcia-Layana, Alfredo] Clin Univ Navarra, Ophthalmol, Pamplona, Spain.
   [Saenz-de-Viteri, Manuel] Univ Hosp Plymouth NHS Trust, Royal Eye Infirm, Plymouth, Devon, England.
C3 University of Navarra; University of Barcelona; Hospital Clinic de
   Barcelona; University of Barcelona; Hospital Clinic de Barcelona;
   IDIBAPS; University of Navarra
RP Fernandez-Robredo, P (通讯作者)，Clin Univ Navarra, Ophthalmol, Expt Ophthalmol Lab, Pamplona, Spain.; Fernandez-Robredo, P (通讯作者)，Inst Invest Sanitaria Navarra IdiSNA, Pamplona, Spain.
EM pfrobredo@unav.es
RI Zarranz-Ventura, Javier/AAB-5390-2021; Casaroli-Marano, Ricardo
   Pedro/D-4535-2014; Saenz+de+Viteri+Vazquez, Manuel/Y-3701-2019; Recalde,
   Sergio/D-1815-2017
OI Zarranz-Ventura, Javier/0000-0003-2338-8143; Casaroli-Marano, Ricardo
   Pedro/0000-0003-1812-9323; Recalde, Sergio/0000-0002-9328-9725
FU Spanish Multicenter Group on AMD; "Red Tematica de Investigacion
   Cooperativa en Salud" OFTARED [RD12/0034, RD16/0008]
FX Spanish Multicenter Group on AMD and the "Red Tematica de Investigacion
   Cooperativa en Salud" OFTARED RD12/0034 and RD16/0008.
CR Akcay T, 2000, J TOXICOL ENV HEAL A, V59, P1, DOI 10.1080/009841000157023
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Cipriani V, 2017, JAMA OPHTHALMOL, V135, P909, DOI 10.1001/jamaophthalmol.2017.2191
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Danesh J, 2004, NEW ENGL J MED, V350, P1387, DOI 10.1056/NEJMoa032804
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Grassmann F, 2015, NEUROMOL MED, V17, P111, DOI 10.1007/s12017-015-8342-1
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hodge AM, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-700
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Johnson LV, 2004, NEW ENGL J MED, V351, P320, DOI 10.1056/NEJMp048131
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Keenan HA, 2008, ATHEROSCLEROSIS, V196, P863, DOI 10.1016/j.atherosclerosis.2007.01.036
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kraus VB, 2007, OSTEOARTHR CARTILAGE, V15, P966, DOI 10.1016/j.joca.2007.02.014
   Lakoski SG, 2005, CLIMACTERIC, V8, P317, DOI 10.1080/13697130500345109
   Markiewski MM, 2007, AM J PATHOL, V171, P715, DOI 10.2353/ajpath.2007.070166
   Mermigkis C, 2012, SLEEP BREATH, V16, P813, DOI 10.1007/s11325-011-0580-3
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Molins B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00808
   Molins B, 2017, AM J PHYSIOL-CELL PH, V312, pC244, DOI 10.1152/ajpcell.00057.2016
   Molins B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22889
   Munaut C, 2001, BRIT J OPHTHALMOL, V85, P877, DOI 10.1136/bjo.85.7.877
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Ogueta SB, 1999, INVEST OPHTH VIS SCI, V40, P1906
   Oh SJ, 2017, INTERACT CARDIOV TH, V25, P260, DOI 10.1093/icvts/ivx107
   Pepys MB, 2006, NATURE, V440, P1217, DOI 10.1038/nature04672
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P1740, DOI 10.1167/iovs.02-0775
   Recalde S, 2008, OPHTHALMOLOGY, V115, P916, DOI 10.1016/j.ophtha.2007.12.012
   Regitz-Zagrosek V, 2012, EMBO REP, V13, P596, DOI 10.1038/embor.2012.87
   Ridker PM, 2004, CIRCULATION, V109, P1955, DOI 10.1161/01.CIR.0000125690.80303.A8
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sole X, 2006, BIOINFORMATICS, V22, P1928, DOI 10.1093/bioinformatics/btl268
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Thiele JR, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/372432
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wang AT, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.005610
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Wilson PWF, 2008, CIRC-CARDIOVASC QUAL, V1, P92, DOI 10.1161/CIRCOUTCOMES.108.831198
   Yasuma TR, 2010, MOL VIS, V16, P2923
   Yates-Siilata KE, 2004, CELL BIOL INT, V28, P33, DOI 10.1016/j.cellbi.2003.09.003
NR 52
TC 4
Z9 4
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD AUG 14
PY 2018
VL 9
AR 1862
DI 10.3389/fimmu.2018.01862
PG 10
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA GQ4OG
UT WOS:000441651700002
PM 30154790
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Yuzawa, M
   Fujita, K
   Wittrup-Jensen, KU
   Norenberg, C
   Zeitz, O
   Adachi, K
   Wang, ECY
   Heier, J
   Kaiser, P
   Chong, V
   Korobelnik, JF
AF Yuzawa, Mitsuko
   Fujita, Kyoko
   Wittrup-Jensen, Kim U.
   Norenberg, Christiane
   Zeitz, Oliver
   Adachi, Kenji
   Wang, Edward C. Y.
   Heier, Jeffrey
   Kaiser, Peter
   Chong, Victor
   Korobelnik, Jean-Francois
TI Improvement in Vision-Related Function with Intravitreal Aflibercept
   Data from Phase 3 Studies in Wet Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; VISUAL FUNCTION QUESTIONNAIRE; RANDOMIZED
   CLINICAL-TRIAL; MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION;
   RANIBIZUMAB TREATMENT; RESOURCE UTILIZATION; NEI VFQ-25; VEGF TRAP;
   RESPONSIVENESS
AB Purpose: To evaluate the effect of intravitreal aflibercept injection on visual function in wet age-related macular degeneration (AMD).
   Design: Prospective, multicenter, double-masked, active-controlled, parallel-group, randomized phase 3 clinical studies (VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD [VIEW] 1 and 2 [clinicaltrials.gov identifiers, NCT00509795 and NCT00637377, respectively]).
   Participants: Patients (n = 2419) with active, treatment-naive, exudative AMD. This analysis included patients who received intravitreal aflibercept 2.0 mg every 8 weeks (2q8; n = 607) or ranibizumab 0.5 mg every 4 weeks (0.5q4; n = 595).
   Intervention: Patients were randomized 1: 1: 1: 1 to receive intravitreal aflibercept 2q8 (after 3 initial monthly doses), intravitreal aflibercept 2q4, intravitreal aflibercept 0.5q4, or ranibizumab 0.5q4 in the study eye. Patients in the intravitreal aflibercept 2q8 group received a sham injection alternating with active treatment.
   Main Outcome Measures: The 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) was administered at baseline and at weeks 12, 24, 36, and 52. The NEI VFQ-25 subscale scores were compared between intravitreal aflibercept 2q8 and ranibizumab 0.5q4 treatment arms, the approved dosing for each agent worldwide. Change in composite NEI VFQ-25 score was evaluated based on categorical change in visual acuity (worsened, unchanged, improved).
   Results: Baseline NEI VFQ-25 scores were similar for both treatments in both studies. Mean change from baseline to 52 weeks was similar for ranibizumab 0.5q4 and intravitreal aflibercept 2q8 across all 12 subscales, with the greatest improvements noted for mental health and general vision (9.0-11.6 points, both treatments, both studies). Improvement of 4 points or more (both treatments, both studies) also was observed for subscales near vision, distance vision, role difficulties, and dependency. Mean change from baseline to 52 weeks in NEI VFQ-25 composite score (pooled data) stratified by clinical response showed meaningful improvement only in patients who gained 5 Early Treatment Diabetic Retinopathy letters or more (7.3 and 7.8 points for intravitreal aflibercept 2q8 and ranibizumab 0.5q4, respectively).
   Conclusions: Visual function outcomes were similar across all NEI VFQ-25 subscales over 52 weeks for intravitreal aflibercept 2q8 and ranibizumab 0.5q4, with clinically meaningful improvement recorded in 6 of 12 subscales. (C) 2015 by the American Academy of Ophthalmology.
C1 [Yuzawa, Mitsuko; Fujita, Kyoko] Nihon Univ, Sch Med, Dept Ophthalmol, Chiyoda Ku, Tokyo 1018309, Japan.
   [Wittrup-Jensen, Kim U.; Norenberg, Christiane; Zeitz, Oliver] Bayer Pharma AG, Berlin, Germany.
   [Zeitz, Oliver] Univ Klinikum Hamburg Eppendorf, Klin & Poliklin Augenheilkunde, Hamburg, Germany.
   [Adachi, Kenji; Wang, Edward C. Y.] Bayer Yakuhin Ltd, Hlth Econ & Outcomes Res, Kita Ku, Osaka, Japan.
   [Heier, Jeffrey] Ophthalm Consultants Boston, Boston, MA USA.
   [Heier, Jeffrey] Tufts Univ, Sch Med, Boston, MA 02111 USA.
   [Kaiser, Peter] Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
   [Chong, Victor] Univ Oxford, Oxford Eye Hosp, Oxford, England.
   [Korobelnik, Jean-Francois] CHU Bordeaux, Hop Pellegrind, Serv Ophtalmol, Bordeaux, France.
   [Korobelnik, Jean-Francois] Univ Bordeaux Segalen, Bordeaux, France.
   [Korobelnik, Jean-Francois] INSERM, ISPED, Ctr INSERM Epidemiol Biostat U897, Bordeaux, France.
C3 Nihon University; Bayer AG; Bayer Healthcare Pharmaceuticals; University
   of Hamburg; University Medical Center Hamburg-Eppendorf; Bayer AG;
   Ophthalmic Consultants of Boston; Tufts University; Cleveland Clinic
   Foundation; University of Oxford; CHU Bordeaux; UDICE-French Research
   Universities; Universite de Bordeaux; Institut National de la Sante et
   de la Recherche Medicale (Inserm)
RP Yuzawa, M (通讯作者)，Nihon Univ, Sch Med, Surugadai Nihon Univ Hosp, Dept Ophthalmol,Chiyoda Ku, 1-8-13 Kandasurugadai, Tokyo 1018309, Japan.
EM yuzawa.mitsuko@nihon-u.ac.jp
RI KOROBELNIK, Jean-Francois/A-5448-2016; Zeitz, Oliver/AAJ-9728-2021;
   Chong, Victor/Q-6565-2018
OI Chong, Victor/0000-0002-7693-522X; Kaiser, Peter/0000-0001-5126-045X
FU Acucela; Seattle; Washington; Aerpio; Blue Ash; OH; Alcon; Fort Worth;
   TX; Alimera; Alpharetta; GA; Allergan; Irvine; CA; Bayer HealthCare;
   Whippany; NJ; Fovea; Cambridge; MA ( acquired by Sanofi); Genentech;
   South San Francisco; Genzyme; MA; GlaxoSmithKline; Middlesex, United
   Kingdom; LPath; San Diego; Neovista; San Francisco; Notal Vision; Tel
   Aviv, Israel; Novartis; Basel, Switzerland; Ohr Pharmaceutical, New
   York, NY; Ophthotech, New York, NY; Paloma, Nagoya, Aichi, Japan;
   Regeneron Pharmaceuticals, Tarrytown, NY; Lecturer - Bayer HealthCare;
   Heidelberg; Ladenburg, Germany; Novartis International AG, Basel,
   Switzerland; Bayer Pharma AG, Berlin, Germany
FX J.H.: Consultant - Acucela, Seattle, WA, Aerpio, Blue Ash, OH, Alimera,
   Alpharetta, GA, Allergan, Irvine, CA, Bausch & Lomb, Bridgewater, NJ,
   Bayer HealthCare, Whippany, NJ, Dutch Ophthalmic, Exeter, NH, Endo
   Optiks, Little Silver, NJ, Forsight, Long Grove, IL, Genzyme, Cambridge,
   MA, Heidelberg Engineering, Carlsbad, CA, Kala Pharmaceuticals, Waltham,
   MA, Kanghong, Chengdu, China, LPath, San Diego, CA, Nicox, Fort Worth,
   TX, Notal Vision, Tel Aviv, Israel, Ohr Pharmaceutical, New York, NY,
   Ophthotech, New York, NY, Oraya, Newark, CA, QLT, Vancouver, BC,
   Regeneron Pharmaceuticals, Rensselaer, NY, Roche, Nutley, NJ, Sequenom,
   San Diego, CA, Thrombogenics, Leuven, Belgium, Vertex, Boston, MA,
   Xcovery, West Palm Beach, FL; financial support - Acucela, Seattle,
   Washington, Aerpio, Blue Ash, OH, Alcon, Fort Worth, TX, Alimera,
   Alpharetta, GA, Allergan, Irvine, CA, Bayer HealthCare, Whippany, NJ,
   Fovea, Cambridge, MA (acquired by Sanofi), Genentech, South San
   Francisco, CA, Genzyme, Cambridge, MA, GlaxoSmithKline, Middlesex,
   United Kingdom, LPath, San Diego, CA, Neovista, San Francisco, CA, Notal
   Vision, Tel Aviv, Israel, Novartis, Basel, Switzerland, Ohr
   Pharmaceutical, New York, NY, Ophthotech, New York, NY, Paloma, Nagoya,
   Aichi, Japan, Regeneron Pharmaceuticals, Tarrytown, NY; Travel support -
   Regeneron Pharmaceuticals, Tarrytown, NY.; V.C.: Consultant - Allergan,
   Irvine, CA, Bayer HealthCare, Whippany, NJ, Novartis, Basel,
   Switzerland, Quantel, New York, NY; Financial support - Allergan,
   Irvine, CA, Novartis International AG, Basel, Switzerland; Lecturer -
   Bayer HealthCare, Whippany, NJ, Heidelberg, Ladenburg, Germany, Novartis
   International AG, Basel, Switzerland; Travel support - Bayer HealthCare,
   Whippany, NJ.; Supported by Bayer Pharma AG, Berlin, Germany. The
   sponsor or funding organization participated in study design, data
   collection, data management, data analysis, and approval of the
   manuscript.
CR AMD Alliance International, GLOB EC COST VIS IMP
   [Anonymous], 2012, EYLEA PRESCR INF
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P144, DOI 10.1016/j.ophtha.2004.06.035
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   European Medicines Agency, EMEA EYL AUTH DET
   Heier JS, 2013, OPHTHALMOLOGY, V120, P209
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Leys A, 2008, EYE, V22, P792, DOI 10.1038/sj.eye.6702900
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Linder M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1611
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   Marella M, 2010, INVEST OPHTH VIS SCI, V51, P2878, DOI 10.1167/iovs.09-4494
   Mejico LJ, 2004, AM J OPHTHALMOL, V137, P908, DOI 10.1016/j.ajo.2003.12.038
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   National Eye Institute, NAT EYE I 25 IT VIS
   Orr P, 2011, INVEST OPHTH VIS SCI, V52, P3354, DOI 10.1167/iovs.10-5645
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Suner IJ, 2009, INVEST OPHTH VIS SCI, V50, P3629, DOI 10.1167/iovs.08-3225
   Suzukamo Yoshimi, 2005, Health Qual Life Outcomes, V3, P65, DOI 10.1186/1477-7525-3-65
   Yanagisawa M, 2011, OPHTHALMIC RES, V45, P47, DOI 10.1159/000316135
   Yuzawa M, 2013, CLIN OPHTHALMOL, V7, P1325, DOI 10.2147/OPTH.S45248
NR 28
TC 35
Z9 35
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2015
VL 122
IS 3
BP 571
EP 578
DI 10.1016/j.ophtha.2014.09.024
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CC2DF
UT WOS:000350154600027
PM 25439429
DA 2022-11-30
ER

PT J
AU Zhang, M
   Zhang, JJ
   Yan, M
   Luo, D
   Zhu, WJ
   Kaiser, PK
   Yu, DC
AF Zhang, Ming
   Zhang, Junjun
   Yan, Mi
   Luo, Delun
   Zhu, Wenjin
   Kaiser, Peter K.
   Yu, De-Chao
CA KH902 Phase 1 Study Grp
TI A Phase 1 Study of KH902, a Vascular Endothelial Growth Factor Receptor
   Decoy, for Exudative Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL INJECTION; RANIBIZUMAB; NEOVASCULARIZATION; TOLERABILITY;
   CONTRIBUTES; EFFICACY; SAFETY; DOMAIN; TRAP
AB Purpose: To determine the safety, tolerability, and bioactivity of KH902, a fully human fusion protein containing key domains from vascular endothelial growth factor receptors 1 and 2 with human immunoglobulin Fc.
   Design: Prospective, single-center, open-label, dose-escalating, interventional case series.
   Participants: Twenty-eight patients with choroidal neovascularization (CNV) resulting from exudative age-related macular degeneration (AMD) with lesion size of 12 disc areas or less and best-corrected visual acuity (VA) of 55 letters or worse.
   Methods: A single intravitreal injection of KH902 at 1 of 6 escalating doses if no dose-limiting toxicity (DLT) occurred through postinjection day 14 of the previous dose level. Follow-up examinations were performed on postinjection days 1, 3, 5, 7, 14, 28, and 42. The primary end point was at 42 days, and patients were monitored for an additional 6 weeks (12 weeks total).
   Main Outcome Measures: The primary safety measures were changes from baseline in VA, intraocular pressure (IOP), intraocular inflammation, and production of anti-KH902 antibody. Dose-limiting toxicity was defined as intraocular inflammation, elevated IOP, significantly reduced vision, or retinal hemorrhage within 42 days after injection. Bioactivity measures included mean change from baseline in VA, central retinal thickness, and total macular volume on optical coherence tomography and CNV changes on fluorescein angiography.
   Results: All patients completed the study with no DLT and no serious or drug-related adverse events. Ocular adverse events were mild to moderate in severity, including transient IOP elevation and injection-site subconjunctival hemorrhage after KH902 injections. No serum anti-KH902 antibodies were detected. On day 42 after injection, the mean change in VA from baseline was +19.6 letters with no subjects losing 1 letter or more and 57% of patients gaining 15 letters or more from baseline. The mean change in center point thickness from baseline was -77.2 mu m and the mean decrease in CNV area was 12.6%.
   Conclusions: No safety concerns were detected after a single, intravitreal injection of KH902 up to 3.0 mg in this phase 1 study. Bioactivity of KH902 was suggested with improvements in VA, reduction in central retinal thickness, and a decrease in CVN area in patients with CNV resulting from exudative AMD, indicating that further study is warranted.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2011;118:672-678 (C) 2011 by the American Academy of Ophthalmology.
C1 [Yu, De-Chao] W China Hosp, State Key Lab Biotherapy, Chengdu 610036, Sichuan, Peoples R China.
   [Zhang, Ming; Zhang, Junjun; Yan, Mi] W China Hosp, Dept Ophthalmol, Chengdu 610036, Sichuan, Peoples R China.
   [Luo, Delun; Zhu, Wenjin; Yu, De-Chao] Chengdu Kanghong Biotech Inc, Chengdu, Peoples R China.
   [Kaiser, Peter K.] Cole Eye Inst, Cleveland, OH USA.
C3 Sichuan University; Sichuan University
RP Yu, DC (通讯作者)，W China Hosp, State Key Lab Biotherapy, Chengdu 610036, Sichuan, Peoples R China.
EM mich204@yahoo.com
OI Kaiser, Peter/0000-0001-5126-045X; Zhang, Ming/0000-0003-0151-7813
FU Chengdu Kanghong Biotech, Inc.; State Key Project grant for Significant
   Drug Research and Development, People's Republic of China; Chengdu
   Kanghong Biotech, Inc., Chengdu, Sichuan, China
FX Ming Zhang - Financial support - Chengdu Kanghong Biotech, Inc.;
   Supported by a State Key Project grant for Significant Drug Research and
   Development, People's Republic of China; and Chengdu Kanghong Biotech,
   Inc., Chengdu, Sichuan, China. Chengdu Kanghong Biotech, Inc., has a
   commercial interest in KH902.
CR Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Do DV, 2009, BRIT J OPHTHALMOL, V93, P144, DOI 10.1136/bjo.2008.138271
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Ferrara N, 2000, RECENT PROG HORM RES, V55, P15
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   MAGDALENA G, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Miller JW, 1997, AM J PATHOL, V151, P13
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Shinkai A, 1998, J BIOL CHEM, V273, P31283, DOI 10.1074/jbc.273.47.31283
   Wang H, 2010, CANCER IMMUNOL IMMUN, V59, P239, DOI 10.1007/s00262-009-0744-1
   Zhang M, 2008, MOL VIS, V14, P37
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
NR 23
TC 90
Z9 107
U1 1
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2011
VL 118
IS 4
BP 672
EP 678
DI 10.1016/j.ophtha.2010.08.008
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 744DS
UT WOS:000289075200010
PM 21146224
DA 2022-11-30
ER

PT J
AU Duvvari, MR
   Saksens, NTM
   van de Ven, JPH
   de Jong-Hesse, Y
   Schick, T
   Nillesen, WM
   Fauser, S
   Hoefsloot, LH
   Hoyng, CB
   de Jong, EK
   den Hollander, AI
AF Duvvari, Maheswara R.
   Saksens, Nicole T. M.
   van de Ven, Johannes P. H.
   de Jong-Hesse, Yvonne
   Schick, Tina
   Nillesen, Willy M.
   Fauser, Sascha
   Hoefsloot, Lies H.
   Hoyng, Carel B.
   de Jong, Eiko K.
   den Hollander, Anneke I.
TI Analysis of rare variants in the CFH gene in patients with the cuticular
   drusen subtype of age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID HEMOLYTIC-UREMIC SYNDROME; FACTOR-H MUTATIONS; HIGH-RISK; DISEASE;
   BINDING; ASSOCIATION; HEPARIN; CELLS; C3B
AB Purpose: Age-related macular degeneration (AMD) and cuticular drusen (CD), a clinical subtype of AMD, have been linked to genetic variants in the complement factor H (CFH) gene. In this study, we aimed to investigate the frequency of rare variants in the CFH gene in 180 cases with CD. In addition, we aimed to determine the frequency of a previously reported rare, highly penetrant CFH variant (p. Arg1210Cys) in a Dutch-German non-CD-type AMD case-control cohort, and to describe the phenotype of patients carrying the p. Arg1210Cys variant.
   Methods: Study subjects were selected from the European Genetic Database (EUGENDA), a joint AMD database of the Radboud University Medical Centre and the University Hospital of Cologne, and graded at the Cologne Image Reading Centre and Laboratory (CIRCL). Additionally, two CD cases were recruited from the VU Medical Centre in Amsterdam. The CFH gene was analyzed in 180 CD cases with Sanger sequencing. All identified variants were analyzed for potential damaging effects with prediction software tools Sorting Intolerant from Tolerant (SIFT) and Polymorphism Phenotyping (PolyPhen). In addition, we genotyped the p. Arg1210Cys variant in 813 non-CD type AMD cases and 1175 controls.
   Results: Sequencing identified 11 rare, heterozygous missense variants, one frameshift variant, and one splice acceptor site variant in 16 CD cases. The p. Arg1210Cys variant was identified in two CD cases but was not identified in our Dutch-German non-CD-type AMD case-control cohort.
   Conclusions: The present study identified the presence of rare variants in the CFH gene in 16 (8.8%) of 180 patients with the CD subtype of AMD. The carriers of rare CFH variants displayed a significantly earlier age at onset than non-carriers (p=0.016). The rare missense variant p. Arg1210Cys was identified in two CD cases, but was not detected in 813 non-CD type AMD cases or in the 1,175 controls of our Dutch-German cohort. The current study suggests that the p. Arg1210Cys variant may be restricted to a subset of patients with the CD subtype of AMD. Detailed clinical pheno-typing, including fluorescein angiography, of patients with AMD carrying the p. Arg1210Cys variant in other cohorts is required to confirm this finding.
C1 [Duvvari, Maheswara R.; Saksens, Nicole T. M.; van de Ven, Johannes P. H.; Hoyng, Carel B.; de Jong, Eiko K.; den Hollander, Anneke I.] Radboud Univ Nijmegen Med Ctr, Dept Ophthalmol, NL-6525 GA Nijmegen, Netherlands.
   [Duvvari, Maheswara R.; Nillesen, Willy M.; Hoefsloot, Lies H.; de Jong, Eiko K.; den Hollander, Anneke I.] Radboud Univ Nijmegen Med Ctr, Dept Human Genet, NL-6525 GA Nijmegen, Netherlands.
   [de Jong-Hesse, Yvonne] Vrije Univ Amsterdam Med Ctr, Dept Ophthalmol, Amsterdam, Netherlands.
   [Schick, Tina; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
   [Hoefsloot, Lies H.] Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Vrije
   Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of
   Cologne; Erasmus University Rotterdam; Erasmus MC
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen Med Ctr, Dept Ophthalmol 409, Phillips van Leydenlaan 15, NL-6525 GA Nijmegen, Netherlands.
EM denHollander@radboudumc.nl
RI de Jong, Eiko/P-3407-2015; Hoyng, C.B./H-8050-2014; Hollander, Anneke
   den/N-4911-2014
OI de Jong, Eiko/0000-0001-6520-0407; 
FU Netherlands Organization for Scientific Research (Vidi Innovational
   Research Award) [016096309]; Foundation Fighting Blindness USA
   [CGE08110548RAD04]
FX This study was supported by Netherlands Organization for Scientific
   Research (Vidi Innovational Research Award 016096309 to A.I.d.H.) and
   the Foundation Fighting Blindness USA (grant CGE08110548RAD04 to
   A.I.d.H.).
CR Adzhubei I, 2013, CURR PROTOC HUM GENE, P7201
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Boon CJF, 2013, PROG RETIN EYE RES, V37, P90, DOI 10.1016/j.preteyeres.2013.08.003
   Caprioli J, 2003, HUM MOL GENET, V12, P3385, DOI 10.1093/hmg/ddg363
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Ferreira VP, 2009, J IMMUNOL, V182, P7009, DOI 10.4049/jimmunol.0804031
   Grassi MA, 2007, ARCH OPHTHALMOL-CHIC, V125, P93, DOI 10.1001/archopht.125.1.93
   Guigui B, 2011, BRIT J OPHTHALMOL, V95, P238, DOI 10.1136/bjo.2009.178400
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Jozsi M, 2006, J AM SOC NEPHROL, V17, P170, DOI 10.1681/ASN.2005080868
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   Maugeri A, 2002, EUR J HUM GENET, V10, P197, DOI 10.1038/sj.ejhg.5200784
   Mukhopadhyay A, 2006, INVEST OPHTH VIS SCI, V47, P3565, DOI 10.1167/iovs.06-0141
   Novembre J, 2008, NATURE, V456, P98, DOI 10.1038/nature07331
   Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201
   Pickering MC, 2007, J EXP MED, V204, P1249, DOI 10.1084/jem.20070301
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Shen Si-kui, 2012, Zhonghua Yixue Yichuanxue Zazhi, V29, P570, DOI 10.3760/cma.j.issn.1003-9406.2012.05.015
   van de Ven JPH, 2012, ARCH OPHTHALMOL-CHIC, V130, P1038, DOI 10.1001/archophthalmol.2012.265
   van de Ven JPH, 2012, MOL VIS, V18, P2271
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 30
TC 21
Z9 21
U1 0
U2 10
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD MAR 15
PY 2015
VL 21
BP 285
EP 292
PG 8
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA CG1FY
UT WOS:000353019700002
PM 25814826
DA 2022-11-30
ER

PT J
AU van Velthoven, MEJ
   de Smet, MD
   Schlingemann, RO
   Magnani, M
   Verbraak, FD
AF van Velthoven, M. E. J.
   de Smet, M. D.
   Schlingemann, R. O.
   Magnani, M.
   Verbraak, F. D.
TI Added value of OCT in evaluating the presence of leakage in patients
   with age-related macular degeneration treated with PDT
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; photodynamic therapy; optical
   coherence tomography; fluorescein angiography
ID OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; ANGIOGRAPHY
AB Background: Evaluating the presence of leakage on fluorescein angiography (FA) in patients with age-related macular degeneration (AMD) retreated with photodynamic therapy (PDT) can be difficult. New diagnostic tools such as optical coherence tomography (OCT) might help to optimize PDT management.
   Methods: Thirty AMD patients scheduled for regular follow-up FA in conjunction with PDT treatment were also scanned with OCT. Follow-up data at 9 months were retrieved from the patients' medical records. Inter-observer agreement [kappa (kappa) coefficient] for the presence of leakage on FA, for OCT parameters for leakage, and agreement between FA and OCT evaluations were calculated. The indication for retreatment was evaluated using the leakage analysis based on FA alone, OCT alone, and both examinations combined, and compared to the actual follow-up of the patients at 9 months.
   Results: Agreement between the two observers for the presence of leakage on FA was moderate (kappa=0.51). OCT agreement between the two observers for the presence of leakage was good (kappa=0.85). Agreement between FA and OCT for the presence of leakage was poor (kappa=0.16). Follow-up data at 9 months on all patients were analyzed. Seven out of 30 patients were not retreated at the time of examination, and four of these patients (57%) remained stable without further treatment. Twenty-three patients did receive a PDT treatment at the time of examination; and eight of these patients did not show leakage on OCT, and five of these patients (62%) remained stable without additional treatment. In contrast, only three out of 15 patients (20%) with leakage on both FA and OCT remained stable during this 9 month follow-up period.
   Conclusions: Inter-observer agreement for the presence of leakage was moderate for FA and good for OCT. There was considerable disagreement between leakage as judged by OCT and by FA. OCT could be of help in the decision regarding PDT retreatment. Assuming that 57% of the patients without leakage either on FA or OCT would remain stable without retreatment, the rate of probable ineffective retreatment could be reduced from 35% to 20%.
C1 Acad Med Ctr, Dept Ophthalmol, Amsterdam, Netherlands.
   Univ Padua, Dept Ophthalmol, Padua, Italy.
   Acad Med Ctr, Ctr Laser, Amsterdam, Netherlands.
C3 University of Amsterdam; Academic Medical Center Amsterdam; University
   of Padua; University of Amsterdam; Academic Medical Center Amsterdam
RP Verbraak, FD (通讯作者)，Acad Med Ctr, Dept Ophthalmol, Amsterdam, Netherlands.
EM f.d.verbraak@amc.uva.nl
RI De Smet, Marc D./E-2451-2013
OI De Smet, Marc D./0000-0002-9217-5603; Verbraak, Frank
   D/0000-0001-7560-1423
CR Bellmann C, 2003, BRIT J OPHTHALMOL, V87, P890, DOI 10.1136/bjo.87.7.890
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   Friedman SM, 2000, AM J OPHTHALMOL, V130, P839, DOI 10.1016/S0002-9394(00)00605-X
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   Kaiser RS, 2002, RETINA-J RET VIT DIS, V22, P683, DOI 10.1097/00006982-200212000-00001
   Montero JA, 2003, GRAEF ARCH CLIN EXP, V241, P797, DOI 10.1007/s00417-003-0752-3
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
NR 11
TC 26
Z9 27
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2006
VL 244
IS 9
BP 1119
EP 1123
DI 10.1007/s00417-005-0209-y
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 076LH
UT WOS:000239959000010
PM 16523305
DA 2022-11-30
ER

PT J
AU Wykoff, CC
   Croft, DE
   Brown, DM
   Wang, R
   Payne, JF
   Clark, L
   Abdelfattah, NS
   Sadda, SR
AF Wykoff, Charles C.
   Croft, Daniel E.
   Brown, David M.
   Wang, Rui
   Payne, John F.
   Clark, Lloyd
   Abdelfattah, Nizar Saleh
   Sadda, SriniVas R.
CA TREX-AMD Study Grp
TI Prospective Trial of Treat-and-Extend versus Monthly Dosing for
   Neovascular Age-Related Macular Degeneration TREX-AMD 1-Year Results
SO OPHTHALMOLOGY
LA English
DT Article
ID 2.0 MG RANIBIZUMAB; ENDOTHELIAL GROWTH-FACTOR; GEOGRAPHIC ATROPHY;
   OUTCOMES; PROTOCOL; THERAPY; NEED; EYE
AB Purpose: To assess prospectively a treat-and-extend (TREX) management strategy compared with monthly dosing of intravitreal ranibizumab in treatment-naive neovascular age-related macular degeneration (AMD) patients.
   Design: Phase IIIb, multicenter, randomized, controlled clinical trial.
   Participants: Sixty patients with treatment-naive neovascular AMD randomized 1: 2 to monthly or TREX management.
   Methods: Patients with Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) from 20/32 to 20/500 (Snellen equivalent) were randomized to receive intravitreal 0.5 mg ranibizumab monthly or according to a TREX protocol. The TREX patients were treated monthly for at least 3 doses, until resolution of clinical and spectral-domain optical coherence tomography evidence of exudative disease activity; the interval between visits then was individualized according to a strict prospective protocol.
   Main Outcome Measures: Mean ETDRS BCVA change from baseline.
   Results: At baseline, mean age was 77 years (range, 59-96 years), mean BCVA was 20/60 (Snellen equivalent), and mean central retinal thickness (CRT) was 511 mm. Fifty-seven eyes (95%) completed month 12, at which point mean BCVA improved by 9.2 and 10.5 letters in the monthly and TREX cohorts, respectively (P = 0.60). The mean number of injections administered through month 12 was 13.0 and 10.1 (range, 7-13) in the monthly and TREX cohorts, respectively (P < 0.0001). Among TREX patients, 7 (18%) were maximally extended, 4 (10%) demonstrated fluid at every visit, and at month 12, 18 (45%) had achieved an extension interval of 8 weeks or more; the mean maximum extension interval between injections after the first 3 monthly doses was 8.4 weeks (range, 4-12 weeks). Most TREX patients who demonstrated recurrent exudative disease activity (17/24 [ 71%]) were unable to extend beyond their initial maximum extension interval.
   Conclusions: The TREX neovascular AMD management strategy used in this prospective, randomized, controlled trial resulted in visual and anatomic gains comparable with those obtained with monthly dosing. Ophthalmology 2015; 122:2514-2522 (C) 2015 by the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Wykoff, Charles C.; Croft, Daniel E.; Brown, David M.; Wang, Rui] Retina Consultants Houston, Houston, TX USA.
   [Wykoff, Charles C.; Brown, David M.] Houston Methodist Hosp, Blanton Eye Inst, Houston, TX USA.
   [Wykoff, Charles C.; Brown, David M.] Weill Cornell Med Coll, Houston, TX USA.
   [Payne, John F.; Clark, Lloyd] Palmetto Retina Ctr, W Columbia, SC USA.
   [Abdelfattah, Nizar Saleh; Sadda, SriniVas R.] Doheny Eye Inst, Doheny Image Reading Ctr, Los Angeles, CA 90033 USA.
   [Abdelfattah, Nizar Saleh; Sadda, SriniVas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
C3 The Methodist Hospital System; The Methodist Hospital - Houston; Cornell
   University; Doheny Eye Institute; University of California System;
   University of California Los Angeles; University of California Los
   Angeles Medical Center; David Geffen School of Medicine at UCLA
RP Wykoff, CC (通讯作者)，6560 Fannin St,Suite 750, Houston, TX 77030 USA.
EM ccwmd@houstonretina.com
RI Abdelfattah, Nizar Saleh/H-6908-2019
OI Abdelfattah, Nizar Saleh/0000-0002-9396-3054; Wang,
   Rui/0000-0002-0900-7714
FU Genentech, Inc.; South San Francisco, California
FX Supported by Genentech, Inc., South San Francisco, California. The
   funding organization had no role in the design or conduct of this
   research.
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   American Society of Retinal Specialists, 2014, PAT SURV
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chow S.-C., 2003, SAMPLE SIZE CALCULAT
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fung AT, 2012, EYE, V26, P1181, DOI 10.1038/eye.2012.174
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Mantel I, 2013, GRAEF ARCH CLIN EXP, V251, P697, DOI 10.1007/s00417-012-2090-9
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Muether PS, 2013, AM J OPHTHALMOL, V156, P989, DOI 10.1016/j.ajo.2013.06.020
   Muether PS, 2012, OPHTHALMOLOGY, V119, P2082, DOI 10.1016/j.ophtha.2012.07.041
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Wykoff CC, 2013, OPHTHALMOLOGY, V120, P1945, DOI 10.1016/j.ophtha.2013.06.030
   Wykoff CC, 2013, OPHTHAL SURG LAS IM, V44, P121, DOI 10.3928/23258160-20130313-04
NR 28
TC 195
Z9 204
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2015
VL 122
IS 12
BP 2514
EP 2522
DI 10.1016/j.ophtha.2015.08.009
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CZ4EZ
UT WOS:000367057500031
PM 26391465
OA hybrid
DA 2022-11-30
ER

PT J
AU Chiu, CJ
   Milton, RC
   Gensler, G
   Taylor, A
AF Chiu, Chung-Jung
   Milton, Roy C.
   Gensler, Gary
   Taylor, Allen
TI Association between dietary glycernic index and age-related macular
   degeneration in nondiabetic participants in the Age-Related Eye Disease
   Study
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE retina; nutrition; carbohydrate; diabetes; insulin; cardiovascular
   diseases; glycation; fat; inflammation; aging; stress; epidemiology;
   risk factor; insulin-like growth factor
ID C-REACTIVE PROTEIN; GLYCEMIC INDEX; CARBOHYDRATE; RISK; GLUCOSE; LOAD;
   FAT; COMPLICATIONS; ANTIOXIDANTS; EXPOSURE
AB Background: Age-related macular degeneration (AMD) is the major cause of irreversible blindness. AMD appears to share several carbohydrate-related mechanisms and risk factors with diabetes-related diseases, including retinopathy and cardiovascular disease (CVD); however, to date, only one small study has addressed this issue.
   Objective: The objective was to test the hypothesis that dietary glycemic index (dGI), which has been related to the risk of diabetes and CVD, is associated with the risk and severity of AMD in nondiabetic elderly populations.
   Design: Dietary information was obtained from 4099 participants aged 55-80 y (56% women) in the Age-Related Eye Disease Study (AREDS). A total of 8125 eligible eyes at baseline were classified into 1 of 5 AMD groups according to the size and extent of drusen, the presence of geographic atrophy, and neovascular changes. We used a generalized estimating approach to evaluate the relations between dGI and risk and severity of AMD with eyes as the unit of analysis.
   Results: Compared with eyes in the first quintile of dGI, eyes in the fourth and fifth quintiles had a significantly or suggestively higher risk of large drusen, geographic atrophy, and neovascularization. The multivariate-adjusted odds ratios (95% CIs) for the highest quintile were 1.42 (1.09, 1.84), 1.78 (0.81, 3.90), and 1.41 (0.95, 2.08), respectively, of which only the odds ratio for large drusen was significant. A significant positive relation between dGI and severity of AMD was also noted (P for trend < 0.001). There was a 49% increase in the risk of advanced AMD (geographic atrophy plus neovascularization) for persons with a dGI higher than the sex median (women: >= 77.9; men: >= 79.3). This result indicated that 20% of prevalent cases of AMD would have been eliminated if the AREDS participants consumed diets with a dGI below the median.
   Conclusion: The association between dGI and AMD from the AREDS cross-sectional analysis at baseline suggests that a reduction in the dGI, a modifiable risk factor, may provide a means of diminishing the risk of AMD.
C1 Tufts Univ, Jean Mayer USDA, Human Nutr Res Ctr, Boston, MA 02111 USA.
   EMMES Corp, AREDS Coordinating Ctr, Rockville, MD USA.
C3 Tufts University; United States Department of Agriculture (USDA); Emmes
   Corporation
RP Taylor, A (通讯作者)，Tufts Univ, Jean Mayer USDA, Human Nutr Res Ctr, 711 Washington St, Boston, MA 02111 USA.
EM allen.taylor@tufts.edu
FU NATIONAL EYE INSTITUTE [R03EY014183] Funding Source: NIH RePORTER; NEI
   NIH HHS [R03-EY014183-01A2] Funding Source: Medline; PHS HHS [R01-13250]
   Funding Source: Medline
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Biddinger SB, 2005, AM J CLIN NUTR, V82, P277, DOI 10.1093/ajcn/82.2.277
   Brand-Miller JC, 2005, AM J CLIN NUTR, V82, P350, DOI 10.1093/ajcn/82.2.350
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Chin CJ, 2005, AM J CLIN NUTR, V81, P1411
   Chiu CJ, 2007, EXP EYE RES, V84, P229, DOI 10.1016/j.exer.2006.05.015
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P1177, DOI 10.1093/ajcn/83.5.1177
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P880, DOI 10.1093/ajcn/83.4.880
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Coutinho M, 1999, DIABETES CARE, V22, P233, DOI 10.2337/diacare.22.2.233
   Ford ES, 2001, ARCH INTERN MED, V161, P572, DOI 10.1001/archinte.161.4.572
   Foster-Powell K, 2002, AM J CLIN NUTR, V76, P5, DOI 10.1093/ajcn/76.1.5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Frost G, 1999, LANCET, V353, P1045, DOI 10.1016/S0140-6736(98)07164-5
   GREENLAND S, 1993, ENVIRON HEALTH PERSP, V101, P59, DOI 10.2307/3431660
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Hu YQ, 2006, AM J CLIN NUTR, V84, P70, DOI 10.1093/ajcn/84.1.70
   JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218
   JENKINS DJA, 1981, AM J CLIN NUTR, V34, P362, DOI 10.1093/ajcn/34.3.362
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002
   KLEIN BEK, 1990, OPHTHALMOLOGY, V97, P1428
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kumagai AK, 1999, DIABETES-METAB RES, V15, P261, DOI 10.1002/(SICI)1520-7560(199907/08)15:4<261::AID-DMRR43>3.0.CO;2-Z
   Liu SM, 2002, AM J CLIN NUTR, V75, P492, DOI 10.1093/ajcn/75.3.492
   Ludwig DS, 2002, JAMA-J AM MED ASSOC, V287, P2414, DOI 10.1001/jama.287.18.2414
   Mares-Perlman J.A., 1999, CRC MOD NUT, P181
   McCarty CA, 1996, B WORLD HEALTH ORGAN, V74, P353
   MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mullins RF, 1999, J HISTOCHEM CYTOCHEM, V47, P1533, DOI 10.1177/002215549904701205
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Shaw LC, 2004, REV ENDOCR METAB DIS, V5, P199, DOI 10.1023/B:REMD.0000032408.18015.b1
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Stitt AW, 2005, ANN NY ACAD SCI, V1043, P582, DOI 10.1196/annals.1338.066
   Tian J, 2005, P NATL ACAD SCI USA, V102, P11846, DOI 10.1073/pnas.0504759102
   Tirosh A, 2005, NEW ENGL J MED, V353, P1454, DOI 10.1056/NEJMoa050080
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366
   WOLEVER TMS, 1994, AM J CLIN NUTR, V59, P1265, DOI 10.1093/ajcn/59.6.1265
   Wright Jacqueline D, 2003, Adv Data, P1
   ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248
NR 48
TC 64
Z9 66
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD JUL
PY 2007
VL 86
IS 1
BP 180
EP 188
DI 10.1093/ajcn/86.1.180
PG 9
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 189IF
UT WOS:000247981900026
PM 17616779
OA Bronze
DA 2022-11-30
ER

PT J
AU Baek, J
   Lee, JH
   Lee, K
   Chung, BJ
   Lee, WK
AF Baek, Jiwon
   Lee, Jae Hyung
   Lee, Kook
   Chung, Byung Joo
   Lee, Won Ki
TI CLINICAL OUTCOME OF POLYPOIDAL CHOROIDAL VASCULOPATHY/ANEURYSMAL TYPE 1
   NEOVASCULARIZATION ACCORDING TO CHOROIDAL VASCULAR MORPHOLOGY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; aneurysmal Type 1 neovascularization;
   Haller layer; pachyvessel; treatment outcome; ranibizumab; PDT
ID MACULAR DEGENERATION; PACHYCHOROID NEOVASCULOPATHY; PHOTODYNAMIC
   THERAPY; EXTEND REGIMEN; NORMAL EYES; AGE; THICKNESS; HYPERPERMEABILITY;
   AFLIBERCEPT; CLASSIFICATION
AB Purpose: To determine the impact of choroidal vascular morphology on clinical outcomes in patients with polypoidal choroidal vasculopathy/aneurysmal Type 1 neovascularization. Methods: Sixty-six eyes with polypoidal choroidal vasculopathy/aneurysmal Type 1 were included. Eyes were subdivided according to the choroidal vascular morphology of the large vessel layer on optical coherence tomography en face images: focal (n = 39) versus diffuse (n = 27) pachyvessels. All patients were treated with intravitreal ranibizumab pro re nata with or without rescue photodynamic therapy. Results: Best-corrected visual acuity at baseline, 6, and 12 months did not differ between groups (P = 0.394, 0.142, and 0.292). At Month 3, best-corrected visual acuity was worse, and the proportion of eyes with fluid was higher in the focal group (P = 0.016 and 0.024). Among responders, the number of injections during 12-month follow-up was higher in the focal group (P = 0.033). During the total follow-up period, photodynamic therapy was required in 15 eyes (10 focal and 5 diffuse group, P = 0.497). The injection-free period after the photodynamic therapy was shorter in the focal group (P = 0.018). Conclusion: The polypoidal choroidal vasculopathy/aneurysmal Type 1 eyes with a diffuse pattern of pachyvessels required fewer injections during 12-month follow-up and showed a longer injection-free period after rescue photodynamic therapy.
C1 [Baek, Jiwon] Catholic Univ Korea, Bucheon St Marys Hosp, Dept Ophthalmol, Coll Med, Seoul, Gyeonggi Do, South Korea.
   [Lee, Jae Hyung; Lee, Kook; Chung, Byung Joo; Lee, Won Ki] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Ophthalmol, Seoul, South Korea.
C3 Catholic University of Korea; Catholic University of Korea; Seoul St.
   Mary's Hospital
RP Lee, WK (通讯作者)，Nune Eye Hosp, Retina Ctr, 404 Seolleung Ro, Seoul 06198, South Korea.
EM wklee0921@gmail.com
CR Baek J, 2019, EYE, V33, P419, DOI 10.1038/s41433-018-0228-7
   Baek J, 2018, GRAEF ARCH CLIN EXP, V256, P2309, DOI 10.1007/s00417-018-4143-1
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Barteselli G, 2012, OPHTHALMOLOGY, V119, P2572, DOI 10.1016/j.ophtha.2012.06.065
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Coscas F, 2011, EUR J OPHTHALMOL, V21, P331, DOI 10.5301/EJO.2010.2803
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Fujiwara A, 2016, AM J OPHTHALMOL, V170, P1, DOI 10.1016/j.ajo.2016.07.006
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Hata M, 2014, INVEST OPHTH VIS SCI, V55, P7874, DOI 10.1167/iovs.14-14610
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Lee WK, 2012, AM J OPHTHALMOL, V154, P355, DOI 10.1016/j.ajo.2012.02.019
   Matsumoto H, 2018, JPN J OPHTHALMOL, V62, P144, DOI 10.1007/s10384-018-0562-0
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Ng DSC, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20519
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Pang CE, 2014, INVEST OPHTH VIS SCI, V55, P5252, DOI 10.1167/iovs.14-14959
   PICCOLINO FC, 1994, RETINA-J RET VIT DIS, V14, P231, DOI 10.1097/00006982-199414030-00008
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447
   Sonoda S, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-43
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoneyama S, 2016, RETINA-J RET VIT DIS, V36, P1535, DOI 10.1097/IAE.0000000000000964
NR 36
TC 7
Z9 7
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2020
VL 40
IS 11
BP 2166
EP 2174
DI 10.1097/IAE.0000000000002723
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OP0WT
UT WOS:000587803100018
PM 31834135
DA 2022-11-30
ER

PT J
AU Tisdale, AK
   Agron, E
   Sunshine, SB
   Clemons, TE
   Ferris, FL
   Chew, EY
   Kassoff, A
   Kassoff, J
   Buehler, J
   Eglow, M
   Kaufman, F
   Mehu, M
   Kieval, S
   Mairs, M
   Graig, B
   Quattrocchi, A
   Jones, D
   Locatelli, J
   Ruby, A
   Capone, A
   Garretson, B
   Hassan, T
   Trese, MT
   Williams, GA
   Manatrey, P
   Streasick, P
   Szydlowski, L
   McIver, F
   Bridges, C
   Stanley, C
   Cumming, K
   Lewis, B
   Zajechowski, M
   Margherio, RR
   Cox, MS
   Werner, JC
   Falk, R
   Siedlak, P
   Neubert, C
   Klein, ML
   Stout, JT
   O'Malley, A
   Lauer, AK
   Robertson, JE
   Wilson, DJ
   Beardsley, C
   Anderson, H
   Wallace, P
   Smith, G
   Howard, S
   Dreyer, RF
   Ma, C
   Chenoweth, RG
   Zilis, JD
   Johnson, M
   Rice, P
   Daniel, H
   Crider, H
   Parker, S
   Sherman, K
   Martin, DF
   Aaberg, TM
   Sternberg, P
   Curtis, LT
   Ju, B
   Gilman, J
   Myles, B
   Strittman, S
   Gentry, C
   Yi, H
   Capone, A
   Lim, JI
   Stribling, B
   Swords, R
   Armiger, D
   Memorial, I
   Orth, DH
   Flood, TP
   Civantos, J
   DeBustros, S
   Packo, KH
   Merrill, PT
   Cohen, JA
   Figliulo, C
   Bryant, DA
   Doherty, D
   McVicker, M
   Drefcinski, T
   Seddon, JM
   Pinnolis, MK
   Davis, N
   Burton, I
   Taitsel, T
   Walsh, D
   Dubois-Moran, J
   Callahan, C
   Evans, C
   Snow, KK
   Jones-Devonish, DA
   Crouse, VD
   Rosenberg, NJ
   Chew, EY
   Csaky, K
   Ferris, FL
   Shimel, KH
   Woods, MA
   Kuehl, EM
   Ciatto, PF
   Palmer, M
   Babilonia-Ayukawa, G
   Foster, GE
   Goodman, L
   Kim, Y
   Kivitz, IJ
   LaReau, A
   Mercer, RF
   Nashwinter, R
   McCarthy, SA
   Ayres, LM
   Lopez, P
   Randalls, A
   Friberg, TR
   Eller, AW
   Gorin, MB
   Nixon, S
   Curtin, DY
   Ostroska, PP
   Fijewski, E
   Alexander, J
   Paine, MK
   Corbin, PS
   Warnicki, J
   Bressler, SB
   Bressler, NM
   Cassel, G
   Finkelstein, D
   Goldberg, M
   Hailer, JA
   Ratner, L
   Schachat, AP
   Sherman, SH
   Sunness, JS
   Schenning, S
   Sackett, C
   Cain, D
   Emmert, D
   Herring, M
   McDonald, J
   Falk, R
   Wheeler, S
   Mcmillan, M
   George, T
   Elman, MJ
   Ballinger, R
   Betancourt, A
   Glasser, D
   Herr, M
   Hirsh, D
   Kilingsworth, D
   Kohlhepp, P
   Lammlein, J
   Raden, RZ
   Seff, R
   Shuman, M
   Starr, J
   Carrigan, A
   Sotirakos, P
   Cain, T
   Mathews, T
   Ringrose, C
   Chandra, SR
   Gottlieb, JL
   Ip, MS
   Klein, R
   Nork, TM
   Stevens, TS
   Blodi, BA
   Altaweel, M
   Klein, BEK
   Olson, M
   Soderling, B
   Blatz, M
   Perry-Raymond, JR
   Burke, K
   Knutson, G
   Peterson, J
   Krolnik, D
   Harrison, R
   Somers, G
   Myers, FL
   Wallow, I
   Olsen, TW
   Bresnik, G
   De Venecia, G
   Perkins, T
   Walker, W
   Miller, JL
   Neider, M
   Wabers, HD
   Weber, G
   Myers, HEL
   Davis, MD
   Klein, BEK
   Klein, R
   Hubbard, L
   Neider, M
   Wabers, HD
   Magli, YL
   Ansay, S
   Armstrong, J
   Lang, K
   Badal, D
   Geithman, PL
   Miner, KD
   Dohm, KL
   Esser, B
   Hurtenbach, C
   Craanen, S
   Webster, M
   Elledge, J
   Reed, S
   Benz, W
   Reimers, J
   Fisher, MR
   Gangnon, R
   King, W
   Gai, CY
   Baliker, J
   Carr, A
   Osterby, K
   Kastorff, L
   Robinson, N
   Onofrey, J
   Glander, KE
   Brickbauer, J
   Miller, D
   Sowell, A
   Gunter, E
   Bowman, B
   Lindblad, AS
   Milton, RC
   Clemons, TE
   Ederer, F
   Gensler, G
   Henning, A
   Ender, G
   McBee, W
   Roberts, K
   Stine, E
   Berlin, SH
   Tomlin, K
   Pallas, S
   Scholl, PR
   Mengers, SA
   Anand, R
   Chairman, S
   Ferris, FL
   Sperduto, RD
   Kurinij, N
   Chew, EY
AF Tisdale, Alanna K.
   Agron, Elvira
   Sunshine, Sarah B.
   Clemons, Traci E.
   Ferris, Frederick L., III
   Chew, Emily Y.
   Kassoff, Aaron
   Kassoff, Jordan
   Buehler, JoAnne
   Eglow, Mary
   Kaufman, Francine
   Mehu, Michel
   Kieval, Shalom
   Mairs, Michael
   Graig, Barbara
   Quattrocchi, Andrea
   Jones, Denise
   Locatelli, Joan
   Ruby, Alan
   Capone, Antonio, Jr.
   Garretson, Bruce
   Hassan, Tarek
   Trese, Michael T.
   Williams, George A.
   Manatrey, Patricia
   Streasick, Patricia
   Szydlowski, Lynette
   McIver, Fran
   Bridges, Craig
   Stanley, Cheryl
   Cumming, Kristi
   Lewis, Bobbie
   Zajechowski, Mary
   Margherio, Raymond R.
   Cox, Morton S.
   Werner, Jane Camille
   Falk, Rachel
   Siedlak, Patricia
   Neubert, Cheryl
   Klein, Michael L.
   Stout, J. Timothy
   O'Malley, Adrian
   Lauer, Andreas K.
   Robertson, Joseph E.
   Wilson, David J.
   Beardsley, Carolyn
   Anderson, Hiroko
   Wallace, Patrick
   Smith, Garland
   Howard, Shannon
   Dreyer, Richard F.
   Ma, Colin
   Chenoweth, Richard G.
   Zilis, John D.
   Johnson, Milton
   Rice, Patrick
   Daniel, Howard
   Crider, Harold
   Parker, Sheryl
   Sherman, Kathryn
   Martin, Daniel F.
   Aaberg, Thomas M., Sr.
   Sternberg, Paul, Jr.
   Curtis, Linda T.
   Ju, Bora
   Gilman, James
   Myles, Bob
   Strittman, Sandra
   Gentry, Christina
   Yi, Hannah
   Capone, Antonio, Jr.
   Lim, Jennifer, I
   Stribling, Barbara
   Swords, Ray
   Armiger, Denise
   Memorial, Ingalls
   Orth, David H.
   Flood, Timothy P.
   Civantos, Joseph
   DeBustros, Serge
   Packo, Kirk H.
   Merrill, Pauline T.
   Cohen, Jack A.
   Figliulo, Celeste
   Bryant, Douglas A.
   Doherty, Don
   McVicker, Marian
   Drefcinski, Tana
   Seddon, Johanna M.
   Pinnolis, Michael K.
   Davis, Nancy
   Burton, Ilene
   Taitsel, Tatiana
   Walsh, David
   Dubois-Moran, Jennifer
   Callahan, Charlene
   Evans, Claudia
   Snow, Kristin K.
   Jones-Devonish, Desiree A.
   Crouse, Valerie D.
   Rosenberg, N. Jennifer
   Chew, Emily Y.
   Csaky, Karl
   Ferris, Frederick L., III
   Shimel, Katherine Hall
   Woods, Merria A.
   Kuehl, Ernest M.
   Ciatto, Patrick F.
   Palmer, Marilois
   Babilonia-Ayukawa, Gloria
   Foster, Guy E.
   Goodman, Linda
   Kim, Youngja
   Kivitz, Iris J.
   LaReau, Antoinette
   Mercer, Richard F.
   Nashwinter, Roula
   McCarthy, Sally A.
   Ayres, Leanne M.
   Lopez, Patrick
   Randalls, Anne
   Friberg, Thomas R.
   Eller, Andrew W.
   Gorin, Michael B.
   Nixon, Shannon
   Curtin, Diane Y.
   Ostroska, Phyllis P.
   Fijewski, Edward
   Alexander, Jane
   Paine, Melissa K.
   Corbin, Patricia S.
   Warnicki, Joseph
   Bressler, Susan B.
   Bressler, Neil M.
   Cassel, Gary
   Finkelstein, Daniel
   Goldberg, Morton
   Hailer, Julia A.
   Ratner, Lois
   Schachat, Andrew P.
   Sherman, Steven H.
   Sunness, Janet S.
   Schenning, Sherrie
   Sackett, Catherine
   Cain, Dennis
   Emmert, David
   Herring, Mark
   McDonald, Jacquelyn
   Falk, Rachel
   Wheeler, Stacy
   Mcmillan, Mary
   George, Terry
   Elman, Michael J.
   Ballinger, Rex
   Betancourt, Arturo
   Glasser, David
   Herr, Michael
   Hirsh, Dahlia
   Kilingsworth, Daniel
   Kohlhepp, Paul
   Lammlein, Joyce
   Raden, Robert Z.
   Seff, Ronald
   Shuman, Martin
   Starr, JoAnn
   Carrigan, Anita
   Sotirakos, Peter
   Cain, Theresa
   Mathews, Terri
   Ringrose, Christine
   Chandra, Suresh R.
   Gottlieb, Justin L.
   Ip, Michael S.
   Klein, Ronald
   Nork, T. Michael
   Stevens, Thomas S.
   Blodi, Barbara A.
   Altaweel, Michael
   Klein, Barbara E. K.
   Olson, Michelle
   Soderling, Barbara
   Blatz, Margo
   Perry-Raymond, Jennie R.
   Burke, Kathryn
   Knutson, Gene
   Peterson, John
   Krolnik, Denise
   Harrison, Robert
   Somers, Guy
   Myers, Frank L.
   Wallow, Ingolf
   Olsen, Timothy W.
   Bresnik, George
   De Venecia, G.
   Perkins, Tracy
   Walker, Wendy
   Miller, Jennifer L.
   Neider, Michael
   Wabers, Hugh D.
   Weber, Greg
   Myers, Helen E. Lyngaas
   Davis, Matthew D.
   Klein, Barbara E. K.
   Klein, Ronald
   Hubbard, Larry
   Neider, Michael
   Wabers, Hugh D.
   Magli, Yvonne L.
   Ansay, Sarah
   Armstrong, Jane
   Lang, Kristine
   Badal, Darlene
   Geithman, Patricia L.
   Miner, Kathleen D.
   Dohm, Kristi L.
   Esser, Barbara
   Hurtenbach, Cynthia
   Craanen, Shirley
   Webster, Mary
   Elledge, Julee
   Reed, Susan
   Benz, Wendy
   Reimers, James
   Fisher, Marian R.
   Gangnon, Ronald
   King, William
   Gai, Chunyang
   Baliker, James
   Carr, Alistair
   Osterby, Kurt
   Kastorff, Linda
   Robinson, Nancy
   Onofrey, James
   Glander, Kathleen E.
   Brickbauer, Judith
   Miller, Dayton
   Sowell, Anne
   Gunter, Elaine
   Bowman, Barbara
   Lindblad, Anne S.
   Milton, Roy C.
   Clemons, Traci E.
   Ederer, Fred
   Gensler, Gary
   Henning, Alice
   Ender, Gary
   McBee, Wendy
   Roberts, Kiana
   Stine, Elaine
   Berlin, Stuart H.
   Tomlin, Kate
   Pallas, Sophia
   Scholl, Phyllis R.
   Mengers, Susan A.
   Anand, Ravinder
   Chairman, Study
   Ferris, Frederick L., III
   Sperduto, Robert D.
   Kurinij, Natalie
   Chew, Emily Y.
CA Age Related Eye Dis Study Res Grp
TI Association of Dietary and Supplementary Calcium Intake With Age-Related
   Macular Degeneration Age-Related Eye Disease Study Report 39
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID VITAMIN-D; RISK-FACTORS; FATTY-ACID; PROGRESSION
AB IMPORTANCE Previous studies of the role of dietary and supplementary calcium in age-related macular degeneration (AMD) have produced mixed results, suggesting that supplementation and decreased dietary intake are both harmful.
   OBJECTIVE To evaluate the association of baseline dietary and supplementary calcium intake with progression of AMD.
   DESIGN, SETTING, AND PARTICIPANTS This study involved secondary analyses of participants enrolled in the Age-Related Eye Disease Study (AREDS). The AREDS study (1992-2001) enrolled patients from academic and community-based retinal practices in the United States. Men and women with varying severity of AMD were included. Data analysis for this article occurred from September 2015 to December 2018.
   EXPOSURES Baseline self-reported dietary or supplementary calcium intake.
   MAIN OUTCOMES AND MEASURES Development of late AMD, geographic atrophy (central or noncentral), or neovascular AMD detected on centrally graded baseline and annual fundus photographs.
   RESULTS A total of 4751 participants were included (mean [SD] age, 69.4 [5.1] years); 4543 (95.6%) were white, and 2655 (55.9%) were female. Compared with those who were in the lowest quintile, the participants in the highest quintile of dietary calcium intake had a lower risk of developing late AMD (hazard ratio [HR], 0.73 [95% CI, 0.59-0.90]), central geographic atrophy (HR, 0.64 [95% CI, 0.48-0.86]), and any geographic atrophy (HR, 0.80 [95% CI, 0.64-1.00]). The participants in the highest tertile of supplementary calcium intake had a lower risk of developing neovascular AMD (HR, 0.70 [95% CI, 0.50-0.97]) compared with those who did not take calcium supplements. When stratified by sex, women in the highest quintile of dietary calcium intake had a lower risk of developing late AMD (HR, 0.73 [95% CI, 0.56-0.97]) compared with those in the lowest quintile. Women in the highest tertile of calcium supplementation had a lower risk of progression to neovascular AMD (HR, 0.67 [95% CI, 0.48-0.94]) compared with those who did not take calcium supplements. Similar findings were found in men for dietary calcium. Too few men took calcium supplements to allow for analyses.
   CONCLUSIONS AND RELEVANCE In this secondary analysis, higher levels of dietary and supplementary calcium intake were associated with lower incidence of progression to late AMD in AREDS participants. The results may be owing to uncontrolled confounding or chance and should be considered hypothesis development requiring additional study.
C1 [Tisdale, Alanna K.; Agron, Elvira; Sunshine, Sarah B.; Ferris, Frederick L., III; Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Clemons, Traci E.] Emmes Corp, Rockville, MD USA.
   [Neubert, Cheryl] Devers Eye Inst, Portland, OR USA.
   [Crider, Harold; Parker, Sheryl; Sherman, Kathryn] Emory Univ, Atlanta, GA 30322 USA.
   [Armiger, Denise; Memorial, Ingalls] Ingalls Mem Hosp, Harvey, IL USA.
   [Drefcinski, Tana] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
   [Snow, Kristin K.; Jones-Devonish, Desiree A.; Crouse, Valerie D.; Rosenberg, N. Jennifer] Natl Eye Inst Clin Ctr, Bethesda, MD USA.
   [Ayres, Leanne M.; Lopez, Patrick; Randalls, Anne] Univ Pittsburgh, Pittsburgh, PA USA.
   [Warnicki, Joseph] Johns Hopkins Med Inst, Baltimore, MD 21205 USA.
   [George, Terry] Elman Retina Grp PA, Baltimore, MD USA.
   [Ringrose, Christine] Univ Wisconsin, Madison, WI 53706 USA.
   [Myers, Helen E. Lyngaas] Univ Wisconsin, Reading Ctr, Madison, WI 53706 USA.
   [Glander, Kathleen E.; Brickbauer, Judith] Ctr Dis Control & Prevent, Cent Lab, Atlanta, GA USA.
   [Anand, Ravinder] Natl Eye Inst Project Off, Bethesda, MD USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Emmes Corporation; Devers Eye Institute; Emory University;
   Harvard University; Massachusetts Eye & Ear Infirmary; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Johns Hopkins University; Johns Hopkins Medicine; University
   of Wisconsin System; University of Wisconsin Madison; University of
   Wisconsin System; University of Wisconsin Madison; Centers for Disease
   Control & Prevention - USA
RP Chew, EY (通讯作者)，NIH, 10 Ctr Dr,MSC 1204,Bldg 10,CRC Room 3-2531, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
RI SanGiovanni, John Paul/AAU-3895-2020
OI Ferris, Frederick/0000-0002-4933-0639
FU National Eye Institute of the National Institutes of Health (NIH)
   [NOI-EY-0-2127]; National Eye Institute; NIH Medical Research Scholars
   Program; NIH
FX This study is supported by the intramural program funds and contracts
   AREDS (contract NOI-EY-0-2127) from the National Eye Institute of the
   National Institutes of Health (NIH). This research was also made
   possible by the National Eye Institute and the NIH Medical Research
   Scholars Program (support for Dr Tisdale), a public-private partnership
   supported jointly by the NIH and generous contributions to the
   Foundation for the NIH from the Doris Duke Charitable Foundation, the
   American Association for Dental Research, the Howard Hughes Medical
   Institute, and the Colgate-Palmolive Company, as well as other private
   donors.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1999, CONTROL CLIN TRIALS, DOI 10.1016/S0197-2456(99)00031-8
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Bailey RL, 2010, J NUTR, V140, P817, DOI 10.3945/jn.109.118539
   Chang JR, 2011, OPHTHALMOLOGY, V118, P2113, DOI 10.1016/j.ophtha.2011.03.032
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cougnard-Greoire A, 2015, J NUTR, V145, P1865, DOI 10.3945/jn.115.214387
   Cox dr, 1984, ANAL SURVIVAL DATA, DOI DOI 10.1201/9781315137438
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ganguli M, 1998, J GERONTOL A-BIOL, V53, pM39, DOI 10.1093/gerona/53A.1.M39
   Gopinath B, 2014, BRIT J NUTR, V111, P1673, DOI 10.1017/S000711451300408X
   Guymer RH, 2006, MED J AUSTRALIA, V184, P455, DOI 10.5694/j.1326-5377.2006.tb00318.x
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin SC, 2014, JAMA OPHTHALMOL, V132, P1414, DOI 10.1001/jamaophthalmol.2014.2876
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Merle BMJ, 2017, INVEST OPHTH VIS SCI, V58, P4569, DOI 10.1167/iovs.17-21673
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   National Institutes of Health, 2001, NIH POL REP RAC ETHN
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rovner BW, 2014, OPHTHALMOLOGY, V121, P2204, DOI 10.1016/j.ophtha.2014.05.002
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   ULSHAFER RJ, 1987, INVEST OPHTH VIS SCI, V28, P683
   van Asten F, 2018, OPHTHALMOLOGY, V125, P559, DOI 10.1016/j.ophtha.2017.09.023
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 32
TC 8
Z9 8
U1 0
U2 14
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAY
PY 2019
VL 137
IS 5
BP 543
EP 550
DI 10.1001/jamaophthalmol.2019.0292
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HX6HB
UT WOS:000467503600017
PM 30896764
OA Green Published
DA 2022-11-30
ER

PT J
AU Sawada, T
   Yasukawa, T
   Imaizumi, H
   Matsubara, H
   Kimura, K
   Terasaki, H
   Ishikawa, H
   Murakami, T
   Takeuchi, M
   Mitamura, Y
   Yamashita, M
   Takamura, Y
   Murata, T
   Kogo, J
   Ohji, M
AF Sawada, Tomoko
   Yasukawa, Tsutomu
   Imaizumi, Hiroko
   Matsubara, Hisashi
   Kimura, Kazuhiro
   Terasaki, Hiroto
   Ishikawa, Hiroto
   Murakami, Tomoya
   Takeuchi, Masaru
   Mitamura, Yoshinori
   Yamashita, Mariko
   Takamura, Yoshihiro
   Murata, Toshinori
   Kogo, Jiro
   Ohji, Masahito
CA J-CREST Japan Clin Retinal Study
TI Ten-year changes in visual acuity at baseline and at 2 years after
   treatment in a Japanese population with age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Baseline visual acuity; Anti-vascular
   endothelial growth factor; Photodynamic therapy; J-CREST Study group
ID PHOTODYNAMIC THERAPY; RANIBIZUMAB; VERTEPORFIN; AFLIBERCEPT; OUTCOMES
AB Purpose We investigated 10-year changes in baseline best-corrected visual acuity (BCVA), as well as functional and anatomical changes at 1 and 2 years after initial treatment, in eyes with treatment-naive neovascular age-related macular degeneration (nAMD).
   Methods This retrospective, multicenter, case series reviewed patients with treatment-naive nAMD who underwent initial treatment from 2006 to 2015, using photodynamic therapy (PDT), anti-vascular endothelial growth factor (VEGF), or a combination of PDT and anti-VEGF. BCVA and central retinal subfield thickness (CRST), were measured at baseline and at 1 or 2 years of follow-up.
   Results In total, 3096 eyes of 3096 patients were included from 14 hospitals. Mean BCVA at baseline became significantly better over the 10-year study period (P < 0.001). BCVA at 1 year significantly improved from baseline in patients who underwent initial treatment from 2009 to 2015 (P = 0.001, 2009; P = 0.004, 2010; P = 0.01, 2011; P < 0.001, 2012-2015). BCVA at 2 years significantly improved from baseline in patients who underwent initial treatment from 2012 to 2015 (P < 0.001, 2012; P < 0.001, 2013-2015). CRST at 1 year decreased significantly from CRST at baseline, each year from 2006 to 2015 (P < 0.001, 2006-2015). CRST at 2 years decreased significantly from CRST at baseline, each year from 2006 to 2015 (P = 0.03, 2006; P < 0.001, 2007-2015).
   Conclusion Baseline BCVA with treatment-naive nAMD tended to become better during the study period. BCVA at 1 year improved in the era of anti-VEGF; BCVA at 2 years improved in patients who underwent initial treatment in 2012 or later; and CRST decreased in each year during the study period.
C1 [Sawada, Tomoko; Ohji, Masahito] Shiga Univ Med Sci, Dept Ophthalmol, Seta Tsukinowa Cho, Otsu, Shiga 5202192, Japan.
   [Yasukawa, Tsutomu] Nagoya City Univ, Dept Ophthalmol, Nagoya, Aichi, Japan.
   [Imaizumi, Hiroko] Sapporo City Gen Hosp, Dept Ophthalmol, Sapporo, Hokkaido, Japan.
   [Matsubara, Hisashi] Mie Univ, Dept Ophthalmol, Tsu, Mie, Japan.
   [Kimura, Kazuhiro] Yamaguchi Univ, Dept Ophthalmol, Ube, Yamaguchi, Japan.
   [Terasaki, Hiroto] Kagoshima Univ, Dept Ophthalmol, Kagoshima, Japan.
   [Ishikawa, Hiroto] Hyogo Coll Med, Dept Ophthalmol, Nishinomiya, Hyogo, Japan.
   [Murakami, Tomoya] Univ Tsukuba, Dept Ophthalmol, Tsukuba, Ibaraki, Japan.
   [Takeuchi, Masaru] Natl Def Med Coll, Dept Ophthalmol, Tokorozawa, Saitama, Japan.
   [Mitamura, Yoshinori] Tokushima Univ, Dept Ophthalmol, Tokushima, Japan.
   [Yamashita, Mariko] Nara Med Univ, Dept Ophthalmol, Kashihara, Nara, Japan.
   [Takamura, Yoshihiro] Shinshu Univ, Dept Ophthalmol, Matsumoto, Nagano, Japan.
   [Murata, Toshinori] Shinshu Univ, Dept Ophthalmol, Matsumoto, Nagano, Japan.
   [Kogo, Jiro] St Marianna Univ, Dept Ophthalmol, Sch Med, Kawasaki, Kanagawa, Japan.
C3 Shiga University of Medical Science; Nagoya City University; Sapporo
   City General Hospital; Mie University; Yamaguchi University; Kagoshima
   University; Hyogo College of Medicine; University of Tsukuba; National
   Defense Medical College - Japan; Tokushima University; Nara Medical
   University; Shinshu University; Shinshu University; Saint Marianna
   University
RP Sawada, T (通讯作者)，Shiga Univ Med Sci, Dept Ophthalmol, Seta Tsukinowa Cho, Otsu, Shiga 5202192, Japan.
EM tsawada@belle.shiga-med.ac.jp
OI Murakami, Tomoya/0000-0001-5421-8580
CR Adrian ML, 2019, ACTA OPHTHALMOL, V97, P91, DOI 10.1111/aos.13864
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brynskov T, 2020, ACTA OPHTHALMOL, V98, P132, DOI 10.1111/aos.14183
   Cohen SY, 2013, GRAEF ARCH CLIN EXP, V251, P2499, DOI 10.1007/s00417-013-2338-z
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Westborg I, 2017, ACTA OPHTHALMOL, V95, P787, DOI 10.1111/aos.13539
NR 14
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2021
VL 259
IS 5
BP 1191
EP 1198
DI 10.1007/s00417-020-05005-y
EA NOV 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RY3DR
UT WOS:000590205800001
PM 33201353
DA 2022-11-30
ER

PT J
AU Soderberg, AC
   Algvere, PV
   Hengstler, JC
   Soderberg, P
   Seregard, S
   Kvanta, A
AF Soderberg, Anne-Catherine
   Algvere, Peep V.
   Hengstler, Jurg C.
   Soderberg, Par
   Seregard, Stefan
   Kvanta, Anders
TI Combination therapy with low-dose transpupillary thermotherapy and
   intravitreal ranibizumab for neovascular age-related macular
   degeneration: a 24-month prospective randomised clinical study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY;
   VERTEPORFIN; BEVACIZUMAB; MOUSE
AB Aim To compare the effect of combined low-dose transpupillary thermotherapy (TTT) and intravitreal ranibizumab with sham TTT and intravitreal ranibizumab in patients with neovascular age-related macular degeneration (AMD).
   Methods A 24-month, double-masked, randomised, active-controlled clinical trial. 100 patients with primary neovascular AMD were randomly assigned (1: 1) to receive intravitreal ranibizumab and sham TTT or intravitreal ranibizumab and low-dose TTT. After an initial loading phase of ranibizumab patients were assigned to receive quarterly low-dose TTT (136 mW/mm) or sham TTT for 24 months. Retreatment with ranibizumab was allowed in both treatment groups using a variable dosing regimen. The primary endpoint was the number of intravitreal injections with ranibizumab. Secondary endpoints included change in best corrected visual acuity (BCVA), central retinal thickness (CRT) and lesion area.
   Results In the per protocol (PP) population (78 patients) the mean number of ranibizumab injections was 8.0 in the sham TTT group versus 6.3 in the TTT group (p<0.05). The mean number of injections between 0-12 months and 13-24 months was 4.8 versus 4.6 (p>0.05) and 3.2 versus 1.7 (p<0.01) in the sham TTT and TTT groups, respectively. There was no statistically significant difference in BCVA (+4.0 vs +0.9 ETDRS letters), CRT (-49.9% vs -36.4%) or lesion area (-0.3% vs -10.6%) between the treatment groups at the final examination. The results of the intent-to-treat population (92 patients) were similar to the PP population.
   Conclusions Treatment with low-dose TTT significantly reduced the number or intravitreal injections of ranibizumab over 24 months. The results suggest that low-dose TTT can serve as an adjuvant in combination with intravitreal ranibizumab for neovascular AMD.
   Clinical trial registration number The trial is registered at http://clinicaltrails.gov (no NCT00599222).
C1 [Soderberg, Anne-Catherine; Algvere, Peep V.; Hengstler, Jurg C.; Seregard, Stefan; Kvanta, Anders] Karolinska Inst, St Eriks Eye Hosp, Dept Ophthalmol, SE-11282 Stockholm, Sweden.
   [Soderberg, Par] Uppsala Univ, Dept Neurosci, Uppsala, Sweden.
C3 Karolinska Institutet; Uppsala University
RP Kvanta, A (通讯作者)，Karolinska Inst, St Eriks Eye Hosp, Dept Ophthalmol, Polhemsgatan 50, SE-11282 Stockholm, Sweden.
EM anders.kvanta@sankterik.se
OI Hengstler, Jan/0000-0002-1427-5246
CR Algvere PV, 2003, ACTA OPHTHALMOL SCAN, V81, P110, DOI 10.1034/j.1600-0420.2003.00041.x
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kumar A, 2008, RETINA-J RET VIT DIS, V28, P1132, DOI 10.1097/IAE.0b013e318170d76d
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lanzetta P, 2002, OPHTHALMOLOGY, V109, P1098, DOI 10.1016/S0161-6420(02)01034-5
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Ming Y, 2004, INVEST OPHTH VIS SCI, V45, P1969, DOI 10.1167/iovs.03-1329
   Odergren A, 2008, BRIT J OPHTHALMOL, V92, P757, DOI 10.1136/bjo.2007.133561
   Odergren A, 2006, CURR EYE RES, V31, P765, DOI 10.1080/02713680600865045
   Odergren A, 2010, ACTA OPHTHALMOL, V88, P426, DOI 10.1111/j.1755-3768.2009.01567.x
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Vallance JH, 2010, EYE, V24, P1561, DOI 10.1038/eye.2010.84
NR 19
TC 16
Z9 16
U1 0
U2 3
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2012
VL 96
IS 5
BP 714
EP 718
DI 10.1136/bjophthalmol-2011-300721
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 927UX
UT WOS:000302936900022
PM 22241923
OA Bronze
DA 2022-11-30
ER

PT J
AU Yu, Y
   Reynolds, R
   Fagerness, J
   Rosner, B
   Daly, MJ
   Seddon, JM
AF Yu, Yi
   Reynolds, Robyn
   Fagerness, Jesen
   Rosner, Bernard
   Daly, Mark J.
   Seddon, Johanna M.
TI Association of Variants in the LIPC and ABCA1 Genes with Intermediate
   and Large Drusen and Advanced Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT FACTOR-H; BODY-MASS INDEX; BRUCHS MEMBRANE;
   CIGARETTE-SMOKING; A1 ABCA1; US TWIN; RISK; SUSCEPTIBILITY; CHOLESTEROL;
   MACROPHAGES
AB PURPOSE. Intermediate and large drusen usually precede advanced age-related macular degeneration (AMD). There is little information about which genes influence drusen accumulation. Discovery of genetic variants associated with drusen may lead to prevention and treatments of AMD in its early stages.
   METHODS. A total of 3066 subjects were evaluated on the basis of ocular examinations and fundus photography and categorized as control (n = 221), intermediate drusen (n = 814), large drusen (n = 949), or advanced AMD (n = 1082). SNPs in the previously identified CFH, C2, C3, CFB, CFI, APOE, and ARMS2/HTRA1 genes/regions and the novel genes LIPC, CETP, and ABCA1 in the high-density lipoprotein (HDL) cholesterol pathway were genotyped. Associations between stage of AMD and SNPs were assessed using logistic regression.
   RESULTS. Controlling for age, sex, education, smoking, body mass index, and antioxidant treatment, the number of minor (T) alleles of the genes LIPC and ABCA1 were significantly associated with a reduced risk of intermediate drusen (LIPC [P trend = 0.045], ABCA1 [P = 4.4 x 10(-3)]), large drusen (LIPC [P = 0.041], ABCA1 [P = 7.7 x 10(-4)]), and advanced AMD (LIPC [P = 1.8 x 10(-3)], ABCA1 [P = 3 x 10(-4)]). After further adjustment for known genetic factors, the protective effect of the TT genotype was significant for intermediate drusen (LIPC [odds ratio (OR), 0.56; 95% confidence interval (CI), 0.33-0.94], ABCA1 [OR, 0.48; 95% CI, 0.27-0.85]), large drusen (LIPC [OR, 0.58; 95% CI, 0.34-0.98)], ABCA1 [OR, 0.41; 95% CI, 0.23-0.74)]), and advanced AMD (LIPC [OR, 0.39; 95% CI, 0.21-0.74)], ABCA1 [OR, 0.35; 95% CI, 0.17-0.71)]). CFH, C3, C2, and ARMS2/HTRA1 were associated with large drusen and advanced AMD.
   CONCLUSIONS. LIPC and ABCA1 are related to intermediate and large drusen, as well as advanced AMD. CFH, C3, C2, and ARMS2/HTRA1 are associated with large drusen and advanced AMD. Genes may have varying effects on different stages of AMD. (Invest Ophthalmol Vis Sci. 2011;52:4663-4670) DOI:10.1167/iovs.10-7070
C1 [Yu, Yi; Reynolds, Robyn; Seddon, Johanna M.] Tufts Med Ctr, Ophthalm Epidemiol & Genet Serv, Dept Ophthalmol, Boston, MA 02111 USA.
   [Fagerness, Jesen; Daly, Mark J.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
   [Fagerness, Jesen; Daly, Mark J.] Broad Inst Harvard & Massachusetts Inst Technol, Program Med & Populat Genet, Cambridge, MA USA.
   [Rosner, Bernard] Channing Labs, Boston, MA USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
C3 Tufts Medical Center; Harvard University; Massachusetts General
   Hospital; Harvard University; Massachusetts Institute of Technology
   (MIT); Broad Institute; Tufts University
RP Seddon, JM (通讯作者)，Tufts Med Ctr, Ophthalm Epidemiol & Genet Serv, Dept Ophthalmol, 800 Washington St,450, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
RI Daly, Mark J/B-2453-2017
OI Daly, Mark J/0000-0002-0949-8752
FU National Institutes of Health, Bethesda, MD [R01-EY11309]; Massachusetts
   Lions Eye Research Fund, Inc.; Research to Prevent Blindness, Inc., New
   York, NY; American Macular Degeneration Foundation, Northampton, MA;
   Elizabeth O'Brien Trust; Virginia B. Smith Trust; Ophthalmic
   Epidemiology and Genetics Service, New England Eye Center, Tufts Medical
   Center, Tufts University School of Medicine, Boston, MA; NATIONAL EYE
   INSTITUTE [R01EY011309] Funding Source: NIH RePORTER
FX Supported by an anonymous donor (JMS); in part by grant R01-EY11309 from
   the National Institutes of Health, Bethesda, MD; the Massachusetts Lions
   Eye Research Fund, Inc.; an unrestricted grant from Research to Prevent
   Blindness, Inc., New York, NY; the American Macular Degeneration
   Foundation, Northampton, MA; the Elizabeth O'Brien Trust; the Virginia
   B. Smith Trust; and the Macular Degeneration Research Fund of the
   Ophthalmic Epidemiology and Genetics Service, New England Eye Center,
   Tufts Medical Center, Tufts University School of Medicine, Boston, MA.
CR Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, METHODS MOL BIOL, V580, P267, DOI 10.1007/978-1-60761-325-1_15
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Duncan KG, 2009, BRIT J OPHTHALMOL, V93, P1116, DOI 10.1136/bjo.2008.144006
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fariss RN, 1997, AM J PATHOL, V150, P323
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2009, HUM MUTAT, V30, P1048, DOI 10.1002/humu.20957
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gonzalez-Navarro H, 2002, J LIPID RES, V43, P671
   Grarup N, 2008, J CLIN ENDOCR METAB, V93, P2294, DOI 10.1210/jc.2007-2815
   Grassi MA, 2007, ARCH OPHTHALMOL-CHIC, V125, P93, DOI 10.1001/archopht.125.1.93
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hasham SN, 2006, CLIN CHIM ACTA, V372, P179, DOI 10.1016/j.cca.2006.04.020
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kathiresan S, 2009, NAT GENET, V41, P56, DOI 10.1038/ng.291
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li CM, 2007, EXP EYE RES, V85, P192, DOI 10.1016/j.exer.2007.04.002
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Losonczy G, 2011, ACTA OPHTHALMOL, V89, P255, DOI 10.1111/j.1755-3768.2009.01687.x
   Lucas A D, 2001, Expert Rev Mol Med, V3, P1, DOI 10.1017/S1462399401003696
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Munch IC, 2010, INVEST OPHTH VIS SCI, V51, P2317, DOI 10.1167/iovs.09-4482
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nong ZX, 2003, J CLIN INVEST, V112, P367, DOI 10.1172/JCI200316484
   Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rufibach LE, 2006, J LIPID RES, V47, P1463, DOI 10.1194/jlr.M600082-JLR200
   Schmitz G, 1999, PATHOBIOLOGY, V67, P236, DOI 10.1159/000028100
   Seddon J, 2007, PRINCIPLES PRACTICE, P413
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2010, MOL VIS, V16, P2412
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Tang CR, 2009, J BIOL CHEM, V284, P32336, DOI 10.1074/jbc.M109.047472
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yvan-Charvet L, 2010, ARTERIOSCL THROM VAS, V30, P139, DOI 10.1161/ATVBAHA.108.179283
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 69
TC 92
Z9 97
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2011
VL 52
IS 7
BP 4663
EP 4670
DI 10.1167/iovs.10-7070
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 800BP
UT WOS:000293332500098
PM 21447678
OA Green Published
DA 2022-11-30
ER

PT J
AU Chen, SN
   Cheng, CK
   Yeung, L
   Chen, JT
   Chan, WC
   Liu, JH
   Sheu, SJ
   Wu, WC
   Lai, CC
AF Chen, San-Ni
   Cheng, Cheng-Kuo
   Yeung, Ling
   Chen, Jiann-Torng
   Chan, Wei-Chun
   Liu, Jorn-Hon
   Sheu, Shwu-Jiuan
   Wu, Wen-Chuan
   Lai, Chi-Chun
TI One-year real-world outcomes of ranibizumab 0.5 mg treatment in
   Taiwanese patients with polypoidal choroidal vasculopathy: a subgroup
   analysis of the REAL study
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE observational study; poly poidal choroidal vasculopathy; ranibizinnab;
   Taiwan; visual acuity
ID VERTEPORFIN PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; CLINICAL
   CHARACTERISTICS; JAPANESE PATIENTS; COMBINATION; GUIDELINES; EFFICACY;
   FEATURES; EVEREST; SAFETY
AB AIM: To assess the effectiveness and safety of ranibizumab 0.5 mg in Taiwanese patients with polypoidal choroidal vasculopathy (PCV) by performing a retrospective exploratory subgroup analysis of the REAL study.
   METHODS: REAL was a 12-month, observational, prospective, non-interventional phase IV post-marketing surveillance study conducted at 9 centers in Taiwan. The study collected data as part of the routine patient visits from the medical records of patients with neovascular age-related macular degeneration treated with ranibizumab 0.5 mg according to local standard medical practice and local label and/or reimbursement guidelines. The presence of PCV at baseline was determined using indocyanine green angiography.
   RESULTS: At baseline, PCV was diagnosed in 64 of the 303 enrolled patients (21.1%). Of these, 41 patients (64.1%) had received prior treatment; 15 (23.4%) patients had received ranibizumab. The intent-to-treat population included 58 patients; 47 (80%) who received ranibizumab and 11 (20%) who received ranibizumab plus photodynamic therapy (PDT; 9 patients received once, 2 patients received twice). Bevacizumab was used as a concomitant medication in a similar percentage of patients who received ranibizumab (43%, n=20) or ranibizumab plus PDT (45%, n=5). In patients who received ranibizumab, visual acuity (VA) at baseline was 50.1 +/- 12.9 Early Treatment Diabetic Retinopathy Study letters, and the gain at month 12 was 1.1 +/- 17.8 letters. In patients who received ranibizumab plus PDT, VA at baseline was 51.4 +/- 15.9 letters, and there was a marked gain in VA at month 12 (14.0 +/- 9.2 letters, P=0.0009). In the intent-to-treat population, the reduction in central retinal subfield thickness from baseline at month 12 was 69.6 +/- 122.6 mu m (baseline: 310.8 +/- 109.8 mu m, P=0.0004). The safety results were consistent with the well-characterized safety profile of ranibizumab.
   CONCLUSION: In real-world settings, ranibizumab 0.5 mg treatment for 12mo results in maintenance of VA and reduction in central retinal subfield thickness in Taiwanese patients with PCV. Improvements in VA are observed in patients who received ranibizumab plus PDT. There are no new safety findings.
C1 [Chen, San-Ni] Changhua Christian Hosp, Changhua 50094, Taiwan.
   [Chen, San-Ni] Chung Shan Med Univ, Coll Med, Taichung 40246, Taiwan.
   [Cheng, Cheng-Kuo] Shin Kong Wu Ho Su Mem Hosp, Taipei 11101, Taiwan.
   [Yeung, Ling] Chang Gung Mem Hosp Keelung, Keelung 204, Taiwan.
   [Chen, Jiann-Torng] Triserv Gen Hosp, Chenggong Rd, Taipei 11490, Taiwan.
   [Chan, Wei-Chun] Mackay Mem Hosp, Taipei 813, Taiwan.
   [Liu, Jorn-Hon] Cheng Hsin Gen Hosp, Taipei 112, Taiwan.
   [Sheu, Shwu-Jiuan] Kaohsiung Vet Gen Hosp, Kaohsiung 81362, Taiwan.
   [Wu, Wen-Chuan] Kaohsiung Med Univ, Chung Ho Mem Hosp, Kaohsiung 807, Taiwan.
   [Lai, Chi-Chun] Chang Gung Mem Hosp Linkou, Taoyuan 333, Taiwan.
C3 Changhua Christian Hospital; Chung Shan Medical University; Shin Kong Wu
   Ho Su Memorial Hospital; Chang Gung Memorial Hospital; Tri-Service
   General Hospital; Mackay Memorial Hospital; Cheng Hsin General Hospital;
   Kaohsiung Veterans General Hospital; Kaohsiung Medical University;
   Kaohsiung Medical University Hospital; Chang Gung Memorial Hospital
RP Lai, CC (通讯作者)，Chang Gung Mem Hosp Linkou, Taoyuan 333, Taiwan.
EM chichun.lai@gmail.com
OI Lai, Chi-Chun/0000-0001-9547-7212
FU Novartis (Taiwan) Co., Ltd.
FX Supported by Novartis (Taiwan) Co., Ltd.
CR Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Chen P-J, 2012, TAIWAN J OPHTHALMOL, V4, P127
   Chen S, 2017 EUR SEP 08 FREE
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Hikichi T, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0026-y
   Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lai T, BASELINE CHARACTERIS, P90
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Levy Jaime, 2009, International Ophthalmology, V29, P349, DOI 10.1007/s10792-008-9243-1
   Li X, RANIBIZUMAB 0 5 MG C, P97
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Singh RP, 2009, BRIT J OPHTHALMOL, V93, P1353, DOI 10.1136/bjo.2008.141879
   Song MH, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329466
   Tan CS, 2016, GRAEF ARCH CLIN EXP, V254, P1923, DOI 10.1007/s00417-016-3333-y
   Tang K, 2015, INT J OPHTHALMOL-CHI, V8, P1056, DOI 10.3980/j.issn.2222-3959.2015.05.36
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110667
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yeung Ling, 2004, Chang Gung Med J, V27, P366
NR 30
TC 12
Z9 12
U1 0
U2 0
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD NOV 18
PY 2018
VL 11
IS 11
BP 1802
EP 1808
DI 10.18240/ijo.2018.11.11
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HA1NB
UT WOS:000449979000011
PM 30450311
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Evans, JR
   Lawrenson, JG
AF Evans, Jennifer R.
   Lawrenson, John G.
TI Antioxidant vitamin and mineral supplements for slowing the progression
   of age-related macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE Dietary Supplements; Antioxidants [therapeutic use]; Macular
   Degeneration [prevention & control]; Minerals [therapeutic use];
   Randomized Controlled Trials as Topic; Vitamins [therapeutic use]; Aged;
   Humans
ID PIGMENT OPTICAL-DENSITY; RANDOMIZED CONTROLLED-TRIALS; LUTEIN
   SUPPLEMENTATION; EYE DISEASE; DIETARY SUPPLEMENTATION; SERUM
   CONCENTRATIONS; ORAL ZINC; ZEAXANTHIN; CAROTENOIDS; MACULOPATHY
AB Background
   It has been proposed that antioxidants may prevent cellular damage in the retina by reacting with free radicals that are produced in the process of light absorption. Higher dietary levels of antioxidant vitamins and minerals may reduce the risk of progression of age-related macular degeneration (AMD).
   Objectives
   The objective of this review was to assess the effects of antioxidant vitamin or mineral supplementation on the progression of AMD in people with AMD.
   Search methods
   We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2012, Issue 8), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to August 2012), EMBASE (January 1980 to August 2012), Allied and Complementary Medicine Database (AMED) (January 1985 to August 2012), OpenGrey (System for Information on Grey Literature in Europe) (www.opengrey.eu/), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 20 August 2012. We searched the reference lists of identified reports and the Science Citation Index. We contacted investigators and experts in the field for details of unpublished studies. We also searched for systematic reviews of harms of vitamin supplements.
   Selection criteria
   We included randomised trials comparing antioxidant vitamin or mineral supplementation (alone or in combination) to placebo or no intervention in people with AMD.
   Data collection and analysis
   Two authors assessed risk of bias and extracted data from the included trials. Where appropriate, we pooled data using a random-effects model unless three or fewer trials were available in which case we used a fixed-effect model.
   Main results
   Thirteen trials (6150 participants) were included in this review. Over half the participants (3640) were randomised in one trial (AREDS in the USA), which found a beneficial effect of antioxidant (beta-carotene, vitamin C and vitamin E) and zinc supplementation on progression to advanced AMD (adjusted odds ratio (OR) 0.68, 95% confidence interval (CI) 0.53 to 0.87) over an average of 6.3 years. People taking supplements were less likely to lose 15 or more letters of visual acuity (adjusted OR 0.77, 95% CI 0.62 to 0.96). The other trials, in general, had shorter follow-up (less than two years). No evidence for an effect of supplementation was seen in these smaller trials of shorter duration. Overall we considered the strength of the evidence to be moderate. We did not consider included trials, in general, to be at risk of bias, although we found it difficult to assess reporting biases. The main reason for downgrading the strength of the evidence was because, for several analyses, only one trial was included and therefore consistency of the findings could not be assessed. The included trials reported the following adverse effects: hospitalisation for genito-urinary problems was more common in people taking zinc and yellowing of skin was more common in people taking antioxidants. Systematic searching of the literature identified other potential harms of vitamin supplementation, in particular an increased risk of lung cancer in smokers associated with beta-carotene supplements, but we were unable to identify a good systematic review of the evidence for harms of nutritional supplementation.
   Authors' conclusions
   People with AMD may experience delay in progression of the disease with antioxidant vitamin and mineral supplementation. This finding is drawn from one large trial conducted in a relatively well-nourished American population. The generalisability of these findings to other populations is not known. Although generally regarded as safe, vitamin supplements may have harmful effects. A systematic review of the evidence on harms of vitamin supplements is needed.
C1 [Evans, Jennifer R.] London Sch Hyg & Trop Med, Cochrane Eyes & Vis Grp, ICEH, London WC1E 7HT, England.
   [Lawrenson, John G.] City Univ London, Div Optometry & Visual Sci, London EC1V 0HB, England.
C3 University of London; London School of Hygiene & Tropical Medicine; City
   University London
RP Evans, JR (通讯作者)，London Sch Hyg & Trop Med, Cochrane Eyes & Vis Grp, ICEH, Keppel St, London WC1E 7HT, England.
EM jennifer.evans@lshtm.ac.uk
OI Lawrenson, John/0000-0002-2031-6390
FU Moorfields Eye Hospital NHS Trust, UK; Guide Dogs for the Blind
   Association, UK
FX Internal sources; Moorfields Eye Hospital NHS Trust, UK.; External
   sources; Guide Dogs for the Blind Association, UK.
CR Abba K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008122.pub2
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Bahrami Hossein, 2006, BMC Ophthalmol, V6, P23, DOI 10.1186/1471-2415-6-23
   Barakat MR, 2006, CURR EYE RES, V31, P629, DOI 10.1080/02713680600760501
   Bartlett HE, 2007, EUR J CLIN NUTR, V61, P1121, DOI 10.1038/sj.ejcn.1602626
   Bartlett H, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-12
   Benzie IFF, 2006, BRIT J NUTR, V96, P154, DOI 10.1079/BJN20061796
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bjelakovic G, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD007176.pub2, 10.1590/1516-3180.20151332T1]
   Bone RA, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-12
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   Cangemi Francis E, 2007, BMC Ophthalmol, V7, P3, DOI 10.1186/1471-2415-7-3
   Christen WG, 1996, ANN EPIDEMIOL, V6, P60, DOI 10.1016/1047-2797(95)00094-1
   Christen WG, 2007, ARCH OPHTHALMOL-CHIC, V125, P333, DOI 10.1001/archopht.125.3.333
   Christen WG, 2012, OPHTHALMOLOGY, V119, P1642, DOI 10.1016/j.ophtha.2012.01.053
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Connolly EE, 2011, INVEST OPHTH VIS SCI, V52, P9207, DOI 10.1167/iovs.11-8025
   Cumurcu T, 2006, TRACE ELEM ELECTROLY, V23, P103
   Dawczynski J, 2012, KLIN MONATSBL AUGENH, V229, P69, DOI 10.1055/s-0031-1273339
   Early Treatment Diabetic Retinopathy Study Research Group, 1980, EARL TREATM DIAB RET, P1
   Eller AW, 2012, OPHTHALMOLOGY, V119, P1011, DOI 10.1016/j.ophtha.2011.10.032
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub3
   Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995
   Franciose JL, 2006, CURR TOP NUTRACEUT R, V4, P69
   Garrett S K, 1999, Ophthalmic Epidemiol, V6, P195, DOI 10.1076/opep.6.3.195.1500
   Garrett SKM, 2000, J CLIN EPIDEMIOL, V53, P541, DOI 10.1016/S0895-4356(99)00153-5
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   Goodrow EF, 2006, J NUTR, V136, P2519, DOI 10.1093/jn/136.10.2519
   Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049
   Holz F., 1993, GER J OPHTHALMOL, V2, P391
   Huang HY, 2006, ANN INTERN MED, V145, P372, DOI 10.7326/0003-4819-145-5-200609050-00135
   Hubbard LD, 2008, INVEST OPHTH VIS SCI, V49, P3269, DOI 10.1167/iovs.07-1267
   Johnson AR, 2007, J UROLOGY, V177, P639, DOI 10.1016/j.juro.2006.09.047
   KAISER HJ, 1995, OPHTHALMOLOGICA, V209, P302, DOI 10.1159/000310646
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khachik F, 2006, INVEST OPHTH VIS SCI, V47, P5234, DOI 10.1167/iovs.06-0504
   Kirkham JJ, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c365
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kopsell DA, 2006, J AGR FOOD CHEM, V54, P7998, DOI 10.1021/jf0614802
   Kvansakul J, 2006, OPHTHAL PHYSL OPT, V26, P362, DOI 10.1111/j.1475-1313.2006.00387.x
   Lai YH, 2011, RETINA-J RET VIT DIS, V31, P1620, DOI 10.1097/IAE.0b013e31820d3ed1
   Landrum J, 2012, ACTA BIOCHIM POL, V59, P167
   Lim JI, 2006, RETINA-J RET VIT DIS, V26, P314, DOI 10.1097/00006982-200603000-00010
   Lonn E, 2005, JAMA-J AM MED ASSOC, V293, P1338, DOI 10.1001/jama.293.11.1338
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Moriarty-Craige SE, 2007, AM J OPHTHALMOL, V143, P206, DOI 10.1016/j.ajo.2006.09.056
   Neelam K, 2008, OPHTHAL EPIDEMIOL, V15, P389, DOI 10.1080/09286580802154275
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Newsome DA, 2008, CURR EYE RES, V33, P591, DOI 10.1080/02713680802178437
   Nolan JM, 2006, CURR EYE RES, V31, P199, DOI 10.1080/02713680500514677
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Nolan JM, 2012, EXP EYE RES, V101, P9, DOI 10.1016/j.exer.2012.05.006
   Nussenblatt RB, 2006, AM J OPHTHALMOL, V141, P193, DOI 10.1016/j.ajo.2005.07.036
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Piermarocchi S, 2012, EUR J OPHTHALMOL, V22, P216, DOI 10.5301/ejo.5000069
   RICHER S, 1996, J AM OPTOMETRIC ASS, V0067
   Richer S, 1996, J Am Optom Assoc, V67, P30
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer Stuart, 2007, Optometry, V78, P213, DOI 10.1016/j.optm.2006.10.019
   Robman LD, 1999, AUST NZ J OPHTHALMOL, V27, P410
   Rodriguez-Carmona M, 2006, OPHTHAL PHYSL OPT, V26, P137, DOI 10.1111/j.1475-1313.2006.00386.x
   Rosenthal JM, 2006, INVEST OPHTH VIS SCI, V47, P5227, DOI 10.1167/iovs.05-1513
   Sasamoto Y, 2011, GRAEF ARCH CLIN EXP, V249, P1847, DOI 10.1007/s00417-011-1780-z
   Schalch W, 2007, ARCH BIOCHEM BIOPHYS, V458, P128, DOI 10.1016/j.abb.2006.09.032
   Schmidl D, 2011, BRIT J CLIN PHARM
   Schtinemann HJ, 2011, COCHRANE HDB SYSTEMA
   Stur M, 1996, INVEST OPHTH VIS SCI, V37, P1225
   Taylor HR, 2001, INVEST OPHTH VIS SCI, V42, pS311
   Tikellis G, 1999, Ophthalmic Epidemiol, V6, P181, DOI 10.1076/opep.6.3.181.1502
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   VANNAS S, 1958, Acta Ophthalmol (Copenh), V36, P601
   Vidal K, 2011, CLIN NUTR
   Wang H., 2004, ZHONGGUO LINCHUANT K, V8, P1290
   Wang W, 2007, AM J CLIN NUTR, V85, P762, DOI 10.1093/ajcn/85.3.762
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Wenzel AJ, 2006, J NUTR, V136, P2568, DOI 10.1093/jn/136.10.2568
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Zhao DY, 2006, CURR TOP NUTRACEUT R, V4, P53
NR 86
TC 78
Z9 78
U1 1
U2 39
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2012
IS 11
AR CD000254
DI 10.1002/14651858.CD000254.pub3
PG 84
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 052LS
UT WOS:000312199800006
PM 23152201
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Blazaki, S
   Blavakis, E
   Smoustopoulos, G
   Bontzos, G
   Stavrakakis, A
   Chlouverakis, G
   Kabanarou, S
   Xirou, T
   Tsilimbaris, M
AF Blazaki, Styliani
   Blavakis, Emmanouil
   Smoustopoulos, Georgios
   Bontzos, Georgios
   Stavrakakis, Anastasios
   Chlouverakis, Gregory
   Kabanarou, Stamatina
   Xirou, Tina
   Tsilimbaris, Miltiadis
TI Progression of Macular Atrophy in Patients Receiving Long-Term Anti-VEGF
   Therapy for Age-Related Macular Degeneration: Real-Life Data
SO OPHTHALMOLOGICA
LA English
DT Article
DE Macular atrophy; Long term; Anti-VEGF therapy; Neovascular age-related
   macular degeneration
ID GEOGRAPHIC ATROPHY; GROWTH
AB Purpose: This study aimed to evaluate the progression of macular atrophy (MA) based on near-infrared reflectance (NIR) and optical coherence tomography (OCT) images, in patients with age-related macular degeneration (AMD), receiving anti-vascular endothelial growth factor (anti-VEGF) treatment for at least a 6-year period. Materials and Methods: This retrospective study included 53 naive patients (53 eyes) with neovascular AMD from 2 centers, who were treated with anti-VEGF intravitreal injections and had no MA at baseline. MA was evaluated in an annual basis using NIR images, while all available OCT images were used to confirm that the atrophic area fulfilled the criteria proposed by the Classification of Atrophy Meetings (CAM) group for complete retinal pigment epithelium and outer retinal atrophy. Incidence and progression of MA were evaluated. Associations with best-corrected visual acuity (BCVA) and total number of injections were also studied. Results: Treatment duration of our patients was 7.34 +/- 1.54 years. The mean number of anti-VEGF injections was 24.4 +/- 13.6. BCVA at baseline was 0.38 +/- 0.27 logMAR, while at the final visit, it was 0.60 +/- 0.35 logMAR (p = 0.731). The cumulative incidence of new MA at years 1, 2, 3, 4, 5, and 6 was 1.89%, 18.87%, 32.08%, 39.62%, 49.06%, and 50.94%, respectively. In patients who developed MA, mean MA area increased from zero at baseline to 5.66 +/- 7.18 mm(2) at the final visit. The estimated annual enlargement of MA was 0.45 mm/year based on square root transformation (1.12 mm(2)/year, untransformed data). MA progression does not appear to be significantly associated with age (R = 0.055; p = 0.784), gender (R = 0.113; p = 0.576), BCVA (R = 0.168; p = 0.404), and total number of injections (R = 0.133; p = 0.255). Conclusion: In this real-life setting, half of the neovascular AMD patients under anti-VEGF treatment, without MA at therapy initiation, developed MA over a period of at least 6 years. In this work, the number of injections did not seem to have a significant association with MA progression.
C1 [Blazaki, Styliani; Blavakis, Emmanouil; Stavrakakis, Anastasios; Tsilimbaris, Miltiadis] Univ Ospital Heraklion, Dept Ophthalmol, Iraklion, Greece.
   [Smoustopoulos, Georgios; Bontzos, Georgios; Kabanarou, Stamatina; Xirou, Tina] Korgialenio Benakio Gen Hosp, Dept Ophthalmol, Athens, Greece.
   [Chlouverakis, Gregory] Univ Crete, Fac Med, Biostat Lab, Iraklion, Greece.
C3 University of Crete
RP Blavakis, E; Tsilimbaris, M (通讯作者)，Univ Ospital Heraklion, Dept Ophthalmol, Iraklion, Greece.
EM blavakism@gmail.com; tsilimb@med.uoc.gr
OI Tsilimbaris, Miltiadis/0000-0002-0130-1150
CR Abdelfattah NS, 2020, AM J OPHTHALMOL, V212, P169, DOI 10.1016/j.ajo.2020.01.005
   Bailey C., 2019, OPHTHALMOLOGY, V126, P75
   Brown DM., 2009, OPHTHALMOLOGY, V116, P57
   Casalino G., 2021, CURR EYE RES, V46, P988
   Chakravarthy U., 2013, LANCET, V382, P1258
   Christenbury JG, 2018, RETINA-J RET VIT DIS, V38, P1276, DOI 10.1097/IAE.0000000000001766
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Dugel PU., 2020, OPHTHALMOLOGY, V127, P72
   Feuer WJ., 2013, JAMA OPHTHALMOL, V131, P110
   Finger RP., 2014, OPHTHALMOLOGY, V121, P1252
   Grunwald JE., 2014, OPHTHALMOLOGY, V121, P150
   Grunwald JE., 2017, OPHTHALMOLOGY, V124, P97
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS., 2012, OPHTHALMOLOGY, V119, P2537
   Holz FG., 2018, JAMA OPHTHALMOL, V136, P666
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Karamat A., 2020, OPHTHALMOLOGY, V127, P523
   Lalwani GA., 2009, AM J OPHTHALMOL, V148, P43
   Li A, 2018, OPHTHALMOL RETINA, V2, P550, DOI 10.1016/j.oret.2017.10.010
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Rosenfeld PJ., 2011, OPHTHALMOLOGY, V118, P523
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sadda SR., 2018, OPHTHALMOLOGY, V125, P537
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Sato T, 2015, RETINA-J RET VIT DIS, V35, P1292, DOI 10.1097/IAE.0000000000000505
   Schmidt-Erfurth U., 2020, AM J OPHTHALMOL, V216, P257
   Schmidt-Erfurth U., 2014, BRIT J OPHTHALMOL, V98, P1144
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   Siedlecki J, 2021, BMC OPHTHALMOL, V21, DOI 10.1186/s12886-020-01766-6
   Sitnilska V, 2019, OPHTHALMOLOGICA, V241, P154, DOI 10.1159/000492924
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong TY., 2008, OPHTHALMOLOGY, V115, P1524
   Wong WL., 2014, LANCET GLOB HEALTH, V2, pe106
   Xu L., 2015, RETINA-J RET VIT DIS, V35, P176
NR 38
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD MAY
PY 2022
VL 245
IS 2
BP 152
EP 160
DI 10.1159/000520595
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1D0PR
UT WOS:000793512700008
PM 34818657
DA 2022-11-30
ER

PT J
AU Burlina, PM
   Joshi, N
   Pacheco, KD
   Liu, TYA
   Bressler, NM
AF Burlina, Philippe M.
   Joshi, Neil
   Pacheco, Katia D.
   Liu, T. Y. Alvin
   Bressler, Neil M.
TI Assessment of Deep Generative Models for High-Resolution Synthetic
   Retinal Image Generation of Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID DIABETIC-RETINOPATHY; VALIDATION
AB IMPORTANCE. Deep learning (DL) used for discriminative tasks in ophthalmology, such as diagnosing diabetic retinopathy or age-related macular degeneration (AMD), requires large image data sets graded by human experts to train deep convolutional neural networks (DCNNs). In contrast, generative DL techniques could synthesize large new data sets of artificial retina images with different stages of AMD. Such images could enhance existing data sets of common and rare ophthalmic diseases without concern for personally identifying information to assist medical education of students, residents, and retinal specialists, as well as for training new DL diagnostic models for which extensive data sets from large clinical trials of expertly graded images may not exist.
   OBJECTIVE To develop DL techniques for synthesizing high-resolution realistic fundus images serving as proxy data sets for use by retinal specialists and DL machines.
   DESIGN, SETTING. AND PARTICIPANTS Generative adversarial networks were trained on 133 821 color fundus images from 4613 study participants from the Age-Related Eye Disease Study (AREDS), generating synthetic fundus images with and without AMD. We compared retinal specialists' ability to diagnose AMD on both real and synthetic images, asking them to assess image gradability and testing their ability to discern real from synthetic images. The performance of AMD diagnostic DCNNs (referable vs not referable AMD) trained on either all-real vs all-synthetic data sets was compared.
   MAIN OUTCOMES AND MEASURES Accuracy of 2 retinal specialists (T.Y.A.L. and K.D.P.) for diagnosing and distinguishing AMD on real vs synthetic images and diagnostic performance (area under the curve) of DL algorithms trained on synthetic vs real images.
   RESULTS The diagnostic accuracy of 2 retinal specialists on real vs synthetic images was similar. The accuracy of diagnosis as referable vs nonreferable AMD compared with certified human graders for retinal specialist 1 was 84.54% (error margin, 4.06%) on real images vs 84.12% (error margin, 4.16%) on synthetic images and for retinal specialist 2 was 89.47% (error margin, 3.45%) on real images vs 89.19% (error margin, 3.54%) on synthetic images. Retinal specialists could not distinguish real from synthetic images, with an accuracy of 59.50% (error margin, 3.93%) for retinal specialist 1 and 53.67% (error margin, 3.99%) for retinal specialist 2. The DCNNs trained on real data showed an area under the curve of 0.9706 (error margin, 0.0029), and those trained on synthetic data showed an area under the curve of 0.9235 (error margin, 0.0045).
   CONCLUSIONS AND RELEVANCE Deep learning-synthesized images appeared to be realistic to retinal specialists, and DCNNs achieved diagnostic performance on synthetic data close to that for real images, suggesting that DL generative techniques hold promise for training humans and machines.
C1 [Burlina, Philippe M.; Joshi, Neil] Johns Hopkins Univ, Appl Phys Lab, Baltimore, MD 21218 USA.
   [Burlina, Philippe M.] Malone Ctr Engn Healthcare, Baltimore, MD USA.
   [Burlina, Philippe M.; Liu, T. Y. Alvin; Bressler, Neil M.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Baltimore, MD 21205 USA.
   [Pacheco, Katia D.] Brasilian Ctr Vis Eye Hosp, Brasilia, DF, Brazil.
C3 Johns Hopkins University; Johns Hopkins University Applied Physics
   Laboratory; Johns Hopkins University; Johns Hopkins Medicine
RP Joshi, N (通讯作者)，Johns Hopkins Univ, Wilmer Eye Inst, 600 N Wolfe St,Maumenee 752, Baltimore, MD 21287 USA.
EM nmboffice@jhmi.edu
FU National Eye Institute [R21EY024310]; Johns Hopkins Applied Physics
   Laboratory; James P. Gills Professorship
FX This work was supported in part by award R21EY024310 from the National
   Eye Institute (Drs Burlina and Bressler), the Johns Hopkins Applied
   Physics Laboratory, the James P. Gills Professorship, and unrestricted
   research funds to the Johns Hopkins University School of Medicine Retina
   Division for Macular Degeneration and Related Diseases Research.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Baur C, ARXIV180404338
   Bowles Nellie, 2018, NY TIMES
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown JM, 2018, JAMA OPHTHALMOL, V136, P803, DOI 10.1001/jamaophthalmol.2018.1934
   Burlina P, 2016, I S BIOMED IMAGING, P184, DOI 10.1109/ISBI.2016.7493240
   Burlina P, 2011, IEEE ENG MED BIO, P3962, DOI 10.1109/IEMBS.2011.6090984
   Burlina P, 2017, COMPUT BIOL MED, V82, P80, DOI 10.1016/j.compbiomed.2017.01.018
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Burlina P, 2018, JAMA OPHTHALMOL, V136, P1305, DOI 10.1001/jamaophthalmol.2018.3799
   Burlina PM, JAMA OPHTHALMOL, DOI [10.1001/jamaophthalmo1.2018.4118, DOI 10.1001/JAMAOPHTHALMO1.2018.4118]
   Costa P, 2018, IEEE T MED IMAGING, V37, P781, DOI 10.1109/TMI.2017.2759102
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Gargeya R, 2017, OPHTHALMOLOGY, V124, P962, DOI 10.1016/j.ophtha.2017.02.008
   Goodfellow IJ, 2014, ADV NEUR IN, V27, P2672
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Jain AK, 2004, IEEE T CIRC SYST VID, V14, P4, DOI 10.1109/TCSVT.2003.818349
   Kaiming He, 2016, 2016 IEEE Conference on Computer Vision and Pattern Recognition (CVPR), P770, DOI 10.1109/CVPR.2016.90
   Kankanahalli S, 2013, INVEST OPHTH VIS SCI, V54, P1789, DOI 10.1167/iovs.12-10928
   Karras T, 2017, ARXIV171010196
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Mahapatra D, 2018, I S BIOMED IMAGING, P1449, DOI 10.1109/ISBI.2018.8363845
   Nie D., 2018, IEEE T BIOMEDICAL EN
   Pekala M, ARXIV1801
   Quellec G, 2017, MED IMAGE ANAL, V39, P178, DOI 10.1016/j.media.2017.04.012
   Schlegl T, 2017, LECT NOTES COMPUT SC, V10265, P146, DOI 10.1007/978-3-319-59050-9_12
   Ting DSW, 2018, NAT MED, V24, P539, DOI 10.1038/s41591-018-0029-3
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Yi X, 2018, J DIGIT IMAGING, V31, P655, DOI 10.1007/s10278-018-0056-0
NR 32
TC 65
Z9 67
U1 0
U2 27
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAR
PY 2019
VL 137
IS 3
BP 258
EP 264
DI 10.1001/jamaophthalmol.2018.6156
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HO8LL
UT WOS:000461203100010
PM 30629091
OA Green Published
DA 2022-11-30
ER

PT J
AU Pedersen, KB
   Sjolie, AK
   Vestergaard, AH
   Andreasson, S
   Moller, F
AF Pedersen, K. B.
   Sjolie, A. K.
   Vestergaard, A. H.
   Andreasson, S.
   Moller, F.
TI Fixation stability and implication for multifocal electroretinography in
   patients with neovascular age-related macular degeneration after
   anti-VEGF treatment
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Fixation stability; Retinal area of fixation (RAF68); Multifocal ERG;
   Electrophysiology; Age-related macular degeneration; Anti-VEGF
ID PREFERRED RETINAL LOCUS; VISUAL-ACUITY; VEIN OCCLUSION; TOPOGRAPHY;
   DISEASE; RETINOPATHY; SCOTOMA; EDEMA; MFERG; HOLE
AB Purpose To quantify fixation stability in patients with neovascular age-related macular degeneration (nAMD) at baseline, 3 and 6 months after anti-vascular endothelial growth factor (anti-VEGF) treatment and furthermore asses the implications of an unsteady fixation for multifocal electroretinography (mfERG) measurements. Methods Fifty eyes of 50 nAMD patients receiving intravitreal anti-VEGF treatment with either bevacizumab or ranibizumab and eight eyes of eight control subjects were included. Fixation stability measurements were performed with the Eye-Link eyetracking system and the retinal area in degrees(2) (deg(2)) containing the 68 % most frequently used fixation points (RAF68) was calculated. MfERG P1 amplitude and implicit time were analyzed in six concentric rings and as a summed response. Patients were examined at baseline, 3 and 6 months. Four different mfERG recordings were performed for the control subjects to mimic an involuntary unstable fixation: normal central fixation, 2.4 degrees, 4.8 degrees, and 7.1 degrees fixation instability. Results For control subjects, a fixation instability of 2.4 degrees (corresponding to the central hexagon) did not reduce mfERG ring amplitudes significantly, whereas 4.8 degrees and 7.1 degrees fixation instability reduced the amplitudes significantly in rings 1 and 2 (p < 0.001) as well as in the peripheral rings in the 7.1 degrees instability condition (p < 0.001). Fixation stability improved non-significantly for patients at 3 and 6 months. The size of the retinal area of fixation was at baseline, 3 and 6 months negatively correlated to visual acuity (VA) (r(baseline) = -0.65, r(3) months = -0.60, and r(6 months) = -0.66 respectively, p < 0.001) and mfERG amplitudes of the three innermost rings (r(baseline) = -0.29, p = 0.042, r(3) months = -0.43, p = 0.003 and r(6 months) = -0.31, p = 0.042). The VA cutoff for a fixation area less than 5 deg(2) (approximately the central hexagon) was 65, 77, and 68 ETDRS letters (corresponding a maximal Snellen equivalent of 0.31) at baseline, 3 and 6 months, respectively. Conclusions MfERG amplitudes in recordings of nAMD patients are at substantial risk of being reduced due to poor fixation as a large number of patients may use a fixation area of more than 5 deg(2). Fixation monitoring during recording as well as interpretation of results should be performed with care, especially in patients with poor visual acuity.
C1 [Pedersen, K. B.] Rigshosp, Dept Ophthalmol, Nordre Ringvej 57, DK-2600 Glostrup, Denmark.
   [Sjolie, A. K.; Vestergaard, A. H.] Odense Univ Hosp, Dept Ophthalmol, DK-5000 Odense, Denmark.
   [Andreasson, S.] Lund Univ, Dept Ophthalmol, S-22100 Lund, Sweden.
   [Moller, F.] Vejle Hosp, Dept Ophthalmol, DK-7100 Vejle, Denmark.
C3 Rigshospitalet; University of Southern Denmark; Odense University
   Hospital; Lund University; University of Southern Denmark; Lillebaelt
   Hospital
RP Pedersen, KB (通讯作者)，Rigshosp, Dept Ophthalmol, Nordre Ringvej 57, DK-2600 Glostrup, Denmark.
EM karenbjerg@yahoo.dk
RI Vestergaard, Anders/J-5961-2019
OI Vestergaard, Anders/0000-0003-1687-4899
FU Danish Eye Health Society; Danish Eye Research Foundation; Velux
   Foundation; Synoptik Foundation; A.P. Moller Foundation for the
   Advancement of Medical Science
FX The following provided financial support to the study:; The Danish Eye
   Health Society; The Danish Eye Research Foundation; The Velux
   Foundation; The Synoptik Foundation; The A.P. Moller Foundation for the
   Advancement of Medical Science; None of the above sponsors had any role
   in the design or conduct of this research.
CR Andreasson S, 2014, GRAEF ARCH CLIN EXP, V252, P1903, DOI 10.1007/s00417-014-2628-0
   Campa C, 2011, INVEST OPHTH VIS SCI, V52, P3446, DOI 10.1167/iovs.10-6588
   Chisholm Jennifer A., 2001, Documenta Ophthalmologica, V102, P131, DOI 10.1023/A:1017536625847
   Chu PHW, 2006, GRAEF ARCH CLIN EXP, V244, P1273, DOI 10.1007/s00417-006-0304-8
   Chung EJ, 2008, RETINA-J RET VIT DIS, V28, P220, DOI 10.1097/IAE.0b013e31813c69df
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   CULHAM LE, 1993, CLIN VISION SCI, V8, P551
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Falkenberg HK, 2007, VISION RES, V47, P126, DOI 10.1016/j.visres.2006.09.014
   Fortune B, 1999, INVEST OPHTH VIS SCI, V40, P2638
   Gerth C, 2006, ARCH OPHTHALMOL-CHIC, V124, P345, DOI 10.1001/archopht.124.3.345
   Greenstein VC, 2008, RETINA-J RET VIT DIS, V28, P1234, DOI 10.1097/IAE.0b013e31817c1b47
   Holm K, 2015, DOC OPHTHALMOL, V131, P43, DOI 10.1007/s10633-015-9495-9
   Hood DC, 2003, J NEURO-OPHTHALMOL, V23, P225, DOI 10.1097/00041327-200309000-00008
   Huang Shizhou, 2000, Documenta Ophthalmologica, V101, P115
   Hvarfner C, 2006, RETINA-J RET VIT DIS, V26, P292, DOI 10.1097/00006982-200603000-00007
   Keating David, 2000, Documenta Ophthalmologica, V100, P77, DOI 10.1023/A:1002723501303
   KOSNIK W, 1986, INVEST OPHTH VIS SCI, V27, P1720
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Mathew R, 2012, AM J OPHTHALMOL, V153, P490, DOI 10.1016/j.ajo.2011.08.034
   McCulloch DL, 2015, DOC OPHTHALMOL, V130, P1, DOI 10.1007/s10633-014-9473-7
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   Moller F, 2006, GRAEF ARCH CLIN EXP, V244, P577, DOI 10.1007/s00417-004-0869-z
   Moller F, 2005, GRAEF ARCH CLIN EXP, V243, P903, DOI 10.1007/s00417-004-1120-7
   Moller F, 1998, ACTA OPHTHALMOL SCAN, V76, P38, DOI 10.1034/j.1600-0420.1998.760107.x
   Moller F, 2002, GRAEF ARCH CLIN EXP, V240, P765, DOI 10.1007/s00417-002-0519-2
   NOORDEN GKV, 1962, AM J OPHTHALMOL, V53, P642, DOI 10.1016/0002-9394(62)91987-6
   Osterberg G, 1935, Acta Ophthalmol., V13, P11
   Parravano M, 2013, DOC OPHTHALMOL, V127, P217, DOI 10.1007/s10633-013-9404-z
   Pedersen KB, 2010, RETINA-J RET VIT DIS, V30, P1025, DOI 10.1097/IAE.0b013e3181cafc8f
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   TIMBERLAKE GT, 1986, INVEST OPHTH VIS SCI, V27, P1137
   Tsang AC, 2015, OPHTHALMOLOGY, V122, P1239, DOI 10.1016/j.ophtha.2015.02.011
   Tyrberg M, 2008, DOC OPHTHALMOL, V117, P185, DOI 10.1007/s10633-008-9120-2
   WHITTAKER SG, 1988, INVEST OPHTH VIS SCI, V29, P268
   Yip YWY, 2010, GRAEF ARCH CLIN EXP, V248, P477, DOI 10.1007/s00417-009-1165-8
NR 37
TC 6
Z9 6
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2016
VL 254
IS 10
BP 1897
EP 1908
DI 10.1007/s00417-016-3323-0
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EB1QL
UT WOS:000387129400005
PM 27080862
DA 2022-11-30
ER

PT J
AU Schmidt-Erfurth, U
   Kaiser, PK
   Korobelnik, JF
   Brown, DM
   Chong, V
   Nguyen, QD
   Ho, AC
   Ogura, Y
   Simader, C
   Jaffe, GJ
   Slakter, JS
   Yancopoulos, GD
   Stahl, N
   Vitti, R
   Berliner, AJ
   Soo, Y
   Anderesi, M
   Sowade, O
   Zeitz, O
   Norenberg, C
   Sandbrink, R
   Heier, JS
AF Schmidt-Erfurth, Ursula
   Kaiser, Peter K.
   Korobelnik, Jean-Francois
   Brown, David M.
   Chong, Victor
   Quan Dong Nguyen
   Ho, Allen C.
   Ogura, Yuichiro
   Simader, Christian
   Jaffe, Glenn J.
   Slakter, Jason S.
   Yancopoulos, George D.
   Stahl, Neil
   Vitti, Robert
   Berliner, Alyson J.
   Soo, Yuhwen
   Anderesi, Majid
   Sowade, Olaf
   Zeitz, Oliver
   Norenberg, Christiane
   Sandbrink, Rupert
   Heier, Jeffrey S.
TI Intravitreal Aflibercept Injection for Neovascular Age-related Macular
   Degeneration Ninety-Six-Week Results of the VIEW Studies
SO OPHTHALMOLOGY
LA English
DT Article
ID VEGF-TRAP; VISUAL IMPAIRMENT; UNITED-STATES; RANIBIZUMAB; BEVACIZUMAB;
   TRIAL; EYE
AB Purpose: To determine efficacy and safety of intravitreal aflibercept in patients with neovascular age-related macular degeneration (AMD) during a second year of variable dosing after a first-year fixed-dosing period.
   Design: Two randomized, double-masked, active-controlled, phase 3 trials.
   Participants: Two thousand four hundred fifty-seven patients with neovascular AMD.
   Methods: From baseline to week 52, patients received 0.5 mg intravitreal ranibizumab every 4 weeks (Rq4), 2 mg aflibercept every 4 weeks (2q4), 0.5 mg aflibercept every 4 weeks (0.5q4), or 2 mg aflibercept every 8 weeks (2q8) after 3 monthly injections. During weeks 52 through 96, patients received their original dosing assignment using an as-needed regimen with defined retreatment criteria and mandatory dosing at least every 12 weeks.
   Main Outcome Measures: Proportion of eyes at week 96 that maintained best-corrected visual acuity (BCVA; lost < 15 letters from baseline); change from baseline in BCVA.
   Results: Proportions of eyes maintaining BCVA across treatments were 94.4% to 96.1% at week 52 and 91.5% to 92.4% at week 96. Mean BCVA gains were 8.3 to 9.3 letters at week 52 and 6.6 to 7.9 letters at week 96. Proportions of eyes without retinal fluid decreased from week 52 (60.3% to 72.4%) to week 96 (44.6% to 54.4%), and more 2q4 eyes were without fluid at weeks 52 and 96 than Rq4 eyes (difference of 10.4% [95% confidence interval {CI}, 4.9-15.9] and 9.0% [95% CI, 3.0-15.1]). Patients received on average 16.5, 16.0, 16.2, and 11.2 injections over 96 weeks and 4.7, 4.1, 4.6, and 4.2 injections during weeks 52 through 96 in the Rq4, 2q4, 0.5q4, and 2q8 groups, respectively. The number of injections during weeks 52 through 96 was lower in the 2q4 and 2q8 groups versus the Rq4 group (differences of -0.64 [95% CI, -0.89 to -0.40] and -0.55 [95% CI, -0.79 to -0.30]; P< 0.0001, post hoc analysis). Incidences of Antiplatelet Trialists' Collaboration-defined arterial thromboembolic events were similar across groups (2.4% to 3.8%) from baseline to week 96.
   Conclusions: All aflibercept and ranibizumab groups were equally effective in improving BCVA and preventing BCVA loss at 96 weeks. The 2q8 aflibercept group was similar to ranibizumab in visual acuity outcomes during 96 weeks, but with an average of 5 fewer injections. Small losses at 96 weeks in the visual and anatomic gains seen at 52 weeks in all arms were in the range of losses commonly observed with variable dosing. (C) 2014 by the American Academy of Ophthalmology.
C1 [Schmidt-Erfurth, Ursula; Simader, Christian] Med Univ Vienna, Dept Ophthalmol, Vienna, Austria.
   [Kaiser, Peter K.] Cole Eye Inst, Dept Ophthalmol, Cleveland, OH USA.
   [Korobelnik, Jean-Francois] Univ Bordeaux 2, CHU Bordeaux, Dept Ophthalmol, F-33076 Bordeaux, France.
   [Brown, David M.] Retina Consultants Houston, Houston, TX USA.
   [Chong, Victor] Univ Oxford, Oxford Eye Hosp, Oxford, England.
   [Quan Dong Nguyen] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
   [Ho, Allen C.] Wills Eye Hosp & Res Inst, Philadelphia, PA USA.
   [Ho, Allen C.] Mid Atlantic Retina, Philadelphia, PA USA.
   [Ogura, Yuichiro] Nagoya City Univ, Dept Ophthalmol, Nagoya, Aichi, Japan.
   [Jaffe, Glenn J.] Duke Univ, Dept Ophthalmol, Durham, NC USA.
   [Slakter, Jason S.] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Yancopoulos, George D.; Stahl, Neil; Vitti, Robert; Berliner, Alyson J.; Soo, Yuhwen] Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA.
   [Anderesi, Majid; Sowade, Olaf; Zeitz, Oliver; Norenberg, Christiane; Sandbrink, Rupert] Bayer HealthCare, Berlin, Germany.
   [Zeitz, Oliver] Univ Klinikum Hamburg Eppendorf, Klin & Poliklin Augenheilkunde, Hamburg, Germany.
   [Sandbrink, Rupert] Univ Dusseldorf, Dept Neurol, Dusseldorf, Germany.
   [Heier, Jeffrey S.] Ophthalm Consultants Boston, Boston, MA 02114 USA.
   [Heier, Jeffrey S.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
C3 Medical University of Vienna; CHU Bordeaux; UDICE-French Research
   Universities; Universite de Bordeaux; University of Oxford; Johns
   Hopkins University; Johns Hopkins Medicine; Jefferson University; Nagoya
   City University; Duke University; Vitreous Retina Macula Consultants of
   New York; Regeneron; Bayer AG; Bayer Healthcare Pharmaceuticals;
   University of Hamburg; University Medical Center Hamburg-Eppendorf;
   Heinrich Heine University Dusseldorf; Ophthalmic Consultants of Boston;
   Tufts University
RP Heier, JS (通讯作者)，Ophthalm Consultants Boston, 50 Staniford St,Suite 600, Boston, MA 02114 USA.
EM jsheier@eyeboston.com
RI Chong, Victor/Q-6565-2018; Zeitz, Oliver/AAJ-9728-2021; KOROBELNIK,
   Jean-Francois/A-5448-2016
OI Chong, Victor/0000-0002-7693-522X; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311; Kaiser, Peter/0000-0001-5126-045X; Simader,
   Christian/0000-0002-1784-2883; Ho, Allen/0000-0003-3921-608X
FU Bayer HealthCare; Regeneron Pharmaceuticals; Allergan; Novartis;
   Genentech; Pfizer; Alcon; Neovista; Ophthotech, Oraya; Acucela; Aerpio;
   Alimera; Fovea; Genzyme; GlaxoSmithKline; GlaxoSmithKline, LPath; Notal
   Vision; Ohr Pharmaceutical; Ophthotech; Paloma
FX Bayer HealthCare; Regeneron Pharmaceuticals; Allergan, Novartis, Bayer
   HealthCare; Genentech, Pfizer, Regeneron Pharmaceuticals; Regeneron
   Pharmaceuticals, Alcon, Allergan, Genentech, Neovista, Ophthotech,
   Oraya.; Acucela, Aerpio, Alcon, Alimera, Allergan, Bayer HealthCare,
   Fovea, Genentech, Genzyme, GlaxoSmithKline, LPath, Neovista, Notal
   Vision, Novartis, Ohr Pharmaceutical, Ophthotech, Paloma, Regeneron
   Pharmaceuticals
CR Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
NR 18
TC 543
Z9 571
U1 0
U2 38
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2014
VL 121
IS 1
BP 193
EP 201
DI 10.1016/j.ophtha.2013.08.011
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 282KG
UT WOS:000329169500034
PM 24084500
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Liao, DS
   Metapally, R
   Joshi, P
AF Liao, David S.
   Metapally, Ravi
   Joshi, Preeti
TI Pegcetacoplan treatment for geographic atrophy due to age-related
   macular degeneration: a plain language summary of the FILLY study
SO IMMUNOTHERAPY
LA English
DT Article
DE age-related macular degeneration; FILLY; geographic atrophy; lay
   summary; pegcetacoplan; plain language summary; treatment emergent
   adverse events
AB What is this summary about?
   This is a summary of a publication about the FILLY study, which was published in Ophthalmology in 2020. The FILLY study looked at an investigational medicine called pegcetacoplan as a possible treatment for geographic atrophy.
   Geographic atrophy, also known as GA, is the late stage of an eye disease called dry age-related macular degeneration, also known as dry AMD. In people with GA, lesions form on a part of the back of the eye called the retina. GA lesions are patches of thin retina. Growth of GA lesions ultimately causes blindness, which cannot be reversed.
   There is currently no approved treatment for GA. Pegcetacoplan, also called APL-2, could be a possible treatment for GA. Pegcetacoplan is an investigational medicine, which means it has not yet been approved. It is currently being studied in clinical studies to see how well it works.
   What happened in the FILLY study?
   The FILLY study included participants with GA and tested how well pegcetacoplan worked compared to a sham injection (an injection that looks like the study treatment but does not have any medicine in it). The study also looked at how safe it was in adults with GA.
   What were the results?
   The main questions the researchers wanted to answer were:
   Did pegcetacoplan slow the growth of the study participants' GA lesions?
   Yes. Overall, the researchers found that pegcetacoplan did slow the growth of the study participants' GA lesions.
   Did pegcetacoplan change the participants' vision?
   No. Overall, the researchers found that pegcetacoplan did not change the participants' vision.
   What medical problems happened after the participants received pegcetacoplan?
   The researchers kept track of any serious medical problems that happened during the study, also called serious adverse events. They also kept track of other medical problems that happened, or got worse, only at some point after the participants received the study treatment. These are called treatment emergent adverse events, also known as TEAEs. The serious adverse events and TEAEs that the participants had are described later in this summary.
   What do the results of the study mean?
   Overall, results from this study showed that participants who received pegcetacoplan had slower growth of GA lesions than participants who received the sham injection. After the participants had stopped receiving pegcetacaoplan, the effect of the treatment seemed to be reduced. Pegcetacoplan did not change how well the participants could see during their vision tests in this trial.
C1 [Liao, David S.] Retina Vitreous Associates Med Grp, 12840 Riverside Dr Ste 333, N Hollywood, CA 91607 USA.
   [Metapally, Ravi; Joshi, Preeti] Apellis Pharmaceut Inc, Waltham, MA USA.
RP Liao, DS (通讯作者)，Retina Vitreous Associates Med Grp, 12840 Riverside Dr Ste 333, N Hollywood, CA 91607 USA.
NR 0
TC 0
Z9 0
U1 4
U2 4
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1750-743X
EI 1750-7448
J9 IMMUNOTHERAPY-UK
JI Immunotherapy
PD SEP
PY 2022
VL 14
IS 13
BP 995
EP 1006
DI 10.2217/imt-2022-0078
EA JUL 2022
PG 12
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 3O4IA
UT WOS:000828081700001
PM 35860926
OA hybrid
DA 2022-11-30
ER

PT J
AU Bailey, C
   Scott, LJ
   Rogers, CA
   Reeves, BC
   Hamill, B
   Peto, T
   Chakravarthy, U
   Harding, SP
AF Bailey, Clare
   Scott, Lauren J.
   Rogers, Chris A.
   Reeves, Barnaby C.
   Hamill, Barbra
   Peto, Tunde
   Chakravarthy, Usha
   Harding, Simon P.
CA IVAN Study Grp
TI Intralesional Macular Atrophy in Anti-Vascular Endothelial Growth Factor
   Therapy for Age-Related Macular Degeneration in the IVAN Trial
SO OPHTHALMOLOGY
LA English
DT Article
ID RANIBIZUMAB
AB Purpose: To report on the development and progression of macular atrophy (MA) and its relationship with morphologic and functional measures in study and fellow eyes in the Inhibition of vascular endothelial growth factor (VEGF) in Age-related Choroidal Neovascularisation trial.
   Design: Reading center analysis of data from a randomized controlled trial.
   Participants: Participants with previously untreated neovascular age-related macular degeneration (nAMD) in the study eye.
   Methods: Color, fluorescein angiography (FA) and OCT images acquired at baseline and during the 2-year follow-up were graded systematically for presence of MA. Regression models were constructed to explore relationships between MA and lesion morphology and vision measures (best-corrected distance and near acuity, reading speed and index, contrast sensitivity).
   Main Outcome Measures: Primary outcome was development of intralesional MA (>= 175 mm greatest linear dimension of choroidal vessels seen on FA and/or color, aided by OCT) lying within the maximum footprint of the neovascular lesion.
   Results: Study eye data were available for 594 of 610 participants; 57 (9.6%) showed intralesional MA at baseline. Incident intralesional MA occurred in 24.4% by the final visit and extralesional MA in only 1.54%. In fellow eyes, an established nAMD lesion was present at baseline in 248 of whom 42 (16.9%) showed intralesional MA at baseline and 32 (12.9%) developed incident intralesional MA. The odds of incident intralesional MA by final visit were lower in study eyes that had <= 50% classic CNV at baseline (odds ratio [OR], 0.39; 95% confidence interval [CI], 0.19-0.80; P = 0.010), subretinal fluid at final visit (OR, 0.41; 95% CI, 0.25-0.76; P = 0.004), or pigment epithelial detachment at final visit (OR, 0.40; 95% CI, 0.21-0.74; P = 0.004). Secondary analyses of incident or progressed intralesional MA in study eyes supported these findings, with odds increasing if the fellow eye had baseline intralesional MA (OR, 2.43; 95% CI, 1.09-5.44; P = 0.030). No significant associations were observed between development of intralesional MA and any other morphologic or visual function measure.
   Conclusions: Macular atrophy frequently develops within an nAMD lesion in eyes receiving anti-VEGF therapy over 2 years. No associations between incident MA and drug or treatment frequency or visual function were detected, providing some reassurance to clinicians; however, the longer-term effects remain unknown. (C) 2018 by the American Academy of Ophthalmology.
C1 [Bailey, Clare] Bristol Eye Hosp, Bristol, Avon, England.
   [Scott, Lauren J.; Rogers, Chris A.; Reeves, Barnaby C.] Univ Bristol, Clin Trials & Evaluat Unit, Sch Clin Sci, Bristol Royal Infirm, Bristol, Avon, England.
   [Hamill, Barbra] Queens Univ Belfast, Belfast Reading Ctr, Royal Victoria Hosp, Belfast, Antrim, North Ireland.
   [Peto, Tunde; Chakravarthy, Usha] Queens Univ Belfast, Dept Ophthalmol, Belfast, Antrim, North Ireland.
   [Chakravarthy, Usha] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Harding, Simon P.] Univ Liverpool, Inst Ageing & Chron Dis, Dept Eye & Vis Sci, William Duncan Bldg,West Derby St, Liverpool, Merseyside, England.
C3 Bristol Eye Hospital; Bristol Royal Infirmary; University of Bristol;
   Queens University Belfast; Queens University Belfast; Queens University
   Belfast; University of Liverpool
RP Harding, SP (通讯作者)，Univ Liverpool, Inst Ageing & Chron Dis, Dept Eye & Vis Sci, William Duncan Bldg,West Derby St, Liverpool, Merseyside, England.
EM s.p.harding@liv.ac.uk
OI Harding, Simon/0000-0003-4676-1158; Rogers, Chris/0000-0002-9624-2615;
   Chakravarthy, Usha/0000-0002-2606-3734; Reeves,
   Barnaby/0000-0002-5101-9487
FU National Institute for Health Research UK Health Technology Assessment
   Programme [07/36/01]
FX The IVAN trial was funded by the National Institute for Health Research
   UK Health Technology Assessment Programme (ref: 07/36/01). The sponsor
   and funding organization had no role in the design or conduct of this
   research. The views and opinions expressed are those of the authors and
   do not necessarily reflect those of the National Institute for Health
   Research UK Health Technology Assessment Programme, the National
   Institute for Health Research, the United Kingdom National Health
   Service, or the Department of Health.
CR Abdelfattah NS, 2017, OPHTHALMOLOGY, V124, P215, DOI 10.1016/j.ophtha.2016.10.002
   Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   Chakravarthy U, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19780
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Dhrami-Gavazi Elona, 2015, Int J Retina Vitreous, V1, P15
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
NR 14
TC 31
Z9 32
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2019
VL 126
IS 1
BP 75
EP 86
DI 10.1016/j.ophtha.2018.07.013
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HE6PG
UT WOS:000453531300022
PM 30301555
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Wu, J
   Cho, EY
   Willett, WC
   Sastry, SM
   Schaumberg, DA
AF Wu, Juan
   Cho, Eunyoung
   Willett, Walter C.
   Sastry, Srinivas M.
   Schaumberg, Debra A.
TI Intakes of Lutein, Zeaxanthin, and Other Carotenoids and Age-Related
   Macular Degeneration During 2 Decades of Prospective Follow-up
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID FOOD FREQUENCY QUESTIONNAIRE; PIGMENT OPTICAL-DENSITY; EYE DISEASE;
   UNITED-STATES; VITAMIN-C; VISUAL IMPAIRMENT; CLINICAL-TRIAL;
   DIETARY-INTAKE; RISK-FACTORS; PREVALENCE
AB IMPORTANCE Despite strong biological plausibility, evidence from epidemiologic studies and clinical trials on the relations between intakes of lutein and zeaxanthin and age-related macular degeneration (AMD) has been inconsistent. The roles of other carotenoids are less thoroughly investigated.
   OBJECTIVE To investigate the associations between intakes of carotenoids and AMD.
   DESIGN, SETTING, AND PARTICIPANTS Prospective cohort study, with cohorts from the Nurses' Health Study and the Health Professionals Follow-up Study in the United States. A total of 63 443 women and 38 603 men were followed up, from 1984 until May 31, 2010, in the Nurses' Health Study and from 1986 until January 31, 2010, in the Health Professionals Follow-up Study. All participants were aged 50 years or older and were free of diagnosed AMD, diabetes mellitus, cardiovascular disease, and cancer at baseline.
   MAIN OUTCOMES AND MEASURES Predicted plasma carotenoid scoreswere computed directly from food intake, assessed by repeated food frequency questionnaires at baseline and follow-up, using validated regression models to account for bioavailability and reporting validity of different foods, and associations between predicted plasma carotenoid scores and AMD were determined.
   RESULTS We confirmed 1361 incident intermediate and 1118 advanced AMD cases (primarily neovascular AMD) with a visual acuity of 20/30 or worse by medical record review. Comparing extreme quintiles of predicted plasma lutein/zeaxanthin score, we found a risk reduction for advanced AMD of about 40% in both women and men (pooled relative risk comparing extreme quintiles = 0.59; 95% CI, 0.48-0.73; P for trend <.001). Predicted plasma carotenoid scores for other carotenoids, including beta-cryptoxanthin, alpha-carotene, and beta-carotene, were associated with a 25% to 35% lower risk of advanced AMD when comparing extreme quintiles. The relative risk comparing extreme quintiles for the predicted plasma total carotenoid index was 0.65 (95% CI, 0.53-0.80; P for trend <.001). We did not identify any associations of carotenoids, either as predicted plasma score or calculated intake, with intermediate AMD.
   CONCLUSIONS AND RELEVANCE Higher intake of bioavailable lutein/zeaxanthin is associated with a long-term reduced risk of advanced AMD. Given that some other carotenoids are also associated with a lower risk, a public health strategy aimed at increasing dietary consumption of a wide variety of fruits and vegetables rich in carotenoids may reduce the incidence of advanced AMD.
C1 [Wu, Juan; Willett, Walter C.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
   [Cho, Eunyoung] Brown Univ, Dept Dermatol, Warren Alpert Med Sch, Providence, RI 02912 USA.
   [Cho, Eunyoung] Brown Sch Publ Hlth, Dept Epidemiol, Providence, RI USA.
   [Cho, Eunyoung; Willett, Walter C.] Harvard Univ, Dept Med, Channing Div Network Med, Brigham & Womens Hosp,Sch Med, Boston, MA USA.
   [Willett, Walter C.; Schaumberg, Debra A.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   [Sastry, Srinivas M.] Bethesda Retina, Bethesda, MD USA.
   [Schaumberg, Debra A.] Univ Utah, John A Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Moran Ctr Translat Med,Sch Med, Salt Lake City, UT USA.
C3 Harvard University; Harvard T.H. Chan School of Public Health; Brown
   University; Brown University; Harvard University; Brigham & Women's
   Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan
   School of Public Health; Utah System of Higher Education; University of
   Utah
RP Wu, J (通讯作者)，Harvard Univ, TH Chan Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.
EM juan.wu@mail.harvard.edu
RI Cho, Eunyoung/AAV-4469-2020
OI Cho, Eunyoung/0000-0001-6594-2582
FU National Institutes of Health [EY017362, EY021900, UM1 CA186107, UM1
   CA167552]; NATIONAL CANCER INSTITUTE [UM1CA186107, UM1CA167552] Funding
   Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY021900, R01EY017362]
   Funding Source: NIH RePORTER
FX This study was supported by grants EY017362, EY021900, UM1 CA186107, and
   UM1 CA167552 from the National Institutes of Health.
CR Beatty S, 2004, ARCH BIOCHEM BIOPHYS, V430, P70, DOI 10.1016/j.abb.2004.03.015
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Borel P, 2011, ANN MED, V43, P47, DOI 10.3109/07853890.2010.531757
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Connolly EE, 2010, CURR EYE RES, V35, P335, DOI 10.3109/02713680903521951
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504
   FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   Hendrickson SJ, 2013, NUTRIENTS, V5, P4051, DOI 10.3390/nu5104051
   Hof KHV, 2000, J NUTR, V130, P503
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Loane E, 2010, INVEST OPHTH VIS SCI, V51, P2636, DOI 10.1167/iovs.09-4397
   MANGELS AR, 1993, J AM DIET ASSOC, V93, P284, DOI 10.1016/0002-8223(93)91553-3
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   McCullough ML, 2002, AM J CLIN NUTR, V76, P1261, DOI 10.1093/ajcn/76.6.1261
   Meyers KJ, 2014, INVEST OPHTH VIS SCI, V55, P587, DOI 10.1167/iovs.13-13216
   Meyers KJ, 2013, INVEST OPHTH VIS SCI, V54, P2333, DOI [10.1167/iovs.12-10867, 10.1167/iovs.13-13216]
   Michaud DS, 1998, CANCER EPIDEM BIOMAR, V7, P283
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Murphy MM, 2012, J ACAD NUTR DIET, V112, P222, DOI 10.1016/j.jada.2011.08.044
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211
   SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366
   WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yeum KJ, 2002, ANNU REV NUTR, V22, P483, DOI 10.1146/annurev.nutr.22.010402.102834
   Zaripheh S, 2002, J NUTR, V132, p531S, DOI 10.1093/jn/132.3.531S
   Zhou HY, 2011, INVEST OPHTH VIS SCI, V52, P4338, DOI 10.1167/iovs.10-6519
NR 52
TC 116
Z9 122
U1 2
U2 35
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD DEC
PY 2015
VL 133
IS 12
BP 1415
EP 1424
DI 10.1001/jamaophthalmol.2015.3590
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CZ4RV
UT WOS:000367091300010
PM 26447482
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Ma, L
   Yan, SF
   Huang, YM
   Lu, XR
   Qian, F
   Pang, HL
   Xu, XR
   Zou, ZY
   Dong, PC
   Xiao, X
   Wang, X
   Sun, TT
   Dou, HL
   Lin, XM
AF Ma, Le
   Yan, Shao-Fang
   Huang, Yang-Mu
   Lu, Xin-Rong
   Qian, Fang
   Pang, Hong-Lei
   Xu, Xian-Rong
   Zou, Zhi-Yong
   Dong, Peng-Cheng
   Xiao, Xin
   Wang, Xun
   Sun, Ting-Ting
   Dou, Hong-Liang
   Lin, Xiao-Ming
TI Effect of Lutein and Zeaxanthin on Macular Pigment and Visual Function
   in Patients with Early Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL-DENSITY; EYE DISEASE; RISK; SUPPLEMENTATION; ANTIOXIDANTS;
   CAROTENOIDS; ACUITY; SERUM
AB Purpose: To determine whether supplementation with lutein and zeaxanthin improves macular pigment and visual function in patients with early age-related macular degeneration (AMD).
   Design: Randomized, double-masked, placebo-controlled trial. Participants:
   Participants with probable AMD who were 50 to 79 years of age were screened for study eligibility from the local communities. One hundred eight subjects with early AMD were recruited. Intervention: Early AMD patients were assigned randomly to receive 10 mg/day lutein (n = 27), 20 mg/day lutein (n = 27), 10 mg/day lutein plus 10 mg/day zeaxanthin (n = 27); or placebo (n = 27) for 48 weeks. Macular pigment optical density (MPOD) and visual function variables were assessed at baseline, 24 weeks, and 48 weeks.
   Main Outcome Measures: The primary outcome was MPOD. Secondary outcomes were visual function variables including best-corrected visual acuity (BCVA), contrast sensitivity (CS), photorecovery time, and Amsler grid testing results.
   Results: Macular pigment optical density increased significantly by a mean +/- standard error of 0.076 +/- 0.022 density unit in the 20-mg lutein group and 0.058 +/- 0.027 density unit in the lutein and zeaxanthin group during 48 weeks. There was a significant dose-response effect for lutein supplementation, and the changes in MPOD from baseline to 48 weeks were correlated negatively with baseline MPOD in all active treatment groups (r = -0.56; P < 0.001). At 48 weeks, a trend toward improvement was seen in BCVA, and there was a significant between-group difference in CS at 3 and 6 cycles/degree between the 20-mg lutein group and the placebo group. The increase in MPOD related positively to the reduction in the logarithm of the minimum angle of resolution BCVA (r = -0.31; P < 0.01) and the increases in CS at 4 spatial frequencies (r ranging from 0.26 to 0.38; all P < 0.05).
   Conclusions: Among patients with early AMD, supplementation with lutein and zeaxanthin improved macular pigment, which played a causative role in boosting visual function and might prevent the progression of AMD. Future studies are required to evaluate the effect of these carotenoids on the incidence of late AMD.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2012;119:2290-2297 (C) 2012 by the American Academy of Ophthalmology.
C1 [Ma, Le; Yan, Shao-Fang; Huang, Yang-Mu; Xu, Xian-Rong; Zou, Zhi-Yong; Dong, Peng-Cheng; Xiao, Xin; Wang, Xun; Sun, Ting-Ting; Lin, Xiao-Ming] Peking Univ, Dept Nutr & Food Hyg, Sch Publ Hlth, Beijing 100871, Peoples R China.
   [Lu, Xin-Rong; Qian, Fang; Pang, Hong-Lei; Dou, Hong-Liang] Peking Univ, Ctr Eye, Hosp 3, Beijing 100871, Peoples R China.
C3 Peking University; Peking University
RP Lin, XM (通讯作者)，Peking Univ, Dept Nutr & Food Hyg, Sch Publ Hlth, Beijing 100871, Peoples R China.
EM douhongliang3736@sina.cn; linbjmu@bjmu.edu.cn
RI Zou, Zhiyong/P-8066-2019
OI Zou, Zhiyong/0000-0001-5049-5425; Huang, Yangmu/0000-0002-3660-1276
FU National Natural Science Foundation of China, Beijing, China
   [NSFC-30872113]
FX Supported by the National Natural Science Foundation of China (grant
   no.: NSFC-30872113), Beijing, China. All authors had access to the data
   and played a role in writing this manuscript.
CR Barker FM, 2011, INVEST OPHTH VIS SCI, V52, P3934, DOI 10.1167/iovs.10-5898
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Brown AM, 2009, OPTOMETRY VISION SCI, V86, P572, DOI 10.1097/OPX.0b013e3181a72980
   Chiang PPC, 2011, INVEST OPHTH VIS SCI, V52, P2790, DOI 10.1167/iovs.10-5460
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Delori FC, 2004, ARCH BIOCHEM BIOPHYS, V430, P156, DOI 10.1016/j.abb.2004.05.016
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hiraoka T, 2007, INVEST OPHTH VIS SCI, V48, P550, DOI 10.1167/iovs.06-0914
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kant AK, 2008, AM J CLIN NUTR, V87, P1464, DOI 10.1093/ajcn/87.5.1464
   Kim SR, 2006, EXP EYE RES, V82, P828, DOI 10.1016/j.exer.2005.10.004
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kruger PB, 2005, VISION RES, V45, P1265, DOI 10.1016/j.visres.2004.11.017
   Kuo HK, 2011, GRAEF ARCH CLIN EXP, V249, P601, DOI 10.1007/s00417-010-1461-3
   LaRowe TL, 2008, OPHTHALMOLOGY, V115, P876, DOI 10.1016/j.ophtha.2007.06.015
   Li BX, 2011, BIOCHEMISTRY-US, V50, P2541, DOI 10.1021/bi101906y
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Neuringer M, 2004, INVEST OPHTH VIS SCI, V45, P3234, DOI 10.1167/iovs.02-1243
   Newsome DA, 2009, CURR EYE RES, V34, P162, DOI 10.1080/02713680802647654
   Nolan JM, 2010, OPHTHALMIC RES, V44, P131, DOI 10.1159/000315531
   Olmedilla B, 2001, J SCI FOOD AGR, V81, P904, DOI 10.1002/jsfa.905
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Richer S, 1999, J Am Optom Assoc, V70, P24
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Sasaki M, 2009, INVEST OPHTH VIS SCI, V50, P1433, DOI 10.1167/iovs.08-2493
   Sasamoto Y, 2011, INVEST OPHTH VIS SCI, V52, P927, DOI 10.1167/iovs.10-5664
   Stringham JM, 2005, NUTR REV, V63, P59, DOI 10.1111/j.1753-4887.2005.tb00122.x
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Thomson LR, 2002, EXP EYE RES, V75, P529, DOI 10.1006/exer.2002.2050
   Trieschmann M, 2006, GRAEF ARCH CLIN EXP, V244, P1565, DOI 10.1007/s00417-006-0289-3
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Wooten BR, 2002, PROG RETIN EYE RES, V21, P225, DOI 10.1016/S1350-9462(02)00003-4
NR 36
TC 115
Z9 117
U1 0
U2 46
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2012
VL 119
IS 11
BP 2290
EP 2297
DI 10.1016/j.ophtha.2012.06.014
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 030OH
UT WOS:000310579500015
PM 22858124
DA 2022-11-30
ER

PT J
AU Essex, RW
   Nguyen, V
   Walton, R
   Arnold, JJ
   McAllister, IL
   Guymer, RH
   Morlet, N
   Young, S
   Barthelmes, D
   Gillies, MC
AF Essex, Rohan W.
   Nguyen, Vuong
   Walton, Richard
   Arnold, Jennifer J.
   McAllister, Ian L.
   Guymer, Robyn H.
   Morlet, Nigel
   Young, Stephanie
   Barthelmes, Daniel
   Gillies, Mark C.
CA Fight Retinal Blindness Study
TI Treatment Patterns and Visual Outcomes during the Maintenance Phase of
   Treat-and-Extend Therapy for Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID RANIBIZUMAB
AB Purpose: To present the treatment patterns, disease activity, and visual outcomes of eyes in the maintenance phase of a treat-and-extend regimen for neovascular age-related macular degeneration (nAMD). To compare the maintenance phase behavior of eyes with a shorter induction phase (<= 3 injections) with those requiring a longer induction phase (> 3 injections).
   Design: Database observational study.
   Participants: Eyes with nAMD receiving anti-vascular endothelial growth factor (VEGF) treatment using a treat-and-extend protocol. Persistently active eyes were excluded, as were eyes with < 12 months follow-up during the maintenance phase.
   Methods: Clinical information from a large prospective international voluntary registry of nAMD was analyzed. The maintenance phase was defined as starting at the first clinician-reported grading of lesion inactivity.
   Main Outcome Measures: For analyses by eye: treatment interval at first reactivation; time to first reactivation; and visual acuity change during the study period. For analyses by visit: choroidal neovascular membrane activity graded by the treating physician; time since previous injection; and visual acuity loss since previous injection (> 0 letters and >= 15 letters).
   Results: The mean change in visual acuity during the maintenance phase was +1.0 letters at 12 months -0.6 letters at 24 months and -1.5 at 36 months. Median treatment interval increased from 35 days at study entry to 63 days at 12 months and was 60 days at 36 months. 38.5% of eyes remained inactive at all observed visits during the maintenance phase (minimum 1 year follow-up, mean 945 days). The most common treatment interval at first reactivation was 8 weeks. Treatment intervals beyond 12 weeks seemed to be associated with increased risk of disease reactivation, with risk of reactivation reaching 37.4% at treatment intervals of >= 20 weeks. Eyes with a longer induction phase had worse visual outcomes in the maintenance phase, and earlier and morefrequent disease reactivation, although they received injections less frequently.
   Conclusions: The detailed behavior of eyes in the maintenance phase of treat-and-extend management for nAMD is presented. Visual acuity was well maintained during the study period. The most common interval at which reactivation first occurred was 8 weeks. Longer duration of induction phase was associated with worse visual acuity outcomes and earlier disease reactivation, perhaps because of undertreatment. (C) 2016 by the American Academy of Ophthalmology.
C1 [Essex, Rohan W.] Australian Natl Univ, Acad Unit Ophthalmol, Acton, Australia.
   [Nguyen, Vuong; Walton, Richard; Barthelmes, Daniel; Gillies, Mark C.] Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW, Australia.
   [Arnold, Jennifer J.] Marsden Eye Specialists, Parramatta, Australia.
   [McAllister, Ian L.] Univ Western Australia, Ctr Ophthalmol & Vis Sci, Lions Eye Inst, Nedlands, WA, Australia.
   [Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Morlet, Nigel] Univ Western Australia, Dept Populat Hlth, Perth, WA, Australia.
   [Young, Stephanie] Gladesville Eye Specialists, Gladesville, Australia.
   [Barthelmes, Daniel] Univ Zurich, Univ Zurich Hosp, Dept Ophthalmol, Zurich, Switzerland.
C3 Australian National University; University of Sydney; Lions Eye
   Institute; University of Western Australia; Centre for Eye Research
   Australia; Royal Victorian Eye & Ear Hospital; University of Melbourne;
   University of Western Australia; University of Zurich; University Zurich
   Hospital
RP Essex, RW (通讯作者)，Australian Natl Univ, Acad Unit Ophthalmol, Acton, Australia.; Essex, RW (通讯作者)，Australian Natl Univ, Canberra Hosp, Acad Unit Ophthalmol, Yamba Dr, Garran, ACT 2605, Australia.
EM rohan.essex@act.gov.au
OI Essex, Rohan/0000-0001-5323-0334; Guymer, Robyn/0000-0002-9441-4356;
   Nguyen, Vuong/0000-0001-9070-9803
FU National Health and Medical Research Council (NHMRC); Walter and Gertrud
   Siegenthaler Foundation, Zurich, Switzerland; Holcim Foundation; Swiss
   National Foundation
FX The author(s) have made the following disclosure(s): D.B. and M.G. are
   among owners of the copyright for the software with which the data for
   this project was collected. M.G. is a Sydney Medical Foundation Fellow
   and is supported by a National Health and Medical Research Council
   (NHMRC) practitioner fellowship. D.B. was supported by the Walter and
   Gertrud Siegenthaler Foundation, Zurich, Switzerland; the Holcim
   Foundation; and the Swiss National Foundation.
CR Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P589, DOI 10.1016/j.ophtha.2014.10.001
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Gillies MC, 2013, INVEST OPHTH VIS SCI, V54, P5754, DOI 10.1167/iovs.13-11993
   Madhusudhana KC, 2016, BR J OPHTHALMOL
   R Core Team, 2015, LANG ENV STAT COMP
   Stoller GL, 2016, JAMA OPHTHALMOL, V134, P545, DOI 10.1001/jamaophthalmol.2016.0379
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
NR 14
TC 41
Z9 41
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2016
VL 123
IS 11
BP 2393
EP 2400
DI 10.1016/j.ophtha.2016.07.012
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EE3QK
UT WOS:000389509500024
PM 27554034
OA Bronze
DA 2022-11-30
ER

PT J
AU Peiretti, E
   Mandas, A
   Abete, C
   Vinci, M
   Piludu, S
   Casu, M
   Caminiti, G
   Dessi, S
   Fossarello, M
AF Peiretti, Enrico
   Mandas, Antonella
   Abete, Claudia
   Vinci, Michela
   Piludu, Stefania
   Casu, Maura
   Caminiti, Giulia
   Dessi, Sandra
   Fossarello, Maurizio
TI Age-related macular degeneration and cognitive impairment show
   similarities in changes of neutral lipids in peripheral blood
   mononuclear cells
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE age-related macular degeneration; cholesterol-ester; cognitive
   impairment
ID ALZHEIMERS-DISEASE; AMYLOID PATHOLOGY; BASAL DEPOSITS; BETA-PEPTIDE;
   CHOLESTEROL; DRUSEN; ATHEROSCLEROSIS; MACULOPATHY; PROGRESSION; STATINS
AB Starting from previous studies showing that patients with cognitive deficit present neutral lipids (NLs) accumulation in cytoplasm of their peripheral blood mononuclear cells (PBMCs) and considering that there is epidemiological evidence linking age-related macular degeneration (AMD) to cognitive deficit, the first purpose of this study was to test whether neutral lipids also accumulated in PBMCs from AMD subjects. Moreover, the impact of statin use on AMD was explored and whether such use in AMD subjects was associated with NLs accumulation in PBMCs. The study was conducted on 222 subjects: 136 AMD (36 of which - 26.5% using statins], 48 cognitive deficit (20 of which - 41.7% using statins) and 38 healthy controls (4 of which -10.1% using statins), AMD lesions were assessed from color fundus photographs. Mini-mental state examination (MMSE), demographics, lifestyle factors and medical history were collected at interview. MMSE score was categorized as normal (24-30), and impaired (<24), NLs content was evaluated by oil red 0 (ORO) staining method. ORO determination showed that neutral lipids were generally absent or very low (score between 0 and 1) in healthy controls while most of PBMCs from cognitive deficit and AMD had ORO staining levels scoring 2-4. Post hoc analysis (Bonferroni) in a one-way ANOVA revealed that ORO score was significantly higher in cognitive deficit and AMD subjects compared to healthy controls and in cognitive deficit compared to AMD. Bonferroni-test also showed that AMD subjects had significantly lower total cholesterol (TC) levels compared to healthy controls while high density lipoprotein-cholesterol (HDL-C) did not reach statistical significance. The results also revealed a significant higher number of statin-users in AMD compared to healthy controls. Likewise when cognitive deficit vs healthy controls was analyzed, the number of statin users were found to be. significant higher in cognitive deficit than in healthy controls. There were no significant differences in statin use between AMD and cognitive deficit. Compared to healthy controls, statin use in cognitive deficit and AMD groups was significantly associated with ORO scores of 2-4. This data supports the hypothesis that AMD and cognitive deficit share similar complex pathophysiology and risk factors including NLs accumulation in their PBMCs, although this does not necessarily imply that one disease causes the other. In addition, they provide further evidence that statin use may increase the risk of AMD. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Peiretti, Enrico; Vinci, Michela; Piludu, Stefania; Casu, Maura; Caminiti, Giulia; Fossarello, Maurizio] Univ Cagliari, Eye Clin, Dept Surg Sci, I-09124 Cagliari, Italy.
   [Mandas, Antonella; Abete, Claudia; Dessi, Sandra] Univ Cagliari, I-09124 Cagliari, Italy.
C3 University of Cagliari; University of Cagliari
RP Peiretti, E (通讯作者)，Univ Cagliari, Osped San Giovanni di Dio, Dipartimento Sci Chirurg & Odontoiatria, Via Osped 48, I-09124 Cagliari, Italy.
EM enripei@hotmail.com
RI Fossarello, Maurizio/AAD-8235-2021; Fossarello, Maurizio/G-2032-2015
OI Peiretti, Enrico/0000-0003-1088-0163; Caminiti,
   Giulia/0000-0002-0662-9307; Fossarello, Maurizio/0000-0003-1520-7760
CR Adler R, 1999, MOL VIS, V5
   Anchisi L, 2013, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00486
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   BOTTI RE, 1991, CLIN NEUROPHARMACOL, V14, P256, DOI 10.1097/00002826-199106000-00010
   Bretillon L, 2008, INVEST OPHTH VIS SCI, V49, P1307, DOI 10.1167/iovs.07-0808
   Bretillon L, 2008, EXP EYE RES, V87, P521, DOI 10.1016/j.exer.2008.08.010
   Butterfield DA, 2002, J ALZHEIMERS DIS, V4, P193, DOI 10.3233/JAD-2002-4309
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Dentchev T, 2003, MOL VIS, V9, P184
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Esenwah E., 2010, J NIGER OPTOM ASS, V16, P40
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   FLIESLER SJ, 1993, FEBS LETT, V335, P234, DOI 10.1016/0014-5793(93)80736-E
   Fliesler SJ, 2010, J LIPID RES, V51, P3399, DOI 10.1194/jlr.R010538
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   FRANCIS CM, 1955, J COMP NEUROL, V103, P355, DOI 10.1002/cne.901030209
   Gehlbach P, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub3
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hutter-Paier B, 2004, NEURON, V44, P227, DOI 10.1016/j.neuron.2004.08.043
   Huttunen HJ, 2008, NEURODEGENER DIS, V5, P212, DOI 10.1159/000113705
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   KRUTH HS, 1984, EXP MOL PATHOL, V40, P288, DOI 10.1016/0014-4800(84)90046-7
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Maguire MG, 2009, OPHTHALMOLOGY, V116, P2381, DOI 10.1016/j.ophtha.2009.06.055
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Mandas A, 2014, NEUROL RES, V36, P247, DOI 10.1179/1743132813Y.0000000287
   Mandas A, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-39
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   Mehlem A, 2013, NAT PROTOC, V8, P1149, DOI 10.1038/nprot.2013.055
   Niikura T, 2006, CURR NEUROPHARMACOL, V4, P139, DOI 10.2174/157015906776359577
   Pani A, 2009, J ALZHEIMERS DIS, V18, P829, DOI 10.3233/JAD-2009-1193
   Pani A, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-66
   Peponis V, 2010, CLIN OPHTHALMOL, V4, P865
   Puglielli L, 2004, J MOL NEUROSCI, V24, P93, DOI 10.1385/JMN:24:1:093
   Puglielli L, 2003, NAT NEUROSCI, V6, P345, DOI 10.1038/nn0403-345
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   VanderBeek BL, 2013, RETINA-J RET VIT DIS, V33, P414, DOI 10.1097/IAE.0b013e318276e0cf
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
NR 42
TC 6
Z9 6
U1 0
U2 7
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUL
PY 2014
VL 124
BP 11
EP 16
DI 10.1016/j.exer.2014.04.017
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AK2TV
UT WOS:000338273300002
PM 24792172
DA 2022-11-30
ER

PT J
AU Rudnicka, AR
   Jarrar, Z
   Wormald, R
   Cook, DG
   Fletcher, A
   Owen, CG
AF Rudnicka, Alicja R.
   Jarrar, Zakariya
   Wormald, Richard
   Cook, Derek G.
   Fletcher, Astrid
   Owen, Christopher G.
TI Age and Gender Variations in Age-related Macular Degeneration Prevalence
   in Populations of European Ancestry: A Meta-analysis
SO OPHTHALMOLOGY
LA English
DT Article
ID OPEN-ANGLE GLAUCOMA; BLUE MOUNTAINS EYE; RISK-FACTORS;
   RACIAL-DIFFERENCES; GRADING SYSTEM; UNITED-STATES; MACULOPATHY; DISEASE;
   OLDER; ATHEROSCLEROSIS
AB Objective: To obtain prevalence estimates of age-related macular degeneration (AMD; late, geographic atrophy, neovascular) by age and gender amongst populations of European ancestry taking into account study design and time trends.
   Design: Systematic review of population-based studies published by September 2010 with quantitative estimates of geographic atrophy (GA), neovascular (NV), and late AMD prevalence. Studies were identified by a literature search of MEDLINE (from 1950), EMBASE (from 1980), and Web of Science (from 1980) databases.
   Participants: Data from 25 published studies (57 173 subjects: 455 with GA, 464 with NVAMD, and 1571 with late AMD).
   Methods: Bayesian meta-regression of the log odds of AMD with age, gender, and year of study allowing for differences in study design characteristics, to estimate prevalences of AMD (late, GA, NVAMD) along with 95% credible intervals (CrI).
   Main Outcome Measures: Log odds and prevalence of AMD.
   Results: There was considerable heterogeneity in prevalence rates between studies; for late AMD, 20% of the variability in prevalence rates was explained by differences in age and 50% by study characteristics. The prevalence of AMD increased exponentially with age (odds ratio [OR], 4.2 per decade; 95% CrI, 3.8-4.6), which did not differ by gender. There was some evidence to suggest higher risk of NVAMD in women compared with men (OR, 1.2; 95% CrI, 1.0-1.5). Compared with studies using fundus imaging and international classification systems, studies using fundus imaging with alternative classifications were more likely (OR, 2.7; 95% CrI, 1.1-2.8), and studies using alternative classifications without fundus imaging most likely to diagnose late AMD (OR, 2.9; 95% CrI, 1.3-7.8). There was no good evidence of trends in AMD prevalence over time. Estimated prevalence of late AMD is 1.4% (95% CrI, 1.0%-2.0%) at 70 years of age, rising to 5.6% (95% CrI, 3.9%-7.7%) at age 80 and 20% (95% CrI, 14%-27%) at age 90.
   Conclusions: Studies using recognized classifications systems with fundus photography reported the lowest prevalences of AMD taking account of age and gender, and were stable over time, with a potentially higher risk of NVAMD for women. These prevalence estimates can be used to guide health service provision in populations of European ancestry.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2012;119:571-580 (C) 2012 by the American Academy of Ophthalmology.
C1 [Rudnicka, Alicja R.; Jarrar, Zakariya; Cook, Derek G.; Owen, Christopher G.] St Georges Univ London, Div Populat Hlth Sci & Educ, London SW17 ORE, England.
   [Wormald, Richard; Fletcher, Astrid] London Sch Hyg & Trop Med, London WC1, England.
   [Wormald, Richard] Moorfields Eye Hosp, London, England.
C3 St Georges University London; University of London; London School of
   Hygiene & Tropical Medicine; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust
RP Owen, CG (通讯作者)，St Georges Univ London, Div Populat Hlth Sci & Educ, Cranmer Terrace, London SW17 ORE, England.
EM cowen@sgul.ac.uk
RI Cook, Derek G/C-3271-2008
OI Cook, Derek/0000-0002-9723-5759; Owen, Christopher/0000-0003-1135-5977;
   Rudnicka, Alicja R/0000-0003-0369-8574
FU Macular Diseases Society, UK
FX The work was supported by a grant from the Macular Diseases Society, UK
   and commissioned on behalf of the Macular Interest Group of Vision 2020,
   UK.
CR Appelros P, 2009, STROKE, V40, P1082, DOI 10.1161/STROKEAHA.108.540781
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bjornsson OM, 2006, ACTA OPHTHALMOL SCAN, V84, P636, DOI 10.1111/j.1600-0420.2006.00696.x
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Bunce C, 2008, EYE, V22, P905, DOI 10.1038/sj.eye.6702767
   Centers for Disease Control and Prevention, TRENDS CURR CIG SMOK
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   DAS BN, 1994, J ROY SOC MED, V87, P219
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   KINI MM, 1978, AM J OPHTHALMOL, V85, P28, DOI 10.1016/S0002-9394(14)76661-9
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kozobolis VP, 1999, ARCH OPHTHALMOL-CHIC, V117, P664
   Lamoureux EL, 2011, BRIT J OPHTHALMOL, V95, P666, DOI 10.1136/bjo.2010.185207
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Pagliarini S, 1997, ARCH OPHTHALMOL-CHIC, V115, P616, DOI 10.1001/archopht.1997.01100150618007
   Pauleikhoff D, 1992, Ger J Ophthalmol, V1, P12
   Petrea RE, 2009, STROKE, V40, P1032, DOI 10.1161/STROKEAHA.108.542894
   Robinson S, 2011, SMOKING DRINKING ADU, P5
   ROUHIAINEN H, 1990, ACTA OPHTHALMOL, V68, P554
   Rudnicka AR, 2006, INVEST OPHTH VIS SCI, V47, P4254, DOI 10.1167/iovs.06-0299
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Topouzis F, 2006, AM J OPHTHALMOL, V142, P1076, DOI 10.1016/j.ajo.2006.07.042
   U.S. Census Bureau, POP PROJ US INT PROJ
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Vinding T, 1995, ACTA OPHTHALMOL SCAN, V73, P3
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vision, VIS 2020 RIGHT SIGHT
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Wong TY, 2010, STROKE, V41, P575, DOI 10.1161/STROKEAHA.109.574475
NR 53
TC 190
Z9 197
U1 0
U2 35
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2012
VL 119
IS 3
BP 571
EP 580
DI 10.1016/j.ophtha.2011.09.027
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 901ID
UT WOS:000300957200021
PM 22176800
DA 2022-11-30
ER

PT J
AU Holz, FG
   Amoaku, W
   Donate, J
   Guymer, RH
   Kellner, U
   Schlingemann, RO
   Weichselberger, A
   Staurenghi, G
AF Holz, Frank G.
   Amoaku, Winfried
   Donate, Juan
   Guymer, Robyn H.
   Kellner, Ulrich
   Schlingemann, Reinier O.
   Weichselberger, Andreas
   Staurenghi, Giovanni
CA SUSTAIN Study Grp
TI Safety and Efficacy of a Flexible Dosing Regimen of Ranibizumab in
   Neovascular Age-Related Macular Degeneration: The SUSTAIN Study
SO OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; OPTICAL COHERENCE TOMOGRAPHY;
   RANDOMIZED CLINICAL-TRIALS; PHOTODYNAMIC THERAPY; VERTEPORFIN; DISEASE
AB Objective: To evaluate the safety and efficacy of individualized ranibizumab treatment in patients with neovascular age-related macular degeneration.
   Design: Twelve-month, phase III, multicenter, open-label, single-arm study.
   Participants: A total of 513 ranibizumab-naive SUSTAIN patients.
   Intervention: Three initial monthly injections of ranibizumab (0.3 mg) and thereafter pro re nata (PRN) retreatment for 9 months based on prespecified retreatment criteria. Patients switched to 0.5 mg ranibizumab after approval in Europe.
   Main Outcome Measures: Frequency of adverse events (AEs), monthly change of best-corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline, the time to first re-treatment, and the number of treatments were assessed.
   Results: A total of 249 patients (48.5%) reported ocular AEs, and 8 (1.5%) deaths, 5 (1.2%) patients with ocular serious AEs of the study eye (retinal hemorrhage, cataract, retinal pigment epithelial tear, reduced visual acuity [VA], vitreous hemorrhage), and 19 (3.7%) patients with arteriothromboembolic events were observed. Most frequent AEs in the study eye were reduced VA (18.5%), retinal hemorrhage (7.2%), increased intraocular pressure (7.0%), and conjunctival hemorrhage (5.5%). The average number of re-treatments from months 3 to 11 was 2.7. Mean best-corrected visual acuity increased steadily from baseline to month 3 to reach +5.8 letters, decreased slightly from month 3 to 6, and remained stable from month 6 to 12, reaching +3.6 at month 12. Mean change in CRT was -101.1 mu m from baseline to month 3 and -91.5 mu m from baseline to month 12.
   Conclusions: The safety results are comparable to the favorable tolerability profile of ranibizumab observed in previous pivotal clinical studies; individualized treatment with less than monthly re-treatments shows a similar safety profile as observed in previous randomized clinical trials with monthly ranibizumab treatment. Efficacy outcomes were achieved with a low average number of re-treatments. Visual acuity in SUSTAIN patients with individualized re-treatment based on VA/optical coherence tomography assessment reached on average a maximum after the first 3 monthly injections, decreased slightly under PRN during the next 2 to 3 months, and was then sustained throughout the treatment period.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2011; 118: 663-671 (C) 2011 by the American Academy of Ophthalmology.
C1 [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, D-53105 Bonn, Germany.
   [Amoaku, Winfried] Univ Nottingham Hosp, Queens Med Ctr, Div Ophthalmol & Visual Sci, Nottingham NG7 2UH, England.
   [Donate, Juan] Univ Fed Sao Carlos, Hosp Clin, Madrid, Spain.
   [Guymer, Robyn H.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Australia.
   [Kellner, Ulrich] Augenzentrum Siegburg, Siegburg, Germany.
   [Schlingemann, Reinier O.] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
   [Weichselberger, Andreas] Novartis Pharma AG, Basel, Switzerland.
   [Weichselberger, Andreas] AO Polo Univ Luigi Sacco Univ, Milan, Italy.
C3 University of Bonn; University of Nottingham; Centre for Eye Research
   Australia; University of Melbourne; University of Amsterdam; Academic
   Medical Center Amsterdam; Novartis; University of Milan; Luigi Sacco
   Hospital
RP Holz, FG (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53105 Bonn, Germany.
EM Frank.Holz@ukb.uni-bonn.de
RI Staurenghi, Giovanni/K-4388-2017
OI Staurenghi, Giovanni/0000-0002-2299-5251; DONATE,
   JUAN/0000-0002-9944-6736; Amoaku, Winfried/0000-0001-5028-7984; Guymer,
   Robyn/0000-0002-9441-4356
FU Novartis Pharma, AG, Switzerland; Novartis Pharmaceutical Corporation;
   Pfizer; Bausch Lomb
FX Supported by Novartis Pharma, AG, Switzerland.; The author(s) have made
   the following disclosure(s): Frank G. Holz: Novartis Pharmaceutical
   Corporation, Genentech, Alcon Laboratories, Acucela, Bayer Schering
   (consultant); Novartis Pharmaceutical Corporation, Alcon Laboratories
   (lecturer). Winfried Amoaku: Novartis Pharmaceutical Corporation,
   Allergan, Pfizer (consultant); Novartis Pharmaceutical Corporation,
   Allergan, Pfizer (lecturer); Novartis Pharmaceutical Corporation,
   Pfizer, Bausch & Lomb (financial support). Juan Donate: no financial
   interests to disclose. Robyn H. Guymer: Novartis Pharmaceuticals
   Corporation (consultant). Ulrich Kellner: Novartis Pharmaceuticals
   Corporation (lecturer). Reinier O. Schlingemann: Novartis
   Pharmaceuticals Corporation (consultant and lecturer). Andreas
   Weichselberger: full-time employee of Novartis Pharma. Giovanni
   Staurenghi: Allergan, GSK (consultant); Novartis Pharmaceutical
   Corporation (lecturer).
CR Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Massin P, 2006, ACTA OPHTHALMOL SCAN, V84, P466, DOI 10.1111/j.1600-0420.2006.00694.x
   Novack GD, 2008, ANNU REV PHARMACOL, V48, P61, DOI 10.1146/annurev.pharmtox.48.060607.174028
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2010, OPHTHALMOLOGY   1209
   Shao H, 2005, J NEUROIMMUNOL, V163, P102, DOI 10.1016/j.jneuroim.2005.03.004
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
NR 21
TC 299
Z9 318
U1 0
U2 26
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2011
VL 118
IS 4
BP 663
EP 671
DI 10.1016/j.ophtha.2010.12.019
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 744DS
UT WOS:000289075200009
PM 21459217
DA 2022-11-30
ER

PT J
AU Pagliarini, S
   Beatty, S
   Lipkova, B
   Garcia, EPS
   Reynders, S
   Gekkieva, M
   Bouazza, AS
   Pilz, S
AF Pagliarini, Sergio
   Beatty, Stephen
   Lipkova, Blandina
   Garcia, Eduardo Perez-Salvador
   Reynders, Stefaan
   Gekkieva, Margarita
   Bouazza, Abdelkader Si
   Pilz, Stefan
TI A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5
   mg in Patients with Neovascular Age-Related Macular Degeneration in
   Routine Clinical Practice: The EPICOHORT Study
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VERTEPORFIN PLUS RANIBIZUMAB; CHOROIDAL NEOVASCULARIZATION; SAFETY;
   EFFICACY; SECONDARY
AB Purpose. To assess the safety profile of ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration (nAMD) in routine clinical practice. Methods. This 2-year, multicentre, observational study was conducted to capture real-world early practice and outcomes across Europe, shortly after European licensing of ranibizumab for nAMD. Being observational in nature, the study did not impose diagnostic/therapeutic interventions/visit schedule. Patients were to be treated as per the EU summary of product characteristics (SmPC) in effect during the study. Key outcome measures were incidence of selected adverse events (AEs), treatment exposure, bilateral treatment, compliance to the EU SmPC, and best-corrected visual acuity (BCVA) over 2 years. Results. 755 of 770 patients received treatment. Ranibizumab was generally well tolerated with low incidence of selected AEs (0%-1.9%). Patients received 6.2 (mean) injections and 133 patients received bilateral treatment over 2 years. Protocol deviation to treatment compliance was reported in majority of patients. The observed decline in mean BCVA (Month 12, + 1.5; Month 24, -1.3 letters) may be associated with undertreatment as suggested by BCVA subgroup analysis. Conclusion. The EPICOHORT study conducted in routine clinical practice reinforces the well-established safety profile of ranibizumab in nAMD. In early European practice it appeared that the nAMD patients were undertreated.
C1 [Pagliarini, Sergio] Univ Hosp Coventry & Warwickshire NHS Trust, Dept Ophthalmol, Coventry CV2 2DX, W Midlands, England.
   [Beatty, Stephen] Inst Eye Surg & Macular Pigment Res Grp, Whitfield Eye Clin, Waterford, Ireland.
   [Lipkova, Blandina] Fac Hosp, Dept Ophthalmol, Zilina 01207, Slovakia.
   [Garcia, Eduardo Perez-Salvador] Hosp Prov Div Valles, Burgos 09006, Spain.
   [Reynders, Stefaan] Oogcentrum Oostende, B-8400 Oostende, Belgium.
   [Gekkieva, Margarita; Bouazza, Abdelkader Si; Pilz, Stefan] Novartis Pharma AG, CH-4002 Basel, Switzerland.
C3 University of Warwick; Novartis
RP Pagliarini, S (通讯作者)，Univ Hosp Coventry & Warwickshire NHS Trust, Dept Ophthalmol, Coventry CV2 2DX, W Midlands, England.
EM sergio.pagliarini@gmail.com
OI Lipkova, Blandina/0000-0002-5754-7547
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kumar A, 2011, BRIT J OPHTHALMOL, V95, P530, DOI 10.1136/bjo.2009.171868
   Kwon OW, 2012, GRAEF ARCH CLIN EXP, V250, P1467, DOI 10.1007/s00417-012-1970-3
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Tano Y, 2011, ACTA OPHTHALMOL, V89, P208, DOI 10.1111/j.1755-3768.2010.02065.x
NR 23
TC 22
Z9 23
U1 0
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2014
VL 2014
AR 857148
DI 10.1155/2014/857148
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AG8VL
UT WOS:000335696300001
PM 24868458
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Nguyen, CL
   Gillies, MC
   Nguyen, V
   Daien, V
   Cohn, A
   Banerjee, G
   Arnold, J
AF Chu Luan Nguyen
   Gillies, Mark C.
   Vuong Nguyen
   Daien, Vincent
   Cohn, Amy
   Banerjee, Gayatri
   Arnold, Jennifer
CA Fight Retinal Blindness Study Grp
TI Characterization of Poor Visual Outcomes of Neovascular Age-related
   Macular Degeneration Treated with Anti-Vascular Endothelial Growth
   Factor Agents
SO OPHTHALMOLOGY
LA English
DT Article
ID RANIBIZUMAB; BEVACIZUMAB; THERAPY; ACUITY
AB Purpose: To investigate the incidence, characteristics, and baseline predictors of poor visual outcomes in eyes with neovascular age-related macular degeneration (nAMD) receiving intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents in daily clinical practice.
   Design: Observational study.
   Participants: Treatment-naive eyes starting anti-VEGF therapy for nAMD between 2007 and 2012 tracked in the Fight Retinal Blindness! registry. Eyes had sustained >= 15 letters of loss from baseline without recovery of visual acuity (VA) at final end point. A subgroup analysis included eyes that sustained >= 30 letters of loss. Controls had not sustained >= 15 letters of loss.
   Methods: Kaplan-Meier curves estimated time to first development of loss of >= 15 letters. Cox proportional hazards models evaluated predictors of loss of >= 15 letters.
   Main Outcome Measures: The proportion of eyes with sustained VA loss within 5 years, the time to development of sustained VA loss, and baseline predictors of sustained VA loss.
   Results: There were 1760 eyes in total and 856 eyes that completed 5 years follow-up. The proportion of eyes with sustained VA loss of >= 15 letters at 5 years was 22.9% (95% confidence interval [CI], 20.7%-25.1 %) and VA loss of >= 30 letters was 10.8% (95% CI, 9.1 %-12.5%). Factors independently associated with higher incidence of sustained >= 15-letter loss included age >80 years (odds ratio [OR], 1.33 for patients >80 years vs. <= 80 years; 95% CI, 1.05-1.69; P = 0.02), fewer injections (OR, 0.97 per injection; 95% CI, 0.96-0.98; P = 0.0005), and more visits at which the choroidal neovascularization was graded as active (OR, 1.97 for eyes in upper quartile of active visits vs. eyes in lowest quartile of active visits; 95% CI, 1.39-2.79; P = 0.0001). Baseline VA >= 70 letters was associated with reduced risk of sustained >= 30-letter loss (OR, 0.61; 95% CI, 0.38-0.98; P = 0.04). Baseline angiographic lesion criteria were not significantly associated with sustained VA loss.
   Conclusions: Twenty-three percent of eyes with nAMD developed sustained VA loss of >= 15 letters over 5 years of anti-VEGF therapy. Baseline predictors of poor outcomes provide more accurate assessment of the potential benefit from anti-VEGF therapy. (C) 2018 by the American Academy of Ophthalmology
C1 [Chu Luan Nguyen; Gillies, Mark C.; Vuong Nguyen; Daien, Vincent] Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW, Australia.
   [Daien, Vincent] Gui De Chauliac Hosp, Dept Ophthalmol, Montpellier, France.
   [Daien, Vincent] Inserm, U1061, Montpellier, France.
   [Cohn, Amy] Melbourne Retina Associates, East Melbourne, Australia.
   [Cohn, Amy] Armadale Eye Clin, Melbourne, Vic, Australia.
   [Banerjee, Gayatri] Nepean Valley Eye Surg, Nepean, Australia.
   [Arnold, Jennifer] Marsden Eye Specialists, Parramaaa, Australia.
C3 University of Sydney; Universite de Montpellier; CHU de Montpellier;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Montpellier
RP Gillies, MC (通讯作者)，Save Sight Inst, 8 Macquarie St, Sydney, NSW 2000, Australia.
EM mark.gillies@sydney.edu.au
RI DAIEN, Vincent/Z-5516-2019
OI DAIEN, Vincent/0000-0001-5675-0861; Nguyen, Vuong/0000-0001-9070-9803;
   Nguyen, Chu Luan/0000-0002-4630-6182
FU Royal Australian NZ College of Ophthalmologists Eye Foundation; National
   Health and Medical Research Council, Australia; Macular Disease
   Foundation, Australia; Novartis; Bayer
FX Supported by grants from the Royal Australian NZ College of
   Ophthalmologists Eye Foundation (2007-2009), the National Health and
   Medical Research Council, Australia (2010-2012), and the Macular Disease
   Foundation, Australia. Funding was provided by Novartis and Bayer. These
   supporting organizations had no role in the design or conduct of the
   research.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Gillies MC, 2013, INVEST OPHTH VIS SCI, V54, P5754, DOI 10.1167/iovs.13-11993
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   R Core Team. R: A, 2018, LANGUAGE ENV STAT CO
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rough K, 2018, OPHTHALMOLOGY, V125, P1136, DOI 10.1016/j.ophtha.2018.04.034
   Schauwvlieghe AME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153052
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Westborg I, 2017, RETINA-J RET VIT DIS, V37, P2035, DOI 10.1097/IAE.0000000000001431
   Ying GS, 2018, OPHTHALMOL RETINA, V2, P525, DOI 10.1016/j.oret.2017.10.003
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zhu MD, 2015, GRAEF ARCH CLIN EXP, V253, P1217, DOI 10.1007/s00417-014-2799-8
NR 21
TC 21
Z9 21
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2019
VL 126
IS 5
BP 735
EP 742
DI 10.1016/j.ophtha.2018.11.036
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HU0XG
UT WOS:000464995000024
PM 30529685
DA 2022-11-30
ER

PT J
AU Finger, RP
   Guymer, RH
   Gillies, MC
   Keeffe, JE
AF Finger, Robert P.
   Guymer, Robyn H.
   Gillies, Mark C.
   Keeffe, Jill E.
TI The Impact of Anti-Vascular Endothelial Growth Factor Treatment on
   Quality of Life in Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID VISION IMPAIRMENT QUESTIONNAIRE; RASCH ANALYSIS; VISUAL-ACUITY;
   RANIBIZUMAB TREATMENT; RELIABILITY; OUTCOMES; DISEASE
AB Purpose: To assess the impact of anti-vascular endothelial growth factor (VEGF) treatment in routine medical practice on vision-related quality of life (VRQoL) in neovascular age-related macular degeneration (AMD).
   Design: Prospective case series.
   Participants: A total of 169 patients with neovascular AMD undergoing anti-VEGF treatment.
   Methods: The VRQoL interviews at baseline (n = 169), 6 months (n = 138), and 12 months (n = 120), routine anti-VEGF treatment with up to monthly follow-ups, and re-treatment as indicated. The Impact of Vision Impairment (IVI) questionnaire was subjected to Rasch analysis to assess its measurement performance and generate interval-level estimates of VRQoL at all time points, anchoring the instrument to its baseline measurement characteristics. Factors associated with a change in reported VRQoL were assessed using generalized linear regression models.
   Main Outcome Measures: The VRQoL as measured by the IVI using its 3 subscales: Accessing Information, Mobility, and Emotional Well-being.
   Findings: The mean age was 70 years (+/- 6 years standard deviation [SD]); 56% were female. Visual acuity (VA) improved by a mean of 8 letters (+/- 17 SD), and mean retinal thickness decreased by 87 (+/- 89.7) mm with an average of 6.5 (+/- 2.6) injections over 12 months. Those who lost > 2 lines (n -13, 11%) reported worse VRQoL at 12 months on the Accessing Information and Mobility subscales (P = 0.007 and P = 0.050, respectively). Conversely, those who gained > 2 lines (n = 29, 24%) reported better VRQoL on the Accessing Information and Emotional Well-being subscales (P = 0.009 and P = 0.008, respectively). Patients who did not experience a change in VA reported no change in their VRQoL. In multivariate analyses, only a change in VA but not whether the better or worse eye was treated predicted a change in VRQoL on the Accessing Information (P = 0.004) and the Emotional Well-being (P = 0.008) subscales.
   Conclusions: We confirmed that anti-VEGF treatment for neovascular AMD improves patients' VRQoL in those who gain vision and maintains VRQoL in those who maintain VA in their treated eye, irrespective of whether the worse or better eye is treated. Against this background, the best possible outcomes should be aimed for even if the worse eye is treated because a loss of VA in the worse eye will adversely affect patients' VRQoL. (C) 2014 by the American Academy of Ophthalmology.
C1 [Finger, Robert P.; Guymer, Robyn H.; Keeffe, Jill E.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Gillies, Mark C.] Univ Sydney, Save Sight Inst, Sydney, NSW 2006, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Sydney
RP Finger, RP (通讯作者)，Univ Melbourne, Royal Victorian Eye & Ear Hosp, Dept Ophthalmol, Ctr Eye Res Australia, Level 1,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM robertfinger@gmx.net
RI CLIHON, Residencia Medica/K-4896-2013
OI CLIHON, Residencia Medica/0000-0001-6734-2513; Finger, Robert
   P/0000-0003-4253-7597; Guymer, Robyn/0000-0002-9441-4356
FU National Health and Medical Research Council [590205, 1027624, 529905];
   Novartis Australia; German Research Council [DFG FI-1540/5-1]; National
   Health and Medical Research Council (NHMRC) Centre for Clinical Research
   Excellence [529923]
FX Supported in part by the National Health and Medical Research Council
   Grant 590205, funding from Novartis Australia, a German Research Council
   grant to R.P.F. (DFG FI-1540/5-1), and by the National Health and
   Medical Research Council (NHMRC) Centre for Clinical Research Excellence
   Grant 529923, NHMRC project Grants 590205 and 1027624, and NHMRC
   practitioner fellowship (R.H.G., 529905). The Centre for Eye Research
   Australia receives Operational Infrastructure Support from the Victorian
   Government. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR ARDITI A, 1993, INVEST OPHTH VIS SCI, V34, P120
   Bressler NM, 2010, OPHTHALMOLOGY, V117, p747 e4
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Chien TW, 2008, RASCH MEAS T, V22, P1171
   Finger R, 2012, BRIT J OPHTHALMOL, V96, P997, DOI 10.1136/bjophthalmol-2011-301201
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Finger RP, 2012, OPHTHALMOLOGY, V119, P2351, DOI 10.1016/j.ophtha.2012.05.031
   Finger RP, 2011, INVEST OPHTH VIS SCI, V52, P3613, DOI 10.1167/iovs.10-7127
   Garamendi E, 2006, VISION RES, V46, P1375, DOI 10.1016/j.visres.2005.07.007
   Heimes B, 2011, GRAEF ARCH CLIN EXP, V249, P639, DOI 10.1007/s00417-010-1524-5
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Kiser AK, 2005, OPTOMETRY VISION SCI, V82, P946, DOI 10.1097/01.opx.0000187863.12609.7b
   Lamoureux E, 2011, AM J OPHTHALMOL, V151, p195 e2
   Lamoureux EL, 2007, INVEST OPHTH VIS SCI, V48, P1001, DOI 10.1167/iovs.06-0361
   Lamoureux EL, 2006, INVEST OPHTH VIS SCI, V47, P4732, DOI 10.1167/iovs.06-0220
   Lamoureux EL, 2004, AM J OPHTHALMOL, V137, P265, DOI 10.1016/j.ajo.2003.08.003
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Marella M, 2010, INVEST OPHTH VIS SCI, V51, P2878, DOI 10.1167/iovs.09-4494
   Norquist JM, 2004, MED CARE, V42, P25, DOI 10.1097/01.mlr.0000103530.13056.88
   Pesudovs K, 2004, J CATARACT REFR SURG, V30, P1921, DOI 10.1016/j.jcrs.2004.01.033
   Pesudovs K, 2007, OPTOMETRY VISION SCI, V84, P663, DOI 10.1097/OPX.0b013e318141fe75
   Pesudovs Konrad, 2006, BMC Ophthalmol, V6, P25, DOI 10.1186/1471-2415-6-25
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Weih LM, 2002, INVEST OPHTH VIS SCI, V43, P927
   Wright B.D., 2003, RASCH MEASUREMENT T, V17, P905
NR 26
TC 42
Z9 43
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2014
VL 121
IS 6
BP 1246
EP 1251
DI 10.1016/j.ophtha.2013.12.032
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AJ0KG
UT WOS:000337339100017
PM 24518613
DA 2022-11-30
ER

PT J
AU Jelstrup, AB
   Pomares, E
   Navarro, R
AF Bures Jelstrup, Anniken
   Pomares, Esther
   Navarro, Rafael
CA BIOIMAGE Study Grp
TI Relationship between Aflibercept Efficacy and Genetic Variants of Genes
   Associated with Neovascular Age-Related Macular Degeneration: The
   BIOIMAGE Trial
SO OPHTHALMOLOGICA
LA English
DT Article
DE Neovascular age-related macular degeneration; Aflibercept; Vascular
   endothelial growth factor; VEGF pathway
ID GROWTH-FACTOR THERAPY; POLYMORPHISMS; VEGF
AB Purpose: To identify the genetic variants of the vascular endothelial growth factor (VEGF) pathway genes and other genes associated with neovascular age-related macular degeneration (nAMD) as possible predictive biomarkers of a favorable treatment response to aflibercept. Design: A 52-week (with extension phase: 104-week), prospective, open-label, single-arm, multicenter, phase IV trial was conducted in Spain. Participants: Patients with nAMD were enrolled. Methods: Aflibercept was administered every 8 weeks until week 48 (after 1-monthly loading doses over 3 months). After week 48, the interval between visits for aflibercept administration was extended by 2 weeks per visit to a maximum of 12 weeks if no evidence of disease activity was observed. A total of 338 SNPs in 90 genes associated with nAMD were analyzed. Main Outcome Measures: Efficacy was evaluated mainly with best-corrected visual acuity (BCVA), and adverse events (AEs) were reported. Treatment efficacy was defined as an increase in BCVA >= 15 letters versus the baseline visit. Univariate and multivariate logistic regressions were used to associate single-nucleotide polymorphisms (SNPs) and treatment efficacy. Results: 194 nonconsecutive patients were enrolled, 170 completed the 52-week follow-up, and of the 85 patients who started the extension phase, 77 completed this phase. Mean BCVA increased from baseline to weeks 52 and 104 by 9 and 10 letters (p = 0.0001 for both), respectively. The percentages of patients gaining >= 15 letters in weeks 52 and 104 were 33 and 31%, respectively. Multivariate logistic regression showed significant associations of 6 SNPs (in 6 genes) with treatment efficacy: rs12366035 (VEGFB; TT; odds ratio [OR] 217), rs25681 (C5; AA/AG; OR 19.7/8.3), rs17793056 (CX3CR1; CT/CC; OR 8.1/6.2), rs1800775 (CETP; CC; OR 6.6), rs2069845 (IL6; GG/AA; OR 5.6/3.3), and rs13900 (CCL2; CT; OR 4.0). One percent of the patients reported arteriothrombolic events related to aflibercept (cerebrovascular accident) according to the Antiplatelet Trialist Collaboration, and 2% reported serious ocular (retinal pigment epithelial tear, retinal tear, and endophthalmitis) and systemic (cardiac failure, hypersensitivity, and transient ischemic attack) AEs related to aflibercept. Conclusions: Results suggest strong pharmacogenetic associations between one genetic variant of VEGFB (TT, rs12366035) and C5 (AA, rs12366035) genes and the BCVA response after 52-week aflibercept treatment in patients with nAMD. Likewise, the results support the efficacy of aflibercept observed in phase III studies and a good safety profile.
C1 [Bures Jelstrup, Anniken; Navarro, Rafael] Inst Microcirugia Ocular, Fundacio Recerca, Med Retina Dept, Barcelona, Spain.
   [Pomares, Esther] Inst Microcirugia Ocular, Fundacio Recerca, Genet Dept, Barcelona, Spain.
RP Navarro, R (通讯作者)，Inst Microcirugia Ocular, Med Retina Dept, Josep Maria Llado 3, ES-08035 Barcelona, Spain.
EM navarro@imo.es
OI Pomares, Esther/0000-0002-3818-3303; Asencio-Duran,
   Monica/0000-0002-6281-3109
FU Fundacio de Recerca; Institut de Microcirurgia Ocular; Bayer Hispania
   S.L.
FX The trial was sponsored by Fundacio de Recerca, Institut de
   Microcirurgia Ocular, and financially supported by Bayer Hispania S.L.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   Baas DC, 2010, OPHTHALMOLOGY, V117, P500, DOI 10.1016/j.ophtha.2009.08.032
   Boltz A, 2012, OPHTHALMOLOGY, V119, P1615, DOI 10.1016/j.ophtha.2012.02.001
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Chen LJ, 2016, INVEST OPHTH VIS SCI, V57, P1714, DOI 10.1167/iovs.IOVS-15-18677
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   Dugel PU, 2018, INVEST OPHTH VIS SCI, V59
   European Medicines Agency (EMA), 2018, AFL EYL SUMM PROD CH
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Hagstrom SA, 2015, OPHTHALMOLOGY, V122, P1563, DOI 10.1016/j.ophtha.2015.04.024
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hermann MM, 2014, OPHTHALMOLOGY, V121, P905, DOI 10.1016/j.ophtha.2013.10.047
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Ingleheam CF, 2012, INVEST OPHTH VIS SCI, V53, P3325
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Ohnaka M, 2017, CLIN EXP OPHTHALMOL, V45, P30
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Schlottmann PG, 2017, ASIA-PAC J OPHTHALMO, V6, P514, DOI 10.22608/APO.2017258
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Singh RP, 2018, AM J OPHTHAL CLIN TR, V1, DOI 10.25259/AJOCT-2-2018
   Spooner K, 2017, CLIN OPHTHALMOL, V11, P161, DOI 10.2147/OPTH.S125676
   Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/PGS.12.53, 10.2217/pgs.12.53]
NR 27
TC 2
Z9 2
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD DEC
PY 2020
VL 243
IS 6
BP 461
EP 470
DI 10.1159/000508902
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PG4NP
UT WOS:000599714000009
PM 32454495
DA 2022-11-30
ER

PT J
AU Mitchell, W
   Resnick, H
   Zebardast, N
AF Mitchell, William
   Resnick, Hannah
   Zebardast, Nazlee
TI Age-Related Macular Degeneration and Visual and Physical Disability in a
   Nationally Representative Sample from the United States
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; macular degeneration; function
ID QUALITY-OF-LIFE; NUTRITION EXAMINATION SURVEY; MAJOR DEPRESSIVE
   DISORDER; FUNCTIONAL IMPAIRMENT; DIABETIC-RETINOPATHY; VISION LOSS;
   POPULATION; OLDER; PREVALENCE; BLINDNESS
AB Purpose: Outline the association between age-related macular degeneration (AMD) and functional difficulty using novel item response theory (IRT) psychometric techniques, and highlight populations particularly at risk of functional impairment.
   Methods: This cross-sectional study included 5604 US adults. Primary outcomes were item response theory-adjusted visual and physical difficulty scores. Secondary analyses of AMD populations at highest risk of reporting greater functional difficulty were undertaken.
   Results: In total, there were 386 participants with early AMD (mean presenting visual acuity [pVA], 0.12) and 55 with late AMD(mean pVA, 0.35). Those with late AMD reported substantially higher item visual difficulty, whereas those with both early/late AMD reported significantly higher item physical difficulty versus those with no AMD(P < .05). In univariate regression, only those with late AMD reported significantly higher visual difficulty versus those with no AMD (10.1 points [95% confidence interval (CI), 8.2-12.1 points] vs 7.1 points [95% CI, 7.0-7.2 points]; P = .003). Both early/late AMD reported higher physical difficulty versus those with no AMD (11.6 points [95% CI, 11.1-12.1 points; P = .005]; 13.4 points [95% CI, 11.8-15.0 points; P = .03], respectively, versus 11.0 points [95% CI, 10.9-11.1 points]. After adjustment for sociodemographic and medical variables (excluding pVA), only those with late AMD reported significantly greater visual and physical difficulty versus those with no AMD (10.0 points [95% CI, 8.2-11.9 points] vs 7.1 [95% CI, 7.0-7.2 points; P = .002]; and 12.7 points [95% CI, 11.3-14.0 points] vs 11.0 [95% CI, 10.9-11.1 points; P = .02], respectively); greater visual difficulty in those with late AMD persisted after additionally adjusting for pVA versus those with no AMD (9.1 points [95% CI, 7.6-10.6points] vs 7.1points [95% CI, 7.0-7.2 points; P = .01]). Among individuals with AMD, lower income, higher medical comorbidities, depression, and pVA predicted greater visual and physical difficulties.
   Conclusions: AMD confers significant functional difficulty among US adults with sociodemographic characteristics influencing dysfunction; highlighting the value of alternatives to Snellen visual acuity in assessing visual characteristics. With aging populations and the increasing prevalence of AMD, health care professionals should be aware of the functional burden of AMD and recognize those at higher risk of functional difficulty.
   Translational Relevance: Contemporary psychometric validation techniques can be effective in accurately describing the level of functional impairment for those with visual impairment.
C1 [Mitchell, William; Zebardast, Nazlee] Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA.
   [Mitchell, William] Harvard TH Chan Sch Publ Hlth, Boston, MA USA.
   [Resnick, Hannah; Zebardast, Nazlee] Harvard Med Sch, Boston, MA 02115 USA.
C3 Harvard University; Massachusetts Eye & Ear Infirmary; Harvard
   University; Harvard T.H. Chan School of Public Health; Harvard
   University; Harvard Medical School
RP Zebardast, N (通讯作者)，Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA.
EM nazlee_zebardast@meei.harvard.edu
CR Banks LM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189996
   Bayliss Elizabeth A, 2004, Health Qual Life Outcomes, V2, P47, DOI 10.1186/1477-7525-2-47
   Bennion AE, 2012, SOC SCI MED, V75, P976, DOI 10.1016/j.socscimed.2012.04.023
   Bonifay W., 2019, MULTIDIMENSIONAL ITE, V1st
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Casten R, 2008, J VISUAL IMPAIR BLIN, V102, P591, DOI 10.1177/0145482X0810201003
   Casten RJ, 2013, CURR OPIN OPHTHALMOL, V24, P239, DOI 10.1097/ICU.0b013e32835f8e55
   Centers for Disease Control and Prevention, 2015, COMM EYE DIS
   Cheng Q, 2017, OPHTHAL EPIDEMIOL, V24, P413, DOI 10.1080/09286586.2017.1337911
   Cimarolli VR, 2016, CLIN OPHTHALMOL, V10, P55, DOI 10.2147/OPTH.S80489
   Coleman AL, 2010, AM J OPHTHALMOL, V150, P683, DOI 10.1016/j.ajo.2010.05.030
   Columbia Public Health, 2012, IT RESP THEOR POP HL
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Edelen MO, 2007, QUAL LIFE RES, V16, P5, DOI 10.1007/s11136-007-9198-0
   Embretson SusanE., 2013, MULTIVARIATE APPL BO
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gibson DM, 2012, AM J PREV MED, V43, P48, DOI 10.1016/j.amepre.2012.02.028
   Gili M, 2013, CAN J PSYCHIAT, V58, P679, DOI 10.1177/070674371305801205
   Gopinath B, 2014, MATURITAS, V77, P263, DOI 10.1016/j.maturitas.2013.12.001
   Gorsuch R.L., 1983, FACTOR ANAL
   Hammer-Helmich L, 2018, NEUROPSYCH DIS TREAT, V14, P239, DOI 10.2147/NDT.S146098
   Hao G, 2017, CLIN INTERV AGING, V12, P971, DOI 10.2147/CIA.S137993
   Harman H.H., 1976, BOOK MODERN FACTOR A
   Ho CSH, 2014, INT PSYCHOGERIATR, V26, P1221, DOI 10.1017/S1041610214000611
   Inan S, 2019, SAO PAULO MED J, V137, P25, DOI 10.1590/1516-3180.2018.0195071218
   Jacob Louis, 2017, Ger Med Sci, V15, pDoc04, DOI 10.3205/000245
   Kang Hee-Ju, 2015, Chonnam Med J, V51, P8, DOI 10.4068/cmj.2015.51.1.8
   Kim J. O., 1978, FACTOR ANAL STAT MET
   Kim J-O, 1978, INTRO FACTOR ANAL QU
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06
   Loprinzi PD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125394
   Maguire M, 2004, OPHTHALMOLOGY, V111, P1307
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Pondorfer SG, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51769-7
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Roh M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196481
   Ryan A, 2018, J GERONTOL A-BIOL, V73, P1538, DOI 10.1093/gerona/glx251
   Sass DA, 2008, APPL MEAS EDUC, V21, P65, DOI 10.1080/08957340701796415
   Schippert AC, 2018, GERONTOL GERIATR MED, V4, DOI 10.1177/2333721418801601
   Seland JH, 2011, ACTA OPHTHALMOL, V89, P608, DOI 10.1111/j.1755-3768.2009.01794.x
   Skrondal A, 2004, GEN LATENT VARIABLE, V1st, DOI DOI 10.1201/9780203489437
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Spooner KL, 2018, CLIN OPHTHALMOL, V12, P2483, DOI 10.2147/OPTH.S185052
   Uddin S, 2019, BMC MED INFORM DECIS, V19, DOI 10.1186/s12911-019-1004-8
   van Nispen RMA, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-125
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   Weiner DE, 2011, NEPHROL DIAL TRANSPL, V26, P3159, DOI 10.1093/ndt/gfr022
   Willis JR, 2017, JAMA OPHTHALMOL, V135, P926, DOI 10.1001/jamaophthalmol.2017.2553
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Health Organization, 2020, AG REL MAC DEG PRIOR
   Yu F, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.1860
   Zhang XZ, 2013, JAMA OPHTHALMOL, V131, P573, DOI 10.1001/jamaophthalmol.2013.2597
   Zhu ZT, 2019, JAMA OPHTHALMOL, V137, P248, DOI 10.1001/jamaophthalmol.2018.6150
   Zlateva GP, 2007, RETINA-J RET VIT DIS, V27, P1292, DOI 10.1097/01.iae.0000300915.81866.b8
NR 59
TC 2
Z9 2
U1 1
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD DEC
PY 2020
VL 9
IS 13
AR 42
DI 10.1167/tvst.9.13.42
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA QG6UN
UT WOS:000617720000009
PM 33442496
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Schmidt-Erfurth, U
   Eldem, B
   Guymer, R
   Korobelnik, JF
   Schlingemann, RO
   Axer-Siegel, R
   Wiedemann, P
   Simader, C
   Gekkieva, M
   Weichselberger, A
AF Schmidt-Erfurth, Ursula
   Eldem, Bora
   Guymer, Robyn
   Korobelnik, Jean-Francois
   Schlingemann, Reinier O.
   Axer-Siegel, Ruth
   Wiedemann, Peter
   Simader, Christian
   Gekkieva, Margarita
   Weichselberger, Andreas
CA EXCITE Study Grp
TI Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in
   Neovascular Age-related Macular Degeneration: The EXCITE Study
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN; THERAPY; ANTIGEN
AB Objective: To demonstrate noninferiority of a quarterly treatment regimen to a monthly regimen of ranibizumab in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
   Design: A 12-month, multicenter, randomized, double-masked, active-controlled, phase IIIb study.
   Participants: Patients with primary or recurrent subfoveal CNV secondary to AMD (353 patients), with predominantly classic, minimally classic, or occult (no classic component) lesions.
   Intervention: Patients were randomized (1:1:1) to 0.3 mg quarterly, 0.5 mg quarterly, or 0.3 mg monthly doses of ranibizumab. Treatment comprised of a loading phase (3 consecutive monthly injections) followed by a 9-month maintenance phase (either monthly or quarterly injection).
   Main Outcome Measures: Mean change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline to month 12 and the incidence of adverse events (AEs).
   Results: In the per-protocol population (293 patients), BCVA, measured by Early Treatment Diabetic Retinopathy Study-like charts, increased from baseline to month 12 by 4.9, 3.8, and 8.3 letters in the 0.3 mg quarterly (104 patients), 0.5 mg quarterly (88 patients), and 0.3 mg monthly (101 patients) dosing groups, respectively. Similar results were observed in the intent-to-treat (ITT) population (353 patients). The mean decrease in CRT from baseline to month 12 in the ITT population was -96.0 mu m in 0.3 mg quarterly, -105.6 mu m in 0.5 mg quarterly, and -105.3 mu m in 0.3 mg monthly group. The most frequent ocular AEs were conjunctival hemorrhage (17.6%, pooled quarterly groups; 10.4%, monthly group) and eye pain (15.1%, pooled quarterly groups; 20.9%, monthly group). There were 9 ocular serious AEs and 3 deaths; 1 death was suspected to be study related (cerebral hemorrhage; 0.5 mg quarterly group). The incidences of key arteriothromboembolic events were low.
   Conclusions: After 3 initial monthly ranibizumab injections, both monthly (0.3 mg) and quarterly (0.3 mg/0.5 mg) ranibizumab treatments maintained BCVA in patients with CNV secondary to AMD. At month 12, BCVA gain in the monthly regimen was higher than that of the quarterly regimens. The noninferiority of a quarterly regimen was not achieved with reference to 5.0 letters. The safety profile was similar to that reported in prior ranibizumab studies.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2011; 118: 831-839 (C) 2011 by the American Academy of Ophthalmology.
C1 [Schmidt-Erfurth, Ursula] Univ Vienna, Dept Ophthalmol, A-1090 Vienna, Austria.
   [Eldem, Bora] Hacettepe Univ, Fac Med, TR-06100 Ankara, Turkey.
   [Guymer, Robyn] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Korobelnik, Jean-Francois] Hop Pellegrin, F-33076 Bordeaux, France.
   [Schlingemann, Reinier O.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands.
   [Axer-Siegel, Ruth] Rabin Med Ctr, Petah Tiqwa, Israel.
   [Wiedemann, Peter] Univ Leipzig, Klin & Poliklin Augenheilkunde, Leipzig, Germany.
   [Simader, Christian] Med Univ Vienna, Dept Ophthalmol, Vienna Reading Ctr, Vienna, Austria.
   [Gekkieva, Margarita; Weichselberger, Andreas] Novartis Pharma AG, Basel, Switzerland.
C3 University of Vienna; Hacettepe University; Centre for Eye Research
   Australia; Royal Victorian Eye & Ear Hospital; University of Melbourne;
   CHU Bordeaux; University of Amsterdam; Academic Medical Center
   Amsterdam; Rabin Medical Center; Leipzig University; Medical University
   of Vienna; Novartis
RP Schmidt-Erfurth, U (通讯作者)，Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
RI KOROBELNIK, Jean-Francois/A-5448-2016
OI Guymer, Robyn/0000-0002-9441-4356; Simader,
   Christian/0000-0002-1784-2883; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311
FU Novartis Pharmaceutical Corporation; Novartis Pharma, AG, Switzerland
FX Peter Wiedemann - Lecture Fee - Novartis Pharmaceutical Corporation;
   Supported by Novartis Pharma, AG, Switzerland.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Waisbourd M, 2007, DRUG AGING, V24, P643, DOI 10.2165/00002512-200724080-00003
NR 13
TC 295
Z9 318
U1 1
U2 25
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2011
VL 118
IS 5
BP 831
EP 839
DI 10.1016/j.ophtha.2010.09.004
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 757MM
UT WOS:000290090300007
PM 21146229
DA 2022-11-30
ER

PT J
AU Nguyen, QD
   Das, A
   Do, DV
   Dugel, PU
   Gomes, A
   Holz, FG
   Koh, A
   Pan, CK
   Sepah, YJ
   Patel, N
   MacLeod, H
   Maurer, P
AF Quan Dong Nguyen
   Das, Arup
   Do, Diana, V
   Dugel, Pravin U.
   Gomes, Andre
   Holz, Frank G.
   Koh, Adrian
   Pan, Carolyn K.
   Sepah, Yasir J.
   Patel, Nikhil
   MacLeod, Heather
   Maurer, Patrik
TI Brolucizumab: Evolution through Preclinical and Clinical Studies and the
   Implications for the Management of Neovascular Age-Related Macular
   Degeneration
SO OPHTHALMOLOGY
LA English
DT Review
ID SINGLE-CHAIN FV; CHOROIDAL NEOVASCULARIZATION; PATIENT PREFERENCES;
   RANIBIZUMAB; AFLIBERCEPT; PENETRATION; CONBERCEPT; FRAGMENTS; OUTCOMES
AB Improving or maintaining visual acuity is the main goal for the treatment of neovascular age-related macular degeneration (nAMD). Current nAMD standard of care dictates frequent intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) injections, which places a substantial burden on patients, caregivers, and physicians. Brolucizumab, a newly developed anti-VEGF molecule for nAMD treatment, has demonstrated longer durability and improvement in visual and anatomic outcomes in clinical studies in a q12-week regimen, indicating its potential to reduce treatment burden as an important therapeutic tool in nAMD management. This review focuses on the development of brolucizumab and the preclinical and clinical studies evaluating its efficacy, tolerability, and safety. Brolucizumab (also known as "RTH258" and "ESBA1008") is a humanized, single-chain variable fragment (scFv) antibody with a molecular mass of approximately 26 kDa that inhibits VEGF-A. Preclinical studies show that brolucizumab readily penetrates the retina to reach the retinal pigment epithelium (RPE)/choroid with minimal subsequent systemic exposure. The safety, tolerability, and efficacy of a single IVT brolucizumab administration in patients with treatment-naive nAMD were first demonstrated in the SEE Phase 1/2 study. The OSPREY Phase 2 study showed brolucizumab to be as efficacious as aflibercept in a q8-week regimen with regard to best-corrected visual acuity (BCVA) and brolucizumab achieving greater fluid resolution. Brolucizumabtreated patients in the OSPREY study were subsequently challenged with a q12-week dosing interval, and the outcomes provided key information for the study design and end points of the Phase 3 studies. In the HAWK and HARRIER Phase 3 studies, after 3 monthly loading injections, brolucizumab treatment regimen (q12-week or q8-week) was guided by individual disease activity assessment using functional and anatomic parameters (central subfield thickness [CST], intraretinal fluid [IRF], or subretinal fluid [SRF]) versus aflibercept (q8-week). Fewer brolucizumab 6-mg treated eyes had disease activity versus aflibercept, and anatomic outcome results at weeks 16 and 48 demonstrate brolucizumab as a potent drying agent. Moreover, of patients treated with 6 mg brolucizumab, 55.6% and 51.0% maintained a q12-week dosing interval immediately after the loading phase until week 48 in HAWK and HARRIER, respectively. These Phase 3 studies demonstrated that the brolucizumab q12week regimen maintains efficacy and safety while reducing treatment burden associated with regular IVT injections for patients with nAMD. (C) 2020 by the American Academy of Ophthalmology.
C1 [Quan Dong Nguyen; Do, Diana, V; Pan, Carolyn K.; Sepah, Yasir J.] Stanford Univ, Sch Med, Byers Eye Inst, 2370 Watson Court,Suite 200, Palo Alto, CA 94303 USA.
   [Das, Arup] Univ New Mexico, Sch Med, Dept Surg, Div Ophthalmol, Albuquerque, NM 87131 USA.
   [Dugel, Pravin U.] Univ Southern Calif, Keck Sch Med, USC Roski Eye Inst, Los Angeles, CA 90007 USA.
   [Gomes, Andre] Univ Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Koh, Adrian] Camden Med Ctr, Eye & Retina Surg, Singapore, Singapore.
   [Patel, Nikhil] Novartis Pharmaceut, E Hanover, NJ USA.
   [MacLeod, Heather] Novartis, Novartis Inst Biomed Res, Cambridge, MA USA.
   [Maurer, Patrik] Novartis, Novartis Inst Biomed Res, Basel, Switzerland.
C3 Stanford University; University of New Mexico; University of Southern
   California; Universidade de Sao Paulo; University of Bonn; Novartis;
   Novartis; Novartis
RP Nguyen, QD (通讯作者)，Stanford Univ, Sch Med, Byers Eye Inst, 2370 Watson Court,Suite 200, Palo Alto, CA 94303 USA.
EM ndquan@stanford.edu
OI Pan, Carolyn/0000-0002-1031-7488
CR [Anonymous], 2010, J BIOL CHEM, DOI DOI 10.1074/JBC.M109.072876
   [Anonymous], 2017, OPHTHALMOLOGY, DOI DOI 10.1016/J.OPHTHA.2017.03.057
   [Anonymous], 2011, OPHTHAL PHYSL OPT, DOI DOI 10.1111/J.1475-1313.2011.00848.X
   [Anonymous], 2001, FEBS LETT
   [Anonymous], 2020, OPHTHALMOLOGY, DOI DOI 10.1016/J.OPHTHA.2019.04.017
   [Anonymous], 2016, OPHTHALMOLOGY, DOI DOI 10.1016/J.OPHTHA.2016.03.045
   [Anonymous], 2017, EYLEA SUMM PROD CHAR
   [Anonymous], 2017, CLIN INTERV AGING, DOI DOI 10.2147/CIA.S143508
   [Anonymous], 2000, ARCH GERONTOL GERIAT
   [Anonymous], 2016, OPHTHALMOLOGY, DOI DOI 10.1016/J.OPHTHA.2015.12.001
   [Anonymous], 2014, AM J OPHTHALMOL, DOI DOI 10.1016/J.AJO.2014.05.014
   [Anonymous], 2019, RETINA J RET VIT DIS, DOI DOI 10.1097/IAE.0000000000002299
   [Anonymous], 2018, LANCET
   [Anonymous], 2017, RETINA J RET VIT DIS
   [Anonymous], 2018, CLIN OPHTHALMOL, DOI DOI 10.2147/OPTH.S151611
   [Anonymous], 2016, OPHTHALMOLOGY, DOI DOI 10.1016/J.OPHTHA.2015.12.030
   [Anonymous], 2005, INVEST OPHTH VIS SCI, DOI DOI 10.1167/IOVS.04-0601
   [Anonymous], 2002, CLIN EXP IMMUNOL
   [Anonymous], 2019, RETINA J RET VIT DIS, DOI DOI 10.1097/IAE.0000000000002152
   [Anonymous], 2018, EYE, DOI DOI 10.1038/EYE.2017.187
   [Anonymous], 2018, J OCUL PHARMACOL TH, DOI DOI 10.1089/JOP.2018.0062
   [Anonymous], 2017, ASIA PAC J OPHTHALMO, DOI DOI 10.22608/APO.2017263
   [Anonymous], 2003, J CELL PHYSIOL, DOI DOI 10.1002/JCP.10246
   [Anonymous], 2017, SURV OPHTHALMOL, DOI DOI 10.1016/J.SURVOPHTHAL.2017.03.004
   [Anonymous], 2019, AM J OPHTHALMOL, DOI DOI 10.1016/J.AJO.2018.08.026
   [Anonymous], 2018, CLIN INTERV AGING, DOI DOI 10.2147/CIA.S151225
   Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Baxter JM, 2016, EYE, V30, P698, DOI 10.1038/eye.2016.18
   Berger B, 2015, 48 ANN SCI M RET SOC
   Berger B, 2015, ANN M ASS RES VIS OP
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2016, OPHTHALMOLOGY, V123, pS78, DOI 10.1016/j.ophtha.2016.04.056
   Chexal S, 2016, RETINA TODAY, P72
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Daniel E, 2017, OPHTHALMOL RETINA, V1, P25
   de Oliveira Dias Joao Rafael, 2016, Int J Retina Vitreous, V2, P3, DOI 10.1186/s40942-016-0026-y
   Escher D, 2015, EUR SOC RET SPEC EUR
   EYLEA, 2019, EYLEA AFL INJ INTR I
   Fernandes CFC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00653
   Frank RN, 2000, T AM OPHTHALMOL SOC, V98, P109
   Gaudreault J, 2012, ANN M ASS RES VIS OP
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Nimz EL, 2016, ANN M ASS RES VIS OP
   O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188
   Regillo C., 2018, OCULAR SURG NEWS
   Roh M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196481
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schippert AC, 2018, GERONTOL GERIATR MED, V4, DOI 10.1177/2333721418801601
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Shibuya Masabumi, 2011, Genes Cancer, V2, P1097, DOI 10.1177/1947601911423031
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Tietz J, 2015, ANN M ASS RES VIS OP
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
   YOKOTA T, 1992, CANCER RES, V52, P3402
   Zhang JX, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0807-1
NR 63
TC 69
Z9 70
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2020
VL 127
IS 7
BP 963
EP 976
DI 10.1016/j.ophtha.2019.12.031
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ND9OC
UT WOS:000562228700023
PM 32107066
OA hybrid
DA 2022-11-30
ER

PT J
AU Nguyen, QD
   Schachar, RA
   Nduaka, CI
   Sperling, M
   Klamerus, KJ
   Chi-Burris, K
   Yan, E
   Paggiarino, DA
   Rosenblatt, I
   Aitchison, R
   Erlich, SS
AF Quan Dong Nguyen
   Schachar, Ronald A.
   Nduaka, Chudy I.
   Sperling, Marvin
   Klamerus, Karen J.
   Chi-Burris, Katherine
   Yan, Eric
   Paggiarino, Dario A.
   Rosenblatt, Irit
   Aitchison, Roger
   Erlich, Shai S.
CA MONET Clinical Study Grp
TI Evaluation of the siRNA PF-04523655 versus Ranibizumab for the Treatment
   of Neovascular Age-related Macular Degeneration (MONET Study)
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; INDUCED
   RETINOPATHY; ANGIOGENESIS; SUPPRESSION; TARGET; INHIBITION; PROTEINS;
   RECEPTOR; RTP801
AB Objective: To evaluate the efficacy of different dosing paradigms of PF-04523655 (PF) versus ranibizumab (comparator) in subjects with neovascular age-related macular degeneration (AMD).
   Design: Multicenter, open-label, prospective, randomized, comparator-controlled exploratory study.
   Participants: A total of 151 patients with subfoveal choroidal neovascularization (CNV) secondary to neovascular AMD who were naive to AMD therapy.
   Methods: In this phase 2 study, patients were randomized to 1 of 5 treatment groups with equal ratio. All groups received ranibizumab 0.5 mg at baseline and (a) PF 1 mg every 4 weeks (Q4W) from week 4 to week 12; (b) PF 3 mg Q4W from week 4 to week 12; (c) PF 3 mg every 2 weeks (Q2W) from week 4 to week 12; (d) PF 1 mg + ranibizumab (combination) Q4W from baseline to week 12; and (e) ranibizumab Q4W to week 12. All study treatments were given as intravitreal injections.
   Main Outcome Measures: The primary end point was the mean change in best-corrected visual acuity (BCVA) from baseline at week 16; secondary end points included the percentage of patients gaining >= 10 and >= 15 letters in BCVA and mean change in retinal central subfield thickness, lesion thickness, and CNV area.
   Results: At week 16, the PF 1 mg + ranibizumab combination group achieved numerically greater improvement in mean BCVA from baseline (9.5 letters) than the ranibizumab group (6.8 letters). The difference was not statistically significant. The BCVA improvement in the PF monotherapy groups was less than in the ranibizumab group. Similar trends were observed in the percentage of patients who gained >= 10 and >= 15 letters. From baseline to week 16 (last observed carried forward), the combination and ranibizumab groups had similar mean reductions in central subfield retinal thickness and total CNV area, which were greater than in all PF monotherapy groups. There were no clinically meaningful differences in reduction of lesion thickness among treatment groups.
   Conclusions: In this early, underpowered study evaluating treatments for neovascular AMD, the combination of PF with ranibizumab led to an average gain in BCVA that was more than with ranibizumab monotherapy. No safety concerns were identified.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2012; 119: 1867-1873 (C) 2012 by the American Academy of Ophthalmology.
C1 [Schachar, Ronald A.; Nduaka, Chudy I.; Sperling, Marvin; Klamerus, Karen J.; Chi-Burris, Katherine; Yan, Eric; Paggiarino, Dario A.] Pfizer Inc, San Diego, CA 92121 USA.
   [Quan Dong Nguyen] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
   [Rosenblatt, Irit] Rabin Med Ctr, Petach Tikava, Israel.
   [Aitchison, Roger; Erlich, Shai S.] Quark Pharmaceut Inc, Fremont, CA USA.
C3 Pfizer; Johns Hopkins University; Johns Hopkins Medicine; Rabin Medical
   Center
RP Schachar, RA (通讯作者)，Pfizer Inc, 10646 Sci Ctr Dr CB10-2109, San Diego, CA 92121 USA.
EM ronald.schachar@pfizer.com
FU Pfizer, Inc., San Diego, California
FX Supported by Pfizer, Inc., San Diego, California.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Brafman A, 2004, INVEST OPHTH VIS SCI, V45, P3796, DOI 10.1167/iovs.04-0052
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Corradetti MN, 2005, J BIOL CHEM, V280, P9769, DOI 10.1074/jbc.C400557200
   Dumont FJ, 1995, LIFE SCI, V58, P373, DOI 10.1016/0024-3205(95)02233-3
   FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008
   Kawai T, 2008, ANN NY ACAD SCI, V1143, P1, DOI 10.1196/annals.1443.020
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kleinman ME, 2012, MOL THER, V20, P101, DOI 10.1038/mt.2011.212
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee MH, 2004, PHARM RES-DORDR, V21, P736, DOI 10.1023/B:PHAM.0000026421.09367.b3
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Robbins M, 2009, OLIGONUCLEOTIDES, V19, P89, DOI 10.1089/oli.2009.0180
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815
   Shiose S, 2011, J BIOL CHEM, V286, P15543, DOI 10.1074/jbc.M111.228551
   Tolentino MJ, 2002, AM J OPHTHALMOL, V133, P373, DOI 10.1016/S0002-9394(01)01381-2
NR 22
TC 53
Z9 57
U1 1
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2012
VL 119
IS 9
BP 1867
EP 1873
DI 10.1016/j.ophtha.2012.03.043
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 030OY
UT WOS:000310581200022
PM 22683252
DA 2022-11-30
ER

PT J
AU Evans, JR
   Lawrenson, JG
AF Evans, Jennifer R.
   Lawrenson, John G.
TI Antioxidant vitamin andmineral supplements for preventing age-related
   macular degeneration (Review)
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE Dietary Supplements; Antioxidants [*administration & dosage]; Macular
   Degeneration [*prevention & control]; Minerals [administration &
   dosage]; Randomized Controlled Trials as Topic; Vitamins
   [*administration & dosage]; alpha-Tocopherol [administration & dosage];
   beta Carotene [administration & dosage]; Humans
ID BETA-CAROTENE SUPPLEMENTATION; LOW-DOSE ASPIRIN; RANDOMIZED
   CONTROLLED-TRIAL; BASE-LINE CHARACTERISTICS; LONG-TERM SUPPLEMENTATION;
   CONTROLLED CLINICAL-TRIAL; KILLER-CELL ACTIVITY; ALPHA-TOCOPHEROL;
   CARDIOVASCULAR-DISEASE; PHYSICIANS HEALTH
AB Background
   There is inconclusive evidence fromobservational studies to suggest that people who eat a diet rich in antioxidant vitamins (carotenoids, vitamins C, and E) or minerals (selenium and zinc) may be less likely to develop age-related macular degeneration (AMD).
   Objectives
   To determine whether or not taking antioxidant vitamin or mineral supplements, or both, prevent the development of AMD.
   Search methods
   We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2017, Issue 2), MEDLINE Ovid (1946 to 29 March 2017), Embase Ovid (1947 to 29 March 2017), AMED (Allied and Complementary Medicine Database) (1985 to 29 March 2017), OpenGrey (System for Information on Grey Literature in Europe) ( www. opengrey.eu/);searched 29 March 2017, the ISRCTN registry (www. isrctn. com/editAdvancedSearch); searched 29 March 2017, ClinicalTrials. gov (www. clinicaltrials.gov); searched 29 March 2017 and the WHO International Clinical Trials Registry Platform (ICTRP) (www. who. int/ictrp/search/en); searched 29 March 2017. We did not use any date or language restrictions in the electronic searches for trials.
   Selection criteria
   We included all randomised controlled trials (RCTs) comparing an antioxidant vitamin ormineral supplement (alone or in combination) to control.
   Data collection and analysis
   Both review authors independently assessed risk of bias in the included studies and extracted data. One author entered data into RevMan 5; the other author checked the data entry. We pooled data using a fixed-effect model. We graded the certainty of the evidence using GRADE.
   Main results
   We included a total of five RCTs in this review with data available for 76,756 people. The trials were conducted in Australia, Finland, and the USA, and investigated vitamin C, vitamin E, beta-carotene, and multivitamin supplements. All trials were judged to be at low risk of bias.
   Four studies reported the comparison of vitamin E with placebo. Average treatment and follow-up duration ranged from 4 to 10 years. Data were available for a total of 55,614 participants. There was evidence that vitamin E supplements do not prevent the development of any AMD (risk ratio (RR) 0.97, 95% confidence interval (CI) 0.90 to 1.06; high-certainty evidence), and may slightly increase the risk of late AMD (RR 1.22, 95% CI 0.89 to 1.67; moderate-certainty evidence) compared with placebo. Only one study (941 participants) reported data separately for neovascular AMD and geographic atrophy. There were 10 cases of neovascular AMD (RR 3.62, 95% CI 0.77 to 16.95; very low-certainty evidence), and four cases of geographic atrophy (RR 2.71, 95% CI 0.28 to 26.0; very low-certainty evidence). Two trials reported similar numbers of adverse events in the vitamin E and placebo groups. Another trial reported excess of haemorrhagic strokes in the vitamin E group (39 versus 23 events, hazard ratio 1.74, 95% CI 1.04 to 2.91, lowcertainty evidence).
   Two studies reported the comparison of beta-carotene with placebo. These studies took place in Finland and the USA. Both trials enrolled men only. Average treatment and follow-up duration was 6 years and 12 years. Data were available for a total of 22,083 participants. There was evidence that beta-carotene supplements did not prevent any AMD (RR 1.00, 95% CI 0.88 to 1.14; highcertainty evidence) nor have an important effect on late AMD (RR 0.90, 95% CI 0.65 to 1.24; moderate-certainty evidence). Only one study (941 participants) reported data separately for neovascular AMD and geographic atrophy. There were 10 cases of neovascular AMD (RR 0.61, 95% CI 0.17 to 2.15; very low-certainty evidence) and 4 cases of geographic atrophy (RR 0.31 95% CI 0.03 to 2.93; very low-certainty evidence). Beta-carotene was associated with increased risk of lung cancer in people who smoked.
   One study reported the comparison of vitamin C with placebo, and multivitamin (Centrum Silver) versus placebo. This was a study in men in the USA with average treatment duration and follow-up of 8 years for vitamin C and 11 years for multivitamin. Data were available for a total of 14,236 participants. AMD was assessed by self-report followed by medical record review. There was evidence that vitamin C supplementation did not prevent any AMD (RR 0.96, 95% CI 0.79 to 1.18; high-certainty evidence) or late AMD (RR 0.94, 0.61 to 1.46; moderate-certainty evidence). There was a slight increased risk of any AMD (RR 1.21, 95% CI 1.02 to 1.43; moderate-certainty evidence) and late AMD (RR 1.22, 95% CI 0.88 to 1.69; moderate-certainty evidence) in the multivitamin group. Neovascular AMD and geographic atrophy were not reported separately.
   Adverse effects were not reported but there was possible increased risk of skin rashes in the multivitamin group. Adverse effects were not consistently reported in these eye studies, but there is evidence from other large studies that beta-carotene increases the risk of lung cancer in people who smoke or who have been exposed to asbestos.
   None of the studies reported quality of life or resource use and costs.
   Authors' conclusions
   Taking vitamin E or beta-carotene supplements will not prevent or delay the onset of AMD. The same probably applies to vitamin C and the multivitamin (Centrum Silver) investigated in the one trial reported to date. There is no evidence with respect to other antioxidant supplements, such as lutein and zeaxanthin. Although generally regarded as safe, vitamin supplements may have harmful effects, and clear evidence of benefit is needed before they can be recommended. People with AMD should see the related Cochrane Review on antioxidant vitamin and mineral supplements for slowing the progression of AMD, written by the same review team.
C1 [Evans, Jennifer R.] London Sch Hyg & Trop Med, Cochrane Eyes & Vis, ICEH, Keppel St, London WC1E 7HT, England.
   [Lawrenson, John G.] City Univ London, Sch Hlth Sci, Ctr Appl Vis Res, London, England.
C3 University of London; London School of Hygiene & Tropical Medicine; City
   University London
RP Evans, JR (通讯作者)，London Sch Hyg & Trop Med, Cochrane Eyes & Vis, ICEH, Keppel St, London WC1E 7HT, England.
EM jennifer.evans@lshtm.ac.uk
OI Lawrenson, John/0000-0002-2031-6390
FU National Institute for Health Research (NIHR), UK; Department of Health
   through the award; NIHR, via Cochrane Infrastructure funding
FX External sources; National Institute for Health Research (NIHR), UK.;
   Richard Wormald, Co-ordinating Editor for Cochrane Eyes and Vision (CEV)
   acknowledges financial support for his CEV research sessions from the
   Department of Health through the award made by the NIHR to Moorfields
   Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for
   a Specialist Biomedical Research Centre for Ophthalmology.; This review
   was supported by the NIHR, via Cochrane Infrastructure funding to the
   CEV UK editorial base which funds part of Jennifer Evans's salary.
CR Albanes D, 1996, J NATL CANCER I, V88, P1560, DOI 10.1093/jnci/88.21.1560
   ALBANES D, 1995, AM J CLIN NUTR, V62, P1427, DOI 10.1093/ajcn/62.6.1427S
   Albanes D, 1997, AM J CLIN NUTR, V66, P366, DOI 10.1093/ajcn/66.2.366
   Albanes D, 1986, J NUTR GROWTH CANCER, V3, P207
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Ambler J S, 1995, Ophthalmic Epidemiol, V2, P137, DOI 10.3109/09286589509057095
   ANDREWS J, 1969, BRIT MED J, V2, P416, DOI 10.1136/bmj.2.5654.416
   [Anonymous], 1994, Ann Epidemiol, V4, P1, DOI 10.1016/1047-2797(94)90036-1
   BENNER SE, 1994, SEMIN HEMATOL, V31, P26
   BENTON D, 1995, PSYCHOPHARMACOLOGY, V117, P298, DOI 10.1007/BF02246104
   Berger K, 1996, STROKE, V27, P238, DOI 10.1161/01.STR.27.2.238
   Berrow EJ, 2016, DOC OPHTHALMOL, V132, P123, DOI 10.1007/s10633-016-9532-3
   BERSON EL, 1993, ARCH OPHTHALMOL-CHIC, V111, P761, DOI 10.1001/archopht.1993.01090060049022
   Bjelakovic G, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD007176.pub2, 10.1590/1516-3180.20151332T1]
   Blok WL, 1997, EUR J CLIN INVEST, V27, P1003, DOI 10.1046/j.1365-2362.1997.2240775.x
   BLUMBERG J, 1994, NUTR REV, V52, P242, DOI 10.1111/j.1753-4887.1994.tb01430.x
   BOGDEN JD, 1990, J AM COLL NUTR, V9, P214
   Bone RA, 2010, ARCH BIOCHEM BIOPHYS, V504, P50, DOI 10.1016/j.abb.2010.06.019
   Brewer GJ, 1997, J LAB CLIN MED, V129, P649, DOI 10.1016/S0022-2143(97)90200-6
   Brown BG, 1998, CAN J CARDIOL, V14, p6A
   Bunce C, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-58
   Buring J E, 1994, Ann Epidemiol, V4, P75
   BURING JE, 1995, ARCH NEUROL-CHICAGO, V52, P129, DOI 10.1001/archneur.1995.00540260031012
   BURING JE, 1990, STAT MED, V9, P29, DOI 10.1002/sim.4780090109
   Buring Julie E., 1994, Annals of Epidemiology, V4, P111
   BUSSEY HJR, 1982, CANCER, V50, P1434, DOI 10.1002/1097-0142(19821001)50:7<1434::AID-CNCR2820500733>3.0.CO;2-F
   Cairns J, 1991, Ann Epidemiol, V1, P395
   Caligiuri MP, 1997, PSYCHOPHARMACOLOGY, V132, P61, DOI 10.1007/s002130050320
   Camargo CA, 1997, CIRCULATION, V95, P577, DOI 10.1161/01.CIR.95.3.577
   CHANDRA RK, 1992, LANCET, V340, P1124, DOI 10.1016/0140-6736(92)93151-C
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Christen W G, 1998, Ophthalmic Epidemiol, V5, P133, DOI 10.1076/opep.5.3.133.8368
   Christen WG, 1999, AM J EPIDEMIOL, V149, P476, DOI 10.1093/oxfordjournals.aje.a009836
   Christen WG, 1996, ANN EPIDEMIOL, V6, P60, DOI 10.1016/1047-2797(95)00094-1
   CHRISTEN WG, 1992, JAMA-J AM MED ASSOC, V268, P989
   Christen WG, 2000, ANN EPIDEMIOL, V10, P125, DOI 10.1016/S1047-2797(99)00042-3
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Christen WG, 2007, ARCH OPHTHALMOL-CHIC, V125, P333, DOI 10.1001/archopht.125.3.333
   Christen WG, 2012, OPHTHALMOLOGY, V119, P1642, DOI 10.1016/j.ophtha.2012.01.053
   Christen WG, 2010, OPHTHALMOLOGY, V117, P1163, DOI 10.1016/j.ophtha.2009.10.043
   Chylack L T Jr, 1995, Ophthalmic Epidemiol, V2, P59, DOI 10.3109/09286589509057085
   Cianfriglia F, 1994, Minerva Stomatol, V43, P255
   Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957
   CLAUSEN J, 1989, BIOL TRACE ELEM RES, V20, P135, DOI 10.1007/BF02919106
   Constans J, 1996, CLIN INFECT DIS, V23, P654, DOI 10.1093/clinids/23.3.654
   Cook NR, 2005, JAMA-J AM MED ASSOC, V294, P47, DOI 10.1001/jama.294.1.47
   COSTANTINO JP, 1988, AM J CLIN NUTR, V48, P1277, DOI 10.1093/ajcn/48.5.1277
   Cucinotta D, 1994, J NEUROL, V241, pS129
   de Klerk NH, 1998, INT J CANCER, V75, P362, DOI 10.1002/(SICI)1097-0215(19980130)75:3&lt;362::AID-IJC6&gt;3.0.CO;2-0
   DECOSSE JJ, 1989, JNCI-J NATL CANCER I, V81, P1290, DOI 10.1093/jnci/81.17.1290
   DOBSON HM, 1984, SCOT MED J, V29, P176, DOI 10.1177/003693308402900308
   Evans JR, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub2
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Evans JR, 2017, COCHRANE DB SYST REV, DOI [10.1002/ 14651858. CD000254. pub4, DOI 10.1002/14651858.CD000254.PUB4]]
   Evans JR, 2012, COCHRANE DB SYST REV, DOI [10.1002/ 14651858. CD000253. pub3, DOI 10.1002/14651858.CD000253.PUB3]]
   Evans JR, 1994, COCHRANE DB SYST REV, DOI [10.1002/ 14651858. CD000253, DOI 10.1002/14651858.CD000253]]
   Fairley CK, 1996, INT J GYNECOL CANCER, V6, P225, DOI 10.1046/j.1525-1438.1996.06030225.x
   Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995
   FONTHAM ETH, 1995, CANCER EPIDEM BIOMAR, V4, P801
   Fotouhi N, 1996, AM J CLIN NUTR, V63, P553, DOI 10.1093/ajcn/63.4.553
   Gail MH, 1998, CONTROL CLIN TRIALS, V19, P352, DOI 10.1016/S0197-2456(98)00016-6
   Galan P, 1997, INT J VITAM NUTR RES, V67, P450
   GANN PH, 1993, JNCI-J NATL CANCER I, V85, P1220, DOI 10.1093/jnci/85.15.1220
   Garewal H, 1995, P AN M AM SOC CLIN, V14, pA1623
   Garrett S K, 1999, Ophthalmic Epidemiol, V6, P195, DOI 10.1076/opep.6.3.195.1500
   Gaziano JM, 2012, JAMA-J AM MED ASSOC, V308, P1871, DOI 10.1001/jama.2012.14641
   Gaziano JM, 2009, JAMA-J AM MED ASSOC, V301, P52, DOI 10.1001/jama.2008.862
   Gerstein HC, 1996, DIABETES CARE, V19, P1225, DOI 10.2337/diacare.19.11.1225
   Girodon F, 1997, J AM COLL NUTR, V16, P357, DOI 10.1080/07315724.1997.10718698
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   GLYNN RJ, 1995, ARCH OPHTHALMOL-CHIC, V113, P1131, DOI 10.1001/archopht.1995.01100090057023
   Glynn SA, 1996, CANCER CAUSE CONTROL, V7, P214, DOI 10.1007/BF00051297
   GRADE Working Group McMaster University, 2014, GRADEPRO VERS
   GREENBERG ER, 1990, NEW ENGL J MED, V323, P789, DOI 10.1056/NEJM199009203231204
   GREENBERG ER, 1989, CONTROL CLIN TRIALS, V10, P153
   GREENBERG ER, 1994, NEW ENGL J MED, V331, P141, DOI 10.1056/NEJM199407213310301
   GUALLAR E, 1995, J AM COLL CARDIOL, V25, P387, DOI 10.1016/0735-1097(94)00370-6
   Hartman TJ, 1998, CANCER EPIDEM BIOMAR, V7, P335
   HEBERT PR, 1993, CIRCULATION, V88, P1437, DOI 10.1161/01.CIR.88.4.1437
   Heinonen OP, 1998, J NATL CANCER I, V90, P440, DOI 10.1093/jnci/90.6.440
   HENNEKENS CH, 1985, PREV MED, V14, P165, DOI 10.1016/0091-7435(85)90031-3
   Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801
   HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301
   Hercberg S, 1998, INT J VITAM NUTR RES, V68, P3
   Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049
   Huang HY, 2006, ANN INTERN MED, V145, P372, DOI 10.7326/0003-4819-145-5-200609050-00135
   Hubbard LD, 2008, INVEST OPHTH VIS SCI, V49, P3269, DOI 10.1167/iovs.07-1267
   Johnson MA, 1997, NUTR REV, V55, P400, DOI 10.1111/j.1753-4887.1997.tb01582.x
   Jyothirmayi R, 1996, ORAL ONCOL, V32B, P373, DOI 10.1016/S0964-1955(96)00010-3
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keating MJ, 2002, COCHRANE HDB SYSTEMA, V99, P3554
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   KUKLINSKI B, 1994, MOL ASPECTS MED, V15, P143, DOI 10.1016/0098-2997(94)90023-X
   Kvansakul J, 2006, OPHTHAL PHYSL OPT, V26, P362, DOI 10.1111/j.1475-1313.2006.00387.x
   LANG JM, 1991, STAT MED, V10, P1585, DOI 10.1002/sim.4780101010
   Laurila AL, 1997, INT J CANCER, V74, P31, DOI 10.1002/(SICI)1097-0215(19970220)74:1&lt;31::AID-IJC6&gt;3.0.CO;2-1
   Lee IM, 1999, STROKE, V30, P1, DOI 10.1161/01.STR.30.1.1
   Lee IM, 2005, JAMA-J AM MED ASSOC, V294, P56, DOI 10.1001/jama.294.1.56
   Leng G C, 1997, Vasc Med, V2, P279
   Levine N, 1997, CANCER EPIDEM BIOMAR, V6, P957
   Li Jun-Yao, 1993, Zhonghua Zhongliu Zazhi, V15, P165
   Li W G, 1992, Zhonghua Yu Fang Yi Xue Za Zhi, V26, P268
   Liede K, 1998, Oral Dis, V4, P78
   Liede KE, 1998, ANN MED, V30, P542, DOI 10.3109/07853899709002602
   Liede KE, 1998, EUR J CLIN NUTR, V52, P872, DOI 10.1038/sj.ejcn.1600646
   Lippman SM, 2009, JAMA-J AM MED ASSOC, V301, P39, DOI 10.1001/jama.2008.864
   Lonn EM, 1996, AM J CARDIOL, V78, P914, DOI 10.1016/S0002-9149(96)00467-5
   Ma J, 1997, CANCER RES, V57, P1098
   MANSON JE, 1991, AM J PREV MED, V7, P150, DOI 10.1016/S0749-3797(18)30931-0
   MANSON JE, 1994, AM J PREV MED, V10, P156, DOI 10.1016/S0749-3797(18)30612-3
   Manson Joann E., 1995, Annals of Epidemiology, V5, P261, DOI 10.1016/1047-2797(94)00091-7
   Marchioli R, 1993, G Ital Cardiol, V23, P933
   Mayne ST, 1998, AM J CLIN NUTR, V68, P642, DOI 10.1093/ajcn/68.3.642
   MCKEOWNEYSSEN G, 1988, CANCER RES, V48, P4701
   MEYSKENS FL, 1994, J CLIN ONCOL, V12, P2060, DOI 10.1200/JCO.1994.12.10.2060
   MORRIS MC, 1995, AM J EPIDEMIOL, V142, P166, DOI 10.1093/oxfordjournals.aje.a117615
   MUNOZ N, 1985, LANCET, V2, P111
   Munoz N, 1996, IARC SCI PUBL, P125
   Newsome DA, 2008, CURR EYE RES, V33, P591, DOI 10.1080/02713680802178437
   NICE, MAC DEG NICE GUID
   NORTON EWD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1460, DOI 10.1001/archopht.1993.01090110018003
   ODonnell CJ, 1997, CIRCULATION, V95, P1132
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   PASTORINO U, 1988, ACTA ONCOL, V27, P773, DOI 10.3109/02841868809094356
   Pemp B, 2010, INVEST OPHTH VIS SCI, V51, P2, DOI 10.1167/iovs.09-3888
   PENG YM, 1993, CANCER EPIDEM BIOMAR, V2, P145
   Piermarocchi S, 2012, EUR J OPHTHALMOL, V22, P216, DOI 10.5301/ejo.5000069
   Pietinen P, 1996, CIRCULATION, V94, P2720, DOI 10.1161/01.CIR.94.11.2720
   PRASAD MPR, 1995, ORAL ONCOL, V31B, P155, DOI 10.1016/0964-1955(95)00013-8
   Primary prevention project (PPP) in the Mario Negri Institute in Milan, 1996, RICERCA E, V12, P175
   Rapola JM, 1998, HEART, V79, P454, DOI 10.1136/hrt.79.5.454
   Rapola JM, 1997, LANCET, V349, P1715, DOI 10.1016/S0140-6736(97)01234-8
   Rapola JM, 1996, JAMA-J AM MED ASSOC, V275, P693, DOI 10.1001/jama.275.9.693
   RECCHIA F, 1995, J INTERF CYTOK RES, V15, P605, DOI 10.1089/jir.1995.15.605
   Reed P. I., 1995, Acta Endoscopica, V25, P45, DOI 10.1007/BF02965773
   Rein DB, 2007, OPHTHALMOLOGY, V114, P1319, DOI 10.1016/j.ophtha.2006.10.041
   RIDKER PM, 1991, ANN INTERN MED, V114, P835, DOI 10.7326/0003-4819-114-10-835
   Ridker PM, 1998, CIRCULATION, V97, P425
   Ridker PM, 1998, LANCET, V351, P88, DOI 10.1016/S0140-6736(97)09032-6
   Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613
   ROBBINS AS, 1994, ANN INTERN MED, V120, P458, DOI 10.7326/0003-4819-120-6-199403150-00002
   Robman LD, 1999, AUST NZ J OPHTHALMOL, V27, P410
   Rodriguez-Carmona M, 2006, OPHTHAL PHYSL OPT, V26, P137, DOI 10.1111/j.1475-1313.2006.00386.x
   RONCUCCI L, 1993, DIS COLON RECTUM, V36, P227, DOI 10.1007/BF02053502
   SALVINI S, 1992, J CLIN ENDOCR METAB, V74, P139, DOI 10.1210/jc.74.1.139
   Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704
   Santos MS, 1997, AM J CLIN NUTR, V66, P917, DOI 10.1093/ajcn/66.4.917
   Santos MS, 1998, AM J CLIN NUTR, V68, P164, DOI 10.1093/ajcn/68.1.164
   Santos MS, 1996, AM J CLIN NUTR, V64, P772, DOI 10.1093/ajcn/64.5.772
   SATTERFIELD S, 1990, AM J PREV MED, V6, P290, DOI 10.1016/S0749-3797(18)30997-8
   Schaumberg D. A., 1996, American Journal of Epidemiology, V143, pS9
   SEDDON JM, 1994, AM J PUBLIC HEALTH, V84, P788, DOI 10.2105/AJPH.84.5.788
   Sesso HD, 2008, JAMA-J AM MED ASSOC, V300, P2123, DOI 10.1001/jama.2008.600
   Sharma Y R, 1989, Indian J Ophthalmol, V37, P134
   SHOULSON I, 1989, ARCH NEUROL-CHICAGO, V46, P1052, DOI 10.1001/archneur.1989.00520460028009
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1246, DOI 10.1001/archopht.1993.01090090098027
   STAMPFER MJ, 1985, STAT MED, V4, P111, DOI 10.1002/sim.4780040202
   STEINER M, 1995, AM J CLIN NUTR, V62, P1381, DOI 10.1093/ajcn/62.6.1381S
   Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1
   TAKAMATSU S, 1995, J INT MED RES, V23, P342, DOI 10.1177/030006059502300504
   TAYLOR H, 2002, BMJ-BRIT MED J, V325, P325
   Taylor HR, 2001, INVEST OPHTH VIS SCI, V42, pS311
   Teikari JM, 1998, J EPIDEMIOL COMMUN H, V52, P468, DOI 10.1136/jech.52.7.468
   Teikari JM, 1997, ACTA OPHTHALMOL SCAN, V75, P634
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P68, DOI 10.1034/j.1600-0420.1998.760112.x
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P224, DOI 10.1034/j.1600-0420.1998.760220.x
   The Nordic Cochrane Centre, 2014, REV MAN 5 REVMAN 5 V
   TOMEO AC, 1995, LIPIDS, V30, P1179, DOI 10.1007/BF02536621
   Tornwall ME, 1997, ARTERIOSCL THROM VAS, V17, P3475, DOI 10.1161/01.ATV.17.12.3475
   Tsubono Y, 1997, JPN J CANCER RES, V88, P344, DOI 10.1111/j.1349-7006.1997.tb00387.x
   Varis K, 1998, SCAND J GASTROENTERO, V33, P294, DOI 10.1080/00365529850170892
   VERHOEF P, 1994, STROKE, V25, P1924, DOI 10.1161/01.STR.25.10.1924
   Veritas Health Innovation, 2015, COV SYST REV SOFTW V
   Virtamo J, 1998, ARCH INTERN MED, V158, P668, DOI 10.1001/archinte.158.6.668
   WAHLQVIST ML, 1994, AM J CLIN NUTR, V60, P936, DOI 10.1093/ajcn/60.6.936
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   WRIGHT JP, 1985, GASTROENTEROLOGY, V88, P512, DOI 10.1016/0016-5085(85)90514-1
   YU SY, 1991, BIOL TRACE ELEM RES, V29, P289, DOI 10.1007/BF03032685
   YU SY, 1990, BIOL TRACE ELEM RES, V24, P105, DOI 10.1007/BF02917199
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
   Zaridze D, 1993, Ann Epidemiol, V3, P225
   Zee RYL, 1999, CIRCULATION, V99, P340, DOI 10.1161/01.CIR.99.3.340
NR 183
TC 50
Z9 50
U1 0
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2017
IS 7
AR CD000253
DI 10.1002/14651858.CD000253.pub4
PG 66
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FC4SO
UT WOS:000406831100002
PM 28756617
OA Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Azab, M
   Benchaboune, M
   Blinder, KJ
   Bressler, NM
   Bressler, SB
   Gragoudas, ES
   Fish, GE
   Hao, Y
   Haynes, L
   Lim, JI
   Menchini, U
   Miller, JW
   Mones, J
   Potter, MJ
   Reaves, A
   Rosenfeld, PJ
   Strong, HA
   Su, XY
   Slakter, JS
   Schmidt-Erfurth, U
   Sorenson, JA
AF Azab, M
   Benchaboune, M
   Blinder, KJ
   Bressler, NM
   Bressler, SB
   Gragoudas, ES
   Fish, GE
   Hao, Y
   Haynes, L
   Lim, JI
   Menchini, U
   Miller, JW
   Mones, J
   Potter, MJ
   Reaves, A
   Rosenfeld, PJ
   Strong, HA
   Su, XY
   Slakter, JS
   Schmidt-Erfurth, U
   Sorenson, JA
CA TAP Grp
   VIP Grp
TI Verteporfin therapy of subfoveal choroidal neovascularization in
   age-related macular degeneration - Meta-analysis of 2-year safety
   results in three randomized clinical trials: Treatment of age-related
   macular degeneration with photodynamic therapy and verteporfin in
   photodynamic therapy study report no. 4
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID COMPLEMENT; INFUSION; ACTIVATION; LIPOSOMES; MECHANISM
AB Purpose: We sought to evaluate the detailed safety profile of photodynamic therapy with verteporfin in patients with subfoveal choroidal neovascularization (CNV) caused by age-related macular degeneration (ARMD) from the combined analysis of three multicenter, double-masked, placebo-controlled, randomized 24-month clinical trials of similar design (TAP Investigation Studies A and B and the VIP ARMD Trial), and to clarify the adverse reaction information in the current verteporfin product prescription information approved in the United States.
   Methods: Nine hundred forty-eight patients were randomly assigned to verteporfin or placebo. Treatment was administered as described in previous reports. All general entry criteria were similar, so systemic safety results were combined for this analysis. Entry criteria for CNV lesion composition and visual acuity in the two TAP Investigation trials was different from those used in the VIP ARMD trial, so ocular safety results for the treated eye were not combined.
   Results: The percentage of patients who experienced at least one ocular or nonocular adverse event, regardless of relationship to therapy, was similar between the verteporfin and placebo groups (92.3 and 89.1%, respectively, P = 0.114). The overall incidence of study eye adverse events was not significantly different between verteporfin and placebo. The only clinically relevant ocular adverse events reported with higher incidence after verteporfin compared with placebo were visual disturbances (22.1 versus 15.5% in TAP [P = 0.054] and 41.7 and 22.8% in VIP [P < 0.001]). Acute severe visual acuity decrease (defined as a visual acuity letter score decrease of at least 20, equivalent to at least four-line decrease, within 7 days of therapy) occurred in 3 patients treated with verteporfin in the TAP Investigation (0.7%) and 11 in the VIP ARMD trial (4.9%). Systemic adverse events with increased incidence after verteporfin compared with placebo, most of which were transient and mild or moderate, were injection site reactions (13.1 versus 5.6%; P < 0.001); photosensitivity reactions (2.4 versus 0.3%; P = 0.016), and infusion-related back pain (2.4 versus 0%; P = 0.004). No clinically relevant difference was observed between the verteporfin and placebo groups in any other adverse event.
   Conclusion: In 948 ARMD patients, verteporfin therapy had an overall safety profile similar to that for placebo, with a few exceptions. Visual disturbances, including acute severe visual acuity decrease, did not affect the net vision outcome benefits associated with treatment that has been reported previously. This detailed safety profile of verteporfin therapy clarifies the adverse reaction information in the current verteporfin product prescription information.
OI Miller, Joan/0000-0003-2046-3996
CR *AM CANC SOC, 2002, CANC FACTS FIG 2002
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Borodoker N, 2002, AM J OPHTHALMOL, V133, P211, DOI 10.1016/S0002-9394(01)01341-1
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   CHONN A, 1991, J IMMUNOL, V146, P4234
   CUNNINGHAM CM, 1979, J IMMUNOL, V122, P1237
   DEVINE DV, 1994, BBA-BIOMEMBRANES, V1191, P43, DOI 10.1016/0005-2736(94)90231-3
   Houle JM, 2002, RETINA-J RET VIT DIS, V22, P691, DOI 10.1097/00006982-200212000-00002
   Houle JM, 2002, J CLIN PHARMACOL, V42, P547, DOI 10.1177/00912700222011607
   Hui YF, 2000, ANN PHARMACOTHER, V34, P810, DOI 10.1345/aph.19236
   LEAR J, 1992, LANCET, V340, P851, DOI 10.1016/0140-6736(92)92726-V
   *NOV OPHTH INC, 2002, VIS VERT INJ PACK IN
   SCULIER JP, 1986, J CLIN ONCOL, V4, P789, DOI 10.1200/JCO.1986.4.5.789
   Skubitz KM, 1998, ANTI-CANCER DRUG, V9, P45, DOI 10.1097/00001813-199801000-00005
   Spaide RF, 2003, AM J OPHTHALMOL, V135, P549, DOI 10.1016/S0002-9394(02)01983-9
   SZEBENI J, 1995, ARTIF CELL BLOOD SUB, V23, P355, DOI 10.3109/10731199509117952
   *TREATM AG REL MAC, IN PRESS AM J OPHTHA
   Winawer Sidney J., 1999, American Journal of Medicine, V106, p3S, DOI 10.1016/S0002-9343(98)00338-6
NR 20
TC 57
Z9 63
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2004
VL 24
IS 1
BP 1
EP 12
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 778HU
UT WOS:000189234200001
PM 15076937
DA 2022-11-30
ER

PT J
AU Song, PG
   Du, YH
   Chan, KY
   Theodoratou, E
   Rudan, I
AF Song, Peige
   Du, Yuhang
   Chan, Kit Yee
   Theodoratou, Evropi
   Rudan, Igor
TI The national and subnational prevalence and burden of age-related
   macular degeneration in China
SO JOURNAL OF GLOBAL HEALTH
LA English
DT Article
ID BEAVER DAM EYE; SOLAR-RADIATION; GRADING SYSTEM; MACULOPATHY; DISEASE;
   METAANALYSIS; EPIDEMIOLOGY; SMOKING; VISION; RISK
AB Background Age-related macular degeneration (AMD) is the third most common cause of blindness, and the fourth leading cause of visual impairment worldwide, but little is known about the burden of this disease in the most populous country-China. This study provides the first comprehensive estimates of the prevalence and burden of AMD in China from 1990 to 2015, with projections till 2050.
   Methods In this study, a systematic review and meta-analysis was conducted to estimate the prevalence of AMD in China. China National Knowledge Infrastructure (CNKI), Wanfang, Chinese Biomedicine Literature Database (CBM-SinoMed), PubMed, Embase and Medline were searched before September 2016. Multilevel mixed-effect meta-regression was performed to define the prevalence rates of AMD and its subtypes. UN population data were used to estimate and project the number of people affected from 1990 to 2050. Based on different demographic and geographic features, the national burden of AMD in 2000 and 2010 was distributed to different regions in China.
   Results Our search returned 2016 citations, of which 25 met the inclusion criteria. The prevalence of any AMD ranged from 2.44% (95% CI = 1.85-3.22) in people aged 45-49 years to 18.98% (95% CI = 15.05-23.66) in people aged 85-89 years. Prevalence of early AMD ranged from 1.79% (95% CI = 1.05-3.02) to 10.05% (95% CI = 6.17-15.97), and, in the case of late AMD, from 0.38% (95% CI = 0.16-0.97) to 3.88% (95% CI = 1.68-9.13). In late AMD, the prevalence of geographic atrophy (GA) was 0.15% (95% CI = 0.05-0.47) in people aged 45-49 years and 1.09% (95% CI = 0.35-3.36) in those aged 85-89 years, and the prevalence of neovascular AMD (NVAMD) ranged between 0.24% (95% CI = 0.11-0.50) and 2.79% (95% CI = 1.33-5.77). The number of people with any AMD was 12.01 million (95% CI = 9.29-15.46) in 1990 and 26.65 million (95% CI = 20.62-34.27) in 2015. Within the same period, the number of people with early AMD increased from 9.44 million (95% CI = 7.74-11.15) to 20.91 million (95% CI = 17.16-24.68), and those with late AMD rose from 2.58 million (95% CI = 1.56-4.30) to 5.74 million (95% CI = 3.46-9.59). In late AMD, the number of people living with GA ranged from 0.87 million (95% CI = 0.40-1.83) in 1990 to 1.93 million (95% CI = 0.89-4.08) in 2015, and NVAMD from 1.71 million (95% CI = 1.16-2.47) to 3.81 million (95% CI = 2.57-5.51). The projected number of people with any AMD in 2020 is 31.23 million (95% CI = 24.18-40.14), increasing to 55.19 million (95% CI = 43.04-70.30) in 2050. Between different regions, the South Central owed the most AMD cases (5.50 million in 2000 and 7.52 million in 2010), whereas the North-West China the least (0.66 million in 2000 and 0.95 million in 2010).
   Conclusions The estimates in this study suggest a substantial burden of AMD in China, with the ageing process in Chinese society, this burden will be increasing in the foreseen future. Primary and secondary prevention and treatment and effective government response are urgently needed. Improved epidemiological studies are also required to better develop eye-care strategies and health services.
C1 [Song, Peige; Du, Yuhang; Chan, Kit Yee; Theodoratou, Evropi; Rudan, Igor] Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Ctr Global Hlth Res, Edinburgh EH8 9AG, Midlothian, Scotland.
C3 University of Edinburgh
RP Song, PG (通讯作者)，Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Ctr Global Hlth Res, Edinburgh EH8 9AG, Midlothian, Scotland.
EM p.song@sms.ed.ac.uk
RI song, peige/AAG-6236-2019; Rudan, Igor/I-1467-2012; Theodoratou,
   Evropi/C-3430-2014
OI Rudan, Igor/0000-0001-6993-6884; Chan, Kit Yee/0000-0002-3465-8383;
   Theodoratou, Evropi/0000-0001-5887-9132
FU China Scholarship Council
FX Peige Song is supported by the China Scholarship Council.
CR Adeloye D, 2015, J GLOB HEALTH, V5, P186, DOI 10.7189/jogh.05.020415
   [Anonymous], 2012, TAB 2010 POP CENS PE
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bonastre J, 2002, Eur J Health Econ, V3, P94, DOI 10.1007/s10198-002-0104-y
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P764, DOI 10.1016/j.ajo.2012.10.013
   China Medical Association, 1987, ZHONGHUA YAN KE ZA Z, V23, pF02
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Damico FM, 2012, ARQ BRAS OFTALMOL, V75, P71, DOI 10.1590/S0004-27492012000100016
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Fowkes FGR, 2013, LANCET, V382, P1329, DOI 10.1016/S0140-6736(13)61249-0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fung ICH, 2008, EMERG THEMES EPIDEMI, V5, DOI 10.1186/1742-7622-5-20
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   Hassan SE, 2002, OPTOMETRY VISION SCI, V79, P697, DOI 10.1097/00006324-200211000-00007
   Higgins JP, 2008, COCHRANE HDB SYSTEMA, V5, P39
   Hox JJ., 2017, MULTILEVEL ANAL TECH, DOI 10.4324/9781315650982
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lamoureux EL, 2011, BRIT J OPHTHALMOL, V95, P666, DOI 10.1136/bjo.2010.185207
   Lee GKY, 2009, HONG KONG J OPHTHALM, V13, P5
   Li T, 2009, BIOL TRACE ELEM RES, V128, P1, DOI 10.1007/s12011-008-8248-y
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Moher D, 2010, INT J SURG, V8, P658, DOI 10.1016/j.ijsu.2010.07.299
   National Bureau of Statistics, 2002, TAB 2010 POP CENS PE
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Reibaldi M, 2016, AM J OPHTHALMOL, V161, P78, DOI 10.1016/j.ajo.2015.09.031
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Rudan I, 2004, B WORLD HEALTH ORGAN, V82, P895
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Shi GY, 2008, J APPL METEOROL CLIM, V47, P1006, DOI 10.1175/2007JAMC1493.1
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Stevens GA, 2016, PLOS MED, V13, DOI [10.1371/journal.pmed.1002056, 10.1371/journal.pmed.1002116]
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Takeda AL, 2007, BRIT J OPHTHALMOL, V91, P1177, DOI 10.1136/bjo.2007.118562
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03
   Vittinghoff E, 2007, AM J EPIDEMIOL, V165, P710, DOI 10.1093/aje/kwk052
   Wild M, 2005, SCIENCE, V308, P847, DOI 10.1126/science.1103215
   Wong Ian Yat Hin, 2011, International Ophthalmology, V31, P73, DOI 10.1007/s10792-010-9397-5
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xia J, 2008, HEALTH INFO LIBR J, V25, P55, DOI 10.1111/j.1471-1842.2007.00734.x
   Yabing Z, 2015, CHINESE HLTH EC, V1, P63
   Ye HH, 2014, INVEST OPHTH VIS SCI, V55, P6374, DOI 10.1167/iovs.14-14899
   Zhang L, 2013, LANCET INFECT DIS, V13, P955, DOI 10.1016/S1473-3099(13)70245-7
   Zhou Q, 2007, OPHTHAL EPIDEMIOL, V14, P399, DOI 10.1080/09286580701331974
NR 58
TC 29
Z9 33
U1 5
U2 15
PU UNIV EDINBURGH, GLOBAL HEALTH SOC
PI EDINBURGH
PA CENTRE POPULATION HEALTH SCIENCES, OLD MEDICAL SCH, TEVIOT PL,
   EDINBURGH, EH8 9AG, SCOTLAND
SN 2047-2978
EI 2047-2986
J9 J GLOB HEALTH
JI J. Glob. Health
PD DEC
PY 2017
VL 7
IS 2
AR 020703
DI 10.7189/jogh.07.020703
PG 16
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health
GA FR2AR
UT WOS:000418869800038
PM 29302323
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Jackson, TL
   Chakravarthy, U
   Kaiser, PK
   Slakter, JS
   Jan, E
   Bandello, F
   O'Shaughnessy, D
   Gertner, ME
   Danielson, L
   Moshfeghi, DM
AF Jackson, Timothy L.
   Chakravarthy, Usha
   Kaiser, Peter K.
   Slakter, Jason S.
   Jan, Ernest
   Bandello, Francesco
   O'Shaughnessy, Denis
   Gertner, Michael E.
   Danielson, Linda
   Moshfeghi, Darius M.
CA INTREPID Study Grp
TI Stereotactic Radiotherapy for Neovascular Age-related Macular
   Degeneration 52-Week Safety and Efficacy Results of the INTREPID Study
SO OPHTHALMOLOGY
LA English
DT Article
ID X-RAY-IRRADIATION; NEEDED RANIBIZUMAB THERAPY; AMD 6-MONTH SAFETY;
   CHOROIDAL NEOVASCULARIZATION; EPIMACULAR BRACHYTHERAPY; RADIATION;
   RADIOSURGERY; BEVACIZUMAB; SECONDARY; OUTCOMES
AB Purpose: To determine the safety and efficacy of low-voltage, external-beam, stereotactic radiotherapy (SRT) for patients with neovascular age-related macular degeneration (nvAMD).
   Design: Randomized, double-masked, sham-controlled, multicenter, clinical trial.
   Participants: Two hundred thirty patients with onset of nvAMD within 3 years who received 3 or more injections of ranibizumab or bevacizumab within the preceding year and who needed continuing ranibizumab or bevacizumab treatment.
   Interventions: Participants were randomized 2:1:2:1 to 16 Gy plus pro re nata (PRN) ranibizumab, sham 16 Gy plus PRN ranibizumab, 24 Gy plus PRN ranibizumab, or sham 24 Gy plus PRN ranibizumab, respectively.
   Main Outcome Measures: The primary efficacy end point was the mean number of ranibizumab injections at 52 weeks. Secondary end points were change in mean best-corrected visual acuity (VA), loss of fewer than 15 Early Treatment Diabetic Retinopathy Study letters, gain of 0 or more and 15 or more letters, and change in angiographic total lesion size and choroidal neovascularization (CNV) lesion size.
   Results: Both the 16-Gy and 24-Gy SRT arms received significantly fewer ranibizumab treatments compared with the sham arms: mean number of treatments, 2.64 (median, 2), 2.43 (median, 2), and 3.74 (median, 3.5), respectively (P = 0.013 and P = 0.004, respectively, vs. sham). Change in mean VA was -0.28, +0.40, and -1.57 letters for the 16-Gy, 24-Gy, and sham arms, respectively. The 16-Gy, 24-Gy, and sham arms lost fewer than 15 letters in 93%, 89%, and 91% of eyes, respectively, with 53%, 57%, and 56% gaining 0 or more letters, respectively, and 4% gaining 15 letters or more in all arms. Mean total angiographic lesion area changed by -1.15 mm(2), +0.49 mm(2), and +0.75 mm(2), respectively; mean CNV lesion area decreased by 0.16 mm(2), 0.18 mm(2), and 0.10 mm(2), respectively. Optical coherence tomography central subfield thickness decreased by 85.90 mu m, 70.39 mu m, and 33.51 mu m, respectively. The number of adverse events (AEs) and number of serious AEs (SAEs) were similar across arms. No AEs were attributed to radiation. No SAEs occurred in the study eye.
   Conclusions: A single dose of SRT significantly reduces ranibizumab retreatment for patients with nvAMD, with a favorable safety profile at 1 year. Whereas chronic nvAMD typically results in loss of VA over time, SRT is associated with relatively well-preserved VA over 1 year. (c) 2013 by the American Academy of Ophthalmology.
C1 [Jackson, Timothy L.] Kings Coll London, London, England.
   [Chakravarthy, Usha] Queens Univ Belfast, Belfast, Antrim, North Ireland.
   [Chakravarthy, Usha] Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland.
   [Kaiser, Peter K.] Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
   [Slakter, Jason S.] Digital Angiog Reading Ctr, Great Neck, NY USA.
   [Jan, Ernest] Cent Mil Hosp Prague, Prague, Czech Republic.
   [Bandello, Francesco] Univ Vita Salute, Inst Sci, Milan, Italy.
   [O'Shaughnessy, Denis] Oraya Therapeut Inc, Newark, CA USA.
   [Gertner, Michael E.] Stanford Univ, Dept Surg, Stanford, CA 94305 USA.
   [Danielson, Linda] Int Inst Drug Dev, Louvain, Belgium.
   [Moshfeghi, Darius M.] Stanford Univ, Sch Med, Byers Eye Inst, Horngren Family Vitreoretinal Ctr,Dept Ophthalmol, Palo Alto, CA 94304 USA.
C3 University of London; King's College London; Queens University Belfast;
   Cleveland Clinic Foundation; Military University Hospital Prague;
   Vita-Salute San Raffaele University; Stanford University; International
   Drug Development Institute; Stanford University
RP Moshfeghi, DM (通讯作者)，Stanford Univ, Sch Med, Dept Ophthalmol, Byers Eye Inst,Horngren Family Vitreoretinal Ctr, 2452 Watson Court,Room 2277, Palo Alto, CA 94303 USA.
EM dariusm@stanford.edu
RI bandello, francesco/AAH-2405-2019; Kousal, Bohdan/B-9489-2017; Kousal,
   Bohdan/ABE-2741-2021; Studnicka, Jan/K-2875-2017; Aslam,
   Tariq/A-8532-2016
OI bandello, francesco/0000-0003-3238-9682; Kousal,
   Bohdan/0000-0003-2824-2266; Kousal, Bohdan/0000-0003-2824-2266;
   Chakravarthy, Usha/0000-0002-2606-3734; Studnicka,
   Jan/0000-0002-9911-4379; Aslam, Tariq/0000-0002-9739-7280; Kaiser,
   Peter/0000-0001-5126-045X; Moshfeghi, Darius
   Mohammad/0000-0003-2254-292X; Jackson, Timothy/0000-0001-7618-1555
FU Oraya Therapeutics
FX Timothy L. Jackson: Financial support-Oraya Therapeutics
CR Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Avila MP, 2012, RETINA-J RET VIT DIS, V32, P10, DOI 10.1097/IAE.0b013e31822528fc
   Barakat MR, 2011, ARCH OPHTHALMOL-CHIC, V129, P628, DOI 10.1001/archophthalmol.2011.99
   Beer PM, 2003, OPHTHALMOLOGY, V110, P681, DOI 10.1016/S0161-6420(02)01969-3
   Canton VM, 2011, OPHTHAL SURG LAS IM, V42, P468, DOI 10.3928/15428877-20110804-01
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   Evans JR, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004004.pub3
   Gertner M, 2010, MED PHYS, V37, P600, DOI 10.1118/1.3291648
   Hadjimichael C, 2005, ANTICANCER RES, V25, P1059
   Hanlon J, 2011, INVEST OPHTH VIS SCI, V52, P2334, DOI 10.1167/iovs.10-6421
   Hanlon J, 2009, MED PHYS, V36, P3671, DOI 10.1118/1.3168554
   Hatjikondi O, 1996, BRIT J CANCER, V74, P1916, DOI 10.1038/bjc.1996.653
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kirwan JF, 2003, EYE, V17, P207, DOI 10.1038/sj.eye.6700306
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lee C, 2008, MED PHYS, V35, P5151, DOI 10.1118/1.2990780
   Mallinckrodt CH, 2008, DRUG INF J, V42, P303, DOI 10.1177/009286150804200402
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Canton VM, 2012, OPHTHAL SURG LAS IM, V43, P20, DOI 10.3928/15428877-20111129-01
   Moshfeghi AA, 2012, BRIT J OPHTHALMOL, V96, P1320, DOI 10.1136/bjophthalmol-2011-301222
   Moshfeghi AA, 2011, OPHTHAL SURG LAS IM, V42, P460, DOI 10.3928/15428877-20110804-03
   Petrarca R, 2013, RETINA-J RET VIT DIS, V33, P1232, DOI 10.1097/IAE.0b013e3182794b22
   Petrarca R, 2011, CLIN OPHTHALMOL, V5, P57, DOI 10.2147/OPTH.S16444
   POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712
   Rodel F, 2007, INT J RADIAT BIOL, V83, P357, DOI 10.1080/09553000701317358
   Taddei PJ, 2010, PHYS MED BIOL, V55, P7037, DOI 10.1088/0031-9155/55/23/S06
NR 34
TC 48
Z9 49
U1 0
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2013
VL 120
IS 9
BP 1893
EP 1900
DI 10.1016/j.ophtha.2013.02.016
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 213HG
UT WOS:000324045800044
PM 23490327
DA 2022-11-30
ER

PT J
AU Altay, L
   Lemke, J
   Schroeder-Braunstein, J
   Gietzelt, C
   Sitnilska, V
   Schaub, F
   Cursiefen, C
   Enders, P
   Fauser, S
AF Altay, Lebriz
   Lemke, Julia
   Schroeder-Braunstein, Jutta
   Gietzelt, Caroline
   Sitnilska, Vasilena
   Schaub, Friederike
   Cursiefen, Claus
   Enders, Philip
   Fauser, Sascha
TI Ocular and Systemic Complement Activation during Anti-Vascular
   Endothelial Growth Factor Treatment and Age-Related Eye Disease Study 2
   Dietary Supplementation in Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related eye disease study 2; Zinc; Complement activation;
   Neovascular age-related macular degeneration
ID BETA-CAROTENE; ZINC; CFH; ANTIOXIDANTS; ASSOCIATION; GENOTYPES; DRUSEN;
   INFLAMMATION
AB Purpose: The aim of this study was to investigate the influence of dietary supplementation using Age-Related Eye Disease Study 2 (AREDS2) on complement activation in patients with neovascular age-related macular degeneration (nAMD) under ongoing treatment. Methods: In this prospective, single-center, controlled, open-label investigator-initiated trial, eligible nAMD patients were randomized at a ratio of 1:1 in 2 groups: those with and without dietary AREDS2 supplementation for 4 weeks. Zinc, plasma, and aqueous humor (AH) complement levels were quantified via enzyme-linked immunosorbent assays. Results: Fifty of 62 enrolled patients completed the trial (AREDS2 n = 27, controls n = 23). Systemic zinc and complement levels were not different at baseline between the 2 groups (p > 0.1). At the final visit, systemic zinc levels were significantly higher in the AREDS2 group (10.16 +/- 2.08 mu mol/L; 8.66 +/- 1.17 mu mol/L; p = 0.007), whereas systemic and AH complement levels were not different (p > 0.1). In both groups, no significant change was observed in systemic levels of C3, C3a, FH, FI, and sC5b-9 (p > 0.1). Only systemic complement component Ba showed an increase from baseline to the end visit (p = 0.01). This increase was higher in the control group (p = 0.02) than in the AREDS2 group (p = 0.23). Conclusions: Short-term dietary AREDS2 supplementation leads to a significant increase in systemic zinc levels without any influence on complement activation levels.
C1 [Altay, Lebriz; Lemke, Julia; Gietzelt, Caroline; Sitnilska, Vasilena; Schaub, Friederike; Cursiefen, Claus; Enders, Philip; Fauser, Sascha] Univ Hosp Cologne, Univ Cologne, Fac Med, Dept Ophthalmol, Cologne, Germany.
   [Schroeder-Braunstein, Jutta] Heidelberg Univ, Inst Immunol, Heidelberg, Germany.
   [Fauser, Sascha] F Hoffmann La Roche & Cie AG, Basel, Switzerland.
C3 University of Cologne; Ruprecht Karls University Heidelberg; Roche
   Holding
RP Altay, L (通讯作者)，Univ Hosp Cologne, Univ Cologne, Fac Med, Dept Ophthalmol, Cologne, Germany.
EM Karger@karger.com
OI cursiefen, claus/0000-0002-1958-411X; Gietzelt,
   Caroline/0000-0002-9145-7385; Enders, Philip/0000-0002-9527-4957
CR Altay L, 2019, EYE, V33, P1859, DOI 10.1038/s41433-019-0501-4
   AMBRUS JL, 1990, J IMMUNOL, V144, P1549
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anzilotti C, 2019, NAT IMMUNOL, V20, P350, DOI 10.1038/s41590-018-0295-8
   Arborea G, 2017, MOL IMMUNOL, V89, P2, DOI 10.1016/j.molimm.2017.05.012
   Aronow ME, 2014, CURR OPIN OPHTHALMOL, V25, P186, DOI 10.1097/ICU.0000000000000046
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Bailey JNC, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017186
   Behnke V, 2020, CELL MOL LIFE SCI, V77, P781, DOI 10.1007/s00018-019-03419-4
   Brown CN, 2019, METABOLITES, V9, DOI 10.3390/metabo9010004
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gao H, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/6872621
   Gilbert R, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201801049
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Heesterbeek TJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.18
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keir LS, 2017, J CLIN INVEST, V127, P199, DOI 10.1172/JCI86418
   Khandhadia S, 2013, OPHTHALMOLOGY, V120, P1612, DOI 10.1016/j.ophtha.2013.01.004
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Nan R, 2013, J BIOL CHEM, V288, P19197, DOI 10.1074/jbc.M113.476143
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Saghiri MA, 2015, CRIT REV ONCOL HEMAT, V96, P143, DOI 10.1016/j.critrevonc.2015.05.011
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2016, BRIT J OPHTHALMOL, V100, P1731, DOI 10.1136/bjophthalmol-2016-308624
   Smailhodzic D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112682
   Vavvas DG, 2018, P NATL ACAD SCI USA, V115, pE696, DOI 10.1073/pnas.1718059115
   Warwick A, 2014, J CLIN MED, V3, P1234, DOI 10.3390/jcm3041234
NR 35
TC 0
Z9 0
U1 2
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD JUN
PY 2022
VL 245
IS 3
BP 258
EP 264
DI 10.1159/000516885
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3E9GV
UT WOS:000830285800007
PM 34034256
DA 2022-11-30
ER

PT J
AU Binns, AM
   Margrain, TH
AF Binns, Alison M.
   Margrain, Tom H.
TI Evaluating retinal function in age-related maculopathy with the ERG
   photostress test
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID SORSBYS-FUNDUS-DYSTROPHY; VISUAL PIGMENT REGENERATION; DARK-ADAPTATION;
   MULTIFOCAL ELECTRORETINOGRAM; FELLOW EYES; MACULAR DEGENERATION;
   STARGARDT-DISEASE; CONE; RECOVERY; FLAVIMACULATUS
AB PURPOSE. To evaluate the diagnostic potential of the electroretinogram (ERG) photostress test and the focal cone ERG in age-related maculopathy (ARM).
   METHODS. The cohort comprised 31 patients with ARM and 27 age-matched control subjects. The ERG photostress test was used to monitor cone adaptation after intense light adaptation. Focal 41- and 5-Hz cone ERGS were recorded monocularly (central 20 degrees) to assess steady state retinal function. Univariate analysis identified electrophysiological parameters that differed between groups, and receiver operating characteristic (ROC) curves were constructed to assess their diagnostic potential. Logistic regression analysis determined the diagnostic potential of a model incorporating several independent predictors of ARM.
   RESULTS. The rate of recovery of the ERG photostress test was reduced (recovery was slower) in subjects with ARM. The parameter exhibited good diagnostic potential (P = 0.002, area under ROC curve = 0.74). The implicit times of the 5-Hz (a-wave, P = 0.002; b-wave, P < 0.001) and the 41-Hz (1 < 0.001) focal cone ERGS were increased, and the 41-Hz focal cone ERG amplitude (P = 0.003) and focal to full-field amplitude ratio (P = 0.001) were reduced in the ARM group. Logistic regression analysis identified three independent predictors of ARM, including the rate of recovery of the ERG photostress test.
   CONCLUSIONS. Early ARM has a marked effect on the kinetics of cone adaptation. The clinical application of the ERG photostress test increases the sensitivity and specificity of a model for the diagnosis of ARM. Improved assessment of the functional integrity of the central retina will facilitate early diagnosis and evaluation of therapeutic interventions.
C1 Cardiff Univ, Sch Optometry & Vis Sci, Cardiff CF10 3NB, Wales.
C3 Cardiff University
RP Binns, AM (通讯作者)，Cardiff Univ, Sch Optometry & Vis Sci, King Edward VII Ave, Cardiff CF10 3NB, Wales.
EM binnsAM@cf.ac.uk
OI Margrain, Tom/0000-0003-1280-0809; Binns, Alison/0000-0001-8621-498X
CR Aguila M., 1954, Optica Acta, V1, P59
   Binns A, 2005, OPHTHAL PHYSL OPT, V25, P492, DOI 10.1111/j.1475-1313.2005.00338.x
   BIRCH DG, 1988, DOC OPHTHALMOL, V69, P211, DOI 10.1007/BF00154401
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BROWN B, 1986, AM J OPTOM PHYS OPT, V63, P450
   Chen CZ, 2004, DOC OPHTHALMOL, V109, P1
   CHENG AS, 1993, OPTOMETRY VISION SCI, V70, P89, DOI 10.1097/00006324-199302000-00001
   Cideciyan AV, 1997, INVEST OPHTH VIS SCI, V38, P1786
   Criswell MH, 2005, INVEST OPHTH VIS SCI, V46, P2168, DOI 10.1167/iovs.04-1442
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   DAWSON WW, 1979, INVEST OPHTH VIS SCI, V18, P988
   Derwent JJK, 2004, INVEST OPHTH VIS SCI, V45, P2447, DOI 10.1167/iovs.03-1178
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   Feigl B, 2005, EYE, V19, P431, DOI 10.1038/sj.eye.6701503
   FISHMAN GA, 1991, OPHTHALMOLOGY, V98, P957
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Hare William A., 2002, Documenta Ophthalmologica, V105, P189, DOI 10.1023/A:1020553020264
   Heinemann-Vernaleken B, 2001, GRAEF ARCH CLIN EXP, V239, P556, DOI 10.1007/s004170100308
   HOLLINS M, 1973, J GEN PHYSIOL, V62, P430, DOI 10.1085/jgp.62.4.430
   Horiguchi M, 1998, BRIT J OPHTHALMOL, V82, P1007, DOI 10.1136/bjo.82.9.1007
   ITABASHI R, 1993, GRAEF ARCH CLIN EXP, V231, P555, DOI 10.1007/BF00936518
   Jaakkola A, 2005, OPHTHALMOLOGY, V112, P567, DOI 10.1016/j.ophtha.2004.11.029
   Jackson GR, 2004, INVEST OPHTH VIS SCI, V45, P3271, DOI 10.1167/iovs.04-0019
   JACOBSON SG, 1995, NAT GENET, V11, P27, DOI 10.1038/ng0995-27
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Kondo M, 2002, INVEST OPHTH VIS SCI, V43, P2500
   Kondo M, 2001, INVEST OPHTH VIS SCI, V42, P305
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Lip PL, 1999, EYE, V13, P16, DOI 10.1038/eye.1999.4
   LOVASIK JV, 1983, INVEST OPHTH VIS SCI, V24, P437
   Mahroo OAR, 2004, J PHYSIOL-LONDON, V554, P417, DOI 10.1113/jphysiol.2003.051250
   Marshall J., 1998, RETINAL PIGMENT EPIT, P669
   Michels S, 2005, KLIN MONATSBL AUGENH, V222, P480, DOI 10.1055/s-2005-858315
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Parisi V, 2002, INVEST OPHTH VIS SCI, V43, P2741
   Parisi Vincenzo, 2001, Documenta Ophthalmologica, V102, P251, DOI 10.1023/A:1017514616801
   Pawlak D, 2004, J FR OPHTALMOL, V27, p3S31
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   REMULLA JFC, 1995, BRIT J OPHTHALMOL, V79, P558, DOI 10.1136/bjo.79.6.558
   ROY M, 1990, Eye (London), V4, P813
   Saari JC, 2000, INVEST OPHTH VIS SCI, V41, P337
   Sandberg MA, 1998, OPHTHALMOLOGY, V105, P441, DOI 10.1016/S0161-6420(98)93025-1
   SANDBERG MA, 1993, INVEST OPHTH VIS SCI, V34, P3477
   SANDBERG MA, 1995, RETINA-J RET VIT DIS, V15, P407, DOI 10.1097/00006982-199515050-00006
   Sandberg MA, 1996, INVEST OPHTH VIS SCI, V37, P930
   Sharpe LT, 1999, TRENDS NEUROSCI, V22, P497, DOI 10.1016/S0166-2236(99)01458-7
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   STEINMETZ RL, 1992, INVEST OPHTH VIS SCI, V33, P1633
   STRAHLMAN ER, 1983, ARCH OPHTHALMOL-CHIC, V101, P1191
   SUNNESS JS, 1985, ARCH OPHTHALMOL-CHIC, V103, P811
   Viswanathan Suresh, 2002, Documenta Ophthalmologica, V105, P223, DOI 10.1023/A:1020505104334
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wang M, 1999, ACTA OPHTHALMOL SCAN, V77, P402, DOI 10.1034/j.1600-0420.1999.770408.x
   Weber U, 2005, OPHTHALMOLOGE, V102, P355, DOI 10.1007/s00347-004-1117-y
   WU G, 1990, ARCH OPHTHALMOL-CHIC, V108, P1556, DOI 10.1001/archopht.1990.01070130058030
   [No title captured]
NR 62
TC 26
Z9 26
U1 0
U2 10
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2007
VL 48
IS 6
BP 2806
EP 2813
DI 10.1167/iovs.06-0392
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 174UA
UT WOS:000246967100045
PM 17525216
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Vallance, JH
   Johnson, B
   Majid, MA
   Banerjee, S
   Mandal, K
   Bailey, CC
AF Vallance, J. H.
   Johnson, B.
   Majid, M. A.
   Banerjee, S.
   Mandal, K.
   Bailey, C. C.
TI A randomised prospective double-masked exploratory study comparing
   combination photodynamic treatment and intravitreal ranibizumab vs
   intravitreal ranibizumab monotherapy in the treatment of neovascular
   age-related macular degeneration
SO EYE
LA English
DT Article
DE neovascularisation; macula; degeneration; treatment-medical; clinical
   trials
ID VERTEPORFIN; THERAPY
AB Aims The aim of this study is to evaluate the effect of standard-fluence verteporfin photodynamic therapy (PDT) delivered on the first day of a ranibizumab regimen for choroidal neovascularisation secondary to age-related macular degeneration compared with ranibizumab monotherapy.
   Methods Patients were randomised to sham or standard-fluence verteporfin PDT at baseline. The first of three monthly loading doses of ranibizumab was given on the same day, and thereafter patients received monthly treatment with ranibizumab as required. All patients underwent monthly visual acuity and OCT assessment and 3-monthly fluorescein angiography with follow-up to 1 year.
   Results In all, 18 patients were recruited. The PDT group gained a mean of 2.2 ETDRS letters at 1 year and the sham group gained a mean of 4.4 letters (P = 0.47). Both groups required a mean of 1.3 injections of ranibizumab following the 3-month loading phase. Fluorescein angiography at 1 month demonstrated marked choroidal hypoperfusion in all patients treated with PDT with reduced choroidal perfusion persisting to month 12. This did not occur in the sham group.
   Conclusion The addition of standard-fluence verteporfin PDT at baseline to a ranibizumab regimen conferred no benefit in terms of visual acuity or number of ranibizumab injections required at 1 year. The combination of these treatments resulted in persistent reduced choroidal perfusion, which raises potential safety concerns. Eye (2010) 24, 1561-1567; doi:10.1038/eye.2010.84; published online 25 June 2010
C1 [Vallance, J. H.; Johnson, B.; Majid, M. A.; Banerjee, S.; Mandal, K.; Bailey, C. C.] Bristol Eye Hosp, Clin Res Unit, Bristol BS1 2LX, Avon, England.
C3 Bristol Eye Hospital
RP Bailey, CC (通讯作者)，Bristol Eye Hosp, Clin Res Unit, Lower Maudlin St, Bristol BS1 2LX, Avon, England.
EM clare.bailey@bristol.ac.uk
FU Novartis UK
FX We acknowledge Ms S Patra for her contribution as one of the assessors
   of fluorescein angiograms in this study and we also like to acknowledge
   the dedication of all the Clinical Research Unit staff at Bristol Eye
   Hospital. This study was funded by a block grant from Novartis UK.
CR Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Kiss CG, 2008, BRIT J OPHTHALMOL, V92, P1620, DOI 10.1136/bjo.2007.135335
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Piermarocchi S, 2008, ARCH OPHTHALMOL-CHIC, V126, P1367, DOI 10.1001/archopht.126.10.1367
   PRUENTE C, ARVO MAY 2009
   Schmidt-Erfurth U, 2008, BRIT J OPHTHALMOL, V92, P1628, DOI 10.1136/bjo.2007.135277
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   Schmidt-Erfurth U, 2009, PROG RETIN EYE RES, V28, P145, DOI 10.1016/j.preteyeres.2009.01.001
   Shah GK, 2009, RETINA-J RET VIT DIS, V29, P133, DOI 10.1097/IAE.0b013e3181960a28
   Spaide Richard F, 2009, Retina, V29, pS5, DOI 10.1097/IAE.0b013e3181ad237a
   GUIDELINES INTRAVITR
NR 12
TC 18
Z9 21
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD OCT
PY 2010
VL 24
IS 10
BP 1561
EP 1567
DI 10.1038/eye.2010.84
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 664JM
UT WOS:000282956200004
PM 20577273
OA Bronze
DA 2022-11-30
ER

PT J
AU Evans, JR
   Fletcher, AE
   Wormald, RPL
AF Evans, JR
   Fletcher, AE
   Wormald, RPL
TI 28,000 Cases of age related macular degeneration causing visual loss in
   people aged 75 years and above in the United Kingdom may be attributable
   to smoking
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OLDER-PEOPLE; CIGARETTE-SMOKING; RISK-FACTORS; MRC TRIAL; MACULOPATHY;
   IMPAIRMENT; MANAGEMENT; BRITAIN
AB Background: Age related macular degeneration (AMD) causing visual impairment is common in older people. Previous studies have identified smoking as a risk factor for AMD. However, there is limited information for the older population in Britain.
   Methods: Population based cross sectional analytical study based in 49 practices selected to be representative of the population of Britain. Cases were people aged 75 years and above who were visually impaired (binocular acuity <6/18) as a result of AMD. Controls were people with normal vision (6/6 or better). Smoking history was ascertained using an interviewer administered questionnaire.
   Results: After controlling for potentially confounding factors, current smokers were twice as likely to have AMD compared to non-smokers (odds ratio 2.15, 95% CI 1.42 to 3.26). Ex-smokers were at intermediate risk (odds ratio 1.13, 0.86 to 1.47). People who stopped smoking more than 20 years previously were not at increased risk of AMD causing visual loss. Approximately 28 000 cases of AMD in older people in the United Kingdom may be attributable to smoking.
   Conclusion: This is the largest study of the association of smoking and AMD in the British population. Smoking is associated with a twofold increased risk of developing AMD. An increased risk of AMD, which is the most commonly occurring cause of blindness in the United Kingdom, is yet another reason for people to stop smoking and governments to develop public health campaigns against this hazard.
C1 Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London WC1E 7HT, England.
   Univ London London Sch Hyg & Trop Med, Non Communicable Dis Epidemiol Unit, London WC1E 7HT, England.
   Univ London London Sch Hyg & Trop Med, Moorfields Eye Hosp, London WC1E 7HT, England.
C3 University of London; London School of Hygiene & Tropical Medicine;
   University of London; London School of Hygiene & Tropical Medicine;
   University of London; London School of Hygiene & Tropical Medicine;
   University College London; Moorfields Eye Hospital NHS Foundation Trust
RP Evans, JR (通讯作者)，Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, Keppel St, London WC1E 7HT, England.
EM Jennifer.evans@lshtm.ac.uk
RI Evans, Jennifer/F-4672-2012
OI Evans, Jennifer/0000-0002-6137-2030
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Evans J., 1995, STUDIES MED POPULATI, V57
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Evans JR, 2004, BRIT J OPHTHALMOL, V88, P365, DOI 10.1136/bjo.2003.019927
   Evans JR, 2002, BRIT J OPHTHALMOL, V86, P795, DOI 10.1136/bjo.86.7.795
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Fletcher AE, 2002, BMC HEALTH SERV RES, V2, DOI 10.1186/1472-6963-2-21
   Hulea S. A., 1995, Journal of Environmental Pathology Toxicology and Oncology, V14, P173
   Kelly SP, 2004, BRIT MED J, V328, P537, DOI 10.1136/bmj.328.7439.537
   Klaver CCW, 1997, ARCH OPHTHALMOL-CHIC, V115, P945, DOI 10.1001/archopht.1997.01100160115033
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Marang-van de Mheen PJ, 2001, J EPIDEMIOL COMMUN H, V55, P24
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   MCGRAW PV, 1993, OPHTHAL PHYSL OPT, V13, P400, DOI 10.1111/j.1475-1313.1993.tb00499.x
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 24
TC 85
Z9 87
U1 0
U2 11
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2005
VL 89
IS 5
BP 550
EP 553
DI 10.1136/bjo.2004.049726
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 917GN
UT WOS:000228444600012
PM 15834082
OA Bronze, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Neuner, B
   Komm, A
   Wellmann, J
   Dietzel, M
   Pauleikhoff, D
   Walter, J
   Busch, M
   Hense, HW
AF Neuner, Bruno
   Komm, Alexander
   Wellmann, Juergen
   Dietzel, Martha
   Pauleikhoff, Daniel
   Walter, Jan
   Busch, Markus
   Hense, Hans-Werner
TI Smoking history and the incidence of age-related macular
   degeneration-Results from the Muenster Aging and Retina Study (MARS)
   cohort and systematic review and meta-analysis of observational
   longitudinal studies
SO ADDICTIVE BEHAVIORS
LA English
DT Article
DE Age-related maculopathy; Age-related macular degeneration; Smoking;
   Systematic review; Meta-analysis
ID LONG-TERM INCIDENCE; BODY-MASS INDEX; RISK-FACTORS; CIGARETTE-SMOKING;
   5-YEAR INCIDENCE; FOLLOW-UP; INFLAMMATORY MARKERS; 10-YEAR INCIDENCE;
   CATARACT-SURGERY; BETA-CAROTENE
AB To compare the association of smoking with age-related macular degeneration (AMD) in the Muenster Aging and Retina Study (MARS) cohort with current evidence. Adjusted risk ratios for incident AMD in MARS were compared with findings of a systematic review and meta-analysis of observational prospective studies. 9.6% of MARS participants progressed to AMD over a median of 30.9 months. In MARS the adjusted risk ratio in current versus never smokers was 3.25 (95% confidence interval [1.50-7.06]), and 1.28 [0.70-2.33] in former smokers versus never smokers. The meta-analysis of previous studies showed a pooled adjusted risk ratio of 2.51 [1.09-5.76] in current versus never smokers. Inclusion of the MARS findings removed between-study heterogeneity and accentuated the pooled adjusted risk ratio for current smokers to 2.75 [1.52-4.98]. Specific analyses in MARS revealed a protective effect for time since smoking cessation in former smokers with an adjusted risk ratio=0.50 [0.29-0.89] per log(year). Current smoking nearly triples AMD incidence, while smoking cessation lowers AMD incidence in a non-linear fashion even in the elderly, (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Neuner, Bruno; Komm, Alexander; Wellmann, Juergen; Dietzel, Martha; Hense, Hans-Werner] Univ Munster, Inst Epidemiol & Social Med, Clin Epidemiol Sect, D-48149 Munster, Germany.
   [Dietzel, Martha; Pauleikhoff, Daniel] St Franziskus Hosp Muenster, Dept Ophthalmol, Munster, Germany.
   [Walter, Jan] Univ Calif Riverside, Dept Plant Pathol & Microbiol, Riverside, CA 92521 USA.
   [Busch, Markus] Robert Koch Inst, Dept Epidemiol & Hlth Surveillance, D-1000 Berlin, Germany.
C3 University of Munster; St. Franziskus-Hospital; University of California
   System; University of California Riverside; Robert Koch Institute
RP Neuner, B (通讯作者)，Univ Munster, Inst Epidemiol & Social Med, Clin Epidemiol Sect, Domagkstr 3, D-48149 Munster, Germany.
EM neuner@uni-muenster.de; a_komm01@uni-muenster.de;
   wellmann@uni-muenster.de; martha.dietzel@gmx.de;
   dapauleikhoff@muenster.de; jan.walter@ucr.edu; buschM@rki.de;
   hense@uni-muenster.de
OI Busch, Markus/0000-0003-4936-983X; Walter, Jan/0000-0003-2247-5560
FU Deutsche Forschungsgemeinschaft [HE 2293/5-1, 2293/5-2, 2293/5-3];
   ProRetina Foundation; IMF Fund of the University of Muenster
FX The authors thank Thomas Behrens, Burkhardt Dasch, Andrea Fuhs, Britta
   Heimes, Katharina Lipinski and Astrid Meister for their examinations and
   grading of fundus photographs during MARS-1 respectively MARS-11 as well
   as Birte Claes for data management during the whole study period. MARS
   was sponsored by the Deutsche Forschungsgemeinschaft (Grants HE
   2293/5-1, 2293/5-2, and 2293/5-3), by the ProRetina Foundation, and IMF
   Fund of the University of Muenster. No financial disclosures were
   reported by the authors of this paper.
CR Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   Behrendt CE, 2004, OPHTHAL EPIDEMIOL, V11, P359, DOI 10.1080/09286580490515125
   Boekhoorn SS, 2007, INVEST OPHTH VIS SCI, V48, P1012, DOI 10.1167/iovs.06-0577
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chan D, 1998, OPTOMETRY VISION SCI, V75, P476, DOI 10.1097/00006324-199807000-00015
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   *COMPR MET, 2007, VERS 2 2 046
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Dandekar SS, 2006, BRIT J OPHTHALMOL, V90, P724, DOI 10.1136/bjo.2005.086355
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   Dasch B, 2005, GRAEF ARCH CLIN EXP, V243, P1028, DOI 10.1007/s00417-005-1176-z
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Egger M, 1998, BRIT MED J, V316, P140
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   FRIBERG TR, 2005, INVESTIGATIVE OPHTHA, V46
   Fuhs A, 2005, KLIN MONATSBL AUGENH, V222, P649, DOI 10.1055/s-2005-858367
   Gentile Ronald, 2007, Surv Ophthalmol, V52, P551, DOI 10.1016/j.survophthal.2007.06.002
   GREENLAND S, 1977, AM J EPIDEMIOL, V106, P184, DOI 10.1093/oxfordjournals.aje.a112451
   Heeringa J, 2008, AM HEART J, V156, P1163, DOI 10.1016/j.ahj.2008.08.003
   HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein BEK, 2000, AM J OPHTHALMOL, V130, P322, DOI 10.1016/S0002-9394(00)00474-8
   Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein R, 2001, AM J OPHTHALMOL, V132, P128, DOI 10.1016/S0002-9394(00)00931-4
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Leffondre K, 2002, AM J EPIDEMIOL, V156, P813, DOI 10.1093/aje/kwf122
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Morrison TC, 1997, CONTROL CLIN TRIALS, V18, P383, DOI 10.1016/S0197-2456(97)00025-1
   Neuner B, 2008, OPHTHAL EPIDEMIOL, V15, P148, DOI 10.1080/09286580802105830
   Neuner B, 2007, J STUD ALCOHOL DRUGS, V68, P133, DOI 10.15288/jsad.2007.68.133
   Neuner B, 2007, ANN EPIDEMIOL, V17, P615, DOI 10.1016/j.annepidem.2007.03.005
   Pham TQ, 2005, AM J OPHTHALMOL, V139, P536, DOI 10.1016/j.ajo.2004.08.070
   PSATY BM, 1994, AM J EPIDEMIOL, V140, P161, DOI 10.1093/oxfordjournals.aje.a117226
   Robman L, 2007, CAN J OPHTHALMOL, V42, P720, DOI 10.3129/i07-116
   Santos Laura Patrícia Ferreira, 2005, Arq. Bras. Oftalmol., V68, P229, DOI 10.1590/S0004-27492005000200014
   *SAS I INC, 2000, SAS VERS 9 13 COMP S
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Spiegelman D, 2005, AM J EPIDEMIOL, V162, P199, DOI 10.1093/aje/kwi188
   Sterne JAC, 2001, J CLIN EPIDEMIOL, V54, P1046, DOI 10.1016/S0895-4356(01)00377-8
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P224, DOI 10.1034/j.1600-0420.1998.760220.x
   Thomas MC, 2002, J PUBLIC HEALTH MED, V24, P285, DOI 10.1093/pubmed/24.4.285
   THOMTON, 2005, EYE, V19, P935
   Tikellis G, 2007, EYE, V21, P169, DOI 10.1038/sj.eye.6702151
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   1998, HARVARD WOMENS HLTH, V6, P2
NR 86
TC 34
Z9 35
U1 0
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4603
EI 1873-6327
J9 ADDICT BEHAV
JI Addict. Behav.
PD NOV
PY 2009
VL 34
IS 11
BP 938
EP 947
DI 10.1016/j.addbeh.2009.05.015
PG 10
WC Psychology, Clinical; Substance Abuse
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychology; Substance Abuse
GA 496TX
UT WOS:000270002800005
PM 19539431
DA 2022-11-30
ER

PT J
AU Holekamp, NM
   Campochiaro, PA
   Chang, MA
   Miller, D
   Pieramici, D
   Adamis, AP
   Brittain, C
   Evans, E
   Kaufman, D
   Maass, KF
   Patel, S
   Ranade, S
   Singh, N
   Barteselli, G
   Regillo, C
AF Holekamp, Nancy M.
   Campochiaro, Peter A.
   Chang, Margaret A.
   Miller, Daniel
   Pieramici, Dante
   Adamis, Anthony P.
   Brittain, Christopher
   Evans, Erica
   Kaufman, Derrick
   Maass, Katie F.
   Patel, Shienal
   Ranade, Shrirang
   Singh, Natasha
   Barteselli, Giulio
   Regillo, Carl
CA Archway Investigators
TI Archway Randomized Phase 3 Trial of the Port Delivery System with
   Ranibizumab for Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Long-acting drug delivery; Ocular
   implant; Sustained release; Vascular endothelial growth factor
ID REAL-WORLD OUTCOMES; VISUAL-ACUITY; AFLIBERCEPT; THERAPY
AB Purpose: To evaluate the safety and efficacy of the Port Delivery System with ranibizumab (PDS) for the treatment of neovascular age-related macular degeneration (nAMD). Design: Phase 3, open-label, randomized, visual acuity assessor-masked noninferiority and equivalence trial. Participants: Patients with nAMD diagnosed within 9 months of screening previously treated with and responsive to anti-vascular endothelial growth factor therapy. Methods: Patients were randomized 3:2 to treatment with the PDS with ranibizumab 100 mg/ml with fixed 24-week (Q24W) refill-exchanges (PDS Q24W) or intravitreal ranibizumab 0.5-mg injections every 4 weeks (monthly ranibizumab). Main Outcome Measures: Primary end point was change in best-corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study letter (letters) score from baseline averaged over weeks 36 and 40 (noninferiority margin,-4.5 letters; equivalence margin, +/- 4.5 letters). Results: Archway enrolled 418 patients; 251 were randomized to and 248 received treatment with the PDS Q24W, and 167 were randomized to and received treatment with monthly ranibizumab. Baseline BCVA was 74.4 letters (PDS Q24W arm) and 75.5 letters (monthly ranibizumab arm; Snellen equivalent, 20/32). Adjusted mean change in BCVA score from baseline averaged over weeks 36 and 40 was +0.2 letters (standard error [SE], 0.5 letters) in the PDS Q24W arm and +0.5 letters (SE, 0.6 letters) in the monthly ranibizumab arm (difference,-0.3 letters; 95% confidence interval,-1.7 to 1.1 letters). PDS Q24W was both noninferior and equivalent to monthly ranibizumab. Of 246 PDS-treated patients assessed for supplemental ranibizumab treatment, 242 (98.4%) did not receive supplemental ranibizumab treatment before the first refill-exchange procedure, including 4 patients who discontinued treatment before the first refill-exchange procedure. Prespecified ocular adverse events of special interest were reported in 47 patients (19.0%) in the PDS Q24W arm and 10 patients (6.0%) in the monthly ranibizumab arm, which included, in the former arm, 4 (1.6%) endophthalmitis cases, 2 (0.8%) retinal detachments, 13 (5.2%) vitreous hemorrhages, 6 (2.4%) conjunctival erosions, and 5 (2.0%) conjunctival retractions. Most ocular adverse events in the PDS Q24W arm occurred within 1 month of implantation. Conclusions: Archway met its primary objective and PDS Q24W demonstrated noninferior and equivalent efficacy to monthly ranibizumab, with 98.4% of PDS-treated patients not receiving supplemental treatment in the first 24-week interval. Ophthalmology 2022;129:295-307 (c) 2021 by the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Holekamp, Nancy M.] Pepose Vis Inst, 1815 Clarkson Rd, Chesterfield, MO 63017 USA.
   [Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
   [Chang, Margaret A.] Retinal Consultants, Sacramento, CA USA.
   [Miller, Daniel] Univ Cincinnati, Sch Med, Cincinnati Eye Inst, Cincinnati, OH 45221 USA.
   [Pieramici, Dante] Calif Retina Consultants, Santa Barbara, CA USA.
   [Adamis, Anthony P.; Brittain, Christopher; Evans, Erica; Kaufman, Derrick; Maass, Katie F.; Patel, Shienal; Ranade, Shrirang; Singh, Natasha; Barteselli, Giulio] Genentech Inc, San Francisco, CA 94080 USA.
   [Regillo, Carl] Wills Eye Hosp & Res Inst, Philadelphia, PA USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; University System of
   Ohio; University of Cincinnati; Roche Holding; Genentech; Jefferson
   University
RP Holekamp, NM (通讯作者)，Pepose Vis Inst, 1815 Clarkson Rd, Chesterfield, MO 63017 USA.
EM nholekamp@gmail.com
OI Maass, Katie/0000-0002-0493-2863; Miller, Daniel/0000-0002-1460-0117
FU Genentech, Inc., South San Francisco, California; Genentech, Inc., a
   member of the Roche Group
FX Genentech, Inc., South San Francisco, California, provided support for
   the study and participated in the study design; conducting the study;
   and data collection, management, and interpretation. Third-party writing
   assistance was provided by Betsy C. Taylor, PhD, and Karlina J.
   Kauffman, PhD, of Envision Pharma Group and funded by Genentech, Inc., a
   member of the Roche Group.
CR American Academy of Ophthalmology Retina/Vitreous Panel, PREF PRACT PATT GUID
   Beck RW, 2007, OPHTHALMOLOGY, V114, P1804, DOI 10.1016/j.ophtha.2007.06.047
   Budenz DL, 2016, AM J OPHTHALMOL, V163, P75, DOI 10.1016/j.ajo.2015.11.023
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Ciulla TA, 2018, OPHTHALMOL RETINA, V2, P645, DOI 10.1016/j.oret.2018.01.006
   Decroos FC, 2017, AM J OPHTHALMOL, V180, P142, DOI 10.1016/j.ajo.2017.06.002
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Ehlken C, 2020, GRAEF ARCH CLIN EXP, V258, P2077, DOI 10.1007/s00417-020-04798-2
   Gedde SJ, 2012, AM J OPHTHALMOL, V153, P789, DOI 10.1016/j.ajo.2011.10.026
   Gohil R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129361
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH HARM GUID INT AD
   Kertes PJ, 2020, JAMA OPHTHALMOL, V138, P244, DOI 10.1001/jamaophthalmol.2019.5540
   Khanani AM, 2021, OPHTHALMOL RETINA, V5, P775, DOI 10.1016/j.oret.2020.11.004
   Khanani AM, 2020, OPHTHALMOL RETINA, V4, P122, DOI 10.1016/j.oret.2019.09.009
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Li E, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012208.pub2
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Rufai SR, 2017, EYE, V31, P1337, DOI 10.1038/eye.2017.67
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stewart WC, 2010, EUR J OPHTHALMOL, V20, P124, DOI 10.1177/112067211002000117
   Tschosik E, 2019, INVEST OPHTH VIS SCI, V60
   Varano M, 2015, CLIN OPHTHALMOL, V9, P2243, DOI 10.2147/OPTH.S92548
   Vukicevic M, 2016, EYE, V30, P413, DOI 10.1038/eye.2015.235
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
NR 30
TC 35
Z9 35
U1 11
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2022
VL 129
IS 3
BP 295
EP 307
DI 10.1016/j.ophtha.2021.09.016
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZG6AZ
UT WOS:000760340600008
PM 34597713
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Gerding, H
   Loukopoulos, V
   Riese, J
   Hefner, L
   Timmermann, M
AF Gerding, Heinrich
   Loukopoulos, Vlassios
   Riese, Juliane
   Hefner, Lars
   Timmermann, Melanie
TI Results of flexible ranibizumab treatment in age-related macular
   degeneration and search for parameters with impact on outcome
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age related macular degeneration; Ranibizumab; Lucentis; Anti-VEGF;
   Macula; Retina
ID VISUAL-ACUITY MEASUREMENT; INTRAVITREAL RANIBIZUMAB; LUCENTIS; REGIMEN
AB Background The aim of this study was to analyse functional results of flexible ranibizumab treatment in exudative age-related macular degeneration (AMD), and to search for parameters with impact on outcome.
   Methods Analysis of a retrospective institutional case series (104 eyes) with a low-threshold re-treatment algorithm and monthly follow-up for 12 months.
   Results Visual acuity (VA) improved at month 3 by +6.7 letters and declined slightly until month 12 to a level of +5.0 letters. On average, eyes received 5.8 injections. A significant loss in VA occurred in the whole group between months 5 and 6 (-2.0 letters), never in the "winner" group (improvement of > 5 letters at month 12), between months 5 and 6 (-3.8 letters) in the "stabilizer" group (a dagger of +/- 5 letters at month 12) and twice, between months 3 and 7 (-7.0 letters) and months 9 and 12 (-6.9 letters), in the "loser" group (loss of > 5 letters at month 12). These major functional declines followed moderate but significant increases in average CFT (OCT-central foveal thickness) of 23 to 33 mu m. Increased CFT followed periods with a low percentage of treated eyes per month in each group. The amount of regained vision was significantly related to the extent of previous functional loss. The critical limit of short-term VA decline that was associated with the possibility for full VA restoration can approximately be quantified at -4 letters. Restoration of short-term VA deterioration (last month) was significantly better than long-term VA loss (related to the end of loading phase). Restoration of VA loss stratifies mainly into two groups: a group that regained -25 to 25% and one that regained 75 to 125%. A significant correlation was found between the number of injections and functional outcome at month 12 for eyes receiving more than four injections. It was calculated that a mean of 8.4 injections per eye would have been necessary to stabilize vision within the first 12 months.
   Conclusions CFT is a sensitive and early predictor of VA deterioration. Four letters of acute VA loss seems to be a critical limit. VA loss of >= 4 letters appears to be associated with incomplete recovery. Eyes with < 1 line of gain at the end of the loading phase should be considered for continuation of treatment at months 3 and 4. According to our calculations an average number of 8.4 injections/eye seems to be necessary to maintain stabilization of vision in the first year of treatment.
C1 [Gerding, Heinrich; Loukopoulos, Vlassios; Riese, Juliane; Hefner, Lars; Timmermann, Melanie] Klin Pallas, Dept Retinol, CH-4600 Olten, Switzerland.
   [Gerding, Heinrich] Univ Munster, Dept Ophthalmol, D-48129 Munster, Germany.
C3 University of Munster
RP Gerding, H (通讯作者)，Klin Pallas, Dept Retinol, Louis Giroud Str 20, CH-4600 Olten, Switzerland.
EM hgerding@klinik-pallas.ch
RI Gerding, Heinrich/M-2363-2019
OI Gerding, Heinrich/0000-0003-3968-5601
FU Pallas Group AG
FX The authors thank Prof. Dr. Daniel Pauleikhoff and Priv.-Doz. Dr.
   Andreas Wenzel for their cooperative contribution in discussing our
   data, Conny Meier for her skilful organization, and the Pallas Group AG
   for financing a fellowship of Dr. Loukopoulos.
CR BLACKHURST DW, 1989, RETINA-J RET VIT DIS, V9, P163, DOI 10.1097/00006982-198909030-00001
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   *EMEA, 2007, LUC SCI DISC
   *EMEA, 2007, LUC SUMM PROD CHAR
   Ernst Benjamin J., 2010, International Ophthalmology, V30, P267, DOI 10.1007/s10792-009-9324-9
   ETER N, 2009, EURETINA NIC
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gerding H, 2010, KLIN MONATSBL AUGENH, V227, P294, DOI 10.1055/s-0029-1245209
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Kang S, 2009, JPN J OPHTHALMOL, V53, P389, DOI 10.1007/s10384-009-0670-y
   Krebs I, 2010, OPHTHALMOLOGY, V117, P1577, DOI 10.1016/j.ophtha.2010.04.032
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Leinonen J, 2005, ACTA OPHTHALMOL SCAN, V83, P328, DOI 10.1111/j.1600-0420.2005.00469.x
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   ROTHENBUHLER S, 2009, OPHTHALMOLOGICA, V223, P383
   SIMADER C, 2009, ARVO 2009
   Taban M, 2010, OPHTHAL SURG LAS IM, V41, P166, DOI 10.3928/15428877-20100303-03
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 24
TC 43
Z9 46
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2011
VL 249
IS 5
BP 653
EP 662
DI 10.1007/s00417-011-1636-6
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 756SN
UT WOS:000290035100005
PM 21387180
DA 2022-11-30
ER

PT J
AU Terheyden, JH
   Holz, FG
   Schmitz-Valckenberg, S
   Luning, A
   Schmid, M
   Rubin, GS
   Dunbar, H
   Tufail, A
   Crabb, DP
   Binns, A
   Sanchez, CI
   Hoyng, C
   Margaron, P
   Zakaria, N
   Durbin, M
   Luhmann, U
   Zamiri, P
   Cunha-Vaz, J
   Martinho, C
   Leal, S
   Finger, RP
AF Terheyden, Jan H.
   Holz, Frank G.
   Schmitz-Valckenberg, Steffen
   Luening, Anna
   Schmid, Matthias
   Rubin, Gary S.
   Dunbar, Hannah
   Tufail, Adnan
   Crabb, David P.
   Binns, Alison
   Sanchez, Clara, I
   Hoyng, Carel
   Margaron, Philippe
   Zakaria, Nadia
   Durbin, Mary
   Luhmann, Ulrich
   Zamiri, Parisa
   Cunha-Vaz, Jose
   Martinho, Cecilia
   Leal, Sergio
   Finger, Robert P.
CA MACUSTAR Consortium
TI Clinical study protocol for a low-interventional study in intermediate
   age-related macular degeneration developing novel clinical endpoints for
   interventional clinical trials with a regulatory and patient access
   intention-MACUSTAR
SO TRIALS
LA English
DT Article
DE Intermediate age-related macular degeneration; Clinical study protocol;
   Disease progression; Clinical endpoint
ID VISUAL-ACUITY LOSS; NATURAL-HISTORY; LOW LUMINANCE; GEOGRAPHIC ATROPHY;
   DARK-ADAPTATION; MICROPERIMETRY; PREVALENCE; DRUSEN; BIOMARKERS;
   MORPHOLOGY
AB Background: There is an unmet need for treatment options in intermediate age-related macular degeneration (iAMD). However, for any new interventions to be tested in clinical trials, novel currently unavailable clinical endpoints need to be developed. Thus, the MACUSTAR study aims to develop and evaluate functional, structural, and patient-reported candidate endpoints for use in future iAMD trials.
   Methods: The protocol describes a low-interventional clinical multicenter study employing a novel two-part design. The cross-sectional part (total duration, 1 month) and the longitudinal part (total duration, 36 months) include participants with iAMD and control groups with early/late/no AMD. The cross-sectional part's primary objective is a technical evaluation of functional, structural, and patient-reported candidate outcomes. The longitudinal part's primary objective is to assess the prognostic power of changes in functional, structural, and patient-reported outcomes for progression from iAMD to late AMD. All data will be used to support a biomarker qualification procedure by regulatory authorities.
   Discussion: The MACUSTAR study characterizes and evaluates much needed novel functional, structural, and patient-reported endpoints for future clinical trials in iAMD and will improve our understanding of the natural history and prognostic markers of this condition.
C1 [Terheyden, Jan H.; Holz, Frank G.; Schmitz-Valckenberg, Steffen; Luening, Anna; Finger, Robert P.] Univ Hosp Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
   [Schmid, Matthias] Univ Bonn, Med Fac, Inst Med Biometry Informat & Epidemiol, Bonn, Germany.
   [Rubin, Gary S.; Dunbar, Hannah] UCL, UCL Inst Ophthalmol, London, England.
   [Tufail, Adnan] Moorfields Eye Hosp, London, England.
   [Crabb, David P.; Binns, Alison] Univ London, Sch Hlth Sci, Div Optometry & Visual Sci, London, England.
   [Sanchez, Clara, I; Hoyng, Carel] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands.
   [Margaron, Philippe; Zakaria, Nadia; Zamiri, Parisa] Novartis Pharma AG, Basel, Switzerland.
   [Durbin, Mary] Carl Zeiss Meditec AG, Dublin, CA USA.
   [Luhmann, Ulrich] Roche Innovat Ctr Basel, Roche Pharma Res & Early Dev, Roche Pharmaceut Res & Early Dev Translat Med Oph, Basel, Switzerland.
   [Cunha-Vaz, Jose; Martinho, Cecilia] Assoc Innovat & Biomed Res Light & Image, Coimbra, Portugal.
   [Leal, Sergio] Bayer AG, Berlin, Germany.
C3 University of Bonn; University of Bonn; University of London; University
   College London; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of London;
   Radboud University Nijmegen; Novartis; Carl Zeiss AG; Roche Holding;
   Universidade de Coimbra; Bayer AG
RP Finger, RP (通讯作者)，Univ Hosp Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM robertfinger@ukbonn.de
OI Crabb, David/0000-0001-8754-3902; Terheyden, Jan
   Henrik/0000-0002-0174-4066; Cunha-Vaz, Jose/0000-0002-0947-9850;
   Brazier, John/0000-0001-8645-4780; Schmid, Matthias/0000-0002-0788-0317;
   Tufail, Adnan/0000-0001-6131-7640
FU Innovative Medicines Initiative 2 Joint Undertaking [116076]; European
   Union's Horizon 2020 research and innovation programme; EFPIA
FX This project has received funding from the Innovative Medicines
   Initiative 2 Joint Undertaking under grant agreement No 116076. This
   Joint Undertaking receives support from the European Union's Horizon
   2020 research and innovation programme and EFPIA.
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Cassels NK, 2018, SURV OPHTHALMOL, V63, P40, DOI 10.1016/j.survophthal.2017.05.007
   Cocce KJ, 2018, AM J OPHTHALMOL, V189, P127, DOI 10.1016/j.ajo.2018.02.012
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Crossland MD, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-5
   Csaky K, 2017, INVEST OPHTH VIS SCI, V58, P3456, DOI 10.1167/iovs.17-22339
   Dimitrov PN, 2012, INVEST OPHTH VIS SCI, V53, P5213, DOI 10.1167/iovs.11-8958
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2019, OPHTHALMOLOGICA, V241, P61, DOI 10.1159/000491402
   Finger RP, 2011, BRIT J OPHTHALMOL, V95, P1061, DOI 10.1136/bjo.2010.194712
   Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Heller G, 2015, ANN ONCOL, V26, P2012, DOI 10.1093/annonc/mdv333
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hsu ST, 2019, OPHTHALMOL RETINA, V3, P637, DOI 10.1016/j.oret.2019.03.010
   Jackson GR, 2014, OPTOMETRY VISION SCI, V91, P925, DOI 10.1097/OPX.0000000000000247
   Lesko LJ, 2001, ANNU REV PHARMACOL, V41, P347, DOI 10.1146/annurev.pharmtox.41.1.347
   Li JQ, 2019, BR J OPHTHALMOL, DOI [10.1136/bjophthalmol-2019-314422., DOI 10.1136/BJ0PHTHALM0L-2019-314422]
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Medeiros FA, 2015, BRIT J OPHTHALMOL, V99, P599, DOI 10.1136/bjophthalmol-2014-305550
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Pfau M, 2018, EYE, V32, P1819, DOI 10.1038/s41433-018-0183-3
   PRENTICE RL, 1989, STAT MED, V8, P431, DOI 10.1002/sim.4780080407
   Psaty BM, 1999, JAMA-J AM MED ASSOC, V282, P786, DOI 10.1001/jama.282.8.786
   Puell MC, 2012, INVEST OPHTH VIS SCI, V53, P7310, DOI 10.1167/iovs.11-8649
   Rohrschneider K, 2008, PROG RETIN EYE RES, V27, P536, DOI 10.1016/j.preteyeres.2008.07.003
   Russell RA, 2012, INVEST OPHTH VIS SCI, V53, P5985, DOI 10.1167/iovs.12-10428
   Russell RA, 2012, INVEST OPHTH VIS SCI, V53, P2760, DOI 10.1167/iovs.11-7976
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Sevilla MB, 2016, AM J OPHTHALMOL, V165, P65, DOI 10.1016/j.ajo.2016.02.021
   Shah N, 2016, BRIT J OPHTHALMOL, V100, P1346, DOI 10.1136/bjophthalmol-2015-307375
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   van Grinsven MJJP, 2015, INVEST OPHTH VIS SCI, V56, P633, DOI 10.1167/iovs.14-15019
   van Grinsven MJJP, 2013, INVEST OPHTH VIS SCI, V54, P3019, DOI 10.1167/iovs.12-11449
   Venhuizen FG, 2017, INVEST OPHTH VIS SCI, V58, P2318, DOI 10.1167/iovs.16-20541
   Welker Susanne G, 2018, Invest Ophthalmol Vis Sci, V59, pAMD152, DOI 10.1167/iovs.18-23878
   Wickstrom K, 2017, INVEST OPHTH VIS SCI, V58, pBIO27, DOI 10.1167/iovs.17-21778
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55345-x
   Wu ZC, 2016, BRIT J OPHTHALMOL, V100, P395, DOI 10.1136/bjophthalmol-2015-306621
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
NR 49
TC 9
Z9 9
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD JUL 18
PY 2020
VL 21
IS 1
AR 659
DI 10.1186/s13063-020-04595-6
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA MP8IQ
UT WOS:000552443600001
PM 32682441
OA Green Accepted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Sayanagi, K
   Sharma, S
   Yamamoto, T
   Kaiser, PK
AF Sayanagi, Kaori
   Sharma, Sumit
   Yamamoto, Takuhiro
   Kaiser, Peter K.
TI Comparison of Spectral-Domain versus Time-Domain Optical Coherence
   Tomography in Management of Age-Related Macular Degeneration with
   Ranibizumab
SO OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULAR MEMBRANES; FLUORESCEIN ANGIOGRAPHY; PHOTODYNAMIC
   THERAPY; SPEED
AB Purpose: To compare the ability to delineate and detect patterns of choroidal neovascularization (CNV) activity in patients with exudative age-related macular degeneration (AMD) after ranibizumab treatment between time-domain optical coherence tomography (TD-OCT) and 4 different spectral-domain optical coherence tomography (SD-OCT) devices.
   Design: Prospective, consecutive case series.
   Participants: Sixty-one eyes of 58 patients with exudative AMD after ranibizumab treatment were included in this study.
   Methods: All patients were imaged with TD-OCT and at least 1 of 4 different SD-OCT devices at the same visit after ranibizumab treatment. The OCT images were analyzed in a masked fashion by 2 independent graders (KS, TY) to delineate and detect the presence of CNV activity defined as the presence of subretinal fluid, intraretinal cysts, intraretinal fluid, sub-retinal pigment epithelium (sub-RPE) fluid, or a combination thereof. The automated evaluation of retinal thickness also was analyzed between devices.
   Main Outcome Measures: Evidence of CNV activity on linear B-scans and 3-dimensional so-called cube scans on SD-OCT and linear B-scan on TD-OCT.
   Results: In linear B-scan mode, all 4 SD-OCT devices were superior in their ability to delineate sub-RPE fluid compared with TD-OCT (P<0.05). Three of 4 SD-OCT devices were superior in delineating intraretinal fluid, and 2 of 4 SD-OCT devices were superior in delineating subretinal fluid and intraretinal cysts (P<0.05). In the 3-dimensional so-called cube mode, all 4 SD-OCT devices were superior in detecting subretinal fluid and 2 of 4 SD-OCT devices were superior in detecting sub-RPE and intraretinal fluid (P<0.05). There were significant correlations in center point thickness between all SD-OCT devices and TD-OCT (P<0.01), and 3 of 4 and 1 of 3 SD-OCT devices showed significant differences from TD-OCT in center point thickness (P<0.01) and center subfield thickness (P<0.001), respectively.
   Conclusions: SD-OCT is superior to TD-OCT in evaluating for CNV activity in patients with wet AMD after ranibizumab injection. Retinal thickness measurements between SD-OCT and TD-OCT also were significantly different.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2009;116:947-955 (C) 2009 by the American Academy of Ophthalmology.
C1 [Sayanagi, Kaori; Sharma, Sumit; Yamamoto, Takuhiro; Kaiser, Peter K.] Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation
RP Kaiser, PK (通讯作者)，Cleveland Clin Fdn, Cole Eye Inst, 9500 Euclid Ave,Desk I3, Cleveland, OH 44195 USA.
EM pkkaiser@aol.com
OI Kaiser, Peter/0000-0001-5126-045X; Sharma, Sumit/0000-0001-5769-0717
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen TC, 2005, ARCH OPHTHALMOL-CHIC, V123, P1715, DOI 10.1001/archopht.123.12.1715
   Eter N, 2005, RETINA-J RET VIT DIS, V25, P691, DOI 10.1097/00006982-200509000-00002
   Forooghian F, 2008, INVEST OPHTH VIS SCI, V49, P4290, DOI 10.1167/iovs.08-2113
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman SM, 2000, AM J OPHTHALMOL, V130, P839, DOI 10.1016/S0002-9394(00)00605-X
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   HOLE FG, 2003, OPHTHALMOLOGY, V110, P400
   Kaiser PK, 2007, INT J CLIN PRACT, V61, P501, DOI 10.1111/j.1742-1241.2007.01299.x
   Leitgeb RA, 2004, OPT EXPRESS, V12, P2156, DOI 10.1364/OPEX.12.002156
   Leung CKS, 2008, INVEST OPHTH VIS SCI, V49, P4893, DOI 10.1167/iovs.07-1326
   Leung CKS, 2007, OPHTHALMOLOGY, V114, P263, DOI 10.1016/j.ophtha.2006.06.059
   Nassif N, 2004, OPT LETT, V29, P480, DOI 10.1364/OL.29.000480
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Van de Moere A, 2006, BRIT J OPHTHALMOL, V90, P304, DOI 10.1136/bjo.2005.079947
   van Velthoven MEJ, 2006, GRAEF ARCH CLIN EXP, V244, P1119, DOI 10.1007/s00417-005-0209-y
   Wojtkowski M, 2002, J BIOMED OPT, V7, P457, DOI 10.1117/1.1482379
   Zhang N, 2007, AM J OPHTHALMOL, V144, P37, DOI 10.1016/j.ajo.2007.03.056
NR 20
TC 75
Z9 76
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2009
VL 116
IS 5
BP 947
EP 955
DI 10.1016/j.ophtha.2008.11.002
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 508DI
UT WOS:000270907500020
PM 19232732
DA 2022-11-30
ER

PT J
AU Childs, AL
   Bressler, NM
   Bass, EB
   Hawkins, BS
   Mangione, CM
   Marsh, MJ
   Miskala, PH
AF Childs, AL
   Bressler, NM
   Bass, EB
   Hawkins, BS
   Mangione, CM
   Marsh, MJ
   Miskala, PH
CA Submacular Surg Trials SST Res Grp
TI Surgery for hemorrhagic choroidal neovascular lesions of age-related
   macular degeneration: Quality-of-life findings - SST report no. 14
SO OPHTHALMOLOGY
LA English
DT Article
ID DEPRESSION
AB Purpose: To present and compare findings from health-related quality-of-life (HRQOL) interviews conducted with patients enrolled in the SST Group B Trial evaluating surgical removal of subfoveal choroidal neovascular lesions associated with age-related macular degeneration versus observation.
   Design: Randomized clinical trial.
   Participants: Eligible patients had predominantly hemorrhagic subfoveal choroidal neovascular lesions (total lesion size of >3.5 disc areas, area of blood at least 50% of the lesion area, and at least 75% of blood posterior to the equator) and best-corrected visual acuity (VA) of 20/100 to <20/1600 but at least light perception in the study eye. Three hundred thirty-six patients enrolled after baseline quality-of-life interviews, 168 assigned to each of surgery or observation.
   Methods: Clinical and HRQOL data were collected before randomization and at 6,12, 24, 36, and 48 months after enrollment. Baseline clinical evidence was used to stratify patients as having unilateral or bilateral neovascularization at the time of randomization. The HRQOL interviews included the National Eye Institute Visual Function Questionnaire (NEI-VFQ), the 36-item Short Form Health Survey, and the Hospital Anxiety and Depression Scale.
   Main Outcomes Measure. Two-year change in NEI-VFQ.
   Results: At 24 months after enrollment, overall NEI-VFQ scores had a median decrease of 1 point from baseline in the observation arm (95% confidence interval [CI]: -4 to 3 points) and no change in the surgery arm (95% CI: -3 to 3 points) (P = 0.70). Changes from baseline on NEI-VFQ subscales also were similar between treatment arms. Differences in scores by unilateral or bilateral involvement seen at baseline in each treatment arm persisted throughout follow-up for most outcomes. Planned analyses stratified by VA showed trends (P = 0.17) in favor of surgery at 24 months in the patients with baseline VA greater than 20/200 for the NEI-VFQ scale (3.5-point median increase from baseline in the surgery arm [95% CI: -4 to 7] vs. a 1-point median loss from baseline in the observation arm [95% CI: -6 to 4]).
   Conclusions: No difference was detected with respect to vision-targeted quality-of-life outcomes for patients randomized to surgery or observation in the SST Group 6 Trial. (C) 2004 by the American Academy of Ophthalmology.
C1 SST Coordinating Ctr, Baltimore, MD 21205 USA.
RP Childs, AL (通讯作者)，SST Coordinating Ctr, 550 N Broadway,9th Floor, Baltimore, MD 21205 USA.
EM achilds1@jhmi.edu
OI Mann, Ashley/0000-0003-3553-5470
FU NEI NIH HHS [U10 EY11547, U10 EY011557-08, U10 EY011557, U10 EY011547,
   U10 EY011558, EY11558, U10 EY011547-07, EY11557, U10 EY011558-07]
   Funding Source: Medline; NATIONAL EYE INSTITUTE [U10EY011557,
   U10EY011547, U10EY011558] Funding Source: NIH RePORTER
CR Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Miskala PH, 2004, OPHTHALMOLOGY, V111, P1981, DOI 10.1016/j.ophtha.2004.07.022
   *SAS INC, 2001, SAS VERS 8 CAR
   SNEDECOR GW, 1980, STATISTICAL METHODS, P144
   *SST, 1998, NTIS PUBL
   *SUBM SURG TRIALS, IN PRESS ARCH OPHTHA
   Talic I, 2022, LEARN INSTR, V81, DOI [10.1016/j.learninstruc.2022.101594, 10.1016/j.ajo.2004.02.011]
   Ware JE., 1993, SCORING SF 36 SF 36
   Ware JE, 1994, SF 36 PHYS MENTAL HL
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 15
TC 41
Z9 42
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2004
VL 111
IS 11
BP 2007
EP 2014
DI 10.1016/j.ophtha.2004.07.024
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 866JZ
UT WOS:000224771100005
PM 15522365
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Schmidt, S
   Postel, EA
   Agarwal, A
   Allen, IC
   Walters, SN
   De La Paz, MA
   Scott, WK
   Raines, JL
   Pericak-Vance, MA
   Gilbert, JR
AF Schmidt, S
   Postel, EA
   Agarwal, A
   Allen, IC
   Walters, SN
   De La Paz, MA
   Scott, WK
   Raines, JL
   Pericak-Vance, MA
   Gilbert, JR
TI Detailed analysis of allelic variation in the ABCA4 gene in age-related
   maculopathy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID STARGARDT-DISEASE GENE; PEDIGREE DISEQUILIBRIUM TEST; MACULAR
   DEGENERATION; LINKAGE DISEQUILIBRIUM; RETINITIS-PIGMENTOSA; RIM PROTEIN;
   ASSOCIATION; TRANSPORTER; DYSTROPHY; MUTATION
AB PURPOSE. Age-related maculopathy (ARM) is one of the most common causes of blindness in older adults worldwide. Sequence variants in a gene coding for a retina-specific ATP-binding cassette (ABCA4) transporter protein, which is responsible for a phenotypically similar Mendelian form of retinal disease, were proposed to increase the risk of ARM. To examine the potential relationship of ABCA4 sequence variation and ARM risk in an independent data set, a clinically well-characterized population of, 165 multiplex patients with ARM from 70 families, 33 unaffected relatives, and 59 unrelated control subjects with confirmed absence of ARM was screened for variants in any of the 50 exons and exon-intron boundaries of this gene.
   METHODS. A combination of denaturing high-performance liquid chromatography (DHPLC) and bidirectional sequencing was used to detect ABCA4 sequence variants. The data set was analyzed with both case-control and family-based association analysis methods.
   RESULTS. No evidence was found of significantly different allele frequencies of ABCA4 sequence variants in patients compared with control subjects, and no evidence for association or cosegregation with disease in family-based analyses.
   CONCLUSIONS. This study confirmed the very high degree of ABCA4 sequence polymorphism in the general population, which makes the detection of potential disease-associated alleles particularly challenging. While this study does not definitively exclude ABCA4 from contributing to a small or moderate fraction of ARM, it adds to the body of evidence suggesting that ABCA4 is not a major susceptibility gene for this disorder. (Invest Ophthalmol Vis Sci. 2003;44:2868-2875) DOE: 10.1167/iovs.02-0957.
C1 Duke Univ, Med Ctr, Ctr Human Genet, Durham, NC 27710 USA.
   Duke Univ, Med Ctr, Duke Eye Ctr, Durham, NC 27710 USA.
   Vanderbilt Univ, Ctr Med, Dept Ophthalmol, Nashville, TN USA.
   Vanderbilt Univ, Ctr Med, Program Human Genet, Nashville, TN USA.
C3 Duke University; Duke University; Vanderbilt University; Vanderbilt
   University
RP Gilbert, JR (通讯作者)，Duke Univ, Med Ctr, Ctr Human Genet, Box 3445, Durham, NC 27710 USA.
RI Haines, Jonathan/C-3374-2012; Scott, William/A-7593-2009
OI Haines, Jonathan/0000-0002-4351-4728; Scott,
   William/0000-0001-9336-6404; Allen, Irving/0000-0001-9573-5250
FU NEI NIH HHS [EY12118] Funding Source: Medline; NIA NIH HHS [AG11268]
   Funding Source: Medline; NATIONAL EYE INSTITUTE [U10EY012118,
   R01EY012118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING
   [P60AG011268] Funding Source: NIH RePORTER
CR Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786
   Abecasis GR, 2000, BIOINFORMATICS, V16, P182, DOI 10.1093/bioinformatics/16.2.182
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Ardlie KG, 2002, NAT REV GENET, V3, P299, DOI 10.1038/nrg777
   Ardlie KG, 2002, AM J HUM GENET, V71, P304, DOI 10.1086/341719
   Azarian SM, 1998, HUM GENET, V102, P699, DOI 10.1007/s004390050765
   Bernstein PS, 2002, INVEST OPHTH VIS SCI, V43, P466
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Clayton D, 1999, AM J HUM GENET, V65, P1170, DOI 10.1086/302577
   Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   Gorin MB, 2001, ARCH OPHTHALMOL-CHIC, V119, P752, DOI 10.1001/archopht.119.5.752
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Hauser ER, 1998, BIOMETRICS, V54, P1238, DOI 10.2307/2533653
   Horvath S, 1998, AM J HUM GENET, V63, P1886, DOI 10.1086/302137
   Johnson GCL, 2001, NAT GENET, V29, P233, DOI 10.1038/ng1001-233
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kuroiwa S, 1999, BRIT J OPHTHALMOL, V83, P613, DOI 10.1136/bjo.83.5.613
   Lewis P.O., 2000, GENETIC DATA ANAL CO
   Lotery AJ, 2000, INVEST OPHTH VIS SCI, V41, P1291
   Martin ER, 2000, AM J HUM GENET, V67, P146, DOI 10.1086/302957
   Martin ER, 2001, AM J HUM GENET, V68, P1065, DOI 10.1086/319525
   Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   Molday LL, 2000, NAT GENET, V25, P257, DOI 10.1038/77004
   NEI M, 1979, P NATL ACAD SCI USA, V76, P5269, DOI 10.1073/pnas.76.10.5269
   PAPERMASTER DS, 1978, J CELL BIOL, V78, P415, DOI 10.1083/jcb.78.2.415
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657
   Sasieni PD, 1997, BIOMETRICS, V53, P1253, DOI 10.2307/2533494
   Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688
   Shroyer NF, 2001, INVEST OPHTH VIS SCI, V42, P2757
   Slager SL, 2001, AM J HUM GENET, V68, P1457, DOI 10.1086/320608
   Souied EH, 2000, INVEST OPHTH VIS SCI, V41, P244
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034
   Sun H, 2000, NAT GENET, V26, P242, DOI 10.1038/79994
   Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269
   Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wacholder S, 2000, J NATL CANCER I, V92, P1151, DOI 10.1093/jnci/92.14.1151
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
NR 48
TC 22
Z9 24
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2003
VL 44
IS 7
BP 2868
EP 2875
DI 10.1167/iovs.02-0957
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 694VL
UT WOS:000183795800008
PM 12824224
DA 2022-11-30
ER

PT J
AU Vergroesen, JE
   Thee, EF
   Ahmadizar, F
   van Duijn, CM
   Stricker, BH
   Kavousi, M
   Klaver, CCW
   Ramdas, WD
AF Vergroesen, Joelle E.
   Thee, Eric F.
   Ahmadizar, Fariba
   van Duijn, Cornelia M.
   Stricker, Bruno H.
   Kavousi, Maryam
   Klaver, Caroline C. W.
   Ramdas, Wishal D.
TI Association of Diabetes Medication With Open-Angle Glaucoma, Age-Related
   Macular Degeneration, and Cataract in the Rotterdam Study
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID METFORMIN; RISK; MELLITUS; INFLAMMATION; PREVALENCE; GLUCOSE
AB IMPORTANCE Recent studies suggest that the diabetes drug metformin has a protective effect on open-angle glaucoma (OAG) and age-related macular degeneration (AMD). However, studies have not addressed the critical issue of confounding by indication, and associations have not been evaluated in a large prospective cohort.
   OBJECTIVE To determine the association between diabetes medication and the common eye diseases OAG, AMD, and cataract and to evaluate their cumulative lifetime risks in a large cohort study.
   DESIGN, SETTING, AND PARTICIPANTS This cohort study included participants from 3 independent cohorts from the prospective, population-based Rotterdam Study between April 23, 1990, and June 25, 2014. Participants were monitored for incident eye diseases (OAG, AMD, cataract) and had baseline measurements of serum glucose. Data on diabetes medication use and data from ophthalmologic examinations were gathered.
   EXPOSURES Type 2 diabetes (T2D) and the diabetes medications metformin, insulin, and sulfonylurea derivatives.
   MAIN OUTCOMES AND MEASURES Diagnosis and cumulative lifetime risk of OAG, AMD, and cataract.
   RESULTS This study included 11260 participants (mean [SD] age, 65.1 [9,8]; 6610 women [58.7%]). T2D was diagnosed in 2406 participants (28.4%), OAG was diagnosed in 324 of 7394 participants (4.4%), AMD was diagnosed in 1935 of 10 993 participants (17.6%), and cataract was diagnosed in 4203 of 11260 participants (37.3%). Untreated T2D was associated with a higher risk of OAG (odds ratio [OR], 1.50; 95% CI, 1.06-2.13; P = .02), AMD (OR, 1.35; 95% CI, 1.11-1.64; P = .003), and cataract (OR, 1.63; 95% CI, 1.39-1.92; P < .001). T2D treated with metformin was associated with a lower risk of OAG (OR, 0.18; 95% CI, 0.08-0.41; P < .001). Other diabetes medication (ie, insulin, sulfonylurea derivates) was associated with a lower risk of AMD (combined OR, 0.32; 95% CI, 0.18 to 0.55; P < .001). The cumulative lifetime risk of OAG was lower for individuals taking metformin (1.5%; 95% CI, 0.01%-3.1%) than for individuals without T2D (7.2%; 95% CI, 5.7%-8.7%); the lifetime risk of AMD was lower for individuals taking other diabetes medication (17.0%; 95% CI, 5.8%-26.8% vs 33.1%; 95% CI, 30.6%-35.6%).
   CONCLUSIONS AND RELEVANCE Results of this cohort study suggest that, although diabetes was clearly associated with cataract, diabetes medication was not. Treatment with metformin was associated with a lower risk of OAG, and other diabetes medication was associated with a lower risk of AMD. Proof of benefit would require interventional clinical trials.
C1 [Vergroesen, Joelle E.; Thee, Eric F.; Klaver, Caroline C. W.; Ramdas, Wishal D.] Erasmus MC, Dept Ophthalmol, POB 2040, NL-3000 CA Rotterdam, Netherlands.
   [Vergroesen, Joelle E.; Thee, Eric F.; Ahmadizar, Fariba; Stricker, Bruno H.; Kavousi, Maryam; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Thee, Eric F.; Klaver, Caroline C. W.] Erasmus MC, EyeNED Reading Ctr, Rotterdam, Netherlands.
   [van Duijn, Cornelia M.] Univ Oxford, Nuffield Dept Populat Hlth, Oxford, England.
   [Klaver, Caroline C. W.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands.
   [Klaver, Caroline C. W.] Univ Basel, Inst Mol & Clin Ophthalmol, Basel, Switzerland.
C3 Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; Erasmus University Rotterdam; Erasmus MC; University of
   Oxford; Radboud University Nijmegen; University of Basel
RP Ramdas, WD (通讯作者)，Erasmus MC, Dept Ophthalmol, POB 2040, NL-3000 CA Rotterdam, Netherlands.
EM w.ramdas@erasmusmc.nl
FU Stichting Lijf Leven; Henkes Stichting; Rotterdamse Stichting voor
   Blindenbelangen; Royal Dutch Academy of Sciences [2018-34]; Landelijke
   Stichting voor Blinden en Slechtzienden; Oogfonds MaculaFonds [2019-12];
   Glaucoomfonds; Erasmus Medical Center, Erasmus University; Organization
   for the Health Research and Development; Research Institute for Diseases
   in the Elderly; Ministry of Education, Culture, and Science; Ministry
   for Health, Welfare, and Sports; European Commission; Municipality of
   Rotterdam
FX This study was supported by Stichting Lijf & Leven; Henkes Stichting,
   Rotterdamse Stichting voor Blindenbelangen; the Royal Dutch Academy of
   Sciences (Dr Klaver); grant 2018-34 from Landelijke Stichting voor
   Blinden en Slechtzienden; Oogfonds MaculaFonds; grant 2019-12 from
   Glaucoomfonds; Erasmus Medical Center, Erasmus University, Netherlands;
   Organization for the Health Research and Development; the Research
   Institute for Diseases in the Elderly; the Ministry of Education,
   Culture, and Science; the Ministry for Health, Welfare, and Sports; the
   European Commission; and the Municipality of Rotterdam.
CR Ahmadizar F, 2019, BRIT J CLIN PHARMACO, V85, P993, DOI 10.1111/bcp.13898
   Becker C, 2018, EYE, V32, P1028, DOI 10.1038/s41433-017-0003-1
   Cameron AR, 2016, CIRC RES, V119, P652, DOI 10.1161/CIRCRESAHA.116.308445
   Chen X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108196
   Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   De Koning-Backus APM, 2019, AM J OPHTHALMOL, V198, P70, DOI 10.1016/j.ajo.2018.09.036
   de Voogd S, 2006, OPHTHALMOLOGY, V113, P1827, DOI 10.1016/j.ophtha.2006.03.063
   HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503
   Howell JJ, 2017, CELL METAB, V25, P463, DOI 10.1016/j.cmet.2016.12.009
   Ikram MA, 2017, EUR J EPIDEMIOL, V32, P807, DOI 10.1007/s10654-017-0321-4
   Kawahara Y, 2020, J DENT RES, V99, P830, DOI 10.1177/0022034520913250
   Kiziltoprak H, 2019, WORLD J DIABETES, V10, P140, DOI 10.4239/wjd.v10.i3.140
   KLEIN BEK, 1985, OPHTHALMOLOGY, V92, P1191
   Lavaju P, 2017, NEPAL J OPHTHALMOL, V9, P17, DOI 10.3126/nepjoph.v9i1.17526
   Laville V, 2019, AM J OPHTHALMOL, V206, P245, DOI 10.1016/j.ajo.2019.05.015
   Lin HC, 2015, JAMA OPHTHALMOL, V133, P915, DOI 10.1001/jamaophthalmol.2015.1440
   Maleskic Sanita, 2017, Acta Med Acad, V46, P116, DOI 10.5644/ama2006-124.196
   Prattichizzo F, 2018, AGEING RES REV, V48, P87, DOI 10.1016/j.arr.2018.10.003
   Ramdas WD, 2011, ARCH OPHTHALMOL-CHIC, V129, P767, DOI 10.1001/archophthalmol.2010.373
   Romdhoniyyah DF, 2021, OPHTHALMOL THER, V10, P245, DOI 10.1007/s40123-021-00344-3
   Saisho Y, 2015, ENDOCR METAB IMMUNE, V15, P196, DOI 10.2174/1871530315666150316124019
   Sivandzade F, 2019, REDOX BIOL, V21, DOI 10.1016/j.redox.2018.11.017
   Springelkamp H, 2017, EUR J EPIDEMIOL, V32, P691, DOI 10.1007/s10654-017-0270-y
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Tham Yih-Chung, 2014, Ophthalmology, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Thee EF, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.26
   Zheng Z, 2012, DIABETES, V61, P217, DOI 10.2337/db11-0416
NR 28
TC 2
Z9 2
U1 2
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUL
PY 2022
VL 140
IS 7
BP 674
EP 681
DI 10.1001/jamaophthalmol.2022.1435
EA MAY 2022
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3C7IR
UT WOS:000798260300001
PM 35587864
DA 2022-11-30
ER

PT J
AU Bikbov, MM
   Zainullin, RM
   Gilmanshin, TR
   Kazakbaeva, GM
   Rakhimova, EM
   Rusakova, IA
   Bolshakova, NI
   Safiullina, KR
   Yakupova, DF
   Uzianbaeva, YV
   Khalimov, TA
   Salavatova, VF
   Panda-Jonas, S
   Arslangareeva, II
   Nuriev, IF
   Bikbova, GM
   Zaynetdinov, AF
   Zinnatullin, AA
   Jonas, JB
AF Bikbov, Mukharram M.
   Zainullin, Rinat M.
   Gilmanshin, Timur R.
   Kazakbaeva, Gyulli M.
   Rakhimova, Ellina M.
   Rusakova, Iulia A.
   Bolshakova, Natalia I.
   Safiullina, Kamilla R.
   Yakupova, Dilya F.
   Uzianbaeva, Yulia V.
   Khalimov, Timur A.
   Salavatova, Venera F.
   Panda-Jonas, Songhomitra
   Arslangareeva, Inga I.
   Nuriev, Ildar F.
   Bikbova, Guzel M.
   Zaynetdinov, Artur F.
   Zinnatullin, Ainur A.
   Jonas, Jost B.
TI Prevalence and Associated Factors of Age-Related Macular Degeneration in
   a Russian Population: The Ural Eye and Medical Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RISK-FACTORS; MACULOPATHY; DISEASE; CLASSIFICATION
AB PURPOSE: To assess the prevalence of age-related macular degeneration (AMD) in a Russian population.
   DESIGN: Population-based prevalence assessment.
   METHODS: The Ural Eye and Medical Study was conducted in a rural and urban area in the Russian republic of Bashkortostan. The study included 5,899 participants aged 40 + years old. AMD, defined according to the Beckman Initiative for Macular Research, was assessed by fundus photographs and optical coherence tomographic images of 4,932 (83.6%) participants.
   RESULTS: The prevalence of any AMD, early AMD, intermediate AMD, or late AMD, geographic atrophy, and neovascular AMD were 18.2% (95% confidence interval [CI], 16.8-19.6), 11.6% (95% CI, 10.4-12.8), 5.0% (95% CI, 4.2-5.8), 1.6% (95% CI, 1.1-2.0), 0.7% (95% CI, 0.4-1.0) and 0.9% (95% CI, 0.6-1.3), respectively, for individuals > 55 years old. Applying an age limit of 40 + years for the AMD definition, prevalence of any AMD, early AMD, intermediate AMD, late AMD, geographic atrophy and neovascular AMD were 14.1% (95% CI, 13.1-15.1), 9.4% (95% CI, 8.6-10.2), 3.8% (95% CI, 3.2-4.3), 1.0% (95% CI, 0.7-1.2), 0.4% (95% CI, 0.2-0.6) and 0.5% (95% CI, 0.3-0.7), respectively, for individuals aged 40 + years. Higher AMD prevalence was correlated with older age (odds ratio [OR], 1.15; 95% CI, 1.13-1.16; P < 0.001), rural region (OR, 1.69; 95% CI, 1.32-2.17; P < 0.001), lower diabetes prevalence (OR, 0.56; 95% CI, 0.38-0.82; P = 0.003), and shorter axial length (OR, 0.89; 95% CI, 0.79-0.99; P = 0.04). AMD prevalence was not significantly (all P >= 0.20) correlated with any systemic parameter examined, except for lower prevalence of diabetes.
   CONCLUSIONS: In this typical, ethnically mixed, urban and rural population from Russia, a higher prevalence for AMD was associated mainly with older age, rural region of habitation, shorter axial length, and lower prevalence of diabetes mellitus. The AMD prevalence was lower than in Europeans and higher than in East Asians. (C) 2019 Elsevier Inc. All rights reserved.
C1 [Bikbov, Mukharram M.; Zainullin, Rinat M.; Gilmanshin, Timur R.; Kazakbaeva, Gyulli M.; Rakhimova, Ellina M.; Rusakova, Iulia A.; Bolshakova, Natalia I.; Safiullina, Kamilla R.; Yakupova, Dilya F.; Uzianbaeva, Yulia V.; Khalimov, Timur A.; Salavatova, Venera F.; Arslangareeva, Inga I.; Nuriev, Ildar F.; Bikbova, Guzel M.; Zaynetdinov, Artur F.; Zinnatullin, Ainur A.] Ufa Eye Res Inst, Ufa, Bashkortostan, Russia.
   [Panda-Jonas, Songhomitra; Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Mannheim, Germany.
C3 Ufa Eye Research Institute; Ruprecht Karls University Heidelberg
RP Jonas, JB (通讯作者)，Med Fac Mannheim, Dept Ophthalmol, Theodor Kutzerufer 1, D-68167 Mannheim, Germany.
EM Jost.Jonas@medma.uni-heidelberg.de
RI Zainullin, Rinat/AAR-6362-2021; Bikbov, Mukharram/AAO-7624-2021
OI Kazakbaeva, Gyulli/0000-0002-0569-1264
CR Bikbov MM, 2019, AM J OPHTHALMOL, V204, P130, DOI 10.1016/j.ajo.2019.02.030
   Bikbov MM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211186
   Bozkurt MK, 2011, J LARYNGOL OTOL, V125, P231, DOI 10.1017/S0022215110002604
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Cipriani V, 2017, JAMA OPHTHALMOL, V135, P909, DOI 10.1001/jamaophthalmol.2017.2191
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe185, DOI 10.1111/j.1755-3768.2011.02316.x
   Jonas JB, 2010, OPHTHALMOLOGY, V117, P2234, DOI 10.1016/j.ophtha.2009.12.006
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Kozobolis VP, 1999, ARCH OPHTHALMOL-CHIC, V117, P664
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   La TY, 2014, CURR EYE RES, V39, P1232, DOI 10.3109/02713683.2014.907431
   Leisy HB, 2017, OPHTHALMOL RETINA, V1, P42, DOI 10.1016/j.oret.2016.08.011
   Morgan IG, 2012, LANCET, V379, P1739, DOI 10.1016/S0140-6736(12)60272-4
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   PRINCE AM, 1987, ARCH OPHTHALMOL-CHIC, V105, P1076
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stevens GA, 2016, LANCET, V388, pE19, DOI 10.1016/S0140-6736(16)30388-9
   Whelton PK, 2018, HYPERTENSION, V71, pE13, DOI [10.1161/HYP.0000000000000066, 10.1161/HYP.0000000000000065]
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Yan YN, 2015, OPHTHALMOLOGY, V122, P1873, DOI 10.1016/j.ophtha.2015.05.031
NR 31
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2020
VL 210
BP 146
EP 157
DI 10.1016/j.ajo.2019.10.004
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KJ7CQ
UT WOS:000512216200018
PM 31606441
DA 2022-11-30
ER

PT J
AU Cuilla, TA
   Ying, GS
   Maguire, MG
   Martin, DF
   Jaffe, GJ
   Grunwald, JE
   Daniel, E
   Toth, CA
AF Cuilla, Thomas A.
   Ying, Gui-shuang
   Maguire, Maureen G.
   Martin, Daniel F.
   Jaffe, Glenn J.
   Grunwald, Juan E.
   Daniel, Ebenezer
   Toth, Cynthia A.
CA Comparison Age-Related Macular Deg
TI Influence of the Vitreomacular Interface on Treatment Outcomes in the
   Comparison of Age-Related Macular Degeneration Treatments Trials
SO OPHTHALMOLOGY
LA English
DT Article
ID POSTERIOR VITREOUS DETACHMENT; OPTICAL COHERENCE TOMOGRAPHY; CHINESE
   ADULT-POPULATION; EPIRETINAL MEMBRANES; RISK-FACTORS; JAPANESE
   POPULATION; PREVALENCE; ADHESION; ASSOCIATIONS; THERAPY
AB Objective: To assess the association of the vitreomacular interface with outcomes of eyes treated with anti-vascular endothelial growth factor drugs for neovascular age-related macular degeneration (AMD).
   Design: Prospective cohort study within a multicenter, randomized clinical trial.
   Participants: Patients enrolled in the Comparison of AMD Treatments Trials (CATT).
   Methods: Treatment was assigned randomly as either ranibizumab or bevacizumab and as 3 different regimens for dosing over a 2-year period. Masked readers at a reading center assessed optical coherence tomography (OCT) scans at baseline and follow-up for vitreomacular traction (VMT) and vitreomacular adhesion (VMA), fluid, and central thickness. Visual acuity (VA) was measured by masked, certified examiners. Main Outcome Measures: Anatomic features and VA at baseline and 1 and 2 years and number of treatments.
   Results: At baseline, 143 patient eyes (12.8%) had VMT or VMA. Compared with those with neither (n = 972), patients with VMT or VMA were younger (mean +/- standard error, 75.5 +/- 0.6 vs. 79.7 +/- 0.24 years; P < 0.0001) and more likely to be male (52.4% vs. 36.2%; P = 0.0003), to be cigarette smokers (68.5% vs. 55.3%; P = 0.003), and to have subretinal fluid on OCT (86.7% vs. 81.0%; P = 0.047). Vitreomacular interface status was not associated with VA at baseline or follow-up. Among eyes treated as needed (n = 598) and followed up for 2 years (n = 516), the mean number of injections was 15.4 +/- 0.9 for eyes having VMT at baseline or during follow-up (n = 60), 13.8 +/- 0.7 for eyes with VMA at baseline or follow-up (n = 79), and 12.9 +/- 0.4 (P = 0.02) for eyes without VMT or VMA (n = 377). In addition, the mean number of injections in eyes treated as needed increased from 13.0 +/- 0.3 when VMT was not observed to 13.6 +/- 1.3 when observed once and to 17 +/- 1.2 when observed more than once during follow-up. At 2 years, geographic atrophy developed in a lower percentage of eyes with VMT or VMA at baseline (11.7%) than with neither condition (22.5%; P = 0.005).
   Conclusions: In eyes in the CATT, VMT and VMA were infrequent. At baseline and follow-up, VMT or VMA were not associated with VA. Eyes with VMT or VMA treated as needed required on average 2 more injections over 2 years. (C) 2015 by the American Academy of Ophthalmology.
C1 [Cuilla, Thomas A.] Midwest Eye Inst, Indianapolis, IN USA.
   [Ying, Gui-shuang; Maguire, Maureen G.; Grunwald, Juan E.; Daniel, Ebenezer] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Jaffe, Glenn J.; Toth, Cynthia A.] Duke Univ, Dept Ophthalmol, Raleigh, NC USA.
C3 University of Pennsylvania; Cleveland Clinic Foundation; Duke University
RP Maguire, MG (通讯作者)，Univ Penn, Dept Ophthalmol, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA.
EM maguirem@mail.med.upenn.edu
RI Ciulla, Thomas/AAA-1299-2020; Toth, Cynthia/L-5534-2019
OI Ciulla, Thomas/0000-0001-5557-6777; Toth, Cynthia/0000-0002-2324-0854;
   Maguire, Maureen/0000-0002-4249-2467
FU National Eye Institute, National Institutes of Health, Bethesda,
   Maryland [U10 EY017823, U10 EY017825, U10 EY017826, U10 EY017828,
   R21EY023689]; NATIONAL EYE INSTITUTE [U10EY017828, U10EY017823,
   U10EY017825, U10EY017826, R21EY023689] Funding Source: NIH RePORTER
FX Supported by the National Eye Institute, National Institutes of Health,
   Bethesda, Maryland (cooperative agreement nos.: U10 EY017823, U10
   EY017825, U10 EY017826, U10 EY017828, and R21EY023689).
CR Aung KZ, 2013, RETINA-J RET VIT DIS, V33, P1026, DOI 10.1097/IAE.0b013e3182733f25
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   Duan XR, 2009, INVEST OPHTH VIS SCI, V50, P2018, DOI 10.1167/iovs.08-2624
   Folgar FA, 2014, OPHTHALMOLOGY, V121, P1956, DOI 10.1016/j.ophtha.2014.04.020
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hayreh SS, 2004, OPHTHALMOLOGICA, V218, P333, DOI 10.1159/000079476
   Kawasaki R, 2008, BRIT J OPHTHALMOL, V92, P1320, DOI 10.1136/bjo.2008.144626
   Kawasaki R, 2009, EYE, V23, P1045, DOI 10.1038/eye.2008.238
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mayr-Sponer U, 2013, OPHTHALMOLOGY, V120, P2620, DOI 10.1016/j.ophtha.2013.05.032
   McCarty DJ, 2005, AM J OPHTHALMOL, V140, P288, DOI 10.1016/j.ajo.2005.03.032
   Miyazaki M, 2003, GRAEF ARCH CLIN EXP, V241, P642, DOI 10.1007/s00417-003-0723-8
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Nomura Y, 2014, JPN J OPHTHALMOL, V58, P443, DOI 10.1007/s10384-014-0333-5
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Shao L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058498
   Shen ZJ, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-33
   Steel DHW, 2013, EYE, V27, pS1, DOI 10.1038/eye.2013.212
   Uchino E, 2001, ARCH OPHTHALMOL-CHIC, V119, P1475
   Waldstein SM, 2014, AM J OPHTHALMOL, V158, P328, DOI 10.1016/j.ajo.2014.04.028
   Waldstein SM, 2012, RETINA-J RET VIT DIS, V32, P424, DOI 10.1097/IAE.0b013e3182278b80
   YANNUZZI LA, 1994, AM J OPHTHALMOL, V118, P754
NR 26
TC 41
Z9 42
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2015
VL 122
IS 6
BP 1203
EP 1211
DI 10.1016/j.ophtha.2015.02.031
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CI9OJ
UT WOS:000355099200026
PM 25824327
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Kaiser, PK
   Boyer, DS
   Cruess, AF
   Slakter, JS
   Pilz, S
   Weisberger, A
AF Kaiser, Peter K.
   Boyer, David S.
   Cruess, Alan F.
   Slakter, Jason S.
   Pilz, Stefan
   Weisberger, Annemarie
CA DENALI Study Grp
TI Verteporfin plus Ranibizumab for Choroidal Neovascularization in
   Age-Related Macular Degeneration Twelve-Month Results of the DENALI
   Study
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; RANDOMIZED CLINICAL-TRIAL; PHOTODYNAMIC
   THERAPY; DOSING REGIMEN; TAP
AB Purpose: To demonstrate noninferiority of ranibizumab in combination with verteporfin photodynamic therapy (PDT) versus ranibizumab monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).
   Design: Prospective, multicenter, double-masked, randomized, phase IIIb clinical trial.
   Participants: Three hundred twenty-one patients randomized to receive either ranibizumab 0.5 mg monotherapy (n = 112), standard fluence (SF) verteporfin PDT combination therapy (n = 104), or reduced fluence (RF) verteporfin PDT combination therapy (n = 105).
   Methods: Ranibizumab was administered monthly in the monotherapy group. In both combination therapy groups, ranibizumab was initiated with 3 consecutive monthly injections, followed by retreatment as needed (pro re nata) with monthly monitoring. All patients were evaluated monthly for 12 months.
   Main Outcome Measures: Mean change in best-corrected visual acuity (BCVA) from baseline at month 12 and proportion of patients randomized to either combination therapy with a ranibizumab treatment-free interval of 3 months or longer.
   Results: Two hundred eighty-six patients (89.1%) completed the 12-month study. Mean BCVA change at month 12 was +5.3 and +4.4 letters with verteporfin SF (n = 103) or verteporfin RF (n = 105) plus ranibizumab, respectively, compared with +8.1 letters with ranibizumab monotherapy (n = 110; adjusted 97.5% confidence interval [CI], (-7.90 to infinity); P = 0.0666; and 97.5% CI, (-8.51 to infinity); P = 0.1178; for combination regimens vs. monotherapy, respectively). Noninferiority of either combination regimen to monthly ranibizumab monotherapy was not demonstrated (primary end point). A ranibizumab treatment-free interval of 3 months or longer was achieved in 92.6% and 83.5% of the patients randomized to verteporfin SF or verteporfin RF groups, respectively, with a mean of 5.1 and 5.7 ranibizumab injections, respectively, and patients in the ranibizumab monotherapy arm received 10.5 injections. At month 12, mean central retinal thickness decreased by 151.7 mu m and 140.9 mu m for the verteporfin SF and RF groups, respectively, and by 172.2 mu m with ranibizumab monotherapy. Safety and tolerability of all 3 regimens were similar to and consistent with previous studies in neovascular AMD. The number of ocular serious adverse events was low and occurred largely as single cases.
   Conclusions: Ranibizumab monotherapy or combined with verteporfin PDT improved BCVA at month 12; however, noninferiority (7-letter margin) of combination regimens to ranibizumab monotherapy was not demonstrated. Verteporfin RF did not confer clinical benefits over verteporfin SF. All treatments were well tolerated.
C1 [Kaiser, Peter K.] Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
   [Boyer, David S.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Retina Vitreous Associates Med Grp, Los Angeles, CA 90033 USA.
   [Cruess, Alan F.] Dalhousie Univ, Dept Ophthalmol & Visual Sci, Halifax, NS, Canada.
   [Slakter, Jason S.] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Pilz, Stefan] Novartis Pharma AG, Basel, Switzerland.
   [Weisberger, Annemarie] Novartis Pharmaceut, E Hanover, NJ USA.
C3 Cleveland Clinic Foundation; Retina Vitreous Associates Medical Group;
   University of Southern California; Dalhousie University; Vitreous Retina
   Macula Consultants of New York; Novartis; Novartis
RP Kaiser, PK (通讯作者)，Cleveland Clin Fdn, Cole Eye Inst, 9500 Euclid Ave,Desk I3-125, Cleveland, OH 44195 USA.
EM pkkaiser@aol.com
OI Kaiser, Peter/0000-0001-5126-045X
FU Novartis Pharma AG; Novartis Pharma AG, Basel, Switzerland
FX The authors thank Ruthline Laylor, Chameleon Communications
   International, for providing medical writing services with funding from
   Novartis Pharma AG, and Ruchika Srinivasan, Medical Communications,
   Novartis Healthcare Pvt. Ltd., for the revisions (based on author input)
   and resubmission of this article.; Supported by Novartis Pharma AG,
   Basel, Switzerland. This study is registered with Clinicaltrials.gov
   (NCT00436553). The sponsor participated in the design of the study, data
   management, data analysis, and review of the manuscript.
CR AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busch T, 2009, RETINA-J RET VIT DIS, V29, pS36, DOI 10.1097/IAE.0b013e3181ad25e8
   Costagliola C, 2010, BRIT J OPHTHALMOL, V94, P180, DOI 10.1136/bjo.2009.159343
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Harhaj NS, 2004, INT J BIOCHEM CELL B, V36, P1206, DOI 10.1016/j.biocel.2003.08.007
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Ishibashi Tatsuro, 1999, Nippon Ganka Gakkai Zasshi, V103, P923
   Kaiser PK, 2007, CURR MED RES OPIN, V23, P477, DOI 10.1185/030079907X167624
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Potter MJ, 2010, BRIT J OPHTHALMOL, V94, P174, DOI 10.1136/bjo.2008.155531
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2008, BRIT J OPHTHALMOL, V92, P1628, DOI 10.1136/bjo.2007.135277
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Spielberg L, 2010, GRAEF ARCH CLIN EXP, V248, P943, DOI 10.1007/s00417-009-1256-6
NR 28
TC 84
Z9 88
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2012
VL 119
IS 5
BP 1001
EP 1010
DI 10.1016/j.ophtha.2012.02.003
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 933XM
UT WOS:000303399800017
PM 22444829
DA 2022-11-30
ER

PT J
AU Li, B
   Powell, AM
   Hooper, PL
   Sheidow, TG
AF Li, Bo
   Powell, Anne-Marie
   Hooper, Philip L.
   Sheidow, Thomas G.
TI Prospective Evaluation of Teleophthalmology in Screening and Recurrence
   Monitoring of Neovascular Age-Related Macular Degeneration A Randomized
   Clinical Trial
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID DIABETIC-RETINOPATHY; FUNDUS PHOTOGRAPHY; DIGITAL IMAGES; VISION;
   SAFETY; MACULOPATHY; BURDEN
AB IMPORTANCE Teleophthalmology has the potential to reduce costs and inconveniences associated with frequent patient visits. Evaluating teleophthalmology in the management of age-related macular degeneration (AMD) will allow for future implementation of this technology.
   OBJECTIVE To evaluate teleophthalmology as a tool for the screening and monitoring of neovascular AMD.
   DESIGN, SETTING, AND PARTICIPANTS Prospective, randomized clinical trial that included 106 referral eyes for suspected neovascular AMD and 63 eyes with stable neovascular AMD. New referrals for patients with suspected neovascular AMD and patients with stable neovascular AMD were randomized into either routine or teleophthalmologic groups. In the routine group, patients received clinical assessment and diagnostic imaging at a tertiary hospital-based retina clinic. In the teleophthalmologic group, patients received basic examination and diagnostic imaging at a stand-alone teleophthalmologic site, where patient information and imaging studies were acquired and electronically sent over to tertiary hospital-based retina specialists. Patients in the teleophthalmologic group were called back to the tertiary treatment center if the teleophthalmologic data set suggested pathology or was inconclusive for diagnosis.
   MAIN OUTCOMES AND MEASURES Patient wait times for diagnosis and/or treatment, referral accuracy, and visual outcome.
   RESULTS For neovascular AMD screening, the average referral-to-diagnostic imaging time was 22.5 days for the teleophthalmologic group and 18.0 days for the routine group, for a difference of 4.5 days (95% CI, 11.8 to -2.8 days; P = .23). The average diagnostic imaging to treatment time was 16.4 days for the teleophthalmologic group and 11.6 days for the routine group, for a difference of 4.8 days (95% CI, 10.7 to -1.1 days; P = .11). For neovascular AMD monitoring, the average recurrence to treatment time was shorter for the routine group (0.04 days) compared with 13.6 days for the teleophthalmologic group, for a difference of -13.5 days (95% CI, -18.2 to -9.0 days; P < .01). There was no difference identified between end-of-study visual acuities in the 2 groups (P = .99).
   CONCLUSIONS AND RELEVANCE A delay of referral to treatment time could not be identified when comparing teleophthalmologic screening for suspected neovascular AMD with retinal specialist-based screening. Teleophthalmologic monitoring for neovascular AMD recurrence resulted in longer wait times for treatment reinitiation, but no adverse visual outcomes were identified.
C1 [Li, Bo; Powell, Anne-Marie; Hooper, Philip L.; Sheidow, Thomas G.] Univ Western Ontario, Ivey Eye Inst, London, ON N6A 4V2, Canada.
C3 Western University (University of Western Ontario)
RP Li, B (通讯作者)，Univ Western Ontario, Ivey Eye Inst, 268 Grosvenor St, London, ON N6A 4V2, Canada.
EM bo.li@londonhospitals.ca
FU Academic Health Science Center Alternate Funding Plan from Academic
   Medical Organization of Southwestern Ontario
FX This study was funded by the Academic Health Science Center Alternate
   Funding Plan from the Academic Medical Organization of Southwestern
   Ontario.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   American Telemedicine Association, 2011, TEL PRACT REC DIAB
   Baker CF, 2004, CAN J OPHTHALMOL, V39, P746, DOI 10.1016/S0008-4182(04)80068-1
   Boucher MC, 2003, CAN J OPHTHALMOL, V38, P557, DOI 10.1016/S0008-4182(03)80109-6
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Bursell SE, 2001, OPHTHALMOLOGY, V108, P572, DOI 10.1016/S0161-6420(00)00604-7
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Cavallerano AA, 2003, RETINA-J RET VIT DIS, V23, P215, DOI 10.1097/00006982-200304000-00013
   Cruess AF, 2012, CAN J OPHTHALMOL, V47, P227, DOI 10.1016/j.jcjo.2012.03.007
   Fransen SR, 2002, OPHTHALMOLOGY, V109, P595, DOI 10.1016/S0161-6420(01)00990-3
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gomez-Ulla F, 2002, DIABETES CARE, V25, P1384, DOI 10.2337/diacare.25.8.1384
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Leys A, 2008, EYE, V22, P792, DOI 10.1038/sj.eye.6702900
   Lin DY, 2002, AM J OPHTHALMOL, V134, P204, DOI 10.1016/S0002-9394(02)01522-2
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   MEYER CH, 2008, INVEST OPHTHALMOL VI, V49
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Tennant MTS, 2001, CAN J OPHTHALMOL, V36, P187, DOI 10.1016/S0008-4182(01)80039-9
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
NR 25
TC 39
Z9 40
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAR
PY 2015
VL 133
IS 3
BP 276
EP 282
DI 10.1001/jamaophthalmol.2014.5014
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CD6UE
UT WOS:000351224200008
PM 25473945
OA Bronze
DA 2022-11-30
ER

PT J
AU Kozhevnikova, OS
   Fursova, AZ
   Derbeneva, AS
   Nikulich, IF
   Tarasov, MS
   Devyatkin, VA
   Rumyantseva, YV
   Telegina, DV
   Kolosova, NG
AF Kozhevnikova, Oyuna S.
   Fursova, Anzhella Zh
   Derbeneva, Anna S.
   Nikulich, Ida F.
   Tarasov, Mikhail S.
   Devyatkin, Vasiliy A.
   Rumyantseva, Yulia, V
   Telegina, Darya, V
   Kolosova, Nataliya G.
TI Association between Polymorphisms in CFH, ARMS2, CFI, and C3 Genes and
   Response to Anti-VEGF Treatment in Neovascular Age-Related Macular
   Degeneration
SO BIOMEDICINES
LA English
DT Article
DE age-related macular degeneration; neovascularization; anti-VEGF therapy;
   regulatory SNP; pharmacogenomics
ID GROWTH-FACTOR TREATMENT; FACTOR-H Y402H; COMPLEMENT ACTIVATION; FACTOR
   THERAPY; RANIBIZUMAB; RARE; AMD; PHARMACOGENETICS; AFLIBERCEPT; VARIANTS
AB Neovascular age-related macular degeneration (nAMD) is the leading cause of vision loss in the elderly. The gold standard of nAMD treatment is intravitreal injections of vascular endothelial growth factor (VEGF) inhibitors. Genetic factors may influence the response to anti-VEGF therapy and result in a high degree of response variability. The aim of the study was to evaluate the association of the polymorphisms in genes related to the complement system (rs2285714-CFI, rs10490924-ARMS2, rs2230199-C3, rs800292-CFH, and rs6677604-CFH) with nAMD its clinical features and optical coherent tomography (OCT) biomarkers of treatment response to anti-VEGF therapy. Genotyping by allele-specific PCR was performed in 193 AMD patients and 147 age-matched controls. A prospective study of the dynamics of changes in OCT biomarkers during aflibercept treatment included 110 treatment-naive patients. Allele T rs10490924 was associated with the increased risk of nAMD. For both rs800292 and rs6677604, carriage of the A allele was protective and decreased the nAMD risk. Associations of rs2230199 with central retinal thickness (CRT) and intraretinal cysts were revealed. The height of pigment epithelium detachment and the height of neuroretinal detachment were significantly higher in carriers of the minor allele of rs2285714, both at baseline and during treatment. The reduction of CRT was associated with higher CRT at baseline and the presence of the T allele of rs2285714. By the end of one-year follow-up the patients homozygous for the minor allele rs2285714 had significantly higher odds of the presence of anastomoses and loops and active neovascular membrane. Furthermore, minor allele carriers had decreased levels of complement factor I level in aqueous humor but not in the plasma, which may be due to the influence of rs2285714 on tissue-specific splicing. Our results suggest that the severity of AMD macular lesions is associated with rs2285714 and rs2230199 polymorphisms, which could be explained by their high regulatory potential. Patients with the minor allele of rs2285714 respond worse to antiangiogenic therapy.
C1 [Kozhevnikova, Oyuna S.; Fursova, Anzhella Zh; Derbeneva, Anna S.; Tarasov, Mikhail S.; Devyatkin, Vasiliy A.; Rumyantseva, Yulia, V; Telegina, Darya, V; Kolosova, Nataliya G.] Inst Cytol & Genet SB RAS, Fed Res Ctr, Pr Lavrentiev 10, Novosibirsk 630090, Russia.
   [Fursova, Anzhella Zh; Derbeneva, Anna S.; Nikulich, Ida F.; Tarasov, Mikhail S.] State Novosibirsk Reg Clin Hosp, St Nemirovich Danchenko 130, Novosibirsk 630087, Russia.
   [Fursova, Anzhella Zh; Derbeneva, Anna S.; Nikulich, Ida F.; Tarasov, Mikhail S.] Novosibirsk State Med Univ, Dept Ophthalmol, Pr Krasny 52, Novosibirsk 630091, Russia.
C3 Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB
   RAS; Novosibirsk State Medical University
RP Kozhevnikova, OS (通讯作者)，Inst Cytol & Genet SB RAS, Fed Res Ctr, Pr Lavrentiev 10, Novosibirsk 630090, Russia.
EM oidopova@bionet.nsc.ru; anzhellafursova@yandex.ru;
   anna.derbeneva93@gmail.com; ida_2207@mail.ru; kalman87@mail.ru;
   devyatkin@bionet.nsc.ru; rumyantseva@bionet.nsc.ru;
   telegina@bionet.nsc.ru; kolosova@bionet.nsc.ru
RI Kozhevnikova, Oyuna S./H-3588-2016; Kolosova, Nataliya G/P-3178-2015
OI Kozhevnikova, Oyuna S./0000-0001-6475-4061; Kolosova, Nataliya
   G/0000-0003-2398-8544; Telegina, Darya/0000-0001-8096-0519
FU RSF [21-15-00047]; State Budget Project [FWNR-2022-0016]
FX Sample collection, genotyping, association study, clinical data,
   analysis of OCT markers, ELISA, Sanger sequencing, and APC were funded
   by the RSF (grant #21-15-00047). Functional annotation of SNPs was
   supported by the State Budget Project FWNR-2022-0016.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Akiyama M, 2018, J HUM GENET, V63, P1083, DOI 10.1038/s10038-018-0493-0
   Armento A, 2021, CELL MOL LIFE SCI, V78, P4487, DOI 10.1007/s00018-021-03796-9
   Balikova I, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000273
   Aygun FB, 2020, OPHTHALMOLOGICA, V243, P187, DOI 10.1159/000503327
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Clark SJ, 2018, SEMIN IMMUNOPATHOL, V40, P65, DOI 10.1007/s00281-017-0649-6
   Dedania VS, 2015, RETINA-J RET VIT DIS, V35, P381, DOI 10.1097/IAE.0000000000000466
   Enders P, 2016, EYE, V30, P1072, DOI 10.1038/eye.2016.97
   Faatz H, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10030694
   Framme C, 2018, OPHTHALMOL RETINA, V2, P539, DOI 10.1016/j.oret.2017.09.017
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fursova A Z, 2021, Adv Gerontol, V34, P823, DOI 10.34922/AE.2021.34.6.002
   Fursova A Zh, 2018, Vestn Oftalmol, V134, P59, DOI 10.17116/oftalma201813406159
   Garrido-Martin D, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20578-2
   Hagstrom SA, 2015, OPHTHALMOLOGY, V122, P1563, DOI 10.1016/j.ophtha.2015.04.024
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Hallam TM, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.18
   Heesterbeek TJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.18
   Hong N, 2016, ACTA OPHTHALMOL, V94, P334, DOI 10.1111/aos.13049
   Hu ZZ, 2015, BRIT J OPHTHALMOL, V99, P593, DOI 10.1136/bjophthalmol-2014-305488
   Huang DD, 2022, NUCLEIC ACIDS RES, V50, pD1408, DOI 10.1093/nar/gkab853
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Keenan TDL, 2015, INVEST OPHTH VIS SCI, V56, P4870, DOI 10.1167/iovs.15-17009
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Lores-Motta L, 2018, MOL DIAGN THER, V22, P315, DOI 10.1007/s40291-018-0332-1
   Maronas O, 2020, CURR MED CHEM, V27, P549, DOI 10.2174/0929867326666190711105325
   Medina FM, 2019, OPHTHALMIC RES, V61, P168, DOI 10.1159/000475995
   Metrangolo C, 2021, J OPHTHALMOL, V2021, DOI 10.1155/2021/9994098
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Oca AI, 2021, J PERS MED, V11, DOI 10.3390/jpm11121329
   Park UC, 2014, MOL VIS, V20, P1680
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Sole X, 2006, BIOINFORMATICS, V22, P1928, DOI 10.1093/bioinformatics/btl268
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Tanaka K, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-87340-6
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Wang VM, 2012, MOL VIS, V18, P2578
   Wu MX, 2017, BRIT J OPHTHALMOL, V101, P976, DOI 10.1136/bjophthalmol-2016-309418
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
NR 45
TC 2
Z9 2
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2227-9059
J9 BIOMEDICINES
JI Biomedicines
PD JUL
PY 2022
VL 10
IS 7
AR 1658
DI 10.3390/biomedicines10071658
PG 18
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA 3H9TN
UT WOS:000832370900001
PM 35884963
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Neelam, K
   Muldrew, A
   Hogg, R
   Stack, J
   Chakravartry, U
   Beatty, S
AF Neelam, Kumari
   Muldrew, Alyson
   Hogg, Ruth
   Stack, Jim
   Chakravartry, Usha
   Beatty, Stephen
TI GRADING OF AGE-RELATED MACULOPATHY Slit-lamp Biomicroscopy Versus an
   Accredited Grading Center
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related maculopathy; slit-lamp biomicroscopy; fundus photography;
   agreement; drusen; pigment abnormalities
ID MACULAR DEGENERATION; VISUAL IMPAIRMENT; PREVALENCE
AB Purpose: To compare clinical age-related maculopathy (ARM) grading using slit-lamp biomicroscopy (SLB) versus photographic grading of stereoscopically captured fundus photographs (FP) using a high-resolution fundus camera.
   Methods: A subset (129) of participants in the Carotenoids in ARM study were clinically graded for ARM signs and the corresponding FPs were graded in an accredited reading center.
   Results: Drusen were said to be present in 192 (94.5%) eyes graded by FP, and in 165 (82.5%) eyes examined by SLB (agreement = 84%, k = 0.23). A good and modest degree of agreement was observed between SLB and FP for quantification of total drusen number (agreement = 81%, k = 0.33) and for classification of drusen subtypes (agreement = 60%, k = 0.33), respectively. Localization of drusen to either the inner zone or the outer zone was comparable for both techniques of ARM grading (inner zone: agreement = 89%; outer zone: agreement = 88%, k = 0.39). Agreement between SLB and FP was 76% (k = 0.46) for identification of any pigment abnormality; however, agreement was less for hypopigmentation abnormalities (agreement = 64%, k = 0.21).
   Conclusions: From the statistical perspective, SLB grading of ARM is generally comparable with findings from standardized grading of FP. However, the lower levels of agreement for classification of drusen subtypes and detection of hypo-pigmentation suggest these features may go unrecorded in a study which relies on SLB for grading ARM.
C1 [Neelam, Kumari; Beatty, Stephen] Waterford Reg Hosp, Dept Ophthalmol, Waterford, Ireland.
   [Neelam, Kumari; Stack, Jim; Beatty, Stephen] Waterford Inst Technol, Dept Chem & Life Sci, Waterford, Ireland.
   [Neelam, Kumari] Natl Healthcare Grp, Alexandra Hosp, Dept Ophthalmol & Visual Sci, Singapore, Singapore.
   [Muldrew, Alyson; Hogg, Ruth; Chakravartry, Usha] Queens Univ, Dept Ophthalmol & Visual Sci, Belfast, Antrim, North Ireland.
   [Hogg, Ruth; Chakravartry, Usha] Royal Victoria Hosp, Dept Ophthalmol, Belfast BT12 6BA, Antrim, North Ireland.
C3 South East Technological University (SETU); Queens University Belfast
RP Beatty, S (通讯作者)，Waterford Reg Hosp, Dept Ophthalmol, Dunmore Rd, Waterford, Ireland.
EM sbeatty@wit.ie
RI Hogg, Ruth E./ABC-9602-2020
OI Hogg, Ruth E./0000-0001-9413-2669; Chakravarthy,
   Usha/0000-0002-2606-3734
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Evans JR, 2004, BRIT J OPHTHALMOL, V88, P365, DOI 10.1136/bjo.2003.019927
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   LANDIS JR, 1977, BIOMETRICS, V33, P174
   NEELAM K, OPHTHALMIC IN PRESS
   Sivagnanavel V, 2005, BRIT J OPHTHALMOL, V89, P554, DOI 10.1136/bjo.2004.046813
   Tikellis G, 2000, CLIN EXP OPHTHALMOL, V28, P367, DOI 10.1046/j.1442-9071.2000.00336.x
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
NR 12
TC 4
Z9 4
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2009
VL 29
IS 2
BP 192
EP 198
DI 10.1097/IAE.0b013e31818c178f
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 407BR
UT WOS:000263339100009
PM 18997640
DA 2022-11-30
ER

PT J
AU Scherer, WJ
AF Scherer, WJ
TI Association between topical prostaglandin analog use and development of
   choroidal neovascular membranes in patients with concurrent glaucoma and
   age-related macular degeneration
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID MATRIX METALLOPROTEINASES MMPS; CILIARY MUSCLE; UVEOSCLERAL OUTFLOW;
   INHIBITORS TIMPS; ORGAN-CULTURES; LATANOPROST; INCREASES; MONKEY; EDEMA;
   CELLS
AB Purpose: Matrix metalloproteinases (MMPs) are a family of enzymes that act to degrade extracellular matrix (ECM) molecules, such as collagen, elastin, and gelatin. The glaucoma medication latanoprost, and possibly other topical prostaglandin analogs, increase uveoscleral outflow and lower intraocular pressure (IOP) in primary open-angle glaucoma (POAG) by activating MMPs 1, 2, 3, and 9 in the ciliary body. It has been reported that latanoprost may also gain access to the posterior segment and induce cystoid macular edema, although the mechanism is unknown. In the choroid, activation of some of the same subtypes of MMPs (particularly subtypes 2 and 9) has been implicated in the formation of choroidal neovascular membranes (CNVMs) in age-related macular degeneration (AMD). This study examined whether topical prostaglandin analog use is associated with a greater risk of CNVM formation in patients diagnosed with both AMD and POAG.
   Methods: A retrospective record review was performed to identify patients with a concurrent diagnosis of AMD and POAG between 1998 and 2004. Four hundred and eighty-four (484) eyes were identified and grouped as wet (n = 65) or dry (n = 419) AMD. Prostaglandin usage was compared between the two groups. Usage of other glaucoma medications was also compared. A minimum of 1 year of topical glaucoma medication was required for inclusion in the study. Exclusion criteria included a history of CNVM prior to starting glaucoma medications and a previous history of glaucoma surgery.
   Results: Fifty-six percent (56%) of dry AMD and 62% of wet AMD eyes were using a topical prostaglandin (P > 0.10; not significant). Analysis of specific topical prostaglandin analog usage in the wet versus dry AMD groups revealed no statistically significant differences in the percentage of eyes treated with latanoprost (37.7% versus 41.5%), bimatoprost (12.9% versus 10.8%), or travoprost (9.2% versus 5.3%), respectively. No significant differences in the use of other glaucoma medications were observed between the two groups.
   Conclusions: No association between long-term topical prostaglandin use and CNVM development was found in patients with AMD and POAG.
C1 Montgomery Eye Ctr, Naples, FL 34103 USA.
RP Scherer, WJ (通讯作者)，Montgomery Eye Ctr, 700 Neapolitan Way, Naples, FL 34103 USA.
EM warrenscherer@hotmail.com
CR Berglin L, 2003, INVEST OPHTH VIS SCI, V44, P403, DOI 10.1167/iovs.02-0180
   Callanan D, 1998, AM J OPHTHALMOL, V126, P134, DOI 10.1016/S0002-9394(98)00082-8
   Cawston TE, 1996, PHARMACOL THERAPEUT, V70, P163, DOI 10.1016/0163-7258(96)00015-0
   Das A, 1999, ARCH OPHTHALMOL-CHIC, V117, P498
   El-Shabrawi Y, 2000, EYE, V14, P375, DOI 10.1038/eye.2000.92
   FLYNN HW, 2003, AM ACAD OPHTHALMOLOG
   GABELT BT, 1989, EXP EYE RES, V49, P389, DOI 10.1016/0014-4835(89)90049-3
   Gaton DD, 2001, ARCH OPHTHALMOL-CHIC, V119, P1165, DOI 10.1001/archopht.119.8.1165
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Kashiwagi K, 2001, J GLAUCOMA, V10, P271, DOI 10.1097/00061198-200108000-00005
   Kvanta A, 2000, CURR EYE RES, V21, P684, DOI 10.1076/0271-3683(200009)21:3;1-R;FT684
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Madlener M, 1998, EXP CELL RES, V242, P201, DOI 10.1006/excr.1998.4049
   Mietz H, 2003, INVEST OPHTH VIS SCI, V44, P5182, DOI 10.1167/iovs.02-0462
   Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Moroi SE, 1999, OPHTHALMOLOGY, V106, P1024, DOI 10.1016/S0161-6420(99)00528-X
   Moses MA, 1996, J CELL BIOCHEM, V60, P379, DOI 10.1002/(SICI)1097-4644(19960301)60:3<379::AID-JCB9>3.3.CO;2-0
   Ocklind A, 1998, EXP EYE RES, V67, P179, DOI 10.1006/exer.1998.0508
   PEPPER MS, 1990, CELL DIFFER DEV, V32, P319, DOI 10.1016/0922-3371(90)90046-Y
   Pereira MLM, 2001, AM J OPHTHALMOL, V132, P928, DOI 10.1016/S0002-9394(01)01143-6
   Plantner JJ, 1998, EXP EYE RES, V67, P637, DOI 10.1006/exer.1998.0552
   Schlotzer-Schrehardt U, 2002, INVEST OPHTH VIS SCI, V43, P1475
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   TORIS CB, 1993, OPHTHALMOLOGY, V100, P1297
   Vetrugno M, 1998, ACTA OPHTHALMOL SCAN, V76, P40
   Wang N, 2001, CURR EYE RES, V22, P198, DOI 10.1076/ceyr.22.3.198.5515
   Watson PG, 1998, OPHTHALMOLOGY, V105, P82, DOI 10.1016/S0161-6420(98)91372-0
   Weinreb RN, 2002, INVEST OPHTH VIS SCI, V43, P716
   Weinreb RN, 1997, INVEST OPHTH VIS SCI, V38, P2772
   WOESSNER JF, 1994, ANN NY ACAD SCI, V732, P11
   Yeh PC, 2002, J CATARACT REFR SURG, V28, P1814, DOI 10.1016/S0886-3350(02)01334-2
NR 34
TC 2
Z9 2
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD APR
PY 2006
VL 22
IS 2
BP 139
EP 144
DI 10.1089/jop.2006.22.139
PG 6
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 040SW
UT WOS:000237401700008
PM 16722800
DA 2022-11-30
ER

PT J
AU Roshanipour, N
   Laleh, MG
   Bonyadi, M
   Bonyadi, MHJ
   Soheilian, M
   Javadzadeh, A
   Yaseri, M
AF Roshanipour, Nasrin
   Laleh, Maryam Ghaffari
   Bonyadi, Mortaza
   Bonyadi, Mohammad Hossein Jabbarpoor
   Soheilian, Masoud
   Javadzadeh, Alireza
   Yaseri, Mehdi
TI Role of complement factor B rs4151667 (L9H) polymorphisms and its
   interactional role with CFH Y402H and C3 rs2230199 (R102G) risk variants
   in age-related macular degeneration: a case control study
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration (AMD); Complement factor B (CFB) gene;
   Complement factor H (CFH) gene; Complement factor 3 (C3) gene; L9H
   polymorphisms; Y402H polymorphism; R102G polymorphism; PCR-RFLP
ID PIGMENT EPITHELIAL-CELLS; CYTOKINE LIGAND 2; FACTOR-H; ASSOCIATION; C2;
   GENES
AB Background Age-related Macular Degeneration (AMD) is a complex eye disease, which is genetically associated with different susceptibility loci. We planned to investigate the possible association of Complement Factor B (CFB) rs4151667 (L9H) variants and their possible interaction with Complement Factor H (CFH) Y402H and Complement factor 3 (C3) rs2230199 (R102G) in AMD. Methods This case-control association study included 216 advanced type AMD patients and 191 healthy individuals for evaluation. Extracted-DNA samples were genotyped for the polymorphic regions of CFB rs4151667 (L9H), CFH Y402H and C3 rs2230199 (R102G). Results The distribution of CFB rs4151667 (L9H) genotypes was not significantly different in the AMD patients compared to that of controls (P = 0.18). The AT genotype frequencies for CFB was non significantly lower in AMD group (6.5% vs. 13.1%, AOR = 0.49, CI = 0.23-1.04,P = 0.064(. The A allele of CFB rs4151667 (L9H) was found to be non-significantly lower in AMD patients. CFB rs4151667 (L9H) had no protective interactional effect against CFH (Y402H) and C3 (R102G) risk variants. Conclusions This study showed that the protective role of CFB rs4151667 (L9H) in AMD is not significant and it has no significant protective interactional effect against CFH (Y402H) and C3 (R102G) risk variants.
C1 [Roshanipour, Nasrin] Islamic Azad Univ, Dept Biol, Tabriz Branch, Tabriz, Iran.
   [Laleh, Maryam Ghaffari; Bonyadi, Mortaza] Univ Tabriz, Fac Nat Sci, Ctr Excellence Biodivers, Tabriz, Iran.
   [Laleh, Maryam Ghaffari; Bonyadi, Mortaza] Tabriz Univ Med Sci, Liver & Gastrointestinal Dis Res Ctr, Tabriz, Iran.
   [Bonyadi, Mohammad Hossein Jabbarpoor; Soheilian, Masoud] Shahid Beheshti Univ Med Sci, Ocular Tissue Engn Res Ctr, Ophthalm Res Ctr, Tehran, Iran.
   [Javadzadeh, Alireza] Tabriz Univ Med Sci, Dept Ophthalmol, Tabriz, Iran.
   [Yaseri, Mehdi] Univ Tehran Med Sci, Dept Biostat & Epidemiol, Tehran, Iran.
C3 Islamic Azad University; University of Tabriz; Tabriz University of
   Medical Science; Shahid Beheshti University Medical Sciences; Tabriz
   University of Medical Science; Tehran University of Medical Sciences
RP Bonyadi, M (通讯作者)，Univ Tabriz, Fac Nat Sci, Ctr Excellence Biodivers, Tabriz, Iran.; Bonyadi, M (通讯作者)，Tabriz Univ Med Sci, Liver & Gastrointestinal Dis Res Ctr, Tabriz, Iran.
EM bonyadijm@yahoo.com
RI ; Yaseri, Mehdi/I-1645-2018
OI Bonyadi, Mortaza/0000-0003-3216-2947; Yaseri, Mehdi/0000-0002-4066-873X
CR [Anonymous], 2014, J OPHTHALMIC VIS RES
   Babanejad M, 2016, OPHTHALMIC GENET, V37, P144, DOI 10.3109/13816810.2014.955585
   Bazyar N, 2012, MOL BIOL REP, V39, P8919, DOI 10.1007/s11033-012-1759-9
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Bonyadi MHJ, 2016, OPHTHALMIC GENET, V37, P465, DOI 10.3109/13816810.2015.1120317
   Bonyadi M, 2019, INT OPHTHALMOL, V39, P551, DOI 10.1007/s10792-018-0835-0
   Bonyadi M, 2017, OPHTHALMIC GENET, V38, P61, DOI 10.3109/13816810.2015.1126612
   Bonyadi M, 2016, ACTA OPHTHALMOL, V94, pE779, DOI 10.1111/aos.13143
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Despriet DDG, 2008, INVEST OPHTH VIS SCI, V49, P364, DOI 10.1167/iovs.07-0656
   Edwards AO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003813
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Holers VM, 2004, MOL IMMUNOL, V41, P147, DOI 10.1016/j.molimm.2004.03.012
   Hollborn M, 2018, MOL VIS, V24, P518
   Karkhane R, 2016, J CURR OPHTHALMOL, V28, P32, DOI 10.1016/j.joco.2016.01.003
   Kaur I, 2010, INVEST OPHTH VIS SCI, V51, P59, DOI 10.1167/iovs.09-4135
   Kim SJ, 2012, EXP EYE RES, V96, P42, DOI 10.1016/j.exer.2012.01.005
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Luo C, 2013, EXP EYE RES, V112, P93, DOI 10.1016/j.exer.2013.04.016
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   Richardson AJ, 2009, INVEST OPHTH VIS SCI, V50, P540, DOI 10.1167/iovs.08-2423
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Thakkinstian A, 2012, AM J EPIDEMIOL, V176, P361, DOI 10.1093/aje/kws031
NR 27
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD AUG 6
PY 2020
VL 20
IS 1
AR 323
DI 10.1186/s12886-020-01552-4
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NC3LF
UT WOS:000561115700001
PM 32762675
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Bressler, NM
   Doan, QV
   Varma, R
   Lee, PP
   Suner, IJ
   Dolan, C
   Danese, MD
   Yu, E
   Tran, I
   Colman, S
AF Bressler, Neil M.
   Doan, Quan V.
   Varma, Rohit
   Lee, Paul P.
   Suner, Ivan J.
   Dolan, Chantal
   Danese, Mark D.
   Yu, Elaine
   Tran, Irwin
   Colman, Shoshana
TI Estimated Cases of Legal Blindness and Visual Impairment Avoided Using
   Ranibizumab for Choroidal Neovascularization Non-Hispanic White
   Population in the United States With Age-Related Macular Degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID DEGENERATION; IMPACT; THERAPY; MODELS
AB Objective: To estimate the number of non-Hispanic white individuals in the United States avoiding legal blindness and visual impairment from neovascular age-related macular degeneration (AMD) with ranibizumab availability.
   Methods: Modeling of visual acuity outcomes from phase 3 ranibizumab trials to incidence rates of neovascular AMD from population-based studies.
   Results: If no treatment were given, of the 103 582 individuals developing neovascular AMD for which ranibizumab would be indicated and available, 16 268 would become legally blind in 2 years. Monthly ranibizumab would reduce the incidence of legal blindness in 2 years by 72% (95% confidence interval [CI], 70% to 74%) to 4484 individuals. If no treatment were given, 34 702 would become visually impaired. Monthly ranibizumab would reduce the incidence of visual impairment in 2 years by 37% (95% CI, 35% to 39%) to 21 919 cases.
   Conclusions: Ranibizumab should have a substantial effect on reducing the magnitude of legal blindness and visual impairment within 2 years after diagnosis of neovascular AMD among non-Hispanic white individuals in the United States. Although racial subgroups other than non-Hispanic whites were not considered (because there is limited information in the literature regarding incidence rates of choroidal neovascularization in other populations) and although these results assume access to and application of monthly ranibizumab for 2 years, the number of individuals developing legal blindness or vision impairment from neovascular AMD should be reduced dramatically if monthly ranibizumab is applied when indicated.
C1 [Bressler, Neil M.] Johns Hopkins Univ Hosp, Wilmer Eye Inst, Sch Med, Baltimore, MD 21287 USA.
   [Doan, Quan V.; Danese, Mark D.] Outcomes Insights Inc, Westlake, CA USA.
   [Varma, Rohit] Univ So Calif, Doheny Eye Inst, Los Angeles, CA USA.
   [Lee, Paul P.] Duke Univ, Sch Med, Duke Eye Ctr, Durham, NC USA.
   [Suner, Ivan J.] Retina Associates Florida, Tampa, FL USA.
   [Dolan, Chantal; Yu, Elaine; Tran, Irwin; Colman, Shoshana] Genentech Inc, San Francisco, CA USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Doheny Eye Institute;
   University of Southern California; Duke University; Roche Holding;
   Genentech
RP Bressler, NM (通讯作者)，Johns Hopkins Univ Hosp, Wilmer Eye Inst, Sch Med, Maumenee 752,600 N Wolfe St, Baltimore, MD 21287 USA.
EM nmboffice@jhmi.edu
OI Lee, Paul/0000-0002-3338-136X
FU Allergan; Bausch Lomb; Carl Zeiss Meditec; Genentech, Inc; Notal Vision
   Inc; Novartis; Othera; QLT; Regeneron; Steba Pharmaceuticals; Department
   of Ophthalmology; Optovue; Pfizer; Alcon; Eyetech
FX Dr Bressler's employer, The Johns Hopkins University (JHU), but not Dr
   Bressler, receives funding from Allergan, Bausch & Lomb, Carl Zeiss
   Meditec, Genentech, Inc, Notal Vision Inc, Novartis, Othera, QLT,
   Regeneron, and Steba Pharmaceuticals for sponsored projects by the
   Department of Ophthalmology for the efforts of Dr Bressler. Dr Bressler
   receives salary support for these sponsored projects; the terms of these
   projects are negotiated and administered by JHU's Office of Research
   Administration. Under JHU's policy, support for the costs of research,
   administered by the institution, does not constitute a conflict of
   interest. Dr Doan is a consultant for Genentech, Inc. Dr Varma's
   institution has received research funding from Allergan, Genentech, Inc,
   Optovue, and Pfizer; he is a consultant for Alcon, Allergan, Aquesys,
   Bausch & Lomb, Genentech, Inc, Replenish, Merck, and Pfizer. Dr Lee's
   institution has received research funding from Alcon, Allergan, and
   Pfizer; he is a consultant for Allergan, Genentech, Inc, and Pfizer. Dr
   Suner's institution has received research funding from Eyetech,
   Genentech, Inc, and Pfizer; he is a consultant for Genentech, Inc,
   Comentis, and Pfizer. Dr Dolan is a consultant for Genentech, Inc. Dr
   Danese is a consultant for Genentech, Inc.
CR Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BOLZ M, 2008, 8 EUR C MAY 22 VIENN
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Briggs A, 1998, PHARMACOECONOMICS, V13, P397, DOI 10.2165/00019053-199813040-00003
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Denavas-Walt C., 2007, INCOME POVERTY HLTH, P60
   ETER N, 2008, 8 EUR C MAY 23 VIENN
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Law A., 2007, J AM STATAL ASS, V4th
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   O'Hagan A, 2007, HEALTH ECON, V16, P1009, DOI 10.1002/hec.1199
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409
   *US BUR CENS, POP EST RAC ETHN
   EFFICACY SAFETY RANI
   SUSTAIN STUDY RANIBI
NR 27
TC 84
Z9 86
U1 0
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUN
PY 2011
VL 129
IS 6
BP 709
EP 717
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 776UJ
UT WOS:000291563500004
PM 21670337
OA Bronze
DA 2022-11-30
ER

PT J
AU Hermann, MM
   van Asten, F
   Muether, PS
   Smailhodzic, D
   Lichtner, P
   Hoyng, CB
   Kirchhof, B
   Grefkes, C
   den Hollander, AI
   Fauser, S
AF Hermann, Manuel M.
   van Asten, Freekje
   Muether, Philipp S.
   Smailhodzic, Dzenita
   Lichtner, Peter
   Hoyng, Carel B.
   Kirchhof, Bernd
   Grefkes, Christian
   den Hollander, Anneke I.
   Fauser, Sascha
TI Polymorphisms in Vascular Endothelial Growth Factor Receptor 2 Are
   Associated with Better Response Rates to Ranibizumab Treatment in
   Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; INTRAVITREAL RANIBIZUMAB; VEGF; BEVACIZUMAB;
   VARIANTS; THERAPY; Y402H; GENE; CFH
AB Purpose: Intravitreal antievascular endothelial growth factor (VEGF) injections are currently the standard treatment for neovascular age-related macular degeneration (AMD), but a broad range of response rates has been observed. We evaluated the association of single nucleotide polymorphisms (SNPs) in VEGF genes and their receptors (VEGFR) with the response rate to ranibizumab in 366 patients with neovascular AMD.
   Design: Case series study.
   Participants: A total of 366 eyes of 366 patients with neovascular AMD.
   Methods: Visual acuity (VA) was determined at baseline, after 3 monthly ranibizumab injections, and after 1 year of treatment. Genotyping of 126 SNPs in the genes encoding VEGF family members VEGFA, VEGFB, VEGFC, VEGFD (FIGF), and placental growth factor (PGF); VEGF receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4); and the gene encoding pigment epithelium-derived factor (PEDF) (SERPINF1) was performed.
   Main Outcome Measures: The changes in VA after 3 injections and after 1 year of treatment and their association with VEGF and VEGFR genotypes.
   Results: Univariate analyses of variance (ANOVAs) revealed a significant effect of SNP rs4576072 in the VEGFR2 gene on VA change after 12 months (F[1,235] = 14.05; P = 0.02). A stepwise linear regression analysis returned a model (P = 0.01) with SNPs rs4576072 and rs6828477 in the VEGFR2 gene as independent predictors for VA change after 12 months, with a mean increase in VA of 0.26 on the logarithm of the minimum angle of resolution (logMAR) scale in patients with 3 contributing minor alleles compared with a loss of 0.03 logMAR in patients with no minor allele.
   Conclusions: Polymorphisms in the VEGFR2/KDR gene significantly influence visual outcome in patients receiving ranibizumab treatment for neovascular AMD. This study shows that genetic variation partially explains the wide range of response to ranibizumab treatment, which in the future might help clinicians tailoring medical interventions to individual needs. Ophthalmology 2014;121:905-910 (C) 2014 by the American Academy of Ophthalmology.
C1 [Hermann, Manuel M.; Muether, Philipp S.; Kirchhof, Bernd; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, D-50924 Cologne, Germany.
   [van Asten, Freekje; Smailhodzic, Dzenita; Hoyng, Carel B.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 ED Nijmegen, Netherlands.
   [Lichtner, Peter] Munchene Deutsch Forschungszentrum Gesundhei & Um, Helmholtz Zentrum Munchene, Inst Human Genet, Neuherberg, Germany.
   [Grefkes, Christian] Max Planck Inst Neurol Res, Neuromodulat & Neurorehabilitat Grp, D-50931 Cologne, Germany.
   [Grefkes, Christian] Univ Hosp Cologne, Dept Neurol, D-50924 Cologne, Germany.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands.
C3 University of Cologne; Radboud University Nijmegen; Helmholtz
   Association; Helmholtz-Center Munich - German Research Center for
   Environmental Health; Max Planck Society; University of Cologne; Radboud
   University Nijmegen
RP Fauser, S (通讯作者)，Univ Hosp Cologne, Dept Ophthalmol, Kerpener Str 62, D-50924 Cologne, Germany.
EM sascha.fauser@uk-koeln.de
RI Grefkes, Christian/H-3972-2013; van Asten, Freekje/P-6028-2015; Hoyng,
   C.B./H-8050-2014; Hollander, Anneke den/N-4911-2014
OI Grefkes, Christian/0000-0002-1656-720X; van Asten,
   Freekje/0000-0002-8141-4234; 
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Chang W, 2013, MOL VIS, V19, P702
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042464
   de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Koch KR, 2012, GRAEF ARCH CLIN EXP, V250, P201, DOI 10.1007/s00417-011-1792-8
   Lambrechts D, 2012, LANCET ONCOL, V13, P724, DOI 10.1016/S1470-2045(12)70231-0
   Lazzeri S, 2013, PHARMACOGENOMICS, V14, P623, DOI [10.2217/PGS.13.43, 10.2217/pgs.13.43]
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/PGS.12.53, 10.2217/pgs.12.53]
   Wang VM, 2012, MOL VIS, V18, P2578
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
NR 24
TC 40
Z9 44
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2014
VL 121
IS 4
BP 905
EP 910
DI 10.1016/j.ophtha.2013.10.047
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AE2MV
UT WOS:000333808100022
PM 24365177
DA 2022-11-30
ER

PT J
AU Lawrenson, JG
   Evans, JR
AF Lawrenson, John G.
   Evans, Jennifer R.
TI Omega 3 fatty acids for preventing or slowing the progression of
   age-related macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE Disease Progression; Fatty Acids; Omega-3 [*therapeutic use]; Macular
   Degeneration [*prevention & control]; Humans
ID POLYUNSATURATED FATTY-ACIDS; DOCOSAHEXAENOIC ACID; SUPPLEMENTATION;
   PREVALENCE; DISEASE; LUTEIN
AB Background
   Evidence from animal models and observational studies in humans has suggested that there is an inverse relationship between dietary intake of omega 3 long-chain polyunsaturated fatty acids (LCPUFA) and risk of developing age-related macular degeneration (AMD) or progression to advanced AMD.
   Objectives
   To review the evidence that increasing the levels of omega 3 LCPUFA in the diet (either by eating more foods rich in omega 3 or by taking nutritional supplements) prevents AMD or slows the progression of AMD.
   Search methods
   We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2015, Issue 1), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to February 2015), EMBASE (January 1980 to February 2015), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 to February 2015), the ISRCTN registry (www.isrctn.com/editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 2 February 2015.
   Selection criteria
   We included randomised controlled trials (RCTs) where increased dietary intake of omega 3 LCPUFA was compared to placebo or no intervention with the aim of preventing the development of AMD, or slowing its progression.
   Data collection and analysis
   Both authors independently selected studies, assessed them for risk of bias and extracted data. One author entered data into RevMan 5 and the other author checked the data entry. We conducted a meta-analysis for one primary outcome, progression of AMD, using a fixed-effect inverse variance model.
   Main results
   We included two RCTs in this review, in which 2343 participants with AMD were randomised to receive either omega 3 fatty acid supplements or a placebo. The trials, which had a low risk of bias, were conducted in the USA and France. Overall, there was no evidence that people who took omega 3 fatty acid supplements were at decreased (or increased risk) of progression to advanced AMD (pooled hazard ratio (HR) 0.96, 95% confidence interval (CI) 0.84 to 1.10, high quality evidence). Similarly, people taking these supplements were no more (or less) likely to lose 15 or more letters of visual acuity (USA study HR 0.96, 95% CI 0.84 to 1.10; French study at 36 months risk ratio (RR) 1.25, 95% CI 0.69 to 2.26, participants = 230). The number of adverse events was similar in the intervention and placebo groups (USA study participants with one or more serious adverse event RR 1.00, 95% CI 0.91 to 1.09, participants = 2080; French study total adverse events RR 1.05, 95% CI 0.97 to 1.13, participants = 263).
   Authors' conclusions
   This review found that omega 3 LCPUFA supplementation in people with AMD for periods up to five years does not reduce the risk of progression to advanced AMD or the development of moderate to severe visual loss. No published randomised trials were identified on dietary omega 3 fatty acids for primary prevention of AMD. Currently available evidence does not support increasing dietary intake of omega 3 LCPUFA for the explicit purpose of preventing or slowing the progression of AMD.
C1 [Lawrenson, John G.] City Univ London, Div Optometry & Visual Sci, Northampton Sq, London EC1V 0HB, England.
   [Evans, Jennifer R.] London Sch Hyg & Trop Med, ICEH, Cochrane Eyes & Vis Grp, London, England.
C3 City University London; University of London; London School of Hygiene &
   Tropical Medicine
RP Lawrenson, JG (通讯作者)，City Univ London, Div Optometry & Visual Sci, Northampton Sq, London EC1V 0HB, England.
EM j.g.lawrenson@city.ac.uk
RI ; Evans, Jennifer/F-4672-2012
OI Lawrenson, John/0000-0002-2031-6390; Evans, Jennifer/0000-0002-6137-2030
FU National Institute for Health Research, UK; Department of Health through
   National Institute for Health Research; NIHR
FX National Institute for Health Research, UK.; Richard Wormald,
   Co-ordinating Editor for the Cochrane Eyes and Vision Group (CEVG)
   acknowledges financial support for his CEVG research sessions from the
   Department of Health through the award made by the National Institute
   for Health Research to Moorfields Eye Hospital NHS Foundation Trust and
   UCL Institute of Ophthalmology for a Specialist Biomedical Research
   Centre for Ophthalmology.; The NIHR also funds the CEVG Editorial Base
   in London.; The views expressed in this publication are those of the
   authors and not necessarily those of the NIHR, NHS, or the Department of
   Health.
CR [Anonymous], 2014, REV MAN REVMAN VERS
   Arnold C, 2013, JAMA OPHTHALMOL, V131, P564, DOI 10.1001/jamaophthalmol.2013.2851
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   Burdge GC, 2002, BRIT J NUTR, V88, P355, DOI 10.1079/BJN2002662
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub3
   Feher J, 2005, OPHTHALMOLOGICA, V219, P154, DOI 10.1159/000085248
   Garcia-Layana A, 2013, NUTRIENTS, V5, P543, DOI 10.3390/nu5020543
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001
   Hodge WG, 2007, RETINA-J RET VIT DIS, V27, P216, DOI 10.1097/01.iae.0000233322.83713.2d
   Hodge WG, 2006, OPHTHALMOLOGY, V113, P1165, DOI 10.1016/j.ophtha.2006.02.043
   Hooper L, 2004, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD003177.PUB2
   Huang LL, 2008, INVEST OPHTH VIS SCI, V49, P3864, DOI 10.1167/iovs.07-1420
   Johnson EJ, 2008, AM J CLIN NUTR, V87, P1521, DOI 10.1093/ajcn/87.5.1521
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Koto T, 2007, INVEST OPHTH VIS SCI, V48, P4328, DOI 10.1167/iovs.06-1148
   Lawrenson JG, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010015.pub3
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   SanGiovanni JP, 2009, ARCH OPHTHALMOL-CHIC, V127, P110, DOI 10.1001/archophthalmol.2008.518
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Scorolli L, 2002, CAN J OPHTHALMOL, V37, P399, DOI 10.1016/S0008-4182(02)80042-4
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
   Ziegler Rosemarie, 2013, Med Monatsschr Pharm, V36, P348
NR 33
TC 31
Z9 31
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2015
IS 4
AR CD010015
DI 10.1002/14651858.CD010015.pub3
PG 34
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA V47DR
UT WOS:000209933000018
PM 25856365
OA Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Ng, DSC
   Bakthavatsalam, M
   Lai, FHP
   Cheung, CYL
   Cheung, GCM
   Tang, FY
   Tsang, CW
   Lai, TYY
   Wong, TY
   Brelen, ME
AF Ng, Danny Siu-Chun
   Bakthavatsalam, Malini
   Lai, Frank Hiu-Ping
   Cheung, Carol Yim-Lui
   Cheung, Gemmy Chu-Ming
   Tang, Fang Yao
   Tsang, Chi Wai
   Lai, Timothy Yuk-Yau
   Wong, Tien Yin
   Brelen, Marten Erik
TI Classification of Exudative Age-Related Macular Degeneration With
   Pachyvessels on En Face Swept-Source Optical Coherence Tomography
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; polypoidal choroidal vasculopathy;
   pachyvessels; pachychoroid
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; CENTRAL SEROUS CHORIORETINOPATHY;
   VASCULAR HYPERPERMEABILITY; HEALTHY EYES; PACHYCHOROID NEOVASCULOPATHY;
   THICKNESS; CHORIOCAPILLARIS; DISEASE; VISUALIZATION; FEATURES
AB PURPOSE. The purpose of this study was to classify exudative maculopathy by the presence of pachyvessels on en face swept-source optical coherence tomography (SSOCT).
   METHODS. Consecutive patients with signs of exudative maculopathy underwent SSOCT, fluorescein and indocyanine green angiography (ICGA), ultra-widefield fundus color photography, and autofluorescence examinations. Images were analyzed in a masked fashion by two sets of four examiners in different sessions: (1) the presence of pachyvessels in en face OCT and (2) features of exudative maculopathy in conventional imaging modalities. Quantitative data obtained were subfoveal choroidal thickness (SFCT) and choroidal vascularity index (CVI), which was the ratio of choroidal vessels lumen area to a specified choroidal area from binarized cross-sectional OCT scans.
   RESULTS. Pachyvessels was observed in 38 (52.1%) of 73 eyes. The pachyvessels group was associated with younger age (69.1 6 9.4 years, odds ratio [OR] = 0.95, 95% confidence interval [95% CI] = 0.90-0.97, P = 0.04), presence of polypoidal lesions (OR = 3.27, 95% CI = 1.24-8.62, P = 0.01), increased SFCT (OR = 1.08, 95% CI = 1.02-1.14, P < 0.01), and increased CVI (65.4 6 5.3, OR = 1.12, 95% CI = 1.02-1.23, P = 0.01). In multivariate regression, CVI significantly correlated with pachyvessels (OR = 1.24, 95% CI = 1.03-1.55, P = 0.04).
   CONCLUSIONS. Exudative maculopathy could be classified based on differences in choroidal vasculature morphology. Current results implied that choroidal hemodynamics may be relevant to variable natural history and treatment response in neovascular AMD and polypoidal choroidal vasculopathy.
C1 [Ng, Danny Siu-Chun; Bakthavatsalam, Malini; Cheung, Carol Yim-Lui; Tang, Fang Yao; Tsang, Chi Wai; Lai, Timothy Yuk-Yau; Brelen, Marten Erik] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Lai, Frank Hiu-Ping] Caritas Med Ctr, Dept Ophthalmol, Hong Kong, Hong Kong, Peoples R China.
   [Cheung, Gemmy Chu-Ming; Wong, Tien Yin] Singapore Natl Eye Ctr, Med Retina Serv, Singapore, Singapore.
   [Cheung, Gemmy Chu-Ming; Wong, Tien Yin] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.
   [Brelen, Marten Erik] Prince Wales Hosp, Dept Ophthalmol, Hong Kong, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Singapore National Eye Center; National
   University of Singapore; Chinese University of Hong Kong; Prince of
   Wales Hospital
RP Ng, DSC (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong Eye Hosp 4F, 147K Argyle St, Mongkok, Hong Kong, Peoples R China.
EM dannyng@cuhk.edu.hk
RI Brelen, Marten E./D-1133-2016; Cheung, Carol Y./G-7895-2016; Ng, Danny
   Siu Chun/AAG-3081-2020; Wong, Tien Yin/AAC-9724-2020; Lai, Timothy Y
   Y/AAC-2120-2020; Cheung, Carol/AAF-1101-2020; TANG,
   Fangyao/AAF-2824-2020
OI Ng, Danny Siu Chun/0000-0001-6566-1019; Wong, Tien
   Yin/0000-0002-8448-1264; Lai, Timothy Y Y/0000-0002-7832-6428; Cheung,
   Carol/0000-0002-9672-1819; Cheung, Carol/0000-0003-0869-859X; Lai, Hiu
   Ping/0000-0002-4446-3790; Cheung, Chui Ming Gemmy/0000-0003-3358-3516
FU Chinese University of Hong Kong Direct Grant [2015.1.044]
FX Supported, in part, by The Chinese University of Hong Kong Direct Grant
   2015/2016, reference 2015.1.044.
CR Adhi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133080
   Agrawal R, 2016, RETINA-J RET VIT DIS, V36, P1646, DOI 10.1097/IAE.0000000000001040
   Agrawal R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21090
   Agrawal R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146344
   Alasil T, 2015, AM J OPHTHALMOL, V159, P634, DOI 10.1016/j.ajo.2014.12.012
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Barteselli G, 2012, OPHTHALMOLOGY, V119, P2572, DOI 10.1016/j.ophtha.2012.06.065
   Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Dansingani KK, 2016, OPHTHALMOLOGY, V123, P2628, DOI 10.1016/j.ophtha.2016.06.060
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   Ferrara D, 2016, PROG RETIN EYE RES, V52, P130, DOI 10.1016/j.preteyeres.2015.10.002
   Ferrara D, 2014, OPHTHALMOLOGY, V121, P719, DOI 10.1016/j.ophtha.2013.10.014
   Gallego-Pinazo Roberto, 2014, Med Hypothesis Discov Innov Ophthalmol, V3, P111
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Kim YT, 2012, BRIT J OPHTHALMOL, V96, P1217, DOI 10.1136/bjophthalmol-2012-301644
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lim LS, 2013, ASIA-PAC J OPHTHALMO, V2, P32, DOI 10.1097/APO.0b013e31827ff5bc
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Mauget-Faysse M, 2006, AM J OPHTHALMOL, V142, P970, DOI 10.1016/j.ajo.2006.06.063
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Miyake M, 2014, INVEST OPHTH VIS SCI, V55, P3223, DOI 10.1167/iovs.14-14059
   Motaghiannezam R, 2012, INVEST OPHTH VIS SCI, V53, P2337, DOI 10.1167/iovs.11-7823
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Niblack W, 1986, ADV COMPUTER GRAPHIC
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Ozkaya A, 2016, EYE, V30, P958, DOI 10.1038/eye.2016.71
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Prunte C, 1996, AM J OPHTHALMOL, V121, P26
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Savastano MC, 2015, OSLI RETINA, V46, P561, DOI 10.3928/23258160-20150521-07
   Sayanagi K, 2015, BRIT J OPHTHALMOL, V99, P29, DOI 10.1136/bjophthalmol-2013-304658
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Semoun O, 2016, BRIT J OPHTHALMOL, V100, P1028, DOI 10.1136/bjophthalmol-2015-307494
   Sohrab M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048631
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447
   Spaide R, 2008, RETINA-J RET VIT DIS, V28, P5, DOI 10.1097/IAE.0b013e318158eca4
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Tan KA, 2016, ACTA OPHTHALMOL, V94, pE612, DOI 10.1111/aos.13044
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   Wei X, 2017, RETINA-J RET VIT DIS, V37, P1120, DOI 10.1097/IAE.0000000000001312
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yasuno Y, 2009, INVEST OPHTH VIS SCI, V50, P405, DOI 10.1167/iovs.08-2272
NR 62
TC 21
Z9 21
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2017
VL 58
IS 2
DI 10.1167/iovs.16-20519
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EO8LC
UT WOS:000396939600043
PM 28195603
OA gold
DA 2022-11-30
ER

PT J
AU Kersten, E
   Geerlings, MJ
   den Hollander, AI
   de Jong, EK
   Fauser, S
   Peto, T
   Hoyng, CB
AF Kersten, Eveline
   Geerlings, Maartje J.
   den Hollander, Anneke I.
   de Jong, Eiko K.
   Fauser, Sascha
   Peto, Tunde
   Hoyng, Carel B.
TI Phenotype Characteristics of Patients With Age-Related Macular
   Degeneration Carrying a Rare Variant in the Complement Factor H Gene
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID GEOGRAPHIC ATROPHY; REFRACTILE DRUSEN; EARLY-ONSET; CFH GENE; MUTATIONS;
   ASSOCIATION; PREVALENCE; ACTIVATION; FAMILIES; BURDEN
AB IMPORTANCE Rare variants in the complement factor H (CFH) gene and their association with age-related macular degeneration (AMD) have been described. However, there is limited literature on the phenotypes accompanying these rare variants. Phenotypical characteristics could help ophthalmologists select patients for additional genetic testing.
   OBJECTIVE To describe the phenotypical characteristics of patients with AMD carrying a rare variant in the CFH gene.
   DESIGN, SETTING, AND PARTICIPANTS In this cross-sectional study, we searched the genetic database of the department of ophthalmology at the Radboudumc (tertiary ophthalmologic referral center) and the European Genetic Database for patients with AMD with a rare genetic variant in the CFH gene. Patient recruitment took place from March 30, 2006, to February 18, 2013, and data were analyzed from November 30, 2015, to May 8, 2017. Phenotypical features on fundus photographs of both eyes of patients were graded by 2 independent reading center graders masked for carrier status.
   MAIN OUTCOMES AND MEASURES Differences in phenotypical characteristics between rare variant carriers and noncarriers were analyzed using univariable generalized estimated equations logistic regression models accounting for intereye correlation.
   RESULTS Analyses included 100 eyes of 51 patients with AMD carrying a CFH variant (mean [SD] age, 66.7 [12.1] years; 64.7% female) and 204 eyes of 102 age-matched noncarriers (mean [SD] age, 67.1 [11.8] years; 54.9% female). Carrying a rare pathogenic CFH variant was associated with larger drusen area (odds ratio range, 6.98 [95% CI, 2.04-23.89] to 18.50 [95% CI, 2.19-155.99]; P = .002), presence of drusen with crystalline appearance (odds ratio, 3.24; 95% CI, 1.24-8.50; P = .02), and drusen nasal to the optic disc (odds ratio range, 4.03 [95% CI, 1.70-9.56] to 7.42 [95% CI, 0.65-84.84]; P = .003).
   CONCLUSIONS AND RELEVANCE Identification of rare CFH variant carriers may be important for upcoming complement-inhibiting therapies. Patients with an extensive drusen area, drusen with crystalline appearance, and drusen nasal to the optic disc are more likely to have a rare variant in the CFH gene. However, it is not likely that carriers can be discriminated from noncarriers based solely on phenotypical characteristics from color fundus images. Therefore, ophthalmologists should consider genetic testing in patients with these phenotypic characteristics in combination with other patient characteristics, such as early onset, cuticular drusen on fluorescein angiography, and family history of AMD.
C1 [Kersten, Eveline; Geerlings, Maartje J.; den Hollander, Anneke I.; de Jong, Eiko K.; Hoyng, Carel B.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Donders Inst Brain Cognit & Behav, Nijmegen, Netherlands.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, Nijmegen, Netherlands.
   [Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
   [Peto, Tunde] Queens Univ Belfast, Ctr Publ Hlth, Sch Med Dent & Biomed Sci, Belfast, Antrim, North Ireland.
C3 Radboud University Nijmegen; Radboud University Nijmegen; University of
   Cologne; Queens University Belfast
RP Hoyng, CB (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol 409, POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM carel.hoyng@radboudumc.nl
RI Geerlings, Maartje/P-3338-2019; Geerlings, Maartje/P-8309-2015;
   Hollander, Anneke den/N-4911-2014; de Jong, Eiko/P-3407-2015; Peto,
   Tunde/G-8812-2018; Kersten, Eveline/P-8173-2015
OI Geerlings, Maartje/0000-0003-1164-3573; Geerlings,
   Maartje/0000-0003-1164-3573; de Jong, Eiko/0000-0001-6520-0407; Peto,
   Tunde/0000-0001-6265-0381; 
FU European Union's Horizon Research and Innovation Programme [634479];
   European Research Council under the European Union's Seventh Framework
   Programme/ERC [310644]; National Institute for Health Research
   Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation
   Trust; UCL Institute of Ophthalmology, London, England
FX This study received funding from the European Union's Horizon 2020
   Research and Innovation Programme under grant 634479. The research
   leading to these results received funding from the European Research
   Council under the European Union's Seventh Framework Programme
   (FP/2007-2013)/ERC grant 310644 (MACULA). Dr Peto received funding from
   the National Institute for Health Research Biomedical Research Centre at
   Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of
   Ophthalmology, London, England.
CR Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Duvvari MR, 2015, MOL VIS, V21, P285
   Ferrara D, 2015, JAMA OPHTHALMOL, V133, P785, DOI 10.1001/jamaophthalmol.2015.0814
   Flanagan SE, 2010, GENET TEST MOL BIOMA, V14, P533, DOI 10.1089/gtmb.2010.0036
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Geerlings MJ, 2017, JAMA OPHTHALMOL, V135, P39, DOI 10.1001/jamaophthalmol.2016.4604
   Hoffman JD, 2014, INVEST OPHTH VIS SCI, V55, P4455, DOI 10.1167/iovs.13-13684
   Hughes AE, 2016, ACTA OPHTHALMOL, V94, pE247, DOI 10.1111/aos.12822
   Jaffe Andrew, 2011, BMC Proc, V5 Suppl 9, pS13, DOI 10.1186/1753-6561-5-S9-S13
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057
   Oishi A, 2017, INVEST OPHTH VIS SCI, V58, P2198, DOI 10.1167/iovs.16-20781
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Ristau T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093459
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P210, DOI 10.1167/iovs.13-13248
   Saksens NTM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0144367
   Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Suzuki M, 2015, RETINA-J RET VIT DIS, V35, P859, DOI 10.1097/IAE.0000000000000503
   Triebwasser MP, 2015, INVEST OPHTH VIS SCI, V56, P6873, DOI 10.1167/iovs.15-17432
   Untergasser A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks596
   van de Ven JPH, 2012, ARCH OPHTHALMOL-CHIC, V130, P1038, DOI 10.1001/archophthalmol.2012.265
   Volz C, 2015, EUR J PHARM BIOPHARM, V95, P158, DOI 10.1016/j.ejpb.2015.02.020
   Wagner EK, 2016, SCI REP-UK, V6, DOI 10.1038/srep31531
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
NR 32
TC 14
Z9 14
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD OCT
PY 2017
VL 135
IS 10
BP 1037
EP 1044
DI 10.1001/jamaophthalmol.2017.3195
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FJ6LL
UT WOS:000412869200010
PM 28859202
OA Green Published
DA 2022-11-30
ER

PT J
AU Okubo, A
   Sameshima, M
   Uemura, A
   Kanda, S
   Ohba, N
AF Okubo, A
   Sameshima, M
   Uemura, A
   Kanda, S
   Ohba, N
TI Clinicopathological correlation of polypoidal choroidal vasculopathy
   revealed by ultrastructural study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL DETACHMENTS; NEOVASCULAR MEMBRANES; MACULAR
   DEGENERATION; BLACK-WOMEN; IPCV
AB Aims: To describe the clinical and histopathological findings in a patient with polypoidal choroidal vasculopathy,
   Methods: A 76 year old Japanese man had a discrete, orange-red lesion of 1 disc diameter in the macula, with the fluorescein and indocyanine green angiographic and optical coherence tomographic findings compatible with polypoidal choroidal vasculopathy, He underwent a surgical removal of the macular lesion, followed by light and electron microscopic examinations.
   Results: The histopothological examination revealed that the specimen consisted of degenerated retinal pigment epithelium-Bruch's membrane-choriocapillaris complex and inner choroid. A tortuous, unusually dilated venule was present adjacent to an arteriole with marked sclerotic changes, appearing to form arteriovenous crossing. These vessels seemed to represent native inner choroidal vessels, and had haemorrhage per diapedesis. Blood cells and fibrin filled the lumina of the vessels and accumulated in the extravascular spaces, indicating vascular stasis.
   Conclusion: Hyperpermeability and haemorrhage due to stasis of a dilated venule and an arteriole involved by sclerosis at the site where they cross in the inner choroid might cause oedema and degeneration of the tissue. Voluminous accumulation of blood cells and fibrin might generate elevation of tissue pressure sufficient to displace the weakened lesion anteriorly. The result suggests that the polypoidal vessels in this case represent abnormality in the inner choroidal vasculature.
C1 Kagoshima Univ, Fac Med, Dept Ophthalmol, Kagoshima 8908520, Japan.
C3 Kagoshima University
RP Okubo, A (通讯作者)，Kagoshima Univ, Fac Med, Dept Ophthalmol, Sakuragaoka 8-35-1, Kagoshima 8908520, Japan.
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   AKITA J, 2001, JPN REV CLIN OPHTHAL, V95, P702
   ASHTON N, 1952, BRIT J OPHTHALMOL, V36, P465, DOI 10.1136/bjo.36.9.465
   BOWERS DK, 1987, RETINA-J RET VIT DIS, V7, P252, DOI 10.1097/00006982-198707040-00011
   FRANGIEH GT, 1982, ARCH OPHTHALMOL-CHIC, V100, P1132
   FRYCZKOWSKI AW, 1997, CHORIOCAPILLARIS ANA, P29
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   HAYASHI K, 1996, FOLIA OPHTHALMOL JAP, V47, P613
   INOMATA H, 1971, FOLIA OPHTHALMOL JAP, V10, P849
   KIMURA T, 1974, EYE EAR NOSE THROAT, V53, P134
   KIMURA T, 1974, EYE EAR NOSE THROAT, V53, P99
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   RING HG, 1967, ARCH OPHTHALMOL-CHIC, V78, P431
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spraul CW, 1997, KLIN MONATSBL AUGENH, V210, P405, DOI 10.1055/s-2008-1035085
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   THOMAS MA, 1994, OPHTHALMOLOGY, V101, P1384
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   UYAMA M, 1980, J JPN OPHTHALMOL SOC, V84, P1893
   WYBER KC, 1954, J ANAT, V88, P94
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   YONEYA S, 1987, ARCH OPHTHALMOL-CHIC, V105, P681
NR 28
TC 144
Z9 150
U1 0
U2 2
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2002
VL 86
IS 10
BP 1093
EP 1098
DI 10.1136/bjo.86.10.1093
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 595YE
UT WOS:000178135200009
PM 12234885
OA Bronze, Green Submitted, Green Published
DA 2022-11-30
ER

EF